<SEC-DOCUMENT>0000950170-22-002295.txt : 20220228
<SEC-HEADER>0000950170-22-002295.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228161617
ACCESSION NUMBER:		0000950170-22-002295
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		129
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vir Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001706431
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				812730369
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39083
		FILM NUMBER:		22689772

	BUSINESS ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-906-4324

	MAIL ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vir-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-02-28T16:08:15.8142+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:vir="http://www.vir.bio/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_772cdc50-ee81-4663-b2c9-159a9a5d4a6d" name="vir:FailedSaleLeasebackTransactionProceedsFinancingActivities" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a4ed1c20-8e73-4bd0-8485-9c5663b1058d" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_35bc7a1f-bacb-46b6-aa07-b09b7bbbd419" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d44a4bed-0ed7-40da-887f-ea79ca6c9d8e" name="vir:InitialFairValueOfDerivativeLiability" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d240cfd0-0689-460a-ba7b-6620318af392" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="C_475e9f82-cbd7-4ec6-8eb2-24bad29614d1">P7Y</ix:nonNumeric><ix:nonFraction id="F_a4de510f-58db-4648-a977-8db678cc72e5" name="vir:ProceedsFromRepaymentOfPromissoryNotes" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_e8ebc668-f14c-4720-8b72-2366a378afeb" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_e5046b1c-890a-4d88-9c47-8d81f489b3cf">P3Y</ix:nonNumeric><ix:nonNumeric id="F_1cc61fe6-ac37-4ae9-8e25-9ed92a418e6e" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonFraction id="F_1425da0a-0d71-41fb-80b4-6e4271d2eaed" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_5f39939e-8498-4156-807d-30af0dfff8cb" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9ed14462-8c3e-4dbb-b16c-fd5a1cb257fe" name="vir:ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c4078763-cec1-4a66-959d-505d3023edad" name="vir:AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c1b7f7bb-24d4-45ce-80d9-0476ded55f8a" name="vir:InitialFairValueOfDerivativeLiability" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e04e83e7-ebaa-41ea-babd-a85bb4d24a9c" name="vir:CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_b3ce71d6-2479-49ff-972d-2870edd2f042" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_2e4d4ce4-f3be-4eb0-bc20-5ce86e739229">P1Y</ix:nonNumeric><ix:nonFraction id="F_98a9a1c1-c922-4685-b412-bdffdfc28ae1" name="us-gaap:CommitmentsAndContingencies" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_736e2b87-7321-4c16-a4d7-00f5d88607fa" name="vir:ProceedsFromRepaymentOfPromissoryNotes" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e68fa7e5-5e36-4a91-a346-039647a55845" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d2953029-da62-484e-a797-93a558adad20" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3b70eb5c-3677-456e-9180-2f5f40bd92cc" name="vir:CommonStockIssuedInConnectionWithLicenseAgreement" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3a2ddd83-9ef6-4dfd-b812-3fef59045e88" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_2224d0d8-f870-4e2c-84eb-afb6268a5d33" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_72defe4c-83c3-481e-b440-b0643489c971" name="vir:ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_20aa9ca2-42ef-403f-9ec6-4ab57c19080b" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9854d74e-7f97-4b0b-a755-45b36915ad92" name="vir:AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e9114fd8-4978-4682-9f50-9246a83ee001" name="vir:CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b4609599-f5b1-4e10-83aa-953f302ed107" name="vir:PaymentOfContingentConsideration" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3a00e3fd-a5c3-445c-8652-f44eb20df66b" name="us-gaap:GainLossOnTerminationOfLease" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e465322f-8ed1-47a7-9a25-aee25f322449" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_6380790d-03b2-4de6-bb8a-563e0a71388f" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d21fc636-e1b9-40a5-b41f-adf66b5a1b58" name="dei:EntityCentralIndexKey" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7">0001706431</ix:nonNumeric><ix:nonNumeric id="F_9283bb71-2e76-49eb-b602-a8f93acfc4c1" name="dei:AmendmentFlag" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7">false</ix:nonNumeric><ix:nonFraction id="F_dec1a281-61d2-4dc6-90d7-76198f647c24" name="us-gaap:AssetsFairValueAdjustment" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_a8d2e9b9-02ae-4ff4-bd78-94a2d05ac43a" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonFraction id="F_9a26d801-8def-40ce-9488-f4b2a2bbc5db" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_58e2eb0c-1180-444f-b3b2-1e0f0b469fc9" name="vir:ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8340aa05-f6fa-415d-aa80-320c4eb517d5" name="us-gaap:ProceedsFromStockPlans" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_aeb0c2d2-3251-4237-b9b3-110fc85a87f2" name="vir:GrantsAgreementAmendedDate" contextRef="C_f5edd5d0-093c-4a7f-9010-06a8b6d0943c" format="ixt:datemonthyear">06-2021</ix:nonNumeric><ix:nonFraction id="F_7bbc2272-0008-492a-b8e3-012702186564" name="vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_63c2423d-7a76-4317-bc96-630517587877" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3cd3f88d-5ec4-4c66-a41f-56053d71af7a" name="vir:FailedSaleLeasebackTransactionProceedsFinancingActivities" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_196c5237-329f-410d-96d8-db2421aa3db7" name="vir:NonCashCommonStockIssuedForContingentConsideration" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_b9df5d21-f326-44cb-9e27-7f6e0364aaa6" name="dei:CurrentFiscalYearEndDate" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7">--12-31</ix:nonNumeric><ix:nonFraction id="F_f6ef5dbd-d8d1-45e0-a55c-433dfbcf55ec" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_7b44663d-1329-47cf-a20b-2f4943e047c2" name="vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" contextRef="C_7d9adb10-9589-4116-8468-f2a901cec9e7">mid-single-digits to sub-teen double-digits</ix:nonNumeric><ix:nonFraction id="F_97880dc8-ea14-4184-b3d1-1c224e174732" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_cd3b816e-2520-4ba4-873e-cb45dd224087" name="us-gaap:GainLossOnTerminationOfLease" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_b3b3c2e2-807e-47e2-9909-7b52a03e1e68" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_e5046b1c-890a-4d88-9c47-8d81f489b3cf">P7Y</ix:nonNumeric><ix:nonFraction id="F_024599b7-5d20-489d-b293-7b709b4ba2ef" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_a869b4e0-c5d1-40f8-a18d-2d9633f8fb52" unitRef="U_pure" decimals="9" scale="0" format="ixt:numdotdecimal">0.222222222</ix:nonFraction><ix:nonFraction id="F_ac7ee1e4-e982-4e16-ba9a-ab3dacbb8803" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8b32ee52-010b-4024-ad9b-e6c4df6d5466" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8f4edfbd-9a9f-42a8-a370-d64708e2323e" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b156a61b-ab05-4999-91a0-ada076026c19" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_4f339869-7320-48dc-b4c4-f4e2638b0fb0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_48a70287-0f05-4e93-92b2-64eb0929682f" name="vir:ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_aa68f18c-5e68-4d0d-83e7-0de7835742ff" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7">FY</ix:nonNumeric><ix:nonFraction id="F_53ca3f31-8c27-4624-bbcd-862d061949e3" name="vir:CommonStockIssuedInConnectionWithLicenseAgreement" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_f4d21755-e71d-4379-982f-e1f0ca56eef1" name="vir:PaymentOfContingentConsideration" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_1dce386a-d15b-43a0-9d69-261d7fc5489b" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" format="ixt:booleantrue">true</ix:nonNumeric><ix:nonFraction id="F_48a607eb-82b2-42f3-9b15-106d86433c4f" name="vir:NonCashCommonStockIssuedForContingentConsideration" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_cd9e3ce9-14e4-4515-a281-682b3f84673d" name="vir:NoncashLeaseExpense" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a7d4385c-0b9b-4afc-a37c-6c1eb232d765" name="us-gaap:AssetsFairValueAdjustment" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="vir-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_7b782a32-6679-4004-9be5-e91a7a28b3e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineTradingServiceLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d9adb10-9589-4116-8468-f2a901cec9e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndInfluenzaBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f546f6f3-d48a-486c-8052-617336a81a7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91330166-4192-4765-8752-a172cb399634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c672b8f5-c39b-47aa-bcad-cd04fd706515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:VaccineProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27d6b8f0-fa5a-4e00-b4fd-9df702316b81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bd2b5a2-2224-4f6d-aacc-dc5934151bac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HcmvVaccinePlatformGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5046b1c-890a-4d88-9c47-8d81f489b3cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ded0a8a-1711-44a2-8906-3b560cb68ef4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:WuXiBiologicsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fa4019b-73c6-4a3b-be6c-7aa4984acca2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:AccruedLiabilitiesAndOtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f17c5a8-e2ce-47e8-9a5f-717bf5afb341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8189099-45c1-41f2-b6ca-954b37c65618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3d7153f-2142-47b5-836a-92c25c9b950c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71a5c221-44c0-4e41-a2fa-4f7fa314d849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7589f598-a536-40ef-ae5d-943416f75b64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74f0b6e6-2f8c-42cd-82e3-2ad83cc03354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f89b46e3-8544-4acc-962d-faf2858aa020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedRevenueVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30a9821b-b5e9-46b1-8ada-d4dccbd412c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9c4cf79-3f00-4bf0-bcd2-f9232b1fcc14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d49462cf-7289-42fd-ade3-fc506e048127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c35f7ee-7ce8-4791-b6e1-4269f4a1e21d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b8fb261-7fe1-496c-8e0b-dba547d8fd42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a57dade-b465-4a49-be9a-5cb7b24a6ffc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfectiousDiseaseProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0be73e2a-ec59-4143-9931-80891ed3a51b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e39b64d-0aec-4926-941a-2eeb4cc3e0c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_810fc216-bb93-4ea9-b973-024c33461e81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c4a05c0-ab68-4442-bfca-80dd0cb82f0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e143173f-1c22-40fb-ba0b-999bdcd9677f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24859036-8402-474d-a1b9-81a9c9af22a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vir:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f3a686d-485c-4e98-8bf8-9cbe259cabcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_813ff2ee-1d90-44ea-b0f0-79248d502136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ad71b1a-ef19-44b7-ae86-72e2d88c9ede"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1aa5fc1c-95ff-4281-9c2e-6292a0baba92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41895c62-83e2-4823-a8d7-01879c19221e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68d98f4f-0d83-475e-8b52-0b892db80670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb6f51fe-eb87-484b-a6ba-f5a1a6fa73d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d72106c-4ece-48a5-890f-cdc4894fc993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandSeventeenGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba75ea58-13bc-4e3d-8ef1-d07deeb228c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1374ee0-34e2-4104-bf31-9dd183c22ca3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2a50417-42a1-40be-8caf-f0cebc94ffff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df4b5d69-777f-4164-ba06-7c95c5c18601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eaf05464-1224-4ae2-8baa-f4387ec342ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd790442-a1c8-4c01-a7b4-906b111a3a51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a16ebff0-6b04-4a9b-bc6e-bc5cd87822d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f41d2de0-2ba6-4580-bbfa-01ae990de9ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3afd1e8b-5267-4120-b240-7f12f4a61a4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7535086-58ed-4942-918e-2201970b8cea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7bf9af0-7a63-47de-aa6e-7c2731d130ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9bbee3cc-0441-482d-a60a-021bdde5fb32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandSeventeenGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_374d06f8-fb5c-49ef-9129-8079100e5579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a27a1fab-d4d1-430e-a2ef-eaaa1ad83180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4700e2f3-e411-4471-9030-da4a2a264740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b12cfb1-fdf1-4522-acd2-8b1f2eb36f1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-14</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a692092-b0fd-48e1-be4e-22e37c497148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0003b2b6-cfb3-4fa2-90d1-98eb440f3fcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15e3e949-97fb-495d-b1d0-55b62ebddcc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3142090-a1b8-4083-8441-c9dd49ecb566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9b5a1f5-d509-4f41-a5b0-00e6735b747a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vir:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-09</xbrli:startDate><xbrli:endDate>2019-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9de06e9c-4123-49c9-9448-9c22581415b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce562ce2-89d4-4006-bd1c-8ec2a20274f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56c9c1ac-6a87-4622-b2fb-da94dac65173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0ace255-aaf9-4b62-af6c-209acf635d22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b2320ed-d560-4b7d-850c-3e4bf7238d2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a0b0601-deb2-4157-ba2f-7613b7f73ba3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vir:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88183c78-6814-4146-96c6-0cba18d5611c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b85c9788-4228-4009-81b0-cb885a8a21d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_488948dd-80d3-45b7-a684-756b5feb098a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5299f27f-f8a0-4e30-874b-2faab774be38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a4d7f99-61b1-4dd9-8b7a-51541fecc5f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc4e105a-e463-4014-aae3-86682a1d49a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d48684e-c8e1-4db3-a973-d66108c108c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:ClinicalDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7c9462b-dcbe-4e0d-ad24-fa03ee7db19f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstInfectiousDiseaseProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_953e43a8-2a7e-48ad-a529-e63d37ac462c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a32e557e-b0ba-4f99-bb95-674d8a7d72ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7f66cdc-e2a5-4776-b99c-d6e4b917eb2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7012ff2-8e91-4fa6-b536-458c48e3b5ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_224cb303-9ce3-44c9-8e2e-6437c0fdeafb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f6d55c2-91b3-4ca7-adf9-970debbec4df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_accfab4e-3a9c-48c5-9d0d-b1f80346071b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_974c0603-8333-4dce-9655-97b1212bed01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c10e626c-f383-4183-bf3d-6e3516f85d94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d214461-dd67-46fd-97ae-535ac3188674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49d8bcd1-7a7f-42e5-892b-9a0cd8d9902d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f8addeb-5f7f-45ee-807d-84c9144573a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9877f0f7-e105-480e-b0a7-fb9e68d056f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_501b75ac-22be-4b07-9759-c03d7aa1ce0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91794362-8b4e-44c7-8392-9d2e078a248a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a35132f-d773-49ba-9363-edcb9df0bf0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstSiRNAProductHBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-31</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b224cd3-1cba-4c7d-b686-ace421bc028d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HcmvVaccinePlatformGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c483ff8-5408-46f2-a03d-22d662c61cf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33252fb3-7851-44e7-9561-2d534fcb41de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9df0518d-0a7a-4d2c-92b4-a8e2b609380f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d7448b7-0904-4443-a40d-a6bc22ea01ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d7fc207-68b5-469e-b2a5-a7be19fc2bad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_301f15e9-11d1-406a-b0be-2ca7cc4b7543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_931f9106-3768-4f05-bd7b-0855dd2f9745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vir:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65bd9d63-ee77-45dd-a499-a8f0b310c5e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d74b360-ce4a-44f2-9de1-d605ea9e3611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_808e2ec7-0dc9-49ea-8101-9ff9a724d929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a31bf7c-9f6e-4b04-9a96-43549f6f4cc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5bc95aa-a39a-42b9-82dc-8f1e49c3c984"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5edd5d0-093c-4a7f-9010-06a8b6d0943c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69329fa9-5ba5-4337-a561-386bfedc0568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb465827-50c0-422c-a785-a18988e1c54b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-14</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb8cdd31-0bed-4661-832a-fa3a50385e05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:WuXiBiologicsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be5c6cf7-b468-4342-99e6-e6f0cb45b27a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e837f6cd-46cf-43d6-8ea9-08f5560d9cf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a567406d-6fcd-4a01-a0c2-596b4cb717b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0b1e9f3-2c15-4ace-bc47-71fc21bcc480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_064e544a-5338-44a5-8d21-57da4323d0ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_079288b4-6cb4-4671-8ab2-600c75753f48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9c4bdc2-99a7-4b17-b04f-d11af920c552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_250f68b2-8222-4f1b-a3b9-f47c995fde57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1073bf6-3fc5-4a5a-97f0-bbd26559fb5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46ac8ad0-5eff-4cd3-9959-e7aa7afae14f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_deffe243-ff55-4872-8584-6b06fc133c1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstSiRNAProductHBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0491c773-5dc7-4c46-bec3-e5a5ab07096c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_714f6509-93e2-40d8-93c7-af8d8831b31d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed3b9e09-2b8e-4a52-a1e4-da67c4059a2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6095766d-f048-4375-875a-769201aac419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_819e77e6-c072-4b31-ba45-3c415b3f67d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8fccfc88-43e9-4439-a516-7a1eda119be4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eaceb94a-8ec3-4208-a7d4-ba474353d176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b3827f4-9f03-4d95-b4e5-11849acbae16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf931caa-5cb0-4310-8883-afbdea037621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5f3ecc6-0f0d-4709-940b-a9657a2029f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d502ed6-15ab-425f-9a22-bfc1d3c39623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-10</xbrli:startDate><xbrli:endDate>2019-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9599deea-454d-4e26-bedc-49ceb4cf2404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_475e9f82-cbd7-4ec6-8eb2-24bad29614d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6595e636-7a23-4034-861a-6a075f66f7cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_348661d6-b9d4-405f-81cc-4d936a14f5b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9001d10-0c10-49dc-a944-46388f818412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd77bc9a-f90c-4d89-9139-053ac79a0a7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec203b07-51b7-4cd9-82e7-1152642f49ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:BiologicalMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f506a175-6fde-4e73-bbbc-20e846b33555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca5007f4-5584-4178-8601-b447870799b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7805a9f3-b0a3-4562-b373-15bbc4dab334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6593689d-6c09-413e-8c82-082f1af9b2e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee4ca4dd-dd89-4390-b7dd-451122361af3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a524056-f9aa-4720-b2b3-0ab25f4155a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndHBVResearchProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14c2d113-77d4-4ecb-aadc-32b535038ad1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c763cb1-70d7-4e23-8984-44c48ee907cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_643ca0ff-cb47-43ec-917c-167fbc2cff60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_405140f2-f0e9-44c0-b8cf-d4d833a30755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c199ed9-32db-4a22-a38e-1c376f297c82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_675e042c-eb56-4fb7-aaea-43c58b4c0aa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a14402f0-9a6d-4005-9600-5bb5f45f3cf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6e46de8-f795-4991-b51d-0af545d01d4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3180a70a-dfa7-4102-9724-38babfd3d0ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31279301-58e0-4e0d-beea-e0a2ac9b9cfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3de3d32-1468-4cb9-b95b-a8d0af66f9af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_050ac877-095b-4637-b981-1aea98d3b192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be140e6e-3761-4ec9-ba59-319fd0975a8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ae824f4-f2da-4275-addc-163ec36b47a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da7048e3-08ee-4a8f-a9eb-1ecdc468ee9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f99ec918-2e4e-432a-970f-3c67447885a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88ec3719-e182-4d88-abf8-cefce0fa050c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-10</xbrli:startDate><xbrli:endDate>2020-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37e02e2b-ecee-41f9-9516-eff5990866ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e52b7462-3e95-4a90-a2ac-eeb96cc91696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-09</xbrli:startDate><xbrli:endDate>2019-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63b7f812-9b12-47ea-b2fb-128ab0685b44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3a8cc93-b738-43bd-abbd-308523b5cd24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9cc53898-90ab-48e4-811b-68336c8459bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d722794-e16e-4e44-9edc-feb0c31aee2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AnotherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2d805bd-8fe4-4a5d-a29f-32025b612cb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_160a64f9-0857-4c36-8f24-34b857e2d49c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b4acd09-0f98-4d80-8e8b-2e3567b35e97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad98faf6-018f-4435-8e8a-c91df1a4d6c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19681061-85d7-43eb-9090-f6c375682fba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4535e3d1-cadf-43e9-a70d-52008cd60dfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_021eeba0-02e7-4697-bcf5-81b5a7722190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HcmvVaccinePlatformGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df0832a0-b752-462c-be11-1620cfe4dc18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34998bcb-fe81-4e6a-839c-342803b38b04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d81f5ee-bce5-4497-8145-ef3258cee1b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_830b2851-70de-48fc-94e9-c824f5a5454c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3e6496b-39fc-4dee-953c-9b3b230bf6cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ae9b192-da16-4b61-9aca-9b2e398bb09f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_518a3141-66a8-47ab-978b-8e77ec8e8f30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:WuXiBiologicsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05bb4f29-b066-4a68-b91c-484f95f96b0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04ff1607-fb14-42a5-912f-34d468278706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcb52d16-86fa-4370-9fc3-793fe22d8181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:SamsungBiologicsCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad2a2cfc-b340-447d-9eaa-b40190d30427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_515a352c-312e-4bf3-9bf8-04b085f91abc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d2840b2-01d0-4017-822e-05963d9d6961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71eb2cf3-b567-474c-8eb2-9294af7f7cd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1a9eeda-0adf-4886-b25f-5e7c6923762a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HcmvVaccinePlatformGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_024bb253-6952-4f27-abbf-00f7a4f1d57c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e120ade-622b-4150-9778-b6f3b2b76cc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0733b4ef-c448-4927-8d8e-84da4192b4ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8765b59-506d-4165-9487-b02bdc930b58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97f0fbad-d4bf-4f2b-8e7f-fa6521b24a9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55353dc3-d2db-42da-a649-4767a86be523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3be2e934-f078-49d4-9962-afce5e0c771d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a58fa995-aa0b-4d6d-9cce-6dbe94de83fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f999fb4c-9967-4386-a71c-e0a64a7891bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef618346-1e5d-4fc9-884c-3b4a0ef0bade"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ffe17dae-8660-4c99-8aab-15f3d99a9a63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e34598c-0a2b-44cb-8608-379e7e560202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2082200e-8d81-44c2-9451-795cb9436f26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2e6a670-5d82-408a-9795-8749e0878917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3200e2aa-d8c3-4db7-a6bc-1e84a8a07638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ce5cca5-d328-4861-8f28-b94590239275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d78f477-8e15-46ec-9ae7-c436d7a5b269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RestrictedStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vir:ExecutiveOfficerAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f145b8a-a89a-4b1f-beee-1a8a6ab8f021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b38fd327-4513-4808-ac50-5d5528a35383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59d377ae-8381-45db-9cc4-7efce0201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a978f36-d4af-4db5-8584-15add2567749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c65ef721-72ea-40b3-878d-db5fb1796225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_786d6b05-a5c6-4c6b-bd8c-08bff9b5679d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d62337c8-04d8-488e-a5b0-e98601a826a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_547d334c-565b-45aa-a31d-cf0b5ec40a45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8d8ecfd-11a2-4d9e-986a-f51ef12015b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c598293-0936-4d1f-99f5-0722e4f7437e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb786dd2-2f22-47d4-9e9e-9a488bff4ab9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4b2018a-b9d9-4637-8c1a-502b5c20c95d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1b89459-ec16-4eeb-8748-5aa7c26b546b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34acf0fd-1b4d-4895-92c2-913b85fb2602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndInfluenzaBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f98ed76-99b8-4408-9b9c-7145868e41b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:BiologicalMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eada5d7f-f2a9-431c-b238-c2280f794f45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_882eeb59-5aa1-48a1-b475-f45ed47e1af4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e8a7542-2dd0-4c48-9150-7dcf5bac672c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05dda014-cb81-49d2-92f9-31d5a59a9ff3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c384113-a0b3-4e9a-b7a6-3c84846d53e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_486aaa19-98ed-45c8-8860-fd4d402399da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9df276b4-bb61-407c-a816-a86f5eb1f323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_513fcea4-6032-4866-8906-83b5dc316354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06f41013-d21d-4546-aa26-d8ece6d9a91a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d93e807-4da6-4761-840c-61b5cefbee6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04e2f054-346c-47c8-89fb-055997c2a180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vir:SeriesAOneConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92381b91-3b42-4fe2-ba53-ec4b175909d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:DevelopmentAndManufacturingCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:WuXiBiologicsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7fe631b5-99f5-4a42-904e-1d5e014789ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a869b4e0-c5d1-40f8-a18d-2d9633f8fb52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-16</xbrli:startDate><xbrli:endDate>2019-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b3dd0d6-7971-4035-8623-0c23e6212871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6639bf66-3f97-4290-be85-57c7e4a0c37c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6f98428-747e-466a-907f-d4b24c98cc45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAResearchProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42be3ce6-3c6d-4c19-ad78-d6bba030babf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f41c076b-5d7a-4003-8cb2-ca3259ad661b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5271e096-8828-4fdb-8093-e81baf518a38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d2c449d-3432-4046-9323-81b3ce04e34a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbb0fecc-7a8b-4c5b-9fec-e7fdd61a01f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:DefinitiveCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16d264b9-1049-422e-959d-522e97231bc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2920cb23-d73e-4b16-b3f4-cc501406683c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_557d1e8e-6875-4184-8347-4aab3a2c9a31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01417e77-f979-4120-a600-156314a4c210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c55f2ce7-7281-48a7-aec6-0a47f77c9a67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cbe6ca1-3aef-4d1a-beac-1c5b67ca8ba9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65508bde-8e9b-433a-b887-54fe70f6560d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f49ec3e-8e45-4cc0-8b2a-a2462edffcfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_333e5067-692a-43e7-8ca4-773333284f0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_587ac654-89df-4445-9d73-21454d8c728f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a145aeb5-af85-4ad6-ba29-68511bbc994c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3776a1e8-74ac-49c3-8bd9-7024d16f0ad2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f3bbd07-1fde-4bfb-b72d-6df34ea170ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5435542f-8093-4105-868b-53ef71ac98a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f3bd2b3-b70a-4d36-b772-a1b2c9072a86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c4b9e6a-a844-4e0c-a296-cb62009d4a06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04d6bf1e-1ec8-4592-84fc-8ca7693ba159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a9da79f-2f51-4ca2-944b-bb5ee3abad70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4723e489-b2c6-419e-a302-89f09c349a7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3ff0ae3-397e-4e79-94d3-974b85c1a48f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7846e4d7-bd1e-4f8d-ab5e-2c405172b5fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d67e94b8-3d90-4a56-820b-3f311ae13e57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66bceed9-522b-4fbd-a22f-c029c32a27fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c0012f8-5960-4879-bdde-f46b368e2ae9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7032bf3-35f9-44e1-bf55-389c77cec434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ad51e18-a052-4618-9f7f-dd217928f54d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BillMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0e8d12f-41e5-4499-bb57-79d3fbd1a9a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a48eca06-2240-404a-95b9-a96f664f0800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bcf35168-3bb5-4a68-9f5c-cf54c4823054"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92042eda-34a8-4b88-8ceb-39eb4ad7e70a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbb0d6a6-cb1d-4c13-9791-01f69f5283a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1a0aec0-6950-4e6b-b8c6-2c448044907e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7e70a8d-2f4b-4760-92ab-0e41dad01baf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1cec4878-722f-49d0-b6df-245adc26d756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21482517-1f7b-44c6-8e55-585d0ec9e391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53a9db5d-ce87-4cee-8476-d28141546bda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec04e3a0-91fd-471d-9c5e-a88bcbb1c70d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90261ef5-9966-431f-a299-6204c1e9115a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1bbbe19-c33f-4c19-83ca-eca625a9d033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a85d530b-5472-4e7a-bcea-2452ef558595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f93128d8-554e-4673-824a-fcf094e10714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c64f8d89-5c82-4a9f-a80a-fb1f5a11ee70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb04a465-c3d8-4109-889c-c33e0ccca055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_647cf94d-4221-49c6-986a-76edcb5f1c62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:EachInfectiousDiseaseSiRNAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd868f7f-a86d-4911-a7c7-759ba388c5ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46e6f289-d1e5-40dd-8d37-0d010f7d5492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10b89020-933b-4851-aad1-03756b00666a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47cc19c9-75f2-422b-8ed8-1c79b990ca5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5f8399f-ee4b-45a3-a103-6773949f9073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95728472-f99b-4600-92ae-c92c93205687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-14</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c53e5c04-9722-48b4-9a77-81a3284044e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b91aebaf-cbdf-4bbc-b802-2169b53b199f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8ddf765-8bda-47c3-81a9-cbdb38c2d9e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d0ed842-ca94-4998-a8f5-2f0beb76b34a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f56ff235-0c3a-41a2-9a37-b0d1d92b94ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c65e2fa1-651b-49f1-8130-e10a86ed4b23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b82d2460-cf24-43b0-b95e-5a0a52709f8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e93d6b9-9d5c-45a3-b71f-00713901c0f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a07820f-763c-4577-b53f-29f5d29d5021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9443ba3-f289-4712-b80e-f1c93e0123cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-09</xbrli:startDate><xbrli:endDate>2019-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5a5ec76-5424-4832-b5c3-f943e156e9d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f134ed1b-0d64-42e6-8b4d-545d2bec9296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_202b895b-631c-490b-893f-c4dd6e2908d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e4d4ce4-f3be-4eb0-bc20-5ce86e739229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccf336f4-a19b-47b9-8dd4-fd55c3edb88c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d0a5b8f-a0b0-4322-af0c-fa4c65561bb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2bc6c04-5732-4690-b9c0-17ebe0b9dbc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e1d64ed-e161-4d09-a7bd-60b59d474ed8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Segment"><xbrli:measure>vir:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Antibodies"><xbrli:measure>vir:Antibodies</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Unit"><xbrli:measure>vir:Unit</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_Milestone"><xbrli:measure>vir:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Program"><xbrli:measure>vir:Program</xbrli:measure></xbrli:unit><xbrli:unit id="U_Product"><xbrli:measure>vir:Product</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_76d6ccb1-4db9-4ff8-9bba-9b4948c6b0ce" fromRefs="F_b1973014-1cf2-4eca-bc28-be136f876b81 F_c0e4b230-b9af-41e0-b35c-1882aab2805f"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:Times New Roman;">   </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:Times New Roman;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:15.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0e3712f-46cc-4e0d-818e-99f85d163819" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:15.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b8d2f34-e65e-4d98-b96b-bd611f71ca23" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_728a69b7-74bb-4209-8086-a2e22f76e3ff" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abda1639-88e9-4f30-addb-83514af6698d" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.998%;"></td>
    <td style="width:96.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68de34c0-a3ac-4900-a33e-fc3b754537c1" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd9ff03e-9f83-4d79-8b85-1abffddee640" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">1-39083</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:22.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6aac2226-e2cd-4c45-ae88-1d14e7f2ccbc" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Exact Name of Registrant as Specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a651b4a-4c56-4695-9cf4-ce0566792117" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6b804f0-4ca7-4293-aec0-32180dc0a96d" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">81-2730369</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or Other Jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Incorporation or Organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b234c126-b306-438d-8dad-8bb91428fb79" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">499 Illinois Street, Suite 500</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41895082-f9c3-4faa-866a-82fc8094129c" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">San Francisco</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b429932c-296a-4a10-8590-ac0b5c85f809" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">California</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dacc7e03-e87d-49db-b3a4-e3dd821c14bd" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">94158</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_575e6e55-2609-44d9-a099-bb04311156a6" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">415</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">) </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_166d5214-bb40-4bdb-b883-6861e58c5510" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">906-4324</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.996%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:37.996%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7c0d66d-5c02-472e-a132-cc562fae269a" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Common Stock,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$0.0001 par value</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_442a0840-599a-4b8d-8b62-aad8d2b5a16f" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">VIR</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62625bd1-7161-4f18-a047-004ce9a1817f" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef6eda16-8537-4943-9cc6-9f786d64d8cc" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746; No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes &#9744; </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86cb201f-5394-41aa-afbc-57370ac54505" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01016075-589b-4f8c-907a-bc04160a4b9c" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746; No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44ea26af-903f-4f5f-ab31-c3b16128fc21" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746; No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.246%;"></td>
    <td style="width:0.596%;"></td>
    <td style="width:54.14%;"></td>
    <td style="width:1.123%;"></td>
    <td style="width:21.131%;"></td>
    <td style="width:0.616%;"></td>
    <td style="width:2.147%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d95953e-622f-43c1-bcac-773384a9bc90" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Non-accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13108c5d-2d21-4e2b-88ea-d60727d576ec" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4b21b73-def7-440a-955b-face178ca406" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b10e40f-e49f-429c-88a1-62585290388a" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e745db0-2c8e-408e-a4e2-35025c70d380" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> No &#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant as of June 30, 2021 was approximately $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aad9ab82-3999-4574-b351-42d6da07df0a" contextRef="C_7c35f7ee-7ce8-4791-b6e1-4269f4a1e21d" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> billion based upon the closing price of its Common Stock on June 30, 2021 of $47.28 per share, as reported by The Nasdaq Global Select Market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The number of shares of the Registrant&#x2019;s Common Stock outstanding as of February 22, 2022 was </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f997664-07e6-4e4e-9d02-2b06ceed39ea" contextRef="C_250f68b2-8222-4f1b-a3b9-f47c995fde57" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">132,303,561</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_eb87f0fc-7f0e-4199-8822-8c46cb571825" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant&#x2019;s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant&#x2019;s fiscal year ended December 31, 2021.</span></p></ix:nonNumeric></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.568%;"></td>
    <td style="width:35.216%;"></td>
    <td style="width:35.216%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Auditor PCAOB ID: </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_370feb5e-b606-4379-9d7f-b8c69d1bb7f7" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">42</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Auditor: </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18f0f6e0-e297-4945-aad4-8694b4e21bcc" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Address: </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c38b138-6980-4da0-939b-56ebeec8c0cc" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Redwood City, California</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:84.405%;"></td>
    <td style="width:5.595%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Calibri;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">182</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disc_re_foreign_jurisdiction"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdiction that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">182</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">184</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our strategy, future financial condition, future operations, research and development, planned clinical trials and preclinical studies, technology platforms, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our product candidates, the potential benefits of collaborations, projected costs, prospects, plans, objectives of management and expected market growth, the timing of availability of clinical data, program updates and data disclosures, the ability of sotrovimab to treat and/or prevent COVID-19, the expected number of therapeutic doses that Vir will be able to supply to patients, and the ability of sotrovimab to maintain activity against circulating variants of concern and interest are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;positioned,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions described in the sections titled &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and elsewhere in this report. Other sections of this report may include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled &#x201c;Risk Factors&#x201d; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this Annual Report on Form 10-K involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RISK FACTOR SUMMARY</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing in our securities involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading &#x201c;Risk Factors&#x201d; in Item 1A of Part I of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks include, among others, the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred net losses and anticipate that we may continue to incur net losses in the foreseeable future and therefore, may not be able to maintain profitability.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We received an Emergency Use Authorization, or EUA, from the U.S. Food and Drug Administration, or FDA, for sotrovimab. If the FDA revokes or terminates our EUA for sotrovimab for the early treatment of COVID-19, the disease caused by the virus SARS-CoV-2, or the federally declared COVID-19 public health emergency ends, we will be required to stop commercial distribution of sotrovimab in the United States unless we can obtain FDA approval for this product and its currently authorized uses.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are committing substantial financial resources and personnel and making substantial capital commitments with third parties in connection with sotrovimab as a therapy for COVID-19. Market demand and utilization of sotrovimab or any of our other COVID-19 product candidates may be adversely impacted by factors such as the development of monoclonal antibodies, or mAbs, of other third parties, the rollout of vaccines and oral antivirals, the emergence of new viral variants and the current challenges in the delivery and administration of mAbs to patients.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our near-term success is dependent on the successful commercialization of sotrovimab for the early treatment of COVID-19, including our ability to enter into additional procurement contracts with government entities. If we are unable to successfully commercialize sotrovimab, our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, sotrovimab may be rendered inferior or obsolete, even if it were to gain widespread market acceptance initially.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of sotrovimab and product candidates in a timely manner. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals and marketing authorizations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside our control.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a party to strategic collaboration and license agreements pursuant to which we are obligated to make substantial payments upon achievement of milestone events and, in certain cases, have relinquished important rights over the development and commercialization of certain current and future product candidates. We also intend to explore additional strategic collaborations, which may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to rely on third parties to produce clinical and commercial supplies of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the current outbreak of COVID-19 pandemic and future outbreaks of the disease.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The market price of our common stock has been, and in the future, may be, volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our information systems, or those maintained on our behalf, fail or suffer security breaches, such events could result in, without limitation, the following: a significant disruption of our product development programs; an inability to operate our business effectively; unauthorized access to or disclosure of the personal information we process; and other adverse effects on our business, financial condition, results of operations and prospects.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">usiness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our mission is to create a world without infectious disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are among the leading causes of death worldwide and can cause trillions of dollars of direct and indirect economic burden each year &#x2013; as evidenced by the coronavirus disease 2019, or COVID-19, pandemic. We believe that now is the time to apply the recent and remarkable advances in immunology to combat current and prepare for future infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current pipeline consists of sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#174;) and other product candidates targeting COVID-19, hepatitis B virus, or HBV, influenza A virus, and human immunodeficiency virus, or HIV. We have assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid, or siRNA, through internal development, collaborations and acquisitions. We have built an industry-leading team that has deep experience in immunology, infectious diseases, and product development and commercialization. Given the global impact of infectious diseases, we are committed to developing cost-effective treatments that can be delivered at scale.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current product and product candidates are summarized in the chart below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_0.jpg" alt="img61678762_0.jpg" style="width:672px;height:307px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.078125;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.078125;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">*Sotrovimab for early treatment by intravenous (IV) administration currently has marketing approval, emergency use authorization (EUA) or temporary authorization in &gt;40 countries; for sotrovimab for early treatment by intramuscular (IM) administration, we and GSK (as defined below) recently filed an amendment request for an IM EUA with the FDA (as defined below).</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.078125;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">**Vaccine designed to establish proof of concept in Phase 1 clinical trial to determine whether unique immune response observed in non-human primates can be replicated in humans; ultimately, any candidates we advance as a potential HIV vaccine will require modifications to VIR-1111 before further clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to the John Hopkins Coronavirus Resource Center, as of February 23, 2022, there were almost 429.0 million recorded infections and almost 6.0 million recorded deaths worldwide from COVID-1</span><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9. To date, the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Food and Drug Administration, or </span><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA, has granted either Emergency Use Authorization, or EUA, or marketing approvals to multiple vaccines, drugs and/or antibodies to prevent or treat COVID-19. The ongoing efficacy of these medicines, however, particularly as the virus mutates while it infects more people and comes under increased immune pressure, is uncertain.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In response to the ongoing COVID-19 pandemic, we have moved rapidly, together with our collaborator Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. (individually and collectively referred to as GSK), to address this global health challenge. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our focus is on treating and preventing severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 (the virus that causes COVID-19 illness), as well as potential future coronavirus outbreaks. To do so, we are developing differentiated monoclonal antibodies, or mAbs, like sotrovimab and VIR-7832, as well as vaccines and small molecules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sotrovimab and VIR-7832 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">are SARS-CoV-2-neutralizing mAbs. Both sotrovimab and VIR-7832 are based on a parent antibody, S309, which was derived from samples previously gathered for research on pan-coronavirus-neutralizing mAbs. Preclinical and clinical data suggest that sotrovimab and VIR-7832 have the potential for &#x2018;dual-action&#x2019;, or the ability to block viral entry into healthy cells and an enhanced ability to clear infected cells. Both mAbs also bind to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for viral resistance to develop. Both mAbs have also been designed to have an extended half-life and to have doses low enough to allow for intramuscular, or IM, in addition to intravenous, or IV, administration. In addition, VIR-7832 has been designed to potentially enhance virus-specific T cell function, which could also help treat and/or prevent COVID-19 infection.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sotrovimab</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Early Treatment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, we initiated the lead-in phase of our Phase 2/3 trial COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early, or COMET-ICE, for the treatment of adults at high risk of hospitalization or death from COVID-19 via IV administration. In October 2020, the trial continued into Phase 3 based on a positive evaluation of the safety and tolerability data. In March 2021, we announced an Independent Data Monitoring Committee recommended the Phase 3 COMET-ICE trial be stopped for enrollment due to evidence of profound efficacy. Later in March 2021, we submitted an EUA request to the FDA for 500 mg IV of sotrovimab based on the interim analysis of efficacy and safety data from COMET-ICE.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the FDA granted an EUA to sotrovimab for the early treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and at high risk for progression to severe COVID-19, including hospitalization or death. We also received a positive scientific opinion from the Committee for Human Medicinal Products in the European Union, or EU, for sotrovimab in May 2021. In June 2021, we announced confirmatory full results for the Phase 3 COMET-ICE trial, which resulted in an adjusted relative risk reduction of 79% (p&lt;0.001) in all-cause hospitalization for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. In December 2021, the European Commission granted marketing authorization to Xevudy&#174; (sotrovimab) in the EU for the treatment of adults and adolescents at increased risk of progressing to severe COVID-19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During and following the fourth quarter of 2021, we announced preclinical data generated through pseudovirus testing demonstrating that sotrovimab retains neutralizing activity against the highly divergent Omicron variant (B.1.1.529). In February 2022, we published pseudovirus data demonstrating a 16-fold shift in neutralization activity against the Omicron BA.2 subvariant. Our BA.2 results were derived from 10 independent experiments that were conducted using an optimized pseudovirus assay. This is the same assay that was used to generate data for previous variants. These data have been shared with regulatory agencies around the world. Initial feedback from the FDA question our conclusion that the 500 mg IV dose of sotrovimab retains activity against the BA.2 Omicron subvariant based on our current modeling assumptions, and the FDA has asked for additional data to support our position. The FDA also requested safety data for higher doses. Both have been provided to the FDA and we are awaiting further correspondence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Health Care Provider Fact Sheet was recently updated to show that sotrovimab&#x2019;s neutralization activity was reduced an average fold change in EC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> value of 16-fold against the SARS-CoV-2 Omicron B.1.1.529/BA.2 spike variant compared to wild-type. The Fact Sheet also noted that the clinical relevance of the 16-fold reduction in sotrovimab activity against the SARS-CoV-2 Omicron B.1.1.529/BA.2 variant is unknown. As of February 28, 2022, the FDA noted on its EUA website that sotrovimab is currently authorized in all U.S. regions until further notice by the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In an effort to facilitate broader patient access through IM administration, we also conducted two IM trials. In February 2021, we initiated COMET-Patient SafEty, TolerAbility, PharmacoKinetics, or COMET-PEAK, a Phase 2 trial, evaluating an IM formulation of sotrovimab in low-risk adults with mild to moderate COVID-19. In June 2021, we initiated COMET-Treatment of Acute COVID-19 with Intramuscular monocLonal antibody, or COMET-TAIL, a Phase 3 trial in adults at high risk of hospitalization or death. In November 2021, we announced that the COMET-TAIL Phase 3 trial&#x2019;s primary endpoint had been met, with headline data demonstrating that IM-administered sotrovimab was non-inferior to IV administration for high-risk populations. In January 2022, we filed an amendment to sotrovimab&#x2019;s EUA to include IM administration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and GSK plan to submit a Biologics License Application, or BLA, for sotrovimab to the FDA in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and GSK continue to work actively with governments and payors around the world to make sotrovimab available to patients in need. Sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name Xevudy&#174;) in more than 40 countries, and we have received binding agreements for the sale of approximately 1.7 million doses of sotrovimab worldwide.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Prophylaxis</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are supporting multiple clinical trials evaluating whether sotrovimab, administered as prophylaxis, can help prevent symptomatic COVID-19 in uninfected immunocompromised adults. Two Phase 3 trials are expected to start in the second quarter of 2022. One is a platform trial and one is a company sponsored trial, COVID-19 Monoclonal antibody Efficacy Trial &#x2013; Stop Transmission of Acute SARS-COV-2, or COMET-STAR. The primary endpoint for both trials is incidence of symptomatic PCR-confirmed COVID-19. The analysis of the primary endpoint of COMET-STAR will be event driven, and could be as early as the second half of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Hospitalized treatment</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we initiated Therapeutics for Inpatients with COVID-19, or TICO, a Phase 3 trial of sotrovimab for the treatment of hospitalized adults with COVID-19 as part of a sub-trial of the National Institutes of Health&#x2019;s, or NIH, Accelerating COVID-19 Therapeutic Interventions and Vaccines, or ACTIV, Program, specifically ACTIV-3. In March 2021, we announced that the sotrovimab arm of the NIH&#x2019;s ACTIV-3 clinical trial met initial pre-specified criteria, and no safety signals were reported. Based on sensitivity analyses of the available data, the independent Data and Safety Monitoring Board recommended the sotrovimab arm be closed to enrollment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, sotrovimab entered the Randomized Evaluation of COVID-19 Therapy, or RECOVERY, trial, a Phase 3 trial in the U.K. evaluating standard of care alone versus usual standard of care plus a single dose of sotrovimab given IV. Initial data is expected in the second half of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-7832.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, we initiated a Phase 1b/2a trial of VIR-7832 for the potential treatment of adults with mild to moderate COVID-19 as part of the U.K.'s National Health Service, or NHS, supported AGILE initiative. The dose-escalation Phase 1b part of the trial evaluates the safety and tolerability of single ascending doses of VIR-7832 for the treatment of mild to moderate COVID-19. The Phase 2a portion evaluates the safety and virologic activity of VIR-7832, as well as T cell responses to SARS-CoV-2 of VIR-7832 and sotrovimab. The Phase 1b trial is ongoing and no safety signals have been reported to date for the 50 mg, 150 mg, and 500 mg dose cohorts. The first patient in the Phase 2a portion of the trial was dosed in February 2022. Additional data are expected in the first half of 2022. In July 2021, VIR-7832's investigational new drug, or IND, application was cleared by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the advancement of our COVID-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19 mAbs, we and GSK have established a strategic manufacturing network, which will enable the manufacture of approximately two million doses of sotrovimab in the first half of 2022, and additional doses in the second half of 2022.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We are actively working to expand our capacity to increase supply through 2022 so that we can continue to serve more patients.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> See the section titled &#x201c;Manufacturing&#x201d; for a summary of our manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">activities and a description of the agreements with WuXi Biologics (Hong Kong) Limited, or WuXi Biologics, and Samsung Biologics Co., Ltd., or Samsung.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to sotrovimab and VIR-7832, we are preparing for future pandemics with coronavirus mAbs that have the potential to be even broader and more potent than sotrovimab, pan-coronavirus vaccines designed with the aim to be variant-proof (initial pre-clinical proof of concept achieved), and small molecules that have the potential to treat multiple respiratory diseases like COVID-19 and influenza (initial pre-clinical proof of concept achieved).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">HBV</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: According to the Hepatitis B Foundation, approximately 300 million people globally are chronically infected with HBV and approximately 900,000 of them die from HBV-associated complications each year. There is a significant unmet medical need for more effective therapies that lead to life-long control of the virus after a finite duration of therapy, which is the definition of a functional cure. For a registrational trial to demonstrate a functional cure, the formal endpoint accepted by the FDA is undetectable hepatitis B virus surface antigen, or HBsAg, defined as less than 0.05 international units per milliliter, or IU/ml, as well as HBV DNA less than the lower limit of quantification, in the blood six months after the end of therapy. Currently, a year-long course of pegylated interferon-alpha, or PEG-IFN-&#x3b1;, is the best available curative therapy. It has a low functional cure rate of approximately three to seven percent. Alternatively, suppressive therapy with nucleotide/nucleoside reverse transcriptase inhibitors, or NRTIs, is commonly used, but patients often require a lifetime of therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing VIR-2218 and VIR-3434 for the functional cure of HBV. Each of these product candidates has the potential to stimulate an effective immune response and also has direct antiviral activity against HBV. We believe that a functional cure for HBV will require an effective immune response in addition to antiviral activity based on the observation that severe immunosuppression can reactivate HBV disease. While monotherapy with VIR-2218 and VIR-3434 may provide a functional cure in some patients, we believe combination therapy will be necessary for a functional cure in many patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-2218</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subcutaneously administered H</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BV-targeting siRNA. By targeting a conserved region of the HBV genome, it is designed to inhibit the production of all HBV proteins: X, polymerase, S, and core. Suppression of HBV proteins, particularly HBsAg, is hypothesized to remove the inhibition of T cell and B cell activity directed against HBV, allowing VIR-2218 to potentially result in a functional cure. VIR-2218 was the first siRNA in the clinic to include Alnylam Pharmaceuticals, Inc.&#x2019;s, or Alnylam, Enhanced Stabilization Chemistry Plus, or ESC+, technology, which has the potential to enhance the therapeutic index.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2021, we announced clinical data from our Phase 2 trial of VIR-2218 alone and in combination with PEG-IFN-&#x3b1;. First, with VIR-2218 as monotherapy, the trial demonstrated a strong safety profile and a substantial, durable and dose dependent reduction of HBsAg through 48 weeks. Second, evaluating VIR-2218 alone and in combination with PEG-IFN-&#x3b1; for 12 weeks, more rapid and substantial declines in HBsAg compared to VIR-2218 alone were observed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we announced additional data evaluating VIR-2218 in combination with PEG-IFN-&#x3b1; for 24 weeks. New findings demonstrated that concurrent initiation of VIR-2218 and PEG-IFN-&#x3b1; therapy resulted in earlier and more substantial HBsAg reductions compared to VIR-2218 alone or with PEG-IFN-&#x3b1; following a VIR-2218 lead-in. Three participants achieved HBsAg loss below the lower limit of quantification by Week 24; two of three achieved anti-HBs seroconversion. Additional data are expected in the first half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2218 is also being evaluated in additional clinical trials with collaborators. Brii Biosciences Offshore Limited, or Brii Bio, continues to lead the Phase 2 trial of VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the treatment of chronic HBV infection. Initial data are expected in the second half of 2022. In December 2021, we and Gilead Sciences, Inc., or Gilead, initiated a Phase 2 clinical trial of VIR-2218 in combination with GS-9688 (selgantolimod), Gilead's investigational TLR-8 agonist, and nivolumab, an approved PD-1 inhibitor, in both nucleos(t)ide, or NUC- suppressed patients and viremic patients. Patients with HBV treatment experience also may receive tenofovir alafenamide fumarate, or TAF.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-3434</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational subcutaneously administered HBV-neutralizing mAb. By targeting a conserved region of HBsAg, it is designed to block entry of all 10 genotypes of HBV into liver cells called hepatocytes and reduce the level of virions and subviral particles in the blood. VIR-3434, which incorporates Xencor, Inc.'s, or Xencor, Xtend and other Fc technologies, has been engineered to potentially function as a T cell vaccine against HBV in infected patients, as well as to have an extended half-life. These modifications are intended to enhance its potential to result in an HBV functional cure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Building on the data previously disclosed in January and June 2021, in November 2021 we announced that a single dose of six mg, 18 mg, or 75 mg of VIR-3434 resulted in rapid HBsAg reductions in most participants within approximately</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one week post-dose, and the largest and most sustained reductions in HBsAg were observed in the 75 mg cohort. Additional data are expected in the first half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2021, we initiated the Phase 2 Monoclonal Antibody siRNA Combination against Hepatitis B, or MARCH, trial to evaluate the combination of VIR-2218 and VIR-3434 as a functional cure regimen for chronic HBV infection. Initial data are expected in the first half of 2022. As some of our clinical trial sites are in Ukraine and Moldova, we are monitoring the situation to determine any impact resulting from the current conflict in this region.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Influenza</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to the World Health Organization, or WHO, on average, each year the influenza virus is estimated to infect 1 billion people and to result in 290,000 to 650,000 deaths globally. According to the Centers for Disease Control and Prevention, or CDC, in the 2018-2019 flu season, despite the availability of the flu vaccine, approximately 36 million people were diagnosed with influenza, 500,000 people were hospitalized, and 34,000 people died from influenza in the United States alone. Influenza vaccines have historically had limited success, with an average efficacy of 40% overall, across all populations. This limited efficacy results from incomplete coverage against seasonal strains and the lack of an effective immune response in many individuals after receiving the vaccine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing VIR-2482 as a universal prophylactic for influenza A and have designed it to overcome both limitations of flu vaccines, which we believe will lead to meaningfully higher levels of protection against seasonal and pandemic strains of influenza A. We anticipate that the initial registration population for VIR-2482 will include individuals at high risk of influenza A complications, such as the elderly with chronic lung disease or congestive heart failure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, we signed a definitive collaboration agreement, or the 2021 GSK Agreement, with GSK to expand our existing</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> collaboration to include the research and development of new therapies for influenza and other respiratory viruses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See the section titled &#x201c;Our Collaboration, License and Grant Agreements&#x2014;Collaboration Agreements with GSK&#x201d; for a description of the 2021 GSK Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-2482</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational IM administered influenza A-neutralizing mAb. In vitro, VIR-2482 has been shown to neutralize all major strains of influenza A that have arisen since the 1918 Spanish flu pandemic and is designed as a universal prophylactic for influenza A. We believe that VIR-2482 has the potential to provide superior protection to flu vaccines and be able to be used year after year because it has broad strain coverage as opposed to the limited strain coverage generated by vaccines. We also believe that it provides passive immunity rather than relying on a person to generate active immunity via a functional immune response, an ability that is known to decline with age. VIR-2482 has been engineered to extend its half-life so that a single IM dose has the potential to last the entire flu season, which is typically five to six months long. VIR-2482 is estimated to have a half-life of 58 days based on preliminary data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, we initiated dosing in the Phase 1/2 clinical trial for VIR-2482. VIR-2482 has been well-tolerated in the approximately 100 healthy volunteers dosed in Phase 1. Anticipating an increase in the incidence of influenza in the Northern Hemisphere this coming winter, we expect to initiate a Phase 2 trial in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">HIV</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: According to the Joint United Nations Programme on HIV/AIDS, or UNAIDS, each year there are approximately 1.5 million new cases of HIV and approximately 700,000 HIV-related deaths globally. Current prevention approaches such as behavioral modification and pharmacological intervention have had only a modest effect on HIV transmission globally, leaving a high unmet medical need for a safe and effective vaccine for the billions of individuals who are or may become sexually active.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing VIR-1111 as a proof of concept HIV vaccine designed to elicit a type of immune response that is different from other vaccines. We anticipate the initial registration population for our eventual HIV vaccine will be individuals at high risk of contracting HIV.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-1111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is an investigational subcutaneously administered HIV T cell vaccine based on human cytomegalovirus, or HCMV. VIR-1111 has been designed to elicit T cells that recognize HIV epitopes that are different from those recognized by prior HIV vaccines and to stimulate a different and specific type of T cell immune response to HIV, known as an HLA-E restricted immune response. An HLA-E restricted immune response has been shown to be associated with protection of non-human primates, or NHPs, from simian immunodeficiency virus, or SIV, the NHP equivalent of HIV. VIR-1111 is a vaccine designed solely to establish proof of concept in a Phase 1 clinical trial to determine whether the unique immune response observed in NHPs can be replicated in humans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we initiated a Phase 1 trial of VIR-1111. No safety signals have been reported to date and we expect to have additional clinical data in the first half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Technology Platforms</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our four current technology platforms are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. We are using our platforms to advance sotrovimab and other current product candidates and generate additional product candidates for multiple indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Antibody Platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We have established a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. We identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. The fully-human antibodies that we discover may also be modified to enhance their therapeutic potential. We have applied these methods to identify mAbs for a range of pathogens including SARS-CoV-2, HBV, influenza A and influenza B virus, Ebola, respiratory syncytial virus, or RSV, malaria, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">clostridium difficile, Staphylococcus aureus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Klebsiella pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acinetobacter spp</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Examples of the power of this platform are Xevudy&#174; (sotrovimab, formerly known as VIR-7831), our anti-SARS-CoV-2 mAb, and Ebanga (ansuvimab-zykl, formerly known as mAb114), the anti-Ebola virus mAb identified by our scientists in collaboration with the NIH and others and marketed by Ridgeback Biotherapeutics LP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">T Cell Platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We are exploiting the unique immunology of HCMV, a commonly occurring virus in humans, as a vaccine vector to potentially treat and prevent infection by pathogens refractory to current vaccine technologies. This approach is based on fundamental observations made in NHPs, with rhesus cytomegalovirus, or RhCMV. HCMV is the most potent known inducer of T cell responses of any human virus and may induce potent and long-lasting T cell responses to a broader range of epitopes than observed for other viral vaccines. In addition, we can make proprietary modifications in the HCMV genome that we expect will elicit different types of pathogen-appropriate T cell responses. We term this approach &#x201c;immune programming.&#x201d; We believe that this platform may also have applicability beyond infectious diseases, to areas such as cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Innate Immunity Platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Moving beyond more traditional approaches that are used to evoke adaptive immunity or that directly target pathogens, where the development of resistance can occur, we plan to target host proteins as a means of creating host-directed therapies with high barriers to resistance. We believe that by leveraging the power of innate immunity, we can create medicines that break the &#x201c;one-drug-for-one-bug&#x201d; paradigm by producing &#x201c;one-drug-for-multiple-bugs.&#x201d; For example, we believe this platform can create a single product for respiratory viruses, such as SARS-CoV-2 and influenza. This is enabled using clustered regularly interspaced short palindromic repeats, or CRISPR, -based genomics, computational biology and machine learning to identify key host factors necessary for each pathogen&#x2019;s survival and the protective effects of the innate immune system. We then identify product candidates that may be able to safely target host proteins to block pathogen replication or induce innate immunity to control infection. We believe that this platform may also have applicability beyond infectious diseases.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">siRNA Platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We are harnessing the power of siRNA to inhibit pathogen replication, eliminate key host factors necessary for pathogen survival and remove microbial immune countermeasures. Our collaboration with Alnylam includes VIR-2218 for HBV and up to four additional programs for infectious diseases. This platform can leverage Alnylam&#x2019;s proprietary N-acetylgalactosamine, or GalNAc, delivery technology, for product candidates targeting the liver, allowing for subcutaneous administration and extended tissue half-life, as well as ESC+ technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Team</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have an industry-leading management team and board of directors with significant experience in immunology and infectious diseases and progressing product candidates from early stage research to clinical trials, regulatory approval and ultimately commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Chief Executive Officer, George Scangos, Ph.D., has spent over 30 years developing treatments in infectious disease, neuroscience and oncology, among other fields, and was previously the Chief Executive Officer of Biogen Inc., or Biogen, the Chief Executive Officer of Exelixis, Inc. and the President of Bayer Biotechnology.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Chief Scientific Officer, Herbert (Skip) Virgin, M.D., Ph.D., is a Member of the National Academy of Sciences, and was previously Chair of the Department of Pathology and Immunology at the Washington University School of Medicine, St. Louis, Missouri. Our Senior Vice President and Senior Research Fellow, Antonio Lanzavecchia, M.D., is a Member of the National Academy of Sciences, was a co-founder of Humabs Biomed SA, or Humabs, which we acquired in 2017, and was the Director of the Institute for Research in Biomedicine in Bellinzona, Switzerland. Our Chief Medical Officer, Phil Pang, M.D., Ph.D., was previously Chief Medical Officer of Riboscience LLC, and before that was the Harvoni</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">&#174;</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> project lead at Gilead, where he led</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the team responsible for worldwide regulatory approval. Our Executive Vice President and Chief Business Officer, Global, Johanna Friedl-Naderer, who is anticipated to start on March 2, 2022, was previously President of Europe, Canada &amp; Partner Markets for Biogen, where she served on the company's Global Leadership Team. Our Chief Technology Officer, Aine Hanly, Ph.D., was previously Vice President of Process Development for Amgen Inc., where she was accountable for clinical manufacturing and global supply of clinical trial materials. Our Senior Vice President of Regulatory Affairs and Program Leadership &amp; Management, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lynne Krummen, Ph.D., previously served in many roles at Genentech, Inc. and F. Hoffmann-La Roche AG, including Head of U.S. Technical Development, Global Head of Technical Regulatory for Biologics, Head of Process Development and Clinical Development Project Team Lead for Avastin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Our Chief Corporate Affairs Officer, Bolyn Hubby, Ph.D., was previously Chief Scientific Officer at Agenovir Corporation, which we acquired in 2018, and before that was the Vice President of Vaccines and Antimicrobials at Synthetic Genomics, Inc. Our Senior Vice President, General Counsel, Irene Pleasure, J.D., Ph.D., was previously Vice President of Intellectual Property at Achaogen, Inc. and before that held various positions at Genentech, Inc., including Senior Associate General Counsel and Head of Patents. Our Chief Administrative Officer, Steven Rice, was previously Chief Human Resources Officer at the Bill &amp; Melinda Gates Foundation, and before that was Executive Vice President of Global Human Resources at Juniper Networks, Inc. Our Chief Financial Officer, Howard Horn, was previously Vice President, Business Planning at Biogen, and before that was a senior consultant at McKinsey &amp; Company and an equity analyst at UBS Group AG.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our board of directors is composed of leaders: from academia, Nobel laureate Phillip Sharp, Ph.D.; from the biopharmaceutical industry, Jeffrey Hatfield, Robert Perez, Saira Ramasastry, Elliott Sigal, M.D., Ph.D., and our Chairman Vicki Sato, Ph.D.; from the life science investment community, Robert More, Robert Nelsen (a co-founder) and Dipchand (Deep) Nishar; and from government, Janet Napolitano.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The core elements of our business strategy include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Maximizing the impact of sotrovimab. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab has been granted EUA, temporary authorization or marketing approval in more tha</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n 40 cou</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ntries. We and GSK will continue to work actively with governments and payors around the world to make sotrovimab available to patients in need.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Rapidly advancing our pipeline</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Currently underway are two Phase 3 clinical trials, five Phase 2 clinical trials, and four Phase 1 clinical trials across four distinct therapeutic areas. We anticipate moving additional preclinical candidates into the clinic and initiating additional later-stage combination trials where applicable in the next 12-18 months. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Expanding our pipeline using our current technology platforms</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We are leveraging our four current technology platforms to discover and develop novel product candidates for COVID-19, HBV, influenza A virus, HIV and tuberculosis, or TB, as well as additional viral, bacterial, fungal and parasitic infections, and potentially cancers. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Acquiring or accessing new technology platforms and assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We continually evaluate external technology platforms and assets that may help us develop therapies to treat and prevent serious infectious diseases. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Scaling our capabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We are investing in our people, processes and systems across all functions of our company to ensure that we are able to take full advantage of our multiple product candidates and multiple technology platforms. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Enabling global access to our future medicines</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have established relationships with organizations seeking to make a global impact like the Bill &amp; Melinda Gates Foundation, the NIH, and the NHS to further enable and facilitate access to our future medicines and to support our clinical development efforts. We will continue to pursue additional relationships like these moving forward. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Pipeline</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current pipeline consists of a product and product candidates that address unmet needs caused by COVID-19, HBV, influenza A virus, and HIV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_1.jpg" alt="img61678762_1.jpg" style="width:672px;height:307px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.078125;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">*Sotrovimab for early treatment by IV currently has marketing approval, EUA or temporary authorization in &gt;40 countries; for sotrovimab for early treatment by IM, we and GSK recently filed an amendment request for an IM EUA with the FDA.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.078125;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">**Vaccine designed to establish proof of concept in Phase 1 clinical trial to determine whether unique immune response observed in non-human primates can be replicated in humans; ultimately, any candidates we advance as a potential HIV vaccine will require modifications to VIR-1111 before further clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Treatment and Prophylaxis for COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Summary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In response to the ongoing COVID-19 pandemic, we have moved rapidly, together with our collaborator GSK, to address this global health challenge. Our focus is on treating and preventing COVID-19, as well as potential future coronavirus outbreaks. To do so, we are developing differentiated mAbs like sotrovimab and VIR-7832, as well as vaccines and small molecules.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing sotrovimab and VIR-7832 for the treatment and prophylaxis of COVID-19.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Both sotrovimab and VIR-7832 are based on a parent antibody, S309, which was derived from samples previously gathered for research on pan-coronavirus-neutralizing mAbs. Preclinical and clinical data suggest that sotrovimab and VIR-7832 have the potential for &#x2018;dual-action&#x2019;, or the ability to block viral entry into healthy cells and an enhanced ability to clear infected cells. Both mAbs also bind to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for viral resistance to develop. Both mAbs have also been designed to have an extended half-life and to have doses low enough to allow for IM and IV administration. In addition, VIR-7832 has been designed to potentially enhance virus-specific T cell function, which could also help treat and/or prevent COVID-19 infection.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During and following the fourth quarter of 2021, we announced preclinical data generated through pseudovirus testing demonstrating that sotrovimab retains neutralizing activity against the highly divergent Omicron variant (B.1.1.529). In February 2022, we published pseudovirus data demonstrating a 16-fold shift in neutralization activity against the Omicron BA.2 subvariant. Our BA.2 results were derived from 10 independent experiments that were conducted using an optimized pseudovirus assay. This is the same assay that was used to generate data for previous variants. These data have been shared with regulatory agencies around the world. Initial feedback from the FDA question our conclusion that the 500 mg IV dose of sotrovimab retains activity against the BA.2 Omicron subvariant based on our current modeling assumptions, and the FDA has asked for additional data to support our position. The FDA also requested safety data for higher doses. Both have been provided to the FDA and we are awaiting further correspondence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Health Care Provider Fact Sheet was recently updated to show that sotrovimab&#x2019;s neutralization activity was reduced an average fold change in EC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> value of 16-fold against the SARS-CoV-2 Omicron B.1.1.529/BA.2 spike variant compared to wild-type. The Fact Sheet also noted that the clinical relevance of the 16-fold reduction in sotrovimab activity against the SARS-CoV-2 Omicron B.1.1.529/BA.2 variant is unknown. As of February 28, 2022, the FDA noted on its EUA website that sotrovimab is currently authorized in all U.S. regions until further notice by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name Xevudy&#174;) for the early treatment of COVID-19 in more than 40 countries, and we have received binding agreements for the sale of approximately 1.7 million doses worldwide. We and GSK continue to work actively with governments and payors around the world to make sotrovimab available to patients in need. We and GSK plan to submit a BLA for sotrovimab to the FDA in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also evaluating the use of sotrovimab in two additional indications: 1) to determine if sotrovimab can prevent symptomatic COVID-19 infection in uninfected immunocompromised adults or those who have a history of severe adverse reactions to COVID-19 vaccines, and 2) to evaluate if sotrovimab treatment can improve clinical outcomes in patients hospitalized with COVID-19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and GSK have established a strategic manufacturing network, which will enable the manufacture of approximately two million doses of sotrovimab in the first half of 2022, and additional doses in the second half of 2022. We are actively working to expand our capacity to increase supply through 2022 so that we can continue to serve more patients. See the section titled &#x201c;Manufacturing&#x201d; for a summary of our manufacturing activities and a description of the agreements with WuXi Biologics and Samsung.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-7832, an anti-SARS-CoV-2 mAb, is currently in a Phase 1b/2a trial for the potential treatment of adults with mild to moderate COVID-19 as part of the U.K.'s NHS-supported AGILE initiative. The Phase 1b trial is ongoing and no safety signals have been reported to date for the 50 mg, 150 mg, and 500 mg dose cohorts. The first patient in the Phase 2a portion of the trial was dosed in February 2022. Additional data are expected in the first half of 2022. In July 2021, VIR-7832&#x2019;s IND application was cleared by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to sotrovimab and VIR-7832, we are preparing for future pandemics with coronavirus mAbs that have the potential to be even broader and more potent than sotrovimab, pan-coronavirus vaccines designed with the aim to be variant-proof (initial pre-clinical proof of concept achieved), and small molecules that treat multiple respiratory diseases like COVID-19 and influenza (initial pre-clinical proof of concept achieved).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">However, there are no assurances that we will secure additional supply commitments from governments. In addition, COVID-19 treatment standards are susceptible to rapid changes in epidemiology and the emergence of new variants, thus, sotrovimab may be rendered inferior or obsolete in the future. The FDA may, under certain circumstances, revise or revoke an EUA. If our EUA is terminated or revoked, sotrovimab will no longer be available in the United States unless and until we have obtained FDA approval of a BLA for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disease Overview and Limitations of Current Standard of Care</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to the John Hopkins Coronavirus Resource Center, as of February 23, 2022, there were almost 429.0 million recorded infections and almost 6.0 milli</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on recorded deaths worldwide from COVID-19. To date, the FDA has granted either EUAs or marketing approvals to multiple vaccines, drugs and/or antibodies to prevent or treat COVID-19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For prophylaxis, despite the high efficacy of the COVID-19 vaccines, there are still populations in whom vaccine immunogenicity is suboptimal, such as the elderly with comorbidities, immunocompromised persons, or those who may not want or be able to tolerate vaccines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For early treatment, both mAbs and small molecules have shown strong efficacy data and have pros and cons around convenience and compliance. For example, for some patients and their physicians, IM or IV mAbs may be preferred to small molecules due to administration in a single treatment visit (&#x201c;one and done&#x201d;), concerns about compliance with small molecules (multiple pills, multiple times per day, over multiple days), and concerns about oral treatment initiation requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For hospitalized patients, there is still significant unmet need. Preliminary data suggest that COVID-19 mAbs may have a role in improving clinical outcomes such as decreasing intensive care unit stays and/or mortality in hospitalized patients who have severe or critical COVID-19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Importantly, the ongoing durability of current vaccines, small molecules, and mAbs in the setting of the continued emergence of variants like Omicron is uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sotrovimab for COVID-19</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Molecular Characteristics. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab is an investigational fully human IgG1 neutralizing anti-SARS-CoV-2 monoclonal antibody that has Fc modifications that are designed to improve bioavailability in the respiratory mucosa and increase half-life, and incorporates Xencor&#x2019;s Xtend</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> technology. Sotrovimab binds with high affinity to the receptor binding domain of the SARS-CoV-2 spike protein. It is designed to have dual-actions of neutralizing the virus by blocking viral entry into healthy cells, while also enhancing the ability to clear infected cells. Sotrovimab potently neutralizes live SARS-CoV-2 in vitro and in vivo, and binds to a highly conserved epitope that is shared with SARS-CoV-1, thus potentially leading to a wide breadth of sarbecovirus coverage and a higher barrier to resistance.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Sotrovimab&#x2019;s dose may allow for both IM and IV administration.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2/3 Trials of Sotrovimab.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COMET-ICE: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab was evaluated as a treatment in adults with mild to moderate COVID-19 at high risk of hospitalization or death. This trial was a Phase 2/3, randomized, double-blind, multi-center, placebo-controlled trial investigating IV infusion of 500 mg of sotrovimab in adults with mild to moderate COVID-19 at high-risk of progression to severe disease, who were not hospitalized and did not require oxygen. The trial included a lead-in phase to evaluate the safety and tolerability of sotrovimab, followed by an expansion phase with 1:1 randomization of sotrovimab and placebo. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated an adjusted relative risk reduction of 79% (p&lt;0.001) in hospitalization for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COMET-TAIL: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab was evaluated in a Phase 3, multi-center, randomized, open-label, non-inferiority trial of IM versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalized adult and pediatric patients (12 years of age and older). The trial included three arms: 500 mg of sotrovimab given IV, and two IM arms, consisting of 500 mg and a low dose of 250 mg. The trial enrolled a total of 983 patients up to seven days after onset of symptoms. The trial&#x2019;s primary endpoint was met, and headline data demonstrated that IM-administered sotrovimab was non-inferior to IV administration for high-risk populations. In February 2022, topline data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2022), and we plan to submit the full COMET-TAIL data set to a peer-reviewed journal for publicatio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n in the first half of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COMET-PEAK: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab was evaluated in a Phase 2, multi-center, randomized, double-blind, two-part, parallel group trial designed to compare 1) the safety, tolerability and pharmacokinetics of second-generation sotrovimab manufactured material to first-generation sotrovimab manufactured material intravenously, and 2) the viral kinetics and safety of IV administration compared to IM administration of sotrovimab in low-risk adults with mild to moderate COVID-19. Data available to date from open label Part B of the trial (500 mg IV vs. 500 mg IM) demonstrated equivalence on the virological response between the IM and IV arms, while also showing an acceptable tolerability profile for IM with only 10/82 participants (12%) reporting any injection site reaction, all of which were low grade (Grade 1).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on the data from the COMET-TAIL and COMET-PEAK trials, in January 2022 we submitted an application to the FDA requesting an amendment to the EUA for sotrovimab to include IM administration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">RECOVERY: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab is being evaluated in a randomized, controlled, open-label, platform trial assessing several possible treatments in patients hospitalized with COVID-19 in the U.K. Trial participants who are hospitalized with COVID-19 are eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus a single dose of sotrovimab given IV. Initial data are expected in the second half of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COMET-STAR:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> This is a planned Phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate IV sotrovimab as prophylaxis for COVID-19. The primary endpoint of this trial is incidence of symptomatic PCR-confirmed COVID-19. Enrollment is planned to initiate in the second quarter of 2022. The analysis of the primary endpoint of COMET-STAR will be event driven, and could be as early as the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-7832 for COVID-19</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Molecular Characteristics. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-7832 is identical to sotrovimab, except that VIR-7832 contains additional modifications in the Fc domain that are designed to further enhance its effector function, such as antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, abrogate C1q binding, as well as elicit enhanced T cell and antibody responses. VIR-7832 incorporates Xencor&#x2019;s Xtend</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and other Fc technologies. These additional modifications may increase potency and induce a &#x201c;vaccinal&#x201d; effect (the induction of antigen-specific T cell responses) in patients with COVID-19.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1b/2a Trial of VIR-7832. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-7832 is being evaluated as part of the U.K.-based, NHS-supported AGILE initiative. The Phase 1b portion of the trial is a double-blinded, randomized, first-in-human dose-escalation trial of VIR-7832 in which adults with mild to moderate COVID-19 infection are randomized to VIR-7832 or placebo in a 3:1 ratio. The primary objective of Phase 1b is to determine the safety and tolerability of single ascending doses of VIR-7832 for the treatment of mild to moderate COVID-19. No concerning safety signals have been reported for the 50 mg, 150 mg and 500 mg dose cohorts to date. The Phase 2a portion of the trial is evaluating 500 mg of VIR-7832, 500 mg of sotrovimab and placebo, randomized in a 2:2:1 ratio in participants with mild to moderate COVID-19. The primary objective of the double-blinded, placebo-controlled, randomized Phase 2a is to investigate the safety and virologic activity of VIR-7832 compared to sotrovimab in patients with mild to moderate COVID-19 infection. Immunologic parameters, such as T-cell responses to SARS-CoV-2, will also be exam</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ined. Additional data are expected in the first half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Functional Cure for HBV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Summary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing VIR-2218 and VIR-3434 for the functional cure of HBV. Each of these product candidates has the potential to stimulate an effective immune response and also has direct antiviral activity against HBV. We believe that a functional cure for HBV will require an effective immune response, in addition to antiviral activity, based on the observation that severe immunosuppression can reactivate HBV disease. While monotherapy with VIR-2218 and VIR-3434 may provide a functional cure in some patients, we believe combination therapy will be necessary for a functional cure in many patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2218, an HBV-targeting siRNA, is currently </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in a Phase 2 clinical trial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In Parts A to C of the trial, 37 healthy volunteers and 24 patients with chronic HBV on NRTIs received VIR-2218. The data suggest that VIR-2218 is generally well-tolerated in healthy volunteers given as a single dose up to 900 mg and in patients given as two doses of 20 mg, 50 mg, 100 mg or 200 mg each dose. The data also demonstrate substantial, durable, dose dependent reductions in HBsAg in patients at doses ranging from 20 mg to 200 mg, which are durable at the higher doses through 48 weeks. Parts D and F evaluating six doses of 200 mg of VIR-2218 with PEG-IFN-&#x3b1; showed rapid and substantial declines in HBsAg levels after 24 weeks of treatment compared to VIR-2218 alone. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2218 is also being explored in additional clinical trials with collaborators. Brii Bio continues to lead the Phase 2 trial of VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the treatment of chronic HBV infec</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">tion. Initial data are expected in the second half of 2022. In December 2021, we and Gilead initiated a Phase 2 clinical trial of VIR-2218 in combination with GS-9688 (selgantolimod), Gilead's investigational TLR-8 agonist, and nivolumab, an approved PD-1 inhibitor, in both NUC-suppressed patients and viremic patients. Patients with HBV treatment experience also may receive TAF.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-3434, an HBV-neutralizing mAb, is currently in a Phase 1 clinical trial. Two analyses from our ongoing Phase 1 trial showed no safety signals in healthy volunteers dosed with up to 3,000 mg, and a rapid reduction in HBsAg levels one week after subcutaneous administration of a single dose of six to 75 mg of VIR-3434 to virally suppressed patients with chronic HBV infection. The largest and most sustained reductions in HBsAg were observed in the 75 mg cohort. In July 2021, we initiated the Phase 2 MARCH trial to evaluate the combination of VIR-2218 and VIR-3434 as a functional cure regimen for chronic HBV infection. Initial data are expected in the first half of 2022. As some of our clinical trial sites are in Ukraine and Moldova, we are monitoring the situation to determine any impact resulting from the current conflict in this region.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disease Overview and Limitations of Current Standard of Care</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to the Hepatitis B Foundation, approximately 300 million people globally are chronically infected with HBV. In the United States, up to two million people are chronically infected with HBV. Chronic HBV can lead to many serious complications, including liver scarring, liver failure and liver cancer. Globally, approximately 900,000 people die each year from HBV-associated complications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The most commonly used therapy for chronic HBV is life-long suppressive therapy with NRTIs, like tenofovir or entecavir. Of the hundreds of millions of people with chronic HBV worldwide, only an estimated two percent of patients are currently taking this suppressive therapy. NRTIs prevent HBV ribonucleic acid, or RNA, from being transcribed into HBV deoxyribonucleic acid, or DNA, which is a process known as reverse transcription. NRTIs therefore have little to no direct impact on covalently closed circular DNA, or cccDNA, the reservoir for HBV. It has been reported that after a year of therapy with NRTIs, zero to three percent of patients experience a functional cure. Additionally, NRTIs reduce, but do not eliminate, the risk of HBV associated liver failure and liver cancer. Despite its low utilization rate, suppressive therapy with NRTIs for HBV represented over a billion-dollar market in 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An alternative treatment option for chronic HBV is a year-long course of PEG-IFN-&#x3b1; therapy, which results in a functional cure approximately three to seven percent of the time. The mechanisms by which PEG-IFN-&#x3b1;, an immune cytokine, achieves a functional cure are not known, but there is additional evidence supporting the need for immune stimulation to achieve a functional cure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HBV Life Cycle and Undetectable HBsAg as a Clinical Endpoint</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The viral life cycle of HBV is shown in the figure below. After infecting a cell, the virus forms cccDNA. This form of HBV DNA is located in the nucleus of hepatocytes and acts like a mini-chromosome. HBV DNA can also integrate into the patient&#x2019;s DNA. This form of HBV DNA is known as integrated DNA, or intDNA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_2.jpg" alt="img61678762_2.jpg" style="width:287px;height:340px;" />&#160;</p>
  <p style="margin-left:5.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">HBV lifecycle with inhibition of processes by currently available therapies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Arrows indicate viral life cycle process. Perpendicularly-ended lines indicate inhibition of viral process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HBV releases infectious virions and subviral particles, or SVPs, from infected cells. Both virions and SVPs include forms of an HBV protein called HBsAg, a blood biomarker that indicates that the HBV cccDNA and/or intDNA in that patient&#x2019;s hepatocytes are actively making HBV RNA and HBV proteins. For a registrational trial to demonstrate a functional cure, the formal endpoint accepted by the FDA, is undetectable HBsAg, defined as less than 0.05 international units per milliliter, or IU/ml, as well as HBV DNA less than the lower limit of quantification, in the blood six months after the end of therapy. Achievement of this endpoint has been shown to predict improved clinical outcomes and the lack of need for further therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-2218 for HBV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Molecular Characteristics. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2218 is an investigational, single siRNA targeting a conserved sequence of HBV that allows for predicted activity against 99.7% of the strains of HBV, including all 10 HBV genotypes. Because this conserved sequence falls within a specific region of the X gene of HBV that exists within all four HBV RNA transcripts, VIR-2218 is able to degrade each transcript, and consequently decrease the expression of all proteins produced by the virus: X, polymerase, S, and core. VIR-2218 is thus potentially a broad-spectrum, potent antiviral.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HBV DNA can become integrated into human DNA as intDNA. Because VIR-2218 targets a region of HBV that is conserved in the large majority of HBV intDNA, this single siRNA is predicted to be able to prevent the production of HBV proteins derived from intDNA, as well as the production of all other HBV proteins from cccDNA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that the large amount of HBV protein that is transcribed in liver cells can suppress the immune system. There are at least two potential mechanisms by which suppression occurs. The first mechanism is T cell</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">tolerance and exhaustion by the presentation of intracellular HBV antigens on hepatocytes. The second is the large quantities of HBV proteins that are released into the blood, especially HBsAg, which may also be immunosuppressive. By directly reducing the amount of HBV proteins made, VIR-2218 has the potential to decrease the ability of HBV to suppress the immune system&#x2014;in effect removing a brake on the immune system. In mice models, siRNAs that are able to reduce HBsAg expression can transform an otherwise ineffective therapeutic HBV vaccine into one that can functionally cure such mice of HBV, suggesting that HBsAg suppression has the ability to enhance the immune response against HBV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that VIR-2218 is the only HBV-targeting siRNA currently in development that includes ESC+ technology. We believe this technology may be able to enhance the potential safety of VIR-2218.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1/2 Trial of VIR-2218.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> VIR-2218-1001 is an adaptive clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of VIR-2218. The current trial design of VIR-2218-1001 is shown below. We initiated dosing of the Part A portion of the trial for VIR-2218 in November 2018.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_3.jpg" alt="img61678762_3.jpg" style="width:671px;height:304px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Status of VIR-2218-1001 trial in healthy volunteers and patients with chronic HBV infection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">. Arrows indicate trial progression. HBeAg- = hepatitis B virus e-antigen negative; HBeAg+ = hepatitis B virus e-antigen positive; MAD = multiple ascending dose; SAD = single ascending dose; SC = subcutaneous.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This trial currently has completed enrollment of 81 subjects across all three parts. Part A is a single ascending dose design in healthy volunteers. Parts B and C are multiple ascending dose designs in patients with chronic HBV on NRTIs. Patients in Part B are hepatitis B early antigen negative, or HBeAg negative, and patients in Part C are hepatitis B early antigen positive, or HBeAg positive. Patients in Parts B and C receive two doses of VIR-2218, four weeks apart.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HBeAg positive patients are generally younger, and thought to have more preserved immune function, as compared to HBeAg negative patients who are generally older and have experienced greater immune exhaustion. HBeAg negative patients are also thought to have larger amounts of intDNA compared to HBeAg positive patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary endpoints across Parts A-C of the trial are safety and tolerability. Key secondary endpoints in Parts B and C include the maximum reduction of serum HBsAg from baseline until Week 16 and the number of patients with HBsAg loss or anti-hepatitis B surface antibody seroconversion. Patients with chronic HBV who experience a greater than 10% decline from baseline at Week 16 in HBsAg will be followed for up to 32 additional weeks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Trial Status.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> VIR-2218-1001 is an ongoing clinical trial. 49 healthy volunteers enrolled in Part A of the trial. Each Part A completed cohort includes six subjects receiving VIR-2218 and two subjects receiving placebo. All cohorts have completed dosing and follow-up. In the 400 mg cohort, a replacement subject was enrolled due to a subject who voluntarily withdrew from the trial. The 900 mg cohort was designed to assess the maximum tolerated dose of VIR-2218.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In Part B of the trial, 24 patients with chronic HBV who are HBeAg negative have been enrolled. Each Part B completed cohort includes three patients receiving VIR-2218 and one patient receiving placebo. All cohorts have completed dosing and have completed follow-up.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In Part C of the trial, eight patients with chronic HBV who are HBeAg positive have been enrolled. Each completed cohort includes three patients receiving VIR-2218 and one patient receiving placebo. All cohorts have completed dosing and have completed follow-up.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Data.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Across healthy volunteers and chronic HBV patients, VIR-2218 has been generally well-tolerated. No clinically significant alanine transaminase or ALT abnormalities, which are a marker of liver inflammation, have been observed. In the Part A 900 mg cohort, asymptomatic Grade 1 ALT elevations with no associated changes in bilirubin, or other markers of liver function, have been observed. Three serious adverse events, or SAEs, have been reported, all in Part B. The first, a Grade 2 headache, resolved with intravenous fluids and non-opioid pain medications. This patient had additional symptoms of fever, nausea, vomiting and dehydration, assessed by us as consistent with a viral syndrome. The second SAE, a Grade 4 depression, occurred over 50 days after the last drug dose was administered, and was assessed by us as not related to VIR-2218. The third SAE, a patient suicide, occurred 241 days after the last dose of study drug and was assessed by us as not related to VIR-2218. Three Grade 3 adverse events of upper-respiratory tract infection, chest pain and low phosphate levels in the blood have also been reported. We did not consider any of these Grade 3 events as related to VIR-2218.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biologic activity of VIR-2218 was assessed by declines in HBsAg. The activity of VIR-2218 through Week 48 for each dose level is shown in the graph below. For Parts B and C, the average baseline HBsAg levels were 3.3 log</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IU/mL and 3.9 log</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IU/mL, respectively. The average decline in HBsAg across HBeAg negative and HBeAg positive subjects at Week 16 was 1.5 log</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or an approximately 32-fold reduction. The declines observed in HBsAg at Week 16 ranged from 0.97 log</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to 2.2 log</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or an approximately nine to 160-fold reduction, after two 200 mg doses of VIR-2218 given four weeks apart. </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The average HBsAg level at Week 16 was 314 IU/mL, with half of the patients achieving HBsAg values &lt; 100 IU/mL and 5/6 achieving HBsAg values &lt; 1000 IU/mL. Five of the 12 patients that achieved HBsAg values of &lt;100 IU/mL maintained it through Week 48. Therefore, even though HBsAg levels gradually rebounded, overall, a durable effect was observed.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of VIR-2218 to result in substantial and durable declines in HBsAg after only two doses suggests that VIR-2218 has the potential to play an important role in the functional cure of chronic HBV. We have initiated and plan to initiate additional clinical trials evaluating VIR-2218 in combination with other immunomodulatory agents.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_4.jpg" alt="img61678762_4.jpg" style="width:672px;height:258px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Change from Baseline in HBsAg following administration of VIR-2218</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">. Each line represents the average decline from baseline in HBsAg  for VIR-2218 for each dosing level or pooled placebo in Parts B and C.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-3434 for HBV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Molecular Characteristics and Preclinical Data</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. VIR-3434 is an investigational mAb targeting a conserved region on HBsAg that allows it to neutralize strains from all 10 HBV genotypes. VIR-3434 specifically targets the antigenic loop, or AGL, on HBsAg. The AGL helps the virus bind to hepatocytes and subsequently infect these liver cells. By binding to the AGL, VIR-3434 prevents viral entry, which prevents the spread of HBV to uninfected hepatocytes. VIR-3434, through a process called opsonization, also helps remove HBV virions and SVPs from the blood. Hepatitis B immunoglobulin, or HBIG, an approved therapy for preventing reinfection after transplantation and which consists of polyclonal antibodies against HBV, acts by similar mechanisms. In vitro, VIR-3434 demonstrates approximately 5000-fold greater potency than HBIG in neutralization assays. As shown in the figure below, VIR-3434 is better able to prevent the spread of HBV to uninfected cells in vivo compared to HBIG.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_5.jpg" alt="img61678762_5.jpg" style="width:486px;height:264px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Progression of infection in primary human hepatocytes with hepatitis B immune globulin or VIR-3434</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">. PHH = primary human hepatocytes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-3434 also has the potential to activate the immune system, via three different processes. First, due to specialized mutations in the Fc domain of VIR-3434, it has the potential to act as a T cell vaccine. VIR-3434, which incorporates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Xencor&#x2019;s Xtend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and other Fc technologies, has been engineered with mutations that enhance binding to the FcR IIa activating receptor and diminish binding to the FcR IIb inhibitory receptor. As such, VIR-3434 is designed to capture virions and SVPs, deliver such virions and SVPs to DCs, and instruct these DCs to mature and stimulate T cells that can eliminate HBV infected hepatocytes. Second, VIR-3434 has the potential to act via antibody-dependent cell cytotoxicity, or ADCC. In this process, by binding to HBsAg at the cell surface, VIR-3434 recruits natural killer cells to eliminate infected hepatocytes. The Fc domain of VIR-3434 has been engineered to promote ADCC. Third, by reducing the amount of HBsAg in the blood, VIR-3434 has the potential to remove a brake on the immune system by decreasing the ability of HBV to suppress it.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have also evaluated the antiviral activity of the combination of VIR-2218 and VIR-3434 in an adeno-associated virus-HBV mouse model. As shown in the figure below, VIR-2218 and VIR-3434 work together to reduce the level of HBsAg.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_6.jpg" alt="img61678762_6.jpg" style="width:612px;height:265px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">VIR-2218 and VIR-3434, which was modified to have a mouse mAb backbone for this experiment, administered alone or together result in reduced HBsAg in a mouse model</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1 Trial of VIR-3434.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> VIR-3434-1002 is an adaptive clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of VIR-3434. The current trial design of VIR-3434-1002 is shown below. We initiated dosing of the Phase 1 trial in May 2020.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Phase 1 clinical trial has four parts. Part A is a single ascending dose design in healthy volunteers. Parts B and C are single ascending dose designs in patients with chronic HBV on NRTIs. Patients in Part B will have HBsAg levels less than 1,000 IU/ml for the 6 mg cohort, or less than 3,000 IU/mL for the other cohorts. It is possible that patients with lower HBsAg levels will have a more profound response to VIR-3434 than patients with higher HBsAg levels. Patients with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HBsAg levels greater than or equal to 3,000 IU/ml may be evaluated in an optional Part C. In Part D, patients with HBV DNA greater than or equal to 1,000 IU/mL who are not currently receiving antiviral therapy will be evaluated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_7.jpg" alt="img61678762_7.jpg" style="width:672px;height:267px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">VIR-3434-1002 is an adaptive clinical trial design in healthy volunteers and patients with chronic hepatitis B virus infection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">. Arrows indicate trial progression. SC = subcutaneous. SAD = single ascending dose. IV = intravenous.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.36pt;font-family:Times New Roman;font-style:italic;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> The six mg SC cohort in Part B enrolled participants with screening HBsAg less than 1,000 IU/ml.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.36pt;font-family:Times New Roman;font-style:italic;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> The 18 mg SC cohort in Part C enrolled participants with any screening HBsAg.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary endpoints across all parts of the trial are safety and tolerability. The key secondary endpoint in Parts B and C is the maximum reduction of serum HBsAg from baseline. In Part D, an additional key secondary endpoint is the maximum change of HBV DNA from baseline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Data.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> To date, all Part A cohorts have completed dosing up to 3,000 mg administered intravenously. The trial&#x2019;s Safety Review Committee, or SRC, has reviewed blinded safety data for at least two weeks post dose from all Part A cohorts. Based on this data, VIR-3434 was generally well tolerated in healthy volunteers with no clinical safety concerns. The majority of adverse events, or AEs, were Grade 1, and no Grade &#x2265; 3 AEs or SAEs were reported. No clinically significant effects on laboratory or electrocardiogram parameters were observed. All dose levels were associated with an acceptable safety and tolerability profile, as determined through a blinded review of data by the SRC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we announced additional preliminary data from Part B in patients with chronic HBV on NRTIs receiving six mg, 18 mg, or 75 mg VIR-3434 or placebo. Blinded data for eight patients per cohort, two of whom received placebo and six of whom received a single dose of VIR-3434, showed that most patients rapidly achieved a &gt; 1 log</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> IU/mL decline in HBsAg within approximately 1 week post-dose, with most patients achieving HBsAg &lt; 100 IU/mL at nadir. The largest and most sustained reductions in HBsAg were observed in the 75 mg cohort, in which mean reductions were 1.96 log</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> IU/mL at nadir and 1.5 log</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> IU/mL at Day 29. VIR-3434 was generally well tolerated, and all adverse events were Grade 1 or 2. The ability of a single dose of VIR-3434 to markedly lower HBsAg demonstrates VIR-3434 has the potential to play an important role in the functional cure of HBV. Additional data are expected in the first half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other HBV Combinations and New Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2 Trial of VIR-2218 in combination with PEG-IFN-&#x3b1;.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> VIR-2218-1001 Parts D and F is a clinical trial evaluating the safety, tolerability, pharmacokinetics and antiviral activity of VIR-2218 alone and in combination with </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PEG-IFN-&#x3b1; in patients with chronic HBV infection on NRTIs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We initiated the dosing in the trial in July 2020. We decided not to pursue Part E evaluating 50 mg of VIR-2218.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2218-1001 Parts D and F will evaluate multiple doses of VIR-2218 200 mg, alone or in combination with PEG-IFN-&#x3b1; starting on Day 1 or at Week 12. The trial cohorts are shown below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_8.jpg" alt="img61678762_8.jpg" style="width:672px;height:290px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">VIR-2218-1001 Parts D and F are evaluating multiple doses of VIR-2218 alone or in combination with</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">PEG-IFN-&#x3b1; in patients with chronic hepatitis B virus infection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we announced additional data on our ongoing Phase 2 trial of 64 virally-suppressed adults with chronic HBV infection assigned to receive subcutaneously injected VIR-2218 alone or in combination with PEG-IFN-&#x3b1; for 24 weeks (cohort 1F). VIR-2218 in combination with PEG-IFN-&#x3b1; for 24 weeks from Day 1 resulted in a more rapid and substantial decline in HBsAg compared to VIR-2218 alone. Forty-eight of the 52 patients (92%) that completed 24 weeks in treatment achieved HBsAg &lt; 100 IU/mL, 3 of these participants had HBsAg &lt; LLOQ, including 2 that had anti-HBs seroconversion. The treatment regimen resulted in no new safety signals. The data continue to support the promising safety profile and potential durable response. Additionally, new findings also demonstrate that concurrent initiation of VIR-2218 and PEG-IFN-&#x3b1; therapy resulted in substantial HBsAg reductions compared to VIR-2218 alone or with PEG-IFN-&#x3b1; following a VIR-2218 lead-in. Additional data are expected in the first half of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2 Trial of VIR-2218 in combination with VIR-3434.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In July 2021, we initiated the Phase 2 MARCH trial to evaluate the combination of VIR-2218 and VIR-3434 as a functional cure regimen for chronic HBV infection. We believe VIR-2218 and VIR-3434 have the potential to act in concert by inhibiting virion production, removing potentially tolerogenic HBV proteins, and stimulating new HBV specific T cells. Initial data are expected in the first half of 2022. As some of our clinical trial sites are in Ukraine and Moldova, we are monitoring the situation to determine any impact resulting from the current conflict in this region.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_9.jpg" alt="img61678762_9.jpg" style="width:672px;height:192px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">VIR-3434 18-75 mg dosing in Part A, dosing TBD for Part B; VIR-2218 200 mg dose in Part B; PEG-IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">&#x3b1;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> 180 mcg dose in Regimen 5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">. QW= weekly; Q4W = every four weeks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">*Not exhaustive - additional cohorts may be added</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Collaborators. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, we and Gilead initiated a multi-center, open-label Phase 2 clinical trial which is designed to evaluate the safety, tolerability and efficacy of various combinations of VIR-2218, selgantolimod, nivolumab and TAF in adults with chronic HBV. The trial will enroll approximately 120 patients ages 18 to 65 who are either viremic or are virally suppressed on an approved HBV NUC reverse transcriptase inhibitor. Patients who are hepatitis B e antigen (HBeAg)-positive (an indicator of acute viral replication), as well as those who are HBeAg-negative, will be enrolled. The primary efficacy endpoint is the proportion of patients who achieve a functional cure (defined as HBsAg loss and HBV DNA &lt;20 IU/mL at follow-up week 24).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Brii Bio initiated a Phase 2 trial of VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the treatment of chronic HBV infecti</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on. Initial data are expected in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, in parallel with the above development programs, research efforts are underway to use our innate immunity platform to identify and disrupt the host proteins necessary for HBV cccDNA formation and stability, which we believe could result in a complete cure. We also have an HBV therapeutic vaccine that leverages our T cell platform in preclinical development. This exemplifies the potential value of combining outputs from our four technology platforms to complex infectious diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Universal Prophylaxis for Influenza A</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Summary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing VIR-2482 as universal prophylaxis for influenza A. VIR-2482 is a mAb that targets a conserved region of the influenza A hemagglutinin protein and consequently has the potential to prevent illness from any strain of influenza A, including seasonal and pandemic strains. In vitro, VIR-2482 has been shown to cover all major strains of influenza A that have arisen since the 1918 Spanish flu pandemic. Since flu vaccines have incomplete strain coverage and limited efficacy, the broad coverage of VIR-2482 may allow it to achieve higher protection levels and for it to be used year after year. In addition, because VIR-2482 is an antibody that can directly confer protection, it does not rely on a person to create his or her own antibodies. Thus, we believe VIR-2482 has the potential to be effective even in a person with a compromised immune system. VIR-2482 has been half-life engineered so that a single dose has the potential to last the entire flu season, which is typically five to six months long. VIR-2482 is currently in a Phase 1/2 clinical trial. VIR-2482 has been well-tolerated in the approximately 100 healthy volunteers dosed in Phase 1. Anticipating an increase in the incidence of influenza in the Northern Hemisphere this coming winter, we expect to initiate Phase 2 in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, we signed the 2021 GSK Agreement to expand our existing </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaboration to include the research and development of new therapies for influenza and other respiratory viruses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See the section titled &#x201c;Our Collaboration, License and Grant Agreements&#x2014;Collaboration Agreements with GSK&#x201d; for a description of the 2021 GSK Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disease Overview and Limitations of Current Standard of Care</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to the WHO, on average, each year the influenza virus is estimated to infect 1 billion people and results in 290,000 to 650,000 deaths globally. According to the CDC, in the 2018-2019 flu season, despite the availability of the flu vaccine, approximately 36 million people were diagnosed with influenza, 500,000 people were hospitalized, and 34,000 people died from influenza in the United States alone. Thus, more Americans died of influenza in the 2018-2019 flu season than from prostate cancer in all of 2019. The large majority of these influenza-related deaths occurred in the elderly and/or those with comorbidities at high risk for severe disease. These patients comprise a population with a high unmet need for better preventive measures. For example, there are 16 million Americans with a known diagnosis of chronic obstructive pulmonary disease, the care of whom is estimated to directly cost up to $49 billion annually. Up to 12% of chronic obstructive pulmonary disease acute exacerbations are thought to be attributable to influenza. Overall, it is estimated that the annual influenza-related economic burden is approximately $87 billion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are two major types of influenza virus: type A and type B. Influenza A has been associated with more severe illness and has been the source of all known influenza pandemics. A recent study of influenza hospitalized patients from 2016-2020 published by the BMC Infectious Diseases showed that 88% had influenza A and 12% had influenza B.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to the CDC, the efficacy of the seasonal flu vaccine has ranged from 10% to 60% over the past 16 years, with an average of 40%, overall, across all populations. The seasonal flu vaccine's efficacy in the elderly, defined as those 65 and older, has been found to be notably lower, in some flu seasons as low as 10%. The limited success rate of influenza vaccines has been attributed to two primary factors. First, flu vaccines have incomplete strain coverage and therefore often do not provide protection against all strains of influenza that circulate in a given season, despite being updated every year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Second, flu vaccines are active immunizations that rely on a person's own immune system to create protective influenza virus antibodies, and many individuals do not generate an effective immune response. Clinical and technological advances in flu vaccines, such as cell-based manufacturing, mRNA-based vaccines and higher dose administration, do not address these two fundamental limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-2482 for Influenza A</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Molecular Characteristics and Preclinical Data. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2482 is an investigational mAb targeting a functionally conserved epitope on the influenza A hemagglutinin protein located within the stem region. We believe that all strains of influenza, past and future, have and likely will contain this conserved epitope within the stem region. In preclinical studies, we have demonstrated that, in vitro, VIR-2482 covers all the major strains of influenza A that have arisen since 1918. Thus, unlike flu vaccines, whose incomplete strain coverage results in limited efficacy despite being updated every year, the broad coverage of VIR-2482 may allow it to achieve higher protection levels and to be used year after year. In addition, because VIR-2482 is an antibody that can directly confer protection, it does not rely on a person to create his or her own antibodies. Thus, we believe VIR-2482 has the potential to be effective irrespective of the status of a person&#x2019;s immune system.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Notably, in a 2019 clinical epidemiology study, it was observed that the presence of rare, stem-binding influenza antibodies correlated with protection from influenza infection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_10.jpg" alt="img61678762_10.jpg" style="width:548px;height:191px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">VIR-2482 targets a highly conserved region of the influenza virus and exhibits potency against the last century of influenza viruses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">. Following vaccination, most anti-influenza antibodies target the variable head region. VIR-2482 binds to the stem region which is highly conserved over time. HA = hemagglutinin.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While other stem-binding influenza A antibodies have been identified, we have demonstrated that VIR-2482 has the broadest coverage when compared to a large representative panel of stem-binding mAbs. In prophylactic lethal challenge studies of influenza A in mice, VIR-2482 was able to protect mice from death at VIR-2482 exposures we believe to be clinically relevant. We have also demonstrated that the parent form of VIR-2482, an antibody that has the same antibody binding domain (Fab) as VIR-2482, has, in general, greater potency, when compared to three other stem-binding mAbs, as shown in the figure below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_11.jpg" alt="img61678762_11.jpg" style="width:624px;height:276px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Neutralization potency of four stem-binding antibodies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">. VIR-2482, and three other third-party antibodies, CR9114, 39.29, and FI6v3, were tested for their neutralization potency against 24 representative strains. These strains were selected to cover the antigenic variation of the seasonal H1N1 and H3N2 strains back to 1938 and 1968, respectively, and strains from other subtypes that infected humans in past pandemics or that caused sporadic animal-derived outbreaks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We engineered the parent form of VIR-2482 to extend its half-life to create VIR-2482, which incorporates Xencor&#x2019;s Xtend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> technology. This half-life extension potentially allows for a single injection of VIR-2482 given at the start of the influenza season to maintain a protective concentration in the respiratory tract for the duration of the influenza season.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1/2 Trial of VIR-2482.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> VIR-2482-3001 is a clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of VIR-2482. The current trial design of VIR-2482-3001 is shown below. This trial is designed to include up to 2,860 healthy volunteers across the Phase 1 and Phase 2 portions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Phase 1 portion of this trial is a single ascending dose trial in healthy adult volunteers with endpoints of safety, tolerability, and pharmacokinetics, or PK, when VIR-2482 is administered IM. Healthy volunteers in the Phase 1 portion may receive a second dose, one year later, to evaluate for the possibility of anti-drug antibodies. The Phase 2 portion of this trial is planned to be a dose-ranging, double-blind, placebo-controlled trial in healthy adult volunteers. The primary efficacy endpoint of the Phase 2 portion is laboratory-confirmed influenza A illness with key secondary endpoints of severity and duration of illness due to influenza A.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">      </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_12.jpg" alt="img61678762_12.jpg" style="width:331px;height:241px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">VIR-2482-3001 clinical trial design in healthy adult volunteers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We initiated dosing of the Phase 1 portion of the trial in August 2019 and have completed enrollment of all four dose cohorts (60 mg, 300 mg, 1200 mg, and 1800 mg) and subjects remain in follow-up. Overall, VIR-2482 was well-tolerated and is estimated to have a half-life of 58 days based on preliminary clinical data. Anticipating an increase in the incidence of influenza in the Northern Hemisphere this coming winter, we expect to initiate the Phase 2 portion of the trial in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Vaccine for HIV Prophylaxis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Summary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing a vaccine to prevent HIV. We have designed VIR-1111 to elicit T cells that recognize HIV epitopes that are different from those recognized by prior HIV vaccines and to stimulate a different and specific type of T cell immune response to HIV, known as an HLA-E restricted immune response. An HLA-E restricted immune response has been shown to be associated with protection of NHPs from SIV. In December 2020, we initiated a Phase 1 trial for VIR-1111. VIR-1111 is a proof of concept vaccine, because, at minimum, changes to the vaccine antigen from HIV will be required before starting subsequent phases of clinical development. The need to alter the antigen within VIR-1111 or other aspects of the vaccine design to allow for further clinical development will require additional Phase 1 work with the altered product candidate. That Phase 1 clinical trial is currently estimated to begin two years after the commencement of the VIR-1111 Phase 1 clinical trial, adding approximately two years to any potential regulatory approval timeline for an HIV vaccine product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disease Overview and Limitations of the Current Standard of Care</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to UNAIDS, each year there are approximately 1.5 million new cases of HIV and approximately 700,000 HIV-related deaths globally. Unless treated, infection with HIV results in an almost universally fatal disease, acquired immune deficiency syndrome, or AIDS. According to the World Health Organization, almost 36 million people have died from HIV-related illnesses globally.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Highly effective HIV treatments are now available, but these medicines only suppress HIV and are not curative. They require life-long administration and carry the risk for viral breakthrough and resistance. Furthermore, while HIV prevention programs based on behavioral modification, pharmacological intervention, use of barrier devices and other methods continue to be developed, such approaches have had at most a modest effect on HIV transmission globally in high-risk populations. Therefore, we believe the most effective means of curbing the worldwide HIV epidemic would be a safe and effective vaccine for individuals who are or may become sexually active. We believe that the target population for an HIV vaccine is comprised of billions of individuals and is potentially larger than the target population for Gardasil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, a vaccine to prevent human papillomavirus and the cancers human papillomavirus causes, due to the higher lethality associated with HIV. In 2020, Gardasil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> revenue approximated $4.0 billion. Despite nearly 30 years of intensive efforts, no vaccine for HIV has been successfully developed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-1111 for HIV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Molecular Characteristics and Preclinical Data. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-1111 is a proof of concept T cell vaccine based on HCMV that is designed to elicit T cells that recognize parts of HIV epitopes that are different from those recognized by prior HIV vaccines, and to stimulate a different and specific type of T cell immune response to HIV, known as an HLA-E restricted immune response. In NHP models, T cell vaccines based on an RhCMV elicited T cells that recognized 3-4 times the number of epitopes compared to other vaccine platforms; the specific epitopes recognized were also different, as shown in the figure below. SIV is the NHP equivalent of HIV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_13.jpg" alt="img61678762_13.jpg" style="width:654px;height:343px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Number of epitopes recognized by T cells using RhCMV compared to other vaccine vector technologies or NHPs naturally achieving SIV control</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Each line represents a different NHP.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Each box denotes the relative location of the epitope within the antigen that is</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">recognized by the T cells elicited by that vaccine vector or SIV. The total number of epitopes recognized is shown on the right. RM = rhesus macaque; SIVmac239-controller = infected with a virulent strain of SIV; EP DNA/gag = electroporation of DNA expressing the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">SIV gag protein; Ad5/gag = Adenovirus type 5 expressing the SIV gag protein; MVA/gag = Modified vaccinia virus Ankara expressing the SIV gag protein.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, in such NHP models, introducing different mutations to RhCMV allows the vector to be programmed to elicit an HLA-E restricted immune response. An HLA-E restricted immune response has been shown to be associated with protection of NHPs from SIV. In these series of experiments, large groups of NHPs were given an RhCMV-based vaccine, which protected more than 50% of the NHPs from repeated exposure to SIV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0541666666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preliminary data suggest the ability to predict which NHPs will be protected from SIV after administration of the RhCMV-based vaccine. This is made possible using transcriptomic signatures, a blood test that evaluates how cells in the body respond to the vaccine. Transcriptomic signatures will be analyzed in human clinical trials. If protection effectiveness is found to be less than 100%, such data may allow us to predict who will be protected as well as to generate next-generation vaccines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1 Trial of VIR-1111. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-1111-2001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is a multiple ascending dose clinical trial designed to evaluate the safety, tolerability, reactogenicity and immunogenicity of VIR-1111 in CMV-positive healthy adult volunteers. The immunogenicity evaluation includes an assessment of the breadth and nature of the T cell response to the vaccine. The current trial design of VIR-1111-2001 is shown below. We initiated a Phase 1 clinical trial for VIR-1111 in December 2020. The manufacture and early clinical development of VIR-1111 is funded by the Bill &amp; Melinda Gates Foundation. Modifications to VIR-1111 will be required before subsequent phases of clinical development, as VIR-1111 is a proof of concept vaccine and will not in its current format result in a commercial product. No safety signals have been reported to date and we expect to have additional clinical data in the first half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_14.jpg" alt="img61678762_14.jpg" style="width:447px;height:64px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">VIR-1111-2001 is a multiple ascending dose escalation trial in CMV seropositive, HIV uninfected healthy adult volunteers. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Arrows indicate trial progression. CMV = cytomegalovirus, HIV = human immunodeficiency virus, SC = subcutaneous, ffu = focus forming units</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Technology Platforms</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Platforms for the Creation of Transformative Medicines for Infectious Diseases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have purposefully assembled a portfolio of technology platforms that we believe will, individually or in combination, allow us to stimulate and enhance the immune system in innovative ways and to exploit the vulnerabilities of pathogens. Our current platforms are focused on antibodies, T cells, the innate immune response and siRNAs. We have assembled these platforms through internal development, collaborations and acquisitions. We are using our platforms, and continue to evaluate others, to advance our current product candidates and generate additional product candidates for multiple indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We follow the science to select the modality, or combination of modalities, that gives us the highest chance of success for a specific infection in a given patient population. The diversity of our different platforms allows us to select the best modality or modalities for a given clinical need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Antibody Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are using specialized mAbs to treat or prevent rapidly evolving and/or previously untreatable pathogens. These mAbs act in a variety of ways, including direct pathogen neutralization and immune system stimulation. We combine high-throughput, rapid isolation of rare, highly potent, broad-spectrum and fully human antibodies with targeted engineering to enhance their therapeutic potential. We expect that these specialized mAbs can be administered to transfer protective immunity to all at-risk individuals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect the following benefits from our antibody platform:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective regardless of an individual&#x2019;s ability to generate his or her own immune response </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diminished likelihood of self-reactivity because they are selected in humans </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Broad coverage of most or all strains of a pathogen, or even multiple pathogens </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">High affinity binding to conserved pathogen antigens, resulting in a high barrier to resistance </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Longer half-life than naturally occurring antibodies </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potential to induce a vaccinal effect, i.e., to elicit continued protection even after the mAb is no longer present </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab (previously VIR-7831), VIR-7832, VIR-3434 and VIR-2482 were generated using our antibody platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_15.jpg" alt="img61678762_15.jpg" style="width:623px;height:173px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use a proprietary antibody screening technology that allows us to characterize the antibodies produced from hundreds of millions of B cells derived from survivors of an infection to identify those rare antibodies that have the characteristics needed to create an effective medicine. Rare characteristics include, for example, the ability to bind to a highly conserved antigen within a pathogen and the ability to neutralize multiple different pathogens. We refer to this technology as High Throughput Isolation since we are able to screen hundreds of millions of B cells to find rare antibodies in just weeks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Following isolation, we clone the antibody genes and express the resulting fully human antibody for further trials, engineering and development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have applied these methods to identify mAbs for a range of pathogens including SARS-CoV-2, HBV, influenza A and influenza B virus, Ebola, RSV, malaria, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">clostridium difficile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Staphylococcus aureus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Klebsiella pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acinetobacter spp</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Examples of the power of this platform are Xevudy&#174; (sotrovimab, formerly known as VIR-7831), our anti-SARS-CoV-2 mAb, and Ebanga (ansuvimab-zykl, formerly known as mAb114), the anti-Ebola virus mAb identified by our scientists in collaboration with the NIH and others and marketed by Ridgeback Biotherapeutics LP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Precision Antibody Engineering to Create the Best Medicines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our strategy is to optimize both the Fab and Fc domains of a mAb to generate the best medicine to treat or prevent infection. Having isolated a rare, fully human antibody via High Throughput Isolation, we then engineer as desired both parts of the mAb, the Fab and Fc domains, to enhance efficacy, potency and manufacturability. The Fab portion binds to the protective antigen on the pathogen. The Fc portion binds to effector proteins and cells in the body to engage the immune system in killing and clearing the infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fab engineering is performed to further increase mAb potency and breadth of coverage. mAb potency and breadth are based on the epitope bound, affinity of binding and valency. In some cases, it may be valuable to create mAbs that bind to more than one epitope, so-called &#x201c;multi-specific&#x201d; mAbs, by engineering the Fab region. There are many approaches to creating multi-specific antibodies, and we are exploring a number of them, including some that naturally occur in people. We believe that naturally occurring multi-specific antibodies can be leveraged to create new and potent therapeutics and to enhance antibody prophylaxis of disease, and have the potential for higher manufacturing yields and better pharmacokinetics in patients, as compared to artificial multi-specific formats currently being developed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fc engineering selects and optimizes the specific ways in which mAbs engage Fc receptors, or FcRs, which in turn govern &#x201c;effector functions&#x201d; such as the half-life of the antibody and the way that the immune system is recruited by the mAb to fight infection. Effector functions can be enhanced or reduced via Fc mutations that alter the binding affinity of the Fc domain of a mAb to the various FcRs, based on a detailed understanding of the role of individual FcRs in half-life and immunity. Examples of immunity that can be altered in this way include the recruitment of serum proteins to infected areas, phagocytosis and destruction of viruses and viral particles, the killing of virus-infected cells through a process known as ADCC and the presentation of antigens to elicit B and T cell immunity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Antibodies as T Cell Vaccines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are using Fc engineering to create antibodies that are designed to not only directly treat or prevent infection but also to immunize an infected individual against future infections. We refer to this property as a vaccinal effect, i.e., eliciting continued protection even after the mAb is no longer present. This technology benefits from the fact that FcRs on specialized antigen-presenting cells, which are called dendritic cells, or DCs, internalize complexes of antibody and antigen. Our strategy leverages the observation that different FcRs on antigen presenting cells can bind different parts of the Fc portion of the mAb. By engineering the Fc region, we can select which FcRs interact with the antibody-antigen complex to generate activated DCs that we believe can effectively induce T cell immunity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_16.jpg" alt="img61678762_16.jpg" style="width:585px;height:253px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Design and mechanism of vaccinal antibodies intended to induce enhanced immunity through induction of T cells</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">The Fc portion of mAbs interacts with FcRs on DCs to trigger uptake of antigen and induction of T cells. Engineering of the Fc portion of the mAb is predicted to increase the induction of T cells by these DCs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specific vaccinal mutations in the Fc domain can enhance immune responses to a pathogen in two ways. First, the mAb can deliver increased amounts of antigen to DCs. Second, FcRs deliver signals that activate DCs. In turn, activated DCs can stimulate T cells specific to the delivered antigen, resulting in T cell immunity. In this way, an antibody with vaccinal mutations can potentially actively immunize infected patients. The in vivo data supporting enhancement of the vaccinal effect through Fc mutants has been demonstrated by others in a CD20 positive tumor model, using mice with humanized Fc receptors. In this experiment, anti-CD20 mAbs and CD20 tumor cells were administered to mice months before being later rechallenged with a lethal dose of CD20 tumor cells. 80% of the mice who received a mAb with Fc mutants that enhanced binding to activating FcRs IIa and IIIa survived. Conversely, 70% or more mice who received a mAb without the enhancing Fc mutations died. This durable protection is believed to be the result of the induction of a T-cell response. We are testing this technology in chronic HBV infection with VIR-3434 and in COVID-19 infection with VIR-7832, and if it performs as expected, we believe it may have applicability to multiple other infections including influenza and HIV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">T Cell Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">T cells can prevent or control infection and cancer. T cells are diverse in how they sense pathogens and cancer cells, the tissues that they protect and the effector functions that they use to control infection or cancer. Our approach is to use HCMV as a vaccine vector to potentially treat and prevent infection by pathogens refractory to current vaccine technologies because HCMV may induce potent and long-lasting T cell responses to a broader range of epitopes than observed for other viral vaccines. In addition, we can make proprietary modifications in the HCMV genome that we expect will elicit different types of pathogen-appropriate T cell responses. Experiments in NHPs demonstrate the ability of vaccine vectors based on the closely related RhCMV to protect against SIV, a close relative of HIV, and TB, two of the most challenging infections for which to create effective vaccines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HCMV infects a large proportion of the human population and causes a life-long asymptomatic infection that typically causes no harm. This is due to millions of years of co-evolution between the virus and host in which the virus evades</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sterilizing immunity using specialized viral genes, while at the same time allowing the generation of certain T cell responses that prevent HCMV infection from becoming lethal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect the following benefits from our T cell platform:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Highly potent and long-lived T cell responses throughout the body </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Induction of high numbers of specialized T cells, known as effector memory cells, that allow control of disease in the first few days after infection </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immune responses to three- to four-fold more antigenic epitopes in a target protein than other viral vectors </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Programmable T cell responses allowing selection of the type of T cells elicited </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Generation of universal T cells that may be active in most or all people despite high genetic variability between people in immune response genes </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Opportunity for repeated vaccination using the same backbone HCMV vector against different infections </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Opportunity to use the same vaccine to protect against multiple pathogens </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potential to induce responses even to proteins that the host is tolerant of, such as self-proteins expressed in a tumor </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-1111 was generated using our T cell platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that the type of T cell response elicited by an HCMV-based vaccine vector can be selected by mutating certain genes in HCMV. We term this approach &#x201c;immune programming.&#x201d; We believe that immune programming is critical to combatting infections such as HIV and TB that have proven intractable, to date, for other vaccine technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immune programming is best understood in the context of the normal processes that elicit T cell immunity. T cells that fight infection and cancer are elicited by DCs, as well as other types of cells. The elicited T cells detect small peptide fragments from antigens on the surface of DCs and other antigen presenting cells, which have been captured in grooves found within specialized proteins encoded by major histocompatibility complex, or MHC, genes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The unique immunology of HCMV depends on the virus&#x2019;s ability to regulate the normal immune processes of antigen presentation by MHC genes. HCMV contains multiple genes that regulate many of the steps in antigen presenting cells that elicit T cell immunity by altering antigen presenting cell biology, the types of antigen presenting cells infected by the viral vaccine and the mechanisms responsible for the ability of a T cell to recognize antigens together with MHC molecules. Through manipulation of the HCMV genome, we believe we can program different types of pathogen-appropriate T cell responses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">MHC-E as a Near-Universal Target for Medicines that Leverage T Cell Receptors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">T cells need to be able to recognize a highly diverse set of pathogen proteins to be effective. This diversity comes from the use of multiple different host immune response MHC genes to present foreign antigens to T cells. Some immune response MHC genes are highly variable between individuals, while others are less variable between individuals as illustrated below. The immune response MHC genes that are highly variable between individuals are responsible for most T cell responses. These MHC molecules enable T cells to recognize foreign proteins through the use of a highly specialized T cell receptor, or TCR, on the T cell surface.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An important consequence of the inter-individual variation in some immune response MHC genes is that a TCR that recognizes an antigenic peptide associated with one person&#x2019;s MHC molecules could attack even normal tissues of a person with different MHC genes. As a result, identifying universal TCRs and universal T cell antigens that work in all people has been very challenging.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our T cell platform may enable us to create vaccines or other types of medicines that are near universal in their effects on human immunity. The programmed T cell responses elicited by engineered HCMV vectors are predicted to use immune response MHC genes that vary minimally between people, instead of the highly variable immune response MHC genes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">targeted by other types of vaccines. As demonstrated by the graphic below, TCRs recognizing antigenic peptides together with MHC-E may be functional in all individuals, potentially allowing for the generation of universal TCR-based medicines, such as off-the-shelf cancer cell therapy. The peptides presented by MHC-E may be immunogenic in all individuals, potentially allowing for the generation of universal infectious disease and cancer vaccines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_17.jpg" alt="img61678762_17.jpg" style="width:516px;height:295px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:0.9199999999999998;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Comparison of standard T cell responses to MHC-E responses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Peptides that are bound to MHC-I, -II or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">-E proteins are expressed on cell surfaces where they are recognized by T cell receptors on T cells (TCRs). This interaction results in the expansion of T cells that can recognize diverse antigen peptides (top row) and that carry out functions that protect the host. Since MHC-I and MHC-II molecules are highly variable between people, peptide presentation to TCRs has a high degree of individual specificity, as illustrated by the different colors of each peptide in the top row. In contrast to MHC-I and MHC-II, MHC-E proteins (bottom row) are conserved in the human population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specifically programmed RhCMV vectors can elicit strong T cell responses that target MHC molecules which vary minimally between NHPs. One such protein is MHC-E. The fundamental discovery, by some of our founders, that enables this part of our T cell platform is that RhCMV responses can be programmed to generate abundant MHC-E-restricted T cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that using our T cell programming approach will allow us to select vaccine antigens and to identify TCRs that work across the human population. An example of a use of such a TCR would be creating a biological product that specifically recognizes infected cells in all individuals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:0.9199999999999998;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Programming T Cell Responses to Create HIV and TB Vaccines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Two of the most challenging infections for vaccine development are HIV and TB. Preclinical studies have demonstrated that programmed RhCMV vectors can be used to vaccinate against either SIV or TB in NHPs. For example, as shown in the figure below, in an NHP study, an MHC-E programmed RhCMV vaccine effectively protected more than half of NHPs from infection when challenged with a highly virulent form of SIV, under conditions in which all animals in the control group became infected. SIV vaccines programmed in other ways were not protective, demonstrating the potential value of having a programmable T cell vaccine platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.9774999999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_18.jpg" alt="img61678762_18.jpg" style="width:653px;height:189px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Primary data for the protective effects of RhCMV-derived T cell vaccines on SIV infection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> Rhesus monkeys were vaccinated with an RhCMV vaccine that elicits CD8 T cells recognizing SIV peptides presented by MHC-E and MHC-II or a control before challenge with SIV by rectal or vaginal routes. SIV genome copies were measured in peripheral blood (vertical axis) at intervals after challenge (horizontal axis). SIV infection was cleared in approximately 51% of intrarectal challenged animals and approximately 60% of intravaginal challenged animals while the infection was progressive in all unvaccinated controls.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Protection has also been observed against TB in preclinical studies of NHPs after immunization with either of two different RhCMV vaccines. One of the protective vaccines was programmed to elicit MHC-II and MHC-E responses, while the other was programmed to elicit a response depending on MHC-I genes. This shows the potential significance of being able to specifically program a T cell vaccine to target a given infection, as the programming of a vaccine to protect against SIV can be different from the programming of a vaccine to protect against TB. These preclinical data support our plans to use our T cell platform to vaccinate against HIV and TB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Bill &amp; Melinda Gates Foundation is providing funds for the process development and manufacturing and early clinical development of our HIV and TB vaccine programs. If proof of concept for the potential efficacy of our T cell vaccine platform is obtained in currently planned clinical trials, we plan to apply this T cell platform for treating additional types of infections, as well as potentially even cancers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Innate Immunity Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Innate immunity protects us during the early stages of infection until antibodies and T cells can be generated by the immune system. Importantly, innate immunity is not pathogen-specific. We believe that we can target innate immunity to create medicines that break the &#x201c;one-drug-for-one-bug&#x201d; paradigm by producing &#x201c;one-drug-for-multiple-bugs.&#x201d; We term this concept &#x201c;host-directed therapy&#x201d; because the medicine would target a host protein instead of pathogen proteins, which are the target of standard antibiotics and antivirals. We can also identify proteins that are critical for a high priority infection, such as HBV, for which host-directed therapy might be part of a functional cure or complete cure. This platform may also identify targets relevant to diseases outside of infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our scientists have developed and applied cutting-edge CRISPR-based genetic technologies to identify host genes that regulate innate immunity and/or pathogen replication. We have built internal capacity to systematically extend such trials to multiple pathogens and multiple aspects of innate immunity. We have joined the Broad Institute&#x2019;s Functional Genomics Consortium, which provides us access to cutting-edge CRISPR reagents and computational services for whole-genome and custom-designed genetic screens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_19.jpg" alt="img61678762_19.jpg" style="width:539px;height:239px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Design of steps in our innate immunity platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">. We are systematically mapping the genes that regulate pathogen control across a diverse set of pathogens. To accomplish this, advanced gene editing technology (CRISPR) is used to create cell libraries in which</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">individual genes are either knocked out or activated. By exposing these cell libraries to pathogens of interest, under different screening conditions, we can systematically create genomic maps that identify genes that could lead to pathogen control. By computationally comparing these genomic maps, genes or pathways that are common to multiple pathogens can be identified and could lead to the development of products that could treat more than a single pathogen. Human rhinovirus = HRV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect the following benefits from our innate immunity platform:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Enhancement of the potency of innate immunity, allowing for control of multiple unrelated pathogens </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">High barrier to resistance since the targeted host protein is not likely to mutate </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identification of key host targets in areas outside of infectious disease </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our innate immunity platform envisions three steps leading to new medicines, as illustrated in the figure above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Step 1: CRISPR Screens to Map the Genomic Landscape of Infection and Innate Immunity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Multiple types of proteins participate in innate immunity and infection, as they may be required for entry, replication, gene expression, pathogenicity and/or innate immune control of an infectious agent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To identify such proteins, we screen CRISPR-derived cell libraries after infection, treatment with cytokines that trigger innate immunity, or both, and then select cells with desired properties. Using next-generation sequencing, we identify genes responsible for the desired property. By combining these data across screens and across pathogens, our team has created, and is continuously expanding, a proprietary database of the genomic landscape of infection and innate immunity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_20.jpg" alt="img61678762_20.jpg" style="width:529px;height:292px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">CRISPR screen for genes involved in RSV replication</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">. A CRISPR cell library was prepared in cells in which RSV can replicate. After a period of infection with an RSV strain expressing a fluorescent protein which serves as a surrogate for viral replication, cells were separated using flow cytometry into populations in which RSV replication was decreased or increased. Deep sequencing of the population exhibiting decreased replication compared to control revealed candidate genes required for efficient replication. Computational analysis represented on the right panel revealed that some of these genes fall into nodes that function in specific cellular processes. These nodes are represented as dots interconnected with a dense network of lines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As an example, to identify genes required for RSV growth, we performed a screen in which a CRISPR-generated cell library was infected with RSV, as shown in the figure above. We then purified and sequenced populations exhibiting low or high RSV growth. Sequencing of the RSV low population revealed genes potentially required for RSV infection. When analyzed computationally, these genes fell into sets involved in specific cellular processes. These genes are potential targets for product candidates. We performed a similar screen with the influenza A virus and HRV and found that certain genes are shared between RSV, influenza A virus and HRV. Targeting such proteins might result in a pan-respiratory virus product candidate capable of treating RSV, influenza A virus and HRV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The result from this step of the innate immune platform is a continuously updated database of the genomic landscape of pathogen replication and innate immunity. We have already performed multiple screens, and additional screens and target validation trials are in progress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Step 2: Computational Analysis for Identification of Product Targets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Results from CRISPR screens provide the critical data that helps identify host targets necessary for a given pathogen. When creating a single drug for multiple pathogens, host targets in common among multiple pathogens are identified. After having identified the critical set of host targets necessary for a pathogen or pathogens, the specific target for a new medicine is selected by computationally integrating diverse data sets that account for tissue gene expression, human genetic variation, redundancies in cellular pathways and protein-protein interaction networks, among other factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Step 3: Product Discovery</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once a specific target has been chosen, the modality used to disrupt the function of the target is then selected. Potential modalities may include small molecules, antibodies or siRNAs. Standard drug discovery efforts are then applied to identify a lead product candidate. Alternatively, machine learning and database mining can be used to identify pre-existing chemical matter that is already known to inhibit an identified host target. This chemical matter can then be verified as having</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">anti-pathogen activity, and serve as a lead compound. There are two potential outcomes from Step 3: one-drug-for-one-bug and one-drug-for-multiple-bugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">siRNA Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gene expression can be altered by two main types of synthetic oligonucleotides: (i) antisense oligonucleotides; and (ii) siRNAs. We believe that our current approach leveraging siRNAs may have safety and potency advantages over antisense oligonucleotides. The first FDA-approved siRNA in the United States was ONPATTRO&#174; (patisiran), which was developed by our collaborator, Alnylam.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_21.jpg" alt="img61678762_21.jpg" style="width:494px;height:323px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Mechanism of siRNA action to regulate gene expression</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> Intracellular double stranded RNA, or dsRNA, is processed by the &#x201c;dicer&#x201d; complex to produce siRNAs that become integrated into a multi-subunit protein complex, the RNA-induced silencing complex, or RISC, which guides the siRNAs to the target messenger RNA, or mRNA, sequence. The siRNA duplex unwinds, and the antisense strand remains bound to RISC and directs site-specific cleavage of the target complementary mRNA sequence, resulting in mRNA degradation and reduced expression of the target protein. (A)n = polyadenylation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">siRNAs act via an RNA interference, or RNAi, mechanism involving sequence-specific knockdown of target RNAs. Our bodies create their own so-called endogenous siRNAs, which act via the RNAi mechanism. This RNAi mechanism can be exploited by chemically synthesizing synthetic siRNAs that are introduced as medicines to knock down target RNAs that express pathogen or host proteins of interest. Pursuant to our collaboration and license agreement with Alnylam, we have an option to license Alnylam&#x2019;s siRNA technology for use in up to four other infectious disease targets in addition to VIR-2218 for HBV. See the section titled &#x201c;Our Collaboration, License and Grant Agreements&#x201d; for a description of the collaboration and license agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect the following benefits from our siRNA platform and siRNAs generally:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cutting-edge siRNA design, through collaboration with Alnylam </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct anti-pathogen activity and potential for immunomodulation </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diminished off-target siRNA effects via use of next generation ESC+ technology as a differentiator compared to other siRNA approaches, which has the potential to increase the therapeutic index </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Efficient targeting of siRNAs to the liver using GalNAc technology </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Extended effects of siRNA may last for weeks to months in humans </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2218 was generated using our siRNA platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have elected to develop modified siRNAs initially for infectious diseases of the liver because these product candidates can be administered subcutaneously, are highly stable in the blood stream and are efficiently delivered into hepatocytes via GalNAc sugar modification. Once in a liver cell, the siRNA can act to reduce pathogen or host gene expression. Such siRNAs can be further modified to reduce off-target activity, and potentially increase the therapeutic index. Since October 2017, we have collaborated with Alnylam to leverage this validated technology, with the goal of eliminating key host factors necessary for pathogen survival and removing microbial immune countermeasures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that HBV persists in part due to the expression of viral proteins such as HBsAg, which potentially inhibit antibody, T cell, and innate immune responses. This prevents the immune response from clearing HBV. By inhibiting the expression of these viral proteins, we envision enhancing immune function in persistently infected individuals. Furthermore, we believe that combining siRNA therapy with products derived from our other platforms, including antibodies, T cells and innate immune modulators, may allow us to rapidly advance a functional cure for HBV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">siRNA Delivery Mechanism</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since unmodified synthetic siRNAs can be unstable in the blood stream, methods to stabilize synthetic siRNAs have been pioneered by Alnylam including using their ESC technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An approach that has been used successfully to deliver siRNA to liver cells is to conjugate siRNAs to a specific sugar known as a GalNAc, whose receptor is exclusively expressed at high levels on hepatocytes, allowing for uptake of large quantities of siRNA into hepatocytes. Importantly, a GalNAc-conjugated siRNA can be delivered to the liver by subcutaneous injection, making administration relatively simple.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Potentially Enhancing the Therapeutic Index by Diminishing Off-Target Activity of siRNAs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A distinguishing characteristic of VIR-2218 siRNA, and of future siRNAs that we may develop with Alnylam, is the application of a new approach to diminish off-target effects of RNAi. siRNAs may cause unwanted alterations to non-target host RNAs, a process known as off-target activity, which can result in short- or long-term toxicity. To reduce off-target activity, which is thought to be due in part to microRNA, or miRNA, activity, it is necessary to preserve the RNAi activity of an siRNA while simultaneously decreasing its miRNA activity, as shown in the figure below. Alnylam scientists have pioneered placement of a modified nucleotide called a glycol nucleic acid, or GNA, into the part of the siRNA that generates miRNA-like activity. GNA modification has been shown to reduce miRNA activity, while preserving the RNAi activity of siRNA. The combination of GNA modification and other chemical modifications that enhance siRNA stability is called ESC+ technology. In animal models, reducing off-target miRNA activity can result in an increased therapeutic index of approximately five-fold. A higher therapeutic index has the potential to allow for higher siRNA doses and/or a longer duration of therapy, while maintaining a favorable safety profile. VIR-2218 was the first siRNA to enter the clinic with ESC+ technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_22.jpg" alt="img61678762_22.jpg" style="width:413px;height:288px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">On-Target and Off-Target Activity of siRNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">siRNAs can have off-target activity when siRNA binds to mRNA with a partial sequence match, leading to translation repression or mRNA destabilization of unrelated messages (right side). This contrasts with the intended on-target activity of an siRNA, which binds to an mRNA through a match to the entire sequence, leading to mRNA cleavage (left side). mRNA = messenger ribonucleic acid; RISC = ribonucleic acid-induced silencing complex.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Collaboration, License and Grant Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration Agreements with GSK</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2020 Collaboration Agreement with GSK</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, we entered into a definitive collaboration agreement with GSK, or the 2020 GSK Agreement, pursuant to which we agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses, or the Antibody Program; (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses, or the Vaccine Program, and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses, or the Functional Genomics Program. The initial antibodies under the Antibody Program are sotrovimab (previously VIR-7831) and VIR-7832.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For a period of four years beginning April 2020, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee, or JSC. During such period, generally, subject to certain rights granted to WuXi Biologics under existing agreements between us and WuXi Biologics, the parties will have an exclusive research collaboration with respect to antibody products directed to SARS-CoV-2 or to any other coronavirus, and in connection with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">functional genomics CRISPR screens for drug discovery and development in connection with SARS-CoV-2 or other coronaviruses. We are primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK is primarily responsible for the commercialization activities for the Antibody Program (except in connection with sales of antibody products licensed to WuXi Biologics in greater China), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. We and GSK are required to use commercially reasonable efforts to conduct the activities assigned to each party under each development plan and to seek and obtain regulatory approval for collaboration products that arise from such activities in the United States and specified major markets. Subject to an opt-out mechanism, we and GSK share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with us bearing 72.5% of such costs for the antibody products, 27.5% of such costs for the vaccine products, and we and GSK sharing equally all such costs for the functional genomics products, and all profits will be shared in the same ratios. If we and GSK elect to conduct a technology transfer of manufacturing technology under our agreement with WuXi Biologics (as further described below), we will bear 72.5% of the costs related to such manufacturing technology transfer and for commercial manufacturing of the antibody products under such agreement with WuXi Biologics, and GSK will bear 27.5% of such costs. The parties will also share the committed costs for the reservation of manufacturing capacity for the drug substance for antibody products in the foregoing ratio under our agreement with Samsung as well as such costs relating to committed manufacturing capacity for antibody products as are approved by the JSC from time to time.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On a collaboration product-by-collaboration product basis, each party has the one-time right, at specified points in development, to opt out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party pays to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, we have a co-promotion right for such antibody product in the United States, under which we have the right to perform up to 20% of details in connection with such antibody product. GSK will lead commercialization and book all sales and is required to use commercially reasonable efforts to commercialize each collaboration product following regulatory approval in the United States and specified major markets. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This definitive agreement superseded and replaced the April 2020 preliminary agreement with GSK. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the 2020 GSK Agreement, we also entered into a stock purchase agreement in April 2020, pursuant to which we issued 6,626,027 shares of our common stock to Glaxo Group Limited, or GGL, an affiliate of GSK, at a price per share of $37.73, for an aggregate purchase price of approximately $250.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2020 GSK Agreement will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, Beecham S.A. assigned and transferred all its rights, title, interest, and benefit in the 2020 GSK Agreement to GlaxoSmithKline Biologicals S.A., including all its rights to bring claims under such agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Expanded GSK Collaboration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, we entered into the 2021 GSK Agreement under which the parties agreed to expand the 2020 GSK Agreement, to include collaboration on three separate programs: (1) a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus, or the Influenza Program, excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties' current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses, or the Expanded Functional Genomics Program; and (3) additional programs to develop neutralizing mAbs directed to up to three non-influenza target pathogens selected by GSK, or the Selected Pathogens, and such programs, or the Additional Programs. Under the Influenza Program, we will collaborate to research, develop and commercialize our next generation mAbs for the prevention, treatment or prophylaxis of influenza. In addition, after we complete and report the Phase 2 clinical trial outcomes for VIR-2482, GSK has the exclusive option to obtain exclusive rights to co-develop and commercialize VIR-2482, or the Option.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the 2021 GSK Agreement, we entered into a stock purchase agreement with GGL pursuant to which we issued 1,924,927 shares of our common stock to GGL for an aggregate purchase price of approximately $120.0 million. The 2021 GSK Agreement superseded and replaced the preliminary agreement entered into with GSK in February 2021, or the 2021 Preliminary Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For a period of three years following the effective date of the 2021 GSK Agreement, or the Research Term, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration. Subject to certain exceptions, we will exclusively collaborate with respect to (a) all of our mAbs that the parties agree to develop for the prevention, treatment or prophylaxis of the influenza virus, until such time there are none of our mAbs being developed under the expanded collaboration, (b) functional genomic screens for targets associated with respiratory viruses during the Research Term, and compounds or products developed through the Expanded Functional Genomics Program directed to a collaboration target for five years following the target selection (unless either party elects to opt-out earlier), and (c) products directed to Selected Pathogens during the Research Term. We will be responsible for continuing the development and clinical manufacturing activities for VIR-2482 unless and until GSK exercises the Option. If GSK does not exercise the Option for VIR-2482, then, in general, we have the right to continue the development and/or commercialization of VIR-2482 by itself or with a third party. GSK will be the lead party for development, clinical and commercial manufacturing, and commercialization activities for products under the Influenza Program (other than VIR-2482 unless and until GSK exercises the Option, if applicable). We will mutually agree upon the allocation of responsibility for the development of products under the Expanded Functional Genomics Program, and for the development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK will be primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, upon execution of the definitive agreement, we will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The parties will share 50% of all development costs in accordance with the budget for each of the collaboration programs (other than for the Selected Pathogens and VIR-2482, unless GSK exercises the Option), with each party having the right (on a target-by-target, or collaboration product-by-collaboration product basis, as applicable) to opt-out of its co-funding obligations at specified points in development. In such case, the party continuing with the program will pay to the opt-out party a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the opt-out is exercised. Following the exercise of an opt-out right by a party the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any opt-out, the parties will also share 50% of all profits and losses arising from any collaboration product. Each party is required to use commercially reasonable efforts to conduct the activities assigned to it under each development plan and, where applicable, to seek and obtain regulatory approval for collaboration products that arise from such activities in the United States and specified major markets. GSK will lead commercialization and book all sales, and is required to use commercially reasonable efforts to commercialize each collaboration product following regulatory approval in the United States and specified major markets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GSK made an upfront payment to us of $225.0 million, 50% became payable at the effective date of the 2021 Preliminary Agreement and 50% of became payable following the execution of the 2021 GSK Agreement. If GSK exercises the Option, GSK will pay us an Option exercise fee of $300.0 million unless certain agreed product criteria for VIR-2482 are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a pre-defined regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to us of up to $200.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to the Influenza Program and each Additional Program, unless earlier terminated, the 2021 GSK Agreement will remain in effect for as long as there is a product from such collaboration program being developed or commercialized by the lead party in the collaboration program or by the non-opt-out party, if applicable. With respect to the Expanded Functional Genomics Program, unless earlier terminated, the 2021 GSK Agreement will remain in effect (a) until the end of the Research Term, if no targets are selected for the Expanded Functional Genomics Program prior to the end of the Research Term, or (b) if at least one target is selected for the Expanded Functional Genomics Program prior to the end of the Research Term, for as long as there is a product from the Expanded Functional Genomics Program being developed or commercialized by the lead party in the Expanded Functional Genomics Program or by the non-opt-out party, if applicable. Either party has the right to terminate the 2021 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or a collaboration product, or as mutually agreed by the parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration and License Agreement with Alnylam</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2017, we entered into a collaboration and license agreement with Alnylam, or the Alnylam Agreement, for the development of siRNA products for the treatment of HBV and following the exercise of certain program options, the development and commercialization of siRNA products directed to up to four other infectious disease targets selected by us. The technology licensed under the Alnylam Agreement forms the basis of our siRNA technology platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Alnylam Agreement, we obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications, such excluded fields, the Excluded Fields. In addition, Alnylam granted us an exclusive option, for each of the infectious disease siRNA programs directed to our selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. Our options are each exercisable during a specified period following selection of candidates for each program, or two years following the initiation of certain activities under an agreed-upon development plan, if earlier. On a product-by-product basis for each product arising from the HBV and, following our option exercise, the infectious disease programs, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and Alnylam are jointly responsible for funding the initial research and development activities for VIR-2218 through completion of proof of concept trials. Prior to the exercise of our option for each siRNA program directed to one of our selected infectious disease targets, Alnylam is responsible for conducting all development activities, at our expense, in accordance with an agreed-upon development plan. Following our exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, we are solely responsible, at our expense, for conducting all development, manufacture and commercialization activities for products arising from each such program unless Alnylam exercises its profit-sharing option. We are required to use commercially reasonable efforts to develop and commercialize one siRNA product directed to HBV and one siRNA product directed to the target of each other infectious disease program for which we exercise our option, in each of the major markets. If Alnylam exercises a profit-sharing option for a product, we will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We retain final decision-making authority with respect to which infectious disease product candidates we advance and the development programs for the HBV and infectious disease product candidates, subject to certain limitations. During the term of the Alnylam Agreement, neither we nor Alnylam may develop or commercialize any gene-silencing, oligonucleotide-based product directed to the same target as any product candidate under the Alnylam Agreement, other than pursuant to the Alnylam Agreement, subject to certain exceptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Alnylam Agreement, we paid Alnylam an upfront fee of $10.0 million and issued to Alnylam 1,111,111 shares of our common stock. Upon the achievement of a certain development milestone, as further discussed below, we were obligated to issue shares of our common stock equal to the lesser of (i) 1,111,111 shares or (ii) a certain number of shares based on our stock price at the time such milestone was achieved. We will be required to pay Alnylam up to $190.0 million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $115.0 million for the achievement of specified development and regulatory milestones for the first product directed to the target of each infectious disease siRNA program for which we exercised our option. Following commercialization, we will be required to pay to Alnylam up to $250.0 million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $100.0 million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which we exercised our option. We will also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and 10 years after the first commercial sale of such product in such country. Alnylam is also entitled to receive a portion of any consideration we receive as a result of granting a sublicense under the licenses granted to us by Alnylam under</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Alnylam Agreement or an option to acquire such a sublicense, determined based on the timing of the grant of such sublicense. In November 2018, in connection with the inclusion of the HBV siRNA program as the subject of a potential grant of a sublicense to Brii Bio under the Brii Agreement, as defined under the section titled &#x201c;&#x2014;Collaboration, Option and License Agreement with Brii Bio,&#x201d; which triggered certain payment obligations under the Alnylam Agreement, we entered into a letter agreement with Alnylam, or the Alnylam Letter, making certain modifications to the payments due to Alnylam as a result of the grant of the option and potential payments that would result from Brii Bio&#x2019;s exercise of rights under such sublicense. As a result of the rights granted under the Brii Agreement and pursuant to the Alnylam Letter, in February 2020 we transferred to Alnylam a specified percentage of the equity consideration allocable to the HBV siRNA program that we received from Brii Bio and its affiliated companies in connection with the entry into the Brii Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until expiration of all royalty payment obligations under the Alnylam Agreement. If we do not exercise our option for an infectious disease program directed to one of our selected targets, the Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. We may terminate the Alnylam Agreement on a program-by-program basis or in its entirety for any reason on 90 days&#x2019; written notice. Either party may terminate the agreement for cause for the other party&#x2019;s uncured material breach on 60 days&#x2019; written notice (or 30 days&#x2019; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Alnylam Agreement on 30 days&#x2019; notice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, we achieved one of the specified development milestones relating to VIR-2218 pursuant to the Alnylam Agreement, as amended. As such, we paid Alnylam $15.0 million in April 2020, and issued Alnylam 1,111,111 shares of our common stock in May 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March and April 2020, we entered into two further amendments to the Alnylam Agreement, or the Amended Alnylam Agreement, to expand our existing collaboration to include the development and commercialization of siRNA products targeting SARS-CoV-2 and potentially other coronaviruses, and up to three targeting human host factors for SARS-CoV-2, or collectively, the COVID Collaboration Targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we and Alnylam entered into a letter amendment, or the Letter Agreement, further amending the Amended Alnylam Agreement to modify certain funding and governance provisions in connection with the siRNA products directed to the COVID Collaboration Targets, including VIR-2703, or the COV Target, and to modify certain rights of each party with respect to products arising from such programs. Pursuant to the Letter Agreement, Alnylam was responsible for conducting pre-clinical research activities set forth in the existing workplan for the COV Target, or the COV Workplan, at its discretion and sole expense, and we were no longer obligated to reimburse Alnylam for any share of costs incurred by Alnylam in conducting activities under the COV Workplan after July 1, 2020. In July 2021, Alnylam elected to discontinue the development of the COV Target, and all other related research and development activities in accordance with their rights under the Letter Agreement. As a result, the COV Target and the siRNA program related thereto are no longer included within the Amended Alnylam Agreement and all rights to the siRNA program directed to the COV Target reverted to Alnylam.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreements with MedImmune</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2012 Sub-License and Collaboration Agreement with MedImmune</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2012, our subsidiary Humabs entered into a sub-license and collaboration agreement with MedImmune, LLC, or MedImmune, as amended, or the 2012 MedImmune Agreement, pursuant to which Humabs conducted certain activities under a mutually agreed research plan for the development of therapeutic antibodies directed to influenza viruses (including influenza A and influenza B) and to Klebsiella bacteria. The 2012 MedImmune Agreement was amended in April 2013, April 2015, December 2015, August 2016, July 2017, and September 2018 to designate Klebsiella as an extra target, to extend the term of the research program and provide for related payments, and to incorporate certain research activities funded by MedImmune under a specified government grant. Under the 2012 MedImmune Agreement, as amended, MedImmune obtained a worldwide exclusive license from Humabs to develop and commercialize products directed to such targets for all uses in humans and animals except for active vaccination. MedImmune is obligated to use commercially reasonable efforts to develop at least one product directed to influenza viruses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, MedImmune made certain upfront payments to Humabs. MedImmune is obligated to pay Humabs development, regulatory and commercial milestone payments of up to $96.5 million in the aggregate for the first product directed to influenza viruses to achieve the applicable milestones, and up to $12.0 million for the first product directed to Klebsiella to achieve the applicable milestones. MedImmune will also be obligated to pay royalties based on net sales of products directed to influenza viruses or Klebsiella at certain fixed percentages in the low to mid-single-digits, with the rate determined based on the specific target to which the product is directed, in each case subject to specified reductions and a royalty floor. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the last to expire valid claim that would, but for the licenses granted under the 2012 MedImmune Agreement, be infringed by the sale of such product in such country, and 10 years from the first commercial sale of the first product in such country. MedImmune also made certain payments to Humabs in consideration for Humabs&#x2019; conduct of the research program. We will be obligated to pass through the milestone payments and royalty payments that we receive under the 2012 MedImmune Agreement, following deduction of certain expenses incurred by us or Humabs thereunder, to Humabs&#x2019; securities holders pursuant to the Humabs SPA, as defined under the section titled &#x201c;&#x2014;Securities Purchase Agreement with Humabs.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2012 MedImmune Agreement will remain in force until MedImmune has fulfilled all of its obligations to make milestone and royalty payments. MedImmune may terminate the 2012 MedImmune Agreement in its entirety, or on a product-by-product, license-by-license or country-by-country basis, for convenience, upon 90 days&#x2019; notice. Either MedImmune or Humabs may terminate the 2012 MedImmune Agreement for the other party&#x2019;s uncured material breach or in the event of bankruptcy of the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2018 License Agreement with MedImmune</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2018, we entered into a license agreement with MedImmune, or the 2018 MedImmune Agreement, pursuant to which we obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of two specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The license from MedImmune includes the grant of a sublicense under MedImmune&#x2019;s license to certain intellectual property controlled by Humabs that was granted to MedImmune pursuant to the 2012 MedImmune Agreement. Under certain circumstances and during certain periods of time we have the right to nominate up to two variants of each of these antibodies for inclusion under the license. MedImmune retained the rights to continue to develop and to commercialize the two specified antibodies that target influenza A and influenza B, in each case that are not the half-life extended versions that are licensed to us. Additionally, we obtained a worldwide, exclusive license under MedImmune&#x2019;s antibody half-life extension technology to develop and commercialize half-life extended antibodies directed to up to two additional targets selected by us for all uses in humans or animals for the prevention, treatment or diagnosis of infectious diseases. We have the right to nominate such additional targets during a specified period following the effective date of the 2018 MedImmune Agreement. In September 2020, the 2018 MedImmune Agreement was amended to adjust the period of time we have the right to nominate up to two antibodies for inclusion under the MedImmune&#x2019;s antibody half-life extension technology license. MedImmune may only refuse our nomination if such targets are already the subject of internal development by MedImmune, are subject to third party rights at the time of our selection, or are the subject of good faith discussions between MedImmune and a third party for a license for products directed to such targets. We are solely responsible, at our sole cost, for the development of products containing half-life extended versions of antibodies directed to the influenza targets and any additional selected targets, and are obligated to use commercially reasonable efforts to develop and obtain regulatory approval for at least one product containing half-life extended versions of antibodies directed to each of influenza A, influenza B and any additional targets, if applicable, in the United States and specified markets in Europe and Asia. We are also obligated to use commercially reasonable efforts to commercialize products containing half-life extended versions of antibodies directed to such targets in such markets. We are developing VIR-2482 using technology licensed under the 2018 MedImmune Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the licenses under the 2018 MedImmune Agreement, we made an upfront payment to MedImmune of $10.0 million. We will be obligated to make development and regulatory milestone payments to MedImmune of up to $92.0 million, of which $5.0 million was paid in the third quarter of 2019, in the aggregate for products containing half-life extended versions of antibodies directed to influenza A that we licensed, up to an additional $39.2 million in the aggregate for such products directed to influenza B that we licensed, and up to $250,000 in the aggregate for certain specified products directed to the additional selected targets, if applicable. We will also be required to make sales-related milestone payments to MedImmune following commercialization up to an aggregate of $200.0 million for the achievement of specified levels of aggregate annual net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B. MedImmune will also be entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the mid-single-digits to sub-teen double-digits and a royalty based on net sales of products containing half-life extended versions of antibodies directed to any additional selected targets, if applicable, at a percentage in the low single-digits, in each case subject to specified reductions. These royalties are payable, on a product-by-product and country-by-country basis, until the latest to occur of expiration of the last to expire valid claim covering such product in such country, expiration of regulatory exclusivity for such product in such country, and 12 years after the first commercial sale of such product in such country. Additionally, we are responsible for paying any royalties due under the 2012 MedImmune Agreement as a result of our commercialization of products under the 2018 MedImmune Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2018 MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of our obligations to pay royalties to MedImmune. We may terminate the 2018 MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#x2019; notice. Either party may terminate the 2018 MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on 60 days&#x2019; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the 2018 MedImmune Agreement for cause on 30 days&#x2019; written notice if we challenge the validity or enforceability of the patents to which we have obtained a license under the 2018 MedImmune Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Master Exclusive License Agreement with OHSU</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2012, our subsidiary TomegaVax, Inc., or TomegaVax, entered into a master exclusive license agreement, or the OHSU Agreement, with Oregon Health &amp; Science University, or OHSU. The OHSU Agreement was revised and restated in August 2014 and again in August 2019, at which time we assumed TomegaVax&#x2019;s rights and obligations as licensee under the OHSU Agreement. Under the OHSU Agreement, we obtained a worldwide exclusive license under certain patent rights</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and a non-exclusive license under certain know-how to make, have made, use, offer to sell, sell, have sold, export and import certain products relating to CMV vectors in all fields of use. The OHSU Agreement provides for us to include within the license grant additional patent or know-how rights covering certain inventions arising at OHSU and relating to the use of CMV vaccine vectors through the execution of technology addenda, each such addendum, a Technology Addendum. Each Technology Addendum relates to a single invention disclosure and family of patent or know-how rights. During the term of the OHSU Agreement to date, we have entered into 17 such Technology Addenda. We must use reasonably diligent efforts to develop and commercialize the CMV vector products consistent with its reasonable business practices and judgment, including by achieving certain specified development and regulatory milestones within certain periods. We use technology licensed under the OHSU Agreement in our T cell platform and in our product candidate VIR-1111.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the initial entry into the OHSU Agreement and certain of the Technology Addenda, TomegaVax issued a specified percentage of its then outstanding common stock to OHSU, which was subsequently exchanged for shares of our common stock as a result of our acquisition of TomegaVax in September 2016. In connection with the second revision and restatement of the OHSU Agreement in August 2019, we issued an additional specified number of shares of our common stock to OHSU. We are obligated to pay OHSU up to $1.3 million upon the achievement of certain development and regulatory milestones for each CMV vector product, and up to $2.0 million upon the achievement of certain aggregate annual net sales milestones for all CMV vector products. We will also be required to pay OHSU a royalty in the low single-digits on net sales of licensed products on a product-by-product basis, subject to specified reductions and offsets, and specified minimum annual royalty payments. The royalties are payable, on a product-by-product and country-by-country basis, until the later of (a) the expiration of all valid claims in the licensed patents covering such product in the country of sale or country of manufacture, as applicable, and (b) 10 years after the first commercial sale of such product in the country of sale. OHSU is also entitled to receive a specified percentage of any consideration received by us as a result of the grant of a sublicense under the rights granted under the OHSU Agreement, with the applicable percentage based on the development stage of the applicable program at the time of the grant of the sublicense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The OHSU Agreement will remain in force until the expiration of all licensed patent rights or 10 years after the effective date of the last Technology Addendum, whichever is the later. Each individual Technology Addendum remains in force until the expiration of the patent rights to which it applies, or 10 years after the effective date of such Technology Addendum, whichever is later. Either party may terminate the OHSU Agreement, or any individual Technology Addendum, for the other party&#x2019;s uncured material breach on 60 days&#x2019; written notice, which may be extended by an additional 120 days under certain conditions. The OHSU Agreement and each Technology Addendum also terminate in the event of bankruptcy of either party. We may also terminate the OHSU Agreement in its entirety, or any Technology Addendum individually, upon 60 days&#x2019;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">notice. OHSU may immediately terminate the OHSU Agreement if we or our sublicensees bring any action or proceeding against OHSU, subject to certain exceptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusive License Agreement with the Institute for Research in Biomedicine</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2011, Humabs Holdings GmbH, or Humabs Holdings, the former parent company of our subsidiary Humabs, entered into an exclusive license agreement, or the IRB Agreement, with the Institute for Research in Biomedicine, or IRB. The IRB Agreement amended and restated an original 2004 exclusive license agreement between the parties in connection with IRB&#x2019;s proprietary technologies relating to human monoclonal antibodies and the discovery of unique epitopes recognized by such antibodies. In May 2008, Humabs entered into an exclusive license agreement with IRB, or the Humabs IRB Agreement, and together with the IRB Agreement, the Current IRB License Agreements. Pursuant to the Humabs IRB Agreement, IRB granted to Humabs an exclusive license under certain intellectual property rights for the development of certain monoclonal antibodies. Following the entry into the Humabs IRB Agreement, in February 2012, Humabs and IRB entered into a research agreement, or the IRB Research Agreement, concurrently with the termination of an original research agreement dated July 2004 between Humabs Holdings and IRB, to provide for a continuing research collaboration between Humabs and IRB, and to coordinate the exploitation of intellectual property rights arising from the IRB Research Agreement with the rights granted under the Current IRB License Agreements. Under the terms of the IRB Research Agreement, IRB performs certain research activities for Humabs, and all intellectual property rights arising under the IRB Research Agreement are either owned by Humabs, or included in and licensed to Humabs pursuant to the terms of the Current IRB License Agreements. In August 2017, we acquired all of the share capital of Humabs as described further below. Prior to the closing of such acquisition, Humabs Holdings was consolidated into Humabs, such that Humabs Holdings ceased to exist as a separate legal entity, and Humabs became the successor-in-interest to Humabs Holdings&#x2019; rights under the IRB Agreement. As a result, Humabs is the licensee under each of the Current IRB License Agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use technology licensed under the Current IRB License Agreements in our antibody platform and in our product candidates VIR-2482 and VIR-3434.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Current IRB License Agreements, IRB granted to Humabs an exclusive, worldwide, royalty-bearing, sublicensable license under patent and know-how rights covering or associated with IRB&#x2019;s proprietary technology platform relating to antibody discovery, as well as rights in certain antibodies, including as a result of activities under the IRB Research Agreement, in each case for all purposes, including to practice the licensed technology platform, and to develop, manufacture and commercialize any drug, vaccine or diagnostic product containing such licensed antibodies. Humabs is required to use commercially reasonable efforts to develop and commercialize licensed products, and must maintain an active program to commercialize licensed products. Humabs is required to pay to IRB a flat royalty on net sales of licensed products approved for non-diagnostic use in the low single-digits, and a flat royalty on licensed products for diagnostic use at 50% of the non-diagnostic product rate, in each case subject to standard reductions and offsets. A single royalty stream is payable on products that include the licensed antibodies (including antibodies that are owned by Humabs, but developed using the licensed technology), irrespective of whether a given product is covered by patents under both of the Current IRB License Agreements. Humabs&#x2019; obligation to pay royalties to IRB, on a country-by-country basis, is reduced upon the expiration of the relevant patents in such country, and expires 10 years after the date of first commercialization of a licensed product in such country. Humabs is also required to pay to IRB a specified percentage in the sub-teen double-digits of consideration received in connection with the grant of a sublicense to a non-affiliate third party, subject to a specified maximum dollar amount for the first up front or milestone payment received under such sublicense for each licensed product, and a lower specified maximum dollar amount for subsequent up front or milestone payments for such licensed product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each of the Current IRB License Agreements remains in force until the expiration of all valid claims of the licensed patent rights and trade secrets included in the licensed IRB know-how. Humabs may terminate the IRB Agreement at will on 90 days&#x2019; written notice to IRB, and either party may terminate either of the Current IRB License Agreements on 60 days&#x2019; written notice for the uncured material breach of the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusive License Agreement with The Rockefeller University</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2018, we entered into an exclusive license agreement with The Rockefeller University, or Rockefeller, which was amended in May 2019, in September 2020, and in March 2021, or the Rockefeller Agreement. Pursuant to the Rockefeller Agreement, Rockefeller granted us a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The licenses granted to us are freely sublicensable to third parties. Rockefeller retains the right to use the licensed patents outside the field of use, and within the field of use solely in connection with educational, research and non-commercial purposes, as well as for certain research being conducted in collaboration with us. We are obligated to grant sublicenses to third parties with respect to products that are not being pursued and are not of interest to us following a specified anniversary of the May 2019 amendment date. Pursuant to the Rockefeller Agreement, we are required to use commercially reasonable efforts to develop and commercialize infectious disease products as soon as reasonably practicable, including by achieving certain specified development milestone events within specified time periods for products arising from our HBV and influenza programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use technology licensed under the Rockefeller Agreement in our antibody platform and in our product candidates VIR-3434 and VIR-7832.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We paid Rockefeller an upfront fee of $0.3 million for entry into the Rockefeller Agreement, and are required to pay annual license maintenance fees of $1.0 million, which will be creditable against royalties following commercialization. In addition, for the achievement of specified development, regulatory and commercial success milestone events, we will be required to pay up to $80.3 million, in the aggregate, for up to six infectious disease products. Any follow-on products beyond six products may result in additional milestone event payments. We will also be required to pay to Rockefeller a tiered royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. Our obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis, upon the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or 12 years following the first commercial sale of the applicable licensed product in such jurisdiction. If we grant a sublicense to a non-affiliate third party under the Rockefeller technology, we will be required to pay to Rockefeller a specified percentage of the consideration received from such sublicensee for the grant of the sublicense, depending on the date of receipt of the applicable sublicense income from such sublicensee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of our obligations to pay royalties to Rockefeller in all jurisdictions. We have the right to terminate the Rockefeller Agreement in its entirety, or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in part, for any reason on 60 days&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#x2019; written notice for our uncured material breach, or if we challenge the validity or enforceability of any of the licensed patents, or immediately in the event of our insolvency. Rockefeller may also terminate the Rockefeller Agreement if we cease to carry on business with respect to the rights granted to us under the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration, Option and License Agreement with Brii Bio</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2018, we entered into a collaboration, option and license agreement with B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">rii Biosciences Limited (previously named BiiG Therapeutics Limited), or Brii Bio Parent, and Brii Bio, and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such agreement, the Brii Agreement, pursuant to which we granted to Brii Bio, with respect to up to four of our programs (excluding mAbs in Vir&#x2019;s active research and development program against coronaviruses), an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau, or collectively the China Territory, for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection, or the Field of Use. Our HBV siRNA program being developed under the Amended Alnylam Agreement (described above) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. Brii Bio may exercise each of its options following the achievement by us of proof of concept</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for the first product in such program. In partial consideration for the options granted by us to Brii Bio, Brii Bio Parent and Brii Bio granted us, with respect to up to four of Brii Bio Parent&#x2019;s or Brii Bio&#x2019;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that we may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program. All options granted to Brii Bio under the Brii Agreement that are not exercised will expire no later than seven years following the effective date, or two years earlier than such date if Brii Bio has not undergone an initial public offering within such shorter period. All options granted to us under the Brii Agreement that are not exercised will expire no later than two years following the expiration of all options granted to Brii Bio.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are responsible, at our expense and discretion, for the conduct of all development activities under our programs prior to the exercise of Brii Bio&#x2019;s options, and Brii Bio is responsible, at its expense and discretion, for all activities under its programs prior to the exercise of our options. Following the exercise of an option for a specified program by either us or Brii Bio, the exercising party is granted an exclusive, royalty-bearing license to develop, manufacture and commercialize products arising from the applicable program in the United States (where we are exercising the option) or the China Territory (where Brii Bio is exercising the option), and such party is thereafter responsible for all development and commercialization activities, at its expense, in the optioned territory. If Brii Bio exercises its option with respect to our development program being conducted under the Amended Alnylam Agreement, Brii Bio&#x2019;s rights will be subject to the terms of such amended agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the Brii Agreement, following our option exercise, we are obligated to use commercially reasonable efforts to develop at least one licensed product arising from each optioned Brii Bio program, and to commercialize each such product in the United States following regulatory approval, and following Brii Bio&#x2019;s option exercise, Brii Bio is obligated to use commercially reasonable efforts to develop at least one licensed product arising from each optioned Vir program and to commercialize each such product in the China Territory following regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to programs for which Brii Bio exercises its options, Brii Bio will be required to pay us an option exercise fee for each such Vir program ranging from the mid-single-digit millions up to $20.0 million, determined based on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the mid-single-digit millions up to $30.0 million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $175.0 million per licensed program. Brii Bio also will pay us royalties that range from the mid-teens to the high-twenties, as described below. On June 12, 2020, Brii Bio notified us of the exercise of its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. Brii Bio paid us a $20.0 million option exercise fee in connection with the option exercise. We separately paid $10.0 million, half of the option proceeds, to Alnylam in connection with the Amended Alnylam Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As partial consideration for our entry into the Brii Agreement, upon closing of Brii Bio Parent&#x2019;s Series A preferred stock financing, we received Class A ordinary shares equal to 9.9% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#x2019;s right to exercise one of its options for our HBV siRNA program, under the terms of the Amended Alnylam Agreement, in February 2020 we transferred to Alnylam a specified percentage of such equity consideration allocable to such program. In July 2021, Brii Bio Parent completed its initial public offering, or the Brii Bio Parent IPO, on the Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exchange of Hong Kong Limited. Upon completion of the Brii Bio Parent IPO, our Class A ordinary shares held at Brii Bio Parent converted into the same single class of ordinary shares issued in the Brii Bio Parent IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon exercise of each option for a Brii Bio program, we will be required to pay to Brii Bio an option exercise fee ranging from the low tens of millions to up to $50.0 million, determined based on the commercial potential of the licensed program. We will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the low tens of millions up to $100.0 million, also determined based on the commercial potential of such program. We will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $175.0 million per licensed program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we are obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay us tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by us to Brii Bio, and by Brii Bio to us on net sales range from mid-teens to high-twenties. Each party&#x2019;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of 10 years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days&#x2019; written notice (if the terminating party has not exercised an option for such program) or 180 days&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on 60 days&#x2019; written notice (or 30 days&#x2019; notice following failure to make payment).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0541666666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent License Agreements with Xencor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we entered into a patent license agreement, which was amended in February 2021, or the 2019 Xencor Agreement, with Xencor, pursuant to which we obtained a non-exclusive, sublicensable (only to our affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. We are obligated to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in our VIR-2482, incorporating Xencor&#x2019;s Xtend technology, and VIR-3434, incorporating Xencor&#x2019;s Xtend and other Fc technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, we paid Xencor an upfront fee. For each of the influenza A and HBV research programs, we will be required to pay Xencor development and regulatory milestone payments of up to $17.8 million in the aggregate, and commercial sales milestone payments of up to $60.0 million in the aggregate, for a total of up to $77.8 million in aggregate milestones for each program and $155.5 million in aggregate milestones for both programs. On a product-by-product basis, we will also be obligated to pay tiered royalties based on net sales of licensed products ranging from low- to mid-single-digits. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, we entered into a patent license agreement, which was amended in February 2021, or the 2020 Xencor Agreement, with Xencor pursuant to which we obtained a non-exclusive license to Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. We are obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the coronavirus research programs. These technologies are used in sotrovimab, incorporating Xencor&#x2019;s Xtend technology, and VIR-7832, incorporating Xencor&#x2019;s Xtend and other Fc technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, we are obligated to pay royalties based on net sales of licensed products at the mid-single-digits. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or 12 years.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2019 Xencor Agreement and 2020 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. We may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon 60 days&#x2019; written notice. Either party may terminate each agreement for the other party&#x2019;s uncured material breach upon 60 days&#x2019; written notice (or 30 days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if we challenge, or upon 30 days&#x2019; written notice if any of our sublicensees challenge, the validity or enforceability of any patent licensed to us under each respective agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0541666666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amended and Restated Letter Agreement with the Bill &amp; Melinda Gates Foundation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2022, we entered into an amended and restated letter agreement with the Bill &amp; Melinda Gates Foundation, or the Gates Agreement, which amended and restated the letter agreement with the Bill &amp; Melinda Gates Foundation that we entered into in December 2016. In connection with the Gates Agreement, the Bill &amp; Melinda Gates Foundation purchased $10.0 million of shares of our Series A-1 convertible preferred stock in December 2016, $10.0 million of shares of our Series B convertible preferred stock in January 2019 and $40.0 million of shares of our common stock in January 2022. We were obligated to use the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s December 2016 and January 2019 investments in furtherance of its charitable purposes to (i) conduct our programs to develop products to treat or prevent infectious disease caused by HIV and TB, respectively, with at least 50% of the funds to be used for such programs and (ii) develop our HCMV-based vaccine technology platform in a manner reasonably expected to result in the generation of products for the treatment or prevention of other specified infectious diseases, and we are obligated to use the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s January 2022 investment in furtherance of its charitable purposes to develop our vaccinal antibody program, in each case for use in specified developing countries. We agreed to use reasonable efforts to achieve specified research and development milestones with respect to our HIV program, TB program and vaccinal antibody program, and, if requested by the Bill &amp; Melinda Gates Foundation, to work with the Bill &amp; Melinda Gates Foundation on an additional mutually agreeable infectious disease program. Additionally, we are bound by specified global access commitments including a commitment to provide any products developed using the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s investment at an affordable price to the people most in need within the specified developing countries, not to exceed a specified percentage over our fully burdened manufacturing and sales costs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to comply with (i) our obligations to use the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s investment for the purposes described in the paragraph above and to not use such proceeds for specified prohibited uses, (ii) specified reporting requirements or (iii) specified applicable laws, or if we materially breach our specified global access commitments (any such failure or material breach, a Specified Default), we will be obligated to redeem or arrange for a third party to purchase all of our stock purchased by the Bill &amp; Melinda Gates Foundation under the Gates Agreement at the Bill &amp; Melinda Gates Foundation&#x2019;s request, at a price equal to the greater of (a) the original purchase price or (b) the fair market value, such redemption or sale, a Gates Foundation Redemption. Following a Gates Foundation Redemption, if a sale of the company or all of our material assets relating to the Gates Agreement occurs prior to the six month anniversary of the first redemption or sale of any stock in such Gates Foundation Redemption, then the Bill &amp; Melinda Gates Foundation will receive compensation equal to the excess of what it would have received in such transaction if it still held the stock redeemed or sold at the time of such sale transaction over what it actually received in the Gates Foundation Redemption. Additionally, if a specified default occurs, if we are unable or unwilling to continue the HIV program, TB program, vaccinal antibody program or, if applicable, the mutually agreed additional program (except for scientific or technical reasons), or if we institute bankruptcy or insolvency proceedings, then the Bill &amp; Melinda Gates Foundation will have the right to exercise a non-exclusive, fully-paid license (with the right to sublicense) under our intellectual property to the extent necessary to use, make and sell products arising from such programs, in each case solely to the extent necessary to benefit people in the developing countries in furtherance of the Bill &amp; Melinda Gates Foundation&#x2019;s charitable purpose.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event that we sell, exclusively license or transfer to a third party all or substantially all of our assets, the technology platform, or products arising from programs that are funded using the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s investment, such third party is required to assume our specified global access commitments on terms that are reasonably acceptable to the Bill &amp; Melinda Gates Foundation. Additionally, we will not grant to any third party any rights or enter into any agreement with any third party that would restrict the Bill &amp; Melinda Gates Foundation&#x2019;s rights with respect to our specified global access commitments unless such third party expressly assumes such commitments to the reasonable satisfaction of the Bill &amp; Melinda Gates Foundation. Consistent with the foregoing restriction, we also specifically will not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">enter into any such agreement negotiated in connection with a decision by us not to pursue the technology platform controlled by us as a result of our acquisition of TomegaVax. The global access commitments will continue for as long as the Bill &amp; Melinda Gates Foundation continues to be a charitable entity.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the purchase of $40.0 million of shares of our common stock in January 2022, we entered into a stock purchase agreement, or the Gates Stock Purchase Agreement, with the Bill &amp; Melinda Gates Foundation. The Bill &amp; Melinda Gates Foundation purchased the shares of our common stock at $45.3841 price per share, which is the average of the volume weighted average price of a share of our common stock for the 30 trading day period prior to the date of the Gates Stock Purchase Agreement. The Gates Stock Purchase Agreement provides that until the first anniversary of the closing date, the Bill &amp; Melinda Gates Foundation will hold and not sell any of the shares purchased pursuant to the Gates Stock Purchase Agreement, subject to certain exceptions. We have also agreed to register the shares for resale following expiration of the one-year lock-up period if Rule 144 under the Securities Act of 1933, as amended, is not available for such resale without any volume or manner of sale restrictions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, in January 2018, March 2018 and January 2022, we entered into three grant agreements with the Bill &amp; Melinda Gates Foundation, pursuant to which the Bill &amp; Melinda Gates Foundation agreed to grant additional funding to us for our HIV, TB and vaccinal antibody programs, respectively, through the award of three research grants totaling in the aggregate up to $12.2 million with respect to the HIV program, up to $14.9 million with respect to the TB program, and up to $10.0 million with respect to the vaccinal antibody program if we achieve all the specified research and development milestones or reporting deliverables under the grants. In February 2020, we amended the HIV grant agreement pursuant to which we were awarded with a supplemental grant of $8.6 million. In addition, the term of the HIV grant agreement was extended through October 31, 2022. The TB grant agreement will remain in effect until March 31, 2022. As of December 31, 2021, we had received $19.7 million with respect to the HIV program and $12.2 million with respect to the TB program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we entered into a grant agreement with the Bill &amp; Melinda Gates Foundation under which we were awarded a grant totaling up to $10.0 million to support the manufacturing and clinical activities of our HIV and TB vaccine programs. This grant agreement will remain in effect until August 30, 2023. As of December 31, 2021, we had received $5.5 million under this grant agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The grant agreements may be terminated early by the Bill &amp; Melinda Gates Foundation for our breach, failure to progress the applicable funded projects, in the event of our change of control, change in our tax status, or significant changes in our leadership that the Bill &amp; Melinda Gates Foundation reasonably believes may threaten the success of the applicable project.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Acquisition Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreement and Plan of Merger with TomegaVax</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2016, we entered into an agreement and plan of merger with TomegaVax, or the TomegaVax Merger Agreement, pursuant to which we purchased all equity interests of TomegaVax, a preclinical private biotechnology company. The primary asset purchased in the acquisition was a CMV vector-based vaccine platform for the development of products directed to HBV, HIV and TB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the entry into the TomegaVax Merger Agreement, we also entered into a letter agreement with TomegaVax, or the TomegaVax Letter Agreement, which provides for certain payments to TomegaVax&#x2019;s former stockholders prior to September 2024, in each case so long as we are continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, we will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of our publicly traded common stock, or implied price per share of our Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of our clinical development at the time of the relevant event triggering the payment. The share price of our publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of our common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of our common stock, at the discretion of our board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The TomegaVax Letter Agreement may be amended, modified or terminated and the observance of any term may be waived only with the written consent of the stockholders&#x2019; representative (as such term is defined in the TomegaVax Merger Agreement) and us.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, we achieved one of the milestones related to the specified per-share price of our common stock, which resulted in a $10.0 million payable to TomegaVax&#x2019;s former stockholders. In July 2021, we made the milestone payment to the former TomegaVax stockholders through a combination of $8.1 million in cash and the issuance of 42,737 shares of common stock with a total fair value of $1.9 million. The remaining milestone payments of up to $20.0 million in the aggregate will be triggered if (i) the per-share price of our publicly traded common stock is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of our clinical development at the time of the relevant event triggering the payment and/or (ii) the per-share price of our publicly traded common stock is at least $90 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Securities Purchase Agreement with Humabs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2017, we entered into a securities purchase agreement with Humabs and its securities holders, or the Humabs SPA, pursuant to which we purchased all equity interests of Humabs. Pursuant to the Humabs SPA,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we are required to pay up to $135.0 million upon the first achievement of certain clinical, regulatory and commercial milestones for an HBV product, or the HBV Milestones, and up to $105.0 million upon the first achievement of certain clinical, regulatory and commercial milestones for another product. Pursuant to the Humabs SPA, we are required to use commercially reasonable efforts to achieve such milestones during a specified period following the closing of the Humabs acquisition. In addition, Humabs&#x2019; securities holders are also entitled to receive certain pass-through payments that Humabs receives under certain license agreements, including the 2012 MedImmune Agreement, following deduction of certain expenses incurred by us or Humabs thereunder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Sales and Marketing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We intend to build a commercial infrastructure to support sales of our product candidates. We expect to manage sales, marketing and distribution through internal resources and third-party relationships. While we may commit significant financial and management resources to commercial activities, we will also consider collaborating with one or more pharmaceutical companies to enhance our commercial capabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently manufacturing product candidates from three of our platforms: antibodies, T cells and siRNAs. We have established our own internal process development, manufacturing and quality capabilities and are working with contract development and manufacturing organizations, or CDMOs, to supply our early- and late-stage product candidates in the near term. We continue to expand our internal capabilities and resources in process development, analytical development, quality, manufacturing and supply chain, which are supported by our San Francisco, California, and Portland, Oregon facilities that include laboratories for process development, production of HCMV research viral seed stock and selected quality control testing for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have established relationships with multiple CDMOs and have produced material to support preclinical studies and Phase 1, Phase 2 and Phase 3 clinical trials. Material for any Phase 3 clinical trials and commercial supply will generally require large-volume, low-cost-of-goods production. For example, for our COVID-19 program, we and our collaborator GSK have executed manufacturing agreements with CDMOs having large-scale capacity to support future scale-up and product supply, particularly for potential commercialization. However, there are no assurances that our manufacturing and supply chain infrastructure will remain uninterrupted and reliable, or that the third parties we rely on to manufacture our COVID-19 therapies will be able to satisfy demand in a timely manner or not have supply chain disruptions due to COVID-19 related shutdowns, stock-outs due to raw material shortages and/or greater than anticipated demand or quality issues given the operational challenges and raw material shortages that have been experienced during the COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Production Modalities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Antibody Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The technology and industrial processes for producing mAbs are well-established across the biopharmaceutical industry. Over the last 30 years, process optimization and standardization has enabled process portability and facilitated manufacturing with high success rates at most biologic CDMOs, as well as the partnered use of excess capacity with other biopharmaceutical companies. We rely on the mAb process platforms and manufacturing facilities of our CDMOs and strategic collaborators for all of our product candidate clinical supplies. For our COVID-19 program, we and our collaborator GSK have executed manufacturing agreements with large-scale CDMOs to support future scale-up and capacity, particularly for potential commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">T Cell Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our T cell platform is based on genetically engineered HCMV. We have attenuated the HCMV for the purpose of patient safety, but this attenuation also reduces its yield in production. To improve manufacturing efficiency and scale-up, we have made significant internal investments in process development, largely funded by the Bill &amp; Melinda Gates Foundation. We have established a reproducible current Good Manufacturing Practices, or cGMP, manufacturing process in support of Phase 1 and Phase 2 clinical trials that has been successfully transferred and executed at CDMOs specializing in live virus manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">siRNA Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alnylam is currently supplying clinical material from their CDMO sites for the current VIR-2218 clinical trials. We initiated a technology transfer of the manufacturing process at the same CDMO sites in the second half of 2021 and will assume responsibility for all additional clinical manufacturing including Phase 3 supplies in the first half of 2022 and subsequently for all commercial manufacturing in advance of any Phase 3 clinical trial. In addition to the current CDMOs supplying our clinical trials, other CDMOs as well as Alnylam are capable of producing kilogram-scale batches of siRNA and we may contract for scale-up and Phase 3 manufacturing at one of these qualified facilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Manufacturing Agreements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ongoing COVID-19 pandemic</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we have entered into the following agreements to date in support of our COVID-19 program:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Letter Agreement, Assignment and Master Services Agreement with Samsung</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, we entered into a binding letter agreement with Samsung pursuant to which Samsung will perform process development and manufacturing services for our SARS-CoV-2 mAbs. Under the terms of the letter agreement, we had committed to purchase a firm and binding capacity reservation for a specified number of drug substance manufacturing slots in 2021 and 2022. Samsung will reserve such manufacturing slots on a non-cancellable, non-adjustable basis and will not offer such manufacturing slots under our capacity reservation to third parties. We were obligated to pay a total of approximately $362.0 million for such capacity reservation on a take-or-pay basis regardless of whether such manufacturing slots are utilized by us, subject to annual adjustment based on the Korean Consumer Price Index. The amounts were to be payable during 2021 and 2022 and invoiced on a per-batch basis, with shortfalls invoiced at the end of the year in which such shortfall occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, we entered into an Assignment and Novation Agreement with GlaxoSmithKline Trading Services Limited, or GSKTSL, and Samsung effective as of July 31, 2020 pursuant to which we assigned and transferred to GSKTSL all of our right, title, and interest in, to and under the letter agreement, and GSKTSL became our successor in interest in and to all of our rights, duties, and obligations in, to and under the letter agreement. On August 4, 2020, GSKTSL entered into a Master Services Agreement with Samsung effective as of July 31, 2020, or the Samsung MSA, thereby superseding the letter agreement, and pursuant to which, among other things, Samsung will perform technology transfer, development, and manufacturing services for clinical and commercial supply of antibody products under our SARS-CoV-2 antibody program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Development and Manufacturing Collaboration Agreement with WuXi Biologics</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, we entered into a development and manufacturing collaboration agreement with WuXi Biologics for the clinical development, manufacturing, and commercialization of our proprietary antibodies developed for SARS-CoV-2. Under the agreement, WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. WuXi Biologics will have the right to commercialize products incorporating such SARS-CoV-2 antibodies in greater China pursuant to an exclusive license granted for the selected SARS-CoV-2 antibodies that have been developed. We will have the right to commercialize such products in all other markets worldwide.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WuXi Biologics will perform mutually agreed process and clinical development and manufacturing activities, under individual statements of work. In addition, the parties agreed that WuXi Biologics will pay us tiered royalties at percentages ranging from the high single-digits to mid-teens on annual net sales of all products sold by WuXi Biologics in greater China.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Letter Agreement, Assignment and Master Services Agreement with WuXi Biologics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, we entered into a binding letter of intent with WuXi Biologics pursuant to which WuXi Biologics will perform certain development and manufacturing services for our SARS-CoV-2 antibody program. Under the terms of the letter of intent, we had committed to purchase a firm and binding capacity reservation for the manufacture of a specified number of batches of drug substance of our SARS-CoV-2 antibody in 2020 and 2021. In addition, we had the right to order an additional specified number of batches of drug substance, provided we make such election by a specified date in the fourth calendar quarter in 2020. WuXi Biologics is obligated to reserve such manufacturing slots on a non-cancellable basis, and will manufacture the agreed number of batches of drug substance in accordance with an agreed manufacturing schedule. We were obligated to pay a total of approximately $130.0 million for such capacity reservation, if all batches are manufactured, inclusive of estimated raw material costs, with between 70% and 80% of the batch production fees owed to WuXi Biologics on a take-or-pay basis regardless of whether we utilize such manufacturing slots. The amounts were to be payable during 2020 and 2021 and invoiced on a per-batch basis. The SARS-CoV-2 antibody drug substance contemplated to be manufactured in accordance with the terms of the letter of intent will be utilized in connection with progressing the development and commercialization of the SARS-CoV-2 antibody product under our collaboration with GSK.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, we entered into an Assignment and Novation Agreement with GSKTSL and WuXi Biologics effective as of July 29, 2020 pursuant to which we assigned and transferred to GSKTSL all of our right, title, and interest in, to and under the letter of intent, and GSKTSL became our successor in interest in and to all of our rights, duties, and obligations in, to and under the letter of intent. On August 4, 2020, GSKTSL entered into a non-exclusive Master Services Agreement for Commercial Manufacture of Drug Substance with WuXi Biologics effective as of July 29, 2020, or the WuXi Biologics MSA, thereby superseding the letter of intent, and pursuant to which, among other things, WuXi Biologics will perform development and manufacturing services for clinical and commercial supply of antibody products under our SARS-CoV-2 antibody program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GSKTSL entered into the WuXi Biologics MSA and Samsung MSA in connection with the performance of GSK and our obligations pursuant to the 2020 GSK Agreement. In accordance with the terms of the 2020 GSK Agreement, we will continue to be responsible for 72.5% of the costs under each of the WuXi Biologics MSA and Samsung MSA, and GSK will bear 27.5% of such costs under each of the Samsung MSA and the WuXi Biologics MSA, subject to certain conditions and exceptions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development and Manufacturing Agreement with Biogen</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, we entered into a clinical development and manufacturing agreement with Biogen pursuant to which Biogen will perform process development activities and specified manufacturing services under agreed statements of work for certain pre-commercial and clinical supply of our SARS-CoV-2 mAbs. We also agreed to collaborate with Biogen to develop highly productive clonal cell lines and clinical and commercial manufacturing processes for our SARS-CoV-2 mAbs. These processes are designed to be transferrable to global biomanufacturing facilities designed for advanced biologics production. Under the agreement, Biogen will conduct cGMP clinical manufacturing in the United States and provide technical support to facilitate process transfer to Samsung, and potentially other large-scale biomanufacturing facilities in the United States and other regions of the world to enable us to obtain a reliable supply of a potential commercial product.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the Biogen agreement, we have agreed to pay fees for Biogen&#x2019;s performance of services as provided in each applicable statement of work, including costs to third parties on a pass-through basis. We entered into three statements of work with Biogen for the process development and certain clinical manufacturing services simultaneously with the execution of the agreement, with the cost of activities under such agreed statements of work totaling approximately $13.8 million. In October 2021, pursuant to the terms of this agreement, we terminated all outstanding statements of work with Biogen.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our executive and scientific team, research, clinical capabilities, development experience and scientific knowledge provide us with competitive advantages, we face increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future. For example, the industry and competitive landscape for COVID-19 treatments is rapidly changing, which could result in more competition from new and existing therapies in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or potentially necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, convenience, and cost/access.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are limited FDA-approved treatments and prophylactic vaccines for COVID-19 and several treatments and a prophylactic vaccine are available under EUA. An IV administered antiviral, remdesivir, marketed by Gilead, is FDA-approved for treatment in the hospitalized and early-treatment settings. Currently, Eli Lilly and Company's antibody, bebtelovimab, is also available under EUA for the treatment of COVID-19 in the mild to moderate setting. Oral antiviral therapies from Merck &amp; Co, Inc., or Merck, and Pfizer Inc., or Pfizer (molnupiravir and nirmatrelvir, respectively), are also available under EUA in the mild to moderate early treatment setting. Additionally, Pfizer&#x2019;s COVID-19 vaccine, Comirnaty&#174;, was approved by the FDA for individuals 16 years of age or older, Moderna, Inc.'s COVID-19 vaccine, Spikevax&#174;, was approved by the FDA for individuals 18 years of age or older and a COVID-19 vaccine is available in the United States under EUA from Janssen Biotech, Inc. Numerous large and small pharmaceutical and biotechnology companies are developing programs with various mechanisms of actions, including prophylactic vaccines, oral antivirals, immunomodulators, and antibodies, some of which are further along in the development process than we are. Companies with antibodies in clinical development include AbbVie, Inc., Adagio Therapeutics, Inc., or Adagio, AstraZeneca plc, or AstraZeneca, Brii Bio, Celltrion Healthcare Co., Ltd. and Regeneron Pharmaceuticals, Inc. Companies with oral antivirals in clinical development include Shionogi Inc., Gilead and others. Companies with prophylactic vaccines in clinical development include AstraZeneca, GSK, Novavax, Inc. and Sanofi S.A. In addition, COVID-19 treatment standards are susceptible to rapid changes in epidemiology and the emergence of new variants, thus, sotrovimab may be rendered inferior or obsolete in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HBV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current FDA-approved treatments for chronic HBV infection include PEG-IFN-&#x3b1;, marketed by Roche, and oral antiviral agents such as NRTIs, marketed by Gilead and Bristol-Myers Squibb Company. These treatments do not lead to either a functional or a complete cure in the vast majority of patients, and in the case of NRTIs, require life-long therapy. Several large and small pharmaceutical companies are developing programs with various mechanisms of action, to be used alone or in combination, with the goal of achieving an HBV functional or complete cure. Companies with RNAi agents in clinical development include Arbutus Biopharma Corporation, Janssen Pharmaceuticals, Inc., or Janssen (part of Johnson &amp; Johnson, in partnership with Arrowhead Pharmaceuticals, Inc.), and Roche Holding AG, or Roche, (in partnership with Dicerna Pharmaceuticals, Inc.) In addition, GC Pharma is developing an antibody against surface antigen. Several companies, including Altimmune, Inc., GSK, Janssen, Vaccitech plc and Transgene SA, have therapeutic vaccines in late-preclinical or early-clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Influenza</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are numerous approved seasonal flu vaccines, including trivalent, quadrivalent, high-dose, and adjuvanted products, marketed by GSK, Sanofi Pasteur, and Seqirus (owned by CSL Limited). In addition, there are approved antiviral agents to treat influenza, such as Xofluza and Tamiflu, marketed by Roche, as well as other neuraminidase inhibitors. Cidara Therapeutics, Inc. (in partnership with Janssen) is working to develop an antiviral conjugate which could be a novel method for long-acting prophylaxis.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While several companies, including AstraZeneca, Janssen and Roche, have conducted clinical trials of antibodies for the treatment of influenza, to our knowledge, there are no other prophylactic antibodies currently in clinical development. Adagio has stated that it intends to develop prophylactic antibodies for influenza.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Several vaccines are in clinical development from large and small pharmaceutical companies including GSK (in partnership with CureVac N.V.), Moderna, Inc., Novavax, Inc., Pfizer (in partnership with BioNTech SE) and Sanofi S.A. (in partnership with Translate Bio). Some aim to improve efficacy or convenience over existing seasonal vaccines, and others are pursuing a universal flu vaccine approach with broad strain coverage and at least one year of protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HIV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No FDA-approved vaccine is currently available for the prevention of HIV. Several large and small pharmaceutical companies, including GSK, GeoVax Labs, Inc., Janssen, Profectus Biosciences, Inc. and Sanofi S.A. are actively engaged in vaccine research and development in this area. These and other companies are developing vaccines using viral vectors, nanoparticles, DNA, or formulations, with the goal of stimulating T cell-mediated and/or neutralizing antibody responses against HIV. To our knowledge, none are using a CMV-based vector. Numerous clinical trials of these vaccines are ongoing with support from the NIH Vaccine Research Center, the Bill &amp; Melinda Gates Foundation, the U.S. military, the International AIDS Vaccine Initiative, the European Vaccine Initiative, the South African AIDS Initiative, and their academic and industry partners. In addition, many of these institutions, as well as pharmaceutical companies like Gilead and Viiv Healthcare Limited, or Viiv, are also studying the passive transfer of broadly neutralizing antibodies against HIV for prophylactic and therapeutic applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also compete with oral or long-acting antiretroviral therapies for pre-exposure prophylaxis of HIV. Truvada, marketed by Gilead, is a once-daily therapy approved for this indication. Viiv recently received FDA approval for long-acting antiretroviral therapy, cabotegravir for pre-exposure prophylaxis of HIV. Gilead, Janssen, Merck and Viiv have additional long-acting formulations in development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our intellectual property is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, new therapeutic approaches and potential indications, and other inventions that are important to our business. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important for the development and implementation of our business. We also rely on the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how that is not patentable, we rely on confidentiality agreements to protect our interests. We require our employees, consultants and advisors to enter into confidentiality agreements prohibiting the disclosure of confidential information and requiring disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patent portfolio includes patents and patent applications that are licensed from a number of collaborators and other third parties, including Alnylam, OHSU, MedImmune, IRB, Rockefeller and Xencor, and patents and patent applications that are owned by us. Our patent portfolio includes patents and patent applications that cover our product candidates sotrovimab (previously VIR-7831), VIR-7832, VIR-2218, VIR-3434, VIR-2482 and VIR-1111, and the use of these candidates for therapeutic purposes. Our proprietary technology has been developed primarily through acquisitions, relationships with academic research centers and contract research organizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For our product candidates, we will, in general, initially pursue patent protection covering compositions of matter and methods of use. Throughout the development of our product candidates, we seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through additional methods of use, process of making, formulation and dosing regimen-related claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In total, our patent portfolio, including patents licensed from our collaborators and other third parties, comprises over 100 different patent families as of December 31, 2021, filed in various jurisdictions worldwide. Our patent portfolio includes issued patents and patent applications in the United States and in many international countries. Our patent portfolio for our product candidates and technology platforms is outlined below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Portfolio by Product Candidate</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sotrovimab</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our sotrovimab intellectual property portfolio includes patents and patent applications that we have non- exclusively licensed from Xencor. As of December 31, 2021, these patents and applications include five issued patents in the United States directed to composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire in 2025, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2021, these patents and applications include 90 issued patents in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the U.K. directed to composition of matter claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2025 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we own, directly or through our subsidiary Humabs, four patent families relating to sotrovimab. These families collectively include, as of December 31, 2021, one issued patent in the United States directed to composition of matter claims. The 20-year term of this patent is presently estimated to expire in 2041, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2021, these families collectively include nine patent applications and provisional patent applications in the United States, two pending international Patent Cooperation Treaty, or PCT, applications and six patent applications in Argentina, Europe, Singapore and Taiwan. The applications in these families include composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from pending patent applications in these families is presently estimated to expire between 2041 and 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also co-own one patent family that includes, as of December 31, 2021, one pending PCT patent application. The application includes composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2041, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also co-own, directly and/or through our subsidiary Humabs, two patent families that collectively include, as of December 31, 2021, three pending provisional patent applications in the United States. These applications include pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-7832</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our VIR-7832 intellectual property portfolio includes a patent family that we have exclusively licensed from Rockefeller, which includes, as of December 31, 2021, issued patents in Nigeria and Organisation Africaine de la Propri&#xe9;t&#xe9; Intellectuelle (OAPI) (Africa), one pending patent application in the United States and 31 pending patent applications in the African Regional Intellectual Property Organization (ARIPO) (Africa), Algeria, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, the Dominican Republic, Ecuador, Eurasia, Europe, Guatemala, Hong Kong, Indonesia, Israel, India, Japan, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Singapore, South Africa, South Korea, Thailand, the Ukraine and Vietnam. The applications in this family include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from the application in this family is presently estimated to expire in 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our VIR-7832 intellectual property portfolio also includes patents and patent applications that we have non- exclusively licensed from Xencor. As of December 31, 2021, these patents and applications include 10 issued patents in the United States directed to composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims, methods of treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2028, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2021, these patents and applications include 121 issued patents in Australia, Austria, Belgium, Bulgaria, Brazil, Canada, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patents and applications we have non-exclusively licensed from Xencor also include, as of December 31, 2021, one patent application pending in the United States and one patent application pending in India, directed to composition of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">matter claims and process (methods of producing) claims. The 20-year term of any patents issuing from these patent applications is presently estimated to expire in 2023, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we own, directly or through our subsidiary Humabs, four patent families relating to VIR-7832. These families collectively include, as of December 31, 2021, one issued patent in the United States directed to composition of matter claims. The 20-year term of this patent is presently estimated to expire in 2041, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2021, these families collectively include nine patent applications and provisional patent applications in the United States, two pending international PCT applications and six patent applications in Argentina, Europe, Singapore and Taiwan. The applications in these families include composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from pending patent applications in these families is presently estimated to expire between 2041 and 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also co-own one patent family that includes, as of December 31, 2021, one pending PCT patent application. The application includes composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2041, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also co-own two patent families that collectively include, as of December 31, 2021, three pending provisional patent applications in the United States. These applications include pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-2218</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our VIR-2218 intellectual property portfolio includes three different patent families that we have exclusively licensed from Alnylam.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One of these families includes, as of December 31, 2021, two issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. This family also includes 47 issued patents in Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Eurasia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Italy, Japan, Jordan, Latvia, Lebanon, Lithuania, Luxembourg, Macao, Monaco, North Macedonia, Malta, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Turkey and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of these patents is presently estimated to expire in 2035, absent any available patent term adjustments or extensions. A third party filed a request for invalidation of the patent issued in China with the China National Intellectual Property Administration on December 31, 2021, and we intend to vigorously defend the patent.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Another of these families includes, as of December 31, 2021, two issued patents in Nigeria and OAPI (Africa) directed to method of treatment claims and composition for use in treatment claims. The 20-year term of these patents is presently estimated to expire in 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Another of these families includes, as of December 31, 2021, one issued patent in Nigeria directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of this patent is presently estimated to expire in 2039, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The three licensed families also collectively include, as of December 31, 2021, three patent applications in the United States and 83 patent applications in ARIPO (Africa), Algeria, Argentina, Australia, Brazil, Canada, China, Eurasia, Europe, Gulf Cooperation Council (GCC), Hong Kong, India, Indonesia, Israel, Japan, Jordan, Malaysia, Mexico, New Zealand, OAPI (Africa), Pakistan, Paraguay, Philippines, Singapore, South Africa, South Korea, Taiwan, Thailand, Ukraine, Venezuela and Vietnam directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from pending patent applications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in these families is presently estimated to expire between 2035 and 2039, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we own two different patent families that are directed to VIR-2218 in combination with one or more other therapeutics. These families collectively include, as of December 31, 2021, two patent applications in the United States and 43 patent applications in ARIPO (Africa), Algeria, Australia, Brazil, Canada, China, Eurasia, Europe, India, Indonesia, Israel, Japan, Malaysia, Mexico, New Zealand, OAPI (Africa), Philippines, Singapore, South Africa, South Korea, Taiwan, Thailand, Ukraine and Vietnam. The applications in these families include method of treatment claims and composition for use in treatment claims for VIR-2218 in combination as a second therapeutic. The 20-year term of any patents issuing from pending patent applications in these families is presently estimated to expire between 2039 and 2040, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-3434</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our VIR-3434 intellectual property portfolio includes a patent family that we have exclusively licensed from Rockefeller, which includes, as of December 31, 2021, issued patents in Nigeria and OAPI (Africa), one pending patent application in the United States and 31 pending patent applications in ARIPO (Africa), Algeria, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, the Dominican Republic, Ecuador, Eurasia, Europe, Guatemala, Hong Kong, Indonesia, Israel, India, Japan, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Singapore, South Africa, South Korea, Thailand, the Ukraine and Vietnam. The applications in this family include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from the application in this family is presently estimated to expire in 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our VIR-3434 intellectual property portfolio also includes patents and patent applications that we have non- exclusively licensed from Xencor. As of December 31, 2021, these patents and applications include 10 issued patents in the United States directed to composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims, method of treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2028, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2021, these patents and applications include 121 issued patents in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patents and applications we have non-exclusively licensed from Xencor also include, as of December 31, 2021, two patent applications pending in the United States and one patent application pending in India, directed to composition of matter claims, method of treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from these patent applications is presently estimated to expire between 2023 and 2034, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also own two different patent families that include, as of December 31, 2021, one pending PCT patent application and five provisional patent applications in the United States. These applications include composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire between 2040 and 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, through our subsidiary Humabs, we own two different patent families that include, as of December 31, 2021, one issued patent in the United States directed to composition of matter claims and pharmaceutical composition claims. These families also collectively include, as of December 31, 2021, 41 issued patents in Albania, Austria, Belgium, Bulgaria,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Croatia, Cyprus, Czechia, Denmark, Estonia, Eurasia, Finland, France, Germany, Greece, Hong Kong, Hungry, Iceland, Indonesia, Ireland, Italy, Japan, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Monaco, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Turkey and the U.K. that include composition of matter claims, pharmaceutical composition claims and composition for use in treatment claims. The 20-year term of these patents is presently estimated to expire in 2036, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These two families owned by Humabs also collectively include, as of December 31, 2021, two pending patent applications in the United States and 51 pending patent applications in ARIPO (Africa), Australia, Bahrain, Brazil, Canada, China, Eurasia, Europe, Hong Kong, India, Indonesia, Israel, Japan, Kuwait, Malaysia, Mexico, Nigeria, New Zealand, OAPI (Africa), Oman, the Philippines, Qatar, Saudi Arabia, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Ukraine, United Arab Emirates  and Vietnam. The applications in these families include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from patent applications in these families is presently estimated to expire between 2036 and 2039, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-2482</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our VIR-2482 intellectual property patent portfolio includes two different patent families that we have exclusively licensed from MedImmune, which collectively include, as of December 31, 2021, two issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. These families also collectively include 51 issued patents in Albania, Australia, Austria, Belgium, Bulgaria, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Gibraltar, Greece, Guernsey, Hong Kong, Hungry, Iceland, Ireland, Italy, Japan, Jersey, Latvia, Lithuania, Luxembourg, Malta, Mexico, Monaco, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Turkey and the U.K. that include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire in 2034, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The two families licensed from MedImmune also collectively include, as of December 31, 2021, two patent applications in the United States and 25 patent applications in Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, Russia, Singapore, South Korea and Taiwan. The applications in these families include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from patent applications in these families is presently estimated to expire between 2034 and 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our VIR-2482 intellectual property portfolio also includes patents and patent applications that we have non- exclusively licensed from Xencor. As of December 31, 2021, these patents and applications include five issued patents in the United States directed to composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire in 2025, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2021, these patents and applications include 90 issued patents in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the U.K. directed to composition of matter claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2025 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also own one patent family that includes, as of December 31, 2021, one pending PCT application. These applications include composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2040, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Through our subsidiary Humabs, we co-own a patent family (with MedImmune) that includes, as of December 31, 2021, two issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. This family also includes 51 issued patents in Albania, Australia, Austria, Belgium, Bulgaria, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Gibraltar, Greece, Guernsey, Hong Kong, Hungry, Iceland, Ireland, Italy, Japan, Jersey, Latvia, Lithuania, Luxembourg, Malta, Mexico, Monaco, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Turkey and the U.K. that include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire in 2034, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This co-owned family also includes, as of December 31, 2021, one patent application in the United States and 14 patent applications in Australia, Brazil, Canada, China, Europe, Hong Kong, Japan, South Korea, Mexico, Russia, Singapore and Taiwan. The applications in this family include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2034, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, through our subsidiary Humabs, we own a patent family that includes, as of December 31, 2021, one pending application in the United States and 32 pending applications in Algeria, Australia, Bahrain, Brazil, Canada, Chile, China, Colombia, Egypt, Eurasia, Europe, India, Indonesia, Israel, Japan, Kuwait, Malaysia, Mexico, New Zealand, Nigeria, Oman, Philippines, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Taiwan, Thailand, Ukraine, United Arab Emirates and Vietnam. The application in this family includes composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from the patent application in this family is presently estimated to expire in 2040, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VIR-1111</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our VIR-1111 intellectual property patent portfolio includes seven different patent families that we have exclusively licensed from OHSU.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Six of these families collectively include, as of December 31, 2021, nine issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2031 and 2037, absent any available patent term adjustments or extensions. Additionally, six of the seven patent families collectively include, as of December 31, 2021, 219 issued patents in Albania, ARIPO (Africa), Australia, Austria, Belgium, Bulgaria, Canada, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Macao, Monaco, North Macedonia, Malta, Mexico, New Zealand, Netherlands, Norway, OAPI (Africa), Poland, Portugal, Romania, San Marino, Serbia, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Tunisia, Turkey, Ukraine and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2025 and 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The seven licensed families also collectively include, as of December 31, 2021, nine patent applications in the United States and 89 patent applications in Algeria, ARIPO (Africa), Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, the Dominican Republic, Ecuador, Eurasia, Europe, Guatemala, Hong Kong, Indonesia, Israel, India, Japan, Mexico, New Zealand, Nigeria, Panama, Peru, Singapore, South Africa, South Korea, Thailand and the Ukraine directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from patent applications in these families is presently estimated to expire between 2025 and 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We co-own a patent family that includes, as of December 31, 2021, one issued patent in the United States directed to composition of matter claims and method of treatment claims. The 20-year term of this patent is presently estimated to expire</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in 2035, absent any available patent term adjustments or extensions. The family also includes two patent applications in the United States and 26 patent applications in ARIPO (Africa), Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Indonesia, Israel, India, Japan, Mexico, New Zealand, Singapore, South Africa, South Korea, Thailand and the Ukraine directed to composition of matter claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2035, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Portfolio by Technology Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">siRNA Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our siRNA intellectual property portfolio includes three additional different patent families that we have exclusively licensed from Alnylam.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Two of the three families collectively include, as of December 31, 2021, 10 issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of these patents is presently estimated to expire between 2024 and 2031, absent any available patent term adjustments or extensions. Additionally, the three patent families collectively include, as of December 31, 2021, 66 issued patents in Albania, Australia, Belgium, Canada, China, Croatia, Denmark, Finland, France, Germany, Hungary, Iceland, India, Indonesia, Ireland, Japan, Latvia, Lithuania, Luxembourg, Macao, Monaco, Netherlands, North Macedonia, Norway, Russia, Singapore, Slovenia, South Korea, Sweden, Switzerland and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of these patents is presently estimated to expire between 2024 and 2031, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The three licensed families also collectively include, as of December 31, 2021, two patent applications in the United States and 12 patent applications in Australia, Canada, China, Europe, Hong Kong, India, Japan, South Korea and Thailand directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of the issued patent and any patents issuing from pending patent applications in these families is presently estimated to expire between 2024 and 2031, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have also exclusively licensed from Alnylam, as of December 31, 2021, three issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of these patents is presently estimated to expire between 2022 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also have an exclusive license to additional Alnylam platform technology for HBV licensed products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Antibody Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have exclusively licensed from Rockefeller a patent family that includes, as of December 31, 2021, issued patents in Nigeria and OAPI (Africa), one pending patent application in the United States and 31 pending patent applications in ARIPO (Africa), Algeria, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, the Dominican Republic, Ecuador, Eurasia, Europe, Guatemala, Hong Kong, Indonesia, Israel, India, Japan, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Singapore, South Africa, South Korea, Thailand, the Ukraine and Vietnam. The applications in this family include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from the application in this family is presently estimated to expire in 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have exclusively licensed from IRB two patent families that relate to our antibody platform technology. One of these families includes, as of December 31, 2021, two issued patents in the United States directed to process (methods of producing) claims, and 23 issued patents in Austria, Australia, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, Portugal, Romania, Singapore, Spain, Sweden, Switzerland, Turkey and the U.K. directed to process (methods of producing) claims. The two families also collectively include, as of December 31, 2021, one</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pending patent applications in the United States directed to process (methods of producing) claims, as well as one patent application in the United States and 19 patent applications in Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, India, Indonesia, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, South Korea, Thailand and Ukraine directed to composition of matter claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of the issued patents and any patent issuing from the pending patent applications in these families is presently estimated to expire between 2024 and 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we have non-exclusively licensed a group of patents and applications from Xencor. As of December 31, 2021, these patents and applications include 10 issued patents in the United States directed to composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims, method of treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2028, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2021, these patents and applications include 121 issued patents in Australia, Austria, Belgium, Bulgaria, Canada, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patents and applications we have non-exclusively licensed from Xencor also include, as of December 31, 2021, three patent application pending in the United States and two patent applications pending in China and India, directed to composition of matter claims and process (methods of producing) claims. The 20-year term of any patents issuing from these patent applications is presently estimated to expire between 2023 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">T Cell Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have exclusively licensed from OHSU 10 different patent families related to our T cell portfolio.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Eight of the 10 families collectively include, as of December 31, 2021, 13 issued patents in the United States, directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and process (methods of producing) claims. The 20-year term of the issued patents in these families is presently estimated to expire between 2031 and 2037, absent any available patent term adjustments or extensions. In addition, nine of the 10 families collectively include, as of December 31, 2021, 253 issued patents in Albania, ARIPO (Africa), Australia, Austria, Belgium, Bulgaria, Canada, China, Croatia, Cyprus, Czechia, Denmark, Germany, Estonia, Finland, France, Greece, Hong Kong, Hungary, Iceland, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, North Macedonia, Malta, Macao, Mexico, Monaco, Netherlands, Norway, New Zealand, OAPI (Africa), Poland, Portugal, Romania, San Marino, Serbia, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Tunisia, Turkey, Ukraine and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treating claims and process (methods of producing) claims. The 20-year term of the issued patents in these families is presently estimated to expire between 2025 and 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 10 patent families also collectively include, as of December 31, 2021, eight patent applications in the United States, a pending PCT application and 74 patent applications in Algeria, ARIPO (Africa), Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, the Dominican Republic, Ecuador, Eurasia, Europe, Guatemala, Hong Kong, Indonesia, Israel, India, Japan, Mexico, New Zealand, Nigeria, Panama, Peru, Singapore, South Africa, South Korea, Thailand and the Ukraine directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treating claims and process (methods of producing) claims. The 20-year term of any patents issuing from pending patent applications in these families is presently estimated to expire between 2025 and 2040, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we own two patent families that include, as of December 31, 2021, two patent applications in the United States directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treating claims and process (method of producing) claims. The 20-year term of any patent issuing in these families is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Innate Immunity Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have know-how relating to our innate immunity platform and are continually developing our intellectual property in this area, as well as evaluating external technologies and assets that may also help grow this platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently license or own any patents related to our innate immunity platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Term and Term Extensions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Individual patents have terms for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. In addition, in certain instances, the term of a U.S. patent can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the restoration period cannot extend the patent term beyond 14 years from FDA approval. In addition, only one patent applicable to an approved drug is eligible for the extension, and only those claims covering the approved drug, a method for using it, or a method of manufacturing may be extended. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and various foreign jurisdictions, must be timely paid in order for the patent to remain in force during this period of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The actual protection afforded by a patent may vary on a product by product basis, from country to country, and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions and the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patents and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business. For more information, see the section titled &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Trademarks and Know-How</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the ongoing development and advancement of our products and services in the United States and various international jurisdictions, we seek to create protection for our marks and enhance their value by pursuing trademarks and service marks where available and when appropriate. In addition to patent and trademark protection, we rely upon know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality agreements with our commercial partners, collaborators, employees and consultants, and invention assignment agreements with our employees and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed by our employees and through relationships with third parties. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our contractors, commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For more information, see the section titled &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation and Product Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs and biologics such as those we are developing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, the FDA approves and regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA. Biological products, or biologics, are licensed for marketing under the Public Health Service Act, or the PHSA, and regulated under the FDCA. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products is typically referred to as a sponsor. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or trials or seek approval or licensure of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. Biopharmaceuticals Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The process required by the FDA before drug and biologic product candidates may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of extensive preclinical laboratory tests and animal trials performed in accordance with applicable regulations, including the FDA&#x2019;s Good Laboratory Practice, or GLP, regulations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">design of a clinical protocol and submission to the FDA of an IND application which must become effective before clinical trials may begin; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an independent institutional review board or ethics committee at each clinical site before the trial is commenced; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials in accordance with FDA&#x2019;s Good Clinical Practice, or GCP, regulations to establish the safety and efficacy of a drug candidate and safety, purity and potency of a proposed biologic product candidate for its intended purpose; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation of and submission to the FDA of a new drug application, or NDA, or BLA, as applicable, after completion of all pivotal clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA Advisory Committee review, if applicable; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs and of selected clinical investigation sites to assess compliance with GCPs;  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval of an NDA or BLA to permit commercial marketing of the product for particular indications for use in the United States; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy, or REMS, and any post-approval studies required by the FDA. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical and Clinical Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent institutional review board for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the trial until completed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulatory authorities, the institutional review board or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For purposes of biopharmaceutical development, human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The investigational product is initially introduced into patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The investigational product is administered to a limited patient population to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 3.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 trials may be made a condition to approval of the application. Concurrent with clinical trials, companies may complete additional animal trials and develop additional information about the characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability trials must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research patients or patients are being exposed to an unacceptable health risk. Similarly, an institutional review board can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the institutional review board&#x2019;s requirements or if the biological product candidate has been associated with unexpected serious harm to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived by the FDA. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee and seeking and receiving informed consent from subjects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the PHSA, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. The failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">NDA/BLA Submission and Review</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical trials and clinical trials are submitted to the FDA as part of an NDA or BLA, as applicable, requesting approval to market the product for one or more indications. The application must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of an application requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. The FDA has sixty days from the applicant&#x2019;s submission to either issue a refusal to file letter, or RTF, or accept the application for filing, indicating that it is sufficiently complete to permit substantive review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once an NDA or BLA has been accepted for filing, the FDA&#x2019;s goal is to review standard applications within 10 months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine whether a drug is safe and effective for its intended use and a BLA to determine whether a biologic is safe, pure and potent. The FDA also reviews whether the facility in which the product is manufactured, processed, packed or held meets standards designed to assure and preserve the product&#x2019;s identity, safety, strength, quality, potency and purity. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving an NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an application, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After the FDA evaluates an application and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be manufactured, the FDA may issue an approval letter or a Complete Response letter, or CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the application, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the application in condition for approval, including requests for additional information or clarification, which may include the potential requirement for additional clinical trials. The FDA may delay or refuse approval of an application if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the application with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market trials and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once an NDA or BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any marketing application for a drug or biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. Priority review designation means the FDA&#x2019;s goal is to take action on the marketing application within six months of the 60-day filing date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical trials</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Emergency Use Authorization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In emergency situations, such as a pandemic, and with a declaration of a public health emergency by the Secretary of the Department of Health and Human Services, or HHS, the FDA has the authority to allow unapproved medical products or unapproved uses of cleared or approved medical products to be used to diagnose, treat or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or nuclear warfare threat agents when there are no adequate, approved, and available alternatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under this authority, the FDA may issue an EUA if the following four statutory criteria have been met: (1) a serious or life-threatening condition exists; (2) evidence of effectiveness exists; (3) a risk-benefit analysis shows that the benefits of the product outweigh the risks; and (4) no other alternatives exist for diagnosing, preventing or treating the disease or condition. The &#x201c;may be effective&#x201d; standard for EUAs requires a lower level of evidence than the &#x201c;effectiveness&#x201d; standard that FDA uses for product clearances or approvals in non-emergency situations. The FDA assesses the potential effectiveness of a possible EUA product on a case-by-case basis using a risk-benefit analysis. In determining whether the known and potential benefits of the product outweigh the known and potential risks, the FDA examines the totality of the scientific evidence to make an overall risk-benefit determination. Such evidence, which could arise from a variety of sources, may include (but is not limited to) results of domestic and foreign clinical trials, in vivo efficacy data from animal models, in vitro data, as well as the quality and quantity of the available evidence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once granted, an EUA will remain in effect and generally terminate on the earlier of (1) the determination by the Secretary of HHS that the public health emergency has ceased or (2) a change in the approval status of the product such that the authorized use(s) of the product are no longer unapproved. After the EUA is no longer valid, the product is no longer considered to be legally marketed and one of the FDA&#x2019;s non-emergency premarket pathways would be necessary to resume or continue distribution of the subject product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA also may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect the public health or safety.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 31, 2020, the Secretary of HHS issued a declaration of a public health emergency related to COVID-19. On February 4, 2020, HHS determined that COVID-19 represents a public health emergency that has a significant potential to affect national security or the health and security of U.S. citizens living abroad and, subsequently, declared on March 24, 2020, that circumstances exist to justify the authorization of emergency use of certain medical products, during the COVID-19 pandemic, subject to the terms of any authorization as issued by the FDA. The declaration of the Secretary of HHS has been further updated and the FDA has issued numerous guidances to sponsors seeking to obtain EUAs to diagnose and treat COVID-19.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orphan Drug Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. Among the benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA or BLA application fee.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA or BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective. In September 2021, the Court of Appeals for the 11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Circuit held that, for the purpose of determining the scope of market exclusivity, the term &#x201c;same disease or condition&#x201d; in the statute means the designated &#x201c;rare disease or condition&#x201d; and could not be interpreted by the FDA to mean the &#x201c;indication or use.&#x201d; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#x201c;indication or use.&#x201d; It is unclear how this court decision will be implemented by the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Biopharmaceutical manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market trials or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning or untitled letters or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal of the FDA to permit the import or export of products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA closely regulates the marketing, labeling, advertising and promotion of biopharmaceutical products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. In September 2021, the FDA published final regulations which describe the types of evidence that the FDA will consider in determining the intended use of a drug or biologic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Biosimilars and Regulatory Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has approved a number of biosimilars and the first interchangeable biosimilar product was approved on July 30, 2021, and a second product previously approved as a biosimilar was designated as interchangeable in October 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical trials, animal trials and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. Since passage of the BPCIA, many states have passed laws or amendments to laws that address pharmacy practices involving biosimilar products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Generic Drugs and Regulatory Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#x2019;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application, or ANDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed &#x201c;abbreviated&#x201d; because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo or other testing. The generic version must deliver the same amount of active ingredient(s) in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug. In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#x2019;s drug or a method of using the drug. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earliest of 30 months after the receipt of the Paragraph IV notice, expiration of the patent and a decision in the infringement case that is favorable to the ANDA or 505(b)(2) NDA applicant. If the applicant does not challenge the listed patents, or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA also cannot approve an ANDA or 505(b)(2) application until all applicable non-patent exclusivities listed in the Orange Book for the branded reference drug have expired. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity upon NDA approval of a new chemical entity, or NCE, which is a drug containing an active moiety that has not been approved by FDA in any other NDA. This interpretation was confirmed with enactment of the Ensuring Innovation Act in April 2021. An &#x201c;active moiety&#x201d; is defined as the molecule responsible for the drug substance&#x2019;s physiological or pharmacologic action. During that five-year exclusivity period, the FDA cannot accept for filing (and therefore cannot approve) any ANDA seeking approval of a generic version of that drug or any 505(b)(2) NDA that relies on the FDA&#x2019;s approval of the drug, provided that the FDA may accept an ANDA four years into the NCE exclusivity period if the ANDA applicant also files a paragraph IV certification.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pediatric exclusivity is a type of non&#x2011;patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of exclusivity. For drug products, the six-month exclusivity may be attached to the term of any existing patent or regulatory exclusivity, including the orphan exclusivity and regulatory exclusivities available under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act. For biologic products, the six-month period may be attached to any existing regulatory exclusivities but not to any patent terms. The conditions for pediatric exclusivity include the FDA&#x2019;s determination that information relating to the use of a new product in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric clinical trials, and the sponsor agreeing to perform, and reporting on, the requested clinical trials within the statutory timeframe. This six&#x2011;month exclusivity may be granted if a sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#x2019;s request, the additional protection is granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Term Restoration and Extension</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, a patent claiming a new product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch&#x2011;Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one&#x2011;half the time between the effective date of the IND involving human beings and the submission date of the NDA or BLA, plus the time between the submission date of the application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#x2019;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension in consultation with the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Federal and State Fraud and Abuse, and Transparency Laws and Regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to strict FDA regulation of marketing of biopharmaceutical products, federal and state healthcare laws strictly regulate business practices in the biopharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business or financial arrangements and relationships with healthcare providers and other parties through which we market, sell and distribute our products for which we obtain marketing approval. These laws include</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">anti-kickback and false claims laws and regulations, and transparency laws and regulations, including, without limitation, those laws described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The U.S. federal Anti-Kickback Statute prohibits any person or entity from, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#x201c;remuneration&#x201d; has been broadly interpreted to include anything of value. The U.S. federal Anti-Kickback Statute has been interpreted to apply to, among others, arrangements between biopharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common arrangements and other activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Courts have interpreted the statute&#x2019;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal civil and criminal false claims laws, including the federal civil False Claims Act, which can be enforced by individuals through civil whistleblower and qui tam actions, and civil monetary penalties laws, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#x201c;any request or demand&#x201d; for money or property presented to the U.S. government. A number of biopharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing payments or other items of value to customers with the expectation that the customers would bill federal programs for their products or services. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#x2019; marketing of products for unapproved, and thus non-reimbursable, uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. As of January 2022, applicable manufacturers are also required to report such information regarding its payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be subject to state laws that require biopharmaceutical companies to comply with the biopharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing, and state and local laws that require the registration of biopharmaceutical sales representatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, implementation of corporate compliance programs, and reporting of payments or transfers of value to healthcare professionals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The future commercial success of our product candidates, if approved, will depend in part on the extent to which third-party payors, such as governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers and other third-party payors, provide coverage of and establish adequate reimbursement levels for our product candidates. Third-party payors generally decide which products they will pay for and establish reimbursement levels for those products. In particular, in the United States, no uniform policy for coverage and reimbursement exists. Private health insurers and other third-party payors often provide coverage and reimbursement for products based on the level at which the government, through the Medicare program, provides coverage and reimbursement for such products, but also on their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement can differ significantly from payor to payor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, the EU and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of products, particularly for new and innovative products, which often has resulted in average selling prices lower than they would otherwise be. Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage. These pressures can arise from rules and practices of managed care groups, judicial decisions and laws and regulations related to Medicare, Medicaid and healthcare reform, biopharmaceutical coverage and reimbursement policies and pricing in general.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors are increasingly imposing additional requirements and restrictions on coverage and limiting reimbursement levels for products. For example, federal and state governments reimburse products at varying rates generally below average wholesale price. These restrictions and limitations influence the purchase of products. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. Similarly, because certain of our product candidates are physician-administered, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may only be reimbursed for providing the treatment or procedure in which our product is used. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of products, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic trials in order to demonstrate the medical necessity and cost-effectiveness of our product candidates, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party payor reimbursement may not be available to enable us to realize an appropriate return on our investment in product development. Legislative proposals to reform healthcare or reduce costs under government insurance programs may result in lower reimbursement for our product candidates, if approved, or exclusion of our product candidates from coverage and reimbursement. The cost containment measures that third-party payors and providers are instituting and any healthcare reform could significantly reduce our revenue from the sale of any approved product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United States and some foreign jurisdictions are considering enacting or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our product candidates profitably, if approved. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the biopharmaceutical industry has been a particular focus of these efforts, which include major legislative initiatives to reduce the cost of care through changes in the healthcare system, including limits on the pricing, coverage, and reimbursement of biopharmaceutical products, especially under government-funded healthcare programs, and increased governmental control of drug pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been several U.S. government initiatives over the past few years to fund and incentivize certain comparative effectiveness research, including creation of the Patient-Centered Outcomes Research Institute under the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#x2019;s product could adversely affect the sales of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ACA became law in March 2010 and substantially changed the way healthcare is financed by third-party payors, and significantly impacts the U.S. biopharmaceutical industry. Among other measures that may have an impact on our business, the ACA established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; a new Medicare Part D coverage gap discount program; and a new formula that increased the rebates a manufacturer must pay under the Medicaid Drug Rebate Program. Additionally, the ACA extended manufacturers&#x2019; Medicaid rebate liability, expands eligibility criteria for Medicaid programs, and expanded entities eligible for discounts under the PHSA. At this time, we are unsure of the full impact that the ACA will have on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for pharmaceutical products under government healthcare programs. Other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#x2019;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. Pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, and subsequent legislation, these Medicare sequester reductions have been suspended through the end of March 2022. From April 2022 through June 2022 a 1% sequester cut will be in effect, with the full 2% cut resuming thereafter.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, or the Tax Act, which was signed by President Trump on December 22, 2017, Congress repealed the &#x201c;individual mandate.&#x201d; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case on November 10, 2020 and, on June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. Congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020 President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed by the Biden administration until January 1, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control biopharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, and wholesale distributors, to disclose information about pricing of pharmaceuticals. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These measures could reduce future demand for our products or put pressure on our pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our product candidates. For example, in the EU, we must obtain authorization of a clinical trial application in each member state in which we intend to conduct a clinical trial. Whether or not we obtain FDA approval for a drug, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the drug in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, some countries outside of the United States, including the EU member states, Switzerland and the U.K., have also adopted data protection laws and regulations, which impose significant compliance obligations. In the EU, the collection and use of personal health data is governed by the provisions of the General Data Protection Regulation, or GDPR. The GDPR, together with the national legislation of the EU member states governing the processing of personal data, impose strict obligations and restrictions on the ability to process personal data, including health data from clinical trials and adverse event reporting. For additional information regarding the GDPR, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Privacy Laws.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Privacy Laws</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We, and our service providers, receive, process, store and use personal information and other data about our clinical trial participants, employees, collaborators and others. We are subject to numerous domestic and foreign laws and regulations regarding privacy and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the federal level, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, impose specific requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. HITECH, among other things, also increased the civil and criminal penalties that may be imposed for non-compliance with the law, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#x2019;s fees and costs associated with pursuing federal civil actions. Penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include significant civil monetary penalties and, in certain circumstances, criminal penalties and/or imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Various states, such as California and Massachusetts, have implemented privacy laws and regulations similar to HIPAA, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information. These laws and regulations are not necessarily preempted by HIPAA, particularly if a state affords greater protection to individuals than HIPAA. Where state laws are more protective, we have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California&#x2019;s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the California Consumer Privacy Act, the CCPA, which took effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches, which is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. It is anticipated that the CCPA will be expanded on January 1, 2023, when the California Privacy Rights Act of 2020, the CPRA, becomes operative. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal information, further restrict the use of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cross-contextual advertising, establish restrictions on the retention of personal information, expand the types of data breaches subject to the CCPA&#x2019;s private right of action, provide for increased penalties for CPRA violations concerning California residents under the age of 16, and establish a new California Privacy Protection Agency to implement and enforce the new law. Some observers have noted that the CCPA and CPRA could mark the beginning of a trend toward more stringent state privacy, data protection and data security legislation in the U.S., which could increase our potential liability and adversely affect our business. Furthermore, the interplay of federal laws&#x2014;such as HIPAA&#x2014;and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and data we receive, use and share, potentially exposing us to additional expense, adverse publicity and liability.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulation of privacy, data protection and data security has also become more stringent in foreign jurisdictions. For example, the EU adopted the GDPR, which imposes onerous and comprehensive privacy, data protection, and data security obligations onto data controllers and processors, including, as applicable, contractual privacy, data protection, and data security commitments, expanded disclosures to data subjects about how their personal information is used, honoring individuals&#x2019; data protection rights, limitations on retention of personal information, additional requirements pertaining to sensitive information (such as health data) and pseudonymized (i.e., key-coded) data, data breach notification requirements, and higher standards for obtaining consent from data subjects. Penalties for non-compliance with the GDPR can be significant and include fines in the amount of the greater of &#x20ac;20 million or 4% of global turnover and restrictions or prohibitions on data processing, which could hinder our ability to do business in the EU, reduce demand for our services and adversely impact our business and results of operations. The GDPR also provides that EU member states may implement further laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to collect, use and share European data, or could cause our compliance costs to increase, require us to change our practices, adversely impact our business, and harm our financial condition. Assisting parties with whom we exchange personal data in complying with the GDPR, or complying with the GDPR ourselves, may cause us to incur substantial operational costs or require us to change our business practices.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, European privacy, data protection, and data security laws, including the GDPR, generally restrict the transfer of personal information from the U.K., European Economic Area, or EEA, and Switzerland to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. There is uncertainty as to how to implement such safeguards and how to conduct such transfers in compliance with the GDPR, and certain safeguards may not be available or applicable with respect to some or all of the personal information processing activities necessary to research, develop and market our products and services. One of the primary safeguards allowing U.S. companies to import personal information from Europe has been certification to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks. However, the EU-U.S. Privacy Shield framework was invalidated in July 2020 in a decision by the Court of Justice of the European Union and the Swiss-U.S. Privacy Shield Framework was declared as inadequate by the Swiss Federal Data Protection and Information Commissioner. The decision by the Court of Justice and the announcement by the Swiss Commissioner both raised questions about whether one of the primary alternatives to the Privacy Shield frameworks, the European Commission&#x2019;s Standard Contractual Clauses, can lawfully be used for personal information transfers from Europe to the United States or most other countries. Authorities in the U.K. may similarly invalidate use of the EU-U.S. Privacy Shield and raise questions on the viability of the Standard Contractual Clauses. In November 2020, EU regulators proposed a new set of Standard Contractual Clauses, which impose additional obligations and requirements with respect to the transfer of EU personal data to other jurisdictions, which may increase the legal risks and liabilities under the GDPR and local EU laws associated with cross-border data transfers, and result in material increased compliance and operational costs. If we are unable to implement a valid mechanism for personal information transfers to the United States and other countries, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal information from Europe, and we may be required to increase our data processing capabilities in Europe at significant expense. Inability to import personal information from Europe to the United States or other countries may limit our ability to conduct clinical trials in Europe and collaborate with other entities subject to European data protection laws. At present, there are few, if any, viable alternatives to the Privacy Shield and the Standard Contractual Clauses. Other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, it is unclear whether the transfer of personal information from the EU to the U.K. will continue to remain lawful under the GDPR in light of Brexit. Pursuant to a post-Brexit trade deal between the U.K. and the EU, transfers of personal information from the EEA to the U.K. are not considered restricted transfers under the GDPR for a period of up to four months from January 1, 2021 with a potential two-month extension. However, unless the EU Commission makes an adequacy finding with respect to the U.K. before the end of that period, the U.K. will be considered a &#x201c;third country&#x201d; under the GDPR and transfers of European personal information to the U.K. will require an adequacy mechanism to render such transfers lawful under the GDPR. Additionally, although U.K. privacy, data protection and data security laws are designed to be consistent with the GDPR, uncertainty remains regarding how data transfers to and from the U.K. will be regulated notwithstanding Brexit.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compliance with U.S. and foreign privacy, data protection, and data security laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We may rely on others, such as health care providers, to obtain valid and appropriate consents from data subjects whose data we process. The failure of third parties to obtain consents that are valid under applicable law could result in our own non-compliance with privacy laws. Such failure to comply with U.S. and foreign privacy, data protection, and data security laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with privacy, data protection, and data security laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Human Capital Management</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 444 full-time employees, 318 of whom were primarily engaged in research and development activities. Substantially all of our employees are located in San Francisco, California; Portland, Oregon; and Bellinzona, Switzerland. None of our employees are represented by a labor union and we consider our employee relations to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the clinical development of our product candidates progresses, we expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research, development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. In addition, we also expect to hire additional personnel in order to sustain operations as a public company.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purpose of our equity incentive plan is to attract, retain, and motivate our employees, non-employee directors, and consultants through the granting of stock-based compensation and performance cash awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Response to COVID-19</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With the global spread of the current COVID-19 pandemic, we have implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on our employees and our business. We continue to closely monitor the COVID-19 situation and will evolve our plans and policies as needed going forward. As a result of these developments, in March 2020, we implemented work-from-home policies for most of our employees. We have also implemented plans, which continue to evolve based on the current climate and response to the ongoing COVID-19 pandemic, to reopen our offices to allow employees to return when appropriate. Although these plans are based on a phased approach consistent with local government requirements, and focused on employee safety, and contemplate returning to remote work should new restrictions be implemented, there is uncertainty regarding recent phased reopening, which may be rolled back, and restrictions re-implemented. We are also working to provide our employees with the support they need to ensure continuity of business operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were incorporated under the laws of the State of Delaware on April 7, 2016. Our principal executive offices are located at 499 Illinois Street, Suite 500, San Francisco, California 94158, and our telephone number is (415) 906-4324. Our corporate website address is www.vir.bio. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this Annual Report on Form 10-K, and the inclusion of our website address in this report is an inactive textual reference only. We make available free of charge through our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. We may use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation Fair Disclosure promulgated by the SEC. These disclosures will be included on our website under the &#x201c;Investors&#x201d; section.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">k Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors as well as the other information in this Annual Report on Form 10-K, including our audited consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d;, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and/or prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. You should consider all of the risk factors described when evaluating our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Financial Position and Capital Needs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have incurred net losses and anticipate that we may continue to incur net losses in the foreseeable future and therefore, may not be able to maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we recorded net income for the year ended December 31, 2021, we have otherwise incurred accumulated net losses since inception in April 2016. We had net income of $528.6 million for the year ended December 31, 2021, and net loss of $298.7 million and $174.7 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2021, we had an accumulated deficit of $138.6 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to continue to incur significant expenses and may continue to incur net losses in the foreseeable future. Since inception, we have devoted substantially all of our efforts to identifying, researching and conducting preclinical and clinical activities of our product candidates, acquiring and developing our technology platforms and product candidates, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. We have received an Emergency Use Authorization, or EUA, from the U.S. Food and Drug Administration, or FDA, and a positive scientific opinion from the Committee for Human Medicinal Products, or CHMP, in the European Union, or EU, for sotrovimab (previously VIR-7831). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name Xevudy&#174;) in more than 40 countries. Althou</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">gh we (through our collaborator Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. (individually and collectively referred to as GSK)) have recently entered into procurement agreements to supply sotrovimab to governments around the world and began to recognize revenue for sotrovimab, the extent of future revenue remains uncertain. However, there are no assurances that we will secure additional supply commitments from governments. In addition, COVID-19 treatment standards are susceptible to rapid changes in epidemiology and the emergence of new variants, thus, sotrovimab may be rendered inferior or obsolete in the future. It could be several years, if ever, before we are able to commercialize any of our other product candidates. Any net losses we incur may fluctuate significantly from quarter to quarter and year to year. To remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our current and future product candidates, obtaining regulatory approval, procuring commercial-scale manufacturing, marketing and selling any products for which we obtain regulatory approval (including through third parties), as well as discovering or acquiring and developing additional product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may not be able to continue to generate revenue that is sufficient to offset our expenses and maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of expenses, or if, we will be able to maintain profitability. If we are required by regulatory authorities to perform studies and trials in addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase. For example, the FDA has asked for additional data to support our conclusion that the 500 mg IV dose of sotrovimab retains activity against the BA.2 Omicron subvariant based on our current modeling assumptions as well as safety data for higher doses. We could be required to perform additional studies and trials on sotrovimab based on any additional feedback we may receive from the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a commercial-stage company founded in April 2016 and our operations to date have been largely focused on identifying, researching and conducting preclinical and clinical activities of our product candidates, acquiring and developing our technology platforms and product candidates, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab has received an EUA from the FDA and marketing authorization in the EU. To date, sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name Xevudy&#174;) in more than 40 countries. We </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">are in the early stages of seeking approval under a biologics license application, or BLA, and expanding our commercialization capabilities for sotrovimab. As an organization, we have not yet demonstrated an ability to successfully manufacture a BLA-approved, commercial-scale product or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have four technology platforms and eight product candidates in our development pipeline. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives, including with respect to our technology platforms and product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, excluding restricted cash, we had cash, cash equivalents and investments of $909.5 million and by also excluding the equity investment in Brii Biosciences Limited, or Brii Bio Parent, we had $766.4 million. Based upon our current operating plan, we believe that the $766.4 million as of December 31, 2021 will fund our current operating plan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s for at least the next 12 months. How</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ever, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned. Moreover, it is particularly difficult to estimate with certainty our future expenses given the dynamic and rapidly evolving nature of our business and the COVID-19 pandemic environment generally. We may also need to raise additional capital to complete the development and commercialization of our EUA product or our product candidates and fund certain of our existing manufacturing and other commitments. We expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing, progress and results of our ongoing preclinical studies and clinical trials of our EUA product and other product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of other product candidates that we may pursue; </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and maintain collaboration, license, grant and other similar arrangements, and the financial terms of any such arrangements, including timing and amount of any future milestones, royalty or other payments due thereunder; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our EUA product and other product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of commercialization activities, including product manufacturing, marketing, sales and distribution, for our EUA product and any of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amount of revenue received from commercial sales of our EUA product or any product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of operating as a public company; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we acquire or in-license other companies&#x2019; product candidates and technologies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic and the evolution of new and existing variants of COVID-19 have resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional capital, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments. In addition, market volatility, inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether terminate our research and development programs or commercialization efforts, which may adversely affect our business, financial condition, results of operations and prospects. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest in our company may be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we raise additional capital through future collaborations, strategic alliances or licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We received an EUA from the FDA for sotrovimab. If the FDA revokes or terminates our EUA for sotrovimab for the early treatment of COVID-19, the disease caused by the virus SARS-CoV-2, or the federally-declared COVID-19 public health emergency ends, we will be required to stop commercial distribution of sotrovimab in the United States unless we can obtain FDA approval for this product and its currently authorized uses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab is currently made available pursuant to an EUA we received from the FDA on May 26, 2021 for the early treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at risk for progression to severe COVID-19, including hospitalization or death. The FDA will periodically review the circumstances and appropriateness of an EUA, including circumstances that might warrant revocation of the EUA. The review will include regular assessment based on additional information provided by the sponsor of the progress made with respect to the approval, licensure, or clearance of the unapproved product, or of the unapproved use of an approved product, for which an EUA was issued. The FDA may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect the public health or safety. Such circumstances may include significant adverse inspectional findings; reports of adverse events linked to, or suspected of being caused by, the EUA product; a material change in the risk/benefit assessment based on evolving understanding of the disease or condition and/or availability of authorized medical products; or a change in the approval status of the product may make an EUA unnecessary. An EUA may also be terminated upon a declaration by the Secretary of the Health and Human Services, or HHS, that the public health emergency has ended. We cannot predict how long our EUA will remain in effect, and we may not receive advance notice from the FDA regarding revocation of our EUA or withdrawal of the public health emergency declaration. If our EUA is terminated or revoked, sotrovimab will no longer be available in the United States unless and until we have obtained FDA approval of a BLA for the product. Changing policies and regulatory requirements could limit, delay or prevent further commercialization of sotrovimab and could adversely impact our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are committing substantial financial resources and personnel and making substantial capital commitments with third parties in connection with sotrovimab as a therapy for COVID-19. Market demand and utilization of sotrovimab or any of our other COVID-19 product candidates may be adversely impacted by factors such as the development of monoclonal antibodies, or mAbs, of other third parties, the rollout of vaccines and oral antivirals, the emergence of new viral variants, and the current challenges in the delivery and administration of mAbs to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In response to the ongoing COVID-19 pandemic, we are pursuing various potential therapies to address the disease, including through mAbs using our antibody platform (in collaboration with several partners), such as sotrovimab and VIR-7832. Sotrovimab has received an EUA from the FDA and marketing authorization in the EU.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> To date, sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name Xevudy&#174;) in more than 40 countries. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also, we (through our collaborator GSK) have recently entered into procurement agreements to supply sotrovimab to governments around the world;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> however, there are no assurances that we will secure additional supply commitments from governments</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We have not received regulatory approval for any of our other product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are committing substantial financial resources, both internally and externally, and personnel to the development of a therapy for COVID-19, which may cause delays in or otherwise negatively impact our other development programs. There are no assurances that there will be sufficient market demand for sotrovimab or our other COVID-19 product candidates. Market demand and utilization of sotrovimab or any of our other COVID-19 product candidates may be adversely impacted by factors such as the development of mAbs of other third parties, the rollout of vaccines and oral antivirals, the emergence of new viral variants, and the current challenges in the delivery and administration of mAbs to patients. In addition, COVID-19 treatment standards are susceptible to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">rapid changes in epidemiology and the emergence of new variants, thus, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sotrovimab may be rendered inferior or obsolete in the future, even if it were to gain widespread market acceptance initially. If sotrovimab is rendered inferior or obsolete in the future, our financial condition and business may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to develop a successful therapy will also depend on the success of our manufacturing capabilities, for which we are dependent on third-party manufacturing organizations and which will require significant additional funding. Our current estimated aggregate commitments to GSK under two separate master services agreements with Samsung Biologics Co., Ltd. and WuXi Biologics (Hong Kong) Limited, or WuXi Biologics, for drug substance, drug product and raw material were approximately $188 million as of December 31, 2021. For additional information regarding our obligations under these agreements, see the section titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x201d; and &#x201c;Business&#x2014;Manufacturing&#x2014;Manufacturing Agreements.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we believe securing such manufacturing capacity and technological expertise is essential to the potential success of our SARS-CoV-2 antibody development programs, such capital commitments plus any future commitments, in the aggregate, may, in the future, exceed our available cash and cash equivalents and investments. We may also need to enter into additional manufacturing arrangements in the future in order to create an effective supply chain for sotrovimab and our other COVID-19 product candidates that will adequately support demand. In the event that there is not enough demand for the manufacturing capacity that we have already secured or regulatory approval of our product candidates is delayed or unsuccessful, we may remain obligated to pay for such excess manufacturing capacity, which could adversely affect our business, financial condition, results of operations and prospects. We will need to raise substantial additional capital to fund the development of sotrovimab and our other product candidates and meet our capital commitments to our manufacturing partners in connection therewith. There can be no assurance that sufficient funds will be available to us on attractive terms or at all and our ability to obtain additional capital could be adversely affected if there is a significant decline in the demand for our products or other significantly unfavorable changes in economic conditions. If we are unable to obtain additional funding from these or other sources, it may be necessary to significantly reduce our rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. Our business could be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable or against which our potential therapies, if developed, may not be partially or fully effective, and may ultimately prove unsuccessful or unprofitable. Furthermore, there are no assurances that we will secure additional supply commitments from governments, which may be material to the commercial success of sotrovimab and our product candidates, either in the United States or abroad.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are also efforts by other companies in developing prophylactic vaccines against COVID-19. For example, in August 2021 Pfizer Inc.&#x2019;s, or Pfizer, COVID-19 vaccine, Comirnaty&#174;, which has been proven to be 95% effective in clinical trials, was approved by the FDA for individuals 16 years of age or older and is also available under EUA for individuals 12 through 15 years of age. In January 2022, Moderna, Inc.'s vaccine, Spikevax&#174;, which has proven to be 94% effective in clinical trials, was approved by the FDA for individuals 18 years of age or older. In addition, in February 2021 Janssen Biotech, Inc. received EUA from the FDA for its COVID-19 vaccine, which has been proven to be 85% effective in clinical trials. These other entities may be more successful at developing, manufacturing or commercializing a therapy for COVID-19. Several of these other organizations are much larger than we are and have access to larger pools of capital, including U.S. government funding, and broader manufacturing infrastructure. There are no assurances that there will be sufficient market demand for our COVID-19 therapies, that we will secure U.S. government funding, that our manufacturing and supply chain infrastructure will remain uninterrupted and reliable, or that the third parties we rely on to manufacture our COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">therapies will be able to satisfy demand in a timely manner and not have supply chain disruptions due to COVID-19 related shutdowns, stock-outs due to raw material shortages and/or greater than anticipated demand or quality issues given the operational challenges and raw material shortages that have been experienced during the COVID-19 pandemic, all of which may adversely impact our ability to commercialize a therapy for COVID-19. In addition, several organizations have already secured significant commitments from governments to purchase COVID-19 antibodies, oral antivirals, and vaccines. The success or failure of other entities, or perceived success or failure, may adversely impact our ability to obtain any future funding for our development and manufacturing efforts or to successfully commercialize a therapy for COVID-19. Additionally, the availability of superior or competitive therapies, or preventative measures such as vaccines or oral antivirals, coupled with the transient nature of pandemics, could negatively impact or eliminate demand for our COVID-19 therapies. For additional information regarding our competition see the section below titled &#x201c;&#x2014;Risks Related to the Development and Commercialization &#x2014; We face substantial competition, which may result in others developing or commercializing products before or more successfully than us.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our near-term success is dependent on the successful commercialization of sotrovimab for the early treatment of COVID-19, including our ability to enter into additional procurement contracts with government entities. If we are unable to successfully commercialize sotrovimab, our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In addition, sotrovimab may be rendered inferior or obsolete, even if it were to gain widespread market acceptance initially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our near-term success is dependent on the successful commercialization of sotrovimab, which is our only currently available commercial product. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The commercial success of sotrovimab will depend on a number of factors, some of which are outside of our control, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to comply with all regulatory requirements applicable to our EUA, including applicable FDA marketing, manufacturing and post-market requirements and other requirements of our EUA;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether we are required by the FDA or other similar regulatory authorities to conduct additional clinical trials or to modify the design of our current trials to support the approval of sotrovimab;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the receipt of additional marketing authorizations and approvals from the FDA and other similar regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to achieve and maintain compliance with all regulatory requirements applicable to sotrovimab;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">perceptions by the public and members of the medical community, including physicians, as to the safety and efficacy of sotrovimab as well as the accuracy and sufficiency of clinical evidence supporting its performance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">demand from the public and members of the medical community for sotrovimab;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability, perceived advantages, relative cost, relative convenience and relative efficacy of sotrovimab compared to other COVID-19 therapies as well as the accuracy and sufficiency of clinical evidence supporting its performance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of sotrovimab to be effective in patients with COVID-19 and its variants;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">positive or negative media coverage of sotrovimab;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effectiveness of our marketing and sales efforts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to raise additional capital on acceptable terms, or at all, if needed to support the commercialization of sotrovimab;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to enter into additional procurement contracts with government entities, and our ability to meet our obligations under such contracts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our reliance on GSK and other collaborators for development, commercialization and manufacturing of sotrovimab; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain, maintain and enforce our intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to maintain a continued supply of sotrovimab that meets our quality control requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of third-party manufacturing partners to meet demand in a timely manner, in accordance with our specifications, and in compliance with applicable regulatory requirements;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitation on use or warnings required by the FDA; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our current and future arrangements with healthcare providers, physicians and third-party payors; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">availability of, or changes in, coverage or reimbursement rates for sotrovimab from government or other commercial or healthcare payors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, COVID-19 treatment standards are susceptible to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">rapid changes in epidemiology and the emergence of new variants, thus, sotrovimab may be rendered inferior or obsolete, even if it were to gain widespread market acceptance initially. Initial feedback from the FDA question our conclusion that the 500 mg IV dose of sotrovimab retains activity against the BA.2 Omicron subvariant based on our current modeling assumptions, and the FDA has asked for additional data to support our position. The FDA also requested safety data for higher doses. Both have been provided to the FDA and we are awaiting further correspondence. We could be required to perform additional studies and trials on sotrovimab based on any additional feedback we may receive from the FDA or the FDA could amend the terms of our EUA to limit the circumstances under which sotrovimab could be used as an early treatment for COVID-19.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to successfully commercialize sotrovimab, our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Development and Commercialization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our EUA product and product candidates in a timely manner. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have invested a significant portion of our time and financial resources in the development of our product candidates. Our business is dependent on our ability to successfully complete development of, obtain regulatory approval for, and successfully commercialize our EUA product and other product candidates, if approved, in a timely manner. We may face unforeseen challenges in our product development strategy, and we can provide no assurances that our product candidates will be successful in clinical trials or will ultimately receive regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We initiated clinical trials for multiple product candidates. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab has received an EUA from the FDA and marketing authorization in the EU. To date, sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name Xevudy&#174;) in more than 40 countries. The FDA may, under certain circumstances, revise or revoke an EUA. If our EUA is terminated or revoked, sotrovimab will no longer be available in the United States unless and until we have obtained FDA approval of a BLA for the product. W</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e have not obtained BLA approval for sotrovimab or any other product candidate to date. We operate in a highly regulated field, and it is possible that any product candidate we may seek to develop in the future will not obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidate is safe and effective for its intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval for further development, manufacturing or commercialization of our product candidates by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program, requiring their alteration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we eventually complete clinical testing and receive approval of a new drug application, or NDA, BLA, or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve or authorize for marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain applicable regulatory approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, even if we obtain regulatory approval for our product candidates, we may still need to develop a commercial organization, establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors, including government health administration authorities. If we are unable to successfully commercialize our product candidates or if there is an insufficient demand for our product candidates, we may not be able to generate sufficient revenue to continue our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The development of additional product candidates is risky and uncertain, and we can provide no assurances that we will be able to replicate our approach for other diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A core element of our business strategy is to expand our product candidate pipeline. Efforts to identify, acquire or in-license, and then develop product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our efforts may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development, approved products or commercial revenue for many reasons.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have limited financial and management resources and, as a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, strategic alliances, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. In addition, we may not be successful in replicating our approach to development for other disease indications. If we are unsuccessful in identifying and developing additional product candidates or are unable to do so, our business may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are developing, and in the future may develop, other product candidates in combination with other therapies, which exposes us to additional risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing VIR-2218 and VIR-3434 for the functional cure of hepatitis B virus, or HBV. Each of these product candidates has the potential to stimulate an effective immune response and also has direct antiviral activity against HBV. We believe that a functional cure for HBV will require an effective immune response, in addition to antiviral activity, based on the observation that severe immunosuppression can reactivate HBV disease. Monotherapy with each of these agents may provide a functional cure in some patients, while combination therapy may be necessary for others. We have an ongoing Phase 2 clinical trial that combines VIR-2218 with pegylated interferon-alpha and a Phase 2 clinical trial that combines VIR-2218 with VIR-3434. We are also evaluating additional combinations with other immunotherapy agents and direct acting antiviral agents. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate. There is also a risk that safety, efficacy, manufacturing or supply issues could arise with these other existing therapies. This could result in our own products being removed from the market or being less successful commercially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also evaluate our future product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market any product candidate we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the FDA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals and market authorizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Success in preclinical studies and earlier clinical trials does not ensure that later efficacy trials will be successful, nor does it predict final results. Our product candidates may fail to show the desired characteristics in clinical development sufficient to obtain regulatory approval, despite positive results in preclinical studies or having successfully advanced through earlier clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A trial design that is considered appropriate for regulatory approval includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. If we do not conduct clinical trials with a large enough patient sample size, we may not achieve statistically significant results or the same level of statistical significance, if any, that would have been possible to achieve in a larger trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval, which could mean we will suffer setbacks. Any such setbacks could negatively impact our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interim, &#x201c;top-line&#x201d; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may publish interim, &#x201c;top-line&#x201d; or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#x201c;top-line&#x201d; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data is available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical product development involves a lengthy and expensive process. We may incur additional costs and encounter substantial delays or difficulties in our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not commercialize, market, promote or sell any product candidate without obtaining marketing approval from the FDA or comparable foreign regulatory authority, and we may never receive such approvals. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We may experience numerous unforeseen events prior to, during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future product sales or other sources. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring competing products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be delayed in obtaining marketing approval, or not obtain marketing approval at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a risk evaluation and mitigation strategy, or REMS; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be subject to the addition of labeling statements, such as warnings or contraindications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be sued; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience damage to our reputation. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, our product candidates are based on certain innovative technology platforms, which makes it even more difficult to predict the time and cost of product candidate development and obtaining necessary regulatory approvals, particularly for our small interfering ribonucleic acid, or siRNA, and cytomegalovirus, or CMV, vector technologies. Relatively few siRNA product candidates have ever been tested in humans and to date few have received regulatory approval and market authorizations. In addition, the compounds we are developing may not demonstrate in patients the chemical and pharmacological properties ascribed to them in preclinical studies, and they may interact with human biological systems in unforeseen, ineffective or harmful ways.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of our T cell platform, our approach is to use human CMV, or HCMV, as a vaccine vector to potentially treat and prevent pathogens refractory to current vaccine technologies because HCMV may induce potent and long-lasting T cell responses to a broader range of epitopes than observed for other viral vaccines. Safety and toxicity trials for this technology have so far only been conducted in animal species, in which HCMV has limited ability to replicate. If our first clinical trial for VIR-1111 causes unexpected side effects that are not tolerable in the treatment of the relevant patient group, the further development of the product candidates and any other potential products based on HCMV-vector technology may be significantly limited or become impossible. Also, because our HCMV-vector technology is novel, regulatory agencies may lack experience with product candidates such as VIR-1111, which may lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates. In addition, our HCMV-vector technology utilizes live-attenuated, genetically-modified organisms for which the FDA, the EMA, and other comparable foreign regulatory authorities and other public health authorities, such as the Centers for Disease Control and Prevention and hospitals involved in clinical trials, have established additional safety and contagion rules and procedures, which could establish additional hurdles for the development, manufacture or use of our vectors. These hurdles may lead to delays in the conduct of clinical trials or in obtaining regulatory approvals for further development, manufacturing or commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, we, the FDA, a foreign regulatory authority or an institutional review board may place a full or partial hold on our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#x2019;s current Good Clinical Practice, or GCP, regulations, that we are exposing participants to unacceptable health risks, or if the FDA or foreign regulatory authority finds deficiencies in our investigational new drug, or IND, applications or clinical trial applications, respectively, or the conduct of these trials. Moreover, we may not be able to file INDs to commence additional clinical trials on the timelines we expect because our filing schedule is dependent on further preclinical and manufacturing progress. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenue from our product candidates may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside our control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identifying and qualifying patients to participate in our clinical trials is critical to our success. We are developing sotrovimab and VIR-7832 for the treatment of COVID-19, VIR-2218 and VIR-3434 for the treatment of HBV, VIR-2482 for the prevention of influenza A, and VIR-1111 for the prevention of human immunodeficiency virus, or HIV. In particular, clinical trials for prophylaxis tend to require enrollment of a larger number of subjects than clinical trials for treatments. We may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depend on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the trial. The enrollment and retention of patients in the clinical trials for sotrovimab and VIR-7832 for the treatment of COVID-19 may be disrupted or delayed as a result of clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of sotrovimab and VIR-7832 in relation to other available therapies, including products that have been recently authorized under EUAs or approved and licensed through NDAs and BLAs to treat COVID-19 as well as any other new products that may be approved in the future for the treatment of COVID-19.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> While we have active clinical trial sites in the Ukraine and nearby European countries</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, if poli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">tical or civil conditions require it, our sites may need to delay or suspend clinical trial activities. In addition, enrollm</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ent and retention of patients in clinical trials could be disrupted by geopolitical events, including civil or political unrest (such as the ongoing conflict between Ukraine and Russia), terrorism, insurrection or war, man-made or natural disasters, or public health pandemics or epidemics or other business interruptions, including, the current COVID-19 pandemic and future outbreaks of the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. Any negative results we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible. In addition, we may rely on contract research organizations, or CROs, and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to ensure their actual performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The continued spread of COVID-19 globally, or the evolution of new variants of COVID-19 that are more contagious, have more severe effects or are resistant to treatments or vaccinations, could adversely impact our preclinical or clinical trial operations in the United States, including our ability to enroll and retain patients as well as CROs and clinical trial site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. In response to the COVID-19 pandemic, the FDA issued guidance on March 18, 2020, and subsequently updated it, to address the conduct of clinical trials during the pandemic. The guidance sets out a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical study report (or as a separate document) contingency measures implemented to manage the study, and any disruption of the study as a result of COVID-19; a list of all study participants affected by COVID-19-related study disruptions by a unique subject identifier and by investigational site, and a description of how the individual&#x2019;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study. There is no assurance that this guidance governing clinical studies during the pandemic will remain in effect or, even if it does, that it will help address the risks and challenges enumerated above. Accordingly, an inability to enroll a sufficient number of patients for the clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions and may require us to pause our clinical trials or require additional testing to confirm these determinations, if they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">previous trials, will be reported by subjects or patients. Many times, side effects are only detectable after investigational products are tested in large-scale pivotal trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our product candidates have side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are a party to strategic collaboration and license agreements pursuant to which we are obligated to make substantial payments upon achievement of milestone events and, in certain cases, have relinquished important rights over the development and commercialization of certain current and future product candidates. We also intend to explore additional strategic collaborations, which may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a party to various strategic collaboration and license agreements that are important to our business and to our current and future product candidates pursuant to which we license a number of technologies to form our technology platforms. These agreements contain obligations that require us to make substantial payments in the event certain milestone events are achieved. We may in the future be required to make these payments, which could adversely affect our financial condition. In addition, we cannot be certain that we will achieve the results or benefits that justify entering into these agreements. For additional information regarding these and other collaboration, license and grant agreements, see the section titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A core element of our business strategy also includes continuing to acquire or in-license additional technologies or product candidates for the treatment and prevention of serious infectious diseases. As a result, we intend to periodically explore a variety of possible strategic collaborations or licenses in an effort to gain access to additional product candidates, technologies or resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At this time, we cannot predict what form such strategic collaborations or licenses might take in the future. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations and licenses can be complicated and time-consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations or licenses because of the numerous risks and uncertainties associated with establishing them. Any delays in entering into new strategic collaborations or licenses related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current and future strategic collaborations and licenses could subject us to a number of risks, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to undertake the expenditure of substantial operational, financial and management resources; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to assume substantial actual or contingent liabilities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disputes may arise between us and our strategic collaborators that result in costly litigation or arbitration that diverts management&#x2019;s attention and consumes resources; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators may experience financial difficulties; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, license agreements we enter into in the future may not provide exclusive rights to use intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the market opportunities for our product candidates are smaller than we believe they are or any approval we obtain is based on a narrower definition of the patient population, our business may suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently focus our product development on product candidates for the treatment and prevention of serious infectious diseases. Our eligible patient population, pricing estimates and available coverage and reimbursement may differ significantly from the actual market addressable by our product candidates. Our estimates of the number of people who have these diseases, the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, and the market demand for our product candidates are based on our beliefs and analyses. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of the diseases we are targeting. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be receptive to treatment with our product candidates, and new patients may become increasingly difficult to identify or access. Additionally, the availability of superior or competitive therapies from our competitors could negatively impact or eliminate market demand for our product candidates. If the market opportunities for our product candidates are smaller than we estimate, it could have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face substantial competition, which may result in others developing or commercializing products before or more successfully than us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and an emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercialization potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. The key competitive factors affecting the success of all our programs are likely to be efficacy, safety, convenience and timing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, regulatory incentives to develop products for treatment of infectious diseases have increased interest and activity in this area and may lead to increased competition for clinical investigators and clinical trial subjects, as well as for future prescriptions, if any of our product candidates are successfully developed and approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in acquiring third-party contract manufacturing capacity and raw materials, recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since the beginning of the COVID-19 pandemic, and even before, there has been substantial research in the development of new drugs and biologics to address diseases caused by the coronavirus. Numerous large and small</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pharmaceutical and biotechnology companies are developing COVID-19 therapy programs with various mechanisms of actions, including prophylactic vaccines, oral antivirals, immunomodulators, and antibodies, some of which are further along in the development process than we are. Other parties may be successful in producing a more efficacious therapy for SARS-CoV-2 or in producing a therapy that is easier to deliver and administer to patients in a timelier manner, which may also lead to the diversion of funding away from us and toward other companies or lead to decreased demand for our potential therapies. Companies with antibodies in clinical development include AbbVie, Inc., Adagio Therapeutics, or Adagio, AstraZeneca plc, or AstraZeneca, Brii Bio, Celltrion Healthcare Co., Ltd., Eli Lilly and Company, or Eli Lilly, and Regeneron Pharmaceuticals, Inc. Companies with oral antivirals in clinical development include Shionogi Inc., Gilead Sciences, Inc., or Gilead, and others. Companies with prophylactic vaccines in clinical development include AstraZeneca, GSK, Novavax, Inc. and Sanofi S.A. The industry and competitive landscape for COVID-19 treatments is rapidly changing, and we could have more competition in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The availability of superior or competitive therapies, or preventative measures such as vaccines, coupled with the unpredictable nature of pandemics and the prevalence of new variants of COVID-19, could negatively impact or eliminate demand for our COVID-19 therapies. Product candidates that we successfully develop and commercialize may compete with existing therapies, including prophylactic vaccines, competing antibody therapies, oral antivirals, and new therapies that may become available in the future. In addition, one or more of our competitors may be successful in producing a more efficacious therapy for SARS-CoV-2 and current and future variants or in producing a therapy that is easier to deliver and administer to patients in a timelier manner. For example, there are FDA-approved treatments for COVID-19 including an intravenously administered antiviral, remdesivir, marketed by Gilead, which is FDA approved for the treatment of COVID-19 in both outpatient and hospitalized settings, and several treatments and a prophylactic vaccine are available under EUA. Additionally, Pfizer&#x2019;s COVID-19 vaccine, Comirnaty&#174;, is approved by the FDA for individuals 16 years of age or older, Moderna, Inc.&#x2019;s COVID-19 vaccine, Spikevax&#174;, is approved by the FDA for individuals 18 years of age or older and a COVID-19 vaccine is available in the United States under EUA from Janssen Biotech, Inc. In December 2021 the FDA approved EUAs for the oral antiviral, molnupiravir, from Merck &amp; Co., Inc., or Merck, for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate, which has shown topline efficacy of 30% reduction in risk for hospitalization or death risk in early treatment clinical trials, and the oral antiviral, paxlovid, from Pfizer for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, which has demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death. In February 2022, the FDA approved an EUA for Eli Lilly's antibody, bebtelovimab, for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Merck, Pfizer and Eli Lilly have all been successful in securing government support and funding. AstraZeneca&#x2019;s AZD7442, a cocktail of two monoclonal antibodies, showed topline efficacy of 50% reduction in risk for hospitalization or death risk in early treatment clinical trials. Other companies like AstraZeneca and Adagio have been successful in securing government support and funding, respectively, and are in the process of developing antibody therapies that, if successful, could be effective against known viral variants and be administered via intramuscular, or IM, injection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of these factors, our competitors may achieve patent protection or obtain regulatory approval of their products before we are able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted or less expensive than ours, and may also be more successful than we are in manufacturing and marketing their products. These advantages could render our product candidates obsolete or non-competitive before we can recover the costs of such product candidates&#x2019; development and commercialization. For additional information regarding our competitors, see the section titled &#x201c;Business&#x2014;Competition.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if any product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name Xevudy&#174;) in more than 40 countries. E</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ven if any product candidates receive marketing approval, they may fail to gain market acceptance by physicians, patients, third-party payors and others in the medical community. If such product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the convenience and ease of administration compared to alternative treatments and therapies; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efficacy and potential advantages compared to alternative treatments and therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effectiveness of sales and marketing efforts;  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the strength of our relationships with patient communities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to offer such product for sale at competitive prices; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of third-party coverage and adequate reimbursement, and patients&#x2019; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of any side effects; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any restrictions on the use of the product together with other medications. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates are approved but fail to achieve market acceptance among physicians, patients, third-party payors and others in the medical community, we will not be able to generate significant revenue, which would compromise our ability to become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain regulatory approvals for our product candidates, they will remain subject to ongoing regulatory oversight.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval trials, post-market surveillance or patient or drug restrictions. Additionally, the holder of an approved BLA is required to comply with FDA rules and is subject to FDA review and periodic inspections, in addition to other potentially applicable federal and state laws, to ensure compliance with current good manufacturing practices, or cGMP, and adherence to commitments made in the BLA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. Moreover, product labeling, advertising and promotion for any approved product will be subject to regulatory requirements and continuing regulatory review. For example, a company may not promote &#x201c;off-label&#x201d; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#x2019;s FDA-approved or authorized label in the United States or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and comparable foreign regulatory agencies do not regulate a physician&#x2019;s choice of drug treatment made in the physician&#x2019;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Failure to comply with such requirements, when and if applicable, could subject us to a number of actions ranging from warning letters to product seizures or significant fines, among other actions. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions on manufacturers&#x2019; communications regarding off-label use and if we market our medicines for uses other than their respective approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws, which violations may result in the imposition of significant administrative, civil and criminal penalties. Any government investigation of alleged violations of laws or regulations could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. For additional information regarding regulatory approval and ongoing regulatory oversight, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be successful in commercializing them, if and when they are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To successfully commercialize any product candidate that may result from our development programs, we will need to build out our sales and marketing capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales force to market any product candidate we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability, and have no experience as a company in commercializing products. Establishing sales and marketing capabilities will be particularly important to the commercial success of our product candidates that target diseases with large patient populations throughout the world. We may seek to enter into collaboration agreements with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. For example, GSK is primarily responsible for the commercialization of sotrovimab. If any current or future collaborators, including GSK, do not commit sufficient time or resources to commercialize our product candidates, or we are unable to develop the necessary capabilities on our own, we may be unable to generate sufficient revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel, and will have to compete with those companies to recruit, hire, train and retain any of our own marketing and sales personnel. We will likely also face competition if we seek third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval outside the United States, which would limit our market opportunities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our product candidates outside the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable foreign regulatory authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for our product candidates in the EU from the European Commission following the opinion of the EMA if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a product candidate is approved, the EMA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Approval of certain product candidates outside of the United States, particularly those that target diseases that are more prevalent outside of the United States will be particularly important to the commercial success of such product candidates. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, on June 23, 2016, the electorate in the U.K. voted in favor of leaving the EU, commonly referred to as Brexit. Following protracted negotiations, the U.K. left the EU on January 31, 2020, and a transition period to December 31, 2020, was established to allow the U.K. and the EU to negotiate the U.K.&#x2019;s withdrawal. As a result, effective January 1, 2021, the U.K. is no longer part of the European Single Market and European Union Customs Union. A co-operation agreement was signed between the U.K. and the EU in December 2020 which has been applied provisionally since January 1, 2021, until it is ratified by all parties to that agreement. The agreement addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. As both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since the regulatory framework for pharmaceutical products in the U.K. covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, the consequences of Brexit and the impact the future regulatory regime that applies to products and the approval of product candidates in the U.K. remains unclear. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to EU rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law of the body of EU law instruments governing medicinal products that pre-existed prior to the U.K.&#x2019;s withdrawal from the EU. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the U.K. for our product candidates, which could significantly and materially harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the applicable regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we commercialize our product candidates outside the United States, a variety of risks associated with international operations could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to seek approval to market our product candidates outside the United States, and may also do so for future product candidates. If we market approved products outside the United States, we expect that we will be subject to additional risks in commercialization.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in which we may operate, with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their products in foreign countries to be challenging.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Negative developments and negative public opinion of new technologies on which we rely may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical and commercial success of our product candidates will depend in part on public acceptance of the use of new technologies for the prevention or treatment of human diseases. For example, we use CMV, a commonly occurring virus in humans, as a vaccine vector to prevent and treat pathogens refractory to current vaccine technologies. We also use CRISPR gene-editing technology as a research tool to systematically identify human genes that control infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Public perception may be influenced by claims that CMV technology is unsafe and products incorporating this technology may not gain the acceptance of the public or the medical community, or that CRISPR gene-editing technology is unethical or immoral. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians specializing in our targeted diseases prescribing, and their patients being willing to receive, our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of the technologies that we rely on may result in fewer physicians prescribing our products or may reduce the willingness of patients to utilize our products or participate in clinical trials for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increased negative public opinion or more restrictive government regulations in response thereto, would have a negative effect on our business, financial condition, results of operations or prospects and may delay or impair the development and commercialization of our product candidates or demand for such product candidates. Adverse events in our preclinical studies or clinical trials or those of our competitors or of academic researchers utilizing similar technologies, even if not ultimately attributable to product candidates we may discover and develop, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential product candidates we may identify and develop, stricter labeling requirements for those product candidates that are approved, a decrease in demand for any such product candidates and a suspension or withdrawal of approval by regulatory authorities of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and may face an even greater risk if we commercialize any product candidate that we may develop. If we cannot successfully</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">defend ourselves against claims that any such product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for any product candidate that we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of revenue;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant time and costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased insurance costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize any product candidate that we may develop; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injury to our reputation and significant negative media attention.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any such outcomes could negatively impact our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify such as cybersecurity-related issues; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. Conditions in the insurance markets relating to nearly all areas of traditional corporate insurance change rapidly and may result in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Regulatory Compliance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The regulatory pathways for our product candidates targeting SARS-CoV-2, the virus that causes COVID-19, are continually evolving, and may result in unexpected or unforeseen challenges.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates targeting SARS-CoV-2, the virus that causes COVID-19, are in various development and approval stages.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> To date, sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name Xevudy&#174;) in more than 40 countries. Sotr</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ovimab completed a Phase 2 clinical trial evaluating an IM formulation. In the second quarter of 2021, we initiated and completed an additional Phase 3 clinical trial evaluating an IM formulation of sotrovimab and a Phase 1b/2a clinical trial for VIR-7832, also a SARS-CoV-2-neutralizing mAb. The speed at which companies and institutions are acting to create and test many therapeutics and vaccines for COVID-19 is unusual, and evolving or changing plans or priorities within the FDA, including changes based on new knowledge of COVID-19, variants of the disease and how the disease affects the human body, which may significantly affect the regulatory timelines for our COVID-19 product candidates. Results from our continued development and planned clinical trials may raise new questions and require us to redesign proposed clinical trials, including revising proposed endpoints or adding new clinical trial sites or cohorts of subjects. As part of these ongoing discussions, the FDA may require us to conduct additional preclinical studies and/or clinical trials than we originally anticipated, which could result in significant delay in our development program for these product candidates. For example, the FDA has asked for additional data to support our conclusion that the 500 mg IV dose of sotrovimab retains activity against the BA.2 Omicron subvariant based on our current modeling assumptions as well as safety data for higher doses. We could be required to perform additional studies and trials on sotrovimab based on any additional feedback we may receive from the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA has the authority to grant an EUA to allow unapproved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when, based on the totality of scientific evidence, there is evidence of effectiveness of the medical product, and there are no adequate, approved, and available alternatives. Our EUA for sotrovimab, for example, authorizes us to distribute sotrovimab prior to full FDA approval. However, the FDA may revoke an EUA where it is determined that the underlying public health emergency no longer exists or warrants such authorization, and we cannot predict how long, if ever, an EUA would remain in place. Such revocation could adversely impact our business in a variety of ways, including if one of our COVID-19 product candidates, such as sotrovimab, is not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">yet approved by the FDA and if we and our commercialization and manufacturing partners have invested in the commercialization and manufacturing of such product candidate under an EUA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If any of our future small molecule drug product candidates obtain regulatory approval, competitors could enter the market with generic or follow-on versions of such products, which may result in a material decline in sales of affected products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application, or ANDA, seeking approval of a generic version of an approved, small molecule innovator drug product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA&#x2019;s prior approval of the small molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations,&#x201d; known as the Orange Book, see the section titled &#x201c;&#x2014;Risks Related to Our Intellectual Property&#x2014; Patent terms may be inadequate to protect our competitive position on our product candidates or any products approved in the future for an adequate amount of time and additional competitors could enter the market with generic or biosimilar versions of such products.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accordingly, if any of our future small molecule drug product candidates are approved, competitors could file ANDAs following the expiration of regulatory exclusivity for generic versions of these products or 505(b)(2) NDAs that reference our products. If competitors are able to obtain marketing approval for generics referencing our small molecule drug product candidates, such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval. They may also be prescribed by healthcare providers for off-label uses that are otherwise protected by regulatory exclusivity. For additional information regarding competition, see the section titled &#x201c;Business&#x2014;Competition.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any biologic, or large molecule, product candidates for which we intend to seek approval may face competition sooner than anticipated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are successful in achieving regulatory approval to commercialize any biologic product candidate faster than our competitors, such product candidates may face competition from biosimilar products. In the United States, large molecule product candidates generally are regulated by the FDA as biologic products subject to approval and licensure under the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, creates an abbreviated pathway for the approval of biosimilar and interchangeable biologic products following the approval of an original BLA. For additional information regarding biosimilars and exclusivity, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Biosimilars and Regulatory Exclusivity.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If competitors are able to obtain marketing approval for biosimilars referencing our large molecule product candidates, if approved and after the expiration of regulatory exclusivity, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval. In addition, the extent to which any regulatory exclusivity may apply to products authorized under an EUA is unclear. For additional information regarding competition, see the section titled &#x201c;Business&#x2014;Competition&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may also face competition from product candidates that receive EUA approval, which could negatively impact sales of our EUA product and other product candidates. For example, numerous large and small pharmaceutical and biotechnology companies are developing COVID-19 therapy programs, including prophylactic vaccines, oral antivirals, immunomodulators, and antibodies, some of which have received full approval or EUAs from the FDA. For additional information regarding competition, see the section titled &#x201c;&#x2014;Risks Related to the Development and Commercialization &#x2014; We face substantial competition, which may result in others developing or commercializing products before or more successfully than us.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of our EUA product and will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws, such as the U.S. federal Anti-Kickback Statute, federal civil and criminal false claims laws, the healthcare fraud provisions of the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and the Physician Payments Sunshine Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our EUA product and additional product candidates, if approved. For additional information regarding these laws, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x201d;. Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant civil, criminal or administrative sanctions, including exclusions from government-funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coverage and adequate reimbursement may not be available for our EUA product and any product candidates that we commercialize, if approved, which could make it difficult for us to sell profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Market acceptance and sales of our EUA product and any product candidates that we commercialize, if approved, may depend in part on the extent to which reimbursement for these product and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. While no uniform policy for coverage and reimbursement exists in the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for our EUA product and any product candidates that we develop will be made on a payor-by-payor basis. Therefore, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. Additionally, a third-party payor&#x2019;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy and on what tier of its formulary it will be placed. The position on a payor&#x2019;s list of covered drugs and biological products, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. In addition, because our EUA product and certain of our product candidates are physician-administered, separate reimbursement for the product itself may or may</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not be available. Instead, the administering physician may only be reimbursed for providing the treatment or procedure in which our product is used.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for our EUA product or any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, our EUA product or any product for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize our EUA product or any product candidates that we develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare legislative reform measures may have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell our EUA product or any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, particularly in light of the new Presidential administration, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our current or any future product candidates or additional pricing pressures. It is possible that additional governmental action is taken in response to the COVID-19 pandemic. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Additionally, in August 2011, the President signed into law the Budget Control Act of 2011, as amended, which, among other things, included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which began in 2013 and, following passage of subsequent legislation, including the Bipartisan Budget Act of 2018, will continue through 2031. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, and subsequent legislation, these Medicare sequester reductions have been suspended through the end of March 2022. From April 2022 through June 2022 a 1% sequester cut will be in effect, with the full 2% cut resuming thereafter. Further, in February 2021 the FDA issued guidance strongly recommending that individual monoclonal antibody products be developed with the expectation that they will be combined with one or more monoclonal antibody products that bind to different epitopes to minimize the risk of losing activity against emergent variants. This type of government action could have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, as a result of litigation challenging the interim final rule implementing President Trump&#x2019;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, on August 10, 2021, the Centers for Medicare &amp; Medicaid Services, or CMS, published a proposed rule that seeks to rescind the Most Favored Nation Model interim final rule. In July 2021 the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to President Biden&#x2019;s executive order, on September 9, 2021, the U.S. Department of HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. Further, it is possible that additional governmental action will be taken in response to the COVID-19 pandemic. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing or new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future product candidates we may develop may lose any regulatory approval or marketing authorizations that may have been obtained and we may not achieve or sustain profitability. For additional information regarding other healthcare legislative reform measures, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Healthcare Reform&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for our EUA product and any approved product, which could have an adverse effect on demand for our EUA product and other product candidates. Any</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act and other anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption and anti-bribery laws have been enforced aggressively in recent years and are interpreted broadly to generally prohibit companies and their employees and third-party intermediaries from authorizing, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of government agencies and government-affiliated hospitals, universities and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad or to obtain necessary permits, licenses and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, collaborators and agents, even if we do not explicitly authorize such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we have policies and procedures to address compliance with such laws in the United States, we cannot assure you that all of our employees and agents will not take actions in violation of our policies and applicable law, for which we may be ultimately held responsible. Detecting, investigating and resolving actual or alleged violations can require a significant diversion of time, resources and attention from senior management. In addition, noncompliance with anti-corruption, anti-bribery or anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, financial condition, results of operations and prospects could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#x2019;s attention and resources and significant defense costs and other professional fees. Enforcement actions and sanctions could further harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Dependence on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We intend to rely on third parties to produce clinical and commercial supplies of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently manufacturing material for product candidates of three different modalities: mAbs, HCMV-based vaccines and siRNAs. Except for limited process development and quality control testing capabilities in certain of our facilities, we do not own or operate facilities for full process development or product manufacturing, storage and distribution, or testing. We are dependent on third parties to develop the manufacturing process and manufacture the clinical supplies of our current and any future product candidates. We have established relationships with multiple contract development and manufacturing organizations, or CDMOs, that have produced material to support our preclinical, Phase 1, 2, and 3 clinical trials. We have limited experience manufacturing our product candidates on a commercial scale, and we do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our future product candidates. Certain of our product candidates may have to compete with existing and future products, such as the annual flu vaccine or any current or future COVID-19 vaccine, that may have a lower price point. The actual cost to manufacture our product candidates could materially and adversely affect the commercial viability of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA or BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with the cGMP requirements. If our third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to secure and/or maintain regulatory approval for our product candidates. In addition, we have no control over the ability of our third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Any significant delay in the supply of a product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also intend to rely on third-party manufacturers to supply us with sufficient quantities of our product candidates to be used, if approved, for commercialization. There is, however, no assurance that our third-party manufacturers will meet our working assumptions of manufacturing titer and yield per batch of our product candidates. Any reduction in anticipated manufacturing titer and yield per batch may adversely impact our ability to meet market demand for any approved product. Furthermore, if we are not able to produce supply at low enough costs, it would negatively impact our ability to generate revenue, harm our reputation, and could have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we currently rely on a strategic collaborator and foreign CDMOs, including a CDMO in China, which we, in part, rely on for the clinical development, manufacturing, and commercialization of our proprietary antibodies developed for SARS-CoV-2, and will likely continue to rely on foreign CDMOs in the future. Foreign CDMOs may be subject to trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the biopharmaceutical industry in particular in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#x2019;s public health, economic, political, and social conditions and the uncertainty around China&#x2019;s relationship with other governments, such as the United States and the U.K., could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, our reliance on third-party suppliers and manufacturers entails risks to which we would not be exposed to if we manufactured product candidates ourselves, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delay or inability to procure or expand sufficient manufacturing capacity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in process development;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issues related to scale-up of manufacturing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">excess manufacturing capacity due to insufficient market demand for our product candidates and responsibility for the associated costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs and validation of new equipment and facilities required for scale-up;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability of our third-party manufacturers to execute technology transfers, manufacturing procedures and other logistical support requirements appropriately or on a timely basis;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">breach, termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reliance on single sources for product raw materials or components;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lack of qualified backup suppliers for those raw materials or components that are currently purchased from a sole or single-source supplier;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lack of ownership to the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disruptions to operations of our third-party manufacturers or suppliers by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disruptions caused by geopolitical events, including civil or political unrest (such as the ongoing conflict between Ukraine and Russia), terrorism, insurrection or war, man-made or natural disasters or public health pandemics or epidemics, including, for example, the ongoing COVID-19 pandemic; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">carrier disruptions or increased costs that are beyond our control.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be sure that single source suppliers for our product raw materials or components will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these raw materials or components for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, there are a limited number of suppliers and manufacturers that supply synthetic siRNAs. Alnylam Pharmaceuticals, Inc., or Alnylam, is currently supplying clinical material for our VIR-2218 Phase 1/2 clinical trial through its CDMOs. We will assume responsibility for technology transfer and manufacturing ahead of any Phase 3 clinical trials for VIR-2218. Alnylam currently relies on a limited number of suppliers and CDMOs for our supply of synthetic siRNAs. There are risks inherent in pharmaceutical manufacturing that could affect the ability of Alnylam and Alnylam&#x2019;s CDMOs to meet our delivery time requirements or provide adequate amounts of synthetic siRNAs to meet our needs. Included in these risks are potential delays or raw materials and component shortages including as a result of the ongoing COVID-19 pandemic, synthesis and purification failures and/or contamination during the manufacturing process, as well as other issues with the CDMO&#x2019;s facility and ability to comply with the applicable manufacturing requirements, including use of the proper raw materials and components, which could result in unusable product. This would cause delays in our manufacturing timelines and ultimately delay our clinical trials and potentially put at risk commercial supply, as well as result in additional expense to us. To fulfill our siRNA requirements, we may need to secure alternative suppliers of synthetic siRNAs and/or key raw materials and components, and such alternative suppliers are limited and may not be readily available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, manufacturers may have little or no experience with viral vector products and therefore may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our HCMV vector-based product candidates. The challenges to HCMV-based vaccine manufacturing include the large size of the virus, which precludes terminal sterile filtration, and the attenuation of the engineered human virus, which dramatically reduces high growth yields during manufacturing. To address these challenges, we have made significant internal investments in process development and scale-up, largely funded by grants from the Bill &amp; Melinda Gates Foundation. We have established a cGMP process in support of Phase 1 and Phase 2 clinical trials that has been successfully transferred and executed at CDMOs specializing in live vaccine manufacturing. However, the existing process will require additional process development and scale-up for later stages of clinical development and commercial supply.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize our current or any future product candidates once approved. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure or total or partial suspension of production.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The U.S. government has made statements and taken actions in recent years that have led to certain changes and may lead to additional changes to U</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.S. and international trade policies, including imposing several rounds of tariffs affecting certain products manufactured in China. In March 20</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18, the Trump administration announced the imposition of tariffs on steel and aluminum entering the United States and in June 2018 announced further tariffs targeting goods imported from China. Both China and the United States have each imposed tariffs indicating the potential for further trade barriers. It is unknown whether and to what extent new tariffs (or other new laws or regulations) will be adopted, or the effect that any such actions would have on us or our industry, and it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. While we have only recently started commercialization of sotrovimab under EUA, any unfavorable government policies on international trade, such as export controls, capital controls or tariffs, may affect the demand for sotrovimab or our product candidates, the competitive position of sotrovimab or our product candidates, and import or export of raw materials and product used in our drug development activities and commercial manufacturing, particularly with respect to raw materials and product that we import from China, including pursuant to our manufacturing arrangements with WuXi Biologics. If any new tariffs, export controls, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if the U.S. government takes retaliatory trade actions due to the recent U.S.-China trade tension, such changes could have an adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research and development activities and our third-p</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">arty manufacturers&#x2019; and suppliers&#x2019; activ</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ities involve the generation, storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds and wastes. We and our manufacturers and suppliers are subject to environmental, health and safety laws and regulations governing, among other matters, the use, manufacture, generation, storage, handling, transportation, discharge and disposal of these hazardous materials and wastes and worker health and safety. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#x2019; facilities pending their use and disposal. We cannot eliminate the risk of contamination or injury, which could result in an interruption of our commercialization efforts, research and development efforts and business operations, damages and significant cleanup costs and liabilities under applicable environmental, health and safety laws and regulations. We also cannot guarantee that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials and wastes generally comply with the standards prescribed by these laws and regulations. We may be held liable for any resulting damages costs or liabilities, which could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental, health and safety laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Failure to comply with these environmental, health and safety laws and regulations may result in substantial fines, penalties or other sanctions. We do not currently carry hazardous waste insurance coverage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently have the ability to independently conduct any clinical trials. We intend to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We rely on CROs to monitor and manage data for our clinical programs, as well as the execution of future preclinical studies. We expect to control only certain aspects of our CROs&#x2019; activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and our CROs are required to comply with the good laboratory practices, or GLPs, and GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we rely on CROs to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our reliance on third parties to conduct clinical trials will result in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with CROs and other third parties can be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines or fail to comply with regulatory requirements, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed. While we will have agreements governing their activities, our CROs will not be our employees and we will not control whether or not they devote sufficient time and resources to our future clinical and preclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities which could harm our business. We face the risk of potential</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our relationship with any of these CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. While we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval or rejection of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we breach our license agreements or any of the other agreements under which we acquired, or will acquire, the intellectual property rights to our product candidates, we could lose the ability to continue the development and commercialization of the related product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We license a number of technologies to form our antibody platform and T cell platform, and the technology we use in our siRNA platform is licensed from Alnylam. We have also developed certain product candidates using intellectual property licensed from third parties. A core element of our business strategy includes continuing to acquire or in-license additional technologies or product candidates for the treatment and prevention of serious infectious diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to meet our obligations under these agreements, our licensors may have the right to terminate our licenses. If any of our license agreements are terminated, and we lose our intellectual property rights under such agreements, this may result in a complete termination of our product development and any commercialization efforts for the product candidates which we are developing under such agreements. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under such agreements, we may not be able to do so in a timely manner, at an acceptable cost or at all. We may also be subject to risks related to disputes between us and our licensors regarding the intellectual property subject to a license agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and our technology. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and our technology that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications with a priority date before March 16, 2013, an interference proceeding in the United States can be initiated by such third party, or by the U.S. Patent and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trademark Office, or USPTO, itself, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In addition, changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products, if approved. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from infringing our patents in all countries outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued and its scope can be reinterpreted after issuance. Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In addition, if the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates, or could result in licensees seeking release from their license agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our owned and in-licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have to be paid to the USPTO and various government patent agencies outside the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our service providers or our licensors to pay these fees. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, nonpayment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or technologies, including as a result of geopolitical events such as civil or political unrest (including the ongoing conflict between Ukraine and Russia), we may not be able to use such patents and patent applications or stop a competitor from marketing products that are the same as or similar to our product candidates, which would have an adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, if we fail to apply for applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us or out-licensed by us, any of the foregoing could expose us to liability to the applicable patent owner or licensee, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent terms may be inadequate to protect our competitive position on our product candidates or any products approved in the future for an adequate amount of time and additional competitors could enter the market with generic or biosimilar versions of such products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent and the protection it affords is limited. In addition, although upon issuance in the United States a patent&#x2019;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given the amount of time required for the development, testing and regulatory review of our product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we have or will obtain patent rights. In the United States, the Hatch-Waxman Act permits a patent term extension of up to five years beyond the normal expiration of the patent, provided that the patent is not enforceable for more than 14 years from the date of drug approval, which is limited to the approved indication (or any additional indications approved during the period of extension). Furthermore, only one patent per approved product can be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the FDA publication, &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations,&#x201d; known as the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any ANDA filed with the FDA to obtain permission to sell a generic version of such product candidate. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents or the outcome of any such suit. For additional information regarding the Hatch-Waxman Act and exclusivity, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents are successfully challenged by litigation, the affected product could immediately face competition and its sales would likely decline rapidly. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends, in part, upon our ability and the ability of others with whom we may collaborate to develop, manufacture, market and sell our current and any future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our EUA product and other product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our EUA product and other product candidates may give rise to claims of infringement of the patent rights of others. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, including interference proceedings, derivation proceedings, post grant review and inter-partes review before the USPTO. If we are found to infringe a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. Under any such license, we would most likely be required to pay various types of fees, milestones, royalties or other amounts. Moreover, we may not be able to obtain any required license on commercially reasonable terms or at all, and if such an instance arises, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Parties making claims against us may also seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our EUA product or other product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may also pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have an adverse effect on our business, financial condition, results of operations and prospects. Furthermore, even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. We may also have to redesign our products, which may not be commercially or technically feasible or require substantial time and expense. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could prevent us from manufacturing and commercializing our EUA product or current or any future product candidates or force us to cease some or all of our business operations, which could harm our business. Even if we are successful in defending against such claims, litigation can be expensive and time-consuming and would divert management&#x2019;s attention from our core business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications as a result of the work they performed on our behalf. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our owned or licensed patents at risk of being invalidated or interpreted narrowly and could put our owned or licensed patent applications at risk of not issuing. The initiation of a claim against a third party might also cause the third party to bring counterclaims against us, such as claims asserting that our patent rights are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter-partes review, post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. Third parties may also challenge inventorship through a derivation proceeding or other litigation proceeding challenging inventorship, which can include claims of misappropriation of intellectual property, filing a patent application without authorization of the true inventor, not listing inventors, or listing non-inventors as inventors. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license, or if the license offered as a result is not on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail and, even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Filing, prosecuting and defending patents covering our current and any future product candidates and technology platforms in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents, and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issued patents may be challenged by third parties in the courts or patent offices in various countries throughout the world. Invalidation proceedings may result in patent claims being narrowed, invalidated or held unenforceable. Uncertainties regarding the outcome of such proceedings, as well as any resulting losses of patent protection, could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Some countries do not enforce patents related to medical treatments, or limit enforceability in the case of a public emergency. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the U.S. government, the World Trade Organization, or WTO, or other governmental body imposes an intellectual property rights waiver, our ability to successfully commercialize our COVID-19 product candidates and protect our related technology could be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The WTO is currently considering a waiver of intellectual property rights for COVID-19 vaccines and the U.S. government recently took a stance in support of the waiver. The current proposal is for a temporary waiver of intellectual property rights that cover COVID-19 vaccines, however, the ultimate timing and scope of the waiver, if approved, is unknown. The scope and timing of such waiver will likely be subject to extensive negotiations given the complexity of the matter, which may result in prolonged uncertainty, which could adversely affect our business. If a waiver is approved and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">covers COVID-19 treatments or prophylactics, such as sotrovimab and VIR-7832, our ability to successfully commercialize our COVID-19 product candidates and protect our related technology could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The current waiver proposal is the result of public health concerns from the COVID-19 pandemic and an effort to make vaccines more widely available worldwide. This proposal may also lead to similar waivers of intellectual property rights in the future in connection with other public health pandemics or epidemics or other situations of public health concern. Given that our business is focused on treating and preventing infectious diseases, there is a risk that our business and our ability to protect our technology could be adversely affected in situations beyond COVID-19.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Because we rely on third parties to help us discover, develop and manufacture our current and any future product candidates, or if we collaborate with third parties for the development, manufacturing or commercialization of our current or any future product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development collaborations or similar agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of these parties to use or disclose our confidential information, including our trade secrets. We also enter into invention or patent assignment agreements with our employees, advisors and consultants. Despite our efforts to protect our trade secrets, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party illegally or unlawfully obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely and expect to continue to rely on trademarks as one means to distinguish any of our products and product candidates that are approved for marketing from the products of our competitors. Additionally, the process of obtaining trademark protection is expensive and time-consuming, and we may not be able to prosecute all necessary or desirable trademark applications at a reasonable cost or in a timely manner or obtain trademark protection in all jurisdictions that we consider to be important to our business. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, any proprietary product name we propose to use with our current or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The exercise by the Bill &amp; Melinda Gates Foundation of its licenses to certain of our intellectual property and its development and commercialization of products that we are also developing and commercializing could have an adverse impact on our market position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We entered into an amended and restated letter agreement with the Bill &amp; Melinda Gates Foundation, or the Gates Agreement, in January 2022, which amends and restates the letter agreement with the Billi &amp; Melinda Gates Foundation that we entered into in December 2016. In connection with the Gates Agreement, the Bill &amp; Melinda Gates Foundation  purchased $20.0 million of shares of our convertible preferred stock and purchased $40.0 million of shares of our common stock. We are obligated to use the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s investment in furtherance of its charitable purposes to perform certain activities set forth in the Gates Agreement. For additional information regarding our obligations under the Gates Agreement, see the section titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x2014;Amended and Restated Letter Agreement with the Bill &amp; Melinda Gates Foundation.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to comply with (i) our obligations to use the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s investment for the purposes described in the paragraph above and to not use such proceeds for specified prohibited uses, (ii) specified reporting requirements or (iii) specified applicable laws, or if we materially breach our specified global access commitments (any such failure or material breach, a specified default), we will be obligated to redeem or arrange for a third party to purchase all of our stock purchased by the Bill &amp; Melinda Gates Foundation under the Gates Agreement, at the Bill &amp; Melinda Gates Foundation&#x2019;s request, at a price equal to the greater of (1) the original purchase price or (2) the fair market value, which amount may increase in the event of a sale of our company or all of our material assets relating to the Gates Agreement. Additionally, if a specified default occurs or if we are unable or unwilling to continue the HIV program, tuberculosis program, vaccinal antibody program or, if applicable, the mutually agreed additional program (except for scientific or technical reasons), or if we institute bankruptcy or insolvency proceedings, then the Bill &amp; Melinda Gates Foundation will have the right to exercise a non-exclusive, fully-paid license (with the right to sublicense) under our intellectual property to the extent necessary to use, make and sell products arising from such programs, in each case solely to the extent necessary to benefit people in the developing countries in furtherance of the Bill &amp; Melinda Gates Foundation&#x2019;s charitable purpose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The exercise by the Bill &amp; Melinda Gates Foundation of any of its non-exclusive licenses to certain of our intellectual property (or its right to obtain such licenses), and its development and commercialization of product candidates and products that we are also developing and commercializing, could have an adverse impact on our market position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on our management, scientific and medical personnel, including our Chief Executive Officer, Dr. Scangos. Our key personnel may currently terminate their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we do not currently maintain &#x201c;key person&#x201d; life insurance on the lives of our executives or any of our employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recruiting and retaining other senior executives, qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have in the past and may in the future acquire or invest in other companies or technologies, which could divert our management&#x2019;s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have in the past and may in the future seek to acquire or invest in additional businesses and/or technologies that we believe complement or expand our product candidates, enhance our technical capabilities or otherwise offer growth opportunities in the United States and internationally. The pursuit of potential acquisitions and investments may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. In addition, we are exposed to market risks related to our investments, including changes in fair value of equity securities we hold, which is discussed in greater detail under Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, we acquired TomegaVax, Inc., or TomegaVax, in September 2016, Humabs BioMed SA, or Humabs, in August 2017, Agenovir Corporation, or Agenovir, in January 2018 and Statera Health, LLC, or Statera, in February 2018. Realizing the benefits of these acquisitions will depend upon the successful integration of the acquired technology into our existing and future product candidates. Furthermore, we may not be able to integrate the acquired personnel, operations and technologies successfully, or effectively manage the combined business following the acquisition. We also may not realize the anticipated benefits from any acquired business. We face many risks in connection with acquisitions and investments, whether or not consummated. A significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. If our acquisitions do not yield expected returns, we may in the future be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in connection with our acquisitions of TomegaVax, Humabs and Agenovir, we are required to make future contingent payments upon the achievement of certain milestones. We may in the future be required to make these payments, which could adversely affect our financial condition. For additional information regarding our obligations under these agreements, see the section titled &#x201c;Business&#x2014;Our Acquisition Agreements&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our business, financial condition, results of operations and prospects may suffer. We cannot assure you that we will be successful in integrating the businesses or technologies we may acquire. The failure to successfully integrate these businesses could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have experienced significant growth in our organization in recent years and expect to continue to expand, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 444 full-time employees, an increase of 117 employees compared to December 31, 2020. We have experienced significant growth in the number of our employees and the scope of our operations in recent years, particularly in the areas o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">f research, development and regulatory affairs, and w</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e expect to continue to experience growth as the clinical development of our product candidates progresses. In addition, if any of our product candidates receives marketing approval, we will need to build out our sales and marketing capabilities, either on our own or with others. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel all within the context of the rapidly evolving global pandemic of COVID-19. We continue to closely monitor the COVID-19 pandemic and will evolve our expansion plans as needed. As a result of the global pandemic, the majority of our workforce has been working from home since March 2020. Despite this, we must continue to effectively integrate, develop and motivate a growing number of new employees, and maintain the beneficial aspects of our corporate culture. We have implemented plans to reopen our offices to allow employees to return when appropriate. Although these plans are consistent with local government requirements, and focused on employee safety, and contemplate returning to remote work should the COVID-19 situation change, there is uncertainty regarding the long-term impact that the COVID-19 pandemic has had on the nature of the office environment and remote working, which could present operational and workplace culture challenges as we seek to expand our organization. The expansion of our operations may lead to significant costs and may divert our management and business development resources. We may not be able to effectively manage the expansion of our operations, recruit and train additional qualified personnel, or succeed at effectively integrating employees that have joined during the global pandemic. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations, and those of our CDMOs, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, public health pandemics or epidemics (including, for example, the ongoing COVID-19 pandemic), geopolitical events, including civil or political unrest (such as the ongoing conflict between Ukraine and Russia), terrorism, insurrection or war, and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to develop our product candidates could be disrupted if our operations or those of our suppliers are affected by geopolitical events, man-made or natural disasters or other business interruptions. Our corporate headquarters are located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the current outbreak of COVID-19 pandemic and future outbreaks of the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the current COVID-19 pandemic, the multiple SARS-CoV-2 variants that have further complicated the fight to subdue the global pandemic and any future outbreaks of the disease. The COVID-19 pandemic has resulted in travel restrictions, quarantines orders and other restrictions by governments to reduce the spread of the disease. As a result, the majority of our workforce has been working from home since March 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effects of the restrictions related to the COVID-19 pandemic and our work-from-home policies, including the evolving nature of such policies, may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In addition, due to the COVID-19 pandemic and our remote workforce, we have experienced an increased risk to our information technology assets and data. We have implemented plans to reopen our offices when appropriate. We may face several challenges or disruptions upon a return back to the workplace, including re-integration challenges by our employees and distractions to management related to such transition. These and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Quarantines, shelter-in-place and similar government orders, or the perception that such orders or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In particular, some of our CDMOs that we use to supply our early-stage product candidates are located in China, where the COVID-19 outbreak was first reported and where there have been government-imposed quarantines. While many of these materials may be obtained by more than one supplier, including suppliers outside of China, port closures and other restrictions resulting from the COVID-19 outbreak in the region or other regions may disrupt our supply chain or limit our ability to obtain sufficient materials for our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our clinical trials have been affected by the ongoing COVID-19 pandemic. Site initiation and patient enrollment has been and may be further delayed due to prioritization of hospital resources toward the COVID-19 pandemic, and some patients may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, has been delayed or disrupted, which has adversely impacted our clinical trial operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The continued spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic, may be difficult to assess or predict, it has already resulted in significant disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The global pandemic of COVID-19 and the evolution of new and existing variants of COVID-19 that are resistant to existing treatments or vaccinations continue to rapidly evolve. The ultimate impact of the ongoing COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our information systems, or those maintained on our behalf, fail or suffer security breaches, such events could result in, without limitation, the following: a significant disruption of our product development programs; an inability to operate our business effectively; unauthorized access to or disclosure of the personal information we process; and other adverse effects on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our computer and information technology systems, cloud-based computing services and those of our current and any future collaborators, service providers and other parties upon whom we rely are potentially vulnerable to malware, computer viruses, denial-of-service attacks (such as credential stuffing), ransomware attacks, user error or malfeasance, data corruption, cyber-based attacks, natural disasters, public health pandemics or epidemics (including, for example, the ongoing COVID-19 pandemic), terrorism, war and telecommunication and electrical failures that may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of our information, including intellectual property, proprietary business information and personal information. We may also experience server malfunction, software or hardware failures, supply-chain cyber-attacks, loss of data or other computer assets and other similar issues. We have recently experienced security breaches of our information technology systems, such as through business email compromises. The techniques used to sabotage or to obtain unauthorized access to information systems, and networks in which cyber threat actors store data or through which they transmit data change frequently and we may be unable to implement adequate preventative measures. Any significant system failure, accident or security breach could have a material adverse effect on our business, financial condition and operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be required to expend significant resources (including financial), fundamentally change our business activities and practices, or modify our operations, including our clinical trial activities, or information technology in an effort to protect against security breaches and to mitigate, detect, and remediate actual and potential vulnerabilities. Relevant laws, regulations, industry standards and contractual obligations, may require us to implement specific security measures or use industry-standard or reasonable measures to protect against security breaches. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">these problems may not be successful, and these problems could result in unexpected interruptions, data loss or corruption, delays, cessation of service and other harm to our business and our competitive position. If the information technology systems of our third-party vendors become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. Although we maintain cybersecurity insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. Furthermore, if a security breach were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, we, our third-party vendors, and our partners' third-party vendors have experienced social engineering efforts (including phishing attacks) designed to gain unauthorized access to our systems and information, including recent business email and system compromises. Similarly, we and our partners' third-party vendors may be a target of other phishing attacks, social engineering attacks and other cyber-attacks in the future. If a data security breach affects our or third parties&#x2019; systems upon which we rely, corrupts our data or results in the unauthorized disclosure or release of personally identifiable information, our reputation could be materially damaged or our operations disrupted. In addition, such a breach may require notification to governmental agencies, supervisory bodies, credit reporting agencies, the media, individuals, collaborators or others pursuant to various federal, state and foreign data protection, privacy and security laws, regulations and guidelines, industry standards, our policies and our contracts, if applicable. Such laws may include HIPAA and the Health Information Technology for Economic and Clinical Health Act, or HITECH. Under these laws specifically, notice of certain security breaches must be made to affected individuals, the Secretary of the Department of HHS, and, for extensive breaches, to the media or state attorneys general. Such a notice could further harm our reputation and our ability to compete. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to a material adverse effect on our reputation, business, or financial condition. Furthermore, a data security breach could result in fines, increased costs or loss of revenue and we could incur liability (such as through regulatory fines and penalties as well as private claims), our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Additionally, federal, state and foreign laws and regulations can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts fail.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We receive, process, store and use personal information and other data, which subjects us to governmental regulation and other legal obligations, liability and risks related to privacy, security, and data protection, and our actual or perceived failure to comply with such obligations could lead to government enforcement actions (that could include fines and penalties), a disruption of our clinical trials or commercialization of our products, private litigation, harm to our reputation, or other adverse effects on our business or prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We receive, process, store and use personal information and other data about our clinical trial participants, employees, collaborators and others. We are, or may become, subject to numerous domestic and foreign laws and regulations regarding privacy, data protection, and data security, industry standards, as well as policies, contracts and other obligations that apply to the processing of personal information by us and on our behalf, the scope of which is changing, subject to differing applications and interpretations and may be inconsistent among countries, or conflict with other rules. We strive to comply with all applicable data protection requirements and obligations; however new laws, policies, codes of conduct and legal obligations may arise, continue to evolve, be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and conflict with one another. Any failure or perceived failure by us or third parties working on our behalf to comply with applicable data protection requirements may result in governmental enforcement actions (including fines, penalties, judgments, settlements, additional reporting requirements and/or oversight, temporary or permanent bans on all or some processing of personal information, orders to destroy or not use personal information, imprisonment of company officials and public censure), civil claims, litigation, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, operations and financial performance, interrupt or stop clinical trials, limit our ability to develop or commercialize our products, or require us to revise or restructure our operations. With substantial uncertainty over the interpretation and application of these laws, regulations and other obligations, we may face challenges in addressing their requirements and making necessary changes to our policies and practices, and may incur significant costs and expenses in our efforts to do so. For additional information regarding these laws, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Privacy Laws.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activities that violates (i) the laws and regulations of FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the U.S. and abroad, (iii) laws that require the true, complete and accurate reporting of financial information or data and (iv) insider trading laws that restrict the buying and selling of shares of our common stock while in possession of material non-public information. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. In addition, during the course of our operations, our directors, executives and employees may have access to material non-public information regarding our business, our results of operations or potential transactions we are considering. We may not be able to prevent a director, executive or employee from violating our insider trading policies and buying or selling, or &#x201c;tipping&#x201d; others who might buy or sell, shares of our common stock on the basis of, or while having access to, material non-public information. If a director, executive or employee was to be investigated, or an enforcement action was to be brought against a director, executive or employee for insider trading, it could have a negative impact on our reputation and our stock price</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to use our</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">net operating losses, or NOLs, to offset future taxable income may be subject to certain limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we recorded net income for the year ended December 31, 2021, we have otherwise incurred accumulated net losses since inception and have no assurances that we will continue to be profitable in the near future. As of December 31, 2021, we had net operating loss carryforwards of $24.2 million for federal tax purposes and $126.6 million for state tax purposes. If not utilized, federal carryforwards will begin expiring in 2035 and state carryforwards will begin expiring in 2031. Our ability to use our federal and state net operating losses to offset potential future taxable income is dependent upon our generation of future taxable income before any expiration dates of the net operating losses, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our net operating losses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#x201c;ownership change&#x201d; (generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period) is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. We may have experienced ownership changes in the past or as a result of the IPO and may experience ownership changes as a result of future offerings and/or subsequent changes in our stock ownership (some of which shifts are outside our control). In addition, Agenovir has experienced at least one ownership change in the past resulting in a limitation under Section 382 of the Code, which has been accounted for in calculating our available NOL carryforwards. As a result, if, and to the extent that we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Tax Cuts and Jobs Act of 2017 and the CARES Act include, among other things, changes to U.S. federal tax rates and the rules governing NOL carryforwards. For example, NOLs arising in tax years ending after December 31, 2017 can be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income for tax years beginning on or after January 1, 2021. Deferred tax assets for NOLs will need to be measured at the applicable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward periods, as well as the new limitation on use of NOLs may impact our ability to utilize our NOLs to offset taxable income in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Ownership of Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our financial condition and results of operations may fluctuate from quarter to quarter and year to year, which makes them difficult to predict.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our financial condition and results of operations to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. In addition, we are exposed to market risks related to our investments, including changes in fair value of equity securities we hold which may fluctuate from quarter to quarter and year to year, which is discussed in greater detail under Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The market price of our common stock has been, and in the future, may be, volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our stock price has been, and in the future, may be, subject to substantial volatility. From October 11, 2019, our first day of trading on The Nasdaq Global Select Market, or Nasdaq, through February 22, 2022, the closing price of our stock ranged from $11.83 per share to $83.07 per share. As a result of the volatility in our stock price, our stockholders could incur substantial losses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The stock market in general and the market for biopharmaceutical and pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The ongoing COVID-19 pandemic, for example, has negatively affected some sectors of the stock market and investor sentiment and has resulted in significant volatility. As a result of this volatility, you may not be able to sell your common stock at or above the price you paid for your shares. Market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, public statements by us, government agencies, our competitors, the media or others relating to the ongoing COVID-19 pandemic (including regarding our and others&#x2019; efforts to develop COVID-19 therapies) and the impact of such statements on investors&#x2019; general perception of our company and our business have in the past resulted, and may in the future result, in significant fluctuations in our stock price. Given the global focus on the COVID-19 pandemic, information in the public arena on this topic, whether or not accurate, has had and will likely continue to have an outsized impact (positive or negative) on our stock price. Moreover, sales of a substantial number of shares of our common stock by our stockholders in the public market or the perception that these sales might occur, have in the past, and may in the future depress the market price of our common stock. Information related to our development, manufacturing, regulatory and commercialization efforts with respect to sotrovimab and VIR-7832, or information regarding such efforts by competitors with respect to their potential therapies, may meaningfully impact our stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming and could divert our management&#x2019;s attention and our resources. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our executive officers, directors and stockholders who own more than 5% of our outstanding common stock beneficially own a significant percentage of our outstanding common stock. If these persons acted together, they may be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. The concentration of voting power and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">transfer restrictions could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the management of our company in ways with which other stockholders disagree.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock will be influenced by the research and reports that industry or financial analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if the clinical trials and operating results fail to meet the expectations of analysts, our stock could decline. If analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have incurred and we will continue incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we have incurred and we will continue to incur significant legal, accounting, investor relations and other expenses. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the Securities and Exchange Commission, or SEC, and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act was enacted, pursuant to which the SEC adopted rules and regulations related to corporate governance and executive compensation, such as &#x201c;say on pay&#x201d; and proxy access. Emerging growth companies are permitted to implement many of these requirements over time, however, we are no longer an emerging growth company as of December 31, 2020, and expect to incur additional compliance-related expenses as a result.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stockholder activism, the current political environment and the current high level of U.S. government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may in turn lead to additional compliance costs and impact the manner in which we operate our business in ways we do not currently anticipate. Our management and other personnel will need to devote a substantial amount of time to comply with these requirements. Moreover, these requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we may also be subject to more stringent state law requirements, such as California Senator Bill 826, which generally requires public companies with principal executive offices in California to have a minimum number of females on the company&#x2019;s board of directors, and California Assembly Bill 979, which generally requires public companies with principal executive offices in California to include specified numbers of directors from &#x201c;underrepresented communities.&#x201d; We are currently compliant with the requirements, but there are no assurances that we will be compliant in the future. If we fail to comply with either Senator Bill 826 or Assembly Bill 979, we could be fined by the California Secretary of State, with a $100,000 fine for the first violation and a $300,000 for each subsequent violation, and our reputation may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reporting issued by our independent registered public accounting firm. We were previously not required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting while we were an emerging growth company. However, we are no longer an emerging growth company as of December 31, 2020. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the Sarbanes-Oxley Act, the requirements of being a reporting company under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and any complex accounting rules in the future, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. We are currently in the process of hiring additional accounting and finance staff as we grow our business. If we are unable to hire the additional accounting and finance staff necessary to comply with these requirements, we may need to retain additional outside consultants. If we or, if required, our auditors, are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot assure you that there will not be material weaknesses in our internal control over financial reporting in the future. Our previous acquisitions and strategic transactions and resulting international operations have increased the complexity of our accounting, and additional acquisitions and transactions and further geographic expansion will likely increase this complexity and the related accounting challenges. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines that we have a material weakness in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Generally accepted accounting principles in the United States are subject to interpretation by the Financial Accounting Standards Board, or FASB, or the SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, may retroactively affect previously reported results, could cause unexpected financial reporting fluctuations and may require us to make costly changes to our operational processes and accounting systems.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. For a summary of these provisions, see the section titled &#x201c;Anti-Takeover Provisions of Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws&#x2014;Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws&#x201d; in Exhibit 4.3 Description of Capital Stock filed as part of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">District of Delaware) will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any derivative action or proceeding brought on our behalf;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, unless we consent in writing to the selection of an alternative forum. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These exclusive-forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1B. Unresolved</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">operties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our corporate headquarters are located in San Francisco, California, where we lease approximately 183,027 square feet of office, research and development, engineering, and laboratory space pursuant to three lease agreements that expire at various dates through 2033, two of which are renewable for additional one and five years, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also have several other locations, including St. Louis, Missouri, where we lease approximately 60,649 square feet of office, research and development, and laboratory space pursuant to two lease agreements that expire at various dates through 2028; Portland, Oregon, where we lease approximately 10,559 square feet of office, research and development, engineering, and laboratory space pursuant to two lease agreements that expire at various dates through 2027, one of which is renewable for an additional five years; and Bellinzona, Switzerland, where we lease approximately 12,500 square feet of office, research and development, engineering, and laboratory space pursuant to a lease agreement which expires on December 31, 2028, with an option to extend for five years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that ou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">r existing facilities are adequate for our near-term needs, but expect to need additional space as we grow, and we believe that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4. Mine Safe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ty Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market Information for Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock has been listed on The Nasdaq Global Select Market under the symbol &#x201c;VIR&#x201d; since October 11, 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders of Record</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of February 22, 2022, there were approximately 162 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently intend to retain future earnings, if any, for use in operation of our business and to fund future growth. We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following graph shows the total stockholder&#x2019;s return on an investment of $100 in cash at market close on October 11, 2019 (the first day of trading of our common stock), through December 31, 2021 for (i) our common stock, (ii) the Nasdaq Composite Index and (iii) the Nasdaq Biotechnology Index. Pursuant to applicable Securities and Exchange Commission, or SEC, rules, all values assume reinvestment of the full amount of all dividends, however, no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder return. This graph shall not be deemed &#x201c;soliciting material&#x201d; or be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img61678762_23.jpg" alt="img61678762_23.jpg" style="width:672px;height:267px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.099%;"></td>
    <td style="width:1.263%;"></td>
    <td style="width:1.273%;"></td>
    <td style="width:11.106%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.263%;"></td>
    <td style="width:1.273%;"></td>
    <td style="width:11.116%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.263%;"></td>
    <td style="width:1.273%;"></td>
    <td style="width:11.165%;"></td>
    <td style="width:0.636%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">VIR</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nasdaq<br />Composite<br />Index</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nasdaq<br />Biotechnology<br />Index</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10/11/2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.00</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.00</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.00</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10/31/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.57</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102.92</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106.95</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12/31/2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89.69</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111.36</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120.19</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3/31/2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244.44</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95.57</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107.67</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6/30/2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292.23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124.84</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136.40</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9/30/2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244.86</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138.61</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12/31/2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">191.01</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">159.96</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">151.06</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3/31/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">365.69</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">164.41</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">149.97</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6/30/2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">337.23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180.02</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">163.40</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9/30/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">310.41</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">179.33</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">161.40</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12/31/2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">298.64</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">194.18</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150.10</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this Item regarding equity compensation plans is incorporated by reference to the information set forth in PART III Item 12 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Proceeds from Registered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 10, 2019, we completed our initial public offering, or IPO, and issued 7,142,858 shares of our common stock at an initial offering price of $20.00 per share. We received net proceeds from the IPO of approximately $126.4 million, after deducting underwriting discounts and commissions of approximately $10.0 million and expenses of approximately $6.4 million. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their associates, or to our affiliates. Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC and Barclays Capital Inc. acted as book-running managers for the IPO.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares of our common stock began trading on The Nasdaq Global Select Market on October 11, 2019. The offer and sale of the shares were registered under the Securities Act on Registration Statement on Form S-1 (Registration No. 333-233604), which was declared effective on October 10, 2019.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC on October 11, 2019, pursuant to Rule 424(b)(4). As of December 31, 2021, we have used all of the net offering proceeds from the IPO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Sales of Unregistered Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 6. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[</span><span id="reserved"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reserved]</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our audited consolidated financial statements and notes and other financial information included elsewhere in this Annual Report on Form 10-K. Unless the context requires otherwise, references in this Annual Report on Form 10-K to the &#x201c;Company&#x201d;, &#x201c;Vir,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Vir Biotechnology, Inc. and its consolidated subsidiaries.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our discussion and analysis below are focused on our financial results and liquidity and capital resources for the years ended December 31, 2021 and 2020, including year-over-year comparisons of our financial performance and condition for these years. Discussion and analysis of the year ended December 31, 2019 specifically, as well as the year-over-year comparison of our financial performance and condition for the years ended December 31, 2020 and 2019, are located in the section titled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; included in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on February 25, 2021. For a detailed discussion on our business environment, please read Item 1. Business, included in this Annual Report on Form 10-K. For additional information on the risks that could negatively impact our business, please read Item 1A. Risk Factors, included in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are among the leading causes of death worldwide and can cause trillions of dollars of direct and indirect economic burden each year &#x2013; as evidenced by the coronavirus disease 2019, or COVID-19, pandemic. We believe that now is the time to apply the recent and remarkable advances in immunology to combat current and prepare for future infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current pipeline consists of sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#174;) and other product candidates targeting COVID-19, hepatitis B virus, or HBV, influenza A virus, and human immunodeficiency virus, or HIV. We have assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid, or siRNA, through internal development, collaborations and acquisitions. We have built an industry-leading team that has deep experience in immunology, infectious diseases, and product development and commercialization. Given the global impact of infectious diseases, we are committed to developing cost-effective treatments that can be delivered at scale.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab is an investigational severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, neutralizing monoclonal antibody, or mAb, that incorporates Xencor, Inc.'s, or Xencor, Xtend&#153; technology.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the U.S. Food and Drug Administration, or FDA, granted an Emergency Use Authorization, or EUA, to sotrovimab for the early treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and at high risk for progression to severe COVID-19, including hospitalization or death. We also received a positive scientific opinion from the Committee for Human Medicinal Products in the European Union, or EU, for sotrovimab in May 2021. In June 2021, we announced confirmatory full results for the Phase 3 COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early, or COMET-ICE, trial, which resulted in an adjusted relative risk reduction of 79% (p&lt;0.001) in all-cause hospitalization for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. In December 2021, the European Commission granted marketing authorization to Xevudy&#174; (sotrovimab) in the EU for the treatment of adults and adolescents at increased risk of progressing to severe COVID-19.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have made significant progress increasing global patient access to sotrovimab in collaboration with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. (individually and collectively referred to as GSK). Sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name Xevudy&#174;) in more th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an 40 countries</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, binding agreements have been received for the sale of approximat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ely 1.7 million doses of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sotrovimab worldwide. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we and GSK announced the sale of more than 750,000 doses globally to date, including multiple contracts with the U.S. government. Approximately 90% of those doses were delivered in 2021 and the remainder are expected to be delivered throughout the first half of 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The delivered doses led to the recognition of $917.2 million of sotrovimab collaboration revenue in 2021.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2022, we and GSK announced the sale of an additional 600,000 doses to the U.S. government, which are expected to be delivered throughout the first quarter of 2022, and the sale of approximately 350,000 additional doses to other countries, which are expected to be delivered throughout the first half of 2022. Based solely on the binding agreements received to date, we expect to recognize approximately $1.1 billion of sotrovimab collaboration revenues when the doses are delivered in the first half of 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">W</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e and GSK expect to manufacture approximately two million doses of sotrovimab in the first half of 2022, and additional doses in the second half of 2022.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During and following the fourth quarter, we announced preclinical data generated through pseudovirus testing demonstrating that sotrovimab retains neutralizing activity against the highly divergent Omicron variant (B.1.1.529). </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2022, we published pseudovirus data demonstrating a 16-fold shift in neutralization activity against the Omicron BA.2 subvariant. Our BA.2 results were derived from 10 independent experiments that were conducted using an optimized pseudovirus assay. This is the same assay that was used to generate data for previous variants. These data have been shared with regulatory agencies around the world. Initial feedback from the FDA question our conclusion that the 500 mg </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">intravenous, or IV,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dose of sotrovimab retains activity against the BA.2 Omicron subvariant based on our current modeling assumptions, and the FDA has asked for additional data to support our position. The FDA also requested safety data for higher doses. Both have been provided to the FDA and we are awaiting further correspondence.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Health Care Provider Fact Sheet was recently updated to show that sotrovimab&#x2019;s neutralization activity was reduced an average fold change in EC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> value of 16-fold against the SARS-CoV-2 Omicron B.1.1.529/BA.2 spike variant compared to wild-type. The Fact Sheet also noted that the clinical relevance of the 16-fold reduction in sotrovimab activity against the SARS-CoV-2 Omicron B.1.1.529/BA.2 variant is unknown. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of February 28, 2022, the FDA noted on its EUA website that sotrovimab is currently authorized in all U.S. regions until further notice by the FDA.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we announced the results of the Phase 3, randomized, open-label </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">COMET-Treatment of Acute COVID-19 with Intramuscular monocLonal antibody, or </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">COMET-TAIL trial, which achieved its primary endpoint, demonstrating that 500 mg intramuscular, or IM, administration of sotrovimab (n=376) was non-inferior to 500 mg IV administration (n=378) for the early treatment of mild to moderate COVID-19 in high-risk, non-hospitalized adults and adolescents. Low rates of serious adverse events (&#x2264;1% in both arms) were observed. Based on the results of the COMET-TAIL trial, in January 2022, we and GSK submitted an application to the FDA requesting an amendment to the EUA for sotrovimab to include IM administration. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and GSK plan to submit a Biologics License Application, or BLA, for sotrovimab to the FDA in the second half of 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and GSK are collaborating to assess the use of sotrovimab in uninfected immunocompromised patients to determine whether sotrovimab can prevent symptomatic COVID-19 infection. Two Phase 3 trials are expected to start in the second quarter of 2022. One is a platform trial and one is a company sponsored trial, COVID-19 Monoclonal antibody Efficacy Trial &#x2013; Stop Transmission of Acute SARS-COV-2, or </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">COMET-STAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The primary endpoint for both trials is incidence of symptomatic PCR-confirmed COVID-19. The analysis of the primary endpoint of COMET-STAR will be event driven, and could be as early as the second half of 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab is also be</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ing evaluated among patients hospitalized with COVID-19 in the U.K. as part of the Randomized Evaluation of COVID-19 Therapy, or RECOVERY, trial. Initial data are expected in the second half of 2022.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-7832 is an investigational vaccinal SARS-CoV-2-neutralizing mAb that incorporates Xencor&#x2019;s Xtend and other Fc technologies. VIR-7832 shares the same characteristics as sotrovimab and has been engineered to potentially be a therapeutic T cell vaccine to further help treat and/or prevent COVID-19. The U.K.'s National Health Service-supported AGILE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiative evaluating VIR-7832 in a Phase 1b/2a trial of adults with mild to moderate COVID-19 remains ongoing. To date, no safety signals have been reported for the 50 mg, 150 mg and 500 mg dose cohorts. The first patient in the Phase 2a portion of the trial was dosed in February 2022. Additional data are expected in the first half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HBV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2218 is an investigational HBV-targeting siRNA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2021, we announced clinical data from our Phase 2 trial of VIR-2218 alone and in combination with pegylated interferon alpha, or PEG-IFN-&#x3b1;. First, with VIR-2218 as monotherapy, the trial demonstrated a strong safety profile and a substantial, durable and dose dependent reduction of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">hepatitis B virus surface antigen, or </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HBsAg, through 48 weeks. Second, evaluating VIR-2218 alone and in combination with PEG-IFN-&#x3b1; for 12 weeks, more rapid and substantial declines in HBsAg compared to VIR-2218 alone were observed. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we announced additional data evaluating VIR-2218 in combination with PEG-IFN-&#x3b1; for 24 weeks. New findings demonstrated that concurrent initiation of VIR-2218 and PEG-IFN-&#x3b1; therapy resulted in earlier and more substantial HBsAg reductions compared to VIR-2218 alone or with PEG-IFN-&#x3b1; following a VIR-2218 lead-in. Also, three participants achieved HBsAg loss below the lower limit of quantification by Week 24; two of three achieved anti-HBs seroconversion. Additional data are expected in the first half of 2022. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2218 is also being evaluated in additional clinical trials with collaborators.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-3434 is an investigational HBV-neutralizing mAb that incorporates Xencor&#x2019;s Xtend and other Fc technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2021, we initiated the Phase 2 Monoclonal Antibody siRNA Combination against Hepatitis B, or MARCH, trial to evaluate the combination of VIR-2218 and VIR-3434 as a functional cure regimen for chronic HBV infection. Initial data are expected in the first half of 2022. As some of our clinical trial sites are in Ukraine and Moldova, we are monitoring the situation to determine any impact resulting from the current conflict in this region.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, we announced that a single dose of six mg, 18 mg, or 75 mg of VIR-3434 resulted in rapid HBsAg reductions in most participants within approximately one week post-dose, and the largest and most sustained reductions in HBsAg were observed in the 75 mg cohort. Initial data are expected in the first half of 2022. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Influenza A virus</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2482 is an investigational mAb designed for the prevention of influenza A that incorporates Xencor&#x2019;s Xtend technology. In August 2019, we initiated dosing in the Phase 1/2 clinical trial for VIR-2482. VIR-2482 has been well-tolerated in the approximately 100 healthy volunteers dosed in Phase 1. Anticipating an increase in the incidence of influenza in the Northern Hemisphere this coming winter, we expect to initiate a Phase 2 trial in the second half of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we and GSK are evaluating the potential of several next-generation mAbs for influenza treatment and prevention, functional genomics applications for respiratory targets, and mAbs for non-influenza diseases under the collaboration agreement with GSK executed in May 2021, or the 2021 GSK Agreement. For details regarding the 2021 GSK Agreement, see Note 7&#x2014;Collaboration and License Agreements to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HIV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-1111 is an investigational HIV T cell vaccine based on human cytomegalovirus, or HCMV. In December 2020, we initiated a Phase 1 trial of VIR-1111. No safety signals have been reported to date and we expect to have additional clinical data in the first half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2022, we announced an expansion of our collaboration with the Bill &amp; Melinda Gates Foundation to include the advancement of innovative platform technologies in the development of broadly neutralizing antibodies designed to provide a &#x201c;vaccinal effect&#x201d; aimed at a functional cure of HIV and the prevention of malaria.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were incorporated in April 2016 and commenced principal operations later that year. To date, we have focused primarily on organizing and staffing our company, business planning, raising capital, identifying, acquiring, developing and in-licensing our technology platforms and product candidates, and conducting preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have financed our operations primarily through sales of our common stock from our initial public offering, subsequent follow-on offering and convertible preferred securities, and payments received under our grant and collaboration agreements. A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s of December 31, 2021, excluding restricted cash, we had $909.5 million in cash, cash equivalents and investments</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and after excluding the equity investment in Brii Biosciences Limited, or Brii Bio Parent, we had $766.4 million. Based upon our current operating plan, we believe that $766.4 million as of December 31, 2021 will enable us to fund our operations for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">at least the next 12 months. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned. See the section titled &#x201c;Liquidity, Capital Resources and Capital Requirements&#x2014;Future Funding Requirements&#x201d; below for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we recorded net income for the year ended December 31, 2021, we have otherwise incurred accumulated net losses since inception and may continue to incur net losses in the foreseeable future. To date, sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name, Xevudy&#174;) in more than 40 countries. Although we (through our collaborator GSK) have recently entered into procurement agreements to supply sotrovimab to governments around the world and began to recognize revenue for sotrovimab, the extent of future revenue remains uncertain. We have not obtained regulatory approval for any other product candidates, and we do not expect to generate significant revenue from the sale of our other product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candidates, if ever. Our</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> net income was $528.6 million for the year ended December 31, 2021. Our net losses were $298.7 million and $174.7 million for the years ended December 31, 2020 and 2019, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had an accumulated deficit of $138.6 million. Our primary use of our capital resources is to fund our operating expenses, which consist primarily of expenditures related to identifying, acquiring, developing, manufacturing and in-licensing our technology platforms and product candidates, and conducting preclinical studies and clinical trials, and to a lesser extent, selling, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. Although we began recognizing revenue for sotrovimab and have substantial deferred revenue under our 2021 GSK Agreement, we may continue to incur net operating losses for at least the next several years as the extent of future revenue remains uncertain. In particular, we expect our expenses and losses to increase as we continue our research and development efforts, advance our product candidates through preclinical and clinical development, seek regulatory approval, prepare for commercialization, as well as hire additional personnel, protect our intellectual property and incur additional costs associated with being a public company. We also expect to increase the size of our administrative functions to support the growth of our business. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently manufacturing product candidates from three of our platforms: antibodies, T cells and siRNAs. We have established our own internal process development, manufacturing and quality capabilities and are working with contract development and manufacturing organizations, or CDMOs, to supply our early- and late-stage product candidates in the near term. We continue to expand our internal capabilities and resources in process development, analytical development, quality, manufacturing and supply chain, which are supported by our San Francisco, California, and Portland, Oregon facilities that include laboratories for process development, production of HCMV research viral seed stock and selected quality control testing for our product candidates. We have established relationships with multiple CDMOs and have produced material to support preclinical studies and Phase 1 through Phase 3 clinical trials. Material for Phase 3 clinical trials and commercial supply will generally require large-volume, low-cost-of-goods production. For example, for our COVID-19 program, we and our collaborator GSK have executed manufacturing agreements with CDMOs having large-scale capacity to support future scale-up and product supply, particularly for potential commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19 Business Update</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have implemented a number of plans and policies designed to address and mitigate the impact of the ongoing COVID-19 pandemic on our employees and our business. We continue to closely monitor the COVID-19 situation and will evolve our plans and policies as needed going forward. As a result of these developments, in March 2020, we implemented work-from-home policies for most of our employees. We have also implemented plans, which continue to evolve based on the current climate and response to the ongoing COVID-19 pandemic, to reopen our offices to allow employees to return when appropriate. Although these plans are based on a phased approach consistent with local government requirements, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">focused on employee safety, and contemplate returning to remote work should new restrictions be implemented, there is uncertainty regarding the recent phased reopening, which may be rolled back, and restrictions re-implemented. We are also working to provide our employees with the support they need to ensure continuity of business operations. We are working closely with our CDMOs to manage our supply chain activities and mitigate any potential disruptions to our clinical trial supplies as a result of the COVID-19 pandemic. However, there are no assurances that our manufacturing and supply chain infrastructure will remain uninterrupted and reliable, or that the CDMOs will be able to satisfy demand in a timely manner and not have supply chain disruptions due to COVID-19 related shutdowns, stock-outs due to raw material shortages and/or greater than anticipated demand or quality issues given the operational challenges and raw material shortages that have been experienced during the COVID-19 pandemic. For some of our clinical development programs, we are experiencing, and may continue to experience, a disruption or delay in our ability to initiate trial sites and enroll and assess patients. In addition, we rely on contract research organizations or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Collaboration, License and Grant Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into collaboration, license and grant arrangements with various third parties. For details regarding these and other agreements, see the section titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x201d; and Note</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6&#x2014;Grant Agreements and Note 7&#x2014;Collaboration and License Agreements to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Acquisitions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have completed various acquisitions. For details regarding our acquisitions, see the section titled &#x201c;Business&#x2014;Our Acquisition Agreements&#x201d; and Note 4&#x2014;Acquisitions to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Operating Results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenues</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name, Xevudy&#174;) in more than 40 countries. We (through our collaborator GSK) have recently entered into procurement agreements to supply sotrovimab to governments around the world, and we have begun recognizing revenue from our profit share under our definitive collaboration agreement with GSK executed in June 2020, or the 2020 GSK Agreement. However, the extent of future revenue remains uncertain. We have not obtained regulatory approval for any other product candidates, and we do not expect to generate any significant revenue from the sale of our other product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candidates, if ever.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our revenues consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration revenue</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> includes recognition of our profit share from the sales of sotrovimab pursuant to the 2020 GSK Agreement. Our contractual share of 72.5% from the sales of sotrovimab is applied to the revenue reported in the period by GSK, net of cost of goods sold and allowable expenses from both GSK and us (e.g., medical affairs, selling and marketing expenses) and adding back our expenses that appear elsewhere in the consolidated statement of operations (e.g., cost of revenue).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contract revenue</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> includes recognition of revenue generated from license rights issued to GSK, from research and development services under other third-party contracts, and from a clinical supply agreement with Brii Biosciences Offshore Limited, or Brii Bio.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Grant revenue</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is comprised of revenue derived from grant agreements with government-sponsored and private organizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License revenue</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">from a related party</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is comprised of revenue related to Brii Bio&#x2019;s exercise of its option to obtain exclusive rights to develop and commercialize compounds arising from VIR-2218 in greater China recognized in the prior year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cost of Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost of revenue currently represents royalties earned by third-party licensors on net sales of sotrovimab by us or our collaborators. We recognize these royalties as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to our licensors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, our research and development expenses have related primarily to discovery efforts and preclinical and clinical development of our product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. We do not track research and development expenses by product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist primarily of costs incurred for our product candidates in development and prior to regulatory approval, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses related to license and collaboration agreements, and change in fair value of certain contingent consideration obligations arising from business acquisitions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">personnel-related expenses, including salaries, benefits and stock-based compensation for personnel contributing to research and development activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other allocated expenses, including expenses for rent and facilities maintenance, and depreciation and amortization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our research and development expenses to increase substantially in absolute dollars for the foreseeable future as we advance our product candidates into and through preclinical studies and clinical trials and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, early clinical data, investment in our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. To date, sotrovimab has been granted EUA, temporary authorization or marketing approval (under the brand name, Xevudy&#174;) in more than 40 countries. However, we may never succeed in achieving BLA or other similar approvals for sotrovimab or any of our product candidates. In addition, COVID-19 treatment standards are susceptible to rapid changes in epidemiology and the emergence of new variants, thus, sotrovimab may be rendered inferior or obsolete in the future. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate significant revenue from the commercialization and sale of sotrovimab or any of our product candidates. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments, our ongoing assessments as to each product candidate&#x2019;s commercial potential and the impact of public health epidemics, such as the COVID-19 pandemic. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our clinical development costs may vary significantly based on factors such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether a collaborator is paying for some or all of the costs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">per patient trial costs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of trials required for approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of sites included in the trials; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the countries in which the trials are conducted; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the length of time required to enroll eligible patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of patients that participate in the trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of doses that patients receive; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the drop-out or discontinuation rates of patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential additional safety monitoring requested by regulatory agencies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the duration of patient participation in the trials and follow-up; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost and timing of manufacturing our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the phase of development of our product candidates; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efficacy and safety profile of our product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Selling, General and Administrative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our selling, general and administrative expenses consist primarily of personnel-related expenses for personnel in executive, finance and other administrative functions, facilities and other allocated expenses, other expenses for outside professional services, including legal, audit and accounting services, insurance costs and change in fair value of certain contingent consideration obligations arising from business acquisitions. Personnel-related expenses consist of salaries, benefits and stock-based compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our selling, general and administrative expenses to increase substantially in absolute dollars in the foreseeable future as we continue to support our continued research and development activities, and commercialization activities for our EUA product or any of our product candidates, if approved, and to grow our business. We also anticipate incurring additional expenses associated with operating as a public company, including increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with the rules and regulations of the SEC and standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Change in Fair Value of Equity Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of equity investments consists of the remeasurement of our investment in Brii Bio Parent's ordinary shares based on the quoted market price at each reporting date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income consists of interest earned on our cash, cash equivalents and investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net consists of gains and losses from foreign currency transactions and the remeasurement of contingent consideration related to our acquisition of TomegaVax, Inc., or TomegaVax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provision for Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes consisted primarily of income tax on our domestic and foreign operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of Years Ended December 31, 2021 and 2020</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations for the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.277%;"></td>
    <td style="width:1.471%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:10.973%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.471%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:10.953%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.471%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:10.973%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenues:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">917,194</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">917,194</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,874</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,498</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125,376</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,347</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,123</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(776</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License revenue from a related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,747</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(22,747</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenues</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,095,415</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,368</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,019,047</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost of revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,865</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,865</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">448,006</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">302,411</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145,595</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160,793</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,937</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,856</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">674,664</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">373,348</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">301,316</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income (loss) from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">420,751</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(296,980</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">717,731</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of equity investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138,049</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138,049</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">439</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,836</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,397</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expense, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(9,437</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(4,467</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(4,970</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129,051</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,631</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130,682</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income (loss) before provision for income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">549,802</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(298,611</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">848,413</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(21,218</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(54</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(21,164</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">528,584</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(298,665</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">827,249</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenues</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in collaboration revenue for the year ended December 31, 2021 compared to the same period in 2020 was due to our profit-sharing arrangement with GSK for the sale of sotrovimab under our 2020 GSK Agreement, for which there were no comparable revenues recognized in the prior year. Our contractual share of 72.5% from the sales of sotrovimab is applied to the revenue reported in the period by GSK, net of cost of goods sold and allowable expenses from both GSK and us (e.g., medical affairs, selling, and marketing expenses) and adding back our expenses that appear elsewhere in the consolidated statement of operations (e.g., cost of revenue).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in contract revenue for the year ended December 31, 2021 compared to the same period in 2020 was primarily due to $168.3 million related to the license granted to GSK upon execution of the 2021 GSK Agreement, partially offset by $43.3 million related to the license granted to GSK upon execution of our 2020 GSK Agreement in the prior year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The decrease in grant revenue for the year ended December 31, 2021 compared to the same period in 2020 was primarily due to a decrease of $3.4 million recognized under the amended grant agreement, originally entered into in January 2018, with the Bill &amp; Melinda Gates Foundation relating to our HIV program attributable to a supplemental award received in the first quarter of 2020, partially offset by $2.2 million recognized in the fourth quarter of 2021 under the grant agreement entered into in November 2021 with the Bill &amp; Melinda Gates Foundation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The decrease in license revenue from a related party for the year ended December 31, 2021 compared to the same period in 2020 was due to the $22.7 million of revenue related to Brii Bio&#x2019;s exercise of its option to obtain exclusive rights to develop and commercialize compounds arising from VIR-2218 in greater China recognized in the prior year.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table shows the primary components of our research and development expenses for the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.798%;"></td>
    <td style="width:1.411%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:10.724%;"></td>
    <td style="width:0.954%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:10.743%;"></td>
    <td style="width:0.954%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:10.743%;"></td>
    <td style="width:0.964%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Licenses, collaborations and contingent consideration</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132,355</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,378</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,977</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121,779</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,624</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,155</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract manufacturing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,613</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,985</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(5,372</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97,505</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,660</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67,845</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64,754</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,764</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,990</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">448,006</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">302,411</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145,595</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in research and development expenses for the year ended December 31, 2021 compared to the same period in 2020 was primarily due to the following factors:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical costs increased by $67.8 million, which was primarily attributable to activities related to our sotrovimab, VIR-2218 and VIR-3434 clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">personnel-related expenses increased by $52.2 million, which was primarily attributable to an increase in our headcount; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">licenses, collaborations and contingent consideration expenses increased by $22.0 million, which was primarily attributable to increases of $58.9 million in costs under our collaboration agreements with GSK, $9.2 million in fair value of the contingent consideration from our acquisition of Humabs Biomed SA, or Humabs, due to the achievement of certain milestones in 2021 as well as changes in assumptions and probabilities used in calculating the fair value of the remaining liability, and $1.0 million in third-party milestone payments, partially offset by decreases of $31.8 million due to achievement of the first development milestone under our amended collaboration agreement with Alnylam Pharmaceuticals, Inc., or the Amended Alnylam Agreement, in the first quarter of 2020, $10.0 million payment to Alnylam resulting from Brii Bio's exercise of its option for VIR-2218 in the second quarter of 2020, and $6.4 million in collaboration costs under our Amended Alnylam Agreement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other research and development expenses increased by $9.0 million, which was primarily attributable to increases of $6.4 million in the allocation of facilities and other costs due to an increase in our headcount and higher lease expense, and $2.7 million in sublicense fees due under a license agreement; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contract manufacturing expense decreased by $5.4 million, which was primarily attributable to a decrease of $13.5 million in costs related to our COVID-19 product candidates mainly resulting from the completion of clinical manufacturing activities in the third quarter of 2020, partially offset by an increase of $8.2 million related to our HBV drug supply in the fourth quarter of 2021.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Selling, General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in selling, general and administrative expenses for the year ended December 31, 2021 compared to the same period in 2020 was primarily due to increases of $39.4 million in fair value of the contingent consideration related to sales-based milestones from our acquisition of Humabs that were achieved in the fourth quarter of 2021, $39.0 million in personnel-related expenses resulting from additional headcount, and $10.6 million in external consulting services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Change in Fair Value of Equity Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2021, Brii Bio Parent became a publicly traded company on the Stock Exchange of Hong Kong Limited. In connection with the initial public offering, our investment in shares of Brii Bio Parent became a marketable equity investment and subsequently remeasured to fair value at each reporting period. For the year ended December 31, 2021, we recognized an unrealized gain of $138.0 million due to the change in fair value of the equity investment. No comparable amount was incurred for the same period in 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The decrease in interest income was primarily due to lower interest rates and higher amortization of premium on investment balances for the year ended December 31, 2021 compared to the same period in 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Expense, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in other expenses for the year ended December 31, 2021 compared to the same period in 2020 was primarily related to the change in fair value of the contingent consideration related to our acquisition of TomegaVax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provision for Income Taxes</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in provision for income taxes for the year ended December 31, 2021 compared to the same period in 2020 was primarily due to taxable income for 2021 attributable to significant collaboration revenue from the sale of sotrovimab as well as unrealized gain from the equity investment in Brii Bio Parent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity, Capital Resources and Capital Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we have financed our operations primarily through sales of our common stock from our initial public offering and follow-on offering; sales of our convertible preferred securities; and payments received under our grant and collaboration agreements. As of December 31, 2021, excluding restricted cash, we had $909.5 million cash, cash equivalents and investments, and after excluding the equity investment in Brii Bio Parent, we had $766.4 million. In addition, as of December 31, 2021, we had a positive working capital balance and an accumulated deficit of $138.6 million. W</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e have also entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, in 2020 pursuant to which we may from time to time offer and sell shares of our common stock for an aggregate offering price of up to $300.0 million, through or to Cowen, acting as sales agent or principal. We will pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of December 31, 2021, no shares have been issued under the Sales Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our primary use of our capital resources is to fund our operating expenses, which consist primarily of expenditures related to identifying, acquiring, developing, manufacturing and in-licensing our technology platforms and product candidates, and conducting preclinical studies and clinical trials, and to a lesser extent, selling, general and administrative expenditures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and investments as of December 31, 2021 as noted above will enable us to fund our operatio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ns for at least the next 12 months. How</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ever, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned. Moreover, it is particularly difficult to estimate with certainty our future revenue and expenses given the dynamic and rapidly evolving nature of our business and the COVID-19 pandemic environment generally. We may also need to raise additional capital to complete the development and commercialization of our product candidates and fund certain of our existing manufacturing and other commitments. We antic</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ipate raising additional capital through the sale of our equity securities, incurring debt, entering into collaboration, licensing or similar arrangements with third parties, or receiving research contributions, grants or other sources of financing to fund our operations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. There can be no assurance that sufficient funds will be available to us on attractive terms or at all. If we are unable to obtain additional funding from these or other sources, it may be necessary to significantly reduce our rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. In addition, the COVID-19 pandemic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continues to rapidly evolve and has already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments. Market volatility, inflation, interest rate fluctuations and concerns related to the COVID-19 pandemic may have a significant impact on the availability of funding sources and the terms on which any funding may be available.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. See the section titled &#x201c;Risk Factors&#x2014;Risks Related to Our Financial Position and Capital Needs&#x201d; for a description of certain risks that will affect our future capital requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have various operating lease arrangements for office and laboratory spaces located in California, Oregon, Missouri, and Switzerland with contractual lease periods expiring between 2022 and 2033. As of December 31, 2021, we expect to make total lease payments of $185.4 million through 2033.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we have entered into collaboration, license and acquisition agreements where the payment obligations are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones, and we are required to make royalty payments in connection with the sale of products developed under those agreements. For additional information regarding these agreements, including our payment obligations thereunder, see the sections titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x201d; and &#x201c;Business&#x2014;Our Acquisition Agreements,&#x201d; as well as Note 4&#x2014;Acquisitions and Note 7&#x2014;Collaboration and License Agreements to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K. For information related to our future commitments under our facilities and manufacturing agreements, see Note 9&#x2014;Commitments and Contingencies to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our cash flows for the periods indicated:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.17%;"></td>
    <td style="width:1.454%;"></td>
    <td style="width:1.802%;"></td>
    <td style="width:13.934%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:1.454%;"></td>
    <td style="width:1.802%;"></td>
    <td style="width:13.971%;"></td>
    <td style="width:1.206%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by (used in):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(47,589</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(190,941</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(140,814</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(9,862</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,331</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">529,474</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net (decrease) increase in cash and cash equivalents and restricted <br />&#160;&#160;&#160;cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(88,072</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">328,671</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, net cash used in operating activities was $47.6 million. This consisted primarily of net income of $528.6 million and </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">non-cash charges of $203.3 million, offset by</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> an unrealized gain of $138.0 million on our equity investment, payment of contingent consideration of $8.1 million for the achievement of a milestone related to our TomegaVax acquisition, a gain of $4.8 million from a sublease termination, and an increase in our net operating assets of $628.4 million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he change in our net operating assets of $628.4 million was primarily due to an increase in receivable from collaboration by $773.1 million resulting from our profit share from the sale of sotrovimab, and an increase in </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prepaid expenses and other current assets of $3.7 million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">partially offset by an increase in deferred revenue of $92.0 million driven by the upfront fee received under the 2021 GSK Agreement, and an increase in accrued liabilities and other long-term liabilities of $58.5 million due to timing of payments. The non-cash charges of</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $203.3 milli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on primarily consisted of $91.8 million for revaluation of contingent consideration, $83.8 million for stock-based compensation expense, $15.2 million for deferred income tax expense, $6.2 million for noncash lease expense, and $5.3 million for depreciation and amortization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, net cash used in operating activities was $190.9 million. This consisted primarily of a net loss of $298.7 million and payments on contingent consideration of $15.8 million related to the milestones achieved related to our Humabs acquisition, partially offset by a decrease in our net operating assets of $29.5 million and non-cash charges of $94.0 million. The change in our net operating assets of $29.5 million was primarily due to an increase in accrued liabilities and other long-term liabilities by $46.6 million, which was partially offset by a decrease in deferred revenue of $7.0 million related to revenue recognized from the Bill &amp; Melinda Gates Foundation grants, a decrease in operating lease liabilities of $3.7 million due to lease payments, and an increase of $4.5 million in prepaid expenses and other current assets primarily related to prepayment of c</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">linical trial cost for our research and development activities. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The non-cash charges of $94.0 million primarily consisted of $38.4 million for revaluation of contingent consideration related to our Humabs acquisition, $16.8 million for the change in fair value of the derivative liability under the Alnylam Agreement, $27.6 million for stock-based compensation expense, and $4.4 million for depreciation and amortization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, net cash used in investing activities was $140.8 million. This consisted primarily of purchases of investments of $420.2 million and property and equipment of $21.8 million, partially offset by $301.2 million in proceeds received from investments that matured during the period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, net cash used in investing activities was $9.9 million. This consisted primarily of purchases of investments of $403.8 million and purchases of property and equipment of $6.5 million, partially offset by $400.3 million in proceeds received from investments which matured during the period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, net cash provided by financing activities was $100.3 million. This consisted primarily of proceeds received from the issuance of our common stock to Glaxo Group Limited (an affiliate of GSK) of $85.2 million in March 2021, from exercises of stock options of $13.1 million, and from issuance of common stock under our employee stock purchase plan of $2.3 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, net cash provided by financing activities was $529.5 million. This consisted primarily of proceeds received from the issuance of our common stock to GSK of $206.7 million in April 2020, the issuance of our common stock related to our follow-on offering of $323.2 million and from exercises of stock options of $4.1 million, partially offset by payments of contingent consideration related to our Humabs acquisition of $4.2 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements requires us to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the related disclosures. We base our estimates on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates. The critical accounting policies, estimates and judgments that we believe to have the most significant impacts to our consolidated financial statements are described below. For more detail on our critical accounting policies, refer to Note 2&#x2014;Summary of Significant Accounting Policies to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration, License and Contract Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, or ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as we satisfy a performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements, or ASC 808, we first determine which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject to the guidance in ASC 606, we apply the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. When we are considered an agent in elements of collaboration arrangements within the scope of ASC 808, we record our share of collaboration revenue in the period in which such sales occur. We are considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the revenue reported by our collaboration partners, net of cost of goods sold and allowable expenses (e.g. medical affairs, selling and marketing expenses) in the period. In order to record collaboration revenue, we utilize certain information from our collaboration partner, including revenue from the sale of the product, and costs incurred for development and sales activities. For the periods covered in the financial statements presented, there have been no material changes to prior period estimates of revenues and expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into a number of license and collaboration agreements that fall within the scope of ASC 606. We evaluate the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to our intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to recognizing revenue, we make estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If there are multiple distinct performance obligations, we allocate the transaction price to each distinct performance obligation based on their estimated standalone selling prices, or SSP. We estimate the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about our customer that is reasonably available to us. We consider estimation approaches that allow us to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. We also consider whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing various assumptions, including treatable patient population, expected market share, probability of success and product profitability, and discount rate based on weighted-average cost of capital, to determine the estimated SSP of a distinct performance obligation requires significant judgment. Accordingly, these assumptions are subject to uncertainty, and changing the methodology and/or assumptions could materially impact the estimated SSP for distinct performance obligations, and as a result, the amount and/or timing of revenue recognition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For performance obligations satisfied over time, we estimate the efforts needed to complete the performance obligation and recognize revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure. For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, and estimating the progress towards satisfaction of performance </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obligations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration and Embedded Derivatives</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration related to business combinations and obligations required to be accounted for as embedded derivative financial instruments under Topic ASC 815, Derivatives and Hedging, are considered to be Level 3 instruments that are initially measured at their estimated fair values on the transaction date and subsequently remeasured with changes recorded in the consolidated statement of operations each subsequent reporting period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical and regulatory milestone payments based on the assessment of the likelihood</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and estimated timing that certain milestones would be achieved, as well as the use of Monte Carlo simulation model that includes significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving clinical and regulatory approval of the development projects and the subsequent commercial success and discount rates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to our acquisition of TomegaVax was determined based on a Monte Carlo simulation model that includes significant estimates and assumptions pertaining to probability and timing to achieve the required share price of our common stock, expected volatility and discount rate. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the definition of an embedded derivative financial instrument.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the periods covered in the financial statements presented, there have been no material changes to prior period estimates of the fair value of our contingent consideration liability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Accounting Pronouncements Not Yet Adopted</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 2&#x2014;Summary of Significant Accounting Policies to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate and market price sensitivities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Rate Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We had cash, cash equivalents and restricted cash and cash equivalents of $363.4 million as of December 31, 2021, which primarily consisted of money market funds. We also had short- and long-term investments of $418.6 million as of December 31, 2021. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. Because our investments are primarily short-term in duration and our holdings in U.S. government treasury bonds mature prior to our expected need for liquidity, we believe that our exposure to interest rate risk is not significant, and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio. We had no debt outstanding as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The functional currency of our foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of our foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. As of the date of this Annual Report on Form 10-K, we are exposed to foreign currency risk primarily related to the operations of our Swiss and Australian subsidiaries and consequently the Swiss Franc and Australian dollar. Transaction gains and losses are included in other income (expenses), net on the consolidated statements of operations and were not material for the years ended December 31, 2021, 2020 and 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Investment Risk</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We hold ordinary shares of Brii Bio Parent, which we acquired in connection with our collaboration, option and license agreement. These equity securities are measured at fair value with any changes in fair value recognized in our consolidated statements of operations. The fair value of these equity securities was approximately $143.1 million as of December 31, 2021. Changes in the fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. A hypothetical 10% increase or decrease in the stock prices of these equity securities would increase or decrease their fair value as of December 31, 2021 by approximately $14.3 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">s and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.857%;"></td>
    <td style="width:7.143%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Audited Consolidated Financial Statements</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_public_accounting_firm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance Sheets as of December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations for the years ended December 31, 2021, 2020 and 2019</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_comprehensive_lo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2021, 2020 and 2019</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit) for the years ended December 31, 2021, 2020 and 2019</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Cash Flows for the years ended December 31, 2021, 2020 and 2019</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_public_accounting_firm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Stockholders and the Board of Directors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of Vir Biotechnology, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Opinion on the Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying consolidated balance sheets of Vir Biotechnology, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income (loss), convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#x2019;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Audit Matter</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.517%;"></td>
    <td style="width:2.897%;"></td>
    <td style="width:81.585%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial accounting for Stock Purchase Agreement with Glaxo Group Limited and Preliminary and Definitive Collaboration Agreement with Glaxo Wellcome UK Limited (collectively &#x201c;2021 Expanded GSK Collaboration&#x201d;)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Description of the Matter</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed in Note 7 to the consolidated financial statements, the Company entered into the 2021 Expanded GSK Collaboration. Auditing management&#x2019;s initial application of the relevant US GAAP guidance under Accounting Standards Codification (ASC) 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue From Contracts With Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and ASC 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, related to the 2021 Expanded GSK Collaboration, was especially challenging due to the complex nature of its terms and conditions and the significant judgment required in estimating the standalone selling price for the identified performance obligations. In particular, the determination of estimated standalone selling price was based on various assumptions, including treatable patient population, expected market share, probability of success and product profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over management&#x2019;s review of the terms and conditions of the 2021 Expanded GSK Collaboration and application of the appropriate accounting guidance. We also tested controls over management&#x2019;s process to estimate the standalone selling price for the distinct performance obligations. For example, we tested controls over management&#x2019;s review of the significant assumptions used to develop the standalone selling price estimates. We also tested controls to validate that the data used in the standalone selling price estimates were complete and accurate.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To test the Company&#x2019;s application of the accounting guidance to the 2021 Expanded GSK Collaboration, we performed audit procedures that included, among others, reviewing the related contracts, obtaining direct confirmation of contract terms and conditions with GSK, assessing management&#x2019;s application of the appropriate accounting guidance, evaluating the Company&#x2019;s use of appropriate estimation methodologies with the assistance from a valuation specialist, evaluating sensitivity analyses to determine which assumptions had the greatest impact on the overall standalone selling price allocation, and testing the completeness and accuracy of the underlying data. Our procedures over the most significant assumptions included comparing assumptions to current industry, market, and economic trends. For example, we evaluated the probability of success rates used by considering the phase of development for the related programs at the transaction date and compared those rates to published industry benchmarks.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young, LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2017.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redwood City, California</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Ba</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">lance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.572%;"></td>
    <td style="width:1.799%;"></td>
    <td style="width:1.163%;"></td>
    <td style="width:14.888%;"></td>
    <td style="width:0.785%;"></td>
    <td style="width:1.799%;"></td>
    <td style="width:1.163%;"></td>
    <td style="width:15.047%;"></td>
    <td style="width:0.785%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">CURRENT ASSETS:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7386950c-f47e-49e9-9db5-e75404b67dca" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">347,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b59d0eab-2bc4-42d4-96bf-47e4b76c3ae2" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">436,575</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Short-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d454f565-16a7-4859-abb3-619129af3374" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">217,182</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98e366cc-73c1-4925-b0d5-276d5aa96baf" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300,286</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents, current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b3bd9cd-615b-4636-8f48-3f5b6ef17f19" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,594</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3ce3550-9e7b-48d8-bd49-03d28c2ce40e" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Receivable from collaboration</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9dc4777e-527c-4b29-a762-aed7b5483c94" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">773,079</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76ef31b7-f542-4336-832d-772e5e79a454" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Equity investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17592b2e-b806-4b1a-b6e2-500cbcedfe99" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:EquityInvestmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">143,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a97f0be-caf3-499b-8b6d-618eff31eb4d" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:EquityInvestmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e5f9b7b-be40-4779-b834-d11ef5eb2270" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,003</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_986e1c41-147b-482e-8664-ca163ca102d9" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d16cee5-8ca4-42e5-9649-0fc504d15115" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,562,821</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87ff9b4a-a6cb-4789-90f4-be61804d3638" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">772,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Intangible assets, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dce86c75-ddc5-483c-bd45-44afad9bff35" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49c0bbd7-24b6-4f32-bb46-89fffdd9159f" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,820</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Goodwill</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61230d7a-caa3-4c73-b1c1-dfbb0cce7902" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8470a6fd-27d9-4cc1-947c-2feafd03d91c" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62ff0933-c306-4b0d-a481-4206d381d15b" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,834</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6975d8cb-9e20-4fa8-863d-f6bf6be68df4" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,946</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51ff6878-fb6a-4429-95d9-62c39143de06" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,220</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9178d439-8c71-426c-934d-bce515544d36" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents, noncurrent</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d357b5cc-3a24-41ef-bf09-5741a3d7ee36" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfba7be0-0629-4baa-856f-3a6b1c4b04ce" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Long-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca7b556a-fa54-4ba3-9dba-defbc958be3b" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,388</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ffa743d-4aba-467f-8f89-4f7b0d437173" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59ca09ff-7c82-41ab-a708-3f253b6ad8e5" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,775</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f500e8c-3f64-489d-b435-082d38e90ea0" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,827</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">TOTAL ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b7baea9-cbf9-4ee5-9833-493d6c34daa4" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,954,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_acc782cd-6c89-4099-9461-64f48143f795" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">918,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">CURRENT LIABILITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0c01844-97d7-4839-83f8-1f6fdbf4fbbd" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_204d89a1-4432-4c04-a630-089a200d81b0" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accrued and other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_591ac35c-ac10-462b-bd6f-efa178944900" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">236,512</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ec56e34-91cf-4695-a605-35abab989183" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,936</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred revenue, current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da58abc5-5877-4e9b-b21a-8dab2529f96d" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98,209</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13afab1e-abe3-4e70-b191-d42b0f5007e7" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Contingent consideration, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd5a46fb-0be3-40fa-9409-21d7ceefc90c" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cfa16a70-6f9e-4619-85ea-556185197740" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f438b442-6bf6-4506-b8b3-2c4b67a6b14e" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">341,242</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11437021-6963-42b1-a837-5cd890b61b8b" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,064</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred revenue, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d95e4d3b-e909-4f9d-ba55-b754693259d0" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f706939-cce7-43f5-89a1-5fe220934340" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a80d6d44-7c90-4fab-8c42-3cbf2ebcf8d0" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,561</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae5146dc-0fb8-4590-aee6-5a71b7106058" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,556</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Contingent consideration, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bec56fb6-1ebe-4887-b1f2-430e42240129" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,822</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb28145d-b9fb-403f-8c0b-6208ede135cb" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,374</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred tax liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60bd5ab7-f0b6-4aa9-90c8-d4b311668035" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bed3f701-99dd-4957-b7bd-94b90dcae940" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,253</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b31db6d-343c-47c0-97c1-8cd9612dd91a" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,540</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5c907c3-c4b5-4fdb-b151-b16388abb238" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,847</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">TOTAL LIABILITIES</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83c91d32-6a6e-4952-9191-eb5dc4935a7d" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">522,419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9a002d4-f7b0-4b2b-ba9a-183394cd5be3" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_98a9a1c1-c922-4685-b412-bdffdfc28ae1;"><span style="-sec-ix-hidden:F_2224d0d8-f870-4e2c-84eb-afb6268a5d33;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">STOCKHOLDERS&#x2019; EQUITY:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Preferred stock, $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56f0bba2-f975-477c-9a54-9c6affe03843" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF"><ix:nonFraction id="F_a51a701d-6ebf-47ed-9bb0-131dbc7fe6a9" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70207c2f-72cc-41af-ad2c-0d02906aed9f" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_1e8d3abe-cb7b-4a48-830c-3860e29e0088" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares authorized as of<br />&#160;&#160;&#160;December 31, 2021 and 2020, respectively; </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff4e8357-6296-44f5-a797-34d0b0499927" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_46a254cd-b761-4003-a0e5-53ccbf131fca" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f5229835-4279-402f-9afe-db6bb2e7793f" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1dae67b6-f096-49b4-87aa-07c62f6bac1b" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares issued and outstanding <br />&#160;&#160;&#160;as of December 31, 2021 and 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d464b2fd-a31d-492c-8405-97ec01c63ea3" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9617ec8c-1a86-4e82-88f0-013a1a416fcf" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_66bb4df6-ace9-427b-8ce6-febf7410ebcc" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4"><ix:nonFraction id="F_f83aea36-4ccd-4174-9d2d-3f18fdce294c" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7050a6f3-b6fd-4041-a737-d5e8869e9b63" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_5c4c4d77-f714-4315-ae4c-ab65adea6731" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares authorized as of <br />&#160;&#160;&#160;December 31, 2021 and 2020, respectively; </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_998f0ecc-d1c6-4181-8743-2d5c84009b40" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_d2ee9303-0bb4-433d-87cc-3521ddff0741" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">131,161,404</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9254a4e9-2be9-4001-9e8b-76c1904dd46f" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_28e7ac10-e295-47fa-8a25-6e5f5124b6f8" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">127,416,740</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares <br />&#160;&#160;&#160;issued and outstanding as of December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90f61365-04ef-49d9-9cd0-2a72fe3d6f07" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73435fc1-6dda-4740-ae6d-0b6343c32333" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ed8a9d8-4b5f-4bd7-8097-b4b8e95f2d80" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,571,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3dfc8596-495c-45ea-8e5c-5a2222c177a3" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,385,301</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2216618-cda2-46bc-945e-60b2e3a3964e" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,099</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c27f351-b5a8-4aa7-ad8f-4daf878c2484" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_626975f8-8e57-4281-a929-51d94cfdb075" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">138,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c21a416d-b9f4-4f5c-8079-e009e4f0c2e4" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">667,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">TOTAL STOCKHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11eff6aa-d634-4ad3-96c0-4b6ffd90606e" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,431,849</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb2f2e6e-d3bc-4722-9a30-845c6765d13e" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">716,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">TOTAL LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1fd4cc0f-9b75-4902-8c1e-64ffd98de228" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,954,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a1ed45c-fc35-4a7c-ad3a-dcba1232ef08" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">918,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Stateme</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">nts of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.179%;"></td>
    <td style="width:1.471%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:11.015%;"></td>
    <td style="width:0.855%;"></td>
    <td style="width:1.471%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:11.015%;"></td>
    <td style="width:0.855%;"></td>
    <td style="width:1.471%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:10.995%;"></td>
    <td style="width:0.855%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenues:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a5f80a6-4c52-4175-a2e7-53a5ccd3d92e" contextRef="C_d4b2018a-b9d9-4637-8c1a-502b5c20c95d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">917,194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b3de68d-9ae8-4431-b619-a21c1bd227f1" contextRef="C_d7535086-58ed-4942-918e-2201970b8cea" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_acc930f9-67ab-4042-9b1d-7c24466ae2b3" contextRef="C_59d377ae-8381-45db-9cc4-7efce0201130" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4f65d0b-dcb7-47cc-a1a6-a01a79319dc6" contextRef="C_f56ff235-0c3a-41a2-9a37-b0d1d92b94ec" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_877f0a76-93a9-448e-9a71-74a5a452787e" contextRef="C_488948dd-80d3-45b7-a684-756b5feb098a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0c12bf8-b7c8-40c1-ac81-72eaf76eec66" contextRef="C_301f15e9-11d1-406a-b0be-2ca7cc4b7543" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">711</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb9f22f0-102d-4eae-9f5f-0d736f698a2d" contextRef="C_f506a175-6fde-4e73-bbbc-20e846b33555" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee766bc6-3a15-4bba-91b2-3e680bc851a3" contextRef="C_65bd9d63-ee77-45dd-a499-a8f0b310c5e6" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,123</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9be634de-fa92-4e92-8e10-46f8d9a040c0" contextRef="C_eaf05464-1224-4ae2-8baa-f4387ec342ad" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,380</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License revenue from a related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92d8ff21-7586-491f-bd22-485e568d5d89" contextRef="C_f93128d8-554e-4673-824a-fcf094e10714" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a137e484-6f25-4450-bbaf-d05d82664551" contextRef="C_5299f27f-f8a0-4e30-874b-2faab774be38" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,747</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a949cdf2-2601-4ab8-a6aa-78854d432e80" contextRef="C_2920cb23-d73e-4b16-b3f4-cc501406683c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenues</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee5e5325-776a-46d9-9790-b7c1e4f62e6e" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,095,415</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02a0d8a3-d4ec-48f4-8de1-643a96146fa0" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9acc94de-ca67-4c76-9de8-457fa3f26a04" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,091</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost of revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c778e5f-6132-42c0-935b-0ed4c96bea5d" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb424f73-cb86-4b2c-aa34-1f263f9c5be8" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07b3d564-2337-41db-8594-4e83644e7be4" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22481c39-4bbd-4361-8813-e6bc75395683" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">448,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67007cb5-6567-45d0-89c8-1a5dcc35177c" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">302,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fb86802-d113-4c36-807e-6ee10f629519" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">148,472</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a6d9ad5-227e-46be-bc6e-aa637a0aee24" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,793</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_649edd30-30a2-4718-8b35-c8f7067d9faf" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b56027a-3a64-472d-8f6c-d027cc154c4c" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,598</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca5450c0-4fa9-461b-8111-b6355a3d8dbc" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">674,664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cc1ea25-cc25-4f94-9dde-f10bf72d1cf8" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">373,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52aad1c3-3a0d-4328-b96d-33afc25c9664" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186,070</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income (loss) from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4b27542-a2b6-49e2-ad64-4a536c297b5d" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">420,751</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d1f2a5a-4241-4262-95af-1d568099606c" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">296,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6da6522-c618-42eb-aa07-5ee0c271a16d" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">177,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of equity investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f9cbfa3-1ac5-4a1e-aeac-be720a791588" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">138,049</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6aee22eb-9c90-45bd-a2bc-2c667c4f8efc" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c93882c5-1583-42db-a492-e86eb55fca83" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb56b4c2-d6f2-41e6-9647-c6a807c1983d" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40bd638f-eb74-4f8e-8090-860fe8e21b93" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,836</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2835001-1c80-46f9-975c-f450b6f10bc8" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expense, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e72ed746-0471-48fb-8e2b-40bb645168f1" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,437</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_efdd7caf-c7ed-488e-a14b-ac76bfda2317" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,467</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f91deee-567a-4577-8f0c-958997b3ce4d" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,061</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12f7dc6c-bf83-4159-a910-bfc000ad3058" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">129,051</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f0cf109-5181-4286-8647-ab46a47c122c" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6366fc8-9e3d-44a3-9d96-c0b7a0b25091" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,450</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income (loss) before provision for income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_933909e0-604c-4f30-9252-5e82fc266cd4" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">549,802</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a708ce3-d1bb-4203-ad50-be0dbd8135bb" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,611</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c4b3c55-a73b-41db-85df-3bd7ca8a2855" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174,529</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb0135d6-c072-4177-88dc-2692320ba405" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,218</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9debc7ab-c623-4fc3-980e-54d276b8ed9b" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_889fc7e7-f133-425c-a248-c1bb7b2d212e" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7aaa0283-8ca8-4ac7-8e67-279b4827c669" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9fc51f7-eba2-40ee-95d1-98509743ff78" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_727ce5b9-a952-4d96-a0ca-938f5602ce15" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174,683</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, basic</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c83c5e3c-868b-4fca-b125-66d8f89e082c" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2">4.07</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7185078f-8044-41a4-9c71-cd358336ee18" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">2.51</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c9da109-eed6-4387-a5e3-928d01ca1097" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">5.76</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cd29008-fb2f-401b-a0a6-58cd49d20d4b" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2">3.96</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3660ed38-fca6-4404-b5f6-7e6c9a9b5101" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">2.51</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43a773b4-6a66-47d1-af54-d09d5f221f42" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">5.76</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, basic</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6cf10d8f-bb11-4f2e-9d21-c0d59e0be784" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">129,884,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34793e73-2133-4800-b475-02843f7f49c4" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">119,159,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_654992f4-254b-405d-b335-66fbe0d6ba56" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">30,349,920</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_980c6d26-e5b8-4087-97ad-cea22547ddd2" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">133,437,126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_401eaeec-4f77-4229-9010-746a268f3aa8" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">119,159,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dea3860d-7fe9-483a-b504-5f301c3fa3f4" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">30,349,920</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_comprehensive_lo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> of Comprehensive Income (Loss)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.788%;"></td>
    <td style="width:1.411%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:10.714%;"></td>
    <td style="width:0.964%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:10.724%;"></td>
    <td style="width:0.964%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:10.763%;"></td>
    <td style="width:0.964%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3299467-0c65-461d-9355-3857782d7f54" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e44d29ed-e69a-483e-8a15-31eaa1b8cf13" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f578f860-b923-42c0-b6bc-f724b33577f5" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174,683</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive income (loss):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized (losses) gains on investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1dee9db-5b68-4b0f-afa9-7d96564cf40e" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_533bd9d1-4e2c-47c4-acb5-269fd698e0eb" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4fd5a13-5c31-4569-b822-f8a413d6dd57" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">149</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization of actuarial loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d0cccc0-dcbe-4b2b-8685-b3a7606dea73" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce51d382-6233-42cc-aa2c-5e1a2fee54eb" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2a959dc-cbdb-4311-8620-64af2b5941d6" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustment to projected benefit obligations, net of tax</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18f0e139-33d5-4960-ac07-48fe0921fb9c" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,081</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c494b6b3-8f4e-4b63-807d-20ccb988f150" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7f59834-39d9-4249-b8c6-23a7e07c80be" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">736</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive income (loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_717de3ea-b179-4789-a1b4-bfdc9a9240f8" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0f65758-2aa7-4fea-98e4-1ca6ddac7fda" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">677</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c205be3-3f0f-403a-b8ca-be43ea9576cd" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">587</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eeeb2881-56e5-4323-92f9-9aa67c144d3f" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e4ab64b-e538-4731-81bf-a4fba096cfae" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">299,342</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5049992-8c01-49f1-ad56-51eb429e3970" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">175,270</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_convertible_pref"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Convertible Prefer</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">red Stock and Stockholders&#x2019; Equity (Deficit)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands, except share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.693%;"></td>
    <td style="width:0.944%;"></td>
    <td style="width:0.381%;"></td>
    <td style="width:7.224%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.944%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:6.858%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.944%;"></td>
    <td style="width:0.944%;"></td>
    <td style="width:0.381%;"></td>
    <td style="width:7.363%;"></td>
    <td style="width:0.381%;"></td>
    <td style="width:0.944%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:6.975%;"></td>
    <td style="width:0.381%;"></td>
    <td style="width:0.944%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:6.858%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.944%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:6.865%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.944%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:6.858%;"></td>
    <td style="width:0.498%;"></td>
    <td style="width:0.944%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:6.865%;"></td>
    <td style="width:0.498%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Convertible Preferred<br />Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Additional<br />Paid-In<br />Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Accumulated <br />Other<br />Comprehensive<br />Loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Accumulated<br />Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Total<br />Stockholders&#x2019;<br />Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2018</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76bd7052-4227-4d84-895d-bebeabd805d6" contextRef="C_c8189099-45c1-41f2-b6ca-954b37c65618" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">69,910,520</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34a2ff36-9fb0-47cd-a050-9dde9e3c3f28" contextRef="C_c8189099-45c1-41f2-b6ca-954b37c65618" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">309,137</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7fe850dd-77fe-4383-ad5a-953fca97447b" contextRef="C_3c763cb1-70d7-4e23-8984-44c48ee907cf" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,858,799</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1bb88c7-5b43-4e42-bf30-ce4e4d2f5d59" contextRef="C_3c763cb1-70d7-4e23-8984-44c48ee907cf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65bcd231-0af0-4f8e-a9ba-c79f719f0b31" contextRef="C_c55f2ce7-7281-48a7-aec6-0a47f77c9a67" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,672</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7004beb5-9f18-4c67-befd-ef6f5cae2b8c" contextRef="C_b85c9788-4228-4009-81b0-cb885a8a21d7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c239c08-9f19-404c-b47a-a12442c6e6e1" contextRef="C_6e8a7542-2dd0-4c48-9150-7dcf5bac672c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">193,836</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06419617-e051-4565-8d1a-e3589c8ba39c" contextRef="C_88183c78-6814-4146-96c6-0cba18d5611c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">179,177</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of Series B convertible preferred stock, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23eeffd0-d7ab-40de-afbd-b494a1635185" contextRef="C_6a0b0601-deb2-4157-ba2f-7613b7f73ba3" name="vir:ConvertiblePreferredStockIssuanceCost" unitRef="U_USD" scale="3" decimals="-3">165</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2543ff9-feaa-467c-9bf9-6a432cabcd5f" contextRef="C_6a0b0601-deb2-4157-ba2f-7613b7f73ba3" name="vir:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,202,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e342622b-3f51-4bd9-943c-75b95003ebfb" contextRef="C_6a0b0601-deb2-4157-ba2f-7613b7f73ba3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">327,475</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Conversion of convertible preferred stock into common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e174013b-0475-4fcf-a04d-15fc363ddd8a" contextRef="C_df4b5d69-777f-4164-ba06-7c95c5c18601" name="vir:TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">88,112,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1fbc6394-acc7-493e-ad00-c58db511c117" contextRef="C_df4b5d69-777f-4164-ba06-7c95c5c18601" name="vir:TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">636,612</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3589814c-4398-4191-94ad-2497380e2178" contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">88,112,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebb0542a-52bd-42aa-8cff-845ccafca44e" contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_798dc5a5-c5d9-4b83-b400-fa763c23cb84" contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">636,603</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_095a4c83-6c5e-4753-af42-e0f847c0e487" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">636,612</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock in connection with initial public offering, net of offering costs of $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83c9584d-d0be-4d05-800a-2da651cc6572" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:InitialPublicOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,446</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10f84674-43c6-42e7-be23-8b8728f40513" contextRef="C_0ad71b1a-ef19-44b7-ae86-72e2d88c9ede" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,142,858</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff627249-f871-4ee4-96f7-c5d2ce474716" contextRef="C_0ad71b1a-ef19-44b7-ae86-72e2d88c9ede" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35458b13-b7da-48da-a5cb-7895693587ae" contextRef="C_9877f0f7-e105-480e-b0a7-fb9e68d056f2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,410</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98cc0aa6-f847-451f-9d87-a23f0b078f7f" contextRef="C_e837f6cd-46cf-43d6-8ea9-08f5560d9cf6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Reclassification of warrant liability to additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33b04b42-074b-4cdc-ac40-ecf00c9c3230" contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d" name="vir:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,073</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_66c80bc8-d093-4c36-b1ad-dd17b8ff7eb9" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,073</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Settlement of fractional shares from reverse stock split</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1d8f9ce-4058-488b-85b8-4f397dbd72ec" contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e25b369-5dbf-4e94-bb1f-9b78eb4c9480" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock in connection with a license agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cdb88cb2-e25e-484b-91f5-f70895491a5e" contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e" name="vir:StockIssuedDuringPeriodSharesLicenseAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38,888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9da2c34-c507-425a-ac8e-a5cfb8e216be" contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d" name="vir:StockIssuedDuringPeriodValueLicenseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">617</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0e7ea70-dd42-4ad0-bef3-acb219e04b24" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:StockIssuedDuringPeriodValueLicenseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">617</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Repayment of promissory notes, net of unvested shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2baa091-5f39-4e4b-9638-189016f451e6" contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e" name="vir:StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,390,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_173a501f-632b-4f26-84b4-50512123cc65" contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d" name="vir:StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e69e72cc-03d8-4d51-ad9d-20d681d5b40d" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,355</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d1521db-588b-489b-9e0d-b8d461033e1e" contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,348,297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68a6f7fb-c3a7-4fc9-977a-87c3842c626c" contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">476</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2739c34-8f1d-405a-9799-2a475f59535b" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">476</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e57e675-e67f-487a-9e6b-20d69d90750c" contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">756,425</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9b12556-a820-4e14-a44a-871776d0b844" contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_efea0d19-d508-4138-ac8e-9e0991d0dc3f" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e52ee706-105f-479f-87c3-2c4807201365" contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ffe655cb-9dfa-4b5d-b9c3-c3950e0af312" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_238ad9a6-21ad-42bd-a302-0233d680bf93" contextRef="C_7c199ed9-32db-4a22-a38e-1c376f297c82" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">587</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4508953d-a636-42a7-a951-a4582a2112d7" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">587</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6920b41-f0d1-424e-8877-e0db3460e812" contextRef="C_675e042c-eb56-4fb7-aaea-43c58b4c0aa3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174,683</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cb48bb7-62a4-4291-bec1-3531248cf026" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174,683</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23589605-c58a-4cec-b3c1-7f5226367225" contextRef="C_10b89020-933b-4851-aad1-03756b00666a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">107,648,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_138aa5d7-1d14-49d6-8b2f-822b201a1a80" contextRef="C_10b89020-933b-4851-aad1-03756b00666a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_235c0ce1-c9bf-4b71-8249-539fb7992338" contextRef="C_3d2840b2-01d0-4017-822e-05963d9d6961" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">793,051</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8be1857a-8ae0-4ed5-8875-14901f349b12" contextRef="C_d5f3ecc6-0f0d-4709-940b-a9657a2029f1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">601</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5c1f20e-ce48-4af0-88b0-ee50cd13a7b1" contextRef="C_c5a5ec76-5424-4832-b5c3-f943e156e9d3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">368,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea8f11a4-4424-4f10-b530-378b16e1fc10" contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">423,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Reclassification of derivative liability to addition paid-in-capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f93953d-5f8a-4b47-971c-6535e71c8802" contextRef="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b16d329c-b23a-4c12-935c-990bc526aa5b" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock in connection with the achievement of a milestone</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_970fe4df-221a-477c-b14d-fe5c10719af2" contextRef="C_a9001d10-0c10-49dc-a944-46388f818412" name="vir:StockIssuedDuringPeriodSharesAchievementOfMilestone" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock in connection with a collaboration agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c75dec4a-98e7-42dc-a980-4c75393567aa" contextRef="C_a9001d10-0c10-49dc-a944-46388f818412" name="vir:StockIssuedDuringPeriodSharesCollaborationAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,626,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e63e5f37-48ea-480e-ae10-9250e70b1177" contextRef="C_a9001d10-0c10-49dc-a944-46388f818412" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cda12e3e-55a4-43b7-9fa5-742311a058a2" contextRef="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,698</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df9447b7-b9a9-40d6-88f8-c09fa489fb05" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock for cashless exercise of warrants</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3c8e029-7ddf-4b35-ac3a-935edc3a3295" contextRef="C_a9001d10-0c10-49dc-a944-46388f818412" name="vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">211,774</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock in connection with a follow-on offering, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c25f1d7-81f1-4c1f-a274-bef1fa79dea1" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="vir:CommonStockIssuanceCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,786</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c594d33-6cb5-4486-a758-26f0412ef1a9" contextRef="C_5435542f-8093-4105-868b-53ef71ac98a3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,214,285</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_121749ad-b6b8-4182-a78a-526e11526c54" contextRef="C_5435542f-8093-4105-868b-53ef71ac98a3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9223169-3a1e-4568-a44f-00b0032d311b" contextRef="C_a58fa995-aa0b-4d6d-9cce-6dbe94de83fd" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">323,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2ef1c0b-3d33-48ef-a38f-e057971312ed" contextRef="C_df0832a0-b752-462c-be11-1620cfe4dc18" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">323,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cf34836-09b7-454f-9bb2-38297b21795f" contextRef="C_a9001d10-0c10-49dc-a944-46388f818412" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,986,250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61960aed-dcea-43d5-bba7-0e456cdb9615" contextRef="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a37168f-b848-4b25-bbb7-edd068bc708f" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ff5f97a-a754-48fe-9d31-bb2aeec8a721" contextRef="C_a9001d10-0c10-49dc-a944-46388f818412" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,618,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8ff7256-d9f6-41c6-9425-9478229784e8" contextRef="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,059</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2cbf057-b10c-4cd5-881f-98cfca98ea75" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,059</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f62f96b7-8592-4b16-955d-e9f80fb629bf" contextRef="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa359a49-3ce1-4ff3-ac37-8dbfab78ca7a" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e776097-f8f2-4a1a-b966-7f05edbd4c9d" contextRef="C_4b3827f4-9f03-4d95-b4e5-11849acbae16" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">677</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e33239fa-c0da-4ff2-8931-47174e64438c" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">677</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_468be4ef-a980-4254-bac9-d7a96efafa64" contextRef="C_f3142090-a1b8-4083-8441-c9dd49ecb566" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6633c424-66c9-46f2-bc5d-868fe6a8c472" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cfe7f33b-f7a5-4e04-8f37-751b92042be3" contextRef="C_d3a8cc93-b738-43bd-abbd-308523b5cd24" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">127,416,740</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4620baa9-b80f-4905-83a9-d7f0fd13acf7" contextRef="C_d3a8cc93-b738-43bd-abbd-308523b5cd24" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea9f4928-5bc3-488a-acca-0eea4e5e681d" contextRef="C_050ac877-095b-4637-b981-1aea98d3b192" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,385,301</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87d6071f-c0a1-45c8-b2f5-92a5e09fe371" contextRef="C_8d7fc207-68b5-469e-b2a5-a7be19fc2bad" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_931cf0fc-ea15-4fb3-9c67-f5dc38478cef" contextRef="C_e1a0aec0-6950-4e6b-b8c6-2c448044907e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">667,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3722b3a-7a89-49a1-a1c8-a93c6b943e41" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">716,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock in connection with a collaboration agreement</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1648da9-76ef-483c-955a-a7a165d57120" contextRef="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc" name="vir:StockIssuedDuringPeriodSharesCollaborationAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,924,927</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43f7ffe6-6fc3-4753-8921-d42a229f8546" contextRef="C_8fccfc88-43e9-4439-a516-7a1eda119be4" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a778ab1c-4c1f-4845-b8b7-2d97883b0edd" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock to settle a contingent consideration</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8241b86d-f327-4e04-bb29-f4ea0ec4e800" contextRef="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc" name="vir:StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">42,737</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf53d25c-80a0-434e-a560-0655e078c3c4" contextRef="C_8fccfc88-43e9-4439-a516-7a1eda119be4" name="vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,860</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a283145-96c5-43a6-9cbc-6e0753bc46a0" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,860</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b5465dc-0f1c-46bc-b45f-70b4444c02c5" contextRef="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">89,261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24ac2c2b-5045-41cc-8577-bec31b076a45" contextRef="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,622,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5738201-779d-4f84-afec-66ae6ef406d8" contextRef="C_8fccfc88-43e9-4439-a516-7a1eda119be4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56f8776d-ca7c-4a2b-8cf0-a9219695e11f" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddb73b15-10a5-4cc3-812f-d0a8817ea7c0" contextRef="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">65,021</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_731a3215-dfc0-4961-99cb-1a2360d69b83" contextRef="C_8fccfc88-43e9-4439-a516-7a1eda119be4" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0334c668-ff5f-4c5c-95f3-d2c68606c4ba" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0479eb70-5b9f-47d4-9b0e-7ab24cc8cfb0" contextRef="C_8fccfc88-43e9-4439-a516-7a1eda119be4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,784</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_498b36aa-01e0-4488-9c30-0985a78639e7" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,784</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Other comprehensive income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17d42d4a-e780-4f69-9cb4-16eed2991f5f" contextRef="C_b82d2460-cf24-43b0-b95e-5a0a52709f8d" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_680c6e9d-4483-403e-8bfa-2cfd9602e600" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Net income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_613b24ae-23c0-4bbd-aed9-28b735230f6b" contextRef="C_486aaa19-98ed-45c8-8860-fd4d402399da" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5914c330-b1d8-48fa-8349-ec4d5f1910e4" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6999d89e-ce90-4ef3-87be-3f47ea11a6be" contextRef="C_c7f66cdc-e2a5-4776-b99c-d6e4b917eb2c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">131,161,404</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5131f971-2b3e-4255-bbd3-460ed2088d15" contextRef="C_c7f66cdc-e2a5-4776-b99c-d6e4b917eb2c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea675401-2410-4840-80d6-d1b7c1d609a8" contextRef="C_b1bbbe19-c33f-4c19-83ca-eca625a9d033" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,571,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e619dd20-0bb3-4c44-ae41-09b25724bcd6" contextRef="C_91794362-8b4e-44c7-8392-9d2e078a248a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,099</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15cf6bea-e54e-49c0-9ab7-0d5e06257c32" contextRef="C_d7012ff2-8e91-4fa6-b536-458c48e3b5ee" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">138,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c7a890b-871d-41b8-aa8c-a86271163d9c" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,431,849</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Stateme</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">nts of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.644%;"></td>
    <td style="width:1.481%;"></td>
    <td style="width:0.845%;"></td>
    <td style="width:11.569%;"></td>
    <td style="width:0.557%;"></td>
    <td style="width:1.481%;"></td>
    <td style="width:0.845%;"></td>
    <td style="width:11.569%;"></td>
    <td style="width:0.557%;"></td>
    <td style="width:1.481%;"></td>
    <td style="width:0.845%;"></td>
    <td style="width:11.569%;"></td>
    <td style="width:0.557%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">CASH FLOWS FROM OPERATING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Net income (loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7be9baf3-10f8-4797-88b4-b52a96360fbe" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a7784cf-fe7a-4113-b0d0-c460c77ca087" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0dbc91b-e4d2-4d78-9553-30f05edab5ac" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174,683</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ba0c5e4-41f6-4a5f-9d60-a6d4d91d08b1" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_cac71a2a-85db-43cf-8612-04ef31b13041" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_6dcb8c2c-3ba3-45b7-b744-5d376fa9eb6f" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,294</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Amortization of intangible assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_36f5b932-27bf-4425-98e0-12aef82937ab" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_310765ed-6f85-40cb-b114-668af456766f" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,042</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba3251ba-3e1c-430f-a5b2-a3eaf4d11c77" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,223</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Impairment of intangible assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_20aa9ca2-42ef-403f-9ec6-4ab57c19080b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_aef3ec73-c0ca-4378-a317-9f005a34d0e5" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d2953029-da62-484e-a797-93a558adad20;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(Accretion of discounts) amortization of premiums on investments, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f96a5fa-6283-4171-93a9-3577799915eb" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae0b697b-3009-4637-99f1-f43bf4013bf2" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,548</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec1f7aa7-10c6-49d2-9102-738eaa662227" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Noncash lease expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb689e22-37ad-4d6a-a4b6-f775a8941954" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,172</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7f08ce1-b657-4f9d-b788-f3d23d50b6ad" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="vir:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cd9e3ce9-14e4-4515-a281-682b3f84673d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Change in fair value of equity investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_52b81cf2-113e-47ab-b6d5-4785553d13ec" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">138,049</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_dec1a281-61d2-4dc6-90d7-76198f647c24;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a7d4385c-0b9b-4afc-a37c-6c1eb232d765;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Change in estimated fair value of contingent consideration</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed7308d8-9340-4859-8f5d-f1c0ca549153" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91,848</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7994e58-6c26-4783-83a9-30cf17f6e076" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,394</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_150613ed-31b4-44a3-9eee-e0b58985fbae" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,330</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Payment of contingent consideration in excess of acquisition date fair value</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8deb8567-0d9e-40e4-93c2-276182831497" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4800ff6-6c56-4713-b998-109ffbdd1249" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,752</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7bbc2272-0008-492a-b8e3-012702186564;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Initial fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c1b7f7bb-24d4-45ce-80d9-0476ded55f8a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d44a4bed-0ed7-40da-887f-ea79ca6c9d8e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b968b53b-98e9-43e0-8b20-c6002489c211" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:InitialFairValueOfDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,599</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Change in estimated fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8f4edfbd-9a9f-42a8-a370-d64708e2323e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca5bf112-97fd-43aa-b6b0-b0b51a4165e0" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16,796</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ea3ea88-1beb-444e-8fef-1d075e23547e" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Change in estimated fair value of convertible preferred stock warrant liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8b32ee52-010b-4024-ad9b-e6c4df6d5466;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f6ef5dbd-d8d1-45e0-a55c-433dfbcf55ec;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d37141f9-b137-4530-a1d0-d6a8dfb75a80" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,049</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_05357b1e-efcb-4963-a7b2-da8f30daeedd" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,784</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8258a829-60ff-4b1b-ad08-e3c936141240" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac52255c-7ae5-4d08-a95e-512b7e9899da" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Change in deferred income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_40135349-b4c6-49db-98b4-c134d01b74ad" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,186</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1fd9353-8b2d-48f6-9ffc-e245774e3a84" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9a26d801-8def-40ce-9488-f4b2a2bbc5db;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Gain from a sublease termination</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b1ddaff-fe2d-47c7-affc-f7f5bf152069" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,844</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3a00e3fd-a5c3-445c-8652-f44eb20df66b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cd3b816e-2520-4ba4-873e-cb45dd224087;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Common stock issued in connection with license agreement</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_53ca3f31-8c27-4624-bbcd-862d061949e3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3b70eb5c-3677-456e-9180-2f5f40bd92cc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a63aebee-e166-47ba-9af2-21f2962e4d08" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:CommonStockIssuedInConnectionWithLicenseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">617</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bf5f4a5-6e40-4c6f-b655-73135ab65fcb" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">697</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc8d5196-8d5e-45c3-98c2-0ac96e860a48" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f054c174-18b9-4950-a0cb-fa18bbbd8564" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Receivable from collaboration</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c61ecf96-44e9-4370-b1b2-8bf4d0844bda" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">773,079</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a4ed1c20-8e73-4bd0-8485-9c5663b1058d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e465322f-8ed1-47a7-9a25-aee25f322449;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:16.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5df0cea-2503-4fea-a4c3-f54fb3d8d712" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e636d61-7163-4b3a-942f-6f38115a203a" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,475</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae160c30-d0fd-44da-b6fc-c72200d46597" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,619</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_518ae512-c6e6-412c-832f-b756aef87302" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,483</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cd2f4a4-05c2-4d55-a346-8d12ee55d10b" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8ed574b-14ec-439e-9eec-86eaa99b5179" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,881</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:16.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_61130947-499f-4ce6-9721-889f7728d970" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_47bc2a84-4bb9-434b-bd52-b9a785fb8bf8" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a8052cd-e8a9-4c82-abc1-9ed98e1e7c51" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">964</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Accrued liabilities and other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ed74285-41c5-40c4-a60b-051879c6849f" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4819237-f6b6-40b4-a07f-f0a12f59df79" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,614</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f04aa775-6908-4bde-8bda-b24b2c5ff189" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,211</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:16.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4eae1c8-26f1-4a4c-a964-a1ed5e7f3c3a" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_672a660d-2999-46bc-8e99-ec6f331194c9" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,684</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5f39939e-8498-4156-807d-30af0dfff8cb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_61de83e3-523f-480b-ac86-e7354871a2fa" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4692b7c5-9a5e-45c9-8340-93e1509bbd51" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,043</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_34c81c5b-1c31-45ad-872d-2907896d6bc4" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,529</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f45591de-478e-4b59-a6d3-430100e496f0" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,589</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3d40e7e-4d38-4935-847f-782c1eeae150" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">190,941</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd22d2d6-a045-4a5b-aa09-d8a4ba04d701" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">129,632</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">CASH FLOWS FROM INVESTING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_165db72f-530a-4ac7-893b-b54ef0f2b514" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,817</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd8cf64a-07d1-42b1-84cb-3c6eb1a55862" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_97d700bb-7cdd-448e-8f43-b180161df675" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,940</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Purchases of investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c787366a-f919-411d-8b50-edc7ef371675" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">420,240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_61815887-353d-4d5b-a165-6f894860b8fa" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">403,841</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6bf2a30-658b-4340-9460-183cd077411b" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">643,898</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Maturities of investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_643f0ac8-1170-469c-8869-02ea9f6f0322" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">301,243</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e69fa984-4f12-4e3f-a439-ad8b17481a58" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">400,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9946495-db11-4082-b612-0d3749951f48" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">396,680</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Proceeds from disposal of an asset held for sale</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_35bc7a1f-bacb-46b6-aa07-b09b7bbbd419;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb190666-19ed-4f2e-bbd3-db3188175418" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1425da0a-0d71-41fb-80b4-6e4271d2eaed;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_87ae7e7a-c1e5-48a0-b7b6-313474cc569e" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">140,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c54b9db-06c8-4f90-a3b1-4aecfb2b28e5" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,862</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfbd8654-354b-49fd-b07b-7113a6cfd626" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">256,158</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">CASH FLOWS FROM FINANCING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Proceeds from issuance of common stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_63c2423d-7a76-4317-bc96-630517587877;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bfae185-e5c8-4577-8141-e72de9718408" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">323,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_23c593d3-6662-4c12-8d4f-ab18d0605a8f" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Proceeds from issuance of common stock in connection with a collaboration agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7bd09cb8-0f10-423e-8594-0f550e570802" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_67705a86-c6c7-4e22-ba25-b0b14652b30e" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_97880dc8-ea14-4184-b3d1-1c224e174732;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Proceeds from issuance of convertible preferred stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e68fa7e5-5e36-4a91-a346-039647a55845;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3a2ddd83-9ef6-4dfd-b812-3fef59045e88;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b7eac74-97da-4b41-a2e9-64fa1634bdc4" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">317,335</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Proceeds received from financing lease obligation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3cd3f88d-5ec4-4c66-a41f-56053d71af7a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_772cdc50-ee81-4663-b2c9-159a9a5d4a6d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_202c0025-e4cb-471b-bb23-a1223e4dc98b" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:FailedSaleLeasebackTransactionProceedsFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,202</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Payment of contingent consideration</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b4609599-f5b1-4e10-83aa-953f302ed107;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1eafafc-3e43-4f7f-832f-354a4dba03d4" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="vir:PaymentOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,248</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f4d21755-e71d-4379-982f-e1f0ca56eef1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Payment of principal on financing lease obligations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_082436f7-7379-4d61-8c3b-1390349b6d76" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_55cb8866-e9c9-4b61-bab0-eb8705c7c815" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_93a7f2e4-d090-47fa-946a-158010553503" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Proceeds from repayment of promissory notes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a4de510f-58db-4648-a977-8db678cc72e5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_736e2b87-7321-4c16-a4d7-00f5d88607fa;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3e8d9ab-ed6b-4dc5-a77e-4b49c18eee27" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:ProceedsFromRepaymentOfPromissoryNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,265</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_32ed496b-0723-4007-b051-2f3c2672e15d" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec790428-70b7-4454-a315-bd699710dc91" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,059</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_debbdadc-d2ab-4d30-9b56-cd635d340625" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Proceeds from issuance of common stock under the employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec550a60-d8ec-4a01-8caa-dc2b3a9ef18c" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8340aa05-f6fa-415d-aa80-320c4eb517d5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Cash paid in lieu of fractional shares related to reverse stock split</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e9114fd8-4978-4682-9f50-9246a83ee001;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e04e83e7-ebaa-41ea-babd-a85bb4d24a9c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5161771-3299-494c-a790-5ab0ac6e5417" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d4604f9-7d5c-4cb8-98ba-3fb8718ff0ca" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d30f9171-b9e8-46a8-b809-7bf233a4d376" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">529,474</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b59aac1-6e08-4c14-943d-10a2e7e984e1" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">449,244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">(</span><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd768bb5-76c4-4f9c-bda6-80b96683fbad" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">88,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_9805df3b-6cdf-4d13-bc8d-08b690f16d4c" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328,671</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_12d81372-0920-4f42-a0bf-6f364d3eb731" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,454</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash and cash equivalents at beginning of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4ef01f5-6a49-4afd-8384-a12525513ab3" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">451,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ff8a97a-c9b5-4d50-8d66-2c1242c4bae1" contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,816</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_493b1bbd-9dcc-4174-8d56-d8b9c6c94e87" contextRef="C_88183c78-6814-4146-96c6-0cba18d5611c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,362</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash and cash equivalents at end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_13cf4633-1aad-4e47-9508-24615729fdbf" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">363,415</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1150f140-5e97-4c78-bf60-36522e9749cd" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">451,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_970bd175-d825-4da6-8957-56eece7c7170" contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,816</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">NONCASH INVESTING AND FINANCING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Property and equipment purchases included in accounts payable and accrued liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_54ea791a-a553-4c6b-a984-7d2f2777abc3" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,731</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ed87162-6c38-4c82-8ef6-87b716e5167f" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">382</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4f13a7e-0f58-4231-935f-f50a413c5f1f" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">892</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Common stock issued for payment of contingent consideration</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec4d523f-099c-4b53-8aff-240e225510d9" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:NonCashCommonStockIssuedForContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,860</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_196c5237-329f-410d-96d8-db2421aa3db7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_48a607eb-82b2-42f3-9b15-106d86433c4f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Conversion of preferred stock into common stock upon completion of initial public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_58e2eb0c-1180-444f-b3b2-1e0f0b469fc9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_48a70287-0f05-4e93-92b2-64eb0929682f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_dbe1e3e4-6cdd-4296-945c-f81bb7ff1d39" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">636,612</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Operating lease liabilities obtained in exchange of right-of-use asset</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_776b7a6e-06d3-4bce-bad7-6e828ca6bb93" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,187</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba3bd97a-9d44-4106-9856-107adcbbc0d3" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,495</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4f339869-7320-48dc-b4c4-f4e2638b0fb0;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Advanced proceeds applied to convertible preferred stock issuance</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c4078763-cec1-4a66-959d-505d3023edad;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9854d74e-7f97-4b0b-a755-45b36915ad92;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_75e1ae96-9005-4996-9e48-3c8448263c3f" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Reclassification of derivative liability to additional paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6380790d-03b2-4de6-bb8a-563e0a71388f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_af61ab95-7f9b-4aeb-82eb-284b3629f957" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ac7ee1e4-e982-4e16-ba9a-ab3dacbb8803;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Reclassification of preferred stock warrant liability to additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_72defe4c-83c3-481e-b440-b0643489c971;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9ed14462-8c3e-4dbb-b16c-fd5a1cb257fe;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_14cdaf9c-9eb3-4858-b49b-002cec51381e" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,073</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">RECONCILIATION OF CASH, CASH EQUIVALENTS AND<br />&#160;&#160;&#160;RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0b30e3d-dddb-499a-b9c0-18039a7ae542" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">347,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_65efccf9-7f6c-46fd-9bf6-27ad5b901e52" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">436,575</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_20cda37b-3314-46c2-985e-99e25fcf6c99" contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,335</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Restricted cash and cash equivalents, current</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_19ef2ea1-583b-4757-81a0-3552efe70e73" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,594</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a7e8e07-9e60-4ab1-91e9-76631f4f98f9" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e1863d7-f5bc-4f14-ba3a-ebd6f4254c42" contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Restricted cash and cash equivalents, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd0240c4-80a2-4e01-918c-d28d26efa261" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_15e70c41-51f3-443f-a402-9a6afa8f1b35" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_428c441b-d78d-4c62-b8da-6cee6e62872a" contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:16.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">Total cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb085999-b514-499a-8a0c-ae87f3a54f55" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">363,415</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_932b8303-cee9-4c90-8525-d114e2a993a6" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">451,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c70149b8-563c-4106-92fc-35efc2b2c1db" contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,816</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a572fd53-a44f-4be6-b3cf-db2b5d0d6b4b" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_a572fd53-a44f-4be6-b3cf-db2b5d0d6b4b_1"><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Organization </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc. (&#x201c;Vir&#x201d; or the &#x201c;Company&#x201d;) is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Its current pipeline consists of sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#174;) and other product candidates targeting coronavirus disease 2019 (&#x201c;COVID-19&#x201d;), hepatitis B virus (&#x201c;HBV&#x201d;), influenza A virus, and human immunodeficiency virus (&#x201c;HIV&#x201d;). Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the U.S. Food and Drug Administration (the &#34;FDA&#34;) granted an Emergency Use Authorization (&#x201c;EUA&#x201d;) for sotrovimab for the early treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and at high risk for progression to severe COVID-19, including hospitalization or death. The Company also received a positive scientific opinion from the Committee for Human Medicinal Products in the European Union (&#x201c;EU&#x201d;) for sotrovimab. In December 2021, the European Commission granted marketing authorization to Xevudy&#174; (sotrovimab) in the EU for the treatment of adults and adolescents at increased risk of progressing to severe COVID-19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 10, 2019, the Company completed its initial public offering (&#x201c;IPO&#x201d;) of its common stock. In connection with its IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c4b51ad-5615-4dee-a080-de814fc1113f" contextRef="C_2d502ed6-15ab-425f-9a22-bfc1d3c39623" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,142,858</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at an initial offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_767e439c-bdf8-441b-b9da-79be05d38ac7" contextRef="C_ccf336f4-a19b-47b9-8dd4-fd55c3edb88c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2">20.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. As a result of the IPO, the Company received approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67376ad3-4c9c-4d19-a049-ed508f863efc" contextRef="C_e52b7462-3e95-4a90-a2ac-eeb96cc91696" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">126.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds, after deducting underwriting discounts, commissions and offering expenses. At the closing of the IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e8b986d-acce-4e42-8f4d-59ad560888c1" contextRef="C_ccf336f4-a19b-47b9-8dd4-fd55c3edb88c" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">88,112,733</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of outstanding convertible preferred stock were automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d825427-ac75-4966-a63b-4da76d3dffb9" contextRef="C_c9443ba3-f289-4712-b80e-f1c93e0123cf" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">88,112,733</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock and a warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9405048c-a313-41ce-81df-92b4793a7242" contextRef="C_04e2f054-346c-47c8-89fb-055997c2a180" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">244,444</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock was converted into a warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81f587d2-8916-4971-9479-9cfbadb7c720" contextRef="C_e9b5a1f5-d509-4f41-a5b0-00e6735b747a" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">244,444</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Follow-On Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 10, 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8e8284c-b104-4e65-8589-436bbe9541b5" contextRef="C_88ec3719-e182-4d88-abf8-cefce0fa050c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,214,285</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock pursuant to a registration statement on Form S-1 (File No. 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) (File No. 333-239747) (collectively, the &#x201c;Registration Statements&#x201d;). The Registration Statements became effective on July 7, 2020. The price of the shares sold in the follow-on offering was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4f6ff43-3d3c-498a-89e9-66eb0fc6ecbb" contextRef="C_c0e8d12f-41e5-4499-bb57-79d3fbd1a9a2" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" decimals="INF">42.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and the Company received total gross proceeds from the offering of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a50e7a7-9cbe-41a8-bf70-567c93b5e385" contextRef="C_88ec3719-e182-4d88-abf8-cefce0fa050c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">345.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. After deducting underwriting discounts and commissions of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7762e11-0f30-40fe-a616-3f65aff9289f" contextRef="C_88ec3719-e182-4d88-abf8-cefce0fa050c" name="vir:PaymentsOfUnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5">20.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94aefcb8-8e02-4dab-8c1b-83d187f1ec73" contextRef="C_88ec3719-e182-4d88-abf8-cefce0fa050c" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, the net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77742d55-b0c5-4bd7-aee3-59a25c24a696" contextRef="C_88ec3719-e182-4d88-abf8-cefce0fa050c" name="vir:NetProceedsFromIssuanceSecondaryPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">323.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), under which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f34f3754-6a90-43d7-9652-4529ef1618c6" contextRef="C_33252fb3-7851-44e7-9561-2d534fcb41de" name="vir:SaleOfStockConsiderationAggregateOfferingPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">300.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, through or to Cowen, acting as sales agent or principal. The shares will be offered and sold under the Company&#x2019;s shelf registration statement on Form S-3 (the &#x201c;S-3 Registration Statement&#x201d;) and a related prospectus filed with the Securities and Exchange Commission on November 10, 2020. The Company will pay Cowen a commission of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2cc6dd2-7874-49ac-af8c-1ed85da54bcd" contextRef="C_91330166-4192-4765-8752-a172cb399634" name="vir:PercentageOfCommissionRateFromSaleOfShares" unitRef="U_pure" scale="-2" decimals="3">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b99465ce-db91-4234-8dd4-2ab91016feb6" contextRef="C_2f8addeb-5f7f-45ee-807d-84c9144573a3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares have been issued under the Sales Agreement.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Need for Additional Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_a572fd53-a44f-4be6-b3cf-db2b5d0d6b4b_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although the Company recorded net income for the year ended December 31, 2021, it has otherwise incurred accumulated net losses since inception. The Company expects its earnings to be volatile and may continue to incur net losses over the next several years. As of December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b259ad3-3260-4e3e-8a30-ea9d26a145ee" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">138.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Management expects to incur additional losses in the future to conduct research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company had, excluding restricted cash, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d8e1610-4fd6-456b-b848-02de6c1bad90" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">909.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of cash, cash equivalents, and investments as of December 31, 2021, and after excluding the equity investment in Brii Biosciences Limited (&#34;Brii Bio Parent&#34;), the Company had </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_872ea01a-0e4c-415a-b1e5-a995810abac5" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">766.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Based on the Company&#x2019;s current operating plan, management believes that the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35e68399-74f1-4a2d-af64-100b16da2be7" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">766.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021 will be sufficient to fund its operations through at least the next 12 months from the issuance date of these consolidated financial statements.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8ab5f61-8a41-455b-b1a2-7feb86c0a459" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6421bb3f-7526-4f47-bd5e-0e78a9ea2044" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. The consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c383f64-875d-4d3b-acbe-4297c26fd4d5" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The functional currency of the Company&#x2019;s foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. Transaction gains and losses are included in other income (expense), net on the consolidated statements of operations, and were immaterial for the years ended December 31, 2021, 2020 and 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f88aedc9-dbf1-4952-89b3-c2142959eac9" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48e93875-26ff-435d-8394-10fa4d2e3710" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company operates as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04371e70-991c-4454-9434-20f7184b4a2e" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a0633fd-125e-4b76-a0cc-557b96667d32" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has implemented a number of plans and policies designed to address and mitigate the impact of the ongoing COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will continue to have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company&#x2019;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although the Company received EUA, temporary authorization or marketing approval for sotrovimab (under the brand name Xevudy&#174;), it is still subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its other product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of sotrovimab and other product candidates and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its other product candidates, it will be unable to generate significant revenue from product sales or maintain profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the consolidated balance sheets. As of December 31, 2021 and 2020, the Company has no off-balance sheet concentrations of credit risk.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#x2019;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#x2019;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. There was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23cda959-5b2b-4760-877c-0e044a46ce1d" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3c3da7ce-8311-4456-8bc7-fb8a39fa78ae" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> allowance for losses on available-for-sale debt securities attributable to credit risk for the years ended December 31, 2021 and 2020.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4612c47d-29ff-47c0-9403-60b8c8674965" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f77c7841-9957-4b45-a8fe-e0a015e238d5" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments include available-for-sale debt securities and equity investments, which are carried at estimated fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Available-for-Sale Debt Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. The cost of securities sold is based on the specific identification method.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">147</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Accounting Standards Update (&#34;ASU&#34;) No. 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, the Company measures its investment in equity securities at fair value at each reporting date based on the market price at period end if it has a readily determinable fair value. Otherwise, the investments in equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer unless the Company has significant influence or control over the investee. Changes in fair value resulting from observable price changes are presented as change in fair value of equity investments </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and changes in fair value resulting from foreign currency translation are included in other income (expense), net </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on the consolidated statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_048edd35-cd41-4436-bfe3-cf08bed0a610" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb5ae719-c83d-4c2e-9624-f2bb430a99fb" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_72920b5d-5b28-4a32-a06c-5ef00bd3d18b" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e8ebc668-f14c-4720-8b72-2366a378afeb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0428a95b-1aef-4390-b9cb-3461d5ea2bed" contextRef="C_ec04e3a0-91fd-471d-9c5e-a88bcbb1c70d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. No material impairment losses have been incurred to date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4854e81b-c83b-4dbc-a6ab-33f2766c24e6" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquired Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s intangible assets were acquired via business combinations or asset acquisitions. Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (&#x201c;IPR&amp;D&#x201d;) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2021, there have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87545169-2d68-4fbb-8cf7-cb6f053ce523" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairments. For IPR&amp;D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses. IPR&amp;D assets acquired as part of an asset acquisition are recorded at cost and expensed immediately if they have no alternative future uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">148</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets acquired are initially recognized at their fair value at the acquisition date. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0326925d-a0c7-42ee-89e8-abb26064ce21" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b3b3c2e2-807e-47e2-9909-7b52a03e1e68;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4830578c-0b13-4b9e-84f3-d48b32361bc4" contextRef="C_ec04e3a0-91fd-471d-9c5e-a88bcbb1c70d" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7dba307b-6fa9-4679-a880-59fc1e4d6298" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e99f9d96-7d7b-4bf3-a014-8ef63e6e8c02" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration, License and Contract Revenue</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when the Company&#x2019;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. When the Company is considered an agent in elements of collaboration arrangements within the scope of ASC 808, it records its share of collaboration revenue in the period in which such sales occur. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the revenue reported by the Company's collaboration partners, net of cost of goods sold and allowable expenses (e.g. medical affairs, selling and marketing expenses) in the period. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partner, including revenue from the sale of the product, and costs incurred for development and sales activities. For the periods covered in the financial statements presented, there have been no material changes to prior period estimates of revenues and expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#x2019;s intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">149</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). The Company estimates the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Grant Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a54b09e2-ccac-499c-bddc-3f017e2967f1" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, research and development expenses have related primarily to discovery efforts and preclinical and clinical development of product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include expenses related to license and collaboration agreements; contingent consideration from business acquisitions; personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel contributing to research and development activities; expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and other allocated expenses, including expenses for rent, facilities maintenance, and depreciation and amortization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. Upfront payments and research and development milestone payments made in connection with acquired license or product rights are expensed as incurred, provided that they do not relate to a regulatory approval milestone or assets acquired in a business combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s expense accruals for clinical trials and manufacturing are based on estimates of contracted services provided by third-party vendors not yet billed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of its outstanding obligations to those third parties as of the period end. The accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. The Company obtains information regarding unbilled services directly from these service providers and performs procedures to support its estimates based on its internal understanding of the services provided to date. However, the Company may also be required to estimate these services based on information available to its internal clinical and manufacturing administrative staff if such information is not able to be obtained timely from its service providers.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_100707e2-72fd-471e-86b4-49b2af5f00c0" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes stock-based compensation to employees and non-employees over the requisite service period based on the grant-date fair value of the awards. The Company calculates the estimated fair value of stock options and employees' purchase rights under the Company's 2019 employee stock purchase plan (&#34;ESPP&#34;) using the Black-Scholes valuation model, which requires the use of subjective assumptions including volatility and expected term, among others. The fair value of restricted stock awards (&#34;RSAs&#34;) and restricted stock units (&#34;RSUs&#34;) is based on the market value of the Company's common stock on the date of grant. Stock-based compensation is recognized using the straight-line method for awards that vest only upon the employee&#x2019;s or non-employee&#x2019;s continued service to the Company. Stock-based compensation expense of the employees' purchase rights under the ESPP is recognized over the offering period. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96c6b97e-5f9c-4f78-a87e-915bfb38e177" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:BusinessCombinationsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisitions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various milestones are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f382009-d6ca-4939-9fac-4b68520913b2" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:DerivativesEmbeddedDerivatives" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Embedded Derivatives</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the consolidated statements of operations based on the nature of the related contingencies.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expense or selling, general and administrative expenses based on the nature of the relevant underlying activities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Otherwise, changes in fair values are recorded within other income (expense), net.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49a86ddb-b0b2-41c6-9b65-fa4bf484b6d8" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with ASU No. 2016-02 (Topic 842), Leases, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#34;ROU&#34;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. On the lease commencement date, the Company estimates and includes in its lease payments any lease incentive amounts based on future events when (1) the events are within the Company&#x2019;s control and (2) the event triggering the right to receive the incentive is deemed reasonably certain to occur. If the lease incentive received is greater or less than the amount recognized at lease commencement, the Company recognizes the difference as an adjustment to right-of-use asset and/or lease liability, as applicable.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">151</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the implicit rate in the Company's leases is generally unknown, the Company uses an incremental borrowing rate estimated based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating its estimated incremental borrowing rates, the Company considers its credit risk, the lease term, the total lease payments and the impact of collateral, as necessary. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. ROU assets and lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. Rent expense for the Company's operating leases is recognized on a straight-line basis within operating expenses over the reasonably assured lease term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc1f68d2-2c30-42ea-a654-a0f42a99cb7d" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_fc1f68d2-2c30-42ea-a654-a0f42a99cb7d_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the asset and liability method of accounting for income taxes. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating losses and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as any related net interest and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a849fafc-233b-4a41-923d-9d088a02cc4e" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Income (Loss) Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per common share is computed by dividing the net income by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6db23eff-7d4a-452f-b27e-4266c9761e62" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_6db23eff-7d4a-452f-b27e-4266c9761e62_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">New Accounting Pronouncement Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_6db23eff-7d4a-452f-b27e-4266c9761e62_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, the Financial Accounting Standards Board (&#34;FASB&#34;) issued ASU No. 2021-10, Government Assistance (Topic 832) (&#x201c;ASU 2021-10&#x201d;), which adds certain disclosure requirements with respect to government assistance, including (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance on financial statements. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2021-10 may have on its consolidated financial statements and related disclosures</span></ix:continuation></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_7f8822cc-734b-49c8-ad0a-b82fca7dddfc" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements </span></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_005debc0-f682-4ad9-bae9-3d868d8146d5" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></div></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of the Company&#x2019;s financial instruments, including receivable from collaboration, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Equivalents and Available-for-Sale Debt Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4869d666-46a6-4b34-a91c-21e194b1e77a" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company&#x2019;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.3%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:9.81%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:8.21%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:8.21%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:8.21%;"></td>
        <td style="width:0.865%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:8.21%;"></td>
        <td style="width:0.646%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br />Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Holding<br />Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Holding<br />Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4539ab16-5659-4ce7-a611-6bc657de6516" contextRef="C_c65e2fa1-651b-49f1-8130-e10a86ed4b23" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d70ead3c-aa30-4a86-b30a-7e805359aad2" contextRef="C_c65e2fa1-651b-49f1-8130-e10a86ed4b23" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_074dc99f-219d-414c-ac63-d8488c88488c" contextRef="C_515a352c-312e-4bf3-9bf8-04b085f91abc" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">419,442</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8990435d-5a94-4203-b936-e3140512568a" contextRef="C_515a352c-312e-4bf3-9bf8-04b085f91abc" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">872</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a787813-b4f9-4dcb-aea2-108be8e529b5" contextRef="C_515a352c-312e-4bf3-9bf8-04b085f91abc" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">418,570</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d224330a-9676-4782-86ba-e59e08ff6228" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">764,540</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d593e7c-b8af-4867-8268-17bef4890f2e" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79cf9ab3-077b-43d3-8bb8-8207268c3ceb" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">872</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e92faf36-1602-4cda-83b7-9f1bcbbc2428" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">763,668</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1) Includes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b39812a-b8e4-4641-8c2f-6727cbb4cba9" contextRef="C_c65e2fa1-651b-49f1-8130-e10a86ed4b23" name="us-gaap:RestrictedCashEquivalents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> of restricted cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.295%;"></td>
        <td style="width:1.044%;"></td>
        <td style="width:9.829%;"></td>
        <td style="width:1.044%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:8.229%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.044%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:8.229%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.044%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:8.04%;"></td>
        <td style="width:0.865%;"></td>
        <td style="width:1.044%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:8.229%;"></td>
        <td style="width:0.646%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br />Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Holding<br />Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Holding<br />Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75dec18e-a8a8-4382-985e-1570e021d392" contextRef="C_37e02e2b-ecee-41f9-9516-eff5990866ee" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">421,835</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_422179d7-8b97-4c8b-8ebf-236b1f31b3a0" contextRef="C_37e02e2b-ecee-41f9-9516-eff5990866ee" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">421,835</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b31846c-a25d-474b-9dfe-8b8272a35b81" contextRef="C_19681061-85d7-43eb-9090-f6c375682fba" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300,201</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44d34173-28bc-4017-9268-a2f8f2040d10" contextRef="C_19681061-85d7-43eb-9090-f6c375682fba" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3">91</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d676ade-211b-485f-8f84-9ee0c6e2a99d" contextRef="C_19681061-85d7-43eb-9090-f6c375682fba" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3de3d4b6-f79c-41ae-bc29-0b042e8499a7" contextRef="C_19681061-85d7-43eb-9090-f6c375682fba" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c603b2f-2f78-4374-8a40-8bf8b288f2c3" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">722,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21fe8562-ea82-4df6-97d2-467d941e36fd" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f119198e-9c79-4656-a98d-b1e9d971860f" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_574f40a3-5d9a-4865-9ece-2af859583bf1" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">722,121</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-2.599%;padding-left:2.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1) Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0f92acc-cdb8-4f34-a607-12a56b1f7201" contextRef="C_37e02e2b-ecee-41f9-9516-eff5990866ee" name="us-gaap:RestrictedCashEquivalents" unitRef="U_USD" scale="6" decimals="-5">14.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million of restricted cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities are presented within prepaid expenses and other current assets, and other assets in the consolidated balance sheets. Accrued interest receivable amounted to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df702d73-3a83-40fb-8786-46eb167a82a3" contextRef="C_b2d805bd-8fe4-4a5d-a29f-32025b612cb1" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab131ca6-47c3-4e33-83fb-c1efcf0ca286" contextRef="C_ed3b9e09-2b8e-4a52-a1e4-da67c4059a2e" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively. The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_325bbf8c-c6ed-4dd4-b43e-606f9755ec4a" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:FinancingReceivableAccruedInterestWriteoff" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_749c67fa-4971-4e95-9547-494d1a465b9f" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:FinancingReceivableAccruedInterestWriteoff" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t write off any accrued interest receivable during the years ended December 30, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized total net unrealized loss of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7a4152b-e6a4-4524-8fbc-dcfc86407693" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and net unrealized gain of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4893e952-7af2-4e2e-8ee6-9631caa38e74" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in accumulated other comprehensive income (loss) as of December 31, 2021 and 2020, respectively. The gross unrealized losses related to U.S. government treasuries as of December 31, 2021 were due to changes in interest rates. As of December 31, 2021 and 2020, there were no investments that have been in a continuous unrealized loss position for longer than 12 months. The Company determined that the gross unrealized losses on our investments as of December 31, 2021 were temporary in nature. The Company currently does not intend, and it is highly unlikely that it will be required, to sell these securities before recovery of their amortized cost basis. As of December 31, 2021, no securities have contractual maturities of longer than</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0427c09d-5c70-43a5-88fe-e4eab8c9ba81" contextRef="C_a8765b59-506d-4165-9487-b02bdc930b58" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">153</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company's equity investment consisted solely of ordinary shares of Brii Bio Parent. The Company acquired the securities as partial consideration for entering into the collaboration, option and license agreement (the &#x201c;Brii Agreement&#x201d;) with Brii Bio Parent and Brii Biosciences Offshore Limited (&#x201c;Brii Bio&#x201d;) in May 2018. The Company concluded it does not have a controlling interest or significant influence over Brii Bio based on its ownership percentage and other factors. See further discussion in Note 7&#x2014;Collaboration and License Agreements. In July 2021, Brii Bio Parent completed its initial public offering (&#34;Brii Bio Parent IPO&#34;) on the Stock Exchange of Hong Kong Limited, prior to which the securities were accounted for as equity securities without a readily determinable fair value. Upon the completion of the Brii Bio Parent IPO, the securities were considered to be marketable equity securities and subsequently remeasured at fair value at each reporting date. The Company classifies its equity investment in Brii Bio Parent as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market. As of December 31, 2021, the Company remeasured the equity investment at a fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ded9fe66-27d0-4020-8b23-a5597967f1f8" contextRef="C_3f145b8a-a89a-4b1f-beee-1a8a6ab8f021" name="us-gaap:InvestmentOwnedAtFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">143.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. For the year ended December 31, 2021, the Company recognized an unrealized gain of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a16461d5-067a-4e86-81ea-2ee6fab5c626" contextRef="C_1cec4878-722f-49d0-b6df-245adc26d756" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">138.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as other income in the consolidated statement of operations, net of an unrealized loss of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9316f140-7f0d-4be0-9e52-255e5f5bed17" contextRef="C_1cec4878-722f-49d0-b6df-245adc26d756" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to foreign currency translation for the period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration includes potential milestone payments in connection with the acquisitions of Humabs Biomed SA (&#x201c;Humabs&#x201d;) and TomegaVax, Inc. (&#x201c;TomegaVax&#x201d;). See further discussion in Note 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquisitions. The Company classifies the contingent consideration as Level 3 financial liabilities within the fair value hierarchy as of December 31, 2021 and 2020.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical, regulatory, and commercial milestone payments based on the assessment of the likelihood and estimated timing that certain milestones would be achieved. In December 2021, the Company achieved the regulatory milestone of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6785a78-51d6-43d2-a671-a40534d484e6" contextRef="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e" name="vir:RegulatoryMilestoneAchieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to sotrovimab. </span><span><ix:nonNumeric id="F_a281a280-c096-4d0a-b2a7-82d7712b00b4" contextRef="C_c3d7153f-2142-47b5-836a-92c25c9b950c" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_a281a280-c096-4d0a-b2a7-82d7712b00b4_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of Decemb</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">er 31, 2021, the Company calculated the estimated fair value of the remaining clinical and regulatory milestones related to the HBV product using the following significant unobservable inputs: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_a281a280-c096-4d0a-b2a7-82d7712b00b4_1" continuedAt="F_a281a280-c096-4d0a-b2a7-82d7712b00b4_2"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.179%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:32.381%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Range<br />(Weighted-Average)1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e9c298f-eb29-41f4-8a2d-547eee0b300a" contextRef="C_f999fb4c-9967-4386-a71c-e0a64a7891bc" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d36d33b-2f89-4456-8f91-0f59f9962b27" contextRef="C_f0ace255-aaf9-4b62-af6c-209acf635d22" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a891e850-a5c8-437d-9fba-752651a758b8" contextRef="C_714f6509-93e2-40d8-93c7-af8d8831b31d" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f35ef763-b249-4cff-bd32-496b3632c61a" contextRef="C_d67e94b8-3d90-4a56-820b-3f311ae13e57" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">22</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_949d1fde-fe74-4d47-a6ea-27cd3ecf4656" contextRef="C_7805a9f3-b0a3-4562-b373-15bbc4dab334" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_717442f3-2751-4e3c-ba15-abe3b111dcd4" contextRef="C_882eeb59-5aa1-48a1-b475-f45ed47e1af4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_a281a280-c096-4d0a-b2a7-82d7712b00b4_2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1) Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the commercial milestones, the Company used a Monte Carlo simulation because of the availability of a discrete revenue forecast. During the year ended December 31, 2021, the Company achieved the specified sales milestones totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5ac8d3a-aa25-4753-9097-35365b98132a" contextRef="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e" name="vir:SalesMilestonesAchieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to sotrovimab</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. A</span><span><ix:nonNumeric id="F_62a2939f-c375-40a3-947b-f133f949dd61" contextRef="C_c53e5c04-9722-48b4-9a77-81a3284044e1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_62a2939f-c375-40a3-947b-f133f949dd61_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s of December 31, 2021, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecast, as well as the following significant unobservable inputs f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or the remaining commercial milestones related to the HBV product: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_62a2939f-c375-40a3-947b-f133f949dd61_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.179%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:32.381%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39f2f4c8-96be-4302-8e0e-c08ff481b4eb" contextRef="C_f89b46e3-8544-4acc-962d-faf2858aa020" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00616786-f7c2-48db-b903-e53eb8b133f4" contextRef="C_405140f2-f0e9-44c0-b8cf-d4d833a30755" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">11</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aefe449c-3d5b-48d0-8dfd-941c55d4f703" contextRef="C_a8d8ecfd-11a2-4d9e-986a-f51ef12015b0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">22</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. As of December 31, 2021 and 2020, the estimated fair value of the contingent consideration related to the Humabs acquisition was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c7a127a-99ad-4ab3-91a0-a9f156017d0d" contextRef="C_8b2320ed-d560-4b7d-850c-3e4bf7238d2a" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bfae5df-4a7f-4552-8a95-bda1687e09ed" contextRef="C_a85d530b-5472-4e7a-bcea-2452ef558595" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, with changes in the estimated fair value recorded in research and development expense, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and selling, general and administrative expense in the consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the TomegaVax acquisition was determined by using a Monte Carlo simulation model which included estimates of both the probability and timing to achieve the required per share price of the Company&#x2019;s common stock, and incorporates assumptions as to expected volatility and discount rate. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">definition of an embedded derivative financial instrument. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company achieved one of the milestones related to a specified per-share price of its common stock resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3b2c1b2-64e5-4c77-9b30-2cf4490e49e7" contextRef="C_3180a70a-dfa7-4102-9724-38babfd3d0ba" name="vir:AssetAcquisitionMilestoneAchieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payable to the former TomegaVax&#x2019;s stockholders which was paid in July 2021. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d45cc52b-ea39-4db9-bacb-82e86e9104fa" contextRef="C_3200e2aa-d8c3-4db7-a6bc-1e84a8a07638" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_d45cc52b-ea39-4db9-bacb-82e86e9104fa_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:</span></ix:nonNumeric></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_d45cc52b-ea39-4db9-bacb-82e86e9104fa_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.179%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:32.381%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a7cd469-fd6e-4509-9e90-111b744a8832" contextRef="C_ba75ea58-13bc-4e3d-8ef1-d07deeb228c1" name="us-gaap:EmbeddedDerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">115</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_457634d7-c360-4650-aa35-a92639ecebac" contextRef="C_c65ef721-72ea-40b3-878d-db5fb1796225" name="us-gaap:EmbeddedDerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the estimated fair value of the contingent consideration related to the TomegaVax acquisition was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5939547d-c64b-47a6-a017-8997cc04ef23" contextRef="C_6639bf66-3f97-4290-be85-57c7e4a0c37c" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d95d734-dbe6-44a7-ac20-9c8d741a5b81" contextRef="C_786d6b05-a5c6-4c6b-bd8c-08bff9b5679d" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, with changes in the estimated fair value recorded in other income (expense), net in the consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the Humabs and TomegaVax acquisitions involves significant estimates and assumptions which give rise to measurement uncertainty.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4681a198-d09f-4cfa-9fe4-1c229490de82" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the changes in the estimated fair value of the Company&#x2019;s Level 3 financial liabilities (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.644%;"></td>
        <td style="width:2.097%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:16.112%;"></td>
        <td style="width:0.865%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contingent<br />Consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ad0c4df-29a7-49c4-b172-9c99620d06a4" contextRef="C_7a978f36-d4af-4db5-8584-15add2567749" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_feab5698-39c1-4f36-85f0-5bd87154220b" contextRef="C_34acf0fd-1b4d-4895-92c2-913b85fb2602" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91,848</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of contingent consideration to accrued liabilities upon achievement of the Humabs milestones</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3943a10e-d845-4a13-a1bc-92768ac2e7e2" contextRef="C_34acf0fd-1b4d-4895-92c2-913b85fb2602" name="vir:FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">95,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of contingent consideration upon achievement of the TomegaVax milestone</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5dd7d16-07ce-41c5-8c5d-3a8e81f4ae91" contextRef="C_34acf0fd-1b4d-4895-92c2-913b85fb2602" name="vir:FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70b427ce-a6fd-43ab-99ea-ab491cebda99" contextRef="C_a567406d-6fcd-4a01-a0c2-596b4cb717b1" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,822</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62c28d6b-4ea9-40c5-84b7-c57685b48ed4" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Acquisitions </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisition of TomegaVax</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2016, the Company entered into an agreement and plan of merger (&#x201c;TomegaVax Merger Agreement&#x201d;) to acquire all of the equity interests of TomegaVax. The primary asset purchased in the acquisition was an in-process cytomegalovirus vector-based vaccine platform for use in HBV, HIV, and tuberculosis. The acquisition was accounted for as an asset purchase. The Company recorded the cash purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0800d118-f098-431e-a73f-61692c183d55" contextRef="C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e" name="us-gaap:AssetAcquisitionConsiderationTransferred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in research and development expenses and incurred transaction costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97c7a7a5-e9fb-4dd7-9294-9daf0a92029e" contextRef="C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2016.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the entry into the TomegaVax Merger Agreement, the Company also entered into a letter agreement with TomegaVax (the &#x201c;TomegaVax Letter Agreement&#x201d;), which provides for certain payments to TomegaVax&#x2019;s former stockholders before September 2024, in each case so long as the Company is continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_236fd857-03f0-4ee9-9208-97603d27cee3" contextRef="C_a32e557e-b0ba-4f99-bb95-674d8a7d72ba" name="vir:MilestonePaymentsRelatedTermsDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_395a4f87-62a9-43cc-a77b-b6aa65bd45d8" contextRef="C_ee4ca4dd-dd89-4390-b7dd-451122361af3" name="vir:AssetAcquisitionMilestonePaymentAggregate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million if the per-share price of the Company&#x2019;s publicly traded common stock, or implied price per-share of the Company&#x2019;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f4eb0e7-0a39-486a-91dc-0ab9e2299935" contextRef="C_71eb2cf3-b567-474c-8eb2-9294af7f7cd4" name="vir:MinimumCommonStockPriceForMilestonePaymentsConsideration" unitRef="U_USDollarShare" decimals="INF">45</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The share price of the Company&#x2019;s publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Company&#x2019;s common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of the Company&#x2019;s common stock, at the discretion of the Company&#x2019;s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">155</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company achieved </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a1cabd5-e85d-4562-8215-13a39718e5b3" contextRef="C_b3ff0ae3-397e-4e79-94d3-974b85c1a48f" name="vir:AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the milestones related to the specified per-share price of its common stock, which resulted in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5576354-1f56-4ac0-bfcc-215b743efb05" contextRef="C_8f3bbd07-1fde-4bfb-b72d-6df34ea170ba" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payable to TomegaVax&#x2019;s former stockholders. In July 2021, the Company made the milestone payment to the former TomegaVax stockholders through a combination of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc7148e3-5cd9-41f7-b3bc-a05200656829" contextRef="C_66bceed9-522b-4fbd-a22f-c029c32a27fd" name="vir:PaymentMadeForAssetAcquisitionMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash and the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddbc09e7-1b45-4bf9-adce-f09f301f946f" contextRef="C_3b4acd09-0f98-4d80-8e8b-2e3567b35e97" name="vir:CommonStockSharesIssuedForMilestonePaymentShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">42,737</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8d268d6-30e1-4771-a145-4f886464691f" contextRef="C_2082200e-8d81-44c2-9451-795cb9436f26" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The remaining milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_447be147-4bfb-4d6f-9f9b-fac28da62f8d" contextRef="C_be140e6e-3761-4ec9-ba59-319fd0975a8c" name="vir:RemainingPaymentForAssetAcquisitionMilestoneAggregate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate will be triggered if (i) the per-share price of the Company&#x2019;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2616a84d-a53d-4574-b52c-63f23d2d3fa7" contextRef="C_0d48684e-c8e1-4db3-a973-d66108c108c4" name="vir:MinimumCommonStockPriceForMilestonePaymentsConsideration" unitRef="U_USDollarShare" decimals="0">45</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment and/or (ii) the per-share price of the Company&#x2019;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1320d7c-f3b1-4314-95bd-9baa9084f31b" contextRef="C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e" name="vir:MinimumCommonStockPriceForMilestonePaymentsConsideration" unitRef="U_USDollarShare" decimals="0">90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the future milestone payments contain net settlement provisions and therefore, they were required to be accounted for as embedded derivatives under the relevant accounting guidance. As of December 31, 2021, the fair value of the embedded derivative was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31ce0454-cee7-45b1-a69a-9ef2c19e6dda" contextRef="C_5f6d55c2-91b3-4ca7-adf9-970debbec4df" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and is included in the contingent consideration liability on the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisition of Humabs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2017, the Company acquired all of the outstanding equity of Humabs, a private Swiss company, which discovers and develops monoclonal antibodies (&#x201c;mAbs&#x201d;) derived from individuals whose immune systems have successfully responded to major diseases. The Company acquired all of Humabs&#x2019; rights, title and interest in and to substantially all of the assets of Humabs except for rights under certain license agreements with third parties. The Company is obligated to pass through to the former Humabs shareholders any amounts received by Humabs under such license agreements, net of any program expenses. The transaction was accounted for as an acquisition of a business. The consideration paid consisted of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9af9bba-ef7e-4b90-ae32-6079882ed77d" contextRef="C_92042eda-34a8-4b88-8ceb-39eb4ad7e70a" name="us-gaap:PaymentsToAcquireBusinessesGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e4ba5a8-0aba-4ef0-9006-64fa0ae4e6b7" contextRef="C_92042eda-34a8-4b88-8ceb-39eb4ad7e70a" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,666,656</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, valued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3863ac55-29fe-49e7-94b0-3d13db5dc455" contextRef="C_92042eda-34a8-4b88-8ceb-39eb4ad7e70a" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of the date of the transaction, to former Humabs shareholders. In addition to the cash payment and issuance of common stock to the former Humabs shareholders at the acquisition date, the Company also agreed to pay additional amounts in cash upon the achievement of specified milestone events: (i) up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1a11051-6ec5-4d04-967f-3bedddf6c8e9" contextRef="C_47cc19c9-75f2-422b-8ed8-1c79b990ca5f" name="vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">135.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the achievement of clinical, regulatory and commercial milestones for an HBV product; and (ii) up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95fc6c09-39e3-4a4f-a7cc-62b9a3aaadd1" contextRef="C_4d722794-e16e-4e44-9edc-feb0c31aee2e" name="vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">105.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the achievement of clinical, regulatory and commercial milestones for another product, which the Company elected as a severe acute respiratory syndrome coronavirus 2 (&#x201c;SARS-CoV-2&#x201d;) product, or sotrovimab.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, the Company achieved </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58dc7e07-5cee-4753-a061-847738a1691f" contextRef="C_16d264b9-1049-422e-959d-522e97231bc4" name="vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the specified clinical milestones for the HBV product and sotrovimab totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_157d7b0e-f70c-430a-b8b7-b784a5bddfae" contextRef="C_bf931caa-5cb0-4310-8883-afbdea037621" name="vir:SpecifiedClinicalDevelopmentMilestonesPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_a6d8719e-2db0-40cf-9257-1ff427600491" contextRef="C_16d264b9-1049-422e-959d-522e97231bc4" name="vir:SpecifiedClinicalDevelopmentMilestonesPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, the Company achieved the specified regulatory milestone of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1fffa82d-4b8e-4d55-a23c-55a31552e2a4" contextRef="C_53a9db5d-ce87-4cee-8476-d28141546bda" name="vir:RegulatoryMilestonesAchieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and sales milestones totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cfd2b535-05f0-42b5-975b-bbad3b93d975" contextRef="C_53a9db5d-ce87-4cee-8476-d28141546bda" name="vir:SalesMilestonesAchieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to sotrovimab. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the remaining contingent consideration was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_585c4b54-4846-48f5-b93e-cefefcfdaec5" contextRef="C_2f3a686d-485c-4e98-8bf8-9cbe259cabcc" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company paid the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d77babd-7c0e-4075-864f-115ce606bf48" contextRef="C_06f41013-d21d-4546-aa26-d8ece6d9a91a" name="vir:PaymentMadeForBusinessCombinationMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million milestone and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4150b83c-d6de-40cd-bfa3-6323865ce520" contextRef="C_34998bcb-fe81-4e6a-839c-342803b38b04" name="vir:PaymentMadeForBusinessCombinationMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million milestone in January and February 2022, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The acquired developed technologies that have associated patents issued are classified as finite-lived intangible assets and are amortized on a straight-lined basis over their estimated remaining useful lives, generally between </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d240cfd0-0689-460a-ba7b-6620318af392;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_322a2c41-63c2-47aa-896e-d555e56cd76b" contextRef="C_333e5067-692a-43e7-8ca4-773333284f0b" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company also acquired indefinite-lived intangible assets consisting of IPR&amp;D. These assets will not be amortized until regulatory approval is obtained in a major market. At that time, the Company will determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned or otherwise impaired, the related IPR&amp;D assets will be written-off and an impairment charge recorded. As of December 31, 2021, there have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4aa9f685-edf5-4dc9-8b81-743573f962d4" contextRef="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairments related to the IPR&amp;D assets. The estimated fair value of the intangible assets was determined using the replacement cost method. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43285025-ef21-46e0-9506-a046295a7391" contextRef="C_8b2320ed-d560-4b7d-850c-3e4bf7238d2a" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">None</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the goodwill is expected to be deductible for income tax purposes.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f222a998-4945-4d5a-837e-1f3370e15c7c" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Goodwill and Intangible Assets </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_477eb28b-8635-4fbd-bcc2-f046bdd50975" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> represents the excess of the purchase price over the estimated fair value of the net assets acquired from Humabs. The Company tests goodwill for impairment on an annual basis or sooner, if deemed necessary. There was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f4e5f52-84b5-42bf-bd05-f37bd3d4a18c" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">156</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ad10787-abbd-43c1-8261-17fa78f7c974" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the carrying amount of the Company&#x2019;s finite-lived intangible assets (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.615%;"></td>
        <td style="width:1.181%;"></td>
        <td style="width:1.803%;"></td>
        <td style="width:11.888%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:1.181%;"></td>
        <td style="width:1.803%;"></td>
        <td style="width:10.768%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:1.181%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:16.377%;"></td>
        <td style="width:0.771%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Remaining Useful</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Developed technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bbc7d00-9db1-4973-a229-7f44ae5f08f9" contextRef="C_21482517-1f7b-44c6-8e55-585d0ec9e391" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8520a667-112f-41eb-8549-6c07afd70ed9" contextRef="C_643ca0ff-cb47-43ec-917c-167fbc2cff60" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8cbc3a65-0d61-4d67-ba83-5f6679a2352b" contextRef="C_27d6b8f0-fa5a-4e00-b4fd-9df702316b81" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract-based intangible asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f54d1b48-b5f7-4e10-8880-abf437fb3d67" contextRef="C_3776a1e8-74ac-49c3-8bd9-7024d16f0ad2" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b9a6dc2-5780-404f-b17f-c5c972b7de05" contextRef="C_9df0518d-0a7a-4d2c-92b4-a8e2b609380f" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7b7cbda-f8d1-4e1d-bd7e-52d188fc1549" contextRef="C_8ae9b192-da16-4b61-9aca-9b2e398bb09f" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.9</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1205e5e-f27d-4517-9401-44e3ecc4a8ae" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f241cfa-0536-4e2b-9f37-e7f93a3e6aee" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c873c03d-cf34-481d-9d85-7a7af03bfe24" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05a32067-7c6d-41c2-a71b-7dc24cbb33f4" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less impairment of intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a70006f7-c066-4023-b3d9-c828e5415b32" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:FiniteLivedIntangibleAssetsAccumulatedImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">832</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e351f7b-356c-4575-86c6-1f28f8ff4e61" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:FiniteLivedIntangibleAssetsAccumulatedImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">832</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88237c45-d556-4f3d-b56a-58eb2d0c0a82" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ffde077e-a64d-4035-a812-8bb5f1a643e9" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets are carried at cost less accumulated amortization. The contract-based intangible asset resulted from the product approval of a sublicensed intellectual property right in December 2020. The intellectual property right was previously accounted for as IPR&amp;D. Amortization expense related to finite-lived intangible assets, included in research and development expenses on the consolidated statements of operations, totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8768382-dbea-4e98-a282-c29053647dcb" contextRef="C_1a31bf7c-9f6e-4b04-9a96-43549f6f4cc3" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6966f44a-b9be-439f-b00d-e1c4689a0dc5" contextRef="C_f41d2de0-2ba6-4580-bbfa-01ae990de9ae" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e588d52-8aec-45ad-b4fc-ac4119b8e1f0" contextRef="C_ad98faf6-018f-4435-8e8a-c91df1a4d6c0" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, like that of property and equipment. During the third quarter of 2020, as a result of the availability of other research and analytics platforms, the Company abandoned certain of its acquired developed technologies and concluded that the full remaining book values of the assets were impaired. Therefore, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3927bf55-4669-4f2c-8e8b-a33379df3776" contextRef="C_bd790442-a1c8-4c01-a7b4-906b111a3a51" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="6" decimals="-5">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was written off as an impairment charge, which was classified as research and development expenses during 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1cbf941-e354-490b-9501-5152da8843ca" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on the finite-lived intangible assets recorded as of December 31, 2021, the estimated future amortization expense for the next five years is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.14%;"></td>
        <td style="width:1.758%;"></td>
        <td style="width:2.671%;"></td>
        <td style="width:17.352%;"></td>
        <td style="width:1.078%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70d11485-9b43-49d9-971d-dd795f1989cd" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c4f9447-c90b-4b14-94e9-64fc172e8d34" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8efa6a1e-8724-4786-9027-4cd72350c04d" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">260</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c11c8560-8403-496c-9b06-580f280d3e22" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0211060-17d2-4f57-9007-230dad7a32a3" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a41b6cb1-aa27-4761-b373-43e8779ec760" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:FiniteLivedIntangibleAssetsAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indefinite-Lived Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company had indefinite-lived intangible assets of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cc6e0d1-7ada-4106-86dc-4ce71f109822" contextRef="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_10c0b74b-bc81-4d33-a990-e9f4762e5753" contextRef="C_3afd1e8b-5267-4120-b240-7f12f4a61a4a" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" unitRef="U_USD" scale="6" decimals="-5">30.7</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, related to the purchased IPR&amp;D from the Humabs acquisition. In December 2020, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d6ce769-9bed-4a98-8f38-2db1790dc270" contextRef="C_a14402f0-9a6d-4005-9600-5bb5f45f3cf4" name="vir:FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" unitRef="U_USD" scale="6" decimals="-5">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was reclassed as a finite-lived intangible asset due to the product approval of a sublicensed intellectual property right. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_009ebcba-5879-4d55-8914-3eae9b8829eb" contextRef="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3476a304-fe0e-4e08-ae41-cc6a4f701faa" contextRef="C_3afd1e8b-5267-4120-b240-7f12f4a61a4a" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment losses have been recorded for the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_046cad85-5901-4267-8b2f-1f9677d69353" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:GrantAgreementsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Grant Agreements </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bill &amp; Melinda Gates Foundation Grants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Campylo/EPEC/EAEC Grant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the Company&#x2019;s acquisition of Humabs in August 2017, the Company acquired a grant agreement with the Bill &amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b50f8b2f-7b0f-41fb-bfc2-d902b79e07e2" contextRef="C_9bbee3cc-0441-482d-a60a-021bdde5fb32" name="vir:GrantAwardedAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the &#x201c;2017 Grant&#x201d;). The 2017 Grant supported the Company&#x2019;s discovery, characterization and selection of human monoclonal antibodies with pre-clinical efficacy against three enteric pathogens responsible for life-threatening diarrhea in neonates. The 2017 Grant expired on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08b952f4-96a4-47b5-a7c8-e019004eff35" contextRef="C_4d72106c-4ece-48a5-890f-cdc4894fc993" name="vir:GrantAgreementExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 31, 2019</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">157</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that were related to future research activities were deferred and recognized as revenue when the donor-imposed conditions were met, which was as the research and development activities were performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d56bded8-9402-4fac-8170-66c9d96ae23f" contextRef="C_064e544a-5338-44a5-8d21-57da4323d0ff" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HIV Grant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 26, 2018, the Company entered into a grant agreement with the Bill &amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b77241a-d0ef-43e0-9283-32f4dba41de3" contextRef="C_9de06e9c-4123-49c9-9448-9c22581415b0" name="vir:GrantAwardedAmountMaximum" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">12.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for its HIV program (the &#x201c;HIV Grant&#x201d;). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the parties amended the HIV Grant under which the Company was awarded a supplemental grant of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c4a2bce-014c-41de-81ae-6ce12275120b" contextRef="C_d9c4cf79-3f00-4bf0-bcd2-f9232b1fcc14" name="vir:GrantAwardedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_aeb0c2d2-3251-4237-b9b3-110fc85a87f2;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 2021</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the parties further amended the agreement under which the grant term was extended from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a0771c1-7626-4600-a46b-962ea826ad6c" contextRef="C_f5edd5d0-093c-4a7f-9010-06a8b6d0943c" name="vir:GrantAgreementExpirationDateBeforeAmendment" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c1aaa7d-f301-47c8-bbe1-671c602085f7" contextRef="C_f5edd5d0-093c-4a7f-9010-06a8b6d0943c" name="vir:GrantAgreementAmendedExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 31, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless earlier terminated by the Bill &amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill &amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company achieved a specified milestone under the HIV Grant which triggered a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dddd9cc5-6513-428d-b31e-c8b1afd9c946" contextRef="C_a48eca06-2240-404a-95b9-a96f664f0800" name="vir:MilestonePaymentDueToCompany" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payment from the Bill &amp; Melinda Gates Foundation. As of December 31, 2020, the Company recorded a receivable, which is included within prepaid expenses and other current assets, and current portion of deferred revenue for the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_637673d9-1946-45a9-92ea-d0a852b91d61" contextRef="C_160a64f9-0857-4c36-8f24-34b857e2d49c" name="vir:MilestonePaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which was subsequently received in January 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f354b2a-f255-4912-a61a-fad412749726" contextRef="C_be5c6cf7-b468-4342-99e6-e6f0cb45b27a" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10f0edd8-0ba3-4aa4-adfc-8dce0bffb019" contextRef="C_a48eca06-2240-404a-95b9-a96f664f0800" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8b5921a-4b9b-4d03-9ace-6cb295243544" contextRef="C_348661d6-b9d4-405f-81cc-4d936a14f5b8" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cdc11571-15bc-49c4-9b83-ba4f22b764b4" contextRef="C_024bb253-6952-4f27-abbf-00f7a4f1d57c" name="us-gaap:DeferredIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98aafa33-f540-4fde-adbf-a578cd72e49a" contextRef="C_b5bc95aa-a39a-42b9-82dc-8f1e49c3c984" name="us-gaap:DeferredIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, under HIV Grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Tuberculosis (&#x201c;TB&#x201d;) Grant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 16, 2018, the Company entered into a grant agreement with the Bill &amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb464845-6ced-47dc-8ab0-fe2fe5c0e52e" contextRef="C_65508bde-8e9b-433a-b887-54fe70f6560d" name="vir:GrantAwardedAmountMaximum" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">14.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for its TB program (the &#x201c;TB Grant&#x201d;). The parties amended the agreement in May 2020, in June 2021 and in December 2021 to extend the grant term. The TB Grant will remain in effect until </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44ff3e1d-c6d7-4e15-aaab-db222aa27eb0" contextRef="C_4700e2f3-e411-4471-9030-da4a2a264740" name="vir:GrantAgreementAmendedExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless earlier terminated by the Bill &amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill &amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f6b3570-8afd-4c74-97e3-331f40d6d47b" contextRef="C_ce562ce2-89d4-4006-bd1c-8ec2a20274f5" name="vir:UnusedFundsReceivedInAdvance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unused funds received in advance and previously recorded as deferred revenue within accrued and other liabilities. As of December 31, 2021 and 2020, the Company has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4db6e1d-69c3-43a9-a106-d925cd6480f0" contextRef="C_74f0b6e6-2f8c-42cd-82e3-2ad83cc03354" name="us-gaap:DeferredIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_295e4b3c-677d-4376-a4e3-012520d77ca8" contextRef="C_1aa5fc1c-95ff-4281-9c2e-6292a0baba92" name="us-gaap:DeferredIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, under TB Grant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c01d2638-1340-4e53-a855-9959cac304e5" contextRef="C_be5c6cf7-b468-4342-99e6-e6f0cb45b27a" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12873c8a-dd26-4e3d-b5bc-48eb03ee98df" contextRef="C_6d2c449d-3432-4046-9323-81b3ce04e34a" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_311e14c8-2a32-4991-a261-89b6d9a3d54b" contextRef="C_4a4d7f99-61b1-4dd9-8b7a-51541fecc5f3" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HCMV-Vaccine Platform Grant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 5, 2021, the Company entered into a grant agreement with the Bill &amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dfa14d28-7689-4ebb-bf20-1f2acc9d9225" contextRef="C_7bd2b5a2-2224-4f6d-aacc-dc5934151bac" name="vir:GrantAwardedAmountMaximum" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to support the manufacturing and clinical activities of its HIV and TB vaccine programs. This grant agreement will remain in effect until </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d24517d-7952-44f2-9f4c-3317b0507a6a" contextRef="C_e1a9eeda-0adf-4886-b25f-5e7c6923762a" name="vir:GrantAgreementExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 30, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unless earlier terminated by the Bill &amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill &amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11ee80b5-b10f-4528-8dda-5352903883e2" contextRef="C_8b224cd3-1cba-4c7d-b686-ace421bc028d" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f76ba7fb-2007-4bee-a27d-b1b322a31071" contextRef="C_021eeba0-02e7-4697-bcf5-81b5a7722190" name="us-gaap:DeferredIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under this grant agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">158</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">National Institutes of Health</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the Company&#x2019;s acquisition of TomegaVax in September 2016, the Company acquired grant agreements related to TomegaVax&#x2019;s research effort in infectious diseases and cancer that entitled them to several awards under the Small Business Innovation Research Program from the National Institutes of Health (&#x201c;NIH&#x201d;). Through July 2021, the Company has acquired or been awarded grants from NIH totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_433b7a6f-b81f-440f-99ba-24ba942fda2b" contextRef="C_0d0ed842-ca94-4998-a8f5-2f0beb76b34a" name="vir:GrantAwardedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. These grants were cost plus fixed fee agreements in which the Company was reimbursed for its direct and indirect costs. Only costs that were allowable under certain government regulations and NIH&#x2019;s supplemental policy and procedure manual may be claimed for reimbursement, subject to government audit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2bcb4ee7-f86d-40fd-9598-97d8ca41806d" contextRef="C_557d1e8e-6875-4184-8347-4aab3a2c9a31" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ad2ba87-c01b-47da-8d58-f146eddceb22" contextRef="C_6595e636-7a23-4034-861a-6a075f66f7cc" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_022cea37-26db-4610-aabb-993010d7e2e5" contextRef="C_ef618346-1e5d-4fc9-884c-3b4a0ef0bade" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2868289c-2adf-4da1-9b05-2a7a8d62b7dd" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Collaboration and License Agreements </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration Agreements with GSK</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2020 GSK Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 9, 2020, the Company, Glaxo Wellcome UK Limited and Beecham S.A. (referred to individually and together, as &#x201c;GSK&#x201d;) entered into a definitive collaboration agreement under the terms set forth in the preliminary collaboration agreement entered into by the Company and certain GSK entities in April 2020 (the &#x201c;2020 Preliminary Agreement&#x201d;) (such definitive collaboration agreement, the &#x201c;2020 GSK Agreement&#x201d;). Concurrently with the execution of the 2020 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2020 Stock Purchase Agreement&#x201d;) with Glaxo Group Limited (&#x201c;GGL&#x201d;), an affiliate of GSK, under which GGL purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a5a072c-8312-462e-92aa-be30b1c27b7f" contextRef="C_810fc216-bb93-4ea9-b973-024c33461e81" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,626,027</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock on April 29, 2020, at a price per share of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_310bdf92-24bc-4299-ab61-b22e0bf22b9f" contextRef="C_e3de3d32-1468-4cb9-b95b-a8d0af66f9af" name="us-gaap:SharePrice" unitRef="U_USDollarShare" decimals="INF">37.73</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d75de9d5-497c-4608-a90c-86a48baf7bc3" contextRef="C_810fc216-bb93-4ea9-b973-024c33461e81" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. After receipt of antitrust clearance on April 22, 2020, the 2020 Preliminary Agreement became effective as of April 29, 2020, which was also the closing date for the associated 2020 Stock Purchase Agreement between the parties (&#x201c;Effective Date&#x201d;). Under the terms of the 2020 GSK Agreement, the Company and GSK agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c407e1e5-b2d0-456d-a91b-243b90c38f98" contextRef="C_224cb303-9ce3-44c9-8e2e-6437c0fdeafb" name="vir:CollaborationTypeAndPrograms"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Antibody Program&#x201d;); (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Vaccine Program&#x201d;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Functional Genomics Program&#x201d;).</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99ded8a5-ed42-4b37-bf90-73b2ef222887" contextRef="C_202b895b-631c-490b-893f-c4dd6e2908d9" name="vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" format="ixt-sec:durwordsen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the Effective Date, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee (&#x201c;JSC&#x201d;). The Company is primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK is primarily responsible for the commercialization activities for the Antibody Program (except in connection with sales of antibody products licensed to WuXi Biologics (Hong Kong) Limited in greater China), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. Subject to an opt-out mechanism, the parties share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with the Company bearing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_475620c2-9401-450a-aabb-b5a0a58605b4" contextRef="C_9cc53898-90ab-48e4-811b-68336c8459bf" name="vir:PercentageOfDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">72.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs for the antibody products, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d9de7ed-8022-4406-aed5-c5009762aed3" contextRef="C_c672b8f5-c39b-47aa-bcad-cd04fd706515" name="vir:PercentageOfDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">27.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs for the vaccine products, and equal sharing of such costs for the functional genomics products.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a collaboration product-by-collaboration product basis, each party has the one-time right, at specified points in development, to opt-out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party pays to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, the Company has a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">159</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">co-promotion </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">right for such antibody product in the United States, under which the Company has the right to perform up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cbae70b-e7f2-499a-be0b-ad667fdc07ba" contextRef="C_202b895b-631c-490b-893f-c4dd6e2908d9" name="vir:MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of details in connection with such antibody product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2020 GSK Agreement will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96f2bba3-9b5d-4d51-a480-4079bf0e3561" contextRef="C_14c2d113-77d4-4ecb-aadc-32b535038ad1" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The 2020 GSK Agreement superseded and replaced the 2020 Preliminary Agreement between the parties. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, Beecham S.A. assigned and transferred all its rights, title, interest, and benefit in the 2020 GSK Agreement to GlaxoSmithKline Biologicals S.A., including all its rights to bring claims under such agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2020 GSK Agreement and 2020 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88716b0d-a595-4f30-9685-3c9b8e692013" contextRef="C_9e120ade-622b-4150-9778-b6f3b2b76cc3" name="vir:FairMarketValueOfCommonStockIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">206.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a61c8e48-d435-477c-817e-8bc32e652203" contextRef="C_7c483ff8-5408-46f2-a03d-22d662c61cf4" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2">36.70</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on the date of execution of the 2020 Preliminary Agreement and 2020 Stock Purchase Agreement and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fcc59594-f608-40ff-8139-962967a29173" contextRef="C_9e120ade-622b-4150-9778-b6f3b2b76cc3" name="vir:PremiumReceivedOnSalePriceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2020 GSK Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2020 GSK Agreement contained </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7fea82ee-3003-4016-887e-6edbcf0a7279" contextRef="C_202b895b-631c-490b-893f-c4dd6e2908d9" name="vir:CollaborationAgreementNumberOfUnitsOfAccount" unitRef="U_Unit" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> units of account: (i) the license granted to GSK under the Antibody Program (the &#x201c;Antibody License&#x201d;); (ii) the research and development activities (including clinical manufacturing) under the Antibody Program; (iii) the research and development activities under the Vaccine Program; and (iv) the research and development activities under the Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2020 GSK Agreement are performance obligations with a customer. The Company determined that the Antibody License is within the scope of ASC 606 and accordingly, accounted for the Antibody License as a distinct performance obligation under ASC 606. The Antibody License is a functional intellectual property and is distinct from the associated research and development activities to be performed under the program due to its significant standalone functionality. All other elements of the 2020 GSK Agreement including the research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price for the Antibody License at inception was determined to be $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df0f4993-249c-4cd9-8b73-a8d19b4965b9" contextRef="C_9cc53898-90ab-48e4-811b-68336c8459bf" name="vir:AntibodyLicenseTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, representing the premium on the sale of common stock to GSK. The Company determined that GSK can benefit from the Antibody License at the time of grant and therefore, the related performance obligation is satisfied at a point in time. As such, the Company recognized the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddc7a078-ff3e-423d-adc0-bc0564660497" contextRef="C_0a9da79f-2f51-4ca2-944b-bb5ee3abad70" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as contract revenue during the second quarter of 2020. Additionally, the Company is entitled to consideration from GSK related to profit and loss sharing arrangements (including royalties) contingent upon future sales of collaboration products under the Antibody Program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The remaining units of account of the 2020 GSK Agreement were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to, based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the products under the Vaccine and Functional Genomics Programs will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 2021, the FDA granted an EUA in the United States for sotrovimab, the first collaboration product under the Antibody Program. As the lead party for all commercialization activities, GSK incurs all of the sales and marketing expenses and is the principal on sales transactions with third parties. As the Company is the agent under the 2020 GSK Agreement, the Company recognizes its contractual share of the profit-sharing amounts or royalties (in case of an opt-out) as revenue, net of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost of sales and allowable expenses (including distribution, selling, and marketing expenses) in the period the sale occurs. During the year ended December 31, 2021, the Company recorded its share of net profit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_268894b1-5f22-4372-bd96-762318c4e5ef" contextRef="C_4535e3d1-cadf-43e9-a70d-52008cd60dfc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">917.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as collaboration revenue in the consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs associated with co-development activities performed under the agreement are included in research and development expenses on the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. Under the 2020 GSK Agreement, the Company recognized additional net research and development expenses of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4dc4703-25ca-48f5-a2d4-22bb077bae2f" contextRef="C_14c2d113-77d4-4ecb-aadc-32b535038ad1" name="vir:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">77.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_106f99e7-c3c8-4b97-9594-f481cd62ad9d" contextRef="C_7fe631b5-99f5-4a42-904e-1d5e014789ce" name="vir:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Expanded GSK Collaboration</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 14, 2021, the Company and GSK entered into a binding preliminary collaboration agreement (the &#x201c;2021 </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preliminary Agreement&#x201d;), under which the parties agreed to expand the 2020 GSK Agreement to collaborate on </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7122d8f3-ea6e-453b-8661-c2b9b9b6769f" contextRef="C_3be2e934-f078-49d4-9962-afce5e0c771d" name="vir:CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> separate programs: (1) a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus (the &#x201c;Influenza Program&#x201d;), excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties&#x2019; current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses (the &#x201c;Expanded Functional Genomics Program&#x201d;); and (3) additional programs to develop neutralizing mAbs directed to up to three non-influenza target pathogens selected by GSK (the &#x201c;Selected Pathogens&#x201d; and such programs, the &#x201c;Additional Programs&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrently with the execution of the 2021 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2021 Stock Purchase Agreement&#x201d;) with GGL under which GGL agreed to purchase shares of the Company&#x2019;s common stock for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab365e03-93af-41ff-949e-8f5eefc0acf3" contextRef="C_7b12cfb1-fdf1-4522-acd2-8b1f2eb36f1e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">120.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The consummation of the transactions under each of the 2021 Preliminary Agreement and the 2021 Stock Purchase Agreement were subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which expiration was effective on March 24, 2021. The 2021 Preliminary Agreement and 2021 Stock Purchase Agreement consummated on March 25, 2021, which the Company used as the measurement date for accounting purposes. On March 31, 2021, the Company closed the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0052c130-8a1e-4fd3-8a26-25aa4e7fc339" contextRef="C_830b2851-70de-48fc-94e9-c824f5a5454c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,924,927</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock to GGL.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Preliminary Agreement was superseded on May 18, 2021 upon execution of the definitive collaboration agreement (the &#x201c;2021 GSK Agreement&#x201d;, or collectively with the 2021 Preliminary Agreement, the &#x201c;2021 GSK Collaboration&#x201d;). The material terms of the 2021 GSK Agreement, including the promised goods and services, are discussed below and is consistent with those of the 2021 Preliminary Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2021 GSK Collaboration, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6edb7d26-60b4-4a55-9228-e9bc832a6cf1" contextRef="C_eb465827-50c0-422c-a785-a18988e1c54b" name="vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" format="ixt-sec:durwordsen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the effective date. Under the Influenza Program, the parties will collaborate to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of influenza, including the Company&#x2019;s influenza mAbs (with respect to VIR-2482, only if GSK exercises its option). The Company may conduct the development and clinical manufacturing activities for VIR-2482 up to the completion of a Phase 2 clinical trial. Provided that the Company conducts and completes a Phase 2 clinical trial for VIR-2482, GSK will have the exclusive option to obtain exclusive rights to co-develop and commercialize VIR-2482 under the Influenza Program (the &#x201c;VIR-2482 Option&#x201d;). GSK will be the lead party for development, clinical and commercial manufacturing and commercialization activities for products under the Influenza Program (other than VIR-2482 unless and until GSK exercises the VIR-2482 Option, if applicable). The parties will mutually agree upon the allocation of responsibility for the development of products under the Expanded Functional Genomics Program, and for the development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK will be primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, upon execution of the definitive agreement, the Company will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The parties will share </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77a45f78-869b-4119-867f-04317b8caf81" contextRef="C_0c4b9e6a-a844-4e0c-a296-cb62009d4a06" name="vir:PercentageOfShareDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of all development costs in accordance with the budget for each of the collaboration programs (other than for the Selected Pathogens and VIR-2482, unless GSK exercises the VIR-2482 Option), with each party having the right to opt-out of its co-funding obligations at specified points in development. In such case, the party continuing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">161</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the program will pay to the opt-out party a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the opt-out is exercised. Following the exercise of an opt-out right by a party, the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any opt-out, the parties will also share </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6077907-0b2f-44ba-810a-72e2875da93f" contextRef="C_0c4b9e6a-a844-4e0c-a296-cb62009d4a06" name="vir:ProfitsAndLossesSharingPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of all profits and losses arising from any collaboration product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GSK was obligated to make an upfront payment to the Company of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9417aaa9-f1d0-4ea3-80bb-f42cd6b3ca78" contextRef="C_d7e70a8d-2f4b-4760-92ab-0e41dad01baf" name="vir:UpfrontPaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">225.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_438ef4f5-0034-4f51-970c-c1d82c377bca" contextRef="C_d7e70a8d-2f4b-4760-92ab-0e41dad01baf" name="vir:PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of which became payable at the effective date of the 2021 Preliminary Agreement and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93d9e1c9-8a2d-45c5-84b4-bcc6b40f30e3" contextRef="C_fbb0fecc-7a8b-4c5b-9fec-e7fdd61a01f0" name="vir:PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of which became payable following the execution of the 2021 GSK Agreement. If GSK exercises the VIR-2482 Option, GSK will pay the Company an option exercise fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_041957d5-6136-4dd7-a47b-24412b254dc1" contextRef="C_d7e70a8d-2f4b-4760-92ab-0e41dad01baf" name="vir:OptionExerciseFeeConsiderationToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">300.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million unless certain agreed product criteria for VIR-2482 are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a pre-defined regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the VIR-2482 Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to the Company of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf984d06-41bd-480e-8427-b2c98d0730d8" contextRef="C_ca5007f4-5584-4178-8601-b447870799b2" name="vir:PreDefinedRegulatoryMilestoneConsiderationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">200.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2021 GSK Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements, under which certain elements are required to be accounted for under ASC 606 where the counterparty is a customer for a good or service that is a distinct unit of account. In addition, the 2021 GSK Agreement is considered a contract modification to the 2021 Preliminary Agreement and will be accounted for prospectively, as a termination of the 2021 Preliminary Agreement and commencement of a new contract. There was no impact to the accounting assessment of the original contract as no goods or services had been delivered to GSK, no performance obligations were satisfied, and accordingly, no contract revenue was recognized under ASC 606 prior to the execution of the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2021 GSK Collaboration and 2021 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89470e9b-0516-4614-b433-c2f418d03002" contextRef="C_f2bc6c04-5732-4690-b9c0-17ebe0b9dbc3" name="vir:FairMarketValueOfCommonStockIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">85.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd06d533-4fbb-435c-80fd-81543f376da2" contextRef="C_e1b89459-ec16-4eeb-8748-5aa7c26b546b" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" decimals="INF">52.70</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on March 25, 2021 and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bea1da0-7f4c-48be-a4b0-9c9d6c9a999b" contextRef="C_f2bc6c04-5732-4690-b9c0-17ebe0b9dbc3" name="vir:PremiumReceivedOnSalePriceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2021 GSK Agreement contained the following units of account: (i) the VIR-2482 Option; (ii) three distinct rights granted to GSK related to the Selected Pathogens (each, a &#x201c;Selected Pathogens Right&#x201d;); (iii) the license and know-how to the next-generation mAbs under the Influenza Program (the &#x201c;Next Gen License&#x201d;); (iv) the research and development activities for next-generation mAbs under the Influenza Program; and (v) the research and development activities, including license rights and know-how, under the Expanded Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2021 GSK Agreement are performance obligations with a customer. The Company determined that the distinct performance obligations under ASC 606 consisted of (i) the Next Gen License and (ii) the three Selected Pathogens Rights, each representing a material right. All other elements of the 2021 GSK Agreement including the VIR-2482 Option, research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer. A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s of December 31, 2021, GSK had not exercised the VIR-2482 Option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price for the 2021 GSK Agreement included fixed consideration consisting of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26d9205f-40f1-4709-aad9-427d5b3f5e25" contextRef="C_95728472-f99b-4600-92ae-c92c93205687" name="vir:CollaborationAgreementTransactionPriceUpfrontFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">225.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront fee paid by GSK and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a198516-c5bd-4387-8f6b-ba34073ade1a" contextRef="C_f99ec918-2e4e-432a-970f-3c67447885a4" name="vir:PremiumReceivedOnSalePriceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, representing the premium on the sale of common stock to GSK for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f7ab338-6f7c-4037-9f4b-19749d7496c9" contextRef="C_95728472-f99b-4600-92ae-c92c93205687" name="vir:CollaborationAgreementTransactionPriceConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">259.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. All potential future milestones and other payments under the 2021 GSK Agreement are constrained since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The respective estimated SSP for each of the performance obligations was determined to allocate the transaction price. The estimated SSP of each performance obligation was determined using methods that considered relevant market </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">conditions, entity-specific factors and information about GSK, while maximizing the use of available observable inputs and using certain management assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital). For the Next Gen License, the Company determined that GSK can benefit from the license at the time the license is granted, and therefore, the related performance obligation is satisfied at a point in time. If any of the Selected Pathogens Rights </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">are exercised, the Company will evaluate the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">162</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">related promises to identify the performance obligations to be transferred and the timing of revenue recognition. If any of the Selected Pathogens Rights expire prior to being exercised, the Company will recognize any deferred revenue allocated to that right as revenue at the time of expiration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research and development activities for the next generation mAbs under the Influenza Program and the Expanded Functional Genomics Program were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the related products will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon execution of the 2021 GSK Agreement, the Company granted the Next Gen License to GSK and therefore, recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_894594e6-fa96-428d-bfb2-fb9775e836e4" contextRef="C_0e93d6b9-9d5c-45a3-b71f-00713901c0f6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">168.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as contract revenue in the second quarter of 2021. As of December 31, 2021, the total unrecognized transaction price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2fdf144-961a-4481-a507-8340be6a13f3" contextRef="C_5d7448b7-0904-4443-a40d-a6bc22ea01ae" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">91.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million is classified as current deferred revenue on the Company's consolidated balance sheet related to the remaining performance obligations, being the material rights resulting from the Selected Pathogens Rights, none of which have been exercised by GSK as of December 31, 2021. The Company expects the rights will be exercised, and thus, the corresponding deferred revenue will be recognized within the next 12 months from the balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs associated with co-development activities performed under the agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. During the year ended December 31, 2021, the Company recognized additional net research and development expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3706b43b-635f-4820-aeac-78928d4d0556" contextRef="C_30a9821b-b5e9-46b1-8ada-d4dccbd412c3" name="vir:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the 2021 GSK Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under both the 2020 GSK Agreement and the 2021 GSK Agreement, the Company has a receivable from collaboration of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51dde34e-7b34-46e7-b0ee-d805d788c44b" contextRef="C_5fa4019b-73c6-4a3b-be6c-7aa4984acca2" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">773.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Brii Biosciences</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2018, the Company entered into the Brii Agreement with Brii Bio Parent and Brii Bio pursuant to which the Company granted to Brii Bio, with respect to up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44eae4fa-24fb-42c0-a5b8-2e00f4068d7c" contextRef="C_04ff1607-fb14-42a5-912f-34d468278706" name="vir:MaximumNumberOfDevelopmentProgramGrantedToCounterparty" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Company&#x2019;s programs, an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau (collectively, the &#x201c;China Territory&#x201d;) for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection (the &#x201c;Field of Use&#x201d;). The Company&#x2019;s HBV </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">small interfering ribonucleic acid (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;siRNA&#x201d;) program being developed under the Amended Alnylam Agreement (described below) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. In partial consideration for the options granted by the Company to Brii Bio, Brii Bio Parent and Brii Bio granted the Company, with respect to up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa56c7ba-b7db-444a-8b92-c807b7ac2a0e" contextRef="C_04ff1607-fb14-42a5-912f-34d468278706" name="vir:MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of Brii Bio Parent&#x2019;s or Brii Bio&#x2019;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that the Company may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As partial consideration for the Company&#x2019;s entry into the Brii Agreement, upon closing of Brii Bio Parent&#x2019;s Series A preferred stock financing, the Company received ordinary shares equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71cd673c-761f-4c92-be54-2e65d68911ab" contextRef="C_04ff1607-fb14-42a5-912f-34d468278706" name="vir:PercentageOfOrdinaryShareEqualToOutstandingShare" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">9.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#x2019;s right to exercise one of its options for the Company&#x2019;s HBV siRNA program, under the terms of the Amended Alnylam Agreement, the Company transferred to Alnylam Pharmaceuticals, Inc. (&#34;Alnylam&#34;) a specified percentage of such equity consideration allocable to such program </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">under a share transfer agreement in February 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to programs for which Brii Bio exercises its options, Brii Bio will be required to pay the Company an option exercise fee for each such Vir program ranging from the</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_202f960a-81b3-4b8b-93da-450739633eb9" contextRef="C_0ae824f4-f2da-4275-addc-163ec36b47a2" name="vir:OptionExerciseFeeLowEndOfTheRange"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> mid-single-digit millions</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5cb096e-3d51-43e5-b6b0-eda036aa30e1" contextRef="C_56c9c1ac-6a87-4622-b2fb-da94dac65173" name="vir:OptionExerciseFeeHighEndOfTheRange" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">determined</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">163</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">based </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d8c1603-c0b6-4fec-9db8-3d8965594319" contextRef="C_0ae824f4-f2da-4275-addc-163ec36b47a2" name="vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mid-single-digit millions</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ac9e0ff-6dbb-4d17-820e-386eb0621f24" contextRef="C_56c9c1ac-6a87-4622-b2fb-da94dac65173" name="vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_496f4386-7936-4532-8271-8e5e800a4db3" contextRef="C_1d93e807-4da6-4761-840c-61b5cefbee6d" name="vir:MaximumAggregateSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per licensed program. Brii Bio also will pay royalties to the Company that range from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d93edd4-cbb2-4fe9-857d-8362ee0d077e" contextRef="C_0ae824f4-f2da-4275-addc-163ec36b47a2" name="vir:RangeOfRoyaltyPaymentToBePaid"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mid-teens to the high-twenties</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon exercise of each option for a Brii Bio program, the Company will be required to pay to Brii Bio an option exercise fee ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b4ede34-3aca-482d-9866-132e496af5c9" contextRef="C_0733b4ef-c448-4927-8d8e-84da4192b4ae" name="vir:OptionExerciseFeeLowEndOfTheRange"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">low tens of millions</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8114159-1a24-43c2-b32e-c1d192e47119" contextRef="C_eada5d7f-f2a9-431c-b238-c2280f794f45" name="vir:OptionExerciseFeeHighEndOfTheRange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, determined based on the commercial potential of the licensed program. The Company will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b92af04-db6a-4d19-90b0-dc9afdef479e" contextRef="C_1d93e807-4da6-4761-840c-61b5cefbee6d" name="vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">low tens of millions</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cc9b569-5efb-4f05-b801-57667fb76930" contextRef="C_eada5d7f-f2a9-431c-b238-c2280f794f45" name="vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, also determined based on the commercial potential of such program. The Company will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d4fb740-2c90-4809-9ffc-e4fe38b993d9" contextRef="C_0ae824f4-f2da-4275-addc-163ec36b47a2" name="vir:MaximumAggregateSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per licensed program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company is obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay the Company tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by the Company to Brii Bio, and by Brii Bio to the Company, on net sales range from mid-teens to high-twenties. Each party&#x2019;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e052461-b05d-43b2-ad25-604c2f997e1f" contextRef="C_974c0603-8333-4dce-9655-97b1212bed01" name="vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13881d61-31cf-430f-8715-0d855b715b86" contextRef="C_d62337c8-04d8-488e-a5b0-e98601a826a0" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96dd9952-9fb4-457d-99bc-9a5ca0fe089f" contextRef="C_8d81f5ee-bce5-4497-8145-ef3258cee1b8" name="vir:WrittenNoticeToTerminateLicensedProgramIfNotExercise" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; written notice (if the terminating party has not exercised an option for such program) or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4651b21-6922-48c1-9169-bbff1a970c01" contextRef="C_8d81f5ee-bce5-4497-8145-ef3258cee1b8" name="vir:WrittenNoticeToTerminateLicensedProgramIfExercise" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50642e08-b26d-4458-bb14-aeb959f0d44d" contextRef="C_8d81f5ee-bce5-4497-8145-ef3258cee1b8" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58804e90-aac1-4c95-8401-f41b8f2f86ad" contextRef="C_8d81f5ee-bce5-4497-8145-ef3258cee1b8" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; notice following failure to make payment).</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From May 2018 until July 2021, the Brii Bio Parent IPO closing date, Brii Bio Parent and its wholly-owned subsidiary Brii Bio were determined to be variable interest entities (&#34;VIE&#34;) due to their reliance on future financing and having insufficient equity at risk. However, the Company did not have the power to direct activities that most significantly impact the economic success of these entities and was not considered the primary beneficiary of these entities. Therefore, the Company did not consolidate Brii Bio Par</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ent or Brii Bio. Subsequent to the Brii Bio Parent IPO, the Company determined that these entities are no longer VIEs. In addition, as Brii Bio Parent is a publicly-traded company, the Company's investment in its ordinary shares became a marketable equity investment with readily determinable fair value and is then subsequently remeasured to fair value at each reporting date (see Note 3&#x2014;Fair Value Measurements). Prior to the Brii Bio Parent IPO, the Company accounted for its investment in Brii Bio Parent, which had a carrying value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_648943a8-ac16-4ebe-bed7-f032cf32198a" contextRef="C_55353dc3-d2db-42da-a649-4767a86be523" name="us-gaap:Investments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment from the same issuer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Brii Agreement, the Company also has a contract liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70b36a0f-beed-4b47-a707-4bd2004dd3b8" contextRef="C_eaceb94a-8ec3-4208-a7d4-ba474353d176" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within noncurrent deferred revenue which represents deferred consideration for the remaining three options that the Company granted to Brii Bio. The deferred consideration will be recognized when Brii Bio exercises its options or the options expire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Option Exercise by Brii Bio</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. In consideration of the Company&#x2019;s grant to Brii Bio of an exclusive license related to VIR-2218 in the China Territory, the Company received a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a47e18da-d3e8-4b0e-a3e2-73785ba82f6c" contextRef="C_c0b1e9f3-2c15-4ace-bc47-71fc21bcc480" name="vir:OptionExerciseFeeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-2218 in the China</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">164</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Territory: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f2659d5-fcb4-46ff-a397-5cb0fbfa2400" contextRef="C_71a5c221-44c0-4e41-a2fa-4f7fa314d849" name="vir:RegulatoryMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million regulatory milestone payment, up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d042f162-cd4a-4fd2-b880-d9c0fac1363b" contextRef="C_05bb4f29-b066-4a68-b91c-484f95f96b0a" name="vir:MaximumSalesMilestonToPay" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in sales-based milestone payments, and royalties on net sales ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0d3ba82-79a6-4783-b73f-23da6853c4b5" contextRef="C_71a5c221-44c0-4e41-a2fa-4f7fa314d849" name="vir:RangeOfRoyaltyPaymentToBeReceived"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">high-teens to high-twenties</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluated the transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price is determined to be $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5539bbf5-40b0-4f91-93db-4a0ac179db85" contextRef="C_c0b1e9f3-2c15-4ace-bc47-71fc21bcc480" name="vir:DeterminedTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which consists of the $20.0 million option exercise fee and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9802f136-4aa0-47ab-87fc-08a6611628c2" contextRef="C_c64f8d89-5c82-4a9f-a80a-fb1f5a11ee70" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the deferred revenue allocated to the VIR-2218 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation under ASC 606. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting other third parties. Brii Bio can benefit from the license at the time of grant and therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021 and 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f5385ee-5a22-42fc-8f3d-57bce802a854" contextRef="C_ec203b07-51b7-4cd9-82e7-1152642f49ca" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c51d49d-fa4f-45f4-9dd6-440b2d857ff5" contextRef="C_3f98ed76-99b8-4408-9b9c-7145868e41b8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, as contract revenue from the supply of biological materials to Brii Bio. During the years ended December 31, 2021 and 2020, the Company recognized </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02ca513a-2cdb-4e5c-837e-96387465fa72" contextRef="C_a16ebff0-6b04-4a9b-bc6e-bc5cd87822d3" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b971198-1cd3-451a-ba1e-3ce839934422" contextRef="C_0be73e2a-ec59-4143-9931-80891ed3a51b" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as license revenue from a related party. The Company separately paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e3d749a-6a03-45fb-83ec-12e2a9ba43cb" contextRef="C_819e77e6-c072-4b31-ba45-3c415b3f67d8" name="vir:PaymentToCollaboratorResultingFromProgramOptionExercise" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, half of the option exercise proceeds, to Alnylam in connection with the Amended Alnylam Agreement that was recognized as research and development expense during the second quarter of 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Alnylam</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">October 2017 Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2017, the Company entered into the collaboration and license agreement with Alnylam (the &#x201c;Alnylam Agreement&#x201d;) for the development of siRNA products for the treatment of HBV and following the exercise of certain program options, the development and commercialization of siRNA products directed to up to four other infectious disease targets selected by the Company. The technology licensed under the Alnylam Agreement forms the basis of the Company&#x2019;s siRNA technology platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Alnylam Agreement, the Company obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications, such excluded fields, the Excluded Fields. In addition, Alnylam granted the Company an exclusive option, for each of the infectious disease siRNA programs directed to the Company&#x2019;s selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. On a product-by-product basis for each product arising from the HBV and, following the Company&#x2019;s option exercise, the infectious disease programs, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company and Alnylam are jointly responsible for funding the initial research and development activities for VIR-2218 through the completion of proof of concept trials. Prior to the exercise of the Company&#x2019;s option for each siRNA program directed to one of the Company&#x2019;s selected infectious disease targets, Alnylam is responsible for conducting all development activities, at the Company&#x2019;s expense, in accordance with an agreed-upon development plan. Following the Company&#x2019;s exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, the Company is solely responsible, at the Company&#x2019;s expense (subject to Alnylam&#x2019;s exercise of a profit-sharing option), for conducting all development, manufacture and commercialization activities for products arising from each such program. If Alnylam exercises a profit-sharing option for a product, the Company will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">165</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Alnylam Agreement, the Company paid Alnylam an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d83f475f-89d1-45dc-8bca-dd078c22de86" contextRef="C_9b3dd0d6-7971-4035-8623-0c23e6212871" name="vir:UpfrontFeePaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and issued to Alnylam </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9206a30-d440-4f71-be49-0f0201f329c1" contextRef="C_cd77bc9a-f90c-4d89-9139-053ac79a0a7a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock. Additionally, the receipt of consideration from Brii Bio as discussed above triggered a requirement under the Alnylam Agreement to transfer a portion of the consideration, consisting of equity in Brii Bio Parent valued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c448ded-a87f-4723-8f36-fe3ec09a43de" contextRef="C_808e2ec7-0dc9-49ea-8101-9ff9a724d929" name="vir:ValueOfSharesTransferredToCollaborator" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, to Alnylam</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the achievement of a certain development milestone, as further discussed below, the Company was obligated to issue shares of the Company&#x2019;s common stock equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76d3dbea-1125-477a-a2c1-c49c27d8449f" contextRef="C_808e2ec7-0dc9-49ea-8101-9ff9a724d929" name="vir:MaximumSharesToBeIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares or (ii) a certain number of shares based on the Company&#x2019;s stock price at the time such milestone is achieved (the &#x201c;Milestone Shares&#x201d;). The Company will be required to pay Alnylam up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17b8680d-05bf-4e7a-aaa7-0768e982b62d" contextRef="C_deffe243-ff55-4872-8584-6b06fc133c1a" name="vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">190.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f9fcc03-c8e4-4c18-865c-125727d5e14a" contextRef="C_647cf94d-4221-49c6-986a-76edcb5f1c62" name="vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">115.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the achievement of specified development and regulatory milestones by the first product directed to the target of each infectious disease siRNA program for which the Company exercised its option. Following commercialization, the Company will be required to pay to Alnylam up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed2c8656-aca2-4584-942b-1114bce44c00" contextRef="C_deffe243-ff55-4872-8584-6b06fc133c1a" name="vir:MaximumAggregateSalesMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0d031f2-2abc-4988-a773-22c9db6ac475" contextRef="C_647cf94d-4221-49c6-986a-76edcb5f1c62" name="vir:MaximumSalesMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which the Company exercised its option. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8cba8fe-1694-4b27-ad96-db9328f1e338" contextRef="C_6a35132f-d773-49ba-9363-edcb9df0bf0b" name="vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e650a4f6-d1cc-4578-b1f4-3a7d749249ae" contextRef="C_deffe243-ff55-4872-8584-6b06fc133c1a" name="vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">low double-digits to mid-teens</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on annual net sales of HBV products, and tiered royalties at percentages ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f85854b-f535-4ed1-a8ae-24a9abd34a7c" contextRef="C_647cf94d-4221-49c6-986a-76edcb5f1c62" name="vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">high single-digits to the sub-teen double-digits</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd26761e-6fbc-4970-bf8a-252d3d8fcc50" contextRef="C_63b7f812-9b12-47ea-b2fb-128ab0685b44" name="vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years after the first commercial sale of such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under the Alnylam Agreement. If the Company does not exercise its option for an infectious disease program directed to one of its selected targets, the Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. The Company may terminate the Alnylam Agreement on a program-by-program basis or in its entirety for any reason on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b356e14-ef7e-417d-86a1-912989890161" contextRef="C_9b3dd0d6-7971-4035-8623-0c23e6212871" name="vir:WrittenNoticePeriodForTerminationOfLicensedProgram" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; written notice. Either party may terminate the agreement for cause for the other party&#x2019;s uncured material breach on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65bd5e96-fbfa-4dcf-b547-516a5e87a3e2" contextRef="C_9b3dd0d6-7971-4035-8623-0c23e6212871" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e70e402-cb2d-4941-8ff0-dc2837e0c354" contextRef="C_9b3dd0d6-7971-4035-8623-0c23e6212871" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Alnylam Agreement on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68189944-af1e-4729-b842-ff110e41b283" contextRef="C_9b3dd0d6-7971-4035-8623-0c23e6212871" name="vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; notice.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company achieved the specified development milestone relating to the Milestone Shares, which was accounted for as an embedded derivative. Consequently, the Company remeasured and reclassified the derivative liability to additional paid-in capital based on the estimated fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bd91e14-0c0c-4bfe-93ff-a0e7d6d9f147" contextRef="C_97f0fbad-d4bf-4f2b-8e7f-fa6521b24a9c" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company issued Alnylam </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c93b84d5-8039-48d4-81a7-4cc5983f2a9c" contextRef="C_46e6f289-d1e5-40dd-8d37-0d010f7d5492" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock and paid Alnylam $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33b7e91b-1bae-4261-9bfa-786a39760047" contextRef="C_cd77bc9a-f90c-4d89-9139-053ac79a0a7a" name="vir:MilestonePaymentsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the second quarter of 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Second and Third Amendments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March and April 2020, the Company and Alnylam entered into the second and third amendments to the Alnylam Agreement (as amended, the &#x201c;Amended Alnylam Agreement&#x201d;) to expand the parties&#x2019; existing collaboration to include the development and commercialization of siRNA products targeting SARS-CoV-2, and potentially other related coronaviruses, and up to three targeting human host factors for SARS-CoV-2 (collectively, the &#x201c;COVID Collaboration Targets&#x201d;).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company and Alnylam entered into a letter amendment (the &#x201c;Letter Agreement&#x201d;), further amending the Amended Alnylam Agreement, to modify certain funding and governance provisions in connection with the siRNA products directed to the COVID Collaboration Targets, including VIR-2703 (the &#x201c;COV Target&#x201d;), and to modify certain rights of each party with respect to products arising from such programs. Pursuant to the Letter Agreement, Alnylam was responsible for conducting pre-clinical research activities set forth in the existing workplan for the COV Target (the &#x201c;COV Workplan&#x201d;) at its discretion and sole expense, and the Company was no longer obligated to reimburse Alnylam for any share of costs incurred by Alnylam in conducting activities under the COV Workplan after July 1, 2020. In July 2021, Alnylam elected to discontinue the development of the COV Target, and all other related research and development activities in accordance with their rights under the Letter Agreement. As a result, the COV Target and the siRNA program related thereto are no longer included within the Amended Alnylam Agreement and all rights to the siRNA program directed to the COV Target reverted to Alnylam.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">166</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses Recognized for the Period</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company incurred expenses under the Amended Alnylam Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80e7f625-ef49-432c-9b85-31d6d3c75c1f" contextRef="C_63b7f812-9b12-47ea-b2fb-128ab0685b44" name="vir:CollaborationAgreementRelatedCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7feeed30-25d8-4ec4-8b42-3a697d09c1f7" contextRef="C_c10e626c-f383-4183-bf3d-6e3516f85d94" name="vir:CollaborationAgreementRelatedCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the years ended December 31, 2021 and 2019, respectively. For the year ended December 31, 2020, in addition to the Milestone Shares, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3efeedc1-7eb7-4622-8336-40e3c8c0434d" contextRef="C_2f49ec3e-8e45-4cc0-8b2a-a2462edffcfb" name="vir:MilestonePaymentsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million milestone payment to Alnylam, and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4101d18-67d2-410d-8bda-af7b34519383" contextRef="C_b7032bf3-35f9-44e1-bf55-389c77cec434" name="vir:PaymentToCollaboratorResultingFromProgramOptionExercise" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payment resulting from Brii Bio&#x2019;s option exercise in the first half of 2020, the Company incurred expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f34c200-80fd-47c3-8384-cc8168dda8c2" contextRef="C_3b8fb261-7fe1-496c-8e0b-dba547d8fd42" name="vir:CollaborationAgreementRelatedCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the Amended Alnylam Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">WuXi Biologics</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the Company entered into a development and manufacturing collaboration agreement with WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Biologics&#x201d;) (the &#x201c;WuXi Biologics Collaboration Agreement&#x201d;), for the clinical development, manufacturing, and commercialization of the Company&#x2019;s proprietary antibodies developed for SARS-CoV-2. Under the WuXi Biologics Collaboration Agreement, WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. WuXi Biologics will have the right to commercialize products incorporating such SARS-CoV-2 antibodies in greater China under an exclusive license granted for the selected SARS-CoV-2 antibodies that have been developed. The Company will have the right to commercialize such products in all other markets worldwide.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WuXi Biologics will perform mutually agreed process and clinical develo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pment and manufacturing activities, under individual statements of work. In addition, the parties agreed that WuXi Biologics will pay the Company tiered royalties at percentages ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a1fa20a-9b5f-487d-bd8c-57c5ec440dbd" contextRef="C_92381b91-3b42-4fe2-ba53-ec4b175909d8" name="vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">high single-digits to mid-teens</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on annual net sales of all products sold by WuXi Biologics in greater China. The royalties are payable for a specified, standard royalty term. In addition, if WuXi Biologics sublicenses its commercialization rights to a third party, WuXi Biologics will pay the Company a percentage of the sublicense revenue received from such third party. The WuXi Biologics Collaboration Agreement will continue until the expiration of WuXi Biologics&#x2019; payment obligations to the Company, unless terminated earlier. If terminated earlier, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2bad9462-ae0e-4c2a-8107-314ac355b5c0" contextRef="C_92381b91-3b42-4fe2-ba53-ec4b175909d8" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days&#x2019; prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within 60 days.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rockefeller University</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2018, the Company entered into an exclusive license agreement with The Rockefeller University (&#x201c;Rockefeller&#x201d;), which was amended in May 2019, in September 2020, and in March 2021 (the &#x201c;Rockefeller Agreement&#x201d;). Under the Rockefeller Agreement, Rockefeller granted the Company a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The Company uses technology licensed under the Rockefeller Agreement in the Company&#x2019;s antibody platform and in the Company&#x2019;s product candidates VIR-3434 and VIR-7832.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company paid Rockefeller an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69919cd3-f9c4-4634-8849-d26d2c09c383" contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b" name="vir:UpfrontFeePaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for entry into the Rockefeller Agreement, and is required to pay annual license maintenance fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f989048-36d8-4125-9296-cedba8e18366" contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b" name="vir:AnnualLicenseMaintenanceFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which will be creditable against royalties following commercialization. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, for the achievement of specified development, regulatory and commercial success milestone events, the Company will be required to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ba4bd22-8f01-4d49-804b-2ae6457ed417" contextRef="C_f7c9462b-dcbe-4e0d-ad24-fa03ee7db19f" name="vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">80.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, in the aggregate, for up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aee6d7dc-4208-4837-8adb-955b3cfaf115" contextRef="C_8a57dade-b465-4a49-be9a-5cb7b24a6ffc" name="vir:MaximumNumberOfProductsCoveredAgainstMilestonePayment" unitRef="U_Product" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infectious disease products. Any follow-on products beyond six products may result in additional milestone event payments. The Company will also be required to pay to Rockefeller a royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. The Company&#x2019;s obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis, upon the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5ba91a8-739e-4386-8a38-de24fa1c5feb" contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b" name="vir:RoyaltyObligationPeriodFromDateOfFirstCommercialSale" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years following the first commercial sale of the applicable licensed product in such jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Rockefeller Agreement, the Company recognized a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_861e8abd-91a9-4acd-bf6f-952e762cf840" contextRef="C_15e3e949-97fb-495d-b1d0-55b62ebddcc8" name="vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10f8847e-d6e8-4a30-a3c9-7ca20635dba0" contextRef="C_079288b4-6cb4-4671-8ab2-600c75753f48" name="vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59160a44-dd25-46d0-8b15-06c7bb38afae" contextRef="C_01417e77-f979-4120-a600-156314a4c210" name="vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the years ended December 31, 2021, 2020 and 2019, respectively, as research and development expenses related to certain development milestone payments, annual license maintenance fees, and estimated sublicense fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of the Company&#x2019;s obligations to pay royalties to Rockefeller in all jurisdictions. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23df60a9-ce25-4269-9ee0-bbe5a14ddd15" contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7f59d64-a24a-44c5-afde-6f09e41f331b" contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b" name="vir:WrittenNoticePeriodToTerminateAgreementByCompany" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b331d8d8-e139-40bd-a66f-ba2d4bdc6a6e" contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b" name="vir:WrittenNoticePeriodToTerminateAgreementByCounterparty" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; written notice for the Company&#x2019;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#x2019;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">MedImmune</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2018, the Company entered into a license agreement, which was amended in September 2020 (the &#x201c;MedImmune Agreement&#x201d;), with MedImmune, LLC (&#x201c;MedImmune&#x201d;), under which the Company obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8302178c-d62f-4778-86ef-e61a3a8fb9a9" contextRef="C_d1073bf6-3fc5-4a5a-97f0-bbd26559fb5f" name="vir:NumberOfAntibodiesToDevelop" unitRef="U_Antibodies" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The Company is developing VIR-2482 using technology licensed under the MedImmune Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the licenses under the MedImmune Agreement, the Company made an upfront payment to MedImmune of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30220f00-8b84-4362-a110-e74fb240db95" contextRef="C_d1073bf6-3fc5-4a5a-97f0-bbd26559fb5f" name="vir:LicenseAgreementUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will be obligated to make development, regulatory, and commercial milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ac0503e-64fa-4ebc-ae0d-bb931a2f47f4" contextRef="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb" name="vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">331.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate relating to influenza A and influenza B products. MedImmune will also be entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7b44663d-1329-47cf-a20b-2f4943e047c2;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mid-single-digits</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to sub-teen double-digits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of the Company&#x2019;s obligations to pay royalties to MedImmune. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_761e59d4-2b43-4ee5-a877-4a7c42fdca2e" contextRef="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_476b5e3e-2be8-4889-b864-df6846303f6c" contextRef="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb" name="vir:WrittenNoticePeriodForTerminationOfLicensedProgram" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89148ab4-17df-49b4-889a-95399cbbcc24" contextRef="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41b03840-a3cc-4edb-8d50-9a33321ba87e" contextRef="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb" name="vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the third quarter of 2019, the Company achieved and paid one of the specified development milestones relating to influenza A under the MedImmune Agreement. The milestone payment was expensed to research and development in 2019.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Xencor</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">August 2019 License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, the Company entered into a patent license agreement, which was amended in February 2021 (the &#x201c;2019 Xencor Agreement&#x201d;) with Xencor, Inc. (&#x201c;Xencor&#x201d;). Under the 2019 Xencor Agreement, as amended, the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in the Company&#x2019;s VIR-2482, incorporating Xencor&#x2019;s Xtend technology, and VIR-3434, incorporating Xencor&#x2019;s Xtend and other Fc technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, the Company paid Xencor an upfront fee. For each of the influenza A and HBV research programs, the Company will be required to pay Xencor development and regulatory milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d5d93b2-3387-47e4-8525-b403a6676003" contextRef="C_3a524056-f9aa-4720-b2b3-0ab25f4155a8" name="vir:MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate, and commercial sales milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77b8d1d8-1741-43aa-987c-c74cf5f15c56" contextRef="C_3a524056-f9aa-4720-b2b3-0ab25f4155a8" name="vir:MaximumAggregateCommercialSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate, for a total of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bc482d3-ab17-4628-aa78-fcdee82c6bb0" contextRef="C_a6f98428-747e-466a-907f-d4b24c98cc45" name="vir:MaximumAggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_c62c5888-b394-48a5-915a-14cc315fcacf" contextRef="C_6593689d-6c09-413e-8c82-082f1af9b2e3" name="vir:MaximumAggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">77.8</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in aggregate milestones for each program and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bed402a3-0e58-4a51-889c-08835daafc91" contextRef="C_3a524056-f9aa-4720-b2b3-0ab25f4155a8" name="vir:MaximumAggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">155.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in aggregate milestones for both programs. On a product-by-product basis, the Company will also be obligated to pay tiered royalties based on net sales of licensed products ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f2a63a0-de64-4e72-a82a-99b8734dd40b" contextRef="C_3a524056-f9aa-4720-b2b3-0ab25f4155a8" name="vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">low- to mid-single-digits</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2019 Xencor Agreement, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4edb7cae-d93b-4ca7-ab66-69fb4234a9cf" contextRef="C_5271e096-8828-4fdb-8093-e81baf518a38" name="vir:SpecifiedResearchAndDevelopmentExpensesMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd1e7cb1-fbd2-49ed-b873-b8f51098361d" contextRef="C_cb6f51fe-eb87-484b-a6ba-f5a1a6fa73d6" name="vir:SpecifiedResearchAndDevelopmentExpensesMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5774112-65fb-464c-958f-968259c79bd8" contextRef="C_0e39b64d-0aec-4926-941a-2eeb4cc3e0c1" name="vir:SpecifiedResearchAndDevelopmentExpensesMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the years ended December 31, 2021, 2020 and 2019, respectively, as research and development expenses related to certain development milestone payments.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">March 2020 License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company entered into a patent license agreement, which was amended in February 2021 (the &#x201c;2020 Xencor Agreement&#x201d;) with Xencor under which the Company obtained a non-exclusive, sublicensable (only to the Company&#x2019;s affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the coronavirus research programs. These technologies are used in the Company&#x2019;s sotrovimab, incorporating Xencor&#x2019;s Xtend technology, and VIR-7832, incorporating Xencor&#x2019;s Xtend and other Fc technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, the Company is obligated to pay royalties based on net sales of licensed products at the</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a75ac003-1aca-45ef-8f00-69315440e502" contextRef="C_9df276b4-bb61-407c-a816-a86f5eb1f323" name="vir:RoyaltiesBasedOnNetSalesOfLicensedProducts"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> mid-single-digits</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_482cfcb9-c831-41e2-9124-435cf7b57f74" contextRef="C_9df276b4-bb61-407c-a816-a86f5eb1f323" name="vir:RoyaltiesPaymentExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47b3968e-b835-4a87-8154-c44d4734069d" contextRef="C_9df276b4-bb61-407c-a816-a86f5eb1f323" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">52.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, as cost of revenue for royalties due to Xencor from the sale of sotrovimab.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amended 2020 Xencor Agreement and 2019 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e803d627-0d25-40ec-a5e2-96c8bb4e6e91" contextRef="C_e143173f-1c22-40fb-ba0b-999bdcd9677f" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14f84538-a00c-4d0a-a84a-9bab4891f26b" contextRef="C_e143173f-1c22-40fb-ba0b-999bdcd9677f" name="vir:WrittenNoticePeriodForTerminationOfLicensedProgram" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; written notice. Either party may terminate each agreement for the other party&#x2019;s uncured material breach upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63329db0-ea5e-4a6b-96b6-7eae3d67c64e" contextRef="C_e143173f-1c22-40fb-ba0b-999bdcd9677f" name="vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_145c1e86-0ad6-4327-b068-9df3b0bb9e8c" contextRef="C_e143173f-1c22-40fb-ba0b-999bdcd9677f" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f384fe4-8d22-4f8b-85d2-06c885319351" contextRef="C_e143173f-1c22-40fb-ba0b-999bdcd9677f" name="vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; written notice if any of the Company&#x2019;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_548a961d-7cde-46fd-bcd8-8de54c630202" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><div style="display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance Sheet Components </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7944e04d-44b4-4213-a300-3ed5b13505a2" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.55%;"></td>
        <td style="width:1.279%;"></td>
        <td style="width:2.132%;"></td>
        <td style="width:14.07%;"></td>
        <td style="width:1.421%;"></td>
        <td style="width:1.279%;"></td>
        <td style="width:2.132%;"></td>
        <td style="width:13.715%;"></td>
        <td style="width:1.421%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_676e7135-c20e-4524-9802-0bfc5bd582c5" contextRef="C_6e34598c-0a2b-44cb-8608-379e7e560202" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,012</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d41be22-17f3-4feb-a394-5bdc10219e99" contextRef="C_c8ddf765-8bda-47c3-81a9-cbdb38c2d9e6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e45b6f63-a118-4979-ba5f-0101faef6102" contextRef="C_bd868f7f-a86d-4911-a7c7-759ba388c5ee" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,112</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10d519c5-438d-44fc-9759-b7f1c12d5450" contextRef="C_42be3ce6-3c6d-4c19-ad78-d6bba030babf" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d10ede1-83b5-43d2-9526-f133aaf038ef" contextRef="C_05dda014-cb81-49d2-92f9-31d5a59a9ff3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,443</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b15857d-ff85-4dad-9655-a0827b72c907" contextRef="C_d49462cf-7289-42fd-ade3-fc506e048127" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,444</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e213d8b-9b3b-48d7-88c5-16dda159b506" contextRef="C_813ff2ee-1d90-44ea-b0f0-79248d502136" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e681285-a7f3-4240-9d5e-3c8191ca1f24" contextRef="C_bbb0d6a6-cb1d-4c13-9791-01f69f5283a1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,274</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae8cce4a-5cbe-4569-a111-11f47f721290" contextRef="C_31279301-58e0-4e0d-beea-e0a2ac9b9cfa" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8327701-8b52-40d6-b3ab-529b4bc089bf" contextRef="C_da7048e3-08ee-4a8f-a9eb-1ecdc468ee9c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,135</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e58b7ead-4ba3-4d40-b479-e32fd1fab63d" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,326</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f54faedb-5701-4cb3-a608-5adfd76576de" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,178</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a8ea73e-f115-4602-a154-660349275608" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90ff0a36-9fa9-4531-92a2-41250aa05f8a" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,232</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5ecab79-00bf-4110-8963-50c99478856f" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ffdbf698-f613-4fcd-9969-5baa84fe4bcd" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,946</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expenses were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e4aebee-23fc-44b3-bd3b-6ef291ef8251" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_afffadbc-4e60-4c2c-9f11-1ebe968eded9" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a74502d-0101-4ad5-85e7-6662ba09eb1c" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued and Other Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cba575e3-5f63-46bd-88d2-b5dc385b0a64" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.825%;"></td>
        <td style="width:1.521%;"></td>
        <td style="width:2.118%;"></td>
        <td style="width:14.895%;"></td>
        <td style="width:0.853%;"></td>
        <td style="width:1.521%;"></td>
        <td style="width:2.118%;"></td>
        <td style="width:14.298%;"></td>
        <td style="width:0.853%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Milestone payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_345e88fd-f917-475c-afd9-fbe6caf35065" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:MilestonePayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e1a0ec1-4a53-4f7f-9f3e-16f627685d59" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:MilestonePayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued royalties</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60dcaa4c-5f80-4a25-ac7f-8cb1d1a0623b" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AccruedRoyaltiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,672</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5beadb1a-f6fd-4129-afa7-2c546e45f75b" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:AccruedRoyaltiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c1c1989-2801-4a8c-b455-735e6b65e413" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:ResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,073</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a94cbb83-206b-4a61-a28d-08ba2c979c76" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:ResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,384</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d70fca5-61f6-421d-a4a3-5d857824ea28" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:PayrollAndRelatedExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,753</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ec475ed-68ab-40af-96d5-8127b71ba4b3" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:PayrollAndRelatedExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,060</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f02c431-966a-4f04-8454-c1e52763cab5" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Excess funds payable under grant agreements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9657390-202a-4ef6-b0a2-ea0466684e50" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:ExcessFundsPayableUnderGrantAgreementsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,825</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be0f29df-9963-4be1-ba5b-d9abe0f08d89" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:ExcessFundsPayableUnderGrantAgreementsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,467</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ecf9ce78-039d-4de2-8a11-a1aa35e42038" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,927</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f698b4e2-9e60-4ffe-84b7-92c771ccf58e" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,625</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other professional and consulting expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3fe8c6b9-d1f9-4a2e-b40c-0504c0ba35ac" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,791</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3edb6ad8-d442-41bb-9d99-e62fb727efad" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a9dad4a-1c7b-42b0-a879-fce2755edae9" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_45658e8e-bded-483c-8a81-ee46d06b7356" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">805</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97a338fd-b0f2-45bf-a412-6a72c937a7dd" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">236,512</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_231f5014-5a71-44ed-a255-7a73d33f2a0d" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,936</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46c37d78-6002-46ae-b89a-69b32f3ae2a7" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_46c37d78-6002-46ae-b89a-69b32f3ae2a7_1"><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commitments and Contingencies </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease Agreements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has various operating lease arrangements for office and laboratory spaces located in California, Oregon, Missouri, and Switzerland with contractual lease periods expiring between </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b1edd13-0b01-4b71-884f-c9ed43c9eca8" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:LeaseArrangementContractualExpirationBeginningYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71ab9ab2-1be3-4efc-b2c0-5a502434f400" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:LeaseArrangementContractualExpirationEndingYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2033</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45601290-fe01-4821-b42f-8e501c367046" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b3ce71d6-2479-49ff-972d-2870edd2f042;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67ac1969-1d7f-4ef7-9488-6193eb03063b" contextRef="C_a8765b59-506d-4165-9487-b02bdc930b58" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> These renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2021, the Company entered into a new sublease agreement for office and laboratory spaces in Missouri that will expire in December 2028, with no option to renew. Under this sublease arrangement, the Company is entitled to tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f9bfacd-b3b3-4a8a-877d-a2590c6879b5" contextRef="C_b2e6a670-5d82-408a-9795-8749e0878917" name="vir:TenantImprovementAllowanceAggregate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">related to the design and construction of certain Company improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company entered into a lease agreement with the new owner of the building at 1800 Owens Street in San Francisco for the lease of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20331f61-83f7-4ae3-b6b4-b266da372ea5" contextRef="C_501b75ac-22be-4b07-9759-c03d7aa1ce0b" name="us-gaap:NetRentableArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">133,896</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet of office and laboratory space of such building. The Company previously occupied the same premises under a sublease agreement with a sublessor, which sublease was terminated concurrently with the execution of the new lease agreement. Accordingly, the related ROU asset and lease liability under the sublease arrangement were extinguished and the Company recognized a gain of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd0a738b-0a4a-4819-b34d-dfb3555ee392" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the consolidated statement of operations for the year ended December 31, 2021. The new lease will expire in December 2033, with no option to renew. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under this lease arrangement, the Company is entitled to tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d73570a-fd98-43f5-afe6-fa5e95dfea6e" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:TenantImprovementAllowanceAggregate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">related to the design and construction of certain Company improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under two of the operating lease arrangements in California and Missouri discussed above, the Co</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mpany expects to fully utilize the tenant improvement allow</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ance, and therefore, such amount is treated as a lease incentive that is payable to the Company at the lease commencement date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Throughout the term of the lease agreements, the Company is responsible for paying certain operating costs, in addition to rent, such as common area maintenance, taxes, utilities and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e38db9ee-8e00-40b4-80f0-53bb53a12559" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table contains a summary of the lease costs recognized under ASC 842 and additional information related to operating leases (in thousands, except weighted average amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.535%;"></td>
        <td style="width:1.511%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:17.119%;"></td>
        <td style="width:2.127%;"></td>
        <td style="width:1.263%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:14.773%;"></td>
        <td style="width:2.127%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f2f4313-c1a8-4593-9df2-30b419b39b61" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,921</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44e8b0d0-726a-4f2b-90f3-6a0a088a3a01" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3bc365ec-16ee-4add-99f0-9518f2f737fa" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0c18e85-1b3a-4b74-be20-720f200f13bb" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">459</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b3b71f1-b17d-4b10-8f7f-45951e1c8751" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,256</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f546f125-1eda-4f85-8866-e77e0ae3a227" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,299</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total least cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e69ef9f-7bbd-439f-acdb-368493c45971" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03d1c5fd-8800-4ca3-8720-84f9b739cd93" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,349</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80ab1b58-c186-413b-9bfd-b474af59b3f3" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25d378cb-0a0e-48e7-b45b-f199fcef0c5f" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4644f78-3b9a-494f-ad70-a23091928eb9" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27ba062d-b796-45ae-acce-b8f725d1c78c" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d24c30e4-d488-4086-b96d-a03437de4fb7" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44800b0a-f35b-4a88-802e-bf13eec4e211" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,081</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU assets obtained in exchange for new operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f868164f-5a78-4d19-8a08-18cbb222e581" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,187</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_166db8a8-d861-4157-8234-ee578acd1cd1" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The discount rate used to determine the present value of the lease payments is our estimated collateralized incremental borrowing rate, based on the yield curve for the respective lease terms, as we generally cannot determine the interest rate implicit in the leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee57452d-2a3a-4b61-8dd3-8559f1cdbab4" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturity of the Company&#x2019;s operating lease liabilities as of December 31, 2021 was as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.861%;"></td>
        <td style="width:2.038%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:15.855%;"></td>
        <td style="width:0.964%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amounts</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e00845f-a617-4aa6-916a-35de30d037f2" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e107de80-2195-4a16-9ab4-b36728a59883" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,082</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5cfc7ac1-a72f-49e8-bc22-1f226a22591e" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,233</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77aeaabb-95c9-4e98-a6be-59719258e629" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,917</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2da9bb99-320a-4706-94c1-39f68c7b0a69" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,353</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3a36286-e6d6-41a1-92c8-b7835f8bf199" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,413</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b2d7a4d-7226-4763-ba9d-7a73ae126b38" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">185,430</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_849f35d4-4725-4706-b868-71b3e5367d70" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: net tenant improvement allowance yet to be received</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c64c693b-49e7-433c-98f3-088c4f53dabe" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1128731d-125c-481b-82eb-cf66a2c07656" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:PresentValueOfOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,952</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f613f67-0010-4d76-b305-daf7b7a4ff7d" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following amounts were recorded in the consolidated balance sheets as of December 31, 2021 and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.716%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:16.938%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.451%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:15.477%;"></td>
        <td style="width:0.636%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1973014-1cf2-4eca-bc28-be136f876b81" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:OperatingLeaseIncentiveOverLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,536</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0e4b230-b9af-41e0-b35c-1882aab2805f" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:OperatingLeaseIncentiveOverLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,913</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating ROU assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7d33294-d9e8-4f13-a3a0-dbd40bf9fbba" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,220</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20cf0a67-d83a-4e6e-9d81-c496aaaddf20" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,947</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1cc61fe6-ac37-4ae9-8e25-9ed92a418e6e;"><span style="-sec-ix-hidden:F_a8d2e9b9-02ae-4ff4-bd78-94a2d05ac43a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bda577f-a682-40db-8893-7dde3b829652" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,927</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c5c673b-566d-4665-a79e-04257a3b886c" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,625</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f73416f0-8ace-4d53-9f34-f42131f8e22f" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,561</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_addbfa14-bdf1-4135-9584-a8e7a5028cdd" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3d09632-076e-4b09-8e6c-affe1c3c4cc8" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">137,488</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37b1c195-a3fd-4e21-8888-553031a3c4ef" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_76d6ccb1-4db9-4ff8-9bba-9b4948c6b0ce" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rent expense under the prior lease accounting standard was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30e3d525-147b-4c90-b884-469bf7da0efd" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:OperatingAndFinanceRentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Manufacturing and Supply Letter Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Letter Agreement, Assignment and Master Services Agreement with Samsung</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 9, 2020, the Company and Samsung Biologics Co., Ltd. (&#x201c;Samsung&#x201d;) entered into a binding letter agreement (the &#x201c;Samsung Letter Agreement&#x201d;), under which Samsung will perform process development and manufacturing services for the Company&#x2019;s SARS-CoV-2 antibody program. Under the terms of the Samsung Letter Agreement, the Company had committed to purchase a firm and binding capacity reservation for a specified number of manufacturing slots in 2021 and 2022. The Company was obligated to pay a total of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48ba9a7e-85aa-446e-9804-888eaf3ec2f7" contextRef="C_dcb52d16-86fa-4370-9fc3-793fe22d8181" name="vir:ObligationToPayCapacityReservation" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">362</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for such capacity reservation on a take-or-pay basis regardless of whether such manufacturing slots are utilized by the Company, subject to annual adjustment based on the Korean Consumer Price Index, which also includes certain fees relating to project management and technology transfer. The amounts were to be payable during 2021 and 2022 and invoiced on a per-batch basis, with shortfalls invoiced at the end of the year in which such shortfall occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 4, 2020, the Company, GlaxoSmithKline Trading Services Limited (&#x201c;GSKTSL&#x201d;) and Samsung entered into an Assignment and Novation Agreement effective as of July 31, 2020 under which the Company assigned and transferred to GSKTSL all of the Company&#x2019;s right, title, and interest in, to and under the Samsung Letter Agreement, and GSKTSL became the Company&#x2019;s successor in interest in and to all of the Company&#x2019;s rights, duties, and obligations in, to and under the Samsung Letter Agreement. On August 4, 2020, GSKTSL entered into a Master Services Agreement with Samsung effective as of July 31, 2020 (the &#x201c;Samsung MSA&#x201d;), thereby superseding the Samsung Letter Agreement, and under which, among other things, Samsung will perform technology transfer, development and manufacturing services for clinical and commercial supply of antibody products under the Company&#x2019;s SARS-CoV-2 antibody program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Letter Agreement, Assignment and Master Services Agreement with WuXi Biologics</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 15, 2020, the Company and WuXi Biologics entered into a binding letter of intent (the &#x201c;WuXi Biologics Letter Agreement&#x201d;), under which WuXi Biologics will perform certain development and manufacturing services for the Company&#x2019;s SARS-CoV-2 antibody program. Under the terms of the WuXi Biologics Letter Agreement, the Company had committed to purchase a firm and binding capacity reservation for the manufacture of a specified number of batches of drug substance of the Company&#x2019;s SARS-CoV-2 antibody in 2020 and 2021. In addition, the Company had the right to order an additional specified number of batches of drug substance, provided it makes such election by a specified date in the fourth calendar quarter in 2020. WuXi Biologics is obligated to reserve such manufacturing slots on a non-cancellable basis and will manufacture the agreed number of batches of drug substance per an agreed manufacturing schedule. The Company was obligated to pay a total of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05730c0c-c62c-4637-9acc-5c2c2c759003" contextRef="C_518a3141-66a8-47ab-978b-8e77ec8e8f30" name="vir:ObligationToPayCapacityReservation" unitRef="U_USD" scale="6" decimals="-5">130.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for such capacity reservation, if all batches are manufactured, inclusive of estimated raw material costs, with between </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e58d1f7b-661c-481f-9e50-2cb0bc41d68e" contextRef="C_0ded0a8a-1711-44a2-8906-3b560cb68ef4" name="vir:PercentageOfEstimatedBatchProductionFees" unitRef="U_pure" scale="-2" decimals="INF">70</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c49aae05-f187-4c01-95db-3436dd6ba79a" contextRef="C_cb8cdd31-0bed-4661-832a-fa3a50385e05" name="vir:PercentageOfEstimatedBatchProductionFees" unitRef="U_pure" scale="-2" decimals="INF">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of the batch production fees owed to WuXi Biologics on a take-or-pay basis regardless of whether such manufacturing slots are utilized by the Company. The amounts were to be payable during 2020 and 2021 and invoiced on a per-batch basis. The SARS-CoV-2 antibody drug substance contemplated to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">172</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufactured per the terms of the WuXi Biologics Letter Agreement will be utilized in connection with progressing the development and commercialization of the SARS-CoV-2 antibody product under the Company&#x2019;s collaboration with GSK.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 4, 2020, the Company, GSKTSL and WuXi Biologics entered into an Assignment and Novation Agreement effective as of July 29, 2020 under which the Company assigned and transferred to GSKTSL all of the Company&#x2019;s right, title, and interest in, to and under the WuXi Biologics Letter Agreement, and GSKTSL became the Company&#x2019;s successor in interest in and to all of the Company&#x2019;s rights, duties, and obligations in, to and under the WuXi Biologics Letter Agreement. On August 4, 2020, GSKTSL entered into a non-exclusive Master Services Agreement for Commercial Manufacture of Drug Substance with WuXi Biologics effective as of July 29, 2020 (the &#x201c;WuXi Biologics MSA&#x201d;), thereby superseding the WuXi Biologics Letter Agreement, and pursuant to which, among other things, WuXi Biologics will perform development and manufacturing services for clinical and commercial supply of antibody products under the Company&#x2019;s SARS-CoV-2 antibody program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GSKTSL entered into the WuXi Biologics MSA and Samsung MSA in connection with the performance of the obligations of the Company and GSK, under the 2020 GSK Agreement. Per the terms of the 2020 GSK Agreement, the Company will continue to be responsible for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58cb4d1d-e1d0-484d-8db3-c25dbdaa1d86" contextRef="C_7b782a32-6679-4004-9be5-e91a7a28b3e9" name="vir:PercentageOfDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="3">72.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the costs under each of the WuXi Biologics MSA and Samsung MSA, and GSK will bear </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c782a5f8-9f4e-4a3d-bd86-cd525263f957" contextRef="C_accfab4e-3a9c-48c5-9d0d-b1f80346071b" name="vir:PercentageOfDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="3">27.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs under each of the Samsung MSA and the WuXi Biologics MSA, subject to certain conditions and exceptions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnification</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_46c37d78-6002-46ae-b89a-69b32f3ae2a7_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Under such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#x2019;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a54c853a-4847-4a1b-b58d-28cc030672ef" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Related Party Transactions </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of the Brii Agreement in May 2018, the Company holds a minority equity interest in Brii Bio through its parent company, Brii Bio Parent. At the time when the Company entered into the Brii Agreement, the Company's Chief Executive Officer, or CEO, and another member of the Company's board of directors served on Brii Bio Parent&#x2019;s board of directors. The Company's CEO, who is also a member of the Company's board of directors, resigned from Brii Bio Parent&#x2019;s board of directors in June 2021. As of December 31, 2021, one member of the Company&#x2019;s board of directors still serves on Brii Bio Parent&#x2019;s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b9e6aac-351c-4439-927c-0fd10c1bb335" contextRef="C_931f9106-3768-4f05-bd7b-0855dd2f9745" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,202,213</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock to existing Series A-1 preferred stockholders. See further discussion in Note 11&#x2014;Convertible Preferred Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b7dd2ab-b1f4-4c9c-97e2-1736ad8bdcd7" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:TemporaryEquityTextBlock" escape="true"><div style="display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Convertible Preferred Stock </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the IPO, under the Company&#x2019;s amended and restated certificate of incorporation, the Company was authorized to issue </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c17b0253-15ea-4fc0-abed-f63800b03786" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:NumberOfClassOfStock" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> classes of shares: preferred stock and common stock. The preferred stock was issued in series.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, under the Amended A&amp;R Series A-1 and B Purchase Agreement, the Company sold an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a24b83f9-d9c7-42be-a91a-14ac864cb0db" contextRef="C_24859036-8402-474d-a1b9-81a9c9af22a3" name="vir:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,202,213</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b729878-5e86-4e77-9c4d-979c6eae4f9d" contextRef="C_931f9106-3768-4f05-bd7b-0855dd2f9745" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_USDollarShare" decimals="INF">18.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a0a5ac5-4eb3-4660-810d-c208f6d0cb18" contextRef="C_24859036-8402-474d-a1b9-81a9c9af22a3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">327.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in two closings. The Company was authorized to sell up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4bb5c4d-d562-4ca3-8f87-ee58e78735dc" contextRef="C_931f9106-3768-4f05-bd7b-0855dd2f9745" name="vir:TemporaryEquityAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,020,009</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of Series B convertible preferred stock in one or more additional closings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon closing of the IPO, all of the outstanding convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_558c8333-7e23-4da5-af34-da359730e727" contextRef="C_c9443ba3-f289-4712-b80e-f1c93e0123cf" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">88,112,733</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. After the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3eb7025d-f69b-4b6f-8171-c23aa7edeeb4" contextRef="C_4723e489-b2c6-419e-a302-89f09c349a7d" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">173</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31467107-e2e8-463f-ba0a-efafc66ed7af" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:ConvertiblePreferredStockWarrantLiabilityTextBlock" escape="true" continuedAt="F_31467107-e2e8-463f-ba0a-efafc66ed7af_1"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Convertible Preferred Stock Warrant Liability </span></div></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_31467107-e2e8-463f-ba0a-efafc66ed7af_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2016, the Company issued a warrant to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cda9a86f-dd42-44b9-bab8-39c50f150116" contextRef="C_04e2f054-346c-47c8-89fb-055997c2a180" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">244,444</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s Series A-1 convertible preferred stock with an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e1fca1a-d4d6-4da3-8c6a-03a8c8e2b53a" contextRef="C_04e2f054-346c-47c8-89fb-055997c2a180" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2">4.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share in connection with the termination of a sponsor research agreement. The warrant was fully vested upon the issuance date and had an expiration date of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_edc1c5ca-b876-4670-b926-efce130f2212" contextRef="C_0c0012f8-5960-4879-bdde-f46b368e2ae9" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 11, 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The warrant was initially accounted for as a liability and was subject to remeasurement at each reporting period, with changes in estimated fair value recognized as a component of other income (expense), net. Upon the completion of the IPO in October 2019, the warrant automatically converted into a warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7ef9065-3b37-4cfa-8b52-5b343b38f199" contextRef="C_b1374ee0-34e2-4104-bf31-9dd183c22ca3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">244,444</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. Therefore, the convertible preferred stock warrant liability was reclassified to additional paid-in capital. In May 2020, the holder exercised its warrant in a cashless exercise for which the Company issued an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9027ab35-1f41-4e1c-8e6d-06f8954dc512" contextRef="C_4f17c5a8-e2ce-47e8-9a5f-717bf5afb341" name="vir:StockIssuedDuringPeriodWarrantExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">211,774</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. </span></ix:continuation></span><span style=""></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0bc030a5-5ece-4934-a3aa-591d23221b7c" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><div style="display:flex;margin-top:18.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">13.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-Based Awards </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2019 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2019, the Company&#x2019;s board of directors adopted, with the approval of its stockholders, the 2019 Equity Incentive Plan (the &#34;2019 Plan&#34;) for the issuance of incentive stock options (&#x201c;ISO&#x201d;), non-qualified stock options (&#x201c;NSO&#x201d;), stock appreciation rights (&#x201c;SARs&#x201d;), restricted stock, other stock awards and performance cash awards, to employees, non-employee directors, and consultants. The 2019 Plan became effective concurrent with the IPO.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Awards granted under the 2019 Plan expire no later than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e704867-a80c-4550-b427-e5aac26146a9" contextRef="C_8d0a5b8f-a0b0-4322-af0c-fa4c65561bb1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years from the date of grant. For ISO and NSO, the option price shall not be less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9bf043b5-a09b-4184-82ab-aa19f2f8fb53" contextRef="C_b91aebaf-cbdf-4bbc-b802-2169b53b199f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07df8ee4-83e2-4c98-af9a-028c4d28afd9" contextRef="C_b91aebaf-cbdf-4bbc-b802-2169b53b199f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period but may be granted with different vesting terms. As of December 31, 2021, there are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a761d56e-b43d-4051-b1f0-f2d82200f99b" contextRef="C_f546f6f3-d48a-486c-8052-617336a81a7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,092,936</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for the Company to grant under the 2019 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2016 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2016, the Company adopted the 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;) for the issuance of ISO, NSO, SARs, restricted stock and other stock awards, to employees, non-employee directors, and consultants under terms and provisions established by the Company&#x2019;s board of directors and approved by the stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Awards granted under the 2016 Plan expire no later than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a12ba7bf-bf4c-4416-8f67-6709c259a23d" contextRef="C_d9c4bdc2-99a7-4b17-b04f-d11af920c552" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years from the date of grant. For ISO and NSO, the option price shall not be less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8fc5352-b9de-4e2a-9d91-8036223ecf3e" contextRef="C_0491c773-5dc7-4c46-bec3-e5a5ab07096c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d1527ce-88e4-44ca-90d5-5c7a49b8a211" contextRef="C_0491c773-5dc7-4c46-bec3-e5a5ab07096c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period but may be granted with different vesting terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In conjunction with adopting the 2019 Plan, the Company discontinued the 2016 Plan with respect to the new equity awards.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2019 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2019, the Company&#x2019;s board of directors adopted, with the approval of its stockholders, the ESPP. The ESPP became effective on the completion of the Company&#x2019;s IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ESPP initially authorized the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05959d48-cee2-46c9-bb2c-f9ffa991a124" contextRef="C_49d8bcd1-7a7f-42e5-892b-9a0cd8d9902d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,280,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock under purchase rights granted to its employees or employees of any of the Company&#x2019;s designated affiliates. The number of shares of the Company&#x2019;s common stock reserved for issuance is subject to an automatic increase at each calendar year. Under the ESPP, the Company may specify offerings with durations of not more than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe5298fb-2090-4be2-8ec0-d358adc24791" contextRef="C_04d6bf1e-1ec8-4592-84fc-8ca7693ba159" name="vir:OfferingPeriodEmployeeStockPurchasePlan" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months and may specify shorter purchase periods within each offering. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b03b5cb5-0d2b-4020-ac9c-61c449c416cf" contextRef="C_49d8bcd1-7a7f-42e5-892b-9a0cd8d9902d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their earnings, subject to any plan limitations. Unless otherwise determined by the Company&#x2019;s board of directors, employees can purchase shares at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89119410-629b-465d-bcc6-0707097fbe56" contextRef="C_5cbe6ca1-3aef-4d1a-beac-1c5b67ca8ba9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the lower of the fair market value of the Company&#x2019;s common stock on the first date of an offering or the purchase date. During the year ended December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_075cfca8-381d-40ba-b992-8c5a5b5a2c2c" contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">65,021</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were issued under the ESPP.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">174</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ded4d50-aaa2-4845-be5b-adbb36977c10" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Activity under the Company&#x2019;s stock option plans is set forth below:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.698%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:0.95%;"></td>
        <td style="width:11.429%;"></td>
        <td style="width:1.016%;"></td>
        <td style="width:1.071%;"></td>
        <td style="width:1.513%;"></td>
        <td style="width:9.375%;"></td>
        <td style="width:0.751%;"></td>
        <td style="width:1.115%;"></td>
        <td style="width:0.894%;"></td>
        <td style="width:9.728%;"></td>
        <td style="width:0.751%;"></td>
        <td style="width:1.115%;"></td>
        <td style="width:1.513%;"></td>
        <td style="width:10.269%;"></td>
        <td style="width:0.751%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_456aabcc-736a-40d9-bb86-023e9ab789ce" contextRef="C_bb04a465-c3d8-4109-889c-c33e0ccca055" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,798,282</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_452a877c-8c6b-4eef-a375-b76ed6066337" contextRef="C_bb04a465-c3d8-4109-889c-c33e0ccca055" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">19.10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_096ce1ca-4f8b-4345-8743-b27472b042af" contextRef="C_1c384113-a0b3-4e9a-b7a6-3c84846d53e8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53dc37ef-cb84-4be2-91d8-326a6c95ce41" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,294,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2d62c37-3d04-41d3-b8ba-7474ca5bb808" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">58.68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59a9f1ee-6c8e-43eb-9138-95a9b4c80237" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,622,718</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f211ecb-4524-4289-906d-81c226ede55d" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">8.06</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1cdec29-9530-4b2c-af00-37586a0aa54c" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,160,636</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17d7a1f0-007c-4041-8e63-749080f38188" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">34.55</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd523523-416f-4740-a088-06536576fe2f" contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,308,928</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfec424a-d61f-4ebc-9999-b2b151740ff6" contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">31.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95679337-bbb9-429f-88d2-059385f2f593" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_116d4451-0ac9-4125-8a09-8a466c7b4a80" contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,378</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75a3272a-7fa8-4492-8363-5fed5ca442fd" contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,308,928</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_803ab477-10d1-4af9-b061-a59177e6f662" contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">31.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36bb5795-f481-4a13-9151-8df357ab2b7d" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4673e61c-d99d-4e1c-9a51-4068ace03f9b" contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,378</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d11879e0-250e-4360-b0b7-ac7e35783ed8" contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,238,107</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bc343ac-0c0d-45e4-b185-5e9f80f779b3" contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">17.29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a33d749-2ec1-4fb5-9297-1d2cd8846a04" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26983bd7-5064-4121-8e90-b8794937b4f2" contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105,698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51300106-7721-4e87-9153-bbe3f868bbdb" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">65.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1631ba9d-bb76-4126-ae58-2d2b97883cf9" contextRef="C_1c384113-a0b3-4e9a-b7a6-3c84846d53e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5">53.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6c717c0-92d6-4900-b8cc-30ffd298689c" contextRef="C_9c4a05c0-ab68-4442-bfca-80dd0cb82f0d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021, 2020, and 2019, the estimated weighted-average grant date fair value of the options granted was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4111aad-fed4-4c0b-9995-757b0864506b" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">47.62</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ee6cdcb-79b8-45fd-97a6-50568da7d581" contextRef="C_1c384113-a0b3-4e9a-b7a6-3c84846d53e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">25.49</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1d2d2a8-0dc1-4c25-8e57-9b9df6b3004f" contextRef="C_9c4a05c0-ab68-4442-bfca-80dd0cb82f0d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">7.83</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company expects to recognize the remaining unamortized stock-based compensation expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14b4fe26-74e2-4a55-9765-b6de441a9ad5" contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">176.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to stock options, over an estimated weighted average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d06edc98-1ac4-4db5-9f3f-2cf295b9987b" contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options Granted to Employees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b6e948f-a5eb-4518-aa13-774a6c1eb38f" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option- pricing model with the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.483%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:15.338%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:15.338%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:15.338%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term of options (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c13881bb-a37b-41fb-8c73-cfe9f33a202d" contextRef="C_e5046b1c-890a-4d88-9c47-8d81f489b3cf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0e0750e-e3b7-47bf-b90c-577a955bdf91" contextRef="C_ec04e3a0-91fd-471d-9c5e-a88bcbb1c70d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e87d991-79b5-4b24-84e7-0b52b4275735" contextRef="C_9599deea-454d-4e26-bedc-49ceb4cf2404" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_643dfa4f-7d44-47cc-bb45-b9e2cd90a30a" contextRef="C_c7bf9af0-7a63-47de-aa6e-7c2731d130ef" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9d280ec-9809-4d3a-a5db-c264f0d5ecd0" contextRef="C_0003b2b6-cfb3-4fa2-90d1-98eb440f3fcd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_831df72d-8573-459c-952c-bf3735bf67e2" contextRef="C_a5f8399f-ee4b-45a3-a103-6773949f9073" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0981f8f7-22e2-4a95-a6c0-4ed992769074" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">103.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1de20286-44fa-4b62-b754-9a607969ff9d" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">112.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6371b364-d593-4a81-8e53-3db571ba1fcf" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">88.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1abde14c-3b93-4e75-afd8-10fa3d3f3daf" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">108.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_caf3db4c-c71b-4bdf-83f8-a5a7898f8f74" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">86.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb953a47-fc21-4bd3-af3f-4e61abdcea0c" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">89.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb475237-e055-4988-8d67-d965b01c1600" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da554592-4996-400d-ad09-a1322494f00a" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e56081d2-31b0-4d51-9beb-2ea081fa5b17" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fbd94a8a-7bf9-415d-9cd3-f8c4fe2152ab" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db756dcd-72fe-4bda-8b04-677c56bc3b82" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_346d6bb5-bc4b-424d-94cd-e169c7b60b73" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f62ef879-a759-4495-ab49-455be9a9e394" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d33084d5-9554-4979-88f8-f8fc95c5a73d" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aae3f2db-6ae7-4445-9051-e2ef0f3e64f7" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The valuation assumptions for stock options was determined as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected volatility was determined by examining the historical volatilities for industry peers and using an average of historical volatilities of the Company&#x2019;s industry peers as the Company does not have a sufficient historical trading history for its stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its stock price becomes available.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Rate&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employees Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2021, the Company initiated its first offering period under the ESPP. Each offering period is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71063a7f-5dc9-4ad8-8f12-a1fe5ef35f7a" contextRef="C_bc4e105a-e463-4014-aae3-86682a1d49a2" name="vir:OfferingPeriodEmployeeStockPurchasePlan" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which commences on the grant date on or after June 1 and December 1 of each year and ends on the purchase date on or before November 30 and May 31 of each year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37c02f4a-1490-4a83-a3a2-7fdb4f07fac9" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of employees' purchase rights under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.603%;"></td>
        <td style="width:2.282%;"></td>
        <td style="width:23.115%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term of ESPP (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c94718a7-a6d3-4320-8816-25af65d908e7" contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4afd197-ec49-428d-a206-24fff296db42" contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">76.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea416616-8b6c-408d-a7b6-a398a6d27ab8" contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">144.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37b653e9-6c25-4c07-8cfc-89cd1e768e1e" contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.04</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dbf78b24-17d9-45de-8ca3-a7a2fddf936b" contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56dea096-9b20-4343-b163-3e678492f1e8" contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected term of employees&#x2019; purchase rights is equal to the purchase period. The expected volatility was determined based on the Company's historical volatility. The risk-free interest rate is based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant over the expected term of the employees&#x2019; purchase rights. The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future. Based on the Black-Scholes option-pricing model, the estimated weighted-average grant date fair value of the employees' purchase rights granted for the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_915fdb7e-d5ae-4da9-b695-571b2df993f3" contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">19.85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b98e6d6-09b5-4f64-9252-87ebbfa1ae33" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s RSAs and RSUs were summarized as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.968%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:9.014%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:9.004%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:8.994%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:8.776%;"></td>
        <td style="width:0.646%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f347851-95b3-4077-a395-5185a1adfecf" contextRef="C_c2a50417-42a1-40be-8caf-f0cebc94ffff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b094e072-332d-426f-afb1-460ad1353f54" contextRef="C_7589f598-a536-40ef-ae5d-943416f75b64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">89,261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71bfab36-bbcd-4414-8ef2-b7ac6e00725e" contextRef="C_c2a50417-42a1-40be-8caf-f0cebc94ffff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32c775cd-ed5f-42b7-a363-4f65838fcd02" contextRef="C_7589f598-a536-40ef-ae5d-943416f75b64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">1.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c461ae35-92fa-4344-9402-6e0ee7527f34" contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,366,189</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31cfb3cb-17e4-4353-80f8-1e0aedb2d274" contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dfa8347c-d41c-4b19-bd13-d04433b285f0" contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">60.35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94bcb0d8-120d-4e33-b654-24a38de4417b" contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_271c61e9-887a-4276-bacf-7ae9166ed7a7" contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bff3dd27-e372-4584-99ae-e3403ea2fe71" contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">89,261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_991883e8-f76c-4aa2-bf12-117f61eb7caf" contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd1ef70e-0a52-4046-b939-214d643e2d75" contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">1.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_215912bd-affd-4f43-aa0c-1417f2b9efac" contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">94,855</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddcafc55-28c4-4618-bfe4-930beb986955" contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1cc38023-1939-47a6-919c-6012d4f7fc36" contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">66.05</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_399fb1fa-71a7-48f0-90fd-d05770af4cb6" contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_82a4ad31-b6fa-47a9-bdb2-e08c52809237" contextRef="C_7846e4d7-bd1e-4f8d-ab5e-2c405172b5fe" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,271,334</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69ae5598-5db4-4db8-9565-f1abef93343f" contextRef="C_a27a1fab-d4d1-430e-a2ef-eaaa1ad83180" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_361c3df7-68ec-4ea4-8f9f-2ce3da66d94a" contextRef="C_7846e4d7-bd1e-4f8d-ab5e-2c405172b5fe" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">59.93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_943ff216-d6d7-40a0-8d2c-7cef362d26c7" contextRef="C_a27a1fab-d4d1-430e-a2ef-eaaa1ad83180" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The unvested shares of RSUs have not been included in the shares issued and outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, the Company entered into a restricted stock purchase agreement with an executive officer and a restricted stock purchase agreement with a director whereby the executive officer and the director purchased an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b0d2287-f288-45a3-8cee-2e18c9b5b049" contextRef="C_7d78f477-8e15-46ec-9ae7-c436d7a5b269" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,624,355</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of restricted stock. The consideration for the restricted stock was the issuance of promissory notes which were non-recourse in nature and were accounted for as in-substance stock options. In August 2019, per the terms of the notes, the Company received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6da09995-7ea2-4d37-a840-003e033728f3" contextRef="C_587ac654-89df-4445-9d73-21454d8c728f" name="vir:RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" unitRef="U_USD" scale="6" decimals="-5">3.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as repayment of the outstanding promissory notes and accrued interest. The Company reduced the restricted stock liability as the common stock vests, which was fully vested as of December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">176</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, there was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_896d8f58-72c2-4b0d-8a8d-2055933f9c77" contextRef="C_46ac8ad0-5eff-4cd3-9959-e7aa7afae14f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">61.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of total unrecognized compensation cost related to unvested restricted stock units, all of which is expected to be recognized over a remaining weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_214ac1c2-89b7-4f66-8284-a118ebdacfdf" contextRef="C_0a07820f-763c-4577-b53f-29f5d29d5021" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92b73988-9fc3-4ec8-9904-76cb7778b946" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the total stock-based compensation expense for all awards granted to employees and non-employees, including shares sold through the issuance of non-recourse promissory notes of which all the shares are considered to be options for accounting purposes, and the ESPP in the consolidated statements of operations:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.649%;"></td>
        <td style="width:1.243%;"></td>
        <td style="width:1.79%;"></td>
        <td style="width:11.375%;"></td>
        <td style="width:0.82%;"></td>
        <td style="width:1.243%;"></td>
        <td style="width:1.79%;"></td>
        <td style="width:11.375%;"></td>
        <td style="width:0.82%;"></td>
        <td style="width:1.243%;"></td>
        <td style="width:1.79%;"></td>
        <td style="width:11.039%;"></td>
        <td style="width:0.82%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb7406e6-7f7c-4031-8ee7-11ec20a9ad92" contextRef="C_1a31bf7c-9f6e-4b04-9a96-43549f6f4cc3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1e0f9ad-a2c6-4ff4-85c3-e72dad6ad38f" contextRef="C_f41d2de0-2ba6-4580-bbfa-01ae990de9ae" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,663</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7fd4fd7-5afc-4894-8f28-c8acf4290f40" contextRef="C_ad98faf6-018f-4435-8e8a-c91df1a4d6c0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,034</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4f60bb7-e345-4d50-9b14-26a009ec5f52" contextRef="C_bcf35168-3bb5-4a68-9f5c-cf54c4823054" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,230</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f637cb5-57a6-4cce-a3aa-d03915792004" contextRef="C_9f3bd2b3-b70a-4d36-b772-a1b2c9072a86" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_580cfd0f-0c76-41a5-80ba-77b14faad1bb" contextRef="C_f41c076b-5d7a-4003-8cb2-ca3259ad661b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,685</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04cd8341-ea6f-4bcd-ac63-09ef8111c2d1" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,784</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08a16d78-e72d-44de-9b0c-2929733009bf" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a03774f0-2ab4-4ac2-a0d9-99a92c33c62e" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7726bb3-3b89-4aac-bfc7-0dfbd67eeaef" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div style="display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">14.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net Income (Loss) Per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed76be21-1b7b-4ae5-86e4-d0a227c79ee5" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following is a calculation of the basic and diluted net income (loss) per share (in thousands, except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.997%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:10.902%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:10.902%;"></td>
        <td style="width:0.865%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:10.892%;"></td>
        <td style="width:0.865%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss), basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9feb058-e6f4-4c42-a5b0-5133f9513eec" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_16a20fa6-71a8-423d-9fbd-5c96b4828916" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfe26a2b-ab27-4c69-8bb0-79e4c8f7d62f" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174,683</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b2aca7b-6b09-4f72-bb49-81535f5dc015" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">129,884,967</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ce9145b-8553-4d66-9b9e-01caca4136cd" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">119,159,424</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df4ef9ee-aa62-4fba-b941-da68f22977c4" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">30,349,920</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average effect of dilutive securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03240b9a-dfad-45a8-9e3e-7d3481eda604" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,513,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62367585-0fff-4815-86c2-360d6c2b66ab" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">35,488</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingently issuable shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11c21c06-cec7-4c13-af6e-d59be7c82fcf" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,233</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42ba86e3-d082-4d40-bc46-e8602a60034a" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">133,437,126</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_481f3460-fd62-4709-b1ae-1da068064faf" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">119,159,424</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27b3bd54-b368-401b-93a9-c41a00be6653" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">30,349,920</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba9a9db7-f5b0-4be4-ad93-5628f2d38780" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2">4.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6706b92c-ed4a-4f16-94e8-35439d57bf6c" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">2.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e96d0e9d-f0a4-4087-ad5d-3c7dfb9220cd" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">5.76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a5b6ee3-6948-4461-b2b7-66692aa0f229" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2">3.96</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ad6c726-9741-4304-a2de-f9f732a92944" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">2.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cdd744e-33f6-40d7-99ed-12bb7ffb91d9" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">5.76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3a88dfb-3f35-423e-9672-631ee387f841" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.036%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:11.628%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:11.628%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:11.628%;"></td>
        <td style="width:0.646%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4ff3e23-a589-45fd-a3aa-22b0982bb900" contextRef="C_90261ef5-9966-431f-a299-6204c1e9115a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,764,308</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_791aa1c7-36bb-431f-9651-5dc4c9fe3660" contextRef="C_513fcea4-6032-4866-8906-83b5dc316354" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,798,282</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4d1e02a-00a6-49bd-b2e8-9c0fa743c0fd" contextRef="C_8a692092-b0fd-48e1-be4e-22e37c497148" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,186,298</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_035013cd-5208-4980-afac-efbfb52df19a" contextRef="C_5e1d64ed-e161-4d09-a7bd-60b59d474ed8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,088,304</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c1982f9-2a6d-4421-b23a-4fcbf3990174" contextRef="C_f134ed1b-0d64-42e6-8b4d-545d2bec9296" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">89,261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_534d26be-2b29-49ef-bad7-29e2beacfb0d" contextRef="C_d3e6496b-39fc-4dee-953c-9b3b230bf6cb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,075,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrants to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb9d7a39-6b82-46d9-b0ac-cc0d68b67948" contextRef="C_8d74b360-ce4a-44f2-9de1-d605ea9e3611" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">244,444</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b21d8ad-1f5a-4481-b72c-45f3a0c00075" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,852,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a75ac93-b1a1-46d6-8998-33724a07c0ad" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,887,543</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1307bb73-218d-44c5-acf6-bc81e8c3aba8" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,506,253</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company estimated shares issuable under the ESPP would be </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c5a6ed5-7f11-4ea6-aabe-7166a20ee1f3" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:EstimatedSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">65,967</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> based on expected total contributions from the plan participants and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_040d3dea-cf07-4721-a9dd-ce7e318b0020" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:EsppDiscountedPurchasePricePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the stock price at the beginning of the offering period.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6996b93c-1f71-4f68-9e8e-9c44c3b69994" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18.0pt;line-height:1.0110416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">15.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Defined Contribution Plan </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2017, the Company began to sponsor a 401(k) retirement savings plan for the benefit of its employees. Eligible employees may contribute a percentage of their compensation to this plan, subject to statutory limitations. The Company made contributions to the plan for eligible participants, and recorded contribution expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b31bfcb9-5d6f-455c-b8c8-563a1d2eac34" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a10e2eb-634e-4f2e-bafa-263c300bdc49" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c643b90-e5e5-4a3a-ad38-651113dba098" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">177</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3266b92c-e231-4b62-8823-c03640c63ad5" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">16.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income Taxes </span></div></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed18daa4-6ccd-43b1-ab3c-e46abc43c685" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income (loss) before provision for income taxes consists of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.829%;"></td>
        <td style="width:1.144%;"></td>
        <td style="width:1.778%;"></td>
        <td style="width:11.563%;"></td>
        <td style="width:0.746%;"></td>
        <td style="width:1.144%;"></td>
        <td style="width:1.778%;"></td>
        <td style="width:11.824%;"></td>
        <td style="width:1.194%;"></td>
        <td style="width:1.144%;"></td>
        <td style="width:1.778%;"></td>
        <td style="width:11.886%;"></td>
        <td style="width:1.194%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ffd4174-d018-4a2e-8a4f-c3b49607762d" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">535,989</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c0d1bc3-f52c-4fb2-a3a0-06a54cef9477" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">309,697</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb253f1b-6617-4561-8225-b74d17e1c445" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">138,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2801dda2-2967-491f-b07f-bb9e2657fc47" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,813</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e17a1362-de43-400d-b920-09fdcb303b76" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,086</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f347c8d5-2d64-42e7-a0bd-1aa7cc9eee90" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,805</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total income (loss) before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bd734f5-c791-4316-a6a6-5f9b1475028c" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">549,802</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa958f58-96b6-4715-86e0-bcf0ad1cf6fa" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,611</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_244d7f35-9cc5-4798-ad73-1ead5bd03606" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174,529</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41529a92-aace-46d9-906f-afce95de93e2" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of income tax expense consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.868%;"></td>
        <td style="width:1.976%;"></td>
        <td style="width:1.802%;"></td>
        <td style="width:17.004%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:1.976%;"></td>
        <td style="width:1.802%;"></td>
        <td style="width:15.935%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:1.976%;"></td>
        <td style="width:1.802%;"></td>
        <td style="width:16.109%;"></td>
        <td style="width:0.771%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98db6041-aea2-431f-9c70-1aef00d9e01a" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,526</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce6f1fd1-3481-407c-83bc-b922c504abc2" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9e9ed32-9d8b-412c-b952-9ec302a2cbd2" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,401</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85a3140c-3f74-4fa6-8952-684e1f17a764" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f4ea125-9a84-4cc3-a8d6-f819b7528b13" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c2ea66d-3593-442c-a651-24327c7566d2" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,032</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f50d0ffa-3e85-4530-85a7-43c1366346de" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f2d495c-90bb-48a9-adbb-be1e19f4febc" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1d35e6e-a40d-48ec-8191-9dd26fd264f3" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6c48f28-adc7-4105-9bd1-59e725632d52" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06794b66-6a46-4cc9-af09-0bc9a26b3b1b" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_961ce5f8-74f4-41fb-b9a1-f13d80416479" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_683c5de1-49f4-4e24-943e-f2591f35e47a" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">52</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05491fff-c876-4b90-88d4-d104bc0e2cda" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,218</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ca96938-8f7a-4972-81d8-f5a311d6e12e" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58678eb5-148d-4462-881c-80b0643de1ea" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59c6cedb-82a2-47f0-a873-11742faba526" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation between the expected income tax provision at the federal statutory rate and the reported income tax expense is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.674%;"></td>
        <td style="width:1.641%;"></td>
        <td style="width:0.746%;"></td>
        <td style="width:13.249%;"></td>
        <td style="width:2.946%;"></td>
        <td style="width:1.641%;"></td>
        <td style="width:0.746%;"></td>
        <td style="width:13.249%;"></td>
        <td style="width:2.946%;"></td>
        <td style="width:1.641%;"></td>
        <td style="width:0.746%;"></td>
        <td style="width:12.652%;"></td>
        <td style="width:4.126%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7da042f6-5713-4c06-916a-b1b108e00f2a" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_585afd9f-c7c4-4c90-ad5b-149decf8c172" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fef30342-66b3-4c38-9ee6-c8fe3e6ed304" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign tax at less than federal statutory rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1dd1198-5548-4979-abd6-a8c285f7be14" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d4def0f-3525-4aca-a399-e9d80700774d" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77a2593a-8b65-4800-97d1-97f28d8a54b5" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior year tax rate adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_638e141b-f515-4c5a-adcb-2e787ff3c611" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32bc0e03-bc5b-4121-a27f-3e6755b48613" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ee131e8-3ca7-4ec8-9a0b-d4bada1cba3f" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f770eb6-1c6b-4672-b016-82b5ec4eaab9" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e79d1a0-5c74-460a-8842-16d63b8749da" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0919172-aa30-4ffc-b25c-958ff7f93731" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb275e9d-18ee-4cfa-9b41-40b84c4bde01" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent items</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ab0ed63-fabb-4eeb-83bf-9db1334a2a28" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da2befe2-ba4d-43bf-9b8f-5699b7ca00e7" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d5e8d27-5248-4f00-a020-f4c431dd6d69" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2905625-f57f-41e5-8027-32261672cc8f" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">17.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69878f41-9f89-4221-81a0-2fdfbe592e19" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">25.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3848315b-9149-4b34-89e8-0c3775eb8f6a" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">24.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9c2633d-aa9d-4b78-b3a5-ef40b7e584ab" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b74df50f-79be-4e10-898f-c6d29e9e6f83" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac665075-71c0-4f41-8a1d-f7f36a740116" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf3f8610-cec5-4fd9-aa5f-66cf207e99b4" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5753f246-554c-4bc9-9e77-5b388b62359e" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ca5c2d7-e9d5-457d-a231-f163030204b8" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">178</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3932c2e5-215a-4e64-abc2-7ec60d8e41cb" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_3932c2e5-215a-4e64-abc2-7ec60d8e41cb_1"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the Company&#x2019;s deferred tax assets and liabilities as of December 31, 2021 and 2020, are related to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.521%;"></td>
        <td style="width:1.915%;"></td>
        <td style="width:1.778%;"></td>
        <td style="width:16.66%;"></td>
        <td style="width:1.194%;"></td>
        <td style="width:1.915%;"></td>
        <td style="width:1.778%;"></td>
        <td style="width:17.046%;"></td>
        <td style="width:1.194%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_982b4d1d-7468-4a0f-94a9-15d5b51f619a" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,030</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41833b55-e8f8-4378-b26c-a3ad8e490873" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">117,433</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credit carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4119d04f-ed1b-4ce5-8e43-0ecc6eb6dafd" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2bc34fa-997e-437a-94f1-91ba5998b5f9" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,246</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity compensations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9266b74-8749-40a0-9412-506c9c306f4c" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,065</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb5294c1-d6dd-4212-9bbf-46ca8d5acb0a" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,193</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb5a3639-cb3c-4d5e-92a4-9481ce5fe388" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe97dde3-c7f7-4fc0-a7f0-e67632ca72de" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,804</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55cac19f-3137-43a5-ade1-4da501770d08" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f6606f7-3503-4b21-a10d-2a6df0e3a858" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7da1de7a-2605-446b-910c-689bc5e11e4c" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,657</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_66238d51-e55f-4a64-aa92-8ee2b2351e96" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,006</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b590a476-f236-444b-85f7-6fb84acf4af6" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,854</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bbc5cba-75a8-46a4-b686-4facdc15fca1" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183,866</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized gain on investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_709b78a5-c3dc-419e-87d3-e88e4eb8f8e5" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,170</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a9b74ea-f5c9-4f2e-8b71-c07ef34bdabf" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,483</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_306e47a6-c834-4989-a1f1-deb863487bde" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16,147</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd0fefd3-7d31-41ed-873e-72e83ae50510" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c89fb6ac-5f48-436a-be70-b4d3a0031308" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,570</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IPR&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b52b0cc-0329-464c-bbe1-acd85c1eec4b" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_777bb395-72bc-4df8-9aef-83c1fb270c5a" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ac65b02-e392-487e-bd9f-3c3ca7543435" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,586</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93489623-49e4-4250-8100-4d59f20a481b" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1dfd22de-cbcd-482d-8ee1-6b3ad73e419b" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,707</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a01abf43-c82b-42cc-a59b-dc3d8fb5e6ef" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">159,891</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5e37c2c-63b2-4d1e-8c2a-916034f9bdb3" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c69bbc64-c3c7-4ad0-98e7-d050c9951a94" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,253</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_3932c2e5-215a-4e64-abc2-7ec60d8e41cb_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although t</span></ix:continuation></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he Company has taxable income for the year ended December 31, 2021, it has otherwise incurred accumulated tax losses since inception. Based on the available objective evidence, the Company cannot conclude it is more likely than not that the net deferred tax assets will be fully realizable.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Accordingly, the Company has provided a valuation allowance against its net deferred tax assets. For the year ended December 31, 2021, the Company recorded a valuation allowance release of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b54a45c-8a1e-47a6-880e-b8fa118353c9" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="vir:ReleaseOfValuationAllowanceDeferredTaxInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">114.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, based on the estimated 2021 taxable income. For the years ended December 31, 2020 and 2019, the valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcdf6b46-58f5-4ce6-b71a-3d5f409f9cd6" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">74.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c299767b-e7b8-4e17-9df9-ee24a5321fe9" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">42.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. As of December 31, 2021, the Company has net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bb22ea7-de97-4488-a37b-d0411d2572d2" contextRef="C_6095766d-f048-4375-875a-769201aac419" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">24.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for federal purposes and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0786420-32d6-4709-9ed4-6c2d9b19c9ca" contextRef="C_953e43a8-2a7e-48ad-a529-e63d37ac462c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">126.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for state tax purposes. If not utilized, these carryforwards will begin expiring in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0926750a-00a7-4ed5-96e8-45b50cb5a3cb" contextRef="C_bb786dd2-2f22-47d4-9e9e-9a488bff4ab9" name="vir:OperatingLossCarryforwardsExpirationBeginningYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for federal and in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f152c85-f25f-4b58-8aca-0778e50b8994" contextRef="C_a145aeb5-af85-4ad6-ba29-68511bbc994c" name="vir:OperatingLossCarryforwardsExpirationBeginningYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2031</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for state tax purposes. The federal net operating losses generated after December 31, 2017, have an infinite carryforward period and subject to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e37c6596-a612-40f2-ae8a-9f2ca6eddd28" contextRef="C_bb786dd2-2f22-47d4-9e9e-9a488bff4ab9" name="vir:OperatingLossCarryforwardsLimitationOnUsePercentage" unitRef="U_pure" scale="-2" decimals="2">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% deduction limitation based upon pre-NOL deduction taxable income. As of December 31, 2021, the Company also has net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0734977e-5b4d-41f2-8c56-f92c187606b1" contextRef="C_ffe17dae-8660-4c99-8aab-15f3d99a9a63" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for Australian tax purposes, which has an infinite carryforward period, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f4c61e8-f565-4898-a070-4aedd19c2794" contextRef="C_5ce5cca5-d328-4861-8f28-b94590239275" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> net operating loss carryforward for Swiss tax purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Tax Reform Act of 1986, the amounts of and benefits from net operating loss carryforwards may be impaired or limited in certain circumstances. Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The Company completed its Section 382 analysis as of December 31, 2021 and based on this analysis, it does not expect that the annual limitations will significantly impact its ability to utilize its net operating loss or tax credit carryforwards prior to expiration.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company has research tax credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef71cdf3-4032-4f60-a4e3-30b2804fc756" contextRef="C_6095766d-f048-4375-875a-769201aac419" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9229a67-879a-484d-99c6-f874d8645591" contextRef="C_953e43a8-2a7e-48ad-a529-e63d37ac462c" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for federal and state tax purposes, respectively. If not utilized, the federal carryforward will expire in various amounts beginning in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97154365-7b2c-4417-b6e3-e3214e3332bc" contextRef="C_8d214461-dd67-46fd-97ae-535ac3188674" name="vir:OperatingLossCarryforwardsExpirationBeginningYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2036</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The California credits can be carried forward indefinitely. To the extent they were not utilized, Oregon carryforward began expiring in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_565a5721-691b-4e07-8073-6e849ac7e363" contextRef="C_547d334c-565b-45aa-a31d-cf0b5ec40a45" name="vir:OperatingLossCarryforwardsExpirationBeginningYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_fc1f68d2-2c30-42ea-a654-a0f42a99cb7d_1"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax Cuts and Jobs Act of 2017</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> subjects a U.S. shareholder to current tax on global intangible low-taxed income (&#34;GILTI&#34;) earned by certain foreign subsidiaries. The FASB </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Staff Q&amp;A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.</span></p></ix:continuation></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">179</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Uncertain Tax Positions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company had an unrecognized tax benefit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02d8658a-c0ef-4abe-a79c-40d7c19be4ac" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c37f3e1b-1f43-481e-877a-fb9619cef4bf" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, related to transfer pricing and research and development tax credits. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1dc6308-589b-4aff-a879-43a7a9b0f4af" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> amount of unrecognized tax benefits as of December 31, 2021, if recognized, would reduce the Company&#x2019;s effective tax rate because the benefits would be in the form of net operating loss and tax credit carryforwards, which would attract a full valuation allowance. There are no provisions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date. Because the statute of limitations does not expire until after the net operating loss and credit carryforwards are actually used, the statutes are still open on calendar years ending December 31, 2017 forward for federal and state purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_308c65bb-68e4-4240-95fd-171c5bc18dd9" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5b3a59e6-d8e4-4323-8a73-f91d07bed816" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0cbaf0a8-a7bf-454a-a2f9-4c342c4e8be6" contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognize any expense for interest and penalties related to uncertain tax positions during 2021, 2020 and 2019, and the Company does </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f57f042-76c8-4dbc-a849-b2ad796d9ba4" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any amounts related to interest and penalties accrued at December 31, 2021. The Company files U.S. federal, state, Switzerland and Australia tax returns. The Company&#x2019;s tax years remain open for all years. As of December 31, 2021, the Company was not under examination by the Internal Revenue Service or any state or foreign tax jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aaa0224f-b0c9-4abb-8b64-47daa14f1614" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending amounts of the liability for uncertain tax positions is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.204%;"></td>
        <td style="width:1.182%;"></td>
        <td style="width:1.791%;"></td>
        <td style="width:10.995%;"></td>
        <td style="width:1.194%;"></td>
        <td style="width:1.182%;"></td>
        <td style="width:1.791%;"></td>
        <td style="width:10.995%;"></td>
        <td style="width:1.194%;"></td>
        <td style="width:1.182%;"></td>
        <td style="width:1.791%;"></td>
        <td style="width:11.306%;"></td>
        <td style="width:1.194%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross unrecognized tax benefits at January 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d8977ee-722b-4856-9057-3c17c1875c5e" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,877</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0d5edc7-a99b-4f17-8a8e-7cbfe71598a9" contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,725</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5415a072-2365-49d4-af4a-0f3007f9a002" contextRef="C_88183c78-6814-4146-96c6-0cba18d5611c" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,404</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Addition for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02a934a7-2af6-4749-be52-f3daf6326a1e" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b156a61b-ab05-4999-91a0-ada076026c19;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c227681-25fe-4f08-8679-8af3a8fdb372" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3">133</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reduction for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4de4d5c4-d61a-4341-894a-b2b026622618" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e9bb1ec-b9ae-41d1-91f8-e50d8e01b7fe" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">588</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff81bc26-1065-4b34-9155-f0e07a3b9a37" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,596</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Addition for tax positions taken in current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e3f4782-b0a9-43ae-b97f-fa17b1be1ffd" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,607</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db517ef2-30fe-4d60-baf7-17bc23403b4d" contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,740</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07d0b0f1-8403-46b1-b093-539963c40fce" contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,784</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross unrecognized tax benefits at December 31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84765d19-b7a7-4a0c-8b39-9a8c3e55e819" contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a758b15-ed82-4acf-9c86-620fc49887bb" contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,877</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32a15f19-f2c7-49e2-926f-82558f5329f8" contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,725</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80250db0-ca68-4f7f-b8e0-b6f27c47a10a" contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7" name="us-gaap:SubsequentEventsTextBlock" escape="true"><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">17.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Subsequent Event </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amended and Restated Letter Agreement with the Bill &amp; Melinda Gates Foundation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2022, the Company e</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ntered into an amended and restated letter agreement with the Bill &amp; Melinda Gates Foundation, which amended and restated the letter agreement with the Bill &amp; Melinda Gates Foundation that was entered into in December 2016 (the &#34;Gates Agreement&#34;), to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">include the advancement of innovative platform technologies in the development of broadly neutralizing antibodies designed to provide a &#34;vaccinal effect&#34; for the treatment of HIV and prevention of malaria</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Under the Gates Agreement, in January 2022, the Bill &amp; Melinda Gates Foundation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b07c5ab6-14fc-4c5c-befd-3fe455348de0" contextRef="C_1ad51e18-a052-4618-9f7f-dd217928f54d" name="vir:StockIssuedGrantAgreement" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">881,365</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company's common stock with total value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24ca4c15-4115-4aea-ad4a-12fb4e013e32" contextRef="C_1ad51e18-a052-4618-9f7f-dd217928f54d" name="vir:ValueStockIssuedGrantAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and made a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70ab7333-c95b-4bd2-8d66-f8ae057a0f61" contextRef="C_1ad51e18-a052-4618-9f7f-dd217928f54d" name="vir:CashGrantAwarded" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million grant to the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9. Changes in and Disagreements With Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Evaluation of Disclosure Controls and Procedures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) under the Exchange Act as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Management&#x2019;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Our internal control over financial reporting is designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management assessed the effectiveness of our internal control over financial reporting based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#x201c;COSO&#x201d;) in Internal Control&#x2014;Integrated Framework (2013 Framework). Based on our assessment, we concluded that our internal control over financial reporting was effective as of December 31, 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effectiveness of our internal control over financial reporting has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their attestation report herein, which expresses an unqualified opinion on the effectiveness of our internal control over financial reporting as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were no changes in our internal control over financial reporting that occurred during our fourth fiscal quarter ended December 31, 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Stockholders and the Board of Directors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of Vir Biotechnology, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Opinion on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited Vir Biotechnology, Inc.&#x2019;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#x2014;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Vir Biotechnology, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income (loss), convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis for Opinion</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redwood City, California</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9B. Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disc_re_foreign_jurisdiction"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9C. Disclosu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">re Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">182</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Proposal 1&#x2014;Election of Directors,&#x201d; &#x201c;Information Regarding the Board of Directors and Corporate Governance,&#x201d; &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Code of Business Conduct and Ethics,&#x201d; &#x201c;Delinquent Section 16(a) Reports,&#x201d; &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Nominating and Corporate Governance Committee&#x201d; and &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Audit Committee&#x201d; in our definitive proxy statement for our 2022 Annual Meeting of Stockholders, or the Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Executive Compensation&#x201d; in our Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; and &#x201c;Executive Compensation&#x2014;Equity Compensation Plan Information&#x201d; in our Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Independence of The Board of Directors&#x201d; and &#x201c;Transactions with Related Persons&#x201d; in our Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Proposal 3&#x2014;Ratification of Selection of Independent Registered Public Accounting Firm&#x201d; in our Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial statements, financial statement schedules and exhibits filed as part of this Annual Report on Form 10-K are as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(a)(1) Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reference is made to the financial statements included in Item 8 of Part II hereof.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(a)(2) Financial Statement Schedules</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All financial statements schedules are omitted because the required information is included in the consolidated financial statements or the notes thereto included in Item 8 of Part II hereof.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(a)(3) Exhibits</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.28%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:77.718%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519268465/d820601dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company&#x2019;s Current Report on Form 8-K (File No. 001-39083), filed with the SEC on October 16, 2019).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519268465/d820601dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.2 to the Company&#x2019;s Current Report on Form 8-K (File No. 001-39083), filed with the SEC on October 16, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519257981/d755217dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Common Stock Certificate of the Company (incorporated herein by reference to Exhibit 4.1 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 30, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312519236592/d755217dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Investors&#x2019; Rights Agreement, by and among the Company and certain of its stockholders, dated November 29, 2017 (incorporated herein by reference to Exhibit 4.2 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000156459020013194/vir-ex44_1069.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of Capital Stock (incorporated herein by reference to Exhibit 4.4 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519267739/d809856dex48.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc. 2019 Equity Incentive Plan, (incorporated herein by reference to Exhibit 4.8 to the Company&#x2019;s Form S-8 (File No. 333-234212), filed with the SEC on October 15, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519267739/d809856dex411.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">2019 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 4.11 to the Company&#x2019;s Form S-8 (File No. 33-234212), filed with the SEC on October 15, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnity Agreement by and between the Company and its directors and executive officers (incorporated herein by reference to Exhibit 10.1 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Forms of Option Grant Notice and Option Agreement under Vir Biotechnology, Inc. 2019 Equity Incentive Plan, (incorporated herein by reference to Exhibit 10.3 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex105_2690.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Restricted Stock Unit Grant Notice and Unit Award Agreement under Vir Biotechnology, Inc. 2019 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc. 2016 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.5 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">184</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.28%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:77.718%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Forms of Incentive Stock Option Notice and Agreement, Non-Qualified Stock Option Notice and Agreement, Restricted Stock Agreement, Restricted Stock Agreement and Restricted Stock Purchase Agreement under the Vir Biotechnology, Inc. 2016 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.6 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex108_229.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.8 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Employment Letter Agreement between the Company and George Scangos, dated August 27, 2019 (incorporated herein by reference to Exhibit 10.9 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Employment Letter Agreement between the Company and Howard Horn, dated August 27, 2019 (incorporated herein by reference to Exhibit 10.10 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Employment Letter Agreement between the Company and Phil Pang, dated August 27, 2019 (incorporated herein by reference to Exhibit 10.12 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Employment Letter Agreement between the Company and Herbert Virgin, dated September 3, 2019 (incorporated herein by reference to Exhibit 10.14 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020052966/vir-ex103_150.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Letter Agreement between the Company and Steven Rice, dated August 22, 2019 (incorporated herein by reference to Exhibit 10.3 to the Company&#x2019;s Form 10-Q (File No. 001-39083), filed with the SEC on November 10, 2020).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.14+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020052966/vir-ex104_149.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Promotion Letter Agreement between the Company and Steven Rice, dated July 30, 2020 (incorporated herein by reference to Exhibit 10.4 to the Company&#x2019;s Form 10-Q (File No. 001-39083), filed with the SEC on November 10, 2020).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.15+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex106_307.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Employment Letter Agreement between the Company and Ann (Aine) M. Hanly, dated May 4, 2021 (incorporated herein by reference to Exhibit 10.6 to the Company&#x2019;s Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.16+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1015.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc. Change in Control and Severance Benefit Plan (incorporated herein by reference to Exhibit 10.15 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.17&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Collaboration, Option, and License Agreement between the Company and Brii Biosciences Limited (previously named BiiG Therapeutics Limited), dated May 23, 2018 (incorporated herein by reference to Exhibit 10.16 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.18&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1017.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated October 16, 2017 (incorporated herein by reference to Exhibit 10.17 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:41.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.19&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1019_1067.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No.1 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 17, 2019 (incorporated herein by reference to Exhibit 10.19 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.20&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1020_1312.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No.2 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated March 3, 2020 (incorporated herein by reference to Exhibit 10.20 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">185</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.28%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:77.718%;"></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.21&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520187304/d945110dex1021.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No.3 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated April 1, 2020 (incorporated herein by reference to Exhibit 10.21 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.22&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex1024_828.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 23, 2020 (incorporated herein by reference to Exhibit 10.24 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.23&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1018.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Common Stock Issuance Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated October 16, 2017 (incorporated herein by reference to Exhibit 10.18 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.24&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1022_1066.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 1 to the Common Stock Issuance Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 17, 2019 (incorporated herein by reference to Exhibit 10.22 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March, 26, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.25&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1019.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated November 13, 2018 (incorporated herein by reference to Exhibit 10.19 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.26&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1020.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">License Agreement between the Company and MedImmune, LLC, dated September 7, 2018 (incorporated herein by reference to Exhibit 10.20 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.27&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex1029_829.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 1 to License Agreement between the Company and MedImmune, LLC, dated September 1, 2020 (incorporated herein by reference to Exhibit 10.29 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.28&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1021.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Second Revised and Restated Master License Agreement between the Company and Oregon Health &amp; Science University, dated August 27, 2019 (incorporated herein by reference to Exhibit 10.21 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.29&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1022.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter Agreement between the Company and the stockholders of TomegaVax, Inc. set forth therein, dated September 12, 2016 (incorporated herein by reference to Exhibit 10.22 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.30&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1023.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Agreement and Plan of Merger between the Company, Vir Merger Sub, Inc., Agenovir Corporation, and Dr. Stephen R. Quake, dated January 2, 2018 (incorporated herein by reference to Exhibit 10.23 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.31&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1024.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Securities Purchase Agreement between the Company, Humabs BioMed SA, the shareholders of Humabs set forth therein, the option-holders of Humabs set forth therein and Fortis Advisors LLC and certain Securityholders, dated August 22, 2017 (incorporated herein by reference to Exhibit 10.24 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.32&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1026.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated January 26, 2018 (incorporated herein by reference to Exhibit 10.26 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.33&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1031_1064.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 1 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated April 18, 2019 (incorporated herein by reference to Exhibit 10.31 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.34&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1032_1065.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 2 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated February 24, 2020 (incorporated herein by reference to Exhibit 10.32 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.28%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:77.718%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.35&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex1038_490.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 3 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated May 22, 2020 (incorporated herein by reference to Exhibit 10.38 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.36&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex1039_491.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 4 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated December 8, 2020 (incorporated herein by reference to Exhibit 10.39 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.37&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017021000935/vir-20210630ex10_3.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 5 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated June 2, 2021 (incorporated herein by reference to Exhibit 10.3 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on August 5, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.38&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1027.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated March 16, 2018 (incorporated herein by reference to Exhibit 10.27 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.39&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1034_1063.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 1 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated April 22, 2019 (incorporated herein by reference to Exhibit 10.34 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.40&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1035_1062.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 2 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated October 28, 2019 (incorporated herein by reference to Exhibit 10.35 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.41&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020039295/vir-ex1012_223.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 3 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated May 29, 2020 (incorporated herein by reference to Exhibit 10.12 to the Company&#x2019;s Form 10-Q (File No. 001-39083), filed with the SEC on August 11, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.42&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017021000935/vir-20210630ex10_4.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 4 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated June 16, 2021 (incorporated herein by reference to Exhibit 10.4 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on August 5, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.43&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex10_43.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 5 to Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated December 8, 2021.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.44&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex10_44.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated November 5, 2021.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.45&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex10_45.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Letter Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated January 12, 2022.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.46</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex10_46.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Stock Purchase Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated January 12, 2022.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.47&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex10_47.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated January 12, 2022.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.48&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1028.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Exclusive License Agreement between the Company (as successor in interest to Humabs BioMed SA (f/k/a Humabs Holding GmbH)) and the Institute for Research in Biomedicine, dated December 16, 2011 (incorporated herein by reference to Exhibit 10.28 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.49&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1029.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment to Amended and Restated Exclusive License Agreement between the Company (as successor in interest to Humabs BioMed SA (f/k/a Humabs Holding GmbH)) and the Institute for Research in Biomedicine, dated February 10, 2012 (incorporated herein by reference to Exhibit 10.29 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.50&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1030.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exclusive License Agreement between the Company (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated December 16, 2011 (incorporated herein by reference to Exhibit 10.30 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">187</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.28%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:77.718%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.51</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1031.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment to License Agreement between the Company (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated February 10, 2012 (incorporated herein by reference to Exhibit 10.31 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.52&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1032.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment Agreement between the Company (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated January 29, 2018 (incorporated herein by reference to Exhibit 10.32 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.53&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1033.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exclusive License Agreement between the Company and The Rockefeller University, dated July 31, 2018 (incorporated herein by reference to Exhibit 10.33 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.54&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1034.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated May 17, 2019 (incorporated herein by reference to Exhibit 10.34 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.55&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex1051_886.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Second Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated September 28, 2020 (incorporated herein by reference to Exhibit 10.51 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.56&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex105_306.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Third Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated March 1, 2021 (incorporated herein by reference to Exhibit 10.5 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.57&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1035.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March 20, 2012 (incorporated herein by reference to Exhibit 10.35 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.58&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1036.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment 1 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated April 19, 2013 (incorporated herein by reference to Exhibit 10.36 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.59&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1037.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment 2 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated April 27, 2015 (incorporated herein by reference to Exhibit 10.37 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.60&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1038.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment 3 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated December 31, 2015 (incorporated herein by reference to Exhibit 10.38 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.61&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1039.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment 4 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated August 29, 2016 (incorporated herein by reference to Exhibit 10.39 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.62&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1040.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment 5 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated July 15, 2017 (incorporated herein by reference to Exhibit 10.40 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.63&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1041.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment 6 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated September 7, 2018 (incorporated herein by reference to Exhibit 10.41 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">188</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.28%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:77.718%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.64</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1042.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease Agreement between the Company and ARE-SAN FRANCISCO NO. 43, LLC, dated March  30, 2017 (incorporated herein by reference to Exhibit 10.42 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.65</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1043.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to Lease Agreement between the Company and ARE-SAN FRANCISCO NO. 43, LLC, dated April 10, 2019 (incorporated herein by reference to Exhibit 10.43 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.66&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex10_66.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease Agreement between the Company and KRE Exchange Owner LLC, dated December 16, 2021.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.67&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1044.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Patent License Agreement between the Company and Xencor, Inc., dated August 15, 2019 (incorporated herein by reference to Exhibit 10.44 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.68&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex103_304.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment 1 to Patent License Agreement between the Company and Xencor, Inc., dated February 23, 2021 (incorporated herein by reference to Exhibit 10.3 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.69&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520174259/d946838dex991.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Patent License Agreement between the Company and Xencor, Inc., dated March 25, 2020 (incorporated herein by reference to Exhibit 99.1 to the Company&#x2019;s Form 8-K (File No. 001-39083), filed with the SEC on June 19, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.70&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex104_305.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment 1 to Patent License Agreement between the Company and Xencor, Inc., dated February 23, 2021 (incorporated herein by reference to Exhibit 10.4 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.71&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520187304/d945110dex1054.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Definitive Collaboration Agreement between the Company, Glaxo Wellcome UK Limited and Beecham S.A., dated June 9, 2020 (incorporated herein by reference to Exhibit 10.54 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.72</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520187304/d945110dex1055.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Stock Purchase Agreement between the Company and Glaxo Group Limited, dated April 5, 2020 (incorporated herein by reference to Exhibit 10.55 to the Company's Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.73&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex101_302.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Preliminary Collaboration Agreement between the Company and Glaxo Wellcome UK Limited, dated February 14, 2021 (incorporated herein by reference to Exhibit 10.1 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.74&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017021000935/vir-20210630ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited, dated May 18, 2021 (incorporated herein by reference to Exhibit 10.2 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on August 5, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.75&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex102_303.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Stock Purchase Agreement between the Company and Glaxo Group Limited, dated February 14, 2021 (incorporated herein by reference to Exhibit 10.2 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.76&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520187304/d945110dex1057.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Binding Letter Agreement between the Company and Samsung Biologics Co., Ltd., dated April 9, 2020 (incorporated herein by reference to Exhibit 10.57 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.77</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520213032/d941033dex992.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Assignment and Novation Agreement among the Company, GlaxoSmithKline Trading Services Limited and Samsung Biologics Co., Ltd., dated July 31, 2020 (incorporated herein by reference to Exhibit 99.2 to the Company&#x2019;s Form 8-K (File No. 001-39083), filed with the SEC on August 7, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.78&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520187304/d945110dex1058.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Development and Manufacturing Collaboration Agreement between the Company and Wuxi Biologics (Hong Kong) Limited, dated February 25, 2020 (incorporated herein by reference to Exhibit 10.58 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">189</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.28%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:77.718%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.79&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312520187304/d945110dex1059.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter of Intent between the Company and WuXi Biologics (Hong Kong) Limited, dated June 15, 2020 (incorporated herein by reference to Exhibit 10.59 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.80</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520213032/d941033dex991.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Assignment and Novation Agreement among the Company, GlaxoSmithKline Trading Services Limited and WuXi Biologics (Hong Kong) Limited, dated July 29, 2020 (incorporated herein by reference to Exhibit 99.1 to the Company&#x2019;s Form 8-K (File No. 001-39083), filed with the SEC on August 7, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.81</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520290303/d862544dex12.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Sales Agreement, dated as of November 10, 2020, by and between the Company and Cowen and Company, LLC. (incorporated by reference to Exhibit 1.2 to the Company&#x2019;s registration statement on Form S-3 (Filed No. 333-250013), filed with the SEC on November 10, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">List of subsidiaries of the Company (incorporated herein by reference to Exhibit 21.1 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Power of Attorney (included on the signature page to this report).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Instance Document the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">+ Indicates a management contract or compensatory plan or arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#134; Certain portions of this exhibit (indicated by &#x201c;[***]&#x201d;) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">* The certification attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.447%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:4.006%;"></td>
    <td style="width:45.507%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: February 28, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;George Scangos</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">George Scangos, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Director</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: February 28, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;Howard Horn</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer and Secretary</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">191</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">POWER OF</span><span id="power_attorney"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints George Scangos, Ph.D., and Howard Horn, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.662%;"></td>
    <td style="width:1.362%;"></td>
    <td style="width:28.668%;"></td>
    <td style="width:17.197%;"></td>
    <td style="width:1.143%;"></td>
    <td style="width:16.968%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Signature</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ George Scangos</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">George Scangos, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Howard Horn</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer and Secretary </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Vicki Sato</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chairman of the Board of Directors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vicki Sato, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jeffrey S. Hatfield</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jeffrey S. Hatfield</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Robert More</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Robert More</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Janet Napolitano</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Janet Napolitano</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Robert Nelsen</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Robert Nelsen</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Dipchand Nishar</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dipchand Nishar</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Robert Perez</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Robert Perez</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Saira Ramasastry</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Saira Ramasastry</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Phillip Sharp</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phillip Sharp, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Elliott Sigal</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Elliott Sigal, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:9.173%;text-indent:2.76%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">192</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.43
<SEQUENCE>2
<FILENAME>vir-ex10_43.htm
<DESCRIPTION>EX-10.43
<TEXT>
<html>
 <head>
  <title>EX-10.43</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit </font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">10.43</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.283%;"></td>
    <td style="width:85.717%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(192,192,192,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">AMENDMENT INFORMATION</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Agreement to be Amended:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Grant agreement between the Bill &amp; Melinda Gates Foundation and Vir Biotechnology Inc effective March 16, 2018, as amended, and bearing Investment ID INV-009475/OPP1182112</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Amendment Purpose:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">No Cost Extension</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Amendment Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date of this email</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Amended &#x201c;End Date&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The term of the Agreement is extended by changing the End Date to March 31, 2022</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.807%;"></td>
    <td style="width:0.161%;"></td>
    <td style="width:19.443%;"></td>
    <td style="width:19.722%;"></td>
    <td style="width:19.797%;"></td>
    <td style="width:20.075%;"></td>
    <td style="width:0.996%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">THIS AMENDMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.</font></p></td>
   </tr>
   <tr>
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">UPDATED REPORTING &amp; PAYMENT SCHEDULE</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Amendment notifies You that the reporting and/or payment schedule for Your grant has changed. Your updated Reporting &amp; Payment Schedule is deleted and replaced with the following:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="6" style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(192,192,192,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">REPORTING &amp; PAYMENT SCHEDULE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p></td>
    <td style="border-top:1.000pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Investment Period</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Target, Milestone, or Reporting Deliverable</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Due By</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Payment Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Payment Amount (U.S.$)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </font>&#160;</p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="background-color:rgba(192,192,192,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Total Grant Amount</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Up to $14,882,418.08</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.44
<SEQUENCE>3
<FILENAME>vir-ex10_44.htm
<DESCRIPTION>EX-10.44
<TEXT>
<html>
 <head>
  <title>EX-10.44</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Exhibit 10.44</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],       HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GRANT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Investment ID INV-016898</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">AGREEMENT SUMMARY &amp; SIGNATURE PAGE</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:22.505%;"></td>
    <td style="width:77.495%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="border-top:0.500pt solid;background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GRANTEE INFORMATION</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Vir Biotechnology Inc</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Tax Status:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Not exempt from federal income tax under U.S. IRC &#167; 501(c)(3)</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You confirm that the above information is correct and agree to notify the Foundation immediately of any change.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expenditure Responsibility:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement is subject to &#x201c;expenditure responsibility&#x201d; requirements under the U.S. Internal Revenue Code.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Mailing Address:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">499 Illinois Street, Suite 500, San Francisco, California 94158, USA</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Primary Contact:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">FOUNDATION INFORMATION</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Mailing Address:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">P. O. Box 23350, Seattle, Washington 98102, USA</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Primary Contact:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">AGREEMENT INFORMATION</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Development of a TB and HIV vaccine using the HCMV vector platform</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201c;Charitable Purpose&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To develop a prophylactic HIV vaccine using the Human Cytomegalovirus (HCMV) vector platform</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201c;Start Date&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date of last signature</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201c;End Date&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">August 30, 2023</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement includes and incorporates by this reference:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement Summary &amp; Signature Page and:</font></p><div style="margin-left:0.05138888888888887in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3347136723038235%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Grant Amount and Reporting &amp; Payment Schedule (Attachment A)</font></div></div><div style="margin-left:0.05138888888888887in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3347136723038235%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Terms and Conditions (Attachment B)</font></div></div><div style="margin-left:0.05138888888888887in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3347136723038235%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Investment Document (date submitted October 13, 2021)</font></div></div><div style="margin-left:0.05138888888888887in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3347136723038235%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Budget (date submitted October 13, 2021)</font></div></div></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">THIS AGREEMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> is between Vir Biotechnology Inc (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">You</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Grantee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;) and the Bill &amp; Melinda Gates Foundation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Foundation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;), and is effective as of date of last signature. Each party to this Agreement may be referred to individually as a &#x201c;Party&#x201d; and together as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.&#x201d; As a condition of this grant, the Parties enter into this Agreement by having their authorized representatives sign below.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.936%;"></td>
    <td style="width:50.064%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">BILL &amp; MELINDA GATES FOUNDATION</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">/s/	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;font-style:italic;">Pervin Anklesaria</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:	Pervin Anklesaria</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Title:	Deputy Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">October 29, 2021</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">VIR BIOTECHNOLOGY INC</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">&#160;/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;font-style:italic;">George Scangos</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:	George Scangos</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Title:	CEO</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">November 5, 2021</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GRANT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Investment ID INV-016898</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">ATTACHMENT A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">GRANT AMOUNT AND REPORTING &amp; PAYMENT SCHEDULE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GRANT AMOUNT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Foundation will pay You up to the total grant amount specified in the Reporting &amp; Payment Schedule below. The Foundation&#x2019;s Primary Contact must approve in writing any Budget cost category change of more than [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">REPORTING &amp; PAYMENT SCHEDULE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Payments are subject to Your compliance with this Agreement, including Your achievement, and the Foundation&#x2019;s approval, of any applicable targets, milestones, and reporting deliverables required under this Agreement. The Foundation may, in its reasonable discretion, modify payment dates or amounts and will notify You of any such changes in writing.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">REPORTING</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will submit reports according to the Reporting &amp; Payment Schedule using the Foundation&#x2019;s templates or forms, which the Foundation will make available to You and which may be modified from time to time. For a progress or final report to be considered satisfactory, it must demonstrate meaningful progress against the targets or milestones for that investment period. If meaningful progress has not been made, the report should explain why not and what adjustments You are making to get back on track. Please notify the Foundation&#x2019;s Primary Contact if You need to add or modify any targets or milestones. The Foundation must approve any such changes in writing. You agree to submit other reports the Foundation may reasonably request.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ACCOUNTING FOR PERSONNEL TIME</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will track the time of all employees, contingent workers, and any other individuals whose compensation will be paid in whole or in part by Grant Funds. Such individuals will keep records (e.g., timesheets) of actual time worked on the Project in increments of sixty minutes or less and brief descriptions of tasks performed. You will report actual time worked consistent with those records in Your progress and final budget reports. You will submit copies of such records to the Foundation upon request.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:22.355%;"></td>
    <td style="width:24.272%;"></td>
    <td style="width:16.788%;"></td>
    <td style="width:15.996%;"></td>
    <td style="width:20.589%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">REPORTING &amp; PAYMENT SCHEDULE</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Investment Period</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Target, Milestone, or Reporting Deliverable</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Due By</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Payment Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Payment Amount (U.S.$)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***].</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td rowspan="2" style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td rowspan="2" style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Total Grant Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Up to $10,034,896.00</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GRANT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Investment ID INV-016898</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">ATTACHMENT B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">TERMS &amp; CONDITIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement is subject to the following terms and conditions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PROJECT SUPPORT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">PROJECT DESCRIPTION AND CHARITABLE PURPOSE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Foundation is awarding You this grant to carry out the project described in the Investment Document (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Project</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;) in order to further the Charitable Purpose. The Foundation, in its discretion, may approve in writing any request by You to make non-material changes to the Investment Document.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">MANAGEMENT OF FUNDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">USE OF FUNDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You may not use funds provided under this Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Grant Funds</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;) for any purpose other than the Project. You may not use Grant Funds to reimburse any expenses You incurred prior to the Start Date. At the Foundation&#x2019;s request, You will repay any portion of Grant Funds and/or Income used or committed in material breach of this Agreement, as determined by the Foundation in its discretion.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">INVESTMENT OF FUNDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You must invest Grant Funds in highly liquid investments with the primary objective of preservation of principal (e.g., interest-bearing bank accounts or a registered money market mutual fund) so that the Grant Funds are available for the Project. Together with any progress or final reports required under this Agreement, You must report the amount of any currency conversion gains (or losses) and the amount of any interest or other income generated by the Grant Funds (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Income</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;). Any Income must be used for the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SEGREGATION OF FUNDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You must maintain Grant Funds in a physically separate bank account or a separate bookkeeping account maintained as part of Your financial records and dedicated to the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GLOBAL ACCESS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GLOBAL ACCESS COMMITMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will conduct and manage the Project and the Funded Developments in a manner that ensures Global Access. Your Global Access commitments will survive the term of this Agreement. &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Funded Developments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d; means the products, services, processes, technologies, materials, software, data, other innovations, and intellectual property resulting from the Project (including modifications, improvements, and further developments to Background Technology). &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Background Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d; means any and all products, services, processes, technologies, materials, software, data, or other innovations, and intellectual property created by You or a third party prior to or outside of the Project used as part of the Project. &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Global Access</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d; means: (a) the knowledge and information gained from the Project will be promptly and broadly disseminated; and (b) the Funded Developments will be made available and accessible at an affordable price (i) to people most in need within developing countries, or (ii) in support of the U.S. educational system and public libraries, as applicable to the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CAVD MEETINGS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You agree to participate in the relevant CAVD sponsored meetings or working groups to which Your attendance is requested. You agree to present the Project&#x2019;s most current progress and data, consistent with any restrictions that are necessary to maintain appropriate rights to intellectual property.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">COLLABORATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Consistent with the programmatic goals and the charitable intent of the CAVD, there is the expectation and requirement that CAVD grantees will communicate and collaborate on a periodic basis with other CAVD grantees pursuing similar overarching objectives. The Foundation will continue to provide information regarding other entities with whom collaborations should be considered. These collaborations will include but will not be limited to the following elements:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Agreeing to meet (with funds either provided in the grant or directly from the Foundation) both individually and as a group with fellow grantees at the call of the Foundation.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Agreeing at all other times to be amenable to communication and prompt sharing of data and other fruits of the research on topics of mutual interest (consistent with potential intellectual property issues subject to the implementation of any necessary nondisclosure agreements).</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Considering complementary collaborative research and development efforts with other investigators that will facilitate removal of roadblocks to the solution either jointly or for the collaborating party.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Each future year of funding will be contingent upon Your continuing success in meeting these commitments, as judged solely by the Foundation. You may confer with Your Foundation Primary Contact any time if you have questions or concerns about the nature of any potential communication or collaboration request.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">TIMELY COMMUNICATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Sharing of new resources, tools and technologies with the general research community should coincide with publication of the discovery. However, since You will be working as a part of a larger overarching multi-grant program, it is expected that You will expeditiously disclose, disseminate, and share new resources with other participants working on common HIV vaccine problems.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PUBLICATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Consistent with Your Global Access commitments, if the Project description specifies Publication or Publication is otherwise requested by the Foundation, You will seek prompt Publication of any Funded Developments consisting of data and results. &#x201c;Publication&#x201d; means publication in a peer-reviewed journal or other method of public dissemination specified in the Project description or otherwise approved by the Foundation in writing. Publication may be delayed for a reasonable period for the sole purpose of seeking patent protection, provided the patent application is drafted, filed, and managed in a manner that best furthers Global Access. If You seek Publication in a peer-reviewed journal, You agree to adhere to the Foundation&#x2019;s Open Access Policy available at: www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy, which may be modified from time to time. Nothing in this section shall be construed as requiring Publication in contravention of any applicable ethical, legal, or regulatory requirements. You will mark any Funded Development subject to this clause with the appropriate notice or attribution, including author, date and copyright (e.g., &#169; 20&lt;&gt; &lt;Name&gt;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">INTELLECTUAL PROPERTY REPORTING</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the term of this Agreement and for 5 years after, You will submit upon request annual intellectual property reports relating to the Funded Developments, Background Technology, and any related agreements using the Foundation&#x2019;s templates or forms, which the Foundation may modify from time to time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBGRANTS AND SUBCONTRACTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBGRANTS AND SUBCONTRACTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You may not make subgrants under this Agreement. You have the exclusive right to select subcontractors to assist with the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RESPONSIBILITY FOR OTHERS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You are responsible for (a) all acts and omissions of any of Your trustees, directors, officers, employees, subgrantees, subcontractors, contingent workers, agents, and affiliates assisting with the Project, and (b) ensuring their compliance with the terms of this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PROHIBITED ACTIVITIES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ANTI-TERRORISM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will not use funds provided under this Agreement, directly or indirectly, in support of activities (a) prohibited by U.S. laws relating to combating terrorism; (b) with persons on the List of Specially Designated Nationals (www.treasury.gov/sdn) or entities owned or controlled by such persons; or (c) in or with countries or territories against which the U.S. maintains comprehensive sanctions (currently, Cuba, Iran, Syria, North Korea, and the Crimea Region of Ukraine), including paying or reimbursing the expenses of persons from such countries or territories, unless such activities are fully authorized by the U.S. government under applicable law and specifically approved by the Foundation in its sole discretion.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ANTI-CORRUPTION; ANTI-BRIBERY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will not offer or provide money, gifts, or any other things of value directly or indirectly to anyone in order to improperly influence any act or decision relating to the Foundation or the Project, including by assisting any party to secure an improper advantage. Training and information on compliance with these requirements are available at www.learnfoundationlaw.org.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">POLITICAL ACTIVITY AND ADVOCACY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You may not use Grant Funds to influence the outcome of any election for public office or to carry on any voter registration drive. You may not use Grant Funds to support lobbying activity or to otherwise support attempts to influence local, state, federal, or foreign legislation. Your strategies and activities, and any materials produced with Grant Funds, must comply with applicable local, state, federal, or foreign lobbying law. You agree to comply with lobbying, gift, and ethics rules applicable to the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">OTHER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PUBLICITY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A Party may publicly disclose information about the award of this grant, including the other Party&#x2019;s name, the total amount awarded, and a description of the Project, provided that a Party obtains prior written approval before using the other Party&#x2019;s name for promotional purposes or logo for any purpose. Any public disclosure by You or Your subgrantees, subcontractors, contingent workers, agents, or affiliates must be made in accordance with the Foundation&#x2019;s then-current brand guidelines, which are available at: www.gatesfoundation.org/brandguidelines.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">LEGAL ENTITY AND AUTHORITY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You confirm that: (a) You are an entity duly organized or formed, qualified to do business, and in good standing under the laws of the jurisdiction in which You are organized or formed; (b) You are not an individual (i.e., a natural person) or a disregarded entity (e.g., a sole proprietor or sole-owner entity) under U.S. law; (c) You have the right to enter into and fully perform this Agreement; and (d) Your performance will not violate any agreement or obligation between You and any third party. You will notify the Foundation immediately if any of this changes during the term of this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">COMPLIANCE WITH LAWS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In carrying out the Project, You will comply with all applicable laws, regulations, and rules and will not infringe, misappropriate, or violate the intellectual property, privacy, or publicity rights of any third party.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">COMPLIANCE WITH REQUIREMENTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will conduct, control, manage, and monitor the Project in compliance with all applicable ethical, legal, regulatory, and safety requirements, including applicable international, national, local, and institutional standards (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;). You will obtain and maintain all necessary approvals, consents, and reviews</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">before conducting the applicable activity. As a part of Your annual progress report to the Foundation, You must report whether the Project activities were conducted in compliance with all Requirements.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If the Project involves:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a. any protected information (including personally identifiable, protected health, or third-party confidential), You will not disclose this information to the Foundation without obtaining the Foundation&#x2019;s prior written approval and all necessary consents to disclose such information;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">b. children or vulnerable subjects, You will obtain any necessary consents and approvals unique to these subjects; and/or</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">c. any trial involving human subjects, You will adhere to current Good Clinical Practice as defined by the International Council on Harmonisation (ICH) E-6 Standards (or local regulations if more stringent) and will obtain applicable trial insurance.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any activities by the Foundation in reviewing documents and providing input or funding does not modify Your responsibility for determining and complying with all Requirements for the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RELIANCE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You acknowledge that the Foundation is relying on the information You provide in reports and during the course of any due diligence conducted prior to the Start Date and during the term of this Agreement. You represent that the Foundation may continue to rely on this information and on any additional information You provide regarding activities, progress, and Funded Developments.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">INDEMNIFICATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If the Project involves clinical trials, trials involving human subjects, post-approval studies, field trials involving genetically modified organisms, experimental medicine, or the provision of medical/health services (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Indemnified Activities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;), You will indemnify, defend, and hold harmless the Foundation and its trustees, employees, and agents (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Indemnified Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;) from and against any and all demands, claims, actions, suits, losses, damages (including property damage, bodily injury, and wrongful death), arbitration and legal proceedings, judgments, settlements, or costs or expenses (including reasonable attorneys&#x2019; fees and expenses) (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;) arising out of or relating to the acts or omissions, actual or alleged, of You or Your employees, subgrantees, subcontractors, contingent workers, agents, and affiliates with respect to the Indemnified Activities. You agree that any activities by the Foundation in connection with the Project, such as its review or proposal of suggested modifications to the Project, will not modify or waive the Foundation&#x2019;s rights under this paragraph. An Indemnified Party may, at its own expense, employ separate counsel to monitor and participate in the defense of any Claim. Your indemnification obligations are limited to the extent permitted or precluded under applicable federal, state or local laws, including federal or state tort claims acts, the Federal Anti-Deficiency Act, state governmental immunity acts, or state constitutions. Nothing in this Agreement will constitute an express or implied waiver of Your governmental and sovereign immunities, if any.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">INSURANCE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will maintain insurance coverage sufficient to cover the activities, risks, and potential omissions of the Project in accordance with generally-accepted industry standards and as required by law. You will ensure Your subgrantees and subcontractors maintain insurance coverage consistent with this section.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">TERM AND TERMINATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">TERM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement commences on the Start Date and continues until the End Date, unless terminated earlier as provided in this Agreement. The Foundation, in its discretion, may approve in writing any request by You for a no-cost extension, including amending the End Date and adjusting any affected reporting requirements.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">TERMINATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Foundation may modify, suspend, or discontinue any payment of Grant Funds or terminate this Agreement if: (a) the Foundation is not reasonably satisfied with Your progress on the Project; (b) there</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">are significant changes to Your leadership or other factors that the Foundation reasonably believes may threaten the Project&#x2019;s success; (c) there is a change in Your control; (d) there is a change in Your tax status; or (e) You fail to comply with this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RETURN OF FUNDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any Grant Funds, plus any Income, that have not been used for, or committed to, the Project upon expiration or termination of this Agreement, must be returned promptly to the Foundation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RECORD KEEPING</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will maintain complete and accurate accounting records and copies of any reports submitted to the Foundation relating to the Project. You will retain such records and reports for 4 years after Grant Funds have been fully spent. At the Foundation&#x2019;s request, You will make such records and reports available to enable the Foundation to monitor and evaluate how Grant Funds have been used or committed.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SURVIVAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A Party&#x2019;s obligations under this Agreement will be continuous and survive expiration or termination of this Agreement as expressly provided in this Agreement or otherwise required by law or intended by their nature.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GENERAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ENTIRE AGREEMENT, CONFLICTS, AND AMENDMENTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement along with the VIR/BMGF Series A/B Financing side letter (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Vir/BMGF Side Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;), dated 23 December 2016 and any subsequent amendments contain the entire agreement of the Parties and supersedes all prior and contemporaneous agreements concerning its subject matter. If there is a conflict between this Agreement and the Investment Document this Agreement will prevail. Except as specifically permitted in this Agreement, no modification, amendment, or waiver of any provision of this Agreement will be effective unless in writing and signed by authorized representatives of both Parties.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">NOTICES AND APPROVALS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Written notices, requests, and approvals under this Agreement must be delivered by mail or email to the other Party&#x2019;s primary contact specified on the Agreement Summary &amp; Signature Page, or as otherwise directed by the other Party.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SEVERABILITY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Each provision of this Agreement must be interpreted in a way that is enforceable under applicable law. If any provision is held unenforceable, the rest of the Agreement will remain in effect.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ASSIGNMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You may not assign, or transfer by operation of law or court order, any of Your rights or obligations under this Agreement without the Foundation&#x2019;s prior written approval. This Agreement will bind and benefit any permitted successors and assigns.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">COUNTERPARTS AND ELECTRONIC SIGNATURES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Except as may be prohibited by applicable law or regulation, this Agreement and any amendment may be signed in counterparts, by facsimile, PDF, or other electronic means, each of which will be deemed an original and all of which when taken together will constitute one agreement. Facsimile and electronic signatures will be binding for all purposes.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>4
<FILENAME>vir-ex10_45.htm
<DESCRIPTION>EX-10.45
<TEXT>
<html>
 <head>
  <title>EX-10.45</title>
 </head>
 <body>
  <p style="margin-left:66.667%;text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit </font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">10.45</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">January 12, 2022	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">499 Illinois Street, Suite 500</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">San Francisco, CA  94158</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Re:  Strategic Relationship between the Bill &amp; Melinda Gates Foundation and Vir Biotechnology, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Ladies and Gentlemen:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This amended and restated letter agreement (including all appendices hereto, this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Letter Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) is entered into as of January 12, 2022 by and between the Bill &amp; Melinda Gates Foundation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Foundation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), a Washington charitable trust that is a tax-exempt private foundation, and Vir Biotechnology, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and is effective on the Amendment Effective Date (as defined below). This Letter Agreement amends and restates in its entirety the letter agreement entered into as of December 23, 2016 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) by and between the Foundation and the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Prior Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), in connection with the investment by the Foundation of twenty million dollars ($20,000,000.00) in the Company through the purchase of (i) ten million dollars ($10,000,000.00) of shares of Series A-1 Preferred Stock, par value $0.0001, of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Series A-1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) at a purchase price of  [***] per share and (ii) ten million dollars ($10,000,000.00) of shares of Series B Preferred Stock, par value $0.0001, of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Series B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) at a purchase price of [***] per share ((i) and (ii) are collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV/TB Investment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). The Series A-1 Shares and Series B Shares were converted into shares of the Company&#x2019;s common stock in connection with the Company&#x2019;s initial public offering (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Conversion Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). This Letter Agreement is amended and restated in connection with the investment by the Foundation of approximately forty million dollars ($40,000,000.00) in the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Antibody Development Investment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; and together with the HIV/TB Investment, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Foundation Investment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) through the purchase of the New Shares (as defined below, and together with the Conversion Shares, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). The Foundation purchased the Conversion Shares pursuant to and in accordance with the provisions of the investment documents executed in connection with the Company&#x2019;s offering of Series A-1 Preferred Stock and Series B Preferred Stock, including, without limitation, the Series A-1 and Series B Preferred Stock Purchase Agreement, dated December 23, 2016, the Investors&#x2019; Rights Agreement, dated December 23, 2016, the Right of First Refusal and Co-Sale Agreement, dated December 23, 2016, and the Voting Agreement, dated December 23, 2016 (together with the Prior Agreement, in each case as amended from time to time in accordance with their terms, collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV/TB Investment Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and is purchasing the New Shares pursuant to and in accordance with the Common Stock Purchase Agreement dated January [   ], 2022, between the Company and the Foundation, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">SPA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, this Letter Agreement and the Grant Agreement INV-033423 (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Antibody Development Investment Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; and together with the HIV/TB Investment Documents, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Investment Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Capitalized terms not defined herein shall have the same meanings given to them in the applicable Investment Document, depending on the context in which such defined term is used herein.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In consideration of the sale and issuance of the Shares by the Company, and the purchase of the Shares by the Foundation, in each case on the terms and conditions stated herein and in the other Investment Documents, and for other good and valuable consideration, the parties hereby agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Definitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. For the purposes of this Letter Agreement the following terms have the meanings indicated.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Affiliate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; of an entity means any person or entity that, directly or indirectly, controls, is controlled by or is under common control with such entity for so long as that control exists, where &#x201c;control&#x201d; (for purposes of this definition of &#x201c;Affiliate&#x201d; only) means having the decision-making authority as to the entity and, further, where that control shall be presumed to exist only where a person or entity owns more than 50% of the equity (or that lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) entitled to vote regarding composition of the board of directors or other body entitled to direct the affairs of the entity.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the date of the closing of the Antibody Development Investment pursuant to the SPA.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Antibody Development Investment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in the introductory paragraph.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Antibody Development Investment Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in the introductory paragraph.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Antitrust Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the Sherman Antitrust Act, the Clayton Antitrust Act, the HSR Act, the Federal Trade Commission Act, as amended, and all other federal, state and foreign laws, that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or significant impediments or lessening of competition or the creation or strengthening of a dominant position through merger or acquisition that are applicable to this Letter Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Binding Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 6(e).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Charitability Default</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 6(b).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Charitability Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 2(a).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Claim</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 14.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CMV Vaccine</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the Company&#x2019;s broadly enabling human CMV (hCMV)-based vaccine platform applicable to the prevention and/or treatment of HIV and TB using a human attenuated hCMV as the base vector to deliver specific vaccine antigens.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">COGS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a product, [***]. In no event shall COGS include [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Confidential Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all processes, formulae, data, know-how, improvements, inventions, chemical or biological materials, chemical structures, techniques, marketing plans, strategies, customer lists, or other information that has been created, discovered or developed by a party, or has otherwise become known to a party, or to which rights have been assigned to a party, as well as any other information and materials that are deemed confidential or proprietary to or by a party (including all information and materials of a party&#x2019;s customers and any other third-party and their consultants), in each case, that are disclosed by such party or its representatives to the other party or its representatives, and that is marked or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">identified as confidential at the time of disclosure or that should reasonably be understood to be confidential based on the nature of the information and the manner of disclosure.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Conversion Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in the introductory paragraph.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Developing Countries</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means [***]. If at the Developing Country Determination Date there is [***], the attached Appendix 1 will be used as the list of Developing Countries. Following the determination of the list of Developing Countries at the Developing Country Determination Date, such list may be modified from time to time by mutual agreement of the Foundation and the Company, provided that if at any time during the term of this Letter Agreement any of the countries listed on the attached Appendix 1 other than [***], such country shall be removed from the list of Developing Countries on the [***] of the date on which it [***] and shall no longer be deemed to be a &#x201c;Developing Country&#x201d; as defined in this Letter Agreement. For the avoidance of doubt, in no event shall any country or other political jurisdiction be added to Appendix 1 as a Permanently Eligible Country without the express written consent of the Foundation and the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Developing Country Determination Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the date on which the Company first commercializes a product relating to or arising out of the HIV Vaccine Program, TB Vaccine Program, Vaccinal Antibody Development Program, or any other Global Health Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Disclosing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 18(a).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Existing Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the existing collaboration or license agreements of the Company set forth on Appendix 2.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Existing </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Grant Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 3(c).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Fair Market Value</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means (i) if the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), is not listed for trading on a national securities exchange, the fair market value of the Foundation Stock as determined by a mutually agreed upon (such agreement not to be unreasonably withheld, conditioned or delayed) independent third-party appraiser or (ii) if the Common Stock is listed on a national securities exchange, the average of the closing bid prices of a share of Common Stock as reported on the applicable securities exchange for the period of thirty consecutive trading days ending on the trading day immediately prior to the closing date of the redemption or purchase (provided that, if there is more than one such securities exchange, the Company shall designate the appropriate securities exchange for purposes of determining the Fair Market Value).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Foundation-supported Entity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means an entity that receives funding, directly or indirectly, from the Foundation, collaborates with the Foundation, or both, for the purpose of accomplishing the Foundation&#x2019;s charitable objectives.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Foundation Indemnities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 14.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Foundation Investment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in the introductory paragraph.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Foundation Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 6(c).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Funded Developments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the products and product candidates (including the HIV Vaccine Product, TB Vaccine Product, HIV Vaccinal Antibody Product, and Malaria Vaccinal Antibody Product), services, processes, technologies, materials, software, data, other innovations, and intellectual property developed by or on behalf of the Company or its subsidiaries in connection with the HIV Vaccine Program, the TB</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Vaccine Program, the Vaccinal Antibody Development Program, or any other Global Health Project (including modifications, improvements, and further developments to Platform Technology).  For clarity, product candidates will include candidates developed as part of a Global Health Project, which have been discontinued by the Company. Funded Developments includes the CMV Vaccine (and any and all data, documentation, methods, processes, test results, or other know how that is owned or controlled by the Company or any of its Affiliates (including through a license) and that are reasonably necessary or useful for the research, development, or operation of the CMV Vaccine, including materials, know-how and intellectual property owned or controlled by the Company or any of its Affiliates, whether existing at closing or later developed, owned or controlled by the Company or any of its Affiliates) to the extent funded by the Foundation or a Foundation-supported Entity with funds provided by the Foundation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Global Access</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means (a) the knowledge and information gained from the Global Health Projects will be promptly and broadly disseminated, and (b) the Funded Developments will be made available and accessible at an affordable price to people most in need within Developing Countries.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Global Access Commitments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 3.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Global Health Projects</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the HIV Vaccine Program, the TB Vaccine Program, the Vaccinal Antibody Development Program, and any other mutually agreed project conducted by the Company under the terms of this Letter Agreement that is funded by the Foundation or a Foundation-supported Entity with funds provided by the Foundation for the project, including through a grant, contract, or program-related investment as contemplated by Section 3(a)(iv).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 3(a)(iv).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV Vaccinal Antibody Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the product applicable to the treatment and/or amelioration of HIV disease developed pursuant to the Vaccinal Antibody Development Program.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV Vaccine Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the product applicable to the treatment, prevention, and/or amelioration of HIV disease developed pursuant to the HIV Vaccine Program.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV Vaccine Program</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the Company&#x2019;s research, development, and product launch of a safe and effective product applicable to the treatment, prevention, and/or amelioration of HIV disease [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV Vaccine Program Report</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 3(a)(vii).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV/TB Investment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in the introductory paragraph.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV/TB Investment Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in the introductory paragraph.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">IAVI</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the International AIDS Vaccine Initiative.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Investment Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in the introductory paragraph.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">License Trigger</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 3(f)(ii).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Malaria Vaccinal Antibody Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the product applicable to the prevention and/or amelioration of malaria developed pursuant to the Vaccinal Antibody Development Program.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Minimum Purchase Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 6(d).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">New Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means shares of the Common Stock issued pursuant to the SPA.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> Grant Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 3(c).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Platform Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the CMV Vaccine and any other intellectual property (in each case including any and [***].  For clarity, the Platform Technology shall include materials, know-how and intellectual property owned or controlled by the Company or its Affiliates, whether existing at closing or later developed, owned or controlled by the Company or its Affiliates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Prior Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in the introductory paragraph.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Public Sector</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means purchases of a product developed in connection with TB Vaccine Project for use in [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Reasonable Efforts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the Company will use [***]. To the extent that any provision in this Letter Agreement identifies specific actions to be taken by the Company as an example, or in connection with the use, of Reasonable Efforts, then the foregoing definition of Reasonable Efforts shall include the requirement of such specific actions in such specific instance; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that in no event shall such specific actions be deemed to be required in connection with the use of Reasonable Efforts in any other instance in which such specific actions are not otherwise expressly stated.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Receiving Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 18(a).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Remaining Funds</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 3(a)(v).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Sale Transaction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a sale or transfer of a controlling number of, or of all or substantially all of the shares of the Company, or an assignment, sale, transfer, or exclusive license of all or substantially all of its material assets to which the subject matter of this Letter Agreement relates, whether by merger, stock transfer or otherwise; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that in no event shall any sale, issuance, or transfer of securities for the primary purpose of providing equity financing to the Company or equity compensation to service providers to the Company constitute a Sale Transaction, unless following such sale, issuance or transfer the Company&#x2019;s stockholders of record immediately prior to such transaction or series of related transactions hold, immediately after such transaction or series of related transactions, less than 50% of the voting power of the Company or other surviving entity.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Securities Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the Securities Act of 1933, as amended.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">SPA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in the introductory paragraph.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Target Diseases and Conditions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">From time to time, if the Foundation identifies more areas of global health as underinvested or disproportionately impacting poor and vulnerable populations, it may so notify the Company and the definition of Target Diseases and Conditions will be so amended with the Company&#x2019;s written consent, such consent not to be unreasonably withheld, conditioned, or delayed.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">TB</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means tuberculosis.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">TB Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the product applicable to the treatment, prevention and/or amelioration of TB developed pursuant to the TB Program.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">5</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">TB Vaccine Program</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the Company&#x2019;s research, development, and product launch of a safe and effective product applicable to the treatment, prevention, and/or amelioration of TB that [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">TB Program Report</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 3(a)(vii).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Vaccinal Antibody Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means collectively (a) the HIV Vaccinal Antibody Product and (b) the Malaria Vaccinal Antibody Product.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Vaccinal Antibody Development Program</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the vaccinal antibody development program set forth in Appendix 3 and any further development to develop an HIV Vaccinal Antibody Product and/or a Malaria Vaccinal Antibody Product.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Vaccinal Antibody Development Program Report</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 3(a)(vii).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Withdrawal Right</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning given in Section 6(c).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Charitable Purposes and Use of Funds; Foundation Technology Access</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a) The Foundation is making the Foundation Investment as a &#x201c;program-related investment&#x201d; within the meaning of Section 4944(c) of the Code. The Foundation&#x2019;s primary purpose in making the Foundation Investment is to further significantly the accomplishment of the Foundation&#x2019;s charitable purposes, including the relief of the poor, distressed, and underprivileged, the advancement of science, and the promotion of health by seeking to (i) address global health challenges that disproportionately impact developing countries, and (ii) increase the access of poor and distressed individuals and families in developing countries to life-saving and other important vaccines, drugs, and technologies that may assist in the prevention, treatment, and detection of the Target Diseases and Conditions (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Charitability Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b) The Foundation is making the Foundation Investment to secure Global Access rights to new, low-cost vaccines and drugs developed (in whole or in part) through the use of the Company&#x2019;s Platform Technology for the Target Diseases and Conditions. The Foundation believes the Platform Technology has potential application in the Target Diseases and Conditions and, therefore, the Platform Technology (and any improvements and developments thereto), in conjunction with the Global Access Commitments described below, will achieve the Charitability Requirements.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Use of Funds</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Company used the proceeds from the HIV/TB Investment solely (1) to further develop and leverage the Company&#x2019;s Platform Technology to create Funded Developments that are reasonably expected to comprise or result in affordable drugs, therapeutics, diagnostics, prophylactics, or other health products, services, and interventions for the treatment, prevention, and/or amelioration of Target Diseases and Conditions for people in Developing Countries in accordance with Global Access and (2) to conduct the HIV Vaccine Program and the TB Vaccine Program. At least fifty percent (50%) of the HIV/TB Investment was used to conduct the HIV Vaccine Program and the TB Vaccine Program. Specific deliverables and objectives with respect to development of the Platform Technology and the performance of the HIV Vaccine Program and TB Vaccine Program are set forth below. The Company will use the proceeds from the Antibody Development Investment solely to conduct the Vaccinal Antibody Development Program. For the avoidance of doubt, (i) use by the Company of the proceeds from the Foundation Investment for [***] the HIV Vaccine Program, the TB Vaccine Program, and the Vaccinal Antibody Development Program or the development of Funded Developments (including allocation of reasonable overhead expenses) shall be deemed to be funds used to conduct the HIV Vaccine Program, TB Vaccine Program, Vaccinal Antibody Development Program, and/or such Funded Development, as applicable, in compliance with this Section 2(c); and (ii) the Company is [***]. The Company shall not use</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">any proceeds of the Foundation Investment for the following matters without the Foundation&#x2019;s approval: (i) a payment of dividends or (ii) any redemption of shares.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Global Access Commitments</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In furtherance of the Charitability Requirements and Global Access, the</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Company agrees to the following (collectively &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Global Access Commitments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;):</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Development of Platform Technology; Additional Global Health Projects; Reports</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i) The Company will use Reasonable Efforts to complete the Platform Technology objectives set forth on Appendix 4 and to utilize the Platform Technology in accordance with the terms of this Agreement, including to advance the HIV Vaccine Program through the completion of Phase 1 clinical trials on the HIV Vaccine Product and to advance the TB Vaccine Program through the completion of IND-enabling studies on the TB Product in furtherance of the Foundation&#x2019;s Charitable Purpose.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(ii) The Company will use Reasonable Efforts to advance the Vaccinal Antibody Program including by completing the activities outlined in Appendix 3 (unless amended pursuant to Section 3(a)(v) below) to achieve the following objectives: [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(A) [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(B) [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(C) [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(D) [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(iii) The Company agrees that after completion of the requirements in the preceding Sections 3(a)(i) and 3(a)(ii) (or at such earlier time as the Foundation may elect), the Foundation may request that the Company continue further development of the HIV Vaccine Product, TB Product, and/or any Vaccinal Antibody Product, including through product launch of a final product as further described in Section 3(a)(vi) below.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(iv) In addition to the HIV Vaccine Program, the TB Vaccine Program, and the Vaccinal Antibody Development Program, the Company may work together with the Foundation on additional Global Health Projects based on the Platform Technology for Target Diseases and Conditions in accordance with Section 3(a)(v) below, if applicable, and/ or if mutually agreed between the Company and the Foundation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(v) If at any time the Foundation and the Company [***] the Antibody Development Investment to achieve the Charitability Requirements to continue some or all of the Vaccinal Antibody Development Program, the parties will [***] on one or more additional Global Health Projects with respect to one or more Target Diseases and Conditions on which to redeploy any remaining funds from the Antibody Development Investment that will not be spent on the Vaccinal Antibody Development Program (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Remaining Funds</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). The parties [***] the Vaccinal Antibody Development Program in part and redeploy a portion of the Remaining Funds to other Global Health Projects. For the avoidance of doubt, the Company will continue the Vaccinal Antibody Development Program [***] and a failure of the work relating to one of malaria or HIV in the Vaccinal Antibody Development Program will not constitute a failure of such program provided that the work on the other indication has not failed.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(A) Any scope of work relating to a Global Health Project to be funded using Remaining Funds will be designed to be completed within [***] after commencement of such scope of work; provided that the Company will continue to perform the activities under such scope of work for a reasonable period if the actual time taken extends beyond such [***] period and provided that there are still Remaining Funds available, for up to a maximum of an additional [***] (or such longer period as the Parties may agree in writing).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(B) If there are Remaining Funds, the Foundation will have until [***] to propose additional scopes of work (whether in connection with a new Global Health Project or further development on an existing Global Health Project) to be funded using such Remaining Funds; provided that if the Foundation has proposed scopes of work to be funded using Remaining Funds but the Company has not agreed to such scopes of work by [***], then such date will be extended until such time as the parties have mutually agreed on the scopes of work (which scopes of work will be designed to be completed within [***] after commencement).  The Company will use (or allocate to agreed scopes of work, as applicable) any Remaining Funds that the Foundation has not requested to be redeployed by [***] (or the extended date pursuant to the preceding sentence, if applicable) solely in accordance with Section 2(c)(1). Any dispute pursuant to this Letter Agreement regarding whether it is scientifically or technically feasible to continue a Global Health Project or whether there has been a scientific or technical failure will be resolved in accordance with the dispute resolution procedure described in Section 17 herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(vi) If the Foundation requests that the Company continue further development of the HIV Vaccine Product, TB Vaccine Product, and/or any Vaccinal Antibody Product, or the Foundation and the Company proceed with one or more additional Global Health Projects pursuant to Sections 3(a)(iv) or 3(a)(v), any such further development or Global Health Project will be documented in a definitive agreement mutually agreed in good faith between the Foundation (or a Foundation-supported Entity) and the Company and project plan, which may include [***]. The Foundation and the Company will [***]. The specific level of funding responsibilities for the additional work will be decided as mutually agreed in good faith in writing by the parties. The Foundation shall be [***]. Any additional work may be divided into milestones or phases. The Foundation will have the right, at its sole discretion, to continue providing funding (directly or through a Foundation-supported Entity) to advance the HIV Vaccine Product, TB Vaccine Product, any Vaccinal Antibody Product, and/or any product developed in connection with any other Global Health Project through to product launch of a final product for the purpose of enabling Global Access. In the event the parties [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In addition, if the HIV Vaccine Product, TB Vaccine Product, any Vaccinal Antibody Product, and/or any products developed under the additional Global Health Project proceeds to [***], the Company will work in good faith with the Foundation to develop and execute [***] that will enable the Company to [***]. The [***] will be determined by the Foundation and the Company based upon [***]. The price of such products in Developing Countries will be such that the products are affordable to the Foundation&#x2019;s target beneficiaries in the Developing Countries, but in no case will the price exceed COGS plus [***]. The [***]. The specific level of funding responsibilities for such plan will be decided as mutually agreed in good faith in writing by the parties. The Foundation shall be [***]. The Foundation will have the right to inspect the Company&#x2019;s records pursuant to Section 7 herein, in order [***] for so long as is necessary to ensure compliance with this Section 3(a)(vi).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(vii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Global Health Project Governance and Oversight. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Parties will cooperate together in good faith to oversee the progress of the Global Health Projects towards meeting the Charitable Objectives according to the following framework.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(A) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Project Level Meetings.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">On a [***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">basis, and in addition on an ad hoc basis as needed, [***] for each of the HIV Vaccine Program, TB Vaccine Program, Vaccinal Antibody</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Development Program, and any other Global Health Project then in process to discuss the progress for each respective project. Should these meetings identify issues that cannot be resolved by the project team, senior leadership may be engaged in alignment with Section 3(a)(vii)(B) below.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(B) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Escalation. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">For issues escalated by the Project Level Meetings or that arise independently that require real time senior-level communication, there will be ad hoc discussions between a designated senior representative of the Company (e.g., VP level or above member of the Company&#x2019;s research leadership team) and one senior representative of the Foundation (e.g., Director or Senior Advisor level).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(C) [***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Evaluation Meetings. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">On a [***], the Company and the Foundation will meet to discuss each of the HIV Vaccine Program, TB Vaccine Program, Vaccinal Antibody Development Program, and any other Global Health Project then in process. Subject to applicable laws including Antitrust Laws, the Company agrees to provide written materials to the Foundation representatives at least </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> days in advance of such meetings to inform the Foundation representatives of the progress of the Global Health Project and form the basis for a discussion of the Global Health Project. Such meetings will include applicable representatives of the R&amp;D, program leadership, global health, alliance management and other relevant functional team membership from the Company, and the relevant program strategy team and the strategic investment fund from the Foundation.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(D) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Significant Milestone Meetings. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company and the Foundation representatives outlined in Section 3(a)(vii)(C) above will also meet at to be agreed upon milestones in the development plan for any Global Health Project (such as upon the results of a clinical trial or when making candidate selection decisions).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(E) All such meetings will be in person if so requested by the Company or the Foundation, and otherwise may be held by videoconference or teleconference. For clarity, the parties may mutually agree to combine meetings for any Global Health Projects as may be appropriate. From time to time, as may be agreed upon by the parties, the discussions may include representatives from other entities, such as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">subject to applicable laws including applicable Antitrust Laws.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(viii) The Company will ensure that any Funded Developments that are applicable for the treatment, prevention, or amelioration of any Target Diseases and Conditions, and all products (at any stage of development, e.g., from discovery through commercialization) relating to or arising out of any Global Health Project, will be made available and accessible at an affordable price to people most in need within Developing Countries, which price will not exceed COGS plus [***]. The Foundation will have the right to inspect the Company&#x2019;s records pursuant to Section 7 in order to [***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">for so long as is necessary to ensure compliance with this Section 3(a)(viii).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Coordination with Foundation-supported Entities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Company acknowledges that the Foundation is currently funding research and development projects at various Foundation-supported Entities that are relevant to the development of the HIV Vaccine Product and the TB Vaccine Product, including [***], and their respective Affiliates. Subject in all respects to applicable law, including applicable Antitrust Laws, in connection with the work to be performed on the Platform Technology, HIV Vaccine Program, and TB Vaccine Program pursuant to this Letter Agreement, the Company shall cooperate with these entities in good faith to coordinate its development efforts on the HIV Vaccine Program and TB Vaccine Program with these entities. This process may include </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. While the coordination, acquisition of rights, and completion of [***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">referred to in this paragraph are the responsibility of the Company to effect, the Foundation will assist in these efforts, in particular those that relate to work funded by the Foundation. Nothing in this Letter Agreement constitutes a commitment by the Foundation to make any grants to the Company or a Foundation-supported Entity and the decision to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">proceed with a grant will be made solely at the Foundation&#x2019;s discretion. For clarity, no provision of this Letter Agreement will limit or restrict the Foundation&#x2019;s rights pursuant to any grant agreement or other contract with any third-party. Notwithstanding anything to the contrary, nothing in this Letter Agreement shall require the Company to cooperate or otherwise coordinate with Foundation-supported Entities if doing so would be reasonably likely to violate or give rise to risk of liability under any applicable law, including applicable Antitrust Laws.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Compliance with Intellectual Property Rights: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company represents and warrants that, as of the Amendment Effective Date, to the actual knowledge of the Company, the Company has all necessary rights to the Platform Technology in existence at the Amendment Effective Date, the HIV Vaccine Product, the TB Vaccine Product, and the Vaccinal Antibody Product (including all rights in any patents, copyrights, trademarks, trade secrets, data, confidential information, know-how, or other intellectual property or proprietary right) required to fulfill the Company&#x2019;s obligations under this Letter Agreement and to grant the licenses expressly granted by the Company hereunder. The Company covenants that in the performance of the HIV Vaccine Program, TB Vaccine Program, Vaccinal Antibody Development Program, and any other Global Health Project, the Company will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> the Platform Technology, the HIV Vaccine Product, the TB Vaccine Product, the Vaccinal Antibody Product, and any product developed in connection with any other Global Health Project (including all rights in any patents, copyrights, trademarks, trade secrets, data, confidential information, know-how, or other intellectual property or proprietary right) required to fulfill the Company&#x2019;s obligations under this Letter Agreement and any other agreement between the Foundation and the Company related to the development of such products and to grant the licenses expressly granted by the Company hereunder. In connection with the Funded Developments the Company shall comply with all applicable laws and regulations and shall not knowingly violate third-party intellectual property.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company will [***] with respect to any Platform Technology acquired or licensed in the future (whether through acquisition of any business, company, or assets, by contract, or otherwise) required to fulfill the Company&#x2019;s obligations under this Letter Agreement and any other agreement between the Foundation and the Company related to the development of any products in connection with a Global Health Project and to grant the licenses expressly granted by the Company hereunder.  Without limiting the foregoing, the Company shall [***], including sufficient use rights for Global Health Projects, sublicense rights encompassing the grant of rights to the Foundation hereunder, and payment provisions that are consistent with those herein and minimize or eliminate any fees, royalties, milestones, or other payments on account of any use for Global Access and the grant and exercise of the sublicense to the Foundation hereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Without limiting the foregoing, the Company agrees that it will [***].  In addition, the Company [***].  In the event any milestones or royalties are payable to [***] on sales of a product developed in connection with any Global Health Project intended for use in the Developing Countries, such amounts would be included in the definition of COGS with respect to such product.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Publication. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company will use [***] to:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i) Publish the scientific results and information developed in connection with each Global Health Project within a reasonable period of time after the information or results are obtained, with due regard to reasonable delays or limitations on content of these publications that are necessary to protect intellectual property.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(ii) [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(iii) [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(iv) If the Company seeks publication of Funded Developments in a peer reviewed journal, such publication must be under &#x201c;open access&#x201d; terms and conditions consistent with the Foundation&#x2019;s Open Access Policy attached hereto as Appendix 7.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(f) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Non-Exclusive License</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i) Solely upon the occurrence, if any, of a License Trigger, and only in such event, the Company hereby grants the Foundation a [***]; provided that, in each case, the license to the Funded Developments and the Platform Technology is limited [***]. The Foundation and the Company agree and acknowledge that, in order to achieve Global Access and make the Funded Developments available and accessible in Developing Countries, certain activities may be required to occur in one or more developed countries, like manufacture, distribution, or sale (such as to an entity procuring a product for use in Developing Countries). Accordingly, the license to the Foundation shall [***]. The definitive agreements with respect to any additional Global Health Project will include, to the extent applicable, license provisions with respect to the Global Health Project consistent with the license provisions set forth in this Letter Agreement. For the avoidance of doubt, to the extent any additional fees, royalties, milestones or other payments are payable to any third-party solely as a result of the Company&#x2019;s grant of, or the Foundation&#x2019;s exercise of, the license granted pursuant to this paragraph, the Foundation shall be responsible for all such payments to the extent such fees, royalties, milestones or other payments are for the benefit of the Foundation or a Foundation-supported Entity and the payment of such fees, royalties, milestones or other payments would not constitute a taxable expenditure under Treasury Regulation 53.4945-6(a)-(b); provided, that the Company may renounce any non-incidental benefit received by the Company related thereto and, in such event, the Foundation shall pay the full amount of such additional fees, royalties, milestones or other payments.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">License Triggers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Notwithstanding the forgoing license grants, the Foundation shall only exercise its rights under the license (including its sublicensing rights) during the pendency of the occurrence of at least one of the following, and, in any event, not prior to the end of the [***] period set forth in the last paragraph of this Section 3(f)(ii) (each a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">License Trigger</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;):</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(A) a Charitability Default;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(B) the Company either: (i) indicates in writing that it is unwilling or unable to commence, proceed, or continue with development of the HIV Vaccine Product, TB Vaccine Product, Vaccinal Antibody Product, or any other Global Health Project previously agreed to by the Company, or (ii) fails to commence, proceed, or continue with development of the HIV Vaccine Product, TB Vaccine Product, Vaccinal Antibody Product, or such other Global Health Project within [***] of receipt of a written notice from the Foundation [***]. For the avoidance of doubt, a License Trigger shall not be deemed to have occurred pursuant to this Section 3(f)(ii)(B) if the HIV Vaccine Program, the TB Vaccine Program, the Vaccinal Antibody Development Program, or any other Global Health Project is [***]; or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(C) the Company institutes any bankruptcy, insolvency, reorganization for the benefit of creditors, dissolution, liquidation, or similar proceeding relating to it under the laws of any jurisdiction or any such proceeding is instituted against the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">If either the Foundation or the Company becomes aware of a License Trigger, it will promptly notify the other party in writing of the occurrence of a License Trigger, setting forth in reasonable detail the reasons therefor. If the Company disputes the Foundation&#x2019;s belief that a License Trigger has occurred, the Company and the Foundation will [***], after which time, such dispute will be decided in accordance with the dispute resolution procedure described in Section 17 herein. If the parties have not resolved such dispute prior to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">the end of the License Negotiation Period, then during the pendency of the dispute resolution procedure described in Section 17 herein, the Foundation may exercise the license pursuant to Section 3(f)(i) and the Company will enable the Foundation to do so pursuant to Section 3(h) (and the dispute resolution procedure shall continue notwithstanding the exercise of such license grant), provided that: [***]; (y) until such time as the dispute is finally decided against the Company pursuant to the dispute resolution procedure described in Section 17: [***]; and (z) if the dispute is finally decided in favor of the Company pursuant to the dispute resolution procedure described in Section 17: [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(g) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Modifications</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The principal purpose of the license granted to the Foundation is to ensure that Global Access is achieved as rapidly as reasonably practicable. The parties acknowledge that product launch and/or distribution of Company products and processes for the benefit of end users in Developing Countries may require worldwide commercialization and /or distribution rights to be maintained by a single party. During the implementation of the Global Health Projects, the Company may demonstrate, on a case-by-case basis, to the satisfaction of the Foundation that Global Access can best be achieved in a particular case without such a license. In such a case, the Foundation and the Company may modify or terminate in whole or in part the foregoing license as mutually agreed as reflected in a signed writing.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(h) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Cooperation; Technology Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Company agrees to use Reasonable Efforts to enable the Foundation or its sublicensees to exercise their rights hereunder, which efforts shall include, as reasonably required, [***]. For the avoidance of doubt in the event of an exercise of the license pursuant to Section 3(f), the obligations under this paragraph shall not require the Company to incur additional expenses or to make additional payments to [***], unless the Foundation or a Foundation-supported Entity is willing to pay such additional expenses or payments.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In connection with the exercise of the foregoing licenses under Section 3(f), the Company&#x2019;s use of Reasonable Efforts shall include, as reasonably required: [***]. The Foundation will pay all reasonable third-party costs and expenses incurred by the Company as a result of complying with the preceding sentence, if any.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Duration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Global Access Commitments commenced on December 23, 2016, and are ongoing and will continue for as long as the Foundation continues to be a charitable entity (including following the exercise of the Withdrawal Right). For clarity, the Global Access Commitments will continue as to any Funded Developments that are assigned, sold, transferred, or exclusively licensed to a third-party.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Third-Party Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Except as otherwise provided in this Letter Agreement, the Company shall be responsible for all costs associated with its technology and intellectual property owned, controlled or licensed-in.  Without limiting the foregoing, the Company shall use Reasonable Efforts to [***].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Obligations in the Event of a Sale of the Platform Technology or Company; Preservation of Global Access Commitments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In the event that all or substantially all of the Company&#x2019;s assets, the Platform Technology owned or controlled by the Company, or the Funded Developments are transferred to, exclusively licensed to, sold or acquired by a third-party, the Company will require the purchaser, transferee, licensee, or acquirer to assume the Global Access Commitments in a written agreement that is reasonably acceptable to the Foundation. The Company will not grant to a third-party any rights or enter into any arrangements or agreements (including any amendment or modification to the Existing Agreements) that would limit or restrict the Foundation&#x2019;s rights pursuant to the Global Access Commitments, including the Foundation&#x2019;s</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">right to enter into Global Health Projects with the Company, unless such third-party expressly assumes such Global Access Commitments to the reasonable satisfaction of the Foundation. Consistent with the preceding sentence, the Company covenants that if the Company decides to no longer pursue the TomegaVax technology and is required to negotiate in good faith with the individuals who are parties to the Existing Agreements (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Consultants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) to find an alternative manner in which the Consultants can continue to develop the TomegaVax technology, the Company will not enter into any exclusive arrangement with the Consultants or grant to the Consultants any rights or enter into any arrangements or agreements that would limit or restrict the Foundation&#x2019;s rights pursuant to the Global Access Commitments. For clarity, notwithstanding anything to the contrary in this Letter Agreement, (a) the Foundation&#x2019;s rights hereunder which exist on the date of the transfer, sale, or acquisition of the Company&#x2019;s Platform Technology, Funded Developments, or other assets to or by a third-party shall not be terminated by such transfer, sale, or acquisition and (b) if a third-party acquires the Company, any capabilities, technology, and intellectual property rights which the third-party acquirer owned prior to the closing of any such acquisition transaction or develops or acquires after the closing of any such transaction without any use of the Funded Developments will not be considered Platform Technology.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Withdrawal Right</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a) The Withdrawal Right described and defined in this Section 6 will be triggered only as a result of a Charitability Default. For the avoidance of doubt, the Withdrawal Right and the Charitability Default will not be triggered by [***], so long as the Company has not breached its obligations under this Letter Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b) A &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Charitability Default</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; will occur if the Company either (i) fails to comply, in any material respect, with the restrictions in Sections 2(c) and 9 of this Letter Agreement on the use of funds from the Foundation Investment or the other related U.S. legal obligations set forth in this Letter Agreement, including without limitation the requirements set forth in Sections 7, 11, and 12 below, or (ii) is in material breach of the Global Access Commitments. Each party agrees to promptly notify the other party in writing if it has knowledge of any Charitability Default and the Company shall thereafter provide to the Foundation a proposed strategy to remedy the Charitability Default.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c) If the Company fails to cure the Charitability Default within [***] of receipt of the above described notice (provided that solely for purposes of this Section 6 in the event the Company disputes that a Charitability Default has occurred, such [***] period will commence upon a decision that a Charitability Default has occurred pursuant to the dispute resolution process described in Section 17); and the Foundation holds any securities of the Company issued in connection with the Foundation Investment, including securities issued in respect of or upon conversion or exercise of such securities (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Foundation Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), the Company shall have the obligation, if requested by the Foundation, to redeem or arrange for a third-party to purchase all (but not less than all) of the Foundation Stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Withdrawal Right</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), provided that any such redemption or repurchase shall be made only to the extent permitted by applicable law concerning distributions to holders of equity interests. Without limiting the foregoing, if the Company is unable to redeem all of the Foundation Stock, and no third-party purchases the Foundation Stock, then the Company shall use commercially reasonable efforts to effect the Withdrawal Right, consistent with the Code and applicable law, as soon as practicable thereafter, provided that to the extent any redemption of the Foundation Stock pursuant to this Section 6(c) would have [***]. For the avoidance of doubt, the Foundation shall cease to be a stockholder for all purposes effective as of the date such Foundation Stock is redeemed and, thereafter, the sole right of the Foundation with respect to its ownership of Foundation Stock shall be to receive such redemption payment. During the period when the Company is unable to exercise its obligation to redeem or find a purchaser of the Foundation Stock, the Company shall [***] until such time as the Company has fulfilled the Withdrawal Right with respect to all of the Foundation Stock).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d) For redemption or purchase by a third-party pursuant to Section 6(c), Foundation Stock shall be valued at the greater of (i) the original purchase price attributable to such shares (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Minimum Purchase Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) or, at the option of the Foundation, (ii) the then current Fair Market Value.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e) If the Foundation Stock is sold or redeemed in connection with a Withdrawal Right, the Foundation will have a look back right by which, in the event that (i) the Company consummates a Sale Transaction or (ii) the Company signed a binding letter of intent or binding term sheet or entered into any definitive agreement (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Binding Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) with respect to such Sale Transaction  at any time prior to the [***] anniversary of the first date that any of the Foundation Stock was redeemed or sold, then the Foundation will receive compensation equal to the excess of what it would have received in such transaction if it still held the Foundation Stock at the time of such Sale Transaction over what it actually received in the sale or redemption of the Foundation Stock; provided that such Sale Transaction  actually closes prior to the first anniversary of the first date that any of the Foundation Stock was redeemed or sold. For clarity, if the Company does not enter into any Binding Agreement until after the [***] anniversary of the initial sale or redemption date of the Foundation Stock, then the Foundation&#x2019;s look-back right set forth in this Section 6(e) will terminate and be of no further force and effect.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(f) If at the time that the Foundation has requested to exercise its Withdrawal Right, the Foundation Stock consists of a class of securities of the Company that (i) is registered under section 12 (or any successor provision) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), (ii) is not subject to restrictions from trading under the Securities Act or state securities laws and (iii) is listed on a U.S. national securities exchange and the Company is current in filing its financial reports and other required filings with the Securities and Exchange Commission (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">SEC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), then the Company will not be required to redeem or find a purchaser for the Foundation Stock if the Foundation elects to and is able to sell the Foundation Stock on a securities exchange for at least the Minimum Purchase Price. If the Foundation elects to sell the Foundation Stock to the public pursuant to this Section 6(f) and the Foundation receives less than the Minimum Purchase Price, then the Company will pay the Foundation as soon as practicable the difference between the amount received by the Foundation as a result of the sale of the Foundation Stock on the securities exchange and the amount of the Minimum Purchase Price.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(g) For the avoidance of doubt, notwithstanding any exercise of the Withdrawal Right, the Foundation will continue to be entitled to enforce its rights under the Global Access Commitments.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Required Reporting; Audit Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In addition to any reports required to be delivered to the Foundation pursuant to the Investment Documents, the Company shall furnish, or cause to be furnished, to the Foundation the following reports and certifications:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a) Within [***] after the end of each of the Company&#x2019;s fiscal years during which the Foundation owns any Foundation Stock or any loans from the Foundation to the Company are outstanding, a certificate from the Company signed by an officer or director of the Company and substantially in the form attached to this Letter Agreement as Appendix 7, certifying that the requirements of the Foundation Investment set forth in this Letter Agreement were met during the immediately preceding fiscal year, describing the use of the proceeds of the Foundation Investment and summarizing the Company&#x2019;s progress toward achieving the Global Access Commitments;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b) Within [***] after the end of the Company&#x2019;s fiscal year during which the Foundation ceases to own any Foundation Stock or all loans from the Foundation to the Company cease to be outstanding, a certificate from the Company signed by an officer or director of the Company and substantially in the form attached to this Letter Agreement as Appendix 8, certifying that the requirements of the Foundation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Investment set forth in this Letter Agreement were met during the term of the Foundation Investment, describing the use of the proceeds of the Foundation Investment and summarizing the Company&#x2019;s progress toward achieving the Global Access Commitments;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c) Any other information respecting the operations, activities, and financial condition of the Company as the Foundation may from time to time reasonably request to discharge any expenditure responsibility, within the meaning of Sections 4945(d)(4) and 4945(h) of the Code, of the Foundation with respect to the Foundation Investment, and to otherwise monitor the charitable benefits intended to be served by the Foundation Investment; provided, that the Foundation will reimburse the Company for any reasonable third-party expenses incurred by the Company in order to prepare any information the Company is required to prepare solely as a result of this Section 7(c); and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d) Full and complete financial reports of the type ordinarily required by commercial investors under similar circumstances to the extent required pursuant to Treasury Regulation 53.4945-5(b)(4); provided that as long as the Company is a reporting company under the Exchange Act, the timely filing of quarterly, annual and current reports pursuant to section 13 or 15(d) of the Exchange Act and all other required filings with the SEC shall be deemed to satisfy the financial reporting obligations in this Section 7(d).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e) The Company will maintain books and records adequate to provide information ordinarily required by commercial investors under similar circumstances, including copies of any reports submitted to the Foundation related to each Global Health Project. The Company will retain such books, records, and reports for [***] and will make such books, records, and reports available at reasonable times to enable the Foundation to [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(f) The Company will permit employees or agents of the Foundation who are bound by written confidentiality obligations or policies at least as restrictive as those set forth herein, at any reasonable time and upon reasonable prior notice, during normal business hours, to examine or audit the Company&#x2019;s books and accounts of record and to make copies and memoranda of the same, in each case, at the Foundation&#x2019;s expense, to audit the Company&#x2019;s compliance with the use of the Foundation&#x2019;s funds; provided that the Foundation will not conduct such an examination more frequently than once per year unless: (i) required due to an audit, request, or inquiry of the Foundation by the Internal Revenue Service; or (ii) the Foundation has a reasonable belief that a Charitability Default has occurred. If the Company maintains any records (including without limitation computer generated records and computer software programs for the generation of such records) in the possession of a third-party, the Company, upon request of the Foundation, will notify such party to permit the Foundation access to such records at reasonable times and to provide the Foundation with copies of any records it may reasonably request in connection with such audit, request or inquiry, all at the Foundation&#x2019;s expense.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Assignment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Notwithstanding anything in this Letter Agreement to the contrary, (a) the Foundation will have the right to assign this Letter Agreement (in whole but not in part) or transfer the Foundation Stock, subject to securities laws, to (i) any successor charitable organization of the Foundation from time to time that is a tax exempt organization as described in Section 501(c)(3) of the Code, or (ii) any tax exempt organization as described in Section 501(c)(3) of the Code controlled by one or more trustees of the Foundation; and (b) the Company will have the right to assign this Letter Agreement (in whole but not in part) without the consent of the Foundation or any other person: (x) in connection with a Sale Transaction, subject to the terms of Section 5; and (y) to any Affiliate of the Company (provided, that: (A) such Affiliate has adequate financial resources to perform the Company&#x2019;s obligations under this Letter Agreement; and (B) in the event any such Affiliate ceases to have adequate financial resources to perform the Company&#x2019;s obligations under</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">this Letter Agreement, the Company shall be secondarily liable for such obligations). Except as provided in the preceding sentence, neither party shall have the right to assign (whether by merger, sale of stock, sale or license of assets, or otherwise) this Letter Agreement without the prior written consent of the other party, which consent will not be unreasonably withheld, conditioned, or delayed. The Foundation or the Company, as applicable, will notify the other party of any such proposed assignment, including the identity of the assignee, in a timely manner. For the avoidance of doubt, if the Foundation transfers the Foundation Stock as permitted by this Section 8, the Foundation may assign to any such transferee all of its rights attached to such Foundation Stock, including the Withdrawal Right.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Prohibited Uses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company shall not expend any proceeds of the Foundation Investment to carry on propaganda or otherwise to attempt to influence legislation, to influence the outcome of any specific public election or to carry on, directly or indirectly, any voter registration drive, or to participate or intervene in any political campaign on behalf of or in opposition to any candidate for public office within the meaning of Section 4945(d) of the Code. The proceeds of the Foundation Investment shall not (a) be earmarked to be used for any activity, appearance or communication associated with the activities described in the foregoing sentence, or (b) be intended for the direct benefit, and will not directly benefit, any person actually known to the Company (including after being identified to the Company by the Foundation) as having a personal or private interest in the Foundation, including without limitation, descendants of the founders of the Foundation, or persons related to or controlled by, directly or indirectly, such persons; provided, that in no event shall the Company (or any of its officers, directors, employees, agents, or representatives) have any duty of inquiry with respect to the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">For the avoidance of doubt, except as otherwise expressly permitted in this Letter Agreement, the Company will not use the Foundation Investment to pay a dividend or redeem shares.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">10. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Disqualified Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company represents and warrants to the Foundation that, as of the Amendment Effective Date, neither the Company nor, to the actual knowledge of the Company, any shareholder of the Company is a &#x201c;disqualified person&#x201d; with respect to the Foundation (as the term &#x201c;disqualified person&#x201d; is defined in Section 4946(a) of the Code). The Foundation represents and warrants to the Company that as of the Amendment Effective Date, the Foundation does not, and one or more disqualified persons with respect to the Foundation do not, directly or indirectly, control the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Anti-Terrorism</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company will not use any portion of the Foundation Investment, directly or indirectly, in support of activities (a) prohibited by U.S. laws related to combatting terrorism; (b) with persons on the List of Specially Designated Nationals (www.treasury.gov/sdn) or entities owned or controlled by such persons; or (c) with countries or territories against which the U.S. maintains comprehensive sanctions (currently, Cuba, Iran, Syria, North Korea, and the Crimean Region of Ukraine), unless such activities are fully authorized by the U.S. government under applicable law and specifically approved by the Foundation in its sole discretion.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Anti-Corruption and Anti-Bribery</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company will not offer or provide money, gifts, or any other things of value directly or indirectly to anyone in order to improperly influence any act or decision relating to the Foundation or any activities contemplated by this Letter Agreement or the Company&#x2019;s organizational documents (e.g.,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">certificate of incorporation), including by assisting any party to secure an unlawful advantage. Training and information on compliance with these requirements are available at www.learnfoundationlaw.org.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">13. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Public Reports; Use of Name</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Each of the Foundation and the Company may include information on this investment in its periodic public reports and may make the investment public at any time on its web page and as part of press releases, public reports, speeches, newsletters, and other public documents; provided that public communications about the Foundation Investment made by the Company shall indicate that the Foundation Investment was made by the Foundation in furtherance of the Foundation&#x2019;s charitable purposes; provided, however, that the Foundation may not publicly disclose this Letter Agreement or the Antibody Development Investment prior to the Amendment Effective Date. Any announcement of the Foundation Investment by any third-party will require the prior written approval of the Foundation and the Company. Other than with respect to the foregoing rights, each party shall also obtain the other party&#x2019;s prior written approval for any other use of the other party&#x2019;s name or logo in any respect; provided, that each party may use the other party&#x2019;s name for any uses that have been previously approved in writing by such party. Notwithstanding the foregoing, each party&#x2019;s name and logo will not be used by the other party in any manner to market, sell or otherwise promote the Company, its products, services, and/or business.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">14. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Indemnification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Company Indemnity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Company will indemnify, hold harmless, and defend the Foundation and its co-chairs, trustees, directors, officers, employees, and representatives other than Foundation sublicensees (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Foundation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Indemnitees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) from and against any and all judgments, settlements, damages, penalties, losses, liabilities, and costs (including reasonable attorneys&#x2019; fees and costs) as a result of third-party causes of action, claims, suits, or legal proceedings (each a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Claim</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) finally awarded to such third-party by a court of competent jurisdiction against any of the Foundation Indemnitees or agreed to as part of a monetary settlement of the Claim and arising out of or relating to:  (a) bodily injury, death, or property damage caused by the activities or omissions of the Company, including any development, product launch, or commercialization activities carried out by the Company (including any failure to comply with applicable laws, regulations or rules in connection therewith), or by any Company product (other than to the extent such Claims were caused by commercialization or other activities conducted by a Foundation sublicensee without the involvement of the Company or any of its Affiliates); or (b) any Claim that the Platform Technology, any Funded Development or any Company product (other than to the extent such Claims were caused by commercialization or other activities conducted by a Foundation sublicensee without the involvement of the Company or any of its Affiliates) infringes upon a patent, proprietary, or other intellectual property right of a third-party. The Foundation will give the Company prompt written notice of any Claim subject to indemnification pursuant to this Section 14(a); provided that the Foundation&#x2019;s failure to promptly notify the Company will not affect the Company&#x2019;s indemnification obligations except to the extent that the Foundation&#x2019;s delay prejudices the Company&#x2019;s ability to defend the Claim. The Company will have sole control over the defense and settlement of each and every Claim subject to indemnification pursuant to this Section 14(a), with counsel of its own choosing which is reasonably acceptable to the Foundation; provided that the Company conducts the defense actively and diligently at the sole cost and expense of the Company and provided further that the Company will not enter into any settlement that adversely affects, in any material respect, any Foundation Indemnitee without the applicable Foundation Indemnitee&#x2019;s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed. The Foundation will provide the Company, upon request, with reasonable cooperation in connection with the defense and settlement of the Claim. Subject to the Company&#x2019;s rights above to control the defense and settlement of Claims, the Foundation and any Foundation Indemnitee may, at its own expense, employ separate counsel to monitor and participate in the defense of any Claim under this Section 14(a). For the avoidance of doubt, the Company shall have no liability to the Foundation or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">any obligation to indemnify the Foundation pursuant to this Section 14(a) to the extent such claim arises out of the Foundation&#x2019;s fraud, negligence, or willful misconduct.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b) The parties will not be liable to each other for any indirect, incidental, consequential, or special damages (including lost revenues, lost savings, or lost profits suffered by such other party) suffered by such other party arising under or in connection with this Letter Agreement, regardless of the form of action, whether in contract or tort, including negligence of any kind whether active or passive, and regardless of whether the party knew of the possibility that such damages could result; provided that to the extent a Foundation Indemnitee is entitled to be indemnified hereunder for Claims of third parties and such third-party has been awarded indirect, incidental, consequential, reliance, or special damages (including lost revenues, lost savings, or lost profits), the Company&#x2019;s indemnification obligations to the Foundation Indemnitee shall extend to and include such third-party&#x2019;s indirect, incidental, consequential, reliance, or special damages (including lost revenues, lost savings, or lost profits). The parties further agree that under no circumstances will any party be liable to the other party (or to any Foundation Indemnitee) more than once for the same losses arising under or in connection with this Letter Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c) The Foundation agrees that it will, as a condition to the grant of any sublicense hereunder, enter into an agreement with the sublicensee(s) that is consistent with industry standards at the time with respect to indemnification of the Company for costs, liabilities, and expenses arising from the conduct of activities by or on behalf of such sublicensee(s) in exercising such sublicense.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Entire Agreement; Modification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The terms and conditions set forth in this Letter Agreement are in addition to the provisions stated in the Investment Documents and the terms and conditions of this Letter Agreement shall prevail over any inconsistent provision in any Investment Document. Unless mutually agreed otherwise by the Parties, to the extent any of the Global Access Commitments (including, for clarity, the definitions of Funded Developments and Platform Technology) in this Letter Agreement are inconsistent with any global access terms in any existing grant agreements between the Parties in connection with the HIV Vaccine Program and TB Vaccine Program, or future grant agreements (including any amendments to existing grant agreements) with respect to the development of the HIV Vaccine Product, TB Vaccine Product, HIV Vaccinal Antibody Product, and/or Malaria Vaccinal Antibody Product up through the completion of the first Phase 2 clinical trial for such respective product, the terms and conditions of this Letter Agreement shall prevail solely to the extent necessary to resolve such inconsistency. The Parties acknowledge that current and future grant agreement-specific global access terms that are not included in this Letter Agreement may be necessary to advance global access objectives prior to the completion of the first Phase 2 clinical trial for each respective product as noted in the preceding sentence, but such terms shall not contravene the Global Access Commitments nor modify the definitions of Funded Developments and Platform Technology in this Letter Agreement unless mutually agreed by the Parties. No change, modification or waiver of any term or condition of this Letter Agreement shall be valid unless it is in writing, it is signed by the party to be bound, and it expressly refers to this Letter Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">16. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Authority; Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Each of the signatories below covenants, represents, and warrants that as of the Amendment Effective Date, he, she, or it had all authority necessary to execute this Letter Agreement and that, on execution, this Letter Agreement will be fully binding and enforceable in accordance with its terms, and that no other consents or approvals of any other person or third parties are required or necessary for this Letter Agreement to be so binding. This Letter Agreement shall be governed by the laws of the State of Washington, excluding provisions of conflicts of laws which would result in the application of the law of any other jurisdiction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">18</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Dispute Resolution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a) Except as specifically otherwise provided herein, any disagreement or dispute between the parties arising out of or related to this Letter Agreement (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Dispute</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), shall be resolved in the manner provided in this Section 17. Should there develop a Dispute, such Dispute shall be resolved in the order of preference of Sections 17(b) - (d) below.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b) [***].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c) [***].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d) [***].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e) [***].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(f) [***].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(g) [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(h) [***].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i) Both parties agree to continue performing their obligations under this Letter Agreement pending the resolution of any Dispute that is being resolved hereunder unless and until such obligations are terminated or expire in accordance with the provisions of this Letter Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(j) Notwithstanding the foregoing, and without waiting for the expiration of the time periods set forth above, each party shall have the right to apply to any court of competent jurisdiction for appropriate interim or provisional relief, as necessary to protect its rights or property. Furthermore, nothing herein shall prevent the parties from resorting to a court of competent jurisdiction in those instances where preliminary injunctive relief would be appropriate, pending final resolution of the Dispute through arbitration. Nothing in this Section 17 shall be construed to prevent a party from instituting formal proceedings at any time to avoid the expiration of any statute of limitations period or to preserve a superior position with respect to other creditors. For the avoidance of doubt, to the extent this Letter Agreement permits the parties to apply for relief to or institute a proceeding in a court of competent jurisdiction, nothing in this Letter Agreement or any other Investment Document will constitute a waiver of the right to a jury trial in such proceeding.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">18. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Confidential Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a) Except to the extent expressly authorized by this Letter Agreement or otherwise agreed in writing, the receiving party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Receiving Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Letter Agreement any Confidential Information of the other party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Disclosing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). Notwithstanding the foregoing, Confidential Information shall not include any information to the extent that: (i) it can be established by written documentation of the Receiving Party that such information is generally available to the public other than through unauthorized disclosure thereof by the Receiving Party; (ii) such information is lawfully acquired from other sources which are not prohibited from disclosing such information, and without obligation of confidentiality; (iii) such information is approved for disclosure by the consent of the Disclosing Party; or (iv) such information is independently developed by the Receiving Party without use or reference to the Disclosing Party&#x2019;s Confidential Information.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">19</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b) Nothing in this Letter Agreement will be interpreted as placing any obligation of confidentiality or non-use on the Receiving Party with respect to any Confidential Information that the Receiving Party is required to disclose pursuant to law, regulation, or court order. In the event that Confidential Information is required to be disclosed by the Receiving Party pursuant to law, regulation, or court order, the Receiving Party shall make all reasonable efforts to notify the Disclosing Party of such requirement, in order to allow the Disclosing Party to seek a protective order or seek confidential treatment of such information.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c) The Receiving Party may disclose Confidential Information of the Disclosing Party to its trustees, directors, officers, employees, consultants, and advisors (including lawyers and accountants) on a need to know basis, in each case subject to appropriate confidentiality provisions (or professional standards) reasonably acceptable to the Disclosing Party.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d) Notwithstanding any other provision of this Letter Agreement, nothing herein shall prohibit the Foundation from any of the following: (i) analyzing Confidential Information; (ii) comparing the Confidential Information to information in the possession of the Foundation; or (iii) making any grant or other investment to, or entering into any agreement with, any third-party in furtherance of the Foundation&#x2019;s charitable purpose, so long as in doing so, the Foundation does not disclose any Confidential Information except as permitted pursuant to Sections 18(a) through (c).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">19. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This Letter Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which shall be deemed to be and constitute one and the same instrument.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[Signature Page Follows]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">20</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties have caused this Letter Agreement to be executed as of the date first written above.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.3%;"></td>
    <td style="width:89.7%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">BILL &amp; MELINDA GATES FOUNDATION</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#160;/s/ Carolyn Ainslie</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Name:  Carolyn Ainslie</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Title:  Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.3%;"></td>
    <td style="width:89.7%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#160;/s/ Howard Horn</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Name:  Howard Horn</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Title:  Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;">		</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Appendix 1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Developing Countries</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Appendix 2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Existing Agreements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Appendix 3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Vaccinal Antibody Development Program</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Appendix 4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Platform Technology Objectives</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Appendix 5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Appendix 6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV Antibody Product &#x2013; Lead Selection Framework</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV Antibody Product &#x2013; Other Key Product Criteria</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Appendix 7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[OFFICER&#x2019;S/DIRECTOR&#x2019;S] CERTIFICATE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[DATE]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This certificate is being delivered by Vir Biotechnology, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of the Letter Agreement between the Company and the Bill &amp; Melinda Gates Foundation dated as of January ___, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Letter Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Letter Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company certifies as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1. During the fiscal year ended [DATE], the Company met the requirements of the Foundation Investment as set forth in the Letter Agreement that were required to be complied with or performed by the Company during such time period.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2. Attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to this certificate is a description of the Company&#x2019;s use of proceeds of the Foundation Investment during the fiscal year ended [DATE].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3. Attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Exhibit B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to this certificate is the Company&#x2019;s evaluation of the Company&#x2019;s progress with respect to the HIV Vaccine Program, TB Vaccine Program, Vaccinal Antibody Development Program, and Funded Developments, including information regarding progress against the Global Access Commitments (as set forth in the Letter Agreement) during the fiscal year ended [DATE].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the undersigned has executed this certificate and has caused this certificate to be delivered on the date first above written.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:33.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.3%;"></td>
    <td style="width:89.7%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Name:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Title:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Appendix 8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[OFFICER&#x2019;S/DIRECTOR&#x2019;S] CERTIFICATE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[DATE]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This certificate is being delivered by Vir Biotechnology, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of the Letter Agreement between the Company and the Bill &amp; Melinda Gates Foundation dated as of January ___, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Letter Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Letter Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Company certifies as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1. During the term of the Foundation Investment, the Company met the requirements of the Foundation Investment as set forth in the Letter Agreement that were required to be complied with or performed by the Company during such time period.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2. Attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to this certificate is a description of the Company&#x2019;s use of proceeds of the Foundation Investment during the term of the Foundation Investment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3. Attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Exhibit B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to this certificate is the Company&#x2019;s evaluation of the Company&#x2019;s progress with respect to the HIV Vaccine Program, TB Vaccine Program, Vaccinal Antibody Development Program and Funded Developments, including information regarding progress against the Global Access Commitments (as set forth in the Letter Agreement) during the term of the Foundation Investment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the undersigned has executed this certificate and has caused this certificate to be delivered on the date first above written.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.3%;"></td>
    <td style="width:89.7%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Name:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Title:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Appendix 9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gates Foundation Open Access Policy</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Bill &amp; Melinda Gates Foundation is committed to information sharing and transparency. We believe that published research resulting from our funding should be promptly and broadly disseminated. We have adopted an Open Access policy that enables the unrestricted access and reuse of all peer-reviewed published research funded, in whole or in part, by the foundation, including any underlying data sets.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">As of January 1, 2015, our Open Access policy will be effective for all new agreements. During a two-year transition period, publishers will be permitted to apply up to a 12-month embargo period on the accessibility of the publication and its underlying data sets. This embargo period will no longer be allowed after January 1, 2017.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Our Open Access policy contains the following elements:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Publications Are Discoverable and Accessible Online. Publications will be deposited in a specified repository(s) with proper tagging of metadata. </font>
   </div>
  </div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Publication Will Be On &#x201c;Open Access&#x201d; Terms. All publications shall be published under the Creative Commons Attribution 4.0 Generic License (CC BY 4.0) or an equivalent license. This will permit all users of the publication to copy and redistribute the material in any medium or format and transform and build upon the material, including for any purpose (including commercial) without further permission or fees being required. </font>
   </div>
  </div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">3.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Foundation Will Pay Necessary Fees. The foundation would pay reasonable fees required by a publisher to effect publication on these terms. </font>
   </div>
  </div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">4.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Publications Will Be Accessible and Open Immediately. All publications shall be available immediately upon their publication, without any embargo period.  An embargo period is the period during which the publisher will require a subscription or the payment of a fee to gain access to the publication. We are, however, providing a transition period of up to two years from the effective date of the policy (or until January 1, 2017). During the transition period, the foundation will allow publications in journals that provide up to a 12-month embargo period.</font>
   </div>
  </div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Data Underlying Published Research Results Will Be Accessible and Open Immediately. The foundation will require that data underlying the published research results be immediately accessible and open. This too is subject to the transition period and a 12-month embargo may be applied.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>5
<FILENAME>vir-ex10_46.htm
<DESCRIPTION>EX-10.46
<TEXT>
<html>
 <head>
  <title>EX-10.46</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit 10.46</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">STOCK PURCHASE AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="ole_link5"><font id="ole_link6"></font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">This Stock Purchase Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) is entered into as of January 12, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Execution Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), by and between</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> the Bill &amp; Melinda Gates Foundation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, a Washington charitable trust that is a tax-exempt private foundation having an office at 500 5th Ave N, Seattle, WA 98109 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Foundation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a Delaware corporation having an office at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Vir</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  The capitalized terms used herein and not otherwise defined have the meanings given to them in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Appendix </font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Recitals</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir has agreed to sell, and the Foundation has agreed to purchase, shares of Common Stock subject to and in accordance with the terms and provisions of this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Contemporaneously with the execution of this Agreement, the Foundation and Vir are entering into amended and restated side letter agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Side Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), dated as of the Effective Date (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Gates Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Agreement</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For good and valuable consideration, the Foundation and Vir agree as follows:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 1.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Sale and Purchase of Stock</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.1</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Purchase of Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Subject to the terms and conditions of this Agreement, at the Closing, Vir will issue and sell to the Foundation, and the Foundation will purchase from Vir, a number of shares of Common Stock equal to $40,000,000 divided by the Share Value, rounded down to the nearest whole share (such shares of Common Stock, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  The aggregate purchase price shall equal the number of Shares multiplied by the Share Value, rounded to the nearest cent (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Purchase Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.2</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  At the Closing, the Foundation will pay the Purchase Price by wire transfer of immediately available funds in accordance with wire instructions, which instructions will have been provided by Vir to the Foundation at least three (3) Business Days prior to the Closing, and Vir will deliver the Shares in restricted book-entry form to the Foundation.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.3</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Closing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Closing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The closing of the transaction contemplated by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Closing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) will be held through the electronic exchange of documents and signatures, as promptly as practicable, and in no event more than five (5) Business Days after the conditions to the Closing set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> are satisfied or waived for the Closing (other than those conditions that by their nature are to be satisfied or waived at the Closing), or at such other time and/or date as may be jointly designated by the Foundation and Vir for the Closing.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Closing Deliverables</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. </font>
   </div>
  </div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(i)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">At the Closing, Vir will deliver to the Foundation: </font>
   </div>
  </div>
  <div style="text-indent:26.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:26.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:26.667%;">A.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a duly executed cross-receipt in form and substance reasonably satisfactory to each party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Cross-Receipt</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); </font>
   </div>
  </div>
  <div style="text-indent:26.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:26.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:26.667%;">B.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a certificate in form and substance reasonably satisfactory to the Foundation and duly executed on behalf of Vir by an authorized officer of Vir, certifying that the conditions to the Closing set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.2(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(b),</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of this Agreement have been fulfilled; </font>
   </div>
  </div>
  <div style="text-indent:26.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:26.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:26.667%;">C.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a certificate of the secretary of Vir dated as of the Closing Date certifying that attached thereto is a true and complete copy of all resolutions adopted by the Board authorizing the execution, delivery and performance of the Gates Agreements and the transactions contemplated herein and therein and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby as of the Closing Date; and</font>
   </div>
  </div>
  <div style="text-indent:26.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:26.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:26.667%;">D.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a duly executed counterpart of the Side Letter; </font>
   </div>
  </div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(ii)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">At the Closing, the Foundation will deliver to Vir:</font>
   </div>
  </div>
  <div style="text-indent:26.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:26.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:26.667%;">A.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a duly-executed Cross-Receipt; </font>
   </div>
  </div>
  <div style="text-indent:26.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:26.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:26.667%;">B.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a certificate in form and substance reasonably satisfactory to Vir and duly executed on behalf of the Foundation by an authorized officer of the Foundation, certifying that the conditions to the Closing set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.1(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of this Agreement have been fulfilled; and</font>
   </div>
  </div>
  <div style="text-indent:26.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:26.667%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:26.667%;">C.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a duly executed counterpart of the Side Letter. </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 2.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Representations and Warranties of Vir</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="ole_link4"><font id="ole_link3"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as otherwise specifically contemplated by this Agreement, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir hereby represents and warrants to the Foundation that:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.1</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Private Placement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Neither Vir nor any Person acting on its behalf, has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under any circumstances that would require registration of the Shares under the Securities Act.  Subject to the accuracy of the representations made by the Foundation in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Shares will be issued and sold to the Foundation in compliance with applicable exemptions from the registration and prospectus delivery requirements of the Securities Act and the registration and qualification requirements of all applicable securities Laws of the states of the United States.  Vir has not engaged any brokers, finders or agents, or incurred, or will incur, directly or indirectly, any liability for brokerage or finder&#x2019;s fees or agents&#x2019; commissions or any similar charges in connection with this Agreement and the transactions contemplated hereby.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.2</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Organization and Qualification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir is duly incorporated, validly existing and in good standing under the laws of the State of Delaware, with full corporate power and authority to conduct its business as currently conducted.  Vir is duly qualified to do business and is in good standing in every jurisdiction in which the nature of the business conducted by it or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not reasonably be expected to have a Material Adverse Effect on Vir. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.3</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Authorization; Enforcement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir has all requisite corporate power and authority to enter into and to perform its obligations under this Agreement, to consummate the transactions contemplated hereby and to issue the Shares in accordance with the terms and conditions hereof.  The execution, delivery and performance of this Agreement by Vir and the consummation by it of the transactions contemplated hereby (including the issuance of the Shares at the Closing in accordance with the terms and conditions hereof) have been duly authorized by the Board and no further consent or authorization of Vir, the Board, or its stockholders is required.  This Agreement has been duly executed by Vir and constitutes a legal, valid and binding obligation of Vir enforceable against Vir in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, or moratorium or similar Laws affecting creditors&#x2019; and contracting parties&#x2019; rights generally.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.4</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Issuance of Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Shares are duly authorized and, upon issuance in accordance with the terms of this Agreement, will be validly issued, fully paid and non-assessable and will not be subject to preemptive rights or other similar rights of stockholders of Vir.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.5</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">SEC Documents, Financial Statements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act.  Vir has delivered or made available (by filing on the SEC&#x2019;s electronic data gathering and retrieval system (EDGAR)) to the Foundation complete copies of its most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any report on Form 8-K, in each case filed with the SEC after December 31, 2020 and prior to the Execution Date (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">SEC Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  As of its date, each SEC Document complied in all material respects with the requirements of the Exchange Act, and other Laws applicable to it, and, as of its date, such SEC Document did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">No inquiries or any other investigation conducted by or on behalf of the Foundation or its representatives or counsel will modify, amend or affect the Foundation&#x2019;s right to rely on the truth, accuracy and completeness of the SEC Documents and Vir&#x2019;s representations and warranties contained in this Agreement.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The financial statements, together with the related notes and schedules, of Vir included in the SEC Documents comply as to form in all material respects with all applicable accounting requirements and the published rules and regulations of the SEC and all other applicable rules and regulations with respect thereto.  Such financial statements, together with the related notes and schedules, have been prepared in accordance with GAAP applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the financial condition of Vir and its consolidated subsidiaries as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Common Stock is listed on Nasdaq, and Vir has taken no action designed to, or that to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq.  As of the date of this Agreement, Vir has not received any notification that, and has no knowledge that, the SEC or Nasdaq is contemplating terminating such registration or listing.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.6</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Internal Controls; Disclosure Controls and Procedures</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir maintains internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act.  Vir has implemented the &#x201c;disclosure controls and procedures&#x201d; (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) required in order for the principal executive officer and principal financial officer of Vir to engage in the review and evaluation process mandated by the Exchange Act, and is in compliance with such disclosure controls and procedures in all material respects.  Each of the principal executive officer and the principal financial officer of Vir has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 with respect to all reports, schedules, forms, statements and other documents required to be filed by Vir with the SEC.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.7</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Capitalization and Voting Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The authorized capital of Vir as of the date hereof consists of: (i) 300,000,000 shares of Common Stock of which, as of January 11, 2022, (A) 131,182,666 shares were issued and outstanding, (B) 12,680,218 shares were reserved for issuance pursuant to Vir&#x2019;s equity incentive plans (including its stock purchase plan) described in the SEC Documents, (C) 10,287,645 shares were issuable upon the exercise of stock options outstanding, and (D) 1,271,334 shares were issuable upon the release of restricted stock unit awards outstanding, and (ii) 10,000,000 shares of Preferred Stock, of which no shares are issued and outstanding as of the date of this Agreement.  All of the issued and outstanding shares of Common Stock (1) have been duly authorized and validly issued, (2) are fully paid and non-assessable and (3) were issued in compliance with all applicable federal and state securities Laws and not in violation of any preemptive rights.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All of the authorized shares of Common Stock are entitled to one (1) vote per share. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as described or referred to in the SEC Documents, as of January 11, 2022, there were not: (i) any outstanding equity securities, options, warrants, rights (including conversion or preemptive rights) or other agreements pursuant to which Vir is or may become obligated to issue, sell or repurchase any shares of its capital stock or any other securities of Vir other than equity securities that may have been granted pursuant to its equity incentive plans, which plans are described in the SEC Documents; or (ii) any restrictions on the transfer of capital stock of Vir other than pursuant to federal or state securities Laws or as set forth in this Agreement.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir is not a party to or subject to any agreement or understanding relating to the voting of shares of capital stock of Vir or the giving of written consents by a stockholder or director of Vir.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.8</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">No Conflicts; Government Consents and Permits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The execution, delivery and performance of the Gates Agreements by Vir and the consummation by Vir of the transactions contemplated hereby and thereby (including the issuance of the Shares) will not (i) conflict with or result in a violation of any provision of Vir&#x2019;s Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws, each as in effect on the date hereof, (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default under, any agreement, indenture, or instrument to which Vir is a party, or (iii)  result in a violation of any Law (including United States federal, state and international securities Laws and regulations and regulations of any self-regulatory organizations) applicable to Vir, except in the case of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">clauses (ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> only, for such conflicts, breaches, defaults, and violations as would not reasonably be expected to have, a Material Adverse Effect on Vir or result in a liability for the Foundation. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory agency or self-regulatory organization in order for it to execute, deliver or perform any of its obligations under the Gates Agreements in accordance with the terms and conditions hereof or thereof, or to issue and sell the Shares in accordance with the terms and conditions hereof other than such as have been made or obtained, and except for (i) any post-closing filings required to be made under federal or state securities Laws and (ii) any required filings or notifications regarding the issuance or listing of additional shares with Nasdaq.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.9</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Litigation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Other than as set forth in the SEC Documents filed prior to the date of this Agreement, there is no action, suit, proceeding or investigation pending (of which Vir has received notice or otherwise has knowledge) or, to Vir&#x2019;s knowledge, threatened, against Vir or that Vir intends to initiate, except where such action, suit, proceeding or investigation, as the case may be, would not reasonably be expected to have a Material Adverse Effect.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.10</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Licenses and Other Rights; Compliance with Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir has all franchises, permits, licenses and other rights and privileges (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Permits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) necessary to permit it to own its properties and to conduct its business as presently conducted and is in compliance thereunder, except where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect.  Vir has not taken any action that would interfere with its ability to renew all such Permit(s), except where the failure to renew such Permit(s) would not reasonably be expected to have, a Material Adverse Effect.  Vir is and has been in compliance with all Laws applicable to its business, properties and assets, and to the products and services sold by it, except where the failure to be in compliance has not had and would not reasonably be expected to have a Material Adverse Effect.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.11</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Intellectual Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Intellectual Property that is owned by Vir or its subsidiaries is owned free from any Liens or restrictions.  All of Vir&#x2019;s material Intellectual Property Licenses are in full force and effect in accordance with their terms, are free of any Liens or restrictions, and, to Vir&#x2019;s knowledge, neither Vir, nor any other party thereto, is in material breach of any such material Intellectual Property License.  To Vir&#x2019;s knowledge, no event has occurred that with notice or lapse of time or both (i) would constitute a breach or default of any such material Intellectual Property License, (ii) would result in the termination thereof, or (iii) would cause or permit the acceleration or other change of any right or obligation or the loss of any benefit thereunder by Vir or its subsidiaries, except, in the case of each of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">clauses (i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> through </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as would not reasonably be expected to have a Material Adverse Effect. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as set forth in the SEC Documents, there is no legal claim or demand of any Person or any proceeding that is pending or threatened in writing, (i) challenging the right of Vir in respect of any Intellectual Property of Vir, or (ii) claiming that any default exists under any Intellectual Property License, except, in the case of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">clauses (i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> above, where any such claim, demand or proceeding has not had, and would not reasonably be expected to have, a Material Adverse Effect.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as set forth in the SEC Documents: (i) Vir or one of its subsidiaries owns, free and clear of any Lien or encumbrance, or, to Vir&#x2019;s knowledge, has a valid license, or an enforceable right to use, as it is used or held for use, all U.S. and non-U.S. patents, trade secrets, know-how, trademarks, service marks, copyrights, and other proprietary and Intellectual Property rights, and all grants and applications with respect to the foregoing (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Proprietary Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) necessary for the conduct of Vir&#x2019;s business, except where the failure to own or have any of the foregoing would not reasonably be expected to have a Material Adverse Effect (such Proprietary Rights owned by or licensed to Vir collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Vir Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); (ii) Vir and its subsidiaries have taken reasonable measures to protect the Vir Rights, consistent with prudent commercial practices in the biotechnology industry, except where failure to take such measures has not had, and would not reasonably be expected to have, a Material Adverse Effect, and (iii) without limiting the generality of the preceding, to the best of Vir&#x2019;s knowledge, Vir&#x2019;s current product candidates, if commercially sold at the projected launch, would not infringe any unlicensed third party granted US or non-US patent claims or, if granted without amendment, any unlicensed third party published US or non-US patent application claims, except to the extent any such infringement would not reasonably be expected to have a Material Adverse Effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.12</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Health Care Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir: (i) has operated and currently operates its business in compliance in all material respects with applicable provisions of the Health Care Laws (as defined below) of the Food and Drug Administration (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">FDA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), the Department of Health and Human Services and any comparable state, foreign or other regulatory authority to which they are subject (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Applicable Regulatory Authorities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) applicable to the ownership, testing, development, manufacture, packaging, processing, use, sale, promotion, distribution, storage, import, export or disposal of any of Vir&#x2019;s product candidates or any product manufactured or distributed by Vir; (ii) has not received any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from any court or arbitrator or the Applicable Regulatory Authorities alleging or asserting non-compliance with any licenses, </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Health Care Laws (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Regulatory Authorizations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); (iii) possesses all Regulatory Authorizations required to conduct its business as currently conducted and such Regulatory Authorizations are valid and in full force and effect and Vir is not in violation, in any material respect, of any term of any such Regulatory Authorizations; (iv) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or the Applicable Regulatory Authorities or any other third party alleging that any product operation or activity is in material violation of any Health Care Laws and has no knowledge that the Applicable Regulatory Authorities or any other third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v) has not received notice that any of the Applicable Regulatory Authorities has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Regulatory Authorizations and has no knowledge that any of the Applicable Regulatory Authorities is considering such action; (vi) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission); (vii) is not a party to and does not have any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Applicable Regulatory Authority; and (viii) along with its employees, officers and directors, has not been excluded, disqualified, suspended or debarred from participation in any government health care program or human clinical research or, to Vir&#x2019;s knowledge, subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, disqualification or exclusion.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.13</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Clinical Trials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Except for sotrovimab, none of Vir&#x2019;s product candidates has received marketing approval from any Applicable Regulatory Authority.  All clinical and pre-clinical studies and trials conducted by or on behalf of or sponsored by Vir, or in which Vir has participated, with respect to Vir&#x2019;s product candidates, including any such studies and trials that are described in the SEC Documents, or the results of which are referred to in the SEC Documents, as applicable (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Company Trials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), were, and if still pending are, to Vir&#x2019;s knowledge, being conducted in all material respects in accordance with all applicable Health Care Laws of the Applicable Regulatory Authorities, including the FDA&#x2019;s current Good Clinical Practices and Good Laboratory Practices, standard medical and scientific research procedures and any applicable rules, regulations and policies of the jurisdiction in which such trials and studies are being conducted.  The descriptions in the SEC Documents of the results of any Company Trials are accurate and complete descriptions in all material respects and fairly present the data derived therefrom as of the date of such SEC Documents.  Vir has no knowledge of any other studies or trials not described in the SEC Documents, the results of which are inconsistent with or call into question the results described or referred to in the SEC Documents.  Vir has not received any written notices, correspondence or other communications from the Applicable Regulatory Authorities or any other governmental entity or any institutional review board (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">IRB</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) or independent ethics committee (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">IEC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) requiring or threatening the termination, material modification or suspension of Company Trials, other than ordinary course communications with respect to modifications in connection with the design and implementation of such studies or trials, and, to Vir&#x2019;s knowledge, there are no </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">reasonable grounds for the same.  No investigational new drug application or comparable submission filed by or on behalf of Vir with the FDA has been terminated or suspended by the FDA or any other Applicable Regulatory Authority.  Vir has obtained (or caused to be obtained) informed consent by or on behalf of each human subject who participated in a Company Trial, and Vir has obtained (or caused to be obtained) applicable IRB or IEC approvals for each Company Trial.  To Vir&#x2019;s knowledge, none of the Company Trials involved any investigator who has been disqualified as a clinical investigator or has been found by the FDA to have engaged in scientific misconduct.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.14</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Absence of Certain Changes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as disclosed in the SEC Documents filed prior to the Execution Date, since September 30, 2021, no change or event has occurred, except where such change or event has not had, and would not reasonably be expected to have, a Material Adverse Effect on Vir. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as set forth in the SEC Documents filed prior to the Execution Date since September 30, 2021, Vir has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, or (ii) sold, exchanged or otherwise disposed of any of its material assets or rights.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Since September 30, 2021, Vir has not admitted in writing its inability to pay its debts generally as they become due, filed or consented to the filing against it of a petition in bankruptcy or a petition to take advantage of any insolvency act, made an assignment for the benefit of creditors, consented to the appointment of a receiver for itself or for the whole or any substantial part of its property, or had a petition in bankruptcy filed against it, been adjudicated a bankrupt, or filed a petition or answer seeking reorganization or arrangement under the federal bankruptcy Laws or any other Laws of the United States or any other jurisdiction.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.15</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Not an Investment Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir is not, and after receipt of the Purchase Price, will not be, an &#x201c;investment company&#x201d; as defined in the Investment Company Act of 1940, as amended. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.16</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">No Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir has not, directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) that is or will be integrated with the Shares sold pursuant to this Agreement in a manner that would require the registration of the Shares under the Securities Act.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 3.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Representations and Warranties of the Foundation</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as otherwise specifically contemplated by this Agreement, the Foundation hereby represents and warrants to Vir that:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.1</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Authorization; Enforcement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Foundation has the requisite corporate or other similar power and authority to enter into this Agreement and to consummate the transactions contemplated hereby.  The Foundation has taken all necessary corporate or other similar action to authorize the execution, delivery and performance of this Agreement.  Upon the execution and delivery of this Agreement, this Agreement will constitute a valid and binding obligation of the Foundation enforceable against the Foundation in accordance with its terms and conditions, except </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&#x2019; and contracting parties&#x2019; rights generally.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.2</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">No Conflicts; Government Consents and Permits.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The execution, delivery and performance of this Agreement by the Foundation and the consummation by the Foundation of the transactions contemplated hereby (including the purchase of the Shares) will not (i) conflict with or result in a violation of any provision of the Foundation&#x2019;s organizational documents, (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default under, any agreement, indenture, or instrument to which the Foundation is a party, or (iii) result in a violation of any Law (including U.S. federal and state and applicable non-U.S. securities Laws and regulations and regulations of any self-regulatory organizations) applicable to the Foundation, except in the case of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">clauses (ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> only, for such conflicts, breaches, defaults, and violations as have not had, and would not reasonably be expected to have, a Material Adverse Effect on the Foundation or result in a liability for Vir. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Foundation is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory agency or self-regulatory organization in order for it to execute, deliver or perform any of its obligations under this Agreement in accordance with the terms and conditions hereof, or to purchase the Shares in accordance with the terms and conditions hereof, other than such as have been made or obtained.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.3</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Investment Purpose</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Foundation is purchasing the Shares for its own account and not with a present view toward the public distribution thereof and has no arrangement or understanding with any other Persons regarding the distribution of such Shares except as would not result in a violation of the Securities Act.  The Foundation will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Shares except in accordance with the Securities Act and to the extent permitted by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.4</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Reliance on Exemptions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Foundation understands that Vir intends for the Shares to be offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities Laws and that Vir is relying upon the truth and accuracy of, and the Foundation&#x2019;s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Foundation set forth herein in order to determine the availability of such exemptions and the eligibility of the Foundation to acquire the Shares.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.5</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Accredited Investor; Access to Information.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Foundation is an &#x201c;accredited investor&#x201d; as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares.  The Foundation has been furnished with materials relating to the offer and sale of the Shares that have been requested by the Foundation, including the SEC Documents, and the Foundation has had the opportunity to review the SEC Documents.  The Foundation has been afforded the opportunity to </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ask questions of Vir.  Neither such inquiries nor any other investigation conducted by or on behalf of the Foundation or its representatives or counsel will modify, amend or affect the Foundation&#x2019;s right to rely on the truth, accuracy and completeness of the SEC Documents and Vir&#x2019;s representations and warranties contained in this Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.6</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Restricted Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Foundation understands that the Shares will be characterized as &#x201c;restricted securities&#x201d; under the U.S. federal securities Laws inasmuch as they are being acquired from Vir in a private placement under Section 4(a)(2) of the Securities Act and that under such Laws and applicable regulations such Shares may be resold without registration under the Securities Act only in certain limited circumstances.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.7</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Governmental Review</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Foundation understands that no U.S. federal or state agency or any other Governmental Authority has passed upon or made any recommendation or endorsement of the Shares or an investment therein.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 4.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Transfer, Resale, Legends, Registration Rights</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.1</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Transfer or Resale.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Foundation understands that:</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Shares have not been and are not being registered under the Securities Act or any applicable state securities Laws and, consequently, the Foundation may have to bear the risk of owning the Shares for an indefinite period of time because the Shares may not be transferred unless (i) the resale of the Shares is registered pursuant to an effective registration statement under the Securities Act; (ii) the Foundation has delivered to Vir an opinion of counsel (in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the Shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration; or (iii) the Shares are sold or transferred pursuant to Rule 144 under the Securities Act (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Rule 144</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); and</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">any sale of the Shares made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and, if Rule 144 is not applicable, any resale of the Shares under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.2</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Lock-Up</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Foundation agrees that it will hold and will not sell any of the Shares (or otherwise make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of the Shares) until the one-year anniversary of the Closing Date.  Notwithstanding the foregoing, this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">will not preclude (i) distributions of Shares to general or limited partners, members, shareholders, Affiliates or wholly-owned subsidiaries of the Foundation or any investment fund or other entity controlled or managed by the Foundation; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, in each case, that following any such transfer such Shares will remain subject to the provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">; (ii) transfers pursuant to a </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">bona fide</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> third party tender offer for all outstanding shares of Common Stock, merger, consolidation or other similar transaction made to all holders of Vir&#x2019;s securities involving a change of control of Vir (including the entering into any lock-up, voting or similar agreement pursuant to which the </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Foundation may agree to transfer, sell, tender or otherwise dispose of Shares or other such securities in connection with such transaction, or vote any Shares or other such securities in favor of any such transaction); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Shares shall remain subject to the provisions of this Section 4.2; or (iii) sales or transfers of the Shares in connection with the Withdrawal Right (as defined in the Side Letter).</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.3</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Legends</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Foundation understands the Shares will bear restrictive legends in substantially the following form (and a stop-transfer order may be placed against transfer of the Shares):</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">THE SHARES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS.  THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS OR A CERTIFICATE AND/OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THESE SECURITIES IS SUBJECT TO THE TERMS AND CONDITIONS OF A STOCK PURCHASE AGREEMENT DATED JANUARY 12, 2022 BETWEEN VIR BIOTECHNOLOGY, INC. AND THE BILL &amp; MELINDA GATES FOUNDATION.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If such Shares may be transferred pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (excluding transfers pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2(i))</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Foundation may request that Vir remove, and Vir agrees to authorize and instruct (including by causing any required legal opinion to be provided) the removal of any legend from the Shares, if permitted by applicable securities Law, within two (2) Business Days of any such request; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that each party will be responsible for any fees it incurs in connection with such request and removal.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.4</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Registration Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If, following the one-year anniversary of the Closing Date, the Foundation proposes to publicly resell the Shares pursuant to Rule 144, and the Foundation in good faith believes it will be unable to sell all of the Shares proposed to be sold by it pursuant to Rule 144 without volume or manner-of-sale restrictions, the Foundation shall notify Vir, and Vir shall file as promptly as practicable a secondary-only registration statement on Form S-3 (or any successor form to Form S-3) promulgated under the Securities Act (which, if Vir is then a &#x201c;well-known seasoned issuer&#x201d; (as defined in Rule 405 under the Securities Act), shall be filed pursuant to General Instruction I.D of Form S-3 (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Automatic Shelf Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;)), registering the resale of such Shares (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Registrable Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) (or, in the event that Form S-3 is not available for the registration of the resale of the Registrable Securities, another appropriate form reasonably acceptable to the Foundation) by the Foundation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">).  Vir shall use commercially reasonable efforts (a) if the Registration Statement is not an Automatic Shelf Registration Statement, to cause the Registration Statement to become effective as promptly as practicable; (b) to cause the Registration Statement to remain effective until the earlier of (i) the date on which the Foundation has disposed of all of the Registrable Securities and (ii) Rule 144 is available for the disposition of all Registrable Securities without volume or manner-of-sale </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">restrictions; (c) to undertake any additional actions reasonably necessary to maintain the availability of, and to facilitate the disposition by the Foundation of the Registrable Securities pursuant to, the Registration Statement; and (d) to obtain any required consent under Vir&#x2019;s Amended and Restated Investors&#x2019; Rights Agreement, dated as of November 19, 2017, by and among Vir and the investors party thereto or any other agreement to which Vir is a party related to the filing of the Registration Statement.  The Foundation agrees to cooperate with Vir as reasonably requested by Vir in connection with the preparation and filing of the Registration Statement, including furnishing to Vir such information regarding itself, the shares of Common Stock held by it and the intended method of disposition of the Registrable Securities as shall be reasonably required to effect the registration of such Registrable Securities.  Vir shall bear all expenses incurred in connection with the performance of its obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that Vir shall have no obligation to pay for any commissions or transfer taxes of the Foundation.  Vir&#x2019;s obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall also apply to any shares in the capital of Vir issued or issuable with respect to the Registrable Securities as a result of any share split, share dividend, recapitalization, exchange or similar event.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 5.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Conditions to Closing</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.1</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Conditions to Obligations of Vir</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir&#x2019;s obligation to complete the purchase and sale of the Shares and deliver the Shares to the Foundation is subject to the fulfillment or waiver of the following conditions at or prior to the Closing:</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Receipt of Funds</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir will have received immediately available funds in the full amount of the Purchase Price for the Shares being purchased hereunder.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Representations and Warranties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The representations and warranties made by the Foundation in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> will be true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties are made as of another date, in which case such representations and warranties will be true and correct in all material respects as of such other date.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  All covenants and agreements contained in this Agreement to be performed or complied with by the Foundation on or prior to the Closing Date shall have been performed or complied with in all material respects.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Absence of Litigation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, will have been instituted or be pending before any Governmental Authority. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">No Governmental Prohibition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The sale of the Shares by Vir and the purchase of the Shares by the Foundation will not be prohibited by any applicable Law at the time of the Closing.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(f)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Closing Deliverables</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  All closing deliverables as required under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 1.3(b)(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall have been delivered by the Foundation to Vir.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.2</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Conditions to the Foundation&#x2019;s Obligations at the Closing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Foundation&#x2019;s obligation to complete the purchase and sale of the Shares is subject to the fulfillment or waiver of the following conditions at or prior to the Closing:</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Representations and Warranties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The representations and warranties made by Vir in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> will be true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties are made as of another date, in which case such representations and warranties will be true and correct in all material respects as of such other date.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  All covenants and agreements contained in this Agreement to be performed or complied with by Vir on or prior to the Closing Date shall have been performed or complied with in all material respects.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Transfer Agent Instructions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir will have delivered to its transfer agent irrevocable written instructions to issue the Shares to the Foundation in a form and substance acceptable to such transfer agent.</font>
   </div>
  </div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Absence of Litigation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, will have been instituted or be pending before any Governmental Authority.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">No Governmental Prohibition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The sale of the Shares by Vir, and the purchase of the Shares by the Foundation will not be prohibited by any applicable Law at the time of the Closing. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(f)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Closing Deliverables</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  All closing deliverables as required under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 1.3(b)(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall have been delivered by Vir to the Foundation.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 6.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Governing Law; Jurisdiction</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.1</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. This Agreement, and any other agreement, document or instrumented delivered pursuant hereto (other than the Side Letter), and all claims or causes of action (whether in contract or tort) that may be based upon, arise out of or relate to this Agreement (or such other document) or the negotiation, execution, termination, performance or nonperformance of this Agreement (or such other document) (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement), shall be governed by and interpreted in accordance with the laws of the State of Delaware without regard to the principles of conflict of laws that would require the application of the substantive Laws of another jurisdiction.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.2</font>
   <div style="display:inline;" id="docxtextref371">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Jurisdiction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Each of the parties hereby </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> expressly and irrevocably submits to the exclusive personal jurisdiction of the Delaware Court of Chancery, any other court of the State of Delaware or any Federal court sitting in the State of Delaware in the event any dispute arises out of this Agreement or any of the transactions contemplated hereby (other than in connection with the Side Letter), </font><font id="docxtextref372"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> agrees that it will not attempt to deny or defeat such personal jurisdiction </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <div style="display:inline;" id="docxtextref373">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">by motion or other request for leave from any such court, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated hereby (other than in connection with the Side Letter) in any court other than the Delaware Court of Chancery, any other court of the State of Delaware or any Federal court sitting in the State of Delaware and </font><font id="docxtextref374"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> agrees that the other party shall have the right to bring any action or proceeding for enforcement of a judgment entered by the Delaware Court of Chancery, any other court of the State of Delaware or any Federal court sitting in the State of Delaware.  Each of Vir and the Foundation agrees that a final judgment in any action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 7.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Miscellaneous </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.1</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Counterparts; Electronic Signatures</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement may be executed and delivered (including by facsimile transmission or PDF or any other electronically transmitted signatures) in two counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.2</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The headings of this Agreement are for convenience of reference only, are not part of this Agreement and do not affect its interpretation.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.3</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Rules of Construction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As used in this Agreement, (i) the words &#x201c;include&#x201d; and &#x201c;including,&#x201d; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#x201c;without limitation&#x201d;, (ii) the words &#x201c;hereby,&#x201d; &#x201c;herein,&#x201d; &#x201c;hereunder&#x201d; and &#x201c;hereto&#x201d; shall be deemed to refer to this Agreement in its entirety and not to any specific section of this Agreement and (iii) &#x201c;or&#x201d; has the inclusive meaning represented by the phrase &#x201c;and/or&#x201d;.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as otherwise indicated, all references in this Agreement to &#x201c;Sections&#x201d; and &#x201c;Appendices&#x201d; are intended to refer to Sections of this Agreement, as appropriate, and Appendices to this Agreement.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As used in this Agreement, the term &#x201c;days&#x201d; means calendar days unless otherwise specified.  When calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded.  If the last day of such period is a non-Business Day, the period in question shall end on the next succeeding Business Day.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Unless otherwise indicated, all monetary amounts herein are in United States dollars.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.4</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If any provision of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the parties will negotiate in good faith a valid, legal and </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">enforceable substitute provision that most nearly reflects the original intent of the parties and all other provisions hereof will remain in full force and effect in such jurisdiction and will be liberally construed in order to carry out the intentions of the parties hereto as nearly as may be possible.  Such invalidity, illegality or unenforceability will not affect the validity, legality or enforceability of such provision in any other jurisdiction.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.5</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Entire Agreement; Amendments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Gates Agreements (including any schedules, appendices and exhibits hereto or thereto and any certificates delivered hereunder or thereunder) constitute the entire agreement between the parties hereto with respect to the subject matter hereof and thereof.  There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein or therein.  This Agreement supersedes all prior agreements and understandings between the parties hereto with respect to the subject matter hereof.  No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the party to be charged with enforcement.  Any amendment or waiver effected in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 8.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall be binding upon the Foundation and Vir.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.6</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  All notices required or permitted hereunder will be in writing and will be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed email if sent during normal business hours of the recipient, if not, then on the next Business Day, or (c) one Business Day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.  The addresses for such communications are:</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15</font></p>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.587%;"></td>
    <td style="width:50.92%;"></td>
    <td style="width:42.494%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If to Vir, addressed to:</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">499 Illinois Street, Suite 500</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">San Francisco, CA 94158</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attention: Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">E-mail: hhorn@vir.bio</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">499 Illinois Street, Suite 500</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">San Francisco, CA 94158</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attention: Head of Legal</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">E-mail: ipleasure@vir.bio</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">with a copy to:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Cooley LLP</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3175 Hanover Street</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Palo Alto, CA 94304-1130</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attention: Laura Berezin</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">E-mail: lberezin@cooley.com</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If to the Foundation, addressed to:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Bill &amp; Melinda Gates Foundation</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1432 Elliott Ave W</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Seattle, WA 98119</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attention: Director, Strategic Investment Fund</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Phone:  (206) 709-3100</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Email: SIFPortfolio@gatesfoundation.org</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Bill &amp; Melinda Gates Foundation</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1432 Elliott Ave W</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Seattle, WA 98119</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attention: Keith Matthews, General Counsel</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Phone:  (206) 709-3100</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Email: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;">Keith.Matthews@gatesfoundation.org</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">with a copy to:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Morrison &amp; Foerster LLP</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">425 Market St.</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">San Francisco, CA 94105</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attention: Jaclyn Liu</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Email: jliu@mofo.com</font></p></td>
   </tr>
  </table>
  <p style="margin-left:33.333%;text-indent:10.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.7</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Successors and Assigns</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement is binding upon and inures to the benefit of the parties and their successors and assigns.  Vir will not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Foundation, and the Foundation will not assign this Agreement or any rights or obligations hereunder without the prior written consent of Vir; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that the Foundation may assign this Agreement together with all of the </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Shares it then owns (subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) to any wholly-owned subsidiary and any such assignee may assign this Agreement together with all of the Shares it then owns (subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) to the Foundation or any other subsidiary wholly-owned by the Foundation, in any such case, without such consent; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> that the assignee agrees to assume the Foundation&#x2019;s obligations under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of this Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.8</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Third Party Beneficiaries</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement is intended for the benefit of the parties hereto, their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.9</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Further Assurances</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Each party will do and perform, or cause to be done and performed, all such further acts and things, and will execute and deliver all other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.10</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">No</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Strict Construction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The language used in this Agreement is deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against a party.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.11</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Equitable Relief</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir recognizes that, if it fails to perform or discharge any of its obligations under this Agreement, any remedy at Law may prove to be inadequate relief to the Foundation.  Vir therefore agrees that the Foundation is entitled to seek temporary and permanent injunctive relief or specific performance in any such case.  The Foundation also recognizes that, if it fails to perform or discharge any of its obligations under this Agreement, any remedy at Law may prove to be inadequate relief to Vir.  The Foundation therefore agrees that Vir is entitled to seek temporary and permanent injunctive relief or specific performance in any such case.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.12</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir and the Foundation are each liable for, and will pay, their own expenses incurred in connection with the negotiation, preparation, execution and delivery of this Agreement, including attorneys&#x2019; and consultants&#x2019; fees and expenses.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.13</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Public Disclosure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  On or within five Business Day of the Execution Date, Vir and the Foundation shall issue a joint press release in a form mutually agreed to by Vir and the Foundation.  In addition, if applicable, Vir shall file a Current Report on Form 8-K with the SEC within the time period required by such form and including such disclosures as required by such form with respect to this Agreement and the transactions contemplated herein, such Current Report on Form 8-K to be in a form mutually agreed to by Vir and the Foundation.  No other written release, public announcement, disclosure or filing concerning the purchase of the Shares, the Gates Agreements or the transactions contemplated hereby or thereby shall be issued, filed or furnished, as the case may be, by any party without the prior written consent of the other party (which consent shall not be unreasonably withheld, conditioned or delayed) and, except as set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 8.13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the parties agree to keep the terms of the Gates Agreements confidential.  Notwithstanding the foregoing, the parties acknowledge and agree that applicable Law or the requirements of a national securities exchange or another similar regulatory body may require either party to file or otherwise disclose a copy of this Agreement and/or the Side Letter.  The party required to make such filing or otherwise disclose shall notify the other party and shall provide the other party with </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17</font></p>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">at least three (3) days to request redactions thereof prior to making such filing or disclosure.  The disclosing party shall use commercially reasonable efforts to procure confidential treatment of such proposed redactions pursuant to the Securities Act and the Exchange Act, in each case as amended, and the rules, regulations and guidelines promulgated thereunder, or any other applicable Law or the rules, regulations or guidelines promulgated hereunder; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> that the foregoing shall not prevent the party from making such public disclosures as it must make to comply with applicable Law.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[Remainder of page intentionally left blank.]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">In Witness Whereof, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Foundation and Vir have caused this Agreement to be duly executed as of the date first above written.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.7%;"></td>
    <td style="width:9.09%;"></td>
    <td style="width:39.069%;"></td>
    <td style="width:7.141%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Bill &amp; Melinda Gates Foundation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">/s/ Carolyn Ainslie</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">/s/ Howard Horn</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Signature page to Stock Purchase Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;" id="appendix_1"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Appendix </font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Defined Terms</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Affiliate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; of an entity means any corporation, firm, partnership or other entity that directly or indirectly through one or more intermediaries controls, is controlled by or is under common control with it.  An entity will be deemed to control another entity if it (i) owns, directly or indirectly, at least 50% of the outstanding voting securities or capital stock (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of such other entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (ii) has the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of the entity.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Applicable Regulatory Authorities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Automatic Shelf Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means the board of directors of Vir.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Business Day</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a day Monday through Friday on which banks are generally open for business in the State of California and the State of Washington.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Closing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 1.3(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Closing Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the date on which the Closing actually occurs.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means shares of Vir&#x2019;s common stock, par value $0.0001 per share.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Company Trials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Cross-Receipt</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 1.3(b)(i)A)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">DOJ</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the U.S. Department of Justice.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the SEC thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Execution Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">FDA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Foundation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">FTC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means the U.S. Federal Trade Commission.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">GAAP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means generally accepted accounting principles in the United States of America.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Good Clinical Practices&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> means the legal, scientific and ethical standards for the performance of clinical research on medicinal products involving humans, including as reflected in the regulations of the FDA at 21 C.F.R. parts 50, 54, 56, and 312.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Good Laboratory Practices&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> means the legal, scientific and ethical standards for the performance of nonclinical laboratory studies, including as set out in the regulations of the FDA at 21 C.F.R. part 58.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Governmental Authority</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any federal, state, provincial, local, municipal, foreign or other governmental or quasi-governmental authority, including any arbitrator and applicable securities exchanges, or any department, minister, agency, commission, commissioner, board, subdivision, bureau, instrumentality, court or other tribunal of any of the foregoing.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Health Care Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395-1395lll (the Medicare statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1396-1396w-5 (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. &#167; 1320a-7b(b); the civil False Claims Act, 31 U.S.C. &#167;&#167; 3729 et seq.; the criminal False Claims Act 42 U.S.C. 1320a-7b(a); any other criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287 and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; 1320d et seq., (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">HIPAA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; 1320a-7a; the Physician Payments Sunshine Act, 42 U.S.C. &#167; 1320a-7h; the Exclusion Laws, 42 U.S.C. &#167; 1320a-7; HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. &#167;&#167; 17921 et seq.; the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq.; the Public Health Service Act, 42 U.S.C. &#167;&#167; 201 et seq.; the regulations promulgated pursuant to such laws; and any similar federal, state and local laws and regulations, each and all as may be amended from time to time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">HIPAA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the definition of &#x201c;Health Care Laws.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">IEC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Intellectual Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean trademarks, trade names, trade dress, service marks, copyrights, and similar rights (including registrations and applications to register or renew the registration of any of the foregoing), patents and patent applications, trade secrets, and any other similar intellectual property rights.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Intellectual Property License</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean any license, permit, authorization, approval, contract or consent granted, issued by or with any Person relating to the use of Intellectual Property.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">IRB</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any federal, state, local or foreign constitution, treaty, law, statute, ordinance, rule, regulation, interpretation, directive, policy, order, writ, decree, injunction, judgment, stay or restraining order of any Governmental Authority, the terms of any permit, and any other ruling or decision of, agreement with or by, or any other requirement of, any Governmental Authority.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Lien</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any lien (statutory or otherwise), claim, charge, option, security interest, pledge, mortgage, restriction, financing statement or similar encumbrance of any kind or nature whatsoever (including any conditional sale or other title retention agreement and any lease having substantially the same effect as any of the foregoing and any assignment or deposit arrangement in the nature of a security device).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Material Adverse Effect</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any change, effect or circumstance, individually or in the aggregate, (a) that is reasonably likely to be materially adverse to the business, operations, assets or financial condition of Vir or the Foundation, as the case may be, taken as a whole, or (b) that materially impairs the ability of Vir or the Foundation to perform its obligations pursuant to the transactions contemplated by this Agreement or the Gates Agreements; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that, none of the following (alone or when aggregated with any other effects), shall be deemed to be a Material Adverse Effect, and none of the following (alone or when aggregated with any other effects), shall be taken into account for purposes of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">clause (a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> above: (A) (1) general market, economic or political conditions or (2) conditions (or any changes therein) in the industries in which Vir or the Foundation conducts business, in each case, including any acts of terrorism or war, weather conditions, global virus pandemics, epidemics or other force majeure events, in the case of each of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">clauses (1)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(2)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, solely to the extent that such effects do not have and are not reasonably likely to have a material disproportionate impact on Vir or the Foundation, as the case may be; (B) this Agreement, the Side Letter and the transactions contemplated hereby and thereby; or (C) changes in the trading price or volume of the Common Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Nasdaq</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means The Nasdaq Global Select Market.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Permits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a human being, labor organization, partnership, firm, enterprise, association, joint venture, corporation, limited liability company, cooperative, legal representative, foundation, society, political party, estate, trust, trustee, trustee in bankruptcy, receiver or any other organization or entity whatsoever, including any Governmental Authority.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Preferred Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means shares of Vir&#x2019;s preferred stock, par value $0.0001 per share.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Proprietary Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.11(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Purchase Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Registrable Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Regulatory Authorizations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Rule 144</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.1(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">SEC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the United States Securities and Exchange Commission or any successor entity.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">SEC Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.5(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Securities Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Securities Act of 1933, as amended, and the rules and regulations of the SEC thereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Share Value</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a price per Share (rounded to the nearest cent) equal to the volume weighted average price of a share of Common Stock for a thirty (30) Trading Day period, starting with the opening of trading on the thirtieth (30</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) Trading Day prior to the date hereof and ending with the close of trading on the Trading Day prior to the date hereof, as reported by Bloomberg, L.P.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Tax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any federal, state, local, or foreign income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental (including taxes under Section 59A of the Internal Revenue Code of 1986, as amended), customs duties, capital stock, franchise, profits, withholding, social security (or similar), unemployment, disability, real property, personal property, sales, use, transfer, registration, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including any interest, penalty, or addition thereto, whether disputed or not.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Trading Day</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a day on which Nasdaq is open for trading.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Vir</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Vir Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.11(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47
<SEQUENCE>6
<FILENAME>vir-ex10_47.htm
<DESCRIPTION>EX-10.47
<TEXT>
<html>
 <head>
  <title>EX-10.47</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit </font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10.47</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],  HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GRANT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Investment ID INV-033423</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">AGREEMENT SUMMARY &amp; SIGNATURE PAGE</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:22.505%;"></td>
    <td style="width:77.495%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="border-top:0.500pt solid;background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GRANTEE INFORMATION</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Vir Biotechnology Inc</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Tax Status:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Not exempt from federal income tax under U.S. IRC &#167; 501(c)(3)</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You confirm that the above information is correct and agree to notify the Foundation immediately of any change.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expenditure Responsibility:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement is subject to &#x201c;expenditure responsibility&#x201d; requirements under the U.S. Internal Revenue Code.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Mailing Address:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">499 Illinois Street, Suite 500, San Francisco, California 94158, USA</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Primary Contact:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">FOUNDATION INFORMATION</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Mailing Address:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">P. O. Box 23350, Seattle, Washington 98102, USA</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Primary Contact:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">AGREEMENT INFORMATION</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Development of Vaccinal Abs for HIV and Malaria</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201c;Charitable Purpose&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">to develop enhanced antibody therapies for the treatment of HIV and prevention of malaria disproportionately affecting those living in low- and middle-income countries (LMICs)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201c;Start Date&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date of last signature</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201c;End Date&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2023</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement includes and incorporates by this reference:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement Summary &amp; Signature Page and:</font></p><div style="margin-left:0.05138888888888887in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3347136723038235%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Grant Amount and Reporting &amp; Payment Schedule (Attachment A)</font></div></div><div style="margin-left:0.05138888888888887in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3347136723038235%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Terms and Conditions (Attachment B)</font></div></div><div style="margin-left:0.05138888888888887in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3347136723038235%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Investment Document (date submitted October 21, 2021)</font></div></div><div style="margin-left:0.05138888888888887in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3347136723038235%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Budget (date submitted October 21, 2021)</font></div></div><div style="margin-left:0.05138888888888887in;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3347136723038235%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">VIR/BMGF Series A/B Financing side letter (&#x201c;Side Letter&#x201d;), dated 23 December 2016 (as subsequently amended and restated)</font></div></div></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">THIS AGREEMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> is between Vir Biotechnology Inc (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">You</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Grantee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;) and the Bill &amp; Melinda Gates Foundation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Foundation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;), and is effective as of date of last signature. Each party to this Agreement may be referred to individually as a &#x201c;Party&#x201d; and together as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.&#x201d; As a condition of this grant, the Parties enter into this Agreement by having their authorized representatives sign below.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.936%;"></td>
    <td style="width:50.064%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">BILL &amp; MELINDA GATES FOUNDATION</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;font-style:italic;">/s/	Omar Vandal</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:	Omar Vandal</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Title:	Senior Program Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">January 12, 2022</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">VIR BIOTECHNOLOGY INC</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;font-style:italic;">/s/ 	George Scangos</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:	George Scangos</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Title:	CEO</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">January 12, 2022</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GRANT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Investment ID INV-033423</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">ATTACHMENT A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">GRANT AMOUNT AND REPORTING &amp; PAYMENT SCHEDULE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GRANT AMOUNT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Foundation will pay You the total grant amount specified in the Reporting &amp; Payment Schedule below. The Foundation&#x2019;s Primary Contact must approve in writing any Budget cost category change of more than [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">REPORTING &amp; PAYMENT SCHEDULE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Payments are subject to Your compliance with this Agreement, including Your achievement, and the Foundation&#x2019;s approval, of any applicable targets, milestones, and reporting deliverables required under this Agreement. The Foundation may, in its reasonable discretion, modify payment dates or amounts and will notify You of any such changes in writing.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">REPORTING</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will submit reports according to the Reporting &amp; Payment Schedule using the Foundation&#x2019;s templates or forms, which the Foundation will make available to You and which may be modified from time to time. For a progress or final report to be considered satisfactory, it must demonstrate meaningful progress against the targets or milestones for that investment period. If meaningful progress has not been made, the report should explain why not and what adjustments You are making to get back on track. Please notify the Foundation&#x2019;s Primary Contact if You need to add or modify any targets or milestones. The Foundation must approve any such changes in writing. You agree to submit other reports the Foundation may reasonably request.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ACCOUNTING FOR PERSONNEL TIME</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will track the time of all employees, contingent workers, and any other individuals whose compensation will be paid in whole or in part by Grant Funds. Such individuals will keep records (e.g., timesheets) of actual time worked on the Project in increments of sixty minutes or less and brief descriptions of tasks performed. You will report actual time worked consistent with those records in Your progress and final budget reports. You will submit copies of such records to the Foundation upon request.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:22.355%;"></td>
    <td style="width:24.272%;"></td>
    <td style="width:16.788%;"></td>
    <td style="width:15.996%;"></td>
    <td style="width:20.589%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">REPORTING &amp; PAYMENT SCHEDULE</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Investment Period</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Target, Milestone, or Reporting Deliverable</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Due By</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Payment Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Payment Amount (U.S.$)</font></p></td>
   </tr>
   <tr style="height:46.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Total Grant Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">$10,000,000.00</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GRANT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Investment ID INV-033423</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">ATTACHMENT B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">TERMS &amp; CONDITIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement is subject to the following terms and conditions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PROJECT SUPPORT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">PROJECT DESCRIPTION AND CHARITABLE PURPOSE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Foundation is awarding You this grant to carry out the project described in the Investment Document (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Project</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;) in order to further the Charitable Purpose. The Foundation, in its discretion, may approve in writing any request by You to make non-material changes to the Investment Document.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">MANAGEMENT OF FUNDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">USE OF FUNDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You may not use funds provided under this Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Grant Funds</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;) for any purpose other than the Project. You may not use Grant Funds to reimburse any expenses You incurred prior to the Start Date. At the Foundation&#x2019;s request, You will repay any portion of Grant Funds and/or Income used or committed in material breach of this Agreement, as determined by the Foundation in its discretion.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">INVESTMENT OF FUNDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You must invest Grant Funds in highly liquid investments with the primary objective of preservation of principal (e.g., interest-bearing bank accounts or a registered money market mutual fund) so that the Grant Funds are available for the Project. Together with any progress or final reports required under this Agreement, You must report the amount of any currency conversion gains (or losses) and the amount of any interest or other income generated by the Grant Funds (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Income</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;). Any Income must be used for the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SEGREGATION OF FUNDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You must maintain Grant Funds in a physically separate bank account or a separate bookkeeping account maintained as part of Your financial records and dedicated to the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GLOBAL ACCESS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GLOBAL ACCESS COMMITMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will conduct and manage the Project and the Funded Developments in a manner that ensures Global Access as further described in the Side Letter and any subsequent amendments. Your Global Access commitments will survive the term of this Agreement. &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Funded Developments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d; means the products, services, processes, technologies, materials, software, data, other innovations, and intellectual property resulting from the Project (including modifications, improvements, and further developments to Background Technology). &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Background Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d; means any and all products, services, processes, technologies, materials, software, data, or other innovations, and intellectual property created by You or a third party prior to or outside of the Project used as part of the Project. &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Global Access</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d; means: (a) the knowledge and information gained from the Project will be promptly and broadly disseminated; and (b) the Funded Developments will be made available and accessible at an affordable price (i) to people most in need within developing countries, or (ii) in support of the U.S. educational system and public libraries, as applicable to the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PUBLICATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Consistent with Your Global Access commitments, if the Project description specifies Publication or Publication is otherwise requested by the Foundation, You will seek prompt Publication of any Funded Developments consisting of data and results. &#x201c;Publication&#x201d; means publication in a peer-reviewed journal or other method of public dissemination specified in the Project description or otherwise approved by the Foundation in writing. Publication may be delayed for a reasonable period for the sole purpose of seeking patent protection, provided the patent application is drafted, filed, and managed in a manner that best furthers Global Access. If You seek Publication in a peer-reviewed journal, You agree to adhere to the Foundation&#x2019;s Open Access Policy available at: www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy, which may be modified from time to time. Nothing in this section shall be construed as requiring Publication in contravention of any applicable ethical, legal, or regulatory requirements. You will mark any Funded Development subject to this clause with the appropriate notice or attribution, including author, date and copyright (e.g., &#169; 20&lt;&gt; &lt;Name&gt;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">INTELLECTUAL PROPERTY REPORTING</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the term of this Agreement and for 5 years after, You will submit upon request annual intellectual property reports relating to the Funded Developments, Background Technology, and any related agreements using the Foundation&#x2019;s templates or forms, which the Foundation may modify from time to time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBGRANTS AND SUBCONTRACTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBGRANTS AND SUBCONTRACTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You may not make subgrants under this Agreement. You have the exclusive right to select subcontractors to assist with the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RESPONSIBILITY FOR OTHERS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You are responsible for (a) all acts and omissions of any of Your trustees, directors, officers, employees, subgrantees, subcontractors, contingent workers, agents, and affiliates assisting with the Project, and (b) ensuring their compliance with the terms of this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PROHIBITED ACTIVITIES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ANTI-TERRORISM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will not use funds provided under this Agreement, directly or indirectly, in support of activities (a) prohibited by U.S. laws relating to combating terrorism; (b) with persons on the List of Specially Designated Nationals (www.treasury.gov/sdn) or entities owned or controlled by such persons; or (c) in or with countries or territories against which the U.S. maintains comprehensive sanctions (currently, Cuba, Iran, Syria, North Korea, and the Crimea Region of Ukraine), including paying or reimbursing the expenses of persons from such countries or territories, unless such activities are fully authorized by the U.S. government under applicable law and specifically approved by the Foundation in its sole discretion.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ANTI-CORRUPTION; ANTI-BRIBERY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will not offer or provide money, gifts, or any other things of value directly or indirectly to anyone in order to improperly influence any act or decision relating to the Foundation or the Project, including by assisting any party to secure an improper advantage. Training and information on compliance with these requirements are available at www.learnfoundationlaw.org.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">POLITICAL ACTIVITY AND ADVOCACY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You may not use Grant Funds to influence the outcome of any election for public office or to carry on any voter registration drive. You may not use Grant Funds to support lobbying activity or to otherwise support attempts to influence local, state, federal, or foreign legislation. Your strategies and activities, and any materials produced with Grant Funds, must comply with applicable local, state, federal, or foreign lobbying law. You agree to comply with lobbying, gift, and ethics rules applicable to the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">OTHER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PUBLICITY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A Party may publicly disclose information about the award of this grant, including the other Party&#x2019;s name, the total amount awarded, and a description of the Project, provided that a Party obtains prior written approval before using the other Party&#x2019;s name for promotional purposes or logo for any purpose. Any public disclosure by You or Your subgrantees, subcontractors, contingent workers, agents, or affiliates must be made in accordance with the Foundation&#x2019;s then-current brand guidelines, which are available at: www.gatesfoundation.org/brandguidelines.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">LEGAL ENTITY AND AUTHORITY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You confirm that: (a) You are an entity duly organized or formed, qualified to do business, and in good standing under the laws of the jurisdiction in which You are organized or formed; (b) You are not an individual (i.e., a natural person) or a disregarded entity (e.g., a sole proprietor or sole-owner entity) under U.S. law; (c) You have the right to enter into and fully perform this Agreement; and (d) Your performance will not violate any agreement or obligation between You and any third party. You will notify the Foundation immediately if any of this changes during the term of this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">COMPLIANCE WITH LAWS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In carrying out the Project, You will comply with all applicable laws, regulations, and rules and will not infringe, misappropriate, or violate the intellectual property, privacy, or publicity rights of any third party.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">COMPLIANCE WITH REQUIREMENTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will conduct, control, manage, and monitor the Project in compliance with all applicable ethical, legal, regulatory, and safety requirements, including applicable international, national, local, and institutional standards (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;). You will obtain and maintain all necessary approvals, consents, and reviews before conducting the applicable activity. As a part of Your annual progress report to the Foundation, You must report whether the Project activities were conducted in compliance with all Requirements.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If the Project involves:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a. any protected information (including personally identifiable, protected health, or third-party confidential), You will not disclose this information to the Foundation without obtaining the Foundation&#x2019;s prior written approval and all necessary consents to disclose such information;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">b. children or vulnerable subjects, You will obtain any necessary consents and approvals unique to these subjects; and/or</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">c. any trial involving human subjects, You will adhere to current Good Clinical Practice as defined by the International Council on Harmonisation (ICH) E-6 Standards (or local regulations if more stringent) and will obtain applicable trial insurance.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any activities by the Foundation in reviewing documents and providing input or funding does not modify Your responsibility for determining and complying with all Requirements for the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RELIANCE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You acknowledge that the Foundation is relying on the information You provide in reports and during the course of any due diligence conducted prior to the Start Date and during the term of this Agreement. You represent that the Foundation may continue to rely on this information and on any additional information You provide regarding activities, progress, and Funded Developments.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">INDEMNIFICATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If the Project involves clinical trials, trials involving human subjects, post-approval studies, field trials involving genetically modified organisms, experimental medicine, or the provision of medical/health services (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Indemnified Activities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;), You will indemnify, defend, and hold harmless the Foundation and its trustees, employees, and agents (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Indemnified Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;) from and against any and all demands, claims, actions, suits, losses, damages (including property damage, bodily injury, and wrongful death), arbitration and legal proceedings, judgments, settlements, or costs or expenses (including reasonable attorneys&#x2019; fees and expenses) (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x201d;) arising out of or relating to the acts or omissions, actual or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">alleged, of You or Your employees, subgrantees, subcontractors, contingent workers, agents, and affiliates with respect to the Indemnified Activities. You agree that any activities by the Foundation in connection with the Project, such as its review or proposal of suggested modifications to the Project, will not modify or waive the Foundation&#x2019;s rights under this paragraph. An Indemnified Party may, at its own expense, employ separate counsel to monitor and participate in the defense of any Claim. Your indemnification obligations are limited to the extent permitted or precluded under applicable federal, state or local laws, including federal or state tort claims acts, the Federal Anti-Deficiency Act, state governmental immunity acts, or state constitutions. Nothing in this Agreement will constitute an express or implied waiver of Your governmental and sovereign immunities, if any.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">INSURANCE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will maintain insurance coverage sufficient to cover the activities, risks, and potential omissions of the Project in accordance with generally-accepted industry standards and as required by law. You will ensure Your subgrantees and subcontractors maintain insurance coverage consistent with this section.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">TERM AND TERMINATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">TERM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement commences on the Start Date and continues until the End Date, unless terminated earlier as provided in this Agreement. The Foundation, in its discretion, may approve in writing any request by You for a no-cost extension, including amending the End Date and adjusting any affected reporting requirements.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">TERMINATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Foundation may modify, suspend, or discontinue any payment of Grant Funds or terminate this Agreement if: (a) the Foundation is not reasonably satisfied with Your progress on the Project; (b) there are significant changes to Your leadership or other factors that the Foundation reasonably believes may threaten the Project&#x2019;s success; (c) there is a change in Your control; (d) there is a change in Your tax status; or (e) You fail to comply with this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RETURN OF FUNDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any Grant Funds, plus any Income, that have not been used for, or committed to, the Project upon expiration or termination of this Agreement, must be returned promptly to the Foundation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">MONITORING, REVIEW, AND AUDIT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Foundation may monitor and review Your use of the Grant Funds, performance of the Project, and compliance with this Agreement, which may include onsite visits to assess Your organization's governance, management and operations, discuss Your program and finances, and review relevant financial and other records and materials. In addition, the Foundation may conduct audits, including onsite audits, at any time during the term of this Agreement, and within four years after Grant Funds have been fully spent. Any onsite visit or audit shall be conducted at the Foundation's expense, following prior written notice, during normal business hours, and no more than once during any 12-month period.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">INTERNAL OR THIRD PARTY AUDIT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If during the term of this Agreement You are audited by your internal audit department or by a third party, You will provide the audit report to the Foundation upon request, including the management letter and a detailed plan for remedying any deficiencies observed (&#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Remediation Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#34;). The Remediation Plan must include (a) details of actions You will take to correct any deficiencies observed, and (b) target dates for successful completion of the actions to correct the deficiencies.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RECORD KEEPING</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You will maintain complete and accurate accounting records and copies of any reports submitted to the Foundation relating to the Project. You will retain such records and reports for 4 years after Grant Funds have been fully spent. At the Foundation&#x2019;s request, You will make such records and reports available to enable the Foundation to monitor and evaluate how Grant Funds have been used or committed.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SURVIVAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A Party&#x2019;s obligations under this Agreement will be continuous and survive expiration or termination of this Agreement as expressly provided in this Agreement or otherwise required by law or intended by their nature.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(217,217,217,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GENERAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ENTIRE AGREEMENT, CONFLICTS, AND AMENDMENTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agreement along with the Side Letter and any subsequent amendments contain the entire agreement of the Parties and supersedes all prior and contemporaneous agreements concerning its subject matter. If there is a conflict between this Agreement and the Investment Document this Agreement will prevail. Except as specifically permitted in this Agreement, no modification, amendment, or waiver of any provision of this Agreement will be effective unless in writing and signed by authorized representatives of both Parties.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">NOTICES AND APPROVALS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Written notices, requests, and approvals under this Agreement must be delivered by mail or email to the other Party&#x2019;s primary contact specified on the Agreement Summary &amp; Signature Page, or as otherwise directed by the other Party.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SEVERABILITY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Each provision of this Agreement must be interpreted in a way that is enforceable under applicable law. If any provision is held unenforceable, the rest of the Agreement will remain in effect.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ASSIGNMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">You may not assign, or transfer by operation of law or court order, any of Your rights or obligations under this Agreement without the Foundation&#x2019;s prior written approval. This Agreement will bind and benefit any permitted successors and assigns.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">COUNTERPARTS AND ELECTRONIC SIGNATURES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Except as may be prohibited by applicable law or regulation, this Agreement and any amendment may be signed in counterparts, by facsimile, PDF, or other electronic means, each of which will be deemed an original and all of which when taken together will constitute one agreement. Facsimile and electronic signatures will be binding for all purposes.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of 7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.66
<SEQUENCE>7
<FILENAME>vir-ex10_66.htm
<DESCRIPTION>EX-10.66
<TEXT>
<html>
 <head>
  <title>EX-10.66</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 10.66</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:36.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">LEASE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">THE EXCHANGE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">KRE EXCHANGE OWNER LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a Delaware limited liability company</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as Landlord,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a Delaware corporation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As Tenant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1800 Owens Street,<br>San Francisco, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">North Tower</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Floors 8, 9, 10, 11 and 12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.998%;"></td>
    <td style="width:88.994%;"></td>
    <td style="width:3.009%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Page</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PREMISES, BUILDING, PROJECT AND COMMON AREAS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">LEASE TERM</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BASE RENT</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ADDITIONAL RENT</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USE OF PREMISES</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SERVICES AND UTILITIES</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">REPAIRS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ADDITIONS AND ALTERATIONS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">COVENANT AGAINST LIENS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">INSURANCE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DAMAGE AND DESTRUCTION</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NONWAIVER</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CONDEMNATION</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASSIGNMENT AND SUBLETTING</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HOLDING OVER</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ESTOPPEL CERTIFICATES</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SUBORDINATION</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DEFAULTS; REMEDIES</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">COVENANT OF QUIET ENJOYMENT</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECURITY DEPOSIT</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">INTENTIONALLY OMITTED</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SIGNS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">COMPLIANCE WITH LAW</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">LATE CHARGES</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">LANDLORD&#x2019;S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PROJECT CONTROL BY LANDLORD; ENTRY BY LANDLORD</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TENANT PARKING</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">MISCELLANEOUS PROVISIONS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">i</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBITS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.005%;"></td>
    <td style="width:79.995%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 1.1.1-1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Premises</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 1.1.1-2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant Work Letter</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 1.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of First Refusal Space</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 2.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Form of Notice of Lease Term Dates</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.4.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mission Bay Requirements</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 5.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rules and Regulations</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 5.3.1.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Environmental Questionnaire</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 7.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant/Landlord Maintenance Responsibility Matrix</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 17</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Form of Tenant&#x2019;s Estoppel Certificate</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 21.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Form of Letter of Credit</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 24.4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recognition of Covenants, Conditions, and Restrictions</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 28.6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Storage Area</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ii</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Index of Defined Terms</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:96.842%;"></td>
    <td style="width:3.158%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Page</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Abatement Period</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional Rent</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alterations</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Applicable Laws</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Audit Period</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bank Credit Threat</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bankruptcy Code</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Base Building</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Base Rent</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BB HVAC System</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bicycle Improvements</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bicycle Storage Area</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bicycles</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Brokers</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Building</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Building Common Areas</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Building Hours</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Building Structure</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Building Systems</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CASp Report</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CC&amp;Rs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Claims</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clean-up</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Closure Letter</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Code</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common Area Meeting Spaces</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common Areas</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company 40 Competitor List</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Complex</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contemplated Effective Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contemplated Transfer Space</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Control</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost Pool</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs of Reletting</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Damage Termination Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Damage Termination Notice</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct Expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dropbox Amendment</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Environmental Assessment</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Environmental Laws</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Environmental Questionnaire</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Environmental Report</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimate</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimate Statement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimated Direct Expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Excess Hours</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Existing Sublease</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Existing Tenant</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expense Year</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">iii</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:96.842%;"></td>
    <td style="width:3.158%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Page</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Extra HVAC Costs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">First Refusal Commencement Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">First Refusal Notice</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">First Refusal Period</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">First Refusal Space</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Force Majeure</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Generator</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Generator Facilities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Governmental Approvals</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hazardous Materials</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hazardous Materials Claims</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HVAC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HVAC System Hours</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intention to Transfer Notice</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">L/C Security</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord Bicycle Storage Area</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord Indemnitees</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord Parties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord Repair Notice</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Completion Notice</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Hazardous Materials</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease Commencement Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease Expiration Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease Term</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease Year</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lender</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lines</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loading Dock Hours</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mail</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Material Service Interruption</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mission Bay Requirements</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net Worth</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Neutral Audit</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non Web-Enabled Water Sensors</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">North Building</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">North Complex</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">North Lobby</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">North Tower</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Notices</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating Expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Original Improvements</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Original Tenant</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other Improvements</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside Restoration Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parking Facilities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parking Rate</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parking Rate Floor</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PCBs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permitted Assignee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">iv</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:96.842%;"></td>
    <td style="width:3.158%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Page</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permitted Transferee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Premises</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prohibited Persons</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Project</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Project Common Areas</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Project Parking Use</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Project Related Parkers</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proposition 13</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provider</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Public Parking Use</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recapture Notice</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Receivership</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redevelopment Agency</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redevelopment Plan</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulations</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">REIT</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Release</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Relet Term</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Renovations</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rent</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Retail Space</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rules and Regulations</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Security Deposit Laws</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Security Personnel</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Service Interruption</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Service Interruption Notice</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Six Month Period</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">South Building</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">South Complex</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">South Lobby</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">South Tower</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stairwell</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Statement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject Space</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Submetering Equipment</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Summary</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental HVAC Equipment</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax Expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant Bicycle Storage Area</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant Energy Use Disclosure</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant Parties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant Work Letter</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Off-Premises Equipment</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Property</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Security System</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">v</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:96.842%;"></td>
    <td style="width:3.158%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Page</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Share</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Subleasing Costs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant-Exempt Tax Expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transfer Notice</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transfer Premium</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transferee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transfers</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Underlying Documents</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unused L/C Proceeds</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Web-Enabled Water Sensors</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">vi</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">THE EXCHANGE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">LEASE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Lease (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), dated as of the date set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary of Basic Lease Information (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), below, is made by and between </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">KRE EXCHANGE OWNER LLC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, a Delaware limited liability company (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, a Delaware corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A.	Tenant presently subleases the same leased premises (as the Premises in this Lease) pursuant to that certain Sublease entered into as of November 4, 2020, by and between Dropbox, Inc., a Delaware corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dropbox</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and Tenant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Existing Sublease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;); Landlord&#x2019;s predecessor-in-interest, KR Mission Bay, LLC, a Delaware limited liability company, consented to the Existing Sublease pursuant to a certain Consent to Sublease made as of December 21, 2020.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">B.	Pursuant to the Existing Sublease, Tenant has been working with Dropbox and Landlord, as master landlord, to process plans for the construction of alterations to the subleased premises to accomplish a build out of the subleased premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">C.	Subject to the terms and conditions of this Lease, Tenant desires to lease the Premises directly from Landlord, terminating the Sublease and replacing it with this Lease thereby eliminating Dropbox from its role as sublandlord (and the tenant under the primary lease with Landlord).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">D.	Effective as of the Lease Commencement Date (as defined below), this Lease supersedes and replaces the Existing Sublease, but notwithstanding the replacement of the Existing Sublease with this Lease, Tenant will remain in occupancy of the Premises without interruption.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SUMMARY OF BASIC LEASE INFORMATION</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:11.146%;"></td>
    <td style="width:40.6%;"></td>
    <td style="width:48.255%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TERMS OF LEASE</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DESCRIPTION</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated as of:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 1, 2021</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Premises<br>(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">).</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1	Project:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">That certain project containing approximately 750,370 rentable square feet of space located at 1800 Owens Street, Sectors 1, 2, 3 and 4, San Francisco, California 94158. The Project is more particularly described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;below.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2	Premises:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Approximately 133,896 rentable square feet of space on floors 8, 9, 10, 11 and 12 of the North Tower (as defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;below), as further set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 1.1.1-1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to the Lease.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease Term</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">).</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1	Length of Term:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Twelve (12) years (i.e., one hundred forty-four (144) months).</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2	Lease Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The later of (i) November 1, 2021, and (ii) the date of Lease is executed and delivered by Landlord and Tenant and the existing lease with Dropbox has either been amended to eliminate floors eight (8) through twelve (12) of the North Tower therefrom or such existing lease has been partially terminated as to such floors (such that Landlord has recaptured such floors).</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3	Rent Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The same date as the Lease Commencement Date.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4	Lease Expiration Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The last day of the one hundred forty-fourth (144</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) full month of the Lease Term (e.g., if the Lease Commencement Date is, in fact, December 14, 2021, then the Lease Expiration Date will be December 31, 2033.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Base Rent (Article 3):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.825%;"></td>
    <td style="width:27.639%;"></td>
    <td style="width:25.716%;"></td>
    <td style="width:22.821%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:bottom;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease Months</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:bottom;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Annual<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Base Rent</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:bottom;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Monthly<br>Installment<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">of Base Rent</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:bottom;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Monthly Base<br>Rent<br>per Rentable<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Square Foot</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 - 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$0.00</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$0.00</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$0.00</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- 12</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$4,251,198.00</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$850,239.60</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$6.35</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13 - 24</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$10,508,158.08</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$875,679.84</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$6.54</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25 - 36</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$10,829,508.48</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$902,459.04</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$6.74</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37 - 48</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$11,150,858.88</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$929,238.24</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$6.94</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49 - 60</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$11,488,276.80</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$957,356.40</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$7.15</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61 - 72</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$11,825,694.72</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$985,474.56</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$7. 36</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73 - 84</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$12,179,179.20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$1,014,931.60</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$7.58</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85 - 96</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$12,548,732.40</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$1,045,727.70</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$7.81</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97 - 108</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$12,918,285.60</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$1,076,523.80</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$8.04</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109 - 120</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$13,303,905.60</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$1,108,658.80</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$8.28</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121 - 132</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$13,705,593.60</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$1,142,132.80</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$8.53</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133 - 144</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$14,123,349.60</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$1,176,945.80</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.060in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.060in;padding-right:0.080in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$8.79</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:66.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Tenant shall be entitled to receive a Base Rent abatement for the first seven (7) full calendar months of the Lease Term (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Abatement Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant shall be obligated to pay Tenant&#x2019;s Share of Direct Expenses attributable to such period. Pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, any partial calendar month of Month 1 shall be excluded from the Abatement Period.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Tenant shall be entitled to a one-time credit against Base Rent for full calendar month 8 of the Lease Term in the amount of $693,666.03 pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease. Accordingly, Tenant&#x2019;s payment amount for month 8&#x2019;s Base Rent will be $156,573.57.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.519%;"></td>
    <td style="width:40.983%;"></td>
    <td style="width:49.498%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant Improvement Allowance:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$36,151,920.00, to be used by Tenant to construct improvements in the Premises in accordance with the terms of the work letter attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">1.1.1-2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant Work Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). In addition, Tenant shall be entitled to an additional $2,343,180.00 to be used by it to construct certain additional improvements in accordance with the Tenant Work Letter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NNN Lease:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the Base Rent, Tenant shall be responsible to pay Tenant&#x2019;s Share of Direct Expenses in accordance with the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;of the Lease.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Share<br>(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shall mean the following percentages, as applicable: (i) 100% with respect to the Operating Expenses allocated by Landlord to the Premises; (ii) 17.844% (133,896 RSF &divide; 750,370 RSF) with respect to Operating Expenses allocated by Landlord to the entire Project; (iii) 44.74% (133,896 RSF &divide; 299,255 RSF) with respect to Operating Expenses allocated by Landlord to the North Tower; and (iv) such percentage as is reasonably calculated with respect to Operating Expenses allocated by Landlord to portions of the Project that include the Premises and consist of less than the entire Project but more than the North Tower.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permitted Use<br>(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Premises shall be used only for general office and life sciences research and development, laboratory, storage and other lawful accessory uses reasonably related to and incidental to such specified uses, all (i) consistent with &#x201c;Comparable Buildings&#x201d; (as defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.2.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;below) in the San Francisco, California area</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and (ii) in compliance with, and subject to, Applicable Laws and the terms of this Lease.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Security Deposit<br>(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$5,708,655.96, in the form of a letter of credit in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;of this Lease and which amount is subject to reduction in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 21.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;of this Lease.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Guarantor<br>(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br>None</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parking Pass Ratio<br>(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 28</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One hundred thirty-four (134) (i.e., one (1) unreserved parking spaces for every 1,000 rentable square feet of the Premises, subject to the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 28</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;of the Lease.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.519%;"></td>
    <td style="width:40.983%;"></td>
    <td style="width:49.498%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Address of Tenant<br>(Section 29.18):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">499 Illinois Street, Suite 500</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Francisco, California 94158</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Attention: General Counsel</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with a copy to (which shall not constitute, nor be required for effective, notice):</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">499 Illinois Street, Suite 500</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Francisco, California 94158</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Attention: Head of Real Estate and Facilities</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Address of Landlord<br>(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 29.18</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KRE Exchange Owner LLC</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">c/o Longfellow Real Estate Partners</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">260 Franklin Street, Suite 1920</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, MA 02110</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Attention: Asset Management and</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KRE Exchange Owner LLC</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">c/o Longfellow Property Management Services CA, Inc.</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1800 Owens Street, Suite 350</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Francisco, CA 94158</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Attention: Property Management</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KRE Exchange Owner LLC</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">c/o Longfellow Property Management Services CA, Inc.</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1800 Owens Street, Suite 350</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Francisco, CA 94158</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Attention: General Manager</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Broker(s)<br>(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 29.24</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;padding-left:0.080in;vertical-align:top;padding-bottom:0.080in;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Newmark Knight Frank, representing the Tenant exclusively</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. PREMISES, BUILDING, PROJECT AND COMMON AREAS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Premises, Building, Project and Common Areas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">The Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the premises set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). The outlines of each floor of the Premises are set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 1.1.1-1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">attached hereto. The parties hereto agree that the lease of the Premises is upon and subject to the terms, covenants and conditions herein set forth, and Tenant covenants as a material part of the consideration for this Lease to keep and perform each and all of such terms, covenants and conditions by it to be kept and performed and that this Lease is made upon the condition of such performance. The parties hereto hereby acknowledge that the purpose of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 1.1.1-1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is to show the approximate location of the Premises in the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; (as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below), only, and such Exhibit is not meant to constitute an agreement, representation or warranty as to the construction of the Premises, the precise area thereof or the specific location of the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common Areas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; (as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below), or the elements thereof or of the accessways to the Premises or the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Project</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; (as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below). Tenant shall accept the Premises in its presently existing &#x201c;as-is&#x201d; condition and Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Premises except as otherwise expressly set forth in this Lease or in the Tenant Work</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Letter attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 1.1.1-2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding the foregoing, Landlord shall deliver to Tenant the Premises with the plumbing, electrical systems, fire sprinkler and life-safety system, lighting, air conditioning and heating systems and all other building systems serving the Premises (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Building Systems</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) in good operating condition and repair, and Landlord will be responsible for all repairs at its sole cost (and not as part of Operating Expenses) during the six (6) months following the Lease Commencement Date; provided, however, if any failure of the Building Systems to be in good operating condition and repair is attributable to Tenant&#x2019;s construction of improvements pursuant to the Tenant Work Letter, then Tenant shall be solely liable for the cost of any such repairs. Tenant acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the Premises, the Building or the Project or with respect to the suitability of any of the foregoing for the conduct of Tenant&#x2019;s business, except as specifically set forth in this Lease and the Tenant Work Letter. The Premises shall exclude Common Areas, including without limitation exterior faces of exterior walls, the entry, vestibules and main lobby of the Building, the common stairways and stairwells, elevators and elevator wells, boiler room, sprinkler rooms, elevator rooms, mechanical rooms, loading and receiving areas, electric and telephone closets, janitor closets, and pipes, ducts, conduits, wires and appurtenant fixtures and equipment serving exclusively or in common with other parts of the Building.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">The Building and The Project</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Premises are a part of the Project set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary, specifically a portion of the twelve-story building known as the North Tower (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">North Tower</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;. The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Project</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;, as used in this Lease, shall mean (i) the North Tower located at 1800 Owens Street, Sector 1, San Francisco, California, containing 299,255 rentable square feet and the Common Areas, (ii) the land (which is improved with landscaping, parking facilities and other improvements) upon which the North Tower and the Common Areas are located, as more particularly described on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 1.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">attached hereto, (iii) the other buildings located in the Project known as &#x201c;The Exchange&#x201d;, more particularly described as that certain (1) six (6)-story building (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">North Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) located at 1800 Owens, Sector 2, San Francisco, California, containing 125,200 rentable square feet, (2) twelve (12)-story building (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">South Tower</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) located at 1800 Owens, Sector 3, San Francisco, California, containing 259,551 rentable square feet, and (3) six (6)-story building (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">South Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) located at 1800 Owens, Sector 4, San Francisco, California, containing 66,365 rentable square feet, and the land upon which such other buildings are located, and (iv) at Landlord&#x2019;s discretion, any additional real property, areas, land, buildings or other improvements added thereto outside of the Complex. The North Tower and the North Building are collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">North Complex</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; containing a total of 424,455 retable square feet. The South Tower and the South Building are collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">South Complex</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,&#x201d; containing a total of 325,916 rentable square feet. The North Complex and the South Complex are each referred to herein as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Complex</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.&#x201d; The North Tower, North Building, South Tower and South Building may be referred herein separately as a sub-building and together as simply the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.&#x201d; The Project contains a total of 750,370 square feet; provided however, approximately 14,670 rentable square feet is retail space on the ground floor of the North Complex (i.e., 12,289 rentable square feet in the North Tower and 2,381 rentable square feet is retail space in the North Building (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Retail Space</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Common Areas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall have the non-exclusive right to use in common with other tenants in the Project, and subject to the rules and regulations referred to in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, those portions of the Project which are provided, from time to time, for use in common by Landlord, Tenant and any other tenants of the Project (such areas, together with such other portions of the Project designated by Landlord, in its discretion, including certain areas designated for the exclusive use of certain tenants, including Tenant, or to be shared by Landlord and certain tenants, including Tenant, are collectively referred to herein as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common Areas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). The Common Areas shall consist of the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Project Common Areas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; and the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Building Common Areas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.&#x201d; The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Project Common Areas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;, as used in this Lease, shall mean the portion of the Project designated from time to time as such by Landlord (inclusive of any exterior landscaped areas). The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Building Common Areas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;, as used in this Lease, shall mean the portions of the Common Areas located within the Building designated from time to time as such by Landlord. The Project includes two (2) ground floor lobbies: one (1) lobby (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">North Lobby</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) provides access to the North Building and North Tower, including the Retail Space; and one (1) lobby (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">South Lobby</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) provides access to both the South Building and the South Tower. The North Lobby is a Building Common Area. For the sake of clarity, Tenant and each of its authorized employees and invitees shall have access to the North Lobby, the Parking Facility and the Bicycle Storage Ares in common with other occupants of the Complex. Landlord shall maintain the Common Areas in a condition consistent with Comparable Buildings. The term &#x201c;Comparable Buildings&#x201d; shall mean the Building and those other office and life science buildings which are comparable to the Building in terms of age (based upon the date of completion of construction or major renovation of the building), quality of construction, level of services and amenities, size and appearance, and are located in the City of San Francisco,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">California. Tenant&#x2019;s use of the Common Areas shall be subject to such rules, regulations and restrictions as Landlord may make from time to time in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below. Any rules and regulations established by the Landlord for use of the Common Areas shall not unreasonably restrict Tenant&#x2019;s access to or use of the Premises for conduct of its business, nor diminish Tenant&#x2019;s rights under this Lease. In the event of any conflict between such rules and regulations and the terms of this Lease, the latter shall control Landlord reserves the right to close temporarily, make alterations or additions to, or change the location of elements of the Project and the Common Areas, provided that, in connection therewith, Landlord shall perform such closures, alterations, additions or changes in a commercially reasonable manner and, in connection therewith, shall use commercially reasonable efforts to minimize any material interference with Tenant&#x2019;s use of and access to the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Stipulation of Rentable Square Feet of Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. For purposes of this Lease, the rentable square feet of the Premises and the North Tower shall be deemed to be as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary, and the rentable square feet of each of the North Building, South Tower and South Building shall be deemed as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above, none of which shall be subject to remeasurement or adjustment during the Lease Term unless the Premises are physically expanded or contracted.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Adjustment of Rentable Square Feet of Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord acknowledges that the installation of the Mechanical Shaft described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 2.2(e)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Tenant Work Letter will result in a reduction of approximately 669 rentable square feet of Premises, and as a consequence thereof, Landlord will give to Tenant a credit against Base Rent for month 8 of the Lease Term in the amount of $693,666.03 as full and complete compensation to Tenant for the loss of such rentable square footage (and in exchange for Tenant enjoying such rent credit, Tenant will nevertheless pay Base Rent under this Lease without any reduction or adjustment in rentable square footage of the Premises).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Right of First Refusal</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord hereby grants to the Tenant named in the Summary (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Original Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and any Permitted Assignee a right of first refusal with respect to the entire seventh (7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) floor of the Building as more particularly described on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">First Refusal Space</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Notwithstanding the foregoing, such first refusal right of Tenant shall commence only following the expiration or earlier termination of the Existing Lease with Dropbox of the First Refusal Space, and such right of first refusal shall be subordinate to all rights of Dropbox which are set forth in the Existing Lease as of the date hereof with respect to such First Refusal Space. Tenant&#x2019;s right of first refusal shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">not </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be applicable after the third (3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">rd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) anniversary of the Lease Commencement Date (which three (3) year period may be referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">First Refusal Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant&#x2019;s right of first refusal shall be on the terms and conditions set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Procedure for Offer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Prior to entering any lease for all or any portion of the First Refusal Space during the First Refusal Period, Landlord shall provide a written notice to Tenant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">First Refusal Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), offering to lease to Tenant the applicable portion of the First Refusal Space. The First Refusal Notice shall describe the terms on which the other prospective tenant may lease the First Refusal Space, including setting forth the rent and the other material economic terms upon which Landlord is willing to lease such space to such other tenant.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Procedure for Acceptance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If Tenant wishes to exercise Tenant&#x2019;s right of first refusal with respect to the space described in the First Refusal Notice, then within seven (7) business days after delivery of the First Refusal Notice to Tenant, Tenant shall deliver notice to Landlord of Tenant&#x2019;s election to exercise its right of first refusal with respect to the entire space described in the First Refusal Notice on the terms contained in such notice. If Tenant does not so notify Landlord within the seven (7) business day period, then Landlord shall be free to lease the space described in the First Refusal Notice to the other tenant or any affiliate thereof on generally the same terms as contained in the First Refusal Notice, provided that, prior to entering into a lease of such space on material economic terms that are more than seven and one-half percent (7.5%) more favorable to the tenant than the Base Rent set forth in the First Refusal Notice, Landlord shall first deliver another First Refusal Notice to Tenant offering such space to Tenant on such reduced terms. Tenant shall respond to any such &#x201c;re-offer&#x201d; within five (5) business days after delivery of such &#x201c;re-offer&#x201d; notice. Notwithstanding anything to the contrary contained herein, Tenant must elect to exercise its right of first refusal, if at all, with respect to all of the space covered by the First Refusal Notice, and Tenant may not elect to lease only a portion thereof. The First Refusal Space shall be leased by Tenant on all of the terms and conditions of this Lease except as set forth in the First Refusal Notice and this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Construction In First Refusal Space</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall take the First Refusal Space in its &#x201c;as is&#x201d; condition unless otherwise set forth in the First Refusal Notice.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment to Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If Tenant timely exercises Tenant&#x2019;s right to lease the First Refusal Space as set forth herein, then the First Refusal Space shall be added to the Premises on the terms set forth herein (except that the term of any such lease shall be appropriately adjusted to be co-terminous with the Lease Term of this Lease) and, at the election of Landlord or Tenant, the parties shall promptly thereafter execute an amendment to this Lease for such First Refusal Space (but the execution of such amendment shall not be required for the lease of the First Refusal Space to become effective). Tenant shall commence payment of Rent for the First Refusal Space, and the term of the First Refusal Space shall commence upon the date of delivery of the First Refusal Space to Tenant in the condition required by the First Refusal Notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">First Refusal Commencement Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and terminate on the Lease Expiration Date.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of Right of First Refusal</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The rights contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall be personal to the Original Tenant (and any Permitted Assignee) and may only be exercised by the Original Tenant (and not any other assignee, sublessee or other transferee of the Original Tenant&#x2019;s interest in this Lease other than a Permitted Assignee) if the Original Tenant or a Permitted Assignee occupies the entire Premises. Except as expressly set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the right of first refusal granted herein shall terminate as to a particular First Refusal Notice (and the First Refusal Space applicable thereto) upon the failure by Tenant to exercise its right of first refusal with respect to such First Refusal Space as offered by Landlord. Tenant shall not have the right to lease First Refusal Space, as provided in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, if, as of the date of the attempted exercise of any right of first refusal by Tenant, or as of the scheduled date of delivery of such First Refusal Space to Tenant, Tenant is in default under this Lease, after the expiration of any applicable notice and cure period, or Tenant has previously been in default, after the expiration of any applicable notice and cure period, under this Lease more than once during the First Refusal Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Condition Precedent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant acknowledges and agrees that this Lease is subject to the following express conditions precedent: (i) Landlord consummating an amendment with Dropbox of its lease covering the entire Project (other than the Retail Space) so as to eliminate floors eight (8) through twelve (12) of the North Tower therefrom (such that Landlord has recaptured such floors) and converting the Project from a single tenant project to a multi-tenant project (which amendment may be referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dropbox Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and (ii) the termination of the Existing Sublease. The terms and conditions of the Dropbox Amendment shall be satisfactory to Landlord in its sole and absolute discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Meeting Rooms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. So long as Tenant is not in default hereunder beyond applicable notice and cure periods, Landlord shall use commercially reasonable efforts to make available Common Area meeting rooms, if any, in the Project (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common Area Meeting Spaces</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) for Tenant&#x2019;s use for business meetings and special events. Such use shall be subject to availability, on a first come, first serve basis, and shall be upon and subject to such rules, regulations and limitations as Landlord may reasonably establish from time to time for use of the Common Area Meeting Spaces (including, without limitation, as to scheduling, catering, hours of use, the provision and cost of janitorial and security services, facility and equipment usage charges, reimbursement of Landlord&#x2019;s costs and expenses reasonably incurred in facilitating such use by Tenant, and cleaning/security deposits); provided, however, that (a) Landlord shall use commercially reasonable efforts to give Tenant equitable access with other tenants to the Common Area Meeting Rooms and, accordingly, not allow other tenants of the Project to block-book the Common Area Meeting Rooms (i.e. reserve spaces for more than three (3) business days in a row unless connected to a special event); and (b) once Tenant has properly booked the use of the Common Area Meeting Spaces for a particular date and time, such booking may not be cancelled without Tenant&#x2019;s prior consent. If requested by Tenant, Landlord will provide a schedule of available dates and times for use of the Common Area Meeting Spaces. In connection with its use of the Common Area Meeting Spaces, Tenant shall enter into Landlord&#x2019;s then-current form of agreement for the use of such spaces. Tenant use of the Common Area Meeting Spaces shall be at Tenant&#x2019;s sole risk and Tenant acknowledges and agrees that Landlord shall have no liability whatsoever to Tenant, its employees and/or visitors for personal injury or property damage or theft relating to or connected with any use of the Common Area Meeting Spaces by Tenant or its employees and/or visitors. Landlord specifically reserves the right to change the location, size, configuration, design, layout and all other aspects of the Common Area Meeting Spaces at any time and Tenant acknowledges and agrees that Landlord may from time to time, on a temporary basis, or on a permanent basis, close, close-off or restrict access to the Common Area Meeting Spaces. The right to use the Common Area Meeting Spaces may not be assigned or in any other way transferred to any other person or entity. Tenant acknowledges that the waiver of claims and indemnification provided in this Lease apply to the use of the Common Area Meeting Spaces by Tenant. Notwithstanding anything to the contrary contained in this Lease, Tenant acknowledges that, as of the date of this Lease, the Project does not have any Common Area Meeting Rooms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. LEASE TERM</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The terms and provisions of this Lease shall be effective as of the date of this Lease. The term of this Lease (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall be as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary, shall commence on the date set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease Commencement Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and shall terminate on the date set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 3.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease Expiration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) unless this Lease is sooner terminated as hereinafter provided. For purposes of this Lease, the term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease Year</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean the consecutive twelve (12) month period following and including the Lease Commencement Date and each subsequent twelve (12) month period during the Lease Term; provided, however, if the Lease Commencement Date is other than the first (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) day of a calendar month, &#x201c;Month 1&#x201d; will include the first full calendar month following the Lease Commencement Date plus any partial calendar month following the Lease Commencement Date. In the event Month 1 includes any partial calendar month, Tenant shall pay the prorated amount of Monthly Base Rent for such partial calendar month pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in addition to the Monthly Base Rent for the ninth (9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) full calendar month of the Lease Term (and to the extent that Month 1 is included as part of the Abatement Period, any such partial calendar month shall be excluded from the Abatement Period). At any time during the Lease Term, Landlord may deliver to Tenant a notice in the form as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, attached hereto, as a confirmation only of the information set forth therein, which Tenant shall execute (or provide factual correction to) and return to Landlord within ten (10) business days of receipt thereof, but execution of such instrument shall not be a condition to Lease commencement or Tenant&#x2019;s obligations hereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. BASE RENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Payment of Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall pay, without prior notice or demand, to Landlord&#x2019;s agent at the management office of the Project or at such place as Landlord may from time to time designate in writing, by a check for currency which, at the time of payment, is legal tender for private or public debts in the United States of America or pursuant to wire or electronic payment instructions provided by Landlord, base rent (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary, payable in equal monthly installments as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary, in advance, on or before the first day of each and every calendar month during the Lease Term, without any setoff or deduction whatsoever, except as may be expressly set forth in this Lease. Base Rent for the first full month of the Lease Term shall be paid at the time of Tenant&#x2019;s execution of this Lease. If any Rent payment date (including the Lease Commencement Date) falls on a day of the month other than the first day of such month or if any payment of Rent is for a period which is shorter than one month, the Rent for any fractional month shall accrue on a daily basis for the period from the date such payment is due to the end of such calendar month or to the end of the Lease Term at a rate per day which is equal to 1/365 of the applicable annual Rent. All other payments or adjustments required to be made under the terms of this Lease that require proration on a time basis shall be prorated on the same basis. Base Rent and Additional Rent shall together be denominated &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;. Without limiting the foregoing, Tenant&#x2019;s obligation to pay Rent shall be absolute, unconditional and independent of any Landlord covenants and shall not be discharged or otherwise affected by any law or regulation now or hereafter applicable to the Premises, or any other restriction on Tenant&#x2019;s use, or (except as expressly provided herein) any casualty or taking, or any failure by Landlord to perform any covenant contained herein, or any other occurrence; and Tenant assumes the risk of the foregoing and waives all rights now or hereafter existing to terminate or cancel this Lease or quit or surrender the Premises or any part thereof (absent a judicial order providing for such termination or cancellation), or to assert any defense in the nature of constructive eviction (in which Tenant asserts that its use and enjoyment of the Premises has been disrupted due to any entry by Landlord of the Premises in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 27.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, any renovation of the Project or any casualty or condemnation affecting the Project) to any action seeking to recover rent (except to the extent Tenant&#x2019;s obligation to pay Base Rent may be expressly abated pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Articles 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease). Tenant&#x2019;s covenants contained herein are independent and not dependent, and Tenant hereby waives the benefit of any statute or judicial law to the contrary.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Rents from Real Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord and Tenant hereby agree that it is their intent that all Base Rent, Additional Rent and other rent and charges payable to the Landlord under this Lease (hereinafter individually and collectively referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall qualify as &#x201c;rents from real property&#x201d; within the meaning of Section 856(d) of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and the Department of the U.S. Treasury Regulations promulgated thereunder (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Regulations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Should the Code or the Regulations, or interpretations thereof by the Internal Revenue Service contained in revenue rulings or other similar public pronouncements, be changed so that any Rent no longer so qualifies as &#x201c;rent from real property&#x201d; for purposes of Section 856(d) of the Code and the Regulations promulgated thereunder, such Rent shall be adjusted in such manner as the Landlord may require so that it will so</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">qualify; provided, however, that any adjustments required pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 7.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall be made so as to produce the equivalent (in economic terms) Rent as payable prior to such adjustment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. ADDITIONAL RENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">General Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In addition to paying the Base Rent specified in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, Tenant shall pay &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Share</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; of the annual &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Direct Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; as those terms are defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Sections 4.2.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">4.2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, respectively. Such payments by Tenant, together with any and all other amounts payable by Tenant to Landlord pursuant to the terms of this Lease other than Base Rent, are hereinafter collectively referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Additional Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;. All amounts due under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as Additional Rent shall be payable for the same periods and in the same manner as the Base Rent. Without limitation on other obligations of Tenant which survive the expiration of the Lease Term, the obligations of Tenant to pay the Additional Rent provided for in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall survive the expiration of the Lease Term, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Definitions of Key Terms Relating to Additional Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As used in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the following terms shall have the meanings hereinafter set forth:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2.1 Intentionally Omitted.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2.2 &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Direct Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; and &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tax Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2.3 &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Expense Year</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean each calendar year in which any portion of the Lease Term falls, through and including the calendar year in which the Lease Term expires, provided that Landlord, upon notice to Tenant, may change the Expense Year from time to time to any other twelve (12) consecutive month period, and, in the event of any such change, Tenant&#x2019;s Share of Direct Expenses shall be equitably adjusted for any Expense Year involved in any such change.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2.4 &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean all expenses, costs and amounts of every kind and nature which Landlord pays or accrues during any Expense Year because of or in connection with the ownership, management, maintenance, security, repair, replacement, restoration or operation of the Project or any portion thereof (including, without limitation, any amenities (e.g., fitness center) available to tenants within the Building or Project). Without limiting the generality of the foregoing, Operating Expenses shall specifically include any and all of the following: (i) the cost of supplying all utilities, the cost of operating, repairing, maintaining, and renovating the utility, telephone, mechanical, sanitary, storm drainage, and elevator systems, and the cost of maintenance and service contracts in connection therewith; (ii) the cost of licenses, certificates, permits and inspections and the cost of contesting any governmental enactments which may affect Operating Expenses, and the costs incurred in connection with providing a shuttle service, if any, and the costs incurred in connection with any federal, state or municipal governmentally mandated transportation demand management program or similar program; (iii) the cost of all insurance carried by Landlord in connection with the Project (including, without limitation, commercial general liability insurance, physical damage insurance covering damage or other loss caused by fire, earthquake, flood and other water damage, explosion, vandalism and malicious mischief, theft or other casualty, rental interruption insurance, and such insurance as may be required by any lessor under any present or future ground or underlying lease of the Building or Project or any holder of a mortgage, trust deed or other encumbrance now or hereafter in force against the Building or Project or any portion thereof or as required pursuant to the Underlying Documents); (iv) the cost of landscaping, re-lamping, and all supplies, tools, equipment and materials used in the operation, repair and maintenance of the Project, or any portion thereof; (v) all costs incurred in connection with the Parking Facilities; (vi) fees and other costs, including management, consulting fees, legal fees and accounting fees, of all contractors and consultants in connection with the management, operation, maintenance and repair of the Project; (vii) payments under any equipment rental agreements and the fair rental value of any management space; (viii) wages, salaries and other compensation and benefits, including taxes levied thereon, of all persons engaged in the operation, maintenance and security of the Project; (ix) costs under any instrument pertaining to the sharing of costs by the Project; (x) operation, repair, maintenance and replacement of all systems and equipment and components thereof of the Project; (xi) the cost of janitorial, alarm, security and other services, replacement of wall and floor coverings, ceiling tiles and fixtures in Common Areas, maintenance and replacement of curbs and walkways, repair to roofs and re-roofing; (xii) amortization (including reasonable interest on the unamortized cost) over such period as Landlord shall reasonably determine, of the cost of acquiring or the rental expense of personal property used in the maintenance, operation and repair of the Project or any portion thereof; (xiii) the cost of capital improvements, capital repairs or other capital costs</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incurred in connection with the Project (A) which are intended to reduce expenses in the operation or maintenance of the Project, or any portion thereof, or to reduce current or future Operating Expenses or to enhance the safety or security of the Project or its occupants, (B) that are required to comply with present or anticipated mandatory energy conservation programs, (C) which are replacements or modifications of nonstructural items located in the Common Areas required to keep the Common Areas in the same good order or condition as on the Lease Commencement Date, or (D) that are required under any federal, state or municipal governmental law or regulation that was not in force or effect as of the Lease Commencement Date; provided, however, that the costs of any capital improvement shall be amortized (including with interest at the Amortization Interest Rate on the amortized cost as reasonably determined by Landlord) over the useful life of the capital item in question, as Landlord shall reasonably determine, in a manner consistent with the practices of landlords of &#x201c;Comparable Buildings&#x201d; (i.e., similar buildings located with the area depicted in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.2.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">attached hereto) and otherwise in accordance with sound real estate management and accounting practices or, with respect to cost saving capital expenditures, their recovery/payback period as Landlord shall reasonably determine, in a manner consist with the practices of landlords of Comparable Buildings and otherwise in accordance with sound real estate management and accounting practices, consistently applied; (xiv) costs, fees, charges or assessments imposed by, or resulting from any mandate imposed on Landlord by, any federal, state or municipal government for fire and police protection, trash removal, community services, or other services which do not constitute &#x201c;Tax Expenses&#x201d; (as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.2.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below); (xv) cost of tenant relation programs reasonably established by Landlord, and (xvi) payments under any Underlying Documents (as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 24</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below). In the event that Landlord or Landlord&#x2019;s managers or agents perform services for the benefit of the Building off-site which would otherwise be performed on-site (e.g., accounting), the cost of such services shall be reasonably allocated among the properties benefitting from such service and shall be included in Operating Expenses. Notwithstanding the foregoing, for purposes of this Lease, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Expenses shall not, however, include</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) costs, including legal fees, space planners&#x2019; fees, advertising and promotional expenses, and brokerage fees incurred in connection with the original construction or development, or original or future leasing of the Project, and costs, including permit, license and inspection costs, incurred with respect to the installation of tenant improvements made for tenants or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space for tenants of the Project (excluding, however, such costs relating to any Common Areas), and any costs or expenses incurred in connection with the relocation of any tenants of the Building or Project;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) except as set forth in items (xii), (xiii), and (xiv) above, depreciation, interest and principal payments on mortgages and other debt costs, if any, penalties and interest, and costs of capital improvements (as distinguished from non-capital repairs or replacements);</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) costs for which Landlord is reimbursed by any tenant or occupant of the Project (other than as Direct Expenses) or by insurance by its carrier or any tenant&#x2019;s carrier or by anyone else (or would have been reimbursed if Landlord had carried the insurance Landlord is required to carry pursuant to this Lease or enforced its rights against such third-party, as applicable), and electric power costs for which any tenant directly contracts with the local public service company or pays directly to Landlord;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) any bad debt loss, rent loss, or reserves for bad debts or rent loss;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e) costs associated with the operation of the business of the partnership or entity which constitutes Landlord, as the same are distinguished from the costs of operation of the Project (which shall specifically include, but not be limited to, accounting costs associated with the operation of the Project). Costs associated with the operation of the business of the partnership or entity which constitutes Landlord include costs of partnership accounting and legal matters, costs of defending any lawsuits with any mortgagee (except as the actions of Tenant may be in issue), costs of selling, syndicating, financing, mortgaging or hypothecating the Project or any of Landlord&#x2019;s interest in the Project, and costs incurred in connection with any disputes between Landlord and its employees, between Landlord and Project management, or between Landlord and other tenants or occupants;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(f) the wages and benefits of any employee who does not devote substantially all of his or her employed time to the Project unless such wages and benefits are prorated to reflect time spent on operating and managing the Project vis-a-vis time spent on matters unrelated to operating and managing the Project; provided, that in no event shall Operating Expenses for purposes of this Lease include wages and/or benefits attributable to personnel above the level of Project manager;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(g) amount paid as ground rental for the Project by Landlord;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(h) except for a property management fee (and subject to the exclusion in item (q) below), overhead and profit increment paid to Landlord or to subsidiaries or affiliates of Landlord for services in the Project to the extent the same exceeds the costs of such services rendered by qualified, first-class unaffiliated third parties on a competitive basis;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) any compensation paid to clerks, attendants or other persons in commercial concessions operated by Landlord, provided that any compensation paid to any concierge at the Project shall be includable as an Operating Expense;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(j) all items and services for which Tenant or any other tenant in the Project reimburses (or is obligated to reimburse) Landlord (other than as Direct Expenses) or which Landlord provides selectively to one or more tenants (other than Tenant) without reimbursement;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(k) rent for any office space occupied by Project management personnel to the extent the size or rental rate of such office space exceeds the size or fair market rental value of office space occupied by management personnel of Comparable Buildings, with adjustment where appropriate for the size of the applicable project;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(l) costs incurred to comply with laws relating to the removal of Hazardous Materials (other than Hazardous Materials typically found in comparable buildings, such as recyclable materials and typical construction materials, and costs to comply with the operation and maintenance plan, if any);</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(m) Landlord&#x2019;s general overhead expenses not related to the Project;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(n) legal fees, accountants&#x2019; fees (other than normal bookkeeping expenses) and other expenses incurred in connection with disputes of tenants or other occupants of the Project or associated with the enforcement of the terms of any leases with tenants or the defense of Landlord&#x2019;s title to or interest in the Project or any part thereof;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(o) any reserve funds;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(p) costs arising due to a violation by Landlord or any other tenant of the Project of the terms and condition of a lease, or arising from the gross negligence or willful misconduct of Landlord, or its agents, employees, vendors, contractors, or providers of materials or services;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(q) any management fee, of which Tenant&#x2019;s Share in a particular Expense Year exceeds three percent (3%) of Tenant&#x2019;s Base Rent (adjusted and grossed up during any period in which Tenant&#x2019;s Base Rent (or portion thereof) is abated);</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(r) advertising and promotional expenditures, and costs of signs in or on the Project identifying the owner of the Project or any tenant of the Project;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(s) fees, penalties and interest resulting from Landlord&#x2019;s failure to pay any Operating Expense as and when due;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(t) costs to comply with Applicable Laws where such violation of Applicable Laws existed as of the date the Project was originally built (i.e., 2018); and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(u) any costs expressly excluded from Operating Expenses elsewhere in this Lease.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Landlord is not furnishing any particular work or service (the cost of which, if performed by Landlord, would be included in Operating Expenses) to a tenant who has undertaken to perform such work or service in lieu of the performance thereof by Landlord, Operating Expenses shall be deemed to be increased by an amount equal to the additional Operating Expenses which would reasonably have been incurred during such period by Landlord if it had at its own expense furnished such work or service to such tenant. If the Project is not at least one hundred percent (100%) occupied during all or a portion of any Expense Year, Landlord shall make an appropriate adjustment to the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">components of Operating Expenses for such year to determine the amount of Operating Expenses that would have been incurred had the Project been one hundred percent (100%) occupied; and the amount so determined shall be deemed to have been the amount of Operating Expenses for such year. Landlord and Tenant acknowledge and agree that the intention of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is to facilitate Landlord&#x2019;s recovery of Operating Expenses as opposed to generating a profit center.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2.5.1 &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tax Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean all federal, state, county, or local governmental or municipal taxes, fees, charges or other impositions of every kind and nature, whether general, special, ordinary or extraordinary (including, without limitation, real estate taxes, general and special assessments, transit taxes, payments in lieu of taxes, business improvement district charges, leasehold taxes or taxes based upon the receipt of rent, including gross receipts or sales taxes applicable to the receipt of rent (inclusive of any so-called &#x201c;Proposition C&#x201d; taxes), unless required to be paid by Tenant, personal property taxes imposed upon the fixtures, machinery, equipment, apparatus, systems and equipment, appurtenances, furniture and other personal property used by Landlord in connection with the Project, or any portion thereof), which shall be paid or accrued during any Expense Year (without regard to any different fiscal year used by such governmental or municipal authority) because of or in connection with the ownership, leasing and operation of the Project, or any portion thereof (including, without limitation, the land upon which the Building, including the Parking Facilities, are located).</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2.5.2 Tax Expenses shall include, without limitation: (i) Any tax on the rent, right to rent or other income from the Project, or any portion thereof, or as against the business of leasing the Project, or any portion thereof; (ii) any assessment, tax, fee, levy or charge in addition to, or in substitution, partially or totally, of any assessment, tax, fee, levy or charge previously included within the definition of real property tax, it being acknowledged by Tenant and Landlord that Proposition 13 was adopted by the voters of the State of California in the June 1978 election (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Proposition 13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and that assessments, taxes, fees, levies and charges may be imposed by governmental agencies for such services as fire protection, street, sidewalk and road maintenance, refuse removal and for other governmental services formerly provided without charge to property owners or occupants, and, in further recognition of the decrease in the level and quality of governmental services and amenities as a result of Proposition 13, Tax Expenses shall also include any governmental or private assessments or the Project&#x2019;s contribution towards a governmental or private cost-sharing agreement for the purpose of augmenting or improving the quality of services and amenities normally provided by governmental agencies; (iii) any assessment, tax, fee, levy, or charge allocable to or measured by the area of the Premises or the Rent payable hereunder, including, without limitation, any business or gross income tax or excise tax with respect to the receipt of such rent, or upon or with respect to the possession, leasing, operating, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises, or any portion thereof; and (iv) any assessment, tax, fee, levy or charge, upon this transaction or any document to which Tenant is a party, creating or transferring an interest or an estate in the Premises or the improvements thereon; and (v) all of the real estate taxes and assessments imposed upon or with respect to the buildings and all of the real estate taxes and assessments imposed on the land and improvements comprising the Project, including any such taxes or assessments relating to the Underlying Documents or Mission Bay Requirements. If at any time during the Lease Term there shall be assessed on Landlord, in addition to or lieu of the whole or any part of the ad valorem tax on real or personal property, a capital levy or other tax on the gross rents or other measures of building operations, or a governmental income, franchise, excise or similar tax, assessment, levy, charge or fee measured by or based, in whole or in part, upon building valuation, gross rents or other measures of building operations or benefits of governmental services furnished to the Building, then any and all of such taxes, assessments, levies, charges and fees, to the extent so measured or based, shall be included within the term Tax Expenses, but only to the extent that the same would be payable if the Building and Land were the only property of Landlord.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2.5.3 Any costs and expenses (including, without limitation, reasonable attorneys&#x2019; and consultants&#x2019; fees) incurred in attempting to protest, reduce or minimize Tax Expenses in good faith shall be included in Tax Expenses in the Expense Year such expenses are incurred. Tax refunds shall be credited against Tax Expenses and refunded to Tenant regardless of when received, based on the Expense Year to which the refund is applicable, provided that in no event shall the amount to be refunded to Tenant for any such Expense Year exceed the total amount paid by Tenant as on account of Tax Expenses under this Article 4 for such Expense Year. The foregoing sentence shall survive the expiration or earlier termination of this Lease. If Tax Expenses for any period during the Lease Term or any extension thereof are increased after payment thereof for any reason, including, without limitation, escape</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">assessment or error or reassessment by applicable governmental or municipal authorities, Tenant shall pay Landlord Tenant&#x2019;s Share of any such increased Tax Expenses within thirty (30) days after Landlord&#x2019;s request, together with supporting documentation of such increase. Notwithstanding anything to the contrary contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.2.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there shall be excluded from Tax Expenses (i) all excess profits taxes, franchise taxes, gift taxes, capital stock taxes, inheritance and succession taxes, estate taxes, documentary transfer taxes (incurred in connection with the sale or financing of the Project or any portion thereof, but any changes in Tax Expenses following a reassessment of the Project relating to a change in ownership shall continue to be includable in Tax Expenses), federal and state income taxes, and other taxes to the extent applicable to Landlord&#x2019;s general or net income (as opposed to rents, receipts or income attributable to operations at the Project), (ii) any items included as Operating Expenses, (iii) any items paid by Tenant under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, (iv) tax penalties, fees or interest incurred as a result of Landlord&#x2019;s failure to make payments and/or to file any tax or informational returns when due, and (v) any assessments on real property or improvements located outside of the Project. For purposes of calculating Tax Expenses for the Project for any Expense Year, if such Tax Expenses do not reflect an assessment (or Tax Expenses) for a one hundred percent (100%) leased, completed and occupied project (such that existing or future leasing, improvements and/or occupancy may result in an increased assessment and/or increased Tax Expenses) with the Project being one hundred percent (100%) occupied by tenants paying full rent, such Tax Expenses shall adjusted, on a basis consistent with sound real estate accounting principles, to reflect an assessment for (and Tax Expenses for) a one hundred percent (100%) leased, completed and occupied project with the Project being one hundred percent (100%) occupied by tenants paying full rent.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2.5.4 Notwithstanding anything to the contrary set forth in this Lease, only Landlord may institute proceedings to reduce Tax Expenses and the filing of any such proceeding by Tenant without Landlord&#x2019;s consent shall constitute a Default by Tenant.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2.6 &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Share</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; is based upon the ratio that the rentable square feet of the Premises bears to the rentable square feet of the Building and initially shall mean the percentage set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary, subject to adjustment in the event that Tenant physically expands or contracts the Premises within the Building. For the avoidance of doubt, and notwithstanding anything to the contrary herein, no remeasurement of the Building or Project shall result in an increase in the Base Rent payable under this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Allocation of Direct Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Method of Allocation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The parties acknowledge that the Project contains four (4) sub- buildings or sectors (i.e., the North Tower, the North Building, the South Tower and the South Building, each a sub- building herein and together comprising the entire Building) and that the costs and expenses incurred in connection with the Project (i.e., the Direct Expenses) should be equitably allocated among those sub-buildings comprising the Project and shared by the tenants of each of those sub-buildings. Accordingly, as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above, Direct Expenses (which consist of Operating Expenses and Tax Expenses) attributable only to a particular sub-building or sub-buildings, but not the Project generally, shall be included in Direct Expenses for such sub-building or sub- buildings, but excluded from Direct Expenses for any other sub-buildings, and Direct Expenses that are attributable to the Project as a whole shall be allocated among the Building pro rata based on the relative rentable square footages of each of the sub-buildings as compared to the rentable square footage of the entire Building in the aggregate. Accordingly, such portion of Direct Expenses allocated to the tenants of the sub-building shall include all Direct Expenses attributable solely to the sub-building and an equitable portion of the Direct Expenses attributable to the entire Building as a whole. Further, Landlord shall have the right, from time to time, to allocate equitably some or all of the Direct Expenses for a sub-building or the Project among different portions or occupants of the sub-building or Project, in Landlord&#x2019;s reasonable discretion, in a manner reflecting commercially reasonable cost pools for such Direct Expenses so allocated. The Direct Expenses within each cost pool shall be allocated and charged to the tenants within such cost pool in an equitable manner.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Cost Pools</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The parties acknowledge that certain of the costs and expenses incurred in connection with the Project (i.e., the Direct Expenses) should be separately allocated to the office space and the Retail Space. Direct Expenses shall be allocated between the office space and Retail Space (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cost Pool</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) based on the estimated benefit derived by the space which is the subject of the Cost Pool, and such allocations shall be reasonably determined by Landlord. Accordingly, Direct Expenses shall be charged to the Retail Space and the office space by virtue of the creation of Cost Pools. Direct Expenses which apply equally to the Retail Space and the office space (such as Landlord&#x2019;s insurance costs), as reasonably determined by Landlord, shall be allocated to the office</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">space Cost Pool and the Retail Space Cost Pool based on the square footage of each of those spaces, respectively, compared to the total square footage of the applicable Building. After the date of this Lease, Landlord may reasonably establish additional Cost Pools in connection with any new leases of the Project, such as a life sciences Cost Pool. Any costs allocated to a Cost Pool (e.g. the Retail Space Cost Pool) which does not include a portion of the Premises shall be excluded from the definition of Direct Expenses for the purposes of this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Costs Attributable to Laboratory Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In addition to the payment of Tenant&#x2019;s Share of Operating Expenses provided for hereinabove, Tenant shall be solely responsible for the payment of one hundred percent (100%) of any costs (whether or not otherwise included in Operating Expenses, but Tenant shall not be directly invoiced for costs already included in Operating Expenses) attributable to, or incurred or payable by Landlord as a consequence of, Tenant&#x2019;s use of any portion of the Premises for the Laboratory Use, as determined by Landlord in its reasonable judgement and following the delivery of reasonable documentation supporting said additional costs as attributable to Tenant&#x2019;s use of a portion of the Premises for the Laboratory Use. If not otherwise included as a special allocation to Tenant as contemplated by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above of any such costs in the Operating Expense payments made by Tenant, Landlord will invoice Tenant, on a periodic basis, for any such costs, and Tenant shall pay such costs as additional Rent hereunder within fifteen (15) days following Landlord&#x2019;s delivery of any such invoice to Tenant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Calculation and Payment of Additional Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall pay to Landlord, in the manner set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below, and as Additional Rent, Tenant&#x2019;s Share of Direct Expenses for each Expense Year.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statement of Actual Direct Expenses and Payment by Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall use commercially reasonable efforts to give to Tenant on or before May 1 following the end of each Expense Year, a statement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) which shall state the Direct Expenses incurred or accrued for such preceding Expense Year, and which shall indicate the amount of Tenant&#x2019;s Share of Direct Expenses. Upon receipt of the Statement for each Expense Year commencing or ending during the Lease Term, Tenant shall pay, with its next installment of Base Rent due, the full amount of Tenant&#x2019;s Share of Direct Expenses for such Expense Year, less the amounts, if any, paid during such Expense Year as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Estimated Direct Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; (as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below), and if Tenant paid more as Estimated Direct Expenses than the actual Tenant&#x2019;s Share of Direct Expenses, Tenant shall receive a credit in the amount of Tenant&#x2019;s overpayment against Rent next due under this Lease or, if Landlord elects, Landlord shall reimburse such overpayment amount to Tenant or, if the Lease Term has ended, Landlord shall refund such amount to Tenant within thirty (30) days of the date of such Statement. The failure of Landlord to timely furnish the Statement for any Expense Year shall not prejudice Landlord or Tenant from enforcing its rights under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">4, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provided, however, that Tenant shall not be responsible for payment of any Direct Expenses first shown on a Statement delivered more than twenty-four (24) months after expiration of the applicable Expense Year. Even though the Lease Term has expired and Tenant has vacated the Premises, when the final determination is made of Tenant&#x2019;s Share of Direct Expenses for the Expense Year in which this Lease terminates, Tenant shall pay to Landlord such amount within thirty (30) days after delivery of the applicable Statement to Tenant, and if Tenant paid more as Estimated Direct Expenses than the actual Tenant&#x2019;s Share of Direct Expenses, Landlord shall, within thirty (30) days after delivery of the applicable Statement to Tenant, pay to Tenant the amount of the overpayment. The provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall survive the expiration or earlier termination of the Lease Term.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statement of Estimated Direct Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In addition, Landlord shall use commercially reasonable efforts to give Tenant on or before May 1 following the end of each Expense Year, a yearly expense estimate statement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Estimate Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) which shall set forth Landlord&#x2019;s reasonable estimate (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Estimate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) of what the total amount of Direct Expenses for the then-current Expense Year shall be and the estimated Tenant&#x2019;s Share of Direct Expenses (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Estimated Direct Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). The failure of Landlord to timely furnish the Estimate Statement for any Expense Year shall not preclude Landlord from enforcing its rights to collect any Estimated Direct Expenses under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, nor shall Landlord be prohibited from revising any Estimate Statement or Estimated Direct Expenses theretofore delivered to the extent necessary (but not more than three (3) times per Expense Year). Thereafter, Tenant shall pay, with its next installment of Base Rent due, a fraction of the Estimated Direct Expenses for the then-current Expense Year (reduced by any amounts paid pursuant to the last sentence of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). Such fraction shall have as its numerator the number of months which have elapsed in such current Expense Year, including the month of such payment, and twelve (12) as its denominator. Until a new Estimate Statement is furnished (which Landlord shall have the right to deliver to Tenant at any time [but not more than three (3) times per Expense Year]), Tenant shall pay monthly, with the monthly Base Rent installments, an amount equal to one-twelfth (1/12) of the total Estimated Direct Expenses set forth in the previous Estimate Statement delivered by Landlord to Tenant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mission Bay Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.4.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">attached hereto, the Project is subject to certain covenants, requirements, and disclosures (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Mission Bay Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), which include, without limitation, certain limitations on (i) Landlord&#x2019;s ability to lease space at the Project to a Tax-Exempt Entity and (ii) Landlord&#x2019;s ability to obtain reductions in the assessed value of the Project below the Minimum Amount. In connection with the foregoing, to the extent that Tenant is exempt from certain Tax Expenses, but Landlord is otherwise obligated to continue to pay such Tax Expenses (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant-Exempt Tax Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), then, notwithstanding Tenant&#x2019;s tax-exempt status, Tenant shall continue to be obligated to pay to Landlord, as part of Direct Expenses, all such Tenant-Exempt Tax Expenses.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Taxes and Other Charges for Which Tenant Is Directly Responsible</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5.1 Tenant shall be liable for and shall pay before delinquency, taxes levied against Tenant&#x2019;s equipment, furniture, fixtures and any other personal property located in or about the Premises. If any such taxes on Tenant&#x2019;s equipment, furniture, fixtures and any other personal property are levied against Landlord or Landlord&#x2019;s property or if the assessed value of Landlord&#x2019;s property is increased by the inclusion therein of a value placed upon such equipment, furniture, fixtures or any other personal property and if Landlord pays the taxes based upon such increased assessment, which Landlord shall have the right to do regardless of the validity thereof but only under proper protest if requested by Tenant, Tenant shall within thirty (30) days after Landlord&#x2019;s demand (together with reasonable back-up evidencing the same) repay to Landlord the taxes so levied against Landlord or the proportion of such taxes resulting from such increase in the assessment, as the case may be.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5.2 If the improvements in the Premises, whether installed and/or paid for by Landlord or Tenant and whether or not affixed to the real property so as to become a part thereof, are assessed for real property tax purposes at a valuation higher than the valuation at which &#x201c;building standard&#x201d; improvements are assessed, then the Tax Expenses levied against Landlord or the property by reason of such excess assessed valuation shall be deemed to be taxes levied against personal property of Tenant and shall be governed by the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above. Landlord and Tenant hereby agree that the valuation of Landlord&#x2019;s &#x201c;building standard&#x201d; improvements for all tenants of the Project shall be equal to One Hundred Dollars ($100.00) per rentable square foot. Landlord and Tenant shall cooperate with respect to the information provided by either of them to the appropriate taxing authority regarding the valuation of the improvements in the Premises so as to avoid duplicative assessments being levied on such improvements.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5.3 Notwithstanding any contrary provision herein, Tenant shall pay prior to delinquency any (i) rent tax (e.g., gross receipts tax on commercial rents) or sales tax, service tax, transfer tax or value added tax, or any other applicable tax on the rent or services herein or otherwise respecting this Lease, or (ii) taxes assessed upon or with respect to the possession, leasing, operation, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises or any portion of the Project, including the Parking Facilities.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Books and Records</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Following Tenant&#x2019;s receipt of a Statement, Tenant shall have the right by written notice to Landlord to commence and complete an audit of Landlord&#x2019;s books concerning the Direct Expenses for the Expense Year which are the subject of such Statement, within the later to occur of (x) six (6) months following the delivery of such Statement and (y) the date that is sixty (60) days after Landlord makes Landlord&#x2019;s books and records available for Tenant&#x2019;s audit, provided that Tenant notifies Landlord of Tenant&#x2019;s intent to audit Landlord&#x2019;s books and records within the six (6) month period described in clause (x) above (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Audit Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Following the giving of such written notice, Tenant shall have the right during Landlord&#x2019;s regular business hours taking into account the workload of Landlord&#x2019;s employees involved in the audit at the time of the audit request and on reasonable prior notice, to audit, at Landlord&#x2019;s corporate offices in the San Francisco Bay area, at Tenant&#x2019;s sole cost, Landlord&#x2019;s records, provided that Tenant is not then in Default. The audit of Landlord&#x2019;s records may be conducted only by a reputable certified public accountant, subject to Landlord&#x2019;s approval, which approval shall not be unreasonably withheld. Any accounting firm selected by Tenant in connection with the audit (i) shall be a reputable independent nationally or regionally recognized certified public accounting firm which has previous experience in auditing financial operating records of landlords of office/life science buildings; (ii) shall not already be providing accounting and/or lease administration services to Tenant and shall not have provided accounting and/or lease administration services to Tenant in the past three (3) years; (iii) shall not be retained by Tenant on a contingency fee basis (i.e. Tenant must be billed based on the actual time and materials that are incurred by the accounting firm in the performance of the audit), a copy of the executed audit agreement, between Tenant and auditor, shall be provided to Landlord prior to the commencement of the audit; and (iv) at Landlord&#x2019;s option, both Tenant and its agent shall be</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required to execute a commercially reasonable confidentially agreement prepared by Landlord. Any audit report prepared by Tenant&#x2019;s auditors shall be delivered concurrently to Landlord and Tenant within the Audit Period. If, after such audit of Landlord&#x2019;s records, Tenant disputes the amount of Direct Expenses for the year under audit, Landlord and Tenant shall meet and attempt in good faith to resolve the dispute. If the parties are unable to resolve the dispute within sixty (60) days after completion of Tenant&#x2019;s audit, then, at Tenant&#x2019;s request, a certified public accounting firm selected by Landlord, and reasonably approved by Tenant, shall, at Tenant&#x2019;s cost, conduct an audit of the relevant Direct Expenses (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Neutral Audit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant shall pay all costs and expenses of the Neutral Audit unless the final determination in such Neutral Audit is that Landlord overstated Direct Expenses in the Statement for the year being audited by more than five percent (5%) in which case Landlord shall pay all costs and expenses of the Neutral Audit, as well as Tenant&#x2019;s reasonable out-of-pocket costs actually incurred by Tenant in the audit of Landlord&#x2019;s books and records. In any event, Landlord will reimburse or provide a credit for any overstatement of Direct Expenses and Tenant shall pay to Landlord any understatement of Direct Expenses. To the extent Landlord and Tenant fail to otherwise reach mutual agreement regarding Direct Expenses, the foregoing audit and Neutral Audit procedures shall be the sole methods to be used by Tenant to dispute the amount of any Direct Expenses payable by Tenant pursuant to the terms of the Lease.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. USE OF PREMISES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Permitted Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall use the Premises solely for the Permitted Use set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary and Tenant shall not use or permit the Premises or the Project to be used for any other purpose or purposes whatsoever without the prior written consent of Landlord, which consent may be withheld in Landlord&#x2019;s sole discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Prohibited Uses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The uses prohibited under this Lease shall include, without limitation, use of the Premises or a portion thereof for (i) offices of any agency or bureau of the United States or any state or political subdivision thereof; (ii) offices or agencies of any foreign governmental or political subdivision thereof; (iii) offices of any health care professionals or service organization (but occupational health professionals employed by Tenant shall not violate the foregoing prohibition); (iv) schools or other training facilities which are not ancillary to corporate, executive or professional office use; (v) retail use or the operation of any restaurant offering services to the public; or (vi) communications firms such as radio and/or television stations. Tenant further covenants and agrees that Tenant shall not use, or suffer or permit any person or persons claiming by, through, or under Tenant to use, the Premises or any part thereof for any use or purpose contrary to the provisions of the Rules and Regulations attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as the same may be amended by Landlord from time to time (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Rules and Regulations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), or in violation of Applicable Laws or any Underlying Documents. Any modifications to the Rules and Regulations shall be reasonable and non-discriminatory and shall be provided to Tenant in writing or posted to a conspicuous place in the Building. In the event of a conflict between any modifications to the Rules and Regulations and the terms of this Lease, the latter shall control. Tenant shall not do or permit anything to be done in or about the Premises which will in any way damage the reputation of the Project or unreasonably obstruct or interfere with the rights of other tenants or occupants of the Building, or injure or annoy them or use or allow the Premises to be used for any improper, unlawful or objectionable purpose, nor shall Tenant cause, maintain or permit any nuisance in, on or about the Premises. Tenant shall comply with, and Tenant&#x2019;s rights and obligations under the Lease and Tenant&#x2019;s use of the Premises shall be subject and subordinate to, all Underlying Documents; provided that, following the date of this Lease, Landlord shall not voluntarily enter into new, or modify existing, Underlying Documents that would unreasonably interfere with Tenant&#x2019;s access to the Premises or use of the Premises for the Permitted Use. Tenant shall only place equipment within the Premises with floor loading consistent with the Building&#x2019;s structural design, and such equipment shall be placed in a location designed to carry the weight of such equipment. Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent sounds or vibrations therefrom from extending into the Common Areas or other offices in the Project.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Bicycles</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant&#x2019;s employees shall be permitted to bring their bicycles (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bicycles</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) into portions of the Project designated by Landlord for Bicycle storage, subject to the provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and such additional reasonable rules and regulations as may be promulgated by Landlord from time to time (in Landlord&#x2019;s reasonable discretion) that do not unreasonably interfere with Tenant&#x2019;s ability to park its Bicycles as contemplated herein and provided to Tenant, and only to the extent such Bicycles are used on a daily basis for commuting to and from work by such employees. AT NO TIME ARE RIDERS ALLOWED TO RIDE ANY BICYCLE IN THE PREMISES, THE PARKING FACILITIES OR THE BUILDINGS. Storage of any Bicycle anywhere on the Project</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other than as expressly set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is prohibited. Tenant shall keep its employees informed of these rules and regulations and any modifications thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Bicycle Storage Area</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Parking Facilities include a secured bicycle storage area that will accommodate at least two hundred (200) Bicycles (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord Bicycle Storage Area</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant shall have the non-exclusive right (at no additional charge other than Tenant&#x2019;s Share of Direct Expenses relating thereto) to use the Landlord Bicycle Storage Area for day use parking of Bicycles by Tenant and Tenant&#x2019;s employees, visitors, invitees and sublessees not to exceed Tenant&#x2019;s pro rata share (which is presently 40 based on the Landlord Bicycle Storage presently accommodating up to 228 Bicycles) of the number of Bicycles that the Landlord Bicycle Storage Area from time to time accommodates (which shall not be less than 200 Bicycles), and Tenant shall also have the right, at Tenant&#x2019;s sole cost and expense, to convert certain areas of the Parking Facilities, reasonably designated by Landlord and approved by Tenant, for additional exclusive day use parking (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant Bicycle Storage Area</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) for Bicycles by Tenant and its employees, visitors, invitees and sublessees, which shall include the installation of Bicycle storage lockers or other Bicycle storage facilities, installed as an Alteration (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bicycle Improvements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). The Landlord Bicycle Storage Area and Tenant Bicycle Storage Area are collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bicycle Storage Area</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;. Other than the Bicycle Storage Area, Tenant and Tenant&#x2019;s employees, visitors, invitees and sublessees shall not be entitled to use any secured bicycle storage areas at the Project, and Tenant&#x2019;s employees shall not be permitted to bring their Bicycles in the Premises. Motorized vehicles of any kind, including motorcycles and mopeds, are prohibited in the Bicycle Storage Area, as is the storage of any property other than Bicycles. Each rider shall use the Bicycle Storage Area at its sole risk. Landlord specifically reserves the right to reasonably change the location, size, configuration, design, layout and all other aspects of the Landlord Bicycle Storage Area at any time (provided that no such action will materially diminish the capacity of the Landlord Bicycle Storage Area on other than a temporary basis), and Tenant acknowledges and agrees that Landlord may, without incurring any liability to Tenant and without any abatement of Rent under this Lease, from time to time, temporarily close-off or restrict access to the Bicycle Storage Area for purposes of permitting or facilitating any such construction, alteration or improvements. Landlord has no obligation to provide any security whatsoever in connection with the Bicycle Storage Area except as expressly set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall provide twenty-four (24) hours per day, seven (7) days per week, reasonable access control services for the Landlord Bicycle Storage Area in a manner materially consistent with the services provided by landlords of Comparable Buildings. Notwithstanding the foregoing, Landlord shall in no case be liable for personal injury or property damage for any error with regard to the admission to or exclusion from the Bicycle Storage Area of any person. Upon the expiration or earlier termination of this Lease, Tenant shall have removed all Bicycles belonging to its employees from the Bicycle Storage Area and Tenant, at Tenant&#x2019;s sole cost and expense, shall repair all damage to the Bicycle Storage Area caused by the removal of Tenant&#x2019;s property therefrom, and if Tenant fails to repair such damage, Landlord may undertake such repair on account of Tenant and Tenant shall pay to Landlord upon demand the cost of such repair. If Tenant fails to remove any Bicycles at the expiration or earlier termination of this Lease, Landlord may dispose of said Bicycles in such lawful manner as it shall determine in its sole and absolute discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Use of Base Building Stairwells</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to Applicable Laws and Tenant&#x2019;s receipt of all necessary governmental or quasi-governmental approvals (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Governmental Approvals</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), Tenant shall have right during the Lease Term to use the base building stairwells between the floors of the Premises (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stairwell</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) solely for purposes of ingress and egress from and between different floors of the Premises. In its use of the Stairwells, Tenant shall comply with all Applicable Laws, Governmental Approvals and the rules and regulations for the Project. Tenant shall have no right to alter or change any Stairwell in any manner whatsoever, except that Tenant may paint or perform other purely decorative Alterations or Improvements to the Stairwells in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or the Work Letter, as applicable, and may install Tenant&#x2019;s Security System as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 6.1.11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below. Tenant acknowledges and agrees that Tenant&#x2019;s use of the Stairwells shall be at Tenant&#x2019;s sole risk and Landlord shall have no liability whatsoever in connection therewith. Tenant hereby waives any and all claims against Landlord for any damages arising from Tenant&#x2019;s exercise of its rights under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Hazardous Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.1.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Prohibitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As a material inducement to Landlord to enter into this Lease with Tenant, Tenant has fully and accurately completed Landlord&#x2019;s Pre-Leasing Environmental Exposure Questionnaire</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Environmental Questionnaire</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), which is attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 5.5.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant hereby represents, warrants and covenants that except for those chemicals or materials, and their respective quantities, specifically listed on the Environmental Questionnaire (as may be updated from time to time as described below), neither Tenant nor Tenant&#x2019;s subtenants or assigns, or any of their respective employees, contractors and subcontractors of any tier, entities with a contractual relationship with such parties (other than Landlord), or any entity acting as an agent or sub-agent of such parties or any of the foregoing (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) will produce, use, store or generate any &#x201c;Hazardous Materials&#x201d;, as that term is defined below, on, under or about the Premises, nor cause or permit any Hazardous Material to be brought upon, placed, stored, manufactured, generated, blended, handled, recycled, used or &#x201c;Released&#x201d;, as that term is defined below, on, in, under or about the Premises or Project. If any information provided to Landlord by Tenant on the Environmental Questionnaire, or otherwise relating to information concerning Hazardous Materials is intentionally false, incomplete, or misleading in any material respect, the same shall be deemed a default by Tenant under this Lease. Upon Landlord&#x2019;s request, or in the event of any &#x201c;Material Change&#x201d; in Tenant&#x2019;s use of Hazardous Materials at the Premises, Tenant shall deliver to Landlord an updated Environmental Questionnaire. As used herein, &#x201c;Material Change&#x201d; shall refer to any change in the use, presence (including, without limitation, a material change in the quantity stored within the Premises at any one time) or handling of Hazardous Materials by Tenant that would (A)reasonably be expected to have a significant effect on the Premises or the Project, (B) violate the compliance with or provisions of any existing permits, licenses, registrations and other similar documents used by any governmental or quasi-governmental authority that authorizes any use, storage or handling of Hazardous Materials in, on or about the Premises or the Project by Tenant or any Tenant Parties, or (C) cause the information provided in the Environmental Questionnaire, as previously updated from time to time, to become untrue or inaccurate in any material respect. Landlord&#x2019;s prior written consent shall be required for any Hazardous Materials use for the Premises not described on the initial Environmental Questionnaire, but such consent not to be unreasonably withheld, conditioned or delayed. Whenever Tenant submits to Landlord an updated Environmental Questionnaire, Landlord shall respond to Tenant within five (5) business days with its approval or disapproval thereof. Tenant shall not install or permit any underground storage tank on the Premises. In addition, Tenant agrees that it: (i) shall not cause or suffer to occur, the Release (as defined below) of any Hazardous Materials at, upon, under or within the Premises or any contiguous or adjacent premises; and (ii) shall not engage in activities at the Premises that give rise to, or lead to the imposition of, liability upon Tenant or Landlord or the creation of an environmental lien or use restriction upon the Premises. For purposes of this Lease, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Hazardous Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; means all flammable explosives, petroleum and petroleum products, oil, radon, radioactive materials, toxic pollutants, asbestos, polychlorinated biphenyls (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PCBs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), medical waste, chemicals known to cause cancer or reproductive toxicity, pollutants, contaminants, hazardous wastes, toxic substances or related materials, including without limitation any chemical, element, compound, mixture, solution, substance, object, waste or any combination thereof, which is or may hereafter be determined to be hazardous to human health, safety or to the environment due to its radioactivity, ignitability, corrosiveness, reactivity, explosiveness, toxicity, carcinogenicity, infectiousness or other harmful or potentially harmful properties or effects, or defined as, regulated as or included in, the definition of &#x201c;hazardous substances&#x201d;, &#x201c;hazardous wastes&#x201d;, &#x201c;hazardous materials&#x201d;, or &#x201c;toxic substances&#x201d; under any Environmental Laws. The term &#x201c;Hazardous Materials&#x201d; for purposes of this Lease shall also include any mold, fungus or spores, whether or not the same is defined, listed, or otherwise classified as a &#x201c;hazardous material&#x201d; under any Environmental Laws, if such mold, fungus or spores may pose a risk to human health or the environment or negatively impact the value of the Premises. Hazardous Materials shall also include any &#x201c;biohazardous waste,&#x201d; &#x201c;medical waste,&#x201d; or other waste under California Health and Safety Code Division 20, Chapter 6.1 (Medical Waste Management Act).  For purposes of this Lease, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Released</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Releases</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean any release, deposit, discharge, emission, leaking, spilling, seeping, migrating, injecting, pumping, pouring, emptying, escaping, dumping, disposing, or other movement of Hazardous Materials into the environment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any use or storage of Hazardous Materials by Tenant permitted pursuant to this Article 5 shall not exceed Tenant&#x2019;s legally permissible quantity of similarly classed Hazardous Materials. Notwithstanding anything contained herein to the contrary, in no event shall Tenant or anyone claiming by through or under Tenant perform work above the risk category Biosafety Level 3 as established by the Department of Health and Human Services (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DHHS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and as further described in the DHHS publication Biosafety in Microbiological and Biomedical Laboratories (5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Edition) (as it may be or may have been further revised, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BMBL</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) or such nationally recognized new or replacement standards as Landlord may reasonable designate. Tenant shall comply with all applicable provisions of the standards of the BMBL to the extent applicable to Tenant&#x2019;s operations in the Premises.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.1.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices to Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Unless Tenant is required by Applicable Laws to give earlier notice to Landlord, Tenant shall notify Landlord in writing as soon as possible but in no event later than five (5) days after (i) Tenant becomes aware of the occurrence of any actual, alleged or threatened Release of any Hazardous Material in, on, under, from, about or in the vicinity of the Premises (whether past or present), regardless of the source or quantity of any such Release, or (ii) Tenant becomes aware of any regulatory actions, inquiries, inspections, investigations, directives, or any cleanup, compliance, enforcement or abatement proceedings (including any threatened or contemplated investigations or proceedings) relating to or potentially affecting the Premises, or (iii) Tenant becomes aware of any claims by any person or entity relating to any Hazardous Materials in, on, under, from, about or in the vicinity of the Premises, whether relating to damage, contribution, cost recovery, compensation, loss or injury. Collectively, the matters set forth in clauses (i), (ii) and (iii) above are hereinafter referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Hazardous Materials Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;. Tenant shall promptly forward to Landlord copies of all orders, notices, permits, applications and other communications and reports in connection with any Hazardous Materials Claims. Additionally, Tenant shall promptly advise Landlord in writing of Tenant&#x2019;s discovery of any occurrence or condition on, in, under or about the Premises that could subject Tenant or Landlord to any liability, or restrictions on ownership, occupancy, transferability or use of the Premises under any &#x201c;Environmental Laws&#x201d;, as that term is defined below. Tenant shall not enter into any legal proceeding or other action, settlement, consent decree or other compromise with respect to any Hazardous Materials Claims without first notifying Landlord of Tenant&#x2019;s intention to do so and affording Landlord the opportunity to join and participate, as a party if Landlord so elects, in such proceedings and in no event shall Tenant enter into any agreements which are binding on Landlord or the Project without Landlord&#x2019;s prior written consent. Landlord shall have the right to appear at and participate in, any and all legal or other administrative proceedings concerning any Hazardous Materials Claim.  For purposes of this Lease, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Environmental Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; means all applicable present and future laws relating to the protection of human health, safety, wildlife or the environment, including, without limitation, (i) all requirements pertaining to reporting, licensing, permitting, investigation and/or remediation of emissions, discharges, Releases, or threatened Releases of Hazardous Materials, whether solid, liquid, or gaseous in nature, into the air, surface water, groundwater, or land, or relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport, or handling of Hazardous Materials; and (ii) all requirements pertaining to the health and safety of employees or the public.  Environmental Laws include, but are not limited to, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 USC &#167; 9601, et seq., the Hazardous Materials Transportation Authorization Act of 1994, 49 USC &#167; 5101, et seq., the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, and Hazardous and Solid Waste Amendments of 1984, 42 USC &#167; 6901, et seq., the Federal Water Pollution Control Act, as amended by the Clean Water Act of 1977, 33 USC &#167; 1251, et seq., the Clean Air Act of 1966, 42 USC &#167; 7401, et seq., the Toxic Substances Control Act of 1976, 15 USC &#167; 2601, et seq., the Safe Drinking Water Act of 1974, 42 USC &#167;&#167; 300f through 300j, the Occupational Safety and Health Act of 1970, as amended, 29 USC &#167; 651 et seq., the Oil Pollution Act of 1990, 33 USC &#167; 2701 et seq., the Emergency Planning and Community Right-To-Know Act of 1986, 42 USC &#167; 11001 et seq., the National Environmental Policy Act of 1969, 42 USC &#167; 4321 et seq., the Federal Insecticide, Fungicide and Rodenticide Act of 1947, 7 USC &#167; 136 et seq., asbestos, polychlorobiphenyls (i.e., PCB&#x2019;s) and petroleum and petroleum by products; and any other State of California or local law counterparts, as amended, as such Applicable Laws, are in effect as of the Lease Commencement Date, or thereafter adopted, published or promulgated.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.1.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Releases of Hazardous Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If due to the acts or omissions of Tenant or any Tenant Party any Release of any Hazardous Material in, on, under, from or about the Premises in violation of, or requiring any Clean-Up (as defined below), in addition to notifying Landlord as specified above, Tenant, at its own sole cost and expense, shall (i) immediately comply with any and all reporting requirements imposed pursuant to any and all Environmental Laws, (ii) provide a written certification to Landlord indicating that Tenant has complied with all applicable reporting requirements, (iii) take any and all necessary investigation, corrective, remedial and other Clean-up action in accordance with any and all applicable Environmental Laws, utilizing an environmental consultant reasonably approved by Landlord, all in accordance with the provisions and requirements of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, including, without limitation, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and (iv) take any such additional investigative, remedial and corrective actions as Landlord shall in its reasonable discretion deem necessary such that the Premises and Project are remediated to a condition allowing unrestricted use of the Premises (i.e., to a level that will allow any future use of the Premises, including residential, without any engineering controls or deed restrictions), all in accordance with the provisions and requirements of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord may, as required by any and all Environmental Laws, report the Release of any Hazardous Material by Tenant or any Tenant Party to the appropriate governmental authority, identifying Tenant as the responsible party. Tenant shall deliver to Landlord copies of all administrative orders, notices, demands, directives or other communications directed to Tenant from any governmental authority with respect to any Release</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of Hazardous Materials in, on, under, from, or about the Premises, together with copies of all investigation, assessment, and remediation plans and reports prepared by or on behalf of Tenant in response to any such regulatory order or directive.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.1.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Indemnification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.1.4.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">In General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Without limiting in any way Tenant&#x2019;s obligations under any other provision of this Lease, Tenant shall be solely responsible for and shall protect, defend, indemnify and hold the Landlord Parties harmless from and against any and all claims, judgments, losses, damages, costs, expenses, penalties, enforcement actions, taxes, fines, remedial actions, liabilities (including, without limitation, actual attorneys&#x2019; fees, litigation, arbitration and administrative proceeding costs, expert and consultant fees and laboratory costs) including, without limitation, consequential damages and sums paid in settlement of claims, which arise during or after the Lease Term, whether foreseeable or unforeseeable, directly or indirectly arising out of or attributable to the presence, use, generation, manufacture, treatment, handling, refining, production, processing, storage, Release or presence of Hazardous Materials in, on, under or about the Premises or Project by any Tenant Party, except to the extent such liabilities result from the negligence or willful misconduct of Landlord following the Lease Commencement Date. The foregoing obligations of Tenant shall include, without limitation: (i) the costs of any required or necessary removal, repair, cleanup or remediation of the Premises and Project, and the preparation and implementation of any closure, removal, remedial or other required plans; (ii) judgments for personal injury or property damages; and (iii) all costs and expenses incurred by Landlord in connection therewith. It is the express intention of the parties to this Lease that Tenant assumes all such liabilities, and holds Landlord harmless from all such liabilities, associated with the environmental condition of the Premises, arising on or after the date Tenant takes possession of the Premises.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.1.4.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Limitations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything to the contrary in this Lease, Tenant shall not be responsible to remediate nor otherwise be liable or responsible for (not shall Tenant be responsible to indemnify Landlord with respect to except to the extent that Tenant&#x2019;s construction activities and/or Tenant&#x2019;s other acts or omissions caused or exacerbated the subject claim) any Hazardous Materials (i) located in, on, under or about the Project, Building and/or Premises prior to the date of the Existing Sublease, (ii) brought upon the Project by Landlord or any Landlord Party(ies), or (iii) that have migrated onto the Project, Building and/or Premises from other properties or premises (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Hazardous Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), except to the extent any of the Hazardous Materials described in items (i), (ii) or (iii) are generated, used, transported, exacerbated, released or disturbed, by Tenant or any Tenant Party. To the extent that Landlord&#x2019;s Hazardous Materials are discovered at the Project, Building or Premises and remediation of the same is required a governmental authority with jurisdiction (which remediation is not triggered because of the particular use of the Premises by Tenant or its subtenants or assigns), any remediation thereof of the Landlord&#x2019;s Hazardous Substances (to the extent required by the applicable governmental authority) by Landlord shall be at Landlord&#x2019;s sole cost and expense, and not subject to inclusion in Operating Expenses.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.1.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Compliance with Environmental Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Without limiting the generality of Tenant&#x2019;s obligation to comply with Applicable Laws as otherwise provided in this Lease, Tenant shall, at its sole cost and expense, comply with all Environmental Laws applicable to the use, handling, storage and disposal by Tenant or by any Tenant&#x2019;s Agents of any Hazardous Materials. Tenant shall obtain and maintain any and all necessary permits, licenses, certifications and approvals appropriate or required for the use, handling, storage, and disposal of any Hazardous Materials used, stored, generated, transported, handled, blended, or recycled by Tenant on the Premises. Landlord shall have a continuing right, without obligation, to require Tenant to obtain, and to review and inspect any and all such permits, licenses, certifications and approvals, together with copies of any and all Hazardous Materials management plans and programs, any and all Hazardous Materials risk management and pollution prevention programs, and any and all Hazardous Materials emergency response and employee training programs respecting Tenant&#x2019;s use of Hazardous Materials. If Landlord has grounds to be concerned that Tenant has failed to comply with the provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, then upon request of Landlord, Tenant shall deliver to Landlord a narrative description explaining the nature and scope of Tenant&#x2019;s activities involving Hazardous Materials and showing to Landlord&#x2019;s reasonable satisfaction compliance with all Environmental Laws and the terms of this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Assurance of Performance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.2.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Environmental Assessments In General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Provided that Landlord gives Tenant no less than two (2) days prior notice of intended entry (other than in any emergency context) and complies with Tenant&#x2019;s security measures then in effect Landlord may, but shall not be required to, engage from time to time such contractors</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as Landlord determines to be appropriate to perform &#x201c;Environmental Assessments&#x201d;, as that term is defined below, to ensure Tenant&#x2019;s compliance with the requirements of this Lease with respect to Hazardous Materials. For purposes of this Lease, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Environmental Assessment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; means an assessment including, without limitation: (i) an environmental site assessment conducted in accordance with the then-current standards of the American Society for Testing and Materials and meeting the requirements for satisfying the &#x201c;all appropriate inquiries&#x201d; requirements; and (ii) sampling and testing of the Premises based upon potential recognized environmental conditions or areas of concern or inquiry identified by the environmental site assessment.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.2.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Costs of Environmental Assessments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All costs and expenses incurred by Landlord in connection with any such Environmental Assessment initially shall be paid by Landlord; provided that if any such Environmental Assessment shows that Tenant has failed to comply with the provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, then all of the costs and expenses of such Environmental Assessment shall be reimbursed by Tenant as Additional Rent within thirty (30) days after receipt of written demand therefor, together with documentation of such cost.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Obligations upon Surrender</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. At the expiration or earlier termination of the Lease Term, Tenant, at Tenant&#x2019;s sole cost and expense, shall: (i) cause an Environmental Assessment of the Premises to be conducted in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 15.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; (ii) cause all Hazardous Materials for which Tenant is responsible for under this Lease to be removed from the Premises and disposed of in accordance with all Environmental Laws and as necessary to allow the Premises to be used for any purpose in a manner consistent with Comparable Buildings (but for the sake of clarity, Tenant&#x2019;s return to Landlord of the Premises in the condition that existed prior to the Lease Commencement Date shall satisfy Tenant&#x2019;s obligation as to removal of Hazardous Materials from the Premises); and (iii) cause to be removed all containers installed or used by any Tenant Parties to store any Hazardous Materials on the Premises, and cause to be repaired any damage to the Premises caused by such removal.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Clean-up</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.4.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Environmental Reports; Clean-Up</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If any written report, including any report containing results of any Environmental Assessment (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Environmental Report</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall indicate (i) the presence of any Hazardous Materials as to which Tenant has a removal or remediation obligation under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and (ii) that as a result of same, the investigation, characterization, monitoring, assessment, repair, closure, remediation, removal, or other clean-up (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Clean-up</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) of any Hazardous Materials is required, Tenant shall immediately prepare and submit to Landlord within thirty (30) days after receipt of the Environmental Report a comprehensive plan, subject to Landlord&#x2019;s written approval (not to be unreasonably withheld), specifying the actions to be taken by Tenant to perform the Clean-up so that the Premises are restored to the conditions required by this Lease. Upon Landlord&#x2019;s approval of the Clean-up plan, Tenant shall, at Tenant&#x2019;s sole cost and expense, without limitation of any rights and remedies of Landlord under this Lease, immediately implement such plan with a consultant reasonably acceptable to Landlord and proceed to Clean-Up Hazardous Materials in accordance with all applicable laws and as required by such plan and this Lease. If, within thirty (30) days after receiving a copy of such Environmental Report, Tenant fails either (a) to complete such Clean-up, or (b) with respect to any Clean-up that cannot be completed within such 30-day period, fails to proceed with diligence to prepare the Clean-up plan and complete the Clean-up as promptly as practicable, then Landlord shall have the right, but not the obligation, and without waiving any other rights under this Lease, to carry out any Clean-up recommended by the Environmental Report or required by any governmental authority having jurisdiction over the Premises, and recover all of the costs and expenses thereof from Tenant as Additional Rent, payable within thirty (30) days after receipt of written demand therefor, together with documentation of such cost.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.4.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Rent Abatement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall continue to pay all Rent due or accruing under this Lease during any Clean-up, and shall not be entitled to any reduction, offset or deferral of any Base Rent or Additional Rent due or accruing under this Lease during any such Clean-up.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.4.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Surrender of Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall complete any Clean-up required by this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> prior to surrender of the Premises upon the expiration or earlier termination of this Lease and shall fully comply with all Environmental Laws and requirements of any governmental authority with respect to such completion, including, without limitation, fully comply with any requirement to file a risk assessment, mitigation plan or other information with any such governmental authority in conjunction with the Clean-up prior to such surrender. If applicable, Tenant shall obtain and deliver to Landlord a letter or other written determination from the overseeing governmental authority confirming that the Clean-up has been completed in accordance with all requirements of such</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">governmental authority and that no further response action of any kind is required for the unrestricted use of the Premises (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Closure Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), unless such governmental authority&#x2019;s standard practices at the relevant time do not provide for such Closure Letter. Upon the expiration or earlier termination of this Lease, Tenant shall also be obligated to close all permits obtained in connection with Hazardous Materials in accordance with Applicable Laws.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.4.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Failure to Timely Clean-Up</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Should any Clean-up for which Tenant is responsible for under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> not be completed, or should Tenant not receive the Closure Letter (unless such governmental authority&#x2019;s standard practices at the relevant time do not provide for such Closure Letter) and any governmental approvals required under Environmental Laws in conjunction with such Clean-up prior to the expiration or earlier termination of this Lease, and Tenant&#x2019;s failure to receive the Closure Letter is prohibiting Landlord from leasing the Premises or any part thereof to a third party, or prevents the occupancy or use of the Premises or any part thereof by a third party, then Tenant shall be liable to Landlord as a holdover tenant (as more particularly provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 16</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) until Tenant has fully complied with its obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Confidentiality</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Unless compelled to do so by applicable law, Tenant agrees that Tenant shall not disclose, discuss, disseminate or copy any information, data, findings, communications, conclusions and reports regarding the environmental condition of the Premises to any Person (other than Tenant&#x2019;s consultants, attorneys, property managers and employees that have a need to know such information), including any governmental authority, without the prior written consent of Landlord. In the event Tenant reasonably believes that disclosure is required by Applicable Laws, it shall provide Landlord ten (10) days&#x2019; advance notice (or such shorter time as may be necessary due to applicable laws) of disclosure of confidential information so that Landlord may attempt to obtain a protective order. Tenant may additionally release such information to bona fide prospective purchasers, lenders, assignees or subtenants, subject to any such parties&#x2019; written agreement to be bound by the terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Copies of Environmental Reports</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Within thirty (30) days of receipt thereof, Tenant shall provide Landlord with a copy of any and all environmental assessments, audits, studies and reports regarding Tenant&#x2019;s activities with respect to the Premises, or ground water beneath the Land, or the environmental condition or Clean-up thereof that are in Tenant&#x2019;s possession or control. Tenant shall be obligated to provide Landlord with a copy of such materials without regard to whether such materials are generated by Tenant or prepared for Tenant, or how Tenant comes into possession of such materials, unless to do so would expose Tenant to a claim of breach of nondisclosure obligation or be a violation of applicable law.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.7 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Signs, Response Plans, Etc</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall be responsible for posting on the Premises any signs required under applicable Environmental Laws. Tenant shall also complete and file any business response plans or inventories required by any applicable Environmental Laws. Tenant shall concurrently file a copy of any such business response plan or inventory with Landlord.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5.8 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Each covenant, agreement, representation, warranty and indemnification made by Tenant set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall survive the expiration or earlier termination of this Lease and shall remain effective until all of Tenant&#x2019;s obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> have been completely performed and satisfied.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Premises Compliance with ADA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding any other provision herein to the contrary, Tenant shall be responsible for all liabilities, costs and expenses arising out of or in connection with the compliance of the Premises with the Americans with Disabilities Act, 42 U.S.C. &#167; 1210 I, et seq., and any state and local accessibility laws, codes, ordinances and rules (collectively, and together with regulations promulgated pursuant thereto, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and Tenant shall indemnify, save, defend (at Landlord&#x2019;s option and with counsel reasonably acceptable to Landlord) and hold Landlord and its affiliates, employees, agents and contractors; and any lender, mortgagee or beneficiary (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lender</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; and, collectively with Landlord its partners and subpartners, and their respective officers, members, directors, shareholders, agents, property managers, employees and independent contractors, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord Indemnitees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) harmless from and against any demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages or judgments, and all reasonable expenses (including reasonable attorneys&#x2019; fees, charges and disbursements) incurred in investigating or resisting the same (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) arising out of any such failure of the Premises to comply with the ADA. Notwithstanding the foregoing or anything to the contrary in this Lease, Tenant&#x2019;s foregoing indemnity obligations shall not apply to any liability arising from noncompliance of the Premises with the ADA where such noncompliance existed prior to the date of the Existing Sublease. The provisions of this Section shall survive the expiration or earlier termination of this Lease.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Rules and Regulations, CC&amp;Rs, Parking Facilities and Common Areas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7.1 Tenant shall have the non-exclusive right, in common with others, to use the Common Areas, subject to the Rules and Regulations. The manner in which the Common Areas are maintained and operated shall be at the sole discretion of Landlord (but such maintenance and operations must be consistent with Comparable Buildings) and the use thereof shall be subject to the Rules and Regulations, as Landlord may make from time to time, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7.2 This Lease is subject to any recorded covenants, conditions or restrictions on the Project or Property (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CC&amp;Rs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), as the same may be amended, amended and restated, supplemented or otherwise modified from time to time; provided that any such amendments, restatements, supplements or modifications do not materially modify Tenant&#x2019;s rights or obligations hereunder, or materially restrict or impair (other than for a reasonable, temporary period) Tenant&#x2019;s access to the Premises or parking facilities. Tenant shall comply with the CC&amp;Rs.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7.3 Tenant shall have a non-exclusive, irrevocable license to use throughout the Lease Term the number of unreserved parking passes set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary in at such locations in the parking facilities serving the Building as may be determined by Landlord from time to time in common with the other occupants of the Building, on an unreserved basis at no cost to Tenant. Tenant shall use only such parking facilities to park Tenant&#x2019;s vehicles. In no event shall Tenant park or store any items other than automotive vehicles at such parking facilities.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7.4 Tenant agrees not to unreasonably overburden the parking facilities and agrees to cooperate with Landlord and other tenants in the use of the parking facilities. Landlord reserves the right to determine that parking facilities are becoming overcrowded and to limit Tenant&#x2019;s use thereof in a non-discriminatory manner with respect to other tenants of the Project (and provided that Tenant still has the right to the number of unreserved parking passes set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary). Landlord may reasonably allocate parking spaces among Tenant and other tenants of the Building or the Project and Tenant shall be entitled to use throughout the Lease Term the number of unreserved parking passes set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary. Nothing in this Section, however, is intended to create an affirmative duty on Landlord&#x2019;s part to monitor parking.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7.5 Landlord reserves the right to modify the Common Areas, including the right to add or remove exterior and interior landscaping and to subdivide real property, in accordance with the terms and conditions of this Lease. Tenant acknowledges that Landlord specifically reserves the right to allow the exclusive use of corridors and restroom facilities located on specific floors to one or more tenants occupying such floors; provided, however, that Tenant shall not be deprived of the use of the corridors reasonably required to serve the Premises or of restroom facilities serving the floor upon which the Premises are located. Landlord reserves the right to close temporarily, make alterations or additions to, or change the location of elements of the Project and the Common Areas. Landlord agrees to use commercially reasonable efforts to mitigate interference with Tenant&#x2019;s use of and access to the Premises in connection with such closures, alterations or additions to the Common Areas.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.8 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Storage Facilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. SERVICES AND UTILITIES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Standard Tenant Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  Landlord shall provide the following services during the Lease Term.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">HVAC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In accordance with the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; definition as provided in Section 1 of the Work Letter, the Building shall be equipped with a heating and air conditioning (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">HVAC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) system serving the Premises (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BB HVAC System</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Subject to limitations imposed by all governmental rules, regulations and guidelines applicable thereto, Landlord shall provide BB HVAC System service during the &#x201c;HVAC System Hours&#x201d; (defined below). Landlord will operate the BB HVAC System for the benefit of the Premises the hours of 8:00 A.M. to 6:00 P.M. on Monday through Friday (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">HVAC System Hours</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant shall cooperate fully with Landlord at all times and abide by all regulations and requirements that Landlord may reasonably prescribe for the proper functioning and protection of the BB HVAC System. If Tenant requires after-hours operation of the BB HVAC System (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Excess Hours</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and Tenant gives Landlord at least twenty-four (24) hours advance notice on a business day, then Landlord shall supply such HVAC to Tenant at Landlord&#x2019;s actual cost (which shall be treated as Additional Rent, but not as an Operating Expense) on a zone-by-zone basis, including the cost of increased depreciation on the BB HVAC</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">System, but excluding the cost of electricity to the extent already paid for directly by Tenant, but including the electrical costs specified as follows; provided, however, if Tenant gives Landlord less than twenty-four (24) hours advance notice, Landlord will nevertheless endeavor to accommodate Tenant&#x2019;s request so long as such shorter notice is given on a business day. Landlord shall reasonably and equitably allocate the portion of the electrical costs of the BB HVAC System attributable to Tenant&#x2019;s use of the BB HVAC System for the Excess Hours to Tenant, and Tenant shall pay for the costs of such use along with the increased depreciation as set forth above, within thirty (30) days after demand, and as Additional Rent under this Lease (and not as part of the Operating Expenses) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Extra HVAC Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Notwithstanding anything to the contrary contained in the foregoing, the HVAC Systems Hours shall not be applicable to the lab portions of the Premises (located on floors 10, 11 and 12); instead, Landlord shall operate the BB HVAC System as to the lab floors on a twenty-four (24) hours per day basis, and Tenant shall have the ability from within the Premises to access thermostats for controlling the temperature settings for the HVAC serving the lab floors of the Premises (it being understood that Tenant needs to operate the HVAC, and all other rooftop equipment exclusively serving the lab floors, outside of Building Hours and will run HVAC, and all other rooftop equipment exclusively serving the lab floors, 24 hours per day), and Tenant shall be liable for the Extra HVAC Costs.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Electricity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall provide electrical wiring and facilities for connection to Tenant&#x2019;s lighting and Tenant&#x2019;s incidental use equipment as described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Schedule 2 to Exhibit B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall not use combined electrical load for Tenant&#x2019;s incidental use equipment and Tenant&#x2019;s lighting fixtures in excess of its pro rata share of the capacity of the feeders, which electrical usage shall be subject to Applicable Laws, including Title 24. Tenant shall bear the cost of replacement of lamps, starters and ballasts for non-Building standard lighting fixtures within the Premises (Landlord, as part of Operating Expenses, will replace Building-standard lamps, starters and ballasts). Tenant shall reasonably cooperate with Landlord at all times and abide by all regulations and requirements that Landlord may reasonably prescribe for the proper functioning and protection of the Building Systems. All electricity usage at the Project shall be monitored using separate submeters (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Submetering Equipment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) which shall be (i) installed by Landlord or any tenant, for other tenant space in the Project, (ii) installed by Tenant for the Premises (not including the &#x201c;Building Systems&#x201d;, as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease), and (iii) installed by Landlord for the Common Areas and Building Systems. Tenant shall have no obligation to pay for any costs of electricity (including as part of Operating Expenses) shown on the Submetering Equipment described in item (i) above. Tenant shall be responsible to pay directly, and not as a part of Operating Expenses, for the cost of all electricity shown on the Submetering Equipment described in item (ii) above. The cost of all electricity shown on the Submetering Equipment described in item (iii) above (except to the extent included in the Extra HVAC Costs) shall be included in Operating Expenses. Tenant may audit Landlord&#x2019;s readings of the Submetering Equipment and Landlord shall deliver reasonably detailed invoices to Tenant reflecting Landlord&#x2019;s reading of the Submetering Equipment and resulting electricity costs.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Water and Sewer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall cause water and sewer to be supplied to the regular Building outlets for drinking, lavatory and toilet purposes within the Building and for laboratory purposes within the Premises (to the extent consistent with usage volumes for life science tenants within Comparable Buildings). Landlord shall reasonably and equitably allocate the portion of such utilities attributable to Tenant&#x2019;s direct use to Tenant, and Tenant shall pay for the costs of such direct use, within thirty (30) days after demand and as Additional Rent under this Lease (and not as part of the Operating Expenses), and other water and sewer costs shall be reasonably and equitably included as part of Operating Expenses, to the extent permitted by the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.2.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above or charged directly to other tenants of the Project. If Landlord determines that Tenant may be using an amount of water in excess of its pro rata share, Landlord reserves the right to install submetering equipment, at Tenant&#x2019;s expense, to monitor Tenant&#x2019;s usage and bill Tenant for such usage. Landlord shall designate the utility providers from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Gas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall cause gas to be supplied to the Project, and Tenant shall be entitled to its pro rata share of gas supplied to the Project. The portion of the gas used in connection with the Retail Space shall be separately submetered and paid for directly by such retail tenants. The cost of all other gas supplied to the Project shall be included in Operating Expenses. Landlord&#x2019;s approval shall be required if Tenant desires gas service within the Premises. If Landlord approves such request, the cost of installing any equipment and lines necessary for such service shall be at Tenant&#x2019;s sole cost and expense, including, without limitation, the cost of installing and maintaining submeters to monitor such gas usage within the Premises. Landlord will invoice Tenant periodically for such direct gas use as shown on such submeters (as a direct expense and not part of Operating Expenses) and Tenant shall be paid by it within fifteen (15) days following Landlord&#x2019;s delivery of any such invoice to Tenant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Janitorial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall provide janitorial services for the Common Areas and exterior window washing services, in a manner consistent with the Comparable Buildings; but Landlord shall not provide janitorial services for the Premises. Tenant shall perform all janitorial services and other cleaning within the Premises in a manner consistent with the standards of other first-class, institutionally owned office/life science buildings in the City of San Francisco (&#x201c;City&#x201d;) using a janitorial contract approved by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed (provided, however, Landlord hereby preapproves AC Janitorial Service and CW Maintenance as janitorial contractors that may be retained by Tenant). Without Landlord&#x2019;s prior consent, Tenant shall not use (and upon notice from Landlord shall cease using) janitorial service providers who would, in Landlord&#x2019;s reasonable and good faith judgment, disturb labor harmony with the workforce or trades engaged in performing other work, labor or services in or about the Buildings or the Common Areas.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Elevator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall provide non-attended automatic passenger elevator service during the building hours reasonably designated by Landlord (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Building Hours</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and shall have one (1) elevator available serving each Building at all other times.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.7 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Loading Dock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall provide use of the loading dock in the North Tower for deliveries to Tenant, provided that (i) Tenant shall schedule its use of such loading dock with Landlord at least 24 hours in advance (provided, however, in the event that Tenant has not given such advance notice, Tenant&#x2019;s use of the loading dock shall be subject to the prior use thereof by users who have scheduled such use in advance), and (ii) use of the loading dock is limited to between 6:00 AM and 5:00 PM Monday through Friday (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Loading Dock Hours</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), such hours subject to change upon written notice from Landlord; provided, however, if Tenant requests access to the loading dock outside of the Loading Dock Hours, Tenant shall pay Landlord an after-hours charge of $50 per visit for Landlord to engage its security personnel in connection with such loading dock access (such after-hours charge subject to adjustment by Landlord from time to time). The Loading Dock Hours shall not apply to Tenant&#x2019;s initial move-in to the Premises and the loading dock shall be made available for Tenant&#x2019;s initial move-in without charge; provided, that Tenant shall reasonably coordinate such initial move-in with Landlord.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.8 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risers, Raceways, Shafts, Conduits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to Landlord&#x2019;s reasonable rules, regulations, and restrictions and the terms of this Lease, Landlord shall permit Tenant, at no additional charge to Tenant, to utilize the Building&#x2019;s risers, raceways, shafts and conduit, provided that there is available space in the Building&#x2019;s risers, raceways, shafts and/or conduit for Landlord&#x2019;s reasonable use and reasonable use by the other tenants of the Project, which availability shall be determined by Landlord in Landlord&#x2019;s sole discretion. Landlord shall have the right to re- route the planned location of Tenant&#x2019;s cabling in such risers, raceways, shafts and conduit, as determined by Landlord in its reasonable discretion.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.9 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Access Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Building and Parking Facilities have an access-control system, including, without limitation, door access controls, lobby turnstiles and elevator access controls; provided however, the parties acknowledge that the North Lobby is open to the public, and access will not be restricted during general business hours. Landlord shall not be obligated to provide any other security equipment. Notwithstanding any provision to the contrary set forth in this Lease, in no case, shall Landlord be liable for personal injury or property damage for any lack of security in the Building or for any error with regard to the admission to or exclusion from the Buildings or Project of any person.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.10 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Personnel</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall provide on-site security services, including security personnel in the North Lobby and the Parking Facilities, consistent with the services provided by landlords at Comparable Buildings (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Security Personnel</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), the costs of which shall be included in Direct Expenses. In addition, (a) the Security Personnel shall be licensed and bonded and shall at all times maintain any and all required licenses or other governmental permits required in connection with any weapons carried by Security Personnel and/or the performance of its duties under this Lease and shall at all times conduct themselves in a manner consistent with a first class office and life sciences building project, (b) a commercially reasonable background check shall be performed on all Security Personnel, and (c) all of the Security Personnel shall be union labor and comply with the Mission Bay Requirements and the Underlying Documents.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.11 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Security System</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord hereby agrees that Tenant shall have the right to install a card key security system (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Security System</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) in the Premises and Stairwells on the floors of the Premises and to connect such system to Landlord&#x2019;s access-control system for the Project; provided that Tenant shall work with Landlord to connect Landlord&#x2019;s existing access card keys for the Project to Tenant&#x2019;s Security System, or, if such</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">connection is not possible, shall provide Landlord with a reasonable number of card keys for Landlord&#x2019;s access to the Buildings and/or the Premises pursuant to the terms of this Lease. Tenant&#x2019;s Security System shall by subject to Landlord&#x2019;s prior review and approval (not to be unreasonably withheld), and the installation thereof shall be deemed an Alteration and shall be performed pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, below or shall be installed as an Improvement pursuant to the Work Letter. In addition, Tenant shall coordinate the selection, installation and operation of Tenant&#x2019;s Security System with Landlord in order to ensure that Tenant&#x2019;s Security System is compatible with the Building Systems and permits Landlord to identify any persons entering and exiting any Buildings, and Tenant shall not be entitled to install and/or operate the Tenant&#x2019;s Security System if Tenant&#x2019;s Security System does not comply with the foregoing. Tenant shall be solely responsible, at Tenant&#x2019;s sole cost and expense, for the installation, monitoring, operation and removal of Tenant&#x2019;s Security System.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.12 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Access</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to Applicable Laws and the other provisions of this Lease, and except in the event of an emergency, Tenant shall have access to the above utilities and the Buildings, the Premises and the Common Areas, other than common areas requiring access with a Building engineer, the Parking Facilities and freight elevator, if any, twenty-four (24) hours per day, seven (7) days per week, every day of the year; provided, however, that Tenant shall pay Landlord&#x2019;s reasonable out-of-pocket costs that are incurred if Tenant uses the loading dock, mailroom and other limited-access areas of the Buildings during other than normal Building Hours.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.13 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Emergency Generator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Base Building has one (1) non-exclusive emergency generator serving the North Complex, the Tenant&#x2019;s pro rata share of which shall be available, on a non-exclusive basis, for connection to Tenant&#x2019;s standby equipment and systems (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Generator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). All connections (cables, cable trays, etc.) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Generator Facilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) from such Generator to the Premises shall be located in areas approved by Landlord, in its sole discretion, and shall comply with Applicable Laws. Commencing on the date that Tenant first connects the Generator Facilities to a Generator, as reasonably determined by Landlord, Tenant shall reimburse Landlord within thirty (30) days of request, as Additional Rent, Tenant&#x2019;s pro rata share (based on Tenant&#x2019;s use of such Generator and use of such Generator by other parties, as reasonably determined by Landlord based on the respective connections to such Generator (not the respective rentable square footage of any space leased in the Project by such users)), of all costs and expenses incurred by Landlord as a result of or in connection with operation, use, repairs, and maintenance of such Generator, including costs for fuel, and depreciation (as reasonably determined by Landlord). Tenant acknowledges that Landlord shall not be liable for any damage that may occur with respect to a Generator.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1.14 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mailroom</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall have no access rights to any of the other tenant&#x2019;s mailrooms located in the Complex. Tenant shall have reasonable access rights to the USPS mailroom serving the entire Complex. Tenant shall be solely responsible for collecting deliveries from the loading dock in the North Tower (such loading dock access shall be subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 6.1.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Interruption of Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant agrees that Landlord shall not be liable for damages, by abatement of Rent or otherwise (except as specifically set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below), for failure to furnish or delay in furnishing any service (including telephone and telecommunication services and Generator service), or for any diminution in the quality or quantity thereof, when such failure or delay or diminution is occasioned, in whole or in part, by breakage, repairs, replacements, or improvements, by any strike, lockout or other labor trouble, by inability to secure electricity, gas, water, or other fuel at the Buildings or Project after reasonable effort to do so, by any riot or other dangerous condition, emergency, accident or casualty whatsoever (other than the gross negligence or willful misconduct of Landlord, its employees or agents), by act or default of Tenant or other parties, or by any other cause; and such failures or delays or diminution shall, except if caused by the gross negligence or willful misconduct of Landlord, its employees or agents, never be deemed to constitute an eviction or disturbance of Tenant&#x2019;s use and possession of the Premises or relieve Tenant from paying Rent (except as specifically set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease) or performing any of its obligations under this Lease. Notwithstanding anything to the contrary contained in the foregoing, in the event that there shall be an interruption, curtailment or suspension of any service required to be provided by Landlord pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 6.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (and no reasonably equivalent alternative service or supply is provided by Landlord) that shall materially interfere with Tenant&#x2019;s use and enjoyment of a material portion of the Premises, and Tenant actually ceases to use the affected portion of the Premises (any such event, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Service Interruption</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and if (i) such Service Interruption shall continue for six (6) consecutive business days following receipt by Landlord of written notice from Tenant describing such Service Interruption (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Service Interruption Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and (ii) such Service Interruption shall not have been caused, in whole or in part, by reasons beyond Landlord&#x2019;s reasonable control or by an act or omission in violation of this Lease by any Tenant Party or by any negligence of Tenant any Tenant</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parties, (a Service Interruption that satisfies the foregoing conditions being referred to hereinafter as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Material Service Interruption</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) then, as liquidated damages and Tenant&#x2019;s sole remedy at law or equity, Tenant shall be entitled to an equitable abatement of Base Rent and Tenant&#x2019;s Share of Direct Expenses, based on the nature and duration of the Material Service Interruption, the area of the Premises affected, and the then current Rent amounts, for the period that shall begin on the commencement of such Material Service Interruption and that shall end on the day such Material Service Interruption shall cease. To the extent a Material Service Interruption is caused by an event covered by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Articles 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, then Tenant&#x2019;s right to abate rent shall be governed by the terms of such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as applicable, and the provisions of this paragraph shall not apply.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Use of Shafts and Utility Connections</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall have reasonable access, and shall be entitled to allow other tenants of the Buildings, if any, reasonable access, through existing Building shafts to other portions of the Buildings (including the roof, mechanical floors and tenant spaces (including the Premises)), or to utility connections outside the Buildings, for the installation, repair, and maintenance of ducts, pipes, connections, and equipment for cables, conduits, transmitters, receivers, and other office, computer, communications and word and data processing equipment and facilities, including any technological devices not yet developed, whether similar or dissimilar to the foregoing, which may hereafter become necessary or desirable for any permitted use of the Project; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, that to the extent such shafts or utility connections are located within the Premises, such access shall not materially and unreasonably interfere with Tenant&#x2019;s occupancy of the Premises (Landlord&#x2019;s efforts in such regard will include, where reasonably possible, limiting the performance of any such work which might be disruptive to weekends or the evening and the cleaning of any work area prior to the commencement of the next business day). To the extent that Landlord installs, maintains, uses, repairs or replaces pipes, cables, ductwork, conduits, utility lines, and/or wires through hung ceiling space, exterior perimeter walls and column space, adjacent to and in demising partitions and columns, in or beneath the floor slab or above, below, or through the Premises, then in the course of making any such installation or repair: (x) Landlord shall not reduce Tenant&#x2019;s usable space, except to a de minimus extent, if the same are not installed behind existing walls or ceilings; (y) Landlord shall box in any of the same installed adjacent to existing walls with construction materials substantially similar to those existing in the affected area(s) of the Premises; and (z) Landlord shall repair all damage caused by the same and restore such area(s) of the Premises to substantially the condition existing immediately prior to such work. The terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 6.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall be subject to the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 29.32</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Supplemental HVAC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to Landlord&#x2019;s prior consent, which consent shall not be unreasonably withheld, conditioned or delayed, Tenant shall have the right to install a supplemental HVAC equipment serving all or any portion of the Premises (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supplemental HVAC Equipment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Any Supplemental HVAC Equipment shall be installed pursuant to the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or the Work Letter, if installed as part of the initial Improvements, and shall be deemed an Alteration (or Improvement, as applicable) for purposes of this Lease; provided, however, it shall be deemed reasonable for Landlord to withhold its approval to the extent any such installation would void the warranties of any Building systems or equipment, interfere with other tenant&#x2019;s systems or equipment, or materially interfere with, or materially increase the cost of, Landlord&#x2019;s maintenance or operation of the Project, unless Tenant agrees to pay for such increased costs, or if any such installation would violate Applicable Laws or the Mission Bay Requirements or the Underlying Documents (as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 24.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below). Tenant shall bear all costs of the equipment, and all costs of installation and removal thereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. REPAIRS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Repair Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall at all times during the Lease Term maintain in good condition and operating order and in a manner reasonably commensurate with the maintenance standards of owners of Comparable Buildings, the structural portions of the Buildings, including, without limitation, the foundation, exterior walls, the structural portions of the floors (including the floor slabs), ceilings, roof, columns, beams, shafts, stairs, stairwells, escalators, elevators, base building restrooms and all Common Areas (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Building Structure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and the Base Building mechanical, electrical, life safety, plumbing, sprinkler, security and HVAC systems installed or furnished by Landlord (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Building Systems</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;); provided, however, if any repairs to the foregoing are required due to the negligence or willful misconduct of Tenant, Landlord shall nevertheless make such repairs at Tenant&#x2019;s expense, or, if covered by Landlord&#x2019;s insurance, Tenant shall only be obligated to pay any deductible in connection therewith. In addition, Landlord shall use commercially reasonable efforts, at all times during the Lease Term, to cause the Building Systems to perform in accordance with the design specifications for such equipment. Except as specifically set forth in this Lease to the contrary, Tenant shall not be required to repair the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Building Structure and/or the Building Systems, except to the extent required because of Tenant&#x2019;s use of the Premises for other than the Permitted Use; provided, however, that Landlord shall nevertheless make such repairs at Tenant&#x2019;s expense, or, if covered by Landlord&#x2019;s insurance, Tenant shall only be obligated to pay any deductible in connection therewith.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Repair Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall, at Tenant&#x2019;s own expense, keep the Premises, including all improvements, fixtures, furnishings, and systems and equipment within the Premises, and any of Tenant&#x2019;s improvements, property or equipment located outside of the Premises if permitted by Landlord in its sole discretion (such items located outside of the Premises, if any, are, collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Off-Premises Equipment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), in good order, repair and condition at all times during the Lease Term. In addition, Tenant shall, at Tenant&#x2019;s own expense, [but under the reasonable supervision and subject to the prior reasonable approval of Landlord to the extent (i) the cost of such repairs are reasonably expected to exceed $25,000.00, (ii) such repairs will affect the Building Structure, Building Systems or equipment, or (iii) such repairs may disturb any other tenants or occupants of the Building], and within any reasonable period of time specified by Landlord, promptly and adequately repair all damage to the Premises and replace or repair all damaged, broken, or worn fixtures and appurtenances, except for damage caused by ordinary wear and tear and casualty; provided however, that if Tenant fails to make such repairs within applicable notice and cure periods, Landlord may, but need not, make such repairs and replacements, and Tenant shall pay Landlord the cost thereof, including a percentage of the cost thereof sufficient to reimburse Landlord for all overhead, general conditions and other costs or expenses arising from Landlord&#x2019;s involvement with such repairs and replacements plus a management fee of [***] of such cost within twenty (20) days after being billed for same. Without limitation, Tenant shall be responsible for electrical, plumbing, heating, ventilating and air-conditioning systems and other utility services either located within the Premises or serving solely the Premises and located outside of the Premises from the Building connection point to the Premises (but only to the extent serving Tenant exclusively) (e.g., any Supplemental HVAC Equipment), and Tenant shall secure, pay for, and keep in force contracts with appropriate and reputable service companies reasonably approved by Landlord providing for the regular maintenance of such systems.  Subject to the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 27</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below, Landlord may, but shall not be required to, enter the Premises at all reasonable times and upon reasonable prior notice to make such repairs, alterations, improvements or additions to the Premises or to the Project or to any equipment located in the Premises as Landlord shall desire or deem necessary or as Landlord may be required to do by governmental or quasi-governmental authority or court order or decree. Tenant hereby waives and releases its right to make repairs at Landlord&#x2019;s expense under Sections 1941 and 1942 of the California Civil Code or under any similar law, statute or ordinance now or hereafter in effect. Tenant&#x2019;s obligation hereunder shall include maintenance and repair of all telecommunications wire and cabling with the Building&#x2019;s network cabling exclusively serving the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant/Landlord Maintenance Responsibility Matrix</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. To clarify the respective obligations of Tenant and Landlord with respect to maintenance and repair under this Lease, the matrix attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 7.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> sets forth the respective obligations of Tenant and Landlord with respect to the mechanical systems of the Building and other Building Systems and Tenant installed systems identified therein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. ADDITIONS AND ALTERATIONS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Consent to Alterations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant may not make any improvements, alterations, additions or changes to the Premises or any mechanical, plumbing, HVAC facilities or other utility or Building systems pertaining to the Premises (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Alterations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) without first procuring the prior written consent of Landlord to such Alterations, which consent shall be requested by Tenant not less than twenty (20) business days prior to the commencement thereof. Landlord shall not unreasonably withhold or delay its consent to any proposed nonstructural Alterations, provided that such Alterations (1) are not visible from the outside of the Building, (2) do not affect the use of or require access to any part of the Building other than the Premises, (3) do not do not violate any certificate of occupancy for the Building or any other permits or licenses relating to the Project, (4) do not adversely affect any service required to be furnished to Tenant or to any other tenant or occupant of the Building, (5) do not affect any Building systems or Common Areas, (6) do not reduce the value or utility of the Building, (7) do not consist of painting the underside or top of the structure slab, and (8) otherwise comply with the Rules and Regulations and this Article 8. Notwithstanding the foregoing, Tenant shall be permitted to make Alterations following ten (10) business days&#x2019; notice to Landlord, but without Landlord&#x2019;s prior consent, to the extent that such Alterations (i) are purely cosmetic in nature (such as painting, carpeting and the like), (ii) do not affect the Building Structure, Building systems or equipment, (iii) don not require a building or construction permit, (iv) are not visible from the exterior of the Building, (v) do not consist of painting the underside or top of the structure slab, and (vi) cost less than $175,000.00 for a particular job of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">work. For the sake of clarity, the construction of the initial improvements to the Premises shall be governed by the terms of the Tenant Work Letter and not the terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 8</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to commencing any Alterations affecting air distribution or disbursement from MEP or other systems serving Tenant or the Building, including without limitation the installation of Tenant&#x2019;s exhaust systems, Tenant shall provide Landlord with a third party report from a consultant, and in a form reasonably acceptable to Landlord, showing that such work will not adversely affect the ventilation systems or air quality of the Building (or of any other tenant in the Building) and shall, upon completion of such work, provide Landlord with a certification reasonably satisfactory to Landlord from such consultant confirming that no such adverse effects have resulted from such work.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Manner of Construction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord may impose, as a condition of its consent to any and all Alterations or repairs of the Premises or about the Premises, such requirements as Landlord in its reasonable discretion may deem desirable, including, but not limited to, the requirement that Tenant utilize for such purposes only contractors, subcontractors, materials, mechanics and materialmen selected by Tenant and approved by Landlord (which approval shall not be unreasonably withheld, conditioned or delayed) and the requirement that upon Landlord&#x2019;s request at the time Landlord approves said Alterations (subject to the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 8.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below), Tenant shall, at Tenant&#x2019;s expense, remove such Alterations upon the expiration or any early termination of the Lease Term. Tenant shall construct such Alterations and perform such repairs in a good and workmanlike manner, in conformance with any and all Applicable Laws and, where required by Applicable Law, pursuant to a valid building permit, issued by the City, all in conformance with Landlord&#x2019;s construction rules and regulations. In the event Tenant performs any Alterations in the Premises which require or give rise to governmentally required changes to the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,&#x201d; as that term is defined below, then Landlord shall, at Tenant&#x2019;s expense, make such changes to the Base Building. The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean the Building Structure, the Building Systems, including the Building Systems on the floor or floors on which the Premises is located as well as the Common Areas. In performing the work of any such Alterations, Tenant shall have the work performed in such manner so as not to obstruct access to the Project or any portion thereof, by any other tenant of the Project, and so as not to obstruct the business of Landlord or other tenants in the Project. Tenant shall not use (and upon notice from Landlord shall cease using) contractors, services, workmen, labor, materials or equipment that, in Landlord&#x2019;s reasonable judgment, would disturb labor harmony with the workforce or trades engaged in performing other work, labor or services in or about the Building or the Common Areas. Upon completion of any Alterations (or repairs), Tenant agrees to cause a Notice of Completion to be recorded in the office of the Recorder of the County in which the Project is located in accordance with Section 8182 of the Civil Code of the State of California or any successor statute, and shall deliver to Landlord final lien waivers from all contractors, subcontractors, design professionals, service providers, suppliers and materialmen who performed such work and whose labor, supplies or services give rise to a lien under California law. In addition to Tenant&#x2019;s obligations under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, upon completion of any Alterations, Tenant shall deliver to the Project management office a reproducible copy of the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">as built</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; drawings of the Alterations in CAD format as well as copies of all permits, approvals and other documents issued by any governmental agency in connection with the Alterations, if applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Payment for Improvements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If Tenant orders any work directly from Landlord, Tenant shall pay to Landlord a percentage of the cost thereof sufficient to reimburse Landlord for all overhead, general conditions and other costs or expenses arising from Landlord&#x2019;s involvement with such repairs and replacements plus a management fee of [***] of such cost. If Tenant does not order any work directly from Landlord, Tenant shall reimburse Landlord for Landlord&#x2019;s reasonable, actual, out-of-pocket costs and expenses actually incurred in connection with Landlord&#x2019;s review of any proposed Alterations. If payment is made directly to contractors, Tenant shall, at Tenant&#x2019;s cost, comply with Landlord&#x2019;s requirements for final lien releases and waivers in connection with Tenant&#x2019;s payment for work to contractors. For purposes of determining the cost of an Alteration, work done in phases or stages shall be considered part of the same Alteration, and any Alteration shall be deemed to include all trades and materials involved in accomplishing a particular result.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Construction Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In addition to the requirements of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, in the event that Tenant makes any Alterations, prior to the commencement of such Alterations, Tenant shall provide Landlord with evidence that Tenant or Tenant&#x2019;s general contractor carries &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Builder&#x2019;s All Risk</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; insurance in an amount approved by Landlord covering the construction of such Alterations, and such other insurance as Landlord may reasonably require, it being understood and agreed that all of such Alterations shall be insured by Tenant pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease immediately upon completion thereof. In connection with any Alterations, Tenant shall cause any architect and engineer to carry professional liability insurance with limits of not less than $2,000,000 per claim and in the annual aggregate covering professional services performed by the respective party, and such coverage</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">must be maintained for the greatest period under which a claim may be properly asserted under the applicable statute of limitations or repose. In addition, Tenant&#x2019;s contractors and subcontractors shall be required to carry Commercial General Liability Insurance in an amount approved by Landlord and otherwise in accordance with the requirements of Article 10 of this Lease and such general liability insurance shall name the Landlord Parties (as defined below) as additional insureds. Landlord may, in its discretion, require Tenant to obtain and record a statutory form of lien bond, or obtain performance and payment bonds, or some alternate form of security satisfactory to Landlord in an amount sufficient to ensure the lien-free completion of such Alterations and naming Landlord as a co-obligee, in each case in form and substance reasonably satisfactory to Landlord (to the extent that the cost of the work shall exceed $100,000). In addition, Tenant&#x2019;s contractors and subcontractors shall be required to carry workers compensation insurance with a waiver of subrogation in favor of Landlord Parties.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All Alterations, improvements, fixtures, equipment and/or appurtenances which may be installed or placed in or about the Premises, from time to time, shall be at the sole cost of Tenant and shall be and become the property of Landlord [other than Tenant&#x2019;s trade fixtures and moveable equipment paid for solely by Tenant and capable of being removed without damage to the Premises (or, if damage is likely to occur, that Tenant will be able to repair and fully restore] and remain in place at the Premises following the expiration or earlier termination of this Lease. Notwithstanding the foregoing to the contrary, if requested by Tenant when procuring Landlord&#x2019;s consent to any Alterations in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 8.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above, Landlord will, by written notice to Tenant give Tenant notice as to whether Landlord will (or reserves the right to) require Tenant, at Tenant&#x2019;s expense, to remove any Alterations and/or improvements and/or systems within the Premises (excluding the Tenant Improvements) and to repair any damage to the Premises and Building caused by such removal and return the affected portion of the Premises to a building standard tenant improved condition as determined by Landlord. If Tenant fails to complete any such removal and/or to repair any damage caused by the removal of any Alterations and/or systems and equipment in the Premises and return the affected portion of the Premises to a building standard tenant improved condition as reasonably determined by Landlord, Landlord may do so and may charge the actual and reasonable cost thereof to Tenant. Tenant hereby protects, defends, indemnifies and holds Landlord harmless from any liability, cost, obligation, expense or claim of lien in any manner relating to the installation, placement, removal or financing of any such Alterations, improvements, fixtures and/or equipment in, on or about the Premises (except to the extent resulting from the gross negligence or willful misconduct of Landlord or any of the Landlord Parties), which obligations of Tenant shall survive the expiration or earlier termination of this Lease. Notwithstanding anything to the contrary in this Lease, Tenant shall not be required to remove any of the Tenant Improvements upon the expiration or earlier termination of this Lease.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. COVENANT AGAINST LIENS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant shall keep the Project, the Building and Premises free from any liens or encumbrances arising out of the work performed, materials or services furnished or obligations incurred by or on behalf of Tenant (which expressly excludes the Landlord Work), and shall protect, defend, indemnify and hold Landlord harmless from and against any claims, liabilities, judgments or costs (including, without limitation, reasonable attorneys&#x2019; fees and costs) arising out of same or in connection therewith. Tenant shall give Landlord notice at least fifteen (15) days prior to the commencement of any work, services or obligations related to the Premises giving rise to any such liens or encumbrances (or such additional time as may be necessary under Applicable Laws) to afford Landlord the opportunity of posting and recording appropriate notices of non-responsibility (to the extent applicable pursuant to then Applicable Laws). Tenant shall remove any such lien or encumbrance by statutory lien bond or otherwise within ten (10) business days after written notice by Landlord, and if Tenant shall fail to do so, Landlord may pay the amount necessary to remove such lien or encumbrance, without being responsible for investigating the validity thereof. The amount so paid all be deemed Additional Rent under this Lease payable within thirty (30) days after demand, without limitation as to other remedies available to Landlord under this Lease. Nothing contained in this Lease shall authorize Tenant to do any act which shall subject Landlord&#x2019;s title to the Project, Buildings or Premises to any liens or encumbrances whether claimed by operation of law or express or implied contract.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. INSURANCE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Indemnification and Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except to the extent arising from the negligence or willful misconduct of Landlord or any Landlord Parties (defined below) but subject to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, to the maximum extent permitted pursuant to Applicable Laws, Tenant hereby assumes all risk of damage to property or injury to persons in, upon or about the Premises, the Bicycle Storage Area and any of Tenant&#x2019;s Off-Premises Equipment from any cause whatsoever</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(including, but not limited to, any personal injuries resulting from a slip and fall in, upon or about the Premises) and agrees that, to the extent permitted pursuant to Applicable Laws, Landlord, its lenders, partners, subpartners and their respective officers, agents, servants, employees, and independent contractors (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall not be liable for, and are hereby released from any responsibility for, any damage either to person or property or resulting from the loss of use thereof, which damage is sustained by Tenant or by other persons claiming through Tenant, except to the extent resulting from the gross negligence or willful misconduct of Landlord or any of the Landlord Parties. Tenant shall indemnify, defend, protect, and hold harmless the Landlord Parties from any and all loss, cost, damage, injury, expense and liability (including without limitation court costs and reasonable attorneys&#x2019; fees) during the Lease Term, or any period of Tenant&#x2019;s occupancy of the Premises prior to the commencement or after the expiration of the Lease Term, incurred in connection with or arising from (i) any cause in, on or about the Premises, the Bicycle Storage Area or Tenant&#x2019;s Off-Premises Equipment (including, but not limited to, a slip and fall), provided that the terms of the foregoing indemnity shall not apply to the extent of any gross negligence or willful misconduct of Landlord or any of the Landlord Parties, (ii) any negligent acts or omissions of Tenant or of any person claiming by, through or under Tenant, or of the contractors, agents, servants, employees, invitees, guests or licensees of Tenant or any such person, in, on or about the Project (including without limitation on account of Tenant&#x2019;s use of the Bicycle Storage Area and any of Tenant&#x2019;s Off-Premises Equipment/Special Systems), or (iii) any breach of the terms of this Lease by Tenant, either prior to, during, or after the expiration of the Lease Term. Should Landlord be named as a defendant in any suit brought against Tenant for which Tenant&#x2019;s indemnity obligation is applicable, Tenant shall pay to Landlord its reasonable and actual out-of-pocket costs and expenses incurred in such suit, including without limitation, its actual professional fees such as appraisers&#x2019;, accountants&#x2019; and attorneys&#x2019; fees. The provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall survive the expiration or sooner termination of this Lease. Subject to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, Landlord hereby indemnifies and agrees to defend, save and hold Tenant and its partners, subpartners and their respective officers, agents, servants, employees, and independent contractors harmless from and against any and all claims for injury or death to persons or damage to property to the extent resulting from the negligent acts or omissions of Landlord or any Landlord Parties. Should Tenant be named as a defendant in any suit brought against Landlord for which Landlord&#x2019;s indemnity obligation is applicable, Landlord shall pay to Tenant its reasonable and actual out-of-pocket costs and expenses incurred in such suit, including without limitation, its actual professional fees such as appraisers&#x2019;, accountants&#x2019; and attorneys&#x2019; fees. Notwithstanding anything to the contrary set forth in this Lease, either party&#x2019;s agreement to indemnify the other party as set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall be ineffective to the extent the matters for which the indemnitor agreed to indemnify the indemnitee are covered by insurance required to be carried by the indemnitee pursuant to this Lease (or would have been covered had the indemnitee carried the insurance required). Further, Tenant&#x2019;s agreement to indemnify Landlord and Landlord&#x2019;s agreement to indemnify Tenant pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> are not intended to and shall not relieve any insurance carrier of its obligations under policies required to be carried pursuant to the provisions of this Lease, to the extent such policies cover, or if carried, would have covered the matters, subject to the parties&#x2019; respective indemnification obligations; nor shall they supersede any inconsistent agreement of the parties set forth in any other provision of this Lease. The provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall survive the expiration or sooner termination of this Lease with respect to any claims or liability arising in connection with any event occurring prior to such expiration or termination.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Compliance With Landlord&#x2019;s Property Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall, at Tenant&#x2019;s expense, comply with all insurance company requirements pertaining to the use of the Premises. If Tenant&#x2019;s conduct or use of the Premises for any purpose other than the Permitted Use causes any increase in the premium for such insurance policies then Tenant shall reimburse Landlord for any such increase. Tenant, at Tenant&#x2019;s expense, shall comply with all rules, orders, regulations or requirements of the American Insurance Association (formerly the National Board of Fire Underwriters) and with any similar body.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall maintain the following coverages in the following amounts:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3.1 Commercial General Liability Insurance on an ISO CG 00 01 occurrence form covering the insured against claims of bodily injury, personal and advertising injury and property damage (including loss of use thereof) arising out of Tenant&#x2019;s operations, products/completed operations, and contractual liability including a Broad Form endorsement covering the insuring provisions of this Lease and the performance by Tenant of the indemnity agreements set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease (including products and completed operations coverage) for limits of liability of not less than those set forth below, which may be accomplished by any combination of primary and excess layers, provided the umbrella sits excess to the underlying commercial generally liability, automobile liability, and employer&#x2019;s liability insurance. Such insurance shall be written on an &#x201c;occurrence&#x201d; basis. Landlord and any other</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">party the Landlord so specifies that has a material financial interest in the Project, including Landlord&#x2019;s managing agent, ground lessor and/or lender, if any, shall be named as additional insureds as their interests may appear using Insurance Service Organization&#x2019;s form CG2011 or a comparable form approved by Landlord. The coverage shall also be extended to include damage caused by heat, smoke or fumes from a hostile fire. The policy shall not contain any intra-insured exclusions as between insured persons or organizations. Limits of liability insurance shall not be less than the following (provided, however, such limits may be achieved through the use of an umbrella/excess policy):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.5in;border-spacing:0;table-layout:fixed;width:73.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:63.018%;"></td>
    <td style="width:36.982%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;vertical-align:top;padding-bottom:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bodily Injury and<br>Property Damage Liability</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;vertical-align:top;padding-bottom:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$11,000,000 each occurrence</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$11,000,000 annual aggregate</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;vertical-align:top;padding-bottom:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personal Injury and Advertising Liability</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;vertical-align:top;padding-bottom:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$11,000,000 each occurrence</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$11,000,000 annual aggregate 0% Insured&#x2019;s participation</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;vertical-align:top;padding-bottom:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant Legal Liability/Damage to Rented<br>Premises Liability</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.080in;word-break:break-word;vertical-align:top;padding-bottom:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$10,000,000</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3.2 Property Insurance covering (i) all office furniture, business and trade fixtures, office equipment, free-standing cabinet work, movable partitions, merchandise and all other items of Tenant&#x2019;s property on the Premises installed by, for, or at the expense of Tenant, and (ii) the Tenant Improvements described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">1.1.1-2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and any other tenant improvements that exist in the Premises (excluding the Base Building) as of the Lease Commencement Date (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Original Improvements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Such insurance shall be written on a Special Form basis, for the full replacement cost value (subject to reasonable deductible amounts) new, without deduction for depreciation of the covered items and in amounts that meet any co-insurance clauses of the policies of insurance and shall include coverage for (a) all perils included in the CP 10 30 04 02 Coverage Special Form, (b) water damage from any cause whatsoever, including, but not limited to, sprinkler leakage, bursting, leaking or stoppage of any pipes, explosion, and backup or overflow from sewers or drains, (c) terrorism (to the extent such terrorism insurance is available as a result of the Terrorism Risk Insurance Act of 2002 (Pub. L. 107-297, 116 Stat. 2322), the Terrorism Risk Insurance Program Reauthorization Act of 2005 (Pub. l. 109-144), and the Terrorism Risk Insurance Program Reauthorization Act of 2007 (Pub. L. 110-160, 121 Stat. 183), any successor statute or regulation, or is otherwise available at commercially reasonable rates) and (d) earthquake insurance. Such insurance shall be written on an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">all risks</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; of physical loss or damage basis, for the full replacement cost value (subject to reasonable deductible amounts) new without deduction for depreciation of the covered items and in amounts that meet any co-insurance clauses of the policies of insurance and shall include coverage for damage or other loss caused by fire or other peril including, but not limited to, vandalism and malicious mischief, theft, water damage of any type, including sprinkler leakage, bursting or stoppage of pipes, and explosion. Notwithstanding the foregoing, Tenant may elect to self-insure terrorism and earthquake insurance required in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and self-insurance shall not reduce the coverage amounts required to be maintained by Tenant hereunder and any self-insured amount shall be deemed to contain all of the terms and conditions applicable to the insurance required in this Lease, including, without limitation, full waiver of subrogation in favor of Landlord.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3.3 Business Income Interruption for one (1) year plus Extra Expense insurance in such amounts as will reimburse Tenant for actual direct or indirect loss of earnings and continuing expenses, including rent, attributable to the risks outlined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above with a three hundred and sixty-five (365) day extended period of indemnity.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3.4 Worker&#x2019;s Compensation and Employer&#x2019;s Liability with limits not less than $1,000,000 each accident; $1,000,000 disease &#x2013; each employee; and $1,000,000 disease policy limit with minimum limits of not less than $1,000,000 each accident/employee/disease or other similar insurance pursuant to all applicable state and local statutes and regulations. The policy will include a waiver of subrogation in favor of the Landlord Parties.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3.5 Environmental/Pollution Liability Insurance. Tenant shall procure and maintain during the Lease Term and for no fewer than three (3) years thereafter, a stand-alone (covering pollution conditions at and migrating from the Project and/or the Project) pollution legal liability insurance policy covering all environmental risks of Tenant&#x2019;s business for claims relating to clean-up, bodily injury, and property damage, with limits of not less than Ten Million Dollars ($10,000,000.00) per claim and Ten Million Dollars ($10,000,000.00) in the aggregate, with</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">respect to environmental contamination and pollution caused or made worse by Tenant. Such coverage shall have no exclusions for medical, special or biohazardous waste, mold, microbial matter, bacteria, viruses, fungi, infectious disease, or for any materials, solutions, solid, liquid or gas and/or particles expected to be handled and/or generated by Tenant Parties in the course of Tenant&#x2019;s operations and occupancy of the Premises. Such policy shall include (i) full terrorism coverage (whether considered certified or non-certified acts), (ii) coverage for any underground storage tanks and/or above-ground storage tanks, where applicable, and (iii) coverage for radioactive materials if such materials are part of Tenant&#x2019;s operations; and (iv) that this Lease and the indemnification requirements herein are included and scheduled as a lease contract on the pollution legal liability policy. In the event of any environmental/pollution condition arising from Tenant&#x2019;s occupancy or operations at the Premises, Tenant shall immediately notify Landlord. Tenant&#x2019;s environmental/pollution liability insurance shall be maintained for a period not less than ten (10) years after expiration of this Agreement or such greater time provided by the statute of limitation and/or repose.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3.6 Commercial automobile liability insurance covering all Owned (if any), Hired, or Non- owned vehicles with limits not less than $1,000,000 combined single limit for bodily injury and property damage.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3.7 Intentionally Omitted.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3.8 Contractor and Vendor Insurance. In addition to the insurance Tenant is required to maintain under this Lease, if Tenant hires or brings a contractor or vendor onto the Premises or Building to perform or provide any services or products, Tenant shall have a written agreement with vendor whereby vendor will be required to carry Commercial General Liability insurance (subject to minimum limits of $1,000,000 per occurrence, $2,000,000 in the general aggregate), $2,000,000 products completed operations, and the same insurance coverages required of Tenant herein for Auto (if applicable) and Worker&#x2019;s Compensation and Employer&#x2019;s Liability insurance; provided, however, Landlord reserves the right to require greater coverage limitations for contractors pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 8.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above. Tenant shall cause written agreement to require each vendor to provide true and complete copies of all insurance policies and endorsements to Tenant promptly after Tenant&#x2019;s request, and Tenant shall deliver the same to Landlord prior to entry onto the Premises by such vendors. Tenant shall also require that such vendors&#x2019; insurance will meet same additional terms as required of Tenant herein with regards to adding Additional Insureds as additional insureds.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord makes no representation that the limits or forms of coverage of insurance specified herein are adequate to cover Tenant&#x2019;s property, business operations or obligations under this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Policies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The minimum limits of policies of insurance required of Tenant under this Lease shall in no event limit the liability of Tenant under this Lease. Landlord, its subsidiaries and affiliates, Landlord&#x2019;s property and/or development manager and any other party Landlord so specifies, shall be named as an additional insured under the policies listed in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Sections 10.3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">10.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">10.3.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> using Insurance Service Organization&#x2019;s form CG2011 or a comparable form approved by Landlord. All insurance policies required to be maintained by Tenant shall (i) cover the liability assumed by Tenant under this Lease, including, but not limited to, Tenant&#x2019;s obligations under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease; (ii) be issued by an insurance company having a rating of not less than A:VIII in Best&#x2019;s Insurance Guide or which is otherwise acceptable to Landlord and licensed to do business in the State of California; (iii) be primary insurance as to all claims thereunder and provide that any insurance carried by Landlord is excess and is non-contributing with any insurance required of Tenant; (iv) be in form and content reasonably acceptable to Landlord (Tenant shall provide full and complete copies of any policies that Landlord reasonably requests); and (v) provide that said insurer shall endeavor to provide written notice to Landlord and any mortgagee of Landlord, to the extent such names are furnished to Tenant prior to the cancellation of such policy. Tenant shall deliver said policy or policies or certificates thereof to Landlord on or before the earlier to occur of (A) the Lease Commencement Date, and (B) the date upon which Tenant is first provided access to the Premises, and at least ten (10) days before the expiration dates thereof. In the event Tenant shall fail to procure such insurance, or to deliver such policies or certificate within ten (10) days after written notice from Landlord, Landlord may, at its option, procure such policies for the account of Tenant, and the cost thereof shall be paid to Landlord within five (5) days after delivery to Tenant of bills therefor.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Subrogation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord and Tenant intend that their respective property loss risks shall be borne by reasonable insurance carriers to the extent above provided, and Landlord and Tenant hereby agree to look solely to, and seek recovery only from, their respective insurance carriers in the event of a property loss to the extent that such coverage is agreed to be provided hereunder. The parties each hereby waive all rights and claims against each other for such losses and waive all rights of subrogation of their respective insurers, provided such waiver of subrogation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">shall not affect the right of the insured to recover thereunder. The parties agree that their respective insurance policies specify now or shall specify that the waiver of subrogation shall not affect the right of the insured to recover thereunder. Tenant will cause all subtenants and licensees of the Premises claiming by, under, or through Tenant to execute and deliver to Landlord a waiver of claims similar to the waiver in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and to obtain such waiver of subrogation rights endorsements. If either party hereto fails to maintain the waivers set forth in items (i) and (ii) above, the party not maintaining the requisite waivers shall indemnify, defend, protect, and hold harmless the other party for, from and against any and all Losses arising out of, resulting from, or relating to, such failure.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Additional Insurance Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall carry and maintain during the entire Lease Term, at Tenant&#x2019;s sole cost and expense, increased amounts of insurance and such additional coverages as Landlord may reasonably require; provided, however, that (a) in no event shall such new or increased amounts or types of insurance exceed that required of comparable tenants by landlords of the Comparable Buildings and (b) Landlord shall not have the right to require that Tenant adjust its insurance coverage more than once in any twenty-four (24) month period, and not during the initial twenty-four (24) months of the Lease Term.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Fire and Casualty Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall insure the Buildings during the Lease Term against loss or damage due to fire and other casualties covered within the classification of fire and extended coverage, vandalism coverage and malicious mischief, sprinkler leakage, water damage and special extended coverage. Such coverage shall be in such amounts, from such companies, and on such other terms and conditions, as Landlord may from time to time reasonably determine. Landlord shall also carry rental loss insurance. Additionally, at the option of Landlord, such insurance coverage may include the risks of earthquakes and/or flood damage and additional hazards, a rental loss endorsement and one or more loss payee endorsements in favor of the holders of any mortgages or deeds of trust encumbering the interest of Landlord in the Project or the ground or underlying lessors of the Project, or any portion thereof. Notwithstanding the foregoing provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the coverage and amounts of insurance carried by Landlord in connection with the Buildings shall, at a minimum, be comparable to the coverage and amounts of insurance which are carried by reasonably prudent landlords of Comparable Buildings (provided that in no event shall Landlord be required to carry earthquake insurance). Tenant shall, at Tenant&#x2019;s expense, promptly following notice, comply with all insurance company requirements pertaining to the use of the Premises. If Tenant&#x2019;s conduct or use of the Premises causes any increase in the premium for such insurance policies then Tenant shall reimburse Landlord for any such increase. Tenant, at Tenant&#x2019;s expense, shall comply with all rules, orders, regulations or requirements of the American Insurance Association (formerly the National Board of Fire Underwriters) and with any similar body.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. DAMAGE AND DESTRUCTION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Repair of Damage to Premises by Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall promptly notify Landlord of any damage to the Premises resulting from fire or any other casualty. If the Premises or any Common Areas serving or providing access to the Premises shall be damaged by fire or other casualty, Landlord will, as soon as reasonably possible following the date of the damage, deliver to Tenant an estimate of the time necessary to repair the damage in question such that the Premises may be used by and accessible to Tenant and the Buildings and Common Areas operable in a manner consistent with the operation prior to such damage; such notice will be based upon the review and opinions of Landlord&#x2019;s architect and contractor (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Completion Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Landlord shall promptly and diligently, subject to reasonable delays for insurance adjustment or other matters beyond Landlord&#x2019;s reasonable control, and subject to all other terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, restore such Common Areas and the Premises to substantially the same condition as existed prior to the casualty, except for modifications required by zoning and building codes and other laws or by the holder of a mortgage on the Building or Project or any other modifications to the Common Areas deemed desirable by Landlord, which are consistent with the character of the Project, provided that access to the Premises shall not be materially impaired. Upon the occurrence of any damage to the Premises, upon notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord Repair Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) to Tenant from Landlord delivered on or before the date that is ninety (90) days after the date of the damage, Tenant shall assign to Landlord (or to any party designated by Landlord) all insurance proceeds payable to Tenant under Tenant&#x2019;s insurance required under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.3.2(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, and Landlord shall repair any injury or damage to the Improvements and the Original Improvements and shall return such Improvements and Original Improvements to their original condition (any such work will be competitively bid by Landlord to ensure that Landlord receives commercially reasonable pricing for the performance of such work so that, to the extent reasonably possible, the cost of such work does not unnecessarily exceed the proceeds of Tenant&#x2019;s insurance); provided that if the cost of such repair by Landlord exceeds the amount of insurance proceeds received by Landlord from Tenant&#x2019;s insurance carrier, as assigned by Tenant, the portion of the cost of such repairs which is not so covered by Tenant&#x2019;s</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">insurance proceeds shall be paid by Tenant to Landlord prior to Landlord&#x2019;s commencement of repair of the damage. In the event that Landlord does not deliver the Landlord Repair Notice within ninety (90) days following the date the casualty becomes known to Landlord, Tenant shall, at its sole cost and expense, repair any injury or damage to the Improvements and the Original Improvements installed in the Premises and shall return such Improvements and Original Improvements to their original condition, or an alternate condition described by Tenant (but subject to Landlord&#x2019;s prior written approval). Whether or not Landlord delivers a Landlord Repair Notice, prior to the commencement of construction, Tenant shall submit to Landlord, for Landlord&#x2019;s review and approval, all plans, specifications and working drawings relating thereto (it being acknowledged that the cost to prepare such plans may be paid for out of the applicable insurance proceeds received by Tenant), and Landlord shall select the contractors to perform such improvement work. Landlord shall not be liable for any inconvenience or annoyance to Tenant or its visitors, or injury to Tenant&#x2019;s business resulting in any way from such damage or the repair thereof; provided however, that if such fire or other casualty shall have damaged the Premises or Common Areas necessary to Tenant&#x2019;s occupancy, and the Premises are not occupied by Tenant as a result thereof, then during the time and to the extent the Premises are unfit for occupancy, the Rent shall be abated in proportion to the ratio that the amount of rentable square feet of the Premises which is unfit for occupancy for the Permitted Use bears to the total rentable square feet of the Premises; provided, further, however, that if the damage or destruction is due to the negligence or willful misconduct of Tenant or any of its agents, employees, contractors, invitees or guests, Tenant shall be responsible for any reasonable, applicable insurance deductible (which shall be payable to Landlord upon demand, not to materially exceed the levels of deductibles for such insurance then maintained by owners of Comparable Buildings). In the event that Landlord shall not deliver the Landlord Repair Notice, Tenant&#x2019;s right to rent abatement pursuant to the preceding sentence shall terminate as of the date which is reasonably determined by Landlord to be the date Tenant should have completed repairs to the Premises assuming Tenant used reasonable due diligence in connection therewith.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Option to Repair</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 11.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, Landlord may elect not to rebuild and/or restore the Premises, Building and/or Project, and instead terminate this Lease, by notifying Tenant in writing of such termination within ninety (90) days after the date of discovery of the damage, such notice to include a termination date giving Tenant ninety (90) days to vacate the Premises, but Landlord may so elect only if the Building or Project shall be damaged by fire or other casualty or cause, whether or not the Premises are affected, and one or more of the following conditions is present: (i) in Landlord&#x2019;s reasonable judgment, repairs cannot reasonably be completed within eighteen (18) months after the date of discovery of the damage (when such repairs are made without the payment of overtime or other premiums); (ii) the holder of any mortgage on the Building or Project or ground lessor with respect to the Building or Project shall require that the insurance proceeds or any portion thereof be used to retire the mortgage debt, or shall terminate the ground lease, as the case may be; (iii) more than One Million Dollars ($1,000,000.00) of the cost of repair of such damage is not fully covered by Landlord&#x2019;s insurance policies (unless such shortfall is a result of Landlord&#x2019;s failure to maintain the insurance that Landlord is required to maintain pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.7 below</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">); (iv) Landlord decides to rebuild the Building or Common Areas so that they will be substantially different structurally or architecturally; (v) the damage occurs during the last twelve (12) months of the Lease Term; provided, however, that if such fire or other casualty shall have damaged the Premises or a portion thereof or Common Areas necessary to Tenant&#x2019;s occupancy and as a result of such damage the Premises is unfit for occupancy, and provided that Landlord does not elect to terminate this Lease pursuant to Landlord&#x2019;s termination right as provided above, and either (a) the repairs cannot, in the reasonable opinion of Landlord&#x2019;s contractor, as set forth in Landlord&#x2019;s Completion Notice, be completed within eighteen (18) months after being commenced, or (b) the damage occurs during the last twelve (12) months of the Lease Term and will reasonably require in excess of ninety (90) days to repair, Tenant may elect, no earlier than sixty (60) days after Tenant&#x2019;s receipt of the Landlord&#x2019;s Completion Notice and not later than ninety (90) days after the date of Tenant&#x2019;s receipt of the Landlord&#x2019;s Completion Notice, to terminate this Lease by written notice to Landlord effective as of the date specified in the notice, which date shall not be less than thirty (30) days nor more than sixty (60) days after the date such notice is given by Tenant. In addition, if such restoration is not substantially complete on or before the later of (i) the date that occurs eighteen (18) months after the date of discovery of the damage, and (ii) the date that occurs ninety (90) days after the expiration of the estimated period of time to substantially complete such restoration, as set forth in Landlord&#x2019;s Completion Notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outside Restoration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), then Tenant shall have the additional right during the first ten (10) business days of each calendar month following the Outside Restoration Date until such repairs are complete, to terminate this Lease by delivery of written notice to Landlord (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Damage Termination Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), which termination shall be effective on a date specified by Tenant in such Damage Termination Notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Damage Termination Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), which Damage Termination Date shall not be less than ten (10) business days, nor greater than thirty (30) days, following the date such Damage Termination Notice was delivered to Landlord. In the event this Lease is terminated in accordance with</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 11.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, Tenant shall assign to Landlord (or to any party designated by Landlord) all insurance proceeds payable to Tenant under Tenant&#x2019;s insurance required under subsections (ii) and (iii) of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 10.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Waiver of Statutory Provisions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The provisions of this Lease, including this Article 11, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, the Building or the Project, and any statute or regulation of the State of California, including, without limitation, Sections 1932(2) and 1933(4) of the California Civil Code, with respect to any rights or obligations concerning damage or destruction in the absence of an express agreement between the parties, and any other statute or regulation, now or hereafter in effect, shall have no application to this Lease or any damage or destruction to all or any part of the Premises, the Building or the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. NONWAIVER</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No provision of this Lease shall be deemed waived by either party hereto unless expressly waived in a writing signed thereby. The waiver by either party hereto of any breach of any term, covenant or condition herein contained shall not be deemed to be a waiver of any subsequent breach of same or any other term, covenant or condition herein contained. The subsequent acceptance of Rent hereunder by Landlord shall not be deemed to be a waiver of any preceding breach by Tenant of any term, covenant or condition of this Lease, other than the failure of Tenant to pay the particular Rent so accepted, regardless of Landlord&#x2019;s knowledge of such preceding breach at the time of acceptance of such Rent. No acceptance of a lesser amount than the Rent herein stipulated shall be deemed a waiver of Landlord&#x2019;s right to receive the full amount due, nor shall any endorsement or statement on any check or payment or any letter accompanying such check or payment be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord&#x2019;s right to recover the full amount due. No receipt of monies by Landlord from Tenant after the termination of this Lease shall in any way alter the length of the Lease Term or of Tenant&#x2019;s right of possession hereunder, or after the giving of any notice shall reinstate, continue or extend the Lease Term or affect any notice given Tenant prior to the receipt of such monies, it being agreed that after the service of notice or the commencement of a suit, or after final judgment for possession of the Premises, Landlord may receive and collect any Rent due, and the payment of said Rent shall not waive or affect said notice, suit or judgment. No payment of Rent by Tenant after a breach by Landlord shall be deemed a waiver of any breach by Landlord.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. CONDEMNATION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the whole or substantially all of the Premises, Building or Project shall be taken by power of eminent domain or condemned by any competent authority for any public or quasi-public use or purpose, or if all reasonable access to the Building is so taken or condemned, or if Landlord shall grant a deed or other instrument in lieu of such taking by eminent domain or condemnation, Landlord shall have the option to terminate this Lease effective as of the date possession is required to be surrendered to the authority; provided, however, that Landlord shall only have the right to terminate this Lease as provided above if Landlord terminates the leases of all other tenants in the Building, if any, similarly affected by the taking and provided further that to the extent that the Premises is not adversely affected by such taking and Landlord continues to operate the Building as office building and/or life sciences building, Landlord may not terminate this Lease. If more than twenty-five percent (25%) of the rentable square feet of the Premises is taken, or if access to the Premises is substantially impaired, in each case for a period in excess of one hundred eighty (180) days, Tenant shall have the option to terminate this Lease effective as of the date possession is required to be surrendered to the authority. Tenant shall not because of such taking assert any claim against Landlord or the authority for any compensation because of such taking and Landlord shall be entitled to the entire award or payment in connection therewith, except that Tenant shall have the right to file any separate claim available to Tenant for any taking of Tenant&#x2019;s personal property and fixtures belonging to Tenant and removable by Tenant upon expiration of the Lease Term pursuant to the terms of this Lease, and for moving expenses, so long as such claims do not diminish the award available to Landlord, its ground lessor with respect to the Building or Project or its mortgagee, and such claim is payable separately to Tenant. All Rent shall be apportioned as of the date of such termination. If any part of the Premises shall be taken, and this Lease shall not be so terminated, the Rent shall be proportionately abated. Notwithstanding anything to the contrary contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, in the event of a temporary taking of all or any portion of the Premises for a period of twelve (12) months or less, and provided that such temporary taking does not materially preclude or unreasonably diminish Tenant&#x2019;s ability to conduct business from the Premises, then this Lease shall not terminate but the Base Rent and Tenant&#x2019;s Share of Direct Expenses shall be abated for the period of such taking in proportion to the ratio that the amount of rentable square feet of the Premises taken bears to the total rentable</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">square feet of the Premises. Tenant hereby waives any and all rights it might otherwise have pursuant to Section 1265.130 of The California Code of Civil Procedure. Landlord shall be entitled to receive the entire award made in connection with any such temporary taking, provided, however, that Tenant shall be entitled to a share of the award for any loss of fixtures and improvements and for moving and other reasonable expenses that do not otherwise reduce Landlord&#x2019;s recovery. If this Lease does not terminate on account of any such eminent domain or condemnation proceeding, then Landlord shall, to the extent practicable, restore the affected area of the Premises, Building or Project. In no event shall Landlord have any obligation to undertake restoration on account of any condemnation or eminent domain proceeding except to the extent of the award actually received by Landlord. Notwithstanding anything to the contrary contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, in the event of a temporary taking of all or any portion of the Premises for a period of twelve (12) months or less, then this Lease shall not terminate but the Base Rent and the Additional Rent shall be abated for the period of such taking in proportion to the ratio that the amount of rentable square feet of the Premises taken bears to the total rentable square feet of the Premises. Landlord shall be entitled to receive the entire award made in connection with any such temporary taking.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. ASSIGNMENT AND SUBLETTING</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transfers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall not, without the prior written consent of Landlord (except in connection with a Permitted Transfer [as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below]), assign, mortgage, pledge, hypothecate, encumber, or permit any lien to attach to, or otherwise transfer, this Lease or any interest hereunder, permit any assignment, or other transfer of this Lease or any interest hereunder by operation of law, sublet the Premises or any part thereof, or enter into any license or concession agreements or otherwise permit the occupancy or use of the Premises or any part thereof by any persons other than Tenant and its employees and contractors (all of the foregoing are hereinafter sometimes referred to collectively as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; and any person to whom any Transfer is made or sought to be made is hereinafter sometimes referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transferee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). If Tenant desires Landlord&#x2019;s consent to any Transfer, Tenant shall notify Landlord in writing, which notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfer Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall include (i) the proposed effective date of the Transfer, which shall not be less than fifteen (15) days nor more than two hundred seventy (270) days after the date of delivery of the Transfer Notice, (ii) a description of the portion of the Premises to be transferred (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Subject Space</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), (iii) all of the terms of the proposed Transfer and the consideration therefor, including calculation of the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfer Premium</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;, as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below, in connection with such Transfer, the name and address of the proposed Transferee, and a copy of all existing executed and/or proposed documentation pertaining to the proposed Transfer, (iv) current financial statements of the proposed Transferee certified by an officer, partner or owner thereof, business credit and personal references and history of the proposed Transferee, (v) any other information reasonably required by Landlord which will enable Landlord to determine the financial responsibility, character, and reputation of the proposed Transferee, nature of such Transferee&#x2019;s business and proposed use of the Subject Space, which information is requested within five (5) business days following Tenant&#x2019;s submission to Landlord of the items described in clauses (i), (ii), (iii), (iv) and (vi) of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and (vi) an executed estoppel certificate from Tenant in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 17</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Any Transfer made without Landlord&#x2019;s prior written consent shall, at Landlord&#x2019;s option, be null, void and of no effect, and shall, at Landlord&#x2019;s option, constitute a default by Tenant under this Lease. Whether or not Landlord consents to any proposed Transfer, Tenant shall pay Landlord&#x2019;s reasonable review and processing fees, as well as any reasonable professional fees (including, without limitation, attorneys&#x2019;, accountants&#x2019;, architects&#x2019;, engineers&#x2019; and consultants&#x2019; fees) incurred by Landlord, not to exceed $5,000 in total, within thirty (30) days after written request by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall not unreasonably withhold, condition or delay its consent to any proposed sublet of the Subject Space or assignment of this Lease on the terms specified in the Transfer Notice and shall grant or withhold such consent within fifteen (15) days following the date upon which Landlord receives a &#x201c;complete&#x201d; Transfer Notice from Tenant (i.e., a Transfer Notice that includes all documents and information required pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease). ). If Landlord fails to respond within such fifteen (15) day period, Tenant may send a written &#x201c;reminder notice&#x201d;. If Landlord fails to respond to such request within five (5) Business Days after delivery of the &#x201c;reminder notice&#x201d;, then such nonresponse shall be deemed Landlord&#x2019;s approval of such Transfer request. Without limitation as to other reasonable grounds for withholding consent, the parties hereby agree that it shall be reasonable under this Lease and under any Applicable Law for Landlord to withhold consent to any proposed sublet or assignment where one or more of the following apply:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.2.1 The Transferee is, in Landlord&#x2019;s commercially reasonable business judgment, of a character or reputation or engaged in a business which is not consistent with the quality of the Building or the Project;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.2.2 The Transferee intends to use the Subject Space for purposes which are not permitted under this Lease;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.2.3 The Transferee is either a governmental agency or instrumentality thereof;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.2.4 The Transferee is a Tax-Exempt Entity (as defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.4.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">attached hereto), unless such Transferee, at no cost to Landlord, complies with and satisfies all of the applicable Mission Bay Requirements relating to a Transfer to a Tax-Exempt Entity as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.4.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">attached hereto, to the extent that Landlord continues to be subject to such requirements at the time of such Transfer;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.2.5 The Transferee is not, in Landlord&#x2019;s commercially reasonable business judgment, a party of reasonable financial worth and/or financial stability in light of the responsibilities to be undertaken in connection with the Transfer on the date consent is requested;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.2.6 The proposed Transfer would cause a violation of another lease for space in the Project, or would give an occupant of the Project a right to cancel its lease; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.2.7 Either the proposed Transferee, or any person or entity which directly or indirectly, controls, is controlled by, or is under common control with, the proposed Transferee, is actively negotiating with Landlord or has negotiated with Landlord during the four (4) month period immediately preceding the date Landlord receives the Transfer Notice, to lease space in the Project and there is space in the Project then available, or will be available timely, for such Transferee within the Project.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.2.8 In Landlord&#x2019;s reasonable determination, the sub-rent, additional rent or other amounts received or accrued by Tenant from subleasing, assigning or otherwise Transferring all or any portion of the Premises is based on the income or profits of any person, or the assignment or sublease could cause any portion of the amounts received by Landlord pursuant to this Lease to fail to qualify as &#x201c;rents from real property&#x201d; within the meaning of section 856(d) of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), or any similar or successor provision thereto or which would cause any other income of Landlord to fail to qualify as income described in section 856(c)(2) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Landlord consents to any Transfer pursuant to the terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (and does not exercise any recapture rights Landlord may have under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease), Tenant may within six (6) months after Landlord&#x2019;s consent, but not later than the expiration of said six-month period, enter into such Transfer of the Premises or portion thereof, upon substantially the same terms and conditions as are set forth in the Transfer Notice furnished by Tenant to Landlord pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, provided that if there are any changes in the terms and conditions from those specified in the Transfer Notice (i) such that Landlord would initially have been entitled to refuse its consent to such Transfer under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, Tenant shall again submit the Transfer to Landlord for its approval and other action under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (including Landlord&#x2019;s right of recapture, if any, under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease). Notwithstanding anything to the contrary in this Lease, if Tenant or any proposed Transferee claims that Landlord has withheld or delayed its consent in violation of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or otherwise has breached its obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, their sole remedies shall be a suit for contract damages (other than damages for injury to, or interference with, Tenant&#x2019;s business including, without limitation, loss of profits, however occurring) or declaratory judgment and an injunction for the relief sought without any monetary damages, and Tenant hereby waives the provisions of Section 1995.310 of the California Civil Code, or any successor statute, and all other remedies, including, without limitation, any right at law or equity to terminate this Lease, on its own behalf and, to the extent permitted under all Applicable Laws, on behalf of the proposed Transferee. Tenant shall indemnify, defend and hold harmless Landlord from any and all Losses, causes of action and proceedings involving any third party or parties (including without limitation Tenant&#x2019;s proposed subtenant or assignee) who claim they were damaged by Landlord&#x2019;s wrongful withholding or conditioning of Landlord&#x2019;s consent.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transfer Premium</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If Landlord consents to a Transfer constituting an assignment of the Lease or a sublease of the Premises, as a condition thereto which the parties hereby agree is reasonable, Tenant shall pay to Landlord fifty percent (50%) of any &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfer Premium</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;, as that term is defined in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, received by Tenant from such Transferee (other than any Permitted Transferee). &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfer Premium</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean all rent, additional rent or other consideration received by such Transferee in connection with the Transfer in excess of the Rent and Additional Rent payable by Tenant under this Lease during the term of the Transfer on a per rentable square</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foot basis if less than all of the Premises is transferred, after deducting the reasonable third party expenses incurred by Tenant for (i) any design and construction costs incurred on account of changes, alterations and improvements to the Premises in connection with the Transfer, (ii) any free base rent and tenant improvement allowances reasonably provided to the Transferee in connection with the Transfer (provided that such free rent and tenant improvement allowances shall be deducted only to the extent the same is included in the calculation of total consideration payable by such Transferee), (iii) any brokerage commissions and marketing costs in connection with the Transfer, and (iv) legal fees and disbursements reasonably incurred in connection with the Transfer (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Subleasing Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfer Premium</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall also include, but not be limited to, any lump sum payment, key money, bonus money or other cash consideration paid by Transferee to Tenant in connection with such Transfer, and any payment in excess of fair market value for services rendered by Tenant to Transferee or for assets, fixtures, inventory, equipment, or furniture (other than Tenant Improvements and Alterations) transferred by Tenant to Transferee in connection with such Transfer. For purposes of calculating any such effective rent all such concessions shall be amortized on a straight-line basis over the relevant term. The determination of the amount of Landlord&#x2019;s applicable share of the Transfer Premium shall be made on a monthly basis as rent or other consideration is received by Tenant under the Transfer. No Transfer Premium shall be payable in connection with any Permitted Transfer.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Option as to Subject Space</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything to the contrary contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, in the event Tenant contemplates a Transfer involving either (1) more than two (2) full floors of the Premises for a term that is either (i) more than five (5) years, or (ii) extends into any portion of the final three (3) years of the Lease Term, or (2) at least one (1) full floor at any time within the final three (3) years of the Lease Term, Tenant shall give Landlord notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intention to Transfer Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) of such contemplated Transfer (whether or not the contemplated Transferee or the terms of such contemplated Transfer have been determined). The Intention to Transfer Notice shall specify the portion of and amount of rentable square feet of the Premises which Tenant intends to Transfer (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contemplated Transfer Space</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), the contemplated date of commencement of the Contemplated Transfer (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contemplated Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and the contemplated length of the term of such contemplated Transfer, and shall specify that such Intention to Transfer Notice is delivered to Landlord pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in order to allow Landlord to elect to recapture the Contemplated Transfer Space. Thereafter, Landlord shall have the option, by giving written notice to Tenant (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recapture Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) within thirty (30) days after receipt of any Intention to Transfer Notice, to recapture the Contemplated Transfer Space. Such recapture shall cancel and terminate this Lease with respect to such Contemplated Transfer Space as of the Contemplated Effective Date. In the event of a recapture by Landlord, if this Lease shall be canceled with respect to less than the entire Premises, the Rent reserved herein shall be prorated on the basis of the number of rentable square feet retained by Tenant in proportion to the number of rentable square feet contained in the Premises, and this Lease as so amended shall continue thereafter in full force and effect, and upon request of either party, the parties shall execute written confirmation of the same. If Landlord declines, or fails to elect in a timely manner to recapture the Contemplated Transfer Space under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">14.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, then, subject to the other terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, for a period of six (6) months (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Six-Month Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) commencing on the last day of such thirty (30) day period, Landlord shall not have any right to recapture the Contemplated Transfer Space with respect to any Transfer made during the Six Month Period, provided that any such Transfer is substantially on the terms set forth in the Intention to Transfer Notice, and provided further that any such Transfer shall be subject to the remaining terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If such a Transfer is not so consummated within the Six-Month Period (or if a Transfer is so consummated, then upon the expiration of the term of any Transfer of such Contemplated Transfer Space consummated within such Six-Month Period), Tenant shall again be required to submit a new Intention to Transfer Notice to Landlord with respect any contemplated Transfer of the Contemplated Transfer Space, as provided above in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding the foregoing to the contrary, Tenant may, within ten (10) days following receipt of any Recapture Notice, rescind the Intention to Transfer Notice (and thereby negate the recapture of the Contemplated Transfer Space) to which it applies provided that Tenant does not proceed with the contemplated Transfer giving rise to the applicable Intention to Transfer Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Effect of Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If Landlord consents to a Transfer, (i) the terms and conditions of this Lease shall in no way be deemed to have been waived or modified, (ii) such consent shall not be deemed consent to any further Transfer by either Tenant or a Transferee, (iii) Tenant shall deliver to Landlord, promptly after execution, an original executed copy of all documentation pertaining to the Transfer in form reasonably acceptable to Landlord, (iv) Tenant shall furnish upon Landlord&#x2019;s request a complete statement, certified by an independent certified public accountant, or Tenant&#x2019;s chief financial officer, setting forth in detail the computation of any Transfer Premium Tenant has derived and shall derive from such Transfer, and (v) no Transfer relating to this Lease or agreement entered into with respect thereto, whether with or without Landlord&#x2019;s consent, shall relieve Tenant or any guarantor of the Lease from any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">liability under this Lease, including, without limitation, in connection with the Subject Space. Landlord or its authorized representatives shall have the right at all reasonable times and upon reasonable prior notice to audit the books, records and papers of Tenant relating to any Transfer at Tenant&#x2019;s office, and shall have the right to make copies thereof. If the Transfer Premium respecting any Transfer shall be found understated, Tenant shall, within thirty (30) days after demand, pay the deficiency, and if understated by more than two percent (2%), Tenant shall pay Landlord&#x2019;s costs of such audit.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Sublease/Transfer Restrictions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything contained herein to the contrary and without limiting the generality of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above, Tenant shall not: (a) sublet all or part of the Premises or assign or otherwise Transfer this Lease on any basis such that the rental or other amounts to be paid by the subtenant or assignee thereunder would be based, in whole or in part, on the income or profits derived by the business activities of the subtenant or assignee; (b) sublet all or part of the Premises or assign this Lease to any person or entity in which, under Section 856(d)(2)(B) of the Code, Longfellow Atlantic REIT, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), or any affiliate of the Company owns, directly or indirectly (by applying constructive ownership rules set forth in Section 856(d) (5) of the Code), a ten percent (10%) or greater interest; or (c) sublet all or part of the Premises or assign this Lease in any other manner or otherwise derive any income which could cause any portion of the amounts received by Landlord pursuant hereto or any sublease to fail to qualify as &#x201c;rents from real property&#x201d; within the meaning of Section 856(d) of the Code, or which could cause any other income received by Landlord to fail to qualify as income described in Section 856(c) (2) of the Code. The requirements of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall likewise apply to any further subleasing, assignment or other Transfer by any subtenant or assignee. All references herein to Section 856 of the Code also shall refer to any amendments thereof or successor provisions thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.7 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Occurrence of Default</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Any Transfer hereunder shall be subordinate and subject to the provisions of this Lease, and if this Lease shall be terminated during the term of any Transfer, Landlord shall have the right to (and each sublease shall provide Landlord with the ability to): (i) treat such Transfer as cancelled and repossess the Subject Space by any lawful means, or (ii) require that such Transferee attorn to and recognize Landlord as its landlord under any such Transfer. If Tenant shall be in default under this Lease beyond any applicable notice and cure periods, Landlord is hereby irrevocably authorized, as Tenant&#x2019;s agent and attorney-in-fact, to direct any Transferee to make all payments under or in connection with the Transfer directly to Landlord (which Landlord shall apply towards Tenant&#x2019;s obligations under this Lease) until such default is cured. Such Transferee shall rely on any representation by Landlord that Tenant is in default hereunder, without any need for confirmation thereof by Tenant. Upon any assignment, the assignee shall assume in writing all obligations and covenants of Tenant thereafter to be performed or observed under this Lease. No collection or acceptance of rent by Landlord from any Transferee shall be deemed a waiver of any provision of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or the approval of any Transferee or a release of Tenant from any obligation under this Lease, whether theretofore or thereafter accruing. In no event shall Landlord&#x2019;s enforcement of any provision of this Lease against any Transferee be deemed a waiver of Landlord&#x2019;s right to enforce any term of this Lease against Tenant or any other person. If Tenant&#x2019;s obligations hereunder have been guaranteed, Landlord&#x2019;s consent to any Transfer shall not be effective unless the guarantor also consents to such Transfer.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.8 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Non-Transfers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything to the contrary contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, (i) an assignment or subletting of all or a portion of the Premises to an affiliate of Tenant (an entity which is controlled by, controls, or is under common control with, Tenant), (ii) an assignment of the Premises to an entity which acquires all or substantially all of the assets or beneficial interests (partnership, stock or other) of Tenant, (iii) an assignment of the Premises to an entity which is the resulting entity of a merger or consolidation of Tenant (or a transaction where Tenant is the surviving corporation of the merger), or (iv) or any other transfer of Tenant&#x2019;s stock, on a nationally- recognized stock exchange (any of the foregoing, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Permitted Transferee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), shall not be deemed a Transfer under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, provided that (A) except in the case of clause (i) above, Tenant notifies Landlord of any such assignment or sublease and promptly supplies Landlord with any documents or information requested by Landlord regarding such assignment or sublease or such affiliate, (B) such assignment or sublease is not a subterfuge by Tenant to avoid its obligations under this Lease, (C) with respect to clause (i), such Permitted Transferee shall be of a character and reputation consistent with the quality of the Building, and (D) with respect to an assignment to a Permitted Transferee or a Transfer pursuant to clauses (i), (ii) or (iii) above, the resulting Tenant under this Lease shall have a tangible net worth (not including goodwill as an asset) computed in accordance with generally accepted accounting principles (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net Worth</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) at least equal to the Net Worth of Tenant on the day that is [three (3)] months prior to the effective date of such assignment or sublease. An assignee of Tenant&#x2019;s entire interest that is also a Permitted Transferee may also be known as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Permitted Assignee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;. &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;, as used in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 14.8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, shall mean the ownership,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">directly or indirectly, of at least fifty-one percent (51%) of the voting securities of, or possession of the right to vote, in the ordinary direction of its affairs, of at least fifty-one percent (51%) of the voting interest in, any person or entity and the ability to direct the day-to-day affairs of such person or entity. No such permitted assignment or subletting or other Transfer permitted with or without Landlord&#x2019;s consent pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall serve to release Tenant from any of its obligations under this Lease. Landlord acknowledges that, as of the date hereof, Tenant&#x2019;s stock is traded on a public exchange (NASDAQ: VIR). For the avoidance of doubt, so long as Tenant&#x2019;s stock is traded on a public exchange, no sale, buy-back, split or other transfer whatsoever of Tenant&#x2019;s stock shall be deemed a &#x201c;Transfer&#x201d; under this Lease.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Surrender of Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No act or thing done by Landlord or any agent or employee of Landlord during the Lease Term shall be deemed to constitute an acceptance by Landlord of a surrender of the Premises unless such intent is specifically acknowledged in writing by Landlord. The delivery of keys to the Premises to Landlord or any agent or employee of Landlord shall not constitute a surrender of the Premises or effect a termination of this Lease, whether or not the keys are thereafter retained by Landlord, and notwithstanding such delivery Tenant shall be entitled to the return of such keys at any reasonable time upon request until this Lease shall have been properly terminated. The voluntary or other surrender of this Lease by Tenant, whether accepted by Landlord or not, or a mutual termination hereof, shall not work a merger, and at the option of Landlord shall operate as an assignment to Landlord of all subleases or subtenancies affecting the Premises or terminate any or all such sublessees or subtenancies.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Removal of Tenant Property by Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon the expiration of the Lease Term, or upon any earlier termination of this Lease, Tenant shall, subject to the provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, quit and surrender possession of the Premises to Landlord in as good order and condition as when Tenant took possession and as thereafter improved by Landlord and/or Tenant, reasonable wear and tear, casualty and repairs which are specifically made the responsibility of Landlord hereunder excepted. Upon such expiration or termination, Tenant shall, without expense to Landlord, remove or cause to be removed from the Premises all Alterations that Tenant is required to remove in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 8.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, any debris and rubbish, and such items of furniture, equipment, free- standing cabinet work, movable partitions and other articles of personal property, including all Lines, owned by Tenant or installed or placed by Tenant at its expense in the Premises, and such similar articles of any other persons claiming under Tenant (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), as Landlord may, in its sole discretion, require to be removed (provided that Tenant, in its sole discretion, may remove all of Tenant&#x2019;s personal property and trade fixtures, at any time, regardless of any such election by Landlord), and Tenant shall repair at its own expense all damage to the Premises and Building resulting from such removal. Tenant&#x2019;s personal property includes only those items that are not built into the Premises and that have not been constructed or installed by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Environmental Assessment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Prior to the expiration of the Lease (or within thirty (30) days after any earlier termination), Tenant shall clean and otherwise decommission all interior surfaces (including floors, walls, ceilings, and counters), piping, supply lines, waste lines and plumbing in or serving the Premises, and all exhaust or other ductwork in or serving the Premises, in each case that has carried, released or otherwise been exposed to any Hazardous Materials due to Tenant&#x2019;s use or occupancy of the Premises, and shall otherwise clean the Premises so as to permit the Environmental Assessment called for by this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 15.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to be issued. Prior to the expiration of this Lease (or within thirty (30) days after any earlier termination), Tenant, at Tenant&#x2019;s expense, shall obtain for Landlord a report (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Environmental Assessment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) addressed to Landlord (and, at Tenant&#x2019;s election, Tenant) by a reputable licensed environmental engineer or industrial hygienist that is designated by Tenant and acceptable to Landlord in Landlord&#x2019;s reasonable discretion, which report shall be based on the environmental engineer&#x2019;s inspection of the Premises and shall state, to Landlord&#x2019;s reasonable satisfaction, that (a) the Hazardous Materials described in the first sentence of this paragraph, to the extent, if any, existing prior to such decommissioning, have been removed in accordance with Applicable Laws; (b) all Hazardous Materials described in the first sentence of this paragraph, if any, have been removed in accordance with Applicable Laws from the interior surfaces of the Premises (including floors, walls, ceilings, and counters), piping, supply lines, waste lines and plumbing, and all such exhaust or other ductwork in the Premises, may be reused by a subsequent tenant or disposed of in compliance with Applicable Laws without incurring special costs or undertaking special procedures for demolition, disposal, investigation, assessment, cleaning or removal of such Hazardous Materials and without giving notice in connection with such Hazardous Materials; and (a) the Premises may be reoccupied for office, research and development, or laboratory use, demolished or renovated without incurring special costs or undertaking special procedures for disposal, investigation, assessment, cleaning or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">removal of Hazardous Materials described in the first sentence of this paragraph and without giving notice in connection with Hazardous Materials. Further, for purposes of clauses (b) and (c), &#x201c;special costs&#x201d; or &#x201c;special procedures&#x201d; shall mean costs or procedures, as the case may be, that would not be incurred but for the nature of the Hazardous Materials as Hazardous Materials instead of non-hazardous materials. The report shall also include reasonable detail concerning the clean-up measures taken, the clean-up locations, the tests run and the analytic results. Tenant shall submit to Landlord the identity of the applicable consultants and the scope of the proposed Environmental Assessment for Landlord&#x2019;s reasonable review and approval at least 30 days prior to commencing the work described therein or at least forty-five (45) days prior to the expiration of the Lease Term, whichever is earlier.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Tenant fails to perform its obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 15.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, without limiting any other right or remedy, Landlord may, on five (5) business days&#x2019; prior written notice to Tenant perform such obligations at Tenant&#x2019;s expense if Tenant has not commenced to do so within said five day period, and Tenant shall within ten (10) days of written demand (together with supporting documentation) reimburse Landlord for all reasonable out-of-pocket costs and expenses incurred by Landlord in connection with such work. Tenant&#x2019;s obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 15.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall survive the expiration or earlier termination of this Lease. In addition, at Landlord&#x2019;s election, Landlord may inspect the Premises and/or the Project for Hazardous Materials at Landlord&#x2019;s cost and expense within sixty (60) days of Tenant&#x2019;s surrender of the Premises at the expiration or earlier termination of this Lease. Tenant shall pay for all such costs and expenses incurred by Landlord in connection with such inspection if such inspection reveals that a release or threat of release of Hazardous Materials exists at the Project or Premises as a result of the acts or omission of Tenant, its officers, employees, contractors, and agents (except to the extent resulting from (i) Landlord&#x2019;s Hazardous Materials, or (ii) the acts or omissions of Landlord or Landlord&#x2019;s agents, employees or contractors).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16. HOLDING OVER</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Tenant holds over after the expiration of the Lease Term or earlier termination thereof, with the express written consent of Landlord, such tenancy shall be from month-to-month only and shall not constitute a renewal hereof or an extension for any further term. If Tenant holds over after the expiration of the Lease Term of earlier termination thereof, without the express written consent of Landlord, such tenancy shall be deemed to be a tenancy at sufferance only and shall not constitute a renewal hereof or an extension for any further term. In either case, Base Rent shall be payable at a daily rate equal to (i) one hundred fifty percent (150%) of the Base Rent applicable during the last rental period of the Lease Term for the first (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) two (2) months of such holdover, and (ii) two hundred percent (200%) thereafter plus one hundred percent (100%) of all Additional Rent. Such month-to-month tenancy or tenancy by sufferance, as the case may be, shall be subject to every other applicable term, covenant and agreement contained herein. Nothing contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 16</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall be construed as consent by Landlord to any holding over by Tenant, and Landlord expressly reserves the right to require Tenant to surrender possession of the Premises to Landlord as provided in this Lease upon the expiration or other termination of this Lease. The provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 16</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall not be deemed to limit or constitute a waiver of any other rights or remedies of Landlord provided herein or at law. If Tenant fails to surrender the Premises upon the termination or expiration of this Lease, in addition to any other liabilities to Landlord accruing therefrom, Tenant shall protect, defend, indemnify and hold Landlord harmless from all loss, costs (including reasonable attorneys&#x2019; fees) and liability resulting from such failure, including, without limiting the generality of the foregoing, any claims made by any succeeding tenant founded upon such failure to surrender and/or any lost profits and consequential or indirect damages to Landlord resulting therefrom. Tenant agrees that any proceedings necessary to recover possession of the Premises, whether before or after expiration of the Lease Term, shall be considered an action to enforce the terms of this Lease for purposes of the awarding of any attorney&#x2019;s fees in connection therewith.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">17. ESTOPPEL CERTIFICATES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within ten (10) business days following a request in writing by Landlord, Tenant shall execute, acknowledge and deliver to Landlord an estoppel certificate, which, as submitted by Landlord, shall be substantially in the form of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 17</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">attached hereto (or such other commercially reasonable form as may be reasonably required by any prospective mortgagee or purchaser of the Project, or any portion thereof), indicating therein any exceptions thereto that may exist at that time, and shall also contain any other information reasonably requested by Landlord or Landlord&#x2019;s mortgagee or prospective mortgagee. Any such certificate may be relied upon by any prospective mortgagee or purchaser of all or any portion of the Project. Tenant shall execute and deliver whatever other commercially reasonable instruments may be reasonably required for such purposes. Failure of Tenant to timely execute, acknowledge and deliver such estoppel certificate or other instruments shall constitute an acceptance of the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Premises and an acknowledgment by Tenant that statements included in the estoppel certificate are true and correct, without exception. At any time during the Lease Term (but not more than twice per year, provided Tenant is not in default hereunder beyond applicable notice and cure periods), but only in the case of (i) a default of Tenant hereunder, (ii) a proposed sale or refinancing of the Project, or (iii) a proposed Permitted Transfer by Tenant, Landlord may require Tenant to provide Landlord with a current financial statement and financial statements of the two (2) years prior to the current financial statement year. Such statements shall be prepared in accordance with generally accepted accounting principles and, if such is the normal practice of Tenant, shall be audited by an independent certified public accountant. If no audited financial statement is prepared, such statement will be certified by the CFO or Treasurer of Tenant. Notwithstanding anything to the contrary contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 17</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, if Tenant is publicly traded on a nationally recognized stock exchange, Tenant will not be required to deliver to Landlord financial statements as and when those documents are publicly available.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18. SUBORDINATION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Lease shall be subject and subordinate to all future ground or underlying leases of the Building or Project and to the lien of any mortgage, trust deed or other encumbrances now or hereafter in force against the Building or Project or any part thereof, if any, and to all renewals, extensions, modifications, consolidations and replacements thereof, and to all advances made or hereafter to be made upon the security of such mortgages or trust deeds, unless the holders of such mortgages, trust deeds or other encumbrances, or the lessors under such ground lease or underlying leases require in writing that this Lease be superior thereto; provided that, for so long as Tenant is not in default hereunder, Tenant&#x2019;s occupancy of the Premises shall not be disturbed. Tenant covenants and agrees that in the event any proceedings are brought for the foreclosure of any such mortgage or deed in lieu thereof (or if any ground lease is terminated), to attorn, without any deductions or set-offs whatsoever, to the lienholder or purchaser or any successors thereto upon any such foreclosure sale or deed in lieu thereof (or to the ground lessor), if so requested to do so by such purchaser or lienholder or ground lessor; provided that, for so long as Tenant is not in default hereunder, Tenant&#x2019;s occupancy of the Premises shall not be disturbed. Notwithstanding any other provision of this Lease to the contrary, no holder of any such mortgage, trustee deed or other encumbrance and no such ground lessor, shall be obligated to perform or liable in damages for failure to perform any of Landlord&#x2019;s obligations under this Lease unless and until such holder shall foreclose such mortgage, trust deed or other encumbrance, or the lessors under such ground lease or underlying leases otherwise acquire title to the Property, and then shall only be liable for Landlord&#x2019;s obligations arising or accruing after such foreclosure or acquisition of title, provided the foregoing shall not release any such holder or ground lessor from performing ongoing obligations of Landlord from and after the date of such foreclosure or acquisition of title, such as repair and maintenance obligations. No such holder shall ever be obligated to perform or be liable in damages for any of Landlord&#x2019;s obligations arising or accruing before such foreclosure or acquisition of title. Tenant shall, within ten (10) business days of request by Landlord, execute a commercially reasonable subordination, non-disturbance and attornment agreement as Landlord may reasonably deem necessary to evidence or confirm the subordination or superiority of this Lease to any such mortgages, trust deeds, ground leases or underlying leases. Tenant waives the provisions of any current or future statute, rule or law which may give or purport to give Tenant any right or election to terminate or otherwise adversely affect this Lease and the obligations of Tenant hereunder in the event of any foreclosure proceeding or sale.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s interest herein may be assigned as security at any time to any Mortgagee. Notwithstanding the foregoing or anything to the contrary herein, no Mortgagee succeeding to the interest of Landlord hereunder shall be (i) liable in any way to Tenant for any act or omission, neglect or default on the part of Landlord under this Lease, (ii) responsible for any monies owing by or on deposit with Landlord to the credit of Tenant (except to the extent any such deposit is actually received by such mortgagee or ground lessor), (iii) subject to any counterclaim or setoff which theretofore accrued to Tenant against Landlord, (iv) bound by any amendment or modification of this Lease subsequent to such mortgage, or by any previous prepayment of Rent for more than one (1) month, which was not approved in writing by the Mortgagee, (v) liable beyond such Mortgagee&#x2019;s interest in the Project, or (vi) responsible for the payment or performance of any work to be done by Landlord under this Lease to render the Premises ready for occupancy by Tenant or for the payment of any tenant improvements allowances. Nothing in clause (i), above, shall be deemed to relieve any Mortgagee succeeding to the interest of Landlord hereunder of its obligation to comply with the obligations of Landlord under this Lease from and after the date of such succession.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No Mortgagee shall, either by virtue of the Mortgage or any assignment of leases executed by Landlord for the benefit of such Mortgagee, be or become a mortgagee in possession or be or become subject to any liability or obligation under the Lease or otherwise until such Mortgagee shall have acquired the interest of Landlord in the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property, by foreclosure or otherwise, or in fact have taken possession of the Property as a mortgagee in possession and then such liability or obligation of Mortgagee under the Lease shall extend only to those liability or obligations accruing subsequent to the date that such Mortgagee has acquired the interest of Landlord in the Premises, or in fact taken possession of the Property as a mortgagee in possession.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">19. DEFAULTS; REMEDIES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Events of Default</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The occurrence of any of the following shall constitute a default of this Lease by Tenant:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.1.1 Any failure by Tenant to pay any Rent or any other charge required to be paid under this Lease, or any part thereof, when due and such failure shall continue for five (5) days after written notice of such failure is given to Tenant; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.1.2 Except where a specific time period is otherwise set forth for Tenant&#x2019;s performance in this Lease, in which event the failure to perform by Tenant within such time period shall be a default by Tenant under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 19.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, any failure by Tenant to observe or perform any other provision, covenant or condition of this Lease to be observed or performed by Tenant where such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant; provided that if the nature of such default is such that the same cannot reasonably be cured within a thirty (30) day period, Tenant shall not be deemed to be in default if it diligently commences such cure within such period and thereafter diligently proceeds to rectify and cure such default; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.1.3 Abandonment of the Premises by Tenant pursuant to California Civil Code Section 1951.3; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.1.4 The failure by Tenant to observe or perform according to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Articles 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">17</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">18</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease where such failure continues for more than two (2) business days after written notice from Landlord; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.1.5 If a receiver, guardian, conservator, trustee in bankruptcy or similar officer shall be appointed by a court of competent jurisdiction to take charge of all or any part of Tenant&#x2019;s or any guarantor&#x2019;s property and such appointment is not discharged within ninety (90) days thereafter or if a petition including, without limitation, a petition for reorganization or arrangement is filed by Tenant or any guarantor under any bankruptcy law or is filed against Tenant or any guarantor and, in the case of a filing against Tenant only, the same shall not be dismissed within ninety (90) days from the date upon which it is filed.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The notice periods provided herein are in lieu of, and not in addition to, any notice periods provided by law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Remedies Upon Default</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon the occurrence of any event of default by Tenant beyond applicable notice and cure periods, Landlord shall have, in addition to any other remedies available to Landlord at law or in equity (all of which remedies shall be distinct, separate and cumulative), the option to pursue any one or more of the following remedies, each and all of which shall be cumulative and nonexclusive, without any notice or demand whatsoever. Tenant hereby waives, for Tenant and for all those claiming under Tenant, any and all rights now or hereafter existing to redeem by order or judgment of any court or by any legal process or writ, Tenant&#x2019;s right of occupancy of the Premises after any termination of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.2.1 Terminate this Lease (pursuant to Section 1951.2 of the California Civil Code), in which event Tenant shall, upon written notice, immediately surrender the Premises to Landlord, and if Tenant fails to do so, Landlord may, without prejudice to any other remedy which it may have for possession or arrearages in rent, enter upon and take possession of the Premises and expel or remove Tenant and any other person who may be occupying the Premises or any part thereof, without being liable for prosecution or any claim or damages therefor; and Landlord may recover from Tenant the following:</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) The worth at the time of award of the unpaid rent which has been earned at the time of such termination; plus</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) The worth at the time of award of the amount by which the unpaid rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iii) The worth at the time of award of the amount by which the unpaid rent for the balance of the Lease Term after the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iv) Any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&#x2019;s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, specifically including but not limited to, brokerage commissions and advertising expenses incurred, expenses of remodeling the Premises or any portion thereof for a new tenant, whether for the same or a different use, and any special concessions made to obtain a new tenant (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Costs of Reletting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;); notwithstanding the above, if Landlord relets the Premises for a term (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Relet Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) that extends past the originally scheduled Lease Expiration Date, the Costs of Reletting which may be included in Landlord&#x2019;s damages shall be limited to a prorated portion of the Costs of Reletting, based on the percentage that the length of the originally scheduled Lease Term remaining on the date Landlord terminates this Lease or Tenant&#x2019;s right to possession bears to the length of the Relet Term. For example, if there are two (2) years left on the Lease Term at the time that Landlord terminates possession and, prior to the expiration of the two (2) year period, Landlord enters into a lease with a new tenant with a Relet Term of ten (10) years, then only twenty percent (20%) of the Costs of Reletting shall be included when determining Landlord&#x2019;s damages; and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(v) At Landlord&#x2019;s election, such other amounts in addition to or in lieu of the foregoing as may be permitted from time to time by applicable law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; as used in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 19.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall be deemed to be and to mean all sums of every nature required to be paid by Tenant pursuant to the terms of this Lease, whether to Landlord or to others. As used in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Sections</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">19.2.1(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, above, the &#x201c;worth at the time of award&#x201d; shall be computed by allowing interest at the rate set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 25</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, but in no case greater than the maximum amount of such interest permitted by law. As used in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 19.2.1(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">worth at the time of award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall be computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.2.2 Landlord shall have the remedy described in California Civil Code Section 1951.4 (lessor may continue lease in effect after lessee&#x2019;s breach and abandonment and recover rent as it becomes due, if lessee has the right to sublet or assign, subject only to reasonable limitations). Accordingly, if Landlord does not elect to terminate this Lease on account of any default by Tenant, Landlord may, from time to time, without terminating this Lease, enforce all of its rights and remedies under this Lease, including the right to recover all rent as it becomes due.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.2.3 Landlord shall at all times have the rights and remedies (which shall be cumulative with each other and cumulative and in addition to those rights and remedies available under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 19.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or any law or other provision of this Lease), without prior demand or notice except as required by Applicable Law, to seek any declaratory, injunctive or other equitable relief, and specifically enforce this Lease, or restrain or enjoin a violation or breach of any provision hereof. The provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 19.2.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> are not dependent upon the occurrence of a default.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.2.4 Any obligation imposed by law upon Landlord to relet the Premises after any termination of the Lease shall be subject to the reasonable requirements of Landlord to lease to high quality tenants on such terms as Landlord may from time to time deem appropriate and to develop the Building in a harmonious manner with an appropriate mix of uses, tenants, floor areas and terms of tenancies, and the like, and Landlord shall not be obligated to relet the Premises to any party to whom Landlord or its affiliate may desire to lease other available space in the Building.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.2.5 Nothing herein shall limit or prejudice the right of Landlord to prove and obtain in a proceeding for bankruptcy, insolvency, arrangement or reorganization, by reason of the termination, an amount equal to the maximum allowed by a statute of law in effect at the time when, and governing the proceedings in which, the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">damages are to be proved, whether or not the amount is greater to, equal to, or less than the amount of the loss or damage which Landlord has suffered.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Subleases of Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Whether or not Landlord elects to terminate this Lease on account of any events of default by Tenant, as set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 19</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, Landlord shall have the right to terminate any and all subleases, licenses, concessions or other consensual arrangements for possession entered into by Tenant and affecting the Premises or may, in Landlord&#x2019;s sole discretion, succeed to Tenant&#x2019;s interest in such subleases, licenses, concessions or arrangements. In the event of Landlord&#x2019;s election to succeed to Tenant&#x2019;s interest in any such subleases, licenses, concessions or arrangements, Tenant shall, as of the date of notice by Landlord of such election, have no further right to or interest in the rent or other consideration receivable thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Efforts to Relet</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No re-entry or repossession, repairs, maintenance, changes, alterations and additions, reletting, appointment of a receiver to protect Landlord&#x2019;s interests hereunder, or any other action or omission by Landlord shall be construed as an election by Landlord to terminate this Lease or Tenant&#x2019;s right to possession, or to accept a surrender of the Premises, nor shall same operate to release Tenant in whole or in part from any of Tenant&#x2019;s obligations hereunder, unless express written notice of such intention is sent by Landlord to Tenant. Tenant hereby irrevocably waives any right otherwise available under any law to redeem or reinstate this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord Default</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.5.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything to the contrary set forth in this Lease, Landlord shall not be in default in the performance of any obligation required to be performed by Landlord pursuant to this Lease unless Landlord fails to perform such obligation within thirty (30) days after the receipt of notice from Tenant specifying in detail Landlord&#x2019;s failure to perform; provided, however, if the nature of Landlord&#x2019;s obligation is such that more than thirty (30) days are required for its performance, then Landlord shall not be in default under this Lease if it shall commence such performance within such thirty (30) day period and thereafter diligently pursue the same to completion. Upon any such default by Landlord under this Lease, Tenant may, except as otherwise specifically provided in this Lease to the contrary, exercise any of its rights provided at law or in equity.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">20. COVENANT OF QUIET ENJOYMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord covenants that Tenant, on paying the Rent, charges for services and other payments herein reserved and on keeping, observing and performing all the other terms, covenants, conditions, provisions and agreements herein contained on the part of Tenant to be kept, observed and performed, shall, during the Lease Term, peaceably and quietly have, hold and enjoy the Premises subject to the terms, covenants, conditions, provisions and agreements hereof without interference by any persons lawfully claiming by or through Landlord. The foregoing covenant is in lieu of any other covenant express or implied.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">21. SECURITY DEPOSIT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Delivery of Letter of Credit.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrently with Tenant&#x2019;s execution of this Lease, Tenant shall deposit with Landlord an unconditional, clean, irrevocable negotiable letter of credit (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">L/C Security</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) in the amount set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary as security for the faithful performance by Tenant of all of its obligations under this Lease as follows:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) Tenant shall provide Landlord and maintain in full force and effect throughout the Term and until the date that is ninety (90) days after the Lease Expiration Date, an evergreen letter of credit substantially in the form of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 21.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issued by an issuer reasonably satisfactory to Landlord, in the amount set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary. Silicon Valley Bank is hereby approved as an issuer of the L/C Security. If at any time during the Term (i) the financial condition of such issuer is reduced below a long term issuer credit rating from Standard and Poor&#x2019;s Professional Rating Service of BBB+ or a comparable rating from Moody&#x2019;s Professional Rating Service or Landlord determines in its sole reasonable discretion that the financial condition of issuer has changed in any materially adverse way from the financial condition of such issuer as of the date of execution of this Lease (any of the foregoing, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bank Credit Threat</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) including, without limitation, if such issuer is declared insolvent or is placed into receivership or conservatorship by the Federal Deposit Insurance Corporation, or any successor or similar entity, if a trustee, receiver or liquidator is appointed for such issuer, if the credit rating of the long-term debt of the issuer of the letter of credit (according to Moody&#x2019;s, Standard &amp; Poor&#x2019;s or similar national rating agency reasonably identified</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">by Landlord) is downgraded to a grade below investment grade, if the issuer enters into any supervisory agreement with any governmental authority or fails to meet any capital requirements imposed by applicable law, Landlord may require the L/C Security to be replaced by an L/C Security issued by a different issuer, in which event Tenant shall, within fifteen (15) business days after written notice from Landlord, deliver to Landlord a replacement L/C Security issued by a commercial bank or savings and loan association acceptable to Landlord in its sole reasonable discretion and that meets all other requirements of this Article. If Tenant has actual notice, or Landlord notifies Tenant at any time, that any issuer of the L/C Security has become insolvent or placed into FDIC receivership, then Tenant shall promptly deliver to Landlord (without the requirement of further notice from Landlord) substitute L/C Security issued by a commercial bank or savings and loan association acceptable to Landlord in its reasonable discretion and that meets all other requirements of this Article. As used herein with respect to the issuer of the L/C Security, &#x201c;insolvent&#x201d; shall mean the determination of insolvency as made by such issuer&#x2019;s primary bank regulator (i.e., the state bank supervisor for state-chartered banks; the OCC or OTS, respectively, for federally chartered banks or thrifts; or the Federal Reserve for its member banks).</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) Landlord may draw upon the L/C Security, and hold and apply the proceeds for the payment of any Rent or any other sum in default, or to compensate Landlord for any other loss or damage that Landlord may suffer by reason of Tenant&#x2019;s default, if: (i) a default beyond applicable notice and cure periods exists (or would have existed with the giving of notice and passage of applicable cure periods, but only if transmittal of a default notice is stayed or barred by applicable bankruptcy or other similar law); (ii) as of the date sixty (60) days before any L/C Security expires Tenant has not delivered to Landlord an amendment or replacement for such L/C Security, reasonably satisfactory to Landlord, extending the expiry date to the date that is ninety (90) days after the then-current Lease Expiration Date; (iii) Tenant fails to pay any bank charges for Landlord&#x2019;s transfer of the L/C Security when due; (iv) the issuer of the L/C Security ceases, or announces that it will cease, to maintain an office in the city where Landlord may present drafts under the L/C Security (and fails to permit drawing upon the L/C Security by overnight courier or facsimile); (v) Tenant has filed a voluntary petition under the U.S. Bankruptcy Code or any state bankruptcy code (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bankruptcy Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;); or (vi) a Bank Credit Threat or Receivership (as such Term is defined in Section below) has occurred and Tenant has failed to comply with the requirements of either Section above or below, as applicable. This Section does not limit any other provisions of this Lease allowing Landlord to draw the L/C Security under specified circumstances. The use, application or retention of the L/C Security, or any portion thereof, by Landlord shall not prevent Landlord from exercising any other right or remedy provided by this Lease or by any Applicable Law, it being intended that Landlord shall not first be required to proceed against the L/C Security and shall not operate as a limitation on any recovery to which Landlord may otherwise be entitled. Tenant agrees not to interfere in any way with payment to Landlord of the proceeds of the L/C Security, either prior to or following a &#x201c;draw&#x201d; by Landlord of any portion of the L/C Security, regardless of whether any dispute exists between Tenant and Landlord as to Landlord&#x2019;s right to draw upon the L/C Security. No condition or term of this Lease shall be deemed to render the L/C Security conditional to justify the issuer of the L/C Security in failing to honor a drawing upon such L/C Security in a timely manner. Tenant agrees and acknowledges that (i) the L/C Security constitutes a separate and independent contract between Landlord and the issuer, (ii) Tenant is not a third party beneficiary of such contract, (iii) Tenant has no property interest whatsoever in the L/C Security or the proceeds thereof, and (iv) in the event Tenant becomes a debtor under any chapter of the Bankruptcy Code, neither Tenant, any trustee, nor Tenant&#x2019;s bankruptcy estate shall have any right to restrict or limit Landlord&#x2019;s claim and/or rights to the L/C Security and/or the proceeds thereof by application of Section 502(b)(6) of the U. S. Bankruptcy Code or otherwise. In the event of any such draw upon the L/C Security, Tenant shall within fifteen (15) business days thereafter provide Landlord with a replacement letter of credit, or amendment to the existing letter of credit increasing the amount of such letter of credit, in the amount of L/C Security, and in the form, required hereunder, and Tenant&#x2019;s failure to do so shall be a material breach of this Lease.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) If Landlord transfers its interest in the Premises, then Landlord shall transfer the L/C Security to the transferee of its interest and notify Tenant of such transfer, and Tenant shall at Tenant&#x2019;s expense, within fifteen (15) business days after receiving a request from Landlord, deliver (and, if the issuer requires, Landlord shall consent to) an amendment to the L/C Security naming Landlord&#x2019;s grantee as substitute beneficiary. If the required Security Deposit changes while L/C Security is in force, then Tenant shall deliver (and, if the issuer requires, Landlord shall consent to) a corresponding amendment to the L/C Security.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) If and to the extent Landlord is holding the proceeds of the L/C Security in cash from time to time, such cash shall be held by Landlord as security for the faithful performance by Tenant of all of the terms,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">covenants and conditions of this Lease to be kept and performed by Tenant during the period commencing on the Execution Date and ending upon the expiration or termination of Tenant&#x2019;s obligations under this Lease. If Tenant defaults (beyond applicable notice and cure periods) with respect to any provision of this Lease, including any provision relating to the payment of Rent, then Landlord may (but shall not be required to) use, apply or retain all or any part of the Security Deposit for the payment of any Rent or any other sum in default, or to compensate Landlord for any other loss or damage that Landlord may suffer by reason of Tenant&#x2019;s default as provided in this Lease. The provisions of this Article shall survive the expiration or earlier termination of this Lease. In the event of bankruptcy or other debtor-creditor proceedings against Tenant, any cash security then being held by Landlord shall be deemed to be applied first to the payment of Rent and other charges due Landlord for all periods prior to the filing of such proceedings. Landlord shall deliver or credit to any purchaser of Landlord&#x2019;s interest in the Premises the funds then held hereunder by Landlord, and thereupon (and upon confirmation by the transferee of such funds, whether expressly or by written assumption of this Lease, generally) Landlord shall be discharged from any further liability with respect to such funds. This provision shall also apply to any subsequent transfers. If Tenant shall fully and faithfully perform every provision of this Lease to be performed by it, then the cash security, if any, or any balance thereof, shall be returned to Tenant (or, at Landlord&#x2019;s option, to the last assignee of Tenant&#x2019;s interest hereunder) within ninety (90) days after the expiration or earlier termination of this Lease. If and to the extent the security held by Landlord hereunder shall be in cash, Landlord shall hold such cash in an account at a banking organization selected by Landlord; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, however, that Landlord shall not be required to maintain a separate account for the cash security but may intermingle it with other funds of Landlord. Landlord shall be entitled to all interest and/or dividends, if any, accruing on such cash security.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter of Credit not a Security Deposit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord and Tenant acknowledge and agree that in no event or circumstance shall the L/C Security, the &#x201c;security deposit&#x201d; (as that term is defined in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 21.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below), if applicable, or any renewal thereof or any proceeds thereof, be (i) deemed to be or treated as a &#x201c;security deposit&#x201d; within the meaning of California Civil Code Section 1950.7, (ii) subject to the terms of such Section 1950.7, or (iii) intended to serve as a &#x201c;security deposit&#x201d; within the meaning of such Section 1950.7. The parties hereto (A) recite that the L/C Security and the Security Deposit (if applicable) are not intended to serve as a security deposit and such Section 1950.7 and any and all other laws, rules and regulations applicable to security deposits in the commercial context (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Security Deposit Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall have no applicability or relevancy thereto and (B) waive any and all rights, duties and obligations either party may now or, in the future, will have relating to or arising from the Security Deposit Laws.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Proceeds of Draw</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the event Landlord draws down on the L/C Security pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">21.1(b)(ii) and (vi)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above, the proceeds of the L/C Security may be held by Landlord and applied by Landlord against any Rent payable by Tenant under this Lease that is not paid when due (subject to applicable notice and cure periods) and/or to pay for all losses and damages that Landlord has suffered or that Landlord reasonably estimates that it will suffer as a result of any breach or default by Tenant under this Lease. Any unused proceeds shall constitute the property of Landlord and need not be segregated from Landlord&#x2019;s other assets. Tenant hereby (i) agrees that (A) Tenant has no property interest whatsoever in the proceeds from any such draw, and (B) such proceeds shall not be deemed to be or treated as a &#x201c;security deposit&#x201d; under the Security Deposit Laws, and (ii) waives all rights, duties and obligations either party may now or, in the future, will have relating to or arising from the Security Deposit Laws. Landlord agrees that the amount of any proceeds of the L-C received by Landlord, and not (a) applied against any Rent payable by Tenant under this Lease that was not paid when due or (b) used to pay for any losses and/or damages suffered by Landlord (or reasonably estimated by Landlord that it will suffer) as a result of any breach or default by Tenant under this Lease (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unused L/C Proceeds</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), shall be paid by Landlord to Tenant (x) upon receipt by Landlord of a replacement L/C Security in the required amount, which replacement L/C Security shall comply in all respects with the requirements of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and (y) immediately after the LC Expiration Date; provided, however, that if prior to the LC Expiration Date a voluntary petition is filed by Tenant, or an involuntary petition is filed against Tenant by any of Tenant&#x2019;s creditors, under the Bankruptcy Code, then Landlord shall not be obligated to make such payment in the amount of the Unused L/C Proceeds until either all preference issues relating to payments under this Lease have been resolved in such bankruptcy or reorganization case or such bankruptcy or reorganization case has been dismissed.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Issuing Bank Placed Into Receivership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the event the issuer is placed into receivership or conservatorship (any such event, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Receivership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) by the Federal Deposit Insurance Corporation or any successor or similar entity (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FDIC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), then, effective as of the date such Receivership occurs, the L/C Security shall be deemed to not meet the requirements of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and, within ten (10) business days following Landlord&#x2019;s notice to Tenant of such Receivership, Tenant shall replace the L/C Security with a substitute L/C Security from a different</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issuer reasonably acceptable to Landlord and that complies in all respects with the requirements of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If Landlord draws upon the L/C Security due to solely Tenant&#x2019;s failure to provide a substitute L/C Security due to a Bank Credit Threat or Receivership, such failure shall not constitute a default hereunder and Tenant shall thereafter have the right to provide a substitute L/C Security that satisfies the requirements of this Lease, in which case, Landlord shall concurrently refund the proceeds of the draw or the Security Deposit, as applicable. In connection with the foregoing, Tenant shall not be entitled to any interest on the Security Deposit, and Landlord&#x2019;s use of the proceeds of the L/C Security shall be subject to the terms and conditions of the Lease pertaining to Landlord&#x2019;s right to use the proceeds of the L/C Security.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Reduction of L-C Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Provided that Tenant has not previously been in default beyond all applicable notice and cure periods within the twenty-four (24) months immediately prior to the effective date of the reduction request and further if Tenant is not in default at the time of such request, upon written request by Tenant given at any time after the first day of the forty-ninth (49th) full calendar month of the Lease Term, the L/C Security amount shall be reduced to $3,805,770.64. The reduction of the L/C Security amount shall be effectuated by Tenant&#x2019;s delivery to Landlord of a certificate of amendment to the existing L/C Security, conforming in all respects to the requirements of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, in the amount of the applicable reduced L/C Security amount. If Tenant is allowed to reduce the L/C Security amount pursuant to the terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 21.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, then Landlord shall reasonably cooperate with Tenant in order to effectuate such reduction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">22. INTENTIONALLY OMITTED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">23. SIGNS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Signage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall not install any signage (including, without limitation, any signs identifying Tenant&#x2019;s name or advertising Tenant&#x2019;s merchandise or otherwise) in or about the Premises that is visible from the exterior of the Premises or in any other part of the Project except as expressly permitted in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 23.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> Section 23.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> below. Subject to Landlord&#x2019;s prior written approval, in its reasonable discretion, and provided all signs are in keeping with the quality, design and style of the Building and Project, Tenant, at its sole cost and expense, may install one sign identifying Tenant at the entry to the Premises on each floor of the Premises, which identification signage shall be consistent with building standard signage as determined by Landlord. All permitted signs shall be maintained by Tenant at its expense in a first-class and safe condition and appearance. Upon the expiration or earlier termination of this Lease, Tenant shall remove all of its signs at Tenant&#x2019;s sole cost and expense. Tenant shall repair any damage to the Premises or Project, inside or outside, resulting from the erection, maintenance or removal of any signs. Tenant&#x2019;s signage must also comply with all Applicable Laws. All Building signage shall be subject to the existing rights of other tenants in the Building and any declaration of covenants for the Project.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Full Floors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to Landlord&#x2019;s prior written approval, in its reasonable discretion, and provided all signs are in keeping with the quality, design and style of the Buildings and Project, (a) to the extent that the Premises includes any full floor(s) of any Building, Tenant, at its sole cost and expense, may install identification signage anywhere on such floor(s), and (b) to the extent that the Premises includes any partial floor(s) of any Building, Tenant, at its sole cost and expense, may install Building standard identification signage in the elevator lobby and at the entrance to the Premises on such floor(s). Subject to Landlord&#x2019;s consent, Tenant will be entitled to Building-standard identification signage in the elevator lobby or lobbies serving the Premises as well as in any ground floor Building lobby directory. Tenant shall be solely responsible, at Tenant&#x2019;s sole cost and expense, for the installation and removal of such signage. Tenant&#x2019;s signage in any ground floor Building Lobby will be limited 9&#x201d; x 18&#x201d; and will be the monochromatic/black and white lettering or logo for Tenant. Additionally, with the prior written consent of Landlord, and in compliance with the provisions of this Lease, Tenant may, at Tenant&#x2019;s sole cost and expense, install customized branding signage in the elevator lobby on the eighth (8th), ninth (9th), tenth (10th), eleventh (11th) and/or twelfth (12th) floor of the North Tower, provided that Tenant will be obligated to remove any such signage and repair any damage caused by the installation and/or removal of such signage at the expiration or sooner termination of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Prohibited Signage and Other Items</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Any signs, notices, logos, pictures, names or advertisements which are installed and are visible from the exterior of the Premises or in any other part of the Project and that have not been separately approved by Landlord may be removed without notice by Landlord at the sole expense of Tenant. Tenant may not install any signs on the exterior or roof of the Project or the Common Areas. Any signs, displays, window coverings, window lettering, or blinds (even if the same are located behind the Landlord-approved window coverings for the Building), or other items or Alterations visible from the exterior of the Premises or Building, shall</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be subject to the prior approval of Landlord, in its sole discretion. Tenant shall not place or install any projections, antennae, aerials, or similar devices inside or outside of the Building, without the prior written approval of Landlord, subject to Tenant&#x2019;s rights pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 23.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exterior Building Signage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the Lease Term for so long as Tenant or a Permitted Assignee occupies at least seventy percent (70%) of the Premises, Landlord shall not allow any Competitor of Tenant to have exterior Building signage on the North Tower above eyebrow signage height. As used herein, &#x201c;Competitor of Tenant&#x201d; means (i) a life science company that primarily focuses on an immunological approach to developing pharmaceuticals for treating and preventing serious infectious diseases and (ii) is identified by Tenant as a competitor of Tenant on the list of competitors delivered by Tenant to Landlord from time to time and then in effect as between Landlord and Tenant as contemplated by this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 23.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. At any time following the execution and delivery of this Lease by Landlord and Tenant, Tenant may deliver to Landlord, in writing, an initial list of competitors containing no more than ten (10) companies, and such list will be valid (i.e., in full force and effect) for the ensuing twenty-four (24) months (which list of competitors, as updated from time to time in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 23.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, may be referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competitor List</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Thereafter, Tenant may update the initial Competitor List and any subsequently updated Competitor List every twenty-our (24) months during the Lease Term. If Tenant either fails to deliver to Landlord (i) an initial Competitor List, (ii) an update to the initial Competitor List after twenty-four (24) months have elapsed, or (ii) an update of the then most recently updated Competitor List after twenty-four (24) months have elapsed, then Landlord may give to Tenant written notice requesting Tenant deliver to Landlord either the initial Competitor List or an updated Competitor List, as applicable, and Tenant shall thereafter have ten (10) business days to deliver to Landlord a Competitor List identifying no more than ten (10) companies, and such Competitors List shall be valid for the ensuing twenty-four (24) months. If Tenant fails to deliver to Landlord an initial Competitor List, Landlord may give to Tenant a second written notice reminding Tenant of the need to provide an initial Competitor List and if Tenant fails to provide such an initial Competitor List, then Landlord shall not be subject to any prohibition relating to exterior Building signage on the North Tower for the ensuing twenty-four (24) months; if Tenant fails to deliver to Landlord an updated Competitor List within the time period for Tenant&#x2019;s response, then the previous Competitor List will continue to remain valid for an additional, ensuing twenty-four (24) months. Notwithstanding anything to the contrary contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 23.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, Landlord shall (i) be entitled to grant any retail tenants the rights to install their standard building sign package, including eyebrow signage, blade signage and store front signage, on or about their premises, (ii) be entitled to grant any tenants monument signage rights, and (iii) have no responsibility or liability for any exterior Building signage in any way attributable to Dropbox.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">24. COMPLIANCE WITH LAW</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">By Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall not do anything or suffer anything to be done by any Tenant Party in or about the Premises or the Project which will in any way conflict with any law, statute, ordinance or other federal, state or local governmental rule, regulation or requirement now in force or which may hereafter be enacted or promulgated (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Applicable Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). At its sole cost and expense, Tenant shall promptly comply with all such Applicable Laws which relate to (i) Tenant&#x2019;s use of the Premises, (ii) any Alterations made by Tenant to the Premises or the Tenant Improvements, or (iii) the Base Building, but as to the Base Building, only to the extent such obligations are triggered by Alterations or Tenant Improvements to the extent such Alterations are not normal and customary business office improvements in Comparable Buildings, or triggered by the Tenant Improvements to the extent such Tenant Improvements ae not normal and customary business office improvements, or triggered by Tenant&#x2019;s particular use of the Premises and Project as opposed to customary business office use. Tenant shall not, however, be responsible for the cost of complying with Applicable Laws to the extent that any such compliance is required as a result of the Base Building failing to comply with Applicable Laws in effect as of date the Building was substantially completed (i.e., 2018). Notwithstanding the foregoing terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 24</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to the contrary, Tenant may defer such compliance with Applicable Laws while Tenant contests, in a court of proper jurisdiction, in good faith, the applicability of such Applicable Laws to the Premises or Tenant&#x2019;s specific use or occupancy of the Premises; provided, however, Tenant may only defer such compliance if such deferral shall not (a) prohibit Tenant from obtaining or maintaining a certificate of occupancy for the Premises, (b) prohibit Landlord from obtaining or maintaining a certificate of occupancy for the Building or any portion thereof, (c) unreasonably and materially affect the safety of the employees and/or invitees of Landlord or of any tenant in the Building (including Tenant), (d) create a significant health hazard for the employees and/or invitees of Landlord or of any tenant in the Building (including Tenant), (e) otherwise materially and adversely affect Tenant&#x2019;s use of or access to the Buildings or the Premises, or (f) impose material obligations, liability, fines, or penalties upon Landlord or any other tenant of the Building, or would materially and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adversely affect the use of or access to the Building by Landlord or other tenants or invitees of the Building. The judgment of any court of competent jurisdiction or the admission of Tenant in any judicial action, regardless of whether Landlord is a party thereto, that Tenant has violated any of said governmental measures, shall be conclusive of that fact as between Landlord and Tenant. Landlord shall comply with all Applicable Laws relating to the Common Areas of the Building, provided that compliance with such Applicable Laws is not the responsibility of Tenant under this Lease, and provided further that Landlord&#x2019;s failure to comply therewith would prohibit Tenant from obtaining or maintaining a certificate of occupancy for the Premises, or would unreasonably and materially affect the safety of Tenant&#x2019;s employees or create a significant health hazard for Tenant&#x2019;s employees, or would otherwise materially and adversely affect Tenant&#x2019;s use of or access to the Premises. Landlord shall be permitted to include in Operating Expenses any costs or expenses incurred by Landlord under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 24</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to the extent not prohibited by the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.2.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">By Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except as provided in the Tenant Work Letter, to the extent required in order for Tenant to obtain a Certificate of Occupancy to legally occupy the Premises for normal and customary office use, assuming normal and customary office occupancy density, or to the extent required in order for Tenant to pull a construction permit or to otherwise comply with the requirements of the applicable permitting authority, Landlord (rather than Tenant) shall comply with all Applicable Laws relating to the Base Building and Common Areas, except to the extent such compliance is triggered by (a) Tenant&#x2019;s particular use of the Premises for other than normal and customary business office use or (b) Tenant&#x2019;s construction of Alterations or Improvements in the Premises that are not normal and customary office improvements for Comparable Buildings in which case compliance with such Applicable Laws shall be the responsibility of Tenant under this Lease. Landlord shall be permitted to include in Operating Expenses any costs or expenses incurred by Landlord under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 24</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to the extent not prohibited by the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certified Access Specialist</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. For purposes of Section 1938 of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that neither the Premises, the Building nor the Common Areas have undergone inspection by a Certified Access Specialist (CASp). Pursuant to California Civil Code Section 1938, Tenant is hereby notified as follows: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x201c;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of any CASp inspection, the payment of the fee for the CASp inspection and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Tenant requests to perform a CASp inspection of the Premises, Tenant shall, at its cost, retain a CASp approved by Landlord (provided that Landlord may designate the CASp, at Landlord&#x2019;s option) to perform the inspection of the Premises at a time agreed upon by the parties. Tenant shall provide Landlord with a copy of any report or certificate issued by the CASp (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CASp Report</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Landlord and Tenant agree that any modifications necessary to correct violations of construction-related accessibility standards identified in the CASp Report shall be the responsibility of Tenant. Tenant agrees to keep the information in the CASp Report confidential except as necessary for the Tenant to complete such modifications.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Underlying Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall comply with all easements, licenses, operating agreements, declarations, restrictive covenants, or instruments pertaining to the sharing of costs by Landlord with respect to the Project, including, without limitation, any covenants, conditions and restrictions affecting the Project, and reciprocal easement agreements affecting the Project, any parking licenses, and any agreements with transit agencies affecting the Project (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Underlying Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), including, without limitation, (i) that certain Amended and Restated Declaration and Agreement of Covenants, Conditions and Restrictions for the UCSF Mission Bay Campus recorded July 19, 1999 in the Official Records as Instrument No. 99&not;G622193-00, (ii) that certain Master Declaration of Covenants, Conditions, Restrictions and Reservation of Easements for Mission Bay Commercial, recorded January 16, 2001 in the Official Records as Instrument No. 2001-G889923-00, (iii) that certain Mission Bay South Owner Participation Agreement between the Redevelopment Agency of the City and County of San Francisco (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Redevelopment Agency</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and Catellus Development Corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CDC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) recorded December 3, 1998 in the Official Records as Instrument No. 98-G477258-00 (as amended, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">OPA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), (iv) that certain Redevelopment Plan for the Mission Bay South Redevelopment Project recorded November 18, 1998 in the Official Records as Instrument</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No. 98-G470337-00 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Redevelopment Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and (v) that certain Mission Bay South Redevelopment Plan Area Declaration of Restrictions recorded December 3, 1998 in the Official Records as Instrument No. 98-G477250-00. Additionally, Tenant acknowledges that the Project may be subject to future Underlying Documents, which Landlord, in Landlord&#x2019;s discretion, deems reasonably necessary or desirable, and Tenant agrees that this Lease shall be subject and subordinate to such Underlying Documents and Tenant shall promptly execute and acknowledge, within fifteen (15) business days of a request by Landlord, a &#x201c;Recognition of Covenants, Conditions, and Restrictions,&#x201d; in a form substantially similar to that attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 24.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">agreeing to and acknowledging the applicable Underlying Document.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">25. LATE CHARGES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any installment of Rent or any other sum due from Tenant shall not be received by Landlord or Landlord&#x2019;s designee within five (5) business days after the date due, then Tenant shall pay to Landlord a late charge equal to five percent (5%) of the overdue amount plus any reasonable attorneys&#x2019; fees incurred by Landlord by reason of Tenant&#x2019;s failure to pay Rent and/or other charges when due hereunder. Notwithstanding the foregoing, Landlord shall not charge Tenant a late charge for the first (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) late payment in any twelve (12) month period unless Tenant fails to timely pay such amount within five (5) business days following notice from Landlord that such amount is past due. The late charge shall be deemed Additional Rent and the right to require it shall be in addition to all of Landlord&#x2019;s other rights and remedies hereunder or at law and shall not be construed as liquidated damages or as limiting Landlord&#x2019;s remedies in any manner. In addition to the late charge described above, any Rent or other amounts owing hereunder which are not paid within ten (10) days after the date they are due shall bear interest from the date when due until paid at a rate per annum equal to the lesser of (i) the annual &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bank Prime Loan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; rate cited in the Federal Reserve Statistical Release Publication H.15, published on the first Tuesday of each calendar month (or such other comparable index as Landlord and Tenant shall reasonably agree upon if such rate ceases to be published) plus four (4) percentage points, and (ii) the highest rate permitted by Applicable Law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">26. LANDLORD&#x2019;S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Cure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All covenants and agreements to be kept or performed by Tenant under this Lease shall be performed by Tenant at Tenant&#x2019;s sole cost and expense and without any reduction of Rent, except to the extent, if any, otherwise expressly provided herein. If Tenant shall fail to perform any obligation under this Lease, and such failure shall continue in excess of the time allowed under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 19.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above, unless a specific time period is otherwise stated in this Lease, Landlord may, but shall not be obligated to, make any such payment or perform any such act on Tenant&#x2019;s part without waiving its rights based upon any default of Tenant and without releasing Tenant from any obligations hereunder. Except as may be specifically provided to the contrary in this Lease, Tenant shall pay to Landlord, within five (5) days after delivery by Landlord to Tenant of statements therefor: (i) sums equal to expenditures reasonably made and obligations incurred by Landlord in connection with the remedying by Landlord of Tenant&#x2019;s defaults pursuant to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 26.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; (ii) sums equal to all losses, costs, liabilities, damages and expenses referred to in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease; and (iii) sums equal to all expenditures made and obligations incurred by Landlord in collecting or attempting to collect the Rent or in enforcing or attempting to enforce any rights of Landlord under this Lease or pursuant to law, including, without limitation, all reasonable legal fees and other amounts so expended. Tenant&#x2019;s obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 26.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall survive the expiration or sooner termination of the Lease Term.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">27. PROJECT CONTROL BY LANDLORD; ENTRY BY LANDLORD</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Project Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord reserves full control over the Building and the Project to the extent not inconsistent with Tenant&#x2019;s enjoyment of the Premises as provided by this Lease. This reservation includes Landlord&#x2019;s right to subdivide the Project; convert the Building or Project to condominium units; change the size of the Project by selling all or a portion of the Project or adding real property and any improvements thereon to the Project; grant assessments and licenses to third parties; maintain or establish ownership of the Building separate from fee title to the Property; make additions to or reconstruct portions of the Building and the Project; install, use, maintain, repair, replace and relocate for service to the Premises and other parts of the Building or the Project pipes, ducts, conduits, wires and appurtenant fixtures, wherever located in the Premises, the Building or elsewhere at the Project; and alter or relocate any other Common Area or facility, including private drives, lobbies and entrances. Landlord&#x2019;s right pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 27.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, including without limitation the rights to construct, maintain, relocate, alter, improve, or adjust the Building or the Project shall be subject to the condition that (i) the exercise of any of such rights shall</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not materially and adversely interfere with Tenant&#x2019;s use of the Premises or materially decrease the number of Tenant&#x2019;s parking spaces, (ii) Landlord shall provide reasonable prior notice to Tenant before exercising any such rights which may materially and adversely interfere with Tenant&#x2019;s use of the Premises, provided that such use of the Premises is in accordance with the Permitted Use, and (iii) Landlord shall use reasonable efforts to minimize to the extent possible any interference with Tenant&#x2019;s business, provided that such business is in accordance with the Permitted Use, including, when reasonable, scheduling such work after business hours or on weekends. Possession of areas of the Premises necessary for utilities, services, safety and operation of the Building is reserved to Landlord. Notwithstanding the foregoing, Landlord shall provide Tenant reasonable prior notice of required access to the Premises for such activities.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Entry by Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord reserves the right at all reasonable times and upon not less than three (3) days&#x2019; prior notice to Tenant (except in the case of an emergency or with respect to regularly scheduled services) to enter the Premises to (i) inspect them; (ii) show the Premises to prospective purchasers, or to current or prospective mortgagees, ground or underlying lessors or insurers or, during the last nine (9) months of the Lease Term, to prospective tenants; (iii) post notices of non-responsibility (to the extent applicable pursuant to then Applicable Law); or (iv) alter, improve or repair the Premises or the Building, or for structural alterations, repairs or improvements to the Building or the Building&#x2019;s systems and equipment.  Notwithstanding the foregoing, if Landlord desires to enter the Premises upon less than three (3) days&#x2019; notice, Tenant shall use good faith, diligent efforts to accommodate Landlord&#x2019;s entry upon such shorter notice. Tenant shall additionally have the right to require that Landlord be accompanied by a representative of Tenant during any such entry as an escort for Landlord&#x2019;s personnel so long as Tenant makes a representative available at commercially reasonable times; provided, however, any entry into the BSL 3 laboratory area shall be restricted to persons (i) with proper training as to Tenant&#x2019;s applicable safety and security protocols, (ii) appropriate personal protective equipment as reasonably required by Tenant, and (iii) accompanied by a representative of Tenant as an escort for such persons (which representative Tenant shall make available at all commercially reasonable times). Provided that Landlord employs commercially reasonable efforts to minimize interference with the conduct of Tenant&#x2019;s business in connection with entries into the Premises, Landlord may make any such entries without creating a default by Landlord and shall take such reasonable steps as required to accomplish the stated purposes. In making any such entry, Landlord shall use commercially reasonable efforts to follow, and cause third parties making entry at the request of Landlord to follow, Tenant&#x2019;s safety and security protocols of which Landlord has prior notice. In an emergency, Landlord shall have the right to use any means that Landlord may deem proper to open the doors in and to the Premises. Landlord also shall have the right at any time, without the same constituting an actual or constructive eviction and without incurring any liability to Tenant therefor, to change the arrangement or location of entrances or passageways, doors and doorways, and corridors, elevators, stairs, toilets, or other public parts of the Building and to change the name, address, number or designation by which the Premises is commonly known, provided any such change does not (A) unreasonably reduce, interfere with or deprive Tenant of access to the Premises nor compromise the safety and security protocols applicable to the laboratory areas within the Premises, or (B) reduce the rentable area (except by a </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">de minimis </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">amount) of the Premises. Any entry into the Premises by Landlord in the manner hereinbefore described shall not be deemed to be a forcible or unlawful entry into, or a detainer of, the Premises, or an actual or constructive eviction of Tenant from any portion of the Premises and the Base Rent (and any other item of Rent) shall under no circumstances abate while said repairs, alterations, improvements, additions or restorations are being made, by reason of loss or interruption of business of Tenant, or otherwise. If Tenant shall not be present when for any reason entry into the Premises shall be necessary or permissible, Landlord or Landlord&#x2019;s agents, representatives, contractors or employees may enter the same without rendering Landlord or such agents liable therefor if during such entry Landlord or Landlord&#x2019;s agents shall accord reasonable care under the circumstances to Tenant&#x2019;s Property, and without in any manner affecting this Lease. Tenant shall, at all times during the Term, be responsible for ensuring that Landlord has any and all keys, cards, codes or other means necessary to access the Premises.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">28. TENANT PARKING</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Parking Passes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the Lease Term Landlord shall provide Tenant with parking passes for use by standard size automobiles in an amount equal to the number of parking passes set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary, which parking passes shall pertain to the Project parking facility facilities (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Parking Facilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). All such parking shall be on a first-come, first-serve basis in common with others entitled to use the same. Tenant&#x2019;s continued right to use the parking passes is conditioned upon Tenant abiding by all rules and regulations which are prescribed from time to time for the orderly operation and use of the parking facility where the parking passes provide access (including</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any sticker or other identification system established by Landlord and the prohibition of vehicle repair and maintenance activities in the parking facilities), and Tenant shall cooperate in seeing that any Tenant Parties and Tenant visitors also comply with such rules and regulations. Tenant&#x2019;s use of the parking passes for parking at the Project shall be at Tenant&#x2019;s sole risk and Tenant acknowledges and agrees that Landlord shall have no liability whatsoever for damage to the vehicles of Tenant, its employees and/or visitors, or for other personal injury or property damage or theft relating to or connected with the parking rights granted herein or any of Tenant&#x2019;s, its employees&#x2019; and/or visitors&#x2019; use of the parking facilities. Landlord shall have the right to assign its obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">28</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to an affiliate of Landlord or a third-party parking manager or operator, in which case Tenant shall make any payments due under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 28</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> directly to such other entity.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Parking Pass Rates</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall pay to Landlord for Parking Passes on a monthly basis the monthly parking rate charged by Landlord, which monthly rate for Parking Passes (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Parking Rate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall initially be equal to, and during the Lease Term shall not be less than, $345.00 per Parking Pass per month (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Parking Rate Floor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Subject to the Parking Rate Floor, the Parking Rate shall be adjusted annually to be consistent with the prevailing monthly parking rate for similar parking spaces then being charged by landlords in Mission Bay. In addition, Tenant shall be responsible for the full amount of any taxes imposed by any governmental authority in connection with the renting of such Parking Passes by Tenant for the use of the Parking Facilities by Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Use of Parking Passes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall cooperate with Landlord to ensure that its employees comply with all reasonable rules and regulations which are prescribed from time to time for the orderly operation and use of the Parking Facilities, including any sticker or other identification system established by Landlord. Landlord specifically reserves the right to change the size, configuration, design, layout and all other aspects of the Parking Facilities at any time and Tenant acknowledges and agrees that Landlord may, without incurring any liability to Tenant and without any abatement of Rent under this Lease, from time to time, temporarily close-off or restrict access to the Parking Facilities for purposes of permitting or facilitating any such construction, alteration or improvements; provided, however, that Landlord will use reasonable efforts to provide Tenant with reasonable advance notice of any such anticipated temporary close-off or restriction in access to the Parking Facilities. Landlord may delegate its responsibilities hereunder to a parking operator in which case such parking operator shall have all the rights of control attributed hereby to the Landlord. The Parking Passes rented by Tenant pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 28</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> are provided to Tenant solely for use by Tenant&#x2019;s own personnel and such passes may not be transferred, assigned, subleased or otherwise alienated by Tenant, except in connection with a Transfer of the Premises pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, without Landlord&#x2019;s prior approval. Tenant may validate visitor parking by such method or methods as the Landlord may establish, at the validation rate from time to time generally applicable to visitor parking. Tenant&#x2019;s use of the Parking Facilities are on a non-exclusive basis.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Electrical Vehicle Charging</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. At least ten (10) electrical vehicle charging stations in the Parking Facilities shall be available for non-exclusive use by Tenant on a first-come, first-served basis.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Public Parking Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall have the right to permit use (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Public Parking Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) of the Parking Facilities by the general public (or for any other use). Landlord may accommodate the Public Parking Use through valet parking, tandem or stack parking, or any other parking program using parking personnel and/or systems and equipment; provided, however, in connection with the Public Parking Use, Landlord shall cooperate with Tenant to minimize interference with Tenant&#x2019;s use of the Parking Facilities, which may include developing a system to partially or totally segregate the areas designated for Public Parking Use in the Parking Facilities from the areas designated for use (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Project Parking Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) by Tenant, other tenants or occupants of the Project, visitors of the Project, transient parkers of the Project, and Landlord and its affiliates and service providers for the Project (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Project Related Parkers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). To account for the shared use of the Parking Facilities for the Public Parking Use and Project Parking Use, Landlord and Tenant agree that any incremental increase in (i) parking and security personnel costs and (ii) costs for parking access control equipment, which is directly attributable to the Public Parking Use shall be excluded from Operating Expenses.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Storage Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">29. MISCELLANEOUS PROVISIONS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Terms; Captions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The words &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; and &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; as used herein shall include the plural as well as the singular. The necessary grammatical changes required to make the provisions hereof apply either to corporations</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or partnerships or individuals, men or women, as the case may require, shall in all cases be assumed as though in each case fully expressed. The captions of Articles and Sections are for convenience only and shall not be deemed to limit, construe, affect or alter the meaning of such Articles and Sections.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Binding Effect</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to all other provisions of this Lease, each of the covenants, conditions and provisions of this Lease shall extend to and shall, as the case may require, bind or inure to the benefit not only of Landlord and of Tenant, but also of their respective heirs, personal representatives, successors or assigns, provided this clause shall not permit any assignment by Tenant contrary to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Air Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No rights to any view or to light or air over any property, whether belonging to Landlord or any other person, are granted to Tenant by this Lease. If at any time any windows of the Premises are temporarily darkened or the light or view therefrom is obstructed by reason of any repairs, improvements, maintenance or cleaning in or about the Project, the same shall be without liability to Landlord and without any reduction or diminution of Tenant&#x2019;s obligations under this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Modification of Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Should any current or prospective mortgagee or ground lessor for the Building or Project require a modification of this Lease, which modification will not cause an increased cost or expense to Tenant or in any other way materially and adversely change the rights and obligations of Tenant hereunder, then and in such event, Tenant agrees that this Lease may be so modified and agrees to execute whatever documents are reasonably required therefor and to deliver the same to Landlord within ten (10) business days following a request therefor.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transfer of Landlord&#x2019;s Interest</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant acknowledges that Landlord has the right to transfer all or any portion of its interest in the Project or Building and in this Lease, and Tenant agrees that in the event of any such transfer, Landlord shall automatically be released from all liability under this Lease accruing from and after the date of such transfer, and Tenant agrees to look solely to such transferee for the performance of Landlord&#x2019;s obligations hereunder after the date of transfer and such transferee shall be deemed to have fully assumed and be liable for all obligations of this Lease to be performed by Landlord and Tenant shall attorn to such transferee.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Prohibition Against Recording</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither this Lease, nor any memorandum thereof, affidavit or other writing with respect thereto, shall be recorded by Tenant or any one acting through, under or on behalf of Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.7 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Title</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord&#x2019;s title is and always shall be paramount to the title of Tenant. Nothing herein contained shall empower Tenant to do any act which can, shall or may encumber the title of Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.8 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Relationship of Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Nothing contained in this Lease shall be deemed or construed by the parties hereto or by any third party to create the relationship of principal and agent, partnership, joint venturer or any association between Landlord and Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.9 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Application of Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall have the right to apply payments received from Tenant pursuant to this Lease, regardless of Tenant&#x2019;s designation of such payments, to satisfy any obligations of Tenant hereunder, in such order and amounts as Landlord, in its sole discretion, may elect.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.10 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Time of Essence</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Time is of the essence with respect to the performance of every provision of this Lease in which time of performance is a factor.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.11 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Partial Invalidity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If any term, provision or condition contained in this Lease shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term, provision or condition to persons or circumstances other than those with respect to which it is invalid or unenforceable, shall not be affected thereby, and each and every other term, provision and condition of this Lease shall be valid and enforceable to the fullest extent possible permitted by law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.12 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Warranty</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In executing and delivering this Lease, Tenant has not relied on any representations, including, but not limited to, any representation as to the amount of any item comprising Additional Rent or the amount of the Additional Rent in the aggregate or that Landlord is furnishing the same services to other tenants, at all, on the same level or on the same basis, or any warranty or any statement of Landlord which is not expressly set forth herein.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.13 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord Exculpation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The liability of Landlord or the Landlord Parties to Tenant for any default by Landlord under this Lease or arising in connection herewith or with Landlord&#x2019;s operation, management, leasing, repair, renovation, alteration or any other matter relating to the Project or the Premises shall be limited solely and exclusively to an amount which is equal to the interest of Landlord in the Project. Neither Landlord, nor any of the Landlord Parties shall have any personal liability therefor, and Tenant hereby expressly waives and releases such personal liability on behalf of itself and all persons claiming by, through or under Tenant. The limitations of liability contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 29.13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall inure to the benefit of Landlord&#x2019;s and the Landlord Parties&#x2019; present and future partners, beneficiaries, officers, directors, trustees, shareholders, agents and employees, and their respective partners, heirs, successors and assigns. Under no circumstances shall any present or future partner of Landlord (if Landlord is a partnership), or trustee or beneficiary (if Landlord or any partner of Landlord is a trust), have any liability for the performance of Landlord&#x2019;s obligations under this Lease. Notwithstanding any contrary provision herein, neither Landlord nor the Landlord Parties shall be liable under any circumstances for consequential or indirect damages, including without limitation injury or damage to, or interference with, Tenant&#x2019;s business, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.14 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. It is understood and acknowledged that there are no oral agreements between the parties hereto affecting this Lease and this Lease constitutes the parties&#x2019; entire agreement with respect to the leasing of the Premises and supersedes and cancels any and all previous negotiations, arrangements, brochures, agreements and understandings, if any, between the parties hereto or displayed by Landlord to Tenant with respect to the subject matter thereof, and none thereof shall be used to interpret or construe this Lease. None of the terms, covenants, conditions or provisions of this Lease can be modified, deleted or added to except in writing signed by the parties hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.15 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">REIT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant acknowledges that the Company, an affiliate of Landlord, elects to be taxed as a real estate investment trust (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">REIT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) under the Code. Tenant hereby agrees to modifications of this Lease required to retain or clarify the Company&#x2019;s status as a REIT, provided such modifications: (a) are reasonable, (b) do not adversely affect in a material manner Tenant&#x2019;s use of the Premises as herein permitted, and (c) do not increase the Base Rent, Additional Rent and other sums to be paid by Tenant or Tenant&#x2019;s other obligations pursuant to this Lease, or reduce any rights of Tenant under this Lease, then Landlord may submit to Tenant an amendment to this Lease incorporating such required modifications, and Tenant shall execute, acknowledge and deliver such amendment to Landlord within ten (10) days after Tenant&#x2019;s receipt thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.16 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Right to Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord reserves the absolute right to effect such other tenancies in the Project as Landlord in the exercise of its sole business judgment shall determine to best promote the interests of the Building or Project. Tenant does not rely on the fact, nor does Landlord represent, that any specific tenant or type or number of tenants shall, during the Lease Term, occupy any space in the Building or Project.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.17 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Force Majeure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Any prevention, delay or stoppage due to strikes, lockouts, labor disputes, acts of God, acts of war, terrorist acts, governmental action or inaction, inability to obtain services, labor, or materials or reasonable substitutes therefor, governmental actions, civil commotions, fire or other casualty, and other causes beyond the reasonable control of the party obligated to perform, except with respect to the obligations imposed with regard to Rent and other charges to be paid by Tenant pursuant to this Lease (collectively, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Force Majeure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), notwithstanding anything to the contrary contained in this Lease, shall excuse the performance of such party for a period equal to any such prevention, delay or stoppage and, therefore, if this Lease specifies a time period for performance of an obligation of either party, that time period shall be extended by the period of any delay in such party&#x2019;s performance caused by a Force Majeure.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.18 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All notices, demands, statements, designations, approvals or other communications (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) given or required to be given by either party to the other hereunder or by law shall be in writing, shall be (A) sent by United States certified or registered mail, postage prepaid, return receipt requested (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Mail</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), (B) delivered by a nationally recognized overnight courier, or (C) delivered personally. Any Notice shall be sent, transmitted, or delivered to Tenant or Landlord, as applicable, at the appropriate addresses set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Sections 12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary, or to such other address for either party as that party may designate in a Notice to the other. Any Notice will be deemed given (i) three (3) business days after the date it is posted if sent by Mail, (ii) the date the overnight courier delivery is made, or (iii) the date personal delivery is made (unless such delivery takes place after hours or on a holiday or weekend, in which event the Notice shall be deemed give on the next succeeding business</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">day. The party delivering Notice shall use commercially reasonable efforts to provide a courtesy copy of each such Notice to the receiving party via electronic mail.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.19 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Waiver of Redemption by Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant hereby waives, for Tenant and for all those claiming under Tenant, any and all rights now or hereafter existing to redeem by order or judgment of any court or by any legal process or writ, Tenant&#x2019;s right of occupancy of the Premises after any termination of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.20 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Joint and Several</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If there is more than one Tenant, the obligations imposed upon Tenant under this Lease shall be joint and several.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.21 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Authority</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If Tenant is a corporation, trust or partnership, Tenant hereby represents and warrants that Tenant (a) is a duly formed and existing entity qualified to do business in the State of Delaware and is qualified as a foreign entity authorized to do business in the State of California and (b) has full right and authority to execute and deliver this Lease, and (c) each person signing on behalf of Tenant is authorized to do so.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.22 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Attorneys&#x2019; Fees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the event that either Landlord or Tenant should bring suit for the possession of the Premises, for the recovery of any sum due under this Lease, or because of the breach of any provision of this Lease or for any other relief against the other, then all costs and expenses, including reasonable attorneys&#x2019; fees, incurred by the prevailing party therein shall be paid by the other party, which obligation on the part of the other party shall be deemed to have accrued on the date of the commencement of such action and shall be enforceable whether or not the action is prosecuted to judgment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.23 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Governing Law; WAIVER OF TRIAL BY JURY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Lease shall be construed and enforced in accordance with the laws of the State of California. Landlord and Tenant agree that any disputes arising in connection with this Lease (including but not limited to a determination of any and all of the issues in such dispute, whether of fact or of law) shall be resolved (and a decision shall be rendered) by way of a general reference as provided for in Part 2, Title 8, Chapter 6 (&#167;&#167; 638 et. seq.) of the California Code of Civil Procedure, or any successor California statute governing resolution of disputes by a court appointed referee. Nothing within this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 29.23</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall apply to an unlawful detainer action. LANDLORD AND TENANT EACH ACKNOWLEDGES THAT IT IS AWARE OF AND HAS HAD THE ADVICE OF COUNSEL OF ITS CHOICE WITH RESPECT TO ITS RIGHT TO TRIAL BY JURY, AND, TO THE EXTENT PERMITTED BY LAW, EACH PARTY DOES HEREBY EXPRESSLY AND KNOWINGLY WAIVE AND RELEASE ALL SUCH RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS LEASE. The waiver of trial by jury in the immediately preceding </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 29.23</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is voluntary and intentionally made by Landlord and Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.24 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Submission of Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of, option for or option to lease, and it is not effective as a lease or otherwise until execution and delivery by both Landlord and Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.25 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Brokers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord and Tenant hereby warrant to each other that they have had no dealings with any real estate broker or agent in connection with the negotiation of this Lease, excepting only the real estate brokers or agents specified in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Summary (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Brokers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and that they know of no other real estate broker or agent who is entitled to a commission in connection with this Lease. Each party agrees to indemnify and defend the other party against and hold the other party harmless from any and all claims, demands, losses, liabilities, lawsuits, judgments, costs and expenses (including without limitation reasonable attorneys&#x2019; fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of any dealings with any real estate broker or agent, other than the Brokers, occurring by, through, or under the indemnifying party. The terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 29.24</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall survive the expiration or earlier termination of the Lease Term. Landlord shall pay a commission to the Brokers pursuant to a separate written agreement between Landlord and the Brokers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.26 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Independent Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Lease shall be construed as though the covenants herein between Landlord and Tenant are independent and not dependent and Tenant hereby expressly waives the benefit of any statute to the contrary; and, except as otherwise expressly provided for herein, Tenant agrees that if Landlord fails to perform its obligations set forth herein, Tenant shall not be entitled to make any repairs or perform any acts hereunder at Landlord&#x2019;s expense or to any setoff of the Rent or other amounts owing hereunder against Landlord.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.27 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Project or Building Name, Address and Signage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall have the right at any time to change the name and/or address of the Project or Building and to install, affix and maintain any and all signs on the exterior and on the interior of the Project or Building as Landlord may, in Landlord&#x2019;s sole discretion, desire. Tenant shall not use the name of the Project or Building or use pictures or illustrations of the Project or Building in advertising or other publicity or for any purpose other than as the address of the business to be conducted by Tenant in the Premises, without the prior written consent of Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.28 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Lease may be executed in counterparts with the same effect as if both parties hereto had executed the same document. Both counterparts shall be construed together and shall constitute a single lease. Delivery by fax or by electronic mail file attachment of any executed counterpart to this Lease will be deemed the equivalent of the delivery of the original executed instrument. This Lease may be executed in so-called &#x201c;pdf&#x201d; format and each party has the right to rely upon a pdf counterpart of this Sublease signed by the other party to the same extent as if such party had received an original counterpart. Counterparts may also be delivered via electronic signature complying with the U.S. federal ESIGN Act of 2000, (e.g., </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">www.docusign.com</font><font style="white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or echosign, etc.) and any counterpart so delivered shall be deemed to have been duly and validly delivered, valid and effective for all purposes and binding upon the parties hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.29 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Confidentiality</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant acknowledges that the content of this Lease and any related documents are confidential information. Tenant shall keep such confidential information strictly confidential and shall not disclose such confidential information to any person or entity other than Tenant&#x2019;s financial, legal, and space planning consultants, or its directors, officers, employees, attorneys, accountants, prospective lenders, prospective purchasers, brokers, underwriters, and current and potential partners or investors, or to the extent that disclosure is mandated by Applicable Laws, the Securities Exchange Commission, the rules of any public exchange upon which Tenant&#x2019;s shares are from time to time traded, or in connection with a stock or debt offering. Additionally, Tenant shall have the right to deliver a copy of this Lease to any proposed subtenant or assignee (with, in the case of a subtenant, economic terms redacted), provided such subtenant or assignee agrees to keep the contents hereof confidential. Notwithstanding the foregoing, the parties acknowledge that Landlord may use the name of Tenant without Tenant&#x2019;s consent (i) on the Building directory, and (ii) to the extent that Tenant is only referenced by name as a customer or tenant of Landlord, in investor presentations and earnings calls or earnings related releases, and in connection with the marketing efforts of Landlord or any real estate broker or agent on Landlord&#x2019;s behalf with respect to the proposed leasing, financing, sale or other conveyance of the Building, or any portion thereof. This provision shall survive the expiration or earlier termination of this Lease for one (1) year.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.30 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Renovations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. It is specifically understood and agreed that Landlord has made no representation or warranty to Tenant and has no obligation and has made no promises to alter, remodel, improve, renovate, repair or decorate the Premises, Buildings, Project, or any part thereof and that no representations respecting the condition of the Premises, the Buildings, or Project have been made by Landlord to Tenant except as specifically set forth herein or in the Work Letter. However, Landlord may during the Lease Term renovate, improve, alter, or modify (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Renovations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) the Project and/or the Buildings, including without limitation, the Parking Facilities, Common Areas, Building Systems and/or Building Structure, which Renovations may include, without limitation, (i) modifying the Common Areas and tenant spaces to comply with Applicable Laws, including regulations relating to the physically disabled, seismic conditions, and Project safety and security, and (ii) installing new floor covering, lighting, and wall coverings in the Building Common Areas, and in connection with any Renovations, Landlord may, among other things, erect scaffolding or other necessary structures in the Project, limit or eliminate access to portions of the Project, including portions of the Common Areas, or perform work in the Project, which work may create noise, dust or leave debris in the Buildings. Landlord shall use commercially reasonable efforts to undertake and complete any Renovations in a manner which does not materially, adversely affect Tenant&#x2019;s use of or access to the Premises. Notwithstanding the foregoing, Tenant hereby agrees that such Renovations and Landlord&#x2019;s actions in connection with such Renovations shall in no way constitute a constructive eviction of Tenant nor entitle Tenant to any abatement of Rent. Landlord shall have no responsibility or for any reason be liable to Tenant for any direct or indirect injury to or interference with Tenant&#x2019;s business arising from the Renovations, nor shall Tenant be entitled to any compensation or damages from Landlord for loss of the use of the whole or any part of the Premises or of Tenant&#x2019;s personal property or improvements resulting from the Renovations or Landlord&#x2019;s actions in connection with such Renovations, or for any inconvenience or annoyance occasioned by such Renovations or Landlord&#x2019;s actions, provided that the foregoing shall not limit Landlord&#x2019;s liability, if any, pursuant to Applicable Law for personal injury and property damage to the extent caused by the gross negligence or willful misconduct of Landlord, its agents, employees or contractors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.31 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Violation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant hereby warrants and represents that neither its execution of nor performance under this Lease shall cause Tenant to be in violation of any agreement, instrument, contract, law, rule or regulation by which Tenant is bound, and Tenant shall protect, defend, indemnify and hold Landlord harmless against any claims, demands, losses, damages, liabilities, costs and expenses, including, without limitation, reasonable attorneys&#x2019; fees and costs, arising from Tenant&#x2019;s breach of this warranty and representation.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.32 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Communications and Computer Lines</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant may install, maintain, replace, remove or use any communications or computer wires and cables serving the Premises (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lines</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) at the Building, provided that (i) Tenant shall obtain Landlord&#x2019;s prior written consent to the installation of any such Lines (such consent not to be unreasonably withheld), use an experienced and qualified contractor approved in writing by Landlord (such approval not to be unreasonably withheld), and comply with all of the other provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Articles 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, (ii) an acceptable amount of space for additional Lines shall be maintained for future occupants of the Project, as determined in Landlord&#x2019;s reasonable opinion, (iii) the Lines (including riser cables) shall be appropriately insulated to prevent excessive electromagnetic fields or radiation, and shall be surrounded by a protective conduit reasonably acceptable to Landlord, (iv) any Lines servicing the Premises shall comply with all Applicable Laws, (v) as a condition to permitting the installation of new Lines, Landlord may require that Tenant remove existing Lines located in or serving the Premises that will no longer be used by Tenant and repair any damage in connection with such removal, and (vi) Tenant shall pay all costs in connection therewith. Landlord reserves the right to require that Tenant remove any Lines located in or serving the Premises which are installed in violation of these provisions, or which are at any time in violation of any Applicable Laws or represent a dangerous or potentially dangerous condition. Upon the expiration of the Lease Term, or immediately following any earlier termination of this Lease, Tenant shall, at Tenant&#x2019;s sole cost and expense, remove all Lines installed by Tenant, and repair any damage caused by such removal.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.33 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transportation Management</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall fully comply with all present or future programs intended to manage parking, transportation or traffic in and around the Project and/or the Building, and in connection therewith, Tenant shall take responsible action for the transportation planning and management of all employees located at the Premises by working directly with Landlord, any governmental transportation management organization or any other transportation-related committees or entities. Such programs may include, without limitation: (i) restrictions on the number of peak-hour vehicle trips generated by Tenant; (ii) increased vehicle occupancy; (iii) implementation of an in-house ridesharing program and an employee transportation coordinator; (iv) working with employees and any Project, Building or area-wide ridesharing program manager; (v) instituting employer-sponsored incentives (financial or in-kind) to encourage employees to rideshare; and (vi) utilizing flexible work shifts for employees.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.34 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Office and Communications Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.34.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">The Provider</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall be permitted to contract with an office and communications services concessionaire (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Provider</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) selected by Tenant and subject to Landlord&#x2019;s reasonable approval (which may include, without limitation, cable or satellite television service).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.34.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant acknowledges and agrees that: (i) Landlord has made no warranty or representation to Tenant with respect to the availability of any such services, or the quality, reliability or suitability thereof; (ii) Landlord shall have no responsibility or liability for the installation, alteration, repair, maintenance, furnishing, operation, adjustment or removal of any such services, equipment or facilities; and (iii) any contract or other agreement between Tenant and Provider shall be independent of this Lease, the obligations of Tenant hereunder, and the rights of Landlord hereunder, and, without limiting the foregoing, no default or failure of Provider with respect to any such services, equipment or facilities, or under any contract or agreement relating thereto, shall have any effect on this Lease or give to Tenant any offset or defense to the full and timely performance of its obligations hereunder, or entitle Tenant to any abatement of rent or additional rent or any other payment required to be made by Tenant hereunder, or constitute any accrual or constructive eviction of Tenant, or otherwise give rise to any other claim of any nature against Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.35 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Development of the Project</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.35.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Subdivision</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord reserves the right to further subdivide all or a portion of the Project. Tenant agrees to execute and deliver, upon demand by Landlord and in the form requested by Landlord, any additional documents needed to conform this Lease to the circumstances resulting from such subdivision.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.35.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">The Other Improvements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If portions of the Project or property adjacent to the Project (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Improvements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) are owned by an entity other than Landlord, Landlord, at its option, may enter into an agreement with the owner or owners of any or all of the Other Improvements to provide (i) for reciprocal rights of access and/or use of the Project and the Other Improvements, (ii) for the common management, operation, maintenance, improvement and/or repair of all or any portion of the Project and the Other Improvements, (iii) for the allocation of a portion of the Direct Expenses to the Other Improvements and the operating expenses and taxes for the Other Improvements to the Project, and (iv) for the use or improvement of the Other Improvements and/or the Project in connection with the improvement, construction, and/or excavation of the Other Improvements and/or the Project. Nothing contained herein shall be deemed or construed to limit or otherwise affect Landlord&#x2019;s right to convey all or any portion of the Project or any other of Landlord&#x2019;s rights described in this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.36 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Water Sensors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In connection with any Tenant Improvements or Alterations to be installed in the Premises where water is utilized (such as sinks, pipes, faucets, water heaters, autoclaves, coffee machines, ice machines, water dispensers and water fountains), Tenant acknowledges and agrees that Landlord and Tenant will consider, as part of the Landlord approval process for the plans and specifications of any such Tenant Improvements or Alterations, whether to install &#x201c;Water Sensors&#x201d; in locations that may be reasonably expected to detect a leak occurring in the Premises. As used herein, &#x201c;Water Sensors&#x201d; are either web-enabled wireless water leak sensor devices designed to alert the Tenant on a twenty-four (24) hour seven (7) day per week basis if a water leak is occurring in the Premises (which water sensor device(s) located in the Premises shall be referred to herein as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Web-Enabled Water Sensors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) or non web-enabled water leak sensor devices of a model and specifications to be approved by Landlord (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non Web-Enabled Water Sensors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). To the extent Landlord and Tenant agree that Tenant will install such Water Sensors, Tenant shall, at Tenant&#x2019;s sole cost and expense, be responsible for installing the Water Sensors. If Tenant installs Non Web-Enabled Water Sensors that are determined by virtue of their performance to be deficient (i.e., fail to detect a water leak with the same or similar speed as the web enabled Water Sensors, or in any way fails to detect a water leak), then Tenant shall, upon Landlord&#x2019;s written demand, at Tenant&#x2019;s sole cost and expense, remove the Non Web-Enabled Water Sensors and install Web-Enabled Water Sensors in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 29.36</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. With respect to the installation of any such Water Sensors, Tenant shall use an experienced and qualified contractor reasonably approved by Landlord and comply with all of the other provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease. Tenant shall, at Tenant&#x2019;s sole cost and expense, pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease keep any Water Sensors located in the Premises in good working order, repair and condition at all times during the Lease Term and comply with all of the other provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease. Notwithstanding any provision to the contrary contained herein, Landlord has neither an obligation to monitor, repair or otherwise maintain the Water Sensors, nor an obligation to respond to any alerts it may receive from the Water Sensors or which may be generated from the Water Sensors. Upon the expiration of the Lease Term, or immediately following any earlier termination of this Lease, Tenant shall leave the Water Sensors in place together with all necessary user information such that the same may be used by a future occupant of the Premises (e.g., the Water Sensors shall be unblocked and ready for use by a third-party).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.37 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Utility Billing Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the event that Landlord permits Tenant to contract directly for the provision of electricity, gas and/or water services to the Premises with the third-party provider thereof, Tenant shall provide Landlord with a copy of each invoice received from the applicable utility provider promptly following Tenant&#x2019;s receipt thereof. Landlord may be required to disclose information concerning Tenant&#x2019;s energy usage at the Project to certain third parties, including, without limitation, prospective purchasers, lenders and tenants of the Project (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant Energy Use Disclosure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant hereby consents to all such Tenant Energy Use Disclosures, and Landlord shall use commercially reasonable efforts to notify Tenant of any Tenant Energy Use Disclosures made by Landlord. Further, Tenant hereby releases Landlord from any and all losses, costs, damages, expenses and liabilities relating to, arising out of and/or resulting from any Tenant Energy Use Disclosure. The terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 29.37</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall survive the expiration or earlier termination of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.38 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Green Cleaning/Recycling Program</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall cooperate if and to the extent Landlord implements a green cleaning program and/or recycling or waste management program for the Project, and Tenant hereby agrees that the reasonable costs associated with any such green cleaning and/or recycling program shall be included in Operating Expenses.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.39 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">LEED Certification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord may, in Landlord&#x2019;s sole and absolute discretion, elect to apply to obtain or maintain a LEED certification for the Project (or portion thereof), or other applicable certification in connection with Landlord&#x2019;s sustainability practices for the Project (as such sustainability practices are to be determined by</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord, in its sole and absolute discretion, from time to time). In the event that Landlord elects to maintain the existing LEED certification for the Project, Tenant shall, at Tenant&#x2019;s sole cost and expense, promptly cooperate with the Landlord&#x2019;s efforts in connection therewith and provide Landlord with any documentation it may need in order to maintain the aforementioned certification (which cooperation may include, but shall not be limited to, Tenant complying with certain standards pertaining to the purchase of materials used in connection with any Alterations or improvements undertaken by the Tenant in the Project (other than with respect to laboratory areas), the sharing of documentation pertaining to any Alterations or improvements undertaken by Tenant in the Project with Landlord, and the sharing of Tenant&#x2019;s billing information pertaining to trash removal and recycling related to Tenant&#x2019;s operations in the Project).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.40 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Approvals</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Whenever this Lease requires an approval, consent, determination, selection or judgment by either Landlord or Tenant, unless another standard is expressly set forth, such approval, consent, determination, selection or judgment and any conditions imposed thereby shall be reasonable and shall not be unreasonably withheld or delayed.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.41 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Prohibited Persons; Foreign Corrupt Practices Act and Anti-Money Laundering</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither (i) Tenant nor any of its officers, directors or managers, or (ii) to Tenant&#x2019;s knowledge, any of Tenant&#x2019;s affiliates, nor any of their respective members, partners, other equity holders (excluding any holders of any publicly traded stock or other equity interests of Tenant, if any), officers, directors or managers is, nor prior to or during the Lease Term, will they become a person or entity with whom U.S. persons or entities are restricted from doing business under (a) the Patriot Act (as defined below), (b) any other requirements contained in the rules and regulations of the Office of Foreign Assets Control, Department of the Treasury (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">OFAC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) (including any &#x201c;blocked&#x201d; person or entity listed in the Annex to Executive Order Nos. 12947, 13099 and 13224 and any modifications thereto or thereof or any other person or entity named on OFAC&#x2019;s Specially Designated Blocked Persons List) or (c) any other U.S. statute, Executive Order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit or Support Terrorism) or other governmental action (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Prohibited Persons</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant is not entering into this Lease, directly or indirectly, in violation of any laws relating to drug trafficking, money laundering or predicate crimes to money laundering. As used herein, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Patriot Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean the USA Patriot Act of 2001, 107 Public Law 56 (October 26, 2001) and all other statutes, orders, rules and regulations of the U.S. government and its various executive departments, agencies and offices interpreting and implementing the Patriot Act.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, Landlord and Tenant have caused this Lease to be executed the day and date first above written as a sealed California instrument.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.511%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:7.011%;"></td>
    <td style="width:42.464%;"></td>
    <td style="width:1.756%;"></td>
    <td style="width:4.003%;"></td>
    <td style="width:7.011%;"></td>
    <td style="width:33.237%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">LANDLORD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">TENANT:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">KRE EXCHANGE OWNER LLC,<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a Delaware limited liability company</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLGY, INC.,<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a Delaware corporation</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Daniel Rudin</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;/s/ Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Daniel Rudin</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Authorized Signatory</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CFO</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ George Scangos</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">George Scangos</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CEO</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-1<br><br>PREMISES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Floors 8, 9, 10, 11 and 12 of the North Tower comprising 133,896 rentable square feet.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2 <br><br>TENANT WORK LETTER</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">THIS TENANT WORK LETTER (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Work Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) is attached to and made a part of that certain Lease (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) between KRE EXCHANGE OWNER LLC, a Delaware limited liability company (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and VIR BIOTECHNOLOGY, INC., a Delaware corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). All capitalized terms used but not defined herein shall have the respective meanings given such terms in the Lease. This Work Letter sets forth the terms and conditions relating to the construction of Tenant&#x2019;s Improvements (defined below) in the Premises.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SECTION 2<br><br>BASE BUILDING</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to the terms and conditions of this Work Letter, Tenant hereby accepts the base, shell and core (i) of the Premises and (ii) of the floor(s) of the Building on which the Premises are located (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), in its current &#x201c;AS IS&#x201d; condition existing as of the date of the Lease and the Lease Commencement Date. Tenant shall be entitled to an improvement allowance in the maximum aggregate amount of Two Million Three Hundred Forty-Three Thousand, One Hundred Eighty Dollars ($2,343,180.00) (i.e., $17.50 per rentable square foot of the Premises) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Building Improvement Allowance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) to be used by Tenant solely to pay for the construction of certain improvements to the Base Building as are more particularly identified in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Attachment 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to this Work Letter (which required improvements are referred to here as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Building Improvement Additions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) . Subject to Landlord&#x2019;s obligation to pay to Tenant the Base Building Improvement Allowance in accordance with the terms and conditions of this Work Letter, Tenant shall be solely liable for all soft and hard costs associated with the Base Building Improvement Additions. Except for the Base Building Improvement Allowance and the Tenant Improvement Allowance set forth below, Landlord shall not be obligated to make or pay for any alterations or improvements to the Premises or the Building.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the sake of clarity, the base building condition of the Base Building to be delivered by Landlord to Tenant on the Lease Commencement Date is identified in the matrix (outlining existing base building conditions of the Base Building, including, inter alia, power, emergency power, lab exhaust, lab air supply and office air supply) attached hereto as Attachment 2 to this Work Letter (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Building Delivery Condition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant acknowledges and agrees that Attachment 1 identifies conditions that are the Tenant&#x2019;s responsibility to install (and, as such, are expressly not included in Attachment 2 as being included in the Base Building Delivery Condition), subject to reimbursement to the extent of the Base Building Improvement Allowance.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord acknowledges that certain of Tenant&#x2019;s laboratory improvements to a portion of the Premises require additional emergency power, and Landlord commits to work cooperatively with Tenant and its consultants to identify one or more solutions for Tenant&#x2019;s additional power needs; provided, however, the cost of designing and installing the Base Building infrastructure (in excess of the portion of the Base Building Improvement Allowance attributable to Tenant&#x2019;s additional power needs) to achieve the availability of additional power capacity to the Premises shall be borne solely by Tenant (i.e., the cost of all upgrades, alterations and/or additions beyond those described in the Base Building Delivery Condition shall be paid solely by Tenant).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SECTION 3<br><br>ALLOWANCE; TENANT IMPROVEMENTS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Allowance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In addition to the Base Building Improvement Allowance, Tenant shall be entitled to a one-time allowance in an amount not to exceed $36,151,920.00 with respect to the Premises in the aggregate (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant Improvement Allowance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; and together with the Base Building Improvement Allowance, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Allowance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), for the costs relating to the design, permitting and construction of the Improvements to be constructed by Tenant that are to be permanently affixed in the Premises (as applicable, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant Improvements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). In clarification of the foregoing, Tenant acknowledges and agrees that the Tenant Improvement Allowance will be used to pay for the cost of Tenant Improvements to the tenth (10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">), eleventh (11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) and twelfth (12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) floors (i.e., which floors are the lab floors), and in no event will Landlord be obligated to make disbursements pursuant to this Work Letter for an applicable portion of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Premises in an amount that exceeds the amount of the Tenant Improvement Allowance applicable to such portion of the Premises; provided, however, Tenant may use up to $1,000,000.00 of the Tenant Improvement Allowance for improvements to the non-lab floors. Notwithstanding anything to the contrary set forth herein, no portion of the Allowance shall be disbursed by Landlord after twenty-four (24) months after the Lease Commencement Date; and any portion, if any, of the Allowance that is not disbursed by Landlord on or before such date shall revert to Landlord and Tenant shall have no rights thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disbursement of the Allowance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Allowance Items</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except as otherwise set forth in this Work Letter, the Allowance shall be disbursed by Landlord only for the following items and costs (collectively the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Allowance Items</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;):</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) Payment of the fees of the Architect, Contractor, Tenant Agents and the Building Consultants (as those terms are defined below);</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) The payment of plan check, permit and license fees relating to the construction of the Tenant Improvements;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iii) The cost of construction of the Tenant Improvements, including, without limitation, after hours charges, testing and inspection costs, trash removal costs, and contractors&#x2019; fees and general conditions;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iv) The cost of any changes to the Building, any portion of the Premises or any building systems serving any portion of the Premises when such changes are required by the Construction Drawings, such cost to include all architectural and/or engineering fees and expenses incurred in connection therewith;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(v) The cost of any changes to the Construction Drawings or Tenant Improvements required by applicable building codes (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;);</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(vi) The fees of Tenant&#x2019;s project manager (if any) up to a maximum sum of $250,000.00;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(vii) The costs of Landlord&#x2019;s charges and fees (Section 2.6) and Landlord&#x2019;s Management Fee (defined below); and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(viii) Sales and use taxes and Title 24 fees.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the sake of clarity, Tenant acknowledges and agrees that Tenant and Tenant&#x2019;s Agents will accept sole responsibility for ADA and building code compliance for all improvements designed by Tenant&#x2019;s Agents; provided, however, Landlord accepts responsibility for ADA and building code compliance for the Base Building of the Building and exterior areas (including path of travel from the public street to the entry of the Premises) limited to the existing conditions. If Tenant&#x2019;s use of the Premises or any Base Building Improvement Additions triggers a change in path of travel, Tenant shall be responsible for any ADA and building code compliance triggered by such change in path of travel.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disbursement of Allowance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the construction of the applicable portion of the Base Building Improvement Additions and the Tenant Improvements, Landlord shall make monthly disbursements of the Base Building Improvement Allowance and the Tenant Improvement Allowance, as applicable, to reimburse Tenant for Allowance Items with respect to such Tenant Improvements and shall authorize the release of funds as follows, and otherwise in accordance with such disbursement procedures as Landlord shall reasonably require from time to time.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Progress Payment Disbursements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(A) On or before the fifth (5th) day of each calendar month during the construction of the Tenant Improvements in the applicable portion of the Premises (or such other date as Landlord may designate), Tenant shall deliver to Landlord with respect to such Tenant Improvements: (A) a request for payment from Contractor (defined below) approved by Tenant, in the form of an AIA G702/G703 application for payment (or comparable forms</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reasonably approved by Landlord), showing the schedule, by trade, of percentage of completion of the applicable Tenant Improvements, detailing the portion of the work completed and the portion not completed (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Payment Request</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;); (B) invoices from all of Tenant&#x2019;s Agents (defined below) for labor rendered and materials delivered to the Premises; (C) executed conditional mechanic&#x2019;s lien releases from all of Tenant&#x2019;s Agents who have lien rights with respect to the subject Payment Request (along with unconditional mechanics&#x2019; lien releases with respect to payments made pursuant to Tenant&#x2019;s prior submission hereunder) in compliance with all applicable laws as reasonably determined by Landlord, including without limitation all applicable provisions of California Civil Code Sections 8132 - 8138; (D) a copy of the check(s) or online banking records which Tenant issued to pay the requested sums to Tenant&#x2019;s Agents; and (E) all other information reasonably requested by Landlord (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Payment Request Supporting Documentation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(B) Within forty-five (45) days after Tenant&#x2019;s delivery to Landlord of all Payment Request Supporting Documentation, Landlord shall deliver a check to Tenant made payable to Tenant (or, at Landlord&#x2019;s election, by wire transfer of immediately available funds) in payment of the lesser of: (x) the amount so requested by Tenant in its Payment Request, less a ten percent (10%) retention (the aggregate amount of such retentions to be known as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Final Retention</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and (y) the balance of any remaining available portion of the applicable Allowance (not including the Final Retention), provided that if Landlord, in good faith, disputes any item in a Payment Request based on non-compliance of any work with the Approved Working Drawings (defined below) or due to any substandard work or for any other reason, and delivers a written objection to such item setting forth with reasonable particularity Landlord&#x2019;s reasons for its dispute (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Draw Dispute Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), Landlord may deduct the amount of such disputed item from the payment. Landlord and Tenant shall, in good faith, endeavor to diligently resolve any such dispute. Landlord&#x2019;s payment of such amounts shall not be deemed Landlord&#x2019;s approval or acceptance of the work furnished or materials supplied as set forth in Tenant&#x2019;s Payment Request. Disbursements of soft costs and costs not to be paid through the Contractor shall be made based upon submittal by Tenant of satisfactory documentation for the same concurrently with Tenant&#x2019;s submittal of its Payment Request, and payment shall be made no later than forty-five (45) days after submittal of such documentation, provided that in no event will Landlord be obligated to pay any amounts in excess of the applicable Allowance.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Final Disbursement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to the provisions of this Work Letter, following the final completion of construction of the Tenant Improvements in the applicable portion of the Premises, Landlord shall deliver to Tenant a check made payable to Tenant (or, at Landlord&#x2019;s election, by wire transfer of immediately available funds) in the amount of the Final Retention for such portion of the Premises, provided that (A) Tenant delivers to Landlord for the entirety of the Tenant Improvements in such portion of the Premises properly executed unconditional mechanics&#x2019; lien releases from all of Tenant&#x2019;s Agents in compliance with all applicable laws, as reasonably determined by Landlord, including without limitation compliance with all applicable provisions of California Civil Code Sections 8132 - 8138; (B) Landlord has determined that no substandard work exists which adversely affects the mechanical, electrical, plumbing, heating, ventilating and air conditioning, life-safety or other systems of the Building or any portion of the Premises), the curtain wall of the Building or the structure or exterior appearance of the Building; (C) Architect delivers to Landlord a certificate, in a form reasonably acceptable to Landlord, certifying that the construction of such Tenant Improvements has been substantially completed in accordance with the Approved Working Drawings; (D) Tenant supplies Landlord with evidence that all governmental approvals required for Tenant to legally occupy such portion of the Premises have been obtained; and (E) Tenant has fulfilled its Completion Obligations (defined below) and has otherwise complied with Landlord&#x2019;s standard &#x201c;close-out&#x201d; requirements regarding city approvals, closeout tasks, closeout documentation regarding the general contractor, financial close-out matters, and Tenant&#x2019;s vendors, and as set forth in the tenant improvement guidelines (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant Improvement Guidelines</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) to be provided to Tenant by Landlord. Disbursements of soft costs and costs not to be paid through Contractor shall be made based upon submittal by Tenant of satisfactory documentation for the same, and payment shall be made concurrently with payment of the Final Retention, provided that in no event will Landlord be obligated to pay any amounts in excess of the applicable Allowance.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Standard Tenant Improvement Package</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord has established specifications for the Building standard components to be used in the construction of the Tenant Improvements in the Premises (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Building Standards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), which Building Standards have been provided to Tenant by Landlord. The quality of the Tenant Improvements shall be equal to or of greater quality than the quality of the Building Standards.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhaust Shaft Reopening</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The parties acknowledge that in connection with the initial construction of the Building, Dropbox caused an exhaust shaft that ran between the 11th floor and the roof of the North Tower to be filled and taken out of service. Landlord has agreed to allow Tenant&#x2019;s Contractor (defined below) to undertake the work of restoring that shaft to a useable condition (as part of the Base Building Improvement Allowance, specifically # 9 in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Attachment 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). Tenant has provided Landlord with the plans and specifications for such work and the Contractor&#x2019;s estimate of the cost thereof, and Landlord has previously approved the same. Tenant shall include the cost of such work in the Payment Request submitted to Landlord following the completion of such work.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mechanical Shaft Space</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord desires to install mechanical shaft space between the 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, 9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> floors of the North Tower in the two (2) locations depicted in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Attachment 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> attached hereto (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Mechanical Shafts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant will allow Landlord to install and pay for such Mechanical Shafts per a mutually agreed upon work schedule plan established between Landlord and Tenant. Landlord, at its sole cost and expense (in addition to and not as part of the Allowance), will relocate the existing conference rooms on floors 8, 9 and 10 to a mutually agreeable location to facilitate the installation of the Mechanical Shafts, which location has been designated pursuant to plans previously approved by Landlord and Tenant. If the installation of the Mechanical Shafts is not completed by Tenant&#x2019;s occupancy of such floors, then Landlord will use commercially reasonably efforts to complete the work during Tenant&#x2019;s nonregular business hours in order to minimize impacts to the conduct of Tenant&#x2019;s business operations within the Premises.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Standby Power</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant acknowledges and accepts that Landlord will provide to it an allocation of 570 kVA of standby electrical power for the Premises. Tenant&#x2019;s use of such standby power must not exceed its allocated share of such standby power. If Tenant&#x2019;s consumption of the standby power regularly exceeds 98% of its allocated share (i.e., such 98% threshold being 558.6 kVA) for the Premises, then Tenant shall, at its sole expense, shed load on the standby power system to ensure that its usage will remain below such allocated capacity. As used herein, &#x201c;shedding load&#x201d; may consist of disconnecting equipment from the standby system, timing the use of equipment for non-peak hours, recircuiting to a power system with available capacity and other appropriate actions to reduce peak usage of standby electrical power. Tenant acknowledges and agrees that it shall be solely responsible for monitoring and managing at all times its consumption level of standby power; Landlord shall have no liability whatsoever for Tenant&#x2019;s excess use of standby power (including, without limitation, any shortfall or lack of available standby power in excess of Tenant&#x2019;s allocated share). Actual electrical consumption is metered and monitored through Landlord&#x2019;s building automation system (BAS), and Landlord will allow Tenant read-only access to Tenant&#x2019;s actual electrical usage data in order to facilitate Tenant&#x2019;s monitoring and managing of its consumption levels of standby power.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Emergency Power</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant acknowledges and accepts that Landlord will provide to it an allocation of 35 kVA of emergency electrical power for the Premises. Tenant&#x2019;s use of emergency power shall be limited to Life Safety code-related functions. Tenant acknowledges and agrees that it shall be solely responsible for monitoring and managing at all times its connected load to such emergency power system; Landlord shall have no liability whatsoever for Tenant&#x2019;s excess use of emergency power (including, without limitation, any shortfall or lack of available emergency power in excess of Tenant&#x2019;s allocated share). If Tenant&#x2019;s connected load to such emergency power exceeds its allocated share for the Premises, then Tenant shall, at its sole expense, shed load on the emergency power system to ensure that its usage will be below such allocated capacity.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SECTION 4<br><br>CONSTRUCTION DRAWINGS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Selection of Architect; Construction Drawings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant has retained DGA (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Architect</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), in connection with the Tenant Improvements. Tenant has retained the engineering consultants listed below (the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Building Consultants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) to prepare all plans and engineering working drawings and perform all work relating to mechanical, electrical and plumbing (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">MEP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), HVAC/Air Balancing, life-safety, structural, sprinkler, and riser work:</font></p>
  <table style="margin-left:0.5in;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:29.995%;"></td>
    <td style="width:70.005%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Structural:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forell Elsesser Engineers</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">MEP:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Affiliated Engineers, Inc. (AEI)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Life Safety:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Seimens</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sprinkler:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BHP</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Air Balancing:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Southland Industries</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Riser Management:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sasco/LANlogic</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Life Safety</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Siemens</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Riser Management</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Metro Electric</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Tenant desires to changes any of the Building Consultants, Tenant shall obtain Landlord&#x2019;s prior approval. not to be unreasonably withheld, conditioned or delayed. The Space Plan and the Working Drawings (as defined below) to be prepared by Architect and the Building Consultants hereunder shall be known collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Construction Drawings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.&#x201d; All Construction Drawings shall comply with the drawing format and specifications as set forth in the Tenant Improvement Guidelines and shall be subject to Landlord&#x2019;s approval (as approved pursuant to Sections 3.2 and 3.3 below, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Approved Working Drawings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). All MEP drawings must be fully engineered and cannot be prepared on a &#x201c;design-build&#x201d; basis. Tenant and Architect shall verify, in the field, the dimensions and conditions as shown on the relevant portions of the base building plans, and Tenant and Architect will be solely responsible for the same, and Landlord shall have no responsibility in connection therewith. Landlord&#x2019;s review of the Construction Drawings shall be for its sole purpose and shall not obligate Landlord to review the same, for quality, design, Code compliance or other like matters. Accordingly, notwithstanding that any Construction Drawings are reviewed by Landlord or its space planner, architect, engineers and consultants, and notwithstanding any advice or assistance that may be rendered to Tenant by Landlord or Landlord&#x2019;s space planner, architect, engineers, and consultants, Landlord shall have no liability whatsoever in connection therewith and shall not be responsible for any omissions or errors contained in the Construction Drawings or the Approved Working Drawings, and Tenant&#x2019;s waiver and indemnity set forth in the Lease shall specifically apply to the Construction Drawings and the Approved Working Drawings.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Space Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall supply Landlord for Landlord&#x2019;s (and Landlord&#x2019;s) review and approval four (4) hard copies and one (1) electronic copy of its space plan for the applicable portion of the Premises signed by Tenant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Space Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) before any architectural working drawings or engineering drawings therefor have been commenced. The Space Plan shall include a layout and designation of all offices, rooms and other partitioning, laboratory improvements, if applicable, the intended use thereof, and equipment to be contained therein. Landlord may request clarification or more specific drawings for special use items not included in the Space Plan. Landlord shall advise Tenant within ten (10) business days after Landlord&#x2019;s receipt of the Space Plan (or, if applicable, such additional information requested by Landlord pursuant to the provisions of the immediately preceding sentence) if the same is approved or is unsatisfactory or incomplete in any respect. If Tenant is so advised, Tenant shall promptly cause the Space Plan to be revised to correct any deficiencies or other matters Landlord may reasonably require. If Landlord fails to respond within such ten (10) Business Day period, Tenant shall deliver Landlord an additional notice requesting approval and if Landlord thereafter fails to respond within three (3) business days of receipt of such additional notice, Landlord will be deemed to have approved such Space Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Working Drawings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. After the Space Plan has been approved (or deemed approved) by Landlord (and Tenant), Tenant shall supply the Architect and the Building Consultants with a complete listing of standard and non-standard equipment and specifications, including, without limitation, B.T.U. calculations, electrical requirements and special electrical receptacle requirements for the applicable portion of the Premises, to enable the Architect and the Building Consultants to complete the Working Drawings (as defined below). Tenant shall cause the Architect and the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Building Consultants to promptly complete the architectural and engineering drawings for such portion of the Premises, and Architect shall compile a fully coordinated set of architectural, structural, mechanical, electrical and plumbing working drawings in a form which is complete (i.e., fully supported with calculations and other back up as requested by Landlord and sufficient to allow subcontractors to bid on the work and to submit to the City and County of San Francisco Department of Building Inspection to obtain all applicable permits) (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Working Drawings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and shall submit four (4) hard copies and one (1) electronic copy signed by Tenant to Landlord for Landlord&#x2019;s (and Landlord&#x2019;s) review and approval. Landlord shall advise Tenant within ten (10) business days after Landlord&#x2019;s receipt of the Working Drawings if Landlord, in good faith, determines that the same are approved or are unsatisfactory or incomplete. If Tenant is advised that the Working Drawings are unsatisfactory or are incomplete, Tenant shall promptly revise the Working Drawings to correct any deficiencies or other matters Landlord may reasonably require. The ten (10) Business Day period shall only commence when the Working Drawings are complete and fully supported with calculations and other back up as requested by Landlord. If Landlord fails to respond within such ten (10) Business Day period, Tenant shall deliver Landlord an additional notice requesting approval and if Landlord thereafter fails to respond within five (5) business days of receipt of such additional notice, Landlord will be deemed to have approved such Working Drawings. After approval (or deemed approval) by Landlord of the Working Drawings, Tenant shall submit the same to the appropriate municipal authorities for all applicable building permits. Tenant hereby agrees that neither Landlord nor Landlord&#x2019;s consultants shall be responsible for obtaining any building permit or for obtaining interim or final signoffs on such permits and that obtaining the same shall be Tenant&#x2019;s responsibility; provided that Landlord shall cooperate with Tenant in executing permit applications and other ministerial acts reasonably necessary to enable Tenant to obtain any such permit or sign-off. In no event shall Tenant commence any construction work in any portion the Premises prior to Landlord&#x2019;s written approval of the Construction Drawings therefor and prior to the date that all required governmental permits are obtained and copies of all such permits are provided to Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Change Orders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Once approved by Landlord, no material change in the Working Drawings may be made without the prior written approval of Landlord; provided however, if the proposed change does not materially affect the Building Structure, Building Systems or equipment or otherwise materially affect the Base Building and the cost implications of any such change will be borne one hundred percent (100%) by Tenant, Landlord agrees that it will not unreasonably withhold consent to such change. In the event Tenant desires to make any such change, Tenant shall deliver notice of the same to Landlord, setting forth in detail the change Tenant desires to make to such Working Drawings. Landlord shall, within seven (7) business days of receipt of such notice, either (i) approve the proposed change, or (ii) disapprove the proposed change and deliver a notice to Tenant specifying in reasonably sufficient detail the reasons for Landlord&#x2019;s disapproval.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Approval</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord&#x2019;s approval of any matter under this Work Letter may be withheld if Landlord determines that the same would violate any provision of the Lease or this Work Letter or would adversely affect the mechanical, electrical, plumbing, heating, ventilating and air conditioning, life-safety or other systems of the Building or any portion of the Building (including the Premises, the curtain wall of the Building or the structure or exterior appearance of the Building). Landlord and Tenant acknowledge and agree that, prior to their mutual execution and delivery of the Lease, Tenant has been working with Dropbox and Landlord, as master landlord, to process plans for the construction of alterations to the subleased premises to accomplish a build out of the subleased premises, and in connection with that process, Landlord has thus far provided to Tenant the approvals identified on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Attachment 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> attached hereto (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Existing Approvals</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Other than the Existing Approvals, Tenant acknowledges and agrees that it must comply with the process described in this Work Letter in connection with obtaining future approvals.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall be responsible for payment of the reasonable out-of-pocket fees incurred by, and the reasonable out-of-pocket cost of documents and materials supplied by, Landlord and Landlord&#x2019;s consultants in connection with the preparation and review of the Construction Drawings and otherwise relating to the construction of the Tenant Improvements, not to exceed $15,000.00.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SECTION 5<br><br>CONSTRUCTION OF THE TENANT IMPROVEMENTS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Selection of Contractors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">The Contractor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. A general contractor selected by Tenant and approved in writing by Landlord shall be retained by Tenant to construct the Tenant Improvements (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant has selected, and Landlord has approved, XL Construction</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Agents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All subcontractors, laborers, materialmen, and suppliers used by Tenant (such subcontractors, laborers, materialmen, and suppliers, and the Contractor to be known collectively as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Agents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) must be approved in writing by Landlord, such approval not to be unreasonably withheld, conditioned or delayed (Landlord will approve or disapprove Tenant&#x2019;s Agents within ten (10) business days following Tenant&#x2019;s written request, and failure to respond within this period shall be deemed approval of the same), provided that Landlord will require Tenant to retain the Building Consultants. All of Tenant&#x2019;s Agents shall be licensed in the State of California, capable of being bonded and shall use only union labor.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Construction of Tenant Improvements by Tenant&#x2019;s Agents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Construction Contract; Cost Budget; Over-Allowance Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord acknowledges that prior to the date of this Lease it has received and approved a copy of Tenant&#x2019;s executed construction contract and general conditions with Contractor (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contract</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Prior to the commencement of the construction of any portion of the Tenant Improvements, Tenant shall provide Landlord with a schedule of values consisting of a detailed breakdown, by trade, of the final costs to be incurred or which have been incurred, in connection with the design and construction of such Tenant Improvements, which costs form the basis for the amount of the Contract (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anticipated Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Landlord and Tenant shall determine the amount equal to the difference between (i) the amount of such Anticipated Costs, and (ii) the amount of the Allowance applicable to such portion of the Premises (less any portion thereof already disbursed by Landlord, or in the process of being disbursed by Landlord, on or before the commencement of construction of such portion of the Tenant Improvements) (such difference, if any, being the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anticipated Over-Allowance Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). As of the date of this Lease, the Anticipated Over-Allowance Amount is projected to be $</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall pay a percentage of each amount requested by the Contractor or otherwise to be disbursed under this Work Letter, which percentage (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Percentage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall be equal to the Anticipated Over- Allowance Amount divided by the amount of the applicable Allowance, and such payments by Tenant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Over- Allowance Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall be a condition to Landlord&#x2019;s obligation to pay any amounts from the Allowance (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Improvement Allowance Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant shall advise Landlord from time to time as such Anticipated Costs are further refined or determined or the costs relating to the design and construction of the applicable Tenant Improvements otherwise change, and the Anticipated Over-Allowance Amount and Over-Allowance Payments shall be adjusted such that the applicable Improvement Allowance Payments by Landlord and applicable the Over- Allowance Payments by Tenant shall accurately reflect the then-current amount of the Anticipated Costs for the applicable Tenant Improvements.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Construction Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s General Conditions for Tenant&#x2019;s Agents and Tenant Initial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Improvement Work</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Construction of the Tenant Improvements shall comply with the following: (A) the Tenant Improvements shall be constructed in strict accordance with the Approved Working Drawings and Landlord&#x2019;s (and Landlord&#x2019;s) construction guidelines; (B) Tenant&#x2019;s Agents shall submit schedules of all work relating to the Tenant Improvements to Landlord and Landlord shall, within five (5) business days of receipt thereof, inform Tenant&#x2019;s Agents of any changes which are necessary thereto, and Tenant&#x2019;s Agents shall adhere to such corrected schedule; and (C) Tenant shall abide by Landlord&#x2019;s construction rules for the Project and all other rules reasonably made by Landlord and Landlord&#x2019;s Building manager with respect to the use of freight, loading dock and service elevators, any required shutdown of utilities (including life safety systems), storage of materials, coordination with other contractors working in any portion of the Building, and any other matter in connection with this Work Letter, including, without limitation, the construction of the Tenant Improvements. Tenant shall pay to Landlord a fee for Landlord&#x2019;s design review, processing of Payment Requests, coordination of the Tenant Improvements with Landlord, and general oversight (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Management Fee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) with respect to the Tenant Improvements in an amount equal to Nine Hundred Sixty-Two</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thousand Three Hundred Seventy Seven and 50/100 Dollars ($962,377.50) (i.e., 2.5% of the Tenant Improvement Allowance and the Base Building Improvement Allowance); the Management Fee shall be deducted from the applicable portion of the Allowance on a pro rata basis with each disbursement of such portion of the Allowance.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Indemnity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant&#x2019;s indemnity of Landlord as set forth in the Lease shall also apply with respect to any and all costs, losses, damages, injuries and liabilities related in any way to any act or omission of Tenant or Tenant&#x2019;s Agents, or anyone directly or indirectly employed by any of them, or in connection with Tenant&#x2019;s nonpayment of any amount arising out of the Tenant Improvements and/or Landlord&#x2019;s disapproval of all or any portion of any request for payment. Such indemnity by Tenant, as set forth in the Lease, shall also apply with respect to any and all costs, losses, damages, injuries and liabilities related in any way to Landlord&#x2019;s performance of any ministerial acts reasonably necessary (A) to permit Tenant to complete the Tenant Improvements, and (B) to enable Tenant to obtain any building permit or certificate of occupancy for any portion of the Premises. The foregoing indemnity shall not apply to claims caused by the gross negligence or willful misconduct of Landlord, Landlord or its or their members, partners, shareholders, officers, directors, agents, employees and/or contractors, or to the failure of Landlord to disburse the Allowance as and when required hereunder.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Requirements of Tenant&#x2019;s Agents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Each of Tenant&#x2019;s Agents shall warrant that the portion of the Tenant Improvements for which it is responsible shall be free from any defects in workmanship and materials, that the materials and equipment used will be new and of good quality (unless expressly specified otherwise in the contract documents), and that the work will conform to the requirements of the contract documents. The foregoing warranties are in addition to any other warranties with respect to the work that may be required by the contract documents. Further, and without limiting the foregoing warranties, each of Tenant&#x2019;s Agents shall agree to be responsible for the replacement or repair, without additional charge, of all defects in the work performed or furnished under its contract that become apparent during the one (1) year period following substantial completion of the Tenant Improvements. The correction of such work shall include, without additional charge, all additional expenses and damages incurred in connection with the removal or replacement of all or any part of the Tenant Improvements, and/or the Building and/or common areas that are damaged or disturbed as a result of the defective work or any replacement or repair work. All of the warranties and agreements described herein shall be contained in the Contract and each subcontract and shall be written such that they inure to the benefit of Landlord, Landlord and Tenant, as their respective interests may appear, and can be directly enforced by either. Tenant covenants to give to Landlord and/or Landlord any assignment or other assurances as may be necessary to affect such right of direct enforcement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Insurance Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">General Coverages</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All of Tenant&#x2019;s Agents shall carry worker&#x2019;s compensation insurance covering all of their respective employees, and shall also carry public liability insurance, including property damage, all with limits, in form and with companies as are required to be carried by Landlord as set forth in the Lease (provided that the limits of liability to be carried by Tenant&#x2019;s Agents and Contractor shall be in amounts as may be required by Landlord).</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Special Coverages</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During construction of any portion of the Tenant Improvements, Tenant shall carry &#x201c;Builder&#x2019;s All Risk&#x201d; insurance in an amount approved by Landlord covering the construction of the Tenant Improvements (at Tenant&#x2019;s option, Tenant shall cause Contractor to carry such Builder&#x2019;s All Risk insurance), and such other insurance as Landlord or Landlord may reasonably require, it being understood and agreed that the Tenant Improvements shall be insured by Tenant pursuant to the Lease immediately upon completion thereof. Such insurance shall be in amounts and shall include such customary extended coverage endorsements as may be reasonably required by Landlord and/or Landlord, and shall be in form and with companies as are required to be carried by Tenant as set forth in the Lease. During construction of any portion of the Tenant Improvements, Tenant shall cause any architect and engineer to carry professional liability insurance with limits of not less than $2,000,000 per claim and in the annual aggregate covering professional services performed by the respective party, and such coverage must be maintained for the greatest period under which a claim may be properly asserted under the applicable statute of limitations or repose.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">General Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Certificates for all insurance carried pursuant to this Section 3.2(c) shall be delivered to Landlord before the commencement of construction of the Tenant Improvements and before the Contractor&#x2019;s equipment is moved onto the site. Tenant shall immediately notify Landlord in the event any policy of insurance carried by Tenant is cancelled or the coverage materially changed. Tenant&#x2019;s Contractor and subcontractors</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">shall maintain all of the foregoing insurance coverage in force until the Tenant Improvements are fully completed and accepted by Landlord, except for any Products and Completed Operation Coverage insurance required by Landlord, which is to be maintained for ten (10) years following completion of the work and acceptance by Landlord and Tenant, where applicable. All policies carried under this Section 3.2(c) (other than Workers&#x2019; Compensation coverage) shall insure Landlord, Landlord and Tenant, as their interests may appear. All insurance, except Workers&#x2019; Compensation, maintained by Tenant&#x2019;s Agents shall preclude subrogation claims by the insurer against anyone insured thereunder, as evidenced by an endorsement or policy excerpt. Such insurance shall provide that it is primary insurance with respect to the Tenant Improvements and that any other insurance maintained by Landlord or Landlord is excess and noncontributing with the insurance required hereunder. The requirements for the foregoing insurance shall not derogate from the provisions for indemnification of Landlord by Tenant under the Lease or this Work Letter.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Governmental Compliance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Tenant Improvements shall comply in all respects with the following: (i) the Code and other federal, state, city and/or quasigovernmental laws, codes, ordinances and regulations, as each may apply according to the rulings of the controlling public official, agent or other person or entity; (ii) applicable standards of the American Insurance Association (formerly, the National Board of Fire Underwriters) and the National Electrical Code; and (iii) building material manufacturer&#x2019;s specifications.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Inspection by Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord shall have the right to inspect the Tenant Improvements at all times, provided however, that Landlord&#x2019;s failure to inspect the Tenant Improvements shall in no event constitute a waiver of any of Landlord&#x2019;s rights hereunder nor shall Landlord&#x2019;s inspection of the Tenant Improvements constitute Landlord&#x2019;s approval of the same. Should Landlord disapprove any portion of the Tenant Improvements, Landlord shall notify Tenant in writing of such disapproval and shall specify the items disapproved. Any defects or deviations in, and/or disapproval by Landlord of, the Tenant Improvements shall be rectified by Tenant at no expense to Landlord, provided however, that in the event Landlord determines that a defect or deviation exists or disapproves of any matter in connection with any portion of the Tenant Improvements and such defect, deviation or matter might adversely affect the mechanical, electrical, plumbing, heating, ventilating and air conditioning or life-safety systems of the Building or any portion of the Premises or the structure or exterior appearance of the Building, Landlord may take such action as Landlord deems necessary, at Tenant&#x2019;s expense and without incurring any liability on Landlord&#x2019;s part, to correct any such defect, deviation and/or matter, including, without limitation, causing the cessation of performance of the construction of the Tenant Improvements until such time as the defect, deviation and/or matter is corrected to Landlord&#x2019;s satisfaction.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(f) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Meetings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant shall hold periodic meetings at a reasonable time with the Architect and the Contractor regarding the progress of the preparation of the Construction Drawings and the construction of the Tenant Improvements, and Landlord shall receive prior written notice of, and Landlord and/or its agents (and Landlord and/or its agents) shall have the right to attend, all such meetings, and, upon Landlord&#x2019;s request, certain of Tenant&#x2019;s Agents shall attend such meetings. In addition, minutes shall be taken at all such meetings, and Landlord and Landlord will be included in the distribution list for such minutes. One such meeting each month shall include the review of Contractor&#x2019;s current request for payment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notice of Completion; Copy of Record Set of Plans</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Within thirty (30) days after completion of construction of any portion of the Tenant Improvements, Tenant shall cause a Notice of Completion to be recorded in the office of the Recorder of San Francisco County in accordance with Section 8182 of the California Civil Code or any successor statute, shall furnish a copy thereof to Landlord upon such recordation, and shall timely give all notices required pursuant to Section 8188 or 8190 of the California Civil Code or any successor statutes. If Tenant fails to do so, Landlord may execute and file such Notice of Completion and give such notices on behalf of Tenant as Tenant&#x2019;s agent for such purpose, at Tenant&#x2019;s sole cost and expense. Within thirty (30) days following the completion of construction of any portion of the Tenant Improvements, (i) Tenant shall cause the Architect and Contractor (A) to update the Approved Working Drawings as necessary to reflect all changes made to the Approved Working Drawings during the course of construction, (B) to certify to the best of their knowledge that the updated drawings are true and correct, which certification shall survive the expiration or termination of the Lease, and (C) to deliver to Landlord such updated drawings in accordance with Landlord&#x2019;s then-current CAD Format Requirements, and (ii) Tenant shall deliver to Landlord a copy of all warranties, guaranties, and operating manuals and information relating to the improvements, equipment, and systems in the Premises as Landlord may require.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SECTION 6<br><br>MISCELLANEOUS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Representative</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant has designated Larry Matarazzi (larry@vir.bio) as its sole representative with respect to the matters set forth in this Work Letter, until further notice to Landlord, who shall have full authority and responsibility to act on behalf of Tenant as required in this Work Letter.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Landlord&#x2019;s Representative</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Landlord has designated Eric Giles (egiles@lfrep.com) its sole representative with respect to the matters set forth in this Work Letter, who, until further notice to Tenant, shall have full </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">authority</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and responsibility to act on behalf of Landlord as required in this Work Letter.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Default</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding any provision to the contrary contained in the Lease, if a Default by Tenant under the Lease (including, without limitation, this Work Letter) has occurred at any time on or before the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">substantial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> completion of the Tenant Improvements, then (i) in addition to all other rights and remedies granted to Landlord pursuant to the Lease, Landlord shall have the right to withhold payment of all or any portion of the Allowance, and (ii) all other obligations of Landlord under the terms of this Work Letter shall be forgiven until such time as such default is cured pursuant to the terms of the Lease.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Attachment 1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Building Improvement Additions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img206306002_0.jpg" alt="img206306002_0.jpg" style="width:526px;height:717px;">&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Attachment 2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Building Delivery Condition</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img206306002_1.jpg" alt="img206306002_1.jpg" style="width:576px;height:749px;">&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img206306002_2.jpg" alt="img206306002_2.jpg" style="width:614px;height:825px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img206306002_3.jpg" alt="img206306002_3.jpg" style="width:595px;height:795px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img206306002_4.jpg" alt="img206306002_4.jpg" style="width:605px;height:806px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img206306002_5.jpg" alt="img206306002_5.jpg" style="width:595px;height:798px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img206306002_6.jpg" alt="img206306002_6.jpg" style="width:624px;height:283px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.1-2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Attachment 3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mechanical Shaft Depiction</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Attachment 4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Existing Approvals</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:0.6756944444444444in;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.54%;"></td>
    <td style="width:72.46%;"></td>
   </tr>
   <tr style="height:23.75pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(217,225,243,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Date</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(217,225,243,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord Approval Letters</font></p></td>
   </tr>
   <tr style="height:34.55pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 18, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR Logistics Plan 1a &amp; Safe-off Plan for floors 10, 11, and 12 in Sector 1</font></p></td>
   </tr>
   <tr style="height:23.75pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 1, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR Demo Work for floors 10, 11, and 12 in Sector 1</font></p></td>
   </tr>
   <tr style="height:23.75pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 4, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Elevator C&amp;D Separation</font></p></td>
   </tr>
   <tr style="height:35.3pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 17, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR Phase 2 Rev. 2 Logistics Plan for floors 10, 11, and 12 in Sector 1</font></p></td>
   </tr>
   <tr style="height:23.75pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 11, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR Elevator D-FASE Protection and Use Plan in Sector 1</font></p></td>
   </tr>
   <tr style="height:35.3pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 1, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR 7/23/2021 Permit Drawings and 8/3/2021 MEPF BOD in Sector 1 (Review comments and partial approval)</font></p></td>
   </tr>
   <tr style="height:35.3pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR Shaft Structural Demolition Work for floors 10, 11 and 12 in Sector 1</font></p></td>
   </tr>
   <tr style="height:35.3pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 3, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR 7/23/2021 Permit Drawings and 8/3/2021 MEPF BOD in Sector 1</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.1.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.3<br><br>FIRST REFUSAL SPACE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Note: Seventh (7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) floor of the North Tower contains 26,657 RSF.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 1.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 2.1<br><br>FORM OF NOTICE OF LEASE TERM DATES</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:41.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.835%;"></td>
    <td style="width:86.165%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.080in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Re:	Lease dated _______________, 20__ between _______________________, a ______________________ (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and ____________________________, a ____________________________ (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) concerning Suite ________ on floor(s) ________________ of the building located at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[INSERT BUILDING ADDRESS]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gentlemen:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with the Lease (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), we wish to advise you and/or confirm as follows:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">1.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Lease Term shall commence on or has commenced on _________________ for a term of __________________ ending on ____________________.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">2.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Rent Commencement Date occurred on</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, subject to the Base Rent abatement set forth in Section 3 of the Lease.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">3.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Your rent checks should be made payable to _____________________ at ______________.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">4.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Share of Direct Expenses with respect to the North Tower is __________________, subject to any Retail Space Cost Pool.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">5.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Capitalized terms used here that are defined in the Lease shall have the same meaning when used herein.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the provisions of this letter correctly set forth our understanding, please acknowledge by signing at the place provided below on the enclosed copy of the letter and returning the same to Landlord.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.846%;"></td>
    <td style="width:6.146%;"></td>
    <td style="width:38.009%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Landlord&#x201d;:</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KRE EXCHANGE OWNER LLC,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a Delaware limited liability company</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Agreed to and Accepted as</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of _________________, 20___</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.305%;"></td>
    <td style="width:3.262%;"></td>
    <td style="width:88.433%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Tenant&#x201d;:</font></p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 2.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">THE EXCHANGE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">MISSION BAY REQUIREMENTS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Environmental Covenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Project may contain hazardous materials in soils and in the ground water under the Project, and is subject to a deed restriction (Covenant and Environmental Restriction on Property) dated as of February 23, 2000, and recorded in the Official Records of the City and County of San Francisco, California (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Official Records</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) on March 21, 2000, as Document No. 2000-G748552 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Environmental Covenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), which Environmental Covenant imposes certain covenants, conditions, and restrictions on usage of the Project. The foregoing statement is required by the Environmental Covenant and is not a declaration that a hazard exists. As required by Section 3.3 of the Environmental Covenant, Landlord hereby states as follows: &#x201c;The land described herein may contain hazardous materials in soils and in the ground water under the property, and is subject to a deed restriction (Covenant and Restriction) dated as of February 23, 2000, and recorded on March 21, 2000, in the Official Records of San Francisco County, California, as Document No. G748552, which Covenant and Restriction imposes certain covenants, conditions, and restrictions on usage of the property described herein. This statement is not a declaration that a hazard exists.&#x201d; The Environmental Covenant references and requires compliance with the provisions of the Risk Management Plan, Mission Bay Area, San Francisco, California, dated May 11, 1999 (as may be amended from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RMP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Tenant hereby acknowledges receipt of a copy of the original RMP, and hereby covenants (i) to comply with the RMP (to the extent the RMP applies to Tenant&#x2019;s activities), (ii) to obligate other entities with which Tenant contracts for construction, property maintenance, or other activities that may disturb soil or groundwater to comply with the applicable provisions of the RMP, and (iii) to refrain (and to cause the entities with which it so contracts to refrain) from interfering with Landlord&#x2019;s or other Occupant&#x2019;s (with &#x201c;Occupant&#x201d; having the meaning ascribed in the Environmental Covenant) compliance with the RMP. Additionally, in all future leases, licenses, permits, or other agreements between Tenant and another entity which authorizes such entity to undertake or to engage in activities that are subject to one or more requirements set forth in the RMP, Tenant will provide a copy of the RMP or its relevant provisions prior to execution of such agreements and ensure that such agreements contain covenants that (i) such entity will comply with the RMP (to the extent the RMP applies to the entity&#x2019;s activities); (ii) such entity will obligate other entities with which it contracts for construction, property maintenance or other activities which may disturb soil or groundwater to comply with the applicable provisions of the RMP; and (iii) such entity (and the entities with which it so contracts) will refrain from interfering with Landlord&#x2019;s, Tenant&#x2019;s, or other Occupants&#x2019; compliance with the RMP.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Special Tax Acknowledgment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In accordance with Section 53341.5 of the California Government Code, Tenant previously has delivered to Landlord acknowledgments, duly executed by Tenant, confirming that Tenant has been advised of the terms and conditions of the &#x201c;CFDs&#x201d; (as defined below), including that the Project is subject to the &#x201c;CFD Assessments&#x201d; (as defined below). As used herein, (a) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CFDs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean, collectively, (i) the Redevelopment Agency Community Facilities District No. 5 (Mission Bay Maintenance) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Maintenance CFD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) (established to pay a portion of the costs of ongoing maintenance of open space parcels in Mission Bay), (ii) the Redevelopment Agency Community Facilities District No. 6 (Mission Bay South Public Improvements) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Infrastructure CFD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) (established to pay a portion of the costs of constructing and installing public infrastructure in Mission Bay), and (iii) the San Francisco Unified School District of the City and County of San Francisco Community Facilities District No. 90-1 (Public School Facilities) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Public School CFD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) (established to pay a portion of the costs of acquiring and/or constructing public school facilities), and (b) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CFD Assessments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; shall mean the special taxes (i) to be levied on the Project and other property in Mission Bay in accordance with the terms and conditions of the &#x201c;Rate and Method of Apportionment of Special Tax&#x201d; applicable to the Infrastructure CFD and the Maintenance CFD, respectively, and (ii) to be levied on the Project and other property in accordance with the terms and conditions applicable to the Public School CFD. Tenant acknowledges that, pursuant to the CFDs, CFD Assessments may be levied on the Project and that, without limiting the generality of any other provision contained in this Lease, Direct Expenses shall include all such CFD Assessments.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Project Labor Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant has been informed by Landlord of the following: (a) Perini Corporation, CDC and its parent, subsidiaries and successor developers in which it holds a majority interest (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CDC Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), the San Francisco Building and Construction Trades Council, AFL-CIO (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Council</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and certain affiliated local unions originally entered into a certain Mission Bay Project Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Original Project Labor Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) for the Mission Bay project on October 8, 1990, pursuant to which (i) CDC Parties</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">agreed, to the fullest extent possible, to award all construction contracts in Mission Bay for &#x201c;Covered Work&#x201d; (as defined in the Original Project Labor Agreement) to unionized construction firms; and (b) CDC and the individual members of the Council entered into an Addendum to Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Addendum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) that amended certain terms of the Original Project Labor Agreement (the Original Project Labor Agreement, as amended by the Addendum, shall be referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Project Labor Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), pursuant to which CDC agreed that CDC would require, as a condition of any sale, conveyance, ground lease, or donation of real property covered by the Project Labor Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Covered Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), that any and all successors in interest and/or assignees, buyers, ground lessees, or donees (any of the foregoing, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Covered Successor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) of Covered Property shall require any contractors to which the Covered Successor contracts work that is covered by the Project Labor Agreement to sign and become a party to a successor project labor agreement (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Successor Project Labor Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;, the form of which is attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Schedule 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.4.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). Tenant acknowledges that the Project is Covered Property, that Landlord is a Covered Successor, and that Landlord has agreed to require any contractors to which Landlord contracts work which is Covered Work to sign and become a party to a Successor Project Labor Agreement. Accordingly, Tenant hereby agrees that Tenant shall require any contractors to which Tenant or any of its contractors contract work which is Covered Work to execute and deliver a Successor Project Labor Agreement. If Tenant acts as a contractor, Tenant shall be required to sign a Successor Project Labor Agreement as project contractor. Tenant will cause its general contractor to execute a Successor Project Labor Agreement prior to the commencement of any construction work on the Project and shall deliver an executed original of each Successor Project Labor Agreement to Landlord. Following Landlord&#x2019;s receipt of such executed original of the Successor Project Labor Agreement, Landlord shall use commercially reasonable efforts to obtain full execution of the Successor Project Labor Agreement by the union signatories, but Tenant acknowledges that Landlord shall have no liability whatsoever if full execution of the Successor Project Labor Agreement is not obtained.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.	First Source Hiring Program. Tenant has been informed by Landlord that there is a City-wide &#x201c;First Source Hiring Program&#x201d; (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FSHP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) (adopted by the City and County of San Francisco on August 10, 1998, Ordinance No. 264-98). Tenant hereby acknowledges that its activities with respect to the Project are or may be subject to the FSHP. Accordingly, Tenant shall comply with any provisions of the FSHP that are applicable to the Premises or any construction in, or use or development of, the Premises by Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Non-Discrimination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Without limiting the generality of any other provision of this Lease, there shall be no discrimination against, or segregation of, any person or group of persons or any employee or applicant for employment on account of race, color, creed, religion, sex, marital or domestic partner status, familial status, national origin, ancestry, lawful source of income (as defined in Section 3304 of the San Francisco Police Code), gender identity, sexual orientation, age, or disability (including, without limitation, HIV/AIDS status) in the sale, lease, sublease, transfer, use, occupancy, tenure, or enjoyment of any part of the Project, nor shall Tenant or any person claiming under or through Tenant, establish or permit any such practice or practices of discrimination or segregation with reference to the selection, location, number, use, or occupancy of tenants, lessees, subtenants, sublessees, or vendees in any part of the Project. All deeds, leases, subleases, or contracts concerning the Project shall contain the non-discrimination and non-segregation clauses specified for each type of document in Section 33436 of the California Health and Safety Code.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tax Exempt Entities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant acknowledges that it has received and reviewed that certain Grant Deed dated May 19, 2014, executed and acknowledged on behalf of FOCIL-MB, LLC, and Landlord, recorded in the Official Records on May 23, 2014, as Document No. 2014-J886903-00 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Grant Deed</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and further that this Lease and Tenant are subject and subordinate to, and Tenant shall not violate, the covenants contained in such Grant Deed. Such Grant Deed contains certain covenants by Landlord regarding payments of taxes (or payments in lieu of taxes) if (a) there is any sale, assignment, conveyance, lease, sublease, or other alienation of any portion of the Project to an entity that is or could be exempt from property taxation (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tax Exempt Entity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), or (b) there is a grant to a Tax Exempt Entity of occupancy rights (such as under a space lease) where, as the result of such grant, all or any portion of any improvements on all or any portion of the Project would or could be exempt from property taxation. Accordingly, Tenant shall not Transfer the Premises, or any portion thereof, or sublease space in, or otherwise grant any occupancy rights, in the Premises to any Tax Exempt Entity without first: (a) obtaining from such Tax Exempt Entity a binding contractual commitment, in form and substance reasonably satisfactory to, and for the benefit of, the Successor Agency to the Redevelopment Agency (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Successor Agency</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and the City and County of San Francisco (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">City and County</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), obligating such entity to make a payment in lieu of taxes (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PILOT Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) equal to the full amount of the property taxes that would have been assessed against the Premises notwithstanding</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such occupancy by a Tax Exempt Entity; or (b) entering into a binding PILOT Agreement, in form and substance reasonably satisfactory to, and for the benefit of, the Successor Agency and the City and County, requiring the full payment of property taxes (or a payment in lieu thereof in an amount equal to the property taxes) that would have been assessed against the Premises notwithstanding such occupancy by such Tax Exempt Entity, or (c) obtaining the written consent of the Successor Agency and the City and County, in their respective sole discretion. Tenant hereby agrees not to request that Landlord request an adjustment to the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Base Year Value</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; (as defined below) for the &#x201c;South Plan Area&#x201d; (as defined in the OPA), or any portion thereof, as a result of any Transfer permitted under this Lease to a Tax Exempt Entity. For purposes hereof, (i) the term &#x201c;Base Year Value&#x201d; means the aggregate assessed value of property within the South Plan Area on the assessment roll last equalized prior to the effective date of the ordinance adopting the Redevelopment Plan, and (ii) the term &#x201c;last equalized&#x201d; has the meaning set forth in Section 2052 of the California Revenue and Tax Code.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mitigation Measures</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant has been informed by Landlord that the Project (along with other property) is subject to the Mitigation Monitoring and Reporting Program for the Mission Bay South Plan Area (including, but not limited to, the Mission Bay South CEQA Mitigation Measures described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Attachment L</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to the Mission Bay South Owner Participation Agreement between the Redevelopment Agency and CDC dated November 16, 1998, and recorded in the Official Records on December 3, 1998, as Document No. 98-G477258). Tenant shall comply with the following mitigation measures (and with any other mitigation measures that Landlord reasonably determines are applicable to Tenant&#x2019;s operations in the Premises):</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mitigation Measure L01 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Biohazardous Materials Handling Guidelines)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Require businesses that handle biohazardous materials and do not receive federal funding to certify that they follow the guidelines published by the National Research Council and the U.S. Department of Health and Human Services Public Health Service, National Institutes of Health, and Centers for Disease Control as set forth in Biosafety in Microbiological and Biomedical Laboratories, Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines), and Guide for the Care and Use of Laboratory Animals, or their successors, as applicable.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mitigation Measure L02 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Use of HEPA Filters)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Require businesses handling biohazardous materials to certify that they use high efficiency particulate air (HEPA) filters or substantially equivalent devices on all exhaust from Biosafety Level 3 laboratories unless they demonstrate that exhaust from the Biosafety Level 3 laboratories would not pose a substantial health and safety hazards to the public or the environment. Require such businesses to certify that they inspect or monitor the filters regularly to ensure proper functioning.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mitigation Measure L03 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Handling of Biohazardous Materials)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Require businesses handling biohazardous materials to certify that they do not handle or use biohazardous materials requiring Biosafety Level 4 containment (i.e., dangerous or exotic materials that pose high risks of life-threatening diseases or aerosol-transmitted infections, or unknown risks of transmitting in the Project Area).</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Declaration of Tax Appeal Waiver Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Tenant acknowledges that it has received and reviewed a certain Declaration of Tax Appeal Waiver Agreement dated May 23, 2014, executed and acknowledged on behalf of FOCIL-MB, LLC, and Landlord, recorded in the Official Records on May 23, 2014, as Document No. 14-J886906 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Declaration of Tax Appeal Waiver Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and further that this Lease and Tenant are subject and subordinate to, and Tenant shall not violate, the covenants contained in such Declaration of Tax Appeal Waiver Agreement. Such Declaration of Tax Appeal Waiver Agreement contains certain covenants by Landlord to not (and waivers of any rights to) take any action or seek to take any action (including filing any appeal, contest, commencing any legal action or otherwise challenging or disputing in any way) that would result in a reduction of the assessed value of the Project for property tax purposes below a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Minimum Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; (as defined in the Declaration of Tax Appeal Waiver Agreement as the sum of (i) $95,000,000.00 plus (ii) the actual construction costs for the Project, provided, however, that the Minimum Amount shall increase on the anniversary of the Completion of Construction (as defined therein) and annually thereafter by 2%). In connection with the foregoing, and notwithstanding the terms and conditions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Article 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Lease, (a) Tenant shall not have the right to require Landlord to seek any reduction in Tax Expenses below the Minimum Amount, and (b) notwithstanding anything to the contrary set forth in this Lease, only Landlord may institute proceedings to reduce Tax Expenses and the filing of any such proceeding by Tenant without Landlord&#x2019;s consent shall constitute an Event of Default by Tenant under this Lease.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SCHEDULE 1 TO EXHIBIT 4.4.3<br><br>THE EXCHANGE<br><br>SUCCESSOR PROJECT LABOR AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">[ATTACHED]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">MISSION BAY<br><br>PROJECT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">MISSION BAY<br><br>PROJECT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Project Agreement (&#x201c;Agreement&#x201d;) is entered into this ______ day of _____________, 200_ by and among _________________________________ (hereinafter referred to as the &#x201c;Project Contractor&#x201d;), and the San Francisco Building and Construction Trades Council, AFL-CIO; and affiliated Local Unions whose names are subscribed hereto and who have, through their duly authorized officers, executed this Agreement (hereinafter collectively referred to as the &#x201c;Union&#x201d; or the &#x201c;Unions&#x201d;). The term Contractor as used in this Agreement includes all contractors and subcontractors of whatever tier. Contractor agrees to comply with the collective bargaining agreements listed in Schedule A for the purposes of the Covered Work only, and any obligation incurred under Schedule A agreements shall expire with the termination of this Agreement. Where specific reference to ________________ only is intended, the term Project Contractor is used. This project is being constructed pursuant to an Owner&#x2019;s Participation Agreement (&#x201c;Owner OPA&#x201d;) for Mission Bay _______________ originally between the Redevelopment Agency of the City and County of San Francisco and Catellus Development Corporation (&#x201c;Catellus&#x201d;) and subsequently transferred in part to _____________________ (the &#x201c;Owner&#x201d;). The project area is generally bound by ________________________________________________________.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Catellus and the Unions entered into the Mission Bay Project Agreement (&#x201c;Original PLA&#x201d;) for the entire Mission Bay project on October 8, 1990. The Original PLA was amended by an Addendum to Agreement effective __________________ 2003 (&#x201c;Addendum&#x201d;), which among other things, requires the execution of this Agreement by the Project Contractor when Catellus sells, conveys, ground leases or donates to a third party any real property covered by the Original PLA, subject to the terms and conditions of the Addendum.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE I.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PURPOSE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The construction at the Owner&#x2019;s project will require substantial numbers of employees from construction and other supporting crafts. The orderly and uninterrupted construction of the work at the Mission Bay project and the Owner&#x2019;s project are of significant interest to the parties to this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is the purpose of this Agreement to ensure that all work covered by this Agreement proceeds efficiently, economically, and with due consideration for the protection of labor standards, wages, and working conditions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consistent with the implementation of the programs described in the Mission Bay Affirmative Action and Economic Development Plan (&#x201c;MBAAWEDP&#x201d;), Project Contractor will, to the fullest extent possible, award all construction contracts to unionized construction firms. Project Contractor further commits that all construction work under its jurisdiction shall be at prevailing wages, fringes and conditions for all trades and crafts pursuant to the appropriate contract identified on Schedule A. Project Contractor will use good-faith efforts to maximize MBE, WBE and LBE contracts with union firms. Should it be determined that Minority Business Enterprise/Women Owned Business Enterprise; (MBE/WBE) goals for .this project are not being reached a a result of this Agreement, the affected crafts, San Francisco Building Trades Council and Project Contractor will meet and confer to arrive at a resolution which allows for MBE/WBE goal attainment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The parties to this Agreement have agreed and do establish and put into practice effective and binding methods for the settlement of all misunderstandings, disputes, or grievances that may arise between or among the parties to this Agreement. To accomplish the purpose that the Contractor be assured of complete continuity of operation and that labor-management peace be maintained, the Unions agree not to engage in any strike, picketing, work stoppage, slowdown, sympathy action or any other disruptive activities directed to or in connection with Covered Work, and the Contractors agree not to engage in any lockout.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE II.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EFFECT OF OTHER AGREEMENTS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The provisions of this Agreement, including the local collective bargaining agreements listed on Schedule A, shall apply to Project Contractor&#x2019;s construction and the Owner&#x2019;s project, notwithstanding the provisions of local and/or national union agreements which may conflict or differ with the terms of this Agreement.  Where a subject is covered by the provisions of this Agreement is also covered by a collective bargaining agreement which is listed on Schedule A, the provisions of this Agreement shall prevail. Where a subject is covered by the provisions of a collective bargaining agreement identified in Schedule A and not covered by this Agreement, the provisions of the appropriate collective bargaining agreement identified on Schedule A shall prevail. Further, the parties are bound by the MBAAEDP which is incorporated in its entirety in this document as though set forth herein. This Agreement is not a collateral agreement within the meaning of Section 56.3(c) and 56.11 of the San Francisco Administrative Code.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE III.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SCOPE OF THE AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Agreement shall apply to all demolition, new construction including exterior landscaping and tenant work, including but not limited to mill cabinet work and built-in furniture work performed on the Owner&#x2019;s project by or otherwise at the control and direction of Project Contractor excluding uses existing at the time of execution of this Agreement (referred to herein as &#x201c;Covered Work&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE IV. 	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">UNION RECOGNITION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Contractor recognizes the Unions signatory hereto as the collective bargaining agents for its employees covered by the terms of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Agreement does not apply to general superintendents, superintendents, assistant superintendents, (unless covered in a collective bargaining agreement listed in Schedule A), office and clerical employees, guards or other professional or supervisory employees as defined in the National Labor Relations Act.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE V. 	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">MANAGEMENT'S RIGHTS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Contractors retain full and exclusive authority for the management of its operations. Except as expressly limited by other provisions of this Agreement and the appropriate collective bargaining agreement listed on Schedule A, the Contractor retains the right to direct the working force, including the hiring, promotion, transfer, discipline or discharge of employees; the selection of foremen; the assignment and scheduling of work; and, the requirement of overtime work and the determination of when it shall be worked. No rules, customs, or practices which limit or restrict productivity, efficiency or the individual and/or joint working efforts of employees shall be permitted or observed. The Contractor may utilize any methods or techniques of construction.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Except as otherwise stated in the appropriate collective bargaining agreement listed on Schedule A, there shall be no limitation or restriction upon the Contractor&#x2019;s choice of materials or design, nor, regardless of source or location, upon the full use and installation of equipment, machinery, package units, precast, prefabricated, prefinished or preassembled materials, tools, or other labor saving devices.  The Contractor may without restriction install or otherwise use materials, supplies or equipment regardless of their source.  The on-site installation of application of such items shall be performed by the craft customarily having jurisdiction over such work under the applicable collective bargaining agreement listed on Schedule A; provided, however, it is recognized that other personnel having special talents or qualifications may participate in the installation, checkout or testing of specialized or unusual equipment or facilities.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Except as otherwise stated in the appropriate collective bargaining agreement listed on Schedule A, it is recognized that the use of new technology, equipment, machinery, tools and/or labor savings devices and methods of performing work will be initiated by the Contractor from time to time during the project.  The Union agrees that it will not in any way restrict the implementation of such new devices or work methods.  If there is any disagreement between the Contractor and the Union concerning the manner or implementation of such device or method of work, the implementation shall proceed as directed by the Contractor, and the Union shall have the right to arbitrate the dispute as set forth in Article VIII of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The failure of the Contractor to exercise rights herein reserved to it or the exercise of those rights in a particular way shall not be deemed a waiver of said rights or of the Contractor&#x2019;s right to exercise said rights in some other manner not in conflict with the terms of this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE VI.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">UNION REPRESENTATION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Authorized representatives of the Union shall have access to the Covered Work provided they do not interfere with the work of employees and further provided that such representatives fully comply with the posted visitor and security and safety rules of the Covered Work.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Union shall have the right to designate working journey workers as stewards. The Union shall, in writing, notify the Contractor as to the identity of the designated steward prior to the assumption of his/her duties as a steward. In addition to his/her work as an employee, the steward shall have the right to receive, but not solicit, complaints or grievances and to discuss and assist in the adjustment of the same with the employee&#x2019;s appropriate supervisor. The Contractor will not discriminate against a steward in the proper performance of his/her Union duties provided that such duties do not interfere with his/her regular work or with the work of other employees. Stewards shall receive the regular rate of pay for their respective craft. There will be no non-working stewards. The steward shall not have the right to determine when overtime shall be worked or who shall work overtime, or to interfere with any of the supervisory functions of the Contractor.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Contractor agrees to notify the appropriate Union twenty-four (24) hours prior to the layoff of a steward, except in the case of discipline or discharge for a cause.  If a steward is protected against such layoff by the provision of any of the collective bargaining agreements listed on Schedule A, such protection shall be recognized to the extent that the steward possesses the necessary qualifications to perform the work remaining.  In any case in which a steward is discharged or disciplined for cause the appropriate Union shall be notified immediately by the Contractor.  For the purpose of this provision, &#x201c;cause&#x201d; for discharge shall mean incompetence, unexcused absenteeism, disobedience of orders, unsatisfactory performance of duties and violation of posted project work rules.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On work where Catellus&#x2019; or Owner&#x2019;s personnel may be working in close proximity of the construction activities, the Union agrees that its representatives, stewards and individual workers will not interfere with Catellus&#x2019; or Owner&#x2019;s personnel or with the work which is being performed by Catellus&#x2019; or Owner&#x2019;s personnel. This is not to be construed to mean that Catellus&#x2019; or Owner&#x2019;s personnel may perform work covered by the collective bargaining agreements listed on Schedule A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE VII	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">WORK STOPPAGES AND LOCKOUTS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the term of this Agreement, there shall be no strikes, picketing, work stoppages, slowdowns, sympathy actions or any other disruptive activities directed at or in connection with Covered Work for any reason by the Union or by any employee, and there shall be no lockout by the Contractor.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Failure of any Union or employee to cross any picket line established at the site of Covered Work is a violation of this Article.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Union shall not sanction, aid or abet, encourage or continue any work stoppage, slowdown, sympathy action, strike, picketing or other disruptive activity at the site of Covered Work and shall undertake all possible means to prevent or to terminate any such activity. No employee shall engage in activities which violate this Article.  Any employee who participates in or encourages any activities which interfere with the normal operations of the Covered Work shall be subject to disciplinary action, including discharge.  The Union shall not be liable for acts of employees for which it has no responsibility.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In lieu of or in addition to any other action at law or equity, any party, including the Project Contractor, who the parties agree is a beneficiary of this Agreement and specifically this Article with full right of participation in any action under this Article, may institute the following procedure when a breach of paragraphs 1, 2, and/or 3 of this Article is alleged:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	The party invoking this procedure shall notify Gerald Mckay or John Kagel who the parties agree shall be the permanent Arbitrator under this procedure. In the event that the permanent Arbitrator is unavailable at any time, he shall appoint his alternate. Notice to the Arbitrator shall be by the most expeditious means available, with notice by telegram to the party alleged to be in violation and the involved International Union President.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	Upon receipt of said notice, the Arbitrator named above or his alternate shall set and hold a hearing within twenty-four (24) hours if it is contended that the violation still exists.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)	The Arbitrator shall notify the parties by telegram of the place and time he has chosen for this hearing. Said hearing shall be completed in one session.  A failure of any party to parties to attend said hearing shall not delay the hearing of evidence or issuance of an award by the Arbitrator.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)	The sole issue at the hearing shall be whether or not a violation of paragraphs 1, 2 and/or 3 of this Article has, in fact, occurred and the Arbitrator shall have no authority to consider any matter in justification, explanation or mitigation of such violation or to award damages. Any issue concerning damages is reserved for court proceedings, if any.  The award shall be issued in writing within three (3) hours after the close of the hearing and may be issued without an opinion.  If any party desires an opinion, one shall be issued within fifteen (15) days, but its issuance shall not delay compliance with, or enforcement of the Award.  The Arbitrator may order cessation of the violation of this Article and other appropriate relief, and such Award shall be served on all parties by hand or registered mail upon issuance.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e)	Such Award may be enforced by any court of competent jurisdiction upon the filing of this Agreement and all other relevant documents referred to hereinabove in the following manner.  Telegraphic notice of the filing of such enforcement proceedings shall be given to the other party.  In the proceeding to obtain an temporary order enforcing the Arbitrator&#x2019;s Award as issued under paragraph 4(d) of this Article, all parties waive the right to a hearing and agree that such proceedings may be </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">ex</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">parte</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  Such Agreement does not waive any party&#x2019;s right to participate in a hearing for a final order of enforcement.  The court&#x2019;s order or orders enforcing the Arbitrator&#x2019;s Award shall be served on all parties by hand or by delivery to their last known address or by registered mail.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(f)	Any rights created by statute or law governing arbitration proceedings inconsistent with the above procedure or which interfere with compliance therewith are hereby waived by the parties to whom they accrue.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(g)	The fees and expenses of the Arbitrator shall be divided equally between the moving parties and the party or parties respondent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE VIII 	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PROJECT COORDINATION COMMITTEE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The parties agree to form a committee comprised of representatives for the Building Trades Council, affected local union and Project Contractor, to meet and discuss issues which may arise from time to time regarding the interpretation, application and enforcement of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event a dispute arises between or among the parties thereto which cannot be resolved by the committee described in the preceding paragraph, then the dispute shall be referred to arbitration as described in Article VII with mutually agreed-upon extensions to time limits set forth therein, as may be required.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE IX	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">WORK ASSIGNMENTS AND JURISDICTION DISPUTES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Work shall be assigned by the Contractor.  There shall be no strikes, picketing, work stoppage, sympathy actions, slowdowns or other disruptive activity arising out of any jurisdictional dispute directed at or in connection with Covered Work during the term of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Except as provided below, all jurisdictional disputes will be settled in accordance with the procedural roles and decisions of the Plan for Settlement of Jurisdictional Disputes in the Construction Industry and shall be binding upon the Contractor and the Unions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Where a jurisdictional dispute involves any Union not a party to the Plan for Settlement of Jurisdictional Disputes in the Construction Industry and is not resolved among the Unions and the site representative of the affected Contractor, it shall be referred for resolution to the International Unions with which the disputed Unions are affiliated.  The International Unions shall hereafter meet with the representative of the affected Contractor to reach a joint resolution of the disputes.  For purposes of all disputes referred to the International Unions shall hereafter meet with the representative of the affected Contractor to reach a joint resolution of the disputes.  For purposes of all disputes referred to the International Unions, the Project Contractor shall be a party in interest. The resolution of the dispute shall be reduced to writing, signed by representatives of the Local and/or International Unions and a copy furnished to the Contractor.  (The Local and/or International Unions and the Contractor, in making their determination, shall have no authority to assign work to a double crew, that is, to more employees than the minimum required to perform the work involved, or to assign the work to employees who are not qualified to perform the work involved.)  This does not prohibit establishment of composite crews following jurisdictional guidelines where more than one employee is needed for the job.  The work shall proceed as assigned by the Contractor until such resolution by the parties has been confirmed in the manner indicated by the disputing Unions to the Contractors.  Any such resolution shall be final and binding on the Contractor and the Unions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE X	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">WAGES, HOURS, WORKING CONDITIONS AND FRINGE BENEFITS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With the exception of black Friday which shall not be observed on construction covered by this Agreement. wages, hours, fringe benefits and other working conditions shall be determined by the appropriate collective bargaining agreements listed on Schedule A.  Make-up days as provided in certain collective bargaining agreements listed on Schedule A shall apply to work covered by this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE XI	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">NO DISCRIMINATION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Contractor and the Unions agree that they will not discriminate against any employee or applicant for employment because of race, color, religion, sex, national origin or age in any manner prohibited by law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE XII	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">APPRENTICES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to meet and fulfill minority and woman apprentices and journey-level goals, to ensure those inducted into apprenticeship programs through Mission Bay Affirmative Action reach status, a continuity of work is required.  All work covered by this Agreement will have an appropriate apprenticeship program equal to or better than those established by the appropriate collective bargaining agreements listed on Schedule A or their respective equivalent.  The work will be done under the wages, hours, conditions, benefits of the appropriate collective bargaining agreement identified on Schedule A.  The recruitment, selection, employment and training of apprentices shall be without discrimination because of age, race, color, religion, national origin, or sex.  This provision shall be applied in manner consistent with the MBAAEDP and the appropriate JATC, except where superseded by the provisions of the Amended Consent Decree in Civil Case No. C-71-1277RFP, as modified, or as may be subsequently modified during the term of this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE XIII 	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SAFETY AND HEALTH</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Contractor, the Unions and the employees shall comply with all applicable provisions of local, state, and federal laws and regulations relating to the job safety and safe work practices.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE XIV 	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SAVINGS AND SEPARABILITY</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is not the intention of either the Contractor or the Union parties hereto to violate any laws governing the subject matter of this Agreement. The parties hereto agree that in the event any provisions of this Agreement are finally held or determined to be illegal or void as being in contravention of any applicable law, the remainder of this Agreement shall remain in full force and effect unless the part or parts so found to be void are wholly inseparable from the remaining portions of this Agreement.  Further, Contractor and Union agree that if and when any or all provisions of this Agreement are finally held or determined to be illegal or void by a court of competent jurisdiction, an effort will be made to then promptly enter into negotiations concerning the substance affected by such decision for the purpose of achieving conformity with the requirements of any applicable law and the intent of the parties hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Article shall not be construed to waive the prohibitions of Article VII, and if the parties arc unable to resolve their differences, the matter shall be referred to the procedure of Article VIII for resolution.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE XV	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">ENTIRE UNDERSTANDING</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The parties agree that the total results of their bargaining are embodied in this Agreement, and any attached exhibits and schedules, and no party signatory hereto is required to render any performance not set forth in the wording of this Agreement.  This Agreement may be amended only by written agreement signed by the parties hereto.  In the event that modification to this Agreement is required, the parties agree to promptly convene the Project Coordination Committee to discuss and negotiate the necessary modification.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ARTICLE XVI 	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">DURATION OF THE AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Agreement shall become effective immediately upon Project Contractor&#x2019;s commencement of any demolition or construction activities at the Owner&#x2019;s project within the scope of the Owner&#x2019;s OPA and this Agreement and shall continue in effect for the duration Owner&#x2019;s construction activities on the Owner&#x2019;s project as described in Article III above.  Construction of any phase, portion, section or segment of Owner&#x2019;s project shall be deemed completed when such phase, portion, section or segment has been turned over to the Owner and has received the final acceptance from the Owner&#x2019;s representative.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The collective bargaining agreements identified on Schedule A attached to this Agreement shall continue in full force and effect until the contractor and union parties to those collective bargaining agreements notify the Project Contractor of the mutually agreed upon changes in such agreements.  The parties agree that any provisions negotiated into said collective bargaining agreements will not apply to work on the Owner&#x2019;s project if such provisions are less favorable to the Contractor than those uniformly required of contractors for construction work covered by those agreements.  Such provisions, negotiated, shall not be recognized or applied on Owner&#x2019;s project if they may be construed to apply exclusively or predominantly to work covered by this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Unions agree that there will be no strikes, work stoppages, sympathy actions, picketing, slowdowns or other disruptive activities affecting the Covered Work by the Unions involved in the negotiation of the collective bargaining agreements listed on Schedule A, nor shall there by any lockout on Covered Work affecting the Unions during the course of such negotiations. Any disagreement between the parties over the incorporation into a collective bargaining agreement listed on Schedule A of such provision agreed upon in the negotiation of the collective bargaining agreement shall be subject to the grievance and arbitration procedures of Article VIII.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Agreement shall be effective until ___________, ______ 200_ and shall renew automatically for additional terms of seven years (7) each unless not less than ninety (90) days prior to the termination date of the initial or any subsequent term either Project Contractor or the San Francisco Building Trades Council give written notice to the other requesting modification or termination of the Owner&#x2019;s OPA.  Notwithstanding, this Agreement shall terminate upon the termination of the Owner&#x2019;s OPA.  Should this Agreement terminate due to the termination of the Owner&#x2019;s OPA, it will be automatically reinstated if the Owner&#x2019;s OPA or a substitute agreement thereto is reinstated within three (3) years of its termination.  If reinstatement of the Owner&#x2019;s OPA or a substitute agreement thereto occurs more than three (3) years after its termination, the parties will negotiate a new project agreement.  Reinstatement of this Agreement is subject to the seven (7) year terms and notice provision stated above.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed and effective as of the day and year above written.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:30.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PROJECT CONTRACTOR</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:30.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SAN FRANCISCO BUILDING AND</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSTRUCTION TRADES COUNCIL, AFL-CIO</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:30.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">UNIONS (See Schedule A Attached)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SCHEDULE A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.178%;"></td>
    <td style="width:38.764%;"></td>
    <td style="width:6.102%;"></td>
    <td style="width:8.178%;"></td>
    <td style="width:38.777%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Insulators &amp; Asbestos Workers Local 16</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boilermakers Local 549</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bricklayers &amp; Allied Crafts Local 3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Carpenters Local 22</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Carpenters Local 2236</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Carpet &amp; Linoleum Layers Local 12</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cement Masons Local 300, Area 580</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Electrical Workers Local 6</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Elevator Constructors Local 8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Glaziers &amp; Glassworkers Local 718</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 18</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:47.001%;"></td>
    <td style="width:5.998%;"></td>
    <td style="width:47.001%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hod Carriers Local 36</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Iron Workers Local 377</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laborers Local 67</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laborers Local 261</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lathers Local 68-L</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laborers Local 102</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating Engineers Local 3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Painters Local 4</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Piledrivers Local 34</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operative Plasterers Local 66</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:47.001%;"></td>
    <td style="width:5.998%;"></td>
    <td style="width:47.001%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Plumbers &amp; Steamfitters Local 38</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Roofers &amp; Waterproofers Local 40</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sheet Metal Workers Local 104</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sign &amp; Display Local 510</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sprinkler Fitters Local 483</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Teamsters Local 853</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional &amp; Technical Engineers Local 21</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Iron Workers Shop Local 790</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">United Steelworkers of America Machinists Local 1304</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Window Cleaners Local 44</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:12.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:24.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit A &#x2013; 20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 4.4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 5.2<br><br>RULES AND REGULATIONS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant shall faithfully observe and comply with the following Rules and Regulations. Landlord shall not be responsible to Tenant for the nonperformance of any of said Rules and Regulations by or otherwise with respect to the acts or omissions of any other tenants or occupants of the Project. In the event of any conflict between the Rules and Regulations and the other provisions of this Lease, the latter shall control.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.	Tenant shall not alter any lock or install any new or additional locks or bolts on any doors or windows of the Premises without obtaining Landlord&#x2019;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. If Tenant shall affix additional locks on doors then Tenant shall furnish Landlord with copies of keys or pass cards or similar devices for said locks. Tenant shall bear the cost of any lock changes or repairs required by Tenant. Two keys will be furnished by Landlord for the Premises, and any additional keys required by Tenant must be obtained from Landlord at a reasonable cost to be established by Landlord. Upon the termination of this Lease, Tenant shall restore to Landlord all keys of stores, offices, and toilet rooms, either furnished to, or otherwise procured by, Tenant and in the event of the loss of keys so furnished, Tenant shall pay to Landlord the cost of replacing same or of changing the lock or locks opened by such lost key if Landlord shall deem it necessary to make such changes. Notwithstanding anything to the contrary contained in the foregoing, Tenant may control entry to Tenant designated laboratory facilities within its Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.	All doors opening to public corridors shall be kept closed at all times except for normal ingress and egress to the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.	Landlord reserves the right to close and keep locked all entrance and exit doors of the Building during such hours as are customary for the Comparable Buildings. Tenant, its employees and agents must be sure that the doors to the Building are securely closed and locked when leaving the Premises if it is after the normal hours of business for the Building. Any tenant, its employees, agents or any other persons entering or leaving the Building at any time when it is so locked, or any time when it is considered to be after normal business hours for the Building, may be required to sign the Building register. Access to the Building may be refused unless the person seeking access has proper identification or has a previously arranged pass for access to the Building. Landlord will furnish passes to persons for whom Tenant requests same in writing. Tenant shall be responsible for all persons for whom Tenant requests passes and shall be liable to Landlord for all acts of such persons. Landlord and its agents shall in no case be liable for damages for any error with regard to the admission to or exclusion from the Building of any person. In case of invasion, mob, riot, public excitement, or other commotion, Landlord reserves the right to prevent access to the Building or the Project during the continuance thereof by any means it deems appropriate for the safety and protection of life and property.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.	No furniture, freight or equipment of any kind (other than inconspicuous freight or equipment) shall be brought into the Building without prior notice to Landlord. All moving activity into or out of the Building shall be scheduled with Landlord and done only at such time and in such manner as Landlord designates. Landlord shall have the right to prescribe the weight, size and position of all safes and other heavy property brought into the Building and also the times and manner of moving the same in and out of the Building. Safes and other heavy objects shall, if considered necessary by Landlord, stand on supports of such thickness as is necessary to properly distribute the weight. Landlord will not be responsible for loss of or damage to any such safe or property in any case. Any damage to any part of the Building, its contents, occupants or visitors by moving or maintaining any such safe or other property shall be the sole responsibility and expense of Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.	No furniture, packages, supplies, equipment or merchandise will be received in the Building or carried up or down in the elevators, except between such hours, in such specific elevator and by such personnel as shall be designated by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.	The requirements of Tenant will be attended to only upon application at the management office for the Project or at such office location designated by Landlord. Employees of Landlord shall not perform any work or do anything outside their regular duties unless under special instructions from Landlord.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 5.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.	No sign, advertisement, notice or handbill shall be exhibited, distributed, painted or affixed by Tenant on any part of the Premises or the Building without the prior written consent of Landlord. Tenant shall not disturb, solicit, peddle, or canvass any occupant of the Project and shall cooperate with Landlord and its agents of Landlord to prevent same.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.	The toilet rooms, urinals, wash bowls and other apparatus shall not be used for any purpose other than that for which they were constructed, and no foreign substance of any kind whatsoever shall be thrown therein. The expense of any breakage, stoppage or damage resulting from the violation of this rule shall be borne by the tenant who, or whose servants, employees, agents, visitors or licensees shall have caused same.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.	Discharge of industrial sewage to the Building plumbing system shall only be permitted if Tenant, at its sole expense, shall have obtained all necessary permits and licenses therefor, including without limitation permits from state and local authorities having jurisdiction thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.	Tenant shall not overload the floor of the Premises, nor mark, drive nails or screws, or drill into the partitions, woodwork or drywall or in any way deface the Premises or any part thereof without Landlord&#x2019;s prior written consent; provided, however, that Landlord&#x2019;s prior written consent shall not be required for the hanging of normal and customary office artwork and personal items. Landlord reserves the right to have Landlord&#x2019;s structural engineer review Tenant&#x2019;s floor loads on the Building at Landlord&#x2019;s expense, unless such study reveals that Tenant has exceeded the floor loads, in which case Tenant shall pay the cost of such survey.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.	Except for vending machines intended for the sole use of Tenant&#x2019;s employees and invitees, no vending machine or other heat generating machines (other than fractional horsepower office machines and laboratory equipment as contemplated by the Permitted Use) shall be installed, maintained or operated upon the Premises without the written consent of Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.	Tenant shall not use or keep in or on the Premises, the Building, or the Project any kerosene, gasoline, explosive material, corrosive material, or other inflammable or combustible fluid, chemical, substance or material, except as permitted by the Lease. Tenant shall provide material safety data sheets for any Hazardous Substances used or kept on the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.	Tenant shall not without the prior written consent of Landlord use any method of heating or air conditioning other than that supplied by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.	Tenant shall not use, keep or permit to be used or kept, any foul or noxious gas or substance in or on the Premises except as permitted by the Lease, or permit or allow the Premises to be occupied or used in a manner offensive or objectionable to Landlord or other occupants of the Project by reason of noise, odors, or vibrations, or interfere with other tenants or those having business therein, whether by the use of any musical instrument, radio, phonograph, or in any other way. Tenant shall not throw anything out of doors, windows or skylights or down passageways.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.	Tenant shall not bring into or keep within the Project, the Building or the Premises any animals (except service animals), birds, aquariums, or, except in areas designated by Landlord, bicycles or other vehicles.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.	No cooking shall be done or permitted on the Premises, nor shall the Premises be used for the storage of merchandise, for lodging or for any improper, objectionable or immoral purposes. Notwithstanding the foregoing, Underwriters&#x2019; laboratory-approved equipment and microwave ovens may be used in the Premises for heating food and brewing coffee, tea, hot chocolate and similar beverages for employees and visitors, provided that such use is in accordance with all applicable federal, state, county and city laws, codes, ordinances, rules and regulations.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.	The Premises shall not be used for manufacturing or for the storage of merchandise except as such storage may be incidental to the use of the Premises provided for in the Summary. Tenant shall not occupy or permit any portion of the Premises to be occupied as an office for a messenger-type operation or dispatch office, public stenographer or typist, or for the manufacture or sale of liquor, narcotics, or tobacco in any form, or as a medical office, or as a barber or manicure shop, or as an employment bureau without the express prior written consent of Landlord. Tenant shall not engage or pay any employees on the Premises except those actually working for such tenant on the Premises nor advertise for laborers giving an address at the Premises.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 5.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.	Landlord reserves the right to exclude or expel from the Project any person who, in the judgment of Landlord, is intoxicated or under the influence of liquor or drugs, or who shall in any manner do any act in violation of any of these Rules and Regulations.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.	Tenant, its employees and agents shall not loiter in or on the entrances, corridors, sidewalks, lobbies, courts, halls, stairways, elevators, vestibules or any Common Areas for the purpose of smoking tobacco products or for any other purpose, nor in any way obstruct such areas, and shall use them only as a means of ingress and egress for the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.	Tenant shall not waste electricity, water or air conditioning and agrees to cooperate fully with Landlord to ensure the most effective operation of the Building&#x2019;s heating and air conditioning system, and shall refrain from attempting to adjust any controls.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.	Tenant shall store all its trash and garbage within the interior of the Premises. No material shall be placed in the trash boxes or receptacles if such material is of such nature that it may not be disposed of in the ordinary and customary manner of removing and disposing of trash and garbage in San Francisco, California without violation of any law or ordinance governing such disposal. All trash, garbage and refuse disposal shall be made only through entryways and elevators provided for such purposes at such times as Landlord shall designate.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.	Tenant shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any governmental agency.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.	Any persons employed by Tenant to do janitorial work shall be subject to the prior written approval of Landlord, and while in the Building and outside of the Premises, shall be subject to and under the control and direction of the Building manager (but not as an agent or servant of such manager or of Landlord), and Tenant shall be responsible for all acts of such persons.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.	No awnings or other projection shall be attached to the outside walls of the Building without the prior written consent of Landlord, and no curtains, blinds, shades or screens shall be attached to or hung in, or used in connection with, any window or door of the Premises other than Landlord standard drapes. All electrical ceiling fixtures hung in the Premises or spaces along the perimeter of the Building must be fluorescent and/or of a quality, type, design and a warm white bulb color approved in advance in writing by Landlord. Neither the interior nor exterior of any windows shall be coated or otherwise sunscreened without the prior written consent of Landlord. Tenant shall abide by Landlord&#x2019;s regulations concerning the opening and closing of window coverings which are attached to the windows in the Premises, if any, which have a view of any interior portion of the Building or Building Common Areas.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.	The sashes, sash doors, skylights, windows, and doors that reflect or admit light and air into the halls, passageways or other public places in the Building shall not be covered or obstructed by Tenant, nor shall any bottles, parcels or other articles be placed on the windowsills.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.	Tenant must comply with requests by Landlord concerning the informing of their employees of items of importance to Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.	No smoking is permitted in the Building or on the Project. Tenant must comply with the State of California &#x201c;No-Smoking&#x201d; law set forth in California Labor Code Section 6404.5, and any local &#x201c;No-Smoking&#x201d; ordinance which may be in effect from time to time and which is not superseded by such state law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.	Tenant hereby acknowledges that Landlord shall have no obligation to provide guard service or other security measures for the benefit of the Premises, the Building or the Project. Tenant hereby assumes all responsibility for the protection of Tenant and its agents, employees, contractors, invitees and guests, and the property thereof, from acts of third parties, including keeping doors locked and other means of entry to the Premises closed, whether or not Landlord, at its option, elects to provide security protection for the Project or any portion thereof. Tenant further assumes the risk that any safety and security devices, services and programs which Landlord elects, in its sole discretion, to provide may not be effective, or may malfunction or be circumvented by an unauthorized third party, and Tenant shall, in addition to its other insurance obligations under this Lease, obtain its own insurance coverage to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 5.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent Tenant desires protection against losses related to such occurrences. Tenant shall cooperate in any reasonable safety or security program developed by Landlord or required by law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.	All large electrical or mechanical office or laboratory equipment shall be placed by Tenant in the Premises in settings approved by Landlord, to absorb or prevent any vibration, noise and annoyance.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.	Tenant shall not use in any space or in the public halls of the Building, any hand trucks except those equipped with rubber tires and rubber side guards.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.	No auction, liquidation, fire sale, going-out-of-business or bankruptcy sale shall be conducted in the Premises without the prior written consent of Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.	No tenant shall use or permit the use of any portion of the Premises for living quarters, sleeping apartments or lodging rooms.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33.	Tenant shall install and maintain, at Tenant&#x2019;s sole cost and expense, an adequate, visibly marked and properly operational fire extinguisher next to any duplicating or photocopying machines or similar heat producing equipment, which may or may not contain combustible material, in the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Landlord reserves the right at any time to change or rescind any one or more of these Rules and Regulations, or to make such other and further reasonable Rules and Regulations as in Landlord&#x2019;s reasonable judgment may from time to time be necessary for the management, safety, care and cleanliness of the Premises, Building, the Common Areas and the Project, and for the preservation of good order therein, as well as for the convenience of other occupants and tenants therein. Landlord may waive any one or more of these Rules and Regulations for the benefit of any particular tenants, but no such waiver by Landlord shall be construed as a waiver of such Rules and Regulations in favor of any other tenant, nor prevent Landlord from thereafter enforcing any such Rules or Regulations against any or all tenants of the Project. Tenant shall be deemed to have read these Rules and Regulations and to have agreed to abide by them as a condition of its occupancy of the Premises.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 5.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 5.5.1.1 <br><br>THE EXCHANGE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">ENVIRONMENTAL QUESTIONNAIRE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ENVIRONMENTAL QUESTIONNAIRE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FOR COMMERCIAL AND INDUSTRIAL PROPERTIES</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.996%;"></td>
    <td style="width:81.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property Address:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Instructions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The following questionnaire is to be completed by the Lessee representative with knowledge of the planned operations for the specified building/location. Please print clearly and attach additional sheets as necessary.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1.0	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PROCESS INFORMATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Describe planned use, and include brief description of manufacturing processes employed.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2.0	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">HAZARDOUS MATERIALS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Are hazardous materials used or stored? If so, continue with the next question. If not, go to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 3.0</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.002%;"></td>
    <td style="width:78.996%;"></td>
    <td style="width:13.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Are any of the following materials handled on the Property?</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Yes  No</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(A material is handled if it is used, generated, processed, produced, packaged, treated, stored, emitted, discharged, or disposed.)  If so, complete this section.  If this question is not applicable, skip this section and go on to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.0</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <table style="margin-left:0.6916666666666667in;border-spacing:0;table-layout:fixed;width:62.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:36.946%;"></td>
    <td style="width:29.33%;"></td>
    <td style="width:33.724%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Explosives</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fuels</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Oils</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Solvents</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Oxidizers</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Organics/Inorganics</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acids</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bases</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pesticides</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gases</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PCBs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Radioactive Materials</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (please specify)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2-2.	If any of the groups of materials checked in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, please list the specific material(s), use(s), and quantity of each chemical used or stored on the site in the Table below. If convenient, you may substitute a chemical inventory and list the uses of each of the chemicals in each category separately.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.996%;"></td>
    <td style="width:33.002%;"></td>
    <td style="width:8.002%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:21.004%;"></td>
    <td style="width:13.996%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="border-top:2.250pt double;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:2.250pt double;vertical-align:bottom;border-bottom:2.250pt double;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Material</font></p></td>
    <td style="border-top:2.250pt double;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Physical State (Solid, Liquid, or Gas)</font></p></td>
    <td style="border-top:2.250pt double;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Usage</font></p></td>
    <td style="border-top:2.250pt double;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Container Size</font></p></td>
    <td style="border-top:2.250pt double;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Number of Containers</font></p></td>
    <td style="border-top:2.250pt double;background-color:rgba(0,0,0,0);border-right:2.250pt double;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Total Quantity</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:2.250pt double;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:2.250pt double;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:2.250pt double;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:2.250pt double;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:2.250pt double;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:2.250pt double;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:2.250pt double;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:2.250pt double;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:2.250pt double;vertical-align:top;border-bottom:2.250pt double;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:2.250pt double;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:2.250pt double;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:2.250pt double;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:2.250pt double;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:2.250pt double;word-break:break-word;vertical-align:top;border-bottom:2.250pt double;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 5.1.1.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2-3.	Describe the planned storage area location(s) for these materials. Please include site maps and drawings as appropriate.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3.0	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">HAZARDOUS WASTES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Are hazardous wastes generated?	Yes  No</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If yes, continue with the next question. If not, skip this section and go to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 4.0</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1	Are any of the following wastes generated, handled, or disposed of (where applicable) on the Property?</font></p>
  <table style="margin-left:0.6902777777777778in;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:53.739%;"></td>
    <td style="width:46.261%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hazardous wastes</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Industrial Wastewater</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Waste oils</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PCBs</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Air emissions</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sludges</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulated Wastes</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (please specify)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3-2.	List and quantify the materials identified in Question 3-1 of this section.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.062%;"></td>
    <td style="width:12.702%;"></td>
    <td style="width:10.501%;"></td>
    <td style="width:23.096%;"></td>
    <td style="width:23.203%;"></td>
    <td style="width:15.436%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.060in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.060in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">WASTE GENERATED</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.060in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">RCRA listed Waste?</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.060in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">SOURCE</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.060in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">APPROXIMATE MONTHLY QUANTITY</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.060in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">WASTE CHARACTERIZATION</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.060in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DISPOSITION</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3-3.	Please include name, location, and permit number (e.g. EPA ID No.) for transporter and disposal facility, if applicable). Attach separate pages as necessary.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31.998%;"></td>
    <td style="width:16.998%;"></td>
    <td style="width:35.662%;"></td>
    <td style="width:15.342%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.060in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.060in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Transporter/Disposal Facility Name</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.060in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Facility Location</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.060in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Transporter (T) or Disposal (D) Facility</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.060in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Permit Number</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.060in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.060in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3-4.	Are pollution controls or monitoring employed in the process to prevent or minimize the release of wastes into the environment?	Yes  No</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3-5.	If so, please describe.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4.0	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">USTS/ASTS</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1	Are underground storage tanks (USTs), aboveground storage tanks (ASTs), or associated pipelines used for the storage of petroleum products, chemicals, or liquid wastes present on site (lease renewals) or required for planned operations (new tenants)?        Yes___   No___<br><br>If not, continue with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 5.0</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If yes, please describe capacity, contents, age, type of the USTs or ASTs, as well any associated leak detection/spill prevention measures. Please attach additional pages if necessary.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 5.1.1.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:11.005%;"></td>
    <td style="width:10.685%;"></td>
    <td style="width:12.897%;"></td>
    <td style="width:25.986%;"></td>
    <td style="width:39.427%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Capacity</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Contents</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year Installed</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Type (Steel, Fiberglass, etc.)</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Associated Leak Detection / Spill <br>Prevention Measures*</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:2.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">*</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Note:	The following are examples of leak detection / spill prevention measures:</font></p>
  <table style="margin-left:0.65625in;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.338%;"></td>
    <td style="width:33.338%;"></td>
    <td style="width:33.324%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Integrity testing</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inventory reconciliation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leak detection system</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Overfill spill protection</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Secondary containment</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cathodic protection</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4-2.	Please provide copies of written tank integrity test results and/or monitoring documentation, if available.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4-3.	Is the UST/AST registered and permitted with the appropriate regulatory agencies?	Yes  No<br>If so, please attach a copy of the required permits.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4-4.	If this Questionnaire is being completed for a lease renewal, and if any of the USTs/ASTs have leaked, please state the substance released, the media(s) impacted (e.g., soil, water, asphalt, etc.), the actions taken, and all remedial responses to the incident.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4-5.	If this Questionnaire is being completed for a lease renewal, have USTs/ASTs been removed from the Property?	Yes  No<br><br>If yes, please provide any official closure letters or reports and supporting documentation (e.g., analytical test results, remediation report results, etc.).</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4-6.	For Lease renewals, are there any above or below ground pipelines on site used to transfer chemicals or wastes?	Yes  No<br><br>For new tenants, are installations of this type required for the planned operations?<br>	Yes  No</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If yes to either question, please describe.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5.0	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">ASBESTOS CONTAINING BUILDING MATERIALS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Please be advised that an asbestos survey may have been performed at the Property. If provided, please review the information that identifies the locations of known asbestos containing material or presumed asbestos containing material. All personnel and appropriate subcontractors should be notified of the presence of these materials, and informed not to disturb these materials. Any activity that involves the disturbance or removal of these materials must be done by an appropriately trained individual/contractor.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6.0	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">REGULATORY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">	</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6-1.	Does the operation have or require a National Pollutant Discharge Elimination System (NPDES) or equivalent permit?	Yes  No<br>If so, please attach a copy of this permit.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 5.1.1.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6-2.	Has a Hazardous Materials Business Plan been developed for the site?	Yes  No<br>If so, please attach a copy.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I am familiar with the real property described in this questionnaire. By signing below, I represent and warrant that the answers to the above questions are complete and accurate to the best of my knowledge. I also understand that Lessor will rely on the completeness and accuracy of my answers in assessing any environmental liability risks associated with the property.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.004%;"></td>
    <td style="width:10.0%;"></td>
    <td style="width:33.996%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Signature:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Telephone:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 5.1.1.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 7.3 <br><br>THE EXCHANGE<br><br>TENANT/LANDLORD MAINTENANCE RESPONSIBILITY MATRIX</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img206306002_7.jpg" alt="img206306002_7.jpg" style="width:624px;height:388px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:55.833%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:55.833%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Exhibit 7.3 will be revised to reflect that gas is not metered or sub metered at the Premises. Further, Tenant has requested that Landlord provide certain services which Tenant is responsible for providing and Landlord may agree to do so at Tenant&#x2019;s cost.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 7.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 17 <br><br>THE EXCHANGE<br><br>FORM OF TENANT&#x2019;S ESTOPPEL CERTIFICATE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The undersigned as Tenant under that certain Lease (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) made and entered into as of ____________, 20 ___  by and between _______________ as Landlord, and the undersigned as Tenant, for Premises on the ____________ floor(s) of the office building located at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[INSERT BUILDING ADDRESS]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, San Diego, California, certifies as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is a true and correct copy of the Lease and all amendments and modifications thereto. The documents contained in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">represent the entire agreement between the parties as to the Premises.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The undersigned currently occupies the Premises described in the Lease, the Lease Term commenced on __________, and the Lease Term expires on __________, and the undersigned has no option to terminate or cancel the Lease or to purchase all or any part of the Premises, the Building and/or the Project.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Base Rent became payable on __________, subject to the Base Rent abatement set forth in the Lease.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Lease is in full force and effect and has not been modified, supplemented or amended in any way except as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tenant has not transferred, assigned, or sublet any portion of the Premises nor entered into any license or concession agreements with respect thereto except as follows:</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intentionally Omitted.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All monthly installments of Base Rent, all Additional Rent and all monthly installments of estimated Additional Rent have been paid when due through __________. The current monthly installment of Base Rent is $__________.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All conditions of the Lease to be performed by Landlord necessary to the enforceability of the Lease have been satisfied and Landlord is not in default thereunder. In addition, the undersigned has not delivered any notice to Landlord regarding a default by Landlord thereunder. The Lease does not require Landlord to provide any rental concessions or to pay any leasing brokerage commissions.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No rental has been paid more than thirty (30) days in advance and no security has been deposited with Landlord except as provided in the Lease.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of the date hereof, there are no existing defenses or offsets, or, to the undersigned&#x2019;s knowledge, claims or any basis for a claim, that the undersigned has against Landlord.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Tenant is a corporation or partnership, each individual executing this Estoppel Certificate on behalf of Tenant hereby represents and warrants that Tenant is a duly formed and existing entity qualified to do business in California and that Tenant has full right and authority to execute and deliver this Estoppel Certificate and that each person signing on behalf of Tenant is authorized to do so.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">12.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are no actions pending against the undersigned under the bankruptcy or similar laws of the United States or any state.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">13.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the best of Tenant&#x2019;s knowledge, Tenant is in full compliance with all federal, state and local laws, ordinances, rules and regulations affecting its use of the Premises, including, but not limited to, those laws, ordinances, rules or regulations relating to hazardous or toxic materials. Tenant has never permitted or suffered, nor does Tenant have any knowledge of, the generation, manufacture, treatment, use, storage, disposal or discharge of any hazardous, toxic or dangerous waste, substance or material in, on, under or about the Project or the Premises or any adjacent premises or property in violation of any federal, state or local law, ordinance, rule or regulation.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:10.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">14.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the undersigned&#x2019;s knowledge, all tenant improvement work to be performed by Landlord under the Lease has been completed in accordance with the Lease and has been accepted by the undersigned and all reimbursements and allowances due to the undersigned under the Lease in connection with any tenant improvement work have been paid in full. All work (if any) in the common areas required by the Lease to be completed by Landlord has been completed and all parking spaces required by the Lease have been furnished and/or all parking ratios required by the Lease have been met.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The undersigned acknowledges that this Estoppel Certificate may be delivered to Landlord or to a prospective mortgagee or prospective purchaser, and acknowledges that said prospective mortgagee or prospective purchaser will be relying upon the statements contained herein in making the loan or acquiring the property of which the Premises are a part and that receipt by it of this certificate is a condition of making such loan or acquiring such property.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Executed at __________________ on the _____ day of ____________, 20__.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.69%;"></td>
    <td style="width:2.142%;"></td>
    <td style="width:2.142%;"></td>
    <td style="width:4.144%;"></td>
    <td style="width:44.737%;"></td>
    <td style="width:1.146%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Tenant&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 21<br><br>FORM LETTER OF CREDIT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IRREVOCABLE STANDBY LETTER OF CREDIT NO. __________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:30.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DATE:___________, 20___</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BENEFICIARY:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:30.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:30.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">APPLICANT:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:30.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AMOUNT: US$__________ ($__________ and 00/100 U.S. DOLLARS)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXPIRATION DATE:_______________, 20___</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">LOCATION: AT OUR COUNTERS IN _______________________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:30.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DEAR SIR/MADAM:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WE HEREBY ESTABLISH OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO. ___________ IN YOUR FAVOR AVAILABLE BY YOUR DRAFT IN THE FORM OF &#x201c;ANNEX 1&#x201d; ATTACHED DRAWN ON US AT SIGHT AND ACCOMPANIED BY THE FOLLOWING DOCUMENTS:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A DATED STATEMENT SIGNED BY AN AUTHORIZED OFFICER OF THE BENEFICIARY READING AS FOLLOWS:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(A)	WE ARE ENTITLED TO DRAW ON THE LETTER OF CREDIT PURSUANT TO THE TERMS OF THAT CERTAIN LEASE BY AND BETWEEN_______________, AS LANDLORD, AND _______________, AS TENANT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">OR</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(B)	_______________  HEREBY CERTIFIES THAT IT HAS RECEIVED NOTICE FROM _______________ THAT THE LETTER OF CREDIT NO.__________ WILL NOT BE RENEWED, AND THAT IT HAS NOT RECEIVED A REPLACEMENT OF THIS LETTER OF CREDIT FROM _________________ SATISFACTORY TO _________________ AT LEAST FORTY-FIVE (45) DAYS PRIOR TO THE EXPIRATION DATE OF THIS LETTER OF CREDIT.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 21</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">THE LEASE MENTIONED IN THIS LETTER OF CREDIT IS FOR IDENTIFICATION PURPOSES ONLY AND IT IS NOT INTENDED THAT SAID AGREEMENT BE INCORPORATED HEREIN OR FORM PART OF THIS LETTER OF CREDIT.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DRAFT(S) AND DOCUMENTS MUST INDICATE THE NUMBER AND DATE OF THIS LETTER OF CREDIT. PARTIAL DRAWINGS ARE PERMITTED.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">THIS LETTER OF CREDIT SHALL BE AUTOMATICALLY EXTENDED FOR AN ADDITIONAL PERIOD OF ONE YEAR, WITHOUT AMENDMENT OR CONDITION, FROM THE PRESENT OR EACH FUTURE EXPIRATION DATE UNLESS AT LEAST FORTY-FIVE (45) DAYS PRIOR TO THE THEN CURRENT EXPIRATION DATE WE NOTIFY YOU AND THE APPLICANT BY REGISTERED MAIL/OVERNIGHT COURIER SERVICE AT THE ABOVE ADDRESSES THAT THIS LETTER OF CREDIT WILL NOT BE EXTENDED BEYOND THE CURRENT EXPIRATION DATE.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">THIS LETTER OF CREDIT MAY BE TRANSFERRED (AND THE PROCEEDS HEREOF ASSIGNED), AT THE EXPENSE OF THE APPLICANT (WHICH PAYMENT SHALL NOT BE A CONDITION TO ANY TRANSFER), ONE OR MORE TIMES BUT IN EACH INSTANCE ONLY IN THE FULL AMOUNT AVAILABLE TO BE DRAWN UNDER THE LETTER OF CREDIT.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ALL DEMANDS FOR PAYMENT SHALL BE MADE BY PRESENTATION OF THE DATED CERTIFICATION PRIOR TO ________ A.M. ______________ TIME, ON A BUSINESS DAY AT OUR OFFICE (THE &#x201c;BANK&#x2019;S OFFICE&#x201d;) AT: ___________________________, ATTENTION: STANDBY LETTER OF CREDIT SECTION OR BY FACSIMILE TRANSMISSION AT: (___)_____________; AND SIMULTANEOUSLY UNDER TELEPHONE ADVICE TO: (___)_______________, ATTENTION: STANDBY LETTER OF CREDIT NEGOTIATION SECTION WITH ORIGINALS TO FOLLOW BY OVERNIGHT COURIER SERVICE.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PAYMENT AGAINST CONFORMING PRESENTATIONS HEREUNDER SHALL BE MADE BY BANK IN IMMEDIATELY AVAILABLE U.S. FUNDS DURING NORMAL BUSINESS HOURS OF THE BANK&#x2019;S OFFICE WITHIN TWO (2) BUSINESS DAYS AFTER PRESENTATION NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THE UNIFORM CUSTOMS AND PRACTICES FOR DOCUMENTARY CREDITS (1993 REVISION), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 500, OR THE &#x201c;INTERNATIONAL STANDBY PRACTICES&#x201d; (ISP 98), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 590.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WE HEREBY CERTIFY THAT THIS IS AN UNCONDITIONAL AND IRREVOCABLE CREDIT AND AGREE WITH THE DRAWERS, ENDORSERS AND BONAFIDE HOLDERS THAT THE DRAFTS DRAWN UNDER AND IN ACCORDANCE WITH THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT SHALL BE DULY HONORED UPON PRESENTATION TO THE DRAWEE, IF NEGOTIATED ON OR BEFORE THE EXPIRATION DATE OF THIS CREDIT.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXCEPT TO THE EXTENT INCONSISTENT WITH THE EXPRESS TERMS HEREOF, THIS LETTER OF CREDIT IS SUBJECT TO THE &#x201c;INTERNATIONAL STANDBY PRACTICES&#x201d; (ISP 98), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 590.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.007%;"></td>
    <td style="width:15.789%;"></td>
    <td style="width:51.203%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AUTHORIZED SIGNATURE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AUTHORIZED SIGNATURE</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 21</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">ANNEX 1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img206306002_8.jpg" alt="img206306002_8.jpg" style="width:615px;height:320px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 21</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT &#x201c;A&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DATE:</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.128%;"></td>
    <td style="width:29.809%;"></td>
    <td style="width:16.232%;"></td>
    <td style="width:7.583%;"></td>
    <td style="width:14.099%;"></td>
    <td style="width:28.151%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TO:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RE:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">STANDBY LETTER OF CREDIT</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NO.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ISSUED BY</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">LADIES AND GENTLEMEN:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FOR VALUE RECEIVED, THE UNDERSIGNED BENEFICIARY HEREBY IRREVOCABLY TRANSFERS TO:</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:35.294%;"></td>
    <td style="width:64.706%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(NAME OF TRANSFEREE)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ADDRESS)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY TO DRAW UNDER THE ABOVE LETTER OF CREDIT UP TO ITS AVAILABLE AMOUNT AS SHOWN ABOVE AS OF THE DATE OF THIS TRANSFER.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BY THIS TRANSFER, ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY IN SUCH LETTER OF CREDIT ARE TRANSFERRED TO THE TRANSFEREE. TRANSFEREE SHALL HAVE THE SOLE RIGHTS AS BENEFICIARY THEREOF, INCLUDING SOLE RIGHTS RELATING TO ANY AMENDMENTS, WHETHER INCREASES OR EXTENSIONS OR OTHER AMENDMENTS, AND WHETHER NOW EXISTING OR HEREAFTER MADE. ALL AMENDMENTS ARE TO BE ADVISED DIRECT TO THE TRANSFEREE WITHOUT NECESSITY OF ANY CONSENT OF OR NOTICE TO THE UNDERSIGNED BENEFICIARY.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">THE ORIGINAL OF SUCH LETTER OF CREDIT IS RETURNED HEREWITH, AND WE ASK YOU TO ENDORSE THE TRANSFER ON THE REVERSE THEREOF, AND</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FORWARD IT DIRECTLY TO THE TRANSFEREE WITH YOUR CUSTOMARY NOTICE OF TRANSFER.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.682%;"></td>
    <td style="width:14.316%;"></td>
    <td style="width:52.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SINCERELY,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:30.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SIGNATURE AUTHENTICATED</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(BENEFICIARY&#x2019;S NAME)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Name of Bank)</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:30.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SIGNATURE OF BENEFICIARY</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(authorized signature)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 21</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 24.4<br><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">THE EXCHANGE<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">RECOGNITION OF COVENANTS, CONDITIONS, AND RESTRICTIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FORM OF RECOGNITION OF COVENANTS, CONDITIONS, AND RESTRICTIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RECORDING REQUESTED BY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AND WHEN RECORDED RETURN TO:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KRE Exchange Owner LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">c/o Longfellow Property Management Services CA, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1800 Owens Street, Suite 350</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Francisco, CA 94158</font></p>
  <p style="text-indent:0.0%;padding-bottom:10.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;border-bottom:2.250pt solid;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Attention: Property Management</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">RECOGNITION OF COVENANTS,<br>CONDITIONS, AND RESTRICTIONS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Recognition of Covenants, Conditions, and Restrictions (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) is entered into as of the _____ day of __________________, 20___, by and between _______________________________ (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and _______________________________ (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), with reference to the following facts:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A.	Landlord and Tenant entered into that certain Lease dated _____________, 20___ (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Pursuant to the Lease, Landlord leased to Tenant and Tenant leased from Landlord space (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) located in certain buildings on certain real property described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">attached hereto and incorporated herein by this reference (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">B.	The Premises is located in a project located on real property which is part of an area owned by Landlord containing approximately ______(__) acres of real property located in the City of ____________, California (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Project</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), as more particularly described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">attached hereto and incorporated herein by this reference.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">C.	Landlord, as declarant, has previously recorded, or proposes to record concurrently with the recordation of this Agreement, a Declaration of Covenants, Conditions, and Restrictions (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Declaration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), dated __________, 20___, in connection with the Project.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">D.	Tenant is agreeing to recognize and be bound by the terms of the Declaration, and the parties hereto desire to set forth their agreements concerning the same.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NOW, THEREFORE, in consideration of (a) the foregoing recitals and the mutual agreements hereinafter set forth, and (b) for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows,</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tenant&#x2019;s Recognition of Declaration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding that the Lease has been executed prior to the recordation of the Declaration, Tenant agrees to recognize and by bound by all of the terms and conditions of the Declaration.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1	This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, estates, personal representatives, successors, and assigns.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2	This Agreement is made in, and shall be governed, enforced and construed under the laws of, the State of California.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 24.4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3	This Agreement constitutes the entire understanding and agreements of the parties with respect to the subject matter hereof and shall supersede and replace all prior understandings and agreements, whether verbal or in writing. The parties confirm and acknowledge that there are no other promises, covenants, understandings, agreements, representations, or warranties with respect to the subject matter of this Agreement except as expressly set forth herein.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4	This Agreement is not to be modified, terminated, or amended in any respect, except pursuant to any instrument in writing duly executed by both of the parties hereto.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5	In the event that either party hereto shall bring any legal action or other proceeding with respect to the breach, interpretation, or enforcement of this Agreement, or with respect to any dispute relating to any transaction covered by this Agreement, the losing party in such action or proceeding shall reimburse the prevailing party therein for all reasonable costs of litigation, including reasonable attorneys&#x2019; fees, in such amount as may be determined by the court or other tribunal having jurisdiction, including matters on appeal.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6	All captions and heading herein are for convenience and ease of reference only, and shall not be used or referred to in any way in connection with the interpretation or enforcement of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7	If any provision of this Agreement, as applied to any party or to any circumstance, shall be adjudged by a court of competent jurisdictions to be void or unenforceable for any reason, the same shall not affect any other provision of this Agreement, the application of such provision under circumstances different from those adjudged by the court, or the validity or enforceability of this Agreement as a whole.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8	Time is of the essence of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.9	The Parties agree to execute any further documents, and take any further actions, as may be reasonable and appropriate in order to carry out the purpose and intent of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.10	As used herein, the masculine, feminine or neuter gender, and the singular and plural numbers, shall each be deemed to include the others whenever and whatever the context so indicates.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 24.4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:18.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURE PAGE OF RECOGNITION OF<br><br>COVENANTS, CONDITIONS AND RESTRICTIONS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.201%;"></td>
    <td style="width:2.152%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:4.561%;"></td>
    <td style="width:57.837%;"></td>
    <td style="width:1.156%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Landlord&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.201%;"></td>
    <td style="width:2.152%;"></td>
    <td style="width:1.092%;"></td>
    <td style="width:4.154%;"></td>
    <td style="width:58.244%;"></td>
    <td style="width:1.156%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Tenant&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 24.4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 28.6<br><br>STORAGE AREA</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 28.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>vir-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">	Exhibit 23.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:13.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">a.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Registration Statement (Forms S-8 Nos. 333-234212, 333-237410 and 333-253547) pertaining to the 2016 Equity Incentive Plan, 2019 Equity Incentive Plan and 2019 Employee Stock Purchase Plan of Vir Biotechnology, Inc.; and</font>
   </div>
  </div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">b.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Registration Statement (Form S-3 No. 333-250013) of Vir Biotechnology, Inc.;</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of our reports dated February 28, 2022, with respect to the consolidated financial statements of Vir Biotechnology, Inc. and the effectiveness of internal control over financial reporting of Vir Biotechnology, Inc. included in this Annual Report (Form 10-K) of Vir Biotechnology, Inc. for the year ended December 31, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young LLP</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redwood City, California</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 28, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>vir-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, George Scangos, Ph.D., certify that:</font></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Vir Biotechnology, Inc.;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.4%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:4.178%;"></td>
    <td style="width:46.426%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: February 28, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;George Scangos</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">George Scangos, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>vir-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Howard Horn, certify that:</font></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Vir Biotechnology, Inc.;</font>
   </div>
  </div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
   </div>
  </div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font>
   </div>
  </div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font>
   </div>
  </div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
   </div>
  </div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
   </div>
  </div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
   </div>
  </div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font>
   </div>
  </div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font>
   </div>
  </div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font>
   </div>
  </div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font>
   </div>
  </div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.4%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:4.178%;"></td>
    <td style="width:46.426%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: February 28, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer and Secretary</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>vir-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report of Vir Biotechnology, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), George Scangos, Ph.D., President, Chief Executive Officer and Director of the Company and Howard Horn, Chief Financial Officer and Secretary of the Company, each hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to such officer's knowledge:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 28</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of February 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.976%;"></td>
    <td style="width:0.684%;"></td>
    <td style="width:3.237%;"></td>
    <td style="width:49.103%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;George Scangos</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">George Scangos, Ph.D.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer and Secretary</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Vir Biotechnology, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img61678762_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2UV17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $.X<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C$W(#$T.C W.C,T   "H $  P    $  0  ZAP !P  " P
M  C@     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M!@$#  ,    !  8   $:  4    !   1/ $;  4    !   11 $H  ,    !
M  (   (!  0    !   13 ("  0    !   <(@        !@     0   &
M   !_]C_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@
M)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!# 0D)"0P+#!@-#1@R
M(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C+_P  1" !U 0 # 2$  A$! Q$!_\0 'P   04! 0$! 0$
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MW@;[2F=)BA&.91(,C\A6E]GA_P F@ ^SP_Y-9][;G>=NFQ70R-NYP,<=\YH
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M !52XN+LS:%2-1<T7=!NE_Y^;?\ []G_ .*HW2_\_-O_ -^S_P#%5)8;I?\
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M#'KW[U8WR\'S1ST^<<T ."W+#(8D'H0PJK<QZN93]DGA5<#*RC./<8(_7TH
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M1BS_ .?&'_O@?X4 &VSQG[%#_P!\#_"C%G_SY0_]\#_"@ Q9_P#/E#_WP/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BDS10 M%%% !129'K10 M%%% !111
M0 4444 %%)FC(]: %HHI,T +1110 4444 %%%% !1110 44F:-P]: %HI,T9
M[=Z %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBD;[IH \-_:)_:,TWX"6>AVJ:->>*/$_B"Z
M\G2=!LFV2SE2OFMO/]T,FU/O,S*J^J]C\*_BQX;^,O@NQ\2>%;[[;I]R=C*Y
M"36TJ\O%*O.V1?[O_LO-?F/\?OAQX^^&/Q6OM(\:B7QK#XHN9;AM4O+SRH=<
M10H@2V79MM;^!=_E_-M^=8E1D;;*SX _%Y_A+XNMT^']]#/K$:10RZ5+&UK:
M^)[?YMMM,K?+;:G%\RJR_+)M.-V[_2/H7EL98=2IN\N_3_@?U?R\GZVXU.6:
MT/UWW%3C'%>?_%_XP>&O@CX,N_$WBB^:VLHB5BA4YEN9?X(HD_B9O_U_+7$-
M^U]X$_X4O_PL2.XN9K5IO[/71UA_XF#:A_SX^3G_ %^[G;_=^;[OS5^>/QN^
M+4OQB\97@\=WMN=4,;1_8+9/M5OH-ON7_0;*/[MQJ,K,JR2?=C_V=O[KBP>7
MSKS]]62.BOB8Q7N[GZ+_ +.W[2%E^T!I.KHVB7_AGQ/H5TMIK&AW>6:UD8ML
M_>[55ON/N7"NK(59?NEO;MO5>G<5^2?P#^'7CWXE?%BQT_P<&\&P>$;J">'5
M;*Z$UKH2.K"YBG79MN[V7Y%D.[:=CHP5/EB_6S_EGQ^-98[#PP]7E@]^G;^O
MZ[N\-4=6&I-12#.!GK2UP'6%%%% !2'@$TM)0!4D^4 J.6/Y50U[7-.\*Z7/
MJ.IW<=E90*7DGF;:B+ZFM%\^8,#Z#\*^:/VOKS[1=>#=.F+?V;,;NXEA.H16
M*M-$L7E'SI%95V[GK>C3]K-0/-S#%?4\-*NEM^KL>Y>"_&-GXXT.UU6SMKJU
MMYBQB2^A\IV4-\K[3_"WWE/H:Z5AM7&,$^IKXS^'?C36K/Q=82:2^H>([[YO
M*TJX^(5M<)/\C?\ +(+\W&6]MGM7V);-+Y(D=&B=ERT9?=MJJU'V4K&.78Y8
MRG?JO)FBOW12TE+7,>P%%%% !1110 4C?=-+3.(UZT 9&I:U9:;]F6[E$)GF
M6WC+=6=NBBLOQ1XH?PY!%=?V?)<62M_I$L+_ #0C^_MQ\U<I\2=-NEOM/%M?
MW%S?75Y$]G8'9Y2,OWG;Y,[%3FM;_A6MK=1E]9N;K6[N0<^=,R1J?]A%.%KX
MVMCLQQ5:MA<+3Y6K6DVK?/??M:]GNCNA3I049S>_]>1NZ'K[ZEI?VJ^M'TK=
MN=(IG^8)_>?^[WK4T_4+?4K>*\MY5F@D0.CI_$*X'7? MYI>F7+>'[N=<V[(
MVFW$KS0R+C^'>?D:K7PTLI%T:SNTU2ZOK%K<116\T:)Y?_ZONUOALPQ<<3#!
M8FEK;65UKYK;3OI=76@I4Z?(ZD&>BTM)2U]6<04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #>QKYM_:8^+GC+PCKV
MEZ=X&>-[K1[&7Q5X@A,2R--I<#JK6ZEA\K2[I<,GS_N*^DMO!%>-R?LV^%O$
M7CKQ-XG\::-H_C6_U>6#[*FK:3'.FFVL42HEO%YN_P#B\V1V&W<TGW1MK:C*
M$)<TT85E.2M J>,OVE-$\)ZBMI;>'?$'BA5T%?$LMUH,4#1)8LS?O=TLL?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /RWO/^"L7Q"M\[/!_AK\1<?_':I?\ #V[XC_\ 0H>%_P#OFX_^/5\L?#/0
MK+Q1\6/!>BZG#]JTW4M;L[*Y@WLGF12SHK+N7YE^5J^[/$'[+/P1\9_$OXG?
M"+0/ LWA+Q-H.B0:IIWB2/6KRY#,RQO\\$C.NQ6=%;[Y96?;M:NF481.>,I,
M\Z_X>W?$?_H4/"__ 'S<?_'J/^'MWQ'_ .A0\+_]\W'_ ,>KE-6_8YU?XAZ'
M\&+#P=X7T'P[J7B+P[<:O>ZO_;MY=?:XHHK5O/GB:W_</NG5?*@\WYI?[J[J
MX:/]B;Q[??$S3? ^G:AX?U+4+O3VU2XN(KZ6)-,B7;N^VQ2Q)/ VV:!MKQ;O
MWJ?[6TY8!>1[)_P]N^(__0H>%_\ OFX_^/4?\/;OB/\ ]"AX7_[YN/\ X]7D
MM]^PG\1'\0>#[#0;_P -^,=-\532P67B#P]J7VK3(FBW^;YLNQ=NQ4=OE5ON
M,J[F^6I==_8+^(.EZEX/MM-U?PIXIMO$NJR:-;ZAH>JM+;6\\:,[+*[Q+]U8
MYV^7=_JG7[VU6.6 7D>J_P##V[XC_P#0H>%_^^;C_P"/4?\ #V[XC_\ 0H>%
M_P#OFX_^/5XWXJ_8C\>^&_%WAKPQ;WN@ZWKVO7,MK!I]I=2P7$/E>;^]E@NH
MHI?(VP3LLJJR,L3;6^9=U+XM_L?^+?A)X)NO%;:[X7\7:'8:A_96I7/A;4FN
MAI]Q\O[J?<B;6W,J[?X=R[NHHY8!>1[C_P /;/B-_P!"AX7_ .^;C_X]1_P]
ML^(W_0H>%_\ OFX_^/5Y=^Q7\&?"?Q"U+QUXK^(NG/?^ /".C/>WR1SSQ.TO
MWDV^6RLWRQ2_+N_NUTOQ0_8;U35OVIO$G@#X?G3M.TLZ.OB/2UU&[F:)[(LD
M;*C[969O,=E7=_<^]3Y87L'-*QUG_#V[XC_]"AX7_P"^;C_X]1_P]N^(_P#T
M*'A?_OFX_P#CU>5:/^PKXLUF/4KP>-_ -GX>L;J+3U\176M,NGW=TZ;_ "()
M?*_>,FY5;^'=\JLS(ZK%IO["/Q%D\2>---UJ\\/^$+'PJT2W^N^(-0:VTV3S
M?]4T4NQMRNNUOFV[=VUMK?+2Y8!>1ZU_P]M^(W_0H>&/^^;C_P"/4?\ #VWX
MC?\ 0H>&/^^;C_X]7RS\<?@CXC_9_P#'DWA/Q.+5[]((KJ.>QF\V":)ONLC,
MJM]Y67YE7[M<!D^E5R0%S,^Y?^'MGQ&_Z%#PO_WS<?\ QZNX^%'_  4H\<_$
M*]\2V]WX7\/VJZ5X<U'6(C;K<?-+;0F55;YS\G%?G#7L?[,__(8^('_8B:]_
MZ1O0X1$IL^@_^'MOQ&_Z$_PO_P!\W'_QZC_A[=\1_P#H4/"__?-Q_P#'J^&:
M_43X._L;?"_Q-\*OA'J\_P *E\1S>(;"&77-7_X2.ZM39;H0_G^5YO[S=)A=
MB;=NZI<8(I2DSR'_ (>W?$?_ *%#PO\ ]\W'_P >H_X>W?$?_H4/"_\ WS<?
M_'J\\\4_L2W-W9^*?&GAKQKX3L_AI:ZU?6-GJFLZC+&PB@D=4+,(F67YE"JR
M,WF,5^7YJHW7_!/_ .)MIX6N-1>\\.'Q!!I9UF3P:FH[M;6U#;=_V?9M_P#'
MO]G[_P E'+ +R/4?^'MOQ&_Z%#PQ_P!\W'_QZC_A[;\1O^A0\,?]\W'_ ,>J
M;]E7]@>+4/%F@7WQ6CT74='US0VU*U\,QZK/!JD66BV3RQ+Y;;%W;6VLVUG3
M=7B&C_L7^-M:O_A1:6VJ: )?B3:75YI#27,^V!8(%G?[1^Z^5MK?P;OFHM /
M>/:?^'MOQ&_Z%#PQ_P!\W'_QZC_A[;\1O^A0\,?]\W'_ ,>KS#PC^P'\0?%6
MGB]FUWPEX=AGU:?1M._MS4V@?5+B&5XG^SHL3,WSQ2[=VUOEW;=M=1X5_8KL
M$_9C^('BSQ/JNGZ-X\T?49M/6WU+5$CM-+\B6+?%+L3_ %\N'2)=[*RSQ,OW
MMU%H![QT_P#P]L^(W_0G^%_^^;C_ ./4?\/;/B-_T)_A?_OFX_\ CU>5?L1?
M 'P[\;O&WB*]\9+<3^%?#.F'4;RTM)FCEN6#?+%\OS;=JR[MK*WW:SO$_P#P
MJ;XV6'AS0OA;\//$'@SXE7NH):1:7'J#:CIUY&[;?GGGD$D3K][=LVK\V[^\
MI:%]@NSV;_A[=\1_^A0\+_\ ?-Q_\>H_X>W?$?\ Z%#PO_WQ<?\ QZO,/&'[
M OCWPC8Q747B+P?K\/\ ;EMX>O3HFJR3-I]U/*L2_:%:)=GSR1[E^9OF7Y:3
MQG^P'\1_!OASQ!JHU'PSKLNB2P17FEZ-J#3WH\PH$?RFB7;G?PK;6/7;BCE@
M%Y'J'_#VWXC_ /0H>%_^^;C_ ./4?\/;?B-_T*'A?_OFX_\ CU2>$_V#[3X>
M_#/XR7GQ&D\/:]XET7PP^J:=:Z1K4S7&DW'V>=]UQ$OE\MM0KNW*VQJY[XC_
M +$^L>+/'NDZ3X3\/>&/ %E;^%8M<U*^N/$5Y>6*IYCJ9I99X%:)FV-\JJR;
M49MU+W ]XW?^'MOQ&_Z%#PQ_WS<?_'J/^'MOQ&_Z%#PQ_P!\W'_QZJ_Q<_8?
M@U)?@?X;^'-AIL7B/7/#\U]KNL)JDMQ83&..UWW7F[G_ '3/+\IB7YO-7Y:Y
MOP#_ ,$_]0O/B7X$T_Q+XP\-ZAX,\2_:GBUKPIJWG"=H%YB@>2+:\OMM9=L<
MG]VG: >\=9_P]L^(W_0H>&/^^;C_ ./4O_#V[XC?]"?X7_[YN/\ X]7">,OV
M'=3O?B;\0_[ \3>"=#\!Z)J$J_VSJ>NLMEI^^=EBL9965F6Y16575ON_WMS"
MO$/C9\$?$GP#\;-X9\3I:M=-;)>6UU83^;;W,#[MDL3?*VW<K+\RK]VCE@Q7
MDCZI_P"'MOQ&_P"A0\,?]\W'_P >H_X>V_$;_H4/#'_?-Q_\>KX:_&C\:?)$
M.=GW-_P]L^(W_0H>%_\ OBX_^/5VUK_P4H\<3?!#4_'#>&- &HV?B.UT9+?;
M/Y+Q2VUQ*S'Y\[@UNO?N:_.6O8--_P"3/_$/_8^:9_Z;[ZAPB+G9]!_\/;/B
M-_T*'A?_ +YN/_CU+_P]M^(W_0G^%_\ OBX_^/5\7>%=1TO2?$FF7VM:3_;^
MCP7*2W>E_:6M?M<6[YXO-7YDW?WEK[?\>^'?@!X._9C\%?%F/X%>>_B:\DLE
MTO\ X2W44^R$>>-_F_Q_ZC[NU?O4I)+H4FWU*'_#V[XC_P#0H>%_^^;C_P"/
M4?\ #V[XC_\ 0H>%_P#OFX_^/5Y?K'[ GQ"T>/PZ@UGPG=ZKXB2WDTG1[?4I
M%OKQ7^9ML31+_JD^>5S\BK_>^[5+QI^POX_\+Z:EYI.I^&/':+J\>@W,?A35
M/M36-XSK$D5QN1/*8NRK_L[OFV\4<L O(]=_X>V_$;_H4/#'_?-Q_P#'J/\
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MLZS)':_9_,9$@^\R.Q<I$NR-F9MO;.(]PKWCG_\ A[9\1O\ H3_#'_?-Q_\
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M&VOM/T+2;G2KF+5M16:_U%9WB=V>ZC@B56_T>W^[%_ V[=N^7[0_X=M_ /\
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MXMU!]2BATBZ_LJ#39MD:Q+%''&WR1>1%M7=_!\V[?7Z'?\.V_@'_ -"I>?\
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MDSX ^(G_  @&B>-+:VT_[1?^(=(_L:.\\[;]DA::)YSMV_-O2+9]Y=N^NO\
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MM/1_"O[8'A_Q)X7M;;Q=X9\'V5S;00V5VL-O=W5VCM<2QSHLF[EU_AY:)O\
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M (-[O_X[5^T1/LV?F)XA7_C$[P/_ -C?K/\ Z2Z?7)?![X@?\*G^*'AGQ?\
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MZK\<;S_A"_)_X6;865AL_M3=_9OD6KP;O]1^]W;]W\-?>7_#N3X"?]"C<_\
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MOEQ)%]_:O]W^[7ZF_P##N7X"_P#0H7'_ (-[S_X[1_P[E^ O_0H7'_@WO/\
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MKG@'+(_&?;[4NWVK]E_^'<OP$_Z%"Y_\&]Y_\=H_X=R_ 3_H4+G_ ,&]Y_\
M':?M(D^S9^-&WVHVU^R__#N7X"?]"A<_^#>\_P#CM'_#N7X"?]"A<_\ @WO/
M_CM'M(A[-GXT;?:C;[5^R_\ P[E^ G_0H7/_ (-[S_X[1_P[E^ G_0H7/_@W
MO/\ X[1[2(>S9^9'[,:_\55XQ_[$CQ#_ .FZ6O'=M?MCX5_87^#?@VZOKG2?
M#=Q;S7EA<:9,SZE<ON@GC:*5?F<\LKM\W7GBL?\ X=R_ 3_H4;G_ ,&]Y_\
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MVG[1![-GXRT5^S7_  [=^ G_ $*=W_X-[O\ ^.4?\.W?@)_T*EW_ .#>[_\
MCE'M$'LV?C+17[-?\.W?@)_T*EW_ .#>[_\ CE'_  [=^ G_ $*EW_X-[O\
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MTCS'E=UBO$B\U?\ 6_>B\IN/^^?T+_X=N? /_H5+O_P;W?\ \<H_X=N_ /\
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M\4#PW_PDQO=633/L?V[[+MW12R;]WE.?^66W;M_BKY5_X? 2?]$E _[F,_\
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MO\P_M##_ ,WX,_1?=1NK\Z?^'NQ_Z)./_"C/_P B4?\ #W9O^B3C_P *,_\
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M.8?\^OQ7^8?VAA_YOP9^B^ZC=7YT?\/=S_T2<?\ A1G_ .1*/^'NY_Z)./\
MPHS_ /(E']@YA_SZ_%?YA]?P_P#-^#/T6W4;J_.G_A[LW_1)Q_X49_\ D2C_
M (>[-_T2<?\ A1G_ .1*/[!S#_GU^*_S#^T,/_-^#/T7W4;J_.C_ (>[-_T2
M<?\ A1G_ .1*7_A[JW_1*!_X49_^1*/[!S#_ )]?BO\ ,/K^'_F_!GZ+;J-U
M?G3_ ,/=6_Z)0/\ PHS_ /(E'_#W5O\ HE _\*,__(E']@YA_P ^OQ7^8?7\
M/_-^#/T6W4;J_.G_ (>ZM_T2@?\ A1G_ .1*/^'NK?\ 1)Q_X49_^1*/[!S#
M_GU^*_S#Z_A_YOP9^BVZC=7YT?\ #W9O^B3C_P *,_\ R)1_P]V;_HDX_P#"
MC/\ \B4?V#F'_/K\5_F'U_#_ ,WX,_1;=1NK\Z?^'NQ_Z)./_"C/_P B4?\
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M_#W@_P#1)Q_X49_^1*/["S#_ )]?BO\ ,/K^'_F_!GZ,[J3=7YS_ /#WEO\
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M1FFT4 .S1FFT4 .S13:* 'Y-&33*-QH ?NJUN_XELG_7:J>ZK6?^);)_UVH
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MQK_>9V^5:9H/B32?$GVXZ7>V]\+2X^SSF%MPCEV)+M_[YE1O^!4 9G]EW/\
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M_N/W?_QVKMF/]W_R87[CS#_AG;XK?]$Q\9?^""[_ /C5+_PSO\5O^B8>,?\
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M,;_PSO\ %7_HF/C'_P $%W_\:H_X9W^*O_1,?&/_ ((+O_XU3O\ AH;XK?\
M13O&/_@_N_\ X[2?\-#_ !6_Z*=XQ_\ !_=__'*/^%+^[_Y,'[CS$_X9W^*O
M_1,?&/\ X(+O_P"-4?\ #._Q5_Z)CXQ_\$%W_P#&J7_AH?XK?]%.\8_^#^[_
M /CE'_#0_P 5O^BG>,?_  ?W?_QRC_A2_N_^3!^X\Q/^&=_BM_T3'QC_ .""
M[_\ C='_  SO\5O^B8^,?_!!=_\ QNE_X:'^*W_13O&/_@_N_P#XY1_PT/\
M%;_HIWC'_P ']W_\<H_X4O[O_DP?N/,3_AG?XK?]$Q\8_P#@@N__ (U1_P ,
M[_%;_HF/C'_P07?_ ,:I?^&A_BM_T4[QC_X/[O\ ^.4?\-#_ !6_Z*=XQ_\
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M'_#0_P 5O^BG>,?_  ?W?_QRC_A2_N_^3!^X\Q/^&=_BK_T3'QC_ .""[_\
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M[O\ ^.4?\-#_ !6_Z*=XQ_\ !_=__'*/^%+^[_Y,'[CS$_X9W^*O_1,?&/\
MX(+O_P"-4?\ #._Q5_Z)CXQ_\$%W_P#&J7_AH?XK?]%.\8_^#^[_ /CE'_#0
M_P 5O^BG>,?_  ?W?_QRC_A2_N_^3!^X\Q/^&=_BK_T3'QC_ .""[_\ C5'_
M  SO\5?^B8^,?_!!=_\ QJE_X:'^*W_13O&/_@_N_P#XY1_PT/\ %;_HIWC'
M_P ']W_\<H_X4O[O_DP?N/,3_AG?XJ_]$Q\8_P#@@N__ (U1_P ,[_%7_HF/
MC'_P07?_ ,:I?^&A_BM_T4[QC_X/[O\ ^.4?\-#_ !6_Z*=XQ_\ !_=__'*/
M^%+^[_Y,'[CS$_X9W^*O_1,?&/\ X(+O_P"-4?\ #._Q6_Z)CXQ_\$%W_P#&
MZ7_AH?XK?]%.\8_^#^[_ /CE'_#0_P 5O^BG>,?_  ?W?_QRC_A2_N_^3!^X
M\Q/^&=_BM_T3'QC_ .""[_\ C5)_PSO\5O\ HF/C'_P07?\ \;IW_#0_Q6_Z
M*=XQ_P#!_=__ !RC_AH?XK?]%.\8_P#@_N__ (Y1_P *7]W_ ,F#]QYC?^&=
M_BM_T3'QC_X(+O\ ^-TG_#._Q6_Z)AXQ_P#!!=__ !NGG]H;XK?]%.\8_P#@
M_N__ ([3?^&B/BM_T4[QC_X/[O\ ^.4O^%+^[_Y,'[CS$_X9V^*W_1,?&7_@
M@N__ (U2?\,[_%;_ *)AXR_\$%W_ /&J=_PT1\5O^BG>,?\ P?W?_P <IO\
MPT1\5O\ HI_C+_P?W?\ \=H_X4?[O_DP_P!SYA_PSO\ %;_HF'C+_P $%W_\
M:I#^SM\5O^B8>,O_  07?_QJE_X:)^*W_13_ !E_X/[O_P".TW_AHCXK_P#1
M4/&7_@_N_P#X[2_X4?[O_DP?N?,/^&=_BO\ ]$O\9?\ @@N__C5(W[.OQ7_Z
M)?XR_P#"?N__ (U1_P -%?%;_HI_C+_P?W?_ ,=IO_#17Q6_Z*AXR_\ "@N_
M_CM+_A1_N_\ DP_W'F'_  SK\5_^B7^,O_"?N_\ XU3?^&=?BO\ ]$O\9?\
MA/W?_P ;H/[1?Q7_ .BH>,O_  H+O_XY33^T9\5_^BH^,_\ PH+O_P".U/\
MPH_W?_)@_<^8O_#.OQ8Q_P DM\9_^$_=_P#QJF?\,Y_%GM\+/&A^GA^[_P#C
M5#?M'?%@-C_A:7C3_P *"[_^.U]:_P#!,WXK>-_'?Q\US3O$?C3Q!XBT^+PU
M-<1VNJZK/<Q)(+FV4.$D=EW;6;YA_>-<>+Q./PE%UY<NGJ;4J=*I-05]3Y(;
M]G'XL_\ 1+/&G_A/W?\ \:II_9Q^+7_1+/&G_A/W?_QJOWQV^PHV^PKYG_6?
M$?\ /N)ZW]F1_F/P,/[./Q:_Z)9XT_\ ">O/_C5-_P"&;_BU_P!$K\:?^$]>
M?_&J_?7;["C;["E_K-B/^?<0_LR/\Q^!/_#-_P 6_P#HE?C7_P )Z\_^-4W_
M (9O^+?_ $2OQK_X3UY_\:K]^-OL*-OL*/\ 6;$?\^XA_9D?YC\!O^&;_BW_
M -$K\:_^$]>?_&J3_AF[XM_]$K\:_P#A/7G_ ,:K]^MOL*-OL*7^LV(_Y]Q'
M_9L?YC\!/^&;_BZ.3\*O&N/^Q>O/_C5?=7_!+WX8^,_ LGQ+;Q+X4UOPV+L:
M:+;^UM-EL_/V_:MVSS57=LW+_P!]+7Z(=A@4%3MPO!K@QF=UL91=&4$KF]+
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M%MW5_EVX_>IS7I^N?#?0-8^'U[X-738-.T*XMWMTL]-B2W2 $YW1*HVHRO\
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M[O\ >_V?_9?FKZ!8)7=ZTM/[QYOM?[J/6 O[*?\ U67_ ,I-._XQ4'_19/\
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M&I,T ;/_  DC_P#/!?SI/^$D?_G@GYUC9I* -K_A)&_YX)1_PDC?\\$K%HH
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MA_=,Z+_JD=MF_P#O_+6C-^T/X0T_3=+DU*]ECN[S0X-?:WT[3KR_2*RD1_\
M2-ZV^[ROE;YG5?X-Z+OHY9!S(]D_X2-O^>"_G2?\)(__ #P7\Z\V\1?&+PGX
M5DMA=ZK),UQ9?VB/[,M)[SRK3_GO+]G5O*BZ?O6VJ^UO[CUU5C?6^H6L-W:2
MPW-M<(DT4T+[TE1_N.CU)1O_ /"1O_SP3\Z3_A)&_P">"5CMTIM &U_PDC?\
M\$H_X21O^>"5BT4 ;7_"2-_SP2C_ (21O^>"5BT4 ;7_  DC?\\$H_X21O\
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M?NO]C_ON@#.HK1_X1^Z_V/\ ONC_ (1^Z_V/^^Z ,ZBM'_A'[K_8_P"^Z/\
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M?=?\9QS_ &6]TV'=X0CT >:S?\?27$,I?[G^J_=??^__ +%?1?\ 8-U_L?\
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M3]W_ /&J/KF'_P"?D?O#V4_Y3@]QHW'TKO/^&=_BU_T2WQI_X3]W_P#&Z/\
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M_?5 %(M4]BW[Y_\ <?\ ] J7^PKG_8_[ZJ:TTNYMYLOLQL?^.@#)W4FZK_\
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M&^A-I>GQW'C6W35Y9K-TAM],OTN'E^P;-^YX,-\KHK;&\P?Q5]A?V'=?[/\
MWU2_V'<_[/\ WU3YV+V9\]7N@^/_ !AXTU'Q;;^$['P]=V_ADZ-;:;XBGBN%
MO)99XI9MWV:5OW6R,HK;MW[T?+57PA\,;BS^(6A:WX8\ W_PLC+^=X@7[?:K
M8WL20,BVZ6MK.RNWFL6\UUBV;7^_OV5](?V#<_['_?=']@W/^Q_WW2YA\I\T
M?#?X3^*/#\/P+6]TO[,/#<.J+JW^D1/]E:6!U3[C_/O;^YNK'M_@IXO;PYX6
ML7TI(9[2Q\70W DNHOW3WTKM:_Q_QK_<^Y_'7U?_ &#<_P"Q_P!]T?V#<_['
M_?=5[1C]FCYP\'_#WQ4-0M+Z]T&;3"OPZC\.ND]Q;LRW2RMA?W4K??38^_[O
MS_W_ )*Y;PS^S!=>++SP=;^.]-O(K'2O UMI7FV^H(AMM269\,FU_G:)'^5O
MG2OKC^P;G_8_[[H_L&Y_V/\ ONESL/9H^9+KPG\2?%5UX,A\1:%YM]X=;5+:
MYUB*[@6+45FL)8H9T7?O5W=EWKL^5G_NTOAGX3>)].T\Q3Z1Y$Q^%UAX<_U\
M3?Z?&D_FQ?>_VE^?[G^W7TQ_8-S_ +'_ 'U1_8-S_L?]]4^8.4^3-'^#/B#P
MK]FNM2\,:[XIBU+PSIMG<66A>*&TUK.ZM;;R6BN-EU$LL3[O]:N[9F7Y/F^;
MZ+\%:#'X9\(Z-H\5G%IL=C9Q0+:0W3W:0%5*>2DK?.R)]S>]=1_8%U_L?]]T
M?\(_=?['_?=1*7,$8\IG-TIM:1T"Y_V/^^Z3_A'[K_IG_P!]U)1G45H_\(_=
M?],_^^Z/^$?NO^F?_?= &=16C_PC]U_L?]]T?\(_=?['_?= &=16C_PC]U_L
M?]]T?\(_=?['_?= &=16C_PC]U_L?]]T?\(_=?['_?= &=16C_PC]U_L?]]T
M?\(_=?['_?= &=6OI'WA4/\ PC]U_L?]]UH:?I<UO@OM_!J -*BEV&B@">BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C5237G[?&KP=;>+&\.-J
ML\VIK>IIS-%8W$MO%<.NY(&N$B\I9/\ 89]W6O0\U\I-XBM_!?QB-O\ #OQP
MVI2ZSXL6#Q!X#N[57ECD=BMW>Q?*LL2(B>9N^:)MO7YJ:5R6['U;Q6;I.K6>
MN6$5[IUW;ZA93KNBN;:598I%_P!EUZU\B_#GQ-<^)+OP!:CQ=KVH?$#5M2N[
M3QGX?DU>X065MY-QYQ\A63[&8I$B6)HO*;Y_XZR?@3#9:]X;^"OAW3_%FO)%
M=1WR>(;/3_$-U&RSQ6RN(&'F[H K?PQ;?_0JKD%SGW%Q67JVJ)H6FSWTZ7,L
M$$9=UM;66YF(]5BB5G=O]E5/6OD;PWXRU*XUKPLI\5:U)\3;KQA+8ZWX9_M2
MX=(--\R5)/\ 0]^U(D@\IUGV[MW.]NT=]XH\<W'ASQSX?GUO6K2?X7^&M9%[
MJBW4B2ZE<2PS?V=*[;M[,MNOF[O^>A5O[M'(+F/LFWF%Q"DJ[MCKN^==M6.*
M^.=>N-<OH[G5QXN\2VER_C+P[X?5;?59DCBM;G3M.6XV1_=WN;J1]S?=8;EV
MMNWT_$7C9_#DM_X5O==UYX8/$VK6]A=7GC"ZTU$ABM[5EBEO%26XE8-<MY47
MS,VUOO[:.0?.?6UOXBT^?Q'>Z)%.6U*SM8+V:#8WRQ3O*L3;ON_,T$O_ 'S6
M[7PYJ7BRQFTF+5O$WC;6=!\27?PMT"[L6LM2FM);^_8WS9*Q_P"ODWO_ *OY
MMV]_E;^'[ \!W&JS^"-!FUY/)UJ2PMWOT9-FRX\I/-&/][=4M6'%W.CHHHI%
M!1110 4444 %%%% !1110 4444 9]_?0:39W-Y<OLMK>)YI&V_=5.37">#OC
MEX/\<:C86.D7][]KU&V-[8)J.EW5C]L@^]OMVGB3S5VLK?)N^6NJ^( _XH;Q
M#_V#KG_T2]?+F@^ ?$<W[/?A/QMJ7BA=GAKP!-<:%9Z38M9-;2RZ7M666X\U
MWD=4;;\GE?, VVJBD3)L^P\T9KY-UB:W\)ZIX(T_QEXWU_1?!=_H$VI2ZQ-K
M]W;->:MMB^1[K>6C41[G2!61&;=\K?=KA+?X@7=QI6F_\+ \=^(_#TS^!A>:
M>L.JRV$MY=?;;M+:79%M\V=XEA;;_%_$K?POD)YS[-TGQ5IVK:]J^CVUP9]0
MTKR?MD'DNGD^:F]/G^ZV5_NYKH/QKX9UR;Q-;^%?BGXUO]7UK0_&NB^'= O9
MH[6\EM(UOC9(TIFB3;YAW!UV/N7D_+7I]C=>+#\<)/AH=3U1]+MM4;Q>=7:]
M;S&TUA\EENW%MGVPLFS_ )YQ[:.0?,>]>%/%6F^,O#^GZWHUP;S2[R+SH+GR
MV7>O3[K_ #5JS3>3"S-N^5=WR+NK\][[XD7&B_"?PU8Z5>ZII6LZ9X9@OK9_
M^$@EL89?])F??;VL:/\ ;&7RVW>;^Z10?N_>KV3_ (3+5%_:(_LYO$6M?\*V
M;Q!Y*W/F/L_MWR/^0;YN_?\ 9?XMGW/-_=8VT<@N<^E]'U*/7M+@O8%N8H+A
M2R+=VLUM,.WS12JKKW^5E]*UJ^%_AG\0+]E^%U_K?C/4/$MYJ%II-M_8:^(+
MBTU&&:6?+3^1]R_B?/[WS?NJHK[G%)QY2HRYA:***DH**** "BBB@ HHHH *
M*** "BBB@ I*6DH ^)/^"L__ ";OX<_[&FV_]([RORF7&!7ZL?\ !6C_ )-X
M\-_]C5;?^D=Y7Y2J?E%?J'#?^Y?]O,^5S#^,=)X5\%:IXN6\;3H-RVD6]FD^
M56;^ZK?WMNYO]U&;^&LQ;2=KS[*L$GVGS/*\C;\V[[NW;_>KI?AW\1)/!\TE
MM<Q_;-&N&W36_P#$K?WE_P"^5W+N7=M7YE98V7T&.^T:'3XO&ZV*M>^>T367
ME_(T'EJV[=N^]NW?\!^6OI7)QEJM.AYAYKXD\&ZGX3^R_;HE9+B-95E@;S(E
MW+NV[ON[MOS?[K*WW6K%KK/'OQ"G\8S16D"M;Z-;LS00-]YF^;YF_P"^FVK_
M  [F^\S,S<E71!/E][<S8N!Z4AQZ44TM5Z (W?Z5_1(H'IVK^=ECU^E?T3KV
M^E?GO%>]'Y_H?095]OY?J.VCTHVCTI:*^!/H+";1Z4;1Z4M% 6$VCTHVCTI:
M* L)M'I1M'I2T4!83:/2C:/2EHH"PFT>E&T>E+10%A-H]*-H]*6B@+";1Z4;
M1Z4M% 6$VCTHVCTI:* L)M'I1M'I2T4!83:/2C:/2EHH"PFT>E&T>E+10%A-
MH]*-H]*6B@+";1Z4;1Z4M)0%@VCTHVCTI:* L)M'I1M'I2T4!83:/2C:/2EH
MH"PFT>E&T>E+10%A-H]*-H]*6B@+";1Z4;1Z4M% 6$VCTHI:*!A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?LUMYVGQR9@;[QGY_>S?W95V[=J[E;]YO!\,?'4.WR/B7J'[@_9K;S]/CDS
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M\"K\;_@ ?^;9B?\ N?\ 4/\ XBOT3(:\Z>&<8TI2U>UOU:/FL=!2JW<DOO\
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M?=KK;S/4P56EAK\\M_7_ "/T:W&C=7YR?\/?&_Z)./\ PI#_ /(E)_P]^/\
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M"/\ T28?^%(?_D.C^P\?_P ^OQ7^8?7L/_-^#/T@W4;J_-__ (?!-_T28?\
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M;R)>;5_WO*?>WS/OY6CW1^\>KTC4M,K,T"BBB@ HHHH **** "BBB@ HHHH
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ME5<T +129HS0 M%)N%)NH =29IM% "[J2BB@ HHHH **** "K>G?ZY_]Q_\
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M4;:;2]:OM-TFXAM]5URS@5['3Y65&V2N[;GV+*K/M1MN_P"?->D5X)JW[/\
M-;^-_$.HV'A;P+XDMM;OAJ O?%%MONK%RJK,B_NF\U/EW+\T6UF>O>B:SERC
MCS#31114E!1110 4444 %%%% !1110 4444 %:^D?>%9%:^D?>% &Y1110!3
MO-(:ZR1(J_5:I_\ ",R?\]H_^^*Z"B@#G_\ A&9/^>T?_?%'_",R?\]H_P#O
MBN@HH Y__A&9/^>T?_?%'_",R?\ /:/_ +XKH** .?\ ^$9D_P">T?\ WQ1_
MPC,G_/:/_OBN@HH Y_\ X1F3_GM'_P!\4?\ ",R?\]H_^^*Z"B@#G_\ A&9/
M^>T?_?%'_",R?\]H_P#OBN@HH Y__A&I/^>T?_?%'_"-2?\ /:/_ +XKH**
M.?\ ^$:D_P">T?\ WQ4]OH;V_F?O_OILK9HH Y__ (1J3_GM'_WQ2_\ "-R?
M\]D_[YK?HH P/^$;D_Y[1_\ ?%'_  C<G_/:/_OBM^B@# _X1N3_ )[)_P!\
MT?\ "-R?\]8_^^*WZ* ,#_A&Y/\ GK'_ -\4?\(W)_SUC_[XK?HH P/^$:D_
MY[1_]\4G_"-2?\]H_P#OBN@HH Y__A&I/^>T?_?%'_"-2?\ /:/_ +XKH**
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MA_X39_\ DNOT@VT;:/[;Q_\ S]_!?Y!]1P_\OXL_-_\ X<^G_HK0_P#";/\
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MS(?^:MC_ ,)L_P#R77V+^S_\"9/@7\(] \##6_[:_LI9U^W?9O(\SS+J6?\
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M_/:/_OBC_A&I/^>T?_?%=!10!S__  C4G_/:/_OBC_A&9/\ GM'_ -\5T%%
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MEU_\K:+!<]!VBC:*\^_MSXI_]"=X1_\ "LNO_E;1_;GQ3_Z$[PC_ .%9=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP'_/Z/WH]=VGU_2C:?7]*\B_X:N^%_\ T,DG_@NN?_C='_#5WPO_ .ADD_\
M!=<__&Z/JU?^1_<']J8#_G]'[T>N[3Z_I1M/K^E>1?\ #5WPO_Z&23_P77/_
M ,;H_P"&KOA?_P!#))_X+KG_ .-T?5J_\C^X/[4P'_/Z/WH]=VGU_2C:?7]*
M\B_X:O\ A?\ ]#')_P""ZY_^-T?\-8?"_P#Z&.3_ ,%UU_\ &Z/JU?\ D?W!
M_:F _P"?T?O1Z[M/K^E&T^OZ5Y%_PUA\+_\ H8Y/_!==?_&Z/^&L/A?_ -#'
M)_X+KK_XW1]6K_R/[@_M3 ?\_H_>CUW:?7]*-I]?TKR+_AK#X7_]#')_X+KK
M_P"-T?\ #6'PO_Z&.3_P777_ ,;H^K5_Y']P?VI@/^?T?O1Z[M/K^E&T^OZ5
MY%_PUA\+_P#H8Y/_  777_QNC_AK#X7_ /0QR?\ @NNO_C='U:O_ "/[@_M3
M ?\ /Z/WH]=VGU_2C:?7]*\B_P"&L/A?_P!#')_X+KG_ .-TG_#6'PN_Z&.3
M_P %US_\;H^K5_Y']P?VI@/^?T?O1Z]M/K^E&T^OZ5Y#_P -8_"[_H8Y/_!=
M<_\ QNC_ (:R^%W_ $,<G_@NN?\ XW1]6K_R/[@_M3 _\_H_>CU[:?7]*-I]
M?TKR#_AK+X7?]#')_P""ZY_^-T?\-:?"W_H9)/\ P77/_P ;H^K5_P"1_<']
MJ8'_ )_1^]'KS,%ZTUW/&%+CV->0#]K#X6Q\_P#"1M^&GW7_ ,:KO_!_C+2/
M'/AVVUK1+C[=IUQO$<_E,F[:S(WRM\WWE:LY4JD%><;&]'&8;$2Y*-12?DTS
MI1TI:0=!2UF=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% ''^+M:M?#^CW^J:A/]GL;"![BXE".^V)%W.VQ/]FN
M'U#XR>$M-^&J?$"YUCRO";)%.NH?997^65T17\K9NX=D_@K5^/G_ "2'QU_V
M KW_ -)WKXO\86/BU?\ @G]!<3ZSHTWA[[!I_P#H,6DRK=A/M<>W]_\ :MOW
M_P#IE_WS6D5S&<I<I]6^(/CQX-\+^)K_ $&^U'4&U;3[9;F]M[+2+VZ\B-L9
MF=XHG1$Y%7?#?Q@\(^+-<LM'TK7H[_4K[35U:V6&-PD]L'V^:K;-KG=_!]],
M&O -4M?$-Y^UG\4D\/:[IOAVY_X1>W\V_P!3LGN8T3:GK*NS_??=_N5Q_A]K
M?P9\#O@E\5]-L)[*V\+7LUAJBL?/>:PGN'AGEW?+N3=DK\O\?6JY(D<\CZ_T
MWQ[HNL>,M9\*VE]]HUS1XHIKVW2*;]PDB;XM[[-GSH?N;ZZ'S3_DUX;^R5HM
MT_@34O&^JQ!=;\;:C+K,Q;[ZP,^R"+_<\LL__ Q7N K.7NLUC\([S3_DT>:?
M\FF45)0_S3_DT>:?\FF44 /\T_Y-'FG_ ":910 _S3_DT>:?\FF44 /\T_Y-
M6+'[T_\ UQ>JE6['[T__ %Q>@"OYI_R:P-)^(.AZQH.IZS:WY?3M,EN(KV6:
M%X?L[0,ZRHZ.F]-@5ZW!7S!\4=)U/2?B-K7PZTR*9-+^*%Q;W8FA+[+0J=NJ
M?7?!%%G_ &I:J,>8F4N4]D/QS\&+HFH:HVL3_8=/@T^XN ME=.46\V&U/EF+
M<X?>GRHF[CYZV?!WQ&T'QV;^/1KV5[K3Y5AO;.[M9;6X@=CO3=%*B,G_ 'Q7
MSC\6[4V][\;+>Q6.TV7'@]( 8]T40^U)L^5 GR?['RUW'PSC\3S^-_B';WVJ
M:;IOQ+EN;5I3<::TUE)IL6[[/+;P).C;/WLN]WE;8V$Z[:KECRD\TN8](\8?
M&'PKX!U(Z?K6JR6]U';_ &N6.&SN+A+6WW[/-E:)72)=_P#$VQ*37OC5X.\+
MZLVFZAK7DSA8FE:&UEEBM4E_U/F2JCQ1[_X/-=:\J^-'Q T2/5+CX<OKOAO0
MO$6NV*1>)=>NGBLDM[,)M^5)7^>5MS+$N]]J/N[Y;-^)GCCX?ZKJ1^%VFZYX
M>T+3+RWM)?$.N7=]!;_Z+&J>3!"[/^]EEB5$W_/MB_X#1RAS'O%U\1O#]GXT
ML/"4FKQGQ%>0-/;Z>F]YO*7EV?9]P\?Q_?K/_P"%T^$?^$J_X1_^V)?[1^U_
M8-WV.X^S_:_^??S]OE>;_L[MU>8_$#7O!?AO]IGX?.-1T/2]5<Z@^JA[J**4
MR-;0+!YW\>YU7:N_[^?DZUY_)J%O!XWG7^V9_P"V_P#A8GVE?AZJ*BRC[3M2
M\SGS/]5_I._=Y&[^"CE#F/L/>:3S#_DTE)69H+YI_P FCS3_ )-,HH ?YI_R
M:/-/^33** '^:?\ )H\T_P"33** '^:?\FCS3_DTRB@!_FG_ ":/-/\ DTRB
M@!_FG_)JQI_6?_K@]5*MZ?UG_P"N#T 5_-/^37GMU\=_"]EKCZ+*/$/]J%&F
M2S7POJC.T*L5:5=L'S+O9?F3Y/G2N_KRV[_Y.DT7_L3K_P#]+;2JB1(]7WFC
M>:^3O%-_XDL?!_BKQ#;Z]K$@;QK<:7>S/K%U!!8:4ERVY$VK+]G3>J+YJ1.R
M*S?,JG!IWGCT0:%9:?<^)7U&VO-4U'^SKC3/'5TEK#%%;VY\A]0^S^?=2"65
MFB5%;?\ =^?;5>S%[0^M/[4M/[2_L_[5%_:'E?:?L?F_OO)W[-^S^YO_ (ZL
M[S7R!I>HP/XR\*:YKNNZA::UJ7PRL[NUE;5[BW-Q?[0S;(UE56_OLFW9_'LH
MM;/59K:RAD\8>+/](^&W_"3RLNO3[WOUV[)=V_Y4^8?ND^5MB;E:CV8>T/K_
M 'FC>:^,_P#A._&.I:\TFH^++71=9"Z3/I$=]XANK..:!X+=BZ6,5N\5YO9Y
M5?YMZ_[.S<W83QZCIMUX<\0CQ-X@N9]7\?ZEH-U:2:M.UI]B^V7\*Q)'OVIM
M2)=K?>7/WMORT>S#VA])Z?J=KJ]K]KL+J*[M=[KYUM-O3>K['3>G]QT=*L>:
M?\FO"OV13I</PS>VMM0N;O6;>ZN5U2SGU*>Z:V;[5<;$:&5F\IW3+_)LW8W/
M7N-3+W9%1]Z(_P T_P"31YI_R:914E#_ #3_ )-'FG_)IE% #_-/^31YI_R:
M910 _P T_P"31YI_R:910 _S3_DT>:?\FF44 2"0G_\ 72^8:8.E+0 \2'_)
MIWF&HUIRT >)?ME#_BU.B_\ 8;3_ -$35\<*.M?8W[9'_))]$_[#:?\ HB:O
MCQ5ZU];EG^[GXGQ5_P C%^B$;Y%XKT+Q?X!@TFTF$'FV_P!A78TTL7R3ON^9
M]W^W_!_P'_?K@1'N7FNZTOPC?^);&VBOTEBNWC6&SE^QS[_]A9?W6UD_VM^Y
M4_W-E>E/W;.Y\O22DG&UV<.*6E5<T[9[5L<HSFEP:?MI=E KD>#ZT8/K4NVC
M;0!%@^M&#ZU+MHVT 18/K1@^M2[:-M $6#ZT8/K4NVC;0!%@^M&#ZU+MHVT
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MF44 /\RI]/\ ]>_^X_\ Z!56K6G_ .O?_<?_ - H @\RCS*910 _S*/,IE%
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M)/\ OBC[+#_SR3_OB@#CZ*['[+#_ ,\D_P"^*/LL/_/)/^^* ..HKL?LL/\
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M6\LX;D?ZB4_=E5E#?+]ZODB/QUJ!)'V70Q_W+]A_\9KZO+>?V'NGXSQ.J?\
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MP3E^*.*ZC_A-K_\ Y]=$_P#!!8__ !FC_A-K_P#Y]=$_\$%C_P#&:.:?\O\
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MX+4/YG]W_!.8XI.*Z?\ X3B__P"?71/_  06/_QBD_X3F_\ ^?71/_!!8?\
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M#^9_=_P3FMP]J;N%=-_PG=__ ,^VB?\ A/V'_P 8II\=ZA_S[:'_ .$_8?\
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M% '&5KZ1]X5N?98?^>2?]\5)'"D?W45?HN* (Z*FQ10 ZBBB@ HHHH ****
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M04(U,:G4UC0 QJ_0;]DO_D@WAK_>N_\ TIEK\]V[5^@_[)?_ "0;PU_O7?\
MZ4RUX>:_P8^I]YP=_OT_\+_-'L=%%%?+'["%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\S_'3XV>)/!WQ0T]-"N%7PEX5CM-0\8-Y"ONAN
M;A((H]S?=*IYDWR?W?:NA\=?&B?X9_%+Q2^L3W5SX6TCPI8:J]C:0(TOG2WM
MQ"[IGYF^58_EW?PU3TW]FBS\2?\ "=7WCFZOI]9\5ZA<&X71]>OX($LPACM[
M=U5HDEV1K_'$WWF^\M<GJG[-/CS7O".H66I:MHESJT_@W3_#?VA+B8I));7T
MDHD;]S]UH63_ ('N_P!ZM-"-3T2^_::T71;/6)-:\.>(] GTFWM;ZYLKZW@$
M_P!CGE\I+I=LS*8U<G=\VY-OW:H_%3XS3:+XDTSPSX?ENH-3M-?T*WU2[6&)
MK9;>\NS']G^?G>\2LV47Y5*_-6MXS^%ZZO\ $'Q'XEUVYM5\(7O@Q]!O=S_O
ME'FRS2O]W;MV-7E_P>^#^O>(?@7X,U*XNHKC7[_Q%I/B:\NM0#1RR6EK) (4
M!^9MWV6",A3_ !.WW:6@:GL?_"YK:S\:V/A[4?#WB#2X+_4)=+L]:OK5(;&Y
MNHD+>6AW^;\ZJVQF38^WY&:N7TG]J;2=971S9^$/%MQ_;LT\&DLMK:C^T)X'
M(FC0-<?)MVLV^3:FU'^;Y:YV+X$_$35?B)H6N:[KUOJ4.E>)'U=9'UB\=9+7
M;.L4:6.Q;>!D615W?.S;?O+\V_8\!? GQ!X9L_A)%=SZ;*_A+4M6NK[RI7_?
M+<QW*IY64^9OWZ[M^W^*C0-3U3X=^.M.^)O@_3_$NF0W,%M<M*/)O(MDT4D<
MKQ2HR]F5D9:ZZO-O@IX'U+X<_#RVT#5&MWNX[[4+G?9NSH5GO)YU^\J_PRK_
M ,"KTFH984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %2?4H;?[[,/HN:K_V[;?\]'_[XK.U?[QK(H ZC^W;;_GH_P#WQ1_;
MMM_ST?\ [XKEZ* .H_MVV_YZ/_WQ1_;MM_ST?_OBN7HH ZC^W;;_ )Z/_P!\
M4?V[;?\ /1_^^*Y>B@#J/[=MO^>C_P#?%']NVW_/1_\ OBN7HH ZC^W;;_GH
M_P#WQ1_;MM_ST?\ [XKEZ* .H_MVV_YZ/_WQ1_;MM_ST?_OBN7HH ZC^W;;_
M )Z/_P!\4^/5[:3>$;[J;_NURE7+#_63_P#7%Z -S^W+;_GHW_?%+_;EK_?;
M_OBN9KC=)^*FCZGX2\1^(2EW96_AR>]M]1AG1?.@>UQYV-KNGW3N3Y_NLE '
MK']N6W]]_P#OBC^W+7^^W_?!KP*;]HO0H=!UG5#HNM Z3;Z7--9^5;I<-_:+
M(MNJ8EV[MS_-O=-G^W74>"/B1:^--2UK2VTO5=#UG1C$+S3=62+S567?Y3(\
M3,K(^UON-_"]5RLGF1ZI_;%K_?;_ +Y-']L6O]]O^^37C/C7XT6'@G4M2L_[
M%UO6DTJR34-4N-)@B>&Q@^;YGW.F[[KOMBW-L3[O6KGB_P"+WA_P>WAA;IYK
MB;Q)>6]E816L>YL22K$DK_W(D:2+<W?>E'+(7,>M?VQ:_P!]O^^31_;%K_?;
M_ODUXEKGQSTK0-:O+232-:N-,T^_M]/O=<MX$:QMKB3;M5SO\U_]:N]E5U7?
M\V:VM:^*FBZ'\0/#O@Z47$VM:T)C&MN R6\:Q2R[Y7_AWK!+MQ]_:]'+(.8]
M4_MRV_OO_P!\4?VY;?WW_P"^*YFBI+.F_MRV_OO_ -\4?VY:_P!]O^^*YFB@
M#IO[<M?[[?\ ?%']N6O]]O\ OBN9HH Z7^W+;_GHW_?%']N6W_/1O^^*YJB@
M#I?[=MO^>C_]\4?V[;?\]'_[XKF&I* .H_MVV_YZ/_WQ1_;MM_ST?_OBN7HH
M ZC^W;;_ )Z/_P!\41ZO;2>9L?[B;_N5R]6]/^]/_P!<'H W?[<MO^>C?]\4
MO]N6O]]O^^*YFO,KSXT7-KXO3PROP^\3W&KRVLE]''%+I>U[>.58FE5WO.N^
M1?D;:WS_ ': /<_[<M?[[?\ ?%']N6W]]_\ OBN9HH Z;^W+;^^__?%']N6W
M]]_^^*X;_A)M,_X2;_A'_/\ ^)S]E^W_ &;8_P#JM^S?O^Y]^M.@#IO[<MO[
M[_\ ?%']N6O]]O\ OBN9HH Z7^W+;_GHW_?%']N6W_/1_P#OBN&\/^)+#Q5I
M4>IZ5/\ ;+-Y98DF*.GS12O$Q^?_ &U>M)J .G_MVV_YZ/\ ]\4?V[;?\]'_
M .^*Y>B@#J/[=MO^>C_]\4?V[;?\]'_[XKEZ* .H_MVV_P">C_\ ?%']NVW_
M #T?_OBN7HH ZC^W;;_GH_\ WQ1_;MM_ST?_ +XKEZ* .H_MVV_YZ/\ ]\4?
MVY;?\]&_[XKEZ<O2@#I_[<MO[[?]\&E&M6W]]O\ O@US%.7M0!T_]LVW]]O^
M^32_VM;G^-O^^37-K4L= 'B?[<&M:#I?PITB\UK7[;0+3^VXXX[J\AN9$>3R
M)_DVP12-]T.>5V_+7Q/_ ,+$^'1.?^%FZ%_X+]5_^0J^A_\ @JM_R;/X9_[&
MV#_TCO*_*K;AJ^_R3"+$83F<GN^W^1\)F^78?$XGVE1:V/M1?B-\-Q_S4S0<
M_P#8/U;_ .0JL+\3/ATL;1K\3M#V,=S+]AU;YO\ R2KYH^%G@?3/%UKJ<E[,
MT\\2^7'8P?ZT,VW9(O\ >^;Y?XOO?WFBCES[?X9ZO-XL31-K9W;O.V_\L_\
M=_O?[/\ [+\U>W_9U-W3F]/3_(\3^Q\':_)^+/JE?B3\-O\ HI>A?^"_5O\
MY"I__"S/ALO_ #4O0O\ P7ZM_P#(5?-/Q.\&Z7X7M]+GL)_(EFC\IK&5F:5F
M7=ND;^[\WR_=5?\ @7FQQ<$<UK'+825U4?X?Y$_V/@^L/Q9]I_\ "R_AO_T4
MK0O_  7ZM_\ (5+_ ,+,^&__ $4K0O\ P7ZM_P#(5?%@Z=?TI<^_Z5?]EP_Y
M^/\ #_(G^Q\'_)^+/M+_ (69\-_^BE:%_P""_5O_ )"H_P"%F?#?_HI6A?\
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MO_!?JW_R%7Q>WUII/O1_9</^?C_#_(K^Q\'_ "?BS[._X61\-U;/_"S-#_\
M!?JO_P A5[-\._@#J_Q4\(V/BOPOXBT'4=#OO,^S7!-W$9=LC1/\LD"LOSJR
M_=[5^9'S;NE?LO\ \$_,C]D#X>X_ZB/_ *<+FO!S>G+ 48U*4G>]M;>?D=^$
MX?P.(J.,ET[GG[?L?>-O^@CH'_@3-_\ &:8?V/O&W_02T#_P)F_^,U]C-3&K
MY#^TL0>O_JGEW\K^\^.C^Q[XV_Z"6@?^!,W_ ,8IO_#'OC;_ *"?A_\ \"9O
M_C%?8C4VE_:6(#_5/+OY7]Y\=G]CWQM_T$_#_P#X$S?_ !BD3]CKQN_W=2T
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MY/[@H\N3^X* (Z*?LD_N"C9)_<% #**?LD_N"C9)_<% #**?LD_N"C9)_<%
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MW:WWJ?;_ +43W7@^?5K*S\+2/9:E-IEW<7/C"WBTK?'%%*GV>\\K]]O29/\
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M$)L&TJ6>2>WGM'E$WE203M!(N['S+NB;YJ[NI*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **H76K+:]8V8^PJI_PDB?\
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MU\/^)O$>MP3W$EWKT\,]TLS+L1HHEB39\O\ =6NJK&_X2-/^>+_E1_PD:?\
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M.UQ^]5OO;-G_ +-69&P6MK[9X5/_ #!-=_\ !U!_\B4HNO"O_0%UW_P=0?\
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MPK?^V^%?^@+KO_@Z@_\ D2D^V>%?^@+KO_@Z@_\ D2CVDOY0]C#_ )^+\?\
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M1*/:2_E#V,/^?B_'_(YW%-:ND^U>%/\ H!Z]_P"#J#_Y$IK77A/_ * >O?\
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M\J -JBL7_A)$_P">+_E1_P )(G_/%_RH VJ*Q?\ A)$_YXO^5'_"2)_SQ?\
M*@#:HK%_X21/^>+_ )4?\)(G_/%_RH VJ*Q?^$D3_GB_Y4?\)(G_ #Q?\J -
MJBL7_A)$_P">+_E1_P )(G_/%_RH VJ*Q?\ A)$_YXO^5/M]<2XDV;'^YOH
MUZ*Q?^$D3_GB_P"5'_"2)_SQ?\J -JBL7_A)$_YXO^5'_"2)_P \7_*@#:HK
M%_X21/\ GB_Y4?\ "2)_SQ?\J -JBL7_ (21/^>+_E1_PDB?\\7_ "H VJ*Q
M?^$D3_GB_P"5'_"2)_SQ?\J -JBL7_A)$_YXO^5'_"2)_P \7_*@#:HK%_X2
M1/\ GB_Y4?\ "2)_SQ?\J -JBL7_ (21/^>+_E2_\)(G_/%_RH V:*QO^$C3
M_GB_Y4?\)&G_ #Q?\J -FBLFWUM+CS/D?Y$WTS_A(T_YXO\ E0!Y7HW[,?A"
M1?$5QXOT;1?&>M:YJ5W?7&J7^E1"5%EQMAA9][HL:JJK\_\ M5S$W[)]U>^%
M;S1KWQJ;R>;PO9^%UNFT[YEBMKR2X25AYWS-LD5/^ ;OXMM>^?\ "1Q_\\9/
MRH_X2*/_ )XR?E5<S)Y4</XD^&MK>>/-7\:ZC)+?:?/X9?0I]%AM7D>:+S6E
M=E9&W,6#;-@7\:\T^#_[/MXOP&\%Z;J5Q=:;K$>MV/BF\%Y'YL^Z"2,Q6[?,
MNQ_(BABW?P[3Q7T'_P )%'_SQD_*C_A(H_\ GC)^5',PY3P73/V4C;>/=/\
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M%% !1110 5:T_P#U[_[C_P#H%5:M:?\ Z]_]Q_\ T"@"K1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %O3_ +T__7!ZKU8T_P"]/_UP>J]
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MU>[_ +$_MMKB_P!8:R4K]H\KRDVP2[W_ .^*P?@3K1\#>$?!_A'5-'U2TO\
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M=+\0Z7J-[8C-Q:6EY#+-#_O(C_+^%?-W@WPQJ\?ASX9>#Y/#&K6_BK0/%/\
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MJW&OZ98ZQ::9<:C:PZG>*S6]G).JS3JOWMB_>;:/2J7_  L+PM_PDG_"-_\
M"2:3_P )%M_Y _V^+[7C_KENW4 5_P"R[C_GB_YT?V7<?\\7_.NNK"U_Q'IG
MA+1KC5M;U.TT?3(-GF7NH3K##%N?8FYV^5?F95S0!G?V7<?\\7_.C^R[C_GB
M_P"=9=G\=/AOJ#2"S^(7A:Z:&/S'\G6K5O+4?Q-M?[OS+6_XF\9:#X)L$OO$
M6MZ=H=D\GE)=:E=);Q%O[FYV^]\I_*@"I_9=Q_SQ?\Z/[+N?^>+_ )U)_P +
M(\)?\([_ ,)%_P )3HO_  CWW?[5_M&+[)GT\W?MK5T77--\1:3;ZAI&H6VK
M:?.I:&ZL9EEAD7_9=?E;I0!B_P!EW/\ SQ?\Z/[+N?\ GB_YUU]<9KGQ8\$>
M%=6&EZUXPT+1=5**WV'4-3@MYVW?=^1WW4 2?V7<_P#/%OSI/[+N?^>+?G4>
MO?%[P-X5U8Z7K/C3P]H^IJ%W66H:K!!+\WW<HS;JZFVN8;V%)H)$F@E3<DB-
MO1UH YK^R[G_ )XM^=']EW/_ #Q;\ZV(]>TU]:?2!J%JVJI!]I;3_/7SUBW;
M-^W[VS=_%ZUL4 <?_9=S_P \6_.I[2QN8O,WPL/W+BNIHH X_P#LNY_YXM^=
M+_9=S_SQ;\ZZ^O.;CX_?#*UN)+>X^(GA."6%FCDCFURU1T9?O*R[Z -?^R[G
M_GBWYT?V7<_\\7_.NOHH Y#^R[G_ )XO^=']EW/_ #Q?\ZZ^B@#D/[+N?^>+
M_G1_9=S_ ,\6_.NOHH Y#^R[G_GBWYTG]EW/_/%OSKL** ./_LNY_P">+?G1
M_9=S_P \6KL** .._LNX_P">+_G1_9=Q_P \7_.NQHH X[^R[C_GB_YT?V7<
M?\\7_.NQHH X[^R[C_GB_P"=']EW'_/%_P Z[&B@#CO[+N/^>+_G2_V7<_\
M/%OSKL** .0_LNY_YXM^=+_9=S_SQ?\ .NNHH Y,:7<_\\6_.G+IEQ_SQ;\Z
MZJB@#YK_ &LM!U/7OAGIEOI>F7NHS1:S'(\-G;M(RKY$N6VK_!EA^=?*$?PY
M\7KG_BDM>/\ W#)__B:^L/VY%V_#71#G(_MB,?\ D">OBM0K$_X5]7EW/[#W
M3\9XG=/^T'SI[+K_ , ZA?AWXO'7PEKO_@MG_P#B:LV/@;QII]U'=6WAC7H;
MB,[DF73IMZ_^.UR2[5__ %5L1^&KR70AJBQ;X79MJJGWE7[S_P"[7I6EUE_7
MWGRD?9-^[!_?_P  TU^'7BX?\REKO_@MF_\ B:=_PKOQ;_T*6N_^"V;_ .)K
MF%"T["^U5RU/YOZ^\B]#^5_?_P  Z;_A7OBW_H4M=_\ !;/_ /$T[_A7GBW_
M *%/7/\ P6S_ /Q-<QM%+@>U'[S^;^OO#FH?RO[_ /@'3?\ "N_%O_0I:Y_X
M+9__ (FE_P"%>^+O^A3US_P6S_\ Q-<SM7U%&!ZBCW_YOZ^\.;#_ ,K^_P#X
M!TW_  KWQ=_T*>N?^"V?_P")H_X5[XN_Z%/7/_!;/_\ $US.!ZBC ]11[_\
M-_7WAS8?^5_?_P  Z;_A7OB[_H4]<_\ !;/_ /$T?\*]\7?]"GKG_@MG_P#B
M:YG ]11@>HH]_P#F_K[PYL/_ "O[_P#@'3?\*]\7?]"GKG_@MG_^)H_X5[XN
M_P"A3US_ ,%L_P#\37,X'J*,#U%'O_S?U]X<V'_E?W_\ Z;_ (5[XN_Z%/7/
M_!;/_P#$T?\ "O?%W_0IZY_X+9__ (FN9P/448'J*/?_ )OZ^\.;#_RO[_\
M@'3?\*]\7?\ 0IZY_P""V?\ ^)I/^%=^+?\ H4M<_P#!;/\ _$US6!ZBC:/4
M4>__ #?U]X<V'_E?W_\  .E_X5WXM_Z%+7/_  6S_P#Q-'_"N_%O_0I:Y_X+
M9_\ XFN:VK[4;5]J/?\ YOZ^\.;#_P K^_\ X!TO_"N_%O\ T*6N?^"V?_XF
MC_A7?BW_ *%+7?\ P6S_ /Q-<UM7VHVK[4>__-_7WAS8?^5_?_P#I/\ A7GB
MW_H4]=_\%L__ ,31_P *\\6_]"GKG_@MG_\ B:YK"T<>U'[S^;^OO#FH?RO[
M_P#@'2_\*\\6_P#0IZY_X+9__B:3_A7GBW_H4M<_\%L__P 37-X'M2;11^\_
MF_K[PYJ'\K^__@'2_P#"N_%O_0I:Y_X+9_\ XFD_X5WXM_Z%+7/_  6S_P#Q
M-<WM%&T4?O/YOZ^\.:A_*_O_ . =)_PKOQ;_ -"EKG_@MG_^)H_X5WXM_P"A
M2UW_ ,%L_P#\37-8'J*0@4?O/YOZ^\.:A_*_O_X!TG_"N_%W_0I:Y_X+9_\
MXFFM\._%W_0I:[_X+9__ (FN<VBFLHHM/^;^OO"]#^5_?_P#HC\._%W_ $*.
MN_\ @MG_ /B:8WPZ\7?]"EKO_@MG_P#B:YTJ*8RBE:I_-_7WCO0_E?W_ / .
MB?X<^+_^A3U[W_XED_\ \37V?^SUHM]I?P>\.VM]8W%I<J)R\%U&T<J#[5*W
MS*W;:WZU\%N  .1^5?H)^R>"WP%\-X.#NNL<?]/,M>/F7-[&/-W/MN$G3^NS
MY$_A?7S7DCN3I=Q_SQ;\Z:=+N?\ GBWYUUM%?,GZZ<C_ &7<_P#/%_SIO]EW
M/_/%OSKL** ./_LNY_YXM^=3Z?I]U'>I(\+^774T4 <=_9=Q_P \7_.C^R[C
M_GB_YUV-% ''?V7<?\\7_.C^R[C_ )XO^==C10!QW]EW'_/%_P Z/[+N/^>+
M_G78T4 <=_9=Q_SQ?\Z/[+N/^>+_ )UV-% ''?V7<?\ /%_SH_LNX_YXO^==
MC10!QW]EW'_/%_SH_LNX_P">+_G78T4 <=_9=Q_SQ?\ .C^R[C_GB_YUV-%
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MUV%% ''_ -EW/_/%J/[+N?\ GBU=A10!QW]EW'_/%_SH_LNX_P">+_G78T4
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M -B1?_\ IPM*]DK%.AV#:TNJFSMY-7AA:W6^\M3*L3,KM%N^]MW*C;?]E::
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M42U94=$+1112*"BBB@ HHHH **** "BBB@ HHHH **** /FW]N?_ ))IH?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MARH\Y_X49X<_Z"7B[_PMM9_^2J/^%&>'/^@EXN_\+;6?_DJO1J*+L.5'G/\
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M?^%MK/\ \E4[_A1GAS_H)>+_ /PMM9_^2Z]$HHNPY4>=_P#"C?#G_02\7_\
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M )*H_P"%&>'/^@EXN_\ "VUG_P"2J]&HHNPY4><_\*,\.?\ 02\7?^%MK/\
M\E4?\*,\.?\ 02\7?^%MK/\ \E5Z-11=ARH\Y_X49X<_Z"7B[_PMM9_^2J/^
M%&>'/^@EXN_\+;6?_DJO1J*+L.5'G/\ PHSPY_T$O%W_ (6VL_\ R51_PHSP
MY_T$O%W_ (6VL_\ R57HU%%V'*CSG_A1GAS_ *"7B[_PMM9_^2J/^%&>'/\
MH)>+O_"VUG_Y*KT:BB[#E1YS_P *,\.?]!+Q=_X6VL__ "51_P *,\.?]!+Q
M=_X6VL__ "57HU%%V'*CSG_A1GAS_H)>+O\ PMM9_P#DJC_A1GAS_H)>+O\
MPMM9_P#DJO1J*+L.5'G/_"C/#G_02\7?^%MK/_R51_PHSPY_T$O%W_A;:S_\
ME5Z-11=ARH\Y_P"%&>'/^@EXN_\ "VUG_P"2J/\ A1GAS_H)>+O_  MM9_\
MDJO1J*+L.5'G/_"C/#G_ $$O%W_A;:S_ /)5'_"C/#G_ $$O%W_A;:S_ /)5
M>C4478<J/.?^%&>'/^@EXN_\+;6?_DJC_A1GAS_H)>+O_"VUG_Y*KT:BB[#E
M1YS_ ,*,\.?]!+Q=_P"%MK/_ ,E4?\*,\.?]!+Q=_P"%MK/_ ,E5Z-11=ARH
M\Y_X49X<_P"@EXN_\+;6?_DJC_A1GAS_ *"7B[_PMM9_^2J]&HHNPY4><_\
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M^%MK/_R57HU%%V'*CSG_ (49X<_Z"7B[_P +;6?_ )*H_P"%&>'/^@EXN_\
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MX/X]=8_G9U^>#,&[5]QE>38;%82%:HW=W_,\'%8RI2K.,=C]8_\ A[7\)?\
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M1_J]@O[WWB_M"N?K!_P]G^$O_0M>-/\ P"M/_DJC_A[/\)?^A:\:?^ 5I_\
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M3_KA'52@#IO^$@MO[TG_ '[H_P"$@MO[TG_?NN9HH Z;_A(+;^])_P!^Z/\
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MV==U*WNIFMXFL[;YMK2K$VQ)9-R_=?[@H_9PDU+P#\2OB)\.]8M;33I&NO\
MA)M,M+*X>>%8+EPDJK*T<3NBR+'_  =Z^B*:U3S>[RCY?>YA****S*"BBB@
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M%%%%26%%%% !1110 4444 %%%% !5O3^L_\ UP>JE6]/ZS_]<'H J5\M^%O
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M !1110 4444 %%%% !1110!;U+_7)_UPCJI5O4O]<G_7".JE !1110 4444
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MU<]2M5K:U9M^KN:1IPI_ K#/+3^ZOY4GDI_=2IJ*S-"'R4_NI2>2G]V.IZ*
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M6/.O^%:>)?\ HK'C#_P$T;_Y H_X5IXE_P"BL>,/_ /1O_D"O1:*+BL>=?\
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M^+__  $T;_Y7UZ'11<+'GG_"M/$G_15_%_\ X":-_P#*^C_A6GB3_HJ_B_\
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M8\8?^ FC?_*^C_A6GB3_ **QXP_\!-&_^5]>AT47"QYW_P *S\2?]%8\8?\
M@)HW_P KZ/\ A6?B3_HK'C#_ ,!-&_\ E?7HE%%PL>=_\*T\2_\ 16/&'_@)
MHW_ROH_X5GXE_P"BL>,/_ 31O_E?7HE%%PL>=?\ "L_$O_16?&'_ (!Z-_\
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M'_"L_$O_ $5CQA_X!Z-_\KZ]%HHN*QYU_P *S\2_]%8\8?\ @'HW_P KZ/\
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MK'IM &U_PD;_ //+_P ?H_X2-_\ GE_X_6+10!M?\)&__/+_ ,?H_P"$C?\
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ME26;'_"1O_SR_P#'Z/\ A(W_ .>7_C]8M% &U_PD;_\ /+_Q^C_A(W_YY?\
MC]8M% &U_P )&_\ SR_\?H_X2-_^>7_C]8M% &U_PD;_ //+_P ?H_X2-_\
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MK+_6_._^?_X1_P C;^Q\'_)^+/6?^%_-_P! 1?\ P+_^PH_X7\W_ $!%_P#
MO_["O)N?[WZ4<_WOTH_UOSO_ )__ (1_R#^Q\'_)^+/6?^%_-_T!%_\  O\
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M$C?_ )Y?^/T?\)&__/+_ ,?K%HH VO\ A(W_ .>7_C]'_"1O_P \O_'ZQ:*
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MZQ:* -K_ (2-_P#GE_X_1_PD;_\ /+_Q^L6B@#:_X2-_^>7_ (_1_P )&_\
MSR_\?K%HH VO^$B?_GC_ ./U/)KS1PP/Y/W_ /;K JU<?\>=K_P.@"[_ ,)
MW_/ ?]]4O_"1/_SP'_?5>5_';QY??#'X2>(O%.E1VMQJ&F6XD@AND=X6;>B$
MOL=/[]<O>_$KQ;X3\::AX:UF]\/ZLZ^'KK6(K_3["XM5LWB"E5NXO-E?8^[[
MR-O^4?+5\I',>^_\) __ #P'_?5'_"0/_P \!_WU7S'XJ_:$\0>']-GGMHM&
MOWC\*Z/K:7$=O<>3++=WK6\NS<ZOY6Q=Z[]K_P!_^Y7J'QB\<W?PX^&>N^(K
M&TCO+JQB1D2X;,*[W1-S#^ZF_<_NE+ED',>F?\)"_P#SP'_?5'_"0O\ \\!_
MWU7GOP_NO%%Y;WI\2G1KM?-1]/U30U:*&ZMW5'W^4SMM^??_ !-OKC/%GQMN
M_"'[0'A_P7=VEN/#VKZ<KM?E'\Z"]EEF2)7X^Z_E!/N?>=?GI\H<Q[M_PD3_
M //(?]]4?\)$_P#SR'_?5>":Y\<IH?VCO#OPUTVTM[BQEMI9=8O&1M\$OV=Y
M8HU_@W;%#/\ ?^5U]*Z _'/PIJ;:E::+J@O=2CMKQ[<-;7"V]T]NGS>5*ZI%
M)LV?/Y3O2Y9#YD>M_P#"1/\ \\A_WU1_PD3_ //(?]]5\_>'?CPJV&C:QXKU
M#1].T>?P;I_B.^2*WNS<P33R;&?^-?L_S[-F_?T_@KL-+^-7@W5]/UF]@UGR
M+;1[=+N^^WVUQ9/';OATEVRJCNK[1L9/E?-')(.:)ZC_ ,)$_P#SR'_?5'_"
M1/\ \\A_WU7@^C?M!:7J_CSQ#:B[2T\*:-X?@U:6[O[">RN%E:616W+*BMM*
M")E^3Y]_\==WX*^(V@_$)+Y=$NI)WL)5BNK>ZLI;66!F7<FZ*5$;YU&_[E'+
M(.9'>?\ "0O_ ,\!_P!]4?\ "0O_ ,\!_P!]5XG9^./&/Q!\3^)K?P>=%TG0
M]#NY-+EU#6+26Y>\NT5&E58HI8MB)N1=VYOF+?+S6EJ?Q6L?AYH^G)X]O+2S
M\02V\US/!H]O=7L*HOWI?EB=EB^Y\S?*N/OT^47,>M_\)$__ #R'_?5'_"1/
M_P \A_WU7B\GQNLO^%P:=X/M[2[N+*\TG^T(KZ#3[J17=YE2$^:B[?)V-\TO
MW%_OUIZ/\=O ^OW%Q!9ZX@\NWFN_M$MK+%;SQ1?ZYHI'1%D5/X_*=\TN60^:
M)ZI_PD+_ // ?]]4?\)"W_/ ?]]5P?@WXA:%\0()I-&FN9UB1)'%W8W%KN1_
MN.OFJFY7_O)\E>?^%?''CWQ]XW\?Z7INJ>'-&T_P[J:Z?$+K1KB]EE1T$F]V
M6\B3O_=I\HN8]\_X2!O^>(_[ZH_X2!O^>(_[ZKR[5/C5X-TGQ%-HUUK#0W<-
MU%:7$OV.X>S@N)<[8IIT3RE9]R_*[[N#6A<?%+PO9Z5K.I3:IML]+U-='O9A
M;S?NKIFBB6+[GSX>2+YT^3YZ7*R^8]"_X2)_^>0_[ZH_X2)_^>0_[ZKR9OCS
MX%A\13:*VLRI?6]^NF7#_89_L\%VSE%B:?R?*5GP=A=_GQS7/_&3]H/2OA_I
M&L6^DSK>^*-/GM8FMI+">6TB>655V2RHNU6\IG959U>CDD3S(]Y_X2)_^>0_
M[ZI/^$B?_GB/^^J\TG^,7A&'Q<GAJ356_MAKO[ ?]&N/L_VC;N^S^?M\KS=O
M&W=NKSRT_:*N/$'A7Q/?Z?%!I-QI/B#^S4FU[2K^.V:V:YB@Y;RO^/A_.'R?
MPX7<BI1RR#F1]'?\)$__ #Q'_?5'_"1/_P \1_WU7ENJ?&KP;I/B*;1;O5VA
MNX;J*TN)/L<[V<%Q+G;%-.B^4K/N7Y7?=P:@;X]>!8?$4VBMK,J7UO?KIEP_
MV&?[/;W;.46)I_)\I6?!V%W^?'-'+(.:)ZS_ ,)')_SQ_P#'JNV>JFZQF/;_
M ,"KFJUM([5)1N>8:*;10!X;^U]X'UKXC? ;Q-X<\.6)U'6;S[+Y%OYBQ;MM
MU$S?,[JOW5>O//BK^SS:-XR^&&I^!?!&BZ>ND^(X+W5)]-M[6R9;52,;Q\CO
MW^5-]?5MU9?:%Z<_6J/]BO\ W?\ QZJC*42>6,CY?\#_  /U6_T_XZ:/XHT_
M['I_C#6;JXL)O-BFW1R!BDOR/\FQL/\ /_<JW^RC\*/%/@O3]?UWQ_"(_%>I
M-:V(VRPR[+*V@2*+YE/\8W-_P&OI;^Q'_N_^/4G]B/\ W?\ QXT<\@Y8F+16
MU_8;_P!T?]]&D_L-_P"[_P"/&I*,:D(K:_L-_P"[_P"/&C^PY/[O_CU &'16
MY_8<G]W_ ,>H_L.3^[_X]0!AT5N?V')_=_\ 'C1_8<G]W_QXT 8=*M;?]AR?
MW?\ QZC^PY/[O_CU &-5C_F&_P#;:M'^PW_N_P#CQJ;^R&^Q^7M&_P WS* ,
M"O ?AW\&=?\ #?QMU"ZO47_A!]#EO=0\-[)$ $]\$:= N_Y4B_>HOO./6OIC
M^PW_ +O_ (\:/[$?^Z/^^C5<Q'*?)6I? WQ#K%C<65_H%O>65S\5'\0SP7$T
M$L4NDO\ \M65F^=/]C[W^Q7:?#;X3W7A%?$O@:XLKNW\#K=?VCHFHZ5J+64R
MK*P9K5W@E27]TWW'^XZ@G^&OH'^Q'_N_^/&E_L1_[O\ X\:.>0^5'@WQX\+Z
MO??"5O"/A7P]JOB":X> ),U]&WV=8KB*7][+=3HS.ZH_][[GS;*;\>K7Q+X\
M^#]_H^C>#=5GU/6(]OV:2ZL$:T"3(_[UFGV_]^F:O>_[$;^[_P"/4?V(_P#=
M_P#'J.87*>$_'./Q)X\^">KZ-I7@W5I=8URRDM5LWN;!6M&# H\K>?MV?]<F
M:M#XJ7?B#Q9\'=>T[3?!.KOJNMZ9>Z:EB\]@LMFTL31(TK>?Y6W[GW&9_G^Y
M7LO]B/\ W?\ QXT?V(_]T?\ ?1HY@Y3@OA_)>OX-TJ/4=&O-#O;6W2U:UO6M
MW9=B;/,_=2LO_C]='6U_8;_W?_'C2?V&_P#=_P#'C4EF-2$5M?V&_P#=_P#'
MC1_8<G]W_P >H PZ*W/[#D_N_P#CU']AR?W?_'J ,.BMS^PY/[O_ (\:/[#D
M_N_^/&@##HK<_L.3^[_X\:/[#D_N_P#CQH PZ5:V_P"PY/[O_CU']AR?W?\
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M #G-[1Z#\Z-H]!^==)_PA]__ - Z\_\  >3_ .)H_P"$/O\ _H'7G_@/)_\
M$T?5ZW\C^YA]8H_SG-[1Z#\Z-H]!^==)_P (??\ _0.O/_ >3_XFC_A#[_\
MZ!UY_P" \G_Q-'U>M_(_N8?6*/\ .<WM'H/SHVCT'YUTG_"'W_\ T#KS_P !
MY/\ XFC_ (0^_P#^@=>?^ \G_P 31]7K?R/[F'UBC_.<W@>@_.F\>@KIO^$/
MO_\ H'WG_@/)_P#$T?\ "'W_ /T#KO\ \!I/_B:/J];^1_<P^L4?YSF<#V_.
MC ]OSKIO^$.O_P#H'7?_ (#2?_$T?\(=?_\ 0.N__ :3_P")H^KUOY']S#ZQ
M1_G.9X]OSIIQZ#\ZZ?\ X0^__P"@==_^ \G_ ,32?\(=?_\ 0.O/_ :3_P")
MH^KUOY']S%]8H_SG+,4W8SSBO>O#O_(LZ1_UXP?^BUKRUO!EZ>?[,O <?\^T
MG_Q->T^']!>+0=,CDC,;K:0HRM\KHP11_2OU+@*E4IXRJYQ:]U;KS/F,[J4Y
MTX<LBL316W_8K_W?_'C2?V(_]W_QXU^Y'R!BT5M?V&_]T?\ ?1I/[#?^[_X\
M: ,:K.I?\?G_  %/_0*T/[#?^[_X\:ENM(::8R*!T4?DN* .?)I*W/[#D_N_
M^/&C^PY/[O\ X\: ,.BMS^PY/[O_ (\:/[#D_N_^/&@##HK<_L.3^[_X\:/[
M#D_N_P#CQH PZ*W/[#D_N_\ CQH_L.3^[_X\: ,.BMS^PY/[O_CQH_L.3^[_
M ./&@##HK<_L.3^[_P"/&C^PY/[O_CQH PZ*W/[#D_N_^/&C^PY/[O\ X\:
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M%6UVTU6WUC3O#&VU71]-UV^M[VZMF1&^T)YL3M^Z_P!5M1F9OD;[G-9?P_\
M@?9R?$KXBZ_XN\)Z7?/?ZU%=Z/?WUM!=R&)88SN5OG:+YE']VOHG^Q7_ +O_
M (\:/[%?^[_X\:GF%RGRGX@^&7C*3P[X_P# MKX>DN[7Q1XC;5K?Q$+NW2VM
MK>65)6W(S^;N78R*JJRME?F7NWQ1\/?'":7XY\+V/A5K^TUWQ9;Z_!K$=_;I
M&MNL]K*R['?S?,3R&_AV]?F_AKZN_L5_[O\ X\:/[%?^[_X\:KV@^4^8=?\
MA3XIO/AA\4-*ATK?J>M>+%U*PA^T1'S;<W%JV_?O^3_5-]_Y_DK+\8_#GQRO
MA_XC>%-.\+R:K!XC\1C7;36$O[>*-(M\#O$Z._F^:GD;/N[>OS5]9?V*_P#=
M_P#'C1_8K_W?_'C1[07*?+?B[PM\4O&GQ L#?VEP-#TGQ;:ZC:0V\FGI9G3X
MI4_>\%KI[@YW,GRK][9N^1:KZG\.?&,WA#X@>&X_#DCMJ7BU-=LKXWMOY4T'
M]HV\[!?WNY'6)6=MRK]SY=U?5G]BOZ?^/&C^Q'_N_P#CQH]H/E/E/Q#\,?&,
MOAWQ_P"!;7P])=VOB?Q&VK6_B(7=NEM;6\LJ2MN1G\W<NQD555E;*_,O>[K_
M ,*/%-W\,/BAI4.E;]3UKQ8NI6$/VB(^;;FXM6W[]_R?ZIOO_/\ )7T__8C_
M -W_ ,>I/[$?^[_X\:/:!RF+6MI/45)_8C_W?_'C5ZTL3;K]WGZFLRBQ12[3
&Z44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img61678762_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2UV17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $.X<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C$W(#$T.C W.C,T   "H $  P    $  0  ZAP !P  " P
M  C@     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M!@$#  ,    !  8   $:  4    !   1/ $;  4    !   11 $H  ,    !
M  (   (!  0    !   13 ("  0    !   <(@        !@     0   &
M   !_]C_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@
M)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!# 0D)"0P+#!@-#1@R
M(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C+_P  1" !U 0 # 2$  A$! Q$!_\0 'P   04! 0$! 0$
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MW@;[2F=)BA&.91(,C\A6E]GA_P F@ ^SP_Y-9][;G>=NFQ70R-NYP,<=\YH
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M !52XN+LS:%2-1<T7=!NE_Y^;?\ []G_ .*HW2_\_-O_ -^S_P#%5)8;I?\
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M#'KW[U8WR\'S1ST^<<T ."W+#(8D'H0PJK<QZN93]DGA5<#*RC./<8(_7TH
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M1BS_ .?&'_O@?X4 &VSQG[%#_P!\#_"C%G_SY0_]\#_"@ Q9_P#/E#_WP/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BDS10 M%%% !129'K10 M%%% !111
M0 4444 %%)FC(]: %HHI,T +1110 4444 %%%% !1110 44F:-P]: %HI,T9
M[=Z %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBD;[IH \-_:)_:,TWX"6>AVJ:->>*/$_B"Z
M\G2=!LFV2SE2OFMO/]T,FU/O,S*J^J]C\*_BQX;^,O@NQ\2>%;[[;I]R=C*Y
M"36TJ\O%*O.V1?[O_LO-?F/\?OAQX^^&/Q6OM(\:B7QK#XHN9;AM4O+SRH=<
M10H@2V79MM;^!=_E_-M^=8E1D;;*SX _%Y_A+XNMT^']]#/K$:10RZ5+&UK:
M^)[?YMMM,K?+;:G%\RJR_+)M.-V[_2/H7EL98=2IN\N_3_@?U?R\GZVXU.6:
MT/UWW%3C'%>?_%_XP>&O@CX,N_$WBB^:VLHB5BA4YEN9?X(HD_B9O_U_+7$-
M^U]X$_X4O_PL2.XN9K5IO[/71UA_XF#:A_SX^3G_ %^[G;_=^;[OS5^>/QN^
M+4OQB\97@\=WMN=4,;1_8+9/M5OH-ON7_0;*/[MQJ,K,JR2?=C_V=O[KBP>7
MSKS]]62.BOB8Q7N[GZ+_ +.W[2%E^T!I.KHVB7_AGQ/H5TMIK&AW>6:UD8ML
M_>[55ON/N7"NK(59?NEO;MO5>G<5^2?P#^'7CWXE?%BQT_P<&\&P>$;J">'5
M;*Z$UKH2.K"YBG79MN[V7Y%D.[:=CHP5/EB_6S_EGQ^-98[#PP]7E@]^G;^O
MZ[N\-4=6&I-12#.!GK2UP'6%%%% !2'@$TM)0!4D^4 J.6/Y50U[7-.\*Z7/
MJ.IW<=E90*7DGF;:B+ZFM%\^8,#Z#\*^:/VOKS[1=>#=.F+?V;,;NXEA.H16
M*M-$L7E'SI%95V[GK>C3]K-0/-S#%?4\-*NEM^KL>Y>"_&-GXXT.UU6SMKJU
MMYBQB2^A\IV4-\K[3_"WWE/H:Z5AM7&,$^IKXS^'?C36K/Q=82:2^H>([[YO
M*TJX^(5M<)/\C?\ +(+\W&6]MGM7V);-+Y(D=&B=ERT9?=MJJU'V4K&.78Y8
MRG?JO)FBOW12TE+7,>P%%%% !1110 4C?=-+3.(UZT 9&I:U9:;]F6[E$)GF
M6WC+=6=NBBLOQ1XH?PY!%=?V?)<62M_I$L+_ #0C^_MQ\U<I\2=-NEOM/%M?
MW%S?75Y$]G8'9Y2,OWG;Y,[%3FM;_A6MK=1E]9N;K6[N0<^=,R1J?]A%.%KX
MVMCLQQ5:MA<+3Y6K6DVK?/??M:]GNCNA3I049S>_]>1NZ'K[ZEI?VJ^M'TK=
MN=(IG^8)_>?^[WK4T_4+?4K>*\MY5F@D0.CI_$*X'7? MYI>F7+>'[N=<V[(
MVFW$KS0R+C^'>?D:K7PTLI%T:SNTU2ZOK%K<116\T:)Y?_ZONUOALPQ<<3#!
M8FEK;65UKYK;3OI=76@I4Z?(ZD&>BTM)2U]6<04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '!_%
MCX4>'/C-X-N_#7BO3X]0TR=<AB/WD$G\,D3_ ,++D_-_]<5\3>+OV,M5^&?P
MU^-/B/Q9X@L_$MH?#LD.GK;VQ66X>$B2.]NPWRBZ7;Y?F+GY2[,VYFS^B!;Y
M1BO(?VM#_P 8R_$P8Y.@WA_\<:N_"8BK3FJ<7HVOS.2M1A-<[/S5L[C7KCQ=
M<:O+K+36IO[J[^SO$N_^T/[ :7[7YG]_.WG^\NZO?O"O[%-Y\3OAO\%O$7AC
MQ''X7MO^$;AAU*(VY9XO.7S9[RT]+B3?Y;.W\(3^ZHKPS1_F:1#_ ,_]U_ZC
M;U^E'[*?_)M?PR]?^$<L/_1*U[^95I4(QE3_ *W/-PM-59-2_K8Z3X8_#'P_
M\(?!MCX:\,:>FGZ39KB.,#YY'_B=V_B=O[W_ -85V@/RT''?FE &/:ODG)R=
MV>W&*BK(6BBBD4%%%% !2'H:6B@"L=K1@[3U[&N/^)7PWTGXF>'?[*U59 J,
M)8+B!]LMO*OW71NS#-=HZMM 4X/Y5YY\8X]9_P"$-N_[,?3?LWE2_P!H+J=O
M-.C6^Q@ZA8CN-73YN=<IR8KD]C+VD>9=CSW0]:_X4]KUO9>,M,TTVLK""S\8
M:;9I$A9OEVW*J/W#'^_]SGMBO?.&4% #GH2>U?G_ *Q9^';73;AY!X6AC\MT
MR-#U:(;O]AG;;NK[1^%<=W'\,/"$=[$ZW"Z5:QSB8_.&$2[MP]<UW8BFHJ,[
MGSN2XR56<Z%ERK5:W^]_EU]3O%^Z/I2T@X I:\X^M"BBB@ I*6B@"-?NBLO7
MH_M&E7J"V^UEH646S-M\WY?N?C6OC;@#I42C<&SUK&K#VD)0[CB^5W/(O#>D
MWGA_Q1H<>KW&?,M[B&U@SN6V;Y&V;_XOD'Z5ZP,[0, $=C7F/Q&TO6KZ]L;?
M[3&;"XOXHHQ;P_O8#][S=_MBK.K>*O$'@>P$FKQ6NI6Y;9%>13B!F'^U&W\7
M^[7PN Q=/)YUJ-2$U2C;5ZVT2UM=VTNGLD[:'IU:;Q')*+7,^AZ%/*4B+ C'
M>O)/#^AZAJ=S9ZC"CWNBR:E-<Q6ZOY7D S?++_M+QOV^]:7B'_A)/$7AN_E9
MH=,T\VCS>1;R>?+-\GW=V-H4_P"S70^!%U9M/MYKUK$6,UO$UO':QLGEC;]W
MGM6E:4,XQ].FX34(JZEM?5;I]-+6:UOMU(BG0IMW5SM5X4?2EHHK[P\X****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #>QKYM_:8^+GC+PCKV
MEZ=X&>-[K1[&7Q5X@A,2R--I<#JK6ZEA\K2[I<,GS_N*^DMO!%>-R?LV^%O$
M7CKQ-XG\::-H_C6_U>6#[*FK:3'.FFVL42HEO%YN_P#B\V1V&W<TGW1MK:C*
M$)<TT85E.2M J>,OVE-$\)ZBMI;>'?$'BA5T%?$LMUH,4#1)8LS?O=TLL?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/M36-XSK$D5QN1/*8NRK_L[OFV\4<L O(]=_X>V_$;_H4/#'_?-Q_P#'J/\
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MLZS)':_9_,9$@^\R.Q<I$NR-F9MO;.(]PKWCG_\ A[9\1O\ H3_#'_?-Q_\
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M&VOM/T+2;G2KF+5M16:_U%9WB=V>ZC@B56_T>W^[%_ V[=N^7[0_X=M_ /\
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MXMU!]2BATBZ_LJ#39MD:Q+%''&WR1>1%M7=_!\V[?7Z'?\.V_@'_ -"I>?\
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MDSX ^(G_  @&B>-+:VT_[1?^(=(_L:.\\[;]DA::)YSMV_-O2+9]Y=N^NO\
MV5?VB/\ AF7XDW?BO_A'_P#A)?/TV73OL?V[[+MWR1-NW^6W_/+[NW^*OTW_
M .';GP$_Z%.[_P#!Q=__ !RC_AVY\!/^A3N__!Q=_P#QRJ]I GD9^5GPH^,7
M_"L?CCIGQ$_LG^TOL6H37_\ 9WVGRM_F*WR^;M;^]_=KTSPG^V4VA^/?BOJ6
MK>#H?$7A+XC3/)JOAZXU&2)XURY1$ND7^[*Z_=_N_=VU^@__  [=^ ?_ $*E
MY_X-[O\ ^.4?\.W?@'_T*EY_X-[O_P".4N> ^61\Z_L\_M?Z/XX\9>*IM8CT
M'P%X2T+P3_8OA[P]J6IJ4VKL_=>;*4:=GV*OR[?D1?XMS-Y]H/\ P46A\*>+
M/!\NA_#./3/!_A;1[C3+'P\FN/(^^5HLRO<M$VX*L2*J;-WS.VYOX?LO_AVY
M\!/^A4N__!O=_P#QRC_AVY\!/^A4N_\ P;W?_P <I7B5:1\)_!CXZW'B[PG\
M'_AE97&A^!KKP/K<GB!/%7B+6OLUI<CSY96@*^5\FY9F7[WS;?\ :KT?]H+]
MM/1_"O[8'A_Q)X7M;;Q=X9\'V5S;00V5VL-O=W5VCM<2QSHLF[EU_AY:)O\
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M (-[O_X[5^T1/LV?F)XA7_C$[P/_ -C?K/\ Z2Z?7)?![X@?\*G^*'AGQ?\
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MZK\<;S_A"_)_X6;865AL_M3=_9OD6KP;O]1^]W;]W\-?>7_#N3X"?]"C<_\
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MOEQ)%]_:O]W^[7ZF_P##N7X"_P#0H7'_ (-[S_X[1_P[E^ O_0H7'_@WO/\
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MKG@'+(_&?;[4NWVK]E_^'<OP$_Z%"Y_\&]Y_\=H_X=R_ 3_H4+G_ ,&]Y_\
M':?M(D^S9^-&WVHVU^R__#N7X"?]"A<_^#>\_P#CM'_#N7X"?]"A<_\ @WO/
M_CM'M(A[-GXT;?:C;[5^R_\ P[E^ G_0H7/_ (-[S_X[1_P[E^ G_0H7/_@W
MO/\ X[1[2(>S9^9'[,:_\55XQ_[$CQ#_ .FZ6O'=M?MCX5_87^#?@VZOKG2?
M#=Q;S7EA<:9,SZE<ON@GC:*5?F<\LKM\W7GBL?\ X=R_ 3_H4;G_ ,&]Y_\
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MVG[1![-GXRT5^S7_  [=^ G_ $*=W_X-[O\ ^.4?\.W?@)_T*EW_ .#>[_\
MCE'M$'LV?C+17[-?\.W?@)_T*EW_ .#>[_\ CE'_  [=^ G_ $*EW_X-[O\
M^.4>T0>S9^8O[-7_ "$OB)_V(FM_^DQKQROVR\*_L(_!OP;-JDNE>'+NV?4=
M/N-+N2VIW+;H)TV2J-S_ -WC=63_ ,.V_@)_T*EW_P"#>[_^.4O:(/9L^!OA
M_P#MH:9IG@'P5X<^('PUM/B%-X+NUNM U+^UI+&6T"E3&CJL3^:%VK][Y655
MW*VW=4UC^W''K-M\0-'\=?#;2/$_A'QAJ2ZO+HNGWLFE^1<+Y7SB>)69MWD1
M,S?>9MS?Q;:^\O\ AV[\ _\ H5+O_P &]W_\<H_X=N? /_H5+O\ \&]W_P#'
M*GF@5RR/A3Q;^W]K'CBP^+-KJWA2V9/&UE#IEDMM>^6FE6T1E*+_ *IO/;]^
M[,WR?,3]WA5U=3_;XT'Q%\3)_%NN_!^PU=FT.UTBT1]8V7FGRP2SO]HM;M8-
MT#-Y_P#RRVLOE(RO7VM_P[<^ ?\ T*=U_P"#B[_^.4?\.V_@'_T*=U_X.+O_
M ..4<T M(^/U_P""ECKXPT3Q WPZ\ZXTWPY=Z!Y,VO2RB?SI;63S69XG=MOV
M;HS,S;_O_P![#T__ (*'7W@S5? ,'@7P%8^%_!WA>"XMYO#TNI2WGVV.9U=_
MW[KNC;Y6V-\WS-\V_P"Y7V[_ ,.V_@)_T*=W_P"#>[_^.4?\.V_@)_T*=W_X
M-[O_ ..4<T0M(^'M+_;TLO"6K> ;?PI\,;;P]X)\)ZA=:HOA]=9EGDN;J>"X
MBW?:7C^54^TR-MVM_+'*?#']K#0? _C'XA>(M8^&%IXDO?%&J3:E9WXU1K._
MTCS'E=UBO$B\U?\ 6_>B\IN/^^?T+_X=N? /_H5+O_P;W?\ \<H_X=N_ /\
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M\4#PW_PDQO=633/L?V[[+MW12R;]WE.?^66W;M_BKY5_X? 2?]$E _[F,_\
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MO\P_M##_ ,WX,_1?=1NK\Z?^'NQ_Z)./_"C/_P B4?\ #W9O^B3C_P *,_\
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M.8?\^OQ7^8?VAA_YOP9^B^ZC=7YT?\/=S_T2<?\ A1G_ .1*/^'NY_Z)./\
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MC/\ \B4?V#F'_/K\5_F'U_#_ ,WX,_1;=1NK\Z?^'NQ_Z)./_"C/_P B4?\
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M_#W@_P#1)Q_X49_^1*/["S#_ )]?BO\ ,/K^'_F_!GZ,[J3=7YS_ /#WEO\
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M1FFT4 .S1FFT4 .S13:* 'Y-&33*-QH ?NJUN_XELG_7:J>ZK6?^);)_UVH
MS]6DO8=-N6TR"WO+Y5_<17=P]O"S_P"VR(^S_OAZ\U\"_%7Q%XDU'Q%_;'A[
M0-#T7P[?S:?J>H?\)%+*\3) L^]5:U5&7,J_.[+_ !?W?F]1KQRS^'^NQ^#/
MC?I[:>?M7B"^U&;3$\U?WZS:=!&G\7R?,K)\^WK51Y29'>7'Q8\$6FF_VA+X
MOT*/3_M+VWVMM4MTB\]/^66_?][_ &*N77Q \-:?J]EI5SXCTF#4[W8]I92W
M\2RW._[GE+OWM_P"O%O&/PK\16FK^!-2TBSU*6TTWP[)H]QINAOIWVBUD;RO
MG1+]7BVOMV/LVO\ =^]]RN1U;X1_$.33;'P]9:)>1Z/9PZ3]E;S=-8NL#1.R
MW5PR^:[1;714B55^Y\W\!OEB1S2/=-!^/O@3Q%?:W;Q^)])MY='O7M9ENK^W
M3S!\GSI\_P!S<^W?_>1EK=TWXH>$-<O+.RT_Q5HE]=WT;R6=O;ZC%,]RJ_?9
M41_F7Y'^Y_<KQ>;X:^*9M0UK2)O#+7.FW7CVV\2#46N+=K:2T\V .FS=NWKM
M;Y&3^#Y-U/\ ^%+Z[,VJ%-*6VNKCXC_VW%>0RQ><ECY17[1][_?^3[_^Q1RQ
M#FD>T6_Q"\*7=SJ<-OXET:YN-*1WU&*&_B=[-$^^\J;_ )?^!US_ (B^/7@3
MP[X5UC71XFTG4K72_DN(]-O[>6<-_!%]_P"\_P#<KPWPW\"_%=EX3&C7FE:V
M^I:5X<U/2K662^TE-/FEEMRG[KRHEG?S6.__ $C9L_B=OO5J_$SX'^)-8M;J
MWT'0[>.)_ L&DB*&6&)&NXKN&58OO_W$;Y_N?[='+$.9GM/C3XH6.D_#2^\6
M^'YK/Q)$46+3FM)DFBN;B65+>)=R^DKHM8OA[XD>,/%FN>(K32?"VA/::%J9
MTFXNKW79;>65_+BD=TB2R?Y/WO\ >[U#\7KB]U#X6PZ]-HMY97.BZE9ZW)I<
MDD+2K%:WL4DJOY3,KMY2L_R.WS;*Y7PGX5U/P[\0O%VKW'A+Q5J\.J>(/[4T
MZ]T/Q#%%I[V[PP+&\MK_ &A$K?,K??B;Y-E$>7E#WN8]>C^(7A>;4M0TV+Q-
MHTNH:>KRW=JM_$\MLJ??>5=^]?\ @=<WJ7QR\+VOB32;.UUK2+S3+R*]:[U:
M'5(?)L7@2)]C_P 'S^>GWW3_ ,?KQIOAK\2?$6OB^U/0S;M':ZW 8(/L$-EO
MN(72)K?RCY[[_DW/*WWW^[_$>^7X/S7T?PSTF\T:--$L/#5]I>L1HR;8O-MK
M==O^WRLOSI1RQ#FD>Q?VO9?VM_9OVVW_ +2\K[3]C\U/.\G?LW[/O[-_\=>8
M?$KX['X<^*KS3I-$^V:;86-CJ=_?+=;'@M[FZDMW;RMGSF+R]P^?[N[^[7*?
ML^> ;CQCX)GU[Q-J-_>W-XT6GV%]I^HW%E))IMF'B@;S8&5_WK^;(_\ ?\U*
MZNZ^%\NL?$[Q M]:3S>%+_P=;:#]JFNO->1UN+G<C;W=G?;(GSO_ 'Z7NQD/
MWI1+GQ4^+6H>#=431]!T=-<U7^R;S6[E9)_*^S6\&WG[GSM,S%%^YVKOM%UB
M#Q!H^GZE9-NL[VW2YMV_O(Z;TKY\\#^%?$?PY^&7C[Q/X]3S-<CTI=%LUCF2
M9GL[:WV6X0IOV-<2LS;?]I:]K^'&AW/A?X<^%M%NQBYT_2[2RF&_?AXHD5__
M $"ID.)TN31DTW=2[JDL7<:4&FT4 2!J>IJ,4Y: )E-2I4*U,E 'QY_P57_Y
M-U\,_P#8UV__ *1W5?E=VK]4?^"J_P#R;IX9_P"QKM__ $CNZ_*]>E?J'#G^
MY+U9\KF'\<]+^'_PQL_&'AN>Y69KW49)/(2"UV^;;M\S+\N[YMVW=N;Y=N[_
M *:26V-IOPRUG4/$@T62!HI#\S2*N[<OS?=7Y=S?*R[6V[65MVW:VW"\/:]J
M'AG4%O=,NFM;I?XMJMN^;<NY6^5OF56_WE5OX:]>US5KO3?!-O+!)Y4]OH6D
MS0R^6NY6^TLWWO\ @/W:^C]Y2T>YYMU]QR/Q2\%Z1X6-A)IDS1B5?+:TE;=*
MVUF5I&_N_P!W[J_\!;=''PV*L7U]<:I>2W5U)YL\GWFV[?\ @*K_  K_ +-1
M;:Z(1?+9LAM#=M+M]J>%I=M:6$1[?:EVU)M%&*+ 1[:-M2XHQ[T[ 1[:-M28
M]Z,>]%@(]M&VI,>]%%@(MM&VI:*+ 1;:-M28HQ18"/;2[:DHHL!'MHVU)CWH
MQ[T6 CVT;?:I,>]&/>BP$>WVHV^U28]Z,>]%A$>WVHVU)CWHQ[T6&1[:3;4M
M%%@(MM&VI:*+ 1;:-M28HQ18"/;2[:DHHL!'MHV^U28]Z,>]%@(]OM1M]JDQ
M[T8]Z+"(]OM1MJ3'O1CWHL,CVT;:DQ[T46 BVT;:DHHL!'MHVU)M%&VE8"/;
M2;?:I-M&VBP$>WVHV^U/HHL S;[4FVI*::0#,4E/IE( II%.II-2 C4VE9J8
M6J64A*1J"PII;WI#%IK=:-U-+"IN -3:-WO32U(H0]*_0W_@DH?F^*_TTG_V
M\K\\6/RU^AG_  25/S?%;Z:3_P"WE?/YY_N%3Y?FCNP'^\1^?Y'Z%LU,9J&:
MF%J_*CZT4M3=U(33<T .W>])NIM&10 [=1NIN11D4 6[ \S_ /7%ZK;JGT_K
M/_UQ>JU 'G%Q\5M:USQ-K6D^"_"]KX@@T20VE]J-_J?]GVYN NYK>+;%*S,B
M,N_"JOS?>JUI/Q0O;CQAI7AW6M"'A^[N]!NM8G\V]2;[+Y5Q'%Y7R_(_^LW[
M]W\'W*X71;G4OA3JOQ T34M,\2166MZM<:YIGB+PWI37[)YY3?"ZK%+LE5D;
M[Z[77;7):*WCV2:V\1^(/"VI>*=4C\$:Y;/:ZA9)%]KW:E&+6"5%3RE9H%3Y
M-F]_F^6M.4RYCZ L?B?X-U"QFN[3Q9H-U:1SI:R7%OJ,30K([;4B=]_WG;^&
MM*\\9:!8?VI]JUK3;?\ LM4>_P#.ND3[$C_<\W^[O_VZ^5FM/$7B"X\>7%_X
M.N-0@UGPK8Z/:6FF^'+O3(9+C[1(J*RRNS+Y/F+NE?;M5/D7Y=[7+7P+XGT+
MP3%I.LZ'J.MZGX?\:6FL:YJ$-L]S_P )#:OOVSQ*?]<R_NMT2?=\CE?NT>SB
M.\CW'QA\:-&T/P=::[H,]IXK74=2M])L5LK^'[/)<2MM5'N%WHBX^^WSUI:;
MXZN=-TNZN?'=KIG@MEN_LT,DFLI+;W'R[]ZRLL7^W\CJK_*]>-2Z3I6N7_Q(
MU7Q#X!U[5? _B74]/BCLDTF5+MGB@?SKW[+\DZ)OVKO1?-^7[M8.D^!==6VT
M2PM=-\1:AX(M?'VG3Z/;>(+>5KN&S6V?SG9)4W);^9]WS>%_.KY8BYI'T?IO
MQ,\(:QJ%E9:?XJT2]O+Z/S+.VM]2BF>9?[RHC_,O^Y7!ZE^T9HWAJ/3#XF;2
M=$NKS79]'$#:Y!-Y,,?F;[AV3[J?NMC)_"S*K?/7GO\ P@&I6TUU+%X;NH7'
MQ;BU!72R;?\ 8_EW7'W/]3][Y_N??I;K1]9T'2--U"?0=:GAT_XJ:EJLT5KI
MTLLWV5FOE65(E3<R-YD7SK_>HY8AS2/7?"/QO\-^(]>UO2+O4M+TF]L]7?2K
M"WFU*(S:A^X@D$T2_)_SWV;$W_=K.UCX^6'A_5/B#:ZAITJ?\(M<V5K EO-Y
MDVIW%U LL4446S[VYMNWY_[]>7^+? U_J'PU^-\]MX9NIM7U+Q+'=Z=)_9K_
M &F>%4LGB:+Y-[(K+-_P+=_MTOB#X1^)-4^-OQ%\;Z+93)KFBZCIFH:)#J"-
M]BU14TY8IHDW_*7X9?-3YE>CEB'-(]#U_P".6L^'9Y]/O_"EG!K5MX=BUZ2S
MGUZ*&)&:X\K[/]HE1$^3[^[_ (!7H%]\2/">FZPFD7OB?1[/5VD2W73[F^B2
MX:7:C;?*W[]VUE?9_M)7S=\9K+7/B))XAUG3_"^O0IJ/@:UACL[C3I5E2X_M
M,.]OLV?>1/GV_P!SY_N5J_$_P+J.I:7^T7/!X>NKG4-0>P;39HK)VEN?*LH-
MOE?)\VV16^Y_%1:(<TCZ"U#QQX<TO7+71;[7=+M-9N_^/;3[B\B6XGSTVQ.^
M]JVLU\K^*OA_._C'X@6?B?\ X3:6+7M5@O;,^&]'@NX+JW6.-84:Z>U9X'B:
M)OO2K_>7[]?4W%92CREQD+D4;J;1FI*';J-U,W4;J '[J-U,W4;J '[J3=3=
MU&Z@!VZC=3=U&Z@!VZC=3=U&Z@!VZMC26Z5B[C6OI)Z4 ;%%%% &;J5G+-G:
MC-]#69_9=S_SQ?\ .NMHH Y+^R[G_GB_YTG]EW/_ #Q:NNHH Y'^R[G_ )XM
M1_9=S_SQ:NNHH Y'^R[G_GBU']EW/_/%JZZB@#D?[+N?^>+4?V7<?\\7_.NN
MHH Y'^R[G_GB_P"=']EW/_/%_P ZZZB@#D/[+N/^>+_G1_9=S_SQ?\ZZ^B@#
MD?[+N?\ GB_YU/:V-S%Y^^)A^Y<"NGHH Y'^R[G_ )XM2_V7<_\ /%_SKK:Y
M:X^)'A2T\1)X>N/$NC0>(9=JKI4E_$MVQ;H/*W;Z (_[,N?^>+?G1_9EQ_SQ
M>NMHH Y/^R[G_GBWYT?V7<_\\6_.NLK+UC6+/0=-N-2U*\ATVRMHVDGNKN18
MH8U7^)V;[JT 8W]F7'_/%Z/[,N?^>+?G7207*7$230LLD#KO1T;[U6: .2_L
MNY_YXO\ G2?V7<_\\6K7CU2"34IM/6YC^VV\:7$EN)%\R.)VD5&9<_=?RI=I
M/]UNZU-_:UI_:7V'[5#]NV;OLOG+YFS^_MH PO[+N?\ GB_YT?V7<_\ /%_S
MKKJ* .0_LNY_YXM^=']EW/\ SQ;\ZZ^B@#D/[+N?^>+?G1_9=S_SQ;\ZZ^B@
M#D/[+N?^>+?G1_9=S_SQ;\ZZ^B@#D/[+N?\ GBWYT?V7<_\ /%_SKKZ* .1_
MLNY_YXO^=3_8;G[ Z>2WF>=FNGHH Y'^R[G_ )XM2_V7<_\ /%_SK7UC6=/T
M#2KG4-4O;73+"V02S7=Y,L442]-S.WRK7,Z#\9O ?B?4K?2]$\<>'-9U2X+>
M38Z?J\%Q,^U=S;$1BS?*K-F@"_\ V9<_\\6_.E_LNY_YXO\ G7644 <G_9=S
M_P \6_.C^R[G_GBWYUUE% ')_P!EW/\ SQ;\Z/[+N/\ GB_YUUE% ')_V7<?
M\\7_ #H_LNX_YXO^=:^MZU9>&]'O]6U*YCLM.LX7N+BXD;Y8XE7<SURUU\;?
MA[INJ#3[SQUX;M=2W*CVEQJ\$=PK-]U3&S[OXJ -+^R[C_GB_P"=']EW/_/%
MOSKK*RKC6;*QU2VT^:\@AO[Q':WMY)56614V[]B_Q;=Z?]]4 9']EW/_ #Q?
M\Z3^S+G_ )XM^==;7,ZQXST#P]=7L>IZWI^FRV=NEU<?;+Q(O)MW<HDK[F^5
M&=67=ZB@"#^R[G_GB_YTG]EW/_/%JUM6US3=!TBXU/4]0M=-TV%!+)?7<ZQ0
MQK_>9V^5:9H/B32?$GVXZ7>V]\+2X^SSF%MPCEV)+M_[YE1O^!4 9G]EW/\
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M_N/W?_QVKMF/]W_R87[CS#_AG;XK?]$Q\9?^""[_ /C5+_PSO\5O^B8>,?\
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M,;_PSO\ %7_HF/C'_P $%W_\:H_X9W^*O_1,?&/_ ((+O_XU3O\ AH;XK?\
M13O&/_@_N_\ X[2?\-#_ !6_Z*=XQ_\ !_=__'*/^%+^[_Y,'[CS$_X9W^*O
M_1,?&/\ X(+O_P"-4?\ #._Q5_Z)CXQ_\$%W_P#&J7_AH?XK?]%.\8_^#^[_
M /CE'_#0_P 5O^BG>,?_  ?W?_QRC_A2_N_^3!^X\Q/^&=_BM_T3'QC_ .""
M[_\ C='_  SO\5O^B8^,?_!!=_\ QNE_X:'^*W_13O&/_@_N_P#XY1_PT/\
M%;_HIWC'_P ']W_\<H_X4O[O_DP?N/,3_AG?XK?]$Q\8_P#@@N__ (U1_P ,
M[_%;_HF/C'_P07?_ ,:I?^&A_BM_T4[QC_X/[O\ ^.4?\-#_ !6_Z*=XQ_\
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M'_#0_P 5O^BG>,?_  ?W?_QRC_A2_N_^3!^X\Q/^&=_BK_T3'QC_ .""[_\
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M[O\ ^.4?\-#_ !6_Z*=XQ_\ !_=__'*/^%+^[_Y,'[CS$_X9W^*O_1,?&/\
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M@N__ (U2?\,[_%;_ *)AXR_\$%W_ /&J=_PT1\5O^BG>,?\ P?W?_P <IO\
MPT1\5O\ HI_C+_P?W?\ \=H_X4?[O_DP_P!SYA_PSO\ %;_HF'C+_P $%W_\
M:I#^SM\5O^B8>,O_  07?_QJE_X:)^*W_13_ !E_X/[O_P".TW_AHCXK_P#1
M4/&7_@_N_P#X[2_X4?[O_DP?N?,/^&=_BO\ ]$O\9?\ @@N__C5(W[.OQ7_Z
M)?XR_P#"?N__ (U1_P -%?%;_HI_C+_P?W?_ ,=IO_#17Q6_Z*AXR_\ "@N_
M_CM+_A1_N_\ DP_W'F'_  SK\5_^B7^,O_"?N_\ XU3?^&=?BO\ ]$O\9?\
MA/W?_P ;H/[1?Q7_ .BH>,O_  H+O_XY33^T9\5_^BH^,_\ PH+O_P".U/\
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M:+;^UM-EL_/V_:MVSS57=LW+_P!]+7Z(=A@4%3MPO!K@QF=UL91=&4$KF]+
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M%MW5_EVX_>IS7I^N?#?0-8^'U[X-738-.T*XMWMTL]-B2W2 $YW1*HVHRO\
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M[O\ >_V?_9?FKZ!8)7=ZTM/[QYOM?[J/6 O[*?\ U67_ ,I-._XQ4'_19/\
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M&I,T ;/_  DC_P#/!?SI/^$D?_G@GYUC9I* -K_A)&_YX)1_PDC?\\$K%HH
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MA_=,Z+_JD=MF_P#O_+6C-^T/X0T_3=+DU*]ECN[S0X-?:WT[3KR_2*RD1_\
M2-ZV^[ROE;YG5?X-Z+OHY9!S(]D_X2-O^>"_G2?\)(__ #P7\Z\V\1?&+PGX
M5DMA=ZK),UQ9?VB/[,M)[SRK3_GO+]G5O*BZ?O6VJ^UO[CUU5C?6^H6L-W:2
MPW-M<(DT4T+[TE1_N.CU)1O_ /"1O_SP3\Z3_A)&_P">"5CMTIM &U_PDC?\
M\$H_X21O^>"5BT4 ;7_"2-_SP2C_ (21O^>"5BT4 ;7_  DC?\\$H_X21O\
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M?NO]C_ON@#.HK1_X1^Z_V/\ ONC_ (1^Z_V/^^Z ,ZBM'_A'[K_8_P"^Z/\
MA'[K_IG_ -]T 9U6_P#F'2?]=JF_X1^Z_P"F?_?=6?[(N19R1_+YF_?]^@#(
MKRJW^%NKQ^%?BUI;36@E\77E]<V$FYO+B2:QC@3S?D^3YHF^YO\ DKV7^P;K
M_8_[[I?[ NO]C_ONJ \ \:_!'6+[5_">M:2\4MYI>B-HUW9?VW?Z2C*-KHR7
M%M\_RNOW778V/X-E<OJW[.OC:^AMM)M[_3K?P]:IIPL["+6M06&R\AE>51;E
M/W^]U?:TK-LW_=KZG_L"Z_V/^^J/[ NO]C_OJCG9/*CY]3X-^*H]:U.!'T4Z
M-<^,X?%4=PUU-]HV++ S1-%Y6Q/]4_S[OGWI]VI)O@9J]Q;ZA!-=V?DWGCO_
M (23Y)7_ ./3RE79]S_7<_[G^W7OW]AW7^Q_WU1_8=U_L?\ ?5'-(7*?+>@?
MLVZ[I?AF30[B/3;C['H=]I&GZM+K^J3[O-M_*1_L<N^*UZ_/MW?[")6Q\2/V
M?=?\9QS_ &6]TV'=X0CT >:S?\?27$,I?[G^J_=??^__ +%?1?\ 8-U_L?\
M?5']@W7^Q_WW5<['[-'DOQ0TOQ!K7PO2\DTJVE\3:5>VNL0Z=83O<(S6UTLX
MB5G57?="KK]Q/O5G>%?@'X=NM8\8ZUXI\,>'O$%SK6LR:C9W%]IZSRQVODP*
MD3B6'>GS1RML_P!JO;/[ NO]C_OND_X1^Z_V/^^Z7,+E/G#P'\&?'/PMM?#-
MWHC^']3U:U\,KH%[;WMQ<16Z/',\R21,D3.WSRMO5U3=\OS+FH_#/P!\2>"=
M0\'1:-+IME!I$6GPW^MVU]<17=_#&F9K>6U1?*E1_P"!G;>J 5])_P#"/W7^
MQ_WW1_PC]U_L?]]U7.Q\L3Y-\"_"#QQXJ\ ^#8-9@T_0[71-(OX[2&1K@7DD
M]Q;2P(MQ$\2^4BK*WW-V[Y/NUT-K\%_B#X7LKZ'PWJVCVUSJ7AC2M(FU![J5
M9K.ZLX94/DKY3%E;S/O?(ZY^XU?2/]@W7^S_ -]4?V#<_P"Q_P!]4>T8<I\U
M>'?@%XHL=:;4KR[M27U_3-6,<NK7.HR+':*Z,IGG3<[_ #IL^54_V4I-%^#G
MCO0-'\%Z*]IX>UO1M!>ZOY;&?6+BV2XO7NII8&<I:R[DB1MVSY/WN6_A6OI?
M_A'[K_8_[ZH_L"Z]$_[ZJ.=ARQ/FQ?V==2A\8:G)(+74- OM?DUU+AM?U&V>
MU,LOF;4L4_</(C?<;=_P&CP_\.O''@:U\%7.H6VBZCI_@'3+N""#29;AKS4U
M,&V+]UY7RL^U/E^;YG^]_!7TE_8-S_L?]]T?V#<_['_?='-(.6)Y_P#!WPA/
MX#^%GA?0;S$=]9V,0N0/N"7;OE"?\"=Z["M#_A'[K_8_[[I?[ NO]C_ONI**
M%2+5S^P;G_8_[[IZZ'<C^[_WU0!62K$=2KHMP/[O_?53)I4R]2O_ 'U0!\9_
M\%6/^3;_  T>_P#PE<'_ *27E?E@F<5^M/\ P4N\"^)/&GP$T&Q\.:%JGB&]
MB\3P3R6NDV4MS*D8MKI2Y6-6;;N9?F_VEK\UU_9V^+/3_A5WC/\ \)^[_P#C
M5?I.08BC2PG+.5M6?+8^,I5M$<=I.J7.BWT5Y93-!/'NVLO]UOE96_O*R_+M
MKUPZU=_\*HBN?,7[6MXURMSY2^;YGD*OWO[NW^'[M<VO[.OQ7_Z)=XS_ /"?
MN_\ XU6@OP1^,WV/['_PKWQZ+/R_*\C^Q;WRMN[=MV[?N[OFKZ5XG#2M^\B>
M;R3[,X#4M4NM9OI+R]F:>YD^\S?^@_[*_P"S5<9KO1^SS\5N_P ,/&7_ ((+
MO_XU2_\ #//Q6_Z)CXQ_\$%W_P#&JZ?K>'C_ ,O(_P#@1/LY]C@^:.:[[_AG
MOXK?]$Q\8_\ @AN__C=(?V>?BL?^:8^,?_!#=_\ QNCZWAO^?D?O)]G/L<!N
M/:DR:[__ (9Y^*W_ $3#QC_X(+O_ .-TA_9W^+'_ $2_QE_X(+O_ .-TOKF&
M_P"?D?O#V<_Y3@-Q]*;N]J[\_L[_ !8_Z)?XR_\ !!=__&Z;_P ,[_%C_HE_
MC+_P07?_ ,:J?KF'_P"?D?O'[*?\IP.XTFZN^_X9X^+/_1+_ !E_X(+O_P"-
M4G_#._Q9_P"B7^,__"?N_P#XU2^N8?\ Y^1^\?LI_P IP.X^E)N^E=]_PSO\
M6?\ HEWC/_PG[O\ ^-4?\,[_ !9_Z)?XS_\ "?N__C=+ZYA_^?D?O'[*?8X'
M=]*-WTKOO^&=_BS_ -$O\9_^$_=__&Z3_AG?XL_]$O\ &?\ X3]W_P#&Z/KF
M'_Y^1^\/93['!;OI1N^E=[_PSO\ %G_HE_C/_P )^[_^-T?\,[_%G_HE_C/_
M ,)^[_\ C='US#_\_(_>'LI]C@MWTHW?2N]_X9W^+/\ T2_QG_X3]W_\;H_X
M9W^+/_1+_&?_ (3]W_\ &Z/KF'_Y^1^\/93['!;OI1N^E=[_ ,,[_%G_ *)?
MXS_\)^[_ /C='_#._P 6?^B7^,__  G[O_XW1]<P_P#S\C]X>RGV."W?2C=]
M*[W_ (9W^+/_ $2_QG_X3]W_ /&Z/^&=_BS_ -$O\9_^$_=__&Z/KF'_ .?D
M?O#V4^QP6[Z4;OI7>_\ #._Q9_Z)?XS_ /"?N_\ XW1_PSO\6?\ HE_C/_PG
M[O\ ^-T?7,/_ ,_(_>'LI]C@MWTHWUWO_#._Q9_Z)?XS_P#"?N__ (W1_P ,
M[_%G_HE_C/\ \)^[_P#C='US#_\ /R/WA[*?\IP6ZC=7>_\ #._Q9_Z)?XS_
M /"?N_\ XW1_PSO\6?\ HE_C/_PG[O\ ^-T?7,/_ ,_(_>'LI_RG!;J-YKO?
M^&=_BS_T2[QG_P"$_=__ !NC_AG?XL_]$N\9_P#A/W?_ ,;I?7,/_P _(_>'
MLI_RG [C1N-=[_PSO\6O^B7>,_\ P07?_P :H_X9W^+/_1+?&?\ X3]W_P#&
MJ/KF'_Y^1^\/93_E.!W&C<?2N]_X9W^+/_1+?&?_ (3]W_\ &J3_ (9W^+7_
M $2WQI_X(+O_ .-4?7,/_P _(_>/V4_Y3@MQHW'TKO#^SO\ %K_HEOC/_P )
M^[_^-4G_  SO\6O^B6^,_P#PG[O_ .-4OKF'_P"?D?O#V4_Y3A-Q]*3>?\FN
M\_X9W^+7_1+?&G_A/W?_ ,:H_P"&=_BU_P!$M\:?^$_=_P#QJCZYA_\ GY'[
MP]E+^4X/<?\ )HWFN\_X9W^+7_1+?&G_ (3]W_\ &J3_ (9W^+7_ $2WQI_X
M3]W_ /&J/KF'_P"?D?O#V4_Y3@]QHW'TKO/^&=_BU_T2WQI_X3]W_P#&Z/\
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M_?5 %(M4]BW[Y_\ <?\ ] J7^PKG_8_[ZJ:TTNYMYLOLQL?^.@#)W4FZK_\
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M&^A-I>GQW'C6W35Y9K-TAM],OTN'E^P;-^YX,-\KHK;&\P?Q5]A?V'=?[/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?LUMYVGQR9@;[QGY_>S?W95V[=J[E;]YO!\,?'4.WR/B7J'[@_9K;S]/CDS
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M\"K\;_@ ?^;9B?\ N?\ 4/\ XBOT3(:\Z>&<8TI2U>UOU:/FL=!2JW<DOO\
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M?=KK;S/4P56EAK\\M_7_ "/T:W&C=7YR?\/?&_Z)./\ PI#_ /(E)_P]^/\
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M"/\ T28?^%(?_D.C^P\?_P ^OQ7^8?7L/_-^#/T@W4;J_-__ (?!-_T28?\
MA2'_ .0Z3_A\(W_1)O\ RY#_ /(=+^Q,?_SZ_%?YA]>P_P#-^#/TA7%'3M7Y
MMG_@L)(/^:2_^7)_]QU]C?L__'";XZ?"'P_XY72!H/\ :RS_ .@M<?:?+\NY
ME@_UNU=W^JW?=_BKCQ.7XK"1YZT++U1M2Q%.L[09[#16"=8G_O1_]\TW^V+C
M^^G_ 'Q7 =)T%%<[_;5Q_?C_ .^*/[:N?[\?_?% '145SG]N7/\ ?C_[XI/[
M<N?[\?\ WQ0!TE%8%GJT\C.&;@([_<J+^W+G^^G_ 'Q0!TE%<W_;ES_?3_OB
MC^W+K^_'_P!\4 =)17-?VY<_WX_^^*3^W+G^_'_WQ0!TU%<S_;ES_?C_ .^*
M3^W+K^_'_P!\4 =/17,?VY=?WX_^^*/[<NO[\?\ WQ0!T]%<O_;ES_?C_P"^
M*/[<N?[\?_?% '445R_]N7/]^/\ [XH_MRY_OQ_]\4 =117+_P!N7/\ ?C_[
MXJ:SU:YN)L.W&Q_X* .BHKEO[<NO^>D?_?NC^W+K^_'_ -^Z .IHKEO[<NO[
M\?\ W[H_MRZ_OQ_]^Z .IHKEO[<NO[\?_?NC^W+K^_'_ -^Z .IHKEO[<NO[
M\?\ W[H_MRZ_OQ_]^Z .IHKEO[<NO[\?_?NC^W+K^_'_ -^Z .IHKEO[<NO[
M\?\ W[H_MRZ_OQ_]^Z .IHKEO[<NO[\?_?NC^W+K^_'_ -^Z .IHKEO[<NO[
M\?\ W[H_MRZ_YZ1_]^Z .IHKE_[<N?[\?_?NC^W+G^_'_P!\4 =117.V>K7,
MF_>WW$>3[E1?VY=?WX_^^* $\4?#7PKXX>&7Q+X8T;7Y8/\ 5G5-/BNO*'HN
M]:1? OARWC14T#2X42S;35C2SB 6U8[G@^Y_JGVKN3[ORT[^W+K^_'_WQ1_;
MEU_?C_[XH S[7X2^"-*CBBT_P=H-A&CH\:V^EVZ*K(V]&^5/X6^9?]JM.[\%
M>'-2.I_;-!TV\_M<(NHF:R1OM:J3L67Y?GV]MU,_MRZ_OQ_]\4O]N7/_ #TC
M_P"^* ($^&/@]/#?_".CPEH:^'M_F?V4NG1?9-_]_P K9MS4ECX!\,:;9V-A
M9^'=)M;*PG6ZL[2"PB2&VF7_ );1)M^5_F^^M/\ [<N?^>D?_?%']N7/_/2/
M_OB@";_A#M ^?&@Z:=U]_:K?Z(G_ !^?\_'W?];_ +?WO>J6H_#KPOJNFS:7
MJ'AC2+[2Y[MK^:RN+**6&2X=BSRLKKM+[F9MWWJG_MRY_OQ_]\4?VY<_WX_^
M^* $/@;P[)I]_IPT'3&T_4)1+>V7V./R;E]JC=*FS#-M5/O?W$JY:>'M,L;[
M4KV'3K:"[U)E:]N8H%5[K:NU/-;^/:GR_/53^W+G_GI'_P!\4?VY<_WX_P#O
MB@"LOPS\'QV9LU\*Z&ME]G^Q_9UTR';]GW^;Y.W;]WS/GV?WOFZU;O/!NAZA
M'JT5SHFGW$.L[?[062V21;W"*H\WC][\JHOS?PKZ4W^W+G^_'_WQ2?VY=?WX
M_P#OB@!-6^'?A/Q1J]MJVK>&M&U35K<9AO+[3X9;B$=MKNFY:ZBN8_MRZ_OQ
M_P#?%']N77]^/_OB@#IZ*Y?^W+G^_'_WQ1_;ES_?C_[XH ZBBN7_ +<N?[\?
M_?ND_MRZ_P">D?\ W[H ZFBN6_MRZ_OQ_P#?NC^W+K^_'_W[H ZFBN6_MRZ_
MOQ_]^Z/[<NO[\?\ W[H ZFBN6_MRZ_OQ_P#?NC^W+K^_'_W[H ZFBN6_MRZ_
MOQ_]^Z/[<NO[\?\ W[H ZFBN6_MRZ_OQ_P#?NM'3]2FN,!V0_1<4 ;%%0^8:
M* ,'5_O&LBM?5_O&LB@ HHHH **** "BBB@ HHHH **** "BBB@ JY8?ZR?_
M *XO5.K=C]Z?_KB] %>O"+KXP:UX)\(_%*TUBY_M'Q+X<O/)TN7R8E>[2\_X
M\/D38GWF\OZ1-7NPKS7QG\$;'QE\5?"_C66^EMCI/_'SIZ1EDOGBWO:.S_P>
M4S,Q^E5'E^T3+F^R>8>+OB5XV\(Z'\1K._\ %6R^\.IX9C&IBUM5\J2YF2.^
MD^:';\YW_?7:M==\-?BS;V^H>-'USQU8ZSX*L+FU@T[Q3J$EK:13RRH_FV_F
MQ(L4NW8OS(G\6?X:UO%OP,_X2J^\:W7]M_9SXEFT:?9]EW_9_L,Z2?W_ )]V
MS9_!L_VZZ+PA\._^$'\4Z_>Z9?[-"UB7[5_8WD_):W0QYLL+[_E27[SKL^]A
MOXJKFCRD>]S'*?&O5M4TOPBWB/PYXXU<7&HK;VNAZ7IL-A+:7-W/\L6QY;65
MG5]V]OG^ZCUYQ\0_BQXP\&^)]9TS_A*+Q]2T:WTR*VCM=*BELK^654,SW\I7
M_1=[_P"U%\NQOFKWC7/ G_"1>/O#FNWEZ'L-"26:UTOROD>ZE3;]H=M_\$6Y
M439_$[UQ_C/X&ZKXDO/&,6G>+!H^B>,$C_M:UFTW[1*W[A8'^SR^:OE;XE5/
MG5NOR41E$)1D9OQ8\2^-/ ^N6>H?\)*;.'4-9M;'3M)AL$;3_(W1+*][=.G[
MJ5]S;?WJ_P *(LHWXL>+M:\<>%?&V@2R^)(KA]:\1I86OA>TM86B?3,?/*[[
M?M'FI$GFNV[RD^[[5=\0?!?5_$3:AI4GC267P;J%_;WL^D7-I]HNTCB=6^SQ
M73R_+$[Q)_"S<-L8\YDT7X4^*=-^)VH>+[GQ3I.JR7\BQ>7>:%+YMK8(V_[+
M;R)>;5_WO*?>WS/OY6CW1^\>KTC4M,K,T"BBB@ HHHH **** "BBB@ HHHH
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ME5<T +129HS0 M%)N%)NH =29IM% "[J2BB@ HHHH **** "K>G?ZY_]Q_\
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M4;:;2]:OM-TFXAM]5URS@5['3Y65&V2N[;GV+*K/M1MN_P"?->D5X)JW[/\
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M^>T?_?%'_",R?\]H_P#OBN@HH Y__A&I/^>T?_?%'_"-2?\ /:/_ +XKH**
M.?\ ^$:D_P">T?\ WQ4]OH;V_F?O_OILK9HH Y__ (1J3_GM'_WQ2_\ "-R?
M\]D_[YK?HH P/^$;D_Y[1_\ ?%'_  C<G_/:/_OBM^B@# _X1N3_ )[)_P!\
MT?\ "-R?\]8_^^*WZ* ,#_A&Y/\ GK'_ -\4?\(W)_SUC_[XK?HH P/^$:D_
MY[1_]\4G_"-2?\]H_P#OBN@HH Y__A&I/^>T?_?%'_"-2?\ /:/_ +XKH**
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MA_X39_\ DNOT@VT;:/[;Q_\ S]_!?Y!]1P_\OXL_-_\ X<^G_HK0_P#";/\
M\ET?\.?3_P!%:'_A-G_Y+K](-M&VC^V\?_S]_!?Y!]1P_P#+^+/S?_X<^G_H
MK0_\)L__ "71_P .?3_T5H?^$V?_ )+K](-M&VC^V\?_ ,_?P7^0?4</_+^+
M/S?_ .'/I_Z*T/\ PFS_ /)='_#GT_\ 16A_X39_^2Z_2#;1MH_MO'_\_?P7
M^0?4</\ R_BS\W_^'/I_Z*T/_";/_P ET?\ #GT_]%:'_A-G_P"2Z_2#;1MH
M_MO'_P#/W\%_D'U'#_R_BS\W_P#ASZ?^BM#_ ,)L_P#R71_PY\/_ $5H?^$V
M?_DROT@VT;:/[;Q__/W\%_D'U'#_ ,OXL_-[_ASV?^BM#_PFS_\ )E'_  Y[
M/_16Q_X39_\ DROTAVT;:/[;Q_\ S]_!?Y!]1P_\OXL_-W_AST3_ ,U;'_A-
MG_Y,H_X<\G_HK8_\)L__ "97Z1;:-M']MX__ )^_@O\ (/J.'_E_%GYM'_@C
MS(?^:MC_ ,)L_P#R77V+^S_\"9/@7\(] \##6_[:_LI9U^W?9O(\SS+J6?\
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M_/:/_OBC_A&I/^>T?_?%=!10!S__  C4G_/:/_OBC_A&9/\ GM'_ -\5T%%
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MEU_\K:+!<]!VBC:*\^_MSXI_]"=X1_\ "LNO_E;1_;GQ3_Z$[PC_ .%9=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP'_/Z/WH]=VGU_2C:?7]*\B_X:N^%_\ T,DG_@NN?_C='_#5WPO_ .ADD_\
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M;0!%@^M&#ZU+MHVT 18/K1@^M2[:-M $6#ZT8/K4NVC;0!%@^M&#ZU+MHVT
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MF44 /\RI]/\ ]>_^X_\ Z!56K6G_ .O?_<?_ - H @\RCS*910 _S*/,IE%
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M)/\ OBC[+#_SR3_OB@#CZ*['[+#_ ,\D_P"^*/LL/_/)/^^* ..HKL?LL/\
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M6\LX;D?ZB4_=E5E#?+]ZODB/QUJ!)'V70Q_W+]A_\9KZO+>?V'NGXSQ.J?\
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MP3E^*.*ZC_A-K_\ Y]=$_P#!!8__ !FC_A-K_P#Y]=$_\$%C_P#&:.:?\O\
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MX+4/YG]W_!.8XI.*Z?\ X3B__P"?71/_  06/_QBD_X3F_\ ^?71/_!!8?\
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M#^9_=_P3FMP]J;N%=-_PG=__ ,^VB?\ A/V'_P 8II\=ZA_S[:'_ .$_8?\
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M% '&5KZ1]X5N?98?^>2?]\5)'"D?W45?HN* (Z*FQ10 ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 2OG.\^-6N^!O!OQ7L=<N3J/BKPS?^5I4G
ME1!KM+S_ )!ORJ$4G<WEM_UR>OHRO(/''P#M/&OQ=\*>.I=0:W;1E7[1IJIF
M._>(LUJSOGY#%*[M_%VJHVZDROT/*?&?Q1\=^!]"^)EC?^,-E]X;B\+P+JRV
MMJJP/=3)'>S_ #1;?G^9OG7:M=E\+/B];6>I>-IM>\?V.M>!=.N;*'3/%VI/
M:VL5Q<21N9;?[1$D4$NS9%\R+_RUV_PUM>,?V?V\6:EXZNO[>%JOBBXT6?;]
MCW_9?[/F23;]_P"?S=NW^';_ +5=)X(^&O\ P@?C#Q'>Z5J.W0-9D%X=$^SG
M;:WO_+66)MV%27[S+M^]\V[YL4[JQ/O7.'^-'B;Q1H?AO6_&FD>.K;1/#MMI
M<4VAVUC:Q7O]KWC;BJ2;T;<DN8U18&5FW[]PJG\7O$GQ(\*:#<^+QX@M]'D4
M:=;:/X5M;6.?^T[J79YUO.SKYN]G=T7R77:B;O[U=#XW^$7B;Q=\4=-\46OB
M?28[/1XS_9FD:OH,UY#;7#8WW6Y;R+=+_"I9<*OW1_'5;6_@_P".-5^)UIXP
M/C/0Y[BQM?L^G65_X;GF@L79?WTL6V^7YW.?F;=M4[1[F@]0U_QEXWTO]H[P
MCHLTUC9^#]5BU 1VELGF7-TT5O&_FS,Z_+\S[55/[OS-_#7!+\:?%3?%YM/'
MB*Z)_P"$T_L/^QUTR'^RA8_WOMNW_CZV?\LO-W[_ )?*KU7Q=\+/%/B/XI^&
M?%MIXGTFQM?#_P!H6UL+C1I;B1UN$1)M\OVI,_=.W"C;_M5BS_L^ZC->3:</
M&*KX+F\1_P#"2OI/]F_Z6T_VG[3Y/VKS?]7Y_P W^JW_ ,.^C07O'2?&3XU:
M%\'=!%[J^HZ6NH.\2P:;=ZC%:S7"O.D3NN[EE16+-A?X*?\ $;Q]#)\!_&7B
MWPCK5K??9=$O[W3]5T^2.YB,L44I5E;YE?:Z?^.UTGCWP/:_$'PW+HE_//;V
MLTUO/(]LR*^Z*5)4^^K?Q1I3/B!X3/COX?>)?#2W0LFUK3+K3?M2Q^;Y(EB>
M/?M^7=MW'Y:6A7O'RAXF^/WB?1O"NO7'A3XB/XSMH?#<6I7NL&VL9/[%O3<0
M((O-AB2)]ZRR_NF5F7RJ]/\ $'Q(_P"$;\$RZCX0^)X^)6IZEJ=EH%@;J33;
MBUL[JYG6-';[';Q'*Y+;7;^&O0OB%\*7\=?!N\\!KJBV)FLX+-=1:U\TKY93
MY_*WK_<_O50U[X8Z_P#$7PSJ>@>-?$.F7=I<>5-9W&@:1+8W%G<12"1)4>6Z
MGW,K*O\ "OU[55T39E'3-0G\ ^,+:W\3?&:VU _V=+=W6B:W%8VDS1HKN]W$
M(EB=(E,3_?\ -78C_-Z-UGXK1ZS\2OA7;^%/$-CJGAO7IM4BO9-.EBNHI_(M
M6D1/-7=C:Y_A:I]-^$?BBZ\=^%?$GBOQG::TWAM+G[';V6B?8WF>:+RG>5O/
MEW';_=5:Z7Q1\/3XF\=^"?$[:@;9O#;W;?9?)#_:/M$'E?>W?)M^]_%2T'J>
M ?#+XL7_ (F^!MYXK'QBFUKQK:>&+O5;C0$;266WE2%\,\$=JLJHKE/O-_=W
M5-X?_:6\2:UX>\(Z/J<L>B>/[7Q1I6E:]:")&6]M)V_U\09/]5*N/F3[OXBO
M8?#OP;_X1WX )\,UU?[1_P 22;1CJ9M=GWXW7S?*W]M_W=U8GC+]FO1_%VO?
M#W7UO6T_7O"5Q:-]MB@XOH(71_(E3=]W>JLO/R55T*TCJ[KXW>!+/2]3U#_A
M*]+O(=,E2VNUT^Z2\EAD=RJ1>7%N?>S*ZJNS<VP^E6_ _P 4O#'Q&;44\/7\
MVH/ILB0WB/:30/ S9/E-YJ+\WR?,OWEQ\V*@^*WP_D^(V@Z?;VFIKHVIZ3J=
MMJUC=26WVB))H&W#='O3<N"Z_>7_ !H_"OX:ZI\-Y_$37OB!=:MM8U!M3*?V
M=Y$J7+H@N"621U9&=-R+L5ESMW-4:6'K<]/HHHJ2PHHHH *^?=2L?%Z_'RU\
M)Q?$OQ)!I-YH%WK+B*STGS(Y8[J")41FL_N;9F^]N;[OS5]!5PDW@/S_ (N6
M/C5;_:MOHESH_P!A6+EO,G@E\W?N_A\G;MV_Q4T3(Y"Z_:2T:S;52?#WB*:'
M3]7?0HYHH(#]NU!9O*^SVZ>;O9B,MNVJFT-N96^6M.#XV>=I,DUKX)\57^J6
MMY-8W^D6MO ;FSECB27]Z[3B+#QRQ,FV5M^]=FZL/Q1^S99>)O!.IZ'>:G#<
M2W'B>?Q-;3W6G)/;QRO*T@BE@=]LJ;7=&Y3=G^&L*^_95DU"STJW.H>%+6"U
MNKNXFTNR\))'I4IG2)-QLO/V>;$(,K+*TOWV^7@56@M35M_VBYM0^(-G8:=X
M9O[_ ,+WGA6#Q0NHQ"W241R<K*V^X4[-OR[=N_</[O--3]J[2'M4G_X0SQ<?
M-T=?$,426=OODTWG?=?\?'"KC[K;9/F3:C9J:R_9UU+1;GPY)IGBB&./3_",
M'A"\2XTWS6NK>-3ME7]\OE/NYQ\U7[3]GG[/]C_XGQ;[/X$_X0G_ (\_O?=_
MTG[_ /L_<_\ 'J- U);K]I/PY!>2M;V&LZEH5J]HM[X@M+=?L-BUPJ-$LI=T
M?A98F;8K;-_S;:CC_:$T^X\016#>'?$=O:W&KW6@6NK2V\"6=U?0/*K0HWG;
MLNT#A7V[<_+N5@V.6A_9)T[3]8%W:S>&[E9([+[8VM>%+>_N_.@BBB+V\[/^
MZ\Q(D^5UEVL[LOWJ[6Z^"8N]+\/V7]LB/^R/&%SXK#_9<^:)+JZN!;_?^7;]
MJV[_ /8^[\U&@:C_ -G_ .*&J_%OP3%KNI>'[G1&DN;C8\C0>3<(L\R+LVS2
MN-BJJONV_-]SY:]8KS7X-?#74OA7X;ET"378M7TJ&XEEL(UL?(E@22665EE?
MS&\UMTOWMJ?<^[S7I53+<<=@HHHI%!1110 4444 %%%% !1110 4444 %%%%
M 'SE^W!S\-=$_P"PS'_Z(GKXO1>M?:/[;W_)-=$_[#$?_HB:OC)%Y-?6Y7_N
MY^)<6?\ (R?HAZI^Z-=_X\UC3=4MS+;Q-+]J?SH&^SJBHG]S=O\ X/N;/_L*
MX)>%Q7H>@V-C_P (CJ?EK%+ ;%Y9WFV[U=?]4VW[5\K>;M16\K^/_:>O4G:+
M3/EJ7-:45U.!5:>%IRKTJ0+6IRD82G;:D"TNWVJ@(ME&VI=OM2[: (MM&VI=
MM&V@"+;1MJ7;1MH BVT;:EVT;: (=M&RIMM)M]J (=E)MJ;;2%:0$)6F%:G*
MTQA2 A*TPBIBM,93Z4@(B*8:D:F-3 8U)2MFD- "-3:7FDH *1J-U)2&%%%)
M04(U,:G4UC0 QJ_0;]DO_D@WAK_>N_\ TIEK\]V[5^@_[)?_ "0;PU_O7?\
MZ4RUX>:_P8^I]YP=_OT_\+_-'L=%%%?+'["%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT\\2^7'8P?ZT,VW9(O\ >^;Y?XOO?WFBCES[?X9ZO-XL31-K9W;O.V_\L_\
M=_O?[/\ [+\U>W_9U-W3F]/3_(\3^Q\':_)^+/JE?B3\-O\ HI>A?^"_5O\
MY"I__"S/ALO_ #4O0O\ P7ZM_P#(5?-/Q.\&Z7X7M]+GL)_(EFC\IK&5F:5F
M7=ND;^[\WR_=5?\ @7FQQ<$<UK'+825U4?X?Y$_V/@^L/Q9]I_\ "R_AO_T4
MK0O_  7ZM_\ (5+_ ,+,^&__ $4K0O\ P7ZM_P#(5?%@Z=?TI<^_Z5?]EP_Y
M^/\ #_(G^Q\'_)^+/M+_ (69\-_^BE:%_P""_5O_ )"H_P"%F?#?_HI6A?\
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MO_!?JW_R%7Q>WUII/O1_9</^?C_#_(K^Q\'_ "?BS[._X61\-U;/_"S-#_\
M!?JO_P A5[-\._@#J_Q4\(V/BOPOXBT'4=#OO,^S7!-W$9=LC1/\LD"LOSJR
M_=[5^9'S;NE?LO\ \$_,C]D#X>X_ZB/_ *<+FO!S>G+ 48U*4G>]M;>?D=^$
MX?P.(J.,ET[GG[?L?>-O^@CH'_@3-_\ &:8?V/O&W_02T#_P)F_^,U]C-3&K
MY#^TL0>O_JGEW\K^\^.C^Q[XV_Z"6@?^!,W_ ,8IO_#'OC;_ *"?A_\ \"9O
M_C%?8C4VE_:6(#_5/+OY7]Y\=G]CWQM_T$_#_P#X$S?_ !BD3]CKQN_W=2T
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MY/[@H\N3^X* (Z*?LD_N"C9)_<% #**?LD_N"C9)_<% #**?LD_N"C9)_<%
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MW:WWJ?;_ +43W7@^?5K*S\+2/9:E-IEW<7/C"WBTK?'%%*GV>\\K]]O29/\
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M$)L&TJ6>2>WGM'E$WE203M!(N['S+NB;YJ[NI*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **H76K+:]8V8^PJI_PDB?\
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MU\/^)O$>MP3W$EWKT\,]TLS+L1HHEB39\O\ =6NJK&_X2-/^>+_E1_PD:?\
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M.UQ^]5OO;-G_ +-69&P6MK[9X5/_ #!-=_\ !U!_\B4HNO"O_0%UW_P=0?\
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MPK?^V^%?^@+KO_@Z@_\ D2D^V>%?^@+KO_@Z@_\ D2CVDOY0]C#_ )^+\?\
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M1*/:2_E#V,/^?B_'_(YW%-:ND^U>%/\ H!Z]_P"#J#_Y$IK77A/_ * >O?\
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M\J -JBL7_A)$_P">+_E1_P )(G_/%_RH VJ*Q?\ A)$_YXO^5'_"2)_SQ?\
M*@#:HK%_X21/^>+_ )4?\)(G_/%_RH VJ*Q?^$D3_GB_Y4?\)(G_ #Q?\J -
MJBL7_A)$_P">+_E1_P )(G_/%_RH VJ*Q?\ A)$_YXO^5/M]<2XDV;'^YOH
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MNQ_(BABW?P[3Q7T'_P )%'_SQD_*C_A(H_\ GC)^5',PY3P73/V4C;>/=/\
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M%% !1110 5:T_P#U[_[C_P#H%5:M:?\ Z]_]Q_\ T"@"K1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %O3_ +T__7!ZKU8T_P"]/_UP>J]
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MU>[_ +$_MMKB_P!8:R4K]H\KRDVP2[W_ .^*P?@3K1\#>$?!_A'5-'U2TO\
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M=+\0Z7J-[8C-Q:6EY#+-#_O(C_+^%?-W@WPQJ\?ASX9>#Y/#&K6_BK0/%/\
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MJW&OZ98ZQ::9<:C:PZG>*S6]G).JS3JOWMB_>;:/2J7_  L+PM_PDG_"-_\
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M?\\7_.NQHH X[^R[C_GB_P"=']EW'_/%_P Z[&B@#CO[+N/^>+_G2_V7<_\
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M!TW_  KWQ=_T*>N?^"V?_P")H_X5[XN_Z%/7/_!;/_\ $US.!ZBC ]11[_\
M-_7WAS8?^5_?_P  Z;_A7OB[_H4]<_\ !;/_ /$T?\*]\7?]"GKG_@MG_P#B
M:YG ]11@>HH]_P#F_K[PYL/_ "O[_P#@'3?\*]\7?]"GKG_@MG_^)H_X5[XN
M_P"A3US_ ,%L_P#\37,X'J*,#U%'O_S?U]X<V'_E?W_\ Z;_ (5[XN_Z%/7/
M_!;/_P#$T?\ "O?%W_0IZY_X+9__ (FN9P/448'J*/?_ )OZ^\.;#_RO[_\
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M2UW_ ,%L_P#\37-8'J*0@4?O/YOZ^\.:A_*_O_X!TG_"N_%W_0I:Y_X+9_\
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MC10!QW]EW'_/%_SH_LNX_P">+_G78T4 <=_9=Q_SQ?\ .C^R[C_GB_YUV-%
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MUV%% ''_ -EW/_/%J/[+N?\ GBU=A10!QW]EW'_/%_SH_LNX_P">+_G78T4
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M -B1?_\ IPM*]DK%.AV#:TNJFSMY-7AA:W6^\M3*L3,KM%N^]MW*C;?]E::
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M42U94=$+1112*"BBB@ HHHH **** "BBB@ HHHH **** /FW]N?_ ))IH?\
MV&(__1$]?%*]Z^U?VZ/^2:Z)_P!AB/\ ]$3U\4K_ %KZS*_]W/Q3BO\ Y&+]
M$3)RI!KLM \12W&BV^D6D$4NJ0[HH%E9_P!ZK,S;%^?;OW,WR_Q_[WW^+5NP
M-=7X+U>TL9/LUU>-IB3-\UW'Y_W?]O9<1?=_W6KU9['RM%M2M>USG-VYFW?>
MH+"K&M:@NK:YJ%\F[;=7,LJ[O]IMU5C5ZG.]&+N/K2[C4=+NIDC]U+N]Z9FC
M- A^[WHW>],S1F@!^[WHW>],S1F@!^[WHW>],S1F@!^[WHW>],S1F@!^[WHW
M>],S1F@!VZC=3<T9H =NHW4W-&: ';J-QINZDW4#'[C2;CZTS)HH"P_<?6DW
M>]-HH'87=1N/K3<T;J %I#3=WO32U QQ-,8TA:FEJ $;M7Z#_LE_\D&\-_[U
MW_Z4RU^>S5^A'[))_P"+"^&O]Z[_ /2F6O#S7^#'U/O.#_\ ?I_X7^:/9***
M*^6/V$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X<^/.O_
M /"6?$?QAXBT^WUBYO\ X=16L'AV2PT:\N[5[^&9;J]5Y8XGCC(58X?GV_>/
M\-=#\5OBE=Z?XF\6^.O!MZ+6>3X<:->Z?=M"DFU)=2N-OR-E?N/WKZ8\)^"]
M(\"V5W9Z/:O;1W5Y+?3L\KRO+<2MNE=GD9V.]JY&/]G7X?)HLNDQ:#Y>GS:?
M%I4D)O;C_CUCN7N%C!W_ "[99&?_ ,=^[6ET9VD>9>,O%7Q+\&:KXS\-Z?XM
MN/$6IZ?X9M_%-C=7EA:Q2;HIV2YMMB1*NR58SM_C7(^:L3QA\2KWXN:EIFNZ
M=>B3P+:^,?"MEID"Q)^_N6N()[B4M]\%%GBB_N_*U?2=UX1M(M>N_%-E8QOX
MJ;3/[.BGN9W6,Q*[2JCX_@\QOO;-U<9\-O@1HOA/X5^%/"&JVUM>2Z+<0ZK+
M-:EXHO[023S_ #%*[,JLI.U6_@"9Z4<R"S.$N?C%J%C\8?#]IIOCNZ\46&I>
M)KC1[W2(M"$.GV<1AG:-4O!%\\\30$,OFMO^;Y4VFN<\#^./B-XHB^%\UQ\0
M+J#_ (3*_P!4L;I8],LO]$2U\^1&@_=?ZTK;%&W[U^?[GRU[?9_ #P-I^O6V
MJVFCR0WMI?-JEJGVZX:VM[IRQ::*#S?*CW;FW;54-6II/P?\*:#!X;6PTWR$
M\.W%Q=:7_I$K>1).LJRMRYW[O.E^_N^_1=!:1C_L^>+-5\:_"K2]4UZ\&H:I
M]IO[26[6-(O/\B\G@5MB?*K,L:M\M<K;PV^N?M=:E'KJ+++I?AJUN?#]K.B/
M&JR3R?:KB+/27>L";A_"#776?P7T/1]?\*:CI=O)86_AQM2>TM5DD?,MXP:9
MW9G/R;M[[?\ :7;MV[6V_&?PO\,>/I=/GUW3GFO;!V>TOK6ZFM;NV9OO>7/$
MZ2)_P%JG2Y7O'AOC+X@:7<ZQIVDZ5X/_ .$7UFS\=Z)%J\.I:;82O.]P"ZRH
MT32KOV[?WN5=/6N0\#>.O%^G^%?A]X1\+QZM =4OO$E]<W6C16#W3K!JDJ^5
M#]N=8/O2[F^\VU5*_P 5?16F? WP1IL2>5HTID;5+?6FN+B^N;BYDNXO]5++
M*SL\NW)^^S+UI\WP+\%W&AZ;H[:5-#9Z;>SWME-;WT]O<6L\\C2RM%.CK*NY
MI&^ZWI571-I'COC/XC>+_#GP^TQ=>\977A#QQ#INHW?]AZ9H,.HWMX8I7\BX
MN%C6X2*)DC5FV;5W._[WY*Q?$GQ"\5_&+P3\0"-?D\,V&C^!+2_N+&RMX)$U
M*XO+"2XEW-*C,D2HNQ43:WWFWU[?-^SKX"N([)/[$G6.TM6L56+4KM?-MVE>
M5XI]LO[]-[,^V7=\S4[6/V=OA_K4=LMQH;!8=.ATC;%?W42S6<6-D4ZI*OGJ
MO'^MW=*+H+,Z'X1_\DL\&?\ 8$M/_1*5V59>CZ3:^'](LM.LX_)L[.)+:"(M
MNVHBA$7\JU*S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MARH\Y_X49X<_Z"7B[_PMM9_^2J/^%&>'/^@EXN_\+;6?_DJO1J*+L.5'G/\
MPHSPY_T$O%W_ (6VL_\ R51_PHSPY_T$O%W_ (6VL_\ R57HU%%V'*CSG_A1
MGAS_ *"7B[_PMM9_^2J/^%&>'/\ H)>+O_"VUG_Y*KT:BB[#E1YS_P *,\.?
M]!+Q=_X6VL__ "51_P *,\.?]!+Q=_X6VL__ "57HU%%V'*CSG_A1GAS_H)>
M+O\ PMM9_P#DJC_A1GAS_H)>+O\ PMM9_P#DJO1J*+L.5'G/_"C/#G_02\7?
M^%MK/_R51_PHSPY_T$O%W_A;:S_\E5Z-11=ARH\Y_P"%&>'/^@EXN_\ "VUG
M_P"2J/\ A1GAS_H)>+O_  MM9_\ DJO1J*+L.5'G/_"C/#G_ $$O%W_A;:S_
M /)5'_"C/#G_ $$O%W_A;:S_ /)5>C4478<J/.?^%&>'/^@EXN_\+;6?_DJC
M_A1GAS_H)>+O_"VUG_Y*KT:BB[#E1YS_ ,*,\.?]!+Q=_P"%MK/_ ,E4?\*,
M\.?]!+Q=_P"%MK/_ ,E5Z-11=ARH\Y_X49X<_P"@EXN_\+;6?_DJC_A1GAS_
M *"7B[_PMM9_^2J]&HHNPY4><_\ "C/#G_02\7?^%MK/_P E4?\ "C/#G_02
M\7?^%MK/_P E5Z-11=ARH\Y_X49X<_Z"7B[_ ,+;6?\ Y*H_X49X<_Z"7B[_
M ,+;6?\ Y*KT:BB[#E1YS_PHSPY_T$O%W_A;:S_\E4?\*,\.?]!+Q=_X6VL_
M_)5>C4478<J/.?\ A1GAS_H)>+O_  MM9_\ DJC_ (49X<_Z"7B[_P +;6?_
M )*KT:BB[#E1YS_PHSPY_P!!+Q=_X6VL_P#R51_PHSPY_P!!+Q=_X6VL_P#R
M57HU%%V'*CSG_A1GAS_H)>+O_"VUG_Y*H_X49X<_Z"7B[_PMM9_^2J]&HHNP
MY4><_P#"C/#G_02\7?\ A;:S_P#)5'_"C/#G_02\7?\ A;:S_P#)5>C4478<
MJ/.?^%&>'/\ H)>+O_"VUG_Y*H_X49X<_P"@EXN_\+;6?_DJO1J*+L.5'G/_
M  HSPY_T$O%W_A;:S_\ )5'_  HSPY_T$O%W_A;:S_\ )5>C4478<J/.?^%&
M>'/^@EXN_P#"VUG_ .2J/^%&>'/^@EXN_P#"VUG_ .2J]&HHNPY4><_\*,\.
M?]!+Q=_X6VL__)5'_"C/#G_02\7?^%MK/_R57HU%%V'*CSG_ (49X<_Z"7B[
M_P +;6?_ )*H_P"%&>'/^@EXN_\ "VUG_P"2J]&HHNPY4><_\*,\.?\ 02\7
M?^%MK/\ \E4[_A1GAS_H)>+_ /PMM9_^2Z]$HHNPY4>=_P#"C?#G_02\7_\
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M )*H_P"%&>'/^@EXN_\ "VUG_P"2J]&HHNPY4><_\*,\.?\ 02\7?^%MK/\
M\E4?\*,\.?\ 02\7?^%MK/\ \E5Z-11=ARH\Y_X49X<_Z"7B[_PMM9_^2J/^
M%&>'/^@EXN_\+;6?_DJO1J*+L.5'G/\ PHSPY_T$O%W_ (6VL_\ R51_PHSP
MY_T$O%W_ (6VL_\ R57HU%%V'*CSG_A1GAS_ *"7B[_PMM9_^2J/^%&>'/\
MH)>+O_"VUG_Y*KT:BB[#E1YS_P *,\.?]!+Q=_X6VL__ "51_P *,\.?]!+Q
M=_X6VL__ "57HU%%V'*CSG_A1GAS_H)>+O\ PMM9_P#DJC_A1GAS_H)>+O\
MPMM9_P#DJO1J*+L.5'G/_"C/#G_02\7?^%MK/_R51_PHSPY_T$O%W_A;:S_\
ME5Z-11=ARH\Y_P"%&>'/^@EXN_\ "VUG_P"2J/\ A1GAS_H)>+O_  MM9_\
MDJO1J*+L.5'G/_"C/#G_ $$O%W_A;:S_ /)5'_"C/#G_ $$O%W_A;:S_ /)5
M>C4478<J/.?^%&>'/^@EXN_\+;6?_DJC_A1GAS_H)>+O_"VUG_Y*KT:BB[#E
M1YS_ ,*,\.?]!+Q=_P"%MK/_ ,E4?\*,\.?]!+Q=_P"%MK/_ ,E5Z-11=ARH
M\Y_X49X<_P"@EXN_\+;6?_DJC_A1GAS_ *"7B[_PMM9_^2J]&HHNPY4><_\
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M^%MK/_R57HU%%V'*CSG_ (49X<_Z"7B[_P +;6?_ )*H_P"%&>'/^@EXN_\
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MX/X]=8_G9U^>#,&[5]QE>38;%82%:HW=W_,\'%8RI2K.,=C]8_\ A[7\)?\
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M1_J]@O[WWB_M"N?K!_P]G^$O_0M>-/\ P"M/_DJC_A[/\)?^A:\:?^ 5I_\
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M3_KA'52@#IO^$@MO[TG_ '[H_P"$@MO[TG_?NN9HH Z;_A(+;^])_P!^Z/\
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MV==U*WNIFMXFL[;YMK2K$VQ)9-R_=?[@H_9PDU+P#\2OB)\.]8M;33I&NO\
MA)M,M+*X>>%8+EPDJK*T<3NBR+'_  =Z^B*:U3S>[RCY?>YA****S*"BBB@
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M%%%%26%%%% !1110 4444 %%%% !5O3^L_\ UP>JE6]/ZS_]<'H J5\M^%O
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M !1110 4444 %%%% !1110!;U+_7)_UPCJI5O4O]<G_7".JE !1110 4444
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MU<]2M5K:U9M^KN:1IPI_ K#/+3^ZOY4GDI_=2IJ*S-"'R4_NI2>2G]V.IZ*
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M6/.O^%:>)?\ HK'C#_P$T;_Y H_X5IXE_P"BL>,/_ /1O_D"O1:*+BL>=?\
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M^+__  $T;_Y7UZ'11<+'GG_"M/$G_15_%_\ X":-_P#*^C_A6GB3_HJ_B_\
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M8\8?^ FC?_*^C_A6GB3_ **QXP_\!-&_^5]>AT47"QYW_P *S\2?]%8\8?\
M@)HW_P KZ/\ A6?B3_HK'C#_ ,!-&_\ E?7HE%%PL>=_\*T\2_\ 16/&'_@)
MHW_ROH_X5GXE_P"BL>,/_ 31O_E?7HE%%PL>=?\ "L_$O_16?&'_ (!Z-_\
M*^C_ (5GXE_Z*SXP_P# /1O_ )7UZ+11<5CSK_A6?B7_ **QXP_\ ]&_^5]'
M_"M/$O\ T5CQA_X!Z-_\@5Z+11<+'G7_  K3Q+_T5CQA_P" FC?_ "!1_P *
MT\2_]%8\8?\ @)HW_P @5Z+11<=CSK_A6GB7_HK'C#_P$T;_ .0*/^%:>)?^
MBL>,/_ 31O\ Y KT6BBX6/.O^%:>)?\ HK'C#_P$T;_Y H_X5IXE_P"BL>,/
M_ 31O_D"O1:*+A8\Z_X5IXE_Z*QXP_\  31O_D"C_A6GB7_HK'C#_P !-&_^
M0*]%HHN%CSK_ (5IXF_Z*QXP_P# /1O_ ) H_P"%:>)O^BL>,/\ P#T;_P"0
M*]%HHN%CSK_A6GB;_HK'C#_P#T;_ .0*/^%:>)O^BL>,/_ /1O\ Y KT6BBX
M6/.O^%:>)O\ HK'C#_P#T;_Y H_X5IXF_P"BL>,/_ /1O_D"O1:*+A8\Z_X5
MIXF_Z*QXP_\  /1O_D"C_A6GB;_HK'C#_P  ]&_^0*]%HHN%CSK_ (5IXF_Z
M*QXP_P# /1O_ ) H_P"%:>)O^BL>,/\ P#T;_P"0*]%HHN%CSK_A6GB;_HK'
MC#_P#T;_ .0*/^%:>)O^BL>,/_ /1O\ Y KT6BBX6/.O^%:>)O\ HK'C#_P#
MT;_Y H_X5IXF_P"BL>,/_ /1O_D"O1:*+A8\Z_X5IXF_Z*QXP_\  /1O_D"C
M_A6GB;_HK'C#_P  ]&_^0*]%HHN%CSK_ (5IXF_Z*QXP_P# /1O_ ) H_P"%
M:>)O^BL>,/\ P#T;_P"0*]%HHN%CSK_A6GB;_HK'C#_P#T;_ .0*/^%:>)O^
MBL>,/_ /1O\ Y KT6BBX6/.O^%:>)O\ HK'C#_P#T;_Y H_X5IXF_P"BL>,/
M_ /1O_D"O1:*+A8\Z_X5IXF_Z*QXP_\  /1O_D"C_A6GB;_HK'C#_P  ]&_^
M0*]%HHN%CSK_ (5IXF_Z*QXP_P# /1O_ ) H_P"%:>)O^BL>,/\ P#T;_P"0
M*]%HHN%CSK_A6GB;_HK'C#_P#T;_ .0*/^%:>)O^BL>,/_ /1O\ Y KT6BBX
M6/.O^%:>)O\ HK'C#_P#T;_Y H_X5IXF_P"BL>,/_ /1O_D"O1:*+A8\Z_X5
MIXF_Z*QXP_\  /1O_D"C_A6GB;_HK'C#_P  ]&_^0*]%HHN%CSK_ (5IXE_Z
M*QXP_P# 31O_ ) H_P"%:>)?^BL>,/\ P$T;_P"0*]%HHN%CSK_A6GB7_HK'
MC#_P$T;_ .0*/^%:>)?^BL>,/_ 31O\ Y KT6BBX6/.O^%:>)?\ HK'C#_P$
MT;_Y H_X5IXE_P"BL>,/_ 31O_D"O1:*+A8\Z_X5IXE_Z*QXP_\  31O_D"C
M_A6GB7_HK'C#_P !-&_^0*]%HHN%CSK_ (5IXE_Z*QXP_P# 31O_ ) H_P"%
M9^)?^BL>,/\ P#T;_P"5]>B;AZT;AZT7#E/._P#A6?B7_HK'C#_P#T;_ .5]
M'_"L_$O_ $5CQA_X!Z-_\KZ]%HHN*QYU_P *S\2_]%8\8?\ @'HW_P KZ/\
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MK'IM &U_PD;_ //+_P ?H_X2-_\ GE_X_6+10!M?\)&__/+_ ,?H_P"$C?\
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ME26;'_"1O_SR_P#'Z/\ A(W_ .>7_C]8M% &U_PD;_\ /+_Q^C_A(W_YY?\
MC]8M% &U_P )&_\ SR_\?H_X2-_^>7_C]8M% &U_PD;_ //+_P ?H_X2-_\
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MK+_6_._^?_X1_P C;^Q\'_)^+/6?^%_-_P! 1?\ P+_^PH_X7\W_ $!%_P#
MO_["O)N?[WZ4<_WOTH_UOSO_ )__ (1_R#^Q\'_)^+/6?^%_-_T!%_\  O\
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M$C?_ )Y?^/T?\)&__/+_ ,?K%HH VO\ A(W_ .>7_C]'_"1O_P \O_'ZQ:*
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MZQ:* -K_ (2-_P#GE_X_1_PD;_\ /+_Q^L6B@#:_X2-_^>7_ (_1_P )&_\
MSR_\?K%HH VO^$B?_GC_ ./U/)KS1PP/Y/W_ /;K JU<?\>=K_P.@"[_ ,)
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M_N_^/&@##HK<_L.3^[_X\:/[#D_N_P#CQH PZ5:V_P"PY/[O_CU']AR?W?\
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M #G-[1Z#\Z-H]!^==)_PA]__ - Z\_\  >3_ .)H_P"$/O\ _H'7G_@/)_\
M$T?5ZW\C^YA]8H_SG-[1Z#\Z-H]!^==)_P (??\ _0.O/_ >3_XFC_A#[_\
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M ./&@##HK<_L.3^[_P"/&C^PY/[O_CQH PZ*W/[#D_N_^/&C^PY/[O\ X\:
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M%6UVTU6WUC3O#&VU71]-UV^M[VZMF1&^T)YL3M^Z_P!5M1F9OD;[G-9?P_\
M@?9R?$KXBZ_XN\)Z7?/?ZU%=Z/?WUM!=R&)88SN5OG:+YE']VOHG^Q7_ +O_
M (\:/[%?^[_X\:GF%RGRGX@^&7C*3P[X_P# MKX>DN[7Q1XC;5K?Q$+NW2VM
MK>65)6W(S^;N78R*JJRME?F7NWQ1\/?'":7XY\+V/A5K^TUWQ9;Z_!K$=_;I
M&MNL]K*R['?S?,3R&_AV]?F_AKZN_L5_[O\ X\:/[%?^[_X\:KV@^4^8=?\
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&Z44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img61678762_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_2.jpg
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MW@D5.VK^XO6S<#$P32=JP#C4$\&Q(?A(@^DKPX>@AP?U1JY"03L@C*17O3.
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M?DZI3BE.*4XI3BE.*4XI3BE.*5YQ=@?N\NWYW63],F\4K>=UO_>'U3^9</\
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M^8#N-G@F\D,GS$A%H:R#$!.C.0@88AJ7O7&5/#D,YQL+>42\R193)$67E]$
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M$9 8$YJMFI#8;L]H"\Z W?+5^V;#J ;NK=[1\ X4,@*P-I6Y%RS'CD8I@E6
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M<]# E'OEB664FC)F*?B38YRN6!Y >0EM''>I DCF0,.K1H4"M"7Z@D[CUQC
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MHHPJ&UG<K76US^:[;;=2XTM8\-9;+%RLRE8L0448297X B,H)Y0NT/@8=>@
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M6N+==#:GV%ILOK[::FDC3IM2!H9-'B9JQ58!=-C@&(L.M).JTO"S#,0U&C,
M*#8D6VGA&\,/X<:SE.2R.D@E5OP@;=N(!.XG.>H(SGKW4:-&3EE?0V[=H) V
M@8QT(.,5]@:-UK%:C@-&1L1, :SJL/5H"MPPMTN[4O!Q-()BBZD-%W3%C_#<
M-ROOPD3F+-8L:#Q$@#MM%);1A/!D<N9"078DD[5P2V=V5QMZY.>G7-!&@01@
M$(H4 ;FR N-N&SN&,#'7U5VFK]2Z_P!-0,E6]=0/R%&S=KL]ZGG'I*6FI2?N
M5TEGYRTV:=G)TZ3F9>8F9,AQX@L\Y]3;*1P1<, """L4=V<@L<D*%'0 !5&
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M#,(@>7U&.[(R?XQ7KGKF/6O*3]F=OZG,N3=OE*38M2^2F1VH;+@$(AA+;V"
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M>U7^)N'6:4MLQK,"M&U0:NI/O,='0]H=L 4O3YN0EDR,5%B I:3*B-A-I6^
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84IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img61678762_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_3.jpg
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M!Q/0A]NNX7;K;5U%VA]HNG7IKV[]F!\ IJD#/#XZIJH?I)>SD_9!HB+SDZT
M6S2>C7OREZ"86+8P=P>@P;Z]!!ZAO>I&F/FBK#Z@Q3[)P'J1ICYHJP^H,4^R
M<#C>IZC/"<H]5E3^CI_-L\_X$1#PD:3C,+/V<;[V=A?@,*- =WB#XQEF!'V[
M +6@WP4I2I@=#!4E7# +VA$"!Q,0=Z_UZ%IJWK?_ /&\#Z]2-,?-%6'U!BGV
M3@/4C3'S15A]08I]DX&.P^&0^'7!,"HC%(U%BEU;0$Q<7'&)K8RUAA$HL8)
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M3D\C3FO#@D0I4RYV,2%;(2&.2LDH!ZX:8C>R4XU1AHB2M[++V$&^F!V6 P&
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M_K &](N/QDA^08#RC%\HH&-3JOI;ZGZ!*)K_ "O8T1;?0D&R>Z1.P>]1O^L
M;TBXO&2'Y!@/*,7RB@8&HE$U_E>QIB^^A(-D]TB=@]RC?]8 WI%Q>,G7R#0>
M08OE$@Q;4;N_CRE\H[_0)1-?Y7L:8OOH2#9/=(G8/<HW_6 -Z1<7C)U\@T'D
M&+Y1(,:U<OE'?Z:"437^5[&F+;Z$@V3W2)V#W*/T@#>D7%XR=?(-#Y!B^42'
M"ZU;60)1-?Y7L:8MOH2#9/=(G8/<H_2 -Z1<783KY!H?(,7QDAP:U9J)1-?Y
M3L:8OOH2#9/=(G8/<H^669TBXNPG7R#0^0P7QDAQ;4;N_CRE\H[_ $"437^4
M[&F+[Z$@V3W2)V#W*/EEF=(N+L)U\@T/D,%\9(<6]V^_1?*._P!-!*)K_*=C
M1%M]" ;*[I$[:[E/RRS.D7%V$:^0<'R&"^,@.%!*)K_*=K3%M]" [*[I$[:[
ME/RRS.D7%V$:^2<'R&"^,@.-:OK,OJ?H$HFO\KV-$6WT3@$3W2)V#W*OTA1O
M2+B\:?7R#P^0P7QIP_&+ZGZYZFP2B:_RO8T1;?1. 1/=(G8/<JW^&6;TBXO&
MGU\@\/D,%\:<&"^M1Q!*)K_*=C1%M]$X1%=TB=@]RO?X91G2+"[$^ODGA\A@
MOC3@P-1*)K_*=C1%]]$X1%=TB=@]ROV]Y1G2+B[$^O9VGA\AHO;U3AP7UT^_
M )1-?Y3L:(OOHG"(KND3L'N5^WO*,Z1<78GU[.T\/D-%[>J<.$OPU3AS\ E$
MU_E.QHB^^B<(BNZ1.P>Y7[>\HSI%Q=B?7L[3P^0T7MZIPX6_OGJK02B:_P I
MV-$6WT3!$5W2)VUW*_EE&=(L+L3:^2>'R&B^-,' "437[OM:(MOHF"(OND3L
M'N6?+*'TBXNQ-KY)X?(:+XTP>GM%]3]<]38)1-?N^UHBV^B8(B^Z1.P>Y9\L
MH?2+B[$VODGA\AHOC3!Z>T7U/USU-@E$U^[[6B+;Z)@B+[I$[![EGRBA](N+
ML3:^2>'R&B^-,' ;437[OM:(MOHE"(OK(G;7<M^44/I%]]B77R5 >\W?QIM=
M/:#:B:_==&B+;_FFA ZR)VUU7?*)%TB^^U)KXE.NX[?QI-?&#:B:_==K1%M_
MS30@=9$[:ZKOE$BZ1??:DU[.BG7<=OXTFNGM%]3]<]39M1-?NNUHBV_YIH0.
MLB=M=5WRB1=(OOM2:]G13KN.W\:373VC6K&U$V^ZZ-$6W_--"!UD3MKJN^,D
M72+[Z)/]2G7<=OXTFL!M1-?NNC1%OQ30@=9$[:ZK_C)%_FOOM2?ZE6NX[?QI
M-=/:-:L;437[KHT1;\4T(/61.VNJ_P!O4D72+[Z)/O=%6NX[[_\ --=/:+ZG
MZYZFVNU$U^ZZ-$7W_,]"#UD3MKJO]O4D72+[Z(_O=%.NX[?M_FFL%]:YWMR:
M;437[KHT1;\3T(/61.VNJ_V]21?YK;Z(_O=%6NIV_;_--8&NU$U]O1HB_P")
M]P>LB=M=7#V]2-_YK[Z(_O?SK74[[_\ ,_\ 62_#5.'/P;437V]&B+_B?<'K
M(G;75P]O4C?^:^^B/[W\ZUU.^_\ S/\ UB_#5/OPVC5,[ULOP,T2'K9)>S?+
M)G@O85&^OE 7V1(WR$A^Y\9HO&,?7?<2#IKJ)_*U*<:U\,MPI@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,",9=^<&I?]Y3']D5^!)V P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P&!&,N_.#4O^\IC^R*_ D[ 8
M# 8# X;@O2-3>N=' [29 VHU*]:H$$P>B$B,D:A2=L!01FCT426,>PE@&8+0
M>@ B%O6MA&Y%QP]222H(;;--(/*+.),#25S["84:#0RQAW\ ?:$8!:%K_P#;
M>!N^MV*?JFS_ .Y&Y_\  . ];L4_5-G_ -R-S_X!P'K=BGZIL_\ N1N?_ .
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MY&Y_\ X#UNQ3]4V?_<C<_P#@' >MV*?JFS_[D;G_ , X#UNQ3]4V?_<C<_\
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MV@M*\-2@:O1+BC&<&:,3\QRAG;Y#&7EJD+ [)@+&I[8W!([-#DD,ZZ+5(')
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M5<L6B"3EZCK4Z2F%MTEL^>FR%+%'M:E/7Q\+X)J;=.HVDY(8O+0IB50S2B@
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M(JZ1*32^-R",K5B)Q8W#:5Z"\1]]0&-TA:&L:IM&N)2T3NG]8]EJL(8# 8#
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M>FAF>'F*.+RV-[FY(42I64H4DEC"6O\ )X*_4G&__IJ1?Q&P'^3P5^I.-_\
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MC[%*HV#CZ\QV3,[9(&!W1<>(\8C=65Y1$.34Y)#-R<.QI5R%20J('L.MB*-
M+IKKTP.Y_P G-!^JJ&_Z=8[_ (HP'^3F@_55#?\ 3K'?\48#_)S0?JJAO^G6
M._XHP)(I8&R($4@VWQELTS2ZS(^!)#XZ3%(_LJ.V7+F(E6C8$ZM<2WJ'$IN
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MEF^^[.R/1\C:$2@"@XL(&Y]4M# J=$9A("CR5:IC:%)@#=>D-J([0TY9ED&
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MK%(@;.&9<S 8# C"HOR4=OI/N[]\\^P)/P& P& P& P& P& P& P& P& P&
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M=375(&Q6U/,B<@F5R@=Y,VN[@T^]:IGCZ1U&V$B(FG&)G?6L5IPO^N]U8GS
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MKG2OW$B0M:>.N]LMIA,%FB\Q$<(""*0]3LMT)1F("RQ-(I3/S%(W;L>LPKM
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MVQ^.P5T?FT&.+.0.2 Q1<9Q0TZQ,-SC[PG-(Z.4:?'ELV)/M;YRBQSCSZU*
M2>.O 9/'W&+IN++.F8W8TPU>C36I4J<PX!\"DU5K48%I/(H"].V.E93&25Z\
MM*942UO4)<?@N[)%C*D0(DI:S_:.T^O+N'>E>#[ZK>EKKQH;59LB97Z/O16[
M3J$E"O:I6SUXPRLDQL3\AR6X"B5M-2UJEE+@2E+<9)\"F ]Z5KE*$!VQ6?[?
M/J^,XYRR%RK[AX\.BUY<^.C4M<G!RL1Y/4GV-20]E/%LRF'SJQ7= 5Z_=$-;
MK*IU (9.G!R;"DBT$WCC9+TAZ:1D[<Q"_P#;+^VZM-W&7#.J[A>>O8',SC6R
M>G1AOB[6R'EV)21/HB*&JK&7QTLPLF_2R5QB)QMZT7(Y2X%JE3FY3Z5N#J<M
M6O*T\T5_[1YWTX<&'@X_<*6R(.4,B%#*8,WN<;FT/&MC5NTV!U11JS(%!ZJL
M9O:U;I?[GIO.F-:5Q#8>XNA!6G1,E8&MT;E:1^1)W0 K/]HW9[IK&[=5,D;*
MX_16.R"(M58NA<8D5L-]UJ&'UJT80UM]@,SY&).QN+(E0WFC+:43))8='I"V
MM*3L;RGI#[Y&$&JCSS#!CCM1/?TE"&V[7-?Q6/PB'P5>RQ6*M*)BCS.395#*
M2&MG;B0ID#>G.77DJ5;3(TX )TX#3S/$0664#>BP #HE/^T>?3?C=RU[$&]0
MTQJ"*69N5OTJE"E(CL'CZ$HZ03>4/$TECJ/0[M'OTI]E3^\O:X6MZ"):X*!
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MCE5CRN3-1*P]E<'5K$K]ZW9$-2!$XK223A#)T>,18MX$B8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M:R7KK,&QO@O/VS1Z+\I199?:VQ??HQ@/PSR^]B%WC-^4$_RE!_1@!A.L^.^
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M,"$>_O;"5HLO73V UEZ1Y]E)_MXAEV13 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M8+!8CY,A)79K:J;;G$#<P"2G+C*ELQ=9HSFUT3OJ=>PERAP7FM:LM*,\YM1
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MYX4:14J$45H9FDR90?L.BB3!!#?P& P& P& P& P& P& P& P& P& P& P&
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M2WKR]&2@"+*++&:8>,!8 "/-T5HTX00Z"(TS1!9).C#-ZV,>B22BM"WO198
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MB9>V'LIB\MS;Q*2+&X# 8# C"HOR4=OI/N[]\\^P)/P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img61678762_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_4.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 7R#WH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,W5/$FD:)(D>HZI96$D@W(EU<)&6'J Q&15/\
MX3[PQ_T,>D_^!T7_ ,57Y_?\%(O#%MXT_:2^$.@W;M#;ZG;-9R31@%T5[A02
MN01GZUW7_#I?X>?]#AXE_P"^;7_XU0!]C_\ "?>&/^ACTG_P.B_^*H_X3[PQ
M_P!#'I/_ ('1?_%5\;_\.E_AY_T./B7_ +YM?_C5'_#I?X>?]#CXE_[YM?\
MXU0!]D?\)]X8_P"ACTG_ ,#HO_BJ/^$^\,?]#'I/_@=%_P#%5\;_ /#I?X>?
M]#CXE_[YM?\ XU1_PZ7^'G_0X^)?^^;7_P"-4 ?9'_"?>&/^ACTG_P #HO\
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M_P )]X8_Z&/2?_ Z+_XJC_A/O#'_ $,>D_\ @=%_\57QO_PZ7^'G_0X^)?\
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M5?&__#I?X>?]#CXE_P"^;7_XU1_PZ7^'G_0X^)?^^;7_ .-4 ?9'_"?>&/\
MH8])_P# Z+_XJC_A/O#'_0QZ3_X'1?\ Q5?&_P#PZ7^'G_0X^)?^^;7_ .-4
M?\.E_AY_T./B7_OFU_\ C5 'V1_PGWAC_H8])_\  Z+_ .*H_P"$^\,?]#'I
M/_@=%_\ %5\;_P##I?X>?]#CXE_[YM?_ (U1_P .E_AY_P!#CXE_[YM?_C5
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M$^\,?]#'I/\ X'1?_%5\;_\ #I?X>?\ 0X^)?^^;7_XU1_PZ7^'G_0X^)?\
MOFU_^-4 ?9'_  GWAC_H8])_\#HO_BJ/^$^\,?\ 0QZ3_P"!T7_Q5?&__#I?
MX>?]#CXE_P"^;7_XU1_PZ7^'G_0X^)?^^;7_ .-4 ?9'_"?>&/\ H8])_P#
MZ+_XJC_A/O#'_0QZ3_X'1?\ Q5?&_P#PZ7^'G_0X^)?^^;7_ .-4?\.E_AY_
MT./B7_OFU_\ C5 'V1_PGWAC_H8])_\  Z+_ .*H_P"$^\,?]#'I/_@=%_\
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M_OFU_P#C5'_#I?X>?]#CXE_[YM?_ (U0!]D?\)]X8_Z&/2?_  .B_P#BJ/\
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MACTG_P #HO\ XJC_ (3[PQ_T,>D_^!T7_P 57QO_ ,.E_AY_T./B7_OFU_\
MC5'_  Z7^'G_ $./B7_OFU_^-4 ?9'_"?>&/^ACTG_P.B_\ BJ/^$^\,?]#'
MI/\ X'1?_%5\;_\ #I?X>?\ 0X^)?^^;7_XU1_PZ7^'G_0X^)?\ OFU_^-4
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M7^'G_0X^)?\ OFU_^-4?\.E_AY_T./B7_OFU_P#C5 'V1_PGWAC_ *&/2?\
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MB7_OFU_^-4 ?9'_"?>&/^ACTG_P.B_\ BJ/^$^\,?]#'I/\ X'1?_%5\;_\
M#I?X>?\ 0X^)?^^;7_XU1_PZ7^'G_0X^)?\ OFU_^-4 ?9'_  GWAC_H8])_
M\#HO_BJ/^$^\,?\ 0QZ3_P"!T7_Q5?&__#I?X>?]#CXE_P"^;7_XU1_PZ7^'
MG_0X^)?^^;7_ .-4 ?9'_"?>&/\ H8])_P# Z+_XJC_A/O#'_0QZ3_X'1?\
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MYM?_ (U0!]D?\)]X8_Z&/2?_  .B_P#BJ/\ A/O#'_0QZ3_X'1?_ !5?&_\
MPZ7^'G_0X^)?^^;7_P"-4?\ #I?X>?\ 0X^)?^^;7_XU0!]D?\)]X8_Z&/2?
M_ Z+_P"*H_X3[PQ_T,>D_P#@=%_\57QO_P .E_AY_P!#CXE_[YM?_C5'_#I?
MX>?]#CXE_P"^;7_XU0!]D?\ "?>&/^ACTG_P.B_^*H_X3[PQ_P!#'I/_ ('1
M?_%5\;_\.E_AY_T./B7_ +YM?_C5'_#I?X>?]#CXE_[YM?\ XU0!]D?\)]X8
M_P"ACTG_ ,#HO_BJ/^$^\,?]#'I/_@=%_P#%5\;_ /#I?X>?]#CXE_[YM?\
MXU1_PZ7^'G_0X^)?^^;7_P"-4 ?9'_"?>&/^ACTG_P #HO\ XJC_ (3[PQ_T
M,>D_^!T7_P 57QO_ ,.E_AY_T./B7_OFU_\ C5'_  Z7^'G_ $./B7_OFU_^
M-4 ?9'_"?>&/^ACTG_P.B_\ BJ/^$^\,?]#'I/\ X'1?_%5\;_\ #I?X>?\
M0X^)?^^;7_XU1_PZ7^'G_0X^)?\ OFU_^-4 ?9'_  GWAC_H8])_\#HO_BJ/
M^$^\,?\ 0QZ3_P"!T7_Q5?&__#I?X>?]#CXE_P"^;7_XU1_PZ7^'G_0X^)?^
M^;7_ .-4 ?9'_"?>&/\ H8])_P# Z+_XJC_A/O#'_0QZ3_X'1?\ Q5?&_P#P
MZ7^'G_0X^)?^^;7_ .-4?\.E_AY_T./B7_OFU_\ C5 'V1_PGWAC_H8])_\
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M7_XU1_PZ7^'G_0X^)?\ OFU_^-4 ?9'_  GWAC_H8])_\#HO_BJ/^$^\,?\
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M_OFU_P#C5 'V1_PGWAC_ *&/2?\ P.B_^*H_X3[PQ_T,>D_^!T7_ ,57QO\
M\.E_AY_T./B7_OFU_P#C5'_#I?X>?]#CXE_[YM?_ (U0!]D?\)]X8_Z&/2?_
M  .B_P#BJ/\ A/O#'_0QZ3_X'1?_ !5?&_\ PZ7^'G_0X^)?^^;7_P"-4?\
M#I?X>?\ 0X^)?^^;7_XU0!]D?\)]X8_Z&/2?_ Z+_P"*H_X3[PQ_T,>D_P#@
M=%_\57QO_P .E_AY_P!#CXE_[YM?_C5'_#I?X>?]#CXE_P"^;7_XU0!]D?\
M"?>&/^ACTG_P.B_^*H_X3[PQ_P!#'I/_ ('1?_%5\;_\.E_AY_T./B7_ +YM
M?_C5'_#I?X>?]#CXE_[YM?\ XU0!]D?\)]X8_P"ACTG_ ,#HO_BJ/^$^\,?]
M#'I/_@=%_P#%5\;_ /#I?X>?]#CXE_[YM?\ XU1_PZ7^'G_0X^)?^^;7_P"-
M4 ?9'_"?>&/^ACTG_P #HO\ XJC_ (3[PQ_T,>D_^!T7_P 57QO_ ,.E_AY_
MT./B7_OFU_\ C5'_  Z7^'G_ $./B7_OFU_^-4 ?9'_"?>&/^ACTG_P.B_\
MBJ/^$^\,?]#'I/\ X'1?_%5\;_\ #I?X>?\ 0X^)?^^;7_XU1_PZ7^'G_0X^
M)?\ OFU_^-4 ?9'_  GWAC_H8])_\#HO_BJ/^$^\,?\ 0QZ3_P"!T7_Q5?&_
M_#I?X>?]#CXE_P"^;7_XU1_PZ7^'G_0X^)?^^;7_ .-4 ?9'_"?>&/\ H8])
M_P# Z+_XJC_A/O#'_0QZ3_X'1?\ Q5?&_P#PZ7^'G_0X^)?^^;7_ .-4?\.E
M_AY_T./B7_OFU_\ C5 'V1_PGWAC_H8])_\  Z+_ .*H_P"$^\,?]#'I/_@=
M%_\ %5\;_P##I?X>?]#CXE_[YM?_ (U1_P .E_AY_P!#CXE_[YM?_C5 'V1_
MPGWAC_H8])_\#HO_ (JC_A/O#'_0QZ3_ .!T7_Q5?&__  Z7^'G_ $./B7_O
MFU_^-4?\.E_AY_T./B7_ +YM?_C5 'V1_P )]X8_Z&/2?_ Z+_XJC_A/O#'_
M $,>D_\ @=%_\57QO_PZ7^'G_0X^)?\ OFU_^-4?\.E_AY_T./B7_OFU_P#C
M5 'V1_PGWAC_ *&/2?\ P.B_^*H_X3[PQ_T,>D_^!T7_ ,57QO\ \.E_AY_T
M./B7_OFU_P#C5'_#I?X>?]#CXE_[YM?_ (U0!]D?\)]X8_Z&/2?_  .B_P#B
MJ/\ A/O#'_0QZ3_X'1?_ !5?&_\ PZ7^'G_0X^)?^^;7_P"-4?\ #I?X>?\
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M.E_AY_T./B7_ +YM?_C5 'V1_P )]X8_Z&/2?_ Z+_XJC_A/O#'_ $,>D_\
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M  Z7^'G_ $./B7_OFU_^-4 ?9'_"?>&/^ACTG_P.B_\ BJ/^$^\,?]#'I/\
MX'1?_%5\;_\ #I?X>?\ 0X^)?^^;7_XU1_PZ7^'G_0X^)?\ OFU_^-4 ?9'_
M  GWAC_H8])_\#HO_BJ/^$^\,?\ 0QZ3_P"!T7_Q5?&__#I?X>?]#CXE_P"^
M;7_XU1_PZ7^'G_0X^)?^^;7_ .-4 ?9'_"?>&/\ H8])_P# Z+_XJC_A/O#'
M_0QZ3_X'1?\ Q5?&_P#PZ7^'G_0X^)?^^;7_ .-4?\.E_AY_T./B7_OFU_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVX)GMG S6_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YQ_\ !6S_ )"/PX^E
MU_[+7WW\._\ DG_AG_L&6O\ Z*6O@3_@K9_R$?AQ]+K_ -EK[[^'?_)/_#/_
M &#+7_T4M '0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY+&E!XG#+1;K]5_D?%9ME$:<7B,.M.J_5'TU1117PY\<%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<EXP^%/A/Q_>07?B#18-3N(8S%'
M)*S JI.2.".]=;10!2T?1[/P_I=MIVGP+:V5L@CAA7.$4=AFKM%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?G'_ ,%;/^0C\./I=?\ LM???P[_ .2?^&?^
MP9:_^BEKX$_X*V?\A'X<?2Z_]EK[[^'?_)/_  S_ -@RU_\ 12T =#1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%-DD6&-Y'8*B@LS'H .IH \X^.GQX\._ 7
MPF=7UMVGNIB4LM-A(\ZZD]!GH!W8\"OSU^(7[=_Q4\:7DW]GZK'X5TYC\EKI
M<2[U';=*P+$_3 ]JY/\ :>^+5W\:OC'JE_&[S:=:RG3],@4D@1JV,@>K-S^5
M?:'[-?[$7A7PAX9L-:\:Z9#XA\2W4:SM;WB[[>SR,A%0\,WJ6S4PBYQYWL5.
M2B^1;GQ=HO[6_P 7M$O!<0>/=3N7'\%XR7"?]\NI%?7/[-?[>D/C[6+/POX]
MM[?2]8N6$5KJML-EM._974GY&/8@X)]*]W\9?LR_#'QQI,EC?>#-)M@RD)<:
M=:I:S1DC[RM&!R/?(K\R?VCO@/J'[/WQ ;1Y+A[O3+A?M&FZAC:TB9Z''1U.
M,X^HJE-1:4EHR7%R5T]3]AJ*\+_8W^+TOQ<^#-A/?S>;K.E-_9]XW=BH&QS]
M5Q^1KW2JE'E=B8RYE<****DH*^=OVG/VP-'^ ^-&TVWCUSQ=,F\6A?$5JIZ/
M,1SSV4<GVKU[XI^/+7X8_#W7?$UX1Y6G6KRJI_C?'RK^)Q7Y"Z'I/B/]H#XL
M1VPD:ZU_Q#>EY9I"2(]QRS'_ &57^51K.?)$K2,>=G:>*_VS/B]XJNVFD\8W
M&DQDY2WTJ-+9$'H"!N/_  (DU)X1_;2^+WA.Y25?%LNLPALO;ZM$EPCCT+$;
MA_P%A7Z _"K]D+X;?#'18+=O#UEX@U/9BXU+5H%N'E;OA6!51GH *I?&']C3
MX>?$_1;E;'1;3PQKFS_1]1TN%80K <!XU 5E]>,^]6_<VU)7O;Z#/V9?VM-%
M_: MY-.N+<:+XKMH_,FL"^Z.9>[PMU(]5/(]^M>^5^+/_%2?L_\ Q8&[=9>(
M/#M]SMZ/M/;U5E_G7[#^ ?%]KX^\%Z+XBLB#;ZE:I<+CL2.1^!R/PJ])14XD
M:QER,WZ***@L**** /SX_;R_Y.]^!/\ O+_Z5+7Z#U^?'[>7_)WOP)_WE_\
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M%Y"LR;6R/F&<9]NE:%>9_LZ:PVI_!;PY<W CB$=N8\C@!58C)R?05UNH^/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\X_P#@K9_R$?AQ]+K_ -EK
M[[^'?_)/_#/_ &#+7_T4M? G_!6S_D(_#CZ77_LM???P[_Y)_P"&?^P9:_\
MHI: .AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^,,_[0WBO]HK]H3X8:MXM73UNM-U*"U@_LZW:%=C2ACN!9LG(K]GJ "BBB@
MHHHH **** "BBB@ HHHH ^;?VV/&ATOP=IGAR"4I-JDWF3*IP?)3GGCD%B!U
M%?&-?0O[;6JSW7Q*TJQ<)Y%KI^^/ ^;+MSD_\!%?/5?!9E4=3%2OTT/W?AN@
MJ&64K;RNW\W_ )6"BBBO,/I@52QP*L)&$&.],CDC50!RV>:O6-J+RX\LL4X)
MW+7ZEE%/!950=?F]I5:OIYZV3V]6?G>=9G.56.'E[D6VEYV=G>W0JLNY2*JU
MJ7=H;68Q[BV.A(ZU2DM)54R>6QC/\0&16'%5'V]"AC8KR?S5U]VIU\/XJ$93
MH2>^J(:DC;=QWJ.G1_ZU.=HSR:^:R#.JN2XM5(ZPEI)=UW]5T^[J?68RC[:D
M[+WEMZGJ.EZ[JK>%[#3)=0N#80K^[M1*1$N23]WIGGK4:J%Z #Z4V$*L,83[
MFT8^F*?7ULY^TDY]S^;]?M*S$VC<#CD=#7:>#OB]XH\%31?9-2EN;-.#97;F
M2(KW !^[]1^M<914 ?:_PU^+FC?$BT MW%GJJKNFT^1LLHSU4X&X>XKQ#]H3
MXL3>(-6F\.:7<XTFU;;<M&1B>0=L@\J/YUX]8:A=:7=QW5G<26MS'G9-"Q5A
MD8."*@8EF)/))R30 4444 %%%% !7JGP)^*\G@?6ETS4)I&T.\<+M)&VWD)X
M?GH#W_.O*Z0C((/2@#]#)+J&&W:X>5$@5=YE9@%"XSG/3%>+^-_VGM)T6>6T
MT&T_MF="5-RS[+<'U4C)<?3 ]Z\(\0?$[7O$GAO3-#N;IEL+&/R]L;$&?'0R
M'/.!QCI[5R= 'I^J?M'>-M2618KRVL%9MR_9K<;D'H"V>/K5.P_: \=6,QD.
MLBZ!&-EQ;QLOUX YKSRB@#WWPK^U9=P^7#XATJ.Y3@-=6+;''N4/!_ BO>_"
M_B[2?&6F)?Z1>1W<#?>"GYXSZ.O53[&O@>MOPCXRU;P/JB7^DW;V\F1YD63Y
M<RC^%QW% 'W3JVK6>A:;<7]_<):VD"EY)9#@ "OE#XH_'K5?&TEQI^F,VF:&
M25VIQ+<+ZN>P_P!D?C4/Q?\ C1)\2K/3K*VMY+&RB427$+D'?-[$?PCMFO,*
M "BBL?6M;DTN:-$B60,N[YB: -BKNBZW?^'=1BO],NY+*\B.5EB//T(Z$>QX
MK+L[@W5I#,0%+KD@5/0!]9_!_P".UMXY:/2=65+'6U0!&W?N[HCJ5_NM_L_E
M7KC,%4DG '4FOSVL[R?3KR"[M96@N8'$D4B]58="*].^('Q\U;QIX9L](B5K
M%6B U"5" ;A^X&.BGKCO]* /6/B+^TAI7A>:6PT2%=:U!,J\N_%O$P/0D<L?
M8<>]>,:O^T!XWU6X=TU;[!&P($-I"BJ ?<@G/OFO.:6@#I8?B9XNMY4D3Q-J
MQ9#D;[R1A^()(/XUU>@_M'>,]'F+75U#J\1.3'=Q!3^!3&*\OHH ^ROAK\<-
M$^(12T.=,U@_\N4S9WX')1OXA^1]JA^.GQ,'@'PR;>TDVZS? QV^,YC7^*3.
M.W;WKX]CE>"19(G:*13E71BK*?4$=*U/$GBK4_%MU;W.JW+74\$"VZ.W7:/7
MW]3WH RGD>61GD=I)&)9G8Y+$]23ZTE%% !1110 49((()4CD$'!'O110!]<
M_ /XI'QQH;:;?NO]L:>BJQYS-'T#\]^QYKU9F"J68A0.237P[\*O%4?@SQM9
M:I.[);QAEEVMC*D<C'?V'K6M\2OC9K?Q"D>V5VTW1MWRV<+<O@\&1NI/MTH
M^D/$?QR\&>&9#%-JZ7<P.&CL09ROU*\?AG-<A<_M6>&H9Y$BTS4[B-3A9 L:
MAO?!;(_&OEJEH ^O](_:0\%:I-%%)=W%@[C)-U 0JGT+#(_I7H^FZI9:Q:K<
MV%W!>V[?=FMY!(A_$'%?GS6[X0\;:SX%U(7NCWC6[GB2(_-'*/1E/!^O4=J
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M+:Q21G*.NY2/2IZ^OIJT(I=C\AQ$G*M.3ZM_F%%%%:& 4444 %%%% !1110
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M.C#(93D$>HH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110!^<?_!6S_D(_#CZ77_LM???P[_Y)_P"&?^P9:_\ HI:^!/\
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MH?\ OV/\*L44 5_[/M?^?:'_ +]C_"C^S[7_ )]H?^_8_P *L44 5_[/M?\
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M3T1I"61OM*(S9P#P<#' ^O4U] T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4457U#4+?2K&>\NY5@MH$,DDCD *H')R: #4-0MM+LYKN\GCM
MK:%2\DLK!54#N37@GC?]J9+>XDM?"]BERJDK]NN\A&]T0<X]R1]*\N^+'Q7O
MOB5JQ +6VC6[G[-:YZ_[;^K']*X.@#N=4^.'CC5ED237YX(W;=MM%6';[!E
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MHKE=.^*?A#596CMO$>GNZC<=TX3CZMBNEMKJ&\@2:WE2>%QE9(V#*P]01UH
MEHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\X_
M^"MG_(1^''TNO_9:^^_AW_R3_P ,_P#8,M?_ $4M? G_  5L_P"0C\./I=?^
MRU]]_#O_ ))_X9_[!EK_ .BEH Z&BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /SX_;R_Y.
M]^!/^\O_ *5+7Z#U^?'[>7_)WOP)_P!Y?_2I:_0>@ HHHH **** "BBB@ HH
MHH **** "BBB@#Y\_;+^$EQ\0_A[%JVF1F75="9K@1 X\R$C]X!SC('(^E?G
MI#.T3+)&Q4]:_8WKP>17PY^U'^RIJ.DZO?\ B_P?:-?:5<%KB^T^%0'M6ZLZ
M*,;D/7 &0<]:X<12YO>L?'9S@:T:BQ^%;4EO;=6V:ZGS?:ZY'(N)OD;U X-7
MUNHG7<)%(^M<K#MFD10<AB!D5KZIHL6GVIECDD9@P'S8KP99;"I>4'8^RR?Q
M$SFGAI/$4HUHP6K;Y9?/=/[D37 %O? ]!(*T+24;MN>:Y)9&5@<G@YKH;:3+
M(PZ$55&^"Q%&K?9GT/#/$4,YJXNG"GR*3O:][<V^ME]I7VZEG6E:;39 I(V_
M-QW%5_!OAN35]0BDDC9;93NW,I ;!YP>^#Z5T&DZ8VL745N/E24[2WM7WM\/
M_@CX.M/A?8Z-'I\5S9S@79F*D/YI RP.<CZ9K[',L.EC7-;22?\ 7W'YQC\L
MG6SJ<JS]RRE;\&E\U=^I\C45[IXH_99U6UN)Y=%U"*]MB<QPRKY<B^H/.#CM
MCK[5Y]J'P;\9Z9#YDV@7C,6PL4$9F=AZ_N]P ^I!K ^E.,HKO]/^!?C'4)(<
M:5+'"XRTLBE/+/H5?:WY CWKU'P/^S&ME>"ZUZYBGC ^6W50Q]\_P_CSQZ&@
M#RKX6_"N]^(6J;6$EM8Q$&27;@^O&1TK[)TC2;?1-/AL[6-8XHE X'4XZGWI
M=+TNUT:QBM+*%8+>,85%R?U/)JW0!Y)\3/V?-*\8R7.H:48]*UB4[G<AC%(?
M=0>">YP?I7A?B#X#^,M *C^RWU#.!NL0903WQCG ]6 ]A7V?10!\&?\ "#:Z
M-0-DVFS).!R6&(Q[;_NY]LYSQ72>'_@5XNUYF!TV6PP<?Z4A0>QR<#:?]DD_
M[.*^SZ* /(_AO^S_ *;X5\F[U,1WNH)SE2< ^AYP1[ #\:[+XC^ [7XA>%KC
M2IML4V-]M,0?W4@Z-@=JZJB@#\^]:T>[\/ZM=:;?1-#=VTAC=6!'3N,]CU%4
MZ^T_B?\ "#2?B3:^9*/L>KQ(5@O8QS[!Q_$O\NU?+'C+X7>(?!%\MO>V,LT;
M<)=6\;-$YZD!OIZXH Y.BA@4^\-OUXI,C=COZ4 +3HXWFD2.-2\CG:JJ,DGT
MK6T;P?J^NWD%M:V$[/,2%)B;''7C&3CT%?1WPN_9[M?#<T6IZRQN;U>8X@<*
M ?[PY&?H30!E?"GX"V6H>#[B3Q':GS[Y3L4X\R ]G5A_+D5Y)\0_A+KGP\OP
MEQ"U[82L1!>6ZEE8#LPQ\K8[?E7VRJA5  P!P *BO+.#4+62VNH8[BWD7:\4
MJAE8>A!H _/6BOK+Q%^S-X8U3S7TUI=(E<E@%S)&"1_=)! 'H"*^:_CIX1E^
M#NO:=IL5TFIBYMFG,SQE#PV,;03C\SGVH P:LZ?IEWJLWE6EO)<.,9\M2=HS
MC)]*]N^&/[.]IXJ\,Z1K]]J9$=];K,;18<[">X?<,_0J1]:]M\(?"_P]X)^;
M3K(>=G=YLOS,#[>G\\<4 >:?"#X!1:;;G4/$UI#<3R#Y+9OG4+VR"./\_2O(
M_C#\,Y_ASXD=8UDETBZ)>UN"N ,G)C..X_#(K[3K.U_P]IWBC2Y=.U2TCO+.
M7[T<@[]B#U!'J* /@"BO9/B-^SCJWAUI;OP^LVM6)8MY"(/.B7TQG+_@,^U>
M2ZAI5YI-QY%Y;26\N[9MD&"6'4#U- %6BI!;3%I%$,A:,9<;#E/KZ?C6GH_A
M'6/$'EG3]/FNA)RAC4G<,X) '+ =R <=Z ,BO??V??A-/->'7M6MS'"@'V>-
MN=_J&!'T_P#K5J_#7]F^"U:&_P#$8:5QAOLA^7#=<Y5N!^I]J]ZM[>.UA2*%
M%CC0855' % #+ZQM]2M9+:[@CN;>0;7BE4,K#T(->+>,/V7]+U6\FN]&OY-/
M>09^RR@-$&]0<9  [<_45[A10!\CZA^S/XPLXY7ACMKTYQ%'!,NYN>K%]H7C
MTS3M/_9H\67:P-,D-IS^^CFE4,O^X5+!OQQ7UM10!XGX-_9GT[1;R*\U*\>Z
MD0<0J!C/KN(_3&1V:O7X]'LH=-?3XK:.&T=&1HHU !!&#^)]:NT4 ?#/Q+\"
M7/P]\57.FRJ3:L3):RX.UXR>!G'4=#BN5K[A^)OPYLOB5X?-A<N8+F(F2UN5
M_P"6;XQR.X/0BOCWQAX%UGP+JC6&K6IC<#<DT>6BD7^\K?Y(H P**** "BBK
MVD:'?:]=)!8VSSNS!-P!V@GH">U #='TFXUS4K>QM4:2:9MH5<9]R,FOJ.3]
MG71=3\$6>GS?Z+J\*%EOH5 .XC[K \LOL3GK@U+\&?@O%X+MX=3U2%6UDC(Y
M#>5D= ?I7KE 'POXV^&VN^ +M8=4MLHYPES &:)N>,-@#)].M<NRE6*L"K*<
M$$8(/I7Z&S0QW$925%D0]589!KCM2^#G@_4[AIY-$MXY]NU7B&T)_NI]T=?2
M@#XCJQ9Z;=7[QK;V\DOF/L0JIP6] >F?:OL#3_V??!>GK(G]GR7,,AR\=Q)O
M!/L<;A] 178Z-X3T?P^JBPT^&!E 42$;GP.@W-DX'89XH \'^%_[.DDEQ!J>
MOR,D<;"2.",8WGT(9<X]^,]O6OHJVMHK.W2&"-8HD&%51P*EHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XKXJ_#:V^)/AQK-BEOJ$
M)\RUNBH)1O[I[[3T-=K10!\!>(O#.I^$]3?3]6LY+.Z7HKCAQG&Y3W'O697W
MGXL\%:/XUL#:ZK9QSX!$<VP>9$3W5B.*\'\1_LIWEJLCZ)JJW@R2D5T C =E
MR.#[MQ]* /!**])OOV>O&MG)$BZ8+HM]]K>5"J#ZLPS^ K9TG]F3Q)<W7^EM
M##:<%7\P*QYY##G;]0&^E 'CT:-+(J(I=V.%51DD^E>[? _X)37US;Z[K<$U
MO%#('A@D!0L0>X[@_E7H_@+X Z+X/)FNG&JW#'GS8EV8[ YR3^@..G:O454*
MH51@#@ 4 "J$4*H"J!@ # %+110 4444 %%%% !1110 4444 %%%% ";1UQS
M6=)X;TB1F+Z79,S$DDVZ9.?PK2HH Y>;X9^&)HW0Z/;IN_B3*D?0@\5F3_!?
MPQ-"R)!<0,>DB7#$C_OK(_,5W=% 'F%Y\!=*DC M=1O('SRTH208], "LJ\^
M ,P9?LFL(PQ\WG0D'\,&O9** /"+OX%ZY%(!;W5E<)CEF9DP?3&#7@_Q TFX
MT'QAJ.GW3(T\#!6\MBR] >"17W?7RC^U%H\UGX^M]09?]'O+551@IQN0D$$^
MO(H \=HHHH **** "BBB@ KWSP/\8M=T7PS96?D64HB&W,D;9QV'RL ./05X
M38V_VR^M[?<%\V0)EF"CD^IZ5]6Z+\ ]/70[19;^]BN?*&00F%)Y (VYR._-
M %;_ (7]<]]%BS_U\'_XFKEK\?H/)'VC1Y1+GGR905_4"HO^&?Q_T'3_ . G
M_P!G5&X^ >I+,P@U2U>+/RM(C*Q^H&?YT =!9_'C299&%Q87ENF.&7:^3Z8R
M*N)\</#C.JE;U03C<T(P/?[U<->? W7X-OD3V=UGKARF/S%4YO@SXGAB9Q;V
M\I49V1SC<?89 'ZT >K?\+:\*?\ 04_\EY?_ (FKMO\ $3PU<0K(NM6BJW($
MDFQOQ!P17A__  JSQ5_T")/^_L?_ ,56?)X)\0Q2,C:)?DJ<';;LP_ @8- '
MT79^,-#OY"EOJUG*X&2JS+T_.KBZQ8,P5;VW+$X $JY/ZU\NWOAW5-/"?:],
MN[<-]WS8&7/TR*IM9S1*7:WD0+R6,9 'XXH ^NJ*^1/MDG_/P_\ W\/^-:%M
MXHUBSA6*#5KZ&)?NI'<N%'T - 'U717S!:>/O$=BS&+6;PENOFR>9^6[./PJ
MY#\4O%,,J/\ VL\FTYVO&A4_7B@#Z3HKYZ_X71XG_P">]M_X#C_&KUO\===A
MA5)+6QG<=9&1@3^ ;% 'N]%>*V?Q\OT9OM>E6\RX^7R9&C(^N=V:NQ?']3(H
MET1ECS\Q2YR0/8%1G\Z /7::S"-2S$*JC))Z 5YE_P +[TG_ *!M]_XY_P#%
M50\:_&_2F\%ZK]@^T1:B]LRQ+)&0%8C'W@?Y4 >%_&CXB2^/_%TYCD/]E63M
M#:Q@_*V#@R8Z9/\ *N!I![DD]R>II: "BBB@ HHHH ?#-);S)+#(T4T;!DD0
MX92.A!K[0^#/Q _X6#X/BN)RHU&U(@NE4YRP'#?\"'/YU\65ZY^SW\0H/!^J
MWUK?&464\>_]V-WS#V'4^Y/3B@#ZTHKSZ;XW^'$C9D^UR.!PGDXS[9)JC_PO
MO2?^@;??^.?_ !5 'I]%>2W7Q^A67%MHTDD6/O33A&S] I_G5:;X_2M"XAT5
M$EQ\K/<EE!]P%&?SH ]CHKPS_A?.M?\ 0/L/R?\ ^*JG=?&WQ'--NB^R6R8Q
MY:Q;A]<DT >_T5\ZW/Q@\47$)C^V10Y_CBA4-^N:I_\ "SO%/_08F_[X3_XF
M@#Z6HKY<G\;>(+B9I'UJ^#-UV3L@_  @#\*K7?B;5[V$Q7.JWL\).2DMP[+^
M1- 'U95635;*&1HY+RWC=>"K2J"/PS7R=]LD_P"?A_\ OX?\:5;>6X_>+#),
M#_&$+9_&@#ZFO/%&CZ?&'N-4M(58X!:9>OYU4_X3[PY_T&['_O\ K7S79Z+?
MWLWE6UA<S2D9V1PL3C\JO?\ "&>(/^@)J'_@*_\ A0![L_Q8\*H[*=4!*G&5
MAD(_ [>:K7GQD\,6J*T=U-=$G!6&!LCW.[%>00_#+Q1<0I(NCS!6&1O9$;\0
M6!'XU9M?A+XIN9=ATX0#&=\TR!?T)H ],_X7EX=_YYWW_?D?_%5G-\?-/#,%
MTJZ9<\'>HR/6N/\ ^%*^)_\ GG:?]_\ _P"M5^'X$:U)$K/?643D<H2QQ[9
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M>$])NEE\_?;)F7.=[ 8)SWY!YH VJ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N&^)GQ;TCX:VJBYW7>I3*3!91$;F]V/\*^
M]:'Q(\=6GP^\+W.IW!5IL;+>#=AI9#T _G^%?$NM:U>^(M4N-1U&X:ZO+AMS
MR,?R ] .PH Z7QI\6_$OCFXE-YJ$EM9.3ML;5RD04_PG'WO^!5QF!G..:6B@
M!" >HS6OX>\7:UX3N!-I&IW%@V=Q6)SL;_>7H?Q%9-% 'U7\*?VA++Q6T.EZ
M_P"7IVKL52*49\JY;VX^1O8\>A[5[+7YW_H:^K/V>_BM_P )9I0T'4Y<ZO8Q
M_))(^6N8QWY[CH: /9**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#\X_^"MG_(1^''TNO_9:^^_AW_R3_P ,_P#8,M?_ $4M? G_  5L
M_P"0C\./I=?^RU]]_#O_ ))_X9_[!EK_ .BEH Z&BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /SX_;R_Y.]^!/^\O_ *5+7Z#U^?'[>7_)WOP)_P!Y?_2I:_0>@ HHHH *
M*** "BBB@ HHHH **** "BBB@ I" P((R#2T4 >(_%7]DOP=\3-074H_M&@Z
MFIRTE@0(Y._S1G@'W7!KP?Q!^PIXQCN)C9Z_9ZCIZC*IN83NW/1'P@'0<R'I
MG)Z5]S45E*E&1Y5;*\-6;;C:^]G:_KT/SVT?]ASXA7]O*+P6>F78/[OS)DD@
M9<<[G1BP;T 0CU(KSB^\'2^&[U[&\;,]NS1N%.1N4X(!P,\CTK]4*^'/VJ/#
M#:'\2+NZ6/9%>A;A6&XAB1AN3[@=*\O'8=*ES1Z'?D6#HY5CZ<J3=IWB[^>J
M_%6^9Y?IK_8VMYTRH5P<X'8U]Q_L^>(/[6\%?92RL;.3:GS#.QOF' _&OA/3
M\/#(O0KR.E?2W[+OBDVNKPV4C'R[V(P]./,3D' ]N,U])*HL1@,/B.J]U_I^
M1[/$])8?'4<2MI.W_@2NO_)D?4U%%%<AY@4444 %%%% !1110 4444 %%%%
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M;<-WUP/I7K/A#X?:)X(M5BTRUVL!CSI#N<YZ^PSWP!GO7244 %%%% !1110
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MM[.VF-NS8DN%3*H!UYZ#ZGBOL?P%X'LO 6@QZ=9C/.^1R<EF/N><4 =& %
M& .@I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AO+6.^M9
MK:4;HID,;#V(P:^%?'G@^Y\">*;W2+E3MC;? _'SQ$_*W]/PK[PK@/C!\+H?
MB5H(CB9+?5;7+VL[*.?5&/7:: /BZBK^N:#J/AG4I+#5+22RO(^3'(,9'8@]
MP?450H **** "GV]O)=3)#$I>1SM55!/Z"B""2ZF2&%&EE<X5%&23[5]#_ S
MX)/!);>(-<@DBF0[X;>0%<?4'J/KQZ>M 'HGP2\#?\(3X/C64?Z7=$328;(Z
M<8_#Z?2O0J** "BBB@ HHHH **** "D(# @C(/44M% %3^R;'_GSM_\ OTO^
M%177A_2[Z$Q7&G6LT1.2KPJ1Q^%:%% &%_P@OAW_ * =A_X#K_A5:\^&OAB^
M93)HUNNWIY.8OSVD9_&NFHH Y'_A4_A3_H$K_P!_Y?\ XJJ-Q\%?#4\S.L=S
M I_Y9QSG:/IG)_6N\HH \^_X4?X<_O7O_?\ '^%9Q^ >F[CC5;L#/ VI_A7J
M5% 'E,WP"L_*;R=7N%E_A,D:LOX@8_G7S3\1O#LOA/QIJ>F2S)<-&X82(" 0
M1D<'H:^[*^7?VI/"9T_Q-8Z[#$1!?1^5*ZJ,"1>F?<C^5 'B-%%% !1110 4
M444 +'M\Q=X)CW#<%ZXSSCWQ7UO\-_B;X;TCPGI.ER37%H8(_+7SHR1MR2"6
M&>Q%?,?@KPU=>+/$=IIUH 99&&2<\#UX_P#U>XKW6_\ @?X@L5/V4VM]&IVJ
M(Y-C$>N&P!^9H ]NTSQ%I>LH&L;^WN>-VV.0%@/4CJ/QK1KY5U#POJ^DL?M>
MF74&!N+-$2H [Y'&*GTKQMKNCL#::K<*H.=COO7IZ-F@#ZCHKP?3?CEKEHH6
M[@M;\ ?>*F-B?<CC]*ZS2OCMI-SM6_L[BR8D#>F)$]R<8./P- 'IE%<[I?Q"
M\.ZQ@6^JP!CGY)3Y;<>S8KH58.H92&4C((Z&@!:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /E']ISQ4=6\:PZ3%*6M]-B&]0>/-;D\8Z@8]>M>.U
MU/Q3U"34OB-XAGE"A_M;)A!@87 '\JY:@ HHHH **** "N@^'^NOX:\9Z3J*
M2-$(9AOVD#<IX())P!CO7/T*45E,@)C!!8*<$COB@#]#()DN8(YHV#QR*'5A
MT((R#4E8/@/4#JW@W1KLIY8EMD(7T&, ?7 %;U !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !11575-3MM&TZYOKR406MNADDD;HJ
MCJ: +$DBQ1L[L$11EF8X 'J:\@\7?M->&]"DDM]+AFURY7C?"0D&<X/SGD_@
M"/>O%_BQ\9M1^(=]+;6LDEGH"G$=J#@S8/WY/Z#M7G% 'L^H_M4>)[E4%II^
MG61!R25>3</3DC%)IW[5'BBV#B[L-.O22-I"O'M_(G->,T4 ?5OA+]ISP[K4
MD=OJT$VB7#<>9(1)!G_>'(_$8'K7L$4J3QI)&ZR1N RNIR"#T(-?GE7HOPJ^
M,VI_#NZBM9G:\T!GS+:D M'GJR'M].AH ^RZ*K:;J-OJVGV][:R"6VN(UDC<
M=U(R*LT %%%% !1110 4444 %%%% !1110!^<?\ P5L_Y"/PX^EU_P"RU]]_
M#O\ Y)_X9_[!EK_Z*6O@3_@K9_R$?AQ]+K_V6OOOX=_\D_\ #/\ V#+7_P!%
M+0!T-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[DDMGOD]:S:^B/VH? ;LEEXEL;<>5"OD7?E(!M7/RN<#H.F>V:^=Z "BBB@
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MKB;+XP^&+QB&O)+;"Y_?0L!]. >:Z'3_ !5HVJ%!::I:3NXW+&LR[\?[N<T
M:M%-5UD7*L&'J#FG4 %%%% !1110 4E+7S]^T%\9I]/FF\+:'-Y<Q7%]=QM\
MR9_Y9KZ''4^] '5_$C]H+1O!,DECIZKK.JKD/'&^(H3CC<V.?H.?I7A>N?M!
M>-M9N/,CU-=,C!R(;&(*H_%LD_B:\X QP*6@#>;Q_P")VD+GQ'JVXMN/^FR
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&4,I5AD'@@TM%
M '">(_@GX1\21N)-+2RD8DF6RQ&<GJ<8VY]\9]"*XZ\_97T":>%K;4;JVACZ
MQLH<R<_QG/\ Z#BO;** /+]%_9W\*:1>"Z*3S2Y!*%\(".FSJZ_@WUKT#1]
MT[P_;^1IME#91=UA0+GZUH44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP:\.+XF\>6-O)&7B0B1CMR%P<YSV/'!P>:^V: "BBB@ HHHH **** "BBB@
MHHHH _./_@K9_P A'X<?2Z_]EK[[^'?_ "3_ ,,_]@RU_P#12U\"?\%;/^0C
M\./I=?\ LM???P[_ .2?^&?^P9:_^BEH Z&BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*UM+>*UMHEVQPPH$1!Z #@"IZ** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI( KIP]1PFET9]+D&.E@\9&-_=GH_P!']Y]S4445[1^UA1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=_M<)=MP;'!##B@#Z)HKF?AGXBNO%G@'0M8OO+^UWMLLTODKM3<?09/%=-0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %#5-!TS7(_+U'3K6_CSG;<PK(..G!%<]<?"/PC=7T5XVC1
MI<0_ZIHI9(Q%CH$"L H]ABNPHH QM/\ !NA:3,9;32+*"<_>F6!?,;W9L9)]
MR:V:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "HIK6&XQYL22XZ;U!Q4M% &$? GALW)N#H&F_:"<F7[)'
MO)^N,UKPV<%L288(XB1@E$ _E4U% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?G'_ ,%;/^0C\./I=?\ LM???P[_ .2?^&?^P9:_^BEK
MX$_X*V?\A'X<?2Z_]EK[[^'?_)/_  S_ -@RU_\ 12T =#1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#\X_P#@K9_R$?AQ]+K_ -EK[[^'?_)/_#/_ &#+7_T4
MM? G_!6S_D(_#CZ77_LM???P[_Y)_P"&?^P9:_\ HI: .AHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@^]?"'Q$_P"")?@76;IY_!?Q UKPPC,6-MJEI'J4:YZ*A5H6 '^T6/N:N_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YQ
M_P#!6S_D(_#CZ77_ ++7WW\._P#DG_AG_L&6O_HI:^!/^"MG_(1^''TNO_9:
M^^_AW_R3_P ,_P#8,M?_ $4M '0T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X5^VA\%_!WQO^!FI
M:9X]\17?A;POI4JZS=ZG9E-\:PH^<[U88PQX R3@"O=:_/G_ (+/?$>]\,_L
M_>&_"ME,T*>)=8_TO;_RT@MT\S8?;S&B/_ :YL0[0^:MZW5G\GJ;T5>?R?W6
M=_O1^4%A\,W^+GQ=D\)_"#1M;UZ"\N&CTNWOS&UW)$O668J%CC'5CGY4!P6.
M,G[Z^&?_  1'UJ^T^"Z\??$>UTBZ;F33="L#=;1V'GR,@SZ@1D>A/6O:_P#@
MCG\&-)\*_L_7?Q"-O')X@\47LT/VHC+1VD#F-8AZ R+(Q]<KG[HK] *[Y05%
M*&[LKO\ K\?,XXR=5N6RN]/33_AC\W]0_P""(_P[DM66Q^(?B>WN?X9+B&VE
M0?50BD_]]5\W?'[_ ((__$KX6Z'=:YX+UJU^(^GVL9EGL[>U:SU *.24A+.L
MF!V5]Q[*:_;&BN>2;V=C>+2W5S^<3]E/X!^&?VB?B='X%\0>/I/A]K%[\FF2
M2Z.+V&ZF&<PLWGQ&-R!\H((8@C(. WV+XP_X(@^*M/TN:7PO\4-)UR_7E+74
M]*DL$?V\Q)9L'_@./>O+?^"J_P ,[3X*_M;6OB/PN/[(?7[.'7P;4[/)OEF=
M9)$Q]TEHUDS_ 'F8U^R?P2\=/\3O@[X(\72IY<VN:-::A*@&-KR0J[#\&)JX
M6K4/:+1IV?KK_D_P)FG2K<CU35U^'^:_$_ 'PIXD^*_[ GQ^CEN+.Z\.>)M+
M=1>Z7</FWU&U8Y*,5)66)P.&4G!&00R\?T"?"/XG:1\9OAGX;\;:$Y;2];LX
M[N)6(+1DCYHVQ_$C!E/NIKX1_P""U7PSL-4^#G@_QTEN@U?2=7&FO<  ,UM/
M&[;2>X#Q*1Z;F]377_\ !&WQ9<Z]^RE?:7<.731/$-U:P _PQO'%-C_ON63\
MZNA-UJ4X3WA_P/\ Y)/R=^Y-:"I5(3CM/_@_Y-?-=C[NHHHK,H**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH _/C]O+_D[WX$_[R_\ I4M?H/7Y\?MY?\G>
M_ G_ 'E_]*EK]!Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK/\0W
MLNFZ!J5W"0)H+:25"PR RH2,_B*^9_V<_P!H;Q?\2OB%!H^M7=E-9O:23%8+
M8(VX 8Y!H ^J*CN(?M%O+%G;O4KGTR,5)10!^77CKP]/X3\::YH]S_KK.\D0
MDD<@G<#P2.016)7UI^V%\&YKME\=:1"TK1H(]3B0#A!]V7UXZ'VYKY+K\[Q>
M'EAZS@]NGH?T-E./AF.$A6B];6?D^O\ 78****XSUQ*I7]D9#YL8R?XEJ]17
MOX3$2^KSI+^K;?Y>AX6:Y7A\TI>PQ"TZ-;KT,2WN'MVRO3NM;FF7D3,9FD$:
MQC+;NU4[JQ6X^9?ED_0U@74F6* Y53CCH:BC&&)DIK1H_"^(<1F/"N#JY94E
MSTJR:C^K2Z;ZK9_B=RNK)?0[K=OW9XSW_P#K5R6MV$EM<&4EGC<\,QR1[&HM
M*U$V$_/,3<,/ZUU$L<5];E3B2-QP?ZUZWPG\ZJ/L):;'%4JLT;!E)5AR"#@U
M-?6;V-P8WY[AO45!5G:FFKHWM)\53VC+'=$SP]-Q^\O^-?1?[.?QL_X0/6X[
M6YN7G\-:@X1UW +;R$X$F#T]^GK7RM6IH.L'2[K#Y:WDX=<\#WH5XOFCN*G*
M>%JK$8?24?Q\C]>HY$FC62-E>-@&5E.00>A!IU>3_LS^+'\3_"^PCGN6NKBQ
M'D&1NI3^#J<D8XS[5Z!XD\8:)X/M?M&M:K:Z;$<[?M$@5GQV5>K'V )KV(R4
MHJ1^RX?%4ZV'CB6[1:OKT-BBO$]8_:X\#Z>LHM!J&IR(VT+#;[%<?W@7(X^M
M4=-_;%\(W4Y2[TW5;"/;D2-&DF3Z85B:CVU.]N8XGG671ERNM'^O/8]ZHKB/
M!_QH\&^./+33-;MQ=/TL[D^3-GT"MC=_P'-=O6JDI*Z9ZE*M2KQYZ4E)>3N%
M%%%,V"BBOF_]ISXY^*/A9XHTFQT*YM(+>YLWFD%Q )"6#8&"3Z4 ?2%%<O\
M"_Q!=^*OA]H.KW[(]Y>6JRRM&NU2Q]!VKJ* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _./\ X*V?\A'X<?2Z_P#9:^^_AW_R3_PS_P!@RU_]%+7P)_P5L_Y"
M/PX^EU_[+7WW\._^2?\ AG_L&6O_ **6@#H:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEYZ]B:T_:U(0CM#_ (/^;?E9=SKZ***S+"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /SX_;R_Y.]^!/\ O+_Z5+7Z#U^?'[>7_)WOP)_WE_\ 2I:_0>@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH :RK(I5@&5A@J1D$54M=%TZP
ME$MM86MO)C&^*%5./3(%7:* "BBB@"&[M(;ZUEMKF))[>52DD<BY5E(P01Z5
M\:?'#]DW4/#MQ<:SX-B?4=*DDW/IB#][:@]2I)^9!Z=0/45]HT5QXG"T\5'E
MG\F>QEN:8C*ZG/1>CW3V?]=S\H)%,4CQOPZ,589!P1U%)7Z3>+_@CX+\;33W
M&I:';_;)L>9=6Z^7*V.FXC[W/9LCUKRS5OV(_"UQ;^5IVL:A9,S;FGG"S2?[
MJXVJ!]5)]"*^8J9/7B_<:9^FX?B[ U$O;)P?I=?A_D?%E/CC>9<HNX#J1TK[
M@T?]C7P=9RP37ES=7,L(VE8@JQ2CU=)/,^;W4J!V K5^)WP1\/VOP_O?[$TV
M&UN+;$[,?F:55&"&9N2=O?/:O3RW*ZL:O+5:2EI\^C^_\+DUN*\%*484DW=[
M['PAJD0TWP[-+L5[B9]@.#NCX[<XP?I7#5Z1XTTM]/D2(_-$Q+1L?XEK@+ZV
M^SR97[C=/;VJ?9/"5I8>:LS\:\1LMK5JT<UA)RA9)KMV:\NC\[%:M;1=6^RL
M()C^Z/W3_=_^M6316^Y^'RBI*S.OU"Q34K;:"N[JC]<5S=UI=S:<O&2O]Y>1
M4NGZQ)9, P\R+NN:W[75+:\P$?#_ -UN#4:HYO?I>:.0HKK;K1[6ZR3'L;^\
MG!K'NO#L\7,1$R^G0U5S6-6,CV_X%_'2\^&?@74[#2;99]5O9 6N;C&R *,*
M54?>."?O=\=:YS7-=U#Q)J<VHZK>2W][,<O-,V2?IV ]A@5Q/@QC')=0,C(P
M 9MWUQ73U$I-^[T.7%8BM-*A*7N1V7374****S//%Z$$<$'(([5[Q\&_VG=0
M\)M#I/BAY=4TC*QQW;',UJOJ3C+K]>1Z]J\&HK2$Y4W>)W8/&U\#456A*S_!
M^J/TVL+^VU2R@N[.=+FUF0/'-&V593T(-6*^4?V4OBY+97Z>"]3EW6DV6TYR
M!^[?J8\^A[=>:^KJ]JG452/,C]MRW'PS+#JO#1[-=F%5+S2+'4'5[JRM[EU&
M TT2N0/3D5;HK4]49##';Q+%%&L4:C"HB@ #T %/HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#\X_\ @K9_R$?AQ]+K_P!EK[[^'?\ R3_PS_V#+7_T4M?
MG_!6S_D(_#CZ77_LM???P[_Y)_X9_P"P9:_^BEH Z&BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]3NX2%F@MI948C(#*A(X^HKYE_9Q_: \8_$CXB0:1K=_:W-D]I),4BMDC.X
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MZFFQQI#&J1HJ(HP%48 IU !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G'_P %
M;/\ D(_#CZ77_LM???P[_P"2?^&?^P9:_P#HI:^!/^"MG_(1^''TNO\ V6OO
MOX=_\D_\,_\ 8,M?_12T =#1110 4444 %%%% !1110 4444 %%%% !1110
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M6Z"LKW"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /SX_;R_
MY.]^!/\ O+_Z5+7Z#U^?'[>7_)WOP)_WE_\ 2I:_0>@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?G'_ ,%;/^0C\./I=?\ LM???P[_ .2?
M^&?^P9:_^BEKX$_X*V?\A'X<?2Z_]EK[[^'?_)/_  S_ -@RU_\ 12T =#11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBH6O_@KOO_C%'_#S#]FG_HJ%K_X*[[_XQ7YB_P##HG]HC_H$Z#_X.(_\*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\MK/'-!(\,T9W))&Q5E/J".E?37P5_:CEDFM="\92;VD;RX=8;"X[*LH _\
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MHKW3]Y"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K\[/^"UGC"?2O@3X,\.PRM&FKZZ9IU4_?2"%C@^VZ1#]5%?HG7YJ
M?\%O-'EF^%_PTU0 ^3;:Q<6S<<;I( P_]%-7+B/@7K'_ -*1T4/C?I+_ -)9
MC_\ !'[]ECPUJ'@:_P#B_P")='M=7U>>_>RT3[;$LJ6D<6!),BL,"1G)7=U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6CH^@ZAX@N##IUG-=R#&[RD+!<G SBI::=CEG2E&HZ6[3:T\BM9V<NH7D%K
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M% !1110 4444 %%%% 'YQ_\ !6S_ )"/PX^EU_[+7WW\._\ DG_AG_L&6O\
MZ*6O@3_@K9_R$?AQ]+K_ -EK[[^'?_)/_#/_ &#+7_T4M '0T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)_WE_P#2I:_0>OSX_;R_Y.]^!/\ O+_Z5+7Z#T %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !115:]U&TTV,R7=S#;1@9+3.%&!WYH$VDKLLT5Y]KGQ
MR\+:0K""YDU.89&RU0D9_P!XX&/<9K@M<_:,U*X9TTG38+./! DN"9']C@8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ<1,0!*$VI_WT<#%>@:'^SKJUTR/JE_;V,9 )C@S+)].R@_B:CVE2?PH\_\
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M4(H50%4#  ' I:*WC%15HH]W#X:CA8\E""BO(****HZ0HHHH **** "BBB@
MHHHH **** /SC_X*V?\ (1^''TNO_9:^^_AW_P D_P##/_8,M?\ T4M? G_!
M6S_D(_#CZ77_ ++7WW\._P#DG_AG_L&6O_HI: .AHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY^E3"ZJ.6Q4[>SL<A\1O^"@'Q,\87DJZ%/;>$=-)(CALXUEGQV+2N#S_ +H
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M=%,N>C#U]QR*^ZOAC\1M/^)_A:'6+%6A;/EW%N_WHI!U7W'H>]?G=7H/P/\
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MAL/_  X*_P![_$3I2T45H=X4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^<?\ P5L_Y"/PX^EU
M_P"RU]]_#O\ Y)_X9_[!EK_Z*6O@3_@K9_R$?AQ]+K_V6OOOX=_\D_\ #/\
MV#+7_P!%+0!T-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5\H?\%+OC5XS^ W[.,?B;P)K;:!KAUJUM3=K;
MPSGRG60LNV5&7DJ.<9XKZOKG_&WP_P##'Q*T4:1XM\/:9XFTH2K,++5K2.YA
M\Q<A6V.",C)P<=S652,I1M%VU7X--_>:4Y*+O)7T?Y'X,_\ #SC]IG_HI\W_
M ()]/_\ D>C_ (><?M,_]%/F_P#!/I__ ,CU^U/_  R!\#/^B.^!?_">M/\
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M HHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M110 444=* "BI;FUFLY!'/&T3E0X##JI&01Z@U%0/5:,****!!1110 4444
M%%%% !1110 4Z.5H)%D5BK(=P93@C'H>U-H;[IXS0!^B'PEUB?7OASH-Y=#;
M=-;*)4R<J1P <\YQCKZUUU>9_LZZ?+IOPMTU);C[7O9I$N.<2*<$$9].GX5Z
M97T%/6*N?T%@92GA:4I;N*_(****L[@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH _./_@K9_R$?AQ]+K_V6OOOX=_\D_\ #/\ V#+7_P!%+7P)_P %;/\
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M77/V<_V<9=:\*:I_8_BO4M3MM/TZ[$4<IC.3+(=DBLI_=Q.O(/WJ^._V=_\
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MB:0=P9&9GP?0$5]L>(/V"_@[KEP9H]"NM*)Y*:??2(A_ DX_"K7A7]AOX/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@#\^/V\O^3O?@3_O+_P"E2U^@]?GQ^WE_R=[\"?\ >7_TJ6OT'H ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@SQ"L[Z+K&HBVNEMI/+D*;6/RMC@Y K2G^]G[..]TOO,ZG[JG[66VOX'U/\
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MX5?AI_P4:_8/U+]GGQI?>-O".G2W7PRU:<S9@3<-'F=N8),=(B3^[<\<A#R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYT9N%16:"BBBD9A117J'P1^!&K_%_7T@%O<6VDHH>:[:)E0J>FUR-O\ ,\<
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MQ$\.>,=+\4^,;G4="OX=0MX;RYM&A>2-PRAPMN"5)'."#[UZ4/AA[3X.9_\
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M1'Q^\/?LS_#"]\=^*+/4[_2+2>&W>'2(HY+@M*X12%DD1<9//S?G7F/[+O\
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MW$@\W@<NG]]/<=.^*WA6C/3J>]@<XP^-?(O=EV?Z'JU%%%;GN!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "JNIZG::+I]Q?7UQ':V=NADEFD
M.%11U)JU7QO^U!\7&\6:^?#.F3M_9&G/BX9"0)YAU!'=5[>]8U:BIQN>/FF8
MPRS#NM+5[)=W_6X_XM?M2:KXH>;3?"S2:/I62IO <7,X!Z@_P*1VZ^XZ5X1(
M[22-([,\C'+.QR2?4GN:;17C3G*H[R9^*XO&U\=4]I7E=_@O1!11169PG:_#
MOXO>)/AG>*^EWC2V6<R:=<,6@?UXS\I]Q^M?:7PM^+FB?%;2WGTUF@O(,"YL
M9\"2,GN,'E<]#_*OSXK=\$>,M0\ ^)K/6]-(^T6[<QL3MD0_>1L=B*ZJ-9TW
M9['T^49Y6RZ:A-\U/JNWFO\ +J?I#16'X+\76/CGPS8:UI[[K>ZC#;>Z-_$I
M]P:W*]A.ZNC]FA.-2*G!W3U04444RPHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *\E_:-^*;?#OP:;>Q<+K.IAH+<@C,2X^:3&#T_F:]:KXC_:J\07&K
M_%::SDRL&FVZ11+G(^;YF/3C/'Y5SXB;A"Z/G,_QLL%@92INTI:+Y[_A<\>)
M+,23DDY)/<GO2445XA^)!1110 4444 >]?LM_%B;PYXBC\+:C<,VDZ@V+;S&
M^6";T''1OJ!FOL2OS,TK4I-'U.UOH@IEMI%E7< >0<]Z^GI/VA_$U_8PF"*R
MLRRJP=8R[XQT.XD'\A7HX>LHQY9'Z-P_G4*&&E0Q#;Y=O3L?2M(S!5))P!R2
M:^3-2^*7BK5/-$VM7$:2=4@(C ^FT C\ZQ))=4UR1IW:]U%P-IE)>4CT!/-=
M'UA=$>]+B"G>U.FW^'^9]97WCKP]IJH;G6K&,,<#]^IY_ US6H?';PE8JWEW
M5Q>NK;=EO WY@M@$?C7A6G?#'Q3J3 0:%=+E=P:91$I'U8@5TFG?L_\ B>\\
MHW#6=BC#+>9*79/8A1C\C2]I4EM$R_M+,:W\*C;Y/_@(ZS4OVD;1/-6PT::7
M'^KDN)0@/U SC\ZYO4/VB/$-PS?9;2QLT*X&5:1@?4$D#]*W--_9M^5&O]<.
M[=\Z6T'!7V9CP?PKIK'X >%K56$PO+TDY#33[<>WR!?UHM6D/V6<U_BER_<O
MRNSQB_\ BUXMU H9-;GCVC'[A5B!^NT#-8#7&J:_((3)>ZDX)<1[GF(]2!S7
MU78?#CPQIK,8-"L@6&#YD0?_ -"S700V\5O&J11I&BC"JB@ #T%'L9/XI!_8
MF(K?QZU_O?YL^2]-^&GBC5/*,&B7023[LDJ^6OXEL8_&NET_]G_Q1=JK3FRL
M1NP5EF+,!Z_*"#^=?2=%4J$>IU4\@PT?CDV>(6/[-8P_VW76)S\OV>W X[YR
M373V'P!\*VC$S)>7V5QMFN"H!]1L"G]:](HK14H+H>C3RO!T]J:^>OYG-Z;\
M.?#.DLC6VB6:R(NT.\8=L>Y.<_C6_;VL-G"(H(8X(EZ)&H51^ J6BM$DMCT(
M4J=/2$4O1!1113-0HHHH ^5OVIO@RUK/)XST6W9H9"!J-O#&,1\?Z[CGGH>#
MZU\U5^GDD:31M'(H=&!5E89!!Z@U\X?%G]E&#49I]5\';+29ER=)X6)F]48G
MY?IT],5YU?#MOF@?F^></3G4EBL&KWWCY]U_E]Q\I45M^(/!.O>%=W]KZ3=:
M=MSN\],8YQG/H3T]>U92V=P\D*+;S,\XS$HC),@]5&/F_"O.LUHS\[E3G!\L
MDTR&BM+2?#>IZY<R6]E9R331ML=>%V,>@;.,'ZU[?\+?V6]1UQH;WQ)'+IMN
M&#?9Y4P67T*G#9/OC'^U5PIRF[11VX3+\3C9J%&#?GT^\X[X'_".^^(7B*UN
M)H6CT:%]TLV2I..A7UY]Z^YK&RATVSAM8$"0Q*%4  ?RJGX;\,Z;X2TJ'3M*
MM5M;2(8"KDD^Y)ZUJ5[%&DJ2\S]ARC*H971Y=YO=_IZ!1116Y[P4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 45G:YXBTOPS8M>:OJ-KIE
MHH),UW,L:\=>2:\EU_\ ;&^%>AQR&/7I=6FCD\LPZ?:2N3ZL&950CW#?3-2Y
M1CNSFJXFC0_BS4?5GM=%>"Z-^VU\+M4N'CGO]0TI57<);VQ<JWL/+WG/X5ZE
MX-^)WA3X@0"7P]K]CJN1DQPR@2KQG#1G#*<=B!24XRV9-+&8>N[4ZB;]3J**
M**LZPHHHH **** "BBB@ HHHH **BN+J&SB,L\J0QCJ\C!0/Q-<3K_QP\%>'
M0XGUV"YF7=^YL\S,2.J_+D _4BDVEN9SJ0IJ\Y)'=T5\^>(OVM+.-9$T/19K
MA\X6:^<(G3KM7)//;(^M>:Z]^T1XWUQF":C'ID1.1'8Q!<<=-S9;'XUDZL4>
M74S7#4]$[^A]C7E];Z?;M/=7$5M O629PBC\37!>(OC[X*\.JP;51J$RDCR=
M/7S6R.HSPH_$BOCV2?6?%EY^\DO]9NN%^9GG<9/ [X&:[/P_^S]XWUYD)TG^
MS8&)!EOW$>,?['+?ICWJ/:RE\*.!YI7K:8>G^IZ+KW[6S9=-%T' R0LU]+^1
MVK_+/XUYSKW[0'C?7MP.K_V?$2#Y=A&(@./[W+8^IKTW0?V2(%PVM:_))US'
M81!/H=SY_+;7HV@_ ;P3X?9'CT:.\F4AA)>L9CD#&<'CGTQBCEJ2W8?5\QQ'
M\2?*OZ['Q[:V>M^,]0"017VMWG3C?,P!/<G.!GUXKO-!_9N\;:TJO-9V^DQ,
M P:^F ;KC&U=Q![\XK[ L[&WT^W2"UMXK:",;4CA0(JCT '2IZ:HKJS:GD]-
M:U9-O[CYBUO]CA=0\)ZG!/KK7.HM"YMTB@"1^8!E,Y)/7^=?">H:?=:3?7%C
M?0/:WMM(8IH9%*LC@X((-?L37R9^U]^S7/XD:3QMX3L5DU&-"=3L;=#YER!T
ME4=W Z@#)'KBLZU'2\3S<WRB/LE5PT=8[KNO^ ?$5%*RM&S(ZLCJ<%6!!!]"
M.U)7 ?!!1110 5;T?2;G7M4MM.LX_-N;EQ''&",DGTR0,_C5:*&2>0)%&TKG
MHJ*23^%?;O[)_P"S6WATP^+?$*;[B:+]Q9R*-BY((;&,\>_'M6D(.;LCT,#@
MZF.JJG!:=7V1[K\$? LGP]^'.DZ5.S27:Q!YFDY8$C.TG Z=/;ISUKO***]9
M*RL?KE.G&E!4X[(****9H%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!E>)O"^D^,M'GTG6]/@U/3IQ^\M[A RG'0^Q'8CD5\G_$+]@DW&H75[X2
MUQ(X) 633KY HC;C $BC[H'8KD^O4U]BT5G*G&>Z.#%8'#XQ?OHW??J?FCK7
M[)7Q-T6":9_#TEPJOMACM9%FDF&>N(RP7CGYB/;)J71?V1?B1K*VL@T9[>-R
M/M"S8BEM_JLI17/^XQ'N*_2FBL?J\3Q/]7<+>_,[?+_(^1OAO^PM%I>I07_B
M74XYU10?L<:++\W<DL-OTRIQ[]:^I_#_ (=TWPKI<6GZ59QV5G']V.,8&>Y/
MJ:TJ*WC",-CW,+@:&#5J,;?F%%%%6=P4444 %%%% !1110 4444 %%%% 'YQ
M_P#!6S_D(_#CZ77_ ++7WW\._P#DG_AG_L&6O_HI:^!/^"MG_(1^''TNO_9:
M^^_AW_R3_P ,_P#8,M?_ $4M '0T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'RA_P %2?\ DR'Q_P#[]A_Z6P5^0_\ P3__ .3R_A/_ -AA?_1;
MU^O'_!4G_DR'Q_\ []A_Z6P5^0__  3_ /\ D\OX3_\ 887_ -%O1@O]Z_[>
MC^@8S_<_E(_HGHHHH *_F:_:,_Y.$^)__8T:I_Z5RU_3+7\S7[1G_)PGQ/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME_F>V_\ "_?"?_/6\_\  8TC?'[PHJDB2\8@<+]G//M7D_\ PHSQA_SX0_\
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M9=7<]_=37-U-)<W,SF26:5BS.Q.223U-<M:KR^['<^4SG-987]Q0?OO=]O\
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M=H6WB5!CTX%7J:H]V:0R>+=ZLV_Z^9\UZ!^R3<R;7UK7HXESS#8Q%B1C^^V
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ML]3\41JT<$,)RKQ6Q."[,,@R8VA3\I8G*_E/>65QI]P8+J"6VF"JQCF0HV&
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M)_E_PWJ>?2TC9]W^;_34[*BBBN8W"BBB@ HHHH **** "BBB@ HHHH ****
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M"KMQTAAU.X#'_OJW _6OG?XU?L;_ !B_9\LS?>-O!%]8:0&V_P!K6K)=V8Y
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M]/DR?:OMBBO5P69XC NU)Z=GL>E@\PKX+^&].SV/S"U#P'XBTF:>*\T6]MC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !15#5=>T[0X3+J%];V4?K-
M(%S],]:\ZU_]H30]/W)IEO/JL@Z-CRH_S(S^E1*<8[LY*V+H8?\ BS2_/[MS
MU2JFI:M9:/;F>^NX;2$?QS.%'ZU\Z>(/CQXDU@LEFT.DP'H(%W28]V;^@%<,
MS:GXFO\ DW>JWCD?WIG/IZFL)5U]E'@5L^II\M"#D_N_X)Z;^T'\2O#GBCX?
M:KHUCOU*Z.V2.94Q%&RMG=N.,D>PQ7Q?JBQWQ6-QNC4YVY."?<=Z^C_&7@+7
M/"/@#6/$FJVRV%G:6Y?RY3ND<G@#:.G)[XQ7R-<>(KF480+"/;D_G7#6YI2O
M(^&S=XC$XB-:O'E=O33\SHL16L?\$2#Z 51N/$%K#D(3,W^ST_.N:EFDF;=(
M[.?]HYIE9<IY,:*^TS5G\17,A_=A8A],FH'UR\=<>=CW4 &J-%.R-O9Q70M?
MVK>?\_,GYU+;:Y>6TR2"=GVGE6Y!]JH44[(.6/8^TOV.?#\/B"_O=8N;:*ZL
M'@*QQ7$(8*X(!89Z^G'K7U=#X>TJUF26'3+.*5#E72W164^H(%?)/[ /BN%8
M?$/AS_EN2+T#<2<?=SC&%'XDD^E?8U>E0BE!'Z?D-"E# PY5??[[B44M%=)]
M(%%%% !1110 4444 %%%% !1110 4444 %%%% !7DO[1GPK?XC>#_M%A'OUK
M3=TUNJKEIEQ\T><CKV]Q7K5%3**FG%G+BL-3QE&5"JM)'YAR1O#(\<B-'(A*
MLCC!4CJ".QIM?6'QV_9H.O75UXC\)QI'>L&DNM, P)V_O1]@Q[CH?K7RQJ&G
M7>DW36U[;36=ROWH9T*.OU!Y%>'4IRINS/P[,,MKY;5<*JTZ/H_Z[%:BBBLC
MR@HI\,+W$R11(TDKG:J(,LQ] *]L^#_[..K>*M0@U#6819:5$^6CF!#2>FWC
M##\?KZ5<82F[1.W"8.OC:BIT8W?Y&U^RS\*6U6^3Q5?1DV<)(M^05<CC![]?
MP[&OK6J>DZ3:Z)I\-E9Q+#;Q#"JH_7ZU<KVZ=-4XV/VW+,OAEN'5&.KZONPH
MHHK4]8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LDBQHSNP1%&
M2S'  ]37RA\</VW+/0I)]'\ "'4[Y3LEU>9";>(@X(C4XWG_ &ON_P"]6%^V
MA^T#<?;)/ /AV^\J%5_XF]Q 1EB>D 8'C_:& >@KX\Z<#I7%5K-/EB?$9MG4
MX3>'PSM;=_HO\SI/%WQ(\4^/IS+XAUZ^U4YW".>4^6ISV084=>PKFRH/) )I
M:*XM]SXB4I3?-)W9<TG6M0T"]2\TR^N=.NT^[/:RM&X]LJ1Q[5]%?"']MGQ-
MX5NHK+QB6\2:0QP;K:!=P\]<C <>Q&?0]J^::*J,I1U3.G#XNOA9<U&5OR^X
M_7?PGXPT;QSHL.K:%J$&IZ?+]V:!L@'NI]".X/(K9K\P_P!GGXX7OP6\91W#
MR3S>'KQ@FH6,;#!'02@'C<OX9&1FOTRTO4[76M-MK^RF2YM+F-98I8V#*RD9
M!!%>E3J>T7F?IF69C',*=]I+=?KZ%JBBBMCV0HHHH **** "BBB@ HHHH **
M** "BHY[B*UC,DTB11CJTC!1^9JC<^)-)L[>2>?4[.&&,;GD>=0%'J3F@3DE
MNS2HKEF^*?@Y5+'Q1I) &>+R,G\LUC?\+_\  '_0PQ_^ TW_ ,14\R[F#Q%&
M.\U]Z/0J*\CD_:@\$QR.H?4'"D@,MJ<'W'/2LFY_:R\/1W+I!I&I7$0.%E^1
M=WO@MD4N>/<P>.PT?^7B/E_]M?QJ_B;XR2Z6I86NB6ZVRJP(S(WS.<9(/48.
M!WKP&NI^*?B27QA\1O$6LRLY-W>.ZB3&Y5X"J<<< 5RU>5-\TFS\JQE7V^(J
M5.[?_ "BBBH.,**** "M7PGXBN_"?B73=9L9C;WEE,LT4@_A(]1W'MWK*I]O
MN^T1;(?M#[UVPD$^8<\+@<\]./6F5%N+36Y]):S\0_$?BQ =1UN]NXYE_P!2
MTI5"&YV[!P?I5W0?A7XM\2L/L&@7CJQ(\R9/)3(Y^\^!7U/\#?#FF6OPX\/W
MJZ+9V&HS6@,Y2 "16R<H6/S<'C!/:O1Z]&-*^K9^C4<J]M%5*U1N_P#6[/ES
MP_\ LGZU>+')K&K6NG*?O0VZF9QQZ\#/Y_6O2-!_9C\':3L>\2ZU>88)-S-M
M3(]%3'!]"37K=%:JG%=#UJ>78:GM&_KJ9&A^$=$\-(%TK2K2PP-NZ"%5;'IG
M&:UZ**T/0C%15HJP4444%!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^<?\ P5L_
MY"/PX^EU_P"RU]]_#O\ Y)_X9_[!EK_Z*6O@3_@K9_R$?AQ]+K_V6OOOX=_\
MD_\ #/\ V#+7_P!%+0!T-%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!XE^V=\$==_:*_9T\4> ?#=WI]EK&J-;&&?5))([=?+N(Y6W,B.P^5#C"G
MG'UKX4_9?_X)2_%KX*?'_P $>.=<\1>"[K2=#OQ=7,.GWMV\[J%8817M54GD
M=6%?JQ113_=3]I'>]_N"I^\I^SEMK^(4444 %?D!\5_^"/WQD\=?%+QCXEL/
M$O@6&QUG6;S4;>.YO[Q95CFG>10X%H0& 89P2,]S7Z_T5'*G)2ZK];?Y%<SY
M7$YSX;>'+GP=\._"V@7KQ2WFE:5:V,SP$F-GBA5&*D@$KE3C(!QV%='116TY
MNI)SEN]3*G!4X*$=EH%>/?M)?LI_#_\ :H\*QZ/XUTUS<VNYK#6+)A'>V3'J
M8W((*G RC J< XR 1[#164HJ2LS6,G%W1^+_ ,4O^",/Q4\-WES+X'\0Z'XR
MTQ1F&*YD:PO6_P!DHP:+\?-&?05Y-#_P2Q_::EN!$WPZCA3./.?7M.VCWXN"
M?TK]^:*<583=S\AO@S_P15\5ZEJ,%U\4/&.GZ)I:E6?3_#I:YNY!W0RR(L<1
M]P)![5^H_P )?A!X2^!O@FR\)^"M&AT71;49$462\KD#=)(Y^9W.!EF)/ [
M"NRHK3G=N5:(SY5?F>X5\D?MI?\ !._PC^UE(OB&TOCX3\?00B%=6BA\R&[1
M?NI<1Y!; X#J0P!YW !1];T5C**E:_0VC)QV/PB\8?\ !)']HKPU>&'3=!T?
MQ9%VN-)UF"-/RN3"WZ5)X-_X)&_M$>)KKR]3T;1?"47>;5M8AE7\!;&8_I7[
MLT5:TWU(>I\+?LN_\$G_ (>?!/4+3Q#XUNA\1?%%NPDACN;<1:;:N.A6 D^:
MP_O2$CH0BD9KS/\ ;4_X):^._CY^T!K7CWP-KGA?3M-UB&W>YMM:N;B&5+A(
MQ&Q416\@*E40Y)SDMQTK]-:*)^^TWTV_K^MD$?<32Z_U_7S/ OV(?@WX\_9_
M^ NF^ ?'U_HNIWFD7,RV%UHES-,AM7;S%5S+%&0RN\@X!&W;S7O-Q;Q7=O+!
M-&LL,JE'C<9#*1@@CT(J2BJJ2=5MSZ_U_P .3"*IJT3\?OVEO^"._C/3_%FH
MZO\ !ZYL-<\.74C30Z'?70MKRS+'/E([XCD0=F9E;& 0<;CY9\,?^"7?[2]G
MXWT;49/"FG>&WT^\AO([W4M;M'C5HW#CBW>5^H[+7[J44J+=&2E'6W<JK:LF
MI==SRW]ISX7:O\:OV?O&O@?1;BRM-8US3S:P37[NENCEE.7959@.#T4_2OSY
M_9?_ ."4OQ:^"GQ_\$>.=<\1>"[K2=#OQ=7,.GWMV\[J%8817M54GD=6%?JQ
M14P7LZOMH[Z?A=K\Q3_>4_92VU_'0****8S\ZOV_O^"=/Q(_:J^.5KXS\)ZW
MX5T_2XM&M].:'6;NYBF\Q))F) CMY%VXD7'S9X/%>_?L ?LS^)_V5/@E>>#O
M%E_I.HZG-K$^H++HLTLL(C>.)0"9(XVW9C/\..1S7TO13IOV491CL_\ ._YB
MJ?O)*4NG^5OR"N/^,?@^]^(7PC\;>%M.E@AU#6]$O=-MY+IF6)))H'C4N5!(
M4%AD@$X[&NPHK.<5.+B]F:0FZ<U..ZU/R*^"G_!(CXQ?#?XQ>!O%FI^)/ \^
MG:%KEEJ=S%:7]XTSQPSI(P0-:*"Q"G ) SW%?KK116[FW!0Z)M_?;_(RY5S.
M15U32[/7--NM.U&TAO["ZB:"XM;F,21RQL,,C*>"""00:_-;]HW_ ((SZ/XF
MU*[UKX0>(H?#,LS%SX>UO?)9*Q(_U4ZAI(UZ_*RR<G@J.*_3.BL'!-\W4U4F
ME;H?@GK_ /P2B_:3T>^>WM/!ECKL2G NM/URS6-O<":6-OS6NA\!_P#!(#X^
M^*KA!KEOH/@RVW#S'U+4TN)-O&2JVPD!(]"R].O>OW+HK2.F^I#UVT/D[]D3
M_@G/\/\ ]E>YCU]YY/&/CG84&N7\*QI:@C#"VARPCR."Q9FZ@$ D5]8T454I
M.6Y,8J.QX#^W'\ ?$/[3'[/>J^!/"]YIEAJ]W>6MPDVKRR1VX6*4.P+1QNV<
M#CY?RKY0_8=_X)H_$_\ 9H_:$TCQWXGUWPE?Z19VEU!)#I-Y=27!:6(HI"R6
MR+C)Y^;\Z_2VBHI_NI2E'=_JK?D.HO:Q49=+?@[_ )A1110,^.O^"C7['/C/
M]KSP_P"";'P=J>@Z;+HEU<S7#:Y<31*ZR(@4)Y4,F3E#G..U<]_P3E_89\>?
MLA>(?&U_XQU;P[J4.MVMK!;+H=S<2LC1O(S%_-@CP,.,8SWK[FHI4U[)N4>M
M_P 58=3]Y%1ET_SO^85\@_M\?L#6?[7FFZ=K6B:G;Z!X]TB!K>VNKM2;:\@)
M+"&8J"RX8DJX#8W,-ISQ]?45,H*=K]"HR<=NI^!^J_\ !*?]I73]3>UM_ ]I
MJ<"M@7MKKEBL3#U DF1\?50:_4/_ ()P?L]>/?V:?@;J/A;Q]_9\=Y<:O)J-
MK;V-UYY@C>*)61R%"YW(Q^4L.>M?5M%;1FX1<5UT_%/]#&45)IOI_P ,%%%%
M06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5\5_P#!6/XWZC\)/V9'TC1IWM=3\7WHT=IXVP\=KL9Y
M\?[RJ(S[2&OM2OS:_P""W'AVZO/A-\.M;C1FM;'69[69@.%::'<I/_?EJY<3
M\"7=I?)M?\,=&'^._9-_<F<S_P $??V4="OO#=U\:?$=A#J.IF\DLM CN%W)
M:B/B6X /&\L2@/50C$?>X_4NO@S_ ((\?%C2?%G[-,O@J.=$USPMJ$_G6I/S
MM;SN98Y0/0LTB_5/<5]YUZ>(TDHK:RM]R_IGGT=F^MW^>GX!574],L]:TVZT
M_4+6&^L;J)H9[:XC#QRQL,,K*>"""00:M45RM)JS.E-IW1^#'[7_ ,-[O]@O
M]LRRU;X?SMIUBIA\1:)'DD0QN[K);,<Y9-R2)@]48 YYK]R? /B^T^('@7P[
MXHL/^/+6M.M]1A![)+&LBC\FK\4O^"NOQ6TOXC?M1II.D7,=W!X5TN/2KF:(
MAE^U&1Y95!'7;O53Z,K#M7Z^?LO^';OPC^S?\,-&OD,5[9>&]/BGC8<HXMTW
M+^!R/PJL,W+!N_26GH^;[]$OZ8L0E'%*W6.OKI^3;/SU_P""SO[/6B:19^&?
MB[H]E%8ZG?7O]CZR84"BZ8QL\$S8ZN!$ZENI&S^[7T3_ ,$D_B)<^./V0M.L
M+N5IIO#>IW.D*SDD^4-DT8^@6<*/917(_P#!9[Q19:7^S/H&BR2+]OU3Q%"\
M$.[#%(H96D?'< L@_P"!BF?\$6])GL_V9?$M[*C)%>>)YS"2.&5;:W4D?\"R
M/PI8/X,1#HK6_P#)?\W]X\5:]"75_P#VW^2^X_0&BBB@04444 %%%% !1110
M!\R?\%)_#-OXG_8L^),<ZJ6LK:&_B9OX7BN(VR/<@$?C7YY?\$6]8FL_VFO$
MFGJ3Y%YX8G9US_$EQ;E3_P"/-^=?>O\ P5&^(5IX$_8W\86TTR1WNOM;Z1:1
ML1F1GE5Y ![1)(?PKX:_X(H^%YM0^/WC/7]F;;3?#IMF;TDFN(BH_*%Z,'_O
M-5K;E?W\K_3E'BK?5X7WYOPYHV_&Y^S%%%% @HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/C]O+_D[WX$_[
MR_\ I4M?H/7Y\?MY?\G>_ G_ 'E_]*EK]!Z "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#.\1F=?#VJ&U\S[2+67RO*SOW[#C;CG.<=*^7OV:[SXF3?$
M:!?%3^*&TO['(6_M9;@0[\#&=XQFOK*B@ HHHH **** "BBB@ HHHH ****
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M> =T;/RO/TK\ZJ_37]JOP^WB+X$^)X8[>.XF@A%S&)"!L9"#N!/<#-?F2&#
M$=#S7!B/C/@N(HM8N+>SBOS8M%%%<I\L%%%% !1110!]%_L,ZA=6OQ>:WAM2
M;>ZM95GNMK':%7<L>>@R>?7CTK]!:_-+]F_QUJ/PW\17.KVEO#>0O&4:"XR!
MGIN4@\-CC.#P:^N?#?[5VA7B(FMZ==:9,2 TEN!-$/4GHP'L 37H49)1LS]
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MBBO8/V2*Y4D@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G'
M_P %;/\ D(_#CZ77_LM???P[_P"2?^&?^P9:_P#HI:^!/^"MG_(1^''TNO\
MV6OOOX=_\D_\,_\ 8,M?_12T =#1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH _/C]O+_D[WX$_P"\O_I4M?H/7Y\?MY?\G>_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%?./QZ_:4?0+J7P]X2GC>_3*W>H@!EA_V$[%O4]OK6<ZD::O(
M\_'8ZAE])UJ[T_%^AZ_XV^+/A7X?+MUK5HH+D@E;6(&29O\ @*Y(^IP/>O']
M8_;0TJ(3+I7AV\N6!_=/=3+$K#U(&XC]:^5KR\N-0NI;J[GENKJ9MTD\SEW<
M^I8\DU#7FRQ4W\.A^98KBG&U9/V%H1]+O\=/P/I[3_VU";C_ $_PKLM\'FUO
M-SY[<,@&/QKT#P?^U)X)\3M'#=W$V@W;D*$OT_=DD]/,7*CZMBOB&BICB:BW
MU.>CQ-F-)WG)27FE^EC].H+B.ZA26&198G&5>-@RL/4$5)7P?\(_CQK?PNN$
MM69M3T%F >QF<GRESR8C_"?;H?UK[;\+^*--\9:':ZOI-PMU97"[D<<$>JD=
MB.XKT:5:-5:;GZ/E><4,TA[NDUNO\NZ-6BBBMSW@HK.U;Q'I>A+NU'4;:R'8
M32JI/&> 3D_A7GFO?M":%I^Y--MY]5D'1O\ 51_F1G]*B4XQW9R5L90P_P#%
MFE^?W;GJE4-6U[3M"A\W4;Z"RC]9I N?IZU\X>(/CAXGUK<D%Q'I<!XVVBX;
M_OHY/Y8KCH+75/$U\?*BN]4NV.25#2N3WR>:PE76T4?/UL^A?EP\')^?]7_(
M][\0?M!Z'I^Y-,@GU24='QY4?YMS^E>;>(/CAXGUK<D$\>EP'^"U7YL>[')_
M+%6_#_P#\1:JRO?M#I,)Z^8?,D_[Y4X_,UZ3H'P%\-Z3M>\$VK3#J9VVIG_=
M7^I-3^]GY'-RYMCM_<C]W_!/GF"UU/Q)?'RHKK5+MCR0&E<_4\_K7>Z#\ O$
M6J;7OF@TJ$\XD;?)C_=7@?B?PKZ)L=.M-,A$-G:PVL*](X8PBC\!5FJC07VF
M==#(*47S5Y.3^[_@GFWA_P" OAO20CWBS:M..IN&VQY]D7^I->@V.GVNEVZP
M6=M%:PKTCA0*OY"K%%=$8J.R/H*.&HX=6I02"BBBJ.D**PO$WCC0?!L!EUC5
M+>R.W<L3N#(X_P!E!\Q_ 5X1XT_:NFF6:V\,Z;Y /"WUZ<M]1&.!^)/TJ)34
M=SCKXRCA_P")+7MU/H?5M9L=!L9+S4;N&RM8QEI9W"J/SKQ3QI^U1I=@DMOX
M;LWU.Y!*BZN08X![@?>8?E7SY?:MXC^(.J1K<W%_KMZS8CB^:4J3V51PH^@
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M+UNSN9&&1#YH67\4;#?I6RE%[,]:EBJ%;X)IG1T4451UA1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI.*_+VI+>XEL[B*X@E>">)@\<L;%61@<@@CH:N-><=]3KPV?8NC+]X^=>?\
MF?L917RO^RO^U1=^.K^+PAXOE$NMLI-EJ(4*+@*.4<#C?CH?XOK7U17?&2FK
MH_0<+BJ6,I*K2>GY!1115G8%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ^K[A1116AZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]UK6MZAJ'_"XH8?M=Q)/Y?\ PC9;;N8MC/VKG&:I?\.-+O\ Z+-#_P"$R?\
MY+K]7**48J,5%;(J4G.3E+=GY1_\.-+O_HLT/_A,G_Y+H_X<:7?_ $6:'_PF
M3_\ )=?JY15$GY1_\.-+O_HLT/\ X3)_^2Z/^'&EW_T6:'_PF3_\EU^KE% '
MY1_\.-+O_HLT/_A,G_Y+KZF_87_80F_8SOO&%Q+XU3Q;_P )!':QA4TLV?D>
M29#G_72;L^9[8QWS7UM15QDXWMU)E%2T84445!04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?GQ^WE_R=[\"
M?]Y?_2I:_0>OSX_;R_Y.]^!/^\O_ *5+7Z#T %%%% !1110 4444 %%%% !1
M110 4444 %%%% &=XC6=O#VJ"U\S[2;641>5G?OV'&W'.<XKY=_9JT_XEVWQ
M'@?Q5'XG72_L<@8ZL\YAWX&,[SC-?6=% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^+NE_"W34:X'VS5)P3;6*-AF_P!MC_"N>,]^W?'3^*O$,'A/PYJ6L7*L\-E
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MK222,QLT4BAE)4\@X(X-4X.W-T)4E>W4WJ***@L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /SX_;R_Y.]^!/^\O_I4M?H/7Y\?MY?\ )WOP)_WE
M_P#2I:_0>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **SO$B3R>'=4
M6U#FY:UE$0CSNW;#C&.^:^7/V:=!^)&G_$B"7Q1!XBCTP6<@9M3EE:+?@8R&
M)&: /K2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHKG, HHHH **** "BBB@ HHHH _./_@K9_R$?AQ]+K_V6OOOX=_\D_\ #/\
MV#+7_P!%+7P)_P %;/\ D(_#CZ77_LM???P[_P"2?^&?^P9:_P#HI: .AHHH
MH **** "BBB@ HHHH **** "OG74_P!KO^S=2N[3_A$_,\B9XM_]I8W;6(SC
MRN.E?15?*>L?LI^+=0U:]NH]1T58YYWE4-/-D!F)&?W77F@#9_X;(_ZE#_RI
M_P#VFC_ALC_J4/\ RI__ &FN:_X9'\8?]!+0_P#O_-_\:H_X9'\8?]!+0_\
MO_-_\:H B^)W[2$GQ$\(W.A)H)TQ9WC9YA>^;D*P;;M\M>X'?M7BU>I^-/V=
M/$W@7PW=ZW>W6F7-I:[?,2UED:3#,%R T8&,L,\UY90 4444 %=A\*_B)+\,
M?%0UB.T^WHT#P26_F^5O5L'[VTXP54].U<?75_#OX;ZM\3M8GT_2FMXI(83/
M)-=,RQJ,@8RJMR2>!CL?2@#VC_ALC_J4/_*G_P#::/\ ALC_ *E#_P J?_VF
MN:_X9'\8?]!+0_\ O_-_\:H_X9'\8?\ 02T/_O\ S?\ QJ@#I?\ ALC_ *E#
M_P J?_VFO4O@_P#%C_A:^GZC=?V5_9?V.58MOVCSM^1G.=BXKPC_ (9'\8?]
M!+0_^_\ -_\ &J]F^ _PMU7X7Z7JMMJMQ9W$EU,DB&S=V  4@YW*M 'J5%%%
M !1110!^/_\ P6\_Y*M\-?\ L"W'_H^OU(^!?_)$?A[_ -B[I_\ Z31U^6__
M  6\_P"2K?#7_L"W'_H^L7P9\2O^"A5OX/T*+P]9Z^= CL(%TXQ^'-+=?LPC
M4189H"Q&S;R3D]ZSP<O]FG&V\W_Z5/\ S'B(WQ$)7VC^:C_D?LU7Y+_\%O?&
M.C7WB+X8>&;>:&;7-/@O;V[C0@O#%,85B#<\;C$YP?[N>_.-_P )E_P4B\3*
M^G_9_$4(F4@O_9&E61';B7RDVGGLPKH?V;?^"5?Q \9?$JW\??M#:H)$6Y6\
MN-'FO_[0O]2D4C"W,X+((^%SAW+ %?EZU7LG5G&[M%._]?UY#57V2;2NVK??
M_7ZGV=\#_#]_X7_X)^^'M,U-'COH? C-)'(,,FZT9PI'8@,!^%?%W_!#G_D.
M?%W_ *]M,_\ 0KFOTU^+"+'\)O&2JH55T2\ 51@ >0_%?F5_P0Y_Y#GQ=_Z]
MM,_]"N:UI3]IC*\UUBG^,C*<?9X2E#M*W_I)]Q?MC_MB>&_V0/ 5MJVIVC:U
MX@U-VATG1(I1&UPR@%W=\'9&N5RV"<LH YX^(-%_:'_;]_:.TF'Q/\._"EKX
M=\.7&6M7M;&PMXYT[,K:B[-(,?QI\IYQ7VY^TM^P]\-OVJ-<TK6O&\FM17NE
M0?9X)--OQ"@BWERI1E9>2>6P#C'/ QT6L?M3? OX9VHTJ\^)W@W2DTU!;#3H
M-6@>2W5!M">3&Q9< 8QCM6$4DG*H];Z+I8VDW=*"TMJ_/^OZ[?G%KG[=/[8O
M[)OB#3U^,_AFWUC3;IQC^T["WACF Y9(;JRQ$),>H?'!*U^H'P'^-&A_M!_"
M?P_X]\/>9'IVK0ES;S8\RWE5BDD3X[JZL,]\ C@U^?/_  42_;P^!?QJ_9WU
MKP-X2UNX\5>(+JZMIK2:'3)XH;5XYE9G,DRIU3>H*!L[L="37LO_  1YD=_V
M/U#,S!/$%\J@G.T;8C@?B2?QKHHWJ0J*2^'5/RT7Z_@85K4Y4W%_%=-?)O\
M3\?0[#]N#]OSP]^R'8VND6E@OB;Q[J,)GM=*,OEPVT62HFN&&2%)!P@Y;:>5
M'-?)6B_&3_@HC\:M-B\6^$M"&B:!=+YMO;1:=I=K'(G4,BWQ,S*1T8$@@\&O
M//AGI,'[67_!5S6IO$\:ZEH]AK=]<&UG^9'M[$-';QD'JNZ.+(Z'YLCDU^TX
M 4  8 Z"L:4>:C&M)ZSU2Z)=/7^NEK;5)6JRI1VCHWW?]?AYW/S2_9J_X*>^
M,=-^+4/PK_:(\.0^&]8DN%L4UA;9K-[>X;&P74))7:Y(Q*FU1N4X*DL/T2\;
M^-M$^''A'5O$_B/4(M*T/2[=KF[O)C\L:*/0<DG@ #DD@#)-?-?[8G_!/?PU
M^UYXQ\,^([SQ#<>%;_2X)+2[FL;))9;Z$L&C4NS#84/F8.&^^>F*\#_X+&>-
MK_P+\ _AO\.H-2N+I=6NBU[=3,/-NX[.*, R8P#NDE1SQC<E34J/V*;5IWMY
M/S^6]O\ ARJ=-.M9:PM?S5M6OG_78X[Q%_P4B^/W[37CR^\,?LW>!VM=/@Y6
M^ELX[J\"9.)9GE/V:W5L<*X//\9/ J:]^T]^W=^R[;)XE^*GA>#Q#X7$BK<-
M>65C)#$I(',VG$>43T#29&2.#TKT#]AW]L3]E_\ 9O\ V=?#7AN[\<1Z;XGN
M(OMVNXT/4)'>\?EE:1+<J^P;8P02,(,&O<]7_P""F'[*NOZ5>:9J7Q"AOM/O
M(7M[BUN/#NIO'+&P*LC*;7!!!((]ZUG'V/NTW=KJ]4W_ )?\/;H90E[36HK)
M]%NOZ_I]3TK]E']JSPI^UG\.5\2>'@UAJ-JP@U71;B0--8S$9 )&-R-@E7P-
MP!X!#*/A'_@N/_Q\_"#_ '-4_G:UY/\ \$U?'VF> ?V^=4\-^$-2>^\#>)7U
M+3K*1@\:SV\?F3VLA5PK!ML6!N /SL,#->L?\%QN;KX0 ==FJ?SM:C$)25&I
M%6YM;=MU;^O^";8>\9U:<G?E3U[KO_78KZ#^VY^T+\=M!T/P-^S+X(E2P\.Z
M/9V-[XANK:!Y&FC@16^>X86\2DAMJMN=@-W'(%&X_;P_:T_9(\4:;;_'KPC'
MKNBWK\R7-I;0-(O.5M[JS_<;QU*L&.,=,YK]&/V6?@_I/P,^ O@WPGI5K';F
M#3X9KV1$PUQ=R(K32MW)+$]>@ '0"HOVLOA1IGQH_9X\=>&-2MXYC+ID]Q:2
M. 3!=1(7AD4]B'4?@2.A-:8N;H2G46MFV[]>]NWD<^%@JT(0V322\NU_U.H^
M#OQ=\-_'3X<Z-XV\)W9N]&U2+S$W@+)$X.'BD7)VNC J1ZC@D8->"_MN_M^^
M&_V1;&VTBVL5\3>/=0A\^UTCS?+BMXB2!-<.,D*2#M4#+;3RH^:OF+_@B'\0
MKRXT_P")?@B>5GL;9[75[6,GA'??%-CZA(?RKQOX)^'[?]KS_@J-K]]XJC35
M-'L]6O\ 47L[@;DDM[1C%;1%3P5!$.5Z$ YZTZE-2KPI0=HR3E?R5KKY/3Y>
M=PIU.6C.I/5Q:5N[>WX?GVN>DZ#\9O\ @HA\<--B\6^#]"71/#]VHEMX(M.T
MNTBDC(!#1K?DS.A'(8$@YX)K<^%?_!4KXD_"'XD0^!/VEO!ITKYECEU>WLFM
M;NV!) GDA!*3Q$C[T(7@$KOX%?J2 %  & .@KX=_X*Z?!_1_&W[+]YXSDM8U
MU_PE<V\]M>!0)#!-,D,L1/=29%;'J@]ZRE45%J25XW5T_/3<UA3=;W6_>Z6[
M^GGL?;.EZG::UIMIJ&GW,5[8W<2SV]S X>.6-@&5U8<$$$$$>M6J^,/^"2OQ
M&O?'O[(>GV5_,]Q+X;U.XT:.1R2?)4)-&N?15F"CV4"OL^NBM#V<W%;;KT:N
MOP,*<G.-WO\ Y:!1116)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4457U#4+;2K&YO;VXCM+.VC:::XF8*D:*"69B>   22?2DVHJ[&D
MV[(L45^5W[0W_!:";3=?O-'^#_ABQO[&VE,?_"0^(1(R7(&06BMT9"JYP0SO
MDCJ@K],?A[XH'C;P#X:\1+MQJVFVU_\ +T_>Q*_'_?55%.<'46VGXW_R)DU"
M:IO?7\+?YG05Y)\9_P!D[X2_M 1.?''@C3=5OF  U2)#;7RXZ#[1$5D(']TD
MKZBODK_@I%_P44U?X"ZTOPV^&DUO#XP,*SZIK,L:S?V<KC*11HP*F5EPQ+ A
M58<$ME?S'D_;&^.LVJ'4&^,/C<3F3S=BZ]<K#G.<>4'V8_V=N/:L8N-7IIW_
M ,C:494^NI]V_&S_ ((H3Q>=??"?QLLZ]5T?Q2NUNY(6YB7!] &C'NU?HE^S
M7X.U;X>_L_?#OPQKUL++6M(T*TLKRW619!'-'$JLNY25;!!Y!(K\]/V%O^"J
MFN^(?&&E^ /C-<6]ZNI2K;:?XK6)()$F9L)'<JH"%6)"B10I!QNW9++^JE=7
M+*G3Y4[QD[_=?_/\NAS<RG.[5FOU_P"&"BBBLC0**** "BBB@ HHHH ***_+
M+_@H3^T%\1?CE\?[7]F7X2RW$ 8I;ZNUK*86O9GC$CQR2#[MO%$<N/XCN!!V
M@&')\RA!7D_ZOZ%)*SG)V2/MCXE?MR? CX27LEEXD^)FC17T3F*6TTXR:A-$
MXZJZ6RR%"/1@*\WE_P""KG[-D=QY:^,[Z5,C]ZNAWFW]8@?TKQ+X;_\ !$OP
M59Z3 _CWQYKNJZJP#21^'TAL[=#CE 98Y6<9S\WR9]!7IUO_ ,$?OV?8;=(W
MM_$L[JN#+)JV&;W.U ,_0"KLX[NY-T]D>F^#?^"BG[.?CJ^%GI_Q1TNTN#_T
M&(;C38_^_EQ&B?\ CU?1%C?6VI6<-W9W$5W:S()(IX'#I(I&0RL."#ZBOSV\
M7?\ !%'X5:AITP\-^-/%FB:B1^[EOVMKV!3ZF-8HF/\ WV*^>_A'XP^*/_!+
M_P#:5TGX=^-M1;5OACK\Z@,CLUF\,DFS[9;AN8I(V/[R/N,@[LH]73Y:DU3V
MD]NS?;^ORNU,^:$74W2W\EW/V4HI 0P!'(I:@H**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/C]O+_D[WX$_[R_\
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M#'KBO>RV$G&<EL?S[XK8>=9X6=.-^52OY)VZ?+?_ "/ :*/X0>QX!HKUS^=
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M/\YKR?XO_"'RO/UW0H?EY>ZLXQT]70?S'XUYOX"\;7/@?7([^ &:W8;)X-Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%<=XN^+'AOP;(T-Y>^=>+G-K:CS) ?0XX7
M\2*TITYU9<L%=FD*<ZCY8*[.QK%\2^,='\(VOVC5;^*U7^%"<N_LJCDU\_>+
M/VB==UI98-*B31K=C@2J=\Q7ZG@'Z#\:X+2?#NO^-[PM96EYJLS-AYVRR@]?
MF<\#\37O4<HE;GQ$N5?UUV/:HY7*W/7ERK^OD>M^+/VEI&9H?#M@%3&/M=Z.
M>G\*#I^)_"O)+[5-?\>:KF>6\UB]?[L2!G('HJ#@#Z"O8?"?[-*HT5QXAU#S
M.,M9V? SZ%SU_ #ZU[#X>\*:1X4MC!I.GPV49^]Y8RS?[S'D_B:W^N8/!*V&
MCS/O_P '_(W^MX3!JV'C=]_^"> >$/V<]8UB-9]:N%T>%@"(5423$>_.%_7Z
M5[3X4^%OAOP=LDL=/1[I1C[5<?O)?KD]/PQ7645X^(Q^(Q&DI679'DU\=7Q&
MDI679!1117G' %%%% !5'5M#T[7K4VVI6-O?P'K'<Q+(O'(.".M7J*:;B[H:
M;3NCRS5OV9OA[JD,T8T3[(9FWRR6\S!W.<_>))'/H14ND_LX^ M)6VVZ/Y[V
MIS;S22LLD7T=-K$^[$FO3J*[?KV*Y>7VLK>K.OZYB;<OM';U91TK0].T.W$&
MG6-O91?W8(P@/J3CJ3Z]ZO445Q-N3NSD;;=V%%%%(04444 %%%% !1110 44
M44 %%%% 'YQ_\%;/^0C\./I=?^RU]]_#O_DG_AG_ +!EK_Z*6O@3_@K9_P A
M'X<?2Z_]EK[[^'?_ "3_ ,,_]@RU_P#12T =#1110 4444 %%%% !1110 44
M44 %%%% !1110!4U72[;6M,N]/O(Q-:W430RH>ZL,'^=?!/Q"\"W_P //$UU
MI-\C;5.Z"?'RS1$_*X/\_0@CM7Z US?CKX?Z-\1-'.GZQ;EU4YBN(L+-"W&2
MC$'&<<C&#W% 'Y^T5[=XJ_93\3:9<NVB3V^LVAR45I!#,.> 0WRYQW!['IQ6
M+IO[,WCZ^N%BFTRWT]"<&:YO(RH]SL+'].] 'EBJSL%4%F8X  R37V9^SU\+
M9OA[X;FN]3A$6M:B5:5,Y,48^ZG3@\DG\/2J_P *?V=-,\!W<.JZG.NKZS'\
MT9V8A@;U4'[S>C'IU !KV&@ HHHH **** "BBB@ HHHH _'_ /X+>?\ )5OA
MK_V!;C_T?7ZD? O_ )(C\/?^Q=T__P!)HZ_.?_@L)\&_'_Q-^)GP_NO!_@?Q
M)XKMK72)XIYM#TBXO$B<S9"NT2,%)'.#7Z/_  9L;G2_@_X%LKVWEM+RWT*Q
MAFMYT*21.MN@9&4\A@000>014X33"33_ )W^<R<1KBH-?R?I [&BBBJ*.3^+
MG_)*?&G_ &!;W_T0]?F1_P $.?\ D.?%W_KVTS_T*YK]//BA9SZA\,_%MK:P
M27-S/I%W%%#"A=Y':%PJJHY))(  K\\/^"./PC\=?##6/BD_C'P7XA\))>6^
MGBV;7-*GLA.5:XW!#*B[L;ESCID>M3AM,15;_D7YR'7UP\%_>_\ D3@_^"H_
MQZ\;?$C]H;2_V?/"^I2:5HI>QM;NWCE:)=0O+K84$S#K$JR1X7IDL2"0N/</
MAS_P1C^$7A^QLY/%VN^(O%FJ*@^TK%<)96;OWV(B&11]9#6-_P %(OV!?&GQ
M<\>6'Q:^%(6\\400PQ7^E+<+!/(T)_<W$#L0N]1@%2P.$4KD\5P_AC]M+]N7
M2K.UT&[^ T^MZG"%@_M74/">HQ^<PXWR/'(D.3W*[5I4+*FXM>_=W\UTM_79
M="JUW--/W;+[^OXG4_\ !0']E_X%_LS_ +(/B.3PGX)TG1O$&IWMG9V%]<N]
MU>F3SE>012SL[K^[CDR$(&,UZ-_P1TD1_P!D.158%D\17H8 \CY(3S^%?/WQ
M6_8O_:6_:>\%^*/B+\:M9^SZQHVEW%QX<\!Z,J3.90"WEB.(LB;@ !AI)7^5
M6*X%>[_\$B?#_BWP'\$?%7A/QCX.\0^$K^UUPWT US2;BR%Q#-#&N4,J*'*M
M$V<=-RYZUOA[Q]LIO5I/\8JWKHV^QA7M+V+@M$W]]GKZ:I'R5^S+>Q_ K_@J
M_KVCZ^PM%O\ 7-6TR.68[1FY+R6Q_P"!YB _ZZ"OVCKX6_X*"_\ !/.Y_:-U
M*W^(7P]O(-)^(UC$D<L$TGDQ:DD?,9$@_P!7,O16/! 4$K@$>"Z/^U)^WK\)
M--A\*ZK\(;KQA>6J^2NK7GAJ[U"5@.!FXLY1"Y Q\QR3C)).36%*25"%*2M*
M&GJOZ_KOK4C^^E5C\,M?1_U^7F?9/[:/[<6B_L;Q>$Q?>'Y/$]YKTTP^QV]Z
MMO)!!&%W2\HV[YG50#MSSSQ7R#_P5XCN_B9\"O@A\4(=,NM+L;CS!+9W0!EM
MOM<$4T2N1P#B%@?>H_A%^P?\:?VJOC1:_%']I>5].TF!T<:+<-&+BZC0[H[9
M88\K;P9)W!L.?FXRQ<?I#\9_@QX:^.WPMUGP%XEMBVBZE (LP862W=2#'+&<
M8#(P4CC'&"""12J4Y*C=_'>Z\DNGJU]S+IU$JON_#9I^;?7T7X^I\7_LB_L.
M_LP_'O\ 9U\$>,I? "7^JW=@D.J2)KNHH?MT8V3Y1;D!<NI8  ###'&*]??_
M ()=_LP1HSO\- J*,EFU_4P /7_CYKXGT3]GO]KO_@GWXLU6;X76K>/O!EU+
MYCPZ?!]LM[O&0K2V0831RXQEHO0#>P%7_&_QF_;M_:DT&Y\%6_PMO? ]A?(8
M;V:ST2XT?SXF&&1KB]E.U2#R(R"1D<@D':I-56Y4EJ^FUO\ @?H8TXNG:-5Z
M+KO?_@_J>O?LDR?L9:]^T;!IOPF\"ZUIWCW1);MK+4IKJ^FM62-6CDF1C=2(
M8V5CM+J,[AP"17GW_!<8E;KX/D=0NJ?SM:^GOV ?V$K7]D?PY?:KKEW;ZQ\0
M-9B6*]NK8$P6<(.[[/"2 6!;!9B!N(7@!>?#/^"QGPE\<?%"Z^%7_"'^#?$'
MBQ;-=1%T=#TN>]\C<;?;O\I&VYVMC/7!]*BLGS481=VGKVOKM_6YMAW>5235
MDT[=[>?]?B?>_P $O'%A\2OA!X-\3Z9.MQ9:II-M<*ZD'#&,;E..A5MRD=B"
M*S/VDOB%IWPK^ OCSQ/JDL<5M8Z/<E1(VWS)6C*11CW9V51[FOSPM_A[^UG_
M ,$_9[NQ^%&ER?%+X77;?:K/3;FR>_DLWDP61[>)DG1P<Y,?[MOO$!B0.3\5
M?#O]L?\ X*&ZQINE^.- D^''@FVG$DL%]8RZ79PL.LOV>5C<3OC.W.5![IDF
MGB8_6N>-/3FO?ROO_P #OH989K#J#GKRV^=MOOZ]M3K?^"'_ (*NUE^*/BZ2
M,K8LMGI4,G/S2 O+(/P!B_[ZKR_]DC5(?V??^"HWB'0/$1%DNH:IJFB1S3G:
M T\ADMFY_P">FV(#_KH*_6#]GWX$^&_V</A7I'@;PQ&WV*R4O-=2_P"MN[AN
M9)I/]ICVZ   < 5\M?\ !03_ ()UR?M(:A'\0/A_=6^E?$2UB6.XM[A_*AU1
M$^X?,'^KF4<!CP0%!*X!%U)QAB(5$KQBG'Y.UVOG?[_*Q%.FYT9PEI*34OFM
MD_E:_IYGW97QK_P5D^(&F^$?V/=?T>ZFC&H>)+RTL+. GYG*3I.[ >BK$<GI
MD@=Q7S%X?_::_;U^"NEP^%-5^$M[XUN+11$FJ7WARZU.7:   ;FRE$<A']YB
MS'J2:S]&_8H_:1_;B^)VG^+?C[=R^$?#5O@+;S^7'.EN6W&"UM$)\HG@%Y<-
MT)\PC%8SI.M:,7I=:^2=_P"OPN;TZGL7SR7O+9>?_ W/I;_@CWX/NO#7[(_]
MH7*.BZ]KUWJ$ 88S&JQP9'L6@:ON&L;P;X/T?X?^%-)\-:!8QZ;HNE6R6EI:
MQ9VQQH,*,GDGU)Y)R3S6S756FJD[K;1+T2LOR.>E%PA:6^K^]W"BBBL#4***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXG_ ."M_P 6;OX<
M_LJS:-I\S07?BW48](=T.&%N%:68?1A&$/LYK[8K\S?^"X%O<-\/?A?,H;[*
MNJ7:/S\N\PH5S[X5_P!:Y<3\"7=Q_-?\,=&'^._9/\F>#_\ !-;_ ()^Z%^T
MAIVH>/\ XABXF\'6=TUC9:3;RM =0F509&DD4AEC7<HPA!+9Y 4AOV)T[3="
M^%/@&"RLH5TOPUX=TX1Q1;V=;>U@CX&YB20J+U))XKY<_P""3=W;7'[%/A=+
M<CS(+_4(Y\=I/M+MS_P%DKH/^"EWQ4'PL_8_\:/'+Y=_KR)H-J,X+&X)$N/I
M")3^%=N-FZ4'&'96\VUH_O?W,Y<)%59IR[N_DD]?P6I^(?C+7M:_:6_:"U'4
M8U:76O&6O[;:)SG:T\P2*/Z*&1?HM?T!_"7]E?X:_"/X8V7@G3O".CWFGK;+
M#?2WMC%-)J,FW#R3EE.\L<G!X .   !7XY?\$J_A>?B-^U_X>O98/-L/#-M/
MK4Y894,B^7#^/FRHP_W3Z5^]57R1HX>%./7\EHOR9#FZM>51]/S>K_0_"O\
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M1=&^)$%QXGM-=ATT6<BLVH3.\>\@8X+'FOK2B@ HHHH **** "BBB@ HHHH
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MJ/0]Q7;3JJIIU/N,MS:GCUR-6FNG?T.WHHHK<]X**** "BBB@ HHHH ****
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M57V<9*<5*+NF?CM6G.C-TZBLUHT%%%%49!1110 4444 %%%% !1110!^<?\
MP5L_Y"/PX^EU_P"RU]]_#O\ Y)_X9_[!EK_Z*6O@3_@K9_R$?AQ]+K_V6OOO
MX=_\D_\ #/\ V#+7_P!%+0!T-%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG%M,F,E)*2ZA1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTS7EE/AF:VF29&9'C8,&4X(QZ'M]:J+<7=&U&K*A4C5@[-'[%QR+-&LB'<C
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M<:5?00K]Z26V=5'U)%9_E'^X?^^:/K#ZH/\ 6"I'2=+\;?H?:WVZV_Y^(O\
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MIWUIO[S[$HKY"_X6)XH_Z&#4?_ AJ/\ A8GBC_H8-1_\"&I_6%V+_P!8:/\
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M]NQVS1\XRR'D#WZ&NBK9--71[-.I"M%3INZ?5!1113- HHHH **** "BBB@
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M5TNE^(M/FRBM;L^URZ'H\3?..X*D=&(/]$2.LB*ZD,K#(8="*VE%<BJ0V?\
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ME#V<%$_=\KP?U#"0H/=;^H4445J>J%)2T4 )12T4 )05# @@$'@BEHH R_\
MA%]&Z_V18Y_Z]D_PH_X1;1?^@18?^ R?X5J44K(S]G#^5?<9?_"+:+_T"+#_
M ,!D_P */^$6T7_H$6'_ (#)_A6I119![*'\J^XR_P#A%M%_Z!%A_P" R?X5
M0O/ASX8U"<S3Z%8O)C&1$%Z>PKHZ*7*NQ,J-*2M**?R.5_X59X2_Z %E_P!^
MZ/\ A5GA+_H 67_?NNJHHY8]C/ZKA_\ GVON1RO_  JSPE_T ++_ +]U\D?M
M0>%+;PK\2E6PL8K"PNK..2-(< ,P)#G'8]*^X:\4_:D^&\_C/P7'JE@ADO\
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M:'1K=@#YEY("^/\ <7)S['%>K>'?V4_#MBL;ZO?WFJS#EHXV$,1XZ8'S=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/2ELUK;Y_P!=F?F6:Y1+ /GA\/XH]#HHHKY\^<"BBB@ HHHH **** "BBB@
MHJA?Z]INEQR27FH6MJD?WVFF5=OUR>*Y+6/CAX-T?S%.K+>2H0#'9HTN<^C
M;3^=9RJ0A\4DCHIX>M6_AP;]$=Y17BFJ?M/:5#YJV&CW=TRG"-,ZQ*P]3U(_
M*N1UC]I;Q'>;UL+.RTY"P*,5:5P/0DD _D*Y)8ZA'K<]6GDN-J?8MZM?\.?3
M-07=];:?&)+JXBMD)P&F<*,^F37Q]J7Q:\7ZHLBS:]=1H[;BMN1%CV!4 @?C
M6%'9ZMXDN-R07VJ33/\ >"O*7;Z\Y-<LLRCM"-STX<.S2O6JI+R_X-CZUU'X
MN^#]+5C-KUJQ5MA6 F5@?H@)KD-4_:8\/6K%;*QOK\AL%BJQ*1Z@DY_,"O%M
M/^%/B>^*?\2Y;16;:3>3QPE/=E9MP'X5NV_P8CM)8EUSQ;H>D%\DQ_: [[?4
M9(!H57&UM*=/\/\ ,Z%EN5T?XE3F?K^BU//_ -I3XF3?$JST:1[".P2RF?:%
ME+E]PP,\#%>%5[G^T+X7\.^%=#T6#1]=77KR>9S-+#+&40*./D7)&?=J\-VG
MTKS,;E.8\\:DJ3?.NBOMIK;8_1<GJX982,:.D5>U_7SU$HI=C4>6?45RQR7,
M9[47^7YGL^WI+[0E%.\OWIP4+[5[&%X7Q=1WQ#4%][_#3\3&>+@OAU&;"?:E
M\LTID';FF,Q;K71B(9)EZY8-U)^3_6UONN3%UZFKT1Z9\)O@KXE^)T=S-H\-
MO';0L$DN+N7RU&1D8&"2.#R!7K=C^R'XBM<-+/IEPX_O3N%_+96C^PYJD*V/
MB+3%+O.62YDW#"Q@?*H'KGD]L8[U]45W5<"H6C-.+:3M?NKGYAFV>8S#XR=&
MFURK;0^7E_9J\5J !-I8 Z 3O_\ $4O_  S7XL_Y[Z7_ .!#_P#Q%?4%%<O]
MGT?,\3^W\;Y?<?+_ /PS7XL_Y[Z7_P"!#_\ Q%'_  S7XL_Y[Z7_ .!#_P#Q
M%?4%%']GT?,/[?QOE]Q\O_\ #-?BS_GOI?\ X$/_ /$4?\,U^+/^>^E_^!#_
M /Q%?4%%']GT?,/[?QOE]Q\O_P##-?BS_GOI?_@0_P#\11_PS7XL_P">^E_^
M!#__ !%?4%%']GT?,/[?QOE]Q\O_ /#-?BS_ )[Z7_X$/_\ $4?\,U^+/^>^
ME_\ @0__ ,17U!11_9]'S#^W\;Y?<?+_ /PS7XL_Y[Z7_P"!#_\ Q%'_  S7
MXL_Y[Z7_ .!#_P#Q%?4%%']GT?,/[?QOE]Q\O_\ #-?BS_GOI?\ X$/_ /$4
M?\,U^+/^>^E_^!#_ /Q%?4%%']GT?,/[?QOE]Q\O_P##-?BS_GOI?_@0_P#\
M11_PS7XL_P">^E_^!#__ !%?4%%']GT?,/[?QOE]Q\O-^S5XL92//TL9&/\
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MBW]K4?!OXJ:!X6T8-=W>D?:-&M;F&1;Z+=L!,MPX*.491\N273FOT=K\:?\
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MAR^0""PYQ7TW10!RGPITV_T?X<^'[+5(Y(=1@M%2>.9MSJW<$Y.3^-=7110
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M% /-A8;9(L]F4]/Y5M&:EL>YAL=1Q6D79]F='1116AZ 4444 %%%% !1110
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MV5W:*,C:Q$S'T",%4#H.7]_:LK2_V3_'%]%(+F&VTZXS\GG3(\)'<ET8L#Z
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M&<DBNMH5%O63-(91*;YL14N_ZZL^9_#O[)=[.L<FN:W%:@\M;V4?F-C'3>V
M#^!KU?PW\!_!?AN,;='CU"?O-J'[X^O /RCGT%>@T5JJ<5T/6I8##T?ACKYZ
MD<,$5M&(X8UBC7HB* !^ J2BBM#O"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC)QFO4J_,_\ X(N_''6O%'A/QC\-M7NI;VS\/B&_TIIF+&"&4LLD()Z(&56
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M)9<+SR5_TE3Q[''YUM1G[2O7D_B<5_Z4_P#@F=6*AAJ,([*3_*-OQL?JI7Y
M?\%NM-CM_BQ\--315$\^C7$#-CDB.<,OZRM^9K]?Z_'S_@MAJJZI\:OAOH4'
M[VZM]%DF,:#+?OK@JH^I\H\?XUR34G6HJ&_-I_X#(Z:>D*CZ6_5'ZT>!]1.L
M>"O#]^Q8M=:?;SDMU^:-6Y_.MNLGPGIO]B^%=&T\KM-I90P;?3;&JX_2M:NV
MM9U9<NUV<-"_LH7WLOR/EW_@IM_R8]\3/^N5E_Z76]?G/^P#^RCJO[:&CI9^
M./$>IVGPG\#S/%9Z78.L9N+R=C+(JD@A>""[D%L,BJ1U'Z,?\%-O^3'OB9_U
MRLO_ $NMZ\M_X(R0I'^RIK#JH5I/$]T6([D06XY_ 5CAHIRK2:V2?Y+]3JKR
M:HTHKK*7_I*?Z'$?MF?\$NOA/X5^ OB;Q=\.K"^\-Z_X;L7U$Q-J$MS!>11C
M=*KB5F(;8&*E"HR!D$5\S?L5_#OQ]^W5INF_"7Q+XQU"P^$'@0&_N8;1AY\C
M3,1# &;(."LA0L"$7?@<BOUJ_:W_ .36_BU_V*VI?^DSU\/?\$/+>,>#OBO.
M%_>M?V"%L]A',0/U-.@KU*O-JDE*W2][?AH_D17]VG2<='*35_*R;^]77S/1
M?C1_P2/^#&H_##54\$6&H^&O%5G:R36>H'49KE)Y50E4F21F7:Q&"4"D9SVP
M?*/^")?Q2U6[B^(7P\O+J2;2[)(-7L()'S]G9F:.<*#T#'RC@<9R>K5^H6K?
M\@J]_P"N+_\ H)K\A/\ @BK_ ,EZ^(__ & 1_P"E4=/#-NO.#>CB_P +O\TO
MN)Q"2P\9K=22^]I?E?[SUW_@KI^U#KWA>'0O@MX-NI[;4O$, NM8DLR1/);N
MYCAME(YQ(RON Y(55Z,0>I_9V_X)$_"OPSX!L9?BII]SXR\77<*RWD0U">UM
M;)R,F*(0.C-MS@LS')&0%'%?,G[63B^_X*Z>&X=5=S8QZ_X<CC#CY1'MMFP,
M_P .]FS]37[-U-"*^K^VZSD_N5K+\?P];Z5[^V5.^D8Q?SDKO^O\D?C]^WE^
MPF?V3?#.H?$GX.:OJFF>$[^%]%\0:+)<&40V]P/+X=N9(6)52K[F5BK!NFWZ
M _X(K_\ )L/BC_L;;C_TDM*^AOV](+>X_8Z^+*W*HT8T.9P'Z;U*E#]=P7'O
MBOGG_@BO_P FP^*/^QMN/_22TJ\+)WKTWK:*:]'-:?>F_F362:I22ZO\([_I
M\C] :***@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^&?^"QG_ ":+
M%_V,5E_Z!-7W-7PS_P %C/\ DT6+_L8K+_T":N3%? O\4?\ TI'3A_C?I+_T
MEGA__!#7_6?&3Z:3_P"WE?JM7\KMO?7%GN^SSRP;NOEN5S]<5/\ VWJ/_/\
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M(HKB(3+%[('R%_#%=716_P!8K6Y>=V]6;^WJVMSNWJQD4*01K'&BQHHP%48
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M]\2IHIU3[+II8;Y6R"4_O!L%?H.I],<UQ7@WQUJ7@?4/M5BMM<H2&>UOH1-
MY'1BAXW#LW4=J^L/A-^V!HGB&:'2_$]E#X;NF^6.Z@)-HY)X4]XS]<CW%5/C
MJAB%R8>+@WUE;]+GA9I0S##4W+#4^9=UNOE_D+XV_9WT'P%X'.H:=J(M'T^
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MXP0.#D&M:6LT>IE<7/&4U'N?=%%%%>L?K@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9&M>+M$\.J3J>J
MVMF0"VR64!R!UPO4_@*J,92=HJ[*C%R=HJYKT5Y7K7[1GA?3F9+-;K4W!QF&
M/8AXZY;''X5Y_KW[2FNWW&EV-KI<>.6D)G?WY( _2O2I9;BJOV;+ST_X)Z%/
M+\34^S;UT/I2L#7/'WA[PVN=1U>U@/3RP^]SCKA5R3^5?(7B'XH:SK"LNJ>(
MIY$(&8?.V*>>/D7 /Y9KFEUA)GS!!<7!+<L$V@^^3BNAX'"X?7%5TO+^O\CV
M*.0U):S?W+]6</\ $RXMM0^(GB2ZLI_M%I/?221RE"FX$^AY%<WY8[\U?\0*
M\&M7JN,-YA)&<]>:SMQ]:^8K8K(</5E4Y74DVWM?\[+\#]<H4Z_LH03LDDOP
M'X [4;AZU']>:*PJ<5.$>3"T5%>?^2M^9NL'?6<A_F#TI/,/I3:*\>IQ'F-3
M::7HD;+"TET%W-36;Y232T^$(T\0E1Y(BXWI']YESR![XS7DU,PQ=;^)4;^9
MJJ<([(]L\'_!'6O$FDZ?-::#>W"7$(E2X<^5&P]=S$#]:]!T;]DW6+A%-VMA
M8*R[OWLK2NI]"!Q^1-?1GPXTM=&\":%9H?W45JGEY.2$(RH/N 1FNDKZRG@X
MN*<Y-OU/QC%<18MU)1I62NSP32?V1]#MI U[J4DH*89+>!4^;V9MW'X5VNC_
M +/O@;1R&&C)=2;=I>Y<L3[X& #]!7HU%=<<-2CM']3PZN:8VM\55_+3\C,T
MWPSI&CL'L=+L[-PNS?# J-M],@9K3HHKH22V/,E*4G>3N%%%%,D**** "BBB
M@ HHHH **** "BBB@ KY*_:N^ \T=U/XU\/6;2Q29?58(R68-Q^^5?3'WL?6
MOK6D(# @C(KT,#C:F!K*K3^:[H[L'BZF"JJK#YKNC\I0<\CD45]M?&#]D[2?
M&4MWJOAIH=&UF8[Y(I WV>1NY 'W">YP1[=Z^;O$O[._C[PPZK+X?NK_ '8&
M[38FN1G&3]P'@>IQ[5^GX3-L)BXIJ5GV?]:GZ)A<TPV)BFI6?9GFN!Z4M;B^
M"=;;5CIIL&6[49*NZ*@XZ;R=N[MMSG/&,\5V'AC]G7QSXGSLT6YL#D@"^A>'
MZ'+ #!]03].]=CJ87#KFO&-_1'H5,32@KSFK>IYG7U1^S%\ )?M4'BK7HD:#
M9NMK9E!^;((?/^'YGFNW^$?[+&E>#_L]_KHCO]33G:N2G/9L\$>P';J:]ZCC
M6- B*$51@*HP!7QF;9[&I%T,+L]W_E_F?'9EG*J1='#;/=_Y#J***^'/C@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SM5\-Z3KT
M:1ZEI=GJ"1G*+=6Z2A3Z@,#BDTOPWI&AHZ:;I5EIZ28WK:VZ1AL=,[0,UI45
M/*KWMJ:>TGR\G,[=A*6BBJ,PHHHH **** "BBB@ HHHH **** "BBB@#\X_^
M"MG_ "$?AQ]+K_V6OOOX=_\ )/\ PS_V#+7_ -%+7P)_P5L_Y"/PX^EU_P"R
MU]]_#O\ Y)_X9_[!EK_Z*6@#H:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O$OC;\!?^$PEEUWP^BQZR1^_M20J770;@20%?'KP?8\GVVBHG!35I'%C,
M'1QU)T:ZNOQ7FC\\]6T>^T&^DL]1M)K*ZC.&BF0J>N,\]1P>:IU^AFI:-I^M
M1"+4+&VOH\$;+F%9!SC/# ^@_*J6G^"_#VD7"W%CH.F64ZG(EM[..-A]"%SW
M/YUPO"N^C/A)\(RY_<K>[YK7\SY4^%?P&U?QO>07>IP3:7H0(=YI%VR3KZ1@
M^O\ >/'UZ5]=Z;IMKH]C!964"6UI @2.&,855'859HKKITHTUH?7Y;E5#+(.
M-/63W;_K1!1116Q[(4444 %%%% !1110 5^7_P#P66^$=SI;^ OC1H2O;:CI
MMPNE7MU ,,A#&:UE)[;7$JY]64>E?J!7#?&WX.^'_C]\,-<\">*!<?V-JT:I
M+)9LJSQ,KJZ21LRL RLH()4CCH:RJ*7NSA\46FOZ]+HUIN.L9[-6?]>NI^1V
ML>,#_P %)?V[/AK911R2^%;#3+%[^!@0D<<42W-\"#TS*S09[X7MBOVH55C5
M550JJ,!0, "OF[]EO]@?X<?LD^)-9U[PE>Z]JNJ:I:K9//KUQ!,88@^\K'Y4
M,>-Q"YSG[BXQSGZ3KJDXJ$80[MOU;U_0Y8J3FY2[)+T2_,*_%#X)_P#*8?4/
M^QTUW_T"ZK]KZ^7?"W_!/'X<^$?VDIOC;9ZUXHD\5RZG=ZLUG/=6QL?-N!('
M4(+</M'FM@;\\#)-9TO<Q$*CV2?XV-YOFPTZ2W;7Y/\ S/I#Q-_R+>J_]>DO
M_H!K\=O^"*/_ "<1XR_[%A__ $J@K]E+ZT34+*XM9"RQSQM$Q7J P(./?FOF
MS]EW_@G[\//V2_&6I^)O"&L^)M1O]0L3I\L>MW5O+$(S(CY41P1G=E!U)&,\
M4\._9UY5);.-OG:7^:,ZW[RC&"W4K_C'_(^FJ\Q_:0^ ^B?M(_!_7O NN*J)
M?1;[.\VY:SNER8IE_P!UNH[J6'0UZ=164XJI%Q9I&3A)21^%_P"Q3\<]>_8/
M_:DU;P'X]W:=X>OKP:1K\$C'R[653B&\7/\ "-P.[O'(3SA:_<Z.1)HUDC97
MC8!E93D$'H0:^8?VFO\ @G;\+?VJ/&UIXL\37.O:+K<-J+26?P_<P0_:D4Y0
MRB6&3+*"0",''!S@8]S^%/P[@^$OP\T/P?:ZQJNO6>CVZVEO>ZU+'+=-$O"*
M[1HBG:N%!VYPHSD\UM&3E22J?$M/5?U^=NAE**C5;I_"_P '_7Y7MJSK:AN[
MN&PM9KFXE6&WA1I))'.%10,DD^@ J:L'QYX/M?B%X(U_PO?7-U9V6M6$^GSW
M%BZI/''+&49HV96 8!C@D$9[5C/FY7R;]#6/+S+FV/P__:>_:9;]NC]H_3M"
MU+Q=;>!OA-87KPV-S?LP@A@7.^\D0<O-(H.U>VY5R/F8_HI\!?V@/V1/V;_
M-KX3\%?$7P_96<>'N;J1G:YO9L8,TS[/F8_@ .%   KBO^'*GP0_Z&GX@?\
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MV_Y,>^)G_7*R_P#2ZWKS#_@C/_R:CJG_ &,]W_Z(MZ^M/CI\&M%_:"^%>N^
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MM#_W['^%?GA_P^T^%W_0A^+O_)7_ ..T?\/M/A=_T(?B[_R5_P#CM42?H?\
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MD$O=DHGME%%% !1110 445\K?M6?MH0?!V\D\+>%(H-3\6;<W$TWS06((XW
M?>?OMZ#OZ5+E8I*Y]4T5^,WBK]H?XD^,KQ[C5?&^L,S,6$=O=M;QKGLJQE0!
M4GA']H[XF>"[I)]*\;:O\K;C#=7)N8V]F63<"*I>9+\C]E:*^9/V5/VQ[3XW
M2?\ ".>(K>'2?%T4>]/*.(+Y1U* G*L.I7GV]*^FZIQ<25*X4445)04444 ?
MGQ^WE_R=[\"?]Y?_ $J6OT'K\^/V\O\ D[WX$_[R_P#I4M?H/0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD.0))B9I,=B.@!^H(K-U(KJ>?4S'#4]Y7]-3ZFKG]>^('AOPQN&J:W96DBD
MQ-,#(,]/E&3^E?&'B'XJ>+/$RNNHZ]=/$_WH8W$4?3'W5P*BT'X:>*/$S(-.
MT&\F1B )6B,<8R,@[FP,8[]*R]M?X4>9+-Y3?+0IW_KLCZ-U[]JCPMIZLNFV
MU[JTN."J"&/.>A9N?R4UYEKW[4OBO4@R:?!9:2A! 94,L@YX(+<9Q[&I=!_9
M5\3WZJ^IWMEI2D F,,9I!SR#C"CCN&->FZ#^RYX2TQ5;4)+S5Y0.?-E\J/.<
MY"I@_F2*/WDO(FV9XG^ZON_X)\TZY\0/$OB>1O[2UN^NMQ+>5YQ5!D8.$7
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MBBNL^N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^/\ D?HE'@W"17[ZI*3\K+]'^9^D.@_'SX?^))H8++Q38>?*NY8IW,+?0[P
M#[=:[Y6#*"#D'N*_)_K7H7PN^.7BCX4WB?V==F\TO.)-+NV9H2.Y7GY&]QQZ
M@UT4<YUM6CIW7^1Y^,X-2BY8.I=]I=?FO\C]'Z*XCX6?%[0?BYHSWNCR/'/"
M0MS97&!+"WN >0>S#K7;U]+"<:D5*#NF?F]:C4P]1TJL;26Z844459B%%%%
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M,C@D8]*]+ 866(JKLMSYO/<SAEV%EK[\M$OU/88(4MH8X8U"1QJ$55&  !@
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M7UOPYJ?AF:VAU6PFTZ:X@6YBBN$V,T3?=;'4 ]LU^JG[$?\ R;3X0_ZYR?\
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MX&6R/][\*]OHK14XH]&GEF&I_9OZ_P!6.7\/_#'PKX79'T[0K.&92&$S1!Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?Q2_Z\(O_2B*OSE_X(L_\G1^)/\ L4KG_P!*[2OT:_X*,?\ )E?Q2_Z\(O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /SC_X*V?\ (1^''TNO_9:^^_AW_P D_P##/_8,M?\ T4M?
M G_!6S_D(_#CZ77_ ++7WW\._P#DG_AG_L&6O_HI: .AHHHH **** "BBB@
MHHHH **** "BBORR\7?&/Q];>+-:AA\<>)(HH[V9$C35K@*JB1@  'X %=6'
MP[Q#:3M8^>S?.*>41A*<'+FOMY'ZFT5^3G_"ZOB%_P!#YXF_\'%Q_P#%T?\
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M6?#CWOBW5TEUB2,O8^'[-@]]=GG&$S\B9!S(^%&,9)P#^3/P7_:.\4?M1?\
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MO1MK[E?]3]9**_'KQ_\ M2?MY?LY"V\5_$/3A_PCCR &*]TBPFL5+'"I)):
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MULBQ\D.6"%L@==K?E6GM.9.$-EO_ ,'^OS,^3E?/+?\ K8]$HHHK,T"BBB@
MHHHH ^4?$O\ P3K\#^)_$6J:Q<>)?$44^H7+W,D<3V^Q68Y(&8B<?6L[_AV=
MX!_Z&CQ-_P!]VW_QFOK^BDDDK(;=W=GR+9_\$U_ =E>6]RGB?Q(SPR+*H9[?
M!*D$ _N?:OK:WA%O;QQ*25C4*">O Q4E%5=VL397N%%%%(9^6_\ P4&_Y.+N
MO^P;;?R-?:7[$?\ R;3X0_ZYR?\ HQJ^+?\ @H-_R<7=?]@VV_D:^TOV(_\
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M_#G[445\O?"?]OWX?>+M$@'BR[_X1+6T3$\=Q&[V[MZQNH/!]#@CWJK\8?\
M@H!X%\*Z)<0^#+D^*M=D3$#Q1LEK$2/O.[ 9Q_= .?:G+W11]X^=?^"B?C*+
MQ!\;+/2(9!(FBV CDP?NR2'<1]< 5]1?\$__  K)X=_9\L;N:-HY-5NI;P;A
MU3.U3^AK\[_"/AGQ'^T!\58;!7EU'6M;NS+=W1&=BDYDD8]E _H*_8SPEX:M
M/!OAC2]#L5VVFGVR6T?'4* ,_CU_&JIQ]G2=]W_P[)J-3J*W3_AC7HHHJ2@H
MHHH _/C]O+_D[WX$_P"\O_I4M?H/7Y\?MY?\G>_ G_>7_P!*EK]!Z "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HI,XY/ IB7$4C821&/HK T 24444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*RR=/WZ/O1_'_@GM]%1PSQW,*2PR++$XW*Z$%6'J".M25\^>&%%%% !1110
M4UE612K ,IX((R#3J* /'_B'^S=H?BR6:^TEQH>HOR5C0&W<^Z#H3ZK^1KYK
M\7_#_P 0?#_4/+U2REM@K_NKR/)B?'0JX[^W!K[TJKJ>EV>M6,UE?VT5Y:3#
M;)#,@96'N#6,J:EJCQL5EE*O[T/=D?*GP]_:5UKPO'#9:U&=<T]/E$K/BY0?
M[Q^__P "Y]Z]2^(/[4'A+P;\/V\0V=RNJ7<I\FVTU"5D,Q&=L@_@4=S[<9KG
M?B1^R_;20S7_ (4F%JZY=["YD)CQCG8QR0?8G'N*^#?%VK2:MKEP7X2W=H47
MTVG!^O(K"4YTU9G@XG&XS+(>RGK?9_U^I:\??$+7_B9X@EUCQ#J$M[<LS&.-
MF/E6ZD_<C7HJ_3KWKG***XM]6?$2E*<G*3NV%%%%(D0@,,$9%?5W[+?[56HZ
M5K%AX0\87C7NE7++;V.H7#@/:-T5'8XRAZ9)R..U?*5(1N&#5QDX.Z.S"XJK
M@ZJJTG_P?)G[(4M> ?L;_%BZ^(GPYDTW4W,NIZ&RVQF*X\R(C]V>F,@#!^@K
MW^O6C)25T?K>&Q$<51C6ALPHJ.2>.'.^14P,G<P'%<]??$SPGIMN\T_B/3 B
M<-LND=O^^5)/Z4[FTIQC\3L=+17FNH?M$^!-/D5/[7:ZW#.ZVMW=1[$XZURN
MI?M::!#"_P!AT;4;J8-A5F,<2,,]=P+$?E^53SQ74Y98[#0WFOS_ "/=**^9
M=1_:XU%YO] \/6L4.WI<3L[9]<@ 8KE=0_:6\<7T)CCN[2Q.[/F6]J-P'I\^
MX?I4>UB<<LVPT=FW\O\ ,^Q*BGN8K5=TTJ1+G&Z1@H_6OAO4?B]XTU29I)_$
MNH*67:5@E\E,?[J8'Z5R\VH7>H@1374]T,Y"22L_/K@FI]LNB.26=0^Q!O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M117J'YL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2*1ASRR7 53^3M^=?KMJW_(*O?\ KB__ *":_(3_ ((J_P#)>OB/_P!@$?\
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M3_X)X_%37+I5U<:5X;MLC?)<78G?'JJ1;@3]6%?I[136@F>1?L__ +-/A?\
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MQY9(****V.0**** "BBB@#F_&/P_T7QQ9M%J5JIFQA+J(!9H_HV/T/%?-?Q
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M,:I(&EO],=B/M+ ??B..'..5. ?:OBB_TV\TJX:"^M+BRG4D&*YB:-P1UX8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8>A7.#7TKH_[/_A#2\&:UFU)^?FO)20<_P"RN!Q]*[72?#.DZ#'LT[3;6R7
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M=:9=Z7=7063 W>7);QR*R9S@G:<=5'2LZ7PRE!VUU7Y/Y_UN:5=XQDKZ:/\
M3Y'QK^TI\*?VE/CU\)/%'Q?^/%U'X,\.^&+-9]'\++&L/F3221QC$ <M']\Y
M>8F0\*!@Y'U#_P $687C_9?\2LRD+)XLN"I/<?9;4?S!KPO]OC_@H-HW[37A
M.W^#GP:TW5?$2:U>0B\U#[&Z/>;'#QV]O"1YC$N%)9E7[F #DD?>W[#'P#O?
MV;_V;/#/A'5@@U]O,U#5%C((2XF;<8\@X.Q=B9'!V9%;X?W8596M%VBO-W3;
M_#7Y=S*MJZ<;WE=M^2M9+^N_D>^T445F4%%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK/U+Q!IFB@?;
M]1M;/*E@)YE0D#J0">:XC6/C]X0TK(BNYM2?CY;.(D<_[38''UK>GAZM7^'%
MLWIT:M7X(MGH]?G)\?M2FU3XR>*I)RI:.[\A=HQ\JJ,?CS7TQJW[3UW(S+IF
MB11+@@/=3%CGL< #\LU\H?$[4)M8\<:GJ5Q%'#->.)W$0(5F(P6 ).,X]:^W
MX?P=7#5I3JJUU^J/K\DPE7#U92JJUU^IRU%%%?='V04444 %%%% !]1D>GK7
MVQ\(?@=H/B;P#HFLZE)>R2WEJKF!9 BQG)&!@9Z#O7QCI5G<7^IVMO:G;<O(
MOEMM+!6!R"0 3C/M7Z;>";$Z;X1TBW9=LBVT9D&<_.1EC^+$G\:^0XBQ,Z-.
MG&F[-L^6S[$3HTX1INS;*>C_  R\+:'M-IH=F'5@XDEC$K@CN&;)'X5TD4,<
M*[8T6->N%&!3Z*_.IU)U'>;;/@Y3E-WD[A11169 445R_BOXE>'O!L;G4=0C
M\]>/LL)#S$^FT=/QQ4RE&"O)V1I3ISJRY*:N_(ZBL+Q3XWT7P;:^=JU_';DC
M*0YW2O\ [JCDUX#XN_:,US5Y&BT6-=&M.1YA"R3,/J1A?PY]ZX'1_#^O>/M4
M?['!<ZK=N?WEP[$@>[.>!^)KRJF8*_+15V?4X?(96]IBY<L?Q^_9?B>G>+OV
MEKZ]62W\/V(L$S@7=R0\A'J$Z*?J37E]K9Z]X_UD^4EWK6H2'YG8ER,^K'A1
M^0KVKPA^S3:01I/XCO&NIC@_9;1BD:^Q;JWX8KV+1]#T_P /V:VFFV<-E;KT
MCA0*/J?4^YK)86OB'S5Y678Z99G@<O3A@H7??_@[O\CPOP;^S3<3.MQXENQ#
M&#G['9MEF_WG[?@/QKVWP_X5TGPM9K;:780V<:]XU^9O=FZD_6M:BO3I8>G1
M^!'S6*S#$8Q_O9:=N@4445TGG!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>B;^Y-GYE:7HOQ,_:J^*4ZV=OJ_C_P ;:LYGF?)ED(R 6=CA8XUR!DE448'
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MZ3B:"Q,<<DC>?*#M#?NV78I9@2,@#FI6LE%;L>R<GLCW*BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\^/V\O
M^3O?@3_O+_Z5+7Z#U^?'[>7_ "=[\"?]Y?\ TJ6OT'H **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN(DG@E4I)'(N593P01Z5S4,VQ-*O&K*5TNG1G/1S/$4ZT:LI7MT/RIHKV/\
M: ^ 5_\ "_5Y]3T^)KGPO<2%XYD7_CT)/^K?'0>A[].M>,F3T_6OO,5Q#EN"
MH1KUJNDMDM9?=_GIYGZE@_\ ;H*I0U3'T5'N)[TFX^IKX^7B!@E.T:,[=]+_
M '7_ %/6_LZI;XD2T5&)#WYKK/AK\/\ 4?B9XFATG3HI&XWSR(A81)G&2>BY
MZ9.!7U&7<3Y9F2?LY\LDKVEH_ET?R;.#$T986+J5/A74[?\ 9K^&=QXY\<6M
MXX9-/L7$LDBL5;CT]>>.XYY%??:J$4*H"J!@ =!7*?#+X=V'PS\+6^D6.7*_
M-)*QRS,>V3S@=OZ5UE?&9MC_ *_B.9?"M$?DV98WZ[6YE\*T044UW6-2SL%4
M<EF. *\]\:_'+P[X1+P0R_VOJ"\?9[5@54_[3]!].3[5X,ZD*:O-V.&CAZN(
MER4HML]$KB/&'QB\->#9&@N+LWEX.MK9@2,O^\<X7\3GVKY]\6_&SQ/XJ26%
MKL:;9,?]19Y0X]"_WC^E4_!GPG\0^-F22TM#;6+'F\NLI']1W;\*\J>.E-\M
M"-V?44<CA1C[7'5$EV7^?^1N>-/CYX@\3;[>P;^Q;%N-L#9F8>[]OPQ7+^%_
MA[XB\;.TFF:?)/$3EKJ9@D>2>3N;K^&37OG@_P#9YT'P^Z7&INVN72G($R[8
M5_X!SG\2?I7J44201K'&BQQJ,*JC  ] *4<'4K/FQ$C2IG&'P<?98"G\W_5W
M\SR#P5^SEI6D^7<Z]-_:UT,'[.F5@4^XZM^.![5ZU8Z?;:;;K!:6\5K O2.%
M JC\!5BBO4IT:=%6@K'R^(Q=?%2YJTK_ )?<%%%%;'&%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M) R0,^XK)23DX+=:_G_D6XM14GM_7^9^R-%?DG_P\J_; _Z(;IO_ (2.L?\
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M6^N:%?+F*Y@)X(^\CJ<,C@\%6 ([BM.5VYNAGS*_+U.JHHHJ2@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY-_X*
M9_L^:A\?OV9[^/0K9KSQ'X;N5UJRMHQE[A41EFB4=R8W9@.[(H[U]95\S_\
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MGT__ .1Z_;K]F7Q=JWC[]GGX<>)->O#J&M:KH-G>7ET45#+,\2L[;5 49)/
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MHSA'NO$6W35C']XI,5D8?[J-7VS\"_\ @BMI>FS6^H_%KQ@=8=2&;0_#8:*
MD'H]RX#LI'4*D9'9J/9R>[M_7S#GBME<^7/'?[87[2O[='B,^#/#27L=G>#:
M?#7@^%X(C&3M+7,Q8L4PP#&1Q'T.!7W3^PC_ ,$Q[7]GG7-.^(7CW4EU?Q];
MJS6=CI\C"STTNA1B6X,TFUF&3A!N. Q :OLGX7_"'P7\%_#<>@^!_#>G^&M+
M7!:&QBVM*P&-\CG+2-C^)R3[UV%:1<:7\-:]^O\ 7]:$2YJGQ[=NG]?UJ%%%
M%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'Y\?MY?\ )WOP)_WE_P#2I:_0>OSX_;R_Y.]^!/\ O+_Z5+7Z#T %
M%%% !1110 4444 %%%% !1110 4444 %%%% &?XBLY=1\/ZG:0@--/;21(&.
M 69"!S]37S+^SC^S[XP^&_Q$@U?6[*T@LDM)(2\-RLC;B!C@5]544 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?
M-O[3WP/\5?%'Q3I-]H-G;7-O;V;PR-/<+&0Q;(&#[5])44 <M\+] O/"WP]T
M'2;]%CO+.U6*548,H8>A'6NIHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHO=C^+,FZNIKVZFN;B5Y[B9S))+(VYG8\DD]S45%%?J)^CA1110 5[K^S?\
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MD2W6/&-HC V@8[8K5JEK6M:?X;T>]U75;V#3M,LH6N+F\NI!'%#&HRSLQX
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M.O\ _!1&RMOBG\>O$VIZOX;T=$T31=(M)O(^U>2BK+,[#) 9OO%<,[[CN4*
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MAB2V#_$B,OH37B<__!<R)9"(?@L\B?WI/%(4_D+,_P Z49*2NARBXNS/O/\
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MT'K\^/V\O^3O?@3_ +R_^E2U^@] !1110 4444 %%%% !1110 4444 %%%%
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M/W?A7X?Z#I%^J)>6=JL4JQMN4,/0]ZZB@ HHHH **** "BBB@ HHHH ****
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MMSA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.\136=MH.HS:@D<EC'
M[S)* 590I)!!K\PM:U(:QK%[?)&L,=Q,TB1J" BD_* "3C QWK] OVDM6_L?
MX+^)I/)\[SK?[/C=C&\@9Z=O2OSPZ<5^A\,4K4JE7N[?=_PY]UP[3M2G4[NW
MW!1117VI]<%%%% !1110!]>?L3^+I;C1M7\.3S!DMY/M-M'M.55N&&>G7D <
M]:^GZ^"OV3=4ATWXO6:R,[2W,3PQ1 ?*21\S$]L ?CTK[UK\JS^BJ.-DU]I)
MGYKG=%4L8VOM:A1117SAX(4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZO+A8YM.@L$)P9KB[C*CZ["Q_3O7ZI#.,OG#G5>-O-V?W/49YFJEV"J"S$X
M Y-?7OP#^&<O@+P[-=:C"(]8U JTBYR8HQ]U/8\DG\/2J_PO_9^TWP/=1:GJ
M4RZMJ\?S1G;B&!O50>I_VC^ !KUJO@>(,^AC(_5<*_<ZOOY+R_KU04445\&(
M**** "BBB@ HHHH CG@CNH)(9462*12CHPR&4C!!K\<OV<%?]B/_ (*<:KX
MN6:U\,:]<R:/ 9"0K6]SB:Q89ZD/Y49/J7K]D:_+_P#X++?".YTM_ 7QHT)7
MMM1TVX72KVZ@&&0AC-:RD]MKB5<^K*/2HC-4:\*LMOA?I+3_ ("]66XNM1G2
M6^Z]5K_P?D>D_P#!8CXU?\('^SS8>"+.?R]3\97HCE520PLX"LDI_%S"ON&:
MO7_^"=GP._X45^ROX5L+JW\C6]:3^W-2R,-YLX!1#[K$(E(]5-?G;K'C _\
M!27]NSX:V44<DOA6PTRQ>_@8$)''%$MS? @],RLT&>^%[8K]J%58U554*JC
M4#  K:G!T:4W+XIM_P#@,=%\GOZIF,YJK.$8[15_^WI:_>EI]PZOQ0^"?_*8
M?4/^QTUW_P! NJ_:^OQ0^"?_ "F'U#_L=-=_] NJG#_[Y3])?H;5?]RJ^J_*
M1^SOB;_D6]5_Z])?_0#7XE_\$E?A3X.^+GQR\5:9XT\-:;XGT^W\//<0VVJ6
MZS1I)]HA7> W0X8C/N:_;3Q-_P BWJO_ %Z2_P#H!K\=O^"*/_)Q'C+_ +%A
M_P#TJ@HPJ3Q4[_R/\IF6);6'A;^9?G$_1[7_ -@G]GSQ'I<UA<_"CP[;Q2C!
MDT^W-I,ONLD15A^!K\OOCS\'O%G_  3!_:%TGQAX/AM?$7@O47+:=-K=C%<C
M (,EI*Y7,<H'*R1E6*\CHRU^WU>8_M(? ?1/VD?@_KW@77%5$OHM]G>;<M9W
M2Y,4R_[K=1W4L.AK&3G3:JT]U^*[?Y?=LV;14)ITZFS_  \_Z]=[#?V;_P!H
M+PU^TS\*M+\;>&I"D5P/)O+&1@9;&Y4#S(7]QD$'^)2I'6O'/^"B?C_XX_#_
M .'OA:Z^!=KK=UKD^J-%?KH>@KJT@M_)8@LC0R[!O"_-@<\9K\XOV*?CGKW[
M!_[4FK> _'N[3O#U]>#2-?@D8^7:RJ<0WBY_A&X'=WCD)YPM?N='(DT:R1LK
MQL RLIR"#T(-;U8QJ0C4I.T96?W6=O1_D_4PIRE3E*G46J_X:_K^J]#\6/\
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ME/(H[*/W'\Y!72?\$F=4AU#]BOPS#$P+V6H:A;R@'.&-P\F#Z?+(I_&OH/\
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M_D[WX$_[R_\ I4M?H/7Y\?MY?\G>_ G_ 'E_]*EK]!Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HILDBQ1L[L$11EF8X 'J:SM/\ $VCZK<""RU6Q
MO)B-PCM[E';'K@&@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[\9*<5*.S/A:E.=&;IS5F@HHHJC(**** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSG/RYZ<UJ_ 7X)Z'^SO\*M%\ >&[K4+W1M)\XP3ZI)')<-YLSRMN9$13\TA
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M+>Z/#<N$%[#* SQQD\&17#MMZD/D [6Q^E]Y;)>VDUO(,QS(T;#V(P:_ _\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(_CI\+?\
MA)[%M=TV-FU6UCP\,:@^?&.W^\.WY5ZY1656G&M!PD=6%Q-3"555I[K^K'Q?
MX \<WW@'7X[VV=OL[,$NK?'$B9Y&/[P[5]@:#KUEXETFWU+3YA/:3KN1AU]P
M1V(KP+X\_"LZ3<R>)-*AD>TF8M>QKR(F/\8[X/?TKG?@[\4I? VK+9WT['0;
MAOWBD;O)8]'7T'K7BT*DL)4=&KL?98[#4\VPZQ>&^-;K]/5=#ZOHJ.">.ZAC
MFB=9(I%#(ZG(8$9!%25[Y\&%%%% !1110 4444 %%%% !1110 4444 %>(_M
M,? X_$S0EU;2(-_B:P7$:[]HN(LY:/'3=W'3FO;J*Z<-B*F%JQK4GJCHP]>>
M&J*K3>J/RGFADMII(9HVAFC8I)'(,,C#@@CL13*_0?XN_L\^'OBIF]9!IVN(
MA6.\B'ROZ"101N'OG(KY1\6?LO\ CWPFLLATX:K"A.)--W3%E X.T#=DGC&*
M_4,%G6%Q<5S/EEV?Z/J?HN$S;#XJ*N^679_H>345L:EX/US1IH(;_2[JRGF.
M%AN$V2#G&64\H/=@ :Z'0_@GXQUZ]\B'1+I4X(N?*9X'&<'9*@*-CV:O8E7I
M0CS2DK>IZLJU.*YI25O4X:O3?A+\#-=^*"R7MDL,=E"<[YSA9,?PYYQ^/\N:
M]B^%G['\D,@O/%SQ@JV4@A<EACOZ<\<G)ZC ZU]0:3I%GH=C'9V%M':VT8PL
M<2A1]?K[U\GF7$$*:=/"ZR[]/^"?,X_.X4UR8;5]^A\4W>EZGX+U5+::&?2[
MZU(,?567!X93W'N*]I^'7[0P_=6'BG _A74HU_\ 1BC^8'X5ZYXL\%Z3XTT\
MVFJ6JS <QRCAXV]5/^17S9\1/@QJW@<R7<&[4M('/VB,?/&/]M?ZCCZ5Y-/$
MX;,H^SKJTOZV?Z'FPQ&'S"/LZRM+^MG^A]5VMU#>6Z3V\J30N-RR1L"I'J#4
MM?'7@/XG:SX!N%%I+]HL"V9+&9CY9]2O]TGU%?3'@7XFZ+X^M0;.807RC,EE
M,P$B^N/[P]Q7BXO+JN%][>/?_,\C%8"IAO>WCW_S.MHHHKRCS HHHH ****
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M%7*SGG4DK4H)+S_I&<\WDM*4$OZ^1\\Z+^S'?S!7U76(;48!,=K&9&SGD9)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQU\(;C0KS4]%GTZVOKF'5M/ED@:.61XEVI*A&&VQ$\'."*TJI4O9-_:_#?\
MR(IWJ<Z_E_X'^9^GGA/P;H'@/1HM(\-:'IWA[2HB3'8Z7:1VT*D]2$0 #\JV
M*_++_@G_ /\ !4+5O$OB;2OAK\8KU+V>_D6UTGQ4ZK&YF)PD-T  #N.%64 '
M. V<EA^IM:SBU:5[I]?ZZ_UM8RA).\;6:"BBBLC0**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% $<\,=S#)%*H>.12K*>A!ZBODWXO?#&3P#K/FVJ22:+=$F&5AD1L>L9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH _./_ (*V?\A'X<?2Z_\ 9:^^_AW_ ,D_
M\,_]@RU_]%+7P)_P5L_Y"/PX^EU_[+7WW\._^2?^&?\ L&6O_HI: .AHHHH
M**** "BBB@ HHHH **** "BBO'[W]KCX3Z=>3VEQXK\NX@D:*1/[.NSM93@C
M(BP>1VK"KB*.'LZTU&_=I?F=%'#5\1=48.5NR;_(]@HKQG_AL3X0_P#0W?\
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M,O<>2Q)ZA-\3$^L1K]QJJ-IT85H[2_!]OQ7Y="9>Y5E2?3\4^OX!117YV_\
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MZE07$,FT$KNP#@G:X4BM/A:53W;_ -:D_%?DUL?L117"_ _XQ:#\?/A;X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG;;-%ST+IL)..<XKJQ-JTTZGN\S3=^CO?\S##_NH^Y[W*FE;KT_X?]#]!O\
M@D/X=U?0?V0+2;5(I(8-3UF[O;!9,@FW.Q-P!Z O'(1Z]>]?:]>0_LL_'OP1
M^T/\(=+\0^ X5T[2[4"PET;RUC?3)(U7_1RB_* %*[2O!4C'H/7JWKMNIJK;
M+Y)67X&%!)0T?=_>[O\ $*^!_"?_  3Q\7VO[=LOQQ\3>(M!USP^VJW6JI8
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?GQ^WE_R=[\"?\
M>7_TJ6OT'K\^/V\O^3O?@3_O+_Z5+7Z#T %%%% !1110 4444 %%%% !1110
M 4444 %%%% %#7K&34]#U&SB*B6XMY(D+G RRD#/MS7SK^S_ /LV^*?A;X]A
MUK5[G2Y;1+62 K9S2.^Y@ .&C48_&OIFB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY[_:.^ /B/XM^)-+U#1K
MC388;6T:!Q>S.C%BV>-J-Q7T)10!S7PW\.W7A'P)HFC7K1/=65LL,C0DE"P]
M"0#C\*Z6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G;X^?"W^S9I?$VEQ(
MEFY'VR",8V,3_K!['O\ G7+_  ;^)K^!-8^R7;*=&O9 )RV?W+=!(/;U%?5L
M\$=U"\,R++%(I5D89# ]017R9\7OAG)X UKS;?,ND7C,T#;2/*.?]63T^GM7
MA8JC+#S]O2/M\KQD,=1> Q6KZ?UW1]:0S1W$*2Q.LD;@,KJ<@@]"#3Z^?/@+
M\51:-'X9U>=([?&+&9^,'/\ JR?3T)^E?0=>K0K1KPYHGR^-P=3!5G2G\GW0
M4445T' %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM%=?\O\ /_ARMINFVNCV45G96\=K:Q#"11+M51["K-%%>SMHCY!MR=V%%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\X_^"MG_(1^''TNO_9:
M^^_AW_R3_P ,_P#8,M?_ $4M? G_  5L_P"0C\./I=?^RU]]_#O_ ))_X9_[
M!EK_ .BEH Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYA_:?_ &3?
M^%C7$_BKPA''#XE8 W5@S*D=]C #!B0$DQUSPV!G!R3]/45QXO"4<;2=&LKK
M\O-'=@\;6P%95J#L_P 'Y,_'CQ!X<U3PIJDVFZQI]QIE]$2'@NHRC<$C(SU&
M0>1P:SJ_8;6_#>D>);<0:OI5EJL ! COK=)EP<9&&!ZX'Y"LS1_AGX/\.WB7
M>E>%-#TRZ0Y6>STZ&)U.",AE4'N?SKXB7"LN?W*ON^FOYGWL.,(\GOT?>\GI
M^1\#? 7]D_Q#\4-2M=0URUN-"\**1))<3*8YKI?[L*D=_P"^1@ Y&3Q7Z(Z+
MHMCX=TFUTS3+6*QL+6,10V\*[411T %7:*^LR[+*.6P:IZR>[_KH?'9GFU?-
M)J532*V2V7^;"BBBO7/%"BBB@ HHHH **** "OQT_:,LG_8G_P""G&@?$&W0
MV?A7Q%>)JLS*"(_)N"8;]?<JS/)CMN3VK]BZ^%O^"O'P0_X61^S?'XPLK?S-
M7\%W0O"RKEC9RXCG7Z ^7(?:,UE*I["I"O\ RO7S3T:]-F_)&D8>VA.B_M+3
MU6WSZ+U/'O\ @LE\5KGQ-J?PX^#7AYC>WNH3+J]S;PG)E=V,%H@]<DS''^Z:
M_0G]G_X3V?P,^"_A#P+9!=FC:?'!-(O26<C=-)_P*1G;\:_);_@GCH.O?M;?
MMD:=X]\8,;^V\$Z3:322$$HTL$"6UHISGYBR&8^K(Q[U^U5=2A[&ERWNYMR^
M2NH_A^AS.;JU$^D$E\WK+\=@K\4/@G_RF'U#_L=-=_\ 0+JOVOK\4/@G_P I
MA]0_['37?_0+JL\/_OE/TE^AT5?]RJ^J_*1^SOB;_D6]5_Z])?\ T U^.W_!
M%'_DXCQE_P!BP_\ Z505^Q/B;_D6]5_Z])?_ $ U^.W_  11_P"3B/&7_8L/
M_P"E4%/"?[U/_ _RF98G_=X?XE^<3]FZ_+G_ (*P_L9)%;O\=? MF;2^M75O
M$EM9*5+#("7R[>C*<!R.V'[,3^HU5-7TFRU_2;W3-1M8KW3[R%[>XMIE#)+&
MZE61@>H()!'O6%2+E:4-)+;^O/\ K4WIR4=)?"]SXQ_X)E_MH3?M(?#V?PGX
MKO%F^(/AJ)1+,Y^?4K/A4N/=U.%?W*M_'@>E?MN?L>_\-C^"O#WA_P#X2W_A
M$/[)U!K_ .T?V;]M\W,;)LV^='M^]G.3TZ5^5'QI\"^*?^":O[9%CK?AKSGT
M2.<ZCHLDC'9>V#G;+:2-W*@M&W?[C\9%?MO\)?BCH7QI^'&@>-?#=P+G1]8M
M5N(N1NC/1XWQT=&#*P[%371/DQ5)5DNJNNS3_P U]Z?2QSQYL/4=*_IZ/_A_
MN:ZW/S:_X<8_]5L_\M3_ .[:^P/V(?V-_P#AC;PGXET7_A+_ /A+_P"V;V.\
M\_\ LS[%Y.V/9MV^=)NSUSD?2OI2N<^)'C2V^''P]\2^*[Q#):Z)IMQJ,L:]
M66*-G*CW.W'XUG*I[*$I/:VOIO\ H6J?M9Q26M]/7;]3YR_;J_;RT+]DGPZF
MEZ=%#KOQ%U*$O8:4['RK9#D"XN,'(3(.$&"Y! ( +#XS_98_88\=?MG>,E^-
M'Q_U+4'\/W[K<6]G<$Q76KQCE0H&/(M<=-H!8?<V@AZ^)X_CY>:[\?I/BKXY
MT:U\>7\VH-J,^EZG*ZVLK_\ +*-@.3%'\H$?3"!3D9!^T5_X+<^.HU"K\-?#
MBJHP +N< "G12BE5GK/\(_YO^NR3JMR;IP?N_B_^!_7F_P!=-!T'3?"VBV.C
MZ/86^F:58PK;VMG:1B.*&-1A551P !V%7Z_'W_A]YX[_ .B;>'?_  +GK[;_
M &F/VH-5^'?["Q^*5A%'8^)=<T:Q-DL1RMM<WB)\RYZ^6'9AGJ4&:*CE&G*L
M];-+U;V^\5-*4XTEI?\ );_<>-_M_?\ !2*3X4ZI=?"WX2D:E\0)&%M?:M%'
MYRZ;(W AA3!$EQR.Q"$@89LA>;_8=_X)EW%OJD'Q5^/$<FL^)KJ7[=:^'-0<
MS>7(QW>?>EB?,E).?+.0.K9/RK^=O[-/[2'_  SO\3)_'DWA'3_''B+:QM+C
M6YY#]EE<DO.,?>D.<;CR,MW.:^O_ /A]YX[_ .B;>'?_  +GITDJ2Y[WF^O;
MT_K\=15&ZCY+6@NG?U_K\#]@0 H  P*6OR>^'?\ P66\;^-/B!X9\/3?#W0+
M:'5M4M;!YH[J<M&LLJH6 /4@-FOUAI\KY5+H_P"OU%S+FY>W]?H%?CAXH_Y3
M40_]C'9_^F^.OV/K\</%'_*:B'_L8[/_ --\=30_WVE_76(8C_<ZO]=)'['U
M^,/_  5TF-[^V7X.LM=EDC\.IHE@.IVK"UU-YS#I@\'O_".:_9ZOD'_@HE^Q
M))^UEX'T[4O#DL%IX^\/K)]@^T-LBO86P7MW;^$Y 9&/ .0<!B1E)N$Z=6UU
M%WM\FOU^XVBN>,Z=[<RM?[G^GWGUEH]G9:?I-E:Z;'%#IT,"1VT<  C6(* @
M4#C  &*Y'X[:/HVO_!7QWI_B%(GT2;1+P7?G8VK&(6);)Z$8R#V(!K\M/AI_
MP4+^.W[&?A^V\!_%SX7WNNVFEI]ET^XU9Y=.N1&GRA1<^7)'<1J,!64=/XF&
M*J_%3]K[]H3_ (*#:*? 'PS^&5YH'A;4F$6H26#R7'G+U,<]\Z1Q1Q'C*X4M
MC!)!VFL1!UXRA2?-S7U]>K)H2]BXRJ+EY;?AV_0Z7_@A[J&H_P#"5?%6Q5W.
MDFRL9G7)VK-YDH4X]2N__OD>E?K57SE^PS^R-9_LC?"4Z--<PZEXKU:1;S6]
M0A!\MI0N%AC) )CC!(!/)+,V!NP/HVNNLTVHIWLK7_KMMZ(YJ2:YI/J[_P!>
MN_S"O!?VO?VOO"G[(_@ :QK(_M/Q!?!H]'T&%PLMY( ,LQYV1+D;GQW  )(%
M>[R2+#&\CG:B@L3Z 5_.1^T9^T1=?'C]I'5?'OB.U.MZ-'J 2ST6:9XXQI\3
MGR[?*\H&498K@EG<C!-<,GS35).U]WV7]?J=L8V@ZC5[=.[_ *_0^G?@M^SI
M\6O^"G'Q(/Q-^*NK76D?#^&4QPS1)Y:R1AN;73XFR%08PTISR.=[ X_7GX=?
M#GPW\)?!NF^%?"6D6^B:#I\?EV]G;+@#N68GEF)R2S$DDDDDU^2VD?\ !:3Q
M=H&EVFF:9\*_"]AIUG$L%O:VUQ-''#&H 5%4<     5;_P"'WGCO_HFWAW_P
M+GKJ;C&/LZ:M'\_-_P!?JWS6E*7/4=W^7I_7X:'ZM?%+PF/'GPS\6^&B,C6-
M)N]/_P"_L+)_[-7Y<?\ !$_Q4F@_$CXI>";\M;:E=V=M>1VTN0P:VEDCE&/4
M>>N>_'M7Z+?LJ_&:^_:"^ ?A3Q_J6G6^E7NLQ3226=JS-''LGDC !;D\(#^-
M?G[^V)^R'\4OV>OVA6^/WP&L;O4;>XNVU"\T_2X3//9W#Y\\- HS+;RY8D*#
MMW-G  -9ZX7$R]ILUROR:O;\?R1;?UC#I0W3YEY[7_)?B?JW7XW?\%8KY_BU
M^V5X$^'FCNMS>V]A9Z:4C^8I<W5PQ"GWV-"<>C5UD_\ P6<^(&J:.?#VE_!N
MV3QZZ>0LRWL\T8GZ$BR$(DZ]$,I/N:ZK_@G[^Q5\0=?^,4_[0/QQ@NX-;DED
MO--T[5EVWDUTXQ]IFC(_=*BDA(R 0<'"A%W.G3YJ\*DO@@[W[Z6LO6_]*]B5
M3DI3C'XI*R\M4[OTM_6S^@_^"F7P\D\1?L/^*[2QB,TF@K9ZA&JCD1P2H)&^
M@C+GZ"N1_P""//C>V\1?LGMH:2@WGA_6;JWECSDA)2)T;'H3(X_X":^UO$&@
MV'BK0=1T75;9+W3-0MY+2ZMY!E98G4JZGV()%?CMJ7PP^.W_  2Z^-&L>)/
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MZ7W%<+_P6,_Y-%B_[&*R_P#0)J[K_@ES_P F.?#KZZA_Z7W%7A?X6(_QQ_\
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M[-7B;X6>/(=:U6^TJXM4M9("EG+(S[F  .&C48_&@#Z5HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&UOQIX?\,SQ
MPZOKFFZ5-(N]([V[CA9EZ9 8C(K9KY__ &B_V?\ Q!\7?$FF:AH]YIMM#:VK
M0.M[)(K%BV<C:C<4 >\V-];:G9Q75G<175K,NZ.:%PZ./4,."*GKF_ASX;N?
M"'@71-%O'BENK*V6&1X"2A(]"0#C\*Z2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "LOQ+X=L_%6B76EWR;K>X3:2 ,J>S#/0BM2BDTI*S*C)PDI1=FCXH\:>
M$;WP'XCFTZY+YC;?!<[2HE7J'7W_ )$5]"_!3XJ+XRTT:7J<X.N6ZGEACSXQ
MT8>K#O\ G71_$SX>VOQ"T!K61C#>0YDMIE_A?'0^H/2ODV&;5O!/B#<IETW5
MK*3!!X*GT/J#^1%?/R4L!5YE\+/O:<J>>87DGI4C_5_1]?\ AC[AHKC_ (9_
M$*T^(&@QW".B:C" MU;C@HWJ!_=/8UV%>]":J14H[,^%JTIT9NG45F@HHHJS
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
M",C!&17E'Q&^ NG^)C+?:*4TS4V^9H^D,I]P/NGW''M7K%%=%&O4P\N>F[,W
MHUJE"7-3=CX@U;1]6\'ZQY%[#-IM_ =R,#M(]&5A_,&O7/A_^T3+:+#8>)D:
MXCR%74(_O*/]M?XOJ.?8U[5XH\(Z5XQT]K/5;5;B/G8_1XR>ZMV-?.OQ$^!6
MI^$Q)>Z67U72UY; _?1#N6 '(]Q^5?34\7ALQBJ>(5I?UL_T/HH8K#X^*IUU
M:7];/]#Z:TW4K76+**[LKB.YMI5W)+&<@BK-?%_@OX@:QX%O/.TRY_<,<RVL
MF3%)[D>ON*^E_A_\7-&\>1+$KBPU3'S64S<G_</\0^G/M7D8S+:N&]Z.L>_^
M9Y>*R^IA_>CK'^MSN:***\@\H**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.XN(K6%YIY$AB0;FDD8
M*J@=22>E8OC;QOI/P^\.W.LZS<K;VD(X'5Y&[(H[L?2O@WXN?'KQ%\6+J6&X
ME;3]"#DQ:9"Q"D9RIE/\;?H.PKVLNRJMF$KK2*W?^7<]? 9;5QSNM(K=_P"1
M]5^+_P!K'P#X7D:&VO9M>N%."FF1[E'.#\[$*?P)S7 7_P"W191W3K9>$+B>
MV_ADN+]8G/U4(P'_ 'T:^2**^YI</8&FK23EZO\ RL?8T\CP<%:2<O5_Y6/M
M'1/VVO"EXUNFIZ/JFF.P_>R($GCC/H""&8>^T5[/X.^(GAOQ_:M<:!J]MJ*K
MP\<;8D3_ 'D.&'XBOS'J]H>O:CX9U2'4=)O9M/OX3\EQ;L58>H]P?3O7-B>&
M\-4BW0;B_O7^9SXC(,/-?N6XO[U_F?J;17A'P!_:6M_B5(NAZZL.G^(E7]TR
M'$=X .2N>C]]OY>E>[U^?XG"U<)4=*LK,^(Q&'J86HZ=568445'-/';0O+-(
ML42#+.[ *!ZDFN4YB2BO.?$WQX\+>'7DABN)-5N5XV60#)GW<G;^6:\M\1?M
M(>(-2W)I=O!I,1Z/CSI?S(V_I7IT<MQ-;51LO/3_ ()Z-'+\16U4;+ST/I*[
MO;?3X&FNIX[>%1EI)7"J![DUYKXB_:%\,:/N2R:;6)AT%NNV//\ OM_0&OF_
M4=9U?Q5>+]LN[O5+ECA$=FD.>P5?\!79>&/@/XI\1*DTL$>DVS<[[PD/CV0<
M_GBO7CE>'PZYL54_3_@L]2.6T*"YL3/]/^"7O$?[1'B75BR:>L&CPGIY0\R3
M_OIAC\@*\]GN]6\5:@HEEO-6O9" H9FF<GL .:^AO#?[-^@:;MDU6XGU>4=4
MSY47Y*<_K7IFC^'],\/P^3IMA;V,>,8@C"Y^N.M#S'"896PU._X?CN-X_"X=
M6P\+_A_P3YJ\._L]^)]9VO>K#H\!ZFX;?)CV5?ZD5ZCX=_9U\-Z3M?4&GUB8
M=?-;RX\_[J_U)KU2BO*K9GB:VG-9>7]7/,JYCB*NG-9>7]7*FFZ39:-;"WL+
M2"R@'2.WC"+^0JW117EMMN[/-;;=V%%%%(04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%<[XT\>:1X$TTW6I3X<C]W;1D&64_[
M*Y_7H*F4E%7D]#2G3G5DH05VS;OKZWTVSFNKJ9+>VA4O)+(<*H'<FOGGXG?'
MZXU8RZ;X:=[6SSM?4!P\PQR%!'RCWZ_2N'^(7Q1U;X@7>+A_LVG1L?)LXB0N
M.Q;^\U=A\,?@+=:\T6I>(4DLM.SE;,Y66<8X)(/RK^I]J\6IB:F)E[*@M._]
M;'V>'R[#Y;3^LXYW?1?UN_P_,XKP#\-=6^(%]LLX_*LHV'GWDOW5!/./[S>U
M?4?@?X>Z1X!T\0:?"'N&&);R1099?J<=/8<5O:=IUMI-C#9V<"6UK"H2.*,8
M"@59KNP^$A05]V>)F&:U<<^5>[#M_F%%%%=QX84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'YQ_\%;/^0C\./I=?^RU]]_#O_DG_AG_
M +!EK_Z*6O@3_@K9_P A'X<?2Z_]EK[[^'?_ "3_ ,,_]@RU_P#12T =#111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO"?C)_P2?^!?Q0\^[T;3;SX?:M(6?SO#\V+8L1@;K:3<@4?W8_+^M?#7Q?\
M^"/'QA\ R27O@C4=+^(5C&08TMY!I]_QR6\J5MG'^S*2>PI^T7VXV]/Z_P A
M<C^R_P"OZ]3]LJ*_ _PK^V9^U)^R1K$.B:_J&NQQ1Y*Z'X\LI9T=1\HV-+B4
M(,<>7(%K[&^#?_!:KPCK7V>R^)G@V^\,W+;4;5-#<7EJ3_$[1-MDC7V7S35)
M*6L62VXZ21^E5%><?"7]HSX9?'2T6;P+XVTCQ$Y3S&L[><)=QKZO;OB5/^!*
M*]'I--;C33V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHDHHHKF.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&8*I).
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M"]#\+1A=+TNWM&Q@R*@,A^K'D_G7QWU[!873#PN^_P#P7J?*_7<'A=*$+O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'Y\?MY?\G>_ G_>7_P!*EK]!Z_/C
M]O+_ ).]^!/^\O\ Z5+7Z#T %%%% !1110 4444 %%%% !1110 4444 %%%%
M %'7+%]4T34+.)E62XMY(59N@+*0"?;FOGOX"_LT^(_A7XZAUO4]2TNZMDM9
M(#':/(7RP !^9 ,?C7TE10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5X%^T1^S[KWQ>\1Z9J&DW^G6D5K:M ZWC
M2!BQ;.1M4\5[[10!SGPZ\-W'@_P/HNBW<D4US8VRPR20DE&([C(!Q^%='110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 1SP1W4,D,J"2*12K*P
MX(/!%?*/QA^%\G@/5S<V<+'0KEOW+YW>4QZQGT'I7UE6;XB\/6/BG29]-U&!
M;BVF&"IZJ>S ]B/6N3$X=8B%NJV/6RW'RP-7FWB]U_74\*^ ?Q3-C-%X8U21
MVAE;%G.[9$9_YYG/8]J^AZ^*O'/@N^\!^()-.N^1_K+>=#Q(F>&'H1W]Z]_^
M!WQ1'BW3AH^H-C5K.,;9&?)N$'\7)SD=ZX<'B'%^PJ;K;_(]K.,!&<?KV&UB
M]7_G_F>K4445[)\>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% "=>#R*\O^(WP+TSQ9YM]I>S2]6;+$@?N9C_
M +0'0^X_6O4:*WHUZF'ESTW9FU*M4H2YJ;LSXBU[P[JW@W5A;:A;RV-W&=\;
M@XS@\,C#^E>J_#K]H2?3_*L/$V^ZM_NK?J,R)_OC^+ZCGZU[IXB\,Z9XLTU[
M'5+1+J!N1N'S(?[RGL?>ODKX^^!#\(;6.ZMKQ;JVO7,5LLA FC.,_,/XL>H%
M?5X?$4,UM0K1M-[?\!GTU"O1S*U"K'WNG_ .X^/?[4L/AE1HW@RYM[[4Y%#3
MZ@N)(K=2/NKZO_Z#WYXKX_U35+W7-0GO]1NYKZ]G.Z6XN'+NY]R:K,Q=BS'+
M,<D^II*^TP.7T<!3Y::UZOJSZS!X&E@H<M-:]7U84445Z1Z 5ZG\'/V@M>^$
M]PEMN?5= 8@/ITTAQ$,\M$?X3[=#^M>645A7H4\3!TZL;IF-:C3Q$'3JJZ9^
MH7A#Q?I7CKP_:ZSHURMU8W"Y5NC*>ZL.S#N*V:^$_P!EWXP3^ _%T.AW]PQT
M'5)!'MD?"6\Q/$@XXST/2ONROR7,\!++Z[I_9>J?E_P#\QS#!2P-;D^R]O0*
M***\@\L**** "BH;J\@L8&FN9X[>%>LDKA5'XFL;4/'_ (;TN-7N==L(U8[0
M1.K<_@35QA*?PJY<82E\*N;]%<+??&[P78.BMK23%AG-O&\H'U*@XK&NOVC_
M  G;SM'&FH72#I+%;J%/_?3 _I73'!XF6U-_<=$<)7EM!_<>IT5X;>?M06JK
M*+709F;GRVFG4 ^A( XK"O/VG-:E@*VVD6-O+D?O'=Y![\<?SKJCE>+E]FWS
M1TQRW%2^S;YH^CZ*^5[[]H;QC>!!%/:6.T\FWM@=WUWEOTQ6)??%[QCJ$PDD
MUZZC(&,0;8E_)0!73')<0_B:7W_Y'1'**[W:1]AU!-?6UO&\DMQ%&B#+,[@!
M1ZD]J^*+KQ;K=Y</-/K-\\KG+-]I<9_(UE_-(V>79C]22?ZUTQR-_:J?A_P3
MHCDS^U/\#[0O/B+X7L;<SR^(-.\L=?+N5D//LI)K"O\ X[>#+%D']J&YW=[>
M%WQ]>*^8[?P;KUU,D46B:@TCG"C[*XS^)&*W-/\ @WXRU!W5-#FA*C.;ATC!
M^A)YJ_[+PE/^)5_%(O\ LW"P_B5/Q2/9KS]I3PQ;S[(;;4;N/ /F1Q*H^F&8
M']*\C^/_ ,=(O&_P]U'2+72IK2.2:(BX>X!)4,#@J!W],FM&P_9U\77D;-,M
MC8D' 2>XR3[C8K"G^)/V8M9/A'4I'U:U-TMN[_9X8F?<0,X#$CKCTKHP\,LP
M]:$U*[375O\ (VHPR[#U8R4KM-=?\CY%HHYZ,-K#@J>Q[BBOT4^["BBB@ HH
MHH *]M_9(2^_X6G;O P%@$87*\9)*G9[XSZ5XE7TY^Q3X7\[7-3UY7R88S;M
MM;( .,*PQP3U!R> >*\C-JBIX*JWVM]YY>9S5/!U&^Q]?T445^/'Y6%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5S7C?X@:1X"T\W&HS;IF'[JTB(,LOT&>GOTKC_B=\<K+PBTNG:3
MLU#6%.V3.?+@X[GNWL/QKYX1-<^('B #-QJVJ7! +'D@9[]E4?D*\S$8Q4WR
M4]9'TV7Y/*NO;8GW8?B_\EYFG\0/B9JWQ O=UW)Y%BC'R+.(G:N>F[^\WO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /SC_X*V?\ (1^''TNO_9:^
M^_AW_P D_P##/_8,M?\ T4M? G_!6S_D(_#CZ77_ ++7WW\._P#DG_AG_L&6
MO_HI: .AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:OJ]]<:GJE]X=LKBZO+N0R2S2-"I9W8\LQ)R2:T4&X.?9I???_(CF]Y1[_\
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MVC;#^6\C/X5MV/[/?C&[A+R6]I9MG'EW%R-WU^0,/UKZIHKFEG6(?PQ2^_\
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MJ??Z&OMGIP*_.N),7&I4CAX/X=_4^#S_ !4:E2-"+^'?U%HHHKXP^3"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#\X_^"MG_ "$?AQ]+K_V6OOOX=_\ )/\ PS_V#+7_ -%+
M7P)_P5L_Y"/PX^EU_P"RU]]_#O\ Y)_X9_[!EK_Z*6@#H:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV> PP0NK98 9R30!]#T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5S'BKXF^%? ]W#:Z]KEII=Q,ADCCN'P64'!(_&
MNGKPKX_?L\ZE\8?$&FZC9:Q:Z<EK:M R7$3.6);.1@T >U:3JUIKFFV]_87"
M75G<()(IHSE74]Q5NN?^'_AJ7P;X+T?1)YDN9;&W6%I8P0K$=P#704 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF*SMI;B=Q'#$AD=ST50,D_E7)^%_C!X-\:ZHNG:'K]KJ-ZR&00P[LE1U/(H
M[&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY&TXNS"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5GZYKVG^&].DOM2NH[2UC'+R'] .I/L*XOXD_&72_ L;VL&W4=8Z
M?94; BR/O.>WTZ_2OFCQ3XPU?QMJ/VK5;I[B3.(X5SY<>>R+V_G7G8C&PH^[
M'5GT.7Y/5QEJE3W8?B_3_,V_CU\1/^%N6+:5;6<=M86\OF6TTH!E9QP&SCY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'YQ_P#!6S_D(_#CZ77_ ++7WW\._P#DG_AG_L&6O_HI:^!/^"MG
M_(1^''TNO_9:^^_AW_R3_P ,_P#8,M?_ $4M '0T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?M._&KP7\;OVJ/@OJ7@G6UURRL;B.WN)5MYH=DC7"L!B1%)X':OT]H ****
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M)$<I+(#(ZG&,AFR0<=QUKI:*FGAZ-/X()&M;,,7B%:K5;7J%%%%=!YX4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?G'_ ,%;/^0C\./I=?\ LM???P[_ .2?
M^&?^P9:_^BEKX$_X*V?\A'X<?2Z_]EK[[^'?_)/_  S_ -@RU_\ 12T =#11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#\X_^"MG_ "$?AQ]+K_V6OOOX=_\ )/\ PS_V#+7_ -%+
M7P)_P5L_Y"/PX^EU_P"RU]]_#O\ Y)_X9_[!EK_Z*6@#H:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOP>HJ82]G-WV?]6*E'VD5;='Z[@A@"#D4V65(8WDD=8XT!9G8X  ZDFOR*\
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M_D[WX$_[R_\ I4M?H/7Y\?MY?\G>_ G_ 'E_]*EK]!Z "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M27S0,=,;\X_"JCF26DX6,Y\.N2O1JIKS_P"!<^T**^7-+_:.\5V.1<K8Z@N
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MO3L34445[!\B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH _./\ X*V?\A'X<?2Z_P#9:^^_AW_R3_PS_P!@RU_]%+7P)_P5L_Y"/PX^
MEU_[+7WW\._^2?\ AG_L&6O_ **6@#H:*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YQ
M_P#!6S_D(_#CZ77_ ++7WW\._P#DG_AG_L&6O_HI:^!/^"MG_(1^''TNO_9:
M^^_AW_R3_P ,_P#8,M?_ $4M '0T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\X_^"MG_
M "$?AQ]+K_V6OOOX=_\ )/\ PS_V#+7_ -%+7P)_P5L_Y"/PX^EU_P"RU]]_
M#O\ Y)_X9_[!EK_Z*6@#H:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_P5L_Y"/PX^EU_[+7WW\._^2?\ AG_L&6O_ **6O@3_ (*V?\A'X<?2Z_\
M9:^^_AW_ ,D_\,_]@RU_]%+0!T-%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?GQ^WE_P G
M>_ G_>7_ -*EK]!Z_/C]O+_D[WX$_P"\O_I4M?H/0 4444 %%%% !1110 44
M44 %%%% !1110 4444 5-7L/[5TF]LB_E"YA>'?C.W<I&<=^M>+?!_\ 9?C^
M$WBZ+7%\1OJA2W>#R&LQ%G< ,YWG^5>Z44 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>-_&S]G6/XR:Y8:B^OMI
M)M;=K?RUM!-NRV<YWKBO9** ,/P1X9'@WPEI6ABX-V+&!8?/*;-^.^,G'YUN
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /SC_X*V?\ (1^''TNO_9:^^_AW
M_P D_P##/_8,M?\ T4M? G_!6S_D(_#CZ77_ ++7WW\._P#DG_AG_L&6O_HI
M: .AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!^<?_!6S_D(_#CZ77_LM???P[_Y)_X9_P"P9:_^BEKX$_X*V?\ (1^''TNO
M_9:^^_AW_P D_P##/_8,M?\ T4M '0T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^?'[>7
M_)WOP)_WE_\ 2I:_0>OSX_;R_P"3O?@3_O+_ .E2U^@] !1110 4444 %%%%
M !1110 4444 %%%% !1110 45!?7D6G65Q=SDK#!&TKD#)"J,GCZ"O/_  )^
MT!X-^(^N)I&AWMQ/>O$TP66U>,;1UY(Q0!Z/1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !117!?$+XW>%/A?J-M8Z_
M=SV]Q<1&:-8K9Y 5!P>5'K0!WM%9WAW7K/Q1H=EJVGNTEE>1B6)F4J2I]0>1
M6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9=74@CC3(!)/89[U^B_P7^&\7PS\%6VGCFZD EG9AALD?=/TYZ<?SKA?V?\
M]G2+X=VT>J:Y'!<:ZQW#82XB]#D@8/MV]37N]?8Y;@707M:GQ/\  _'N),[C
MCI+#8=^Y'=]W_D%%%%>\?"A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M^<?_  5L_P"0C\./I=?^RU]]_#O_ ))_X9_[!EK_ .BEKX$_X*V?\A'X<?2Z
M_P#9:^^_AW_R3_PS_P!@RU_]%+0!T-%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?GQ^WE_
MR=[\"?\ >7_TJ6OT'K\^/V\O^3O?@3_O+_Z5+7Z#T %%%% !1110 4444 %%
M%% !1110 4444 %%%% %35K :KI=Y9,YC6YA>$N!DKN4C/ZUXY\(_P!F&R^$
M_BR/7(-?N=1D2!X/)EMU0$,,9R#7MU% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7D'QF_9WM/C%K5CJ-QK=QIC
M6MNT CA@5PP+9SDFO7Z* ,7P7X93P;X5TO1(YVNDL8%A$SJ%+X[D#I6U110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YQ_\ !6S_ )"/PX^E
MU_[+7WW\._\ DG_AG_L&6O\ Z*6O@3_@K9_R$?AQ]+K_ -EK[[^'?_)/_#/_
M &#+7_T4M '0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!^>_[>K+'^UU\"F9@JJ5)9C@
M?:5K[Z_M[3?^@C:_]_U_QKYC_:^_8KO_ -I[Q;H&LVGBRV\/)I=E):-#-8-<
M&0LX;<")%QTQC%>!_P##H[5_^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^O^-'
M]O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)7_\
MCU 'Z+_V]IG_ $$;3_O^O^-']O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__ ()7
M_P#CU'_#H[5_^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^O^-']O:9_P!!&T_[
M_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)7_\ CU 'Z+_V]IG_
M $$;3_O^O^-']O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#H[5_
M^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^O^-']O:9_P!!&T_[_K_C7YT?\.CM
M7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^O^-'
M]O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)7_\
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M (T?V]IG_01M/^_Z_P"-?G1_PZ.U?_HI.G_^"5__ (]1_P .CM7_ .BDZ?\
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M[_K_ (U^='_#H[5_^BDZ?_X)7_\ CU'_  Z.U?\ Z*3I_P#X)7_^/4 ?HO\
MV]IG_01M/^_Z_P"-']O:9_T$;3_O^O\ C7YT?\.CM7_Z*3I__@E?_P"/4?\
M#H[5_P#HI.G_ /@E?_X]0!^B_P#;VF?]!&T_[_K_ (T?V]IG_01M/^_Z_P"-
M?G1_PZ.U?_HI.G_^"5__ (]1_P .CM7_ .BDZ?\ ^"5__CU 'Z+_ -O:9_T$
M;3_O^O\ C1_;VF?]!&T_[_K_ (U^='_#H[5_^BDZ?_X)7_\ CU'_  Z.U?\
MZ*3I_P#X)7_^/4 ?HO\ V]IG_01M/^_Z_P"-']O:9_T$;3_O^O\ C7YT?\.C
MM7_Z*3I__@E?_P"/4?\ #H[5_P#HI.G_ /@E?_X]0!^B_P#;VF?]!&T_[_K_
M (T?V]IG_01M/^_Z_P"-?G1_PZ.U?_HI.G_^"5__ (]1_P .CM7_ .BDZ?\
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M]0!^B_\ ;VF?]!&T_P"_Z_XT?V]IG_01M/\ O^O^-?G1_P .CM7_ .BDZ?\
M^"5__CU'_#H[5_\ HI.G_P#@E?\ ^/4 ?HO_ &]IG_01M/\ O^O^-']O:9_T
M$;3_ +_K_C7YT?\ #H[5_P#HI.G_ /@E?_X]1_PZ.U?_ **3I_\ X)7_ /CU
M 'Z+_P!O:9_T$;3_ +_K_C1_;VF?]!&T_P"_Z_XU^='_  Z.U?\ Z*3I_P#X
M)7_^/4?\.CM7_P"BDZ?_ ."5_P#X]0!^B_\ ;VF?]!&T_P"_Z_XT?V]IG_01
MM/\ O^O^-?G1_P .CM7_ .BDZ?\ ^"5__CU'_#H[5_\ HI.G_P#@E?\ ^/4
M?HO_ &]IG_01M/\ O^O^-']O:9_T$;3_ +_K_C7YT?\ #H[5_P#HI.G_ /@E
M?_X]1_PZ.U?_ **3I_\ X)7_ /CU 'Z+_P!O:9_T$;3_ +_K_C1_;VF?]!&T
M_P"_Z_XU^='_  Z.U?\ Z*3I_P#X)7_^/4?\.CM7_P"BDZ?_ ."5_P#X]0!^
MB_\ ;VF?]!&T_P"_Z_XT?V]IG_01M/\ O^O^-?G1_P .CM7_ .BDZ?\ ^"5_
M_CU'_#H[5_\ HI.G_P#@E?\ ^/4 ?HO_ &]IG_01M/\ O^O^-']O:9_T$;3_
M +_K_C7YT?\ #H[5_P#HI.G_ /@E?_X]1_PZ.U?_ **3I_\ X)7_ /CU 'Z+
M_P!O:9_T$;3_ +_K_C1_;VF?]!&T_P"_Z_XU^='_  Z.U?\ Z*3I_P#X)7_^
M/4?\.CM7_P"BDZ?_ ."5_P#X]0!^B_\ ;VF?]!&T_P"_Z_XT?V]IG_01M/\
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MIG_01M/^_P"O^-?G1_PZ.U?_ **3I_\ X)7_ /CU'_#H[5_^BDZ?_P""5_\
MX]0!^B_]O:9_T$;3_O\ K_C1_;VF?]!&T_[_ *_XU^='_#H[5_\ HI.G_P#@
ME?\ ^/4?\.CM7_Z*3I__ ()7_P#CU 'Z+_V]IG_01M/^_P"O^-']O:9_T$;3
M_O\ K_C7YT?\.CM7_P"BDZ?_ ."5_P#X]1_PZ.U?_HI.G_\ @E?_ ./4 ?HO
M_;VF?]!&T_[_ *_XT?V]IG_01M/^_P"O^-?G1_PZ.U?_ **3I_\ X)7_ /CU
M'_#H[5_^BDZ?_P""5_\ X]0!^B_]O:9_T$;3_O\ K_C1_;VF?]!&T_[_ *_X
MU^='_#H[5_\ HI.G_P#@E?\ ^/4?\.CM7_Z*3I__ ()7_P#CU 'Z+_V]IG_0
M1M/^_P"O^-']O:9_T$;3_O\ K_C7YT?\.CM7_P"BDZ?_ ."5_P#X]1_PZ.U?
M_HI.G_\ @E?_ ./4 ?HO_;VF?]!&T_[_ *_XT?V]IG_01M/^_P"O^-?G1_PZ
M.U?_ **3I_\ X)7_ /CU'_#H[5_^BDZ?_P""5_\ X]0!^B_]O:9_T$;3_O\
MK_C1_;VF?]!&T_[_ *_XU^='_#H[5_\ HI.G_P#@E?\ ^/4?\.CM7_Z*3I__
M ()7_P#CU 'Z+_V]IG_01M/^_P"O^-']O:9_T$;3_O\ K_C7YT?\.CM7_P"B
MDZ?_ ."5_P#X]1_PZ.U?_HI.G_\ @E?_ ./4 ?HO_;VF?]!&T_[_ *_XT?V]
MIG_01M/^_P"O^-?G1_PZ.U?_ **3I_\ X)7_ /CU'_#H[5_^BDZ?_P""5_\
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M_P"@C:?]_P!?\:_.C_AT=J__ $4G3_\ P2O_ /'J/^'1VK_]%)T__P $K_\
MQZ@#]%_[>TS_ *"-I_W_ %_QH_M[3/\ H(VG_?\ 7_&OSH_X=':O_P!%)T__
M ,$K_P#QZC_AT=J__12=/_\ !*__ ,>H _1?^WM,_P"@C:?]_P!?\:/[>TS_
M *"-I_W_ %_QK\Z/^'1VK_\ 12=/_P#!*_\ \>H_X=':O_T4G3__  2O_P#'
MJ /T7_M[3/\ H(VG_?\ 7_&C^WM,_P"@C:?]_P!?\:_.C_AT=J__ $4G3_\
MP2O_ /'J/^'1VK_]%)T__P $K_\ QZ@#]%_[>TS_ *"-I_W_ %_QH_M[3/\
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MK_\ 12=/_P#!*_\ \>H_X=':O_T4G3__  2O_P#'J /T7_M[3/\ H(VG_?\
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M,_Z"-I_W_7_&OSH_X=':O_T4G3__  2O_P#'J/\ AT=J_P#T4G3_ /P2O_\
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M?^WM,_Z"-I_W_7_&C^WM,_Z"-I_W_7_&OSH_X=':O_T4G3__  2O_P#'J/\
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M/[>TS_H(VG_?]?\ &OSH_P"'1VK_ /12=/\ _!*__P >H_X=':O_ -%)T_\
M\$K_ /QZ@#]%_P"WM,_Z"-I_W_7_ !H_M[3/^@C:?]_U_P :_.C_ (=':O\
M]%)T_P#\$K__ !ZC_AT=J_\ T4G3_P#P2O\ _'J /T7_ +>TS_H(VG_?]?\
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MO.&<9ZX%;_\ PZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\
M01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_
M]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_
MPZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^=
M'_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[
M_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^
M"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?
M_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\
M01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_
M]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_
MPZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^=
M'_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[
M_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^
M"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?
M_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\
M01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_
M]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]7E
M?[27[ ]]^SE\-7\7W7C"SUV);N&T^R0Z:T#9D.-VXR-T],4 ?K7_ &]IG_01
MM/\ O^O^-']O:9_T$;3_ +_K_C7XG?LO_LV3_M->,]4\/6FMV_A][&R^VFXF
MM#<!QO"[=H9<=<YS7TU_PZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C
M1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__
M (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""
M5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/
M^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_]O:9
M_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U
M?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H
M[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C
M1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__
M (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""
M5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/
M^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_]O:9
M_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U
M?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H
M[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C
M1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""5_\ X]1_PZ.U?_HI.G_^"5__
M (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XU^='_#H[5_^BDZ?_P""
M5_\ X]1_PZ.U;_HI.G_^"5__ (]0!^B_]O:9_P!!&T_[_K_C1_;VF?\ 01M/
M^_Z_XU_/_JGAX:7XJO-$+I(]MJ#V!G"8#%93'OQZ<9Q7W':?\$EM6N[6&<?$
MC3U$J*^W^Q7XR,X_UU 'Z._V]IG_ $$;3_O^O^-']O:9_P!!&T_[_K_C7YT?
M\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^
MO^-']O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)
M7_\ CU 'Z+_V]IG_ $$;3_O^O^-']O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__
M ()7_P#CU'_#H[5_^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^O^-']O:9_P!!
M&T_[_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)7_\ CU 'Z+_V
M]IG_ $$;3_O^O^-']O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#
MH[5_^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^O^-']O:9_P!!&T_[_K_C7YT?
M\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^
MO^-']O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)
M7_\ CU 'Z+_V]IG_ $$;3_O^O^-']O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__
M ()7_P#CU'_#H[5_^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^O^-']O:9_P!!
M&T_[_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)7_\ CU 'Z+_V
M]IG_ $$;3_O^O^-']O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#
MH[5_^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^O^-']O:9_P!!&T_[_K_C7YT?
M\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)7_\ CU 'Z+_V]IG_ $$;3_O^
MO^-']O:9_P!!&T_[_K_C7YT?\.CM7_Z*3I__ ()7_P#CU'_#H[5_^BDZ?_X)
M7_\ CU 'Z+_V]IG_ $$;3_O^O^-']O:9_P!!&T_[_K_C7XZ?M4?L:W?[+ND>
M'[^[\3VOB(:O<R6RQPV!MS$53=DDNV<].U0_LJ_L?77[45KXBGM/$MKX=_L>
M6*)EFL3<>;O4G(PZXQCWH _9'^WM,_Z"-I_W_7_&C^WM,_Z"-I_W_7_&OSH_
MX=':O_T4G3__  2O_P#'J/\ AT=J_P#T4G3_ /P2O_\ 'J /T7_M[3/^@C:?
M]_U_QH_M[3/^@C:?]_U_QK\Z/^'1VK_]%)T__P $K_\ QZC_ (=':O\ ]%)T
M_P#\$K__ !Z@#]%_[>TS_H(VG_?]?\:/[>TS_H(VG_?]?\:_.C_AT=J__12=
M/_\ !*__ ,>H_P"'1VK_ /12=/\ _!*__P >H _1?^WM,_Z"-I_W_7_&C^WM
M,_Z"-I_W_7_&OSH_X=':O_T4G3__  2O_P#'J/\ AT=J_P#T4G3_ /P2O_\
M'J /T7_M[3/^@C:?]_U_QH_M[3/^@C:?]_U_QK\Z/^'1VK_]%)T__P $K_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'D7[77_)LOQ)_[ L_\J_+/]A/_ ).H\!_]=9?_
M $6:_4_]K*WENOV:_B-%!%)-*^C3A8XU+,QQT ')K\O_ -AWP[JUG^U%X%FN
M-)U"WA667=)-:2(J_NSU)7 H _9JBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "OR*_X*8?\G2W7_8&LO\ VI7ZZU^2
M_P#P4FT+4]0_:?NIK33+ZZA_L>S'F06SR+G]YQD B@#[9_X)[?\ )J/@_P"D
MW_HUJ^CZ^=O^"?\ :3V/[*_A"&Y@EMIE$VZ.:,HP_>-U!&:^B: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\2_;7_P"3
M5/B7_P!@E_\ T):]MKQ;]L^WFN_V6OB1#!#)/,^E.%CB0NS'<O  Y- 'YJ?\
M$]_^3K_"?_7"[_\ 11K]E*_'K]@'P_JMC^U3X5FN=*O[:%8+O,DUK(BC]T>I
M(Q7["T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?.' + <U^H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'X$>+/\ DK6M?]C%-_Z5FOWKT;_D#V/_ %PC_P#017X3
M>*O#&M-\5M9<:+J10^(9F#"RE((^UDYSMZ5^[.C@KI-B",'R$X/^Z* +E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M? G_  5K_P"1/^'7_83N/_1%4O\ @DG_ ,@GXD_]?5I_Z+:M?_@J]I=[J?A'
MX>K965S>,FIW!86T+2%1Y/4[0<52_P""4&EWVF:5\1A>V-U9E[JT*_:8&CW?
MNVZ;@,T ??U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M24M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !24M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 E+110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 E+110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %)2T4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4M%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5P/QJ^,VA? WP3<>(=<<OSY=K9QD>;<RGHB_P!3V%=]7Y5_MR?%:Y^(
MOQLOM*BE9])\/G[#;0J<JTO'F-CU)('X5G)NZBMV7%*SD^A0^(_[:'Q3^).J
M2"TUN?PY82MLATW1<QG!Z R#YV;\1["N0C^+GQ<\(S1WLGBGQ?IYW?+)?7-Q
ML)],2Y4_E7Z#?LA_LTZ-\*/ NG:UJ6GPW7B_4H5N)[J9 S6RL,K%'G[N!C)'
M)->_:UH>G>(M.FL-4L;?4;*92LEO=1"1&!Z@@BM91Y-%N9J7/J]CX@_9H_;X
MO]4URS\,?$EH'%TXBMM>B01[7/ 691Q@G^(8]Z^[%8,H(.0>017Y4?ME_L\6
MOP+\<VMQHF]?#6LAI+6)B2;:0'YH@?3N*^W/V*?BM-\4O@GIYOIO.U;1V_L^
MY9CEF"CY&/U7^55%JI%R6Z$TZ<DNC/?****@H**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J6LZQ9>'])N]3U&XCM+&TB:::>0X5
M$ R235VOSW_;Q_:2D\3ZLWPR\+7#36,$BKJLUL23<39^6W7'4 XSZG J)-[1
MW9<4MWLCSGXS?MM^/_%7CK4[SPCXCO?#OAR,F*RM;=4!=%_Y:/N4G<W7V&*_
M1WX.ZM>:]\*_"NHZA</=WUUIT,LT\F-SN5!).*_'+Q]X(U3X=Z]/H>LQK!J4
M,$<LL(.3'O7<%/\ M 'FOV"^ _\ R1CP7_V"K?\ ] %;125-^J_4QDVZB]'^
MAWE%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'D7[1G[1VA_L]^&8[N\C_M'6KS<MAI<;[6E8=68_P *#N?P%?G7XX_:\^+/
MQ&U)_P#BI;S2H9FQ%IVAY@4<\*"OSL?J<U8_;6\87GBS]H;Q*EQ*7@TMEL+6
M//"*J@G\R>:^\?V5/V>?#?PG^'ND:BMA!=^)=1MH[FZU*9 \@WJ&"(3]U0".
M!U[U--<\?:/8J;Y)<B/SEC^+7Q<\(RI>R>*?&&G'.%EOKFYV$^F)<J:^E?V=
M_P#@H%JBZO9Z!\2O*N[.X=8H]>B01R0L>!YRCAE_V@ 1WS7WCJNCV.N6,MEJ
M-G!?V<RE9(+B,2(P/4$$8K\L/VT_@?I?P7^)T*:#']GT/6(#=06F<BW8'#HO
M^SW'I5<_+))K1D\G,FT]4?JQ#,EQ$DL3K)&ZAE=3D,#R"#W%/KP/]A_QE>>,
MOV>=#DOY6FN+"26P\Q^2RQGY<GZ$#\*]\JY1Y96)C+F5PHHHJ"@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N<^(/Q T/X8^%;[Q#X@O4LM.M4
MW%F/S.W9%'=B> !7FWQT_:T\$? Y9[&[NCJ_B54W)HUD<R D<&1ND8^O/L:_
M._XB?%+XA?M8>/+:U,$U](6/V'0]/!,-NO=L=SCJ[?ITJ+N6D2[):R.AD_:2
M\:?%#]H/2=577]6TK2KS5H(X=)M;Z6.!( X 5D5@I)'7(YS7ZM5^*?PRMY+/
MXN>%[:4 2PZS#$X!R RR8//U%?M96R25*-O/]#)MNH[^7ZBUQ7Q<^+6@?!?P
M;=>(O$$Y2WC^2&WCYEN)#]V-!W)_(5VM?F3_ ,%#_B1-XD^,<7AI;C.G:#;+
M^Y#<>?(,L2/4# _&L)-Z)=36*W;Z&/\ $[]O'XF>.;Z4:1J"^#]*W?NK?3E!
MFV]M\K DG_=P*\Y/Q"^+TW^F_P#"0>-V0_/YRW-YY>/7@[<5]P_L4_LQ^'_#
M'@/2_&FNZ=;ZIXDU2/[1 UU&'6SB/W0BD8#$<ENO-?6(C54V!5"8QMQQCTK9
MQY-.IFI<VO0_*?X:_MP_%'P!?Q?;M8/BK3%8"6RU8!G*CC"R@;E/US[BOT:^
M"?QK\/\ QT\&Q:]H4C(5/EW=E,1YMK+CE&_H1P17B_[9G[,'A_QKX%U7Q=HF
MG6^F>*=+B:Y>6VC""\C499) ."V.C=:^6_V!_B#=>$_CM8:4DC_V=KT36TT.
M[Y2X&Y&QZ@C]:*;]HW![BFN1*:V/U,HHHJ2@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **R?%7BS1_!&A76LZ]J-OI6EVJ[I;JY?:B_XGV')KX1_:*_
MX*!3Z];W6@?#436%E(#'-KTR[)G'?R4/W!_M'GT J7+HMRE&^YU_[<G[58\/
MVLG@'P9JLD.M.P.IZA8RE&M5'/E*ZG(<]\'@5U?_  3R\4:SXJ^%>N7.M:O?
MZQ<)JC(DVH73SNJ[1P"Y) ]J_.O6O!^OZ7H.G^(M5L;FWT_5Y7%K=760UTPY
M9QGDC_:[U^@/_!-3_DD>O_\ 86;_ - %:4XV4[[_ /!1%25W&VW_  &?7M%%
M9WB+7+;PSH.H:M>-LM;&![B0DX^502?Y5#:BKLI)MV1Y%^TK^U%H?[/FCQQ&
M)=7\3WB%K/2U?: /^>DI_A3/XGM7Y]>,OVM/B[\2-2=!XFOK!)CB/3M!4P*!
MZ+L^=OQ)-<[K&H>(OVF/C9)+ &N-6\07WEV\;$E8(<X4>RJO)_&OU%^!O[/?
MA7X&>&X++2K&&?564&[U::,&>=^_S8R%ST4<"B,6X\\PE)*7)$_+VW^,WQ;\
M$W<=PWBSQ9ITS?<_M&YG*O[;9L@_E7U]^RW^W9/XRUJT\)?$/[/!J-TPCLM:
MA41QS/V25>BL>S#@^@KZZ\6>#=$\=:+<:1K^EVVJZ?.I5X;F,,/J/0^XYK\C
M_P!H?X2S?!+XQ:GX>L&F>VC*WFFR8)D\ICE>G4J1C/M3C.TN62T8G&\;Q>J/
MV*HKSWX >-+CX@?!WPMKEXKI>SV:+<"0$-YB_*Q.?7&?QKT*JE'E;1,9<R3"
MBBBI*"BBB@ HHHH **** "BBB@ HHHH **** &R2)#&TDC!$4%F9C@ #J37P
MC^T-_P %!KVRUB\T#X:);B*W8Q2Z]<Q^9O8'!\E#Q@?WFSGL.]>V_MS?$B?X
M>? 74ELKC[-?ZO*FG1R X(5_OD>^T'\Z^*_V+?@#I_QN\?W,NN*9O#NBQK-<
M6X)'VER?DC)'\/<^M3%.I)KHBI-0BGU9Q%U\:OB]XXG>=?%GBO464X;^SIYU
M5?;$. *L:+^T9\7?A]J"!/%^O6\RD,;75G>8-]4F!.*_7?1= TSPWI\5CI6G
MVNFV<2A$@M8EC10.@  K!^(_PJ\+_%?0;C2?$ND6^H02*0DKH/-A;'#(_52/
M8U3]WX25K\1X#^RU^VQ:_%_4(?"WBR"#2?%3K_HT\.1;WV!R #]Q^^W.#V]*
M^JZ_&'XJ>"=1^ _Q<U/18;MS=:-=+/9WB_*S)]Z-OKC@_0U^NGPK\6'QU\./
M#?B!QB34+&*=Q_M%1N_7-7I.'.B;.$N1FMXF\3:;X.T"^UK6+J.RTVQB::>>
M0X"J!_.OS=^-G[?7C7QKJEQ;>#;EO"7A]&*Q2Q*INYU_O.Y!V9_NKT[DUZ1_
MP4D^*]Q$VB?#^RF:.&5?[0U *<;P#B-#[9R?PIG[ _[->DZQHQ^(OB?3X]09
MY3'I-K<H&C0*<&8J>"<\#/3%907M&V]D:3?(DNK/EIOB;\6X5_M1O$OC1(?]
M9]I:ZNQ%CUR3MQ^E>R_!/]O[QGX.U2VM/&TY\5>'W8+).Z*+R '^-6&-^/1A
M]#7Z6M;Q20&%HD:$C:8RH*X],>E? _[>/[,6C^%]+/Q$\*V<>FQ&98]4L+=0
ML66.!,BCA3GJ!QSFGS\CVT%R\_J?=?AWQ#I_BS0['6-)NH[W3KV)9H)XSE74
MC@UHU\.?\$V_BM+>6.M^ +Z8N+0?;]/#MT1CB1!]#@_G7W'6DHV>FS,XNZUW
M04445!84444 %%%% !1110 4444 %%%% !1110 5Y/\ M"_M$:#^S[X72^U%
M3?ZM=96PTN)L/.PZDG^%!W->L5^1'[67Q!NOB=\?O$#+-Y\%E<_V78Q!LA54
M[>![L3FHE=R4%U+C9)R?0T?'W[:?Q8\?WS^5X@D\/VDA*QV&B+Y6 ?X=_+L?
M?-<BWQ&^+NE_Z=)XB\;6Z+\QFFNKP1CW.X[:_2+]FG]F?PU\&_!NGSR:=;WW
MBFZ@66\U.>(/(&89\M,_<49Q@=>]>WR0QS1M'(BR1L,%6&0?PK1QY'9&:DY:
ML_,3X0_M]^/_  3J$$7BBX_X3'0RP$JW"JMTB]RD@ R?9@?PK]'/ 'C[1?B;
MX3L/$?A^[6\TR\3<C8PRGNC#LP/!%?&W[>7[,NA:-X:D^(GABQATJ>"55U.S
MM4"13*QP)0HX5@>N.M8?_!-7X@7=KXK\1>#I96>PN;<7\$9;B.13AB![@]O2
MG!^T3B]T*:Y+26S/T'HHHJ2@K\^?VO/VS-=C\<?\(U\.M=DTNRTEV2]U&SVE
MKB?H4!((VK[=3]*]B_;>_:6'PI\*GPKH%TJ^*]7B(:1&^:RMSP9/9CT7\Z_.
MGQ!X%UCPWX;T#7=3A:"VUY99;/S,^9(B-@R'/8D\'OS6?Q._1?G_ %_6AI\*
M\V?II^P[X^\1?$;X,OJOB;5KC6=1&HS1?:+C;NV#&!P!7T-7RU_P3G_Y(%)_
MV%+C_P!EKZEKHGO\E^1ST]OF_P PHHHK,T"BBB@ HHHH **** "BBB@ HHHH
M **** "HYYX[6&2:9UBBC4N[L<!5 R23Z5)7S9^WU\1KCP)\#)[.RN/LUWKM
MPM@'#8;RR,R8_P" C]:B4N57145S.QXO\?\ _@H5J7]KW>B?#1((+.!C$^NW
M,?F/*1P3"A^4+_M,#GL!7S7<?&;XO>-IFN4\5^+=293AFT^><*OMB' %>C?L
M1?L]Z9\:O&E]J/B"+[1X=T0(SVG(6YF;[J,1_" ,D=^E?IYI.BZ?H-E'9Z;8
MV^GVD:A4@M8EC10.@  Q6G)RI-O5D<W,]%H?D3H/[2?Q>^'NH($\7ZY%+&=Q
MM-89IPW^\DP)Q7W'^RU^VA8_&BZC\->)+>'1_%NS,)A)%O? #G9G[K]]I//;
MTKVSXG_"#PK\7O#]QI7B32;>\612([G8!/ V.'1^JD5^2'CSPUJOP&^+M_ID
M5VPU'P_?+);W<9*EE!#(WXCK^-$9KFY)]1RB^7FB?M'7*_$SXE:'\)?!U]XD
M\07/V>PM5^ZHR\KG[J(.[$]!5OP#XD_X3#P3H6MXVG4+**X8>A903^N:^'/^
M"F7B^[D\1^$O#"2E;".WDOY(P>&DW;5)^@S45+P?+UO8JG:2YNFYYI\6/V[O
MB-X^U&9=#OV\':+N(BMK#'GE>QDE(SD^BX'\Z\W_ .%D?%RW7^T3XC\:I$OS
M_:'NKORL>N2=N/TKZW_X)_\ [/OAV^\'CXAZW8PZKJD]P\5A'<H'CM40X+A3
MQO)[]NU?;;0QO$8FC5HR-I0J,8],5HX\FG4A2YO0_,CX-_M^>.O!&H00>+)S
MXPT%FQ(9@JW<2_WDD &['HP.?45^C_@OQEI/Q \,Z?K^AW:WNF7T8EBE7WZ@
MCL0>"*^'/^"@?[/N@>%-.LO'WAVRATJ2XNA;:C:VZA(I&;[L@4<!L\' YK:_
MX)F^,KRYTWQ;X7FD:2SM'CO;=6/$9?Y7 ^I -$'[1-=4*:<&FMF?<E%%%24%
M%%% !1110 4444 %%%% !1110 4444 %%%% 'F/Q\^/F@? +PB=6U8FZOIR8
M['38F DN9/Z*.[=J_.3X@_MD_%;XCZDXCU^?0;25ML6G:'F$ $\+N'SL??/X
M4[]LSQ]J7Q"^.VM>:EQ_9^ER?V;81R(P7"_>(SQEF/\ *ONW]EG]FWP_\(?
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M98\[I#D]^PK&SJ3Y$;:0ASL?J?QX^+WQ!O9)?^$L\37TJG+1Z3++&L>>VV'
M ^M7_"?[4GQ<^&NJ )XJU29HSF2PUPM<*?9ED^8?@17ZM^"/ .@?#G0;;1O#
MNEV^EV$"!0D* %O]IFZLQ[DUR7QQ^ 'A?XY>%[C3]6LHHM3"DV>J1(!/;R8X
M.[&2N>JG@U;?+K$E+F^(YS]F/]J#2?VA-#FC>!=*\3V*@WFG!LJP/_+2,GDH
M3V/(KW"OQR^'?B;6/V<_CM;3S,8KK1M0-E?QJ2%EBW;7'T(.:_8:QO(M2L;>
M[MW$D$\:RQL.A5AD'\C5NTHJ<>I.L9.#)Z***@H**** "BBB@ HHHH ****
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MU_X*=?\ (T^!O^O2X_\ 0UIU+1Y81V3_ $9-.\G*<MVCU_\ X)S_ /) I/\
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M[MD=];-+_P!\"3=GVQ5N3DDVK$**B[)W/0OVV_VJ-'^+T=GX3\*.USH-E/\
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M,IZAAD56LM)LM-:5K2SM[5I3F1H8E0N?? YJW10!%<7<%JC//-'"BC):1@H
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MN?\ :!X)[]:^H:J4>5DQ=T%%%%24%%%% !1110 4444 %%%% !1110 4444
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M^3@C_P!@N?\ I7Z?UM+X8^GZLQCO+^NB"BBBLS0**** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?9?D<\-Y+S"BBBLC0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH **** "BBB@ HHHH **** /A+_@IY_J? 7_76X_]!%=A_P $U/\
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MJ"77[0/DJ0?LVE0*V.Q)8XK[6_8UTY]-_9O\&(X(,ELTO/HSL:_-WX_^+?\
MA<'QZ\0ZAIF9XKZ^6RLMO.]5(C4CV)R:_6GX<^&1X-\ ^'M#  -A8PP-CIN"
M#=^N:=+2BV^K_P V%76JEV7^2.CHHHI %%%% !1110 4444 %%%% !1110 4
M444 -=A&K,>BC)K\C_VJ?C?J'QL^*EX9V>RT/29WLK*U/S>6JMM>4CNQ(S]
M!7ZWS*9(G4=64BOSP\0?\$X?B!JWB#5+^+Q'X;2*ZNI9T5Y+C<%9RP!_==>:
MSM>:OL6G:+[G<?!7]KCX'_!/P!I_AK2AKKF(;[FZ_LS#7$Q^\Y^?UZ#L,5W?
M_#Q7X2>NO?\ @N_^SKY]_P"':/Q#_P"AE\,_]_+C_P"-4?\ #M'XA_\ 0R^&
M?^_EQ_\ &JUDW)W9FDHJR/G_ ..OC+3OB)\7O%/B72/._LW4KSSX/M";'V[5
M'*Y.#P:^Z_!__!0#X5Z'X5T73;@ZY]HM;2&WDVZ?E=RH%.#NZ9%?GY\1/!%Y
M\-?'&L>%]0G@N;W3)_L\LUJ6,;-@'*[@#CGN*^B]"_X)S^/M>T?3]3@\1>&T
M@NX8[E%DDN-P5@& .(NN#2IVY$EMH.?QW>Y]B?M,?'9_A/\ !*3Q/I,#37VI
M)'#8,XP(VE7*NP]@<X]:_-OX(^(/!EG\4(_$OQ-N;^^LK>4WIAM[?SWO+DMD
M>9R,*#R?7I7Z*?M&? #7/C#\&=$\'Z3?Z?9ZA8O;M)->-((F\M IQM4GD].*
M^6/^':/Q#_Z&7PS_ -_+C_XU2C[M24E\AOWJ:C]Y] K_ ,%%/A&J@#^W@!P
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M0P'Y9I5;>ZD53O[Q9_X)U?!'3-4M;_XB:M;1W=S!<-::8LJ[EA*@;Y #_%R
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MAI.G0B"QLH5@AC7^%5&!6A110VV[L$K*R"BBBD,**** "BBB@ HHHH ****
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MF?)S^M%W+2062U1\7_'#]I+QG^T-J=M!JA6VTV.3_1-%T]6,>\\ G^*1_K^
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M \=>!](^(_A74/#FNP/<Z5?IY<\4<K1LRYSPRD$=.U1.+E%I%PERR39^;_\
MP3N_Y."/_8+G_I7Z?UY'\,?V5_AU\'_$W]O^&-*N;/4_):#S);Z:8;&ZC:[$
M5ZY6TG=)=C&*LW_70****@L**** "BBB@ HHHH **** "BBB@ HHHH ****
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M+X5^$_BII8L/%6A6FL0+]QID_>1^Z.,,I^AKP35/^"<?PLOK@R6UYXBTR/\
MYXV]]&ZC\9(V;]:I.5K,32O='SC\:/V_O%WQ'T>YT;P]I\?A'3+E3'--',9;
MMT(P5#X 0>X&?<5F?L>_LOZG\7/%ECXEUBT>V\&:=,)FEF!'VZ13D1IGJ,_>
M;I7V%X+_ &#_ (2>#[N*ZDTFZ\07$9W*VL7)E3/O&H5#^*U] 6MI!8VT5O;0
MQV]O$H6.*)0J(HZ  < 54;0?,MQ2O)<O0E50BA5 55&  .!2T45(PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
MBNKJ*RMI;B>188(4,DDCG"JH&22>P KRJQ_:W^">J:A!8VGQ7\'W-Y/((8K>
M/6K=G=R<!0-W))XQ1N[(.ESUJBBB@ HI*\DOOVN_@CIM[<6EW\6?!MO=6\C1
M2PR:W;JR.IPRD;^"""*/(#URBL3P;XX\/?$/08=;\+ZW8>(-'F++'?:;<+/"
MY!P0'4D$@UMT]@"BBN"\>?'SX;?"W5(M-\8>._#WAC4)8_.CM=5U**WD9,XW
M!78'&>]3<9WM%<]X'^(7ACXF:(-8\):_IWB323(T0O=+N4GAWCJNY21D9Z5T
M-5L(****0!1110 4444 %%%% !1110 45Y]XY_:$^&/PQUH:1XN\?^'/#6JF
M-9A9ZIJ<5O+L/1MK,#@X/-=7X5\6Z+XYT&UUOP[JMGK>CW2[H+ZPF6:&4 XR
MKJ2#R.U"U5T&VC-:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH CGA2YADAE4/'(I1E/0@C!%?S<_M(>"[CX(?M,>,-'A1H&T
MG6GN+4=/D+^9'CVP17])5?BS_P %E/AC_P (O\?]$\701[;;Q%IBK(57 \Z$
M[3D^I4K^58R?)5A->GZ_H:Q7-3E%^OZ?J?KK\&_&</Q$^%'A'Q+ XD35-+M[
MDL#GYFC&[G_>S78U\=_\$I_B%_PG'[(^AV,DOF7.@7,VFLIZJ@;<GZ-7V)79
M6251VV_SU.6D_<5_ZMH>9?M+_$J+X0_ ?QOXLD=4?3],F:'<>LK+M0?7<17\
MW4>EZKXDBUC6$@DNH[7%Q?7 Z)O? 8_5C7[!?\%F_BL_AOX*^'?!%K,4G\0W
M_GW"J<9@A&?R+E?RKPK_ ()^?LR_\+&_8]^..JW,&9_$-JVG:>Q4YS OFY'O
MOVCBN**O[2K_ "K\O^"_P.N6BIT_YG_7X*YZ]_P17^*G]L?#;QAX#N)]T^CW
MBZA;1%N1#*,.0/3>H_.OTGK\'/\ @EG\2Y/AC^UQI&E73F"V\01R://&Q('F
M'F,'W#K^M?O'7=4]Y1FNJ_+3\K')#W7*'9_G_P &X5_/Y_P4H^(__"S/VO/%
MS6\AGM=):/28-O(_=CYL?\")K]XOB)XL@\"^ _$'B*Z<1P:78S7;,W3Y$)'Z
M@5_/!\!?"-W^T3^U1X<TZ<-))KVO_:[ML;L(93+(3GMC-<L8^UKQA_6NG^9T
M2E[.C*?]::_Y'[F_L2_"Q?@]^S#X#\/M&([QK!;V[^7!,TW[QB1ZX('X5[G4
M5M;QV=O%!"@CBB0(BKT"@8 _*I:WJ2YYN1C3CRQ40HKQOXK?MA_!OX)WDUCX
MN\?:58:E$,OI\,AN;E?9HX@S*?8@5YKHG_!47]F_7-02T3QX]FS<"6^TNZAC
M_%C'@5DFI;&C3CN?5U%<_P""?B!X:^)6AQZSX4U[3_$.ER<"ZTVX69,^A*G@
M^QYKH*IIK1DWOL%%%4-=U_3/"^E7&IZQJ-KI6FVZ[YKR]F6&*-?5G8@#\:G;
M5E;Z(OT5\N^*O^"F7[.?A&]-K/\ $*+4) 2"VEV5Q=("/]I$(_(UT7PV_;V^
M WQ6O8++1/B+IL5].VV.UU0/8R.?0><J@GVS3C[VPG[NY] 44BL&4$'(/((I
M: /Q _X+%_\ )V$'_8"M?YO7Z4?\$X?^3,_AQ_UZ/_Z,:OS7_P""Q?\ R=A!
M_P!@*U_F]?I1_P $X?\ DS/X<?\ 7H__ *,:GAO]WGZ_JPQ'\:'HOR1]+T45
MX[XX_;!^"_PV\37?A[Q+\1]#TG6K0@7%E-,2\1(R VT'!QVZU-UL.SW/8J*Y
M#X9_%SPA\9-#DUGP5KMOXATJ.4P->6@;R]X'*@D#)&>U=?5--;D[A1112&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\&?\%B/AF?%O[-MEXF
M@CWW/AO4HY6P,GRI?W;?@"0:^\Z\Y_:*^'T7Q4^!OC?PK+&)/[2TJ>)%_P!L
M*67_ ,> K"M\#:Z:_=J;4G[Z3ZZ?>?G'_P $2?B(8=8^(7@F67Y)HH=4@1F_
MB4E'P/H0?PK]8J_ ?_@FMXYD^%W[97A:UNV^SIJ4LVBW"MQAG!4 _1@*_=SQ
MQXIM? _@W6_$%[(L5KIEG+=R.YP $0M_2NRM)>SC5>UOR_X%CEIQ?M)4^M_S
M_P"#<_$'_@JY\5F^)'[5E_HULYDLO#-O'ID2J=P,I^>0C\6 _"OUK_8Q^%:?
M"7]F'P+X;EA5;@Z<EU=KUW2S#>V?P8#\*_$/X#^'[W]I[]L30TNT:9M=U\ZC
M><9VQ"0RMGV &*_HHBC6&-(XU"(@"JH'  Z"LZ4>3#I2WD]?U_%_@74ESUW;
M:*_X"_!?B?SO_M'>&[O]FO\ ;.\0K9AK<:3KZZI9LHQF)I!*N/;!(_"OZ!_
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MU?Y]/Q;/=O\ @BU\*QK7Q2\6>/+F#=%HMD+*VD*])IC\V#Z[ ?SK]AZ^/_\
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M6BJ<O:Q^%_U^'Y'[6T445)04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?P_X0L9%N;;2+U3'=:DXY7<AY2+."=V"W0<<U^RL4:0QI'&BI&@"JJC  '0
M4^BKE*Z26Q$8V=WN?A__ ,%BS_QEA"/^H%:_S>OTI_X)P'_C#/X<?]>C_P#H
MUJ^A[[P_I>IS>=>:;:74N,>9- KMCTR15NUM8+&!8;:&.WA7A8XE"J/H!4T_
MW=.4.[O^+?ZEU/WDU/LK?@D)=VL-]:S6UQ$LUO,C1R1N,JZD8((]"*_ C_@H
M3^RK<_LO?&V>?2()(O!NN2->Z/.F<0-G+P9[%">/8CTK]_:JW^E66JHJ7MG;
MWB*<JMQ$K@'U&16;C[RDMT6I>ZXL^//^":/[7T?[1'PI3PWKUXK>.O#42P7(
M=OGO+<<1SCU/\+>X![U]FU0L=!TS2YC+9Z=:6DI&TO! J-CTR!5^MIRYWS&,
M8\JL%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
9%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img61678762_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_5.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $$ =T# 1$
M A$! Q$!_\0 'P !  (" P$! 0$           8'!0@$"0L# @H!_\0 1A
M @(" @$$ @$ !@@#!@,) P0"!0$&  <($1(3% D5%A<A(B,QEQ@X55=WMM77
M)$&8&3(T45)A"AK6)3-46&B4EK34_\0 '0$!  (# 0$! 0            4&
M P0' 0(("?_$ %$1  (#  $$ @ # @<,"0$##0(# 00%  81$A,4(14B,2-!
M!S)187&3TQ8D-%-C<X&1H;'1\#-"4I2RL\'2X?$8)51B<I47-5:BU$-5DL+5
M_]H # ,!  (1 Q$ /P#^_CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCFH/G:YW)3>+?;^U=%;[V-H'8
M>F:1LVV4#?4/5>F]P]E7MO24CS=%K.LZ9OU3L6LV$;:[C7ANA&U]VR8I</+T
M]A06! W*CGH_K'?MV[_OGM'^OO'^_FMU+^0@'77XP_'WSO[##_354W/6?0=M
MW7M_7J$M0K:MK>RZUIO8'98-:O4UWU-5U#>;9A[9*D" 7ZO7E[2R30D&L^E)
MSV8_-,1]?<]O]'?M'^G].1RM_+_TG/K/RH[6O](VFDUWQ!N^R:GM"O%95MEL
M5BIK4.L2=4;)J-=(->H_J_D@OVE46?3U_=66OU=K25UM:6#24*^P"DX\9^O_
M ,KMV_T_[^W[^?K9ORVZ%JMR;1G.BNX;3M.E3[BV?8="U^AN+)JWZ[Z6V7K;
M7[G<NG3GUU"S[BCN8^TZ![K:MIM?J![$:DW>GM+/7;77!+VCCQ_?W^OK[_DF
M>_:)^_K]/O\ D^OY>0+Q(_(=M.V=]>;G0^_;.KV]O?4_EYY$IZ!U_5YTS7.Q
M],\5>I>KNG=B!95^GT6OU%KV%+.][R?3-=@T-K<;Z_OE@-V)Z37]BN-<<](>
MT#/:?L8F?Y._>?\ TCERZ;Y_5GE+^._R3\L>@WE=/M-"ZE[?M-4=1N-?W*UU
M7>=-Z8!OX$]GH+N@A_']MTW8[+&L[7I&[:I#VV^OONUT=DTBXUG:;]SR1[%$
M3_+'_/\ ])Y3N@_E84T#JS\?E?WKI^W;)O7DYU%X%3V3L@ =<UI#:>Q/+NE!
M0'V'1M72742V.GT?? *-]R JH:PIH%;V#HL=<KMC-;8IT7/?'O)=NT=O*>WW
M^D??^V/T_H^_Y><#KO\ +TU8:[;/[_TJ4&Y[CY5>670'1?7VI;1BT<V6M\1M
M>W*\WUR]M,TI"+7#:^AY3H5ZRKL\W^X;[K% ):KU]*YVRO<2/;]_UXC,S_\
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M"M17A*4!52SM5^HDO=F4[65%"#7L6*:&FJN[LWXJDU"AS*Y-4@O8UK)$[DM
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MAB.TP,F'B4%)=P@(\N_?MK,?79S5*$1[%>=R!:IOJ^F"=K-G7B:&9MPF!&,
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M7H[)*[J=2^JQ8>_8MJ*K^S3*%M#Q%T*]!%^T(@\')8!2"X"2B8"(X_C7X_\
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MRMUN&C[% 'C3KHD5%V,A\R[SWF99$]YO/Q"4VRV\I_&]:S8N-0CGR)\?-\=
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M,-4\^Q5VYTILQ;M2NN@6(%;0TJ;J[%W/E0B02X&%Y,&"M-?T:&95Z?D VEL
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ME9W=NNGZK9-0VVGK(WFHUEZMBZJ-MW5>M8UJP<]\/T[S]3!?ZQB9F.W?_?\
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M"K-,MC#4.V6K4-;4RPUJZ%A")'8[71O]TC^IQ3DQ6K9=&Y7;H)O9C&3G9L:
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MLR;S-@B@20J/6F1;LAFC3BCF5XJ*PP#&R4]/YG4U!;VI^;\L1!MNQZ) WNM
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MA7G2SY1:BO,,6:UMBPO6,K-C$8.B.N>]H.*]2KH(\T*'HL#5= J(03*S2L[
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M3>RSE1;(EW%!V9 7*X$@Y$0$SGN(SMQ*NO!"4V&TU.^43KHU^O5K]0==-%9
M, MNP$OBJ+%\ZRHF&VFL2=;;<*WCW&,3UIFAU-\-^IE4LJAH5V,2FKK9:K.6
MI;Z_:I5LU ]]<3EZ([E%VLPS;/<^T_G+H&1T36NUZI7]Z;52!O.H8F^2M&%"
MQ_OMPPCB65EI5 1_>IJ*._9<_4CR#:KK-4EKIMQOL(5$:M&Y2U;!/W]UKV/M
M68U D&F-_!9*5S#V3N0)%KWL!Q(ZY#>F)R5?0TXL447MK4SZU;PO952YGRW\
M3M56 YV:J7!%4*IL@9N-B&+A7F,J;)C(067TSBU\2WO-SLH;==-_+^55MWGY
M]*M=;\2CI/J5[2K+/C&40"_%ID?C/8/7//E>2JJ&\):7]JQE3;I2L),IH36J
MZ\Y#+O@K:<5HZ0@H9B1>Q2S^O'(:Q0KM_/ QL8LR]9]/4UKMZK0!VK#;<Y^9
M1588L;=BCHT]I"],T"@;"3E]<ZSW%W[ ]<K@U\B-K,SZJJ0/U[S:MYBYG1>R
M[4SDLJ**M:P4^-I[B("(70,Y]>1@@DV-+N0SO7KZCN+VVUDE@@RI>?97KJJ]
M#7"E9'N7XQ&V<0*^576.54"2L)LC8635+@_T4V29P*5>/#SNL^I]?4?L.QV6
M=4CR;3Z2E7'G>M>A0VAI>G-J4UUY8S7(S2/Q@EU<6VRCUR4-SZ>=F8!UATSI
M9L$5(+X. B36]KX7^(4GV7VH*#'.D"\%V&E)*[24S&:E':M+7AHP]E7NYEL6
M:^H&W@L@9K)G+F"BBX\.9=KG++$&S P*<<9)EO HSS,N([2KMZCZ@7@C9?9J
MYNA9Q*CJIB^H]]G2\@LU%KGV>-HF$\)DC ?>P(F2C\VWG9;.E.G$1IEG7K39
M#<I5]FM'S,M=6DY@+7(R[VF@X[-A8C*A]C)[+\RCZZ>6U%=V];V#^GM;!&=H
MQ$JM,.Q6@Q$3)40OGPD$JXFV1"%4F/$BZHSX+C"HOFE&UYV;<]ST46?%#I4=
M!%<W88VEVK@"ZF V;/QOFJI>^J":C;WDBNV#.1"L@@G3RK<RVPKJ\*6C<V8"
MP$4WK,:2B_OI4 !S%6NYA'[%Q2_,\)\H,B8,Q):;7GL4@=PN!.Z_JK]HYK;1
MU&JMG[$$C.&'6->\T&;W)#'K%RM0S.94(L28B>'P9YM6.HJ]^]U!EU[>G0O4
M,MSKU',;GQ5S>GJYN6Y5AMV?+J30;=*BJ21X.*F3B('P!QRLY%ZC6ULK#O6*
M'SFO&R\;H/8VY=)W:J8FD6AGU8JR8%$>8&8C'8>WE$)L;5@#E!9"5B]BO!^F
M/AN*CR3598-3:JJZ0ZM5-GY%IP*6";)6B8SA;.,#Q'$"2=R]NKK=+LLU(U[J
MLJBI]9-FG:S;]>XYNEFT+-&C6J,JN\TFSTN*PR&C59'J)9>W9A68F[J7<N H
MTQOW4.?924V4DZ859M*LL[^U:^XBJ0  A9S!>4G,QEQ655L$;=BVL]FIE:Q5
ML=>R=W)$ K"IOJ)(+RB1.6';0J8*W/PC#!L$_249>R0L_;M&[U<RV5?8U,MB
M$6WUZ]FQ8=17B?A-R@FJ,59IA8T]BU2J5#1 2%NI!B M(#.-D$XF9-A][/-M
M5<*"+:E0%ANI-Q1JLK*>_IJ($V,]WEY++Q^Q\IYF?KD80%5[/JZ]0O8R7N,+
M9>&I:6I<EP)9M \$7O>,ORFR<YFAB)&$CS^3(8KXCJ&!1P%V2ZRH:Z;[*J;%
M5=MZLRSJK*XRFF,ACLVVT/"LT_DT[%D*<"NM:6MG@)#,/V[O58*S^G58JZC;
MYQHM7X7?1:15EI-N_&OU6$37@$!:'RDB(A,9&2"?N32Q[*[E&C6NY#J[Y<;U
MJI=4-K4E+()43J#S*LKFO8PR2/U0R<F 2LC0)%J,,3CBZQV<1E:]D]/96I:O
MV=.A3JG4NT]+)= J=64=:XC.FXAULS,55?F JQ!-DE3)>UV3IWI/?U-6G;L7
MEQDTBM%=L*A%6[7LMD897>#GK&5($8"S!"P@,BB6$$R \+7=<V#-R:F"O:+5
M-S%FNV4)+7W5IV3D@']=Z!87E<-%J3-!.HIB1%#%/[I"$&1,;-#'UG='VW6*
M][-Q'^%:WKZ;ISTAO3>KURO5ZK;\/V/B#56&=7-/M!C' ;8$63S4KMK+ZXJ8
M2O)VG:3?F[E5V?/]^8Q/;\.LV5+CXI7ZIM^5,,@%^ >91,CR[!VR&IQJ=!NE
M8BZZGK#U82EKY8;=S;&*KE=?+T[:)5\M6$&F%?E5(58$02B8D2P8+3-L8P.H
M,VW:Z6&NJDM&F_)OZF>Q]U&C0#+W"7H5E66K6ZU5#2HPRZ)UU+;94 I>J9ZQ
MBV8_!G]*SLK9B6J.AA+L9F?8 J>B-BOHX5)B[>C7]U@46&JL&-8PGQ%9-DPD
M(ZXNQM$-2OM6=4+.=?:<9,H+&"3/6+%:8&BM8GR* 9F*)<OQ$"0D397-*6!$
M]89M0 C5HV=S&'MEA?L(?5.Q[;6.)V7SG(T6D?Q_.S6B"K368P"@?$IAL3W_
M !UU+TY=Z6OKS[TRP75P=5N^,PFW 1X6)7V[S!+?!"8%$$,]OUB8F?53_#;C
MT_%IX*X__IXTC_\ UC<T)CM]3_-^L3'ZQW_28B>5$YB3+M]QWYV7<\Y\<<<<
M<<<<<<<<<<<<<<<<<<<<<<<<<<<HI/\ UF=C_P"!6E?\_P"_<SS_ (,/^?9_
MY:^88_P@O\R/_C/EZ\P<S<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<TJ_(]8*U
M/@;Y;63R@'TTNB>P#LI,FL@+LAA2,9($QJ9M"U%"<?7$IUSJKD?\0&&3VRQ'
MZU8+>9?K,9"0=4>!,*4# 1*Y^YFR#*\1W^I]P$O[_-$QS[7%F6!%-[JUKRCX
M[Z\B+U-[_E-1'!")Q/\ %DHF(G[F.>>AWTO5ZM5PZOH.R]:[#8V_70[11ZJX
MCL:5@/:!KG17@8)HM+??32_8P9V)^_%9BF\N.4&9P9,M^>NEZ]LVG>N9=G-"
MAIJ7<";*5+90$&VG-'P]9'5= I%-<8'O!'"P_:!SZI6;'413HZ66&7H(%M=6
MC;77L"^JIG<X)_IG]JQL"QOI UD8 0'^68F,Z#M-%IG2.A-]LSJP[!L&V;!K
MA:[<!#V0L0ZZY7Q0O$7J<+UBA0XKK%BE5.4,I_M%78K$9#+Y:Z2L5Z+MVZ[&
M1?OC3;2O6:M28HT69EFO^UJ&YS5OC2FVDV$(Q*QIN0R9%O[-NGK>_?<ZD5<Z
MIU*LN3J)/Q4;V1!DIJ1$0,2D8./&([1^62_-VY2]AI'75;V7V!?:G&]F(& %
M=N["T87RQG8\)V \Z L %1969ERR. 1G\+CE 82Q@&,\CS8<S\1ZAJU,E9BM
ME@K,X6741%VR5BH38"AI]_8,>Q,1'L6)%)>4E!EVCFVBR5&HM^CEIM62JR+T
M_FA$K$)'Y SY>$',0)2'<I@N_P!3]\[$:+M+N?KRVUF=;WOJE1I.K:: >RK]
MQ]?6FT:3=55<2TC3P+V"F%^T1MC"?6RE5JWP%W+,V&LNGB<:O.<Z>=DW*]FM
M'3FK7MZ5B3JGT[IISM-1L: V)6@Y3-FI!UR%YN3,BM,JE'[$2GED4,NX+M!>
M>3;=BT9TT*;$S4C[[+^.PR4)DSS(6>@2[D,^<>,2-Q]Z^7'CYKNLZC3/)W5'
MUS<4JU=J2O7NF(3(Y>40[I2+9-GCO=2U64$,7*C-5586MFT\19P-DT6<3S7N
MG>C-^QK.LB:]'44*VV3U-5:O7G-;4-ZVI'+E;-"?AL4=F(KRT/C^R.XP7,F9
MTMK[OMM)?GT+5'0D- ;UFQ+6V6 V1+M(L)BV+)QC,V+ *(I!<^/?STW-7]@;
M184*:!Z+8;16MM=EUVZH[5*[V2X<V*N=JL6+LZ5@5-;6!PU@]<-C8P0:9FFJ
M8[(T(SL%.ATMKIG-N75:537=T[I$5.ICO8C,M5[)*8JK:?=E9LKIS;\C;*H#
M@180SRA!2SLSNN)T9TR'3FK:$X'41*@<V0L,B/CF$RBF/D$%7(CG\HB40;/+
MZCZY!M7V6YZ7L-AO-5V-ZKN?XW3,:D[N=2A;T=7NPGT M:_MFEVZ+ 5@*4<[
M,E?;9+;"JF8 *&+0F,$5GNI=*]U-B9.3U11OW3JVBS/>-FPF[/3R\]+JR<?4
M@0M#ZGS4<*:UFHME&W =O&?)G/YZ?N;-JM-:I%=,VSFP7D0#*XGQ6<RTC6$F
M:R[K,9\H&8[3/?G8%L?F#K%!J5NZ'3F>P'3=>:3L-O=]2HRURK#V&TC%6ZIG
M8_JZ?:4-$-LA8FN+5EW8+I3+X:>K-5#:F@3C-/I'3:X5.MQFVF[F@*AZCL6;
M^A^"Q[HKV5)L6;&6Z^RC("DBKH$V5X>SW$!M.B7ND)!PMM?'4@+CJ-=%_P"B
M\8/R(H(1[29-[M4B"@I6,>LD#/KC7GI'=?(BX)756B^(U+X];ULH'+%/O6\6
MV*.BZMK=E:*2L"+:]>:Y;6YS&5K9UY<%O;;.9,1FJG7#Q F+7U&GHY>:0V^K
M;752Z-N1NX]>S3+1US34":51Y)=7KKFM8EKE-&4":_%9AXK+R^MM5%DUV:6Z
MU].NM8(IB @V&=AK3<6T1F2^CCS,?/Q'RF._?QY;Z]$ G<FS;90]J=9:=J^R
M7&M/ZS:56S&PCV'L0*O9H_3NM-V=D""9F]I3O!4PJJN!FK'BXK9Q=,=-K&U<
MU;>WTGEU=GIK5T+R3+.C4',]%C'K)/-)E4K>4?HT:^3CL!_H./E6+#*[_E&H
M)1$KB[URUG5>F[U)VG6JU;-*'MJ1-K/J00$G\/M>$6%1968^:QB)D@B)@1[P
M66N.RJV@US>.Y=MK]3L=]U+LSLA'J'8.N&CV%45&]I J:S:[/FTM&E+"[UZV
MA$Y%T9E!#[ 23J%OK2E*G5<&S>33SJ$W:>!H9N9_=._7(!815[])MRE60"@*
M -+88<?].Q??Q:R!*8VZF9LV=FO@E885:5>JU7OS"B!5;O[0J.3$/6F1A,QV
MGL<P<RWR#\V,UK;+;M]:BCV(SHVX=_EJ]VO- U^X'4ZSM5C:/5N @KV]*HJR
M9K;2+FMIV6KG8'0*-5^(R-4!;7G8'C*;V)1P[-U&=HNL=(L97<>V@FE2.LBZ
M*VG9T;[5OSM(4K&*&:#&+:1*7W V (R-VNSI/27:S/(*YG6KW167O"N@%6(4
MT9_Z0S8VQ('$]YD2B"F#[R4'[U8H]3V/.T;?1:ELMO<:V\EV#K.L5N-O_2;K
M6U]"T[60%L=>"U)5T=I=5[:.VT9+)BQ!7NH$LX)XL3"W^E<O"U:66+-"]C4E
M=2(0]SM.M4[]+ZXMC.T<U-5UEC;=152_&GGWI'QE]$(4MI1Y77HFWHZ47J-;
MY54!LKLUG37*1L"+8-BV^8AXR1P2XF!GUE,EY']QS1#2D_)Y4JGD[U_ONNZM
M::IL%@EN#E/:BI-MM*2+]79*RV&E67FSL%39"*L@QDS;ZL)+A79 J, &6N@,
MH]*UMAO\'+*6J:=N$4L9VNDTT11K"VH#_D2V%4EMK-*PT8B1FNYAB3!GL&3K
M.D_3U*R^H(K!%E2S3944#"VTS. ? K;!#:5!P0R7YN\E]1'Z]KM#?]P>4FNU
M5JPXO156JKN;%GKZH W&UN["6:J5387%NU6[VJJI3@8V2UZZ>E2U[[=BG]3-
MBH1U=TO+-7I_HCH:II+)EMG4HZ:<IKO777GTUR1(OFHBN4V6*SK%>G6M0MG@
MP+'L-/@F 'D3#SNF=.RB&'IKN*< WFG8953"9EXK :\&?R 4V(LP]8@N#(1D
MR:'G>/16A==3[\\0>P;O-EU;V1_3CX]Z7^FVATEIME_0U'8.L%0UYJDJ+5;5
M:H#]_5R/#9UU6A,) 727Q%]AE<^STIJ:S>LJF7GT4[.2>@K2-U)#2IY;OF+F
MU<K6738M.%-1O<ZEDH.IYF_SA2E$&CT9HW#TM-GPJ6PGY)RIZ%C%*M\P12VW
M(F@'"RL!$560(A)L+@ICQ84_W-<_6/.H<<<<\E#2;[6-JT^_7I;P=WMFJU'[
M\Z<SLQJ;89&XVTD6';T0+-UK+BY$S@2Q%,IR5T1SC,GOYU>M8S^J.EJ^W=L$
M_K#HJC\U577.2S=)GRZ^K;-BG?*L7;\#0<1+H^H+0I567(5FS$==R+]C)U[G
M2W30IO=+=0K+\0=F#=L7LPWH:FK3.^5:I"*3[C:Z0L6_8JFRPQY%#A7(U%?]
M@W.N4-3:;/3D6V+9 /*YTQ<4%Z<U<%X3Z&YD6P)GW6TK@.5XAB=>;"BF"^^(
M6,^O/ZO5O4<:K1T'5M##;2'4B8^!_?+[M@[U)+(KUS"LBE?JU;/BE52T*5C6
M]@KGSF?VVU\K!R+]_,LYO5-IUK-# 5%N*PYU"%HGJ6$.,IN:=B&6* DY[%/&
M8OCYES(HUFS;O9N8['N3KW%;5/\ 8-#KJ(0Z_85BEC$.;)RS.Q6B,(<U9+S4
M5.<Q"1C$HRQ!G&#P75-WK'7N6*KLZRB4?,O:4:R[*4U$6?7>^:H;!$RY7+LE
M-5Y&<Q[*U9,PL2$9SI'(SM$PG?WJ8NKTOQ?IO,P)H4;2%#/PKB+C0JJ!#UK$
MI;3&>\,%UAGV)0<6+9U>V+6>P:=:7X=B)6UU9M&+2N6;&R;T$IFP]%8EE+XH
MRAG+0IB9Q#))F3QF,BR@="Q;?K5XTV#=F]_?K[EEP(:JXH/*Q,,0"ZZJ4"(=
MI>,-7XGW.9\)+:IV<K8R=#4Z-N:F=I*ITLC5K.HC;38 I!"+1^HG&5A<D7L;
M68+)CN14X[3//MK>H=U/DDT?99DIDK0[%J'8=A3/KS0*K(,L_9IVK/!'O6,1
MC"G!61&!1'D7MQ'$XRM^/[HFZK7 =JQFXMO9.^\K*397K+%)LS=)@DBR;EJ!
M2CJL]CUIF(&? IB,Z>Z?_A!Q?P\5Z_Q<IO4'PGT+=JM8QFDJ?=8B_C"\'DGN
M?G*S3 >1"?L7,C/)%=UFP]GU!:&_O]62F&Q=?U>-55)1G9U2GMS%B)%68,PR
MJ$#8OEN"0,NLO\2_VAF]R^(]W#3ETUOFU3LX.>VD%-/3\(![OBU&J1IZ4.5>
ML6KMD(!7LK65!V59*4RXH&7M]-]5=93I4-'0PA1K:\Z>9;7:8;K%"DQR9;F9
MOG"*=3.IBWLVP]#R2+*XHM]EO&%U-1?9+>5]SHSV\)TE?85ZVS:NN2;Q6 CP
MS PK-2=B!T8$O>TU%.#)@ CEDV!A$?FCE5Z=QRXJOTXNZ%2U9KX]8HL$-N*T
MQYNI%4=,5$Q#0NS/K/PCO+43 %R*)>Y3C6K;'3*NH\S"4.='5>>DUO?'L"8^
M/I5[#4FWU-"8A0V&K\08ROZP=!6XEN3'7>HYN*K4*C?4BZX'44,7E=FWL*6O
M+9KW<+1<_P !2UYUSH,(?LUXP:$I:MU6207>(.&-BMK2K9MKJ J 9DQ8S: ,
MD$3%=%@[7QX&FVI8CV.*T<&QI3*&,7W\8'QW>H,S)IT:%_)#<V%Y!5'NSZ-I
MT,=%BA86ANJ^*MV3STH,P:@%KB+4TSD@)<\PC$6/4]LXYLM/>OU/V7*!W+_V
M1&8JEE*JB"4F!S9JUEI-8:"4$<JBFO"7R>N1QMV%OJMXMDXWM ]=-/1Q2?3,
M//1HK4*,JHNLMEF;.=70MHV_:A0H!D^MD+D#XU.GVQ=^39RV41NC2W'XNDJX
MQF=>M("7UYLFFO$D!GY)\_,Y.1FQ$E!C$4#<9)6M"DS.2'SD7;8:%)H5?-P:
MK89*J8![U7C&K )%L1GB3*^<+RC@/K[I3/J_B.98U-=RZ3+C%8VKL31H7&4,
ML8G2RPKTJR_=6FU?"%!:"Q+/!Q00 OMWJ5RU31=\L^NNZ5<2;6(C:EWR)F5V
M$S9^_,:JR[^HXCQ+[CO/U&5UAUIV)%+>K8A7U:%@RMF%F&IBR*5<6\6.S9I8
M'A]VJ/9UQ\JC8*[&.05V%QYE@.)K,7=P=BFAU-QXE+-T[51*BK4V.\D'LUUV
M=%;%JL6LUNHBT*1M_-\3*O")7,+Y\UKE?J7&TD$7Q[LVJOL8WV/2:):*73\<
M5G,+9"I0)"$AY%!_K!%SF4M6C?U.W(KVDRUU/](%>O[XHA>PN*P-FRMUBKPL
M1##)F;2#\UGYA]F*UAM21DH0DNG,M]S%ZEU"WENI8*F5J,#\3.1;"I^(>C1T
M :EUQ3*P60M5++8*RJ BM[EJA0KCMC3S_P 0IX*,\H'0<KSAY/9*62I7DH"8
MM"Y&RY?YE!)=X&3$I_-$?L>U-R>%5UI0CM:&ZSB@;5?-: (6$IK,A#4X!):R
ML+UJ%=-2Q^K\V3)!%/TD24HQ_P ^Y[=%&,96[M?9E_3NC?N4KS@LNRYAR,RK
M\5OS-+;L_$.M<97-AQ/E8/P"1Y(G963Z<V6U:*:5&:6K3S_D>M_IN(E!:)>X
M00NJDV^:^\"!C,1V\>_+7I!6]\>57!"U#0ITZ,W-6D0[*=\PG<KKV*HCQ($R
M##>7;1F()%(91B4B!]2>F>1U/;.G=QD=28UBY6OTZ.74PABSOZVP[$OO!E=
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MS>G*W4NAHVF6JS\^P>*NVS+JR/OMY:[<MAM9MA\RQCUD%98=I]T!)\L5??X
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MT<'\LV><ABV&P@J\WC%;4U]HP)Y>L 5/XSD7DJRTM(2Y)#'.,(IJQZ8H!;_
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ML:UF"SWM^R"$+)2<12KV\E&0)A!QC,H^Z$K'T+N:#-^0%RU*<JZ\EVVE-$&
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MUZ!O J5@P8B4".$V2YNK5_$+._M155=KI0E2KZ+ $KURK7L!)E2A)M*V?BG
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M/'\K\@/]S/7_ /G=8?\ :'CQ1_C6?U,?VW'D_P#Q2_ZZ?['C^5^0'^YGK_\
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M/BR0F1\HGM,QSL3YFY"<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<HI/_69V/\
MX%:5_P _[]S//^##_GV?^6OF&/\ ""_S(_\ C/EZ\P<S<<<<<<<<<<<<<<<<
M<<<<<<<<<<<<<<<T,_*+LVTZ9^.OS/VO2-HO-*V_7_'GLFUUS;=:M+"DO]>M
MU*!DJ5K46]29:SKGU"XB1=M$XF@DQB89QGC'/DA,QD06;3+\HK7W]AE/U AX
M_?E/_5[???\ 3FU1#V7*R_8M7FY8^QH0Q8=RC[8N1*#&/^L/B7>/W3^G/,L+
MY[><,5F06OG9Y9D;E( 555._NY539D.6,2E[@[=@D<%_^J683+G'_N>N?ZH6
M8THMIIHI6/8#6 SS:PV>4_4*%)SY-.)[1 #!%$3$1'USJC,_#BG;+3NYY/(4
M#516R55"*5]H,Y:M(RH2'[DBD);/>2[3R3*^=/F_6OUN+3S/\M["OM!B47!6
M^1/=8WHJ%]@\NJ$:VKXOV61YE(.6R-#^>6<S 2&,3Q8-+-'*78BG<3MVKM/^
M\D6%Z55E<M!<,S]&0 @68P[Q6%:)_.)3$CV[3S[SJ6>RUG%I97Q\YK K%^'U
MJ+',KURA%M:6VTL\;I++V#9>1]F]BG\OW&&!YK>?>EVUA?VWFGY;M5*>6(UJ
MMOY+]K^[YR-C77#;51-W/,AX!-ZG6"#V?-">1G^(4YPVL=I)3.M?RIL?#82#
MI_)JK4&I7<";"+M1IS?^(ITD +) L;(C[9A,-*(2YTVO"T+4M-?P_ SILNUP
M8PD6YDJD,@193*[Z.Q-!4L4MGG"B^ESSD:SY^>7O['V[CYD>:#:SS 8_9JO)
MCN &1QQF!Y9&M'>$5PB..6 _)DN,+8S,V<%R+(9X,G0SDVRG<JM=38-9I#2$
M@<D%LAC5+KL?5%WR51\>9^:KXQ3\D)LS^R+;7E8[O.'T_*R\F*6Z/6FJ;6A'
MI=/H$0I*21PPO!+?9X2ID+'N42Q[S@\WM5O&*>R\UO*!C5R(5UE#Z_DUVY;7
M1&XU-B)>23PMPP[.NL7QC;L8!+A."KBF5IQ+!?TNTIK5JD1H5L5V2R:3ZM"A
M:"WLW;;JERO417NI36T&INN$-"XH'#7KJ95A3Q+L$Z%W%J9N\RB@2BLRG[CO
M6:XL555X+:QD),6K[@1"M9^'=A0<1^29+D"H?/GSA+8G:QYC^6!,9MY8%4N>
M2W>!O>!K$\"4#&>Y$EGXIS $.9Y(>;$8RG&<)DQFJ#:33U9O5Z*K/GJNIHZ4
M>ES6#7;,0F"L/A@PZNWP4(L,FG/EY0?8N^+-R*=M!(M*2/B*[!Z<LA0M(@D9
M6E*8$H$O*##P" DX&/KR^K(VO\@OEPO8B?LO,CRQ$:#584U*GY'=O5L)&A2!
M+;*271V,1O;BZ^?$@Y&N,8<X7!'/]1N:?6#J>J6IH=.+L9-V[=K(?3)E4:>>
MR<]'XC\6A-=3$BO3BRA+4FNG B/9!'^EG/*SLBG1I;2<EKZ@AZ/74]-EZH[F
ML;;ZP/9<L#7E4V$604UC9F);V[SR%->??EUETNQO^<7F'3 <JBLQUJ?D)WEC
MUL)EDF$%;+.SP7RE/$(.>XA\$5'DD9'<:Q@<X 7DLDYR*VA8&NA=>Y=;HTB?
M-X:\FVR4 E1)0-J1@*IH)QI'U,8'E[X+RNE5D>YK6$T8LTC>G&G'NBLS*Q-5
M":I$J$L]M8!M'8AJAKM,B$;1C*"C+'FOYRM)*O)^=_F!6F;<G_</>2O<DT?J
M9Q$BLDGH[G\YLRC@OV8.)JR!B(O69/?/V8!TKB6,6VO\A:UQ$NKP4,]P#,M%
MBYF5A^Z0]36>7W/:(CO.BWH_*M5J]RI='.9:M3X(O^#*<U2CSK%3O"$-=W&)
M]\7*M4U3X1,E$E,6.]Y??D$W45#/6O-3RYD2L'4TM[,'D=VG%$GVFRB0="&F
MVH;^<9C ^7FC"=.3$/>8T<1A#%FZ<PNJ=^O\BLBK<SQ;6K+<D@5;R)OO-"(V
M:Q=K;0-OD\;8(>(U0,I+Q7VC;ZKS^G2=C5Z\A4TEU/3>7\6G&=K+HC#"LY+L
MY(C#%)DPN199%AS2"9(IB(CEO>:GG@FOM1DO,;RM?U_4V%*:SE+R-[<F9^W(
MQD4%JZ]/N2#7]N47&\%6'E@*:V!F Q'$B0V=K!M8[.I5B^XBMGV:5'\0]-;7
MJSJ@-=ITXL JK--3H&P[NE 220]+H8PX[^TEY-RNEE;)RKJ*M0FV<NQ"\W4L
MUSL2@&UGM/Y+V);83#F"9&C\I0+EB4#&X_D+\MZE7"@O.7RNGGW!PS)CR([G
M?;C&Q%@;,%"DV<_NPC"18EFU(!,&@,U<2&98ESYSJ]5;6Q.HAGM8C/N7[%:S
M,'0N_3K.9E-K$I+Z-=C)M67/KV%N6DZ#2G\O-*X_I6K576#.3)!#+H5/%#;"
M[4+'M4?K#!N?7*?R@HD>N9\R.5Q,3,=;_)'Y>#/ 0_,KS!<( ,U2-*^0_<0E
MV"08/[G$Q%WL4_C*#(OKX<5FS'US,F(2S$8HS0H@NQ**%^Q82!2%FW+!D+3U
M6[ S8HHFK5:JFZI-9BJSFJ;#A:+.P&';73N=*&N"MX0R^%^E0U\]*/ 2"#(F
M=]!RV/$Y)0O.N788$X&)'G$-^1_S*^Q7@KO,CS#R@LU@LHV'DCV^-RQ#_5DH
M6& ;DV121<^L1>S+45_='.,S]N.2&3614WILOM1H9J7+:E.@EE*+*(/Q-+55
MGZ8UC(!, 83+(PSP,PGO(S%ZFGBV<Q5+.R?A/%;1)GA7MV)8Q7CYS8FNAQC#
M9\UAVB _BC,3$%$@1\Z_-R=7]F7FGY>'&NY$<VY^1?>'U99G"!9 P=?;(SF4
M0RC]T,9E&/KG.<^Z4<\PAF:(V&6X4LJ"[RED\KJ6Y !$_):BVP#BZT(0:O(Z
M(?(\3[> G/CR80'3'X7X-2PKP"1Q,YMB'G!!XQ\>5U)3-CRCNM=@I3_*4_NV
MP\&_-;S%V_S%\,:;9/+/R:L-<O?+;H36;ZBV/R,[5M:[::FT[5U!=^IL=8L=
MH+*TU^TJVC(OAM0-U;X#E38A.)#0Y,+R4.R;%U4^3OF6*=BT-U#*J)I+_$%%
M1S!6K377M5Q&M\RY$CW?'M$2$8Y!Z-NB:AIEC!0)=)EBHV:4KL6R-1J.7V#&
M%$*B*&B 0,B2X\.TS/?U!.0?*5QQQSQH)M6MDXBJ*QMILZ\I*J#;'M_JA*I+
MW'##WE !CT9)&#@PGE_=K_$ F3Y'@Q>B=5=2O,,[(I6=L]B@EN8FW%L@FWF1
M$RRQ K?7?_?T+1<2+R]BDRM9RPX!QVSIGIQCK;;!#6^,D?<9&Y:@3;)92M+#
M:+!EL#Y_D[=B\"+O]2/)-8E7K[6JU<]Y865DPAB.,G3Q"3YV#.,YQ8+C*04R
MYRVXD%AEEHWPE^3Y%XYB -3ZAO!80WIS)7I7JN>V5V7M18S[6CK?B,V62=%3
MW/>RK[K=87W+%OW^TG+@1]0A?\RJ&9IU(V-5,ZVA3DJR ";U95,DDM:7V"%*
M("ZA8>4 M8J _P Q^427)^2HUV^K<&=*76'D,0H==J!E-3ILK*/0%%RPJPS>
MEC)I'(\RRVQ/*\@S]WS>F<#J#6,9L7LBI8&*3KN-F6-6Y5C'S84"&HF-RMZF
MFJ^))&R,E9:Q0L?+?)L> =+C/Q='"IZFE69BZ5"A=3AX-&VXG6%A<4<-J5A,
M_.LTGL(F.&8F87 ^(!$3#6-BHV\UJH9R NC=/U[HV5# <,SCZ\5BC.G@0<J^
M[,X^C 8LPD/W,Q)\GMCF"$HQ<\!.+5^7V+]^HE]KSE1H *YA<M6#4^#1YHE5
M?T.KC!1YE#(D8!FU1NZ05^Q5LRG<9G RU46NRVU!3$% 4U)D5 V0[E;\R9,#
M+!_7DQQ5KL8K*9NV/\E.2NLG]BV!3-6\232G[$:!GD)L3'7S,XN@*1#XB>$U
M["<ABS$8]NIEUZ6M1Q[K:%;*V5TM)-F]GG1%3F8:+84^WO)ZZK#LR(6 :I;F
MFN\Z*@K..2##9?RA:%K0L:O3MHTV]%[5C9-<WI'R.PA8)D4^2UE6/S*8_9^;
M8[>45LM:ZU!>DMIL*PM:Y_-A;UB%A;&"=PF)V"]9$I*IT8BER.*H&Q1. [!(
MY+\(R1/'1S+";5A]6T!4Z%M.A-:;!M$,J:LNA->I<K+OVKT/(%UO.]04"A.6
MF]\1)S'Z^#TI1M+U5&O0WLS0I6-BI2LOD+]FQ V3AB+-9-*F<QYG$T[#!><0
MM:0@UCRR:?7T->I$YRN;.VH:=7-G4U[:"N<UK1B#?M[2PN!8L'JM=-4#-2NG
MC*49FRE<@@.),!+M5Z6=FB74B55-ZQI4<\:((O,H:8WV, ;PEEYTW?V&>FM>
ML^RQH9=RQ48%H94*0,;'6J.IU:N46K>KY&(VW;,+^77T*=5!K^6=XM^YZSS_
M "!JJ(!4J6J:[:H"%^3B*?G8=@!:_=*4M%(=2385PZT.[GC"-J(-<RG9R4:F
ML\2P1$I,OJ@%Q9T2MB!D%C V6,XLG3_553$Z3TDZ>95AUJ^>YF4EQ)_'1<._
M4LUK-FVIUFW5H_)?GL.&)O\ A:<"&C\5S)J&_%K8ZF \";-7/6^,D+&E*A1J
MNK5:)G9H2$D)6'K25Z$BJ4_'BLPBCW^KGXOU:QQ!Q:IK]DKQ7$*'+8+ H?XW
M45E6Q\K3CUA[W#&E-TF9(5RADFTDFUQ9R][_ &3MG3#SWL'<IT66:T:HXU'O
M\\;^3T[BTOVUFPS0,8;-DW.8%?)+XUM"6UR4=D.PS7NN:-;-V,>Q"+$) ;ED
MD7$'5M:=\X\%A"UM*N*Q 8:5P',A@R*S0GM[)C)P)5:-S-:G9(@VL,"\&S2Q
M"L%8V. K':79G]IN$@CC,J9%IPD-R9,QB4'NG%T!MX6KO:]!1OHT*S<FQ6V*
MUNE&-F:FSWS[)*L>5O4IVJX0TJRZ\M-EDS[FU/<=C4',T<6IG-KSVU"1;IG3
ML(MQ8NUJ_C9@FA/:HU)F(G+"\97$1';N7?CB5/7WHP+Z-05]!8PBBM<+AA86
M7Z,MA*N_9X7L"&+"PC]&(<.1KZ]X@(F:6P$[,697V>I,?&97#3Z3SLS%W&,1
M3LA1^99L9D6&4XM-IV1FRNQXJJEXOI5[)5W&Q0+9W=/-:O26Q<O:(8UM]VWC
M'7.R2K0H]3[ >Q2@<LQ%H]X(8E1FORC^-_U>2Q.9ZVS0IBI-.X$-L9QI!4LE
MK6*N JIR;4:!5SG1V3 7LY<@S-UI4LHR$.:YSGK YMCIS7'*IT;#9OA;2I&=
M\.]'4"J15UYHWD-JU(K8]PXTO/0FV)65N(6R)JDCZ8&J&Y4HS;$?#,2N;ONB
M4OR&,!@7&BPY,[CA+T2JN,>7L"9[_G_+_NY++:Z)JCS7VRM)=T(]LUA.HM5;
M@HW?O-8">X, 0PL)^U,:.(D'DR"QB&$0F0Q^7-IU<VA4U,N]2U<[/T\K1U,#
M*R="II5_.#>J=76;5!==B \*ZPB3LA1KR=@6$:H<J-LVK?LI#F7*=\Z#ZRM.
MT^@VK;FSY@3:526BPE#W<@1#P"6E/I*>WZ8BG6>>-KQ[X:Z7R-DE8NVKF/O_
M $Q7%3\UBE6)PC9@?16=BN'[$;"+H9M.C (:,O2*Z>R*VG5IVK]>LR@M6JO:
MV=+::5JJJCH9GLTQ6E(7$VZU4(536UMD9DV6%PE:"(M[4T]BBZJF8:N[-JFW
M+RARUJ+1)T6O55)D/\%P=HUP3C6J#@_"9G\L3;%]L!+ -@*BV%=Y'7RKFEL%
MVW*FR>!F&2.#R(1VBLA14B-<K4 X?^JG@TL'B6<90?4I8+'5XZ7V'#ETU8BT
M;K;]K/T4%:L6,3YX9!++0T4TJI,JV74XK7)J-:^Q\P?!H]&R-+J=N/HCNT,Y
MF@%K8LMJ20VLURU@W3LU&[!.FM5EY*42OD#ZU366I;0]C%S6^+-JDPM7YRM<
M*.)6KF+4_P!9YM*IC\@H))%B=1?U$%,S-+\JJ\Y!=S,R\L-!B"N9E.E3<FE>
MS,G0JA0U;#K>4QK+URM;:BFFWZK)J*E:KGDBZA[(^3"[Q-E8N9XC@N7]A*Y^
M!HZ<S8^.Y!Z<4FU*2JJW6#SD-JJ@+5=]>Y ^<%X'*87'B,E/(/63V0$:@Z>Q
M18N#N$7C[3_))"J2!@)D8B,: DA,B<R"O]Q2^Z<&!#PO&'K+-8ZA;5I9VL5F
MI%E"YJ9[JMUS-/)I5JYK]'PW 2!3:1J/4H(+Z&JQ:R 5CX5C+Q[S;)9M.R1O
MMVE7KD371&98@C.6P#I<KTV%2E<1Y20R;Q_3]2]2'\5 /K?CD\-E_E;-\/16
MFC^5X(UVY^U6>/4P!-.C'+_RQ&#1\>W$?[S/_E]$VHZ?;0M6+M,X&:UJV +L
MO5XQ FY8,: ']=I&&'V[1'E,_?.)]2JN(W]=.@D:]U=YXV4"4&*V07V,%'>"
M^NT]XGM/?Z^N=@7/GD'QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQRBD_P#69V/_
M (%:5_S_ +]S//\ @P_Y]G_EKYAC_""_S(_^,^7KS!S-QQQQQQQQQQQQQQQQ
MQQQQQQQQQQQQQQSKL_+@3 OQC>=9<XCG _&;M27I+_W<^FM-YQC/]>/\<^F/
M\<?U_P#GCC[_ '&:Y_<Q??S&?W2/;[B?Y)C]/UYLTSA=I#)@2\&"7B4]AGM/
M>(F?YYYY3=)7WFR4ZUJK7UZ1!6$*V-G=$(BL:+8S_ VNZQ[0SP@58LCS^2>0
M_P!SF6,P]T<9J&!L,,]5#[8566ZZ8NR;5+78<32)QV(2<*KK%!C;L>P8K"0F
M4C,P4=)1;+3SDD-;-3= F*@] I#Y-=J_!+*Q-.!>Q+O*!6,&9S^7L0#X\X-A
M/<=9JY5C[BRTZ^Q$>3,[0#8BQ:ADH1JX7PT-L.90RP)H>"0SF6)#+GTCR*:J
M:6E=I03DFY8*M(KQ/J8RG*VH=-E,PM@>)I8B19,0$@2^XEWYL/9U%FXB$VK%
M<8I7HM*M/NK=W#044PFO7$7>T>ZR(FPN>Q]P]D3]<EE1JVR;.J78!T]GL];F
M B(N*YRU79L?M!R<39(+$R9@/N/F=>;"K\L3$S_\'"42R]/%U]'.?8#%T[0F
MMU2I=I@L3#0L:"O^FF%NL7F.%K9% ,&QW,; Q-9+(G*('9<F\=A-VMV5<@7L
M]U0E(44M$IGUKK%69 ^T;"PF!&%R/YQGG^JIF/; B?#EDZ5E,(T)*.LS<!""
MX!I0:#B6$EQ5P"#&U )\JQ&&61_'_;A%T['XK>6S77>T3JUD@NH@Q!MV,N:U
M6,TV1^UJ"%13/[X!=@EPGQ)!?F.) L]E8H52)8V;=SMXV*MIZQ&Z$L!X$$2K
MU1,]HB27 P8G[!B1F)K.F%?)E/&\L)[2N1=<M4^ *B)\%R->*D;' ZQ<"HU\
M!'58RP!ETA/K#]OJN7-YFK?THM6[-NPG:I6LNU;RKE=%>K%J9^+5>6O7.K7H
MIM4)I5ZE>L36VF5X&"2=I+$_'A0^,E56XYK)5:JK<3I[L44][5!-9J8=:BFV
M'-!SVU9D+$J$6^GR9C\:U?:G'-LYJ3WZL[ A@(]11 [!Q@3(8C2)E]AU<:A)
M%.F^9J K8ZP('59# T8ZV]T[HX>9>T=/,E.=NS" 1K4Q!JM-T6B& =\MNJ%"
MI[&M1<)\#I,JH T6%$;%1^!=$])04EML.RK %[\Y0,>5<B%," $+*H7&>,=E
MM\YKDV/6<,$2+":Q0K4_\N-LMMC#[]<J2D595:^6Q;;:G/%AA_"CJZQU<?W[
M49$'%B$B(R+ N<QA6QS*9H39TGJS7II5K&5GDY]>+RM%)*KV56Z8/0JKFG$6
MCK6_4;Y3*X]1B7CO92WY5C=5;:^\W1\U%:94B218K6_?88[YD2TKMV(-'OH2
M:X)W9LRO\LR$M[1K;(=2RJ9[ IE4 7G-IMLM4H[&+F''[\[" XLS7RD6,8UX
MIE?D2$L_W[I\)CD5XJK74BJ]U-0]%4@_;U[.TRY6<[Y2K&AMFY!U9L(+/,5#
M1837><K*5'9(4AEN]54LRO;**.ALYA5_CYU*[52*Z[Q&? #]@N%<K9^>&+A7
M> \9[A)%%8[ _?[!8.%6J5<)M.FQ53@M*82 "2$!1K9M#![X16F+.?C7CG,9
M#Q)<69PC&$V?@!LZ#)O-;6^?9@7B80LZ\-8 .(*]>FO_ *(0[3\6M,#^;UQW
MF>0GXAU)NUT2O%KI^0 !37%8SB)5"HBOGE<,S_(MPD4@5B)[B/:9,.<JK7;V
M&ZK:PFT&:,DB)40:RK<"I!=>62S5>9^-4J@LPD7W,Y4)G)8PA[?=*$\2E?2L
M71(]&A<MTLW/"O7HU)D#T:U1\/KU3.D#94N5'9ME9:+W@*?$$^9#(8*.45[3
MKT*G4X?+<Z99932MKK9IL&1?+#LKKD'>1A'8%*6UL@,3]Q,V"?K5_95+Y77&
MRD3154M?XGKP[:[/8/K)>B\A9.W*)VYR8;D4DH$PE$C %,D%*8X:^[OU57(Q
MJ"APAU6]-G4Z;3J7M>I>T;X@!&5R4FF+U)-G]HHS "<T45C,O*>2?]PH%1NZ
M=KJ.K;7G*UB8Z:M6G?;-+L^O5KA:N(-B[AH;Y2I;"KA7ELQ,L(>1O&I=4T(Z
MQ+9;2Z/M;JPF&JM0*[515S:'DL!V3"CD#X=6_LB9K@S 06<8DS@<XR 64Z?+
M-HV+G]U]&T(#6:6:=5M:XB&S,K1-VDFY5M$P6"V+--UNE*I"!,IF('FEK]/=
M,5*F-4H[#F[KSJMU*+0,*E=3H)S5_/6BV"FK42QCT5[,E,3)@KM^;DZOJ>G.
MK.V=5.P<@*N<!FRD991:KN %FR"8AV5;\EA,B Q$@HK*+'J3)X$A.&0#ARNY
M]..P"5C87C7+RIKZ[<HJNA5TF?$T%RY*H:3*@)\,U%ACY-AE#Y>'J&<Q>E\G
M3"Q=SGV2RXN?!?<LYJ+21DJ7N;4!=@":;._YYMBI<K"/9ZUC/G&7L-(JEP4-
M@*DL9$9 W*8SWB-F:U>SA=S+X9*F7@'V@R0;B@%225^,_P!LT#1ACEGZS!&5
MTRHF6!.]?MLESK6FG6&@UU;/NN:]]< 4G3LC)5UT;0/,%M-C[1L;76S0Z=PJ
M5W4H/5BWIK+IN\%Q$4V[5I=AZ196K/.&EGJ!9,=9JB"_))KB!\6%SXEG:$KX
MN*21N8R>1K?U&/U@[5BQE*0,&3&*<SB14-)94^5AC(4Q03-C'K_52'RW4I[%
MM4U_0NKDOV[UJMF5[=9LR:E)HK%86FUB%<PYM:(!G8!L]_R1RT&Y^>O-(2&^
M/S'T:>.MT3-I\$,V++# S4E54I0KQ+Q>4GYHF!\Y'<+P@H;/'GWX2DN "GBM
M\L_'*"[@9F(#YP=S:%\B8V\^R#ITL'!# ?67UE2DG\,X^A12>-L6G],-T1JO
ME=^]%->AI^:9<M)UJYJ2]Q%.K<KI<*AJ%,%10^U96#8@6UH?JK-FY8LQ<)8'
MGXENVA%$I8(K-%@T^Z0\22@G"7BQD0+O4(SYQ]'ZO'/.</XXXYX[=3J>U[ @
MW0V=Y1ZFVEL%;)XUJA\N;EA[$5D51OUZSD7[,GUS37!$^!-"'G'RY]DL2LO5
M?3_5-C9H,U.E;UQI6#QSN55UH?#]%@"B;E@+*47"]80G.;$DX30V/6R7S(]D
MZ1^+<P;^;6ZTPNGV*M5-9Z-B#D-"M6KBJ/C$NL]TVH?).M*GUI8+AB6!"_$I
MA=:1'.Q["WIJM@.3EHNBR>4DF\J*LEQ%$*8Q!FRNJ_!4N,B_\3.,%I>DAC]?
M=&[F8="R63T_G;R["+%O%T LV++77HNO;.79>=>C13"M)5&TP50]A^8G["),
M3,WJME+O7-':1;SF1INJW:]I*,]BLJLL4P^K7%EV[;$4$4),Q4(B';Q$/XL8
MN-'?/'O#&V!UAFEEG]Q1P([]XKZI&OKY9.U+ )-_#-H0Y9GF&!O1'$F22)&-
M5UVZU;(/W6UV%7[2M'<7<<$S1TZIW<Q<:5>9AURPA?FV'5/:(*)<M*.\3$AG
MXTZ&KH6AN68L].H?3KTZRFPZX@03>#XUN2]-<'1/IA393Y3'BJ"\)F(CMUS^
MW6L\-!V#7G<(K7,V3I@;*O\ 8RN(0\34PM">& BCG!@#!B/RQD;))0(0@G6;
M'PQT:=%EA"O03TK.I\Z26N:%R^EL=H6I PBM*@_/!R\_9Y?<'OW:]FMKCWW<
M1Q(1LD=E*+T9\M/Q=6KG4A1'-LX\V%YAZ3*(*?RE,R39-,4M.H%=TCMUD*"Z
M]-63I$,N6-U<&/A?+]E;('RJ&M24^LKB$9VCAB_*N2 <"]91D=O0OC=PT!C>
MI6GG FW:M6EO4BYF0-2G5JL%4_%MMJS7>ZJ<BWU6DLF9AG;E9MP^_0L5/7U@
M.10Q*6D.[1I =+0=HVTQ:KZ59^LJVQ@,$S3*EM$5J8P_J.\_*>FU>O"54H:R
M=C:[#5S.CBSA-QVRMUTFR5KXZX!9"2"%U<P3#89.OB?V3,9.HOC$I+&H3K4,
MVW;Q6PZYF;0UXI.N:=VW82=P*^A3HTE@*JXMK'5@;$_4H<^4.4'8IG5I9/2\
MW*F*]5FY8=ER9ZZE)\;Q4U/2D_<3 !P&SW,@6&/E:%4OF%SVYU*6R3FB'9=]
MQ2[7;(MI_P /0,+-(T%U=@(VF05>)4Z]A]=HRTEYY&,\IS!C/S0*O*L:FKM9
M;[!9)"O+:%6[;M8MGXR:S6)"C8K_ !ZB8K(8E7FN\E:Y.M)N%O\ 'F.67#J*
M:.<OJ[=BIU5:IWLBOTY8%=BE=0;"95O'VERH=[#*:XM8"K1J7"I\TR,R,1ZR
MUU2ZCK5;5WQ]9RE69$,T2AIP- A ;^MN9PBS3MV]X#,&!10S 2C<XQ<G,A\8
MO-BGD4L/;LA;LVE8]7/S--EY(:2T4+3?->W@W+\4V4G6MVPY=JJ%0P&@\6)5
M';R*"JZKM*Q4J4\G):(MNNRQHW9H.KW1ILKCFN32%J$D=%%=H6S>(E:"4RV)
MF%C&:?1=HLJO50UN; QC*[6RWJSI,W&$!U0A6C#2[KAEU0,A1R5M6.2QG @/
M[K)R9G"-<?6<C(H/K,LJN7]#1<53S"@B0QZ>9;^>%4V0; *D]TL)BX[KIB2#
M*9^O*]"[,TEV%,&I7S@59I7H=OFEVQJ.1\8+1K"O4L#9"M%<8;^RL/\ )D=P
M9,R39:(F5%]A1//"Q6M?$:4PXKGOO'39K2J_L#6]C1078Q6NOMGRH(*S[0<1
M-,62PEU#:O=-=99L6LMR+Z(U>D\SJ%19]C*V+KVHFH-)EMU_\/""!-O1[Q2)
M2;)++V>N".:92Q.J^D+,.O*=5AM39O81JL5KU,!48013"@(H*9<NL03(%,C/
MY9GQCD.$JG5*6](U.V=VBX4KS*UA+)'XI.+M6# 7)685A*BRI2#JX9AD;$6D
MF'(P91B81!SMRM32FSTM:IAK/NYN<&<IEZ@+JUDKE\4W6Z H%=?PRU9H /I+
MY2?DC[5^9!RK5V7%D>V%RY0O!:<QXN%JUW4KA4S7A QYM[N-T3/E'HB5SX2/
MYXEB:<! 2;J!W3C)7H$N*&%] 25Y7Z^M.;8E;),(!*G4:L+!?ZRULP:(&!9R
M*42?,3XTJ&?TU6RTHL]0,)UJK5L9Q:X%1V$YE1S[TA;KU$(H-3)W@FE6O1!S
MZE0$^X8Y8<5]_J2SH65#49837=;+XZI79I0YP+KH@&M(F3$D)^R5??B1D?B'
MU]:6M_D\X7,**T4I*N($'IK.,?LFP,IV;3:9'W(>R<!-9]K.,3Q(=5,(L99.
M,S$Z1H%G'F%U(:]/I[I+'JJZ355II^7KZ%G4;>=(P1V!KK ;,MIMJDS[S+"4
M&),F!*XX5:Y<U!R0IJU=?4>SJ.TUUAE%%;-HIJJL5FR:&V7.+R5;)Z5%['";
M8, $C#/;3055>(_SQ:A96E*LNBY[4P$# -J<8#,NL@,>:,$_L@?D)C+SUA@+
M!9Y5Q&.<E;8J3TA83>C4?<V,DTTR&CCYD7Z.)>=X7O.0F49L@3:6E3/WZ-ZU
M'MJA->5,B2ZBZ3A?4Z648S5%4NU1NO?;OVCSROJDE5?*T9FRW7F%VJEM<+IU
MH9)&L3F>T;:7Q21)I\J*5GL2\96JS5HR.WU9ZKBK@U>K;3&OF1<OX9+DN(L1
MC\@8*D](DG,5>NU>FL2KF568EQW5HZ_RUL5H)N 5-TKM9HCGU8=4OU7+)++:
M5=C%(%!R(,.1V0;O.LZ.2EM>QD_A%DJR]*FXZ%EM;V)=&CK-*M:29$%E:P8,
M!+@B/(A 9G(.:\^VH1PZ26',5RWT!H/54*B-4) !9'375*3 0HCB80U9@&4*
M8<9)/^QB)*9U!:U-35'5U+&53"WE5=5:5U8K2U##^)G5EII2Q"+)"I9+HFR'
M5^XP404QRY8^14KX!UZ=*U8;EE.2MOS4MK"FK4"U<O*]GYVUJIDQ8M%1&: '
ML9=I\H_J6OS#<?&]<(UZTB,Y!86Z2=C7$8;KS"B#ZF4VUOHM#CF)'&%9?6*'
M)H^I!9S&:Z?L:3]K/TEULFDAZRJ?/UZ,LQ*JVIN5D';$X-$L:^K8K+[J:*S8
M;#D&" LK#\5%>KI4+>A>9"V%;4J@ZM&I;?"T,94H0'80JN4U96&MA?>%> Q^
M8HYZ?OXJHDA^.?PZP6:LRYZ.U*9)(@@LE[R!,244UQQ@,"L,RS!<0H0% 481
M'",,1CC;:3#<\VIKUV&]YFFH"UU5R;3+QK@J(4*OO\D!^7Q[=N?G7J>O\3?U
M:WN-_IM$OW,\O8<"(Q$G)S)R<1]$13W(HF9_7G8#SXY \<<<<<<<<<<<<<<<
M<<<<<<<<<<<<<<<HI/\ UF=C_P"!6E?\_P"_<SS_ (,/^?9_Y:^88_P@O\R/
M_C/EZ\P<S<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<ZY_R[X'+\8/G?@ONP//C
M'VK[\P_]_&/XTW_7'_[X_P <<^2F8&?']?W=Y[??[ON/T_IYF1 $Y8LDH7)Q
M!R'\:(_?(_S_ ,G/*%4M);!6DJH!+5H0'@R/NR#&2QJU"$/'[C9%I2ED(C3"
M"!?=(Q9 77(9C$9LQ&FWVY=1]1WF5K3M+L,K40GT5VM,X<?B9&%<#6FK+3A\
MG/K5[9*2Z!8TZE^E(N1<SJD#3J9\K!ELI],P,K@R\/'R.99+ B( C(?&1[<S
M%^+-VJCEQ7V?705!DJK 2,05![9IY8B#,QP+/,IR8&?V&',GM) 9(Y]^D.18
MREE"UFQ]@0V"8MZ+2!I7E+](N!(^51@EY% ,9+  A6U,>$3R:U;H]1JK%83Z
M@HU4Y4R RNW$T"GP(RF?!\,$OS3(1,3/\?\ =,IU-1"LKJLH?Y?7%J[.1GB1
M]4*HU;908PR8%R/[$86)U%)J*KL(D@:<CQ$)CX)0E;L')8RNO2AURHT;=([F
MB4SG4*% XNQYTM22;,:%J$C6KI93<JQ[71%=T#$CIA<IYR:F>*] 31-]RJ<2
M1QH_(E(O82AB!8I2X*'0;5RLO7VF"F(+DM7M4E\3=,&P1)8EL$FGG[3U86^R
M1<<2HU]9!& 8J+C:C*4IN@>6>9QE0$H*##GVK'2T%05FH3\FZ6B&QM6V%9=6
M^3:K)+235R)K(47K7994$?:A]>[97\-0&I2?*-[:KLMW/?:J5O8"<^DIHUS.
M!4[]B9/EK&"/D'N.(B1@8_/,_P =I4T;7;JZ-F^&MI%4VX+-!'(5A:W@DW35
M9*X#XR^OI922'[_@PG(((R+B)BYGR(Z?L8%75K#;58[4TW@^72;9=9O7_*R.
M);%!IM5J]B'MH0E#JLUTA7EME<E'?DBM.IJ6U@B[0J5#96%,WD*03)]?G;76
M6^Q6?96,#8(K"2+V3ZX&.\P/)R'8VG[J>F$V(HU36R,SEN;/ZGZ7.2@G]M1C
M&4D1NQ"5IAR9%H9_J(,?ML"2^6XQJKN:]?)T;EFC3?K5M2Z&G=FP-)U.U,0Z
ME;HSF5J=QU6;-O1BPM42'Y!2.G%E;<\FRN5M&?85<MKI_&#PA>9+!L5UF =K
M,M]@"<*4CQ841 C,,)?8HPMR"KK79H+L!NRE$& W +OL$9P9G(93!\XW?A='
M*7V/E9BB/ <3@LO$^199KVU4QZ%Y]?#N9.O[*(RHJY7[;;AW;_QK&912X;QT
M]<ER-AMNSZ"6WNNK7AG<SS*?:\5_BE;00Z+,R[V^B94*E=QNV+:R\&U%V>XK
M2 ]F)[$Q@E/(T:5* RR[32\G)+)8JZJ":DY62XIQPJD4BRXAQ<((YHD>;]Q&
M# P,H9$E"4*_.OH[ZKF:U:J":%;X&-65AJLVF7ZMHZ-:NQR55W3877<PG6)0
M9VB6/FECI7SXL9^#B,J,FPJY<O$%LZS[P_&=GO3-CR]9BY $3(@(]C0]<041
M$#$S-IOT;8^NZ5M3L?KQC:,;0_:K:0]47B=QHFMH*3,_975@6@7TN0&F8(#E
M6(V5T\R0$<@#\\VQYJ6?1N[.@>4Q.D-#&RMCY7OO!5KJ:B5.L>M5EB;@/L>M
MD"M<1:-Y"ARE&:HG0?N=7Y[KV:=&M6IUHSM''U3"@Y/D\2(UTISV/,)KPU*W
MG;\51-2"@@[Q+(]M[+@SKN(0L$ZS;F:W-M9ZG1Q6%8S47Q!]L+D"K3@D^TV2
M=5"6 #C >93!DB^(8S9>@FBI:LDKV<A V!(=3J/WZ39#U]UNJ*$*J!KA,]B*
MM+9AWA-DQ\CYT7?B\RO0M-38]?4TYL:-W!Z>0$.E*O"R]NB-F63\UKXE'@]:
M.Z&-^,3%C!;$:]VKNG7?6NX=1:<EL.S/=L[&M:V_:BUPA0W6O4E5FUJ_X^6_
M:$51%>X&X)FU?>?5$NJVTO"4LLG^&,ZO1E[5O&ZBNZ%%D9U[JEZ"=4KMN]1S
MHNQVIT+M"M?L:R;5<J3&(S[Z :N;7L1!AV*>;=??P5Z6U9Z>^(/46U<R:Y$*
M;$3;Z<R/.6+15<X:P5+!UA77L,M)M>EQ^I;10Q#%1KWV%HNB+1U!/K[7ZFPO
MP:D4.['>VMT]&SLTGK9R=LB=IJNP=Y:D<ID#)5+!*6=K7--5T7UFHYSH9^GM
M#\MFU=N5J%JV%O)!&<GYGX?ZE(A3UUPL,4@[5>U8!MQ:[7HL LX62Y(MWISH
MS1#)\+N+CW=Z'7$^&EMA5SJ]24575K(R%VE\FZGY#%*K*ML'NJ":NP1^,7!I
MWC.E==;WN\U=\A3$T:BJ+[:Q_=,[310L2JUC;E4EG,FW-B7M+6JK24Y&D(YQ
M/&(0]L"SCIIZMHV=ZO@:YWDT[FE<7^,5Z8V;'Q4(-E%/PVS1B$2:7E-HGSWB
MSY3,>H?/#UG89T#=Z7&AGCZ]:BNE%=-NR-!W4APAERV+FL*4*"I8%+)A@#59
M7+W(BO(\A/8_0[6H4=;ONK/;1O5 >FM+76[BR0M*%&O%AE.#!(G;7FNQ"I:8
M=^28[2:SA,#_ +$@QS\^+-ZS'0L3A7U9^=*K2D6 K*KL=9@Q:<@:QCY$'8[)
M"":+"2,>,3'U _&-IU[@1>^/K'U'37?_  [/M[U9U/'EK =3?%I)3XDFLN_=
M&J;5!9.0&5L'S]D"I+G=;6OULU_4).##;S21N!5XIR,O/W%,NN[20"3WKF-"
M92%D0TXYCC,\C'B/+A3T\C,V*3/:X%8Z4M^/GKJKNKA#[=M!G^(K8FRX[-LY
M [0LGQ$%GY""8"Y6.HM[^YZD_JFOC$NU>MI5KZ,1%=M1B5K>JL[)?6LUX3X+
MALURAC#+R\HGR\]I_"-BWUCS\\+:>[K2*MJ>9?C33%3DZ;/UW2]N:6%HK$#E
M).+'NGB1@BG'!9+BA*$1"P+DSE]66=5H6:Y5&HM(EC/;7:<L:RN=!]Y4&V1K
MVK*OS66U0K)-XJB%0A8IBN[THI=/V&$MC5.JC2H6:FC!JFN^G\I(-(HDGI7+
M1]:2,F^(S!'Y0<EZPG)+G$....>0"6^6%. MBKK!=6N9H<[!K5?6)V4$Z^;S
MR=B*3,&;)X9&1VS;:T&+&O;5L1-JR.N?"\L_KP+Y+1$[%=X,J%0+1QZM:G:5
M604OJ68]R67+ JM%:=95#[(/KO6]7L#P".13X@VV#K,A@L98BNUD^$S$P,AW
MB($9'\H]^RRCP[3VF.\<JC4[=MFZ=.LZ88:N%E:69&[?--9XK(*NHJ+563,F
M^9BN2LF#KDQ\DPB(89<3#D0Y<KHRO2L[OY&VF .AI;%>]I_AUTZ:$W*.?1S/
M>]BN]&K;::;:&#*EN;#H,6I@K+GZ-JG:RS&X=*4M!%>RA8=ZWM,3<<D"Q(PD
MY\BAGEW[=@D8@>TRDXV!!?891/*O]T&6TS!8DH\ZR&8EV6"0]A&O:"8C_7R3
MVQ_L-"G#V8E/C[BJPBLNK6JW%KLQ9+*T*9_AZ;^I4^)<JJNG*[@N^)%1W93(
MK-; O4/?R@OT%WLQ7GJ)[+M<6)2%HU6)DM 5&<TK=BN(G7>F6&Z#2Q4L$)[P
MP)[%/%=L-L9+6&E9JZ]A1R(+AN]9$;Z04A*G7C-6)7K&81I%%("XD\P-#&%D
MB$*$D.:^ITE;1<&>K+4#Z3K8L6&VQMOHPE=4JYMI4Y*\VO4K6DBM\K-?L6R"
M;/8A&/7UCHWJE5_2[JM"$$_1OG;A:*ED5/*?2JS9-XL<?@7>D(=_$@$.Y%'E
MRPW5G6;+5V$+:2<'6V+M*QG,=C)RPL196E6X2>#)<"[(?9(8##).(\B(;&)8
M^/D++[F9"M'.M+N7P=<[UI#SLYL#YU&ON4[HO#W6:T^X&,3W:E\>$#*@F):S
MXV]A=:_8L9F=>L5M:MI"\R"_=M+%J\ZD:I3-:N+9"93$K>H@#Y'Y")19.WEV
MU-#8;HE+KILM &>N8B^HHWFHPP8CI0IK6(%RO#BNM!M1F$7!@Q*,$R+Y,/%F
M9J:N7GVK%FXZ4]74Z%UNA4?76NI-QAJKA67E,2%"Q<^&ZN=:43*T460X5R;9
M/1N5NJ--FA87B8AOZ=L/J9R7-6NVZG4DK%IA*O6/#0.HNU0L>;&B<DXC '@!
M .,0L=@>U^N.MJM;:[E1LKSKK\YH_<J1&+.:U:(";_UIA.9K)%" !!U>R("'
MVH9,$$MA#BU.G')M84ZM;,O9U:E?!UDK/QO<\IQ[%<7!8NY[2<V!*(:R7O!;
M'%/I#D3):E6Y5U*DT5]0HJ6K+XM?AXHH/8*B1I5WI-B:]Q:_"$K6:H68$<JB
M9DBX-9L55JM@SK.TZ.H3;6FTK.YF%UZE#66H#,N .V,QS!:.FFY#WH#7%60-
M#!BKM%@2!*78EVA3UVB9>#YE&8]I#[J80V0M5( P8;J3V%'W::VX!5ZTJL@"
MR@Y*AM9N+:KY>EBUG;;Y3KZ[Z#F5Z17R!MFGI-F&DBS;IUK"Y&M3 ,8I;8:^
MH^QZS7-4KK7=FRV2H>O]O/;5V:DN+)G-;G7FF$8I"+B$<"()EME6,5F8@:1!
M'^W($R?U#8]#J:T5E =/YSF"E=67L)ELR^0_U9TU[-IY>KX_CW4AKEDV6,7X
M$'AVM2]KI;4JG:J[6[HMMKL ZNVQ6S0S6_#);VM0 2<C>.".;2*MA-82AWKA
MH]^8S5Z2M+IW\<3-<ZT5L3.SV1G;=9MU1*M;@N1FHA%>LGA>?QXRM*0,E.:+
M0PG]LY^RWY>)=TCK6QN_AE:K1L:NA:^;5E#ZN63TV;*\93(M-T4?+6I*GW*P
M/)#1 BD?$:E-C&R.EGX24ZE70UGA"Z]@YL6:K'MB:\!HG7KJJ8SRKD;K?Q6P
M$GY,F(*._'MC@RJ6TV!8]D^^]\2F;5:U5QM@D0D^VPW:IYS$[ZLS*0+!1I%N
M<W RD?"T?KXW\^BLU6^JKOXCLVK6S6#+_$4W:M>]VEDZ\#8J,B6%-J%U6(<X
MVTVFLUM+ULDM/7OK-<=/M^)FV$9OC<)$JBPV$J6&7+A-3XAT!)L6U:T18'LM
MDRB5@.=7I=D7VQQ)7 UJ=--6KI46WJ)T"I\5U<R[5LDKG5JVC89D-NRL;.1D
MFIB7:,>3+@Y0CUC4P-VU;,Y?GYF15JH'/SO?F6A7H5EUK)91.&5(S?8T'W=#
M3@JUV5^UHN-T+@>;],:J\RZY:DV+%JRQHV++U/KM^&WV+*PRO$D3?""$4JF6
M!,EWD/"8YPKJ\NY#*ZI8*(/Q;8LWPHV!LM2,:0VBBFJ=X\3U2DX,1@P&$/29
M/861HEQG'-XU=*U3UK6@.<V*F];.,E9__M32U;@ZM>M9QK9,K6<W/L!9^/?K
M@RT1+\46.TR9=/O*^*>4C+N6*UDL5+G6X;/R:57/J#0L$B],PU;+8G7*5 2D
M3'E^PD9()S:1;_67U[%EV5=>P4#L-3(BQ7%;@F;();'+>8$ !6O7J6K;TPK(
M,<F#E07L-.$8_>2)4-T]^_D!E;F/2G8H!7H-FCMN<^S-US$)6BJFO7HS>4%>
MM96+6*56[$\D@6;85HCG)P5:LVJFQ(U+MIUZ76,](H4T3EK(8PREC!+N?E(R
MTV#,#$QR9Z-]7:ME3URUL[+YZ@+5@VTM"G3&T1Z!X*V]=D)\8+)')QXN4\#C
ME!'+;.60"698CDZ7Z*Q+W6:GT=VTO;-]NQ>.O^$J7*;9.>(YTP10A@W&!\ZF
ML#<A!M%=E5=1P,AL]9:57 LYVE2BS2QZ*Y3\A#FS<=(&H[39K#$R05X8E3BB
M%2V5>:V.;$,^5_N1FZJZS5U]3K;Q7*C77*F5= -KF-9EQ"Q;5',0D$%50D7"
MRXY"!B1@T>!BE*4T_=C53"=##'*P\O7?/3]7=R74@*(OYUUJ@?3*3+/%:FMI
M*AMMTS(+?(F9>]LYZ]A]NJCJ"EH76T5V]&,UE> "U.9<K NR5E;0^5 H63.Q
MJ$ 'Q\P%8^D(_=YLU4T +:NH/>Q6096]_466$ZI5829*]:SQ.J8L*<,&&J^=
MJM6 2A]NQ(80VB$?Q(MUG3#1V7Q;Z9SV=,9U7-.SNT=\JTT5U%/>BRS.S'.R
M:0!?KV[B5"C^^V^M0$PCB#HCR+*P<L<_8UT=1W77&LJ6L^LZI:^2Z(L$B[:"
M=&S[*DH3,$^01$&4"$^??TNOQ5,!;_'+X;,@&,0C]$Z86$!LD<C'WJ3SGU9)
MC$RSS+UR26<>F"9G&/\ 9QCG(]24EHW2KRJ4G88Q<ILE<"89/L[Q9/[<4R4R
MP_XLLDH#\D#SFFXR6Z]\R&1(K!=Q((7(S$1$QX1,^,1V^H[S/;MWGOSL YH<
MBN..............................44G_ *S.Q_\  K2O^?\ ?N9Y_P &
M'_/L_P#+7S#'^$%_F1_\9\O7F#F;CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCG7
MU^5U8CGXU_-]42WW"L>-W: H*^XD/GE/7&\8A[PS&6.,Y_QS D98QC^K/-S/
M0=F]5KKK+N&YZU#6<;EJ=)E ^#&5S6\%SW[F2C%D#$^,]^W-BI'E91$D0=V#
M'D';S'[_ %'R^O+^3O\ 7?\ 7GE&VUC042J$#*MMN2P#,/<'Y()$](3P6>3>
MB[$,3Q_6OC/M)B.,Y+&,L<JM M1.O\VJ=544K9M4)C%D&RLR\0E+))GC$1$0
M3Y(_J?(.\?79=BSTYG9=>K:KW;ENQ76/:!-<43(!.72TH6E_>>\?'7(B41!>
M^.\<RF$Q2*NZ R-NU;/0R*165,388Q!1J39$I-X^DH<SDQ2R>&0MQ$;^L,PE
M'"R'<%KF7"^,^MJ7:X7G:4+'1HVEG4M:+&*0PA"@VQ:,$6##U6$K8L1'P8,:
M:L]?MJJJD%JW,Q--:'B-'1!H2%,Y6V0)!#'?W5X(O$_&9/M$>4^L-]5:O8TN
MSVCVO4]?2@7_ $%'$?T+&-8*P( 3,_L%E.R.]8$;J;,[#(JB!/K*B&E!40+%
MD=;@^M\-LNK=/U?"$Y]>P]R;=2JZP[XTL(6W)T9>^;&9<^4-+->E*JR5U16M
M&7=IU8ZA;.J\J6NO/:,"*$F(/*L"H$#!\+K5['K7[A0N3:B6-(B>4DR*[;>4
M1/F_1:VQ5431E&1A$ 9[)IS XP9RS8R][652%E+ 5!N%'/'Q3*/YO>257V]:
MAH.*ED5JU:A76HA9?KUAU8;\209+K*&RYJQ<9Q"B,Q,%ILVH=:@C+Z80UZY6
M74;"AN/(Y#/EC%62*S)0)28+D1E4+'LN2GSDA@17/WQF0-,U?[37=0V6PN:T
MB*LKFR6+C]+EQ?,LQ063R 3,2O9/!<K"T\IKS",QB$-$L<$+PCR=.4^Z%0[-
M-[FVJ[ K(BLP;K2A!+(@N7!F1AB6"E" ECB>\^^4QZA.:-[.P-.WJTO=57==
M1M*93FRT#I!45$>MI51E@0R1'Q.V4E'K%9#(-6ZZV?M^]HJ"IUL?[VR/D(8,
M68XMV5AF6,#C"#-E$*N)'D-%89?URF1$%-@N)0(Q&%M[-.AF>X/A+#)"R5VS
M[FH_$?:\6)ARK#?4=BNEL(6-%7O<M<G*V-*1YJ=0RU6?;ZJZCIVJ]!0J>^6$
M-VQ4E*@!S45ZI'<55ET3V&R"U@!B S'B/:8=H:QOG59YZE?URRFQ4,HKMA$]
MKY) *A9V0" R[1,F VQ6V(&JZP$Q:6$LLK_4^WE 00PWJ&D%SI[*NYQ"FJQ1
M'>8I>4QR7QJ7;&:VOZ*Z]ZH3%C99\FY)V/25>(A5-M5?,N9U2.YDEJ91'H+8
MT)S?D!I48FLBHJO:%R+!JI6JRV_' T?==\L I-OD]G,/IEOH]_L1;3=M(;.]
M'52EIGJBWDI%39:U58W[*QKEJ8J!489@\_!7!%I*A@-.-AG H9%H[I[EZY%G
MI=UNM=EHWM, ]5YK[*1._I;";/='X?[&I*VZLD)32$3D8\ 811>J>SHACVJ.
M9@+OUFH$WW%$"G8]<)!>1-0H9G?) 3 *UU\M8P?V,=Y]2 C)JMZV<W0-85AP
M,5KQ0)OVZ\)'LELSR\5Z1R&%)?*P)X6519)DAYJ_ 1GTE"6>4L"W;K;)A;W*
M _+.R%JK-+U9UP1O.!S_  *[W0-CT#7E=MY>#$@8D*V6=:[VC4N/SB<JA<JV
M\XDG:8RT>K8J%[$69D06A*V" R,#*1#P'OY#)#&>I*IO>MKK-9OK$S.JU$6+
M>PHCW!:_[R-9F4C5U440IR&T49RSC[,1EF$2RC+),0CS%J5O55N6<@:E;;M"
MNK0<VK+76KUAJ:J*X>*6@RP9&,A#Y4F8$I-L3]37>D*FUU;>3T^_1G\(S4V=
M&S0O:!IJA4S?-C13 FHX\5FTY%,R41$GXD,3')INE%+=+>W.@^UJU7K)8KSH
MK+%@9F2JDA*8.FM,<CM$'C$!'6Q[BB^+.8SG'W1QMV)L#[K.DNI9ZG!?KUTR
ME&60#G5Z=5MFV^U9%*[YV&>H\RF$'$KDJ]-:?RC;-3*CJ%I_ANG>Q^FLCXT5
M$6YM7!M+<92+,ZI5JRYU8 @"E]B2B/+N5DRF(C"[J+>;],6IWV$:URJV#TJJ
MLQ%TQL+C4@B&(V,!_KD+"</BR1F,6,FE. Y$S/.-2,)/2EQU=V3J*V) BO$4
M,L=DS/M_(D))9A#":7OKDY9#V'OW N:^WH=0]<YM;.9;QU)KZX#BTX--(+*
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MCCCCCCCCCCCCCCCCCCCCCCCCCE%)_P"LSL?_  *TK_G_ '[F>?\ !A_S[/\
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MU=**$&5X$C(HXRCB)?[,88E_9YJW%Z=A[ \C#3]D' 0JE2BPWU!8]:A*555
MQ9C)3$A R4@<BR"B.KTL@FZ]->AEU'T=6)5YC>MW%*412B++FT?8)VJL]I8/
M<S@HB1B1*._#NMGTFE;85TBGM-=9P^9%AZYLE;G&*^.5LRBM JJV4V<'&>/N
MD*1,JYA[)"GDD<[MEDNO7G4I=5P-+/4B,DY78LJEB43>0RV2R&PN7B1I<$)<
M!1VF(@ICD&6KCY'C3S*1U-K.TS6S=LOEH,KH=,"U% Y[4'0'[,U%+^ZY,A+R
MF/'F,J0LLW%];K!#*TS,E(4(\ #-=-?W@E]G&& ^]N,!+QC @QQ8)DA,C!',
MHQM9E3R=D9=T$9M*;=SSOIEN@UBQ,:U"3J+-Z6L$N_B812\HCR,)GV#/WD.N
M#?ZEW,_SO;!)5F30)=>E%=4 1W/<]AUS60C(0"VP^2*9D/ >W.5<N6Y)AL*Y
M:NKP*5]=)ND&*;"RR1\#)*RBZU(_H9R<!YS)>4RC]TXP^(9,#SX.A6&U> ,Y
M-0-Q4552%0F1/QX4HUY_RR?9#VMKL8Q_LB&,8X%E(1 C]WAUI32MUW*@<6O4
MLVL^"\U(JW/)XWK%H8&NTF ] BL08:P%9' E/><FV$I*0B*]B! [-C^UGAD4
MUS3?! JRU4QF5E*&1SG QUILII%B4QXRR2(X>S+<;^$)I'-1<7;,:-+1"J;%
MVZU5+*:RK7,_\IBB)5+3\JZS=-AL=W+$?#94#]6KHUDZ@543<HZM/Y=?P1:T
M85:%*56_?X3+B,_3+B 52F"_(4SWE4*3M)RQU[8-@6H*G7;P;GO-58K10;RC
M LG)3@G*)U&09Q$N(G:3 +&81!.$)1CF!O!D6_;:KU65BTFOL4_2HZ]*N-4H
M4]5-#IBNM*C7,$E8&0 4E*_7$E%SKXW\(%RYD.ZE#$5A6JLU[XJ*DUE\5H83
M"NRCN\;1 ,&,OLUTP0]E,CO %Q'OUQ+*IMK?<&("4IK=)!UB#-BE39"@0J#
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M+]I)1/?\O>.5?8Z\[3D9?O FLJUJQ>8F)*T10 K:/GS(L9SFR%6;R4Y8A%(
MTT<),8-F:K2T6><KZ@ <R[8I[M"WM96JY[%@BW434&WK6939I.,[2!FY5!DP
MM*5Q7.HZ&2RM8K>PK9C9]^\#K^:U-5F2*GP;I+W2(1)K8F)$OKR"1F9+\Y_E
M[%W\>?"IIZ^3*<;.TNW::WBW:5+ZE=$52$0D"J3;]2-07D_A\446QQF5<TTB
M# ?V>V$^4;&)G=+V*5+4T=:YTO<85S&',J_(=9-M9Z+-T%1:0H[>;>BJEE1
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M0RH"QCG-4=2YBY:03?!: 35M9R6IA:;$Q!K48-B;(^/Y'2CSFOY3!DMTQ/\
MKD-HG15J&WWZ)IZ[@#:*C@'PE&*Q:%(5=7B*LO73C[(QL1BA $2CSD4&IDQ
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M]&;#5=6JRU4@J6L%K[*>QK;BNU5';^6.; V'X.>P4QV_3M$3':?TF)F9GO\
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M5 N"!R7C=$U$*@D-CKJ%7L#D5%<J!$<"4!*VZXI' Z()8.ALQI(*9A/)!/\
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MK0;@MJ>W4U7>U+UMKH7FG$?1.YKX-3_O51,G@*#1<3',FU7M(LK2:C'NY"[
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M6C<U]!6<%FUEIDML)=HQ<LN>-:E*7FH(!E:L-X72--?G86X"B(CSG$U]DO\
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M*=;,=JZ8W)7Q.\>?&:=B?7KF:S1>B/(^Q[SGM!D9LSS]+9ZRQEJ\:3)R2J&
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M?$W/0HI043V+I[HHL;3R$=>:L=)5[&<QV7H^X1)MA$C$^ZW1^3\%M2&A8?\
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M-_WD:)__ &NP?_\ !S\>?_9/ZJ__ 'HZ?_J='_\ E^4;^XNY_P#C*W_^+?\
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'_O\ ]?/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img61678762_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_6.jpg
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M!9Y5@F$T:QIR<^9P"D;N"JLAFK5A7BL)%/-6DA!Y2K7;?EW"I$;$)AE9WXJ
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MY\$G&E9\,8\<Y\,0LY\,8^N<_HQ]<\^CSX5^'0[GI+1@/I,+#_\ <SB?\?\
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M'&,<8QQC'&,<8QQC'&,YO_%5_P#%-1_+]U=__L%KOG2O"?\ \+O_ /'^JO\
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M'J7CZX2_FMI1]/%417U3SRFU/H"@.3:7KE@?UM2ZATZA']9XU](9MA]'G_\
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MB+(R<2ZAB=MHJV>JA6KF:AH\LGD1<^6I7(9B_EKR,J?)3QI*6WYJC%%;<*2
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MRY59SLHW.49@HW/IE0C-WW!=G%R#=R>H0MW.<LU'7.8[#C#*L^*6C%Y)CWK
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MUAKV,;03<HP*P3QSVR+.@T)A"2-7!2V"HQ-FK4Y+4]LEZ+.-GN!N-_K ^_\
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MK2XVXE*T+0K"D+0K&%)6A2<Y2I*DYQE*L9SC.,XSC/ASQ(V['L1V(/PS*!!
M((((!!!W!![@@CL01Z'/UQE<\;SF6677<-./9:;6YAEG"<O.Y0G*L--86I",
MN.>'E1A2T)RK.,*4G'CG%0-R!N!N0-SZ#?XG8$[#U.P/V91CQ5FV+; GBNW)
MMAOLNY W/H-R!OZD9J--ND>Z1I\R&$L(B/ (3Q2G#T.)#]S/$E200M'BIC3Y
MJW,C2@J7$D..)::6KTG8JY+#F'>9%FL:K(K2PR%T23:%F;BDD:2QEN2)MSCD
M5@!N1W#!2-LC].U%-2262.M;KI%-+ 3:CCCYRUYYJUA$"2RD^3/!)&Y/%2>+
M(74AL^<OXQ74#XA6VNYNCMP=)B=MIT69J,+J8C;J'ND=J,_(M8BP;DO4T6^X
MFTUTK*C1:1*G2&IDA#HQS$J2*;=6_)>BK[-X<=1='Z?TUJFG=3I7LLNHRZ@E
M>WICZC$*\D.FU%D7>O-&K-:55*@AQQ60@!0PT'K+1NHK>MT;FB--"K4XZ;35
M[RTY#,DEZPRDB:)R! 20QW7N4'<D'LUJKH7UWUI:HNS#02P;RW5'PG.-Y=B;
M).W#L^,ZE>%I77"5GPZ#U\RC.,(:':UK]-%,M8PTU!0WCR\YKJ'5FLWJ[48Y
M8=+TL_\ W5HT*:;0(^B:.#:6X?I>]-9D)[ER<W6IT_IM686GCDO7A_Y?J,K7
M+0/K^3:7>.N/H2M'"@] HS9-_32K]WTO6\PV"E9+W(G&/BIVI+3?ADZ 5U1N
M .2B$"0P^/"*ASH,CV,L%-&R76(\A9:<N0+]2'GPTE(Q5U*;D4GCK(8I$U""
MHZ/'J&G2(R(\3RAE8<UE5P"P$:@/LV>.KR61<TR%):RP6+#1-%/I=JZ9&-+4
M7D7SHKL$05H(W4PO"Q38RN[I^2RJM.=D=!;\(Z[7V7.)='MS&EU?KK?"D^8Z
MYUTO%D6ZB/UGO)U;^);.L[,\\\UH*X3):)%=F*^ZPM,<0FH3U3UD#JVI)K-1
M53JC38Q8UFI&B@:S5@ +:Y5B XF]!L#J]95XS+_+XUW]I08<)/3UA--L%FT*
MZYBTVP[,3IL\NX&ESR;\A5E)/R?,S;QD^RNVPA;-A-[\AZ IH;4&CJAC:7:;
M<M^W,G5FIWCA5T?#'B=L7,5/VMM4R_((2:3INC,I84>-^#<RP3FX]5JS$^QD
M<9B^,>DMJ]F74=4L>P:%IM/3/;]0$48=GDT^M(FGT(PJ+:U*V2WDQ=UB0M8G
M*0)[UWMZ:;62EI\ LZK=LWS4IAVX@"]8$ERV^[&"G"3REE^=*_Y.(-*Y(G'K
MSUIKW7RN7B^;1N"-F[SVDAJP=A-\VAI@6_9I$*.O$6O XRG<QJ-J6DQ771=%
MHPY]H8#&)5+EKF&YQ,G+B]9UF769:U*E6]BTFEO#I&D0%I!"KD<II6 #6M0M
M, ]JVXYRO[J\(E1%D=-TR/3HY[-J86M0M;2:CJ$H"F4J.T<8/:"G /=KP*0D
M:CD=Y&9CO/6,_0C.FJZ1HYZNF!#*9Z)\\"7ADX#,UN=)RZW(EQI+[+3S;&65
M+0IQ.4(RA6<8QGQSAZU7L0:E/'/#+"[%65)8V1BI10"%8 D$@]P/4'/72;52
MQI\4]:Q!/![_ .6AE22+=78-^41BO;;8]^WQR*-E[JZK5GLCJ=N^;'TD(M$S
M7FW'8$^R'Z<Q+BS 9_3LV&J2:GOX;$3(S*)KX;$^;#?>S'G_ "K#JXTK#<A2
MTS7I]&U U*>IR0+<T\.D,-DJRRPZDC;1(N\BD\1+Q5@-T\S;==]:U7J/H>GK
M>GC5-7Z;@NR0VS%+<M:>KI)5:K+'SLRMM7D11(U?S9(V8K+Y'(H^TE2NYO3Z
M#X^][6];8F4_CB3O/6#.<?\ X7+0G/\ S>'CS#7IKJ)_FZ!K3?V=+O']4&9#
M^(GA_'_.=<]'I]3]3:*I^XW0<KM;>]_2H?N.E%W.W6LY4>-2+["SFJVZG6VL
MQ5SSFMI209$I7X!QZ,5L20,F6-'K)-DI;(4FH;AI#2TN8YZ4ZT?4(*D='6(*
MEF&?4):<M"O 7?3)*59#&UJHMGV;CJTHMLLONR20<)(@"#[GQ4\*8-*LVINH
M^EK5JM:J:?'J-75Y[L<7RM#J5D1RG3K\E);K'1U:C$\.\D4-LO%,>)7;3/Q'
M^L405/*UTGLR\L08SKZYE9TCN%%:PK&/+&1+OIVD!J -;FRE,PHL@A9X[+TR
M1'C-*<??9:<BNMO.Z Z5U?J[J&%(=.T:"*6:O#?TR;49WL6H*5>"M16[Y[R2
MV;,,9+*D<2,TTSI%'(ZS'AQK6D>*O6V@=!]'VK=W5^H;$\%:W-H/4=;1*T=6
ME9U&U9NZS+I"T(8(J=2=UXSO+/(J5Z\<EB:*-X5U?\02IWV!K_3U *:[UQL-
M--KT.>3WO= U<%(F0XJ1$ABA5R,28.;0G8>@O/,1HDBNMLMKC*)KBJ=5'3R3
MHOJGK'Q"Z5J7_#SI"TFET@FDZGU3U&%;2].O4Z\'GPU]-TFQ9OZE,(989D:6
M33*0\U$DM^8'C7N?B%H/AQX6=<W-"\5?$'3(^H=2#:]H_1/3<_E:SJ^FZC;M
M+6L2ZOKM:EINFPM8@L5V2O#J^HD022I06-HI7M68ZW "X<@=VIDQV2N#L-;4
M>+<2$(-5H"9WEC2\TVH1%QJG5?1BN+D,DLM$+'^8QA-@<D+2ODS#X8Z+J;M-
MUQ>M]97I8Y4:?6@5TNCYD;*XTC0*1CH:=OV5+"I/J*'9S?9@6R/D\6==TH)!
MX?T:?06G12PR+!H)\S5[_E2*Z-K74=X2ZEJH!W9ZK/6TJ0$H--52%R2^OU?'
M5?3]$#"ZA"I,)@"/?0&@/Q93+KLV*S,DEG'XGBER27DONSI"GU+E>J\KUUY7
M^&S=+:/I6A].Z-IVC5X*M%-.JS+#7B,*":S"L]AV#$L\LDTCO+*S,TCL6+'-
M3ZQUO5NH>J-<U36[EF]?EU*W$UBU*)9#!6F>O6C4C9(XHH(TCBB0*D:*%"C.
M%_Q6OB^]N.CNT*;1]5=703%>.-W+T[ANB JUCK^Q7B :+"/Z^9U+N"&5"A<M
MD'/?1-@A@IMUU^&J)"2VU+PGZ$Z!\.^GNJ*-FU?UV4S1&MO6TU_9WJ&9)&:&
MV=0TYHY9-T'%J<LL0 8,V_'?B75G6&L:%:@@J:7&(Y/._+7E\Y; C9 )*XIW
M5=(]F]X6$20DKLHV;.VW6?;-YW7J.M[ V%IZUZ3L1:*/<<JMM(4PA()1Y(,.
M339PRJ3<+M#BUPM((26A,$P68LD9N"XDL.C*RRX_S#6]/JZ9J$U2GJ-?4X8V
M<">NEE A661/(E%JM59IHPBF1XXS"W(&-R-P-XTRW/=IQ6+%.6E(X4F*9H&+
M HC>:GD33J(W+$(KN)0%]]1V)I+:.W6^!,,K"C0JU',:9L2=1;?F2JW-7$LN
MTB1&Z$ LP%'^8M?9V(_JFFTK;V0RWBF7*WV#HS>)K;HB3B1$Y);?JW'X^_[C
MVS/: [3;D,#=CP=O#3X(J'UWJVU@IMDUF$G&JNY>:-<;06V;; >HK_8*Z9Z_
MJDA8(JG$AEF%WF=:*MM*HV*('FB@DIYE#V[?$;[_ '_C]'UYH5;[U;1EVW3=
M)<CQC%?.[CW!2[AO,/JBZ[!UM9:N$UAN6TZPS4+3J22?UQ-.,$*=7S^UG85V
M837!L.558XILI)MQG7;&WW[?9MWV[[[9[M&[Q;0+W?45"3$C7FOG^R1#6=CW
M=4=:6NTZ[M]*G4?YS3X]4M^MI-PUH*L,XT39*68S/MRA]%K]<E58Z*D65=G.
M5)E=NV_U;_9WV_/^C]&V3;OS>F[:):]]U^NGM-5<75Z?U$-ZWL&P9,VNA ZM
MO;DV31MHD-B6\@_+#QLJ"4K$6D1(H3VP\SD:Z0D'7S^! UE.WU_']7;_ %Y^
M;#W"N8&F=6RE8U7$O!/?NNJC;2#]SNSFL7J_)L^RNL^HAJ7X->HVSXDQZ=9>
MR LX1;A2V!PROUHP\+FG'9(Z.ZQMZ]_3]Q/[/TY%8SXBAJZ&1NO1&O:E3KQ=
M(@FKUU$S9RK)905\M 33R1MF?UZY0@$D]I\7:-Q,"6KQ\[%RSCU)LC#E7$2,
M*CQ65V^W;?Z/MW_0,U[7/Q,#)2GZ15<=:UH1;[U,U96[-'MVQON],3BE\,=>
MZNV8HM3Q3+7#LDJPN[QSL:IU"%;/,]J\:)GE["'MA.PT^ELIMZ[?CU/Z-N^=
M=.,IG++3_P"]+J[^3JD_S:&<ED^8O]E?U#, ^I^T_KR1>793/9A/-QYD1]U'
MJ-,26'G&_#&?.VVZA:T>&?IGS)3E/AGZ?7E"-P1]((^_ R_,:0Q,CL2XSB7H
M\EEM]AU&?%#C3J,+;6G/\"DJQG']_D0002#V([$?6,D 01N.X.5"[>;@GZF@
MZHAT#7%3V3O[:NP/NLTE N'DA@@!8\$(D;7:; <9C/F1M1"5@-+EV6+7U(*F
MV4Q!;.,(>7(C0&OZO8TR*G#1KQVM3U2XE&A#,YCKK(8WEDL677WQ7KQ1L\@C
MWD<\57;<LO9/!OPWT;KW4>I]4ZOUJ[T]T%X?],V.KNL=3TJK%=UJ6C%;J:=1
MT;0JUADJMK.M:C=KTZ<MUA2K#S;%CF(UAEHQL;<O:[KC8=;Z:V;UQZI[AM^]
M8DK6772S:J$%Z10*T>?)A9-GI6T*_;$FRL&APQ<MRVY=JDII!EBO9AOC$377
MR0?6KNO=5Z-8J:?>HZ3J-O6&\C2+-!K-:M'<#1^;'J,=AI91!'$[3K+ W)UB
M*%069XNY]+>#O\';Q1T;J/K/I+K#Q&Z&Z=\,JXUCQ(T/K&MH.OZ_>Z;D@N>P
MW>BKVBP:=0?5+VH5(=)EH:M7\FK8OQVQ/)%%#5N>_L3LAVSZ?D];47;FB>NF
MV36WBWV)ZT%- Q#FOJ_6]S6 B+%)J-V&71\H^(KY*&=F$6K5694:3,A"IH\G
M"8S.>)#5_J'JC0)*M;5*&F:G-JSBKI,NEM8K1+J3O$J5KJ6WD80L)&=)HFY%
M8BK*"Q>._H_P3\ ?&.CKVN^'_5_7W06F>'%6;J+Q'T_Q KZ+K]^;H:I3O6;.
MN]*6.G*U&&358Y*,=.QI%^%HTFU"*>O8F6%:EJ58FP>Q6H]GZMI?<C7?5^YZ
MZ[*W"%K<9=-*UNS0%5/:R19>R5"KW@'?W2^;:!,?*RT6M'XBHLP:19DRB,2.
MVZUAV0CU7J+2[^FU^H8])FJ:O8]B@MZ4+49J7VB>6&O/':>0S13B*1(I8^#*
MREI% V&:5=\//!3K_H_KG6O!:]XCZ7U)X;:(>K-7Z>\17Z=OQ]2='UK]/3M3
MUG2+W3U:FNF:EI,E^I9OZ=<6S!-!-''1G:02,O0':MNM-!HAJVTS7!C:Y8 T
MQ.70JR5$"+.;$QWVU&&JKD\[$#$K)&&8DR 8 B3"1CQ!I@2HT+5*3+;W3/EK
M*5H[==8LLV6WWC7@0-5R.L6>Q.H;TS7 -I:[#Z\*$*E#FS*! CCF+4[MX=>C
M>O*O8=5F!$>X?:FW:U8%.G9I;#8=E=OW'ZOQ^PY38Y\26RBNQ$_28CX?=2*;
MAJ3)*TM"6=QZX7<HHYNML;*LM<$RQ-%*AI>Y1\0P2,'J+5K6<4Z601:'&3LI
M[WLCG6I==6:FOVM!HZ(NI3UAY@>/4HX7GC2G';L0PQ-7<-<B#2;5EE9W6/<#
MDW!?MOH7^"-H74?@[T_XP]6>*TO0NE:](:3UK?0E[5*^DW+?4M_I[1=1U/4(
M-<K/6Z7U*2O3+:_-0AJ59[C+(QKP>T2RM;?B@:F*5AXOU_T/]_%"!ZQQNK?<
MGYM6J9"US$N?S$7"UXX*FB#C5YW]>S*YU6%ZW@Y9EV@T2CC8YB:R2G2A\KIW
M5U?6KU*KHU62[!)42YJ=PR)#'I22K((:\J$.9KKS1E'@1AP3>57D56X\[ZV_
M@U:WX6=(]4=1>*'4-'I35J?45GICH/IF.C9U.YXBV].GIG5-9TVRDE9-,Z6K
M:=;2W7UFW#+[5.8Z,E:I8GK^=8KK#VUK>X[#3)-@T4K2!G=M-.'=3'I12LGI
M%R@:XG)$7C4]RG"1PHI1=X:GD-K9N.GS+)%D8V)LV*M9+-BBWA-:W#/FC;]'
MK^S[_AD^;SG15J CDJ2N8S[R6[C'AE3+#V&&FL*_@]=;+F<8_'P8QG/TSCF9
M5!]]O@=@/K(WW^[,:<C=1\1N3]6^VWW[97WF9F/F.,?VI*?X.F_Y,[QC+GZ8
M_>>U1_)K1?YKB^1!]3]I_7F>/0?8/U9)7*97'&,<8QQC'&,A_:5$V'L!$834
M=X7#1XV.RF1+-ZRKFKS5](35N/(1&]YN.@[4I0X"AA.,NM-T22:G2\X7'.BH
M\-V.18_-O^/JSTM"R+1)I+GVCO5GV)B ?M%=C62_5VDUO8BYU/M)VGV.%<(^
MLAP/7!*1%/ )ORHU3JW6AL\2Y$PL2I]E90FP?QM^K\V3;QC'&,<8RO%"A-Q>
MQF_WD0?:*(4W1LQU[Y+ %?,7$O;7A8FYF0UJ?L/@W#;A?.2>$3D>S^2I1[ /
M!6IE?A^<_LRP_&4QQC'&,<8QQC'&,<8R/=@:Y@;$8%QY]DNU?;%3&IS>*=9Y
ME<]W(8G#2,91'$5*DS/9RA;#D)3B?4AJ<D.1EM/.X=1B7*TMN-(DN35%2>M8
M;R:VEV#))4LPVZ_(ZEIU_@J30J66'RA*K,DWF+PX9-2:"O*TLM*.XYKVZJ>9
MJ&N4ECBO5)J5G9=&U;2Q*[PSMY;V?/:O(JR5O)8R%XYWOUCUEV"IRJO=QJ7R
M# =P.-M3L>(2,,Q7$(P["+H(,O1+*$GN-H=+@3;,D=/<\9*412*(T^/#:UTW
M%JMBCJU2]=T+JG1V,NB=5:0T=;5]-F]67DB+!;T^P25NZ59B>A:C9T,*,4D2
M<T;J/Y/H:IT]JFE:;U/T3U!&*W4?1.OQR7M"UBMV"EDF>2Q4U*L K4-:JS)J
M=.=(Y5L2 .C\BS=^WMT=M=&TSN5F7N#1C-A%%:.:Q=;#%N]+J0DI#^8L50LX
M07)O (;$_J<15-A$8-NIDI,,6.O-EK<B++@:EU7XKZ+I24:/BBE_I;J[VJ%8
M]>Z1^45Z4ZRTLR!+>JS4=-N0W=#O1$1C5].:&]%SF\_3EE28KDWT-X'=76I[
M]GP:?2_$#PW%2>3^+'7\FEMU]X;:O'&9*.@TM6UBA8T[JO2IE\UNG=3DM:9;
MA2NM75K$1KHPZJ::[H=8-\H0.UQMH%+L.6U-+HM@R3IFQFG6D92_'12K;&#6
MR:]'4E32Y0R!.CK>PG,>8]ZC3B^LBFTE=9ZLU34:3QJR7]*U"KJE)HG4%)#>
MH6+$2<E(;E)*D@[EN+ [<EK]1Z=-::I8]LTC54F>.31>H-*O]/ZND\3$2PC1
M]8J4K4WENI1A7KS0GL$9E9=_YKWL1H95=OUL>VV-'UNHV"7 L%DOUH.AJ^"8
MS*G*$Q'2]_E0QD62N,P\I;3$C$QQ#:,R\*SAKPU?I T]:?48] U).HYX=3MT
MY(M-UT]225Q#*XAC:*"]J#5^2$E'XIYZKRYR!-UW7KFS+TY#IUKJK39.CJ4F
MD4;Z6M?Z=/1M:P;$"&Q*EC4-.TF.UQD7:2-7D]D=N+)"90&AVU?$&IAD,9D]
M>-1[.[*QH TC+?M0<5&UMI5;$"*](FMYVYM/->!V)O,=M7E;UX,O\B5ZB&H\
M1]QU#:N@6-!JZ9&S]5Z[H?35?BWGQ:C;BGNK%L>;2Z?6:1X4"\O,]N>HBJ"6
M8 '.0P>(%K7&">''1_5G7]L'>M:T;3IM/T1YU.Z)%KNIK6AM2%@OEC1X=4E=
MRBQHS,HRG71OLCWCWW$VNU2-7=6: R M#%@S'N[MSCS\"MB3;%8!E>:F:ZAR
M()9%-F,F >)Q1D;/D14Q)*8[B7W'.:CT3KG@GKE"Z_1NM7-4>IJFJ0:H-)TR
M/3713JVH2Z5;FKZI6I6#7U"@ZS4WC$T$96S6#1RP2Q+MO6VB_P *;0]3J1=?
M]*:!T[%<T;0[NB'J/6K6KHYDT/3(];TVO;Z>N:G3]KT75HI*FH).U:U*CTKA
MCF@LPSR93M%M?XK%&VIUL%UC3.BMA#\;!G'B!;6T*Z3 &7Y.OMCUMVMGW+C8
M@AAQ<2ND;#<U-UF.Q-PX!%M*(.-2WA<WKNA:?T%:H:W)/J>J4W]C6%([K5EE
MV6W3G$\0K02Q@-.D%4&=F7\M(> *AUXGU3KOCCIFIZ+!2Z=Z9U:(2^U2V-'C
MU*2KR?S*;4[1OVZU@F.G-;U$BDJR;U8%\UE=H);OX5\2!.?JSTB=Q_%(WNQG
M_)9/X?\ Q_B\/KJ__P!3?@>IP?[.E-_\2_CX'-ZW\7OZOAN?_3ZG7_X&RE/8
MS='Q2Z3N?KU5@ND]*VT-(MRRA2XZ[";+ME,AOG*U=:FL?8FSA"IGGGZO7Y9^
M^RAU7DMRI<86/CKF^60Y!?VC1M,Z#M:9K$\NJ:G6E6N(XZUV6C7LN(IZUCG"
M8DL1 3RK#45YQQ#2.0O;D.<=7=1>-VF]0])TJ_3?3=^NU\SSZAI-;6+VGQM9
MI:E1,5M;4U"T[TJDEK5'AHN))$@B4R[.8FEKM'U.[U]E.NVY-4V'LWH9N3L*
M@GZ_"H]<Z[SJ]4IQ65$4L0P6O5OV+M.RAH;)1N)(P="5=PX(=8:(BTXGL,*1
M':%K_2NBZQIE^'1-6VIVX9GM3:PDUA8U;\HT=6O2H0R,R%E\F2<12 E'/!B#
MOESIKQ(U2M-%J?6?3PAF0B32M*Z1>M7G'8^0^I:EK6K6HD8@ SPU5GC^?'LX
M!%#_ (4_PF-\:+K.W3^\.R5VJ=FN%JQ7QL[KCL*%F48"T0S: 1>';;+?]/+M
M[+#5H;(3P< "<C#769SY&;$9)O+\NU]?>(&E:K-IT.EZ-6L05J_G.FLU'XQ2
M6XH)8VKP5-1%<DP%$E>6)G!545BBC(_1_#K4Y!--<ZKU_1V+M"$Z9U"K7%E8
MI9%<VY[NCV+8*2!C"M>Q$G%V9T\P[CJ-<OA^@[34K&%:[,=Q$V,J&(P MG.=
MF-ODH==*3(SC$4[BHUVWTT 6>&NK3+8'S6DCI#S3;<QA^)EV.[HE7JZ6O8AE
M.B=.&&.1&D@BT33D:9%()B]HGK69HPX'$NIY@$E2&V89VH^%5:[1N5UZR\01
M<GKS15[MGK+7Y8ZDTB,J61I]/4-.J3M"Q$B12*(795$J.G)&@'IW\*GKI0=1
M#QVWQ0SLA.F%YQD(4V,'(Y9KPJ1EIK-<8KKUH,5B3#:)1IQ=J7@1$F*?+RVI
M*I*$,*1+]1]?:S<U%Y-.=]$58TBDCI2)O*XW/G&8013JQ1EC*^8R[1J5"DMO
MJOA]X'=(Z3H$4.OP0]7RO8EL5I]7KR\:D#\5]C2FUVQ2>-9HY)U?R$D+3R*Y
M<!2/>O'P].CK7;K3MKBZ1FU@T%JY4D.#Z[U_9A&K<%:U:=>8K:C FI5%6OYT
M.5@\?1<))Y<B._%E--6B4Q$1 0FRMUAU2>GM1KMJBSQRV(T>6Y;@DO\ ESU[
MGG^7+8L>V*R^3#[,L6Q5E)KJ6+G)JYX0^&QZGTN]'T_%0M0K%<@IZ96:GI3/
MI4T*PM-1J5EH3HQU"5+QL*_GI*J66**@7I7$TWJ&!X>QU5K>'Y?#R^THU8C^
M'A^'AZ(M'AX?H\/PYI3:EJ+_ #K]UO[5J<_KD.=-3I[0(_YO0]'CV].&F4DV
M_P F 91G;FL.B=)[0U+;UP"B(6\:T#2=$,5>U7MJSH/ 7@([7XL-0:G8HXA4
MHH.-6B-&K203<"U-%24DW!)-2'Y/-.ZA\7*/2UVMH6J=1Q)ST/65&B)7AOZI
M=^5+^B-#7KUTKS79[=^>CQI*&$I>OO"T:1%EV_IO^#T.LH;'5^D]&S-8@ZDZ
M<F7J0W[^DZ-IS:#IO4D36K$WM];2J]#3*^K2G4B835=+C"Y'/+,JM.,G6]^W
M:RNW[?K8K(&.IN30NNIPZ\/K>/,XA*#^X#0H18\'+1[5;DF!7(PDI6ZTZAEA
M2"!5R04AZK4Z9O=<V8=3\0J[4]!5O-TKH9?+MQ1#BWE:AU0!+%!JFJ'<&+31
M,=-TH'?^5W TJ]%M]6:;X?5Y=(\-;0N=0LOE:SXB<7JV)FW'FZ9T?SC>QI&C
MJ05FU4Q)JNL'?^\Z)2!]CUKI;7-DT+4:'L#36IIE7E@A4U^GK$"[I5R+LX/!
M6Z<GQCU1#,Y.$E94Z04L=*>;=PCRE9F<86C>NCX:O3>AZ)#TSYFD01Z;3E1:
M$8TTI-8B2>PP6K,_)I9I'EDE9^<TCL\B\B=^:^((_CIKW4+]905^HWL:K=CE
M&M*FKI)%7F>M65A>A*J(*\4<,,:IQ@BC2.,A5 %8=U]*;-K+6-O+="+GMC3^
MS6X33=3UF"VMAW1\^9.FQ89!XE0]LQ+W4JS#@!WILUO%$AU6>J1#BL0GV'5I
M=1TK3NIH+UR&/JRMI^HT3R-B[+0VU1%5&9 EK3VJ6)V>4*I]K:PG%F+ @;'A
M/4/AS=T;2+L_A=J.N]/ZT$1:&CUM<Y=-RR2S1QRM-IFO)JE"G'%7:21?DR.C
M+RBC2)E8\A:'I]G<B.N>L(&^A@X?LH, 9"DI(HM$,PSP<:I4>JV/,J'X);(&
M*RD5(-QG$-.,G/F7D;Q'4PI6DI\F^RZ<^E.[TI-*TN1%DC:-HI7H5S8AXMZI
M'/Y@B8$@Q</COG5Z7\8 =1BZG@BAUBOK6M5IG@GCL1VJ\.J6DHW.<?82V*8@
M>RA"E;/G;#AQ)LOQF;CC&0_,[ :6'#Z>5G;)JT4??Z^_:J=*=GX2V?K\;(M,
M@I#_ "/-AAE9H:TXE]++R7I&6<M^JQ)0RQBG;^TY? UFL%;OP9T13 <*TVR4
M7Q-K"J[524(F2&VPQ%M$0-,@50E!"&Y(ZS2(Z 4]H(9S$GO9$D,1F-OQZYC!
M'970YHB"#"]F5MTM89^!0\4ZN7!(12CL_(N",/09L2-)JA R3Q\MKD*SM!Y-
ME(*;A5]HE)<;:4QGMPNQ.BB*Z<@7M2DDV]@%3H2FRQ1J*2&GB=<M_P!WYB-#
M*0%2!J<,7U35)CR)$IF,2M\J%6QKTPS/APGV,VH5M'7A^['];";:&(W>M1W)
M!RM,OY5/B,QVPKL_RX4A+$Q8ENRUE1UB$[)> _::MX,MP<GQ&)K&;YYT?7\M
M/Y.,Y5^5CZ83G.%9S]?IA.<9QG.?PSC.,\8R%(PW1\3?4S+"0*=^$Z++L[\-
M4R<Z;S2?>UBJE;##&//N"8/NY 6E #A:!%CEB40-5!Y:1)@# S;#'ZOQ^/OS
M;[;K"@WTO53]MKD,Z3I1%HI6Y$E^:EF%/B%PM@AN2(<:4S!+('62LURQC8QB
M-/C#++7@=@@LQS(@?-CL9OW&,Y9:?_>EU=_)U2?YM#.2R?,7^ROZAF ?4_:?
MUY(O+LICC&2C1=F3:JE(Z>VX1">;.4-)5C$J!E2LJ6J(I><(6TK.<K5%<4A&
M5Y\[;C.5.>ICRP"3WA[K?H/V_O\ T'/2.0IV]5^CZ/K'[OU9Y-_ZAK/:BG59
MBK;'GZXV9K:YB=EZHV*#APB)RBW<-'F0FI4^LE%L1[%7B(XC/%6"NS7&AQF#
M(RA4E*F674ZOKVAMJM>!5L34+M*U'=T^_$BR-6M1AD#-&^R3PNCNDT#L%D1M
MB00#G7O"7Q1;PTUG5IK6A4>K^ENJ]!N=*]9](:C9GHU]>T"])!8DAAOUE>SI
M6I5+=6M<TS5J\<D]&S%R1&5W5JM7#H%OG>1L%L/L#V\GO[2U7Z4_KT2U#K47
M2*?JVX-E!)*5>C5;*&CKVPR9QL+"$E I8B.#MA7B4")A*IC4F)K-GI+5M4EB
MN:OU$YOT-GT=].I1U:U"R'C=K4L,DDIN/+Y2QR12.D8B+HOS@4[GH?\ "2\.
MO#W3]1Z8\-?!*M%T?UCSK>)E7K;JNYU!K?5^B-3NU(>GJ&JU*&G1],5-/;4)
M[M._2JVKSWXZEF<D5WBG_MU^'WN?L+/%6;M%VMGG;?K9I,_0;^F=?PM9A-8;
M!C%!!:)M8A!E&S\FYV?U@<"+@3/E00PX>X39%YCRYS1""M=(:GK#QSZ[K[RV
M:0YZ2VF5%I14;BO'(M]T:65K,^\2+Y;,D:(7"<68.C0/X2W0OAE6N:3X1>#=
M;3M$ZJ<UO$>/KOJ6?JV_U=TS+3NTINC:UB'3],BT'2>&H69C<K16+UJRM1[?
MFP5WK6)2IO4[>MIVEK79';#L2'W) TB2E6'5]$H^KX>LJRY>GA<H)'V3=_*>
M/R3EB'#)\WY**A?+PX.?(<F0590]*BR<^MT_JL]^E=Z@UF/4DTMVFH5*M%:,
M!ME&B%VUM+*TLR(S>5&O".)R63L65M0UWQE\/-'Z0ZKZ6\&O#"]T+9Z_J0Z7
MU=U%U!U?/U;JR].I<AU"7I7I_?3M-BT_2[5NM7]ON6/:KVHUHE@L ,D,T707
MFWY\TY0/8OPU^M.RK##L13.UP#@#8A#<M""TW;UYK56U?NLN0?+%MMZXK$(I
MD+6+:4+3")DE"8AO4V?8"QFS2ZJ]9"Y$M)M=>:.G)DYJR\D/%UY#;DC=^+#U
M4[=CWVS(JV35L5['E06/(FAF,%J/S:TXA=7\BQ'NOFP2<>$L?)>49*AEWWSV
M7/AP];,Z<'ZACQ;X/E"K^_MJ#N0?=B,??+6VI>?"=LQ6S,-*(/6R<SA$:4\_
M$<%N,,Q,)%H<A0G(^K'HS13IJ:<JVT:.V=034DM.NK#4&^?>]NVYFPX[,2I0
M@+[@*(5^A$_A2>*HZYL];2S=.V8;?3<?1=CH6SH%67PY?HN $U^DATGS%5-%
MK.6EACCF6VLDDQ-QEL6%EUK2WPR>M6@3[=I%'=O6F-%M '8LFO;'V?/,4<CL
M^KN37P>TK)6840&'LMT%3IRC J;962@H'8X@BT@Q(RRA!!>%E:!TQ0Z=]K%"
M2[*;S0R6/:YQ.7FB\W>8;1H1+-YI,Q]&*)LJ['> \9/'SK/QP;IM^L*'2U =
M)P:E2T9>FM'?2$KZ9J#4"FE.K7;8DT_3/D]%TN,[25ULVQ)+/YJ^7[VS]*]>
MB$B]N HMPCF;M>0^UL2JAL"W5D70=QAF",-S;FLU"RC&*+>[)")S(-]E4S T
M-LB#-,1KU"/(LUL0?VJ.LS;%_='T?TB/V?G[_5G#7GV[+[QVVW^'V?7^H? Y
M[Y C-*S'R!&0Y*F25^=Y]W.,J5GPPE.,8QC"4(0G&$-MHPE#:$I0A*4XQC&:
MJA0%4; 9BDDDDG<G/2Y=E,QQC^U)3_!TW_)G>,9<_3'[SVJ/Y-:+_-<7R(/J
M?M/Z\SQZ#[!^K)*Y3*XXQCC&.,8XQG./OO0J.U%INRIXN\$KK8CU>U)"^S&T
M^WE?C10L8=L.\(E1=4]1C35XV<<:?CDF%QH("9-#!)<^TDBD"L50NAUE1^;[
MA^L_5D^=-!<0-UTHX^#$G08Z"VR)'MR</=< FE^?M&Z3Y;A&+V+2G=22$B7*
M?D37+]YB<B2Z[)B..B'1SBV#Z_\ =^SMEH.,ICC&.,9 M-Q"_=#;N]JDVE[-
M T?DADLL\J&N9\SW'A*J[@RXN$V%]GB&E:*REH%\[296XW\^6<<6ROP'VG]G
MX_ R>N,ICC&.,8XQCC&.,8XQCC&.,95SLKKK3]^QKW.T:.2MSPFU0U"71E:O
M1M46%+EPD&84M^E09/EBD$M1/$64<\A!3'FBQGUL.Y1I/670O3?6:Z.VOZ73
MU!M.U2LM5K-PTG1;<L:SP\DM56GKS")/.AD,D)*(74'8YO?0_B3U3T ^MITY
MJ^I:8NJ:/<>VM+3)-321J$,C5YB!0O)6LP&>3V>9/)L$.XC9@& SMJZO]>K6
M*F^XTMK1N9(@/^UFQZ.-&36GW(ZLQGG?D[80HXXRYE"\L>]B2?,GTTOQG?!Q
M"WX9^'UYC[3T?T^C$\6GI:=3T^R ?=)2W2BBD5@/F2<F"G8]QV-:GBOXF4(C
M[)UQU+(H7FE?4=3O:G3+*.2++0OSR121\MO,A(C+C=25)W%#.I_P_*&)E7>1
MNF&-V\TT\+'5Y%CU>9H> A 5),,')L/+FR+7%(MFL.C_ %1KT-N0$R/;3\T(
MIG+PUI?27@7T!T]'J[*FIZPUK5K==%U'5_,B@T^C+)'4A:#3*NEI/.?,D:>W
M8$D<_N"O5IA9?/W/J[^$/XH=63Z(+S:'HRZ?H6GV.>E=,R5+%C5M1A234[26
M=:U/7I*]-O*@6II]3R9:G&0V[^I&2#V6^J.K'6D;&?7C1FMW6VX[OGR[3!Y>
M7Z2&E>;$?#T.;.7(\F,X9Q%PJ5ESRXCXR[Y,<VZ+PM\.DW5>BNFV+[J6GTNI
M,WO]B3+81V5N^_F<P5/O<@1OFJS>,'B@P#MU]U6BQ;.$K:O>@39/>"B"HZ+(
M.VWE"-@X]S@P/$P#T@I] H-F[*52EUXB%3!V**E#WC4*R02S]%E#IT2K09#%
MGC0R&$"S@R[-HR]'3+RI]:9JW5(95S3?"3IK1NDM9\2-#TRFE=JO455H9?:F
MN22:*U66+3H#,99><=6_7UI8Y-R[EV\R24H"-X\:.KM<ZXT'PJZBU6]-92WT
MO;2>%]/.G1Q:\EN*;5+ KM7KLDMO3K.@O+$5"QA$*1Q"0J;7[!_NMT9_*F7_
M ,R>XN=]I_WOJO\ Q"/_ #IIN?.]G^>H?\;?_J-W)3Y@9EY'=U_NEU#_ "B$
M_P#--M#F96_F=1_XFG^<*.1&I?WYT_\ \KS?YAUO)$YAY+Y%^G_[CI7\H&WO
M\[5VYG:C_?"_\3T[_-]7,6G_ #)_XQ<_ZW/DH<P<RLCK4O[W57_Y$_\ Y=+Y
MF:A_?D_]H?\ L+D3H7^U-+_S;?\ O7S G[55X&ZJ&'G60#"+OT38<=D5+,#X
MQ%Z01L>ITCV&H+TA$EQZ>IMQ,-I#65RE-KPPE>4J\/6*"=],M2+#*T8MTV,B
MQN4 2#4.9+@%0$W'([[+N-]M\Q+=ZE%U'I=>6Y5BG;3-6189+$23,\UO0Q"J
MQLX<M*581J%W<@\0=CDQ\CLV'.;QW3M!V'\0YNP2XA7W>OM75?8)!^*22U"F
M[#$'X ^N1YD=;#KV8XZMO!R;T>')B)=DLCLR<+8?DM3.&S^'N@]2^,>H]42^
MU";I'3^D;<\<4P6"UU!<;6)-/:8,C/Y='3='I3-%#)$)))*YDW3S$F^@:_BC
MU'TEX(Z3T5#[&T'7-_KJM7EF@+6*736FCIR+4T@*NB&34M4ZBO0I//',88H+
M"P[2>4]?I#SN6?/V:;KK][ZB?^QM8_\ DD'D7H?^TNC_ /)>G_\ 5(<EM?\
M]O=:_P"5M1_ZY-FSSH$$G%=@DH40C"?\GK0YT9F7%>]-Q#K?JQY"'&G/3=;0
MZCSHSY7$(6GP4G&<9\\$%F)H+,,5B%^/.&>-)8GXL'7E'(&1N+*K+N#LP!'<
M Y'U[%BK*EBK/-6GCY>7-7E>&5.2E&X21LKKR1F1MF&ZL5/8D9XQHH8&B-P
MXZ *@M9SEJ$-AQX,1O*O#S9;C16VF49SX8\?*C'CX8\>6UJM:G$L%2O!5@7<
MK#6AC@B7?UXQQ*J#?X[#OEUJW;O3-8NVK%RP^P>>U-)8F;;TY2RL[MM\-V.V
M4)[2]Q]AZ)+UP77-$60K%)V2:(58K-[9 .QMP\P\,Q*<JKE3)#,\IB2XJ*NP
MPADA"64YCA2GFDX@\*\3O%[J#H>WIU73^A]1LQVM1FJ?*&I>6M+45A,(2'1S
MIEJY/[1:$C&(WX:TBA!Y=*UO+Y'T3X1^"'37B%2U2YJ?B%I=.:IID%P:9I7F
MMJ&F-,)S)-K8U:I1K>SU#$HF&F3VXF+GS;]3:+S[H4*V$KF!P9*T:V:^E>Z<
MC?(+FD$@NI#;$=W$Y&*^;/0_9O*?6RSZTMB;ZD9_#\)C&&\N=CT+5;.L4?;+
M6B:KH$OFM'[#K HBV55(W$ZBA=O1>2Y<HGF2QS<HWYPQCB6X7U%H]70]1-&G
MU!HW4D/DK+\HZ&=0-(,TDJ&NQU*AIT_GH(UD?RX9(.,L?ESR'EQIA:^DE8S'
MV60(;2R#%6C84*TUYTF"@I'Z]J3I78MMFT5B0^>A,STE=M[IV3:&3BE"LL B
ME-H*!#\6E#2LV9R#W[;?CX?N&8H#U[UKUQBWZ4+[.LT62JDZ^B8)[-N<@]BM
M6FBU=VCCYEV)7K8V3]CTP^1O5*.C-&DK$%K=;MMF/2:[8(3FU\LQ&-]_TGM]
M_P"#]&WT9CJ=I E7P^K-F6_M3HV[:9J)F1L:\'9NNR0VN;AV*6L*/9[<M.Q7
M^R)8(_9!$A:1]''$6+!K*GG'!\RK4(>]4M:P*,QZ]@/V]ON_'?Z<\UJZEZ_K
M]DH-V+[NIU3!ZHO5OV\\T?$Q!30.OW;M=)[&M,5XDWL( !JPDB3?@:OL!RU@
M+P,, Q0Z54Q]&L.'WWV-_J^'[-O]>6,%ZKD/]CG]RD]H C7N=4VNF4NE#0'R
MXPS3+4?UP?DDS)E-R(CK7  'JJZFMDP](J\B/#N<D=83%D>CBI2&4^&WX^/[
M\YVV/H'J32=)$?8NZ:87;H!?6=,B +16J)4P^RIU3$]01Y+7]CB3K<,9MB3D
MKK@4V0_K>>:&)L=FV7-CRCH.5A^YD&7;[_#Z?I^._?M\._Z,DFC_  W2\>EZ
M*F6K9[0+9&K*NRW*&4H*^Q1&S,VO]< LNOPHLDMY)]7J[&BRLNBK)BI.:KL&
MV!=NUP<'M^O*ZAYE-_7ZSOWV^O\ ?DV=)]0'^L.M]@PMMM:GU\]>]K CH432
MX@JFUV-'$Z(TMJ5#4J(DP2&/66P&]5GK$]*A%'GCL4G$+RAH$G+(5L,P3O\
MCZR?VY?7C*9RRT_^]+J[^3JD_P VAG)9/F+_ &5_4,P#ZG[3^O)%Y=E,<8QQ
MC/TA:VUI<;6IM:,X4A:%92M*L?AE*DYQE.<?HSC.,XXQF[#-CW,5A*&3<B0T
MGPQZ1!+<].<8_!/J24./I3C\,8;>1X8^GX<\FAC;U4 _2O;]7;]&7B1QZ,?L
M/?\ 7FYQ-X'V\8Q,%"I7A^*F?=1%J_CSE3TE'C_Z+:<?Q8YY&JGP9A]NQ_8,
MO$[?$ _>/VYFFM[)\,>M6,XS^G+1?&<9_O)4-QG'_P";/]_EIJ?0_P!Z_P"O
M+O/_ ,7]/^K-0I?:B%<F[0XS2Y4'-9NECIJTNG6G\3':]);CKGIRD4WZ+<K+
MF%ICYPXIKPSC+KGX\M6L3O[_ *$CYOQ!V^G!GV_H_1_2^D;_ $9LDC>LQ6,^
MUKL5G/Z,R"#LC'\7BEN+%\?[V%8_O\O%0?%R?L7;]IRAG/P4#[23^[-9G[BN
M4O"DQW1XW&?IC,.%A:\8_P#2G+F8\?XTI3G^#PY>*T8]=V^T_NVRTS.?H'V#
M]^^: 3.&#*_.5)S9^<9\4IDR''&T9_\ -M95Z36/KGZ-H3C'\'/945?FJ!]@
M_6?4YYDD^I)^TYBN793'&,<8S'&/[4E/\'3?\F=XQES],?O/:H_DUHO\UQ?(
M@^I^T_KS/'H/L'ZLDKE,KCC&.,8XQCC&4][+BP]TG#*>;F;)?AA4 KPD%4*=
MV.8AS"#;EM$CLP-M];GA%FJ9*2WDE'-#RLRU0FHJ !1NH+SES)1C\?3^C_5D
MP:#@5X9J>L0JLB6T'9?LOECD;Q>]C$X9%VUG'CL M;=GQX>PII> =<)0BP^X
MPX9ZN$6)5;GPXCHC,=ME3Z_@?J[9,7&4QQC'&,A.L.$5]@-NIG1(4:.UK/2#
M8EV(0?FO31WV@W@XJ418>&0$"YN"2R$1,"-(+L*A189#))+\]\8.97X#[3^S
M)LXRF.,8XQCC&.,8XQCC&.,8XQFM6*OR#^!^&CI(,D?-CD,)'QQ#WN),5U#T
M?+V2@V?G"&U(SCR,^EYTK5Y\JSA&4QNHT'OBN%O6*8KSI8'D1U7\R2)E>/G[
M37GV"$'LG'D&/+?8;2FF:E'IQLE]/JWC9KR5B;,EU/+BF1DE">R6JP+.&!W?
MGQ*CCL"P.QIQE*$X4O*LI3C"EJPE.59QCZK5A.$IQG/XYPG&$X_1C&/IR1'8
M#<[[#N3L-_K.VP[^O;89&'N3L-MSV4;G;<]@-]R=O0;DG-0IK[#S![#+S3N4
MVNQY5AMQ"_+A1)[RYSY<Y\,*\,^&<_CX?3D3I$B.E[@Z/MJFH;\6#;;V&VWV
M)VR:UN.1)-/YHZ;Z/I@')2NY%5-P-P/3X_1FX\E\A,J+6/\ 6WV5A2,_F8FU
M-?[0%*RGPPB2>U3N4N3AX<QC./,_D'L0OE"\XRK+,'*4_DHSY>3:7_<[Q'BD
M/N0]4:#U/5)'I)?Z6ZQMV8@P].9H]0VB&/<I!Q'93MV?5O[J>%D\8]^;I'J3
MI*X ?6+3NL.AZ=2<K_\ RQJ'3-(,!V#V 3L6&\M;$T=1=H'JU9+4@XLI4G<O
M@EC#DX6Q%DYCDX:I"X\5:6I#RH9DE$4I["\98DJ3Y?,AM:>U4]4M48IH8/*X
M6!M+SB5RPY1ML&;N!RB1NVW=?K._ [^D5]0GKSS37(WK'E$*]J2!.7&1>3HG
M:0E9779^2^A Y*K"8.1V2N1W=?[I=0_RB$_\TVT.9E;^9U'_ (FG^<*.1&I?
MWYT__P KS?YAUO)$YAY+Y%^G_P"XZ5_*!M[_ #M7;F=J/]\+_P 3T[_-]7,6
MG_,G_C%S_K<^2AS!S*R.M2_O=5?_ )$__ETOF9J']^3_ -H?^PN1.A?[4TO_
M #;?^]?)!4RRI>'%--J<QX9PM3:<KQE/U3G"LX\V/#/UQX9^GZ.8>Y^G)0JI
M.Y521Z$@$C;T[^O;/)QEV45T@:9+;BNFQ'!MHE-7BZ[D"1#L6F6^:!P*KIO4
M^NJ:PJQ0PCX%F)*9UK8R7N'"*(T+"Y&2#T5Q:,+TOPZB-_3^M^I"\!/4/7-U
MZC-9KK++I73,4_2U9DA:42F,OIDDT8"<G]I+*&!)S<?%2PNFZ_X<=*B&Z%Z8
M\-J\%[R]/ORU8-;ZQM:;UC866W'6>JLICU-()F,P2$4N,K(5 -X)LAV+&=?8
M@RB3K>$Y1"A+A-R7_,M*<X:61F0(>,H2K+BO7ELXRA"L(RIS*$*V^:1XHGD2
M"6RR[;0PF%97W(&R&Q-!"-@2QYRH-@=B6V4ZI!&DTJ1R6(:J-ORGG6=HH]E)
M!<5H;$YY$!1Y<+GDPW 7=AHVI2"R>LJ#,5 FCDNTZL*99G*@*>=84"'K:DI^
M7SI[26GTJPIM#KK<A/AG#S#6?#&<32H+533ZE*[6DJ6J%>&C/%))7D_*U(D@
MD9'JSV(VC9T;@>8<@;LB[@9DZG;I:A>LZGIUN.[1U2:74ZL\<5J'>O>D>S"L
MD=RO6F2412)YB^645CLKML<D/DAF!CC&/#Q_'^_QC'&,K*&ZS"V@'8ZIW/85
M^V-5^QQ JHP)LY"%C-1!F]?B:"2#5B7 AQG8[CT8>[.01\K2HZ\C&V(J)0Y\
MB38_9E4S/1;:ES:UT?NFU 2]GH.3K5N2^59@@!F6*QK[&=-=D!9M/9>&D(PO
M[/:AZH#==P<S8J4.DVP4YZ/Z+Y20PRX'X?=]S?M.2=6^KFS:/J2508-P";!7
M'L&PIR EM)/UB);9M]VK:[Y+W)-V4$I)[8FNNP#@^V2/?&::DAKJ+8HTZ93:
M%38)87'J+*>I^[\?C[\BK7_1K<.M"<FR/[#UIM\I(T-J?4;@RTU@OK9V-,UH
M2JV!;U0N5259'M=#JB.%GSVM)-=IS\BK7XV[:OECAJ86,SF-^_T>OU^H^O\
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M$+_%6/\ L^7;GZ3]YRG!/ZJ_Y(_=CY:._P!P0O\ %6/^SXW/TG[SC@G]5?\
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MI !ZDNH'_L8&IV3V"Q$GL $;O_\ [YXOW:.V_P!6TC_W.6_^O\K\F5OZTO\
ME+_H8^4[']6+_);_ $\_N.Z.VLYQCY;2/Q_4Y;_Z_P ?)E?^M+_E+_H8^4['
M]6+_ "6_T\ZFX^N,9_BY 9/#N ?JS&''$,A3#KBL);:%D'%JS],)0B(\I2LY
M_1C"<9SGC*Y=73K;C.H]6,NH4VZUKBD-N-JQX*0XW61B5H5C]"DJQG&<?HSC
MD0?4_:?UYGCT'V#]62/RF5QQC'&,<8QQC*Y;=ZHZ3WK9(EKV6'N1,O!#APD7
M[/[;VYKX>B& -$[")=>%:[O%4&SB,(P5D38Q0A%ED(SC<7VTAG$9K&&5!(_
M/Z\E/6NN*KJ6F"J!2F"T>M!7S,@>R<LEBMY5*SQTE8B&9=CMI0U8BBEDRTU;
M;Q4K-D-,*:C)>]%EI*64]<J+;RW9>N;B[<YUN5*;(),Z)ZO6K1&O;,'!P-<!
M+J8V'V3 VRML3T$:>]F&='5>HS]BVDE:C-E #)$0L&#DF1E;I9!E>W;[3O\
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M0Q[\?H\UL0"82&/BCKY<D8] L@;SRA(/Q8F,=B!LNXVWRJTYN(U-F-#Y#LN
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M%*%_G&DB9"1N $696)[[;_E!L""#WW'IOL[.QM$JD$F"% BOC6ZO1X@M<(!
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M%YVZ_#L,AD*Q&RY(QG,%J$E"(F<>*<M8QG"L_CROMTWQL/ZG^D?I.#2K_P"
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MH]FKT4]/M-= A7++2X7VCUW8Y[&O8I/8),E%8B9AT>GQ[3[ZF HQ^5(=.S)
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M6S<JK)(%2Q&SU[<:%V2*W >%B-&DCC9T60'@_ !T*L/7-^L!T75P)NS');<
M+71!(Z8G.Y\&H8L1#>($);F?T-QXD=YY>?\ :HSS8:]>6U8@JP(9)[,T5>&,
M>KRS.L<:#ZV=@!]9S)FFCKPRV)F"101232N?18XD+NQ^I54G\V<Q-%_%_P"J
M&X*;JJTV%5ZT]+W-LVPZAUX!NU9D&)%INU:8HRR#0B50EVM& KLS8E:#PS9M
M@''>,N3H3C;'LENKZCKW@YU;HUW5JE?V#64T32Z^L:E8HVA"E2C::^(VF74!
M4WG":;:F>"!IV6$(X+<P!H>D>)73NIU=/L3&WIC:I?FTRE#;@,K6+< J%Q$:
M9L_DBUV")991"IE+(=N.YZI<Y1G0<<8QQC'&,<8QQC'&,<8R,A6YM5'+Y?M9
M"+[6B%ZU9$H,O8M>C$6G)--^]*6?@Z_@GI'T@0C-ID5DM\N .2_GGH_+)4@>
MQ%/ 7B3'UY^#.Z]2U^Z4C71?8-7BWG8RK5BEU?!1F27.-4<:7*V^:U%B9?5$
M&5R*"*MEBQ',09#(Q?D[LO!=^-!>8S4]?=G=*;2<!,T>U$BSUE-M 0C,NCWZ
MOO3I$NB3]F"2B6;)5Q#K=4L5'&3CU3NSR&Z=;F(ZHU9.EIV4Q<L$;9G0?[_6
MS/Y)M)?SNWYQE?@/M/ZADO\ &4QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,
M<8QQC'&,<8QQC/@[[5[H[O[!I/=/7.U]V[!.[5Z/=S*7?ZJ=7-BU,>3U1/-W
M#44R>FMU&'7P.10VUN:7L%>SD(N.RU=S:F6V5%I7K?6G3?2>D&WTC<T[1:<&
MG=7]/VZJ^</,VU&&M%J0"6++33B5J:ZK%*5?DWLJC=N VX'K?4=M(.H*]S4[
M$USIW5()W6+W6-.6=Z.[11"*+@MAJ#H&!5?/;<+SW/VT:;V4SN_1NL]LUR1#
M@XVCK&JW<8[AI9"(*EVNMPBR67HN7XCLK F;,5&E0UR8CZEQ78SKL=WS*1\N
MZ[I5G1=6U?1I2$M:9>NZ>SLO)?,JS20K+QW3G&W 2+L5#H000"#G;-.O)JNE
MTM1K,%34*,%J%BO,)[1"LBAT##<QLW%TY@[J5+ ]\X5=AJE=ZY;B?SE2$606
MK;<NP7!G7\2F!Y.QK 4'_9O<4G74"S75_%=*+&63$&W2<2&YC,B65("AHV>0
M1'^/>J8)M-ZLNMJ;*D]B&0UKK:>M.&:SYKK);2LMBV(XYY@\@D9QY_,2F) ^
MPYCJ]:W$YYG\O VJM8L+36M'[=8DC]FU5J"3VF,#B.<+:8,I!9Y(TC:3; :,
M W2W'1.5QQ!HR3#4:&/LP"C+LX:P70(>B/C[]]W)BW5I-VS2YJX5B.7$4^*$
MIK46',@B'A]3D!$8VAQ3:EU1I"TO+L6JJLUJQ7I"Y&C+LL$\M5K-9;0K66CG
MD*2J(D3SQ"5KM'GEI<-NP066.626*DD<\-4S16+D,ZLMT4IK,'M?LAXS36X_
M+B\@(R1M'7,0^CL%'+Q @>)8"<4T>BBQ\<V8A#<AH98LS$9;)$X@?,TED5&G
MS$O2F!N2,_,%IU$7,V5Z7KK^M(5E2&)9Y%FG6-%FE2/R4EE"@22+%SD\I7;=
MA'YC\ >/-MMSU^(2+%&LSK+*L:"614\M9) H#NL?)_+5VW8)S?@#QY-MN<KS
MUSTQQC(IW7?2NMM=&;0"&LDC*) <.*S.BD90(81L1>$"A';4D3_7%BI!))!H
MG99D3RNPP\:7(RZPAM3[4%U)JTFB:19U&*.&22)ZT2FS(T56'VFU#6-FW(BL
MZ5JPE,TQ4<BB%0R;\UP=1M24ZDDT2<Y=XXX^2.\223.L22V!'[XK1,X>=U[I
M$&8D $BGZ,Q=EF\O0??]M+FVJ1[<C,RW7^K.N(UJK,8G PAMG#%?V0"Q."P?
M;S8,?95OCI+9<S+&KRO"-!7CJUE63S.O=5@<$3/M1Z)TB='(WB $U>Q8B5P=
MT^4K<JQ@^9 P[0'N79-TYZ]8][B[;1:'32W666/TXPWZ_."/BZ"]93SB>2'M
MF^;%U[L>N5<GMNQ7NSF]DAX>!PN1K:H(+QM2T^RKJC-_CZRH#0HJ]=R6< %/
MPB=K&F3Z8,AYMC(]F/\ D2FJZ5KU*J-;DOS:AK,305!\G44]ET32K=NN-5ET
M;3&$TEFXE5-O.M26)9(XP1$O )F3<J6X:\M^>W8>Y%&5C:C7\WV""85A;2E3
M6.3VMBT!9'L123A'8*T:CML02M7?<&F[>$MA6TCK+ V!;)NI;D; !J9<&8-:
M.9D4.RMQ&VS341"TY<#)./AX!0Q67USI8:'))KP[D4Z6I=1=,6H+LUI;45^6
M?I[5+U7V*_M2D2;2-2MU5AKF&;SE9)%$$+3U069!YS;^Z0V;]"S%/).DZV[#
M4;#PQ5;"I#,36E0#SPH*_DA.T:220L7:)"_?7-,7J38]TK(0 IP46N=!E-;Z
MK#@VX2J_0-L:Y?KPB'''6,ND=66DE(ATM#9:"ADR;E%'Q+$J5AL5)0K%Z=U)
M[74C2059Z\NH:5SZJH25IH$TS6M.>*M7G$LD?ES-?B::!5BE<R5ZM>PWQSQT
MZRTVHEUCD22Q59=4AXVI(:M^D8(PD=B3RZZAA/( (H0UH*)^0$3 P1\:;?V>
MO/PY=_GX;Z&K#L$4,TS6V5N9:S,D[,(- [$RVXA27$.L4+-O(MY;\5^:#C'T
MQG*T_1/A=1]LZYT*0Q"6/3;/RM*K;\?[GCSX.6WP-L5E_P#2^/H<7KF?RNE]
M5B$AC>] =/5EVY;7/R4VV_Q]G,Q_-\/7. _0[7J-@_$(Z!=;9 EW$#J#UH ]
MA]F0T>20T,V3L:"YOUQZ<XKR924"6G;6FZ;._-K]LNJMPO-AV-C*>\]7=8)'
MT/U_JW!X[O6.MMH]&0,#'\F45AT0PJ?=?RY*NG:O:0A=F:X6.RMG)>G^EF/5
M'1]'S$DI]-Z:-1M(0PE-ZRTVJ>:5V9.26+FG5W]_W5K*H[C;/M*Y\C9]#XXQ
MCC&.,8XQCC&.,8XQE6-B=7*[M2S;[>MI>0U2-]Z4T[INR  42#",(':WO&]+
M78I*34Z*398S<Q^XFP/OQP^%9:[@9+-5X\+L+@8N%97?;;;X$G[]OW9AWNH-
M2A4_KUK>N&IT&C:'D6P;&:(1Q[]C*4D_I;;FH!-:;-"X0AM,BMQ-GMR8APE!
M)%230=R2>E%K$6)'Y3&_K]?[P?V9^NNO6P]K&6]9-H6.K7BYPJQJ2B5J?5JX
M1K0@77M,4BVTH$=R/)FSCZ+79F]AWZ<;]"7\M%C3H^LPL$/DCA\NP3O^/]6>
MG-K77F'9]_;@*;K/Q0VNA0JN;F>8[$[6#!-3$:&,L6TCF+<0&[.BP:TVQ4-H
M!CSE<E1AL&LA%1)T2.S&,J0VQ\ /M_/OL/V9,4335#GQ8TZ'8=MR8DR.S+BR
M&NPV_%M/QI#:7F'FE8V7X*;=:6E:%8^F4JQG]/&4SV/N/IGZZV_^T)OS^DOC
M&/N/IGZZV_\ M";\_I+XQC[CZ9^NMO\ [0F_/Z2^,8^X^F?KK;_[0F_/Z2^,
M8^X^F?KK;_[0F_/Z2^,9#VM:YHZ\VC:0:I;OV!?R=;M$?YM71/8W>#TC7\=J
M W3'0J_;[0<7/@O76B7S*RV$^W;M$>UU7U/F-4),1V/Q^/QZ;?#;)A^X^F?K
MK;_[0F_/Z2^,8^X^F?KK;_[0F_/Z2^,8^X^F?KK;_P"T)OS^DOC&/N/IGZZV
M_P#M";\_I+XQC[CZ9^NMO_M";\_I+XQFM7*A:?UW4[%>[Y?MB4ZEU$//L-HM
M5D[+;R#@:^#%QURR)4L4G;/9B08,.,TMY^0^ZAM"$YSG/CX8RQFNBM=:IKIP
M!KVP;=V05O=Y^\6ZTX+-[%[O@6 U3A=FCDIOR<.C:3DF>&U\-NE/K$TNVC*/
M*^'D3?;R2K;'&/K_ !^.V2/]Q],_76W_ -H3?G])?&,?<?3/UUM_]H3?G])?
M&,?<?3/UUM_]H3?G])?&,?<?3/UUM_\ :$WY_27QC'W'TS]=;?\ VA-^?TE\
M8R.ME"] :>$0CVS]H; I DE/<&#YA[LCOJ*F=.CC"!R8S$:QLI;\C T$(+GR
MKK32V1( 05-DG(HH;-EL,>N:QK@7H X:=U2*WU=]A[(K0=TH;C#^RF[%E98]
MK(.3*(HBP=I2(LAL5&M]0P8P.DR\AV[/5W"V(?VC#^]8[^N39]Q],_76W_VA
M-^?TE\8Q]Q],_76W_P!H3?G])?&,?<?3/UUM_P#:$WY_27QC'W'TS]=;?_:$
MWY_27QC'W'TS]=;?_:$WY_27QC-4N%&TY0QH\G=-A;%J8\U9JI2!$XYV4WF.
M8(W"^6(;4*97("Y.SF\2S5ELYD6$##F?/(G$9K$=E"E+^C&9_4&T-;VF,YKJ
MK[8![.N6LA L#=9D0DW),RYXAZ;4R1^<UF3+5(Q,M%;L(LE-BS"42+9Q1T#*
M(*+B2$=ECZ]O7[OS9-?&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,X,]C?A<
M;5V_WIWUMFID:."T9V6ZR&]9[,FERDU)Z)?9=22)K$\+58 N4V5Q7KSK[4E[
M(N3R(6-,;:*^UFNEFO2<[[TWXJ:5HW0>@:1;CO3Z]TQU1!JFEI#$AKOIZVS-
M:CGMR2H8?::.HZO0C$<<S(3#R00G<<AUSH#4-3ZMUC4:[U8M)UW09:%]Y9'$
MRW&K".N\5=(V$HAMTM-MOS>)6 D*N9!L>GW2GKJ<ZG]9]9]?K!L).T)FNX9F
M"Q;DUY=82_ *V(M8(@M MPT>7B."06R&A25S\+D0(45:HL57BRGEO6_4<'5O
M4^J=0U]..EIJ3PR-3-@6N,D5:&N\IE$%<<IS#YTBB/99'<!W^=F^]*Z)-T[H
M-#1IKOR@U)94%D0FONDD\DR1B,RS'C")/*1B_O(BGBOIFS;9TOJ:U..GCRQ-
M*M9XJ,CM6^/*B!)EDLS%<L53I,"R(4_#:O;01-DFRJ[5C+DR.HDS&7%CX6UG
M&>::OTOI&N+(+=*%YG(E:;RE8R20UK%>L]E=@+*55L.\4<I*HX4CCWWS;FET
M[+--L*]EV4FS$?+>61()X*XL %?:HX!.SQPRED#JI &V8+3.B=44O(57S8/L
MG9-1&55\G9ITB%/EB;0*J4O5Q>X5VNXF$6=>2;NNO65FQ-!UL),&HQMHA)GS
MQ\I;7CH?2&DZ##7\BG"UB-:S&R:ZQ@VX:*4I;=:+WEJR6XB7L>2V\IE+2,Y(
M.>5#2*E7R7D;VVY"D!-F;WBMB.H*<MBO$6=:;6E5S.L) D<L7+L-\LF/(CRT
M&*3%3H9,;.91)A$!\IB;!F1W<>9M^++C+<8D,N)^J'6G%H7CZI5G'-G(()!!
M!'8@]B/M&3(((W!W!]".XSW.4QCC&:S)M%.=&1I<RQ5EP,:<?&Q),DN+6,+/
M84]&E0(SSLC,6>YA;,B._%:4ZK"FGFG&_%"TX-$7#1M'R!4AT9.0*L-B&4@@
MJ0=B"-B#W[9:2A7WBI5MU[D%6]01W['X@C[=\Q42XZR!@H#L&U40/64-OQQ;
MD0Y7QX)#4 G'"26("V93(]+<(S,BB'VH^<)C$Y4> XE$I]MI2.OY2K%%#Y:(
M %CCCX*@V+ *BJ HVW(  [;G+4,,:*J&-(U&RJG%44 [;*!LH /;8=@>V;C"
MG0B<.*1&S(I ?.CLRX4Z%(:EPYD60A+K$F+*86XQ(COM*2XR\TM;;B%)6A2D
MYQGE2""0001V(/8C[1GH""-P=P?0CN,^:CXY.UM6IV_H^@[,(=I]7MT"J$[A
M4MVZ1&!"=5&6B_E/E<X43!')E#F6 R$&4H611*KNU!4@?!/28GRIZ2\MSGTY
MX$Z3JWR-KNH:7'TIJK:A;BI6]#UV6:*W+5T^+S4FBL0+?2O#/+>EC*6=)E61
MZZOYRJNV<(\6=1T_Y3TFG??J#3Q3KR6:VJZ5'%)7CL7'\MXWAE:FTTL258WY
MP:A&T:3,OE,QRA/7KM]WW3LZET#J=\3;1G9."</5VL1]1=G_ )M2MF3)9.>P
MRAK*=U5V+/-2D1)B?2$:MWE;2L[+*H4 80)(BQ7,OK;0.DP]V?6/#Z]TS)4K
M/)+9Z?>"UIWF+&TI?S-)=HXD<E%,MS2*ZQ#WI/+',Y7I+5->,-9*'5T&NQV)
MPL4>KK+!<\LNL00IJ"B1V4JQ"5]1G9R>*%O=SM9W6[[:U+Z7W_K8)01.R=_]
M;)^N-E;=Z\GWH%@ ,U2D;/I9NP%Y!F-#F@[K4!T7 V39(8Q+5@!""J9%K @7
MH10;'Y3T;X<ZSJEWIN[J,]GIO0^H+LE+3=<50TD]I87EAKP(D\<L#W_+E@I6
M)^$,LR%8O./%'WCJ7K73=/K:W6HQ0ZUJNCU5M7=*W(2*NTBQ2S3.T4B2I4,D
M<MJ&+>6.)@7,0)9;1]&!/4G=0 ?WUT7JNI4W9^_*5%!;/.!/<,F&"@J9!Q9J
M6=AM2D"L2PEC"1V/F+8J',+CQX<CAQP=(A8S#=;UNH^G=1L]%ZQ>L6:>BW&D
MH)(!Y4L$JNU6["2I?C/7E+<#(ZQ2/+$=I%?)7I>UH^MT:_4NG5HH;&I5PELH
M3YD<R,!8K2@$+RBF3;GP4R(L<@]QESH1S1LVG'&,<8QQC'&,<8QQC'&,<8QQ
MC-.N]9-6L1'&@=B7'6<QDI!(.'Z1"U_/+RXD12U2 <AG9%&V"!2+*86E$YZ*
M$C&FTM(R,,#EY<4XQE"-U=#S6SJ-V=H]2O #6(?=.WW-N! (.L"Y57-$$==:
M/K.*,V2'D"$M>DG;58=VTY. IES5GQU;/R79I)J>/6RN_IN-]AM^G\#+^4,$
M4J]'IM:-E4'3->JM?!EC;45J"T7)"A,2!.)MPF4H9B-SI+#LI$9I"6V$NX;0
ME*4XQAE,VSC&.,8XQCC&.,92/K3UQV!J2X))7,A3G@-%U@YIO73U6*G")JW5
MMW9-DNV;?L*&5K8*'7K)@=(K8[ 0.2N$3YJJV%\V+TBT4?%94D;;#[?U=OL[
M?;^V[G&4QQC'&,<8QQC(4['ZEC[UT+M_43D.NRIM_P!=7"L@';7!00"";25
M$(=7L$II4,@ZPNO'GAYF-/A1'B(Z1";FCD^]88SQ@=B#]&0"QU,NL/N#3^SB
M-L_,PPVJ6.I':47K@E<P: DTZJ@JW4:=8(\%$]FJ0[2,LM^G,D'VYN+%9RRF
MW940C[8>RO;;;;O]/W_CMMEZ>,ICC&.,8XQCC&57[7T+=^R:<!JFF&-?^B5-
M3(&SI=LOEBUG:G-;$ 9&$:KNM;Y7-6;:F4T_:Y+T(.;M#%=;,BZ@X=:J1$#;
MYP*W5AE1M\?S=M_VC(,Z_P#3^[ZG[%3-L3$T@)6?E.VH$<?5KW>#\5T7LN?J
M.57J0 U69J5?USJ@=K@7JX17"MYH$A%BW>H #MVP@T([-EQQK&_;[OT;_'?Z
M_HSHWQE,<8QQC'&,<8RD?;OJK<^QA34AZJ[852Y6IMB:QO NN%JX(/U=9*I;
MHUG?S%Q83*A29L:^0:A2SE6J<U/C&;B6<^ ?>&AK;8Y+K*@[;_6"/T9E^O>K
M-TUW9VT-B[P :J06L#;E;H!76NQ+,;&576 VSF2M9H G79?3E 'U)2F"*+#?
M;7BY7<]?+R\^Z^Z)IX2C5:I,'X;?@_C[,N+QE,<8QQC'&,<8QQC'&,<8QQC'
M&,<8QQC'&,<8QQC(CWKJF/NK5=JUZHL[6RI-D>5J-LC1DRYE+OM6*P;10KI"
MC*<9Q(E52X!PIUN+Z\?$S$%4-;[3<A:\>L,ODRJ^W(#<.F^W-&!5T)[[<E)7
M?8[;[_#/*:,2QLF_$G8JVV_!U(9'']E@#MN-]MOCD,V/K9;C&X*Y=(6TK&*H
M0]O6+5DI@FS7*M2[9BCUOLW!L#A&?5S0EK+ETM.\:/;S2<MY:G$=4P<DD37I
M\&0%]5L*(F0Q*7_*<7*(W'FU<KL&!^8L+J#\!(=MMCR\FKL95<2L$'E\D#.O
M/@LX;<J1\]I48^NYC&^^XXQ"!Z=[Z$!PXB1V@MTN*,106GXL8U<Q:)HZKV;K
M44+@DSH)]LE"ADQ.EMI04D67UD92^QERBD?4&AEL6;U-J!B3[.NYY^JHVQ86
M #L5V)!FB/T#V=-N[>[Y"K, ![0QVX=MW&X4UR1ORWV812 GU_+MON 0TEZ_
MZ][PIVO=D5DMOLQ;[+;]0ZOI8*P6 A:I6*[L"E:]53+5?!LJ*7''Q$>\$6!]
MHFCHI>849L:2IIX[+P40+@V23PN\;" (JRR.P4*.2._-4(V*G@-U!V X[#CV
MW-Z5YD213.7+Q1H&);W71.#.#N".?9B =^6YY=^T70^H79&.E2G.U=J>DXH+
ME.RZHW?%1Y<AH>U&9(NP%63,2!+).0H:")D>A%BB-NRI< FJ;A"W/3VJO_N9
M=O,Y^B;CN>V_'<[;G93[IV (VRP59_C88_D^'SI-B=@-R.7;?8 D>\-R0V^V
M;U^Y%L&-8:NID2^J V[6YG9)D9?:Y,/0IL%[8%ZD6EX?*%SI)(1?J=(%2WPM
MQHEZ@SAUO=9&$T% !(7%F8L]J7S9',?)9%C!1MMCY:!=]P 4;<;JZ$%>XV()
M&7>RMY<:"3BT9D(D7EN/,?F1L20Z$'9T?<-L#N" <R%KZ@*(4C<5+KEQS"&;
M'W94]MU4=/B.(@:XBQ-D:]V[L*O G(3GNL_;[8M7M%G?F-^V1 FVB%C$:2V!
M:Q,HEK9XG9-RD+Q-L>\F\<D2,=QM^3C=5V[[A3Z<CM<U7=)45M@\RRJ.^R;2
M)*ZC;^O(K-OVVY#L>/>4-/Z'5IFX6G%5LA%C44NN54/2=7S"A<W"ID\/%]N;
M)"9Q>2],CHL+C;4XK%FRS:YQER8=9DBYY0[@UY2S>:J\E'F\F9Y  "_([@$#
MM[OH" NPV4[@+Q](H?*9N+'RRJA(R2P3B-B02=_>]3N6W.[;@EMY^)BQAJ!*
M%&1T$L+G,JCS1I.)'GP)C"_[-F5#E-NQY#*O]DV\VM"OTISRR*66"1)H9)(9
M8V#1RQ.T<B,/1D="&5A\"I!&>DD<<J-'*B21N-G210Z,/H96!5A]1!&4RC?#
M@Z-C=T4[L)7^M6M:AMVAG';)6[31QDFD,LFWH4R LD2K54F!ZH=F>G.??;D&
MP9!]F?ADBRXW.8:D)V.3K/JF>A:TRSK=ZW2N1B*Q'<E]K=T#*W$6+(EL1C=0
M"(Y5!3=""IVR(CZ<T.&S!;@TRK6GK-SA:LGLZ*Q!7<PPE(6[,3[\;;-[PV8
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M8E7K5>$[&JU4D5DA3H\*J7'Y4^6".":X5("0KL=W.!D*7(BQT)BOOLN,IO\
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M#]92SHBO0DICXL)6,CM!5\+A1I$?#D2GW@BT^N-!%Y+9"TB\?F+(I7@7W*D
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M=W)1UY(X)1VC]U=8EDU>&6XT,4EH"5GKM(ME54;W"D#5TF2.15(@"3P2>7-
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M:H$/;44JDX-+AFR!!N:(GS_">.! OE2&0EGW.XV #$#W>(8'8 \CV<,"H&Q
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2XQCC&.,8XQCC&.,8XQCC&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img61678762_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" (X!9@# 2(  A$! Q$!_\0
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M6-B?E#?* V7X/\.>>.HQ5_5< DGIKY_\$GVV)\_N_P" =[_PT7_U*W_E0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\_>H?]_$_P#B*/\ A4^A_P#/WJ'_ '\3_P"(KN**KZS6_F,_[)P/_/I'#_\
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MO_T,/A__ ,$,_P#\F5TE% '-_8?&_P#T,/A__P $,_\ \F4?8?&__0P^'_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HJ"]O(-.T^XO;Q_+M[:)II7VD[449)P.3P.U<?_PN+P)_T'?_ "3G_P#B
M*TA2J3UA%OT1,IQC\3L=O17$?\+B\"?]!W_R3G_^(H_X7%X$_P"@[_Y)S_\
MQ%7]6K_R/[F3[6G_ #+[SMZ*XC_A<7@3_H._^2<__P 11_PN+P)_T'?_ "3G
M_P#B*/JU?^1_<P]K3_F7WG;T5Q'_  N+P)_T'?\ R3G_ /B*/^%Q>!/^@[_Y
M)S__ !%'U:O_ "/[F'M:?\R^\[>BN(_X7%X$_P"@[_Y)S_\ Q%'_  N+P)_T
M'?\ R3G_ /B*/JU?^1_<P]K3_F7WG;T5Q'_"XO G_0=_\DY__B*/^%Q>!/\
MH._^2<__ ,11]6K_ ,C^YA[6G_,OO.WHKB/^%Q>!/^@[_P"2<_\ \11_PN+P
M)_T'?_).?_XBCZM7_D?W,/:T_P"9?>=O17$?\+B\"?\ 0=_\DY__ (BC_A<7
M@3_H._\ DG/_ /$4?5J_\C^YA[6G_,OO.WHKB/\ A<7@3_H._P#DG/\ _$4?
M\+B\"?\ 0=_\DY__ (BCZM7_ )']S#VM/^9?>=O17$?\+B\"?]!W_P DY_\
MXBC_ (7%X$_Z#O\ Y)S_ /Q%'U:O_(_N8>UI_P R^\[>BN(_X7%X$_Z#O_DG
M/_\ $4?\+B\"?]!W_P DY_\ XBCZM7_D?W,/:T_YE]YV]%<1_P +B\"?]!W_
M ,DY_P#XBC_A<7@3_H._^2<__P 11]6K_P C^YA[6G_,OO.WHKB/^%Q>!/\
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M'U:O_(_N8>UI_P R^\[>BN(_X7%X$_Z#O_DG/_\ $4?\+B\"?]!W_P DY_\
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M6K_R/[F'M:?\R^\[>BN(_P"%Q>!/^@[_ .2<_P#\11_PN+P)_P!!W_R3G_\
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M_A<7@3_H._\ DG/_ /$4?5J_\C^YA[6G_,OO.WHKB/\ A<7@3_H._P#DG/\
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M?_XBCZM7_D?W,/:T_P"9?>=O17$?\+B\"?\ 0=_\DY__ (BC_A<7@3_H._\
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M]HR4+$J&R2".N<#D"DE<;=CUNBO.=&TGQOH'B:T$>IR>(=$GQYTTLRY12>6
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M_P"BFKX_K[ \:_\ (@>(/^P9<_\ HIJ^/Z^ARCX)>IY>.^)!1117M' %%%%
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MNF/=VR3_ &=G21,A\ XVDYZ,#G&!Z\&NC^-M[%=_$RY2$@_9H(H7(_O8W?\
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MSJ-.^U_/:Q$TTN6,;JV__!.2HHHKU#C"BBB@ HHHH **** /4OV?O^1_O?\
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MJI\&+2ZT+XG?9-:M+C3[BYT^00Q7431,_P RG@, 3PC?D:X8U9QPLG?WE?\
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MKC:L7][-J6I7-]=MNGN96ED([LQR?YU7KV:47""BW=G!-J4FT%%%%62%%%%
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MUYUH.I6KZOXD\=:FVVRA/V2U8#),:8!('^T=OXDU??QWJMOIRZM>>$KJ'22
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M\++X<DU%FTI0%%N8TZ!MP&[&[&??VZ5A45I[.%DK+38GFE>]PHHHJR0HHHH
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ME//K&ST"7Q[IL-OKNM:[?6JO,CFXCG@@!&#O8 8SQT]JT/AX!_:OBXXY.M3
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M"V0@P!UP,\* .!@"N6KNPM.5.BHRW.>M)2FV@HHHKH,@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ]2_9^_Y'^]_[!DG_HV*OHFOG;]G[_D?[W_L&2?^
MC8J^B:^7S/\ WA^B/8P?\(****\PZPHHHH ^)*]2_9^_Y'^]_P"P9)_Z-BKR
MVNI^'_C3_A!=?GU/[!]O\VU:W\OSO*QEE;.=I_N8QCO7V>*A*I1E&.[/!HR4
M:B;/5/!6LS>-+'Q?HFM06K:;9ILM;>*!46!?G "X';8"#U![TWX:_P#"?_\
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M O\ R<@_^+H^LT/YU]Z#V53^5_<<117;_P#"G?'?_0"_\G(/_BZ/^%.^._\
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MZ/\ A3OCO_H!?^3D'_Q='UFA_.OO0>RJ?RO[CB**[?\ X4[X[_Z 7_DY!_\
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M'_Q='_"G?'?_ $ O_)R#_P"+H^LT/YU]Z#V53^5_<<117;_\*=\=_P#0"_\
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MV53^5_<?4E%%%?%GOA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<W\./\ DEGA3_L"V?\ Z(2NDKF_AQ_R2SPI_P!@
M6S_]$)0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5S?PX_Y)9X4_[ MG_P"B$KI*YOX<?\DL\*?]@6S_ /1"4 =)1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<W\./^26>%/\
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MP^M5N_Y'MO\ PT7_ -2M_P"5#_[51_PT7_U*W_E0_P#M5>)44?V=A?Y?Q?\
MF'UJMW_(]M_X:+_ZE;_RH?\ VJC_ (:+_P"I6_\ *A_]JKQ*BC^SL+_+^+_S
M#ZU6[_D>V_\ #1?_ %*W_E0_^U4?\-%_]2M_Y4/_ +57B5%']G87^7\7_F'U
MJMW_ "/>]$^/7]L:_I^F?\(WY/VVZCM_,^W;MF]@N<>6,XSG&:]@KX_\%?\
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M_P"PKS2BM/JE#^7\SF_MS,/^?GX1_P CTO\ X6__ -0/_P F_P#["C_A;_\
MU __ ";_ /L*\THH^J4/Y?S#^W,P_P"?GX1_R/2_^%O_ /4#_P#)O_["C_A;
M_P#U _\ R;_^PKS2BCZI0_E_,/[<S#_GY^$?\CTO_A;_ /U _P#R;_\ L*/^
M%O\ _4#_ /)O_P"PKS2BCZI0_E_,/[<S#_GY^$?\CTO_ (6__P!0/_R;_P#L
M*/\ A;__ % __)O_ .PKS2BCZI0_E_,/[<S#_GY^$?\ (]+_ .%O_P#4#_\
M)O\ ^PH_X6__ -0/_P F_P#["O-**/JE#^7\P_MS,/\ GY^$?\CTO_A;_P#U
M _\ R;_^PH_X6_\ ]0/_ ,F__L*\THH^J4/Y?S#^W,P_Y^?A'_(]+_X6_P#]
M0/\ \F__ +"C_A;_ /U _P#R;_\ L*\THH^J4/Y?S#^W,P_Y^?A'_(]+_P"%
MO_\ 4#_\F_\ ["C_ (6__P!0/_R;_P#L*\THH^J4/Y?S#^W,P_Y^?A'_ "/2
M_P#A;_\ U __ ";_ /L*/^%O_P#4#_\ )O\ ^PKS2BCZI0_E_,/[<S#_ )^?
MA'_(]+_X6_\ ]0/_ ,F__L*/^%O_ /4#_P#)O_["O-**/JE#^7\P_MS,/^?G
MX1_R/>O"?B3_ (2C29;W[+]E\N<Q;/,WYPJG.<#^]^E;E</\)_\ D5+G_K]?
M_P! 2NXKQZT5&HXK8^]R^K.MA85*CNV@HHHK$[@HHHH XW1/$?C'7M T_5[/
MPWH:6^H6L=U$LNNS!U5U# ,!:$9P><$U>^W>-_\ H7O#_P#X/I__ )#H^''_
M "2SPI_V!;/_ -$)5SQ%XITOPM:)/JTK+YI(BCC0LTA&,@=N_?%&X%/[=XW_
M .A>\/\ _@^G_P#D.C[=XW_Z%[P__P"#Z?\ ^0ZQ['Q)XO\ $FJ6C:9HG]EZ
M0)D::>\_UDD>?F"@^HST!^HKK=<U,:-H-[J+)YGV6%I G]X@<#\Z=K"N97V[
MQO\ ]"]X?_\ !]/_ /(='V[QO_T+WA__ ,'T_P#\AUQ+>+/%]CX6L_%]SJ-K
M/9W$^UM-%N%"IN(&'ZY^4]^..M;_ (D\6:C=:QH>B>&)4MKC5H1<FYDC#F.(
M@D84\'A6/X4^5BYD:_V[QO\ ]"]X?_\ !]/_ /(='V[QO_T+WA__ ,'T_P#\
MAUD^&_%6I6NO:WH/BB=+J;2X3<BZCC"&2( $Y4<9PRG\36 /%?C"Z\*W7C"W
MO[:*RAN-JZ:;=2&CW!2=_P![.2/UZ=*.5AS([7[=XW_Z%[P__P"#Z?\ ^0Z/
MMWC?_H7O#_\ X/I__D.MC2-1CU?1K34(1M2ZA64*3G;D9Q^'2LJ]\=^&M.O+
MJUOM42&>T($J-&^03V'R_-^&:5F.Z&?;O&__ $+WA_\ \'T__P AT?;O&_\
MT+WA_P#\'T__ ,ATQ_B/X22R2Z;6H?*D8JH".7R/5 NX=>XK9AUK39]&_M:*
M]A-AL+_:-V% '7.>GTHLPNC)^W>-_P#H7O#_ /X/I_\ Y#H^W>-_^A>\/_\
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M114%A1110 4444 %%%% !1110 4444 %%%% !1110!B>-?\ D0/$'_8,N?\
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M "/][_V#)/\ T;%7T37R^9_[P_1'L8/^$%%%%>8=84444 >'_$/_ )'S4?\
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M!YP,\*!T'2N6K2C1FJ'LY.S=]O4BI4BZO,M4?1GA7PAXC\&ZV]]JOC*.3PY
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M]CY_H>C@?M?+]3HJ*YO[=XW_ .A>\/\ _@^G_P#D.C[=XW_Z%[P__P"#Z?\
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MKN*\S^'MQK\/AF4:%IFFWD9O'\QKS49+8J=B< +!)D>^174?;O&__0O>'_\
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M4\[3V^+I(9(2W56W<$?3Z^U=Y11<=CE[&U\7SZ!J,E_?V]KJ=PVZSB2-62U
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MO7MH6NHT,:3F,%U4]5#=0/:IZ* /+?V@?^1 LO\ L)Q_^BI:^=J^B?V@?^1
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MVU[=11_:.*_F_!?Y!]5H]OS/$?\ AG3_ *FG_P I_P#]MH_X9T_ZFG_RG_\
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M3_Y3_P#[;7MU%']HXK^;\%_D'U6CV_,\1_X9T_ZFG_RG_P#VVC_AG3_J:?\
MRG__ &VO;J*/[1Q7\WX+_(/JM'M^9XC_ ,,Z?]33_P"4_P#^VT?\,Z?]33_Y
M3_\ [;7MU%']HXK^;\%_D'U6CV_,\1_X9T_ZFG_RG_\ VVC_ (9T_P"II_\
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M^_QE_F>:?\*@_P"HY_Y*?_9T?\*@_P"HY_Y*?_9UZ711];K_ ,WY!_8>7_\
M/O\ &7^9YI_PJ#_J.?\ DI_]G1_PJ#_J.?\ DI_]G7I=%'UNO_-^0?V'E_\
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MHMH(0"[1H2282?N]Q17044 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S?CS_D7;7_ +#6
ME?\ IPMZZ2N;\>?\B[:_]AK2O_3A;UTE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <WX\_P"1=M?^PUI7_IPMZZ2O#/C?\6-1
M\':Q;Z#/X=2>U>:TU"VO1=E?-$-Q'*R%=AP=T>WJ<!@>^*](^''BV^\<>#(-
M?U#2%TD73M]GA$YE+Q@X#D[5QDAL#T />@#JZ*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P <KYVHKM_LS#]G]YA]<JGT3_PT#X5_Z!^L?]^8O_CE'_#0/A7_ *!^L?\
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M10!SGB'QOIOAK4$L[Z"ZDD>(2@PHI&"2.[#GY365_P +8T/_ )]-0_[]I_\
M%US7Q8_Y&NV_Z\D_]#>N&KUJ.%I3IJ3/A\?G6+H8J=*#5D^QZ]_PMC0_^?34
M/^_:?_%T?\+8T/\ Y]-0_P"_:?\ Q=>0T5M]2HG%_K!CNZ^X]>_X6QH?_/IJ
M'_?M/_BZ/^%L:'_SZ:A_W[3_ .+KR&BCZE1#_6#'=U]QZ]_PMC0_^?34/^_:
M?_%T?\+8T/\ Y]-0_P"_:?\ Q=>0T4?4J(?ZP8[NON/7O^%L:'_SZ:A_W[3_
M .+H_P"%L:'_ ,^FH?\ ?M/_ (NO(:*/J5$/]8,=W7W'KW_"V-#_ .?34/\
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M .?34/\ OVG_ ,77D-%'U*B'^L&.[K[CW/P]XWTWQ+J#V=C!=1R)$929D4#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KS:YTO4&^/=IJ"V-R;)82&N1"WE@^0X^]C'4@5Z3133L)JX5Y
M5XITF^M_BK'K.H:%=:YI+1JJ16\/G;,)C&WIPV3S@<UZK10G8&KGDOA.QU>/
MXM2ZG?:#=:?:WD3^7^Y)2(%1M!8# .%Z<<FK7PVTG4;#QQK\]]I]U;0RE_+D
MFA9%?]YG@D8/%>H453D+E/,?B1INKQ>,]$U_2M,GU&.S"[HX$+'*N6P< D9!
MZXKT#1KRYU#1K:[OK-[*XE3=);OG,9].:O45+=U8=K,\X\;>%]9M?%EMXO\
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MV 7CGDDYKTNBFY HA1114%!1110 4444 %%%% !1110 4444 %%%% !1110
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MC</_ .XKU84445QGOA1110!S?A?_ )&+QG_V&H__ $WV==)7-^%_^1B\9_\
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M?:<Q_P!&B;):/GKSTXZ@<=Z3274:;?0ZZBBBI*"BBB@ HHHH **** .;L?\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >6_M _\
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M6KZXTS1[B\L[)[^:%=RVT;89^1G'![9/3M63X7_Y&+QG_P!AJ/\ ]-]G724
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MB76]*:TM]2N]-EW!UN+20JP(['!&1STJN;4GET/*?B)XNL?%&E:.VEQS,B7
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MC[ZNDKF['_DJ>N_]@73?_1]]724 %%%% !1110 4444 %%%% !1110 4444
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M]>!'.63:K+GUPP(K*HIRBI*S1-.I.E+F@VGY:%W4]7O]9NOM&IW+W$H& 6P
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M;^(-%N-+O'D2"X #M$0&&"#QD$=O2LW6_!ECKMEIMM/=WMM_9I!MY;:14<$
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M)(8[W5(=/D?>^G176+<G.3\N,X_&NOHHNPLAD$$=M;QP6Z+'%$H1$48"J!@
M?A65K_AJS\1_8OMTD\?V*X%Q'Y+ 98=CD'BMBBD,S==\/Z=XCT_['JT'FQ@[
MD8'#(WJI[&L ?#33)#&NH:IK.HVT9!6UN[TO$/;  _G78T4[M"LF9MYH-G>W
MVF7,N]1IC,\$,>!'DKM&1CL.F,4FK:%;:S<Z?/=/,C:?<BYB$9 #,.S9!X^F
M*TZ*+A8RM5\/VNKZGIE]<R3++ILIEA$; *Q./O9!R..V*74O#]KJFLZ7J=Q)
M,LVF,[0JC *Q< '=D$GH.A%:E%%V%CE=1\ VE_X@NM8BU?6+"ZN@JR_8;D1
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M=?1-%']IXCNON#ZG2/G;_AG[Q5_T$-'_ ._TO_QNC_AG[Q5_T$-'_P"_TO\
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MKI** .;_ .$HU?\ Z$3Q!_W_ -/_ /DJC_A*-7_Z$3Q!_P!_]/\ _DJNDHH
MYO\ X2C5_P#H1/$'_?\ T_\ ^2J/^$HU?_H1/$'_ '_T_P#^2JZ2B@#F_P#A
M*-7_ .A$\0?]_P#3_P#Y*H_X2C5_^A$\0?\ ?_3_ /Y*KI** .;_ .$HU?\
MZ$3Q!_W_ -/_ /DJC_A*-7_Z$3Q!_P!_]/\ _DJNDHH Y;P^-2O/&FL:O?Z)
M>:3;S:?96L*WDL#/(T<ERSD"*1P !,G4COZ5U-%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M $%/_)>+_P")KF:*/8TOY5]P?7\9_P _9?\ @3_S.F_X6'XH_P"@I_Y+Q?\
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M31_PL/Q1_P!!3_R7B_\ B:YFBCV-+^5?<'U_&?\ /V7_ ($_\SIO^%A^*/\
MH*?^2\7_ ,31_P +#\4?]!3_ ,EXO_B:YFBCV-+^5?<'U_&?\_9?^!/_ #/4
M/A[XJUG7/$$]MJEYY\*VK2*OE(N&#J,Y4#L37HU>1?"?_D:[G_KR?_T-*]=K
MQ\7%1JVBK'WN1U:E7!J523;N]]0HHHKD/;"BBB@#C;:VUC7O$GB15\5:IIMO
MI^H1VL%O9PVA15-I;RDDR0.Q):5N_I5[_A%]7_Z'OQ!_WXT__P"1:/"__(Q>
M,_\ L-1_^F^SKI* .;_X1?5_^A[\0?\ ?C3_ /Y%H_X1?5_^A[\0?]^-/_\
MD6NDHH YO_A%]7_Z'OQ!_P!^-/\ _D6C_A%]7_Z'OQ!_WXT__P"1:Z2B@#F_
M^$7U?_H>_$'_ 'XT_P#^1:/^$7U?_H>_$'_?C3__ )%KI** .;_X1?5_^A[\
M0?\ ?C3_ /Y%H_X1?5_^A[\0?]^-/_\ D6NDHH YO_A%]7_Z'OQ!_P!^-/\
M_D6C_A%]7_Z'OQ!_WXT__P"1:Z2B@#F_^$7U?_H>_$'_ 'XT_P#^1:/^$7U?
M_H>_$'_?C3__ )%KI** .;_X1?5_^A[\0?\ ?C3_ /Y%H_X1?5_^A[\0?]^-
M/_\ D6NDHH YO_A%]7_Z'OQ!_P!^-/\ _D6C_A%]7_Z'OQ!_WXT__P"1:Z2B
M@#F_^$7U?_H>_$'_ 'XT_P#^1:/^$7U?_H>_$'_?C3__ )%KI** .;_X1?5_
M^A[\0?\ ?C3_ /Y%H_X1?5_^A[\0?]^-/_\ D6NDHH YO_A%]7_Z'OQ!_P!^
M-/\ _D6C_A%]7_Z'OQ!_WXT__P"1:Z2B@#EO#YU*S\::QI%_K=YJUO#I]E=0
MM>10*\;227*N 8HT!!$*=0>_K74US=C_ ,E3UW_L"Z;_ .C[ZNDH **** "B
MBB@#A/">F:]KW@O1-7O/'&N)<:AI\%U*L5O8!%9XU8A0;8G&3QDFM?\ X1?5
M_P#H>_$'_?C3_P#Y%H^''_)+/"G_ &!;/_T0E=)0!S?_  B^K_\ 0]^(/^_&
MG_\ R+1_PB^K_P#0]^(/^_&G_P#R+7244 <W_P (OJ__ $/?B#_OQI__ ,BT
M?\(OJ_\ T/?B#_OQI_\ \BUTE% '-_\ "+ZO_P!#WX@_[\:?_P#(M'_"+ZO_
M -#WX@_[\:?_ /(M=)10!S?_  B^K_\ 0]^(/^_&G_\ R+1_PB^K_P#0]^(/
M^_&G_P#R+7244 <W_P (OJ__ $/?B#_OQI__ ,BT?\(OJ_\ T/?B#_OQI_\
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MA>^-] LM6MM,-\L][<SI L-O\Y5F8*-Q' Y/KGVK=FFCMX))IW"11J7=VZ*
M,DUY;X/U30_#VJ6NDZKX5ET;59G6*.XD0R^8Q. 0YY )(Z9'O7H7B339-8\,
MZCI]NP66XMW1"W3<1QG\:;23$G='/P_%+0);B(-%?PVDTIBCOY;?; [#L&SG
M]..];'B+Q7IWAJ*W-[YTTURVV"WMDWR2GV&1ZC\Z\EURYU*T^%<'A^_T"^M)
M+&XS+=2QXA(+L1M;N26QQ]<UMVSM=?$SP,+GY\Z''*0W]_RI3GZY _*JY43S
M,[_P[XLT[Q,+A;(3P7%LVV>VN8]DL9]QD^AK'E^*6@Q7,BB*_DM(Y?)>_CM\
MVZMZ;LY_2N8N99;;XL^,%MAM5M'=FVC[I\F,[OKG^=5M.C3_ (9WOCM&3(6/
M'?SE&?THY4',SV%'26-9(V5T8!E93D$'N#3JY_P'+)-X"T=IL[OLRKSZ#@?H
M!7&6ZZOK_P 5->T@:]J-E8Q)YA6WG(*XV@!,Y"\MG(':IL5<]3HKQCPP=?\
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M;Z3'9>5-.8S&MU(3Q@=^W_?/TJGU$NA=\$+_ &!XJUWPN_RPK)]NLE[>6_!
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MSXI,$D%G=*EM9>:N&D10-SX/(!(&/_K5U&M_\@#4/^O63_T$U+W&MCSK3_\
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MB@ HHHH **** .;\+_\ (Q>,_P#L-1_^F^SHH\+_ /(Q>,_^PU'_ .F^SHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R+XL?\C7;?\
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M **** "BBB@ HHHH **** "BBB@ HHHH YOPO_R,7C/_ +#4?_IOLZ*/"_\
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M 73_ /P%3_"BBJYI+9F3HTI.[BON#_A&]#_Z NG_ /@*G^%'_"-Z'_T!=/\
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M%(Y57.U%&<?PBH_^$#TC_G\\0?\ A1ZA_P#'Z** #_A ](_Y_/$'_A1ZA_\
M'Z/^$#TC_G\\0?\ A1ZA_P#'Z** #_A ](_Y_/$'_A1ZA_\ 'Z/^$#TC_G\\
M0?\ A1ZA_P#'Z** #_A ](_Y_/$'_A1ZA_\ 'Z/^$#TC_G\\0?\ A1ZA_P#'
MZ** #_A ](_Y_/$'_A1ZA_\ 'Z/^$#TC_G\\0?\ A1ZA_P#'Z** #_A ](_Y
M_/$'_A1ZA_\ 'Z/^$#TC_G\\0?\ A1ZA_P#'Z** #_A ](_Y_/$'_A1ZA_\
M'Z/^$#TC_G\\0?\ A1ZA_P#'Z** #_A ](_Y_/$'_A1ZA_\ 'Z/^$#TC_G\\
M0?\ A1ZA_P#'Z** #_A ](_Y_/$'_A1ZA_\ 'Z/^$#TC_G\\0?\ A1ZA_P#'
MZ** #_A ](_Y_/$'_A1ZA_\ 'Z/^$#TC_G\\0?\ A1ZA_P#'Z** #_A ](_Y
M_/$'_A1ZA_\ 'Z/^$#TC_G\\0?\ A1ZA_P#'Z** #_A ](_Y_/$'_A1ZA_\
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M(/\ PH]0_P#C]'_"!Z1_S^>(/_"CU#_X_110 ?\ "!Z1_P _GB#_ ,*/4/\
MX_1_P@>D?\_GB#_PH]0_^/T44 '_  @>D?\ /YX@_P#"CU#_ ./T?\('I'_/
MYX@_\*/4/_C]%% !_P ('I'_ #^>(/\ PH]0_P#C]'_"!Z1_S^>(/_"CU#_X
M_110 ?\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/T44 '_  @>
MD?\ /YX@_P#"CU#_ ./T?\('I'_/YX@_\*/4/_C]%% &EHN@6'A^&YCTU;C_
= $J;SYY+F[EN9)'V*F2\K,WW448SC HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img61678762_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" )>!7L# 2(  A$! Q$!_\0
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MJP50,GW.,T :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC*S*6 YVYSCM0!UE%%9$WB2S@\8VOAMXYS>75G)>)(%'EA$95()SG.6';\:
M->BBB@ HJ&\N[?3[&>\O9D@MK>-I9I7.%1%&68GT !-%G=P7]C!>6DGF6]Q&
MLL3@$;E89!Y]C0!-17.^)_'>@^$KBPMM6NQ]LU"YCMK:TB(:5V=@N[;D849R
M2?U. 6>*_&UMX4OM*LGTO4M4N]5>5+:#3HXW8F-=[9WNO\//X&@#I:*Y#2_B
M-87VO6^C:II.KZ!?788VD>JVZQK<E1E@CHS*2!V)!KKZ "BBB@ HHHH ****
M "N$U#XNZ#INIW5C/::BTMK,\+E(HRI96(.,OTXKNZ^8?%G_ ".FM_\ 80G_
M /1C5Z67X>GB)24^AY69XJIAH1=/J>M?\+J\._\ /EJG_?J/_P"+H_X75X=_
MY\M4_P"_4?\ \77A]%>Q_9>'[/[SP_[7Q7=?<>X?\+J\._\ /EJG_?J/_P"+
MH_X75X=_Y\M4_P"_4?\ \77A]%']EX?L_O#^U\5W7W'N'_"ZO#O_ #Y:I_WZ
MC_\ BZ/^%U>'?^?+5/\ OU'_ /%UX?11_9>'[/[P_M?%=U]Q[A_PNKP[_P ^
M6J?]^H__ (NC_A=7AW_GRU3_ +]1_P#Q=>'T4?V7A^S^\/[7Q7=?<>X?\+J\
M._\ /EJG_?J/_P"+H_X75X=_Y\M4_P"_4?\ \77A]%']EX?L_O#^U\5W7W'N
M'_"ZO#O_ #Y:I_WZC_\ BZ/^%U>'?^?+5/\ OU'_ /%UX?11_9>'[/[P_M?%
M=U]Q[A_PNKP[_P ^6J?]^H__ (NC_A=7AW_GRU3_ +]1_P#Q=>6Z?X(\1:I8
MQW=EIK-!+_JV>5(R_P#NAF!/X5FP:1J%SJPTN&SE:^+E/(VX8$=<YZ5FL!@W
M>SV\S5YECDDVM]M-SV3_ (75X=_Y\M4_[]1__%T?\+J\._\ /EJG_?J/_P"+
MKR;6/"NM:#;I/JMBT,,C;%D619%W>A*D@'V-/TGPAKNN6ANM,L&E@W;!(TB1
MAF]!N(S^%+ZC@^7FOIWN']HX[FY+:]K:GJW_  NKP[_SY:I_WZC_ /BZ/^%U
M>'?^?+5/^_4?_P 77BMW9W%A>26M["\$\3;7C<8*FH:T6689JZO]YF\VQ2=G
M;[CW#_A=7AW_ )\M4_[]1_\ Q='_  NKP[_SY:I_WZC_ /BZ\/HI_P!EX?L_
MO%_:^*[K[CW#_A=7AW_GRU3_ +]1_P#Q='_"ZO#O_/EJG_?J/_XNO#ZDMX)+
MJYBMX &DE<(@) R2<#D\"E_9F&\_O'_:V*?;[CVS_A=7AW_GRU3_ +]1_P#Q
M='_"ZO#O_/EJG_?J/_XNO&=3TR[T?49;#4H?)N82 \>X-C(!'()'0BGC1[[^
MQ#JY@Q8^=Y E9U&7QG !.3QZ"E_9V%LGW\RO[4QEVNWD>Q_\+J\._P#/EJG_
M 'ZC_P#BZ/\ A=7AW_GRU3_OU'_\77E7_"':Z/$']B&Q_P")AY?F>3YT?W<9
MSNW;>GO5P?#KQ0QPFGQL>P6\A)/X!ZS>"P2WE^)HL?F#VC_Y*>D_\+J\._\
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M7FFQ*Q'[HL'&XG(Y"CKWK-\ >*],T/3+Z'67P89!>6*^66+3!&4C(!QD$#G
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ME6?BF*R\"WUO;7\\6J2ZLMW&&+,[* IW,^-I.1SGJ1TJ.6M*-HWZ;WW[Z_\
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M%>XT4_[4Q'=?<+^R,+V?WGAW_"E?$7_/[I?_ ']D_P#B*/\ A2OB+_G]TO\
M[^R?_$5[C11_:F([K[@_LC"]G]YX=_PI7Q%_S^Z7_P!_9/\ XBC_ (4KXB_Y
M_=+_ ._LG_Q%>XT4?VIB.Z^X/[(PO9_>>'?\*5\1?\_NE_\ ?V3_ .(H_P"%
M*^(O^?W2_P#O[)_\17N-%']J8CNON#^R,+V?WGAW_"E?$7_/[I?_ ']D_P#B
M*/\ A2OB+_G]TO\ [^R?_$5[C11_:F([K[@_LC"]G]YX=_PI7Q%_S^Z7_P!_
M9/\ XBK<WPH\77&FV]A/J6EO;6I8PJ7?*;NH#>7G!],XKV:BD\RQ#WM]PUE.
M&6U_O/#O^%*^(O\ G]TO_O[)_P#$4?\ "E?$7_/[I?\ W]D_^(KW&BG_ &IB
M.Z^X7]D87L_O/#O^%*^(O^?W2_\ O[)_\11_PI7Q%_S^Z7_W]D_^(KW&BC^U
M,1W7W!_9&%[/[SP[_A2OB+_G]TO_ +^R?_$4?\*5\1?\_NE_]_9/_B*]QHH_
MM3$=U]P?V1A>S^\\._X4KXB_Y_=+_P"_LG_Q%'_"E?$7_/[I?_?V3_XBO<:*
M/[4Q'=?<']D87L_O/#O^%*^(O^?W2_\ O[)_\15NT^%'BVQM[J"TU+2XDNX_
M+FP[Y9,YV[O+R >X!Y[U[-12>9XAZ.WW#64X9.ZO]YX=_P *5\1?\_NE_P#?
MV3_XBC_A2OB+_G]TO_O[)_\ $5[C13_M3$=U]PO[(PO9_>>'?\*5\1?\_NE_
M]_9/_B*/^%*^(O\ G]TO_O[)_P#$5[C11_:F([K[@_LC"]G]YX=_PI7Q%_S^
MZ7_W]D_^(H_X4KXB_P"?W2_^_LG_ ,17N-%']J8CNON#^R,+V?WGAW_"E?$7
M_/[I?_?V3_XBC_A2OB+_ )_=+_[^R?\ Q%>XT4?VIB.Z^X/[(PO9_>>'?\*5
M\1?\_NE_]_9/_B*/^%*^(O\ G]TO_O[)_P#$5[C11_:F([K[@_LC"]G]YX=_
MPI7Q%_S^Z7_W]D_^(H_X4KXB_P"?W2_^_LG_ ,17N-%']J8CNON#^R,+V?WG
MAW_"E?$7_/[I?_?V3_XBO<:**Y<1BJF(MS]#KPV#I8:_L^H4445S'6%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 445\Z^)O$VO6_BW5X8-;U&**.^F5$2[D"JHD(  !X%=F%PLL3)I.UCA
MQF,CA8J4E>Y]%45\P_\ "6>(O^@_JG_@9)_C1_PEGB+_ *#^J?\ @9)_C7?_
M &14_F1YW]MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XT?\)9XB_Z#^J?^!DG^
M-']D5/YD']MT_P"1GT]17S#_ ,)9XB_Z#^J?^!DG^-'_  EGB+_H/ZI_X&2?
MXT?V14_F0?VW3_D9]/45\P_\)9XB_P"@_JG_ (&2?XU]/5PXK!RPUKN]ST,'
MCHXOFY5:UOQ"BBBN([PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP<X;G' /0\5A:UH>NZSHWB?Q!_85[:G6];TR2UL&A)N!# \:F61%R5S@G!Y
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MIH^O1OI";=,OK>.YM<$L I'(R<YY!/XBG:GI%CI/@'2[B>#.K:G*TRN7/[N
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M;ZQ]F^Y]LDZ9^]N.[]<UBUVPES14NYP5(\DW'L%%%%60%%%% !1110 4444
M%%%% !7UI7R77UI7@9Q]CY_H?29'_P O/E^H4445X)]&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\P^+
M/^1TUO\ ["$__HQJ^GJRY?#.@W$SS3Z)ITLLC%G=[2,LS$Y))(Y-=^"Q4<-)
MMJ]SSL?@Y8J,8Q=K'R_17T]_PB?AW_H :7_X!Q_X4?\ ")^'?^@!I?\ X!Q_
MX5Z?]KP_E9Y']B5/YT?,-%?3W_")^'?^@!I?_@''_A1_PB?AW_H :7_X!Q_X
M4?VO#^5A_8E3^='S#17T]_PB?AW_ * &E_\ @''_ (4?\(GX=_Z &E_^ <?^
M%']KP_E8?V)4_G1\PT5]/?\ ")^'?^@!I?\ X!Q_X4?\(GX=_P"@!I?_ (!Q
M_P"%']KP_E8?V)4_G1\PT5]/?\(GX=_Z &E_^ <?^%'_  B?AW_H :7_ . <
M?^%']KP_E8?V)4_G1\PT5]/?\(GX=_Z &E_^ <?^%'_")^'?^@!I?_@''_A1
M_:\/Y6']B5/YT>%GXF>+6^]JBGMS:0__ !%9,WB;5Y]=367O674$QMFC14Q@
M8Z* .GMS7T5_PB?AW_H :7_X!Q_X4?\ ")^'?^@!I?\ X!Q_X5E',</'X:=O
MN-I97BI?%5O]Y\\:QXJUK7K=(-5OFFAC;>L:QK&N[U(4 $^YI^D^+]=T.T-K
MIE^T4&[>(VC20*WJ-P./PKZ$_P"$3\._] #2_P#P#C_PH_X1/P[_ - #2_\
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MY%3+\2?%:1I&NIKM10J@VD)P!T'W*]U_X1/P[_T -+_\ X_\*/\ A$_#O_0
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MWVB7PO-+G\B<*4#[%;@C!X8$53KZ*^P^%_\ H5[/_P  H*/L/A?_ *%>S_\
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ML_\ P"@H^P^%_P#H5[/_ , H*/[7A_*P_L2I_.CYUHKZ*^P^%_\ H5[/_P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU]% '(>?#_SU3_OH5T&BD'28R#D%GP1_OFK]% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0TA&69A[ <9K3^S:'/R<^NYG_:F(]G[3V:M>Q[Y_PEGAW_H/Z7_X&1_XT?\
M"6>'?^@_I?\ X&1_XUX^WA#PS;>((?#-W?ZC_:\@5&N$5/LZ2LN0NTC<1R!U
M[UQ%]:/8:A<6<Q!DMY6B8KT)4D''Y4J>74:FTGWVZ#JYI7I*\H+MOU['TO\
M\)9X=_Z#^E_^!D?^-'_"6>'?^@_I?_@9'_C7S99:5J.I[O[.L+J[V?>\B%I-
MOUP*;'IM]+<30165P\T"EY8UB8M&HZEAC( ]ZT_LJEMSF7]LUK7]G^9]*_\
M"6>'?^@_I?\ X&1_XT?\)9X=_P"@_I?_ (&1_P"-?,]K975](R65M-<.B%V6
M&,N54=20.WO4UEH^IZE&SZ=IUW=HAPS00,X7ZX%#RJDMY@LYK/:'YGTE_P )
M9X=_Z#^E_P#@9'_C1_PEGAW_ *#^E_\ @9'_ (U\T06%Y<W36UM:SS3KG=%'
M&688ZY YXJQ/H&L6MNT]SI-]#"BAFDDMG55!X!)(QBC^RJ2=G/\ (%G%9JZI
M_F?1_P#PEGAW_H/Z7_X&1_XT?\)9X=_Z#^E_^!D?^-?,\5G<SV\T\%O+)#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\P^+/\ D=-;_P"PA/\ ^C&KZ>KYA\6?\CIK?_80G_\
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M"  7\EIF;(& V<XS[XKE[FYFO+J6YN9#)-,Y>1VZLQ.2:QP]&5.5VK:6WO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>>?!L1CP[K8DYU'^W[[^T,X
MW>=YI^]_P#97H=<CJ_PZT_4==FUG3=4U;0=0N5"W4NDW(B%S@8!=&5E) XW8
MS[T 97C_ ,566CZ;KD/A>XM+7Q*9+*WN[@0#=;B>18XY'.,,0I) )./I534M
M.U#X?:]X8N;'Q)J^IP:IJD>F7UKJMX9UE\Q&(D3/W&4KG"X!!Q726?PX\.6O
MAC4=#FMIKV#56WW\]W.TD]T_'SO)G.X8!&,8(XQ4.D_#?3].UFSU.^U?6=;G
MT\,+%=4NQ*EJ2-I*@*N6QQN;<??- 'F>EZ%>GX;^,_$=KXFUJPN--U#5;FS@
MLKGRH4:)W?YT _>;B.=V>.!COU%O=ZIX^\56&E7>MWNEV$'A^UU*>/3)S;RW
M4\Q/)=?F"+MZ CD\^E=?;>!=,M?".L^'8Y[LVFL-=-<.SKYBFXW;]IVX&-QQ
MD'WS5;4/AQI=XNER6M_J>F7^EV:V4&HV%P(YV@  V/E2K#C/*\'D8H \[U_6
M_$.D>'_%7AV#Q#>23:+K&FQV6IM)FX6*X:-MDA&-^W)'/W@<&KOC/P-!;>,/
M UH=?\13?:=1G1II=6E,B?N&;*-GY#D=L<$CI7:#X8:$/#,VC>=?,+F^CO[J
M\></<7,R.KAG=@0?N 8  QTQ6EXJ\(6GBM+ SWM]I]SI\_VBVN["14EC8J5.
M"RL,$,0>* -/5VTU-(N6UTVBZ<$/V@WI40[.^_=\N/K7F_C@:OIWCSPOK&M&
MSN?"]OJD<%I;V>8YH9I5\N.63.?,4%F^5-N,@X;%>E:GIMIK.E76FZE MQ:7
M<30S1-T96&"/;ZURNF?"_2[#4K"ZN]5UK5H],8/86FHW@EAM6 PK*H4$E1P"
MQ8CM0!5^''_(S>/O^P^?_1$50Z.<_M$>)?LA7R1HMH+P+_SVWOLW>^S/X8J[
M-\,HO[9U/4=-\5^(]*;5+C[3<0V5Q"L>_:%R T1/11WK<\,>$M,\)VD\6F">
M26ZE,UU=W4QEFN9.FYW/4X^@]J -NBBB@ HHHH **** "OF'Q9_R.FM_]A"?
M_P!&-7T]65J.HW-M>^3!Y6WRPQ+J2<DD=B/2NW!XKZM)NU[G!CL'];BH\UK>
M5SY@HKZ5_MB^_P"G?_OVW_Q5']L7W_3O_P!^V_\ BJ]'^V/[GX_\ \O^P_\
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M ._;?_%41S*,))J&R[]]^@IY5*<6G4U;3>G;;J?-5%?2O]L7W_3O_P!^V_\
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M?9X]O"[I&Y ]% )_*EIH&IU%M.+JTAG0865%<#V(S4M16T"VUK% GW8D"#Z
M8J6H+"I[#_D*VO\ OM_Z U05/8?\A6U_WV_] :@#I**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I7>EQ7EQYS
MRRHVT+A",$ D]P?6KM% &7_8,/\ S\W'YI_\31_8,/\ S\W'YI_\36I10!E_
MV##_ ,_-Q^:?_$T?V##_ ,_-Q^:?_$UJ44 9?]@P_P#/S<?FG_Q-']@P_P#/
MS<?FG_Q-:E% &7_8,/\ S\W'YI_\31_8,/\ S\W'YI_\36I10!E_V##_ ,_-
MQ^:?_$T?V##_ ,_-Q^:?_$UJ44 9?]@P_P#/S<?FG_Q-']@P_P#/S<?FG_Q-
M:E% &7_8,/\ S\W'YI_\31_8,/\ S\W'YI_\36I10!E_V##_ ,_-Q^:?_$T?
MV##_ ,_-Q^:?_$UJ44 9?]@P_P#/S<?FG_Q-']@P_P#/S<?FG_Q-:E% &7_8
M,/\ S\W'YI_\34*^%K!+M[I"ZW#@!Y@D8=AZ$[<FMJB@#+_L&'_GYN/S3_XF
MF-X;M'F29I)6EC!".0FY0>N#MXS6O10!E_V##_S\W'YI_P#$T?V##_S\W'YI
M_P#$UJ44 9?]@P_\_-Q^:?\ Q-']@P_\_-Q^:?\ Q-:E% &7_8,/_/S<?FG_
M ,31_8,/_/S<?FG_ ,36I10!E_V##_S\W'YI_P#$T?V##_S\W'YI_P#$UJ44
M 9?]@P_\_-Q^:?\ Q-,;PY:/*DCRRL\>=C$(2N1@X.WCBM>B@#+_ +!A_P"?
MFX_-/_B:/[!A_P"?FX_-/_B:U** ,O\ L&'_ )^;C\T_^)J2WT>*WN8YA-,[
M1DD!BN.01V'O6A10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%<KXH^(6E>$]3CL=1M[R662$3 P(A7:6([L.?E-:4Z<Z
MDN6"NS.I5A2CS3=D=517G?\ PNKP[_SY:I_WZC_^+H_X75X=_P"?+5/^_4?_
M ,76_P!2Q'\C.;Z_A?YT>B45YW_PNKP[_P ^6J?]^H__ (NC_A=7AW_GRU3_
M +]1_P#Q='U+$?R,/K^%_G1Z)17G?_"ZO#O_ #Y:I_WZC_\ BZ/^%U>'?^?+
M5/\ OU'_ /%T?4L1_(P^OX7^='HE%>=_\+J\._\ /EJG_?J/_P"+H_X75X=_
MY\M4_P"_4?\ \71]2Q'\C#Z_A?YT>B45YW_PNKP[_P ^6J?]^H__ (NC_A=7
MAW_GRU3_ +]1_P#Q='U+$?R,/K^%_G1Z)17G?_"ZO#O_ #Y:I_WZC_\ BZ/^
M%U>'?^?+5/\ OU'_ /%T?4L1_(P^OX7^='HE%>=_\+J\._\ /EJG_?J/_P"+
MH_X75X=_Y\M4_P"_4?\ \71]2Q'\C#Z_A?YT>B45YW_PNKP[_P ^6J?]^H__
M (NC_A=7AW_GRU3_ +]1_P#Q='U+$?R,/K^%_G1Z)17G?_"ZO#O_ #Y:I_WZ
MC_\ BZ/^%U>'?^?+5/\ OU'_ /%T?4L1_(P^OX7^='HE%>=_\+J\._\ /EJG
M_?J/_P"+H_X75X=_Y\M4_P"_4?\ \71]2Q'\C#Z_A?YT>B45YW_PNKP[_P ^
M6J?]^H__ (NC_A=7AW_GRU3_ +]1_P#Q='U+$?R,/K^%_G1Z)17G?_"ZO#O_
M #Y:I_WZC_\ BZ/^%U>'?^?+5/\ OU'_ /%T?4L1_(P^OX7^='HE%>=_\+J\
M._\ /EJG_?J/_P"+H_X75X=_Y\M4_P"_4?\ \71]2Q'\C#Z_A?YT>B45YW_P
MNKP[_P ^6J?]^H__ (NC_A=7AW_GRU3_ +]1_P#Q='U+$?R,/K^%_G1Z)17G
M?_"ZO#O_ #Y:I_WZC_\ BZ/^%U>'?^?+5/\ OU'_ /%T?4L1_(P^OX7^='HE
M%>=_\+J\._\ /EJG_?J/_P"+H_X75X=_Y\M4_P"_4?\ \71]2Q'\C#Z_A?YT
M>B45YW_PNKP[_P ^6J?]^H__ (NC_A=7AW_GRU3_ +]1_P#Q='U+$?R,/K^%
M_G1Z)17G?_"ZO#O_ #Y:I_WZC_\ BZ/^%U>'?^?+5/\ OU'_ /%T?4L1_(P^
MOX7^='HE%>=_\+J\._\ /EJG_?J/_P"+H_X75X=_Y\M4_P"_4?\ \71]2Q'\
MC#Z_A?YT>B45YW_PNKP[_P ^6J?]^H__ (NC_A=7AW_GRU3_ +]1_P#Q='U+
M$?R,/K^%_G1Z)17G?_"ZO#O_ #Y:I_WZC_\ BZ/^%U>'?^?+5/\ OU'_ /%T
M?4L1_(P^OX7^='HE%>=_\+J\._\ /EJG_?J/_P"+H_X75X=_Y\M4_P"_4?\
M\71]2Q'\C#Z_A?YT>B45YW_PNKP[_P ^6J?]^H__ (NC_A=7AW_GRU3_ +]1
M_P#Q='U+$?R,/K^%_G1Z)17G?_"ZO#O_ #Y:I_WZC_\ BZ/^%U>'?^?+5/\
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M_A=7AW_GRU3_ +]1_P#Q='U+$?R,/K^%_G1Z)17G?_"ZO#O_ #Y:I_WZC_\
MBZ/^%U>'?^?+5/\ OU'_ /%T?4L1_(P^OX7^='HE%>=_\+J\._\ /EJG_?J/
M_P"+H_X75X=_Y\M4_P"_4?\ \71]2Q'\C#Z_A?YT>B45YW_PNKP[_P ^6J?]
M^H__ (NC_A=7AW_GRU3_ +]1_P#Q='U+$?R,/K^%_G1Z)17G?_"ZO#O_ #Y:
MI_WZC_\ BZ/^%U>'?^?+5/\ OU'_ /%T?4L1_(P^OX7^='HE%>=_\+J\._\
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M7;7UO_D$:5*<'52T5]+]K6_/\#FM<T"\\/W4<5X8I(YHQ+!<0/OBF0]U;O\
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M&N;UH@9KD-@L^X#.W!. /Z<=-J>E2IY\ND^%=#UO03&1$UAM%PHQP=XRQ;Z
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M&. ,=^.?QKF/$SS:?XK$\>C'0;B+9(+=6W*'!^^O&,$CMD<5HJ_/)PCHU?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8K^1GGE%>A_\*5\1?\_NE_\ ?V3_ .(H_P"%*^(O^?W2_P#O[)_\11]=P_\
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M<^W0_J:TK'Q1X4TC7&UW2K+58;PAF%BK1K;!B.F0<[<G.,?X5/\ \*5\1?\
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M@O#%:RM+:7%EM+Q[OO*0Q ()YJ]J7C:P@'AL^&+6XM_[$:7Y;D*1('*]P>K
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MN;N&#[0T$9D\K=MW <GG![5-AW-W^W9O^?1/^_Q_^)H_MV;_ )]$_P"_Q_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$"DC\*YX+J^F^)M7NK;1WO8+PPF-TN(T^[& >&.>O\J[/^Q[[_IW_P"_C?\
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MZ@]AIZZC;7LOGIMG6-HW( (.[J.!TKL?['OO^G?_ +^-_P#$T?V/??\ 3O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?]!C_P E9O\ XBC_ (6CX._Z#'_DK-_\11]6K_R/[F'UO#_\_%]Z.MHKDO\
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M_P C^YA];P__ #\7WHZVBN2_X6CX._Z#'_DK-_\ $4?\+1\'?]!C_P E9O\
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MVBN2_P"%H^#O^@Q_Y*S?_$4?\+1\'?\ 08_\E9O_ (BCZM7_ )']S#ZWA_\
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M (BC_A:/@[_H,?\ DK-_\11]6K_R/[F'UO#_ //Q?>CK:*Y+_A:/@[_H,?\
MDK-_\11_PM'P=_T&/_)6;_XBCZM7_D?W,/K>'_Y^+[T=;17)?\+1\'?]!C_R
M5F_^(H_X6CX._P"@Q_Y*S?\ Q%'U:O\ R/[F'UO#_P#/Q?>CK:*Y+_A:/@[_
M *#'_DK-_P#$4?\ "T?!W_08_P#)6;_XBCZM7_D?W,/K>'_Y^+[T=;17)?\
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MUB-[6=^POJT[7NK;WO\ (XRBNMU/P;'%X\L=%TR62:SU 12V\K,"YA899B<
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M?H:U%%%?.GU 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUQI'-FX<YW*OECD'.,_2FZ/J37@O]3T/Q&NBZO<7LDTUM>W"I!)&Q+ C*X+
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M*Z6<26N]3G<5'S?D21^%<G6P_A;Q+)(SR:%JKNQ)9FLY"2?4G%-_X1/Q%_T
M-4_\ Y/\*WI.G3@H<RT.>K&K5J.;B]?(R:*UO^$3\1?] #5/_ .3_"C_ (1/
MQ%_T -4_\ Y/\*T]K#^9&?LJG\K^XR:*UO\ A$_$7_0 U3_P#D_PH_X1/Q%_
MT -4_P# .3_"CVL/YD'LJG\K^XR:*UO^$3\1?] #5/\ P#D_PH_X1/Q%_P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% %8:=9#2_[,%G;_ &#R?L_V3RE\KRMNW9LQC;MXQC&.*Q/^%<>"/^A-\/\
M_@K@_P#B:Z2B@"O'86<5_-?16D"7<Z*DMPL8$DBKG:&;J0,G /3-6*** "BB
MB@ HHHH **** "LK4=1N;:]\F#RMOEAB74DY)([$>E:M8&L?\A7_ +8I_P"A
M-0 ?VQ??].__ '[;_P"*H_MB^_Z=_P#OVW_Q54Z* +G]L7W_ $[_ /?MO_BJ
M/[8OO^G?_OVW_P 55.B@"Y_;%]_T[_\ ?MO_ (JC^V+[_IW_ ._;?_%53HH
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M_OVW_P 55.B@"Y_;%]_T[_\ ?MO_ (JC^V+[_IW_ ._;?_%53HH N?VQ??\
M3O\ ]^V_^*H_MB^_Z=_^_;?_ !54Z* +G]L7W_3O_P!^V_\ BJ/[8OO^G?\
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M9=:?,B+8Q1MLGP<F1%5G!.<<!O2E9CNCKO[8OO\ IW_[]M_\51_;%]_T[_\
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MY@D61KZ9[9A]]5CRON?EY'^?J3"Y@D61KZ9[9A]]5CRON?EY'^?J_P#X\?\
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M]0!DPN8)%D:^F>V8??58\K[GY>1_GZDPN8)%D:^F>V8??58\K[GY>1_GZO\
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M>V8??58\K[GY>1_GZO\ ^/'_ *:64GX[,_S'^?J?\>/_ $TLI/QV9_F/\_4
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M8?\ GYN/S3_XF@#(HK7_ +!A_P"?FX_-/_B:/[!A_P"?FX_-/_B: ,BBM?\
ML&'_ )^;C\T_^)H_L&'_ )^;C\T_^)H R**U_P"P8?\ GYN/S3_XFC^P8?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O#OC5_P CI:?]@]/_ $9)7N->'?&K_D=+3_L'
MI_Z,DKT\K_WCY,\G-_\ =7ZH\\HHHKZH^."BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKB\@ADEDM(;AFD&S&5P%QNYQC/KZ5C:7H=SJMEJ-W"\,4&GP>=,\K$9YP%&
M<L3T[>]"K4VKIA*A4B[-?TMS-HHKTO2O"VGZ9X&UK^TX(IM:-A]I*21@FT0@
M[!ST<X)/<<"E6K1I)-]2J%"59M+H>:445T$O@S4HO%%GH0DMI+B\19(94=C&
M58$[LXSC /;M6DIQC\3_ *1E&G*?PK^F<_16_'X.U!_$5_H[RVT4VGQ/-/+(
M[",(H!+9QG&".W>GV/@N]N]*AU&[OM/TNWN"1 ;^?RS-CNH /'N<5#K4UU-%
M0JMVY?Z1SM%;+>$]87Q,N@_92;YC\J@_*RXSO#=-N.<_UJW?^"+ZSL;JZMK[
M3M16S_X^8[&X,CPCU8$#@>HS1[:FFE?<2H56F^78YNBNPO=$:_\ !_@^+2K%
M'O[UKQ7:.,!Y=LH W-W '<]!5"/P7?3:[=Z9!>6,GV%"]U=B4B"$#J&8J.0>
M. ?T-)5X-7;MO^#L5+#U$TDKWM^*N<]16YJ_A2ZTG3(]16\L=0LWE\KS[*8R
M*KXS@Y (X_STK/T?3)M9UFTTZWXDN91&#C.T'J?P&3^%6JD''F3T,W2G&2@U
MJRG176ZAHZ>(/&D^C^'X[:UAL8FBC9QM\P1#YG8J"68G)S]*P](T6YUK[=]E
M>)/L-G)>2>82,HF,@8!YY]OK4QJQ<;O3_@E2HR4K+7=?=N9U%=+9>![V[T&U
MUB74--LK&ZW!);N<IAE8KM/RGD[21C/ YQ69KN@WOAZ_%K?A#O0212Q-NCE0
M]&4]Q3C5A*7*GJ$J-2,>9K3_ #,VBNW\"^'K'5O#^OW-Y+9+-';E(6N&/^CD
MC_6'@X'H>3P:R-/\'7E]9S7KWMA96$<IA2\NYBD<S#/W."6Z>G]:CZQ#FE%]
M"_JU3EC):W_0Y^BM37?#U[X?GA2\,4L5Q'YD%Q;OOBF7U5N]1:+86NHZFL&H
M:A%I]L%9Y)Y!G  S@#N3V%:\\7'G6QE[.2GR-690HKM_B#I^D6.E^'GT& 1V
M\]L[B5D DFY&&<]SS^&:9I^O:<LFF:9H/ABUU#<J+=&\MA)-/(3\VULG:/3T
M_"L57<H*<8]_P-Y8=1J.$I;6\[W['%T5N>--,M-&\9:C8::<VT,@V#=G;E02
MN?8DC\*9HGAB\URVN+N.:UL[.VP);J\E\N-6/1<X.3[8_F*T56/(JCT3_4Q=
M&?M'36K5_P #&HKN]=\.II7PSL#Y5I<7<NI%4N[4!_.0HV ' R1GMZBJ"_#K
M5#)';2W^EPZA(FY=/DNL3GC(&,8S[9K..)IM7;MO^!K+"U4^5*^B_$Y.BMS2
M_"6H:E]M>22VT^"Q?R[B>^D\M$?.-G0G.>V*;J_A:^T@V1\RWOHK[(MIK*3S
M$D(.-HX!SD],5I[6'-RWU,O8U.7FMH8M%=8_PZU1)#;"]TQ]1";SIRW6;CIG
M&W&,X[9K.TGPK=ZK93WKW5GI]I#+Y+3WTIC4R8SL& 23CGI25>FU=,IX>JG9
MQ,2BMV_T>[\(ZI87-VMG?P2 3PLA$L-P@/(Y'\QWI?&.CV^DZXK:>2;"^A2\
MM<]HWYQ^!R/P%-58R:2ZBE1E&+;Z;_,P:***U,0HHHH **** "BBB@ HHHH
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M(1OB/N>F?7->558AU"]M[6:UM[N>*WG_ -;"DI5)/]X X/XUVUZ3JI<KL_\
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M#<0.%FB>(@HX)!&05';%;]% %>UM!;Z9#9SS27@CA6)Y;G#/-@8+/@ $GJ<
M#GI7%0_"#0HEAM'U'69]%@E$L6B37NZS4@[@-N-S*#SM+$>U=[10!D6GANSL
M_%FH^(8I)S=ZC!#!*C,/+58MVTJ,9S\QSDG\*UZ** "BBB@ HHHH **** "H
M9;NV@8+/<11,1D!W ./QJ:L#6/\ D*_]L4_]":@#6_M*Q_Y_+?\ [^K_ (T?
MVE8_\_EO_P!_5_QKG:* .B_M*Q_Y_+?_ +^K_C1_:5C_ ,_EO_W]7_&N=HH
MZ+^TK'_G\M_^_J_XT?VE8_\ /Y;_ /?U?\:YVB@#HO[2L?\ G\M_^_J_XT?V
ME8_\_EO_ -_5_P :YVB@#HO[2L?^?RW_ ._J_P"-']I6/_/Y;_\ ?U?\:YVB
M@#HO[2L?^?RW_P"_J_XT?VE8_P#/Y;_]_5_QKG:* .B_M*Q_Y_+?_OZO^-']
MI6/_ #^6_P#W]7_&N=HH Z+^TK'_ )_+?_OZO^-']I6/_/Y;_P#?U?\ &N=H
MH Z+^TK'_G\M_P#OZO\ C1_:5C_S^6__ ']7_&N=HH Z+^TK'_G\M_\ OZO^
M-']I6/\ S^6__?U?\:YVB@#HO[2L?^?RW_[^K_C1_:5C_P _EO\ ]_5_QKG:
M* .B_M*Q_P"?RW_[^K_C1_:5C_S^6_\ W]7_ !KG:* .B_M*Q_Y_+?\ [^K_
M (T?VE8_\_EO_P!_5_QKG:* .B_M*Q_Y_+?_ +^K_C1_:5C_ ,_EO_W]7_&N
M=HH Z+^TK'_G\M_^_J_XT?VE8_\ /Y;_ /?U?\:YVB@#HO[2L?\ G\M_^_J_
MXT?VE8_\_EO_ -_5_P :YVB@#HO[2L?^?RW_ ._J_P"-']I6/_/Y;_\ ?U?\
M:YVB@#HO[2L?^?RW_P"_J_XT?VE8_P#/Y;_]_5_QKG:* .B_M*Q_Y_+?_OZO
M^-']I6/_ #^6_P#W]7_&N=HH Z+^TK'_ )_+?_OZO^-']I6/_/Y;_P#?U?\
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MGTZTEKJ%G>EQ97<%P4X812A]OUP>* .K_M*Q_P"?RW_[^K_C1_:5C_S^6_\
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M^<$QG<;>3'Y[:#J=LL>\^<$QG<;>3'Y[:B_X\?\ II92?CLS_,?Y^I_QX_\
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M*3\=F?YC_/U )3J=LL>\^<$QG<;>3'Y[:#J=LL>\^<$QG<;>3'Y[:B_X\?\
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M\_62BW_QX_\ 32RD_'9G^8_S]3_CQ_Z:64GX[,_S'^?K%'<"VE,217$MJ_\
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M?YCD?Y^I'<"VE,217$MJ_P#";=\Q_F.1_GZ@$O\ QX_]-+*3\=F?YC_/U/\
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img61678762_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" &"!44# 2(  A$! Q$!_\0
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MQ5_T#]'_ ._,O_QRC_AH'Q5_T#]'_P"_,O\ \<H_LS$=E]X?7*1]$T5\[?\
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M (:!\5?] _1_^_,O_P <H_LS$=E]X?7*1]$T5\[?\- ^*O\ H'Z/_P!^9?\
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M9?\ XY1_9F([+[P^N4CZ)HKYV_X:!\5?] _1_P#OS+_\<H_X:!\5?] _1_\
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M'_[\R_\ QRC_ (:!\5?] _1_^_,O_P <H_LS$=E]X?7*1]$T5\[?\- ^*O\
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M/_WYE_\ CE']F8CLOO#ZY2/HFBOG;_AH'Q5_T#]'_P"_,O\ \<H_X:!\5?\
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M%1;COZ::"5).^NQXI17KL/A#PGK7Q.E\,6.ERV%OI9FFNKAKQF:Y48P@!X0
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MNR9X7;0-=744$9 >5PBEN@).*O\ B+0;KPSX@NM'OY(9+BU*AVA)*'*AA@D
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MVN_);;Y]K)OB?W5NXKU-8=(\2:)X/UL^']-L)YO$4=C-%:0!8I8BV<,O\7
MYSW]<5HWEOHV@:-XVU5?#NDWDNGZNL=M%<6JF.,,$7&!CY1N)VC I/%VE:WE
M;SO8?L=-_P"K7/$:*]WLO"7AK4_&.FZQ<:=:VUO=>'5U-M.B@+1>;QDA%^\
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MIN;F2T;?;;MF(W7SEYXEPN=_UXK*.(J>SA)K63+=*//))['DE%>U^)[/0O\
MA-]"\))H6DVEKJ<5O-<WB0!)L[C\B,,;-VS:<==U+XTM?!4FD:WI=M%9Q:C9
M$+:QV.BS02PR9PJR2\JX8\ G .<CL:%C$W'W7K^6P.@U?78\3JU/IEY;:;:7
M\\#):WA<6\IQB380&Q]"17MEUX7MI?".NVVJZ!X9T^2QTEKF*&QE\R^@D5-P
M,C8R5./7V^;.:SO$>LH? '@J!=!T@Q:DL@<_8\_9L21Y,7/R;B?FZYI+&<S2
MBNOZ7&Z%DVW_ %<\:HKWW4;;P[_PDGB[3'\)Z1Y&@V2ZC$T<&QY7$8DVL1_
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M>M=K=!Q<7LW;YG/:I>_6WX%Z/XL:['K&G:D+73?.TZ&6&!! RIL<\@JK#I@
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M"QG[R[,G@X'?L,8Q27GQ(U*ZNK&:#2M%L5LIS<)#:6(5)'(()8$DG@GN/7J
M1<TOX?Z3/X)L/$FN^*1I,-[,\"(=/:8!@S#&5;N%)R0!6'XR\)S^#M>_LVXN
M8[I7B6>&:,8#HV<''8Y!XIQ6&E/DBM5=;/Y^H2]JH\S9-XE\<ZCXGT^VT^:S
MT_3[*WD:5;;3[?RD+GJQ&3SR?S-2:#\0=5T#0GTB.UT^_LS+YT27]OYWD/\
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MS3K:$22J1CYFW9XZ@=,]JY>\\1WM[H.CZ2ZQ1PZ.9C;R1AA(3(X<ECG'!'&
M*R:*4:%.'PH<JDY;L[34/BCK&J:;-;WFGZ.]S<6_V>;4?L0^TR)C!!;./R'T
MQ5"Z\<ZA?>#H/#M[9Z?/!;)Y<%T\!-Q$NX-M5\X ^4#IR!S7-44E0I+9>8.I
M-[L[;QIXI@O_  IX;\/:=?M>P:=;!KB78RAICP$&Y0<(,@'N#6-XOU73=7UB
M.;1[&"S@CMHXF\B 0K*X'S/L!.,D^I. ,UA44X48PM;S_$)3<MS<UWQ9?>(=
M)T?3[V*W2+2(/(@:)6#,N%&6R3D_*.F*72O%U_I'AC5-"MH;9K75,><\BL77
M']TA@!^(-85%5[.'+RVT_IBYY7O<Z>S\;7K:#8Z!JD5G>6%K=)-#+=0M*\ #
M E1AAE<9RIZ@D9'&*FLZY;R^-I=:T"SCT^%+E9K6!(PJILQ@[1P,D9Q[UAT4
ME2@G=+^F#G)JS.YU/XL:UJEMJ$,FGZ3 NHP&"Y:WM2C29Q\Q;=DL ,#.1R>*
MI-\1=6?Q5I.OFWLOM6E6JVL";'\MD 898;LD_.>A':N3HJ5AZ25E$IU9OJ=E
M9?$_6;/3Y[-[33+N&2Z>[B%W:^;]FE8EBT>3Q@DD9SC-8'B/7[OQ1K]QJ^H)
M$ES<! XA4A?E0(, DGHH[]:S**J-&G"7-%:DN<I*S84445H2%%%% !1110!]
MMT445\(?1A7EO[0/_(@67_83C_\ 14M>I5Y;^T#_ ,B!9?\ 83C_ /14M=>"
M_P!XAZF&(_A2/G:M+4_$.J:S8Z?9ZE=>=;Z;%Y-JGEJOEI@#&0 3]T=<]*S:
M[[6_A/K>E>%]+U);9Y)YR5O8S+&%@9I%2$#GG=N&<9 ]J^KJ3IPE'GW>QXT8
MSDGRG/:#XU\0^&+2>VT+4GM(9VW2($1LG&,C<#@X[BGR>.O$DTEU)+J3.]Y9
M?8)V:&,F2#!&TG;[GYNOO6UI?PY\1:9KMC_;GA1M0AN)9($LVOT@\YQ&S??#
M9  4MGH<8[U0LOAUXHUU6N]&T1FM9)I$0"XCPA5B"I+,.G3)ZXK'GPS;D[>N
MG]="^6K:VOIJ9OA[Q=KOA4W!T#4&M/M( E 17#8SCA@<$9/(]:JZ5KFHZ)K<
M>KZ9<>1?1EF27RU;!8%3\I!'1CVKL/#W@R%-#\:IXDTYDU/1[1'A5I&!A<AS
MGY3AL@*><BL6U^'7BR]T,:O:Z+/)9-'YJN&7<RXSD)G<1CI@<U7M*#<KVZ)[
M:Z?CH+EJ65O^&)-6^)GB_7-.DL-2UJ22VE&V1$BCCWCT)102/:N6J:SL[C4+
MV*TLH7GN)F"1QH,EB>PK<UCP!XHT$6IU31YHOM<HA@",LA=ST7"$\GTK1>RI
M>ZK*_38E\\]7=F;JVNZCKGV7^U+CS_LD"V\'R*NR->@^4#/U/-;=O\3_ !C:
MVMI;0:Y*L-F (5\J,X & "2N6&/[V:KZW\/_ !1X<TW[?K.DR6]KD RB1'"D
M],[6..>.:5/AYXJDT#^VET:;[!Y7G>:70'9C.[9G=C'/3I4-X>45>S738I*J
MGI>Y%I/CKQ+H6CR:7I.K36UG(23&JJ2N>NUB,K_P$CUI]MX^\3V?B"ZUNVU5
MX]0O%"W$@B3$@  &4V[> !SCU]370>(O GVB/PK;^$],9[S4-&CO+H"4X9MH
M+.2[;5'/L.0*AA^%.M7'@-M;AMS)=?:"5B2>(QFV$9)E#;L'YA@ 'WQ67M,,
MUS225^]OQ^XKEJWLKZ&._P 0?%$FJ6.HRZL\EWIYE-M*\2,8_-SOZKSG.,'.
M.V*BTKQQXBT6UO+;3-2:"&^=I+A/+1@[$8)Y!QD>F*F?X=^+(]!.LOHLRV*Q
M^:9"Z;@F,[MF=V,<]*Z;PEX6T_5-:\'VNL>&?L]KJ27+/=?;V;[<$B)SL4@Q
M[3M],TYRP\8MV37E;I=A&-5O=K[_ $.1'C7Q"MUIMS'J<D<VEP"VM'C15,<0
M& IP/F&!_%G-/UCQWXEUZYM)]6U62X>SD$L \M%5'!R&VJ "?J*MQ?#OQ)JT
M=Y?Z)H\LVGQ3R(CB11D*Q'RAFW-C&. >E<I6L8T9.\4KKTT(;J):WU-U?&OB
M!=<OM86_Q?ZA ;>YF\F/]Y&0H(QMP.%7D 'BKUO\3_&-K:VEM!KDJPV8 A7R
MHS@ 8 )*Y88_O9K,_P"$4UHC2"MEN&M';8%94;SB" >A^7!(SNQBG-X/UU)=
M6C>P*MHZAK[=*@\D'ISGYLXXVYS2<<.]TOP]/^ -.JMK_P!:E:?7]3N?#]KH
MD]SNTZTD:6&'RU&QFSD[@,G[QZFKGA_QKXA\+0S0Z#J;VD4S;GCV(ZDXQG#
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MW-BP6X ECVQL1D#>6VDX[ U-2GAYRYY-:>8X2JQ7*NI'%X]\30Z+:Z2FJ/\
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M0^E06L$DDJJ;MU$FXH#RW+ <9_45IMXTL;]=.UO1]2\(6:PV863^U(F-[;L
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MP<;74;)HU,<3G4)@R8V. V01G@D8'&0*R;'QAI2?#J/7VO(1XGL=-?1XXO,
ME8%EV2!3R=JY.>F2U>/T5E'!045&_7^D6\1)NY[GH'BJPO\ P9X>6PO?"MK=
M:4GE3IKZ'S(F7'[R'!&2<9X]>H(KG-8\16U]\+_$:'4K)KV\\1--Y5LWE^='
MM3YUC8[MI(SSGFO+Z*<<'&,N9/K?\;B==M6/8_!7B&T3X9-K.J1&2]\)O(EA
M(P.&\Y=J)GOACT[  UYGX=UQ-&\56NM7UF-3\B4S-#*^WS'P<$M@\AB&Z'D5
M7.N:@?#ZZ)YX&G+/]H\E8U&9,8W%@-QXXY-4*TIT%%SO]K\OZNR95&^6W0]?
MB\=>%=6\)^+[JZ\/1V]S=FV:6UFUB1Y+]O,."N0"/+^]A1C& <"N-^&>MV^B
M>.;5M0E2*QO$>TNFDX4(XQR>PW!23Z"N2HHCAH1C*"VE_E8'6DVF^A[UIOBG
MPP^KW&CW]_9G2_#0MI]+F:88G>&,ABISAF+,, 9SUYK%\%^+;34_".KZ?=2^
M'H-4N=2>^9->0FVN ^"><\,"..O ''<>/T5E]2A9J_;\/\^I?UB5]CW73_&]
MDWBO6[+4]3\/2SW>G0V]O<B%Q8%H]Y,;[F.1^\Z@X( [\4_3/$MK!X_\/Q:K
MK'A>.WLK2Y&=()BMX-X7"EV;:<[> ,=^.17@]%2\##77I^EA_69=OZW/5]5U
MRR\3CPMXCTW6K+0[VPE2TN+*1@([0@Y$L<6<E#P#CMC)&TD9_P 1XM'_ +#M
M[E=3TRYUVYOGEN4T>Z>2WD0@_O"I)"/D*.,9R>O;SBBMHX91DFGHOZL0ZMTT
MUN%%%%=1B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %=O\'?^2LZ-_P!M_P#T1)7$5V_P=_Y*SHW_ &W_ /1$E88G
M^!/T?Y&E+^)'U1]24445\6>^4=9T:P\0:3-IFKP?:+.?;YD>]EW;6##E2#U
M/6N6_P"%.^!/^@%_Y.3_ /Q==O16L*U2"M"37HR)0A)WDKG$?\*=\"?] +_R
M<G_^+H_X4[X$_P"@%_Y.3_\ Q==O15?6:_\ ._O8O94_Y5]QQ'_"G? G_0"_
M\G)__BZ/^%.^!/\ H!?^3D__ ,77;T4?6:_\[^]A[*G_ "K[CB/^%.^!/^@%
M_P"3D_\ \71_PIWP)_T O_)R?_XNNWHH^LU_YW][#V5/^5?<<1_PIWP)_P!
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M<G_^+KMZ*/K-?^=_>P]E3_E7W'$?\*=\"?\ 0"_\G)__ (NC_A3O@3_H!?\
MDY/_ /%UV]%'UFO_ #O[V'LJ?\J^XXC_ (4[X$_Z 7_DY/\ _%T?\*=\"?\
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M$_Z 7_DY/_\ %T?\*=\"?] +_P G)_\ XNNWHH^LU_YW][#V5/\ E7W'$?\
M"G? G_0"_P#)R?\ ^+H_X4[X$_Z 7_DY/_\ %UV]%'UFO_._O8>RI_RK[CB/
M^%.^!/\ H!?^3D__ ,71_P *=\"?] +_ ,G)_P#XNNWHH^LU_P"=_>P]E3_E
M7W'$?\*=\"?] +_R<G_^+H_X4[X$_P"@%_Y.3_\ Q==O11]9K_SO[V'LJ?\
M*ON.(_X4[X$_Z 7_ ).3_P#Q='_"G? G_0"_\G)__BZ[>BCZS7_G?WL/94_Y
M5]QQ'_"G? G_ $ O_)R?_P"+H_X4[X$_Z 7_ ).3_P#Q==O11]9K_P [^]A[
M*G_*ON.(_P"%.^!/^@%_Y.3_ /Q='_"G? G_ $ O_)R?_P"+KMZ*/K-?^=_>
MP]E3_E7W'$?\*=\"?] +_P G)_\ XNC_ (4[X$_Z 7_DY/\ _%UV]%'UFO\
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MNC_A3O@3_H!?^3D__P 77;T4?6:_\[^]A[*G_*ON.(_X4[X$_P"@%_Y.3_\
MQ='_  IWP)_T O\ R<G_ /BZ[>BCZS7_ )W][#V5/^5?<<1_PIWP)_T O_)R
M?_XNC_A3O@3_ * 7_DY/_P#%UV]%'UFO_._O8>RI_P J^XXC_A3O@3_H!?\
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MNNWHH^LU_P"=_>P]E3_E7W'$?\*=\"?] +_R<G_^+H_X4[X$_P"@%_Y.3_\
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MX]Q8'_"C_A9'CT<&U.?>Q->V7\CQ6,CQG:PQ@_B*L4<R[!RON>%_\+)\>?\
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MV?E7Y?O<'KP.]'-(.6)QO_"M-8_Y^;'_ +^/_P#$T?\ "M-8_P"?FQ_[^/\
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M?48)KL7D=M<I>%"9KUT6,!O]68MNTY'?.:[%=/LEBCC6T@$<<GFH@B7"/_>
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M=,X)Z<&F\0U>\OZ9'+!?(I>&] ;PY:W%E#=F:P\TO:0,F#;*>3'NS\RYZ<#
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M,G=HFHHHK(L**** (T,1GE"8\P8W\>W%25#' 8[J>4G(DVX'I@8J:@ HHHH
M*C0Q&>4)CS!C?Q[<5)4,<!CNIY2<B3;@>F!B@":BBB@ HHHH CA,1\SR<??.
M_ _B[U)4-O 8/-R<^9(7'MFIJ "BBB@ J.W,1@4V^/+YQ@8[U)4-I ;:U2(G
M<5SR/KF@":BBB@ HHHH CMS$8%-OCR^<8&.]25#:0&VM4B)W%<\CZYJ:@ HH
MHH ;(4$3^9]S:=V?2B,H8D\O[FT;<>E),GFP21@X+*5S]11"GE01QDY*J%S]
M!0 ^BBB@ ILA01/YGW-IW9]*=3)D\V"2,'!92N?J* %C*&)/+^YM&W'I3J9"
MGE01QDY*J%S]!3Z "BBB@ HHJ*YG^S6LL_EO+Y:%]D8!9L#.!GO0]-0):*HQ
MZQ:2Z$-75\6A@\_<>H7&?S]O6JB>)K5U;=;W,973QJ!5E7/EG/'WOO?+T_6L
MW5@K:[D\R-FBL6W\30RO9?:+"\M([X@6\TP0HY(R!E';!(]<5IWMY!I]C-=W
M;[(84+NWH!3C4C)73&I)JY/1659Z]'<WL-K/97=E+<1F2'[2B@2 =<;6.",Y
MP<&I)=<M(M>@TCYWNIE+?( 5CP"?F.>"0#@4O:PM>_D+F1HT5AR^*K2-IG^S
M7;VEO-Y,MXJ*8D;.#_%N(!X) (JWK>N6>@:>;N^+E>BQQC+OQDX'L 3^%+VM
M.S=]@YE:YHTC*'4JP#*1@@C@BAW6-&=V"JHR6)P /6L4>)XGM6NX-.U":R )
M^U)$NTK_ '@I;>1[A:J52,-V-M+<OZ5I-EHE@MEID1AME9F6/S&8+DY(&XG
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M$\I0D>:_3Y3N/MQ712:/82Z-_93VX^P^6(_)#$?*.@R#GMZU*+&W&I-?B/\
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M0,Y1BK$MMY![=:UZX+Q#J,6DK?7MPKM%#(Q81@%CEL<9(]: .A_X23_IU_\
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MR>_^[5NJ]C$\%FD<@PRYSS[F@!=]W_SQA_[_ !_^)HWW?_/&'_O\?_B:GHH
M@WW?_/&'_O\ '_XFC?=_\\8?^_Q_^)J>B@"I;B>*!4ABA*#.#YY/?_=J3?=_
M\\8?^_Q_^)I+&)X+-(Y!AESGGW-6* (-]W_SQA_[_'_XFC?=_P#/&'_O\?\
MXFIZ* *TAN7B=7AA"LI!_?'I_P!\T1FY2)%2&$JJ@#]\>G_?-2SH9+:5%ZLA
M _*B!#';1(W54 /Y4 ,WW?\ SQA_[_'_ .)HWW?_ #QA_P"_Q_\ B:GHH @W
MW?\ SQA_[_'_ .)ILAN7B=7AA"LI!_?'I_WS5FHYT,EM*B]60@?E0!%&;E(D
M5(82JJ /WQZ?]\T[?=_\\8?^_P ?_B:? ACMHD;JJ '\JDH 1"Q4;P W< Y'
MYTM%% !5&_OY;"/S&@1T+;1B0@]/3'M5ZLKQ#_R#T_ZZC^1H @_X23_IU_\
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M_P#$T;[O_GC#_P!_C_\ $U/10!!ON_\ GC#_ -_C_P#$T;[O_GC#_P!_C_\
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M/_?X_P#Q-&^[_P">,/\ W^/_ ,34]% $&^[_ .>,/_?X_P#Q-&^[_P">,/\
MW^/_ ,34]% %2&.YA\S;%$=[ESF8]3_P&I-]W_SQA_[_ !_^)I+.-X_/WC&Z
M9F'N*L4 0;[O_GC#_P!_C_\ $T;[O_GC#_W^/_Q-3T4 0;[O_GC#_P!_C_\
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M_C_\31ON_P#GC#_W^/\ \34]% $&^[_YXP_]_C_\339/M4D3H880&4@XF/\
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M:%KVG>)-)CU+1[E;BVDXR."I'56!Y!'I6C7CO[/,%VFBZS-*&%I)/&(<C@N
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M8P&!.=P(^7UJ8T8R2=GU_!:#=1IM7['6Z+K4&MVTTD$4T$EO,UO/!<*%>*0
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M>&;W5IXIO/&H3ET1DP((MS,(AR<C<['MUZ5T,EQ!#+%'+-&DDQ(C1F +D#)
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MMT%RM-LY"PO9H]&32HX+R'S;N=;^:VMGD6W^<EHX]@;&<X![#)ZUL^"9+?\
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M_?F7_P".4?\ "_/%'_/AI'_?F7_XY1R,.='T)17SW_POSQ1_SX:1_P!^9?\
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MRPCD>Y8P[BQVIM5\=.Q7%=90U8$[A6_H5M!-8NTL,<C>81ED!["L"ND\/?\
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ME:@Y%M"#_P!<Q3IX//\ +^;;Y<@?IUQVJ6@ HHHH **** .*^+__ "2G6/\
MMA_Z/CKYAKZ>^+__ "2G6/\ MA_Z/CKYAK:&QE/<****L@**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *MZII=YHNJ
M3Z=J</D74!VR1[@VTXSU!(/!JI7KGBAH+35?B#J+6-G=75M<V2P/=6ZR^5O5
M@2 P(].#D<#(.*3=AI'E]AI-[J<5W)8P^:EE ;B<[U79&.">3SUZ#FI[7P[J
MMYJEGIUO9LUU?1B6WC9U7S$()!R2 . >M=[)INGR/<WITZS62X\'?;RB6ZA$
MG\T+O5<84X'8#J?6KZR?VOX_\%V=_8V,]E-IEK+*IL(0&8PO\N0OW<@X3[HQ
MP.*7,.QY"P*L0>H.#5FXTV[M=/M+V>+9;WH<P/N!W[&VMP#D8/K7HW@;P^UQ
M+HMCK-KHB6>HQR/Y4EN9+NYC;=B3>%;9@C@AD''.37,>(/\ D0/"/^Y=_P#H
M^G?45M#F[2UFOKV"TM4\R>XD6*-,@;F8X R>!R:2YMY;2ZEMKA=DT+F.1<@X
M8'!&1[UZ1I$?]D7_ ((M](TJUNX]1$5S<W4EHLTCR&4AU#XRGEA0?E(QU/>K
M>E:3*_B:$7UIH8L=1UBX4+=6S37-XGFE'VD*VP+S@@H 1DG'-+F'8\O^PW/]
MF_;_ "6^R^;Y/F]M^-VW\N:@KT;4'GL_AK<Z;806\HB\0W%FH-G$[^6(A@Y*
MD[NOS_> '7 XMWGA_/A?Q'!JUOHD-UIMM%)'#IUL1):N& *O+M^;(SD%V/>B
MX6/+J*[+P19Z>=!\0ZG>Q&2XL8X?*(LTN_*5F;?)Y3LJMC"C)Z9SBMFR@T;6
M=9N('T@VFESZ2);W4)[%+8VTBEMMQ$JLV%8A5V*<,2>*=Q6/-**]5O+2+3K?
MQ@T/A[3\Z3%9I8![5)OW19AYY./G++\Q)R/7(%/L-&TN\FT[4=1TR&+47T&>
M\DL;>T1@TB2A8Y!;Y56)0EMO .VES#L>3U-:V=Q>R/':Q-*R1/*P'9$4LQ_
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MH/\ A&_^GO\ \A__ %ZT=.L?L%NT7F>9E]V=N.P_PI#+=%%% !1110 4444
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MBS223&YLYQ]:GH **** ([@,;64)G=L.,=<XHMPPM8@^=VP9SUSBEF?RH'D
MSM4MCUP*(7\V!)",;E#8],B@!]%%% !4=P&-K*$SNV'&.N<5)3)G\J!Y ,[5
M+8]<"@!+<,+6(/G=L&<]<XJ2F0OYL"2$8W*&QZ9%/H **** *]^'-C((@Q?C
M&WKU%6*ANYS;6KRA=Q7''XXJ:@ HHHH *KW@<^1Y88XF4MM]/\*L5#<3F#RL
M+GS) GTS0!-1110 4444 5[P.?(\L,<3*6V^G^%6*AN)S!Y6%SYD@3Z9J:@
MHHHH **** .*^+__ "2G6/\ MA_Z/CKYAK[&UC1['7M*FTW5H/M%I/M\R/>R
M[L,&'*D'J!WKE_\ A4'@;_H!_P#DW/\ _%UI&22(E%MGS#17T]_PJ#P-_P!
M/_R;G_\ BZ/^%0>!O^@'_P"3<_\ \75<Z)Y&?,-%?3W_  J#P-_T _\ R;G_
M /BZ/^%0>!O^@'_Y-S__ !='.@Y&?,-%?3W_  J#P-_T _\ R;G_ /BZ/^%0
M>!O^@'_Y-S__ !='.@Y&?,-%?3W_  J#P-_T _\ R;G_ /BZ/^%0>!O^@'_Y
M-S__ !='.@Y&?,-%?3W_  J#P-_T _\ R;G_ /BZ/^%0>!O^@'_Y-S__ !='
M.@Y&?,-%?3W_  J#P-_T _\ R;G_ /BZ/^%0>!O^@'_Y-S__ !='.@Y&?,-%
M?3W_  J#P-_T _\ R;G_ /BZ/^%0>!O^@'_Y-S__ !='.@Y&?,-%?3W_  J#
MP-_T _\ R;G_ /BZ/^%0>!O^@'_Y-S__ !='.@Y&?,-%?3W_  J#P-_T _\
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M /%T?\*@\#?] /\ \FY__BZ.=!R,^<+77=7L;3[+9:I>VUONW^3#<.B;NN<
MXSQUI\7B/6X(6AAUC4(XF<R,B73A2Y.2V,]<\Y]:^C/^%0>!O^@'_P"3<_\
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MQIEKKFK6,T\MEJ=Y;R7'^N>&X=&E_P!X@\]3U]:^D/\ A4'@;_H!_P#DW/\
M_%T?\*@\#?\ 0#_\FY__ (NCG0<C/F6XN9[N8S7<TD\I 4O*Y9B   ,GT  '
ML*T4\4^(([-;2/7=36V6/REA6\D"!,8V[<XQCC%?1/\ PJ#P-_T _P#R;G_^
M+H_X5!X&_P"@'_Y-S_\ Q='.@Y&?,\]Y<W,4,5S<2RQP+LA21RPC7.<*#T&>
MPJS;Z]J]I,DUKJM]!+'#]G1X[AU98LY\L$'A<\XZ5]'_ /"H/ W_ $ __)N?
M_P"+H_X5!X&_Z ?_ )-S_P#Q='.@Y&?.5[XBUK4DC34=8O[M8W$B+/=.X1AT
M89/!]Z;=:]K%]+!+>ZK?7$ENP:%Y;EW,1'0J2>#QVKZ/_P"%0>!O^@'_ .3<
M_P#\71_PJ#P-_P! /_R;G_\ BZ.=!RL^>)O%GB.YMY(+C7]4EAE4I)')>R,K
MJ>"""<$'TIP\9>)P,#Q'JP'I]NE_^*KZ%_X5!X&_Z ?_ )-S_P#Q='_"H/ W
M_0#_ /)N?_XNCGB'*SYAHKZ>_P"%0>!O^@'_ .3<_P#\71_PJ#P-_P! /_R;
MG_\ BZ?.@Y&?,-%?3W_"H/ W_0#_ /)N?_XNC_A4'@;_ * ?_DW/_P#%T<Z#
MD9\PT5]/?\*@\#?] /\ \FY__BZ/^%0>!O\ H!_^3<__ ,71SH.1GS#17T]_
MPJ#P-_T _P#R;G_^+H_X5!X&_P"@'_Y-S_\ Q='.@Y&?,-%?3W_"H/ W_0#_
M /)N?_XNC_A4'@;_ * ?_DW/_P#%T<Z#D9\PT5]/?\*@\#?] /\ \FY__BZ/
M^%0>!O\ H!_^3<__ ,71SH.1GS#17T]_PJ#P-_T _P#R;G_^+H_X5!X&_P"@
M'_Y-S_\ Q='.@Y&?,-%?3W_"H/ W_0#_ /)N?_XNC_A4'@;_ * ?_DW/_P#%
MT<Z#D9\PT5]/?\*@\#?] /\ \FY__BZ/^%0>!O\ H!_^3<__ ,71SH.1GS#1
M7T]_PJ#P-_T _P#R;G_^+H_X5!X&_P"@'_Y-S_\ Q='.@Y&?,-%?3W_"H/ W
M_0#_ /)N?_XNC_A4'@;_ * ?_DW/_P#%T<Z#D9\PT5]/?\*@\#?] /\ \FY_
M_BZ/^%0>!O\ H!_^3<__ ,71SH.1GS#17T]_PJ#P-_T _P#R;G_^+H_X5!X&
M_P"@'_Y-S_\ Q='.@Y&?,-%?3W_"H/ W_0#_ /)N?_XNC_A4'@;_ * ?_DW/
M_P#%T<Z#D9M^#/\ D0] _P"P9;?^BEK:J&RLX-/L+>RLT\NWMHEBB3).U%&
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M_OE47<,K6\[(,!V4 [@.V0P_'->87'[/>M#466TU>Q:RS\LDH=9,?[H!&?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ$@_A4E-D<1Q.[#(522!0 VW8O:Q,QRS("3^%24V-Q)$CJ,!E! -.H ****
M*]_*\-C(\9VL,8/XBK%1W$RV\#22 E5QD#ZU)0 4444 %5[N5X_(V'&Z95/N
M#5BHYIEA\O>"=[A!CL30!)1110 4444 5[N5X_(V'&Z95/N#5BHYIEA\O>"=
M[A!CL34E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2"3N&,< <8XJ31-%M= TM+"QWF)6+;I""S$G/) 'T_"FR^(=*@\/IK<EVO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]^I/_BZ]5;PQX:65$;0],#MG:/L:<XZ]J?\ \(IX>_Z .F?^ <?^%'U;%_\
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MI/\ XNO6/^$4\/?] '3/_ ./_"C_ (13P]_T =,_\ X_\*/JV+_Y^!]:P?\
MSZ/)_P#A<_B'_GSTS_OU)_\ %T?\+G\0_P#/GIG_ 'ZD_P#BZ]8_X13P]_T
M=,_\ X_\*/\ A%/#W_0!TS_P#C_PH^K8O_GX'UK!_P#/H\G_ .%S^(?^?/3/
M^_4G_P 71_PN?Q#_ ,^>F?\ ?J3_ .+KU6/PQX:??Y>AZ8=K%6_T-.#^5/\
M^$4\/?\ 0!TS_P  X_\ "CZMB_\ GX'UK!_\^CR63XR^(WB9%MM.C+ @.L3Y
M7W&7(S7$SZI?W-Z;N>\GDN2<^:TAW9^M?1TGA'PY+$\;:%IP#J5)6U12,^A
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME_T/?_E'A_QH_P"$=\9?]#W_ .4>'_&NNHHYF%D<C_PCOC+_ *'O_P H\/\
MC1_PCOC+_H>__*/#_C7744<S"R.1_P"$=\9?]#W_ .4>'_&C_A'?&7_0]_\
ME'A_QKKJ*.9A9'(_\([XR_Z'O_RCP_XT?\([XR_Z'O\ \H\/^-==11S,+(Y'
M_A'?&7_0]_\ E'A_QH_X1WQE_P!#W_Y1X?\ &NNHHYF%D<C_ ,([XR_Z'O\
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M9_9L?^KQ_J]F<=>=W7M74T4786.1_P"$=\9?]#W_ .4>'_&C_A'?&7_0]_\
ME'A_QKKJ*.9A9'(_\([XR_Z'O_RCP_XT?\([XR_Z'O\ \H\/^-==11S,+(Y;
M_A'_ !-]CV_\):/MOF9^V?V;'_J\?ZO9G'7G=U[5%_PCOC+_ *'O_P H\/\
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M1=A8Y'_A'?&7_0]_^4>'_&C_ (1WQE_T/?\ Y1X?\:ZZBCF861R/_".^,O\
MH>__ "CP_P"-2P>'_$R^9]M\6B[S&1#G38X_)D_ADX/S8Y^4\'-=311=A8Y'
M_A'?&7_0]_\ E'A_QH_X1WQE_P!#W_Y1X?\ &NNHHYF%D<C_ ,([XR_Z'O\
M\H\/^-'_  COC+_H>_\ RCP_XUUU%',PLCEH/#_B9?,^V^+1=YC(ASIL<?DR
M?PR<'YL<_*>#FHO^$=\9?]#W_P"4>'_&NNHHNPL<C_PCOC+_ *'O_P H\/\
MC5O2M%\2VFIQ3ZGXL_M"U7.^V_LV.+?D$#Y@<C!P?PKHZ*+L+!1112&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img61678762_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_10.jpg
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MQ2GBE=6??T^M2ZI9)<;ZAC,2(+&)/MOB#&,L]<$DRZ[YSKKI]#74[77;&?\
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M*1<M6"D,6A2.R[[?.$80:.4B;78UV9-M'%'MMI"GQOCY11[8Q7PWX$?NR/\
MTJ.,K^1\?@?Y^?ZXJT'I30^G<^4W("[U@VOI7)*ELCP>0%J5D^.(D1IK*MC*
ME.%S,-JLSC8L8;_FNVN/KSG&-8N0<8J: C.?']?*KR>0J=/%*>*5J.U HFYO
M[+>DU'9CET?9/S]JVFV-_D355&B:/ORLA9G_ '3)'#"F/:?<_.,511KB)Y!(
M]8<*5J%XJ/$JS50[G=Z'0HZSPU(SMR%@915+;^FZFL+-V9[*G!#)S3DDJY:L
M^[##6!8C=]188 X9)=88O%,UC.53<%[0GH'M7S*N4VPYZOSRKV^C]>_@L*6[
M/N>W% $XK<LC-ZC5WA<"P0GAR?I'.@)8<4F S5XTT<D&BJG(R#\CS^8KB7+H
M' O5I=1@WL=>Y:K[/VVK<LJ 57I1D05J[5UP\@="&:)2T)40C.TG@S?L+4^B
M"5QR1:S/'0VNT<FR@!/CY G]PY-;^?RSF+2N,Z<SYS0V-1=-)'CFK'U"OF5Q
MLZF,C8S.&:,A?(L/:2L(HCI&!0LI<AD496TV9]-=\*I7%:<>Y(\4BH77+><M
MT85@FM@:9I2*RP4B6DB:0F>RBKBUDP<%@G(FFGF<Q0Z,9)I9)=R=M]]MLJ5Q
M+VLY)4<MN]7JKU*!IS"FV)P9TDJHA-[?5Z8E5L&]AT5MQ%1UIT!C6QL)YE*;
M:20WZYH80R)I_M2*<^*PW+(N%=1YG0^G\QJ]+:<XZGRM4YI34>C"HHGO)^I
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MD[4;G&HR35"I\TO#JJ/QU<L,S&I!5U=H2+E/ON=<%VPQ]FA*8V'W>TB%(5.
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M'[MG&S!J;073 QX10L3Q.B>XC[(NRALDDY>61F^I<XP, /A@>X3(Y:1)$9^
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MM(D9=3L+>*\A-G.[RYMIB]RDQ5XWA5<;KDQ?U@]S8F]O7BUI(9S6MXB34O\
M*-# L 9GYI8L0H&^S9A$P-F'@CW)U(%'S'"K%*Q)G'UQ1=>J?6?4+K5#)I\D
M^AV#NMI'++;S*=N&E@@CMWCN&;X<;UD=-NT;2=YK<Z7-Z.?H%:%H_3;VW4FI
M_P#&==7=QJ?45S!;P6?P]K=/;&+5Y)+@C38;2*[G>UALXKF>6&&XD, <1QOA
M.:W;O?LM0+1S$(;*]9S"R86=!2J&>@3,M@Q:2[[JI+4M!+&"8 9C:RGP*2@Q
M!%X:N$S8O]B4-Y[WZ6ZSJNL=._ ZCW_BM&NDMFFD@%N9E0%46-,Y/:3;&2RH
M3L+#Y$_EM^F3T'TUT=ZEVFN]$-#-TMUMIUIU):Z?%J(U"6TO1<F[NVO)'6)(
M_C))I+FU1&D98IE29(74HN_>T5VL]'Q03><QVDB("BI$-B:5*94@B(;A'Q*1
MC-)%,ZG<[?[XI1*^ @(;0C8'61?/B.33Z>,]=_UG81Z!?:?JDUE:R"59Q!/+
M&HNHAF,R%$;$>_'&?</*^*]]_P"#E@].NJ]5]1] ZMZ!L.K=3'3^@ZC9W=V%
M$L.EQ:C=V&JK:6_<6-O@9;M4DNB%F<QN&#;5+=9_9?8GHG2GYUSM=LPN85,.
M6K"P$#D%GB"P"?DB985%>+)$4ZL+$@47+DD+4<" 00DLN3(Q&)//9KWJCJ;0
MM-EUK4._IEN&2-H@0#+']HLTK; '3#! Y);<-NT 9KZHTG0?1?T1]5>IM/\
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MC/V3,8B[,H=;>)25!<D[9+B4J22RB-B,$9%,RNR*S./M HE"*K%&GE8 D(%
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M50 /!2A5<Y4;8&=(XH"0NQ&*I!N8NQ)>90S$KW8E$<7*.=Z['(+%@0M2DEF
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MY!)]?D$6HT&D7U9SK%K\OJWVSGY8Q_?.<[;9SGY8_P#KVSG/R_OMMG/SSYO
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M6<87Q+VU6DHQ8<]LOYP\=*WN*#H$5071GVLK5-5P;E64K]2@48!5)C!I\*1
MH&+*$S!70-(0,JV:@/$82#+.P[/>2X[*[I3LB6:-)$C3:B$>P ,P/23^J77M
MS+#--U!*TL%Z-1CD6QTN-CJ L+G2VOY3%8I\1>2:?>7%K/=3]R>XC=>^\C10
MM'LUB]=O5CV -MUS85RM7MH_LM.ALMOJMV>P-!+EP@VSJJKJ%8Z79@3:I:N>
MG62V*)]D)J=R+*S:JW.9<9D'UNR:?IE^TLS1QSL\D0DEBFD#+-8F5(MLD,BM
M%+ TDJ'84<%F5\\BL.TZKZTZ7CL-/BN[S38;6SOVL["]TZV:%]/ZE2SGO3):
M:A9R1WMEJL=I8W"_$QSV[B&":WQA7.K,/AZ>G+-2M2$\461K4P-R5J8 +3?5
M4BU9T*PYM-X6A%J[4&8,OM+K:>9T#$1J*:$8P3RQ93L3@"+3:!I#(L9LUVHL
MRH%EG7:L\G<F4%900LKY+KG#*S(1L=E.=%ZJ]?PSS7"=13&:XET^>=I;+2YA
M-/I5I\%ILTD<UC)&\UE;A5MY"I>.2.*<-WXHY4W6P>G'K-9A7@;3DJ+2)_#R
MV G=.=8*V6MQQ-:T3\HGJI]<<*CJ2=15#MLK1,:<0B/A7L"@Y29AY<Q^7I-(
MTV0.K6J .+4'8TD97X)62U,31NC0F!&94:$HP5BI)!Q6MM>O^L+-[:2'7+DM
M:MK3(+B*UNTF/44L-QK:WL=W;SQZC'J4]O!-<Q:@ES$TL22*BNN:F'F_-J-R
M&E(N=\WK@-3IE;A(@3HP-B981_S3261Y$Q1LY1YY[)D88R9LV)9;%DQ+*./*
M(+(FFWR[:V@M(4M[:-8H8P0B+D@;F+,26)9F9F+,S$LS$LQ))-:'5]7U+7=1
MN=6U>[DOM0NV1KBYE"*S]N-(8D5(U2***&&..&&&)$BABC2*)$1%4<P"^49I
M4R;ZLN=38T8(9V:9<P+$G,J8@=:(/$L99-B',D3P#5\M6S%=SRF:1*B%Q\)^
M\$@A&L<EG@>(SK-$T #L9ED0Q 1EA(3("4 C*L').%*L&Q@U;ETS4H+Y-,FT
M^^AU*1[>./3Y;2>.^>2\6)[2-+1XQ.SW230O;JL9:=98FB#"12<\L9K72U>X
M3L 6RAL"(S5-5A<!ZUFM/@C*!8+SA9)13 3!98B1"QI9("()(YH9-X]]=LS5
ME=5=&5T=0RLI#*RL,JRL,AE8$$$$@@Y%8LT,UO-+;W$4D$\$CPSP3(T4T,T3
M%)(I8W"O')&ZLCHZAD8%6 ((KG>2JW58_<&E]SOWK[?ZWZW7@/GG925F":59
M&/W8U^K,&>(S"LTP?24I4.\B@D3R.182)U>IN2]1Y]8]H\ZW5K6YO;&:WM;I
MK.9QE;B/F2/;S[!XR?\ M<<8/!-=+T?JNCZ)U'I>IZ]H4'46EVUP&N=*N)7B
MAG4C ,C1Y)5?F,$D'@9K_/'[95)ZU8I^46[DEKXM[8QVRTL>TE6YHLPD:RO"
M<%SF+GN\#'8R##/?+0%DD"QNW6N"BA&.1B@MH>9EDT/2-$TB\UVXZ@U;7=#U
M*2<21VR(]T\A86\4DD?F!!V1L+%1C<1NR:]@L+;U,ZVZ^ZUZ9].]*]/^CO2S
MU#Z7BCNK)M6CN!IL-MV3=ZO!:W4@BAU662VECFD>./\ Q>.)BYVBK-T_FG9/
M5WF!5YLBRDGGW27]<9'T>+1S9JQ$!#K_ !S2 >8$1P^8X7EPSK%46V%T!)$$
MDY<&<%9#]FZ>U?5+WI^34;^SCN)+@=ZQL;E!O3"G; X.26()'.%SD$Y(!_/?
MU5Z.Z5Z:]3K7IWH_J2Z?1-/GCM=8ZCT>16L;B]#_ ./7$-S W91+$;R1O ;*
MM%NVBJ9.YD]E>AI^1/EB'JEC8Q78QBRKWZ56%@?:3)09J19^4M6Y.V^YN4O1
M@@Z08S.3B#>7[^2/E/7KHW_4%]<:SIJ6%H;KX.>" +&MM(S;Q<RA/O*RR %4
MW#$?@\U^X'IOH*='^E&EZ+T-UI<]7]5V^B+U5INJZSV;I)M-%E;/)I$4RM-(
M6N<F.)9&61#<DN(TR:WI94H+,TULUUNU!ZRZHZ>PK6G)!JDV7?J")%N6C$^Q
M#V(A:Q!AV9PC)6)2(H? )!HAD!I^FT@\G6'3>G^AH-.U2QO+#JF/5'W2V,[J
MGP]NF7DV(!A=IRGN"O\ -N<UXI_A)ZJ?I/:MUAT1U-TWU'Z$:ET=IVG1:5U7
M;WS0W5[JKWDLS64K7,/:EL9HE20BTGN(GC[95FVH:U?L/JW95953<H>2(;C6
M^G@Q,%5K02V]M6: SUB6I3J^3,ZLI14506/"LZCVMJ8"A!-U9X CU%%%^]M]
M5Z6GUP6?4?2D;0Z7J\8FDLDAC[5C<' E5)0-Q5AM//MP/;Y(K@>B?6G1?34=
M5>E/K=)#U!UMT;-.=+ZFNM7&L7&LV9ACN;&W33K.2-&DD54<*6?MNR[XU9<5
MNEO]6[5RVL#Q=@[0/6*R2BLTB%?SZU/+(ZL_0%40A^B1T7#"2<$D)$GG8X>)
MX<[#0[;1?BXQ],<V3#Z43YGO)=1LTN-D)MY9(@\49[:]Q9(P"6.[<,$-X.!C
MFL'4OTZ898-!TW1NG.L(;"YOVL-=MUUZ&PU"6.X=YUG;6Y+<Q01*'41PL(I+
M>/9;,6:-F.0HM/[29Z5A":U]+=N5 7IET![7][K*;?*JDRN&-P"Q@E,5B*UK
M95)EA+/))*TFF,_*9+1Y#2!HL[4[;6=.].(]/73F-O/J,UU)=0-(W9M_,:F$
M89(WP1C;M7YBN4Z)ZFZ ZC_2S/63=9PZ?/I73\.DV^@ZA-8WSZS>M;O!<0_K
MF=XA-(O<7+,K+*<*)"6!&IUAGW*61A7%6VZGDY*]=)+%BQ:+73.+64D1.$Q7
M$G_IS)!&0R>"SL/J.@7C:KRAB8RCP!]?$+:Y^ @4VM_JMD]Q,8B(IW6U"L?<
MYB[JHS9SPL>?D1BOT1ZCT.RZMU*+3]?Z$Z,UBUTG2+*:"^N;."[ZGL#;P?$]
MFPF$B(THF9K>2.28Q11'[-E.57_0N]'-;-KZE\"WM]]7].?E<SK)YMY5;ES+
M7F&(6#1OP2V$<+ \9<)..JB8L8HF##0'4XZ*,LB;7'O^BI*FEV*RW'Q1%M#M
MG*E6D3MKL=@0#N8<G(K\P>OKFVN^M.I[BTTI-$@DUK4"FE1@"*P_QF0-:QJK
MR*JPG* *[#CACYJ..Y5+JM@Z,S4I(K8]KQHJ\X .&8W*$+2<?6 @>3?>2)0/
MO^<,5OC$V^DF8MH\[9VQC&WFY4J!\L\Y^M<8P8GYXXQ]*T6+U_:*X]";_<:?
M0Q]M<;9'8-(3VV<9_P _L@#2QCDYQCY_+6!AOMMG^V,?+YYQ7=] 3_=_&J;?
MJ0/W\_PJ'&0'J-SHXJ$[/0NN.89=MM@Q]<56L:;;XQ-''F7ZEC?$6-=]<8DA
MG91R8^7RT^GYYV>\_1?YG_P_NI[1]3_(?E5OO5KJ5,ZDKO-$5<Z1T1"K@$GA
MKJ\K<[5LN=:%@M"&!.PP>Y)6F1@X9R,Q:RYT)@U^[MF/&VL&!&#DD_7^ZIJ0
M<C&!_/\ 'FL1T;U7,!Q,SYR1L>+KC;?:MGRZ:'0:8_O]"P[?[<)>FF/[1C%_
M8(UTUQC4DR;;&N:A_D?X_P!>/Z\50I\Q_#^O/]>:BBG]=O7-)9JTY$D;HX<[
M!L:?9X9<?CQ9Q],@PV2HMR%WSTSG'X^\4X.V-\[;@R;;8WQ(J#S\_J*B&(X^
M7T-;]-S_ )AU^*1ARYK#4K9M'O.31G6WVA9Y-<9WE_6YUS+M%'\_JVQN!L8'
M'I]O20)9C;/TTR5\\CZ_U_O_ )U7"MXX/T/]?U]!4>5TWKW([8*@7C,ES-D;
M /'7S8\E)GLLTN@\68H\2?AE:2;[:188+R(YHL?/3!<7RWQBIVL,_P _I_7T
MJ@W X\'^OW5V?B_E9%&R;B#!GX\/Y>!L[Y&P5]O7[^!\R_ZS,&)?K^UF3_']
MOZ?K_P 7S\LU>K@6 %BT0NUBAQ+7FS%0R!5OX!!SYT;$L.8<)Q""7_LALJPF
M2(V,0K_9R-X,0S?ZO?;Q2NH+EGP1/4[AV?5>W<B+N%,[QZS=!K?0"^^:-F3B
MY]BG_4O$W5D-_5MVI5;@3=J#LKG^8?QY:K8#23C[+C=-8)-252+D[L^&\CY#
M'C'TQ_=7. ^#ER,7C/'.)D]9Z(57N/\ J#[>>GH;/1?7!FSRH>X$*H>VVLO;
M\284.QU2-5IFNPP#R+9Y)MMF8\^NN-,J!L<X_:#?PSQ_.L;9?@]I+N@:#6_V
M=ZF3=G'/?3*@D]%K]1YY7G0/^A1U1_U#G=D2J,J&E<"=-"'(R=CJ:K:+X84X
MA^P9I,YNLZJ[OP'ECCG]H8-9B'X3$(C2+LH7M1U07W,']B+-['0^TNM)Y=+/
ME]:^0!\!:T2?D$U=DYY+S>3D2X"OZJ<01OHVXVM@@LL.^V0,*IN^6/;C&,GZ
MYSGZY_EQ6JR?!;HR)$L$Y;[-=LYM;;%Q#N/ /83H,"7F-IL?L%1_8?HSSK_2
MC'@UAJ!".C6LCI%GL31!8*.L6S5Y(X(KX,'RA"8BJKO/S (R"!\A@8^OC'!'
MSP*XUK^"#PRWTAW56_2;(T.D']&RJFPM%%YW=Z\@LWHMR*P<7I;2P<^MZ5Q4
M>@(N@U"UV(6_5"R@[K"-&DL:N<&2$<B)3><#_P#Z^O[6,_W5@^I_ RY'U#B?
M,N(E=6%3(J2FZ,M=%*_6+U66:$..GVG2U/+_ ,K75KE=:CX1T91OI$BK%GHA
M.=($ "C2R+;2Z7Y>$JH'(.1YX^9^7UYY_?FN[.L(!JI6J]5PBV9X=;1J4 AS
ML^9JY-&3@#KH"VS0G.2&3,B(?28\^?.9C"MY2)<YWDV\5&LYXI3Q2H_Z1S\/
MI*=(B9,)PERJ^<]O14,$,4W[2;G%S27Q.JGS+G&(@R+!75,IF^F-]]QH)!_I
MSI/OG%R.0QEF R3'(G/R$B-&Q_/:QQ^-0D02 *3@!T?\^VX<#\MRC-53LWHI
M3;,\)>&V2 TBPD]!BNV]BH]9MA#-)?NJV7J$X%9R^U*7U=@OULYE(_9F*[,*
MPJ BJ I1AJI6-!,A;QU7 7&WM[-KLF&CB6,%MN"V=@? *D/G!P2*QFLT8YW9
M+;]^Y%;<KR-(0N>%(W%,D,-@'MR 1C[!Z')+0_;/G/1#B2_O=(+JQVU34D6!
M29>K2KM*;9^_9G,2+*KY[HM_AM3K0D%;K,?/29*T4HE)TT<^2%ZR@ 1@ B,.
M-Q"L$4J=H&-IDSO=LLW<]P/.*HUF&8DR$X[FWV@D;V##).=P3&Q5&U=AVD?.
MIT6<)9CT7N-=8]+L&]Q[PR?.K#T2N #51M6VS;GM9YPMEIH@91>Z@>K(ZFGP
M@^^S-:1;C_D&MS6<A#2>R9P7@81KL@"JL;996 D:0A\_>W,YW< <\ # J\(3
MLF4R-OF)+2*-I4E%C!3!.-H4;>2?J2>:CSG'IZEH-XUZ%_)P2'NEB,MHX"*D
MJZQ6EU@SS"3EJB=<LC8M&&1DJAQ=V$67+ETX-8WEY^<ZE'U&BTG)=L\?;VD+
MMVDLY9B.Z)3DX R2J#@  (,#)-0CM0C[]P+9W85 JANWVP0,DX +GDDY<Y-:
MK!Z*)Q:UM4A^FV")0,EKJY,3JD R^7'U[UIMGKB,RG:;&;0LH]([:?TX(.==
M'()T"8X^8XT8N" "?QIW;S&I.6+<G!#7*W!&,<?=$9(/,>!@8.8?!C;L[C;0
M%"\#<"MNT&<_/[QDQ@?:9.2#@;>+ZJ- 7Z'H8O4M]NK5;>OJZ]9BZ.MDJP5'
MJE+O%&05*2C!N -=]@@NC7&Q;NQ; "7O;G9<T, U0VUI>D#<@JT?;^R?)9=Y
MW;V='9]^/F8T7!4C8 /O^^I_#'<LG<^T7 5M@V[%1T"[,_(.[9# [V)^[[*P
MZKTN%K>,*JYU*PC5,^W<QZ3:5C:OHG+ZU])Y:P!>JK$PLG^P0B*W-L3I+N\K
MJU&+%FV+Y"E!ZE.R9(RJF[W<M$NX+)&NUF55CDR"H'.2%)0,2?:>06 :J"T"
M\+(P4M'(P*J2TD>"&)XX+ .P 'OYR 2#BJQZ%42J/*^:NL?W%:4/E\^V3Z75
M'%RS9^0\[JO/*8W57-Z*UPC6AZTFL77*H=#.RBOZV1Z#8PQ6354;5KUW# KR
M3)X=@FV61I'!08SG>R9W ;#@J2 11;)$((;@"/\ 94MNBC6-"&((&-BOC;G>
M,A@"09QX-PK;BD5MQFU:O,VPQ49,K35Z"ET\ U:,5$?8%]."9M%"RVW,HR1K
M?6B+"5-86T APU:43:%;&69Y^\5]NW;D LV]\'&%+D E4QA V2H.-Q&,788>
MSN]^[<02 NQ00.6" D!G/+E<!CSM%6"\L5?IXI3Q2GBE/%*>*4\4IXI3Q2GB
ME/%*>*5YL[GUKW5,N?<FW/M/;E-&XY3[Q@RU.R+NHV<JJ7VGS1D<*VKDT/(:
M/R^L.6HH9C#G:CCYMO()K9"N"SVQ_866FY/G<MWK#37K0?K5-]KK2F*1;F4Q
M31'-D8R+2&UB=ADVZ6C2DQE!)*\C<_7-AH?IY'I_3<&J'H6X:WUOTWE6^LY=
M&LX[[2[\%.I1=J^O:CK-Y;P/(D6K7&O16*+=K.]G8VMK 0DN.$7N)3[ATQFE
MZG[:V0/G?3O0)U15C?=HW1VJ'L#*O@^SD+04>JQ:V>JI@8RIV5:&EUJW,=I#
MRAEJ3>3>2/*9-7BGN66ZU61;>YT)X%;<R2_%L@U(,!$.Y$B@EH@>U;9)"IFM
M'!<] ZA8:/#<:)T+:2:MHWJ?;ZG- (;>YLFT&*ZDZ.,#M?'X*^N)"@BO'4WN
ML@1(\UP  >#6T/M;:K%BHSV+V2YK4I9/B86A@11 GU*W9.D':5)/ XR6L2#Z
MHMF*T@AC3=PY!C[8IA,'$*:)#FXYE(X]4ED,7<U&VB_]HI28%>$NZ7:FQR_;
M/WE):$C#2J" 61G#2NKKHFRM/CQ:](ZO?*OH_9QIJ<EKJ AM[KIV=.IRD#76
M#V956/4!(KQ6,[1O(D-Q% \>FV'IOO.PK*!J_;>UR/O!'KEZA-_5ZJ47G5B_
MIET7KKJLK"?8&+V%C"IQ=46M@K?L6-<$_46M/!J]/Q^S1BPFR?=ULR7.MF-&
MD?5$OOU?I+:9%!;2?#W-V\:F_P#C\0F)767(F2Y>%8H3N0 GC8VFD>FT5Y=0
MVMOT1<],IU;UY;]9WVI:M:?KG2="M[R=.EFZ5,M_'>RV\E@(WL)]%@U"6]OS
MV;EVC7:;M_$LN'9U0'*ZMRR+OBEG8*]UQGFT\8-O\->'NJ*LI]J56K*-RSE]
M[O#IXZ:G&34E2RL/..?D[+W1%U:MX!1!5^YZCEO$6UCM?CT:2.[;N69N.V)D
MB3LQR"UM9YGD=F)@1Y+>W.US,S@ +YUZ06&@3RZU>ZTW3$\-I=:#%\%U#'I;
M73Z?<WDXU&\LVUK6=-TVWMK:&.,:E/#:ZOJB"6W33X(&=Y):^\TZ5[%.>K\U
M*[R\]UDUF:T_TJ/Y#5N0<X.TYU<([)S2LE^QY/:86E5AYXG)5]++M8_2H>A.
M:W::751ETU%"B8ZC8EP+:YU![JW-\^LI*T.C-:16EN1;R]RVC.HF\#Q"W4I<
M&47(G>.6&( P+NQGJM8T?I2VT/5X^F;;T[N+."_]0XM>OM?U:(ZMIYM-8O(^
MD4Z>:&^?5;A9]'CL7T=]*M[RRU&^>9=3D,._;6YW+[.F\)74;ID?M=7:M8_5
MSW##H%=Y3SBY$SW7V0:^PG9%J&H=:3UREM9H*XTY(142ZV->(4=-8HCWKR)M
MH;#$?'K7.IM8K!<C5(XI-,U<6\=K;SDS:BVH7BQPW:10L1$UH86C$P2)HVDD
M#Y :NNMUZ-CZEFU+1ST1=WMIUIT#)JEWK>KZ>BZ=TC!TKT_-<W^A3W>HP*]W
M#KJWT=X^FM<ZA%<Q6MLT!C=HC+'-;'[54/V&]9:Y_P#2!?T7:O\ JC5)>7KD
MG6.?*Z'5B>+5-+?VC/\ )YO<^!]"Y]7WFKNQWXRRV7G?8*_8(I*FG."D!78E
MS+:34X-0TV/_ !]X.WI<7PRI=6Z0QFRB2X9LV\UA<6Z/OEG,DEO=QR Q(P*J
M:T>L6G1.I]*=8W?_ ++6VIB\ZXOAK,UQHFJ3:G>)U#?7.EP0[-7T_J?2M5NK
M8VUII<=G9ZMH%W:D7]Q'())MOH0\[VOEBO@3-H./-/)M'I'%'O))O-O]N+2/
M7&<[[R;_ "S].FFN,[;9SCY8QC/SSC']\,@<DX Y)^@%256=E159F=@JJ@W.
MS,< *HP223P :\8?QA:11NN^T](Z?S[N'.^X#O0-HP>;JU,UD@K+9$(D3+E1
M3FMV3]8[&8[0,7$.VZ[2RUK?$\NNI(#30KS7V_5^AKJND:(\%M?OJ5P8H]H#
M=F96Q&9!VW+C?@'!4(H).<8.WUKT+]3I.CNN?4K2KW4.DK?I'2[.:]%_+>:7
M=ZC9W+A67387@DBO8Q&=LR;D5E;!)]U40-O1Q71*^=T9VH<=>JUE$3<_]?6C
ME)6^.TZY,F,2#]MJZB8,[#B#[T2[*L646$>1N=LSD-6P0[:D[%_42WM>JTT"
MXL+M)K>[2T+) 5TX2LVT()@A4L<EERO*J?D<UR4/Z+6K:MZ*2^J6F:OT_+IF
MJ=.'JDJ-6$.KW6FB_,&HI!IB2A&O&>"7_%T5)-D;'N*,@U?D85.N/^J5[IY5
M<KUNM%L@*/*K!FQ.T)JB+;2<D2Z1R0LQ)*^,RS]2\4<\61/+D]@><(-!"+Y)
MZFK(G5-['%:RSVR7,+7=O%$6E; ,SR(I4AHY$8(K@C[16(!(X^]?T++VW'HM
MHEQJ^HZ9IM_*NMV6@:G>7<=N@MNT(--MM6C:5GANC]D[1O))BV6W<#$@"R,&
M@IZIRXQ4"KB=5&0,T\Y%IPGL#J<ANJ)7G2S.<"#C$"9BQ]\,G&-"!?L@31ZZ
M;11[Y\QUO5M.GOY9-%T\6D!5$^#N6,[P.JXNF)*Q;6FD)8IM';)*;G R?LGT
MJZ.ZWTWH]-+]3>J-&ZHZ@GN'OQJFB6\L$,MJS"2Q:[$,,/=6VM"(PI>_5S[]
M\@&3.1_MJNY]Q!7SAM5 VN(.?Q4^,0QM&V%<(I-?N&#R##P#29W>A0C2_>))
M80KM86.D&LWY>T OL6D^LNI66@Z;H.EZ+;6Z6L)@N)%8$2,X58WQ\-]F=VXA
M-QY/WN*^">O/^#]TOJ+KSJ[U!ZB]5+S45UB>XU704@MY%UPWL<DLMC8SM86(
MQI\$6RV0K;0O*$.^5B $K'T2>;FS!894=4%*:]Q0BD05C["P(X&@FB+M(,$-
M 8YQ*2LV'UQ*[:Q_2V9!?.%W*,9^.1C96G675W2A"=0:;%<6.KV\EY97>QGF
M1=[!H^SVSW<.2%977V@>SZ><ZG^COZ'>ML<0]+^I[S2NI>B'M="ZMZ3FM=;M
M]%O==%O<"_U6>>X@+*S7-E+*T3;D:2<NLD2;8JDZ'NU+XUHK9TH*S,+3T!/?
ME3\WZS[Q':F$@J;]W8*VMC@ KHTF)6A^H)P2&'(\ [04B8[&HDF*=0>I'4LN
MBVTFE6":/\9\78WEOJ'VCW,179'+';M!%V!<;@HY?M$9S)XK*]*/T3O2S3_4
MCJFRZ^ZEF]0YNE8] U/IYNCXX6_5UQ;S2W-WIFH7FGRSS3ZL!!;RO9$('M)Q
M.[!2(VPOK?3J^[]D>8\E]H:)9.<\@+8@U^ZW326JU6PRU+J+ *&BY?V$[%E0
M" Q[$B$60\7;]]H "2N_*4L8X)].+?1+73-1TG3NH-KI<R0W, @8_9331K,#
M*1G"@D*0<9&#GY5].+ZFZIUKT%U?U-Z81(]II4^MK-J\^G3?&7)2ZDM;G3K9
M)GC:,VY3:TB&8"53'M!&*_T1>9A41+2:Y6>;ZHAZ;55(-:KZVN3A3J5*M"-$
MK#6!_@22C:0@#C1#8CCWS]OZ/IW^6_S\]EB,7;586C9$ 0=L@JH4 !1CQ@<8
MK\];X7HNI7U*.XCO;AC=3BZ1HYW:X)D,KJX#?:$ELGS]:B3V4BOGZ>M34DRR
M:XG8EJV:ZM['?DFY*&U)"WDC6X_+VBBP$9%OCY_9VR1IK)KG.=?G?3'.<?+S
M_7Y5A/D8QQ58T?KIU>R2?DG+H$D<^WU[F6-AK'/OG;/SWVD%&P<RQ)_U$#19
MVV_MG;&/GG$RZC\?RJ&QOI_7]]2()Z*U5DRC:W*WN#=LPPZS+J\,*J@WDBSM
MC_6'FZLR)H]M/HCVS$,%)].F/IWTV_Q8B7^@_C4@GU/\*LWSKB?,^5;S3TBM
M0JSRA,A&-)BSV#(L;,L4^\,I1Y)&VD6\\$,NT ^((/N1:9Q%CZ<?*!)/DU,*
M!X%2KY2JUH-YYG3^AB?8L2O20J./.@C<3Z1FX7S^?R^P9KIMG>/&<YV_%*T(
M$VV_Q;0;;8QG%0Q'C^'RJA4'S_'YU13H/KY=:%+NX0;3V-*+O^1&P5QR1.%N
M(]OKTE+ AVWGU^Q\OJ_- WGBTQIF>; >/EIBZ&!X\?@:M%2/Q_$597UV<W*Y
M5F1I=MA&X"P_6&JLV >DCK8B"*6$\G\W;^TD<&LNH<1OV\FS2['13E;XCSKF
M#X!X_?\ U_7RJ:9(Y_<?[ZLIY"IT\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*>
M*4\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q
M2J_"]Z_9OIH$7-;Y8*2)<I*$9T),,J.616$8[]8?- @@9;V@VN*V/U!L;&.I
MV @WA)ECQ-!#F7;:-IFR(&6[MHKDV_Q*VDA=7,17N*#*4[*S.GN2(N&.0."<
M#CDZO[]XR6FA:Q>:7'J3:1+K-K';S0+>I+V)62S2<W\MC!-F.>^2W[*%78;D
M7<9.@Z-0"K(=3AKK5I[8LAFG85R%ZMD=!Q#1_=)V(6Z$Y*CR+%\I2M-HL;C1
M9UDGUCTVUVSAFTNEA6X:WG$#D!)C$XC8G@;7V[3N/"X/)X&:WJ:WH\E]+IB:
MII[ZC K/-8K=P-=1*@W.7@#]Q>VON<%<HON8 '-8Q;U_E+C1M*JZ11V$2)5&
M]=2B6A-/$K2RZQ[Z-3Y8S-HQE_TRP_45+MK#'F:'63?7:6/&TWL+V/8'M+E#
M)(8HPT,@+R#]A05Y;@X4<G!QX-68.I.GKD7#6^MZ5,MI;B[NFCO[5UM[4@$7
M$K+*0D/N7,C$*I902"R@_P!SUWEF*UFXYZ'3=:MJP_4;/MK$KU6:MOIQO^KV
M*R3B/5EB/.)L@[9P5B#/W\Q8B_Q^4^!O.]\/\+/W]G<[7:??L_S]N,[,\;O&
M>,YXI_A)T^+$ZF=:TP:>)OAC>&]M^P+G&?AS)W,"?;[C"?M GO*[>:_3CK?+
MJ_L!H\Z'2U6S18,[6X.LBD?]@F,T-E%;A_65C!*PB-<?)"?#]8N^@D^VLN<1
M[9PCL;V7=VK2X?8YC?;"YVR*5#1MA>'!=05/N&X<<TN>H] LC"+O6M,MS<6Z
M7<'>O;=.]:RB1H[F,M( \#B&4K,N8R(W(;@UDV70J(FB,G;7&LK85Z4"Q'2F
MNEXV@B%H1N(K;S[2D:XC 9%Q[BKR=LXC-(US -M++_A\BEK<R%0EO,Y>1H5"
MQN2TJ ,\8 '+HI!=?*CEL"LB?6=)MEE>XU.QA2&UAO96ENH46.TN',=O<N6<
M!89Y 8X9#[97&V,LW%8=OU[F26O++09>ZCHF?:%9KAVUB41BV&833;,HJ<F0
MO6 V?237 \NL.^WX\^VL1'V]\XUS-+"\DE>%;:?N1$=Y>TY:(,1@R*%RH.<C
M/D<C(K%N>I-!M;*WOY=7TX6MXLALI?C;81WK1 [X[5S($E=2-C!6.QR%?:>*
MS="MP=_I56NR\4D$&U(UST0,S,62AH&0T9,<)&8=]X<S1ZR8UWS'OMI]6,_3
MMG']_(75NUK<S6SLK-!(T;,N=I*G&1G!P?QK+TC4HM8TNPU2&.2*+4+6&[CC
MEV]Q$F0.%?867< <':2,^#6V^8];&M,Z*K>.Z#=$]9F%@L3.K/@$<IT6LP4;
M<M64.NW,AWUWUE%U,DAV(CSIOC>+&^OT;?/Z<V+E'DMKB.,[9)()4C;_ #7:
M-E4\Y'#$'D&LS3IX[74+"ZF0R0VU[:3S1@LIDAAN(Y)4#(58;T5ERK*PSP0>
M:_SYZS<:M1?9D!/TI+<$ULY>,&NQR5ALL28(?+J@#4;RZ0-P=--W39,] >D?
MJ#25VT[<C63,H\&F=H_)='U"PZ3ZML-:72TN[6P8)>0RO,[0SL D]P.X[,K%
MM\R@80;CM"J #]P]2=-]8^KGHCK7IQ?=:76C:KK%]J_4?3LS6LO8U'IZ%8M2
MTO2HKNTEA21+?3V.G 2HP:0=RY6:X#R/,W3/2+EON#T.K]QYK*+S*Q),51XX
M$,'GD+Z54\2Q;(; 6,*TVT16.2!46MV+'CEV*VA@)89W(UT)A^DWZ?T+JF]L
MM;L9]C!DOKH;2!*LQ$D&02$5D QW%4/YR37Y1V7J-ZA^D_375'IQK&A7/P]K
M^M="T%[NU-O%#$97M[Z>W>62X^)1S(^WMB*")Y2Z1H[*5DOW:JO/K&4)67/&
MU3?4UE5JK=+^)LE :571JJ)/$U!/QO*:I3:*Q"I7A^Y.X4,&I,I(?T:SFPXO
MJ7;78MM)DTC3K>2YU#5+73KZ]$"-/'8ED!)8QM@D-(58!6X;#_3:_HTZSH=O
MJO7EMUIK^NV.G=-= ZMU?H^FC49OU-=]1:-!"L5C)!WE83E7M. "LL:*"K;7
MJCEUXS>:^I-<C],H'%N)POF56I\AJ\^Q=(:5Q5OC7\14M0B,$]BEU6S;R+7(
M<N<,PH@2)8E\$T\@7F5YZ%V?ZTN[MM4 M3<3.$(.Q2TS$%FC.]AR,Y<YSDY\
MGZZT;_A*NIUZ*T3I]^F9#KEEI:60U*SGD)+6=O':HS"<LEN"4*A8$C1"VT!0
M% I<H-X,U'LL74;S9R[#7"E(W/+"GDB2+VRY?(1"R .(&2B?/^1@S3R"08BR
M[ R/C24N',NT7G)ZOH]GTMIVH67PT6H:R+X&V6V,G;BMX2)(WN&+9*R%R 5.
M05(/R(]PZ)]1>J/7/JCIO7[K7K[HOT_MNDY-&UM-;$8U^7J:]$BF/0/A(8X&
MCL @EDDG$LCI<QC=[:LW0.@C^U'M DY7:UE;5K5U#9UOA34"OK9 53]8$+:U
MLCF4@$O:P+XERDL">,?4:0LR.#(V=MI\;:>B=.]2KUAJ>BV>M:596DB:6VF6
MYB:2:""\#%HG42LP+M&%9HWRH<DA3Q7RCZK>C.I>A_2?7&H]&]=:UK:2=4Z5
MU#J5[%/-;7>K:3<O,+ZWEF@*R@Q?%2I/+"T<B@9#J-I'=)V)1P)%6M_ZA5FM
MVR==^%OF%ND,:PJ1CUT:<-:BQ -/+7PC!A]=U"PLC5>)M'N3@/&^GW,>C]36
MG2W3VA_K+7H;&Y-E#BV^+5@)9UYAME,;HS/(^%X.<G+$@5\Q^E6K>KGJ1ZBV
M'0_ICJ?4&D:KU7?1V][-HDKQW5EIL@B_6>MW<Z3VT[RV.G6[3+<3W0F:* 0(
MS)(8WZ5.N<R6^SG5W(/&IFG-(0T0^>B"F6YZSI42VB*P#\[D 3113L78>&(F
MXR=;NJ'''_'D^J2'ZI(_$=/O%]4-:$\&AMHUT;1V21U)B=(B8E:$\JF(T5%'
M# @MC)R?O7JK0M5_0SZ#O;+4?4!^OHAK4!N=$L3);7FGMJQCU""VU.&>\O))
MXKV:5Y+NX5ED)D)8Y]U>H[X#=BZ91T'4_6E[4'MAI-'LE@LH?L#HK;+*39[(
M8<H43TE#ECN6O.E7)P1CL2(6,T87XAT#6+8J4<LJYTY9:AH][J>CW=DT$5M<
MS=FX,DDO?"2% Y+LP4R ;B%P,\8X%8'JMK?1W6^E=(>H.@=56NJZEU%H]A'?
MZ-;645LNF?#6B9C5HHHBZPNQA#2AI7QN:1R#7HL\["O$Z>*4\4IXI3Q2GBE/
M%*^<4,(^F(H(HX8\;;[XCBTUCTQM+OM+)MC33&-?JDDWWDWS\OGOOMMOMG.V
MV<Y4KZ>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*>*4
M\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2JPUSE77J49+5J?=JHJ
MYG/T!A=,GRIS#+\(I<NYK$YI@\)>I-;F%,.()"B?SXP>,O)WVU"V+CBDQN);
MVQN%$]Q;S27@M4M]HD5;5GCC$4=P2NV8,JA6,0]K.,;@IQ7!V73_ %)I<K:?
MINJ:=;Z"^L3:GW6MI9-8BM[FZ:]N=,19!)8M')*\D2W;CO1PN6$1D"D:XM]=
M[<,Z3+R7E4S3*KT:]=,2MA0F6E_;,KD/8(]4;\G?7]=HO$DL4VC%B,020Z#6
M+!MEX/VOKTO/JL#1R,(YOB)[2VLY$+)\*B6YA^TB'W]S"$;5( C9W(9LX.#!
MT7J4=U;0O=:=^K+#6M6UVUN8XIUUBXGU-+P"TO'([(AC:]83SI)(]U'!!&88
M]N1C(O5]Y%6JJCW.IANR'@K/E1P[ 9_E8S=F6BM62-EG*<E&UA!UD2E[QFCL
M1F0+,D=C&.5F*6"69UF,S3RA;A>[J:7RE#%O2-89H2GVBR(6(D4$%&1D4J2,
M@BP.@KL6.GVIETN4VG2$_3TJ3)>&":[EO[*^$_\ BSVEPL.ZUD(E2:.>&=TG
M5)"K(V-QZU=.RM2'$7D8Y]6KXTM"10PMEP(&'4MZCK5RUY'1H 0[J6PCEQE@
M$:2OF_&%SNFV^\-++/M/]<6>^11;%8YK9(9)$A@!+QSF96%H6:W5"/84##+
M2>0!5C_ ;7C!:S/JT<MY8ZO<:A:VTVHZD\:V]SIWP$D+ZVD,6JR3*WVT4SPM
MLCS:G<CLYDCGGKW'4WRXYSK6V2<?B:_EI*L2!O)'@S:UV&QN]@LO#&QVB0J)
MWH'!J0VF,S@?Y;1P0XABCP[O5._$ZQ]U'.HM>J[&,>T0111[NVL:F53'N)5
MO/S.36\T7HQ=.NX);H6,]M'TK%T^]O&MRR]PZA>7MT8_BY;B86LBW0B0/<O*
M=G(1=JK'HOJE8A:&Q437,=I<1[S1'E=;D3-0!=J=RR")71:BQ.78C:KY!UFQ
MY9+19K/,,]-_.'T)VA^N3+.MQ-=)(+<I;FVN8Y8U$;D7%Z2]S.BO['!?:%1\
M Q+L. :TL?IY>QZ1-;-JB3ZFFK:3=V5R[7$*'3- 40:5IT\L&VXA*6YFE>>
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MU_M(UGLH$=))?M,-*D8(  -9 @CJMAY4+V!CV:=G2.V@#6ZWL(UDE>L-7/J
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M15VOXIKV[G+NXL5N48"&6%5D53M#!JP7KC\*V2]\68=;[_T+JUB;6-\.H?\
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MNQD!7*Q')]L@))D8JZ,CJV!()!MP<G<>4]Q==\Z#=ZE5;%6+&7>*A-0^JF=
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MGEB:5 &"RQ,H):-0^\KO"$@AE!&#7?=ZR^XE/[PRL',[-77G%O8SGHT<G3.
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M?\T[O'U ^E:_4K@VT"/VXY<RJFV1=RC*2'<!GS[<#\":ZP/]/QQ_^'GUW_\
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MG8P,:!J6OW@E7_8%AH+J49QL'+,,11^TNH1ROM]I=54,1@\ @@\T-M$<9WG
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MF2\T4MQ:RLQQE.^9 &(Q.Y8D!=I';*D +CY8XK%2&2*WN8E49P_9V$J#F%0
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MB 4[8/?BL@>Q@\4FD1619)9-QLSZ;Y@WDWVB^G.^V<]%H"JQNMRAL"'R ?\
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M =D)N;ACEU)BOJ2X:GJB9V7'\9B<:V':-9)06DA"X:/<PC;9N(8+*-R,Q*[
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M/I_S=_E#_?+7/Z[_ .Z__'__  U5OK'_ $&_5+_M=U[_ -K7/FPM_P#E6_\
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04\4IXI3Q2GBE/%*>*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img61678762_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_11.jpg
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M-CEV=[+!(R0E01@W<;4T0D-2@491D:&B_\0 ' $!  $% 0$
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M;?S.$YGH]OX)[9SOR6)^V_F<)S/1[?P3VSG?DL3]M_,X3F>CV_@@T_WYC<=
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M.4H2N!U7@G#<$Y#!Y.QQ!;ABOQRRC^UNE5DJ5AA HIZT+2 UDSD>1OA!.Q&
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MQ,5YYVS_ ._,O_Y&Y]>:X1G/WSE/]_:^N-?:!Z K^[T!?YR[J_C%[G:.%/\
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M+9((2B,H;BV2"0L[LVK[IV8<<!VD<!\.\:QXV;$?KRK/*>.GDYQ5IZEVUC[
MQS\N'GUSGJ22U9WBB>:L<4A1@1.#;;YA5OJ<(L'N^M-?;*C#X>P*96[C&%2\
MSAK-B$PRB(,E6$I<<C>::<RUA]"$(DM)SAJ4VA")"'4(2G&0H97)8HI3QM^U
M1.8.7*56>2%Y ;5V8]A-NVN[N+OU!W=Q=G=UK7$O!O"?&,-2OQ7P[A^(8:$[
MV:<>7H5[PUIG86,X>?&;@THB(S +L$XB(S"8BS-FC++,9EJ/':;8CL-MLL,,
MMI:999:3A#3332,)0VVVA*4-MH3A*$XPE.,8QC'/@(B(G(G<B)W(B)W<B)WU
M=W=^KN[]7=^KOU=;%'''#''%%&$440#'%%&(A''& L(1Q@+,(  LPB(LPB+,
MS,S,O9R%6G")PB<(G")PB<(G")PBSFD_C"/R(W^I_A7(_'U?:OS5[A_;2[_X
MWN7\3%>>=L_^_,O_ .1N?7FN$9S]\Y3_ ']KZXU]5WHGMZ:FTEZ-;7KVWP9$
MZ L>^NH4C 9B" YJ+$(ZD79-XNDY<4P3'IQ+""];D3]?\DW,(OV 0-B"V%F)
M UI[JV&O5*7#6&>X!21R1RD+, &S%4>Q>W.QD/P@"L4D>UB)Y %@;>XL_3<1
M=JT^'<2]L"..2.8A9@ V8JKV+KD[$0]0&N4@;6(G,!86WN.MQI:P]'DXL0N]
MALNGVCCMNJ1(N7/6,.-*(O=4%VV+3L$F24^+)8M5='5V^#!<&4PV4&*KEQ%)
MCLR09R+$SQ28<C*>26FTG.B(S.4!-IX@F&'>Q$SC-&,=@1%V8QY<PZ,X&S9L
MY,4YE,<E1CYL1&9R )\Z(96B8F(F=I8QCG$1=MX\N4=&<#9N(8:Z*#%4J&F#
M4_0TRG0K"B%1];3#E5]2M6)F:#%L0*[7%3DL*DL3-FU@?#@P8RFV,WRMQHK*
M&[&(1+@_U*<4-(RH/"TFD%8I(MG,8@%ACCW:.[%:B$1%NG/B9FTD!GI/]3G%
M%4,J)0M)MAKN<6SF:@+#''KIJSV8A%A;ISXV;I(.N> *GT\[T!Q-IA*K1[P'
MO4=F<S:O4<9SVF'Q(1>MM8F./QVI$X:^))&!$@<0;5%FC"$N#/B.QWW&<WXX
ML?>C:T$4$X3LSM+L;]J+"<?75F<A<",'$FT("=B9V?17XXJ%T&LA'#,$[,[2
M;&=I!83CZZLSN+B1BXDVCB3L3.SKL(O3AH:$^5E1]24-,HZ9(V$S)77H+TDH
M<+O>8*%IS[[;CTB>0D=K\N0XM3C[ZENN94XM2LU-CJ(N;M4@UD,I3?EB[G(;
MZF9.[:N1/U=_%^JK:A29R=JL.IF4AOL;4C-]2,G\2)^KN_5WZNH[76YVRC]6
M]:J5<&B(&O;7!HDRPE,V&%78@NX6:R7J,2:72T6L5.OE@V#$A#68QD91+GD)
M)$R2-@,UB)&<GY^U?9X>OW?^_1Z_">G"A:[V1JJB[;$1@5^#K-B8N+*EN&DD
M3&8RW;Z';M9V!M;PJ9"DJ3.IMYLPO&?&PN*N>@A$4P0APY3!%UK.O*[2M8&:
M6!C$7QBO:PV^HA/%&RY*P6RP%KE8C4J??&BH*04+VHT3-K4<BNA(TN5X3<&.
M-88B,D4"MG=*VJ.L?I$H^D=Q1C:JL3IFMS40G6B,859*\>#5Z"H<;!SGH)(8
MW.8:D3(:T311$;(AS9<=V$XAU/<V3A3BK+<&YF'.8<H/*HHY8#BLQO+6L5YF
M9I()P XI' G$#9XY8Y!, (39VZX/.8:EGJ4V.OM)R#D&03A-@EBDC)W"2(B$
MQ8F9R'X8&+B1,XOJMB]*G2SJGHYTX%TCIZ,:151) F9E$K*19*V2P'3#J'")
MLY.BPAD%V<^VQ$B)0.&#8,>'"B1XT-I#7W3BOBK*\99F?.9@H7M31Q0C%6C>
M*M7@A9VC@@ CE-HQ<B+62620C,B(W=U&%PU+ T(\=0:3DQD<CG,;'-+)(^IR
M2D(@+D^C#\  %A$6869EJKK^Z&J9U]Z6':DMEP.T*57KD.O57M8.%&+9'FX
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MC;HLSP-?.;$Q6<&9$C$IA[$ *V:<;D%(^"&8K^!B42X>"68CV(WG<L+Y]?\
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M*GSI+$.%"CORYDN2ZAF-%BQFE/2),AYS*6V6&&4+===6I*&VTJ6K.$XSGE0
M<AC'&)&9D(  LY$9D["(BS=7(G=F9FZN[Z,J3,(P*20A  $C,S)A  %G(B(B
M=F$19G<B=V9F9W=]%&_1O5QI'J(.V6MZS.F)9BL1_6+\0[6#M:64!YEMP<'P
MN#,**J:-3,>8CR&UICE("Y4%1(=#;(0%R=FS_!V>X:KU;65K110VRY8'#9@L
MM'/L>3R>9X3-@EV,1#HY1R,$C1R&\<C#S_@OM4X [0K>4H\'\24\U:PSMY=#
M ,\1C$4CQ#:@:Q%%Y34*1MC6:_,AW$#.;<R/=)CFKKH2<(G")PBVM5?@6/\
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M(G")PB<(JS>H78O6:!ZHJ37=55TU+U7)<J^&$P*I'*UDXS*?:Q:EVVRK'2G
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MC=MHSD;=7U)A9^FK/9SCT?-<D2([YS8Q:VR(5Z%VY@S:P7KBPSX$+4=ZU4Z
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MYV4P=L&#;ADN*:O"=RK;ARV-NY*,SQ5NU7"6L5'($$D90!)6MSS06&:39/
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M9/C-,(\8V.9SX?*?)"/EC=>IOYWDSD[/OV[N4[6-GD_[5:ZW%6#?,O@6N?\
MZBQ/'LY<G*>=AWO7:?;R^<P]XZZ;V>+=S6Y:L:I/XPC\B-_J?YHRV:/Q]7VK
M\U>X?VTN_P#C>Y?Q,5YYVS_[\R__ )&Y]>:X1G/WSE/]_:^N-?:!Z K^[T!?
MYR[J_C%[G:.%/^GL7_H%]=*NN\,?N'&_Z)_72*Z?FPK/)PB<(G"*$EZW+IO:
M#IOIJN6P:/.V=9MD.U&?HZM6"!&W#'I(VX8=AV.93ITDG9(H?V7&1-AEK>]7
MX%>>ILE;H2:RY*#G)!3H[==.GS=/S^7;P4Q*^%B5L$&KP_+F8 (4/#P<O88P
M[Y,;$:AQ<.8C,1H_?PPRC"O!CLM]N/N&T8[$X*%V_")PBB/J;_RKUI_E_3?X
M<&\*R?QR_P Q>]UL#A4IPB<(G")PB<(G")PB<(G")PB<(NP$_"@[Y]%^O1PI
M;O;YV]ZW1PKZP6[?@#?E2OW1^%;D\/7]BI2->D)Z%!WI!X'380HA-[J&</#-
M=HW"FCUYRM1+Z5@1XPNH.6)19-J45<Q+C5?!EFN/0XLZ0V'R30-3)DQ]N#L
MELX9^UW]1\.%=AI26@MG$'_$+XV 2KG=&7R5XFY=83VN5MK7D(N ,PN,)?'_
M /,V3@%^S >(^(1PDMD0/%!;F;!/<ED:PU8H&L:[3LN,AQM!Y,]QVE-GE9Y6
MMOYJ*^A.$3A%0_TFWWH=,>D0V!3-8[SM=HVL *;*77:D2ITH55YYYELM'OP\
M%>W)CZ+IFMPG3RH[3@@*U+APGC XC8(P]<US2<9^B'F.SO-/VQV;=J7%7I+5
MNCBR\G:?%/Q",D8RY*4;$DMB"2.X<5:-X(I89)8/+"><68NT<3?I<-VA\$P=
MD X>C5N5(<=3R68CEG./*1\/'!+&&/J%6CCI3M-2AEM2#:L1RA'.-6.. _@7
MP<W9<759W2=9NM8MO:_PM["CT2@,PC"GO7(**,KD(VV2C("L4$FU#C^MX.8N
M9;65P)9&"[ 3B61D*(YC.O>:^RK)=M%KCK/P<<U;T6 ""XY>5T8JV.@NC9B:
MD&!LA#'Y7"\7-'6&6Q"4#<VP?E#QD7K;MIQ/8!2[.>&K'9S=QLW$IV*#1M0R
M,MO*V,>565\A)Q+4.>7R&PTK0GMLPU; 62Y%6-JK2A'9$5&QC(LD(F>+Y,K
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MB:L(Z8Y!64&2G,09@Y^*0@MRX3G;EB8MR+,:>4Y%<0M'@N-R7<8Q7:QV;_\
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MJI.,>)([,*H!U6?QR_\ OC92<?\ ^<<TS6/Y!_S!_M+8Q8]K:$'C_@?SO_\
MR,LA\ALC\ZZ1]'Q[^IG&L?R3_F#_ &U5I)\H/Y9?W%J W!V%ZVG]ZT4S.?,K
M[<XH9S&,_>^]C.QU9Q__ #G_ ->3K%\B3^8/]I6B8]S_  A\/\#^;_.NK\CL
M'\YZ;^HAO^HO&L7R)/YH_P!E4Z'\H?X7_K76&:O:+&,EA;"1UT=#3V\,SQ)G
M6I$H,FM86ES#4N!-V _%DMX<0A>$/-+3A:4J[.U.,X^:Y4QV0K2T[]&*]3G'
M9/4N#!9K3!JQ;98)JYQ2#N9GVF+MJS/IJS+ZZ%_(XNW!?QE^SCK]8M]:[0GG
MIVZYN+BYP6:\T<T1;2(=T9B^UW;71W7L%URW Q\00%+:^$"A[*8T 8+UP3'C
MX4=';W&(D*)L%J-&91VY[K3+:$)[<]B<<JJUJ%&O#4I4PIU:X-'!6JM#7KP1
MC\6.&&*N$<8-X" B+>#*FY<O9"U/=OW)[UVS(\MFW<EFLVK$I?&DGL32G++(
M_B<AD3^+KG^1V#^<]-_40W_47E_6+Y$G\T?[*^;0_E#_  O_ %IY'8/YSTW]
M1#?]1>-8OD2?S1_LIH?RA_A?^M1-ZK>DFV=3X:I09VSP%8G4Z>3EP'8E +2(
M4MHTV/9GMS8SNPU94\R@<PY!?1G"FLYDLJQW)2EM\I[5.R^AVFTL3!-D;N,G
MQ%BS+ 411202C<& )QFB*'J8#7 H#%V<7>0'^#*Y#VGL8[8[_9#?S5BOB:67
MKYVM4ALA.TD=B Z!69*Q5Y@E%FC,K4@V8R9V/2&1GW0L)[UU=K*XZKUY4-=B
MKM7"8^H!(@6*0)T<PJ=+1%3GM??\+8B6F^^M2LML-)PU':\-AO[AM.>;QPQ@
MJ7"W#^(X>JR6[-?$48:4=BS-&\TS1-UD/;"PCN)W<8Q;;&&V,?@BRYUQAQ+=
MXQXGSG%%V"I4M9S(3WYJU2,QKP%,[:1Q[Y",MHL+'(;N<I[I#^$;J-?5MT;7
M?J==I$U6TZW79M/R4B88]A3+@Z1 -.CW9DA+6;W*4@C'4.9PWA.&VYC:L-/O
M,^"TO'-^UGLEJ]II82;]9VL=-B/*HF#F =>2"Z4!32,'DLCM8C>N##IM&47V
MF8[ ==8[$^VZSV1!Q!7;#U<I7SGD<[R;"&U%9H!9"")S:S"Q59&M'NUWE ;.
M<8'S#%Y4TBD7BC4RI4J%<ZT1AU&L@JS$GD:09=(38P(9%%L2YKB-AH0N5(:B
MI=?RA"$>*M7<2E/8G'4L)C*N$PV)PL)VK$6)QM'&16+$P%//'1K150EF)H69
MY9!B8ST9AW.^UF;1EQOB',6.(L]F\_8AJU9\WELCEYJU2(@K5Y<C;FN20UQ*
M0B&&(YG"-B(BV,VXG+5WRCR.P?SGIOZB&_ZB\RFL7R)/YH_V5A]#^4/\+_UI
MY'8/YSTW]1#?]1>-8OD2?S1_LIH?RA_A?^M/([!_.>F_J(;_ *B\:Q?(D_FC
M_930_E#_  O_ %IY'8/YSTW]1#?]1>-8OD2?S1_LIH?RA_A?^M/([!_.>F_J
M(;_J+QK%\B3^:/\ 930_E#_"_P#6GD=@_G/3?U$-_P!1>-8OD2?S1_LIH?RA
M_A?^M4C;3]+KLC7'I&P/0TC5E=+ )VP-;ZR)7_U-9(]CP<V3! R89X54TVEV
M/)K8E^SC?,>(6Q*GBX9 K%<:PY%B9[=BNQ^')=G$_'3YQHIX\?DLI'C^7&5?
MD8T[ G7EN;A(+,K59-ND+A'*<<1L^A&W/;O'1U.*XN'/U<YQ%9J5#M;B:7F6
MQC(90@9G8H8^<&[4]Q )F/\ A%[N?([!_.>F_J(;_J+SB.L7R)/YH_V5T+0_
ME#_"_P#6GD=@_G/3?U$-_P!1>-8OD2?S1_LIH?RA_A?^M;1UFQ8F73'KTJ%)
M)4W"\M@2 G!<LYPJ5XN7U3+(?Q(PO&6_#PVF+EK*5Y4I[OIPW23ATVB3>?<3
M%]&@#I[5=CUZZNS]W<SMY_\ N=? 9,Z4['9RAVQL;/"#63ECLA5H>]KF?/=A
M-SCQ&2F,Y.1L: B6MG#F&U2$PHB7<I[^([6,]S'V!V'X3- .7FS.4AER8M>D
MBBCJ/'&=G]J0 YQ.3B+D[#N=WT;J^J^\>Q["Y81RDV5RD4N09KDD<35.6!V&
MYI &Z BVBY.P[G=]&ZNOK*]!W59-)Z&F:K,*,&9 ;=NYX[A.,-<$,R\KM/F,
M+0.=)%UQL8P]A'<41D]N4]_OX[W=3\LN#AX;D+!UYI;$./TBCFF8&ED8V:;4
MV!F#5GD=O@LS:,R^<\/#@"?#UY99H:/[*.6;;S38FYKN>QA'74W;X(LVC-T5
MP7+:I3A$X1.$4"=LIIY_?U#M$/<E(,0XY@'JJVZI3<[ 4/Y7-LY &2$1M>0=
MQ5_695@D:+P8=Y<N^J+M:@H0.0D"'7)<(![*E+?-U\_F^WV^93VX4)PBQNXL
MQY%5L+$IF!(C.B)S;[!2LS;F.>:4PO"VYM3&NL3[%&4GMP\'AO-2)R.UAI:5
MKQGA%!O6-0J;RM#VYVKUQVUQ=$-0XMG6!')L$:&V-U\PW$C%G(RBD6*A@D19
M1$3*PAIDA-9[O=DR,.7&,^40;BV.8NX;GVN^A=7'737HWAX-YE\L@B\V[:VY
MN9H3LVYFW-X][=[_ $OYUJ?=FTNK.@;0V08UMJX?LW4%'U)JTP&J"1IR+<MA
M[,NETV-7;0"IU@%CR41MJDAA>OK0<60A26(8PJ0C*0O)1)>I6U=%@=FU?1W)
M]7\S,S:?;]'AX\8CU(]4$:)F3!Z0R$I<HY<&!D9VY'D/JK5?VY[G0@J31&UO
M+]6&CE65#VHP!D]V)(II):A)XF5 %QN"G:'RO=WZ:^IM=6\?F7NB=1W4JQK2
MHW$KTGV&5=+;N6LTN7K$27FM$Z5KD]"!29]W/'Y05\7*77,3B;Q!U;0,0X]!
M2&=DP"*)*FR;1UTW>'?T[^OS>9OI6/!NH7K"+6"/(5TM>'79,2+)ABE&S86:
MN 2?Z?O$DE2]HJHI$*Q 8EYW&^]6G( YF3-U=-$-DID8D&L\LFT-.I=?1IZ?
M3\WG[_0[+)M6;XZCB^RF:-LC28ZNB#5ZO(6O&W#RQYU5+J^91*/L"17Y4-&2
M55F16D5I4D4K)$%9S.NXQN$\,O>;$%(XCH[L_<W=T[^[\?I\W6<W"MIPB<(G
M")PB<(G"+L!/PH.^?1?KT<*6[V^=O>MT<*^L%NWX WY4K]T?A6Y/#U_8L!X5
MM.$3A$X1.$3A%"C0/H\NDGICVO==TZ8U:Q5+]>8Y&%-G9-G2@\&-,$&"I<74
M@Q,A*&UL>1(1H[SK(Z.WF/'9;%CUPQ&,C\[MQ!VB<7<3XFEA,UE"MX^B49A'
MR((I)Y(8RBAEMS11C)9DCC(F8I"?<1/+(QS?M%K^,X7PF'NV,ACZ306K+&)%
MS)#&,)#8Y @C,R"$#-F=V!FT9F =L?P%-?FDK8$X1.$3A%H_J7UU+VYT_P"X
M-90!(D[,O%!L5=C!S>&O5Q%XA!<:1%<<>4AF/(<SGL@3'7&FX)#RLQ;K26,N
M)Q6=M<44L-E+?!-TL=Q9!1LR</W0...2ODQB+R>2*25GA"7=\&(YV> 9'%YF
MY3&MBX2#A63B? AQQ4\NX1+*4VXAJ;))!GQG.'R@9(X7:>2%A^%/' _/DA8P
MA_:N"@YZ+[I6LO34!W#*LFL0&L7;Z6IJ8L$=##0RQ-NIQ+&PY))-A'78R1[*
MCB4"$NY0^I]PO*RWEF4R^_SKLBR7;1=PV1A[7L_Q%FFK7M_#@<49F3.96HU@
M2?,'Y;8LW+(T[,D5#R:"6RX@5>8X8HXI!*3KG;^W8D^;P<O8YB,!C7/'3!Q+
M+PQAQPF'LO&</ZF :<-6E7.]7C+(/<L0UMT@6*T<\TDT1A%=35?@6/\ I)'U
MR^=:7!P^*WK][K(N%4H,]8$[< [5&P9>BXTF5L-MZ%B @=%8G&4#5$8J33P.
M%);>9EEFQN9&8S.&7I.4^*L>TX11$0K0.T^?BZOP3F)N!XY9.(1&OY.U>()[
MC5WLQ-=*C!()A+;&L\CQAL.33<\ %8:)ETCL@K\#6NT/!P=HLL,/"YE:\I*U
M-)7H%;&I*] ,C8B(#AI';:-I3WA%NV#9,*I3$VO^C,EO<KIB-*ZA(I6-<?:$
MJT(S88#8NR/U1$<=D>]8("6(KT<A@DHPPUYV,Q.=',P7I*%K<P^]B>QRSQU:
MX-CE[0(K4>8_6%H:GZP@&KDI,4T=?R<[\#!&<<[67N /.CCG.N$!R"[DTAYC
MMYJ=G%+CV6'LQFIRX/\ 5=,[S8RR5S$Q9EY;368\99>28):SU&HR'R)9*X6I
M+$<1"PO&$KN=57%TX1.$3A$X1.$3A$X1.$3A$X1.$3A$X15)[&W66&>D)J%5
M3T[ZQ,%8D^LT\3L0CKZ'.V][*V2'&<+V&O;"4WD@, "$$B;KL&(K(K$$<58)
M.LONR7(/GS,]N7:+B>U6KV7TJ,[\(7<EBJ\V.WY-BOPWHZTEC.@,=H<>\5%R
MDDW%4EC&.E,,\P2LY5_5?#_8#V;YCL.O=JM[.%'Q93Q>9NQVVDQS4\?:QTUF
M*KP]-$=4KSSY!HX8M&MQ3'/?KG6ADB< LVV<]!KRHG"+.:3^,(_(C?ZG^%<C
M\?5]J^,*N?!+7SHG_P"Z3.=[P?[FQ?\ L*OU(+M>(_=6._V5;ZD%]!'HF+A7
M:[TQ#@AF>J$1NG43N\/6FE02#S!(K DR#L@?F='B/0(4K(D80FQF2$F(J:W"
MDHA8D.LK;QRGB2O-+F\S+&.X*Q0R3/N!G",PKQ,>QR8R'F& NX"6UR'=HSLZ
MYMG899,ME9 '<$!1G*^X6<0(8HV+:[L1-O(1=Q8MNYMVC/JK''=WZT9EY'N'
M9^)V"-4$^335+>Y*R2O N49JT-##8%3BWBPV')D(2A*L1LM>!-S&DK0RK%-B
M[KCO:(-FRQ)N\HKLVRK(,4Y.[RLS-&9"SZ_&9]P[AU=8UL?;<=[1CMVS'NYT
M&FRN;!,6KR:: 1,S^?74=6ZKL)^W-?#J&,V<^=<=HA>/ F0["/"GRT9,$BGO
M,$9T<6+F3Q0UE/:HD0*18<(1A*O6K\+NJ[+88^V=HZ+1,UJ,C$H3DBC+>#Z.
M .9B$AN_Q!C(BDU;EL6K*D:5D[!U&C_^P#D)1%)&#[@?1Q%S,1,G?XH@Y$?^
M!BU7'L6Z-850I/"GK;"@E!;K#)"$F*2F.Q'7P1>S)0]Y&%)0G+5?!%"\K[K/
MDX4=#DOP?-P\2*H<;=GC"6*N11R:N!;@%B9I8X.F\A[YI0C'Y1.[#KM+2J*A
M;F 9(X2(#U<2W +$S2!#TW$W?+((-\HG=AUVEIY,[EUL[--#7;*@>0KY588I
M#-"S8*2U-1#A$$+CM&1L!9 =)@D84N 8'8EB",>0AV!.DHPK*8?'7&&(V@<P
MFC:6,HCCE%Q<B#J\1FP&)@0G&>V0"9V,!=0]&TP@7*W#(&\" XY&<=Q#U<#+
M:3$)"0%H8NSL0LZB<T7-5'J*10SND]&F6R]M5;Q^WX8O8:;0)&VZ[V.>+S92
M=>Z796IZ[=X[2QX"OB[5O0#9+;-BLG$SS)8\U$>^)?+X=[_-X>_['4_^%"<(
MNI//MQ@I20Z:9KC;,&0XL])S!PP'2AM6<D'LDL9'X;BXQXJ\S,9C]B<^+]QV
M\(HA:WKU?.ZLU0\:"ACCL/7531#D$QD @MAN770JI6(JY+#W@-S%1(JWTL90
MA[,>/E>%>"UW:F(AUVD0Z]^CNVNG=KIYM7^E6#9MQ:Z.[$773T]?I6H+[3>H
M0SL5GV#LL6GT6L677S,()&=P- V35EBJ%ZJ&RHN5PH;TV'?Z983078=6PUY0
M:[[$U &U*AL'[*^FEW=WU=]7?O=^KJIG%F9G;P?P\6=G;U:-IT\ZT$$H'I !
M>W*[8'+>.):['WW;DPQ7C-OA]PI33>XNK CJ8:OPAQ3&(8+65JZ8!=H1D<NP
M-#Z><4!,NV,5(:N15:AH_GZ=S>@==.[Q8O1U;YES=BTOK\*R+:G65DAU@>:V
M5MDFVJQ7RMS9X.LS^FJP4K7;-!9:U^8;D56/O58K9;(>TDZ_8(,G X/+6T'8
M+D7RAG#IJVO1O#_N9^OITZ=/3WZLR[RK!>NFJZTV?-RZ.M.Y/<WZ? 5'@6^S
MUXKK<IL01$>B[HNHAB$@.>K4(DR40TNOGBQ%E^34!9<=-)$CQ]Z<4:@[MYM7
MUT;KIX-Z?9W^"]I>%Z0NPF!<B)/U?3XN#NPF5PFHK,\",'IM(QG6)@KEBPYL
M=J8;I^'R=C%Q9M<P^<?/ 5C7H8ZM64L4_L_2_1O/J_G^;\^E>?;UYCK_ "2$
MF106:I9;)4XPX S&FV@:)9,5_I[CW7,LO$A(*"(=/<A]0LVIE7( @%9"(VNL
M6,8.)7*!(CD^!Z>FO7N\7T\W?T]/7T+/K;CK@&3XL>KRM,V<<ZAR7*(M@B0B
M2PPBR5>-."XB%;<A+1I5.DVHO4C*/68:1:1<$':QPT,22<B%#;/'5OSW_?Z.
M[JM#6.X>D^K:9!"92M+FA\B?KX*W"H0DB<*PY]HZ@*W5[24',$K;"<EUZM:4
MF3[,R0.-"<#BN)Y"P86.%>5R53-&_G];^CN[O/Z?8M@ "WI&)#QE=JK.CQK4
M /?Y(YBN*=((/GF(U,BZ_%CI16UQ71 N;(S>2D\F9BR)+?A!(TN#';DNLPRC
M]GZ7^?7IW^;T]%T0>3Z3A Z(\4@:!66).UZ688=\P\.KN']:BO:H;7X\,M!D
MSV(&T$(P!P7+R7Y@!^\Y(%FU,414@G[/KWMYOSU\/L]++<%H(=9D?;PP35@V
MM9VE$NU1@W;9332;FXQ@0A-AG!Z^]:843Q%VI]M9&//D-ICTN*0S7T3+/%'M
M6 H;9IUZ/UZ=?/T^AOQ6I*4 ](<BL0F+N=UO+,2<ZQFV"1&E9CE_7 4+T[Q]
MA-A5C7V +5=LAC/4#,CQ&&02H$>NU1K XDJ\DU!BG4->G=X/]/?Z6Z>=NOH9
M;'T5+ZR%&=0C]L/UHA*$6[6PW9A,.$<#,386>G6?(VMXV9$2,*,18_4%@'*I
M-DI3<>--"EV*_(@Q\UNWR)1/@:]/.VG7_NZ=/F[]?-X:LK2N%<6"W;\ ;\J5
M^Z/PK<GAZ_L6 \*VG"*D/7EMZK7O2/'0!:O[Q;J:-@7AHD\4!6QG3[6H&4F\
MU,M%L\B(G7<N!+%H"*!PA$^38_:5[RDV#&+QCZX7#<;V7]L5/M6N<;7^)J$G
M9[-+<M0F/%6/L-;HVH9!H<-1<'A?+,5LACII88K-BSB:M"(J<^3AR%D9ZQ7?
M469[3>PNWV&4.#,;PW)'VC14L;5DC_X7N5[57,59H"RG$D_%I46QUBCD BLS
M00096S;FCM08R2C6:&8:5WG.Y+RZG")PB<(G")PB<(G")PB<(MK57X%C_I)'
MUR^%>#XK>OWNLBX52TX<^%R'SE?^W"LG\9_5[F75<*E.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A%X9;1E>',H1EQ*5(2YE..^E"LIRI.%]G>PE64IRI.,]F<
MI3G..W&.1M'<Q:-N9G9BT;<S/H[LS][,[LSNW<^C>95;B87!B+8[L3CJ^UR;
M5F=Q[G=F=V9W;5M7T[UY\E4IPBSFD_C"/R(W^I_A7(_'U?:OC"KGP2U\Z)_^
MZ3.=[P?[FQ?^PJ_4@NUXC]U8[_95OJ05[WHT@= LO1I@/?SD %&:ZGMBV,+*
MDFX8*8HM5+A".>$.ERGFEJ3*@19@XPW&SEUP!/*,96RAY3J.8YF6W#Q'EI*D
M1RNXO#*(Q'*/+L58XM3$6?XID)Q[NG."-]'=M'YYE)+,6=R1UHRD=]T4@C&4
M@[)H CU-A9^XB$@UZ<P0?J[:*QNW].]8NQ\^;,%BBF++9*/9"(MC##,;*J,"
M+5^# CR6<-S8\:?",27)C[,A$YJ2VP\.E0LM]BL36S$]6***../6&&U"$CZN
M7_VI8YC-V?47("B%A9V<'%W8Q+58Z#*35XXXXP#6**Q$)OJ[_P#V) E(G9]1
M<A*,=K.VW35B$M5[L:&8C4@53!FP+O P.B5H6\5>F0C+<\-4D(;"CEU$[$)4
M =G*8P[)>8%J@R2><@8667*Q-((E1^M7>S)9.I5/>4\C1L)Q.$MCK*?E$1!;
M/J1\L9+!C$Q_LV':#C'ZQ=YSG.M7+>4IL#"4;B<_60N?&062[RV-),8QL7P&
M;:+CC%DZ4-?V<E8"3QRY(38SHNPRHKEDGEF1QL-&L<>&8!.EGITD.:'3K'-+
MBIT5_"1)9B,MJ*N*VJ&J]#GK< 1 T59WAB.$2:$(W.*0H7*.5HV 9(C"$8S%
MVU.-WU)BT)KL68LPC&+1P/RHSB9^4(.<<CQ.02,#"QQD,0QF+M\,'?4F?0FV
M) U:7@S+!.]TFRN/V$_,/2LY T+'A+DLQ8D>$AU=4=E2(PP?!A#(#D^3+F-C
MH<2*Y)=1&;SCY"OQD,(>10LT,(Q-^UM==KD1&[-.PB1F1&; (BYD1,+.3KYW
MN@XQ#Y)%I%&,8_M;/5F<B<G9IF%G,B(RVL(N1.[,VJTSLJ6/1U1:J01T8*M+
MS0N"V%V<]7=F$RX>;,F'6'WV3@769C4-?ATZ*I^5&=V'LVM6>2]9BD*G"V"$
M\9'O..7P^'?^>GIU]GVZ3&X4)PBX).7&@#YLV8S*D1(L9U^0Q!&SS,QUEM&5
M+;C"A<6<1(O*3C.&X<*')DOJ[&V67%YPG)%%/4F<*U3K+.,9QC.O:9G&,IRC
M.,9K@W.,90K&%)SC'WTJQC*<^]G&,X[.%9/XQ?YG][K87"I3A$X1.$3A$X1.
M$3A$X1.$3A$X1=@)^%!WSZ+]>CA2W>WSM[UNCA7U@MV_ &_*E?NC\*W)X>O[
M%@/"MIPB<(G")PB<(G")PB<(G")PB<(G"+:U5^!8_P"DD?7+X5X/BMZ_>ZR+
MA5+3ASX7(?.5_P"W"LG\9_5[F75<*E.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A%G-)_&$?D1O]3_"N1^/J^U?&%7/@EKYT3_]TF<[W@_W-B_]A5^I
M!=KQ'[JQW^RK?4@KQ/1LZCC;7Z7:HT6<9<K-:ZD>HZ5:12I1&#)/A+55[5KZ
M8(C31BV9,7#S-M<?E.HDL+<BQW8;:VU2_,1^:YG(%0SF=>-GYTWD@P2;0(8I
M():-L9"$V<2T>OH+.+LQ.Q.SL.CZ!E+KT\MF=C/S97KM">T2:.2&6K9$W$]6
M?3DZ,VU^KL[]&T>PN'HS87M1-DD=B2TTI^[P34>L!K'=!/E:K!QMF)FNL2(Y
M-,N.F6/N5&Q)89(8'I?I#,> Q %Q@4$5C"RE/D"PTQ>RU8XWGD@JR;K!^0%S
MB$@VEM.M:T=PWZ67(W.0ICDQSWZW*%AJCY0T!1O-)% >LQ>1ES79Q=G<2@L;
M7<=VD[N3D;R$?7,:'VTB33);^WS$B17C/K \[FPV9IBSI:O^H#J7G!D5R/"B
M>L:=KZVUZ<)?P1@,$-B'9T=]QJ1-;EU'E*#M8$<?&+2Q[(FY,#E!K4R$6C2.
MSD6RS;KRC(VPR"G$!,SL.VX61INTXM2!FD#;%I%#K%K6NQZ;GU)]L]F"03;:
M3A6C$FU87;?>J*9,U[KNITH@026FUP6@=)*(<EN8(N-.NJS.5F<Z])0Y+PK#
M[K*W74QW7%L-.NM-H<7BK]D;=RQ9 .6,TCFT?P6V,[-\#X#,+L.FC.S-JS,[
MLSNZQMR<;-J:<1V#*>Y@T9MK.S?!^#HWP>YG9FU9M79G?1;#Y\B^95@[:U9.
M#]9^M]@0]>Q"=6<,:YCXM'L/KQE=5+G+9=9TN(&LS'2==+&U$*GRQ^W6":1Z
MB]>RO:,Q/AR,PBUTH<6\E.O3\]?#KU]7<K/N%"<(N&0(CQ$&64*SH8P; CNR
MYQ$A*8A0845E.5O29<N2MJ/&CM(QE;KSSB&VTXRI:L8QG/"**6I%)5JK62DY
MPI*M?4Q25)SC*5)S7!N<9QG'O9QG'OXSCWLX]_'"LG\<O\Q>]UL'A4IPB<(G
M")PB<(G")PB<(G")PB<(NP$_"@[Y]%^O1PI;O;YV]ZW1PKZP6[?@#?E2OW1^
M%;D\/7]BP'A6TX1.$3A$X1.$3A$X1.$3A$X1.$3A%M:J_ L?])(^N7PKP?%;
MU^]UD7"J6G#GPN0^<K_VX5D_C/ZO<RZKA4IPB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(LYI/XPC\B-_J?X5R/Q]7VKXPJY\$M?.B?_ +I,YWO!_N;%
M_P"PJ_4@NUXC]U8[_95OJ05XGHY->&[UTA!Y-9FMPC%>ZH-NYF)DR7V(1&FV
M<B]4;Q!DH9SW7W8M?-/V(0VI*7,GZ^)2R_%4O+Z>:Y:W%5X@S0SBY1S"&W:S
M.068(J]BJ;.[:LSS1-#([=.5-([L6FBY_DK,=?-95I1W!*S;=&9R">((IJY,
M^FK,\D;1'UTY<IN[/IHK!:[3>H2G M<!!QD(4>&88#W8H]B Z^5'UVZZX @2
M$MTDTJ4M)33X>_$BB!F62"+X:&=W"8:9#S.,FL8FS+=E..2-CUDK V]FC.:M
M<EE 6C?;^SR,E4 YFH/5C/74MK/\,L^,GDM2/'(#'J< ,Y,P%+!:DD%F#HVR
M[)7$-VH^3QGWD[,_$\CU9CP5<?8-1CQJ348$BX02D;7\-0NV,SHJ2D6LRAD2
M%"(HFB&IZ8$,JF+ C&Y(^?(LN1B981JO?@#EF8HBAC:P;5SC*V6^!P+EE,,A
M$0;9'!S*/<;Q,8-!S'&53NPQR2LX/$#3$T) ]DM\+B^QY1,B(=IN.X@=R>-B
M%H=^V1Y35UHLP ",GIBB!MD2/:+SUPX@]R:2;B-)FRW($"3-@0G9$C#CKD6#
M+E0H[BU-17W6$MK5@IGC>65XAV1/(;Q@Q$;"#D^P6,Q$R9AT9B,1)VZDS/JR
MQ$K@\DCQCMC<R<!W.6T')]H[B82+1M&U(6)^]V9UW'+:H4"0?1&H'U"S=^M;
M#"ORB%]+7>56W=8#5(DR218PXP1G$W+([&)7\/4C"]= =H$@4NY5VA1TT^M3
M@E9D3!#Y5:]--/;]CZ^S37Z%/;A4IPB<(HCZF_\ *O6G^7]-_AP;PK)_'+_,
M7O=; X5*<(G")PB<(G")PB<(G")PB<(G"+L!/PH.^?1?KT<*6[V^=O>MT<*^
ML%NWX WY4K]T?A6Y/#U_8L!X5M.$3A$X1.$3A$X1.$3A$X1.$3A$X1;6JOP+
M'_22/KE\*\'Q6]?O=9%PJEIPY\+D/G*_]N%9/XS^KW,NJX5*<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G"+3.U>L;I^Z4IM9B;SM%IK#NQ?6C-/4!U)
MN#9,<K*K;+,LO!<EZQH=QB"R#$*<U.CCS#T":1@L$IHUB7%$%78?T5JMBY)R
M:L,D\NURY<0N1N(Z:NPMU?37KIW-U[E]=2M/:,HZT132:;M@:.;BW>[#KJ[-
MKUT9].]?*Y57?, ($KP)D9,S$F:TP0@S1DYMB;,D2F,2QI%B*0@2,LO-Y>AS
MHT>9&7G+,EAIY"VT]VP\4D.*QT4H%'+'2KA(!MH0&,0L0DS]6=G;1V\'79\9
M&<6.HQ2"X21U( ,"Z$)#$+$+MX.SMHZN/]&%UE]/VJ* %Z;;U8;L*W'L'J$O
M,"G5F'I;=MA&G7[F2]: 5Q;M6]=EZ&W$6)B3BY4A*LS$"NB1I0I8I(J +(2(
MW*^*J-P,K?NG6F&H<T8A8(':(G>&,683?H[NXEHS=^UW[F=<XXCI6PR-VV4$
M@UCE#;,[:1EK& LS$_>[NS]&U?H_F=7Y<U5:XG")PB<(G")PBCM5=^+LVT+3
MKQ%,D(BCHFR'ZD5A'HLLK9Y&H#%%K5]A% ,^"&@U1Q=AV$"BTMYZREH]E',D
MBY)RKLL169A%F&M=JM7S4E:VL1K1JLH.B,$YE688DW$X'=Q->@/#?!J4,DZ9
MEQGV5)>4%BS6,]CCK+CT5OS*B*,^M=@#1>NJ",(UC;4,@.I55@3H<C1FZ6WX
MDR("@1Y49]O-![4/,/MK:<1GWTK2I.??QPK9"[D3LW1R?Q;SK-?=. ?$.U/H
M/W1]@>%3L+S>UOO3W3@'Q#M3Z#]T?8'A-A>;VM]Z>Z< ^(=J?0?NC[ \)L+S
M>UOO3W3@'Q#M3Z#]T?8'A-A>;VM]Z>Z< ^(=J?0?NC[ \)L+S>UOO3W3@'Q#
MM3Z#]T?8'A-A>;VM]Z>Z< ^(=J?0?NC[ \)L+S>UOO3W3@'Q#M3Z#]T?8'A-
MA>;VM]Z>Z< ^(=J?0?NC[ \)L+S>UOO3W3@'Q#M3Z#]T?8'A-A>;VM]Z>Z<
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MC2(<BY'3XW:\@>6%S5MX4F*1A/Y;DM%"CGTP=-*>FP/9 L&XLE0I^4/F0Z8
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M0[9[HJM?1=D"Z0MJEWD&X4.A2,8R*&BRL0Y)J2;*5IE]A@2=C'34UA,O$6Q
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EF2^2,)QQ+:1.&,Y*=>FGW_/Y_L]JL:X4)PB<(G")PB<(G"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img61678762_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_12.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M,,-0AV-#.#@(ORC^$'(&0#CGF@#T*@ H * "@ H P?!/_(CZ)_UYQ_\ H(H
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M)JZ[=0:!3.-NT[L=QV/M0!JT % !0 4 % &'XL_Y ]O_ -A&Q_\ 2N*@#<H
M* "@ H * "@ H * ,7Q-9WEYIUO]A@6>>"[AG\MI-FX(X8C/;@4 1?VKXA_Z
M%D?^!R?X4 ']J^(?^A9'_@<G^% !_:OB'_H61_X')_A0 ?VKXA_Z%D?^!R?X
M4 ']J^(?^A9'_@<G^% !_:OB'_H61_X')_A0 ?VKXA_Z%D?^!R?X4 ']J^(?
M^A9'_@<G^% !_:OB'_H61_X')_A0!:\,V%QI?A?2[&Z"K<6]LD<@5L@,!S@]
MZ -*52\3J.I4B@#E=$F\2:5H.G:<_AU'>TMHX69;Y,,54#(X]J +W]J^(?\
MH61_X')_A0 ?VKXA_P"A9'_@<G^% !_:OB'_ *%D?^!R?X4 ']J^(?\ H61_
MX')_A0 ?VKXA_P"A9'_@<G^% !_:OB'_ *%D?^!R?X4 ']J^(?\ H61_X')_
MA0 ?VKXA_P"A9'_@<G^% "^'[;45U#5[[4+1;0W<L92(2B0@+&%R2!ZB@ \*
M?\>>I?\ 83NO_1K4 5D&MZ7K.LO;:.EY;WETL\<@NE0@""*,@@CUC- %C^U?
M$/\ T+(_\#D_PH /[5\0_P#0LC_P.3_"@ _M7Q#_ -"R/_ Y/\* #^U?$/\
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M#U'X8W]]J7@#3KK4;I[J[;>'E<Y+$.1_2@#KJ "@##\6?\@>W_["-C_Z5Q4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * .6ANK[2=:US.@W]W%=7:312VYB*LOV>)#]YP<[D;M0!;_P"$ANQ_S*VK
M_E;_ /QV@!#X@NF&&\*ZN1[BW_\ CM "'7K@KM/A/5MO7&+?_P".T ._X2*\
M_P"A6UC_ ,@?_': #_A(KS_H5M8_\@?_ !V@ _X2*\_Z%;6/_('_ ,=H /\
MA(KS_H5M8_\ ('_QV@ _X2*\_P"A6UC_ ,@?_': #_A(KS_H5M8_\@?_ !V@
M"AJU_J&KV]K9Q>'-3A/VZUE:28PA$5+B-V)Q(3]U3T% '6T % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M: *OVSQ3_P! 32__  :2?_&* #[9XI_Z FE_^#23_P",4 'VSQ3_ - 32_\
MP:2?_&* #[9XI_Z FE_^#23_ .,4 'VSQ3_T!-+_ /!I)_\ &* #[9XI_P"@
M)I?_ (-)/_C% !]L\4_] 32__!I)_P#&* #[9XI_Z FE_P#@TD_^,4 'VSQ3
M_P! 32__  :2?_&* #[9XI_Z FE_^#23_P",4 'VSQ3_ - 32_\ P:2?_&*
M#[9XI_Z FE_^#23_ .,4 'VSQ3_T!-+_ /!I)_\ &* #[9XI_P"@)I?_ (-)
M/_C% !]L\4_] 32__!I)_P#&* #[9XI_Z FE_P#@TD_^,4 'VSQ3_P! 32__
M  :2?_&* #[9XI_Z FE_^#23_P",4 'VSQ3_ - 32_\ P:2?_&* #[9XI_Z
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ML5&1@0I!^]CTXQF@#L/#.JR:YX8TS5)4$<EU;I*ZKT#$<X]LT :M !0 4 %
M&#HO_(R^)?\ KXA_]$)0!O4 % !0 4 9%[X=L[_Q%INMRO,+K3ED2)58;"'
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M *&+2_\ P,C_ ,: #_A+_#/_ $,6E_\ @9'_ (T '_"7^&?^ABTO_P #(_\
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MH_LTT32#?<"5R "/O-T..>M 'H?C.UUR\^&FD+%!?33![5]2@MR1<21 #S5
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M .3* #^U/B!_T"(O_ 2+_P"3* #^U/B!_P! B+_P$B_^3* #^U/B!_T"(O\
MP$B_^3* #^U/B!_T"(O_  $B_P#DR@ _M3X@?] B+_P$B_\ DR@ _M3X@?\
M0(B_\!(O_DR@ _M3X@?] B+_ ,!(O_DR@ _M3X@?] B+_P !(O\ Y,H O^#9
M+V:]UV34XS%?FYC\V/REC5?W2;<;9),\8[_A0!U= !0 4 % !0 4 % !0 4
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M=V]M"NZ2635+A54>I/F4 2Q^$=$EC62-KYD8!E8:G<8(/?\ UE #O^$-T?\
MZ?\ _P &5S_\<H KWOAOP[IMH]U>SWD%NA :1]3N HR0!D^9ZD4 6/\ A#='
M_P"G_P#\&5S_ /'* #_A#='_ .G_ /\ !E<__'* #_A#='_Z?_\ P97/_P <
MH /^$-T?_I__ /!E<_\ QR@ _P"$-T?_ *?_ /P97/\ \<H /^$-T?\ Z?\
M_P &5S_\<H BN?"V@65M)<W4UW!!$NYY)-4N%51ZDF3B@"@+'P6=*_M0:L_V
M#=M^T?VS/LW>F?,Z^U "W-AX,L[*"]N=6>*UN#B*9]9G"2?0^9@T :2^#]%9
M0RF^*D9!&IW&#_Y$H 7_ (0W1_\ I_\ _!E<_P#QR@ _X0W1_P#I_P#_  97
M/_QR@ _X0W1_^G__ ,&5S_\ '* #_A#='_Z?_P#P97/_ ,<H B\,VZV.K:_9
M123M;PW$7EK-.\I7,*$X+DGJ<T =)0 4 % !0 4 % !0 4 % !0 4 8'BO\
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MT5R)6,<X!P1N0*IX^ZI/0&@#V?PC)<R^#-$DN\FX:QA,A;J3L'7WH V: "@
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M0 ?:?%?_ $"M(_\ !C+_ /&: #[3XK_Z!6D?^#&7_P",T 'VGQ7_ - K2/\
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MWLR.L=O*TBJ%C5>695Y^7TH VZ "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
, H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img61678762_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_13.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 3T"7 ,!$0 "$0$#$0'_Q  ?  $
M @(# 0$! 0          !P@%!@,$"0(!"@O_Q !D$  !! (! 08"!@0("0@%
M Q4$ @,%!@$'"  )$1(3%!46%QA76)C7V"$BEI<C)#%55I74U1DE.4%4>+?3
MUCA167>3F;;2,D)A<90*)B<S-#61P2@W4X&UT?!$15)B9&9R=>'_Q  = 0$
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M-(1'1_>/U/!EWXS$AOA[A2X*CN3GI$I,;$)+;CS<76\XIV6TL)/9XH&-82=
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M8F:?Y'=F=3:T9+XV5Q$G180)K*(2FV#45VM)K3:FAVQXBN0)LG/S9:4J2M3
M0I166D.OKQE+;B\<O;;=-OMS8M\-*7IT]Y26DK6AI*W2E;JM2UE*$9"5')(&
M=JN9<MFVPW94@K;C16P5E*5K*4 I0,)&5'&0*T:7V+V3V]:U59:WWKBB"*,3
M[[$PMDV!1-66J)-QE8^$SU=38ZQ/AO>%OQ^V3XN49:6V_P"E[G$+S:HF<1\$
M7.YV^/*-NG!/8K@EGLTA*T82YR]:T/(([X.IL@YVSM4%4>U\1PX<IUCM<8GM
M$4N<YLI5DHUZ4J0H'ND85GV5N-UV!V6>PZX=4[9MCA,?!2*Q'#!0]M:>@B'%
M EL'#91)U^T1<J/A!0[*UI'-:2\A*F7\.,..-KJ+7=;A99K5QM<E42:P' T^
MA#:U(#K:V7 $NH<0=3:U).4G .1@X-3YD)BX1UQ)C//CN%!6THK"5%"TN(R4
M*2KNK2E6Q&XWVK2K=9^R3]IJ$W*W_B--XTI'YE*3&5G:U#EI].( :,+&!#K]
M<MJY38,N_BNQC $/+"6,^9,1@)H<LB3*;+M[5>N)'IDZWVZ<M,CB^2B%<4%,
M9*;@]<'7F EU;C6E@.+GOA2VBR$ATG("4Z8$VW6MN/&E2XH+5B94_$5]<HQ&
MXR&W,MI0K4LH3&;("@LGECKDYA+8',CLE=HPC-<NM;C9*(8D6)5H<#45LK;R
M3AF"AF75'UF-AY!;:63"$J&<*4(XI:7'65N,LK;[RS_@\_"=P_*5.M#3$*4M
ME<=3R)UL<)96MM:T:7E.(P5--JSIU#3L0"<\S/XKX0NC*8T];LAE+B70A<>4
ME(<2E2$KRC2=DK4-SC?IG%;@C_ V:6RG9U=LO&>6F:MG#X,=4-LQFTK(0N2_
MQ,ZF-H(EWLA-@6V/(NNDLMPAV0!&R)12&4 J)9YUGB7COC-U/#'TJY/^E,M]
MD>1 CMO=F29A"G@PUHT]FU@\Q.HI"<G.#;N6CASA]!O'84QA"PL/M]I<6WSB
M(^4HYB\ZN:$GNG .3C&1"LCN[L7[;<G+5+4X/XCF)H:0)DWZALV#B42*GVO
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M]Q@;J>++ WPW/CP&;PQ>6WX#,U4B, EMM;KTAHQE)3(D@K;Y 625I.'$Y0G
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M7?3&"KH9,UUS(E[OK^$N4AQ<Y'PITL"86_# TP:9"%6,88,AEJ7-D*\84AU
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M"*]([9)2E39+:VDAG"Y$8:E\PJ'UF<(/=/4>KY<UVF$)3<)RXJ+[;/9V2H*
M6E:N82&7>ZG1@]SJH;BL39N<LS%;&UK24\0M_P D!=XY)1TV76&QCX)6<$9\
MB/AVQI(*8;QEE/\ "FV*N*SXU9]/WHQAR1 X;9E6*_7@WR-%=LSQ::MRDIYU
MQ T#F,GM2%)!U'T67O1._EKE79;-SMD#Z/=>1/;UKE@JY<0][N.#DJ!/=\5H
MZC8TK'.::E=A[+IF>(>_XT&C +*CYH.LMD'3JD>5G#,A$.#1H<*WG+F?X0*P
M616/#C.&,^+/@S<.&F8MCL%W%\C27;R\&G;>E*>=;0=7UCRNU+4I/=WU,L]1
MO6(MV6]<KG!-N=91;VRM$HE7+EXQW6QR4@$Y\%N=#67TSS:FMLTMRR3O$[D/
M6R,3)L9[5'51JT!J:#:#>;)5(2V::1YKBB584/[.IMKRD+08\IQ2&8O%5@9X
M9NJ;?&NT>[H,5J3VR(E*&PIU3J"SAN1)&I ;R?K,D+&4CQW62YKO$(RGH3D!
M7.6UV=\J4HA 0H.94TT=*BK [G5)W-=;9?.6>H%IU;6XOB9R&FP[[8/8Y XV
MLH@GZ^,B1KX&"XV/ 19!IM[#4P^]@(Z4K#&%AL,8D/++>( V6#AQB]V[B*>]
M>(UN78X0F-1GTH4Y<UEB:]R&"N2P4KS$2WE*'SJ?02C( 7XNEU<MTNU16X+L
MM-RD=G6\TI240QS([?-= 9<RG#Y5@J;&&E=[?(Y-Y<W9G5]/%L49Q+Y"V\A^
M>"BE1<U56JX(TT2'(DJ-2?&XNI"WVE!H:0-F(::<0^XXHYE32&2//"/#[7$E
MT<@/7B/9$HANRA+DI2IM2FW6&PP J1&&I8>*P>83AM7=/49OMS7:(:)3<%RX
MJ5(0SR&2H*2%H=7S20R[W4\O2>[U6-QXXS17.69VU79N3F>(6_JBJ.F$QR(^
M&K#=H%,;]&,5ZI\B5&H[C#V%N^7AA$>8WX6T.^KPM666Y'&'#3/"\V)&CWR/
M?!(BF09$5*4)84'5M\E6B5*[V$A>=:3A0[OB==ANR[S'?>=MSENY3W*#3Y4H
MN#0E?,&6&MLJT^B=QZ7@.Y2.:DC:MA[%IA?$/?T4#1R!&8Z:#J TF=-8(<?0
MI9L04B%#AE->2E24A6"Q87E6<*<:PE*EZKO846RR6*[MWIF:Y>4.K=@-8#UO
MT)0H)?4)+JE%>H@:F6<%)P#X>X-R,RXW*"J N.BWJ0E$I>2W*U%0U-CDH TZ
M03A:^N^*N7KV]+O\.7+N4J^47(LD['8BMA08\!,$X:%$)]P$$&DI-#L:YDO(
MS1.7T*44*6UEK&&DK7RE77VY^_KK!;PO+NM]86J["TR4OY]<CGYB+K$3!S5@
M*.E(IIR3 7Z*OPM@EFDL$AMNMF"Q1"AB4CK\8W?ZIE05^:=O3M]@)\Y5,E**
MQ"W:S5L"&F(*;KIA$?'$M/"3"XV<A8)Y"Y1LSU)*@!S8I)V2V 9B60PHYY2M
M1MO_ "IM%_\ 4KR2_P#%W&GKI(?]Z=__ ,^<,?T/BBJI_P#=JV_YNN_](L]6
M(ZYNK6G2E.E*=*4Z4ITI3I2G2E.E*=*57GD+R5HO&<354KL2)MK\!MC<U T6
M!9*\##%P=0N&SI%4)39"^ERD]#.0-4E)_(L J>'8DVQ9>3BQ"6&LR ZEJR 3
MG'@,_8.M8A[EIJJ*OI]&N+[NNV8ZO;-M9%UOMFUC7*:FO:KV%2]6S<N\^_L!
MVQ QLM=[HS"5^0DZV""^7!S0TH3$%O5T:P*8_J\_$9^_PS7!NOESK#3&BK)R
M1:$GMO:?I]3V!>;1;]*E4BY14/5=91TL;;I3,F?<Z_#R;@)D*= -Q,))2DX_
M/M/@8C$H E2 % "2!XG 'V]*^;9R[UKKG0,IR,V?"WG7-)!>JP<9$6"'B).X
M6Z1OS]: UY%4R)IE@M05BE+Y-6Z K]>!#EO.;G"R )M,,J-E%AJ8.<>._P .
MONK>AMZ5N.P7G:,/+:&2PFN)#)W%.:X@XF<.LHUC+'A8"QUV^6FLRL]&L568
M>F80>9S) BM#R'IG8PL<UQ3'V_U>WWU"^J.>&F=P[LSH2LQ&P0;MB2Y/1'J)
MV$@Q8#)_$C:-'U'M=G!X%FDR^Y=GV%7"*N[F.PU,0[A91"XXH50*E9*2!D_R
M?YP)'[#5*K5VBO"W5^^]X;MM-:W[$[#UW3>2^EIY2H.H24!:0^%(50VUNB,I
MT?%W0Q]$M$5Z\05@AI:U/UB)L@+A,1'D9GV/:UVZ[W-78V>'CR?H]BY.71&&
MSS^U.,=F5J<UX+?+Z(T A6^KPJ"FV,"XKN@U]J=B(A*[WU89#O-3W-.RRO\
M2U'88QXUZ27CEAQPUO4KO<[ON?7=?B];5N/M=]#)ML$_8:E$2YK,5$*FZX">
M5-!E3$V2/7X@-87GRL^^S#QZ"3W6V%5%30"<8!WZ5'U-YW<<[ML7;E"CKG&1
MD;I>WA:[MFSK'9]?0.LSMB&T2K;*12*S+GW1N>G)I%-M*991+-::@7<5VWC"
M3))-:D6FU,';U[@>K)&?>,5+,KR8XX04K-P,WR!TE#SE:.5&6.&E=K42/E:_
M))F(>O*CYN.+GF3(HY,_88"#4(>RP_B8G(>,RWZV3"8?5C!\OO\ <&MAU]NK
M3FVG#VM5;:UGLUV*C8.9E&]?7RK7-R-A[-@]5;E3T5R5DE!QM@Q%2F8,XC#8
MLMB-/R Z1@,CRU,5)G2E1R#.7=_:4]!$1,;C78=3BBHR99!GV9C%N4<[F5"D
M39(<* ,C"8HN-<A$U=<\\P7'6%NS%P;WLH4FI79V%9;E5XH,VE:WD]FR+\@D
M4J&B[)5JP\"$H8AU4FX9;)&,!?:0^TP+D4=Y9>5E(=2UEEIY25/MQ]_559]E
M[VY30%&L$O2>'EBD+0$..Y$!R.QM;S@;[RSA67DOQ57M*YXQ*17'UI1'(4ZA
M:4NN8].V[GJXL$2VS[O"B7>:;=;GG%IE304@QT)9<6E65I4GO.)0C=)]+SJ#
M='Y<6!(?@L"7+;2DLQL*/-47$)4.[I.R"I6Q'HU4>O<P>TI-GX,*7X*,L1)<
MQ&"RC['O8;[,<08RT:ZR7(V%,>*ZT,MU;9)ZL!,+QATO*64KZ^F3>#_P:LPY
M;T7CA<B2U%?=CL:XOUS[;2U,M;1P?K' E&Q![VQ%<?&OW%SDAAM[AQ+3+CS2
M'7=+WU;2EI2XYNZ1W$DJW! QN#5G-R<@>756IBY77'#:<EK)B3 '2)+7NC68
M3(+WG>J<S&4FT.S>7$>%OP/I3Z5KOSZC./$CKY]PM;K+=+J(M_NAM%O,=YPS
M 4 AY&GEM9<0M/?RK]'.VQKJ;U*N$*$7K9$$^5S6TB/A9^K5G6ONE![N!X^/
M2LQ([XY5,:Q)L ?#NPN7ANDYEF8Y>Q-<O1RK-[+@KT:H(:TYM2P_<N]KVMI&
M9WR?XKA'KOT=16(=L7Q W =G%NSJNW9%W+*,IM_:N5VS)3H_Z/\ 79TZ?Y.-
MJW./RTVM4I$<*GB#STP\*WE\C7V?P/YWZOTL^O.]<FM-[<II^C5^7NW#RQ1]
MH-'(<EPX[8VMX,-AY!Q3+*6(JT6E$\&E0K;"U(D4)=6M2G6\>G<:SUB_Q+;
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MY],OM.OL'"?_  ]H_P"(.NI_$O\ !=_C\O\ UXG_ )>J7\8>,O\ %E/^J_\
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MQ:^TD"'W_OW?XT]YX\[**6<Y+\@K%7WA<M89S'0L04VXV4X<DA0JR,8Z$GX
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M^T8_SI^/O#O^&D_JKE/\+]PI_I7=_P!W\[_Y.G]QWC?^"0?]HQ_G3\?>'?\
M#2?U5RG^%^X4_P!*[O\ N_G?_)T_N.\;_P $@_[1C_.GX^\._P"&D_JKE/\
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M;GF&:8+,<\:DY5XRBB25]_B?(>=RIQ7SQY:7'G7$(#:%N+6AL8PVE2BI*!@
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M4E0"AJRDD$ C"@=COU%5!U1P0Y<T:^PEHL7:'[@GX>-3)X+B<-RL[DK)L0>
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M(UPN=J8O4-E$A+ENDI94R\76'&FU*3(9D-$M+6EU.II6%(!24J (M+O#DW"
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M).4C!!WJBW^#CYJ?])1M_P#K/:'XJ_\ _.OL']TK@C_X967_ +BT?_:*X/\
M%+B+_&^X?]Y._P#/5Z$XTENS&,8SS)W'WXQC&?\ Z.N-'_W=(YS_ /;SG/\
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M*0)$%JS6RXB1,5++TY*U.(*F66>6C3MH 9U#QU+57N]\,M7N2U)7/EQ"TP&
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MD.D\M20E:7%Y"2%Z@,#.QZ5+NQ^&S^R*/-T>3Y-\E,1\XP$R^HBUT\ICPAR
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MS+AI@!AJ&PWFO5X'8;9;V\073BCC1HW^X0R_$M+8A/38D0M18X6Z'$H?4%*
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MDQT%0%9JT=+ 0KD2B C#V0C&VXZ*%BQ9,D&-$:'4K2;;_P J;1?_ %*\DO\
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M_P"$JR6>;=;/%5$M-TM2)DQ\2;$[S[8F*[(0X6I+[LEO$9]U>AMMN1W])1S
ME(XVX73A*Y3X\*>_SYT*:J/':+5R1RIA>0TI&MIM#*OKFD))6M37=SG223/?
M@[''^;.SA_J/C=_8>OF%=EW_ .5\:Q$]+]C/78@V:-@NS\-% ;2Z\+6]?Z/M
MTV\E3K;6$Q];JM>F;!*NX4XE2F(R,+>0REQ];:6&G7$3K9;9MXG1[;;F.TS9
M:RB.SS&FN8I*%.$<Q]QII&$(4K*W$C;&<D QIDQF!&=F2W%,QV$A3KFEQ>E)
M4$@Z6TK6>\H#"4D[^5:9 [+[%*UCS>0J=PZC41$8\>9FR<>JO0B2!TH<\3->
MS:M<UXR>F,X0KT\76/<)Q3F6O3"9=<9\707/@GBNPNV[Z1MG9';A,;B6_P#+
M;<_SI94GEM_42WDM]Y2>^]H;WW5C-5</B*SW1$KLDPOHBL*?E?42V^6P K4K
MZUELJV!V;U*\ATK0Z?(=AY9H\O7T6!I0)$BZN6<L5\@=A4^>%R+D):A(W=.Q
MP86QP(KOI&DHKD5>8\0]+\FRW&$)E)9!?57]C\*5FF1^,KX%1ID%M-O8N7,X
M?>++;XDH2SV6&IUM>L29 YBXRBGF;K&E&FDMCG!MPCN\/VT\Z/)493L,)NC8
M6IHM++G.?"%ITEEHZ4O#.G&D@JS(MAJO8M#1$1(&O\/LBT(%9C#54MU<?G;
MS',"O*:M$73)IRQ;DD2$1J$ICK>)=I29(*D!TC'$SLFW(<G:N(>*79]QB6N8
MHSN+Y*8UP1R8"?I&1-<?;""N0R&HO-<G/C4TJ,A'-R5)"$E%Y.M5G1&B/S8Y
M$:PLEV(HN2SV1J.AI14$M.%;VA$9LX<#RE:,845*U?IVQ^Q5CZK&7!ZG\+WH
MV5*P(/&1W'ZE2MR&<SZW^%E]?1FNR[W!!_Q%WOD)NN1X./.C^\C_ !I&^KUQ
M^#.)9=ZF</1[;S+Q 9[1+A]L@(Y3/Y/W^T+E)BN?]*8[K;ZU?6=.ZO3Z=XAM
M3%N8NKLQ2($ISE,2.1*/,<^M[O*2R7D_F'=UMI'=Z[ISC=6O=BB<!,FU\#B>
MIA^4[B6MVPT>W)LD890]X:Y&\@1$RT?">!_"?!5A1J_DA"F.[)(BVV9W&J>,
MF9-NC<9:A)9A?^ST%5L7HAEPM[*MA4V?K&B/KE%WNY]$@F/PZ;$XS+>X?R67
M)/Y4H":-4C0%])@"AW7 ?JP$;XZC;6KE;.Q!L4RQ3)*!X^Q)@<VV"F6UMK.S
M4"%?+?7@-+A>R=4UBN5^5KJ,O8></-LY=6&2C,DZ0TD;)35OP[8OPD6. [Q)
MP_&,2#*MRI+LT2+&[S+>TDR5+[/,>=>3I#97I2PE\XTA))TF!=KEPI<I*+1=
M7N?(9EI:1&+=R;TREGDA/-80ALY*].2X6QG)(QD2M6:OV,U5CEQ@2^"<PRLI
MPO)=YLFJ=DS*5NH:;4RW8-ARMHG6@4892IB,:D41PSJR'QQ6GBB7'N)O5]NW
M$,M,^\RS-EI81&2Z68[.&6U.+0C1&:9;V4ZLZBC4=6"2  .BMULB6I@Q;>P8
M[!<4Z6PMYS+BPE*E:GEN+W"$C&K QL.M=>LVSL8+9[I[?6>"<;[0;D GXNU%
MJFA^I>3X^]Z'^-J?7_?X_P#4SW2L%[C&*[T>$O/F-^+W>.'KQ8.Q?2T/LGTA
M'$J'^417^<P=.'/R9][E^DGN.Z%[^CL:Q NL*Y]H[#(4_P!E=Y#_ -4^WRW1
MGN_7-MZNAW1J3MUK9G/\#@VVMQ47V<BDMH4O*6J_QR><SA.,JSAMIJ/6ZZO.
M,=R&VT+<6KN2A*E9QC-.E*EJ2A(RI:@E(R!E2C@#)P!DGJ2!YU/)4D%1U )!
M).^P R>E1&U'=B;N$=$^RGC'4&XYYZ(P"P:3QI?)6A#!BBGZB.3JXF<:S@M#
M(]B(ACV5J:(C1I)2P"11^]^D.._P;NKM//597)J&[BJ.$VFX!U"E.1D/<T)G
M)1DQW$<L.(5W-2D84E2N8[)PYQ<A,XM_2*(ZEQ4NYGQM"@$.K;T:HQ5LZA6H
MH4.]@*V(&_M1_8RUJM.">FX'R8,1&%J426G4E[NA3#+3S[F43)N;!?K%-*3X
MD Y;.DI]][ XT=EPC S6.6<EW2^7E,IQPRKO<9K&EPICLEZ8XMMICNA+49O*
M^6G=*&AU7@9-72&(MMMZF$(4S B1W,HR\X&XZ$J6YN2MU6$ZCU4L]!OBH>J4
MGV'UKC7=>1D?HV/;(\V358[O6[W1K$U@=\<A0P^[-@QT!9P4.+0AMJ"%O8[9
M@JRPF8]X-\UASOKY%_"?89S?&=Z2J+-8"(+=SYE@?* \T\RAKLD1;S9U-+=3
MK,8XSDK!"2.7MKW!]SC*X>MQY\9S5)5#";HV"6UH<4OGO);6,+2@X#PSC !&
M16XJI_8J4:M6IY9G%6; /CO#(9=O8VU[D&RT@EKQT1+MBM][K\PO!BUJ(USB
M-G"76 B%..O18#HE#^,W&?%5XL:.W*GW>#,UV0<BV1BU+<4RYD'D1XRLJC,J
M_*BIL<O&P4H*L_H:PV2!<E"+V6#)8TW'#DUW6PD.(P?K'74@)><'U.%][;)
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ML0I_H;#8^/;+Q-*MMBC&+Q'$MY=DLB19W>7!?,4E7-E/.05ZR]&.E#BGAJV
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M/)'::42_EM"<NN>+0W=KJS%DP6KE/;A35J<F1&Y<A$:4XO2%N2&$N!MY:@A
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MQ(^VRDOE[%@&<!G(@L\O!IU<D(4WTXX;X;25/O\ ?[:C^V_\J;1?_4KR2_\
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MCO.H(&0 >59OZ5621>DVA]M<=X-=BQB0O4XPUK20R"!A[4>X>ZA6_EL^C>T
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MD/3M<V"TS==A;6% -,RGP_-Y5Y<DZ&\A[#,8RU!60@R>2VEUR$ %B'R#I%#
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MAG^;?I3 \Q\?E3Y][4^Q/R<_:OAG^;?I3 \Q\?E3Y][4^Q/R<_:OAG^;?I3
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M'+UO5^UC#9!)B1&4QK\)'C+&>(*S*H=&:$+4]OW^(KP^(N/_ ,H*]0_Y&J-
MX8\YWR<8E-8.8PUXU>7C"W-BLK7W([OUULM+5_*IM&<Y3B\";%@9<?SX[.?V
M=4I7>O!IG'M;_M:]+]=6GGXJ@TS-^TAQF>N^:Q"9MSKW):_0+SECS'#^\+=A
M*_Q;NL%$K4?Y^51T/;[/&AYSE@*>E1T-FO4[W+YKG))+6M7+)SDHR=).<'.,
M9R!5NUK+39=V=*$\P # 7@:@,*(P#G&#5/N0]N[:A&Q7DZ'U!QW$H7LL7EIH
M/8<'>F<2_P##>Y*]^O\ 'Z8L"U*_@?$(NE-AC?H]-*'^-?E6$1-K+7Y6MQ+V
MI6R LC3MI]%)&>OC4"4JY!W$5#:FM(W7H!U;ZANL''3YU'NO+AV\2K]3,7O4
MO'QVD9M,%BVM/6>BP3+E:S)C>](=FX"QW.=B4*CO485)0]0L\F'C.2 H"6(;
M;!?VNILW*<Y3CQ=T*Y8(<P5X.G.48QG&<GIXUK:7=RXV'6V@UK3S""WD(R-1
M&'#OC/05:/DU;.U2;JE?SQVTQQN#LV;#W3C@.[)'83BH+VTW]1<;LC4VB8L%
M'N'I,^N L$P?XL8']F].Z\:-"AB&7%=M4M+>CNZ-6=>1UTA6VG-3)AE!">QI
M2M>KO!>D (P=QJ6-\XK(<;+7VH;E"D,\@]+\;#+MBTR& '3=Z3- >Q6_;(;(
M*,0NN],[Q@WT8D<RV<2+]O#DW\J4._ !C""'2?F8(@='8U+4UH&2O5G7E61W
M@#C&GP\ZS$,DM$RPE#NLX"-)&C"<'NJ(SG5XUIM1MO:WYD^2GQ3IOCBY'(38
M_H^)<V\J+2&K#]K]@]$1%:_L9-_\#.*QA&-B :.P?AMM<@J%7)RC5>V+$'3#
MT*65'1VS.KN^AJT93_V_1U>&/#.M!FYEZTI &OL>-'?W7HU]\XR-&=6.I^R3
M- 6OM+%ZTBU;QTIQK*V'Z^7Q)/%[_LM)?4%Z]WVO"J_1-"[AK@R4A>4E+PUY
M/?*QCSRPXU]2A&],H1P\KLI4IG"=)5G.<#5Z0!ZY\*W12^6090"7LJR$!)&,
M]W<*(Z>NII^*.9WU&<8?O6;6_)IU'J1MYGW#YU7&BVSM3,[WV6BZ:7XW.:53
M&X^7@SN[Y2&$9D//AN_+%SA-0VR[V!66<RW\7L>I*,/C"E*]=E8@;4I+=$/L
MK):4OM6KZY)U:0.]N,I"?WO0GK41LRC)=#@2(P3]2H!.HJ[O4!9(QWNH'A5C
MOBCF=]1G&'[UFUOR:=1*E[>9]P^=/BCF=]1G&'[UFUOR:=*;>9]P^=/BCF=]
M1G&'[UFUOR:=*;>9]P^=/BCF=]1G&'[UFUOR:=*;>9]P^=/BCF=]1G&'[UFU
MOR:=*;>9]P^=/BCF=]1G&'[UFUOR:=*;>9]P^=:M>;3SSQ2KAFF:/XR-W#%6
ML&:HXUR:V',.-V3$27F"6W$37%2J0TJM,IZ52(Z6M-:C#E8P,?/PPKKLB-[;
MT<QOF$AO6GF$=0C4-9&,G.G.-C7AS5RW.7NYH5RP0,%>DZ0<JQC5C.:JG.6[
MMC,<;*BN&T[QT3R#S87\6DQ&T03#7(+W:S>2ER@&U>*UW%H]KQ74^NBMXV,]
M>$(*7#,E2$C'04Y*;=VQP*6YV/3]6H!>LJTHV/=U>EK\/ >%0E*G]D04H099
M6=:.YH"-2\$'7I)TZ#U\35SQ[1S3\AGS]&\8<O>2WYW?RIVFC/F^!/F=Z&^'
M+R$?K]_ZJ'G4)_D2XO&,*S7'U=*GC&!DG/CL/G7-\4<SOJ,XP_>LVM^33I6=
MO,^X?.GQ1S.^HSC#]ZS:WY-.E-O,^X?.GQ1S.^HSC#]ZS:WY-.E-O,^X?.GQ
M1S.^HSC#]ZS:WY-.E-O,^X?.GQ1S.^HSC#]ZS:WY-.E-O,^X?.J_:KM?:@JV
M5N5.R]+<;7M>IF@\:E9(WK,UMD>(]9->K2-8*QI?8%BMB5"XB.\NWT;6)C.$
MH=9BRGBS!HN4^(H9C\A2B\4GM 5JP%83@)R ,9U=">@J*R9)>D!\)2R%#LY3
MI)4G*LE6%$@XT]0.IJP/Q1S.^HSC#]ZS:WY-.HM2MO,^X?.GQ1S.^HSC#]ZS
M:WY-.E-O,^X?.GQ1S.^HSC#]ZS:WY-.E-O,^X?.GQ1S.^HSC#]ZS:WY-.E-O
M,^X?.GQ1S.^HSC#]ZS:WY-.E-O,^X?.GQ1S.^HSC#]ZS:WY-.E-O,^X?.GQ1
MS.^HSC#]ZS:WY-.E-O,^X?.GQ1S.^HSC#]ZS:WY-.E-O,^X?.GQ1S.^HSC#]
MZS:WY-.E-O,^X?.GQ1S.^HSC#]ZS:WY-.E-O,^X?.GQ1S.^HSC#]ZS:WY-.E
M-O,^X?.GQ1S.^HSC#]ZS:WY-.E-O,^X?.GQ1S.^HSC#]ZS:WY-.E-O,^X?.J
M[R]K[4C'(^KHB]+\;4Z S4R,V01.\98H)=G]'8O(<<OI>G(W84<Y@K$#G$9&
M:2GXM>4H:<L3+1\@1"RTB)V-945]LY@T)[V@MY1DG;3G&OJ0>GVQ5&3VM 2E
M/9-!UJ[NL+PO  U:L9T>!ZG?R:8M?:D*O&Z\;;TOQM(IR+6C&H&R=XRU3:'K
M'N]J\;8TQ3].[/FK<W[7BLI]SN-5U;*82A!6*\LJ2DXZOI B!N/V=2E.%O\
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M_<=9_)W=/&8\#XP'^8RTZ$L=*])4_/ ]0_D>U[TVP_9L89]=GV>!-H,FYX?
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M5H;=QAQ6%*RWZ:?;7FASQBMUS=K[+22X:6;$!S*U;P.W9M*N1VPQ@2]#W[2
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M?F.V"22^V.!(EKBK=S$;4VUH TKSG7DY.ZU[$8_2]U:(B9"&B)2PX[K)"D$
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M(AD J$G=E[2+,D&S$'$.2C4\$.Z,2*(F(9<#=,.HZN?9]_@*Z6VJ]:+50YF
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M'U@?^EC?]NU_YNJ[!\C[C4_(\Q[Q3U@?^EC?]NU_YNF#Y'W&F1YCWBGK _\
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MEUQ>/+\KR^YS*DXB2NRK4OE-O:DZ,.=!N#D;'O;8!]M)<8RD)1S5-:5:LM@
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M\1U[^?8;^M ?]_TI3XCKW\^PW]: _P"_Z4K0]E[QU%IZG2>P-E["K%1IT,X
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M'EQN/?./$# '>I"\KS^^/E:".5AK^%1Y;WE^6[^MX%9\.>[2_'=C.<IY(2O
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M2M)WW2H @X\-CTK,^Z=EI_0;BI^Y.G_\$=>:]=_^5\:>Z=EI_0;BI^Y.G_\
M!'2G?_E?&GNG9:?T&XJ?N3I__!'2G?\ Y7QK6[;#=DW=X$RM6"B\:511ZA5D
M8A=:@561\093)C'D3E6KD--B8\]AOS4B2+"26?&,3AT9UUE>QIUQA8<:44+3
MG"AC(R"#U!&X)%:W6DOH+;J2M"L92=6#@@CH0=B,UA*'1>R(UJS),56B<>$M
MRSHSQOQ%32;NO*Q$O(9]*[=XNQ.QR/"^YYK4<L5LC/@40AU3364>WI+\@I+S
MA<* 0G( P#C(& /(5X8C-Q@H,-\L+P58U'.,XZD],FM_]T[+3^@W%3]R=/\
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MXLE\ESQ//.+5E2E+45+4I:CU4HE2CX;DY)VVWK"4)0D)0E"4CHE.E*1OG8#
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M^W'W]51%\X=Z^+"OHA; \6,9QA7S2T/XL8SW9SC&?F'WXQG.,9SC^3/=CO\
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MIK95=9;$]ZFY&,H!WC:DY-SRJ[:Y<W/H/$V.MIB26'+<893&:>3(2MY:L+8
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MI\ <K?M)ZS^[87^.72E/@#E;]I/6?W;"_P <NE*? '*W[2>L_NV%_CETI3X
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M\5 LB')(6/&WVVW.HE*4Z$VVI$U6)9A+:UN,LM%H')8W,/+CNH>0$E;9)2%
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M)>G>S>;K5=X_Z%Y 2NWY.JQE@EQ@8;E+?,V9^**L)4S)R)->U;<*7511 3K
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M\O\ U^-6BZ4K%*@H5<XS9EQ,<JQ#Q1,$/.J#'S+LPII@D@7$M2&6_5-QQ1P
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=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img61678762_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_14.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M10?,MAG!'7D_G0!H?\(AX9_Z%W2__ ./_"@ _P"$0\,_]"[I?_@''_A0 ?\
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M"KF-&E7* GU/2@#&LOC!Y?A^.^U;1IHKJ2>94AC(&Z.,G<V3Z="/7I0!M/\
M%'11XAL=*BCED6Z,*?:!C:CRC,:D=3GCGMF@"E9_%JVO;?398M"OA_:4K1VH
M?"^:% WL">N"<8[]J /1: "@ H * "@ H YW0/\ D9O%?_7Y#_Z314 6TUS=
MXK;0S93)BV-PMPW"/@J"H[G[XYZ=1VH M#5]/:^-B+N(W0?R_*W?-NV[L8_W
M>: ,>Y\816=WK$,]A.BZ=&KAVP//W' "CZX&: *<OB^^,$;C3OLL\-_':7<$
MN9-@<IAMZ\ ;7SD]\"@"/Q)X^BT+5;^R5(7-E:1S/O?!+R,511[# )_WA0!T
M=EK-G<QVR&Z@-Q*?+VQMD&0)N91]!S]* ,B3QFD5QK#-I[_8M+8QR3B52S2<
M84)][G< #0!KZ-?WU_;/)?Z4^G2*V%C>59-PP#G*_7&/:@"EX>_Y#?BO_L)I
M_P"D=O0!OT % !0!S]W_ ,E#TC_L%WO_ *-MJ '^(_$$WA]8)CISW%HS!995
ME53'E@!A3RQYZ#TH OW6L:?8W M[F[BBF*JP1FP2"VT8_'B@"M>:[]C\1:=I
M)LIG%XKD7 X1"H)Q[G@].E '/O\ $)/LDTK6)M5E@,UA+/(-EPOF",,<<J,N
MAY[-0!/=^-X[33?#DS>09M702'+855$>]L?R'UH N>'?%UGK&BK?SSV\)9@0
MBOG:K-M3/N: +%SX@DC\4Q:';V#3OY*SS2>:J>6C,R@A3RW*G..G% #=!\0W
M&NR&:/298=,D5FM[QI%(F ; .T<C/49[4 1S?\E(L_\ L%3?^C8J .BH * "
M@#G9O^2D6?\ V"IO_1L5 %O4==_L_7--TTV4T@O2P\\<)&0,X/J3CH* +5QJ
M^GVET+6>[BCG.S$;-@G>Q5<#W((_"@"I/KP@\30:.UG,%E@>87)X3Y<94>IP
M: .;G^(,S6ZF'2Y('N DMJ\G[P2PE]IDVKR.QP?44 7M:\;V^D2Z7'F)_M=M
M)=.6.W]VB;OE'J: +^A^)[74M'M[NYN+>.63R]R(^0ID.$'U/% #I_$3IXH.
MBP6#3>5 D\\WFJOEHQ8 A3RWW#G'3(H - \07.NDSC29;;3Y$+V]T\BGSES@
M':.5R.1GM0!"O_)29/\ L%+_ .C6H Z.@ H P=0\,17_ (CBUA[EE>.REM/+
MV@@AR#NSZC% ',VWPI@L;K2[BUU5E>SMXK>7S+9)/.6-MP//W3SC(H A;X06
MS7NISG6)MM[#<Q!?(7<@F());.6QCC/:@#0O/ALEU<:J1K$\=MJ/V5I(?*!"
MO 8\,#[B/&/>@#*\6_#=]0B@@M1)<FZUW[?/(2J^1&R@..O(POUYH ZCQKX)
ML_&FDVUA/.]J+>82*\:@G&,%?H0<4 9TWPW@D\1"_35)X]/-W%>R6"H-CS1J
M K;NHZ X]J ,V[^$,4VG06EOK]U;;;:>UF=(U)FBEE,NT\\88_B* ->;X>V\
MUS=S'490;BXL[@C8.#;C '_ N] &5+\)E9$\K7) \%S-+;F6V218TE.6CVDX
M//.: -%?AW%#XJBUNWU )_J3/"ULK"1HP "I/*9P,XH K7GPPCN_"&D>&O[7
MD6SL,[V,"EI<L&!!_@(Y&1ZF@#T#I0 4 % !0 4 % '.Z!_R,WBO_K\A_P#2
M:*@!9=.UE_'-OJBBQ_LV*V>WP7?SCN*,3C&."F.O0T 5H_#-ZGQ D\2^=;[)
M(OLIBVG/E 9#9Q]_>2/]V@"IJOAG6]5U;5W=[".RNK=(X&5W,@9&#(6&,8SU
MP: -#2?#):6XO]>M[.?4)[D7 \H%DB*JBKM+ '.(U/UH 9K7AFYU*^U6>*6%
M1>6MI"@;.5,4LKL3QW$@ ^AH K6_AC5HO&"7S36G]EQWDMVH!;S2SP^7M(QC
M .3UH JZYX,U'7=;NKIVL;.,PM''-!N,LWS*R>:",85ESP3UH ZG1O[9^S/_
M &T+,3[OE%HS,NW'<L <YS0!FZ-=6]KK/BIKB>.$'4TP9'"Y_P!#M_6@#5;7
M-(3[VJ68^LZ_XT 1-XET%/O:WIX^MTG^- &5KWQ!\.:%HMSJ/]J6=V8 #Y$%
MS&TCC(!VC/)YS^% &;HGBS1?%WC+2+W1KU+A%TR\$B='C)EMN&4\CH?KB@#1
M\8^';[Q#]EAMHK )&P87,Q;SK=@0=T> 1G [D4 )XC\,7NL>(=(U2":W0:6X
MDC60$EV)PP;CIMZ>] %K6=.UF[\1Z->60L?L=D[-+YSN)#N!5MH (X!R,GK0
M!1\->%K_ $N\MSJ$MM+;:?9O8V8BR6:-G5LOD8!Q&@P,]Z -+4] -S=Z,UIY
M,-OI_F#R\8^5HF10N/3(_ 4 <[)X+UJ-;2"VN+'R/+MTN2^X,#%)N^3 YR/6
M@#7U_0=0U?7M+N(DLH[>SF287)+"X3!RR+@8VL!@Y/0F@"3PMI6M:';Q:5<R
M6<FE6<1BMGC+><R@_)O!&!A>."<T .F_Y*19_P#8*F_]&Q4 =%0 4 4-:UFQ
M\/Z5-J>I2^39P[?,DVD[06"@X'N10!B6]_::EX\T^[L;F*YMY-)F*R1,&4_O
M8NXH L:_INLWNLZ/<:>+'[-9R^9+Y[N'.1@A0 1T/?O0!7USPS>ZIXMTC6H9
MK9%TL@QHZG+[LB3<<=EP5]\],T 3ZGI>L7?BO3KV 6(T^VBDB?>[B4[]NX@
M8XVC'/>@#.T3P7-&T<6NK9W=K9V@LK:- 6WQAPP9P1PWRKTST- &EK?AV34;
MB%K9H8HX[*>V"L#P74!<8[#% &3<>$M8^WVOV:>R%F39O<;]P<&!LD* ,8(
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M^P\#"Z^TQ/JMM:QS3*,?,0 7X[ \T =-%(LL22(<JZAA]#0 ^@ H * "@ H
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MJ?\ ?0H /.B_YZI_WT* #SHO^>J?]]"@ \Z+_GJG_?0H /.B_P">J?\ ?0H
M/.B_YZI_WT* #SHO^>J?]]"@ \Z+_GJG_?0H Y^-U?XD2E6!_P")4O0_]-6H
M Z2@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Q=0\(>&]6O'
MO-1T'3[NY< -+-;([' P,DCTH J_\*^\&_\ 0JZ3_P" <?\ A0 ?\*^\&_\
M0JZ3_P" <?\ A0 ?\*^\&_\ 0JZ3_P" <?\ A0 ?\*^\&_\ 0JZ3_P" <?\
MA0 ?\*^\&_\ 0JZ3_P" <?\ A0 ?\*^\&_\ 0JZ3_P" <?\ A0 ?\*^\&_\
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;0]"DD?2=(L[%Y0 [6\"QE@.@.!S0!J4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img61678762_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_15.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MEP(> P$1  (1 0,1 ?_$ !\   (" @,! 0$            '!@@%"0,$"@(!
M"__$ #T0  (" P " 04  0(""0($!P0% P8! @< "!,)$1(4%18A)!<C&"(E
M,5=WE;;7-#@*&3(W)C,Y0D1VM?_$ !T! 0 !!0$! 0             ! @,$
M!@<%" G_Q !0$0 " @$# @,%!08$ P,* PD! @,$!0 &$1(A!Q,Q%")!46$5
M<9&A\ @C,H&QT18D0L%2X?$S8K,7-#4V0W1UDJ*T-W*R)2=$4V1VI+7"_]H
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M/>/,$.Q_[>L8^IX;LN/0K6X&![=_P_MJV5(^7X_WXTC8VF,0"EZB.<;R[?\
M*QL"5K/MC:3 XN)M!MB"?VYQ_@)ATEGU8#J/PVV(; Q1J<5?H??W/UU3^C]W
M;7WEDNBVQO*<)'I-JODTP1G06."+:')2N?\ 4EDA)#UUUBSL&1%F.%?B&.0
MFLRZ#@ROK_+X_K_EIK):XS+%\._YYQIIO+!%C2'?3:+3\921X/O!@2;0?;>
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ME5KV%,A0*JN74CD.5_B4<J5[#T[CMK<<9&C22M(&>Q7(0.SLRA7#<% W\+$
MANY^G')YVK>>#KV]'C32@ZMTUG0@XH$%+L-L=&PR202"JV>:VKBTQO\ D6\<
MB!E8BTB_#.^ 0XB#I\8UU_$?66.7:H#GU( ^_OJDGCT!)^X\:U[V6T/+BZ_L
M71Y(U90:R3@B9(U!!61:9CVDA1(])X8DGX1RZ?*U)-RQFTQ'@]^H.C(6R70
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MR+#]$8'')<A  >#R?X2/N?I^7 Y;X:7U7O+;7L(53Z&M2D6^,.P@+6HAL/\
M+4"[,3+)(+7)"UX1[,XJL67F"5MC4%:200J:';X(# VEGNO$I@,D);RP49@1
MPQ) 0=7!( $B3%>[< @>NK:R$3A)0I?WE5@>0/5ST\J">4>%6[#N">X YK=[
MF>T9_KK:=WE#HZMA;F0&U#?V9IIK%H'&0K7VBKDP?KP2;,B8OVW>!Q&F_P"M
M#LNDVR.7!/MI'N_A_LM-ZW+E";+)C$IXZ?*(7C$HD,,L4#H0TT CC_>*\TP9
MBB#^ ^HU[<^X&V_%#9BI&T\]B.FW#=!3KC:56!"2=;>Z52,@=3?'CL;@^O\
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M/ZS7:7CK*JOV.IBA)JT-FFSOZE9J03.!$)"]0,!3R!VGQ#B_&P3M!"!#1_\
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M4))4@DZJ7VOBDM/ZC'RE6'5*X*W*3V^KV"-Q-5:Q0PX<PCV)IM:;M96SB>1
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MR2@6A;/JVK4DK73/]?Z1W%X;8CQ)VU!N/;$]./)+548MX.B*M>KUQT?9UY5
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M!ZRT!DCBX(<*.7U%[)>SPRV?(MV1$+MM860+(0L1:." ,Y5FZ498QRHYEZ>
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M86'_ ,*K[_ZCR_\ ^2/' ^8_/^VFJ^+YM_8+H5[J?2."]4HRGF+,8>I7YU9
M(ZC:I"ER\R2=0H7OYA9G04QY(V6*Y39U$'\V766T@M=8TT4\E?0@\_#]#G^G
MT^>J2 ?4'\?Z=_ZC4$ZMS[F'.8=X-;O83+48&1J!6\BH734F,C$.-22X!1T
M@2_22#,Q)[^;],W/Y_MX8[Q10ZUJS'X#CXG]?V_#5#!1\3S\OU_UU6Z##K72
M*'09=H7O)%*7+!*SVVS(1C.XT(<& MS)HOY.<;"SK=YB6LVL6JJ9@ES&)Y7\
M_P"?\OS_ $-4:XL&[:#0E?SB=ET,8$DNPQ"XC7&OX_?3;4R([2??08S$(HOV
M' %G-)@&225^;'XY::[^QD4?Y2$Z_P"N?VM!YIP#!P(I MA=B\;1R#1#R?\
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ML/+9;.X+:&YJ&QZ=#'9K<4B?;6;K1NN>MX=(62QBJ%CK*5O.;IE<P)'--S,
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M>9E<C0?76./?]R#](C!\:^7;?>.#6Q)ZR[_*"7<A$,/L-.3#%4!)8!5!)8D
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MAS!\.0P5SL@O^85 D.9.%VN[,04225F5C:'O$RH2A/;NH8GJX)()7DJ!SRP
M/8DZ-$P%8\J!$PZ^/7WBH'22.XZN Q/'N\D#GC6-Z?2['?\ K%+L'.&]?G&$
MKPI3]F4RQ@9=)6[0=M4V*:4()M&X*B+9W.(U;O%&/&0 OB*/ _8VS(AD6.%T
ME##ESTJ![QZD'6&Y(Z0>F/@]SP3V/&DT;23(T17LHZF)[#H<]!7@'J(ZI/=[
M#D#DCUUJN^I%ZP7.I6^T>QQEL56"LWFX*%&JS>$D.P(YI:_)"M#WCQ%(O.5@
MA5W]*(N,J(S.N1<RA;9S.1K](^!F\\<DJ;5FIFM<FJ],-X3+[/8%:S<M)%+'
M(0R6)9,C.J%&*OTQ1+&&[GE/B)@+?#YI;"S0"8==<H1+$9888BRE1TM$B58^
M>>&'O.21Z7 ^G]S+2:"L]J0&1D51IZ_H^7-8FTF9G,W0$MJ+8/M@8XE\ V*H
MO#T#4C;3%2F[%P2";:2PA8*DYCXEY!AE\Q@YE<STMX[CRBS'C@U<J* @CYY+
M=:BH9". H$@Z>Y(&W;0J TZ62C*B*Q@\92:/OSY],V#*_''3TGS@@/)8]'![
M :L.AJ\Z?UFL/)+@[ AO=9YJQKC/^9.-O'+/SZC5I<K>H 98P96*S5-K2VK6
M2<6+<EFYEP]S"P9SZ[<]9P]M9T4F-I4(Y''9W;E6/?@DAU'T7E>PULRQ]%1X
M78>8L;@\'UZ$'#*#P2.GH)^I][@GC78 XMTEI0X%ME.JP;O'6Q;_ )K@3!D3
M7AZN+% L_P 1$;Z)QC5TLZ2*0?)&RUX,N***D#S/KA?*N&Q"LG**_'D&,L0
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M>9$6!,;]#,O4O#=+$<\'6ECZYG_[3\,_\P[#_P"V]?.W>!'_ *6SW_PZM_\
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MLLCDN\CL2SNQ+,Q))).O4CCCAC2*)$BBB18XXXU"1QH@"JB(H"JJJ %50
M .-9?RUJO1XTT>--'C31XTU&:U2Z?3,/<5"JUVK8M%B9V^RXKR5<FQ8+6ZS%
MEQ9G7\X8?^H_:Y@@RQ;F_.>9\,7[!$GQZ?;)LW+=SR/:[5BS[-7CJ5_:)I)O
M(JP\^36A\QF\J"+J;RXDZ8TZCTJ.3JU%!!!YGD0Q0^=*\\OE1K'YLTG'7+)T
M@=<C\#J=N6;@<DZ\Q?J1_P#UB'__ )V>U/\ _P 7K/GU)N[_ /!J'_X%M/\
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MDD/ +/':O7#-36J1==MW#&L]%<69I]XSHPYXHYJ\H+B6L-B0Q\ /"Y"!C=B
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MNU>JL+6>L.9H$B25XZR3<P97Q+T%G1^R\3*4DR.F9JH1R58K4!EG\Q+W5>N
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M+>P$EHO]#:E(4$L;6K.[_5FZW1S",3"IT;K5R&T D3 YB(W(GWI-AG7?A%-
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ME-PH0?-BEY]Z1IBP(]T*![Q)]3R"_4 /0#U)X&;*5\N6+IX6-8@I! /4Q]P
M$<#I(3@\\<GT''?LW&J6BJ^W]ZM;@.%E4:3SCFW/A[&K8"91;NCO7WFKL0(-
M?F&,_!>8N5] (C:;_(+JK,'$UQ!-O+%O=9D>FJCL[S,Y7CW@HGE4DGGC_P!K
M$.GMR1SSJRJLMMG;NBQ*H8$$<F&,@<< \_NY#SW]>.WQ?WKXBZAU[K7.F2FM
M*1*=7->.]/Z/$P=Q0LZ5:U+.^X6JXHLB1E/H_P!?-YKY<(L8^8; ,@,-'B"C
M(F"L-Y<,<REB6ZIHX_=[.I503_W3R(V'T+#[[Z>9+)$P7A>B&1P3W1@S$#N
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MA@L80 %P932LD;.O3R%5 2/X>Z$*O#?Q+YA^88=75R.QQQ&LCJIZN"S,>/\
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M**86L[PSUB\XL2MY53#+2C@DDR;2WHS$)8)7,A6.">NT:JH;BY<H6+4BR,Q
M*QXFBE=0B\O+<,Y=5KA9MQJM=?Y_ZS4:F/P: 7V6B\L#J8PJANXCYXTL=52;
M)*U-(TD0P.%ZEMHO5%.,0(YI56Y1HP,9T8L$T_H_YV/%VA2K203Q^WIBJULU
MK%J&FMB=<3'=,-M*=N_%1%46S'=JU;EM9")L?%-_E[<2]/D+,\3NL4 L/"94
M@DG$2"=HB\)FB@>;K*<P2R0QL!T6&0>8J>5^J=CY;+ZN, .@C-F/%:GU:H]
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MC[??;;;.=MML_;_7;;.<YS_KG.<Y\:IU]>--'C31XTTN^F<\@Z8@'KICYHD
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M32L&5]G#T'OEV]D+?;BH JDM;Q6MUT_HEG(QJ"[%K *8L90NK(V X",-.?\
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MNE]:/IQ<TM71_6?HQ?6>V"R^JE?XTCYO5AF'-9*J65Q:*ZA*++8!#>9%L/\
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M#&B2/GC=)1>8T_@EE#Z+8ZD U3M-X"DW6VEAB<JK"M:1'?T13#5# 8Y<7.U
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M4.M<+KCBWW8[N_!N:=45VM0(O7<OKO3/=]EZ0VJ-Z6+<!)][D'T*F=.CJ?\
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M-/1=$37+G>_5XSS+6EKX5?=[<3[:[]?NC?X^<GM3TV7"3HB3<>'9NL3:M%3
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M+KO>^0UAVW6S7F<)?STQKR1&R3&EP)+>"#8BMK#5(/U-=M6A7M]>6![_ /"
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MZYY]?O//WZR:OU;]/3JG8+&EIZ$6D=X6TZ1\8LNMQ1UF_CV&J5_G5:.R,+:
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'XTT>--?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img61678762_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_16.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5S?:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,3DM,#8M,C94,3,Z,30Z,S(K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3DM,#8M,C94,3,Z,30Z,S,K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#$Y+3 V+3(V5#$S.C$T.C,S*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,3$R/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G06-!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E+,TTV=U%037=,2V=Q46]Q
M8TMP)B-X03M60C5I9U-D27(R4DDQ=4=P87ED05-F,E0W-'%M;#-D,C%N8E-8
M3GI)26]):'ED,C9!67%L5G U:%=E9%A!<F%4545(2&1J=CER8G1I)B-X03MQ
M9%EQ-T9867$W1EA9<3=&6%EQ-T974#-/<UA':S8R.71E4WE8:6%N5U13<F5/
M3F5A;4I6.5=)8V0R<'9)5V)O3G0X:D=*,TYT:S5X)B-X03M)04%O:FXU<#A:
M5E=)>7EK4DMQ.&Y,14%+04MM<#9B6DE"<E-A5'IP-5IJ=35B4C<P0S5H=5DW
M3U-,,#53,W)Z531+2TQU1'E(>$0T)B-X03M26&,U8TY03W)R87)98UE4=DM7
M8G-646UR45@Y>' P.$]N,U Q3SA:9C-.>4575&E1469S=CA*<4YT.&A-16EG
M84Q::6Q'36=:1&E()B-X03MD>5%E9RM9;W181"MJ0S0Y06U/-&M)+V1I5D1X
M6D9B.7%L3S)426$W5%HS4TY'95)G:4M+<WI'9T%(8VLT9TMK<65D9DQ$-FXK
M:3%V)B-X03MG9%%&>6)-,B]#5&PV-%5V>"MZ4VY%2#1V<RLK6&9L<#A01E<Q
M5W<T>&1*,VQ,3C)+=7A6,DMU>%8R2V]Q,2MW9FYG5E=X5C)+=7A6)B-X03LR
M2W!F:%9I;7-E5#0U<GEE-V58;'!P:5HU8DTW14]G<79P3E0T9CA!4')86E%X
M5%,O3S9E8DQJ>35O3C59*VQ&9GAZ5%-Y<DI8-'):)B-X03M*;%@T94,W17A6
M,E!F-S5M1DU23S9:>C5:.'1Y855K:C-5+S%M-6M9.%-"4D558D%)=F%O*S=O
M4&5$3E!C5E%7<S-'<#(K;51Y-EAA)B-X03MI.78Q03E#,EHQ:E9M2D$S6FEO
M04$S-C5$25-"-E):8F-%65-M0DTX365P67).-3$X-G=8.71A4V55;45T-GII
M0TTS:T%O<V9(:WI/)B-X03MV<4HY;'$P,C9D.7-X>FYM1%)J>C@S6E(P3VY-
M5$E:9G O;VXY:DMR5%4Q93%74RM68D<U4D9.,6)V27)#2FYP.$IK2'=N<G1M
M44IB)B-X03M79&Y74V=/26E*-'8P+T)&4%!#:VE2=31%:VQF5%AU861A9F9K
M,G1F:7)S5E-,5F9/1VDR96UZ,VM6,T1-64A-6E532T)Z4U%2>4Q5)B-X03MK
M0W%K-S<T26M3-4TX;4]54'%&9%AA>')'9S)7;U=.>G%34FA22$I*<"MO;&5F
M1FU!5U)66E%33V%-3VY8-DUX<RMR:FEK0E!A2DA0)B-X03LY1&MA9E)4>E)*
M:'9)2&PU2'%W0U18-V9Z6D9A84)R:S=7=6UY5%-4-FA.-G!I37%H;6MJ:$Q!
M-TIU1DYF;V]A6G$K>BLR<'AY4G-G)B-X03MF5EI0;F1E-3-E=C=$:4UC:D5'
M4CE.069#+V4Y0C!R4U!,1C=P='901'!D=CE764%W0U=&1UEQ=G=O-4Q!;F16
M0G%D.#,R3%9Y>5(T)B-X03MW5'4X-VYW94A-=U!-2C-I,75X5DDW+WIH;V1V
M64<X:7992EEW+W!K*V]O1E$O<'9U4U!S;G)K6453-4TX;4]51%5H4E=83W0V
M1#5E)B-X03MC5W)X<%I7,#!B6$9T2D=T27!(3&9'=$5'>#-5+U1M3'%.8DA&
M2W W8F)(.41L86)15'I2=4<Y1VE/-WI91"MM9% X04YS5VXV3#5K)B-X03MM
M34=M,C-+-79N37)2+U=*27E3:V)%2#=&0TYU<%!4=&UV-TXW8FY#64))1E).
M:R]O9'8R:C)(2&=L2TE-:5-+039D+W9E:F%D<%!L)B-X03LV-6AT=%-I,'4S
M4U=256YH;&5'4#%H6#0P6711='DK2W1A,7)M.'@V;54T03)A265E>31E0UII
M95E.2G9I=V1I<G-6465R87IP=6M7)B-X03MN,7)52G929TQ"065,3WA99VUI
M<6=:;4Y!5'-/;5-H07E.0DE&<71H9C)D+UIX6&QN2W,Y<D]V2TM696A'0U54
M13!5155R-$925G(Y)B-X03MG+U!!<71I<G-69&ER<U93+T-Q:'%!2G-,:T%6
M2FEC040O5D])5C1B*UA.:F5X*V)02T1Y5SAI26QV96@R6D=!1F9R3DMK:F)R
M;#!Z)B-X03MS5VU),T0S;DM7-3)+;UA69%1T9$PP-F953'-S3&$S6&Y+559N
M86QA8DMO2D]1;DU21FQS=S1P6DI#365:4WDO8GDU<70Q66E33F)M)B-X03LV
M<DMT<$MO26MH-4EV<4=T2V]E3$Q52$1W9S!61U-545EG-TAN-3!H=$PX;T96
M,6DP,6]X86YP.2]/<VM#>6=V2C9354M2>6MG5CE-)B-X03MQ3U!8>'=Z:4I#
M:6I$;&YJ;'A23D96:3AT,W1V-6]T.5%G=49F4S!G;%(W5UEL;FIM:V%V<5%N
M:G15554O1C K95-V6G)R9$]P;G9W)B-X03LY25E9;E0K6C5743$K46IF.65"
M2VA*2G)D62]4=#=91&U05DQ43V9G+V$T,&E'+VAI<F,R:6%.3F)3,G-L;$$Q
M=E!Y.5=0,#%!675A)B-X03MS5%%D4V0V*T]#24$U37!3375:=#5N<E!L<2LX
M<S(P5FA$3&-A:#5D=&)G,VE*3VEK5S9U84-.6FTS8F-N-&8V-7!U,V,R5$I-
M16=C)B-X03M%835$-&,O>#!E9S=#:&EJ06='<VMR2% T.'4W>E-(>DYR;6Y4
M=W!/<4@P<EE&-35'53!#:V=54$AE;&,P-'AY,4]334U1-'!&,V-3)B-X03M.
M3D-5.&MU1TPR8GDW9DYE-DYB5'1B9E9#54-I1E-'44M".$I2:'-Y371#<$=D
M6' U4TU+;$AG:TYQ.7IX5W%H1T]1.$UU34AE+V5R)B-X03MM5%9+;6QV05(R
M2FUC1VXO04-+>3EX,F]:3EA.-$).1$%L;G=.5U-6,VLU,3(R36%#;$U653=R
M44Y&=6)'87=L<V]F<7,V<W-K84E%)B-X03MR>5!):T9A14AL.%92=EAF<F=I
M3TAK;6-J3&UB95HV<F]E;RM7;W)3=VMM=4Y3,$A42D,X171X1W19;&PR:FI7
M46US;D-V46)F=S!F)B-X03MB969*4$QX>6HV0C-$.%<Y2C)*:GAJ15EX4#=Y
M6&YF,F1%:C$O5W1/;G5B5UI66&A'-G$W5&9!<FPR059'3E)19E1M<6IJ;G%-
M9VII)B-X03MI6D5B=31%;S9F1U1L;'=G=F%T375R;30P>4]:-U0V<F,X4W)7
M:FUG4FM*5VY)02]$='-13VUD6F=M6E%"2314,U!%86I'27I)175))B-X03MD
M+V5V.5169BM7940O:V4O+U9(3&UL9%IT<41E<CEC:FEJ;S,W;C!N6C9P469A
M-4ML1%A&57-J,#-83&4K;5,S=45A=W5N:VML;FUL)B-X03MM:VYI3&]1:5%X
M=GEJ05(V3EAL=C T:6=Y,'II4G9Z1$MW.#DQ8E)B-WDU87EF<'0O<C!6-#9M
M,FEH=359;%=70D=,5$Y.2W(P:V18)B-X03M+.$]*<4MK;F%U6C!-9WE(,#=6
M-4YG3CAN;R]L2F)&9DQ7;2]524AT<E(T16MI:&M*6C%$:FUE4E!5:W17=5E'
M82M-,WIA<&,P,GET)B-X03M#2W1F<T@U-$96<U9D:7)S5F1I<5@T5EE0<5!K
M,WI:2C5H=4Y1<W1D;514-4IO<&]R0C=M-%911F5)>7!T>55)>2MR44%F>2]2
M25-&)B-X03M-84YS6C%',R].6'DO67AF-VYO-WI61UHP5S%I3%A5:VEM0E1#
M1FIK:"LQ>'1*5W%F=$XT:W176313=SE16C4U4G1V3U58,7%8>D9E)B-X03MW
M,U55=VEA>&IJ5&DX66]3-&M0<%%68F1F,F4S4F5M5GER;WI&.5=264=4<U93
M:5AY>'!Z*UE,6%A5-5%89'1(2D=Y>&-65UE3:B]D)B-X03MU,51X<5-+2')H
M=F%K56TK0DQS5F1I<G-69&ER1G9-;6DV-60V>F(V9S$P<S)G-F9(-G8V15--
M;#=I-4))57E/035+<E5%04PY2&9")B-X03MN3U!W4T1$:FQD+TIU,'!M36]Q
M6$%$=#@O=T%E5&-/;#9426UR-FAE85<X360Q8FQ,-C!)6GA-:%1K.4EY:3%9
M.5!H3R]E:EIG-E-))B-X03MJ3U=54DU*9FIY+TAV8W965$UO4GA'46Q'+VPP
M-3-Y.2]W04YK.3!G,EHP<7I.;$(Y5G-Z1$=B93)+96U9-'EO2V]52#)A1'0R
M>E T)B-X03MZ3#%(<31%-&-"364W8F)K:3A73'-69&ER1DYD,')54# K3F(Q
M2RM%=FPS5&]L9412,&I7<EA$5E5Y4W4W0E1W<4-V.$MF1DA65'=J)B-X03M$
M-F\R66TW+T%"-RMR9G!";$]4:&A+=4E6*VXS.4]I*S(X=6563EII,5%.6FPW
M5%5'4F(R,&M:4D=Z>$YZ5G=Q3GE2=5(W,%!T;4QO)B-X03M$1T4U6DU6>$HY
M,S-F<F-J6%-Y1T5C95-P06-U9C,Y9F@X,#<P:E5,83ET0SET1DQ$1$1).75Q
M>DE9>6928FAY54AQ<' X2C=J37%-)B-X03LK3&1X36U,9TE&9S=8='5J8VLQ
M=7A6,DMR2C1)2C1Z2%!'<W-:;U-J<4=88F-B2$5%:FMQ+T9867%I<E@W0BME
M0E9B1EA9<3=&6%EQ)B-X03ML*T95<3AZ*U<W2'I(<$5M;%AS:W-D=DEY3WIW
M;$$T2TYY1D,V=4(Y,D5':T57>&QF>64X=FAM-5@Y*SA43TI405AT+U0U3#9N
M1VEI)B-X03M%8V50<E!X<#EM=3%$5$IC6EDX1$\X9WID:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<54K6DY,,5A5-U-/,7-,,6)&1V-F5S-A25-S,%DS)B-X03LT
M<E4P1E-0."LV149(,DUD,4AB2DAD3VIY<4M&;W=656=D3FII;%AX5C)+=7A6
M,DMO4%=)3E1N,#)A2%,W;&)3*V-!43-,;TI!;31Q)B-X03ME2C)0=S%P:45&
M4C!(5')Z5')&3$\T;E,T5T5"63565#!Y9'9I3$Q59U9B9F)%<%1,1EA9<3=&
M6%EQ-T9867%I<E@W0BME0E9B1EA9)B-X03MQ-T9867$Q>%AW1TMU-'(T1$95
M2' Y=SEW.31*1E=K1G<P4U5(-TE65'8X03A&:7%--'(T1$988U8X0FER=4LK
M07A6<&Q!56M+0V%B)B-X03M$>'A62V9+,7IQ=#-P0WHV<VM3,UIL;$@W:S%8
M9W-J0F5W-F9:*VEU2W!V>%AW1TMU-'(T1$988U8X0FER=4LK07A6,T9F05EQ
M-VEV)B-X03MG359D>%AW1TMU-'(T1$988U8X0FER=4LK07A6,T9F05EQ-VEV
M9TU69'A8=T=+=31R-$1&6&-6.$)I<6IE,V1H63)K=#5E>E)7='!!)B-X03MP
M96$T;5I9-#!59%=:,DE64C@X5E9U2RM!>%94;6UT64%H;FM325-/<V-:8VAE
M5'5A2V]R,5IJ,$=+<6Y&9D%9<3)!0C!&359D:7)S)B-X03M69&ER<U958GDY
M<S=',6MU-S)E3S%T65)Y;'5*;E=/3D(P<7IS44(Y3TM#44]A,E!5=$]K<U P
M:$AD47998T1,.6-74E1$-F%I<&8Q)B-X03M!95!%061A-#!T:7)99C5&,3-Z
M6&1A=&97;7-A3V)7,VYE-G5R92]%33EU:DI&3TQE3D-K=G%F2$EQ97!U>2]$
M4VEK5DEN241O,5DU)B-X03MY2C-(97I71V5'6D,X36EY24=:0WE%34$P8D9(
M5V\W<7EL4T]X>41C=GA60S9T3'%-5VPS:W5M=W)C86EK16I78T5H-'!*345*
M:E)I)B-X03M3=$%Z54A567%X2TAZ4#A!;65K,&-%,VMT6FM,<7(S<39J8E%R
M>$II<DE90UIM5V=E5#11-V99-B]%3591*VXK879Z5&%'4C5F24,R)B-X03M9
M:E-S9&XK;$Q2:3AH:T93<W%F1%1G>&)D0G8S>%9.<EA7+U!D>G%/:W=Y*UA&
M,"MX;E-/5%9R;5,V:'5$05=G:V%31D5J6D-X5UI5)B-X03M14T1K0T=R>#8P
M5EI4:7)S5EE(-3!.>D1R8C-T=#4Y=%!,05,R:6AN<S=P65IK0B\P:&QK2UA%
M-E)O6#5Q86A!>$5D3U)864MS92]3)B-X03LR<7@V<7-Z+T%*>&%C8D9P5VQA
M,V5X,#<P9E-J9%I'9U<U16EG3TET:E9I,T4X<60X5F-S=7%13%!!,S5T,C!/
M<4,T5G)Q-75,4S)#)B-X03MC6DEB6EDT,&AM;3E&1F15-4E9=T%X9&E+;75+
M<4=L87)R,3%:43-Y+VY(67I1=E-C<$IP5FQ"25DS25I%848U1FU3<7A3059(
M23$Y)B-X03MS5F5L955*2E<P4T]'-#$R4'I(95=Z>5)897%22D1&>6LU1G5$
M4E<O=TEY27ER5'(S4%A&539X5C1H-7,X>&9K;D(U<3%,54Y6,6TW)B-X03M8
M54IR;')F54EL<W<X150R<7<R-VPQ:W1'*W-)1V=J559-;T1.>5%!9D5Q<7DO
M.$%-=C53=CEE=DHO4"MV6$9V1F1#9C9V1$IC1T]")B-X03MP;&UM:FIT>DAB
M2U5J-$\S0F<O=V=,.%EO34MO83EV9GEZ=&)I84-B>B\U<6HQ5S5I:6U.<TQQ
M5G)M1T<U4DHT-#%L.4)L0T)B;%-+)B-X03MY2'=Q4TU66E0U5#%V.'12-2M.
M-W O;6$O=F1C,6DR5%126C-);$9V3#E4-6]R;71V1W9Q:')38C1M9G%Z52LP
M=4)8<5=+=7A6:%@U)B-X03MK96-.1C!P3%AY+W%7:C9N<E@V9FAU15<P,&Q/
M57)2=SA05496;&=K5V]L+UE044A&5T%06F9L=$1&87EX+VQN-6UK8W58=&<Y
M<&1T)B-X03LV37%&8G13,RMK4TY&5V$T2SAG=EAM4'-J1E5B;S-L>CAT8E17
M23E2="]Y+S$V,C%44W)E2SAT-W!O8G@Q3#)S8U-2=U)-.#E(9%9))B-X03M#
M;WDP4$4Y.%9E<6583EAU=%<P<U@Q>EE3-F%Z>7IX<&$S05I::$A&2S!33S9S
M<6-4244U9V)I:$9#8U944$9867$W1EA9<3=&578X)B-X03MW84QB-C5O;#=P
M1GI*2D1B,SA4451346Q2245C56)I6%8Q,T<S5$-$4EEZ:GA!:G9E6#9R+W=!
M-#DV9DIE5S5S=%%U2G)3-6-,<3=8)B-X03MS<6U947AX96UH=&94:%922C=V
M6#E93F=Y3T]D2T\O;GIB<V8K8V5026,X3GAB9EAD5V%/,VQ-3DAU26%65D=)
M2VA944]S-5!4<CAZ)B-X03M6.%5O+TIW<7)+=F,O:TAP3FYR5VUA<&]C=%1"
M<6DS=#=B6'!2669Q-5E--E%R8E)23E9E2RMM:DYW07(T-"M*,W(K5D%)23<S
M<D=6)B-X03M/5W<W>D@K5WDV,W%C.2MV;698.4I.=T%(='1-=E)B=T%H151K
M13E.+VEP1TXV*T]+;U-Z+TM9,C%X1DUF3V9M:6-20TYF4FTQ24UJ)B-X03M#
M3U):4&E!:55K<U8T<V$Q2VMJ<&EQ<G$O=T-7=C983GA.1#5V.'<R:&YM9610
M<65O8TDP679),W!Q<7 O9'%:95!'=E)61F1S5E,R)B-X03LP+TI54G=)6G9/
M9FU8-BLX8UEV8G$S,4)O0DY+<6A7:TM%4T@T9TM$:WI&5F]!,G=/2W,P.',V
M0BMG9$M45&AQ3CEQ9U(S8UAE<'HO)B-X03M!1FTU4$YU6$5Y14M3<3E&.7-6
M5%A&57,Q3'EV-5HQ4U(U3E,P:7EV<$I1<7E08S(X57I-141"47AD5W)X1'14
M-6YX>%8U9' O;#-Z)B-X03MB83)/;G@O.'$V,%@Q6DPT6%=P2E,R:U)9<FAP
M0DU)4DIC3C95<5)X>$0T4S9F1GA!-')80W%9,S)N86ID4G594'ET,'%396%Z
M44<V)B-X03MK:S R-%=/-6=S>5EO2&I):$UQ=UA+3&(O=T(T=7=Q0T%-0V\S
M>60U2&EL=6UU9&8X<#98<$UL;DDU,#A73G)$0C9I<VI2.'!F475:)B-X03LQ
M87%44T%X<W!55C)9,7A6;G1H<&UM-F9'.&1H85$R:V-R;5=224DQ:59P1T%"
M9&=G1E=.0G9I<5<K8DIV3CAD:$%02W-&<$YQ16QW)B-X03MI5$<O3&E#3T%Q
M>&51*VUY4%5%2T)X<C$V67%K57<O3S124VE&=DQ45&-V,T)C6#18:BLK*S!!
M4V$O,TA1+WHO04]4:7$R1U X-T9C)B-X03M'96)Y.7=74TU"4CEB*TM0:E-4
M;#A!*TUS5'AP46)$,W%Q:3=E1#@Q6E=T,79R:E-927!,47)F4%IE=C9S9#)"
M2GAA,DTX8W%C0S-P)B-X03LQ.597,G(X4&-Q;TMF4E!Z47,Y1V<P,U%B;E(W
M6GA(03%X9E!'>5-T8T9883AK0U)1:3,O04AK,T1I9E,K>5=Q03%$:7),=$5'
M=414)B-X03LQ1W5',D]O8S5E4G,K9F\K;C9J96HO955B;#982&XR-59P=&EQ
M3WA6:%AN4'E6-7DQ,U56;C!V>FI0;U9L1VEE:EHR.7-'2WI+,5=K)B-X03MA
M4EI9:DE'6&(P,T)8=E1R5E9Q,CAO+VU,2$=I>F5E;FUB;7I4>69O>3%6;E%H
M47%G8VEQ531N9%)U5#!X5G$Y.&EE87AO.3%P,FIE)B-X03MB-VY4;75:8G1Z
M9%-X>5@X>7)C4V\P2TDY,U!)-F5H0VI2:F=Y,35C-DMW>%904$LK:F$W<%5D
M-4AQ;7-T<D-3>D=3>D1W:4IR94YH)B-X03MV1GI,>79)3U930S5Q3VY167%N
M94MU>%8R2W5X5C)+<68Q;40K8UEE17-E34\K<W=F>FI(:$LX65-V4F)!861,
M<41Y6'HS279,;' T)B-X03LQ9G!':D%!25!L-"M&34Y&94U*<#E:9R]N1T1H
M2SA99#E:9R]N1U!#5C1W-S9Z0B]/365%<GAH<')I17%12D%$5%DK1U!#5C1W
M;%AL)B-X03MD3#9Z,&A)3E5M:6$W16MP4&]G:$],4TU6<%5N<418.$U00U8T
M=VTS,6U$*V-93T5R>&@S,6U$*V-9.$I8:D1V<DU(.#1X-%-V1TAF)B-X03M7
M65 U>&IW;&5-3RMS=V9Z:DAH2SA94V9Y=VUO,FQJ4$9Q<S!4>DYD6$5K4FE&
M0C9C:W)/0V0R,UES5SEG85EE17)X:$]0<DU(.#1W)B-X03MC2EAJ1'9R34@X
M-'@T4W9'2&9765 U>&IW;&5-3RMS=V9Z:DAH2SA94W)Z2DYQ3&%A4#!325IB
M=%HT1S145C1L5FQ6:61I=E-L5#=6)B-X03MW.$I8:D-A0S5H<'4T<C-W8TI8
M:D1F,6U$*V-9.$I8:D1V<DU(.#1X-%-V1TAF5UE0-7AJ=VQE34\K<W=F>FI(
M:$LX65-V>E!*4$XU)B-X03MD,4='=T-Z6&-T=DEK551%:FQY56=G93E#864K
M2&A+.%E2.7)D13(P4G574F)G;W!M5D-3;V5N>$)393%C2$-6-'=Q+U=94#5X
M:G=L)B-X03ME34QK:U)X5E151$5H24YR<T-867$W1EA9<6M&-6-.8G='44E8
M<#%P,DAJ.4=8175,15=5<G1F34YT1F1X5TXU2U!7;G%B95AO<F5X)B-X03LX
M1#1905=C;V1Y3C%F5V)(4W)B,3=T*TE9.%DP1S=-9EEE,V9#4W=J1S%$5'14
M;FUN-$]/9G$O14%V-T$Y.&E#>FQ!56UU5&$S67$W)B-X03M&6%EQ-T9867$W
M1EA9<3=&541Q,G5A5'!/;7IA;'%.>6QV6E%6.5-::E560C0X44)5;'57,4)V
M6$I9;TA)86IU5FPV965Z1S X*S9P)B-X03M.8TDQ<C5E=7)J5$HU22]Q=6]2
M*V]694(K2$]::T526F5):W%&+V%O,BLR6E U84E'.&AF9"M#=S1V2FU766I.
M,DMU>%8R2W!4<DAM)B-X03MR>2]O*VQ,<3)O6'-C5F<U0WA403@K8DXP5D%T
M4W@R4%1,365'57I54G5X;$E$;6QC6&Y(5T@Q=V%F.$$T975H6G1C:49.5$A-
M>$=&)B-X03MG,4HY;W5N2E%+13DV,7!L<# X94<K25A83#E#.%)V:WER35IK
M;UA6.5I7:6\Q,V-2,C9Y345J37)Q9UIJ,%5C:4MN,G=I2E!*24)0)B-X03M*
M3&9.96]A=%EA5CE9,'E,,5IH26]K4'!T355J24I:+U11:&TS04AT5W54>%)"
M3D9L:FE#9#),6%!N8GI59$-S3&DP=%DS,49H24PV)B-X03M&27!*>6MI4'AI
M:6%+3G5C4FM8-'9I*UAB3'AH:'A%2&LS1$9'>EHR6DY9*V(Y2&YU-#E/;6U%
M1W K;GEM9UE.=U=21C544FE5:F=X)B-X03MJ;V561"](2UI96D%8,&%J:DE&
M.44T=#=M,G59;&UT<%5M:&(W36MB0C%0>4EQ37%)235T6D9*;EEF,V)F-C,X
M37)M,UEU4TIY1&$W)B-X03M&6%EQ-T95;DE"0D)&465O>35X1TIA=#5:=&)'
M,S%056QK95)&:F$T=#=D='A(3V]R>E9J6'!4669F6$I9.&9&241V66%N54A(
M:FQ/)B-X03MR-%)A2'0W:'9-,F]I0S95479$67!08E-*52MN3$]%2F%H-C W
M5B]8=FQU6$%):2]/;D(P6&%%<W,K16EV4TIF4&]Y5%%T1F<P;7A7)B-X03LR
M:EEY4#EQ5U9U<DUE=$(R2'1L041S<%-T36-+141R4S9Y,6E2;S=13&4X,$MM
M-4Q#4&=R075P-'$U*TI15C9B5G(R>79*>%8V96)F)B-X03MP>FHT=C-L.$\O
M3&XU9G)9;F8V>"M9,6QQ,6Q:4W1O<2]P0U-546U34U5+16DT='-#56-V=THV
M0FA7;5ES<#5O>4%01'4W6$9P.490)B-X03M(2U$X6#!!6'-/=GI&6#=M4W!R
M;'1A5TQV<D9Z8G=4,F%2;E5:15EI0D=K;T9O6#-#=%AA=5I02'=X=51Q+T(X
M4V9$:4)..&@Q4GI8)B-X03LY;W-S15AQ<5I,:FPV24)"-6-25G%F3$Q,84]%
M<2M&1'-663=D95HS9E0R=55S8C(P5TUL<%AU24-N1DDU06IL9U=(63AH-V(Y
M36IH)B-X03MV2GE&93EL<7=.4%I*17=+*VYF;BMR<7,Q6'IB1F)73FQR3VY&
M9%0P;39R1E=&9V9J4#)'53!09%=6:"](34QT2%54,'A"27-C:5!0)B-X03MO
M-T1S>E-1,59X=FAL>D(X=7)",C%3-VEV3%I.9G0R;#!9,U5L,CES46IH,V-L
M:'I"2E4X5RM+:#DX-3-$<G-M3$I%>G-216I,8FYV)B-X03LK4'9E<WDY;C0X
M;4M1>#A0:4=!:G8U9FIN-VYQ1VI88SDU<&M&,TY&-DQ49W5S6&19,EEM34@S
M-%5R;E4V8DQ,2FI%:4MV-W5N,E!%)B-X03LV=D1(2&Q-26UX2&$O4'(Y<4YZ
M26-D,DMS9G4O37IM>&5E3WEV8E99>51*2F-11D%Q4GE"2$I"6E11:C1H-V(U
M2$9E5&M+.3=,5C%P)B-X03MX6DEK3G9P,S4O<38Y>D1V4&XU<3-N;'5A=S%$
M5$E"<E=H-CEB=$994&)U;V%'.&EB-&UQ5F)K1U)X.$QD0V@V8C5K:D1Z0C))
M67=))B-X03MK3$1X8GER-3@Q3'DW<C)H+W=#37)E93@P=E),968X05)D;6Y"
M>#8X:%HP;&%R1D=C32](;#%554DS1RM163)$=SE74DAE*W%V3#%X)B-X03MQ
M;'IO5FAC-G)%3&95<#1)-6)U,U5%0T]2,41.2%)T+V=R>$]937%V6FEM1T)5
M2G%L=&)4,F(O5TI':%-,.3AS-D=J4G-G<4I"545F)B-X03M$,3-"2'1K;VMG
M-TII9#-M,G!F;41C5U5L=EHV4F-Y>3)S26I%:S)O;V95;6%74GEE8WI'4&=V
M<'(X2C)0,UIM># T3S4K>'DT-$PS)B-X03M04'E38GDO1&581GIE4C9,3$I(
M8TQB;S9-:S!C1$Y:<50X16MI9V-:=5)2:CA62T$U6FM)04A&*T,R5$E&8U-I
M.6YD,V-Y96MO,4]E)B-X03M)2V(V-G1X2F-Q4%9Q,#!P64522S-&4TXQ*U!F
M<GEW,D(U3%E!-VUA9FQ097=M2%5R2E50<6E68G534D=6;U-*,6]O54M"=UE#
M4&-B)B-X03LQ-C%/63)Q:GE,4G%2=4,Y3W-0-W1V.$%7+VAM0DYH:35)9E4Y
M97-B1%%,=EA$>75,2WIT-4QQ45%C4S=2=W%89FE(2T1K07 R2D=$)B-X03MH
M3C!N>%DX4$5.=WA8+VQD2&MO5VEY>4YC>#-80DI8,#5O5#E94TM3-E<Q5U$X
M4UEZ.&)H=4MU6#0O<S$R=RM'5T@U:5 T.3E)<7@O)B-X03M.+SA!3'$O=G)E
M>'1.5SE7-G4R:E-#35<Y>4MM6C%J:G%X:4-R>60Q1E-C2$%5:E!!;7)1.3DK
M9% U9E<Q<$IC4C,P=#-):UIL5S%H)B-X03MT-6A--FA05G%O;%-.865N.%E,
M34)X,S994FI+;E51074R4359,4IF-6AH;&XP2R]H:%%Y4WE13W%);W%34W5W
M1U1X1W!!;G9C6%=W)B-X03M-<TUW3GE9;&HS;$A43E%T=%E-='AB=D9(*VHT
M275B2U%/87%L5BM9<&PK95E-9&HO15A89&TT2G=Y6$E%1'<T:C1S>'I&9#(W
M1E5,)B-X03MQ9#8Q:EE4,V$R.#$R,$LX:&)7-C@U6"]!36Q&,G%C:$]80TQQ
M,C-$:C0U:4YI3CE4>5,K5%5T2S%'-6=T9G$T;FY*6EI%:U5"-%)W)B-X03M(
M4&,W:EIQ5E@U63%E.4UE3&A*:GAC+W16-TA1<F$R5SAH9FI06C-4:&QT<$8U
M2V]!<'@K27169'1H,GEY9%-!0D129VI,2$EY16IU)B-X03MB2&LV3%$T24Y5
M4RMT;3E*3TQI5T1C<7I/83AX52]#9F\V8EE14G<Q4TI9>6-G;F93<5)S='9+
M-SAL=5I):"])9VI)+S1:1U T-4)T)B-X03M52F)'.5E,-F5O5$E1>6QQ<$-W
M2V<O178R0C%',6-5,FI'5E=5<7=$2W=O>6YC14AS8TM(;EAM;GEH<"MJ45)3
M84]S5FI!<S-Q>%=G)B-X03ME4FUM=5I(<GAJ:"MZ-&1$,#=51V%8='9$;'EN
M>&)V:')V4%=H='EE:C=!,5=/1C1I4'%V;T)1<7E43&XS<UDX>3-E='9"9%)Z
M864T)B-X03MF5$EZ9%A6=DA1=45(1E,K-49103ED=3(K86Y4-DQ,<7-W=S=1
M4%<O>#AN95I.6F<P=4AX-S0T;EE6*U!*-G@U66MV6DY&=#5,=61B)B-X03MK
M>4MR=WIH4VAA2FQ"6&UP031S2S!)>G%.4&EY-#0X3U$S2618:616;'<U2CAE
M259%.5 Q95--83%N3$5I.&U513%#9U$P2'1V1V-V)B-X03MC83)O-U,W4S97
M53-S:VM!56AO2%-+:%EK56)K<7%25'=X5S!3>7%Y;%=!6E=&1U4W9V<Y:FA6
M.#4O;34K6$9X;V5V5V5Q*UAL:&I3)B-X03LU=5)&<'5I4GEZ5%0S1GA-2WEL
M24-O4TI&5V\K1FE+5396,GI96E1-97(U<&A1-5!08G%Y.#)A-7%S<E!A;E1J
M-61N:FIV5T97:W1P)B-X03M:6E%G8V]0:F(T,"]:1D]N:4LS66]!-T$X,%IC
M=$-Z>6982&QE3%@Q.'4R<T]U,U5D>G%Y<7EZ6#%S045L2$TK;DMQ;%%!5VHT
M:VIJ)B-X03M3=&,Q<S9V6F)#3RMQ6$@O04,R>F9D1"]!3E4X:71R23=D<F5+
M-F$K=D1C5WI662MU<V%,2$5&*TE-5D-G:G%35&A&,FXS4$9"<')3)B-X03M3
M86YE,F%K-F9"5T]E4TXP2U(X,T5C4W$W*W1*-F9P='E026)!9',R=D9Y0C5U
M=S1U439Q;#EB86)D84YA6#!C;'9:>5)M1S%3,%EL)B-X03LU2D9G9C O5VAC
M1D=+4U9.9F@V:'0O05)*16E/84EK9VM)=3%K,6949DPU,794-7!O2C4U6'0W
M:55T1'EC4F=F5E1':W%)9E1.6#5!)B-X03M!<V5V5$EM<%,T5"M/.4)Q57%+
M6BM7.5)E>#@Q,C Q>G%K8E=T-U5Z3F).2SEV2DQC:CDQ1U8T:4]0:50Q2# P
M<FM-:V)H<T]40V-B)B-X03MH<T]4,#(W<TPK-FEB-G-A9'9T8V-W4DE$;38K
M94M5:#95:#!U>FPP:GDY<F5R835%8FY1>&)35'IA4U535#%);VM,>4]5;$MP
M=6DO)B-X03M:2C,W.7-N;FU*14%C*SEX=$)G;FI%<%10;U X4#95=F@X,B]K
M5S5D5W-R1TLT:6I(<E%0<&)C,%@V>7-F1#191U9U3GEW1D5*2$QC)B-X03ME
M3U5C36Y0.%1&9C=04#A!5S%"-78O24\R*W S;'9B-F1%,&AJ3FQ,1G!B:'=X
M;6-2.$].=GE5*W)!>$AU2RM'4$1*07E99&E+*U-Y)B-X03M(>F8K4T8Q9%AD
M=3)K,F=I=#%T>3$P*VQQ.%5Q,TUF<7<X945B=CA!14A)0612=G0S,V5'4U)K
M>&TY=G-:,6LR3'I4>DYP=FY(4G15)B-X03MM=C=,>F)A-F9:,S%Z25ER9E9B
M;FEO:EI!+W!W*W9(3V=94W,Y3TLO0V=8-U%Q=45.36=2,5-/4R]W1'I*;#%H
M<F5X.#=A6C8Y-7IT)B-X03LW1DI*165.-4EM4UI646EX15)95SDS2%5+951-
M83%)6&ES=&U"33<R22](=V5L*U1D4#A!361H;V%7+VU+-U,Y,55Y>E-46$54
M=39%)B-X03M3>4TV:&5A>#A1;V)I1D%O04M$8DE&=6=#0G9Z5'I&;3=&55!,
M65=S=#5"94]P3GAB:&A%=TI'>FEH<4(Q*VY#2D5#;7%72TIK2DAN)B-X03M&
M15E',3)+=7A6,DMQ5C%&3$Q!.&-5<&AK669$2T%#5E!J431&0EET6BM78EA6
M<C)0>D9E=6)V57)54W@V5SAH6#!O=#9,2494:W!9)B-X03M%9%0P.$LW-5ED
M4DDT:D=',2]E=W@T1&IY;5=1:S<X=59$*WA/9%!S3E%75U-F551&8U1M25))
M-FAA.%11<W O9&]A16IF96@X0C!Z)B-X03M!,"M,24IC57E$2W%V.$%F:F](
M66%N3FEL2&AX9VE.,U(O-E-0,V9%;T\R.'0V:$992DAB86Q,65A(2E-W:D%K
M:596:TQL56IK-54U)B-X03MJ66MK-6LU94MF5VDT=6M'4$1T=SA59#EI5#%:
M1&LR1'-643)O<$LQ<7AI;DYS>69'6DM!-TQU86=K64-M4$]M33)8;&U.<'8X
M5T=0)B-X03LV+S5K84QJ85-Y:T9)-'E32U)Q<G%M-D]D*U<O=&MS*W%Y2$9W
M-'@X3R\W=G99-E140T=3<S!J>C-09#DY9DI.661,37DV:&183VXR)B-X03LP
M97!88UIG9552<41,1V])4EI(5GEZ<4\Q95!Y1U5936U7=EAS461V>%HO4C=M
M+U99.%(Y351X4DDS=BMW9G Y-U9R;T8Y8GA746<Q)B-X03M+84%14$<Y>D)2
M6EDS5D4T=$-V269!:DAF8F-D<VYK17!'-W!H<"]$>%%-94AI1E5.*UAN*TYK
M-WEB0E-V3%='-W1*-U-C1F],:4YO)B-X03MP5D))2E8Q2W-+:G!S8TE.1S%"
M;S(X:G1:<&\S,793<DE3>$5Q,3%E6$5S:BMQ<U9K4U!3;4U586-!-E9P>$A8
M8C1G835S0T]24#1T)B-X03MZ:C!*4UEZ>79(8F,P=7)I.71843-.<DM79%I3
M<VY/0T)(55-0<VAP6&M+.4MB5GEY=FLR5GHV0DTY9CAU>#9:9%!.85@P5C-D
M55E0)B-X03M(1W!A5S-92&M$3W-43U=K8W-Y8VU!2%AA<$%Y1U!*>$1C34E:
M3#4W33@X=6543D%';394951A66)E*V=J:6TT4U-31FQM*S-Y9&%H)B-X03M7
M8TUX,UIA:C)Z17E:<%=297IJ5'EY<VDY;6172#DR,RMT+T1-4V$T=5-P9%=L
M<F0R,&QR9'=P8U<P>6Q*;TI61'AU<#9Q>7-#0T0W)B-X03LU0G-)=$MH-4DX
M;&AM66%"<&]:>%)Z.55G<5)Z16Q$.$@X-#5F4&9$>$9J-&-E-$Y(>4XU2TMX
M;V9,*VUL268W;&9Q8T9%*TET.$DT)B-X03MB9D5X3S-C-#A26'<T.7=75&52
M9DMZ1T4R*VY7.6E9-7)E85$R='9"15I284U(:&EK8C!Y,W!O>4M105(Y:T-T
M2V=N:4LK2$AU4DAP)B-X03M39GE..7AY>3)I:6Q7=CA!;$Q34$U%9'1(<3%Q
M.#97:V]U3&)J2DY#56Q5541G>$UH<4\R15-9>7@S>D-5-EHK5DAK<E,W<4<V
M<V1,)B-X03MK:6UT,U=326TT=6Y537!6;%!"-5=5,$UA;F-D5DAG365*:4U)
M2$E-<CE+5"M2=G5/0S)Y:3<P<% U1RLT-#)T1C-P4V9Y3CEX>'1A)B-X03M,
M=E-K+VMB-VIJ83!896Q*+TDS,TA',6]U.4M4*U)V=4].<E)D-E5N.&IF8V-B
M5VDW,'!0-4<K-#0R=$8S<%-F>4XY>'AT84M(,"]3)B-X03MR8E1R4DQ/>'1H
M8C)S6$PP-%DQ;W$X;4Q'9SDR66Y)>&E):6AY8DUU4V536$9-:WE05D5E;$HO
M23,S2$I7,3!896Q*+TDS,TA',6]U)B-X03LY2U0K4G9U3TYR4F0V56XX:F9C
M8V)7:7-M=$)01$I$3D8V:U5Q;$I%659$2W=O45(W:D%A26]P:5I224DU:&)A
M5T5D<&%X5W1T0C96)B-X03MV06EX=WA+0T961D9&02M1>&E!0E%4:VQ+8VI+
M5S5+<C95;CAJ9F-C3G-A3'93:R]K8C=J:F$P6&5L2B]),S-(1S%O=3E+5"M2
M=G5/)B-X03M.<E)A:W1J2D<P8VM83TYW5F1'5W%L4TM%14AQ1&IA,%5*<&UH
M5T=L>%!&<#EM='1(23-.>$=T3U1(=50S>55S:&QZ2UI'4C5P3F\O)B-X03MK
M1S(P>EA',59*6EI'0WE,0D-604-#6G545EE#<BLQ9C$W-6)056-586)*6DI'
M3E5Y6#!P4#5'*S0U4F)64E)T:7),1S-)16(Y+VQL)B-X03MC,C='3FM4:U=X
M,DMU>%8R2W8X02\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @
M(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P
M9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @
M(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O
M<FUA=#X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-H86YD<F%S96=A<F%N(%!A
M<F1U(%-A;FIE:3PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @
M(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ
M;&%N9STB>"UD969A=6QT(CXU-3PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SID97-C
M<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z(" @(" @
M(" @(" @(" @-34N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(R
M,S W,C@F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(U+4IU;BTR,#$Y
M(#$Q.C,Q.C$Y)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#(U+4IU;BTR
M,#$Y(# R.C Q.C$Y)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C4F
M(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI
M8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^* HB Q(&=R87ES
M8V%L92!O8FIE8W1S(&AA9"!G<F%Y('!E<F-E;G1A9V5S(&UO9&EF:65D+B8C
M>$$[)B-X03OB@*(@,S8@:&%I<FQI;F4@<G5L97,@8VAA;F=E9"!T;R P+C(U
M+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN
M('1H92!D;V-U;65N=#HF(WA!.R8C>$$[5&EM97-.97=2;VUA;E!3+4)O;&0F
M(WA!.U1I;65S3F5W4F]M86Y04R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M
M93H@(" @(" @(" @(" @("!G,3AG,3 N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(Q,3<U-S(F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(#(V+4IU;BTR,#$Y(#$S.C$T.C(T)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(#(V+4IU;BTR,#$Y(# S.C0T.C(T)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!
M.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E
M;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S
M+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[5&EM97-.97=2;VUA;E!3+4)O
M;&0F(WA!.U1I;65S3F5W4F]M86Y04R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S
M8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @
M(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&
M;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G
M.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E
M;F-Y/E1R=64\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @
M(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G
M.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G
M95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \
M<W1$:6TZ=SXU.34N,C<U,SDQ/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$
M:6TZ:#XX-#$N.#DP,3,W/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ
M=6YI=#Y0;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA
M>%!A9V53:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @
M(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M3F%M93Y4:6UE<TYE=U)O;6%N4%,M0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/E1I;65S($YE=R!2
M;VUA;B!04SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT
M5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^
M,# Q+C P,3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/DU40E]?7U\N
M4$9".R!-5$)?7U]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT3F%M93Y4:6UE<TYE=U)O;6%N4%,\+W-T1FYT.F9O;G1.86UE/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y4:6UE<R!.97<@
M4F]M86X@4%,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%C93Y2;VUA;CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O
M;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN
M9SXP,#$N,# Q/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^35127U]?
M7RY01D([($U44E]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @
M(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E
M3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-
M86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0
M;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.
M86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP
M1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P
M<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X
M;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^
M"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-45"-T8U135$
M0SDW13DQ,3A#-T%%-C=!1C@Y,$8Q-4,\+WAM<$U-.D1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-45"-T8U135$0SDW
M13DQ,3A#-T%%-C=!1C@Y,$8Q-4,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @
M(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I$0S%".4%%
M,3 V.3=%.3$Q.3-%0CE#140U03(P,S1&-CPO>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-41"-T8U135$0SDW13DQ,3A#
M-T%%-C=!1C@Y,$8Q-4,\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-41"-T8U135$0SDW13DQ,3A#
M-T%%-C=!1C@Y,$8Q-4,\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I$0S%".4%%,3 V
M.3=%.3$Q.3-%0CE#140U03(P,S1&-CPO<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R
M:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#I$0S%".4%%,3 V.3=%.3$Q.3-%0CE#
M140U03(P,S1&-CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C Q.2TP-BTR-50Q,3HQ-CHP."LP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z-45"-T8U135$0SDW13DQ,3A#-T%%-C=!1C@Y,$8Q-4,\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,3DM,#8M,C94,3,Z,30Z,S,K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S
M=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M .8"$@,!$0 "$0$#$0'_Q  >  $  @(" P$             !P@&"00% @,*
M ?_$ %$0  $$ @( ! 0$ @4&" P' 00" P4& 0< "!$2$Q0)%194(9.4TR(Q
M%R,U<[,D,CA!5=8E,U%A=G>5E@H8-#E69G&!E[*VMR8V0G*QU>31_\0 '0$!
M   ' 0$               $" P0%!@<("?_$ %(1  (" 0($ @4&"P0'!@8"
M P$" P0 !1$&$A,A%#$'(D%1814R4J'1\"-3<8&1DI.QP=+A"!8S0B0T8G*R
ML_$E-38W<W0X=7:TM<(70T2"HO_:  P# 0 "$0,1 #\ ^Y#C+?'&,PN6V!5H
M2?CZU(R2&9(_'_-D<)2\)]LB0?\ -A(JS,J\!\*QG\/*X]Z+3C3CDP4D;_<_
MDQF:<EQCC&.,9Q#C@XP,F0D"6A A&E/DDOJPAIII&/'*E9S_ .["4XQE2U92
MA"5*5C&7GV&,Z&J7*!N8+IT&2IU+#RF"1WT89+&5A2L-*>8\RLI;(0GU1W,9
M4A:/,G.4O-/--Q((\\9E/(8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC-?,]WXC8#OO7>C96H;=EVP55NP-[:7(,L0+1)%;-L@R68)<7E1E<5D
M3Z;>LR9YE3-O<^1)AWO)DO.N/Q $XBCX?\#.3)!UO& _@Q^":7M'R;F+93&9
MNH-IMTY.Q;.Y5?0I)9]"%[TS_P![=)C2GJHTW^[#0DVY/^TH--*M?\4!'J3-
M,MZ+3/ OU-,VM^+4L(LV#<V/.&XXQCC&.,8XQCC&.,8XQCC&.,9"W8O<;77S
M1VS=TO52:O#6N*N99%U6OYPW)R^!5M-^DDE3!2001_6]Y+2>1"\1<2.=(Y$*
MP+Z#ECJ=X:;I]N^87G%6%I3#'V9^7;MOL>51ON[['D0,VQVVS;^ >$VXZXRX
M=X034ZFC-Q!J46GKJ5X%J]4R!FYC&'C,\TG)T:M<2Q&S:DAK]6/J<ZX7T\[+
M!=N.O]*WH'3937^;9\W:)J4N>W+$1A$1+FQ:G!I5L*,^:Q<@@5$A&2*HN-44
M&2TO(;7_ .JAHNI_+&FUM1%>2KX@/^!D/,1R2-&2K\J=2-BNZ/R+N/\ *",R
MGI5X ;T8<=:WP4^LT]?.CM4_[3IQ>'646Z<%Q8YZAGLFG;A$XBL5C9GZ;KVE
M8,,L[S*YSS'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8SOJW_
M &LS_=O_ .$KC)D^</S_ +CDE<96QQC'&,<8QQC'&,<8QQC'&,<8R%^,M\C_
M &999FJU4R4@XY9I>%8943A*7&8EEQ*L*DGV,YRMY+.<)2A.$*90XM+I.?00
MI#DR@$]S_7&5>)8#VL&Y( ML!;$!']22C6_*R/;1AV\84?'H_!#<NTVG&2!4
M^&'TX\S>/#_BZGS?R>P^[X'X>X^SR.,XFO\ MC3*O;X?3VPIS LN9G D;,%9
MQ@6&)5E#8$)9S'%I]BZ9E7IQ[[V,Y'\&FY)0P[XK_#1D@L!^7X_$?Q_ZXR]G
M*.,Z>P6"$JL))V.QR8<-!0P;I\I*'NI8$#$83YENNK5_/.?P0VVC"G7G5(99
M0XZXA"@!)V'<G&4&9WP/V=D<P^N%%KB0I%P9,*2C DBYEMQQ+,W,LX6O#(+[
M",E!J4M3 S.5H=S@]LAINL%Y//S]I^S[]\9G2;8)K5T:OT3VLS,X*'S99]3'
MN6I8EM?A\AB48\5IC4.*RTLAG.""7OXF5ISC"U-N;N?S#W?$_'X>S&7)C"B#
M8X(LL%V-*)%9>(CWUH<=#><;2IP=QQO.4+4TK.4^;'ESGP_B0A7F0FB>Q]^,
MYW&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,BW;=*7<ZLZR'/,U6
M1CW&BL6-X9)*08C#S*K TI.76,MY?B6R%B%8>0J.E&(^31GSA)QF93L>PW)[
M?'X#?\N1W.VVYVWWVW[;CV[>6^WMRG^@^P^Q>T5+JDKK(*0$K-?^EJML:QVG
M$=#S4S,3>M:KL)BQQQ<8>3EF.1"VJOKDXJ+C6I<B>F'XYLZ'C(UR5)NK%<U7
M"R%68\Q 4GL%D:/N"!MZR-MW\AY>ZA!.LZEE# #E!YMO-D60;;$[^JZ[^7?-
MA8R'VQAVRGDD$H9:000AKT$/OI0E+KR&,N/>BEU>%+2UZKOIX5A'J+\/-FSR
MMGM4I*$J6M24(0G*E*5G"4I2G'BI2E9\,)2G&,YSG.<8QC'CG@ D@ ;D]@!W
M))\@!C(=M.YH.I7_ #1I5D<7 U.8O,A,'2K(3#$#[FR(E'QQECN9)S Q]6DY
MJ5]4@1"(UO'M%%G*;#<S531+%S3O'PEGYKIH)"D1=FL<M8Q*S!AR^(DM101;
M*YZI]?DCW<6,UZ.&SX=P%V@%AI&<*!'O+SD#8[]-8FD?<J.3YO,WJG'V>Q57
M*W+#:9#AIPR9G(L>7',;'4*1'QK@^R,F3,[795N-L$37(F7UJ75I.>="=$8L
M]PUY%(2[]5(?"N3PW:719]:>:!(:\K0LA8.LDH;3.2"O9A,M>:S-#JB6XJX<
M.U6GJ,I*^$*R4QJ<1O1T!'(9)(UD5@-BJ$6^:22)^25(HWJ&%Y.4@36*J;'K
M;K83FN9DL<8QQC'&,<8QG'C^&?QQG\,XS_KXQFO/;VW6>JFXZPP07-6H/=#4
MG#TW7<"!'MLQ!JK5JREP)DN20<R04W_2'LR.B@EA,H?&KL]((RDW%=!%5>05
MFL1R,I51#L6+;@;!)'(&P.VR1,?B=AMWWRC-86)T5P[-*3W&Q[ET3=MR#W>1
M1OW]I]F6LU8%MA.)60VB9&>_<+-!8#B\XR&4,(<[B/F 0V"RAH$,H7*O1C'2
MYF6>86P1,2C1:?EH=JQ78!1^<_?O]7P[96R8.2XQQC, V3?P=<5-=L,&]^*B
MQ4VM9;26T(TT7=+K T8,HHM;;R6 8V2GQRY5Q+3S[( QBF!R"4-C.Y#3-/DU
M*V*B-TW-:[9W*%R4I4;%]T1 06>6*NR1#<*TCIS,JDL+:U96K"9F',.K!%YA
M0&L6(JZLS'?95:4,YV)"AM@3L#%MX[-4BBU=BQR66%X;.B@YGSR.(^!A&I6*
M1-LG%VZ0"'@,LIB2XJ2<&60Q)# 3$>_( @Y=4VC+T.%K]^TU:/F&\<KP[1]2
MQ.893 T:TXW:SS=5)H@P1HGDAD6.1]@3:6-5KUH>JY!V9%D];EB0.@D#&=U6
M,CD9'VW#<KJ65=R!.];F?J.O0-A^5S$'\^A8N9^26('Y98(?YH"P=\KG8WU'
MOE\Q'^O[23!]9WVAK+['J+]/S9U^S!X:S8K=6&?P\\L'7K2=6O-TI&CZL$NR
M]2&3EYXI.5>="K;#?;,A%)U8HY>22/J1I)TY5Y)8^=0W)(FYY9%WY77<\K C
M<[9W7*&5,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC.^K?\ :S/]V_\ X2N,F3YP
M_/\ N.25QE;'&,<8QQC'&,<8QQC'&,<8QQC(7XRWSQ6A#B%MN(2XVXE2%H6G
M"D+0K&4J0M*L92I*DYSA2<XSC.,YQG'AQC-=?;2MW+3U6-V/J:,*?99)0X:2
M'_6.T-*_,I4ZV-CS.DQ[3GE0U_ MB,=<2Z=YP&_356C()V;_ *_E^_VXREPM
M4B>[PGS:LIAZCV1A& UWF/>0J.JNRH+!(D<[>!EBL.MQ-BCLD,*G0T,Y0>C.
M'!&W%K;;8J;F+L>Z'R/M!]WY,9LXZ@6R3.UL=K*X*F&=GZ0G2=>; CYV1;EB
M4$-H3*UN8B9-(@+LC4I^LG1QM6+*%04F/0J/(=*>CW"GJ#[%MP  >XV^_GC(
M"[?0U[[)WG_Q?]1K=<7J^"'O&TC)&;^45)N3LR$?050>8:CBR)2V&@B25@%]
MP2'$1$2X@@A;Q9X^1)HV">L1Y]A[]O:?OW.,II8]A1O69"]*Z+].P;%=D1H[
M;NR/ESCY5@F!R<-/:WIPJV_>#5P4SS!'$#X;D)<SQPPM&<8<S5 Y_7;LO^4>
M[XGXXS;+HK61<;"0UQNT,J+MYX Y>*\2XT5FKNOM)4XRZZWXMO2:?-E*EXQC
M(B<^EY4$>KY*+L-R%/;W^_[_ %XRR7*>,<8QQC'&,XXI8AS/N BAS&/5(8]<
M5YLAGUQ"'1"F?4:4M'JC%,/#$-^;SLD,NLN82XVM.( AANI!&Y&X((W4D$;C
MV@@@CV$$'N,J212PMR31R1/RQOR2(R-R2QK+$_*P!Y9(G22-MMGC=74E6!/X
MP8&4LIH4H8ET%Y QK;#[3RPR'!1CFV"D-J4H=YP(P0Q#3N$+6*4,0E.67VEJ
M!@=P"#RG9MB#L2 VQV\CRLK;'V$'R(P\4L8C:2*2-9D,D+.C()8UEDA9XRP
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MBS03/9[;,V'$5J)9% (L+%-=0<Q8)>$DI:2 A*E+8>P.W%V*<:-8;'&FUQS
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M?<<F9'0*61E#KS(64@.NY7F4D#F7F!&XW&X(\P<X$Q, 00*Y&1=4T,AX4?\
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M;O\ K#[1?X5[YMFH?]SQ_P#IU?W)FN4O^\F_W['_ .^?GP)O]-38/_4#>_\
M[B:NY'7/]1C_ /7C_P"7+C2/]9?_ -!O^9%GUT<U+-CQQC'&,<8QQC'&,<8S
M6)\07X=1O>*RZ2LH.[YW5#NHSY9Y88,,]--'-2IL-(?-8%UF=A55RUANPK3
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M'F/,S=MND^E/TQ<9>F"]I-[BZ330=$IRTZ%;2J;4ZR>(>-[=EUDGLRO9MM#
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M9>="3.EV.;L+('O]_P!.6#XQCC&.,9@U^,UJY"KJFT2J,Y7;U_\ A-RM7Y^
M7"W+YVZ/$?3*X>Q*R#8?F[\B+&?)E#&?,'3APO;.K*;:6QE<CMG=+D-5.@MK
MT+-T;8MD..',BEZHD]6M7R#C*7.1#=@>1(?*6[K.1EFJ!U/RD$V4D6'HEYAY
MALB&66R.Q^_GMY?H]GU9FUXFNH<]$@5_9,MUOF8*JSA];BX.\'ZQD8FMV5B-
M>BY.  C9YUX.'G&8@XB./BQV1SVXTQX,AC I"VULA]_O^C..;6NG,4B?C)&O
M]9XUL6U2AMICS8K5H:!KML-P\2:+GQ'V&TLVJ\NP$H-*/R+:9>S.0A[):S51
MI"661[_'Z_(?9G'E)?K#M2Y;7UQ;*EJVY+U5#5?:6QI2VP.OK'4(Y^[1^RM9
M*D9:0/=DD@VB&K6I+35;<Y8 XPR+J+<;%.E$0[[@PK'?MY_#[_E^O.GL,YT6
MKX,[)V OJV*-]/S&P9WU6]7%&'UVNKV!>9FU/1X[9$A,!QC^=HVDB09&,RV:
MY>I7"\EO3KRV!OOL-]]_K\OW[9E@,SUE -M$@Z)I.L+.EI2DGSAA>J!$W7ZV
M%I=FL 'N8^4)-*'M$I=*RS-P5F:C)B>FBHR2)A#HR;JTU-LAW^_W]V=;5L],
M-8V (ZE9ZPZ]M2AV=71YE6_HIJ=@R*-(P#P^N@B(GY?(Y''EKE5W6:BPOTVI
M&U0#C<>DF<CLE,CW^/O]OZ?ZY9[C(8XQCC&.,8XQD4;AW-2M'5=FV7AV11'%
M&'QX3,8&DHDLR+JUDNAS*7"'PXX3+=;J4\8PJ1/"0>6*-"1JC)Z5B(P]C(=-
M[FZV'4U@*G[?F6S9(>OQ!T9KXM,),VQ1!\=)TT2RR9L;6A+17IR.?@9N,FI>
M*]$]))(;QL+$SLK%,CM]_O\ D^^XS@I[PZA.C8^:K%?VQ=8.<;IS=;GZOKJ5
M(KMBF;R92XZ"JP-BDG8N#"M"Y#853$>AI^0AG\Y+F"A<E 4ZZEUUC;[[CX_9
M]]QF.VSO?K>.$O#<!#6T@FBUG<\]9IDZ%BW8JG,Z?UK5=DR!T[!IM,;8Y1!L
M3=H/+-<B6F;*R0+-1,Z-6Y4-EA]C;^'UD^X'W9G,[W*U)"S;%=8$N5@F)>Q6
MFIU$2!@PWL7>P4/:&=)WZ/KQ,A+QHC"J3MEV.HUC?LC]?%&.FHJ8&?+JK[L^
M.R'W^_Y<[PSMCIP6%UM8FY27.A-H5#7=_A3@X=_/RFE;6LE2IU"LEF#(6/(1
M4=.VB[5^(SY!"R8OU).5F!X^!@9R5CF-OJSO^O&S;3N/7R-CV&OAU:.LDS-+
MJ4$AQMZ9CZ[&294*RU9"1)68BS99XR-+,]Y%OB"J%*'&5&CO".$&,9.O&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,JUW4[#R/4_K'M3L+%U8&[$ZRC865S5
M9&6(@1YEB3L\)77F/G(T?+.QS@Z)G)S;ORLY+RA?:*::P1[H>ZI5A;M15RYC
M$I8<X7F*[(S#U25WWY=O,;;[]]MCAN(=5?1-'NZJD*V#32-^BSF(2!YHXB.H
M$D*D=3FWY&WVVV&^XP:P=W];ZII4=>=W'-Q$%<)W:HVM9'7U<V!=\VVN:;U[
M,["O<R?#AU3$O6"XB*I.QR\A2#;P9$-5&9-J4]Q*HC!JBT9)7*0#=D6(RB1H
MX^1II!'&H8ORL"7B&XV.[[;=M\MI>(JE*NEG46Z<<\ET5&JQ6K'7BH59+5F1
MHU@ZD+1QU[;<K@J8X P?F<(,=V9\1GKW5*SLPFH6L:R6>DT';EKC5R<!L .A
M%R>H-.TO=MK G+17J79Y2-CH"C;-US.3I<56YP]8ME<C*U%V*T0L[ 1LT6FV
M':(.O*LDD2'9XC(!+-) I5&D0,6DBE506 W3=RJ,K-3N<5:9!#<:"82S5JUZ
M92\5I:Q>C0KZA,LDT5>9T2.M<JRR%(I'*RE(4EFCDB3@L=S^C<#M"\V";)K5
M0VU7J;<1=E[)?U58@2,0&G=;4C=5LK3VTGJ6"79X^LZ_V36[E&031I#KH4DI
M(L2Q-8<C<1\%>:)%7F>%G0Q1]5=N::5X$?H]0A"\D;(6V[$=VV[Y(.(.'([E
MF:0PP78J\XN7#2F4B*C4KZA-";IKJTR0U;D5A(PQ)5SL@DW3.=K3M?T2J5@%
MIFJB*)2+1M*Z2[LW6Z90!:M(26P3;K/4=TVZM040&.18+=?(.;A8B>/>-Q:#
MT*DA9(N,+:DWDM34'4O,))%B1>5I)"X$8C5]DYB3RI&RL5 '*.Q (VR>IK7#
MD$HKTC6KS7+$ADAKUA"SVGL2URUCIHJF6>S'+''*Q;K."RN5(8]2GXE6AY-K
M7UV@#Y;.E;=J7=VY2KW:=>[GJ4I*4?3%#HNQ9JQZS@Y+5^0+Y"1M>MQ/U,1F
M>A"A9*.7"U@2V3HLQ%Q<?DR<=1&"]=9H(1&DD+@23R/&JRL)=XV+(.7U6!!Y
MF*+L33_O;IKBK9B=_DZ>CJ&H-9FJZA [UJ%6M;DFIQO3Y;,:13GK'J(P=>G"
MLT@D1,E.^)3U&CJV=:"[Y/L Q,AL$*7#?UY?!9R)&U9 Z]M%YF9""+KX\HQ$
M0E>VSK256_[91!0]SB4!B$$M2;$?*-,N%@@C4DB,@B6,J3*TB1J&#;<S-#*O
M<[ H=R!L36;BW0UB:9K,H6-K2R*:ME9(Q2BJS69'B:,.(XXKM1]^7<B= H+!
MPM[67</LM/)2XA+S:'4H>;6R\C#B<+PEUES"7&G$XSX+;<2E:%8RE6,*QG',
M?FQ@[@'OW&_<;'O[P>X/P/EGLXR.<8PL< 0HXIUM@4(9\LEYYYD=ED<9I3SS
MKI!+C([#;;:%+<>?>:9:3C*W7$(2I6&,@X#M#UZ*9BDG[KU'!3$I&0DFJM2N
MU=;KG(_$_%U"8CQ"VXFURD>0^X%?J4\T3$R$E%GL6NMFQ4C(1T_#&',9CS^X
MNFQUH<LA6T>LY=SBASRWK 1==7/V:.$K5?LLK)E.2SDDJ4#%@:M!W&1-(40V
MS%P$/9BWUL1\?*N,LCL?<=C^7O[L\H\GIQ59:N4F)?ZT5R<8EW(2HU*.<U=$
M2K$]$W4@QZ)KL"+D<MF6C=C>Z)< CA4F"7;UWE--SV7%<9#;.=$P_4KZ'EY*
M#B>N_P#1O&N257G3HF.UM]% NV&:C)^7KLJ0&S\C'<GK"="S9\06I"I:8-BI
M-\<@TH-]QD=S\??G#:L'3JNY!(8FNM4%D &NGQI#,AJ^,]G&V# T!4S 'D.L
M88"F4[<"A:^0.M+!Z-GB1\>MU-V8:DV._P ?:?M_KF/)VMT0CHB%ET[&ZE@0
M4;\I$KTFFV:?%B8_&7@MAP8\,9@]L01."$1]XBVPG&TI?;$L@N,.-M&I8[_'
M[^?[_KSM ME]9+<!8;'<Q=95(JP6W:.NYP?:J==Q$W;7M%WBV4JR$%^^D3DS
MU=&*U-*V*&<++?6/6((24D 8=^*+"C&._P"CO^3?8Y*_]-.F\"0IN-L:SP#8
MEGM5XS%ZJ_LYM<4R81)MPY.)3T)%4:/&R#QR0UO9$: ,6_AM(KV4,AM[/;F<
M0L["V2.:EZ]+QD[$OO&#LR<.<+) .OQQI$;(,-EANO,+> D1"P#6DN9<%-%(
M%?2V^RXVEC.UXQCC&.,947?8O9\VUFAZ7R6''DZJG7M?6,65H0=2KFZP&;.D
M1G=\3:PY.TS^N[(.?46X)&M8B2F(Z5@["F:=@QY2*G061&WM_1[\@N<JO>J0
MM,01!6>_P- 5;XJ2&AGI30I5RB*69L3J1]1P%TDR!)>.G)X*I,=PR(0NOG%@
MHK9VO!727+@R.RVR/;[[[>1_/Y[?GW]F5UEZCW=W+1^P.H9NQ6NR3<5KFY:Q
MM%*L[VCV:C88^_=2;%'U5@:4B @97.Q#-W':]N+MGS+,5*/@%7L!PL,Q0D".
MQV!!^._MW[,??\/SY92P0W>F0CMH2467;(VT@;.,(I<"%+:6"HMJUC"V+:DF
MP)7),XVPV:)GKWJR5UY1ACK6#6PZ-NJNUJW&5RST0#94CM-D.WW_ #=OT_5\
M=LSS:VK-X2/8JM[4U87-U84JE:7K-B/')UT]'&0%2W#/6+9M2O8%@9E9PU^0
MU=;K*%KLJH*?##V*0"?.2(,2'[QQCMM^<_7M]SO^;*^U>J_$7J]4IZ6\R19L
M34]=04_363M Q4$/$Q6E.NK.Q1:0B(9C!(V\F[%K^]HO7Q4@7BD1,Q.P[QS,
M=0E"O1[';V=OT_';W]AVW]N<&CZ7[BTP6>A*@);:%7)>R6 YAV-D^O[UM;AY
M_='?^_%,&S1.9UQ2WP]G=:YA8[9I#$1*O3C5<^7>%R:,9$D?GVV^H#^!^K)6
MZJ;,WS>=SWJK[8FK>ANJ5"0B9N+0'J!NL-7,1VBA$O$A5ZR2FR:1+PLGFY U
M)V4KT93-OUY\Z_0)I\3&5Q9#!&P_CW^/E[-O+X@]CG9]<*CW.K>=*0NTY645
M%U.,I$7L R>L5.M UBIP76QN M4<>:$7(6D[;N.U4=]9@VQMS-=D=,RS,8?(
MXM*#8<9D#M[/C^_]VWY]\V'\9#'&,<8R!MJ:"K^UKWJV_2D[*1Q^K\6(1B'1
M"4>PU^R1%FFZ#9S0I<"Z52R.1L@%8M94^1A+352:_:H+ \HW%3 CTG@H5D=_
MO]_RY6QGX=.NQZVS5F]D[(^7,ZK"U&AU3=*R9\@!U'5M--267<5-+.)U=;J4
M?(.$I'2#F;?,>3'HCW&8YAC??OL/N2?XY^S7P[Z38L;#Q-[<VK(JV3%;!B)M
MY]O7V"11MA47:^MSWHXAND-N)*BJGMF2&B,G9.$%(@*^G ?R@<B&(8W]NP]G
MU??OF1R?2RC'G 1,GMBX&O8NVQ+]"UV=A=,V-MVF7F;MDML37Q$5:-:3#MFI
M#=@VP6['RTXB5L]16[5@!+(VR;86K>QO[=OA[?S'S\_J^&9!4>FT#2Z[M>N1
M&U=GY9V9J")TC'R!"Z7F6H%*K=AW/8JNJMR#%08(D9R"<W=88YN9M2YXH\"'
M@'I/)<RB5EI1C?R^'?\ =]F1L;\.'6DH%,QTELG9I(LX-<@"\-IH83K4?=PN
MY4=*"BY"I3##/MA>[VTO8.9'7Z#]>HBU(<9CY\>R,CS'[_#;^49BNP^L3UFW
MI7[-0MK4RP3[EXE+QL *XVRMLSK=IB(SJQ&PPP]$K>N)!=B@8XOJC3;E-UUR
MRT-YNX"Y+9E&0VXEBLLAOV^_EWW_ $[_ ),SV/\ A[Z\C*S#U=G8-W6- 52P
MT2-D_D>K8^;<J,J;JYZ'"G)*"U]#O6F8J\?J6M1 %MLOS6S289,JNP2<J^['
MN1S(\QWWV'O]OQ^/QR\L58Z]/9<Q!SL-,Y:&#-=Q%2@4CEH.044@ MS ;[V4
M#'+!-0&^KP:)4&4EE:\CNX0R7.YXQCC&.,8XQE7>UU.UU=]=L?TC;&EM>P>O
M+#%;%/-KQHH\F2EL*<JD>"^E##D^TR>;8E?)7:V7$2[]I"AQD&G1V92!EF1&
M_L^_Z<P/3E3ZH;#>D#Z969L^9'FJ\1,V>X!WV"F9[8E/CY.I21!4I.KBT2FT
MX==1-$VN@)*;*1*1D5,7ADOSUR2<9#^OE_3_ *9G4#I#J?69A8E=KE!AY<&.
MI%Q= C;"Z.L.-U6]"U^G6M^/9F<,C,P;]$K<*[//,(S+.46!CYDN254(YJ-8
MW^_Y<X<GULZJUBO6!A[5\8]$E11T-.0\")<K5*EU^UUP;79D S7ZX_,6 FNE
MU$N*JZ(&-CW(B.K497AAP@XNKPF8ID1OO]?Y_P ^<?64/U7W)7_Z5:'6G'J^
M_.8V"'9YRK;*URPB7*EU6^0M< U=XVJ/"L35H'<M5LDH(9J.L5Q%=G[2N0LH
MKA;;'<?N_>/M_-F26RG];]>0^LR)^M00<;KDC4NI=>, !RTN]7!+OL6@5+4]
M;=#BE&E+K"MBQ>OR8=R?:(@82:KL19?6"(@6Y$1D//ZS_$YG&DI?5DAKBGYU
M"MH>CR,(JP5:,=3+!2*(25DSG\G/1-CRBQA-$R;AN<HE!V767\N#J;96WEE#
M&2YQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC(@WSH^A=D-46W2NT!I0Z@W@
M< 2RQ\/*DPAQXD;+ S8PS<J%Y3PD?,8T)YQP)X=]:&<L9>PRZ\VY6KSR5IDG
MBV$B;E2PY@"05)V/8]B?/?W^>6.I:=6U:E/I]P.U:R%694<QLRHZR !U]9?7
M122I![;;[$Y$>Q^E.G=NM,IV4;?[:0.7LHI@TZWD"NC(VSJ&PZ.NH((T4+'Q
MD;&R&O[?;AV08P -D6P6>:M[>/J@K$LW6CNS0_X0C0;1#8)N/P4RV$)YB22)
M$0DDG=55/F#;+&WP]0O "VUJ<AK;!FG*D>-H2Z;850@541JL\X"HJ@2S23_X
MS<XKHGX;PY>Q-EOS&TIXG2NU:;.ZLN>LVXK7BU3FH)S154TJY1QK:]K'^F.J
M2ZDTJJV.4M\)N]V(EG(),>QKV(</;DHFY^4CTXN6)>O$ZRI+O)ZLRSO,'Y!+
MT''KN@0UP5#;]1MMCBO[IAK5OJ7)6T^[7EI6*82J>I1DTV'3_#K,:?CX)-J\
M$KV(]1*.8^458^8/'E=_Z,]1@K%%YNU/N%F?W=;-D44\-VS&N1,A([>ZZQVK
MKN],LM&Q3T>!(:BTA7X$4B$5@R)FHX&8C!QI(^4E>41J-I0 K*O)TBI"+N.C
M.\\>V^_E+*S'??F!Y6W  R]?A31I7E:6&67Q'BQ,CSOR2>-T^#3+&X7E(YJ=
M2"->0KR,G43:1F8SY7^I>M:W=J;LD"?VF_?J?K5.I'+7);,M$E*7&B"2[UAA
M(>^8+,<#LZ:W/$FRT(Z4(VMDB2EQS/>QTQ*A&4FN2LCQ%8NF\O6Y!$@"2<O*
MS1[#=.==@VQ]BD;%01>1:)4BL06UEN&S!4%(SO;F=YZRR&6..SS,5FZ4K,\9
M9=P7<'F61U;"#>@'7(_7&L=4$0]I^B=0Z4VOU[I,<BV2:" ]5[IJL?2K[ FR
M./\ +I$H^M1,9' S93ZYF*R&@P(YHY\LDBH-0LB668%.I-/#8<\@_P 6!R\;
M >0 8DE?FG?8C8#:W;AC2FJ4Z)CF\/1T^[I==!,P*TM0A2O9B9OG,6BC1%D)
MZB<O,K!BQ,&;4^&I$2>83&D-DV'5:6+7?-BS3Q8=!OCQFT+14=14:N714?MS
M6.VJJ_&U2N:EC1":K&UFL34PZ7ZT/L6FI=LC-JKQ:FPYNO&LNZ)$-C(FT2O-
M(R;PS0N"[S'URSJ!V,;^KRXV[PDC]/Y.MRTB)[-N0LM6SS7)H*-:.P4O4[T)
M6&&DBF%(H9'+;QVH-YA-M ":(8#$8,*R<6R,PT4=EAL;)A#;2$/E9&9_JA\D
M.X4]Z#7]6UY_31_"G',6=B3L-AOV'GL/=O\ #-Q4$*H9N9@ "VP',0.[;#L-
MSWV'8>0SD\AD<XAXB9  T!3SPZ31"1%$#^C[AA)+*V<O,>X9(8]9K"_.UZ[#
M[/G2GU&7$>9"F,HR/\/C5(M5,I[-^VZF*.J)U+?<S):]4;\ID-&Z9Z_/.H>5
MK?+:3DTO1E0D&W?1RSBRFV Y0ZXXN/B(ID=_9]_;]N)SX>VHK)'EQDS=]LF!
MR%<(JIS?S6B#J)AS(?M-!%M+<%UZPXVZ1']O-H(4\.IE;;D=376/15%RWSYC
M<_?\WV#S_?G-+Z%:WF$R.+-L;;UG5-6 2RSJY$[7 &9B0&W+2MY/((Q7-:0:
M1!3[?1(H(MN)Q'.-P!DH''O GNA28#&^WW^&W\3F;1/4NM0FGH34D=LG90I-
M;N%1O4#M ,34L7L4*Q4A4&Q!%E,P^JX_7,^K,' "5F5=LNO9DJ;A7BLRA),M
MD:5%8W[[[#^&=&;TAU<?/!V%^T[&]W%7J(V+!LIDJDH:#LP5]T;LJ9=C_6IC
MI*@;A;- 4XVPQQQ)@P[,K:1:NFN,&Q*81C?[_F(_CD4V;X>5:D)BE@Q5YN!5
M&52IO5^S1IZ3J>)N4UX1KC=-) BZZW'ZSP#\QE'MV3^+$>81'K8C@(M<+D<M
MDI!S([^>_P!_+<D[[^S):B>EE$KMQ<NU<OVR(:4((OYA+&!M438BC;OLO9.V
MXLX%=HU9.R-?,UW==M7<NG%5F0A7I*.D!879"]@1<8"*PR&_\/X?OV'\,Z2%
MZ$:IK2XH:!MNP1*W#5JP4J/IDF-JJWUL2F'V"TV:H54)%YU=9Y>.B-52MUM+
M="Q&RX9CD'*(JMY,NU6BH2&C&-_;[?/+,ZDUA Z:H$+KBL'S\C 5]^=<BG+)
M)_-9 ,6<L,K840PKR6!6 Z_7U2RH.J080HT=7*O'0]?C6&0(P9M+(>>21QC'
M&,<8QQC/6[CQ:=QZJF/%M>/71Z?F9\4Y_K4^LAQGS-_Y^/5;<;\<8\Z%)\4Y
M8S6)H3MS=_Z"^ME^VJ6F4M?8VC4J4KK^P;1J[7=)FIIG6=?O-L>I$]38,YM$
MM;B;%)C4/6UJ;18SA-?V,\B0AQV7,/,F(\_AO^7V_<G,#U!W8VH/.;J+O>5W
M: ILKLF.I-:-&J4%;-A-U/N[M3KPW/ZB=IX2T7&NTFD0E/&V+678Z8VR9?S*
M\)5Z:IO8E$%N#&P[??\ R@_O/GOMEM+GV^B*SG4N(JHN6G^E*D4#80J@YLF.
MP_6K]L?5NM67*6S(UMLVZ2$%(;4A9R;BGQ*P<) YCUN,HE9R/BN,AM]_^F_V
M>??MD)G]V;'?NEG9K>M7AXK5MVU=UW#W%4G&+/&;!CV%V_KM";QI:Y1R7JD"
M%[D8R957)F(=B3!"6X_W<?+*=D?0BQ\CD=MB!Y]_XD?PS@/=H-D"=F6-"M7>
M-E-*GWZJ0..S28^J)?BK),:EV==I/0#\J/&XUH_L1B=IM-F1YU=::;32+VS2
M7(-=[<B[8XQMVW]ON_1W^O\ >?AFQNFJ*57(]9EI8NKBU'K:LXXL>&W+ KD2
MU1KN6HG"8MQYB.R*(29'-#A2! [IXPHC)*!FF2YD_&,<8QQC*,]N@MT6.UZO
MI&F+5=:A/6BD;SS%SE;E!XNO0NP8F*I1FK['?LEI6/*56 L2GSY>N('DBK)!
MHG(A$'.!$2$<ZR8;;'?X?G\]_P#K[,CEG4_<!B1QEV\[-R%*R&W9\(Z&VM2F
M)"H2ZKW?$4:'G(JW5.X05AIT]IXO74-!148QEZH7VM2LQ*+'.M$E=@&0[;?'
MM^[[?/??X>6="7K+O@?%RPTA;IX&<%HMA13IF@;$A8&ND314S?@1(ZZTZ]IV
M//M3CPYVOKU$F1>S[ -6\ 2=%?O,Q"UTD/;;';[^?YO9[_/W^68_;M-=Y@@=
MJDT6>LQ%BLM4GZ7KJ5/W*ZI=3$@]F=TI75DK+Q<C)K$EI$.H[#ZL#3TZB4;L
MQS=*GR[27?L01=%V:R.X^WZM_=\?A[OAG^-4]M(B8C3*^9+)BUWS>]@NX9^S
M,RLA/4K8?:W1>RZY6Z=)RDH\94IF,Z]1FW-<1(T<578.%L/L00I2&".B+M"L
MAV]OU?D^W;Z\RC2VM^W59V95);9UYG+16AI D"?]:U19,([3GM1QXH#3]?94
M.DNV![)BHS$K8AHP<@TE,[+QR@8BR2H)3';X_5Y_9M]><#6&INV56N%=#D[6
M<S2XB[*F$EG7TVWMF0#^T^P<ML2/M@,Z67+33M[I%ITM_1Z4@@QZGR%;.]RW
M4OEAX5Z8[??\W]<G"IZ:<ANV6W=N+I\ '4[+I?057JDLP/"8/3?Z3?\ MG9]
MB2R!&/$^.?EHS?4*TN:4AHJ;)(M#1:L-)0]),>P?E/\ #('CZ%W(-SKI%BF+
M='Y:L10VU3*CMVI#JD+;#GTQZ VO3Q)ZB38\9IBQA0-M'M.G#$$R8OULPU&5
M1*X!,B8QV^SM^_X^WV_ER-*MUU[2440<RBL!UF>^@M$5 IGZ@C<14WC7UN[B
M6*R0L\="66(FHF!>1N'6[\98H-Z9-BIT=$F?1-A5R FZ#:V-P?TD_IV_=FV7
MC(8XQCC&.,91C9G2Y&R;SMZVG7J'R+LYNO$1 T]0B[)-T Z/'T['V2*@YE=[
MC8=RAVP32=2EC*RW4XZ<:NBRK"9<Y:+8BZQ'LCOMY=ON?K[^>^8E.]  9Z1D
M/6V4T)7I^?W5-SD2!2B0I",)VGL>3V;7K#KR6#O X=.V+0IJ5=CV[I)P5O&G
M(@&%RQ6Z],0<9,#,;_P'Z-O/]&=NUTC.7)0=I(O]$C;D&%K;ZA)I6CXZFU"T
MS.L-IC[(BSCZ@'>3'?EMC3F0#N,6;890L^?=B+1!3-;;KX,"IC?V=]OR_#\G
MP[?#<>W).ZQ]4*MUD&N+, ?&SY=I=IN!IPFJB1MABHVHZHUQK%NO.2[,B60?
M7%_T<@S43#-_+@X%LS$,,@E@ 4OC!._W^.^>@#K+,0O62C: A-DL"3NO)+7T
MW WLNEY/ASY'7&R878T4)9:']5C.2U=F'H1B"LD2)<8DXJ-*+)B)N$DL!%A,
M;]R??O[??D9QW10:,F#C1;M5QHYJUZ.LM/#C]6YC#*/':EV#H/8DOKV =!OC
M-?C]:V&2Z^U8"KUB%JT(Y0XLOV#\G< (*MAQ;&_\=_COOW^O,[T+U+7I"Y0U
MN;V(1.XB]8DZX,AAH V(C9S*C:@5'V8T62MMH BIJ-'J[D:Z15 *Z398\^.%
MNAME8I=';K[!.^_Y=_M^_LRX_&0QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8Q
MQC'&,<8RL^^K%7XVX=<1I&=AP"1][#FD#FR80K[ :]/[B806\T^^VXT,IY:&
M4OK2EI3JTMX7E:L8S$>W\G\1D#[/R_P.649>:(::?8=;?8?;0\R\RM+C3S3B
M<+;=:<1E2'&W$*PM"T9RE:<X4G.<9QGD,CGLXQCC&.,8XQCC&.,8XQCC&1IM
M>['T"M0\W'""&OR.R].4EUDWUO1; V1MJE:]E"V_0<:7[L"-LY1P'F5EGWPX
M_N&WF/4:7$?P/U#?&27R&,<8QQC'&,<8QQC'&,<8QQC/%24K2I"TI6A:<I4E
M6,*2I*L>"DJ3GQPI*L9SC.,XSC.,^&>,9Q<1T?AD<;  >!Q'FR16,"L>B,0T
MO+K3X[7D\C+S;BE.-NMI2M"U96E6%9SGC&<9V"A'QLAOP\4\)GU<9%=CQ'!L
M^X\OK^+"V<M?UWE3ZO\ #_6>5/G\?#'&,P"GVM=PNFVH"3B8O#.K+U"5R +2
MQETMUF:U31K@48\HA3J6#,/W.2BTK"2.A48VTTXE:UOK=C[OB/XD8]_P^P'^
M.2(F)BD,O#HC(]#!"6DD,)"&2R^ECPPREYO#>$.I9QC'I86E6&_#'D\/#D,9
MY/Q<:2 N+)C@2(QQO#+D<^(.Z MK"L*PTL1QM0ZF\*QA6$9;RG"L8SX>.,<8
MSFXQA.,)3C"4IQC"4XQC&,8QCPQC&,?AC&,?AC&/PQCC&?O&,<8QQC'&,<8Q
MQC'&,Z6R3&*[79^P*'R6F#A9284+AW#.2<1@+YN1\/90[AK+V&/3P[EIS#>5
M>;R+\/+E@]N^<:G6%-NJ-5M:!5 (L]<@["D%3V"%!IFHP622*HC#;.'U#X)P
MSE[#+6'<H\^&T>;RX'MVQF1\8QQC'&,<8QQC'&,<8QQC'&,<8QQC,+L-WCZY
M9Z!5BA#'S-AR\W#QA ^&/;!/P56F+60Z?ZCJ'<-/!0SX[/MVWE^Z=9PM*&O.
MXA[_ (?],>[X_P#7,TXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQFN3NUT(KW;386A+J\Z+'.4JTLQ&S'%*4P38]2^)<\_$#OMI4[F3'
MFALQ<1Y?(D5FWS$@ZM6 FFU3!M@1^C\N2E=R/A]_R?E[9L4%%&"&'"#'9$#$
M8:%%%&:0R.,,.VEI@=AEM*6V666D);::;2E#:$I0E.$XQCDN39[^,8XQCC&.
M,8XQCC&.,8XQFL#XG<UV8J]#U;.Z"<$E(UW;.NXZR5ARN S)ZK<)?*Q9=2S(
MA3Z,.C@9OD%&P4L*MS(YSTM##>5MMXQ:ITVW._N_Z_5DK$C;;V]OS^S[^6;%
MZ0':8^G5<*\S E@N8T#%-6N: ":C8^3L20F?G)<< PAML./=D/<9!'\N5M">
MBAU;CN%N*D/P\LFS*.,8XQCC&.,8XQCC&.,8XQCC&.,9X.I4MMQ"'%,K6A:4
MO(PVI;2E)SA+B$NH<:RI&<X4G#C:V\YQC"T*3XIRQFI[I#(=OY'L_P!K(G=D
MO#YI=-M@8LV8!4(^'Q?+J_5JQ!TV5AR4)4X%#)UC7X&PR 0RTNI)FX3+^?$L
MQO,[;;#8>?Q/;[G?ODJ[]]_^OQ]WE[OSYMDY)DV.,8XQCC&.,8XQCC&.,8XQ
MCC&56[JW?9>M^M>SKOJZN0=LF*_ F%3T).(DE8=I;PI 5ID(S,86(XB2@8XE
M4_XD+=&5'QD@UEAQ]QCRQ4 G8Y*WD<ZSHI=ME;%ZOZMN&S:Y!U4^5@ &ZM$0
MJ))*E46, #BJQ+RWS(HI2I*PB@N3R%"J:$S%249Y&6WO6QF+;;G;\_Y<B#N
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MM.M.)4AQM2D*3E.<XX\)!]$_K-]N/E6]^.'[*+^3/ "Q244 %%QGLP(Z-$&
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M4169^F8PIC;E4E0QDW(Y"1S<XW'\YCFA8XQCC&.,9E--_M\;^Z)_P%\MK?\
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MCYE7GFF=8XDYG*HO,[*O,S*HWW8@;G*W0O9N(=C81-EIEKAK0=-6&OS=;&9
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MJ^JT)1XWA*JC*PYJK(N@L#-)<U&IJ]D/'.B"2]'>V*F.2/=186=/FE"KH\;
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M]]R.Y^)[=L[KD<IXXQCC&1/O;6\CN'3.SM61-NDJ')W^E3]5!N$2EQPZODS
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M )*Z?/3(IBV_#'XOCCULMEI?F\<>5LEY/AC&?-XYSC$._L _3_3)O5]I;?\
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MC3W=:O&E.0K?KEO:;%6'J9XAQ*TJ==UL.XXFD.+SE=96XMZ(R(\M3F91<M
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M;$4P.WX6-:LT\R4Y&!)7E>51RMR!'C 3:>(=3U72:Z+"M(QWD>,:A7CECEW
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MZ*0AC:15*A>HQ0ORK@.)OE.[/!J-;3[U>G1A00V'C*3^JYD\0Z F6%5.Q0N
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M;3IFPJ"^8X&RC$KA8WRU0ON?X<2&"LH]CEK_ "G!'D]#^L\.8'2-_E.GMO\
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M\?M:6U+J_<%LFBH>Z'G6,JVZRU7J';Q4=*8+AEE@Q,DUM2; P*-&3#U5J%-
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MZ9E*QCDYR^3V%?:S=%S%:'A)"=4&WF/M\(4!%NM1+1DY-5=X*;%//2*>RZ3
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MI6U'BG432H225?P%274[9C@,&G"Y*#6K369.2-[,PD*,O7E W"[%&[U5W25
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M7(O3BWZ4$2".&,GS(0$DL0-N9V8@=@0"1EOZ;_;XW]T3_@+YK-O_  &_*O\
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MP3#-C(>>;2*2P^N)CF$2R^L8W+C<$G;D*AN;V $N-M_/?():I-<FI?@TLP+
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M>NMJ2.%TF&]0R=<!PH'*8^H0>T9W&:W3X>UN/P^HIIYD6%XK2P-)$)I$C=9
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>R?\ +;)GYB,V['&,<8QQC'&,<8QQC'&,<8QQC/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img61678762_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_17.jpg
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MDIBSN-/6)"<T<J$F,T-48I&4N2A$66ASDZ*QLM+G_\0 '0$!  $% 0$!
M          0! @,%!@<("?_$ &D1  $# @,#! @-# T(" <!  $  @,$$042
M(08Q01-187$'%"*!D:&Q\!46,C0U4G)TL[3!T=(C,S938G-UDJ*RM>$(%QA"
M5%6"DY25ML+3)#=65W:6I/%#8V5GP]7DYB6CI<34UN5$_]H # ,!  (1 Q$
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M>_AUNH%5 ]U-21"!PJ+N8\D-N]_:TQ?W=^[SN;GS'AZH@FQFSJKK>\Z_C=H
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M76NVQ66D9R<#6<FZ*SGGDW%IRYWN?E:&/>T,:7%K '$Y ">Z)5]Z?^>43_\
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M:TYC;2C$*&P>#W<8,1/; E#2^0_50Y^52+U9>[ UN%VTQ9ZI>W[NS:Q!W3]
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M+6XYT%L#CCBE+6M>G>NZEK6K.5*6M2K'E2E*5G.5*SG.<YSG.<^>:+TLX_\
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M/X\\[,[?]C-Q+G;!T[G.)+G' \ )))N227W))U).I*W@VEJ@ !4X@ - !4R
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ME"?4I*?*LXQYSC'Y>==L/LIM+0[68)5UF!XG34T%67S3S4DL<4;>1E&9[W-
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MI(R%:Q#\.[/3!C! =V_3F]T#QOJ>KO+(JGT3(R+YKV[6G0VCZ\"$ZU[0_/\
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MT^.9GQ_?2&2M6*]=>VU+[)3IH^M4C9%+?9UGKG;@S-_A4R,W8:1LTWL.M@R
MI5/N]R4Q*@'=86@>9'G$AY;.4CIHYLF,GM3<%6WGX/G4*/=V6MBV[4%=U7#,
MU.1.[#T36>T ]]!5V84S6MA=?]I[5#(@*KEO.L 34 Q4AXZPBB[D.S R@8X
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MJIJ1;9:J!S<*)%+,NS'B7(-QY!P7\*]&^JD#%IL1X#:8D FY;SECDE=Z[GA
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MTK071APU7&#[4UE80UFL0/85+*@:2J4FYF(5F#/CJ@J")8/34VJ6B9EFNJB
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M#V:]' -:Q!9/%1804(=5#"C2LL>/$K<CJ:2+@3IL=*H.(TZ8_B3-?SDJ@7(
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M(2H\;"([SSV%N85EK",*7@LD3@UQ+C89;<3Q',O3/_D"WM=OU$>QO\I=8?\
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F)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img61678762_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_18.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M'VOHEIN?5%%X>O:WT*HV-_V&N<OUI=%K<W"^8GUVW6@R]XS TU:MZU*%-%'
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MEM'QXW#&?3&#V]^?CR/JI#['^L-[F\A]?..=A=K_ %I_=W6D?L'UM10(N7W
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MGY*FVKUKE-*V52U3G\*$M)5$U%5LUW-GL+@2FUX48-)6<.OV]EM*E6#!BQ"
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MA;/\)XZ;>J?>1_FIU%]'^[D_+1^Z%O\ 36+^T+9_A/'3;U3[R/\ -3J+Z/\
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MTX]:8U8_5D]2K7;I*PKGZ\0(QFXBLHS\+A'8G W1+3W:L]2MM:I]<2):2PM
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M)K:FI!5VGJZJRL;QQ#F+RU.PU<;&URUXJ%\0</9[;$^5&3\/?[A[\@^[XG]
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M4^Q*6>W2E#4M"^J>B5NO/WZ03!UU8<0O+(&(WNI<-^#FWVV>$1O8R)-5/?\
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M]AC>TETQY;:9HO:Q:VD\:2L=1\+3SFREN[RYU&U@:TTW4HRC7G6WRSB!H$O
ML>B33O%+LLZ7@25-W1ZL\;,BBTUF*,7"0P16DT@GN[-P1!LVQQF19&@RSK:<
MP_5!TYW+.J[T$7T2&Q57"P A3R-6I)J$*6\RM8'>_P"PW/X^S2OCN>!O7@;:
MSJQ!:^W<)*I:82C:K9JT6I?LV]O ET-UL#;W74=9=5EE6[,UD(FA'MT/4MA
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M%I$O5U) PBOS$(HK,*;AO9%M!AH&9K9%]LD12\$N_IK-)L/EZ%\/#Z@OY)0
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M:H8*S^4MG:@6.)LX3YVT[2W&<M@M_*HBC68 ASN;:S*G( &Y\R2H5R^,;EW
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M6(]LD1Y#M16<X+84%C@#).![@*Q=TC&YV5%R!EB ,L< 9/J:M0*4,:,.:$1
M6&7!$4(6++&0,4,1'K+ 0//%MO%-!-%OI)%+'OM')'MKOIMMKMC.<:RK/XI1
MXI7/W]0G6JR4KCD-T;\B1UZ7L>VIC+V/KB:V>M<,FO*>H2":=H1/;OSU>8OF
M*TBBHN=[+!(-T[>FE1"E[0?2\5DOO[]O<<'N/IJPWJM(/-ZT\#E$EL$XN_(>
M?[#SVK6#1]-!FL+?I2L,"F,1/FDT^&P^PC%B)L)F#88\V#,9,JH/<_35.[(K
M]ME+2C 1/>Q67,/6>U[J'46$,(Y<T_LKRLCEW\48:DJ0I=>7B^O4G7 X8S5
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MAJC)!$IZ>>(L7.0R]R<KCQ7B_ >X@Z\\#;3;9D%]M5GMDG,8D19%7)(;((;
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MX?3[=.MY)/FC9G(!/2:0B#S$NV5'$O 4E0Q;#42_G;HY:,')W@<D 2(@,_E
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MNC4%AM$FP%B<C<H;<56/.""VTM5/9+&+;9+L$C,V%D8[3DQE]JC@E2R[4+2
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M =ILQ#QP3RXQZB%E ?YRLPP>"HV^8D=@,C!R!SCDXK+IOASL)VN%)P00Q+<
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M5,[5Y+IE;N5)*&I'TQ.7I$)_UJ>'/T=I!M)OJ3P?',^AG54+LR*H/=VVK\[
MRW('/'O'P]U%C9G"*KL2.R+N;M[@/=[R<=OMK??I$27]O@$1VU<\S.7^[UKB
MO1KR%<.3((P=%&A#&*=H1L%@B:;0T1)%&3],722;3YBL0K.P<CIE<?)LK[@Q
MYR6\I"C..Q;C)P.U9.B*4!ZBMD]163!'(^;V).,\%4 ]V<YJT'3>.G<^J>7W
M)*3[(#*VXXQSQ]<*TO3)@D&F8RH(#U2H9BTPR%;0C'A/#C$HZN&.'[,0DK?9
MM)1@N!+)MN);(LN0J1R%W+G/9F(7:5R"JA\G@D#RB[/;F)-]O%>!6&6:2,*H
M3@X*@,Q;< P9BNWC +<U&\G-NH7ZU23VVPU2M.6%/C.DFNUFK]"'A6JEL:H&
MN:J]?L- "AH QAAJ] !!I +'$2:.,-B??3?UH8DQ&DKJ)"/DT>8EBQ9GSR2"
M227).2>">*TF">60]1XT9HP?E)$BPJKM";1C'880 8&"1CFLU<];.N6"LUKH
MJD$$I,ZM "&(S2TJ=FJ=V8T@6JH&PT[%7E.:4?@$8;<]@+\^6R?.=A,DCR^1
M)>01N\+$AD0OCIMM9 N6*D!MP R3M!QM8<X-$L[AU290"K2!<F0$JY("A@2N
MTD@#)(^<O;@U>O\ 3VKW1D_3>Y;7$:R1;C_26VF5N7OO'+>=7A1<^K'ZA!7Y
M=WL%,2;^5T((^F(=MMN1-"S#FEY6KO"T%KTS&<Y9-H_^5M XX&U<@#;@<CL"
MI ZNDI,LUSU X["0L>.KN)(/+;FQYMV3@-Z,*ZO><&N[28Z/+5IVC(%*RLAH
M"\LP2OIIDX[=V2-!)-"I63V%JB0PGL)--11)7+I2KTGETV.9!#8D(C4JB"7W
MHFLZ6HV"N\@8'+KI0Z^<I'WMT&CS'6;3ZO/_ &S3<YV505XB*:NYYRARI,Z"
M.RWGCN#(!4'2SP-&3=>J<<D>A_KC/>I =]2#N%K],-62&RUBT6Z^GV^:OGUN
MR3!)8R?6OV&U)7&VS1+I6-#AB8"(X1)V8QYPV!V P.PAHLDJG;/V?B*H7Z1>
MQO'/8KWE]@J]SB$[-@XE8.ZR7%F8BPL'<D/>BHZVD,3F_-M.<M'7K3 ?D/B
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MTR>";1^=VDO8V>%5GB*O&3CDR%@%(*E1L&?,I1@AR"0 04''>R<),QAD#)(
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M8#4NRD)/M//'#N/9FNIK,MSL3\!*Y";5QI8LV((@>6"4V2.OJJT5Y<+)!NM
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M"[E5%V@KM"R+L)#>5:>A%=ZI*OZ,_7"-RZU'"J*?6=13H*_^WU!A6P-88+W
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M:)C%C.<1F:S:X_T\XKMO=FY\S,WF8L>23RQY8\\L>2>37:1=J*OEX4#R@*O
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M]$Z&^<UNWODL<R,2RRM8U<TD:R0:6]RF5^8 =%,(NVKS46O-8 /W#^/^P!M
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MG=5YC78JS40=Q -2)3"IR9Y#&+,^;2..4]F=-\9C"LP0#BQ[;YQ&,$*( )'
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MAVCP,,$\K' (&UEQMR#AL@DA5 (Q3/KOI#SY0DE6,+1<F;#6Q;-U[>-L2/\
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MOEII;UI9EW-L=^F&(4&OL_[.=274+76RL)M\ZJUX+<__ "$O(4Z<2\#Y.-(
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M;/9ND)(("27"""%<8(=^K(D>,B5B [C!.8N]3O7'N;ZCG43GVF):IS;V+O\
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MA1MIR<%Y X!7R.0B[$Y+;F##*E<88J\\>L O!(+5T:?D:%NH,8$2EQ2LA((
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MUS#'TA;02BY:61VBB-W7-9U#3M4T2SLK6VFMKJ=1J4DCR*UI;RSPV<#G8C)
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M5=$=#6EYHM((9UMK6")]-YA1L+JT Y$&+;V:3[W+6!45"OAE5*FLFQ46(I2
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MBE'BE'BE'BE'BE,GI5&4]-Y[=N>/1%ARFZ5=W6C1W*L9VKS&W7SAZ3&*3/\
MJS"(:66,G[:7.FLF\.N,21[?+OJI53*MZ;EI[Y&V=7R!E2-,#O9%254ZJUR(
MN'_-^Y5ZZF#[VY7:?^BH\M8Y=#99$4*[!Q]C<CCGLI%-?T'<JG/'X?B3^O\
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M0A\T!Y'T-3(79LFA&6KLV]Y6G[8ZKU&08060CJ]J,JK)K=#M?N%DI!H@2B;
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MQ +# YIE\CNPHO/ZGGI/M.YCDL=@8J5*E#,GD+6Z:F8C^WM=CM5*-O0L<91
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M0YO$.C3Z9;SQ6\LCPNCS1+*A,3AMI)5GB+8XEBPZ_-Y1F!J4)^B7U5?VS>\
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M/  &22<#U)Y/?N234\_P*XC_ ,'.5_\ A[4O\1XID^I^TT?P*XC_ ,'.5_\
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MX>T,W#71TFPZS6WLA;V:/:;?.=G2V]+)[%]G4V )NV>6FVK_ $Z_1U,IY(D
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M)EB5I92;?+)(,C;Y+ F^H65K'\L.L![+7/W6ZGKCM[JEU][!C5@&!D]Y)V@
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MQ4MXSRF;2,"K(*A6@:;&J(VT[-MH> 0G3@ULQR^+-"7UQ<ZT8+#CE",'%/\
MY[VY!:+CTRC+ZF17/X>"COC,R&H8I2R'>Q;-[ELO%)T$KC"5Q(42.8U8["6N
M*8NR!L) L$$^*4RN<>S2B_6+E0X=!U"9]< M.96@;Y2UG"KE(FN4J6P8V%"A
M9MZ&R)5%QI["PA1K"6%R3;U".TA,7K-2I6I>_;.CTK;J;&T528D'C5DJZ=>X
M$9(V,!UALT-I 9CZM)MH4M4<5Q$H;M78TSL@W2N/%2:3Z=W=S4.!3'Z_7/Z^
M%7$\4H\4I";5:LOAB GM<1.@RSP&I0C90O8C$LU6XLBMB1 8/-%,>MW!"W ,
MDTV(#W#%V'DCR/%G12HI]A[N?1^>C;K1*M.5<[QSWE^"[T#,TI">#IER3TLE
MK:E0[%/*Y6P#N)8!4&'"?2QN255?E;JXFFYXZE;?+.JD="]?:%VHT!*B+M_)
MD'1R@#7FP=873MZJ-89M-[.0%OM#68Y)MMXK%.MSMA-]-I*!C/S#84IF^J?3
M;#U?G3:SNEU/A7_O%C%5K!1D[>KH+PE8I:_9F-L@I]D./M-;VFN5@M:/7:S;
MBM;D*B&Z5HK4K+NN6BJD_KL?Q%(_.O8#%W]INT<8@HQ=?74&B4]L);F]9LZ5
MU>&6EDM2&Q3P$LT8*DJEI2H@EE2.C9E%V [2UMU8^]8PJ;,U1[J;G6_8IS2/
M9GG/*X*8KGK>RSG)UBO#4($PJ GMM\M7,JVFK$W[J56%<4$ZJ4,S\E!2ND"S
M#OT<5LQSJN:E7:%4XXS]/U8&:7O<KM-EXGS6NM*=4$]WL]KO&M=2H7((#2&0
MM!1KUU3)(JQQ;^>(RS1H.;S;12M[_5(U$>9GRN6QV%4FI%I4'_/ZY_E3GZ-V
MJQ5_@E8[+2*_6K!+8,\C83@.GKQ0M$K?1K#55C1DLGTJ\K5JQ5+K'L6G4M%E
M7PTGBCB9G(<YECU4 _K^%1_PKOMEOMYZ7SP.LT45731>@CT%(@G/49K0O+>W
M]0X& @OQ46CD==%<YN:16RK')*T!$K4SV&NPH7NU0C>OU"!_+\1GCZ/IYIA<
MB]H+Y>[WP!+I6^4 E]AYI5>F]@K%9GL!]EJ,KZE7W.]OGMK"*OI)4XS^A4KG
MU.0'*''0.@+65@LL0-2K/,&7W:A&,_21].,?WS6CV'W%M'* ^PMVW)U32S<U
M]AUW%JDQKXMWN"@+ESSFW">KO;G>; HI49U::L@+W$N%IR\6<!C<A:DFT<M5
M"UW=%JF.WT$]P/>1[_UWJ0O:/V)MW%W<RX?F]7N=;SPGH/6$!);>>9YMT7GG
M4>%T].*S1'KE2!-44FW7%UM-M&]PR?\ ]D&YVBJD"71PV4 S^O@?[5L!^PMW
M:<1Y=T#-3J#8NT]W1<-Z:&R,,10HX"N_$\!LQZ2O+9N@JG+@=X/O%,BUZ(QJ
M@>LIS!-T&_*5RW>TJ8Y^K/X9_7\A[H?Y1[J6>W\I[#<'BGGG-X*()R^P49BZ
M!>;5O'..JV%G6ZJUBK]1=6RP7<G31"QBI%7$_AGT?IEEU74=ER[CY35*U9*8
M^OZL=OZ^OI\:7.#>U'0+ET2N4RTTF@56![;V=&;URO[3:W+:P?P15^P&W;)X
M8'C1<MY_8PW0]'95@B)PZK'1#8E[/H3TS!(&BA _M]N/T?PYXC^L^Y73GQE-
M8J5W!; QZ';5J6MG5N*WZ&]2IRJ7FL]A%IA+8\"<+G?.)^DWB;3V+O6Z2H7"
M4&HRT/D1V_9*UG93'Z^W\>W'/OY&*ECI'M)9*CV3HE7%I]8Z:AY@K'D"74]'
M<7EUI?0;(HYJOI'[M;A+VT0V]ETZ=;)K8HHM/L+/EW(TH71K<_F'Z(EINRF/
MU]OU?B/2I.XQTDCL<'JUUHL.%<;TSU;LU[/7C#L!10&%JE]>'9X0D#731CH&
M*8;- )DS&9Y!HXI-MY/GQ)LI[C](_K5K_%12%!5JR*T#>"UQ$,Z7I,5I>X@4
M+X6@-<UFB)UKX;",?4L9)J1#"1A5#-H!B:**7$'SQZ[84J+.F=;14.^\GJ#:
MNY<EW9@P(6LM9P<$U^6%_1^<QFJP28]S&1\S/K:F%CA?()LLIN+:X**DB!U5
MM5,9_7PS_2E#N_1UG*^8V"V-J\/; ]?M$^U7)-"#UL6SPF-9JC@B,&/D;'-L
M$;+UR$!4U.=L"1EN@>L!!!8JE2B0R&#5SMS?J"!B@2LB_GTS/*,- /L41\T8
M62LS20Q:[_-H)DC,FVN=8,S?'3YE*C'AO3JOV'G(-_IZK9*C:V3H &BZ3*O)
M.C"M] L]:=%FX3$%K]3VKA0<W-UB*)EP2?+]T1.7]>7=3M2'RKL]9Z??^OUI
M/7RE+;FK0!"T9'ADBFO@Q;+T"I0E?-.K%AD706>C7.--]DU=CRK9(&,DBTQD
M6J%4_7Z_7],XK%VJNJ/8"C\2+K)1KZP(-7B^S_1^H*FE;J^DGB"Z39!E&&R8
MMY3:HC=9FZUL3O.IPC36-7!<6-.4Q^OL_O6YUKKR/G<[-;8JBT?+%O&>L=O(
M.CRBD5R!<6,HLIU>U&8,-#?SY\EP7L$Y4@&J@7*R;<AG 5]O'E4XS]H'VU\B
M[<+GG59Z!M5FA.COI==Y8Q7JF"DR!.[<=>'XN:\A:G$J='=0"L\VQZ]HN#RS
M>5^0%B.C'R7+ &J,?W_#/\J]\MZH%=EW1AJY3)15W++6^H:@) Q0%K['FIQ9
M$^PKI&)U" ,T<H;=*4N_(Y1H&>GX-A8!W"NR*Z^I38YQ[&42]7FCTI(B+4V'
MJ'$!/84G<C"L?Z(!,'.UPBH_Z,WWCI_"KMB:,MB/!,M# 5B!882[YC%#5./P
M.#2%8O:"J(+M6$#2BO!7K7K3GC(K0^ 8C"\7\]S%',ZC9U^&QQB+[.\Z!025
MBAB6GP:OBE,>DIW":-)LJ/U^OU^&2'9U[N";G15@5.:2S>_@*Q2[DN*WP$2I
M:M[%T<"C(%@0:_1]:L,DEC)4-C)@*FQ9_;DA_LU;:;'I^&C4[UKE>PJ8FN^O
M[D.K%,Q?8<.J&JTI#-7&Z6);<)62)R)4NGWLSC2OAVL9E99]-1*XN2K&N";!
MK83Z;6;>IBD&L>SU<<</L'6@*S D654FGJQDC!\O"79@N]=Y[9ZA'JR !,WT
M(C0=+K(;:NH4;ZP1VL9Q2Z4GO+:)!K85",4[N8]E NMX?49?1RJWNIK%<N3J
M7)Z0F=.ZN26N6F:O6X)+(2&HM4T%JCGU#C:MFI>BQH]<AI:^ZY^ZO:E1W3?;
M.CV5[QX66J3*GG>+;:*16W S)&R3F):+1G_01W45IBV$CL2B:?:6M)ATNK$-
ME86#MW33+-0(A[R[5.._P[_K]?'!XJXGBHKSMKKOKMIOKKMIMKG7;7;&-M=M
M=L?#;7;7/QQG7.,YQG&<?#./Y9\4K5T7+XC,L(P XV&P<2[)V@L&AF5\$LDT
M .2==,39#AFEEEB&SO\ 1CEEDDTTQMOMG*E4\Z?[ 6"G^S-'Y8$#19E9(7)<
M;KVP9L_1[AGL]E[#6W$W.CHW@(BT+DH?)5]VOX^]=M67%6<3[3E5'*<0YLJ<
M<9_0[=_I["E3W)[<XX?SRNM:TQY;#:[);<I:JAZB,>8+<;*NJ]DM==K*#2"P
MT].E9EV"O*IS[W<+:BJ?/D [6TL-V)@"U2:H!GU^KZ?K_ 58._73:AT"R7G]
MM62X$($4[4>IT5,SM=EL1VL6/LTM?6)P2CF!+ R2$6(C4/48:*39B?L* .3/
M"J*C?U9Z8S[!P'F_0G2)?66[M4>,Q0*$-HK*=277WC2MS!ITMS6I[*(IBV4?
M!9LT6 R%!9@+@&B%G@TPJ2,$BH?]./9-_P"P4_3-K)64]3/5;UBTCI%RQ2*R
M5*[<SO-= 2VYFEZ-T"%M<4>O.95C_P#-@\TMP!$&HSGF%;7Y1%MU0?U^OU]=
M:P7LK:"/=QGP/>NU76FB"SUK2QQB"[6S:QC\OK/7(AYC<7?:S8!W7/S8<C[\
M@BYG%H.-)%W.?H1DW*1E3CC/Z_7X_#'-;/?O8&^\VZ UK J3F8*,-'PUC4;S
M:Y7+K->>]9[PHX=9+-;$D4U3%!0TY':9688BJVP&6+/W83*QU5>3++HI@8]^
M>WV@X_ES6<#V&N5BH?J%92ZOSHBN>P[1Z@Z:<V<M0TP:P;@?7.EKG5*#D7-0
MCJC;V7/("\-+&WDT645I'OJ!8C&'WJQ0CO\ #^_\^?2H_J7MGU.Q^GW?O8I+
M%QGH+;F:>UV:A-4!%FJE$N58JO,*U=F[4U"2UNMZ42 NB;>JKZJR_LUU>U"2
MNV E;SY3< V :IQR!R,^H^/U?KUJ8>==]=6SV6[3PP7G;.K5?G5(06:KN'U*
MOM5S=[&UMEO67-T.^9UP6I35(MP*"+7#%,C1K9"@K;:AI&B603:%48X!]<_T
M_O5<:O[J=(+ZCRJH66B4FM9MS&)7?F**&*P0-VK7V!Z]PA"BIC-Q?*+=CM*;
MOS=>ZLS]/RCIL?V-M":6M%QVL:R/,*8_7O\ I^'VU[]I?<?K/$2^F?AJ+S(M
MQ3[VIJE#*/,U:DL:LV]>>G=P:D.B+5<.,(%#5BVY3 GG617: 5<EWRV6[]!M
M JBF-%  <_1_7'QI9]CO<6R\YN$:.H;<<M(8'&9>Q/J39H; -;*VO$I73+<B
MZ Z;-V]8!"1+;A3:9!!2DU3LO12$&+K>3_V0JJD)DJI R/?GM\/=_P!_P]:^
MW?W$O==XG5;<LL/"Y^A/.L=GYA7M&8[T2I=B9<KM5XK"?2C1RWL5=0DUHWK(
M1=KZ#=NC-ZMS#7)P\8_03S4 9ZHQ]/N_O\/=]O?.*WZC[:MR*)[(6O-Q]>@:
M#QB:OI:G>E 5M_9]=.GN%LJ;VL,JH [/O71=*@ HJT%-<URN\T5=NN+8ZE<_
M#7+5\%PG5..W?)S^'V?'Z!6CQ[W-M]AZS1N>W'F)BI'9..=5Z-8+W2>8=+L:
MZZW"L7[DJ.ID4J>DB] JN4^_/+V,TZ,*)=^B3U"_,1^:36S)]&:FV54$8_#^
MN>._?]<BNE'BHH\4H\4K3.7@,Q\B,@0V(F9AB,BG#0ECY(")B-#GS"1I)'F8
M0P> L:7Y?G@)ABGBVTECTVU4K,0..6/.*5!"2*3#*.2,1%I,.0/-IM'-!/#)
MKM'+#+'MM'+%)KMI)IMMKMKG7.<>*5A 7@*@X%ZL$-: -KG08$ :$,,?3;?:
M3;6 8?2.&+7;????.L>FN,[[;;9Q\=LYRI6SK%'IM)OI'IIO-MC>;?7377:7
M?732+7>3;&,9WVUBCCCQMMG.<::::8S\NN,84K6RN7Y8:-L@AY:QAR+M&>18
M,L-%\LT9,H.AN=/N=0Y"(8B)!L28AWFBCEVTSOIKMA2OAJU<R^T_(KPC_L#1
MV0/WHL!7V3$3.V16 GUXY/MS1L[[Y'*A^2>'.VV8Y-?FS\5*V9(HI<:XECCD
MQI)I+IB337?&LL>V-XY-<;8S\LD>^,;:;X^&VFV,;:YQG'Q\4K6%6K@8B( E
MX0<!A19I<(HL \11C"7><\LB.&/32<HV>228N>7&TI,N^\DV^^^VV<J5A@2)
MAF,K<90L';3BQ@SM( !8F,P47TOI!RFQQ:DR"Q?0A^F/O+F+3Z,7RZ8^GI\%
M*W,"C:XTQJ/!C$<\I4>,11XQH3-M+O,1IC&O^S/+O//M++K\))-II=MMLYDW
MSE2M<]4K:#F!LUH#$1B-J&P%/#','.#US+MJ(9 1')$2-KM/-MK!/KO%C,TN
M<:_&3?XJ5M[0Q;YBVWBCVV'WS)!G;37;,,F8I(,R19SC.8]\PS2PYVT^7;Z4
MLD?Q^3?;&5*1MJO6MU&*_O746Z#7?:3"392!LHQ)L3N;M)A;D?(6-]C)-R]M
ML0_-DG?>?.?J[9WRI6["I5#RFS0+%\$S*,>%C+"&-'*?$)!D46(V32/7<J,8
M;.1Q])\R:PP9S#'C6//R^*4GAU*JKI5Y"^LU\&=1J3HJF#2K195FAN9LF:+Y
M(!M-PM2\D3Y)U&VCQ/F>;,N-_J;_ #*5MP(D@L[(H9,J')=;1[N"(%XD,[;>
M+$F(MF4L<.LA^T>)I<1[%;2YTQ+)\N<?/M\5*5?%*/%*/%*37"9185AR1^J6
MO$S,?<1DH< BLUC 63X?4&. -BG$+'W^&/GAGBDCV^&/FUSXI6SL&'N'LOW%
M&W W&R'L#M!%L'L'M%]#878;.N8=AMH<YAS!G3,68L_3SK\G\O%*3*_6*U4P
MMUM5KR.M+I2=S)%]?4@)@I"Y8XH92MQ5PXT&Y,D4$$6\^T>9=XX8M-MLZQZ8
MPI2M@<?!&Q>((<%;PZ#[DXBTP1N/%O)+'!M-\OU-H8Y)I9-(L[9TTWEDWUUQ
MMOMG*E)QE?0L6BAXP2*#G=>^^R@<&+0RFB/\I!J*S_$,)X=RUOY$7748[[*:
M'[N#76$CZD>,:^*5Y?5VOVI9,EM")-9$Q$@\TZE\L"<+)Y1)XRA)9@&$! LL
M@Q4,1(^^\6VT,\4<T>=9--=L*4I3C#%0Y'*'@)'VS'MM!/%'-#G:&326+.8I
M-=M,YBECTDCSG7XZ2::;Z_#;7&<*5H (4:LYNS6)E*YE8"!S'S !<&(<[+$%
MC"%*;ECPQD,B!@XHA!YS9)I818XQX]M8M-=,*4FZTBEZN +%K4*OK8%0VH:M
M[J@4X<+0]8IX-1 &>!/O0QM8"B8=8!YXXL1$3QXU^263&RF?=[J7-UR^34S2
M0 /?1A-&2?IN+!MJ<1%",/$09KMIG!,T8X0<$<LV-Y-(1!HM=L:01:Z*5Y-5
MK&6LNC%<"?I,"<KFT-$'*UE6,\089+I=9XY,2 L,##8.$VQD<O \&"(Y,11_
M*I6 )$C6JUZ-<F5 )5$8,2E.$N$%5K(EF\4BV->O@AC$"C7R00;@Z#0Q:B;P
MQ;#XCVCTSA2DG%#H^%SQ/BF53"BS,YG=D5XKJC\=8'),T!!#9X#]G]LV9SSB
MBSS'GQ$%2S#02;R[;PQ[:J9/K6572Z<C+@/2U.LJ#Q4VM<&-5HE:\L:O:F;L
M-44!(@L,T*;5A+*=JKCWU!P9)N3B#ZV^V^5*0X.1\H%R'D;F//1\KS-F &8*
M76XL@G[?;?,<'F-;K]L9M]D'\Q,/R39^T&^._P#T$7R*G)]3]M.""HU,5^5:
MQJQ71[2=#]N=98$JV%^8/]."+Z!3F,;5B1#](4:/Z4Q.^GTQX-/E^6&/&JHS
M[O=3(/''#[+S<02"$447DW71QAAXM(!QQX+5PJ*&""&+76.&&&/76.**/772
M/377337&N,8\5/N/TC^1J6?%11XI6G.O *)!,*!#)+62S3K2IQH9B5\Q \H9
M$P,\FFTHDLXDTPLTD&T>\H\LL&^=HI-]<J5C:*%3L3=>Z6+VX$F^DFX30(8\
M3?>+;YX]]QBXI8=MX]L8VTVSIG.FW\]<XS_/Q2M_77&N,:ZXQKKKC&NNNN,8
MQKC&/AC&,8_EC&,?RQC'\L8\4KS'%'#KG2*/2+7.\LN=8]-=-<R32;S329QK
MC&,[S32;RR[YQ\TDF^^^^<[;9SE2M8=<O$)/,$!#&,:30D,RAQ8(26,XXT08
M\Q\\>FLI<T D$ L,A&TF\0T,4&FVL4>FN%*^;K5TK =M(O"D:B"DA"L]Q8-V
M P9DD$I8@YFT>2812I119"8(Y-8IY!H-Y=-MH8\ZJ5GE&'GSG,X\,V<PS#9S
M+%')G(Y/T_N!\YWUS\82/HQ?6B_]7+]*/ZFNWR:_!2L(ZY>($(M%!#&7 1B0
M@@#C0PA!P@?2R#$(+'IK /&%F"'(D<,>FHWT8OHXT^GI\%*PKTZA1DO*I4M6
M98%2''Y7@C!9--E_]:87D:*+[DJ7_P#>$3?/+O\ ^UOGQ2MN,4:+Z'TAX(OM
MH,BC?3BCT^W&V^C\P\'RZX^E!G[>#XQ1_+'GZ$/QU_Z/3Y5*UB%*HO<:4I8O
M)D"/U:AR$!C3;B--8)!=60V\D>VT!^HLTPVID6=",02R0XD^G)MKE2O1RQ:S
M'*$9+P6 IPDJ\T8X2 L<P"?&VLX14)$<D9 DVNVVLHTVN\,F-ML;Z9QG/BE8
M"420W=9(8G5%R)9=)D^Y*\2?=3-'B/$<JS:6'?8"73$,6-)!<Q;ZXBC^7./D
MU^"E8]Z[7Y5A"61$FD3%SSE%*=U@6ZPDDH[9F200!M!D6:<AEONPGFDBVDF.
MWV+DVVGVS)E2O8:!$N+G8+TJD \D<8,DT-<&*60('%$.(+.3!#I-*.+!!#"-
M!)OM%!%#%'%KKI'IC"E?5J)(F&A#4)U2H0>>0J 5:O$!&A)FCWAE)A@%ABBC
MGEBDDBDFTUUDWCDWTVVSKMMC*E*OBE'BE'BE:L@(4Q8I\P8LIP6A$01L@\6Y
M8D9>(L%QBD;:9F'T*Q!#@C2+?36?$,6),;?3T^"E8SUBUI'I$S7@L8H]_J1Q
M'B#EQQR?+G7ZFFA$<FNN_P NV=?FUQC;Y<YQ\?AG/BE;N,8QC&,8QC&,?#&,
M?RQC&/\ 3&,?[L8\4KSI'I%KC2/32/37X_#337&FN/CG.V?AKKC&,?'.<YS\
M,?SSG.<_SSXI6N* "#L5L$$('L<5(<=L*-"/L8=+I''*85F+33)!4D<,6DA$
MWSS;Z11Z[;YUTUQA2OGX\#!^6N 0\--A,+\LOMH?O\@:S9(U"R9\GW&1,$;9
MGP-F3Z.)LYEQI\^<[>*5]+ !/A('.#$-',&D"+@+'A(A*#FQMK,(1%-IOI.-
M+KMMK)!+KM%OC;;&VF<9SXI67(P^T<46P\.8H<?"&/,4>8XL?2W@^$6F=?EC
MQ]"22'X:XQCZ6^\?_H;;8RI6J(I5 #3!@K%X8A&=]IQ1 QAQI\R1ZQ29F@AC
MTBDS)%KK'OG?7;.T>NNFWQUQC'BE;OT],;YE^33ZF=-8\R?+CY\Z:YVVUTSO
M\/FSIKMOMMKKG/PQG;;.,?'.?BI6ILL6[D!E[KP=RE^Q6P!.PD&Q .QVORF[
M!S9CS(-L9KGY2LP[:9(U_E-\^/%*#5:QC%O P7 GPR2C3R0FB#E123A2Z3AS
M;QSQ[Z;2B3QQS#2;8SO!+'I)%G3?77.%*\RJ%4YFK"=8OF/TCS#H=*$-(9I%
MMIO'M%J3O'F;6/:.633.F-\:YTDWUSCY=]L94K!O7T,@8:Z1(HW7KH](EX&Z
MT/8,"*/3$<<88NT.8!8XX]=8]-(---==,8TUQC7&,>*5]T0HXXC((TJG2%AG
M78^'1<'K$=MIOM)IDR/6'&A.=-]]]]<S8WSKOMMMCX9VSG*E;@P(0<<,0@8H
ML0T<D0\8P\4$<$4N^LDL4.D6FNL4<LFFDDFFF-==]]-=ML9VUQG"E;7BE'BE
M'BE'BE'BE'BE'BE'BE'BE'BE'BE'BE'BE'BE5.]CKKW:H7'@2;DULY*A5=:Z
MA)R]UIT3D]QZ"P6D_P ,^H]'CL*LRM=NY:-B#73G@Z7=(6N)DWV9S,]7,>!M
M%TJI&.<YX^/Q ]#ZU68#]2;;2I;V>3B5NM"9!43K#:[8J:TZJAR3U?UXYW[-
MW7"BH-;:_;P1@\UO\$*<2=XQRPN0T%=D91*""[:M5.WX^_'XX[_4?=V%3=SG
MW@J70!^XN).==%J52XU5[G=Q;=;4\E6KEYJM"L-XJ]B.46*W1UNI@$1,*(:R
MB^\LDB:"N.D;)T]3,(;0EK*HQ]!^@Y_7]ZKHT_40Z8RO%&4TSB(X*/:T T7I
MRN^36*O6E99W7L+ZF\F EK>CM=5FXZH&I^R&+#/K8J)$:Y=87#!: )54[*R*
MG ]?=D?8?I]X]?\ M+W%??Y;W)ES5;6>&=939ZL;5FE6/N*O:GJ_X96^DO\
MH"N_3E6<1/NSE@05AJ,Q04^"U0QNR$8X#]DD:[6$)4$?A_/X?H4V[;^H";5X
M^C! <J:VHJAD7P,FR:G(ZQ7X7.O;?:OBO+D$B8BQOGK+5C9/60\2V6(>8""%
M?8E-G!3";%,:I75,>OZX!_J/^U(]._4=E*A1UNS<6OS&Z$#<WH\]H05MM7N4
MV+O%N9\4J#:JJK&_RT3URJ073M2Z!<R)MUJ<ZJJO;=I%II4-.S>U"N#CC/\
MS_;\16RG_4#LDO0+)4[#R+\3*-:=*%3:ZNM-5L1EAM[8;T;6JAWE]3V<FI5M
M>JN7MY]@U)7+K5AM7UD9ZR0*RI_VC;U,<9^'YOZ"I3Y5[Q)^J7Y!3 N5W!&
MUZ8[XBQLS-S5"!4_7JWS.]]/>UO5>M9EE-D"U7S&Y+,W("39:Q8YK$Z0=JI>
M',42F/Y9^W']ZC"V?J5TKE@Y+#IU*LFJQA:;YI7BZL*&3B.ATOJ79N1$V%A
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MG=6W;/XC^X58NL,[2HP/-]>=*JOZ?W)\A/ Y^<Z/W/72.HT.A4X2M3'&>_\
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MG#&AUA:,^+\G8L[<C#K%L8G\ZIY9UGK:[";5?7K"60GD(=(P=:[7\!J64A(
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B^+/BE3=XI1XI1XI1XI1XI1XI1XI1XI1XI1XI1XI1XI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img61678762_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_19.jpg
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MM,'3)4-35'*%AJ76X1EB<W1UE]+C\2:R-C=V@J*VPO_:  P# 0 "$0,1 #\
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MHTIG9;?2*71"I;?<S57S8[ZCC9J[T$JZVW3!&I:93_L% [X KM#C"[1<M/V
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MD)*5.E#IH"8@$Q2(:.8,>37[!/QL8DJ[!Q>WQ!RJ-,P29XI.D>2$A,W)>H
M *MGD<#DJDXCU 5TO$,RQ+SA25#E\ M*(N+8!)))!7  Z\2V/5J1>J/:W8W8
MC>VM7;![:MPTCU^[,KL=,@#VCJH==M1]H:-JJ-MX*TE2JD.%0>))8[#4U+BB
M-3)0X\I+#I'D7J=52QT\$G'U$3T_%R/4$EIGE*'H.S8Z\1G .!VU4IJEYY4Y
M>D>34<E!RI>.=(PPZGW9]Y R<$]]=3N8W60TXTTXTTXTU4#O/;+33^O4U(4O
M9L/J2Q2%OUS AVV>DRZS&O,35Y@@I*KN7T>K7,7695RC'#*O&[%F*Z;#522E
M1#SG0$X1("W=$BO. \;2J$D8JH#'THQ#<"R>8$.&,:L&8 @9[&VJV98&*R"(
MED',DJ,%U!7F$?RRXRH<J0I(/3OKFOKGNEN6M9UBVU:Y&TUBK; [=P^RJS?;
M+2MAV:U%:?U/6MD5[7M W+1(]B(V0PRS9%!5>S8 C+!(61:X"TQ3RZ^IE[(R
M4D+><>(5FCI3$T:O&J>;*T3220N<Q9X@LN2H7U(?5TL(ZJ5?+]3,JO4B179)
M"QBB61429  ^.7I..1;(8>G4E5'ZDVV+16Z$HJKZ)K$S?]N:TH =OL%Y?9U]
M"Q.TM([#VF ]-" 34A809JO2E+!B&,2KT.#?0)Z+*B$0#QK^(JD]NB5GPTS"
M.*20HJ?C"8IHXVXD@*597+97D4*D'..M1:^1@GIA4O*B<F?T 20O("0#R!!7
M S@.""..>EH6-].;JZ64S<$[?&^O,IL!^-CL35?M45#Q\C81+N960J[6MA6F
MN3(=:KFV)*&; K]V)@2CXJO68.1"PY(I'>7;>1Y-8\2I[0(\GBREB%*!BS1J
MREFB!RR<@"RD' SJX\[S:192_D%\=0RJ"0_'B'8$*LI&%;!(# ]]9'I!N2\;
M1U)I@BY7BGVN5DM86TJS/2$B&QM&;M5*VA(:_*L,=$PK;=>L6M&D1A$>WL:.
M:#;MAZX.='C8YFP*!&A60I'+,%1U D4* #Y:J\8?B6/J63J#Y9^@.2DDKI22
MO)%$6=6)1^1)_&%ED*9 '1H^F.8QR." ,X%.Z';.X=DWKMF]U.>V4;K;5':C
M?<'<RK?>]</Z5)U!1X&<4%KVOZZ:"(VBS=6)UZO9C;(P[&PPHZ7_ '!9;>76
MDW;K2+!$CK&))::$H$203>:[C\8TF1%PX\@5.6R.@'<VR-5--(R%RD=3,'+N
MGE>4@.$$?]DYYQ@C ^)/NS,O]1+>5:UI0[S9JAU^@C[/U8<[BYBYJYVV$&M5
M$?%K;T1I[7Y1H3CLGN(S$D8Z>1EDZ(C7Y2HQ0\-**DWY-N44$+.Z*\[!:@4F
M51&XR9;,K@'I",#'8G#G(QC4372K&CLL*EJ?VK!=@&3"D1)GJ9CGZP,J,'.O
M@N_>K;,]N2CBUY-0IM7K._=U4<W5CLY()W!: ]7]6MB7]E[85<4UZ M0L-H7
M!248B+0.5&YCJ^XJ0E\SBDQTR442PORY.[0PN)>(\I/-JHX_Q;=^87D#GOD]
M!CK!ZN1I8^/%%6:53'R/FMY=.[@NN.B,W$C'; ZG/3<V_J2S<S% 9K,-JQXR
M:I/1XS-FD+0:JBT&Y]L"+TU9/V0C@"'7@J_0VZI'-@@^YC)20D9V/CY$\!)C
M134AMP5CR,F%DK1Q"@/(E*$X^6#W9^1ST( 4D XQJ?VXGZ(CZI2'D6]"-4E@
MQ<@]%0*,#H22 2,YU*.@NQNVMG=IFZ;8+II&5UX3U?@K\'&:LFS['#3%RQN'
M9VOYVP5"RRL3#RLP*G-&2/-1K[1<=6\>T  *D2<GSLM2GIXHZ4NJ3"05)0F4
M!65/)CD"NH+ ?3Z'(+=R!T45(9Y9*@*SPE#3AP(V+ OYLB%E8@$C"=1UX]@3
MU8U>I.];\+MV'DHOLC:K=L*Q?4=W'H*9ZX2=CI\_"MZ#B]A[%B'I<"D-0V+K
M64Z\J\''V0:V,2S$>V/%>RD\%"RJ6573P1F$AJ=4C6WPSK4!65O:#'&>)?/!
M_-9BI0CEDY7'$ZMTF<2 B=G=JZ6$P%E(\D22#(3'-?+50P;.,#!SG66T5]0K
M8#AW5:FVB)KY-6VC5].B3=SF[&1>;J_;=L3%FAHV/GE5)]4U2Y)T\"&8K3UN
MURBLW%LF0)7<:R-'/.HEFH(^-2Z%N<32D(JA$"1*C$KRZ. "Q?C)R3IZ&SJ,
M5;)FG1@I618N3EN3\I"PPW'U*V0..8^+ GU+C6WP?U&+Y,:VC+XH/KH,;L>7
MUC'5"KN[%LC<YI1C96T937/R78\/,.L>.B*UD)K$E)Q<C7WB+?EVGIBA&/"R
M(E:WQK(8\U&(UD+MY:XE,<0DQ3GEU+ ],A@$]>3]$S"N<QA\09D:,(OF,#$)
M)"F9QCH%QU((]7HQ^5KZ7?J);0$AJQYM7TR?F=C6K9.A]5S52EYZ7H=][$T+
M<L!K>.S%3/HH=_8MMU4GI"_B2><^]BAM>WV,>DS\ AGNP]@B+-^-=5C6.>56
M4"2.!XFD.1V\U&41D' )DC.!D@/;I0JYB4F1GAC922CSI*(Q@_\ )LI+@]QP
M<9. =:B7]3C:B&=UF@:DHI#-(QL)BH1!]N5%V,20USV J>C71;[#*D"IW(UK
M^T1%@;DX&!0)22QX^ ELSJIB/DWYQ;8CY(\U\OPYD+E2'@>?,9P%]/'CZFR^
M2PXX(U+[?)^-_%IA.?$<L,#',L7K&<^K);*CT$ '.0=65B^U.Y8KL;6>J-YI
M=#?VC.2U1MN9RJJM#%/?T&7K^URUXO0#<NZ_(8EZ[L^GO:U#$)(]N\]9JO)F
M,#X)<&7;&FA-.U4CR")0Z<6XE_/#H(T)  PT;^8?AQ8#W'5P*B43K3.B>82C
M97EQ\DHQ=QDYRLB^6/\ I+GOKH;RPU>Z<::<::<::<::<::<::<::P+M6K#P
M$Q%/5R!=B["24;8(UV(CW )PP[#>#2Y@-0^1Y,DS#+6"GS6WW2,--X=6O"$^
M$W)L@\FRHPIR<J!V /N ^K4O%<$<5PW4C P2>Y(]^?KU6O9V^M3:(NL?2(;5
M=VOFQW:3+W<RJZ.UJ%8K'6]<O6(I<A9)UQ!,&)'PTY;4R2PHUF0(F;//BRC\
M9#21@Q;J+B."6="YE1(^83E-(55I./11W)*IC)QA5(!(!&J$DT<+!!&[OQ+<
M8D!98^75CU4!2V>F<LV< G.I(@;]HJ=1K\4:3HD7,;+8&VI1*;8V(BK7F;*D
MQERR[4'19]J.M2+$SA\ER6+5$(FH\Q)K4BM@EHA*:;1S+S)#D1_BG=<LBXZ!
M"ZY7B<=!G!&,=-5 \+<!E 7_ !B*V%<GOR"-AN7?)QD=<ZPT-8^JAK-P/KT]
MU\+'A1F[5?S8:4UP0S$B2!PM@:L=P)!?6V ,=)18,VW,32VFB3HX6220M\1E
MYN)6I'$,LXR>* B09('$JH/<@'&!V!Q[]0#4Y#%3"0/4Y!CP,D-R;';) .3[
MP#[M9(R[]:\#U0D^W:.P)LUV=11R#)^A>WV"]:761+,FJ.O%^G;';&\X.-.I
MB%'KEW7&69#!"U(3D$J?6 D_XOB7 63T!>J%QCT\1U7.,>[0O!Z26A_&<@A+
M)Z^6 W'KZLG ;&<],ZD&+UY0(1+"(6C4^(0*AUL9$7684!([;\8/"OH82($U
MAE#T,(+$NI;PG#D8,. O&166VDTS(Y[NY^UB?>6]Y_OB3]I)[ZJ!$'9%'V*!
M[N/P^'3[.G;6S @A1@0<;&ABQ\='BC@@  CM"! A"-(8%##%'0VP,*,PVAD<
M=EM#3+2$-MH2A.,8E)))))))R2>I)/<D^\G4P    P!T '0 #L -?5R&FM8E
MZ33+!+P]@GJC6)N>KKGJU^;EX"*DI>"=]3#OJ0\D8(\;&.>KC#GG">85ZF,+
M\?-C&>3!W4%59E5NC*&(#?: <'[]2E%)#%5++]%B 2/L)&1]VL?(ZSUO,8D4
MRVOZ1*8EY@6Q2V)&J0)N)2P L>V!G9'!(#N#9@,;_-Q9,GU31V/W)E]#?XO(
MB208Q(XPI489AA3U*C!Z*3U('0Z%$.<HIR0QRH.6'8GIU(]Q[ZJ3L>X]>^JF
MUC)K&L[Q?MS[XD;EME0=#J,?=KH)&4FEZ\HMUFX5V4.AWH>"&@(JF"%5R D"
MI>=-<?=CH23<]WAFZC2>JC"^8B0P!(LNQ1,N\CH&P""W(N0S  #N1JU=H::0
MGRW>68O)A%#OA%17(R1@8"#B#ECV4]=64'VAIJ;EZ(T7;:2+<[#64W:B5RSG
M1,'L3[.3,0LHF6C:I8%A6^-;7$I(;F<8C1G16AS!)-+2A26F[<Q3*']#E%;@
M[*"T?)3@ NN4/7MUZ]QWU<"2)BGJ7DR\T5B ^",Y"G##IWZ?$'6/B=N==51,
M)"P>SM+*@K+*D4^MQ,3=*-F)GYLD4&1*J\( ')>SE94@*?C3B(0!I\MT6;!*
M<&4U),+>B8:C+$Q3<E'-B4?*KDCDQ(R!E2.1Z9!&>FH"6#  DBPQXJ Z8)P#
MQ !ZG!!P/<1\=?S&SG7.O(FJI#S&E(-O5<@Q8+#6XV0HL8C7$J9E8XLW-0XK
MS*:A(%9-<88DCAHXE_):VFWE>NI*Q%0<,1,?-!56(<^8!W )^F/B!D:!H%Y*
M#$OED,R@H/+)[%@/H$^XG&=8]>S.K\> WL=>P-"!1<I9)6#:OB[7KT8"1MY(
M@P,Y#MVC)Z!R[(0""&'*QZ3G)-T0,8<ME3([2$1\NI)\ORY\A0QCXR9"CJIX
MXR%&20<8]XU#S*<#GSA 9B _) "QZ$<L]6. ",YU(T+KK7,$ @"NT6E0T6J7
M%LK8<+6(*/ 5/"K;("GT#@@LCYEQW$-/"RJ4>\96AMQE]*DISBF9)&.6=R<<
M<EF)X^]>I[?5VU.$11A40#/+HH S[FZ#O]??6SOQ<82>!*DQP)$I%MF,QDD^
M(.Z?'-2*6$2#0!CC:B!&SDC#),0.XVDI([&'\+PTWA,N3@C)P<9&>AQVR/?C
M)Q\-38&0<#(S@^\9[X^&??K\XJ'B((3V$)%1L.#D@HO(44"+'B>Z.(<+-)]N
M(TRS[@PIYTDI[R>H00ZX\ZI;BU*R)).223VR3D].W?X:  #   [X P.O?M\=
M9+D-1U\<A'@2P)<9* AR4:>.\(?'R S)@)HA",MOBEB$(<8)'>;4IMYEYM;;
MB%90M*DYSCD02"""01U!'0C[#J! (((!!Z$'J#]HUK NN-> Q4- @T.F!P==
MEQ[!7X86KP8\5!3PCCCPLW#1S(* XR7&>==='D@F6#67''%MO)4M6<S&20DL
M7<LP*L2Q)*GN"<Y(/O!Z:E$: !0B *>0 4 !AV8#& ?K'76CV_KOIVZ@0<3*
M4:!#BH/9$3M;$9!Q<;#1\S<X=@\9D^RA AMC6!HMB2+9DQY-M],BVM*"E+2G
M&.3K/*A)#L28S%EB6(0XZ*3]'&!C&,>[4K01, "B@"0284!07'O8#Z6<]<]Q
MWU(A5)IAU=&J!M1K!E3#:$8#JY4!%$5T5@#R^Q9&A'1%QK#0?D1[1MH9*!_*
MGT<(\N/"GS<,6#,&.<MR/(Y[Y.<]??J?@I7CQ7B, +@<>G;IC'3W:^!N UYK
MZ*=FQJ_4J?#U.'G"ER $+%0PL!!N^G,6);3@0K"0(\A4<S(RJ&?3:)="9))2
MXXPVI,<NYX\F8L0,$D\CV7N>IZX&H81!RXJH4$Y  XCNW8=!TR=5YU9V-ZL;
MNH%9[0BFTVK@.GV"H15OVQ'UJCW.O2$)B7(E*Z_(6%]!T0\]"@GV5N-8D_\
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M!&EB-90P2\VMS?B$YMQ&<+R/$9.3@9QU(!/3J1G3@G+EQ7ET]7$<N@P.N,]
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M5Z48'DVIL94L_-1\BDIA++L?G/\ &,YC9@TS28+@E5:G:#BI*D<E#<@<8/$
MC!U*;<>"IYB@K"(\A3AF6=9@S88'!X\3@\NI(/Q_J:^FE>28C7WV6V?3:-;H
M>1N\C:+5!@;;D"&W;QM4;9YC(<;:]KV6O; A6C&/5*K.R8$Z,.MOGN<>Y7U$
MD0:H"XH&<M&[J0G%6,0'HC\L9*1*T9QTY1L"$]'7HVHF@?"<9%1@7+,HD_+D
M$GY4C*XZ9*NI!?+#&2-=@N8K63TXTTXTTXTTXTU1KN5U6M79=NK,1,AIN1AH
M6'M,454]TZN<N8,;,S^8I45LBAW"KS52V)2KM6,1KXJ1XRRX@)\$_"3Q!#XX
M&13>TE2E/RR)0Q96#Q2<257.8W1@T;JV<@E>2D'!(.-6E53M/QP8BH# K+'S
M )QB1&4JZ.N,=&XD'J,@'4:U#HQL"D7,<]G:5#O\!,0.F476S[5U>JX;==M&
MFM.?L1#R=.M)UC>!K:+<A@:SGRBQ#;% 2LA:<1\@>[8GS6)WK(W7!B>,AIN"
MQ2<(^,LOFX=0N6X?1 Z*P R!C5-*1T;/F(X*Q<VDCY2<HHO+RK<O3RQRS@E2
M6QG.HMG_ *7#AE7T!6H:ZU 8;7>@*IH79 A,)>8:*M"82?K%EE]AP0^OK[29
M#[33DC!E9-#L$F6R21]G99V1097&VSJRW/#5!9'/F3M/&0R%E)5U5"9(W'%0
MW3B!TY ##:IM;\K"H=<)"L+@JP5L,K%P$=#R)&3ECUXGN.OX27TNIF0:WI%N
M[*KA4?L:)W3&5&;D8S8)MG"9WCM^!VS81+:$[L)5%.!BWH1J%5\541S+&\Q%
MSY!,,8(:)*A<U'DGRV_%F$L@,?$^3"8AQ/E\QR+%NK84$C#9!#YO)\T%UPXF
M"G#EL32+(0WKX]..,A<MT.1@YVS<GTY[#>3MD2=%O-.IYMRW+;-E5Q]F)N\"
M;28VY:3UGJ>4C(TJE7.!BY-D@O7SDQ8ZW9*Y/U6Z1LDQ#R D6Z$N1*EAN"IY
M8DC=PL21OZD/,I-)*"0Z,1TD"JRLK(1D$CIJ:6A+ERCJG.1W'1P4YPQQ'!1U
M!R4)96!5@<8&,GIW488VN52L5Z2ELS\C!5Z%ACYW,>'$9FC8N-&!*ELQ,<E,
M?&9D7V'#,QX*4AA9>]L,G##2,<QK$,S,!Q!8D+DG )R!D]3CMD]3WU?J"JJI
M/(A0"V ,D#!.!T&>^!T'NUL/)=3:<::<::<::<::<::<::@CLQJ2=WQI.[:<
M@[;FCM;&&CJO:+$R*X6>S09&7 1L"+B&T.M-MRUCIR9JN &$Y<% >EL'/CE(
M']L[6IY5@F25DY^7EE4G Y@'RR?J5^+$>_&-49XC-$\0;ASPK-[^&1S ^!9<
MJ#[LYP<8U3:!^G2_4MD5Z2BMKG6[549OC6G88VH[,AXV>GUWJDZIV7J69]G(
M0H-?KR Y^$L.N2ALN5U)$:70<K4X6[((?'O&N'.-@8@DIAD@#Q$JO!Y8I1D,
M6;*LD@^E@B3W8ZVHH>,@/F%XQ-'-QD 8\TBDB/4!5 (9#]'H4[G/2.AOII['
M#3I6*;W%3WJSJ,K3\J,!BH3\09\AJKL%8MR/B#$0%FC&9F,L43.CP 0]X8M$
M?23(I^2JL,(=.E2(53YQC_''R7Y3"4$\U(Q) L63R0E2I7D2A4N#AR0H!D]@
M<>4/-7C'Y1QP(/*.9I?R6 *L&X@/R"$94 L<? /T<N,-M_JC0QV9J6HE$C[G
M/]B+ZQ'P\=0+_7(;>\GV!T70,!F3Q%A-LU5VOE!9P>(AV(56)><??/\ $UL#
M@UJ&*J<X#R<! F271C"()G) "A6B['.>:J,="=0%&PEIT&2B!C.^%"2!9C-"
MF"Q;DLG?ICB3UZXUL,3]-V^ #;:A4;<K,74KP927J]4XB!N,A Q#E5[$US>3
MTF&S=;K;)>F-$APLC7TTJH3Z*6N8GS[1D =QL2.'@;A&?*/E,73GR<LG(\Z=
MH<'@B!^K!N;CGA0N>Y,PH7 E'FJ%?AQ4*W$%9Q-GUN[+V(XJW#+%L#MJ=NM7
M3VX:&W?L+8[^P8,FBV>,N@,1KFO1MLS&#R%PV*F_?/CYO%MN1%']AYY(.0J=
M'D0Z?8IB;/L[D5$OL 1H]"HJDGA2/RV#J4)D8IDA8_+XG@B<\]"&?+*H"Y/4
MFM!3/#*[^8"C!L1@-C+2<^7K9RF,D%4(5B2W$= +^\L=7FG&FG&FG&FG&FG&
MFG&FG&FH![11>RIG1-[C=2*GOML0BN9:8JDPS7K<?66+; D; B:?//G1C<+;
MYG7[5GBJK*XE(MV/L!D:4Q)QS[39K%>F,8F0R\>'J^FO) W!A&77!RHDXEA@
MY4'((Z:HU D,+B/ES]/T3Q8J&!<*V1ABG(*<C!(ZCOJ@8^.Z-3QL-_0T!M*O
MZJ4ULBX:MJ&XU(V-L!Z5JE*TNB!IYI]]M5IM=>JFPKZ[M#X>*E; Y-B@,2A4
M?BN!E5W(M_\ UFW#SVC:7\6DC0_BXP&>;DX"(JL\:>5D@<22 >1#$V7]=+YG
MDK((_6\:R_C')5(L*2[,RJ[^9@%LXR1CIJ9J%;^]\\;NF/MFO*>W',64N*KF
M)JQR-+7$U9ZQ[, >E=<2U=H=@7=)1JEA:TEX>%FRQA2YN7E'C]FP!+SU.J5"
M1*("'A(^>.6(4/EN,9Q(K.O <S("0,\0,1L/6]9&JR90Z+CD0,DKA>4@RA56
MY'@(R >F2<R#/!(,T#6>X,$_JF.K;6\*+4)V%Z^5G=A^[9Q_:4^-?X?7^[93
M>%RI06PKE=SZ[6YJP":BK[Y3"XV")F#D%5^M>5F;))KSM2-YK-Y+L&J&A$($
M2^69(! C^6B!F"F5AW.!ZF[:H0K5+Y8'G(I$"S&4^8>824S,@=G(#,(U)Z#)
M!"]SK4]I]L>Y.K:-&V/9(&=5!LU2LQ)\Y.5S689TYN**UIO2=LL360;/:0(>
M6J4W=JKKT0YX)_$QBO/NEU-I@.3(GP)HJ6DE<K&3+ZV(4-)Z83) J,Q520ZH
M\G?T\L!NW$PDJ:F- T@\O"J"2L8Y2".5F"AF *EU0=.O')4#/(3-MI'>&RS&
MG]C5>&2 FH:QV78A:Y2[0=+1UKLLM!:Q!@)+8M.G(/70 MV!#F]AR=2H*IZT
MUE4U ,@D3PZ)(M+E*+V)1-&S9Y21J6=0"J@R%O+=6DRA*QAI.*MALX.-59!5
M,T3J,<8Y&"JQPS$1\3(K!!R&7*IDC*XY#)U(.K['WEFYV6,EXB*<@(&GF%4>
M'V4!%ZRQLV0+VM?H.',V//52M[#E]?SHFK0:K:2X&M5%;1<L3%MG1]:3(S$3
M&TY%H@HP3R9AS,9,GE 1(Q$:NT8=3*67DSY"YP7P"9XVJR22 0%](D C\PF1
MP"Y4.481\6(5<$XZ+D@=!V,O999R2AILC+3>7VV'5O,MO91C+J&7G&F%NM)7
MYDMNK896XC&%*:;SG*,6&KT?7W]^-?KQIKXY#!V0#L1BATR60R<1ZB\+R(D[
M+*_:**PW^Z9'P_Z>7L-_CY;\V$_C>'(C&1GMGKCX>_4#G!QWQTS\?=KCOK-7
M<6!)URJHQ^_QK.?3-<U7M));V<L%_JC.YK)N;44+:[EIZ!G+0]!LURLT C>$
M\6]JS,-JL: 31<N +D0U"C9604C"3F8.(:1J;R.*/Y20RE$E*IGD\@A7\;F4
MMSZ@')QB&J!CXB8,51:@S<G42M+$&:(%BO$)YS?B\(!P^&!*VM-O_4%D]B5Z
M'M6H:>Y MT5;QX\\';J$#9)<.M3RU3C]SC:I?(.F2IU[#A(=VMF/EFL5HXJ9
MC:G)LNC28M.2*A$;%96Y%^F"LA4<E]/ M&7' DAL <AQ+#!!J1RUI=0T2XX#
M((9 QXMD\PKA27P./<+DA3TU#D@9W.K]IV/;]?U;>3NT8^Y=CIN;@K?/WZ]:
M -H+E&F7-,5O7,)9Y:*K4O)";.54T0K^O*W5I@ZK#63-@P".4R*FJ!2,D:N\
M'E%:=5951)Q)S'G-(5!8#R^182,RAN/')U3/M2L[1K-Y@:<LK,[PE.!\I4#$
M*<2<<< K%>6<#4G[@[ =N=1IV" _#CFPU"EY59^W)W7XT#2W]>O4;2*XNX1\
M@98XZKGV1JVS6YUA5!J=R03)UV#K,H@?$A$O35**"EE\L@D-(!B)7Y/YG.;*
M$!68+Q6'+E>S%AG!Q4EFJ8^8QT3/XTIA>'&'# E@I;DTV%!ZE0IP<9Q0FP^U
M/971>O#:OE0-:G.PV8>?VO0)^<IU]EJ'2.W%CU^2 JB5H?Q@*J;J>OQUKM5V
M@]O*?(6U*U]$ N(D'I/DWETU-,X?JZTY*Q2*K1J[TJN#S;Z3"5BJ(8O@W+H!
MJ4/4SQ)QZ*9\-(A*N46H9,!%[+Y8#,XEZ]5Q@DZVC6FS^^MQLE#AK+46:E$R
MUHJBMCSLKJPF&;IQ_P"QUNNR[&UQ *+LLDS8*5#VZIZ?J=6W2EHH.;<V#)*#
M'FR04L RRQ42!RC\L*WEJ)0W,>9"L<C852KE&E9H<Y'EC)7/6:.2L<J"O$%E
MYDQXXGA*SH,MAE#+$JR]B7. 2.G1>EG7"2K$6=?JW!U&W/H)S,5VMVHN[0D:
MX@TEH1 -H.J]+*E4D (%+>6[6(K(Q)#P24$H&2:3CW"!B$9F7IAF4(QZ=<J&
M<#KD?2.1UZ9QJ^0L5!=55NN55BX'4XPQ5"<C!^B,'IUQD[1R74VG&FG&FG&F
MG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&F
MG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&F
MG&FM*V5+VBO:ZOT_2(5-END'2K5+U"N+2ZM$_:(V"/-@(52&5M/+3*RS(@*D
MM.MNJP_G#:T+SA6)XPK2(KMQ1G4.W]ZI8!F^X9.I)"P1R@RX1BH^+ $J/O.!
MKE_K?M'O),] P=+M[W9:*NL5IV.E[AL&F!Z[B]3[;O";^[;Z6\YKZ@5W+X$#
M'UN,DB:;-QTI=*>XMF/M-N4Y88UP?)24T/%S(GLS1F4A(W\PRQ(4"L/,D;JQ
M8@.I"/W5>AS81U$V5"-[0'$0+NO 1R-SYKZ$7L%!XD%E/1FZC&\:;[[[1V=:
MA8Q_J];% /ZCI.PLP%8L]/=V(X;:M=ZDN[KL?7KS8J(R756I39,U4&)LYZ'"
MS)T.42U(G3;TK6*U)+0QQH3[2N1,\>65_+PLDJ=617PV(U<J,G$@Z!0&::*L
M>1@/(;!C1^*LOF>J.-^BNR97+E<]!E.Y;*K7BE=U>PD#L?9)]P-DK[4Z].=C
MFY*BF1M.<;UW#4'LO TBARDZU2]75BQ:_C8W5),S*JE;3?-M,7MP(6:$<K@Z
MGGD7#T=.T<? "-B*?UY?,ADIF=PO.5ED)E &%CB,>2#RQJBE5,KN7/-0TWH(
M3T!)PB%N$:LBB/+99WYD CB-6#@^_MLG-C4JK)UQ 1E:N.T44*&F).2M;4A;
MX.0[%;LTX'<*6E%97"E 0U9U96+7/,R<J(I9&SH!D5; :8AVS6YH46.1O,8N
MD?F$ +A"*>&4H_JR"S2LJD>Z)L@G/&L*URZ+Y:A7DX DMEE,TT0=/3@@+&K-
MD]?,7!QCEU!YC=9#3C33C37SEK6T*2ZW]RVQWEHSX>/XZ&U*3]V?NS]^,?=G
M]_D1U('UZ@>@)^K7 G1'U$>T!+5+GMLQ@,O U?KSFV[/2NMA5 .R7FQRVO-@
M1M@8EQHLCX&"I6A]MT"4ET!LHC2Y-Z>>-0(W'X>;S<MOIO4L9(9YPD?J+%54
M/&R\2?4SSQ2!?> !C.=8:&NJ,*9 "%@#2>D*&=S&X;('I5(9$)P,$\B>W2=I
MOOMM:5V&HFEC48'5Q5UI5(9+FI+U0'XM[>7>35A-RK-K9A%C%R6R ]!:O+JT
M:>V?"MG6 6'C'379YJ7=HBAB6,<^9DXN^%'7(@HY0C+R[1F>4,1@X7) XXU6
M-9(9/2%$99$&3TP9:N/FK<>ID$,94'TY8+^5RUA"OJ.;)D:D_7H.KUQBZB5.
MA*>EVK0S/[ C9*8T;H_<\E>+1K9NAQ4$!1#W]GG:]9G1I%AE5R1'L"P@39>!
MA)A;XPW)F;AS;(X\8R!/-$$63S"W,",2<2/H9))QDP]OD*X"KSXI^5RD!,,4
MI=X^"@)ZRG('Z>!Q'7$V5CO/<-ET#?QHVB;%&FT1F7A8<BN3-3OZZ\<0)LD9
M"]MUDTJ%/IAE4<I$=)VZ#+CY=[ ELB1 0I1MDLAV@U$D;P SJ>>">09.0!C_
M +$P#!PW,A&! RI)(S@55K'=)R(6!0$#B5?B<2?V5205*\ 67!/J  .J^:#^
MH->:_5WR]F2%9OM:4ND @6T68H<=6ZS*SO7W>.S,U1VT:X@ *>J=DKWJ.#U^
M!KPR)!M]8(O4$LZ1L!LY!0[EQ44"E@(PR-ZR4*R<V"SPQ\^,AY<0DID,@)5N
M#=%"LVJ,-:ZKF0JZ^C# H%4F&:3CRC4+RYQA.!4,O)22Q8#4D'_4RLXRYAIK
M3M10<%49JSMUV4VTW 6B'&@;#H>">E;@+9:G UROUVP [E-M='DG[5ANT0M5
M2.IV*+EEKBZ0MRG'XYL<@I81<E)99F 0H[,6!B"../H9\]0.M3V]NOXI0>)/
M$R888:$$L&50H(E+(>7J"^XGITATGLA&X-2Z]V>@!F+^V]7C)]R/&=DR!0WS
M&<9(8"+F(:O2!X*'TN8!DG88%J2$]$\1#@9##[MA-'Y4LD><\&*Y( )Q[R 6
M /Q&3CMJ^B?S8TDQCFH;'7IGX9 )'P.!D==2CREJIIQIIQIIQIIQIIQIIQII
MQIK7[38PZG R,^>T4\/'CN/9:$&()<=6E"LM-9R.R]@9MUS"6E&$^D&-Y\.$
MOM-8RK$RJ68*,#/Q_I_ .I]VH$X&3J#0-QV)%CBAS H2SQ<T"^7F.URIZV2T
M EL<=W_O F-+,:(<$(=4$>K(@4<_A\,J.D''O/'.U/+'$]2I&.KX4-]@(!Z]
M".I('<8ZZEY'/N(_]7J1]O\ 3[-2;0=A!745:7FF(B<943DFOOFM?+#M#DY8
M=<>BW_;RXR!G%M"$N'1X?B9Y\-M^BIE;DCIP/Q'3#>X_?V^S!/345.?J/P_I
M_3.I%Y)J;3C33C33C33C33C33C36NSMMK58>AQ[!- Q+T_((BH=LQWTE'GN>
M7RCL_=G&,^*VTJ<<RAE"W6D+<2MUM*M-W9XA;)V+4;<I-W[FM.WJC=UXBL&V
MXKG4"!KM=YN(CHZ;H0"6DB1II3'3QR3T\4DR25$*ODK?9[I=4K9+=0U%8ENI
MFJZUH$Y"GIUR3(_;W*Q"KEV".54A&(CU&]]>Y3C)!4N"XNP-U]@<R$D$%$Y?
M=PP-.,#--.O9K1+RL,LS3B&QE/\ @/GROY2WGC\7RKO!\H#5UVXK7-+O"':%
M)17':UYBN%;[54+2T6ZJ6AAIJBI.R*ZH84]+NB6.*@>IQ2,4JV2!MC;8&XP?
MQ<5'.JVY[C))#7TQAB\M#)+022NZ(+I%&.;T*LTHC_&=8P6$L!2,?)MN/1QP
M<@RR0\(ZZ$4P6VT4.OTR!G'&%N)00PO\1YE6<.-+_%6E.?NYZ!MEXM-ZAEJ;
M-=+==J>GJZF@GJ+96TU?##74<GE5='++2RRQQU=+*#'4T[L)H)!PE16Z:U">
MFJ*5E2I@FIW>-)D2>)X6>*4<HY5615+1R+ZD< JXZJ2-?9S(ZHZ<::<::<::
M<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::
M<::<::<::<::CR8U)K"P7B$V9.4"I2VP:X.,)!7*0@H\JQ1@P2Y-V/:%E'6%
M%(3&NS4R]%YRYE48],2KH&1W)$Q3U02RJC1K(XC;/) Q"G.,Y';KQ7/QP,]M
M2&*,N)"BEU[.5!88SC![],G'PR<=SJ0^4]3Z<::<::P\_/1%7AI"P3QK<=#Q
M0ZBCS74.N)892I*?'TF&W7W5J6M#;;3+3CKKBTMMH4M6$YUS=V[=N[#VU>-X
M;MND-FVY8*-Z^[7.>.HFCI*9&2/EY%)#4551(\DD<4-/3035$\TD<4,4DCJI
MO+?;ZRZUM-;K? U36U<@BIX%9%,CD$XY2,D: *"S.[JBJ"S, "=161O[7K)^
M16R),P)R#8F )L,%+L3+EELH)"JT4XI]LPNX&#.(?'K_ +-!F4J\B_(ZE;:>
M"UGRN?!^ENC4457?;C;)MJTFY+1NFW6I:C;NX[C<::.NMNP;!,]7%<:_Q'N5
M#-#5T>S_ )MBN$D<GEOY=0DD*[;'X>;CDIQ*T=+#.M>]%44$U04K*.&)S%-=
MJM1&T,-FAE5HY+CYS0@CD.2$,=^K%YK-N8#5$23'OBXIB95!%N-"V$*/?<]%
M#TA#+=R:(C#^,LY<6WZ*G/+Z;KB5MJ7UG8GBIL?Q$I+;+MV]TOSK<;!2;F?:
MEQFIZ'>%KM%9,::.JO&VI)VN=OC%6K4K3RPFE>;B(*B:.6&237[K8+K9I)UK
M*63V>&K>A%PA5Y;;/41KS,=-7!!!,QC_ !@16\P+GDBE6 R$/6*_7S;-(PD0
M%&'7.>;L]J*$9PT]/6!JOP55;EY%6/\ ]<U%<K%?ATO9\,X!B F?WF<<Z,69
M@H))"+Q4'\E>3-@?5R9C]I.L(%52Q P6;DWUM@+D_<H'V :SW)=3:<::C>&U
M!K*O7N9V;"TN$CKY8!SQ96S#CKQ(/LRSL._,I9PMQ0X*IPBOP),\X P*[.$P
ML41++,>CQ5M5#+(R",NQ1<84GITSC[>/)N(/T<G&,G4@CC5RX0!SG+>_KC/V
M9P,X[X&>PU)'*>I].--.--.--.--.--.--.--.--0=OW/A2E9\LYGP=,QAR,
M96]%BJ5$R"4%61"!WL_'I7E(P:U+&0/,%1YBB1/:X-$J1?2]WN^WN.W4??WZ
M9'OP96[?T^![_P!.^-0,-]]@I.5X"+]K#O9]/1CF)*5CG68T(93TJMHNPJ<,
M&2XJ-DC%>V:/&="4F8*RE4<NM^2WVC^R] >I[=%[]"![O[T=]2>\?9^3W[??
M^GWCWZVK4K^6)FN,9?I8R,31PZHV<=P)LP1#$38A6!1QGCP',L1Q#[<>6/F"
M%42^;,&MQ0F&\$/RR]<_2/I'4?0/T3\/?W[]@.IU%?=V^SW^_P#IV'<ZN!RW
MU4TXTU_GCC'[^<<::>./_GC_ /..--/''_SQ_P#G'&FL JV5=%F12EV*#1<'
M8=-@9JRY0)%@?@EE$A8F&(A3V#WXS!@A(JSFF%CMOM*:<<2OPQEIK)2<B)#Q
MLA+GN*: BP2Y$UU+;CRFA 1W"27$M-)6ZZI#+2U8;;0MQ><>5"5*SC&<5?;U
M;]N62\;AN\S4]IL-JN%ZN=0D,U0\%OM=)-75LRT].DD\[14T$KK#!')-*5"1
MH[LJFXI:::MJJ:CIU#U%740TT"%E0/-/(L42EW*H@9W4%G957.6( )UREW/=
M[=>; 6% '6B=KIUB#<A%F1PH_HYOU=#(@*S%CM#NFA^O%+/8PW[_ !\\TXI]
M\!IUE:W_ ( ?*:\4_$;Q4W=7VK9]TWYNO9EVWC:Y]KS7&S4-%[.WB[LVVU6T
M-C6&DIZ2>YVWVNPM=Z7ROG=6W9#+)4U=IIYZ:26J]<;(L-FL%NBJ+E3VF@N5
M/;9UKEAJ99>8V]<IH[C=:N1Y%@F\NK%-)R]G_P"#W4)'4.DBJD+L4;83#(D@
M-6[*TS(H:;#+&",2DE!#:WQT-NM)_&20V,MP=.<XP_Z.?2PO*<8YYBI/"CQF
MI*:W7F@V3OBGI;Q#3Q6ZX4-NN2+605D$U;1Q1STP!,59#0S34D;%5JC3$0"2
M1 NMZ>_[<DDFII;I:VDIB[30R3P$Q-&RQR,RN>AC:15D(ZQ\_7@'5LNM>RK!
M#R4+#394!6JK/R4M-2),A#8B_M,9,(9K\&Y#'B^ 69!4Y"E"/LY%C@LAQYSB
M7#2T/9$^A?R(O&W>.WKQM?;FZ*W:.R-A;MO>X=RWFMO&VQ83OFX[D2EVAM2H
MVU=:#%L:[R[LVU<K=50&@LMK:WVBYR+-<KA%4"@X_P"*&U[=6TU=6T,5QNEV
MMU+245-%35OM?S5!1%[C<%K:>7,_LPH*Z&:-_-J9Q/4TZ<8863S>CW/M-KS+
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQI
MIQIK\T/,N..M(=;6ZQE"7VT+2IQE3B,.(2ZC&<J;RMM25HPO&,J0K"L>*<XS
MQIJN'9G9]JU;5:_+U-X)DR1L'QQ*C@T&MY&^--)\$-K4G"%^JPWGSXSX^7&<
M?Z^>)OER>.V_O 3P_P!H[B\/I[73W*\[Q%EK6NMMCN<+4/S+=*[C'%))&(Y?
M:*2$^8"3P#+CU:Z=X6[5M&[+Q<:.\).\%-;351""=H&$OM5/%EF4$E>$C>GM
MG!]VJGA=DNQ<C'BRP0T21&FD3 @QJ( /T'"8&+^;EF,K41C#;H<5XFY0YY,O
M,H<]OZJFW$I^?5K^6S\M"]6>@W!:[;MVMLESK-QV^AN<6TJ#V2:NVE8?V4;A
MI#*]>HBGMU@#W0QS>6U3313^QBHD@F1.P3^&/AI35,M)/)61U,$=%-+ UPG\
MQ8KA5^PT<G$1GDLU7B %<A'*^9P#*3@/VW>[/N_SJ#^_"<X_\/,_?A:5*1G'
MX_WX6E"U)SC[E)2K./'"<^&H'^J+?*A''-5M0<EC=<[-B]2RHTD3+^/ZK)&C
MO&1T=$9E)"DC(_@;V+_R5?T)!_X2?H00"/H]P2 ?@2 >IUGX#LGV'M"S&X--
M?+4 RP09ER+B@6V6BGFQQ<Y=D#A6E*)?=::';0M3KSCB$MH5E6.;=M#Y;GRR
MM^2W*':T.S;B]HIJ2KN)FL5BM<=+!7U,-%0LTUWN]!"[UE7404]+#%(\U1+-
M&D4;EUSCKCX8>&UI6%J\W&$5#R1P\:JLG9WB1I90%IH)6 BC1GD=@$15)9A@
MZQ!?;#>H)!(AJHD0H,AX4L<BM(:>&)&>4,0.\VM6%-O,D)4PZVO&%(=3EM6,
M+QX<UVX?U0;Y6%IK*VWW-=NV^NMM94V^X4E9L=:>HHJZBJ7HZNDJ8I9E>&HI
MJN.2FGAD"O%.C1. X*ZO8?"#8%1%%- *R:*:-)H9([HSI+%(@ECD1E!#(\9$
MB,"0R$,#CKKYL]N]UI3YU%06$^.4^;->9PGS)SX*QXY<\/%.<XQG'CXXS]V>
M63_U1CY4$:>8]7M-(^3)S?9T*IS0\73D:@+R5@59<Y4]" =5!X-[%)P(:\G
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M_+GIW])M*_OOFM?L>O\ _@.\?O96_P"XUUC\*'AG_C$V+_G=8/YPT_;$=?\
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M]?=T'3W@=P<]!WU3]X__ .#U_P!O_G\=2%IF!./<"/;17VXR F'U/I/$)<O
M);(<R"/&Y,8)#'CV06I%8AC!4.&H]Y^:<Q%@>LAXF25@,]3ZE';' C(.>W4]
M.^3[NOPF4?P?I'<8_P!N.G?ZM6GY;ZJ:<::U*?H%$M1C4A:*54K(>R,@-DZ?
MK<-,&-"-NNO(%:)D0B'FQD/$/NH82O#277G7,)PIQ><QR1V)TQ[_ 'ZP?[#6
MH/R4ZV_,:K_W7QD_$_I.FG[#6H/R4ZV_,:K_ -U\9/Q/Z3IK&1V@])Q%X!V3
M%:JH<;>HN)^$B[(!68H0^*C\O&/N(B_0&0Q&DD*/+:*D066)$L5W 113P;33
M#;)[9.FI-E63B8N2'BRF@I)\ QF.-?824P(<Z.X@0IX97XI+0Y"FW7&%?BO(
M1EO/W*YB+_376ML5ZH[%74]KO=7:;E36:YU5(M?2VZZST<T5OKJFA<A*RGI*
MMX:B:D<A:B.-H6.'.KBD>"*JII*J)YZ6.HA>I@CD,4DT"2*TT22CK$\D89%D
M'5"0PZC7)HB^.ZUL).&AH>?]W?*I:I*1:9BI!B0,IN)>*MJ0Q)F$R36CIFPO
MR!\:0.!%DPX+K"8OS1[PSJ_SX5WBS/X'[SK1!0;<W:+GXN>'^_[W>J>FL%YI
M+Q<O#1=Q6#Q&CMEMW-MEJ[8]VW+O*KNUWLE71VNQUVV[7/2I82UGJ:*>3U_'
MM]-T6V+G+6V[R=O7>T4M,[U=-)307LT=79S/-0UWE72GH;;'3T]5'+4545;.
MCFKQ4I*@^ S>#*86-'B80@2<CFZ9[>0<7"MLCETX]D\<S+X,(-/2>"?16-B.
MEIHJ+%;)<?9$]RR*MK#W+Y55*NV;)2;>VO6V_=-D@\,_8[M-)MB&FI;AX;7>
MENU)<7K+5MBAW=?$KA3RT LVX=S5]BH8*Z>IIK>*RGHI:>YAV%(:^JDK*^*6
MWU37OS*=5KFDDAO=.]/+"(ZBNEMU(8N:R^U4=#%52M$L<DOE22JTD:ER]LO:
M@DM!0T'#0L:15T0U9LIGO(]NI5MU2YS$0'[/"I:QAFO-R@9J/;,1IDD<M[\0
MC&$=L^3PT_CAX^T.XMJ;9VKMG:]DJ]B1[9V+O>Y+<+1!X>;*J'DW5^QRV?-W
M/<.]+==:J"^VRYQ"CH[)<KU=I:EO+J@L>L;Q$>U]I2T=?6U]=754=U-;=;7#
MY-2UXN: 4!K9O/(H[9- CTL].QEDJH::G5.L9+=#+M1*SL.(:@[6*>9&LG,R
M3;4=/V"N/X,89(':6H^MRD0>MK#1;^%#.%*%<4I#CC*W&65M_=$''],Z\K$9
M_IC45?M6M*__ ,%:OTJ[9_7CD<GZOT#^+4,#Z_TG^/6AMZVJNK^PVF6*2FQ1
M@UEJ6XD3H9MXN]A!DL1#%$?C%/@V2Q2XF' G2R5L/-,MNHR\O\?PSX<=P>W<
M>X#X_#3'V_I)_7JX'(:CIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQII
MQIIQIIQIJ+=N,^[KL( HF0&'DM@:[CS51DG(PY3P)=QAVBA??Q101S;)3.5,
MD(:);P^PM;+OF:6M"HC_ &']1U _[1^L:^C]B2D_^C9OT@7_ /6?D-1UK-5Z
M[ZPINT9W<4(!8$WNP0$=6#9"0N5LE0\0D9ZJF DQ<A,$ /\ BZ\I_P!Q(,&D
MCN__  +PC:EMKCDXQ[AJ&.N??VU$'=D=\BAU)([#SZDV[S92RVMU6$_#26/-
MG"$JSC'CG&/'/W>.<8_U\^97]5#HZRM\)?#V.CI:FKD3Q%#LE-!+.ZI^QJ^+
MR98E=@O(@<B ,D#.2-=P\"Y(XMPWAI)$C!LQ +LJ GVZE. 6(&< G'U:IE4-
MCS]3K:JNFKOR,:\S<\$((]RWC)MIA 88&4&3@)S(I\$V,9AMW"W,' R\C'K2
M,E[U^?-'PX\;=X>'NR#L--@UEZLL]+XFK5QU?M\(-TW]MFU[;M=_H46US>P7
M;:<%%<DAG#SBZVK<5YL\@H8ZDU6NW7K;-MO%S%V-VCI:I'L?EM$8F/D6FNJ*
MV>DE)G7S:>X-+"67"^SST=-4*92GEZWES?EA5-?+IHSCC:0EI8CC7,$" 2CI
M;BO=1_H0(;C<8+%'S<1&1!BCE1[,P2^B1<<QE+O59?E=[R;<HW"OA/43Q);)
M$IK+<Y_;+=:K[-<)W]NM'LNT;=-#8[?8+MNC;MCVY<GNK6FFW)65<=XFG0K/
M@%\/+8*'V,[@56,X,E3 OES5%*L*CRJGS+A.K54M93T-;55D(IQ4/11QFF53
ME8\:N.29&\OSM+F#XJYXCV41D;)NQ3L.%#R0AL1'L'OP,M[@4(0$2,\,B#NN
M"M>9#K+F<93QJ#Q*:NOGBM6;K\+]R76P>)JV:GBL5COM1MZ?;5KVS>[?<]N6
MBDNU5M+</ME!;+?:;=8B#;Z.HFH:?S(YZ:8@ILCV414U@CM]]HJ>KL9J7:KJ
MJ1*Q:V>MI9H*VH>GCN%'Y4T\M1-59\V5%E?#)(H.=G,W%89<QYR;JTJ3'%QD
MR(9$Q\D9'BYD);93NR4R@B7XJ19&<8)2%"O(<'*)+C15JR<P^\A0^^7'Y2N\
M]Q7*>?='A_N"NLU=8=SVZOV_:+U<[10&\;A\;IO&N*_4"56W[S3T<M'6QVO;
M%3%-25U9<;+02.;I25-3&U)BH=E6VCA1:&[T<53#54,T-944T%1,*:CVNNV#
M23&.KIGE62(SUR%)(8H:J51Y$B(PE^V]; %M=#) ; L+$[+2@!3\-ADY4)%-
MAS-ME'71V5L(8P64F=%04<PZMR6>1DA\**4PI!>1\5O&"A\0/"6OL\-HWE2[
MKW%?K/7U6VA2W5]K[?@MFY/$&_5$U%3RT<5&MPK5W70Q7"[4DTTVXJF)JRJM
M5@>E9+E1L&W9;1N"*I:HMKT%'25,*5IDIQ75;3T5GI461Q(93%$;?*8J>152
MC1A''/5APT.T=?\ KK7MK5R:F++)62&*C9OXT=B/P"PVZ/[$4KU5I/CR7,K]
M1]:/,A24>5.,>7S8SG.]?)!^1?L[Y0&RMS[DWQ>M[[9N%EW2;)24EG6UTD%1
M1_--OK_:)4N]FKIFE\ZKECY12)%P11PYAF.)\1/$NX[1N=#16NEM==#4T'M4
MDE29Y&23VB:+@IIZF)0O&-6PP+9;OC&IR+Z34!D4EUBS71U]H=YQEKU(57J.
MH;4IMORHAL+5YUXPGRISYL^/@G[_  YZJK_ZEWX04]!6U%+OGQ.J*F"DJ9J>
M 3[7?SIXH7>&+A'MD._F2*J<4(=LX4Y(UH4/CKN)YHDDM5C2-I$5WXUPXHS
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MEV/)=>0:O=]RW/<*V>_UTU7<)9)'F>J8.8WC!CJX >7EK2U%-(QIH(XXDB*
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MCJ9 & R0RHHE93EN.2 1WBSI;/LU^!VW(2#!"G;A/1>QHV!RI/NBV9R4G8V
MBD)QAQ?O%L1\>P0M]*D,"A+)*6@81QU.5WK :JIM:1D!*2)Z!YU&(E:&&GDJ
M)&]W .\C@^DGF %R>.K;:]0*:W322HQ>6&)S!RS*TPJ*GRH\]?QA22G5^I5
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M?W!5?[O3]H-\I;\U+)_G=M[^7:OCUW[':J[2Z[3M+3DQ(3E.7-R=>2=)0LE
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MUZS5\*^L>ZSUEKL2T=5J-); D5G,C.0D5-5R")9$<9)<=D5&6B3BHY;+#K3
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M&TU$H4^9,0XHJO*@(R4-,=4.EO#B):+*D1FU.8$D1X]U+;A# QG.3\,'^G\
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ME;M_3K^O[<_PCOJ+H/+U>%S;VLDU+#\9$PX]BN3^3()_,K*FG&S@<:RX*X)
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MI^$1[E_ENE?S6H7ZJ<?@[V9_@2+]UW#^5Z?MH_'G_&#6?O-MK^9=/PB/<O\
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MJ*Z5Y(69QD-#1*0'X..DM<D964/[-!3)PC2T477BU,IPO8LU)MM)<QA@%NK
ML81C[L,8]G!Y+0RSGQPTE9BG$8\J5.9\,Y5KDD\0)9:"&,GNSFIE<X)))+S
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M35Q?V[?4W\O>O/\ B^?^CS3OV$[L_P  7'_(_P#GKNW[8'P6_P 9.UOW>/\
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MM=CNYWS::2.OIJEIZ2.OO=90QT,%0ZFJ:@H*RJE_K6.L03U'<JZZ_HFR8EJ
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M-X3&LMHND3+?"PPN)$.;2EL2N)/ADX#E52>%51_$>#\4#99!E2 U!9&G+O\
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M%#''./+_ %NFG&FG&FG&FG&FG&FN%GUC/]*>M'^YL3_F.O\ G=/!W^U=S?\
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M=>??>=4EMEEEM*G'77%)0VA*EK5A.,YY,JL[*B*SN[!41069F8X5549+,Q(
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MU/1U5"S55^LU5!M^JGM@MTJ2O>JJ6.6C(J5CM!G2>1XHEYF8ML=K.I>SKB1
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M^6R;KM3F]>F:NFQM]]&Q6OL1LR*L;4]K;M<7/'0@-J)L.J<)&,CPJX:#?*Q
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ME>5/V8[A;G$L;&1>+4 #<E!'$D YP3C6]?\ 9WO]$>T_\X]3?\LOW,;\J?\
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M-W:*LBAN%6C^(^[KM4R669;Q[);*OYAK;34B.OBJ:>:DD2U>;3SP2"*V&_\
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MGEK_ .I1U^EM44_8>V);.IIRUP%[N#E)'CKOL@F(I5%VE;-7'6\R5J5%4EN
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;G&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img61678762_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_20.jpg
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MPH8 ;3EV1,N&N,Y;2D1Y@94,\(BT /RED8EU=X59KUO+[39 4*Z_E);$D\1
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MI0_(K6?ZW/\ [8X^1,5_>2OK/_CT^R[XD?XV9'_0J?U;3YCG2A^16L_UN?\
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MJ?PVEG$SY8[9,%;QV$]D-AW"#=#FO+:\3(,D[*0V'%/Q)&$QU>9"3JF1&=>
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MJ4_,#N/]7=CY'Y;]BLG][[O\69K<_#C]L/@/_//A?^7*.I-UW][^B_S.K/\
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M16:!&,XM,E-'5O7FC:;D@GHOA"&KZAE+^FV9LD5<%P,RMG2 FVG/..B@/+U
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M9V6BQZK)O"DR4V\Y(#1D.61$EM\S&86P,MD75R6I4L!O/(A8Y8,C!$R.S#"
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M]BLG][[O\69K<_#C]L/@/_//A?\ ERCJ3==_>_HO\SJS_<@/,JO^MT?O*OX
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MP1V^$>OQG5J]>U<&D4*E4N+C!82,J-3KM8C88%Y1 ,1'P,2)%A183ZVF5O"
M#"M"#.+9:6MEI"E-H5G*<-5UF'&FG&FN+@$)*5(2(*E"E)4I&!VL)4I'?PJ4
MG".V5)[Y\.<X[X[Y[=N_*<H_"/CZ1Z_'5R6MF8*6,DHB8B9,MXB?6(G?>(GW
M_'47;-TG0]M9H?RL"*[:ZV? ;?KR8M]J/0N\5L22!C#Y9"1W$RHV!)<]DH$K
M"F#$NH]1A>66<HQ+5&O;\OUAG]+6EW%\DP,2]<$(D?;VXY3*"&>Q1/?TC;8<
M!Q9F.&_ECY-:O?.</W.&;TV )TQB+[$.L)K3)C-=DLK)-;E[&J1GDF(,^:4,
M@ YPE.0A,I0VAE&,C,YPAIO&,-M)QX.R6T8QC"$8[)3C&,)QCMCF5RC_ &H_
M#TCT^&M>ZS>\]5F\E)3/.7<B]2GOW*=YWGUG?OK]8##2MYQ(@R5D+8<(7AAK
M"WW!L(P,X\K">[JQ\-MX84O*E-80C#>4^%/:NT=YVC>=IGMZ[>F_QV]WPU3J
MLF!&6'(A!B$<Y; +-^I QOL,'S3SQ&T%O.^^\Z_N1!58PE0PZDI2XE*<LMYP
ME+RTN.IQC*>V$NN(0XYC'P6M"5*[J3C.&T>FT>_W1[^\_7/KIU&;[]0]YD9F
M>8M]QB1&?7U$2D1GUB)F([3.OSZ$+S%/>C%\U0R0U.^G9\Q0:%*6@12_!XLC
M(4I2DL9SY25*5G"<9SG/'*/KRQOMR[[1]S_:_1\WIJO5;R\O49RPR6P/.7+U
M9B(EFV^W4F(B)/[K:(C?MKZ-##L95EAAEG*L)PK+32&\JPG'9.%>!..^$XSG
M"<9^K&?AQ$1'I$1]$;>GIKR1F>W.9%MOMS%);;^NV\SMO[_CK[<KKSIQIJ >
MJ_\ !:ZE/S [C_5W8^1^6_8K)_>^[_%F:W/PX_;#X#_SSX7_ )<HZDW7?WOZ
M+_,ZL_W(#S*K_K='[RK^ .H#.?LUF/OID/XV[68\O:B].--.--54WWTV/[HM
M%:L0]NS HBH]$/(".@N&H4&@\D[!L;X"F$M2"LENLNI>QY3R&A%9=1Z?*';J
MV<D3&V_?>/J_Z:YQQGP$?%>0H7@R?DHK(BJY1)EL2J'&[JHV8$"Z980%!>R4
M"N>:.38K R-LJ%5)@X&>MD%$2<MY84(%.3D>%*33K?EL8P&P80R1(/K<4VA>
M6&UY60ZAO&/,=0E4=9R./J.0BW>IU7VBY:R7V4I;8+?;E0MAB;)WF!V""]J1
M'UF(G?#M4Z<UZS[:%,9 K0%BPL'/D8@8Y8,A)IS.T3(Q.Y3MZS$:@;J3U5K/
M?Y6J]+;2H51V/5I.WD[#FX"X0$;806(77<6\K!K \B.^D5XFT6&J091#.67"
M(>8EHUQ3HAI0[LOC,UE\+DT6<-D[V*LA7M&VQ1LMK&U) -6*C920R8&RS%P!
M/<.>A!0,F D&7-2K:4[S:$V%*7S"MZQ8$O9/17M!1.S  VO"8[_:2_<\VHNW
M;IP?2E-D[MHJ#@8FJ18R&K7HHBF1MCU$?&NCXB\6>N4M*@A]?V"OH6.8>?54
MLP$U$C&MVFM29'IIN*E^%\?6SO%%5.;RCEU+K[-BX^R_F>VU(-?$!>LR9**W
M8B.K#)8),+FKPE[6D_0^.K5_AWAG)Y?AZ@-B\A:1*D*)?2:EC5(=9L4%[=4J
ME<B/J)E1R"UQ;)].O"1ULZYU3)V_UCM(HFKH^?HE=IM?%A(ZQ":XM#V9K+4%
M7;#8ZHS6II^Q@6T@_P!&S:4>XA"I=DA/KGFX=P)C3/';@;'V3R7#F%OY3)TQ
M\J]2%9''MI8;/W;++!HO=2R3/-D+DVV@=-#QQEQ0IL[$XFRG@1Q5=(5<<93A
MVC6SY6\A5>5>BK%QE,<=<9\\UL<]@8'J6 7$J8HSIG*=A(@C@ZMUCLC=]:#V
M,/<7-8R%5L>WH:W4QMD6=9K$MJ0\ZI3"CAY!IM^5E"$V*#\H48&((*%G&!V4
MO.MM*SIO#6!#@/#XC'TF9RW2NTBXB/(T<G:QMFY9<FI4<FM31GD4%RFRQV/2
MJUCKSVL0)$4M8*D;UQAG+7%^:=EMIQIH@J*J?+5N(FM7:QE)S>:M7MR=NN]=
MHQ\PN>F\ 5"XB#G&;_TC[-U(JNS.YIG3:C+'-#NPGR2L,G2]A%R9PC(A=?K]
M'BX>18D(]([8T984Q]S"A'1").75%^_" 2<6^)"RN$INR?"5GBY?$&WFRQ5B
M<?G0L*EW4ML<5-P/)-$"8Y5OY+$B*NA-EI*,E'D\!8OY9XEK8CB6<6KAZZFV
MO(LK RM,A%.S*Y8RW-R*HNL2I,'-KG5+/8L\\@.K8Z+Z3P-N5YNNG575]"I5
M7]) VTI-) L>Y+.\@ 8J/').O+<^S41DQ)()<=/@@"2KQ>,F"-/)SDA%. AO
M<1</#;XKB\?+;?4''$=Q"<FA()-;K\MMGTJRS::0I4*M!T]!;EWDH+HOVWQ&
MQ^'P?$!5L!>=<HOJK<U$73L5*EHVN%U07+;),@5BETHDX)$O""88?:8O5JKH
MYZ?-%7\"[:[HZHF>=@S(,61.G9V;]$YD<1M]R/9EI$QH60EP&9#,@6A'F*:2
M0R-D5@HE@CK]_BW.V:6-X>?: <*I$H15770J(*D*9H5NHM<--::J[$@##(9B
MNLCDF )3RE>.IIM,N+2(O;)R11V&".=SE:XV6OFWG>%@(C&XA C,QJV?(C6=
MJ"]I4Z)VXD6"B+A%#3=8,(?-CFB&)!3:"DM,/8/!&*22*\PMI&&77$=D96\P
MM*<O>-'$_$W@_&>*P5<+B>+,;6S'#5M[KE!;TWY6%D5(;%ZG7LC8KN02AA+&
M#L$FY!",MY@VO Y*QP[++=G&V#JWU@"G$!I@I7)&/2::Y!@G!3)#$[S$ <3,
M#M,KUB$36J]"P"2G34P\:+'X+>QX7'_3-);RYX/$ORTYSC[6UA:\,M^!K"U8
M1XL]1X;PH\.X##X(++;@XG'U:$6G1RL?Y=0KEDAS'"QF8^UJ@SA2^5<&?+S3
MK]ZU-VY9MRL539<QW3'O <Y3.V^T<T_VQ;1S%N6T;Z[WDWK$U32_:&N]XWU"
M[+AK>,#7(0Z!P[AX@]N3C<P>6<R<= ,,,.B$C&N(>P2X\8(V@\R3&)8>P.I#
M^[X3C#%5N',CAF8YK7[VJ_6$$S5MN=$S)L,F0S>F1"DI%9\K$=,2%BSY.)\3
M>&_$&:\0\9Q74S::^-J-QK"6;;(W:049"7UZ*@4:&+MR)F4FY(]2P^&K,8V9
M<E:T-(6ZZM+;;:5+<<6K"$(0C&5+6M:LX2E*4XRI2E9QA.,9SG.,8YI,1,S$
M1$S,SM$1WF9GTB(]\SKM9% Q)%,"(Q)$13$0,1&\S,SVB(CO,SVB-:Q6(EQ&
MQANJY:CD:G-VPX.V8HE>)9NIE876@]A/84.EMNDD6-2$X&4I)3=-=8DLJ4PK
M*<9KK7+6OH0'6+&C(OF/1WE9#Y6BM <Q,/&1YF"C;>TRA:A,3!5R=RQ? C!X
MT3Q8S(L"O8N':"I*RBR%AJR76KM<1C (<'*$K)4/!S%8GH&139C9WC.%8PI.
M<*2K&,I5C.,XSC..^,XSCX9QG'QQG'PSCF!$Q,1,3$Q,;Q,=XF)])B??$ZZI
MJHNRNEUZ_P"YX/:2+F]%A!/U\F0BL!N.G-N5UQIQA$*:DEMH1LS##>5Y<94H
M,I9!C>"LO88;Z1@^/1P_#%O 3C!L-:-P$V.K JD;HE!S:5R23)5SEM G$-7
M*F5\O//&^*/"@^(N-\?Q9&<9517/',L4^@1O$L:8$L:5B&B*1?R1S203*6RQ
MP]63Y!MWSG&NR:<::\K7V2W]V=&7\FZ@_P"UTGSE7B9ZX7Z,C^6CKZ)_H"?U
M/Q4_R^"?X/%NO5+SJNOG9K6Q[56KWJV]+68VK5W74M3F-AU61WM9+Q(TR#L6
MJ]#B!SG[H>VM)V78)L=4*CO6B#. RFM[=*%I=K4CZB6BFGI@8!')/$D VMR)
MD'TSBN"X,A<^9'II>*XDSKL[PT(C8H[%,#OK4^,TV7X;D2JJ=>+2#R3K)H6Z
MEC1AGFKV.=9($(R5:)%E1YENDXDPB60,:\2'3%U1ZVZ4]0VKI^W-6-GU;9[&
MW-\'+,^2BU2^JT;+Z9C])Q5@DJ3.SL)#7:0$DSR!K+K^U#HB"JK+.S,9+9G8
M^.&7N]FJRTX+"342NDCMSSLWI6H?(PP!F0B8B)!@3OSQ$3$#,SK\\8;-4\)0
ML8O()N)N#>R1<W0GGI>;PYXX&E68Q:[!B93#JKXA<I/J SJ@$:X,#UY:EKUE
MZ>9J1I1,Y\DTR&H=^O5(&1IT9NOI<LFGZYHZR0=RUX=8I:DYW,-1Q)6&BKS3
MV:S&62.@:%/VV-:M(*!Z^*BXAL"+(CGV=7@]CE%H7$\2!D!!]&6;$0'SR,DP
M0GDGVO*^)J*FXMA5Y;*.:CDY2!UUY##-H*QSE6*A-.MY\:XF 6*\)!H*JM<$
M."!5Q/9S:QN'4UOS8(E-T7+=1=>$C-9Q\ST_RT^?7Z?,:CC]ET6$COEYL*+L
MU.,B&M:Q<37Y*)6&Z81/2T=DN8AI:JBVV,.KD6A6KA)OBL4RSEL",$8NE3"G
MIKD3YI9,E$Q[HG:"$Y H\\*5'YC)VQKXUF52(4@/%FPUUSH!<K+#S-H'((/)
MK6HPVDI:83+%L3#P+_2L;;;9;;990AIII"6VFFTX0VVVA.$H0A"<82A"$XPE
M*4XQA*<8QC&,8YS37ZWB-NT=HCM$1[M?OC33C33C33C33C33C36/LU.K#6(N
MWCUN"8M9X+48=9F8D!NP&1K"DK9CRIA#&) @%E:$+:$=(6PVI"5(;QE.,\:;
M>_WZR#C33C377R,3%3#+8\M&@R@[)<?(-,2 C!C+9T3("RT6:AHAMQM)4;*@
MA20!&$X=#/#%,'6V0.TXAIK@5JJ5>F1B(2H5R"JL,V\00W$5R) A(ML@QY9!
M;[<?&L#"-NDD.+??<0SA;SJU..94I6<\;[^NFN_XTUB+FOZ([81K:[2ZH[:@
MY R6#LKE>B7)\65D(:-KA\D/,+$S(,GG5Z&AX(LQLA)!,-$QD8\XL( 5AIOI
MMJ-M@=3_ $[ZMD_<-\W1KJ LZE*0S35V>-D+R8M'?QMQ]'B7C[;(N(SCLIL"
M&(6G.<8RG&<XQG L93'53Z=B[66V=]D=42>6WKRH"2<6WOY0G6X87P^XWXAK
M^=P_"N<NX^-I/*QC["<.J)])?E[()QB!GW$ZVN)C>8G:)U$\UU'U783"1:ET
MM]16\0_WVD51^D!]<0+WO"+D(,QT<_J@E--1I )L-+RL42<#ZL8Z'DY 5E1@
M9[K1&/\ *_/^M<=E;7PF*GDPGX3!Y)E&)'?T*-XGU'?MJ9^QL=3_ +0\;>'G
M#VWZHMG$P<36%[;[B=;@.IQ:T&QZ2EL+,2GD9"Y@N7[Q%JZK/=84'K_I0T[K
M.N@CMB1P6QNH!$*J'"93A+(XE0T]I_94&I+6.R4A#7&/&1C&? 7G&,84\SF6
M3]KQ=5,3^ZN9+8X__+J5+0E/S=>(_P#%I\A^%]+]?<?\0Y,Q_P"[X9X%!E8Y
M^$7>(N)N'K"A^!_)+B^*8UU7[D_5=+S0ED<G^C+7\X(1)&"R\;T[[ V=9HXJ
M9:2S,/1EH/W1J_(Y<JTAMF2-5!KS(-MMX+%=2A"$UY,Z?_TK%UX]\#2MVB]W
MH97ZH_6J8^;5/.>$57L'#_B'FBC[DW\5\.</**>^Q,K)X0XA;([[3(!? M_^
M]UE?[CG4[(8_ROUC248K/^?\@]#:JA&T]_\ [%-X;V:M&,?B\YTC/_FRKCR>
M3+[O,D'_ -WH5 ^KKQ:_'O\ 3I_91X?I_6WA>BQ$>GRSQCQ%;F?7[J<07#\3
M\_*(>G;;3YN.U2?I2G7%U3%9S\,M 0725!C8_APC$5TML'8^.<]LKD'58QVQ
MXOARGR;;G[K.Y6?F%>(7'_\ )BH+_P#FT_LZX<#];^$7AVKX$VYXEW&3_E>9
M\1#3/S\J1CYO3;]8Z7[(K/<CJXZL"<_CSFU:H#QG/\/AC--@HQ_#VPG&/]G;
MX<K\EM]^7RT__FU!_@4AC5/L@4(^X\-/#@(^'R=Q(W\=CBEQ3^&9G3/2]8._
M=KJSZL&5=NW?%QUD_C\?Q\!FHR6^_P#O1G'PQ\./DIGNR^6C_P#.JS_"ISJO
MV0:7[KPV\-RCX?)G$ ?C5Q,LOQZ_/S:]CL?&-ZV^JZ/5C_-PX+TLS;?P[?!:
M+'TQ3"EISV[9^V)7VSGLM.>V</DRS'W.<RP[?$<4SZ^KBSW_ "_/&D<>8(NU
MCPF\.'Q/K,-\1:A>_P!)H>(-2(GO_:S'IVF.VO[C2?4>!\8KK0NLEG&/H8O.
MEM%3*%9_%YV*53M;+7C_ ,V&7!\YQ_FY1]?'D<D/W&:>7[_2H']?016_FT_L
MLX%=^N?"O$UXF>_R/Q5Q?5F(^ 3ELIGXCYI,6;>^)]_Y^2G6]#Y[A;MZ:[J.
MG_-%L?3OL6GR2^V?J=L%?ZB9Z.^EC_6;IB/!GOGPKQG"<.EG ^YO8Q\?VK,=
M927_ .L7D6#_ /X?KU7Y1\);4;-X3X]Q3)]6T>.,'DZ\?.-*[P-3?V^!96=_
MC$]Y_GRUZTX#/^6=!:)O8B?\XO7O4':8*<=[?7ANJWW20$*WE6/BCS-C*QXL
M^!>483YJW7S:_N\?0?'O*OD6K/\  JQ1$/\ _9_IE\E>%-S]:\9\88=L^BLW
MP3CKE,?7;FR.&XM=;+:>Q<N"CM[4;]QA\Z2>@/ALSI8ZGZ$VW_IY.'I-8W=$
MY3C_ #GQ&>GNZ;4M;P_;OG"2JF =G&,^(!&>V,T^56+_ %UBLI7V]2!*KP?3
M$8Y]MLQ]*1+_ ,.GV/*=SO@/$3P^S)3]Q7LY?(<)6=Y] 87&^)X<QH,^/3R3
MD]XV=/?;)*IU?=,UREV:W&;GI47;2.V&:1=SGM;7YS.5>'.$T+88]7N.<I7G
M"',>Y/M3F4MN>%:L)S=5F,8XX6-U -GT0\IK6)__ $>S"G?3]K[=M8.2\,N/
M\76*_8X5RUC&!]UE\2D<[A1[;]\SA#R&+[QO(_IOVHB9C>(F=6/QG"L84G.,
MXSC&<9QGOC.,_'&<9Q\,XSCXXSCZ^26M$F-NT]ICM,3[M?WC34 ]5_X+74I^
M8'<?ZN['R/RW[%9/[WW?XLS6Y^''[8? ?^>?"_\ +E'4FZ[^]_1?YG5G^Y >
M95?];H_>5?P!U 9S]FLQ]],A_&W:S'E[47IQIIQIKYO/,CLND$.ML,,-K>??
M>6EIEEEI.5N.NN+RE#;;:$J6M:U82A.,J5G&,9SRDS Q)%,"(Q,D4S$1$1&\
MS,SVB(CO,SVB-4(A$9(I@1&)(B*8@1&(WF9F>T1$=YF>T1WG5%-HZ U_U67:
M&V)5-MB.!5\8*M60. 2+.^,< \V28P 8U),9A3B$G$MI>>&-%=3Y)P[2\M/(
M*YEQ#P9CN-<I5RU;-P 55JJ6U5Q"SS+4UKAZ+(<'EFEU#'F(&A/LM$9D2AFA
M9+ XSBZZK)4LRLUUA"K9"KR6.RV,9'(<-'H,+G*((@8$QLP8G:8*Q52Q\H=L
M[)L^>[@50"K^K852OI808R(W=+B4.O/QRDY^PU>)+SCX9*J>49RI;2L)Z+7C
MF*R_W-:-=<Q.XFBC# @N_?J!>?D4G.\<T+"=IV@BZ-/L55C[WL)Q>L[K3S)3
M/?TF&3;B8CO,2,SOVU]=ZK63KLZL,*6DK8,M7==->6K*'<"W2;"A)PAK*?I]
MX^N$S,FM24.>6R$XZMM;2%XXL;'-='KU[21D9^Y8E$S=M*/?MRMIU;"]IB8.
M2@)V@IF%6-["IF((5S+S&8B>8*X%88.T]ID@40QOVWF-^VL6W!J:L[/M.O L
M9)J]OJ34U9Z[L.L(!#MU2'C6P@ X^-/(#,8=BY&<DHJ2.K<H(;7)UBNN#R@!
M+;26U8[Z_5O*L(/H6ZZ#*;0"+"F&22DU;JC]BS2L R^739]L6U<NIMK6@&RJ
MJMQ"Q9_[SEBN![010=F9(YGF[$!I2\#WYIDC&8C?VAT?:OVOOU'7[MW0%9@*
MV+,6_:]LEI*1EZY."5N(L]?KU8%D]P.5<0\EW$);W-95'8@\$[+)"*LRX%+<
M_P"YR703.K9'PWQD<!8CB(\\]-JJLK@+KKJV:H#FKL7;F,IKL0!R^MD[-FW5
M.XRX-.T.[:UE=: *&5:@LB:S20J(YZ@K*>H4K7RP4&R"@!. 6L3(&=)0KGE<
M03#=WNI>FRK:XD'+E9YV?V]MR0[N3.UMA+%-G5O+RI2AZW%"LL0-*A6,K<:C
MX>M@B-!".*$\]YK.>^@ Q=9!5**O*USGF?,L-]R\STZV1O,^W6V3$1 A/3J)
M$074JUTK6H)IUMC0A(""*PS$Q73$B!$/HUY3,LL.WWF&N(Y7S$"(2GE4.7[
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M\5.1FKP=\KQC#:S'P>_%'D961R0>:E?F/-0HMHB$2R(=+)GVS<_16OD/J/\
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MT9XBQBE279:%+@5Q/.O]3ZMU/&^YM7:WHFN8G*4I5'46I0-4"<PGMG&71X(
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MSK&.H+9VX*/*0)5-@RA:PU'$2,R<_#BS#+SXCK[A@DF0*L]N*CQXYELK+Z"
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M(P9[J;M$[@7KRD2R8N(87?P'QME\5^-)E>:[_P"Q, *[A/\ PR^K/_Q<K_\
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MLKD&*<$,4U9QW$P.)C:??$Q$Q/NB8[0-NSIGUUM@2EZNC!ETX>MERMO(-K;
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MP EQCN?1DOM+:I$[=XU4ECV6'3(-&VJ*9,V<D6XA1 ,SWM<8IS+<'U;73K:
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MUN*A(!3:]JWD6XTVQLBF,UCFQ-+VY$ZMO+-"AOWQ1)N]#RC-BCG(MJ3@8@O
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ML?6'!.HWO(!:PBJ<C9J9 P8\K]-RZ?(RM%?=-E=JVR9-G.B5D )W?AGB+/\
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MPWZ!3[Z_=N&,N+S!0<S B.V\;^N^_?O\^_T?1OJ&.ZOE(FL,AB#/F (V#TD
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MWOZ+_,ZL_P!R \RJ_P"MT?O*OX Z@,Y^S68^^F0_C;M9CR]J+TXTU#^X?\M
M5;73?TU;'M0$/*MX[*[4Z&0Y9[IYR<_# LC!Q#M9<<5C*$DV(-O*5K=0A>.S
MVW5DQ[F>;9MZPNF0, HW[2,W2I)8/K*G',;;20WZWLLZO][C+]_@83$)[>^)
ML$F"C^TDI](F8F#F1JQJOVX]7Z?E'$[-V.+'BM5@<;,Q)R4P]#Q3T*,^K*TR
MJDE"LO*#00\\)C"DDENH9CU9(:6V/RU=R[L7CVLBP*:RR$G\W8N@<P%CHD/V
MV'0HB:D$;N8Y8+4,F>TZME^$.'LMD:V:R52&6Z4+F&RYBE&"#EB_,K$Q6T4E
M,E$EMO'L,DUQ :I'+:H"WR?(5;1]2BZ!J*"(>^4.RM@5W&59D@L9RL'7\*Q[
MAM'O16,+"EYZ]SQJH>.>.%>K;!"H_P!5I&1FYQ11OX]5@EX,ED+[F4!1MF%?
M;0\E:(>K7!<C!M=:\XR0D>:4F+09G95UK/5;&*46]5XPNW?MAU24$&#.G4Y]
MG2T^7F@I8M:XD&$#U-$3KO<-"[>U)8(^ICL25IK]SRY)5R+AE$OB6*2K<6:_
M,KCA7%BJ&LH(3W^34S\1# 2T6>\XF?C@X:0*)N\ *#@+JBQ+[%'+-6H[S0D6
M%=7#F+&HL&R2Z14E-;SW*59CFUW$3EH&IYC3\IX7*R/#44:V4)#D915VQ<L5
MR(#(UMK+K!658^XA!,>#"W9#$O&9@&+B)TIEY%@J02_#]2EGJ@=;&(;>I!U:
M'.EP)AD8J055\0.92&GZC,R3C!CHPMBA)&$.><4_7;39(_&"\[!F>)\>B#R6
M0R)8\+1R-41;AFU;#!Y5]*M:L8PR(@GDAWFW(D)EC8GRBR>/7^#>#L@G#8W!
M86M<XA9C:0@VPBM5811U/;;$'3:0UP8T5I0ZV%A*NFLUK 8.8CO.IS,NUZQ;
M>L8YECV*=)6:5,A+C"OS,T%D!#0]+I5(9TY)-6N<CC#Z^#)V<*3-CYN2Q*G1
M?;"GAXC%7PO4<VOGSR3NHTT6CLV85C\;4F1\RBPZS2?1-)3 IK@L+7F++&0P
M41)\NM?N<(<*5<Z_,V4M?F!D(^2W(:M$6RD@\]<IH=+:JYZ+51#B0H'RMEH4
M$4$=8K[42=;S4LY7:AO"&@-;UR"LT@->I^G3DGKD:PRKJH1QF"ISZI.F'V0U
M9TH'%23Q5H,%CW)0B.AA6&4D=KX"XGP^)<:>)3'+NN L<-9G! IBU&Z:%LE^
M>864\M?LLIT!?>73\TRH0H2ZO5MV5<_\2<%Q!Q#5JVL-8HXY&&AQWUAD;5!0
MUU@LZYDVPX:0!B =8@:U8133'(-*HZR+GC7YAV_=TW&O2#^PK(5;JR5$G,AX
MFH.[R<?7 )")*CXARTP?KX:L*7EI\9\FPS44\W@G*GU2ZBAGL$<?XF33R%G*
M9/&X[(.ID_,VE4*98N[=PY+YX!9T,N)5J:U+N#"7X#)Y,WB .K581(J7O?"V
M3F<+4J7L9>?EL9771S%BFROE[,7ZX HGV*\K*[7-[/MD%15<#IE%AKAV(58A
M?7(,[574))W"_56O:RN( >RZ@.)IN#-9)NC8S[=3"A55"[3$9409TFVR,:3+
MQA!X#D0>0PH?PDM#N\UQ^;X=RG'M_ G<R=\VWL:0C-8%/M9#'/>>1JI79JU'
MUKU46-A;(8,J=3!] _-(JEK=^,.$N-:' 6;XJP%=(Y)W#MYV N6KQVHJ9"SC
MW?(=V_3=3Y_(Q?;4:V"$B2'VU@)$9,-=^J.IF_ZXNL/)R6P;@J-]8J.DAZU,
M2[\V]&E-% N10Q4-,!CC0."U,&2,,;YT<:AM#C S7J7B7>_9V>';!(_L;N4<
M8U-,ZKWV+"<51;6W"O44WY1Q-IUH*W)8\O:3;QE/&.2,V,D+_*57?.OP!X;_
M $0Z,%QV?B<GB)2,B5,^'6Y6^D;J<BD"R.3<H:UM358^[CGU:M?>#4;'33HU
M^BV^LKP"[DLD1=YNR:2%U9(S\ $$7,3=Y C91CT_IRI#-JB9-HJ1::Q%-L>Z
M\2F8ER8P<4PU#G@H?')+YE9 ;U>3?F;:S(7#:-/R!:4BNOIFH\DW*Y[#68JM
M!<NI.AMJDLH-U$D7J^195_67 M/-X;#.JY6:-TQ<2Z5>SQ*FL=)$ LV40VJ9
M)HB3XALTE+&%L('0HS>):JKN/J!WO8[C(2FS1+!'W1F*$/C6&:$77$U5N8+<
MS5B@Q7Y08J!21#$S4E$I$AG?,*+%+"21,NFO\IP];X?X>S&&M9#)X^_@5E9N
M/QB;%5R\CB#-6-SF1\FO'+KK4XKBWQ8IY+Y/K4,>JI8M&W(/%FWBB^S<#Q14
MIMG(-L!G<3>KD%.K;N0Q/**+3JE2TG'[.! G$LRC!0L&LB-D71-')UB+,5O9
M6[4PM-W:S"2UBEYV,AY *.OK+.2*](-66<>))CB7_4N@,3S109:YIN#*8?&<
M0C*//V;\5XB\96<'P_P>S 8:BO+%3M89-9_RGCUFI9VL]AYP;T)792$2PAB1
M0#0IW3M "W*@,7D5/OG0NK:4L+HU378Z=@+"2/I HR4PX*>9O36KEF&$41!=
M0X+;W"F;(@B8V/G.H-Z=I,PX*#3-H1E7H,I&&%.80RQ 7$]D(D8&<(>SAJ+F
M_.]U6%:FQUNA3;K8)FR JO*>M4RE^S35$B\ALXRPVD0>LM;\F'+JD#(_IDRE
M]:-XO<PQ%Y^V"^O#.BY-@3(BZ3!LIA=B.Y<L1Y*(597$3#$;S# 'S-:9#S->
MA*5BU+<[9"2-?L.VS)>)E!G!BX^0U]0"@WD*QW1EQER'SGQM.82ZTZVMMYEU
M"'6'&GD(<3Z;1!P<AW,B6Q"83)XZ)!@3!+8!ABP8MBSB#6Q1K:LH@EL H@HO
M'*.0H5%M+N4ND\+2>93-O8:,>3CVEEL<>U$[QZQ[H,T-J3;VB9^U6"W$JMU;
MEFLB&@5N6/FI9;Z"FB&[=[E-#'>D\CC-D#OB!$O6)ULQQ(47*/(;85'UT7J)
ML:8^: Y^V MLR[;??K #!$&E$S[02P&2'-(0QD H^9\%\,9W WLG9RE\+*;0
M\HK78<^;#^K!^=;U0'E9RP01O),+JGS;<H\UV(>9BK!'L2L*>+)1Y'CPT4(Z
MEQOS&7%-/L.8Q]-DD9Y#@Y0KR6R!2&W!R&FGFUH3+I>JP'42<&.\C.V\$!Q]
MTM@%$&IH3V8I@BQ9;B8B43&NC:U0]2O0OU [=ZUM:]0--VS&0-"K1%*?6R7+
MSHMDI ]8)9>G8ZK1(@#\;(CV?#;Y:L/24>T2;*'BR[606FW"NL\.\:X+%<'Y
M' V\4Q]ZP-R(D%(*O=*R)0AEII,%JRK;B&\*9(K6LDSSS,#'/J.9:!PLB 'D
M]\\P<OW4#$1M/-Z^L=YG?MZ[<><KU(Z<::\K7V2W]V=&7\FZ@_[72?.5>)GK
MA?HR/Y:.OHG^@)_4_%3_ "^"?X/%NO5+SJNOG9IQIIQIIQIIQIIQIIQIIQIJ
MK>Q*]8)#<NNB?<;TW'@%0TH_8!ZD6XFOB!6B45@9FS,27[Q)5B3A13XQD=MJ
M6AF9:;FE.B1 L<J!N)<>2IETI: DMDNBN4]$1>S88>)^Q/VQ<&$#LQ4,:V9%
M8AKKG#&2QM;@;B=7R@NA9L)O5%XQN92,Y)S\13B6GB65?TPJ)J7W5[;&D=*^
MRECZ @ZZZV-H?+1]?AQGZ\_'X]LY^.>V/Q?\.3VN1ZP#:B$(UK?5YGW*HVFG
M63+M@85$(<B&_=!?<YM<\%)0J%C?Z1*I( L/&<8\]AQONC+3\_SG5%]>N89Z
MZ]0X=7CQ.>S@2VCZL>)?[L%$7VQ]7Q\*%JSCX_5GMR!G_M.'WA;_ "@G78%_
MM V__.#'_P"Y>3UL2,(02"2AT=]MIS&67,.NY$7EIS.$+=;=8<R\UC&,Y\"T
M*:>\6,9;RE7@5R>[^[M/]/TZXV4B0E$QO&WIOMO&_KVG?:/P:@NYST?F'+C8
M\R3]X0[7G) CRV#$XD':^^ZEEDPAT=TIM:3FBBE&FA>N\.,_3460AW.0J=XF
M>7OZ]_=$=NWU>[^B82[97T6 LG$2XW@5Q$[3,3[Y[3Z^\O7:.^\ZIC<+X+ZX
M 01IZ*.?;'3,-/80V='ECNMM '"C1KDD<MB3"9,B51IHS/IPI%#F4K'\P=Z>
MK5BA9LGED1CV8Y=X*.^\;S,;;3M.\;]MH[3.^N=Y/-J\RFFJ90UTPMW4*9-!
MB0D%N%I*=Q-7.GIND(CG%T[@) >N/KKF'C='W5Q^0D5L-W37\- BR:%'$%0(
M^S:F8(XV8RVR":<,4_()6XRVIMT9(S+;[@S'@:C^*T\G#-H>4>:"Q#F2,;03
M)S6."(G?>>\;;CZ[Q.^\SK<_T.V1)WCCP\;+%H!;7\2\?058YK)-H)\,N,+0
M-%HI6MK5MZFT#S280(P_I]M?FP',RLJ6TP\*H?+:VQ'"VT.'H(QF,CVS7) A
MH-8 IHS3@SP[AKN,+=R^V!@A:O3=1K*Z2QYAV/GW:"X]F0D>80Y!W'<3VV]G
MTVCF@>7?\'YRX&1RMM2WUY0:B!3VB#GQ:%E6MYLK3HKS76],&DH*RSEYY:*(
M(RE6&!RAXSC1 V%$^E=PTCSL*>5YI;?D9<?7CP^5XT92EHG"DO,.#,B^8IE*
MQ^29)0<#O,![ S'3[;B4Q,#.W:9D1ZG-/I)2)1OL>M2JY&_7.&IB;$)=*MG%
MUBDV+E1$R-YD.;V5@4>R'04K<EQTM9%ZB5?AV,EHEWQ'S60(<DEPP=:WV<F8
M,"$^V.J\MMWR"/&T*0IEQE0[.17E9PO#A*@L$,=F0$2\8")&%G&\'!3VWF"C
M>9^YWWWWVU.3>NV,8HW+O-05A%;&M:;U,*P,V.NI);G,R#1$H,4-F)$UKFN<
MQ!<[$O(2)30TLZX:0U'G, -X2P[EC*17 DN^2MQ;C[RCWU/R"5M-I4PUCR#'
M!64,-8Q5E+4WECIK8<;LDBDY#FC?O);SRC.XS/:)]8WWWDT9FW=M@&0<=AZ:
M-L*R5PLQ6,)\L,"MA,ZC9<9/M2\)(Q5'*XP$0&YO3Y"SUNM0!#P.1@B$".NF
MX'+>9B$^E<(:EW&%AGBI/9EF HD< K(0^5L(\AH9\EXHO4LX:*ZB "DYYIB)
M*8[\O-L,[[04;1O[/-,S,[[^FOT'X;+RN2OA;:B$UWJKLW$3(*0G7ZA6ADDO
MA5GS413E$'4$1"#$%R1&S<G 1[T5%!A/FN2+K3+6'"W6VV%NJRWCQN9::0AM
MO"E^)26TIQX,9PGOGP]\Z$4\T[S^#Z]X_.-?I50$L(&2DYW]J9V^'>?K]W?7
M=\IJ]IQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIJ >J_\ !:ZE/S [C_5W
M8^1^6_8K)_>^[_%F:W/PX_;#X#_SSX7_ )<HZDO7JDHU[1UK4E"$4RM*4I6<
M)2E*80+*E*5GMA*4XQG.<YSC&,8[YYDHF(K)F9B(A"YF9G:(B%Q,S,SVB(CU
MG4!G/V:S'WTR'\;=K(XR6BIH;UL/)Q\L'YBV?5QA@QXWFM9QAQKSQ7'6O,;S
MG&%H\?B1G.,*QCE*UJK<7UJEFO:3S$'5K.6]?./8AYU$0\PSV(=]X]\:B 8#
M!YEF#!WF.8"@AWCUC<9F-X]_PUV',C7O4/0G_6?<5MG,_;([7$$#0(I7UI38
M[*B.N%T<3_JYRB(3K\1MW'=;3J90?NC"G4KQT^VRR[W<PU5>^.2O$FYBR]T-
ML.*NX(W^V8X.:9D8$,C[BM$?NGLYOGZ28D1F-O46--D%$_NJXSM[]?2U[8$C
MY&0J]*C<7>YQK>5RX;![495Z:UY."/6[!M[K1,?66$,923B+:9D[48+GU,=7
MBQ$/E,8-G*"!-34$;+U04O,CA=.E ;R9W+,^POD$3*5!S-W'E.%"4,B/98$"
MZ8#+G;;]()CV8GM!-.?94':9B3[ERE"Q8<<LP !29C<4H#9KM89">KK!&78J
M3 %(A )HC&,X6%IRKK)=?@('P*6R9MN>+-NTR(LI=5EZW52T2.8$J\WV!8OL
M<]1E,) 0D&W3G>9KX^J4Q->G$3]OLMF'.4 %9<FN#Y*/A1WB@F,YE#,3!!O"
M>:)WY*HS^JD,Q'/>;'LR,346HS,TVBJ< )%QPT%Z(./ K.608:O@--LQ<?'-
M(0]$NX;0E&#26F%(:64II S<B(1D1I1 [AY$IBJ<PN*ML1&,:P55:0;2A5<8
MAM)QSM$VWBLA63S$4A;KMZ"Y:HK3918"L8 8@1'T&(B(C>=]YV]9F9F9GWEO
M,[SWU"N\!BYN@;GO,3"25BGM:U">?U:#"95B<7>Z7'O6I9];=2P0ZB0,M0,1
M6GAFQ25&YKAL<Z+(!R+@1&PX^G7RN612MNBO3:ZOCG6)GDZ$7'5FV+,'$\L3
M5&*;JSY(2JVTN+[62^>9(&2@4IVB1='/9"9F(,'1$* ]IVGIKB+"3WW4QW./
M*8;ZU6=*UJWO[2F1M-DVR+4:!!ZPP!"!V>KTB3%]_'S;\D4?!IQ)3+V9 ^$:
MC@<EKS-89A1C <*B%E2CQ3WOQN\'<"YV C'9>TJT0/FR;RJ63"N )CJS7KU:
MI-9>.0@&MMJ57&J?00V&&(;YP/QY8\/W9"48].31E%(%Z6O*LY;J?6\LU;P4
MZ.G^F7PY)(F63(2MJ>0H9+=B97T@6B5-I<@/([*O,L+K;64E80(NSU2<3'^F
M<L4G:52LB'>=8Q%7<DSU21L+:%ZYP]7W2"01VL#PC6MTL3&(K*>-^YDZV#K5
M,3C\9EB&Q8?;\K!IQG#SE'431*_7\HNT?0=T$UG6&+>V")NHYNZS.7KEE85T
M9#*6+&8NJ6L%^59D&$4LJD(0M[+ "I=2M;%]IS.78W N^],JJH4CK[74-J:X
MT]R9M.W=M@S-ZV$%8F)8_:UHF&)"4E)W!LP)7HKRLQ$3B+@*\FQYDHN%CH\,
M.(8&2VO%47+Z3?<RU0CRC[V(LVO+,$TBJKE\<"*%!;81(T*%8834K51>P5\U
MF[$9"Y8-\2^C-C&92H@HZ9XUE00B)ZE<6V$B?52<RPYW8QUA\$Z7O-K[+SM.
M:155@M@P6E*V9>)*T':YL=)K[<I'*GH@X0.R(D&QGY?6D@P<V%$VX=QYWT8(
MP9V"W%1=UE(DEO-:B6W+;+B59'G 2;9E"J)4W*8BQF;]NVZI8KI18A3H*[D<
M=;KX^5@-:L^JH;1^:RQ/3SV*3R!6<I% 6:U9?FMF;]>@"P()MM@&"U])#:SF
MN.(;%2_7KU:=A=$:%[4ELG9/41?()R68C":AK),RRR=:86N.IB*ZJ+D@!AB%
M2$=EA^4CX0YMP9W >0TORH&"3Y!A?FQS<-B>'?#+A[B6V.0MX?-\;6\%5NLX
M?=;5<^4KF41F59W$IHL483>S-=E:SCH1,78J6*:^9+;-Q[L_B[Q+XNXGX,JX
M:;.11PO4N*AY FO1L6<3150*K=M73ACET,796S( [<5M2DWU+-RM6Q&>LU]K
MD<DJ:F7)2"386P3)I@V1+,FVR%%,RST2Q*9D(81QP.6BW&&2TOQ2++DL(",%
M;!<CEK$=RTNOOR'"ESA<;M&UFJE+KS5IV\I8HLR54[];)Q@,>==3J!!?=A_D
MVSEU54LR^69D,77<1-KQ_#F60ZAD\98K5GPNP]M4DG3JIKOQY<U7#V[M^S4<
ME]@5%--O0QE%L %H;CG=7HR[0-OQ-2]Z@9I,MZPUR#$#)9/DBB)HK K<>R;,
M.64I1D,A3+8Y<B*D<7,.EW(K4 G"!5&]DX#XZP7!B>*,=?Q^6MWEY)Y9U4.J
M9)F(>JC=L,JV2)&+D,-8FE<+$5JJ<Y>\RR^BU9>Z.FG5^+.$<[Q';3D!R]=J
MJ]<_*+8$J9(I%CS2EB&64WLRQBW?;$.71RH*B_BW'7&X:.'&MW7:8<<0?%FE
MD6BZ2EYEY%8+D[,HE2&FZ]''2)AH*[C;&(RO FSA0 LT;%&&% O! +DFW!R>
M$\45Z]#.YW'^?H\05\G:Q=-V/K6_+3D*..&Y>+"NM&]U:FBUDVBD&%<%E8+-
MRG*JI-WJ]\K\ <;,X15QRW$YJ<$-%V-M<26ZE")J MRFW[?1MPUA<N6KEB:F
M1LTAQ=1:3&[%FB9K=Z6M":RZ=R^GR)T_1M@';"[4QB+MC=6K-*M,^-+R/J#"
M7IXV3U^3*0I(<T08[")N!X#PF!66QO+0,EMO;L*(XG(,NUDL5GW%YG)L517A
M[-HW,ZSU2RRBB2Z(R7)4J=85U:8UZ]4! *X:YKD<=B<A693.W8M+M*%@)KX[
M'9. &)D:KI.<39GE Q_2[[CYZLK*2>>S"TKO2/7]@5M]$3%R.E9YD]^ O?R)
MG(BCHS/Q+B&)H9ZAZWA :O*UN>;RS*A!RTKC$C R,<2MK."&"TSN2*[9:TK%
MI+G$J9I9-]95G*@M@%Y<YR"T8[(UG#S\TS7R3P':5,%D$Q08U'&Y.S67%2Q=
MQ:Q8*K%:P^@U%1R#B+5>CBAI7**JO4 H6==M!YQ(V:[%'*K)6)UO1]A:BD)>
M8F&EV:O%H](<%7CRI"580VZVXU81X,@1I<I@5I+K1  )*IS([SN(V.EB4LAN
M_G?PI\/^,> LKG;W$&3#(X^^OH"BC:MW3=8&P+1RSJ[DK*)%0L3RJZUN9L%$
MJ( YM="<T3@>4)C;UGW_ $=O6/?OZ_-ZZLU$3$7/1X\K#'C24<5A>6"Q'4NM
M*4TXIEYI7;Z31 [[;@Y0SJ4/BDM.CD-MO-.-I[ZMBV@+%&#%G',#%E!@0SZ2
M)#,Q,?/$ZLZQF8IF'9!^Q5>0S5K0_P"#)9S V"XB?PRVEIIFUP7G"LS"6VT-
M-,R+!$=8@V&D"@3@H2B!2,=U03/KI.:]G:(ZP1$BV!^Y"RK>!L*CO$04BU8D
M?EW(,Y/5-OAVG\OT_GO\)UA\_NN U^*A.TA3*A)*<PR-@060L$+.8QV\PNOR
MX .//8:[]R@I86(F0L^%3T;D4@ PZ S?%V*X70MO$39I2YDJKDE3K2[<C$29
M(A*S8'3&1)P/%?3(N0#>/(QD[@N',QQ)8;5Q%3S#$+ZKB)JDJ4$SRC)M:8#!
M&7L@$3)E,%,1(@9#*T/,1M@BH^;AC&CXJ5$8.CS&?%Y9 I#>'&G$X6E+B,Y2
MK'B;<0AUM>%-N(0XE2<;#2N5<C4KWJ3@L5+:5OKO#?E8I@P0%$%$$.\3W$A$
MQG<2$2B8B+MU+-"T^G;22+55II>D]N9;5S(D,[3(SM,=B&9$HV(9D9B9[+F3
MK'UY6OLEO[LZ,OY-U!_VND^<J\3/7"_1D?RT=?1/] 3^I^*G^7P3_!XMUZI>
M=5U\[-.--.--.--.--.--.--.--4RM$K,5;>T!$S=U>"9L]AB)."ALW2Z9Q*
M 2%B3%-0T?66Y9F/DBF4M.$RH$= G1<+"I?F)PD>+',D6]:>QJ,JE;;4C#W+
M-2O,V?; W=.% B&0)S&TDP02:U*YF-(5B1QW3$TZ.7\/,E<H8!;V8G&7:F1O
M?(6!B:EBMC)N'>LY8J9VJJF28JI6+61KV[]^5T<>IMMJ:Q7-YLNN%ZC_ &KE
M[&M[WEB%58EIJ%C5B$2Z RN3RF(+RD-#DH^-'H4_G[7A1A#(^/%W<<2G'?C3
M5#M>,+?ZZ]4LOI\+.?9PL.-J:>4E><IW)K]Q6,X3C"DX\S'A4GQJ2XWW3G'@
MSE.8&?\ M.OX_(+?Y03MKKP1S> -R"CM]F#'?[E9/ZN_OC_KJ^TV+G$J"IDA
MQ@46+<'R)V=4%YRB!\1^%BH6WAU2',><IUKZ0PX:T/.LCDJ\>QA]S,1$S,S&
MT[[?@W_!M^'U^'%F1/5$X9 "*C"1+O!26XQ'+[]]_P 7?MOJLUZ@[I),!1T=
M'9Q B8&<,*K4@_6W@ATE')>*#6T.&2[C#(;1@*0U&^ID2T8]"X(T"ODE6)"_
M:W"&3$1LP.>/=Z;1Z_3M^+6JY2M>L@I2Q9*5S!'Y1WECB)+VB(@(63L,>Q"]
MYYB[A,;;5;NFKSXJ3#)&B#D129(X>*1+QR52_CEG %$OG24B;(($8/5&N9;?
M\M+W=E3+2PG24.,3E>Z,P8%(^W P4KW$8$8G:(&(W[\W?:=IG;WQWY_E.&FC
M:3<!!.4#GK2#@@K*_.2$63*P9G&Q](-ID89$3(1.[)-5&.N6AHB^GNS20N)0
MI4M:-:QRIN0%<2[A)6TJN:GS&@1A$($P>[^\D&MMR*&5ML"J;;40*/!\66Y9
MP[?"2$(6_%'R;QL8CF<?MM,]YGEG?X;1.\:ZO^AXX=75\9>%FI&TZU?Q7B+5
M.]:WDEG9\...+!#$504N%+M,@$2V!,$GR#R%,C'76O7=IAS2F9(5#TF.3]OC
MV$DB'.J*896G <8L5+[@^7,%)>(7ZMI[ V6TD/L)"5GK-+*5B@I@0"#*9$I+
M;;O[4B<%.Q]XVWY8GWQ'?7S^XBX(SM1[(LK&Q;6PX>A'66Y\M "CRU8T0;D_
MJBR;$O X5/MF,)F>JAM<VB3P^D.()7Y'A1(AO/!!E,BLJ7@A)$>>4.^XXA33
MSXRVNW^G'(4IA_(2&[UC+51B>HPID=N0QB2YHGUB97$@/LS&X]]_2)VF9F)Q
M7 F=M]8J-%T0',%BJYM:M9A,074ZM:PX&D>W.U1#$1,,%LR)"H5YH[I^TK:2
M*)&N'^4^*:[*/"ML@1J7D#N.#M+1+'.Y20R:.:EWPCJRIMQ0;)J2&B^1H9BI
M!,;S $GZ+CFGJ<HQ&QS/;>8&8VGV/3>8V[[@7AQG9@*05"M JQ7M%?>KE37&
M6!!K2 7K!O!L6 ,SA:F#T2E(-YX;$@173];5 X?R,5'C$R<>/B//$&8(DR,Q
MD<<HP40CSB5*8*,);C$,-NB%/O>4[X0F'E9CVYY/,,&0MY$R,1WV'<IF8YI]
MHNT;?=1$?5K;<?X3Y.$V)@7U0.W5ZM=J$P-AJZM=KF"<%S1";#+,5@"&JGFB
M&B2XF-;0.F'2)E$A7921?,*78'5D&_2:@NQH*_)P:[%1K(XY2C_*PVT^ZK*E
M!(0^ZIQTTIQ_1\QD(N,&($8A<1RQ]U]UWF-_3Y]AV&/2.T1K])<!<(SPW4L2
M=IUIUUY.L.):JTM8&PBR4I!0<Q[3N7)!E&TLDF29S=!..R<8^KMC&/Z,?\>0
M>NC:_O&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FH!ZK_P %KJ4_,#N/
M]7=CY'Y;]BLG][[O\69K<_#C]L/@/_//A?\ ERCKG1\;$;%TNUKX.RBB2$EK
M6%AY!<:6,7(PJCZ\(TVX: T0E]#:LY\+PSZA\E#Y=9PXCS/&G$RN+^6N'K>)
ME[*ORCC#J197&Y*ZJ>3GY>8.H$3.S%\X]0.9?,/-O&H\1E6OY7B2@JVGK^?R
M2G"EJV.K]2RZ(EJA/G#??T/EYHWB)C??4!:WUH;TW0LPAW?FNX20DSTE'Q%N
M!$<K+K0;7DCY0V[9J[/"RJT.JP\4*8H?*5"LNQAN1VG%ZIX<\$V^#*V1J3>K
MYA]ZRIS*R5V5=&$K,%B@Q8Z5M?![O-E"Q)""5K#V.<M*IUZ^"$DMS]*O9>S<
M*[SK0ILC$1$>78U5IC(&9G9#U3,\D%!P,1/!L'757:XV7%8C*Q;[*E*TQ[]$
MM[\O5WG67$(?]Z&RE>A)&,>;1YSF 0@9Q*G&5#*D6^SS[':^%>'SXDS(8=Y/
MP[8K-MMBTM1'*E2(R%53&U;CSDC'F-U&HL!AA^UR@#87C+C]O"&%;E#Q%C(S
MUDUJK01DJ5%S&\T]5EFUC_+@D1 HY*MJ\R72M)2$'+0YNJ)F>NVJB;99[4WK
M'6I,[:9RV24(<4U=KK-S-@,/E1VK!Z5A=2K[19J:W$"5C$E<I(<$(6.L,&2U
M@<K7N,>'F\,92SB;>4"<724@^O6@U7+YVEQ9;+H"2*L;K363Y.I+#;)3 LE;
MA2$MPCQ:?&W#M+/>6G"UR!M=RB?#IZM1AKL'6L$M0#7:X3;+"7+(,W)Y0)</
M+#-WP.Y'Z358_5FNR*OJ]4JZMBA0<%D^SF>2Z,;'SE^AT-%MN"SQ:RBRJ^<-
M(Y;<8;,NA9$K)*C(G59J/<I7Z4BM260E7QXQ&\<LB2W7 #<6,WB"%4R:U%',
M748(-B(XU9Q.JC3'AFG8&LU[/-^6K^8NLVA4I)Z36UG1?/4ZY,$C* $;4B)D
M!7NH0TXFJ5TVVCMLW$N!BU6-*/*RD:24(TLL$=+'[V%%&(RM"1 NPB',.+2I
M]U;A+TW6K"K[:?,=AHQU&LVDX'U% ;1 J2K?85+$0WW84&XV,/?,7-PL=1/(
M@*\@52O-P Y8$+$J&6B,#,@,0>_LA,C$]AF8B)U'^Y-O06H,1<B<P6?*3H<F
M&#&"-(5A_,>AM\4TUYQYE+(@)A21EH;5DEUN4(=9;=4+E'-)XVXYPW C\9;R
M87+!Y(;%;RE!:C<Q-65MBR1/:E0C58^5"$E!,\Z9C!0F1U>?;15-4OZDB9;%
M"H&3Y!F.8HYB$=XB=AB9[S/PB=I&H:(Y-,K+D48J1!,A@I)N3<;RT]*NRC*9
M$J6);5A*D%RA93\@6E:4KP22[XTX5WQS<,391=QE"]6;#T7ZJ;ZWB)!#HO!%
MJ70LO:5#2=)PJ8CI<W3@1@>6,HG18F7QZ-]L8C?81+N(C$[S @.PB/[D8@8[
M1K@;'OL3K*G3=MD13)'W6"64# Q#6'YFP2#;2W6(F($Q])\XY[PMX5G'E#I6
MLHI;8[3KJ?.3SN!P2TV.(<WC<%3:WI#;R=I==<D($P@2)E#+#14!$-= L<?+
MR@$S,:]K19L3(5*[;+?9B 6)E$<YB$&P@$Y6H9*)8SE+D""*!*8@9JATD:FL
MYK1'4#N4=)&R+P$6FO1136?*IE0F"GY(A@09Y.,B$V4HPB2+2XCU6!2LY+4D
M^3F&E>*I#E'*RD#RT%0^<)6E@.%2;K"?8ORU<REMB[)\L/1)KFJ*PKO=2\K"
MSEBMS1B9,^H4N9MM!MB(#E6.Y0%>LL0JU0YCF$*$C8UK&-/OMU5+-,FM.C44
M(:7BY39DD2]IV5>:^2D@Q'ZMV29)$U[S@I!RI,MM90V4 ,,_3UO$LK<AH\XQ
M^2?E+,)M)&M<"#4U]6);(0<C-5P7P$Q+L[]93R"7VSV8@#$1VU(5G<Z;1V9(
M04A>]T(F;"N6PA@#O$Q-@N5)=)93#9Z8@MREC,:T<]5FP*X_0+D.;&GDCVN6
MEX76U<\8A9,5,S\U8;558N'1*$.CH^2LB<=)1;'F$]E"K:%8==(2,YQ.[AN)
MW^(>.XHPG$5BEBJ=KSCPNV;W2QE"O4,LF3[ V(4,9DCR"RN6[>+2BYE5K=E*
MD'%U? *_$M;B>[?QQ5+[*!DV94"C?S8GJDC>Y4QXK;*$U7BJ] #8WJ'9*T1H
M\P10E'7K;E'US5M(;,H@^8VU@R4.Q;(XM\LC,<_@DPB#,"A,$9#G&WBAQ!S4
MOB(?C7LDC83*A$838X&X?\)>+?%*KQU;X@=7PM'+J=G,9F;I4G><*H2\;F>O
M8;9MV<3:R2ELS!>>DL29%8N79QI$Y=O-9O)5:I8,<=7KUKR'(JNK234<LFYC
MJ33+RM>J<THV7,0R+MB6UZU14&@=5*V"<#1M@FN0[\@L-0Z43T+)2LDV&NP%
M$,87B,8*]81*3+03XI3C HAI$8!@EEA+3!ZD,?JNMG?#S@WCO&QX>IQN;J.P
MX_*%+AQ,9J,=4L\JPRD9P<E8K87'!4HJ)K[-9%"TL!5;S:050KABX$\A97<.
M^AE:LI9&65N-"E69(<S!J+)U65O,7&8 E=VFKS3V?:K-A5B:\WZ'DB0+#=+
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MQDBE.JIW#K/J"H>O[/L]ZU%VU0ASTT9@*/$O,'&1;Z"2Y*.CVDAJL \+#O1
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M;Q@_Y>1J!Z_Y3(C\?;WZB+'&E2O$R6"XQ9M_>_">;?,_1"JA;ZY5,V52*#7
M*K6]9;[8B8]V1);P7J+8YY9!LQ*&S<N>887%.D$F24O(G2!3JU]E$%.>6EMO
MP-IN_(K?[_P__JU+_P"+J/\ LBT/\6/$'_83B/\ J.LH_=[A?R<[T_0O?_V/
MQ\C-_O[#_P#JU+_XNGV1:'^+'B#_ +"<1_U'45Q,IJ6#N#5ZC=3;_8L#*YYY
M+JM6;1>#458YRS6&1,6 ]'K%R4F2N=JR&YY>/1BSIH;"4C8';8?(K?[^P_\
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M'^M4_/8L\T1WF>1=3EB?_P!87US[IUQ]U]-=?OU$V _4ZI0X'<-KC0FQ;NW
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MZE/S [C_ %=V/D?EOV*R?WON_P 69K<_#C]L/@/_ #SX7_ERCJ3==_>_HO\
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MQR$"GV<^.K,1E.700R9V5@,R10S1'J<>7-16W:<J63"4N2,P7)S)2(<Q%MO
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$TU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img61678762_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_21.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M"M3'W3)TO"[GUG,K._\ PT]9QN$-M9:,G'-*6"^KC_G7:X'^('=.UTXYT?\
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M/R,CB7]X?,3IJLM=1_IGPJ?_ !%8*?\ \OZR>!_W6_TG^4CC3]Y?]0_G./\
M-58]?3\Q@?7^7U@?Z_[OF,<#]>!MO\I_E'&G[R_ZA_.<B;'7E_Z!X*O_ ,)2
M"K_\/[QP/^ZW^D_RCC3]Y?\ 4/YSN-$QKW_(D(+OK^GPI<=SU_\ [7-Y'"PZ
MJ?D9/$IZ,/F)W=;UO6MZWK>M_IO6_76_\-ZR),^XB,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1*Q7GQ)Y-?+05
MM,ULT$?.N1BYD96WPXX43O(AHTQ5^CS$/!)DYZV5=NR'_DF%S]U(V\2U)N=7
MM$D:&='8K8.&Q=FQJ2UEB7.2B[M:F_ Y.W-AQ-S_ ,3;[\3;]51VX[7XU.)C
MX_:36*:,#3<O1\*I,VX)C:9G&HY6%2.+V*+>XQ_9'V/5\<5E!CT\&'M^#O+8
M\ALC!L_0(!F+-39QIIB127Y@OIS\D/(-]5A,$*--%_F.QZ C(Y&J21\GD<!E
MN0JM\V!2IDJ2[ P,,,K#&I#+:URMP#<6MMQ/OYG8>[< [;@2JSMWVRMHNQ;.
MTNL/CY&ET:+?4V=>4MTK&-AHPG7BV:FOO;@"?;*W6HSLMM@;A7X(<70PU#&$
M;R''CHKXNMP8A8',15P)P>1%W\$.F'*V7)E(G1X98DFP3[9/L9^OOROFN:F:
M')C0G8T#3L$!0,6C9%L11P#DMNXL7X,&8'W$@; F7;/2%VXM?)LL[5:VSYF1
MI^5DN<^\-=D:2:FTZYB&!%F*]--E;+MO95799QNBD=K?@UQK:]ZW-NFXF_\
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MK17"5HJ_5>#?)6MM.#3M\%2!RG"-<D,S*F2U6;65CBH-TND"#8*<9%%#=]'
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M,(WK?_5]GI_3+HQL9>?<U?>BG\09;.3DMR-UGP#$?AM.I\UU,W]_F.@%_?\
MO\6QS_?Z_P!?<[[O7_;ZXVQE\*%__&)&^2WC>W_Y#/NN;]4);TK\AW^=O?W]
M^ZQ8I&O\=K5"5K7^.]^G]<=]C+_>TCX.@_C'<Y+?W5Q_Z'/\)WFN*]<>]/9S
MBXZ]?_Y0,]C_ 'Z>9;WK_;Z9'K6-_P ^O_4)(Q,D_P!Q9]ZD?CM.XG@W8E_I
MSNRZ_P#%"TC_ /W<3Z?[<CUS&_YR?,_RD^IY7_)?Z?SG)_8%V3T]?[/+#_\
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M0@L(A%?7^25.0Y(;T]?TVO36_3]?9O\ 3+ZZJ_[=*G_*Q7\0TL-I2?L6N/\
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MB=)G4U4VJE0(W7B8$D@;D@ ;\^@\2?";S!NMOJ9[2#[7"I  W  W)VY=3MR
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M!FOMU#(LW 85J?!!SV_S'<_+:1T!YWU+I<K<\57K)9')2M;<-SOC:B/*WO\
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MG\];N7&#T>H7"D+D,V7\S#[%(O'UBC5I9NL"@5AM=8.C8)O:-!Y!A&WY_/\
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M^D1OA7[H])B":R)MM6N%G(+E6=U^'8' H.Y$"5QJ@$!99TDDYN!Z/.UA7?\
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M.JVI:GI<B4_O3B?G_M+VGSNTN6+;_P!1BT\0Q,-&+5TJ>KNVP[V]P!QV%1R
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MU;VI6]J4K>U*4K>][5O>_7>][W]][WO[[WO[[WGITXJ?,1/0%B2IR?&%!1I
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M)DN8B,1&(C$1B(Q$8B,1/GKK^>OU]/\ ;O\ ;_'$3[ZZ_G_3_;K]=?\ #?\
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M''(Q%WA@GKM:NM*1,M[A^PP+7*)P=!:.0YJ'FR^9&(G4VKLML9.JTA(V^?\
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MX/FO29OX4'D+7 /@]QTQMCO5$D0Y]XMK-CZ&0GS"ML(1G^.\X7$<A:#_ $E
MFM6&2EW1RUDI)*NJ60^4';9G^19;V]F\Q/T/B;-G4E#;8+;V)>P[XF/LPX2O
M#6_[=K$U^ULNS?;>CT8?I0T.[^NVM%J] S%O3$Q[,33JU%6,K#5M1_5GOA8+
M,C'&W<8B(N1M7QV<2;S:<14=A_EPE6H%2D JE3B<>#6[8BW!XL VH^*8"Z)N
M  3B2(*35)L0BPB$[%2A<-<:=(4IYMCUK3,RT\-34U5FNJEMDL[U%5^\3@XN
M&O9JS259>$KMPD,=R!\5=K^S^&O>9->H9N4N7F:A4SWXRX=[6XPQKVO-1LRE
M-62N;6];=X'.U@>M1LS[$/$KR9X9XZMRAQWFAR(;.Z9C6'IT$I&LA27'0[I;
M<109^&(6' QGO\X5##RI\B0I#3LIDC*C1UZT':SLUKO:(K91J5#44;MCZ8]3
M8U2-L06%RM:+KV7V0]RUJNY"FM683N?0YZ4?1WZ*UMQ\_LMJ%.?J2I7J?:VC
M+JU3,NK#AEH. ]&$V%IU-A%C48-V1;:55[J\JZFIIN%DWJO=)X]9;?S(]"LX
MXK3K*H$1%.*7\0@@1,2U%<96AN5#(1Y7L:D0)C$>;$?U\*0PTYK:=>0C!R--
MU?'P]2H?&MJS,87UVC;:LVH2P8$J];)N5L1F1E]I6(YS[=_K%I?:KL9J.N=E
M-2Q]7Q,S1]3.GY>$Y;BR4Q+E6ED8+;1DUW 5VX]U=>138"EE:.-II'-7;;[:
M]?&TK?WUK6M^G_'^O]/U^WIZZSVBC "L-QMY\NOCO[_'_JZ[3XBU#M K(>&P
ML2.O/^.QY<]]OO\ ?!5E/>_3JEN>N]^OZ[]/]GI_P_?TU^WWWF]QJ.G+D/K_
M !Z;?3;PW\UUC5 W&>,;\R>?UY<O<-^NW(;"<%5I%HM0@=9QX\!8!@J?<!^Z
MW:; 1K@]Z:38IJX-@C3(%3MVY3@M(PR-^2<'QT.?5WW436EQEM2>9[6X&+G9
M6-C9&#@Y]=6.7-6=4+*UN=V[JP UV;,BAAR"DUVL.(*2)[#Z!^U_:#LKIVK:
MUH?:?M1V5OR]4]4&=V9SK,#+R--JHI]=Q&LKR<4O3?<U;KQO8E>5AUV"OO*P
MZX;5B4EN(//68@ZU7K,#A$Z_IYYQ?SD<@S#FP)$.%&^(Z/BI@24[<0ZS$;9T
MZW&6TEU'L9\@[*:QK?9/5+;>V6JOAZ3F8[UX5%]KYE-MZ64FFW3\3$6\X6)3
M065F%6+0B/53P<:JM/Z1^GOT?>B_^D+V"T_$_HU]@,?M'V][.ZM1J':;5-+P
M*.SFHZ?I>1A:H-0PNU_:#7K=+7M-VAU/54JNJJ?4-<U?*RL;/U(91HOMOS_4
M,!Q3CC4E:7I$?2VWEM-RMH1*8TI*]M_&TE;B$OM^J/BM;TI.E>]&]*TG/HK#
MRVMJ6VBRMZ[JELIN4+8C+8H:NVL@A64AE9>H9=O \_QK[1=GZ\+.R,'4\3,Q
M<O3\VW$U# O-F-D49&+<U67AY-=B=[1=79793<A"VUNKK[+*=MGWCCYW\+HP
M0'S SSO?'P,%7RT0N"DOV.NJE2%ZV^2/K>918V)$M[>MRB#WYB>6OT=F2VHZ
M=J9\X[1=A==S[[]3IU#],7N.-JKT&/D\"CV:L<*3CLJ#DE:^KKMR1"Q ;Z8]
M&7](;T==F<#3^R.;V9/8C3L<]W3FZ?99JFEFZQ@;,K4F=!JB6W.0;LJS])V$
MCCONKJ4FO;$/(0"T"$4%S8I(82BQYP\A!D-2X4Z%+:0_%EQ)3"W&),:2PXAY
MA]E:VG6EI6A2DJUO?E-E=E5CU6H]=M;M7978I1ZW0E71T8!E96!#*0""""-Y
M]D8N5C9N-CYF'D4Y>)ETU9.+E8UJ78^1CW(ME-]%U;-7;3;6RO78C,CHP920
M09H7M'@QV\KR7R+YKQ;E5JXMS/R&\)?)JL7[Q9Z+T3FEXX%7_*_H%3%HY@2\
M8V(-RNI7D@E=YGW,C;V4.4SF:XNJM81]*%VJ.[('43*!&XWY[,#OMS(\0?/H
M/KS/A*]E\6;R0L'D_P!0%>(S3QRS3?%#?&ZD2N/-@I$?2Q">>BN_U^M,U'K0
MRK"S8\ %)2RE).VBM\Q[$4KP:FVVP6&B3Y3JDI'Q\_PY'I_N)7TWX/>1MHYO
M;JF=X4:*DQGCG^+CSWG$HS>N+_YI=>^^5E6Z]X-2!Z0=Y&":]*H5)A$55L@-
M$!!G&3<6-&K+->;9&*C)5OTY^*[_ '#8[\MCOX]=_&6%1P;R3,=ZYW;.@\*)
MVTO4O."L=S&]U_-_('D O'XKXP6+F2^=*C3>@1KX,+<XNII<:Q4ZNUTI2;&\
MY(Z)7C9^Q&R[<=(WY$;]1MX\]B#]^_O^@VD@^3_CUY/WKNUKN?!7]UV78N;W
M*A#;GT!=(GUGGITGX\==K%$Z[QZU ;! [9SZXUWI%P&UVZ4$I5KOS.U@9WYT
M",5JXLSSB$<MAOY[[<__ %\-B#SY^ZK5FXPY!L'A?,Z;XMWJH2>P^;3X;I'
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M#B=V/"!R%%;M7J[3[$!""QMY35F:S.8CZB:Z-T"*T1C31,2O@X+SV[7#IXJ
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ME/8"B2QA^.V,%SY<=$^T?H]-Z.P?>IY=9)=4L"JI:(,L68!&*W9D!0EC6"/
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MU0QC[[[HA\]6YY$-MYY J=#:=<;5O,#7LG"Q3@VXV!J>!WK7UX>IX[9%5%[
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MHX=E]W,^?3ER'P^?A/+]8U3O.-F;<G?;;EM[ONY[^?,_#W>)LR3B;AM4MV/
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MZI$KR7GNVB T-B5@)7JC;3D_ZFXXD?(? U;H% L1X5%DOF @2]THF5@1(=L
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*B,1&(C$1B)__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img61678762_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_22.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 1(!B ,!$0 "$0$#$0'_Q  >  $
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MV\]^SCVV_B=?ZL>W)$>DT#75>ME8UY>Y>S+.6:'&C*RD&OURJ-U*'!-LFY1
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M$TGKZ.DZNU8$?O.Q;%/S;C8F%%JM;>G%2$ >!;O&QI%,K-<HNOPKHRO#1R)
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M07,0EI3J!EH0]E;3C+^S7U2E>E2VOC&4&_,?4%:$%V1N([7H6X5^?4?$?.'
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MW;8\J#7G6-QB(H4FDT*AMU>X*@X*?;W$/?Z7GU;^=\OYK]WV<<?3^5^7WO\
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MSWF'CC&,Y\/SG\8Q^<YS_+C&8X7N%5 FZI6S5A#B[#>IY(730DXA&CE+.0#
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MW'7Y+6KP4?7B9=XFXB#7A-])1BCTB3);-+ PS/I08CDV)(N&*%H;,L08^7-
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MM?KI^FVTC0A\0*"L($;:);H0\A<@.B!OM=H;6QJO>>:E0HI)Y'KME92K!).
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ME*J\TLLK)'%$A=>^1V55Y')R[##+._EQ+WMP6/N %4< LS,0JJ.1RS$ ?4Y
M'72CVRYW>X=K-O5LA6;M?H+-3U-0K TA!O4&C1LG,L6(*0TJ=0*O6Q"F5W38
M$9#SSX]:Z_5WW4*KCK&-QN[=:K4J]/:V=)ZM-S9V5R$\P[/;2#MDEC;@&2G2
MCXJTF( <>?8 /G@YDVI$CC2G ZO'&>^:5?PSV"."0?;F.(?=Q?0_$_OWC,H[
M.ZCL]T%5/9^I6X+&_=(&';?K%^:^F##M4)]G$6ZZFL,_/E]*K[,K^'0TAQU:
M&11YJOV+U&EAL*S8T.RKU9+%#8EVT^VC%:^JCN:NP/=5V,*?6Q0FXE7@$R0F
M:'@B4C/%29$9X9N?36%[)>!R4(Y\N91_KPL>X?FO<O\ 2R,7OJ&Z,S7%1X,:
MZR]Y+C>RC=85T^Q1=W+NBD>DBHR*VZ*RB(R@CGV\FXK>736(*5F<&G1Z4K7G
MCHO;>>&9JJZGN[VWXLPMJ15^?J1.).6/9\2U>!:+_=>4)/87?LVQW<DQBOSR
M;?>OD=GS[PW/N>/DGX^?AXYRH/8WH?L6Q=:/VVP4Q"??>E;(C=JU680C,U^=
M=!*H,MW3E;E>*Y3]1JM3#A:S2!3+OI$350$2L>VR=)*7K][LX+]J&O15H]/K
M811U<+CM;R%):6U*OL!9O3E[=AN.X,ZQDD1+EBY,LS*L0(@KJ(ZZGGGM!Y:1
M@/\ I)6Y=O;GDA?D!F-=PJ=$W!0>M?U-^O9,]1]D @5=(6"?2(S$ZTS:K8QV
M6E19X1;.8]XGZU/NS UJI<K##MOIZK16DSX\N"#PSM>F_+W->;I>[((U=VO:
MBU)\4=&_&O$\+DLO94V,($<OQ!$LQUYBOXVS"N[*O3ULR6K%>MYCHNOFMS"M
M76_+\$4$MEDD6M%;]HS-(ABAE$4L@[%<Y7+9/:!O;0+%8U596K9LZXQVH1NQ
M!HQAT/K[$YI";%;3D\I$B.CWA+:Y2@8<GEDW/+9@150,8Q)RUT_5Z"37F.79
M5TKUJRJP@Y7^-.GX(*Z@GOC=P S@=B1=S$\\<_.=S26-5>L=1==5Y*6DH2R7
M!7V%BL;O4EF-N^IK*4<<LK6DN2]@NW(@]2"H9Y?.!$?.-Q(0N@A M?JN'!L"
MLPV(@Q33GA)2IC'F<FO/I\JGI\Q]3LR;*5CU)4M]Y]W*E.JSS:_':>1[ #M.
MQ:0,.5X/R0+Q[*HX51]%4<?+/F+J[JC8;C=7=_9LO]HV[36O.B8H8G!'E)![
M\PQ0(L<->)/ABA1(U^%0,Q>F;,C:;CD@UE]47J6PSI]@I9]N+(=K]),S93J[
M51"CD1IQFOBGR^7[)4%R&XXQ,,O-"MR4N#8[*UO7&](KP\/?B5(IXR0);,2@
M&O:7N(\Z18^(+''<Y:-9>#WL1W"E?N>+'3.KW>I"7>L]?6^R^I-3')''=VR4
M3Z>GOJ$,K(;LKPHE;9Q0M)8C=*]CRC',[C%#AE>\[.*E"H<^;J:H2D&W"KH^
M8R,O=N85_P S1!J9+#:B5=K*LNE)<W"50)YM(YF/E]N \YS,@C&MA=7=%O3K
MY?8'5I*T)'QEN&/9+-^%5Y+JG<3QW<9'=LMWPYT.S:TK0]>=2P2:N"I XGL]
M*].2@_:5FW+ TJ5-SNT"T:U;N%NIK3<FE,+VHDS@W@)]UPIE:EBIA!HVCXU,
M%J*^Y*DOR581&1#;0VIY4W$A32X>6$J>3)PTMG'J)3XYM1TB(E,J+Y?QL[.H
M5$3W9F8D!5"]W<6X';]?GGS57Z@WW3.^U.[T(LQ;G7WX+%#RX)96FL=X056A
M1>;,5M6-6>H.19@EDKNI60J=C/079E=Z9TZ]4CM_8RVG+V?*@S5:A7L$:A"K
MI5(H5+0RQ58E$AS8):TDE2G(%GJ$=>+4()#&(LL5A3C:&^9==5INK;=&STU#
M%MJE2&>O8GI31/)#8:<EXK$;,CQ5T"J\%EN:\JRNR2D>Y_1?P8\-CTU5ZCZC
MUE.[J=?U]=UO44/1UR/R;/1LTE &_J+$;/R/+OSV8ZK%(V&K@UT=A4LI-''>
MK3@.P=@-PN=I;_635:I%1%SZCU<H]N&R1)Z*),82F[;PL%<((1. V/8*&HP"
MHP"+$,N&H,%QZ7#C2;5*0F#[.:#3:P=/TYXI[=F1+/4%NLZRPM)$3Z34P3H2
MDT%,EIK+QEHI;C@*S+74YVV=EK0^DC96D=@]N1#W*67^3@5A[,L7)9R.0TAX
M!(09,?9'2SNZ]>9'5\HS5]H4PO OVF[TIK*W:9LNMJ5) D'?(E;CP,KXOUVV
MCO(ZV5JQ<M!6PXIUK*-9H]H-7=#SQM8U]J-Z>TJ \"U0G';,@YX FC]IZS\@
MQV(HG! !YL59_3R\L.^%U,<\?TDB;V8?^TOXD/T=0<ZC079(%N#UZ38Q)+7.
M^ZB)1(VAI^Q0)\,M6ID:0P-G%0<^1'2-MM&($7FGJS;0,T@.*#)L!QQR--7(
MAL7-QHYM9Q:@DCO:>S(1K]G Z-'.C*72.5 WF5K:(")ZTR(\<B. &4*QK9JM
M!]XK"6NY^ZG4@AP1R PYY20#\<; %2#\QP39?FBS%QQC'&,<8QQC'&,<8QQC
M'&,<8QQC'&,<8QQC'&,H?VOV0_!.#J4R^IJ%$&,%YK2593[F;,=DMQ\.8QG]
M]$6,PE37Z>#DMW.<9RE"L3GI;7*\$ETJ&=I3"A_U40*6_=W,??\ 1!^HSA/B
MMU+)7O5M+&Y6&*LEN=0>!)-,TBQ]WO[B&- R^WSE8GY+FKC;VV*W3!R2!^<X
MU[U]<(9!B191$F7(99=?;'BQ\)I^5,FO(:7Z32$>'[N5N*0TE2T],UNNFG8+
M&O/:.79F5$1>1\3LQ 4 GW/)_<3SG"X=9MNJK4U+40QR/#$;-VS9LP4Z.NI]
MZ1R7;]RS)'!6JQ%U[I'?GW 1'<A3J(KW?T-JG=-^G6/5VV36P6RS8 _ KHH&
M6C *<WA#@>J15I.H=P[C#BBI);C$5$NQK=_=4U#85CJS>'UC;::F\>RU,%.6
M'SZ[699XG>Q[AYFY@(]N/+'#/Q"?]KWS=_.];^#NEZ6W6O'2FE$OJ)WEFK_P
MIW%QE3<[MHS%Q(I*15-*DK.]>A5KGO1K$ZGN]H?4.!68_5+O5= =AQ%TJ<Q4
M;+Y*D06(9VH%7$(L-6+/1#,E_,=Y"6R@EY4:3@<;@Q9#;24/2LJM4/#FQ!%/
M6FZ@Z=DKSJ&X2[(6BG3WBGC#0@=P]T<=P\R-B"20,W&KNF*ANM#N6,VCW55G
M @;OLZS<U49M9MZ4<QAB9XY.:MZ/SH?5:^>:,OW)$,Z0Y]2JHD,SX O2N[EG
M&8SRVATRN"VU(?\ 3SECWK<<W(F1XV7%-^LXF,M:6UY4A"LY3C.9#X<W$[7D
MW>C["1\269>..?DI, !]OD.?<CWSEDW06PF:K9V%N.MJ);,26+D4<S-Z<R@6
M/2&:.&M+96,/Y43V(T:10CNB]S"&JIVY P(4<;+U#O::;.$\D;06B4B%*G$S
M!)Y'O7X,%1V.J1B,WG$,0/7(C)Q$C1(OJ,?ONIVS='3IW.-QHPD4?$*/<=45
M4'*AY/)/:"0"[A&]RS=K<!3J?$GI+:>('4,/HMMI=7T]0AJ:'IC3"S8LSZGI
M^G]S6AC@2%4L[*QW2W[S><OK=G:L,9U1U9=L$'ZQ&G]';7K&VZ5U7[AU;7CN
ML0^L=^#[CKRN!HUDC48=$&:FV-#GIMRAF+T"5[FI%GC,B#&,U<Q&CXF)F A;
M#W*)/!K<[JC9U]KJGH^S?;8S;'3M4OV96@:Y(\NRHLGI/,]'*.+,2Q*[16(F
M;M[)I&'VYJ.OM+H.F=5H!INI34T&NU^MH6;%6OWK7I5H:0%B1K2C[U(HW)'_
M $W/ ^,\;<)W;P#W=U;2-<]2BU@>.[VJU9G[-ND&"\EKK;K&U"()2Z(M%DB8
MDUQC;_P\R93:M5 QD@0CVI]XXM^.)">]D<@;I>?H_:W['4L< CTENU#2K%P?
MMW85)I(:QK0/VSG6&6-;4]F:*-#6 B"F27L7K6I=)J5'<S1F.M:IUK]2";L\
MV?U,*3UT**S#M4.K3,"4X!56;N&;%JK1:C2:2#US60 T72:Y7XE6$UQJ,VL9
M' PH21[0Y<=U*T265Q4Y;E9DX=7,4MUR4IUQYQ2H+8MV;5J6[8FDDMSS-8EG
M+$2-,[]Y?D<=I[O=>W@+P O  RT\CO(TK,3(S%RW/OW$\\\_3W^7'R^F4/HF
MR:YT8*6'1VZR<JHZ$;+3K!UNVP6BDY5+$5$W(<(3M'VJPL1YC-9.:\+/SH](
M58)+$2P4-\/"'R_?@I$%4ON49^K8X-MJHUL[@QI!O-=&T:VY;40[$VU> LIL
M0W8PAM>2I>&XLKR+V3*^;&2)M@%GK@/8[0MJ$%1(77V%A%)'>LJ\&3M!*R!B
M1PP.=]5YB>Y&Z:KLM@:47U?T1(6<UG*.B2 >%NO=TIIR&UL48(,QHLR?0]4!
MW9D.FF9,&/&-78W/-B'94>MPI2K-A3TQJ[%$O&-_N%\F^L4B2/JM2K!C2>2)
MF5+FQE56M1!F:*I"D4@5IW4>7'H8'BY7U=CX9>U@37@'N8BRD@23'@R*#\,:
MA6]V(RUFZM1UC>>LK7K&V8?9'62!A$(O!5Z1BL6"$ZW/KENK\K"D+A6"K&XT
M$X'EMK1EJ="9POS,J=;7'M5LK&IOU[];@O _QQM[QV(7!2>M,ON&AL1,\4JD
M'E'/'N 1AP3/7E25/FA]U/R=3[,C#ZJZ\JP_(Y4ZD=V:?J^NMZ[[@6)O5^^*
M0WD$=9G ; L3MY [_-1NQ]1+%B9B+@+O$9MHGFO D2+!73;\^N$1$=Z$PN3(
MK72MK83&[TS =AJ+9\V(I-")-:7^)Z.R\R1/3256)C\^8K#/$$G20AR%S)*#
MS-YM)/.KR<,O#+S"6]S%-RP*-&>5[GX5U 8,0<S#0E2M6U-F'^V.UZN5JLR>
M)=H_7G75JBYC6#6NIUO(E%[38!+F5)!;&VV2;9)'H64Y*5ZI#:U59<O+Z"\;
MF-N+-?7T(>G==8CL*D@M[J[7;N@O;'CMBKPR#^6HZV,F.%_:.>R\]E5X,39X
MLND,2TX75P#YEF5#RLL_N BM_2BA7X5/R9R[@>X.9]V<TX<V?4@EFUQ)@AMZ
MZ@.M[!TO8YOBS&19(3*F"M,.2F\H?^S-D@ES*=;8N'/0]F0CE5,O2@\+"</0
M[.+7V98+RM-J=E":6T@7W8P,>8[42GD>JHS=EJLW'=WHT8(65\M5)UB=DEY:
MO.OESJ/GV$\AU'^O$W#I^H(^1.=IHCL92]Z0R0Z%#-T[9M0BCL;.U+<!<\/<
MM>%YRI3'L2;,R)&C%1K\N!.2%LH5V:$/0V$S8$I2%J;;M[?26M2R.[16J%EG
M]!LJTB25;L:]I[XRK,T<@5T,L$H2:%B4=>1R:6*LE?AB5>)R?*F1@T<@'!Y'
M!Y4\$=RL RGV(RP7--F-CC&.,8XQD:[@IECV%K>TTZI70EKVPFXD9D;;17KX
MFBW&"$28\A"XLF'+::(QH[PR2]$E,268TQUQE2E)]->-<ADL5I88IFKR. %F
M3GN7A@2/8J0& *$@@@,2.?D9+T?NM=T]U)J]QMM+6ZAU]*:1[.HM]GD6EDKS
M0H6$L4\+-7DD2U$DL,D;R0HK@ ]RZ^7-4=T2+<A;EAV -S9*!7].+:7LRON/
MU6R@':C\SN:9B(7]N[1;'@-<LP205^9NB2P<!Y+4X4\:.1ZEK&UET^9QM)_C
MIQUQ[-\,J&/NE_'_ -)V,"W\K]ZWWAX]^D5_$OHJ+[/[_"_1OZ7K#8]03<&N
MWGZFXM\5],>^C\24C;K&.%^=:?LVOVTD\P^5QH^H^ZCKLYR19MB,_/Z^'Z>Q
MA_9=;6FNVP7$KZ)^WW,QS+N7-:%71MB<'G1R7-[R)!4?@IK\6@@1D!@UEX>9
M_I6?AJ:5U_%\,JA 9OY3YMV,>X?>_>-]Y^=W_E.Z([*"CPKT*&IU=:WTQ5JY
M]1JII+;Q:IN:/+"%;$$:P/SJ^*,7;142<1>).H>ZLMQ:DV?8D/WNOQ^F\^GL
MROK:B6T5'"ID;C?S\TA>-8&78AM:;!$:=W[AR7%]QKAM,Z5D>.KNDGC:V /1
MI7'XOY50H,O\I_2*DEN?-Y8_><?.L'B?T1$(@_A7H9"G5]O?L6-;WU4[V&AU
M/\P^(5Q-&B5VYU7%>,^@!;[N(K5UB[4 ]?E(=9$W!\7!KK]770QNP:[B*5V$
MH\FR6K<T05@Q@9]B6HE(L99!-A*-XD"Y1N>0UMF83)LM[#64;T5L*-W8K>HU
M[:X6>77T\TR]BVBPDY14?M,DJ_?K&79'[@,C74_B#T19T[.W@_H=H-=US'UJ
MVL[:LOVCIZ;M,_3B1MKRLTDD)9*M*3G3264KI+0$3.%UGS;3N%OS)E5@SEQI
M'VFXR_=PR5)GX2ZEVW*QZBE8IK3B6\)(N)QL5?F5YJ&A2,)7TZ'HKJKGD=4;
M)@VE;4\^;["XZGMV2D6B#74D,LX(VI(YX]\^5-C^TWX%,HC;P%Z+B>+Q0K]>
M-_%8RS=-5ID>3HU@^E!&QF57B?6\?P)4.WW)(S 2UPV6C]S[((2W&9&*\VWB
MY!<JER<Y<\EE1^N?M%2E1\+F.8S>4^+^4T9W++6)&PBZ)ZO/EL.K-H@CT4FG
M<><>&O,LJC:$M:X%>,O&QG/&V!CX0?+(M<_:B_9[078Y_P!GGH6R]SQ6J^(<
M/F4HN^#I>&>E)+T0BQZ)B=E92M9A75J/X"2"ZPEB;AN^Q0,-O4+7HZVZF;&8
M7 G5I8'[X ,J26,R"3S-V]%+[D5BGP$21&)TQU;>RFLL%%1*(ZN%!B$=#)T[
MU&\Z_P#E/?G,&FDTWG>:Y,]H^<J;,%I^6AC[T,<K'[1,<*'GN/&=+I^-7@W#
MKK!C\!ND-6-IXG4?$A=>*U>,:SI]/LZ2ST6RPZD+%<N)4LBU0AYZ16UL;*BJ
MT2ACBA=[<T/.<+K)<@J RY5D9<NX%*"4V7@KENX-96\M::9 R\'2_.G-M; 3
MY"&8U(EX&PTEK]3I/JE3"3U1LG\K3W-8P\X_'<LK:6'8#FS[PUC/ 1*W^D>:
MJE3QV\8>]_:#\#K*;2,> G14#7O$CI[KF%O2PDU>G=+-HI-CTD>W3#LM[V/6
M;2*:C 1TD%WMGSZ[$2&2/3);:,/,C.*5/FJ&/9"1U)N(-"S#KZB"V+-&]=:/
M1K47#H=)!\@J-;8Z\&<#ZL52,&.6#8Q=(=6\U..K-KQ5TMO4R!9?YS<LK<$.
MQ^.R%,=9K%8^;-SL1Z-?*;D(PB5_]HWP!9.I%?\ 9ZZ$9M[XG=/]?4C-3C4:
M;IW2S=-OL>D.Z'2,Z6MTFFW*^CH%.D6_A'.+M5H?4029(*[7=JM<MSTUN7>G
M(@YLK58 M_:#<@?*AG81&$NR!1\^0Y!&P1^'0LMLC(P/M8B<@G+%5\BZ$&(L
M]H>%>VM>A:SN;$KT]1<ULSH(EENW[,FP>GM'D:<-)!2-NFLGJ6-Z2*CV)[=@
M/FS^W%X::@=51ZCPCZ?HQ=1>)/376VM@G>Q+2Z=Z2TM;I*OO^B(:T.I*5+_4
MOV#U!-$NHB3IF"WU5+-9C[EF==P?116[-SL:RV^=V+L.!2* $LU,-UZS6:$>
M8V/9U'+:IR=$8&F9SN:\)%%JLB,7N\6);GR =4*(&A!XHPM*YQM.E-KTSN(Z
M%_9O9-.'XNWS/*MQSB22&4=[DCA9$5A(K.K0]H;CM*_3_3W[0/AQXR>'FZWG
M2GAIKM W5.W@FI6']*NPZ;EU8HU=A0_B]1$[I9J5F9/02UJ4T.V>2:N95D$^
MV'C(MCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQE$=YZC[$D=C6:PZUV%<I5:V
M934T2("&66)7A>I#:7*^XU<YK1 HPJ36WX8RQJ)DJ= G;"B&C(\>-$3Q$\B7
MK^IL:^U-8LS1[":%)JXBCB7N[87^#XQPX'OVD]P D!D;A@!P>M=/=?=*:G1=
M-:O8>'VHV][3=0/M=AM;!@\_;T7]7Q2G#U'=O+]1 J0V)9Z#)0@,E9GD8I"<
MG4/=67EUS%GV)"5.H S3?IM;,K[B85L$L 42MQO*^:1_U8FGX9YSY^&ES?B4
M3(BW]=(5/F,#;+:NZ>>-K8'\32N/Q?RJA>9?Y3V[BO);WE^(_>>WON8/$_HB
M(0A_"O0RF/J^YOV+&MR=59:RT.I_\W_$*HGB1*[<ZHBK&114L/+Y2M3]T'6_
M/FP[ 9R_KF-I-3>=F5_+T:W,.1D2-VKPV7]%6LY"F)2FSS;J]_+AR&'GM=L2
M77HD6IUEWWXVD_\ ,A7_ *?\L./OOQ_7@_%_*^_\IEI?$SHI?+Y\+M$>WK23
MJ,^]?WU#B0+ICS1]TC[U(K>VI)C7_1XY('%C:B[JHSYW;/L1SU=>KTSEMW9M
M?QZ%P<8<;7N1.6S2_-JQAU*7(UC\4]@G\Y1EW6C'[R>4&KN_^E;!_B9K_P!+
M^5/_ $OX_I_K?RW_ *S+C^)_1#*H7PJT,9'6";\E36^+5(X8ZHDT/PN 4-;_
M ,T@$D4.<JKVCU3VNJ08#>RP&UVB%7J\,U/9#+M[ 2I#YN$B6J+L];C4R3)_
M9605-B0D6(WEC;,:?'?9FZ\REP8Y.D_36IV]N=Z4'4MZJ[ZR:I7A21E22U,I
M'J>'G1>83VR.T7-\JH:%B$?MY3XH>*WAGI=='O=AX$=*;>"+Q U_4U^_/7@D
MFJ]/TYH9#H.8-1/(5NJ):L%:T8^E1).5O54,D7G:_P G;]I-)<RNIDI68RE5
MIO"[J&PJ:\XJ5Z=N3YE92BIHPN#Z\M]6+VVG$W+=+D*B1DD.A0]%]6#R@.I]
ME]WHY].WWK<O>E$_E[3CU/'DP^9$/.;_ $H!!\'OVD?-VP_:;\!9%OAO ;HH
M"WXJZOQ%C+4X"E;I>A]F>KZ()72]WK=AZ&[S1B_\BN[9N)8#&)%:CO5L7L*P
M=K>U+0"O9*3\V&MH+RH]F@0(H'Q</MB34LB7P.<DBDS$1E$<C8\RRPH3C\H3
M73DB(["SU?K72;VGX<^'-4=07?6TM)U!J[4T,DADV%K8U*]>M<F:64R&+7NO
MJ1*2UI7$0A*,[',&#Q/\,>H.HMAU#_R.=.S]-]2];=&]<:74WJE-:?2&BZ1W
MR;;>=/:]*.M%9+/6%60::2DL$.CEKO;>]%9BK5U.TD[+W1$\?^;RQ#X6#(J#
M?EV#74Y/SIF#&8=V9]S*0EFH0L2P22$PFIG8$=<4O@;4">!@MX_PV#I/JCFJ
M5ZBV8]/J;.M<*[??6IUM"*]PTX'EP&: F1P;P]*"C=P4CJ][Q[\&"F]$G@7T
M:YV_B)I>M*AEKQ*-9T_JY=')=Z7'E:@LMC:KJ]FAJ52G3)&^F]55>-98I(U+
MF=HPTO\ _1N414)R]7&DYO=?;6><F+,>UMD7UG,MMUN![@![YPJY$M[+39M0
M^L%' XIFT;6KTCU9%Z,GJ7:-Z;37]5(HD;FQ;M^M]/LAWV".REZJH5>4^OXH
MKY9'P*87N_V@? ZV.I O@+T7%]N>)?2W7=,M3C"ZGISIX=,?:_1S&MIPR3=1
MC2;L35J0'3)/5%D6X' D<1X9LM^AXEI33'"/QTK AE7WK7VD&$RE$<L'X2GE
M>H@%"PL-\LHHB%8XR5F<B:^<R)&(L6;3Z,ZSA:B3U7MY!4U&QUDH\UN+%J\M
M]:NQ0/:^-*)MTW+V0]U?0J(/81*L<ZE_:/\ V?MC!U4D7[.G0=-NH?$/HWK>
MA(:$8;5Z#I>;I.3=](S^ET4;03=41Z'?0-7TK0=.2#JJQ]IQLYN33P7V_P"P
MN]B?6;:NN2Y>X+HJ(HD'D?+V6X6 SQ#UH%D43!U?6XXE\=&?'@,KB%&!,V"4
M>(Y&1),85&)&IIX:>&^XUO7G16XM;>6?[$AV$&Q[HP&V\\\.Y:*WYGG&1Q%%
M;JU7:Z&L\5%\ON0(V>;_ .U[X==6T/$;H/2^%&NT<OB=U+K=QT=/#*X7P^UF
MKTO3=:_HEK_9<=:N^QO=/[S<UX.G7J:<2]1V&MA93)&WUB?3; %*WT(Z@P2]
MBF6:3+Z\ZE.,39J<I7!&V&D!#8D QYW7W%0ZZ-GQ0L1;CJO,Q!1Z+46-Z$./
MQSK2-X^M>M \C2ENK^IY 6_HI)O+SI&.23VQ(P0>_P E]@J\*/H*K?J['4=-
M3T]=#K(XNDNE*,D,!Y6Q:U_3VNI6]A)PJ*)ME9@ENS!4'$D[=[2R^9-)=KD:
MSWC.,9QX9QXXS^N,_G'&,<8QQC'A^G^'YQ_A_+\?^F<X_P#7C&.,8XQCC&.,
M8XQCC&.,8XQCC&.,8XQCC&55VQTTT?MXI(/&!!6MV":XITB9IA%D/()/+SXK
MD3H4J$3#O2W%94MZ;\8F;)6I2Y,AY7AG$IU/6.[U$2P0RQ6:\8XCANQF98Q\
MNU'5XYE0#V5/,[% ^%5]^>1=8>"/0?6=N787:=S5[&PQ>U>T=E*4EIS[F2Q!
M-!;I/*QY,D_I1/*3S+*Y (JW8?I_C-?SL6+64:7=51\)=88M!&&Y81KJ$^*G
M8'ECBP4M6%8RZT^F-$(L9REF,AY7BXN45^OI;\?I]FZT@WL35C<5Y 2. _+2
MSIP/8KW/&PY+< \#E-S]G#6]-VAM>F(9][+%P\2[FU#)L:K@#N>L!%4UTC @
MNL@AAM1^T</>>2U;[N(MM:6\BQUL\$RA2DYR4%3X*%9_.,*0[(80RZE7ZI<;
M6IM2<XRA2L9QGDAI2U;/!K6()^[@_=2QR'Z<\JK<CW^G X(^(#C('O:VVU7>
M-CK;](@D'U56> $_F'>-5=3QR"K$-]"1E>S1'U%+5E7C^O\ /Q_']W_^X_O_
M +_'DBAC[0 /G\C]./K[_P">3^0^6<NV-SN+$GW//']?[OT_7]^1L_#+GI.8
M0062,35YQA,05!E$)*E*\<)PF/$:>=5E7AG&,83^<^'ACFP5X8%[YIHX8P.2
M\KI&@]OJ795_4GD?X9#YHKNPD,-&I:NSGX4@J5Y;4S$_E%"DCGD^PX4DGVYY
MR;=;]!^P>V9T512O.ZRK#RTYF'[NRN#.;84KQ=]A55*;/S)7I_O1VYD87 >5
MY4N$V,9RM.HV/7O3VHC?R;"[.T.>RO2(=">/826@#71>?F4:61?FL3?(R;IO
M]G'Q-ZWM1&YK'Z3U#L//V74"-7L+$2#(:VF++LIYNWDQ)/%3K2-P&N1#EAOI
MTKJ"K:*UM7=9U#$A8H"R\IZ?-RA1 P4G/N3"A>>IM*4>XG3'7',--XPS$CX8
MA1\)CQFDIX/N]Q:WNRL[.YVB6PP[8TY\N&)%"10Q\\GMC0 <GXG;N=B68G/T
M8Z Z'T_AUTIJNDM)YKT];&YDLV"ILWKEB1I[EZR5 7S;,[NX1 (X(_+@B BB
M0"5>:K)ECC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&5S[ =I.OW
M6^**9WQ<OM2#:J]?[!$0Y3;K;H3]4UJ%BG=D&S&:E6;'&$UZI5P@T9L9(]F
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M;I.>U*UY,BW0=)APWHQ2MOME1KLJ(KU.7_M2AV!_4IVL2J\*Y+$0"U\*A"S
MUV$ZD AXB'4E??-.OA_UB]AZHT5D31QK++WRU8XH4;<2=/DSV'L+7A:/=Q2:
MJ=)94>O?1JTZQRCMSA;+[&5"FT:ZVJJ/#K\5I]91:\AHA&</%D1?I5 @]EBV
M1@AH1B4V"O-8-M06<293\(X&><;C0B3<]OS9V,,,$TL16PT,0E[ S*K)Q"QX
ME".G(CGB<*.21(A("MW"[H>AMGM-OJ==L5GTU?:7VUPM2013V(+'=LX%[];)
M;J6?+-S4;"HTK&.-):EI5:2:!H6["T]E-/5-@NY,LT@H^$/ :U.'UP$=L$]1
M6P;)CZA8:@,"QTC!9D7L>1]HV.2*7,9KAUE\295#))3$7ZFV=.$.6E+F.2.)
MEBC>1N^2R*8"A5/>$LGR92G(BD!1^UO;+.NZ#ZGV35A%02NENG=OQ37[E.C"
M*]'0OU.[3/9GC],UC1)]IT$L")K]-TLU!+ 3(.0C?NN1XX\5M%LJPF$$/W@<
M^^.(F2Z!P:@3!\2T'[3AZN"G:Q!JBRHQ-Y)2VI%3ISQ$>V2MBT38[JZC85E6
M1Y9HD"23J2K._:E=E$LDO,2&)8N]!.Q!AA+*&F^(9;/1N\FGIUM?K=A9FN4]
M3/&DT%6L9[6YBFEU]+7E;UE=A-L16L'45XF39;1()VKZT&%U'? ]U:MLMRE:
M_!7,62M\)X_&D"(Z9GCB;5LA\V(>U.<BH&R"8=FP!9<X;'F.SVAY.(1S'S =
MQ)Y<2[5EF->.9&F4R H.?Q1=GF*&X[2R"1"R@E@K!N.T\YAV^E.H:&KCW5S5
M6(-9*E*1++F+@P['U0HSM$)#.E>TU*W%#8>)86FKRP=_G*4SAO;WU.T?LM53
M;V)=FJ$]P38 (P6=+EH9AD0*L+H9F +%S))(RW7C8RP+$BVYI%(&0HSF-\9&
ME2F/)OU/,EB\X&6%NR2-4D=PX1)"@55)=Q'(DA1.YO+/?QV@D75Z/ZD:E0V)
MUCQ4-G"MFE<L6*E:M+5:U9HK:::Q8BC@JM>J6*0LV&B@-Q!5$GJ'CC;'(?:G
MKN1G11X_;=1G/SF?7@O0YCTD=.0K7T+:\=$(LS'6*ER"&M9[-X$1(\QR49K3
M4\H*9F1A9-<2VNUUSD!;D+=PY4AB58>G%L=K@=C%JQ\] &)>(,Z@A6(SY?#O
MK>"&2:?IG:0K"W9,DL(CGA(W<O3;M+5=Q9CC@W\+ZBS(\2QU;[0UK#126*XE
M[47V,TF8C@IL#80=8ZR/Q8P8I(9)P1$ETDV4=#9=+3H,8;!9L;84LNK29\J+
M'M6!\K[==)^EGGI-E1D$;+80K*0$<AU0]W>4Y=E"J).Q_*+$"7M/EEN,QK'0
M_5E5[D4VDM":@DDEJNC0368U@:NMKMK0S23S-1:W6&Q2".1]=Y\?KEK]PSNX
MNYM;3'!;,>QJ4^9EL0H$986P,2EKE/5=B+)DQGQ3<B ,E/76HMQ3!!N*)DYL
M8CT9J\36<JN"Y6)0"3WD(51V2 _$8@I(*<JI,\(#L I\Q.#\0S$DZ7WL2V'>
MB E6)Y9I%M4GC C78/)&DB662:Q&NIV9DJPM)904;7?$/)?CH06_-=30M=)&
M;=4X;]B>A-1W A0J;K\;!RWD:35')Y^97@20[=JLH]ZM@7K% "1S=L8G5NOO
M&9L/S/6X[]9DC9YH09"O'8SO&/,F:"$M(T<?9YLBF.,R*@>4-'&7(]\RWT;O
M(K5V"KK-E*E%)6<6ZU>G=D]'K(-MLA#2CO7#:.NH3I?N+1FMO4UKPW[JU8I>
M%[^C[GU?LDH0#4>XC;"2%Q'I\N-$;FM>,.*=*UB;)B.RXL=@BR.L04F$*+'.
MRL"R<;$,A[9Y^.AZY!<JV69()ED906('=\ED>)B"0 W;*CQOVD]C#M;@D<X>
MVZ6Z@T5>&UMM78I5[$JPQR2&)N)9*=;811RK'([P-/1MU[=<3K'ZBO)YL'F(
MDA6/^VU%O.RNOM_I6ML%LW4VFM)"9!VAVF$4Y@V\ 3(99L3)8(Y 3\5#G8>P
MDBS[IK*XF4NX?RTO*R/C]?EFNRS]0M^LP=NC*?5;!@?=:C]0370<=/VI$G"E
M4S=XFO3-"A'!QJZS(<  +M:;).8A-1L.4QTJ6>C16&3<],IGH$?WJ?[/8_\
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M9_-KS2P2=K+YD,CQ/VL.UE[T*MVL"0PYX(]C[9TSE)IKV%)=J58=2O,C*TN
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M8QQC'&,<8QQC'&,\>&,9SG&,>.?#QSX8\<^'Z>.?USX?RXQD$ZS_ +6NR/\
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MHV_:@4!0H 4   76YN\Y1CC&.,8XQCC&.,8XQCC&.,8XQD&]AMQ/:3UTNR"
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MU7:C6!QJTG?8M.-.3UB0\QN"AYA4M;.'VLKV6MT^RVS2KKZK3B!0\\I>*"O
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M/7=16>FXN=G6)];6DMQS6'X)XI]]&UPX[K#>7SZ;XT[O?,[OZ B*?:D&#_\
M"UZ-V.O&*R16EP,79A/0QR?W?R8<:)0\K97A(YOUO*LEC+;N$4.\H+S\<GPU
MTL^T3>Z.%*J/]OAE]CPHY_%['$/@?U_,$:.EK^'ZAL]-CG9U@5N4WG2:PWO_
M #,-6F"NO-ENSD5N&3NB#>W<G4I#7LFO54D<^0,4^N79./M^9%C-UF>0B9Q
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MZBEU$&JMP@_BUDLN_P!2LLLICN0^J+24>V"R8HJ)?!S),/U2<]N'*0F4^IJ
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MCP2K.*G=T1]9?:J+?\F?Y,D +\_Q^X_V/]O+:^"/73=H\K5#OZG?I4<[./\
MGT8<M9/"'^(@1O[^]P\>U+W&<=CO+H>0IQ#4RUJRUKE[9B_&L24XP'8:R\X,
M_>>QXF<(QG.,8\0ZLX\$F,YSCQH-[0/R,W\V-G^2/X![E/G^/@<_]7_ZS+C^
M!G7D84O#J0'ZC3ID?Z3B/\<D8(MH\)_,BQ /_P!-'UI92OLEVAI]IM=>(!Y)
MCX.?K@59!3<H8]&=;CSGB+[[+[&5J2DCEQO++N6UNPUXCM81.6G"<YF73W5N
M@IUI(K#6A.U:?9,5K,ZF&)!Q#R&Y\WMC9U' A'OW3 GC.*^(W[-7C!N=E':U
M\&A?7P]14.AHTDWT$,@VERP$;8=DD8'V<);4$;E6.R(4,FM9$+"A.SMBEK..
MC0*;9VZL]/C.3R)>;7%F9[ GT9"7&0S"R4.%&,^LWCTY4]HG!:0E:LQGEY;S
MF=:[K_I.%HVF382A]--NHD%=HT\FN90\4Q'<YE^XEX2,K"Q7^= ,">7UOV6/
M$NG:V-G>]/Z/?0ZWK[6^&\.M@ZSKZRO8ZEV4FM:G>NR_9\\\W3A3:5#/%7EI
M;IFF[?1H(Y0NEVIBMQW3>VZZ+K?L9?-65?65B@21"6F9!Z1*6;=E.SIK^4&@
MJDDG9L>3/EO*6]B;(F.)Q[="4)5WJWUYT/J.CND.H-IT^NR'5&EV^QB9H/+D
M$&EK);LQ2JL=@+)Y#]D0)$7,1!E^)>Z([WP3\2MSUCOJ=O1=+[7JSICK#HOH
MK=^GW46LUVLM]7;B/IOI?[$-FJ!-I*DYJU3#&D=RK5:%S4L$6FALW:.JF]K,
M/B"S_P!038AV 5%8L[40AK BII&!$B1+95G_ *R5J9(1)8EY^,\QG*&WHR'6
MY2<J0K,&K>/7AK"]9HN@U@:SK+.RC99 2*\"6?.BD[=>?O&6K8' [X6"^\O#
MKSTB']ECQCU,^WV&MJ=/I:T/66NZ M30]15HI)=AU$-13AFA,L(674SQ]2:V
M*RMCR[ICMNIUKF*94Q(GU>[$%65P)W>6\3A94+,DY3(IA3#DB&G$J/-C2F,7
MC*6\*1%E(\42WDNI3X>.,.)\<VMX[^&C>C9.BC$]G5W=S'SV\)6U_K#.KE:9
M/GC[/M%%"M$?*]I?CC[XQ;_90\3])/L]A!TYTM)L>E/$?I;H.1XNHJ2 =1=2
MOTU-H+]"2>!?,I>9U7T\TKV(:URJ]PMZ)A4M&'B5[J5LY3D$<?[O;%!@VHC+
M<10+5"#V8L6+A<=+7Q<S;5:80S';CX2A#,MWQ;3E*4?NI2NH_: \/YO2FGT:
MLD]W6[';J+$\E95KZU;TEE7EBU=IO4$:ZX8UC1XB8AS,I=><'<?L<==M>ZIV
M75_1_3%C[)\0>E^BMIL:N^UVZN[/J+KRWTTFMOQQ;!]1YE&:UUGH6O3W[%6\
MAO22>@E6O89):[/BM]ZNU6/WF/\ JN;LVG>-2"G+-KZLO:?*TR?69Y@A#I!4
M)]VHVJ>36)4\!/EN/L#A9P.2&16(DUQIN3$=1B]#^)/AWU7U'I>E8?"REK$Z
MSBL.+,EJ.S#+!1-^7S)X/LZ+SF6WK+$:'S0R2*9 X!'?UWJGP4\3^BNF/$+=
M?PXKVJ7AILM7H>HZ-&?L,=N_K^GMK3AK)YY'E1ZOJ?27!W1QNB6UBCB,L4Z0
M_0)T<JVSNVVA>IN]>Q6XH&R:O6*/K^WUO78*DDZPT:VC7J]"A-7[<5C/6BRD
M-B6H"81.*P$"(U9J;MG].TX%+?;BP('*.J=IIM3O.K]9TUK):+_;N_T]FW8L
M)*8*M7:VJL]'55XJ]>.G4D,'E=[M8G-7[CS "S-(:]>YJ--HHKB'U^TZ5Z:V
M\UMK"V&FK;W14-M$R]BKY3SPVT,ZR=TJ,7C)(^-MMW.>YB94B^Z!V,+V:<W/
MUOV16];W&[P1<'9]/OU,GWK5^QI(&-\> M,T6#M%,L5<NP@5E(A9\*<RP;#Q
M!HXP+?5 BS&I'3W-*2A%J]Y1GO5:CR/K[-.TE3845E8O-7226O:AGJ2R?>"&
M6'F*1G>*1>]D.;'9B,2P6HFECC),+QN(YH@QY9 S*ZM&3\7:R_"Q)4CDC,GT
MGH8I0+'<-I[-O&=K;PV#%&B;#=D@6ZP!K]1".2) /7FNZJDB855Z:-F2Y9*4
MV^7)E[(<DOG#Y&7*]HU"L;7;QW(*VOH5/L[4TVDDAJ><;$TUF4!9;MVQV1>H
MM.BK&I$<<<$2B*%%7N+^)[ D5(8H_)KQDLL?=WLSMP&ED?A>YV  '"JJJ J@
M#DFQ^<85C*58PI*L9PI.<8SC.,X\,XSC/XSC./QG&?QG'-'F+E&8'7#?FI%&
MJIUFWA1:1J \5)E1='V7JDEL.;J"0<EO$3$?4Y43L"F1OMQPE*E$!%/MPXR+
MK[SSL8?)^,<;@QI:^\T^R\JSOM3;M;*&-(Y+=#8QTDV8B4)$VQCDIVF\\(JI
M+9JR123 !G7S 7;8&U7F[7M02/,J@&2*81>?V@!?.#12?%P &D0@M\R.??+
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M(M;(YI0VD3<DRJGJA%RV"960RN##AJ& LBHE'X1:)2..J^ERRQF%2D\2E*[
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M'NRE.+3:_80<K#S_ #SCL[A[^X(/((^@7D@@_/D<_IQ\_GE5]O\ 9,DWMBX
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MRA_ H^O)Y_M '/\ 9[<G\\KP17MQ5R[AKZZ/W#/:R+]:^DHT(Q5GS7NW-#/
MM1IVRS96("_;+ZM_;^-CNW7)U&=8L6=KU5*;N&!ZN,K]!S\NP\_ES\7;S^O'
M;^O''TS:GOIPSCZI&MV^QZXJ.C?]!V^KU]]\*91I%SMC^UP3BX8O*B6<595^
M;T9Z"M<(M^<^4)G8;E.Q\EBP92SS[=O^UW?W<?3^OY\?IS\\UW:CT3W)W)UQ
MZQW&M;3NFL^Z.A9';C;?4-&USAZ(9VEH$+NNE#--ZC[.U\[,C6*QT;8VIRAJ
MMA2%OQBRU860$V9B<Q+9L31!GHE>3Q\B%!]OT]R/GQP?\D<9M2ZOVO8NY=0Z
MPJ&P.F-BH.L-QQMAWS;2S%WI0:-J6VD]J;&LY#3UGU^N4)O5BP-*"PU3(2QP
M-(,D,+MM2F&Q,8G&99Y/L3[_ *#]?;CGW^A^8_J_?E-/I]S!-%U]W6V)#@)1
MN&;]1SNIH?0LM3PR*071-E[=JSFMQ=9AV,B(KY>A5T;7(5RI M^;&K;-;KYB
M)5I4"$6G>X8;Z?\ L@G_ '_W_P!_M\\IUL+;&Y)OTS+9UAVU,MIOLMTL[Z=>
M=%S+':)JE6G:6GH_8:D&*'L:<=K[UAC3QQO2)"=4]GRQ!&P,1%U*[)L67HJY
M+3S/7P]W(^14G]Q[3^?R^+\/('TXSV #G89H.7J-PQLC7=)B?6$ $N[_ %XK
M[]FFZ\T'U,.!/"@1-;VY"8DJW=-=GFQU2ONS[8##4>G(C6.QA3]$JU,C7!\T
M_P _Y_S_ '8(!_(GL]O<>YY]^?U ]@/?D@>YR4OJ([)H=MZ]]X0/7S6A2CR-
M5=AOI_TN'?*6==FZEV=F=M&E7LT9TT-JT:.(A,@M=W6QU[>CM94QA>81D;8&
MYT,=.+S&% !4DCW#'W^GL0/[QR/ZN/GDP]UJMK<G],#NO:J'$I!3>=#I6R&E
MEM#N37=>U[<M['ZW:>C:08$O+AQ#CE0J&O'8SU:;58QDDT78(346ZQWIA]GE
M?Q+S\NX<\_ES[\_[^<VA!Y]3T3UF!EM9#Q0NQ;3A4./3Q0U\0P.,;9V!6*M5
M!DX6.+$A=?0VER U:[# 8E#HD] VQFY:_D)Q&8\P?<_I[_I[#^K^H>WZ9HME
M;C[;1NE!#JG;B6Y"MKZ=_4.TYICN'>1KY*9MV^_38-[!S:G=I1#FO)A2=)D/
M:Y*5^B[8?U\8)S0 BKWE!68Q"7/=RSUPO//MP5) /'XN/E_;[CGCZ9L_[1ZQ
MZJGNI';_ &+I"%3RLFM=7=BOU)>LIN)&LPUY!ZBW!!H)FD0:PO-!3LYE5XFQ
M_=UWU;8TY)I$F:VQ+9I\G+/(YY'/U(^?Y<@_OX_S^>4!L5/$5SKQ] ^Q 1\@
M;9=@=@.EI?>SL1R8B0<Q#ZHV85?2NPXV%_U9%UB56+?Y!QM#,ZXP0*[+ZMB;
MC.*H/D.?GQE1Q\?R^7M\N.>X?+]>.>./?CGC+>]9]';%UMVX[;=2[332A_JV
MYM[7O?+46Q#C?R0<:-V-\VW/Z^1B,IQ4@<Y1-ZZX?ME3$0W),>#K"-.KA=$(
M'8A V;7*$\A3]?=3_5]?ZP?<_,GDYK<)5%LO]*?ZLMZQ +3=ITKM+]0H5HXD
MRZ4<L84!:MK5S% >UW';<S+:2^!KX:'K8D :]6%7G9L"HR&!9<@S*9Z'XU_+
MX.?RXX'=S^G//=].>><N3WYH,/KEU8ZV=^.N4!J!MKK3L?36R5T '(()K.^*
MAN&%0]-[>UJ1 "438>,D:X33L(>;A@B<BGV.NV.[08+9,U8B4AGE?<D-]01S
M]0>>1\_U]C^A.;NM54H30Z2,#BID(LX0?(VD[8H$:/$C6JTVV?(L5EM#4:*[
M(C1HQLP1ES1\"+(>@B1;D$0-6D; AMH9YR1>,9KG^HM&)1X/3FUQVIC%;IO>
M?11;9QUC#S8NOZODP;H,L$ZXS6O!B%1U&YE7;/O%EH!MO?&22F4-QFWFHWU&
M'"Z:50PCAWU!K3CGMCJ%9TD,Q'L(/,,7F=_W?/:7]EY'<O YZ\DOBCK9&B>_
MM/"#K"MT_3?L:Q=ZACFU-FE#JXF^.7;BI%L#22L#<9?41U@6D96Q+?6F%;XD
MN/:DV3^R?94O9]IVKU\V;79Z8<(E;J5K[64!MTK"B>*+KK>Q6(39A=K%OQ2@
MDZ.D2K!&BD5I'RGK>PI>O)-.SZ.T;4MK7VHV"AYH*]9?C4?R]661)%E0ADD4
MF0!OA)V'1O50Z.15ZET(ZDT$?3VOZ<ZVT%Z$RRP:S;;O?S%:TLG#:K?4:-FC
M8UMA):]FG.D=)Y(!Y\:5@L5CLUO)?3]M&\-;0-0V,]VKWY'[#4>=EE-7A_"T
MN^UDO+.S'_ >1U^;M0<29JA$P_,&3(Q"L28\^;*7"F/:J:669NGI;U9:<DFV
MOC8P,1Y0\N&Q$[2,?A:L\R(\+N2C!HF#%BI/0:-#7ZN#QIU_26]FZFH5/#KH
MV3HG;PASL)?5[337ZT5.-/OH-U4U]JQ4V,%5(K$4D%^.2&%%EB2"W'-^H5TX
M:M3[V(6>Q7?%C4CN_P!1AR#(Z]XUW:T]?%[G^ZE8)O 5F\Q,4U=\RK*F?M-Q
MKSXS#\V!_I#_ $,)2>T[+?BI]H=Y4Z[TT_V=Z[S?B,??V^1ZC_U/']')>!T:
M1XHMKD7SOX$>#K]3+T6*HFCZU.\UQZU'2GV<#76VM3S?M0:;@!_M)6X^]XM-
MV#)$J]:P.Q.N,FI[=UE7=7U^J%>M%M^>!6DW6).X-DCH=ZZ?;!:<<<3LJ03C
M31$@-&8DP3],!:[4MZ7'F5-"MKL2T4L=G6F&Y5BJQPOJY?,29XC<LJ)]/8')
M]46#*4 (DACK'D@PC.>=%05[VNNZ/KI-ETSO[W4-W95NOM;Z.YKJ>Q3IC0SR
MZ?Q/TK*H.@2N\5M++NDU/:W-XH2)XMF17O=CIE-1^H1D9F8X31]0WK:BFM)?
MF,K54,E=-_<[(-V.W(?9J3B<W=%D4*8>%I95:E3V7<8*(5K[Q?R>H>SN+_PB
MU@@ +#[GNH^:(R 2(?>SYO8"G!F[@?BR:]*)5^T_!06!$M<^"?79VC%(F V8
MK=4^@>VCLB/LE_T2:(L.M@L-<(77FN1U=\*W5G0^Z 5F^:I&SQ_U)=/DYFDW
MG2\R@ZGUN4NE2;B9U:?<]L[:]*WJEPYMUL!@6+JM>0DQ9ALFG 8\64^4\6&G
M%"[')WP6EZFIL:/+FO4K//"!Z63V,M*Q K3R.JQ1_'*K0Q@-W9.HKZI^L.E;
MFO\ 2[?I^?P'ZG@CZL1:T6YZDWM?5;-I/X0TE\Q==U9I]M+%J:=:Q9V5TFK0
MGCVMQY(TK61W7(I7GZ)1H;]+4W'[B 8G8;[+4VG47RK^@ITO8K _][-?SK')
MZ76'"#?F56FK0ZE@EG%E:F-M[.ZT/.A ,) W"#8^3_,^_P"SV:P%_P"C]*)3
M$6_Z(2GXN)0W$$Z3CVW'C!)*FU#R>&%V3HG[5!_A-Z5.LXHM&\_L+O\ "#T<
M=\0MP+[4%+UQZ!HBWB(KN.U]-_NLG5Z]F.71C<6\F^H;Q!1YW:;G6!%]"IKK
MM=<,Y5<G2GV5]^YU<[*RJQN"4U%8#.4Y"9Y13N?X-[OTOJ?.%V\-.6\TVCJQ
M/'Y?E]_,Y?R?4"KS]X4\GR^1V9ZD'A:WCKX3_P (!H5U3]+=(-XFK"**].KX
MA'36S>6ZM7C4K6^U?L7^$*IQ0%G[46]P?6 >O=3GAL ECJ^X\O1/_)[[\5O#
M()<I=039,5UO.@G"JDYS"QOA9OYCQ5(SC8K@/$I1CS1T0<I7C_&'^RR?0_P=
MV/KO+)\@2]@^S^[W[/M#S/,^?\9\OGO^'MRG2:_Z&KGQ!5!UA_RU=&+TEZP1
MC9FB;Q'6:UP?O?X&BIZ7VC_T$+AC%7B0S<PO=Z5;!_TO=1WPB+!C]EG&^CX@
M25JK9:)93E89?T5)N;FS6D.8)$KS"LBMKL7DB]CWV*Z^6C%W/:*FMMX4\$J]
M+T[#)&MI_L)$>'O662(&@9_4C\33B3U8L,??RRX?X>[)7J=MK9_V@^IM/#8N
M3:"F_BY9LUMB:TE"G?9>L$U8T#%?(KZB77CIQ]1 I\GUJ5Y*R^9Y3-MJK%5M
MU:%HUM)T>)*5;<$RVR]L6K7-P 56B51LXRY5&E *M.*1+/B&3I@D%,7]L1TR
M,DYDTI)5@W*(2');%%-&GIC11HKC3&W+6FCBKQ!QY0,<3,).'@2-ONASW%F/
MQECGS;L-CK;]D[V/JVS7V/3$6MCZ<U^\U=S8[C8M4<;)A=V,->37F6OM;-R)
M3L'*>GBBKH/21P1BG?6=VM4B]]\KK("P,FJ+VUG@M(0W76@T54>V:OHE,K-1
M /N2!\&-13%Q*D(KT5M]FK#RS! X_P"VEA9$V+IM7Y<%C?SLB]]?;O'0!/8O
M$U6"&*&/W517>9V! (B5PSGM*%AT_KY;VVTW@[JH[4XJ[?PVAN=6RJCVI0VM
MZ@V^UO[.ZBI--+MZNKK0RK(R/L9ZSPU$\R.VD4E6=Q[ V^+Z,?4/ZT;&*W@U
MNC1UX8L.L[@35'5=KSK?;NQ@.P:>3@$JI-(0)MNJ[INQ56RPJE.?:KD..''Y
M;AQI+47&KN6+B:+J+66&L/=H3+)6F;CSYZURS'8A=6A9E,T7F212K$Q\M0@(
M56 SHO2NEZ8L>+_@?U[I*VHJ]*=7:EZ6^U<'>-3J-]TQHKFDVE>:OL8H9H=7
ML%J4=E0FV<*->EDM3=TKQO(?=;RV](KO;,((9N^OHL[MMU=);*TUK&38B-.K
M?29ID0+OFVNOUH#,#9I\;MF#Z1G;N:0!K<VK1XY4>;#L.+FEBJ9KX^UD03UU
M.XU36J55I6ACT@[%L6]?-&$9TN)P]SR(XC$%='0'N=[>MK=(2)X:V[+:C=R1
M>&OB%!H>J>H$HP;._P"+#/:LZ?IKK776WL0TK'34O=5Z9&WN7XM@\E:>I:=1
M#6K2)WLNU%,:%[U5+0M%FA2=$T[I%0:_ZQ,8<H=K(6>_-$ 8_7XNJ,(&,[!!
MCX9ENUS0JVCB@;]=BS7RHYH>D3D[Z>N]#>PT(&1Z].AV6*K\UY6EL<HM=81V
MBQ&JN)F3B3RS$K%T"]FC\']3MZO67@_LNL=O#;K[CJCJP6=-U!5[=SKJ^OTK
M0VY]S8V3FP^EMSRU6UT5H-4%M+TD25YVF-FQ.Q .MS74_M=/A,4$ELFH:GW3
M:,.ZI4I=$%6PQ3]F@]3DZPT/=<%M;&328E9:D-P<J.PC$L806VV8)19;^RL)
M6?4[5E].UB&K=EYJ'^+I,\5E*C1A24%D0"($#XU=E;CO<,81H[F\J>)/AQ#,
M^Z@T.SZDZ3UY7J0!=Q8UM;9Z"WU)7V#3JMAM$=M+?9&FXIRU8K$(9JT$L23_
M -7I%1U1TTU5LF9%2/D3= ZFM=\4E]+,L[<X>L:R,(JE-S'FV<6XR3BM")^7
MU,S")_*<$<K)./N+V&K,-32U++#M)U]26?WX+S"M$K$]Q \YW 1N>"TGXOBY
M.0SQ!CV?4?BGU'H8I#.D76?4FMTX["\5/5R]07[$ B,2,WV95KR-9A[ \4%(
M$P 0*BC7?:-G]RJ;K;ZB77@ _=C'83%:C]B^N9R/[ @?D4G;$F!^UBE4)RL$
M#,",:U>9C7)[6H*"1?M:Q9VKS(<3W*&$IC<MO<PUNH]=&9WV/E#9:V0=K2&"
MWV^K@KF)G4/5D6<UHU8R]DD1 YXSMVNZ>\+=KO?!#K>ZNJK=$&^_0W7--_.@
MI)MNFXYATWM=R-A#5EDJ=0U7U:[ZY- FM6Q3V,4L@C9B=B>K:'U+NU>I,^C,
M@3@P!0HKQ**S.ER(TF%[ZIGO=[IC*<5'GWN*;KL.:]G92EV_W[5P]9M["K0E
M,DJP:F>.!H.QTCK@LO<Q!7F*3F\.>&G#QJQ]3S-W";GG[W.']0[GQ)U5W;0[
M=[E2Q<W$BP2-#&CI+Y6RI^5TI)VAX=/)4O2PI]@@:WR&UG8R<:XG4()KSK'T
M@-77;,4PSM\OM'70.RE<NDT7,D.%]RIDAUDTG*\%7W(&OIY1$B1+1F0BC2I$
M:4YFO80VB'K&1TA5GX<6WN5HYGY?SF1=T21)[]Q[:[,&)]_()!/E\#/IJU=5
MOVG.H=3YE5NF:O3^]N:^MVUSJH)K'A=&BM4]O3(LVZAKE$C/8=O&CHHN\D["
M).K+I4NZNRJ&'KDZQ]=NYNJ@U[/%,8]Y7]7V_4)<+7=CA(N,N80&%[<IMJK[
MHI8U]J:U=Y4^QAXS7QA:>W(C5GAW=F!(VEUVYJ).[>QBJ34W2.RB_P"HMR&6
M,IVGN\\M*@'8S9Q2/J'5;+PHT.XLWH:/7'A9U':T]*M_)7>H-7U-5M7M%;D/
M:3:L=,[76WEL"=&A.ICAHVI6]35A,8TRK #^U?JJJL(]N8*IUMJ5AUO'FY<P
M%'RHO5]P3+E5^&M6!SL6%:C!YQQJ(TY$B77&2.4-V*"S(8Q(8DDM]6>8O<D$
ML,E4-^!"-5V,8U/P\+,\G(4<+/RWM(O(W^TV-RGT[^SJ*4S16-IK=E2WKQ=O
MJIXY/$%;,<=V4 SJ\VOJTU5I&$DNJ^X!:C,Z/'C.GLD_I.:PW/69T^H]A-2Z
M-U=OD58_$@X4.[4TB$E61RKW(+Z[3MFGWY62M&M @LW(G'ITP&@LP0F5X.Q'
MQ_1E^DJMV)FAV-.A4V"R_$7DMT4,IAG3D&5K![H)4?EI&:/O#-&@&\/5 K_M
M(=0=+7XH=GT5U+U=U!T;9HGR!7I].]66XJ V&KME'77PZ8"MM]?9K%(J4,5M
MJSPQ7;3OM>ZY3&[5JRL[9ECX@^S[L"U_:-MBQ?WDBRMCKHE4:J^KEMA;B:4*
M9@5-;SD6$_/FB9QDA!BERI)&99K6\VI%;*A9;R1VIE']!Y8T(B^G\@@6(GA2
MS(SLH=VSYQZXB.NZAO\ 3<<TDVOZ4MWNG];))\[%>C>L^9L>WN<*=M9>;9!%
MDE2"*S%5@FDK5X#D[\S\A^.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
;8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img61678762_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61678762_23.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3J#&,# 2(  A$! Q$!_\0
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH \@CO+B-0J3R(HZ*KD"BH** /0/A__ ,@:;_KX;_T%
M:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q
MFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH \9HHHH ] ^'_\ R!IO^OAO_05KIJYGX?\ _(&F
M_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF33);Q/+*ZQQ
M(I9G<X"@<DD]A0 ^OGCXO?\ !0#X$_!6_;3M=\=VE[JR$A]/T1&OY8R.H<Q
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M#X>URSDT[6=+NM(LKRTDQNBFC;4%=21P<$'D'![5^H% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?.'[2G[?GPG_9:\1V
M?A[Q5=ZEJ6OSQK/)INAVRSRVT3'"O*7=%7/)"[BV!G;@C/K'P;^,WA+X^> ;
M#QCX+U,:IHEX60,4*20R+P\4B'E74]1[@C(()_+;_@I!^P=\6/%W[1FM?$#P
M3X=N_&6A^)%MY&6Q97GLIHX8X3&Z%@Q4^6&# 8 ;!QCG[-_X)J_LS^*?V9?@
M+=Z7XR*6VOZWJCZK-IL<HD6R4Q1QK&S*2I<B/<Q4D<@9.V@#ZSHHHH ****
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M+;[:R*6^SS*@ D#@;58\JVW!QN![O_@GCQ^Q=\*@>#_9C_\ H^6@#Z*HHHH
M***YKXD?$;P]\)? ^L>+O%.HQZ7H6E0&>YN)/0=%4=6=CA54<DD =: .EHKX
M/_X)P_M*:Y^U)\8?V@_%^IR3P:69-%ATC2I)"R6%H/MX1 ,XWD ,Y'5B>V /
MO"@ HHHH *X;XN?&SPA\"_#J:]XUO[O3-(9RAN[;2[N]6/"EB9/L\4AC7 ^\
MV!VS7<U#=VD-_:S6US$D]O,C1RQ2*&5U(P5(/4$'% 'RW_P]&_9B_P"BF?\
ME U3_P"1J^E_#/B33O&7AO2=?T>X^V:3JMI#?6=QL9/-AE0/&^U@&7*L#@@$
M9Y K^7'4(5M[ZYB3[D<C*,^@)%?TK?LR_P#)MOPH_P"Q2TG_ -(XJ /2ZR_%
M'B2Q\'^'[[6M2^T_8+./S9OL=I-=R[<X^6*%6D<\]%4FM2B@#YEU[_@I+^SO
MX5U*33M:\<WFD:A%_K+2_P##.K02IGU1K4$?E6?_ ,/1OV8O^BF?^4#5/_D:
MOF'_ (+A>'+#^Q?A5KRVT*:G]HOK)[E8P))(ML3JC-U(5MQ /3>V,9.?B_\
MX)SVL-Y^VI\+X;B&.>%[RX#1R*&4_P"B3=0: /UQA_X*@_LR7$R1+\35#,<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'__ "!IO^OA
MO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLCMA0R@$,PSD'*_IOXF766T&^'AZ2QBUORC]D?4XW>V$G;S%1@Q7Z'-?S#^
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M_#+5/''P_P!.\-:U8Z%9R7NJ:?K:SB=HDP6>%HW5?E3<Q5NH7@YX/YY>%_\
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MD&@ HHKE_BGXZ@^&/PS\6>,+F/SH-!TJZU-XLXWB&)I-OX[<?C0!\J?MP?\
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M5KC<6EC\^1ODE8%G#,K[L-WQD ]W_P"",?@'5=:_:-UWQ5#%(FBZ'H<L%S<
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M9BOH*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1?%[PGJGP^\*?#_3]>L=0\4VFNC4+W3K6999;.-+:5!YP4GRRQF4A6P2.>E
M'R]_P23_ .3TO#__ &#-0_\ 1!K]*?\ @JI_R8YX^_Z[:;_Z7V]?E7_P39^)
MOA[X3_M=>$]9\4ZK:Z'HDL%W92ZC>R"."!I+=PA=SPJEPJ[CP-V3@9(_1_\
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M ()P_M=']F/X0O;_ !#T"^@^%>L:S/\ 8/%^GV[7"6=^$B$UO<(F6"LGELI
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M6_9#F_:J^$$#>'XXO^$[\-N]WI'F,$%RC ":V+'@;PJE2>-Z*"0"30!\R?\
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MF4,-RO@KGD"@#\/?^"JG_)\?C[_KCIO_ *06]??_ /P1A_Y-0UO_ +&V\_\
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MXW_(J_"3_K]U+_T7;UXK_P $5/\ DZ;Q3_V)EU_Z76-?7_\ P5Q^ OB7XP?
MO1-;\+6$VKW?A.^DO+NQMT+S-:R1[9)$4<L4*H2H&=I8_P -?FC^P/\ M+Z3
M^RG\?!XKU_2[_5-'O-,GTFZBTU5:YC$CQNKHC,H8AXE!!8<,2,D8(!_0Q7\V
MW[8G_)U_QA_[&W5/_2J2OW4^$GQNUC5O!.O_ !-^)R6OPP\%WL\?]@Z9XBEB
MM;BULPN!/=R,P"RSNQ(B_A54 R6)K\#_ -HOQAI_Q!^/_P 2?$VD2^?I.K^(
M]0OK.;:5\R"2X=HVP>1E2#CWH _<7_@F7_R8Y\,/^N-]_P"E]S7N_P 4_AUI
M7Q<^''B3P9K:;]+URQEL9B!EDWJ0'7_:4X8>A45\I_\ !*?XQ>$?$O[*W@_P
M5;:_IY\7Z']NCO-%:X1;I4-W+*LJQ$[F0I*GS@8SD=J^U: /Y??''A#6_A#\
M1M:\-ZGOL=?\/:C):2O$2I6:*0@.A]"0&5AU!!%?L!^Q_P#$74/VY/CEH'Q6
MUFSDAT7X;>&X=,MXY% CF\074?\ IMQ&.FU8P%QQC=&17SW_ ,%E_P!GUO#?
MQ,\/_%72K4_8?$T:Z;J1C7I?0IB)CQUDA  '_3!O6OT1_8E^ Z_LY_LV^$O"
M<\(BUIX/[1U<XY-[-AY%/^X-L0]HQ0![K7\VG[7VBS:!^U3\7+.8DO\ \)5J
M4P+=2LER\BD_\!<5_277Y/?\%;_V-]=O/%G_  NGP=I,NI:?<6R0^([>RB+R
MV\D:[4NRJC)C,856/\/E@GAB0 ?1?_!.?PC\+_B]^R-X)U*\\$>$]5UK3TFT
MK4YKC1K:6830R,%\QBA)9HC$^2<D.*^EO^&>_A9_T33P?_X(;7_XW7X1_L:?
MML^*?V._$^H3Z;81>(?#.K;/[2T.XF,/FL@8))%+M;RW&XC.TAAP0<*5_0WP
M?^V)\1?^"@3-X#^&/@N]^'WA:XVQ>*/&UY=^:]I:, )8+4J@43NI*JV20#NP
MN-R@'Z!Z1IMAH^EVMCI=K;V.G6\:QV]O9QK'#'&!\JHJ@ *!T XJY6;X:\.Z
M;X/\.Z7H6CVD=AI.F6L=G:6L7W8H8U"(@]@H K2H ***Y#Q_\8/ OPJA67QE
MXQT/PNKH9(UU;4(K=Y%!P2BNP+<\?*#0!^ O[?G_ ">3\6/^PT__ * M?>O_
M  0^_P"1!^*?_83LO_14E?G%^U=\1=)^+7[1WQ#\7:"[RZ+JNKS36<LBE3)$
M,*KX/(W!=V#R,\U]E_\ !'W]HKP'\);CXA>&?&OB:P\+2ZN]G>:?<ZM<+;VT
MIC$J2(97(56^>,@$C(S_ ': /V&K^:7]J#P_=>%OVD/BAI=X&$]OXEU#ENK*
M;AV5O^!*0WXU_29HFNZ;XFTNWU/1]0M=5TVX!:&\L9UFAD )!*NI(/((X/:O
MS$_X*O?L/ZWXIUX_&;P#I,VK3/ L7B33+*,O/^[4+'=H@&7&P!' Y 16P1O(
M /J?_@F/*LW[#7PP9#D"*_7IW&H7(/Z@U^<O_!9:Z%Q^UMI\8QF#PO9QG!]9
M[EN?^^J^E/\ @EA^U]\-O#/[.Z^ /&7B_1_"&L^'KVYDA77+R.SCN;::0RAH
MY)"%9@[R H#N& <8-?'O[4U_JW[>7[:VN)\)]+NO$UK(+?3;"XAC*QF"%%1[
MF1B,1Q&0N0S8^4KW.* /JG_@ASH=W;^&?B[K+AOL-W>:9:1'MYD*7+O^D\?Z
M5Y9_P6T_Y+[X%_[%D?\ I5/7Z9_LF_L[Z?\ LO? _0O MI,E[>P[KK4[Y%(%
MU>28,K@'^$85%SSM1<\YKXB_X+.? 3Q-XIMO"'Q,T33YM3TC1;273M7%NA=[
M1#('BF8#G82SJ6Z*=N?O4 9/_!#'_FMG_<$_]OZ_4K4]3M-%TVZU#4+F&RL+
M2)I[BYN'"1Q1J"S.S'@  $DGTK\*_P#@FO\ M@:-^ROXP\7VNN>'=:\0P>*+
M>VAMH= A2>Z^TPM)Y<8C9EW!_.89!R"%X.3C].?BIH?Q:^+_ .Q#\1X=7TQ=
M*\=>(]/NKBR\-VH#2V-H2#'8,X_UDS0JP8\?/*5P !0!\0?M%_\ !3#XA?M#
M_$>T^&'P-ED\+:/JVI1Z1::Q&QCU#4I))!$C!_\ EVC+,"-OSXY+#)4=_P#M
M@?L>^#OV7?V!]>%C"NM^-KW4-/;6?%5XN^[O)6G4N%9B3''NZ(#S@%MS9-?E
MWX2\3:W\,?'6DZ_I9?3O$.@ZA'=V_G1_-#<0R!@&1O1EP5/N#7Z2?M ^*/VG
M_P!L']D?7?$6N^"--\$^"M)A@U-],M[68ZCKI21"TL:2$M%!&I:;/!8+@%QD
M@ ^4/^";W_)[7PM_Z_;C_P!))Z_H4K^:W]E3XG'X-_M$>!/& TF]UW^S=14G
M3=.&ZYN ZM$4B'\3D/PO<\<9K]_9OCYIG@7X06/CCXL"Q^&4EQ#).VDZAJ*2
M3)]YHX02%\R<QA28T!(8E1NQD@'\VVK?\A6]_P"NS_\ H1K^E/\ 9E_Y-M^%
M'_8I:3_Z1Q5_-/=W'VJZFFV[?,=GVYSC)SBOZ(/V&?C%X4^*'[-OP[M-#U_3
M]1UC1O#FGV.J:=!<(US:310+"WFQ [D!:-B"0 1TS0!]!T453UC6=/\ #VF7
M&HZK?6VF:?;KOFN[R98HHE]6=B ![DT ?FO_ ,%P?^1!^%G_ &$[W_T5'7P_
M_P $WO\ D]KX6_\ 7[<?^DD]?2?_  6(_:'\#?%"X\ ^$O!WB.P\37.CRW=W
MJ-QI<ZW%O"7$:1Q^:A*L_P LF5!^7 SUKXY_9 ^)FD?!W]ICX>^,->FDMM%T
MS4E:\GC4L8HG1HV? Y( ?) R2 >#0!^S/_!0W]CV#]JCX2-/H]O&OQ \.I)<
MZ/-PINEQF2T8^CX&TG[KA>0"V?P7L+[5?!OB*WO+66ZT?6]+NEEBD7,4]M/&
M^0?565E^H(K^F[P+\4_!OQ.M9+GPAXKT7Q1#&B/(VD7\5SY8;.W>$8[<[6ZX
M^Z?0U^6W_!6W]C+_ (1W59?C=X/L-NEW\JIXFM8%X@N&(5+L =%D)"O_ +95
MN2Y( /N#]A/]K:Q_:Q^#L&I7#Q0>--'"6FOV,>!B7!V3HO:.4*6'HP=>=N3G
M?\%-M%FUS]B#XEQ0$[X8K.Z('=8[V!VS_P !4G\*_%G]E3]I'7?V6OC#I7C/
M2-]Q9 _9M5TT-M6^LV8&2,^C<!E;LRJ>1D'][O _Q4^%W[7GPOU6V\/:[8>)
M]#U;3VM=3TY)5^U6T<Z,ICGA/S1,1O W#DJ2,@9H _ +]EOQ)H?A']HKX=ZI
MXFMK*Z\.QZU;Q:C'J4*36XMY&\N1I$<%2%5RW(_AS7]"_P#PSW\*SR/AIX/(
M_P"P#:__ !NOY]OVG?V8_%_[+OQ(OO#?B2QF.GM*YTO65C(M]1@S\KHW3=@C
M<F<J>#Q@GZY_9G_X+ :W\+/A[IGA#QWX0D\9?V7 MK8ZO97HM[@PHH6..9&1
M@[# 'F @D 9#')(!^KNB_!OX>>%]6M=2TGP-X9TG4X6)@O++2+>&9&*D'8ZH
M"#C/0],U^>?_  7&_P"15^$G_7[J7_HNWKZ1_9MA^(7[1GC:Q^-?Q-T#_A#M
M#T^WDB\$^#I'9Y;;SEVS:A<DJI,KI^[3*C".^%&[<W!_\%<?@+XE^,'P+T36
M_"UA-J]WX3OI+R[L;="\S6LD>V21%'+%"J$J!G:6/\- 'R!_P14_Y.F\4_\
M8F77_I=8U^U-?SS_ + _[2^D_LI_'P>*]?TN_P!4T>\TR?2;J+355KF,2/&Z
MNB,RAB'B4$%APQ(R1@_MY^SOX\\;_%71M7\9>*-!F\(:'JLZ'PYX=OXE6^@L
ME3_7W1!XDF8EO+_@55Y))- 'X5_MX0M!^V)\6E;&3KTS<>AP1^AK]>O^"5;!
MOV'? 8!!*SZD#[?Z?/7YO_\ !5WX(ZU\.?VHM:\6R6<K>&O%XBOK*^5#Y0F6
M)8YH2W3>&0OC^[(OO7I'["?_  4<M/@;\$;?X6#P!KOC'Q;'?3G0K;1MA2[,
MS;Q%)U=6#EN51\@C@8H \$_X*:?\GQ_$_P#Z[6/_ *06U?I5_P $>O\ DS]/
M^Q@OOY15^2W[72^._P#AHKQE+\3/LJ>.+F:"ZU&"S8&*V,MM%)' I':*-XX^
MI^Y]YOO'],O^"-?Q=\+S? W4/ %QKMC;>+H-=N;F#1Y[A$N;BW>&)O,B0D&0
M I+NVYV[<G (H ]A_P""JG_)CGC[_KMIO_I?;U^/W[#<*3_M??"-77<H\16K
M8]PV0?S K]3_ /@K;\7/"FA_LOZ]X&FUW3SXMUFYL#!HJW"M=B)+E)C*T0.Y
M4Q"PW$8)XZU^2O[)_C;2/AQ^TI\-O$VOW7V+1=-UNVGO+HJ6$,>\!G('. #D
MXYP#0!_2C163X7\6Z'XWT:'5_#NLZ?KVE39\J^TRZ2X@?'7#H2I_.I]=U[3/
M"^CW>K:SJ-II&E6<9FN;Z^G6""!!U9W8A5 ]2<4 ?SX?\%#O^3TOBK_V$U_]
M$15^JG_!)/\ Y,M\/_\ 83U#_P!'FOR*_;0\>:+\3?VIOB1XE\.WBZAHE]JC
M?9;M/N3*B+'O7U4E"0>X(-?IY_P2'^,GA%OV9;CPG=>(].L]?T*^OKVZT^[N
M8XI8[,E9#<!6()B&\AGZ*1@XXR ?!W_!53_D^/Q]_P!<=-_](+>OO_\ X(P_
M\FH:W_V-MY_Z2VE?FO\ \%"OB5H/Q9_:^\?>(O"^HP:OH4DEK;6U];-NBG\F
MTAB=D;HR[T?##@@ C(.:^^/^",'Q:\*Q_!W7OA]<ZY8VGB]O$4]_;:3/.J3W
M5N]K!\\2$YDVF"7=M!VA03@&@#[%_:&^#OPZ_::\-WOPN\8302ZDUL-5M8X)
M56_L1N,:7<0.2 &RI)!4Y*G.:_$/]K3]ACX@_LFZPTVJV_\ ;O@V:799>)K&
M,^0V?NI,O)AD_P!EC@\[6;!Q]\?\%%?CAX@_9H_:[^#GQ!\/VIU)TT2[L[[3
M<G%Y:><#+&<#@X8,&Y 9%)! P?=;G]O;]F?XK_!C5;[7_%VEMHEY8NFH>&=9
M0+?NI4[H?LW)D;L#'N&<$-WH _,S_@E_^T=KWP?_ &C/#_A);R67PCXQO$TV
M]TUF)C%Q(-D$Z#^%P^Q21U4D'HN/WBK\,/\ @EW^S/K?Q8_:*T7QU_9UQ;>!
MO"-V;^34)E(2:Y0$P0(V,,X<H[8Z*IS@LN?W/H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \9HHHH ] ^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\
M05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N8\9?"WP9\1EC7Q9X
M1T+Q0(UV(-9TV&[VKG.!YBM@9YKIZ* /'+7]C?X$VEU]HC^#_@HR<G$FA6[K
MS_LLA'Z<5ZMH^BZ?X=TZ'3]*L+73+"$;8K6SA6*)!Z*J@ ?A5VB@ HHHH X+
MQS\ _AI\3;HW7BWX?^&?$=X1M^UZGI,$\X&0<"1E+#H.AK2\"_"?P1\,(I8_
M!_@_0?"J2@"7^QM-AM/,QC[QC4;N@Z^E=710 5G7'AO2;R9YI]+LIYG.6DDM
MT9C]216C10!D_P#")Z'_ - ;3_\ P%C_ ,*FN?#^EWC(;C3;.<H@C4R0(VU1
MT49' 'I6A10!D_\ ")Z'_P! ;3__  %C_P *ED\.Z5-###)IEF\,.?+C:W0J
MF3D[1CC)]*T:* ,G_A$]#_Z VG_^ L?^%7K'3[738C%9VT-I$6W%((P@)Z9P
M!UX'Y58K,\3:I>Z+H-]?:=HUUX@OH(B\.EV4L,4URW9%:9TC4^[,!0!^"G_!
M4?\ Y/L^)O\ W#/_ $UVE?H3_P $@]'L-?\ V-=4T[4[*WU+3[CQ)>I-:W<2
MRQ2KY5OPR,""/8BODG]J+]B7]I[]HSX]>+OB(/A$VDQ:U/&8;-O$6ENT444,
M<$89A<@%MD2DXXR37UA_P3C\"?&[]F'P5J'@#QU\'=2_LJ_UG^T(-:TW6]*F
M%MYJ112>=$;L-L41!\Q[V.6 4G&0#ZR\+?LU?"7P/K:ZQX?^&7A'1=6C?S([
MVQT2VBFB;UC94RG_  '%>DT44 ,EB2:-XY$62-P59&&0P/4$>E87AWX>^%?!
M]U<7.@^&='T2XN"3--IUA%;O(2<DL44$Y]ZZ"B@"MJ&G6FKV4UG?6L-[:3+M
MEM[B,21NOHRD8(^M9?A?P+X:\#PS0^'/#VE>'X9B&ECTNRBME<CH6"*,GZUN
MT4 4[[1[#5&1KRQMKMD&%,\*N1],BJO_  B>A_\ 0&T__P !8_\ "M:B@"M8
MZ;9Z9&R6=I!:(QRRP1J@)]3@5+<6\5U"\,T:31.,-'(H96'H0>M244 9/_")
MZ'_T!M/_ / 6/_"I;?PWI-G,DT&EV4$R'*R1VZ*P^A K1HH RH_"NC0Z]?ZV
MFEVBZQ?V\=I=7WDKYT\,9<QQLV,E5,CD \?,?6N$NOV6_@W?:Y_;%Q\*?!<^
MJ%MYNI- M2[-G.\_N^6S_$>?>O4** ([>WBM8(X((TAAC4(D<:A550,  #H
M.U2444 <AXZ^#O@/XH*@\8>"_#_BDQC$;:QID-TT?!'RLZDJ<$\C%5O ?P+^
M'/PON/M'A#P'X;\,W178UUI6E06\S+SPTB*&/4]37<44 %4+S0=,U"8S76G6
MES+C'F30*[8],D5?HH R?^$3T/\ Z VG_P#@+'_A4T_A[2KI8EFTRSE6)=D8
MDMT8(OH,C@>U:%% &3_PB>A_] ;3_P#P%C_PK0M;2"QMU@MH8[>%<[8XD"J,
MG)P![FIJ* "BBB@"&\LX-0M9;:Z@CN;>52LD,R!T=3U!!X(KRVX_9+^"5UJ9
MU";X1>!Y+LY+.WAZTPQ))+,OEX+9/4C->L44 5=+TNRT/3X+#3K.WL+&!=D5
MM:Q+''&OHJJ  /I4MQ;0WD+PSQ)/"XPT<BAE/U!J6B@#)_X1/0_^@-I__@+'
M_A2KX5T1&#+H]@K Y!%JF1^E:M% !1110 4444 <QXR^%O@SXC+&OBSPCH7B
M@1KL0:SIL-WM7.<#S%; SS7!VO[&_P ";2Z^T1_!_P %&3DXDT*W=>?]ED(_
M3BO8Z* *6CZ+I_AW3H=/TJPM=,L(1MBM;.%8HD'HJJ !^%7:** "O-+_ /9E
M^$.J>)7\0WGPO\'W>MR/YKWTVAVSRO)G=YC$IR^>=QY]Z]+HH J7&DV-Y;1V
M]Q96\]O'C9#)$K(N!@8!&!QQ53_A$]#_ .@-I_\ X"Q_X5K44 5IM-M+FT6U
MFM89;50 (7C!0 =!M(QQ5+_A$]#_ .@-I_\ X"Q_X5K44 9]OX?TNU640:;9
MPB5#'((X$7>IZJ<#D>U0_P#")Z'_ - ;3_\ P%C_ ,*UJ* ,ZU\.Z58S+-;Z
M99P3+G;)%;HK#(P<$#T)J+_A$]#_ .@-I_\ X"Q_X5K44 9D/AG1[>5)8M)L
M8Y48,KI;("I'((..#6G110!POCSX$_#CXI:A!?>,/ ?ASQ/?0 +'=:MI<-Q*
MJ@Y"[W4MMR?NYQ[5T>@^$="\+:%'HFBZ+IVD:-&I1-.L+2."W53U C4!0/;%
M:]% &3_PB>A_] ;3_P#P%C_PJU#H]A;V<EI%96\=K)DO D2A&SURN,'H*N44
M 9/_  B>A_\ 0&T__P !8_\ "I;?PWI-G,DT&EV4$R'*R1VZ*P^A K1HH S]
M<\/Z7XHTV73M9TVSU?3Y?]9:WT"31/\ 5&!!_*F>'_#.C^$]/6PT/2;'1K%3
MD6VGVR01 ],[4 %:=% &-XF\&^'_ !K9I:>(="TW7K1&W+!J=I'<QJWJ%<$9
MJYH^BZ?X?TV'3]*L+;3+" ;8K6SA6**,>BJH  ^@J[10 5S,7PO\&P>(/[=C
M\):''KF_S/[37381<[LYW>;MW9SSG/6NFHH @O+*WU"$PW4$5S"3DQS('4X]
MC5#_ (1/0_\ H#:?_P" L?\ A6M10!0L]!TS3IO.M-.M+67&/,A@5&QZ9 J_
M110!B>*_!.@>.K&VLO$6C6.MVEM=17L,%_ LR1SQG,<@# X93T-;=%% !111
M0!Y?K7[+?P;\2:L=4U7X4^#-0U!F+O<W&@VKO*Q&"7)3Y_\ @6:]#T;1-.\.
M:9;Z;I-A:Z7IUNNV&TLX5ABC7KA44  ?05=HH **** "J=]HVGZHRM>6-M=L
MHPK3PJY ]!D5<HH R?\ A$]#_P"@-I__ ("Q_P"%'_")Z'_T!M/_ / 6/_"M
M:B@"*VM8;.!(;>&."%.%CC4*H^@%2T44 >;>+OV:OA+X\U%]0\1?#/PGK.HN
MP9[R\T6W>=\9^](4W$<G@G%=5X.^'_A?X=Z<VG^%/#>D>&;!FW-:Z/8Q6D1/
MJ5C4#/)_.M^B@ I&4.I5@&4C!!Z&EHH YK0_AEX.\,ZJ^J:/X3T/2=2D^_>6
M.FPPS-D$'+JH)X)[]ZZ6BB@#G)?AQX2G\1#7Y/"^BR:]D'^U&T^$W7!R/WNW
M=U]ZZ.BB@#FM,^&?@_1=>DUO3_"FB6&M29+ZC:Z=#'<-GKF15#'/UK<OM-L]
M3C5+RT@NT4Y59XU< ^HR*LT4 9/_  B>A_\ 0&T__P !8_\ "K5CH]AI;.UG
M8VUHSC#&"%4)^N!5RB@ J.XMXKN%X9XDFB<8:.10RL/0@]:DHH R?^$3T/\
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MGK73444 97B;PKHGC;1;C1_$6CZ?KVDW&!-8:G:I<P28.1NC<%3SZBN;\ _
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#QFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05K
MIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_\ R!IO^OAO_05K
MIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH ***^6/VXOVD?$'PAN/AGX!\&7-OI
M?C#XD:VFC6VMW4*S1Z7"988I+@1L<,X:XCVAOEX8GH* /IF'7-.N-8N=(BU"
MUDU6UACN9[%)E,\44A=8Y&CSN56,<@5B,$HV.AJ]7Q)I7[,-S?\ [27C[2K7
MXN?$FQUNU\):'=1^(%UYFFDFDN=37][%M\IX@8E(BV!5W28P78GV?]D/Q)\0
M]8\#^*-)^)^JV^N^*O#/B6[T-]4MK5+<7<,:0O%,44!0764-P!P1WH ]THJG
MK&KV7A_2;W5-2NH;'3K*%[FYNKAPD<,2*6=V8\   DGVK\SO!/[2WCWXQ_\
M!3CX7?:)]4\/_#O4]-OKK0=">9XDO+ V5]Y5W<0Y +RO%YJA@=J^5CID@'Z>
MT5S7Q*^(6C?"?P#K_C#Q!<?9M&T6SDO+F0#+%5&=JCNS'"@=R0*^2/V:_#'C
M+]M'P'<?%OXA^-_%OA:QURYG7PSX;\'ZY-I<&EVD<AC$KF+:9YBZ/\TNX8Y
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M?+QU8%?KWQ]\3= ^&_PUUCQUJ]ZJ^'=,L&U&2XB.[S(PNY0G]XMD!1W+ =Z
M.KHKXC_9K\,>,OVT? =Q\6_B'XW\6^%K'7+F=?#/AOP?KDVEP:7:1R&,2N8M
MIGF+H_S2[ACD !L#?_9/_:*\21_&_P ?_L\?$O4_[:\8>$G^T:1K\D8CEU;3
MB$=#,!A?.6.6%B1]X,W="S 'U[1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!XS1110!Z!\/\ _D#3?]?#?^@K735S/P__ .0--_U\-_Z"M=-0 4444 %?
M)_\ P4,_9!U']J;X=:/>>%;T6/CWPG-+>:.7E\I;@.$\R#?D>6Y,43*YX#(
M<!BP^L*Q)O&.DV_C.T\*R7.W7+NPFU.&VVGY[>*2*.1\].&GB&.OS4 ?F9^R
M3^W3?>#/VAO$.B?M(K-X1\876CZ9X=&IWMJ8(M]K-=NKW9)PAD%V,2*/+.W<
M2H.:_42QMK*,2W-G% @O'%Q)- JCSV*JH<D?>.U5&3V4#H!7QO\ 'K]E/P9^
MUA^T1\2= \4PO;W]GX+T&32=9M_]?I\S76K LHSAU.U=R'A@!T(##S[_ ()D
M>,OB/<?"KXV?"N34X[_5_ %U)IGA[4KIC)#'.ZW,:Q!SG,*2VZN!@X67'3
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MY7_"C^Q=/_Y\+7_ORO\ A0!2_P"$PTC_ )^__(3_ .%'_"8:1_S]_P#D)_\
M"KO]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!2_X3#2/^?O_P A/_A1_P )
MAI'_ #]_^0G_ ,*N_P!BZ?\ \^%K_P!^5_PH_L73_P#GPM?^_*_X4 4O^$PT
MC_G[_P#(3_X4?\)AI'_/W_Y"?_"KO]BZ?_SX6O\ WY7_  H_L73_ /GPM?\
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M_P#R$_\ A1_PF&D?\_?_ )"?_"KO]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
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M_P"?"U_[\K_A0!2_X3#2/^?O_P A/_A1_P )AI'_ #]_^0G_ ,*N_P!BZ?\
M\^%K_P!^5_PH_L73_P#GPM?^_*_X4 4O^$PTC_G[_P#(3_X4?\)AI'_/W_Y"
M?_"KO]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^% %+_A,-(_Y^_P#R$_\
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M_P#GPM?^_*_X4 4O^$PTC_G[_P#(3_X4?\)AI'_/W_Y"?_"KO]BZ?_SX6O\
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MY7_"C^Q=/_Y\+7_ORO\ A0!2_P"$PTC_ )^__(3_ .%'_"8:1_S]_P#D)_\
M"KO]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!2_X3#2/^?O_P A/_A1_P )
MAI'_ #]_^0G_ ,*N_P!BZ?\ \^%K_P!^5_PH_L73_P#GPM?^_*_X4 4O^$PT
MC_G[_P#(3_X4?\)AI'_/W_Y"?_"KO]BZ?_SX6O\ WY7_  H_L73_ /GPM?\
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M_P#R$_\ A1_PF&D?\_?_ )"?_"KO]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
MA0!2_P"$PTC_ )^__(3_ .%'_"8:1_S]_P#D)_\ "KO]BZ?_ ,^%K_WY7_"C
M^Q=/_P"?"U_[\K_A0!2_X3#2/^?O_P A/_A1_P )AI'_ #]_^0G_ ,*N_P!B
MZ?\ \^%K_P!^5_PH_L73_P#GPM?^_*_X4 4O^$PTC_G[_P#(3_X4?\)AI'_/
MW_Y"?_"KO]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^% %+_A,-(_Y^_P#R
M$_\ A1_PF&D?\_?_ )"?_"KO]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A0!2
M_P"$PTC_ )^__(3_ .%'_"8:1_S]_P#D)_\ "KO]BZ?_ ,^%K_WY7_"C^Q=/
M_P"?"U_[\K_A0!2_X3#2/^?O_P A/_A1_P )AI'_ #]_^0G_ ,*N_P!BZ?\
M\^%K_P!^5_PH_L73_P#GPM?^_*_X4 4O^$PTC_G[_P#(3_X4?\)AI'_/W_Y"
M?_"KO]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^% %+_A,-(_Y^_P#R$_\
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M_P#GPM?^_*_X4 4O^$PTC_G[_P#(3_X4?\)AI'_/W_Y"?_"KO]BZ?_SX6O\
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MY7_"C^Q=/_Y\+7_ORO\ A0!2_P"$PTC_ )^__(3_ .%'_"8:1_S]_P#D)_\
M"KO]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!2_X3#2/^?O_P A/_A1_P )
MAI'_ #]_^0G_ ,*N_P!BZ?\ \^%K_P!^5_PH_L73_P#GPM?^_*_X4 4O^$PT
MC_G[_P#(3_X4?\)AI'_/W_Y"?_"KO]BZ?_SX6O\ WY7_  H_L73_ /GPM?\
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M_P#R$_\ A1_PF&D?\_?_ )"?_"KO]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
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M_P"?"U_[\K_A0!2_X3#2/^?O_P A/_A1_P )AI'_ #]_^0G_ ,*N_P!BZ?\
M\^%K_P!^5_PH_L73_P#GPM?^_*_X4 4O^$PTC_G[_P#(3_X4?\)AI'_/W_Y"
M?_"KO]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^% %+_A,-(_Y^_P#R$_\
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M_P#GPM?^_*_X4 4O^$PTC_G[_P#(3_X4?\)AI'_/W_Y"?_"KO]BZ?_SX6O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /&:*** /0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;_P!!6NFK
MF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ&[O+?3[=
MY[J>.V@3EI9G"*OU)X%06&M:?JHS97UM>#_IWF5_Y&IYXI\K>I?))QYDM"[1
M115$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C-%
M%% 'H'P__P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\
MC1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455
M_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\
M/W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y
M^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]
M_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_O
MXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H
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MH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\
MC1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455
M_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\
M/W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y
M^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]
M_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_O
MXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H
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MH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\
MC1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455
M_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\
M/W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y
M^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]
M_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_O
MXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H
MM455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI
M9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M
M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S
M]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?
MN#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_
M !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_X
MT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M4
M55_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:
MEG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S
M_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_
MW\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^
M_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_Q
MH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\
MC1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455
M_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\
M/W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y
M^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]
M_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_O
MXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H
MM455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI
M9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M
M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S
M]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?
MN#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_
M !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_X
MT?VI9_\ /W!_W\7_ !H M5@>-/&VE^ M#EU/59O+B7Y8XEY>5^RJ.Y_EU-5/
M&_Q(T3P+HDFH7MU'*WW8;:%PTDS_ -T#^9Z"OC7Q]X^U3XB:X^HZE)@#Y8+9
M"?+A3^ZH_F>IKY7.\\IY9#V=/6J]EV\W_EU/KLBR&IFL_:5/=I+=]_)?J^A/
M\1?B/JGQ(UHWM^WEV\>5MK1#\D*D]!ZD\9;O], :/PI^$NH_$S5,)NM-(A;_
M $F]*\#_ &$]6(_+J>P+OA/\*Y_B'JF^YG73]%@8>?<NP5G_ -B//5O?H._8
M'["T.UT3PUI5OINFM:VEE;KMCB20<>Y.>2>I)Y-?&9/DM;-JOUW&M\C=_.7_
M  /^&7E]OG6>4<GI+ X!+G2MIM'_ (/_  [\Y?#?AO3O">CP:9I=LMK:0C"J
MO4GNS'N3W)K3JK_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^-?K4(QIQ4(*R1^.S
MG*I)SF[M]2U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&K(+5%5?[4L_P#G
M[@_[^+_C1_:EG_S]P?\ ?Q?\: 'W=C;7\?EW-O%<Q_W)D##\C7,:G\(_!FKY
M^T>&]/!/5H(1"3^*8-=)_:EG_P _<'_?Q?\ &C^U+/\ Y^X/^_B_XUA4H4JV
ME6"EZI,Z*6(K4-:4W'T;7Y'F&I?LQ>";[/D17VG9Z?9[DMC_ +^!JY/4OV1;
M9LG3_$<L7HES:A\_BK#^5>]_VI9_\_<'_?Q?\:/[4L_^?N#_ +^+_C7D5<AR
MVM\5%+TT_*Q[-'B#-*/PUV_6S_.Y\L:G^RKXKM<M:7FFWR]@)'C?\BN/UKE-
M2^!?CK2\F3P]<3*/XK9TFS^"L3^E?:7]J6?_ #]P?]_%_P :/[4L_P#G[@_[
M^+_C7CU>$L!/X'*/SO\ FOU/:H\8YC3^-1E\K?D_T/@'4O#NK:-G^T-+O+''
M7[3;O'_,"L^OT._M.S_Y^X/^_B_XUB:EX;\(ZQDWVFZ/=,?XI88F;\\9KR*O
M!KWI5_O7ZI_H>S1XW6U:A]S_ $:_4^#X9I+>0212-%(O1D)!'XUT>F?$[Q;H
M^T6OB/4HT7I&URSH/^ L2*^HM2^!_P .-2R?L,%JY_BMKQD_3=M_2N3U+]F'
MPE-DV/B*ZM#Z3212@?D%/ZUYKX9S7#.]"2?I)K\['J+BG*,4K5X-?XHI_E<\
MUTS]I3QSI^T2WUMJ"CM=6J?S3::ZO3/VN-3CV_VAX?M+CU-K.T7Z,&JGJ7[+
M=W%G^S_%6EW/I]I!A_D7KD]2^ ?B[3\F.&QOE'>VOHOY,5/Z4K\1X/\ G?\
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M_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\
MY^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W
M\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_
MB_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"
MU157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?V
MI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U
M+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/
MW!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@
M_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7
M_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_
MXT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U1
M57^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9
M_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/
M_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_
M '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/
M^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&
M@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT
M?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XU8CD65 Z,'4]&4Y!H =1110
M 4444 %%%% !1110 4444 >,T444 >@?#_\ Y TW_7PW_H*UTU<S\/\ _D#3
M?]?#?^@K734 %%%% !5%]<T^/6HM':]@759K=[N.S+CS7A1E1Y O4J&D0$]B
MP]:O5\Y?M&_"_P"+5]\6O /Q,^$]WH,U_P"&[*^T_4-!UV:2!-4MKAH6:)9$
M1MI!A5@3@!E4\@$$ \1_:B_8K\.?M:?M$_$>R:X_L#Q5IWA#0[S2]4A&(S<2
M7&IHPN$ _>*RPPJ6^\H1<' VG7_X)7_&KQOXY\$^//AW\0+B?4-?^'>IQZ;]
MMNG\R7RG\U/(=_XS&]O(-Q).UE'89L6'Q!^..J_M$_$8:#\)=/T7QC>>$-$M
MO^)SXE@EL=. N-3\NZ9HD9YE+._[M45OW39*AE)]H_9&_9>L_P!F#P'J%A+J
MA\1>+->O6U37]<:/R_M=RV3A5R=J+DX]2S-QNP #VZZM(+ZWDM[F&.X@D&UX
MI4#*P]"#P:_,#_@H!^SGH_P7_: ^"/Q-^%^FP^&=;UGQ1;Z?=6FFJ(H9;OS8
MVBD6,<*7!D5P!M;C(R26^@M#\9?MF>"?'GB"'6?AYX1^)?A:2ZD;3IM/UJ+2
M)(XBQ\L!G#' 7&0\9;/\9KOO#OP5\8_%#XK^'OB3\7AI-B?#*R-X;\&:+.]W
M;6%Q( 'N[FX=$\^<* JA45$QD9)S0!]"TC*&4@C(/!!KS?\ :)T7XC^(/A#K
MMG\)M=L_#OCMEC:PO;Z))(^'4R)\Z.JED#*&*G!(Z?>'A?PN\5_MF:AHEOH/
MBOP-X%TO5 FQ_%U[JF^,#&-YL[8MOD[X#1H2,?** .#_ &4?A3;_  E_X*.?
MM!Z/X6MUMO!O]D6=Y+;0KMCM+JY,,Z0@#A1\UR54=%P!TK@_V?\ 19?A9_P6
M!^*>F7Z_9/\ A)=,OKJRW=+A9WM[S*^O^KDS[HWI7WK\&_@[8?!_1-1B6_N=
M>\0:U>OJ>M^(+Y5%QJ-V^ 78* $15 1(U^5$4 =R?*?VH/V8=8\??$+P/\7_
M (<WEEIGQ4\%RXMUU%F6UU6S.[S+25E!*96255<#CS6!QD,H!<_X*&Z[#X=_
M8O\ BK<SML673%LU]VFFCA4?G(*YC_@EQX)N_!7[&'@PWL?E3ZO)=:L(R,$1
MRS-Y1]]T:HWT85!\7_A+\4?VR+'0O!WCCPS;_"SX<V]Y%J&OQ1:U'J&H:LT>
M2EM 8EV1Q;L$R.=V0I"#;S]36^D1Z'X=CTO0H+;3HK.T%M80"/$$ 1-L:[1C
MY%PHP,<"@#2K\RO^"5FBR_"W]I3]H_X>7Z_9-0M;F%DMFZM%!<W*!QZKMN(R
M#Z.*^IOV*]!_:"T'PWXHC^/VKVFJZC)J ;23 T#NL6&\PDPJJ["VTHI&5&1@
M# &/\7OV;?%'AK]HW3OC_P#"2&PO/%#69TSQ+X8U"Y^RQ:Y:;553'/M813+L
MB^\-I\I,D8(< X?_ (+":[#I/['\EI(VV35-?L;6)?5E$DQ_2$UYU^U9\$=6
MTO\ X).>#-'>T9]3\*V>E:O>0*/FA)4K-Q_L?:6S[*QKW+QE\ _&O[67Q,\'
M:M\5M!L_!OPY\(7)U&V\))J":A=:O??+MDNF0>4D*@$!%+,P+@X#<?3_ (F\
M-Z;XR\-ZIH.LVB7VDZI:RV5Y:R9VRPR(4=#CU4D4 >2?L1Z]#XC_ &1?A%=P
M2K,D?ANSLRR]F@C$#+^#1D?A7QEXZT67XF_\%H/#]K9#S(O"MA;75\^,B)8[
M-IAGZO/"OU<5[W\#_AG\8_V/= U7X>^&O"UG\5? :7<]YX:OFUN+3KK3TE;>
M;:Z21,,H<LWF1[C\S';R%7NOV7_V8KSX3^)/&GQ&\;:A::[\5?&UR9]5O+%6
M^RV4(;,=G;%P'\M0%!9L%MB<?("0#Z&HHHH **** "JVH:?!JEN8+A2T9(.
M2.E6:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_
MQH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,
M+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?
M^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_Y
MX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_
MQK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&
MC_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO
M^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_Y
MX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@
MW_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&
MMVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/
M^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X
M0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@
MW_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?
M]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W
M:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X
M0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"
M])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?
M]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W
M\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=H
MH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"
M])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+T
MG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W
M\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?Q
MO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@
M#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+T
MG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?
M^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?Q
MO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_
MQH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,
M+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?
M^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_Y
MX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_
MQK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&
MC_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO
M^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_Y
MX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@
MW_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&
MMVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/
M^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X
M0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@
MW_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?
M]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W
M:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X
M0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"
M])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?
M]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W
M\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=H
MH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"
M])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+T
MG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W
M\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?Q
MO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@
M#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+T
MG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?
M^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?Q
MO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_
MQH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,
M+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?
M^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_Y
MX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_
MQK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&
MC_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO
M^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_Y
MX-_W\;_&MVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@
MW_?QO\:/^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&
MMVB@#"_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/
M^$+TG_G@W_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X
M0O2?^>#?]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:/^$+TG_G@
MW_?QO\:W:* ,+_A"])_YX-_W\;_&C_A"])_YX-_W\;_&MVB@#"_X0O2?^>#?
M]_&_QH_X0O2?^>#?]_&_QK=HH PO^$+TG_G@W_?QO\:Y3XBZEX5^&^B->W\;
M27$F5MK-)3OG8=AZ =V[?7 .K\3?B?IGPTT8W%T1/?R@BULE;#2MZGT4=S_6
MOC/Q=XNU/QMK<^J:K<&:XD.%4<)&O9$'8#_ZYY.:^0SS/H9;%T:.M5_^2^;\
M^R^_S^SR#A^>9R5>OI27_DWDO+N_DO*/Q-XDO/%6JRWUV0"QPD*D[(E[*N>U
M=Q\'/@Q>?$>^%Y=[[30(7Q+/T:8CJD?]3V^M6?@O\$KGX@W2:EJ2O;>'HFY8
M?*]RPZJGMZM^ YZ?76GZ?;:5906=G EM:PH$CBC&%51T %?*Y+D=3,9_7<==
MQ>NN\O/T_/T/KL\SZGEE/ZA@+*2TTVCY+S_+U,.Q^'NA:;9Q6MK9^3!$NU(U
M=L ?G4__  A>D_\ /!O^_C?XUNT5^L1BHI1BK)'Y!*3DW*3NV87_  A>D_\
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M^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\
M/!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_
M #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_
M  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1
M_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?X
MUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \
M&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\
M/!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\
M"%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_
M  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6
M[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;
M_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \
M&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (
M7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\
M"%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M
M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^
M_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;
M_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>
MD_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (
M7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4
M 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^
M-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^
M_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3
M_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>
MD_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!
MA?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW
M^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^
M-_C6[10!A?\ "%Z3_P \&_[^-_C6O:VL=E;QP1#;'&,*,YJ:B@ HHHH ****
M "BBB@ HHHH **** /&:*** /0/A_P#\@:;_ *^&_P#05KIJYGX?_P#(&F_Z
M^&_]!6NFH **** "BBB@"!;&VCO);M;>);N5%CDG" 2.BDE5+=2 6; [;CZU
M/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"_%
M3XKZ=\,])WR;;K59E_T:Q#8+?[3>BCU[]![5_BU\7[#X9Z;L79>:W.N;>SW?
M=_VW]%_4]!W(^.=>U^_\3ZM<:EJ=R]W>3MN>1_T '8#L!TKXK/<_C@$\/AW>
MJ_\ R7_@^7W^?W/#_#LLP:Q.)5J2_P#)O^!W?W>4GB;Q-J/B[6)]4U6Y:YNY
MCRQZ*.RJ.RCL*],^"?P-F\<31ZQK*/;Z C91/NO=D'H/1/5N_0=R+?P/^!,G
MBQX==U^)HM%4AH+=N&N_<^B?S[>M?54,,=O"D44:Q11J%1$ "J!P  .@KP,C
MR&>,E]=QVJ>J3WEYOR_/TW^BS[B&&#C]1R_22T;6T?)>?Y>NS;6UAL;:*WMX
MD@@B4)''&H554<  #H*EHHK]3225D?DK;;NPHHHIB"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"AJ6@:9K (O]-M+X$8(N8%D_F#7*:G\#_ VK;O-\.VT1/>U+0X_!"!
M7=45RU<+AZ_\6FI>J3.NCB\1A_X-24?1M'C.I?LK^$KO)M;K4K%NP6570?@R
MY_6N4U/]D69<MIWB.-_1+JU*_P#CRL?Y5](T5Y%7A_+*V]%+TNOR9[-'B/-*
M.U9OUL_S1\A:G^R_XTL=QMUL-1';[/<[2?\ OL+7*:E\'_&FDY^T>&[]@O4V
M\7G#\TS7W117CU>$<%/6G.4?N?Z?J>U1XSQ\-*D(R^33_/\ 0_.^\T^ZTV3R
M[NVFM9/[LT90_D15>OT4F@CN8S'-&LL;=5=00?P-<YJ?PQ\):QN^U>'--=FZ
MNENJ.?\ @2@']:\>KP;47\*LGZJWY-GM4>-J;_C4&O1W_-(^&+'5KW2VWV=Y
M<6C?WH)60_H:ZG3?C-XWTG'D>)+Y\?\ /RPG_P#1@:OI+4OV:_ VH9,5E<Z>
M3WMKIC^C[A7*:G^R/ILFXZ?XANK?T%U LOZJ5K@_U=SC"_P)?^ RM^=CT/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >,T
M444 >@?#_P#Y TW_ %\-_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__
M "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0_PH Z:BN9_X06W_ .?VZ_[Z'^%'_""V_P#S^W7_ 'T/\* .FHKF?^$%M_\
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M0_PH Z:BN9_X06W_ .?VZ_[Z'^%'_""V_P#S^W7_ 'T/\* .FHKF?^$%M_\
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M']B9[3^"3^4_^"@_MWA^I\<5\X?\!GF$'[17CZ'[VMK,,8Q):0_GP@-:%O\
MM/>-H<;Y;&?C'[RVQGWX(KKYOV0Y5QY/BE'YZ/8%?Y2&LZ;]DG6U_P!3KMA)
MS_'&Z\?@#1]4XDI]9_\ @:?ZL/KG#%7I#_P!K_VU%*W_ &K_ !7'M$NG:1*
M.<12J3[_ .LQ^E:-O^UOJR[?/T"RD]?+F=,_GFLNX_93\719,=[I$PS@!9Y
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MQB2TF_/A"*[3P[XJTGQ;8F[T>_AO[<':S0MRI]".H/UK\_Y89(&VR(T;==K
M@U](_LC:?=6]GXENY+>2.VN&MEBF92%D*^;N"GOC<,_6O;R?B+%X_&1PU:$;
M.^J3TLF^[]#P<[X9P>7X*6*HSE=6T;33NTNR]3Z$HHHK]$/S4**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHKFZAL
MH6FN)HX(E^])(P51]2:X77_COX)\/[EDUJ.]E'_+.Q4SD_\  E^7\S7-6Q5#
M#*]::CZM(ZJ&%Q&*?+0IN3\DV=_17SOK_P"UM"NY-$T%W_NS7\H7_P <3/\
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MC"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%,FFCMX7EE=8HHU+.[D!5 Y))/04!N+)(L4;.[!$499F.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UT612K*&4C!5AD&EI
M:* "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_\ R!IO^OAO_05KIJYG
MX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGS;L"!<>OSX)_ &O2= _9+U&;:^M:W;VHZF*SC,K?3<VT _@:^FJ*^EP_">
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MPR&4Y!IU>N>*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_P#^0--_U\-_
MZ"M=-7,_#_\ Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%8^N>,-#\,J3JNK6=@<9VSS*K'Z+G)_
M5$YQIQYINR\S2%.=27+!-OR-BBO(-?\ VH/"&E[DL1>:Q)V,$7EI^)?!_(&O
M-]?_ &KM?O=R:3IEGIB'H\I,\@^AX7_QTU\]B.(<MPVCJ<S_ +NOX[?B?1X;
MAO,\3JJ7*O[VGX;_ ('U/7/:_P#$'PWX7W#5-;L[21>L32AI/^^!EOTKXPU_
MXH>*_$VX:CKUY+&W6&.3RHS_ , 3"_I7+U\QB.,EMAJ7SD_T7^9]7AN"7OBJ
MWRBOU?\ D?5^O_M4>&-/W)IEI>ZM(.C;1#&?Q;YO_':\VU_]J?Q3J6Y--MK/
M2(ST94\Z0?BWR_\ CM>8Z%X.USQ,P&E:1>7XSC?#"S(/JV,#\37H^@?LO^+M
M4VO?M9Z/&>HFE\R3\%3(_,BO(_M+/<S_ (":3_E5E]__  3V?[+X?RO6NXMK
M^9W?_@/_  #S[7O'OB/Q1N&J:U>WB-UB>8B/\$'RC\JP:^J- _91\/V.U]5U
M*\U20=4C @C/U RW_CU>D:!\,?"GAC:=.T&SAD7I,\?F2#_@;Y;]:VI<+9CB
MI<^*FH^KYG_7S,*O%F6X2/)A(.7HN5?Y_@?&&@_#WQ+XHVG3-$O;J-NDHB*Q
M_P#?9POZUZ1H'[*OB;4-KZG>66DQGJNXSR#\%^7_ ,>KZOHKZ/#\(X*GK6DY
MO[E^&OXGS.)XRQU72A%07WO\=/P/&= _99\*Z;M?4KB]U>0=59_)C/X+\W_C
MU>D:#X$\.^%]O]EZ+963C_EK'"/,_%S\Q_.MZBOI\/EN#PG\&DD^]M?OW/E,
M3F>-QG\>JVNU]/N6@4445Z1Y@4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6'KO@?P_XF#?VIHUE>NW_+22%?,_!NH_.MRBLYTX58\M1)KSU-*=
M2=*7-3DT_+0\=U[]ESPEJ>Y]/DO-(D[+%)YL?Y/D_P#CU><:]^RCXAL=SZ5J
M5GJB#HDF8)#^!RO_ (]7U317S^(X=RW$:NGRO^[I^&WX'T>&XES/#:*KS+^]
MK^._XGP?KWPO\6>&=QU#0+V*->LL<?FQC_@:97]:Y>OT8K U[P#X<\3[CJFB
M65Y(W65X0)/^^Q\WZU\QB.#5OAJWRDOU7^1]5AN-GMB:/SB_T?\ F?#FA^+-
M:\-ONTK5;S3^<E;>9E4_4 X/XUZ+H/[3GC'2=JWCVFKQ#@_:80CX]F3'/U!K
MU?7OV6?"NI;GTVXO=(D[*LGG1C\'^;_QZO.=>_94\26&Y]+O[+58QT5B8)#^
M!RO_ (]7D?V7GN6ZT&VE_*[K[O\ @'L_VMD&::5TDW_-&S_\"_X)VV@_M9:+
M=;4U?1[S3W/!>W=9T^ISM('T!KT?0?BYX/\ $FT66OV?F-TBN'\ER?0*^"?P
MKX[U[X:^*?#.XZEH5[!&O658C)&/^!KE?UKFJUI\3YEA)<F*@GZKE?Z?D9U.
M%,KQD>?"3<?1\R_&_P"9^BZL'4,I#*1D$=#2U^?^A^,M=\,L#I6KWE@H.=D,
MS*A^JYP?Q%>C:#^U!XOTO:M\+/6(QU,\7EO^!3 _,&OH</Q?A*FE>#@_O7Z/
M\#YK$\&8RGK0FIK[G^J_$^NJ*\,T']K#0KS:FK:5>::YZO"RSH/<_=/Y UZ/
MH/Q6\(^)-HL-?LWD;I%,_DR'Z*^":^FP^;8'%?PJJ;[7L_N=F?*XG*,?A/XU
M%I=[77WJZ.LHI 0P!!R#2UZQY 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7[O5_>[GRF)SG,,7_%K.W9:+[E9"*H10J@*JC  & *6BBO7/&"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KG=>^'?AGQ-N.IZ'974C=93$%D_[[7#?K7145E4I4ZT>6
MI%->:N:TZM2C+FI2<7Y.QXMKW[*_AC4-SZ9=WNDR'HNX31C\&^;_ ,>KSC7O
MV5_$^G[GTR[LM6C'1=QAD/X-\O\ X]7UA17SV(X<RW$:^SY7_=T_#;\#Z3#<
M39IAM/:<R_O*_P"._P")\$Z]\._$WAG<=3T.]M8UZRF(M'_WVN5_6N=K]&*Y
MG7OAKX6\3;CJ6A64\C=95B$<A_X&N&_6OF<1P;UPU;Y27ZK_ "/JL-QMTQ-'
MYQ?Z/_,^*-"\<>(/#.W^R]9O;)!_RSBF;9^*]#^5>CZ#^U%XMTS:FH1V>KQ]
MVEC\J3\TP/\ QVO2M>_93\-W^Y]+O[W2I#T5B)XQ^!PW_CU><:]^RSXJTW<^
MG7%EJ\?95D\F0_@_R_\ CU>3_9V?99_!<FE_*[K_ ,!_X![']I\/YI_'44W_
M #*S_P# O^">AZ#^U=X>OMJ:KIM[I;GJT>)XQ^(PW_CM>CZ#\4/"?B;:-/U^
MRED;I%))Y4A_X ^&_2OB[7O /B/PQN.J:+>V<:]97A)C_P"^Q\OZU@UM3XIS
M'"RY,5!2]5RO^OD8U>$\MQ4>?"S<?1\R_P _Q/T8HKX%T'Q]XC\,;1I>M7MG
M&O2))B8_^^#\OZ5Z/H/[4WBK3=J:C;V6KQ]V:/R9#^*?+_X[7T6'XNP=32M!
MP?WK_/\  ^9Q/!N-IZT)QFON?XZ?B?6=%>)Z#^U7X;O]J:I87NE2'JR@3QC\
M1AO_ !VO1M!^)7A;Q-M&FZ[97$C=(FE$<A_X V&_2OIL/FF"Q7\&JF^U[/[G
MJ?*XG*<=@_XU&27>UU]ZT.FHHHKU#R@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK4^#SS/JN;5.2'NTELN_F_ZT"BBBOJ#Y0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_ /(&F_Z^&_\ 05KIJYGX?_\
M(&F_Z^&_]!6NFH **** "O*OVA_VBO#O[.?A.QU/6+>ZU?5M6O$TS1=!TT!K
MO4[Q^$BC!( &2,L>!D=25!]5KX _X*P^"_&EE9_";XP^$;-M33X;:O)J-Y;!
M#((<R6TL5PRCGRU>VVN>P<'@ F@#N;#XO?M(#XV>,8X_A]X9U!++PWI.H?\
M"%+XJ<2P"6>^&8K@VHB:=_)97!P@"18<_-7N7[./Q^L/VC/ -SXCL]"U3PS<
MV.I3Z1J&E:NJ":VNX=OFI\I.0"P&3@\'(%>#?L;_ +4'A3]J+X]>./%6@F33
MKB?P?H5M<Z3>D">&XANM2,RK_P ]$7SHCO7C$BYVDE1]3>"?A_IW@.Z\3S:<
MTA'B#5Y-:N(WQA)I(HHW"X'0^4&YSRQ]J /G#X[?ML>)_#_C[5/ ?P9^%>J_
M%GQ'HI":U>V^Y-.TZ0J&$!D53OEP1E<KCIDG(7D/V<?^"F$?C_XM#X5_%?P-
M=?"_QQ/.+:T2X=_)EF*Y6&19%5XG;C9]X/N R"1N^O\ X>_#W2?AGX>;2-(6
M1HY;NXO[FZN"K3W5S/*TLTTK  ,[.Y.<#C &  *^!/\ @J!\/8_&G[1G[--I
MX<@V>.M4U2:V^TVZ_O!;13VSI(Y[+$6F<'L/,/:@#](:^0?VF/V]]7^"?Q/G
M\%^"_A!K?Q8N=/MHI=6NM(GECCL)I 72!O+MILN8]K\D<.O7G'U'XVUZ[\+^
M#]:U>PTFZUZ_L;.6XM]+LUS-=RJA*1)[LV%ST&<U^5OP=_;\^(O[))OM-^,W
MP2UBRC\1:U<:Q?\ B PS65S<SSON=PLRF.;8@6-45T 6-1V- 'V=^R;^UKX\
M_:0\3ZW8^(/@?JWPRTC3+19CJ>K7TKF>9G 2%(Y+6+=\HD8L&.W: 1\PKN/V
MCOVFM*^ 4/A[2K?2KCQ9X\\47:V/A_PM92".6]E+*"[R$$11+N&YR#C/0\D=
MI\(_C!X2^.G@>R\6^"M8AUK1+K*B6,%7BD &Z*1#RCKD94C/(/0@U\!?#WQ5
M+\:/^"QGB*XO#)-9>!],N[+389&W+!Y42P2$#H,RW$[?\#'I0!](^*_VGO'?
M[/NJ^';CXW^%?#^F>"]=N4L!XG\*ZE/=1:5=,"52[CFB1O+;!_>ID#:<CD5]
M.QR)-&LD;*Z, RLIR"#T(-?-W_!1KPQ;^*OV+?B=;SH&-K8QZA$V!E'@GCE!
M'IPI'T)JE_P33^(UY\2OV-_ ESJ$S7%_I<<VC2R/G)6WE9(>>^(?*&?4&@#Z
M@KP?XX?M/?\ " _$/PY\+_!>AKXT^*?B%3-;Z2]R;>UT^U 8M=WDP5BD8VL0
MJJ6;:0,97/O%?F?_ ,$Y_%4OQN_;<_:&^)=^9)YPGV&R:5MQ@M7N2(HP?:.U
MC7C^Z: /I^W_ &GO$GPQ^+'AWP#\:?#VD>'6\5,T7A[Q/X?OI;G3;JX!4&TE
M$L:/#+EEP3E6W  C!KZ-GGCM89)II%BAC4N\DC!550,DDGH *^'?^"Q'AR+5
M/V3K?5L%+O1/$-G=0S)PR[UDB(!Z@?O ?JH]*R_VHOVD-5N/^"6VD>,$N98]
M?\8Z/IVE3W4;;#YTR@79]<,L5PO']\4 >L>$/VH/'W[0MUXBU#X(^$=!U'P5
MHMR]C%XC\6:C/:)K-PH!=;2.*%R(US_K'(!+#@8;'?\ [.?[2ND_M 6.O63:
M9/X7\;>&;QM.\0^%[V023:?.&9<JX $L3%6VR #.#P*Y_P#X)_\ AN#PK^QK
M\*;2"(1+-HZW[#'5[AVG8_B9#7R?K'B"3X/?\%FK=;)F@T[QQIL-MJ$*#Y9/
M,L]J' _Z;VT3$_[WK0!^F=%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444V21(8V>1E1%&2
MS'  ]S0 ZBN)U_XT>#/#>Y;K7K:65?\ EE:$SMGT^3(!^I%>;Z_^UIIT.Y-&
MT2XNST$MY((E^NU=Q(_$5X^(SC 87^+65^RU?W*Y[>&R7,,7K2HNW=Z+[W8]
M^J&ZNX+&%IKF:.WA7[TDK!5'U)KX^U_]I#QKK6Y8;R#28FXV6,(!Q_O-N8'Z
M$5YYJNNZEKLWG:E?W5_+_?N9FD/ZFOE\1QAAH:8>FY>NB_5GU6&X+Q,]<144
M?35_HOS/LK7_ (\>"?#^Y7UJ.]F7_EG8J9L_\"'R_K7FVO\ [6T:[DT306;^
M[-J$H7\T3/\ Z%7SE'$\TBQQHTCL<*JC))]A7::!\%O&GB3:UMH-S#$W_+6\
M @7'K\^"1] :\"?$6;8Y\F%C;_#&[_&_Z'T<.&LGR]<^*E?_ !2LOPM^IHZ_
M^T'XWU[<HU4:;"W_ "ST^,18^C<M_P"/5P%]J5WJEP9[VZFNYVZR3R%V/XDU
M[OH'[)6H3;7UK7+>U'4Q649E/TW-M _(UZ3H'[.'@G1=K364VJRKSOOIB1_W
MRNU3^(-2LCSG,7S8F5E_>E^BO^@Y9_DF6KEPL;O^Y']7:_WL^/+6SGOIUAMH
M)+B9ONQQ(68_0"N[T#X"^-_$&UDT:2QB/_+2_80X_P" GYOTK[*TO0].T.#R
M=.L+:PB_N6T*QC\@*O5[N'X.HQUQ%5OR2M^=_P!#P,3QK6EIAJ27FW?\%;]3
MYPT#]DESM?6]>5?[T.GQ9_)W_P#B:])T#]GWP1H.UO[*_M&9?^6FH2&7/U7A
M?_':]&HKZ?#Y'EV%UA23?=Z_F?*8G/LRQ6DZS2[+3\K%>QT^UTRW6"SMH;2!
M>D<$811^ JQ117N)**LCP6W)W84444Q!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<MKWPO\)^)MQU#0+*61NLL<?E
M2'_@:8;]:ZFBLJE&G6CRU8J2\U<VI5JM"7-2DXOR=CP_7OV4?#U]N?2M2O-+
M<]$DQ/&/P.&_\>KSG7OV7?%NF;GT^2SU>/LL4GE2?D^!_P"/&OK:BOG,1PWE
MN(U4.5_W7;\-5^!]+AN*,SP^CJ<Z_O*_XZ/\3X"UWP/X@\,EO[4T:]LD'_+2
M6%MGX-T/YUB5^BY 8$$9!KE->^%/A'Q)N-_H%F\C=984\F0_5DP37S.(X-EO
MAJORDOU7^1]5AN-H[8FC\XO]'_F?&N@_$3Q-X9VC3-<O;6->D0E+1_\ ?#97
M]*]&T']JCQ/I^U-3M++5HQU;:89#^*_+_P".UWNO?LGZ#>;GTG5;S37/1)E6
M>,?3[I_4UYQKW[+_ (OTO<]B;/6(^P@E\M_Q#X'Y$UY?U'/LL_A.32_E?,ON
M_P" >K_:'#V:?QE%-_S+E?\ X%_P3U'0?VJ/#&H;4U.TO=)D/5MHFC'XK\W_
M ([7H^@_$3PSXGVC3-<LKJ1ND(E"R?\ ?#8;]*^(M<\&Z[X98C5=(O+!0<;Y
MH6"'Z-C!_ UC5O2XJQ^'?)B::EZKE?\ E^!A6X1R[%1Y\+4<?1J2_P _Q/T8
MHKX,T'XE>*?#.T:;KM[;QKTB:4R1C_@#97]*]'T']JSQ)8;4U2PLM5C'5E!@
MD/XC*_\ CM?1X?B[!5-*T7!_>OPU_ ^9Q/!N.I:T91FON?XZ?B?5E%>,Z#^U
M-X5U+:NI07ND2=V:/SHQ^*?-_P".UZ/H/C[PYXGVC2]:LKR1ND23 2?]\'YO
MTKZ;#YE@\5_!JIOM?7[MSY7$Y7C<'_'I22[VT^]:&_1117I'F!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA&T<J ^?O$  ^PZ*** "BBB@ JGJNFKJUH;=Y'B4D'='UXJY10!S/_""V_\
MS^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_
M )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\
M(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X
M06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5T
MU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\
M?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z
M'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V_
M_/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y
M_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\
MP@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_
M (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-
M10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_W
MT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_O
MH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\
MS^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_
M )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\
M(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X
M06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5T
MU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\
M?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z
M'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V_
M_/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y
M_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\
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M/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\
M"C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5
MTU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7
M_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;
MK_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_
M //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_
M .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% '
M,_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_P
MH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=
M-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=
M?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_
M +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO
M_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06
MW_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S
M#> [9E(-Y<D'@@D?X5S^J? /PIK&XW-I\[=9(@(V^N5 S^->CT5C5H4JZY:L
M%)>:N;T<16P\N:C-Q?DVOR/!M:_9+TBX4MI>MW=D_7;<1K,OTXVD?F:\[U[]
MF/QCI.YK-+36(AR/LTP1\>ZOMY^A-?7M%?-XCAG+<1JH<K_NO]'=?@?38;BG
M,\/HY\Z_O*_XJS_$_/W6_"6M^&V*ZKI-Y8<XW7$#*I^C$8/X5DU^BTD:R(R.
MH=&&"K#(-<=KWP=\&^(]QN] M$D;K+:J8'SZDIC)^N:^9Q'!LUKAZJ?E)6_%
M7_(^JPW&T'IB:+7G%W_!V_,^-M+\<^(-%P+35[J-%Z1M(70?\!;(KL='^.^J
MVK :E:I?Q]S%(87/XX8?I7J.O?LF:3<[GT?6;JQ;J([I%F7Z9&T@?G7G.O?L
MS^,](W-:PVNKQ#G-K,%;'^Z^WGV&:\WZIG^6?P^9I=GS+[M?R/3^N<.YK_%Y
M4WW7*_OT_,[C0?C1X*U/:NH7.K:1(>K2H)8_S3)_\=KTG0+;PWXICWZ3XB%_
MQDK#.I<?5>H_$5\<ZUX7UCP[)LU32[S3SG ^T0L@/T)&#^%9T<CPR*\;,CJ<
MAE."#[&NBCQ9C</+DQ5-2M_VZ_\ +\#FK\'X'$1Y\)4<;^DE_G^)]X?\(+;_
M //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%?(_ASXW>,_#.U8-:FNH%_Y8WW[]<>F
M6^8#Z$5ZCX=_:V/R)KNA?[T^GR?RC?\ ^*KZG#<59?7TJ-P?FM/O5_QL?)XK
MA',:&M)*:\GK]SM^%SV?_A!;?_G]NO\ OH?X4?\ ""V__/[=?]]#_"LGP[\<
M/!?B7:D&M0VD[?\ +&^S <^F6^4GZ$UW,<J31K)&ZR(PRK*<@CV-?4T<31Q,
M>:C-27D[GR=?#5\++EKP<7YJQSG_  @MO_S^W7_?0_PH_P"$%M_^?VZ_[Z'^
M%=-170<QS/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V_
M_/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y
M_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\
MP@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_
M (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-
M10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_W
MT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_O
MH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\
MS^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_
M )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\
M(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X
M06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5T
MU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\
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M!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU%
M',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_
MPH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH
M?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[
M=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?V
MZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\
M""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X0
M6W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!
MS/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#
M_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'
M^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _
MMU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_
M;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""
MV_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A
M!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU%
M',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_
MPH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH
M?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[
M=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?V
MZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\
M""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X0
M6W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!
MS/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#
M_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'
M^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _
MMU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_
M;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""
MV_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A
M!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU%
M',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_
MPH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH
M?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[
M=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?V
MZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\
M""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X0
M6W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!
MS/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#
M_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'
M^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _
MMU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_
M;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""
MV_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A
M!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU%
M',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_
MPH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH
M?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[
M=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?V
MZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\
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M&.C28[>B]/7/&//O#?AO4O%FK0Z;I5J]W=RGA5Z*.[,>@ ]36O\ #[X;ZO\
M$?5A::;%L@0@W%Y(#Y<*^Y[GT4<GZ9(^Q/A]\-](^'&DBTTV+?.X!N+R0#S)
MF]SV'HHX'UR3\#@<MQG$%=XK%2:AW_2*_I+U/T3,,TP7#F'6$PD4Y]%^LG_3
M?DCG/A7\#])^']FMQ=I%J>MN/WES(F4B_P!F,'H/]KJ?;I7IM%%?K6&PM'!T
MU2H1M%'X[BL77QM5UJ\N:3_K3L%%%%=1R!1110 4444 %%%% !1110 4444
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MI2JJ_9Z/\3Y#%9)F&#NZM%V[K5?>KG:T4BL&4,IR#R"*6O9/#"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?\ _(&F_P"O
MAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *X#XJ?&#2_AK8F-BM[K,JY@L5;D>C.?X5_
M4]NY',_&/X_6W@T3:1H31WFN<K)-]Z.U/O\ WG_V>@[^A^5-1U&ZU:^FO+VX
MDNKJ9M\DTK%F8^I-?"9WQ''"7P^$=ZG5]%_F_P %^!^@9#PS/&6Q.,5J?1=9
M?Y+\7^)H>+/%VJ>-M8EU+5KEKBX?@#HD:]E4=@/\\UV/PE^"NI?$BZ6ZGWV&
MA1MB2[(^:7'58P>I]^@]SQ74?!O]GN?Q)Y&M>)8WMM*X>&R.5DN1V+=U3]3[
M#D_4-K:PV-K%;VT*06\2A(XHU"JJCH !T%>)D_#]3'2^N9A?E>MGO+S?E^+/
M>SKB2E@(?4LNMS+2ZVCY+N_P12\-^&]-\)Z3#INE6J6EI$.%7JQ[LQZDGU-:
M=%%?J<(1IQ4(*R1^23G*I)SF[M]0HHHJR HHHH **** "BBB@ HHHH ****
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M38M4J2M!;+HEW?G_ ,,C]EPV&P7"V#=:L[S>[ZM]EY?\.RG\#O@,_B1H-?\
M$4+1Z2"'MK-Q@W7HS>B?^A?3K]21QI#&L<:JD:@*JJ,  = !2JH50JC '  I
M:_4<MRRAE='V5):O=]6_ZV1^3YIFE?-:WM:KLELNB7];L****]<\8**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \9HHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^@W)^1_QH Z:BN9_X1O5_P#H-R?D?\:/^$;U?_H-R?D?\: .FHKF?^$;U?\
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M *#<GY'_ !H_X1O5_P#H-R?D?\: .FHKF?\ A&]7_P"@W)^1_P :/^$;U?\
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M .@W)^1_QH Z:BN9_P"$;U?_ *#<GY'_ !H_X1O5_P#H-R?D?\: .FHKF?\
MA&]7_P"@W)^1_P :/^$;U?\ Z#<GY'_&@#IJ*YG_ (1O5_\ H-R?D?\ &C_A
M&]7_ .@W)^1_QH Z:BN9_P"$;U?_ *#<GY'_ !H_X1O5_P#H-R?D?\: .FHK
MF?\ A&]7_P"@W)^1_P :/^$;U?\ Z#<GY'_&@#IJ*YG_ (1O5_\ H-R?D?\
M&C_A&]7_ .@W)^1_QH Z:BN9_P"$;U?_ *#<GY'_ !H_X1O5_P#H-R?D?\:
M.FHKF?\ A&]7_P"@W)^1_P :/^$;U?\ Z#<GY'_&@#IJ*YG_ (1O5_\ H-R?
MD?\ &C_A&]7_ .@W)^1_QH Z:BN9_P"$;U?_ *#<GY'_ !H_X1O5_P#H-R?D
M?\: .FHKF?\ A&]7_P"@W)^1_P :/^$;U?\ Z#<GY'_&@#IJ*YG_ (1O5_\
MH-R?D?\ &C_A&]7_ .@W)^1_QH Z:BN9_P"$;U?_ *#<GY'_ !H_X1O5_P#H
M-R?D?\: .FHKF?\ A&]7_P"@W)^1_P :/^$;U?\ Z#<GY'_&@#IJ*YG_ (1O
M5_\ H-R?D?\ &C_A&]7_ .@W)^1_QH Z:BN9_P"$;U?_ *#<GY'_ !H_X1O5
M_P#H-R?D?\: .FHKF?\ A&]7_P"@W)^1_P :/^$;U?\ Z#<GY'_&@#IJ*YG_
M (1O5_\ H-R?D?\ &C_A&]7_ .@W)^1_QH Z:BN9_P"$;U?_ *#<GY'_ !H_
MX1O5_P#H-R?D?\: .FHKF?\ A&]7_P"@W)^1_P :/^$;U?\ Z#<GY'_&@#IJ
M*YG_ (1O5_\ H-R?D?\ &C_A&]7_ .@W)^1_QH Z:BN9_P"$;U?_ *#<GY'_
M !H_X1O5_P#H-R?D?\: .FHKF?\ A&]7_P"@W)^1_P :/^$;U?\ Z#<GY'_&
M@#IJ*YG_ (1O5_\ H-R?D?\ &C_A&]7_ .@W)^1_QH Z:BN9_P"$;U?_ *#<
MGY'_ !H_X1O5_P#H-R?D?\: .FHKF?\ A&]7_P"@W)^1_P :/^$;U?\ Z#<G
MY'_&@#IJ*YG_ (1O5_\ H-R?D?\ &C_A&]7_ .@W)^1_QH Z:BN9_P"$;U?_
M *#<GY'_ !H_X1O5_P#H-R?D?\: .FHKF?\ A&]7_P"@W)^1_P :/^$;U?\
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M_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_(_XT?\(WJ_\ T&Y/R/\
MC0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (T =-17,_\ "-ZO_P!!
MN3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_(_XT?\(WJ_\ T&Y/
MR/\ C0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (T =-17,_\ "-ZO
M_P!!N3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_(_XT?\(WJ_\
MT&Y/R/\ C0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (T =-17,_\
M"-ZO_P!!N3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_(_XT?\(W
MJ_\ T&Y/R/\ C0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (T =-17
M,_\ "-ZO_P!!N3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_(_XT
M?\(WJ_\ T&Y/R/\ C0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (T
M=-17,_\ "-ZO_P!!N3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_
M(_XT?\(WJ_\ T&Y/R/\ C0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_
M (T =-17,_\ "-ZO_P!!N3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\
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M_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_(_XT?\(WJ_\ T&Y/R/\
MC0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (T =-17,_\ "-ZO_P!!
MN3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_(_XT?\(WJ_\ T&Y/
MR/\ C0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (T =-17,_\ "-ZO
M_P!!N3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_(_XT?\(WJ_\
MT&Y/R/\ C0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (T =-17,_\
M"-ZO_P!!N3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_(_XT?\(W
MJ_\ T&Y/R/\ C0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (T =-17
M,_\ "-ZO_P!!N3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_(_XT
M?\(WJ_\ T&Y/R/\ C0!TU%<S_P (WJ__ $&Y/R/^-'_"-ZO_ -!N3\C_ (T
M=-17,_\ "-ZO_P!!N3\C_C1_PC>K_P#0;D_(_P"- '345S/_  C>K_\ 0;D_
M(_XT?\(WJ_\ T&Y/R/\ C0!TU%<S_P (WJ__ $&Y/R/^-;]C#);6<44TIGD4
M8:0]6]Z )Z*** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_ /(&F_Z^&_\
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MPY^QC^T)H7P ^#O_  J3XVZY8_#[QMX$>XM6CUZY6!-0LO,:2&:U=L"==K;
M$R2$&!S3/V3_ (3ZO\6_VK_B'^T[XBTBZT;1M27^S?!UGJ,317$MJL:0?;&B
M8;HP\40V@]?.D.,;2?MJ^T>PU*6"6\LK>[DMVWPO/$KF-O521P?I5R@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !15>;4+6VSYUS#%_ON!_.J$WB[0[?_ %FKV*GT^T(3^6:X
MZN,PU#^+5C'U:7YFL:-2?PQ;^1KT5S,WQ*\-6_WM6B/^XCM_(&J$WQ?\-Q9V
MW$TW^Y P_GBO&J\39)1_B8VFO^WX_E<ZXY?C)_#1E]S.UHKSN;XW:*F1%:7T
MA]T11_Z%5";X[0+_ *K1Y'_WYPO\E->/5X[X;H_%C(_)2?Y)G7')<PGM2?X+
M\V>IT5X[-\=+UO\ 5:7;I_OR,W\L50G^-6O29V0V4([;8V)_5J\>KXF\.4_A
MJ2EZ0?ZV.N/#N/EO%+YK]+GN-%?/\WQ:\32_=ODA_P!R!/Z@U0F^(7B.?[VK
MW _W"%_D*\:KXM9-'2G1J2^45_[<_P CJCPQBW\4XK[_ /(^CZ*^:O\ A./$
M'_08O/\ O\:/^$X\0?\ 08O/^_QKE_XBYEW_ $#3^^/^9K_JOB/^?B_$^E:*
M^:O^$X\0?]!B\_[_ !H_X3CQ!_T&+S_O\:/^(N9=_P! T_OC_F'^J^(_Y^+\
M3Z5HKYJ_X3CQ!_T&+S_O\:/^$X\0?]!B\_[_ !H_XBYEW_0-/[X_YA_JOB/^
M?B_$^E:*^:O^$X\0?]!B\_[_ !IR^.O$*,"-8N\^\I(H_P"(N9;UPT__ "7_
M ##_ %7Q'_/Q?B?2=%?.'_"P?$?_ $%[C\Q_A1_PL'Q'_P!!>X_,?X5I_P 1
M<RK_ *!ZG_DO_P D3_JOB?\ GY'\?\CZ/HKYP_X6#XC_ .@O<?F/\*/^%@^(
M_P#H+W'YC_"C_B+F5?\ 0/4_\E_^2#_5?$_\_(_C_D?1]%?.'_"P?$?_ $%[
MC\Q_A1_PL'Q'_P!!>X_,?X4?\1<RK_H'J?\ DO\ \D'^J^)_Y^1_'_(^CZ*^
M</\ A8/B/_H+W'YC_"C_ (6#XC_Z"]Q^8_PH_P"(N95_T#U/_)?_ )(/]5\3
M_P _(_C_ )'T?17SA_PL'Q'_ -!>X_,?X4?\+!\1_P#07N/S'^%'_$7,J_Z!
MZG_DO_R0?ZKXG_GY'\?\CZ/HKYT7XD^)54 :M+@>J(?Z4O\ PLKQ-_T%9/\
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M_P"?-7_P&'_RP/\ 5C&?SQ^]_P#R)]"45\]CXJ^*,_\ (3S_ -N\7_Q-2_\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_\
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M\TC*7%&'7PTY/[E^K/F:IX;&YN<>3;RR_P"XA/\ *OJ&'3[6VQY-M#%CILC
M_D*L5[%+P?ZU<=]T/U<_T.27%7\M'_R;_@'S+#X1UNX_U>D7S#U^SN!^>*OP
M_#?Q+<?=TF4?[[*G\R*^BZ*]BEX1Y9'^+B:C].5?FF<DN*,0_AIQ7WO_ "/
MX?A#XDFQNMX8>GWYU/\ +-7X?@CK3\R7=C&/0.['_P!!KVVBO9I>%O#]/XN>
M7K+_ "2.27$F.EM9?+_-L\AA^!5PW^MU>-/]R M_-A5^'X%V:X\[59W_ -R)
M5_F37I]%>Q2\/>&:7_,+=^<IO_VZQRRSW,)?\O+?)?Y'F_\ PH[2O^?^\_\
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M?_R0?VYF/_/W\%_D>6?\*)@_Z#$G_?@?_%4?\*)@_P"@Q)_WX'_Q5>IT4?\
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M (AWPO\ ] G_ )/4_P#DP_M[,?\ G[^$?\CR?_A0_P#U'/\ R4_^SH_X4/\
M]1S_ ,E/_LZ]8HH_XAWPO_T"?^3U/_DP_M[,?^?OX1_R/)_^%#_]1S_R4_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8QEV).*CKGEQ*_LTOQ_X!F\T?2'X_P# /T/_ .$Z\-?]##I7_@;%_P#%4?\
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M3_UDI?\ /M_>@_M.'\K/T&HK\^X_BCXRC<,/%>MDC^]J$I'Y%JL?\+>\;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^A$5X6 2< 9-7K?0=3O/]1IUW/\ ]<X&;^0KQ)>*'$.+?+AJ,%_AC)O\9/\
M([%PY@*2O4D_FTOT/4KCXZ6JY\C29I/^NDP3^0-95Q\<M0;/D:;:Q_\ 71F?
M^6*Y:W^'?B2ZQLTF=?\ KIA/_0B*U+;X/>(Y\;XK>W_ZZ3 X_P"^<U']N\?Y
MA_#C42\J22^_E_4?U+(Z'Q.-_.5_PN+<?&+Q%/G9);V__7.$'_T(FLNX^(WB
M2ZSOU:9?^N85/_00*ZBW^!NHM_K]2M8_^N:L_P#,"M2W^!=LN//U::3_ *YP
MA/YDT?V'X@9A_$E42\ZJBONYOT#ZYD=#X5&_E&_XV/+[C7]4O/\ 7ZC=S?\
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M'QA6[P_'_,PU^#WB,J"8;<'T,PJ2/X,^(6'/V5/9IC_05L?\-3>!/^?B^_\
M 4_XU/'^T[X D0,VHW,9_NM9R9'Y UT1\/.%/^?TG_V_'_Y$C_6ZN_M0_KYF
M(GP5U]FP9;%!ZM*W]%J3_A2.N_\ /WI__?R3_P"(K:_X::^'_P#T%9__  #E
M_P#B:/\ AIKX?_\ 05G_ / .7_XFMX^'_"2WFW_W$)_ULQ/_ #\C^!E?\*.U
M7_G_ +/_ ,?_ ,*D7X&ZAM&[4K8-Z!&(K1_X::^'_P#T%9__  #E_P#B:/\
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M !JI#\=_ 5QG;XEM1C^^KI_-14O_  N[P)_T,]C_ -]'_"NB/#_#*6F&H_\
M@,"?[9Q+_P"8A_\ @7_!+G_"J_"W_0+_ /)B7_XJI$^&/AB-<#2D(_VI9#_-
MJS_^%W>!/^AGL?\ OH_X4?\ "[O G_0SV/\ WT?\*Z(Y-PY'58:A_P" 4_\
M(C^U:[WQ#_\  G_F:D?PY\-QDD:3"?\ >+'^9IZ_#_PZK C2+;CU7-9'_"[O
M G_0SV/_ 'T?\*DA^-'@:=B%\4:<".?GEV_SK>.6Y%'2-"C_ . P_P B/[2J
MO_E^_P#P)_YFQ_P@_A__ * ]G_WY%2KX0T)5 &BZ?@>MJA_I6/\ \+>\$_\
M0TZ5_P"!2_XT?\+>\$_]#3I7_@4O^-=$<'E$?AI4U\HD_7JCWJO_ ,"_X)N1
M^&='B!":38H/]FV0?TJ1-!TR-LIIUHI]5@4?TKG_ /A;W@G_ *&G2O\ P*7_
M !H_X6]X)_Z&G2O_  *7_&MXTLNC\,8+Y1,_K;>]3\3I/[)L?^?*W_[]+_A4
MOV.#_GA'_P!\"N9A^+/@N9MJ^*M(!Z_/>1J/S)J;_A9W@[_H;-#_ /!E#_\
M%5T1>$7P\OX$^W3^W^)TBHL:A54*H[ 8%.KF?^%G>#O^ALT/_P &4/\ \51_
MPL[P=_T-FA_^#*'_ .*K=5J*T4E]Z)]I#^8Z:BN9_P"%G>#O^ALT/_P90_\
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MSKAMIKDD0Q/*1U"*3_*M:V\$^(KPXM]!U.<YQ^[LY&Y].%K]$%41J%4!548
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M_P 3YV@^-'CFWSM\4:B<\_O)=_\ /-:4/[1'Q#M\[?$<AS_?M8&_FAKV6?\
M8]T)O]3KVH1\?\M(XVY_ "LV?]C:)L>3XL=/7S-/#9_*04?V?F\/A;^4O^"'
MU;&1V;^__@GGT/[4'CZ+.Z_M9L_W[1./R K2@_:U\:0_?M='GX_Y:6\@_E(*
MW9OV.M37'E>)+5_7?;,O\F-9LW[(/BI<>5JVCOZ[Y)5_E&:/99U#^;[[_J'+
MCH]_O)[?]L#Q"O\ KM#TR3C_ )9F1>?Q8UI6_P"V1<KCS_"L4G'/EWQ3GUYC
M-<I/^RGXXAQL_LV;G_EG<D?S45FW'[-'Q"A^YHT4_./W=Y"/Q^9Q1[?.H=)?
M^ W_ $#VF.CW^X]/M_VQK%L>?X8N(^.?+NU?G\4%:5O^U_X:;;Y^C:M'Z^6(
MGQ^;BO#+CX">/[;._P -7)P<?NY(W_\ 06/YUFW'PC\:VN=_A75FP<?N[1W_
M /00:/[2S:'Q1?SC_P  /K6,CNOP/I>W_:P\$S[=\6JV^>OF6RG'UVN:TK?]
MIOX?S;=^J7%OGKYEG*<?7:IKY$N/ _B.SW>?X?U2#:<'S+*1<?FM9MQIMY9[
MO/M)X-OWO,C9<?7(H_MW'0^**^:?^8?VAB([I?<?;]O^T%\/KK&SQ)"N3C]Y
M!*G_ *$@K2M_C%X(NL;/%.EC)Q^\N%3_ -"Q7P+15QXCQ'6$?Q_S*69U>L4?
MH9;_ ! \+W7^H\2:1-SM_=WT3<^G#5I6^M:==?ZF_M9N<?NYE;GTX-?G#16T
M>))_:I+[_P#@&BS276'XGZ5T5^;,-U/;9\F:2+/78Q&?RK2A\8:_;9\G6]2B
MW==EW(,_D:WCQ)'K2_'_ (!:S1=8?B?HI17Y_0_%7QG;YV>*M8.?[]](W\R:
MT8/CIX]M_N>)KP\8_>!'_FIK=<1T.L'^!HLSI]8L^\**^(;?]I+XAP===688
MP!)9P?GD(#6E;_M4>.H<;Y=/N,#'[RU S[_*16T>(<(]U)?)?YEK,J/9GV91
M7R+;_M=^+H\";3='F ')$,JL?_(F/TK2M_VQ-87;Y_AZQD_O>7,Z9^F<XK>.
M>X%[R:^3-%F%!]?P/JBBOFFW_;)^Z+CPG_O-'J'\@8_ZUI6_[8FD-M\_P]?1
M^OES(^/SQ6T<YP,O^7GX/_(M8W#O[7YGT)17AMO^UWX2DP)M,UB$DXR(HF ]
M_P#69_2M*W_:H\"S8WRZA!SC]Y:YQ[_*36\<SP<MJJ-%BJ#^VCV"BO,;?]I+
MX>3?>UUH3G $EG/^?"$5W'AOQ9H_C"Q-YHVH0ZA;AMK-"W*GT8'D'ZBNJGBJ
M%9VIS3?DTS6-6G-VC),UJ***Z34**** "BBB@ HHHH **** /&:*** /0/A_
M_P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH *YOXB?#KPY\6/!N
MI^%/%NDP:WH&I1>5<V=P#AAU# C!5@0"&4@J0"""*Z2OG?XW?M0Z9\!OVBOA
MOX=\6ZO#HW@WQ5I6HQ-=W*HD$%_'+;&!Y)2,HA1IDZ[<R*3P,@ _/GQI\&?B
ME_P3U^/GB_7/@1>WWB;PCH^E6&L:YIEZ@EQ97$MTB)/&I!E6,VTI\Y K('SP
M-Y/Z1_LE_M3^&_VM/A?'XJT.%]-O[:3[+JND3.'DLKC:#C<,;T8'*O@9&> 0
M0.5F^)WA#P1^T9\5/%GB#Q!IMCX9A\"^'YGU"6=6A=!=:P2$()\PG! 5<DG@
M FO)?^"5/PIU/PSH'Q2^(4^CS>&_#_CO6UNM!TBXC,;16,3SM'($(^56%QM7
MU$0(X() /KKXW?\ )%_'W_8OZA_Z325\J_\ !'K_ ),_3_L8+[^45?3O[0VL
MV/A_X#_$.^U*\AL;./P_?!YKAPB@FW< 9/<D@ =22 *^4O\ @C;KEE??LIWN
MG17,+7MCXAN_.MUD!D17CA969>H!R<'OM- 'W7<6\5W"\,\231.,-'(H96'H
M0>M>$_'3]B#X/?'W0+JRUOP=INF:I(A$&NZ/;):WL#XX;>@'F ?W)-R]>.]=
MW\=/C;X<_9Y^&NI^.?%8O3HNGM$DJZ?;F:4M)(J* N0!\S#DD#WZ5POAW]NK
MX#>)O!2>)[?XG:!;VC(&:QO+M8M05B/]7]D/[YGSD *IW8.W(YH ^9O^":5[
MXP^"7QG^+'[-?BK4/[3M?"P&JZ5*0<+$[QAF3).U)$G@DV9^5F?N37$_L=VK
M6O\ P5H^/":@<W)@UF2#H.&OK5D_\A'M7UI^S;\-M0U[XQ?$;X]:_I-WX?O?
M&"V^FZ+HVH1^7=6NEVZ(JRSKU22=D$GEGE%"@\Y \,^/GA5_V6_^"@7@WX]O
M&UK\.?%T7]A^)M0128[&Z>+R4DE(&$C8I;/N]8Y,\D9 /H_]NZ98?V//BTSG
M .@SK^)P!^IKR3_@D3:S6_[&FE22DE)]8OY(N,?*) OX_,K5<_X*.>/X_%GP
M+C^$_@F:+Q)X^^(ES:V>EZ5ILRR2M;+*DTMPV#A8=L6TNQ"X<G.%)'OGP%^%
MNG_LZ? ;PMX,6X1K;P[I@%W=*I"R2\R7$H&,X:1I&QUP: /2Z_+?_@C+:M9?
M$+X_V]\=VJPSZ?&YX&2)KT2?^/!?\XK[=_9E_:X\"?M9:7X@OO! U2--$NEM
MKJ/5+987.\,8Y%"NP*,%;&2&XY KY>\%^'T_8O\ ^"B7BF?5RND?#/XMP22Z
M;J<GR6L6I[Q,8)'/RH=YN J],31^^ #O_P#@KA,L?[&&N*QP9-5T]5^OG _R
M!KYF_:8TN_B_X(__  =^8[8KK3KB;*XS"Z7.P?G)'^5>Z_\ !1Q;C]I+4/A]
M^SWX%N(]3\2:EK$>LZW):L)$TC3XD=/.N2#A03-N )RQC  RRY^A?CS^S;I?
MQ0_97UGX1:9'';P1Z-%9:,9CA8)K95-J6(' #1H&('W2WK0!<_8[\C_AD_X/
M?9_]7_PB>F9Z??\ LL>_I_M;J^%/V@HI-1_X+'?"^&V)\R*'3V?"YX6.>1O_
M !W-?1G_  3K^+]K'^SO!X#\8WL7A_QO\.FGTC6],U61;>6VAC=FAE(8C]V(
MBB[^F4//2N!_9@\ S?M!_MR?$7]I,P2?\(-9 Z-X2O)%*KJ#)"MK+<PYY,6U
M)>< $SX!RC  'W[1110 4444 %4]56]:T(L'1+C(P9.F._:KE% ',^1XH_Y^
M+7\A_P#$T>1XH_Y^+7\A_P#$UTU% ',^1XH_Y^+7\A_\31Y'BC_GXM?R'_Q-
M=-10!S/D>*/^?BU_(?\ Q-'D>*/^?BU_(?\ Q-=-10!S/D>*/^?BU_(?_$T>
M1XH_Y^+7\A_\37344 <SY'BC_GXM?R'_ ,31Y'BC_GXM?R'_ ,37344 <SY'
MBC_GXM?R'_Q-'D>*/^?BU_(?_$UTU% ',^1XH_Y^+7\A_P#$T>1XH_Y^+7\A
M_P#$UTU% ',^1XH_Y^+7\A_\31Y'BC_GXM?R'_Q-=-10!S/D>*/^?BU_(?\
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MBU_(?_$T>1XH_P"?BU_(?_$UTU% ',^1XH_Y^+7\A_\ $T>1XH_Y^+7\A_\
M$UTU% ',^1XH_P"?BU_(?_$T>1XH_P"?BU_(?_$UTU% ',^1XH_Y^+7\A_\
M$T>1XH_Y^+7\A_\ $UTU% ',^1XH_P"?BU_(?_$T>1XH_P"?BU_(?_$UTU%
M',^1XH_Y^+7\A_\ $T>1XH_Y^+7\A_\ $UTU% ',^1XH_P"?BU_(?_$T>1XH
M_P"?BU_(?_$UTU% ',^1XH_Y^+7\A_\ $T>1XH_Y^+7\A_\ $UTU% ',^1XH
M_P"?BU_(?_$T>1XH_P"?BU_(?_$UTU% ',^1XH_Y^+7\A_\ $T>1XH_Y^+7\
MA_\ $UTU% ',^1XH_P"?BU_(?_$T>1XH_P"?BU_(?_$UTU% ',^1XH_Y^+7\
MA_\ $T>1XH_Y^+7\A_\ $UTU% ',^1XH_P"?BU_(?_$T>1XH_P"?BU_(?_$U
MTU% ',^1XH_Y^+7\A_\ $T>1XH_Y^+7\A_\ $UTU% ',^1XH_P"?BU_(?_$T
M>1XH_P"?BU_(?_$UTU% ',^1XH_Y^+7\A_\ $T>1XH_Y^+7\A_\ $UTU% ',
M^1XH_P"?BU_(?_$T>1XH_P"?BU_(?_$UTU% ',^1XH_Y^+7\A_\ $T>1XH_Y
M^+7\A_\ $UTU% ',^1XH_P"?BU_(?_$T>1XH_P"?BU_(?_$UTU% ',^1XH_Y
M^+7\A_\ $T>1XH_Y^+7\A_\ $UTU% ',^1XH_P"?BU_(?_$T>1XH_P"?BU_(
M?_$UTU% ',^1XH_Y^+7\A_\ $T>1XH_Y^+7\A_\ $UTU% ',^1XH_P"?BU_(
M?_$T>1XH_P"?BU_(?_$UTU% ',^1XH_Y^+7\A_\ $T>1XH_Y^+7\A_\ $UTU
M% ',^1XH_P"?BU_(?_$T>1XH_P"?BU_(?_$UTU% ',^1XH_Y^+7\A_\ $T>1
MXH_Y^+7\A_\ $UTU% ',^1XH_P"?BU_(?_$T>1XH_P"?BU_(?_$UTU% ',^1
MXH_Y^+7\A_\ $T>1XH_Y^+7\A_\ $UTU% ',^1XH_P"?BU_(?_$T>1XH_P"?
MBU_(?_$UTU% ',^1XH_Y^+7\A_\ $T>1XH_Y^+7\A_\ $UTU% ',^1XH_P"?
MBU_(?_$T>1XH_P"?BU_(?_$UTU% ',^1XH_Y^+7\A_\ $T>1XH_Y^+7\A_\
M$UTU% ',^1XH_P"?BU_(?_$T>1XH_P"?BU_(?_$UTU% ',^1XH_Y^+7\A_\
M$T>1XH_Y^+7\A_\ $UTU% ',^1XH_P"?BU_(?_$T>1XH_P"?BU_(?_$UTU%
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M]5C4#]6_I7SU?BS(</\ Q,;3^4D_RN=T,LQM3X:,ONM^9M>1XH_Y^+7\A_\
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MKR1F5!EB%'J35>35+*($O>0(!UW2J/ZUX=3Q5SNOIAL/!?*4G_Z4OR.K_5S
MT=:U5_>E^AZI)\8[M20C,_OY2 56D^,VK_P(@]V"_P"%>5-XGTE<@ZC;\>D@
M-5G\;Z'&^UK]<^JQNP_,"O.GQGQIB_X7-%/^6DOS<7^8OJF08?\ B5(_.?\
MP3U63XQ>(6X1[=/^V0)JG-\5/$\P(_M'RQ_L0QC]=M>7R_$+1(>?.FF&.D4)
MS_X]C^=12?$S15Y2*_DZ\-$B9].=Y_E^=<<J_&V.^*M47_;ZA^31F\QX;P_V
MH/Y.7Z,]#N/&FO77$FKWF/19F4?D*R[B]N+LYGGEF/\ TT<M_.N*;XL:8O"Z
M'=2<_>:_5<\>GE'O[U"WQB$?^I\.6#<?\O,T[_\ H#I7)+A?/<;_ +S77_;T
MY/\ )2,WQ9DM#^%=^D;?G8[6BN%;XV:NO^HTO1;?TQ9^9C_OXS5&WQR\9_\
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ME3K)'P!4]K875\V+:VFN#G&(D+<_A7Z(VOAG1['_ (]M)L;?_KE;(O\ (5I
M!0 !@5TQX;?VJOX?\$U65OK/\#\[T\$>(Y%#)H&J.IY#+9R$'_QVG?\ ""^)
M?^A>U7_P"E_^)K]#Z*V_U;I_\_']Q?\ 9D?YC\\/^$%\2_\ 0O:K_P" 4O\
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M0 54U;2;'7M-N=.U.RM]1T^Y0QSVMW$LL4JGJK(P(8>Q%6Z* .,\!?!?X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU11_K*_^?7X_\ /[4?\ )^/_  #]*Z*_-2BG_K+_ -.?_)O^ /\ M3^Y^/\
MP#]*Z*_-2BC_ %E_Z<_^3?\  #^U/[GX_P# /TKHK\U4=HV#(Q5@<AE."*L?
MVI>?\_<__?QO\:?^LJZT?_)O^ ']J?W/Q_X!^D5%?F[_ &I>?\_<_P#W\;_&
MC^U+S_G[G_[^-_C3_P!95_SZ_'_@#_M1?R?C_P  _2*BOS=_M2\_Y^Y_^_C?
MXT?VI>?\_<__ '\;_&C_ %E7_/K\?^ ']J+^3\?^ ?I%17YS?\)-K X&K7W_
M ($O_C2_\)/K'_06OO\ P)?_ !JO]9(?\^G]_P#P!_VHOY/Q/T8HK\Y_^$GU
MC_H+7W_@2_\ C1_PD^L?]!:^_P# E_\ &C_62'_/I_?_ , /[47\GXGZ,45^
M<_\ PD^L?]!:^_\  E_\:GC\;>(H4")KVJ(@Z*MY( /_ !ZG_K)#K2?W_P#
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ME5.3QQHD76]#'T6-C_2O(J='&TKA$4NQZ*HR36,.!\%]NK-_<OT9C/CK'/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBHYYX[6&2::18H8U+/)(P55 Y))/04;#WT1)7AWQD_:$@\-^?HOAN
M1+G5N4FO!AH[8]PO9G_0>YR!R7QD_:(EU?S]$\+3-#8\I/J*_*\WJL?=5]^I
M]AU\*L[.?4+J*VM89+BXE8)'%$I9F8]  .IK\USKB35X7 /79R7Y1_S^[N?I
M^1<+Z+%9BM-U%_G+_+[^P7=W/J%U+<7,LEQ<2L7DED8LSL>I)/4U[O\ !O\
M9WDU7R-;\50M#9</!IK95Y?1I.ZK_L]3WP.O6_!O]GR#PSY&L^)(X[K5^'AM
M#AH[8]B>S/\ H.V3S7M]/)>&M5BL>M=U%_G+_+[^P9[Q1H\+ESTV<E^4?\_N
M[C(88[:%(88UBBC4*D:* J@<  #H*?117Z2?E^X4444 %%%% !1110 4444
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M^ITQX/I?:J+_ ,!_X)['-\._A5!_K-/T-.,X,ZY_]"JG-X1^$,.=VGZ2<?W
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M4M%=,81C\*L:**6R"BBBK*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;
M_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH ****
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M4;./H:T8Y%E0.C*Z'HRG(-;J2ELS1-/8=1115#"BBB@ HHHH **** "BBB@
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M*  .@%+117<8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!XS1110!Z!\/_\ D#3?]?#?^@K735S/P_\ ^0--_P!?#?\
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M0V^-NL71QC[\F_\ GFK\/Q5\3P\?VB)!Z/#&?UVYKZ.GXB<-5/XV$J1]+/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_>:VC9O_'B:^$_VAM\G_!8SX7+:E?-6+3O,QZ!)BV?^ 4 ?J;1110 4444
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MF'Z"O<?[6\1?] J/_OK_ .RH_M;Q%_T"H_\ OK_[*O&J^$F52_A8BHO7E?\
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M_M;Q%_T"H_\ OK_[*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH
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MJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T"H_^^O\
M[*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_ .RH_M;Q%_T"H_\ OK_[
M*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T"H_^
M^O\ [*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_ .RH_M;Q%_T"H_\
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M_M;Q%_T"H_\ OK_[*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH
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MJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T"H_^^O\
M[*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_ .RH_M;Q%_T"H_\ OK_[
M*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T"H_^
M^O\ [*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_ .RH_M;Q%_T"H_\
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M_M;Q%_T"H_\ OK_[*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH
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MJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T"H_^^O\
M[*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_ .RH_M;Q%_T"H_\ OK_[
M*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T"H_^
M^O\ [*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_ .RH_M;Q%_T"H_\
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MP\ Z%_:)U+;]F^S_ &G6/,\W?\NS;G.>,9KYZ_X)$^!Y]%T/XP>*-,MKFS\
M:_X@">&H[C/SV\#S@R+GDC;)$A;N8B.QKU_3/^">_P -8?B=K>JZEI,VL>#[
MC2]/MK+0]2UW4;M(KB&6Y>5I$EF99(R)HMB,652)"%7<<_3VFZ;::/I]M86%
MK#8V-M&L,%M;1B.*)%&%55  4 < #@4 <A\=)DM_@E\099'6.-/#VH,S,<
M6TA)-?*7_!'.Z2X_9#E13EH/$=[&_/?RX6_DPKZW^(?PH\*_%?3AI_BS2AK.
MG[&C:TEGE2&16()#HC ./E'W@>E8'PY_9I^&?PAOOM?@OPI;>&I=_F,NGS31
MQNVTKEX]^UC@D?,#B@# _;,^!\G[0W[-WC/P9:('UB:U%WI>3MS>0L)8ER>
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M$_'%EGS/#=XV/^>.V3_T$FC^TN(J/Q1E\X?K87]F<-5_@E&_E/\ 3F/?K/\
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M:;JZ/?S)0!_XZ!7>45];A>!>',)\&$B_\5Y?^E-H\NIG6/J[U6O2R_(Y^S\
M>';''E:1;-C_ )[+YG_H6:VK>S@LUVP01P+Z1H%'Z5-17UN&R_!X-6PU&,/\
M,4OR1YE2O5K?Q)M^K;"BBBN\P"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >,T444 >@?#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_\ ^0--_P!?#?\ H*UT
MU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>8IB,C?-D@KP<%@0#[:KF/%'Q1\&>![Z*R\1^+M"\/WDL?G1V^J:E#;2.A)
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MG^QG\!?$L%BJ_$J2UT72M)DLD_TN]C>R!:$A?F<*P0J>2K$ 8WG(!^F'Q"\
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M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/
M=?K_ /$UOV-RUY9Q3-$T+.,F-NHJ>B@ HHHH **** "BBB@ HHHH **** /&
M:*** /0/A_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH ****
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MBG0-3T74HO/T[4K66SN8LD;XI$*.N1TRI(K0HH \A_9K_9<\$_LJ^$]2\/\
M@E=0:UU&]:_N)M3N!-,SE0JKD*H"JJ@ 8SUR2>:W_C)\"_!_QWT&TTSQ7I\D
MTEA<+>:=J5G,UM?:=<*05FMYT(:-P0#P<' R#BN_HH \;\'_ ++/A7P[XVT[
MQCK>K>(?B!XITN-H=*U/Q=J'VMM-1N&\B-42-&(P#)L,AP,M7LE%% '@=U^Q
MCX-M=8UV[\+:_P"+?A]8Z]*T^K:+X3U<V=A>2,,/)Y11O)=A@%H3&<*.>N?5
M?AO\,_"_PA\'V/A;P?HUOH.@V0(AL[8'&2<LS,26=B>2S$DGJ:Z>B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_ /R!IO\ KX;_ -!6
MNFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:**
M* /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#QFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO
M^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKG?#/Q T/Q
M?K?B;2-+O/M%_P"&[Y=/U*+:5\F9H(YP!G[PV3)R.,Y'4&NBH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_\ R!IO^OAO
M_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BB
MB@ KX6_;"^*]WXF_;$^#G[/U_K5YX=\!^(K?^T==DL;E[674R[7"069E0AE1
MI+8(0C#=YV.PK[IKY1_;P_8?M?VK_#NGZQH=^N@_$?0$(TK4G9EBF3=O\B4K
MRHW?,KCE&)X()H Y#P!^Q7\)/''B?XXZ.GA6W\/7.D>*(;71M8T,M:7VE@Z/
MIT@:&9"&XDD=\,2"7;(.XY]__9-L_%.E_ 'PSIWC;4KW6/%.GO>6%]J&H.[S
M7#PWD\0=F?YFRJ+@DG(QUK\^_P!DO]N;5_V9?BMXS^&O[1MM>6FO:EJ\4]]X
MFE=9FMYUL[>W07 CR'C,,,+>:A)^;<P.XL/U:T_4+75["VOK&YAO;*YC6:"Y
MMY!)'+&P!5U8'#*0001P0: +%%%% !1110 4444 %%%% !116?K&MVVBPH]P
M6)8X5$ +'UZGW% &A17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\
M^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\
M%4 =-17,_P#"P-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"
MP-/_ .>-U_WRO_Q5'_"P-/\ ^>-U_P!\K_\ %4 =-17,_P#"P-/_ .>-U_WR
MO_Q5;]C>)J%I%<1A@D@W -UH GHHHH **** "BBB@ HHHH **** /&:*** /
M0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@
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MN9\5?\AG0/\ KX_]F2NFJG?:5!J%Q:S3!B]NV^/!QSD'G\A0!<HHHH ****
M"BBB@ HHHH **** "BBB@ KF? 7_ "#;G_KX/_H(KIJIZ9I4&DPO%;A@K-O.
MXYYQC^E %RBBB@ HHHH **** "BBB@ HHHH **** "N9\!?\@VY_Z^#_ .@B
MNFJGIFE0:3"\5N&"LV\[CGG&/Z4 7**** "BBB@ HHHH **** "BBB@ HHHH
M *YGP%_R#;G_ *^#_P"@BNFJGIFE0:3"\5N&"LV\[CGG&/Z4 7**** "BBB@
M HHHH **** "BBB@ HHHH YGP%_R#;G_ *^#_P"@BNFJGIFE0:3"\5N&"LV\
M[CGG&/Z5<H **** "BBB@ HHHH **** "BBB@ HHHH YGP%_R#;G_KX/_H(K
MIJIZ9I4&DPO%;A@K-O.XYYQC^E7* "BBB@ HHHH **** "BBB@ HHHH *YGQ
M=_R$M#_Z^/\ V9*Z:J=]I4&HS6TLP8M;MO3:<<Y!_H* +E%%% !1110 4444
M %%%% !1110 4444 %<SXN_Y"6A_]?'_ +,E=-5.^TJ#49K:68,6MVWIM..<
M@_T% %RBBB@ HHHH **** "BBB@ HHHH **** "N9\!?\@VY_P"O@_\ H(KI
MJIZ9I4&DPO%;A@K-O.XYYQC^E %RBBB@ HHHH **** "BBB@ HHHH **** "
MN9\!?\@VY_Z^#_Z"*Z:J>F:5!I,+Q6X8*S;SN.><8_I0!<HHHH **** "BBB
M@ HHHH **** "BBB@ KF? 7_ "#;G_KX/_H(KIJIZ9I4&DPO%;A@K-O.XYYQ
MC^E %RBBB@ HHHH **** "BBB@ HHHH **** .9\7?\ (2T/_KX_]F2NFJG?
M:5!J,UM+,&+6[;TVG'.0?Z"KE !1110 4444 %%%% !1110 4444 %%%% ',
M^+O^0EH?_7Q_[,E=-5.^TJ#49K:68,6MVWIM..<@_P!!5R@ HHHH **** "B
MBB@ HHHH **** "BBB@#F? 7_(-N?^O@_P#H(KIJIZ9I4&DPO%;A@K-O.XYY
MQC^E7* "BBB@ HHHH **** "BBB@ HHHH **** .9\!?\@VY_P"O@_\ H(KI
MJIZ9I4&DPO%;A@K-O.XYYQC^E7* "BBB@ HHHH **** "BBB@ HHHH ****
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M1110!XS1110!Z!\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_P#^0--_U\-_Z"M=-7,_#_\
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MHK@M!^.7@OQ-\7/$?PTTW68KGQAX?LX;Z_L5_P"6<<AX /=ES&6 ^[YL?<X
M!WM?-6J?M!?%+XGV%_JGP+\!:'XB\-V5W+:1Z_XFU=K6+57A<I,+.*-26C#J
MR":1T4LIPI R?=/B)9W^I?#_ ,3VFE%QJ=QI=U%:F/[WG-$P3'ON(KY&_P""
M3WQPTGQ_^S98>!FE2V\4^"GDL[RP?Y9&@>5WBF"GM\Q0^C1G.,C(!N_L]_\
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MK=-VXA:^R*^//^"EW[)]O^T-\%;KQ%H]F#X\\)027VGRPI^]N[=06FM3CDY
M+(.SJ ,;VS/_ ,$R_P!I^X_:,^ ,=GKMX;OQEX3=--U*20YDN(2I-M<-ZED5
ME)/):)SWH ^O**** "BBB@ HHHH ***3..3P* %HKYD\;?\ !2;]G?P'XFET
M+4/B##=7L,ABG?3+*XO((F#8(,L4;(<'.=I/2O?O!/CKP_\ $GPO8^(_"VL6
M>O:%?*7M[^QE$D4@!((R.A!!!!Y!!!P10!XUXE^,WQ"^(7Q \5^#O@Q9>%S)
MX2:.WUG7_%SW#VHO)$WBT@AM\,[*NTNY=0I8 !B#7E_@W_@H)?\ @7XP#X4_
MM#>$[?X<>)YF7[#K]A<--HU\K'".KO\ -&C$$!B6 .0^PJ17"?L!_$S_ (1O
M]KW]ICX6Z[)Y&K:AXHO=>T]93\TP%Q*)0">I,;P.!_=#'L:]Z_;T_93L_P!J
M;X(W^GVMO&/&>C*]_H-V0 WG!?FMRW]R4#;Z!MC?PT ?26<\CD4M?"G_  2>
M_:6O_BU\(=0^'_B:XDE\5>!VCMD:XR)9K!LK#NSR6B9&C/H!'GDFONN@ HHH
MH **** "BBB@ HHI&8(I9B%4#))Z"@!:*^8?%G_!2O\ 9U\&^)GT*\^(4-U=
M12>7+/IME<7=M&V<']]'&R,!WVEJ^A?!_C+0OB#X;L/$/AK5K37-$OD\RVO[
M&4212KD@X8=P001U!!!Y% 'B6N?&7XD_$WQMXO\ #7P6L?"BP>$+D:;JOB#Q
MBUR]M+J!C$C6L$-N0Q\L,@>1G&"V K8R?-_A_P#\%!+CPS\83\)?C]X4@^&G
MC%W5;+5[6Y,VCWX<XC=789C5^@8EAD$,4(*UY]_P3?\ BBWA_P#:%_:)^$?B
M&7R=>?Q7?Z_:B0Y-PWGM%<G<>IP+=AZ@L>QKVW_@H1^RA;?M0? ^]73K-7\<
M^'TDO]#G51YDK 9DM<_W90, =G"'H#D ^HJ*^(_^"5/[35Y\;/@G=>$/$EVU
MQXN\$NED[SD^=/8L"()')Y+*5>-O9$)Y:OMR@ HHHH **** "BBB@ HHK@/C
M%\>O 'P \/QZUX_\36?ARQF9D@$^YY;A@,E8XD!=R!C.U3C(SUH [^N!^./Q
MBTOX%_#N^\4ZG;S7[))%:6.FVQ FOKN9Q'! A/ +.PY/09/:N#^"G[<WP5_:
M \1?\(_X.\90W&NL"8M-OK:6TFG 4L?*$JKYA !)"DD $D8YKQ#_ (*^7VK:
M!\ /!/B/2U+G0O&MCJ$@_@!2&X\LL.XW[1_P(4 =9\6OC9^T[\"_#LGCG6_
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MW!IFEZ3;L%EU"^G<)! K'A=S')8]%5C@XP>+^"/[;GP9_:&UU]#\%^,H;K7
M&9-,O;>6TGF4#<3$LJKYF!DD+D@ D@#FO _^"N>M:SX+^%_PL\8Z8AFB\.>-
M[347C)^7SHXI7A+#TRC+GMNQWH [+XO?'+]I?]GW07\<>)? G@;QKX*M1YNJ
M:?X2NKR/4=-AYW2&28%9D48)98UQSE0N6'MG[.O[2?@C]I[P''XG\%Z@9HT(
MBO=.N $NK"4C/ERIDX[X8$JV#@G!QV7@?QEHWQ1\"Z+XFT69;[0]<L8[RW9@
M#OBD0':P[$ X*GH00:_*CXG:+>?\$Q_VZ-&\7:"LEK\(O&DA^TV<:DPQ6[2
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MM\V1E5FS@87)Y_\ 9_\ V_-&^)'Q(NOA9\0_#=U\*_BK:2_9SHNI3K+;W<F
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MBEF8_@.@Y-?-G[$G[=.D?M?3^-;);!-#U;1;YI;2Q+DR3Z8S8AF;)/[P$;9
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M!R:^=_V'_P!N#2OVP+#Q;&;"/0M<T6_<QZ;ORTFGNQ^SS')Y< %7QP& (P&
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MG+_@EW\>-7ET/Q!\ ?'H>S\=_#Z62WMX;A@7ELEDV% ?XO)<A01P4>+&0":
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M']G[Q]OL_'7P_ED@M8;@_/+8J^PH#_%Y+D $<&.2+&0":^]J "BBB@ HHHH
M**** "BBB@ HHKY:^)7_  4P_9_^&'BB;P_?>+Y-5U"WD:*Z.BV4EW#;N#@J
MTJC:Q!SD(6Q@YP: /J6OE7XW?\% /!OP7_:7\%?">\$4XU)PFN:IYN$TEIAB
MU5ATRS%6?)&Q&5N<\>__  R^*GA+XR^$;;Q/X*UVU\0Z%<,42[M2<!AC*.K
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MY!J(DP/WIGSEFR,[2"G4;<'%<Q^P=^VA:?M9:+<>%_'.F6MA\4?"SBXNK62
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M(=]I>H^/]4TZ+1H(-$206&DZ?&YD^SPM)\\A>1C(\C!<D* JA>?9: "BBB@
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M^&/C/PU\2_!>F^-/"<D%QI'B*)-02ZBC"/,2BIF3'/F*(UC(/*^7M_AKS/\
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MH>HS:3;^./%EEH6KWL ^>+3S%//.0?<6ZC'1L[3PQKSWX]_L!Q>&O#\OB_\
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M_"=KX+T.+3+6ZU"^56+R76JWLMY<3.?O.\DC$\^@PHZ*  !0!MT444 %%%%
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MG:^"]#BTRUNM0OE5B\EUJM[+>7$SG[SO)(Q//H,*.B@  5MT %%%% !1110
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MC=@!N, .   /T2KYS\+^'UU;]OSQYXDB^9-'\!:5HTK=A)<7EU<;?KLA0_\
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M[66BPW4?6%+R]@M97SG( CF?D<CKQC-<WX)_X)S? +PE\.X/"EU\/]+\0-Y
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MX"^!_B?X7N&ED\(ZU#?I>6S K';W"J$G![XE2VQ_OYKWS]O_ ,!Z;\0/V/\
MXGVNI1*W]G:1-K%M)M!:*>U'G(5/8G84)'\+L.];?P9\"V'C[]CGX?\ A'Q9
M9_;K#5/ VFV&I6TQ.Y@UC$K\]0P.2&'((!'(H U_V8_C?9?M%? WPIX\M!'%
M-J5J!>VT9R+>[0E)X_4 .K8SR5*GO7P#_P %*_AKJ/[-'[07@/\ :9\$6XB\
MW48HM7@C^1&O$4D%L?PW$"R1M[H3U>LWX*^(O$W_  2Q_:$U/P'\0&O;OX)>
M*[DOIOB!8R\,4@P$N,#[KA,)-&/F^56 (5=WV+_P4&M_#_CO]BKQLS7-OJ-O
M?6MK-HTUJXE^TW33QFU$!4_.9&*J-N<ACVH ^B_#GB"R\5>'=+US3I1-IVI6
MD5[;R]FBD0.C?BK"OS3\,_\ !1![-O%>@?!GP7??$KXJ>,?$^I:L8UMW^QV4
M/F"WM6D*X:7%M;VQ;!5%W<R<$5][?#'X:SZ'^SEX3^'VJ7,]K<V?A2TT&ZN+
M-PDL;)9I [QM@@,""0<$9 ZU)\%/V?? '[//AD:%X#\.6NB6S!?M%PH+W-TP
M'WYI6RSGKU.!G  '% 'SU^Q_^RO\5O"GQ8U;XU_&KQQ_:_CS6M+;2CH=F%>W
ML[9I$E$9<?*-K(,)$ H))W-N-?9-%% !1110 4453UG2K?7M'OM,NUWVMY!)
M;S*.,HZE6'Y$T 8/Q,^)6A?"7X=:[XV\070@T+1[-[V>1""74#Y43G#,Y*JH
MSR6 [U^>&J?M&?MR_&S29?'?PS^'=KX8\"2 S:;9R0VLEY=VYR5D*W+[Y20!
M@QHH;<-H;K7N7P[^'M]^T!_P3UT7X>73+)J6GM;^'[Z&1MN[^RM42.2)B>F^
M.TQSV>OL2&&.WACBBC6**-0J1H %50,  #H* /DG]@;]MJ]_:CT_Q#X;\8Z/
M%X<^)'AEA_:%E#&\,<\6XH9%C<EXW1QM=#T)7^]A?G#]CWQY<?LN?\% ?BO\
M%O$1:UT;QAJTMSI,UP<#SBSS6I!Z?O892I]75%]:]^T#X>VGA#_@JQKFK:5$
M84\1?#4ZGJ"QKM3SQ?0V^XXX)80(?<Y/J:Q?^"E7[&FK_&S2-*^)OPZBG7XG
M>%50QPV;[)KZV1S(HC.1^^B<ETP<G++R=E 'U1\=/@_HOQ[^$_B3P)KT:M8Z
MO:M$DQ7<UM,.8IE_VD<*P]<8/!-?"W_!)/QOX@\!^)/BC^SWXM/EZIX5O)+^
MT@+;A'B7R;I4/>/>877'!\UCWKZ!_8;_ &T-+_::\&+HVMN-(^*>AQ"#7-&N
M$\F25T^5KB)#CY2P^9<9C8E2,;2W-_#OX<VLW_!3WXG^,]#16T^T\'6ECK,T
M8^1=3G>(I'G.-WV>V1R!TW#/WLD W_V_/C7X5^$OAGX<VOBZ\>VT74?%5K?W
ML<<1E>:VT_\ TTHJ#[Q>>*UCP<#][EB!DU\\ZQ\0OVB?^"D5K<Z+X$T9O@_\
M$KX-#=>(-5!-UJ=N<AE7&#(K#.4BPG57E(.*^W/B5^S/X ^,7Q \-^+?&NC_
M /"277AV&2+3=/OWWV,+.ZL\IAQAW.Q!\^5PH^7(S7J$420QI'&BQQH JHHP
M% Z #TH Y+X/?#F+X0_"SPKX)@U&XU>#0-.ATZ.]NE59)5C4*I(' X  '8 <
MGK78444 %%%% !1161XO\.P>,/">MZ#='%MJEC/8RD=DEC9#^C&@#%^+'Q6T
M'X-?##7_ !YX@G(T/1[,W<K089I>@2./) +.S*BY(!+#D5^>NK?M#?MV_%S1
M6\?_  _^'5KX:\$2J9]/T[R+66\N+8_,LA2X?S925Q@QHN[<"JGK7N_P\\#W
M7[3/_!/_ , ^%;Y$FN[5]+T[4[69P%E72]2BBN8G)'5DM)/Q(K["15C5550J
MJ,!5& !Z4 ?*/[!/[:TW[5GA[7M)\3Z1'X>^(?AF14U2QA1XXI48LHE1')="
M&5E="3M.WGYL#YE_82\<77[,?[;_ ,5/@#KY-OI6O:I/<:0\S 8F3=+ V?\
MIM;,I]=R(.YKWSP'\/[;P?\ \%5O'NH:7$8;37OAS'JE\D8"QBZ:^@A!P.[+
M;,Q/<LY[USW_  4H_8VUSXJ1Z1\7OAA'<)\3O"_ELT%@VV>]@C<R1O%ZSQ-R
MN.64E>2J"@#ZI_:%^">C_M#?!_Q)X#UH*D&J6Y%O=%-S6MPOS0S+[JX!]QD=
M":^*O^"17Q!UWPW_ ,+*^ WBM?(U?P;?O<VT#MEHU,K1748_V%E5&!'4SL?2
MOH3]B/\ ;(T;]J3P'':W\B:7\2=&B6'7M#F7RI/,7Y6N(D/)C9AR.J,=I_A+
M<7\'_AK;1_\ !3#XT^-]$"G2X?#-GIFI/$/W8U*<V\C)GIO$=JC,!T,HSUY
M-_\ ;T^/'A'X,Q?"F+QC=RV^D7'B9-8N8[>$S2S1:?$UPB(@ZL;K[&H)(49)
M) &:^>=9\6?M%_\ !2BUFTCPKI+?!KX&WF8[C5]1#&[U6 \$#&&E5A_!'MCY
M*M(W%?;WQ"_9E^'WQ8^)>A>-_&6C#Q+J.A6IMM-L=0;S+&W)D+M+Y&-KR'Y1
ME]PPBX (S7J2*L:JJJ%51@*HP /2@#F/A7X#C^%OPT\*^#H+^?5(- TRWTN*
M\N@HDE2&-8U9@. <*/\ Z]=3110 4444 %-\Q1($+ .02%SR0,9/ZC\Z=7S]
M\5V/A/\ :V^"7B)<QV^NV6L^$[N0_=):*.]MU^I:SD'U84 <%^UK^UUX[\&_
M$;3_ (/_  .\'+XV^*-Y9C4+MYUW6NEVS$A3)\Z*'/!S(ZHH9,[MX%?-US^V
MU^U5^R;XZT=_VAO"5OJ7@G4YUA>\L[6WRB\[C!/;-Y?F 9;RY>6"\;?O5]^?
M#WX1_P#"(_&[XK^.)HHWE\6R:9Y%QD%UBMK183%Z@;U9O??[5@_MN> =-^(_
M[)_Q0TO4XU9+?0KK4X'*@F.>VC,\3#T^:, X[$CO0!\\?\%:/#-SX\_9>\+?
M$3PI</=)X;U:UUB.\M#D"TGC*K.OT=K<@]@2:^G/V4_CU9?M)? CPOXYMC&E
M[=P>1J5M'TM[V/Y9DQV&X;ESU5E/>LO]G+PG9>-/V+_AMX;\1VGV[3=5\#Z?
M97MK.3^\ADLD5E/<?*?J*^"?A;JGB?\ X)2_M$:IX9\91ZAJ/P)\6W/^AZZD
M9DCB?_EG.0O25%RDJ !F50ZA@J@@&_\ \%0OA7J?P'^,?@7]IKP-$EK=PZA!
M;ZLL8VAKJ,$PR.!U66)7A?MA4')<U^EW@OQ59>.O!^A>)-,;?IVL6$&H6S>L
M4L:R(?R85X)^W5<>%O'G[$OQ NI;VUU/2;_2DN-*N;5Q*MS=&1&LQ$5/S%Y?
M+ V]=W>O0O@/\/-0\)_LT^!?!.LS3V6J6?A>TTR[DMV"RV\HME1PAP0&0Y .
M#]T&@#X7TG_@H8NB>(?B!H_PG\'7WQ-^*_C+Q7?7<,$,#FUM+6$)96AD*_-)
M^XM8Y"%(11*<R @BO;/V2_V6_B[I7QBO/CE\;O&HO?&^HZ8^F1^'; (T%E:N
MZN(6=?D 5E!"1@C.6+L2:^A/@=^SI\/OV<_#?]B^ _#MMH\3@?:;S'F75VP_
MBEF;YG[X&=HR< "O2J "BBB@ HHHH *:9$$BQEE#L"P7/) QDX_$?F*=7SY\
M1G;PC^V=\(=:4D0>*-#UGPO<%C\N^,17T'XGR;@?_KH \\_:K_:\^(.@_%.'
MX,_ 7P<GC/XEFT2^U*ZN@&M=*A<90/ET4.04;=(P0!T^^7P/GF/]N+]I_P#9
M/^(6CP?M'^$X;WP9JLXA;4+.U@#1KSEX)K9O+9@/F,4GS$#C;UK[W^%OP?\
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MG,C%5&W.0Y[5ZK\,?AK/H?[.7A/X?:I<SVMS9^%+30;JXLW"2QLEFD#O&V"
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MK_$S1=-_:5\+0S^#]7G$1U2UM8 T2@X,D$ULWE/MR&:-AOQC[O?[U^$/P?\
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M_#SP3=_M)?\ !/\ \#^$K]$GN[=M,TS4[6:0!9AI>IQ1W,3DC^)+.3KW(/-
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M 0=V#ST%7O@W\"/ GP!\+IH'@3PY9Z#8\&:2%=T]RP&-\TK9>1O=B<=!@<4
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M'(3$Y+1RH[*&7H=P(QR!]B:;IMIHNFVFGV%M%9V-I$D%O;PH%CBC50JHH'
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M  52TSQ!I41B?Q!X N;K4TC7"M)%<1PB1L=<@0CGNH/>@#P+]G/Q[<?LH_\
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M(/'.D?\ "1GPVL_]GZ9>/NL1)*8R\LD.,2-B)0 ^5Q_#GF@#XCUOXN?M"_\
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M&Y&8CZK5KX$_LT_#S]G#0&TSP-X?ATZ290+O4ICYM[>L.=TTS?,W.3MX4$G
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M2WU[7_@5\=OBO^S=XIE!?3I9-4L68D*TD;1QNT8/\,T+P2@=@A/<U[Y^P/\
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M!Q_P9^&L7P<^%/A7P1!J5QJ\.@:?%8)?7*JLDJHN 2HX QP!S@ <GK79T44
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M+?1(9(Q?WBJLDI>5Y6^5>%4-(0J\X4 $DC)]"M[>*U@C@@C2&&-0B1QJ%55
MP  .@ [5)0 4444 %%%% !7$_%KXO^'/@Q\+M<\?>(+K_B0:3;?:'>V*NTQ)
M"I''R 6=V55Y RPY%=I)&LT;1NH=&!5E8<$'J*^)?AG\))?B]^R+HOPON(UU
M#_A!O'\>BZI93LNRYLK#6@9(V+=OL95L=6V@#K0!X[K_ .V!^VKXXTG_ (3_
M ,#?!N'2O &/M%I:R6'VNZN;?.Y69#*LT@*X^:*-00<CUKZF_89_;.L/VOO
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MT6C+=18]]\"X]Z /9Z\+_;/M4\0? Z;P?_RW\8ZQI?AR-<X^6XO85F/_  &
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MMT.-\"?^"9^@Z+XB'CSXWZY-\8?B+.RS2OJKO+I]NXZ!4?F;'0>8-F,8C7%
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M220(1A3O5F4KC&1C%>+_  +_ ."9^A:/XD'CWXWZ[/\ &'XB3LLTK:H[RZ?
MXY "/S,!T'F )C&(UQ7VO##';PQQ11K%%&H5(T "JH&  !T% 'C'PX_8S^#G
MPFUJTU7PSX,2TN[*4SV8N]0N[V*TD.?WD,4\KI$_S'YD4'GK7M5%% !1110
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M /K*OGG]L;_BG;+X5>/%'ECPIXZTR:ZN!UCL[MFL9\^V+I3_ ,!%9W_!/_\
M:AC_ &G_ ("Z?J&H7"OXQT/;IFNQ9^9IE7Y+C'I*HW>FX2 ?=KO/VM?!<GQ
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M*E<$9X(KQ?X"_P#!-#PUX7\1?\)W\9-:G^,/Q&G<3RW&KLTMA!)VVQODS$=
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M4#OD@'Q#]NC5/C/XG^.7PO\ "7P2T1KG7M)M+O6;G6KN &RTUKE'M(IFD?\
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M_M+_ /!1'X3?LPZ__P ([K=SJ'B#Q.JJ\^D:#$DLEJK8(,SNZHA*\A<EL$'
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M?Q5T93[@@U\B_P#!2S]F"7XT?!>'Q5X4MVA\>^!<ZEIDEFNV::W3#2P*1SN
M42(!SNCP/OF@#['KP']N>UFA_9SUCQ)9QL^H^#[_ $_Q3;%>JM97<4SG_OTL
MH_&F?L._M,6_[4?P%TCQ'-)&/$UCC3M=MUP-ETBC,@'99%*N.PW%?X37L'Q#
M\)0>/O /B7PQ<X^SZUIESILF[IMFB:,_HU &W:74-]:PW-O(LL$R+)'(O1E(
MR"/J#7B7[:D7]K?L]ZWX8C;%WXLO-/\ #-NHZE[R\A@8C_=1W?/8(35_]CGQ
M;/XU_9=^&FHW887T>C0Z?=[OO?:+7-M-GW\R%\^]>*?M^:Y\6-7\:_"7P?\
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MD( +R.26D?  W,2>!S75444 %%%% !17R_\ M1?\%#OA;^RSK?\ PCNL/?\
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M+AA_VULCG_>%?0E?/?C+_BD/VX/ASJV/W/C#PGJGAV3T\ZTEBO8<^^Q[K'_
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M)!'TKY4\3?\ !+WX.?$"^UC6?&,WB;Q3XMU>1Y[SQ%>:LR7)D8  HB*L2JH
M"KL(4 #D"N _8+\!^*?V5?VD/B7^S]JNJ2ZWX6.E1>+?#]U)P! 9Q QV_P +
M,6"L!QN@)'7D ]"_X*3_ +,,W[0'P1;7/#T#_P#"?>#2^J:3);9$\T8 ,]NI
M'.Y@H=<<[XU QN-=5^P5^U#!^U)\!M-U>\GC/B_2 NG:] I ;SU7Y9\?W95
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M@#\X? ]PW_!-O]NR\\(WCM:?!?XF,)=/FD8B"PD+D1\G@>3(YB;G_52QNQX
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MTN/@A=:A9'4?AD0_BK5+-I!Y-S)]FC-C%(,_.A,\C$8P0A!Z\\Q_P4*_9\\
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M73/V??!G_"WO@3K&L:+XC\%_\3:>SNKKS]\,67>6)MH(9%!+*V59 PP/XOT
M\)S:+^T5\!?#E_XET.UO]&\8:!9ZA=:3>1B2+;<0)+L(/=2W!'((!!R,T =!
M\/OB!X>^+'@G2O%7AC48=8T#58!-;W,1R&4\%6'9E.593R""#R*^,?\ @GG\
M*S\&?VDOVIO"NFAE\,V.KZ;]A13^[C$BW,R1CW2.6-3]!FNV^'G["WB?]G_6
M]33X,_&?4/!W@_4I3<3>&-;T6/688I#@%H7:6,H<#&2&) 7<7P*^@OA#\(]+
M^#_A^]LK*ZNM5U/5+V75-7UJ_*FYU&\DQYDTFT!1P%554!5554#B@#E_V5?
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MTKQ1?>$O!/A/4OB-XPL8EEOK'39X+:UTT. T:W5U,RI&[J<K&H>0CYMH4@T
M>L5Y+^UAXL\2> OV=_&_B?PE=&SUO0[(:FDBQH^889$DN$PP(^:%95SC(W9&
M" :XKX1?MG6?C7XS7?PC\;^"]5^&7Q(CA:ZM=+U*>*ZM[^$*6+07$?RN=JLW
M3&%;!)4@>[^,O#5MXT\(:YX?O!FTU:QGL)LC/R2QLC?HQH \6^+_ ,&;']H_
MXH?":\UNP76_AGH]G?:_+;2L#;7=^WV5;%98\_.HCDN7P1CY<-PV#YE_P4N_
M9[\!>*OV6O$6NRZ1I&AZYX;2"?3-7C@2 PYFCC,#,H'[MPY7:> Q4XR!7L7[
M%GB:Y\4?LL_#F:^/_$QL-,&C78)RPGLW:TDS[[H#FKG[1'[-.C?M-Z7IV@^+
M==UJU\)VLGVB?1=(F2W2_F'^K:>0JS%$Y(12HW'))P, &A\%OCS\-?BKI\6E
M>"O'NC^+;W3;9$GBM+I6N-JJJF1HSAMI./FQC)QFO4*_+']J;_@GU!^R7HUE
M\<?@1K&J:=J7@V9+Z^TR^N//W0A@&DC< ' !(DC;(9"W3&&_3;P;XB3QAX0T
M/7HH6MX]4L8+Y87.2@EC5PI/J-V* /S4^*MO+_P3E_;JT_XAZ?%);_![XDNT
M.L6\*GRK.9F!F^4< QNPG3C.QY448!K].(;RRU:TB:&>"[MKJ'S8RCAUEB8#
M##'52".>G->*?M:_LYR?M4>#=,\!WT]KI7AHWT>HWVK &2^A:+.V.UC*[%9P
MSJ968[5)&Q]WR]A\%?V?? _[/_AN'1_!VD"T"0I#+?W4C3WEPJ]!),V6*@DD
M(,(N3M44 8?[)/@?Q!\,?@/H/@_Q):-:7N@SWNGV^Z59/-LTNYA:R J3@-!Y
M1P>1W Z5[%110 4444 %%87CCQQH7PW\)ZEXE\2ZE#I&AZ=%YUS>3YVHN0
M "68D@!0"22  20*^:OB+_P4 C^%4,&M^)?@K\2M+\"R[/\ BI)].A58]S;0
MTD/F[HE/&/,*L<@;<D9 /K*O'?"7CW7%_:F^(7@?6+XSZ5_8&E:[H-OY2*(8
MF>X@NAN !;]['&WS$D;\<# KL/A1\8/!WQP\(0>)_ ^OVOB#1I6V&:V)#12
M F.1& :-P""58 X(..17E_Q2_P"*1_:^^"_B)/W</B'3=9\)W<AZ$^7'?6ZY
M]=UK,!_O>] $/[*O[,.B_#7X9K?>*?#ME??$+Q1YFJ>*+[48DNIY;FX8R20L
M[;OD3<%V@[25)Y))/@OPQD^#W[&_[;WQGAO/%>A^!-"US3=*FLM'GE\B&*>7
MS'F51C:BJ5#@<*HG & ,#] ) S1L$(5\<,1D ^N*^-?&'_!*[X5?$K5-8U_Q
MGKWB[Q'XPUB1Y[S7YM1CCD,C# *1K'Y:H@ 5$VD*JJO(% '=_MJ?L]V'[8W[
M-]SIOAZ\L;W5XMFL>'-2AF62"695.%$BG!26-F3<#@%E;G;7B/\ P2Y_:MF\
M4>%YO@=X\=M,\?>#@UG8P7Q\N:ZM(B5,.T\^;!M*E>NP*<':YJQ_P3\\*^,?
MV9_CE\3?V>?$.IOKGA^PLHO$OAZ].0HMY)3&Q53]W>67<@.U7BDQG<2?9/VD
M?V%/!?[0'B2P\9V-_?> /B1ISI+:^*] PDS,A&PS)QYA7'#95A@#=@8H \=_
MX*\?"I_%7P?\&^,=(5D\5^'?$$%M8R18$C+=,$V+_M>:D##TP?6OI'XQ> =<
MU?XS?!3QEH5E]M_X1_5;^TU0"14\K3[NQD5Y#N(R%EBM_E&221QUK'\+_LY^
M+M4UCPY??%KXGM\3(?#ERNH:;I]OH,.DVQO$4B.YN%220S2)EB@RJ!CNVD@$
M>^4 %%%% !1110 45D^+/%6D>!?#.J>(=>OXM+T72[9[N\O)R=D42*69CCD\
M#H,D]!DU\T>,_P!N36O 'AV'QKK?P)\<VOPSF"R#Q"KVCW,<+8VS2V2RF2%#
MD8,A4\\@$@$ ^K:\=^#?Q'USQ#\7/C3X-U^YCN9/#&LV<NF^7$L>S3KNRBDA
M3@98B1+C+-DDY&<  =5\'?C7X,^/?@NW\4^!M<@US2)6,;-&"DD$@ZQRQL R
M./1@,@@C(()\O?\ XHW]O2,_ZFR\<>!"OM->:=>9_/R+W\E]Z +G[*O[.>F?
M"OX=S7VO:);3>/?%,TVK>);Z\19YY[B>1I#$SG/R(&"[0=N03R22?G3POJWP
M9_8U_;U^*<VI>)=)\#:1XAT'3IK?2Q&ZPQW,TCF8 (I6,#R5DP< ?:!CC@?H
M,V2IP<'UKY$\4?\ !+_X/_$+4-8UOQK<^)O%?B[5Y&FO/$5YJICN/,8  I'&
MJQ*J@ (FPA0 .0* /JOP]XBTKQ;HEGK&B:E:ZOI-Y&);:^L9EFAF0]&5U)!'
MTKY;_P""D7[,$G[0GP/DU70(&/CSP@7U32)(.)ID !FMU(YRRJ&7'.^-!QDU
MYW^P?\/_ !7^RG^T=\1O@#JFJR:[X3DTB/Q;H%W)E=D)G$#?+T5F+ .!QNAR
M/O5]XZA-/;V%S+:V_P!KN8XF:*WWA/-< E4W'A<G R>F: /G7]@7]J"+]J'X
M"Z=JE].K>,-&VZ;KT/ 8SJOR3X_NRJ W0#=O4?=KL_C-\/\ 7->^*'P9\6^'
M[5;J?PWKURFHAI5C":==6,\4S\D;B)!;D*,DG![5XU\#/^"<_A3P/X]\5>/?
M%S_VGK/B2^N+R7PSIT\B:'9QRRM(+<Q_+]K5=V/WJA#VB& :^P^G X% "T44
M4 %%%% !17C/[2W[5O@C]EC1_#]]XON)"^M:E'8V]K;8,HC+#SK@J3_JXE.Y
MB.Y51RPKV&UNH;ZUAN;:5+BWF19(Y8V#*ZD9# CJ"#G- 'D_[5OQ"UWX2_ _
M6O&?A^=(;G1+FQO+H/"L@DLA>0B[3!!P3 9>0,CM@\C._:%^!T'[0'B7X9:7
MK=H-4\!Z7JDVM:O9-(!#=/';LMJCC/SKYDI8KR"%(/!KO_C!X)7XE?"?QGX3
M=58:YHUYIPW=FEA= ?;!8'/M7,_LJ>-G^(G[-OPU\03,S7=UH5JET6SG[1'&
M(Y@<_P#31'H \W_;X^"7@3QG^R?X\EU;1M-LY_#FB7&HZ1>QVZ1R6DT$9>*.
M-@!M5RHC*C@A^F<5K?LJ?M&?"CQYX#\(^!O#7Q!TCQ%XATG1+2QGL@[13S-#
M;HDC)'*JLXX))4$5V_Q\_9_T;]HWPW9^&?%&KZQ;>%DG^T7VDZ5<+;IJ3*5,
M:3OM+^6I!;:I7+;23\HKX=_:R_X)C>&?A;\/[CXF? VZU3PMXJ\'H=8-JU])
M,LT< ,C/$S9=)D"[EP=K;<8R<T >=WD&H_\ !+?]N*35I+>1O@SXZ>1-\*-Y
M<%L\H8H /^6EJ[# Y+1-QR_'ZN7EKH?Q&\&W%M(UKK?AS7+%HF:)Q)!=VTT9
M!PPX961NHZ@UYCI?AKPO^V%^S'X3D\?:!;ZGI_BC0[+4YK:08:WGE@5R\+CE
M'4LV&4@XXZ$BO*/A+^R'\7_V=[6?PM\.OC=;-\/9'=[6P\4>'A?W>E[CDB!U
MFC5LY+8(5-W.SEB0#E_^"4G@O4OAKX+^,O@ZYFDN;#P]X^OM*@F;&UY(8XXY
M&'U"QD_6OH;]E[X>ZY\*_ NO^&-7M5M;"T\4:O-H@617W:;/=R7$#':3M_UK
MC:<$8Z"NL^$/PHTCX,^"8?#ND27%WF>:]O=1O6#7-_=S.9)[F9@ "[NQ)P
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M0>$N=$\-Z1_9L6J(O07DID9W1NK11B-6^ZVY"5/OL<:0QK'&JHB@*JJ,  =
M!0 ZBBB@ HHHH **Q_%_B_1? /AG4O$7B+4[;1M$TZ$SW=]=N$CB0=R?7.
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MHM#XHUZUCEV)./L)>VA< @LAFF4LN.=G.*^EIH4N(GBD19(W4JRL,@@\$&O
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MID5ZC^T'\/=<\8:O\*=;\-VJW.J>%_&-IJ,^9%C*V#Q36]Y@L1G]U,6VCDE
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M_(B@#Y\^,W_!0+X4?!'XD7'@#59-=UKQE L6[1]!TM[F8R2HKQQ+DJ&=D=&
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M[J7B?Q'XADBN-:U:_?"SRQ[]ICBR=@S*Y)+,Q+<L< #Z#HHH **** "BBB@
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M^(_A2!]<LM2T");,7#6X,I21$VKO(4E9,!@P7G&10!ZQ^VQ_Q(_AGX9\;_\
M0D^+]&UZ0C@^0+I;>XY]/)N9<^V:^@J\,UBVNOVD?V)W^VPK_:?C3P(ER8U7
M 6YN;$2+@>TC @>U=E^SWXX;XE? GX?>*7<R3ZMH-E=SL>OFM"ID'X/N'X4
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M\KR(BO\ [&XG. <9KOOV;OVM/AS^U3H-SJ'@?5)FN[,*;[2-0B\F]L]V=N]
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M/-MGEL9_J=OV7/\ P&@#U[XE?$?0/A'X%UGQAXIO?[.T#28?/NK@1M(57(4
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M-^'/$/Q \2Z3#J7Q+\4:]JTVK:GJ$8EFA"7T\(@C+#Y$VQ@D#J6/4!0/%O\
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M*SMXK>"-88(D$<<:#"JH&  .P J6BB@ HHHH **** /FG]N+X9W/QJT/X7>
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M10 4444 %%%% 'F?[3FM?\([^S?\5-3#;7M?"VJ2H?\ ;%K)M'XG%?G)\6O
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M1W/YGUH ]D\<>-M$^&W@_5_%'B2_32]"TFV>[O+MU9Q%&HR3M4%F/H%!))
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M =I[5]>U!?6-MJ=G/9WEO%=VEQ&T4UO.@>.1&&&5E/!!!((/6@#Y[\ ?M]?
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M)=_M*:A^T#^SZ;#Q#>O?^*_"5PNF7=S*<R7%NR[K:5SW8J&0D\DQ$G).:I>
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MW\JX@/T'M7T!?V%MJEE/9WMM#>6EPACFM[A \<B$8*LIX(([&@#X[/[8EO\
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M:NO!UK;Z0VB^%O#NJ!1J$-O+(LEQ=W2C(BEE*1(L0)*(ASR_'T+110 4444
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MRT ?"7_!._\ 9M^.WP9\$OI?BSQ7'X:\%O??;['PW]EBN=352P+*\C;H[=)
M 6C4.WS-@Q-DG[G^QP?:S=>1']J*>49M@W[,YV[NN,G.*FHH **** "BBB@
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MC(S^ _*G44 %%%% !1110 4444 %%%% !1110!\>?MS_ +"LO[1%YI'C_P
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M#*X5?B#X!U8:QI=J[JGVK[I9%9B%#YCC8!B 0K*>M:GPS_:L\?>.M!@L+O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2,-RD'OZ'%+10!S_@OP#X?^'NF
MRV/A[2X=.AFE:XN)%+/-<S-]Z6:5B7ED/=W9F/<FN@HHH **** "BBB@ HHH
MH **** "BBB@ KG_ !/X!\/^-+S2KG7=,BU8Z7*;BT@NF9[=)>,2F$GRW=<?
M*[*63)VE<G/044 %%%% !1110 4444 %%%% !1110 4444 %8'B+P)H/B[4-
M)O=;TV+5)=*E,]G'=%GABE.,2^43L,BX^5RI9,MM(W-G?HH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >,T444 >@?#__ ) TW_7PW_H*
MUTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C
M-%%% 'H'P_\ ^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 445DVOBW0[[Q#=Z!;:SI]QKMG$L]SI<5U&US!&QPKO
M$#N52>A(P: -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*R-7\8:#X?U+3-.U36].TW4-4E\FPM+R[CBENY,9V1(Q!=L=E!-:] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >,T444 >@?#_P#Y TW_ %\-_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HKE_B-XBN?#/AF2ZM !<22+"CD9"9R=V/H/UKP^3QCKTCECK-^"?[MRX'Y
MU^8\3<>8+AK%1P=2E*<VKNUDDGMJ^NG_  3Z++\EK9A2=6,E%7L?3%%?,O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_ /R!IO\ KX;_ -!6NFKF
M?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 1E#J58!E88((R#7D.J?LN^#M1O
MIKF.74K!9#N^SVLR>6O^[N1B!^->OT5Q8G!8?&)+$04K;7.["X[$X)MX:HXW
MWL>+?\,G^$?^@CK7_?\ A_\ C5'_  R?X1_Z".M?]_X?_C5>TT5P?V'EO_/A
M'H_V]FG_ #_D>+?\,G^$?^@CK7_?^'_XU1_PR?X1_P"@CK7_ '_A_P#C5>TT
M4?V'EO\ SX0?V]FG_/\ D>+?\,G^$?\ H(ZU_P!_X?\ XU1_PR?X1_Z".M?]
M_P"'_P"-5[311_8>6_\ /A!_;V:?\_Y'BW_#)_A'_H(ZU_W_ (?_ (U1_P ,
MG^$?^@CK7_?^'_XU7M-%']AY;_SX0?V]FG_/^1XM_P ,G^$?^@CK7_?^'_XU
M1_PR?X1_Z".M?]_X?_C5>TT4?V'EO_/A!_;V:?\ /^1X]I_[+7@ZQO(IY)]4
MO4C;<8+B=/+?V.U%./QKU^.-8HU1%"(HPJJ,  = !3J*[\-@L-@TUAX*-]['
MGXK'8K'-/$U'*VUS!\>>"]+^)'@G7?"NMP_:-)UJRFL+J/N8Y$*M@]B <@]B
M :_&S]G_ ,>^._@K_P +<_9&BCN&\4>)]:31M(O$0[+1I7$%[<]<A&M )5(/
M&S/>OVQKQ-_V4_"[_M7Q_'<O_P 3Y=$.E?8O)&PSYV"[WYSO\C,.,8VX]*[3
M@/4O!/A'3?A_X/T/PQHT/V?2='LH;"TB[K%$@1<^IPHR>YJ3Q9_R*NL_]>4W
M_HMJUJX;XL^!_$?Q \-W.C:%XRE\&QW=O+;7-U:Z?'<W!5P%S&SG"$#=SM)Y
MR,$4 ? G_!#[_D0?BG_V$[+_ -%25Z]_P5Z8#]C?4,G&=:L /^^VK=_9A_8'
MO/V3M2U*;P9\5-4ET_5&B:_TS4=*@EAG,>[:000R, [#*D=>0<"NI_:G_9%U
M+]JW14\/:]\1[W1O"T5XM['I>F:7""9%5E3S)68L^T,W P.<D$@4 8'PC^"?
MAO\ :._X)X_#SP/XDC$EAJ'A:R$5TB@R6=PL0\N>/T9&_,;E/!(KP#]@'XY>
M(?V;?BQJO[*_Q<G%M<6=TP\+ZC,Q$4F\[A C'K'*#YD6>0Q9#R54?9O[./P*
MUK]GWP;IOA!O'=SXK\-:7;M;V-O?Z=%%/ I;<H\U#\RKE@ P)P1S@ 5R/[7'
M[#OA']K27P]J.HZE>^%_$NB.1;ZYI:*9VA)+>4V>H#X=3G*G=C[QH ^CZ*\Y
M^#?PY\6_#;2/[,\1_$?4/B%;Q1+%;3ZM80PW,>WNTL>#(<=W!8XR2:]&H **
M** "BBB@"GJVE6NMV$MG>1":WD&&4\?0@]C7$GX(Z$23]JU >WF)_P#$5Z%1
M7@9CD&5YM.-7'8>-225DVM;=K]CNP^.Q.%3C1FXIGGO_  I'0O\ G[U#_OY'
M_P#$4?\ "D="_P"?O4/^_D?_ ,17H5%>3_J5P[_T!P_'_,ZO[7Q__/UGGO\
MPI'0O^?O4/\ OY'_ /$4?\*1T+_G[U#_ +^1_P#Q%>A44?ZE<._] </Q_P P
M_M?'_P#/UGGO_"D="_Y^]0_[^1__ !%'_"D="_Y^]0_[^1__ !%>A44?ZE<.
M_P#0'#\?\P_M?'_\_6>>_P#"D="_Y^]0_P"_D?\ \11_PI'0O^?O4/\ OY'_
M /$5Z%11_J5P[_T!P_'_ ##^U\?_ ,_6>>_\*1T+_G[U#_OY'_\ $4?\*1T+
M_G[U#_OY'_\ $5Z%11_J5P[_ - </Q_S#^U\?_S]9R/AWX8Z-X;U!;V'[1<W
M"?<:X<,$/J  .?K71ZN<:3>D\#R'_P#035NN)^*W@OQ%X]\.3Z1H/B^3P<EU
M!-;W-U;Z?'=3E74*#&9#M0@;N<'[PZ8KZ/+\MP>54O88&DJ<;WLEU[^9Y]?$
M5<3+GK2<GYGE7_!/ Y_8M^%6/^@8_P#Z/EKQ?_@I'^Q5??$VSA^,7PSBFLOB
M?X<"7,R:=E)]1AAPR.A7G[1%M!0CEE&WDA!7T/\ LS_L\ZM^S;X,T_P=!X\N
MO$_A73EE%G9ZAIT4<T&]RY F0Y*[F8X8'K@$  5[97I'.?G3_P $R/C]J_[2
M7QD^)OB_Q!;1V^NKX=T/3[Z2'A+B6%KE3,%Q\N\88J. 2<<8KT_]I+]H[Q1J
M7[57@#]G'P1JZ^$KCQ#;_;M;\41HCW5M;A)I#!:AP425HX&^<JV#(F!D&O9/
MA=^S!X8^#_QH^('C_P ,G[ GC.&V-]H\<0$,5S&\K//&0>!)Y@)3'#!CGYL#
MS_\ :J_8-T/]I3QUX=\=V'BS5? 'CG142&'6M)0.SQHY>/(W*5=&9MKJP."0
M<X& #Y/_ ."M/P2\&?"7X$^#9]"TXOKM]XB47NN:E</>:I?!;6;)FN92TCC)
M!VYV@G@"OT*^.5OX!\4>%]+\%_$*PAU;0?&>H)HD5O,,QM<-%+/%E@04/^CG
M:ZG(<IC'4> _%[_@FKX<^-'PXM](\1^/?$NL>-(KQ+H^--9=;RZ**KJ;9(B5
M2* [RVR/;EE5F+$5UWQ!_8=TOQY\%?#O@%O'/B2VO=+UJWU^?Q7-/]HU2[NX
M8'BC<R,?DV[H]NT858E48^]0!\;?'']CWXF_\$^UU+XM_ ;Q[J$GA&QD6?5-
M!OF#/'"6"_O4_P!7<QC."2JN@.1G!8:O_!3+QOJ?QT_85^#/Q(BL)+&SU'4+
M>\U"SC!9()I;64 Y_N!PZJQZ[U[FOK_Q5^S-\0?B=X-?P/X\^,KZYX*NA''J
M$6G^'(K#4[^%"&,4MT)G0*Q"[C'"A(R,C)KU?Q'\%O!?BKX32_#/4-!MY/!#
MV$>FC24RB1P1A1&$(.5*;%*L#D%0<YH ?\%_'FF_%#X2^$/%>D7$=SI^K:9!
M<H\?124 =".Q5@RD=BI':OAG]ANX"_\ !1;]J2#'S/<W#CG^[>X_]FKOOA3_
M ,$X_$GP4U*]T_P9^T-XQT'P%=S&67P_:6D(FY(R5N&8JCE0 72%6./PK:^#
M?_!-OPS\(?C3XC^(=KXZ\4/+J=Q*T.FZ?>RV:+;O(LAAN)Q(TUP=RJ2Q==Q&
M2,T 9?B;X[>)?VA/VT]9_9^\/>(+KP3X/\+Z<U_KVJZ1*(M4U1P(<VT$QR8$
M#7"!F0!_W<F& (KQ']M#X6>#OA'^V!^R58>%-%M-'6?Q1;W%Y,I+W%T_]HV0
M$MQ,Y,DK<$;I&)X/-?1?QL_X)ZZ;\2/CU#\7O"'Q!UWX9>,'""]N-&C5Q<%4
M$>]<LNQFC 5@=RL ,K][.9\7/^"9?A7XH2>#M3A\=>)],\8Z%=&ZNO%MS,+W
M4]38F,JTDKD;&C,0\L)A(]S83F@#R+_@J!XD?X:_M/?LR^.M5W'POHVJ&XN&
M$1<1>5=VTDQX_B,>T@=?DXSBOT=L]8L=0TF'5+:\@GTR: 7,=Y'(#$\17<'#
M="I7G/3%>0?%+]D;P%\7O@>GPQU^*^NM-A8W-OJTMR9=0CO#N+7AF;.^5F=R
MQ8$-O8$8Z>)? W_@FJ_PMN%TWQ'\8_%GC;P!!)YEOX(9Y+/2W.2=MQ$)W69"
M3DQA45C]X,.* . _X(U2I-X1^,,D;K)&_B5&5U.0P,;8(/I7Z+U^=/\ P1L5
M8_"?QB55"JOB50%48 'EMQ7Z+4 %%%% !1110 4444 %%%% !1110 4C*)%*
ML RL,$$9!%+10!XUJW[*7@O4M0FN8Y=4T]9&W?9[2=/+3_=#(Q ]LU4_X9#\
M'?\ 02US_O\ P_\ QJO<**\QY9@V[NDCE^JT/Y$>'_\ #(?@[_H):Y_W_A_^
M-4?\,A^#O^@EKG_?^'_XU7N%%+^R\%_SZ0OJE#^1'A__  R'X._Z"6N?]_X?
M_C5'_#(?@[_H):Y_W_A_^-5[A11_9>"_Y](/JE#^1'A__#(?@[_H):Y_W_A_
M^-4?\,A^#O\ H):Y_P!_X?\ XU7N%%']EX+_ )](/JE#^1'A_P#PR'X._P"@
MEKG_ '_A_P#C5'_#(?@[_H):Y_W_ (?_ (U7N%%']EX+_GT@^J4/Y$>'_P##
M(?@[_H):Y_W_ (?_ (U5G3?V3_!=A>Q7$D^JWR1L&-O<SQ^6_L=L:G'T->ST
M4+*\$G?V2']5H?R(;'&L,:HBJB* JJHP !T %?-?[,; _M$?M/8.?^*FT_\
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M!!4 X/\ X* _M8:A^RC\([#4/#]G:WGBO7K[^S=--]_J+;Y"SSN,C=M 4 9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \9HHHH ] ^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KI
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#QFBBB@#T#X?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (*L?!7PCHWQ4^#_ (EMK&\_MSQ5K[VNK7D^J7<S2Q*]N$CC#RD0JOF/@1!
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M2,U]C4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'C-%%% 'H'P__P"0--_U\-_Z"M=-7,_#_P#Y TW_
M %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$6W!4C9Y>T#'KV'3% 'Z$5^4OC;QE<_\$T/VV/&VH6UE-=_#OXBZ5<ZK9Z?
MA*B^ D>*)0.ZW.Z/CA8[I3VK[B_8T\3>)=4_9YT&Y\;^(4\0W\=[>V%IXAF_
M=G5K6*ZEBMKKYCD^;&BLK9)=2K9.[)XS]H/PSH7Q^_:F^$/@%[*UU)O!,LOC
M77+@C<UG&H6.TMB>@\^;:[(>2EN#C!H ]._93^%5Y\(?@AH.DZRQF\57_F:S
MX@NGY>?4KIS-<,Q[D.^P'T05Z[110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >,T444 >@?#__ ) T
MW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[XCOI'EN6\,7A6VD=B22(\AE!8DE%<)@D!172>#_ -AO8\0^)'Q?^('Q6L%
M,FA:UJKQ:5<-US-;H<RKD#Y'<KU#!J^H:* /G;]KC]BWPW^UEX)\-^'KS6;W
MPHGA^<R6#:7&A@5"@0QM"<*0%50N"-O.."175?LT_LO>#/V6_!LVA^%8KBZO
M+UUFU/6M0827E_*H(4R, ,*H)"H.%R>I+$^OT4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XS
M1110!Z!\/_\ D#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UTU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB>6_M]-@,9N5ME12XFD$BJK*,CYB.<$>1_M,_ OX1^/?@EJNF^ _@OXI\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_P#R!IO^
MOAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?\$W_@/K7B+0-6O_  K/=_V/;F%+26_E,=U(9"YGN6SYD\I+?>=R" HQ@ 4
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M?'KP!=^#?&<CVOQ3\&G[#JUO=_)/=1HWEBX*GG>&&R0=G&3C>!7U_7S;H?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_\
M\@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /&:*** /0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /&:*** .X\#ZA:VFDRI/<PPN9R0LD@
M4XVKSR:Z'^VM/_Y_[7_O\O\ C7EEXH6\G & )&  ^M0T >L_VUI__/\ VO\
MW^7_ !H_MK3_ /G_ +7_ +_+_C7DU% 'K/\ ;6G_ //_ &O_ '^7_&C^VM/_
M .?^U_[_ "_XUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-10!Z
MS_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\
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MQH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\
MO\O^->344 >L_P!M:?\ \_\ :_\ ?Y?\:/[:T_\ Y_[7_O\ +_C7DU% 'K/]
MM:?_ ,_]K_W^7_&C^VM/_P"?^U_[_+_C7DU% 'K/]M:?_P _]K_W^7_&C^VM
M/_Y_[7_O\O\ C7DU% 'K/]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XU
MY-10!ZS_ &UI_P#S_P!K_P!_E_QH_MK3_P#G_M?^_P O^->344 >L_VUI_\
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M_P#G_M?^_P O^->344 >L_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^->344
M>L_VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"->344 >L_VUI__/\ VO\ W^7_
M !H_MK3_ /G_ +7_ +_+_C7DU% 'K/\ ;6G_ //_ &O_ '^7_&C^VM/_ .?^
MU_[_ "_XUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-10!ZS_;6
MG_\ /_:_]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\ &C^V
MM/\ ^?\ M?\ O\O^->344 >L_P!M:?\ \_\ :_\ ?Y?\:/[:T_\ Y_[7_O\
M+_C7DU% 'K/]M:?_ ,_]K_W^7_&C^VM/_P"?^U_[_+_C7DU% 'K/]M:?_P _
M]K_W^7_&C^VM/_Y_[7_O\O\ C7DU% 'K/]M:?_S_ -K_ -_E_P :/[:T_P#Y
M_P"U_P"_R_XUY-10!ZS_ &UI_P#S_P!K_P!_E_QH_MK3_P#G_M?^_P O^->3
M44 >L_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^->344 >L_VUI__ #_VO_?Y
M?\:/[:T__G_M?^_R_P"->344 >L_VUI__/\ VO\ W^7_ !H_MK3_ /G_ +7_
M +_+_C7DU% 'K/\ ;6G_ //_ &O_ '^7_&C^VM/_ .?^U_[_ "_XUY-10!ZS
M_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-10!ZS_;6G_\ /_:_]_E_QH_M
MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\ O\O^
M->344 >L_P!M:?\ \_\ :_\ ?Y?\:/[:T_\ Y_[7_O\ +_C7DU% 'K/]M:?_
M ,_]K_W^7_&C^VM/_P"?^U_[_+_C7DU% 'K/]M:?_P _]K_W^7_&C^VM/_Y_
M[7_O\O\ C7DU% 'K/]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XUY-10
M!ZS_ &UI_P#S_P!K_P!_E_QH_MK3_P#G_M?^_P O^->344 >L_VUI_\ S_VO
M_?Y?\:/[:T__ )_[7_O\O^->344 >L_VUI__ #_VO_?Y?\:/[:T__G_M?^_R
M_P"->344 >L_VUI__/\ VO\ W^7_ !H_MK3_ /G_ +7_ +_+_C7DU% 'K/\
M;6G_ //_ &O_ '^7_&C^VM/_ .?^U_[_ "_XUY-10!ZS_;6G_P#/_:_]_E_Q
MH_MK3_\ G_M?^_R_XUY-10!ZS_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (UY
M-10!ZS_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\ O\O^->344 >L_P!M:?\
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M "_XUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-10!ZS_;6G_\
M/_:_]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\ &C^VM/\
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MZS_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\ O\O^->344 >L_P!M:?\ \_\
M:_\ ?Y?\:/[:T_\ Y_[7_O\ +_C7DU% 'K/]M:?_ ,_]K_W^7_&C^VM/_P"?
M^U_[_+_C7DU% 'K/]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\ C7DU% 'K/]M:
M?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XUY-10!ZS_ &UI_P#S_P!K_P!_
ME_QH_MK3_P#G_M?^_P O^->344 >L_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\
MO^->344 >L_VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"->344 >L_VUI__/\
MVO\ W^7_ !H_MK3_ /G_ +7_ +_+_C7DU% 'K/\ ;6G_ //_ &O_ '^7_&C^
MVM/_ .?^U_[_ "_XUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-
M10!ZS_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?
MY?\ &C^VM/\ ^?\ M?\ O\O^->344 >L_P!M:?\ \_\ :_\ ?Y?\:/[:T_\
MY_[7_O\ +_C7DU% 'K/]M:?_ ,_]K_W^7_&C^VM/_P"?^U_[_+_C7DU% 'K/
M]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\ C7DU% 'K/]M:?_S_ -K_ -_E_P :
M/[:T_P#Y_P"U_P"_R_XUY-10!ZS_ &UI_P#S_P!K_P!_E_QH_MK3_P#G_M?^
M_P O^->344 >L_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^->344 >L_VUI__
M #_VO_?Y?\:/[:T__G_M?^_R_P"->344 >L_VUI__/\ VO\ W^7_ !H_MK3_
M /G_ +7_ +_+_C7DU% 'K/\ ;6G_ //_ &O_ '^7_&C^VM/_ .?^U_[_ "_X
MUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-10!ZS_;6G_\ /_:_
M]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\
MM?\ O\O^->344 >L_P!M:?\ \_\ :_\ ?Y?\:/[:T_\ Y_[7_O\ +_C7DU%
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M7_&C^VM/_P"?^U_[_+_C7DU% 'K/]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\
MC7DU% 'K/]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XUY-10!ZS_ &UI
M_P#S_P!K_P!_E_QH_MK3_P#G_M?^_P O^->344 >L_VUI_\ S_VO_?Y?\:/[
M:T__ )_[7_O\O^->344 >L_VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"->344
M >L_VUI__/\ VO\ W^7_ !H_MK3_ /G_ +7_ +_+_C7DU% 'K/\ ;6G_ //_
M &O_ '^7_&C^VM/_ .?^U_[_ "_XUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\
MG_M?^_R_XUY-10!ZS_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;
M6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\ O\O^->344 >L_P!M:?\ \_\ :_\
M?Y?\:/[:T_\ Y_[7_O\ +_C7DU% 'K/]M:?_ ,_]K_W^7_&C^VM/_P"?^U_[
M_+_C7DU% 'K/]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\ C7DU% 'K/]M:?_S_
M -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XUY-10!ZS_ &UI_P#S_P!K_P!_E_QH
M_MK3_P#G_M?^_P O^->344 >L_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^->
M344 >L_VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"->344 >L_VUI__/\ VO\
MW^7_ !H_MK3_ /G_ +7_ +_+_C7DU% 'K/\ ;6G_ //_ &O_ '^7_&C^VM/_
M .?^U_[_ "_XUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-10!Z
MS_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\
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MQH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\
<O\O^->344 %%;FFV\4EE&S1(S<\E03U-% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img206306002_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206306002_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .  I(# 2(  A$! Q$!_\0
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MY""X!&?>O0:]#!8^&+3<$U;N<U?#RHM*3W%HI**[C 6BDHH 6BDHH 6BDHH
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M;TW_ ,"T_P :R=8M+:\^(>@QW5O%/&--OV"RH&&?,M><&MK^P='_ .@38?\
M@,G^% $?_"2Z#_T&]-_\"T_QH_X270?^@WIO_@6G^-8'BC1=*CU#PR$TRS4/
MJZJP$"C</(F.#QR.!^5='_8.C_\ 0)L/_ 9/\* (_P#A)=!_Z#>F_P#@6G^-
M'_"2Z#_T&]-_\"T_QJ3^P='_ .@38?\ @,G^%']@Z/\ ] FP_P# 9/\ "@"/
M_A)=!_Z#>F_^!:?XT?\ "2Z#_P!!O3?_  +3_&I/[!T?_H$V'_@,G^%']@Z/
M_P! FP_\!D_PH C_ .$ET'_H-Z;_ .!:?XT?\)+H/_0;TW_P+3_&I/[!T?\
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M>O/]GFOU6&9"[E5+8)Z,/X3S7H_]@Z/_ - FP_\  9/\*/[!T?\ Z!-A_P"
MR?X4WM;SN!Y;>65W>:Q-=)K^A6L;C*+!K&/+38H\D+LQC<&;?U^;&*T?"5O!
MH^NP:AJ.M:%(?[.6VD:'4R2KK)(V0&^]E67))'(/'->@_P!@Z/\ ] FP_P#
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M\V>.N*U+>_T&71YM0DT/34$-R8)$5$.SW9MH'0@\9'/6CI?^OZU%=:^1T/\
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M^T?&7_0MZ/\ ^#J3_P"1J .DHKF_[1\9?]"WH_\ X.I/_D:C^T?&7_0MZ/\
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M)NH\-QZFUF!*]T;41AVV[AGG.S=C _NU2;2=;:Y:X/A#1_-90I8:],.P&?\
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MM,;QMIRF51;W;R1RF(QHJ$G@'</FQC!]:S+/3M=L&5K;PAHRNNX!CKLK'Y@
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MI*X&[O/$<OCKPP+_ $;3K=<W(!AU)I3M*#<<&%>0.@[^HKOJ "BBB@#F[_\
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M.[/(Y<MDDGIGVQ6G10*P4444#.;UG_D=_#'TN_\ T6M=)7-ZS_R._ACZ7?\
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M_P#':/\ A++G_H4_$'_?J'_X[6(P\7"62UD-]+$1(B2KY:'F-2&)P<_-N4
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M ..UTE% '-_\)9=?]"GX@_[]0_\ QVC_ (2RZ_Z%/Q!_WZA_^.UTE% '-_\
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M4@.;_P"$LNO^A3\0?]^H?_CM'_"677_0I^(/^_4/_P =KI** .;_ .$LNO\
MH4_$'_?J'_X[1_PEEU_T*?B#_OU#_P#':Z2B@#F_^$LNO^A3\0?]^H?_ ([1
M_P )9=?]"GX@_P"_4/\ \=KI** .;_X2RZ_Z%/Q!_P!^H?\ X[1_PEEU_P!"
MGX@_[]0__':Z2B@#F_\ A++K_H4_$'_?J'_X[1_PEEU_T*?B#_OU#_\ ':Z2
MB@#F_P#A++K_ *%/Q!_WZA_^.T?\)9=?]"GX@_[]0_\ QVNDHH YO_A++K_H
M4_$'_?J'_P".T?\ "677_0I^(/\ OU#_ /':Z2B@#@;O7I[WQUX85] U:UYN
M5S<)&!R@&>'/ ZG^M=]7-ZS_ ,COX8^EW_Z+6NDH **** .-\1Z39ZSX^T"V
MO4D:(:=?.!',\1R'MAU0@]SQ5[_A _#W_/O>?^#&X_\ CE%__P E(T'_ +!E
M_P#^C+6NDH \[\2^"]#M[[PXL<%T!-JHC?-].<KY$QXR_'('(YKH/^$#\/?\
M^]Y_X,;C_P".4GBO_D(>%O\ L,+_ .D\]=+0!S?_  @?A[_GWO/_  8W'_QR
MC_A _#W_ #[WG_@QN/\ XY7244 <W_P@?A[_ )][S_P8W'_QRC_A _#W_/O>
M?^#&X_\ CE=)FB@#F_\ A _#W_/O>?\ @QN/_CE'_"!^'O\ GWO/_!C<?_'*
MZ,D 9)X]:-R\<CGD<]: .<_X0/P]_P ^]Y_X,;C_ ..4?\('X>_Y][S_ ,&-
MQ_\ '*Z2B@#F_P#A _#W_/O>?^#&X_\ CE'_  @?A[_GWO/_  8W'_QRNDHH
M YO_ (0/P]_S[WG_ (,;C_XY1_P@?A[_ )][S_P8W'_QRNDHH YO_A _#W_/
MO>?^#&X_^.4?\('X>_Y][S_P8W'_ ,<KI** .;_X0/P]_P ^]Y_X,;C_ ..4
M?\('X>_Y][S_ ,&-Q_\ '*Z2B@#F_P#A _#W_/O>?^#&X_\ CE'_  @?A[_G
MWO/_  8W'_QRNDHH YO_ (0/P]_S[WG_ (,;C_XY1_P@?A[_ )][S_P8W'_Q
MRNDHH YO_A _#W_/O>?^#&X_^.4?\('X>_Y][S_P8W'_ ,<KI** .;_X0/P]
M_P ^]Y_X,;C_ ..4?\('X>_Y][S_ ,&-Q_\ '*Z2B@#F_P#A _#W_/O>?^#&
MX_\ CE'_  @?A[_GWO/_  8W'_QRNDHH \[\:^"]#M/"-]/#!="1?+P6OIV'
M,BCH7(KH/^$#\/?\^]Y_X,;C_P".4>/O^1*U#_ME_P"C%KHV94&68 'CDT <
MY_P@?A[_ )][S_P8W'_QRC_A _#W_/O>?^#&X_\ CE=)10!S?_"!^'O^?>\_
M\&-Q_P#'*3_A O#W_/O=_P#@QN/_ (Y72T9&,YXH YO_ (0/P]_S[WG_ (,;
MC_XY1_P@?A[_ )][S_P8W'_QRNDR/6C(QG/% '-_\('X>_Y][S_P8W'_ ,<K
ME+OPWX>TWQ?K#SPW/V>WTBUF .H3@[C+<#[V_..![#\37I^1ZUR;V-MJ'Q$U
M6WNX5FA.D69*-T.)KGKZTG>V@(Y-Y/#']A17B:5?M=,I,L*:G.ZPX<H=S>8.
M,@XP*DDD\(0ZE-#)IVJB!44QN+Z?=*Q>13M'F]!Y9]*[>7P=H$TC.VG(I=MS
M"-V12>.P(&.!QTZ^IIK>"_#[.\C6&6=@Q)F?@@LW'S<<LQX]:KH"ZG+I8^%K
MK5;6RM+#4I$E(#S-?W 5"45PO^LSG:RGIWJM*GA./5/LRZ;JKQ'<D;K?3YED
M#,I"?O>>58<XZ5W<7AW28M074(K;%P,8<2MCA0N<9P3A0,X[57D\':#+*\K6
M)WNQ?(F<8)))(^;CDD\>M+K_ %V#I]W_  3D9T\%PO$BV&L2F1%;]W>SG:26
M4*<R]<HWY4@_X09G=4M=6?RXP[E;RX.TE5;:?WGWL,/;WKMU\-Z0FS;9J-@5
M5^9NBEB._J[?G42>$]$CDEDCLMC2IL<K(XW# 'KZ #/M0_(%YG'/;>%EO/).
MF:DD?[H^<^HS[2'#'M(>1MJ^NB^%3I*ZD;#55AD8+"IOI]TN1E2H\WH1ZXKH
MU\*:*ACVV0'EJJJ/,; "[L<9_P!IOSJ5?#FEKIATX6[?9=P8(97.TCI@YR/P
M- +;4X;48/"EI%<*FG:F)HA@>;?SA2^%)3(E/(#BI[/3O#-]JDEM#IVH^1'$
M[F9K^XPY1BK!?WG."I'..E=6?"6B-*\C619G&&W2N0> ,X)ZX5>?:I[+0-*L
M;J6[M;8+++N#'S&8<DDX!.!DD]*.W]=/\P>VF_\ 7Z'$Q)X%N3(D,.HRNJ[C
M&+^<$C8K=Y0.C@?4$=J@ \%%R/[,U7[.D"RI)]NFY8NZ; /-Z@HU=G_PA?AW
M;(O]FIB1#&WSMRI8N1U_O,?Y= *7_A#= \E8?L \M8_+ \Q_N[F?U_O,QS[T
M=/,.IS=GI?A34?.%I8:H3%"969[ZX55Z_*?WG7@U1L5\)7%A!)-IFK)=R1K(
M;=;Z<L5*@[E_>\K^OM7H5KI%C9I(D$&T2($?YB=P QW-9R>#- CA$26)"@@@
M^?)N'&, [L@>W2A^0+;4Y3R_!!!=;757BV;UE6]N"K?*K;1^]SG#KVIDT?A"
MWED6;3-66-4C9'&H3'S"^<*,2]>#78KX4T-9G9;,*[)L(65P NT+P,X'"@9'
MI2/X/T*2)8VL!L5%10)'& I)'?KECS[T <[8:3X1U+[28++5-ELBO([7UP ,
MJ'V_ZW.<$56L[?P5>!<6FJ1,REPLE]."5V*X/$IX*NIKMX]'LK>UN8+>/RA<
M@"0AB2<*$'4_W5 _"LRU\#:%;Z=!9M:O((@,R-,^YB%5<D[L]%''3BA[.PU;
MJ<M*/!44I4V&L%!SY@O)]N!C)_UO;(S]:N6.F>#[^6Y2.UU-! K,6DOK@!PK
MLA*_O>?F1AVZ5U3>&M'>(Q&R780PQN;HV,]_85%I/A73=(2X\N-I)+AI#(\C
ML<AW9]H&<  N>E'V?,E7ZG&Z=#X4O;FY273]3MT1OW.^_N-SKY4<FXCS./\
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M1)^ZC!6,>9G:>>#B/J,]>>>.HU)+Z73]1BC53NMV$&PG>6VG^N*SO^$6O_\
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M,H@$:ADW;LY+ACUZ=^U;O_"+7_\ T.?B#_R5_P#C%'_"+7__ $.?B#_R5_\
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M'/B%EBV;Y<6H4%BPQS!_L&II(=/F@BDD\?:T\;N53<EJ?F&.WV?CJ/SI6?\
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MDDA;SG&QF\W< %P" N-N:=H>NZMJ7B6RLYY!'"EI('C$+!]VV$AV8\'.YL
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M67C'78ECA-G'/LAWLSQN&ER2=RGH .FTC/'6KFF^(]4&BZK?RR13O]M1(Y!
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M^6:%3(8) L(<99&&[)9?4$ YZ4UKMU&]'KT+"_#C2H[-[6*^U*-&8,2DJ@X
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M1C"CMGWH>[%T7]=_^ 9,L"1QHX\?:XX<X7:+/T!/_+OZ$?G56.XM9)+@?\+
MUU8X653(5M,,2.@_T>MD> -(4S;9+H++%''LWC"[%VY''!( S]!40^'NG[(P
MVH7[O%M$;LT>555"A<!,$8 Z\^](!D.FFY6=X?'VN.L'^L8+:87C/7[/6;;7
M-M<B=O\ A/\ 7DCCF\E79+7#G8K9'^C]/G YKI8/"=G E]&+FZ,5Y&L;1Y55
M0#H5"J #[^U4?^$!LSO9M4U%I)6)ED)BRX*HNT_N\ 80= #UJEO\OQ H 6OV
MHVP^(FM^<&V;=MKUR1U^SXZ@TXQVX>1/^%B:WOC<1N MH2&R1C_CW]0:UAX)
MTP0-")+@*0X^\N0&D9SV]6(^E0#P%IZ13QQWMZGFR^:&4Q[D^8MA6V9 RQI(
M.K,F.2"1CCQ[X@"H\D;,T=H,,APP_P"/?G\*ORZ:T"V[2>/=>47(S%E+7YO_
M "7JU<>![&XD20WU\C12R30E63]VSX)QE#GG)YSU-:-WH*W<]I.U_=I-;QM&
M779F56Z[LKC\L4+9?B#W=CEIVBB9 GCW7I/WXA<JMH-A.>3FWZ<&I-/C&HPW
MD\/CK7Q;VTPB:5EM &)16S_Q[_[57Y/A]IDR;)[R^D"[%CRR#8BEBJC"C@%C
MUR?>KL/A*T32-0TZ:[N[A;]@TTLA0/D(J#&U0!PH[4U:SO\ UM_P0ZF-)%!'
M'YC?$/6]G]X+:$#YBO:W]5(_"H1):YF#_$+74\F7R6W):CYL \?Z/SU%7E^&
M^EQ6;VL-_J42.P8E)5!Q@9'W>A(+'W9OI4]QX#T^XF65KR]!1]ZJ"A RBJ1R
MO((0'GOFDM]?ZV_X(/I8J+9JUO<SK\0-<,-LQ69]MIA2.H_X]ZBACCGO)K5/
M'VOB6(H&#1VHR74,N/\ 1_0BNB3PY:1Z'/I,<DJP3/(Y;Y2P+L6.,KCJ>.*H
M2>";5X@BZGJ*$&)M^]&;=&H4-ED.20!FCJ!D:<%U/4[BP@\=Z^9XF 4;;3]X
M"BOD?Z/Z,*L"T1KF6W'Q!USS8CM==MIP>F/^/?FM#2?!-EI%_'=17U[*(P-L
M4ICVY$:1[N$!SA!WQG/%-D\#6,CRM]NOEW/))$ R?N&=R[%?DYR6/WLT=@?6
MQDE[87<]L?B%KPDA(#_):XR21C/V?KD$5<O-.-@T2W7C[78C+RFY;3G_ ,E^
M*L+X$LT@DB&I:A^\R7;,>XL79RV=G!RYZ8XQ5S5/"EKJOEB6[NT"P"WDV,I\
MU!SALJ??D8HZ@95K8B]FN(K;Q_KDCV^?- 6T^7!(/_+OZ@C\*KHMM)$LJ_$3
M6S&S^6&"VN-WI_Q[\=1706?A:PLFF,;SD31O&P9AT>1Y#T'K(?PQ62WPYTYM
M/BLO[1U)8D/.UT!D& H#83G 44UOY ]M"A>/%9N@?Q[K[*9C"[JEKA&'7/\
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MUX,W+;;@6^,! 2/DB7@]#W],5WU<WK/_ "._ACZ7?_HM:Z2@84444 <W?_\
M)2-!_P"P9?\ _HRUK3U^YN;/0KRXLUW7")E/;GK^ R:Y[Q&FJ2>/M &DW%G!
M<?V=?9:[@:5-N^VR,*ZG.<<Y_"KOV;QM_P!!;P__ ."R;_Y(I-75AIV=SE[[
M5;N]T+0KEC-]HAU9@DDA#%R+28AAA5XR?3M6A#XLUV*V,LMK#+$@\H9B8.6V
M(V\D'&/F/  Z=:@\26_BY;[PX)]3T-F.J@1;-.E4*_D3<MF8Y&,\#')'/&#O
M_9O&W_06\/?^"R;_ .2*<M=@6BL<Y9^-=2M(YWN1%<^?<2>3(L+JIQY "J,D
M@?O'//I5G_A+M9DDBD46ZJC7*2Q_9GP[*J&,*V[T+<_48K:^R^-O^@MX>_\
M!9-_\D4?9?&W_06\/?\ @LF_^2*'J);&'>^+]8TV51-'&\TL%O(%6V<QY<ON
M ^;*D#;R2?I5TZMK(TFTGMD:6XEU/RS$YV@QE&."<' R!SBK_P!F\;?]!;P]
M_P""R;_Y(H^S>-O^@MX?_P#!9-_\D4/>_P#73_(/Z_/_ #,"T\7:\B1036\0
MN#D[)(V9I29)%PK# &P(I.1R#VK0GUK5X_!D.K><);F"=O/2& KYBY90N#D]
M2IR/2K_V;QM_T%O#W_@LF_\ DBC[-XV_Z"WA[_P63?\ R11T!ZRN<Y9>*->M
MM/O9;]F,UBB1DM;;EEDDW/T4@X5=HX/?O3YO&FN0*\WDV["58#'&;=_W6X2;
MF.&Y&4 QVR*Z#[-XV_Z"WA[_ ,%DW_R11]E\;?\ 06\/?^"R;_Y(H#K<G\.:
MIJ>JR7CWL4$,,+K&BHC;F.Q6+9)Z?-C&.W6MZN:^S>-O^@MX>_\ !9-_\D4O
MV;QO_P!!;P__ ."R;_Y(H Z2BN;^S>-_^@MX?_\ !9-_\D4?9O&__06\/_\
M@LF_^2* .DHKF_LWC?\ Z"WA_P#\%DW_ ,D4?9O&_P#T%O#_ /X+)O\ Y(H
MZ2BN;^S>-_\ H+>'_P#P63?_ "11]F\;_P#06\/_ /@LF_\ DB@#I**YO[-X
MW_Z"WA__ ,%DW_R11]F\;_\ 06\/_P#@LF_^2* .DHKF_LWC?_H+>'__  63
M?_)%'V;QO_T%O#__ (+)O_DB@#I**YO[-XW_ .@MX?\ _!9-_P#)%'V;QO\
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M'J* .WHKE%?Q<PR-=\-<#<?^)=+P/?\ TBG$>,!&LAUSPV$;HW]G38/X_:*
M.IHKC[NZ\567E?:->\-IYD@B7.FS?>/ _P"7BI_^*OW8_MSPUG&[']G3=/7_
M (^* .IHKE9&\70AC)KOAI=HR<Z=-P/_  (JM<:AXHMUM&;7?#K"[($.W39C
MO]Q_I'2@#LZ*Y7=XN(4_V]X9PW"G^SY>?I_I%-FD\6V]O)/+KWAI(HOON=.F
MPOU_TB@#K**Y=%\8R/L36_#;-C.T:=,3C_P(J3[-XW_Z"WA__P %DW_R10!T
ME%<W]F\;_P#06\/_ /@LF_\ DBC[-XW_ .@MX?\ _!9-_P#)% !K/_([^&/I
M=_\ HM:Z2N!NX?$R>.O#']H7^DRKFYP+>RDC.W8-PYE;DCH>WO7?4 %%%% '
M-W__ "4C0?\ L&7_ /Z,M:Z2N;O_ /DI&@_]@R__ /1EK724 <WXK_Y"/A;_
M +#"_P#I//725S?BO_D(^%O^PPO_ *3SUTE !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S?C[_D2M0_[9?^
MC%KI*YOQ]_R)6H?]LO\ T8M=)0 4444 %%%% !1110 5RCV_VKQ_K5N&VF70
M[5-V,XS+<UU=<5J6J+HOC;6K]HO-$6C67R;MN<SW(Z]NM#UT ?)X$W"%UO52
M>-(8_.6/#;4C*D9ST)YIUOX*DA\'W>B?:H#+<,&,IB8H2 HY7=WV\X(ZTD7C
MSS1<$:80+>(-(?/&-QD= H..1\A.:7_A.XR!$;%TN&!"@/N4D,ZM@XY V _\
M"%%^O]=Q;%)O 5^\EEG5+98;=V=HDM-HR6<D*=VY5PP&,]O>IK/P)<P7VGW$
M^HQ3+:1A/+$)0 !W8%<-P<. 2<YVC-5/^%C29M;DV:_8VMG<XD^=W&SMCY!E
MCZYK>F\5O'H5GJ*Z<S27,IB$!E P06YW8Z?+GIWIV:LQO6Z92OO!<]YKM[?K
M>01)<2"0%8#YH(C5-I?=RORYQCOUJNO@2_E^TO=ZO&TLY4GRH655PBIP"Q_N
MY_&GQ_$>VD2YE&GR"&"$2,YD'!*HV",<??'/L:!\0E9;918QB:Y5BB"YW$$,
MP4XV_=.PG-2EU025]RLOP[N#:/"VH6Z%@H)AMRNX* ,M\QRQQR?>HKWPAJ-O
MXBLWM$BFT^-Q(L13"J=Q)'^SUSD=<^U7K?Q[Y=I#<ZA:JBRQ1L?*?<%=U!"Y
M[YR?IBM#1_%Z:M)>C[$T$=J&R[R9!*L58'CCE3Z\46M*_;^OT$]8V&WOA6XN
M-8;4(KV-&-T)QOB+E5\M$*C)QSLSG'?CW@UCP2VIW5]=1WHAGN90ZR"/+*H1
M%V9STRA/XU57XAQRP^?%:!PGF!HTDW!BH0C#8Z$2#M6IK/B>XT6Z@6>QC,+6
MIFDQ-\RL"!M''(YZT^71>>WY_H/FNW]WXD&G^$)+/4+&^>:T:2"25F1+<JBA
MPHQ&-QVXVYZGDFJ4G@2]N-2O+N?58F$\JNJI;!,!6<C.#R<.!G_9K0F\5W']
ME+<P6,7G+>+:RQM/E!D9R'QSP1VK,@^($UM9R&_L-TPF982DF%D7SI47/'R_
MZL^M&Z_KJ-7Z?UK_ )CD^'\PRDFHQF,0A%=82)<B-$Y;=]T%,@8[TEG\/[JW
MW--K+2L9%<90X'WB_P#%_$[N?8$#M6W<>)O)M]-869\V]C:39)*$"!0"W..3
MSQZUFGQ[DA(],+R2%#$HG&&5BP!8X^4_(>.>U/6Y-KI&'JW@34;9;*&P:.>W
M# RQ^7A21%$G3/&3&S;ASS73:EX174M0N+EC;(ES'$LB&'<V4S_%GD8(&,=J
MJ3^.G-N[VU@GF"*&55FGV[E=02>G09QGU%2MXYCAB:6XL?+CW3+&WG [_*;:
MW;USCZ4?%^(VKNWHOO(M*\#2:;KB7S7RS1)(SI&8R#&"S$*I#<* 0,8Q4>I>
M Y+W4);B.[MXXGN6G,7D'YMRH#N(89(*D@^]6+CQE<F".>TL(6A>]^R[I+C#
M<,RL2N..5./45%#X^0A]]D76-_*9UDP2^ P 7'3##G/6DW;5^?Z/_(.O]>@C
M^!9TMI5M+^&.:4R>9(]N)-X:1F 8$\X#8_"F#X?%K6*.:]CDE01KYAA_A4$%
M<9Z'T]JTX_%I;1KN^>P*2VLBI)#YH(&Y%<'=CIM8=JJ'Q];B[FB-M&(8UR)S
M<<$^6DG3;PN)!S2<>C_K^KB6KYEU_K]"S<>%'GL-'A\VU6;3XS'O%O\ *05
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M=)]F+F.*429+N #MQCC.>.>U']T%+EU74@7P5?2WK75UJ%H[RAEF"VQPP/\
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M1\+?]AA?_2>>NDKF_%?_ "$?"W_887_TGGKI* "BBB@ HHHH **** "BBB@
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MU;P3W!)8PP%0 8XD"CGH/+) _P!JHKWX>R7$0\F_2.4S/+*QB)$P,C,%?GD
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M (W1_:WBO_H5;;_P:C_XW0!TE%<W_:WBO_H5;;_P:C_XW1_:WBO_ *%6V_\
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M_P#C= '245S?]K>*_P#H5;;_ ,&H_P#C=']K>*_^A5MO_!J/_C= '245S?\
M:WBO_H5;;_P:C_XW1_:WBO\ Z%6V_P#!J/\ XW0!TE%<W_:WBO\ Z%6V_P#!
MJ/\ XW1_:WBO_H5;;_P:C_XW0!TE%<W_ &MXK_Z%6V_\&H_^-T?VMXK_ .A5
MMO\ P:C_ .-T &L_\COX8^EW_P"BUKI*X&[O]>G\=>&!>Z%#:KFY&5OA)P4&
MX_<'0=N]=]0 4444 <W?_P#)2-!_[!E__P"C+6NDKF[_ /Y*1H/_ &#+_P#]
M&6M=)0!S?BO_ )"/A;_L,+_Z3SUTE<WXK_Y"/A;_ +#"_P#I//724 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '-^/O^1*U#_ME_P"C%KI*YOQ]_P B5J'_ &R_]&+724 %%%% !1110 44
M44 %<W;?\E,U3_L#V?\ Z.N:Z2N+U#4UT?QOK5^T9D$6C664!QG,]P/ZT>0'
M:45D:=XDL-4EN8[<3;K<%FWIC< S+E?7YD8?A5=_%EE_9,NH0P7,JQ3B!X@G
MSJQP>1]"#^-'D&QOT5@3^,=*M\*3.TN_88DCRX;) !'OM-,M?&6GW<C)$DTC
MF4QHD:9?A59B1VQO -"U"QT5%8$7BFVNM1CL[>.3?YQAD$@VE< $$>H.:KGQ
MG;0V@DN(9$D>6:*/:,J2CNH!/;.RE=!_7]?<=/17-VGC&TN?#4VKF"9&@C1I
M877:P+*K#'L=PYJGJ_C*\T5].AN]*1)[QFPBW&X #'?'N?RJK.]@Z7.PHK#L
M_$27GB"73%A5$6-9(I6DYF4J#N5<<CG&<]14&K>+$TVZN[<65Q(UL(RS!?E8
M/G[OJ>*3T!Z'1T5@6?C'2;Z^BLX7E,LA*\I@(V2-K>C<'BF77C72K2[DMY5N
M<QL59Q%E>,9YSVR,_6CK8#HJ*YZ/QII$K3)$TSO'((PJQ\R,2R_+Z\JP_"H[
M3QC:SS74,UM<Q20LVU?+^^% )QSU&1D4=; ]#I:*YL^-]()B"&=C*FX'R^%R
MS* Q['*,/PJ>W\56=Q9O<)#<.D<:.[1QY7+*&V@YY.&% &[17/6?BVSNK/4;
MXJXM+1T4,HRS!HT?IZY;'X4VW\7VTNK75C+;SIY3*(WV<-F-'P3GAOGZ4!8Z
M.BN,U#X@06WD2VUC<S0%)&F_=_,FUMN.O!_^M706>N6MZ+HQ)./LW$@=,<XS
M@4=+AUL:=%<Y_P )MI BCD/V@!BP;,7^KVG!+<\#(I]EXJMK[5KNUBAE$%M!
MYIF9<!\.Z';Z@%#S1TN!T%%<[8^-=+U"810I=!BNX%XL _*' Z]2K*1]:B7Q
MSIC,2%GP !LV?O-Q9EV[?^ FCR"QT]%9%CXCL=1G\JW$Q81"4Y3 4>A]_:J9
M\<Z"#*OVH[X@K.NWE<@'^M '1T5A+XNTLPS.YFB:%2TL<B89,>H_(_C5!?&\
M+/;0BVD:>:[:W8*,JBB5XP2?4[,T[:7 ZRBN>UKQ;:Z0;J$QR-<P1^8%885P
M,$X/MFFIXVTA[F*#_2 \K87,7&-Q7=],@C/M26JN!T=%<[/XRTZ);A5CN7N(
M7*>2(_F8@9R!GISUI^B^*[/6=.@FBR+A[83O#C[G'0_T]:%JKH#?HKD;7XA:
M4]A:RW4=Q!<31J_D>7DD$ EAZKSUJ]?^*K;3M82SGBD,#VRS^>BY"[F(^;T'
M% '045S>H^,;&TMU>',KL%8*>.&8J/U4TU?&,)T74-1:QN@MCC>H7[YV@_+[
M<T+5V0K[>9TU%9%IXDL;S4!9()EE;<%+IA2RCYE!]1T(JI/XVTBV!,C3C]Z\
M7^K[H<,?I[T#.BHK ;QCI*/.':91$\B;FCX=D.&"^N"#5K2?$-AK4LT=FSDQ
M=2RX##.,CU%&X%#6?^1W\,?2[_\ 1:UTE<WK/_([^&/I=_\ HM:Z2@ HHHH
MYN__ .2D:#_V#+__ -&6M=)7-W__ "4C0?\ L&7_ /Z,M:Z2@#F_%?\ R$?"
MW_887_TGGKI*YOQ7_P A'PM_V&%_])YZZ2@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ]_R)6H?]LO\
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MKF_^$Q7_ *%_Q!_X+V_QH_X3%?\ H7_$'_@O;_&@#I**YO\ X3%?^A?\0?\
M@O;_ !H_X3%?^A?\0?\ @O;_ !H Z2BN;_X3%?\ H7_$'_@O;_&C_A,5_P"A
M?\0?^"]O\: .DHKF_P#A,5_Z%_Q!_P""]O\ &C_A,5_Z%_Q!_P""]O\ &@#I
M**YO_A,5_P"A?\0?^"]O\:/^$Q7_ *%_Q!_X+V_QH Z2BN;_ .$Q7_H7_$'_
M (+V_P :/^$Q7_H7_$'_ (+V_P : .DHKF_^$Q7_ *%_Q!_X+V_QH_X3%?\
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MBO\ Y"/A;_L,+_Z3SUTE<WXK_P"0CX6_[#"_^D\]=)0 4444 %%%% !1110
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M1($CS,#C@C;@8  X J1? ]M'?17*7]RJI/Y[1[4(=O,>09)7(Y<C@CI6+?\
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M93YPYP<=V'Z_2HV/@UFN)#X\#3S2*_FO,CLH D&T9!XQ*>OH*%\.N_\ P?\
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MQE;L849-@D10ZEBP#$ %@-QQGID^IIZ"U/1:*YO_ (6#X0_Z&+3_ /O\*/\
MA8/A#_H8M/\ ^_PI#.DHKF_^%@^$/^ABT_\ [_"C_A8/A#_H8M/_ ._PH Z2
MBN;_ .%@^$/^ABT__O\ "C_A8/A#_H8M/_[_  H Z2BN;_X6#X0_Z&+3_P#O
M\*/^%@^$/^ABT_\ [_"@#I**YO\ X6#X0_Z&+3_^_P */^%@^$/^ABT__O\
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MA+'6+2X8&Y3$<@/S,@"C\37?4AA1110!S=__ ,E(T'_L&7__ *,M:Z2N;O\
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M@W91XE.,[2I&0<<@\'CTKH/'W_(E:A_VR_\ 1BUTE ',I\0/"*QJ&\3::S
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MG"\%X+&V^T@DB;RAN!/OUI=;^OYZ [VT,.?QO;0"Y<V<QBB\T1L&'[TQL4<
M=L$'K51/'D:7\GVNW:"V50C D$I+YKQD$CME*Z0:%I(EN)1IMIYEQ_KF\E<R
M=_FXYJ"_T'1[NVFCFM;=(W;,Q5 -WS%N3]6)_&CH/J4K[Q='820+)8S$/;)<
MRG<!Y2L2.1W(P>E5CXYC +-ILXC5?,9MZ\1[F4-CODJ>.M;%QH&E7^K1ZI<V
ML-Q<1QB.-I$#;,$G(ST.2:F?1-*EE@DDTZU9X/\ 5,85)3G/''')-'4'Y?TS
MG9?']DK!TA<QQJ_GCNKJH)3ZC/-0IXXN(IVCNM/82M.84@5QNSG RW3M74'1
M-**NITZUP[.[CR5^9G^\3QU/?UIL.@:/;+&L&EV<8C;<@2%1M/7(XZTNMPEJ
ME8R;#QG;ZAJUMIT-I)YLB;I,N,Q'&2".I^HXK1L=2NI]:U*RG2$);E3$4SD@
MJ#\WO5=/"6F1:Z-6BC\N;(.U  ,@ ?@..G2KW]AZ2+N6[_LVT^T2L&DE\E=S
MD="3C)IKS#_@?\$IZ7K<L\=P+X0I,ET]N@BR0<'C.?PI='U6\U#1+BYG%M%<
MQ3SP\9\O]W(R GOT6K]EI>G6"R_8;*VMUG8O)Y,87>3U)QU-5?\ A'M MK62
M/^R=/CMVW%U\A IW?>R,=^_K2Z6\OQ'U^?X:_P# #PWJ-UJNC)=W<<:N\D@1
MHL[9$#$*XSV90#^-:U5[.QL]-MA;V5M#;0+TCA0(H_ 5/O7;NW#;ZYJF)'.:
MS_R._ACZ7?\ Z+6NDKFM8(/C;PN0<@B[_P#1:UTM( HHHH YN_\ ^2D:#_V#
M+_\ ]&6M=)7-W_\ R4C0?^P9?_\ HRUKI* .;\5_\A'PM_V&%_\ 2>>NDKF_
M%?\ R$?"W_887_TGGKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#F_'W_ ")6H?\ ;+_T8M=)7-^/O^1*
MU#_ME_Z,6NDH **** "BBB@ HHHH *XC5HK^;QIK2::6^TG1K+:$?8Q'GW.0
M&[&NWKCKO44TKQ[J]TZ-)MT>R 1>K$SW.!28%,^&M8\Z[GMI+VW:ZN(V;-\2
MXC6+&-V?[WYT^TTC6B]MINI-<W%NQ%Q+))*9/F6-04R3P"Q8X]JL2>+[ZTU"
M^%UID@BBECMXH5D0DN4WDD_2I4\6RZE91K96KP7DTJ)&DA#?*R!]WTP0*8&+
M9>#=0DU*V$MI#;6%O<32IYB12.=P3&>.>0>3S6OKEE>3:OJ@ATQ+_P [3X8X
M8YMHC)#R;OO<9&0?Q%55\8ZI]NMK![2-+MYY$EB$$C-&J[<' Z@[OO=*TM2\
M5OI/B.6SN+9GLEMXG,RD?(S&3J.IX2ENOZ[#NU_7FS)AT&ZFTV6VDTUR+.T6
MT@BD"-\Y^9V7=\I'*CT^7':K1TG7;;PMI-E;I(LD"LLT=O<")O\ 8.X$<#N!
MQ48^(*2O:31V4RV\JR$!L9DP$*E3TYW_ (58F^(>G6I5;NVGA?.&4X.TAG4\
MCL"G7_:%-Z_U_7<5N77^NWZ#=+T#6;33=;=YY!J5XT;I+YV066&-2>O&65A6
M4/#WB[41&-4N) (KA)8_+N,,N0S-R#_"7"#V2M[5?%5Q:QV#VEB9$O;5[@,S
M % H4CC_ (%5:/Q]"J013:?<?;&;;+"A!*?*C9XZ\.IP*:NY?=_E^@GLBI'I
M/B='7SQ-+&Y!F6&Z$;L?)B4$MGD;E?([U<TK0]8L+"\M&DD>.2W!C62;>%E+
MN6 R>!MV>U7=2\5?V5K,]K<V;"SAMXYWN0X^4.SCD=<?)5"Y^($$<,LJ64RQ
M*RHLS$8+,JLHQUY5P<U+5U;N7JY)]B?3['Q!%#JD,QE&^-/LTC7&2&Q@@ '"
M@8K/GT?Q9'? 6M[<F%+=!&S7.06Q\P8$\G=G#=ACTK7E\811:;+J!M&^S+,T
M,;M,B^:58JV 3V*GCO5>'Q7+<:5;ZA&J>5-?+"-W'[LKG/UIO5O^O+]25I;^
MO/\ 0I?V+X@FGA9#=6L12%92UYNDX:0MEP<D<KW]JEAM=6B.FBXM[EKU+II'
M=[CS Z@#=M.<(IX^7CI33X^,]W$+.R,T:O*DZI*IX5(W#*W0C#UL7GBJVM)8
M 8)#'/;"YCD)"A@?X1GJ?8=,BAOK_7?] Y;:?UV&:[X?BUF\TVZET^WEDA)+
MF55)08Z9[\YKGCH7B?3].>VL?.D5U5@#>E#&^]RVTYX&W9QTK4'Q LT=8Y[1
MX9!($DC:52R!D#AL=2"K#I4MQXVBMK>TE;3YV^V,QMU5E)D1<9;VZCCK2M;Y
MB6KN5+'1]?@T_6][SB^NUA>*3[3D;Q#&KXY^4[E;FH)M$\4VUO<K97UU([B1
M5\V[+$#.4P2>#R>:V-4\5KIFH?9OLLDY:.)D1?E.7+=<]/NU#J7BR:"WTZ6S
MLC(E]:O<!F8#R\!3@CO]ZG)Z\S_K3_(:7,E%&4-.\8)/IZHTYC13YTLEYDX+
M,=I7."0"N#UJ73]*\4V=W9&6:YN(DEC:427A(P8DWD\Y.'#X'3FK">/X4C@B
MGTZX^VL0LL*$$K\BMGCKD.#@4[7/%UWI/BJWTY+9&LVBBDEE96^0.S@DM]U<
M;1U]:JS1*::OY%;6/#.I7VN74T37(ADNX)TD6[*A0L84A1GY3D=NN:E\/:=X
MHAUGS=7N)FMQ"JX\\,C'RU!RN>NX-SWS4T?Q T]TD9H) $D,>4<.K$*K#!'!
MR'&/QJ75?&,6F>*[/2'\D+*BF3<_SAFSM 'X'/U%2M+?UN6^MS$L-'\5::]P
M;>.<1"Z>7RC=@K*&FD?Y1G"_*R9%)/H7BJ:Z2] "7*P2!6,R[E9@N!G/MC-;
M,7CJ"2]@M?[.N THW@Y!PFYE#8],J:U-%\0V^MS7D42;6MI-A(D5PPQD$$4M
M]17L[G(6/AKQ%%<S%?M%M#/(A8F\W2[=[ELN#D\%>]+H$NOIXW>RU*6\:" %
M$_?,RL/+3!89P><_-W.?2KEWX]V:GK=G!]F;[''FW(?+.RX#AAVP>*T/^$UA
M.8UL97N1+(AA\Q0P"8)8CMP00#R0136B3Z6_#:XVM_G_ )D>DZ?KUIK,33AS
M9GS]X\_Y%S*[(0H/)*D=>E9%A8^*=0FF<S7T-N]XZLSW9!9%GD&4&<J-FP>^
M*ZO4]=:TTBSO[.V-RMT\81=P4[7&0>:PK?Q^(;:;[?8R"99WCB",,2CSI(UQ
MZ?<[TWUN)=T0C3?%T;W,L,MQOC8LB2W>Y9L.V  3\HV%?RJGJWAOQ1/9W-J&
MFN$FQDQW0C+MY48W-SR-P;BNAU'Q1<6RZ1/!8221WD<DDD+$*Z!0#W],U#)X
M^LEF=(K9YE"(X=)%(VMW;^YCOFDMVA[6D9Z:/XFMG699ID2%V811SX4@S2,<
MJ#@_(4J/PM/KU[X2U)Y%NI=2?;L26Y8 '8N0K9^7G.0#P<BNBT[Q7;ZIJ4]I
M;6\I6(-B<8*,5ZCCIS^=4--\;K((H;ZSDBN)&&P@@AU+LH;VY4\&G>[]?\R5
M9*W8PK.W\8K=B.<W@>W(+/\ :LH(\D[2,_.VW;SS5C0M-\57=G937,][#$R"
M5EEO"7+&).O.<%]QV]LU:/C\->6YBMR\,QVI&.&8F)'49/'\=+9>.YV;RKC3
MV>X9I (8V *[9G3D].B46]V_?];AL[%9-,\9"VC\N2Y0B13(LEX'9AL4. <\
M9;=CTJ;^PO$_VR2X-[=G,C.L9NR4_P!:^!MSC'E[.*V-*\96NL:E]EM;>0H(
M5F:7</E#('&5ZC@UGIXYE;4]@TV0V\J1?9AO4&0N[*&SV&!WIV>P7,R30_%L
MZ1V;*\5L+ 0NT=X0&?RU'W<X!W;N12W>@>*+U;V!WN!;26PCAC>Z#+_JU&#D
M]0V>>]:\OQ"T^W2ZDF@<1V[E"\;JX;@$8(]<XQ3(_']K<.LEK;23PR)'Y0!
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M2D:#_P!@R_\ _1EK724 <WXK_P"0CX6_[#"_^D\]=)7-^*_^0CX6_P"PPO\
MZ3SUTE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!S?C[_D2M0_[9?\ HQ:Z2N;\??\ (E:A_P!LO_1BUTE
M!1110 4444 %%%% !7(SZA;Z7X_UB\NG*PQZ-9EB 2?]?<]A775Q.J:4-;\:
M:UI[2M$)=&LOG0X(Q/<'@_A0!KIXRT:3?MFFS''YCCR&R@W%,'C@Y5ACKQ3A
MXOT=HBRW!W@#]VZ%6R2P (/0Y1ORI@\)Z-:VEQ$WFJ)U"R2/.V\X=F!W$YSE
MSS1%X2T5C!*J/*T(D42&4L6+'+%CW.<]>G- %7_A/=*^T0+F00/ TSS;#L&
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MR\ ]<U9G\,:9<VEE;21R>59Q&&("0CY" ,'UX ZT= CYDMKKUE>V4]U!Y[+
M<21^2PD4X!'R8SR""..A%5/^$QT8Q&43R%%B,K$1,=J@E<'C@Y!&#SQ3U\*Z
M:-*N].83R179!F>29F=\ */F)SP !^%5T\#Z-''#&BW(6%)$3%PW <EF[]22
M:'Y?U_3!>9>?Q'IL:N9)F0H0'5D(925# $>N&%44\<:$X<FXEC"*6/F0LG0
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M^1W\,?2[_P#1:UTE<WK/_([^&/I=_P#HM:Z2@ HHHH YN_\ ^2D:#_V#+_\
M]&6M1:C+<1^+U11JAM7T^42&*.0Q*^Y=N"!@-C=[U6\1Z8FJ^/M MY+F\MP-
M.OGWVEPT+_?MN-RG..>E7O\ A#+;_H->(/\ P:S?_%4K?K^*L!S=[-J$OAKP
MN2MX+]=4D5/M:,LA;R+C;G=SZ5.FH:I9:9!]ACUHW#J3=/<6LLI$H'"J&'"D
M[LL.!@>U,\2^$[>&^\.*-6UQ_-U4(2^I2L5_<3'*Y/!XZCL3ZUO_ /"&6W_0
M:\0?^#6;_P"*JF[MON"T5C N]3\4WHEMWM+M"=A>-+9@$PT1RKX^;.9,C/\
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M:\0?^#6;_P"*H Z2BN;_ .$,MO\ H->(/_!K-_\ %4?\(9;?]!KQ!_X-9O\
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MU7_"&Z1YD;!)@J!?W8E.PE1@,1T) XS5]M$LFM+.V*-Y5H@CB&X\  #\>!7
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M?]!OQ!_X-)?\:/\ A#(/^@WX@_\ !I+_ (UTM% '-?\ "&0?]!OQ!_X-)?\
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M02 $%?T(-/L;&WTZU6VMDV1@EL>I)))/N22:IO<78L45%+<PP21))(JM*VU
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M1W\,?2[_ /1:UTE<WK/_ "._ACZ7?_HM:Z2D,**** .;O_\ DI&@_P#8,O\
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M^A!'%6ZBMK6"SMH[>VB6*&,;411@ 5+0QHYO6?\ D=_#'TN__1:UTE<WK/\
MR._ACZ7?_HM:Z2@ HHHH YN__P"2D:#_ -@R_P#_ $9:UTE<W?\ _)2-!_[!
ME_\ ^C+6NDH YOQ7_P A'PM_V&%_])YZZ2N;\5_\A'PM_P!AA?\ TGGKI* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#F_'W_(E:A_VR_\ 1BUTE<WX^_Y$K4/^V7_HQ:Z2@ HHHH ****
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MH0LRM.LBJ[M&+:1F5%=DR0%XR4/!YXZ597Q9H3"(_P!HQCS<; RL">O8C/\
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MFB>X:'9,(D\V)U+?(K;B",J/FQEL=*L0^*K&[U"]M+7S)?LD'FN^QE4G<RD
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M=1M6W,233?%4S6Q-W=H%6)7VRHI(Q\Y/)YJ75QXK_L/2%LK::34!"INF2X1
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M)@C'2CHOZZ?YA_7]?(J+XI\/1+<3)>*/WH60K$Y+/C P ,MTQD9'% \9^'S
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M"4VS*=V.#CGGH:!JNG-$)1?VIC+;0XF7&[TSGK0!;HJ$W=L%9C<1!57<3O&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '-^/O\ D2M0_P"V7_HQ:Z2N;\??\B5J'_;+_P!&+724 %%%% !1110
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MJ&[\=76GW\]I-8V\D@NWAB"7&/E54/S97ACOX'ZU3U]WU_R?YDI)?/\ X?\
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M>>/RSJZ;1#Y8+6FYL^6B$D[^1\F<>]7;;P9-:ZMITYNEDCC>26Y*IY8=BY=
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M' /'S8!&>E))\0I(I9HSI2EH+=)9 +@'YFC5\#CYE^;&X=P>*"E=Z?UT_P"
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MXEG3_ 0M'B,]^DXB"*H%MMR%4*"WS')XR34<OP[CDMS%_:<BC[(L Q'_ ,M
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M]W'X5Q\W@'4+G7+U#-'%8R(%AD" [ (XUR!G))*'(Z=.>36R? 430;#>A7$
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M:0-N.,$=NE3>?H\P6'SK%_,PRIN0[L<9 []*Q=*\'-IRWHDOHY?M$)A4+;[
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MAS<!@'^U),X_\!O<U+%/XP@C$<7A[0(T'15U:4 ?^2U"![Z'3T5S?VWQK_T
MM"_\&\O_ ,C4?;?&O_0"T+_P;R__ "-0!TE%<W]M\:_] +0O_!O+_P#(U'VW
MQK_T M"_\&\O_P C4 =)17-_;?&O_0"T+_P;R_\ R-1]M\:_] +0O_!O+_\
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M]M\:_P#0"T+_ ,&\O_R-0!TE%<W]M\:_] +0O_!O+_\ (U'VWQK_ - +0O\
MP;R__(U '245S?VWQK_T M"_\&\O_P C4?;?&O\ T M"_P#!O+_\C4 =)17-
M_;?&O_0"T+_P;R__ "-1]M\:_P#0"T+_ ,&\O_R-0!TE%<W]M\:_] +0O_!O
M+_\ (U'VWQK_ - +0O\ P;R__(U '245S?VWQK_T M"_\&\O_P C4?;?&O\
MT M"_P#!O+_\C4 =)17-_;?&O_0"T+_P;R__ "-1]M\:_P#0"T+_ ,&\O_R-
M0!TE%<W]M\:_] +0O_!O+_\ (U'VWQK_ - +0O\ P;R__(U !K/_ "._ACZ7
M?_HM:Z2N!N[GQ+)XZ\,"_P!+TN!<W(!@U"24[=@W'!A7D#H._J*[Z@ HHHH
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M (T?\)+H/_0;TW_P+C_QJ3^P='_Z!-C_ . R?X4?V#H__0)L?_ 9/\* (_\
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M&3_"@"/_ (270?\ H-Z;_P"!<?\ C1_PDN@_]!O3?_ N/_&I/[!T?_H$V/\
MX#)_A1_8.C_] FQ_\!D_PH C_P"$ET'_ *#>F_\ @7'_ (T?\)+H/_0;TW_P
M+C_QJ3^P='_Z!-C_ . R?X4?V#H__0)L?_ 9/\* .9\<^(-%G\'7\<.KV$CG
MR\*ERA)_>+V!IOBS4=-U%K!]/U/27N(I#B9]0C7R@<9)4AMP./8]*F\=:+I4
M7@V_>/3+-''EX98%!'[Q?:NB_L'1_P#H$V/_ (#)_A0!"GB70Q&H?7-,+ #)
M%T@!/YT[_A)=!_Z#>F_^!<?^-2?V#H__ $";'_P&3_"C^P='_P"@38_^ R?X
M4 <;J]S;W/B7^U+/5/#["*V>*-;C44PY;;U4)QTZY;H.*J;K>X\,'P]_;6BV
M6%,LLRWB312N[.60#*D#)!]L@<UWO]@Z/_T";'_P&3_"C^P='_Z!-C_X#)_A
M1;2P[G(::-*MY;*6\UG0)7LM.6WC*7"#?+C#%L_PX5 /QJ*0:?#H5O9VVJZ
M\HN#=SA[Y421R3E. ?EP0,X_A'%=I_8.C_\ 0)L?_ 9/\*/[!T?_ *!-C_X#
M)_A0]?Z^8OZ_0\\L+&TM;ZV=];T!HA,)WD%\N^([Y&V(,<K^\'.1T/%:=UJN
MB7WC36HSJNF&.;1;:-'DN$V%O-N>,YZC(_,5V']@Z/\ ] FQ_P# 9/\ "N=M
MM%TH_$?4HCIEGY8TBT8)Y"X!,UQDXQUX'Y4/4$8,>GV%L89;;Q!HL4R10PML
MOE"E5C*L,=.6P:OZ1/!9"_CG\0:,R3VL4:-_: 9O,5-K>@"\#'&>M=C_ &#H
M_P#T";'_ ,!D_P */[!T?_H$V/\ X#)_A3;O?S%8X[0;B+3K.^@N?$.C9E@1
M8I%U .V\+@Y)P O3&!ZUAVMK<623&VU[0(VG<F1?[7) _=PKOR5R3F-SCWZU
MZ;_8.C_] FQ_\!D_PH_L'1_^@38_^ R?X47UN4G8X[1)+:TN=4?4/$NES"Y#
MJC+J"G()8KE3TP"!P>U4+&&.TN=."Z]HJ0VRHI9=5R4VL^["D8;<"IY(QT[<
M^@?V#H__ $";'_P&3_"C^P='_P"@38_^ R?X4NMQ=SSZ\@1]>U6\L_$&BP)=
M.9$D&IC<W[N)0K)C Y1N03UI9U>^N8+FX\1:%&Z3^:4740X0<XP2!GJ/2O0/
M[!T?_H$V/_@,G^%']@Z/_P! FQ_\!D_PI6V\E8&[JQYE!IQ5Y)/^$BT.%WA,
M;LNJ;R[80;\D#&=K' Z9I+V]BL?$-A;IK%C/IT<GF($U 9Y8Y .>O<[N,8Q7
MIW]@Z/\ ] FQ_P# 9/\ "C^P='_Z!-C_ . R?X4UHTP>L>4XJ^-I<:K>>7K>
MA_8[B]2]\QK]0ZE85CV;<8_ASG/?I5(:3I%GHUM'::WI,NI+L+S2:C&BQE0!
M\H"'<..XS[UZ%_8.C_\ 0)L?_ 9/\*/[!T?_ *!-C_X#)_A0];#N<-KXAU'6
M8KVSU_1$D^QQP&X.HA&B=6<E@@R&'S#@D52CM&&BFV?Q3I'VHR;G?^T@0W"@
ML.,@G!./>O1O[!T?_H$V/_@,G^%']@Z/_P! FQ_\!D_PH%UN>8WU[%8^(+&W
M36+&?3HY/,0)J SRQR <]>YW<8QBM;7$MK^ZOKFU\2Z4&FN8V1&U$*/)6-05
MXS@[@Q_&NX_L'1_^@38_^ R?X4?V#H__ $";'_P&3_"DEHEV#JWW.">RLI[@
MRS>)]-;&Q5SJ8SM$2+@XQ_&K'\?PJ!(9R69O%6CI<B)O])74@?-<A=N4QA0N
M",@G/6O1/[!T?_H$V/\ X#)_A1_8.C_] FQ_\!D_PI]6P>IYX;>4W?G'Q;I6
MYH@=RZB!LD/+J!C!7<3@\'!]JEAMK(>%=;T]M7T..>^E62.,:IO08C13ER >
M2I/3O7??V#H__0)L?_ 9/\*/[!T?_H$V/_@,G^%-.U[=?\[@<#I%PEEKEI'<
M>(M,%EAYI8H]05UC82,44,<%AM(!X'2G7L%I=W]X1K'A^**2X:=+A;]?-;*@
M;&&.!D>I^E=Y_8.C_P#0)L?_  &3_"C^P='_ .@38_\ @,G^%0XI[]FOOM_D
M@ZW^?]?>SRZVT6)+&.&37_#ZM',)A_Q,%?=B-%V$A5^4E3GCTZ]:],7Q+H6T
M9UK3 <<@7:8'ZU+_ &#H_P#T";'_ ,!D_P */[!T?_H$V/\ X#)_A5MW$DD1
M_P#"2Z#_ -!O3?\ P+C_ ,:/^$ET'_H-Z;_X%Q_XU)_8.C_] FQ_\!D_PH_L
M'1_^@38_^ R?X4AD?_"2Z#_T&]-_\"X_\:/^$ET'_H-Z;_X%Q_XU)_8.C_\
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MK_Y"/A;_ +#"_P#I//725S?BO_D(^%O^PPO_ *3SUTE !1110 4444 %%%%
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M.-+:&"5H;J-99/+.]5!0]<D;NF.XS2V7B^"[O+[=;S0V=M;).LL@&9 S,N0
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M1H/C!VBF\X,RVN2=JK@D..,(.*]+HIW#I8\WO[6TU&_:\G\*>*?-:1Y"%6W
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M@_[\P_\ QR@#I ,# HKF_P#A++C_ *%3Q!_WYA_^.4?\)9<?]"IX@_[\P_\
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/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>img206306002_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206306002_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -\ JX# 2(  A$! Q$!_\0
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M#1N ,EMP/0=*E;PXQVR+J5R+A8MGFGDD[MV3^>,5$GA8HS7 OV%\91*)UB4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:)_X'Q?_ !5 '145SO\ PGW@[_H:M$_\#XO_ (JC_A/O!W_0U:)_X'Q?_%4
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M_@?%_P#%4 =%17._\)]X._Z&K1/_  /B_P#BJ/\ A/O!W_0U:)_X'Q?_ !5
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M !5 '145SO\ PGW@[_H:M$_\#XO_ (JC_A/O!W_0U:)_X'Q?_%4 =%17._\
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M*?\ @$E']@8SLOQ_R#Z]2$HI?^$%\2?]#2G_ (!)1_P@OB3_ *&E/_ )*/[
MQG9?C_D'UZD)12_\(+XD_P"AI3_P"2C_ (07Q)_T-*?^ 24?V!C.R_'_ "#Z
M]2$HI?\ A!?$G_0TI_X!)1_P@OB3_H:4_P# )*/[ QG9?C_D'UZD)12_\(+X
MD_Z&E/\ P"2C_A!?$G_0TI_X!)1_8&,[+\?\@^O4A**7_A!?$G_0TI_X!)1_
MP@OB3_H:4_\  )*/[ QG9?C_ )!]>I"44O\ P@OB3_H:4_\  )*/^$%\2?\
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M*?\ @$E']@8SLOQ_R#Z]2$HI?^$%\2?]#2G_ (!)1_P@OB3_ *&E/_ )*/[
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M_P"@W#_X!1T?\)WXR_Z#</\ X!1T?4*_;\0^LT^Y[M17A/\ PG?C+_H-P_\
M@%'1_P )WXR_Z#</_@%'1]0K]OQ#ZS3[GNU%>$_\)WXR_P"@W#_X!1T?\)WX
MR_Z#</\ X!1T?4*_;\0^LT^Y[M17A/\ PG?C+_H-P_\ @%'1_P )WXR_Z#</
M_@%'1]0K]OQ#ZS3[GNU%>$_\)WXR_P"@W#_X!1T?\)WXR_Z#</\ X!1T?4*_
M;\0^LT^Y[M17A/\ PG?C+_H-P_\ @%'1_P )WXR_Z#</_@%'1]0K]OQ#ZS3[
MGNU%>$_\)WXR_P"@W#_X!1T?\)WXR_Z#</\ X!1T?4*_;\0^LT^Y[M17A/\
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MWXR_Z#</_@%'1]0K]OQ#ZS3[GNU%>$_\)WXR_P"@W#_X!1T?\)WXR_Z#</\
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MYVDM/ZM^I$HQMHS%HHHKH,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSYO_ +9TO_H)6?\ W_7_ !H_MG2_^@E9_P#?]?\ &OI#R(?^>2?]\BCR(?\
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M:/[9TO\ Z"5G_P!_U_QKZ0\B'_GDG_?(H\B'_GDG_?(H_M.?\J#ZI'N?-_\
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MUITC^(.A/(RHHTR_RS' '[RUK;CECEC$D;JZ'HRG(/XT 8']O:[_ -"=?_\
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MZ$L 0"0">@]:19$<X5U;Z'- '/\ ]O:[_P!"=?\ _@9;?_'*/[>UW_H3K_\
M\#+;_P".5T5!( R3@"@#G?[>UW_H3K__ ,#+;_XY1_;VN_\ 0G7_ /X&6W_Q
MRNB!! (.0>])N4KNW#;ZYXH Y[^WM=_Z$Z__ / RV_\ CE']O:[_ -"=?_\
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M_M[7?^A.O_\ P,MO_CE=%10!SO\ ;VN_]"=?_P#@9;?_ !RC^WM=_P"A.O\
M_P #+;_XY7144 <[_;VN_P#0G7__ (&6W_QRC^WM=_Z$Z_\ _ RV_P#CE=%1
M0!SO]O:[_P!"=?\ _@9;?_'*/[>UW_H3K_\ \#+;_P".5T5% '._V]KO_0G7
M_P#X&6W_ ,<H_M[7?^A.O_\ P,MO_CE=%10!SO\ ;VN_]"=?_P#@9;?_ !RC
M^WM=_P"A.O\ _P #+;_XY7144 <[_;VN_P#0G7__ (&6W_QRC^WM=_Z$Z_\
M_ RV_P#CE=%10!SO]O:[_P!"=?\ _@9;?_'*/[>UW_H3K_\ \#+;_P".5T5%
M '._V]KO_0G7_P#X&6W_ ,<H_M[7?^A.O_\ P,MO_CE=%10!SO\ ;VN_]"=?
M_P#@9;?_ !RC^WM=_P"A.O\ _P #+;_XY7144 <[_;VN_P#0G7__ (&6W_QR
MC^WM=_Z$Z_\ _ RV_P#CE=%10!SO]O:[_P!"=?\ _@9;?_'*/[>UW_H3K_\
M\#+;_P".5T5% '._V]KO_0G7_P#X&6W_ ,<H_M[7?^A.O_\ P,MO_CE=%10!
MSO\ ;VN_]"=?_P#@9;?_ !RC^WM=_P"A.O\ _P #+;_XY7144 <[_;VN_P#0
MG7__ (&6W_QRC^WM=_Z$Z_\ _ RV_P#CE=%10!SO]O:[_P!"=?\ _@9;?_'*
M/[>UW_H3K_\ \#+;_P".5T5% '._V]KO_0G7_P#X&6W_ ,<H_M[7?^A.O_\
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M2:NCX.5#LI.>1P<^I_.M"V\-Z?:,6B$HW')!<D'@C^1--G\-6<\T,IDG#Q<
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M ;BV0@R<^IK?HH%8QI?#ZR.&%TZD=]O; ']/UJWI>F+I<$D:R&0R2&0L1CG
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M-_C3_GWT#_O_ #?_ !%=%10!SN_QI_S[Z!_W_F_^(HW^-/\ GWT#_O\ S?\
MQ%=%10!SN_QI_P ^^@?]_P";_P"(HW^-/^??0/\ O_-_\17144 <[O\ &G_/
MOH'_ '_F_P#B*-_C3_GWT#_O_-_\17144 <[O\:?\^^@?]_YO_B*-_C3_GWT
M#_O_ #?_ !%=%10!Y_X=?Q9_:/B3R8-%+?VI^]WS2@!_L\'W<+TQMZ]\UO;_
M !I_S[Z!_P!_YO\ XBCPQ_R%/%7_ &%__;:WKHJ .=W^-/\ GWT#_O\ S?\
MQ%&_QI_S[Z!_W_F_^(KHJ* .=W^-/^??0/\ O_-_\11O\:?\^^@?]_YO_B*Z
M*B@#S_QF_BP^$[W[3!HHA_=[C%-*6_UBXQE<=:WM_C3_ )]] _[_ ,W_ ,12
M>._^1,O_ /MG_P"C%KHZ .=W^-/^??0/^_\ -_\ $4;_ !I_S[Z!_P!_YO\
MXBNBHH YW?XT_P"??0/^_P#-_P#$4;_&G_/OH'_?^;_XBNBHH YW?XT_Y]]
M_P"_\W_Q%8-N_BS_ (3[4"(-%^T?V7:[@9I=FSS9\8.W.<[L_A7H%<Y;?\E(
MU/\ [!%I_P"CKF@!=_C3_GWT#_O_ #?_ !%&_P :?\^^@?\ ?^;_ .(KHJ*
M.=W^-/\ GWT#_O\ S?\ Q%&_QI_S[Z!_W_F_^(KHJ* .=W^-/^??0/\ O_-_
M\11O\:?\^^@?]_YO_B*Z*B@#G=_C3_GWT#_O_-_\11O\:?\ /OH'_?\ F_\
MB*Z*B@#G=_C3_GWT#_O_ #?_ !%&_P :?\^^@?\ ?^;_ .(KHJ* .=W^-/\
MGWT#_O\ S?\ Q%&_QI_S[Z!_W_F_^(KHJ* .=W^-/^??0/\ O_-_\11O\:?\
M^^@?]_YO_B*Z*B@#G=_C3_GWT#_O_-_\11O\:?\ /OH'_?\ F_\ B*Z*B@#G
M=_C3_GWT#_O_ #?_ !%&_P :?\^^@?\ ?^;_ .(KHJ* .=W^-/\ GWT#_O\
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MLW0=>WO6]10 4444 %%%% '.^&/^0IXJ_P"PO_[;6]=%7.^&/^0IXJ_["_\
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M'_T'-?\ _!B]+X8_Y"GBK_L+_P#MM;UT5 '.?\(A'_T'-?\ _!B]'_"(1_\
M0<U__P &+UT=-,B*VTNH;T)YH Y[_A$(_P#H.:__ .#%Z/\ A$(_^@YK_P#X
M,7KHZ* //_&?A>.V\)WLHUC6I"OE_++?.RG]XHY%;O\ PB$?_0<U_P#\&+T>
M._\ D3+_ /[9_P#HQ:Z.@#G/^$0C_P"@YK__ (,7H_X1"/\ Z#FO_P#@Q>NC
MHH YS_A$(_\ H.:__P"#%Z/^$0C_ .@YK_\ X,7KHZ* .<_X1"/_ *#FO_\
M@Q>L*W\+QGQ]J%O_ &QK0"Z7:OO%\^\YEG&"?08X'N?6O0*YRV_Y*1J?_8(M
M/_1US0 ?\(A'_P!!S7__  8O1_PB$?\ T'-?_P#!B]='10!SG_"(1_\ 0<U_
M_P &+T?\(A'_ -!S7_\ P8O71T4 <Y_PB$?_ $'-?_\ !B]'_"(1_P#0<U__
M ,&+UT=% '.?\(A'_P!!S7__  8O1_PB$?\ T'-?_P#!B]='10!SG_"(1_\
M0<U__P &+T?\(A'_ -!S7_\ P8O71T4 <Y_PB$?_ $'-?_\ !B]'_"(1_P#0
M<U__ ,&+UT=% '.?\(A'_P!!S7__  8O1_PB$?\ T'-?_P#!B]='10!SG_"(
M1_\ 0<U__P &+T?\(A'_ -!S7_\ P8O71T4 <Y_PB$?_ $'-?_\ !B]'_"(1
M_P#0<U__ ,&+UT=% '.?\(A'_P!!S7__  8O1_PB$?\ T'-?_P#!B]='10!S
MG_"(1_\ 0<U__P &+T?\(A'_ -!S7_\ P8O71T4 <Y_PB$?_ $'-?_\ !B]'
M_"(1_P#0<U__ ,&+UT=% '.?\(A'_P!!S7__  8O1_PB$?\ T'-?_P#!B]='
M10!SG_"(1_\ 0<U__P &+T?\(A'_ -!S7_\ P8O71T4 <Y_PB$?_ $'-?_\
M!B]'_"(1_P#0<U__ ,&+UT=% '.?\(A'_P!!S7__  8O1_PB$?\ T'-?_P#!
MB]='10!SG_"(1_\ 0<U__P &+T?\(A'_ -!S7_\ P8O71T4 <Y_PB$?_ $'-
M?_\ !B]'_"(1_P#0<U__ ,&+UT=% '.?\(A'_P!!S7__  8O1_PB$?\ T'-?
M_P#!B]='10!SG_"(1_\ 0<U__P &+T?\(A'_ -!S7_\ P8O71T4 <Y_PB$?_
M $'-?_\ !B]'_"(1_P#0<U__ ,&+UT=% '.?\(A'_P!!S7__  8O1_PB$?\
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MP'7[/ ,CYN1D$9]0:WO^$V\*?]#/HO\ X'Q?_%4 ;M4KG3A<W]O=F4JT'W5
MXYZY_2L__A-O"G_0SZ+_ .!\7_Q5'_";>%/^AGT7_P #XO\ XJ@#=HK"_P"$
MV\*?]#/HO_@?%_\ %4?\)MX4_P"AGT7_ ,#XO_BJ (?'?_(F7_\ VS_]&+71
MUPGC3Q=X:NO"5[#;^(=)FE;R]J1WL;,<2*> &K>_X3;PI_T,^B_^!\7_ ,50
M!NT5A?\ ";>%/^AGT7_P/B_^*H_X3;PI_P!#/HO_ ('Q?_%4 ;M%87_";>%/
M^AGT7_P/B_\ BJ/^$V\*?]#/HO\ X'Q?_%4 ;M<Y;?\ )2-3_P"P1:?^CKFI
MO^$V\*?]#/HO_@?%_P#%5@V_B[PT/B!J-R?$.DB!]+M8UE-['M+"6X)4'=C(
M#*2/<>M '=T5A?\ ";>%/^AGT7_P/B_^*H_X3;PI_P!#/HO_ ('Q?_%4 ;M%
M87_";>%/^AGT7_P/B_\ BJ/^$V\*?]#/HO\ X'Q?_%4 ;M%87_";>%/^AGT7
M_P #XO\ XJC_ (3;PI_T,^B_^!\7_P 50!NT5A?\)MX4_P"AGT7_ ,#XO_BJ
M/^$V\*?]#/HO_@?%_P#%4 ;M%87_  FWA3_H9]%_\#XO_BJ/^$V\*?\ 0SZ+
M_P"!\7_Q5 &[16%_PFWA3_H9]%_\#XO_ (JC_A-O"G_0SZ+_ .!\7_Q5 &[1
M6%_PFWA3_H9]%_\  ^+_ .*H_P"$V\*?]#/HO_@?%_\ %4 ;M%87_";>%/\
MH9]%_P# ^+_XJC_A-O"G_0SZ+_X'Q?\ Q5 &[16%_P )MX4_Z&?1?_ ^+_XJ
MC_A-O"G_ $,^B_\ @?%_\50!NT5A?\)MX4_Z&?1?_ ^+_P"*H_X3;PI_T,^B
M_P#@?%_\50!NT5A?\)MX4_Z&?1?_  /B_P#BJ/\ A-O"G_0SZ+_X'Q?_ !5
M&[16%_PFWA3_ *&?1?\ P/B_^*H_X3;PI_T,^B_^!\7_ ,50!NT5A?\ ";>%
M/^AGT7_P/B_^*H_X3;PI_P!#/HO_ ('Q?_%4 ;M%87_";>%/^AGT7_P/B_\
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M4_Z&?1?_  /B_P#BJ/\ A-O"G_0SZ+_X'Q?_ !5 &[6-X%_Y E[_ -A?4?\
MTKEJ/_A-O"G_ $,^B_\ @?%_\51\/IXKGPY<SP2I+#+JNH/')&P974W4I!!'
M!!'>@!-9C23XAZ"KHK#^S;\X89_Y:6M;'V6W_P"?>+_O@5B:].EMX^T*5\[1
MIM\./>6U']:T#K=BLC(\I5U)&-A.<>G% %O[+;_\^\7_ 'P*/LMO_P ^\7_?
M JD?$&FC&)R692RJ$;+ >G'-*-=TXV?VH7 ,6[;D DYQG&* +GV6W_Y]XO\
MO@4?9;?_ )]XO^^!54:U8%-QFVX(&"I!R1D#I0-:L=C,TI7:P4AD(.3TXQ[&
M@"U]EM_^?>+_ +X%'V6W_P"?>+_O@54CURPE\W;,2(F"L=IX)R<?D#43^(]-
M6-G$Q< X^52<FAZ :'V6W_Y]XO\ O@4?9;?_ )]XO^^!51=;L7.U9&+C&5$;
M9&?PI5UNP=]@F^?TVGZ9Z=/>CR M?9;?_GWB_P"^!1]EM_\ GWB_[X%5(M;L
MI9!'N=7+E%4H?F(]*1M;M899$N<P;'* N0=Q !.,?4?G0%BY]EM_^?>+_O@4
M?9;?_GWB_P"^!5)O$&F*R*;@[G&578V2/IBI8-7M+AR@=E8(7PRD?+Z_2@"Q
M]EM_^?>+_O@4?9;?_GWB_P"^!5%?$&G-*Z"8X3 W!202>@!'?B@>(-.:=X1,
MQ:/[WR'@\\=.>E 6+WV6W_Y]XO\ O@4?9;?_ )]XO^^!5-]=L$M_/$I:/<%S
M@CKGGGMP?RIO_"0:>94C$K%G_P!@^F?2@=F7OLMO_P ^\7_? H^RV_\ S[Q?
M]\"J$?B+390Y6<[4."VP_P"'OUJS;:I9W<_DPS;I-N[;M(./QH6HMB;[+;_\
M^\7_ 'P*/LMO_P ^\7_? J:B@"'[+;_\^\7_ 'P*/LMO_P ^\7_? J:B@#F/
M#-M =4\4YAC.-6P/D''^C05T/V6W_P"?>+_O@5A^&/\ D*>*O^PO_P"VUO71
M4 0_9;?_ )]XO^^!1]EM_P#GWB_[X%344 0_9;?_ )]XO^^!1]EM_P#GWB_[
MX%344 <QXZMH%\&WY6&,']WR$'_/1:Z'[+;_ //O%_WP*PO'?_(F7_\ VS_]
M&+71T 0_9;?_ )]XO^^!1]EM_P#GWB_[X%34A. 3C.* (OLMO_S[Q?\ ? H^
MRV__ #[Q?]\"F65]%?Q/)#NVHY0Y&.1UJS0!#]EM_P#GWB_[X%<];6T'_"Q]
M37R8\?V1:'&P?\]KFNGKG+;_ )*1J?\ V"+3_P!'7- &[]EM_P#GWB_[X%'V
M6W_Y]XO^^!4U% $/V6W_ .?>+_O@4?9;?_GWB_[X%344 0_9;?\ Y]XO^^!1
M]EM_^?>+_O@5-10!#]EM_P#GWB_[X%'V6W_Y]XO^^!4U% $/V6W_ .?>+_O@
M4?9;?_GWB_[X%344 0_9;?\ Y]XO^^!1]EM_^?>+_O@5-10!#]EM_P#GWB_[
MX%'V6W_Y]XO^^!4U% $/V6W_ .?>+_O@4?9;?_GWB_[X%344 0_9;?\ Y]XO
M^^!1]EM_^?>+_O@5-10!#]EM_P#GWB_[X%'V6W_Y]XO^^!4U% $/V6W_ .?>
M+_O@4?9;?_GWB_[X%344 0_9;?\ Y]XO^^!1]EM_^?>+_O@5-10!#]EM_P#G
MWB_[X%'V6W_Y]XO^^!4U% $/V6W_ .?>+_O@4?9;?_GWB_[X%344 0_9;?\
MY]XO^^!1]EM_^?>+_O@5-10!#]EM_P#GWB_[X%'V6W_Y]XO^^!4U% $/V6W_
M .?>+_O@4?9;?_GWB_[X%344 0_9;?\ Y]XO^^!1]EM_^?>+_O@5-10!#]EM
M_P#GWB_[X%'V6W_Y]XO^^!4U% $/V6W_ .?>+_O@4?9;?_GWB_[X%344 0_9
M;?\ Y]XO^^!1]EM_^?>+_O@5-10!#]EM_P#GWB_[X%'V6W_Y]XO^^!4U% $/
MV6W_ .?>+_O@4?9;?_GWB_[X%344 0_9;?\ Y]XO^^!67X$ 70KP   :OJ
M';_2Y:VJQO O_($O?^POJ/\ Z5RT 0ZW&DWQ T..10R-IE^"#W_>6M6Y/#VF
M2 _Z.%SW7C%97BG4X-)\=Z!<7$=U(AT^^3%M:R3MG?;'[L:DXXZXQ4W_  FN
ME_\ /IKG_@DN_P#XW18#4_L73?ES9Q$J-H)7H*?_ &38>1Y'V2+RMV[9MXSZ
MUD?\)KI?_/IKG_@DN_\ XW1_PFNE_P#/IKG_ ()+O_XW0!K/I.GR;=]I$=IR
M,KT-']D:?G/V.+/^[63_ ,)KI?\ SZ:Y_P""2[_^-T?\)KI?_/IKG_@DN_\
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M)KI?_/IKG_@DN_\ XW0!T=%<Y_PFNE_\^FN?^"2[_P#C='_":Z7_ ,^FN?\
M@DN__C= '1T5SG_":Z7_ ,^FN?\ @DN__C='_":Z7_SZ:Y_X)+O_ .-T 'CO
M_D3+_P#[9_\ HQ:Z.O/_ !GXNTZZ\)WL,=KK"LWEX,FD72+Q(IY+1@"MW_A-
M=+_Y]-<_\$EW_P#&Z .CI" P((R#P17._P#":Z7_ ,^FN?\ @DN__C='_":Z
M7_SZ:Y_X)+O_ .-T ;T-O#;@B&-4#')VCKVJ6N<_X372_P#GTUS_ ,$EW_\
M&Z/^$UTO_GTUS_P27?\ \;H Z.N<MO\ DI&I_P#8(M/_ $=<T?\ ":Z7_P ^
MFN?^"2[_ /C=85OXNTX>/M0N3:ZQL?2[6, :1=;LB6<G*^7D#YA@D8/..AH
M] HKG/\ A-=+_P"?37/_  27?_QNC_A-=+_Y]-<_\$EW_P#&Z .CHKG/^$UT
MO_GTUS_P27?_ ,;H_P"$UTO_ )]-<_\ !)=__&Z .CHKG/\ A-=+_P"?37/_
M  27?_QNC_A-=+_Y]-<_\$EW_P#&Z .CHKG/^$UTO_GTUS_P27?_ ,;H_P"$
MUTO_ )]-<_\ !)=__&Z .CHKG/\ A-=+_P"?37/_  27?_QNC_A-=+_Y]-<_
M\$EW_P#&Z .CHKG/^$UTO_GTUS_P27?_ ,;H_P"$UTO_ )]-<_\ !)=__&Z
M.CHKG/\ A-=+_P"?37/_  27?_QNC_A-=+_Y]-<_\$EW_P#&Z .CHKG/^$UT
MO_GTUS_P27?_ ,;H_P"$UTO_ )]-<_\ !)=__&Z .CHKG/\ A-=+_P"?37/_
M  27?_QNC_A-=+_Y]-<_\$EW_P#&Z .CHKG/^$UTO_GTUS_P27?_ ,;H_P"$
MUTO_ )]-<_\ !)=__&Z .CHKG/\ A-=+_P"?37/_  27?_QNC_A-=+_Y]-<_
M\$EW_P#&Z .CHKG/^$UTO_GTUS_P27?_ ,;H_P"$UTO_ )]-<_\ !)=__&Z
M.CHKG/\ A-=+_P"?37/_  27?_QNC_A-=+_Y]-<_\$EW_P#&Z .CHKG/^$UT
MO_GTUS_P27?_ ,;H_P"$UTO_ )]-<_\ !)=__&Z .CHKG/\ A-=+_P"?37/_
M  27?_QNC_A-=+_Y]-<_\$EW_P#&Z .CHKG/^$UTO_GTUS_P27?_ ,;H_P"$
MUTO_ )]-<_\ !)=__&Z .CHKG/\ A-=+_P"?37/_  27?_QNC_A-=+_Y]-<_
M\$EW_P#&Z .CHKG/^$UTO_GTUS_P27?_ ,;H_P"$UTO_ )]-<_\ !)=__&Z
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M^'9/%@U'Q)Y-KHI;^U/WN^YE #_9X/NX3D8V]<<YK>\WQI_SYZ!_X%3?_&Z
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M[YOC3_GST#_P*F_^-T>;XT_Y\] _\"IO_C= '145SOF^-/\ GST#_P "IO\
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M]![7_P#P//\ A0!M45B_\(5%_P!![7__  //^%'_  A47_0>U_\ \#S_ (4
M;5%8O_"%1?\ 0>U__P #S_A1_P (5%_T'M?_ / \_P"% &U16+_PA47_ $'M
M?_\  \_X4?\ "%1?]![7_P#P//\ A0!M45B_\(5%_P!![7__  //^%'_  A4
M7_0>U_\ \#S_ (4 ;5%8O_"%1?\ 0>U__P #S_A1_P (5%_T'M?_ / \_P"%
M &U16+_PA47_ $'M?_\  \_X4?\ "%1?]![7_P#P//\ A0!M45B_\(5%_P!!
M[7__  //^%'_  A47_0>U_\ \#S_ (4 ;5%8O_"%1?\ 0>U__P #S_A1_P (
M5%_T'M?_ / \_P"% &U16+_PA47_ $'M?_\  \_X4?\ "%1?]![7_P#P//\
MA0!M45B_\(5%_P!![7__  //^%'_  A47_0>U_\ \#S_ (4 ;5%8O_"%1?\
M0>U__P #S_A1_P (5%_T'M?_ / \_P"% &U16+_PA47_ $'M?_\  \_X4?\
M"%1?]![7_P#P//\ A0!M45B_\(5%_P!![7__  //^%'_  A47_0>U_\ \#S_
M (4 ;5%8O_"%1?\ 0>U__P #S_A1_P (5%_T'M?_ / \_P"% &U16+_PA47_
M $'M?_\  \_X4?\ "%1?]![7_P#P//\ A0!M45B_\(5%_P!![7__  //^%'_
M  A47_0>U_\ \#S_ (4 ;5%8O_"%1?\ 0>U__P #S_A1_P (5%_T'M?_ / \
M_P"% &U16+_PA47_ $'M?_\  \_X4?\ "%1?]![7_P#P//\ A0!M45B_\(5%
M_P!![7__  //^%'_  A47_0>U_\ \#S_ (4 ;5%8O_"%1?\ 0>U__P #S_A1
M_P (5%_T'M?_ / \_P"% &U16+_PA47_ $'M?_\  \_X4?\ "%1?]![7_P#P
M//\ A0!M5C>!?^0)>_\ 87U'_P!*Y:3_ (0J+_H/:_\ ^!Y_PIOP_@%MX=N8
M!))((M5U!-\C;F;%U*,D]SZF@!FN7'V3QYHT^T'9I=^<$X'^LM>]7+/Q5;7$
M,DDD;(L>=S@C;^O/Z=JHZ_,\'CK19(XS(PTR^^4*6)'FVF>![5<DUJX%U-%#
MH\KP(NX.8F7=TX (Z\_H:74;VN2#Q78[D)#+&XRK%EY_#.12MXGM_M45LL,G
MFR(T@!QT )]?I^=5(M9OB/GT=V+. H\EAQ^7;WJTNIWGD23?V86=9=@0(P.,
M'GD>WZT)Z7$]QDGBVVMTC\^WE#NVT*N#S@'U]ZD7Q1;&Y,)AE!"[FZ?+]>?I
MTJ!M;O#$'_L2?>!DKY9[].WL?TIZZO<36UTSZ+,K1H/E:,_/GL,#GO3 GD\2
MVJ06TNQML[$#YEX ZGKSU[4P>*K)MI2.5E9RBL,8..O?MD?G5:#4;B-(K>+1
MFAC."O[MB%R>1TX-$WB&2"[: Z4X4;BK&-@" 0,CCWI=+@2'QGIH5VVRX1MA
MX'7MCGFI+KQ79VUS!!L=FE7=V&!CGJ>O2JJZA)+)'<MH;;LL%/EMNP,'T]^,
MU;L-2N;W5O(ETMX8!&6\QXR,GC R1[U0=1&\66"PF0K+CL N21W/'ID=?45+
M<^([2V 9XY=IC63/ X.?4]>*UO*C_N+^5*8T/5%/U%(#$7Q&)(VECMF,095!
M+#N&)Z'V_6IH=;%[83W-I#GR6"GS& !/'<9]16J(T P$4#TQ0$51@* /0"D"
M,,>*K19F@DBE\Q!ER!\H_.BV\56EV\ BAEVRR% S8'(&3W[<?G6YY:'/R+S[
M4"-!C"*,=.*8&%_PEVG9;(D4*VTE@!2_\)79F01K'([,3M"8Y_6ME[:"0J7B
M0E3D97H:5;>%'9UB0,W4@=:0&&OBZR<[4AN"^<;=H'/USBIV\26<2QF4.F^/
MS,\8 W8ZUK^6@_@7\J#'&>J*?PI@8'_"7609]R/A06^7YLCCT_K5B#Q#!=1M
M)%$Q41E_O+DXQVSQU[UIFU@,JRF%-Z@@''0'K_(5((T'1%'T%+H!3TS5(=4A
M:2$$;3@@D'^57J155!A5 'L*6F".;\+?\A7Q9_V&/_;6WKI*YOPM_P A7Q9_
MV&/_ &UMZZ2@ HHHH **** .;\??\B5J'_;+_P!&+725S?C[_D2M0_[9?^C%
MKI* "@D 9/ HI&!*D X)'6@!%='^XRM]#FG52TS3AIL,D:RF0/(9.1C!/6KM
M !7+QSPV_P 2M4>:5(U_L>S&78 ?ZZY]:ZBN3>U6\^(>K0L=H.CV7.,_\M[F
M@#JD=9%#(P93T(.0:=6)%X=$-VDT=Y*JJ[.8P."22?Z_I44WA?S"Q2_FC+/N
M.T>P]_J?QH WP020",CJ*,C.,C/I7/OX7+C(OG5^C,J=1Q[_ (_C3H_#31*
MM^Y(Z[DSD^O7K0!O!@20",CJ*1G1,;V5<G R<9-8D/ASRK>2)KZ1R\HEW;<8
MXQCKTJ!_"GF* ^H2'#;A\G3VZ]!_6A>8(Z2BL2Z\/O<I;J-0FC\J,1MM'WQ[
M\U';>&3;R0O_ &A,S1N6.1]X8''7MC]: -X,"2 1D=10"#T(/TKGI?"S2SO*
M-1E0NY;"KCK^-1CPQ<?;(B]]NMT!SD?,Q[#Z4E<#I2RKC<0,G R:175UW(P9
M>F0<U@V_AAH98W?4)9=DGF8=>OZ\5-:^'TMKKSA<LR!BPCVX&?SI@:J7-O(^
MQ)XV;)&%<$Y'6GNZQJ6=@JCJ2<"L:#P]Y%XUP+ICEMP39@#KT_,U"GAEC,)9
M[UF^8L8POR_SH!F^)$)P'7)[9I20HR2 !W-9G]E3+?"X2]PH=F">6#][&1G/
MM4YTR,B[#22,+EMS!SD+P!Q^5+H,L"Y@+;1-'N)QC>,Y]*D9E52S$ #J2:PX
MO#8BN8Y1=L0F?EV=023USZDU$?#,DI9IKYOFD=BBKQ@MD#\L4Q+S.A!# $$$
M'D$4%@" 2 3T&>M8EYX<6ZEFD6\DB:3;@J/N@#&!S[4S_A&<A=UZY95(5BGS
M D#G.?:@#>) QD@9X&:&=5.&8#ZFN<C\*-'#L&I2EBY8L4ZCCCKTZ_G5B+PZ
M4O)+AKUVWQ>7L"8 ]QS1T#J;F1C.>/6D!#*"I!!Y!'>N<_X15_.+_P!I28VX
MV[.#]>>:T='TEM)B:/[4TRG'WEQC  _I0'0TZ*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_!'_('O_P#L,:C_ .E<M=)7
M-^"/^0/?_P#88U'_ -*Y: "__P"2D:#_ -@R_P#_ $9:UTE<;XCTC3]:\?:!
M;:E:QW,"Z=?.$?H&#VPS^IJ]_P *_P#"?_0"M?R/^- '245S?_"O_"?_ $ K
M7\C_ (T?\*_\)_\ 0"M?R/\ C0!TE%<W_P *_P#"?_0"M?R/^-'_  K_ ,)_
M] *U_(_XT =)2$ ]0#7.?\*_\)_] *U_(_XT?\*_\)_] *U_(_XT =)17-_\
M*_\ "?\ T K7\C_C1_PK_P )_P#0"M?R/^- '245S?\ PK_PG_T K7\C_C1_
MPK_PG_T K7\C_C0!TE%<W_PK_P )_P#0"M?R/^-'_"O_  G_ - *U_(_XT =
M)17-_P#"O_"?_0"M?R/^-'_"O_"?_0"M?R/^- '245S?_"O_  G_ - *U_(_
MXT?\*_\ "?\ T K7\C_C0!TE%<W_ ,*_\)_] *U_(_XT?\*_\)_] *U_(_XT
M =)17-_\*_\ "?\ T K7\C_C1_PK_P )_P#0"M?R/^- '245S?\ PK_PG_T
MK7\C_C1_PK_PG_T K7\C_C0 >%O^0KXL_P"PQ_[:V]=)7G?ASP1X:N-2\3)+
MH]LZP:KY<8(/RK]G@; Y]6)_&N@_X5_X3_Z 5K^1_P : .DHKF_^%?\ A/\
MZ 5K^1_QH_X5_P"$_P#H!6OY'_&@#I**YO\ X5_X3_Z 5K^1_P :/^%?^$_^
M@%:_D?\ &@ \??\ (E:A_P!LO_1BUTE>=^-?!'AJS\(WT]OH]M'*OE[64'(S
M(H]?>N@_X5_X3_Z 5K^1_P : .DHKF_^%?\ A/\ Z 5K^1_QH_X5_P"$_P#H
M!6OY'_&@#I**YO\ X5_X3_Z 5K^1_P :/^%?^$_^@%:_D?\ &@#I*YNV_P"2
MF:I_V![/_P!'7-'_  K_ ,)_] *U_(_XUS]OX(\--\0=1M3H]L8$TJUD5,'
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M_A7_ (3_ .@%:_D?\:/^%?\ A/\ Z 5K^1_QH Z2BN;_ .%?^$_^@%:_D?\
M&C_A7_A/_H!6OY'_ !H Z2BN;_X5_P"$_P#H!6OY'_&C_A7_ (3_ .@%:_D?
M\: .DHKF_P#A7_A/_H!6OY'_ !H_X5_X3_Z 5K^1_P : .DHKF_^%?\ A/\
MZ 5K^1_QH_X5_P"$_P#H!6OY'_&@#I**YO\ X5_X3_Z 5K^1_P :/^%?^$_^
M@%:_D?\ &@#I**YO_A7_ (3_ .@%:_D?\:/^%?\ A/\ Z 5K^1_QH Z2BN;_
M .%?^$_^@%:_D?\ &C_A7_A/_H!6OY'_ !H Z2BN;_X5_P"$_P#H!6OY'_&C
M_A7_ (3_ .@%:_D?\: .DHKF_P#A7_A/_H!6OY'_ !H_X5_X3_Z 5K^1_P :
M .DHKF_^%?\ A/\ Z 5K^1_QH_X5_P"$_P#H!6OY'_&@#I**YO\ X5_X3_Z
M5K^1_P :/^%?^$_^@%:_D?\ &@#I**YO_A7_ (3_ .@%:_D?\:/^%?\ A/\
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MM^91NXY[]JZ2B@#!N;O7A(8[:S#,(%8DE0N\DY&2?8?G3;.;Q$U[";FU5(&
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M: )J*** .;\??\B5J'_;+_T8M=)7-^/O^1*U#_ME_P"C%KI* "BBB@ HHHH
M*YNV_P"2F:I_V![/_P!'7-=)7-VW_)3-4_[ ]G_Z.N: .DHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\$?\ ('O_
M /L,:C_Z5RUTE<WX(_Y ]_\ ]AC4?_2N6@"CXCU6VT?Q]H%S=+<M&=.OD MK
M62=LE[8_=C5CCCKC%7O^$ZT;_GCK7_@DO/\ XU1?_P#)2-!_[!E__P"C+6ND
MH YO_A.M&_YXZU_X)+S_ .-4?\)UHW_/'6O_  27G_QJNDHH YO_ (3K1O\
MGCK7_@DO/_C5'_"=:-_SQUK_ ,$EY_\ &JZ2B@#F_P#A.M&_YXZU_P""2\_^
M-4?\)UHW_/'6O_!)>?\ QJNDHH YO_A.M&_YXZU_X)+S_P"-4?\ "=:-_P \
M=:_\$EY_\:KI** .;_X3K1O^>.M?^"2\_P#C5'_"=:-_SQUK_P $EY_\:KI*
M* .;_P"$ZT;_ )XZU_X)+S_XU1_PG6C?\\=:_P#!)>?_ !JNDHH YO\ X3K1
MO^>.M?\ @DO/_C5'_"=:-_SQUK_P27G_ ,:KI** .;_X3K1O^>.M?^"2\_\
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M#6']WN,5Y*S?ZQ<8!B ZX[UT'G>-_P#H'^'_ /P.F_\ C5'C[_D2M0_[9?\
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M'$HTN_*^Y$EKQ^/2I8G\3)-*6MP58KM!=" .<]_I3K__ )*1H/\ V#+_ /\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7-^"/^0/?_P#88U'_ -*Y:Z2N;\$?\@>__P"PQJ/_ *5RT <K
M\3M7U+1?%'AVYTN>*&X:TO4+21>8-I:W)&,CT%<U_P + \9?]!2R_P# $?\
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M \9?]!2R_P# $?\ Q5<_11]2H?R_F'UBIW.@_P"%@>,O^@I9?^ (_P#BJ/\
MA8'C+_H*67_@"/\ XJN?HH^I4/Y?S#ZQ4[G0?\+ \9?]!2R_\ 1_\51_PL#Q
ME_T%++_P!'_Q5<_11]2H?R_F'UBIW-35/%WBK5].EL;K4[3R9=N[;9 '@@CG
M=Z@5<_X6!XR_Z"EE_P" (_\ BJY^BCZE0_E_,/K%3N=!_P + \9?]!2R_P#
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ML7Z*H?VS:>EU_P" DO\ \31_;-IZ77_@)+_\31[2'=!RR[%^BJ']LVGI=?\
M@)+_ /$T?VS:>EU_X"2__$T>TAW0<LNQ?HJA_;-IZ77_ ("2_P#Q-']LVGI=
M?^ DO_Q-'M(=T'++L7Z*H?VS:>EU_P" DO\ \31_;-IZ77_@)+_\31[2'=!R
MR[%^BJ']LVGI=?\ @)+_ /$T?VS:>EU_X"2__$T>TAW0<LNQ?HJA_;-IZ77_
M ("2_P#Q-']LVGI=?^ DO_Q-'M(=T'++L7Z*SEURQ<L%-P2IPP%K+P>N#\ON
M*=_;-IZ77_@)+_\ $T>UAW0<DNQ?HJA_;-IZ77_@)+_\31_;-IZ77_@)+_\
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M/&.1]:+M#2OL;?V6W_Y]XO\ O@4?9;?_ )]XO^^!63=>)(H(+:58P?.S\C.
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M^\7_ 'P*FHHNPL0_9;?_ )]XO^^!1]EM_P#GWB_[X%344786(?LMO_S[Q?\
M? H^RV__ #[Q?]\"IJ*+L+$/V6W_ .?>+_O@4?9;?_GWB_[X%344786(?LMO
M_P ^\7_? H^RV_\ S[Q?]\"IJ*+L+$/V6W_Y]XO^^!1]EM_^?>+_ +X%3447
M86(?LMO_ ,^\7_? H^RV_P#S[Q?]\"IJ*+L+$/V6W_Y]XO\ O@4?9;?_ )]X
MO^^!4U%%V%B'[+;_ //O%_WP*/LMO_S[Q?\ ? J:BB["Q#]EM_\ GWB_[X%'
MV6W_ .?>+_O@5-11=A8A^RV__/O%_P!\"C[+;_\ /O%_WP*FHHNPL0_9;?\
MY]XO^^!1]EM_^?>+_O@5-11=A8A^RV__ #[Q?]\"C[+;_P#/O%_WP*FHHNPL
M0_9;?_GWB_[X%'V6W_Y]XO\ O@5-11=A8A^RV_\ S[Q?]\"C[+;_ //O%_WP
M*FHHNPL0_9;?_GWB_P"^!1]EM_\ GWB_[X%344786(?LMO\ \^\7_? H^RV_
M_/O%_P!\"IJ*+L+$/V6W_P"?>+_O@4?9;?\ Y]XO^^!4U%%V%B'[+;_\^\7_
M 'P*/LMO_P ^\7_? J:BB["Q#]EM_P#GWB_[X%8'@<!=&O@  !K&H@ =O]+E
MKI:YOP1_R![_ /[#&H_^E<M*XQ-14-\1M"# $'3+_@_]=+6MZ6SMIH6AD@C:
M-NJ[>#7*>([VYL/'V@2VNF7.HR'3KY3#;/&K ;[;YLR.HQQZYYZ5>_X236/^
MA)UK_P "+/\ ^/T ;PM;<1>4(4"8VXQVH6UMTD\Q84#;=N0.WI6#_P ))K'_
M $).M?\ @19__'Z/^$DUC_H2=:_\"+/_ ./T ;SVENY4M!&=AW+\HX/^33C!
M">L2'_@(KG_^$DUC_H2=:_\  BS_ /C]'_"2:Q_T).M?^!%G_P#'Z .A,4;=
M44_44GDQ8QY:?]\BN?\ ^$DUC_H2=:_\"+/_ ./T?\))K'_0DZU_X$6?_P ?
MH W(K&UAB:*.!%1F+,H'4^M/2U@C0(D*!1T&VL#_ (236/\ H2=:_P# BS_^
M/T?\))K'_0DZU_X$6?\ \?H Z$11KC"*,>@H\F+_ )YI_P!\BN>_X236/^A)
MUK_P(L__ (_1_P ))K'_ $).M?\ @19__'Z -^6VAFB,<D2,AZ@BB*U@@0+%
M"B # P.U8'_"2:Q_T).M?^!%G_\ 'Z/^$DUC_H2=:_\  BS_ /C] '0&"(XS
M$AQT^44>1#_SR3_OD5S_ /PDFL?]"3K7_@19_P#Q^C_A)-8_Z$G6O_ BS_\
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M_P#"2:Q_T).M?^!%G_\ 'Z/^$DUC_H2=:_\  BS_ /C] '245S?_  DFL?\
M0DZU_P"!%G_\?H_X236/^A)UK_P(L_\ X_0!TE%<W_PDFL?]"3K7_@19_P#Q
M^C_A)-8_Z$G6O_ BS_\ C] '245S?_"2:Q_T).M?^!%G_P#'Z/\ A)-8_P"A
M)UK_ ,"+/_X_0!TE%<W_ ,))K'_0DZU_X$6?_P ?H_X236/^A)UK_P "+/\
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M ,"+/_X_0!TE%<W_ ,))K'_0DZU_X$6?_P ?H_X236/^A)UK_P "+/\ ^/T
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MS?C[_D2M0_[9?^C%KI* "BBB@ HHHH *YNV_Y*9JG_8'L_\ T=<UTE<W;?\
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M '245S?]D^+/^AIM/_!4/_CE']D^+/\ H:;3_P %0_\ CE '245S?]D^+/\
MH:;3_P %0_\ CE']D^+/^AIM/_!4/_CE '245S?]D^+/^AIM/_!4/_CE']D^
M+/\ H:;3_P %0_\ CE '245S?]D^+/\ H:;3_P %0_\ CE']D^+/^AIM/_!4
M/_CE '245S?]D^+/^AIM/_!4/_CE']D^+/\ H:;3_P %0_\ CE '245S?]D^
M+/\ H:;3_P %0_\ CE']D^+/^AIM/_!4/_CE '245S?]D^+/^AIM/_!4/_CE
M']D^+/\ H:;3_P %0_\ CE '245S?]D^+/\ H:;3_P %0_\ CE']D^+/^AIM
M/_!4/_CE !X6_P"0KXL_[#'_ +:V]=)7G?AS3/$SZEXF$7B.VC9=5Q(3IH;>
MWV> [A^\XX(&.>F>]=!_9/BS_H:;3_P5#_XY0!TE%<W_ &3XL_Z&FT_\%0_^
M.4?V3XL_Z&FT_P#!4/\ XY0!TE%<W_9/BS_H:;3_ ,%0_P#CE']D^+/^AIM/
M_!4/_CE !X^_Y$K4/^V7_HQ:Z2O._&NF>)H_"-\UQXCMIHAY>Y%TT(3^\7OY
MA[UT']D^+/\ H:;3_P %0_\ CE '245S?]D^+/\ H:;3_P %0_\ CE']D^+/
M^AIM/_!4/_CE '245S?]D^+/^AIM/_!4/_CE']D^+/\ H:;3_P %0_\ CE '
M25S=M_R4S5/^P/9_^CKFC^R?%G_0TVG_ (*A_P#'*Y^WTSQ,?B#J*#Q';"<:
M5:EI?[-&&4RW&%V^9Q@ACG/.?:@#T2BN;_LGQ9_T--I_X*A_\<H_LGQ9_P!#
M3:?^"H?_ !R@#I**YO\ LGQ9_P!#3:?^"H?_ !RC^R?%G_0TVG_@J'_QR@#I
M**YO^R?%G_0TVG_@J'_QRC^R?%G_ $--I_X*A_\ '* .DHKF_P"R?%G_ $--
MI_X*A_\ '*/[)\6?]#3:?^"H?_'* .DHKF_[)\6?]#3:?^"H?_'*/[)\6?\
M0TVG_@J'_P <H Z2BN;_ +)\6?\ 0TVG_@J'_P <H_LGQ9_T--I_X*A_\<H
MZ2BN;_LGQ9_T--I_X*A_\<H_LGQ9_P!#3:?^"H?_ !R@#I**YO\ LGQ9_P!#
M3:?^"H?_ !RC^R?%G_0TVG_@J'_QR@#I**YO^R?%G_0TVG_@J'_QRC^R?%G_
M $--I_X*A_\ '* .DHKF_P"R?%G_ $--I_X*A_\ '*/[)\6?]#3:?^"H?_'*
M .DHKF_[)\6?]#3:?^"H?_'*/[)\6?\ 0TVG_@J'_P <H Z2BN;_ +)\6?\
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M'"CM_HMO744 %%%% !1110!S?C[_ )$K4/\ ME_Z,6NDKF_'W_(E:A_VR_\
M1BUTE !112."48#&2.,T +15#2K2YLX94N95E9I"RL"3@'''X=*OT %<W;?\
ME,U3_L#V?_HZYKI*YNV_Y*9JG_8'L_\ T=<T =)1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<WX(_Y ]__ -AC4?\
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M /$T ;DEC:RRQ2O A>+[AQ]VI#;P'.88SG_9%<__ ,(@_P#T,OB#_P "U_\
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M?$'_ (%K_P#$T =)17-_\(@__0R^(/\ P+7_ .)H_P"$0?\ Z&7Q!_X%K_\
M$T =)17-_P#"(/\ ]#+X@_\  M?_ (FC_A$'_P"AE\0?^!:__$T 'C[_ )$K
M4/\ ME_Z,6NDKSOQKX7:W\(WTO\ PD&N2[?+^26Z!4_O%'(VUT'_  B#_P#0
MR^(/_ M?_B: .DHKF_\ A$'_ .AE\0?^!:__ !-'_"(/_P!#+X@_\"U_^)H
MZ2BN;_X1!_\ H9?$'_@6O_Q-'_"(/_T,OB#_ ,"U_P#B: .DKF[;_DIFJ?\
M8'L__1US1_PB#_\ 0R^(/_ M?_B:Y^W\+L?B#J,'_"0:X-NE6K^8+H;SF6X&
M"=O08R/J: /1**YO_A$'_P"AE\0?^!:__$T?\(@__0R^(/\ P+7_ .)H Z2B
MN;_X1!_^AE\0?^!:_P#Q-'_"(/\ ]#+X@_\  M?_ (F@#I**YO\ X1!_^AE\
M0?\ @6O_ ,31_P (@_\ T,OB#_P+7_XF@#I**YO_ (1!_P#H9?$'_@6O_P 3
M1_PB#_\ 0R^(/_ M?_B: .DHKF_^$0?_ *&7Q!_X%K_\31_PB#_]#+X@_P#
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M^!:__$T?\(@__0R^(/\ P+7_ .)H Z2BN;_X1!_^AE\0?^!:_P#Q-'_"(/\
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M??\ (E:A_P!LO_1BUTE !1110 4444 %<W;?\E,U3_L#V?\ Z.N:Z2N;MO\
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M  H_LG3O^@?:_P#?E?\ "@"E_P )=X:_Z&'2?_ V/_XJC_A+O#7_ $,.D_\
M@;'_ /%5=_LG3O\ H'VO_?E?\*/[)T[_ *!]K_WY7_"@"E_PEWAK_H8=)_\
M V/_ .*H_P"$N\-?]##I/_@;'_\ %5=_LG3O^@?:_P#?E?\ "C^R=._Z!]K_
M -^5_P * *7_  EWAK_H8=)_\#8__BJ/^$N\-?\ 0PZ3_P"!L?\ \55W^R=.
M_P"@?:_]^5_PH_LG3O\ H'VO_?E?\* *7_"7>&O^AATG_P #8_\ XJC_ (2[
MPU_T,.D_^!L?_P 55W^R=._Z!]K_ -^5_P */[)T[_H'VO\ WY7_  H I?\
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M_P#?E?\ "C^R=._Z!]K_ -^5_P * *7_  EWAK_H8=)_\#8__BJ/^$N\-?\
M0PZ3_P"!L?\ \55W^R=._P"@?:_]^5_PH_LG3O\ H'VO_?E?\* *7_"7>&O^
MAATG_P #8_\ XJC_ (2[PU_T,.D_^!L?_P 55W^R=._Z!]K_ -^5_P */[)T
M[_H'VO\ WY7_  H Y'PUXG\/PZGXH:77=,19=6WQEKN,!U^S0#(YY&01GV-=
M#_PEWAK_ *&'2?\ P-C_ /BJRO"^FV#ZIXJ#65L0NKX4&)>!]FMS@<>YKHO[
M)T[_ *!]K_WY7_"@"E_PEWAK_H8=)_\  V/_ .*H_P"$N\-?]##I/_@;'_\
M%5=_LG3O^@?:_P#?E?\ "C^R=._Z!]K_ -^5_P * *7_  EWAK_H8=)_\#8_
M_BJ/^$N\-?\ 0PZ3_P"!L?\ \55W^R=._P"@?:_]^5_PH_LG3O\ H'VO_?E?
M\* .1\<>)_#]QX/OHH-=TR61O+PB7<;$_O%/0&NA_P"$N\-?]##I/_@;'_\
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MO_?E?\*/[)T[_H'VO_?E?\* *7_"7>&O^AATG_P-C_\ BJ/^$N\-?]##I/\
MX&Q__%5=_LG3O^@?:_\ ?E?\*/[)T[_H'VO_ 'Y7_"@"E_PEWAK_ *&'2?\
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M%O\ D*^+/^PQ_P"VMO724 %%%% !1110!S?C[_D2M0_[9?\ HQ:Z2N;\??\
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MG_\ 'Z;J3K'\1="9V"J-+O\ ))P!^\M:Z1)$D0.CJRGHRG(H YW_ (2?5/\
MH2M>_P"_EG_\?H_X2?5/^A*U[_OY9_\ Q^NB21)!E'5AG&5.:5F5<;F R<#)
MH YS_A)]4_Z$K7O^_EG_ /'Z/^$GU3_H2M>_[^6?_P ?KI*0,K?=(./0T <Y
M_P )/JG_ $)6O?\ ?RS_ /C]'_"3ZI_T)6O?]_+/_P"/UTA( R3@49!&0>*
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M$K7O^_EG_P#'ZZ2F":(RF(2(9 ,E PR/PH Y[_A)]4_Z$K7O^_EG_P#'Z/\
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M_P#C]=)10!S?_"3ZI_T)6O?]_+/_ ./T?\)/JG_0E:]_W\L__C]=)10!S?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]XZ.C'&._P P_,9^E.N+WQ<DP6/3T="S99=GRC/R]7';_/H#ZV+/VGQO_P!
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M?VGQO_T"/#__ (-)O_D>C[3XW_Z!'A__ ,&DW_R/7244 <W]I\;_ /0(\/\
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MXW_Z!'A__P &DW_R/7244 <W]I\;_P#0(\/_ /@TF_\ D>C[3XW_ .@1X?\
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M?V_XD_Z&;5?^_B__ !-4J*/JM'^5![:IW+O]O^)/^AFU7_OXO_Q-']O^)/\
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M5_[^+_\ $T?V_P")/^AFU7_OXO\ \35*BCZK1_E0>VJ=R[_;_B3_ *&;5?\
MOXO_ ,31_;_B3_H9M5_[^+_\35*BCZK1_E0>VJ=R[_;_ (D_Z&;5?^_B_P#Q
M-']O^)/^AFU7_OXO_P 35*BCZK1_E0>VJ=R[_;_B3_H9M5_[^+_\31_;_B3_
M *&;5?\ OXO_ ,35*BCZK1_E0>VJ=R[_ &_XD_Z&;5?^_B__ !-']O\ B3_H
M9M5_[^+_ /$U2HH^JT?Y4'MJG<N_V_XD_P"AFU7_ +^+_P#$T?V_XD_Z&;5?
M^_B__$U2HH^JT?Y4'MJG<N_V_P")/^AFU7_OXO\ \31_;_B3_H9M5_[^+_\
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MS'44W,__ $#]3_\ !?-_\11F?_H'ZG_X+YO_ (BCV]+^9?>@]G/LQU%-S/\
M] _4_P#P7S?_ !%&9_\ H'ZG_P""^;_XBCV]+^9?>@]G/LQU%0QSM*TBQV>H
M.T;;'"V,Q*M@'!^7@X(./<5)F?\ Z!^I_P#@OF_^(H]O2_F7WH/9S[,=13<S
M_P#0/U/_ ,%\W_Q%&9_^@?J?_@OF_P#B*/;TOYE]Z#V<^S'44W,__0/U/_P7
MS?\ Q%&9_P#H'ZG_ ."^;_XBCV]+^9?>@]G/LQU%0S3M;Q&6:SU".->KO8S
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MJ?\ X+YO_B*,S_\ 0/U/_P %\W_Q%'MZ7\R^]![.?9CJ*;F?_H'ZG_X+YO\
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M_P! _4__  7S?_$4>WI?S+[T'LY]F.HIN9_^@?J?_@OF_P#B*,S_ /0/U/\
M\%\W_P 11[>E_,OO0>SGV8ZBFYG_ .@?J?\ X+YO_B*,S_\ 0/U/_P %\W_Q
M%'MZ7\R^]![.?9CJ*;F?_H'ZG_X+YO\ XBC,_P#T#]3_ /!?-_\ $4>WI?S+
M[T'LY]F.HIN9_P#H'ZG_ ."^;_XBC,__ $#]3_\ !?-_\11[>E_,OO0>SGV8
MZBFYG_Z!^I_^"^;_ .(HS/\ ] _4_P#P7S?_ !%'MZ7\R^]![.?9CJ*;F?\
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MEU&:>-[&:W$>,,XX;Z5J4!<**** "BBB@ HHHH **** "BBB@ HHHH ****
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M5[[7XV_Z OA__P &TW_R/0!T;*&4JP!![&@*% "@ #H!7.?:_&W_ $!?#_\
MX-IO_D>C[7XV_P"@+X?_ /!M-_\ (] '245S?VOQM_T!?#__ (-IO_D>C[7X
MV_Z OA__ ,&TW_R/0!TE(5##! (]#7.?:_&W_0%\/_\ @VF_^1Z/M?C;_H"^
M'_\ P;3?_(] '245S?VOQM_T!?#_ /X-IO\ Y'H^U^-O^@+X?_\ !M-_\CT
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MM?C;_H"^'_\ P;3?_(] '245S?VOQM_T!?#_ /X-IO\ Y'H^U^-O^@+X?_\
M!M-_\CT =)17-_:_&W_0%\/_ /@VF_\ D>C[7XV_Z OA_P#\&TW_ ,CT =)1
M7-_:_&W_ $!?#_\ X-IO_D>C[7XV_P"@+X?_ /!M-_\ (] '245S?VOQM_T!
M?#__ (-IO_D>C[7XV_Z OA__ ,&TW_R/0!TE%<W]K\;?] 7P_P#^#:;_ .1Z
M/M?C;_H"^'__  ;3?_(] '245S?VOQM_T!?#_P#X-IO_ )'H^U^-O^@+X?\
M_!M-_P#(] '245S?VOQM_P! 7P__ .#:;_Y'H^U^-O\ H"^'_P#P;3?_ "/0
M!TE%<W]K\;?] 7P__P"#:;_Y'H^U^-O^@+X?_P#!M-_\CT =)17-_:_&W_0%
M\/\ _@VF_P#D>C[7XV_Z OA__P &TW_R/0!TE%<W]K\;?] 7P_\ ^#:;_P"1
MZ/M?C;_H"^'_ /P;3?\ R/0!TE%<W]K\;?\ 0%\/_P#@VF_^1Z/M?C;_ * O
MA_\ \&TW_P CT =)17-_:_&W_0%\/_\ @VF_^1Z/M?C;_H"^'_\ P;3?_(]
M'245S?VOQM_T!?#_ /X-IO\ Y'H^U^-O^@+X?_\ !M-_\CT =)17-_:_&W_0
M%\/_ /@VF_\ D>C[7XV_Z OA_P#\&TW_ ,CT =)17-_:_&W_ $!?#_\ X-IO
M_D>C[7XV_P"@+X?_ /!M-_\ (] '245S?VOQM_T!?#__ (-IO_D>C[7XV_Z
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MDKC?$>GMJ7C[0($O[RR(TZ^;S;1U5S\]MQD@\<^G:KW_  B4_P#T-/B#_O\
MQ?\ QN@#I**YO_A$I_\ H:?$'_?^+_XW1_PB4_\ T-/B#_O_ !?_ !N@#I**
MYO\ X1*?_H:?$'_?^+_XW1_PB4__ $-/B#_O_%_\;H Z2BN;_P"$2G_Z&GQ!
M_P!_XO\ XW1_PB4__0T^(/\ O_%_\;H Z2BN;_X1*?\ Z&GQ!_W_ (O_ (W1
M_P (E/\ ]#3X@_[_ ,7_ ,;H Z2BN;_X1*?_ *&GQ!_W_B_^-T?\(E/_ -#3
MX@_[_P 7_P ;H Z2BN;_ .$2G_Z&GQ!_W_B_^-T?\(E/_P!#3X@_[_Q?_&Z
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MB4__ $-/B#_O_%_\;H Z2BN;_P"$2G_Z&GQ!_P!_XO\ XW1_PB4__0T^(/\
MO_%_\;H Z2N;MO\ DIFJ?]@>S_\ 1US1_P (E/\ ]#3X@_[_ ,7_ ,;KG[?P
MS,?B#J,'_"2:X"NE6K^:)H][9EN!M)V8P,9''<T >B45S?\ PB4__0T^(/\
MO_%_\;H_X1*?_H:?$'_?^+_XW0!TE%<W_P (E/\ ]#3X@_[_ ,7_ ,;H_P"$
M2G_Z&GQ!_P!_XO\ XW0!TE%<W_PB4_\ T-/B#_O_ !?_ !NC_A$I_P#H:?$'
M_?\ B_\ C= '245S?_")3_\ 0T^(/^_\7_QNC_A$I_\ H:?$'_?^+_XW0!TE
M%<W_ ,(E/_T-/B#_ +_Q?_&Z/^$2G_Z&GQ!_W_B_^-T =)17-_\ ")3_ /0T
M^(/^_P#%_P#&Z/\ A$I_^AI\0?\ ?^+_ .-T =)17-_\(E/_ -#3X@_[_P 7
M_P ;H_X1*?\ Z&GQ!_W_ (O_ (W0!TE%<W_PB4__ $-/B#_O_%_\;H_X1*?_
M *&GQ!_W_B_^-T =)17-_P#")3_]#3X@_P"_\7_QNC_A$I_^AI\0?]_XO_C=
M '245S?_  B4_P#T-/B#_O\ Q?\ QNC_ (1*?_H:?$'_ '_B_P#C= '245S?
M_")3_P#0T^(/^_\ %_\ &Z/^$2G_ .AI\0?]_P"+_P"-T =)17-_\(E/_P!#
M3X@_[_Q?_&Z/^$2G_P"AI\0?]_XO_C= '245S?\ PB4__0T^(/\ O_%_\;H_
MX1*?_H:?$'_?^+_XW0!TE%<W_P (E/\ ]#3X@_[_ ,7_ ,;H_P"$2G_Z&GQ!
M_P!_XO\ XW0!TE%<W_PB4_\ T-/B#_O_ !?_ !NC_A$I_P#H:?$'_?\ B_\
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M444 %%%% !7-VW_)3-4_[ ]G_P"CKFNDKF[;_DIFJ?\ 8'L__1US0!TE%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S
M?@C_ ) ]_P#]AC4?_2N6NDKF_!'_ "![_P#[#&H_^E<M !?_ /)2-!_[!E__
M .C+6NDKC?$>DV6L^/M MK^$RPC3KYPH=DY#VPZJ0>YJ]_P@/AK_ *!S?^!,
MO_Q5 '245S?_  @/AK_H'-_X$R__ !5'_" ^&O\ H'-_X$R__%4 =)17-_\
M" ^&O^@<W_@3+_\ %4?\(#X:_P"@<W_@3+_\50!TE%<W_P (#X:_Z!S?^!,O
M_P 51_P@/AK_ *!S?^!,O_Q5 '245S?_  @/AK_H'-_X$R__ !5'_" ^&O\
MH'-_X$R__%4 =)17-_\ " ^&O^@<W_@3+_\ %4?\(#X:_P"@<W_@3+_\50!T
ME%<W_P (#X:_Z!S?^!,O_P 51_P@/AK_ *!S?^!,O_Q5 '245S?_  @/AK_H
M'-_X$R__ !5'_" ^&O\ H'-_X$R__%4 =)17-_\ " ^&O^@<W_@3+_\ %4?\
M(#X:_P"@<W_@3+_\50!TE%<W_P (#X:_Z!S?^!,O_P 51_P@/AK_ *!S?^!,
MO_Q5 '245S?_  @/AK_H'-_X$R__ !5'_" ^&O\ H'-_X$R__%4 =)17-_\
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M&PN-]]"0Y(C4.1A?KMZT?U^/]?(!9;SQ"B[HK$.3CA@H^O\ %Q^N?:GR7WB
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M\ Y__B*\<HH_LN/\P?6WV/8_^%I^#?\ H+M_X!S_ /Q%'_"T_!O_ $%V_P#
M.?\ ^(KQRBC^RX_S!];?8]C_ .%I^#?^@NW_ (!S_P#Q%'_"T_!O_07;_P
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M@W_H+M_X!S__ !%'_"T_!O\ T%V_\ Y__B*\<HH_LN/\P?6WV/8_^%I^#?\
MH+M_X!S_ /Q%'_"T_!O_ $%V_P# .?\ ^(KQRBC^RX_S!];?8]C_ .%I^#?^
M@NW_ (!S_P#Q%'_"T_!O_07;_P  Y_\ XBO'**/[+C_,'UM]CV/_ (6GX-_Z
M"[?^ <__ ,11_P +3\&_]!=O_ .?_P"(KQRBC^RX_P P?6WV/8_^%I^#?^@N
MW_@'/_\ $4?\+3\&_P#07;_P#G_^(KQRBC^RX_S!];?8]C_X6GX-_P"@NW_@
M'/\ _$4?\+3\&_\ 07;_ , Y_P#XBO'**/[+C_,'UM]CV/\ X6GX-_Z"[?\
M@'/_ /$4?\+3\&_]!=O_  #G_P#B*\<HH_LN/\P?6WV/8_\ A:?@W_H+M_X!
MS_\ Q%'_  M/P;_T%V_\ Y__ (BO'**/[+C_ #!];?8]C_X6GX-_Z"[?^ <_
M_P 11_PM/P;_ -!=O_ .?_XBO'**/[+C_,'UM]CV/_A:?@W_ *"[?^ <_P#\
M11_PM/P;_P!!=O\ P#G_ /B*\<HH_LN/\P?6WV/8_P#A:?@W_H+M_P" <_\
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MA_OKC'E^_6N9_P"%/ZG_ -#3!_X*S_\ 'J]8HKRX5ZD%:,K([)4X2=VCR?\
MX4_J?_0TP?\ @K/_ ,>H_P"%/ZG_ -#3!_X*S_\ 'J]8HJ_K5;^9D^QI]CR?
M_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^
MI_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\
M0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?
M^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L_
M_'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/
M^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/Z
MG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-
M,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@
MK/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\
M\>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KU
MBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZ
MU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F
M8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI
M]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?
M_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^
MI_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\
M0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?
M^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L_
M_'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/
M^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/Z
MG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-
M,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@
MK/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\
M\>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KU
MBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZ
MU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F
M8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI
M]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?
M_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^
MI_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\
M0TP?^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?
M^"L__'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L_
M_'J/^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/
M^%/ZG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/Z
MG_T-,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-
M,'_@K/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@
MK/\ \>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J/^%/ZG_T-,'_@K/\
M\>KUBBCZU6_F8>QI]CR?_A3^I_\ 0TP?^"L__'J[OPAX=;PMX<ATI[L7;)++
>*TPB\L,7D9S\N3C&['6MVBLYUJE32;N5&$8[(__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>img206306002_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206306002_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -T I(# 2(  A$! Q$!_\0
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M /)%;*ZC9NFX7,6  3EAQGUJ5[F&.$3-(HC/1\\?G0!@_P#"3:C_ -"9K_\
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M[/\ ^2*/^$FU'_H3-?\ ^^[/_P"2*Z.B@#G/^$FU'_H3-?\ ^^[/_P"2*/\
MA)M1_P"A,U__ +[L_P#Y(KHZ* .<_P"$FU'_ *$S7_\ ONS_ /DBJ]WXTN+'
MR/M/A'7X_/F6"/FT.YVZ#B?VKJZYSQ=_S O^PO;_ /LU !_PDVH_]"9K_P#W
MW9__ "11_P )-J/_ $)FO_\ ?=G_ /)%='10!SG_  DVH_\ 0F:__P!]V?\
M\D4?\)-J/_0F:_\ ]]V?_P D5T=% '.?\)-J/_0F:_\ ]]V?_P D4U_%.H1Q
ML[^#=?"J"2=UGP/_  (KI:@OO^/"Y_ZY-_(T <[9^,;K4+&WO;7PAK\EO<1K
M+$^ZT&Y6&0<&?/0U-_PDVH_]"9K_ /WW9_\ R15CP9_R(OA__L&VW_HI:VZ
M.<_X2;4?^A,U_P#[[L__ )(H_P"$FU'_ *$S7_\ ONS_ /DBNCHH YS_ (2;
M4?\ H3-?_P"^[/\ ^2*/^$FU'_H3-?\ ^^[/_P"2*Z.B@#G/^$FU'_H3-?\
M^^[/_P"2*/\ A)M1_P"A,U__ +[L_P#Y(KHZ* .<_P"$FU'_ *$S7_\ ONS_
M /DBC_A)M1_Z$S7_ /ONS_\ DBNCHH YS_A)M1_Z$S7_ /ONS_\ DBC_ (2;
M4?\ H3-?_P"^[/\ ^2*Z.B@#G/\ A)M1_P"A,U__ +[L_P#Y(H_X2;4?^A,U
M_P#[[L__ )(KHZ* .<_X2;4?^A,U_P#[[L__ )(H_P"$FU'_ *$S7_\ ONS_
M /DBNCHH YS_ (2;4?\ H3-?_P"^[/\ ^2*/^$FU'_H3-?\ ^^[/_P"2*Z.B
M@#G/^$FU'_H3-?\ ^^[/_P"2*/\ A)M1_P"A,U__ +[L_P#Y(KHZ* .<_P"$
MFU'_ *$S7_\ ONS_ /DBC_A)M1_Z$S7_ /ONS_\ DBNCHH YS_A)M1_Z$S7_
M /ONS_\ DBC_ (2;4?\ H3-?_P"^[/\ ^2*Z.B@#G/\ A)M1_P"A,U__ +[L
M_P#Y(H_X2;4?^A,U_P#[[L__ )(KHZ* .<_X2;4?^A,U_P#[[L__ )(H_P"$
MFU'_ *$S7_\ ONS_ /DBNCHH YS_ (2;4?\ H3-?_P"^[/\ ^2*/^$FU'_H3
M-?\ ^^[/_P"2*Z.B@#G/^$FU'_H3-?\ ^^[/_P"2*/\ A)M1_P"A,U__ +[L
M_P#Y(KHZ* .<_P"$FU'_ *$S7_\ ONS_ /DBC_A)M1_Z$S7_ /ONS_\ DBNC
MHH YS_A)M1_Z$S7_ /ONS_\ DBC_ (2;4?\ H3-?_P"^[/\ ^2*Z.B@#G/\
MA)M1_P"A,U__ +[L_P#Y(H_X2;4?^A,U_P#[[L__ )(KHZ* .<_X2;4?^A,U
M_P#[[L__ )(H_P"$FU'_ *$S7_\ ONS_ /DBNCHH YS_ (2;4?\ H3-?_P"^
M[/\ ^2*/^$FU'_H3-?\ ^^[/_P"2*Z.B@#G/^$FU'_H3-?\ ^^[/_P"2*/\
MA)M1_P"A,U__ +[L_P#Y(KHZ* .<_P"$FU'_ *$S7_\ ONS_ /DBB/Q9*-0L
M;2]\.:Q8B]F\B*:X-N4W[&?!V3,>B-VKHZYSQ1_R$?"__87'_I//0!T=%%%
M'-^,L?9]'W?=_M:VS_WU5'R/#D[RO#YT8)16$9*C<N3GKR<'KZ5?\8 &'1@>
M1_:]K_Z%6T-/LATM(!_VS%'4/(YN67PWL8/#,40C=RV ><9YZ\FGVL_AZPG\
MR&*:*2+MEL>W&<5T8L;0*5%K#M/4>6.:&LK1R2UK"2>N8Q0&ECEKV]\-W]R6
MNXIC(1YC#<V!P!T!QG  _"IKC_A'EF^S2PRAI$7 5F^< 9 Z_2NA&GV0Z6<
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M: ,OP9_R(OA__L&VW_HI:VZQ/!G_ "(OA_\ [!MM_P"BEK;H **** "BBB@
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M)_L;_B>ZV^_5($^>[SMSNY''!]Z]!KG/%W_,"_["]O\ ^S4 '_")?]3#K_\
MX&__ &-'_")?]3#K_P#X&_\ V-='10!SG_")?]3#K_\ X&__ &-'_")?]3#K
M_P#X&_\ V-='10!SG_")?]3#K_\ X&__ &-0WGA/;97!_P"$@UXXC8X-[P>/
MI74U!??\>%S_ -<F_D: .,\)^%O/\&Z'+_;NN1[]/@;9'=X5<QJ< 8X%:_\
MPB7_ %,.O_\ @;_]C5CP9_R(OA__ +!MM_Z*6MN@#G/^$2_ZF'7_ /P-_P#L
M:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #
M?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_Z
MF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\
MA$O^IAU__P #?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:
MZ.B@#G/^$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_ZF'7_
M /P-_P#L:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\ A$O^
MIAU__P #?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:Z.B@
M#G/^$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_ZF'7_ /P-
M_P#L:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\ A$O^IAU_
M_P #?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:Z.B@#G/^
M$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L
M:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #
M?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_Z
MF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:Z.B@#G/^$2_ZF'7_ /P-_P#L:/\
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M&##.  .X]OU-1VGABSLT=4GNF+ C<SC(!!& 0/\ :_,"J_\ PFNG?\^&O_\
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M1J.&$9!'N.#6Q_PFNG?\^&O_ /@BO/\ XU0!T=%<Y_PFNG?\^&O_ /@BO/\
MXU1_PFNG?\^&O_\ @BO/_C5 '1T5SG_":Z=_SX:__P""*\_^-4?\)KIW_/AK
M_P#X(KS_ .-4 ='17.?\)KIW_/AK_P#X(KS_ .-4?\)KIW_/AK__ ((KS_XU
M0!T=%<Y_PFNG?\^&O_\ @BO/_C5'_":Z=_SX:_\ ^"*\_P#C5 '1T5SG_":Z
M=_SX:_\ ^"*\_P#C5'_":Z=_SX:__P""*\_^-4 ='17.?\)KIW_/AK__ ((K
MS_XU1_PFNG?\^&O_ /@BO/\ XU0!T=%<Y_PFNG?\^&O_ /@BO/\ XU1_PFNG
M?\^&O_\ @BO/_C5 '1T5SG_":Z=_SX:__P""*\_^-4?\)KIW_/AK_P#X(KS_
M .-4 ='17.?\)KIW_/AK_P#X(KS_ .-4?\)KIW_/AK__ ((KS_XU0!T=%<Y_
MPFNG?\^&O_\ @BO/_C5'_":Z=_SX:_\ ^"*\_P#C5 '1T5SG_":Z=_SX:_\
M^"*\_P#C5'_":Z=_SX:__P""*\_^-4 ='17.?\)KIW_/AK__ ((KS_XU1_PF
MNG?\^&O_ /@BO/\ XU0!T=%<Y_PFNG?\^&O_ /@BO/\ XU1_PFNG?\^&O_\
M@BO/_C5 '1T5SG_":Z=_SX:__P""*\_^-4?\)KIW_/AK_P#X(KS_ .-4 ='1
M7.?\)KIW_/AK_P#X(KS_ .-4?\)KIW_/AK__ ((KS_XU0!T=%<Y_PFNG?\^&
MO_\ @BO/_C5'_":Z=_SX:_\ ^"*\_P#C5 '1T5SG_":Z=_SX:_\ ^"*\_P#C
M5'_":Z=_SX:__P""*\_^-4 ='17.?\)KIW_/AK__ ((KS_XU1_PFNG?\^&O_
M /@BO/\ XU0!T=%<Y_PFNG?\^&O_ /@BO/\ XU1_PFNG?\^&O_\ @BO/_C5
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MWN/,34&97D#.,$?*!C Y/H*$-^1OT444 %%%% !1110 4444 %%%% !1110
M4444 %<Y;_\ )2=0_P"P1:_^CIZZ.N<M_P#DI.H?]@BU_P#1T] '1T444 (6
M4'!8 ^F:6J-UIQN;^WNO.*>1T0+PWUYJ]0 5SGB[_F!?]A>W_P#9JZ.N<\7?
M\P+_ +"]O_[-0!T=%%% !1110 5!??\ 'A<_]<F_D:GJ"^_X\+G_ *Y-_(T
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MK:)_X+XO_B: -O[1#_SVC_[Z%<[!/%_PLC4#YJ8_LBUYW#_GM/4__"#>$?\
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M0!M_:(?^>T?_ 'T*/M$/_/:/_OH5B?\ "#>$?^A6T3_P7Q?_ !-'_"#>$?\
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M?_P:+_\ $5T=% '.?VMXI_Z%>W_\&B__ !%']K>*?^A7M_\ P:+_ /$5T=%
M'.?VMXI_Z%>W_P#!HO\ \11_:WBG_H5[?_P:+_\ $5T=% '.?VMXI_Z%>W_\
M&B__ !%']K>*?^A7M_\ P:+_ /$5T=% '.?VMXI_Z%>W_P#!HO\ \11_:WBG
M_H5[?_P:+_\ $5T=% '.?VMXI_Z%>W_\&B__ !%']K>*?^A7M_\ P:+_ /$5
MT=% '.?VMXI_Z%>W_P#!HO\ \11_:WBG_H5[?_P:+_\ $5T=% '.?VMXI_Z%
M>W_\&B__ !%8,&I^(_\ A/[YQX<@,QTNW#1?VB,!?-FP<[.Y)&/;WKT&N<M_
M^2DZA_V"+7_T=/0 ?VMXI_Z%>W_\&B__ !%']K>*?^A7M_\ P:+_ /$5T=%
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MSG]K>*?^A7M__!HO_P 11_:WBG_H5[?_ ,&B_P#Q%='10!SG]K>*?^A7M_\
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MB[_F!?\ 87M__9JZ.N<\7?\ ,"_["]O_ .S4 ='1110 4444 %07W_'A<_\
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M*P;:V"!QQ_G%,EU_5+6',VE2G:3ND5#M '<\<"@!_P#PC&H?]#CK_P"5I_\
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M8A'(]\CVKT&N<\7?\P+_ +"]O_[-0 ?\(QJ'_0XZ_P#E:?\ QBC_ (1C4/\
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M-0_Z''7_ ,K3_P",5T=% '.?\(QJ'_0XZ_\ E:?_ !BC_A&-0_Z''7_RM/\
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MUX?_ .?FY_\  "?_ .(H_P"$Z\/_ //S<_\ @!/_ /$4 ='7.6__ "4G4/\
ML$6O_HZ>C_A.O#__ #\W/_@!/_\ $5@P>,M#'C^^N3<7'E-I=O&#]BFSN$LQ
M/&S/<<T >@T5SG_"=>'_ /GYN?\ P G_ /B*/^$Z\/\ _/S<_P#@!/\ _$4
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M_P# "?\ ^(H Z.BN<_X3KP__ ,_-S_X 3_\ Q%'_  G7A_\ Y^;G_P  )_\
MXB@#HZ*YS_A.O#__ #\W/_@!/_\ $4?\)UX?_P"?FY_\ )__ (B@#HZ*YS_A
M.O#_ /S\W/\ X 3_ /Q%'_"=>'_^?FY_\ )__B* .CHKG/\ A.O#_P#S\W/_
M ( 3_P#Q%'_"=>'_ /GYN?\ P G_ /B* .CHKG/^$Z\/_P#/S<_^ $__ ,11
M_P )UX?_ .?FY_\  "?_ .(H Z.BN<_X3KP__P _-S_X 3__ !%'_"=>'_\
MGYN?_ "?_P"(H Z.BN<_X3KP_P#\_-S_ . $_P#\11_PG7A__GYN?_ "?_XB
M@#HZ*YS_ (3KP_\ \_-S_P" $_\ \11_PG7A_P#Y^;G_ , )_P#XB@#HZ*YS
M_A.O#_\ S\W/_@!/_P#$4?\ "=>'_P#GYN?_   G_P#B* .CHKG/^$Z\/_\
M/S<_^ $__P 11_PG7A__ )^;G_P G_\ B* .CHKG/^$Z\/\ _/S<_P#@!/\
M_$4?\)UX?_Y^;G_P G_^(H Z.BN<_P"$Z\/_ //S<_\ @!/_ /$4?\)UX?\
M^?FY_P# "?\ ^(H Z.BN<_X3KP__ ,_-S_X 3_\ Q%'_  G7A_\ Y^;G_P
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MGKHZYRW_ .2DZA_V"+7_ -'3T ='1110 450N]1:VU"VMA'N$W5O[GU^M7Z
M"N<\7?\ ,"_["]O_ .S5T=<YXN_Y@7_87M__ &:@#HZ*** "BBB@ J"^_P"/
M"Y_ZY-_(U/4%]_QX7/\ UR;^1H R_!G_ "(OA_\ [!MM_P"BEK;K$\&?\B+X
M?_[!MM_Z*6MN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLPX*^;-@;?-X(.><]^G% 'H-%<Y_9GBW_H9=/_\ !2?_ (]1_9GBW_H9=/\
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M&73_ /P4G_X]0!T=%<Y_9GBW_H9=/_\ !2?_ (]1_9GBW_H9=/\ _!2?_CU
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M&73_ /P4G_X]0!T=%<Y_9GBW_H9=/_\ !2?_ (]1_9GBW_H9=/\ _!2?_CU
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M&73_ /P4G_X]0!T=%<Y_9GBW_H9=/_\ !2?_ (]1_9GBW_H9=/\ _!2?_CU
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MW_HI:VZQ/!G_ "(OA_\ [!MM_P"BEK;H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *YSQ1_R$?"__87'_I//71USGBC_ )"/A?\
M["X_])YZ .CHHHH YSQ?_JM%_P"PO:_^A5T=<MXZM8+ZPTJUNHEE@EU6V5T;
MHPW=*F_X0+PK_P! .T_[Y/\ C0!T=%<Y_P (%X5_Z =I_P!\G_&C_A O"O\
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M?\(%X5_Z =I_WR?\: .CHKG/^$"\*_\ 0#M/^^3_ (T?\(%X5_Z =I_WR?\
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M_P#0#M/^^3_C1_P@7A7_ * =I_WR?\: .CHKG/\ A O"O_0#M/\ OD_XT?\
M"!>%?^@':?\ ?)_QH Z.BN<_X0+PK_T [3_OD_XT?\(%X5_Z =I_WR?\: .C
MHKG/^$"\*_\ 0#M/^^3_ (T?\(%X5_Z =I_WR?\ &@#HZ*YS_A O"O\ T [3
M_OD_XT?\(%X5_P"@':?]\G_&@#HZ*YS_ (0+PK_T [3_ +Y/^-'_  @7A7_H
M!VG_ 'R?\: .CHKG/^$"\*_] .T_[Y/^-'_"!>%?^@':?]\G_&@#HZ*YS_A
MO"O_ $ [3_OD_P"-'_"!>%?^@':?]\G_ !H Z.BN<_X0+PK_ - .T_[Y/^-'
M_"!>%?\ H!VG_?)_QH Z.BN<_P"$"\*_] .T_P"^3_C1_P (%X5_Z =I_P!\
MG_&@#HZ*YS_A O"O_0#M/^^3_C1_P@7A7_H!VG_?)_QH Z.BN<_X0+PK_P!
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M $)U_P#^!EM_\<H_M[7O^A.O_P#P,MO_ (Y71T4 <Y_;VO?]"=?_ /@9;?\
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M ,(7NO\ F!3818 )+=C@=!\W?I[>]%Q?:\MU,L&G1M"K81F/+#/U_'\:W:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5SGBC_D(^%_^PN/_ $GGKHZYSQ1_R$?"_P#V%Q_Z3ST
M='1110!RWCJ*6>PTJ*"X:WE;5;8+,JABAW=0""#^-3?V%K__ $.%Y_X!6_\
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M_B*/["U__H<+S_P"M_\ XBNB5U=0R,&4]"#D4M '.?V%K_\ T.%Y_P" 5O\
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MT=% '.?V%K__ $.%Y_X!6_\ \11_86O_ /0X7G_@%;__ !%='10!SG]A:_\
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MN /RJQ<Z+:W< AD\S:$5.&P<#I6;_P )]X4_Z#UE_P!_*/\ A/O"G_0>LO\
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M@]9?]_*/^$^\*?\ 0>LO^_E '1T5SG_"?>%/^@]9?]_*/^$^\*?]!ZR_[^4
M='17.?\ "?>%/^@]9?\ ?RC_ (3[PI_T'K+_ +^4 ='17.?\)]X4_P"@]9?]
M_*/^$^\*?]!ZR_[^4 ='17.?\)]X4_Z#UE_W\H_X3[PI_P!!ZR_[^4 ='17.
M?\)]X4_Z#UE_W\H_X3[PI_T'K+_OY0!T=%<Y_P )]X4_Z#UE_P!_*/\ A/O"
MG_0>LO\ OY0!T=%<Y_PGWA3_ *#UE_W\H_X3[PI_T'K+_OY0!T=<YXH_Y"/A
M?_L+C_TGGH_X3[PI_P!!ZR_[^5DZMXHT/6=;\,6VFZG;W4XU7>4C;)"BWF&?
MU% '<T444 <YXO\ ]5HO_87M?_0JZ.N;\8MM@T=L9QJUL>/]ZK \36J!3,!\
MW(\M@VT?[0Z@]<CG% 6-RBL ^+M/_?$1W!6(!F.SL2 ._N*5?%-JR)*(G\IW
MV*<C/3/KQ^- &]17-R^,]/5-T:2,!)L.<#MG/7G_ #FKD7B.SEDD39*K1QF1
M@V. !GU]/PH#S-BBL!/%EDR ^6X<J6 W+V]\_P#Z^V:FE\2V4,%K*R3'[0N4
M"KSUQ@^A]NW?%).X>1LT5@GQ99"<1F.0##9.5R"N,C&?K]<<9IT/BK3[C:(Q
M*79P@3 SD]^O2JL'2YN45A_\)/:M##<)#*8) ?F. 01[$U)<^)+*TM;>XG69
M$N%+(-F3@=SCZC\Q2#R-BBN<?QC9;@D,$[OL9\$ = 3CD^U6[;Q':75X;6..
M<2*I9LJ %QU[T ;%%8$GBVQ2&201S,$4,?NXYZ#.?\_@:(_%EE-'NBCE)"[L
M-A>/Q/- &_16-9>)+2^G2&-)-S8YXP,\#OG]*V:=@N%%%%( HHHH *YRW_Y*
M3J'_ &"+7_T=/71USEO_ ,E)U#_L$6O_ *.GH Z.BBB@ HJC=ZDMK?V]J4W&
M?^('A?K_ $_&KU !7.>+O^8%_P!A>W_]FKHZYSQ=_P P+_L+V_\ [-0!T=%%
M% !1110 5!??\>%S_P!<F_D:GJ"^_P"/"Y_ZY-_(T 9?@S_D1?#_ /V#;;_T
M4M;=8G@S_D1?#_\ V#;;_P!%+6W0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5SGBC_D(^%_^PN/_2>>NCKG/%'_ "$?"_\ V%Q_
MZ3ST ='1110!SGB__5:+_P!A>U_]"KH?+3^XOY5S'CH7+6&E"S>)+DZK;>6T
MR%D!W=P""1^(J;[/XT_Z">@?^"^;_P"/4 =#Y:<_(O/M1Y:8QL7'TKGOL_C3
M_H)Z!_X+YO\ X]1]G\:?]!/0/_!?-_\ 'J .@\J/^XOY4S[);_:#<>2GG%=N
M_'./2L+[/XT_Z">@?^"^;_X]1]G\:?\ 03T#_P %\W_QZ@#H?+C_ +B_E1L4
MX^4<>U<]]G\:?]!/0/\ P7S?_'J/L_C3_H)Z!_X+YO\ X]0!T/EIG.Q?RH$:
M Y"*#]*Y[[/XT_Z">@?^"^;_ ./4?9_&G_03T#_P7S?_ !Z@#H=B8QM7'IBE
M**0 5!Q[5SOV?QI_T$] _P#!?-_\>H^S^-/^@GH'_@OF_P#CU '0^6G]Q?RH
M\M#GY%Y&#Q7/?9_&G_03T#_P7S?_ !ZC[/XT_P"@GH'_ (+YO_CU &^L$2($
M6- JC  ' IWEI_<7\JY[[/XT_P"@GH'_ (+YO_CU'V?QI_T$] _\%\W_ ,>H
M Z$(@Z*H^@IU<Y]G\:?]!/0/_!?-_P#'J/L_C3_H)Z!_X+YO_CU '1T5SGV?
MQI_T$] _\%\W_P >H^S^-/\ H)Z!_P""^;_X]0!T=%<Y]G\:?]!/0/\ P7S?
M_'J/L_C3_H)Z!_X+YO\ X]0!T=<Y;_\ )2=0_P"P1:_^CIZ/L_C3_H)Z!_X+
MYO\ X]6#!!XM_P"$_O@-0T3[1_9=ON8V,NPKYLV !YV<YSSGTX]0#T&BN<^S
M^-/^@GH'_@OF_P#CU'V?QI_T$] _\%\W_P >H Z(@$Y(&:6N<^S^-/\ H)Z!
M_P""^;_X]1]G\:?]!/0/_!?-_P#'J .CKG/%W_,"_P"PO;_^S4?9_&G_ $$]
M _\ !?-_\>K!\3P>+1_8WGZAHC9U2#9LL91A_FP3F8Y'MQ]: /0:*YS[/XT_
MZ">@?^"^;_X]1]G\:?\ 03T#_P %\W_QZ@#HZ*YS[/XT_P"@GH'_ (+YO_CU
M'V?QI_T$] _\%\W_ ,>H Z.H+[_CPN?^N3?R-8?V?QI_T$] _P#!?-_\>J&\
M@\9_8I]VI:"5\MLXT^;.,?\ 7:@"]X,_Y$7P_P#]@VV_]%+6W7">$X/%Q\&Z
M&;?4=#6$Z?!Y:R6$K,%\M< D3 $X[X%;'V?QI_T$] _\%\W_ ,>H Z.BN<^S
M^-/^@GH'_@OF_P#CU'V?QI_T$] _\%\W_P >H Z.BN<^S^-/^@GH'_@OF_\
MCU'V?QI_T$] _P#!?-_\>H Z.BN<^S^-/^@GH'_@OF_^/4?9_&G_ $$] _\
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M_P!<F_D: ,OP9_R(OA__ +!MM_Z*6MNL3P9_R(OA_P#[!MM_Z*6MN@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/%'_(1\+_\
M87'_ *3SUT=<YXH_Y"/A?_L+C_TGGH Z.BBB@#G/%_\ JM%_["]K_P"A5T=<
MMXZM8KVPTJVG#&*75;96"N4.-W8@@C\#4W_""Z!_SPO/_!C<?_'* .CHKG/^
M$%T#_GA>?^#&X_\ CE'_  @N@?\ /"\_\&-Q_P#'* .CHKG/^$%T#_GA>?\
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M+H'_ #PO/_!C<?\ QRC_ (070/\ GA>?^#&X_P#CE '1USGB[_F!?]A>W_\
M9J/^$%T#_GA>?^#&X_\ CE8/B?P;HEO_ &-Y<-T/,U2"-LWTYX.[/5^/J.:
M/0:*YS_A!= _YX7G_@QN/_CE'_""Z!_SPO/_  8W'_QR@#HZ*YS_ (070/\
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MW'_QRC_A!= _YX7G_@QN/_CE '1T5SG_  @N@?\ /"\_\&-Q_P#'*/\ A!=
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M-_(T <7X3\27D/@W0XE\*ZY,J:? HDC%OM<"->1F8'!]P*V/^$HOO^A0U_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<YXH_Y"/A?_ +"X_P#2>>NCKG/%
M'_(1\+_]A<?^D\] '1T444 <MXZMS=6&E0":6 R:K;+YD+8=?FZ@^M3?\(G)
M_P!#+K__ (%+_P#$4>,"!#HQ/0:O;?\ H5;L-W;W"EH9D< X)!H PO\ A$Y/
M^AEU_P#\"E_^(H_X1.3_ *&77_\ P*7_ .(KH'FCC0N\BJJC))/04OF)@'>N
M#R.: .>_X1.3_H9=?_\  I?_ (BC_A$Y/^AEU_\ \"E_^(K=>ZMT^],@^;;R
M>_I3C/"HR94 R!U]: ,#_A$Y/^AEU_\ \"E_^(H_X1.3_H9=?_\  I?_ (BN
MB#J3@,,_6F^='S^\7CKSTH Y_P#X1.3_ *&77_\ P*7_ .(H_P"$3D_Z&77_
M /P*7_XBN@::)1EI% ^M(;B%0I,J#<<+SU- &!_PB<G_ $,NO_\ @4O_ ,11
M_P (G)_T,NO_ /@4O_Q%="'0]&'YTWSXC(8_,7>!DC/(% &!_P (G)_T,NO_
M /@4O_Q%'_")R?\ 0RZ__P"!2_\ Q%=!YL>[;O7.,XS0)8VZ.I_&@#G_ /A$
MY/\ H9=?_P# I?\ XBC_ (1.3_H9=?\ _ I?_B*Z%I$12S.H ZDFFK/$\7F+
M(I3KN!XH P/^$3D_Z&77_P#P*7_XBC_A$Y/^AEU__P "E_\ B*Z'S$_OK^=-
M%Q"96C$J;UQN7/(H P/^$3D_Z&77_P#P*7_XBC_A$Y/^AEU__P "E_\ B*Z$
MNBC)90.O)IK7$**&:5 IX!)H P/^$3D_Z&77_P#P*7_XBC_A$Y/^AEU__P "
ME_\ B*Z,'(R** .<_P"$3D_Z&77_ /P*7_XBL&#PRY\?WT'_  D&M@KI=N_F
M"X7><RS#!.WH,?J:]!KG+?\ Y*3J'_8(M?\ T=/0 ?\ ")R?]#+K_P#X%+_\
M11_PB<G_ $,NO_\ @4O_ ,171T4 <Y_PB<G_ $,NO_\ @4O_ ,11_P (G)_T
M,NO_ /@4O_Q%='10!SG_  B<G_0RZ_\ ^!2__$5@^)_#+P_V-_Q4&MR;]4@3
MY[A3MSNY'R]:]!KG/%W_ # O^PO;_P#LU !_PB<G_0RZ_P#^!2__ !%'_")R
M?]#+K_\ X%+_ /$5T=% '.?\(G)_T,NO_P#@4O\ \11_PB<G_0RZ_P#^!2__
M !%="\B1+N=@HZ9-*K*ZAE(*D9!% '._\(G)_P!#+K__ (%+_P#$5#>>%)%L
MK@_\))KQQ&QP;E<'C_<KJ:@OO^/"Y_ZY-_(T <7X3\,//X-T.4>(=<CWZ? V
MR.Y4*N8U. -O2MC_ (1.3_H9=?\ _ I?_B*L>#/^1%\/_P#8-MO_ $4M;= '
M.?\ ")R?]#+K_P#X%+_\11_PB<G_ $,NO_\ @4O_ ,171T4 <Y_PB<G_ $,N
MO_\ @4O_ ,11_P (G)_T,NO_ /@4O_Q%='10!SG_  B<G_0RZ_\ ^!2__$4?
M\(G)_P!#+K__ (%+_P#$5T=% '.?\(G)_P!#+K__ (%+_P#$4?\ ")R?]#+K
M_P#X%+_\171T4 <Y_P (G)_T,NO_ /@4O_Q%'_")R?\ 0RZ__P"!2_\ Q%='
M10!SG_")R?\ 0RZ__P"!2_\ Q%'_  B<G_0RZ_\ ^!2__$5T=% '.?\ ")R?
M]#+K_P#X%+_\11_PB<G_ $,NO_\ @4O_ ,171T4 <Y_PB<G_ $,NO_\ @4O_
M ,11_P (G)_T,NO_ /@4O_Q%='10!SG_  B<G_0RZ_\ ^!2__$4?\(G)_P!#
M+K__ (%+_P#$5T=% '.?\(G)_P!#+K__ (%+_P#$4?\ ")R?]#+K_P#X%+_\
M171T4 <Y_P (G)_T,NO_ /@4O_Q%'_")R?\ 0RZ__P"!2_\ Q%='10!SG_")
MR?\ 0RZ__P"!2_\ Q%'_  B<G_0RZ_\ ^!2__$5T=% '.?\ ")R?]#+K_P#X
M%+_\11_PB<G_ $,NO_\ @4O_ ,171T4 <Y_PB<G_ $,NO_\ @4O_ ,11_P (
MG)_T,NO_ /@4O_Q%='10!SG_  B<G_0RZ_\ ^!2__$4?\(G)_P!#+K__ (%+
M_P#$5T=% '.?\(G)_P!#+K__ (%+_P#$4?\ ")R?]#+K_P#X%+_\171T4 <Y
M_P (G)_T,NO_ /@4O_Q%'_")R?\ 0RZ__P"!2_\ Q%='10!SG_")R?\ 0RZ_
M_P"!2_\ Q%'_  B<G_0RZ_\ ^!2__$5T=% '.?\ ")R?]#+K_P#X%+_\11_P
MB<G_ $,NO_\ @4O_ ,171T4 <Y_PB<G_ $,NO_\ @4O_ ,11_P (G)_T,NO_
M /@4O_Q%='10!SG_  B<G_0RZ_\ ^!2__$4?\(G)_P!#+K__ (%+_P#$5T=%
M '.?\(G)_P!#+K__ (%+_P#$5DZMH;:;K?AB<ZQJEX#JNWR[J970?Z/-S@*.
M>/UKN:YSQ1_R$?"__87'_I//0!T=%%% '-^,5#V^CJ>AU:V'_CU6&\-0D BY
MF,@"J'?&0@[# %4_'%S!9V.DW-U/'!!'JULSRRN%51NZDG@"K?\ PFWA/_H9
M]%_\#XO_ (JE8".3PA9RQLC7EZ0V<_O >OX>G%6+KPW:W<XEDGN!M38%5@ !
MC&>G6H_^$V\)_P#0SZ+_ .!\7_Q5'_";>$_^AGT7_P #XO\ XJF%B4^&[0V9
MMFEF(W[]^5W9P!Z>@J)O"EDY7=-<%5Q\FY<=0>F/4"C_ (3;PG_T,^B_^!\7
M_P 51_PFWA/_ *&?1?\ P/B_^*H%8DM/#=M9W8N8[FZ9P2<.X(Y_"BW\-VMO
M%.@GN&$[!G+%<Y'T%1_\)MX3_P"AGT7_ ,#XO_BJ/^$V\)_]#/HO_@?%_P#%
M4K#$/A2T*.@N;H*S!B-RD<9XP5Z<FGIX8M(X'B$]P=Q)W,P)!((XX]Z;_P )
MMX3_ .AGT7_P/B_^*H_X3;PG_P!#/HO_ ('Q?_%4P'6_ABUMS!MN;IA Q9<L
MO.?4@<T]?#MJJW8\Z?-T ';(! !)P,#W[YJ+_A-O"?\ T,^B_P#@?%_\51_P
MFWA/_H9]%_\  ^+_ .*H C'@^R#JWVJ\)7IF0?SQFIXO#-I%-#()IR(B"$)4
M@X]>*9_PFWA/_H9]%_\  ^+_ .*H_P"$V\)_]#/HO_@?%_\ %4 )=>%+2Z,V
M^ZNP)6W%0XPIYSC(XSG]!4MKX<@L;9X8+B<ABA_>$'[IR.@'I4?_  FWA/\
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M_H9]%_\  ^+_ .*H W:*PO\ A-O"?_0SZ+_X'Q?_ !5'_";>$_\ H9]%_P#
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M_P#S[Q?]\"C[+;_\^\7_ 'P*FHH A^RV_P#S[Q?]\"C[+;_\^\7_ 'P*FHH
MA^RV_P#S[Q?]\"C[+;_\^\7_ 'P*FHH A^RV_P#S[Q?]\"C[+;_\^\7_ 'P*
MFHH A^RV_P#S[Q?]\"C[+;_\^\7_ 'P*FHH A^RV_P#S[Q?]\"C[+;_\^\7_
M 'P*FHH A^RV_P#S[Q?]\"C[+;_\^\7_ 'P*FHH A^RV_P#S[Q?]\"C[+;_\
M^\7_ 'P*FHH A^RV_P#S[Q?]\"C[+;_\^\7_ 'P*FHH A^RV_P#S[Q?]\"C[
M+;_\^\7_ 'P*FHH A^RV_P#S[Q?]\"C[+;_\^\7_ 'P*FHH A^RV_P#S[Q?]
M\"C[+;_\^\7_ 'P*FHH A^RV_P#S[Q?]\"C[+;_\^\7_ 'P*FHH A^RV_P#S
M[Q?]\"C[+;_\^\7_ 'P*FHH A^RV_P#S[Q?]\"C[+;_\^\7_ 'P*FHH A^RV
M_P#S[Q?]\"C[+;_\^\7_ 'P*FHH A^RV_P#S[Q?]\"C[+;_\^\7_ 'P*FHH
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M>-/^>>@?]]S?X4;O&G_//0/^^YO\* .CHKG-WC3_ )YZ!_WW-_A1N\:?\\]
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M;1^= '045SRV/B)L^;?0 8X",>3]=M2OI>J++/-!?(LCLQ53D@#/&?\ ZP%
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MY?[P_.C<O]X?G7/?\(#X._Z%71/_   B_P#B:/\ A ?!W_0JZ)_X 1?_ !-
M'0[E_O#\Z-R_WA^=<]_P@/@[_H5=$_\  "+_ .)H_P"$!\'?]"KHG_@!%_\
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ML[&-2221R2:V/^$!\'?]"KHG_@!%_P#$T =#N7^\/SHW+_>'YUSW_" ^#O\
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MC  ["@!U07W_ !X7/_7)OY&IZ@OO^/"Y_P"N3?R- &7X,_Y$7P__ -@VV_\
M12UMUB>#/^1%\/\ _8-MO_12UMT %%%% !1110 4444 %%%% !1110 4444
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M:/\ A+E_Z &O_P#@ ?\ &NCHH YS_A+E_P"@!K__ ( '_&C_ (2Y?^@!K_\
MX '_ !KHZ* .<_X2Y?\ H :__P" !_QH_P"$N7_H :__ . !_P :Z.B@#G/^
M$N7_ * &O_\ @ ?\:P8/%"CQ_?3_ -B:V=VEVZ>6+([QB68Y(STYZ^QKT&N<
MM_\ DI.H?]@BU_\ 1T] !_PER_\ 0 U__P  #_C1_P )<O\ T -?_P#  _XU
MT=% '.?\)<O_ $ -?_\   _XT?\ "7+_ - #7_\ P /^-='10!SG_"7+_P!
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M (T?\)<O_0 U_P#\ #_C71T4 <Y_PER_] #7_P#P /\ C1_PER_] #7_ /P
M/^-='10!SG_"7+_T -?_ /  _P"-'_"7+_T -?\ _  _XUT=% '.?\)<O_0
MU_\ \ #_ (T?\)<O_0 U_P#\ #_C71T4 <Y_PER_] #7_P#P /\ C1_PER_]
M #7_ /P /^-='10!SG_"7+_T -?_ /  _P"-'_"7+_T -?\ _  _XUT=% '.
M?\)<O_0 U_\ \ #_ (T?\)<O_0 U_P#\ #_C71T4 <Y_PER_] #7_P#P /\
MC1_PER_] #7_ /P /^-='10!SG_"7+_T -?_ /  _P"-'_"7+_T -?\ _  _
MXUT=% '.?\)<O_0 U_\ \ #_ (T?\)<O_0 U_P#\ #_C71T4 <Y_PER_] #7
M_P#P /\ C1_PER_] #7_ /P /^-='10!SG_"7+_T -?_ /  _P"-'_"7+_T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJG_0Z:[_ -^K/_Y'KHZ* .<_X1K5/^ATUW_OU9__ "/1_P (UJG_ $.FN_\
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M^K/_ .1ZZ.B@#G/^$:U3_H=-=_[]6?\ \CT?\(UJG_0Z:[_WZL__ )'KHZ*
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M</%]LTY18'V@XR2.?_K58MO$L%U+Y:P2JQC,@W=QC(_0T 6?^$=T3_H#:?\
M^ J?X4?\([HG_0&T_P#\!4_PJ"'Q%!+;O*8F79MR"1WSW[=#4(\56Q<#[/,0
M2!N SUH6H/0N_P#".Z)_T!M/_P# 5/\ "C_A'=$_Z VG_P#@*G^%5+CQ1;07
M,T'D2N8B0Q4<<<46GBBUO;K[/'#*'*E@3T/&<?H?RH M_P#".Z)_T!M/_P#
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M:?\ ^ J?X5I44 9O_".Z)_T!M/\ _ 5/\*/^$=T3_H#:?_X"I_A6E10!F_\
M".Z)_P! ;3__  %3_"C_ (1W1/\ H#:?_P" J?X5I44 9O\ PCNB?] ;3_\
MP%3_  H_X1W1/^@-I_\ X"I_A6E10!F_\([HG_0&T_\ \!4_PH_X1W1/^@-I
M_P#X"I_A6E10!F_\([HG_0&T_P#\!4_PH_X1W1/^@-I__@*G^%:5% &;_P (
M[HG_ $!M/_\  5/\*/\ A'=$_P"@-I__ ("I_A6E10!F_P#".Z)_T!M/_P#
M5/\ "C_A'=$_Z VG_P#@*G^%:5% &;_PCNB?] ;3_P#P%3_"C_A'=$_Z VG_
M /@*G^%:5% &;_PCNB?] ;3_ /P%3_"C_A'=$_Z VG_^ J?X5I44 9O_  CN
MB?\ 0&T__P !4_PH_P"$=T3_ * VG_\ @*G^%:5% &;_ ,([HG_0&T__ ,!4
M_P */^$=T3_H#:?_ . J?X5I44 9O_".Z)_T!M/_ / 5/\*/^$=T3_H#:?\
M^ J?X5I44 9O_".Z)_T!M/\ _ 5/\*/^$=T3_H#:?_X"I_A6E10!F_\ ".Z)
M_P! ;3__  %3_"C_ (1W1/\ H#:?_P" J?X5I44 9O\ PCNB?] ;3_\ P%3_
M  H_X1W1/^@-I_\ X"I_A6E10!F_\([HG_0&T_\ \!4_PH_X1W1/^@-I_P#X
M"I_A6E10!F_\([HG_0&T_P#\!4_PH_X1W1/^@-I__@*G^%:5% &;_P ([HG_
M $!M/_\  5/\*/\ A'=$_P"@-I__ ("I_A6E10!F_P#".Z)_T!M/_P# 5/\
M"C_A'=$_Z VG_P#@*G^%:5% &;_PCNB?] ;3_P#P%3_"C_A'=$_Z VG_ /@*
MG^%:5% &;_PCNB?] ;3_ /P%3_"L+7])TVQU;PO+::?:V\AU8*7BA5#C[//Q
MD"NOKG/%'_(1\+_]A<?^D\] '1T444 <YXO_ -5HO_87M?\ T*N@:&)V+/$C
M$@ DJ#D Y'ZUS/CIKE+#2FLXHI;D:K;>6DTA1&.[H6"L0/?!J;[7XT_Z F@_
M^#>;_P"1J .CHKG/M?C3_H":#_X-YO\ Y&H^U^-/^@)H/_@WF_\ D:@#HZ*Y
MS[7XT_Z F@_^#>;_ .1J/M?C3_H":#_X-YO_ )&H Z.BN<^U^-/^@)H/_@WF
M_P#D:C[7XT_Z F@_^#>;_P"1J .CHKG/M?C3_H":#_X-YO\ Y&H^U^-/^@)H
M/_@WF_\ D:@#HZ*YS[7XT_Z F@_^#>;_ .1J/M?C3_H":#_X-YO_ )&H Z.B
MN<^U^-/^@)H/_@WF_P#D:C[7XT_Z F@_^#>;_P"1J .CHKG/M?C3_H":#_X-
MYO\ Y&H^U^-/^@)H/_@WF_\ D:@#HZ*YS[7XT_Z F@_^#>;_ .1J/M?C3_H"
M:#_X-YO_ )&H Z.C&>M<Y]K\:?\ 0$T'_P &\W_R-1]K\:?] 30?_!O-_P#(
MU '1*BHH5%"J.@ P*6N<^U^-/^@)H/\ X-YO_D:C[7XT_P"@)H/_ (-YO_D:
M@#HZYRW_ .2DZA_V"+7_ -'3T?:_&G_0$T'_ ,&\W_R-6#!=>+?^$_OF&D:+
M]H_LNW#(=4EV!?-FP0WV?).<\8XP.3G@ ]!HKG/M?C3_ * F@_\ @WF_^1J/
MM?C3_H":#_X-YO\ Y&H Z.BN<^U^-/\ H":#_P"#>;_Y&H^U^-/^@)H/_@WF
M_P#D:@#HZYSQ=_S O^PO;_\ LU'VOQI_T!-!_P#!O-_\C5@^)[KQ:?[&\_2-
M%3&J0%-FJ2MEOFP#FW&![\_2@#T&BN<^U^-/^@)H/_@WF_\ D:C[7XT_Z F@
M_P#@WF_^1J .CHKG/M?C3_H":#_X-YO_ )&H^U^-/^@)H/\ X-YO_D:@#HZ@
MOO\ CPN?^N3?R-8?VOQI_P! 30?_  ;S?_(U0WEWXR^Q7&[1=""^6V2-6F)Q
MC_KVH O>#/\ D1?#_P#V#;;_ -%+6W7">$[KQ<O@W0Q;Z/HCPC3X!&TFJRJS
M+Y:X) MR <=LGZFMC[7XT_Z F@_^#>;_ .1J .CHKG/M?C3_ * F@_\ @WF_
M^1J/M?C3_H":#_X-YO\ Y&H Z.BN<^U^-/\ H":#_P"#>;_Y&H^U^-/^@)H/
M_@WF_P#D:@#HZ*YS[7XT_P"@)H/_ (-YO_D:C[7XT_Z F@_^#>;_ .1J .CH
MKG/M?C3_ * F@_\ @WF_^1J/M?C3_H":#_X-YO\ Y&H Z.BN<^U^-/\ H":#
M_P"#>;_Y&H^U^-/^@)H/_@WF_P#D:@#HZ*YS[7XT_P"@)H/_ (-YO_D:C[7X
MT_Z F@_^#>;_ .1J .CHKG/M?C3_ * F@_\ @WF_^1J/M?C3_H":#_X-YO\
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MT_Z F@_^#>;_ .1J .CHKG/M?C3_ * F@_\ @WF_^1J/M?C3_H":#_X-YO\
MY&H Z.BN<^U^-/\ H":#_P"#>;_Y&H^U^-/^@)H/_@WF_P#D:@#HZ*YS[7XT
M_P"@)H/_ (-YO_D:C[7XT_Z F@_^#>;_ .1J .CHKG/M?C3_ * F@_\ @WF_
M^1J/M?C3_H":#_X-YO\ Y&H Z.BN<^U^-/\ H":#_P"#>;_Y&H^U^-/^@)H/
M_@WF_P#D:@#HZ*YS[7XT_P"@)H/_ (-YO_D:C[7XT_Z F@_^#>;_ .1J .CK
MG/%'_(1\+_\ 87'_ *3ST?:_&G_0$T'_ ,&\W_R-63JT_B&76_#"ZKIVF6]O
M_:N0]K?R3-N^SS8&UH4&.O.?PH [FBBB@#F_&+!+?1V/0:M;'_QZK47BC3W3
M=(S1D_=&-V[ITQ]>E5?&1 M]'+?=&K6V?^^J9=ZYH:20E[)78!54M$,JO;'M
MS0M6-)O8O1^)M.DG:(LZ,HR=RG\?R&2?2K=IK%E>RB."4LY7< 5(XK(&H>&W
M<,EG [,P7*P+DL>@^M7+>XTF6QAU&*VC520$*Q@,#TQ3\Q$MUX@T^T!\R4AL
MD 8(SC@X_P ]J8GB337B\PRL ,9^4\?YR/SJE)JGAPRSK);0EHR6?, /.1DU
M')>>&;N.,?9XRL;AMJQ[0#UY ^GZ4N@=37N=9M;>PCO?GDA<C!4=O6F'Q!IP
MQB5B3T&P]>N/RY^AJ.QN=*OK>X6.V01Q-AXWC&./:J,6J^'BGF06,9*-M7$"
MCG.#C\Z/(#5MM;L;N2..*1BTAP!M/7!/]#^1IMSX@TZT+K+-M96V8*D9-9UQ
M/H45VTDMLL4UDV$P-HS@=,?[U,M[WP_=;I&L8F,F96+Q!BS9Z<]Z?F'F7_\
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M(.*7^R--((_L^UYQG]RO.!@=O3BI([&TAD$D5O%&XZ%$ /3':A>8%BN<M_\
MDI.H?]@BU_\ 1T]='7.6_P#R4G4/^P1:_P#HZ>@#HZ*** "BBB@ KG/%W_,"
M_P"PO;_^S5T=<YXN_P"8%_V%[?\ ]FH Z.BBB@ HJKJ,=S+9NEF^R<_=?/W?
M?WJ6V$BVT2R_ZP* W.>>] $M07W_ !X7/_7)OY&IZ@OO^/"Y_P"N3?R- &7X
M,_Y$7P__ -@VV_\ 12UMUB>#/^1%\/\ _8-MO_12UMT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<YXH_Y"/A?_ +"X_P#2>>NC
MKG/%'_(1\+_]A<?^D\] '1T444 <YXP&8M%!_P"@O:_^A5N-96C$%K6$D=,Q
MCBN=\=6L%]8:5:W,8DAEU6V5T/<;JF_X0/PQ_P! B+_OM_\ &@#;%C:*P86L
M (.01&.#ZTX6EL%*""/:>J[1C\JPO^$#\,?] B+_ +[?_&C_ (0/PQ_T"(O^
M^W_QH VO[/LAG%I!SU_=CFE^PV?_ #ZP=0?]6.U8G_"!^&/^@1%_WV_^-'_"
M!^&/^@1%_P!]O_C0!O"UMP21#&">N%'/UI@L+,*%%I  #G'ECKZUB?\ "!^&
M/^@1%_WV_P#C1_P@?AC_ *!$7_?;_P"- &X]C:2,S/:PL6.26C!R:%L[5 P6
MVA4,,$! ,BL/_A _#'_0(B_[[?\ QH_X0/PQ_P! B+_OM_\ &@#=BM+: YAM
MXHSZH@'\JFKG/^$#\,?] B+_ +[?_&C_ (0/PQ_T"(O^^W_QH Z.BN<_X0/P
MQ_T"(O\ OM_\:/\ A _#'_0(B_[[?_&@#HZ*YS_A _#'_0(B_P"^W_QH_P"$
M#\,?] B+_OM_\: .CHKG/^$#\,?] B+_ +[?_&C_ (0/PQ_T"(O^^W_QH Z.
MBN<_X0/PQ_T"(O\ OM_\:/\ A _#'_0(B_[[?_&@#HZ*YS_A _#'_0(B_P"^
MW_QH_P"$#\,?] B+_OM_\: .CKG+?_DI.H?]@BU_]'3T?\('X8_Z!$7_ 'V_
M^-8,'@OPZ?']];'2XO)72[>0)N;AC+,">OH!^5 'H-%<Y_P@?AC_ *!$7_?;
M_P"-'_"!^&/^@1%_WV_^- '1T5SG_"!^&/\ H$1?]]O_ (T?\('X8_Z!$7_?
M;_XT ='7.>+O^8%_V%[?_P!FH_X0/PQ_T"(O^^W_ ,:P?$_@OP[;_P!C>5I<
M2^9JD$;X9N5.[(ZT >@T5SG_  @?AC_H$1?]]O\ XT?\('X8_P"@1%_WV_\
MC0!T=%<Y_P ('X8_Z!$7_?;_ .-'_"!^&/\ H$1?]]O_ (T ='4%]_QX7/\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N<\4?\A'PO\
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M^$UT[_GPU_\ \$5Y_P#&J/\ A-=._P"?#7__  17G_QJNCHH YS_ (373O\
MGPU__P $5Y_\:H_X373O^?#7_P#P17G_ ,:KHZ* .<_X373O^?#7_P#P17G_
M ,:H_P"$UT[_ )\-?_\ !%>?_&JZ.B@#G/\ A-=._P"?#7__  17G_QJL&#Q
M=8#Q_?7'V+6]C:7;H%&C76_(EF.2OEY YZXP>?0UZ#7.6_\ R4G4/^P1:_\
MHZ>@ _X373O^?#7_ /P17G_QJC_A-=._Y\-?_P#!%>?_ !JNCHH YS_A-=._
MY\-?_P#!%>?_ !JC_A-=._Y\-?\ _!%>?_&JZ.B@#G/^$UT[_GPU_P#\$5Y_
M\:K!\3^+K"?^QMMEK:^7JD#G?HUTF0-W S'R?8<UZ#7.>+O^8%_V%[?_ -FH
M /\ A-=._P"?#7__  17G_QJC_A-=._Y\-?_ /!%>?\ QJNCHH YS_A-=._Y
M\-?_ /!%>?\ QJC_ (373O\ GPU__P $5Y_\:KHZ* .<_P"$UT[_ )\-?_\
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MKIW_ #X:_P#^"*\_^-4?\)KIW_/AK_\ X(KS_P"-5T=% '.?\)KIW_/AK_\
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M'_":Z=_SX:__ ."*\_\ C5='10!SG_":Z=_SX:__ ."*\_\ C5'_  FNG?\
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MGB[_ )@7_87M_P#V:NCKG/%W_,"_["]O_P"S4 ='1110!5U%KI+-S9*&N/X
M>GX^U2VQD:VB,H(D*C<#Z]ZEHH *@OO^/"Y_ZY-_(U/4%]_QX7/_ %R;^1H
MR_!G_(B^'_\ L&VW_HI:VZQ/!G_(B^'_ /L&VW_HI:VZ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M65P3XMF($;9'V&'GCZ5U-07W_'A<_P#7)OY&@#B_">CZ])X-T-XO%,T4;:?
M5C%E"=@\M<#)&3BMC^Q/$7_0W3_^ $/^%6/!G_(B^'_^P;;?^BEK;H YS^Q/
M$7_0W3_^ $/^%']B>(O^ANG_ / "'_"NCHH YS^Q/$7_ $-T_P#X 0_X4?V)
MXB_Z&Z?_ , (?\*Z.B@#G/[$\1?]#=/_ . $/^%']B>(O^ANG_\  "'_  KH
MZ* .<_L3Q%_T-T__ ( 0_P"%']B>(O\ H;I__ "'_"NCHH YS^Q/$7_0W3_^
M $/^%']B>(O^ANG_ / "'_"NCHH YS^Q/$7_ $-T_P#X 0_X4?V)XB_Z&Z?_
M , (?\*Z.B@#G/[$\1?]#=/_ . $/^%']B>(O^ANG_\  "'_  KHZ* .<_L3
MQ%_T-T__ ( 0_P"%']B>(O\ H;I__ "'_"NCHH YS^Q/$7_0W3_^ $/^%']B
M>(O^ANG_ / "'_"NCHH YS^Q/$7_ $-T_P#X 0_X4?V)XB_Z&Z?_ , (?\*Z
M.B@#G/[$\1?]#=/_ . $/^%']B>(O^ANG_\  "'_  KHZ* .<_L3Q%_T-T__
M ( 0_P"%']B>(O\ H;I__ "'_"NCHH YS^Q/$7_0W3_^ $/^%']B>(O^ANG_
M / "'_"NCHH YS^Q/$7_ $-T_P#X 0_X4?V)XB_Z&Z?_ , (?\*Z.B@#G/[$
M\1?]#=/_ . $/^%']B>(O^ANG_\  "'_  KHZ* .<_L3Q%_T-T__ ( 0_P"%
M']B>(O\ H;I__ "'_"NCHH YS^Q/$7_0W3_^ $/^%']B>(O^ANG_ / "'_"N
MCHH YS^Q/$7_ $-T_P#X 0_X4?V)XB_Z&Z?_ , (?\*Z.B@#G/[$\1?]#=/_
M . $/^%']B>(O^ANG_\  "'_  KHZ* .<_L3Q%_T-T__ ( 0_P"%']B>(O\
MH;I__ "'_"NCHH YS^Q/$7_0W3_^ $/^%']B>(O^ANG_ / "'_"NCHH YS^Q
M/$7_ $-T_P#X 0_X5DZMIVK6FM^&)+[79+Z(ZK@1-;1Q@'[/-SE1GU_.NYKG
M/%'_ "$?"_\ V%Q_Z3ST ='1110!S?C(XM]'.,XU:VX]?FJ'^UBSH%\/.&#D
M$M <!<<$';[_ *&E\=7=O8V&E75U,D-O%JMLTDCG"J-W4FIO^$^\(_\ 0QZ9
M_P"!"T 12ZJZVP==!9OGP8O);)X//W:235"ZA/\ A'9MK#YOW>.1VX'2IO\
MA/O"/_0QZ9_X$+1_PGWA'_H8],_\"%H 76M4AMQ$$T];B2Y^4@QG<>Q&,9XQ
M_*JL>HJTL*?\(Y(-C#:QB.!VS]WT-6/^$]\($@_\)%IF1T_TA:7_ (3[PC_T
M,>F?^!"T!T(GUMR3_P 4[.<$_>A//H>E.;6+E"/^)#(XEPX*H>,_WN.M/_X3
M[PC_ -#'IG_@0M'_  GWA'_H8],_\"%H FCN5ELYW;2ECGB)*1M$3N QR/E]
MZIKJ+31-&WA]\2-M9?**Y'KTZ5-_PGWA'_H8],_\"%H_X3_PC_T,>F?^!"T
M00ZJRQQP+H$L:*IV[XV(4CM]T]>*E35YTB95T)N(PS!8R ><8^[R>2?I3O\
MA/O"/_0QZ9_X$+1_PGWA'_H8],_\"%H!&W!#;O"'6W1-Z\@QX_ C%/-K;D8,
M$1'^X*P?^$_\(_\ 0QZ9_P"!"T?\)_X1_P"ACTS_ ,"%H WEM;=?NP1#C'"#
MIZ4@M+<*5$$84]1M&/RK"_X3_P (_P#0QZ9_X$+1_P )_P"$?^ACTS_P(6@#
M<^QVO/\ HT//7Y!2BSM1TMXA_P  %87_  G_ (1_Z&/3/_ A:/\ A/\ PC_T
M,>F?^!"T ;BV5JD(A$$?E@Y"E<C/XTJV=LIRMO$#ZA!6%_PG_A'_ *&/3/\
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M -#'IG_@0M'_  G_ (1_Z&/3/_ A: .CKG/%'_(1\+_]A<?^D\]'_"?^$?\
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MG_H5[?\ \&B__$4 ='17.?VMXI_Z%>W_ /!HO_Q%']K>*?\ H5[?_P &B_\
MQ% '1T5SG]K>*?\ H5[?_P &B_\ Q%']K>*?^A7M_P#P:+_\10!T=%<Y_:WB
MG_H5[?\ \&B__$4?VMXI_P"A7M__  :+_P#$4 ='17.?VMXI_P"A7M__  :+
M_P#$4?VMXI_Z%>W_ /!HO_Q% '1T5SG]K>*?^A7M_P#P:+_\11_:WBG_ *%>
MW_\ !HO_ ,10!T=%<Y_:WBG_ *%>W_\ !HO_ ,11_:WBG_H5[?\ \&B__$4
M='17.?VMXI_Z%>W_ /!HO_Q%']K>*?\ H5[?_P &B_\ Q% '1T5SG]K>*?\
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MNO\ XY1_P@VA_P!W4?\ P:W7_P <H Z.BN<_X0;0_P"[J/\ X-;K_P".4?\
M"#:'_=U'_P &MU_\<H Z.BN<_P"$&T/^[J/_ (-;K_XY1_P@VA_W=1_\&MU_
M\<H Z.BN<_X0;0_[NH_^#6Z_^.4?\(-H?]W4?_!K=?\ QR@#HZ*YS_A!M#_N
MZC_X-;K_ ..4?\(-H?\ =U'_ ,&MU_\ '* .CHKG/^$&T/\ NZC_ .#6Z_\
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M$&T/^[J/_@UNO_CE '1T5SG_  @VA_W=1_\ !K=?_'*/^$&T/^[J/_@UNO\
MXY0!T=%<Y_P@VA_W=1_\&MU_\<H_X0;0_P"[J/\ X-;K_P".4 ='17.?\(-H
M?]W4?_!K=?\ QRC_ (0;0_[NH_\ @UNO_CE '1T5SG_"#:'_ '=1_P#!K=?_
M !RC_A!M#_NZC_X-;K_XY0!T=%<Y_P (-H?]W4?_  :W7_QRC_A!M#_NZC_X
M-;K_ ..4 ='17.?\(-H?]W4?_!K=?_'*/^$&T/\ NZC_ .#6Z_\ CE '1T5S
MG_"#:'_=U'_P:W7_ ,<H_P"$&T/^[J/_ (-;K_XY0!T=%<Y_P@VA_P!W4?\
MP:W7_P <H_X0;0_[NH_^#6Z_^.4 ='17.?\ "#:'_=U'_P &MU_\<H_X0;0_
M[NH_^#6Z_P#CE '1T5SG_"#:'_=U'_P:W7_QRC_A!M#_ +NH_P#@UNO_ (Y0
M!T=%<Y_P@VA_W=1_\&MU_P#'*/\ A!M#_NZC_P"#6Z_^.4 ='17.?\(-H?\
M=U'_ ,&MU_\ '*/^$&T/^[J/_@UNO_CE '1T5SG_  @VA_W=1_\ !K=?_'*/
M^$&T/^[J/_@UNO\ XY0!T=%<Y_P@VA_W=1_\&MU_\<H_X0;0_P"[J/\ X-;K
M_P".4 ='17.?\(-H?]W4?_!K=?\ QRC_ (0;0_[NH_\ @UNO_CE '1T5SG_"
M#:'_ '=1_P#!K=?_ !RC_A!M#_NZC_X-;K_XY0!T=%<Y_P (-H?]W4?_  :W
M7_QRC_A!M#_NZC_X-;K_ ..4 ='17.?\(-H?]W4?_!K=?_'*/^$&T/\ NZC_
M .#6Z_\ CE '1USGBC_D(^%_^PN/_2>>C_A!M#_NZC_X-;K_ ..5DZMX:TW2
M-;\,7%H+L2'5=A\Z^FF&#;S'[KN1VZXS0!W-%%% '-^,21!HQ'7^U[;'_?5-
MCUS5X_/9],GE5" N(64L3GH,<CCK3O&6XV^C[?O?VM;8^NZG1KXF5CO: JJ\
M?=RQQWI#Z#X=7U06EU/+ILC.A0Q1*C D$X/;M0-;U$J,Z5,K%0V-C'KVZ8S1
M;#Q"&A>Z,>!O,B)C^Z=OZX_*D8^)&A1H_)5R>5?'3M0^W]?UH(%\07VR8OH]
MU\G";8G^?Z<5)#K-^]TL,FDSHI=5,FTD $=>E,*^(TP5:%SD]2!QDX_3%6=-
M.M?:C_: B\G9QLQG=G_"F@Z$=MJ6HOJ M9;%@A<_O=K!0O;G&*CN-3U2SD*"
MQENMTC!62,@*,\9QFMZBA= .=?7M3S.J:-/^[3<&*-ACTP..>?TI+[5M8A>9
M8-/D<*A=&6)CGY>G3KG'%='10!A6-]JTLDSRVS^2@^7S(]C,< \#.>I/Y5&-
M=U)5(;1KAF#A>$;&.<GI[#\ZZ&BA@8O]KWPMYW.E3&2,@(B@_/GTXJO_ &UJ
MK3*5TN;R2N[#1L&'H.G7VKHJ*30&'<:Q?PZ8TZZ9,]P)-BQ*C$D;<[NGX5!!
MKVI>0AFTFX#D'=^Z?C\ .]='13&MK'-)XAU0LX;1+D =#L;T^G-;D$\KZ<L\
MD1$I3<8\$'/I@\U9HH$<X/$=Z<A=(N68?>58V)'Z>E3#6KYP<:7<#]VSY\MN
MHZ#! YK=HH0=3&DU:^CL1-_9DK2YQY85CV!],]\?4&EN]7N[5D']FSR@QAF\
MM&;!()QP/4 ?C6Q10!ARZKJ0M+<QZ>_GRJ"WR-A"3CGCMUYJ"W_Y*3J'_8(M
M?_1T]='7.6__ "4G4/\ L$6O_HZ>@.IT=%%% !1110 5SGB[_F!?]A>W_P#9
MJZ.N<\7?\P+_ +"]O_[-0!T=%%% $<]Q%;1&69PD8ZL>@^M.C=98UD0Y5AD'
MU%1W5K%>0&&=2T;=5SC/UI\4:PQ)&F=J  9.3B@!]07W_'A<_P#7)OY&IZ@O
MO^/"Y_ZY-_(T 8'@[4K1/!FAQ/+M,>G6RLS*0H)B4XW=,X(K?-]:*@<W4(0D
M@,9!@D=:YOPGHMA<^"-#>6 %I;"UD<Y()(A0#]!6P-!T\6QMQ$PC+%B Y')Q
MG^5'0.I835;!RP6\@^4D'YQVZT\7]H9%C%S#O90RC>.0<X(_(UF?\(MIBP2Q
MQ))&9!]X2$D8.1C-3KH-G^X:3S'DBC$8<N1N .>?QIZ7 N/?V<9P]W N#CYI
M .:8VIV*A2;R##' Q(#FJ\F@6$K*760[6W >8V,YW=,^HS4,GAG3Y&R1)@'*
MKO. ?7'>D/0TWN[>,$O/&,9_B':HH=3L;B.22*[A9(CASO&%^OI59_#VGR_9
MS+&SO!&(T8N<X'K3DT.Q2&2)4<*YRQ#G/;O^%'4DMB]M&?8+J$O_ '1(,TW^
MT++_ )^X.N/]8.M5%T"Q7[OG 8VX$S8 _.J\7A33(U0,LK[&)3=*>!G./UH&
M:J7MK(<)<PL<9PL@/'2D%_9G_EZA^]M^^.OI5)?#]E'+&\?F*$E\TIO)#-CT
M/^>!4<WAJRGO#<.9/FSE0V 0001].: -%KZT5%<W,01CA6WC!/IFB:^M(/\
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M .@BIK+1;+3YO-MD96QC&\D?E0#-"BBB@ HHHH **** "BBB@ HHHH ****
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M;+)(C_\ 'Q9Y&TYQS/0!MCQ5<D CPIKQ!Z$1P?\ QVC_ (2JY)Q_PBFO\?\
M3.#_ ..US[1:UYL9C\-ZZD29_=_:;3!&3@?Z_L"!^%)+'X@=%5- UU,#'$]G
MSSG_ )[T =#_ ,)3=?\ 0IZ__P!^X/\ X[1_PE-U_P!"GK__ '[@_P#CM4=-
MU+7;!)%?PIK4^]L@M<6?'_D>KW_"0ZU_T)>K_P#@39__ !Z@ _X2FZ_Z%/7_
M /OW!_\ ':/^$INO^A3U_P#[]P?_ !VC_A(=:_Z$O5__  )L_P#X]1_PD.M?
M]"7J_P#X$V?_ ,>H /\ A*;K_H4]?_[]P?\ QVC_ (2FZ_Z%/7_^_<'_ ,=H
M_P"$AUK_ *$O5_\ P)L__CU'_"0ZU_T)>K_^!-G_ /'J #_A*;K_ *%/7_\
MOW!_\=H_X2FZ_P"A3U__ +]P?_':/^$AUK_H2]7_ / FS_\ CU'_  D.M?\
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MC_A(=:_Z$O5__ FS_P#CU !_PE-U_P!"GK__ '[@_P#CM'_"4W7_ $*>O_\
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M7_\  FS_ /CU'_"0ZU_T)>K_ /@39_\ QZ@ _P"$INO^A3U__OW!_P#':/\
MA*;K_H4]?_[]P?\ QVC_ (2'6O\ H2]7_P# FS_^/4?\)#K7_0EZO_X$V?\
M\>H /^$INO\ H4]?_P"_<'_QVC_A*;K_ *%/7_\ OW!_\=H_X2'6O^A+U?\
M\";/_P"/4?\ "0ZU_P!"7J__ ($V?_QZ@ _X2FZ_Z%/7_P#OW!_\=H_X2FZ_
MZ%/7_P#OW!_\=H_X2'6O^A+U?_P)L_\ X]1_PD.M?]"7J_\ X$V?_P >H /^
M$INO^A3U_P#[]P?_ !VC_A*;K_H4]?\ ^_<'_P =H_X2'6O^A+U?_P ";/\
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M_P"$AUK_ *$O5_\ P)L__CU'_"0ZU_T)>K_^!-G_ /'J #_A*;K_ *%/7_\
MOW!_\=H_X2FZ_P"A3U__ +]P?_':/^$AUK_H2]7_ / FS_\ CU'_  D.M?\
M0EZO_P"!-G_\>H /^$INO^A3U_\ []P?_':/^$INO^A3U_\ []P?_':/^$AU
MK_H2]7_\";/_ ./4?\)#K7_0EZO_ .!-G_\ 'J #_A*;K_H4]?\ ^_<'_P =
MH_X2FZ_Z%/7_ /OW!_\ ':/^$AUK_H2]7_\  FS_ /CU'_"0ZU_T)>K_ /@3
M9_\ QZ@ _P"$INO^A3U__OW!_P#':/\ A*;K_H4]?_[]P?\ QVC_ (2'6O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>img206306002_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206306002_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -T I8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBN2NO'
M-M8^(KC3+J,*D0;#@\Y"AN>W.<#W% [.USK:*XNU^(5O<S+&MHY8DC 89/I@
M5;A\;6MU!YMM;2N0Z J2 0#GGKQT/6CJUV)3OL=317&O\2-)5Y%6*5C&N\_,
MHR.F1SZ\4^3Q_91O%_HTH60CEF5>",@\FCR'<Z^BN;L_&FFWU_\ 8X5D+[2Q
M)' .,X/O5.Y^(5C; "2SN [!2JDKR&Z'K[C\Z Z7.PHKCO\ A8=@1N%K.$4[
M26 &3@D >YQ4R^.+4Q0S&WE,<L;R#;U"JQ&3^5-*^H?U]QU=%<>WQ%TM8HW,
M,Y\Q20J@$C!(Y Z=*<?'UD';,#>6$#;@ZG/4XZ\'CH?IUI7"QUU%<S)XVL(=
M.2\DAF5'8 *<9P1D'\J2V\:6UU<I"EK*I,+2L&8;AC;@8SW##GI1_7ZAUL=/
M17(K\0=-:80FWG1R&X? Z8'?W/X=3Q4]OXS@NK*XNX[2410KN^9ERPS@D<T"
MN=/17._\)C8BRM[HQOLFW8&1_#Z<\]>@K-/Q CF6 VNGS-YTHB7S& ).0#@>
MV:$KNR!M([2BN7NO&<$"P2QVDLL$B,^\$#Y5/) /6HHO'=G<QW4D-NYCME5F
M+,HSDD<<^@S^-']?U]XWH=;17&7/Q%T^+[.8HGD$JEF!(&WK@'L.GZBI5\?6
M2HC36TJ[E+ @C!QUY_SGM1;6P/3^NQUU9NJZK_9MSI4/D^9]OO/LN=V-G[N1
M]W3G[F,<=:CM]?MY]<ETK8PF0$[NQQ5+Q1_R$O"__87'_I//0G=70=;'1T44
M4 %%%% !5;4;O[!IEW>;-_D0O+LSC=M!.,_A5FLWQ#_R+6J_]><W_H!H LZ?
M=?;M-M;S9L\^%)=N<[=P!QG\:LUG>'_^1;TO_KSB_P#0!6C0 4444 %%%% '
M+KXNO'U/4[2#PQJEXEC<_9_/M)("K?NT?_EI(A!^?I@CISV$O_"3:C_T)FO_
M /?=G_\ )%'A?_D(^*/^PN?_ $G@KHZ .<_X2;4?^A,U_P#[[L__ )(H_P"$
MFU'_ *$S7_\ ONS_ /DBNCHH YS_ (2;4?\ H3-?_P"^[/\ ^2*/^$FU'_H3
M-?\ ^^[/_P"2*Z.B@#G/^$FU'_H3-?\ ^^[/_P"2*/\ A)M1_P"A,U__ +[L
M_P#Y(KHZ* .<_P"$FU'_ *$S7_\ ONS_ /DBC_A)M1_Z$S7_ /ONS_\ DBNC
MHH YS_A)M1_Z$S7_ /ONS_\ DBC_ (2;4?\ H3-?_P"^[/\ ^2*Z.B@#G/\
MA)M1_P"A,U__ +[L_P#Y(H_X2;4?^A,U_P#[[L__ )(KHZ* .<_X2;4?^A,U
M_P#[[L__ )(H_P"$FU'_ *$S7_\ ONS_ /DBNCHH YS_ (2;4?\ H3-?_P"^
M[/\ ^2*/^$FU'_H3-?\ ^^[/_P"2*Z.B@#G/^$FU'_H3-?\ ^^[/_P"2*/\
MA)M1_P"A,U__ +[L_P#Y(KHZ* .<_P"$FU'_ *$S7_\ ONS_ /DBC_A)M1_Z
M$S7_ /ONS_\ DBNCHH YS_A)M1_Z$S7_ /ONS_\ DBC_ (2;4?\ H3-?_P"^
M[/\ ^2*Z.B@#G/\ A)M1_P"A,U__ +[L_P#Y(H_X2;4?^A,U_P#[[L__ )(K
MHZ* .<_X2;4?^A,U_P#[[L__ )(H_P"$FU'_ *$S7_\ ONS_ /DBNCHH YS_
M (2;4?\ H3-?_P"^[/\ ^2*/^$FU'_H3-?\ ^^[/_P"2*Z.B@#G/^$FU'_H3
M-?\ ^^[/_P"2*/\ A)M1_P"A,U__ +[L_P#Y(KHZ* .<_P"$FU'_ *$S7_\
MONS_ /DBC_A)M1_Z$S7_ /ONS_\ DBNCHH YS_A)M1_Z$S7_ /ONS_\ DBC_
M (2;4?\ H3-?_P"^[/\ ^2*Z.B@#G/\ A)M1_P"A,U__ +[L_P#Y(H_X2;4?
M^A,U_P#[[L__ )(KHZ* .<_X2;4?^A,U_P#[[L__ )(H_P"$FU'_ *$S7_\
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M9KV-(WW;68XS@@']2*3_ (2'2,+_ *?#\W YZTQ_#.CRVJ6TEDKPQ@A59V.
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MMP\SW_P__P BWI?_ %YQ?^@"M&OF^.[U2&)(HM>UI(T4*JKJ,P"@= !NI_\
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M51_9M;NOZ^0?6X>9]&T5\Y?VAJ__ $,&N?\ @RF_^*H_M#5_^A@US_P93?\
MQ5']FUNZ_KY!];AYGT;17SE_:&K_ /0P:Y_X,IO_ (JC^T-7_P"A@US_ ,&4
MW_Q5']FUNZ_KY!];AYGT;17SE_:&K_\ 0P:Y_P"#*;_XJC^T-7_Z&#7/_!E-
M_P#%4?V;6[K^OD'UN'F?1M%?.7]H:O\ ]#!KG_@RF_\ BJ/[0U?_ *&#7/\
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MJC^T-7_Z&#7/_!E-_P#%4?V;6[K^OD'UN'F?1M%?.7]H:O\ ]#!KG_@RF_\
MBJ/[0U?_ *&#7/\ P93?_%4?V;6[K^OD'UN'F?1M%?.7]H:O_P!#!KG_ (,I
MO_BJ/[0U?_H8-<_\&4W_ ,51_9M;NOZ^0?6X>9]&T5\Y?VAJ_P#T,&N?^#*;
M_P"*H_M#5_\ H8-<_P#!E-_\51_9M;NOZ^0?6X>9]&T5\Y?VAJ__ $,&N?\
M@RF_^*H_M#5_^A@US_P93?\ Q5']FUNZ_KY!];AYGT;6)XS_ .1%\0?]@VY_
M]%-7AO\ :&K_ /0P:Y_X,IO_ (JJ6KWVJMHM\KZ[K,B&WD#(^H2LK#:>""V"
M/:D\NJI7NOZ^0+%0;L?2=C_QX6W_ %R7^0HHL?\ CPMO^N2_R%%<!TE?6_\
MD :C_P!>LO\ Z":\.T#PZ;WPI;ZDUT(HPH3:(F<Y" \XZ#FO<=;_ .0!J/\
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MA6:5H]G<%>]9=;.J^(9]7TZTM9XUW6^?WN>7^M8U;T^?E]_<F?+?W0HHHJR
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M^J1[GS%_:5I_SV'Y&JFIZA:OI-XJR@DP. ,'^Z:^J*Q/&?\ R(OB#_L&W/\
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M_I5>XO?&<GRPZ4(]A7!,D9\SCYL_/P,_G[5,7S#>A?\ L_C3_H*:!_X+9O\
MX_1]G\:?]!30/_!;-_\ 'ZAL]5\1->SVESIX#I:/(C*F$:0%=H#;L9.3Q[=:
MJQ7WC<2QI)I,)B.-[^8@8?AN_P ?QHN.QH?9_&G_ $%- _\ !;-_\?H^S^-/
M^@IH'_@MF_\ C]5M)U?Q'<W<INM-*6L4BQG*!6;(^8C+<@'OCGVHN=2\6M>3
M+9:3$]NK$))*RJ3Z<;LD>_']:?5+^NG^8NERS]G\:?\ 04T#_P %LW_Q^C[/
MXT_Z"F@?^"V;_P"/U6FG\89(6UA*\8*;0>G/5^?2H'U+Q=96L<D^GK)_#)L4
M.P..H ;IGM24@_K\_P#(T/L_C3_H*:!_X+9O_C]'V?QI_P!!30/_  6S?_'Z
M@U75O$*VMN^FZ6[N8/,F5@ 5(ZCD]>.@SG/:H/[3\6QJ]Q)IJB (#C"LY^BA
MNHZX[XZBGY_UO8'M?^MKE[[/XT_Z"F@?^"V;_P"/U@^(X/%HO_#GG:CHC,=4
M B*6$H ;R)N6S,<C&>!CG'/8]GHUW<7VD6MS=P/!<21J9(W7:5;'/%97BC_D
M)>%_^PN/_2>>AJP!]G\:?]!30/\ P6S?_'Z/L_C3_H*:!_X+9O\ X_71T4 <
MY]G\:?\ 04T#_P %LW_Q^C[/XT_Z"F@?^"V;_P"/UT=% '.?9_&G_04T#_P6
MS?\ Q^J&N6_C >']2,NIZ$T?V67<%T^8$C8<X/G'!KLJS?$/_(M:K_UYS?\
MH!H Y_0[?QB= TTQ:GH0C^RQ;0VGS$@;1C)\X9-7_L_C3_H*:!_X+9O_ (_6
MEX?_ .1;TO\ Z\XO_0!6C0!SGV?QI_T%- _\%LW_ ,?H^S^-/^@IH'_@MF_^
M/UT=% '.?9_&G_04T#_P6S?_ !^C[/XT_P"@IH'_ (+9O_C]='10!Y]X<@\6
MF_\ $?DZCHBL-4(E+V$I!?R(>5Q,,#&.#GG//IO?9_&G_04T#_P6S?\ Q^LK
M3?$-EHVM>((;O>/.U9V#+C"JL%L"3DY/WAT![GM6])XJTL:>][!,UQ$DB1'8
M-OS,0 ,M@=3ZT 5OL_C3_H*:!_X+9O\ X_1]G\:?]!30/_!;-_\ 'ZED\8:/
M$TB/.P>--SJ$)VG.-N1QGCUJ:V\3Z7=QR/%*^V.#SW+(1M7'?/0^U#T J?9_
M&G_04T#_ ,%LW_Q^C[/XT_Z"F@?^"V;_ ./U>_MZVDT6+5;6.6YMY,;1%MSR
M<?Q$"H1XMT/=(AOE#1 F0!&.W'J0,4=; 5_L_C3_ *"F@?\ @MF_^/T?9_&G
M_04T#_P6S?\ Q^K,?BO1Y_\ 47+2_NFERD3<J" 2..>3^A]*<GBK17N;>W%\
MOG7&/*0HP+9.!V]:+:V J?9_&G_04T#_ ,%LW_Q^C[/XT_Z"F@?^"V;_ ./U
M>?Q)I,<TT)N_WD+;9%6-B5/O@5%)XLT2.5H3>YE499!&Y(^O''6BX%;[/XT_
MZ"F@?^"V;_X_1]G\:?\ 04T#_P %LW_Q^K=OXHTB\NX;6VNO.EE<H B-A2%+
M<G&!PI_*HIO%NDQ^04E:5)I#'O48"D=<@X/Y T;!YD/V?QI_T%- _P#!;-_\
M?H^S^-/^@IH'_@MF_P#C]6!XOT%MN-2C^8X&589.2/3U!H3Q7I;:E/8O*8Y(
M<_,V,-A0QQ@D\ YYQ0M0*_V?QI_T%- _\%LW_P ?H^S^-/\ H*:!_P""V;_X
M_3XO&>C3$!9Y.I!/ED@8^G7Z"K(\3:2\/G1W7F1Y W*C8YS@].>A''I1M?R!
M:[%/[/XT_P"@IH'_ (+9O_C]'V?QI_T%- _\%LW_ ,?JR/%FB%0WVW@G:,Q.
M.>F.G^<'TI9/%>AQ1>9)?HBYQ\R,#^6,T 5?L_C3_H*:!_X+9O\ X_1]G\:?
M]!30/_!;-_\ 'ZL-XNT%-V_4$7:<$LC ?@<<_A1)XLT=+2[NOM),-HB/*WEL
M,!R0O4#/3^7K1N!7^S^-/^@IH'_@MF_^/T?9_&G_ $%- _\ !;-_\?J1?&6A
MEY5>[\KRR 6=#MYZ<CC\ZF;Q9H:NRG4$RH#'",1CUR!T]Z+"3N5?L_C3_H*:
M!_X+9O\ X_1]G\:?]!30/_!;-_\ 'ZN'Q-I)$HCN3))'%YIC5&W%?4 CGJ/S
M!J-?%VB-'&_VLC>,J#"^??MV[T#*_P!G\:?]!30/_!;-_P#'Z/L_C3_H*:!_
MX+9O_C]:7]N:?Y#W!GQ D8E,FTXVGH?6L^;QMH,5LEP+MI(W<(&2)N,]SD=.
MO/L?2C<$KZ(;]G\:?]!30/\ P6S?_'Z/L_C3_H*:!_X+9O\ X_5H^*M'WB-+
MEI)"Z)L6)L@NP49XX&2.M2Q^(M+E$Q%P1Y()<-&PQC\.?PH H?9_&G_04T#_
M ,%LW_Q^C[/XT_Z"F@?^"V;_ ./U,GC'0G  OE#G'R,I##Z\<5:L_$&EW]U]
MFMKG?-TVF-ASC.,D8Z GWQ0M=@,_[/XT_P"@IH'_ (+9O_C]'V?QI_T%- _\
M%LW_ ,?JY<^*-%M)7CN+](W1BA#*W4=>W-0R>+]%C_Y>7)\SR\>2X.[.,<@9
MQ0M=@>A#]G\:?]!30/\ P6S?_'Z/L_C3_H*:!_X+9O\ X_6K>:Q86$ICN9]C
MA0Q 1FP#GT'L?R/H:I'Q=HF^)%O=SRL BK&^3DX!Z=/>@"O]G\:?]!30/_!;
M-_\ 'Z/L_C3_ *"F@?\ @MF_^/U<_P"$GT?RT=;O=O3>JK&Y8KZXQG%.G\2Z
M1:W,-M/=B.>9 Z(4;)![]/\ ]5 %'[/XT_Z"F@?^"V;_ ./T?9_&G_04T#_P
M6S?_ !^KP\2:686F-P5B5RFXQMC(&2>G3 Z]*B?Q;H:,X>]P8_OYB?Y3Z'Y>
M#[=: *WV?QI_T%- _P#!;-_\?H^S^-/^@IH'_@MF_P#C]6!XMT0S"+[: Q3>
M-R,..O3&1QSSZT?\);H@!+7H !QG8Q[9[#TR?H#Z46 K_9_&G_04T#_P6S?_
M !^C[/XT_P"@IH'_ (+9O_C]:$_B#2K6Z>VFO$29%W,I!X&,^E5?^$QT'=@W
MZCD 9C;YL@'CCGJ* L0_9_&G_04T#_P6S?\ Q^C[/XT_Z"F@?^"V;_X_5N?Q
M3HUO8?;9+S;!O,8/EMDL!G&,9S6M&ZRQK(N=K#(R,4 <]]G\:?\ 04T#_P %
MLW_Q^L?Q9!XN'@W7#<:EH;0C3Y_,6/3Y58KY;9 )F(!QWP:[NL3QG_R(OB#_
M +!MS_Z*:@#4L?\ CPMO^N2_R%%%C_QX6W_7)?Y"B@"OK?\ R -1_P"O67_T
M$UR-CI6M3Z'I$ECK4=LS6D15')X7RTX ^H)_*NNUO_D :C_UZR_^@FN,TW2M
M!O\ 0M.FGUN*.5K.$C$T6Z-@B="1D=.GN?6C6^@T:]MI7B*VEBFDUE+C8X9H
MV8@,N.E-U+1-4.L7EY::TEK'<J!&A8Y#  ?EP>/>LJY\,Z(;*6*T\2Q)-)QY
MDTT;X'ICCZCT-75T+PU]CAMI-<CF6)V<&6YC<DL #U^F?K3O_7W?U_PXHZ(N
MSZ=XC>Y_<:E$J);(FYV.'D^;<<#_ ("<U6.C>)DEMC'K0D!!$Q+G .#\P'IG
M'%-M](T*ULGMHO$K#>X?>;Q"PPK+CGCHQ_(>E16.@^'K%I63Q([&2-X_FO4^
M4,""1COSGZT+1C6FG]=ORU+=[9:S/KD\T&OPPVXP%MPY^5L<9_"HM0\.Z]<Z
M+:65OK$<,BM(T[EV/F OD#/7@4BZ/X<6TF@&MPXEE\YF\^+K@#&,8P,<#'%-
M?1]#=+*$^(8C;VPD^4SQEG+E3U].#^=)77]>7^8N9K5&A<Z9K;.HM]5CC4*!
MRS=0,=/KS[]*JQZ'KOR2+KV\%.3YC?,<?RJJ?#OADW4MP==4M(I !NHR$R,9
M7/0CM]*C'AGP[Y>S_A)I"-^__C\CZT=!;LT9='UXV%I:P:W$DJ*QN6.3O)8D
M$?F1^%49+/6(+0O;Z]%-+"ZK*@F*[LG&"3T/3%6GTOP^TD$G]O1!H8HX@1/%
M\P1F(S[_ #$9_P 35]3H2:E+>+JMD%F51)!YD11BN<,>^>?6AZL:VOU*L5MJ
M<]]:[-8B$T,2"ZA\TD[AUX%']D^(_M5[(=8B,4KDPIO8>6,]/R_*HKC3="N)
MS(?$$2C>TBH)H2%+')ZCG\<XJM<:)HTL:(GB=$4*%*^=#@@$G)XY;GK^/6AO
MK_6XK6+@T7Q"S@OKJJ%1L*KMRV#@GVZ<4?V%XD6!5CUT-)M.YF9C\W8CV'I5
M"/PUX<C<O_PD>Y]RMN:YB/3/&,8P<\CO@5MZ1+I6E_:<ZW:S&:3<-UPN%'8
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M\: +U%4?[;TG_H)V7_@0G^-']MZ3_P!!.R_\"$_QH O5F^(?^1:U7_KSF_\
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MPF+.R9$P03\@'U._'XUV0\.Z,8HU_LRWVH=Z@H/E)ZFGR:KHLRA9;_3W 8,
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M<#M^I_.H_P#A'='\R.3^S;??$ $.P?*!TQ4O]MZ3_P!!.R_\"$_QH_MO2?\
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M#4?^O67_ -!-8_AWPYH<GAC27?1M.9VLX2S-:H23L')XK8UO_D :C_UZR_\
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M\(SH/_0$TW_P$C_PK4HH R_^$9T'_H":;_X"1_X4?\(SH/\ T!--_P# 2/\
MPK4HH R_^$9T'_H":;_X"1_X4?\ ",Z#_P! 33?_  $C_P *U** ,O\ X1G0
M?^@)IO\ X"1_X4?\(SH/_0$TW_P$C_PK4HH R_\ A&=!_P"@)IO_ ("1_P"%
M'_",Z#_T!--_\!(_\*U** ,O_A&=!_Z FF_^ D?^%'_",Z#_ - 33?\ P$C_
M ,*U** ,O_A&=!_Z FF_^ D?^%'_  C.@_\ 0$TW_P !(_\ "M2B@#+_ .$9
MT'_H":;_ . D?^%'_",Z#_T!--_\!(_\*U** ,O_ (1G0?\ H":;_P" D?\
MA1_PC.@_] 33?_ 2/_"M2B@#+_X1G0?^@)IO_@)'_A1_PC.@_P#0$TW_ ,!(
M_P#"M2B@#+_X1G0?^@)IO_@)'_A1_P (SH/_ $!--_\  2/_  K4HH R_P#A
M&=!_Z FF_P#@)'_A1_PC.@_] 33?_ 2/_"M2B@#+_P"$9T'_ * FF_\ @)'_
M (4?\(SH/_0$TW_P$C_PK4HH R_^$9T'_H":;_X"1_X4?\(SH/\ T!--_P#
M2/\ PK4HH R_^$9T'_H":;_X"1_X5B^+_#NB0^"M>EBT?3TD33KAE9;5 5(C
M;!!QP:ZZL3QG_P B+X@_[!MS_P"BFH U+'_CPMO^N2_R%%%C_P >%M_UR7^0
MHH KZW_R -1_Z]9?_0353P[:6TOA72/,@B;_ $2!_F0'YO+ S]:MZW_R -1_
MZ]9?_037->'_ !)>Q^&M*C7PGKL@6SB =/LVUL(.1F8''U% '5'3K%HQ&;.
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MRH73K%0P6S@&Y2AQ&.5/;Z5B_P#"3W__ $)^O_\ DK_\?H_X2>__ .A/U_\
M\E?_ (_0!KC2=-!!%A; CIB)>/TI?[+T_P LQ_8;;83DKY2X)_*L?_A)[_\
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MLV&^4<C,V<5?_P"$GO\ _H3]?_\ )7_X_0!T=%<Y_P )/?\ _0GZ_P#^2O\
M\?H_X2>__P"A/U__ ,E?_C] '1T5SG_"3W__ $)^O_\ DK_\?H_X2>__ .A/
MU_\ \E?_ (_0 >%_^0CXH_["Y_\ 2>"NCKS[PYXBO8K_ ,1E?"NMR&35"Q"?
M9LQGR(1M;,PYXSQD8(YZUO?\)/?_ /0GZ_\ ^2O_ ,?H Z.BN<_X2>__ .A/
MU_\ \E?_ (_1_P )/?\ _0GZ_P#^2O\ \?H Z.BN<_X2>_\ ^A/U_P#\E?\
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ML:S2_P!FD0HV%W*=Q&>O6@#H**RGU&\%G')'9,TN2'3:>,=/SJH=4ULN,::
MN&ZJ><#COW-'6P=+G045S4VK:\EWA-++Q#@X4XS]:T)[[4%LHI(K3?/OQ)&
M>!@D?THZ7#R-6BN?AU/6IXY2^G&%E1M@*DY;:2/U ILNKZW$95&D&0IPK*#A
M_4B@#HJ*Y^VU36I;](9--VPNPS(RD;!CG]:Z"@ HHHH **** "BBB@ HHHH
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M_P"ADU__ ,"E_P#B*/\ A$W_ .ADU_\ \"E_^(H Z.BN<_X1-_\ H9-?_P#
MI?\ XBC_ (1-_P#H9-?_ / I?_B* .CHKG/^$3?_ *&37_\ P*7_ .(H_P"$
M3?\ Z&37_P#P*7_XB@#HZ*YS_A$W_P"ADU__ ,"E_P#B*/\ A$W_ .ADU_\
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MNINM8CM6Z4 ?*.!\O2K_ /PB;_\ 0R:__P"!2_\ Q% '1T5SG_")O_T,FO\
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M(YT8@X.#4OF)_?7\ZPI/"=K+*)&O+P8;< KJ .<\#;Q2R>$[%R,3W*8).$<
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M_H!K2K-\0_\ (M:K_P!><W_H!H 7P_\ \BWI?_7G%_Z *T:SO#__ "+>E_\
M7G%_Z *T: "BBB@ HHHH YSPO_R$?%'_ &%S_P"D\%='7.>%_P#D(^*/^PN?
M_2>"NCH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,&$7_Q5'_";^$_^AHT7_P &$7_Q5;/V:W_YX1?]\"C[-;_\\(O^^!0!C?\
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MM2CC\2Z,\CVLJJJW\1+$H< #=74?9K?_ )X1?]\"L[Q!;0#PWJA$,8/V.7^
M?W#0!D:'XS\+1>']-CD\2Z,CI:Q*RM?Q @A!D$;JO_\ ";^$_P#H:-%_\&$7
M_P 55C0+: ^'-+)AC)^R1?P#^X*T?LUO_P \(O\ O@4 8W_";^$_^AHT7_P8
M1?\ Q5'_  F_A/\ Z&C1?_!A%_\ %5L_9K?_ )X1?]\"C[-;_P#/"+_O@4 8
MW_";^$_^AHT7_P &$7_Q5'_";^$_^AHT7_P81?\ Q5;/V:W_ .>$7_? H^S6
M_P#SPB_[X% '#^&_&'AF"_\ $C2^(](C6752\9>]C =?(A&1\W(R",^QK?\
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M_P!\"@#&_P"$W\)_]#1HO_@PB_\ BJ/^$W\)_P#0T:+_ .#"+_XJMG[-;_\
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M%X._Z%71/_ "+_XFKK>(=-4J/.9LOL^5#UI[ZYIR%1]H!#="H)% /0S_ /A
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MX 1?_$UT-% '/?\ "!>#O^A5T3_P B_^)H_X0+P=_P!"KHG_ ( 1?_$UT-%
M'/?\(%X._P"A5T3_ , (O_B:/^$"\'?]"KHG_@!%_P#$UT-% '/?\(%X._Z%
M71/_   B_P#B:/\ A O!W_0JZ)_X 1?_ !-=#10!SW_"!>#O^A5T3_P B_\
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M :,6@Z='%)$8 \<D@D*N<@$# Q4T6E6$+9CM8U.<\#OT_J:R/^$N'_0OZ_\
M^ )_QH_X2X?]"_K_ /X G_&@#2BT+38;AITM4#E@WT([_6FP^']-A,F+<,)&
MW$,<@?3TK/\ ^$N'_0OZ_P#^ )_QH_X2X?\ 0OZ__P" )_QH UIM)L+@DS6L
M;DG))'MC^@J--!TM'#K91!@<@X[_ .0*S?\ A+A_T+^O_P#@"?\ &C_A+A_T
M+^O_ /@"?\: -671].GDDDEM(F>3[Y(ZTY-+L8Y1*EK&L@  8#G &!_(5D?\
M)</^A?U__P  3_C1_P )</\ H7]?_P# $_XT ;$FF64LJRR6T;.I+!B.03C/
M\A40T+2UW8LHOFZ\>^:S/^$N'_0OZ_\ ^ )_QH_X2X?]"_K_ /X G_&@#7?2
MK&2<SO;1M*5VEB.<8 _H*CBT/3(7#QV42L"&! [BLS_A+A_T+^O_ /@"?\:/
M^$N'_0OZ_P#^ )_QH Z.BN<_X2X?]"_K_P#X G_&C_A+A_T+^O\ _@"?\: .
MCHKG/^$N'_0OZ_\ ^ )_QH_X2X?]"_K_ /X G_&@#HZYSQ1_R$O"_P#V%Q_Z
M3ST?\)</^A?U_P#\ 3_C6#XC\4"6_P##C?V)K:>7J@?#V9!;]Q,,+SR><X]
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MHKG/^$N'_0OZ_P#^ )_QH_X2X?\ 0OZ__P" )_QH Z.BN<_X2X?]"_K_ /X
MG_&C_A+A_P!"_K__ ( G_&@#HZ*YS_A+A_T+^O\ _@"?\:/^$N'_ $+^O_\
M@"?\: .CHKG/^$N'_0OZ_P#^ )_QH_X2X?\ 0OZ__P" )_QH Z.BN<_X2X?]
M"_K_ /X G_&C_A+A_P!"_K__ ( G_&@#HZ*YS_A+A_T+^O\ _@"?\:/^$N'_
M $+^O_\ @"?\: .CHKG/^$N'_0OZ_P#^ )_QH_X2X?\ 0OZ__P" )_QH Z.B
MN<_X2X?]"_K_ /X G_&C_A+A_P!"_K__ ( G_&@#HZ*YS_A+A_T+^O\ _@"?
M\:/^$N'_ $+^O_\ @"?\: .CHKG/^$N'_0OZ_P#^ )_QH_X2X?\ 0OZ__P"
M)_QH Z.BN<_X2X?]"_K_ /X G_&C_A+A_P!"_K__ ( G_&@#HZ*YS_A+A_T+
M^O\ _@"?\:/^$N'_ $+^O_\ @"?\: .CHKG/^$N'_0OZ_P#^ )_QH_X2X?\
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M5-;3P_I<UJ-\?V: *F\?<\H<X.._O0!V-%8L4^O-%<^9:0JZK^YPX.YOSXJ
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M/,!#[1NSZT /K-\0_P#(M:K_ -><W_H!K2K-\0_\BUJO_7G-_P"@&@!?#_\
MR+>E_P#7G%_Z *T:SO#_ /R+>E_]><7_ * *T: "BBB@ HHHH YSPO\ \A'Q
M1_V%S_Z3P5T=<YX7_P"0CXH_["Y_])X*Z.@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K$\9_P#(B^(/^P;<_P#HIJVZQ/&?_(B^
M(/\ L&W/_HIJ -2Q_P"/"V_ZY+_(446/_'A;?]<E_D** *^M_P#( U'_ *]9
M?_0347AK_D5='_Z\8?\ T 5+K?\ R -1_P"O67_T$US7A_P[J4GAK2G7QAK<
M:M9Q$(D=IA1L' S 3@>Y- ':45SG_"-:I_T.FN_]^K/_ .1Z/^$:U3_H=-=_
M[]6?_P CT ='17.?\(UJG_0Z:[_WZL__ )'H_P"$:U3_ *'37?\ OU9__(]
M'1T5SG_"-:I_T.FN_P#?JS_^1Z/^$:U3_H=-=_[]6?\ \CT ='17.?\ "-:I
M_P!#IKO_ 'ZL_P#Y'H_X1K5/^ATUW_OU9_\ R/0!T=%<Y_PC6J?]#IKO_?JS
M_P#D>C_A&M4_Z'37?^_5G_\ (] '1T5SG_"-:I_T.FN_]^K/_P"1Z/\ A&M4
M_P"ATUW_ +]6?_R/0!T=%<Y_PC6J?]#IKO\ WZL__D>C_A&M4_Z'37?^_5G_
M /(] '1T5SG_  C6J?\ 0Z:[_P!^K/\ ^1Z/^$:U3_H=-=_[]6?_ ,CT ='1
M7.?\(UJG_0Z:[_WZL_\ Y'H_X1K5/^ATUW_OU9__ "/0!T=%<Y_PC6J?]#IK
MO_?JS_\ D>C_ (1K5/\ H=-=_P"_5G_\CT ='7.>*/\ D)>%_P#L+C_TGGH_
MX1K5/^ATUW_OU9__ "/6#XC\/ZC'?^' WBW693)J@52\=IF,^1,=RX@'/!'.
M1@GC." #T&BN<_X1K5/^ATUW_OU9_P#R/1_PC6J?]#IKO_?JS_\ D>@#HZ*Y
MS_A&M4_Z'37?^_5G_P#(]'_"-:I_T.FN_P#?JS_^1Z .CK-\0_\ (M:K_P!>
M<W_H!K._X1K5/^ATUW_OU9__ "/5#7/#NI1^']2=O&&MR*MK*2C1VF&^0\'$
M ./H: .A\/\ _(MZ7_UYQ?\ H K1KC=#\.:D^@::Z^,-;C5K6(A%CM,+\HX&
M8"<?4U?_ .$:U3_H=-=_[]6?_P CT ='17.?\(UJG_0Z:[_WZL__ )'H_P"$
M:U3_ *'37?\ OU9__(] '1T5SG_"-:I_T.FN_P#?JS_^1Z/^$:U3_H=-=_[]
M6?\ \CT 'A?_ )"/BC_L+G_TG@KHZ\^\.>']1DO_ !&%\6ZS$8]4*L4CM,R'
MR(3N.8#SR!Q@8 XSDG>_X1K5/^ATUW_OU9__ "/0!T=%<Y_PC6J?]#IKO_?J
MS_\ D>C_ (1K5/\ H=-=_P"_5G_\CT ='17.?\(UJG_0Z:[_ -^K/_Y'H_X1
MK5/^ATUW_OU9_P#R/0!T=%<Y_P (UJG_ $.FN_\ ?JS_ /D>C_A&M4_Z'37?
M^_5G_P#(] '1T5SG_"-:I_T.FN_]^K/_ .1Z/^$:U3_H=-=_[]6?_P CT ='
M17.?\(UJG_0Z:[_WZL__ )'H_P"$:U3_ *'37?\ OU9__(] '1T5SG_"-:I_
MT.FN_P#?JS_^1Z/^$:U3_H=-=_[]6?\ \CT ='17.?\ "-:I_P!#IKO_ 'ZL
M_P#Y'H_X1K5/^ATUW_OU9_\ R/0!T=%<Y_PC6J?]#IKO_?JS_P#D>C_A&M4_
MZ'37?^_5G_\ (] '1T5SG_"-:I_T.FN_]^K/_P"1Z/\ A&M4_P"ATUW_ +]6
M?_R/0!T=%<Y_PC6J?]#IKO\ WZL__D>C_A&M4_Z'37?^_5G_ /(] '1T5SG_
M  C6J?\ 0Z:[_P!^K/\ ^1Z/^$:U3_H=-=_[]6?_ ,CT ='17.?\(UJG_0Z:
M[_WZL_\ Y'H_X1K5/^ATUW_OU9__ "/0!T=%<Y_PC6J?]#IKO_?JS_\ D>C_
M (1K5/\ H=-=_P"_5G_\CT ='17.?\(UJG_0Z:[_ -^K/_Y'H_X1K5/^ATUW
M_OU9_P#R/0!T=%<Y_P (UJG_ $.FN_\ ?JS_ /D>C_A&M4_Z'37?^_5G_P#(
M] '1T5SG_"-:I_T.FN_]^K/_ .1Z/^$:U3_H=-=_[]6?_P CT ='17.?\(UJ
MG_0Z:[_WZL__ )'H_P"$:U3_ *'37?\ OU9__(] '1T5SG_"-:I_T.FN_P#?
MJS_^1Z/^$:U3_H=-=_[]6?\ \CT ='17.?\ "-:I_P!#IKO_ 'ZL_P#Y'H_X
M1K5/^ATUW_OU9_\ R/0!T=%<Y_PC6J?]#IKO_?JS_P#D>C_A&M4_Z'37?^_5
MG_\ (] '1T5SG_"-:I_T.FN_]^K/_P"1Z/\ A&M4_P"ATUW_ +]6?_R/0!T=
M8GC/_D1?$'_8-N?_ $4U5_\ A&M4_P"ATUW_ +]6?_R/6/XL\/:E#X-UR1_%
MVM3*FGSL8I([3:X$;?*<0 X/3@@^] ':6/\ QX6W_7)?Y"BBQ_X\+;_KDO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7R(1GA>.0>M;W_"=^'/^?Z3_ ,!9O_B*/"__ "$?%'_87/\ Z3P5T= '.?\
M"=^'/^?Z3_P%F_\ B*/^$[\.?\_TG_@+-_\ $5T=% '.?\)WX<_Y_I/_  %F
M_P#B*/\ A._#G_/])_X"S?\ Q%='10!SG_"=^'/^?Z3_ ,!9O_B*/^$[\.?\
M_P!)_P" LW_Q%='10!SG_"=^'/\ G^D_\!9O_B*/^$[\.?\ /])_X"S?_$5T
M=% '.?\ "=^'/^?Z3_P%F_\ B*/^$[\.?\_TG_@+-_\ $5T=% '.?\)WX<_Y
M_I/_  %F_P#B*/\ A._#G_/])_X"S?\ Q%='10!SG_"=^'/^?Z3_ ,!9O_B*
M/^$[\.?\_P!)_P" LW_Q%='10!SG_"=^'/\ G^D_\!9O_B*/^$[\.?\ /])_
MX"S?_$5T=% '.?\ "=^'/^?Z3_P%F_\ B*/^$[\.?\_TG_@+-_\ $5T=% '.
M?\)WX<_Y_I/_  %F_P#B*/\ A._#G_/])_X"S?\ Q%='10!SG_"=^'/^?Z3_
M ,!9O_B*/^$[\.?\_P!)_P" LW_Q%='10!SG_"=^'/\ G^D_\!9O_B*/^$[\
M.?\ /])_X"S?_$5T=% '.?\ "=^'/^?Z3_P%F_\ B*/^$[\.?\_TG_@+-_\
M$5T=% '.?\)WX<_Y_I/_  %F_P#B*/\ A._#G_/])_X"S?\ Q%='10!SG_"=
M^'/^?Z3_ ,!9O_B*/^$[\.?\_P!)_P" LW_Q%='10!SG_"=^'/\ G^D_\!9O
M_B*/^$[\.?\ /])_X"S?_$5T=% '.?\ "=^'/^?Z3_P%F_\ B*/^$[\.?\_T
MG_@+-_\ $5T=% '.?\)WX<_Y_I/_  %F_P#B*/\ A._#G_/])_X"S?\ Q%='
M10!SG_"=^'/^?Z3_ ,!9O_B*/^$[\.?\_P!)_P" LW_Q%='10!SG_"=^'/\
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M+.N>=I]O<VL)8S2^7L8'*]>N/I5:W\3^:95DMS'Y2.7<@[05..?;!KH  "2
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M;_T T +X?_Y%O2_^O.+_ - %:-9WA_\ Y%O2_P#KSB_] %:- !1110 4444
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M)N.D'DD!0"3QCW]S^57]-N]0N)6%Y:B%=F1@'KGI0#,__A _#'_0(B_[[?\
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M^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\,?\
M0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .
M<_X0/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_
M ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_
M[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0
M/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:/
M^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_[[?_
M !KHZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_
MT"(O^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\
M,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_[[?_ !KH
MZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O
M^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\,?\
M0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .
M<_X0/PQ_T"(O^^W_ ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_
M ,:/^$#\,?\ 0(B_[[?_ !KHZ* .<_X0/PQ_T"(O^^W_ ,:Q_%G@GPY;>#=<
MGATN))8M/G=&#-P1&Q!ZUW=8GC/_ )$7Q!_V#;G_ -%-0!J6/_'A;?\ 7)?Y
M"BBQ_P"/"V_ZY+_(44 5];_Y &H_]>LO_H)KG]"BUV70--^S31Q0"TAV;\$D
M>4N.WKG_ #UZ#6_^0!J/_7K+_P"@FO-M$^+-K::#IUL?#^J.8K6*,LKP8;"@
M9&9*N%.<_A5Q.2CNSM?L?B7R.;VW,N[Z*!_WS4T,'B(7,;37-L81MWJO4\<]
MJY/_ (7#:?\ 0N:M_P!]P?\ QRC_ (7#:?\ 0N:M_P!]P?\ QRK]A6_D?W$>
MTAW1V$=OK2//F>)D*OY>6Z$GY?X>PS^E010>)!;8EG@,WJK@#_T"N6_X7#:?
M]"YJW_?<'_QRC_A<-I_T+FK?]]P?_'*/J];^5_<-U8/JCK/LOB G)O8AD8P,
M''_COTIDMKXB*JBW4)&W#-NP2><_P^N/P_.N6_X7#:?]"YJW_?<'_P <H_X7
M#:?]"YJW_?<'_P <I?5JW\K^X7M(=T=-!:>)EEB:2[MRH<;QG/R_]\CFM,6E
MQ]L<,[-;/A@?-(93Z8QT_&N&_P"%PVG_ $+FK?\ ?<'_ ,<H_P"%PVG_ $+F
MK?\ ?<'_ ,<I_5ZW\K^YA[2'\QU[PZ[]I8K-#Y66P-V#UX_A],?CGGM4#IXD
MW!4:#KD-YF>/?Y?Y5R__  N&T_Z%S5O^^X/_ (Y1_P +AM/^A<U;_ON#_P".
M4OJ];^5_</VL.Z.JCM_$2J3)<PN>RJ0./KMZUJZ?]J-C$;W'V@C+A1@#GC]*
MX#_A<-I_T+FK?]]P?_'*/^%PVG_0N:M_WW!_\<I_5ZW\K^X7M(?S'I-%>;?\
M+AM/^A<U;_ON#_XY1_PN&T_Z%S5O^^X/_CE'U>M_*_N'[6'='I-%>;?\+AM/
M^A<U;_ON#_XY1_PN&T_Z%S5O^^X/_CE'U>M_*_N#VL.Z/2:*\V_X7#:?]"YJ
MW_?<'_QRC_A<-I_T+FK?]]P?_'*/J];^5_<'M8=T>DT5YM_PN&T_Z%S5O^^X
M/_CE'_"X;3_H7-6_[[@_^.4?5ZW\K^X/:P[H])KG/%'_ "$O"_\ V%Q_Z3SU
MS/\ PN&T_P"A<U;_ +[@_P#CE96L?$V+4;O1Y8O#^I*+&^%S(&>#YE\J1,#]
MYURX_(T?5ZW\K^X/:P[H]>HKS;_A<-I_T+FK?]]P?_'*/^%PVG_0N:M_WW!_
M\<H^KUOY7]P>UAW1Z317FW_"X;3_ *%S5O\ ON#_ ..4?\+AM/\ H7-6_P"^
MX/\ XY1]7K?RO[@]K#NCTFLWQ#_R+6J_]><W_H!KB/\ A<-I_P!"YJW_ 'W!
M_P#'*J:I\5[>^TF\M(_#VJ*\\#Q*6># +*0,_O/>CZO6_E?W![6'='H?A_\
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M.5E^)/BO;7_A;5[-= U.,SV4T0=WAPNY",G$F<<]J/J]7^5_<'M(=T>K6/\
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M  C_ -#)IG_@0O\ C71T4 <Y_P )_P"$?^ADTS_P(7_&C_A/_"/_ $,FF?\
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M_P"$?^ADTS_P(7_&C_A/_"/_ $,FF?\ @0O^-='10!SG_"?^$?\ H9-,_P#
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M,_\  A?\:/\ A/\ PC_T,FF?^!"_XUT=% '.?\)_X1_Z&33/_ A?\:/^$_\
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M/^0EX7_["X_])YZ #^UO%'_0K0?^#-?_ (BC^UO%'_0K0?\ @S7_ .(KHZ*
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M1X7_ .0CXH_["Y_])X*Z.@#G/[6\4?\ 0K0?^#-?_B*/[6\4?]"M!_X,U_\
MB*Z.B@#G/[6\4?\ 0K0?^#-?_B*/[6\4?]"M!_X,U_\ B*Z.B@#G/[6\4?\
M0K0?^#-?_B*/[6\4?]"M!_X,U_\ B*Z.B@#G/[6\4?\ 0K0?^#-?_B*/[6\4
M?]"M!_X,U_\ B*Z.B@#G/[6\4?\ 0K0?^#-?_B*/[6\4?]"M!_X,U_\ B*Z.
MB@#G/[6\4?\ 0K0?^#-?_B*/[6\4?]"M!_X,U_\ B*Z.B@#G/[6\4?\ 0K0?
M^#-?_B*/[6\4?]"M!_X,U_\ B*Z.B@#G/[6\4?\ 0K0?^#-?_B*/[6\4?]"M
M!_X,U_\ B*Z.B@#G/[6\4?\ 0K0?^#-?_B*/[6\4?]"M!_X,U_\ B*Z.B@#G
M/[6\4?\ 0K0?^#-?_B*/[6\4?]"M!_X,U_\ B*Z.B@#G/[6\4?\ 0K0?^#-?
M_B*/[6\4?]"M!_X,U_\ B*Z.B@#G/[6\4?\ 0K0?^#-?_B*/[6\4?]"M!_X,
MU_\ B*Z.B@#G/[6\4?\ 0K0?^#-?_B*/[6\4?]"M!_X,U_\ B*Z.B@#G/[6\
M4?\ 0K0?^#-?_B*/[6\4?]"M!_X,U_\ B*Z.B@#G/[6\4?\ 0K0?^#-?_B*/
M[6\4?]"M!_X,U_\ B*Z.B@#G/[6\4?\ 0K0?^#-?_B*/[6\4?]"M!_X,U_\
MB*Z.B@#G/[6\4?\ 0K0?^#-?_B*/[6\4?]"M!_X,U_\ B*Z.B@#G/[6\4?\
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M9.%..#T]:K_V7KA1%DU%&^7#\D9/J.*Z&BCK</(Q)[#6&E<Q7ZA6W<%CQR<
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M;_T T +X?_Y%O2_^O.+_ - %:-9WA_\ Y%O2_P#KSB_] %:- !1110 4444
M<YX7_P"0CXH_["Y_])X*Z.N<\+_\A'Q1_P!A<_\ I/!71T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8GC/_D1?$'_8-N?_ $4U
M;=8GC/\ Y$7Q!_V#;G_T4U &I8_\>%M_UR7^0HHL?^/"V_ZY+_(44 5];_Y
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M\%_X<5!?XEU01ONU.Y;CR)CQF3@Y Y&#^9KT&N<\4?\ (2\+_P#87'_I//0
M?\(-H?IJ7_@VNO\ XY1_P@VA^FI?^#:Z_P#CE='10!SG_"#:'Z:E_P"#:Z_^
M.4?\(-H?IJ7_ (-KK_XY6]<7,-I%YL\@CC!P6/05(K!T#*<@C(H YW_A!M#]
M-2_\&UU_\<JAKG@K18O#^I2(-1W):RL,ZI=$9"'L9,&NRK-\0_\ (M:K_P!>
M<W_H!H Y_0_!6BRZ!ILCC4=SVL3'&J70&2H["3 J_P#\(-H?IJ7_ (-KK_XY
M6EX?_P"1;TO_ *\XO_0!6C0!SG_"#:'Z:E_X-KK_ ..4?\(-H?IJ7_@VNO\
MXY71T4 <Y_P@VA^FI?\ @VNO_CE'_"#:'Z:E_P"#:Z_^.5T=% 'GWASP=H\]
M_P"(U<7^(M4,:;=3N5X\B$\XDY.2>3D_D*WO^$&T/TU+_P &UU_\<H\+_P#(
M1\4?]A<_^D\%='0!SG_"#:'Z:E_X-KK_ ..4?\(-H?IJ7_@VNO\ XY71T4 <
MY_P@VA^FI?\ @VNO_CE'_"#:'Z:E_P"#:Z_^.5T=% '.?\(-H?IJ7_@VNO\
MXY1_P@VA^FI?^#:Z_P#CE='10!SG_"#:'Z:E_P"#:Z_^.4?\(-H?IJ7_ (-K
MK_XY71T4 <Y_P@VA^FI?^#:Z_P#CE'_"#:'Z:E_X-KK_ ..5T=% '.?\(-H?
MIJ7_ (-KK_XY1_P@VA^FI?\ @VNO_CE='10!SG_"#:'Z:E_X-KK_ ..4?\(-
MH?IJ7_@VNO\ XY71T4 <Y_P@VA^FI?\ @VNO_CE'_"#:'Z:E_P"#:Z_^.5T=
M% '.?\(-H?IJ7_@VNO\ XY1_P@VA^FI?^#:Z_P#CE='10!SG_"#:'Z:E_P"#
M:Z_^.4?\(-H?IJ7_ (-KK_XY71T4 <Y_P@VA^FI?^#:Z_P#CE'_"#:'Z:E_X
M-KK_ ..5T=% '.?\(-H?IJ7_ (-KK_XY1_P@VA^FI?\ @VNO_CE='10!SG_"
M#:'Z:E_X-KK_ ..4?\(-H?IJ7_@VNO\ XY71T4 <Y_P@VA^FI?\ @VNO_CE'
M_"#:'Z:E_P"#:Z_^.5T=% '.?\(-H?IJ7_@VNO\ XY1_P@VA^FI?^#:Z_P#C
ME='10!SG_"#:'Z:E_P"#:Z_^.4?\(-H?IJ7_ (-KK_XY71T4 <Y_P@VA^FI?
M^#:Z_P#CE'_"#:'Z:E_X-KK_ ..5T=% '.?\(-H?IJ7_ (-KK_XY1_P@VA^F
MI?\ @VNO_CE='10!SG_"#:'Z:E_X-KK_ ..4?\(-H?IJ7_@VNO\ XY71T4 <
MY_P@VA^FI?\ @VNO_CE'_"#:'Z:E_P"#:Z_^.5T=% '.?\(-H?IJ7_@VNO\
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MT*FO_P#?N'_X[1_PE5U_T*FO_P#?N'_X[0!T=%<Y_P )5=?]"IK_ /W[A_\
MCM'_  E5U_T*FO\ _?N'_P".T ='17.?\)5=?]"IK_\ W[A_^.T?\)5=?]"I
MK_\ W[A_^.T ='17.?\ "577_0J:_P#]^X?_ ([1_P )5=?]"IK_ /W[A_\
MCM '1T5SG_"577_0J:__ -^X?_CM'_"577_0J:__ -^X?_CM '1T5SG_  E5
MU_T*FO\ _?N'_P".T?\ "577_0J:_P#]^X?_ ([0!T=%<Y_PE5U_T*FO_P#?
MN'_X[1_PE5U_T*FO_P#?N'_X[0!T=%<Y_P )5=?]"IK_ /W[A_\ CM'_  E5
MU_T*FO\ _?N'_P".T ='17.?\)5=?]"IK_\ W[A_^.T?\)5=?]"IK_\ W[A_
M^.T ='17.?\ "577_0J:_P#]^X?_ ([1_P )5=?]"IK_ /W[A_\ CM '1T5S
MG_"577_0J:__ -^X?_CM'_"577_0J:__ -^X?_CM '1T5SG_  E5U_T*FO\
M_?N'_P".T?\ "577_0J:_P#]^X?_ ([0!T=%<Y_PE5U_T*FO_P#?N'_X[1_P
ME5U_T*FO_P#?N'_X[0!T=%<Y_P )5=?]"IK_ /W[A_\ CM'_  E5U_T*FO\
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M^BFK;K$\9_\ (B^(/^P;<_\ HIJ -2Q_X\+;_KDO\A118_\ 'A;?]<E_D**
M*^M_\@#4?^O67_T$UCZ'X?TR]\.:5-<6N^1[*#<=[#/[L>AK8UO_ ) &H_\
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M^+?^AET[_P %!_\ CU4-<T[Q4OA_4C)XBT]XQ:REE&E$$C8<C/G<4 =#X?\
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MS?%O_0RZ=_X*#_\ 'J/[-\6_]#+IW_@H/_QZ@#HZ*YS^S?%O_0RZ=_X*#_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5B>,_^1%\0?]@VY_\ 135MUB>,_P#D1?$'_8-N?_134 :EC_QX6W_7
M)?Y"BBQ_X\+;_KDO\A10!7UO_D :C_UZR_\ H)K"\.^+/#D7AG2HY/$&E(Z6
M<*LK7D8*D(,@C-;NM_\ ( U'_KUE_P#036!X>O-"30=,@GCMHY$LX0SR1 *6
M\M3C<1@GD<4 :G_"7^&?^ABTC_P-C_\ BJ/^$O\ #/\ T,6D?^!L?_Q5.6Y\
M.NVU9--8YQ@;*;'>>'9I&2-]/8J0IP$QD]!GUH /^$O\,_\ 0Q:1_P"!L?\
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M6'V#:'V$X3[WI]: (?\ A+_#/_0Q:1_X&Q__ !5'_"7^&?\ H8M(_P# V/\
M^*I_GZ!AR#I[;%W,%"$@9Q_/BG1R:#*&,9T]@JEFP$X ZDT 1?\ "7^&?^AB
MTC_P-C_^*H_X2_PS_P!#%I'_ (&Q_P#Q5/$_A]MN'TX[FVC&SD^E(;GP^KNC
M-IZLAVD,$'/^0?RH ;_PE_AG_H8M(_\  V/_ .*H_P"$O\,_]#%I'_@;'_\
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M_2_X4 <?X;\4^'H=0\2-+KVEH)-5+QEKR,;U\B$9'/(R",^QK?\ ^$O\,_\
M0Q:1_P"!L?\ \56=X8L+-M1\3AK2 A=6(&8QP/L\%=%_9UC_ ,^=O_WZ7_"@
M#._X2_PS_P!#%I'_ (&Q_P#Q5'_"7^&?^ABTC_P-C_\ BJT?[.L?^?.W_P"_
M2_X4?V=8_P#/G;_]^E_PH SO^$O\,_\ 0Q:1_P"!L?\ \51_PE_AG_H8M(_\
M#8__ (JM'^SK'_GSM_\ OTO^%']G6/\ SYV__?I?\* ,[_A+_#/_ $,6D?\
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M9UC_ ,^=O_WZ7_"@#._X2_PS_P!#%I'_ (&Q_P#Q5'_"7^&?^ABTC_P-C_\
MBJT?[.L?^?.W_P"_2_X4?V=8_P#/G;_]^E_PH SO^$O\,_\ 0Q:1_P"!L?\
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MOLMI &&FW!!$8R#Y;>U &[8_\>%M_P!<E_D**+'_ (\+;_KDO\A10!7UO_D
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M59OB'_D6M5_Z\YO_ $ T +X?_P"1;TO_ *\XO_0!6C6=X?\ ^1;TO_KSB_\
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MT=% '.>9XT_Y]- _\"9O_C='F>-/^?30/_ F;_XW71T4 <YYGC3_ )]- _\
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M,\:?\^F@?^!,W_QNNCHH YSS/&G_ #Z:!_X$S?\ QNCS/&G_ #Z:!_X$S?\
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MW71T4 <YYGC3_GTT#_P)F_\ C='F>-/^?30/_ F;_P"-UT=% '.>9XT_Y]-
M_P# F;_XW1YGC3_GTT#_ ,"9O_C=='10!SGF>-/^?30/_ F;_P"-T>9XT_Y]
M- _\"9O_ (W71T4 <YYGC3_GTT#_ ,"9O_C='F>-/^?30/\ P)F_^-UT=% '
M.>9XT_Y]- _\"9O_ (W1YGC3_GTT#_P)F_\ C=='10!SGF>-/^?30/\ P)F_
M^-T>9XT_Y]- _P# F;_XW71T4 <YYGC3_GTT#_P)F_\ C='F>-/^?30/_ F;
M_P"-UT=% '.>9XT_Y]- _P# F;_XW1YGC3_GTT#_ ,"9O_C=='10!SGF>-/^
M?30/_ F;_P"-T>9XT_Y]- _\"9O_ (W71T4 <YYGC3_GTT#_ ,"9O_C='F>-
M/^?30/\ P)F_^-UT=% '.>9XT_Y]- _\"9O_ (W1YGC3_GTT#_P)F_\ C=='
M10!SGF>-/^?30/\ P)F_^-T>9XT_Y]- _P# F;_XW71T4 <YYGC3_GTT#_P)
MF_\ C='F>-/^?30/_ F;_P"-UT=% '.>9XT_Y]- _P# F;_XW1YGC3_GTT#_
M ,"9O_C=='10!SGF>-/^?30/_ F;_P"-T>9XT_Y]- _\"9O_ (W71T4 <YYG
MC3_GTT#_ ,"9O_C='F>-/^?30/\ P)F_^-UT=% '.>9XT_Y]- _\"9O_ (W6
M/XLD\7'P;K@N+70Q#_9\_F&.XE+!?+;. 4QG%=W6)XS_ .1%\0?]@VY_]%-0
M!J6/_'A;?]<E_D**+'_CPMO^N2_R%% %?6_^0!J/_7K+_P"@FN3T;2->_L?3
M[VRU"- ]K"$B8MC9Y2]<Y'WAT"YP3SZ=9K?_ " -1_Z]9?\ T$U%X:_Y%71_
M^O&'_P! % [G-KI?C@^2KZA:[4!#$2<DX(R?DY'MQ]:T$L?%3:7+%+?VWVGS
M"8V3@;<# /'KG_&NHHH>KO\ UO<2T=SD(['QL95$NHV:QA6SL'.<';U7UQGV
MJ>^M/%LEA:QVMW9+-Y16Y+Y^9CQE2!QZ_A7444#N<UING^)+6RG2?4(IIVB'
MEESN D]>%'&*J+8^-C=B1KZQ";67&2<$XP<;1GD#_OHUV%%"T$]3DTLO%ZPL
MSWMLT[ CY6V@>AY0YZGCCMS3M-A\7FPD%]-;BY# 95AR >2IV\ CU!KJJ* .
M3-CXP=Y3_:%M&"RA "&P,G<?N>FW'7O[4TV/C)Q<I)?VI5XV$1C;85;& 3E#
MQ_7\JZZB@#CX]/\ &BPJO]H6@95 QG()S[IGI^M6;VT\53)8K!=VR!8T%R=V
M"[;OF(^7T _,UT]%-/6X/4Y.[M?&;7DAMKVR%N9 4!X(7N/NGG'?U'>I8]*\
M0/;2QSZ@ 9) _P LF2@W9P"%'&WVKIZ*72P'(6UAXS14CDO[7:H4%MV3P>?X
M/3&/QZ]K#Z=XD359W@U"/['+.CC>V66/ W #;UXXY[GU&.GHJN;6XK=#F;_2
MM=COY)])NXHUDD4L)W9OEQR #D#G'2JLEAXU:1U34K41 ,$;C<>?E)^3CCK7
M845(SFKVV\5?988K&YM0XB0/)*W.X;MW\/.<K],5H:-%K,9N/[7G@EW,#%Y0
M^Z,<YXK5HH *YSQ1_P A+PO_ -A<?^D\]='7.>*/^0EX7_["X_\ 2>>@#HZ*
M** ,[6[:^N].:'3IA!<%@1*6QM'?L<YZ?CGM5VW5TMHUD_U@4!N<\_6I** "
MLWQ#_P BUJO_ %YS?^@&M*LWQ#_R+6J_]><W_H!H 7P__P BWI?_ %YQ?^@"
MM&L[P_\ \BWI?_7G%_Z *T: "BBB@ HHHH YSPO_ ,A'Q1_V%S_Z3P5T=<YX
M7_Y"/BC_ +"Y_P#2>"NCH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *Q/&?_ "(OB#_L&W/_ **:MNL3QG_R(OB#_L&W/_HIJ -2
MQ_X\+;_KDO\ (446/_'A;?\ 7)?Y"B@"OK?_ " -1_Z]9?\ T$US7A_PC:S>
M&M*D.J:ZI>SB8A-5G51E!T ;@>U=+K?_ " -1_Z]9?\ T$UQ6DZCXLM;*P%I
MIK7-E]BA$8;;MQY:'(Y!S]X<Y[<4#MH=#_PAMI_T%M?_ /!O/_\ %4?\(;:?
M]!;7_P#P;S__ !59=QJ7C2:WN/(TY87PAB.Q<YS\RX+'MGG]*OVFK^)I+Z"*
M?1$2W?'F2[L;,CTR<X.1GOP>.E.P-65R7_A#;3_H+:__ .#>?_XJC_A#;3_H
M+:__ .#>?_XJJAUKQ3+&\EMH\+*)61?,!4D D _>]OQW>W*OK'BUG'EZ% BE
M"WS-N(.,X^\.XQ^-)"+7_"&VG_06U_\ \&\__P 51_PAMI_T%M?_ /!O/_\
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M /Q54-<\(6L7A_4I!JFNL5M96 ;59R#A#U!;D5V59OB'_D6M5_Z\YO\ T T
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M_P#XJC_A#;3_ *"VO_\ @WG_ /BJ@M=0\57!3[1IT-OOMV<@+G9)N "GYN>
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M&VG_ $%M?_\ !O/_ /%4W4=8UZUU-H(-*26W8*(I.<EB.<\] :I#6/&.]?\
MB20D.PZ\;!@9_BYYR:06+_\ PAMI_P!!;7__  ;S_P#Q5'_"&VG_ $%M?_\
M!O/_ /%5!>ZIXJBTL-;Z5#)>F4I@#Y0G9L;OQZ]JZ: NT$9E&)"HW#&.:!&!
M_P (;:?]!;7_ /P;S_\ Q58_BSPE:V_@W7)EU37',>GSN%DU2=E.(V.""V"/
M8UW=8GC/_D1?$'_8-N?_ $4U &I8_P#'A;?]<E_D**+'_CPMO^N2_P A10!7
MUO\ Y &H_P#7K+_Z":Y/1K'Q-<Z+8-;7T5M;"UB\H,V2R^2N. ./FS_GKUFM
M_P#( U'_ *]9?_037->'_%L,7AK2HSH^NL4LXEW)ITA4X0<@XY% #_[$\7&U
MP=:@:X+9R2=H'M\O7.*GMM-\6)>PR3ZI:O NSS(USDX'/\-3_P#"80?] 77_
M /P62?X4?\)A!_T!=?\ _!9)_A3N*Q7FT?Q*8;I(]2AQ+*Q0;V78AS@ [3ZC
M/TJ%]'\6R^0KZE:!8U .V1OF([D;>:O?\)A!_P! 77__  62?X4?\)A!_P!
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MH_X3"#_H"Z__ ."R3_"CI8#HZYSQ1_R$O"__ &%Q_P"D\]'_  F$'_0%U_\
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M0Z%6&01@U!:6-M8QLEK"L2L=Q"]SZUB?\)A!_P! 77__  62?X4?\)A!_P!
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MD?(M6-;_ .0!J/\ UZR_^@FN;T?2[9] TR8ZF()FM83@L!M!B48QD'MG\.E
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MUJO_ %YS?^@&M*LWQ#_R+6J_]><W_H!H 7P__P BWI?_ %YQ?^@"M&L[P_\
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M $.FK?\ @-9__&:/^$>UK_H=-6_\!K/_ .,T ='17.?\(]K7_0Z:M_X#6?\
M\9H_X1[6O^ATU;_P&L__ (S0!T=%<Y_PCVM?]#IJW_@-9_\ QFC_ (1[6O\
MH=-6_P# :S_^,T ='17.?\(]K7_0Z:M_X#6?_P 9H_X1[6O^ATU;_P !K/\
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M $.FK?\ @-9__&:/^$>UK_H=-6_\!K/_ .,T ='17.?\(]K7_0Z:M_X#6?\
M\9H_X1[6O^ATU;_P&L__ (S0!T=%<Y_PCVM?]#IJW_@-9_\ QFC_ (1[6O\
MH=-6_P# :S_^,T ='17.?\(]K7_0Z:M_X#6?_P 9H_X1[6O^ATU;_P !K/\
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MHH KZW_R -1_Z]9?_037-Z'XIM;/1]-M+B,@1V4(W*<DGRT[<>OKV-=)K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6)XS_Y
M$7Q!_P!@VY_]%-6W6)XS_P"1%\0?]@VY_P#134 :EC_QX6W_ %R7^0HHL?\
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MW_7_ !K!@@\%S^:5TC3%2/@N]BB@G!8XRN> I-)''X&G'[G3M(D)0N%6R3)
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MAX:6/1=.02:J$<+:H-R_9YC@\<C(!_"@#J?[7TS_ *"-I_W_ %_QH_M?3/\
MH(VG_?\ 7_&JW_"+>'O^@#I?_@''_A1_PBWA[_H Z7_X!Q_X4 6?[7TS_H(V
MG_?]?\:/[7TS_H(VG_?]?\:K?\(MX>_Z .E_^ <?^%'_  BWA[_H Z7_ . <
M?^% %G^U],_Z"-I_W_7_ !K/U_5M-;PYJBKJ%J6-I* !,O/R'WJ?_A%O#W_0
M!TO_ , X_P#"L_7O#.@1^'=3=-#TU76TE*LMI&"#L/(XH LZ#JVFKX=TQ6U"
MU!%I$"#,O'R#WK0_M?3/^@C:?]_U_P :QM"\,Z!)X>TQWT/36=K2(LS6D9).
MP<GBM#_A%O#W_0!TO_P#C_PH L_VOIG_ $$;3_O^O^-']KZ9_P!!&T_[_K_C
M5;_A%O#W_0!TO_P#C_PH_P"$6\/?] '2_P#P#C_PH L_VOIG_01M/^_Z_P"-
M']KZ9_T$;3_O^O\ C5;_ (1;P]_T =+_ / ./_"C_A%O#W_0!TO_ , X_P#"
M@#'\,ZIIZ:CXF+7]JH;5B5S,HR/L\'(Y]JZ'^U],_P"@C:?]_P!?\:Y;PUX;
MT*74/$JR:+ISB/52B!K5#M7R(3@<<#))_&N@_P"$6\/?] '2_P#P#C_PH L_
MVOIG_01M/^_Z_P"-']KZ9_T$;3_O^O\ C5;_ (1;P]_T =+_ / ./_"C_A%O
M#W_0!TO_ , X_P#"@"S_ &OIG_01M/\ O^O^-']KZ9_T$;3_ +_K_C5;_A%O
M#W_0!TO_ , X_P#"C_A%O#W_ $ =+_\  ./_  H L_VOIG_01M/^_P"O^-']
MKZ9_T$;3_O\ K_C5;_A%O#W_ $ =+_\  ./_  H_X1;P]_T =+_\ X_\* +/
M]KZ9_P!!&T_[_K_C1_:^F?\ 01M/^_Z_XU6_X1;P]_T =+_\ X_\*/\ A%O#
MW_0!TO\ \ X_\* +/]KZ9_T$;3_O^O\ C1_:^F?]!&T_[_K_ (U6_P"$6\/?
M] '2_P#P#C_PH_X1;P]_T =+_P# ./\ PH L_P!KZ9_T$;3_ +_K_C1_:^F?
M]!&T_P"_Z_XU6_X1;P]_T =+_P# ./\ PH_X1;P]_P! '2__  #C_P * +/]
MKZ9_T$;3_O\ K_C1_:^F?]!&T_[_ *_XU6_X1;P]_P! '2__  #C_P */^$6
M\/?] '2__ ./_"@"S_:^F?\ 01M/^_Z_XT?VOIG_ $$;3_O^O^-5O^$6\/?]
M '2__ ./_"C_ (1;P]_T =+_ / ./_"@"S_:^F?]!&T_[_K_ (T?VOIG_01M
M/^_Z_P"-5O\ A%O#W_0!TO\ \ X_\*/^$6\/?] '2_\ P#C_ ,* +/\ :^F?
M]!&T_P"_Z_XT?VOIG_01M/\ O^O^-5O^$6\/?] '2_\ P#C_ ,*/^$6\/?\
M0!TO_P  X_\ "@"S_:^F?]!&T_[_ *_XT?VOIG_01M/^_P"O^-5O^$6\/?\
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M&T_[_K_C1_:^F?\ 01M/^_Z_XU6_X1;P]_T =+_\ X_\*/\ A%O#W_0!TO\
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MI90@F0%5SL7@,>">1QG/- "_VAXP_P"A<TC_ ,'+_P#R/1_:'C#_ *%S2/\
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M,%0B0'<2,@#\*?'J=A*',=];/Y:EWVRJ=JCJ3SP* ,;^T/&'_0NZ1_X.7_\
MD>C^T/&'_0NZ1_X.7_\ D>M4ZUIB@$W]OST_>#D>OT]Z276]+A@DF:_MC'&%
M9RL@;:#T)QZT 9?]H>,/^A=TC_P<O_\ (]']H>,/^A=TC_P<O_\ (]:O]M:4
M$WG4K,+P,F=?\:8^NZ;'>/:R7:)(BAB7^5<$9^\>.GO0!F_VAXP_Z%W2/_!R
M_P#\CT?VAXP_Z%W2/_!R_P#\CUL#4[!MP6]MV*@DA9 3QUX%5X_$&ER63W8N
MU$,9PQ8%2#C/0\].: 2N9_\ :'C#_H7=(_\ !R__ ,CT?VAXP_Z%W2/_  <O
M_P#(]:<>NZ5)-Y*ZA;%\@8\P<D]!]?:GMJ^G+''(;ZVV2$A&$H(;'7!H#<R?
M[0\8?]"[I'_@Y?\ ^1Z/[0\8?]"[I'_@Y?\ ^1ZUFU?3$;:^HVBG .#,HX/X
MT_\ M*R^T?9_M< FRHV&09)/08]Z ,;^T/&'_0NZ1_X.7_\ D>L'Q'?>*FO_
M  X9M!TM&75 8PNJNV]O(FX/[@8&,G//0#'.1Z#7.>*/^0EX7_["X_\ 2>>@
M _M#QA_T+ND?^#E__D>C^T/&'_0NZ1_X.7_^1ZZ.B@#G/[0\8?\ 0NZ1_P"#
ME_\ Y'H_M#QA_P!"[I'_ (.7_P#D>NCHH YS^T/&'_0NZ1_X.7_^1ZH:Y?\
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M&'_0NZ1_X.7_ /D>NCHH YS^T/&'_0NZ1_X.7_\ D>C^T/&'_0NZ1_X.7_\
MD>NCHH YS^T/&'_0NZ1_X.7_ /D>C^T/&'_0NZ1_X.7_ /D>NCHH YS^T/&'
M_0NZ1_X.7_\ D>C^T/&'_0NZ1_X.7_\ D>NCHH YS^T/&'_0NZ1_X.7_ /D>
MC^T/&'_0NZ1_X.7_ /D>NCHH YS^T/&'_0NZ1_X.7_\ D>C^T/&'_0NZ1_X.
M7_\ D>NCHH YS^T/&'_0NZ1_X.7_ /D>C^T/&'_0NZ1_X.7_ /D>NCHH YS^
MT/&'_0NZ1_X.7_\ D>C^T/&'_0NZ1_X.7_\ D>NCHH YS^T/&'_0NZ1_X.7_
M /D>C^T/&'_0NZ1_X.7_ /D>NCHH YS^T/&'_0NZ1_X.7_\ D>C^T/&'_0NZ
M1_X.7_\ D>NCHH YS^T/&'_0NZ1_X.7_ /D>C^T/&'_0NZ1_X.7_ /D>NCHH
M YS^T/&'_0NZ1_X.7_\ D>C^T/&'_0NZ1_X.7_\ D>NCHH YS^T/&'_0NZ1_
MX.7_ /D>C^T/&'_0NZ1_X.7_ /D>NCHH YS^T/&'_0NZ1_X.7_\ D>L?Q9?>
M*V\&ZXL^@:5'"=/G$CIJSLRKY;9('D#)QVR/J*[NL3QG_P B+X@_[!MS_P"B
MFH U+'_CPMO^N2_R%%%C_P >%M_UR7^0HH KZW_R -1_Z]9?_037#63:!;Z9
MIZ:G9&)GM+9S=*_S.SQ%0O'(&U6R.E=SK?\ R -1_P"O67_T$U2T"QM+GPMH
M[3VL$K?8H#EXPQX08Z^F3^9H&F<H(/!$4B#%YY@R@3S'R>VW&>>O2K-Q#X.A
MTA+:>.>.UNG,P0,V6(.WU]J[+^R=-\WS?[/M/,SG=Y*YS]<4-I6G-MW6%J=G
MW<PKQSGCCU)HZW_K>Y.IQUMJ/@V"Z?R9)@X0QE2S8P60'C/7Y5_*MZ#P?HB&
M.1+=R!EE#2L0-W7C/>M$Z+I1=G.FV>YNI\A<G]*N@!0   !P *%M_7]=Q^1S
MR^"](\QW=)6+.[ "0J%#,3M '&!FHSX"T%D=&@G97;<P,[G<??FNFHH\PZW,
M%_!^C/:1VI@D$2 @*LK#()!YYYY _*HE\#:$EN\"V\H1B"1YS=1TQSQ71T4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P# B/\ ^(H_X127_H9M?_\  B/_ .(K6&L:<T<D@O82D>-[;QA<],_6H?\
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MO_\ "*2_]#-K_P#X$1__ !%:7A__ )%O2_\ KSB_] %:- '.?\(I+_T,VO\
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MDO\ T,VO_P#@1'_\171T4 <Y_P (I+_T,VO_ /@1'_\ $4?\(I+_ -#-K_\
MX$1__$5T=% '.?\ "*2_]#-K_P#X$1__ !%'_"*2_P#0S:__ .!$?_Q%='10
M!SG_  BDO_0S:_\ ^!$?_P 11_PBDO\ T,VO_P#@1'_\171T4 <Y_P (I+_T
M,VO_ /@1'_\ $4?\(I+_ -#-K_\ X$1__$5T=% '.?\ "*2_]#-K_P#X$1__
M !%8_BSPQ+!X-UR4^(M<D":?.VR2="K8C8X(V=#7=UB>,_\ D1?$'_8-N?\
MT4U &I8_\>%M_P!<E_D**+'_ (\+;_KDO\A10!7UO_D :C_UZR_^@FL/1/#.
MD7WAS3)KFV:1I+.%F!FDVY\M1G;NP#@8R!6]K"-)HE^B*6=K:0*JC))VG@5S
M6A^+]+L_#^FVL\&L)-#:Q1R+_8MX<,$ (R(O44FD]P-;_A$-#V(HLW&QQ(I%
MQ("&'?.[-,'@O0 @063A0VX 7$O!]OFXJ/\ X3C1O^>6L?\ @DO/_C5'_"<:
M-_SRUC_P27G_ ,:I@]=RT_A;26MFMU@>.-]N_9*V6 W8!.<_Q-^=5[?P1H-L
M01:N^V0O&'F<A,]ASTIO_"<:-_SRUC_P27G_ ,:H_P"$XT;_ )Y:Q_X)+S_X
MU0M-@N36GA+3+6WG@99IHII ^V20_+@  #&.  *E3PMHR3/,+0^8[*S$S.>5
M)(QD\ %CP/6JG_"<:-_SRUC_ ,$EY_\ &J/^$XT;_GEK'_@DO/\ XU0!-<^#
MM N[U[R?3U>X<EF<R/R?IG%3/X9TEXXD-O(%B550+<2# 48'1N2/4\U3_P"$
MXT;_ )Y:Q_X)+S_XU1_PG&C?\\M8_P#!)>?_ !JCI8":'P;H,&X1V) ;JOGR
M$=CP-W'05-#X8T>WO8KN*TVSQ?<<2OQU[9]S5/\ X3C1O^>6L?\ @DO/_C5'
M_"<:-_SRUC_P27G_ ,:HZW"W0Z.BN<_X3C1O^>6L?^"2\_\ C5'_  G&C?\
M/+6/_!)>?_&J .CHKG/^$XT;_GEK'_@DO/\ XU1_PG&C?\\M8_\ !)>?_&J
M.CHKG/\ A.-&_P">6L?^"2\_^-4?\)QHW_/+6/\ P27G_P :H Z.BN<_X3C1
MO^>6L?\ @DO/_C5'_"<:-_SRUC_P27G_ ,:H Z.BN<_X3C1O^>6L?^"2\_\
MC5'_  G&C?\ /+6/_!)>?_&J .CKG/%'_(2\+_\ 87'_ *3ST?\ "<:-_P \
MM8_\$EY_\:K%U[Q3I][>Z#);VVL.EKJ0GF/]C78VIY,JYYBYY91QZT =[17.
M?\)QHW_/+6/_  27G_QJC_A.-&_YY:Q_X)+S_P"-4 ='17.?\)QHW_/+6/\
MP27G_P :H_X3C1O^>6L?^"2\_P#C5 '1UF^(?^1:U7_KSF_] -9W_"<:-_SR
MUC_P27G_ ,:JEK/C#2[K0]0MX8-8:66VD1%_L6\&6*D <Q>M &_X?_Y%O2_^
MO.+_ - %:-<?H_C'2[71+"WF@UA98K:-'7^Q;PX8* 1Q%5W_ (3C1O\ GEK'
M_@DO/_C5 '1,H="IS@C!P<56L=.M=-B:*TB\I&;>5W$C/<\FL;_A.-&_YY:Q
M_P""2\_^-4?\)QHW_/+6/_!)>?\ QJ@#HZ*YS_A.-&_YY:Q_X)+S_P"-4?\
M"<:-_P \M8_\$EY_\:H /"__ "$?%'_87/\ Z3P5T=<%H/BG3[*]UZ2XMM81
M;K4C/"?[&NSN3R8ESQ%QRK#GTK:_X3C1O^>6L?\ @DO/_C5 '1T5SG_"<:-_
MSRUC_P $EY_\:H_X3C1O^>6L?^"2\_\ C5 '1T5SG_"<:-_SRUC_ ,$EY_\
M&J/^$XT;_GEK'_@DO/\ XU0!T=%<Y_PG&C?\\M8_\$EY_P#&J/\ A.-&_P">
M6L?^"2\_^-4 ='17.?\ "<:-_P \M8_\$EY_\:H_X3C1O^>6L?\ @DO/_C5
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M'_@DO/\ XU0!T=%<Y_PG&C?\\M8_\$EY_P#&J/\ A.-&_P">6L?^"2\_^-4
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>img206306002_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206306002_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -J I # 2(  A$! Q$!_\0
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MGC5[;I_O5H0>(-,FC9S=+#M)!$_[L\'!.&QQG(SZB@#/_P"$FU'_ *$S7_\
MONS_ /DBC_A)M1_Z$S7_ /ONS_\ DBM-]=TJ,?-J-L/;S14CZOIT3LDE];JR
MD@AI ""* ,C_ (2;4?\ H3-?_P"^[/\ ^2*/^$FU'_H3-?\ ^^[/_P"2*TSK
MNE!MO]H6Q.>0) <?6I4U.PDG6!+R!I6Z() 2>,]/I0!C_P#"3:C_ -"9K_\
MWW9__)%'_"3:C_T)FO\ _?=G_P#)%:8UW2C+)'_:%L&C^\#(!BE_MO2]@?\
MM&UVD9!\T<C.* ,O_A)M1_Z$S7_^^[/_ .2*/^$FU'_H3-?_ .^[/_Y(K3CU
MS3)8II$O866%#(^&Z*.I^GO2IK6F2211QWUNSRC**L@)88S_ "H R_\ A)M1
M_P"A,U__ +[L_P#Y(H_X2;4?^A,U_P#[[L__ )(K5FUK3+=-\M_;HI) )D')
M!Q2C5].9)'2]@<18+[7!V@G'/IS0!D_\)-J/_0F:_P#]]V?_ ,D4?\)-J/\
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MC_T)FO\ _?=G_P#)%'_"3:C_ -"9K_\ WW9__)%='10!SG_"3:C_ -"9K_\
MWW9__)%5[OQI<6/D?:?".OQ^?,L$?-H=SMT'$_M75USGB[_F!?\ 87M__9J
M#_A)M1_Z$S7_ /ONS_\ DBC_ (2;4?\ H3-?_P"^[/\ ^2*Z.B@#G/\ A)M1
M_P"A,U__ +[L_P#Y(H_X2;4?^A,U_P#[[L__ )(KHZ* .<_X2;4?^A,U_P#[
M[L__ )(IK^*=0CC9W\&Z^%4$D[K/@?\ @172U!??\>%S_P!<F_D: .=L_&-U
MJ%C;WMKX0U^2WN(UEB?=:#<K#(.#/GH:F_X2;4?^A,U__ONS_P#DBJO@_7M-
MB\)Z':2W(BECTVW#&0;5SY*' )X)PR_G6[)K=A'+ GG[_.5G1HU++M! ))'
M R.30!F?\)-J/_0F:_\ ]]V?_P D4?\ "3:C_P!"9K__ 'W9_P#R15YO$NC+
MR=0@QYGE$[Q@-Z&I6UO3EM_/-W&(A*(2V?X_[OUH S/^$FU'_H3-?_[[L_\
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MR#S7.U4#C)/TIIUK2U:13J%MNB!+CS1E0.N: ,K_ (2;4?\ H3-?_P"^[/\
M^2*/^$FU'_H3-?\ ^^[/_P"2*UO[7TX!-U[ N]0RAG )!. :C_M[2,9_M.TQ
MG'^N7K^= &;_ ,)-J/\ T)FO_P#?=G_\D4?\)-J/_0F:_P#]]V?_ ,D5JKK6
MFL&(O8/E.TC>,Y_R*=#JVGW$JQ17D#2MT0.-QXSTH R/^$FU'_H3-?\ ^^[/
M_P"2*/\ A)M1_P"A,U__ +[L_P#Y(K7_ +6T[;N^W6^W=MSY@Z^GUJ)=?TAH
MUD&I6NU@""91R",B@#-_X2;4?^A,U_\ [[L__DBC_A)M1_Z$S7_^^[/_ .2*
MUWU6P2XA@:\A$TV/+3>,MD$C _ U<H YS_A)M1_Z$S7_ /ONS_\ DBB/Q9*-
M0L;2]\.:Q8B]F\B*:X-N4W[&?!V3,>B-VKHZYSQ1_P A'PO_ -A<?^D\] ">
M,6"P:,QZ#5[8G_OJL22]\&SW3W'V::2<"2/(+#<<EV'7_;)^AK<\8 &'1@1D
M'5[;@_[U:XTK3@NT6%KMSG'DKU_+V'Y4=0Z6.1%KX1L=S&WG5FPC-YKDCC=U
MW=J@\WPG=W5T;B"\FD:5@3(6^4N<E0,\<FNW?3;&1MSV5NS9!R8E/]*4Z=8G
M=FRMSNY;]TO/UXHUZ!_7]?B<-*O@I;"S$MNZH58VZ>8_*[V'KZ@FG6DW@^SO
MS?QVEQ%<PN 'W,>2O Z]P#^ KMVTZQ<(&LK=A']P&)3M^G''4U#=:+IE[;26
M]Q8P-%(06 0+DCIR.:'NV&ZL_P"NYS5_9^%M)BBO)HIB)%!3]^Y7 Z9&<<5G
M$>");B/-I*6\I<,';A<#&>?3;7<-I&G2+&LEG"ZQ@A Z[@H_&FIHFEQVPMTL
M+=8@FP (,[?3/6E;<%MYG,1W7A73$1T6Z U16BV>8[>9SMP06QG@@&FV]SX7
MMY)=3@@G M2!O\QL?-P<+G%=5!HVFVT,,45C $@_U6Y Q3G/!//4FI5TVQ57
M5;*W"N<L!$N&/OQ5.S=V)[67]?UJ<)]E\#"%X_L\JB$^:8S*X^8*/]KKTS[Y
MHLM1\'"SOK2WM)E@N&B6Y!9OF;YBH!S_ +)]*[EM+T]V+-8VS$]285/]*0:1
MIJJ5&GV@!.2!"O/Z4D[(=W>Z_K^D<?,G@Z:SDOY([E(IF"MB61<[AUP&] >:
M2V7PG(5AM[2XVR12$[I' 5>">_4Y%=H=-L6C$;65N4'13$N!^&*!I]DK[UL[
M<,%VY$2YQZ=.E+T_K0%YG"%_!4>GM8_9)S%'-]I:,LV=QVKG);D8*G'3C-49
M[KP'%/)*]E</Y:Y#&1SD^F-U>CMI>GOG?8VS9&#F)3G]/:FG1]+/73;0_6!?
M\*I.P:Z'*3W/A2^:.QN+:4^4OD* 6PJI[@]JI26O@2UG6S>WFWB1BJ>8YRRG
M;G[WJ"*[L:;8+(9%LK8.>K")<G]*9'I&G1$E+&WW%V?<8P3N)R3D\]32=GJ)
M+0YN[C\+VL=U;3P2K'<JOG+N;!"_-Z\8 S5:QC\)ZUJODQ17(N7=I5'G.HSW
M88; -=C)I]E-)OEM('?IN:,$T0Z?96SAX+2")AT9(PI'Y"@>JV,<>"M#6!XE
MMI-KKLYF=L#VR>.E(/!NG-91VEQ)<3PJ[.0\I&_( P<8R!@<>U=%10"TV.<;
MP+X>>9YGLF>1SN9FF<G/KR:KZ38VVF^/;VTM(_+@32+;:N2<9GN">ON:ZNN<
MM_\ DI.H?]@BU_\ 1T].[M8#HZ***0!1110 5SGB[_F!?]A>W_\ 9JZ.N<\7
M?\P+_L+V_P#[-0!T=%%% %#6(KV?39(].D\JZ.-DA. OO[_2K%FLR64"W',P
M0!SNSEL<\U/10 5!??\ 'A<_]<F_D:GJ"^_X\+G_ *Y-_(T >;Z2/#T7A;2X
M]7TQ%66PLI6N V6D8PA5Z<CA#W_G6G?:AX/N7MHKB*X+6\3PQ*I92$(!8<'G
M@9Y["MKPE:6UQX&\/F:WBD/]FVWWT!Z1KCK]3^=:YTS3S)YAL;8N?XO*7/3'
MIZ<4 <=96?A2^CMH_LES"4C:>(&9P=N<DY#4V75/!J6<-L\#O:EC(JOE@K87
MD G@@$?3-=LMC:(05M8 5&T$1C@>E1_V3IW_ #X6O_?E?\*3N]_ZU_X8&E>Z
M,._OM >VBM[WS9HQ%M5F).5(W=<YS@9_"L6*V\%7NF32K:3_ &.S93_K'&23
MD8&[FNY?3K&1@TEG;LP&,M$"<?E2+IM@L;1K96P1CEE$2X)]^*?GU&M#DH+[
MPM=[X(()W6YE\Z3+,.6&[=UX! '2JUO<^"]-O+HQ)<13W43+,2[Y96 )ZGC@
M#\_>NV73;!&5ELK9648!$2@@8QCIZ4V?2=.N4=9K&W<.NTYC&<8QUIZ"6UCC
M(I/!UN4@B2\55W?(LTFT<$MD;O3.:H+_ ,(7;03.MO<R6T_SA6E;:#T(QGC)
M%>A)I.G1XV6%L,+MSY2YQC&.E!TG32 #I]J0.@\E>/TI6V_K^M07F<AH(\+Z
MG:S6%M;7$27>(VB:9R&"Y?@YX +'.,<FMN?P7H5R[M+:N2Z!&Q.XRHZ#K6K%
MI=A!<I<0VD4<J*R*R+MP#C/ XYVC\JMT.P.U]#"MO!VAVET;F&T(E*E=QE8\
M'KU-0)X$\/1P>2MG((SC*_:),' P,\\XR?SKI**+V%96L<\W@G0S;2P"WD D
M7;DS.Q'<8R?4"I8O">FBU6&X$MR0&!DDD.X[CDYQ[FMRB@9@1^#='2664Q3,
M\F1N,SC:"=V%P>.?2E_X0S0OM*7'V+]ZC%@QD;J<>_M6]12225@:ON8*^#-"
M2YAN%LL2PXV-YC<8Z=Z>?"6BM:PVS6>Z.$,(MSL6CW$D[3G())/3Z5MT4P>N
MYS@\"^'P8C]C<^4VZ/,[G:<@\<^PSZU)'X,T.)5$=M(I63S%83OD-Z@YK?HH
M!:;&+%X4T:&S>U2T(A>3S&4R,<MP,YS["B/PIH\4K2K;N79TD):5SROW>I[9
MZ5M44 8=WX1T>^01W,,TB"3S0C7$F W7@9XIC^#-#>Z%P;:7S5SM(G<!<DDX
M&>.2?SK?HHV'<QH/"ND6PQ#;NB^4T6T2OC:Q!/&>ORCGKQ36\)Z0]HMJT$IB
M5MV#.^3VP3G)'MTK;HH>NXCF7\":&(F6WAEMY#TDCE;*^XR:N6GAFPL; V=N
M9D1K8V['S"2PY.?KEF.?>MJBCOY@<]#X*T*&02BU9I?+,9=I6)8%=ISSW!JS
M!X8TNVOX[VWBDBN$4*&65ON@8P1G!XK8HHO;8#%F\*:1/-YLD,K'S/,QY[[=
MVXMTSCJ2?Q-,B\':)#-)*EJP:0@O^^?!.X-TSZ@5NT4!<QK3PMI5C-YL$<ZO
MYGF'-Q(<MZG)YJ)?!NAHURZVT@>Y;=*WGODGUSGC\*WJ* ,:?POI5PR&2*8[
M4V "=P",$<C//#,,^A--C\):+&\#):$&#_5_O&X_6MNB@+'.IX'T"-75+-U#
MD$XG?J/Q]ZLV7A;2+">.:WMV5X\;"96;;@, !D]/G;\ZV:*=V%SG%\$:*)6;
MR9-AZ)YK  YSD'.<YJ2+P7H,,K2)9D.R;"?-;I^=;]%(#('AG2AJ5OJ @?[3
M;ILB?S6^5<8QC.*UZ** W"N<\4?\A'PO_P!A<?\ I//71USGBC_D(^%_^PN/
M_2>>@"'QU;_:K#2H/.EA\S5;9?,A;:Z_-U![&IO^$2_ZF'7_ /P-_P#L:/&!
M AT8GH-7MO\ T*MXW,("$RH _P!W)ZT 8/\ PB7_ %,.O_\ @;_]C1_PB7_4
MPZ__ .!O_P!C70F1!U=1]32>=%OV>8F[TS0!S_\ PB7_ %,.O_\ @;_]C1_P
MB7_4PZ__ .!O_P!C70F2,'!=<^F::LT3H'612I[YXH P/^$2_P"IAU__ ,#?
M_L:/^$2_ZF'7_P#P-_\ L:Z#SHMQ7S$R!DC/:@31,.)%ZXZT <__ ,(E_P!3
M#K__ (&__8T?\(E_U,.O_P#@;_\ 8UT(D0C(=2/K4:74#RF)9D,@ZJ#S0!A?
M\(E_U,.O_P#@;_\ 8T?\(E_U,.O_ /@;_P#8UT'FQ@X\Q<_6E,B#JZCZF@#G
MO^$2_P"IAU__ ,#?_L:/^$2_ZF'7_P#P-_\ L:Z#SH_^>B?]]"D-Q"'V&5-W
MIF@# _X1+_J8=?\ _ W_ .QH_P"$2_ZF'7__  -_^QKH1(A. ZD^QH$B$X#J
M3[&@#GO^$2_ZF'7_ /P-_P#L:/\ A$O^IAU__P #?_L:Z S1#K(GYTPWEN#&
M#,G[P$IS]X>WYT 87_")?]3#K_\ X&__ &-'_")?]3#K_P#X&_\ V-=!YL?_
M #T7\Z:MS \0D65"A&<@]J ,'_A$O^IAU_\ \#?_ +&C_A$O^IAU_P#\#?\
M[&MV&[MYXQ)%,C(>AS3C/$.LJ=<?>[]* ,#_ (1+_J8=?_\  W_[&L&#PQGQ
M_?0?V[K8VZ7;OY@N_G.99A@G'08Z>YKORZ X+*#]:YZV(/Q(U @@C^R+7D?]
M=IZ #_A$O^IAU_\ \#?_ +&C_A$O^IAU_P#\#?\ [&NCHH YS_A$O^IAU_\
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M^QH_X1+_ *F'7_\ P-_^QKHZ* .<_P"$2_ZF'7__  -_^QH_X1+_ *F'7_\
MP-_^QKHZ* .<_P"$2_ZF'7__  -_^QH_X1+_ *F'7_\ P-_^QKHZ* .<_P"$
M2_ZF'7__  -_^QH_X1+_ *F'7_\ P-_^QKHZ* .<_P"$2_ZF'7__  -_^QH_
MX1+_ *F'7_\ P-_^QKHZ* .<_P"$2_ZF'7__  -_^QH_X1+_ *F'7_\ P-_^
MQKHZ* .<_P"$2_ZF'7__  -_^QH_X1+_ *F'7_\ P-_^QKHZ* .<_P"$2_ZF
M'7__  -_^QH_X1+_ *F'7_\ P-_^QKHZ* .<_P"$2_ZF'7__  -_^QH_X1+_
M *F'7_\ P-_^QKHZ* .<_P"$2_ZF'7__  -_^QH_X1+_ *F'7_\ P-_^QKHZ
M* .<_P"$2_ZF'7__  -_^QH_X1+_ *F'7_\ P-_^QKHZ* .<_P"$2_ZF'7__
M  -_^QH_X1+_ *F'7_\ P-_^QKHZ* .<_P"$2_ZF'7__  -_^QH_X1+_ *F'
M7_\ P-_^QKHZ* .<_P"$2_ZF'7__  -_^QH_X1+_ *F'7_\ P-_^QKHZ* .<
M_P"$2_ZF'7__  -_^QH_X1+_ *F'7_\ P-_^QKHZ* .<_P"$2_ZF'7__  -_
M^QH_X1+_ *F'7_\ P-_^QKHZ* .<_P"$2_ZF'7__  -_^QH_X1+_ *F'7_\
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M4L8'#B>Y=A*DN793RIR!TZ?X"H?^$UT[_GPU_P#\$5Y_\:H_X373O^?#7_\
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M_%UA/_8VVRUM?+U2!SOT:Z3(&[@9CY/L.: /0:*YS_A-=._Y\-?_ /!%>?\
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MAK__ ((KS_XU1_PFNG?\^&O_ /@BO/\ XU0!T=%<Y_PFNG?\^&O_ /@BO/\
MXU1_PFNG?\^&O_\ @BO/_C5 '1T5SG_":Z=_SX:__P""*\_^-4?\)KIW_/AK
M_P#X(KS_ .-4 ='17.?\)KIW_/AK_P#X(KS_ .-4?\)KIW_/AK__ ((KS_XU
M0!T=%<Y_PFNG?\^&O_\ @BO/_C5'_":Z=_SX:_\ ^"*\_P#C5 '1T5SG_":Z
M=_SX:_\ ^"*\_P#C5'_":Z=_SX:__P""*\_^-4 ='17.?\)KIW_/AK__ ((K
MS_XU1_PFNG?\^&O_ /@BO/\ XU0!T=%<Y_PFNG?\^&O_ /@BO/\ XU1_PFNG
M?\^&O_\ @BO/_C5 '1T5SG_":Z=_SX:__P""*\_^-4?\)KIW_/AK_P#X(KS_
M .-4 ='17.?\)KIW_/AK_P#X(KS_ .-4?\)KIW_/AK__ ((KS_XU0!T=%<Y_
MPFNG?\^&O_\ @BO/_C5'_":Z=_SX:_\ ^"*\_P#C5 '1T5SG_":Z=_SX:_\
M^"*\_P#C5'_":Z=_SX:__P""*\_^-4 ='17.?\)KIW_/AK__ ((KS_XU1_PF
MNG?\^&O_ /@BO/\ XU0!T=%<Y_PFNG?\^&O_ /@BO/\ XU1_PFNG?\^&O_\
M@BO/_C5 '1T5SG_":Z=_SX:__P""*\_^-4?\)KIW_/AK_P#X(KS_ .-4 ='1
M7.?\)KIW_/AK_P#X(KS_ .-4?\)KIW_/AK__ ((KS_XU0!T=%<Y_PFNG?\^&
MO_\ @BO/_C5'_":Z=_SX:_\ ^"*\_P#C5 '1T5SG_":Z=_SX:_\ ^"*\_P#C
M5'_":Z=_SX:__P""*\_^-4 ='17.?\)KIW_/AK__ ((KS_XU1_PFNG?\^&O_
M /@BO/\ XU0!T=%<Y_PFNG?\^&O_ /@BO/\ XU1_PFNG?\^&O_\ @BO/_C5
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MD8T^1]Z!@0#A3SG/'M1</(WJ*Q)?$#0I 3I]PQE3?\H.%'?/%5AXIF89&DW
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M&VW_ **6MN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N<\4?\A'PO_V%Q_Z3SUT=<YXH_P"0CX7_
M .PN/_2>>@!/&!"PZ,20 -7M>3_O5T'VB'_GM'_WT*YOQQ:V][8Z3;74$4]O
M+JULLD4J!E<;NA!X(JS_ ,(-X1_Z%;1/_!?%_P#$T ;?VB'_ )[1_P#?0H^T
M0_\ /:/_ +Z%8G_"#>$?^A6T3_P7Q?\ Q-'_  @WA'_H5M$_\%\7_P 30!M_
M:(?^>T?_ 'T*/M$/_/:/_OH5B?\ "#>$?^A6T3_P7Q?_ !-'_"#>$?\ H5M$
M_P#!?%_\30!M_:(?^>T?_?0H^T0_\]H_^^A6)_P@WA'_ *%;1/\ P7Q?_$T?
M\(-X1_Z%;1/_  7Q?_$T ;?VB'_GM'_WT*/M$/\ SVC_ .^A6)_P@WA'_H5M
M$_\ !?%_\31_P@WA'_H5M$_\%\7_ ,30!M_:(?\ GM'_ -]"C[1#_P ]H_\
MOH5B?\(-X1_Z%;1/_!?%_P#$T?\ "#>$?^A6T3_P7Q?_ !- &W]HA_Y[1_\
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MC[1#_P ]H_\ OH5B?\(-X1_Z%;1/_!?%_P#$T?\ "#>$?^A6T3_P7Q?_ !-
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MQ?\ Q-'_  @WA'_H5M$_\%\7_P 30!M_:(?^>T?_ 'T*/M$/_/:/_OH5B?\
M"#>$?^A6T3_P7Q?_ !-'_"#>$?\ H5M$_P#!?%_\30!M_:(?^>T?_?0H^T0_
M\]H_^^A6)_P@WA'_ *%;1/\ P7Q?_$T?\(-X1_Z%;1/_  7Q?_$T ;?VB'_G
MM'_WT*/M$/\ SVC_ .^A6)_P@WA'_H5M$_\ !?%_\31_P@WA'_H5M$_\%\7_
M ,30!M_:(?\ GM'_ -]"C[1#_P ]H_\ OH5B?\(-X1_Z%;1/_!?%_P#$T?\
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M0!M_:(?^>T?_ 'T*/M$/_/:/_OH5B?\ "#>$?^A6T3_P7Q?_ !-'_"#>$?\
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M2,]@@ .$4%>?_'O\^]7;K3KV9[EHIXX_-A$8Y/7CD_K^=)#IVHHVG,]VA^S
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M@'T^]^/Z>]=#10!D74^M1SOY%M'+$H7:. 6/?JU5$N?$K%7>SA4!&)0$<G.
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M@L-R_,.1TXH PO[6\4_]"O;_ /@T7_XBC^UO%/\ T*]O_P"#1?\ XBMPWUH
M";J'!Z'S!2_:[;:K>?$%;H2X&: ,+^UO%/\ T*]O_P"#1?\ XBC^UO%/_0KV
M_P#X-%_^(K<^VVF<?:82?0.,TOVRV/\ R\1?]]B@#"_M;Q3_ -"O;_\ @T7_
M .(H_M;Q3_T*]O\ ^#1?_B*W&O+9696N(U90"06 P#WIJ:A9R(&6YBP>F7 _
MSTH Q?[6\4_]"O;_ /@T7_XBL&#4_$?_  G]\X\.0&8Z7;AHO[1& OFS8.=G
M<DC'M[UW1O+82%#/&&&,@MZ]*P[?_DI.H?\ 8(M?_1T] !_:WBG_ *%>W_\
M!HO_ ,11_:WBG_H5[?\ \&B__$5T=% '.?VMXI_Z%>W_ /!HO_Q%']K>*?\
MH5[?_P &B_\ Q%='10!SG]K>*?\ H5[?_P &B_\ Q%8/B?4_$;_V-YOAR"/;
MJD!3&HAMS?-@?<X^M>@USGB[_F!?]A>W_P#9J #^UO%/_0KV_P#X-%_^(H_M
M;Q3_ -"O;_\ @T7_ .(KHZ* .<_M;Q3_ -"O;_\ @T7_ .(H_M;Q3_T*]O\
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MSG]K>*?^A7M__!HO_P 11_:WBG_H5[?_ ,&B_P#Q%='10!SG]K>*?^A7M_\
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M;K$\&?\ (B^'_P#L&VW_ **6MN@ HHHH **** "BBB@ HHHH **** "BBB@
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M:A_T..O_ )6G_P 8H_X1C4/^AQU_\K3_ .,5T=% '.?\(QJ'_0XZ_P#E:?\
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M?_&*/^$8U#_H<=?_ "M/_C%='10!SG_",:A_T..O_E:?_&*/^$8U#_H<=?\
MRM/_ (Q71T4 <Y_PC&H?]#CK_P"5I_\ &*/^$8U#_H<=?_*T_P#C%='10!SG
M_",:A_T..O\ Y6G_ ,8H_P"$8U#_ *''7_RM/_C%='10!SG_  C&H?\ 0XZ_
M^5I_\8H_X1C4/^AQU_\ *T_^,5T=% '.?\(QJ'_0XZ_^5I_\8H_X1C4/^AQU
M_P#*T_\ C%='10!SG_",:A_T..O_ )6G_P 8H_X1C4/^AQU_\K3_ .,5T=%
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M4IG>>A&#_.I)= T^:.)'B8B)0J_.>@&!_*L__A.O#_\ S\W/_@!/_P#$4?\
M"=>'_P#GYN?_   G_P#B* +D?AK3(F9DA8%I%D)WG[P)(_F:UZYS_A.O#_\
MS\W/_@!/_P#$4?\ "=>'_P#GYN?_   G_P#B* .CHKG/^$Z\/_\ /S<_^ $_
M_P 11_PG7A__ )^;G_P G_\ B* .CHKG/^$Z\/\ _/S<_P#@!/\ _$4?\)UX
M?_Y^;G_P G_^(H Z.BN<_P"$Z\/_ //S<_\ @!/_ /$4?\)UX?\ ^?FY_P#
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M /GYN?\ P G_ /B* .CHKG/^$Z\/_P#/S<_^ $__ ,11_P )UX?_ .?FY_\
M "?_ .(H Z.BN<_X3KP__P _-S_X 3__ !%'_"=>'_\ GYN?_ "?_P"(H Z.
MBN<_X3KP_P#\_-S_ . $_P#\11_PG7A__GYN?_ "?_XB@#HZ*YS_ (3KP_\
M\_-S_P" $_\ \11_PG7A_P#Y^;G_ , )_P#XB@#HZ*YS_A.O#_\ S\W/_@!/
M_P#$4?\ "=>'_P#GYN?_   G_P#B* .CHKG/^$Z\/_\ /S<_^ $__P 11_PG
M7A__ )^;G_P G_\ B* .CHKG/^$Z\/\ _/S<_P#@!/\ _$4?\)UX?_Y^;G_P
M G_^(H Z.BN<_P"$Z\/_ //S<_\ @!/_ /$4?\)UX?\ ^?FY_P# "?\ ^(H
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M_7)OY&IZ@OO^/"Y_ZY-_(T 9?@S_ )$7P_\ ]@VV_P#12UMUB>#/^1%\/_\
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M?_CU']F>+?\ H9=/_P#!2?\ X]0!T=%<Y_9GBW_H9=/_ /!2?_CU']F>+?\
MH9=/_P#!2?\ X]0!T=07W_'A<_\ 7)OY&L/^S/%O_0RZ?_X*3_\ 'JAO--\5
MBRN"WB2P(\ML@:21GC_KM0!>\&?\B+X?_P"P;;?^BEK;KA/">G>*'\&Z&T'B
M&QCA.GP%$;2RQ5?+7 )\T9P.^!6Q_9GBW_H9=/\ _!2?_CU '1T5SG]F>+?^
MAET__P %)_\ CU']F>+?^AET_P#\%)_^/4 ='17.?V9XM_Z&73__  4G_P"/
M4?V9XM_Z&73_ /P4G_X]0!T=%<Y_9GBW_H9=/_\ !2?_ (]1_9GBW_H9=/\
M_!2?_CU '1T5SG]F>+?^AET__P %)_\ CU']F>+?^AET_P#\%)_^/4 ='17.
M?V9XM_Z&73__  4G_P"/4?V9XM_Z&73_ /P4G_X]0!T=%<Y_9GBW_H9=/_\
M!2?_ (]1_9GBW_H9=/\ _!2?_CU '1T5SG]F>+?^AET__P %)_\ CU']F>+?
M^AET_P#\%)_^/4 ='17.?V9XM_Z&73__  4G_P"/4?V9XM_Z&73_ /P4G_X]
M0!T=%<Y_9GBW_H9=/_\ !2?_ (]1_9GBW_H9=/\ _!2?_CU '1T5SG]F>+?^
MAET__P %)_\ CU']F>+?^AET_P#\%)_^/4 ='17.?V9XM_Z&73__  4G_P"/
M4?V9XM_Z&73_ /P4G_X]0!T=%<Y_9GBW_H9=/_\ !2?_ (]1_9GBW_H9=/\
M_!2?_CU '1T5SG]F>+?^AET__P %)_\ CU']F>+?^AET_P#\%)_^/4 ='17.
M?V9XM_Z&73__  4G_P"/4?V9XM_Z&73_ /P4G_X]0!T=%<Y_9GBW_H9=/_\
M!2?_ (]1_9GBW_H9=/\ _!2?_CU '1T5SG]F>+?^AET__P %)_\ CU']F>+?
M^AET_P#\%)_^/4 ='17.?V9XM_Z&73__  4G_P"/4?V9XM_Z&73_ /P4G_X]
M0!T=%<Y_9GBW_H9=/_\ !2?_ (]1_9GBW_H9=/\ _!2?_CU '1T5SG]F>+?^
MAET__P %)_\ CU']F>+?^AET_P#\%)_^/4 ='17.?V9XM_Z&73__  4G_P"/
M4?V9XM_Z&73_ /P4G_X]0!T=%<Y_9GBW_H9=/_\ !2?_ (]1_9GBW_H9=/\
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M@BU_]'3T ='1110 4444 %<YXN_Y@7_87M__ &:NCKG/%W_,"_["]O\ ^S4
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MP_\ ]@VV_P#12UMUB>#/^1%\/_\ 8-MO_12UMT %%%% !1110 4444 %%%%
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M"=?_ /@9;?\ QRNCHH YS^WM>_Z$Z_\ _ RV_P#CE']O:]_T)U__ .!EM_\
M'*Z.B@#G/[>U[_H3K_\ \#+;_P".4?V]KW_0G7__ (&6W_QRNCHH YS^WM>_
MZ$Z__P# RV_^.4?V]KW_ $)U_P#^!EM_\<KHZ* .<_M[7O\ H3K_ /\  RV_
M^.4?V]KW_0G7_P#X&6W_ ,<KHZ* .<_M[7O^A.O_ /P,MO\ XY6#!K6M#Q_?
M2CPK>F4Z7;J8?M5OD 2S8;._&#DCKGBO0:YRW_Y*3J'_ &"+7_T=/0 ?V]KW
M_0G7_P#X&6W_ ,<H_M[7O^A.O_\ P,MO_CE='10!SG]O:]_T)U__ .!EM_\
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MC^WM>_Z$Z_\ _ RV_P#CE='10!SG]O:]_P!"=?\ _@9;?_'*/[>U[_H3K_\
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M($.C$]!J]M_Z%6XM[:MTN(^@/+8X- &'_86O_P#0X7G_ (!6_P#\11_86O\
M_0X7G_@%;_\ Q%;_ )\.,^:F,9SN'2FM>6R1&5IX_+'\6X8H PO["U__ *'"
M\_\  *W_ /B*/["U_P#Z'"\_\ K?_P"(K;-]:  FXBY&?O"@WUJ(?.-Q'Y?
MW;O6@#$_L+7_ /H<+S_P"M__ (BC^PM?_P"APO/_  "M_P#XBMX7,#' FC)Z
MX##-,CO[26-9$N8BC#<#O'2@#$_L+7_^APO/_ *W_P#B*/["U_\ Z'"\_P#
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MS^PM?_Z'"\_\ K?_ .(H_L+7_P#H<+S_ , K?_XBNCHH YS^PM?_ .APO/\
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M_?RL&#QKX:'C^^N3K5H(&TNWC5]_!82S$C\B/SH ]!HKG/\ A/O"G_0>LO\
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M] '1T444 %%%% !7.>+O^8%_V%[?_P!FKHZYSQ=_S O^PO;_ /LU '1T444
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MV)G.U>/:N8\="Y:PTH6;Q)<G5;;RVF0L@.[N 02/Q%3?9_&G_03T#_P7S?\
MQZ@#?D@BE_UD:-R#R.XZ4"")7+B- QZG%8'V?QI_T$] _P#!?-_\>H^S^-/^
M@GH'_@OF_P#CU '0[$SG:OY4V2"*50LD:LH(."/0YK ^S^-/^@GH'_@OF_\
MCU'V?QI_T$] _P#!?-_\>H Z'RTSG8OY4;%QC:,?2N>^S^-/^@GH'_@OF_\
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M]!/0/_!?-_\ 'J .CHKG/L_C3_H)Z!_X+YO_ (]1]G\:?]!/0/\ P7S?_'J
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M>H Z.BN<^S^-/^@GH'_@OF_^/4?9_&G_ $$] _\ !?-_\>H Z.BN<^S^-/\
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M<H Z.BN<_P"$%T#_ )X7G_@QN/\ XY1_P@N@?\\+S_P8W'_QR@#HZYSQ=_S
MO^PO;_\ LU'_  @N@?\ /"\_\&-Q_P#'*P?$_@W1+?\ L;RX;H>9JD$;9OIS
MP=V>K\?4<T >@T5SG_""Z!_SPO/_  8W'_QRC_A!= _YX7G_ (,;C_XY0!T=
M%<Y_P@N@?\\+S_P8W'_QRC_A!= _YX7G_@QN/_CE '1U!??\>%S_ -<F_D:P
M_P#A!= _YX7G_@QN/_CE0WG@?05LIV$%YD1L1_Q,+CT_WZ +W@S_ )$7P_\
M]@VV_P#12UMUPGA/P9H=SX-T.>6&[,DFGP.Q%_.HR8U)X#X'T%;'_""Z!_SP
MO/\ P8W'_P <H Z.BN<_X070/^>%Y_X,;C_XY1_P@N@?\\+S_P &-Q_\<H Z
M.BN<_P"$%T#_ )X7G_@QN/\ XY1_P@N@?\\+S_P8W'_QR@#HZ*YS_A!= _YX
M7G_@QN/_ (Y1_P (+H'_ #PO/_!C<?\ QR@#HZ*YS_A!= _YX7G_ (,;C_XY
M1_P@N@?\\+S_ ,&-Q_\ '* .CHKG/^$%T#_GA>?^#&X_^.4?\(+H'_/"\_\
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M?\\+S_P8W'_QR@#HZ*YS_A!= _YX7G_@QN/_ (Y1_P (+H'_ #PO/_!C<?\
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M8I!-"D@! =0P!]Z)(HYEVR(KJ#G##/-*B)&BHBA448"J, "@!U07W_'A<_\
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M_P#CU'_"47W_ $*&O_E;?_'JZ.B@#G/^$HOO^A0U_P#*V_\ CU0WGB>]:RN
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M.F:A-(XU9U\] ?+#C Y'(!_+\:U;?0=,M69H;;:6!!.]CP?J::?#NE&99C:
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M# Y)]*'U$DD8\=GI TV>U75.)9 S2!@#TP!QV[_C4%OHMA.K@ZQ,[( KE9.
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MZ_\ ^!2__$5OBXA,8D$J%",AL\4Y9$8 JZG/3!H Y[_A$Y/^AEU__P "E_\
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M /$4?\(G)_T,NO\ _@4O_P 170O(D2[G8*.F32JRNH92"I&010!SO_")R?\
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M,NO_ /@4O_Q%'_")R?\ 0RZ__P"!2_\ Q%='10!SG_")R?\ 0RZ__P"!2_\
MQ%'_  B<G_0RZ_\ ^!2__$5T=% '.?\ ")R?]#+K_P#X%+_\11_PB<G_ $,N
MO_\ @4O_ ,171T4 <Y_PB<G_ $,NO_\ @4O_ ,11_P (G)_T,NO_ /@4O_Q%
M='10!SG_  B<G_0RZ_\ ^!2__$4?\(G)_P!#+K__ (%+_P#$5T=% '.?\(G)
M_P!#+K__ (%+_P#$4?\ ")R?]#+K_P#X%+_\171T4 <Y_P (G)_T,NO_ /@4
MO_Q%'_")R?\ 0RZ__P"!2_\ Q%='10!SG_")R?\ 0RZ__P"!2_\ Q%'_  B<
MG_0RZ_\ ^!2__$5T=% '.?\ ")R?]#+K_P#X%+_\11_PB<G_ $,NO_\ @4O_
M ,171T4 <Y_PB<G_ $,NO_\ @4O_ ,11_P (G)_T,NO_ /@4O_Q%='10!SG_
M  B<G_0RZ_\ ^!2__$4?\(G)_P!#+K__ (%+_P#$5T=% '.?\(G)_P!#+K__
M (%+_P#$4?\ ")R?]#+K_P#X%+_\171T4 <Y_P (G)_T,NO_ /@4O_Q%'_")
MR?\ 0RZ__P"!2_\ Q%='10!SG_")R?\ 0RZ__P"!2_\ Q%9.K:&VFZWX8G.L
M:I> ZKM\NZF5T'^CS<X"CGC]:[FN<\4?\A'PO_V%Q_Z3ST 'B_\ U6B_]A>U
M_P#0JM2^&K2:?S6FN,D,-N\8Y8MTQZM^@JAXXN8+.QTFYNIXX((]6MF>65PJ
MJ-W4D\ 5;_X3;PG_ -#/HO\ X'Q?_%4!Y")X3LU))N+ER1@%BIQ^E/E\+V<U
MX;AI;C)<N4##:23GIBF_\)MX3_Z&?1?_  /B_P#BJ/\ A-O"?_0SZ+_X'Q?_
M !5 $0\(6V7#7=UL\S>BJP&.!P3CGD&IO^$6LQ,)%GN1A@VW<"./8BD_X3;P
MG_T,^B_^!\7_ ,51_P )MX3_ .AGT7_P/B_^*H!ZA<>%K6YN))FN[Q=YR5#C
M ^F1QBGV7ABSL<[)KAOD*#>XX!]..*9_PFWA/_H9]%_\#XO_ (JC_A-O"?\
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M1?\ P/B_^*H_X3;PG_T,^B_^!\7_ ,50!NU!??\ 'A<_]<F_D:R?^$V\)_\
M0SZ+_P"!\7_Q507GC7PJUC<*OB;1B3&P %_%SQ_O4 6?!G_(B^'_ /L&VW_H
MI:VZXGPEXP\,6_@S0H)_$>D12QZ?;H\;WT2LK"-0006X(-;/_";>$_\ H9]%
M_P# ^+_XJ@#=HK"_X3;PG_T,^B_^!\7_ ,51_P )MX3_ .AGT7_P/B_^*H W
M:*PO^$V\)_\ 0SZ+_P"!\7_Q5'_";>$_^AGT7_P/B_\ BJ -VBL+_A-O"?\
MT,^B_P#@?%_\51_PFWA/_H9]%_\  ^+_ .*H W:*PO\ A-O"?_0SZ+_X'Q?_
M !5'_";>$_\ H9]%_P# ^+_XJ@#=HK"_X3;PG_T,^B_^!\7_ ,51_P )MX3_
M .AGT7_P/B_^*H W:*PO^$V\)_\ 0SZ+_P"!\7_Q5'_";>$_^AGT7_P/B_\
MBJ -VBL+_A-O"?\ T,^B_P#@?%_\51_PFWA/_H9]%_\  ^+_ .*H W:*PO\
MA-O"?_0SZ+_X'Q?_ !5'_";>$_\ H9]%_P# ^+_XJ@#=HK"_X3;PG_T,^B_^
M!\7_ ,51_P )MX3_ .AGT7_P/B_^*H W:*PO^$V\)_\ 0SZ+_P"!\7_Q5'_"
M;>$_^AGT7_P/B_\ BJ -VBL+_A-O"?\ T,^B_P#@?%_\51_PFWA/_H9]%_\
M ^+_ .*H W:*PO\ A-O"?_0SZ+_X'Q?_ !5'_";>$_\ H9]%_P# ^+_XJ@#=
MHK"_X3;PG_T,^B_^!\7_ ,51_P )MX3_ .AGT7_P/B_^*H W:*PO^$V\)_\
M0SZ+_P"!\7_Q5'_";>$_^AGT7_P/B_\ BJ -VBL+_A-O"?\ T,^B_P#@?%_\
M51_PFWA/_H9]%_\  ^+_ .*H W:*PO\ A-O"?_0SZ+_X'Q?_ !5'_";>$_\
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MQ?RIU%;6,QOEQ_W%_*CRX_[B_E3J*+ -\N/^XOY4>7'_ '%_*G446 ;Y<?\
M<7\J/+C_ +B_E3J*+ -\N/\ N+^5'EQ_W%_*G446 ;Y<?]Q?RH\N/^XOY4ZB
MBP#?+C_N+^5'EQ_W%_*G446 ;Y<?]Q?RH\N/^XOY4ZBBP#?+C_N+^5'EQ_W%
M_*G446 ;Y<?]Q?RH\N/^XOY4ZBBP#?+C_N+^5'EQ_P!Q?RIU%%@&^7'_ '%_
M*CRX_P"XOY4ZBBP#?+C_ +B_E1Y<?]Q?RIU%%@&^7'_<7\J/+C_N+^5.HHL
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MB5E##4='(/.<R?X5''\-=?E=DCU71'93@@-(2/TH^OT._P" ?5JG8Y6BNO\
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MH^OT._X!]6J=CCZ*[#_A5?B?_G_TC_R+_A1_PJOQ/_S_ .D?^1?\*/K]#O\
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M](_\B_X4?\*K\3_\_P#I'_D7_"CZ_0[_ (!]6J=CCZ*[#_A5?B?_ )_](_\
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M_I'_ )%_PH^OT._X!]6J=CCZ*[#_ (57XG_Y_P#2/_(O^%'_  JOQ/\ \_\
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M-+_86F<?Z(ORXQ\QXQ^-'0!\.KV$\S0QW"&13C;^&?ZT^/5+&9F6.Y1BJEF
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M87DKR3VX=W #')&0.G0U''H6FQ !+50 <CYB>Q'K[FD ^36-/C@$[74?EDD
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M>V0A=H5,>F!0J0H<JJ ^P%8/_" ^#O\ H5=$_P# "+_XFC_A ?!W_0JZ)_X
M1?\ Q- &[Y4']R/\A4<EG9RRI(\,3.GW21TK&_X0'P=_T*NB?^ $7_Q-'_"
M^#O^A5T3_P  (O\ XF@#>,<+9W)&<]<@4GE0?\\X_P A6%_P@/@[_H5=$_\
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MT%/!4# ( ':N;'@CP2R*X\,Z%M89!-C%R/\ OFE/@CP2H!/AG0L$X_X\8O\
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M>&+G2]$TZRG;5=AEMK5(V*FWF.,J <<#\J -7QB2(-&(&2-7ML#U^:I;6;Q
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M99(E:1/NL>HJ:@ KG/%W_,"_["]O_P"S5T=<YXN_Y@7_ &%[?_V:@#HZ***
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M*9XD017OA2-22%U95&3SQ;SUN6NGVEEN^S0)%NZ[1UK%\4?\A'PO_P!A<?\
MI//1LK(&0^.KC[)8:5/Y4LOEZK;-Y<*[G;YN@'<U-_PER_\ 0 U__P  #_C1
MXO\ ]5HO_87M?_0JZ.@#G/\ A+E_Z &O_P#@ ?\ &C_A+E_Z &O_ /@ ?\:Z
M.B@#G/\ A+E_Z &O_P#@ ?\ &C_A+E_Z &O_ /@ ?\:Z.B@#G/\ A+E_Z &O
M_P#@ ?\ &C_A+E_Z &O_ /@ ?\:Z.B@#G/\ A+E_Z &O_P#@ ?\ &C_A+E_Z
M &O_ /@ ?\:Z.B@#G/\ A+E_Z &O_P#@ ?\ &C_A+E_Z &O_ /@ ?\:Z.B@#
MG/\ A+E_Z &O_P#@ ?\ &C_A+E_Z &O_ /@ ?\:Z.B@#G/\ A+E_Z &O_P#@
M ?\ &C_A+E_Z &O_ /@ ?\:Z.B@#G/\ A+E_Z &O_P#@ ?\ &C_A+E_Z &O_
M /@ ?\:Z.B@#G/\ A+E_Z &O_P#@ ?\ &C_A+E_Z &O_ /@ ?\:Z.B@#G/\
MA+E_Z &O_P#@ ?\ &C_A+E_Z &O_ /@ ?\:Z.B@#G/\ A+E_Z &O_P#@ ?\
M&L&#Q0H\?WT_]B:V=VEVZ>6+([QB68Y(STYZ^QKT&N<M_P#DI.H?]@BU_P#1
MT] !_P )<O\ T -?_P#  _XT?\)<O_0 U_\ \ #_ (UT=% '.?\ "7+_ - #
M7_\ P /^-'_"7+_T -?_ /  _P"-='10!SG_  ER_P#0 U__ , #_C6#XG\4
M+-_8W_$DUM-FJ0/\]D1NQNX'/)]J]!KG/%W_ # O^PO;_P#LU !_PER_] #7
M_P#P /\ C1_PER_] #7_ /P /^-='10!SG_"7+_T -?_ /  _P"-'_"7+_T
M-?\ _  _XUT=% '.?\)<O_0 U_\ \ #_ (U#>>+5:RN!_8.O#,;#)L3CI]:Z
MFH+[_CPN?^N3?R- '%^$_%*P>#M#B.AZW)LT^!=\=D65L1J,@YY%:S>*HG96
M;P[KI*'*DZ>>#C''/N:M>#/^1%\/_P#8-MO_ $4M;= '.?\ "6IC'_"/Z_\
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MU_\ \ #_ (T?\)<G_0OZ_P#^ !_QKHZ* .<_X2Y/^A?U_P#\ #_C1_PER?\
M0OZ__P" !_QKHZ* .<_X2Y?^A?U__P  #_C1_P ):G_0OZ]_X '_ !KHZ* .
M<_X2Y/\ H7]?_P#  _XT?\)<O_0OZ_\ ^ !_QKHZ* .:?Q5%(NU_#NNL,@X.
MGD\@Y'?UIW_"6I_T+^O_ /@ ?\:Z.B@#FD\50QL[)X=UU2YRQ&GGD^IYIW_"
M7+_T -?_ /  _P"-='10!SG_  ER_P#0 U__ , #_C1_PER_] #7_P#P /\
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M86"X7>$+#(QSRH&>W%4'N_&;R(RZ8L:M@LN^,[?7G?\ C4B7GC-RR-IEO&,
MK*9$/\0!!4-UP2>O:IU?]>7^>H^M_P"MRK8ZS#,8K.X\+HD<\^WY(@4 S@,0
M5'-4KO4-+DBN?-\*H;E&P-D!VN<DYX YX&?KU->@PF1H4,JA9,?,!V-/JNM_
MZ_JV@E>QY];:]!&MS<GPP%0QJLBHA V@C/!7'4^G;KQ5L^(-.ATR/[+X<26&
M=FW10Q#:2IP"?EP>:[4@,"" 0>"#WI$C2)0L:*BCLHP*%YCUMH<5'J-F!=E?
M"]O&((PX7R.KDD'^#IP.1D\CI5>U\0V3K Q\)>3(06W?9AA3C)Q\O<YKOZ,
M]12UM8>AP2^++.2SD>/PR)H8I@@$2 @OZXV_K4B:A8_V:UV/"ML(C*%\K[.
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MK?P/X:B,,;*\4D4&"_ Y)V\D$_@ ?I7<T4+3<?<XPZC:36(O7\,0%6F<,K1
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MW_0EZY_W^LO_ )(H_P"$DU;_ *$O7/\ O]9?_)%5[?QU:W<PC@LYB-X4NQ
MR>/TYKJZ/Z_45];'.?\ "2:M_P!"7KG_ '^LO_DBL&#7]3'C^^E_X1+6"YTN
MW4PB6TW*!+,=Q_?XP<D=<\'@<9]!KG+?_DI.H?\ 8(M?_1T] P_X235O^A+U
MS_O]9?\ R11_PDFK?]"7KG_?ZR_^2*Z.B@#G/^$DU;_H2]<_[_67_P D4?\
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MUS_O]9?_ "11_P ))JW_ $)>N?\ ?ZR_^2*Z RQ@@%U&>G-.# C((- '._\
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M/XF_Z&M?_!='_C4DWBF& SJ]K*#%)LYZ-R1GI_G-)'XH22[2(6L@0\%O]HD
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M>GZ4MQXA,%]) +.1DCSN?\L8X]S^5 $']C^)O^AK7_P71_XT?V/XF_Z&M?\
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M']C^)O\ H:U_\%T?^-='10!SG]C^)O\ H:U_\%T?^-']C^)O^AK7_P %T?\
MC7022I"F^1@J^IIRLKH&4Y4C(([T <[_ &/XF_Z&M?\ P71_XU#>:1XE%E<%
MO%*D>6V1_9T?/'UKJ:@OO^/"Y_ZY-_(T <7X3TKQ%)X-T-X?$PBB;3X"D?\
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M-='10!SG]C^)O^AK7_P71_XT?V/XF_Z&M?\ P71_XUT=% '.?V/XF_Z&M?\
MP71_XT?V/XF_Z&M?_!='_C71T4 <Y_8_B;_H:U_\%T?^-']C^)O^AK7_ ,%T
M?^-='10!SG]C^)O^AK7_ ,%T?^-']C^)O^AK7_P71_XUT=% '.?V/XF_Z&M?
M_!='_C1_8_B;_H:U_P#!='_C71T4 <Y_8_B;_H:U_P#!='_C1_8_B;_H:U_\
M%T?^-='10!SG]C^)O^AK7_P71_XT?V/XF_Z&M?\ P71_XUT=% '.?V/XF_Z&
MM?\ P71_XT?V/XF_Z&M?_!='_C71T4 <Y_8_B;_H:U_\%T?^-']C^)O^AK7_
M ,%T?^-='10!SG]C^)O^AK7_ ,%T?^-']C^)O^AK7_P71_XUT=% '.?V/XF_
MZ&M?_!='_C1_8_B;_H:U_P#!='_C71T4 <Y_8_B;_H:U_P#!='_C1_8_B;_H
M:U_\%T?^-='10!SG]C^)O^AK7_P71_XUDZM8:Q:ZWX8DO];%["=5P(A:+%@_
M9YN<@_7CWKN:YSQ1_P A'PO_ -A<?^D\] ">,MWV?1]OWO[6ML?7=3H[WQ)N
MP^GQ;57KD98_]]<5!XYN[>QL-*NKN>."WBU6V:265@JH-W4D\ 5/_P )_P"#
MO^AJT7_P/B_^*H EM+O7I)(&N;*.-"7\Q5P2,*=O.[N<5$E_XC(#/ID7WRI
M89V^O6C_ (3_ ,'?]#5HO_@?%_\ %4?\)_X._P"AJT7_ ,#XO_BJ&!;TF?5+
MOSEU6QCA48V8((;D^Y]JU/*CP!L7 .X<=#ZU@?\ "?\ @[_H:M%_\#XO_BJ/
M^$_\'?\ 0U:+_P"!\7_Q5 '145SO_"?^#O\ H:M%_P# ^+_XJC_A/_!W_0U:
M+_X'Q?\ Q5 '145SO_"?^#O^AJT7_P #XO\ XJC_ (3_ ,'?]#5HO_@?%_\
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MH_X3_P '?]#5HO\ X'Q?_%4 =%17._\ "?\ @[_H:M%_\#XO_BJ/^$_\'?\
M0U:+_P"!\7_Q5 '145SO_"?^#O\ H:M%_P# ^+_XJC_A/_!W_0U:+_X'Q?\
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MP9H<$_B31XIH]/MT>-[Z)65A&H((+<$&MC_A./"7_0T:)_X,(O\ XJA 4$U
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M'_/&/_OD4?9H/^>,?_?(K#">)6B+-<6BD]"N,#\QS4[0ZXM@(UFA:X$ARQ.
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M/_OD5+10!%]F@_YXQ_\ ?(H^S0?\\8_^^14M% $7V:#_ )XQ_P#?(H^S0?\
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M ,#H/_BJ5@&3^%;F=-IU>4'!!81G)'I]ZK?]@2E) VH2,S2F1&*_<]AS5?\
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M1M5<EPO_ "S/&.A^]_G-']N>(?\ H4;C_P #H/\ XJC^W/$/_0HW'_@=!_\
M%47#I8E7P]<>:K/JLS1C'[L+@>_.<U7L8VB^(5Y&SEV71;12Q_B(EGYI_P#;
MGB'_ *%&X_\  Z#_ .*K!@UC7!X_OI!X7G,ITNW4Q?;(<A1+-ALYQSDC'M1Y
M >@T5SG]N>(?^A1N/_ Z#_XJC^W/$/\ T*-Q_P"!T'_Q5 '1T5SG]N>(?^A1
MN/\ P.@_^*H_MSQ#_P!"C<?^!T'_ ,50!T=<YXN_Y@7_ &%[?_V:C^W/$/\
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M^W/$/_0HW'_@=!_\51_;GB'_ *%&X_\  Z#_ .*H Z.BN<_MSQ#_ -"C<?\
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MAK__ (/+O_XY0!T=%<Y_PA6G?]!#7_\ P>7?_P <H_X0K3O^@AK_ /X/+O\
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M!W<C,G!]QS0!Z#17.?\ "%:=_P!!#7__  >7?_QRC_A"M._Z"&O_ /@\N_\
MXY0!T=%<Y_PA6G?]!#7_ /P>7?\ \<H_X0K3O^@AK_\ X/+O_P".4 ='4%]_
MQX7/_7)OY&L/_A"M._Z"&O\ _@\N_P#XY4-YX,T];*X8:AKV1&QYUN[(Z?\
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M6G?]!#7_ /P>7?\ \<H Z.BN<_X0K3O^@AK_ /X/+O\ ^.4?\(5IW_00U_\
M\'EW_P#'* .CHKG/^$*T[_H(:_\ ^#R[_P#CE'_"%:=_T$-?_P#!Y=__ !R@
M#HZ*YS_A"M._Z"&O_P#@\N__ (Y1_P (5IW_ $$-?_\ !Y=__'* .CHKG/\
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M?QR: +,=_:3;?+G1MV,8[YZ4X7ML95B$R%V8J!GJ1U%48O#NFPL2D)Y(."W
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MP_Z%_7__  !/^-'_  EP_P"A?U__ , 3_C70O(D?WW5?J<4T3PDX$J$^FX4
M8'_"7#_H7]?_ / $_P"-8,'B@#Q_?3_V'K9W:7;IY8LSO&)9CDC/3GK[&O0:
MYRW_ .2DZA_V"+7_ -'3T '_  EP_P"A?U__ , 3_C1_PEP_Z%_7_P#P!/\
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M /@"?\:/^$N'_0OZ_P#^ )_QKHZ* .<_X2X?]"_K_P#X G_&C_A+A_T+^O\
M_@"?\:Z.B@#G/^$N'_0OZ_\ ^ )_QH_X2X?]"_K_ /X G_&NCHH YS_A+A_T
M+^O_ /@"?\:/^$N'_0OZ_P#^ )_QKHZ* .<_X2X?]"_K_P#X G_&C_A+A_T+
M^O\ _@"?\:Z.B@#G/^$N'_0OZ_\ ^ )_QH_X2X?]"_K_ /X G_&NCHH YS_A
M+A_T+^O_ /@"?\:/^$N'_0OZ_P#^ )_QKHZ* .<_X2X?]"_K_P#X G_&C_A+
MA_T+^O\ _@"?\:Z.B@#G/^$N'_0OZ_\ ^ )_QH_X2X?]"_K_ /X G_&NCHH
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M+XR3^M;E%38#+O=%2[6';,8VBC,8.,Y''7FJ:>&!'&@2\<2IC9)MY&,^_O\
MI70455P$ (4 G)]:YVW_ .2DZA_V"+7_ -'3UT=<Y;_\E)U#_L$6O_HZ>D!T
M=%%% %"[NKJ+4+:*&%GA?_6N$)V>G^>U7Z** "N<\7?\P+_L+V__ +-71USG
MB[_F!?\ 87M__9J .CHHHH **** "H+[_CPN?^N3?R-3U!??\>%S_P!<F_D:
M .,\,ZCJ]MX2T5HK)Y;5+&U0 (26'D(<C&21DD9Q6Y!K=^XEDN-,D@BCMWER
MRL,D=NGL:?X,_P"1%\/_ /8-MO\ T4M;= S!&N:@W(TF8KD!3M;YO?IT^M0R
MZ_J:2(4T>Y=&R<>4P('&,\<?SS7244"1D#4;^;3!<1V+QS;RK12*V<8Z]/7%
M0G5M1CM(96T^5F9B&7RVR/0D '%;M% &);ZO?SR&-],EB)A\P,RM@-C(7IUY
MQ]<TVVU74YX'#:<\<JP,^YD8 N.B].M;M%,#GEUS4D*I)I4[-CDK&^/Y8J<Z
MK>FTG=K&:.6-PJA8F??[CCI6U14@9#:C?),<V4K*+<N5"'[X(P >ASD\=>*I
M'Q!J3HX71[E'V$J6B<@MZ<"NDHI@9$^I7@L]R6SB<2;"BQ,_X].GO4)U74$M
MC*+*63]\R!3"ZMM &#C&<9SS6[10!C6VKWLM[%#)IDT<;]9"K87COQ3;'5-2
MFG2&?3W0E"S2%6 'H.E;=% '.1ZYJB(BS:5,SGJ5B? _3\/PJT-5U![6[8:9
M*)HD!C7!^<GZ^E;-%*V@=3&74M0^UHK:?,L7E%C\N<G'KV^E51X@U%EQ_8UR
MC$'DQN0#^ ^E='13 R/[4O$TR:=[%VN8@O[E58EL^G'^<&H[75[^XN8(Y--E
MA5QN9F1L*,=,XX-;=% &-;7^H2Y9K9O+VR$;XF1LCID$<9[5 FNZDT:DZ//G
M9N;Y&'/ITZ_TKH**.@&)/JNH1/"Z:?*\4D8)4(VY6]#QQ^--N]4U2VNHL6#2
MPM&"P1&;:V.>0*W:*!6,*'6K^2<*VE3I'O52Q1N <\].W%6)+G48XKQT@,A3
M/E97'0>G4Y[8K5HIC,1]5OHK6XF%C/.5FV(@B96*^N",D>]0)KNI3,@729H_
MF^8/&XR,$\'&/3\:Z*BD@&HQ9%8@@D9P>U.HHH **** "BBB@ HHHH ****
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MXT_Z#.@?^"F;_P"2:Z.B@#G/LOC3_H,Z!_X*9O\ Y)H^R^-/^@SH'_@IF_\
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IB;0_$5]J>F3ZKJVER6]C<_:1':Z?)$[MY;H!N:9@!\Y/3M7444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>img206306002_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206306002_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -O I # 2(  A$! Q$!_\0
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M17ENI>&+>%)A:^ -$<B5DC*Z>ARHZ,>.AJ.71=-LK:*6Z\ :-M;*LW]GIPV
M>@'0]!]*0_Z_4]6HKSV]\*Z&K6<EAX&TB:&6,O+NL$^7VZ=:QY]!B^RL8OAQ
MI/FLX4 :<GRC R>G/.:=M;?UV%<]:HKR>+0(&56?X=:2N#M(_LY/FX')X]:U
M(/#6@KH]Y<WO@71XKB*W::.,6"8; /R].O _.BP7/1**\N?0K! &7X:Z5*N
M2%L$!_E5BR\,:?/!>/<?#S18GA0&)/L2?O3GH#CM2*L>DT5YA'X:LII%(^'N
MD1(R X>P0X.<8/'XU+I.A^';V>XM[GP+I$4\49(06"#YAVR102G<]*HKS)O#
MFGEPL7P]T<C'+-IRCT_Q/_?/O21^&+)I8(W\ Z,JO<!&<:<G"9&6Z<<4TKNP
M-V/3J*\PG\-V)OFAA^'>DB)9-GFFQC(8>HXZ40Z+H<>J06=]X#T>)9"OS+IZ
MDD$?3C!X-):C[GI]%>8WWANQM;^\A@^'>CW$$;?NI18I\PP/;GO5<Z'86MHD
M]WX T95R!(3IR?)GO@#D4F[#L>K45YG<^'M,\RQ%G\/-'ECGA621VL$Q&Q&2
M.GX5J:'X+\/7L%S)J'@W1[=A-MB0V$8^3:I].>2>?:JM9V$G?4[BBN<_X5_X
M._Z%;1O_  "C_P *P?"?@CPK=6%^T_AS2I635+V-2]HA(59W"J..@   I >@
MT5SG_"O_  =_T*VC?^ 4?^%'_"O_  =_T*VC?^ 4?^% '1T5SG_"O_!W_0K:
M-_X!1_X4?\*_\'?]"MHW_@%'_A0!T=%<Y_PK_P '?]"MHW_@%'_A6#_PA'A7
M_A/_ ++_ ,(YI7V?^R_,\K[(FW=YN-V,=<<9H ]!HKG/^%?^#O\ H5M&_P#
M*/\ PH_X5_X._P"A6T;_ , H_P#"@#HZ*YS_ (5_X._Z%;1O_ */_"C_ (5_
MX._Z%;1O_ */_"@#HZ*YS_A7_@[_ *%;1O\ P"C_ ,*P?%G@CPK:V%@T'AS2
MHF?5+.-BEH@)5IT#*>.A!((H ]!HKG/^%?\ @[_H5M&_\ H_\*/^%?\ @[_H
M5M&_\ H_\* .CHKG/^%?^#O^A6T;_P  H_\ "C_A7_@[_H5M&_\  */_  H
MZ.BN<_X5_P"#O^A6T;_P"C_PH_X5_P"#O^A6T;_P"C_PH Z.BN<_X5_X._Z%
M;1O_  "C_P */^%?^#O^A6T;_P  H_\ "@#HZ*YS_A7_ (._Z%;1O_ */_"C
M_A7_ (._Z%;1O_ */_"@#HZ*YS_A7_@[_H5M&_\  */_  H_X5_X._Z%;1O_
M  "C_P * .CHKG/^%?\ @[_H5M&_\ H_\*/^%?\ @[_H5M&_\ H_\* .CHKG
M/^%?^#O^A6T;_P  H_\ "C_A7_@[_H5M&_\  */_  H Z.BN<_X5_P"#O^A6
MT;_P"C_PH_X5_P"#O^A6T;_P"C_PH Z.BN<_X5_X._Z%;1O_  "C_P */^%?
M^#O^A6T;_P  H_\ "@#HZ*YS_A7_ (._Z%;1O_ */_"C_A7_ (._Z%;1O_ *
M/_"@#HZ*YS_A7_@[_H5M&_\  */_  H_X5_X._Z%;1O_  "C_P * .CHKG/^
M%?\ @[_H5M&_\ H_\*/^%?\ @[_H5M&_\ H_\* .CHKG/^%?^#O^A6T;_P
MH_\ "C_A7_@[_H5M&_\  */_  H Z.BN<_X5_P"#O^A6T;_P"C_PH_X5_P"#
MO^A6T;_P"C_PH Z.BN<_X5_X._Z%;1O_  "C_P */^%?^#O^A6T;_P  H_\
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M!NI?]A>__P#2AZZ.N<\&?\@W4O\ L+W_ /Z4/2 Z.BBB@ HHHH *YS_FI/\
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M]*K6O@Z>VU&.[.M7+[&#%-N V!CGGOUI=;_UM_P2;$NIZ5KJW$\VC7<43S2
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M910#U.5N+3Q>\DH@O;:-2WR$L#A<GML]-N.3CGKD8;)IWBXBX"ZG PV[8E;
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M(RA&<_E3U\0Z2]C]M6^B-MYGE^9SC=Z4 9_]L^)?^A3/_@QC_P */[9\2_\
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MXI[^(]*BF,4MVJ.&*X*GJ*FZM<91_MGQ+_T*9_\ !C'_ (4?VSXE_P"A3/\
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M_<(_]K5T=<Y_S4G_ +A'_M:@#HZ*** ,G5/[5^WV7V!2;<./M/*_=SVR>O\
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M'O)))!YR3D\U-_PB.@Y!_LV+@DCD]3U[U>L=+L]-,QM(1'YS!G Z9"A1CT&
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M8PAD)$@/R@9)Q]"/SH R/^$'T?\ Y[:U_P"#R]_^.T?\(/H__/;6O_!Y>_\
MQVMB+5+"=-\=Y R[2_\ K!P!U-..H62A2;RW ?E<RKS].: ,7_A!]'_Y[:U_
MX/+W_P".T?\ "#Z-_P ]M9_\'E[_ /':UAJ^FMG%_;8'?S1@_0]Z=_:NG;-_
MV^UVC^+SEQ_/WH Q(_ 6A0H$B;5T4?PKK5X!_P"C:?\ \(/H_P#SVUK_ ,'E
M[_\ ':UXM6TZ:988KV"21LX5'!/'6AM6TU(VD:_M=BC)/FK_ (^QH R/^$'T
M?_GMK7_@\O?_ ([1_P (/H__ #VUK_P>7O\ \=K6BU?39T5H[ZW(8@#,@!R>
M@P>>:NT <Y_P@^C_ //;6O\ P>7O_P =H_X0?1_^>VM?^#R]_P#CM='10!SG
M_"#Z/_SVUK_P>7O_ ,=H_P"$'T?_ )[:U_X/+W_X[71T4 <Y_P (/H__ #VU
MK_P>7O\ \=H_X0?1_P#GMK7_ (/+W_X[71T4 <Y_P@^C_P#/;6O_  >7O_QV
MC_A!]'_Y[:U_X/+W_P".UT=% '.?\(/H_P#SVUK_ ,'E[_\ ':P?"?@_2KBP
MOVDEU8%=4O8QLUB[086=P,A91DX')/)ZG)KT&N<\&?\ (-U+_L+W_P#Z4/0
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MO0:YSQF<:;IQ/_07L?\ TH2@ _X0?1_^>VM?^#R]_P#CM'_"#Z/_ ,]M:_\
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MH_\ SVUK_P 'E[_\=KHZ* .<_P"$'T?_ )[:U_X/+W_X[1_P@^C_ //;6O\
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MD1BV^:2"I%2?\)YX:_Z")_[\2?\ Q-'_  GGAK_H(G_OQ)_\31<"./P%HJB
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M .)H Z.BN<_X3SPU_P!!$_\ ?B3_ .)H_P"$\\-?]!$_]^)/_B: .CHKG/\
MA//#7_01/_?B3_XFC_A//#7_ $$3_P!^)/\ XF@#HZ*YS_A//#7_ $$3_P!^
M)/\ XFC_ (3SPU_T$3_WXD_^)H Z.N<\&?\ (-U+_L+W_P#Z4/1_PGGAK_H(
MG_OQ)_\ $U@^$_&?A^VL+]9;_:6U2]D'[F0Y5IW(/"^AH ]!HKG/^$\\-?\
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M!(LVU(UB!60@[1NP,_\  C5?_A//#7_01/\ WXD_^)H_X3SPU_T$3_WXD_\
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M\UG-K.K_ &-V_P"$=99L'9_H[$G'J .#2R:]JLL\<4/AV98@ 6WV[=2!GM@
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M3[GQ;JEE&DMSH\D<3DJ'=6&"!D#IW[4NP^MOZVN=C7.>#/\ D&ZE_P!A>_\
M_2AZZ")_,A20C!90<>F:Y_P9_P @W4O^PO?_ /I0] '1T444 %%%% !7.?\
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MGV#QC_T,6C?^":3_ .2:/L'C'_H8M&_\$TG_ ,DT ='17.?8/&/_ $,6C?\
M@FD_^2:/L'C'_H8M&_\ !-)_\DT ='17.?8/&/\ T,6C?^":3_Y)H^P>,?\
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M\A&L.J.<X&>.G?/M0@.BHK,T^QO;6ZF>XO6GA881&R2OYUIT %%%% !1110
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M%,HTAR!(@8 ^<OK6Y_8VE_\ 0-L_^_"_X4 5_P#A*/#_ /T'=,_\"X_\:/\
MA*/#_P#T'=,_\"X_\:L?V-I?_0-L_P#OPO\ A1_8VE_] VS_ ._"_P"% %?_
M (2CP_\ ]!W3/_ N/_&C_A*/#_\ T'=,_P# N/\ QJQ_8VE_] VS_P"_"_X4
M?V-I?_0-L_\ OPO^% %?_A*/#_\ T'=,_P# N/\ QH_X2CP__P!!W3/_  +C
M_P :L?V-I?\ T#;/_OPO^%']C:7_ - VS_[\+_A0!7_X2CP__P!!W3/_  +C
M_P :/^$H\/\ _0=TS_P+C_QJQ_8VE_\ 0-L_^_"_X4?V-I?_ $#;/_OPO^%
M%?\ X2CP_P#]!W3/_ N/_&C_ (2CP_\ ]!W3/_ N/_&K']C:7_T#;/\ [\+_
M (4?V-I?_0-L_P#OPO\ A0!7_P"$H\/_ /0=TS_P+C_QH_X2CP__ -!W3/\
MP+C_ ,:L?V-I?_0-L_\ OPO^%']C:7_T#;/_ +\+_A0!7_X2CP__ -!W3/\
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M^-'_  E'A_\ Z#NF?^!<?^-6/[&TO_H&V?\ WX7_  H_L;2_^@;9_P#?A?\
M"@"O_P )1X?_ .@[IG_@7'_C1_PE'A__ *#NF?\ @7'_ (U8_L;2_P#H&V?_
M 'X7_"C^QM+_ .@;9_\ ?A?\* *__"4>'_\ H.Z9_P"!<?\ C1_PE'A__H.Z
M9_X%Q_XU8_L;2_\ H&V?_?A?\*/[&TO_ *!MG_WX7_"@"O\ \)1X?_Z#NF?^
M!<?^-'_"4>'_ /H.Z9_X%Q_XU8_L;2_^@;9_]^%_PH_L;2_^@;9_]^%_PH K
M_P#"4>'_ /H.Z9_X%Q_XT?\ "4>'_P#H.Z9_X%Q_XU8_L;2_^@;9_P#?A?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG(/\
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MI,[DJ<S#D'@]N."17H-<YX,_Y!NI?]A>_P#_ $H>@ _X2+6?^A+UC_P)L_\
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M3J6^UI'\S+B7Y2<#)QGM0!1_X2+6?^A+UC_P)L__ (_1_P )%K/_ $)>L?\
M@39__'ZT9]?TV"V:X^TK(BNL9\KYB&)P!@4V3Q%I444,KWD828;D;/&*+!<H
M?\)%K/\ T)>L?^!-G_\ 'Z/^$BUG_H2]8_\  FS_ /C]:,?B#29%#"^A&1D!
MFP<>M.;7-,24Q27L*2!BNUFP2:5P,S_A(M9_Z$O6/_ FS_\ C]'_  D6L_\
M0EZQ_P"!-G_\?K377=*9@JZA;DDX #BA]=TJ/=OU"W78=K9<<'_(I@9G_"1:
MS_T)>L?^!-G_ /'Z/^$BUG_H2]8_\";/_P"/UH2^(=(A1WDU&W 0$M\XX &:
M2Z\0Z793RP3W2+)%MWK_ '=W2BP7*'_"1:S_ -"7K'_@39__ !^C_A(M9_Z$
MO6/_  )L_P#X_6G_ &YI9C:3[?;[%ZMO'%']N:7S_I]OQU^<<<9H S/^$BUG
M_H2]8_\  FS_ /C]'_"1:S_T)>L?^!-G_P#'ZT7U_2X[@0/>Q*YC$@)/!4^A
MIZ:WIDI<1WL,A1=S!&R0/7]: ,O_ (2+6?\ H2]8_P# FS_^/T?\)%K/_0EZ
MQ_X$V?\ \?K5EUC3H)U@FO88Y7P51G )STXJO#XFT:<S!-0A_=,5<EL<B@"E
M_P )%K/_ $)>L?\ @39__'Z/^$BUG_H2]8_\";/_ ./UHCQ!I1#G[;%M23RB
MV[C=@''Y$4^;6M-MY4CFO849TWC+?P^OZT 9?_"1:S_T)>L?^!-G_P#'Z/\
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M7L#1Q8,C!QA<],T 9/\ PD6L_P#0EZQ_X$V?_P ?H_X2+6?^A+UC_P ";/\
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M6TVZI>IB._=0<3N,GW.,D]S7H-<YX,_Y!NI?]A>__P#2AZ #_A#XO^@YK_\
MX,I*/^$/B_Z#FO\ _@RDKHZ* .<_X0^+_H.:_P#^#*2C_A#XO^@YK_\ X,I*
MZ.B@#G/^$/B_Z#FO_P#@RDK!_P"$6B_X3_R/[8UO']E[]_V]]_\ K<8SZ>U>
M@USG_-2?^X1_[6H /^$/B_Z#FO\ _@RDH_X0^+_H.:__ .#*2NCHH YS_A#X
MO^@YK_\ X,I*/^$/B_Z#FO\ _@RDK?DN(HG5))%5F^Z#WJ2@#G/^$/B_Z#FO
M_P#@RDK!\6>%HH+"P8:QK;[M4LTQ)?NP&9T&1[C/![&O0:YSQG_R#M-_["]C
M_P"E"4 '_"'Q?]!S7_\ P924?\(?%_T'-?\ _!E)71T4 <Y_PA\7_0<U_P#\
M&4E'_"'Q?]!S7_\ P925T=% '.?\(?%_T'-?_P#!E)1_PA\7_0<U_P#\&4E=
M'10!SG_"'Q?]!S7_ /P924?\(?%_T'-?_P#!E)71T4 <Y_PA\7_0<U__ ,&4
ME'_"'Q?]!S7_ /P925T=% '.?\(?%_T'-?\ _!E)1_PA\7_0<U__ ,&4E='1
M0!SG_"'Q?]!S7_\ P924?\(?%_T'-?\ _!E)71T4 <Y_PA\7_0<U_P#\&4E'
M_"'Q?]!S7_\ P925T=% '.?\(?%_T'-?_P#!E)1_PA\7_0<U_P#\&4E='10!
MSG_"'Q?]!S7_ /P924?\(?%_T'-?_P#!E)71T4 <Y_PA\7_0<U__ ,&4E'_"
M'Q?]!S7_ /P925T=% '.?\(?%_T'-?\ _!E)1_PA\7_0<U__ ,&4E='10!SG
M_"'Q?]!S7_\ P924?\(?%_T'-?\ _!E)71T4 <Y_PA\7_0<U_P#\&4E'_"'Q
M?]!S7_\ P925T=% '.?\(?%_T'-?_P#!E)1_PA\7_0<U_P#\&4E='10!SG_"
M'Q?]!S7_ /P924?\(?%_T'-?_P#!E)71T4 <Y_PA\7_0<U__ ,&4E'_"'Q?]
M!S7_ /P925T=% '.?\(?%_T'-?\ _!E)1_PA\7_0<U__ ,&4E='10!SG_"'Q
M?]!S7_\ P924?\(?%_T'-?\ _!E)71T4 <Y_PA\7_0<U_P#\&4E'_"'Q?]!S
M7_\ P925T=% '.?\(?%_T'-?_P#!E)1_PA\7_0<U_P#\&4E='10!SG_"'Q?]
M!S7_ /P924?\(?%_T'-?_P#!E)71T4 <Y_PA\7_0<U__ ,&4E4=$TQ=+^(.I
M0K=WER&TJV;==SF5A^]G& 3VXZ5V-<Y!_P E)U#_ +!%M_Z.GH BN[=+KX@?
M9Y,A)-&=6QUP95J\_ABQ=I6,EP&DD,A(<<$GMQTK'U;58M)^(=O++;7LX?2G
M4"TM7G8?O5ZA 2![U?\ ^$SL_P#H%:__ .">X_\ B* N6X/#5C "%>8Y# EF
M!)!&/2G1>'K.&Z6='FRK!@I(P"/PJE_PF=G_ - K7_\ P3W'_P 11_PF=G_T
M"M?_ /!/<?\ Q% K+8E?PCI\B[6FNMN_>!Y@./;ITJQ:^'[.T%SY;S$W&-Q9
M@2.2>./>J7_"9V?_ $"M?_\ !/<?_$4?\)G9_P#0*U__ ,$]Q_\ $4#)$\(:
M>BE?-N2",<N/\*E?PS9LTY$UROG$EMK 8R<D#BJW_"9V?_0*U_\ \$]Q_P#$
M4?\ "9V?_0*U_P#\$]Q_\10'6Y93PO8H\3"2<^7RH+#'\J;=>&8;N9Y7NIE8
MRAQMQ@#CCWZ=:@_X3.S_ .@5K_\ X)[C_P"(H_X3.S_Z!6O_ /@GN/\ XBA:
M; 2R^%[=C&T-S-&R\$MAMPJ>7PY92L[%IE+LS-M8#.XY/:J?_"9V?_0*U_\
M\$]Q_P#$4?\ "9V?_0*U_P#\$]Q_\10!>7P_9+#Y0,H3_>']UAGI_M'\A4$?
MA6PC>)O,N&\LY 9P0?KQ4'_"9V?_ $"M?_\ !/<?_$4?\)G9_P#0*U__ ,$]
MQ_\ $4 ;5A91Z?9I:Q,[(F<%SD\G/]:LUSG_  F=G_T"M?\ _!/<?_$4?\)G
M9_\ 0*U__P $]Q_\10!T=%<Y_P )G9_] K7_ /P3W'_Q%'_"9V?_ $"M?_\
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M_B*P?%GBRUN+"P5=-UM=NJ6;YDTN=00)T.!E>3QP.I/% 'H-%<Y_PF=G_P!
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M_P! K7__  3W'_Q%'_"9V?\ T"M?_P#!/<?_ !% '1T5SG_"9V?_ $"M?_\
M!/<?_$4?\)G9_P#0*U__ ,$]Q_\ $4 ='17.?\)G9_\ 0*U__P $]Q_\11_P
MF=G_ - K7_\ P3W'_P 10!T=%<Y_PF=G_P! K7__  3W'_Q%'_"9V?\ T"M?
M_P#!/<?_ !% '1T5SG_"9V?_ $"M?_\ !/<?_$4?\)G9_P#0*U__ ,$]Q_\
M$4 ='17.?\)G9_\ 0*U__P $]Q_\11_PF=G_ - K7_\ P3W'_P 10!T=%<Y_
MPF=G_P! K7__  3W'_Q%'_"9V?\ T"M?_P#!/<?_ !% '1T5SG_"9V?_ $"M
M?_\ !/<?_$4?\)G9_P#0*U__ ,$]Q_\ $4 ='17.?\)G9_\ 0*U__P $]Q_\
M11_PF=G_ - K7_\ P3W'_P 10!T=%<Y_PF=G_P! K7__  3W'_Q%'_"9V?\
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M7XT_Y^= _P# >;_XN@#HZ*YSR_&G_/SH'_@/-_\ %T>7XT_Y^= _\!YO_BZ
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M71Y?C3_GYT#_ ,!YO_BZ .CKG/&?_(.TW_L+V/\ Z4)1Y?C3_GYT#_P'F_\
MBZP?%B>+186'VBXT0K_:EGM\N"4'=YZ;<Y?IG&?:@#T&BN<\OQI_S\Z!_P"
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M<\OQI_S\Z!_X#S?_ !='E^-/^?G0/_ >;_XN@#HZ*YSR_&G_ #\Z!_X#S?\
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M_P 30!I?;[+_ )^X/^_@_P :YWQC>VC:=IP6ZA.-6L2<2#I]H2M#_A#O"_\
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MV^R_Y^X/^_@_QH^WV7_/W!_W\'^-9O\ PAWA?_H6]'_\ 8O_ (FC_A#O"_\
MT+>C_P#@#%_\30!I?;[+_G[@_P"_@_QH^WV7_/W!_P!_!_C6;_PAWA?_ *%O
M1_\ P!B_^)H_X0[PO_T+>C_^ ,7_ ,30!I?;[+_G[@_[^#_&C[?9?\_<'_?P
M?XUF_P#"'>%_^A;T?_P!B_\ B:/^$.\+_P#0MZ/_ . ,7_Q- &E]OLO^?N#_
M +^#_&C[?9?\_<'_ '\'^-9O_"'>%_\ H6]'_P# &+_XFC_A#O"__0MZ/_X
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ME);S3J[E(5+/^[/ 'X=?;K4C:1ISJBM90$(<J"@X/^12II5A&LBI:0J)%*N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZCH?>O0:YSP9_P @W4O^PO?_ /I0] !_PE<__0KZ_P#]^(O_ (Y1_P )7/\
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M<_\ T*^O_P#?B+_XY1_PE<__ $*^O_\ ?B+_ ..5T=% '.?\)7/_ -"OK_\
MWXB_^.4?\)7/_P!"OK__ 'XB_P#CE='10!SG_"5S_P#0KZ__ -^(O_CE'_"5
MS_\ 0KZ__P!^(O\ XY71T4 <Y_PE<_\ T*^O_P#?B+_XY1_PE<__ $*^O_\
M?B+_ ..5T=% '.?\)7/_ -"OK_\ WXB_^.4?\)7/_P!"OK__ 'XB_P#CE='1
M0!SG_"5S_P#0KZ__ -^(O_CE'_"5S_\ 0KZ__P!^(O\ XY71T4 <Y_PE<_\
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M["]C_P"E"4 ='1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5SD'_)2=0_[!%M_P"CIZZ.N<@_Y*3J'_8(MO\ T=/0!0U;3I-2
M^(=O'%J=[8%=*=B]H4#-^]7@[E;BK_\ PBUW_P!#9K__ 'W!_P#&JHZQ/<VW
MCI9+2-Y)?[*(VHFXX\]<\5)'K/B!HD\S3I4/S%CY))QV&/7K0.VERU_PBUW_
M -#9K_\ WW!_\:H_X1:[_P"ALU__ +[@_P#C56IM5O(@-MF\C>7&Q0(202&S
MP/\ = _&JTVNZE##-,VE.(XESDJV3].*=N@KB?\ "+7?_0V:_P#]]P?_ !JC
M_A%KO_H;-?\ ^^X/_C5))K>KM/LCTF94"YWF-N3^52V6L:I-</'-I4J+@E7*
MD X'O[_SI)W'8C_X1:[_ .ALU_\ [[@_^-4?\(M=_P#0V:__ -]P?_&J0ZSK
M,C+Y6E21C<%(D1O7G\*MWFK7ML)_+T^>9@5\M5C;!! SR!V-'2XEJ[%7_A%K
MO_H;-?\ ^^X/_C5'_"+7?_0V:_\ ]]P?_&J5]9U;S(U&ER 8!;Y&/49ZX[9Y
M^E/35M5F>(#3GB#,<ED;H/PXS2N!'_PBUW_T-FO_ /?<'_QJC_A%KO\ Z&S7
M_P#ON#_XU5E]7O([6"9M.D!?/F @C9CUJL==U-FW1Z1,T>S<ORGG.,?S-, _
MX1:[_P"ALU__ +[@_P#C5'_"+7?_ $-FO_\ ?<'_ ,:JQ::KJ$T]NMQ8F 2L
M1@@YX'3G\_P-5YM9U=BZQ:5*A3C+(2&/;% !_P (M=_]#9K_ /WW!_\ &J/^
M$6N_^ALU_P#[[@_^-5;M-0U&>[DAELGB09 E*G&?;U%5UU35X94A?3Y)LJ6:
M780!C/''?@?F*!)W&?\ "+7?_0V:_P#]]P?_ !JC_A%KO_H;-?\ ^^X/_C5/
MBUG59C%_Q*I(U:0*Q96X7UZ4K:AK4#3.;!IH]\@C4#!PK$#IZC!YH&1_\(M=
M_P#0V:__ -]P?_&J/^$6N_\ H;-?_P"^X/\ XU4C:QJN"W]E28P" %.<\\?I
M^HIUOK6H37D44FDSQQ,P!D*GCWH6H7(?^$6N_P#H;-?_ .^X/_C5'_"+7?\
MT-FO_P#?<'_QJII=7U.-I/\ B52,H/R[58YXSZ5$VLZLMTJG2I3&4R2$8@'@
M]<?A]:%J#$_X1:[_ .ALU_\ [[@_^-5@^$_#=S-87[+XFUN+;JEZF(WAP2)W
M&XYB/)ZGW/:M^37=1MX1-/IS)&2 Q8'Y,^M0> 9C<Z#>3E=ADU2]8J>V;AZ
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M=_\ 0V:__P!]P?\ QJNCHH YS_A%KO\ Z&S7_P#ON#_XU1_PBUW_ -#9K_\
MWW!_\:KHZ* .<_X1:[_Z&S7_ /ON#_XU1_PBUW_T-FO_ /?<'_QJNCHH YS_
M (1:[_Z&S7_^^X/_ (U1_P (M=_]#9K_ /WW!_\ &JZ.B@#G/^$6N_\ H;-?
M_P"^X/\ XU1_PBUW_P!#9K__ 'W!_P#&JZ.B@#G/^$6N_P#H;-?_ .^X/_C5
M'_"+7?\ T-FO_P#?<'_QJNCHH YS_A%KO_H;-?\ ^^X/_C5'_"+7?_0V:_\
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M/^$YT+^_J'_@KNO_ (W1_P )SH7]_4/_  5W7_QN@#HZ*YS_ (3G0O[^H?\
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MD_\ B*/J=?\ E#V]/N>O5SG_ #4G_N$?^UJX3_A;.O?] /3?_ N3_P"(K/\
M^%BZY_PD7]K_ -D:=N^R?9?+^U/C&_=G.RCZG7_E#V]/N>W45Y#_ ,+9U[_H
M!Z;_ .!<G_Q%'_"V=>_Z >F_^!<G_P 11]3K_P H>WI]SUZBO(?^%LZ]_P!
M/3?_  +D_P#B*/\ A;.O?] /3?\ P+D_^(H^IU_Y0]O3[GKU<YXS_P"0;IO_
M &%['_TH2N$_X6SKW_0#TW_P+D_^(K/UCXBZYJ]O;PMI&G1B&[@N@1=.<F.1
M7Q]SOMQ1]3K_ ,H>WI]STVX\&Z=<W8N))KO(W_*)!M.YBQXQZL:J1_#_ $I'
MW-<WLAW(W[QT/W<X_A]^?H*XW_A;.O?] /3?_ N3_P"(H_X6SKW_ $ ]-_\
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M(@G=,]'T308]$$ZQSO(CE1&K#'EHJ@!>/?)S[UKUY#_PMG7O^@'IO_@7)_\
M$4?\+9U[_H!Z;_X%R?\ Q%'U2O\ RB]O3[GKU%>0_P#"V=>_Z >F_P#@7)_\
M11_PMG7O^@'IO_@7)_\ $4?4Z_\ *'MZ?<]>HKR'_A;.O?\ 0#TW_P "Y/\
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MO^@'IO\ X%R?_$4?4Z_\H>WI]SUZBO(?^%LZ]_T ]-_\"Y/_ (BC_A;.O?\
M0#TW_P "Y/\ XBCZG7_E#V]/N>O45Y#_ ,+9U[_H!Z;_ .!<G_Q%'_"V=>_Z
M >F_^!<G_P 11]3K_P H>WI]SUZBO(?^%LZ]_P! /3?_  +D_P#B*/\ A;.O
M?] /3?\ P+D_^(H^IU_Y0]O3[GKU%>0_\+9U[_H!Z;_X%R?_ !%'_"V=>_Z
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MJGF@\CO\A_.NN52I=V6GH^W^9SJ,;*^YGIX:U.2S2[6%3"X!4[ASFEF\+ZM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKM_A+_R-&M_]>5O_ .ARUQ%=O\)?^1HUO_KRM_\ T.6N+,/X#.C#?Q"+XK_\
MCCIG_8/?_P!&"N-KV#6-#TK7?B';PZKI]O>QQZ4[(L\88*?-49&:O?\ "O/!
MW_0LZ7_X#+_A7!A\=[&GR<M_F=-7#\\N:YXC17MW_"O/!W_0LZ7_ . R_P"%
M'_"O/!W_ $+.E_\ @,O^%;_VI_<_'_@&?U/S/$:*]N_X5YX._P"A9TO_ ,!E
M_P */^%>>#O^A9TO_P !E_PH_M3^Y^/_   ^I^9XC17MW_"O/!W_ $+.E_\
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M_P */^%>>#O^A9TO_P !E_PH_M3^Y^/_   ^I^9XC17MW_"O/!W_ $+.E_\
M@,O^%8/A3P+X5N["_>X\/Z=*R:I>1J7@4X19W51]   */[4_N?C_ , /J?F>
M7T5[=_PKSP=_T+.E_P#@,O\ A1_PKSP=_P!"SI?_ (#+_A1_:G]S\?\ @!]3
M\SQ&BO;O^%>>#O\ H6=+_P# 9?\ "C_A7G@[_H6=+_\  9?\*/[4_N?C_P
M/J?F>(T5[=_PKSP=_P!"SI?_ (#+_A6#_P (+X5_X3[[)_PC^G?9_P"R_,\K
MR%V[_-QG'KCBC^U/[GX_\ /J?F>7T5[=_P *\\'?]"SI?_@,O^%'_"O/!W_0
MLZ7_ . R_P"%']J?W/Q_X ?4_,\1HKV[_A7G@[_H6=+_ / 9?\*/^%>>#O\
MH6=+_P# 9?\ "C^U/[GX_P# #ZGYGB-%>W?\*\\'?]"SI?\ X#+_ (5@^*_
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M^ R_X4?\*\\'?]"SI?\ X#+_ (4?VI_<_'_@!]3\SQ&BO;O^%>>#O^A9TO\
M\!E_PH_X5YX._P"A9TO_ ,!E_P */[4_N?C_ , /J?F>(T5[=_PKSP=_T+.E
M_P#@,O\ A1_PKSP=_P!"SI?_ (#+_A1_:G]S\?\ @!]3\SQ&BO;O^%>>#O\
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M^ R_X4?\*\\'?]"SI?\ X#+_ (4?VI_<_'_@!]3\SQ&BO;O^%>>#O^A9TO\
M\!E_PH_X5YX._P"A9TO_ ,!E_P */[4_N?C_ , /J?F>(T5[=_PKSP=_T+.E
M_P#@,O\ A1_PKSP=_P!"SI?_ (#+_A1_:G]S\?\ @!]3\SQ&BO;O^%>>#O\
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M^ R_X4?\*\\'?]"SI?\ X#+_ (4?VI_<_'_@!]3\SQ&BO;O^%>>#O^A9TO\
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M798Y&@TP*IC)C;J=WTR*O"\U1;YXWM0UN!D/C'ZY_I6M10!S$6LZ[<^4T.F
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MHZ* .<_MSQ#_ -"C<?\ @=!_\51_;GB'_H4;C_P.@_\ BJZ.B@#G/[<\0_\
M0HW'_@=!_P#%4?VYXA_Z%&X_\#H/_BJZ.B@#G/[<\0_]"C<?^!T'_P 51_;G
MB'_H4;C_ ,#H/_BJZ.B@#G/[<\0_]"C<?^!T'_Q5']N>(?\ H4;C_P #H/\
MXJNCHH YS^W/$/\ T*-Q_P"!T'_Q58/A/6-<CL+\1>%YY0=4O6)%Y",,9W)7
MD]CQGVKT&N<\&?\ (-U+_L+W_P#Z4/0 ?VYXA_Z%&X_\#H/_ (JC^W/$/_0H
MW'_@=!_\571T4 <Y_;GB'_H4;C_P.@_^*H_MSQ#_ -"C<?\ @=!_\571T4 <
MY_;GB'_H4;C_ ,#H/_BJP?[8US_A/_,_X1>?S?[+V^5]LASM\W[V<X]L5Z#7
M.?\ -2?^X1_[6H /[<\0_P#0HW'_ ('0?_%4?VYXA_Z%&X_\#H/_ (JNCHH
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M Z.BBB@"A;&__M*X$ZD6G_+$\9]\\_E[5?HHH *YS_FI/_<(_P#:U='7.?\
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M[]JWJ* .7C'B)IBTD.")#L/R'Y?3K[#'XU=N)=;6&V\JW#.V6E *_+Z#)/\
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M<16WQ$CEF;:@TAAG!/)F7L*W5U&S9%<7,0#=,MC^= &-_P (_KG_ $.6I?\
M@):__&J/^$?US_H<M2_\!+7_ .-5M1W]I,',=S$VPX;YNE*M_:.N1<Q8_P!\
M"@#$_P"$?US_ *'+4O\ P$M?_C5'_"/ZY_T.6I?^ EK_ /&JZ.B@#G/^$?US
M_H<M2_\  2U_^-4?\(_KG_0Y:E_X"6O_ ,:KHZ* .<_X1_7/^ARU+_P$M?\
MXU1_PC^N?]#EJ7_@):__ !JNCHH YS_A']<_Z'+4O_ 2U_\ C5'_  C^N?\
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MO_T&(/R;_"C_ (3WPO\ ]!B#\F_PH Z.BN<_X3WPO_T&(/R;_"C_ (3WPO\
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M82E^R^-/^@SH'_@IF_\ DFL'Q9;>+5L+#[1JVB.O]J6841Z9*I#>>FTG,YR
M<9'<=QUH WX/"4$"*HO+@[1A<XXJ6S\,Q6<MO(MU,[PR,X+ '.1C'X<X^IJ'
M[+XT_P"@SH'_ (*9O_DFC[+XT_Z#.@?^"F;_ .2:=V!:E\/1R7,EPMW<(\C;
MGPW!]L?3(_&J/_"&0X8?VA<_-ZXXYS4GV7QI_P!!G0/_  4S?_)-'V7QI_T&
M= _\%,W_ ,DTK:6'=C[?PNEK)))'>SEV5@ <!02,=!^'Y"D_X192A!OYU8@
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M RY'H*1*ZBYDVF/RU 4#8,YXH_X1^ P6L3SRN+<G;D]<^HJG]E\:?]!G0/\
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MR^-/^@SH'_@IF_\ DFC[+XT_Z#.@?^"F;_Y)H Z.BN<^R^-/^@SH'_@IF_\
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M%&H*YC8*P1&;!/T'^<CUJS%X=T>&)(TTVV"J<@>6.N,$_E3DT'24)*Z=; G
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MCHKG/^$$\._\^4W_ (&3?_%T?\()X=_Y\IO_  ,F_P#BZ .CHKG/^$$\._\
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MM;7[F8V+IG=QP1T[G\JD,GC,*V(;<L4!7#)PW<'VKK**0SF)D\4^;!-&T>3
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MG'^9XU,$6ZWM_,'WL.HYS_A5R)O%(L+PR1P&YV@VXRO7<0<XX^[M/U-=)12
MX_[1XRN$4QV\,>& ;=M!."#GGL1D5/8MXO,L;7JVZH) '5=O*=SGUKJ:*$!A
M:*?$#:G>MJR1I:<"W"%3QD\G'?G'X5NT44 ]PKG(/^2DZA_V"+;_ -'3UT=<
MY!_R4G4/^P1;?^CIZ ,W6[I[;Q_!MT6ZU57TIPT5OY.5_?*<GS748^A)K0C\
M0WT*!(O!&NHH& JM9 #_ ,F*<W_)28_^P0__ *.6NCH YS_A)M2_Z$S7_P#O
MNS_^2*/^$FU+_H3-?_[[L_\ Y(KHZ* .<_X2;4O^A,U__ONS_P#DBC_A)M2_
MZ$S7_P#ONS_^2*Z.B@#G/^$FU+_H3-?_ .^[/_Y(H_X2;4O^A,U__ONS_P#D
MBNCHH YS_A)M2_Z$S7_^^[/_ .2*/^$FU+_H3-?_ .^[/_Y(KHZ* .<_X2;4
MO^A,U_\ [[L__DBC_A)M2_Z$S7_^^[/_ .2*Z.B@#G/^$FU+_H3-?_[[L_\
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M_P#DBC_A)M2_Z$S7_P#ONS_^2*Z+(]12Y'K0!SG_  DVI?\ 0F:__P!]V?\
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M1ZTQY8X\;W5<G R>IH Y_P#X2;4O^A,U_P#[[L__ )(H_P"$FU+_ *$S7_\
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M110!0MI;UM2N$FC(M1_JFV]?7/\ 2K]%% !7.?\ -2?^X1_[6KHZYS_FI/\
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M>)_^AIB_\%J?_%5T'G19(\Q<CWH\Z+&?,3'^\* .?_LCQ/\ ]#3%_P""U/\
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M<*2F#GJ2-M!\*V3 AIKDY&/O+Q^E,_X3SP?_ -#7H?\ X,(O_BJ/^$\\'_\
M0UZ'_P"#"+_XJ@"_<Z/#>"+[1)(YB/RD8'?Z5GGP=8%G;[1>9<Y)\P>_M[FE
M_P"$\\'_ /0UZ'_X,(O_ (JC_A//!_\ T->A_P#@PB_^*H 6Z\*P2Q2B"YEA
MDDXW$!@!C'3BI+OPU;W,\LXN;B.608/S J/P(J+_ (3SP?\ ]#7H?_@PB_\
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M81?_ !58'A/QIX6MM/OUG\2Z/$S:I>R*'OHE)5IW*L,MT(((/<&@#OZ*Y_\
MX3SP?_T->A_^#"+_ .*H_P"$\\'_ /0UZ'_X,(O_ (J@#5@TZ*WOIKQ6<RS?
M?R1@^G:K=<__ ,)YX/\ ^AKT/_P81?\ Q5'_  GG@_\ Z&O0_P#P81?_ !5
M'05SG_-2?^X1_P"UJ?\ \)YX/_Z&O0__  81?_%5@?\ ":>%O^%@?:?^$ET?
M[/\ V7Y?F_;HMN[S<[<[L9QSB@#OZ*Y__A//!_\ T->A_P#@PB_^*H_X3SP?
M_P!#7H?_ (,(O_BJ .@HKG_^$\\'_P#0UZ'_ .#"+_XJC_A//!__ $->A_\
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MY<?]Q?RIU% #?+C_ +B_E1Y<?]Q?RIU% #?+C_N+^5'EQ_W%_*G44 -\N/\
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MN<QXT_O:!^4W^-&/&G][0/RF_P : .CHKG,>-/[V@?E-_C1CQI_>T#\IO\:
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M,VF:P+MIK:\C 90-KL>"%QZ>M206>MI+"\MY$RAOG0$G(_[YZY_I3$;5%%%
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M\'MY_P#': .CHKG/^$)TK_G[UW_P>WG_ ,=H_P"$)TK_ )^]=_\ ![>?_':
M.CHKG/\ A"=*_P"?O7?_  >WG_QVC_A"=*_Y^]=_\'MY_P#': .CHKG/^$)T
MK_G[UW_P>WG_ ,=H_P"$)TK_ )^]=_\ ![>?_': .CHKG/\ A"=*_P"?O7?_
M  >WG_QVC_A"=*_Y^]=_\'MY_P#': .CHKG/^$)TK_G[UW_P>WG_ ,=H_P"$
M)TK_ )^]=_\ ![>?_': .CHKG/\ A"=*_P"?O7?_  >WG_QVC_A"=*_Y^]=_
M\'MY_P#': .CHKG/^$)TK_G[UW_P>WG_ ,=H_P"$)TK_ )^]=_\ ![>?_':
M.CHKG/\ A"=*_P"?O7?_  >WG_QVC_A"=*_Y^]=_\'MY_P#': .CHKG/^$)T
MK_G[UW_P>WG_ ,=H_P"$)TK_ )^]=_\ ![>?_': .CKG/!G_ "#=2_["]_\
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M_P (3I7_ #]Z[_X/;S_X[1_PA.E?\_>N_P#@]O/_ ([0!T=<YXS_ .0=IO\
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M^(BQR*&1M'<,IZ$><M;#:/IS[]UG$=[;F^7J?6@>A''KFG3/MCN-W!)(1L
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ME8_@S_D&ZE_V%[__ -*'I@='1110 4444 %<Y_S4G_N$?^UJZ.N<_P":D_\
M<(_]K4 ='1110!5N;^&UG@AEW;YVVQX&<GTJU4,MK!-(KRQ*[K]TD=*FH *Y
MSQG_ ,@[3?\ L+V/_I0E='7.>,_^0=IO_87L?_2A* .CHHHH **** "BBB@
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M_P#BJ/\ A+6_Z%S7_P#P$'_Q5='10!SG_"6M_P!"YK__ ("#_P"*H_X2UO\
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MPGX=OIK"_*^*];A"ZI>J1&+;#$3N"QS">3U/;)X Z5Z#7.>#/^0;J7_87O\
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M?_&*/^$8U#_H<=?_ "M/_C%='10!SG_",:A_T..O_E:?_&*/^$8U#_H<=?\
MRM/_ (Q71T4 <Y_PC&H?]#CK_P"5I_\ &*/^$8U#_H<=?_*T_P#C%='10!SG
M_",:A_T..O\ Y6G_ ,8H_P"$8U#_ *''7_RM/_C%='10!SG_  C&H?\ 0XZ_
M^5I_\8H_X1C4/^AQU_\ *T_^,5T=% '.?\(QJ'_0XZ_^5I_\8H_X1C4/^AQU
M_P#*T_\ C%='10!SG_",:A_T..O_ )6G_P 8H_X1C4/^AQU_\K3_ .,5T=%
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M\))H7_0:T[_P*3_&C_A)-"_Z#6G?^!2?XT@-.BLS_A)-"_Z#6G?^!2?XT?\
M"2:%_P!!K3O_  *3_&@#3HK,_P"$DT+_ *#6G?\ @4G^-'_"2:%_T&M._P#
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M^@UIW_@4G^- &G169_PDFA?]!K3O_ I/\:/^$DT+_H-:=_X%)_C0!IT5F?\
M"2:%_P!!K3O_  *3_&C_ (230O\ H-:=_P"!2?XT :=%9G_"2:%_T&M._P#
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M?_ =/\*RO^$O@()6TFPN-V:N2^((H[NVMUA=FGC63.>%!..:!7+/]AZ1_P!
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M'_0*L?\ P'3_  J_10!0_L/2/^@58_\ @.G^%']AZ1_T"K'_ ,!T_P *OT4
M4/[#TC_H%6/_ (#I_A1_8>D?] JQ_P# =/\ "K]% %#^P](_Z!5C_P" Z?X4
M?V'I'_0*L?\ P'3_  J_10!0_L/2/^@58_\ @.G^%']AZ1_T"K'_ ,!T_P *
MOT4 4/[#TC_H%6/_ (#I_A1_8>D?] JQ_P# =/\ "K]% %#^P](_Z!5C_P"
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M%']AZ1_T"K'_ ,!T_P *OT4 4/[#TC_H%6/_ (#I_A1_8>D?] JQ_P# =/\
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MG/M/C3_H$Z!_X,YO_C%'VGQI_P! G0/_  9S?_&* .CHKG/M/C3_ *!.@?\
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M,YO_ (Q1]I\:?] G0/\ P9S?_&* .CHKG/M/C3_H$Z!_X,YO_C%'VGQI_P!
MG0/_  9S?_&* .CHKG/M/C3_ *!.@?\ @SF_^,4?:?&G_0)T#_P9S?\ QB@#
MHZ*YS[3XT_Z!.@?^#.;_ .,4?:?&G_0)T#_P9S?_ !B@#HZ*YS[3XT_Z!.@?
M^#.;_P",4?:?&G_0)T#_ ,&<W_QB@#HZ*YS[3XT_Z!.@?^#.;_XQ1]I\:?\
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M_P! G0/_  9S?_&* .CHKG/M/C3_ *!.@?\ @SF_^,4?:?&G_0)T#_P9S?\
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MC_A O"O_ $!+7\C_ (T ='17.?\ "!>%?^@):_D?\:/^$"\*_P#0$M?R/^-
M'1T5SG_"!>%?^@):_D?\:/\ A O"O_0$M?R/^- '1T5SG_"!>%?^@):_D?\
M&C_A O"O_0$M?R/^- '1T5SG_"!>%?\ H"6OY'_&C_A O"O_ $!+7\C_ (T
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M5_Z EK^1_P :/^$"\*_] 2U_(_XT ='17.?\(%X5_P"@):_D?\:/^$"\*_\
M0$M?R/\ C0!T=%<Y_P (%X5_Z EK^1_QH_X0+PK_ - 2U_(_XT ='17.?\(%
MX5_Z EK^1_QH_P"$"\*_] 2U_(_XT ='17.?\(%X5_Z EK^1_P :/^$"\*_]
M 2U_(_XT ='17.?\(%X5_P"@):_D?\:/^$"\*_\ 0$M?R/\ C0!T=%<Y_P (
M%X5_Z EK^1_QH_X0+PK_ - 2U_(_XT ='17.?\(%X5_Z EK^1_QH_P"$"\*_
M] 2U_(_XT ='17.?\(%X5_Z EK^1_P :/^$"\*_] 2U_(_XT ='17.?\(%X5
M_P"@):_D?\:/^$"\*_\ 0$M?R/\ C0!T=%<Y_P (%X5_Z EK^1_QH_X0+PK_
M - 2U_(_XT ='17.?\(%X5_Z EK^1_QH_P"$"\*_] 2U_(_XT ='17.?\(%X
M5_Z EK^1_P :/^$"\*_] 2U_(_XT ='17.?\(%X5_P"@):_D?\:/^$"\*_\
M0$M?R/\ C0!T=%<Y_P (%X5_Z EK^1_QH_X0+PK_ - 2U_(_XT ='7.0?\E)
MU#_L$6W_ *.GH_X0+PK_ - 2U_(_XU;TGPMH^A7\]YIEFMM)/$D4@0G:0I8C
'CU^8T ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>img206306002_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206306002_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *D!= # 2(  A$! Q$!_\0
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M^AXTO_P 3_XB@#T^BO,/^$=^+W_0\:7_ . "?_$4?\([\7O^AXTO_P  $_\
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M^AXTO_P 3_XB@#T^BO,/^$=^+W_0\:7_ . "?_$4?\([\7O^AXTO_P  $_\
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M6[^*MUX\O?":^+[!;FTM%NFF-C'L925&!\F<_-71?\([\7O^AXTO_P  $_\
MB* /3Z*\P_X1WXO?]#QI?_@ G_Q%'_"._%[_ *'C2_\ P 3_ .(H ]/HKS#_
M (1WXO?]#QI?_@ G_P 11_PCOQ>_Z'C2_P#P 3_XB@#T^BO,/^$=^+W_ $/&
ME_\ @ G_ ,11_P ([\7O^AXTO_P 3_XB@#T^BO,/^$=^+W_0\:7_ . "?_$4
M?\([\7O^AXTO_P  $_\ B* /3Z*\P_X1WXO?]#QI?_@ G_Q%'_"._%[_ *'C
M2_\ P 3_ .(H ]/HKS#_ (1WXO?]#QI?_@ G_P 11_PCOQ>_Z'C2_P#P 3_X
MB@#T^BO#O%5W\5?"ATD7'B^PG_M*^2R3R[&,;&;H3E.E=%_PCOQ>_P"AXTO_
M , $_P#B* /3Z*\P_P"$=^+W_0\:7_X )_\ $4?\([\7O^AXTO\ \ $_^(H
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M^AXTO_P 3_XBC_A'?B]_T/&E_P#@ G_Q% 'I]%>8?\([\7O^AXTO_P  $_\
MB*/^$=^+W_0\:7_X )_\10!Z?17F'_"._%[_ *'C2_\ P 3_ .(H_P"$=^+W
M_0\:7_X )_\ $4 >GT5YA_PCOQ>_Z'C2_P#P 3_XBC_A'?B]_P!#QI?_ ( )
M_P#$4 >GT5YA_P ([\7O^AXTO_P 3_XBC_A'?B]_T/&E_P#@ G_Q% 'I]%>8
M?\([\7O^AXTO_P  $_\ B*/^$=^+W_0\:7_X )_\10!Z?17F'_"._%[_ *'C
M2_\ P 3_ .(H_P"$=^+W_0\:7_X )_\ $4 >GT5YA_PCOQ>_Z'C2_P#P 3_X
MBC_A'?B]_P!#QI?_ ( )_P#$4 >GT5YA_P ([\7O^AXTO_P 3_XBC_A'?B]_
MT/&E_P#@ G_Q% 'I]%>8?\([\7O^AXTO_P  $_\ B*/^$=^+W_0\:7_X )_\
M10!Z?17F'_"._%[_ *'C2_\ P 3_ .(H_P"$=^+W_0\:7_X )_\ $4 >GT5Y
MA_PCOQ>_Z'C2_P#P 3_XBC_A'?B]_P!#QI?_ ( )_P#$4 >GT5YA_P ([\7O
M^AXTO_P 3_XBC_A'?B]_T/&E_P#@ G_Q% 'I]%>8?\([\7O^AXTO_P  $_\
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M^AXTO_P 3_XBC_A'?B]_T/&E_P#@ G_Q% 'I]%>8?\([\7O^AXTO_P  $_\
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M^AXTO_P 3_XBC_A'?B]_T/&E_P#@ G_Q% 'I]%>8?\([\7O^AXTO_P  $_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \PTC_ ).-U_\ [ L?_H4=>GUYAI'_ "<;K_\ V!8__0HZ]/H
M**** "BBB@ HHHH **** "BBB@ HHHH \P^,?W_!G_8P6_\ 6O3Z\P^,?W_!
MG_8P6_\ 6O3Z "BBB@ HHHH **** "BBB@ HHHH **** ,+QK_R(?B+_ +!E
MS_Z*:LKX3_\ )+/#_P#U[?\ LS5J^-?^1#\1?]@RY_\ 135E?"?_ ))9X?\
M^O;_ -F:@#LJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#KV_\ 9FK5\:_\B'XB_P"P9<_^BFK*^$__ "2SP_\ ]>W_ +,U '94444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH ]/HKS#_B]/_4J?^1:/^+T_]2I_Y%H ]/HKS#_B]/\ U*G_ )%H_P"+T_\
M4J?^1: /3Z*\P_XO3_U*G_D6C_B]/_4J?^1: /3Z*\P_XO3_ -2I_P"1:/\
MB]/_ %*G_D6@#LO&O_(A^(O^P9<_^BFK*^$__)+/#_\ U[?^S-7'>)?^%N_\
M(MJ_]H?\(S]A^Q3?:/*\S?Y>P[MN>^,XJAX"_P"%J?\ "#:3_8G_  CO]F>3
M_H_VGS/,V[C]['&<YH ]RHKS#_B]/_4J?^1:/^+T_P#4J?\ D6@#T^BO,/\
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M#_B]/_4J?^1:/^+T_P#4J?\ D6@#T^BO,/\ B]/_ %*G_D6C_B]/_4J?^1:
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MDX%0K>VSQ+*LZ%&;:&!X)]* )Z*** "BBF-*BMM+ -Z4 /HHIOF)NV[AN]*
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ML4444 >8:1_R<;K_ /V!8_\ T*.O3Z\PTC_DXW7_ /L"Q_\ H4=>GT %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[_H2-*_\#T_^+H ]/HKS#_A(OB]_T)&E?^!Z?_%T?\)%\7O^A(TK_P #T_\
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M[_H2-*_\#T_^+H_X2+XO?]"1I7_@>G_Q= 'I]%>8?\)%\7O^A(TK_P #T_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M8?'S_DF,O_7Y#_,UZ?7F'Q\_Y)C+_P!?D/\ ,UZ?0!YK\>/^257W_7>#_P!#
M%=/J6NS:7! L<<;#RT)W ^GUKF/CQ_R2J^_Z[P?^ABNOE\.V6H^5<S^;YAA5
M/E? QBIE?H5&VMS)7QC<&%+DPP_9G.%;#9XZ\9JQ%K%[=ZCI[E(UMIW.PJ3E
MA[C-75\)Z:ME%:#SO*C)*_/SS^'O3[7PS86ES'/'YV^,Y7+Y%:1<5)/U_+_,
MS:;IVZW_ %*6H>*)+"^:)XX_)5F#-@D\' [U2E\2WAG$SQQ+;;<97.<]N,UK
M3^$]-N)II9/.W3.7;#]R<\<4R/P;I<4F]?/SC',G_P!:L[/E\[EOXGVL8\OB
M34[36V2XAA 9 JJ"2,G'O5E_%\\5^;26*$.C /A3P#^-7H_!FE)="Y'GF08Z
MR<<?A5B?PQI]Q?-=OYOFL03A^.!CT]JN7D.ZLNYE'QA)BY98XBL1 &5//ZU-
M'XGGDTN6Z$46]6  P<<X]ZM2>$=-E?>WG9SV?_ZU">$=-CC9%\[#')R__P!:
MD_A2ZD*^MS#LO$]_J6ILUK%"RK&<J<@<'D]:1O&9AO7D3:R. JA@V,_G6O#X
M(TFW8M']H!/K)_\ 6J63P?I<C9(FS_O_ /UJI-<S?0<]6K%6\UK[7H7GES&3
M&Q<QY&/I56ROH;:R6XBO+F9BH9A*20":Z)-%M([5+<!]B# ^:GW&D6MU D,@
M8(BA1M..*RDI6ER[MK\E<%J_>VL_UL<[)XNN8&$,D,(F8;D&"05]3SUJ]?:Z
M7T>"YM\?OK@0$D$8!!Y'O5JX\-V%PRLPDRJA1ANU66TBU:R^R$/Y0;=UYS5N
MUF$-'%OYF;Y,NC)).L\TQ*G"S/N''-4I/%5_'-!$;>WWW&?*'/..N>>*TH?"
MNGPI*JF<B1=IS)GC\J;!X1TR"XBG7SM\9RN7R/Y4G>W]?UN$=-RG#XGN_M:P
MW$,"CG.T'M^-,/B;4OMGV<6UMNV[QU^[^=:[>';!Y_./F[N?XO6G'0+(W/VC
M]YOV;/O<8HE>[MVT]1Q^S?YF'>^,Y+68#RXC&2 "5;.?SJ8>*;I8$FEAA"3Y
M$! /S$=<\\5/)X*TF4*K>?A3N'[SO^56YO#6GS6<-JWF^7#G9A^>:I6T_$G7
MDMU*>DZG>W5S(URD:H6RFTGD<^]06R7.IK=7+3RH\4[1*B.0I'J??FM;3?#]
MEI3LUOYN6.3O;-5YO">G3N[,9QO8LV),<G\*4=/ZVU8^K;_K1&9'XT#$D*AB
M P&VMG=^=(/$^H2PAS! %;.TC/)_.M5/"FFQGY1+C']__P"M4I\-V!MQ#^]V
M#/\ 'ZU,D^2RWO\ @#^)VVZ&%#XSE$P@>.+*'#_*W'ZUT.D7]Q?I))+'&L>[
M]V5SRO8FJ<?@_3(Y-Z^=G.>7_P#K5L6MK%:1^7%G;QU-7]ILFSLE]Y/1112*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
MPTC_ ).-U_\ [ L?_H4=>GUYAI'_ "<;K_\ V!8__0HZ]/H **** "BBB@ H
MHHH **** "BBB@ HHHH \P^,?W_!G_8P6_\ 6O3Z\P^,?W_!G_8P6_\ 6O3Z
M "BBB@ HHHH *H7NE0W]Q'+,[E4!!BX*-]0>M7Z*+ 4--TN/3(V2*65U9BV'
M(XS_ /JJ_110 4444 %%%% &%XU_Y$/Q%_V#+G_T4U97PG_Y)9X?_P"O;_V9
MJU?&O_(A^(O^P9<_^BFK*^$__)+/#_\ U[?^S-0!V5%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^%I^!O\ H9K#_OH_X4?\+3\#?]#-8?\ ?1_PH Z^BN0_X6GX&_Z&:P_[Z/\
MA1_PM/P-_P!#-8?]]'_"@#KZ*Y#_ (6GX&_Z&:P_[Z/^%'_"T_ W_0S6'_?1
M_P * .OHKD/^%I^!O^AFL/\ OH_X4?\ "T_ W_0S6'_?1_PH Z^BN0_X6GX&
M_P"AFL/^^C_A1_PM/P-_T,UA_P!]'_"@#KZ*Y#_A:?@;_H9K#_OH_P"%'_"T
M_ W_ $,UA_WT?\* .OHKD/\ A:?@;_H9K#_OH_X4?\+3\#?]#-8?]]'_  H
MZ^BN0_X6GX&_Z&:P_P"^C_A1_P +3\#?]#-8?]]'_"@#KZ*Y#_A:?@;_ *&:
MP_[Z/^%'_"T_ W_0S6'_ 'T?\* .?TC_ ).-U_\ [ L?_H4=>GUX?IOCGPQ#
M\<]:UF36K5=.FTJ.&.X+':S@QY4<=>#^5>@_\+3\#?\ 0S6'_?1_PH Z^BN0
M_P"%I^!O^AFL/^^C_A1_PM/P-_T,UA_WT?\ "@#KZ*Y#_A:?@;_H9K#_ +Z/
M^%'_  M/P-_T,UA_WT?\* .OHKD/^%I^!O\ H9K#_OH_X4?\+3\#?]#-8?\
M?1_PH Z^BN0_X6GX&_Z&:P_[Z/\ A1_PM/P-_P!#-8?]]'_"@#KZ*Y#_ (6G
MX&_Z&:P_[Z/^%'_"T_ W_0S6'_?1_P * .OHKD/^%I^!O^AFL/\ OH_X4?\
M"T_ W_0S6'_?1_PH Y_XQ_?\&?\ 8P6_]:]/KP_XH^.?#&L/X5.G:U:W/V76
MH9Y_+8_NXQG+'CI7H/\ PM/P-_T,UA_WT?\ "@#KZ*Y#_A:?@;_H9K#_ +Z/
M^%'_  M/P-_T,UA_WT?\* .OHKD/^%I^!O\ H9K#_OH_X4?\+3\#?]#-8?\
M?1_PH Z^BN0_X6GX&_Z&:P_[Z/\ A1_PM/P-_P!#-8?]]'_"@#KZ*Y#_ (6G
MX&_Z&:P_[Z/^%'_"T_ W_0S6'_?1_P * .OHKD/^%I^!O^AFL/\ OH_X4?\
M"T_ W_0S6'_?1_PH Z^BN0_X6GX&_P"AFL/^^C_A1_PM/P-_T,UA_P!]'_"@
M#2\:_P#(A^(O^P9<_P#HIJROA/\ \DL\/_\ 7M_[,U97BOXE>#+WP=KEK;>(
MK*6>?3YXXXU8Y9FC8 #CN36=\-_B'X1TGX>:+8W^O6=O=0P;9(G8Y4[CP>*
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M&:P_[Z/^%'_"T_ W_0S6'_?1_P * .OHKD/^%I^!O^AFL/\ OH_X4?\ "T_
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M257W_7>#_P!#%>BVO_'I#_US7^5 &)_P@G@__H5-#_\ !=#_ /$T?\()X/\
M^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P7
M0_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!
M10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P
M@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-
M#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_
M /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()
MX/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T
M/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
MQ-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S
M_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@_
M_H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\
M!=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T
M?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\
M^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P7
M0_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!
M10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P
M@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-
M#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_
M /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()
MX/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T
M/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
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M /$UT%% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%%
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M)X/_ .A4T/\ \%T/_P 37044 <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\
MZ%30_P#P70__ !-=!10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_
M /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/
M_P 37044 <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-=
M!10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/
M_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044 <__ ,()
MX/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-=!10!S_\ P@G@_P#Z
M%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\
M%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044 <__ ,()X/\ ^A4T/_P70_\
MQ-'_  @G@_\ Z%30_P#P70__ !-=!10!S_\ P@G@_P#Z%30__!=#_P#$T?\
M"">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_
M .A4T/\ \%T/_P 37044 <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30
M_P#P70__ !-=!10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=
M#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 3
M7044 <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-=!10!
MS_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"
M">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044 <__ ,()X/\
M^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-=!10!S_\ P@G@_P#Z%30_
M_!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_
M ,31_P ()X/_ .A4T/\ \%T/_P 37044 <__ ,()X/\ ^A4T/_P70_\ Q-'_
M  @G@_\ Z%30_P#P70__ !-=!10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#
M_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4
MT/\ \%T/_P 37044 <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P
M70__ !-=!10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\
M$UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044
M <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-=!10!S_\
MP@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_
M /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044 <__ ,()X/\ ^A4T
M/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-=!10!S_\ P@G@_P#Z%30__!=#
M_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_ ,31
M_P ()X/_ .A4T/\ \%T/_P 37044 <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G
M@_\ Z%30_P#P70__ !-=!10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H
M5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\
M\%T/_P 37044 <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__
M !-=!10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%
M% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044 <__
M ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-=!10!S_\ P@G@
M_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5
M-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044 <__ ,()X/\ ^A4T/_P7
M0_\ Q-'_  @G@_\ Z%30_P#P70__ !-=!10!S_\ P@G@_P#Z%30__!=#_P#$
MT?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P (
M)X/_ .A4T/\ \%T/_P 37044 <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\
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M 6H4444 %%%% 'F'QC^_X,_[&"W_ *UZ?7F'QC^_X,_[&"W_ *UZ?0 4444
M%%%% !1110 4444 %%%% !1110!A>-?^1#\1?]@RY_\ 135E?"?_ ))9X?\
M^O;_ -F:M7QK_P B'XB_[!ES_P"BFK*^$_\ R2SP_P#]>W_LS4 =E1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'F'Q\_Y)C+_U^0_S->GUYA\?/^28R_\ 7Y#_
M #->GT >:_'C_DE5]_UW@_\ 0Q753:!+>74-_#J$ENWD)'M1,\?7-<K\>/\
MDE5]_P!=X/\ T,5Z+:_\>D/_ %S7^5%AIM7.,U7PWJ*7-Q<6D\LTEPGENP !
M(QCUK0TWPU(=#2WN9F25DPV5!(.?K7444+1+R%_7W'+Q^#A&I47[8/4>7_\
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M?^S-0!V5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\)EX7_Z&31__  .B_P#BJ -NBL3_ (3+PO\ ]#)H_P#X'1?_ !5'_"9>%_\
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M\)EX7_Z&31__  .B_P#BJ -NBL3_ (3+PO\ ]#)H_P#X'1?_ !5'_"9>%_\
MH9-'_P# Z+_XJ@#;HK$_X3+PO_T,FC_^!T7_ ,51_P )EX7_ .ADT?\ \#HO
M_BJ -NBL3_A,O"__ $,FC_\ @=%_\51_PF7A?_H9-'_\#HO_ (J@#;HK$_X3
M+PO_ -#)H_\ X'1?_%4?\)EX7_Z&31__  .B_P#BJ -NBL3_ (3+PO\ ]#)H
M_P#X'1?_ !5'_"9>%_\ H9-'_P# Z+_XJ@#B](_Y.-U__L"Q_P#H4=>GUX[I
M?B+0T^/VN7[ZSIZV<FD1QI<&Z01LVZ/Y0V<$\'CVKT?_ (3+PO\ ]#)H_P#X
M'1?_ !5 &W16)_PF7A?_ *&31_\ P.B_^*H_X3+PO_T,FC_^!T7_ ,50!MT5
MB?\ "9>%_P#H9-'_ / Z+_XJC_A,O"__ $,FC_\ @=%_\50!MT5B?\)EX7_Z
M&31__ Z+_P"*H_X3+PO_ -#)H_\ X'1?_%4 ;=%8G_"9>%_^ADT?_P #HO\
MXJC_ (3+PO\ ]#)H_P#X'1?_ !5 &W16)_PF7A?_ *&31_\ P.B_^*H_X3+P
MO_T,FC_^!T7_ ,50!MT5B?\ "9>%_P#H9-'_ / Z+_XJC_A,O"__ $,FC_\
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M XO_ (5)X#_Z%NU_[Z?_ .*H_P"%2> _^A;M?^^G_P#BJ[2B@#B_^%2> _\
MH6[7_OI__BJ/^%2> _\ H6[7_OI__BJ[2B@#B_\ A4G@/_H6[7_OI_\ XJC_
M (5)X#_Z%NU_[Z?_ .*KM** .+_X5)X#_P"A;M?^^G_^*H_X5)X#_P"A;M?^
M^G_^*KM** .+_P"%2> _^A;M?^^G_P#BJ/\ A4G@/_H6[7_OI_\ XJNTHH X
MO_A4G@/_ *%NU_[Z?_XJC_A4G@/_ *%NU_[Z?_XJNTHH XO_ (5)X#_Z%NU_
M[Z?_ .*H_P"%2> _^A;M?^^G_P#BJ[2B@#B_^%2> _\ H6[7_OI__BJ/^%2>
M _\ H6[7_OI__BJ[2B@#B_\ A4G@/_H6[7_OI_\ XJC_ (5)X#_Z%NU_[Z?_
M .*KM** .+_X5)X#_P"A;M?^^G_^*H_X5)X#_P"A;M?^^G_^*KM** .+_P"%
M2> _^A;M?^^G_P#BJ/\ A4G@/_H6[7_OI_\ XJNTHH XO_A4G@/_ *%NU_[Z
M?_XJC_A4G@/_ *%NU_[Z?_XJNTHH XO_ (5)X#_Z%NU_[Z?_ .*H_P"%2> _
M^A;M?^^G_P#BJ[2B@#PS3? 'A:;XX:SHDFC0-IL&E)-';DMM5R8\MUSW/YUW
M_P#PJ3P'_P!"W:_]]/\ _%5B:1_R<;K_ /V!8_\ T*.O3Z .+_X5)X#_ .A;
MM?\ OI__ (JC_A4G@/\ Z%NU_P"^G_\ BJ[2B@#B_P#A4G@/_H6[7_OI_P#X
MJC_A4G@/_H6[7_OI_P#XJNTHH XO_A4G@/\ Z%NU_P"^G_\ BJ/^%2> _P#H
M6[7_ +Z?_P"*KM** .+_ .%2> _^A;M?^^G_ /BJ/^%2> _^A;M?^^G_ /BJ
M[2B@#B_^%2> _P#H6[7_ +Z?_P"*H_X5)X#_ .A;M?\ OI__ (JNTHH XO\
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M#31@^["@"2BF+-$YPDB,1V# T^@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8?
M'S_DF,O_ %^0_P S7I]>8?'S_DF,O_7Y#_,UZ?0!YK\>/^257W_7>#_T,5N3
MO=6FOQ74>GW-Q$;-$W1H2,_7%8?QX_Y)5??]=X/_ $,5Z+:_\>D/_7-?Y4#3
MLFNYY]J]U.=3OIKRRG\EHAY"LI7:^T<Y[T^UT^:]T2.Y^R3-*J;HL*<YS[=>
ME=U<V%K>?\?$"2?[PJ6&&.WA6*% D:C"J.@HBDDO+_*PNC7>QYY9Z?J%NDI6
MPN5D=MQ/E'K^5.U&SOK&5'@AEBC* LQC)&XYSR:]%J.:"*XC\N9 Z9S@U,4X
MW?<OF3J<[.0T.837MZ+2W>*'[*VQ/O?-D=ZJ:=IU_*+N6ZM)_-CCW0%HROS>
MWKVKMK:PM;0DP0)&2,9458K1NZ7E;\"(MJ,H]SD[VSN9VT69[:9Y(D;>0A^4
MD#KZ5S5U8ZXTUPR6MT3YAV$0'IGZ5ZC14_:;[C3M;R5C@-5L;VU=(+.PN7@*
M!B$C+#?WYJ.PT[4);%X[FSN!Y:LT8:(CYNW:O0^M%*VWD3;W;'%^&+&YM;JX
MEN+*=7?;\S(1TS6=>V^JMK\TT-C=!!*^&$)((.>>E>BT8I27,M66Y>\WW_RL
M>>WFEZBDR+#;S^0Z!I$$1.7]<X^G%4[ZUUJ5P&LKIW!!WB X_E7IV,T8JN_F
M3'2WD<3X8AU&&]9[JUN%#[1EHBN.?I7;444[Z6$EJV%%%%(84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >8:1_R<;K__ &!8_P#T*.O3Z\PTC_DXW7_^P+'_ .A1UZ?0
M 4444 %%%% !1110 4444 %%%% !1110!YA\8_O^#/\ L8+?^M>GUYA\8_O^
M#/\ L8+?^M>GT %%%% !1110 5S_ (HM9]2MO[-AADS, ?/"DJF#G!^N/UKH
M**35]QIV,/PQ'+;V#02VTL)$AY=2,\#GFMRBBJE)R=V2DEH@HHHI#"BBB@#"
M\:_\B'XB_P"P9<_^BFK*^$__ "2SP_\ ]>W_ +,U:OC7_D0_$7_8,N?_ $4U
M97PG_P"26>'_ /KV_P#9FH [*BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M14/VRU_Y^8?^^Q1]LM?^?F'_ +[% $U%0_;+7_GYA_[[%'VRU_Y^8?\ OL4
M345#]LM?^?F'_OL4?;+7_GYA_P"^Q0!-14/VRU_Y^8?^^Q1]LM?^?F'_ +[%
M $U%0_;+7_GYA_[[%'VRU_Y^8?\ OL4 345#]LM?^?F'_OL4?;+7_GYA_P"^
MQ0!-14/VRU_Y^8?^^Q1]LM?^?F'_ +[% $U%0_;+7_GYA_[[%'VRU_Y^8?\
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M_@7)_C1_PHGP#_T#+C_P+D_QKTFB@#S;_A1/@'_H&7'_ (%R?XT?\*)\ _\
M0,N/_ N3_&O2:* /-O\ A1/@'_H&7'_@7)_C1_PHGP#_ - RX_\  N3_ !KT
MFB@#S;_A1/@'_H&7'_@7)_C1_P *)\ _] RX_P# N3_&O2:* /-O^%$^ ?\
MH&7'_@7)_C1_PHGP#_T#+C_P+D_QKTFB@#S;_A1/@'_H&7'_ (%R?XT?\*)\
M _\ 0,N/_ N3_&O2:* /-O\ A1/@'_H&7'_@7)_C1_PHGP#_ - RX_\  N3_
M !KTFB@#S;_A1/@'_H&7'_@7)_C1_P *)\ _] RX_P# N3_&O2:* /-O^%$^
M ?\ H&7'_@7)_C1_PHGP#_T#+C_P+D_QKTFB@#S;_A1/@'_H&7'_ (%R?XT?
M\*)\ _\ 0,N/_ N3_&O2:* /-O\ A1/@'_H&7'_@7)_C1_PHGP#_ - RX_\
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M_0,N/_ N3_&C_A1/@'_H&7'_ (%R?XUZ310!YM_PHGP#_P! RX_\"Y/\:/\
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MY/\ &C_A1/@'_H&7'_@7)_C7I-% 'FW_  HGP#_T#+C_ ,"Y/\:/^%$^ ?\
MH&7'_@7)_C7I-% 'FW_"B? /_0,N/_ N3_&C_A1/@'_H&7'_ (%R?XUZ310!
MYM_PHGP#_P! RX_\"Y/\:/\ A1/@'_H&7'_@7)_C7I-% 'FW_"B? /\ T#+C
M_P "Y/\ &C_A1/@'_H&7'_@7)_C7I-% 'FW_  HGP#_T#+C_ ,"Y/\:/^%$^
M ?\ H&7'_@7)_C7I-% 'FW_"B? /_0,N/_ N3_&C_A1/@'_H&7'_ (%R?XUZ
M310!YM_PHGP#_P! RX_\"Y/\:/\ A1/@'_H&7'_@7)_C7I-% 'FW_"B? /\
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M7'_@7)_C7I-% 'FW_"B? /\ T#+C_P "Y/\ &C_A1/@'_H&7'_@7)_C7I-%
M'FW_  HGP#_T#+C_ ,"Y/\:/^%$^ ?\ H&7'_@7)_C7I-% 'FW_"B? /_0,N
M/_ N3_&C_A1/@'_H&7'_ (%R?XUZ310!YM_PHGP#_P! RX_\"Y/\:/\ A1/@
M'_H&7'_@7)_C7I-% 'FW_"B? /\ T#+C_P "Y/\ &C_A1/@'_H&7'_@7)_C7
MI-% 'FW_  HGP#_T#+C_ ,"Y/\:/^%$^ ?\ H&7'_@7)_C7I-% 'FW_"B? /
M_0,N/_ N3_&C_A1/@'_H&7'_ (%R?XUZ310!YM_PHGP#_P! RX_\"Y/\:/\
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MVN+,8R<R'"\5/0 4444 %%%,25)'=5/*'!H ?1103@9H **K6]_!=2&.)B6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/,/CY_R3&7_K\A_F:]/KS#X^?\DQE_Z_(?YFO3Z /-?CQ_R2J^_Z[P?^ABMF
M>\%AXCBFDAG=#9(N8TSSQ6-\>/\ DE5]_P!=X/\ T,5Z+:_\>D/_ %S7^5 T
M[)KN>>ZMJ*S:K?27$4PA$0, "X.[:.OM2P6[7FCQW>R3?&FY.#_GM7<WNE6>
MH?\ 'S%O_P"!$?R-6+:VBM+=((%VQH,*,DX_.B*24?+_ "L+HUWL>=Z7:/(\
MD4D<P\YMQ."/>J\DM_&[1+$^T-P=AKU&BB.B:?4T51*;G8\\U7.F7)M2LGV1
M0&! R=Q]_P ZT[2Z7_A%KJ2,/Y2V[E01\W>NFO=/MM1B$=U'O0'<!N(Y_#ZT
MV+2[.&R-FD6("I7;N/0]><Y[TNB3_K5&/+IIWO\ @SA=/9[R"*.&.98Y5'FE
MU(SZ8IQ\Z.*4>5-]JC?;"=IV;/?WZUZ!!!';0I#$NV-!A1G.!4F.<T65WZW'
MJ[^AY19"]1#"D4@@W%_F0YW?X5H/(TPG34(+AI3&0IA0XSCBO1L TN*MRNV^
MX_M)]CS>0R06.E1+#.826$XVDMC(Z4ZS22]U9+7RIEM&9A\RD' !(Y_ 5Z-1
M4KX>4(NS;[W.2\VY_P"$>N1L;<ESL4;3G:,5EQ7%W;Z-'M&V8S8.]3C&#^M>
M@U6N["VOD1+B/>J.'4;B,$?3ZTY-N3D@27*HOH<")+V2]MY)(V/[Q2VU3TR*
MK3?:TU6\^SQ2B.5_WF]#SZ8KTY455  X%.Q2T5TNO^=QIMM2?8\TDCOKAXUF
M1MJKA=JGI[UT.EP/:ZM]F57\EK<N2P/WOK75457-K?RM_P $A1T2[,\WMK<V
MMEB6&<QC/EA%.=WO[5I>%X9;N^EEN4D41;6CR".>:[:BIA[JL:2ES.3MN>?3
M@Q:MJDB0S_:?/)A;;\G4YS^%,@U6[>-X&@F\S=U\L[:]$Q14M7@XA)WFY^1Y
MNIEV.MU#,8-IVB-3NW?X=:HZ4MRYMK80RK T@4[D(."W/->K44X+EAR!3ER-
M^9YMJ,WV.ZDMIUE^SQ';'M')'?GOVKHENMGA5YE21E"1[ %RV#BMJ_TJSU((
M+J+S-F<?,1UZ]#[58M[:*U@2&%=J(H4#)/ X%/=6?:Q$5RN+[.YYO:1W-QJ?
MV:2.40,ADSM(Y^M.MY)G5X[V&<Q!28_+0YW]L^W6O2P,44DO=Y1K3F??\#D)
M1+%X0MBD;EU20[=O/4]JYR*YNI8BKP2@MZ1D5ZE0>:)*\Y3[NXK>ZH]E;\;G
ME,$^H20S(8I !)@90]*MO<:E)=Q/Y9W?*OW#C&:]+P*,55_?YARU21Q7BN6Y
MAG5HHF<LX!PA/:L];^ZM8[61H)2&SD+&2>*]%HJ(1Y;_ #_$4E=I]K?@K'G4
MUQ>SR"6.)P3RNY#QGUJA>$KJD4EK;W/F>5ABZ$C.3FO5***,?9WZE)VGS'G:
MI<P:.E^J/]H>4Q."#C9@GI^%6O#EU%+?.L*R[_EW[^F,]J[B2-949'&588(J
MC9Z+86$K2VT&QVQD[V/3ZFJ78F:YN9]_\SCH+^\L_$VJA8&,;3#GRR<@9IES
M>R&.>6>*47&_]T0N%"Y[^]>B5!=6<%["8KA-Z'J,D?RIWO:_2PY:II=3@;?5
M;F6W,0@F#YSDQG&*@FNW;/EQ3FX_B.SY<5Z4$54"@< 8J*"S@MB3$FTD8ZDU
M*5JKGW!_9MT."-E,=.AN"DOG."6&#V]JK02ZH903'S'Q%\AZ>]>FT8YS3Z)=
MOZ_X V[J7F><P6D[Q23R))YN_' .*Z_PX%&E (LBC>>''-:]%.^LGWM\K$.-
MW%]@HHHI%!1110!YAI'_ "<;K_\ V!8__0HZ]/KS#2/^3C=?_P"P+'_Z%'7I
M] !1110 4444 %%%% !1110 4444 %%%% 'F'QC^_P"#/^Q@M_ZUZ?7F'QC^
M_P"#/^Q@M_ZUZ?0 4444 %%%% !7.>*XWOK0Z; K?:9E!1R/D&&!.2/8&NCH
MI-7&G8P/"I$>G-"4D5ED.=P]A6_1152DY.[)2MH@HHHI#"BBB@#"\:_\B'XB
M_P"P9<_^BFKEO R%_@OHH52Q^QG&!G^(UU/C7_D0_$7_ &#+G_T4U97PG_Y)
M9X?_ .O;_P!F:CM\@Z%;4-.-S+HY9)/DML';D8^6LZ\FU,S@^6=R+M7"'&T?
MUKTRC'-'VU+M_FV*VECS::*]71(;I$;SGFV,-I^[@]OPK>LWNU\*3[EY$$A4
M;3G/-=712:TL.7O.YP/AF:Y74HA/%(/-;@A#@<'K5K789G\ZX5',D;;5P#TS
M7:8Q15-W<7V%%6O?JT>?6EQ<F-9?*E%]OVY*'9Y?^-.\2-=0^(IY(8V(*ISM
M)'05W^.<TUT62-D<95@01[4^;2UC2$^6;EW/,+N9;BWCB193<2Y6?CCVQ5H6
M)M;.$>7.5*#< "37;P:)86T_G10;7!!!WL?ZUH5#5X1CV=S)IMR\SSJTAG@A
M:Y2.3>&VJ"IZ?2ENH[D6:W:H_G%]I&TXQ@]J]$I&4.I5AD$8-%OWCG_2&E\-
M^GXGG^GW@:^L#B3[6\ZB8X^7&[C'X8JYXBN0MX5,<K2!F\O8N0.G6NDAT/3X
M)Q-'!AP00=['D?C5H6< G,P3]X3G.3UI_P GE?\ &XWO*W6WYHX&WCG?2[FZ
MGCEW1N JJIR0<=JCL4/]O":*&X6/[.0=ZG[V:])HQ2:N.3O?S/*[>?4@Z-)$
M^UF"R80_=[X]ZNZTL12Q:T@N\1N2N]?IUKT? HQ5Q=I<PGJT><6]Q<M;R/+#
M+]J3'V<A#M'KNJ[HD-PEP;J1'$H)'0XY'I7=8HI)V7S_ *7S%/WFWW1POB*2
MY&N(5C<QE%'RJ3SFDO[FZENKK3H>1:Q^9G'7(SP>_6NZ(!ZU6ATZUM[J2YCC
MQ-( K-N)R![5*5K>0WJCSFR6>74K9I89LQ/U"G%1WLNI?:KHK$WRRL$^0],U
MZIBC%5?6Y5]4^QYY=6,D"1-&DI+(K-P3R>M;'C&V:YTZW94=G6X5@%'H#75T
M4)VY?(E'G,CW!LE\J*47,@*W!9#M([;?PK:O;81^"&#)*S/ NY5Y/4=*ZRBB
M_NI>=_\ @":O)L\]T^[DLX8I(8+CR%4!U9,MNQV]JRI[J^O%_P!1*%#9&8R#
M7JV!2T1?*GU-(2Y).1YE,7DMX9&@N/M@?+G8=F.V/TJ:UBNF,MT4=98\,F5(
M&:]'I'4.A5AD'@TFW[-P7]:_TC-+]YSGGEGJ,4?B.Q(28RMO,W'&[:<XYZ5Z
M%&X= P!&1WJA%HFGPWHO$@Q."2&WMWZ\9QWK1IMZ)!8****0PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S#X^?\ ),9?^OR'
M^9KT^O,/CY_R3&7_ *_(?YFO3Z /-?CQ_P DJOO^N\'_ *&*]%M?^/2'_KFO
M\J\Z^/'_ "2J^_Z[P?\ H8KT6U_X](?^N:_RH EHHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /,/CY_R3&7_ *_(?YFO3Z\P^/G_ "3&7_K\A_F:]/H
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M^;.[[O?UKM_M?QI_Z!_A3_OJ7_XNC2/^3C=?_P"P+'_Z%'7I] 'F'VOXT_\
M0/\ "G_?4O\ \71]K^-/_0/\*?\ ?4O_ ,77I]% 'F'VOXT_] _PI_WU+_\
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M _X5>H **:)%9MH/-.H **A-U LHB,@#DX Q4U !1110 444U9$9F4-DKU%
M#J*** "BH/MEO]I-OYH\Y0"5P>E3T %%-,B*ZH6PS=!ZTZ@ HHH)P,F@ HIJ
MNKYVG..M.H ***8945]I;YO2@!]%%% !1136D53ACB@!U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >8:1_P G&Z__ -@6/_T*.O3Z\PTC
M_DXW7_\ L"Q_^A1UZ?0 4444 %%%% !1110 4444 %%%% !1110!YA\8_O\
M@S_L8+?^M>GUYA\8_O\ @S_L8+?^M>GT %%%% !1110 445$]Q%'*L3. [#(
M'K0!+14<5Q%-GRW#8.*DH **** "BBB@#"\:_P#(A^(O^P9<_P#HIJROA/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO1?:O0?*CSG8N?I0(HQ_ OY5IS+F3:T0Y:P45N<_H4TL</ER2R2;SOW.Q)'
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M&7_K\A_F:]/H \U^/'_)*K[_ *[P?^ABO1;7_CTA_P"N:_RKSKX\?\DJOO\
MKO!_Z&*]%M?^/2'_ *YK_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#T3RT_\&<7_P 77I]% 'F'_"5?%?\ Z)Y:?^#.+_XNC_A*OBO_ -$\M/\
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M 4444 %%%% !1110 4444 %%%% 'F'Q\_P"28R_]?D/\S7I]>8?'S_DF,O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MROA/_P DL\/_ /7M_P"S-0!A?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\
M?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"
MS?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\
M?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2
M_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT
M4 >8?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2
M_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"
MS?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\
M?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"
MS?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\
M?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2
M_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT
M4 >8?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2
M_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"
MS?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\
M?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"
MS?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\
M?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2
M_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT
M4 >8?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2
M_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"
MS?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\
M?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"
MS?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\
M?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2
M_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT
M4 >8?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2
M_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"
MS?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\
M?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"
MS?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\
M?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2
M_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT
M4 >8?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2
M_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"
MS?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\ ?_84?\+-\6?]$OUG_O\
M?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2_6?^_P!_]A7I]% 'F'_"
MS?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT4 >8?\+-\6?]$OUG_O\
M?_84?\+-\6?]$OUG_O\ ?_85Z?10!YA_PLWQ9_T2_6?^_P!_]A1_PLWQ9_T2
M_6?^_P!_]A7I]% 'F'_"S?%G_1+]9_[_ '_V%'_"S?%G_1+]9_[_ '_V%>GT
M4 ?//Q5\:Z]KO@I[+4/!&HZ1;FXC8W5Q)E00>!]T=:^AJ\P^/G_),9?^OR'^
M9KT^@#S7X\?\DJOO^N\'_H8KT6U_X](?^N:_RKSKX\?\DJOO^N\'_H8KT6U_
MX](?^N:_RH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%;^;)A7)3)SNSW/?O7>_\*<^'_\ T+D7_?\ E_\ BZ .E_X2CP__ -!W3/\
MP+C_ ,:/^$H\/_\ 0=TS_P "X_\ &N:_X4Y\/_\ H7(O^_\ +_\ %T?\*<^'
M_P#T+D7_ '_E_P#BZ .E_P"$H\/_ /0=TS_P+C_QH_X2CP__ -!W3/\ P+C_
M ,:YK_A3GP__ .A<B_[_ ,O_ ,71_P *<^'_ /T+D7_?^7_XN@#I?^$H\/\
M_0=TS_P+C_QH_P"$H\/_ /0=TS_P+C_QKFO^%.?#_P#Z%R+_ +_R_P#Q='_"
MG/A__P!"Y%_W_E_^+H Z7_A*/#__ $'=,_\  N/_ !H_X2CP_P#]!W3/_ N/
M_&N:_P"%.?#_ /Z%R+_O_+_\71_PISX?_P#0N1?]_P"7_P"+H Z7_A*/#_\
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M/_&C_A*/#_\ T'=,_P# N/\ QKFO^%.?#_\ Z%R+_O\ R_\ Q='_  ISX?\
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M'=,_\"X_\:/^$H\/_P#0=TS_ ,"X_P#&N:_X4Y\/_P#H7(O^_P#+_P#%T?\
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M#S#2/^3C=?\ ^P+'_P"A1UZ?7F&D?\G&Z_\ ]@6/_P!"CKT^@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0!A>-?\ D0_$7_8,N?\ T4U97PG_ .26>'_^O;_V9JU?&O\ R(?B+_L&7/\
MZ*:LKX3_ /)+/#__ %[?^S-0!V5%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8
M?'S_ ))C+_U^0_S->GUYA\?/^28R_P#7Y#_,UZ?0!YK\>/\ DE5]_P!=X/\
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M_P ^M[_X%-1_PH/P+_SZWO\ X%-0!Z;N7^\/SHW+_>'YUYE_PH/P+_SZWO\
MX%-1_P *#\"_\^M[_P"!34 >F[E_O#\Z-R_WA^=>9?\ "@_ O_/K>_\ @4U'
M_"@_ O\ SZWO_@4U 'INY?[P_.C<O]X?G7F7_"@_ O\ SZWO_@4U'_"@_ O_
M #ZWO_@4U 'INY?[P_.C<O\ >'YUYE_PH/P+_P ^M[_X%-1_PH/P+_SZWO\
MX%-0!Z;N7^\/SHW+_>'YUYE_PH/P+_SZWO\ X%-1_P *#\"_\^M[_P"!34 >
MF[E_O#\Z-R_WA^=>9?\ "@_ O_/K>_\ @4U'_"@_ O\ SZWO_@4U 'INY?[P
M_.C<O]X?G7F7_"@_ O\ SZWO_@4U'_"@_ O_ #ZWO_@4U 'INY?[P_.C<O\
M>'YUYE_PH/P+_P ^M[_X%-1_PH/P+_SZWO\ X%-0!Z;N7^\/SHW+_>'YUYE_
MPH/P+_SZWO\ X%-1_P *#\"_\^M[_P"!34 >F[E_O#\Z-R_WA^=>9?\ "@_
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M_P ^M[_X%-1_PH/P+_SZWO\ X%-0!Z;N7^\/SHW+_>'YUYE_PH/P+_SZWO\
MX%-1_P *#\"_\^M[_P"!34 >F[E_O#\Z-R_WA^=>9?\ "@_ O_/K>_\ @4U'
M_"@_ O\ SZWO_@4U 'INY?[P_.C<O]X?G7F7_"@_ O\ SZWO_@4U'_"@_ O_
M #ZWO_@4U 'INY?[P_.C<O\ >'YUYE_PH/P+_P ^M[_X%-1_PH/P+_SZWO\
MX%-0!Z;N7^\/SHW+_>'YUYE_PH/P+_SZWO\ X%-1_P *#\"_\^M[_P"!34 >
MF[E_O#\Z-R_WA^=>9?\ "@_ O_/K>_\ @4U'_"@_ O\ SZWO_@4U 'INY?[P
M_.C<O]X?G7F7_"@_ O\ SZWO_@4U'_"@_ O_ #ZWO_@4U 'INY?[P_.C<O\
M>'YUYE_PH/P+_P ^M[_X%-1_PH/P+_SZWO\ X%-0!Z;N7^\/SHW+_>'YUYE_
MPH/P+_SZWO\ X%-1_P *#\"_\^M[_P"!34 >F[E_O#\Z-R_WA^=>9?\ "@_
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M_P ^M[_X%-1_PH/P+_SZWO\ X%-0!Z;N7^\/SHW+_>'YUYE_PH/P+_SZWO\
MX%-1_P *#\"_\^M[_P"!34 >F[E_O#\Z-R_WA^=>9?\ "@_ O_/K>_\ @4U'
M_"@_ O\ SZWO_@4U 'INY?[P_.C<O]X?G7F7_"@_ O\ SZWO_@4U'_"@_ O_
M #ZWO_@4U 'INY?[P_.C<O\ >'YUYE_PH/P+_P ^M[_X%-1_PH/P+_SZWO\
MX%-0!Z;N7^\/SHW+_>'YUYE_PH/P+_SZWO\ X%-1_P *#\"_\^M[_P"!34 >
MF[E_O#\Z-R_WA^=>9?\ "@_ O_/K>_\ @4U'_"@_ O\ SZWO_@4U 'INY?[P
M_.C<O]X?G7F7_"@_ O\ SZWO_@4U'_"@_ O_ #ZWO_@4U 'INY?[P_.C<O\
M>'YUYE_PH/P+_P ^M[_X%-1_PH/P+_SZWO\ X%-0!Z;N7^\/SHW+_>'YUYE_
MPH/P+_SZWO\ X%-1_P *#\"_\^M[_P"!34 -^/A!^&,N"/\ C[A_F:]0KS$?
M /P*#G[+>_\ @4U>G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>img206306002_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206306002_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,X!2P# 2(  A$! Q$!_\0
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M/_ R3_&C_A*O$7_0?U3_ ,#)/\:/J<NX?VG#^5GU#17R]_PE7B+_ *#^J?\
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M5\O?\)5XB_Z#^J?^!DG^-'_"5>(O^@_JG_@9)_C1]3EW#^TX?RL^H:*^7O\
MA*O$7_0?U3_P,D_QH_X2KQ%_T']4_P# R3_&CZG+N']IP_E9]0T5\O?\)5XB
M_P"@_JG_ (&2?XT?\)5XB_Z#^J?^!DG^-'U.7</[3A_*SZAHKY>_X2KQ%_T'
M]4_\#)/\:/\ A*O$7_0?U3_P,D_QH^IR[A_:</Y6?4-%?+W_  E7B+_H/ZI_
MX&2?XT?\)5XB_P"@_JG_ (&2?XT?4Y=P_M.'\K/J&BOE[_A*O$7_ $']4_\
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MB+_H/ZI_X&2?XT?4Y=P_M.'\K/J&BOE[_A*O$7_0?U3_ ,#)/\:/^$J\1?\
M0?U3_P #)/\ &CZG+N']IP_E9]0T5\O?\)5XB_Z#^J?^!DG^-'_"5>(O^@_J
MG_@9)_C1]3EW#^TX?RL^H:*^7O\ A*O$7_0?U3_P,D_QH_X2KQ%_T']4_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M' [URWA'PE%K?B>ZTR\:58K8,9#&0#PP4]0?6O1-!U#^SOAYX=D)P))5A/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*3D[O<****H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '??!__ )'9O^O2
M3^:U[U7@OP?_ .1V;_KTD_FM>]5YF+_B'NY=_!^9YO\ &C_D5;+_ *_E_P#0
M'KP^OK66&*=0LL:2*#D!U!%5WM=.BQYEO:IGIN113I8CV<>6PL3@76GS\UCY
M2HKZJ\K2O[EE^2T>5I7]RR_):U^N?W3G_LS^_P#A_P $^5:*^JO*TK^Y9?DM
M'E:5_<LOR6CZY_=#^S/[_P"'_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_L
MS^_^'_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^_^'_!/E6BOJKRM*_N
M67Y+1Y6E?W++\EH^N?W0_LS^_P#A_P $^5:*^JO*TK^Y9?DM'E:5_<LOR6CZ
MY_=#^S/[_P"'_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^_^'_!/E6BO
MJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^_^'_!/E6BOJKRM*_N67Y+1Y6E?W++
M\EH^N?W0_LS^_P#A_P $^5:*^JO*TK^Y9?DM'E:5_<LOR6CZY_=#^S/[_P"'
M_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^_^'_!/E6BOJKRM*_N67Y+1
MY6E?W++\EH^N?W0_LS^_^'_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^
M_P#A_P $^5:*^JO*TK^Y9?DM'E:5_<LOR6CZY_=#^S/[_P"'_!/E6BOJKRM*
M_N67Y+1Y6E?W++\EH^N?W0_LS^_^'_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N
M?W0_LS^_^'_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^_P#A_P $^5:*
M^JO*TK^Y9?DM'E:5_<LOR6CZY_=#^S/[_P"'_!/E6BOJKRM*_N67Y+1Y6E?W
M++\EH^N?W0_LS^_^'_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^_^'_!
M/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^_P#A_P $^5:*^JO*TK^Y9?DM
M'E:5_<LOR6CZY_=#^S/[_P"'_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_L
MS^_^'_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^_^'_!/E6BOJKRM*_N
M67Y+1Y6E?W++\EH^N?W0_LS^_P#A_P $^5:*^JO*TK^Y9?DM'E:5_<LOR6CZ
MY_=#^S/[_P"'_!/E6BOJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^_^'_!/E6BO
MJKRM*_N67Y+1Y6E?W++\EH^N?W0_LS^_^'_!/E6BOJM8-,=@J16C,>@"J34O
MV"R_Y](/^_8_PH^N?W0_LQ_S?@?)]%?6'V"R_P"?2#_OV/\ "C[!9?\ /I!_
MW['^%+ZXNP_[+?\ -^!\GT5]5M!IB,5:*S5AU!50:3RM*_N67Y+3^N?W1?V9
M_?\ P_X)\JT5]5>5I7]RR_):/*TK^Y9?DM'US^Z']F?W_P /^"?*M%?57E:5
M_<LOR6CRM*_N67Y+1]<_NA_9G]_\/^"?*M%?57E:5_<LOR6CRM*_N67Y+1]<
M_NA_9G]_\/\ @GRK17U5Y6E?W++\EH\K2O[EE^2T?7/[H?V9_?\ P_X)\JT5
M]5>5I7]RR_):/*TK^Y9?DM'US^Z']F?W_P /^"?*M%?57E:5_<LOR6CRM*_N
M67Y+1]<_NA_9G]_\/^"?*M%?57E:5_<LOR6CRM*_N67Y+1]<_NA_9G]_\/\
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MO_79/YBHJ2Y8.78<(\TDNY%-;SVS!9X9(F(R ZE21^-1UU?CP8U6W_Z]U_\
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MKA94Y55+2._E\CDEE^(C.--QUEL9-.5&?.U2V!DX&>*Z>'PBD^^)+^%KA.J
MGC]*TO#>CVZZ5>F?RC,R$$LN3'D'VX]:Y,3GV%I4I3@^9IK2SZ]?0Z*&45ZE
M10EHG?7T.)@MI[EBL$,DK 9(C4L0/PJ,@J2"""."#79^#[=+;7[V&.595$)
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M #KF618APJJ35YQ4=Y/5.]VWW-GFU%2IM)VC)O9+1K;0W_#+L?%DN6)S(_\
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M?*&?N_>R?7\*9>)<2>$93K(43@C!XS]\>GX5RG_"3:U_T$)?T_PJI=ZI>WX
MNKAY0.F[%>/A\BQ,8TJ<^1*#3YHI\SMY^9Z5;-J$G4G'F;DFK.W+J=5'IUOI
MVD6]PMJ]Y-(<#]Z5 .3VY%3>*A(^BZ7A!'(63Y<@[3M/&:Y6WUS4K6V^SPW3
MI'C 48J*YU2^NX!#/<O)&#N"G'6MX91BGB8UJDD^63=[N[3Z6V5O(REF6']A
M*E"+5TELMUY[L[8WUPD,$&I::)05PLJRCICV'TJE?6=EI7BBR,;';(1D$DX.
MX8Y-<[!XAU6VB$45Y(J#H..*I3W4]S/YTTA>3.=QI8?)*T*CO)1BTTU%NSOL
M[/16\AULUI3@K)RDFFFTM+>:WOYGH%^Q77(S'I)GD/*2BYVCJ>U4;6]+^-@;
MF!;>4KC&\/C"'N*YN/Q%JL4 A2\D" 8 XX%9QFD,OF[COSG=4X?(:BA*%5KX
M7%-.3>O75V2\DAULW@Y1G33^)2::BE^"N_4Z^'2;]?%IE92$W@[MPY''O6;X
MQ_Y#S?[G_LS53D\1:K*BJUY(0I!'3K5&ZNY[V;SKF4R28QN-=F#R_%0Q,*U=
MQ]V/+I?[SFQ.,P\J,J5)/65];'6>#V673[VWC8+,0N/?DFCPKIU[8:C+<W:E
M(4C8-E@?ZUR5O<36LHE@<HXZ,*NW.OZG=PF*:[=D/4''-9XK*L1.I65*4>2K
M:][W5E;0TP^848PINHGS4[VML^NIUD<JOX8UZ2(X5KJ8J1Z<53\,$G0K\$YX
M7_T(UR\6HW<-D]G'.RV\A):,=#G_ /51;ZC=VL+Q03LD;XW*.]0\EJ>QJ4HR
M7O24EZ*V_GH-9I#VL*C3TBT_5W_S*M%%%?2'BA1110 5]"?"K_D0;/\ ZZ2_
M^AFOGNOH3X5?\B#9_P#727_T,URXO^'\SORW^,_3_([2BBBO-/=/GOXJ_P#(
M_7G_ %SB_P#0!7%UVGQ5_P"1^O/^N<7_ * *XNO8I?PUZ'S.)_C2]6%%%%:&
M(4444 %%*,$@'I76V7AK1KTJD>IR&4C.T%37%C,?1P<5*K>WDF_R.G#82IB7
MRT[7\VD<C175:CX>T>QCF U)S/&#A"5Y-<P(G;)1&8#N!FGA,=1Q4'.G>WFF
MOS#$82IAY<L[7\G?\AE%&"3C'-/$4A;:(V)],5UMI;G-9L912D$'!!!IQAE"
M[C&X'J5-#:068RBE56;[JD_04OER;=VQMOKCBBZ068VBKVE:9-JMZMO#@'J2
M>PJ&]M6L[V>W;/[J1DSZX.*R5>FZKHI^\E>WD:.C-4_:6]W:Y7HK=\.:%#K8
MN_-F>/R%4C:!SG/^%9-I +B^@MV) DD5"1VR<5G'&4I5*E-/6%K_ #5U^!;P
MU10A-K2=[?)V(**U_$6D1Z+J*6T4KR*T8?+#GDD?TK+\J0+N*-M]<<5>'Q-.
MO2C5IOW9;$UJ,Z-1TYK5;C**U?#^E1ZQJ1M99&C7RR^5'/&*I7MN+74+BV0E
MA%*R GJ<$BE'$TY5W03]Y)-^C!T)JDJS^%NQ7HK5T32!J>HK;3M)$K G('/
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M\Z4$[PVI^TW\[6V_$Z(98Y6][>?)MY7O_P  XBBM>\T^>_\ $E[;VL>6\]^
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MB%K>=HG^\O6HZ]^,E))K9GCM-.S"BBBJ **** "BBB@#K?AE_P E#TKZR_\
MHIZ^BZ^=/AE_R4/2OK+_ .BGKZ+KS<9\:]#V\L_A/U_1!1117*>B?-_Q%_Y'
M[5O^NB_^@+7+UU'Q%_Y'[5O^NB_^@+7+U[-/X%Z'R]?^++U844459F%%%% !
M1110 4444 %%%% !1110 4444 %%%% !16_X4L5NM3,THS#"I<D^HYK8\7VD
M%W81ZA:*OR-L;:,8 !/]:\BMF].EC8X1QWZ]$WLCT:673J85XA/;IW75G$45
M:L-.N=2G$-M'O;Z@?S^E:-YX6U"SMS.55T7[Q#+Q^M=E7'8:E45*I-*3Z7.6
M&%KU(.I"#:76QB45V>B^'$G\.7$S1@W,RGRFW= 0".^/6L"?0;RWTU[YU'DH
MVTD$?WL>OK7-1S?"U:LJ2E9Q?+KU;[&]7+L13IQJ<MTU?T7F9=%:$&CW,^GO
M>HH\I.IR/\?:GZ9H=YJJL\"@1J<%BP'IZD>M=4\9AX1E*4TE'1Z[,PCAJTFH
MQB[O;S,RBMB_\/7NF!)I5!B+#Y@P/<>A/K6QXWMM^J644$:AG4@!0!DY%<O]
MJT95J5.FU)3YM4]%RV_S-_[/JJG.<U9QMI;>YQ]%="/!^I&,'""0C.S>O^-8
M4T,EO,T4@PZG!&:ZL/C</B&U1FI-=F85L+6HI.I%J_<CHHHKJ, HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *^A/A5_R(-G_ -=)?_0S7SW7T)\*O^1!
ML_\ KI+_ .AFN7%_P_F=^6_QGZ?Y':4445YI[I\]_%7_ )'Z\_ZYQ?\ H KB
MZ[3XJ_\ (_7G_7.+_P! %<77L4OX:]#YG$_QI>K"BBBM#$**** "M[PA_P A
MZ/\ W3_,5@UK>';VWT_5DGN7V1A2"<$]QZ5PYE"4\'4C%7;3.K RC'$PE)V2
M:)=<B,_B:>(=6E8?^/&NLFLGT^&WAL-,MYE(_>.\(8GIW_.N+U:^CGUN6[MG
MW*9&96QCN3WKH9M3T?6(8)+F[DMI8QAE4.V>@[8]*^?QU#$.EATXOD2U5F[.
MVETK/_(]C"5:/M*VJYF]'=+2_1NZ(M<TNWM?$6G-#$JQS2H6CVC ^8#&*OZU
M?6FDZW#;1:?:MYBAG+0J>"3P/RKG;R_T]M=M9K4.MM%*K,S,S9 (.<'D5)XB
MU.TO]>BNK:4O"L84MM(YR3T/UHA@:U25"%92:4)7O=:]+V;U^83Q5.$:LJ32
M;DK==.MO(T]9M+6WU^TECLA(LJDF"-%P?E';IWS6O9PR7<\L-YIEK# 4.U?(
M 8?TK-D\2Z:-7M)EDWQ*A#L48;?DQTQZTMMJNB6.K278OGE,@(YC<!1QV[UY
MM:CBYT(PE3ES*&CM)N]WIV3]=3NIU,/&M*2G'E<M5=+2R^_Y$'AFRMF\2:K;
MR0QO%'O"AE!QA\59T?4+34-2FL&TZU$0)"XA7/ ).?RK/T;6-/LO$.IW4LY$
M$^\QML;G+Y'&/2J6@:E:V.N27-Q(4B+,0VTGJ&]/J*[\3@ZU9UYRC)M0CR[_
M !6UMYG'0Q-*E[&*DK<TK[;7TOY&MX69;3Q)<621H5P2&*\CIQFL3Q->BZUB
MY3R8X_*E9,HN"V&/)]35C3=7MK3Q1)>LV8'&W=@]\=L>U5O$+:=+?R3V,YD\
MYC(_R,,$DD]:[,-AY0S-5:D'[T%K9VOUOV.:O64L"Z<)+23TTVZ6-SP!C.I9
MZ;4S_P"/4EG;>&1?VYAGG,HE78"Z_>R,=JH^$M6LM+%]]LE,?FJH3Y2<XW>@
M]Q6'8RI#J=M-(<1I,C,<= "":BIE]6MC<5.\HIJ-K:*7N_C8N&,IT\+AX6C)
MWE>_3WOP.UUNP34/&EK%(,QB!2P]1N:KHMW.H_96TFV%AC&[R!GIZ_6L'5?$
M5L?$]O?V;F6%(U5^"N<$G'(]Q5B6\\/S79OGO92".80)!SC'7_ZU>1+"8I4:
M49QE;DLK1;:EZ)JS[-GHK$8=U:CC)7YKO5*Z];.Z\D)H5DEAXVN;>/\ U:Q,
M%_2DTJPMY_$.K7-S&LB0S2$*P!&=_O\ 6L[0M5LK/Q%+=REH;=HV502SD$X]
MLU)IFO6UGKU]+(=UI<R.=V", MG.,9KT,3AL8Y57%-OV<%?NT]5Z_,XZ%?#<
MM-2:2YY.W;33Y&QH&L17^L/$;.WB9<B-HX@IZ'.3^%<AK7_(8N?][^@KI[&_
M\.Z3J!FBN&;S,DML<;.#V[YS7*:G/'<ZE/-$VY&;(.,=JZ<IH\N.G4ITY1@X
MJW,FM;Z[_P!=3#,*E\+&$YJ4E)[-;6.KT\^3X#NVAX8DY(X(^5:X^UDN$N5:
MV=UFYP48@].>:V_#VNPV,,EC>KNM)<[N3QG'H,]JU+>Y\,:7,;NWD,DW\"E7
M&,\'KQWJ85*N!J5X2HRFYN\;*Z=ULWT\QRA3Q<*4E44>56=W9KS7<S?#UB=1
MU:274"\HB4NPD.XDC!YSFM2VUBRN];.F/IMJ(&D,2$0KD8./Y5D6'B,PZ[)>
MRQCRIOE9 >@..>![5JQW7ANUOFU..=FF+%Q'L<88G/6L,?1JRJR=:G)WBN7E
MNU&7RVUZFV$J4U32IS2M)\W-NU\_R+FCZ/:6FJ:Q;R0I*D:Q,N]0<9#'CBJ^
MC7MKK,=U;/I]JB+&Q0K" 1Q_/FJ^D^);47>J7%](8VN%01C:6SC([#Z5F>&=
M2M=.FG:ZD*!XV4?*3R1[5A+ XJ4:\ZL9.:5.V^_*KV[Z[FL<70C*E&FTHMSO
MMM=VOVT-OP;*L6J7UDL:81F(?;\V-P&,U/H<EMJ=UJLD]G;XC*@ 1#_:_P *
MP] UBUL-?NKB9\0S%@&P>A;.<8K2L=4T33)-1$=V2LX4K^[?D\D_SJ,PPE7V
MM9PIRYI1A9I/NN;8K!8FG[.DI35HN5TVNSL8EYJT.HW=LJ6,21HZ_)'& 6YZ
M5U=D)9;F"-M(MH+1@!B6 ;C^7%<-I-W'9:E#/*N45AGV&1S75RZKHG]K1:E]
MN=B,$1;' 4\G^OI79FV$E#EHT:;<5%V:3EK\GH_-G-EV(4KU:LU>ZNM%I^OH
MBJ-%MI?&;VNP"W4;BH _N$^F.M/N?$%C!J$]I+IEL;505&R%0W3\JJW.O6\/
MBLZC;.98"H!&"O\ #CN/>KKW7AD7<FH><7D8$^44<9/;G\*RG3JMTY8FG.2]
MG%*U[J76_9^;-(SIVFJ$XQ?.[WMK'I;NO)&CINIPGPO?7,%K&L43,%C9!@@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =]\'_\
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MQ&[1LN=PQQR#TYHNPLC&_P"%)> STTVX_P# Z;_XJC_A2/@3_H&7'_@;-_\
M%5;_ +6U%M1T]+/8+=[A5<,<$]<_IBM2;Q!?.T\EC:1RVT& [,3N)S@A<=>:
M+L+(P/\ A2/@3_H&7'_@;-_\50/@EX#/33;@_P#;[-_\56S+XHGN[CR-.MDE
MC92Q=\C"CKT[U;M-5\K1)KI$RRN0 W3.T'GT%%V%D<W_ ,*2\"#KIEQ_X&S?
M_%4?\*2\"'_F&7'_ (&S?_%5HR^)IKF"[M93:B4*C(UM)O')SS^%=)I#M)I4
M#.<L0<G\31=A9'%?\*1\"?\ 0,N/_ V;_P"*H_X4CX$_Z!EQ_P"!LW_Q5>AT
M47861YY_PI'P)_T#+C_P-F_^*H_X4CX$_P"@9<?^!LW_ ,57H=%%V%D>>?\
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M*YA=E(C)*D# R"?<FJ?B_41!9Q6"7"6\]X2$D9@-NW#'K[4GKN"26Q@M\%O
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M,]R/PK98BHE9,Y98*A)MN/XLX+_A7/Q _P"A83_P8P_XT?\ "N?B!_T+"?\
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MG<_^ [_X4?;XO^>=S_X#O_A7V%11];GV0?V;1[O^OD?'OV^+_GG<_P#@._\
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MR6P-P05$2E57YL]*FN?#T\UI:0K-&#"K*2<\Y.:QO^%0>$/^?:__ /!C/_\
M%T?\*@\(?\^U_P#^#&?_ .+H TAX:O83:/#<0;X;D2MN!(*@=![T/H6L6PN(
M=/NK1;>8[L2JQ8-G)Z>]9O\ PJ#P?_S[7_\ X,9__BZ#\(?!X&3;WP'OJ4__
M ,70!LV'AHZ?-+Y4J^48V10>HR.],F\/7G]B-9PW*++YIDSSM8;<88=Q[5D+
M\(O!S#*P7Q^FI3__ !=+_P *@\(?\^U__P"#&?\ ^+H G3PA?&X>9WT^+>JJ
M1!$4SCO75V%LUI8Q0,P9D!R1TZUQO_"H/"'_ #[7_P#X,9__ (NC_A4'@_\
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MA#_GVO\ _P &,_\ \71_PJ#PA_S[7_\ X,9__BZ .[HKA/\ A4'A#_GVO_\
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MO^-']H67_/Y;_P#?U?\ &@"S15;^T++_ )_+?_OZO^-']H67_/Y;_P#?U?\
M&@"S15;^T++_ )_+?_OZO^-']H67_/Y;_P#?U?\ &@"S15;^T++_ )_+?_OZ
MO^-']H67_/Y;_P#?U?\ &@"S7"?"/_D1O^W^[_\ 1S5V7]H67_/Y;_\ ?U?\
M:XWX1$'P+D'(-_=X/_;9J .[HHHH X3P\<?%WQL3T%M8?^@/6EXAU.UU#PU+
M);R!EW!?Q(-9OAWGXO>-A_T[:?\ ^@/6U+X*T6;4/MK02>9O$A F<+N'0XSC
MM0!S5HT%Y+:PPZ?+?31V,:/YX62&,CKA3T/]#60DD\WA":$W$B[9\#RV(V_O
M1P/3TKT&Z\)Z3=W?VF2&02%=AV2LH(SGH#[TL?A+1H[9K=;9A$Q!(\UNH.?7
MUH PM7LH-)\169LE\@/ X<1X4-R.3CJ:PX[:&YOM/:>))6;77C)=0V5V].>W
MM7H]WI5G>W,=Q/&6DC4JI#$8%4;CPGI%S;?9Y+=]GGFY&)6!$A&"<@T 8FBV
M=MJVHZI)J"+-)&%58Y &$0^8 J#G&0!T]*YXF2\M+2S:YF>V2]A17+DET)Y!
M/<<UW=[X2TF^F$TL4@DVA24F=<@# S@U8'A[3%@MH1 0ELP>,;SP0<COSSZT
M <WK\5MHVI:4D1,-NLREMAV]CZ?2L'5 K^&I[JVT]X4$HQ>7*JTO,@'#CG';
MZ&O2+[1[+49HI;J(N\1W)\Q&#_DUECP1H>TJ8)2A);:9WQG.?6@#+TB1I?&$
M#NQ9C:R9)/N*[:LZUT2PL[I+F&(K*B%%)<G@]>]:- !1110 4444 %%%% !1
M110 4444 %%%% '">*O^2K?#_P"NH_\ H@5W=<)XJ_Y*M\/_ *ZC_P"B!7=T
M %<E\1?^14E_ZZ1?^C$KK:IZGI=IJ]F;6]C,D)()4,5Y!!'(]P* ,_Q=<3VW
MAZX>W+*[ J64X(!!R:XB>UNX]&T^Z2..V<JC_:0NUYLK_$PY;/7FO3YX([F!
MX95W1NI5A[$8K"B\%Z+%.)5AE.T[E4SN0#],T <G;:7 WP[>]D+/>";BX)RX
M_>@<-U'''TJ_/<Q:AJ-O&+.?4+E86#K)AX5Y[J>]=:NAV"Z4=,$)^R%MQ3>>
MN[=UZ]:J7/A+2;J9)7AD#HI4%967@_0T <"DD_\ 8>N6WFM$%NI@$B)41\@8
M [8Z5OZGI\&F7F@SVB^5(Z2>8R84R?(/O8Z]3U]:WX_".C102PI;/LESO!E8
MYS^-7[G2;.[-L9HRQM@1%\Q&,@#\>@H YSPA9VT.N>(7C@B1DNE52J $#8.!
M5SQ/'IM[-9V-[+-!,\@^SS0N$=7P>AQD<9K1M]!L+75YM4AC=;J?_6-YC8/3
MMG'85+JFD66LVWD7L1=,Y&UBI'XCF@#D+XZKX7FMFEO$OK23<-DY:27H!P2<
M=2,_2FZ1I]E>)XBFNCYSQL=K288Q?N\Y7(X]>*WK'P9I&G7 N88I6E4':9)G
M8#((Z$D=ZRM,\&V]S>:A/J4$@:28%-LQ 9<#.0I_G0!EP7J3V5E:3Q7=[+'/
MMAB#AE:,+A2X/4&H8+B[L-:U>."-;8[(?W$(V*N0>PX[YKN+OPQI=[!;120,
M%M@!$5D92,# Y!Y_&BR\+Z5I]P9X('\TC!9I6;/!'<^YH P]/TK1U\/Z9>3W
M#0RF5"+I6 DE;<<*S8R0<=/:LV1KK4O%MXA@6\CCC(CBF7>H4.<-@]_>NG@\
M&Z-;W23I!)N1@R@S.5!'(XSBK&I^&M,U6X6>XB?S0NT-'(R<<^A'K0!G>"Q<
M1VUS#-.)$1OD&22N2V1S7454T[3+72K46UHA2,$GEBQY.>IJW0 4444 %%%%
M !1110 4444 <)?_ /)<-'_[ EQ_Z,6N[KA+_P#Y+AH__8$N/_1BUW= !7">
M,/\ DI7P_P#^OB]_]$&N[KA/&'_)2OA__P!?%[_Z(- #];EA;Q8D-W)+Y/EL
M0J 'G JUX>NYK9M0ED-S_9L1=D,Z;2,8^[V(QWK5?0Q+X@&HRB&2((5V,N3R
M!_A6A<V45Q8RVFT)'(A0A1C@T <Y!XQ#7$;2FT^S2,RCRY<R#'JN?I3XO%,T
MNH>4([98MZIY;/B<9[E/2H;7PK=13QQRQ:4;=&8EEM\2$'I\WKTI)_"U_/>K
M)YEC&%E23SHXRLS $9!?OF@"W8WNIR^,;JVE,9M$B)0;CG[^,_7%)J\D^H>(
M+;2EG:& 9:7;_'E<C\B*NQ:5=P>)'OXYHOLSP^6R,"7W;LYSTZ4W6-'N;F\M
M[_3IHHKR$G!E!*-D8Y Y/&: $M],.CWC3Q7+"S$;,\)QQ@=OUJK_ ,)'> "\
M-K'_ &:9-HDYWXZ[L=,8[YJ:WTG5+F[>XU6\C*^4T2Q6Y94PPP2P/4^E5/\
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M0;F;5KB9IH?LMQ;&&1,'=DMDD=L8JC:>%;J&>))8M*-NC,2R6^)"#T^;UZ4
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M:Q.C#GDEL\4 5U\42C2KBX>V7[1;W36LB+DC>J@G'J.:CC\0ZM+=R62V-O\
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MUJ:UMK#4++Q!J&H7C7,:3&.[<VK*6YPAYZ#^= '>?\*H\"?]"U9_^/?XT?\
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M:[*B@#C?^%4>!/\ H6K/_P >_P :/^%4>!/^A:L__'O\:[*B@#C?^%4>!/\
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M2WZF]^QI'<R&-_W(W[R1D87ICO76_;OBC_T!O#7_ (&2_P#Q-'BK_DJWP_\
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M0'Q%"^G7%U%;W(:$*3%)'A\$X'% '._\(Q\0?^BBP_\ @BB_^+H_X1CX@_\
M118?_!%%_P#%UNV'B6&70K>_N8I4>7I$%^8\D< ]>E3CQ)8?9'N'\R((Q5HY
M%"N#C/(S0!S?_",?$'_HHL/_ ((HO_BZ/^$8^(/_ $46'_P11?\ Q=;H\6V+
M;E6WO#(H!\H0_.0>A SG'>M>SO(;^TCNK=P\4@RK @YYQVH XO\ X1CX@_\
M118?_!%%_P#%T?\ ",?$'_HHL/\ X(HO_BZ[NB@#A/\ A&/B#_T46'_P11?_
M !='_",?$'_HHL/_ ((HO_BZ[NB@#A/^$8^(/_118?\ P11?_%T?\(Q\0?\
MHHL/_@BB_P#BZ[NB@#A/^$8^(/\ T46'_P $47_Q=<E\.M!\977AJ>33O&L5
MC +^Y4Q'28Y<N)"&;)8=3SCM7M%<)\)?^1/N?^PI>?\ HUJ #_A&/B#_ -%%
MA_\ !%%_\71_PC'Q!_Z*+#_X(HO_ (NN[K.UO4SI6FO.BAY3D1*>C-C('Z4
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MC:_]"IXO_P#!0_\ C0!W=%<)_P +1M?^A4\7_P#@H?\ QH_X6C:_]"IXO_\
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M-T@E:6.Y\K&PM('/R[N>F.M+IWA+5AJ\-]K&NI?+ I"1QV2P<Y!!RK>U5/\
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MRH4 _3FN;T[6M*T?XO>,3J>IV=D);>P\LW,ZQ[\(^<;B,XR/SKK/^$U\*?\
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MB#_T4:'_ ,$47_Q='_",?$'_ **-#_X(HO\ XN@#NZ*X3_A&/B#_ -%&A_\
M!%%_\71_PC'Q!_Z*-#_X(HO_ (N@#NZX3X2_\B?<_P#84O/_ $:U'_",?$'_
M **-#_X(HO\ XNN2^'6@^,KKPU/)IWC:.Q@%_<J8CI,<N7$A#-DL.IYQVH ]
MHK)\1:?+J.ELD'^OC.^,'NV#C^=<U_PC'Q!_Z*-#_P""*+_XNC_A&/B#_P!%
M&A_\$47_ ,70!HMJVMS6<=G::1<6]S@+Y\P!C7&,DX.><''UHNX[S3M:O+A=
M/EO8[I3M* '9\H&.?6L[_A&/B#_T46'_ ,$47_Q='_",?$'_ **+#_X(HO\
MXN@"73-$O8M2MKF:U8(T@FVD?ZG/\/MCVJ*YT2];P=JMLEDWVF:;<B #+#S0
M?Y<T?\(Q\0?^BC0_^"*+_P"+H_X1CX@_]%&A_P#!%%_\70!NZY8S7>HV+I 9
M$C8%CC('(K+FT>Z;2O$J+:'S;F28P\#+@XQBJW_",?$'_HHT/_@BB_\ BZ/^
M$8^(/_11H?\ P11?_%T 7OL]YI>HV][]@ENE>WCC*H!F(JF#UZ9SV]*HVFBW
MSW<-U)9,B22*_DD#]U@^G0>O%'_",?$'_HHL/_@BB_\ BZ/^$8^(/_11H?\
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M /I/7=UY+=:7XBT[XI^!SKOB1-85Y+WR@M@EMY1%N<_=)W9X^F*]:H ****
M."\'$CQK\0".HO8?_1 JMX,\964+>(H-9U@":+6[E(EGD9BL0VX SG SGBK'
M@[_D=/B!_P!?L/\ Z(%5?A_H5G>#Q/+>VI,AU^ZVELC*X3']: *]OJMQXG\8
M>+K+2]8G-JEM9M;O#,P$;?,7V^F=N#CK71>&?$S7GP_&KW1Q<PV\DDRMU!&X
M@'GT%97AG3X[#XL^*XX(#';FUL]O!P3M?/-8>MVU]IGB:XT"TB<P:M>13K@?
M*D*@*X_')[@T ;NFZS>Z;X!U3Q#=7$LTEV\EY:)(Y;;&ZJRHN3P!SP.*9X#U
M/4K36+S2-8NI9VDCCN+9Y9&8MO#.R@D]A@5'XQT^;4K_ $3PAI[M;QVXCGDE
M\O<HB^:/&#CV[YK,\3>'=4\)SV/BG^TFOQIVY6C2W"'#@1#H3G[WH>GXT :T
M O\ QYK^IQG5+W3],L)%CC^PW#0R294')(R#SFMK0-'UG0M<EM7U"XO](:'<
MDEW*TLRR;L8+'C&T=,=2:YW2]8M_ FOZK!JJRI87LJR6LZ1L^0J@$%5!(YSU
MK=T/Q5=>)?$DG]FQO_8D4.#.Z[2TH;E=K ,/E(.>E '8T444 %%%% !1110
M4444 %<)\9/^25:Q_OVW_I1'7=UPGQD_Y)5K'^_;?^E$= '=T444 <MXE?Q=
M!*\^BW&E):(H.VZA=G[=P0.M9/@K5O&GB+3K#6+N?1UL+E2QCC@D$@ ;'7<1
MV-=GJW_(*N/]VN2^';2+\(--:+_6BTE*?7<^* .CNO$^B65^MC<ZC#'=-P(F
M)R>2/Z&I[W6]-TY5:\O(X0PR"W<?Y->/Z=;7UUH6O&62)$DNYO/=RN]6(7.,
MG/Y5I6%B+OQ?X5CO)FN0GV@9(*@CR3C(S["@#TVPUO3-4M'N[&\CGMXQEI$Z
M"JMMXMT"\OQ8V^J0271.WRE)SG.*X&ZFL]'\0>)E>W:2WD./(20H&8QC R/N
M_6LC5I;L6GAB9K:*PM_M,7DQ)*DK ;#@%QR>.Y]* /6+[Q1HFFL5O=2@A(ZA
MB:QV^(&DGQ?9Z+'=1,EQ"S>8/[X( 7\<UA>$M.MKSQ5XBGN(_-;[/;XW$D#Y
M7[5S/@"*"+QUH\;A0BZ?-MWGOO&.3WH ]KN;VVLVA6XF6,S/Y<8;^)O0?E3/
M[1M/MHLO/3[21D1]\8S_ "K \?VKR^%Y[R($SV(-Q$!W8 C^M>9_VLPUVS\?
M/(XL(XS#*O.-WE^5]?O-Z?XT >L:CK>V>**QO+0$3I',LH)/)Z#'?%<WKOCC
M4=,U?4;6&. I;6YE0LA))#D<\^U<ZMK-!X?\-W5SE;N[O87G&>XDQ_+%1>+O
M^1DUO_KR;_T8: /5;K4)8/#XOU"^9Y2/@CC)Q_C6/X8\<:;K&FV0N;ZW74IU
M):!<C!W8Z?E5W4<?\(5ST^SQ_P#LM>>6=MH\?PETA[<K]H$BF(ACOW[VVY[]
M?7B@#U#5-?TK10IU*^BM@WW=YZ_YP:MVMU!>VZSVTJRQ-]UEZ&O&]+_MFZ\6
M,TYC^U+8*,3%-NW?U^;C.<^]=C\.()+:WOHS=&:/S,JNS 4EFS@YYH [FBBB
M@ HHHH **** "BBB@ HHHH *X3X1_P#(C?\ ;_=_^CFKNZX3X1_\B-_V_P!W
M_P"CFH [NBBB@#S;3]$TG6?B]XQ&J:797PBM[#RQ=6Z2[,H^<;@<9P/RK3UW
M2/!&@I"9_">CR&1PNU+"'(!/+<KT%1>'?^2O^-O^O;3_ /T!ZI:QJ=O?^*;U
M9T=XK:WDM1M4D9< YX% '2VW@[P?=6L5Q'X7T0QRH'4_V?%T(R/X:E_X0?PE
M_P!"MHG_ (+XO_B:Y.P\0SCPE-8PN8IX9FM8F89*QJH"M@BM6YTDZ#:PZI8W
MK(^S,T3Y?SBP &,D[<%B>!0!K_\ "#^$O^A6T3_P7Q?_ !-'_"#^$O\ H5M$
M_P#!?%_\361I?A]I=/L=3&I-'?,ZM+,02K@-RNW=@9P.16?J=\^I^);BUNHY
M)K:W0JL<;E"6#$;LCGIVH Z?_A!_"7_0K:)_X+XO_B:/^$'\)?\ 0K:)_P""
M^+_XFN'#ZI-Y,=];M<Z="S[@DXC90>GW?F/./RKH=,N#=>&+Z/2;UIW3*B-T
M*%,J?ERW7/K0!K_\(/X2_P"A6T3_ ,%\7_Q-'_"#^$O^A6T3_P %\7_Q-<QX
M?GMK75[.&5YK&]DVK+$Q:99F[X;HN2#T]*]%H P#X(\(@9_X1?1/_!?%_P#$
MUS4]MX3%W/#8?#^PU!8)&BDD@L(-JLIP1R/I^=>A2%1&Q?[H!S]*XJ#2]4L[
MF]NO#VHI-;3W#RR6IA4'S"<GYV.?0=* +&C^'_!.LV?VB#PMHHP2&0V$.5(.
M.?E]JT?^$'\)?]"MHG_@OB_^)KF)]3N)]'N+JWM/LFH6#KYL*R!PV]PN<XQT
MR>]6M2O;O7=3G?2I<PVT#QLN0-[D9')QB@#</@CPBH)/A?1,#_J'Q?\ Q-5=
M.\,>"]4M!<V_AC1#'O9,_P!GQ=5.#_#[5SFF&S%U#9W+S6-W,H2:$L\HF;OA
MNBY([>E4[.9]&\$@V)9)KNYE5G+;L!)?0^Q(H [K_A!_"7_0K:)_X+XO_B:/
M^$'\)?\ 0K:)_P""^+_XFN7M9)]/U)/[/@DB@>,B5))BV3GJ"W/ ["JTEI-+
MX<US6I+J0W=G<S?9R,@(!C QG!ZGJ* .Q_X0?PE_T*VB?^"^+_XFC_A!_"7_
M $*VB?\ @OB_^)KG9K672Y-(U)+EVN9E8RDYPWR@#C.!C)KT"@#!_P"$'\)?
M]"MHG_@OB_\ B:/^$'\)?]"MHG_@OB_^)K>K"C\30R:F+$6[AB2-V#C@9]*
M$_X0?PE_T*VB?^"^+_XFC_A!_"7_ $*VB?\ @OB_^)K>HH \M\2^%/#D'Q,\
M#6L.@:5';W!O_/B2SC"2[805W ##8/(STKM/^$'\)?\ 0K:)_P""^+_XFL+Q
M5_R5;X?_ %U'_P!$"N[H P?^$'\)?]"MHG_@OB_^)KD]43PMI(=[GX<6@A0@
M>;]@M]IR<#MZD5Z57)?$4#_A%9?^ND7_ *,2@"#2?#_AK4G99O &GV0'>?3X
M.?R%:W_"#^$O^A6T3_P7Q?\ Q-2^)[^73="GF@&)&!13Z$@\UP?FW,%G:7MI
M'(MVX5YY&E)$F1DX!X&3SQ0!V_\ P@_A+_H5M$_\%\7_ ,31_P (/X2_Z%;1
M/_!?%_\ $UQ\-A--X+.MRW4G]H++A7!. /,VXQG!XXZ5I:K>6E]=6JWUW)*S
M0L1:1HR9.>N]>GT]Z -[_A!_"7_0K:)_X+XO_B:/^$'\)?\ 0K:)_P""^+_X
MFN)AU&]3P[JT$$C0B&XE$.3O* 8 &3UP/6M>YL3HFH:/<VT[[KE'\\,20_R#
M'4G'WCTH T[/PSX*OKBZAA\,:(6MG$<G_$OBX)&?[M0:SH7@O1H8FD\):/++
M,^R*)+"'<[8S@97VJ/P9IEM;:]K\D8?='<JBY<G@H#ZUI>)]/BU*6RCCOA:7
M\,HDMW,6\;L$#C('KUH P;.S\(RW\-I?> ].TYYL^4;BP@P^!DXP#[?G71_\
M(/X2_P"A6T3_ ,%\7_Q-8=SJ.K:3<6XUVU2ZMSN"W894*<?W%!)R2!4-CIAU
M8ZU<75TY>W?-OM)7RSLR,X////- '1?\(/X2_P"A6T3_ ,%\7_Q-'_"#^$O^
MA6T3_P %\7_Q-<R^J)=:1:0ZC?NHBG\@Q)$29PJ_WE^[FJ^FZI+I6H:I%:1O
M';!8MD;R%R,@Y.3SU.: .N_X0?PE_P!"MHG_ (+XO_B:/^$'\)?]"MHG_@OB
M_P#B:R=+\/M)86.IC4FCOF=6EF8$K(,\KMW8&<#D5FZE?/J?B6YMKN.2:VMT
M*K''(4.X,1NR.>G:@#J/^$'\)?\ 0K:)_P""^+_XFC_A!_"7_0K:)_X+XO\
MXFH/!UQ>R64L-V.(C^[;()()/''IQ72T 8/_  @_A+_H5M$_\%\7_P 31_P@
M_A+_ *%;1/\ P7Q?_$UO44 8/_"#^$O^A6T3_P %\7_Q-'_"#^$O^A6T3_P7
MQ?\ Q-;U% &#_P (/X2_Z%;1/_!?%_\ $T?\(/X2_P"A6T3_ ,%\7_Q-;U%
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M1?\ @BB_^+KNZR/$M_+IVC2W$+A' .&)P!P: .;_ .$8^('_ $4:+_P0Q?\
MQ='_  C'Q _Z*-%_X(8O_BZT-,NY[B: G7+:4NN3$DZECQGIUK5_X2+3^5WM
MYHD6,P\;P3TRN<T <U_PC'Q!_P"BC1?^"*+_ .+H_P"$8^(/_11HO_!%%_\
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M7.L:V]Q/:RK;V\4K1Q ''F <@GCN#V]*?8^*8X[1QJ:^7<1,594[C. >3WH
MR?\ A&/B#_T4:+_P11?_ !='_",?$#_HHT7_ ((8O_BZZ6VUR"^M[KR4FBFA
M0DQSIL;.,]*AT;7$NR(+@[9VY7/0CCCZ]: ,#_A&/B#_ -%&B_\ !%%_\71_
MPC'Q _Z*-%_X(8O_ (NNRL[^"_5V@)958J6[9!P:LT <)_PC'Q _Z*-%_P""
M&+_XND'A7Q^K%A\18<GJ?[!B_P#BZ[RB@#A/^$8^(/\ T4:+_P $47_Q='_"
M,?$'_HHT7_@BB_\ BZ[NB@#A/^$8^(/_ $4:+_P11?\ Q='_  C'Q!_Z*-%_
MX(HO_BZ[NB@#A/\ A&/B!_T4:+_P0Q?_ !='_",?$'_HHT7_ ((HO_BZ[NB@
M#A/^$8^('_11HO\ P0Q?_%T?\(Q\0?\ HHT7_@BB_P#BZ[NB@#A/^$8^(/\
MT4:+_P $47_Q='_",?$'_HHT7_@BB_\ BZ[NB@#A/^$8^(/_ $4:+_P11?\
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MW3_!?A[2KY;VRTN"&X0DJZYRN00>_H36S<VT-Y:RVUQ&)(94*.AZ,I&"/RH
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M=OO8X'R_+CBJK>$1%)#)8:E<V;I L#-$%RX'<Y'4T <="T]AX9N52;<RSXW
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M$H^('_1-X_\ P?0__$4 ;AL)T\2PS)"WV=$"[^PPI%9L.D72Z/<QFT(E>5&
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M<CIS7=2Q++;R0]%=2O'N*XC_ (2CX@?]$WC_ /!]#_\ $4?\)1\0/^B;Q_\
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M0 4444 %%%% !7"?&3_DE6L?[]M_Z41UW=<)\9/^25:Q_OVW_I1'0!W=%%%
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ME9Q2S0$6TDOV-]['(4\^8>N/3WH:8V6A^'],@#^1<00S3C><ON3! /4=!TH
M]0HKSNQGN[.>[@MHVBLG5=JO)N*$ DG)Y.35%[&>W\+Z1JRWDGV^ZN8H)).<
M;68@_+G'84 >I45Q=M;-HWBRWBAF=EN85,H8D[F+')Y)QTZ"NTH **** "BB
MB@ HHHH **** "BBB@!&177:ZA@>Q&:%147:BA1Z 8I:* "BBB@#A/%7_)5O
MA_\ 74?_ $0*[NN$\5?\E6^'_P!=1_\ 1 KNZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A+__ )+AH_\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .$\6_P#)4/A]_P!=;_\
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M !1110 4444 %%%% !1110!PGBK_ )*M\/\ ZZC_ .B!7=UPGBK_ )*M\/\
MZZC_ .B!7=T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '"7_P#R7#1_^P)<?^C%KNZX2_\ ^2X:/_V!+C_T
M8M=W0 5YM\1[J_L_&O@:XTS3AJ-ZD]WY=J9Q#YG[G!^<@@8&3^%>DUPGC#_D
MI7P__P"OB]_]$&@ _P"$H^('_1-X_P#P?0__ !%'_"4?$#_HF\?_ (/H?_B*
MZ3^W$_X2-=(V'>49]V/0 _UJK?\ B86FLW>F1P-)-!IYO0 N=V'VXH Q?^$H
M^('_ $3>/_P?0_\ Q%'_  E'Q _Z)O'_ .#Z'_XBNEA\064F@G5GD"P+PY)
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MED0YPI^T)\Q]!SS0!R?_  E'Q _Z)O'_ .#Z'_XBC_A*/B!_T3>/_P 'T/\
M\1797.H65DBO=7EO C_=:655!^F32/J5C' L[WMLL3#*R&50I'L<T <=_P )
M1\0/^B;Q_P#@^A_^(H_X2CX@?]$WC_\ !]#_ /$5VEK>VM]$9;2YAN(P<%HI
M XSZ9'U%4O$.M1:!H\U_(I?R\8C499LL!P._6@#F/^$H^('_ $3>/_P?0_\
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M2VO5@^T ;"$*;MO4\YSF@#(_X2CX@?\ 1-X__!]#_P#$4?\ "4?$#_HF\?\
MX/H?_B*Z^XU;3;2;R;G4+2&7^Y),JG\B:=<:GI]I(D=S?6T+O]U9954M] 30
M!QW_  E'Q _Z)O'_ .#Z'_XBC_A*/B!_T3>/_P 'T/\ \179SWUI:P+/<74$
M,+=))) JG\34D%Q!=1"6WFCFC/1XV# _B* .(_X2CX@?]$WC_P#!]#_\11_P
ME'Q _P"B;Q_^#Z'_ .(K1U7Q5=VNN_V796/VB0*6)VD],>GUJ]H/B:VUFUN'
M=3;2VUPUM*LPV?O% )QD].: ,#_A*/B!_P!$WC_\'T/_ ,11_P )1\0/^B;Q
M_P#@^A_^(KM_M$/F>6)8S)C(7<,_E6"?%")>06[Q@F4@ KSCG'K0!C?\)1\0
M/^B;Q_\ @^A_^(H_X2CX@?\ 1-X__!]#_P#$5OZMXHT[32D8NK>6<R>6T22*
M74\]1G(Z5:L-52[CDDD:.-$ .2V,9]: .6_X2CX@?]$WC_\ !]#_ /$4?\)1
M\0/^B;Q_^#Z'_P"(KL(-5TZZG,%O?VLLP&3'',K,/P!IIUC3!<-;G4;03*<&
M/SUW _3.: /,KK5?$6I?%/P,-=\,KHRI)>^41J"7/FDVYS]T#;CCZYKUJN$\
M6$'XG_#X@Y!EO\$?]>]=W0 4444 <)X)_P"1Z\>_]?\ !_Z)%=W7">"?^1Z\
M>_\ 7_!_Z)%=W0 4444 %%%% !1110 4444 %%%% !1110 4444 %<)\9/\
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M0 4444 %%%% !1110 5PGPC_ .1&_P"W^[_]'-7=UPGPC_Y$;_M_N_\ T<U
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MVHN[R\5]&W%[V8RM_K\8R>W'3W->A>6F_?L7?_>QS1Y:>9YFQ=^,;L<X],T
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M/B/6#HFD2W2())R"L*'HSX) /?MVK6K"\6:3-J^BM';$"YB/F0YZ%P"!G\Z
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MB70#H=Q<.SJHO %*MG/S\G/&>OM6U<:+?13^&XUC>869A$T@[;002: .@O\
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M'_7[!_Z(%<YX0U;5K&Z\4Q6.E?:HCK]TQDV.<'Y>./H/SKI/!@W>-_'P];Z
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MC'3YFXH ["BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A/%7_ "5;X?\
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M4/A]_P!=;_\ ])Z[NN$\6_\ )4/A]_UUO_\ TGKNZ "BBB@#A/!/_(]>/?\
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MN#P=_P _E[_X+I__ (BCQ5_R5;X?_74?_1 KNZ .$_X7!X._Y_+W_P %T_\
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M'@[_ )_+W_P73_\ Q%=W10!PG_"X/!W_ #^7O_@NG_\ B*/^%P>#O^?R]_\
M!=/_ /$5W=% '"?\+@\'?\_E[_X+I_\ XBC_ (7!X._Y_+W_ ,%T_P#\17=T
M4 <)_P +@\'?\_E[_P""Z?\ ^(H_X7!X._Y_+W_P73__ !%=W10!Y7IGBG2O
M%7QGTV?2I9I(X='G1S+ \1!\Q3T<#->J5PE__P EPT?_ + EQ_Z,6N[H *X3
MQA_R4KX?_P#7Q>_^B#7=UYM\1[6_O/&O@:WTS41IUZ\]WY=T8!-Y?[G)^0D
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M@?\ 12(__!##_P#%T =W7"?"7_D3[G_L*7G_ *-:C_A%_B!_T4B/_P $,/\
M\77)?#K0/&-WX:GDT[QNEA +^Y4Q'2(I<N)"&;)8=3SCM0![165X@TVXU33&
MM[9K?S,YVW";HVX/##N/:N9_X1?X@?\ 12(__!##_P#%T?\ "+_$#_HI$?\
MX(8?_BZ %TWP5?V\6J":XM(OMB1*D-JA2*,H<D[>V:TH?"]Q%J&DW)N(BME#
M)&XP<L6;/%9(\.>/&;:/B7"6]!H<.?\ T.G_ /"+_$#_ **1'_X(8?\ XN@"
M?_A"KD66J*MU$+F?5I=2M7P=J%E 4-W.,'I44WA'6-6E,^K7EHTL2JMOY*,
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M2(__  0P_P#Q='_"+_$#_HI$?_@AA_\ BZ .[HKA/^$7^('_ $4B/_P0P_\
MQ='_  B_Q _Z*1'_ ."&'_XN@#NZ*X3_ (1?X@?]%(C_ /!##_\ %T?\(O\
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MC3QA_P"Z7&:<\L<2[I)%1?5C@4 <K8_#_3[35(-2EU'5;RZA&U&N[KS0!D'
MR/:N@U72[76=/ELKM-T4BE21C*^X)Z&K<<D<J[HW5QZJ<UG:[K$>B::]RT?F
MRGB*+=M\QL9VYP<4 8,'PYTV.]MKN?4M6NGM=WDK<77F*F1@X!'''IZ5+?>
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M^M/KSZ7X@ZWI]DFHZQX2%EIQ"DW"ZBLI ; 7Y53/)('XUWT,J3Q++&<HW(-
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M#@JT87"EP>HJ&">[L-;U>.&-;9MD/[B(;%7(/8<=\UW%YX8TJ]@MHI8&VVP
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M<)SU=/X1V/OQ7:5P47@K4_[<M;MY=.AC@NQ.9+6$QRRJ/X7;^+/4Y[UWHX%
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M7@5WVM:+9Z]ISV5ZIV-C#I@,N"#P2..@K&L/ EA9WGVJ>^U*_E"%$^W7'G!
M?3(X- '#6F@P:CX2\3ZI=NTM[!?7 MY3UB VD8^F3^=>D^%[B6Z\-VTDSEWV
M;<GOCBDM_"VGVVD7^F(T_P!GOI7EE)<;LMC.#CCH*T-/T^'3+%+2 N8DSC<<
MF@#RSP_IFN7OB/Q4VEZDUJ@NT! ;&3Y8YZ&L6[>>T\+^+M)O"DM^'GG>Z0[M
MP)"X)_O9!)&*]#G^&>G2ZG=W\.M:_9R7;AY4M+\Q(2 !T ]!5D?#W1O["O-*
M>2\D6[W>=<R2AIVR!GY\9[9^M '&>(=#\3#P1'+-JZRV@BA9H99,*PW)@'CM
M7IGAZ]BU'0;2[AA,,<JDK&1C;R17-)\+]."+%+KOB.X@7 \B?42\9 Z J1CC
MC\J[2""*V@6&"-8XT&%1  !^ H DKA/A'_R(W_;_ '?_ *.:N[KA/A'_ ,B-
M_P!O]W_Z.:@#NZ*** .$\._\E?\ &W_7MI__ * ]=W7">'?^2O\ C;_KVT__
M - >N[H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#A/%7_ "5;X?\ UU'_ -$"N[KA/%7_ "5;X?\ UU'_ -$"N[H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?X@?]%(C_P#!##_\77=T4 <)_P (O\0/^BD1_P#@AA_^+H_X1?X@?]%(C_\
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M10!PG@G_ )'KQ[_U_P '_HD5W=<)X)_Y'KQ[_P!?\'_HD5W= !1110 4444
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M@#I=)\9:)K5X;2RN9#, 6VR0O'P/]X"F7?C70;/4#83W;"8':<0NR@Y(Y8#
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MSXI?] KPO_X%3?\ Q- '=T5PGVSXI?\ 0*\+_P#@5-_\31]L^*7_ $"O"_\
MX%3?_$T =W17"?;/BE_T"O"__@5-_P#$T?;/BE_T"O"__@5-_P#$T =W17"?
M;/BE_P! KPO_ .!4W_Q-'VSXI?\ 0*\+_P#@5-_\30!W=%<)]L^*7_0*\+_^
M!4W_ ,31]L^*7_0*\+_^!4W_ ,30!W=%<)]L^*7_ $"O"_\ X%3?_$T?;/BE
M_P! KPO_ .!4W_Q- '=T5PGVSXI?] KPO_X%3?\ Q-'VSXI?] KPO_X%3?\
MQ- '=T5PGVSXI?\ 0*\+_P#@5-_\31]L^*7_ $"O"_\ X%3?_$T %_\ \EPT
M?_L"7'_HQ:[NO*],E\1R_&?33XDMM.@F&CS^4+&5W4KYB]=P'.:]4H *X3QA
M_P E*^'_ /U\7O\ Z(-=W7FWQ'M;^\\:^!K?3-1&G7CSW?EW1@$WE_N<GY"0
M#D9'XT :FH>&?[4\<"XO++S+/R77S2H(!('3/>J5CX;O]+EUK0K>S LKR&2:
M&]50"K,0H0GKG"YZ5/\ \(O\0/\ HI"?^"&'_P"*H_X1?X@?]%(3_P $,/\
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M%(3_ ,$,/_Q5'_"+_$#_ **0G_@AA_\ BJ .[HKA/^$7^('_ $4A/_!##_\
M%4?\(O\ $#_HI"?^"&'_ .*H [NBN$_X1?X@?]%(3_P0P_\ Q5'_  B_Q _Z
M*0G_ ((8?_BJ .[HKA/^$7^('_12$_\ !##_ /%4?\(O\0/^BD)_X(8?_BJ
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M2 >_;M6Q6#XNTF;5]#>.V_X^8B9(0>[8('\Z ,D#Q7:VT6IK)'<EP&>U+,0
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MYB$:,!UP2>:XZQT/4?,FN[6PU5;F*- G]I3"59.Q  ]!G]*I6^AZO-?6,_\
M9FKX2-ED2ZF#QC)[+G@8H ]!M/%MA>:A]DC@NU!D\M)WBQ$[>BMGGU^E;]>6
MV6CZK!XCM'M=/U**-;[=.+F4-;JG=HT!^7MCVXKU(=.: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#A/%O_ "5#X??]=;__ -)Z[NN$\6_\E0^'W_76
M_P#_ $GKNZ "BBB@#A/!/_(]>/?^O^#_ -$BN[KR32X/%LWQ!\;'PY>Z5;Q"
M]A\X7T+N2WDKC&TC KH/L7Q1_P"@QX9_\ Y?_BJ .[HKA/L7Q1_Z#'AG_P
MY?\ XJC[%\4?^@QX9_\  .7_ .*H [NBN$^Q?%'_ *#'AG_P#E_^*H^Q?%'_
M *#'AG_P#E_^*H [NBN$^Q?%'_H,>&?_  #E_P#BJ/L7Q1_Z#'AG_P  Y?\
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M*/\ T&/#/_@'+_\ %4?8OBC_ -!CPS_X!R__ !5 '=T5PGV+XH_]!CPS_P"
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M!+6<TLGA'2HIX21);M8P[EQU_AQUXKHHO!WA.6%)!X8T8!U##_0(N_\ P&@
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M4?\ "<>$O^AHT3_P81?_ !5+_P (5X4_Z%C1?_ "+_XFC_A"O"G_ $+&B_\
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M_P"$W\)?]#1HG_@PB_\ BJ7_ (0KPI_T+&B_^ $7_P 31_PA7A3_ *%C1?\
MP B_^)H RAK_ (/&O?VI_P )9HQ;RVCV?VA#CG'^U[5J#QOX2 P/%&B?^#"+
M_P"*I?\ A"O"G_0L:+_X 1?_ !-'_"%>%/\ H6-%_P# "+_XF@!/^$X\)?\
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MND:9I'QKTJ/3-.M+)'T:=G6VA6,,?,7DA0,UZ/0 5PGC#_DI7P__ .OB]_\
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MEI4\"ZQ(,I\1->8=,KY1_P#9: .]HKA/^$!UO_HH7B#\HO\ XFC_ (0'6_\
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MDM 'H=%<)_P@.M_]%"\0?E%_\31_P@.M_P#10O$'Y1?_ !- !XM_Y*A\/O\
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M=?$?PW.MK-);1_:A+*L9*)F @;CT&3QS7+Z)H&K)+?:?<V5P+32+&>UMBT3
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M#*9]_F*<$'&T$9!S71UE>&(9+?PII$,L;1R1V<*LCC!4A ""#T-:M !1110
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M;ZUMLXA%BL1;(P/F5LC'!_"@#M**** .$\6_\E0^'W_76_\ _2>N[KA/%O\
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MS$87KV&<]J .T  Z "EHHH ",]:  !@#%%% !1110 4444 %%%% !7"?"/\
MY$;_ +?[O_T<U=W7"?"/_D1O^W^[_P#1S4 =W1110!Y08/$\WQ=\6_\ "-WF
MFVQ%O8^?]NA>3=\C;=NTC'?/X5N?8OBC_P!!GPS_ . <O_Q5)X?_ .2N^-_^
MO:P_] >N3\-ZE=V'Q8U:6>=FT^258-IZ"1E4+_6@#K?L7Q1_Z#/AG_P#E_\
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M9;BU?RXI@F%F89/F =0!W%:FK^,Y;'Q FB6.EF]O7C:14\[RP0" >2I'<=Z
M*'V+XH_]!GPS_P" <O\ \51]B^*/_09\,_\ @'+_ /%5O>'/$J:\MQ%);_9;
MVVD:*:WW[]K+@'YL $9.,CTK=H X3[%\4?\ H,^&?_ .7_XJC[%\4?\ H,^&
M?_ .7_XJN[HH \7\06OCY?B%X-6ZU/0FOV-[]C>.VD$:?N1OW@G)RO3'>NM^
MQ?%'_H,^&?\ P#E_^*H\5?\ )5OA_P#74?\ T0*W?$GA72_$40?4(Y6,2'9L
MF=/?^$B@#"^Q?%'_ *#/AG_P#E_^*H^Q?%'_ *#/AG_P#E_^*KG/ ?@[1+J+
M6;^]%PS:?K%Q;Q,;F7"QIC:,;N>O>NA'Q%*6YO8M)#:-&_E&\-UA@0=O^KV[
MC\W'ZT .^Q?%'_H,^&?_  #E_P#BJ/L7Q1_Z#/AG_P  Y?\ XJK>H>.Q#K$>
MEZ;IWV^ZEB:6-?.\L,H.#R5(')%+9>/()]%U"\N+)X;JQE>&:U5B^'7&1N"\
M\G&0.U %/[%\4?\ H,^&?_ .7_XJC[%\4?\ H,^&?_ .7_XJIK?QW=1ZO966
MK:,EA'>AS!*MX)BP5=QRH7CMU]?:H9?B'<22Z@-/T0W46G-BZ<W/E[ %W$@%
M>>/2@ ^Q?%'_ *#/AG_P#E_^*H^Q?%'_ *#/AG_P#E_^*K-\0>,=3N;WPI<:
M19"2VO)XV8&8+O9D),?*Y&..:]&EN1;V9N)E*[5RRCYL'TXH XO[%\4?^@SX
M9_\  .7_ .*H^Q?%'_H,^&?_  #E_P#BJ;_PL2[C6SNKG01#IEW,D4=R;P%L
ML<#,>W<._7TK0OO&D@U7^S]&TS^TI4B$TI,_DA%)([J<G../>@"C]A^*/_09
M\,_^ <O_ ,52"P^)XSC6/#(SZ6<O_P 56-X2\8Q:=X9OM2N@[N9RJ0DG)/F%
M2,X[9':GW?B+4;GQYI4.I:<=-<0%S&+@2A@'&3D "@#7^Q?%'_H,^&?_  #E
M_P#BJ/L7Q1_Z#/AG_P  Y?\ XJG7/Q#=9+R:TTI;C3;*5XKBZ-T$*LIP<(5R
MW;IZU=U'QO'$]C;Z39_VC>W@8QP^;Y0^4!CEBI X)//I0!0^Q?%'_H,^&?\
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MXGB9E+(C*0<$99: -I65U#*00>A!I:\[TWQ'K6C:393ZJ(7M9HVV!5.]&R0
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MSMQZ\<UZ3K,UZ= FFTZ-OM112BL#N&2,\#OC-:E5;[4;/381+>3K#&3@,WU
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M]_E_QH_M33_^?^U_[_+_ (US+?"[P&@R_AO3U!]01_6E_P"%5^!2,CPU8_\
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M?VII_P#S_P!K_P!_E_QKFO\ A5?@;_H6;'_OD_XT?\*K\#?]"S8_]\G_ !H
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MOV!;HW,=OY$?R\8"[M^3QWK4_P"%5^!O^A9L?^^3_C1_PJOP-_T+-C_WR?\
M&@!NIZ'IVI77G?V[;1_(J8^4_=&/[U5)?#L4)8Z7XHM;,RQLEP3&DGF$\9Y?
MC ]*N_\ "J_ W_0LV/\ WR?\:/\ A5?@;_H6;'_OD_XT 9\/A.QCMXHY/$EL
M[H@5GVJ-Q'?&_BK\NBZ=)IUI:?VY;#[.[MN^7YMV.V[CI2_\*K\#?]"S8_\
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M9%+7:ROYK+G)[8SS^E:MWX2U3_A,%O(/LLNFSZ:FGW)E<B0 .6+* ,$].IH
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M6E:AJ%RLEC?*Y>T$:#RL*,'>!DY+ ]!C%7&\':D? ?B'1-]O]JU">:2$[SM
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M_P"_R_XT 6Z*J?VKIW_/_:_]_E_QH_M73O\ G_M?^_R_XT 6Z*J?VKIW_/\
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M_,FMR@ HHHH *X3X1_\ (C?]O]W_ .CFKNZX3X1_\B-_V_W?_HYJ .[HHHH
MX3P[_P E?\;?]>VG_P#H#UW=<)X=_P"2O^-O^O;3_P#T!Z[N@ HHHH ****
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MA*X:UG\B;!VR8!V\>AKFM5T__A$%TG5M.G?SI4;[0C,6\[*J!C<3MQN)X'-
M'J=%>>Z%?3R:)XN=Y26A#["?X?W6:YS?>:LGAJS:\9(;J9%GP/OJ8\XSP1^%
M 'LM%>3:?X<2?QCXA\/O=2G2;"*"2.#<V=SHS$[]V[[P!Z^U9GVG4+O1-(TT
MWS*@OH8'?:,NC,=P_'/7.: /;**\\AM?^$3\<6=EI\KFTO459(6)8AR22^6)
M/. ,<"O0^M '"7__ "7#1_\ L"7'_HQ:[NN$O_\ DN&C_P#8$N/_ $8M=W0
M5YS\0]+L=:\<^!=/U&V2YM)I[P212?=;$.1G\0#7HU<)XP_Y*5\/_P#KXO?_
M $0: )9?AM\/8&"S:#I<9/0.<?S-*GPU^'LJ;X]!TQTSC<IR,^G6HM>D;_A+
MX8S:7-VGE/\ NXF [#UK2DE6RT6.1+26WWS\QR$$_=]J *X^%G@4]/#5@?\
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MOI]W,;B26+<HC61RVPX_QH H?\*K\#?]"S8_]\G_ !H_X57X&_Z%FQ_[Y/\
MC45IXR<R;9;BVG+Q;T$*$;"3T.:G@\0:H&MKJX2'[',[J45,.-HZYSCKB@!O
M_"K/ N<?\(U89_W3_C1_PJOP-_T+-C_WR?\ &H-9UB^TKQ,TSW"?9!&P6,YZ
MX'7G'6K.C^*VNM1AMIKBWG$Z@J(5(*$GH<^E #?^%5^!O^A9L?\ OD_XT?\
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MV)/MUE!M&)XD<G'3)/\ A65=:[)++L=!\CLHP/>@!O\ PJOP-_T+-C_WR?\
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M\*K\#?\ 0LV/_?)_QKL** ./_P"%5^!O^A9L?^^3_C1_PJOP-_T+-C_WR?\
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M:5Y-JZNLG]H0[C@D\\X[UTO_  A?A7_H6=&_\ (O_B:/^$+\*_\ 0LZ-_P"
M$7_Q- ''7!\*?:Q/IWQ&LK#,0B=8-0M\-SG=R>IX_*GS1^ 9?!<WAE?&.DQP
M2OYC3+?P;]WF"0GKCDC]:Z[_ (0OPK_T+.C?^ $7_P 31_PA?A7_ *%G1O\
MP B_^)H XEH_"PNXKV'XDVD=V$*2S+J%ONESW;GKCBHX=.\"Q6U]$_CS3Y#>
MNTDKM?P9+MC+=>O%=U_PA?A7_H6=&_\  "+_ .)H_P"$+\*_]"SHW_@!%_\
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MVQ@M_&NEVUU9E62[CU"#S&8+C)R<>]+H<G@_2-;FU>;Q]I]]>3*JN\^H0<@
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M'^SO[0^TI]DZ^;SCKB@#!O/ UI=>&[#2$O+B(V+K)#<H!O#*21VQU/Z5#8>
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MEH W1X9E6:Z*ZAB&XC1#'Y(XV]\Y[U-/X<6>WM86N?EA4J?D^\"<^O%8'_"
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M_A -:_Z*#XA_.+_XFC_A -:_Z*#XA_.+_P")H [NBN$_X0#6O^B@^(?SB_\
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MWW>4I!^3=UQ]<5-_PC>FV^@WNDV-I%;V]S"\3(O .Y2/ZT :T<B31K)&P9&
M96!R"#7ELE^;W6]:.E:;# -B":ZFN0Q? .,1N/EQ@CCKFO1]'T]-)T6QT^,
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MK'MX()R#SFFQ^' FG26GVK.]U;=Y?3'MF@"A#K6I7T;G35B$5LF)/,7)9QU
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M#+F,#U_#FE?Q- ;:W>""2>:;&($(W#(]^/:@# _X0#6?^B@^(?SB_P#B:/\
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MT?\ " :S_P!%!\0_G%_\37=UB>*KN:RT626&3RWY&[)XX/I0!S__  @&L_\
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MR&47 BV\\9 Z_CZUHG0[]M&L;<P*)(F;>N\' .,<]ZH_\(!K/_10?$7YQ?\
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MV$7EHJ >6)Q$5.WGD<GG^54+/P]JUIIMNBV2^9%.C>7YX^Z&R3FG?\(!K/\
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M.WKD9[]:Q9?#&L3Z%J\<L:M=7!C6%-ZXVI(#USC[M/\ ^$ UG_HH/B+\XO\
MXFC_ (0#6?\ HH/B+\XO_B: .[HKA/\ A -9_P"B@^(OSB_^)H_X0#6?^B@^
M(OSB_P#B: .[HKA/^$ UG_HH/B+\XO\ XFC_ (0#6?\ HH/B+\XO_B: .[HK
MA/\ A -9_P"B@^(OSB_^)H_X0#6?^B@^(OSB_P#B: .[HKA/^$ UG_HH/B+\
MXO\ XFC_ (0#6?\ HH/B+\XO_B: #Q;_ ,E0^'W_ %UO_P#TGKNZ\ENO#U[H
M?Q3\#M=^(M2U<2R7H47A7$>+<_=V@=<_I7K5 !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <)X=
M_P"2O^-O^O;3_P#T!Z[NN$\._P#)7_&W_7MI_P#Z ]=W0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F'Q-4OXW\$JH))&
MH< ?],5JC':2Z;X8\*ZJ]LQMK4*LR!3N7]X6W8ZG 'I70>+I$B^*?@!Y'5$!
MU'+,< ?N!7<PSPW4"S02I+$XRKQL&5A[$4 >6:U+_P )YKT:Z$DHC@A5GFDB
M,>>2-N& ]0:8GB>RM_!<FAO:3_VF)-OD>2^T_O,YW[<=.:]9"A1@#%0W-U:6
M:B6ZN(8%[-*X4>G?ZT ><>%=)N=-\:6$%W&QDAL)49R,C.X'KTI-#M770/'.
MZ!@SZS>E<IRP++C'J*])@N[:Z,@M[B*4QG:XC<-M/H<=*FH \9NH=-6STDZI
M;W%I,IF\B]C620KTW9C7VP.?6NH\#ZS>Q:)K-WJEPUQ863%X+DVPB:2)4W,?
M+ R#D'@Y/%=ZRAA@C(J.X@2YM9;=_N2H4;Z$8- %2"_@U;0HK^U+-!<P++&2
MI!*L 1P>1P:\W\%^!=*UOP$PO[25;F2YN#N,CJ1B9B. 1Z"O4K6V2SLX;:+_
M %<,:QK] ,"IJ /+=(AO=1\,:KX3O8BNIV*,L4H0!9VV$@\84<L!U-7=%^(&
MGZ'HMOI.LQ74&H6$2V[HEO)('**%+!E7')!X&:]%II16() )'2@#R_33?V-E
MXC\87-LT<NI_9XDA'S$*C&,'@=PP/05'XSLE\.>%/#,+I(T5CJ5L\AC0N0JN
M6)P,GI7JK*'7:PR/2@D $DX ZDT >:>(_&MGXLT2YT+P_%<SWEZAB#2V[Q!,
M]\NH!^F14G@C39-,^(WBB%HV"BUL!N(X)$3YP?K782>+?#<,[P2^(=)25&*/
M&U[&&5AP01G@UHK>VC6OVI;J$V_7S1(-GY]* ./^(B:>]I:_VE:2O )5*W$3
M.6B?)P=J\G'7TK/\!7E[-K][9)>/?Z*MONCFEM! RR;@-F"-S87')/.:[&V\
M3^'KZ<6]KKNEW$S<".*[C=C^ .:MO<6\SR6,%W$MTJ;C&D@WHN<9QU SQF@#
MR6RTRY/C%/!C(7TRT>2><YZF13*H]?O#UJ'5)+.RU#49],DN=*U<29^SBV>Y
M2>3;\HW-\J@\#.,"O2O#WADZ/>WU_<WDMW>WFT222X)PN0HX ['%:M]J>FZ;
MM?4+ZUM<\*;B98\_F: //?$EY<06/@35M4B</'-#+=^7'N*-Y)W<*/4]A6";
M>VTGQ#JG]K7-S;BX6-X'CMGE\T$$X.W[N 1U]:]FM[JWO8%FMIXIX6&0\3AE
M/?J*?(8UC+2E51>26. * /'(-,"6&@RPV4B12ZA;R '<W ?J0>E=:MN3\9YY
M3"?+&C1 /MXSYK<9]:[&TOK._MQ<6=U!<0'D20R!U/XCBG6UY;7@D-K<0SB.
M0Q2&)PVQQU4XZ$>E 'GO@_5K;2_$$NF72RQW&HR/]G'EMAO+W,W.,#@CK7I%
M9TB:?>ZU$PN(7O=/!)B5P7C$BX^8=1D#CUK1H ***SY]>T:UN_LEQJUA#<_\
M\9+E%?U^Z3F@#E+_ /Y+AH__ &!+C_T8M=W7"7__ "7#1_\ L"7'_HQ:[N@
MKA/&'_)2OA__ -?%[_Z(-=W7">,/^2E?#_\ Z^+W_P!$&@#0\9:?";)+H%UE
M:YB4E3C@G%3W;_\ "/Z+'-9)NDD(&&YR2/\ ZU:FL:9_:UFEOYWE;94DW;=W
MW3G'44FH:5]OLH;?SMGEL&W;<YP"/7WH Q;G6M3L[2V^U7%I;R2Y8RO&=F,
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M )*_XV_Z]M/_ /0'KNZX3P[_ ,E?\;?]>VG_ /H#UW= !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >7_$\D>-O!1'7&H?^
MB5JOX9USQ)I/@S1]0GB@;3"5C:+RSYJJ6.6+9Q@ &KOQ%M9KSQ]X'MX%#2O_
M &AM!./^6*U!9:5XQE\,Z=X:N]&BABB=1->"[C;<F3N^0>Q['M0!U6A^*'UC
MQ%/9*J_9A:BXC;')RV!^E<7XG\07&M^')7E 0Q3[1M&/^6H']*UQHWB#POXF
M%UH^E)JEH]BEM\URL&U@Q.><D\ ?G64G@KQ&_AJ:VFM4^UR3&3;YJ8 ,F[&<
MXZ4 ,T/Q7_9VM:QI-DOGZI<WB;(^NQ-H!<^P)&:]/DO&T_1OM>H,N^*(-,4&
M!G'./;->>?\ "O;XG5=02!8M3%XEU:,) ?,V+PIYP,L ,G\J[@P7&H^$Q!K,
M8M[B6V5;E58/M; W<KC/.>E ''7/BWQ5%H4OB%+>V-@) BVWE'S<;PF<[L=\
M_2M6^U_7YH[4V$=O:Q20M(]W<QEHP0?NX!SS_2N-UC4-?M/ =QI@M+=K19E"
MWXNHRQ'G @>5C/MU]ZT)/#6L'5+.^;1_[4MU@944W@M_*)/ P/O=.IH N6WQ
M'NE\-ZI<7 ADN[&>2$S1IB([,#=@G."<UL>&=>UJ^NE^V/:7MG(N[[1:1E%C
M^4G#;CGK@?@:P-&\,^*-,M=7D2PBCDN9I)HK8RQN"&((CW'T_O>U2Z)X6U1O
M&%AJIT8:/!"LHN0M[]H%P6C*CC(V;3Z#G/M0 ^Z\>ZA=7>H2:;/9PVEB>4GC
M+/. N[Y"#QZ<]Z??_$6673M+:RDM[2:[98WFN4+(CE<D8!SQ5$^%-7T:[U&"
MTT!-2AN&S!<M>B'R_EQ]WG///-:=UHFOVNC6,2Z=%J"-M-S9F5(O+.WYL/R3
MSQQ0!T?A?4=5O[>7^TXH]R8V3Q+M27)/09SQ@5M7/_'K-_N-_*O,](LM9\%V
M&NZU'HWEI.ULMOIGVP2;/G*N?-.3SOW8Q[5Z9*K26TBXPS(0!GOB@#Q30+W1
M83XB&H>&UU"8:Q=8F,4;,!N' +#/K^=6](LM1USX47EOI-Y-),UQE(A(V]5$
M^2N?H"*UM#A\:>&Y-7MH?!UO?P7.I3W4<[:G'&2KD8^4@]AG\:6T\%^((M$O
MKN.86FKW+HP@4(ZJ%?.,YV\J3VH SS?>%YWLK:[T7_A&KY;B,I($2.1FSPI9
M!D@G''M6YX?)_P"%K7RB4R*-'3#$YW?O3S5;4CXP\36T>F7?A.WL%:1?-NA?
MQRE%Z'"[1G@YX/:HXM'\5^&/%:WNDZ#'JUL-+BLM[WR0'*L3G!R>F/SH ]/K
MEO$6BV9NCK-Y:R:B(861;-B&0YYSM;C/'7WK1T&_UN^BE;6M$32W7&Q5O%GW
M]<\@#';\ZS-:D\46&MI=:;:)J=@\9#6S2I#L;/!W$$G_ .O0!F?"^X$UCJ^)
M2JG4YV2U8\VZ_+B/T 7I@<5<^).K/8^'?L=M)LO+QE6(Y/170OT_V2:D\'Z'
MJ%I>ZAJ^IPK;7-Y*Y%LK!PBL0P^8<'N.G:JVL^%+CQ+XU@GU6VW:18J?LY$N
M#(73#<*01@@=<T 9?@J:'0M>U7PRDYD@8-/9@G[L:J ?U-9W@OQ7)I#>)+8:
M5=78_MZ[;S(V4 ?,!CD^U;.N> C8:CI^J>&+0_:HYDCG5YSS"6RYRY/8#@#-
M:W@70KW1K36EU*W2-[O5[F[B 8/F-R-IR/H>* .4\-^(7E\=^-]5-G-%MAL<
M0.P)'R.,^GO6KX9\6:[K,EI<K)97UG<8W1VT15X03C+$G''7BK<'A[5[?QMX
MKU2%$B@OXK-;63*MN,:,'!4].N.?6N>7PMKNHZIIEQ)X?33+JWNHI9[Q+\2!
MT5@63RQ@<CN/2@#UAF"J23@"OG_5+R+4?$U]IT;021:A)']EU>1-QB,7S2*&
M^\.FSC^5>[ZA9_;]/FM"Y3S5V[@.E>57GAKQ/<^%I/"LGAZ*2,R%EU 7J*P'
MF;_N#Z8ZT ;7VFWN/C/HQMY_.5=$N 6R3_RU6O1:\6\&:/J>@?%#1]*U*$ V
MVC3I%-Y@8S+YBG<0/N\G&,FO:: "N$\8?\E*^'__ %\7O_H@UW=<)XP_Y*5\
M/_\ KXO?_1!H ZB]UVSL+H6T@D>4C.V, G\LU+8:M::B62"0>8OWHV(#@>N,
M].:Y?54O7\9*;)8&<1.<2INSP*BT:::.;5]6N/)2_MXI(?L\2;1@$-DCUR<9
MS0!W=%>>VE_JXDAO5MK\EW;<9)LQ$=L+GWK9NS/JFNW5JUW-;16J_+Y3E=QV
M@Y..HH ZFBN$.K7>F-<Z:UW]HFFMC);RY)^<G 7GGL35YOM.H:G!ILUU/"B1
M*[M%(59BRY(S[$4 =)<WT%JZ)*^&<9 R.:E@G2X0NF< XYKB]0,D<=DKW2W#
MQHW[P9YYSWJ&"XN[VZM[47,D4<D@#F-RIQWP?6@#OJ*XZUU2[T[1M1_>-.]J
MPV-(2S$%\<D^U1%+G3KS3F349Y1/_K%DE9@?FQQZ4 =M1110 4444 %%%% !
M1110 4444 %%%% !7"?"7_D3[G_L*7G_ *-:N[KA/A+_ ,B?<_\ 84O/_1K4
M =W1167KVI3:98":! [EMH!'L3_2@#4HKE!XDO-.DE&JB)UV(Z&)=N-W8Y/N
M*EBUC5+26V?4EA,%P=H$:8*,3@ \T =-36D1<;G49Z9-<K>ZMJ]SJ-W9V)AB
MC@5BTCJ3P#C P>O2L>2YU1?#MO(\_FSF:4 J3S\P]30!Z)32Z!@I90QZ GFL
M72M2OFU*?3]0\II4Y5XEVJ1C/?ZU4UZ^^P:Y#.[-Y4<(=E!Z_,: .GHKE3KF
MIVL<5_>+$;&0GY53#*.Q)SWR*KZCXIN;*^*FXMHU$J)]G="9"#COTH [*H_/
MASCS4_[Z%8E[K%U+<VMGIPC6XFC68M*N0J$D=O>N=L]0NX?,^UY:7S&!].">
ME 'H-%<>/$.K2(]TBPBVBE1&4I\S ]P<UI7NL74MS:V>G!%N)HEF+2KN"H21
MV]Z -Z@D 9)P!6)H&J7>H&XCO$59(3CY1@'DC/Z55U34]0N+J\L]-,2BWC;S
M6D4G)VY &#P<4 =(KJXRC!AZ@YI:XG2-6U!K:'3[;;]M?$CM*"P52 /7UJRW
MBB[C5K!HE.IYPN!\I&>N,^F: .L9E099@H]2<4 @@$$$'H17*ZI=:G!I%S_:
M.T>5(I$T0*JPQD]\U8\*ZS+K5MYL6/LD(\G)Y9G&#G/I@T ='44-M#;@B&-4
M!ZXJ6B@ HHHH **** "BBB@ HHHH **** .$\6_\E0^'W_76_P#_ $GKNZX3
MQ;_R5#X??]=;_P#])Z[N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .$\._P#)7_&W_7MI_P#Z
M ]=W7">'?^2O^-O^O;3_ /T!Z[N@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** //O&EREI\3? 4\F=B?VB3CK_J!4]M\5-,
MNK=+I-$\0+:.,BZ:QQ$%[L7W8P.<GVK-^)'_ "/?@G_=U'_T0M<_H+^*Y/A7
M;PVUE;2V36<B\Q98H=V><]>M 'IU_P"+]*L-'M=2,C7$=T%,$=OM>24E=P"K
MGDX["J6F>/M/U'4([*?3M5TN67/E?VG;?9Q)@$G;D\X [>H]:Y&STR'7?">@
M)I=Y';:KIDB%8KD%U$RQ!2I [#-6[K6M0LM0LE\7:.C*N\17\,:JD9Q@]23S
M\HXH [O2M>L]9N+Z"U$F^RE$4N\ #<1GC!]#6DRJZE6&0>HKA/A[_P AKQ9_
MU_I_Z+%=Y0!Y3?R^#=.\0W.FQ^&-5OY;4K)+'967G(A<;@3ALC/7GTKK;3QQ
M:W%E>74NC:W90VD3S.;RS\K(49.,GDXKCK2;6XOB=XK_ +(@BES'9^9YB;L?
M(V.X]ZW]7FUJ7P/KYU:"*,BRGV;$VY_=M[F@!T/Q/L[F".>#PSXHEAE4/')'
MIA974C(((;!!'>NTMIQ<VZ3".2,.,[)5VL/J*\X\&W?BH>%-!2.Q@-J+& (Q
MCY*>6N#U]*G\=7&IQ:E8"87\>D[7\Z6QF\ED.U<9.>?F]O6@#T6BN5\"7\=]
MI,OE:JNHQQN%5\LSIQT8MU-<KXNN[Z#Q+.=4N-2L].6+]Q<6MP8HP=S8W ')
MX]O2@#OKO5[#^V+?1+A'>>YW%!@;?E7=SSFM:O&WCGU_Q9X;6#5Q*D@N0UU;
MLRL0(^,'KGC!J\-;U+PU+K6E+>37067R;:6YD:1T)3@DD^I[4 >K45YC=P:G
MX;TK3O$(U:[GEE"2W<,T[O&05W$(I/'/3VK7\)ZO=ZAJFO":9V2.&!XU+$[=
MRL3C\A0!TFJ:Y::3/:Q7(DW7,JQ)M /+' SS6G7C2:A<ZC::!-=2M))]O@^9
MF)_C]ZZ/;>^+/%NH6QU"ZL[2QW1HMM,T99U<C)QU&#0!U^CZY::VDKV@DQ$V
MUMX YR1V)]#0NN6C:[_8X$GVKRS)T&W QGOGOZ5R7PJAF@TN]BN)!)(LS#=Z
MC>^*HZKI,^K_ !32!+R:UA^R2%F@D*/G*]"* /3J*\BOO%FJ^&[+5M'^T-<3
MQ/(+6>5BS! =J[B3DG Y^M&G:MJ%AJNGS6,VHW:2AC=1W5P9!G;\NP$\<D_D
M* /7:*P?%^JS:1H$DUO@3RMY,;'HK,#@_G7'W<&I^&]*T[Q NK7=Q+*$ENX9
MIW>,@KN(12>.>GM0!Z=17ENG1ZGXIUO6TGU6\M[:UB@DA6VG:,Y96)S@^JC]
M:ZCX?ZG>:EX9A:^D$D\8VL_/S=?6@#JJ*** .$O_ /DN&C_]@2X_]&+7=UPE
M_P#\EPT?_L"7'_HQ:[N@ KA/&'_)2OA__P!?%[_Z(-=W7FWQ'L)M3\:^!K."
M_N+"62>[VW-MCS(\0YXR".<8_&@#O_[/M?MXOO+_ -( *[]QZ'VZ4PZ19-J3
M:@8?]):+R2VXX*YSC&<=>]<=+X%U2%"\OQ%\01J/XF>(#_T&DA\#ZE<+N@^(
M^O2KZI)$P_1: .F@\+:3;WBW4<#B16++^]<@$]>,X[U-J.@:=JDRS74+-(H(
M!61EX/7H17+_ /"O]8_Z*#XB_P"^HO\ XFC_ (5_K'_10?$7_?47_P 30!JR
M:"T^KV2_8Q#96&UX9/-W%BI( (Z]#WS6KJ.B6.J-&]U$6>/.PJ[+C/T(S7*_
M\*_UC_HH/B+_ +ZB_P#B:8O@75'=D3XBZ^SK]Y0\1(^ORT =6N@::EO# +<^
M7""J#S&X!.3SGFG0Z'I\$R2QP$.ARIWL<'\ZY+_A!=4\SR_^%B^(/,Z[=\6?
MRVT__A7^L?\ 10?$7_?47_Q- '5MI<,,-Q]E39)-C<2<YYSWKE]+\+SC5+:>
M73/L*0J<G[5YVXYR.,\5%_P@>K;]G_"P_$.[^[OBS_Z#3O\ A7^L?]%!\1?]
M]1?_ !- '=T5P@\ :P>GQ!\1?]]1?_$T?\*_UC_HH/B+_OJ+_P")H [NBN$_
MX5_K'_10?$7_ 'U%_P#$T?\ "O\ 6/\ HH/B+_OJ+_XF@#NZ*X3_ (5_K'_1
M0?$7_?47_P 31_PK_6/^B@^(O^^HO_B: .[HKA/^%?ZQ_P!%!\1?]]1?_$T?
M\*_UC_HH/B+_ +ZB_P#B: .[HKA/^%?ZQ_T4'Q%_WU%_\31_PK_6/^B@^(O^
M^HO_ (F@#NZ*X3_A7^L?]%!\1?\ ?47_ ,31_P *_P!8_P"B@^(O^^HO_B:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3_(18M?M4D69) ^4/"G.,;N]+<V%N;N6>R\1V=N9E/F@I')N<G);EN.W ]*
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M-A)Z\%L#/M5_0_[,T;3OLO\ :UK,V]G+F55R2<],F@#>HJG_ &MIO_00M/\
MO\O^-']K:;_T$+3_ +_+_C0!<HJG_:VF_P#00M/^_P O^-']K:;_ -!"T_[_
M "_XT 7**I_VMIO_ $$+3_O\O^-']K:;_P!!"T_[_+_C0!<HJG_:VF_]!"T_
M[_+_ (T?VMIO_00M/^_R_P"- '(>+?\ DJ'P^_ZZW_\ Z3UW=>?>);RVNOBC
MX %O<0S%9;_/EN&Q_H_M7H- !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <)X=_Y*_XV_Z]M/\
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M>M '&SWD6J:O:1)IUQJ=ZENXD$K*\"<]T;OTY^M<RDES_P (UXGLS,T(2]N
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M?AJ_T1-'N+BU>QCB$2Q_:L$*!@#<&ST'K65!X2\$6\T<RO 98_NLU^QQ^;T
M9'AS3=.UBRU^]UH^9,K$RRO\S6PV<E"02N!SQWJ'PE8:0OQ-D-ALN8(]%B>*
M=P&9CYA^<DC.XC'/O70ZCX9\&:IJ#WUU);F=VW.5OF4,?H' J?\ L3PB-6LM
M366V6[LXDAA<7A 5%SM!&[!Z]\T =2K!AE3D4M8FD)X?T.R^R:?=VT<.]GVM
M=;SEB6/+,3U)J_\ VMIO_00M/^_R_P"- %RBJ?\ :VF_]!"T_P"_R_XT?VMI
MO_00M/\ O\O^- '(7_\ R7#1_P#L"7'_ *,6N[KS^XNK>Z^-VD-;SQ2@:+<
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M^-'_  JWP-_T+-A_WP?\:Z^B@#D/^%6^!O\ H6;#_O@_XT?\*M\#?]"S8?\
M?!_QKKZ* .0_X5;X&_Z%FP_[X/\ C1_PJWP-_P!"S8?]\'_&NOHH Y#_ (5;
MX&_Z%FP_[X/^-'_"K? W_0LV'_?!_P :Z^B@#D/^%6^!O^A9L/\ O@_XT?\
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M*J/XTU^'0KK6)([;[/8R^7,@C.9/G"#;SQR<\]J -O\ X5;X&_Z%FP_[X/\
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M%FP_[X/^-'_"K? W_0LV'_?!_P :Z^B@#D/^%6^!O^A9L/\ O@_XT?\ "K?
MW_0LV'_?!_QKKZ* .0_X5;X&_P"A9L/^^#_C1_PJWP-_T+-A_P!\'_&NOHH
M\LU'PIH/AKXI^!6T;2[>R:>2^$IA7&_%N<9_,UZG7">+?^2H?#[_ *ZW_P#Z
M3UW= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >6P^%]#\2_%WQ>-:TV"]$%O8F(3#.S*-G'UP
M/RJA=6OPWM]5O-/@^']]?2V;B.9[+3S*BL0"!D-Z'O73>'O^2O>-O^O:P_\
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M%FP_[X/^-'_"K? W_0LV'_?!_P :Z^B@#D/^%6^!O^A9L/\ O@_XT?\ "K?
MW_0LV'_?!_QKKZ* .0_X5;X&_P"A9L/^^#_C1_PJWP-_T+-A_P!\'_&NOHH
MY#_A5O@;_H6;#_O@_P"-'_"K? W_ $+-A_WP?\:Z^B@#D/\ A5O@;_H6;#_O
M@_XT?\*M\#?]"S8?]\'_ !KKZ* /(/$7@#PG:_$;P580:%9QVEX;[[1$JG;)
MLA#+GZ'FNP_X5;X&_P"A9L/^^#_C5/Q5_P E6^'_ -=1_P#1 KNZ .0_X5;X
M&_Z%FP_[X/\ C7$ZK%\-M%:3[;\/-2CBC;:9CIQ$9).!ABP'4C\Z]EK@?B\J
M_P#"#3G SYL/;_IM'0!1T+PKX#UZ1T7P#<V.WO?V+0@_3FMW_A5O@;_H6;#_
M +X/^-:'C#5GT+PW<W=NH\X@HAQT8J<'\Q7F(UG4[:RLM2L[K49KN8*]TDMP
M6BY7)V+GY>>GM0!WW_"K? W_ $+-A_WP?\:/^%6^!O\ H6;#_O@_XUQ5NNM7
M/@ ^)Y=8NUOTF(6-9W$6/-"8*YY^7WZULZ]JT=]=V2WNMR6R2P,PM;.1XIF;
M. =PXQ0!N?\ "K? W_0LV'_?!_QH_P"%6^!O^A9L/^^#_C7"6_B76(_"6N10
M74_F6MU,MM+/(SOL7 7<V<GC]:V[F'4?#NJZ#<KJMW<+?1R?:(YYV=>(QC:"
M>.6/Y"@#4L_ 'P\O[B[@M_#NG/):2".4 9VL1GL?2KG_  JWP-_T+-A_WP?\
M:QOAWI*VOBGQ5*+N[D\J\6/;),6#9C4Y([GWK6\=7J6XLHIM9%A!)* ZQLR2
MRC!X5AT/U]* '_\ "K? W_0LV'_?!_QJAJ_@3X>Z+:QW%UX8L]CRK$-D>3N;
MIU(KF]*\4W6BZCK4,,]Y<6<:0^2;R8RN"P.>2?4T:UHFH_\ "+:3JTVJW,US
M->PF>.29FB^\<[5/3@4 =A#\,O D\$<R>&;';(H890]",^M4-'\$_#O6TE:T
M\,6@$3;6WQXYR1V)]#533%O?%FKR6YU"ZM+2Q@$:+;3-&6=3C)QU&#7+V6M:
MCX<\)7-O%*#>3W#*)>> )>>^<X- 'HO_  JWP-_T+-A_WP?\:JZC\// &EZ=
M/?7'ABR\F%=[;4YQ^=<Y::W?:)J8DL7U"[L_)9IA>7!E(8=QD\#%-O[#4M>\
M&:WKLNJ72S%I/)@69A"(^&4%,X)^:@#IK#X=> =1LTNH/#-EY;]-R<_SJS_P
MJWP-_P!"S8?]\'_&M+PEN'A6U'!<*?SS7G6H:C>6VNW3ZW?ZAILRSK]GD^TL
M+9A@=4!/&?ZT =G_ ,*M\#?]"S8?]\'_ !H_X5;X&_Z%FP_[X/\ C535-4O-
M.OO#6HK>>?9WHBAF9"0A&PL9 #Z\>]<_JNK:_K!UG4=):XET[,*PI;R%7X.U
M\'.!R#0!TMW\-_ -E:374_AO3TBB0N[%<8 &3U/M1:?#?P#?64%W!X;T]H9X
MUEC8+G*L,@\'T-<;+/:ZCH.M65OKUZZI9S2FUN+AWG!5#U;IMYY'O2_VI<:3
MX8\*Z-;W5WY5W:6\\\@F/F!&B'RHW\."!B@#M_\ A5O@;_H6;#_O@_XT?\*M
M\#?]"S8?]\'_ !KE],UG4[.:_M()+R6Q**89KF8R.AP2<MGN>*SG_MRT\):#
MKXUFZ:^U&\AM9$:=S$%=B"0N>O H [G_ (5;X&_Z%FP_[X/^-'_"K? W_0LV
M'_?!_P :Q%_M;0/%26MO?SW1O+96*7$K2*LC,<[03P..!6'I^JS6NH1-J>K7
M^FZF97#1WMRSPN,G&$&<<?J10!KV?AS1_#?QITR'1M/@LHY=&G=UB& Q\Q1D
MUZ?7"7__ "7#1_\ L"7'_HQ:[N@ KA/&'_)2OA__ -?%[_Z(-=W7">,/^2E?
M#_\ Z^+W_P!$&@#>U+0KN?4!?:=J1LIB"'_<B4-T_O' Z4:=X=\B&[^W7/VN
M>ZW!Y!'Y?RG'& <=1U]ZW:* .;MO#5Y#+&CZHLEHC,?)^RJ,@]!NSGCB@>&K
MN&4I:ZJ8;(NK^1Y . .HW$YYY_.NDHH YJ^\,7,UU,]GJAM89XC')'Y ?.3D
MG).?3\JL:=X<^P7<5P;OS#&,8\O&>,>M;M% &)>>'A=W=S<?:=AF0J!LSM.,
M9Z\US[Z,9M;TRT%P\\UDB">0Q; \2D@KUQU.>.:[NB@!%4*H4#  P*6BB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KA/A+_P B?<_]A2\_]&M7=UPGPE_Y
M$^Y_["EY_P"C6H [NJ&LZ3!K6ESV%QPDJE=W/RY&,\$5?JGJ>I6VDV3W=TVV
M)!DG(_J: .6D\%ZO?6Z:?J?B5KG2UP&MA9K&74?=&]6W#! .>^*O:GX6O)M3
MFOM*U;^SWN%*SK]G$N\XP#\QXP/2K%IXNL+V>.**"[R_W6,8QTSUS6_0!RNG
M^"H["[M;H7I>6,J\Q\K'FOW;K\N?05'<^!A<>%=0T3^T"HO)?,\[R<[/W@?&
M-W/3'6NG6\MWNFM4GC:=5W-&'!8#.,D=>M3T 9&JZ&-3O[2Z^T>7]G.=NS.[
MD'KGCI6=+X/$NF:]9_;B/[6DE??Y7^JWXXQGG&/:NG=@B,QZ*,FHK:Y2ZC,D
M>< XYH YRZ\)W2W%K=:7JOV*YBA6*5_LXD\X*NT<,<+CGIZU#9^!1;/;3R:@
M9;E&#S2^3M\T@Y'&["\<<5U]% &1I^ABQUB[U#[1O^T;ODV8VY;/7/-1'PXD
MOB:75[F<3+L58(#'@1$ ACG/.<]QQBG2^*=*AU1;!IP9&?RMX9=BR9QL)SPW
MMUK9R",@Y'7- '/-X51==FU&VNO(CN(7CF@$60[$ !LYXP.P'-12>#8Y- ;3
M?M?[T2F:*<Q9\M]NT';G!_&M;3]=T[5+BY@M+F.26V8+*BNI*DC(R >.*FL=
M1MM1^T?9I _V>=H),$'#KC(X^HH YE?!E[<6]Q%J6LBY#JBQ[;-8C'M/7*GG
M/%5[;P)J$=Q9SW.OB8V@.P"Q1,\YZAJ[FHYIXK>)I9I$C1>2SL /UH I:.NI
M*EW_ &E*)2;ES 0JKB+ VCC\>O-8^N^%=0U+6[;5--UW^S9H<_\ +HLV[*[?
MXC]?SK;_ +6LO/@A$R,TZAX\,"&!Z$<\U>H XV'P-*Z7LNI:N;R^N.4N?LPB
M\LXP#M5L'M^5.TOP;J%KJEI?7^NF]-K$L*)]D6/Y5.1R#]:Z5=2M6U$V D'V
M@ G;D9Q^>>]6Z .1D\#+)<M,=0/S,6V^3Z_\"JM<>!+UE:TM-=-MIIE61;;[
M(K[=O;<6R<\_G7;T4 <<? 0))_M$]<_ZG_[*M9?#P76HM2^TY\N,)Y>SKA-O
M7-:5[?V^GQI)<.$5VV@D@<_C1:WL5YN\K=\N#S0!Y/J,-PLS:/8ZA/"GVJ+%
MA]B+*H[_ +T]>OZ^U>L:= UKIMK;O]Z.)4/U JS10 45%<7$=K \TK81>IK!
MM?'&BW)C/FM#'(<)+,55"<XP#F@#HZ*1'61%=&#*PR&!R"*6@ HJ"\O(;&#S
MIW"ID#)('/XU)#*D\*2QG*.H93Z@T </XM_Y*A\/O^NM_P#^D]=W7">+?^2H
M?#[_ *ZW_P#Z3UW= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <)X=_P"2O>-O^O;3_P#T!ZW=
M!\-C0]4UJ]%T9O[3N%GV>7M\O"!<9R<],]JPO#O_ "5_QM_U[:?_ .@/7=T
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MXZ^'S:M_:ACU,W?D^1O^PW.-F[=C&,=3Z52M?$WPUL]02]A@U59D9G4FTNR
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MX=:1<O<6<.II,X*LS6=TV0?J#0 S4+:>^TBQUJ74;@RSW@9H6E8QJI3=M"]
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M(Z9R2,^U8MKXO^'-I;2V\<.J;)G#R;K.Z.2.G4<5:A\?^ ;?48]0BCU);F.
M6RN+&YQY8.0,;<=>_6@#2\6_\E0^'W_76_\ _2>N[KRB?Q9IGBWXH>"CI*WC
MK:27AF:6TDB"AH"!RP'<&O5Z "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X3P[_P E?\;?]>VG
M_P#H#UW=<)X=_P"2O^-O^O;3_P#T!Z[N@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .$\5?\E6^'_UU'_T0*[NN$\5?\E6
M^'_UU'_T0*[N@ K@_"Q9_''BV>3F;R[;@]L*^*[RN7_LJXT[QRVIVR;K?4U"
MWASC9Y:$)QWR2>F/QH \\T^+4M8.OW,UM'<2!B&EF4.;?Y/X"3E<=>.]8^J7
M-]I=G"VG:A))>- L=YY;L-EL!_K.WS;N,UZ]J7@+P]JM^][=6;F>0Y<K<2*&
M_ ,!5K3/".B:.TALK+RS)'Y;;I&?*^GS$^E $GAR.RMO#]K]C?,!7<6]6/7]
M<UIW'_'M+_N'^58W_"':'_8$NB?9'&GR2"1HA/("6W[_ +V[</FYZ^W2MORU
M\LQX^4C&,T >1^#-/\471\1OI.IV-O:_V[=@I-$[-NR.<@^F*;XL\)MH?A>4
MR7DLE]>2I]HG1R-P61< 'KT)%>HZ5HUAHL=REA!Y2W-P]U*-[-ND?&X\DXS@
M<#BC5=&L-:MU@OX/-C4Y WLO.0>Q'<"@#SSQW9'2#I.F:9%Y5K-<QET3@2-N
MP%(&,@YQ@U4*ZWHOBF&6QLHXI'B56LH4"*XR3NP#C)Z9]J].U?1K#7;(VFH0
M^;"3NP'*G/U!![U0T3P=HOA^Y>XT^V=)F786>9W^7.<?,QH YKQ+J\LOA=4U
MS3[V.XF<!+:WD".^'7OR/0_3-<U>27NF>-+5X[&+3)'LI"L$,8CW'<.3MX->
MK:WH.G>(;$V>IP&:$D' =D/4'JI!Z@5F6?@+P[97<=W%9/\ :(R"KM<2-T.>
MA;':@#EM#TK1M1\+:QJ&L2L)/M<IFNR?WEN?E)"-@E0"3C'K6?HUGIT7B'QC
M)9)&RPV]EY,NT;AE6R0<=^]=M=_#[PW>ZA)>S6+F:1S(^+B0!F)))P&QU/I5
MB7P5H$NL'56LF^V%!&SB9P"H7:!M#8Z>U ' QRO<Z!X0LKF:1;.8H9,,?WC>
M:0%/J"">#5_Q#;P:%XNMH=)'D">%5F@B^5-N6^;:,#.0!GVKMI_"NC7&APZ-
M):$V,/\ JXQ(X*]?XLY[GO5?2O!.@Z,TS6=HRM*NQR\TCY7.<?,QQTH \\@T
M6U/PGFOW#-?"Y.VY8YD7_2,8#=1QQ]*]4T6=IM(M7D<M(Z9)/4\U$OAO2ET1
MM'%L?L#-O,7F-UW;NN<]>>M5/^$;AC\46.IQ*RQVMH]NJ[SCYF#=,\]/2@#H
M**** "BBB@ HHHH **** .$O_P#DN&C_ /8$N/\ T8M=W7"7_P#R7#1_^P)<
M?^C%KNZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH X3P[_ ,E?\;?]>VG_ /H#UW=<)X=_Y*_XV_Z]M/\ _0'KNZ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X3Q5_R
M5;X?_74?_1 KNZX3Q5_R5;X?_74?_1 KNZ "O*[FXOM7^(/B#3YO%UUH]K91
MVQACCF1 Q="6^\/8?G7JE>7Z7H-EK7Q2\7_; Y\J*RV[3CJC9[>U &I<0WFB
M^#]7NK;Q/=:I*(9&CFDE1O+(0XP5'J,TWX6>)+W6/"Y.LW!:]C;=ND."T>U<
M-SV))YZ5H>)=*MM)\"ZK!:A@AMY#\QS_  -7GURUUH>EZ)-9!E.LZ);6,(4X
M F*[RWUP.M $VG^*/%NN>(=7BL)W",T:6\3E@(PN=QX!Z@9KHY;[4O"7B6VM
M)M9N=5AFMVEDCN&#.F"!D 8X [FN9U77K7P#XEOKHH-RP6^$ ZLR88_FV:T_
M#.I^&]4DN9+GQ#;ZCK]["\:A0^U-PVX0,/E&<<9ZT 6_M/B'5--U7Q%;ZK/
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MLS#!X&/0$=?6N[^'%M%!X=#V_F?9Y2&CWMD8]O04 =A1110!PE__ ,EPT?\
M[ EQ_P"C%KNZX2__ .2X:/\ ]@2X_P#1BUW= !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(22>?2O2Z* .1OM+OI?B';:@ENQM%MT1I>, AF)'ZUUU%% '"7__ "7#1_\
ML"7'_HQ:[NN$O_\ DN&C_P#8$N/_ $8M=W0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '">'?^2O\ C;_KVT__ - >N[KA
M/#O_ "5_QM_U[:?_ .@/7=T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!PGBK_ )*M\/\ ZZC_ .B!7=UPGBK_ )*M\/\
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M<)?_ /)<-'_[ EQ_Z,6N[H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_P1V_\ C7=T4 <)_P (KX^_Z*2?_!';_P"-'_"*^/O^BDG_ ,$=O_C7=T4
M<)_PBOC[_HI)_P#!';_XT?\ "*^/O^BDG_P1V_\ C7=T4 <)_P (KX^_Z*2?
M_!';_P"-'_"*^/O^BDG_ ,$=O_C7=T4 <)_PBOC[_HI)_P#!';_XT?\ "*^/
MO^BDG_P1V_\ C7=T4 >+^(/#_B^+XA>#;>X\<F>[F-[]FNO[)A7[-B$%OD!P
M^X<<].HKK?\ A%?'W_123_X([?\ QH\5?\E6^'_UU'_T0*[N@#A/^$5\??\
M123_ .".W_QJA9?#SQ?I]Y=7=K\0RD]UM\YO[&A.[;G'!; ZGI7I5% '"?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>U/_ ,%L_P#\30!W=%<)_P +=\*?WM3_ /!;/_\ $T?\+=\*?WM3_P#!;/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>img206306002_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206306002_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" * !,X# 2(  A$! Q$!_\0
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M^AA_\DKC_P"-T >@45Y__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\
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MT,/_ ))7'_QNC_A=OP\_Z&'_ ,DKC_XW0!Z!17G_ /PNWX>?]##_ .25Q_\
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M=OP\_P"AA_\ )*X_^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\
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MA_\ )*X_^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C=
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M^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C= 'H%%>?\
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MZ/\ A=OP\_Z&'_R2N/\ XW0!Z!17G_\ PNWX>?\ 0P_^25Q_\;H_X7;\//\
MH8?_ "2N/_C= 'H%%>?_ /"[?AY_T,/_ ))7'_QNC_A=OP\_Z&'_ ,DKC_XW
M0!Z!17G_ /PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\ C= 'H%%>?_\
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MT?\ "">#_P#H5-#_ /!=#_\ $T ?,'_"6_#S_HF'_E?N/\*/^$M^'G_1,/\
MROW'^%?3_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q- 'S!_P
MEOP\_P"B8?\ E?N/\*/^$M^'G_1,/_*_<?X5]/\ _"">#_\ H5-#_P#!=#_\
M31_P@G@__H5-#_\ !=#_ /$T ?,'_"6_#S_HF'_E?N/\*/\ A+?AY_T3#_RO
MW'^%?3__  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\30!\P?\
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M!\P?\);\//\ HF'_ )7[C_"C_A+?AY_T3#_ROW'^%?3_ /P@G@__ *%30_\
MP70__$T?\()X/_Z%30__  70_P#Q- 'S!_PEOP\_Z)A_Y7[C_"C_ (2WX>?]
M$P_\K]Q_A7T__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$T
M?,'_  EOP\_Z)A_Y7[C_  H_X2WX>?\ 1,/_ "OW'^%?3_\ P@G@_P#Z%30_
M_!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $T ?,'_"6_#S_HF'_E?N/\*/^$M^
M'G_1,/\ ROW'^%?3_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
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M/_Q- 'S!_P );\//^B8?^5^X_P */^$M^'G_ $3#_P K]Q_A7T__ ,()X/\
M^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !- 'S!_PEOP\_Z)A_Y7[C_"
MC_A+?AY_T3#_ ,K]Q_A7T_\ \()X/_Z%30__  70_P#Q-'_"">#_ /H5-#_\
M%T/_ ,30!\P?\);\//\ HF'_ )7[C_"C_A+?AY_T3#_ROW'^%?3_ /P@G@__
M *%30_\ P70__$T?\()X/_Z%30__  70_P#Q- 'S!_PEOP\_Z)A_Y7[C_"C_
M (2WX>?]$P_\K]Q_A7T__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\
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M- 'S!_PEOP\_Z)A_Y7[C_"C_ (2WX>?]$P_\K]Q_A7T__P ()X/_ .A4T/\
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M49.,^U;-)WZC"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5S_CO_ ))YXE_[!5U_Z*:N@KG_ !W_ ,D\\2_]@JZ_]%-0
M!\P?\V]?]S7_ .VE?3_@3_DGGAK_ +!5K_Z*6OF#_FWK_N:__;2OI_P)_P D
M\\-?]@JU_P#12T <_P#&W_DD.N_]N_\ Z41UX!_S;U_W-?\ [:5[_P#&W_DD
M.N_]N_\ Z41UX!_S;U_W-?\ [:4 ?3_@3_DGGAK_ +!5K_Z*6N@KG_ G_)//
M#7_8*M?_ $4M=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<_X[_P"2>>)?^P5=?^BFKH*Y_P =_P#)//$O
M_8*NO_134 ?,'_-O7_<U_P#MI7T_X$_Y)YX:_P"P5:_^BEKY@_YMZ_[FO_VT
MKZ?\"?\ )//#7_8*M?\ T4M '/\ QM_Y)#KO_;O_ .E$=> ?\V]?]S7_ .VE
M>_\ QM_Y)#KO_;O_ .E$=> ?\V]?]S7_ .VE 'T_X$_Y)YX:_P"P5:_^BEKH
M*Y_P)_R3SPU_V"K7_P!%+704 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %4M2UG2]&B275-2L[&-VVH]U.L08]< L1DU=KF/B,JM\./$0901
M]@E."/\ 9-*3LKCBKNQ=M?&'AB^N%M[3Q'I%Q.WW8XKZ)V/T ;-;58UIIECJ
MWA*RLM0M(;FVDM(U:*50P(V"N7^%U]<H?$/AV>>2>+1-0:WMI)&+-Y)Y523R
M<8Q5M6DX]O\ .Q"=XJ7<[UIX4GCA>5%ED!*(6 9@.N!WQD?G45_J-CI5HUUJ
M-[;V=LI ,UQ*L: GIRQ KSGQPMQ#-:^/("Y&B7H01@DAK0G9,<>I))SZ(*]&
M>&UU&&WE95FB#+/&3R"<?*?US4[J_P#7]6_$IZ,R/^$[\'_]#7H?_@QA_P#B
MJGE\7^&8+>"XF\1:3'!< F&1[V,+( <':2V#@\'%<]:?\EQU+_L!0_\ HUJK
M?%:TMK#X=W AA"1B_MYBJ+G#&=2Q '<DGIZT+9>?^=@[KM_E<Z:+QMX4GF2&
M'Q/HLDLC!41+^(LQ/0 !N36[7-GQ)I6JW-MI9LM2;[4Y7_2M,N+=!M4OG=(B
MC/R\ '-:X_M3^VCG['_9/D#'WO/\[//^SLQCWS3$7:***0PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y_QW_R3SQ+_ -@JZ_\ 135T%<_X[_Y)YXE_[!5U_P"BFH ^8/\ FWK_ +FO
M_P!M*^G_  )_R3SPU_V"K7_T4M?,'_-O7_<U_P#MI7T_X$_Y)YX:_P"P5:_^
MBEH Y_XV_P#)(==_[=__ $HCKP#_ )MZ_P"YK_\ ;2O?_C;_ ,DAUW_MW_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KG_'?_)//$O\ V"KK_P!%-705S_CO
M_DGGB7_L%77_ **:@#Y@_P";>O\ N:__ &TKZ?\  G_)//#7_8*M?_12U\P?
M\V]?]S7_ .VE?3_@3_DGGAK_ +!5K_Z*6@#G_C;_ ,DAUW_MW_\ 2B.O /\
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M4L%G(!\S7,1R^3V!!('NM:_B[3]?O=(D?PWK<FFZA$C-&OD121S'LK;U)'3
M((Z\@UR'C+PSXEC\'QSIJNE3/H;+?VRQ:;)%(S1<GYS.PY&[/R\YKOM!UFT\
M0Z'9ZK92+)!<Q!P5/0D<@^X/%*UXVZK^D_S^X5[2OW_K_(YOPMX@;5?A\+V?
M5+Y[\!H)W>.$7$-QG:8P@0)G=]T%3U&<UM^'-.UBPL?^)UKD^IW<@!;?#%&D
M9]%V(I/U.>G:N3M[2VL_CI<06YVQ76EB^F@#?(;@/L$FWLVPD5Z-3O=<W?\
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M-SC5+GRE.,_ZKS-FW_9QBGI=_+]0?ZO]#T#3XKF'3K>*]N!<721JLLP4+YC
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MZVTT\T21W%L['Y7)0*C)V/R@CWIFIR:X?B;9Z+!XGU"WT^\L9;O9'!:DQLK
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/^
M._\ DGGB7_L%77_HIJZ"N?\ '?\ R3SQ+_V"KK_T4U 'S!_S;U_W-?\ [:5]
M/^!/^2>>&O\ L%6O_HI:^8/^;>O^YK_]M*^G_ G_ "3SPU_V"K7_ -%+0!S_
M ,;?^20Z[_V[_P#I1'7@'_-O7_<U_P#MI7O_ ,;?^20Z[_V[_P#I1'7@'_-O
M7_<U_P#MI0!]/^!/^2>>&O\ L%6O_HI:Z"N?\"?\D\\-?]@JU_\ 12UT% !1
M110 4444 %%%% !1110 4444 %07EE::C:26E]:PW5M(,/#/&'1N<\J>#4]%
M &5I_A?P_I-U]ITW0M,LKC:5\VVM(XWP>HRH!Q4FI>']%UIXWU72+"^>($1M
M=6R2E >N-P.*T:* *M[IMCJ5D;*^LK:ZM6QF">)70XZ?*1CBH],T32=%21-*
MTRRL$D(+K:VZ1!B.A.T#-7J* ,;_ (1#PS]M^V_\([I'VOS/-\_[%'OWYSNW
M;<YSSFMFBBCR KWUA9ZG:/:7]I!=VSXWPSQB1&P<C*D8/-5M,T#1M%,ATK2;
M"P,N!(;6V2+?CIG:!GJ:T:* *][86>I6S6U_:075NWWHIXPZGZ@C%-L-,L-*
MMA;:=8VUG #D16\2QK^2@"K5% !61?\ A7P[JMVUUJ.@Z7>7+  S7%G'(Y Z
M<L":UZ* *-]HNE:I:1VFH:99W=M&08X;B!9$0@8&%((''%10^'=#M]-FTV#1
MM.BL)CNEM4M46)SQRR 8/0=1VK3HH PU\&>%D@D@3PUHRPR$%XQ81!6(Z9&W
MG&3^=1_\()X/_P"A4T/_ ,%T/_Q-=!10!'!!#:V\=O;Q1PPQ*$CCC4*J*.
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MK>..2<(3&DCE%9L< L 2!GO@X]#4E% '/_;/&'_0"T/_ ,',W_R+1]L\8?\
M0"T/_P ',W_R+7044 <_]L\8?] +0_\ P<S?_(M'VSQA_P! +0__  <S?_(M
M=!10!S_VSQA_T M#_P#!S-_\BT?;/&'_ $ M#_\ !S-_\BUT%% '/_;/&'_0
M"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R+7044 <_]L\8?] +0_\ P<S?_(M'
MVSQA_P! +0__  <S?_(M=!10!S_VSQA_T M#_P#!S-_\BT?;/&'_ $ M#_\
M!S-_\BUT%% '/_;/&'_0"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R+7044 <_
M]L\8?] +0_\ P<S?_(M'VSQA_P! +0__  <S?_(M=!10!S_VSQA_T M#_P#!
MS-_\BT?;/&'_ $ M#_\ !S-_\BUT%% '/_;/&'_0"T/_ ,',W_R+1]L\8?\
M0"T/_P ',W_R+7044 <_]L\8?] +0_\ P<S?_(M'VSQA_P! +0__  <S?_(M
M=!10!S_VSQA_T M#_P#!S-_\BT?;/&'_ $ M#_\ !S-_\BUT%% '/_;/&'_0
M"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R+7044 <_]L\8?] +0_\ P<S?_(M'
MVSQA_P! +0__  <S?_(M=!10!S_VSQA_T M#_P#!S-_\BT?;/&'_ $ M#_\
M!S-_\BUT%% '/_;/&'_0"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R+7044 <_
M]L\8?] +0_\ P<S?_(M'VSQA_P! +0__  <S?_(M=!10!S_VSQA_T M#_P#!
MS-_\BT?;/&'_ $ M#_\ !S-_\BUT%% '/_;/&'_0"T/_ ,',W_R+1]L\8?\
M0"T/_P ',W_R+7044 <_]L\8?] +0_\ P<S?_(M'VSQA_P! +0__  <S?_(M
M=!10!S_VSQA_T M#_P#!S-_\BT?;/&'_ $ M#_\ !S-_\BUT%% '/_;/&'_0
M"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R+7044 <_]L\8?] +0_\ P<S?_(M'
MVSQA_P! +0__  <S?_(M=!10!S_VSQA_T M#_P#!S-_\BT?;/&'_ $ M#_\
M!S-_\BUT%% '/_;/&'_0"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R+7044 <_
M]L\8?] +0_\ P<S?_(M'VSQA_P! +0__  <S?_(M=!10!S_VSQA_T M#_P#!
MS-_\BT?;/&'_ $ M#_\ !S-_\BUT%% '/_;/&'_0"T/_ ,',W_R+1]L\8?\
M0"T/_P ',W_R+7044 <_]L\8?] +0_\ P<S?_(M'VSQA_P! +0__  <S?_(M
M=!10!S_VSQA_T M#_P#!S-_\BT?;/&'_ $ M#_\ !S-_\BUT%% '/_;/&'_0
M"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R+7044 <_]L\8?] +0_\ P<S?_(M'
MVSQA_P! +0__  <S?_(M=!10!S_VSQA_T M#_P#!S-_\BU8L;GQ))>1K?Z5I
M4%J<[Y(-3DE=>#C"F!0><?Q#UYZ5L44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %<_X[_Y)YXE_[!5U_P"BFKH*Y_QW_P D\\2_]@JZ_P#134 ?,'_-
MO7_<U_\ MI7T_P"!/^2>>&O^P5:_^BEKY@_YMZ_[FO\ ]M*^G_ G_)//#7_8
M*M?_ $4M '/_ !M_Y)#KO_;O_P"E$=> ?\V]?]S7_P"VE>__ !M_Y)#KO_;O
M_P"E$=> ?\V]?]S7_P"VE 'T_P"!/^2>>&O^P5:_^BEKH*Y_P)_R3SPU_P!@
MJU_]%+704 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/\ CO\ Y)YXE_[!5U_Z
M*:N@KG_'?_)//$O_ &"KK_T4U 'S!_S;U_W-?_MI7T_X$_Y)YX:_[!5K_P"B
MEKY@_P";>O\ N:__ &TKZ?\  G_)//#7_8*M?_12T <_\;?^20Z[_P!N_P#Z
M41UX!_S;U_W-?_MI7O\ \;?^20Z[_P!N_P#Z41UX!_S;U_W-?_MI0!]/^!/^
M2>>&O^P5:_\ HI:Z"N?\"?\ )//#7_8*M?\ T4M=!0 4444 %%%% !1110 4
M5Q7Q6TRPO_AUK,UW9P3RVUJ\D$DD89HFQU4GD'Z5O:)I&FVGAJVT^WT^UBLY
M(!O@2)0C[E&[*XP<]\]:%LP?0UZ*\X@T#^S/ WB4^$M-MK75I;BZ2)K:-8W8
M+*P"@CI@9"CH#5;PY<>"_%%N+71XQHNO1.DES;$&WNF9&!99>\H/(.=W7GFF
MM0>GX_@>H4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKS[XNZ3IU]X6AN;
MJQMYKB*]MDCEDC!95:9 R@]<$'D=#6MJ/P_\/RV4HTJP@T:]V'RKS3(Q;R(W
M49* ;AD#@Y%*^E_ZZ?YAUL=717C\7Q&U:]^'.C[9!#KNH:F-'>X5 0C!L-*!
MTSMP?3)KO6\#>'F@P;!/MFS9_:.3]KSC&[S_ +^??-4U;7^N_P"J#R_KL='1
M7CESJ(\5?"7Q7;:[;PWNHZ US;+<RQ*260';*/[K8ZD8[^M>A^"M)T[2?">F
MKI]C;VHFMHI)?)C"^8Y099L=3[FBV_R_$3T:7K^!T%%>:?$[0=)OM>\(376F
MVLTL^KQP32/$"TD>QCL8]2N1T/%>C6UK;V5M';6L$4%O$H6.*) JH/0 < 4E
MJK^?^7^8WO;^NO\ D2T5EZ])*U@+*VD:.YO6^SQR)UC!!+./=5#$>X'K7-_#
M&\GBT6\\.7TA:^T&Y:S8L<L\76)_Q4C\J%K?^OZZ ]+'<45Y5XET[PA9?%RQ
MGURTT2"VN=+F>5[Z.)8Y9?,7#'?P7QGGK5[P1"R^.-7ET!'C\'-;)Y*A2L#7
M&<LT /&S'4J-I-$=4OG^%_\ ():?A^)Z/17D]SJ^BZ;XYU.U\?V"!I[G?I&H
M7D6^W6+:,*CG(B8$$DC'/4]*]$T#3H],TTP0W4EU"\KRQ2R3&5BK'(&\DDXS
M@<G@"A:JX/1V-2F22QPIOE=47(&YC@9/ I]<QIMS'XA\4:K)(!):Z1,MI A&
M5\[8&D?W(W!1Z8;UH Z>BO-O"WAO0[+XK^*'M=(L86MHK1K?RX%'DED?<4X^
M7/?&,UM>*O#NBZIXB\/7%_I-E=3-=-&SS0*Q91#(P4DCD C.#QFG;8'NSKZ*
M\IU35M'TGQ[J$'CS3U-E<21G1[ZZA\VVB0*,H,Y$;[MQ+8!]3@"O0/#^GPZ?
M9S?9;MKJUN)C/#(TQE.Q@,#<2<@8P.>F*2U5_P"O0'H[&J2 "2< =2:2.1)H
MDEB=7C<!E=3D,#T(/<5Q'Q%^V0C3+Q["74="@>3^TK2%=[,K)A7*9^=5))*X
M/KCBK7@&UT=M L-1T.>+[++9QQR0VS8B$@Y9M@.%?).> 3WH6M_Z[@]+'7T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R26.)0TDBH"0H
M+'&2> *?45S;07EM);7,22PR*5='&0P]#0!+17.^%]0=Y]6T:>1Y)=)N1"LD
MARSQ,H>,D]R =N>^W/>NBH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_'?_
M "3SQ+_V"KK_ -%-705S_CO_ ))YXE_[!5U_Z*:@#Y@_YMZ_[FO_ -M*^G_
MG_)//#7_ &"K7_T4M?,'_-O7_<U_^VE?3_@3_DGGAK_L%6O_ **6@#G_ (V_
M\DAUW_MW_P#2B.O /^;>O^YK_P#;2O?_ (V_\DAUW_MW_P#2B.O /^;>O^YK
M_P#;2@#Z?\"?\D\\-?\ 8*M?_12UT%<_X$_Y)YX:_P"P5:_^BEKH* "BBB@
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M )'H Z"BN?\ ^$>U3_H<]<_[\V7_ ,CT?\(]JG_0YZY_WYLO_D>@#H**Y_\
MX1[5/^ASUS_OS9?_ "/1_P (]JG_ $.>N?\ ?FR_^1Z .@HKG_\ A'M4_P"A
MSUS_ +\V7_R/1_PCVJ?]#GKG_?FR_P#D>@#H**Y__A'M4_Z'/7/^_-E_\CT?
M\(]JG_0YZY_WYLO_ )'H Z"BN?\ ^$>U3_H<]<_[\V7_ ,CT?\(]JG_0YZY_
MWYLO_D>@#H**Y_\ X1[5/^ASUS_OS9?_ "/1_P (]JG_ $.>N?\ ?FR_^1Z
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M -E7!B$CNI )V8(P#D]!W-.TUKSX>ZS)HYT_4;[PU=,TUC-9VKW!L23EHG5
M3LR<J<>U>A44+1)?UO<'K_7R.1N=2AN]/O;/Q1H%[/:-<2)%C3WNEGCW'8=D
M:LRX'&6 Z9[TWX<Z!<^'=$O+619X;*2]EEL+6=LO;P$_*I.3[G&>,\\YKL**
M%H#U"N/\&6K:;KOBVRE/SOJ?VQ,G[T<L:D'\U8?A7850N],$]]!?03-;W<0V
M%U&1)'G)1AW'<=P>AZ@BT?X?E_D'2QS;Q7'ASQWJNLS6=U<Z;J=M IEM(&G>
M&2/*X:- 7((8$$ ]#G%:<=PVOZMI]S#97<-G9L\WG74#P,[E60*(W ?HQ))
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M'/7/^_-E_P#(] '045S_ /PCVJ?]#GKG_?FR_P#D>C_A'M4_Z'/7/^_-E_\
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M7_8*M?\ T4M=!7/^!/\ DGGAK_L%6O\ Z*6N@H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5+R73;F. DG'^L:,+U]ZZBVN8+RVBN;::.:"50\<D;!E93T((ZBBP7):***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_'?_
M "3SQ+_V"KK_ -%-705S_CO_ ))YXE_[!5U_Z*:@#Y@_YMZ_[FO_ -M*^G_
MG_)//#7_ &"K7_T4M?,'_-O7_<U_^VE?3_@3_DGGAK_L%6O_ **6@#G_ (V_
M\DAUW_MW_P#2B.O /^;>O^YK_P#;2O?_ (V_\DAUW_MW_P#2B.O /^;>O^YK
M_P#;2@#Z?\"?\D\\-?\ 8*M?_12UT%<_X$_Y)YX:_P"P5:_^BEKH* "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#12UT%<_X$_P"2>>&O^P5:_P#HI:Z"@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH2%%O-0NS;";!P3&BQN2.OWMO\\7CXCU&6+54MM#9+W3@I:*]N!$DRD$[D=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_X[_P"2>>)?^P5=
M?^BFKH*Y_P =_P#)//$O_8*NO_134 ?,'_-O7_<U_P#MI7T_X$_Y)YX:_P"P
M5:_^BEKY@_YMZ_[FO_VTKZ?\"?\ )//#7_8*M?\ T4M '/\ QM_Y)#KO_;O_
M .E$=> ?\V]?]S7_ .VE>_\ QM_Y)#KO_;O_ .E$=> ?\V]?]S7_ .VE 'T_
MX$_Y)YX:_P"P5:_^BEKH*Y_P)_R3SPU_V"K7_P!%+704 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7/^._^2>>)?\ L%77_HIJZ"N?\=_\D\\2_P#8*NO_ $4U
M 'S!_P V]?\ <U_^VE?3_@3_ ))YX:_[!5K_ .BEKY@_YMZ_[FO_ -M*^G_
MG_)//#7_ &"K7_T4M '/_&W_ ))#KO\ V[_^E$=> ?\ -O7_ '-?_MI7O_QM
M_P"20Z[_ -N__I1'7@'_ #;U_P!S7_[:4 ?3_@3_ ))YX:_[!5K_ .BEKH*Y
M_P "?\D\\-?]@JU_]%+704 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/^._\
MDGGB7_L%77_HIJZ"N?\ '?\ R3SQ+_V"KK_T4U 'S!_S;U_W-?\ [:5]/^!/
M^2>>&O\ L%6O_HI:^8/^;>O^YK_]M*^G_ G_ "3SPU_V"K7_ -%+0!S_ ,;?
M^20Z[_V[_P#I1'7@'_-O7_<U_P#MI7O_ ,;?^20Z[_V[_P#I1'7@'_-O7_<U
M_P#MI0!]/^!/^2>>&O\ L%6O_HI:Z"N?\"?\D\\-?]@JU_\ 12UT% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5S_CO_DGGB7_ +!5U_Z*:N@KG_'?_)//$O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5S_CO_ ))YXE_[!5U_Z*:N@KG_ !W_ ,D\\2_]@JZ_]%-0!\P?\V]?]S7_
M .VE?3_@3_DGGAK_ +!5K_Z*6OF#_FWK_N:__;2OI_P)_P D\\-?]@JU_P#1
M2T <_P#&W_DD.N_]N_\ Z41UX!_S;U_W-?\ [:5[_P#&W_DD.N_]N_\ Z41U
MX!_S;U_W-?\ [:4 ?3_@3_DGGAK_ +!5K_Z*6N@KG_ G_)//#7_8*M?_ $4M
M=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %<_X[_Y)YXE_P"P5=?^BFKH*Y_Q
MW_R3SQ+_ -@JZ_\ 134 ?,'_ #;U_P!S7_[:5]/^!/\ DGGAK_L%6O\ Z*6O
MF#_FWK_N:_\ VTKZ?\"?\D\\-?\ 8*M?_12T <_\;?\ DD.N_P#;O_Z41UX!
M_P V]?\ <U_^VE>__&W_ ))#KO\ V[_^E$=> ?\ -O7_ '-?_MI0!]/^!/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<_X[_P"2>>)?^P5=?^BFKH*Y_P =_P#)//$O
M_8*NO_134 ?,'_-O7_<U_P#MI7T_X$_Y)YX:_P"P5:_^BEKY@_YMZ_[FO_VT
MKZ?\"?\ )//#7_8*M?\ T4M '/\ QM_Y)#KO_;O_ .E$=> ?\V]?]S7_ .VE
M>_\ QM_Y)#KO_;O_ .E$=> ?\V]?]S7_ .VE 'T_X$_Y)YX:_P"P5:_^BEKH
M*Y_P)_R3SPU_V"K7_P!%+704 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/^._
M^2>>)?\ L%77_HIJZ"N?\=_\D\\2_P#8*NO_ $4U 'S!_P V]?\ <U_^VE?3
M_@3_ ))YX:_[!5K_ .BEKY@_YMZ_[FO_ -M*^G_ G_)//#7_ &"K7_T4M '/
M_&W_ ))#KO\ V[_^E$=> ?\ -O7_ '-?_MI7O_QM_P"20Z[_ -N__I1'7@'_
M #;U_P!S7_[:4 ?3_@3_ ))YX:_[!5K_ .BEKH*Y_P "?\D\\-?]@JU_]%+7
M04 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7/^._\ DGGB7_L%77_HIJZ"N?\
M'?\ R3SQ+_V"KK_T4U 'S!_S;U_W-?\ [:5]/^!/^2>>&O\ L%6O_HI:^8/^
M;>O^YK_]M*^G_ G_ "3SPU_V"K7_ -%+0!S_ ,;?^20Z[_V[_P#I1'7@'_-O
M7_<U_P#MI7O_ ,;?^20Z[_V[_P#I1'7@'_-O7_<U_P#MI0!]/^!/^2>>&O\
ML%6O_HI:Z"N?\"?\D\\-?]@JU_\ 12UT% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_8*M?_12UT% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S_CO_ ))YXE_[!5U_
MZ*:N@KG_ !W_ ,D\\2_]@JZ_]%-0!\P?\V]?]S7_ .VE?3_@3_DGGAK_ +!5
MK_Z*6OF#_FWK_N:__;2OI_P)_P D\\-?]@JU_P#12T <_P#&W_DD.N_]N_\
MZ41UX!_S;U_W-?\ [:5[_P#&W_DD.N_]N_\ Z41UX!_S;U_W-?\ [:4 ?3_@
M3_DGGAK_ +!5K_Z*6N@KG_ G_)//#7_8*M?_ $4M=!0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<_X[_Y)YXE_P"P5=?^BFKH*Y_QW_R3SQ+_ -@JZ_\ 134
M?,'_ #;U_P!S7_[:5]/^!/\ DGGAK_L%6O\ Z*6OF#_FWK_N:_\ VTKZ?\"?
M\D\\-?\ 8*M?_12T <_\;?\ DD.N_P#;O_Z41UX!_P V]?\ <U_^VE>__&W_
M ))#KO\ V[_^E$=> ?\ -O7_ '-?_MI0!]/^!/\ DGGAK_L%6O\ Z*6N@KG_
M  )_R3SPU_V"K7_T4M=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP.#GH*D3PCH$>K:CJBZ9#]MU&+R;N4DGS4Q@@C.!GO@<XYH?EY_\#_@@O/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\
MX[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=X
MP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]
M^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0
M!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?
M\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\
MH&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^
M)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_
MPT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!
MNA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_
M ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T
M5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>
M,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'
M_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\
MX[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=X
MP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]
M^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0
M!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?
M\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\
MH&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^
M)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_
MPT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!
MNA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_
M ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T
M5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>
M,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'
M_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\
MX[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=X
MP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]
M^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0
M!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?
M\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\
MH&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^
M)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_
MPT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!
MNA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_
M ([0!]/T5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T
M5\P?\-'>,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>
M,/\ H&Z'_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/T5\P?\-'>,/\ H&Z'
M_P!^)O\ X[1_PT=XP_Z!NA_]^)O_ ([0!]/US_CO_DGGB7_L%77_ **:O /^
M&CO&'_0-T/\ [\3?_':IZM\??%6LZ-?:7<:?HRP7MO);R-'#*&"NI4D9D(S@
M^AH R_\ FWK_ +FO_P!M*^G_  )_R3SPU_V"K7_T4M?,'_-O7_<U_P#MI7T_
MX$_Y)YX:_P"P5:_^BEH S_BEHFH^(_AQJVDZ3;_:+Z?R?+BWJF[;,C'EB .
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GQ_.O?_"=C<:9X-T.PO(_+NK73[>&9-P.UUC4,,C@X(/2MBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>45
<FILENAME>vir-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-02-28T16:08:26.2026+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.vir.bio/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:vir="http://www.vir.bio/20211231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" id="DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" id="StatementConsolidatedStatementsOfCashFlows2">
        <link:definition>100040 - Statement - Consolidated Statements of Cash Flows 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100050 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" id="StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>100060 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100080 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100090 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>100100 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100110 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitions" id="Role_DisclosureAcquisitions">
        <link:definition>100130 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" id="Role_DisclosureGoodwillAndIntangibleAssets">
        <link:definition>100140 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreements" id="Role_DisclosureGrantAgreements">
        <link:definition>100150 - Disclosure - Grant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100160 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100170 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100180 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100190 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100200 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability" id="Role_DisclosureConvertiblePreferredStockWarrantLiability">
        <link:definition>100210 - Disclosure - Convertible Preferred Stock Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwards" id="Role_DisclosureStockBasedAwards">
        <link:definition>100220 - Disclosure - Stock-Based Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShare1" id="DisclosureNetIncomeLossPerShare1">
        <link:definition>100230 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlan" id="DisclosureDefinedContributionPlan">
        <link:definition>100240 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100250 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEvent1" id="DisclosureSubsequentEvent1">
        <link:definition>100260 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100280 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" id="Role_DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>100290 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100300 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100310 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" id="Role_DisclosureStockBasedAwardsTables">
        <link:definition>100320 - Disclosure - Stock-Based Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables" id="DisclosureNetIncomeLossPerShareTables">
        <link:definition>100330 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100340 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" id="Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>100350 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" id="Role_DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" id="Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails">
        <link:definition>100380 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" id="Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails">
        <link:definition>100390 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" id="Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails">
        <link:definition>100410 - Disclosure - Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails">
        <link:definition>100420 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" id="Role_DisclosureAcquisitionsAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Acquisitions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails">
        <link:definition>100450 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails">
        <link:definition>100460 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" id="Role_DisclosureGrantAgreementsAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Grant Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100490 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails">
        <link:definition>100510 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails">
        <link:definition>100530 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100540 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails">
        <link:definition>100550 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Convertible Preferred Stock Warrant Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" id="Role_DisclosureStockBasedAwardsAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Stock-Based Awards - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" id="Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails">
        <link:definition>100600 - Disclosure - Stock-Based Awards - Summary of Stock Option Plans Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" id="Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails">
        <link:definition>100610 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" id="DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails">
        <link:definition>100620 - Disclosure - Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" id="Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails">
        <link:definition>100630 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100640 - Disclosure - Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" id="DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails">
        <link:definition>100650 - Disclosure - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" id="DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
        <link:definition>100660 - Disclosure - Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails" id="DisclosureNetIncomeLossPerShareAdditionalInformationDetails">
        <link:definition>100670 - Disclosure - Net Income (Loss) Per Share (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" id="DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>100690 - Disclosure - Income Taxes - Schedule of Loss Before Provision for (Benefit from) Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" id="Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails">
        <link:definition>100700 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" id="Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails">
        <link:definition>100710 - Disclosure - Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100720 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100730 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" id="Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails">
        <link:definition>100740 - Disclosure - Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>100750 - Disclosure - Subsequent Event - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="vir_ConvertiblePreferredStockWarrantLiabilityAbstract" name="ConvertiblePreferredStockWarrantLiabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_OperatingLeaseAbstract" name="OperatingLeaseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_OperatingLeaseOtherInformationAbstract" name="OperatingLeaseOtherInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" name="AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_AnnualLicenseMaintenanceFees" name="AnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AntibodyLicenseTransactionPrice" name="AntibodyLicenseTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AssetAcquisitionMilestoneAchieved" name="AssetAcquisitionMilestoneAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AssetAcquisitionMilestonePaymentAggregate" name="AssetAcquisitionMilestonePaymentAggregate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" name="AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" name="BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" name="BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_BusinessAgreementEquityInvestmentCommitment" name="BusinessAgreementEquityInvestmentCommitment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_BusinessAgreementGrantAmount" name="BusinessAgreementGrantAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" name="BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" name="CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_CashGrantAwarded" name="CashGrantAwarded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" name="CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" name="CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementNumberOfUnitsOfAccount" name="CollaborationAgreementNumberOfUnitsOfAccount" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementRelatedCostsAndExpenses" name="CollaborationAgreementRelatedCostsAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_CollaborationAgreementTerminationDescription" name="CollaborationAgreementTerminationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementTransactionPriceConsideration" name="CollaborationAgreementTransactionPriceConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CollaborationAgreementTransactionPriceUpfrontFee" name="CollaborationAgreementTransactionPriceUpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CollaborationTypeAndPrograms" name="CollaborationTypeAndPrograms" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CommonStockIssuanceCost" name="CommonStockIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_CommonStockIssuedInConnectionWithLicenseAgreement" name="CommonStockIssuedInConnectionWithLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_CommonStockSharesIssuedForMilestonePaymentShares" name="CommonStockSharesIssuedForMilestonePaymentShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" name="ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ConvertiblePreferredStockIssuanceCost" name="ConvertiblePreferredStockIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" name="DeferredTaxLiabilitiesInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_DeterminedTransactionPrice" name="DeterminedTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" name="EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_EquityInvestmentCurrent" name="EquityInvestmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_EsppDiscountedPurchasePricePercentage" name="EsppDiscountedPurchasePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_EstimatedSharesEmployeeStockPurchasePlans" name="EstimatedSharesEmployeeStockPurchasePlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" name="ExcessFundsPayableUnderGrantAgreementsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities" name="FailedSaleLeasebackTransactionProceedsFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FairMarketValueOfCommonStockIssued" name="FairMarketValueOfCommonStockIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" name="FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" name="FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FinancialAssetsAmortizedCostBasis" name="FinancialAssetsAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FinancialAssetsFairValue" name="FinancialAssetsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FinancialAssetsGrossUnrealizedHoldingGains" name="FinancialAssetsGrossUnrealizedHoldingGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FinancialAssetsGrossUnrealizedHoldingLosses" name="FinancialAssetsGrossUnrealizedHoldingLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" name="FiniteLivedIntangibleAssetsAccumulatedImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FiniteLivedIntangibleAssetsAmortizationExpense" name="FiniteLivedIntangibleAssetsAmortizationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" name="FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FormerBusinessCombinationContingentConsiderationLiability" name="FormerBusinessCombinationContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FundsReceivedInAdvance" name="FundsReceivedInAdvance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_GrantAgreementAmendedDate" name="GrantAgreementAmendedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementAmendedExpirationDate" name="GrantAgreementAmendedExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementEffectiveEndDate" name="GrantAgreementEffectiveEndDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementExpirationDate" name="GrantAgreementExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementExpirationDateBeforeAmendment" name="GrantAgreementExpirationDateBeforeAmendment" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAwardedAmount" name="GrantAwardedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_GrantAwardedAmountMaximum" name="GrantAwardedAmountMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_GrantsAgreementAmendedDate" name="GrantsAgreementAmendedDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" name="IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" name="IncreaseDecreaseInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" name="IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_InitialFairValueOfDerivativeLiability" name="InitialFairValueOfDerivativeLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_InitialPublicOfferingCosts" name="InitialPublicOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_IssuanceOfCommonStockToSettleAContingentConsideration" name="IssuanceOfCommonStockToSettleAContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_LeaseArrangementContractualExpirationBeginningYear" name="LeaseArrangementContractualExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_LeaseArrangementContractualExpirationEndingYear" name="LeaseArrangementContractualExpirationEndingYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" name="LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_LicenseAgreementUpfrontPayment" name="LicenseAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateCommercialSalesMilestonePayments" name="MaximumAggregateCommercialSalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" name="MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" name="MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateMilestonePayments" name="MaximumAggregateMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateSalesMilestonePayment" name="MaximumAggregateSalesMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateSalesMilestonePayments" name="MaximumAggregateSalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" name="MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" name="MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" name="MaximumNumberOfDevelopmentProgramGrantedToCounterparty" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" name="MaximumNumberOfProductsCoveredAgainstMilestonePayment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" name="MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumSalesMilestonePayment" name="MaximumSalesMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumSalesMilestonToPay" name="MaximumSalesMilestonToPay" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_MaximumSharesToBeIssued" name="MaximumSharesToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" name="MaximumTermOfOfferingPeriodSpecifiedUnderPlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MilestonePayable" name="MilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MilestonePaymentDueToCompany" name="MilestonePaymentDueToCompany" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MilestonePaymentReceived" name="MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_MilestonePaymentsPaid" name="MilestonePaymentsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_MilestonePaymentsRelatedTermsDescription" name="MilestonePaymentsRelatedTermsDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" name="MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" name="MinimumCommonStockPriceForMilestonePaymentsConsideration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_NetProceedsFromIssuanceSecondaryPublicOffering" name="NetProceedsFromIssuanceSecondaryPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_NonCashCommonStockIssuedForContingentConsideration" name="NonCashCommonStockIssuedForContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_NumberOfAntibodiesToDevelop" name="NumberOfAntibodiesToDevelop" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_NumberOfClassOfStock" name="NumberOfClassOfStock" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" name="NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ObligationToPayCapacityReservation" name="ObligationToPayCapacityReservation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_OfferingPeriodEmployeeStockPurchasePlan" name="OfferingPeriodEmployeeStockPurchasePlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_OperatingAndFinanceRentExpense" name="OperatingAndFinanceRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_OperatingLeaseIncentiveOverLeaseLiabilities" name="OperatingLeaseIncentiveOverLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_OperatingLossCarryforwardsExpirationBeginningYear" name="OperatingLossCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_OperatingLossCarryforwardsLimitationOnUsePercentage" name="OperatingLossCarryforwardsLimitationOnUsePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_OptionExerciseFeeConsiderationToBeReceived" name="OptionExerciseFeeConsiderationToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_OptionExerciseFeeHighEndOfTheRange" name="OptionExerciseFeeHighEndOfTheRange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_OptionExerciseFeeLowEndOfTheRange" name="OptionExerciseFeeLowEndOfTheRange" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_OptionExerciseFeeReceived" name="OptionExerciseFeeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" name="OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PaymentMadeForAssetAcquisitionMilestone" name="PaymentMadeForAssetAcquisitionMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentMadeForBusinessCombinationMilestone" name="PaymentMadeForBusinessCombinationMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentOfContingentConsideration" name="PaymentOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentsOfUnderwritingDiscountsAndCommissions" name="PaymentsOfUnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentToCollaboratorResultingFromProgramOptionExercise" name="PaymentToCollaboratorResultingFromProgramOptionExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PayrollAndRelatedExpensesCurrent" name="PayrollAndRelatedExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" name="PercentageOfAggregateGrossProceedsFromSaleOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfCommissionRateFromSaleOfShares" name="PercentageOfCommissionRateFromSaleOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfDevelopmentCosts" name="PercentageOfDevelopmentCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfEstimatedBatchProductionFees" name="PercentageOfEstimatedBatchProductionFees" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" name="PercentageOfOrdinaryShareEqualToOutstandingShare" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfShareDevelopmentCosts" name="PercentageOfShareDevelopmentCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" name="PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" name="PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" name="PreDefinedRegulatoryMilestoneConsiderationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PremiumReceivedOnSalePriceOfCommonStock" name="PremiumReceivedOnSalePriceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PresentValueOfOperatingLeaseLiabilities" name="PresentValueOfOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" name="ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ProceedsFromIssuanceSecondaryPublicOffering" name="ProceedsFromIssuanceSecondaryPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ProceedsFromRepaymentOfPromissoryNotes" name="ProceedsFromRepaymentOfPromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ProfitsAndLossesSharingPercentage" name="ProfitsAndLossesSharingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RangeOfRoyaltyPaymentToBePaid" name="RangeOfRoyaltyPaymentToBePaid" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RangeOfRoyaltyPaymentToBeReceived" name="RangeOfRoyaltyPaymentToBeReceived" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" name="RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" name="ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" name="ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" name="ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" name="ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RegulatoryMilestoneAchieved" name="RegulatoryMilestoneAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" name="RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" name="RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RegulatoryMilestonePaymentToBeReceived" name="RegulatoryMilestonePaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_RegulatoryMilestonesAchieved" name="RegulatoryMilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" name="ReleaseOfValuationAllowanceDeferredTaxInAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" name="RemainingPaymentForAssetAcquisitionMilestoneAggregate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RemainingPaymentMadeForAssetAcquisitionMilestone" name="RemainingPaymentMadeForAssetAcquisitionMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RemainingPaymentMadeForBusinessCombinationMilestone" name="RemainingPaymentMadeForBusinessCombinationMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" name="RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ResearchAndDevelopmentExpensesCurrent" name="ResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" name="ResearchAndDevelopmentExpenseUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" name="RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" name="RoyaltiesBasedOnNetSalesOfLicensedProducts" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RoyaltiesPaymentExpirationPeriod" name="RoyaltiesPaymentExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" name="RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" name="RoyaltyObligationPeriodFromDateOfFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" name="RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_SaleLeasebackTransactionProceedsFromFinancingObligations" name="SaleLeasebackTransactionProceedsFromFinancingObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SaleOfStockConsiderationAggregateOfferingPrice" name="SaleOfStockConsiderationAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SalesMilestonesAchieved" name="SalesMilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SpecifiedClinicalDevelopmentMilestonesPayment" name="SpecifiedClinicalDevelopmentMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" name="SpecifiedResearchAndDevelopmentExpensesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SpecifiedSalesDevelopmentMilestonesPayment" name="SpecifiedSalesDevelopmentMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" name="StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" name="StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" name="StockIssuedDuringPeriodSharesAchievementOfMilestone" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" name="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" name="StockIssuedDuringPeriodSharesCollaborationAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" name="StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesLicenseAgreement" name="StockIssuedDuringPeriodSharesLicenseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodValueAchievementOfMilestone" name="StockIssuedDuringPeriodValueAchievementOfMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodValueCollaborationAgreement" name="StockIssuedDuringPeriodValueCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" name="StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodValueLicenseAgreement" name="StockIssuedDuringPeriodValueLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodWarrantExercised" name="StockIssuedDuringPeriodWarrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedGrantAgreement" name="StockIssuedGrantAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_TaxCreditCarryforwardsExpirationBeginningYear" name="TaxCreditCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_TemporaryEquityAdditionalSharesAuthorized" name="TemporaryEquityAdditionalSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock" name="TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" name="TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_TenantImprovementAllowanceAggregate" name="TenantImprovementAllowanceAggregate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_UnusedFundsReceivedInAdvance" name="UnusedFundsReceivedInAdvance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_UpfrontFeePaid" name="UpfrontFeePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_UpfrontPaymentReceivable" name="UpfrontPaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" name="ValueOfCommonStockSharesIssuedForMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ValueOfSharesTransferredToCollaborator" name="ValueOfSharesTransferredToCollaborator" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ValueStockIssuedGrantAgreement" name="ValueStockIssuedGrantAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" name="WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" name="WrittenNoticePeriodForTerminationOfLicensedProgram" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateAgreementByCompany" name="WrittenNoticePeriodToTerminateAgreementByCompany" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" name="WrittenNoticePeriodToTerminateAgreementByCounterparty" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" name="WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" name="WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" name="WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" name="WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticeToTerminateLicensedProgramIfExercise" name="WrittenNoticeToTerminateLicensedProgramIfExercise" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" name="WrittenNoticeToTerminateLicensedProgramIfNotExercise" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" name="ReconciliationOfEffectiveIncomeTaxRateLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" name="ScheduleOfGoodwillAndIntangibleAssetsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" name="AccruedLiabilitiesAndOtherLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AlnylamAgreementMember" name="AlnylamAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AlnylamPharmaceuticalsIncMember" name="AlnylamPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AnotherProductMember" name="AnotherProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AntibodyProgramMember" name="AntibodyProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BillAndMelindaGatesFoundationMember" name="BillAndMelindaGatesFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BillMelindaGatesFoundationMember" name="BillMelindaGatesFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BiologicalMaterialsMember" name="BiologicalMaterialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BriiAgreementMember" name="BriiAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BriiBioParentMember" name="BriiBioParentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BriiBiosciencesOffshoreLimitedMember" name="BriiBiosciencesOffshoreLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ClinicalAndRegulatoryMilestonesMember" name="ClinicalAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ClinicalDevelopmentMember" name="ClinicalDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_CollaborationAgreementMember" name="CollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_CommercialMilestonesMember" name="CommercialMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ContingentConsiderationLiabilityMember" name="ContingentConsiderationLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ContractRevenueMember" name="ContractRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ConvertiblePreferredStockWarrantLiabilityMember" name="ConvertiblePreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DefinitiveCollaborationAgreementMember" name="DefinitiveCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DevelopedTechnologyMember" name="DevelopedTechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DevelopmentAndManufacturingCollaborationAgreementMember" name="DevelopmentAndManufacturingCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DevelopmentProgramsExercisedByBriiMember" name="DevelopmentProgramsExercisedByBriiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DevelopmentProgramsExercisedByVirMember" name="DevelopmentProgramsExercisedByVirMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_EachInfectiousDiseaseSiRNAMember" name="EachInfectiousDiseaseSiRNAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_EstimatedSharesIssuableUnderTheESPPMember" name="EstimatedSharesIssuableUnderTheESPPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ExecutiveOfficerAndDirectorMember" name="ExecutiveOfficerAndDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstAndSecondClosingsMember" name="FirstAndSecondClosingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstInfectiousDiseaseProductMember" name="FirstInfectiousDiseaseProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstPlanMember" name="FirstPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstSiRNAProductHBVMember" name="FirstSiRNAProductHBVMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstSiRNAProductMember" name="FirstSiRNAProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FollowOnOfferingMember" name="FollowOnOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoGroupLimitedMember" name="GlaxoGroupLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" name="GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoSmithKlineTradingServiceLimitedMember" name="GlaxoSmithKlineTradingServiceLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" name="GlaxoWellcomeUKLimitedAndBeechamSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HBVProgramMember" name="HBVProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HcmvVaccinePlatformGrantMember" name="HcmvVaccinePlatformGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HepatitisBVirusProductMember" name="HepatitisBVirusProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HumabsBiomedSAMember" name="HumabsBiomedSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HumanImmunodeficiencyVirusGrantMember" name="HumanImmunodeficiencyVirusGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfectiousDiseaseProductMember" name="InfectiousDiseaseProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfluenzaAAndHBVResearchProgramsMember" name="InfluenzaAAndHBVResearchProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfluenzaAAndInfluenzaBMember" name="InfluenzaAAndInfluenzaBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfluenzaAResearchProgramsMember" name="InfluenzaAResearchProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_LetterAgreementMember" name="LetterAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MeasurementInputExpectedRevenueVolatilityMember" name="MeasurementInputExpectedRevenueVolatilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MeasurementInputExpectedVolatilityMember" name="MeasurementInputExpectedVolatilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MeasurementInputProbabilityRateMember" name="MeasurementInputProbabilityRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MedImmuneAgreementMember" name="MedImmuneAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MedImmuneLimitedLiabilityCompanyMember" name="MedImmuneLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_NationalInstitutesOfHealthMember" name="NationalInstitutesOfHealthMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_PreliminaryCollaborationAgreementMember" name="PreliminaryCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RestrictedStockAwardsRSAMember" name="RestrictedStockAwardsRSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RestrictedStockPurchaseAgreementMember" name="RestrictedStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RockefellerAgreementMember" name="RockefellerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RockefellerUniversityMember" name="RockefellerUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SamsungBiologicsCompanyLimitedMember" name="SamsungBiologicsCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SARSCoV2ProductMember" name="SARSCoV2ProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SecondPlanMember" name="SecondPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SeriesAOneConvertiblePreferredStockMember" name="SeriesAOneConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SeriesATwoConvertiblePreferredStockMember" name="SeriesATwoConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ThirdClosingMember" name="ThirdClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TomegaVaxIncMember" name="TomegaVaxIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TuberculosisTBGrantMember" name="TuberculosisTBGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyGskAgreementMember" name="TwoThousandAndTwentyGskAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyOneGSKAgreementMember" name="TwoThousandAndTwentyOneGSKAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyOneGSKCollaborationMember" name="TwoThousandAndTwentyOneGSKCollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" name="TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" name="TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" name="TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandNineteenXencorAgreementMember" name="TwoThousandNineteenXencorAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandSeventeenGrantMember" name="TwoThousandSeventeenGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandSixteenEquityIncentivePlanMember" name="TwoThousandSixteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" name="TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" name="TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" name="TwoThousandTwentyOneStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyStockPurchaseAgreementMember" name="TwoThousandTwentyStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyXencorAgreementMember" name="TwoThousandTwentyXencorAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_VaccineProgramMember" name="VaccineProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" name="WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_WuXiBiologicsLimitedMember" name="WuXiBiologicsLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_XencorAgreementsMember" name="XencorAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_XencorIncorporationMember" name="XencorIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" name="ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ReconciliationOfEffectiveIncomeTaxRateTable" name="ReconciliationOfEffectiveIncomeTaxRateTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" name="ScheduleOfGoodwillAndIntangibleAssetsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" name="ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" name="ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" name="SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock" name="ConvertiblePreferredStockWarrantLiabilityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementsDisclosureTextBlock" name="GrantAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_TemporaryEquityTextBlock" name="TemporaryEquityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>46
<FILENAME>vir-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-02-28T16:08:29.9637+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LeaseArrangementContractualExpirationEndingYear" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementExpirationDateBeforeAmendment" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonePaymentToBeReceived" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AlnylamPharmaceuticalsIncMember" xlink:label="vir_AlnylamPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoGroupLimitedMember" xlink:label="vir_GlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MeasurementInputExpectedVolatilityMember" xlink:label="vir_MeasurementInputExpectedVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeConsiderationToBeReceived" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" xlink:label="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LaboratoryEquipmentMember" xlink:label="vir_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsFairValue" xlink:label="vir_FinancialAssetsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AlnylamAgreementMember" xlink:label="vir_AlnylamAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesATwoConvertiblePreferredStockMember" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentsPaid" xlink:label="vir_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:label="us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumanImmunodeficiencyVirusGrantMember" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ClinicalDevelopmentMember" xlink:label="vir_ClinicalDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyGskAgreementMember" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopmentProgramsExercisedByVirMember" xlink:label="vir_DevelopmentProgramsExercisedByVirMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NationalInstitutesOfHealthMember" xlink:label="vir_NationalInstitutesOfHealthMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodWarrantExercised" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_UpfrontPaymentReceivable" xlink:label="vir_UpfrontPaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementExpirationDate" xlink:label="vir_GrantAgreementExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BillMelindaGatesFoundationMember" xlink:label="vir_BillMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLeaseIncentiveOverLeaseLiabilities" xlink:label="vir_OperatingLeaseIncentiveOverLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:label="us-gaap_AccountingStandardsUpdate201813Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeLowEndOfTheRange" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InitialPublicOfferingCosts" xlink:label="vir_InitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstPlanMember" xlink:label="vir_FirstPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LeaseArrangementContractualExpirationBeginningYear" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityTextBlock" xlink:label="vir_TemporaryEquityTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WarrantsToPurchaseCommonStockMember" xlink:label="vir_WarrantsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_VaccineProgramMember" xlink:label="vir_VaccineProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AnotherProductMember" xlink:label="vir_AnotherProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopmentProgramsExercisedByBriiMember" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TuberculosisTBGrantMember" xlink:label="vir_TuberculosisTBGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCompany" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RestrictedStockAwardsRSAMember" xlink:label="vir_RestrictedStockAwardsRSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AssetAcquisitionMilestoneAchieved" xlink:label="vir_AssetAcquisitionMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SARSCoV2ProductMember" xlink:label="vir_SARSCoV2ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenXencorAgreementMember" xlink:label="vir_TwoThousandNineteenXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementTransactionPriceConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SalesMilestonesAchieved" xlink:label="vir_SalesMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SummaryOfSignificantAccountingPoliciesTable" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementAmendedDate" xlink:label="vir_GrantAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfExercise"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MedImmuneLimitedLiabilityCompanyMember" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_UnusedFundsReceivedInAdvance" xlink:label="vir_UnusedFundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedGrantAgreement" xlink:label="vir_StockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLeaseOtherInformationAbstract" xlink:label="vir_OperatingLeaseOtherInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateMilestonePayments" xlink:label="vir_MaximumAggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EquityInvestmentCurrent" xlink:label="vir_EquityInvestmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OfferingPeriodEmployeeStockPurchasePlan" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAwardedAmountMaximum" xlink:label="vir_GrantAwardedAmountMaximum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstInfectiousDiseaseProductMember" xlink:label="vir_FirstInfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncomeTaxesLineItems" xlink:label="vir_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLossCarryforwardsLimitationOnUsePercentage" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAwardedAmount" xlink:label="vir_GrantAwardedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:label="us-gaap_SalariesWagesAndOfficersCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodValueAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementAmendedExpirationDate" xlink:label="vir_GrantAgreementAmendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiBiosciencesOffshoreLimitedMember" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NumberOfAntibodiesToDevelop" xlink:label="vir_NumberOfAntibodiesToDevelop"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentDueToCompany" xlink:label="vir_MilestonePaymentDueToCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:label="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" xlink:label="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonesAchieved" xlink:label="vir_RegulatoryMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityAdditionalSharesAuthorized" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN" xlink:label="country_CN"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RockefellerUniversityMember" xlink:label="vir_RockefellerUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BillAndMelindaGatesFoundationMember" xlink:label="vir_BillAndMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FailedSaleLeasebackTransactionProceedsFinancingActivities" xlink:label="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiAgreementMember" xlink:label="vir_BriiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PayrollAndRelatedExpensesCurrent" xlink:label="vir_PayrollAndRelatedExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstSiRNAProductHBVMember" xlink:label="vir_FirstSiRNAProductHBVMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TenantImprovementAllowanceAggregate" xlink:label="vir_TenantImprovementAllowanceAggregate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CashGrantAwarded" xlink:label="vir_CashGrantAwarded"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProfitsAndLossesSharingPercentage" xlink:label="vir_ProfitsAndLossesSharingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfluenzaAAndHBVResearchProgramsMember" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateSalesMilestonePayments" xlink:label="vir_MaximumAggregateSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromRepaymentOfPromissoryNotes" xlink:label="vir_ProceedsFromRepaymentOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementsDisclosureTextBlock" xlink:label="vir_GrantAgreementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RockefellerAgreementMember" xlink:label="vir_RockefellerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RemainingPaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AnnualLicenseMaintenanceFees" xlink:label="vir_AnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_OR" xlink:label="stpr_OR"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HcmvVaccinePlatformGrantMember" xlink:label="vir_HcmvVaccinePlatformGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeferredTaxAssetsLeaseLiabilities" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommonStockIssuedInConnectionWithLicenseAgreement" xlink:label="vir_CommonStockIssuedInConnectionWithLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumSalesMilestonToPay" xlink:label="vir_MaximumSalesMilestonToPay"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfluenzaAResearchProgramsMember" xlink:label="vir_InfluenzaAResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfShareDevelopmentCosts" xlink:label="vir_PercentageOfShareDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SaleLeasebackTransactionProceedsFromFinancingObligations" xlink:label="vir_SaleLeasebackTransactionProceedsFromFinancingObligations"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementTransactionPriceUpfrontFee" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SalesAgreementMember" xlink:label="vir_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfEstimatedBatchProductionFees" xlink:label="vir_PercentageOfEstimatedBatchProductionFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ExecutiveOfficerAndDirectorMember" xlink:label="vir_ExecutiveOfficerAndDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumSharesToBeIssued" xlink:label="vir_MaximumSharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstAndSecondClosingsMember" xlink:label="vir_FirstAndSecondClosingsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePayable" xlink:label="vir_MilestonePayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FundsReceivedInAdvance" xlink:label="vir_FundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HBVProgramMember" xlink:label="vir_HBVProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EachInfectiousDiseaseSiRNAMember" xlink:label="vir_EachInfectiousDiseaseSiRNAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ResearchAndDevelopmentExpensesCurrent" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FormerBusinessCombinationContingentConsiderationLiability" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentReceived" xlink:label="vir_MilestonePaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstSiRNAProductMember" xlink:label="vir_FirstSiRNAProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommonStockIssuanceCost" xlink:label="vir_CommonStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ObligationToPayCapacityReservation" xlink:label="vir_ObligationToPayCapacityReservation"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RestrictedStockPurchaseAgreementMember" xlink:label="vir_RestrictedStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumSalesMilestonePayment" xlink:label="vir_MaximumSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NetProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementMember" xlink:label="vir_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentMadeForBusinessCombinationMilestone" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLeaseAbstract" xlink:label="vir_OperatingLeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SecondPlanMember" xlink:label="vir_SecondPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantsAgreementAmendedDate" xlink:label="vir_GrantsAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfluenzaAAndInfluenzaBMember" xlink:label="vir_InfluenzaAAndInfluenzaBMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateSalesMilestonePayment" xlink:label="vir_MaximumAggregateSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_UpfrontFeePaid" xlink:label="vir_UpfrontFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_XencorAgreementsMember" xlink:label="vir_XencorAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfCommissionRateFromSaleOfShares" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementTerminationDescription" xlink:label="vir_CollaborationAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FairMarketValueOfCommonStockIssued" xlink:label="vir_FairMarketValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BiologicalMaterialsMember" xlink:label="vir_BiologicalMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeHighEndOfTheRange" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AntibodyLicenseTransactionPrice" xlink:label="vir_AntibodyLicenseTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ValueOfSharesTransferredToCollaborator" xlink:label="vir_ValueOfSharesTransferredToCollaborator"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationTypeAndPrograms" xlink:label="vir_CollaborationTypeAndPrograms"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HepatitisBVirusProductMember" xlink:label="vir_HepatitisBVirusProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SamsungBiologicsCompanyLimitedMember" xlink:label="vir_SamsungBiologicsCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TaxCreditCarryforwardsExpirationBeginningYear" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NonCashCommonStockIssuedForContingentConsideration" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentsRelatedTermsDescription" xlink:label="vir_MilestonePaymentsRelatedTermsDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IssuanceOfCommonStockToSettleAContingentConsideration" xlink:label="vir_IssuanceOfCommonStockToSettleAContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestoneAchieved" xlink:label="vir_RegulatoryMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201704Member" xlink:label="us-gaap_AccountingStandardsUpdate201704Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeterminedTransactionPrice" xlink:label="vir_DeterminedTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AssetAcquisitionMilestonePaymentAggregate" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RangeOfRoyaltyPaymentToBeReceived" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockIssuanceCost" xlink:label="vir_ConvertiblePreferredStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ValueStockIssuedGrantAgreement" xlink:label="vir_ValueStockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NumberOfClassOfStock" xlink:label="vir_NumberOfClassOfStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LicenseAgreementUpfrontPayment" xlink:label="vir_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfectiousDiseaseProductMember" xlink:label="vir_InfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltiesPaymentExpirationPeriod" xlink:label="vir_RoyaltiesPaymentExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EsppDiscountedPurchasePricePercentage" xlink:label="vir_EsppDiscountedPurchasePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopedTechnologyMember" xlink:label="vir_DevelopedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201814Member" xlink:label="us-gaap_AccountingStandardsUpdate201814Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAgreementGrantAmount" xlink:label="vir_BusinessAgreementGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncomeTaxesTable" xlink:label="vir_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PresentValueOfOperatingLeaseLiabilities" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MeasurementInputProbabilityRateMember" xlink:label="vir_MeasurementInputProbabilityRateMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentToCollaboratorResultingFromProgramOptionExercise" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ThirdClosingMember" xlink:label="vir_ThirdClosingMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MedImmuneAgreementMember" xlink:label="vir_MedImmuneAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncome" xlink:label="us-gaap_DeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InitialFairValueOfDerivativeLiability" xlink:label="vir_InitialFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EstimatedSharesEmployeeStockPurchasePlans" xlink:label="vir_EstimatedSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RangeOfRoyaltyPaymentToBePaid" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_XencorIncorporationMember" xlink:label="vir_XencorIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityTextBlock" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeReceived" xlink:label="vir_OptionExerciseFeeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandSeventeenGrantMember" xlink:label="vir_TwoThousandSeventeenGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAgreementEquityInvestmentCommitment" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember" xlink:label="us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingAndFinanceRentExpense" xlink:label="vir_OperatingAndFinanceRentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsAmortizedCostBasis" xlink:label="vir_FinancialAssetsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementEffectiveEndDate" xlink:label="vir_GrantAgreementEffectiveEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SpecifiedSalesDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility,maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease arrangement, contractual expiration ending year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Contractual Expiration Ending Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease arrangement, contractual expiration period, ending year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition, transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate development and regulatory milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Development And Regulatory Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate development and regulatory milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium received on sale price of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premium Received On Sale Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium received on sale price of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in payment of contingent consideration in excess of acquisition date fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of contingent consideration in excess of acquisition date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice period to terminate licensed program if under challenges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant agreement expiration date before amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Expiration Date Before Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement expiration date before amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of common stock shares Issued for milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payment to be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payment to be received by the company upon exercised of the development programs by counterparty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone payment to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alnylam Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alnylam Pharmaceuticals Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alnylam Pharmaceuticals Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities in process research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities In Process Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">IPR&amp;D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under the employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo Group Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Group Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GGL</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Expected Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input expected volatility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock shares Issued for milestone payment| shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total number of common shares issued for milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares Issued for milestone payment| shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2021 and 2020, respectively; 127,416,740 and 107,648,925 shares issued and outstanding as of December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee Consideration To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise fee consideration to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs and expenses for the period incurred under the collaboration agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Related Costs And Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses incurred under agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate commercial sales milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Commercial Sales Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate commercial sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares cashless exercise of warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Cashless Exercise Of Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cashless exercise of warrant (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid in lieu of fractional shares in reverse split of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid In Lieu Of Fractional Shares In Reverse Split Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid in lieu of fractional shares related to reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets, Aggregate Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity Securities, FV-NI, Unrealized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of equity investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of years conduct certain research and development activities under mutually agreed development plans.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Years Conduct Certain Research And Development Activities Under Mutually Agreed Development Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of years conduct certain research and development activities under mutually agreed development plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains (losses) on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alnylam Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alnylam Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alnylam agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized gain on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Unrealized Gains on Trading Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful lives description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in estimated fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2018-18 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-18</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A -2 convertible preferred stock member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Two Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice period to terminate licensed program if under challenge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value contingent consideration measurement input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Embedded Derivative Liability, Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-lived Intangible Assets Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived intangible assets IPR&amp;D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of actuarial loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Number Of Milestones Achieved Related To Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition number of milestones achieved related to contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value contingent consideration measurement input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Technology Rights [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developed Technologies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TomegaVaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TomegaVax, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TomegaVaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tomega Vax Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TomegaVaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TomegaVax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SwissFederalTaxAdministrationFTAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Swiss Federal Tax Administration (FTA) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SwissFederalTaxAdministrationFTAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Swiss Federal Tax Administration (FTA)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasuries</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, Accrued Interest, Writeoff</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write off of accrued interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Human immunodeficiency virus grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Human Immunodeficiency Virus Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Human Immunodeficiency Virus ("HIV") Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated remaining useful lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 GSK Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty GSK Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Twenty GSK Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-lived intangible assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Manufacturing Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Manufacturing Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and manufacturing collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from sale of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pension Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issued under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash and cash equivalents at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash and cash equivalents at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Embedded Derivatives [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Embedded Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByVirMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Programs Exercised by Vir [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByVirMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development Programs Exercised by Vir [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByVirMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Programs Exercised by Vir</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">National institutes of health.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National Institutes Of Health [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">National Institutes of Health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the aggregate offering price for which the entity may sell shares of its common stock under the sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Consideration Aggregate Offering Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued for conversion of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Warrant Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of new shares issued in the exercise of warrant during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Employees Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Smith Kline Intellectual Property Development Limited And Glaxo Smith Kline Biologicals S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value of investment at cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Preliminary Collaboration Agreement and Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one preliminary collaboration agreement and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow associated with the amount received from entity's follow on offering of stock to the public.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Secondary Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deducting underwriting discounts, commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The date the grant agreement expires.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant agreement expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo SmithKline Trading Service Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Smith Kline Trading Service Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSKTSL</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bill &amp; Melinda Gates Foundation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bill &amp; Melinda Gates Foundation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bill &amp; Melinda Gates Foundation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Stock Price Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible assets, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification&#8203; of derivative liability&#8203; to additional paid-&#8203;in capital upon achievement of development milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Derivative Liability To Additional Paid In Capital Upon Achievement Of Development Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of derivative liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in deferred income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseIncentiveOverLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseIncentiveOverLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Incentive Over Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseIncentiveOverLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Incentive Over Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to Purchase Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pension Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2018-13 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-13</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Liability for Uncertain Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Accretion of discounts) amortization of premiums on investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the low end of the range of option exercise fee upon exercise of a program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option exercise fee, low end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee, low end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible assets, amortization method description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets, excluding goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment of Intangible Assets (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity compensations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written notice to terminate licensed program if not exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice to terminate licensed program if not exercise.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice to terminate licensed program if not exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period for termination of licensed program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Termination Of Licensed Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for termination of licensed program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expenses related to certain development milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Research And Development Expenses Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified research and development expenses milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, existence of option to extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value of embedded derivative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Embedded derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability net tenant improvement allowance yet to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Net Tenant Improvement Allowance Yet To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: net tenant improvement allowance yet to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease arrangement, contractual expiration beginning year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Contractual Expiration Beginning Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease arrangement, contractual expiration period, beginning year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, if recognized, would reduce effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of key terms, rights and preferences of convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of convertible preferred stock converted to shares of common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuXiBiologicsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi Biologics Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuXiBiologicsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wu Xi Biologics Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuXiBiologicsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WuXi Biologics</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition number of specified clinical milestones achieved.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Number Of Specified Clinical Milestones Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of specified clinical milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Support to Nonconsolidated Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Addition for tax positions taken in current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Allowance for losses on available-for-sale debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of derivative liability to accrued liabilities upon achievement of development milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Reclassification Of Derivative Liability To Accrued Liabilities Upon Achievement Of Development Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value reclassification of derivative liability to accrued liabilities upon achievement of development milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock in connection with asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccineProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vaccine Program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccineProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vaccine Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccineProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vaccine Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current income tax expense (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnotherProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Another product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnotherProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Another Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnotherProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Another Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income (loss) before provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) before provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2021 and 2020, respectively; no shares issued and outstanding as of December 31, 2021 and 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Programs Exercised by Brii [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development Programs Exercised by Brii [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Programs Exercised by Brii</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number of Products Covered Against Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum number of products covered against milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of products covered against milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reconciliation of effective income tax rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Effective Income Tax Rate [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation Of Effective Income Tax Rate [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TuberculosisTBGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tuberculosis (&#8220;TB&#8221;) grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TuberculosisTBGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tuberculosis T B Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TuberculosisTBGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tuberculosis ("TB") Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Letter agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TomegaVax Letter Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Letter Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period to Terminate Agreement by Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate agreement by company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period to terminate agreement by company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for (benefit from) income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments Excluding Equity Investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and short-term investments, excluding equity investment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments, excluding equity investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Acquisition, Consideration Transferred, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo Wellcome U K Limited And Beecham S A.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Wellcome U K Limited And Beecham S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockAwardsRSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards (RSAs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockAwardsRSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards R S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockAwardsRSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock awards (RSA).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of underwriting discounts and commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Underwriting Discounts And Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options,Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of new stock classified as temporary equity issued during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance cost (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition milestone achieved during the reporting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition milestone achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Milestone Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Excess funds payable under grant agreements current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Excess Funds Payable Under Grant Agreements Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excess funds payable under grant agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred income tax expense (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SARSCoV2ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SARS-CoV-2 product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SARSCoV2ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">S A R S Co V2 Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SARSCoV2ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SARS-CoV-2 Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total least cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Xencor Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Xencor Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen xencor agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and Regulatory Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Transaction Price Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement transaction price consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement Transaction Price Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestones achieved during the reporting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestone achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition number of milestones achieved related to contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Number Of Milestones Achieved Related To Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued, exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible asset, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Remaining Useful Life (Years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average incremental borrowing rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate gross proceeds from sale of shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Gross Proceeds From Sale Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate gross proceeds from sale of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant agreement amended date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Amended Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement amended date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written notice to terminate licensed program if exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice to terminate licensed program following the exercise of an option for such program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior year tax rate adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MedImmune, limited liability company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Med Immune Limited Liability Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MedImmune</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input expected revenue volatility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Revenue Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Expected Revenue Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options,Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options,Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligation period from date of first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligation Period From Date Of First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligation period from date of first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnusedFundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unused funds received in advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnusedFundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unused Funds Received In Advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnusedFundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unused funds received in advance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued in connection with the grant agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued Grant Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total common stock issued in connection with the grant agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease other information.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Other Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EquityInvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Investment Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EquityInvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Investment Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EquityInvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Investment Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deducting underwriting discounts, commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Period Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Duration of offering period under the Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmountMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant awarded amount. maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmountMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Awarded Amount Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmountMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum grant awarded amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified clinical development milestones payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Clinical Development Milestones Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified clinical development milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstInfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Infectious Disease Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstInfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First infectious disease product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstInfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Infectious Disease Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of preferred stock warrant liability to additional paid-in capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Preferred Stock Warrant Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock warrant liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes line items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards limitation on use percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitation On Use Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss deduction limitation as percentage of taxable income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant awarded amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Awarded Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant awarded amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT ASSETS:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash and cash equivalents, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant to Purchase Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price as percentage of lower of fair market value on purchase date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of preferred stock into common stock upon completion of initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Preferred Stock Into Common Stock Upon Completion Of Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock upon completion of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of separate programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Number Of Separate Programs Agreed To Collaborate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement, number of separate programs agreed to collaborate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value achievement of milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Achievement Of Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with the achievement of a milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility,minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares subject to future vesting using the treasury stock method.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted shares subject to future vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Shares Issuable Under the E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated Shares Issuable Under the E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Shares Issuable Under The E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Not from Contract with Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term of options (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term of ESPP (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Amended Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement amended expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant agreement amended expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value of Significant Unobservable Inputs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payment obligation expiration period after first commercial sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payment Obligation Expiration Period After First Commercial Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment obligation expiration period after first commercial sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Share-based Payment Arrangements, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brii Biosciences Offshore Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brii Biosciences Offshore Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brii Bio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reconciliation of effective income tax rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Effective Income Tax Rate [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation Of Effective Income Tax Rate [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of goodwill and intangible assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Goodwill And Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Goodwill And Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining payment for asset acquisition milestone, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Payment For Asset Acquisition Milestone Aggregate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the remaining consideration which may be paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfAntibodiesToDevelop_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of antibodies to develop</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfAntibodiesToDevelop_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Antibodies to Develop</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfAntibodiesToDevelop_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of antibodies to develop.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Selected Quarterly Financial Data</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Gross unrecognized tax benefits at December 31</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Gross unrecognized tax benefits at January 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock into common stock shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Convertible Preferred Stock Into Common Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentDueToCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment due to company under grant agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentDueToCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Due To Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentDueToCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment due to Vir</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate milestone payment for achievement of specified milestones, including development, regulatory and commercial.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum aggregate milestone payment for achievement of specified milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development expense under license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense under license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestones Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestones achieved during the reporting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent items percent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity additional shares authorized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, additional shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of indefinite-lived intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China Territory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DefinitiveCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Definitive collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DefinitiveCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Definitive Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DefinitiveCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Definitive Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rockefeller University.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rockefeller University [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rockefeller</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bill &amp; Melinda Gates Foundation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bill &amp; Melinda Gates Foundation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Settlement of fractional shares from reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of cash inflow received in a failed sale-leaseback recognized in financing activities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Failed Sale Leaseback Transaction Proceeds Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds received from financing lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 606</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, company contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in estimated fair value of convertible preferred stock warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brii Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brii Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brii Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other comprehensive income loss pension and other postretirement benefit plans adjustment to projected benefit obligations net of tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment To Projected Benefit Obligations Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Adjustment to projected benefit obligations, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayrollAndRelatedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payroll and related expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayrollAndRelatedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payroll And Related Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayrollAndRelatedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of the derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of convertible preferred stock, net of issuance cost (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value of common stock shares Issued for milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of common shares issued for milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of common stock shares Issued for milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments aggregate amount payable, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductHBVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First siRNA Product HBV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductHBVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Si R N A Product H B V [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductHBVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First SiRNA product HBV.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TenantImprovementAllowanceAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TenantImprovementAllowanceAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowance Aggregate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TenantImprovementAllowanceAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of tenant improvement allowance available.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashGrantAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business agreement grant amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashGrantAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Grant Awarded</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashGrantAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of cash grant awarded.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of equity investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitsAndLossesSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of share Profit and loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitsAndLossesSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profits And Losses Sharing Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitsAndLossesSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profits and losses sharing percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Influenza A and HBV research programs member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Influenza A And H B V Research Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Influenza A and HBV Research Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to settle a contingent consideration (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Settlement Of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued for settlement of contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, contribution expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/decrease in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Intangible Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase Decrease In Equity Securities Fv Ni</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Acquisition, Contingent Consideration, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBioParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brii Bio Parent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBioParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brii Bio Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBioParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brii Bio Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antibody Program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antibody Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antibody Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Sales Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate sales milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromRepaymentOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from repayment of promissory notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromRepaymentOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Repayment Of Promissory Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromRepaymentOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from repayment of promissory notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreements disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rockefeller Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rockefeller Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rockefeller agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining payment made for asset acquisition milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Payment Made For Asset Acquisition Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining payment made for asset acquisition milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Glaxo Wellcome U K Limited And Beecham S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one Glaxo Wellcome UK Limited and Beecham S.A.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fees required to pay annually.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of goodwill and intangible assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Goodwill And Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Goodwill and Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of contingent consideration upon achievement of the TomegaVax milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Reclassification Of Contingent Consideration To Accrued Liabilities Upon Achievement Of Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, reclassification of contingent consideration to accrued liabilities upon achievement of milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Plans Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of upfront payment receivable at execution date of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of upfront payment receivable at execution date of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_OR_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OREGON</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_OR_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oregon</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Range of tiered royalties to pay on net sales of products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range of Tiered Royalties to Pay to Net Sales of Products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Range of tiered royalties to pay on annual net sales of products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Payment Range on Net Sales of Licensed Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties payment range on net sales of licensed product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties payment range on net sales of licensed product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HcmvVaccinePlatformGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hcmv Vaccine Platform Grant [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HcmvVaccinePlatformGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hcmv Vaccine Platform Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HcmvVaccinePlatformGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HCMV-Vaccine Platform Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, shares issued value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 and 2020 Xencor Agreement member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen And Two Thousand Twenty Xencor Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Nineteen And Two Thousand Twenty Xencor Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued in connection with a collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a collaboration agreement (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum milestone payment for achievement of specified development and regulatory.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Milestone Payment For Achievement Of Specified Development And Regulatory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone payment for achievement of specified development and regulatory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant, expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Release of Valuation Allowance Deferred Tax In Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Release of valuation allowance deferred tax in amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockIssuedInConnectionWithLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued in connection with license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockIssuedInConnectionWithLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued In Connection With License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockIssuedInConnectionWithLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued in connection with license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Sales Mileston To Pay</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of proceeds to pay upon achievement of sales milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum sales milestone to pay</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of employee payroll deduction on earnings, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of employee payroll deduction on earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Influenza A research programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Influenza A Research Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Influenza A Research Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities obtained in exchange of right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROU assets in exchange for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-defined regulatory milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Defined Regulatory Milestone Consideration Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-defined regulatory milestone consideration receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfShareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of share development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfShareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Share Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfShareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of share development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock option (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options,Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties accrued related to uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number of Development Program Granted from Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Number of Development Program Granted from Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of development program granted from Brii to Vir | Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to settle a contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock issued for settlement of contingent considerations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issued For Settlement Of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of operating lease amounts recorded in condensed consolidated balance sheet.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Lease Amounts Recorded In Condensed Consolidated Balance Sheet Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleLeasebackTransactionProceedsFromFinancingObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">sale leaseback transaction proceeds from financing obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleLeasebackTransactionProceedsFromFinancingObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Leaseback Transaction Proceeds From Financing Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleLeasebackTransactionProceedsFromFinancingObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale leaseback of financing obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A One Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalties based on net sales of licensed products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Based on Net Sales of Licensed Products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties payment based on net sales of licensed products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock issued in connection with a collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of promissory notes related to vested shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Repayment Of Promissory Notes Net Of Unvested Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of promissory notes, net of unvested shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period of awards from issuance date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price as percentage of lower of fair market value on offering date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill expected to be deductible for income tax purposes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Transaction Price Upfront Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received under the Collaboration agreement, which represents part of the transaction price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Shares Subject to Future Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfEstimatedBatchProductionFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of estimated batch production fees owed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfEstimatedBatchProductionFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of estimated batch production fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfEstimatedBatchProductionFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Estimated Batch Production Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExecutiveOfficerAndDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Executive officer and director.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExecutiveOfficerAndDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer And Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExecutiveOfficerAndDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive Officer and Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price,Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum shares to be issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Shares To Be Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum shares to be issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options,Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock issued in connection with a license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a license agreement (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstAndSecondClosingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First and second closings.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstAndSecondClosingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First And Second Closings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstAndSecondClosingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Closings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NONCASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funds received in advance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funds Received In Advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funds received in advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written notice period to terminate licensed program for uncured material breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate licensed program for uncured material breach.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Liabilities And Other Liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities And Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">HBV program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">H B V Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HBV Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets gross unrealized holding gains.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Gross Unrealized Holding Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets, Gross Unrealized Holding Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant, expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in estimated fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative, Gain (Loss) on Derivative, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advanced proceeds applied to convertible preferred stock issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advanced Proceeds Applied To Convertible Preferred Stock Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advanced proceeds applied to convertible preferred stock issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EachInfectiousDiseaseSiRNAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Each infectious disease siRNA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EachInfectiousDiseaseSiRNAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Each Infectious Disease Si R N A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EachInfectiousDiseaseSiRNAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Each Infectious Disease siRNA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Support to Nonconsolidated Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Estimated Fair Value of Financial Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finite-lived Intangible assets, reclassified from Indefinite-lived.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Reclassified From Indefinite Lived</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible asset, reclassified from indefinite-lived asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of lease cost and other information related to operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Lease Cost And Other Information Related To Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Costs and Additional Information Related to Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finite lived intangible assets accumulated impairment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Preliminary Collaboration Agreement and Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty preliminary collaboration agreement and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum term of offering period specified under plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Term Of Offering Period Specified Under Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum term of offering period specified under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combinations additional consideration payable upon achievement of specified events.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Additional Consideration Payable Upon Achievement Of Specified Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional consideration payable upon achievement of specified milestone events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of former contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Former Business Combination, Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of former liability recognized arising from contingent consideration in a business combination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties expense related to uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum common stock price for milestone payments consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Common Stock Price For Milestone Payments Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum common stock price that triggers milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term,Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First siRNA Product HBV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First siRNA product member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Si R N A Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of finance lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Unrealized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrealized gains recorded in accumulated other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issuance cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issuance Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ObligationToPayCapacityReservation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount obligated to pay for capacity reservation under the agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ObligationToPayCapacityReservation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to pay capacity reservation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ObligationToPayCapacityReservation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligation To Pay Capacity Reservation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreliminaryCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preliminary Collaboration Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreliminaryCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preliminary Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreliminaryCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preliminary Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, cash consideration paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, term of contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Activities, Cash Flow Statement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum milestone payment for achievement of specified annual net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Sales Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum sales milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant to purchase of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance secondary public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net proceeds From Issuance Secondary Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow associated with the amount received from entity's follow on offering of stock to the public, net of commissions and expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number of Development Program Granted to Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Number of Development Program Granted to Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of development program granted from Vir to Brii | Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Net (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment made for business combination milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment made for business combination milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment made for business combination milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of right to perform details in connection with antibody product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Right To Perform Details In Connection With Antibody Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of right to perform details in connection with antibody product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SecondPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SecondPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SecondPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options,Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantsAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Agreement Amended Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantsAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grants Agreement Amended Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndInfluenzaBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Influenza A and Influenza B member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndInfluenzaBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Influenza A And Influenza B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndInfluenzaBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Influenza A and Influenza B</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of derivative liability to additional paid In capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Derivative Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of derivative liability to addition paid-in-capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of common stock issued in connection with a license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Humabs Biomed SA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Humabs Biomed S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Humabs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Humabs IP Transfer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining payment made for business combination milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Payment Made For Business Combination Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining Payment Made For Business Combination Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate milestone payment for achievement of specified annual net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Sales Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate sales milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of total amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in the next five years following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from disposal of an asset held for sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period for licensed program, uncured material breach.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Licensed Program Uncured Material Breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for uncured material breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets gross unrealized holding losses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Gross Unrealized Holding Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Financial Assets, Gross Unrealized Holding Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Xencor Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Xencor Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Xencor Agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commission rate from sale of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of commission rate from sale of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of maximum commission rate, based on aggregate gross proceeds from sale of shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written notice period to terminate licensed program for failure to make payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate licensed program for failure to make payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period to terminate licensed program for failure to make payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum common stock conversion price for milestone payments consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Common Stock Conversion Price For Milestone Payments Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum common stock conversion price for milestone payments consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected stock price volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign tax at less than federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration beginning year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Beginning Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net operating loss carryforwards expiration beginning year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated weighted average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserves and accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability, Defined Benefit Pension Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net liability recognized under pension plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement termination description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Termination Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairMarketValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair market value of common stock issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairMarketValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Market Value Of Common Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairMarketValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair market value of the common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payment On Licensed Product Low End Of The Range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payment on licensed product, low end of the range.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone payment on licensed product, low end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone payment on licensed product, high end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payment On Licensed Product High End Of Range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payment on licensed product, high end of the range.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiologicalMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biological Materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiologicalMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biological Materials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiologicalMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biological materials.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivable from collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option exercise fee, high end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the high end of the range of option exercise fee upon exercise of a program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee, high end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of upfront payment receivable at effective date of agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Upfront Payment Receivable At Effective Date Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of upfront payment receivable at effective date of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Xencor Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Xencor Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty xencor agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares authorized to issue under purchase rights granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyLicenseTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antibody license transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyLicenseTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antibody License Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyLicenseTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price for the Antibody License under the collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfSharesTransferredToCollaborator_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of shares transferred to collaborator under the terms of the collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfSharesTransferredToCollaborator_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value of shares transferred to collaborator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationTypeAndPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration type and program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationTypeAndPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Type and Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationTypeAndPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Type and Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HepatitisBVirusProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hepatitis B Virus Product Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HepatitisBVirusProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hepatitis B Virus Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HepatitisBVirusProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HBV product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares sold, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Acquired Finite Lived Intangible Asset By Major Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase (decrease) in research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in research And development expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingently issuable shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BankTimeDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bank Time Deposits [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BankTimeDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bank Time Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SamsungBiologicsCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Samsung Biologics Co., Ltd.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SamsungBiologicsCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Samsung Biologics Company Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SamsungBiologicsCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Samsung Biologics Co., Ltd</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT LIABILITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforwards expiration beginning year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforwards Expiration Beginning Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax credit carryforwards expiration beginning year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Common Stock Issued For Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash common stock issued for contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for payment of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsRelatedTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments related terms description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsRelatedTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Related Terms Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsRelatedTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments related terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of finance lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financing lease obligation, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IssuanceOfCommonStockToSettleAContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to settle a contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IssuanceOfCommonStockToSettleAContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock to settle a contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IssuanceOfCommonStockToSettleAContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock to settle a contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestones achieved during the reporting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash and cash equivalents, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201704Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2017-04 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201704Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2017-04</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeterminedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Determined transaction price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeterminedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Determined Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeterminedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determined transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other professional and consulting expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments aggregate amount payable, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Milestone Payment Aggregate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range of Royalty Payment to be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Range of royalty payment to be received by the company upon exercised of the development programs by counterparty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of royalty payment to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of units of account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Number Of Units Of Account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement, number of units of account.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock issuance cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Issuance Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, net of issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding convertible preferred stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueStockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of common stock issued in connection with the grant agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueStockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value Stock Issued Grant Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueStockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total value of common stock issued in connection with the grant agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Owned At Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned, at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfClassOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of class of stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfClassOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfClassOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of class of stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock liability recognized for portion of promissory note repayment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Liability Recognized For Portion Of Promissory Note Repayment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock liability recognized for portion of promissory note repayment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vested shares related to repayment of promissory notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Repayment Of Promissory Notes Net Of Unvested Common Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of promissory notes, net of unvested shares (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares achievement of milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Achievement Of Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with the achievement of a milestone (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayment of outstanding promissory notes and accrued interest received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment Of Outstanding Promissory Notes And Accrued Interest Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of outstanding promissory notes and accrued interest received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Infectious Disease Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Infectious Disease Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in connection with a collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance of Common Stock in Connection With Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Issuance of Common Stock in Connection With Collaboration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalties payment expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Payment Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of years that royalties payment expired.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employee contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One G S K Collaboration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 GSK Collaboration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 GSK Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EsppDiscountedPurchasePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP discounted purchase price percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EsppDiscountedPurchasePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ESPP Discounted Purchase Price Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EsppDiscountedPurchasePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ESPP Discounted Purchase Price Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Amortization of Discount and Premium, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Developed technology.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Technology [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developed Technology</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transaction Gain Loss Unrealized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued liabilities and other liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities And Other Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Glaxo Wellcome U K Limited And Beecham S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand wenty Glaxo Wellcome UK Limited and Beecham S.A.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent Consideration Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal statutory income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS&#8217; EQUITY:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201814Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2018-14 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201814Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-14</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business agreement grant amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Agreement Grant Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business agreement grant amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reduction for tax positions taken in the prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes table.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Present value of lessee's discounted obligation for lease payments from operating lease, net of tenant improvement allowance yet to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Present Value Of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputProbabilityRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input, probability rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputProbabilityRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Probability Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputProbabilityRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of Achievement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment to collaborator resulting from program option exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of payment to a collaborator due to a program option exercise under a separate agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to collaborator resulting from program option exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain from a sublease termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain from a sublease termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Termination of Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third closing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Closing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Closing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period to Terminate Agreement by Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate agreement by counterparty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period to terminate agreement by counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Contingent Consideration, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MedImmune Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Med Immune Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MedImmune agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Income (loss) Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment made for asset acquisition milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Made For Asset Acquisition Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment made for asset acquisition milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InitialFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial fair value of derivative liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InitialFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Fair Value Of Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InitialFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated shares to be issued under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Shares Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated Shares Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of royalty payment to be paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range of Royalty Payment to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Range of royalty payment to be paid by counterparty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Xencor, incorporation member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Xencor Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Xencor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi biologics and Samsung letter agreement assignments and master services agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wuxi Biologics And Samsung Letter Agreement Assignments And Master Services Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WuXi Biologics MSA and Samsung MSA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of key terms of the warrant agreement and valuation assumptions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of warrant liability to additional paid-in capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Warrant Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise fee received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSeventeenGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSeventeenGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSeventeenGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business agreement equity investment commitment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Agreement Equity Investment Commitment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business agreement equity investment commitment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractBasedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract-Based Intangible Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractBasedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract-Based Intangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Australian Taxation Office [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Australian Taxation Office</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of principal on financing lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingAndFinanceRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance rent expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingAndFinanceRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating And Finance Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingAndFinanceRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized stock-based compensation expense related to stock option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock into common stock shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Convertible Preferred Stock Into Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of ordinary share equal to outstanding share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Ordinary Share Equal To Outstanding Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ordinary share equal to outstanding share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets amortized cost basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Assets, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementEffectiveEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant agreement effective end date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementEffectiveEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Effective End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementEffectiveEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement effective end date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk credit loss and other risks and uncertainties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk Credit Loss And Other Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price as percentage of lower of fair market value on offering date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Option price as a percentage of estimated fair value on the date of grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses And Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Addition for tax positions taken in the prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified sales development milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Sales Development Milestones Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified sales development milestones payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One G S K Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 GSK Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 GSK Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock in connection with a collaboration agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LeaseArrangementContractualExpirationEndingYear" xlink:to="vir_LeaseArrangementContractualExpirationEndingYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:to="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:to="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementExpirationDateBeforeAmendment" xlink:to="vir_GrantAgreementExpirationDateBeforeAmendment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="vir_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestonePaymentToBeReceived" xlink:to="vir_RegulatoryMilestonePaymentToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AlnylamPharmaceuticalsIncMember" xlink:to="vir_AlnylamPharmaceuticalsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:to="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoGroupLimitedMember" xlink:to="vir_GlaxoGroupLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MeasurementInputExpectedVolatilityMember" xlink:to="vir_MeasurementInputExpectedVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:to="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NoncashLeaseExpense" xlink:to="vir_NoncashLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeConsiderationToBeReceived" xlink:to="vir_OptionExerciseFeeConsiderationToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:to="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:to="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:to="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" xlink:to="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LaboratoryEquipmentMember" xlink:to="vir_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SeriesBConvertiblePreferredStockMember" xlink:to="vir_SeriesBConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsFairValue" xlink:to="vir_FinancialAssetsFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:to="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AlnylamAgreementMember" xlink:to="vir_AlnylamAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201818Member" xlink:to="us-gaap_AccountingStandardsUpdate201818Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SeriesATwoConvertiblePreferredStockMember" xlink:to="vir_SeriesATwoConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:to="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:to="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePaymentsPaid" xlink:to="vir_MilestonePaymentsPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="vir_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TomegaVaxIncMember" xlink:to="vir_TomegaVaxIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:to="us-gaap_SwissFederalTaxAdministrationFTAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:to="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HumanImmunodeficiencyVirusGrantMember" xlink:to="vir_HumanImmunodeficiencyVirusGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ClinicalDevelopmentMember" xlink:to="vir_ClinicalDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyGskAgreementMember" xlink:to="vir_TwoThousandAndTwentyGskAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:to="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionPlansDefinedBenefitMember" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesEmbeddedDerivatives" xlink:to="us-gaap_DerivativesEmbeddedDerivatives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopmentProgramsExercisedByVirMember" xlink:to="vir_DevelopmentProgramsExercisedByVirMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NationalInstitutesOfHealthMember" xlink:to="vir_NationalInstitutesOfHealthMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:to="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodWarrantExercised" xlink:to="vir_StockIssuedDuringPeriodWarrantExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:to="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:to="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UpfrontPaymentReceivable" xlink:to="vir_UpfrontPaymentReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementExpirationDate" xlink:to="vir_GrantAgreementExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BillMelindaGatesFoundationMember" xlink:to="vir_BillMelindaGatesFoundationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLeaseIncentiveOverLeaseLiabilities" xlink:to="vir_OperatingLeaseIncentiveOverLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201813Member" xlink:to="us-gaap_AccountingStandardsUpdate201813Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseMember" xlink:to="us-gaap_OtherExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeLowEndOfTheRange" xlink:to="vir_OptionExerciseFeeLowEndOfTheRange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InitialPublicOfferingCosts" xlink:to="vir_InitialPublicOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstPlanMember" xlink:to="vir_FirstPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" xlink:to="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:to="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LeaseArrangementContractualExpirationBeginningYear" xlink:to="vir_LeaseArrangementContractualExpirationBeginningYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TemporaryEquityTextBlock" xlink:to="vir_TemporaryEquityTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WuXiBiologicsLimitedMember" xlink:to="vir_WuXiBiologicsLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:to="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WarrantsToPurchaseCommonStockMember" xlink:to="vir_WarrantsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" xlink:to="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_VaccineProgramMember" xlink:to="vir_VaccineProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AnotherProductMember" xlink:to="vir_AnotherProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopmentProgramsExercisedByBriiMember" xlink:to="vir_DevelopmentProgramsExercisedByBriiMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" xlink:to="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TuberculosisTBGrantMember" xlink:to="vir_TuberculosisTBGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LetterAgreementMember" xlink:to="vir_LetterAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateAgreementByCompany" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" xlink:to="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:to="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RestrictedStockAwardsRSAMember" xlink:to="vir_RestrictedStockAwardsRSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:to="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AssetAcquisitionMilestoneAchieved" xlink:to="vir_AssetAcquisitionMilestoneAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:to="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SARSCoV2ProductMember" xlink:to="vir_SARSCoV2ProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandNineteenXencorAgreementMember" xlink:to="vir_TwoThousandNineteenXencorAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ClinicalAndRegulatoryMilestonesMember" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementTransactionPriceConsideration" xlink:to="vir_CollaborationAgreementTransactionPriceConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SalesMilestonesAchieved" xlink:to="vir_SalesMilestonesAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:to="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="vir_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:to="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentOfContingentConsideration" xlink:to="vir_PaymentOfContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementAmendedDate" xlink:to="vir_GrantAgreementAmendedDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticeToTerminateLicensedProgramIfExercise" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MedImmuneLimitedLiabilityCompanyMember" xlink:to="vir_MedImmuneLimitedLiabilityCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:to="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:to="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UnusedFundsReceivedInAdvance" xlink:to="vir_UnusedFundsReceivedInAdvance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedGrantAgreement" xlink:to="vir_StockIssuedGrantAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLeaseOtherInformationAbstract" xlink:to="vir_OperatingLeaseOtherInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateMilestonePayments" xlink:to="vir_MaximumAggregateMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EquityInvestmentCurrent" xlink:to="vir_EquityInvestmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OfferingPeriodEmployeeStockPurchasePlan" xlink:to="vir_OfferingPeriodEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAwardedAmountMaximum" xlink:to="vir_GrantAwardedAmountMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:to="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstInfectiousDiseaseProductMember" xlink:to="vir_FirstInfectiousDiseaseProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" xlink:to="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLossCarryforwardsLimitationOnUsePercentage" xlink:to="vir_OperatingLossCarryforwardsLimitationOnUsePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAwardedAmount" xlink:to="vir_GrantAwardedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConvertiblePreferredStockWarrantLiabilityMember" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" xlink:to="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:to="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:to="us-gaap_SalariesWagesAndOfficersCompensationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodValueAchievementOfMilestone" xlink:to="vir_StockIssuedDuringPeriodValueAchievementOfMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FollowOnOfferingMember" xlink:to="vir_FollowOnOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:to="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:to="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementAmendedExpirationDate" xlink:to="vir_GrantAgreementAmendedExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:to="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BriiBiosciencesOffshoreLimitedMember" xlink:to="vir_BriiBiosciencesOffshoreLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:to="vir_ReconciliationOfEffectiveIncomeTaxRateTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="vir_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="vir_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" xlink:to="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NumberOfAntibodiesToDevelop" xlink:to="vir_NumberOfAntibodiesToDevelop_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" xlink:to="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePaymentDueToCompany" xlink:to="vir_MilestonePaymentDueToCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:to="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" xlink:to="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestonesAchieved" xlink:to="vir_RegulatoryMilestonesAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:to="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TemporaryEquityAdditionalSharesAuthorized" xlink:to="vir_TemporaryEquityAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DefinitiveCollaborationAgreementMember" xlink:to="vir_DefinitiveCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RockefellerUniversityMember" xlink:to="vir_RockefellerUniversityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BillAndMelindaGatesFoundationMember" xlink:to="vir_BillAndMelindaGatesFoundationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities" xlink:to="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BriiAgreementMember" xlink:to="vir_BriiAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" xlink:to="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PayrollAndRelatedExpensesCurrent" xlink:to="vir_PayrollAndRelatedExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:to="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstSiRNAProductHBVMember" xlink:to="vir_FirstSiRNAProductHBVMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TenantImprovementAllowanceAggregate" xlink:to="vir_TenantImprovementAllowanceAggregate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CashGrantAwarded" xlink:to="vir_CashGrantAwarded_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueAdjustment" xlink:to="us-gaap_AssetsFairValueAdjustment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProfitsAndLossesSharingPercentage" xlink:to="vir_ProfitsAndLossesSharingPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfluenzaAAndHBVResearchProgramsMember" xlink:to="vir_InfluenzaAAndHBVResearchProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" xlink:to="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationRevenueMember" xlink:to="vir_CollaborationRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BriiBioParentMember" xlink:to="vir_BriiBioParentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AntibodyProgramMember" xlink:to="vir_AntibodyProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateSalesMilestonePayments" xlink:to="vir_MaximumAggregateSalesMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProceedsFromRepaymentOfPromissoryNotes" xlink:to="vir_ProceedsFromRepaymentOfPromissoryNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementsDisclosureTextBlock" xlink:to="vir_GrantAgreementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RockefellerAgreementMember" xlink:to="vir_RockefellerAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RemainingPaymentMadeForAssetAcquisitionMilestone" xlink:to="vir_RemainingPaymentMadeForAssetAcquisitionMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:to="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AnnualLicenseMaintenanceFees" xlink:to="vir_AnnualLicenseMaintenanceFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:to="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_OR" xlink:to="stpr_OR_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" xlink:to="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" xlink:to="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HcmvVaccinePlatformGrantMember" xlink:to="vir_HcmvVaccinePlatformGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DeferredTaxAssetsLeaseLiabilities" xlink:to="vir_DeferredTaxAssetsLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" xlink:to="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:to="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" xlink:to="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommonStockIssuedInConnectionWithLicenseAgreement" xlink:to="vir_CommonStockIssuedInConnectionWithLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumSalesMilestonToPay" xlink:to="vir_MaximumSalesMilestonToPay_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfluenzaAResearchProgramsMember" xlink:to="vir_InfluenzaAResearchProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" xlink:to="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfShareDevelopmentCosts" xlink:to="vir_PercentageOfShareDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" xlink:to="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" xlink:to="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SaleLeasebackTransactionProceedsFromFinancingObligations" xlink:to="vir_SaleLeasebackTransactionProceedsFromFinancingObligations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SeriesAOneConvertiblePreferredStockMember" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" xlink:to="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:to="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementTransactionPriceUpfrontFee" xlink:to="vir_CollaborationAgreementTransactionPriceUpfrontFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SalesAgreementMember" xlink:to="vir_SalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfEstimatedBatchProductionFees" xlink:to="vir_PercentageOfEstimatedBatchProductionFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ExecutiveOfficerAndDirectorMember" xlink:to="vir_ExecutiveOfficerAndDirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumSharesToBeIssued" xlink:to="vir_MaximumSharesToBeIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:to="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstAndSecondClosingsMember" xlink:to="vir_FirstAndSecondClosingsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePayable" xlink:to="vir_MilestonePayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FundsReceivedInAdvance" xlink:to="vir_FundsReceivedInAdvance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:to="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HBVProgramMember" xlink:to="vir_HBVProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" xlink:to="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EachInfectiousDiseaseSiRNAMember" xlink:to="vir_EachInfectiousDiseaseSiRNAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfDevelopmentCosts" xlink:to="vir_PercentageOfDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" xlink:to="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:to="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:to="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" xlink:to="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:to="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ResearchAndDevelopmentExpensesCurrent" xlink:to="vir_ResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FormerBusinessCombinationContingentConsiderationLiability" xlink:to="vir_FormerBusinessCombinationContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePaymentReceived" xlink:to="vir_MilestonePaymentReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" xlink:to="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstSiRNAProductMember" xlink:to="vir_FirstSiRNAProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommonStockIssuanceCost" xlink:to="vir_CommonStockIssuanceCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ObligationToPayCapacityReservation" xlink:to="vir_ObligationToPayCapacityReservation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PreliminaryCollaborationAgreementMember" xlink:to="vir_PreliminaryCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RestrictedStockPurchaseAgreementMember" xlink:to="vir_RestrictedStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumSalesMilestonePayment" xlink:to="vir_MaximumSalesMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NetProceedsFromIssuanceSecondaryPublicOffering" xlink:to="vir_NetProceedsFromIssuanceSecondaryPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementMember" xlink:to="vir_CollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandSixteenEquityIncentivePlanMember" xlink:to="vir_TwoThousandSixteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentMadeForBusinessCombinationMilestone" xlink:to="vir_PaymentMadeForBusinessCombinationMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLeaseAbstract" xlink:to="vir_OperatingLeaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:to="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SecondPlanMember" xlink:to="vir_SecondPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantsAgreementAmendedDate" xlink:to="vir_GrantsAgreementAmendedDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfluenzaAAndInfluenzaBMember" xlink:to="vir_InfluenzaAAndInfluenzaBMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:to="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HumabsBiomedSAMember" xlink:to="vir_HumabsBiomedSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:to="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateSalesMilestonePayment" xlink:to="vir_MaximumAggregateSalesMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="vir_FiniteLivedIntangibleAssetsAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:to="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommercialMilestonesMember" xlink:to="vir_CommercialMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UpfrontFeePaid" xlink:to="vir_UpfrontFeePaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_XencorAgreementsMember" xlink:to="vir_XencorAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfCommissionRateFromSaleOfShares" xlink:to="vir_PercentageOfCommissionRateFromSaleOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:to="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:to="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLossCarryforwardsExpirationBeginningYear" xlink:to="vir_OperatingLossCarryforwardsExpirationBeginningYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:to="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementTerminationDescription" xlink:to="vir_CollaborationAgreementTerminationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FairMarketValueOfCommonStockIssued" xlink:to="vir_FairMarketValueOfCommonStockIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BiologicalMaterialsMember" xlink:to="vir_BiologicalMaterialsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeHighEndOfTheRange" xlink:to="vir_OptionExerciseFeeHighEndOfTheRange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyXencorAgreementMember" xlink:to="vir_TwoThousandTwentyXencorAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AntibodyLicenseTransactionPrice" xlink:to="vir_AntibodyLicenseTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ValueOfSharesTransferredToCollaborator" xlink:to="vir_ValueOfSharesTransferredToCollaborator_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationTypeAndPrograms" xlink:to="vir_CollaborationTypeAndPrograms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HepatitisBVirusProductMember" xlink:to="vir_HepatitisBVirusProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankTimeDepositsMember" xlink:to="us-gaap_BankTimeDepositsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SamsungBiologicsCompanyLimitedMember" xlink:to="vir_SamsungBiologicsCompanyLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TaxCreditCarryforwardsExpirationBeginningYear" xlink:to="vir_TaxCreditCarryforwardsExpirationBeginningYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NonCashCommonStockIssuedForContingentConsideration" xlink:to="vir_NonCashCommonStockIssuedForContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePaymentsRelatedTermsDescription" xlink:to="vir_MilestonePaymentsRelatedTermsDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IssuanceOfCommonStockToSettleAContingentConsideration" xlink:to="vir_IssuanceOfCommonStockToSettleAContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestoneAchieved" xlink:to="vir_RegulatoryMilestoneAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201704Member" xlink:to="us-gaap_AccountingStandardsUpdate201704Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DeterminedTransactionPrice" xlink:to="vir_DeterminedTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AssetAcquisitionMilestonePaymentAggregate" xlink:to="vir_AssetAcquisitionMilestonePaymentAggregate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RangeOfRoyaltyPaymentToBeReceived" xlink:to="vir_RangeOfRoyaltyPaymentToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:to="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConvertiblePreferredStockIssuanceCost" xlink:to="vir_ConvertiblePreferredStockIssuanceCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ValueStockIssuedGrantAgreement" xlink:to="vir_ValueStockIssuedGrantAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NumberOfClassOfStock" xlink:to="vir_NumberOfClassOfStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LicenseAgreementUpfrontPayment" xlink:to="vir_LicenseAgreementUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" xlink:to="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:to="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" xlink:to="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfectiousDiseaseProductMember" xlink:to="vir_InfectiousDiseaseProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltiesPaymentExpirationPeriod" xlink:to="vir_RoyaltiesPaymentExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:to="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EsppDiscountedPurchasePricePercentage" xlink:to="vir_EsppDiscountedPurchasePricePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopedTechnologyMember" xlink:to="vir_DevelopedTechnologyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ContractRevenueMember" xlink:to="vir_ContractRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:to="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ContingentConsiderationLiabilityMember" xlink:to="vir_ContingentConsiderationLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201814Member" xlink:to="us-gaap_AccountingStandardsUpdate201814Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessAgreementGrantAmount" xlink:to="vir_BusinessAgreementGrantAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncomeTaxesTable" xlink:to="vir_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PresentValueOfOperatingLeaseLiabilities" xlink:to="vir_PresentValueOfOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MeasurementInputProbabilityRateMember" xlink:to="vir_MeasurementInputProbabilityRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentToCollaboratorResultingFromProgramOptionExercise" xlink:to="vir_PaymentToCollaboratorResultingFromProgramOptionExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ThirdClosingMember" xlink:to="vir_ThirdClosingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MedImmuneAgreementMember" xlink:to="vir_MedImmuneAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentMadeForAssetAcquisitionMilestone" xlink:to="vir_PaymentMadeForAssetAcquisitionMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncome" xlink:to="us-gaap_DeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InitialFairValueOfDerivativeLiability" xlink:to="vir_InitialFairValueOfDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EstimatedSharesEmployeeStockPurchasePlans" xlink:to="vir_EstimatedSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RangeOfRoyaltyPaymentToBePaid" xlink:to="vir_RangeOfRoyaltyPaymentToBePaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_XencorIncorporationMember" xlink:to="vir_XencorIncorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:to="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:to="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeReceived" xlink:to="vir_OptionExerciseFeeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandSeventeenGrantMember" xlink:to="vir_TwoThousandSeventeenGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessAgreementEquityInvestmentCommitment" xlink:to="vir_BusinessAgreementEquityInvestmentCommitment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="us-gaap_ContractBasedIntangibleAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AustralianTaxationOfficeMember" xlink:to="us-gaap_AustralianTaxationOfficeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingAndFinanceRentExpense" xlink:to="vir_OperatingAndFinanceRentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock" xlink:to="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:to="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsAmortizedCostBasis" xlink:to="vir_FinancialAssetsAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementEffectiveEndDate" xlink:to="vir_GrantAgreementEffectiveEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SpecifiedSalesDevelopmentMilestonesPayment" xlink:to="vir_SpecifiedSalesDevelopmentMilestonesPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:to="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>47
<FILENAME>vir-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-02-28T16:08:30.5142+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="vir-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="vir-20211231.xsd#StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganization" xlink:href="vir-20211231.xsd#Role_DisclosureOrganization" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="vir-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitions" xlink:href="vir-20211231.xsd#Role_DisclosureAcquisitions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:href="vir-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreements" xlink:href="vir-20211231.xsd#Role_DisclosureGrantAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:href="vir-20211231.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:href="vir-20211231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="vir-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="vir-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:href="vir-20211231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability" xlink:href="vir-20211231.xsd#Role_DisclosureConvertiblePreferredStockWarrantLiability" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwards" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwards" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShare1" xlink:href="vir-20211231.xsd#DisclosureNetIncomeLossPerShare1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlan" xlink:href="vir-20211231.xsd#DisclosureDefinedContributionPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEvent1" xlink:href="vir-20211231.xsd#DisclosureSubsequentEvent1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vir-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="vir-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:href="vir-20211231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="vir-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables" xlink:href="vir-20211231.xsd#DisclosureNetIncomeLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:href="vir-20211231.xsd#Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="vir-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="vir-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="vir-20211231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" xlink:href="vir-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" xlink:href="vir-20211231.xsd#DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="vir-20211231.xsd#DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="vir-20211231.xsd#DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails" xlink:href="vir-20211231.xsd#DisclosureNetIncomeLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="vir-20211231.xsd#DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="vir-20211231.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EquityInvestmentCurrent" xlink:label="vir_EquityInvestmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="vir_EquityInvestmentCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesATwoConvertiblePreferredStockMember" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodValueAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IssuanceOfCommonStockToSettleAContingentConsideration" xlink:label="vir_IssuanceOfCommonStockToSettleAContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_37"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_38"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_39"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_40"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FollowOnOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesATwoConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueAchievementOfMilestone" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_IssuanceOfCommonStockToSettleAContingentConsideration" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueCollaborationAgreement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueLicenseAgreement" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesLicenseAgreement" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_37" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_38" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_39" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_40" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockIssuanceCost" xlink:label="vir_ConvertiblePreferredStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InitialPublicOfferingCosts" xlink:label="vir_InitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommonStockIssuanceCost" xlink:label="vir_CommonStockIssuanceCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ConvertiblePreferredStockIssuanceCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_InitialPublicOfferingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_CommonStockIssuanceCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementMember" xlink:label="vir_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NonCashCommonStockIssuedForContingentConsideration" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FailedSaleLeasebackTransactionProceedsFinancingActivities" xlink:label="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromRepaymentOfPromissoryNotes" xlink:label="vir_ProceedsFromRepaymentOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InitialFairValueOfDerivativeLiability" xlink:label="vir_InitialFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" xlink:label="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommonStockIssuedInConnectionWithLicenseAgreement" xlink:label="vir_CommonStockIssuedInConnectionWithLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_CollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_NonCashCommonStockIssuedForContingentConsideration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_PaymentOfContingentConsideration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_NoncashLeaseExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetsFairValueAdjustment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_ProceedsFromRepaymentOfPromissoryNotes" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_InitialFairValueOfDerivativeLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_CommonStockIssuedInConnectionWithLicenseAgreement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementsDisclosureTextBlock" xlink:label="vir_GrantAgreementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="vir_GrantAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityTextBlock" xlink:label="vir_TemporaryEquityTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="vir_TemporaryEquityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityTextBlock" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwards" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShare1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEvent1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesEmbeddedDerivatives" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SalesAgreementMember" xlink:label="vir_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NetProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfCommissionRateFromSaleOfShares" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="vir_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FollowOnOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PaymentsOfUnderwritingDiscountsAndCommissions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_NetProceedsFromIssuanceSecondaryPublicOffering" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_ProceedsFromIssuanceSecondaryPublicOffering" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PercentageOfCommissionRateFromSaleOfShares" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_SaleOfStockConsiderationAggregateOfferingPrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SummaryOfSignificantAccountingPoliciesTable" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201704Member" xlink:label="us-gaap_AccountingStandardsUpdate201704Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:label="us-gaap_AccountingStandardsUpdate201813Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201814Member" xlink:label="us-gaap_AccountingStandardsUpdate201814Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vir_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201704Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="vir_SummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201814Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsAmortizedCostBasis" xlink:label="vir_FinancialAssetsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsFairValue" xlink:label="vir_FinancialAssetsFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_BankTimeDepositsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestoneAchieved" xlink:label="vir_RegulatoryMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SpecifiedSalesDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SalesMilestonesAchieved" xlink:label="vir_SalesMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FormerBusinessCombinationContingentConsiderationLiability" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AssetAcquisitionMilestoneAchieved" xlink:label="vir_AssetAcquisitionMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="vir_LetterAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="vir_BriiBioParentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InterestReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancingReceivableAccruedInterestWriteoff" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_OwnershipAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_RegulatoryMilestoneAchieved" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_SpecifiedSalesDevelopmentMilestonesPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_SalesMilestonesAchieved" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FormerBusinessCombinationContingentConsiderationLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_AssetAcquisitionMilestoneAchieved" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MeasurementInputProbabilityRateMember" xlink:label="vir_MeasurementInputProbabilityRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MeasurementInputExpectedVolatilityMember" xlink:label="vir_MeasurementInputExpectedVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputProbabilityRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputExpectedVolatilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputExpectedRevenueVolatilityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HepatitisBVirusProductMember" xlink:label="vir_HepatitisBVirusProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AnotherProductMember" xlink:label="vir_AnotherProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ClinicalDevelopmentMember" xlink:label="vir_ClinicalDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SARSCoV2ProductMember" xlink:label="vir_SARSCoV2ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AssetAcquisitionMilestonePaymentAggregate" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentsRelatedTermsDescription" xlink:label="vir_MilestonePaymentsRelatedTermsDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonesAchieved" xlink:label="vir_RegulatoryMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SalesMilestonesAchieved" xlink:label="vir_SalesMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentMadeForBusinessCombinationMilestone" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RemainingPaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HepatitisBVirusProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AnotherProductMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="vir_ClinicalDevelopmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_SARSCoV2ProductMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_AssetAcquisitionMilestonePaymentAggregate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MilestonePaymentsRelatedTermsDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_SpecifiedClinicalDevelopmentMilestonesPayment" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RegulatoryMilestonesAchieved" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_SalesMilestonesAchieved" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_PaymentMadeForBusinessCombinationMilestone" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_PaymentMadeForAssetAcquisitionMilestone" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_CommonStockSharesIssuedForMilestonePaymentShares" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentMadeForBusinessCombinationMilestone" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentMadeForAssetAcquisitionMilestone" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopedTechnologyMember" xlink:label="vir_DevelopedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember" xlink:label="us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="vir_DevelopedTechnologyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ContractBasedIntangibleAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="vir_FiniteLivedIntangibleAssetsAmortizationExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandSeventeenGrantMember" xlink:label="vir_TwoThousandSeventeenGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BillAndMelindaGatesFoundationMember" xlink:label="vir_BillAndMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAwardedAmount" xlink:label="vir_GrantAwardedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAwardedAmountMaximum" xlink:label="vir_GrantAwardedAmountMaximum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumanImmunodeficiencyVirusGrantMember" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NationalInstitutesOfHealthMember" xlink:label="vir_NationalInstitutesOfHealthMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TuberculosisTBGrantMember" xlink:label="vir_TuberculosisTBGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementExpirationDate" xlink:label="vir_GrantAgreementExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HcmvVaccinePlatformGrantMember" xlink:label="vir_HcmvVaccinePlatformGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementExpirationDateBeforeAmendment" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementAmendedExpirationDate" xlink:label="vir_GrantAgreementAmendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementAmendedDate" xlink:label="vir_GrantAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantsAgreementAmendedDate" xlink:label="vir_GrantsAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncome" xlink:label="us-gaap_DeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentDueToCompany" xlink:label="vir_MilestonePaymentDueToCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentReceived" xlink:label="vir_MilestonePaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_UnusedFundsReceivedInAdvance" xlink:label="vir_UnusedFundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FundsReceivedInAdvance" xlink:label="vir_FundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementEffectiveEndDate" xlink:label="vir_GrantAgreementEffectiveEndDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandSeventeenGrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BillAndMelindaGatesFoundationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmountMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_HumanImmunodeficiencyVirusGrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_NationalInstitutesOfHealthMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TuberculosisTBGrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementExpirationDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_HcmvVaccinePlatformGrantMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementExpirationDateBeforeAmendment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementAmendedExpirationDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementAmendedDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantsAgreementAmendedDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncome" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentDueToCompany" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentReceived" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UnusedFundsReceivedInAdvance" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_FundsReceivedInAdvance" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementEffectiveEndDate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN" xlink:label="country_CN"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoGroupLimitedMember" xlink:label="vir_GlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_VaccineProgramMember" xlink:label="vir_VaccineProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiBiosciencesOffshoreLimitedMember" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopmentProgramsExercisedByVirMember" xlink:label="vir_DevelopmentProgramsExercisedByVirMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AlnylamPharmaceuticalsIncMember" xlink:label="vir_AlnylamPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfShareDevelopmentCosts" xlink:label="vir_PercentageOfShareDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopmentProgramsExercisedByBriiMember" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyGskAgreementMember" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RockefellerUniversityMember" xlink:label="vir_RockefellerUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BiologicalMaterialsMember" xlink:label="vir_BiologicalMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MedImmuneLimitedLiabilityCompanyMember" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstSiRNAProductMember" xlink:label="vir_FirstSiRNAProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementTerminationDescription" xlink:label="vir_CollaborationAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_XencorIncorporationMember" xlink:label="vir_XencorIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstSiRNAProductHBVMember" xlink:label="vir_FirstSiRNAProductHBVMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiAgreementMember" xlink:label="vir_BriiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FairMarketValueOfCommonStockIssued" xlink:label="vir_FairMarketValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AlnylamAgreementMember" xlink:label="vir_AlnylamAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EachInfectiousDiseaseSiRNAMember" xlink:label="vir_EachInfectiousDiseaseSiRNAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstInfectiousDiseaseProductMember" xlink:label="vir_FirstInfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RockefellerAgreementMember" xlink:label="vir_RockefellerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfectiousDiseaseProductMember" xlink:label="vir_InfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AntibodyLicenseTransactionPrice" xlink:label="vir_AntibodyLicenseTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MedImmuneAgreementMember" xlink:label="vir_MedImmuneAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HBVProgramMember" xlink:label="vir_HBVProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenXencorAgreementMember" xlink:label="vir_TwoThousandNineteenXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfluenzaAAndInfluenzaBMember" xlink:label="vir_InfluenzaAAndInfluenzaBMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCompany" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfluenzaAResearchProgramsMember" xlink:label="vir_InfluenzaAResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_XencorAgreementsMember" xlink:label="vir_XencorAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfluenzaAAndHBVResearchProgramsMember" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RangeOfRoyaltyPaymentToBeReceived" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonePaymentToBeReceived" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AnnualLicenseMaintenanceFees" xlink:label="vir_AnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumSalesMilestonToPay" xlink:label="vir_MaximumSalesMilestonToPay"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentToCollaboratorResultingFromProgramOptionExercise" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltiesPaymentExpirationPeriod" xlink:label="vir_RoyaltiesPaymentExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProfitsAndLossesSharingPercentage" xlink:label="vir_ProfitsAndLossesSharingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeLowEndOfTheRange" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RangeOfRoyaltyPaymentToBePaid" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeHighEndOfTheRange" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateSalesMilestonePayments" xlink:label="vir_MaximumAggregateSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_UpfrontPaymentReceivable" xlink:label="vir_UpfrontPaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeConsiderationToBeReceived" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementTransactionPriceUpfrontFee" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementTransactionPriceConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ValueOfSharesTransferredToCollaborator" xlink:label="vir_ValueOfSharesTransferredToCollaborator"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationTypeAndPrograms" xlink:label="vir_CollaborationTypeAndPrograms"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeReceived" xlink:label="vir_OptionExerciseFeeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeterminedTransactionPrice" xlink:label="vir_DeterminedTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_UpfrontFeePaid" xlink:label="vir_UpfrontFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumSharesToBeIssued" xlink:label="vir_MaximumSharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateSalesMilestonePayment" xlink:label="vir_MaximumAggregateSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumSalesMilestonePayment" xlink:label="vir_MaximumSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateMilestonePayments" xlink:label="vir_MaximumAggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentsPaid" xlink:label="vir_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NumberOfAntibodiesToDevelop" xlink:label="vir_NumberOfAntibodiesToDevelop"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:label="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" xlink:label="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LicenseAgreementUpfrontPayment" xlink:label="vir_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyStockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_GlaxoGroupLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_PreliminaryCollaborationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBioParentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DefinitiveCollaborationAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_VaccineProgramMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBiosciencesOffshoreLimitedMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_DevelopmentProgramsExercisedByVirMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_AlnylamPharmaceuticalsIncMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfShareDevelopmentCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_WuXiBiologicsLimitedMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_DevelopmentProgramsExercisedByBriiMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKCollaborationMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyGskAgreementMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_RockefellerUniversityMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_BiologicalMaterialsMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_MedImmuneLimitedLiabilityCompanyMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstSiRNAProductMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKAgreementMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTerminationDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_XencorIncorporationMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstSiRNAProductHBVMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BriiAgreementMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_FairMarketValueOfCommonStockIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_AlnylamAgreementMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_EachInfectiousDiseaseSiRNAMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstInfectiousDiseaseProductMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PremiumReceivedOnSalePriceOfCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DevelopmentAndManufacturingCollaborationAgreementMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_RockefellerAgreementMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfectiousDiseaseProductMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AntibodyLicenseTransactionPrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_MedImmuneAgreementMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HBVProgramMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandNineteenXencorAgreementMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndInfluenzaBMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyXencorAgreementMember" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAResearchProgramsMember" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_XencorAgreementsMember" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndHBVResearchProgramsMember" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfRoyaltyPaymentToBeReceived" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentToBeReceived" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AnnualLicenseMaintenanceFees" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfExercise" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestonToPay" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PaymentToCollaboratorResultingFromProgramOptionExercise" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesPaymentExpirationPeriod" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfUnitsOfAccount" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ProfitsAndLossesSharingPercentage" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeLowEndOfTheRange" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfRoyaltyPaymentToBePaid" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeHighEndOfTheRange" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateSalesMilestonePayments" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontPaymentReceivable" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationToBeReceived" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceUpfrontFee" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceConsideration" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" order="49" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" order="50" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" order="51" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" order="52" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ValueOfSharesTransferredToCollaborator" order="53" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="54" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Investments" order="55" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationTypeAndPrograms" order="56" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeReceived" order="57" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_DeterminedTransactionPrice" order="58" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontFeePaid" order="59" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSharesToBeIssued" order="60" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" order="61" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateSalesMilestonePayment" order="62" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestonePayment" order="63" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateMilestonePayments" order="64" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" order="65" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="66" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentsPaid" order="67" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementRelatedCostsAndExpenses" order="68" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_NumberOfAntibodiesToDevelop" order="69" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" order="70" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" order="71" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" order="72" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_LicenseAgreementUpfrontPayment" order="73" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" order="74" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateCommercialSalesMilestonePayments" order="75" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfRevenue" order="76" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="77" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" order="78" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" order="79" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" order="80" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LaboratoryEquipmentMember" xlink:label="vir_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="vir_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SaleLeasebackTransactionProceedsFromFinancingObligations" xlink:label="vir_SaleLeasebackTransactionProceedsFromFinancingObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_SaleLeasebackTransactionProceedsFromFinancingObligations" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePayable" xlink:label="vir_MilestonePayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ResearchAndDevelopmentExpensesCurrent" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PayrollAndRelatedExpensesCurrent" xlink:label="vir_PayrollAndRelatedExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_MilestonePayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_ResearchAndDevelopmentExpensesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_PayrollAndRelatedExpensesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LeaseArrangementContractualExpirationBeginningYear" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SamsungBiologicsCompanyLimitedMember" xlink:label="vir_SamsungBiologicsCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LeaseArrangementContractualExpirationEndingYear" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TenantImprovementAllowanceAggregate" xlink:label="vir_TenantImprovementAllowanceAggregate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingAndFinanceRentExpense" xlink:label="vir_OperatingAndFinanceRentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ObligationToPayCapacityReservation" xlink:label="vir_ObligationToPayCapacityReservation"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfEstimatedBatchProductionFees" xlink:label="vir_PercentageOfEstimatedBatchProductionFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationBeginningYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_SamsungBiologicsCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_WuXiBiologicsLimitedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationEndingYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_TenantImprovements" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_TenantImprovementAllowanceAggregate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_OperatingAndFinanceRentExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_ObligationToPayCapacityReservation" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfEstimatedBatchProductionFees" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLeaseOtherInformationAbstract" xlink:label="vir_OperatingLeaseOtherInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseOtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseOtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseOtherInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseOtherInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_OperatingLeaseOtherInformationAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PresentValueOfOperatingLeaseLiabilities" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_PresentValueOfOperatingLeaseLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLeaseAbstract" xlink:label="vir_OperatingLeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLeaseIncentiveOverLeaseLiabilities" xlink:label="vir_OperatingLeaseIncentiveOverLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_OperatingLeaseAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="vir_OperatingLeaseIncentiveOverLeaseLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstAndSecondClosingsMember" xlink:label="vir_FirstAndSecondClosingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ThirdClosingMember" xlink:label="vir_ThirdClosingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityAdditionalSharesAuthorized" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NumberOfClassOfStock" xlink:label="vir_NumberOfClassOfStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FirstAndSecondClosingsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_ThirdClosingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_TemporaryEquityAdditionalSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_NumberOfClassOfStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodWarrantExercised" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="vir_StockIssuedDuringPeriodWarrantExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RestrictedStockPurchaseAgreementMember" xlink:label="vir_RestrictedStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ExecutiveOfficerAndDirectorMember" xlink:label="vir_ExecutiveOfficerAndDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OfferingPeriodEmployeeStockPurchasePlan" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_RestrictedStockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandSixteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="vir_ExecutiveOfficerAndDirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_OfferingPeriodEmployeeStockPurchasePlan" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RestrictedStockAwardsRSAMember" xlink:label="vir_RestrictedStockAwardsRSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="vir_RestrictedStockAwardsRSAMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:label="us-gaap_SalariesWagesAndOfficersCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WarrantsToPurchaseCommonStockMember" xlink:label="vir_WarrantsToPurchaseCommonStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_EstimatedSharesIssuableUnderTheESPPMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_WarrantsToPurchaseCommonStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EstimatedSharesEmployeeStockPurchasePlans" xlink:label="vir_EstimatedSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EsppDiscountedPurchasePricePercentage" xlink:label="vir_EsppDiscountedPurchasePricePercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="vir_EstimatedSharesEmployeeStockPurchasePlans" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="vir_EsppDiscountedPurchasePricePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstPlanMember" xlink:label="vir_FirstPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SecondPlanMember" xlink:label="vir_SecondPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="vir_FirstPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="vir_SecondPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="vir_ReconciliationOfEffectiveIncomeTaxRateTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:to="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeferredTaxAssetsLeaseLiabilities" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="vir_DeferredTaxLiabilitiesRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="vir_DeferredTaxAssetsLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncomeTaxesTable" xlink:label="vir_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:label="us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_OR" xlink:label="stpr_OR"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncomeTaxesLineItems" xlink:label="vir_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLossCarryforwardsLimitationOnUsePercentage" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TaxCreditCarryforwardsExpirationBeginningYear" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="vir_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_SwissFederalTaxAdministrationFTAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_OR" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_OperatingLossCarryforwardsExpirationBeginningYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesTable" xlink:to="vir_IncomeTaxesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_OperatingLossCarryforwardsLimitationOnUsePercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_TaxCreditCarryforwardsExpirationBeginningYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAgreementGrantAmount" xlink:label="vir_BusinessAgreementGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CashGrantAwarded" xlink:label="vir_CashGrantAwarded"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ValueStockIssuedGrantAgreement" xlink:label="vir_ValueStockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedGrantAgreement" xlink:label="vir_StockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAgreementEquityInvestmentCommitment" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BillMelindaGatesFoundationMember" xlink:label="vir_BillMelindaGatesFoundationMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_PreliminaryCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_BusinessAgreementGrantAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_CashGrantAwarded" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DefinitiveCollaborationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_ValueStockIssuedGrantAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_StockIssuedGrantAgreement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_BusinessAgreementEquityInvestmentCommitment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BillMelindaGatesFoundationMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>48
<FILENAME>vir-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-02-28T16:08:30.7550+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="vir-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="vir-20211231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" xlink:href="vir-20211231.xsd#DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:href="vir-20211231.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="vir-20211231.xsd#DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="vir-20211231.xsd#DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="vir-20211231.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesATwoConvertiblePreferredStockMember" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock" xlink:label="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodValueAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IssuanceOfCommonStockToSettleAContingentConsideration" xlink:label="vir_IssuanceOfCommonStockToSettleAContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesATwoConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueAchievementOfMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_IssuanceOfCommonStockToSettleAContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueCollaborationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockIssuanceCost" xlink:label="vir_ConvertiblePreferredStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InitialPublicOfferingCosts" xlink:label="vir_InitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommonStockIssuanceCost" xlink:label="vir_CommonStockIssuanceCost"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ConvertiblePreferredStockIssuanceCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_InitialPublicOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_CommonStockIssuanceCost" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementMember" xlink:label="vir_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NonCashCommonStockIssuedForContingentConsideration" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FailedSaleLeasebackTransactionProceedsFinancingActivities" xlink:label="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromRepaymentOfPromissoryNotes" xlink:label="vir_ProceedsFromRepaymentOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InitialFairValueOfDerivativeLiability" xlink:label="vir_InitialFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" xlink:label="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommonStockIssuedInConnectionWithLicenseAgreement" xlink:label="vir_CommonStockIssuedInConnectionWithLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_CollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_NonCashCommonStockIssuedForContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_PaymentOfContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_NoncashLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetsFairValueAdjustment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_ProceedsFromRepaymentOfPromissoryNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_InitialFairValueOfDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_CommonStockIssuedInConnectionWithLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SalesAgreementMember" xlink:label="vir_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NetProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfCommissionRateFromSaleOfShares" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="vir_SalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PaymentsOfUnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_NetProceedsFromIssuanceSecondaryPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_ProceedsFromIssuanceSecondaryPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PercentageOfCommissionRateFromSaleOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_SaleOfStockConsiderationAggregateOfferingPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SummaryOfSignificantAccountingPoliciesTable" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201704Member" xlink:label="us-gaap_AccountingStandardsUpdate201704Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:label="us-gaap_AccountingStandardsUpdate201813Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201814Member" xlink:label="us-gaap_AccountingStandardsUpdate201814Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="vir_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201704Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201814Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsAmortizedCostBasis" xlink:label="vir_FinancialAssetsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FinancialAssetsFairValue" xlink:label="vir_FinancialAssetsFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingGains" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingLosses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_BankTimeDepositsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestoneAchieved" xlink:label="vir_RegulatoryMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SpecifiedSalesDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SalesMilestonesAchieved" xlink:label="vir_SalesMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FormerBusinessCombinationContingentConsiderationLiability" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AssetAcquisitionMilestoneAchieved" xlink:label="vir_AssetAcquisitionMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="vir_BriiBioParentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="vir_LetterAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InterestReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancingReceivableAccruedInterestWriteoff" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_RegulatoryMilestoneAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_SpecifiedSalesDevelopmentMilestonesPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_SalesMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FormerBusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_AssetAcquisitionMilestoneAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MeasurementInputProbabilityRateMember" xlink:label="vir_MeasurementInputProbabilityRateMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MeasurementInputExpectedVolatilityMember" xlink:label="vir_MeasurementInputExpectedVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputProbabilityRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputExpectedVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputExpectedRevenueVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HepatitisBVirusProductMember" xlink:label="vir_HepatitisBVirusProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AnotherProductMember" xlink:label="vir_AnotherProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SARSCoV2ProductMember" xlink:label="vir_SARSCoV2ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ClinicalDevelopmentMember" xlink:label="vir_ClinicalDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AssetAcquisitionMilestonePaymentAggregate" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentsRelatedTermsDescription" xlink:label="vir_MilestonePaymentsRelatedTermsDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonesAchieved" xlink:label="vir_RegulatoryMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SalesMilestonesAchieved" xlink:label="vir_SalesMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentMadeForBusinessCombinationMilestone" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RemainingPaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HepatitisBVirusProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AnotherProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_SARSCoV2ProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="vir_ClinicalDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_AssetAcquisitionMilestonePaymentAggregate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MilestonePaymentsRelatedTermsDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_SpecifiedClinicalDevelopmentMilestonesPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RegulatoryMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_SalesMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_PaymentMadeForBusinessCombinationMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_PaymentMadeForAssetAcquisitionMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_CommonStockSharesIssuedForMilestonePaymentShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentMadeForBusinessCombinationMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentMadeForAssetAcquisitionMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopedTechnologyMember" xlink:label="vir_DevelopedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember" xlink:label="us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="vir_DevelopedTechnologyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ContractBasedIntangibleAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAwardedAmount" xlink:label="vir_GrantAwardedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BillAndMelindaGatesFoundationMember" xlink:label="vir_BillAndMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandSeventeenGrantMember" xlink:label="vir_TwoThousandSeventeenGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NationalInstitutesOfHealthMember" xlink:label="vir_NationalInstitutesOfHealthMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumanImmunodeficiencyVirusGrantMember" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAwardedAmountMaximum" xlink:label="vir_GrantAwardedAmountMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementExpirationDate" xlink:label="vir_GrantAgreementExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TuberculosisTBGrantMember" xlink:label="vir_TuberculosisTBGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HcmvVaccinePlatformGrantMember" xlink:label="vir_HcmvVaccinePlatformGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementExpirationDateBeforeAmendment" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementAmendedExpirationDate" xlink:label="vir_GrantAgreementAmendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementAmendedDate" xlink:label="vir_GrantAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantsAgreementAmendedDate" xlink:label="vir_GrantsAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncome" xlink:label="us-gaap_DeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentDueToCompany" xlink:label="vir_MilestonePaymentDueToCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentReceived" xlink:label="vir_MilestonePaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_UnusedFundsReceivedInAdvance" xlink:label="vir_UnusedFundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FundsReceivedInAdvance" xlink:label="vir_FundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GrantAgreementEffectiveEndDate" xlink:label="vir_GrantAgreementEffectiveEndDate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BillAndMelindaGatesFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandSeventeenGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_NationalInstitutesOfHealthMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_HumanImmunodeficiencyVirusGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmountMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TuberculosisTBGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_HcmvVaccinePlatformGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementExpirationDateBeforeAmendment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementAmendedExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementAmendedDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantsAgreementAmendedDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentDueToCompany" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UnusedFundsReceivedInAdvance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_FundsReceivedInAdvance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementEffectiveEndDate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN" xlink:label="country_CN"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoGroupLimitedMember" xlink:label="vir_GlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiBiosciencesOffshoreLimitedMember" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_VaccineProgramMember" xlink:label="vir_VaccineProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfShareDevelopmentCosts" xlink:label="vir_PercentageOfShareDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AlnylamPharmaceuticalsIncMember" xlink:label="vir_AlnylamPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopmentProgramsExercisedByVirMember" xlink:label="vir_DevelopmentProgramsExercisedByVirMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopmentProgramsExercisedByBriiMember" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyGskAgreementMember" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BiologicalMaterialsMember" xlink:label="vir_BiologicalMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RockefellerUniversityMember" xlink:label="vir_RockefellerUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementTerminationDescription" xlink:label="vir_CollaborationAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstSiRNAProductMember" xlink:label="vir_FirstSiRNAProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MedImmuneLimitedLiabilityCompanyMember" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstSiRNAProductHBVMember" xlink:label="vir_FirstSiRNAProductHBVMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FairMarketValueOfCommonStockIssued" xlink:label="vir_FairMarketValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_XencorIncorporationMember" xlink:label="vir_XencorIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BriiAgreementMember" xlink:label="vir_BriiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EachInfectiousDiseaseSiRNAMember" xlink:label="vir_EachInfectiousDiseaseSiRNAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AlnylamAgreementMember" xlink:label="vir_AlnylamAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstInfectiousDiseaseProductMember" xlink:label="vir_FirstInfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfectiousDiseaseProductMember" xlink:label="vir_InfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AntibodyLicenseTransactionPrice" xlink:label="vir_AntibodyLicenseTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RockefellerAgreementMember" xlink:label="vir_RockefellerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HBVProgramMember" xlink:label="vir_HBVProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MedImmuneAgreementMember" xlink:label="vir_MedImmuneAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfluenzaAAndInfluenzaBMember" xlink:label="vir_InfluenzaAAndInfluenzaBMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenXencorAgreementMember" xlink:label="vir_TwoThousandNineteenXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCompany" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfluenzaAResearchProgramsMember" xlink:label="vir_InfluenzaAResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RangeOfRoyaltyPaymentToBeReceived" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_XencorAgreementsMember" xlink:label="vir_XencorAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InfluenzaAAndHBVResearchProgramsMember" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonePaymentToBeReceived" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AnnualLicenseMaintenanceFees" xlink:label="vir_AnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumSalesMilestonToPay" xlink:label="vir_MaximumSalesMilestonToPay"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentToCollaboratorResultingFromProgramOptionExercise" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltiesPaymentExpirationPeriod" xlink:label="vir_RoyaltiesPaymentExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProfitsAndLossesSharingPercentage" xlink:label="vir_ProfitsAndLossesSharingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeLowEndOfTheRange" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RangeOfRoyaltyPaymentToBePaid" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeHighEndOfTheRange" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateSalesMilestonePayments" xlink:label="vir_MaximumAggregateSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_UpfrontPaymentReceivable" xlink:label="vir_UpfrontPaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeConsiderationToBeReceived" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementTransactionPriceUpfrontFee" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementTransactionPriceConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ValueOfSharesTransferredToCollaborator" xlink:label="vir_ValueOfSharesTransferredToCollaborator"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationTypeAndPrograms" xlink:label="vir_CollaborationTypeAndPrograms"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OptionExerciseFeeReceived" xlink:label="vir_OptionExerciseFeeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeterminedTransactionPrice" xlink:label="vir_DeterminedTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_UpfrontFeePaid" xlink:label="vir_UpfrontFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumSharesToBeIssued" xlink:label="vir_MaximumSharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateSalesMilestonePayment" xlink:label="vir_MaximumAggregateSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumSalesMilestonePayment" xlink:label="vir_MaximumSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateMilestonePayments" xlink:label="vir_MaximumAggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePaymentsPaid" xlink:label="vir_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NumberOfAntibodiesToDevelop" xlink:label="vir_NumberOfAntibodiesToDevelop"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:label="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" xlink:label="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LicenseAgreementUpfrontPayment" xlink:label="vir_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_GlaxoGroupLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_PreliminaryCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBioParentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DefinitiveCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBiosciencesOffshoreLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_VaccineProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfShareDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_AlnylamPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_DevelopmentProgramsExercisedByVirMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_WuXiBiologicsLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKCollaborationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_DevelopmentProgramsExercisedByBriiMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyGskAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_BiologicalMaterialsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_RockefellerUniversityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTerminationDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstSiRNAProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_MedImmuneLimitedLiabilityCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstSiRNAProductHBVMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_FairMarketValueOfCommonStockIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_XencorIncorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BriiAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_EachInfectiousDiseaseSiRNAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_AlnylamAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PremiumReceivedOnSalePriceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstInfectiousDiseaseProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DevelopmentAndManufacturingCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfectiousDiseaseProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AntibodyLicenseTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_RockefellerAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HBVProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_MedImmuneAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndInfluenzaBMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandNineteenXencorAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCompany" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAResearchProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyXencorAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfRoyaltyPaymentToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_XencorAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndHBVResearchProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AnnualLicenseMaintenanceFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestonToPay" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PaymentToCollaboratorResultingFromProgramOptionExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesPaymentExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfUnitsOfAccount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ProfitsAndLossesSharingPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeLowEndOfTheRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfRoyaltyPaymentToBePaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeHighEndOfTheRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateSalesMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontPaymentReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceUpfrontFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="49" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="50" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="51" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="52" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="53" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ValueOfSharesTransferredToCollaborator" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="54" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="55" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Investments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="56" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationTypeAndPrograms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="57" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="58" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_DeterminedTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="59" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontFeePaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="60" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSharesToBeIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="61" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="62" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateSalesMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="63" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="64" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="65" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="66" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="67" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentsPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="68" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementRelatedCostsAndExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="69" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_NumberOfAntibodiesToDevelop" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="70" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="71" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="72" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="73" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_LicenseAgreementUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="74" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="75" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateCommercialSalesMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="76" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="77" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="78" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="79" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="80" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LaboratoryEquipmentMember" xlink:label="vir_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="vir_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LeaseArrangementContractualExpirationBeginningYear" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SamsungBiologicsCompanyLimitedMember" xlink:label="vir_SamsungBiologicsCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LeaseArrangementContractualExpirationEndingYear" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TenantImprovementAllowanceAggregate" xlink:label="vir_TenantImprovementAllowanceAggregate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingAndFinanceRentExpense" xlink:label="vir_OperatingAndFinanceRentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ObligationToPayCapacityReservation" xlink:label="vir_ObligationToPayCapacityReservation"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfEstimatedBatchProductionFees" xlink:label="vir_PercentageOfEstimatedBatchProductionFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationBeginningYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_SamsungBiologicsCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationEndingYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_WuXiBiologicsLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_TenantImprovementAllowanceAggregate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_OperatingAndFinanceRentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_ObligationToPayCapacityReservation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfEstimatedBatchProductionFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstAndSecondClosingsMember" xlink:label="vir_FirstAndSecondClosingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ThirdClosingMember" xlink:label="vir_ThirdClosingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TemporaryEquityAdditionalSharesAuthorized" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NumberOfClassOfStock" xlink:label="vir_NumberOfClassOfStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FirstAndSecondClosingsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_ThirdClosingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_TemporaryEquityAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_NumberOfClassOfStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedDuringPeriodWarrantExercised" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="vir_StockIssuedDuringPeriodWarrantExercised" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ExecutiveOfficerAndDirectorMember" xlink:label="vir_ExecutiveOfficerAndDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RestrictedStockPurchaseAgreementMember" xlink:label="vir_RestrictedStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OfferingPeriodEmployeeStockPurchasePlan" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="vir_ExecutiveOfficerAndDirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_RestrictedStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandSixteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_OfferingPeriodEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_RestrictedStockAwardsRSAMember" xlink:label="vir_RestrictedStockAwardsRSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="vir_RestrictedStockAwardsRSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_WarrantsToPurchaseCommonStockMember" xlink:label="vir_WarrantsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_EstimatedSharesIssuableUnderTheESPPMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_WarrantsToPurchaseCommonStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FirstPlanMember" xlink:label="vir_FirstPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_SecondPlanMember" xlink:label="vir_SecondPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="vir_FirstPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="vir_SecondPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="vir_ReconciliationOfEffectiveIncomeTaxRateTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncomeTaxesLineItems" xlink:label="vir_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncomeTaxesTable" xlink:label="vir_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_OR" xlink:label="stpr_OR"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:label="us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OperatingLossCarryforwardsLimitationOnUsePercentage" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TaxCreditCarryforwardsExpirationBeginningYear" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_OR" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_SwissFederalTaxAdministrationFTAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_OperatingLossCarryforwardsExpirationBeginningYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_OperatingLossCarryforwardsLimitationOnUsePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_TaxCreditCarryforwardsExpirationBeginningYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAgreementGrantAmount" xlink:label="vir_BusinessAgreementGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CashGrantAwarded" xlink:label="vir_CashGrantAwarded"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ValueStockIssuedGrantAgreement" xlink:label="vir_ValueStockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_StockIssuedGrantAgreement" xlink:label="vir_StockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BillMelindaGatesFoundationMember" xlink:label="vir_BillMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_BusinessAgreementEquityInvestmentCommitment" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_BusinessAgreementGrantAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_PreliminaryCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_CashGrantAwarded" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DefinitiveCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_ValueStockIssuedGrantAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_StockIssuedGrantAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BillMelindaGatesFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_BusinessAgreementEquityInvestmentCommitment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>49
<FILENAME>vir-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-02-28T16:08:30.9764+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" xlink:href="vir-20211231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" xlink:href="vir-20211231.xsd#StatementConsolidatedStatementsOfCashFlows2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="vir-20211231.xsd#StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="vir-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="vir-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="vir-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="vir-20211231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" xlink:href="vir-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="vir-20211231.xsd#DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="vir-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="vir_EquityInvestmentCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EquityInvestmentCurrent" xlink:label="vir_EquityInvestmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="vir_PresentValueOfOperatingLeaseLiabilities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PresentValueOfOperatingLeaseLiabilities" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfRevenue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" order="2" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vir_PaymentOfContingentConsideration" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_NoncashLeaseExpense" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vir_ProceedsFromRepaymentOfPromissoryNotes" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetsFairValueAdjustment" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_InitialFairValueOfDerivativeLiability" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="12" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="15" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="16" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_CommonStockIssuedInConnectionWithLicenseAgreement" order="17" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="18" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="20" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="21" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="22" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="23" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="24" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="25" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="26" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="28" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FailedSaleLeasebackTransactionProceedsFinancingActivities" xlink:label="vir_FailedSaleLeasebackTransactionProceedsFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ProceedsFromRepaymentOfPromissoryNotes" xlink:label="vir_ProceedsFromRepaymentOfPromissoryNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock" xlink:label="vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_InitialFairValueOfDerivativeLiability" xlink:label="vir_InitialFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_CommonStockIssuedInConnectionWithLicenseAgreement" xlink:label="vir_CommonStockIssuedInConnectionWithLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" order="2" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_ResearchAndDevelopmentExpensesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_MilestonePayable" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_PayrollAndRelatedExpensesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="9" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ResearchAndDevelopmentExpensesCurrent" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_MilestonePayable" xlink:label="vir_MilestonePayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_PayrollAndRelatedExpensesCurrent" xlink:label="vir_PayrollAndRelatedExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="8" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="vir_DeferredTaxLiabilitiesRightOfUseAssets" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="vir_DeferredTaxAssetsLeaseLiabilities" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20211231.xsd#vir_DeferredTaxAssetsLeaseLiabilities" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563450184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 22, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vir Biotechnology, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001706431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,303,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-39083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2730369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">499 Illinois Street, Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">906-4324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant&#8217;s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant&#8217;s fiscal year ended December 31, 2021.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Redwood City, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559584760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 347,815<span></span>
</td>
<td class="nump">$ 436,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">217,182<span></span>
</td>
<td class="nump">300,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents, current</a></td>
<td class="nump">8,594<span></span>
</td>
<td class="nump">7,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivable from collaboration</a></td>
<td class="nump">773,079<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_EquityInvestmentCurrent', window );">Equity Investment Current</a></td>
<td class="nump">143,148<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">73,003<span></span>
</td>
<td class="nump">27,511<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,562,821<span></span>
</td>
<td class="nump">772,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">33,287<span></span>
</td>
<td class="nump">33,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">16,937<span></span>
</td>
<td class="nump">16,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">42,834<span></span>
</td>
<td class="nump">17,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="nump">87,220<span></span>
</td>
<td class="nump">61,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash and cash equivalents, noncurrent</a></td>
<td class="nump">7,006<span></span>
</td>
<td class="nump">6,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">201,388<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">2,775<span></span>
</td>
<td class="nump">8,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,954,268<span></span>
</td>
<td class="nump">918,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,521<span></span>
</td>
<td class="nump">5,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">236,512<span></span>
</td>
<td class="nump">76,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">98,209<span></span>
</td>
<td class="nump">6,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration, current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">341,242<span></span>
</td>
<td class="nump">99,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">3,815<span></span>
</td>
<td class="nump">3,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">133,561<span></span>
</td>
<td class="nump">66,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, noncurrent</a></td>
<td class="nump">22,822<span></span>
</td>
<td class="nump">25,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">18,439<span></span>
</td>
<td class="nump">3,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,540<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">522,419<span></span>
</td>
<td class="nump">201,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2021 and 2020, respectively; no shares issued and outstanding as of December 31, 2021 and 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2021 and 2020, respectively; 127,416,740 and 107,648,925 shares issued and outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,571,535<span></span>
</td>
<td class="nump">1,385,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,099)<span></span>
</td>
<td class="num">(1,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(138,600)<span></span>
</td>
<td class="num">(667,184)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">1,431,849<span></span>
</td>
<td class="nump">716,852<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 1,954,268<span></span>
</td>
<td class="nump">$ 918,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_EquityInvestmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investment Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_EquityInvestmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559502984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">131,161,404<span></span>
</td>
<td class="nump">127,416,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">131,161,404<span></span>
</td>
<td class="nump">127,416,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563734280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 1,095,415<span></span>
</td>
<td class="nump">$ 76,368<span></span>
</td>
<td class="nump">$ 8,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">65,865<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">448,006<span></span>
</td>
<td class="nump">302,411<span></span>
</td>
<td class="nump">148,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">160,793<span></span>
</td>
<td class="nump">70,937<span></span>
</td>
<td class="nump">37,598<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">674,664<span></span>
</td>
<td class="nump">373,348<span></span>
</td>
<td class="nump">186,070<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">420,751<span></span>
</td>
<td class="num">(296,980)<span></span>
</td>
<td class="num">(177,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Change in fair value of equity investments</a></td>
<td class="nump">138,049<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Interest income</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">2,836<span></span>
</td>
<td class="nump">8,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(9,437)<span></span>
</td>
<td class="num">(4,467)<span></span>
</td>
<td class="num">(5,061)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">129,051<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="num">(3,450)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="nump">549,802<span></span>
</td>
<td class="num">(298,611)<span></span>
</td>
<td class="num">(174,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(21,218)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 528,584<span></span>
</td>
<td class="num">$ (298,665)<span></span>
</td>
<td class="num">$ (174,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
<td class="num">$ (5.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted</a></td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
<td class="num">$ (5.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">129,884,967<span></span>
</td>
<td class="nump">119,159,424<span></span>
</td>
<td class="nump">30,349,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">133,437,126<span></span>
</td>
<td class="nump">119,159,424<span></span>
</td>
<td class="nump">30,349,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 917,194<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember', window );">Contract Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">169,874<span></span>
</td>
<td class="nump">44,498<span></span>
</td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">8,347<span></span>
</td>
<td class="nump">9,123<span></span>
</td>
<td class="nump">7,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,747<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559526520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 528,584<span></span>
</td>
<td class="num">$ (298,665)<span></span>
</td>
<td class="num">$ (174,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) on investments</a></td>
<td class="num">(957)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax', window );">Amortization of actuarial loss</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax', window );">Adjustment to projected benefit obligations, net of tax</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="num">(650)<span></span>
</td>
<td class="num">(736)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">179<span></span>
</td>
<td class="num">(677)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 528,763<span></span>
</td>
<td class="num">$ (299,342)<span></span>
</td>
<td class="num">$ (175,270)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income loss pension and other postretirement benefit plans adjustment to projected benefit obligations net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459552427544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Follow-on Offering</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Follow-on Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Follow-on Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,910,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (179,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (193,836)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,858,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, net of issuance cost (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,202,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,910,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(179,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(193,836)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,858,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, net of issuance cost (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,202,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">636,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares', window );">Conversion of convertible preferred stock into common (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,112,733)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (636,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,112,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital', window );">Reclassification of warrant liability to additional paid-in capital</a></td>
<td class="nump">3,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Settlement of fractional shares from reverse stock split</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodValueLicenseAgreement', window );">Issuance of common stock in connection with a license agreement</a></td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesLicenseAgreement', window );">Issuance of common stock in connection with a license agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue', window );">Repayment of promissory notes, net of unvested shares</a></td>
<td class="nump">1,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares', window );">Repayment of promissory notes, net of unvested shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,390,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(174,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174,683)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">423,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">793,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(601)<span></span>
</td>
<td class="num">(368,519)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,648,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Issuance of convertible preferred stock, net of issuance cost (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,202,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital', window );">Reclassification of derivative liability to addition paid-in-capital</a></td>
<td class="nump">29,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesAchievementOfMilestone', window );">Issuance of common stock in connection with the achievement of a milestone (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodValueCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement</a></td>
<td class="nump">206,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,626,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant', window );">Issuance of common stock for cashless exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,214,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,986,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">4,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,618,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">27,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(298,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(298,665)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 716,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,385,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,278)<span></span>
</td>
<td class="num">(667,184)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">127,416,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,416,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodValueCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement</a></td>
<td class="nump">$ 85,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration', window );">Issuance of common stock to settle a contingent consideration</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration', window );">Issuance of common stock to settle a contingent consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">13,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">83,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">528,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528,584<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,431,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,571,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,099)<span></span>
</td>
<td class="num">$ (138,600)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">131,161,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,161,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability to additional paid In capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vested shares related to repayment of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of promissory notes related to vested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares cashless exercise of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in connection with a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for settlement of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued in connection with a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodValueCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in connection with a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodValueCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for settlement of contingent considerations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodValueLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued in connection with a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodValueLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock into common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock into common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459561402248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_InitialPublicOfferingCosts', window );">Initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CommonStockIssuanceCost', window );">Common stock issuance cost</a></td>
<td class="nump">$ 21,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vir_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ConvertiblePreferredStockIssuanceCost', window );">Convertible preferred stock, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommonStockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommonStockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ConvertiblePreferredStockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ConvertiblePreferredStockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_InitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_InitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vir_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vir_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459553270984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 528,584<span></span>
</td>
<td class="num">$ (298,665)<span></span>
</td>
<td class="num">$ (174,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,278<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">3,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">(Accretion of discounts) amortization of premiums on investments, net</a></td>
<td class="num">(244)<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">6,172<span></span>
</td>
<td class="nump">3,371<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Change in fair value of equity investments</a></td>
<td class="num">(138,049)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in estimated fair value of contingent consideration</a></td>
<td class="nump">91,848<span></span>
</td>
<td class="nump">38,394<span></span>
</td>
<td class="nump">8,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue', window );">Payment of contingent consideration in excess of acquisition date fair value</a></td>
<td class="num">(8,140)<span></span>
</td>
<td class="num">(15,752)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_InitialFairValueOfDerivativeLiability', window );">Initial fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in estimated fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,796<span></span>
</td>
<td class="num">(1,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in estimated fair value of convertible preferred stock warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">83,784<span></span>
</td>
<td class="nump">27,600<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred income taxes</a></td>
<td class="nump">15,186<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain from a sublease termination</a></td>
<td class="num">(4,844)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CommonStockIssuedInConnectionWithLicenseAgreement', window );">Common stock issued in connection with license agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivable from collaboration</a></td>
<td class="num">(773,079)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,665)<span></span>
</td>
<td class="num">(4,475)<span></span>
</td>
<td class="num">(4,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,483)<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
<td class="num">(1,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(790)<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued liabilities and other long-term liabilities</a></td>
<td class="nump">58,498<span></span>
</td>
<td class="nump">46,614<span></span>
</td>
<td class="nump">10,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(535)<span></span>
</td>
<td class="num">(3,684)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">92,041<span></span>
</td>
<td class="num">(7,043)<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(47,589)<span></span>
</td>
<td class="num">(190,941)<span></span>
</td>
<td class="num">(129,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(21,817)<span></span>
</td>
<td class="num">(6,549)<span></span>
</td>
<td class="num">(8,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(420,240)<span></span>
</td>
<td class="num">(403,841)<span></span>
</td>
<td class="num">(643,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">301,243<span></span>
</td>
<td class="nump">400,348<span></span>
</td>
<td class="nump">396,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from disposal of an asset held for sale</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(140,814)<span></span>
</td>
<td class="num">(9,862)<span></span>
</td>
<td class="num">(256,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">323,214<span></span>
</td>
<td class="nump">126,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration', window );">Proceeds from issuance of common stock in connection with a collaboration agreement</a></td>
<td class="nump">85,213<span></span>
</td>
<td class="nump">206,699<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">317,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FailedSaleLeasebackTransactionProceedsFinancingActivities', window );">Proceeds received from financing lease obligation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,248)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of principal on financing lease obligations</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ProceedsFromRepaymentOfPromissoryNotes', window );">Proceeds from repayment of promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">13,077<span></span>
</td>
<td class="nump">4,059<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock', window );">Cash paid in lieu of fractional shares related to reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">100,331<span></span>
</td>
<td class="nump">529,474<span></span>
</td>
<td class="nump">449,244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents</a></td>
<td class="num">(88,072)<span></span>
</td>
<td class="nump">328,671<span></span>
</td>
<td class="nump">63,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents at beginning of period</a></td>
<td class="nump">451,487<span></span>
</td>
<td class="nump">122,816<span></span>
</td>
<td class="nump">59,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">363,415<span></span>
</td>
<td class="nump">451,487<span></span>
</td>
<td class="nump">122,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NONCASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued liabilities</a></td>
<td class="nump">8,731<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_NonCashCommonStockIssuedForContingentConsideration', window );">Common stock issued for payment of contingent consideration</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering', window );">Conversion of preferred stock into common stock upon completion of initial public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">636,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities obtained in exchange of right-of-use asset</a></td>
<td class="nump">77,187<span></span>
</td>
<td class="nump">48,495<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance', window );">Advanced proceeds applied to convertible preferred stock issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone', window );">Reclassification of derivative liability to additional paid-in capital</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,245<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital', window );">Reclassification of preferred stock warrant liability to additional paid-in capital</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">347,815<span></span>
</td>
<td class="nump">436,575<span></span>
</td>
<td class="nump">109,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents, current</a></td>
<td class="nump">8,594<span></span>
</td>
<td class="nump">7,993<span></span>
</td>
<td class="nump">6,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash and cash equivalents, noncurrent</a></td>
<td class="nump">7,006<span></span>
</td>
<td class="nump">6,919<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 363,415<span></span>
</td>
<td class="nump">$ 451,487<span></span>
</td>
<td class="nump">$ 122,816<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advanced proceeds applied to convertible preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid in lieu of fractional shares in reverse split of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommonStockIssuedInConnectionWithLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued in connection with license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommonStockIssuedInConnectionWithLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock into common stock upon completion of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FailedSaleLeasebackTransactionProceedsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow received in a failed sale-leaseback recognized in financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FailedSaleLeasebackTransactionProceedsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in payment of contingent consideration in excess of acquisition date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_InitialFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_InitialFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NonCashCommonStockIssuedForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash common stock issued for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NonCashCommonStockIssuedForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Common Stock in Connection With Collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProceedsFromRepaymentOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from repayment of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProceedsFromRepaymentOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification&#8203; of derivative liability&#8203; to additional paid-&#8203;in capital upon achievement of development milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of preferred stock warrant liability to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559342792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Organization </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc. (&#8220;Vir&#8221; or the &#8220;Company&#8221;) is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Its current pipeline consists of sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#174;) and other product candidates targeting coronavirus disease 2019 (&#8220;COVID-19&#8221;), hepatitis B virus (&#8220;HBV&#8221;), influenza A virus, and human immunodeficiency virus (&#8220;HIV&#8221;). Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the U.S. Food and Drug Administration (the "FDA") granted an Emergency Use Authorization (&#8220;EUA&#8221;) for sotrovimab for the early treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and at high risk for progression to severe COVID-19, including hospitalization or death. The Company also received a positive scientific opinion from the Committee for Human Medicinal Products in the European Union (&#8220;EU&#8221;) for sotrovimab. In December 2021, the European Commission granted marketing authorization to Xevudy&#174; (sotrovimab) in the EU for the treatment of adults and adolescents at increased risk of progressing to severe COVID-19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 10, 2019, the Company completed its initial public offering (&#8220;IPO&#8221;) of its common stock. In connection with its IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,142,858</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at an initial offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. As a result of the IPO, the Company received approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds, after deducting underwriting discounts, commissions and offering expenses. At the closing of the IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88,112,733</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of outstanding convertible preferred stock were automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88,112,733</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock and a warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244,444</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock was converted into a warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244,444</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Follow-On Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 10, 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,214,285</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock pursuant to a registration statement on Form S-1 (File No. 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) (File No. 333-239747) (collectively, the &#8220;Registration Statements&#8221;). The Registration Statements became effective on July 7, 2020. The price of the shares sold in the follow-on offering was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and the Company received total gross proceeds from the offering of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">345.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. After deducting underwriting discounts and commissions of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, the net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">323.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;), under which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, through or to Cowen, acting as sales agent or principal. The shares will be offered and sold under the Company&#8217;s shelf registration statement on Form S-3 (the &#8220;S-3 Registration Statement&#8221;) and a related prospectus filed with the Securities and Exchange Commission on November 10, 2020. The Company will pay Cowen a commission of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares have been issued under the Sales Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Need for Additional Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although the Company recorded net income for the year ended December 31, 2021, it has otherwise incurred accumulated net losses since inception. The Company expects its earnings to be volatile and may continue to incur net losses over the next several years. As of December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Management expects to incur additional losses in the future to conduct research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company had, excluding restricted cash, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">909.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of cash, cash equivalents, and investments as of December 31, 2021, and after excluding the equity investment in Brii Biosciences Limited ("Brii Bio Parent"), the Company had </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">766.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Based on the Company&#8217;s current operating plan, management believes that the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">766.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021 will be sufficient to fund its operations through at least the next 12 months from the issuance date of these consolidated financial statements.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559753976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. The consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The functional currency of the Company&#8217;s foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. Transaction gains and losses are included in other income (expense), net on the consolidated statements of operations, and were immaterial for the years ended December 31, 2021, 2020 and 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company operates as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has implemented a number of plans and policies designed to address and mitigate the impact of the ongoing COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will continue to have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company&#8217;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although the Company received EUA, temporary authorization or marketing approval for sotrovimab (under the brand name Xevudy&#174;), it is still subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its other product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of sotrovimab and other product candidates and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its other product candidates, it will be unable to generate significant revenue from product sales or maintain profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the consolidated balance sheets. As of December 31, 2021 and 2020, the Company has no off-balance sheet concentrations of credit risk.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#8217;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#8217;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#8217; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#8217; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. There was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> allowance for losses on available-for-sale debt securities attributable to credit risk for the years ended December 31, 2021 and 2020.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments include available-for-sale debt securities and equity investments, which are carried at estimated fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Available-for-Sale Debt Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. The cost of securities sold is based on the specific identification method.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Accounting Standards Update ("ASU") No. 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, the Company measures its investment in equity securities at fair value at each reporting date based on the market price at period end if it has a readily determinable fair value. Otherwise, the investments in equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer unless the Company has significant influence or control over the investee. Changes in fair value resulting from observable price changes are presented as change in fair value of equity investments </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and changes in fair value resulting from foreign currency translation are included in other income (expense), net </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on the consolidated statements of operations.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e8ebc668-f14c-4720-8b72-2366a378afeb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. No material impairment losses have been incurred to date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquired Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s intangible assets were acquired via business combinations or asset acquisitions. Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (&#8220;IPR&amp;D&#8221;) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2021, there have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairments. For IPR&amp;D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses. IPR&amp;D assets acquired as part of an asset acquisition are recorded at cost and expensed immediately if they have no alternative future uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets acquired are initially recognized at their fair value at the acquisition date. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b3b3c2e2-807e-47e2-9909-7b52a03e1e68;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration, License and Contract Revenue</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company recognizes revenue when the Company&#8217;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. When the Company is considered an agent in elements of collaboration arrangements within the scope of ASC 808, it records its share of collaboration revenue in the period in which such sales occur. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the revenue reported by the Company's collaboration partners, net of cost of goods sold and allowable expenses (e.g. medical affairs, selling and marketing expenses) in the period. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partner, including revenue from the sale of the product, and costs incurred for development and sales activities. For the periods covered in the financial statements presented, there have been no material changes to prior period estimates of revenues and expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#8217;s intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#8220;SSP&#8221;). The Company estimates the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Grant Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, research and development expenses have related primarily to discovery efforts and preclinical and clinical development of product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include expenses related to license and collaboration agreements; contingent consideration from business acquisitions; personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel contributing to research and development activities; expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and other allocated expenses, including expenses for rent, facilities maintenance, and depreciation and amortization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. Upfront payments and research and development milestone payments made in connection with acquired license or product rights are expensed as incurred, provided that they do not relate to a regulatory approval milestone or assets acquired in a business combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s expense accruals for clinical trials and manufacturing are based on estimates of contracted services provided by third-party vendors not yet billed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of its outstanding obligations to those third parties as of the period end. The accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. The Company obtains information regarding unbilled services directly from these service providers and performs procedures to support its estimates based on its internal understanding of the services provided to date. However, the Company may also be required to estimate these services based on information available to its internal clinical and manufacturing administrative staff if such information is not able to be obtained timely from its service providers.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes stock-based compensation to employees and non-employees over the requisite service period based on the grant-date fair value of the awards. The Company calculates the estimated fair value of stock options and employees' purchase rights under the Company's 2019 employee stock purchase plan ("ESPP") using the Black-Scholes valuation model, which requires the use of subjective assumptions including volatility and expected term, among others. The fair value of restricted stock awards ("RSAs") and restricted stock units ("RSUs") is based on the market value of the Company's common stock on the date of grant. Stock-based compensation is recognized using the straight-line method for awards that vest only upon the employee&#8217;s or non-employee&#8217;s continued service to the Company. Stock-based compensation expense of the employees' purchase rights under the ESPP is recognized over the offering period. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisitions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various milestones are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Embedded Derivatives</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the consolidated statements of operations based on the nature of the related contingencies.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expense or selling, general and administrative expenses based on the nature of the relevant underlying activities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Otherwise, changes in fair values are recorded within other income (expense), net.</span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with ASU No. 2016-02 (Topic 842), Leases, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. On the lease commencement date, the Company estimates and includes in its lease payments any lease incentive amounts based on future events when (1) the events are within the Company&#8217;s control and (2) the event triggering the right to receive the incentive is deemed reasonably certain to occur. If the lease incentive received is greater or less than the amount recognized at lease commencement, the Company recognizes the difference as an adjustment to right-of-use asset and/or lease liability, as applicable.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the implicit rate in the Company's leases is generally unknown, the Company uses an incremental borrowing rate estimated based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating its estimated incremental borrowing rates, the Company considers its credit risk, the lease term, the total lease payments and the impact of collateral, as necessary. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. ROU assets and lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. Rent expense for the Company's operating leases is recognized on a straight-line basis within operating expenses over the reasonably assured lease term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the asset and liability method of accounting for income taxes. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating losses and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as any related net interest and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Income (Loss) Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per common share is computed by dividing the net income by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">New Accounting Pronouncement Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, the Financial Accounting Standards Board ("FASB") issued ASU No. 2021-10, Government Assistance (Topic 832) (&#8220;ASU 2021-10&#8221;), which adds certain disclosure requirements with respect to government assistance, including (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance on financial statements. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2021-10 may have on its consolidated financial statements and related disclosures</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559762376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements </span></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of the Company&#8217;s financial instruments, including receivable from collaboration, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Equivalents and Available-for-Sale Debt Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company&#8217;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.3%;"/>
        <td style="width:1.024%;"/>
        <td style="width:9.81%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.21%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.21%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.21%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.21%;"/>
        <td style="width:0.646%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">345,098</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">345,098</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">419,442</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">872</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">418,570</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">764,540</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">872</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">763,668</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1) Includes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">15.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> of restricted cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.295%;"/>
        <td style="width:1.044%;"/>
        <td style="width:9.829%;"/>
        <td style="width:1.044%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.229%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.044%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.229%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.044%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.04%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.044%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.229%;"/>
        <td style="width:0.646%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">421,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">421,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300,201</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722,036</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722,121</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-2.599%;padding-left:2.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1) Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">14.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million of restricted cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities are presented within prepaid expenses and other current assets, and other assets in the consolidated balance sheets. Accrued interest receivable amounted to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively. The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t write off any accrued interest receivable during the years ended December 30, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized total net unrealized loss of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and net unrealized gain of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in accumulated other comprehensive income (loss) as of December 31, 2021 and 2020, respectively. The gross unrealized losses related to U.S. government treasuries as of December 31, 2021 were due to changes in interest rates. As of December 31, 2021 and 2020, there were no investments that have been in a continuous unrealized loss position for longer than 12 months. The Company determined that the gross unrealized losses on our investments as of December 31, 2021 were temporary in nature. The Company currently does not intend, and it is highly unlikely that it will be required, to sell these securities before recovery of their amortized cost basis. As of December 31, 2021, no securities have contractual maturities of longer than</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company's equity investment consisted solely of ordinary shares of Brii Bio Parent. The Company acquired the securities as partial consideration for entering into the collaboration, option and license agreement (the &#8220;Brii Agreement&#8221;) with Brii Bio Parent and Brii Biosciences Offshore Limited (&#8220;Brii Bio&#8221;) in May 2018. The Company concluded it does not have a controlling interest or significant influence over Brii Bio based on its ownership percentage and other factors. See further discussion in Note 7&#8212;Collaboration and License Agreements. In July 2021, Brii Bio Parent completed its initial public offering ("Brii Bio Parent IPO") on the Stock Exchange of Hong Kong Limited, prior to which the securities were accounted for as equity securities without a readily determinable fair value. Upon the completion of the Brii Bio Parent IPO, the securities were considered to be marketable equity securities and subsequently remeasured at fair value at each reporting date. The Company classifies its equity investment in Brii Bio Parent as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market. As of December 31, 2021, the Company remeasured the equity investment at a fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. For the year ended December 31, 2021, the Company recognized an unrealized gain of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as other income in the consolidated statement of operations, net of an unrealized loss of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to foreign currency translation for the period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration includes potential milestone payments in connection with the acquisitions of Humabs Biomed SA (&#8220;Humabs&#8221;) and TomegaVax, Inc. (&#8220;TomegaVax&#8221;). See further discussion in Note 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquisitions. The Company classifies the contingent consideration as Level 3 financial liabilities within the fair value hierarchy as of December 31, 2021 and 2020.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical, regulatory, and commercial milestone payments based on the assessment of the likelihood and estimated timing that certain milestones would be achieved. In December 2021, the Company achieved the regulatory milestone of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to sotrovimab. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of Decemb</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">er 31, 2021, the Company calculated the estimated fair value of the remaining clinical and regulatory milestones related to the HBV product using the following significant unobservable inputs: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.179%;"/>
        <td style="width:2.44%;"/>
        <td style="width:32.381%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Range<br/>(Weighted-Average)1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1) Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the commercial milestones, the Company used a Monte Carlo simulation because of the availability of a discrete revenue forecast. During the year ended December 31, 2021, the Company achieved the specified sales milestones totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to sotrovimab</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. A</span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s of December 31, 2021, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecast, as well as the following significant unobservable inputs f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or the remaining commercial milestones related to the HBV product: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.179%;"/>
        <td style="width:2.44%;"/>
        <td style="width:32.381%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. As of December 31, 2021 and 2020, the estimated fair value of the contingent consideration related to the Humabs acquisition was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, with changes in the estimated fair value recorded in research and development expense, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and selling, general and administrative expense in the consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the TomegaVax acquisition was determined by using a Monte Carlo simulation model which included estimates of both the probability and timing to achieve the required per share price of the Company&#8217;s common stock, and incorporates assumptions as to expected volatility and discount rate. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">definition of an embedded derivative financial instrument. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company achieved one of the milestones related to a specified per-share price of its common stock resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payable to the former TomegaVax&#8217;s stockholders which was paid in July 2021. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:</span></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.179%;"/>
        <td style="width:2.44%;"/>
        <td style="width:32.381%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the estimated fair value of the contingent consideration related to the TomegaVax acquisition was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, with changes in the estimated fair value recorded in other income (expense), net in the consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the Humabs and TomegaVax acquisitions involves significant estimates and assumptions which give rise to measurement uncertainty.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level 3 financial liabilities (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.644%;"/>
        <td style="width:2.097%;"/>
        <td style="width:1.282%;"/>
        <td style="width:16.112%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contingent<br/>Consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,974</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91,848</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of contingent consideration to accrued liabilities upon achievement of the Humabs milestones</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of contingent consideration upon achievement of the TomegaVax milestone</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,822</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459653152088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Acquisitions </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisition of TomegaVax</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2016, the Company entered into an agreement and plan of merger (&#8220;TomegaVax Merger Agreement&#8221;) to acquire all of the equity interests of TomegaVax. The primary asset purchased in the acquisition was an in-process cytomegalovirus vector-based vaccine platform for use in HBV, HIV, and tuberculosis. The acquisition was accounted for as an asset purchase. The Company recorded the cash purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in research and development expenses and incurred transaction costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2016.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the entry into the TomegaVax Merger Agreement, the Company also entered into a letter agreement with TomegaVax (the &#8220;TomegaVax Letter Agreement&#8221;), which provides for certain payments to TomegaVax&#8217;s former stockholders before September 2024, in each case so long as the Company is continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million if the per-share price of the Company&#8217;s publicly traded common stock, or implied price per-share of the Company&#8217;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#8217;s clinical development at the time of the relevant event triggering the payment.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The share price of the Company&#8217;s publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Company&#8217;s common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of the Company&#8217;s common stock, at the discretion of the Company&#8217;s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company achieved </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the milestones related to the specified per-share price of its common stock, which resulted in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payable to TomegaVax&#8217;s former stockholders. In July 2021, the Company made the milestone payment to the former TomegaVax stockholders through a combination of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash and the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,737</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The remaining milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate will be triggered if (i) the per-share price of the Company&#8217;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Company&#8217;s clinical development at the time of the relevant event triggering the payment and/or (ii) the per-share price of the Company&#8217;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the future milestone payments contain net settlement provisions and therefore, they were required to be accounted for as embedded derivatives under the relevant accounting guidance. As of December 31, 2021, the fair value of the embedded derivative was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and is included in the contingent consideration liability on the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisition of Humabs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2017, the Company acquired all of the outstanding equity of Humabs, a private Swiss company, which discovers and develops monoclonal antibodies (&#8220;mAbs&#8221;) derived from individuals whose immune systems have successfully responded to major diseases. The Company acquired all of Humabs&#8217; rights, title and interest in and to substantially all of the assets of Humabs except for rights under certain license agreements with third parties. The Company is obligated to pass through to the former Humabs shareholders any amounts received by Humabs under such license agreements, net of any program expenses. The transaction was accounted for as an acquisition of a business. The consideration paid consisted of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,666,656</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, valued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of the date of the transaction, to former Humabs shareholders. In addition to the cash payment and issuance of common stock to the former Humabs shareholders at the acquisition date, the Company also agreed to pay additional amounts in cash upon the achievement of specified milestone events: (i) up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the achievement of clinical, regulatory and commercial milestones for an HBV product; and (ii) up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the achievement of clinical, regulatory and commercial milestones for another product, which the Company elected as a severe acute respiratory syndrome coronavirus 2 (&#8220;SARS-CoV-2&#8221;) product, or sotrovimab.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, the Company achieved </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the specified clinical milestones for the HBV product and sotrovimab totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, the Company achieved the specified regulatory milestone of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and sales milestones totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to sotrovimab. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the remaining contingent consideration was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company paid the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million milestone and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million milestone in January and February 2022, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The acquired developed technologies that have associated patents issued are classified as finite-lived intangible assets and are amortized on a straight-lined basis over their estimated remaining useful lives, generally between </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d240cfd0-0689-460a-ba7b-6620318af392;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company also acquired indefinite-lived intangible assets consisting of IPR&amp;D. These assets will not be amortized until regulatory approval is obtained in a major market. At that time, the Company will determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned or otherwise impaired, the related IPR&amp;D assets will be written-off and an impairment charge recorded. As of December 31, 2021, there have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairments related to the IPR&amp;D assets. The estimated fair value of the intangible assets was determined using the replacement cost method. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the goodwill is expected to be deductible for income tax purposes.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559246024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Goodwill and Intangible Assets </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> represents the excess of the purchase price over the estimated fair value of the net assets acquired from Humabs. The Company tests goodwill for impairment on an annual basis or sooner, if deemed necessary. There was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the carrying amount of the Company&#8217;s finite-lived intangible assets (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.615%;"/>
        <td style="width:1.181%;"/>
        <td style="width:1.803%;"/>
        <td style="width:11.888%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.181%;"/>
        <td style="width:1.803%;"/>
        <td style="width:10.768%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.181%;"/>
        <td style="width:1.02%;"/>
        <td style="width:16.377%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining Useful</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Developed technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract-based intangible asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">502</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">502</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.9</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,114</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,581</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less impairment of intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,089</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets are carried at cost less accumulated amortization. The contract-based intangible asset resulted from the product approval of a sublicensed intellectual property right in December 2020. The intellectual property right was previously accounted for as IPR&amp;D. Amortization expense related to finite-lived intangible assets, included in research and development expenses on the consolidated statements of operations, totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, like that of property and equipment. During the third quarter of 2020, as a result of the availability of other research and analytics platforms, the Company abandoned certain of its acquired developed technologies and concluded that the full remaining book values of the assets were impaired. Therefore, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was written off as an impairment charge, which was classified as research and development expenses during 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on the finite-lived intangible assets recorded as of December 31, 2021, the estimated future amortization expense for the next five years is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.14%;"/>
        <td style="width:1.758%;"/>
        <td style="width:2.671%;"/>
        <td style="width:17.352%;"/>
        <td style="width:1.078%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">532</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">260</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indefinite-Lived Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company had indefinite-lived intangible assets of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, related to the purchased IPR&amp;D from the Humabs acquisition. In December 2020, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was reclassed as a finite-lived intangible asset due to the product approval of a sublicensed intellectual property right. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment losses have been recorded for the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559298280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAgreementsDisclosureTextBlock', window );">Grant Agreements</a></td>
<td class="text"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Grant Agreements </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bill &amp; Melinda Gates Foundation Grants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Campylo/EPEC/EAEC Grant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the Company&#8217;s acquisition of Humabs in August 2017, the Company acquired a grant agreement with the Bill &amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the &#8220;2017 Grant&#8221;). The 2017 Grant supported the Company&#8217;s discovery, characterization and selection of human monoclonal antibodies with pre-clinical efficacy against three enteric pathogens responsible for life-threatening diarrhea in neonates. The 2017 Grant expired on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 31, 2019</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that were related to future research activities were deferred and recognized as revenue when the donor-imposed conditions were met, which was as the research and development activities were performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HIV Grant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 26, 2018, the Company entered into a grant agreement with the Bill &amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for its HIV program (the &#8220;HIV Grant&#8221;). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the parties amended the HIV Grant under which the Company was awarded a supplemental grant of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_aeb0c2d2-3251-4237-b9b3-110fc85a87f2;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 2021</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the parties further amended the agreement under which the grant term was extended from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 31, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless earlier terminated by the Bill &amp; Melinda Gates Foundation for the Company&#8217;s breach, failure to progress the funded project, in the event of the Company&#8217;s change of control, change in the Company&#8217;s tax status, or significant changes in the Company&#8217;s leadership that the Bill &amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company achieved a specified milestone under the HIV Grant which triggered a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payment from the Bill &amp; Melinda Gates Foundation. As of December 31, 2020, the Company recorded a receivable, which is included within prepaid expenses and other current assets, and current portion of deferred revenue for the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which was subsequently received in January 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, under HIV Grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Tuberculosis (&#8220;TB&#8221;) Grant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 16, 2018, the Company entered into a grant agreement with the Bill &amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for its TB program (the &#8220;TB Grant&#8221;). The parties amended the agreement in May 2020, in June 2021 and in December 2021 to extend the grant term. The TB Grant will remain in effect until </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless earlier terminated by the Bill &amp; Melinda Gates Foundation for the Company&#8217;s breach, failure to progress the funded project, in the event of the Company&#8217;s change of control, change in the Company&#8217;s tax status, or significant changes in the Company&#8217;s leadership that the Bill &amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unused funds received in advance and previously recorded as deferred revenue within accrued and other liabilities. As of December 31, 2021 and 2020, the Company has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, under TB Grant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HCMV-Vaccine Platform Grant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 5, 2021, the Company entered into a grant agreement with the Bill &amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to support the manufacturing and clinical activities of its HIV and TB vaccine programs. This grant agreement will remain in effect until </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 30, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unless earlier terminated by the Bill &amp; Melinda Gates Foundation for the Company&#8217;s breach, failure to progress the funded project, in the event of the Company&#8217;s change of control, change in the Company&#8217;s tax status, or significant changes in the Company&#8217;s leadership that the Bill &amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under this grant agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">National Institutes of Health</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the Company&#8217;s acquisition of TomegaVax in September 2016, the Company acquired grant agreements related to TomegaVax&#8217;s research effort in infectious diseases and cancer that entitled them to several awards under the Small Business Innovation Research Program from the National Institutes of Health (&#8220;NIH&#8221;). Through July 2021, the Company has acquired or been awarded grants from NIH totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. These grants were cost plus fixed fee agreements in which the Company was reimbursed for its direct and indirect costs. Only costs that were allowable under certain government regulations and NIH&#8217;s supplemental policy and procedure manual may be claimed for reimbursement, subject to government audit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant agreements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559771080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Collaboration and License Agreements </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration Agreements with GSK</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2020 GSK Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 9, 2020, the Company, Glaxo Wellcome UK Limited and Beecham S.A. (referred to individually and together, as &#8220;GSK&#8221;) entered into a definitive collaboration agreement under the terms set forth in the preliminary collaboration agreement entered into by the Company and certain GSK entities in April 2020 (the &#8220;2020 Preliminary Agreement&#8221;) (such definitive collaboration agreement, the &#8220;2020 GSK Agreement&#8221;). Concurrently with the execution of the 2020 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#8220;2020 Stock Purchase Agreement&#8221;) with Glaxo Group Limited (&#8220;GGL&#8221;), an affiliate of GSK, under which GGL purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,626,027</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock on April 29, 2020, at a price per share of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.73</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. After receipt of antitrust clearance on April 22, 2020, the 2020 Preliminary Agreement became effective as of April 29, 2020, which was also the closing date for the associated 2020 Stock Purchase Agreement between the parties (&#8220;Effective Date&#8221;). Under the terms of the 2020 GSK Agreement, the Company and GSK agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses (the &#8220;Antibody Program&#8221;); (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses (the &#8220;Vaccine Program&#8221;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses (the &#8220;Functional Genomics Program&#8221;).</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the Effective Date, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee (&#8220;JSC&#8221;). The Company is primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK is primarily responsible for the commercialization activities for the Antibody Program (except in connection with sales of antibody products licensed to WuXi Biologics (Hong Kong) Limited in greater China), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. Subject to an opt-out mechanism, the parties share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with the Company bearing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs for the antibody products, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs for the vaccine products, and equal sharing of such costs for the functional genomics products.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a collaboration product-by-collaboration product basis, each party has the one-time right, at specified points in development, to opt-out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party pays to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, the Company has a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">co-promotion </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">right for such antibody product in the United States, under which the Company has the right to perform up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of details in connection with such antibody product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2020 GSK Agreement will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The 2020 GSK Agreement superseded and replaced the 2020 Preliminary Agreement between the parties. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, Beecham S.A. assigned and transferred all its rights, title, interest, and benefit in the 2020 GSK Agreement to GlaxoSmithKline Biologicals S.A., including all its rights to bring claims under such agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2020 GSK Agreement and 2020 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">206.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36.70</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on the date of execution of the 2020 Preliminary Agreement and 2020 Stock Purchase Agreement and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2020 GSK Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2020 GSK Agreement contained </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> units of account: (i) the license granted to GSK under the Antibody Program (the &#8220;Antibody License&#8221;); (ii) the research and development activities (including clinical manufacturing) under the Antibody Program; (iii) the research and development activities under the Vaccine Program; and (iv) the research and development activities under the Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2020 GSK Agreement are performance obligations with a customer. The Company determined that the Antibody License is within the scope of ASC 606 and accordingly, accounted for the Antibody License as a distinct performance obligation under ASC 606. The Antibody License is a functional intellectual property and is distinct from the associated research and development activities to be performed under the program due to its significant standalone functionality. All other elements of the 2020 GSK Agreement including the research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price for the Antibody License at inception was determined to be $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, representing the premium on the sale of common stock to GSK. The Company determined that GSK can benefit from the Antibody License at the time of grant and therefore, the related performance obligation is satisfied at a point in time. As such, the Company recognized the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as contract revenue during the second quarter of 2020. Additionally, the Company is entitled to consideration from GSK related to profit and loss sharing arrangements (including royalties) contingent upon future sales of collaboration products under the Antibody Program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The remaining units of account of the 2020 GSK Agreement were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#8217;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to, based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the products under the Vaccine and Functional Genomics Programs will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 2021, the FDA granted an EUA in the United States for sotrovimab, the first collaboration product under the Antibody Program. As the lead party for all commercialization activities, GSK incurs all of the sales and marketing expenses and is the principal on sales transactions with third parties. As the Company is the agent under the 2020 GSK Agreement, the Company recognizes its contractual share of the profit-sharing amounts or royalties (in case of an opt-out) as revenue, net of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost of sales and allowable expenses (including distribution, selling, and marketing expenses) in the period the sale occurs. During the year ended December 31, 2021, the Company recorded its share of net profit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">917.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as collaboration revenue in the consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs associated with co-development activities performed under the agreement are included in research and development expenses on the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. Under the 2020 GSK Agreement, the Company recognized additional net research and development expenses of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Expanded GSK Collaboration</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 14, 2021, the Company and GSK entered into a binding preliminary collaboration agreement (the &#8220;2021 </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preliminary Agreement&#8221;), under which the parties agreed to expand the 2020 GSK Agreement to collaborate on </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> separate programs: (1) a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus (the &#8220;Influenza Program&#8221;), excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties&#8217; current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses (the &#8220;Expanded Functional Genomics Program&#8221;); and (3) additional programs to develop neutralizing mAbs directed to up to three non-influenza target pathogens selected by GSK (the &#8220;Selected Pathogens&#8221; and such programs, the &#8220;Additional Programs&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrently with the execution of the 2021 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#8220;2021 Stock Purchase Agreement&#8221;) with GGL under which GGL agreed to purchase shares of the Company&#8217;s common stock for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The consummation of the transactions under each of the 2021 Preliminary Agreement and the 2021 Stock Purchase Agreement were subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which expiration was effective on March 24, 2021. The 2021 Preliminary Agreement and 2021 Stock Purchase Agreement consummated on March 25, 2021, which the Company used as the measurement date for accounting purposes. On March 31, 2021, the Company closed the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,924,927</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock to GGL.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Preliminary Agreement was superseded on May 18, 2021 upon execution of the definitive collaboration agreement (the &#8220;2021 GSK Agreement&#8221;, or collectively with the 2021 Preliminary Agreement, the &#8220;2021 GSK Collaboration&#8221;). The material terms of the 2021 GSK Agreement, including the promised goods and services, are discussed below and is consistent with those of the 2021 Preliminary Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2021 GSK Collaboration, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the effective date. Under the Influenza Program, the parties will collaborate to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of influenza, including the Company&#8217;s influenza mAbs (with respect to VIR-2482, only if GSK exercises its option). The Company may conduct the development and clinical manufacturing activities for VIR-2482 up to the completion of a Phase 2 clinical trial. Provided that the Company conducts and completes a Phase 2 clinical trial for VIR-2482, GSK will have the exclusive option to obtain exclusive rights to co-develop and commercialize VIR-2482 under the Influenza Program (the &#8220;VIR-2482 Option&#8221;). GSK will be the lead party for development, clinical and commercial manufacturing and commercialization activities for products under the Influenza Program (other than VIR-2482 unless and until GSK exercises the VIR-2482 Option, if applicable). The parties will mutually agree upon the allocation of responsibility for the development of products under the Expanded Functional Genomics Program, and for the development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK will be primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, upon execution of the definitive agreement, the Company will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The parties will share </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of all development costs in accordance with the budget for each of the collaboration programs (other than for the Selected Pathogens and VIR-2482, unless GSK exercises the VIR-2482 Option), with each party having the right to opt-out of its co-funding obligations at specified points in development. In such case, the party continuing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the program will pay to the opt-out party a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the opt-out is exercised. Following the exercise of an opt-out right by a party, the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any opt-out, the parties will also share </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of all profits and losses arising from any collaboration product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GSK was obligated to make an upfront payment to the Company of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of which became payable at the effective date of the 2021 Preliminary Agreement and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of which became payable following the execution of the 2021 GSK Agreement. If GSK exercises the VIR-2482 Option, GSK will pay the Company an option exercise fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million unless certain agreed product criteria for VIR-2482 are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a pre-defined regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the VIR-2482 Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to the Company of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2021 GSK Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements, under which certain elements are required to be accounted for under ASC 606 where the counterparty is a customer for a good or service that is a distinct unit of account. In addition, the 2021 GSK Agreement is considered a contract modification to the 2021 Preliminary Agreement and will be accounted for prospectively, as a termination of the 2021 Preliminary Agreement and commencement of a new contract. There was no impact to the accounting assessment of the original contract as no goods or services had been delivered to GSK, no performance obligations were satisfied, and accordingly, no contract revenue was recognized under ASC 606 prior to the execution of the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2021 GSK Collaboration and 2021 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52.70</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on March 25, 2021 and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2021 GSK Agreement contained the following units of account: (i) the VIR-2482 Option; (ii) three distinct rights granted to GSK related to the Selected Pathogens (each, a &#8220;Selected Pathogens Right&#8221;); (iii) the license and know-how to the next-generation mAbs under the Influenza Program (the &#8220;Next Gen License&#8221;); (iv) the research and development activities for next-generation mAbs under the Influenza Program; and (v) the research and development activities, including license rights and know-how, under the Expanded Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2021 GSK Agreement are performance obligations with a customer. The Company determined that the distinct performance obligations under ASC 606 consisted of (i) the Next Gen License and (ii) the three Selected Pathogens Rights, each representing a material right. All other elements of the 2021 GSK Agreement including the VIR-2482 Option, research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer. A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s of December 31, 2021, GSK had not exercised the VIR-2482 Option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price for the 2021 GSK Agreement included fixed consideration consisting of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront fee paid by GSK and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, representing the premium on the sale of common stock to GSK for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">259.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. All potential future milestones and other payments under the 2021 GSK Agreement are constrained since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The respective estimated SSP for each of the performance obligations was determined to allocate the transaction price. The estimated SSP of each performance obligation was determined using methods that considered relevant market </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">conditions, entity-specific factors and information about GSK, while maximizing the use of available observable inputs and using certain management assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital). For the Next Gen License, the Company determined that GSK can benefit from the license at the time the license is granted, and therefore, the related performance obligation is satisfied at a point in time. If any of the Selected Pathogens Rights </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">are exercised, the Company will evaluate the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">related promises to identify the performance obligations to be transferred and the timing of revenue recognition. If any of the Selected Pathogens Rights expire prior to being exercised, the Company will recognize any deferred revenue allocated to that right as revenue at the time of expiration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research and development activities for the next generation mAbs under the Influenza Program and the Expanded Functional Genomics Program were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#8217;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the related products will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon execution of the 2021 GSK Agreement, the Company granted the Next Gen License to GSK and therefore, recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as contract revenue in the second quarter of 2021. As of December 31, 2021, the total unrecognized transaction price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million is classified as current deferred revenue on the Company's consolidated balance sheet related to the remaining performance obligations, being the material rights resulting from the Selected Pathogens Rights, none of which have been exercised by GSK as of December 31, 2021. The Company expects the rights will be exercised, and thus, the corresponding deferred revenue will be recognized within the next 12 months from the balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs associated with co-development activities performed under the agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. During the year ended December 31, 2021, the Company recognized additional net research and development expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the 2021 GSK Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under both the 2020 GSK Agreement and the 2021 GSK Agreement, the Company has a receivable from collaboration of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">773.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Brii Biosciences</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2018, the Company entered into the Brii Agreement with Brii Bio Parent and Brii Bio pursuant to which the Company granted to Brii Bio, with respect to up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Company&#8217;s programs, an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau (collectively, the &#8220;China Territory&#8221;) for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection (the &#8220;Field of Use&#8221;). The Company&#8217;s HBV </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">small interfering ribonucleic acid (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8220;siRNA&#8221;) program being developed under the Amended Alnylam Agreement (described below) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. In partial consideration for the options granted by the Company to Brii Bio, Brii Bio Parent and Brii Bio granted the Company, with respect to up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of Brii Bio Parent&#8217;s or Brii Bio&#8217;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that the Company may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As partial consideration for the Company&#8217;s entry into the Brii Agreement, upon closing of Brii Bio Parent&#8217;s Series A preferred stock financing, the Company received ordinary shares equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#8217;s right to exercise one of its options for the Company&#8217;s HBV siRNA program, under the terms of the Amended Alnylam Agreement, the Company transferred to Alnylam Pharmaceuticals, Inc. ("Alnylam") a specified percentage of such equity consideration allocable to such program </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">under a share transfer agreement in February 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to programs for which Brii Bio exercises its options, Brii Bio will be required to pay the Company an option exercise fee for each such Vir program ranging from the</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> mid-single-digit millions</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">determined</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">based </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mid-single-digit millions</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per licensed program. Brii Bio also will pay royalties to the Company that range from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mid-teens to the high-twenties</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, as described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon exercise of each option for a Brii Bio program, the Company will be required to pay to Brii Bio an option exercise fee ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">low tens of millions</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, determined based on the commercial potential of the licensed program. The Company will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">low tens of millions</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, also determined based on the commercial potential of such program. The Company will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per licensed program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company is obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay the Company tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by the Company to Brii Bio, and by Brii Bio to the Company, on net sales range from mid-teens to high-twenties. Each party&#8217;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; written notice (if the terminating party has not exercised an option for such program) or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#8217;s uncured material breach on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; notice following failure to make payment).</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From May 2018 until July 2021, the Brii Bio Parent IPO closing date, Brii Bio Parent and its wholly-owned subsidiary Brii Bio were determined to be variable interest entities ("VIE") due to their reliance on future financing and having insufficient equity at risk. However, the Company did not have the power to direct activities that most significantly impact the economic success of these entities and was not considered the primary beneficiary of these entities. Therefore, the Company did not consolidate Brii Bio Par</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ent or Brii Bio. Subsequent to the Brii Bio Parent IPO, the Company determined that these entities are no longer VIEs. In addition, as Brii Bio Parent is a publicly-traded company, the Company's investment in its ordinary shares became a marketable equity investment with readily determinable fair value and is then subsequently remeasured to fair value at each reporting date (see Note 3&#8212;Fair Value Measurements). Prior to the Brii Bio Parent IPO, the Company accounted for its investment in Brii Bio Parent, which had a carrying value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment from the same issuer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Brii Agreement, the Company also has a contract liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within noncurrent deferred revenue which represents deferred consideration for the remaining three options that the Company granted to Brii Bio. The deferred consideration will be recognized when Brii Bio exercises its options or the options expire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Option Exercise by Brii Bio</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. In consideration of the Company&#8217;s grant to Brii Bio of an exclusive license related to VIR-2218 in the China Territory, the Company received a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-2218 in the China</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Territory: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million regulatory milestone payment, up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in sales-based milestone payments, and royalties on net sales ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">high-teens to high-twenties</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluated the transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price is determined to be $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which consists of the $20.0 million option exercise fee and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the deferred revenue allocated to the VIR-2218 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation under ASC 606. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting other third parties. Brii Bio can benefit from the license at the time of grant and therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021 and 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, as contract revenue from the supply of biological materials to Brii Bio. During the years ended December 31, 2021 and 2020, the Company recognized </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as license revenue from a related party. The Company separately paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, half of the option exercise proceeds, to Alnylam in connection with the Amended Alnylam Agreement that was recognized as research and development expense during the second quarter of 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Alnylam</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">October 2017 Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2017, the Company entered into the collaboration and license agreement with Alnylam (the &#8220;Alnylam Agreement&#8221;) for the development of siRNA products for the treatment of HBV and following the exercise of certain program options, the development and commercialization of siRNA products directed to up to four other infectious disease targets selected by the Company. The technology licensed under the Alnylam Agreement forms the basis of the Company&#8217;s siRNA technology platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Alnylam Agreement, the Company obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications, such excluded fields, the Excluded Fields. In addition, Alnylam granted the Company an exclusive option, for each of the infectious disease siRNA programs directed to the Company&#8217;s selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. On a product-by-product basis for each product arising from the HBV and, following the Company&#8217;s option exercise, the infectious disease programs, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company and Alnylam are jointly responsible for funding the initial research and development activities for VIR-2218 through the completion of proof of concept trials. Prior to the exercise of the Company&#8217;s option for each siRNA program directed to one of the Company&#8217;s selected infectious disease targets, Alnylam is responsible for conducting all development activities, at the Company&#8217;s expense, in accordance with an agreed-upon development plan. Following the Company&#8217;s exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, the Company is solely responsible, at the Company&#8217;s expense (subject to Alnylam&#8217;s exercise of a profit-sharing option), for conducting all development, manufacture and commercialization activities for products arising from each such program. If Alnylam exercises a profit-sharing option for a product, the Company will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Alnylam Agreement, the Company paid Alnylam an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and issued to Alnylam </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,111,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock. Additionally, the receipt of consideration from Brii Bio as discussed above triggered a requirement under the Alnylam Agreement to transfer a portion of the consideration, consisting of equity in Brii Bio Parent valued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, to Alnylam</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the achievement of a certain development milestone, as further discussed below, the Company was obligated to issue shares of the Company&#8217;s common stock equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,111,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares or (ii) a certain number of shares based on the Company&#8217;s stock price at the time such milestone is achieved (the &#8220;Milestone Shares&#8221;). The Company will be required to pay Alnylam up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the achievement of specified development and regulatory milestones by the first product directed to the target of each infectious disease siRNA program for which the Company exercised its option. Following commercialization, the Company will be required to pay to Alnylam up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which the Company exercised its option. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">low double-digits to mid-teens</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on annual net sales of HBV products, and tiered royalties at percentages ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">high single-digits to the sub-teen double-digits</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years after the first commercial sale of such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under the Alnylam Agreement. If the Company does not exercise its option for an infectious disease program directed to one of its selected targets, the Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. The Company may terminate the Alnylam Agreement on a program-by-program basis or in its entirety for any reason on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; written notice. Either party may terminate the agreement for cause for the other party&#8217;s uncured material breach on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Alnylam Agreement on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; notice.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company achieved the specified development milestone relating to the Milestone Shares, which was accounted for as an embedded derivative. Consequently, the Company remeasured and reclassified the derivative liability to additional paid-in capital based on the estimated fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company issued Alnylam </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,111,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock and paid Alnylam $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the second quarter of 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Second and Third Amendments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March and April 2020, the Company and Alnylam entered into the second and third amendments to the Alnylam Agreement (as amended, the &#8220;Amended Alnylam Agreement&#8221;) to expand the parties&#8217; existing collaboration to include the development and commercialization of siRNA products targeting SARS-CoV-2, and potentially other related coronaviruses, and up to three targeting human host factors for SARS-CoV-2 (collectively, the &#8220;COVID Collaboration Targets&#8221;).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company and Alnylam entered into a letter amendment (the &#8220;Letter Agreement&#8221;), further amending the Amended Alnylam Agreement, to modify certain funding and governance provisions in connection with the siRNA products directed to the COVID Collaboration Targets, including VIR-2703 (the &#8220;COV Target&#8221;), and to modify certain rights of each party with respect to products arising from such programs. Pursuant to the Letter Agreement, Alnylam was responsible for conducting pre-clinical research activities set forth in the existing workplan for the COV Target (the &#8220;COV Workplan&#8221;) at its discretion and sole expense, and the Company was no longer obligated to reimburse Alnylam for any share of costs incurred by Alnylam in conducting activities under the COV Workplan after July 1, 2020. In July 2021, Alnylam elected to discontinue the development of the COV Target, and all other related research and development activities in accordance with their rights under the Letter Agreement. As a result, the COV Target and the siRNA program related thereto are no longer included within the Amended Alnylam Agreement and all rights to the siRNA program directed to the COV Target reverted to Alnylam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses Recognized for the Period</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company incurred expenses under the Amended Alnylam Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the years ended December 31, 2021 and 2019, respectively. For the year ended December 31, 2020, in addition to the Milestone Shares, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million milestone payment to Alnylam, and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payment resulting from Brii Bio&#8217;s option exercise in the first half of 2020, the Company incurred expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the Amended Alnylam Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">WuXi Biologics</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the Company entered into a development and manufacturing collaboration agreement with WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;) (the &#8220;WuXi Biologics Collaboration Agreement&#8221;), for the clinical development, manufacturing, and commercialization of the Company&#8217;s proprietary antibodies developed for SARS-CoV-2. Under the WuXi Biologics Collaboration Agreement, WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. WuXi Biologics will have the right to commercialize products incorporating such SARS-CoV-2 antibodies in greater China under an exclusive license granted for the selected SARS-CoV-2 antibodies that have been developed. The Company will have the right to commercialize such products in all other markets worldwide.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WuXi Biologics will perform mutually agreed process and clinical develo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pment and manufacturing activities, under individual statements of work. In addition, the parties agreed that WuXi Biologics will pay the Company tiered royalties at percentages ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">high single-digits to mid-teens</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on annual net sales of all products sold by WuXi Biologics in greater China. The royalties are payable for a specified, standard royalty term. In addition, if WuXi Biologics sublicenses its commercialization rights to a third party, WuXi Biologics will pay the Company a percentage of the sublicense revenue received from such third party. The WuXi Biologics Collaboration Agreement will continue until the expiration of WuXi Biologics&#8217; payment obligations to the Company, unless terminated earlier. If terminated earlier, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days&#8217; prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within 60 days.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rockefeller University</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2018, the Company entered into an exclusive license agreement with The Rockefeller University (&#8220;Rockefeller&#8221;), which was amended in May 2019, in September 2020, and in March 2021 (the &#8220;Rockefeller Agreement&#8221;). Under the Rockefeller Agreement, Rockefeller granted the Company a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The Company uses technology licensed under the Rockefeller Agreement in the Company&#8217;s antibody platform and in the Company&#8217;s product candidates VIR-3434 and VIR-7832.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company paid Rockefeller an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for entry into the Rockefeller Agreement, and is required to pay annual license maintenance fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which will be creditable against royalties following commercialization. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, for the achievement of specified development, regulatory and commercial success milestone events, the Company will be required to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, in the aggregate, for up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infectious disease products. Any follow-on products beyond six products may result in additional milestone event payments. The Company will also be required to pay to Rockefeller a royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. The Company&#8217;s obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis, upon the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years following the first commercial sale of the applicable licensed product in such jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Rockefeller Agreement, the Company recognized a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the years ended December 31, 2021, 2020 and 2019, respectively, as research and development expenses related to certain development milestone payments, annual license maintenance fees, and estimated sublicense fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of the Company&#8217;s obligations to pay royalties to Rockefeller in all jurisdictions. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; written notice for the Company&#8217;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#8217;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">MedImmune</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2018, the Company entered into a license agreement, which was amended in September 2020 (the &#8220;MedImmune Agreement&#8221;), with MedImmune, LLC (&#8220;MedImmune&#8221;), under which the Company obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The Company is developing VIR-2482 using technology licensed under the MedImmune Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the licenses under the MedImmune Agreement, the Company made an upfront payment to MedImmune of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will be obligated to make development, regulatory, and commercial milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">331.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate relating to influenza A and influenza B products. MedImmune will also be entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7b44663d-1329-47cf-a20b-2f4943e047c2;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mid-single-digits</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to sub-teen double-digits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of the Company&#8217;s obligations to pay royalties to MedImmune. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#8217;s uncured material breach on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the third quarter of 2019, the Company achieved and paid one of the specified development milestones relating to influenza A under the MedImmune Agreement. The milestone payment was expensed to research and development in 2019.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Xencor</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">August 2019 License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, the Company entered into a patent license agreement, which was amended in February 2021 (the &#8220;2019 Xencor Agreement&#8221;) with Xencor, Inc. (&#8220;Xencor&#8221;). Under the 2019 Xencor Agreement, as amended, the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#8217;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#8217;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in the Company&#8217;s VIR-2482, incorporating Xencor&#8217;s Xtend technology, and VIR-3434, incorporating Xencor&#8217;s Xtend and other Fc technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, the Company paid Xencor an upfront fee. For each of the influenza A and HBV research programs, the Company will be required to pay Xencor development and regulatory milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate, and commercial sales milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate, for a total of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in aggregate milestones for each program and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">155.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in aggregate milestones for both programs. On a product-by-product basis, the Company will also be obligated to pay tiered royalties based on net sales of licensed products ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">low- to mid-single-digits</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2019 Xencor Agreement, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the years ended December 31, 2021, 2020 and 2019, respectively, as research and development expenses related to certain development milestone payments.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">March 2020 License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company entered into a patent license agreement, which was amended in February 2021 (the &#8220;2020 Xencor Agreement&#8221;) with Xencor under which the Company obtained a non-exclusive, sublicensable (only to the Company&#8217;s affiliates and subcontractors) license to incorporate Xencor&#8217;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#8217;s licensed technologies, for each of the coronavirus research programs. These technologies are used in the Company&#8217;s sotrovimab, incorporating Xencor&#8217;s Xtend technology, and VIR-7832, incorporating Xencor&#8217;s Xtend and other Fc technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, the Company is obligated to pay royalties based on net sales of licensed products at the</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> mid-single-digits</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, as cost of revenue for royalties due to Xencor from the sale of sotrovimab.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amended 2020 Xencor Agreement and 2019 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; written notice. Either party may terminate each agreement for the other party&#8217;s uncured material breach upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; written notice if any of the Company&#8217;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559409592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div style="display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance Sheet Components </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.55%;"/>
        <td style="width:1.279%;"/>
        <td style="width:2.132%;"/>
        <td style="width:14.07%;"/>
        <td style="width:1.421%;"/>
        <td style="width:1.279%;"/>
        <td style="width:2.132%;"/>
        <td style="width:13.715%;"/>
        <td style="width:1.421%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,012</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,112</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,443</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,834</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,274</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,326</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,178</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,232</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,834</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,946</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expenses were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued and Other Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.825%;"/>
        <td style="width:1.521%;"/>
        <td style="width:2.118%;"/>
        <td style="width:14.895%;"/>
        <td style="width:0.853%;"/>
        <td style="width:1.521%;"/>
        <td style="width:2.118%;"/>
        <td style="width:14.298%;"/>
        <td style="width:0.853%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Milestone payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued royalties</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,672</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,073</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,384</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,753</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,060</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,217</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Excess funds payable under grant agreements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,825</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,467</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,927</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other professional and consulting expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,791</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,595</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">236,512</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,936</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559398776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commitments and Contingencies </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease Agreements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has various operating lease arrangements for office and laboratory spaces located in California, Oregon, Missouri, and Switzerland with contractual lease periods expiring between </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2033</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b3ce71d6-2479-49ff-972d-2870edd2f042;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> These renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2021, the Company entered into a new sublease agreement for office and laboratory spaces in Missouri that will expire in December 2028, with no option to renew. Under this sublease arrangement, the Company is entitled to tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">related to the design and construction of certain Company improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company entered into a lease agreement with the new owner of the building at 1800 Owens Street in San Francisco for the lease of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,896</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet of office and laboratory space of such building. The Company previously occupied the same premises under a sublease agreement with a sublessor, which sublease was terminated concurrently with the execution of the new lease agreement. Accordingly, the related ROU asset and lease liability under the sublease arrangement were extinguished and the Company recognized a gain of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the consolidated statement of operations for the year ended December 31, 2021. The new lease will expire in December 2033, with no option to renew. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under this lease arrangement, the Company is entitled to tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">related to the design and construction of certain Company improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under two of the operating lease arrangements in California and Missouri discussed above, the Co</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mpany expects to fully utilize the tenant improvement allow</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ance, and therefore, such amount is treated as a lease incentive that is payable to the Company at the lease commencement date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Throughout the term of the lease agreements, the Company is responsible for paying certain operating costs, in addition to rent, such as common area maintenance, taxes, utilities and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table contains a summary of the lease costs recognized under ASC 842 and additional information related to operating leases (in thousands, except weighted average amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.535%;"/>
        <td style="width:1.511%;"/>
        <td style="width:1.272%;"/>
        <td style="width:17.119%;"/>
        <td style="width:2.127%;"/>
        <td style="width:1.263%;"/>
        <td style="width:1.272%;"/>
        <td style="width:14.773%;"/>
        <td style="width:2.127%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,921</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">261</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">459</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,256</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,299</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total least cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,438</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,349</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,081</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU assets obtained in exchange for new operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,187</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,495</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The discount rate used to determine the present value of the lease payments is our estimated collateralized incremental borrowing rate, based on the yield curve for the respective lease terms, as we generally cannot determine the interest rate implicit in the leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2021 was as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.861%;"/>
        <td style="width:2.038%;"/>
        <td style="width:1.282%;"/>
        <td style="width:15.855%;"/>
        <td style="width:0.964%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amounts</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,082</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,233</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,917</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,353</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,413</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">185,430</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,261</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: net tenant improvement allowance yet to be received</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,217</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,952</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following amounts were recorded in the consolidated balance sheets as of December 31, 2021 and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.716%;"/>
        <td style="width:1.581%;"/>
        <td style="width:1.282%;"/>
        <td style="width:16.938%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.451%;"/>
        <td style="width:1.282%;"/>
        <td style="width:15.477%;"/>
        <td style="width:0.636%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,536</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,913</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating ROU assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,220</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,947</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1cc61fe6-ac37-4ae9-8e25-9ed92a418e6e;"><span style="-sec-ix-hidden:F_a8d2e9b9-02ae-4ff4-bd78-94a2d05ac43a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,927</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,561</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137,488</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.</span></div></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rent expense under the prior lease accounting standard was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Manufacturing and Supply Letter Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Letter Agreement, Assignment and Master Services Agreement with Samsung</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 9, 2020, the Company and Samsung Biologics Co., Ltd. (&#8220;Samsung&#8221;) entered into a binding letter agreement (the &#8220;Samsung Letter Agreement&#8221;), under which Samsung will perform process development and manufacturing services for the Company&#8217;s SARS-CoV-2 antibody program. Under the terms of the Samsung Letter Agreement, the Company had committed to purchase a firm and binding capacity reservation for a specified number of manufacturing slots in 2021 and 2022. The Company was obligated to pay a total of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">362</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for such capacity reservation on a take-or-pay basis regardless of whether such manufacturing slots are utilized by the Company, subject to annual adjustment based on the Korean Consumer Price Index, which also includes certain fees relating to project management and technology transfer. The amounts were to be payable during 2021 and 2022 and invoiced on a per-batch basis, with shortfalls invoiced at the end of the year in which such shortfall occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 4, 2020, the Company, GlaxoSmithKline Trading Services Limited (&#8220;GSKTSL&#8221;) and Samsung entered into an Assignment and Novation Agreement effective as of July 31, 2020 under which the Company assigned and transferred to GSKTSL all of the Company&#8217;s right, title, and interest in, to and under the Samsung Letter Agreement, and GSKTSL became the Company&#8217;s successor in interest in and to all of the Company&#8217;s rights, duties, and obligations in, to and under the Samsung Letter Agreement. On August 4, 2020, GSKTSL entered into a Master Services Agreement with Samsung effective as of July 31, 2020 (the &#8220;Samsung MSA&#8221;), thereby superseding the Samsung Letter Agreement, and under which, among other things, Samsung will perform technology transfer, development and manufacturing services for clinical and commercial supply of antibody products under the Company&#8217;s SARS-CoV-2 antibody program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Letter Agreement, Assignment and Master Services Agreement with WuXi Biologics</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 15, 2020, the Company and WuXi Biologics entered into a binding letter of intent (the &#8220;WuXi Biologics Letter Agreement&#8221;), under which WuXi Biologics will perform certain development and manufacturing services for the Company&#8217;s SARS-CoV-2 antibody program. Under the terms of the WuXi Biologics Letter Agreement, the Company had committed to purchase a firm and binding capacity reservation for the manufacture of a specified number of batches of drug substance of the Company&#8217;s SARS-CoV-2 antibody in 2020 and 2021. In addition, the Company had the right to order an additional specified number of batches of drug substance, provided it makes such election by a specified date in the fourth calendar quarter in 2020. WuXi Biologics is obligated to reserve such manufacturing slots on a non-cancellable basis and will manufacture the agreed number of batches of drug substance per an agreed manufacturing schedule. The Company was obligated to pay a total of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for such capacity reservation, if all batches are manufactured, inclusive of estimated raw material costs, with between </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of the batch production fees owed to WuXi Biologics on a take-or-pay basis regardless of whether such manufacturing slots are utilized by the Company. The amounts were to be payable during 2020 and 2021 and invoiced on a per-batch basis. The SARS-CoV-2 antibody drug substance contemplated to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufactured per the terms of the WuXi Biologics Letter Agreement will be utilized in connection with progressing the development and commercialization of the SARS-CoV-2 antibody product under the Company&#8217;s collaboration with GSK.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 4, 2020, the Company, GSKTSL and WuXi Biologics entered into an Assignment and Novation Agreement effective as of July 29, 2020 under which the Company assigned and transferred to GSKTSL all of the Company&#8217;s right, title, and interest in, to and under the WuXi Biologics Letter Agreement, and GSKTSL became the Company&#8217;s successor in interest in and to all of the Company&#8217;s rights, duties, and obligations in, to and under the WuXi Biologics Letter Agreement. On August 4, 2020, GSKTSL entered into a non-exclusive Master Services Agreement for Commercial Manufacture of Drug Substance with WuXi Biologics effective as of July 29, 2020 (the &#8220;WuXi Biologics MSA&#8221;), thereby superseding the WuXi Biologics Letter Agreement, and pursuant to which, among other things, WuXi Biologics will perform development and manufacturing services for clinical and commercial supply of antibody products under the Company&#8217;s SARS-CoV-2 antibody program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GSKTSL entered into the WuXi Biologics MSA and Samsung MSA in connection with the performance of the obligations of the Company and GSK, under the 2020 GSK Agreement. Per the terms of the 2020 GSK Agreement, the Company will continue to be responsible for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the costs under each of the WuXi Biologics MSA and Samsung MSA, and GSK will bear </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs under each of the Samsung MSA and the WuXi Biologics MSA, subject to certain conditions and exceptions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnification</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Under such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#8217;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559286008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Related Party Transactions </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of the Brii Agreement in May 2018, the Company holds a minority equity interest in Brii Bio through its parent company, Brii Bio Parent. At the time when the Company entered into the Brii Agreement, the Company's Chief Executive Officer, or CEO, and another member of the Company's board of directors served on Brii Bio Parent&#8217;s board of directors. The Company's CEO, who is also a member of the Company's board of directors, resigned from Brii Bio Parent&#8217;s board of directors in June 2021. As of December 31, 2021, one member of the Company&#8217;s board of directors still serves on Brii Bio Parent&#8217;s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,202,213</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock to existing Series A-1 preferred stockholders. See further discussion in Note 11&#8212;Convertible Preferred Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559460488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_TemporaryEquityTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><div style="display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Convertible Preferred Stock </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the IPO, under the Company&#8217;s amended and restated certificate of incorporation, the Company was authorized to issue </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> classes of shares: preferred stock and common stock. The preferred stock was issued in series.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, under the Amended A&amp;R Series A-1 and B Purchase Agreement, the Company sold an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,202,213</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">327.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in two closings. The Company was authorized to sell up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,020,009</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of Series B convertible preferred stock in one or more additional closings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon closing of the IPO, all of the outstanding convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88,112,733</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. After the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_TemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of key terms, rights and preferences of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_TemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559746808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ConvertiblePreferredStockWarrantLiabilityAbstract', window );"><strong>Convertible Preferred Stock Warrant Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ConvertiblePreferredStockWarrantLiabilityTextBlock', window );">Convertible Preferred Stock Warrant Liability</a></td>
<td class="text"><div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Convertible Preferred Stock Warrant Liability </span></div></div><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2016, the Company issued a warrant to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244,444</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s Series A-1 convertible preferred stock with an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share in connection with the termination of a sponsor research agreement. The warrant was fully vested upon the issuance date and had an expiration date of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 11, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The warrant was initially accounted for as a liability and was subject to remeasurement at each reporting period, with changes in estimated fair value recognized as a component of other income (expense), net. Upon the completion of the IPO in October 2019, the warrant automatically converted into a warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244,444</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. Therefore, the convertible preferred stock warrant liability was reclassified to additional paid-in capital. In May 2020, the holder exercised its warrant in a cashless exercise for which the Company issued an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">211,774</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. </span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ConvertiblePreferredStockWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ConvertiblePreferredStockWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ConvertiblePreferredStockWarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of key terms of the warrant agreement and valuation assumptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ConvertiblePreferredStockWarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459564411384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Awards</a></td>
<td class="text"><div style="display:flex;margin-top:18.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">13.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-Based Awards </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2019 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2019, the Company&#8217;s board of directors adopted, with the approval of its stockholders, the 2019 Equity Incentive Plan (the "2019 Plan") for the issuance of incentive stock options (&#8220;ISO&#8221;), non-qualified stock options (&#8220;NSO&#8221;), stock appreciation rights (&#8220;SARs&#8221;), restricted stock, other stock awards and performance cash awards, to employees, non-employee directors, and consultants. The 2019 Plan became effective concurrent with the IPO.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Awards granted under the 2019 Plan expire no later than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years from the date of grant. For ISO and NSO, the option price shall not be less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period but may be granted with different vesting terms. As of December 31, 2021, there are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,092,936</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for the Company to grant under the 2019 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2016 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2016, the Company adopted the 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) for the issuance of ISO, NSO, SARs, restricted stock and other stock awards, to employees, non-employee directors, and consultants under terms and provisions established by the Company&#8217;s board of directors and approved by the stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Awards granted under the 2016 Plan expire no later than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years from the date of grant. For ISO and NSO, the option price shall not be less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period but may be granted with different vesting terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In conjunction with adopting the 2019 Plan, the Company discontinued the 2016 Plan with respect to the new equity awards.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2019 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2019, the Company&#8217;s board of directors adopted, with the approval of its stockholders, the ESPP. The ESPP became effective on the completion of the Company&#8217;s IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ESPP initially authorized the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,280,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock under purchase rights granted to its employees or employees of any of the Company&#8217;s designated affiliates. The number of shares of the Company&#8217;s common stock reserved for issuance is subject to an automatic increase at each calendar year. Under the ESPP, the Company may specify offerings with durations of not more than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months and may specify shorter purchase periods within each offering. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their earnings, subject to any plan limitations. Unless otherwise determined by the Company&#8217;s board of directors, employees can purchase shares at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the lower of the fair market value of the Company&#8217;s common stock on the first date of an offering or the purchase date. During the year ended December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were issued under the ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Activity under the Company&#8217;s stock option plans is set forth below:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.698%;"/>
        <td style="width:1.06%;"/>
        <td style="width:0.95%;"/>
        <td style="width:11.429%;"/>
        <td style="width:1.016%;"/>
        <td style="width:1.071%;"/>
        <td style="width:1.513%;"/>
        <td style="width:9.375%;"/>
        <td style="width:0.751%;"/>
        <td style="width:1.115%;"/>
        <td style="width:0.894%;"/>
        <td style="width:9.728%;"/>
        <td style="width:0.751%;"/>
        <td style="width:1.115%;"/>
        <td style="width:1.513%;"/>
        <td style="width:10.269%;"/>
        <td style="width:0.751%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,798,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,294,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58.68</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,622,718</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.06</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,160,636</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34.55</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,308,928</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160,378</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,308,928</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.75</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160,378</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,238,107</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021, 2020, and 2019, the estimated weighted-average grant date fair value of the options granted was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.83</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company expects to recognize the remaining unamortized stock-based compensation expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">176.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to stock options, over an estimated weighted average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options Granted to Employees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option- pricing model with the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.483%;"/>
        <td style="width:1.501%;"/>
        <td style="width:15.338%;"/>
        <td style="width:1.501%;"/>
        <td style="width:15.338%;"/>
        <td style="width:1.501%;"/>
        <td style="width:15.338%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term of options (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The valuation assumptions for stock options was determined as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected volatility was determined by examining the historical volatilities for industry peers and using an average of historical volatilities of the Company&#8217;s industry peers as the Company does not have a sufficient historical trading history for its stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its stock price becomes available.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Rate&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employees Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2021, the Company initiated its first offering period under the ESPP. Each offering period is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which commences on the grant date on or after June 1 and December 1 of each year and ends on the purchase date on or before November 30 and May 31 of each year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of employees' purchase rights under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.603%;"/>
        <td style="width:2.282%;"/>
        <td style="width:23.115%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term of ESPP (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.04</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected term of employees&#8217; purchase rights is equal to the purchase period. The expected volatility was determined based on the Company's historical volatility. The risk-free interest rate is based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant over the expected term of the employees&#8217; purchase rights. The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future. Based on the Black-Scholes option-pricing model, the estimated weighted-average grant date fair value of the employees' purchase rights granted for the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s RSAs and RSUs were summarized as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.968%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:9.014%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:9.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.994%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.776%;"/>
        <td style="width:0.646%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,261</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,366,189</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.35</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,261</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94,855</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66.05</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,271,334</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The unvested shares of RSUs have not been included in the shares issued and outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, the Company entered into a restricted stock purchase agreement with an executive officer and a restricted stock purchase agreement with a director whereby the executive officer and the director purchased an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,624,355</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of restricted stock. The consideration for the restricted stock was the issuance of promissory notes which were non-recourse in nature and were accounted for as in-substance stock options. In August 2019, per the terms of the notes, the Company received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as repayment of the outstanding promissory notes and accrued interest. The Company reduced the restricted stock liability as the common stock vests, which was fully vested as of December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, there was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of total unrecognized compensation cost related to unvested restricted stock units, all of which is expected to be recognized over a remaining weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the total stock-based compensation expense for all awards granted to employees and non-employees, including shares sold through the issuance of non-recourse promissory notes of which all the shares are considered to be options for accounting purposes, and the ESPP in the consolidated statements of operations:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.649%;"/>
        <td style="width:1.243%;"/>
        <td style="width:1.79%;"/>
        <td style="width:11.375%;"/>
        <td style="width:0.82%;"/>
        <td style="width:1.243%;"/>
        <td style="width:1.79%;"/>
        <td style="width:11.375%;"/>
        <td style="width:0.82%;"/>
        <td style="width:1.243%;"/>
        <td style="width:1.79%;"/>
        <td style="width:11.039%;"/>
        <td style="width:0.82%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,663</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,034</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,230</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,937</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,685</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83,784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559297560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><div style="display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">14.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net Income (Loss) Per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following is a calculation of the basic and diluted net income (loss) per share (in thousands, except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.997%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.282%;"/>
        <td style="width:10.902%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.282%;"/>
        <td style="width:10.902%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.282%;"/>
        <td style="width:10.892%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss), basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">528,584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">298,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">174,683</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129,884,967</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119,159,424</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,349,920</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average effect of dilutive securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,513,438</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,488</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingently issuable shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,233</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,437,126</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119,159,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,349,920</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.07</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.51</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.76</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.96</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.036%;"/>
        <td style="width:1.401%;"/>
        <td style="width:0.646%;"/>
        <td style="width:11.628%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.401%;"/>
        <td style="width:0.646%;"/>
        <td style="width:11.628%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.401%;"/>
        <td style="width:0.646%;"/>
        <td style="width:11.628%;"/>
        <td style="width:0.646%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,764,308</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,798,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,186,298</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,088,304</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,261</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,075,511</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrants to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244,444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,852,612</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,887,543</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,506,253</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company estimated shares issuable under the ESPP would be </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,967</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> based on expected total contributions from the plan participants and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the stock price at the beginning of the offering period.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559761816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><div style="display:flex;margin-top:18.0pt;line-height:1.0110416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">15.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Defined Contribution Plan </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2017, the Company began to sponsor a 401(k) retirement savings plan for the benefit of its employees. Eligible employees may contribute a percentage of their compensation to this plan, subject to statutory limitations. The Company made contributions to the plan for eligible participants, and recorded contribution expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559298280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">16.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income Taxes </span></div></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income (loss) before provision for income taxes consists of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.829%;"/>
        <td style="width:1.144%;"/>
        <td style="width:1.778%;"/>
        <td style="width:11.563%;"/>
        <td style="width:0.746%;"/>
        <td style="width:1.144%;"/>
        <td style="width:1.778%;"/>
        <td style="width:11.824%;"/>
        <td style="width:1.194%;"/>
        <td style="width:1.144%;"/>
        <td style="width:1.778%;"/>
        <td style="width:11.886%;"/>
        <td style="width:1.194%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">535,989</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">309,697</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138,724</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,813</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,086</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,805</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total income (loss) before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">549,802</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">298,611</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">174,529</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of income tax expense consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.868%;"/>
        <td style="width:1.976%;"/>
        <td style="width:1.802%;"/>
        <td style="width:17.004%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.976%;"/>
        <td style="width:1.802%;"/>
        <td style="width:15.935%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.976%;"/>
        <td style="width:1.802%;"/>
        <td style="width:16.109%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,526</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,401</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,032</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,218</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation between the expected income tax provision at the federal statutory rate and the reported income tax expense is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.674%;"/>
        <td style="width:1.641%;"/>
        <td style="width:0.746%;"/>
        <td style="width:13.249%;"/>
        <td style="width:2.946%;"/>
        <td style="width:1.641%;"/>
        <td style="width:0.746%;"/>
        <td style="width:13.249%;"/>
        <td style="width:2.946%;"/>
        <td style="width:1.641%;"/>
        <td style="width:0.746%;"/>
        <td style="width:12.652%;"/>
        <td style="width:4.126%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign tax at less than federal statutory rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior year tax rate adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent items</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the Company&#8217;s deferred tax assets and liabilities as of December 31, 2021 and 2020, are related to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.521%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.778%;"/>
        <td style="width:16.66%;"/>
        <td style="width:1.194%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.778%;"/>
        <td style="width:17.046%;"/>
        <td style="width:1.194%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,030</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117,433</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credit carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,246</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity compensations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,065</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,193</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,115</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,612</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,184</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,657</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,006</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96,854</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183,866</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized gain on investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,170</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,483</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,147</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,422</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,570</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IPR&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,586</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,228</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,707</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">159,891</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,439</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,253</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although t</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he Company has taxable income for the year ended December 31, 2021, it has otherwise incurred accumulated tax losses since inception. Based on the available objective evidence, the Company cannot conclude it is more likely than not that the net deferred tax assets will be fully realizable.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Accordingly, the Company has provided a valuation allowance against its net deferred tax assets. For the year ended December 31, 2021, the Company recorded a valuation allowance release of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, based on the estimated 2021 taxable income. For the years ended December 31, 2020 and 2019, the valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. As of December 31, 2021, the Company has net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for federal purposes and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for state tax purposes. If not utilized, these carryforwards will begin expiring in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for federal and in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2031</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for state tax purposes. The federal net operating losses generated after December 31, 2017, have an infinite carryforward period and subject to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% deduction limitation based upon pre-NOL deduction taxable income. As of December 31, 2021, the Company also has net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for Australian tax purposes, which has an infinite carryforward period, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> net operating loss carryforward for Swiss tax purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Tax Reform Act of 1986, the amounts of and benefits from net operating loss carryforwards may be impaired or limited in certain circumstances. Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The Company completed its Section 382 analysis as of December 31, 2021 and based on this analysis, it does not expect that the annual limitations will significantly impact its ability to utilize its net operating loss or tax credit carryforwards prior to expiration.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company has research tax credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for federal and state tax purposes, respectively. If not utilized, the federal carryforward will expire in various amounts beginning in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2036</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The California credits can be carried forward indefinitely. To the extent they were not utilized, Oregon carryforward began expiring in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax Cuts and Jobs Act of 2017</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> subjects a U.S. shareholder to current tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Staff Q&amp;A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Uncertain Tax Positions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company had an unrecognized tax benefit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, related to transfer pricing and research and development tax credits. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> amount of unrecognized tax benefits as of December 31, 2021, if recognized, would reduce the Company&#8217;s effective tax rate because the benefits would be in the form of net operating loss and tax credit carryforwards, which would attract a full valuation allowance. There are no provisions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date. Because the statute of limitations does not expire until after the net operating loss and credit carryforwards are actually used, the statutes are still open on calendar years ending December 31, 2017 forward for federal and state purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognize any expense for interest and penalties related to uncertain tax positions during 2021, 2020 and 2019, and the Company does </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any amounts related to interest and penalties accrued at December 31, 2021. The Company files U.S. federal, state, Switzerland and Australia tax returns. The Company&#8217;s tax years remain open for all years. As of December 31, 2021, the Company was not under examination by the Internal Revenue Service or any state or foreign tax jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending amounts of the liability for uncertain tax positions is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.204%;"/>
        <td style="width:1.182%;"/>
        <td style="width:1.791%;"/>
        <td style="width:10.995%;"/>
        <td style="width:1.194%;"/>
        <td style="width:1.182%;"/>
        <td style="width:1.791%;"/>
        <td style="width:10.995%;"/>
        <td style="width:1.194%;"/>
        <td style="width:1.182%;"/>
        <td style="width:1.791%;"/>
        <td style="width:11.306%;"/>
        <td style="width:1.194%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross unrecognized tax benefits at January 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,725</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,404</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Addition for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b156a61b-ab05-4999-91a0-ada076026c19;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reduction for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">588</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,596</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Addition for tax positions taken in current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,607</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,740</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,784</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross unrecognized tax benefits at December 31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,725</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559269976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">17.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Subsequent Event </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amended and Restated Letter Agreement with the Bill &amp; Melinda Gates Foundation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2022, the Company e</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ntered into an amended and restated letter agreement with the Bill &amp; Melinda Gates Foundation, which amended and restated the letter agreement with the Bill &amp; Melinda Gates Foundation that was entered into in December 2016 (the "Gates Agreement"), to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">include the advancement of innovative platform technologies in the development of broadly neutralizing antibodies designed to provide a "vaccinal effect" for the treatment of HIV and prevention of malaria</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Under the Gates Agreement, in January 2022, the Bill &amp; Melinda Gates Foundation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">881,365</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company's common stock with total value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and made a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million grant to the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459553187624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. The consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The functional currency of the Company&#8217;s foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. Transaction gains and losses are included in other income (expense), net on the consolidated statements of operations, and were immaterial for the years ended December 31, 2021, 2020 and 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company operates as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock', window );">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has implemented a number of plans and policies designed to address and mitigate the impact of the ongoing COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will continue to have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company&#8217;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although the Company received EUA, temporary authorization or marketing approval for sotrovimab (under the brand name Xevudy&#174;), it is still subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its other product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of sotrovimab and other product candidates and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its other product candidates, it will be unable to generate significant revenue from product sales or maintain profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the consolidated balance sheets. As of December 31, 2021 and 2020, the Company has no off-balance sheet concentrations of credit risk.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#8217;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#8217;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#8217; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#8217; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. There was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> allowance for losses on available-for-sale debt securities attributable to credit risk for the years ended December 31, 2021 and 2020.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments include available-for-sale debt securities and equity investments, which are carried at estimated fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Available-for-Sale Debt Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. The cost of securities sold is based on the specific identification method.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Accounting Standards Update ("ASU") No. 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, the Company measures its investment in equity securities at fair value at each reporting date based on the market price at period end if it has a readily determinable fair value. Otherwise, the investments in equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer unless the Company has significant influence or control over the investee. Changes in fair value resulting from observable price changes are presented as change in fair value of equity investments </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and changes in fair value resulting from foreign currency translation are included in other income (expense), net </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on the consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e8ebc668-f14c-4720-8b72-2366a378afeb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. No material impairment losses have been incurred to date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Acquired Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquired Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s intangible assets were acquired via business combinations or asset acquisitions. Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (&#8220;IPR&amp;D&#8221;) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2021, there have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairments. For IPR&amp;D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses. IPR&amp;D assets acquired as part of an asset acquisition are recorded at cost and expensed immediately if they have no alternative future uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets acquired are initially recognized at their fair value at the acquisition date. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b3b3c2e2-807e-47e2-9909-7b52a03e1e68;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration, License and Contract Revenue</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company recognizes revenue when the Company&#8217;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. When the Company is considered an agent in elements of collaboration arrangements within the scope of ASC 808, it records its share of collaboration revenue in the period in which such sales occur. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the revenue reported by the Company's collaboration partners, net of cost of goods sold and allowable expenses (e.g. medical affairs, selling and marketing expenses) in the period. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partner, including revenue from the sale of the product, and costs incurred for development and sales activities. For the periods covered in the financial statements presented, there have been no material changes to prior period estimates of revenues and expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#8217;s intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#8220;SSP&#8221;). The Company estimates the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Grant Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, research and development expenses have related primarily to discovery efforts and preclinical and clinical development of product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include expenses related to license and collaboration agreements; contingent consideration from business acquisitions; personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel contributing to research and development activities; expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and other allocated expenses, including expenses for rent, facilities maintenance, and depreciation and amortization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. Upfront payments and research and development milestone payments made in connection with acquired license or product rights are expensed as incurred, provided that they do not relate to a regulatory approval milestone or assets acquired in a business combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s expense accruals for clinical trials and manufacturing are based on estimates of contracted services provided by third-party vendors not yet billed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of its outstanding obligations to those third parties as of the period end. The accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. The Company obtains information regarding unbilled services directly from these service providers and performs procedures to support its estimates based on its internal understanding of the services provided to date. However, the Company may also be required to estimate these services based on information available to its internal clinical and manufacturing administrative staff if such information is not able to be obtained timely from its service providers.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes stock-based compensation to employees and non-employees over the requisite service period based on the grant-date fair value of the awards. The Company calculates the estimated fair value of stock options and employees' purchase rights under the Company's 2019 employee stock purchase plan ("ESPP") using the Black-Scholes valuation model, which requires the use of subjective assumptions including volatility and expected term, among others. The fair value of restricted stock awards ("RSAs") and restricted stock units ("RSUs") is based on the market value of the Company's common stock on the date of grant. Stock-based compensation is recognized using the straight-line method for awards that vest only upon the employee&#8217;s or non-employee&#8217;s continued service to the Company. Stock-based compensation expense of the employees' purchase rights under the ESPP is recognized over the offering period. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisitions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various milestones are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesEmbeddedDerivatives', window );">Embedded Derivatives</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Embedded Derivatives</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the consolidated statements of operations based on the nature of the related contingencies.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expense or selling, general and administrative expenses based on the nature of the relevant underlying activities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Otherwise, changes in fair values are recorded within other income (expense), net.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with ASU No. 2016-02 (Topic 842), Leases, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. On the lease commencement date, the Company estimates and includes in its lease payments any lease incentive amounts based on future events when (1) the events are within the Company&#8217;s control and (2) the event triggering the right to receive the incentive is deemed reasonably certain to occur. If the lease incentive received is greater or less than the amount recognized at lease commencement, the Company recognizes the difference as an adjustment to right-of-use asset and/or lease liability, as applicable.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the implicit rate in the Company's leases is generally unknown, the Company uses an incremental borrowing rate estimated based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating its estimated incremental borrowing rates, the Company considers its credit risk, the lease term, the total lease payments and the impact of collateral, as necessary. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. ROU assets and lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. Rent expense for the Company's operating leases is recognized on a straight-line basis within operating expenses over the reasonably assured lease term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the asset and liability method of accounting for income taxes. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating losses and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as any related net interest and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax Cuts and Jobs Act of 2017</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> subjects a U.S. shareholder to current tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Staff Q&amp;A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Income (Loss) Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per common share is computed by dividing the net income by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">New Accounting Pronouncement Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, the Financial Accounting Standards Board ("FASB") issued ASU No. 2021-10, Government Assistance (Topic 832) (&#8220;ASU 2021-10&#8221;), which adds certain disclosure requirements with respect to government assistance, including (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance on financial statements. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2021-10 may have on its consolidated financial statements and related disclosures</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesEmbeddedDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=107671284&amp;loc=SL5844817-113951<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515679&amp;loc=d3e40733-113955<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56949186&amp;loc=d3e50579-113967<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123589689&amp;loc=d3e48542-113965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesEmbeddedDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk credit loss and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459757822744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company&#8217;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.3%;"/>
        <td style="width:1.024%;"/>
        <td style="width:9.81%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.21%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.21%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.21%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.21%;"/>
        <td style="width:0.646%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">345,098</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">345,098</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">419,442</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">872</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">418,570</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">764,540</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">872</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">763,668</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1) Includes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">15.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> of restricted cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.295%;"/>
        <td style="width:1.044%;"/>
        <td style="width:9.829%;"/>
        <td style="width:1.044%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.229%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.044%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.229%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.044%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.04%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.044%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.229%;"/>
        <td style="width:0.646%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">421,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">421,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300,201</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722,036</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722,121</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-2.599%;padding-left:2.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1) Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">14.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million of restricted cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Estimated Fair Value of Financial Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level 3 financial liabilities (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.644%;"/>
        <td style="width:2.097%;"/>
        <td style="width:1.282%;"/>
        <td style="width:16.112%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contingent<br/>Consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,974</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91,848</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of contingent consideration to accrued liabilities upon achievement of the Humabs milestones</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of contingent consideration upon achievement of the TomegaVax milestone</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,822</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Estimated Fair Value of Significant Unobservable Inputs</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of Decemb</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">er 31, 2021, the Company calculated the estimated fair value of the remaining clinical and regulatory milestones related to the HBV product using the following significant unobservable inputs: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.179%;"/>
        <td style="width:2.44%;"/>
        <td style="width:32.381%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Range<br/>(Weighted-Average)1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1) Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Estimated Fair Value of Significant Unobservable Inputs</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s of December 31, 2021, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecast, as well as the following significant unobservable inputs f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or the remaining commercial milestones related to the HBV product: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.179%;"/>
        <td style="width:2.44%;"/>
        <td style="width:32.381%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Estimated Fair Value of Significant Unobservable Inputs</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.179%;"/>
        <td style="width:2.44%;"/>
        <td style="width:32.381%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459561197480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the carrying amount of the Company&#8217;s finite-lived intangible assets (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.615%;"/>
        <td style="width:1.181%;"/>
        <td style="width:1.803%;"/>
        <td style="width:11.888%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.181%;"/>
        <td style="width:1.803%;"/>
        <td style="width:10.768%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.181%;"/>
        <td style="width:1.02%;"/>
        <td style="width:16.377%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining Useful</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Developed technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract-based intangible asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">502</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">502</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.9</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,114</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,581</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less impairment of intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finite-lived intangible assets, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,089</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on the finite-lived intangible assets recorded as of December 31, 2021, the estimated future amortization expense for the next five years is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.14%;"/>
        <td style="width:1.758%;"/>
        <td style="width:2.671%;"/>
        <td style="width:17.352%;"/>
        <td style="width:1.078%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">532</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">260</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563286216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.55%;"/>
        <td style="width:1.279%;"/>
        <td style="width:2.132%;"/>
        <td style="width:14.07%;"/>
        <td style="width:1.421%;"/>
        <td style="width:1.279%;"/>
        <td style="width:2.132%;"/>
        <td style="width:13.715%;"/>
        <td style="width:1.421%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,012</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,112</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,443</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,834</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,274</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,326</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,178</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,232</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,834</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,946</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.825%;"/>
        <td style="width:1.521%;"/>
        <td style="width:2.118%;"/>
        <td style="width:14.895%;"/>
        <td style="width:0.853%;"/>
        <td style="width:1.521%;"/>
        <td style="width:2.118%;"/>
        <td style="width:14.298%;"/>
        <td style="width:0.853%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Milestone payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued royalties</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,672</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,073</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,384</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,753</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,060</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,217</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Excess funds payable under grant agreements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,825</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,467</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,927</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other professional and consulting expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,791</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,595</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">236,512</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,936</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued liabilities and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459561638968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock', window );">Summary of Lease Costs and Additional Information Related to Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table contains a summary of the lease costs recognized under ASC 842 and additional information related to operating leases (in thousands, except weighted average amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.535%;"/>
        <td style="width:1.511%;"/>
        <td style="width:1.272%;"/>
        <td style="width:17.119%;"/>
        <td style="width:2.127%;"/>
        <td style="width:1.263%;"/>
        <td style="width:1.272%;"/>
        <td style="width:14.773%;"/>
        <td style="width:2.127%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,921</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">261</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">459</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,256</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,299</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total least cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,438</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,349</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,081</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU assets obtained in exchange for new operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,187</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,495</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2021 was as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.861%;"/>
        <td style="width:2.038%;"/>
        <td style="width:1.282%;"/>
        <td style="width:15.855%;"/>
        <td style="width:0.964%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amounts</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,082</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,233</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,917</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,353</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,413</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">185,430</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,261</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: net tenant improvement allowance yet to be received</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,217</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,952</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock', window );">Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following amounts were recorded in the consolidated balance sheets as of December 31, 2021 and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.716%;"/>
        <td style="width:1.581%;"/>
        <td style="width:1.282%;"/>
        <td style="width:16.938%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.451%;"/>
        <td style="width:1.282%;"/>
        <td style="width:15.477%;"/>
        <td style="width:0.636%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,536</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,913</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating ROU assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,220</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,947</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1cc61fe6-ac37-4ae9-8e25-9ed92a418e6e;"><span style="-sec-ix-hidden:F_a8d2e9b9-02ae-4ff4-bd78-94a2d05ac43a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,927</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,561</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137,488</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating lease amounts recorded in condensed consolidated balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of lease cost and other information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559389336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Plans Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Activity under the Company&#8217;s stock option plans is set forth below:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.698%;"/>
        <td style="width:1.06%;"/>
        <td style="width:0.95%;"/>
        <td style="width:11.429%;"/>
        <td style="width:1.016%;"/>
        <td style="width:1.071%;"/>
        <td style="width:1.513%;"/>
        <td style="width:9.375%;"/>
        <td style="width:0.751%;"/>
        <td style="width:1.115%;"/>
        <td style="width:0.894%;"/>
        <td style="width:9.728%;"/>
        <td style="width:0.751%;"/>
        <td style="width:1.115%;"/>
        <td style="width:1.513%;"/>
        <td style="width:10.269%;"/>
        <td style="width:0.751%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,798,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,294,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58.68</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,622,718</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.06</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,160,636</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34.55</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,308,928</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160,378</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,308,928</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.75</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160,378</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,238,107</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option- pricing model with the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.483%;"/>
        <td style="width:1.501%;"/>
        <td style="width:15.338%;"/>
        <td style="width:1.501%;"/>
        <td style="width:15.338%;"/>
        <td style="width:1.501%;"/>
        <td style="width:15.338%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term of options (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s RSAs and RSUs were summarized as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.968%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:9.014%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:9.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.994%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.282%;"/>
        <td style="width:8.776%;"/>
        <td style="width:0.646%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,261</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,366,189</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.35</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,261</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94,855</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66.05</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,271,334</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Employees Stock Purchase Plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of employees' purchase rights under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.603%;"/>
        <td style="width:2.282%;"/>
        <td style="width:23.115%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term of ESPP (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.04</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the total stock-based compensation expense for all awards granted to employees and non-employees, including shares sold through the issuance of non-recourse promissory notes of which all the shares are considered to be options for accounting purposes, and the ESPP in the consolidated statements of operations:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.649%;"/>
        <td style="width:1.243%;"/>
        <td style="width:1.79%;"/>
        <td style="width:11.375%;"/>
        <td style="width:0.82%;"/>
        <td style="width:1.243%;"/>
        <td style="width:1.79%;"/>
        <td style="width:11.375%;"/>
        <td style="width:0.82%;"/>
        <td style="width:1.243%;"/>
        <td style="width:1.79%;"/>
        <td style="width:11.039%;"/>
        <td style="width:0.82%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,663</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,034</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,230</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,937</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,685</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83,784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459558565656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Income (loss) Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following is a calculation of the basic and diluted net income (loss) per share (in thousands, except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.997%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.282%;"/>
        <td style="width:10.902%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.282%;"/>
        <td style="width:10.902%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.282%;"/>
        <td style="width:10.892%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss), basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">528,584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">298,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">174,683</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129,884,967</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119,159,424</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,349,920</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average effect of dilutive securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,513,438</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,488</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingently issuable shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,233</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,437,126</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119,159,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,349,920</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.07</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.51</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.76</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.96</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.036%;"/>
        <td style="width:1.401%;"/>
        <td style="width:0.646%;"/>
        <td style="width:11.628%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.401%;"/>
        <td style="width:0.646%;"/>
        <td style="width:11.628%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.401%;"/>
        <td style="width:0.646%;"/>
        <td style="width:11.628%;"/>
        <td style="width:0.646%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,764,308</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,798,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,186,298</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,088,304</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,261</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,075,511</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrants to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244,444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,852,612</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,887,543</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,506,253</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459561274792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income (loss) before provision for income taxes consists of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.829%;"/>
        <td style="width:1.144%;"/>
        <td style="width:1.778%;"/>
        <td style="width:11.563%;"/>
        <td style="width:0.746%;"/>
        <td style="width:1.144%;"/>
        <td style="width:1.778%;"/>
        <td style="width:11.824%;"/>
        <td style="width:1.194%;"/>
        <td style="width:1.144%;"/>
        <td style="width:1.778%;"/>
        <td style="width:11.886%;"/>
        <td style="width:1.194%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">535,989</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">309,697</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138,724</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,813</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,086</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,805</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total income (loss) before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">549,802</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">298,611</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">174,529</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of income tax expense consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.868%;"/>
        <td style="width:1.976%;"/>
        <td style="width:1.802%;"/>
        <td style="width:17.004%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.976%;"/>
        <td style="width:1.802%;"/>
        <td style="width:15.935%;"/>
        <td style="width:1.206%;"/>
        <td style="width:1.976%;"/>
        <td style="width:1.802%;"/>
        <td style="width:16.109%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,526</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,401</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,032</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,218</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">154</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation between the expected income tax provision at the federal statutory rate and the reported income tax expense is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.674%;"/>
        <td style="width:1.641%;"/>
        <td style="width:0.746%;"/>
        <td style="width:13.249%;"/>
        <td style="width:2.946%;"/>
        <td style="width:1.641%;"/>
        <td style="width:0.746%;"/>
        <td style="width:13.249%;"/>
        <td style="width:2.946%;"/>
        <td style="width:1.641%;"/>
        <td style="width:0.746%;"/>
        <td style="width:12.652%;"/>
        <td style="width:4.126%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign tax at less than federal statutory rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior year tax rate adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent items</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the Company&#8217;s deferred tax assets and liabilities as of December 31, 2021 and 2020, are related to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.521%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.778%;"/>
        <td style="width:16.66%;"/>
        <td style="width:1.194%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.778%;"/>
        <td style="width:17.046%;"/>
        <td style="width:1.194%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,030</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117,433</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credit carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,246</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity compensations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,065</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,193</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,115</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,612</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,184</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,657</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,006</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96,854</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">183,866</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized gain on investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,170</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,483</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,147</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,422</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,570</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IPR&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,586</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,228</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,707</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">159,891</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,439</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,253</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although t</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Liability for Uncertain Tax Positions</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending amounts of the liability for uncertain tax positions is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.204%;"/>
        <td style="width:1.182%;"/>
        <td style="width:1.791%;"/>
        <td style="width:10.995%;"/>
        <td style="width:1.194%;"/>
        <td style="width:1.182%;"/>
        <td style="width:1.791%;"/>
        <td style="width:10.995%;"/>
        <td style="width:1.194%;"/>
        <td style="width:1.182%;"/>
        <td style="width:1.791%;"/>
        <td style="width:11.306%;"/>
        <td style="width:1.194%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross unrecognized tax benefits at January 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,725</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,404</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Addition for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b156a61b-ab05-4999-91a0-ada076026c19;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reduction for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">588</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,596</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Addition for tax positions taken in current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,607</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,740</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,784</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross unrecognized tax benefits at December 31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,725</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459555951320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th">
<div>Jul. 10, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 16, 2019</div></th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 11, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.222222222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds after deducting underwriting discounts, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 323,214<span></span>
</td>
<td class="nump">$ 126,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SaleOfStockConsiderationAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,600<span></span>
</td>
<td class="nump">$ 667,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment', window );">Cash, cash equivalents and short-term investments, excluding equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 766,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Outstanding convertible preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,910,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vir_SeriesAOneConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase of convertible preferred stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of convertible preferred stock converted to shares of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,112,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase of convertible preferred stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfCommissionRateFromSaleOfShares', window );">Percentage of commission rate from sale of shares</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Outstanding convertible preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,112,733<span></span>
</td>
<td class="nump">88,112,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of convertible preferred stock converted to shares of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,112,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock | Warrant to Purchase Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of convertible preferred stock converted to shares of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vir_FollowOnOfferingMember', window );">Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vir_FollowOnOfferingMember', window );">Follow-on Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,214,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,214,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Payments of underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_NetProceedsFromIssuanceSecondaryPublicOffering', window );">Net proceeds from issuance secondary public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and short-term investments, excluding equity investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NetProceedsFromIssuanceSecondaryPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's follow on offering of stock to the public, net of commissions and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NetProceedsFromIssuanceSecondaryPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentsOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentsOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfCommissionRateFromSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of maximum commission rate, based on aggregate gross proceeds from sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfCommissionRateFromSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SaleOfStockConsiderationAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate offering price for which the entity may sell shares of its common stock under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SaleOfStockConsiderationAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vir_SeriesAOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vir_SeriesAOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=vir_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=vir_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vir_ConvertiblePreferredStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vir_ConvertiblePreferredStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vir_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vir_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459552394280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for losses on available-for-sale debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, estimated useful lives description</a></td>
<td class="text">Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod', window );">Finite-lived intangible assets, amortization method description</a></td>
<td class="text">Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally seven to 15 years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 35<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121554622&amp;loc=d3e15372-109273<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459552407928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsAmortizedCostBasis', window );">Financial Assets, Amortized Cost</a></td>
<td class="nump">$ 764,540<span></span>
</td>
<td class="nump">$ 722,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingGains', window );">Financial Assets, Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingLosses', window );">Financial Assets, Gross Unrealized Holding Losses</a></td>
<td class="num">(872)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsFairValue', window );">Financial Assets, Aggregate Fair Value</a></td>
<td class="nump">763,668<span></span>
</td>
<td class="nump">722,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsAmortizedCostBasis', window );">Financial Assets, Amortized Cost</a></td>
<td class="nump">345,098<span></span>
</td>
<td class="nump">421,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsFairValue', window );">Financial Assets, Aggregate Fair Value</a></td>
<td class="nump">345,098<span></span>
</td>
<td class="nump">421,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsAmortizedCostBasis', window );">Financial Assets, Amortized Cost</a></td>
<td class="nump">419,442<span></span>
</td>
<td class="nump">300,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingGains', window );">Financial Assets, Gross Unrealized Holding Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingLosses', window );">Financial Assets, Gross Unrealized Holding Losses</a></td>
<td class="num">(872)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsFairValue', window );">Financial Assets, Aggregate Fair Value</a></td>
<td class="nump">$ 418,570<span></span>
</td>
<td class="nump">$ 300,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsGrossUnrealizedHoldingGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets gross unrealized holding gains.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsGrossUnrealizedHoldingGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsGrossUnrealizedHoldingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets gross unrealized holding losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsGrossUnrealizedHoldingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563452376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalents', window );">Restricted cash equivalents</a></td>
<td class="nump">$ 15.6<span></span>
</td>
<td class="nump">$ 14.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563740216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Total unrealized gains recorded in accumulated other comprehensive income (loss)</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAccruedInterestWriteoff', window );">Write off of accrued interest receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=vir_BriiBioParentMember', window );">Brii Bio Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment Owned At Fair Value</a></td>
<td class="nump">143,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Increase Decrease In Equity Securities Fv Ni</a></td>
<td class="nump">138,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign Currency Transaction Gain Loss Unrealized</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Securities contractual term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RegulatoryMilestoneAchieved', window );">Regulatory milestone achieved</a></td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SalesMilestonesAchieved', window );">Sales milestone achieved</a></td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Estimated fair value of contingent consideration</a></td>
<td class="nump">17,100,000<span></span>
</td>
<td class="nump">29,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Estimated fair value of contingent consideration</a></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=vir_ContingentConsiderationLiabilityMember', window );">Contingent Consideration Liability | TomegaVax Letter Agreement | TomegaVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_AssetAcquisitionMilestoneAchieved', window );">Asset acquisition milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses And Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on financing receivable recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267969-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5D<br> -Subparagraph (SX 210.12-13D(Column C))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=SL120429264-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AssetAcquisitionMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition milestone achieved during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AssetAcquisitionMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestones achieved during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SalesMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestones achieved during the reporting period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SalesMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=vir_BriiBioParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=vir_BriiBioParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=vir_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=vir_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=vir_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=vir_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459552130936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Measurement Input, Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Measurement Input, Discount Rate | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="num">(0.04)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="num">(0.31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Probability of Achievement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Measurement Input Expected Revenue Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Measurement Input Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">1.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure embedded derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputProbabilityRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputProbabilityRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedRevenueVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedRevenueVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559591832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details) - Level 3 - Contingent Consideration Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 35,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in fair value</a></td>
<td class="nump">91,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone', window );">Reclassification of derivative liability to accrued liabilities upon achievement of development milestone</a></td>
<td class="num">(95,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone', window );">Payment of contingent consideration upon achievement of the TomegaVax milestone</a></td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2021</a></td>
<td class="nump">$ 22,822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, reclassification of contingent consideration to accrued liabilities upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value reclassification of derivative liability to accrued liabilities upon achievement of development milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=vir_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=vir_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459556710536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Asset acquisition, transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentMadeForAssetAcquisitionMilestone', window );">Payment made for asset acquisition milestone</a></td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CommonStockSharesIssuedForMilestonePaymentShares', window );">Common stock shares Issued for milestone payment| shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Value of common stock shares Issued for milestone payment</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MinimumCommonStockPriceForMilestonePaymentsConsideration', window );">Minimum common stock price for milestone payments consideration | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate', window );">Remaining payment for asset acquisition milestone, maximum</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Clinical Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MinimumCommonStockPriceForMilestonePaymentsConsideration', window );">Minimum common stock price for milestone payments consideration | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | TomegaVax Letter Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_AssetAcquisitionMilestonePaymentAggregate', window );">Milestone payments aggregate amount payable, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MilestonePaymentsRelatedTermsDescription', window );">Milestone payments related terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company&#8217;s publicly traded common stock, or implied price per-share of the Company&#8217;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#8217;s clinical development at the time of the relevant event triggering the payment.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Estimated fair value of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration', window );">Number of milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MinimumCommonStockPriceForMilestonePaymentsConsideration', window );">Minimum common stock price for milestone payments consideration | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100,000<span></span>
</td>
<td class="nump">$ 29,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Business acquisition, cash consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business acquisition, shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SalesMilestonesAchieved', window );">Sales milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be deductible for income tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Developed Technologies | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated remaining useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Developed Technologies | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated remaining useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | HBV product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents', window );">Additional consideration payable upon achievement of specified milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SpecifiedClinicalDevelopmentMilestonesPayment', window );">Specified clinical development milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Another Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents', window );">Additional consideration payable upon achievement of specified milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | SARS-CoV-2 Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved', window );">Number of specified clinical milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SpecifiedClinicalDevelopmentMilestonesPayment', window );">Specified clinical development milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RegulatoryMilestonesAchieved', window );">Regulatory milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SalesMilestonesAchieved', window );">Sales milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | SARS-CoV-2 Product | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentMadeForBusinessCombinationMilestone', window );">Payment made for business combination milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AssetAcquisitionMilestonePaymentAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AssetAcquisitionMilestonePaymentAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition number of milestones achieved related to contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition number of specified clinical milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combinations additional consideration payable upon achievement of specified events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommonStockSharesIssuedForMilestonePaymentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares issued for milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommonStockSharesIssuedForMilestonePaymentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePaymentsRelatedTermsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments related terms description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePaymentsRelatedTermsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MinimumCommonStockPriceForMilestonePaymentsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum common stock price that triggers milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MinimumCommonStockPriceForMilestonePaymentsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentMadeForAssetAcquisitionMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment made for asset acquisition milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentMadeForAssetAcquisitionMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentMadeForBusinessCombinationMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment made for business combination milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentMadeForBusinessCombinationMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestones achieved during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the remaining consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SalesMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestones achieved during the reporting period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SalesMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SpecifiedClinicalDevelopmentMilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specified clinical development milestones payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SpecifiedClinicalDevelopmentMilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_ClinicalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_ClinicalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_HepatitisBVirusProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_HepatitisBVirusProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_AnotherProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_AnotherProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_SARSCoV2ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_SARSCoV2ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459552326648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems', window );"><strong>Schedule of Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 16,937,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,937,000<span></span>
</td>
<td class="nump">$ 16,937,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,000<span></span>
</td>
<td class="nump">1,042,000<span></span>
</td>
<td class="nump">$ 1,223,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">832,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived', window );">Finite-lived intangible asset, reclassified from indefinite-lived asset</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems', window );"><strong>Schedule of Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Indefinite-lived intangible assets IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,700,000<span></span>
</td>
<td class="nump">30,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems', window );"><strong>Schedule of Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-lived Intangible assets, reclassified from Indefinite-lived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563498792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 7,502<span></span>
</td>
<td class="nump">$ 7,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(4,114)<span></span>
</td>
<td class="num">(3,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Less impairment of intangible assets</a></td>
<td class="num">(832)<span></span>
</td>
<td class="num">(832)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="nump">2,556<span></span>
</td>
<td class="nump">3,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_DevelopedTechnologyMember', window );">Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Remaining Useful Life (Years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Contract-Based Intangible Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 502<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Remaining Useful Life (Years)</a></td>
<td class="text">13 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FiniteLivedIntangibleAssetsAccumulatedImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets accumulated impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FiniteLivedIntangibleAssetsAccumulatedImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_DevelopedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_DevelopedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563494872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FiniteLivedIntangibleAssetsAmortizationExpense', window );">Total</a></td>
<td class="nump">$ 1,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FiniteLivedIntangibleAssetsAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of total amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in the next five years following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FiniteLivedIntangibleAssetsAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459556818216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 05, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Mar. 16, 2018</div></th>
<th class="th"><div>Jan. 26, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,347,000<span></span>
</td>
<td class="nump">$ 9,123,000<span></span>
</td>
<td class="nump">$ 7,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_BillAndMelindaGatesFoundationMember', window );">Bill &amp; Melinda Gates Foundation | Grant Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_NationalInstitutesOfHealthMember', window );">National Institutes of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAwardedAmount', window );">Grant awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_NationalInstitutesOfHealthMember', window );">National Institutes of Health | Grant Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandSeventeenGrantMember', window );">2017 Grant | Bill &amp; Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAgreementExpirationDate', window );">Grant agreement expiration date</a></td>
<td class="text">May 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandSeventeenGrantMember', window );">2017 Grant | Bill &amp; Melinda Gates Foundation | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAwardedAmount', window );">Grant awarded amount</a></td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember', window );">Human Immunodeficiency Virus ("HIV") Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAwardedAmount', window );">Grant awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAgreementExpirationDateBeforeAmendment', window );">Grant agreement expiration date before amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAgreementAmendedExpirationDate', window );">Grant agreement amended expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantsAgreementAmendedDate', window );">Grants Agreement Amended Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember', window );">Human Immunodeficiency Virus ("HIV") Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAwardedAmountMaximum', window );">Grant awarded amount. maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember', window );">Human Immunodeficiency Virus ("HIV") Grant | Bill &amp; Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember', window );">Human Immunodeficiency Virus ("HIV") Grant | Bill &amp; Melinda Gates Foundation | Grant Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MilestonePaymentDueToCompany', window );">Milestone payment due to Vir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember', window );">Tuberculosis ("TB") Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAgreementAmendedExpirationDate', window );">Grant agreement amended expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_UnusedFundsReceivedInAdvance', window );">Unused funds received in advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember', window );">Tuberculosis ("TB") Grant | Grant Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember', window );">Tuberculosis ("TB") Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAwardedAmountMaximum', window );">Grant awarded amount. maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember', window );">Tuberculosis ("TB") Grant | Bill &amp; Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HcmvVaccinePlatformGrantMember', window );">HCMV-Vaccine Platform Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAgreementExpirationDate', window );">Grant agreement expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HcmvVaccinePlatformGrantMember', window );">HCMV-Vaccine Platform Grant | Grant Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HcmvVaccinePlatformGrantMember', window );">HCMV-Vaccine Platform Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAwardedAmountMaximum', window );">Grant awarded amount. maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAgreementAmendedExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant agreement amended expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAgreementAmendedExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAgreementExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date the grant agreement expires.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAgreementExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAgreementExpirationDateBeforeAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant agreement expiration date before amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAgreementExpirationDateBeforeAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant awarded amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAwardedAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum grant awarded amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAwardedAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantsAgreementAmendedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grants Agreement Amended Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantsAgreementAmendedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePaymentDueToCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment due to company under grant agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePaymentDueToCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_UnusedFundsReceivedInAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unused funds received in advance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_UnusedFundsReceivedInAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandSeventeenGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandSeventeenGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_HcmvVaccinePlatformGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_HcmvVaccinePlatformGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459471152920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 14, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 14, 2021 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Apr. 29, 2020 </div>
<div>USD ($) </div>
<div>Unit </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 28, 2020</div></th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>Antibodies</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($) </div>
<div>Product</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,865,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivable from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,079,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember', window );">Contract Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,874,000<span></span>
</td>
<td class="nump">44,498,000<span></span>
</td>
<td class="nump">711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,747,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917,194,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember', window );">2020 GSK | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_GlaxoWellcomeUKLimitedAndBeechamSAMember', window );">GSK | Accrued Liabilities And Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivable from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember', window );">2021 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember', window );">2020 Stock Purchase Agreement | GGL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,626,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2020 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans', window );">Number of years conduct certain research and development activities under mutually agreed development plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct', window );">Maximum percentage of right to perform details in connection with antibody product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementNumberOfUnitsOfAccount', window );">Number of units of account | Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,300,000<span></span>
</td>
<td class="nump">25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationTypeAndPrograms', window );">Collaboration type and program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses (the &#8220;Antibody Program&#8221;); (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses (the &#8220;Vaccine Program&#8221;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses (the &#8220;Functional Genomics Program&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2020 GSK | Antibody Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_AntibodyLicenseTransactionPrice', window );">Antibody license transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2020 GSK | Vaccine Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2021 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate', window );">Number of separate programs | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_UpfrontPaymentReceivable', window );">Upfront payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement', window );">Percentage of upfront payment receivable at effective date of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeConsiderationToBeReceived', window );">Option exercise fee to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2021 GSK | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PreDefinedRegulatoryMilestoneConsiderationReceivable', window );">Pre-defined regulatory milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember', window );">2020 Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FairMarketValueOfCommonStockIssued', window );">Fair market value of the common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PremiumReceivedOnSalePriceOfCommonStock', window );">Premium received on sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_DefinitiveCollaborationAgreementMember', window );">Definitive Collaboration Agreement | 2021 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement', window );">Percentage of upfront payment receivable at execution date of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember', window );">2021 Stock Purchase Agreement | GGL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember', window );">2021 Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FairMarketValueOfCommonStockIssued', window );">Fair market value of the common stock issued</a></td>
<td class="nump">$ 85,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="nump">$ 52.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PremiumReceivedOnSalePriceOfCommonStock', window );">Premium received on sale price of common stock</a></td>
<td class="nump">$ 34,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember', window );">2021 GSK Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans', window );">Number of years conduct certain research and development activities under mutually agreed development plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfShareDevelopmentCosts', window );">Percentage of share development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ProfitsAndLossesSharingPercentage', window );">Percentage of share Profit and loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember', window );">2021 GSK Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PremiumReceivedOnSalePriceOfCommonStock', window );">Premium received on sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTransactionPriceUpfrontFee', window );">Upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTransactionPriceConsideration', window );">Collaboration Agreement Transaction Price Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember', window );">2021 GSK Agreement | Contract Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days&#8217; written notice (if the terminating party has not exercised an option for such program) or 180 days&#8217; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#8217;s uncured material breach on 60 days&#8217; written notice (or 30 days&#8217; notice following failure to make payment).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach', window );">Written notice period to terminate licensed program for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticeToTerminateLicensedProgramIfExercise', window );">Written notice to terminate licensed program if exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise', window );">Written notice to terminate licensed program if not exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment', window );">Written notice period to terminate licensed program for failure to make payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Development Programs Exercised by Vir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeLowEndOfTheRange', window );">Option exercise fee, low end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low tens of millions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange', window );">Regulatory milestone payment on licensed product, low end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low tens of millions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange', window );">Regulatory milestone payment on licensed product, high end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeHighEndOfTheRange', window );">Option exercise fee, high end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateSalesMilestonePayments', window );">Maximum Aggregate Sales Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Development Programs Exercised by Brii</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RangeOfRoyaltyPaymentToBeReceived', window );">Range of royalty payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">high-teens to high-twenties<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentToBeReceived', window );">Regulatory milestone payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumSalesMilestonToPay', window );">Maximum sales milestone to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeLowEndOfTheRange', window );">Option exercise fee, low end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> mid-single-digit millions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange', window );">Regulatory milestone payment on licensed product, low end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">mid-single-digit millions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange', window );">Regulatory milestone payment on licensed product, high end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RangeOfRoyaltyPaymentToBePaid', window );">Range of royalty payment to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">mid-teens to the high-twenties<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeHighEndOfTheRange', window );">Option exercise fee, high end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateSalesMilestonePayments', window );">Maximum Aggregate Sales Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentToCollaboratorResultingFromProgramOptionExercise', window );">Payment to collaborator resulting from program option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty', window );">Maximum number of development program granted from Vir to Brii | Program | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty', window );">Maximum number of development program granted from Brii to Vir | Program | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfOrdinaryShareEqualToOutstandingShare', window );">Percentage of ordinary share equal to outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Carrying value of investment at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeReceived', window );">Option exercise fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_DeterminedTransactionPrice', window );">Determined transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent | Biological Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales', window );">Royalty payment obligation expiration period after first commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Alnylam Pharmaceuticals Inc | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentToCollaboratorResultingFromProgramOptionExercise', window );">Payment to collaborator resulting from program option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember', window );">Alnylam Agreement | Alnylam Pharmaceuticals Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach', window );">Written notice period to terminate licensed program for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge', window );">Written Notice period to terminate licensed program if under challenge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales', window );">Royalty payment obligation expiration period after first commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ValueOfSharesTransferredToCollaborator', window );">Value of shares transferred to collaborator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_UpfrontFeePaid', window );">Upfront fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumSharesToBeIssued', window );">Maximum shares to be issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Estimated fair value of the derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MilestonePaymentsPaid', window );">Milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementRelatedCostsAndExpenses', window );">Expenses incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="nump">18,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram', window );">Written notice period for termination of licensed program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment', window );">Written notice period to terminate licensed program for failure to make payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember', window );">Alnylam Agreement | Alnylam Pharmaceuticals Inc | First siRNA Product HBV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts', window );">Range of tiered royalties to pay on net sales of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low double-digits to mid-teens<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory', window );">Maximum milestone payment for achievement of specified development and regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateSalesMilestonePayment', window );">Maximum aggregate sales milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember', window );">Alnylam Agreement | Alnylam Pharmaceuticals Inc | Each Infectious Disease siRNA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts', window );">Range of tiered royalties to pay on net sales of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">high single-digits to the sub-teen double-digits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory', window );">Maximum milestone payment for achievement of specified development and regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumSalesMilestonePayment', window );">Maximum sales milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_DevelopmentAndManufacturingCollaborationAgreementMember', window );">Development and Manufacturing Collaboration Agreement | WuXi Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days&#8217; prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within 60 days.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct', window );">Royalties payment range on net sales of licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">high single-digits to mid-teens<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember', window );">Rockefeller Agreement | Rockefeller</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days&#8217; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#8217; written notice for the Company&#8217;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#8217;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateAgreementByCompany', window );">Written notice period to terminate agreement by company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_AnnualLicenseMaintenanceFees', window );">Annual License Maintenance Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateAgreementByCounterparty', window );">Written notice period to terminate agreement by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_UpfrontFeePaid', window );">Upfront fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale', window );">Royalty obligation period from date of first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement', window );">Research and development expense under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember', window );">Rockefeller Agreement | Rockefeller | Infectious Disease Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones', window );">Maximum aggregate milestone payment for achievement of specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember', window );">Rockefeller Agreement | Rockefeller | Infectious Disease Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment', window );">Maximum number of products covered against milestone payment | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember', window );">MedImmune Agreement | Influenza A and Influenza B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct', window );">Royalties payment range on net sales of licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">mid-single-digits to sub-teen double-digits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember', window );">MedImmune Agreement | MedImmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_NumberOfAntibodiesToDevelop', window );">Number of antibodies to develop | Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_LicenseAgreementUpfrontPayment', window );">License agreement upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember', window );">MedImmune Agreement | MedImmune | Influenza A and Influenza B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#8217; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#8217;s uncured material breach on 60 days&#8217; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on 30 days&#8217; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach', window );">Written notice period to terminate licensed program for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones', window );">Maximum aggregate milestone payment for achievement of specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram', window );">Written notice period for termination of licensed program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges', window );">Written Notice period to terminate licensed program if under challenges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments', window );">Specified research and development expenses milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor | HBV Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor | Influenza A Research Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor | Influenza A and HBV Research Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct', window );">Royalties payment range on net sales of licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low- to mid-single-digits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments', window );">Maximum aggregate development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateCommercialSalesMilestonePayments', window );">Maximum aggregate commercial sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember', window );">2020 Xencor Agreement | Xencor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltiesPaymentExpirationPeriod', window );">Royalties payment expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltiesBasedOnNetSalesOfLicensedProducts', window );">Royalties based on net sales of licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> mid-single-digits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember', window );">2019 and 2020 Xencor Agreement member | Xencor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon 60 days&#8217; written notice. Either party may terminate each agreement for the other party&#8217;s uncured material breach upon 60 days&#8217; written notice (or 30 days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon 30 days&#8217; written notice if any of the Company&#8217;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach', window );">Written notice period for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram', window );">Written notice period for termination of licensed program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges', window );">Written Notice period to terminate licensed program if under challenges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment', window );">Written notice period to terminate licensed program for failure to make payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License maintenance fees required to pay annually.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AntibodyLicenseTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction price for the Antibody License under the collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AntibodyLicenseTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement, number of separate programs agreed to collaborate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementNumberOfUnitsOfAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement, number of units of account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementNumberOfUnitsOfAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementRelatedCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs and expenses for the period incurred under the collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementRelatedCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementTransactionPriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement transaction price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementTransactionPriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementTransactionPriceUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received under the Collaboration agreement, which represents part of the transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementTransactionPriceUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationTypeAndPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Type and Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationTypeAndPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DeterminedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Determined transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DeterminedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FairMarketValueOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair market value of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FairMarketValueOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in research And development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateCommercialSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate commercial sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateCommercialSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate development and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone payment for achievement of specified milestones, including development, regulatory and commercial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone payment for achievement of specified annual net sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payment for achievement of specified development and regulatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Number of Development Program Granted from Counterparty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Number of Development Program Granted to Counterparty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of products covered against milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of right to perform details in connection with antibody product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumSalesMilestonToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of proceeds to pay upon achievement of sales milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumSalesMilestonToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payment for achievement of specified annual net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum shares to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NumberOfAntibodiesToDevelop">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of antibodies to develop.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NumberOfAntibodiesToDevelop</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of years conduct certain research and development activities under mutually agreed development plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeConsiderationToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise fee consideration to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeConsiderationToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeHighEndOfTheRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the high end of the range of option exercise fee upon exercise of a program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeHighEndOfTheRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeLowEndOfTheRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the low end of the range of option exercise fee upon exercise of a program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeLowEndOfTheRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise fee received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentToCollaboratorResultingFromProgramOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to a collaborator due to a program option exercise under a separate agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentToCollaboratorResultingFromProgramOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfOrdinaryShareEqualToOutstandingShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of ordinary share equal to outstanding share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfOrdinaryShareEqualToOutstandingShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfShareDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfShareDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment receivable at effective date of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment receivable at execution date of agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PreDefinedRegulatoryMilestoneConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-defined regulatory milestone consideration receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PreDefinedRegulatoryMilestoneConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PremiumReceivedOnSalePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium received on sale price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PremiumReceivedOnSalePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProfitsAndLossesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profits and losses sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProfitsAndLossesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RangeOfRoyaltyPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of royalty payment to be paid by counterparty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RangeOfRoyaltyPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RangeOfRoyaltyPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of royalty payment to be received by the company upon exercised of the development programs by counterparty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RangeOfRoyaltyPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of tiered royalties to pay on annual net sales of products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payment on licensed product, high end of the range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payment on licensed product, low end of the range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payment to be received by the company upon exercised of the development programs by counterparty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense under license agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltiesBasedOnNetSalesOfLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties payment based on net sales of licensed products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltiesBasedOnNetSalesOfLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltiesPaymentExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of years that royalties payment expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltiesPaymentExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties payment range on net sales of licensed product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty obligation period from date of first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment obligation expiration period after first commercial sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses related to certain development milestone payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_UpfrontFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_UpfrontFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_UpfrontPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_UpfrontPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ValueOfSharesTransferredToCollaborator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares transferred to collaborator under the terms of the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ValueOfSharesTransferredToCollaborator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period for licensed program, uncured material breach.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period for termination of licensed program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForTerminationOfLicensedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateAgreementByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate agreement by company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateAgreementByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateAgreementByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate agreement by counterparty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateAgreementByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate licensed program for failure to make payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate licensed program for uncured material breach.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticeToTerminateLicensedProgramIfExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice to terminate licensed program following the exercise of an option for such program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticeToTerminateLicensedProgramIfExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice to terminate licensed program if not exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_GlaxoWellcomeUKLimitedAndBeechamSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_GlaxoWellcomeUKLimitedAndBeechamSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=vir_AccruedLiabilitiesAndOtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=vir_AccruedLiabilitiesAndOtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_GlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_GlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_AntibodyProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_AntibodyProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_VaccineProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_VaccineProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_DefinitiveCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_DefinitiveCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByVirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByVirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByBriiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByBriiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_BriiBioParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_BriiBioParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_BiologicalMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_BiologicalMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_BriiBiosciencesOffshoreLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_BriiBiosciencesOffshoreLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_AlnylamPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_AlnylamPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_FirstSiRNAProductHBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_FirstSiRNAProductHBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_EachInfectiousDiseaseSiRNAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_EachInfectiousDiseaseSiRNAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_DevelopmentAndManufacturingCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_DevelopmentAndManufacturingCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_WuXiBiologicsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_WuXiBiologicsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_RockefellerUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_RockefellerUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_FirstInfectiousDiseaseProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_FirstInfectiousDiseaseProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfectiousDiseaseProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfectiousDiseaseProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfluenzaAAndInfluenzaBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfluenzaAAndInfluenzaBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_MedImmuneLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_MedImmuneLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_XencorIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_XencorIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_HBVProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_HBVProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfluenzaAResearchProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfluenzaAResearchProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfluenzaAAndHBVResearchProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfluenzaAAndHBVResearchProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563223464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 57,326<span></span>
</td>
<td class="nump">$ 27,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(14,492)<span></span>
</td>
<td class="num">(9,232)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">42,834<span></span>
</td>
<td class="nump">17,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vir_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">20,012<span></span>
</td>
<td class="nump">16,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">1,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,834<span></span>
</td>
<td class="nump">7,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 26,925<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vir_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vir_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459564121544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 5,278<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 3,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563348616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MilestonePayable', window );">Milestone payable</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">58,672<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">28,073<span></span>
</td>
<td class="nump">49,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PayrollAndRelatedExpensesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">29,753<span></span>
</td>
<td class="nump">17,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income taxes</a></td>
<td class="nump">6,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ExcessFundsPayableUnderGrantAgreementsCurrent', window );">Excess funds payable under grant agreements</a></td>
<td class="nump">1,825<span></span>
</td>
<td class="nump">3,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">3,927<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Other professional and consulting expenses</a></td>
<td class="nump">2,791<span></span>
</td>
<td class="nump">2,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">10,254<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued and other liabilities</a></td>
<td class="nump">$ 236,512<span></span>
</td>
<td class="nump">$ 76,936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ExcessFundsPayableUnderGrantAgreementsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess funds payable under grant agreements current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ExcessFundsPayableUnderGrantAgreementsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PayrollAndRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll and related expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PayrollAndRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459470710072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 04, 2020</div></th>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 09, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_LeaseArrangementContractualExpirationBeginningYear', window );">Lease arrangement, contractual expiration period, beginning year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_LeaseArrangementContractualExpirationEndingYear', window );">Lease arrangement, contractual expiration period, ending year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain from a sublease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,844<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from one to five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,437)<span></span>
</td>
<td class="num">(4,467)<span></span>
</td>
<td class="num">(5,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_TenantImprovementAllowanceAggregate', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">5,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,187<span></span>
</td>
<td class="nump">$ 48,495<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OperatingAndFinanceRentExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_SamsungBiologicsCompanyLimitedMember', window );">Samsung Biologics Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ObligationToPayCapacityReservation', window );">Obligation to pay capacity reservation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_WuXiBiologicsLimitedMember', window );">WuXi Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ObligationToPayCapacityReservation', window );">Obligation to pay capacity reservation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineTradingServiceLimitedMember', window );">GSKTSL | WuXi Biologics MSA and Samsung MSA | Antibody Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="nump">72.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember', window );">GSK | WuXi Biologics MSA and Samsung MSA | Antibody Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="nump">27.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | WuXi Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfEstimatedBatchProductionFees', window );">Percentage of estimated batch production fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | WuXi Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfEstimatedBatchProductionFees', window );">Percentage of estimated batch production fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LeaseArrangementContractualExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease arrangement, contractual expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LeaseArrangementContractualExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LeaseArrangementContractualExpirationEndingYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease arrangement, contractual expiration ending year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LeaseArrangementContractualExpirationEndingYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ObligationToPayCapacityReservation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount obligated to pay for capacity reservation under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ObligationToPayCapacityReservation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingAndFinanceRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingAndFinanceRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfEstimatedBatchProductionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of estimated batch production fees owed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfEstimatedBatchProductionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_TenantImprovementAllowanceAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of tenant improvement allowance available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_TenantImprovementAllowanceAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_SamsungBiologicsCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_SamsungBiologicsCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_WuXiBiologicsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_WuXiBiologicsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineTradingServiceLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_GlaxoSmithKlineTradingServiceLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_AntibodyProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_AntibodyProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459555874152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 11,921<span></span>
</td>
<td class="nump">$ 4,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">4,256<span></span>
</td>
<td class="nump">2,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total least cost</a></td>
<td class="nump">$ 16,438<span></span>
</td>
<td class="nump">$ 7,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OperatingLeaseOtherInformationAbstract', window );"><strong>Other Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">10 years 4 months 24 days<span></span>
</td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 6,250<span></span>
</td>
<td class="nump">$ 5,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets in exchange for operating lease liabilities</a></td>
<td class="nump">$ 77,187<span></span>
</td>
<td class="nump">$ 48,495<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingLeaseOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease other information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingLeaseOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459561416520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 12,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">19,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">18,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">15,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">16,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">103,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">185,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(45,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived', window );">Less: net tenant improvement allowance yet to be received</a></td>
<td class="num">(52,217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PresentValueOfOperatingLeaseLiabilities', window );">Present value of operating lease liabilities</a></td>
<td class="nump">87,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 137,488<span></span>
</td>
<td class="nump">$ 70,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability net tenant improvement allowance yet to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PresentValueOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, net of tenant improvement allowance yet to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PresentValueOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563318296">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OperatingLeaseAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OperatingLeaseIncentiveOverLeaseLiabilities', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 49,536<span></span>
</td>
<td class="nump">$ 7,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating ROU assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 87,220<span></span>
</td>
<td class="nump">$ 61,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Accrued Liabilities and Other Liabilities<span></span>
</td>
<td class="text">Accrued Liabilities and Other Liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,927<span></span>
</td>
<td class="nump">$ 3,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">133,561<span></span>
</td>
<td class="nump">66,556<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 137,488<span></span>
</td>
<td class="nump">$ 70,181<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingLeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingLeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingLeaseIncentiveOverLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Incentive Over Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingLeaseIncentiveOverLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459564218744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vir_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">18,202,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vir_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vir_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459552218584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 10, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 11, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from sale of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 317,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_NumberOfClassOfStock', window );">Number of class of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,112,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">88,112,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vir_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Convertible preferred stock, shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,202,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,202,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Convertible preferred stock, shares sold, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from sale of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_TemporaryEquityAdditionalSharesAuthorized', window );">Convertible preferred stock, additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,020,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,910,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock (in shares)</a></td>
<td class="nump">88,112,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NumberOfClassOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of class of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NumberOfClassOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_TemporaryEquityAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity additional shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_TemporaryEquityAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vir_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vir_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459562260456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock Warrant Liability - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 11,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vir_SeriesAOneConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants issued, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodWarrantExercised', window );">Common stock shares issued for conversion of warrants</a></td>
<td class="nump">211,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the exercise of warrant during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vir_SeriesAOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vir_SeriesAOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459557561864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RestrictedStockPurchaseAgreementMember', window );">Restricted Stock Purchase Agreement | Executive Officer and Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,624,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.1<span></span>
</td>
<td class="nump">$ 53.1<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.62<span></span>
</td>
<td class="nump">$ 25.49<span></span>
</td>
<td class="nump">$ 7.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock-based compensation expense related to stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived', window );">Repayment of outstanding promissory notes and accrued interest received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Share issued under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,261<span></span>
</td>
<td class="nump">1,986,250<span></span>
</td>
<td class="nump">1,348,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Option price as a percentage of estimated fair value on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of awards from issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Option price as a percentage of estimated fair value on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,092,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of awards from issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OfferingPeriodEmployeeStockPurchasePlan', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Share issued under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Option price as a percentage of estimated fair value on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized to issue under purchase rights granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of employee payroll deduction on earnings, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OfferingPeriodEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Duration of offering period under the Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OfferingPeriodEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of outstanding promissory notes and accrued interest received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_RestrictedStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_RestrictedStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vir_ExecutiveOfficerAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vir_ExecutiveOfficerAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vir_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vir_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vir_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459553442216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Stock Option Plans Activity (Details) - Stock Option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options,Outstanding, Beginning Balance</a></td>
<td class="nump">9,798,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options,Granted</a></td>
<td class="nump">3,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options,Exercised</a></td>
<td class="num">(1,622,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options,Forfeited</a></td>
<td class="num">(1,160,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options,Outstanding, Ending Balance</a></td>
<td class="nump">10,308,928<span></span>
</td>
<td class="nump">9,798,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options,Vested and expected to vest</a></td>
<td class="nump">10,308,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Options,Vested and exercisable</a></td>
<td class="nump">4,238,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 19.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">58.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">8.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">34.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">31.75<span></span>
</td>
<td class="nump">$ 19.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Vested and expected to vest</a></td>
<td class="nump">31.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Vested and exercisable</a></td>
<td class="nump">$ 17.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term,Vested and expected to vest</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term,Vested and exercisable</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Balance</a></td>
<td class="nump">$ 160,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">160,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">$ 105,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459557495064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility,minimum</a></td>
<td class="nump">103.10%<span></span>
</td>
<td class="nump">88.80%<span></span>
</td>
<td class="nump">86.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility,maximum</a></td>
<td class="nump">112.10%<span></span>
</td>
<td class="nump">108.60%<span></span>
</td>
<td class="nump">89.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459563202168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility,minimum</a></td>
<td class="nump">103.10%<span></span>
</td>
<td class="nump">88.80%<span></span>
</td>
<td class="nump">86.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility,maximum</a></td>
<td class="nump">112.10%<span></span>
</td>
<td class="nump">108.60%<span></span>
</td>
<td class="nump">89.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of ESPP (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility,minimum</a></td>
<td class="nump">76.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility,maximum</a></td>
<td class="nump">144.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459560681528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Restricted Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Beginning Balance | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">1,366,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited | shares</a></td>
<td class="num">(94,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Ending Balance | shares</a></td>
<td class="nump">1,271,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">60.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">66.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 59.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vir_RestrictedStockAwardsRSAMember', window );">Restricted Stock Awards (RSAs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Beginning Balance | shares</a></td>
<td class="nump">89,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(89,261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Ending Balance | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">1.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vir_RestrictedStockAwardsRSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vir_RestrictedStockAwardsRSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459560622952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 83,784<span></span>
</td>
<td class="nump">$ 27,600<span></span>
</td>
<td class="nump">$ 8,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">42,554<span></span>
</td>
<td class="nump">13,663<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 41,230<span></span>
</td>
<td class="nump">$ 13,937<span></span>
</td>
<td class="nump">$ 5,685<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459471134696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 528,584<span></span>
</td>
<td class="num">$ (298,665)<span></span>
</td>
<td class="num">$ (174,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">129,884,967<span></span>
</td>
<td class="nump">119,159,424<span></span>
</td>
<td class="nump">30,349,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Options to purchase common stock</a></td>
<td class="nump">3,513,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting', window );">Restricted shares subject to future vesting</a></td>
<td class="nump">35,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares', window );">Contingently issuable shares</a></td>
<td class="nump">3,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">133,437,126<span></span>
</td>
<td class="nump">119,159,424<span></span>
</td>
<td class="nump">30,349,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
<td class="num">$ (5.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted</a></td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
<td class="num">$ (5.76)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares.  Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 54<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2603-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 44<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2062-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1828-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2600-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2597-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2538-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2538-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2574-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares subject to future vesting using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459560540536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">6,852,612<span></span>
</td>
<td class="nump">9,887,543<span></span>
</td>
<td class="nump">9,506,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">5,764,308<span></span>
</td>
<td class="nump">9,798,282<span></span>
</td>
<td class="nump">7,186,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares Subject to Future Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,088,304<span></span>
</td>
<td class="nump">89,261<span></span>
</td>
<td class="nump">2,075,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459564234824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_EstimatedSharesEmployeeStockPurchasePlans', window );">Estimated shares to be issued under plan</a></td>
<td class="nump">65,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_EsppDiscountedPurchasePricePercentage', window );">ESPP discounted purchase price percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_EsppDiscountedPurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ESPP Discounted Purchase Price Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_EsppDiscountedPurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_EstimatedSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Shares Employee Stock Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_EstimatedSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459561491240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, contribution expenses</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459556760104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Provision for (Benefit from) Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 535,989<span></span>
</td>
<td class="num">$ (309,697)<span></span>
</td>
<td class="num">$ (138,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">13,813<span></span>
</td>
<td class="nump">11,086<span></span>
</td>
<td class="num">(35,805)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="nump">$ 549,802<span></span>
</td>
<td class="num">$ (298,611)<span></span>
</td>
<td class="num">$ (174,529)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459552417112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 3,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">2,401<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="nump">6,032<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">15,186<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">15,186<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">$ (21,218)<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
<td class="num">$ (154)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459562265768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ReconciliationOfEffectiveIncomeTaxRateLineItems', window );"><strong>Reconciliation Of Effective Income Tax Rate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax at less than federal statutory rate</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior year tax rate adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent', window );">Permanent items</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">(17.90%)<span></span>
</td>
<td class="num">(25.30%)<span></span>
</td>
<td class="num">(24.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent items percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReconciliationOfEffectiveIncomeTaxRateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of effective income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReconciliationOfEffectiveIncomeTaxRateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459471056120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 15,030<span></span>
</td>
<td class="nump">$ 117,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforward</a></td>
<td class="nump">11,375<span></span>
</td>
<td class="nump">12,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity compensations</a></td>
<td class="nump">15,065<span></span>
</td>
<td class="nump">4,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals</a></td>
<td class="nump">7,115<span></span>
</td>
<td class="nump">10,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">28,612<span></span>
</td>
<td class="nump">16,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">19,657<span></span>
</td>
<td class="nump">23,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">96,854<span></span>
</td>
<td class="nump">183,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities', window );">Unrealized gain on investments</a></td>
<td class="num">(30,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_DeferredTaxLiabilitiesRightOfUseAssets', window );">ROU assets</a></td>
<td class="nump">28,483<span></span>
</td>
<td class="nump">16,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(2,422)<span></span>
</td>
<td class="num">(2,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment', window );">IPR&amp;D</a></td>
<td class="nump">8,511<span></span>
</td>
<td class="nump">8,511<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(69,586)<span></span>
</td>
<td class="num">(27,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(45,707)<span></span>
</td>
<td class="num">(159,891)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (18,439)<span></span>
</td>
<td class="num">$ (3,253)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities in process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459552198504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase/decrease in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,100,000<span></span>
</td>
<td class="nump">$ 42,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ReleaseOfValuationAllowanceDeferredTaxInAmount', window );">Release of valuation allowance</a></td>
<td class="nump">$ 114,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit</a></td>
<td class="nump">7,422,000<span></span>
</td>
<td class="nump">4,877,000<span></span>
</td>
<td class="nump">2,725,000<span></span>
</td>
<td class="nump">$ 2,404,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits, if recognized, would reduce effective tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties expense related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued related to uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 24,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OperatingLossCarryforwardsExpirationBeginningYear', window );">Net operating loss carryforwards expiration beginning year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OperatingLossCarryforwardsLimitationOnUsePercentage', window );">Net operating loss deduction limitation as percentage of taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OperatingLossCarryforwardsExpirationBeginningYear', window );">Net operating loss carryforwards expiration beginning year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 126,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OperatingLossCarryforwardsExpirationBeginningYear', window );">Net operating loss carryforwards expiration beginning year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Oregon | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OperatingLossCarryforwardsExpirationBeginningYear', window );">Net operating loss carryforwards expiration beginning year</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Swiss Federal Tax Administration (FTA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingLossCarryforwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingLossCarryforwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingLossCarryforwardsLimitationOnUsePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards limitation on use percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingLossCarryforwardsLimitationOnUsePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReleaseOfValuationAllowanceDeferredTaxInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release of valuation allowance deferred tax in amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReleaseOfValuationAllowanceDeferredTaxInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_OR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_OR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459559557736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at January 1</a></td>
<td class="nump">$ 4,877<span></span>
</td>
<td class="nump">$ 2,725<span></span>
</td>
<td class="nump">$ 2,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Addition for tax positions taken in the prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reduction for tax positions taken in the prior years</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(588)<span></span>
</td>
<td class="num">(1,596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Addition for tax positions taken in current year</a></td>
<td class="nump">2,607<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at December 31</a></td>
<td class="nump">$ 7,422<span></span>
</td>
<td class="nump">$ 4,877<span></span>
</td>
<td class="nump">$ 2,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140459564248120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Details) - Subsequent Event - Bill &amp; Melinda Gates Foundation [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CashGrantAwarded', window );">Business agreement grant amount</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ValueStockIssuedGrantAgreement', window );">Value of common stock issued in connection with the grant agreement</a></td>
<td class="nump">$ 40.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedGrantAgreement', window );">Common stock issued in connection with the grant agreement | shares</a></td>
<td class="nump">881,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CashGrantAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash grant awarded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CashGrantAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedGrantAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total common stock issued in connection with the grant agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedGrantAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ValueStockIssuedGrantAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total value of common stock issued in connection with the grant agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ValueStockIssuedGrantAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_BillMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_BillMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>vir-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vir="http://www.vir.bio/20211231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vir-20211231.xsd" xlink:type="simple"/>
    <context id="C_7b782a32-6679-4004-9be5-e91a7a28b3e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineTradingServiceLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="C_7d9adb10-9589-4116-8468-f2a901cec9e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndInfluenzaBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_f546f6f3-d48a-486c-8052-617336a81a7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_91330166-4192-4765-8752-a172cb399634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_c672b8f5-c39b-47aa-bcad-cd04fd706515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:VaccineProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_27d6b8f0-fa5a-4e00-b4fd-9df702316b81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0125c984-0483-44b4-9fe9-ea8280d5aef7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7bd2b5a2-2224-4f6d-aacc-dc5934151bac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HcmvVaccinePlatformGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-05</instant>
        </period>
    </context>
    <context id="C_e5046b1c-890a-4d88-9c47-8d81f489b3cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0ded0a8a-1711-44a2-8906-3b560cb68ef4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:WuXiBiologicsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="C_5fa4019b-73c6-4a3b-be6c-7aa4984acca2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:AccruedLiabilitiesAndOtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4f17c5a8-e2ce-47e8-9a5f-717bf5afb341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_c8189099-45c1-41f2-b6ca-954b37c65618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_c3d7153f-2142-47b5-836a-92c25c9b950c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_71a5c221-44c0-4e41-a2fa-4f7fa314d849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_7589f598-a536-40ef-ae5d-943416f75b64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_74f0b6e6-2f8c-42cd-82e3-2ad83cc03354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f89b46e3-8544-4acc-962d-faf2858aa020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedRevenueVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_30a9821b-b5e9-46b1-8ada-d4dccbd412c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d9c4cf79-3f00-4bf0-bcd2-f9232b1fcc14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_d49462cf-7289-42fd-ade3-fc506e048127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7c35f7ee-7ce8-4791-b6e1-4269f4a1e21d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_3b8fb261-7fe1-496c-8e0b-dba547d8fd42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8a57dade-b465-4a49-be9a-5cb7b24a6ffc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfectiousDiseaseProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_0be73e2a-ec59-4143-9931-80891ed3a51b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0e39b64d-0aec-4926-941a-2eeb4cc3e0c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_810fc216-bb93-4ea9-b973-024c33461e81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_9c4a05c0-ab68-4442-bfca-80dd0cb82f0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_e143173f-1c22-40fb-ba0b-999bdcd9677f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_24859036-8402-474d-a1b9-81a9c9af22a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vir:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_2f3a686d-485c-4e98-8bf8-9cbe259cabcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_813ff2ee-1d90-44ea-b0f0-79248d502136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0ad71b1a-ef19-44b7-ae86-72e2d88c9ede">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_1aa5fc1c-95ff-4281-9c2e-6292a0baba92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_41895c62-83e2-4823-a8d7-01879c19221e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_68d98f4f-0d83-475e-8b52-0b892db80670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cb6f51fe-eb87-484b-a6ba-f5a1a6fa73d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4d72106c-4ece-48a5-890f-cdc4894fc993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandSeventeenGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="C_ba75ea58-13bc-4e3d-8ef1-d07deeb228c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b1374ee0-34e2-4104-bf31-9dd183c22ca3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_c2a50417-42a1-40be-8caf-f0cebc94ffff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_df4b5d69-777f-4164-ba06-7c95c5c18601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_eaf05464-1224-4ae2-8baa-f4387ec342ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_bd790442-a1c8-4c01-a7b4-906b111a3a51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_a16ebff0-6b04-4a9b-bc6e-bc5cd87822d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f41d2de0-2ba6-4580-bbfa-01ae990de9ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_3afd1e8b-5267-4120-b240-7f12f4a61a4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d7535086-58ed-4942-918e-2201970b8cea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c7bf9af0-7a63-47de-aa6e-7c2731d130ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9bbee3cc-0441-482d-a60a-021bdde5fb32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandSeventeenGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="C_374d06f8-fb5c-49ef-9129-8079100e5579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_a27a1fab-d4d1-430e-a2ef-eaaa1ad83180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4700e2f3-e411-4471-9030-da4a2a264740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7b12cfb1-fdf1-4522-acd2-8b1f2eb36f1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-14</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_8a692092-b0fd-48e1-be4e-22e37c497148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0003b2b6-cfb3-4fa2-90d1-98eb440f3fcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_15e3e949-97fb-495d-b1d0-55b62ebddcc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f3142090-a1b8-4083-8441-c9dd49ecb566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e9b5a1f5-d509-4f41-a5b0-00e6735b747a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vir:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-09</startDate>
            <endDate>2019-10-10</endDate>
        </period>
    </context>
    <context id="C_9de06e9c-4123-49c9-9448-9c22581415b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-26</instant>
        </period>
    </context>
    <context id="C_ce562ce2-89d4-4006-bd1c-8ec2a20274f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_56c9c1ac-6a87-4622-b2fb-da94dac65173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_f0ace255-aaf9-4b62-af6c-209acf635d22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8b2320ed-d560-4b7d-850c-3e4bf7238d2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6a0b0601-deb2-4157-ba2f-7613b7f73ba3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vir:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_88183c78-6814-4146-96c6-0cba18d5611c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_b85c9788-4228-4009-81b0-cb885a8a21d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_488948dd-80d3-45b7-a684-756b5feb098a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5299f27f-f8a0-4e30-874b-2faab774be38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4a4d7f99-61b1-4dd9-8b7a-51541fecc5f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_bc4e105a-e463-4014-aae3-86682a1d49a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0d48684e-c8e1-4db3-a973-d66108c108c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:ClinicalDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_f7c9462b-dcbe-4e0d-ad24-fa03ee7db19f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstInfectiousDiseaseProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_953e43a8-2a7e-48ad-a529-e63d37ac462c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a32e557e-b0ba-4f99-bb95-674d8a7d72ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c7f66cdc-e2a5-4776-b99c-d6e4b917eb2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d7012ff2-8e91-4fa6-b536-458c48e3b5ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_224cb303-9ce3-44c9-8e2e-6437c0fdeafb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_5f6d55c2-91b3-4ca7-adf9-970debbec4df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_accfab4e-3a9c-48c5-9d0d-b1f80346071b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="C_974c0603-8333-4dce-9655-97b1212bed01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_c10e626c-f383-4183-bf3d-6e3516f85d94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_8d214461-dd67-46fd-97ae-535ac3188674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_49d8bcd1-7a7f-42e5-892b-9a0cd8d9902d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_2f8addeb-5f7f-45ee-807d-84c9144573a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9877f0f7-e105-480e-b0a7-fb9e68d056f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_501b75ac-22be-4b07-9759-c03d7aa1ce0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_91794362-8b4e-44c7-8392-9d2e078a248a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6a35132f-d773-49ba-9363-edcb9df0bf0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstSiRNAProductHBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-31</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_8b224cd3-1cba-4c7d-b686-ace421bc028d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HcmvVaccinePlatformGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7c483ff8-5408-46f2-a03d-22d662c61cf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="C_33252fb3-7851-44e7-9561-2d534fcb41de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_9df0518d-0a7a-4d2c-92b4-a8e2b609380f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5d7448b7-0904-4443-a40d-a6bc22ea01ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8d7fc207-68b5-469e-b2a5-a7be19fc2bad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_301f15e9-11d1-406a-b0be-2ca7cc4b7543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_931f9106-3768-4f05-bd7b-0855dd2f9745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vir:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_65bd9d63-ee77-45dd-a499-a8f0b310c5e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8d74b360-ce4a-44f2-9de1-d605ea9e3611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_808e2ec7-0dc9-49ea-8101-9ff9a724d929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_1a31bf7c-9f6e-4b04-9a96-43549f6f4cc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b5bc95aa-a39a-42b9-82dc-8f1e49c3c984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f5edd5d0-093c-4a7f-9010-06a8b6d0943c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_69329fa9-5ba5-4337-a561-386bfedc0568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_eb465827-50c0-422c-a785-a18988e1c54b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-14</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_cb8cdd31-0bed-4661-832a-fa3a50385e05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:WuXiBiologicsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="C_be5c6cf7-b468-4342-99e6-e6f0cb45b27a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e837f6cd-46cf-43d6-8ea9-08f5560d9cf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_a567406d-6fcd-4a01-a0c2-596b4cb717b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c0b1e9f3-2c15-4ace-bc47-71fc21bcc480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_064e544a-5338-44a5-8d21-57da4323d0ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_079288b4-6cb4-4671-8ab2-600c75753f48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d9c4bdc2-99a7-4b17-b04f-d11af920c552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_250f68b2-8222-4f1b-a3b9-f47c995fde57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="C_d1073bf6-3fc5-4a5a-97f0-bbd26559fb5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_46ac8ad0-5eff-4cd3-9959-e7aa7afae14f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_deffe243-ff55-4872-8584-6b06fc133c1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstSiRNAProductHBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_0491c773-5dc7-4c46-bec3-e5a5ab07096c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_714f6509-93e2-40d8-93c7-af8d8831b31d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ed3b9e09-2b8e-4a52-a1e4-da67c4059a2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6095766d-f048-4375-875a-769201aac419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_819e77e6-c072-4b31-ba45-3c415b3f67d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_8fccfc88-43e9-4439-a516-7a1eda119be4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_eaceb94a-8ec3-4208-a7d4-ba474353d176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_4b3827f4-9f03-4d95-b4e5-11849acbae16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_bf931caa-5cb0-4310-8883-afbdea037621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d5f3ecc6-0f0d-4709-940b-a9657a2029f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_2d502ed6-15ab-425f-9a22-bfc1d3c39623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-10</startDate>
            <endDate>2019-10-10</endDate>
        </period>
    </context>
    <context id="C_9599deea-454d-4e26-bedc-49ceb4cf2404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_475e9f82-cbd7-4ec6-8eb2-24bad29614d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6595e636-7a23-4034-861a-6a075f66f7cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_348661d6-b9d4-405f-81cc-4d936a14f5b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_a9001d10-0c10-49dc-a944-46388f818412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_cd77bc9a-f90c-4d89-9139-053ac79a0a7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_ec203b07-51b7-4cd9-82e7-1152642f49ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:BiologicalMaterialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f506a175-6fde-4e73-bbbc-20e846b33555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ca5007f4-5584-4178-8601-b447870799b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-14</instant>
        </period>
    </context>
    <context id="C_7805a9f3-b0a3-4562-b373-15bbc4dab334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6593689d-6c09-413e-8c82-082f1af9b2e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_ee4ca4dd-dd89-4390-b7dd-451122361af3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="C_3a524056-f9aa-4720-b2b3-0ab25f4155a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndHBVResearchProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_14c2d113-77d4-4ecb-aadc-32b535038ad1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3c763cb1-70d7-4e23-8984-44c48ee907cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_643ca0ff-cb47-43ec-917c-167fbc2cff60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_405140f2-f0e9-44c0-b8cf-d4d833a30755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7c199ed9-32db-4a22-a38e-1c376f297c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_675e042c-eb56-4fb7-aaea-43c58b4c0aa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_a14402f0-9a6d-4005-9600-5bb5f45f3cf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e6e46de8-f795-4991-b51d-0af545d01d4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_3180a70a-dfa7-4102-9724-38babfd3d0ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_31279301-58e0-4e0d-beea-e0a2ac9b9cfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e3de3d32-1468-4cb9-b95b-a8d0af66f9af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="C_050ac877-095b-4637-b981-1aea98d3b192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_be140e6e-3761-4ec9-ba59-319fd0975a8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="C_0ae824f4-f2da-4275-addc-163ec36b47a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_da7048e3-08ee-4a8f-a9eb-1ecdc468ee9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f99ec918-2e4e-432a-970f-3c67447885a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_88ec3719-e182-4d88-abf8-cefce0fa050c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-10</startDate>
            <endDate>2020-07-10</endDate>
        </period>
    </context>
    <context id="C_37e02e2b-ecee-41f9-9516-eff5990866ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e52b7462-3e95-4a90-a2ac-eeb96cc91696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2019-10-09</startDate>
            <endDate>2019-10-10</endDate>
        </period>
    </context>
    <context id="C_63b7f812-9b12-47ea-b2fb-128ab0685b44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d3a8cc93-b738-43bd-abbd-308523b5cd24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9cc53898-90ab-48e4-811b-68336c8459bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4d722794-e16e-4e44-9edc-feb0c31aee2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AnotherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="C_b2d805bd-8fe4-4a5d-a29f-32025b612cb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_160a64f9-0857-4c36-8f24-34b857e2d49c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_3b4acd09-0f98-4d80-8e8b-2e3567b35e97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_ad98faf6-018f-4435-8e8a-c91df1a4d6c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_19681061-85d7-43eb-9090-f6c375682fba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4535e3d1-cadf-43e9-a70d-52008cd60dfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_021eeba0-02e7-4697-bcf5-81b5a7722190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HcmvVaccinePlatformGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_df0832a0-b752-462c-be11-1620cfe4dc18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_34998bcb-fe81-4e6a-839c-342803b38b04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_8d81f5ee-bce5-4497-8145-ef3258cee1b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_830b2851-70de-48fc-94e9-c824f5a5454c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_d3e6496b-39fc-4dee-953c-9b3b230bf6cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_8ae9b192-da16-4b61-9aca-9b2e398bb09f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_518a3141-66a8-47ab-978b-8e77ec8e8f30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:WuXiBiologicsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="C_05bb4f29-b066-4a68-b91c-484f95f96b0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_04ff1607-fb14-42a5-912f-34d468278706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_dcb52d16-86fa-4370-9fc3-793fe22d8181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:SamsungBiologicsCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="C_ad2a2cfc-b340-447d-9eaa-b40190d30427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_515a352c-312e-4bf3-9bf8-04b085f91abc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3d2840b2-01d0-4017-822e-05963d9d6961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_71eb2cf3-b567-474c-8eb2-9294af7f7cd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_e1a9eeda-0adf-4886-b25f-5e7c6923762a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HcmvVaccinePlatformGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_024bb253-6952-4f27-abbf-00f7a4f1d57c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9e120ade-622b-4150-9778-b6f3b2b76cc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_0733b4ef-c448-4927-8d8e-84da4192b4ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_a8765b59-506d-4165-9487-b02bdc930b58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_97f0fbad-d4bf-4f2b-8e7f-fa6521b24a9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_55353dc3-d2db-42da-a649-4767a86be523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_3be2e934-f078-49d4-9962-afce5e0c771d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_a58fa995-aa0b-4d6d-9cce-6dbe94de83fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f999fb4c-9967-4386-a71c-e0a64a7891bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ef618346-1e5d-4fc9-884c-3b4a0ef0bade">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_ffe17dae-8660-4c99-8aab-15f3d99a9a63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6e34598c-0a2b-44cb-8608-379e7e560202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2082200e-8d81-44c2-9451-795cb9436f26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="C_b2e6a670-5d82-408a-9795-8749e0878917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2021-10-30</instant>
        </period>
    </context>
    <context id="C_3200e2aa-d8c3-4db7-a6bc-1e84a8a07638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5ce5cca5-d328-4861-8f28-b94590239275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7d78f477-8e15-46ec-9ae7-c436d7a5b269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vir:ExecutiveOfficerAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RestrictedStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="C_3f145b8a-a89a-4b1f-beee-1a8a6ab8f021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b38fd327-4513-4808-ac50-5d5528a35383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_59d377ae-8381-45db-9cc4-7efce0201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_7a978f36-d4af-4db5-8584-15add2567749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c65ef721-72ea-40b3-878d-db5fb1796225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_786d6b05-a5c6-4c6b-bd8c-08bff9b5679d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d62337c8-04d8-488e-a5b0-e98601a826a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_547d334c-565b-45aa-a31d-cf0b5ec40a45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a8d8ecfd-11a2-4d9e-986a-f51ef12015b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1c598293-0936-4d1f-99f5-0722e4f7437e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_bb786dd2-2f22-47d4-9e9e-9a488bff4ab9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d4b2018a-b9d9-4637-8c1a-502b5c20c95d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e1b89459-ec16-4eeb-8748-5aa7c26b546b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="C_34acf0fd-1b4d-4895-92c2-913b85fb2602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndInfluenzaBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_4d962b66-b38e-4b66-95b7-9a327531b9c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3f98ed76-99b8-4408-9b9c-7145868e41b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:BiologicalMaterialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_eada5d7f-f2a9-431c-b238-c2280f794f45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_882eeb59-5aa1-48a1-b475-f45ed47e1af4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6e8a7542-2dd0-4c48-9150-7dcf5bac672c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_05dda014-cb81-49d2-92f9-31d5a59a9ff3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1c384113-a0b3-4e9a-b7a6-3c84846d53e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_486aaa19-98ed-45c8-8860-fd4d402399da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9df276b4-bb61-407c-a816-a86f5eb1f323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_513fcea4-6032-4866-8906-83b5dc316354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_06f41013-d21d-4546-aa26-d8ece6d9a91a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_1d93e807-4da6-4761-840c-61b5cefbee6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_04e2f054-346c-47c8-89fb-055997c2a180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vir:SeriesAOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="C_92381b91-3b42-4fe2-ba53-ec4b175909d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:WuXiBiologicsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:DevelopmentAndManufacturingCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="C_7fe631b5-99f5-4a42-904e-1d5e014789ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a869b4e0-c5d1-40f8-a18d-2d9633f8fb52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2019-09-16</startDate>
            <endDate>2019-09-16</endDate>
        </period>
    </context>
    <context id="C_9b3dd0d6-7971-4035-8623-0c23e6212871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_6639bf66-3f97-4290-be85-57c7e4a0c37c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a6f98428-747e-466a-907f-d4b24c98cc45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAResearchProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_42be3ce6-3c6d-4c19-ad78-d6bba030babf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f41c076b-5d7a-4003-8cb2-ca3259ad661b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_5271e096-8828-4fdb-8093-e81baf518a38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6d2c449d-3432-4046-9323-81b3ce04e34a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fbb0fecc-7a8b-4c5b-9fec-e7fdd61a01f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:DefinitiveCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-28</instant>
        </period>
    </context>
    <context id="C_16d264b9-1049-422e-959d-522e97231bc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2920cb23-d73e-4b16-b3f4-cc501406683c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_7ea779b6-e470-44f4-8cd2-792b82ad5755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_557d1e8e-6875-4184-8347-4aab3a2c9a31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_01417e77-f979-4120-a600-156314a4c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_c55f2ce7-7281-48a7-aec6-0a47f77c9a67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_5cbe6ca1-3aef-4d1a-beac-1c5b67ca8ba9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_65508bde-8e9b-433a-b887-54fe70f6560d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-16</instant>
        </period>
    </context>
    <context id="C_2f49ec3e-8e45-4cc0-8b2a-a2462edffcfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_333e5067-692a-43e7-8ca4-773333284f0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_587ac654-89df-4445-9d73-21454d8c728f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_a145aeb5-af85-4ad6-ba29-68511bbc994c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3776a1e8-74ac-49c3-8bd9-7024d16f0ad2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8f3bbd07-1fde-4bfb-b72d-6df34ea170ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_5435542f-8093-4105-868b-53ef71ac98a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9f3bd2b3-b70a-4d36-b772-a1b2c9072a86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0c4b9e6a-a844-4e0c-a296-cb62009d4a06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_04d6bf1e-1ec8-4592-84fc-8ca7693ba159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0a9da79f-2f51-4ca2-944b-bb5ee3abad70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_4723e489-b2c6-419e-a302-89f09c349a7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-11</instant>
        </period>
    </context>
    <context id="C_b3ff0ae3-397e-4e79-94d3-974b85c1a48f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_7846e4d7-bd1e-4f8d-ab5e-2c405172b5fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d67e94b8-3d90-4a56-820b-3f311ae13e57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_66bceed9-522b-4fbd-a22f-c029c32a27fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="C_0c0012f8-5960-4879-bdde-f46b368e2ae9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="C_b7032bf3-35f9-44e1-bf55-389c77cec434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_1ad51e18-a052-4618-9f7f-dd217928f54d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BillMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_c0e8d12f-41e5-4499-bb57-79d3fbd1a9a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-10</instant>
        </period>
    </context>
    <context id="C_a48eca06-2240-404a-95b9-a96f664f0800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_bcf35168-3bb5-4a68-9f5c-cf54c4823054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_92042eda-34a8-4b88-8ceb-39eb4ad7e70a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="C_bbb0d6a6-cb1d-4c13-9791-01f69f5283a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e1a0aec0-6950-4e6b-b8c6-2c448044907e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d7e70a8d-2f4b-4760-92ab-0e41dad01baf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-14</instant>
        </period>
    </context>
    <context id="C_1cec4878-722f-49d0-b6df-245adc26d756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_21482517-1f7b-44c6-8e55-585d0ec9e391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_53a9db5d-ce87-4cee-8476-d28141546bda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ec04e3a0-91fd-471d-9c5e-a88bcbb1c70d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_90261ef5-9966-431f-a299-6204c1e9115a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b1bbbe19-c33f-4c19-83ca-eca625a9d033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a85d530b-5472-4e7a-bcea-2452ef558595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f93128d8-554e-4673-824a-fcf094e10714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c64f8d89-5c82-4a9f-a80a-fb1f5a11ee70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_bb04a465-c3d8-4109-889c-c33e0ccca055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_647cf94d-4221-49c6-986a-76edcb5f1c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:EachInfectiousDiseaseSiRNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_bd868f7f-a86d-4911-a7c7-759ba388c5ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_46e6f289-d1e5-40dd-8d37-0d010f7d5492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_10b89020-933b-4851-aad1-03756b00666a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_47cc19c9-75f2-422b-8ed8-1c79b990ca5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="C_a5f8399f-ee4b-45a3-a103-6773949f9073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_95728472-f99b-4600-92ae-c92c93205687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-14</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_c53e5c04-9722-48b4-9a77-81a3284044e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b91aebaf-cbdf-4bbc-b802-2169b53b199f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_c8ddf765-8bda-47c3-81a9-cbdb38c2d9e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0d0ed842-ca94-4998-a8f5-2f0beb76b34a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f56ff235-0c3a-41a2-9a37-b0d1d92b94ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c65e2fa1-651b-49f1-8130-e10a86ed4b23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b82d2460-cf24-43b0-b95e-5a0a52709f8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0e93d6b9-9d5c-45a3-b71f-00713901c0f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0a07820f-763c-4577-b53f-29f5d29d5021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c9443ba3-f289-4712-b80e-f1c93e0123cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-09</startDate>
            <endDate>2019-10-10</endDate>
        </period>
    </context>
    <context id="C_c5a5ec76-5424-4832-b5c3-f943e156e9d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_f134ed1b-0d64-42e6-8b4d-545d2bec9296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_202b895b-631c-490b-893f-c4dd6e2908d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_2e4d4ce4-f3be-4eb0-bc20-5ce86e739229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ccf336f4-a19b-47b9-8dd4-fd55c3edb88c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-10</instant>
        </period>
    </context>
    <context id="C_8d0a5b8f-a0b0-4322-af0c-fa4c65561bb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_f2bc6c04-5732-4690-b9c0-17ebe0b9dbc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="C_5e1d64ed-e161-4d09-a7bd-60b59d474ed8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_Segment">
        <measure>vir:Segment</measure>
    </unit>
    <unit id="U_Antibodies">
        <measure>vir:Antibodies</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Unit">
        <measure>vir:Unit</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_Milestone">
        <measure>vir:Milestone</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Program">
        <measure>vir:Program</measure>
    </unit>
    <unit id="U_Product">
        <measure>vir:Product</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <vir:FailedSaleLeasebackTransactionProceedsFinancingActivities
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_772cdc50-ee81-4663-b2c9-159a9a5d4a6d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_a4ed1c20-8e73-4bd0-8485-9c5663b1058d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_35bc7a1f-bacb-46b6-aa07-b09b7bbbd419"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:InitialFairValueOfDerivativeLiability
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_d44a4bed-0ed7-40da-887f-ea79ca6c9d8e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="C_475e9f82-cbd7-4ec6-8eb2-24bad29614d1"
      id="F_d240cfd0-0689-460a-ba7b-6620318af392">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <vir:ProceedsFromRepaymentOfPromissoryNotes
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_a4de510f-58db-4648-a977-8db678cc72e5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e5046b1c-890a-4d88-9c47-8d81f489b3cf"
      id="F_e8ebc668-f14c-4720-8b72-2366a378afeb">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      id="F_1cc61fe6-ac37-4ae9-8e25-9ed92a418e6e">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_1425da0a-0d71-41fb-80b4-6e4271d2eaed"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_5f39939e-8498-4156-807d-30af0dfff8cb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_9ed14462-8c3e-4dbb-b16c-fd5a1cb257fe"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:AdvancedProceedsAppliedToConvertiblePreferredStockIssuance
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_c4078763-cec1-4a66-959d-505d3023edad"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:InitialFairValueOfDerivativeLiability
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_c1b7f7bb-24d4-45ce-80d9-0476ded55f8a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_e04e83e7-ebaa-41ea-babd-a85bb4d24a9c"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_2e4d4ce4-f3be-4eb0-bc20-5ce86e739229"
      id="F_b3ce71d6-2479-49ff-972d-2870edd2f042">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      id="F_98a9a1c1-c922-4685-b412-bdffdfc28ae1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:ProceedsFromRepaymentOfPromissoryNotes
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_736e2b87-7321-4c16-a4d7-00f5d88607fa"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_e68fa7e5-5e36-4a91-a346-039647a55845"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_d2953029-da62-484e-a797-93a558adad20"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:CommonStockIssuedInConnectionWithLicenseAgreement
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_3b70eb5c-3677-456e-9180-2f5f40bd92cc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_3a2ddd83-9ef6-4dfd-b812-3fef59045e88"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      id="F_2224d0d8-f870-4e2c-84eb-afb6268a5d33"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_72defe4c-83c3-481e-b440-b0643489c971"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_20aa9ca2-42ef-403f-9ec6-4ab57c19080b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:AdvancedProceedsAppliedToConvertiblePreferredStockIssuance
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_9854d74e-7f97-4b0b-a755-45b36915ad92"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_e9114fd8-4978-4682-9f50-9246a83ee001"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:PaymentOfContingentConsideration
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_b4609599-f5b1-4e10-83aa-953f302ed107"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_3a00e3fd-a5c3-445c-8652-f44eb20df66b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_e465322f-8ed1-47a7-9a25-aee25f322449"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_6380790d-03b2-4de6-bb8a-563e0a71388f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_d21fc636-e1b9-40a5-b41f-adf66b5a1b58">0001706431</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_9283bb71-2e76-49eb-b602-a8f93acfc4c1">false</dei:AmendmentFlag>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_dec1a281-61d2-4dc6-90d7-76198f647c24"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      id="F_a8d2e9b9-02ae-4ff4-bd78-94a2d05ac43a">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_9a26d801-8def-40ce-9488-f4b2a2bbc5db"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_58e2eb0c-1180-444f-b3b2-1e0f0b469fc9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_8340aa05-f6fa-415d-aa80-320c4eb517d5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:GrantsAgreementAmendedDate
      contextRef="C_f5edd5d0-093c-4a7f-9010-06a8b6d0943c"
      id="F_aeb0c2d2-3251-4237-b9b3-110fc85a87f2">2021-06</vir:GrantsAgreementAmendedDate>
    <vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_7bbc2272-0008-492a-b8e3-012702186564"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_63c2423d-7a76-4317-bc96-630517587877"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:FailedSaleLeasebackTransactionProceedsFinancingActivities
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_3cd3f88d-5ec4-4c66-a41f-56053d71af7a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:NonCashCommonStockIssuedForContingentConsideration
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_196c5237-329f-410d-96d8-db2421aa3db7"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_b9df5d21-f326-44cb-9e27-7f6e0364aaa6">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_f6ef5dbd-d8d1-45e0-a55c-433dfbcf55ec"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct
      contextRef="C_7d9adb10-9589-4116-8468-f2a901cec9e7"
      id="F_7b44663d-1329-47cf-a20b-2f4943e047c2">mid-single-digits to sub-teen double-digits</vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_97880dc8-ea14-4184-b3d1-1c224e174732"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_cd3b816e-2520-4ba4-873e-cb45dd224087"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_e5046b1c-890a-4d88-9c47-8d81f489b3cf"
      id="F_b3b3c2e2-807e-47e2-9909-7b52a03e1e68">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_a869b4e0-c5d1-40f8-a18d-2d9633f8fb52"
      decimals="9"
      id="F_024599b7-5d20-489d-b293-7b709b4ba2ef"
      unitRef="U_pure">0.222222222</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_ac7ee1e4-e982-4e16-ba9a-ab3dacbb8803"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_8b32ee52-010b-4024-ad9b-e6c4df6d5466"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_8f4edfbd-9a9f-42a8-a370-d64708e2323e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_b156a61b-ab05-4999-91a0-ada076026c19"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_4f339869-7320-48dc-b4c4-f4e2638b0fb0"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      id="F_48a70287-0f05-4e93-92b2-64eb0929682f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_aa68f18c-5e68-4d0d-83e7-0de7835742ff">FY</dei:DocumentFiscalPeriodFocus>
    <vir:CommonStockIssuedInConnectionWithLicenseAgreement
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_53ca3f31-8c27-4624-bbcd-862d061949e3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:PaymentOfContingentConsideration
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_f4d21755-e71d-4379-982f-e1f0ca56eef1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_1dce386a-d15b-43a0-9d69-261d7fc5489b">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <vir:NonCashCommonStockIssuedForContingentConsideration
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_48a607eb-82b2-42f3-9b15-106d86433c4f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <vir:NoncashLeaseExpense
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_cd9e3ce9-14e4-4515-a281-682b3f84673d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      id="F_a7d4385c-0b9b-4afc-a37c-6c1eb232d765"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_e0e3712f-46cc-4e0d-818e-99f85d163819">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_6b8d2f34-e65e-4d98-b96b-bd611f71ca23">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_728a69b7-74bb-4209-8086-a2e22f76e3ff">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_abda1639-88e9-4f30-addb-83514af6698d">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_68de34c0-a3ac-4900-a33e-fc3b754537c1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_fd9ff03e-9f83-4d79-8b85-1abffddee640">1-39083</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_6aac2226-e2cd-4c45-ae88-1d14e7f2ccbc">Vir Biotechnology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_0a651b4a-4c56-4695-9cf4-ce0566792117">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_f6b804f0-4ca7-4293-aec0-32180dc0a96d">81-2730369</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_b234c126-b306-438d-8dad-8bb91428fb79">499 Illinois Street, Suite 500</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_41895082-f9c3-4faa-866a-82fc8094129c">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_b429932c-296a-4a10-8590-ac0b5c85f809">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_dacc7e03-e87d-49db-b3a4-e3dd821c14bd">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_575e6e55-2609-44d9-a099-bb04311156a6">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_166d5214-bb40-4bdb-b883-6861e58c5510">906-4324</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_f7c0d66d-5c02-472e-a132-cc562fae269a">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_442a0840-599a-4b8d-8b62-aad8d2b5a16f">VIR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_62625bd1-7161-4f18-a047-004ce9a1817f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_ef6eda16-8537-4943-9cc6-9f786d64d8cc">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_86cb201f-5394-41aa-afbc-57370ac54505">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_01016075-589b-4f8c-907a-bc04160a4b9c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_44ea26af-903f-4f5f-ab31-c3b16128fc21">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_8d95953e-622f-43c1-bcac-773384a9bc90">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_13108c5d-2d21-4e2b-88ea-d60727d576ec">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_b4b21b73-def7-440a-955b-face178ca406">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_9b10e40f-e49f-429c-88a1-62585290388a">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_4e745db0-2c8e-408e-a4e2-35025c70d380">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_7c35f7ee-7ce8-4791-b6e1-4269f4a1e21d"
      decimals="-8"
      id="F_aad9ab82-3999-4574-b351-42d6da07df0a"
      unitRef="U_USD">2700000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_250f68b2-8222-4f1b-a3b9-f47c995fde57"
      decimals="INF"
      id="F_4f997664-07e6-4e4e-9d02-2b06ceed39ea"
      unitRef="U_shares">132303561</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_eb87f0fc-7f0e-4199-8822-8c46cb571825">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant&#x2019;s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant&#x2019;s fiscal year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_370feb5e-b606-4379-9d7f-b8c69d1bb7f7">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_18f0f6e0-e297-4945-aad4-8694b4e21bcc">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_9c38b138-6980-4da0-939b-56ebeec8c0cc">Redwood City, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_7386950c-f47e-49e9-9db5-e75404b67dca"
      unitRef="U_USD">347815000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_b59d0eab-2bc4-42d4-96bf-47e4b76c3ae2"
      unitRef="U_USD">436575000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_d454f565-16a7-4859-abb3-619129af3374"
      unitRef="U_USD">217182000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_98e366cc-73c1-4925-b0d5-276d5aa96baf"
      unitRef="U_USD">300286000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_9b3bd9cd-615b-4636-8f48-3f5b6ef17f19"
      unitRef="U_USD">8594000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_c3ce3550-9e7b-48d8-bd49-03d28c2ce40e"
      unitRef="U_USD">7993000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_9dc4777e-527c-4b29-a762-aed7b5483c94"
      unitRef="U_USD">773079000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_76ef31b7-f542-4336-832d-772e5e79a454"
      unitRef="U_USD">0</us-gaap:AccountsReceivableNetCurrent>
    <vir:EquityInvestmentCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_17592b2e-b806-4b1a-b6e2-500cbcedfe99"
      unitRef="U_USD">143148000</vir:EquityInvestmentCurrent>
    <vir:EquityInvestmentCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_7a97f0be-caf3-499b-8b6d-618eff31eb4d"
      unitRef="U_USD">0</vir:EquityInvestmentCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_5e5f9b7b-be40-4779-b834-d11ef5eb2270"
      unitRef="U_USD">73003000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_986e1c41-147b-482e-8664-ca163ca102d9"
      unitRef="U_USD">27511000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_5d16cee5-8ca4-42e5-9649-0fc504d15115"
      unitRef="U_USD">1562821000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_87ff9b4a-a6cb-4789-90f4-be61804d3638"
      unitRef="U_USD">772365000</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_dce86c75-ddc5-483c-bd45-44afad9bff35"
      unitRef="U_USD">33287000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_49c0bbd7-24b6-4f32-bb46-89fffdd9159f"
      unitRef="U_USD">33820000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_61230d7a-caa3-4c73-b1c1-dfbb0cce7902"
      unitRef="U_USD">16937000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_8470a6fd-27d9-4cc1-947c-2feafd03d91c"
      unitRef="U_USD">16937000</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_62ff0933-c306-4b0d-a481-4206d381d15b"
      unitRef="U_USD">42834000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_6975d8cb-9e20-4fa8-863d-f6bf6be68df4"
      unitRef="U_USD">17946000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_51ff6878-fb6a-4429-95d9-62c39143de06"
      unitRef="U_USD">87220000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_9178d439-8c71-426c-934d-bce515544d36"
      unitRef="U_USD">61947000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_d357b5cc-3a24-41ef-bf09-5741a3d7ee36"
      unitRef="U_USD">7006000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_bfba7be0-0629-4baa-856f-3a6b1c4b04ce"
      unitRef="U_USD">6919000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_ca7b556a-fa54-4ba3-9dba-defbc958be3b"
      unitRef="U_USD">201388000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_0ffa743d-4aba-467f-8f89-4f7b0d437173"
      unitRef="U_USD">0</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssets
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_59ca09ff-7c82-41ab-a708-3f253b6ad8e5"
      unitRef="U_USD">2775000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_2f500e8c-3f64-489d-b435-082d38e90ea0"
      unitRef="U_USD">8827000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_7b7baea9-cbf9-4ee5-9833-493d6c34daa4"
      unitRef="U_USD">1954268000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_acc782cd-6c89-4099-9461-64f48143f795"
      unitRef="U_USD">918761000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_c0c01844-97d7-4839-83f8-1f6fdbf4fbbd"
      unitRef="U_USD">6521000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_204d89a1-4432-4c04-a630-089a200d81b0"
      unitRef="U_USD">5077000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_591ac35c-ac10-462b-bd6f-efa178944900"
      unitRef="U_USD">236512000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_9ec56e34-91cf-4695-a605-35abab989183"
      unitRef="U_USD">76936000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_da58abc5-5877-4e9b-b21a-8dab2529f96d"
      unitRef="U_USD">98209000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_13afab1e-abe3-4e70-b191-d42b0f5007e7"
      unitRef="U_USD">6451000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_cd5a46fb-0be3-40fa-9409-21d7ceefc90c"
      unitRef="U_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_cfa16a70-6f9e-4619-85ea-556185197740"
      unitRef="U_USD">10600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_f438b442-6bf6-4506-b8b3-2c4b67a6b14e"
      unitRef="U_USD">341242000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_11437021-6963-42b1-a837-5cd890b61b8b"
      unitRef="U_USD">99064000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_d95e4d3b-e909-4f9d-ba55-b754693259d0"
      unitRef="U_USD">3815000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_5f706939-cce7-43f5-89a1-5fe220934340"
      unitRef="U_USD">3815000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_a80d6d44-7c90-4fab-8c42-3cbf2ebcf8d0"
      unitRef="U_USD">133561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_ae5146dc-0fb8-4590-aee6-5a71b7106058"
      unitRef="U_USD">66556000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_bec56fb6-1ebe-4887-b1f2-430e42240129"
      unitRef="U_USD">22822000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_cb28145d-b9fb-403f-8c0b-6208ede135cb"
      unitRef="U_USD">25374000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_60bd5ab7-f0b6-4aa9-90c8-d4b311668035"
      unitRef="U_USD">18439000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_bed3f701-99dd-4957-b7bd-94b90dcae940"
      unitRef="U_USD">3253000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_9b31db6d-343c-47c0-97c1-8cd9612dd91a"
      unitRef="U_USD">2540000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_a5c907c3-c4b5-4fdb-b151-b16388abb238"
      unitRef="U_USD">3847000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_83c91d32-6a6e-4952-9191-eb5dc4935a7d"
      unitRef="U_USD">522419000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_b9a002d4-f7b0-4b2b-ba9a-183394cd5be3"
      unitRef="U_USD">201909000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="INF"
      id="F_56f0bba2-f975-477c-9a54-9c6affe03843"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="INF"
      id="F_a51a701d-6ebf-47ed-9bb0-131dbc7fe6a9"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="INF"
      id="F_70207c2f-72cc-41af-ad2c-0d02906aed9f"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="INF"
      id="F_1e8d3abe-cb7b-4a48-830c-3860e29e0088"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="INF"
      id="F_ff4e8357-6296-44f5-a797-34d0b0499927"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="INF"
      id="F_46a254cd-b761-4003-a0e5-53ccbf131fca"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="INF"
      id="F_f5229835-4279-402f-9afe-db6bb2e7793f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="INF"
      id="F_1dae67b6-f096-49b4-87aa-07c62f6bac1b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_d464b2fd-a31d-492c-8405-97ec01c63ea3"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_9617ec8c-1a86-4e82-88f0-013a1a416fcf"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="4"
      id="F_66bb4df6-ace9-427b-8ce6-febf7410ebcc"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="4"
      id="F_f83aea36-4ccd-4174-9d2d-3f18fdce294c"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="INF"
      id="F_7050a6f3-b6fd-4041-a737-d5e8869e9b63"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="INF"
      id="F_5c4c4d77-f714-4315-ae4c-ab65adea6731"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="0"
      id="F_998f0ecc-d1c6-4181-8743-2d5c84009b40"
      unitRef="U_shares">131161404</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="0"
      id="F_d2ee9303-0bb4-433d-87cc-3521ddff0741"
      unitRef="U_shares">131161404</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="INF"
      id="F_9254a4e9-2be9-4001-9e8b-76c1904dd46f"
      unitRef="U_shares">127416740</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="INF"
      id="F_28e7ac10-e295-47fa-8a25-6e5f5124b6f8"
      unitRef="U_shares">127416740</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_90f61365-04ef-49d9-9cd0-2a72fe3d6f07"
      unitRef="U_USD">13000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_73435fc1-6dda-4740-ae6d-0b6343c32333"
      unitRef="U_USD">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_0ed8a9d8-4b5f-4bd7-8097-b4b8e95f2d80"
      unitRef="U_USD">1571535000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_3dfc8596-495c-45ea-8e5c-5a2222c177a3"
      unitRef="U_USD">1385301000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_d2216618-cda2-46bc-945e-60b2e3a3964e"
      unitRef="U_USD">-1099000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_8c27f351-b5a8-4aa7-ad8f-4daf878c2484"
      unitRef="U_USD">-1278000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_626975f8-8e57-4281-a929-51d94cfdb075"
      unitRef="U_USD">-138600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_c21a416d-b9f4-4f5c-8079-e009e4f0c2e4"
      unitRef="U_USD">-667184000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_11eff6aa-d634-4ad3-96c0-4b6ffd90606e"
      unitRef="U_USD">1431849000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_fb2f2e6e-d3bc-4722-9a30-845c6765d13e"
      unitRef="U_USD">716852000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_1fd4cc0f-9b75-4902-8c1e-64ffd98de228"
      unitRef="U_USD">1954268000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_7a1ed45c-fc35-4a7c-ad3a-dcba1232ef08"
      unitRef="U_USD">918761000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d4b2018a-b9d9-4637-8c1a-502b5c20c95d"
      decimals="-3"
      id="F_9a5f80a6-4c52-4175-a2e7-53a5ccd3d92e"
      unitRef="U_USD">917194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d7535086-58ed-4942-918e-2201970b8cea"
      decimals="-3"
      id="F_7b3de68d-9ae8-4431-b619-a21c1bd227f1"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_59d377ae-8381-45db-9cc4-7efce0201130"
      decimals="-3"
      id="F_acc930f9-67ab-4042-9b1d-7c24466ae2b3"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f56ff235-0c3a-41a2-9a37-b0d1d92b94ec"
      decimals="-3"
      id="F_c4f65d0b-dcb7-47cc-a1a6-a01a79319dc6"
      unitRef="U_USD">169874000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_488948dd-80d3-45b7-a684-756b5feb098a"
      decimals="-3"
      id="F_877f0a76-93a9-448e-9a71-74a5a452787e"
      unitRef="U_USD">44498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_301f15e9-11d1-406a-b0be-2ca7cc4b7543"
      decimals="-3"
      id="F_d0c12bf8-b7c8-40c1-ac81-72eaf76eec66"
      unitRef="U_USD">711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_f506a175-6fde-4e73-bbbc-20e846b33555"
      decimals="-3"
      id="F_fb9f22f0-102d-4eae-9f5f-0d736f698a2d"
      unitRef="U_USD">8347000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_65bd9d63-ee77-45dd-a499-a8f0b310c5e6"
      decimals="-3"
      id="F_ee766bc6-3a15-4bba-91b2-3e680bc851a3"
      unitRef="U_USD">9123000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_eaf05464-1224-4ae2-8baa-f4387ec342ad"
      decimals="-3"
      id="F_9be634de-fa92-4e92-8e10-46f8d9a040c0"
      unitRef="U_USD">7380000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f93128d8-554e-4673-824a-fcf094e10714"
      decimals="-3"
      id="F_92d8ff21-7586-491f-bd22-485e568d5d89"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5299f27f-f8a0-4e30-874b-2faab774be38"
      decimals="-3"
      id="F_a137e484-6f25-4450-bbaf-d05d82664551"
      unitRef="U_USD">22747000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2920cb23-d73e-4b16-b3f4-cc501406683c"
      decimals="-3"
      id="F_a949cdf2-2601-4ab8-a6aa-78854d432e80"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_ee5e5325-776a-46d9-9790-b7c1e4f62e6e"
      unitRef="U_USD">1095415000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_02a0d8a3-d4ec-48f4-8de1-643a96146fa0"
      unitRef="U_USD">76368000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_9acc94de-ca67-4c76-9de8-457fa3f26a04"
      unitRef="U_USD">8091000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_8c778e5f-6132-42c0-935b-0ed4c96bea5d"
      unitRef="U_USD">65865000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_cb424f73-cb86-4b2c-aa34-1f263f9c5be8"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_07b3d564-2337-41db-8594-4e83644e7be4"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_22481c39-4bbd-4361-8813-e6bc75395683"
      unitRef="U_USD">448006000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_67007cb5-6567-45d0-89c8-1a5dcc35177c"
      unitRef="U_USD">302411000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_6fb86802-d113-4c36-807e-6ee10f629519"
      unitRef="U_USD">148472000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_3a6d9ad5-227e-46be-bc6e-aa637a0aee24"
      unitRef="U_USD">160793000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_649edd30-30a2-4718-8b35-c8f7067d9faf"
      unitRef="U_USD">70937000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_6b56027a-3a64-472d-8f6c-d027cc154c4c"
      unitRef="U_USD">37598000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_ca5450c0-4fa9-461b-8111-b6355a3d8dbc"
      unitRef="U_USD">674664000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_2cc1ea25-cc25-4f94-9dde-f10bf72d1cf8"
      unitRef="U_USD">373348000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_52aad1c3-3a0d-4328-b96d-33afc25c9664"
      unitRef="U_USD">186070000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_f4b27542-a2b6-49e2-ad64-4a536c297b5d"
      unitRef="U_USD">420751000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_6d1f2a5a-4241-4262-95af-1d568099606c"
      unitRef="U_USD">-296980000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_b6da6522-c618-42eb-aa07-5ee0c271a16d"
      unitRef="U_USD">-177979000</us-gaap:OperatingIncomeLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_3f9cbfa3-1ac5-4a1e-aeac-be720a791588"
      unitRef="U_USD">138049000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_6aee22eb-9c90-45bd-a2bc-2c667c4f8efc"
      unitRef="U_USD">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_c93882c5-1583-42db-a492-e86eb55fca83"
      unitRef="U_USD">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_fb56b4c2-d6f2-41e6-9647-c6a807c1983d"
      unitRef="U_USD">439000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_40bd638f-eb74-4f8e-8090-860fe8e21b93"
      unitRef="U_USD">2836000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_a2835001-1c80-46f9-975c-f450b6f10bc8"
      unitRef="U_USD">8511000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_e72ed746-0471-48fb-8e2b-40bb645168f1"
      unitRef="U_USD">-9437000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_efdd7caf-c7ed-488e-a14b-ac76bfda2317"
      unitRef="U_USD">-4467000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_0f91deee-567a-4577-8f0c-958997b3ce4d"
      unitRef="U_USD">-5061000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_12f7dc6c-bf83-4159-a910-bfc000ad3058"
      unitRef="U_USD">129051000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_8f0cf109-5181-4286-8647-ab46a47c122c"
      unitRef="U_USD">1631000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_f6366fc8-9e3d-44a3-9d96-c0b7a0b25091"
      unitRef="U_USD">-3450000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_933909e0-604c-4f30-9252-5e82fc266cd4"
      unitRef="U_USD">549802000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_9a708ce3-d1bb-4203-ad50-be0dbd8135bb"
      unitRef="U_USD">-298611000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_8c4b3c55-a73b-41db-85df-3bd7ca8a2855"
      unitRef="U_USD">-174529000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_bb0135d6-c072-4177-88dc-2692320ba405"
      unitRef="U_USD">21218000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_9debc7ab-c623-4fc3-980e-54d276b8ed9b"
      unitRef="U_USD">54000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_889fc7e7-f133-425c-a248-c1bb7b2d212e"
      unitRef="U_USD">154000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_7aaa0283-8ca8-4ac7-8e67-279b4827c669"
      unitRef="U_USD">528584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_f9fc51f7-eba2-40ee-95d1-98509743ff78"
      unitRef="U_USD">-298665000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_727ce5b9-a952-4d96-a0ca-938f5602ce15"
      unitRef="U_USD">-174683000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="2"
      id="F_c83c5e3c-868b-4fca-b125-66d8f89e082c"
      unitRef="U_USDollarShare">4.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="2"
      id="F_7185078f-8044-41a4-9c71-cd358336ee18"
      unitRef="U_USDollarShare">-2.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="2"
      id="F_8c9da109-eed6-4387-a5e3-928d01ca1097"
      unitRef="U_USDollarShare">-5.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="2"
      id="F_7cd29008-fb2f-401b-a0a6-58cd49d20d4b"
      unitRef="U_USDollarShare">3.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="2"
      id="F_3660ed38-fca6-4404-b5f6-7e6c9a9b5101"
      unitRef="U_USDollarShare">-2.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="2"
      id="F_43a773b4-6a66-47d1-af54-d09d5f221f42"
      unitRef="U_USDollarShare">-5.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="0"
      id="F_6cf10d8f-bb11-4f2e-9d21-c0d59e0be784"
      unitRef="U_shares">129884967</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="0"
      id="F_34793e73-2133-4800-b475-02843f7f49c4"
      unitRef="U_shares">119159424</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="0"
      id="F_654992f4-254b-405d-b335-66fbe0d6ba56"
      unitRef="U_shares">30349920</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="0"
      id="F_980c6d26-e5b8-4087-97ad-cea22547ddd2"
      unitRef="U_shares">133437126</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="0"
      id="F_401eaeec-4f77-4229-9010-746a268f3aa8"
      unitRef="U_shares">119159424</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="0"
      id="F_dea3860d-7fe9-483a-b504-5f301c3fa3f4"
      unitRef="U_shares">30349920</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_c3299467-0c65-461d-9355-3857782d7f54"
      unitRef="U_USD">528584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_e44d29ed-e69a-483e-8a15-31eaa1b8cf13"
      unitRef="U_USD">-298665000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_f578f860-b923-42c0-b6bc-f724b33577f5"
      unitRef="U_USD">-174683000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_b1dee9db-5b68-4b0f-afa9-7d96564cf40e"
      unitRef="U_USD">-957000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_533bd9d1-4e2c-47c4-acb5-269fd698e0eb"
      unitRef="U_USD">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_f4fd5a13-5c31-4569-b822-f8a413d6dd57"
      unitRef="U_USD">149000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_5d0cccc0-dcbe-4b2b-8685-b3a7606dea73"
      unitRef="U_USD">-55000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_ce51d382-6233-42cc-aa2c-5e1a2fee54eb"
      unitRef="U_USD">-23000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_b2a959dc-cbdb-4311-8620-64af2b5941d6"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_18f0e139-33d5-4960-ac07-48fe0921fb9c"
      unitRef="U_USD">-1081000</vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax>
    <vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_c494b6b3-8f4e-4b63-807d-20ccb988f150"
      unitRef="U_USD">650000</vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax>
    <vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_c7f59834-39d9-4249-b8c6-23a7e07c80be"
      unitRef="U_USD">736000</vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_717de3ea-b179-4789-a1b4-bfdc9a9240f8"
      unitRef="U_USD">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_c0f65758-2aa7-4fea-98e4-1ca6ddac7fda"
      unitRef="U_USD">-677000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_3c205be3-3f0f-403a-b8ca-be43ea9576cd"
      unitRef="U_USD">-587000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_eeeb2881-56e5-4323-92f9-9aa67c144d3f"
      unitRef="U_USD">528763000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_5e4ab64b-e538-4731-81bf-a4fba096cfae"
      unitRef="U_USD">-299342000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_a5049992-8c01-49f1-ad56-51eb429e3970"
      unitRef="U_USD">-175270000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_c8189099-45c1-41f2-b6ca-954b37c65618"
      decimals="INF"
      id="F_76bd7052-4227-4d84-895d-bebeabd805d6"
      unitRef="U_shares">69910520</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_c8189099-45c1-41f2-b6ca-954b37c65618"
      decimals="-3"
      id="F_34a2ff36-9fb0-47cd-a050-9dde9e3c3f28"
      unitRef="U_USD">309137000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3c763cb1-70d7-4e23-8984-44c48ee907cf"
      decimals="INF"
      id="F_7fe850dd-77fe-4383-ad5a-953fca97447b"
      unitRef="U_shares">8858799</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3c763cb1-70d7-4e23-8984-44c48ee907cf"
      decimals="-3"
      id="F_a1bb88c7-5b43-4e42-bf30-ce4e4d2f5d59"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c55f2ce7-7281-48a7-aec6-0a47f77c9a67"
      decimals="-3"
      id="F_65bcd231-0af0-4f8e-a9ba-c79f719f0b31"
      unitRef="U_USD">14672000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b85c9788-4228-4009-81b0-cb885a8a21d7"
      decimals="-3"
      id="F_7004beb5-9f18-4c67-befd-ef6f5cae2b8c"
      unitRef="U_USD">-14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6e8a7542-2dd0-4c48-9150-7dcf5bac672c"
      decimals="-3"
      id="F_5c239c08-9f19-404c-b47a-a12442c6e6e1"
      unitRef="U_USD">-193836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_88183c78-6814-4146-96c6-0cba18d5611c"
      decimals="-3"
      id="F_06419617-e051-4565-8d1a-e3589c8ba39c"
      unitRef="U_USD">-179177000</us-gaap:StockholdersEquity>
    <vir:ConvertiblePreferredStockIssuanceCost
      contextRef="C_6a0b0601-deb2-4157-ba2f-7613b7f73ba3"
      decimals="-3"
      id="F_23eeffd0-d7ab-40de-afbd-b494a1635185"
      unitRef="U_USD">165000</vir:ConvertiblePreferredStockIssuanceCost>
    <vir:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6a0b0601-deb2-4157-ba2f-7613b7f73ba3"
      decimals="INF"
      id="F_c2543ff9-feaa-467c-9bf9-6a432cabcd5f"
      unitRef="U_shares">18202213</vir:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_6a0b0601-deb2-4157-ba2f-7613b7f73ba3"
      decimals="-3"
      id="F_e342622b-3f51-4bd9-943c-75b95003ebfb"
      unitRef="U_USD">327475000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <vir:TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares
      contextRef="C_df4b5d69-777f-4164-ba06-7c95c5c18601"
      decimals="0"
      id="F_e174013b-0475-4fcf-a04d-15fc363ddd8a"
      unitRef="U_shares">88112733</vir:TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares>
    <vir:TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock
      contextRef="C_df4b5d69-777f-4164-ba06-7c95c5c18601"
      decimals="-3"
      id="F_1fbc6394-acc7-493e-ad00-c58db511c117"
      unitRef="U_USD">636612000</vir:TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e"
      decimals="INF"
      id="F_3589814c-4398-4191-94ad-2497380e2178"
      unitRef="U_shares">88112733</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e"
      decimals="-3"
      id="F_ebb0542a-52bd-42aa-8cff-845ccafca44e"
      unitRef="U_USD">9000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d"
      decimals="-3"
      id="F_798dc5a5-c5d9-4b83-b400-fa763c23cb84"
      unitRef="U_USD">636603000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_095a4c83-6c5e-4753-af42-e0f847c0e487"
      unitRef="U_USD">636612000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <vir:InitialPublicOfferingCosts
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_83c9584d-d0be-4d05-800a-2da651cc6572"
      unitRef="U_USD">16446000</vir:InitialPublicOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0ad71b1a-ef19-44b7-ae86-72e2d88c9ede"
      decimals="INF"
      id="F_10f84674-43c6-42e7-be23-8b8728f40513"
      unitRef="U_shares">7142858</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0ad71b1a-ef19-44b7-ae86-72e2d88c9ede"
      decimals="-3"
      id="F_ff627249-f871-4ee4-96f7-c5d2ce474716"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9877f0f7-e105-480e-b0a7-fb9e68d056f2"
      decimals="-3"
      id="F_35458b13-b7da-48da-a5cb-7895693587ae"
      unitRef="U_USD">126410000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e837f6cd-46cf-43d6-8ea9-08f5560d9cf6"
      decimals="-3"
      id="F_98cc0aa6-f847-451f-9d87-a23f0b078f7f"
      unitRef="U_USD">126411000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vir:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d"
      decimals="-3"
      id="F_33b04b42-074b-4cdc-ac40-ecf00c9c3230"
      unitRef="U_USD">3073000</vir:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital>
    <vir:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_66c80bc8-d093-4c36-b1ad-dd17b8ff7eb9"
      unitRef="U_USD">3073000</vir:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d"
      decimals="-3"
      id="F_a1d8f9ce-4058-488b-85b8-4f397dbd72ec"
      unitRef="U_USD">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_2e25b369-5dbf-4e94-bb1f-9b78eb4c9480"
      unitRef="U_USD">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <vir:StockIssuedDuringPeriodSharesLicenseAgreement
      contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e"
      decimals="INF"
      id="F_cdb88cb2-e25e-484b-91f5-f70895491a5e"
      unitRef="U_shares">38888</vir:StockIssuedDuringPeriodSharesLicenseAgreement>
    <vir:StockIssuedDuringPeriodValueLicenseAgreement
      contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d"
      decimals="-3"
      id="F_f9da2c34-c507-425a-ac8e-a5cfb8e216be"
      unitRef="U_USD">617000</vir:StockIssuedDuringPeriodValueLicenseAgreement>
    <vir:StockIssuedDuringPeriodValueLicenseAgreement
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_b0e7ea70-dd42-4ad0-bef3-acb219e04b24"
      unitRef="U_USD">617000</vir:StockIssuedDuringPeriodValueLicenseAgreement>
    <vir:StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares
      contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e"
      decimals="INF"
      id="F_e2baa091-5f39-4e4b-9638-189016f451e6"
      unitRef="U_shares">1390925</vir:StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares>
    <vir:StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue
      contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d"
      decimals="-3"
      id="F_173a501f-632b-4f26-84b4-50512123cc65"
      unitRef="U_USD">1355000</vir:StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue>
    <vir:StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_e69e72cc-03d8-4d51-ad9d-20d681d5b40d"
      unitRef="U_USD">1355000</vir:StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e"
      decimals="INF"
      id="F_8d1521db-588b-489b-9e0d-b8d461033e1e"
      unitRef="U_shares">1348297</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d"
      decimals="-3"
      id="F_68a6f7fb-c3a7-4fc9-977a-87c3842c626c"
      unitRef="U_USD">476000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_a2739c34-8f1d-405a-9799-2a475f59535b"
      unitRef="U_USD">476000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_41895c62-83e2-4823-a8d7-01879c19221e"
      decimals="INF"
      id="F_4e57e675-e67f-487a-9e6b-20d69d90750c"
      unitRef="U_shares">756425</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d"
      decimals="-3"
      id="F_c9b12556-a820-4e14-a44a-871776d0b844"
      unitRef="U_USD">1129000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_efea0d19-d508-4138-ac8e-9e0991d0dc3f"
      unitRef="U_USD">1129000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e6e46de8-f795-4991-b51d-0af545d01d4d"
      decimals="-3"
      id="F_e52ee706-105f-479f-87c3-2c4807201365"
      unitRef="U_USD">8719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_ffe655cb-9dfa-4b5d-b9c3-c3950e0af312"
      unitRef="U_USD">8719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_7c199ed9-32db-4a22-a38e-1c376f297c82"
      decimals="-3"
      id="F_238ad9a6-21ad-42bd-a302-0233d680bf93"
      unitRef="U_USD">-587000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_4508953d-a636-42a7-a951-a4582a2112d7"
      unitRef="U_USD">-587000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_675e042c-eb56-4fb7-aaea-43c58b4c0aa3"
      decimals="-3"
      id="F_a6920b41-f0d1-424e-8877-e0db3460e812"
      unitRef="U_USD">-174683000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_0cb48bb7-62a4-4291-bec1-3531248cf026"
      unitRef="U_USD">-174683000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_10b89020-933b-4851-aad1-03756b00666a"
      decimals="INF"
      id="F_23589605-c58a-4cec-b3c1-7f5226367225"
      unitRef="U_shares">107648925</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_10b89020-933b-4851-aad1-03756b00666a"
      decimals="-3"
      id="F_138aa5d7-1d14-49d6-8b2f-822b201a1a80"
      unitRef="U_USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3d2840b2-01d0-4017-822e-05963d9d6961"
      decimals="-3"
      id="F_235c0ce1-c9bf-4b71-8249-539fb7992338"
      unitRef="U_USD">793051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d5f3ecc6-0f0d-4709-940b-a9657a2029f1"
      decimals="-3"
      id="F_8be1857a-8ae0-4ed5-8875-14901f349b12"
      unitRef="U_USD">-601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c5a5ec76-5424-4832-b5c3-f943e156e9d3"
      decimals="-3"
      id="F_d5c1f20e-ce48-4af0-88b0-ee50cd13a7b1"
      unitRef="U_USD">-368519000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579"
      decimals="-3"
      id="F_ea8f11a4-4424-4f10-b530-378b16e1fc10"
      unitRef="U_USD">423942000</us-gaap:StockholdersEquity>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital
      contextRef="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3"
      decimals="-3"
      id="F_8f93953d-5f8a-4b47-971c-6535e71c8802"
      unitRef="U_USD">29245000</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_b16d329c-b23a-4c12-935c-990bc526aa5b"
      unitRef="U_USD">29245000</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
    <vir:StockIssuedDuringPeriodSharesAchievementOfMilestone
      contextRef="C_a9001d10-0c10-49dc-a944-46388f818412"
      decimals="INF"
      id="F_970fe4df-221a-477c-b14d-fe5c10719af2"
      unitRef="U_shares">1111111</vir:StockIssuedDuringPeriodSharesAchievementOfMilestone>
    <vir:StockIssuedDuringPeriodSharesCollaborationAgreement
      contextRef="C_a9001d10-0c10-49dc-a944-46388f818412"
      decimals="INF"
      id="F_c75dec4a-98e7-42dc-a980-4c75393567aa"
      unitRef="U_shares">6626027</vir:StockIssuedDuringPeriodSharesCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_a9001d10-0c10-49dc-a944-46388f818412"
      decimals="-3"
      id="F_e63e5f37-48ea-480e-ae10-9250e70b1177"
      unitRef="U_USD">1000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3"
      decimals="-3"
      id="F_cda12e3e-55a4-43b7-9fa5-742311a058a2"
      unitRef="U_USD">206698000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_df9447b7-b9a9-40d6-88f8-c09fa489fb05"
      unitRef="U_USD">206699000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant
      contextRef="C_a9001d10-0c10-49dc-a944-46388f818412"
      decimals="INF"
      id="F_e3c8e029-7ddf-4b35-ac3a-935edc3a3295"
      unitRef="U_shares">211774</vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant>
    <vir:CommonStockIssuanceCost
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_3c25f1d7-81f1-4c1f-a274-bef1fa79dea1"
      unitRef="U_USD">21786000</vir:CommonStockIssuanceCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_5435542f-8093-4105-868b-53ef71ac98a3"
      decimals="INF"
      id="F_5c594d33-6cb5-4486-a758-26f0412ef1a9"
      unitRef="U_shares">8214285</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5435542f-8093-4105-868b-53ef71ac98a3"
      decimals="-3"
      id="F_121749ad-b6b8-4182-a78a-526e11526c54"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a58fa995-aa0b-4d6d-9cce-6dbe94de83fd"
      decimals="-3"
      id="F_e9223169-3a1e-4568-a44f-00b0032d311b"
      unitRef="U_USD">323213000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_df0832a0-b752-462c-be11-1620cfe4dc18"
      decimals="-3"
      id="F_b2ef1c0b-3d33-48ef-a38f-e057971312ed"
      unitRef="U_USD">323214000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_a9001d10-0c10-49dc-a944-46388f818412"
      decimals="INF"
      id="F_7cf34836-09b7-454f-9bb2-38297b21795f"
      unitRef="U_shares">1986250</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3"
      decimals="-3"
      id="F_61960aed-dcea-43d5-bba7-0e456cdb9615"
      unitRef="U_USD">1435000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_1a37168f-b848-4b25-bbb7-edd068bc708f"
      unitRef="U_USD">1435000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a9001d10-0c10-49dc-a944-46388f818412"
      decimals="INF"
      id="F_7ff5f97a-a754-48fe-9d31-bb2aeec8a721"
      unitRef="U_shares">1618368</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3"
      decimals="-3"
      id="F_f8ff7256-d9f6-41c6-9425-9478229784e8"
      unitRef="U_USD">4059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_f2cbf057-b10c-4cd5-881f-98cfca98ea75"
      unitRef="U_USD">4059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_10a8dbbd-dfe1-4e3c-8eda-539e387c6ab3"
      decimals="-3"
      id="F_f62f96b7-8592-4b16-955d-e9f80fb629bf"
      unitRef="U_USD">27600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_aa359a49-3ce1-4ff3-ac37-8dbfab78ca7a"
      unitRef="U_USD">27600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_4b3827f4-9f03-4d95-b4e5-11849acbae16"
      decimals="-3"
      id="F_8e776097-f8f2-4a1a-b966-7f05edbd4c9d"
      unitRef="U_USD">-677000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_e33239fa-c0da-4ff2-8931-47174e64438c"
      unitRef="U_USD">-677000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_f3142090-a1b8-4083-8441-c9dd49ecb566"
      decimals="-3"
      id="F_468be4ef-a980-4254-bac9-d7a96efafa64"
      unitRef="U_USD">-298665000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_6633c424-66c9-46f2-bc5d-868fe6a8c472"
      unitRef="U_USD">-298665000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d3a8cc93-b738-43bd-abbd-308523b5cd24"
      decimals="INF"
      id="F_cfe7f33b-f7a5-4e04-8f37-751b92042be3"
      unitRef="U_shares">127416740</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_d3a8cc93-b738-43bd-abbd-308523b5cd24"
      decimals="-3"
      id="F_4620baa9-b80f-4905-83a9-d7f0fd13acf7"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_050ac877-095b-4637-b981-1aea98d3b192"
      decimals="-3"
      id="F_ea9f4928-5bc3-488a-acca-0eea4e5e681d"
      unitRef="U_USD">1385301000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8d7fc207-68b5-469e-b2a5-a7be19fc2bad"
      decimals="-3"
      id="F_87d6071f-c0a1-45c8-b2f5-92a5e09fe371"
      unitRef="U_USD">-1278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e1a0aec0-6950-4e6b-b8c6-2c448044907e"
      decimals="-3"
      id="F_931cf0fc-ea15-4fb3-9c67-f5dc38478cef"
      unitRef="U_USD">-667184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_c3722b3a-7a89-49a1-a1c8-a93c6b943e41"
      unitRef="U_USD">716852000</us-gaap:StockholdersEquity>
    <vir:StockIssuedDuringPeriodSharesCollaborationAgreement
      contextRef="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc"
      decimals="INF"
      id="F_f1648da9-76ef-483c-955a-a7a165d57120"
      unitRef="U_shares">1924927</vir:StockIssuedDuringPeriodSharesCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_8fccfc88-43e9-4439-a516-7a1eda119be4"
      decimals="-3"
      id="F_43f7ffe6-6fc3-4753-8921-d42a229f8546"
      unitRef="U_USD">85213000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_a778ab1c-4c1f-4845-b8b7-2d97883b0edd"
      unitRef="U_USD">85213000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration
      contextRef="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc"
      decimals="0"
      id="F_8241b86d-f327-4e04-bb29-f4ea0ec4e800"
      unitRef="U_shares">42737</vir:StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration>
    <vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration
      contextRef="C_8fccfc88-43e9-4439-a516-7a1eda119be4"
      decimals="-3"
      id="F_bf53d25c-80a0-434e-a560-0655e078c3c4"
      unitRef="U_USD">1860000</vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration>
    <vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_8a283145-96c5-43a6-9cbc-6e0753bc46a0"
      unitRef="U_USD">1860000</vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc"
      decimals="INF"
      id="F_0b5465dc-0f1c-46bc-b45f-70b4444c02c5"
      unitRef="U_shares">89261</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc"
      decimals="INF"
      id="F_24ac2c2b-5045-41cc-8577-bec31b076a45"
      unitRef="U_shares">1622718</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_8fccfc88-43e9-4439-a516-7a1eda119be4"
      decimals="-3"
      id="F_d5738201-779d-4f84-afec-66ae6ef406d8"
      unitRef="U_USD">13077000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_56f8776d-ca7c-4a2b-8cf0-a9219695e11f"
      unitRef="U_USD">13077000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_727a00cf-e15d-40ba-bf21-0bf0a70ac7bc"
      decimals="INF"
      id="F_ddb73b15-10a5-4cc3-812f-d0a8817ea7c0"
      unitRef="U_shares">65021</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_8fccfc88-43e9-4439-a516-7a1eda119be4"
      decimals="-3"
      id="F_731a3215-dfc0-4961-99cb-1a2360d69b83"
      unitRef="U_USD">2300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_0334c668-ff5f-4c5c-95f3-d2c68606c4ba"
      unitRef="U_USD">2300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8fccfc88-43e9-4439-a516-7a1eda119be4"
      decimals="-3"
      id="F_0479eb70-5b9f-47d4-9b0e-7ab24cc8cfb0"
      unitRef="U_USD">83784000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_498b36aa-01e0-4488-9c30-0985a78639e7"
      unitRef="U_USD">83784000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_b82d2460-cf24-43b0-b95e-5a0a52709f8d"
      decimals="-3"
      id="F_17d42d4a-e780-4f69-9cb4-16eed2991f5f"
      unitRef="U_USD">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_680c6e9d-4483-403e-8bfa-2cfd9602e600"
      unitRef="U_USD">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_486aaa19-98ed-45c8-8860-fd4d402399da"
      decimals="-3"
      id="F_613b24ae-23c0-4bbd-aed9-28b735230f6b"
      unitRef="U_USD">528584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_5914c330-b1d8-48fa-8349-ec4d5f1910e4"
      unitRef="U_USD">528584000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c7f66cdc-e2a5-4776-b99c-d6e4b917eb2c"
      decimals="INF"
      id="F_6999d89e-ce90-4ef3-87be-3f47ea11a6be"
      unitRef="U_shares">131161404</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c7f66cdc-e2a5-4776-b99c-d6e4b917eb2c"
      decimals="-3"
      id="F_5131f971-2b3e-4255-bbd3-460ed2088d15"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b1bbbe19-c33f-4c19-83ca-eca625a9d033"
      decimals="-3"
      id="F_ea675401-2410-4840-80d6-d1b7c1d609a8"
      unitRef="U_USD">1571535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_91794362-8b4e-44c7-8392-9d2e078a248a"
      decimals="-3"
      id="F_e619dd20-0bb3-4c44-ae41-09b25724bcd6"
      unitRef="U_USD">-1099000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d7012ff2-8e91-4fa6-b536-458c48e3b5ee"
      decimals="-3"
      id="F_15cf6bea-e54e-49c0-9ab7-0d5e06257c32"
      unitRef="U_USD">-138600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_1c7a890b-871d-41b8-aa8c-a86271163d9c"
      unitRef="U_USD">1431849000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_7be9baf3-10f8-4797-88b4-b52a96360fbe"
      unitRef="U_USD">528584000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_6a7784cf-fe7a-4113-b0d0-c460c77ca087"
      unitRef="U_USD">-298665000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_b0dbc91b-e4d2-4d78-9553-30f05edab5ac"
      unitRef="U_USD">-174683000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_0ba0c5e4-41f6-4a5f-9d60-a6d4d91d08b1"
      unitRef="U_USD">5278000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_cac71a2a-85db-43cf-8612-04ef31b13041"
      unitRef="U_USD">4400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_6dcb8c2c-3ba3-45b7-b744-5d376fa9eb6f"
      unitRef="U_USD">3294000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_36f5b932-27bf-4425-98e0-12aef82937ab"
      unitRef="U_USD">533000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_310765ed-6f85-40cb-b114-668af456766f"
      unitRef="U_USD">1042000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_ba3251ba-3e1c-430f-a5b2-a3eaf4d11c77"
      unitRef="U_USD">1223000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_aef3ec73-c0ca-4378-a317-9f005a34d0e5"
      unitRef="U_USD">832000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_2f96a5fa-6283-4171-93a9-3577799915eb"
      unitRef="U_USD">244000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_ae0b697b-3009-4637-99f1-f43bf4013bf2"
      unitRef="U_USD">-1548000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_ec1f7aa7-10c6-49d2-9102-738eaa662227"
      unitRef="U_USD">179000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <vir:NoncashLeaseExpense
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_eb689e22-37ad-4d6a-a4b6-f775a8941954"
      unitRef="U_USD">6172000</vir:NoncashLeaseExpense>
    <vir:NoncashLeaseExpense
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_a7f08ce1-b657-4f9d-b788-f3d23d50b6ad"
      unitRef="U_USD">3371000</vir:NoncashLeaseExpense>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_52b81cf2-113e-47ab-b6d5-4785553d13ec"
      unitRef="U_USD">-138049000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_ed7308d8-9340-4859-8f5d-f1c0ca549153"
      unitRef="U_USD">91848000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_c7994e58-6c26-4783-83a9-30cf17f6e076"
      unitRef="U_USD">38394000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_150613ed-31b4-44a3-9eee-e0b58985fbae"
      unitRef="U_USD">8330000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_8deb8567-0d9e-40e4-93c2-276182831497"
      unitRef="U_USD">-8140000</vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue>
    <vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_f4800ff6-6c56-4713-b998-109ffbdd1249"
      unitRef="U_USD">-15752000</vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue>
    <vir:InitialFairValueOfDerivativeLiability
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_b968b53b-98e9-43e0-8b20-c6002489c211"
      unitRef="U_USD">13599000</vir:InitialFairValueOfDerivativeLiability>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_ca5bf112-97fd-43aa-b6b0-b0b51a4165e0"
      unitRef="U_USD">-16796000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_6ea3ea88-1beb-444e-8fef-1d075e23547e"
      unitRef="U_USD">1150000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_d37141f9-b137-4530-a1d0-d6a8dfb75a80"
      unitRef="U_USD">2049000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_05357b1e-efcb-4963-a7b2-da8f30daeedd"
      unitRef="U_USD">83784000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_8258a829-60ff-4b1b-ad08-e3c936141240"
      unitRef="U_USD">27600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_ac52255c-7ae5-4d08-a95e-512b7e9899da"
      unitRef="U_USD">8719000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_40135349-b4c6-49db-98b4-c134d01b74ad"
      unitRef="U_USD">-15186000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_d1fd9353-8b2d-48f6-9ffc-e245774e3a84"
      unitRef="U_USD">52000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_3b1ddaff-fe2d-47c7-affc-f7f5bf152069"
      unitRef="U_USD">4844000</us-gaap:GainLossOnTerminationOfLease>
    <vir:CommonStockIssuedInConnectionWithLicenseAgreement
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_a63aebee-e166-47ba-9af2-21f2962e4d08"
      unitRef="U_USD">617000</vir:CommonStockIssuedInConnectionWithLicenseAgreement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_1bf5f4a5-6e40-4c6f-b655-73135ab65fcb"
      unitRef="U_USD">697000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_dc8d5196-8d5e-45c3-98c2-0ac96e860a48"
      unitRef="U_USD">23000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_f054c174-18b9-4950-a0cb-fa18bbbd8564"
      unitRef="U_USD">345000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_c61ecf96-44e9-4370-b1b2-8bf4d0844bda"
      unitRef="U_USD">773079000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_d5df0cea-2503-4fea-a4c3-f54fb3d8d712"
      unitRef="U_USD">3665000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_0e636d61-7163-4b3a-942f-6f38115a203a"
      unitRef="U_USD">4475000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_ae160c30-d0fd-44da-b6fc-c72200d46597"
      unitRef="U_USD">4619000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_518ae512-c6e6-412c-832f-b756aef87302"
      unitRef="U_USD">1483000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_8cd2f4a4-05c2-4d55-a346-8d12ee55d10b"
      unitRef="U_USD">1100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_e8ed574b-14ec-439e-9eec-86eaa99b5179"
      unitRef="U_USD">1881000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_61130947-499f-4ce6-9721-889f7728d970"
      unitRef="U_USD">-171000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_47bc2a84-4bb9-434b-bd52-b9a785fb8bf8"
      unitRef="U_USD">-790000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_4a8052cd-e8a9-4c82-abc1-9ed98e1e7c51"
      unitRef="U_USD">964000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_0ed74285-41c5-40c4-a60b-051879c6849f"
      unitRef="U_USD">58498000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_a4819237-f6b6-40b4-a07f-f0a12f59df79"
      unitRef="U_USD">46614000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_f04aa775-6908-4bde-8bda-b24b2c5ff189"
      unitRef="U_USD">10211000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_b4eae1c8-26f1-4a4c-a964-a1ed5e7f3c3a"
      unitRef="U_USD">-535000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_672a660d-2999-46bc-8e99-ec6f331194c9"
      unitRef="U_USD">-3684000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_61de83e3-523f-480b-ac86-e7354871a2fa"
      unitRef="U_USD">92041000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_4692b7c5-9a5e-45c9-8340-93e1509bbd51"
      unitRef="U_USD">-7043000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_34c81c5b-1c31-45ad-872d-2907896d6bc4"
      unitRef="U_USD">3529000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_f45591de-478e-4b59-a6d3-430100e496f0"
      unitRef="U_USD">-47589000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_a3d40e7e-4d38-4935-847f-782c1eeae150"
      unitRef="U_USD">-190941000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_dd22d2d6-a045-4a5b-aa09-d8a4ba04d701"
      unitRef="U_USD">-129632000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_165db72f-530a-4ac7-893b-b54ef0f2b514"
      unitRef="U_USD">21817000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_cd8cf64a-07d1-42b1-84cb-3c6eb1a55862"
      unitRef="U_USD">6549000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_97d700bb-7cdd-448e-8f43-b180161df675"
      unitRef="U_USD">8940000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_c787366a-f919-411d-8b50-edc7ef371675"
      unitRef="U_USD">420240000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_61815887-353d-4d5b-a165-6f894860b8fa"
      unitRef="U_USD">403841000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_e6bf2a30-658b-4340-9460-183cd077411b"
      unitRef="U_USD">643898000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_643f0ac8-1170-469c-8869-02ea9f6f0322"
      unitRef="U_USD">301243000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_e69fa984-4f12-4e3f-a439-ad8b17481a58"
      unitRef="U_USD">400348000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_b9946495-db11-4082-b612-0d3749951f48"
      unitRef="U_USD">396680000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_eb190666-19ed-4f2e-bbd3-db3188175418"
      unitRef="U_USD">180000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_87ae7e7a-c1e5-48a0-b7b6-313474cc569e"
      unitRef="U_USD">-140814000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_1c54b9db-06c8-4f90-a3b1-4aecfb2b28e5"
      unitRef="U_USD">-9862000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_bfbd8654-354b-49fd-b07b-7113a6cfd626"
      unitRef="U_USD">-256158000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_1bfae185-e5c8-4577-8141-e72de9718408"
      unitRef="U_USD">323214000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_23c593d3-6662-4c12-8d4f-ab18d0605a8f"
      unitRef="U_USD">126411000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_7bd09cb8-0f10-423e-8594-0f550e570802"
      unitRef="U_USD">85213000</vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_67705a86-c6c7-4e22-ba25-b0b14652b30e"
      unitRef="U_USD">206699000</vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_4b7eac74-97da-4b41-a2e9-64fa1634bdc4"
      unitRef="U_USD">317335000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <vir:FailedSaleLeasebackTransactionProceedsFinancingActivities
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_202c0025-e4cb-471b-bb23-a1223e4dc98b"
      unitRef="U_USD">1202000</vir:FailedSaleLeasebackTransactionProceedsFinancingActivities>
    <vir:PaymentOfContingentConsideration
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_a1eafafc-3e43-4f7f-832f-354a4dba03d4"
      unitRef="U_USD">4248000</vir:PaymentOfContingentConsideration>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_082436f7-7379-4d61-8c3b-1390349b6d76"
      unitRef="U_USD">259000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_55cb8866-e9c9-4b61-bab0-eb8705c7c815"
      unitRef="U_USD">250000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_93a7f2e4-d090-47fa-946a-158010553503"
      unitRef="U_USD">95000</us-gaap:FinanceLeasePrincipalPayments>
    <vir:ProceedsFromRepaymentOfPromissoryNotes
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_e3e8d9ab-ed6b-4dc5-a77e-4b49c18eee27"
      unitRef="U_USD">3265000</vir:ProceedsFromRepaymentOfPromissoryNotes>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_32ed496b-0723-4007-b051-2f3c2672e15d"
      unitRef="U_USD">13077000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_ec790428-70b7-4454-a315-bd699710dc91"
      unitRef="U_USD">4059000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_debbdadc-d2ab-4d30-9b56-cd635d340625"
      unitRef="U_USD">1129000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_ec550a60-d8ec-4a01-8caa-dc2b3a9ef18c"
      unitRef="U_USD">2300000</us-gaap:ProceedsFromStockPlans>
    <vir:CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_f5161771-3299-494c-a790-5ab0ac6e5417"
      unitRef="U_USD">3000</vir:CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_8d4604f9-7d5c-4cb8-98ba-3fb8718ff0ca"
      unitRef="U_USD">100331000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_d30f9171-b9e8-46a8-b809-7bf233a4d376"
      unitRef="U_USD">529474000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_5b59aac1-6e08-4c14-943d-10a2e7e984e1"
      unitRef="U_USD">449244000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_fd768bb5-76c4-4f9c-bda6-80b96683fbad"
      unitRef="U_USD">-88072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_9805df3b-6cdf-4d13-bc8d-08b690f16d4c"
      unitRef="U_USD">328671000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_12d81372-0920-4f42-a0bf-6f364d3eb731"
      unitRef="U_USD">63454000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_d4ef01f5-6a49-4afd-8384-a12525513ab3"
      unitRef="U_USD">451487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579"
      decimals="-3"
      id="F_7ff8a97a-c9b5-4d50-8d66-2c1242c4bae1"
      unitRef="U_USD">122816000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_88183c78-6814-4146-96c6-0cba18d5611c"
      decimals="-3"
      id="F_493b1bbd-9dcc-4174-8d56-d8b9c6c94e87"
      unitRef="U_USD">59362000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_13cf4633-1aad-4e47-9508-24615729fdbf"
      unitRef="U_USD">363415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_1150f140-5e97-4c78-bf60-36522e9749cd"
      unitRef="U_USD">451487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579"
      decimals="-3"
      id="F_970bd175-d825-4da6-8957-56eece7c7170"
      unitRef="U_USD">122816000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_54ea791a-a553-4c6b-a984-7d2f2777abc3"
      unitRef="U_USD">8731000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_0ed87162-6c38-4c82-8ef6-87b716e5167f"
      unitRef="U_USD">382000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_d4f13a7e-0f58-4231-935f-f50a413c5f1f"
      unitRef="U_USD">892000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <vir:NonCashCommonStockIssuedForContingentConsideration
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_ec4d523f-099c-4b53-8aff-240e225510d9"
      unitRef="U_USD">1860000</vir:NonCashCommonStockIssuedForContingentConsideration>
    <vir:ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_dbe1e3e4-6cdd-4296-945c-f81bb7ff1d39"
      unitRef="U_USD">636612000</vir:ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_776b7a6e-06d3-4bce-bad7-6e828ca6bb93"
      unitRef="U_USD">77187000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_ba3bd97a-9d44-4106-9856-107adcbbc0d3"
      unitRef="U_USD">48495000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <vir:AdvancedProceedsAppliedToConvertiblePreferredStockIssuance
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_75e1ae96-9005-4996-9e48-3c8448263c3f"
      unitRef="U_USD">10140000</vir:AdvancedProceedsAppliedToConvertiblePreferredStockIssuance>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_af61ab95-7f9b-4aeb-82eb-284b3629f957"
      unitRef="U_USD">29245000</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone>
    <vir:ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_14cdaf9c-9eb3-4858-b49b-002cec51381e"
      unitRef="U_USD">3073000</vir:ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_f0b30e3d-dddb-499a-b9c0-18039a7ae542"
      unitRef="U_USD">347815000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_65efccf9-7f6c-46fd-9bf6-27ad5b901e52"
      unitRef="U_USD">436575000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579"
      decimals="-3"
      id="F_20cda37b-3314-46c2-985e-99e25fcf6c99"
      unitRef="U_USD">109335000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_19ef2ea1-583b-4757-81a0-3552efe70e73"
      unitRef="U_USD">8594000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_5a7e8e07-9e60-4ab1-91e9-76631f4f98f9"
      unitRef="U_USD">7993000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579"
      decimals="-3"
      id="F_3e1863d7-f5bc-4f14-ba3a-ebd6f4254c42"
      unitRef="U_USD">6181000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_fd0240c4-80a2-4e01-918c-d28d26efa261"
      unitRef="U_USD">7006000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_15e70c41-51f3-443f-a402-9a6afa8f1b35"
      unitRef="U_USD">6919000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579"
      decimals="-3"
      id="F_428c441b-d78d-4c62-b8da-6cee6e62872a"
      unitRef="U_USD">7300000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_eb085999-b514-499a-8a0c-ae87f3a54f55"
      unitRef="U_USD">363415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_932b8303-cee9-4c90-8525-d114e2a993a6"
      unitRef="U_USD">451487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579"
      decimals="-3"
      id="F_c70149b8-563c-4106-92fc-35efc2b2c1db"
      unitRef="U_USD">122816000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_a572fd53-a44f-4be6-b3cf-db2b5d0d6b4b">&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;1.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vir Biotechnology, Inc. (&#x201c;Vir&#x201d; or the &#x201c;Company&#x201d;) is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Its current pipeline consists of sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#xae;) and other product candidates targeting coronavirus disease 2019 (&#x201c;COVID-19&#x201d;), hepatitis B virus (&#x201c;HBV&#x201d;), influenza A virus, and human immunodeficiency virus (&#x201c;HIV&#x201d;). Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2021, the U.S. Food and Drug Administration (the "FDA") granted an Emergency Use Authorization (&#x201c;EUA&#x201d;) for sotrovimab for the early treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and at high risk for progression to severe COVID-19, including hospitalization or death. The Company also received a positive scientific opinion from the Committee for Human Medicinal Products in the European Union (&#x201c;EU&#x201d;) for sotrovimab. In December 2021, the European Commission granted marketing authorization to Xevudy&#xae; (sotrovimab) in the EU for the treatment of adults and adolescents at increased risk of progressing to severe COVID-19.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 10, 2019, the Company completed its initial public offering (&#x201c;IPO&#x201d;) of its common stock. In connection with its IPO, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,142,858&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at an initial offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. As a result of the IPO, the Company received approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;126.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in net proceeds, after deducting underwriting discounts, commissions and offering expenses. At the closing of the IPO, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88,112,733&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of outstanding convertible preferred stock were automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88,112,733&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock and a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;244,444&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of convertible preferred stock was converted into a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;244,444&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Follow-On Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On July 10, 2020, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,214,285&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock pursuant to a registration statement on Form S-1 (File No. 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) (File No. 333-239747) (collectively, the &#x201c;Registration Statements&#x201d;). The Registration Statements became effective on July 7, 2020. The price of the shares sold in the follow-on offering was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share and the Company received total gross proceeds from the offering of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;345.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. After deducting underwriting discounts and commissions of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, the net proceeds were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;323.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Sales Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2020, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), under which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, through or to Cowen, acting as sales agent or principal. The shares will be offered and sold under the Company&#x2019;s shelf registration statement on Form S-3 (the &#x201c;S-3 Registration Statement&#x201d;) and a related prospectus filed with the Securities and Exchange Commission on November 10, 2020. The Company will pay Cowen a commission of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares have been issued under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Need for Additional Capital&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Although the Company recorded net income for the year ended December 31, 2021, it has otherwise incurred accumulated net losses since inception. The Company expects its earnings to be volatile and may continue to incur net losses over the next several years. As of December 31, 2021, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;138.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Management expects to incur additional losses in the future to conduct research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company had, excluding restricted cash, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;909.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of cash, cash equivalents, and investments as of December 31, 2021, and after excluding the equity investment in Brii Biosciences Limited ("Brii Bio Parent"), the Company had &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;766.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Based on the Company&#x2019;s current operating plan, management believes that the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;766.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; as of December 31, 2021 will be sufficient to fund its operations through at least the next 12 months from the issuance date of these consolidated financial statements.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2d502ed6-15ab-425f-9a22-bfc1d3c39623"
      decimals="INF"
      id="F_8c4b51ad-5615-4dee-a080-de814fc1113f"
      unitRef="U_shares">7142858</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_ccf336f4-a19b-47b9-8dd4-fd55c3edb88c"
      decimals="2"
      id="F_767e439c-bdf8-441b-b9da-79be05d38ac7"
      unitRef="U_USDollarShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_e52b7462-3e95-4a90-a2ac-eeb96cc91696"
      decimals="-5"
      id="F_67376ad3-4c9c-4d19-a049-ed508f863efc"
      unitRef="U_USD">126400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_ccf336f4-a19b-47b9-8dd4-fd55c3edb88c"
      decimals="INF"
      id="F_4e8b986d-acce-4e42-8f4d-59ad560888c1"
      unitRef="U_shares">88112733</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_c9443ba3-f289-4712-b80e-f1c93e0123cf"
      decimals="INF"
      id="F_6d825427-ac75-4966-a63b-4da76d3dffb9"
      unitRef="U_shares">88112733</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_04e2f054-346c-47c8-89fb-055997c2a180"
      decimals="INF"
      id="F_9405048c-a313-41ce-81df-92b4793a7242"
      unitRef="U_shares">244444</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_e9b5a1f5-d509-4f41-a5b0-00e6735b747a"
      decimals="INF"
      id="F_81f587d2-8916-4971-9479-9cfbadb7c720"
      unitRef="U_shares">244444</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_88ec3719-e182-4d88-abf8-cefce0fa050c"
      decimals="INF"
      id="F_b8e8284c-b104-4e65-8589-436bbe9541b5"
      unitRef="U_shares">8214285</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_c0e8d12f-41e5-4499-bb57-79d3fbd1a9a2"
      decimals="INF"
      id="F_f4f6ff43-3d3c-498a-89e9-66eb0fc6ecbb"
      unitRef="U_USDollarShare">42.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_88ec3719-e182-4d88-abf8-cefce0fa050c"
      decimals="-5"
      id="F_2a50e7a7-9cbe-41a8-bf70-567c93b5e385"
      unitRef="U_USD">345000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vir:PaymentsOfUnderwritingDiscountsAndCommissions
      contextRef="C_88ec3719-e182-4d88-abf8-cefce0fa050c"
      decimals="-5"
      id="F_f7762e11-0f30-40fe-a616-3f65aff9289f"
      unitRef="U_USD">20700000</vir:PaymentsOfUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_88ec3719-e182-4d88-abf8-cefce0fa050c"
      decimals="-5"
      id="F_94aefcb8-8e02-4dab-8c1b-83d187f1ec73"
      unitRef="U_USD">1100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <vir:NetProceedsFromIssuanceSecondaryPublicOffering
      contextRef="C_88ec3719-e182-4d88-abf8-cefce0fa050c"
      decimals="-5"
      id="F_77742d55-b0c5-4bd7-aee3-59a25c24a696"
      unitRef="U_USD">323200000</vir:NetProceedsFromIssuanceSecondaryPublicOffering>
    <vir:SaleOfStockConsiderationAggregateOfferingPrice
      contextRef="C_33252fb3-7851-44e7-9561-2d534fcb41de"
      decimals="-5"
      id="F_f34f3754-6a90-43d7-9652-4529ef1618c6"
      unitRef="U_USD">300000000.0</vir:SaleOfStockConsiderationAggregateOfferingPrice>
    <vir:PercentageOfCommissionRateFromSaleOfShares
      contextRef="C_91330166-4192-4765-8752-a172cb399634"
      decimals="3"
      id="F_c2cc6dd2-7874-49ac-af8c-1ed85da54bcd"
      unitRef="U_pure">0.030</vir:PercentageOfCommissionRateFromSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2f8addeb-5f7f-45ee-807d-84c9144573a3"
      decimals="INF"
      id="F_b99465ce-db91-4234-8dd4-2ab91016feb6"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-5"
      id="F_0b259ad3-3260-4e3e-8a30-ea9d26a145ee"
      unitRef="U_USD">-138600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-5"
      id="F_6d8e1610-4fd6-456b-b848-02de6c1bad90"
      unitRef="U_USD">909500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <vir:CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-5"
      id="F_872ea01a-0e4c-415a-b1e5-a995810abac5"
      unitRef="U_USD">766400000</vir:CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment>
    <vir:CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-5"
      id="F_35e68399-74f1-4a2d-af64-100b16da2be7"
      unitRef="U_USD">766400000</vir:CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_e8ab5f61-8a41-455b-b1a2-7feb86c0a459">&lt;div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;2.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. The consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. Transaction gains and losses are included in other income (expense), net on the consolidated statements of operations, and were immaterial for the years ended December 31, 2021, 2020 and 2019.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company operates as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reportable segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has implemented a number of plans and policies designed to address and mitigate the impact of the ongoing COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will continue to have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company&#x2019;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Although the Company received EUA, temporary authorization or marketing approval for sotrovimab (under the brand name Xevudy&#xae;), it is still subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its other product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of sotrovimab and other product candidates and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its other product candidates, it will be unable to generate significant revenue from product sales or maintain profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the consolidated balance sheets. As of December 31, 2021 and 2020, the Company has no off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#x2019;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#x2019;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; allowance for losses on available-for-sale debt securities attributable to credit risk for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Investments include available-for-sale debt securities and equity investments, which are carried at estimated fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Equity Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under Accounting Standards Update ("ASU") No. 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, the Company measures its investment in equity securities at fair value at each reporting date based on the market price at period end if it has a readily determinable fair value. Otherwise, the investments in equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer unless the Company has significant influence or control over the investee. Changes in fair value resulting from observable price changes are presented as change in fair value of equity investments &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and changes in fair value resulting from foreign currency translation are included in other income (expense), net &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e8ebc668-f14c-4720-8b72-2366a378afeb;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. No material impairment losses have been incurred to date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquired Intangible Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s intangible assets were acquired via business combinations or asset acquisitions. Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2021, there have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such impairments. For IPR&amp;amp;D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses. IPR&amp;amp;D assets acquired as part of an asset acquisition are recorded at cost and expensed immediately if they have no alternative future uses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finite-lived intangible assets acquired are initially recognized at their fair value at the acquisition date. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b3b3c2e2-807e-47e2-9909-7b52a03e1e68;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Collaboration, License and Contract Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when the Company&#x2019;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. When the Company is considered an agent in elements of collaboration arrangements within the scope of ASC 808, it records its share of collaboration revenue in the period in which such sales occur. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the revenue reported by the Company's collaboration partners, net of cost of goods sold and allowable expenses (e.g. medical affairs, selling and marketing expenses) in the period. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partner, including revenue from the sale of the product, and costs incurred for development and sales activities. For the periods covered in the financial statements presented, there have been no material changes to prior period estimates of revenues and expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#x2019;s intellectual property.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). The Company estimates the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Grant Revenue&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To date, research and development expenses have related primarily to discovery efforts and preclinical and clinical development of product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include expenses related to license and collaboration agreements; contingent consideration from business acquisitions; personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel contributing to research and development activities; expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and other allocated expenses, including expenses for rent, facilities maintenance, and depreciation and amortization.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. Upfront payments and research and development milestone payments made in connection with acquired license or product rights are expensed as incurred, provided that they do not relate to a regulatory approval milestone or assets acquired in a business combination.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s expense accruals for clinical trials and manufacturing are based on estimates of contracted services provided by third-party vendors not yet billed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of its outstanding obligations to those third parties as of the period end. The accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. The Company obtains information regarding unbilled services directly from these service providers and performs procedures to support its estimates based on its internal understanding of the services provided to date. However, the Company may also be required to estimate these services based on information available to its internal clinical and manufacturing administrative staff if such information is not able to be obtained timely from its service providers.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes stock-based compensation to employees and non-employees over the requisite service period based on the grant-date fair value of the awards. The Company calculates the estimated fair value of stock options and employees' purchase rights under the Company's 2019 employee stock purchase plan ("ESPP") using the Black-Scholes valuation model, which requires the use of subjective assumptions including volatility and expected term, among others. The fair value of restricted stock awards ("RSAs") and restricted stock units ("RSUs") is based on the market value of the Company's common stock on the date of grant. Stock-based compensation is recognized using the straight-line method for awards that vest only upon the employee&#x2019;s or non-employee&#x2019;s continued service to the Company. Stock-based compensation expense of the employees' purchase rights under the ESPP is recognized over the offering period. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various milestones are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;    &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Embedded Derivatives&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the consolidated statements of operations based on the nature of the related contingencies.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expense or selling, general and administrative expenses based on the nature of the relevant underlying activities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Otherwise, changes in fair values are recorded within other income (expense), net.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In accordance with ASU No. 2016-02 (Topic 842), Leases, the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. On the lease commencement date, the Company estimates and includes in its lease payments any lease incentive amounts based on future events when (1) the events are within the Company&#x2019;s control and (2) the event triggering the right to receive the incentive is deemed reasonably certain to occur. If the lease incentive received is greater or less than the amount recognized at lease commencement, the Company recognizes the difference as an adjustment to right-of-use asset and/or lease liability, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As the implicit rate in the Company's leases is generally unknown, the Company uses an incremental borrowing rate estimated based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating its estimated incremental borrowing rates, the Company considers its credit risk, the lease term, the total lease payments and the impact of collateral, as necessary. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. ROU assets and lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. Rent expense for the Company's operating leases is recognized on a straight-line basis within operating expenses over the reasonably assured lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company uses the asset and liability method of accounting for income taxes. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating losses and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as any related net interest and penalties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per common share is computed by dividing the net income by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;New Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2021, the Financial Accounting Standards Board ("FASB") issued ASU No. 2021-10, Government Assistance (Topic 832) (&#x201c;ASU 2021-10&#x201d;), which adds certain disclosure requirements with respect to government assistance, including (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance on financial statements. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2021-10 may have on its consolidated financial statements and related disclosures&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_6421bb3f-7526-4f47-bd5e-0e78a9ea2044">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. The consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_9c383f64-875d-4d3b-acbe-4297c26fd4d5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. Transaction gains and losses are included in other income (expense), net on the consolidated statements of operations, and were immaterial for the years ended December 31, 2021, 2020 and 2019.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_f88aedc9-dbf1-4952-89b3-c2142959eac9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_48e93875-26ff-435d-8394-10fa4d2e3710">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company operates as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reportable segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="INF"
      id="F_04371e70-991c-4454-9434-20f7184b4a2e"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_4a0633fd-125e-4b76-a0cc-557b96667d32">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has implemented a number of plans and policies designed to address and mitigate the impact of the ongoing COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will continue to have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company&#x2019;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Although the Company received EUA, temporary authorization or marketing approval for sotrovimab (under the brand name Xevudy&#xae;), it is still subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its other product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of sotrovimab and other product candidates and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its other product candidates, it will be unable to generate significant revenue from product sales or maintain profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the consolidated balance sheets. As of December 31, 2021 and 2020, the Company has no off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#x2019;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#x2019;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; allowance for losses on available-for-sale debt securities attributable to credit risk for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;</vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_23cda959-5b2b-4760-877c-0e044a46ce1d"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_3c3da7ce-8311-4456-8bc7-fb8a39fa78ae"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_4612c47d-29ff-47c0-9403-60b8c8674965">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_f77c7841-9957-4b45-a8fe-e0a015e238d5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Investments include available-for-sale debt securities and equity investments, which are carried at estimated fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Equity Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under Accounting Standards Update ("ASU") No. 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, the Company measures its investment in equity securities at fair value at each reporting date based on the market price at period end if it has a readily determinable fair value. Otherwise, the investments in equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer unless the Company has significant influence or control over the investee. Changes in fair value resulting from observable price changes are presented as change in fair value of equity investments &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and changes in fair value resulting from foreign currency translation are included in other income (expense), net &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_048edd35-cd41-4436-bfe3-cf08bed0a610">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_cb5ae719-c83d-4c2e-9624-f2bb430a99fb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e8ebc668-f14c-4720-8b72-2366a378afeb;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. No material impairment losses have been incurred to date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_72920b5d-5b28-4a32-a06c-5ef00bd3d18b">Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years.</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_ec04e3a0-91fd-471d-9c5e-a88bcbb1c70d"
      id="F_0428a95b-1aef-4390-b9cb-3461d5ea2bed">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_4854e81b-c83b-4dbc-a6ab-33f2766c24e6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquired Intangible Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s intangible assets were acquired via business combinations or asset acquisitions. Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2021, there have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such impairments. For IPR&amp;amp;D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses. IPR&amp;amp;D assets acquired as part of an asset acquisition are recorded at cost and expensed immediately if they have no alternative future uses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finite-lived intangible assets acquired are initially recognized at their fair value at the acquisition date. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b3b3c2e2-807e-47e2-9909-7b52a03e1e68;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="INF"
      id="F_87545169-2d68-4fbb-8cf7-cb6f053ce523"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_0326925d-a0c7-42ee-89e8-abb26064ce21">Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally seven to 15 years.</us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_ec04e3a0-91fd-471d-9c5e-a88bcbb1c70d"
      id="F_4830578c-0b13-4b9e-84f3-d48b32361bc4">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_7dba307b-6fa9-4679-a880-59fc1e4d6298">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_e99f9d96-7d7b-4bf3-a014-8ef63e6e8c02">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Collaboration, License and Contract Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when the Company&#x2019;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. When the Company is considered an agent in elements of collaboration arrangements within the scope of ASC 808, it records its share of collaboration revenue in the period in which such sales occur. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the revenue reported by the Company's collaboration partners, net of cost of goods sold and allowable expenses (e.g. medical affairs, selling and marketing expenses) in the period. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partner, including revenue from the sale of the product, and costs incurred for development and sales activities. For the periods covered in the financial statements presented, there have been no material changes to prior period estimates of revenues and expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#x2019;s intellectual property.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). The Company estimates the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Grant Revenue&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_a54b09e2-ccac-499c-bddc-3f017e2967f1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To date, research and development expenses have related primarily to discovery efforts and preclinical and clinical development of product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include expenses related to license and collaboration agreements; contingent consideration from business acquisitions; personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel contributing to research and development activities; expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and other allocated expenses, including expenses for rent, facilities maintenance, and depreciation and amortization.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. Upfront payments and research and development milestone payments made in connection with acquired license or product rights are expensed as incurred, provided that they do not relate to a regulatory approval milestone or assets acquired in a business combination.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s expense accruals for clinical trials and manufacturing are based on estimates of contracted services provided by third-party vendors not yet billed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of its outstanding obligations to those third parties as of the period end. The accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. The Company obtains information regarding unbilled services directly from these service providers and performs procedures to support its estimates based on its internal understanding of the services provided to date. However, the Company may also be required to estimate these services based on information available to its internal clinical and manufacturing administrative staff if such information is not able to be obtained timely from its service providers.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_100707e2-72fd-471e-86b4-49b2af5f00c0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes stock-based compensation to employees and non-employees over the requisite service period based on the grant-date fair value of the awards. The Company calculates the estimated fair value of stock options and employees' purchase rights under the Company's 2019 employee stock purchase plan ("ESPP") using the Black-Scholes valuation model, which requires the use of subjective assumptions including volatility and expected term, among others. The fair value of restricted stock awards ("RSAs") and restricted stock units ("RSUs") is based on the market value of the Company's common stock on the date of grant. Stock-based compensation is recognized using the straight-line method for awards that vest only upon the employee&#x2019;s or non-employee&#x2019;s continued service to the Company. Stock-based compensation expense of the employees' purchase rights under the ESPP is recognized over the offering period. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_96c6b97e-5f9c-4f78-a87e-915bfb38e177">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various milestones are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;    &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:DerivativesEmbeddedDerivatives
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_1f382009-d6ca-4939-9fac-4b68520913b2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Embedded Derivatives&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the consolidated statements of operations based on the nature of the related contingencies.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expense or selling, general and administrative expenses based on the nature of the relevant underlying activities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Otherwise, changes in fair values are recorded within other income (expense), net.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesEmbeddedDerivatives>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_49a86ddb-b0b2-41c6-9b65-fa4bf484b6d8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In accordance with ASU No. 2016-02 (Topic 842), Leases, the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. On the lease commencement date, the Company estimates and includes in its lease payments any lease incentive amounts based on future events when (1) the events are within the Company&#x2019;s control and (2) the event triggering the right to receive the incentive is deemed reasonably certain to occur. If the lease incentive received is greater or less than the amount recognized at lease commencement, the Company recognizes the difference as an adjustment to right-of-use asset and/or lease liability, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As the implicit rate in the Company's leases is generally unknown, the Company uses an incremental borrowing rate estimated based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating its estimated incremental borrowing rates, the Company considers its credit risk, the lease term, the total lease payments and the impact of collateral, as necessary. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. ROU assets and lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. Rent expense for the Company's operating leases is recognized on a straight-line basis within operating expenses over the reasonably assured lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_fc1f68d2-2c30-42ea-a654-a0f42a99cb7d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company uses the asset and liability method of accounting for income taxes. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating losses and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as any related net interest and penalties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax Cuts and Jobs Act of 2017&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; subjects a U.S. shareholder to current tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Staff Q&amp;amp;A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_a849fafc-233b-4a41-923d-9d088a02cc4e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per common share is computed by dividing the net income by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_6db23eff-7d4a-452f-b27e-4266c9761e62">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;New Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2021, the Financial Accounting Standards Board ("FASB") issued ASU No. 2021-10, Government Assistance (Topic 832) (&#x201c;ASU 2021-10&#x201d;), which adds certain disclosure requirements with respect to government assistance, including (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance on financial statements. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU 2021-10 may have on its consolidated financial statements and related disclosures&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_7f8822cc-734b-49c8-ad0a-b82fca7dddfc">&lt;div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;3.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including receivable from collaboration, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash Equivalents and Available-for-Sale Debt Securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables summarize the Company&#x2019;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.3%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:9.81%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.21%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.21%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.21%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.21%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;345,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;345,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;419,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;418,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;764,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;763,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(1) Includes &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;15.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; of restricted cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.295%;"/&gt;
        &lt;td style="width:1.044%;"/&gt;
        &lt;td style="width:9.829%;"/&gt;
        &lt;td style="width:1.044%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.229%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.044%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.229%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.044%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.04%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.044%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.229%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;421,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;421,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;722,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;722,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-2.599%;padding-left:2.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(1) Includes $&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;14.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; million of restricted cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities are presented within prepaid expenses and other current assets, and other assets in the consolidated balance sheets. Accrued interest receivable amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021 and 2020, respectively. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t write off any accrued interest receivable during the years ended December 30, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognized total net unrealized loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and net unrealized gain of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in accumulated other comprehensive income (loss) as of December 31, 2021 and 2020, respectively. The gross unrealized losses related to U.S. government treasuries as of December 31, 2021 were due to changes in interest rates. As of December 31, 2021 and 2020, there were no investments that have been in a continuous unrealized loss position for longer than 12 months. The Company determined that the gross unrealized losses on our investments as of December 31, 2021 were temporary in nature. The Company currently does not intend, and it is highly unlikely that it will be required, to sell these securities before recovery of their amortized cost basis. As of December 31, 2021, no securities have contractual maturities of longer than&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Equity Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company's equity investment consisted solely of ordinary shares of Brii Bio Parent. The Company acquired the securities as partial consideration for entering into the collaboration, option and license agreement (the &#x201c;Brii Agreement&#x201d;) with Brii Bio Parent and Brii Biosciences Offshore Limited (&#x201c;Brii Bio&#x201d;) in May 2018. The Company concluded it does not have a controlling interest or significant influence over Brii Bio based on its ownership percentage and other factors. See further discussion in Note 7&#x2014;Collaboration and License Agreements. In July 2021, Brii Bio Parent completed its initial public offering ("Brii Bio Parent IPO") on the Stock Exchange of Hong Kong Limited, prior to which the securities were accounted for as equity securities without a readily determinable fair value. Upon the completion of the Brii Bio Parent IPO, the securities were considered to be marketable equity securities and subsequently remeasured at fair value at each reporting date. The Company classifies its equity investment in Brii Bio Parent as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market. As of December 31, 2021, the Company remeasured the equity investment at a fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;143.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. For the year ended December 31, 2021, the Company recognized an unrealized gain of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;138.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as other income in the consolidated statement of operations, net of an unrealized loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to foreign currency translation for the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingent consideration includes potential milestone payments in connection with the acquisitions of Humabs Biomed SA (&#x201c;Humabs&#x201d;) and TomegaVax, Inc. (&#x201c;TomegaVax&#x201d;). See further discussion in Note 4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquisitions. The Company classifies the contingent consideration as Level 3 financial liabilities within the fair value hierarchy as of December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical, regulatory, and commercial milestone payments based on the assessment of the likelihood and estimated timing that certain milestones would be achieved. In December 2021, the Company achieved the regulatory milestone of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to sotrovimab. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of Decemb&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;er 31, 2021, the Company calculated the estimated fair value of the remaining clinical and regulatory milestones related to the HBV product using the following significant unobservable inputs: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.179%;"/&gt;
        &lt;td style="width:2.44%;"/&gt;
        &lt;td style="width:32.381%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Range&lt;br/&gt;(Weighted-Average)1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(1) Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the commercial milestones, the Company used a Monte Carlo simulation because of the availability of a discrete revenue forecast. During the year ended December 31, 2021, the Company achieved the specified sales milestones totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to sotrovimab&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. A&lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;s of December 31, 2021, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecast, as well as the following significant unobservable inputs f&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;or the remaining commercial milestones related to the HBV product: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.179%;"/&gt;
        &lt;td style="width:2.44%;"/&gt;
        &lt;td style="width:32.381%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. As of December 31, 2021 and 2020, the estimated fair value of the contingent consideration related to the Humabs acquisition was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, with changes in the estimated fair value recorded in research and development expense, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and selling, general and administrative expense in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated fair value of the contingent consideration related to the TomegaVax acquisition was determined by using a Monte Carlo simulation model which included estimates of both the probability and timing to achieve the required per share price of the Company&#x2019;s common stock, and incorporates assumptions as to expected volatility and discount rate. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;definition of an embedded derivative financial instrument. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2021, the Company achieved one of the milestones related to a specified per-share price of its common stock resulting in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million payable to the former TomegaVax&#x2019;s stockholders which was paid in July 2021. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.179%;"/&gt;
        &lt;td style="width:2.44%;"/&gt;
        &lt;td style="width:32.381%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;115&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, the estimated fair value of the contingent consideration related to the TomegaVax acquisition was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, with changes in the estimated fair value recorded in other income (expense), net in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated fair value of the contingent consideration related to the Humabs and TomegaVax acquisitions involves significant estimates and assumptions which give rise to measurement uncertainty.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the changes in the estimated fair value of the Company&#x2019;s Level 3 financial liabilities (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.644%;"/&gt;
        &lt;td style="width:2.097%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:16.112%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassification of contingent consideration to accrued liabilities upon achievement of the Humabs milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payment of contingent consideration upon achievement of the TomegaVax milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_005debc0-f682-4ad9-bae9-3d868d8146d5">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_4869d666-46a6-4b34-a91c-21e194b1e77a">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables summarize the Company&#x2019;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.3%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:9.81%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.21%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.21%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.21%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.21%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;345,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;345,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;419,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;418,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;764,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;763,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(1) Includes &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;15.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; of restricted cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.295%;"/&gt;
        &lt;td style="width:1.044%;"/&gt;
        &lt;td style="width:9.829%;"/&gt;
        &lt;td style="width:1.044%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.229%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.044%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.229%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.044%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.04%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.044%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.229%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;421,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;421,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;722,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;722,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-2.599%;padding-left:2.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(1) Includes $&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;14.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; million of restricted cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_c65e2fa1-651b-49f1-8130-e10a86ed4b23"
      decimals="-3"
      id="F_4539ab16-5659-4ce7-a611-6bc657de6516"
      unitRef="U_USD">345098000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsFairValue
      contextRef="C_c65e2fa1-651b-49f1-8130-e10a86ed4b23"
      decimals="-3"
      id="F_d70ead3c-aa30-4a86-b30a-7e805359aad2"
      unitRef="U_USD">345098000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_515a352c-312e-4bf3-9bf8-04b085f91abc"
      decimals="-3"
      id="F_074dc99f-219d-414c-ac63-d8488c88488c"
      unitRef="U_USD">419442000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_515a352c-312e-4bf3-9bf8-04b085f91abc"
      decimals="-3"
      id="F_8990435d-5a94-4203-b936-e3140512568a"
      unitRef="U_USD">872000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_515a352c-312e-4bf3-9bf8-04b085f91abc"
      decimals="-3"
      id="F_2a787813-b4f9-4dcb-aea2-108be8e529b5"
      unitRef="U_USD">418570000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_d224330a-9676-4782-86ba-e59e08ff6228"
      unitRef="U_USD">764540000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_2d593e7c-b8af-4867-8268-17bef4890f2e"
      unitRef="U_USD">0</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_79cf9ab3-077b-43d3-8bb8-8207268c3ceb"
      unitRef="U_USD">872000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_e92faf36-1602-4cda-83b7-9f1bcbbc2428"
      unitRef="U_USD">763668000</vir:FinancialAssetsFairValue>
    <us-gaap:RestrictedCashEquivalents
      contextRef="C_c65e2fa1-651b-49f1-8130-e10a86ed4b23"
      decimals="-5"
      id="F_8b39812a-b8e4-4641-8c2f-6727cbb4cba9"
      unitRef="U_USD">15600000</us-gaap:RestrictedCashEquivalents>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_37e02e2b-ecee-41f9-9516-eff5990866ee"
      decimals="-3"
      id="F_75dec18e-a8a8-4382-985e-1570e021d392"
      unitRef="U_USD">421835000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsFairValue
      contextRef="C_37e02e2b-ecee-41f9-9516-eff5990866ee"
      decimals="-3"
      id="F_422179d7-8b97-4c8b-8ebf-236b1f31b3a0"
      unitRef="U_USD">421835000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_19681061-85d7-43eb-9090-f6c375682fba"
      decimals="-3"
      id="F_9b31846c-a25d-474b-9dfe-8b8272a35b81"
      unitRef="U_USD">300201000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_19681061-85d7-43eb-9090-f6c375682fba"
      decimals="-3"
      id="F_44d34173-28bc-4017-9268-a2f8f2040d10"
      unitRef="U_USD">91000</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_19681061-85d7-43eb-9090-f6c375682fba"
      decimals="-3"
      id="F_1d676ade-211b-485f-8f84-9ee0c6e2a99d"
      unitRef="U_USD">6000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_19681061-85d7-43eb-9090-f6c375682fba"
      decimals="-3"
      id="F_3de3d4b6-f79c-41ae-bc29-0b042e8499a7"
      unitRef="U_USD">300286000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_4c603b2f-2f78-4374-8a40-8bf8b288f2c3"
      unitRef="U_USD">722036000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_21fe8562-ea82-4df6-97d2-467d941e36fd"
      unitRef="U_USD">91000</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_f119198e-9c79-4656-a98d-b1e9d971860f"
      unitRef="U_USD">6000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_574f40a3-5d9a-4865-9ece-2af859583bf1"
      unitRef="U_USD">722121000</vir:FinancialAssetsFairValue>
    <us-gaap:RestrictedCashEquivalents
      contextRef="C_37e02e2b-ecee-41f9-9516-eff5990866ee"
      decimals="-5"
      id="F_f0f92acc-cdb8-4f34-a607-12a56b1f7201"
      unitRef="U_USD">14900000</us-gaap:RestrictedCashEquivalents>
    <us-gaap:InterestReceivable
      contextRef="C_b2d805bd-8fe4-4a5d-a29f-32025b612cb1"
      decimals="-5"
      id="F_df702d73-3a83-40fb-8786-46eb167a82a3"
      unitRef="U_USD">1100000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="C_ed3b9e09-2b8e-4a52-a1e4-da67c4059a2e"
      decimals="-5"
      id="F_ab131ca6-47c3-4e33-83fb-c1efcf0ca286"
      unitRef="U_USD">800000</us-gaap:InterestReceivable>
    <us-gaap:FinancingReceivableAccruedInterestWriteoff
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="0"
      id="F_325bbf8c-c6ed-4dd4-b43e-606f9755ec4a"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAccruedInterestWriteoff>
    <us-gaap:FinancingReceivableAccruedInterestWriteoff
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="0"
      id="F_749c67fa-4971-4e95-9547-494d1a465b9f"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-5"
      id="F_c7a4152b-e6a4-4524-8fbc-dcfc86407693"
      unitRef="U_USD">900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-5"
      id="F_4893e952-7af2-4e2e-8ee6-9631caa38e74"
      unitRef="U_USD">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="C_a8765b59-506d-4165-9487-b02bdc930b58"
      id="F_0427c09d-5c70-43a5-88fe-e4eab8c9ba81">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_3f145b8a-a89a-4b1f-beee-1a8a6ab8f021"
      decimals="-5"
      id="F_ded9fe66-27d0-4020-8b23-a5597967f1f8"
      unitRef="U_USD">143100000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="C_1cec4878-722f-49d0-b6df-245adc26d756"
      decimals="-5"
      id="F_a16461d5-067a-4e86-81ea-2ee6fab5c626"
      unitRef="U_USD">138000000.0</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_1cec4878-722f-49d0-b6df-245adc26d756"
      decimals="-5"
      id="F_9316f140-7f0d-4be0-9e52-255e5f5bed17"
      unitRef="U_USD">600000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <vir:RegulatoryMilestoneAchieved
      contextRef="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e"
      decimals="-5"
      id="F_d6785a78-51d6-43d2-a671-a40534d484e6"
      unitRef="U_USD">35000000.0</vir:RegulatoryMilestoneAchieved>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_c3d7153f-2142-47b5-836a-92c25c9b950c"
      id="F_a281a280-c096-4d0a-b2a7-82d7712b00b4">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of Decemb&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;er 31, 2021, the Company calculated the estimated fair value of the remaining clinical and regulatory milestones related to the HBV product using the following significant unobservable inputs: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.179%;"/&gt;
        &lt;td style="width:2.44%;"/&gt;
        &lt;td style="width:32.381%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Range&lt;br/&gt;(Weighted-Average)1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(1) Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.&lt;/span&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_f999fb4c-9967-4386-a71c-e0a64a7891bc"
      decimals="2"
      id="F_1e9c298f-eb29-41f4-8a2d-547eee0b300a"
      unitRef="U_pure">0.03</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_f0ace255-aaf9-4b62-af6c-209acf635d22"
      decimals="2"
      id="F_4d36d33b-2f89-4456-8f91-0f59f9962b27"
      unitRef="U_pure">0.05</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_714f6509-93e2-40d8-93c7-af8d8831b31d"
      decimals="2"
      id="F_a891e850-a5c8-437d-9fba-752651a758b8"
      unitRef="U_pure">-0.04</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_d67e94b8-3d90-4a56-820b-3f311ae13e57"
      decimals="2"
      id="F_f35ef763-b249-4cff-bd32-496b3632c61a"
      unitRef="U_pure">0.22</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_7805a9f3-b0a3-4562-b373-15bbc4dab334"
      decimals="2"
      id="F_949d1fde-fe74-4d47-a6ea-27cd3ecf4656"
      unitRef="U_pure">0.40</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_882eeb59-5aa1-48a1-b475-f45ed47e1af4"
      decimals="2"
      id="F_717442f3-2751-4e3c-ba15-abe3b111dcd4"
      unitRef="U_pure">-0.31</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <vir:SalesMilestonesAchieved
      contextRef="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e"
      decimals="-5"
      id="F_c5ac8d3a-aa25-4753-9097-35365b98132a"
      unitRef="U_USD">60000000.0</vir:SalesMilestonesAchieved>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_c53e5c04-9722-48b4-9a77-81a3284044e1"
      id="F_62a2939f-c375-40a3-947b-f133f949dd61">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;s of December 31, 2021, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecast, as well as the following significant unobservable inputs f&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;or the remaining commercial milestones related to the HBV product: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.179%;"/&gt;
        &lt;td style="width:2.44%;"/&gt;
        &lt;td style="width:32.381%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_f89b46e3-8544-4acc-962d-faf2858aa020"
      decimals="2"
      id="F_39f2f4c8-96be-4302-8e0e-c08ff481b4eb"
      unitRef="U_pure">0.65</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_405140f2-f0e9-44c0-b8cf-d4d833a30755"
      decimals="2"
      id="F_00616786-f7c2-48db-b903-e53eb8b133f4"
      unitRef="U_pure">0.11</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_a8d8ecfd-11a2-4d9e-986a-f51ef12015b0"
      decimals="2"
      id="F_aefe449c-3d5b-48d0-8dfd-941c55d4f703"
      unitRef="U_pure">0.22</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_8b2320ed-d560-4b7d-850c-3e4bf7238d2a"
      decimals="-5"
      id="F_3c7a127a-99ad-4ab3-91a0-a9f156017d0d"
      unitRef="U_USD">17100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_a85d530b-5472-4e7a-bcea-2452ef558595"
      decimals="-5"
      id="F_5bfae5df-4a7f-4552-8a95-bda1687e09ed"
      unitRef="U_USD">29200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <vir:AssetAcquisitionMilestoneAchieved
      contextRef="C_3180a70a-dfa7-4102-9724-38babfd3d0ba"
      decimals="-5"
      id="F_e3b2c1b2-64e5-4c77-9b30-2cf4490e49e7"
      unitRef="U_USD">10000000.0</vir:AssetAcquisitionMilestoneAchieved>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_3200e2aa-d8c3-4db7-a6bc-1e84a8a07638"
      id="F_d45cc52b-ea39-4db9-bacb-82e86e9104fa">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1164583333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.179%;"/&gt;
        &lt;td style="width:2.44%;"/&gt;
        &lt;td style="width:32.381%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;115&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:EmbeddedDerivativeLiabilityMeasurementInput
      contextRef="C_ba75ea58-13bc-4e3d-8ef1-d07deeb228c1"
      decimals="2"
      id="F_7a7cd469-fd6e-4509-9e90-111b744a8832"
      unitRef="U_pure">1.15</us-gaap:EmbeddedDerivativeLiabilityMeasurementInput>
    <us-gaap:EmbeddedDerivativeLiabilityMeasurementInput
      contextRef="C_c65ef721-72ea-40b3-878d-db5fb1796225"
      decimals="3"
      id="F_457634d7-c360-4650-aa35-a92639ecebac"
      unitRef="U_pure">0.001</us-gaap:EmbeddedDerivativeLiabilityMeasurementInput>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_6639bf66-3f97-4290-be85-57c7e4a0c37c"
      decimals="-5"
      id="F_5939547d-c64b-47a6-a017-8997cc04ef23"
      unitRef="U_USD">5700000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_786d6b05-a5c6-4c6b-bd8c-08bff9b5679d"
      decimals="-5"
      id="F_1d95d734-dbe6-44a7-ac20-9c8d741a5b81"
      unitRef="U_USD">6800000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_4681a198-d09f-4cfa-9fe4-1c229490de82">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the changes in the estimated fair value of the Company&#x2019;s Level 3 financial liabilities (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.644%;"/&gt;
        &lt;td style="width:2.097%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:16.112%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassification of contingent consideration to accrued liabilities upon achievement of the Humabs milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payment of contingent consideration upon achievement of the TomegaVax milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_7a978f36-d4af-4db5-8584-15add2567749"
      decimals="-3"
      id="F_0ad0c4df-29a7-49c4-b172-9c99620d06a4"
      unitRef="U_USD">35974000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_34acf0fd-1b4d-4895-92c2-913b85fb2602"
      decimals="-3"
      id="F_feab5698-39c1-4f36-85f0-5bd87154220b"
      unitRef="U_USD">91848000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <vir:FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone
      contextRef="C_34acf0fd-1b4d-4895-92c2-913b85fb2602"
      decimals="-3"
      id="F_3943a10e-d845-4a13-a1bc-92768ac2e7e2"
      unitRef="U_USD">-95000000</vir:FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone>
    <vir:FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone
      contextRef="C_34acf0fd-1b4d-4895-92c2-913b85fb2602"
      decimals="-3"
      id="F_d5dd7d16-07ce-41c5-8c5d-3a8e81f4ae91"
      unitRef="U_USD">-10000000</vir:FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_a567406d-6fcd-4a01-a0c2-596b4cb717b1"
      decimals="-3"
      id="F_70b427ce-a6fd-43ab-99ea-ab491cebda99"
      unitRef="U_USD">22822000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_62c28d6b-4ea9-40c5-84b7-c57685b48ed4">&lt;div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;4.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquisition of TomegaVax&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2016, the Company entered into an agreement and plan of merger (&#x201c;TomegaVax Merger Agreement&#x201d;) to acquire all of the equity interests of TomegaVax. The primary asset purchased in the acquisition was an in-process cytomegalovirus vector-based vaccine platform for use in HBV, HIV, and tuberculosis. The acquisition was accounted for as an asset purchase. The Company recorded the cash purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in research and development expenses and incurred transaction costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in 2016.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the entry into the TomegaVax Merger Agreement, the Company also entered into a letter agreement with TomegaVax (the &#x201c;TomegaVax Letter Agreement&#x201d;), which provides for certain payments to TomegaVax&#x2019;s former stockholders before September 2024, in each case so long as the Company is continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million if the per-share price of the Company&#x2019;s publicly traded common stock, or implied price per-share of the Company&#x2019;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The share price of the Company&#x2019;s publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Company&#x2019;s common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of the Company&#x2019;s common stock, at the discretion of the Company&#x2019;s board of directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2021, the Company achieved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the milestones related to the specified per-share price of its common stock, which resulted in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million payable to TomegaVax&#x2019;s former stockholders. In July 2021, the Company made the milestone payment to the former TomegaVax stockholders through a combination of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in cash and the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42,737&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock with a total fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The remaining milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate will be triggered if (i) the per-share price of the Company&#x2019;s publicly traded common stock is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment and/or (ii) the per-share price of the Company&#x2019;s publicly traded common stock is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determined that the future milestone payments contain net settlement provisions and therefore, they were required to be accounted for as embedded derivatives under the relevant accounting guidance. As of December 31, 2021, the fair value of the embedded derivative was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and is included in the contingent consideration liability on the consolidated balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquisition of Humabs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2017, the Company acquired all of the outstanding equity of Humabs, a private Swiss company, which discovers and develops monoclonal antibodies (&#x201c;mAbs&#x201d;) derived from individuals whose immune systems have successfully responded to major diseases. The Company acquired all of Humabs&#x2019; rights, title and interest in and to substantially all of the assets of Humabs except for rights under certain license agreements with third parties. The Company is obligated to pass through to the former Humabs shareholders any amounts received by Humabs under such license agreements, net of any program expenses. The transaction was accounted for as an acquisition of a business. The consideration paid consisted of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in cash and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,666,656&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock, valued at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of the date of the transaction, to former Humabs shareholders. In addition to the cash payment and issuance of common stock to the former Humabs shareholders at the acquisition date, the Company also agreed to pay additional amounts in cash upon the achievement of specified milestone events: (i) up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;135.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the achievement of clinical, regulatory and commercial milestones for an HBV product; and (ii) up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the achievement of clinical, regulatory and commercial milestones for another product, which the Company elected as a severe acute respiratory syndrome coronavirus 2 (&#x201c;SARS-CoV-2&#x201d;) product, or sotrovimab.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the year ended December 31, 2020, the Company achieved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the specified clinical milestones for the HBV product and sotrovimab totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the year ended December 31, 2021, the Company achieved the specified regulatory milestone of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and sales milestones totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to sotrovimab. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated fair value of the remaining contingent consideration was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Company paid the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million milestone and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million milestone in January and February 2022, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The acquired developed technologies that have associated patents issued are classified as finite-lived intangible assets and are amortized on a straight-lined basis over their estimated remaining useful lives, generally between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d240cfd0-0689-460a-ba7b-6620318af392;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company also acquired indefinite-lived intangible assets consisting of IPR&amp;amp;D. These assets will not be amortized until regulatory approval is obtained in a major market. At that time, the Company will determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned or otherwise impaired, the related IPR&amp;amp;D assets will be written-off and an impairment charge recorded. As of December 31, 2021, there have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such impairments related to the IPR&amp;amp;D assets. The estimated fair value of the intangible assets was determined using the replacement cost method. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;None&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the goodwill is expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e"
      decimals="-5"
      id="F_0800d118-f098-431e-a73f-61692c183d55"
      unitRef="U_USD">5200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e"
      decimals="-5"
      id="F_97c7a7a5-e9fb-4dd7-9294-9daf0a92029e"
      unitRef="U_USD">500000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <vir:MilestonePaymentsRelatedTermsDescription
      contextRef="C_a32e557e-b0ba-4f99-bb95-674d8a7d72ba"
      id="F_236fd857-03f0-4ee9-9208-97603d27cee3">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company&#x2019;s publicly traded common stock, or implied price per-share of the Company&#x2019;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment.</vir:MilestonePaymentsRelatedTermsDescription>
    <vir:AssetAcquisitionMilestonePaymentAggregate
      contextRef="C_ee4ca4dd-dd89-4390-b7dd-451122361af3"
      decimals="-5"
      id="F_395a4f87-62a9-43cc-a77b-b6aa65bd45d8"
      unitRef="U_USD">30000000.0</vir:AssetAcquisitionMilestonePaymentAggregate>
    <vir:MinimumCommonStockPriceForMilestonePaymentsConsideration
      contextRef="C_71eb2cf3-b567-474c-8eb2-9294af7f7cd4"
      decimals="INF"
      id="F_5f4eb0e7-0a39-486a-91dc-0ab9e2299935"
      unitRef="U_USDollarShare">45</vir:MinimumCommonStockPriceForMilestonePaymentsConsideration>
    <vir:AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration
      contextRef="C_b3ff0ae3-397e-4e79-94d3-974b85c1a48f"
      decimals="INF"
      id="F_5a1cabd5-e85d-4562-8215-13a39718e5b3"
      unitRef="U_Milestone">1</vir:AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="C_8f3bbd07-1fde-4bfb-b72d-6df34ea170ba"
      decimals="-5"
      id="F_d5576354-1f56-4ac0-bfcc-215b743efb05"
      unitRef="U_USD">10000000.0</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <vir:PaymentMadeForAssetAcquisitionMilestone
      contextRef="C_66bceed9-522b-4fbd-a22f-c029c32a27fd"
      decimals="-5"
      id="F_fc7148e3-5cd9-41f7-b3bc-a05200656829"
      unitRef="U_USD">8100000</vir:PaymentMadeForAssetAcquisitionMilestone>
    <vir:CommonStockSharesIssuedForMilestonePaymentShares
      contextRef="C_3b4acd09-0f98-4d80-8e8b-2e3567b35e97"
      decimals="INF"
      id="F_ddbc09e7-1b45-4bf9-adce-f09f301f946f"
      unitRef="U_shares">42737</vir:CommonStockSharesIssuedForMilestonePaymentShares>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="C_2082200e-8d81-44c2-9451-795cb9436f26"
      decimals="-5"
      id="F_c8d268d6-30e1-4771-a145-4f886464691f"
      unitRef="U_USD">1900000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <vir:RemainingPaymentForAssetAcquisitionMilestoneAggregate
      contextRef="C_be140e6e-3761-4ec9-ba59-319fd0975a8c"
      decimals="-5"
      id="F_447be147-4bfb-4d6f-9f9b-fac28da62f8d"
      unitRef="U_USD">20000000.0</vir:RemainingPaymentForAssetAcquisitionMilestoneAggregate>
    <vir:MinimumCommonStockPriceForMilestonePaymentsConsideration
      contextRef="C_0d48684e-c8e1-4db3-a973-d66108c108c4"
      decimals="0"
      id="F_2616a84d-a53d-4574-b52c-63f23d2d3fa7"
      unitRef="U_USDollarShare">45</vir:MinimumCommonStockPriceForMilestonePaymentsConsideration>
    <vir:MinimumCommonStockPriceForMilestonePaymentsConsideration
      contextRef="C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e"
      decimals="0"
      id="F_a1320d7c-f3b1-4314-95bd-9baa9084f31b"
      unitRef="U_USDollarShare">90</vir:MinimumCommonStockPriceForMilestonePaymentsConsideration>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="C_5f6d55c2-91b3-4ca7-adf9-970debbec4df"
      decimals="-5"
      id="F_31ce0454-cee7-45b1-a69a-9ef2c19e6dda"
      unitRef="U_USD">5700000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_92042eda-34a8-4b88-8ceb-39eb4ad7e70a"
      decimals="-5"
      id="F_a9af9bba-ef7e-4b90-ae32-6079882ed77d"
      unitRef="U_USD">30000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_92042eda-34a8-4b88-8ceb-39eb4ad7e70a"
      decimals="INF"
      id="F_6e4ba5a8-0aba-4ef0-9006-64fa0ae4e6b7"
      unitRef="U_shares">1666656</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="C_92042eda-34a8-4b88-8ceb-39eb4ad7e70a"
      decimals="-5"
      id="F_3863ac55-29fe-49e7-94b0-3d13db5dc455"
      unitRef="U_USD">2500000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents
      contextRef="C_47cc19c9-75f2-422b-8ed8-1c79b990ca5f"
      decimals="-5"
      id="F_c1a11051-6ec5-4d04-967f-3bedddf6c8e9"
      unitRef="U_USD">135000000.0</vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents>
    <vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents
      contextRef="C_4d722794-e16e-4e44-9edc-feb0c31aee2e"
      decimals="-5"
      id="F_95fc6c09-39e3-4a4f-a7cc-62b9a3aaadd1"
      unitRef="U_USD">105000000.0</vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents>
    <vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved
      contextRef="C_16d264b9-1049-422e-959d-522e97231bc4"
      decimals="INF"
      id="F_58dc7e07-5cee-4753-a061-847738a1691f"
      unitRef="U_Milestone">2</vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved>
    <vir:SpecifiedClinicalDevelopmentMilestonesPayment
      contextRef="C_bf931caa-5cb0-4310-8883-afbdea037621"
      decimals="-5"
      id="F_157d7b0e-f70c-430a-b8b7-b784a5bddfae"
      unitRef="U_USD">20000000.0</vir:SpecifiedClinicalDevelopmentMilestonesPayment>
    <vir:SpecifiedClinicalDevelopmentMilestonesPayment
      contextRef="C_16d264b9-1049-422e-959d-522e97231bc4"
      decimals="-5"
      id="F_a6d8719e-2db0-40cf-9257-1ff427600491"
      unitRef="U_USD">20000000.0</vir:SpecifiedClinicalDevelopmentMilestonesPayment>
    <vir:RegulatoryMilestonesAchieved
      contextRef="C_53a9db5d-ce87-4cee-8476-d28141546bda"
      decimals="-5"
      id="F_1fffa82d-4b8e-4d55-a23c-55a31552e2a4"
      unitRef="U_USD">35000000.0</vir:RegulatoryMilestonesAchieved>
    <vir:SalesMilestonesAchieved
      contextRef="C_53a9db5d-ce87-4cee-8476-d28141546bda"
      decimals="-5"
      id="F_cfd2b535-05f0-42b5-975b-bbad3b93d975"
      unitRef="U_USD">60000000.0</vir:SalesMilestonesAchieved>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_2f3a686d-485c-4e98-8bf8-9cbe259cabcc"
      decimals="-5"
      id="F_585c4b54-4846-48f5-b93e-cefefcfdaec5"
      unitRef="U_USD">17100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <vir:PaymentMadeForBusinessCombinationMilestone
      contextRef="C_06f41013-d21d-4546-aa26-d8ece6d9a91a"
      decimals="-5"
      id="F_5d77babd-7c0e-4075-864f-115ce606bf48"
      unitRef="U_USD">35000000.0</vir:PaymentMadeForBusinessCombinationMilestone>
    <vir:PaymentMadeForBusinessCombinationMilestone
      contextRef="C_34998bcb-fe81-4e6a-839c-342803b38b04"
      decimals="-5"
      id="F_4150b83c-d6de-40cd-bfa3-6323865ce520"
      unitRef="U_USD">60000000.0</vir:PaymentMadeForBusinessCombinationMilestone>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="C_333e5067-692a-43e7-8ca4-773333284f0b"
      id="F_322a2c41-63c2-47aa-896e-d555e56cd76b">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e"
      decimals="INF"
      id="F_4aa9f685-edf5-4dc9-8b81-743573f962d4"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="C_8b2320ed-d560-4b7d-850c-3e4bf7238d2a"
      decimals="INF"
      id="F_43285025-ef21-46e0-9506-a046295a7391"
      unitRef="U_USD">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_f222a998-4945-4d5a-837e-1f3370e15c7c">&lt;div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;5.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill and Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; represents the excess of the purchase price over the estimated fair value of the net assets acquired from Humabs. The Company tests goodwill for impairment on an annual basis or sooner, if deemed necessary. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairment for the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangible Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the carrying amount of the Company&#x2019;s finite-lived intangible assets (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.615%;"/&gt;
        &lt;td style="width:1.181%;"/&gt;
        &lt;td style="width:1.803%;"/&gt;
        &lt;td style="width:11.888%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.181%;"/&gt;
        &lt;td style="width:1.803%;"/&gt;
        &lt;td style="width:10.768%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.181%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:16.377%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining Useful&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contract-based intangible asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finite-lived intangible assets, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less impairment of intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finite-lived intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finite-lived intangible assets are carried at cost less accumulated amortization. The contract-based intangible asset resulted from the product approval of a sublicensed intellectual property right in December 2020. The intellectual property right was previously accounted for as IPR&amp;amp;D. Amortization expense related to finite-lived intangible assets, included in research and development expenses on the consolidated statements of operations, totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, like that of property and equipment. During the third quarter of 2020, as a result of the availability of other research and analytics platforms, the Company abandoned certain of its acquired developed technologies and concluded that the full remaining book values of the assets were impaired. Therefore, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was written off as an impairment charge, which was classified as research and development expenses during 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Based on the finite-lived intangible assets recorded as of December 31, 2021, the estimated future amortization expense for the next five years is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.14%;"/&gt;
        &lt;td style="width:1.758%;"/&gt;
        &lt;td style="width:2.671%;"/&gt;
        &lt;td style="width:17.352%;"/&gt;
        &lt;td style="width:1.078%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, the Company had indefinite-lived intangible assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, related to the purchased IPR&amp;amp;D from the Humabs acquisition. In December 2020, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was reclassed as a finite-lived intangible asset due to the product approval of a sublicensed intellectual property right. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairment losses have been recorded for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-5"
      id="F_477eb28b-8635-4fbd-bcc2-f046bdd50975"
      unitRef="U_USD">16900000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="INF"
      id="F_7f4e5f52-84b5-42bf-bd05-f37bd3d4a18c"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_4ad10787-abbd-43c1-8261-17fa78f7c974">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the carrying amount of the Company&#x2019;s finite-lived intangible assets (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.615%;"/&gt;
        &lt;td style="width:1.181%;"/&gt;
        &lt;td style="width:1.803%;"/&gt;
        &lt;td style="width:11.888%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.181%;"/&gt;
        &lt;td style="width:1.803%;"/&gt;
        &lt;td style="width:10.768%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.181%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:16.377%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining Useful&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contract-based intangible asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finite-lived intangible assets, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less impairment of intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finite-lived intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_21482517-1f7b-44c6-8e55-585d0ec9e391"
      decimals="-3"
      id="F_4bbc7d00-9db1-4973-a229-7f44ae5f08f9"
      unitRef="U_USD">7000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_643ca0ff-cb47-43ec-917c-167fbc2cff60"
      decimals="-3"
      id="F_8520a667-112f-41eb-8549-6c07afd70ed9"
      unitRef="U_USD">7000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_27d6b8f0-fa5a-4e00-b4fd-9df702316b81"
      id="F_8cbc3a65-0d61-4d67-ba83-5f6679a2352b">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_3776a1e8-74ac-49c3-8bd9-7024d16f0ad2"
      decimals="-3"
      id="F_f54d1b48-b5f7-4e10-8880-abf437fb3d67"
      unitRef="U_USD">502000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_9df0518d-0a7a-4d2c-92b4-a8e2b609380f"
      decimals="-3"
      id="F_5b9a6dc2-5780-404f-b17f-c5c972b7de05"
      unitRef="U_USD">502000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_8ae9b192-da16-4b61-9aca-9b2e398bb09f"
      id="F_e7b7cbda-f8d1-4e1d-bd7e-52d188fc1549">P13Y10M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_d1205e5e-f27d-4517-9401-44e3ecc4a8ae"
      unitRef="U_USD">7502000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_8f241cfa-0536-4e2b-9f37-e7f93a3e6aee"
      unitRef="U_USD">7502000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_c873c03d-cf34-481d-9d85-7a7af03bfe24"
      unitRef="U_USD">4114000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_05a32067-7c6d-41c2-a71b-7dc24cbb33f4"
      unitRef="U_USD">3581000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <vir:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_a70006f7-c066-4023-b3d9-c828e5415b32"
      unitRef="U_USD">832000</vir:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <vir:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_3e351f7b-356c-4575-86c6-1f28f8ff4e61"
      unitRef="U_USD">832000</vir:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_88237c45-d556-4f3d-b56a-58eb2d0c0a82"
      unitRef="U_USD">2556000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_ffde077e-a64d-4035-a812-8bb5f1a643e9"
      unitRef="U_USD">3089000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_1a31bf7c-9f6e-4b04-9a96-43549f6f4cc3"
      decimals="-5"
      id="F_d8768382-dbea-4e98-a282-c29053647dcb"
      unitRef="U_USD">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_f41d2de0-2ba6-4580-bbfa-01ae990de9ae"
      decimals="-5"
      id="F_6966f44a-b9be-439f-b00d-e1c4689a0dc5"
      unitRef="U_USD">1000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_ad98faf6-018f-4435-8e8a-c91df1a4d6c0"
      decimals="-5"
      id="F_6e588d52-8aec-45ad-b4fc-ac4119b8e1f0"
      unitRef="U_USD">1200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_bd790442-a1c8-4c01-a7b4-906b111a3a51"
      decimals="-5"
      id="F_3927bf55-4669-4f2c-8e8b-a33379df3776"
      unitRef="U_USD">800000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_a1cbf941-e354-490b-9501-5152da8843ca">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Based on the finite-lived intangible assets recorded as of December 31, 2021, the estimated future amortization expense for the next five years is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.14%;"/&gt;
        &lt;td style="width:1.758%;"/&gt;
        &lt;td style="width:2.671%;"/&gt;
        &lt;td style="width:17.352%;"/&gt;
        &lt;td style="width:1.078%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_70d11485-9b43-49d9-971d-dd795f1989cd"
      unitRef="U_USD">532000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_5c4f9447-c90b-4b14-94e9-64fc172e8d34"
      unitRef="U_USD">532000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_8efa6a1e-8724-4786-9027-4cd72350c04d"
      unitRef="U_USD">260000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_c11c8560-8403-496c-9b06-580f280d3e22"
      unitRef="U_USD">213000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_d0211060-17d2-4f57-9007-230dad7a32a3"
      unitRef="U_USD">213000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <vir:FiniteLivedIntangibleAssetsAmortizationExpense
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_a41b6cb1-aa27-4761-b373-43e8779ec760"
      unitRef="U_USD">1750000</vir:FiniteLivedIntangibleAssetsAmortizationExpense>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e"
      decimals="-5"
      id="F_7cc6e0d1-7ada-4106-86dc-4ce71f109822"
      unitRef="U_USD">30700000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="C_3afd1e8b-5267-4120-b240-7f12f4a61a4a"
      decimals="-5"
      id="F_10c0b74b-bc81-4d33-a990-e9f4762e5753"
      unitRef="U_USD">30700000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <vir:FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived
      contextRef="C_a14402f0-9a6d-4005-9600-5bb5f45f3cf4"
      decimals="-5"
      id="F_5d6ce769-9bed-4a98-8f38-2db1790dc270"
      unitRef="U_USD">500000</vir:FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_b27a1d42-6dd2-4a13-8c65-9555485f4f1e"
      decimals="INF"
      id="F_009ebcba-5879-4d55-8914-3eae9b8829eb"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_3afd1e8b-5267-4120-b240-7f12f4a61a4a"
      decimals="INF"
      id="F_3476a304-fe0e-4e08-ae41-cc6a4f701faa"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <vir:GrantAgreementsDisclosureTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_046cad85-5901-4267-8b2f-1f9677d69353">&lt;div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;6.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Grant Agreements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Bill &amp;amp; Melinda Gates Foundation Grants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Campylo/EPEC/EAEC Grant&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As part of the Company&#x2019;s acquisition of Humabs in August 2017, the Company acquired a grant agreement with the Bill &amp;amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million (the &#x201c;2017 Grant&#x201d;). The 2017 Grant supported the Company&#x2019;s discovery, characterization and selection of human monoclonal antibodies with pre-clinical efficacy against three enteric pathogens responsible for life-threatening diarrhea in neonates. The 2017 Grant expired on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;May 31, 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payments received in advance that were related to future research activities were deferred and recognized as revenue when the donor-imposed conditions were met, which was as the research and development activities were performed. The Company recognized grant revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2019.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;HIV Grant&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On January 26, 2018, the Company entered into a grant agreement with the Bill &amp;amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for its HIV program (the &#x201c;HIV Grant&#x201d;). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2020, the parties amended the HIV Grant under which the Company was awarded a supplemental grant of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. In &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_aeb0c2d2-3251-4237-b9b3-110fc85a87f2;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the parties further amended the agreement under which the grant term was extended from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;October 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, unless earlier terminated by the Bill &amp;amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill &amp;amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company achieved a specified milestone under the HIV Grant which triggered a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million payment from the Bill &amp;amp; Melinda Gates Foundation. As of December 31, 2020, the Company recorded a receivable, which is included within prepaid expenses and other current assets, and current portion of deferred revenue for the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which was subsequently received in January 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, the Company has deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, under HIV Grant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Tuberculosis (&#x201c;TB&#x201d;) Grant&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 16, 2018, the Company entered into a grant agreement with the Bill &amp;amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for its TB program (the &#x201c;TB Grant&#x201d;). The parties amended the agreement in May 2020, in June 2021 and in December 2021 to extend the grant term. The TB Grant will remain in effect until &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;March 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, unless earlier terminated by the Bill &amp;amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill &amp;amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; As of December 31, 2021, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of unused funds received in advance and previously recorded as deferred revenue within accrued and other liabilities. As of December 31, 2021 and 2020, the Company has deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, under TB Grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;HCMV-Vaccine Platform Grant&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On November 5, 2021, the Company entered into a grant agreement with the Bill &amp;amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to support the manufacturing and clinical activities of its HIV and TB vaccine programs. This grant agreement will remain in effect until &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;August 30, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;unless earlier terminated by the Bill &amp;amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill &amp;amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2021. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company has deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million under this grant agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;National Institutes of Health&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As part of the Company&#x2019;s acquisition of TomegaVax in September 2016, the Company acquired grant agreements related to TomegaVax&#x2019;s research effort in infectious diseases and cancer that entitled them to several awards under the Small Business Innovation Research Program from the National Institutes of Health (&#x201c;NIH&#x201d;). Through July 2021, the Company has acquired or been awarded grants from NIH totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. These grants were cost plus fixed fee agreements in which the Company was reimbursed for its direct and indirect costs. Only costs that were allowable under certain government regulations and NIH&#x2019;s supplemental policy and procedure manual may be claimed for reimbursement, subject to government audit.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognized grant revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</vir:GrantAgreementsDisclosureTextBlock>
    <vir:GrantAwardedAmount
      contextRef="C_9bbee3cc-0441-482d-a60a-021bdde5fb32"
      decimals="INF"
      id="F_b50f8b2f-7b0f-41fb-bfc2-d902b79e07e2"
      unitRef="U_USD">4700000</vir:GrantAwardedAmount>
    <vir:GrantAgreementExpirationDate
      contextRef="C_4d72106c-4ece-48a5-890f-cdc4894fc993"
      id="F_08b952f4-96a4-47b5-a7c8-e019004eff35">2019-05-31</vir:GrantAgreementExpirationDate>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_064e544a-5338-44a5-8d21-57da4323d0ff"
      decimals="-5"
      id="F_d56bded8-9402-4fac-8170-66c9d96ae23f"
      unitRef="U_USD">900000</us-gaap:RevenueNotFromContractWithCustomer>
    <vir:GrantAwardedAmountMaximum
      contextRef="C_9de06e9c-4123-49c9-9448-9c22581415b0"
      decimals="INF"
      id="F_6b77241a-d0ef-43e0-9283-32f4dba41de3"
      unitRef="U_USD">12200000</vir:GrantAwardedAmountMaximum>
    <vir:GrantAwardedAmount
      contextRef="C_d9c4cf79-3f00-4bf0-bcd2-f9232b1fcc14"
      decimals="-5"
      id="F_7c4a2bce-014c-41de-81ae-6ce12275120b"
      unitRef="U_USD">8600000</vir:GrantAwardedAmount>
    <vir:GrantAgreementExpirationDateBeforeAmendment
      contextRef="C_f5edd5d0-093c-4a7f-9010-06a8b6d0943c"
      id="F_8a0771c1-7626-4600-a46b-962ea826ad6c">2021-12-31</vir:GrantAgreementExpirationDateBeforeAmendment>
    <vir:GrantAgreementAmendedExpirationDate
      contextRef="C_f5edd5d0-093c-4a7f-9010-06a8b6d0943c"
      id="F_0c1aaa7d-f301-47c8-bbe1-671c602085f7">2022-10-31</vir:GrantAgreementAmendedExpirationDate>
    <vir:MilestonePaymentDueToCompany
      contextRef="C_a48eca06-2240-404a-95b9-a96f664f0800"
      decimals="-5"
      id="F_dddd9cc5-6513-428d-b31e-c8b1afd9c946"
      unitRef="U_USD">1900000</vir:MilestonePaymentDueToCompany>
    <vir:MilestonePaymentReceived
      contextRef="C_160a64f9-0857-4c36-8f24-34b857e2d49c"
      decimals="-5"
      id="F_637673d9-1946-45a9-92ea-d0a852b91d61"
      unitRef="U_USD">1900000</vir:MilestonePaymentReceived>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_be5c6cf7-b468-4342-99e6-e6f0cb45b27a"
      decimals="-5"
      id="F_6f354b2a-f255-4912-a61a-fad412749726"
      unitRef="U_USD">3000000.0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_a48eca06-2240-404a-95b9-a96f664f0800"
      decimals="-5"
      id="F_10f0edd8-0ba3-4aa4-adfc-8dce0bffb019"
      unitRef="U_USD">6400000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_348661d6-b9d4-405f-81cc-4d936a14f5b8"
      decimals="-5"
      id="F_b8b5921a-4b9b-4d03-9ace-6cb295243544"
      unitRef="U_USD">3700000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DeferredIncome
      contextRef="C_024bb253-6952-4f27-abbf-00f7a4f1d57c"
      decimals="-5"
      id="F_cdc11571-15bc-49c4-9b83-ba4f22b764b4"
      unitRef="U_USD">2300000</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome
      contextRef="C_b5bc95aa-a39a-42b9-82dc-8f1e49c3c984"
      decimals="-5"
      id="F_98aafa33-f540-4fde-adbf-a578cd72e49a"
      unitRef="U_USD">3800000</us-gaap:DeferredIncome>
    <vir:GrantAwardedAmountMaximum
      contextRef="C_65508bde-8e9b-433a-b887-54fe70f6560d"
      decimals="INF"
      id="F_eb464845-6ced-47dc-8ab0-fe2fe5c0e52e"
      unitRef="U_USD">14900000</vir:GrantAwardedAmountMaximum>
    <vir:GrantAgreementAmendedExpirationDate
      contextRef="C_4700e2f3-e411-4471-9030-da4a2a264740"
      id="F_44ff3e1d-c6d7-4e15-aaab-db222aa27eb0">2022-03-31</vir:GrantAgreementAmendedExpirationDate>
    <vir:UnusedFundsReceivedInAdvance
      contextRef="C_ce562ce2-89d4-4006-bd1c-8ec2a20274f5"
      decimals="-5"
      id="F_9f6b3570-8afd-4c74-97e3-331f40d6d47b"
      unitRef="U_USD">1800000</vir:UnusedFundsReceivedInAdvance>
    <us-gaap:DeferredIncome
      contextRef="C_74f0b6e6-2f8c-42cd-82e3-2ad83cc03354"
      decimals="-5"
      id="F_b4db6e1d-69c3-43a9-a106-d925cd6480f0"
      unitRef="U_USD">1300000</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome
      contextRef="C_1aa5fc1c-95ff-4281-9c2e-6292a0baba92"
      decimals="-5"
      id="F_295e4b3c-677d-4376-a4e3-012520d77ca8"
      unitRef="U_USD">2600000</us-gaap:DeferredIncome>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_be5c6cf7-b468-4342-99e6-e6f0cb45b27a"
      decimals="-5"
      id="F_c01d2638-1340-4e53-a855-9959cac304e5"
      unitRef="U_USD">3000000.0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_6d2c449d-3432-4046-9323-81b3ce04e34a"
      decimals="-5"
      id="F_12873c8a-dd26-4e3d-b5bc-48eb03ee98df"
      unitRef="U_USD">2200000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_4a4d7f99-61b1-4dd9-8b7a-51541fecc5f3"
      decimals="-5"
      id="F_311e14c8-2a32-4991-a261-89b6d9a3d54b"
      unitRef="U_USD">1900000</us-gaap:RevenueNotFromContractWithCustomer>
    <vir:GrantAwardedAmountMaximum
      contextRef="C_7bd2b5a2-2224-4f6d-aacc-dc5934151bac"
      decimals="-5"
      id="F_dfa14d28-7689-4ebb-bf20-1f2acc9d9225"
      unitRef="U_USD">10000000.0</vir:GrantAwardedAmountMaximum>
    <vir:GrantAgreementExpirationDate
      contextRef="C_e1a9eeda-0adf-4886-b25f-5e7c6923762a"
      id="F_3d24517d-7952-44f2-9f4c-3317b0507a6a">2023-08-30</vir:GrantAgreementExpirationDate>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_8b224cd3-1cba-4c7d-b686-ace421bc028d"
      decimals="-5"
      id="F_11ee80b5-b10f-4528-8dda-5352903883e2"
      unitRef="U_USD">2200000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DeferredIncome
      contextRef="C_021eeba0-02e7-4697-bcf5-81b5a7722190"
      decimals="-5"
      id="F_f76ba7fb-2007-4bee-a27d-b1b322a31071"
      unitRef="U_USD">3300000</us-gaap:DeferredIncome>
    <vir:GrantAwardedAmount
      contextRef="C_0d0ed842-ca94-4998-a8f5-2f0beb76b34a"
      decimals="-5"
      id="F_433b7a6f-b81f-440f-99ba-24ba942fda2b"
      unitRef="U_USD">5100000</vir:GrantAwardedAmount>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_557d1e8e-6875-4184-8347-4aab3a2c9a31"
      decimals="-5"
      id="F_2bcb4ee7-f86d-40fd-9598-97d8ca41806d"
      unitRef="U_USD">100000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_6595e636-7a23-4034-861a-6a075f66f7cc"
      decimals="-5"
      id="F_7ad2ba87-c01b-47da-8d58-f146eddceb22"
      unitRef="U_USD">600000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_ef618346-1e5d-4fc9-884c-3b4a0ef0bade"
      decimals="-5"
      id="F_022cea37-26db-4610-aabb-993010d7e2e5"
      unitRef="U_USD">900000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_2868289c-2adf-4da1-9b05-2a7a8d62b7dd">&lt;div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;7.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Collaboration and License Agreements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Collaboration Agreements with GSK&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2020 GSK Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On June 9, 2020, the Company, Glaxo Wellcome UK Limited and Beecham S.A. (referred to individually and together, as &#x201c;GSK&#x201d;) entered into a definitive collaboration agreement under the terms set forth in the preliminary collaboration agreement entered into by the Company and certain GSK entities in April 2020 (the &#x201c;2020 Preliminary Agreement&#x201d;) (such definitive collaboration agreement, the &#x201c;2020 GSK Agreement&#x201d;). Concurrently with the execution of the 2020 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2020 Stock Purchase Agreement&#x201d;) with Glaxo Group Limited (&#x201c;GGL&#x201d;), an affiliate of GSK, under which GGL purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,626,027&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock on April 29, 2020, at a price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.73&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. After receipt of antitrust clearance on April 22, 2020, the 2020 Preliminary Agreement became effective as of April 29, 2020, which was also the closing date for the associated 2020 Stock Purchase Agreement between the parties (&#x201c;Effective Date&#x201d;). Under the terms of the 2020 GSK Agreement, the Company and GSK agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Antibody Program&#x201d;); (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Vaccine Program&#x201d;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Functional Genomics Program&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; following the Effective Date, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee (&#x201c;JSC&#x201d;). The Company is primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK is primarily responsible for the commercialization activities for the Antibody Program (except in connection with sales of antibody products licensed to WuXi Biologics (Hong Kong) Limited in greater China), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. Subject to an opt-out mechanism, the parties share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with the Company bearing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of such costs for the antibody products, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of such costs for the vaccine products, and equal sharing of such costs for the functional genomics products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;a collaboration product-by-collaboration product basis, each party has the one-time right, at specified points in development, to opt-out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party pays to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, the Company has a&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;co-promotion &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;right for such antibody product in the United States, under which the Company has the right to perform up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of details in connection with such antibody product.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2020 GSK Agreement will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The 2020 GSK Agreement superseded and replaced the 2020 Preliminary Agreement between the parties. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2021, Beecham S.A. assigned and transferred all its rights, title, interest, and benefit in the 2020 GSK Agreement to GlaxoSmithKline Biologicals S.A., including all its rights to bring claims under such agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considered the ASC 606 criteria for combining contracts and determined that the 2020 GSK Agreement and 2020 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;206.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, based on the closing stock price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36.70&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on the date of execution of the 2020 Preliminary Agreement and 2020 Stock Purchase Agreement and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;43.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2020 GSK Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company concluded that the 2020 GSK Agreement contained &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; units of account: (i) the license granted to GSK under the Antibody Program (the &#x201c;Antibody License&#x201d;); (ii) the research and development activities (including clinical manufacturing) under the Antibody Program; (iii) the research and development activities under the Vaccine Program; and (iv) the research and development activities under the Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2020 GSK Agreement are performance obligations with a customer. The Company determined that the Antibody License is within the scope of ASC 606 and accordingly, accounted for the Antibody License as a distinct performance obligation under ASC 606. The Antibody License is a functional intellectual property and is distinct from the associated research and development activities to be performed under the program due to its significant standalone functionality. All other elements of the 2020 GSK Agreement including the research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The transaction price for the Antibody License at inception was determined to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;43.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, representing the premium on the sale of common stock to GSK. The Company determined that GSK can benefit from the Antibody License at the time of grant and therefore, the related performance obligation is satisfied at a point in time. As such, the Company recognized the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;43.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as contract revenue during the second quarter of 2020. Additionally, the Company is entitled to consideration from GSK related to profit and loss sharing arrangements (including royalties) contingent upon future sales of collaboration products under the Antibody Program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The remaining units of account of the 2020 GSK Agreement were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to, based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the products under the Vaccine and Functional Genomics Programs will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;May 2021, the FDA granted an EUA in the United States for sotrovimab, the first collaboration product under the Antibody Program. As the lead party for all commercialization activities, GSK incurs all of the sales and marketing expenses and is the principal on sales transactions with third parties. As the Company is the agent under the 2020 GSK Agreement, the Company recognizes its contractual share of the profit-sharing amounts or royalties (in case of an opt-out) as revenue, net of&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;any &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;cost of sales and allowable expenses (including distribution, selling, and marketing expenses) in the period the sale occurs. During the year ended December 31, 2021, the Company recorded its share of net profit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;917.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as collaboration revenue in the consolidated statement of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs associated with co-development activities performed under the agreement are included in research and development expenses on the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. Under the 2020 GSK Agreement, the Company recognized additional net research and development expenses of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2021 Expanded GSK Collaboration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On February 14, 2021, the Company and GSK entered into a binding preliminary collaboration agreement (the &#x201c;2021 &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Preliminary Agreement&#x201d;), under which the parties agreed to expand the 2020 GSK Agreement to collaborate on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; separate programs: (1) a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus (the &#x201c;Influenza Program&#x201d;), excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties&#x2019; current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses (the &#x201c;Expanded Functional Genomics Program&#x201d;); and (3) additional programs to develop neutralizing mAbs directed to up to three non-influenza target pathogens selected by GSK (the &#x201c;Selected Pathogens&#x201d; and such programs, the &#x201c;Additional Programs&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Concurrently with the execution of the 2021 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2021 Stock Purchase Agreement&#x201d;) with GGL under which GGL agreed to purchase shares of the Company&#x2019;s common stock for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;120.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The consummation of the transactions under each of the 2021 Preliminary Agreement and the 2021 Stock Purchase Agreement were subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which expiration was effective on March 24, 2021. The 2021 Preliminary Agreement and 2021 Stock Purchase Agreement consummated on March 25, 2021, which the Company used as the measurement date for accounting purposes. On March 31, 2021, the Company closed the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,924,927&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock to GGL.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2021 Preliminary Agreement was superseded on May 18, 2021 upon execution of the definitive collaboration agreement (the &#x201c;2021 GSK Agreement&#x201d;, or collectively with the 2021 Preliminary Agreement, the &#x201c;2021 GSK Collaboration&#x201d;). The material terms of the 2021 GSK Agreement, including the promised goods and services, are discussed below and is consistent with those of the 2021 Preliminary Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the 2021 GSK Collaboration, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; following the effective date. Under the Influenza Program, the parties will collaborate to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of influenza, including the Company&#x2019;s influenza mAbs (with respect to VIR-2482, only if GSK exercises its option). The Company may conduct the development and clinical manufacturing activities for VIR-2482 up to the completion of a Phase 2 clinical trial. Provided that the Company conducts and completes a Phase 2 clinical trial for VIR-2482, GSK will have the exclusive option to obtain exclusive rights to co-develop and commercialize VIR-2482 under the Influenza Program (the &#x201c;VIR-2482 Option&#x201d;). GSK will be the lead party for development, clinical and commercial manufacturing and commercialization activities for products under the Influenza Program (other than VIR-2482 unless and until GSK exercises the VIR-2482 Option, if applicable). The parties will mutually agree upon the allocation of responsibility for the development of products under the Expanded Functional Genomics Program, and for the development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK will be primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, upon execution of the definitive agreement, the Company will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The parties will share &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of all development costs in accordance with the budget for each of the collaboration programs (other than for the Selected Pathogens and VIR-2482, unless GSK exercises the VIR-2482 Option), with each party having the right to opt-out of its co-funding obligations at specified points in development. In such case, the party continuing&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;with &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the program will pay to the opt-out party a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the opt-out is exercised. Following the exercise of an opt-out right by a party, the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any opt-out, the parties will also share &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of all profits and losses arising from any collaboration product.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;GSK was obligated to make an upfront payment to the Company of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of which became payable at the effective date of the 2021 Preliminary Agreement and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of which became payable following the execution of the 2021 GSK Agreement. If GSK exercises the VIR-2482 Option, GSK will pay the Company an option exercise fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million unless certain agreed product criteria for VIR-2482 are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a pre-defined regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the VIR-2482 Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to the Company of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company concluded that the 2021 GSK Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements, under which certain elements are required to be accounted for under ASC 606 where the counterparty is a customer for a good or service that is a distinct unit of account. In addition, the 2021 GSK Agreement is considered a contract modification to the 2021 Preliminary Agreement and will be accounted for prospectively, as a termination of the 2021 Preliminary Agreement and commencement of a new contract. There was no impact to the accounting assessment of the original contract as no goods or services had been delivered to GSK, no performance obligations were satisfied, and accordingly, no contract revenue was recognized under ASC 606 prior to the execution of the 2021 GSK Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considered the ASC 606 criteria for combining contracts and determined that the 2021 GSK Collaboration and 2021 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, based on the closing stock price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52.70&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on March 25, 2021 and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2021 GSK Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company concluded that the 2021 GSK Agreement contained the following units of account: (i) the VIR-2482 Option; (ii) three distinct rights granted to GSK related to the Selected Pathogens (each, a &#x201c;Selected Pathogens Right&#x201d;); (iii) the license and know-how to the next-generation mAbs under the Influenza Program (the &#x201c;Next Gen License&#x201d;); (iv) the research and development activities for next-generation mAbs under the Influenza Program; and (v) the research and development activities, including license rights and know-how, under the Expanded Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2021 GSK Agreement are performance obligations with a customer. The Company determined that the distinct performance obligations under ASC 606 consisted of (i) the Next Gen License and (ii) the three Selected Pathogens Rights, each representing a material right. All other elements of the 2021 GSK Agreement including the VIR-2482 Option, research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer. A&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;s of December 31, 2021, GSK had not exercised the VIR-2482 Option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The transaction price for the 2021 GSK Agreement included fixed consideration consisting of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upfront fee paid by GSK and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, representing the premium on the sale of common stock to GSK for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;259.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. All potential future milestones and other payments under the 2021 GSK Agreement are constrained since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The respective estimated SSP for each of the performance obligations was determined to allocate the transaction price. The estimated SSP of each performance obligation was determined using methods that considered relevant market &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;conditions, entity-specific factors and information about GSK, while maximizing the use of available observable inputs and using certain management assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital). For the Next Gen License, the Company determined that GSK can benefit from the license at the time the license is granted, and therefore, the related performance obligation is satisfied at a point in time. If any of the Selected Pathogens Rights &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;are exercised, the Company will evaluate the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;related promises to identify the performance obligations to be transferred and the timing of revenue recognition. If any of the Selected Pathogens Rights expire prior to being exercised, the Company will recognize any deferred revenue allocated to that right as revenue at the time of expiration.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The research and development activities for the next generation mAbs under the Influenza Program and the Expanded Functional Genomics Program were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the related products will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon execution of the 2021 GSK Agreement, the Company granted the Next Gen License to GSK and therefore, recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;168.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as contract revenue in the second quarter of 2021. As of December 31, 2021, the total unrecognized transaction price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million is classified as current deferred revenue on the Company's consolidated balance sheet related to the remaining performance obligations, being the material rights resulting from the Selected Pathogens Rights, none of which have been exercised by GSK as of December 31, 2021. The Company expects the rights will be exercised, and thus, the corresponding deferred revenue will be recognized within the next 12 months from the balance sheet date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs associated with co-development activities performed under the agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. During the year ended December 31, 2021, the Company recognized additional net research and development expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million under the 2021 GSK Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under both the 2020 GSK Agreement and the 2021 GSK Agreement, the Company has a receivable from collaboration of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;773.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Brii Biosciences&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2018, the Company entered into the Brii Agreement with Brii Bio Parent and Brii Bio pursuant to which the Company granted to Brii Bio, with respect to up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the Company&#x2019;s programs, an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau (collectively, the &#x201c;China Territory&#x201d;) for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection (the &#x201c;Field of Use&#x201d;). The Company&#x2019;s HBV &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;small interfering ribonucleic acid (&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x201c;siRNA&#x201d;) program being developed under the Amended Alnylam Agreement (described below) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. In partial consideration for the options granted by the Company to Brii Bio, Brii Bio Parent and Brii Bio granted the Company, with respect to up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of Brii Bio Parent&#x2019;s or Brii Bio&#x2019;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that the Company may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As partial consideration for the Company&#x2019;s entry into the Brii Agreement, upon closing of Brii Bio Parent&#x2019;s Series A preferred stock financing, the Company received ordinary shares equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#x2019;s right to exercise one of its options for the Company&#x2019;s HBV siRNA program, under the terms of the Amended Alnylam Agreement, the Company transferred to Alnylam Pharmaceuticals, Inc. ("Alnylam") a specified percentage of such equity consideration allocable to such program &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;under a share transfer agreement in February 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;With respect to programs for which Brii Bio exercises its options, Brii Bio will be required to pay the Company an option exercise fee for each such Vir program ranging from the&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; mid-single-digit millions&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;determined&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;based &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;mid-single-digit millions&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;175.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million per licensed program. Brii Bio also will pay royalties to the Company that range from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;mid-teens to the high-twenties&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, as described below.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon exercise of each option for a Brii Bio program, the Company will be required to pay to Brii Bio an option exercise fee ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;low tens of millions&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, determined based on the commercial potential of the licensed program. The Company will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;low tens of millions&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, also determined based on the commercial potential of such program. The Company will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;175.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million per licensed program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, the Company is obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay the Company tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by the Company to Brii Bio, and by Brii Bio to the Company, on net sales range from mid-teens to high-twenties. Each party&#x2019;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; written notice (if the terminating party has not exercised an option for such program) or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; written notice (or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; notice following failure to make payment).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From May 2018 until July 2021, the Brii Bio Parent IPO closing date, Brii Bio Parent and its wholly-owned subsidiary Brii Bio were determined to be variable interest entities ("VIE") due to their reliance on future financing and having insufficient equity at risk. However, the Company did not have the power to direct activities that most significantly impact the economic success of these entities and was not considered the primary beneficiary of these entities. Therefore, the Company did not consolidate Brii Bio Par&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ent or Brii Bio. Subsequent to the Brii Bio Parent IPO, the Company determined that these entities are no longer VIEs. In addition, as Brii Bio Parent is a publicly-traded company, the Company's investment in its ordinary shares became a marketable equity investment with readily determinable fair value and is then subsequently remeasured to fair value at each reporting date (see Note 3&#x2014;Fair Value Measurements). Prior to the Brii Bio Parent IPO, the Company accounted for its investment in Brii Bio Parent, which had a carrying value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment from the same issuer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Brii Agreement, the Company also has a contract liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million within noncurrent deferred revenue which represents deferred consideration for the remaining three options that the Company granted to Brii Bio. The deferred consideration will be recognized when Brii Bio exercises its options or the options expire.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Option Exercise by Brii Bio&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2020, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. In consideration of the Company&#x2019;s grant to Brii Bio of an exclusive license related to VIR-2218 in the China Territory, the Company received a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-2218 in the China&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Territory: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million regulatory milestone payment, up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;175.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in sales-based milestone payments, and royalties on net sales ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;high-teens to high-twenties&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluated the transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price is determined to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million which consists of the $20.0 million option exercise fee and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the deferred revenue allocated to the VIR-2218 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation under ASC 606. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting other third parties. Brii Bio can benefit from the license at the time of grant and therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the years ended December 31, 2021 and 2020, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively, as contract revenue from the supply of biological materials to Brii Bio. During the years ended December 31, 2021 and 2020, the Company recognized &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as license revenue from a related party. The Company separately paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, half of the option exercise proceeds, to Alnylam in connection with the Amended Alnylam Agreement that was recognized as research and development expense during the second quarter of 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Alnylam&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;October 2017 Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2017, the Company entered into the collaboration and license agreement with Alnylam (the &#x201c;Alnylam Agreement&#x201d;) for the development of siRNA products for the treatment of HBV and following the exercise of certain program options, the development and commercialization of siRNA products directed to up to four other infectious disease targets selected by the Company. The technology licensed under the Alnylam Agreement forms the basis of the Company&#x2019;s siRNA technology platform.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Alnylam Agreement, the Company obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications, such excluded fields, the Excluded Fields. In addition, Alnylam granted the Company an exclusive option, for each of the infectious disease siRNA programs directed to the Company&#x2019;s selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. On a product-by-product basis for each product arising from the HBV and, following the Company&#x2019;s option exercise, the infectious disease programs, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company and Alnylam are jointly responsible for funding the initial research and development activities for VIR-2218 through the completion of proof of concept trials. Prior to the exercise of the Company&#x2019;s option for each siRNA program directed to one of the Company&#x2019;s selected infectious disease targets, Alnylam is responsible for conducting all development activities, at the Company&#x2019;s expense, in accordance with an agreed-upon development plan. Following the Company&#x2019;s exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, the Company is solely responsible, at the Company&#x2019;s expense (subject to Alnylam&#x2019;s exercise of a profit-sharing option), for conducting all development, manufacture and commercialization activities for products arising from each such program. If Alnylam exercises a profit-sharing option for a product, the Company will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Alnylam Agreement, the Company paid Alnylam an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and issued to Alnylam &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,111,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock. Additionally, the receipt of consideration from Brii Bio as discussed above triggered a requirement under the Alnylam Agreement to transfer a portion of the consideration, consisting of equity in Brii Bio Parent valued at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, to Alnylam&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon the achievement of a certain development milestone, as further discussed below, the Company was obligated to issue shares of the Company&#x2019;s common stock equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,111,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares or (ii) a certain number of shares based on the Company&#x2019;s stock price at the time such milestone is achieved (the &#x201c;Milestone Shares&#x201d;). The Company will be required to pay Alnylam up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;190.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;115.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the achievement of specified development and regulatory milestones by the first product directed to the target of each infectious disease siRNA program for which the Company exercised its option. Following commercialization, the Company will be required to pay to Alnylam up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which the Company exercised its option. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;low double-digits to mid-teens&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on annual net sales of HBV products, and tiered royalties at percentages ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;high single-digits to the sub-teen double-digits&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years after the first commercial sale of such product in such country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The term of the Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under the Alnylam Agreement. If the Company does not exercise its option for an infectious disease program directed to one of its selected targets, the Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. The Company may terminate the Alnylam Agreement on a program-by-program basis or in its entirety for any reason on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; written notice. Either party may terminate the agreement for cause for the other party&#x2019;s uncured material breach on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; written notice (or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Alnylam Agreement on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, the Company achieved the specified development milestone relating to the Milestone Shares, which was accounted for as an embedded derivative. Consequently, the Company remeasured and reclassified the derivative liability to additional paid-in capital based on the estimated fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company issued Alnylam &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,111,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock and paid Alnylam $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the second quarter of 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Second and Third Amendments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March and April 2020, the Company and Alnylam entered into the second and third amendments to the Alnylam Agreement (as amended, the &#x201c;Amended Alnylam Agreement&#x201d;) to expand the parties&#x2019; existing collaboration to include the development and commercialization of siRNA products targeting SARS-CoV-2, and potentially other related coronaviruses, and up to three targeting human host factors for SARS-CoV-2 (collectively, the &#x201c;COVID Collaboration Targets&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company and Alnylam entered into a letter amendment (the &#x201c;Letter Agreement&#x201d;), further amending the Amended Alnylam Agreement, to modify certain funding and governance provisions in connection with the siRNA products directed to the COVID Collaboration Targets, including VIR-2703 (the &#x201c;COV Target&#x201d;), and to modify certain rights of each party with respect to products arising from such programs. Pursuant to the Letter Agreement, Alnylam was responsible for conducting pre-clinical research activities set forth in the existing workplan for the COV Target (the &#x201c;COV Workplan&#x201d;) at its discretion and sole expense, and the Company was no longer obligated to reimburse Alnylam for any share of costs incurred by Alnylam in conducting activities under the COV Workplan after July 1, 2020. In July 2021, Alnylam elected to discontinue the development of the COV Target, and all other related research and development activities in accordance with their rights under the Letter Agreement. As a result, the COV Target and the siRNA program related thereto are no longer included within the Amended Alnylam Agreement and all rights to the siRNA program directed to the COV Target reverted to Alnylam.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses Recognized for the Period&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company incurred expenses under the Amended Alnylam Agreement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during the years ended December 31, 2021 and 2019, respectively. For the year ended December 31, 2020, in addition to the Milestone Shares, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million milestone payment to Alnylam, and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million payment resulting from Brii Bio&#x2019;s option exercise in the first half of 2020, the Company incurred expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million under the Amended Alnylam Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;WuXi Biologics&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2020, the Company entered into a development and manufacturing collaboration agreement with WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Biologics&#x201d;) (the &#x201c;WuXi Biologics Collaboration Agreement&#x201d;), for the clinical development, manufacturing, and commercialization of the Company&#x2019;s proprietary antibodies developed for SARS-CoV-2. Under the WuXi Biologics Collaboration Agreement, WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. WuXi Biologics will have the right to commercialize products incorporating such SARS-CoV-2 antibodies in greater China under an exclusive license granted for the selected SARS-CoV-2 antibodies that have been developed. The Company will have the right to commercialize such products in all other markets worldwide.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;WuXi Biologics will perform mutually agreed process and clinical develo&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;pment and manufacturing activities, under individual statements of work. In addition, the parties agreed that WuXi Biologics will pay the Company tiered royalties at percentages ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;high single-digits to mid-teens&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on annual net sales of all products sold by WuXi Biologics in greater China. The royalties are payable for a specified, standard royalty term. In addition, if WuXi Biologics sublicenses its commercialization rights to a third party, WuXi Biologics will pay the Company a percentage of the sublicense revenue received from such third party. The WuXi Biologics Collaboration Agreement will continue until the expiration of WuXi Biologics&#x2019; payment obligations to the Company, unless terminated earlier. If terminated earlier, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days&#x2019; prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within 60 days.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Rockefeller University&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2018, the Company entered into an exclusive license agreement with The Rockefeller University (&#x201c;Rockefeller&#x201d;), which was amended in May 2019, in September 2020, and in March 2021 (the &#x201c;Rockefeller Agreement&#x201d;). Under the Rockefeller Agreement, Rockefeller granted the Company a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The Company uses technology licensed under the Rockefeller Agreement in the Company&#x2019;s antibody platform and in the Company&#x2019;s product candidates VIR-3434 and VIR-7832.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company paid Rockefeller an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for entry into the Rockefeller Agreement, and is required to pay annual license maintenance fees of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, which will be creditable against royalties following commercialization. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, for the achievement of specified development, regulatory and commercial success milestone events, the Company will be required to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, in the aggregate, for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;six&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; infectious disease products. Any follow-on products beyond six products may result in additional milestone event payments. The Company will also be required to pay to Rockefeller a royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. The Company&#x2019;s obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis, upon the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years following the first commercial sale of the applicable licensed product in such jurisdiction.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Rockefeller Agreement, the Company recognized a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during the years ended December 31, 2021, 2020 and 2019, respectively, as research and development expenses related to certain development milestone payments, annual license maintenance fees, and estimated sublicense fees.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of the Company&#x2019;s obligations to pay royalties to Rockefeller in all jurisdictions. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; written notice for the Company&#x2019;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#x2019;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;MedImmune&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2018, the Company entered into a license agreement, which was amended in September 2020 (the &#x201c;MedImmune Agreement&#x201d;), with MedImmune, LLC (&#x201c;MedImmune&#x201d;), under which the Company obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The Company is developing VIR-2482 using technology licensed under the MedImmune Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In consideration for the grant of the licenses under the MedImmune Agreement, the Company made an upfront payment to MedImmune of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company will be obligated to make development, regulatory, and commercial milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;331.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate relating to influenza A and influenza B products. MedImmune will also be entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7b44663d-1329-47cf-a20b-2f4943e047c2;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;mid-single-digits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to sub-teen double-digits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of the Company&#x2019;s obligations to pay royalties to MedImmune. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;120&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the third quarter of 2019, the Company achieved and paid one of the specified development milestones relating to influenza A under the MedImmune Agreement. The milestone payment was expensed to research and development in 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Xencor&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;August 2019 License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2019, the Company entered into a patent license agreement, which was amended in February 2021 (the &#x201c;2019 Xencor Agreement&#x201d;) with Xencor, Inc. (&#x201c;Xencor&#x201d;). Under the 2019 Xencor Agreement, as amended, the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in the Company&#x2019;s VIR-2482, incorporating Xencor&#x2019;s Xtend technology, and VIR-3434, incorporating Xencor&#x2019;s Xtend and other Fc technologies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In consideration for the grant of the license, the Company paid Xencor an upfront fee. For each of the influenza A and HBV research programs, the Company will be required to pay Xencor development and regulatory milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate, and commercial sales milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate, for a total of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in aggregate milestones for each program and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;155.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in aggregate milestones for both programs. On a product-by-product basis, the Company will also be obligated to pay tiered royalties based on net sales of licensed products ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;low- to mid-single-digits&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the 2019 Xencor Agreement, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during the years ended December 31, 2021, 2020 and 2019, respectively, as research and development expenses related to certain development milestone payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;March 2020 License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, the Company entered into a patent license agreement, which was amended in February 2021 (the &#x201c;2020 Xencor Agreement&#x201d;) with Xencor under which the Company obtained a non-exclusive, sublicensable (only to the Company&#x2019;s affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the coronavirus research programs. These technologies are used in the Company&#x2019;s sotrovimab, incorporating Xencor&#x2019;s Xtend technology, and VIR-7832, incorporating Xencor&#x2019;s Xtend and other Fc technologies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In consideration for the grant of the license, the Company is obligated to pay royalties based on net sales of licensed products at the&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; mid-single-digits&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. During the year ended December 31, 2021, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, as cost of revenue for royalties due to Xencor from the sale of sotrovimab.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The amended 2020 Xencor Agreement and 2019 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; written notice. Either party may terminate each agreement for the other party&#x2019;s uncured material breach upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; written notice (or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; written notice if any of the Company&#x2019;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_810fc216-bb93-4ea9-b973-024c33461e81"
      decimals="INF"
      id="F_9a5a072c-8312-462e-92aa-be30b1c27b7f"
      unitRef="U_shares">6626027</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_e3de3d32-1468-4cb9-b95b-a8d0af66f9af"
      decimals="INF"
      id="F_310bdf92-24bc-4299-ab61-b22e0bf22b9f"
      unitRef="U_USDollarShare">37.73</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_810fc216-bb93-4ea9-b973-024c33461e81"
      decimals="-5"
      id="F_d75de9d5-497c-4608-a90c-86a48baf7bc3"
      unitRef="U_USD">250000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vir:CollaborationTypeAndPrograms
      contextRef="C_224cb303-9ce3-44c9-8e2e-6437c0fdeafb"
      id="F_c407e1e5-b2d0-456d-a91b-243b90c38f98">The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Antibody Program&#x201d;); (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Vaccine Program&#x201d;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Functional Genomics Program&#x201d;).</vir:CollaborationTypeAndPrograms>
    <vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans
      contextRef="C_202b895b-631c-490b-893f-c4dd6e2908d9"
      id="F_99ded8a5-ed42-4b37-bf90-73b2ef222887">P4Y</vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans>
    <vir:PercentageOfDevelopmentCosts
      contextRef="C_9cc53898-90ab-48e4-811b-68336c8459bf"
      decimals="3"
      id="F_475620c2-9401-450a-aabb-b5a0a58605b4"
      unitRef="U_pure">0.725</vir:PercentageOfDevelopmentCosts>
    <vir:PercentageOfDevelopmentCosts
      contextRef="C_c672b8f5-c39b-47aa-bcad-cd04fd706515"
      decimals="3"
      id="F_2d9de7ed-8022-4406-aed5-c5009762aed3"
      unitRef="U_pure">0.275</vir:PercentageOfDevelopmentCosts>
    <vir:MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct
      contextRef="C_202b895b-631c-490b-893f-c4dd6e2908d9"
      decimals="2"
      id="F_2cbae70b-e7f2-499a-be0b-ad667fdc07ba"
      unitRef="U_pure">0.20</vir:MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_14c2d113-77d4-4ecb-aadc-32b535038ad1"
      id="F_96f2bba3-9b5d-4d51-a480-4079bf0e3561">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</vir:CollaborationAgreementTerminationDescription>
    <vir:FairMarketValueOfCommonStockIssued
      contextRef="C_9e120ade-622b-4150-9778-b6f3b2b76cc3"
      decimals="-5"
      id="F_88716b0d-a595-4f30-9685-3c9b8e692013"
      unitRef="U_USD">206700000</vir:FairMarketValueOfCommonStockIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_7c483ff8-5408-46f2-a03d-22d662c61cf4"
      decimals="2"
      id="F_a61c8e48-d435-477c-817e-8bc32e652203"
      unitRef="U_USDollarShare">36.70</us-gaap:SaleOfStockPricePerShare>
    <vir:PremiumReceivedOnSalePriceOfCommonStock
      contextRef="C_9e120ade-622b-4150-9778-b6f3b2b76cc3"
      decimals="-5"
      id="F_fcc59594-f608-40ff-8139-962967a29173"
      unitRef="U_USD">43300000</vir:PremiumReceivedOnSalePriceOfCommonStock>
    <vir:CollaborationAgreementNumberOfUnitsOfAccount
      contextRef="C_202b895b-631c-490b-893f-c4dd6e2908d9"
      decimals="INF"
      id="F_7fea82ee-3003-4016-887e-6edbcf0a7279"
      unitRef="U_Unit">4</vir:CollaborationAgreementNumberOfUnitsOfAccount>
    <vir:AntibodyLicenseTransactionPrice
      contextRef="C_9cc53898-90ab-48e4-811b-68336c8459bf"
      decimals="-5"
      id="F_df0f4993-249c-4cd9-8b73-a8d19b4965b9"
      unitRef="U_USD">43300000</vir:AntibodyLicenseTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0a9da79f-2f51-4ca2-944b-bb5ee3abad70"
      decimals="-5"
      id="F_ddc7a078-ff3e-423d-adc0-bc0564660497"
      unitRef="U_USD">43300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4535e3d1-cadf-43e9-a70d-52008cd60dfc"
      decimals="-2"
      id="F_268894b1-5f22-4372-bd96-762318c4e5ef"
      unitRef="U_USD">917200</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <vir:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_14c2d113-77d4-4ecb-aadc-32b535038ad1"
      decimals="-5"
      id="F_f4dc4703-25ca-48f5-a2d4-22bb077bae2f"
      unitRef="U_USD">77300000</vir:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <vir:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_7fe631b5-99f5-4a42-904e-1d5e014789ce"
      decimals="-5"
      id="F_106f99e7-c3c8-4b97-9594-f481cd62ad9d"
      unitRef="U_USD">25400000</vir:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <vir:CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate
      contextRef="C_3be2e934-f078-49d4-9962-afce5e0c771d"
      decimals="INF"
      id="F_7122d8f3-ea6e-453b-8661-c2b9b9b6769f"
      unitRef="U_Program">3</vir:CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7b12cfb1-fdf1-4522-acd2-8b1f2eb36f1e"
      decimals="-5"
      id="F_ab365e03-93af-41ff-949e-8f5eefc0acf3"
      unitRef="U_USD">120000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_830b2851-70de-48fc-94e9-c824f5a5454c"
      decimals="INF"
      id="F_0052c130-8a1e-4fd3-8a26-25aa4e7fc339"
      unitRef="U_shares">1924927</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans
      contextRef="C_eb465827-50c0-422c-a785-a18988e1c54b"
      id="F_6edb7d26-60b4-4a55-9228-e9bc832a6cf1">P3Y</vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans>
    <vir:PercentageOfShareDevelopmentCosts
      contextRef="C_0c4b9e6a-a844-4e0c-a296-cb62009d4a06"
      decimals="INF"
      id="F_77a45f78-869b-4119-867f-04317b8caf81"
      unitRef="U_pure">0.50</vir:PercentageOfShareDevelopmentCosts>
    <vir:ProfitsAndLossesSharingPercentage
      contextRef="C_0c4b9e6a-a844-4e0c-a296-cb62009d4a06"
      decimals="INF"
      id="F_d6077907-0b2f-44ba-810a-72e2875da93f"
      unitRef="U_pure">0.50</vir:ProfitsAndLossesSharingPercentage>
    <vir:UpfrontPaymentReceivable
      contextRef="C_d7e70a8d-2f4b-4760-92ab-0e41dad01baf"
      decimals="-5"
      id="F_9417aaa9-f1d0-4ea3-80bb-f42cd6b3ca78"
      unitRef="U_USD">225000000.0</vir:UpfrontPaymentReceivable>
    <vir:PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement
      contextRef="C_d7e70a8d-2f4b-4760-92ab-0e41dad01baf"
      decimals="INF"
      id="F_438ef4f5-0034-4f51-970c-c1d82c377bca"
      unitRef="U_pure">0.50</vir:PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement>
    <vir:PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement
      contextRef="C_fbb0fecc-7a8b-4c5b-9fec-e7fdd61a01f0"
      decimals="INF"
      id="F_93d9e1c9-8a2d-45c5-84b4-bcc6b40f30e3"
      unitRef="U_pure">0.50</vir:PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement>
    <vir:OptionExerciseFeeConsiderationToBeReceived
      contextRef="C_d7e70a8d-2f4b-4760-92ab-0e41dad01baf"
      decimals="-5"
      id="F_041957d5-6136-4dd7-a47b-24412b254dc1"
      unitRef="U_USD">300000000.0</vir:OptionExerciseFeeConsiderationToBeReceived>
    <vir:PreDefinedRegulatoryMilestoneConsiderationReceivable
      contextRef="C_ca5007f4-5584-4178-8601-b447870799b2"
      decimals="-5"
      id="F_cf984d06-41bd-480e-8427-b2c98d0730d8"
      unitRef="U_USD">200000000.0</vir:PreDefinedRegulatoryMilestoneConsiderationReceivable>
    <vir:FairMarketValueOfCommonStockIssued
      contextRef="C_f2bc6c04-5732-4690-b9c0-17ebe0b9dbc3"
      decimals="-5"
      id="F_89470e9b-0516-4614-b433-c2f418d03002"
      unitRef="U_USD">85200000</vir:FairMarketValueOfCommonStockIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_e1b89459-ec16-4eeb-8748-5aa7c26b546b"
      decimals="INF"
      id="F_dd06d533-4fbb-435c-80fd-81543f376da2"
      unitRef="U_USDollarShare">52.70</us-gaap:SaleOfStockPricePerShare>
    <vir:PremiumReceivedOnSalePriceOfCommonStock
      contextRef="C_f2bc6c04-5732-4690-b9c0-17ebe0b9dbc3"
      decimals="-5"
      id="F_1bea1da0-7f4c-48be-a4b0-9c9d6c9a999b"
      unitRef="U_USD">34800000</vir:PremiumReceivedOnSalePriceOfCommonStock>
    <vir:CollaborationAgreementTransactionPriceUpfrontFee
      contextRef="C_95728472-f99b-4600-92ae-c92c93205687"
      decimals="-5"
      id="F_26d9205f-40f1-4709-aad9-427d5b3f5e25"
      unitRef="U_USD">225000000.0</vir:CollaborationAgreementTransactionPriceUpfrontFee>
    <vir:PremiumReceivedOnSalePriceOfCommonStock
      contextRef="C_f99ec918-2e4e-432a-970f-3c67447885a4"
      decimals="-5"
      id="F_1a198516-c5bd-4387-8f6b-ba34073ade1a"
      unitRef="U_USD">34800000</vir:PremiumReceivedOnSalePriceOfCommonStock>
    <vir:CollaborationAgreementTransactionPriceConsideration
      contextRef="C_95728472-f99b-4600-92ae-c92c93205687"
      decimals="-5"
      id="F_2f7ab338-6f7c-4037-9f4b-19749d7496c9"
      unitRef="U_USD">259800000</vir:CollaborationAgreementTransactionPriceConsideration>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0e93d6b9-9d5c-45a3-b71f-00713901c0f6"
      decimals="-5"
      id="F_894594e6-fa96-428d-bfb2-fb9775e836e4"
      unitRef="U_USD">168300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="C_5d7448b7-0904-4443-a40d-a6bc22ea01ae"
      decimals="-5"
      id="F_a2fdf144-961a-4481-a507-8340be6a13f3"
      unitRef="U_USD">91500000</us-gaap:DeferredRevenue>
    <vir:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_30a9821b-b5e9-46b1-8ada-d4dccbd412c3"
      decimals="-5"
      id="F_3706b43b-635f-4820-aeac-78928d4d0556"
      unitRef="U_USD">500000</vir:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_5fa4019b-73c6-4a3b-be6c-7aa4984acca2"
      decimals="-5"
      id="F_51dde34e-7b34-46e7-b0ee-d805d788c44b"
      unitRef="U_USD">773100000</us-gaap:AccountsReceivableNetCurrent>
    <vir:MaximumNumberOfDevelopmentProgramGrantedToCounterparty
      contextRef="C_04ff1607-fb14-42a5-912f-34d468278706"
      decimals="INF"
      id="F_44eae4fa-24fb-42c0-a5b8-2e00f4068d7c"
      unitRef="U_Program">4</vir:MaximumNumberOfDevelopmentProgramGrantedToCounterparty>
    <vir:MaximumNumberOfDevelopmentProgramGrantedFromCounterparty
      contextRef="C_04ff1607-fb14-42a5-912f-34d468278706"
      decimals="INF"
      id="F_aa56c7ba-b7db-444a-8b92-c807b7ac2a0e"
      unitRef="U_Program">4</vir:MaximumNumberOfDevelopmentProgramGrantedFromCounterparty>
    <vir:PercentageOfOrdinaryShareEqualToOutstandingShare
      contextRef="C_04ff1607-fb14-42a5-912f-34d468278706"
      decimals="INF"
      id="F_71cd673c-761f-4c92-be54-2e65d68911ab"
      unitRef="U_pure">0.099</vir:PercentageOfOrdinaryShareEqualToOutstandingShare>
    <vir:OptionExerciseFeeLowEndOfTheRange
      contextRef="C_0ae824f4-f2da-4275-addc-163ec36b47a2"
      id="F_202f960a-81b3-4b8b-93da-450739633eb9"> mid-single-digit millions</vir:OptionExerciseFeeLowEndOfTheRange>
    <vir:OptionExerciseFeeHighEndOfTheRange
      contextRef="C_56c9c1ac-6a87-4622-b2fb-da94dac65173"
      decimals="INF"
      id="F_d5cb096e-3d51-43e5-b6b0-eda036aa30e1"
      unitRef="U_USD">20000000.0</vir:OptionExerciseFeeHighEndOfTheRange>
    <vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange
      contextRef="C_0ae824f4-f2da-4275-addc-163ec36b47a2"
      id="F_9d8c1603-c0b6-4fec-9db8-3d8965594319">mid-single-digit millions</vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange>
    <vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange
      contextRef="C_56c9c1ac-6a87-4622-b2fb-da94dac65173"
      decimals="-5"
      id="F_6ac9e0ff-6dbb-4d17-820e-386eb0621f24"
      unitRef="U_USD">30000000.0</vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange>
    <vir:MaximumAggregateSalesMilestonePayments
      contextRef="C_1d93e807-4da6-4761-840c-61b5cefbee6d"
      decimals="-5"
      id="F_496f4386-7936-4532-8271-8e5e800a4db3"
      unitRef="U_USD">175000000.0</vir:MaximumAggregateSalesMilestonePayments>
    <vir:RangeOfRoyaltyPaymentToBePaid
      contextRef="C_0ae824f4-f2da-4275-addc-163ec36b47a2"
      id="F_0d93edd4-cbb2-4fe9-857d-8362ee0d077e">mid-teens to the high-twenties</vir:RangeOfRoyaltyPaymentToBePaid>
    <vir:OptionExerciseFeeLowEndOfTheRange
      contextRef="C_0733b4ef-c448-4927-8d8e-84da4192b4ae"
      id="F_6b4ede34-3aca-482d-9866-132e496af5c9">low tens of millions</vir:OptionExerciseFeeLowEndOfTheRange>
    <vir:OptionExerciseFeeHighEndOfTheRange
      contextRef="C_eada5d7f-f2a9-431c-b238-c2280f794f45"
      decimals="-5"
      id="F_e8114159-1a24-43c2-b32e-c1d192e47119"
      unitRef="U_USD">50000000.0</vir:OptionExerciseFeeHighEndOfTheRange>
    <vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange
      contextRef="C_1d93e807-4da6-4761-840c-61b5cefbee6d"
      id="F_1b92af04-db6a-4d19-90b0-dc9afdef479e">low tens of millions</vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange>
    <vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange
      contextRef="C_eada5d7f-f2a9-431c-b238-c2280f794f45"
      decimals="-5"
      id="F_0cc9b569-5efb-4f05-b801-57667fb76930"
      unitRef="U_USD">100000000.0</vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange>
    <vir:MaximumAggregateSalesMilestonePayments
      contextRef="C_0ae824f4-f2da-4275-addc-163ec36b47a2"
      decimals="-5"
      id="F_3d4fb740-2c90-4809-9ffc-e4fe38b993d9"
      unitRef="U_USD">175000000.0</vir:MaximumAggregateSalesMilestonePayments>
    <vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales
      contextRef="C_974c0603-8333-4dce-9655-97b1212bed01"
      id="F_2e052461-b05d-43b2-ad25-604c2f997e1f">P10Y</vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_d62337c8-04d8-488e-a5b0-e98601a826a0"
      id="F_13881d61-31cf-430f-8715-0d855b715b86">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days&#x2019; written notice (if the terminating party has not exercised an option for such program) or 180 days&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on 60 days&#x2019; written notice (or 30 days&#x2019; notice following failure to make payment).</vir:CollaborationAgreementTerminationDescription>
    <vir:WrittenNoticeToTerminateLicensedProgramIfNotExercise
      contextRef="C_8d81f5ee-bce5-4497-8145-ef3258cee1b8"
      id="F_96dd9952-9fb4-457d-99bc-9a5ca0fe089f">P30D</vir:WrittenNoticeToTerminateLicensedProgramIfNotExercise>
    <vir:WrittenNoticeToTerminateLicensedProgramIfExercise
      contextRef="C_8d81f5ee-bce5-4497-8145-ef3258cee1b8"
      id="F_d4651b21-6922-48c1-9169-bbff1a970c01">P180D</vir:WrittenNoticeToTerminateLicensedProgramIfExercise>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach
      contextRef="C_8d81f5ee-bce5-4497-8145-ef3258cee1b8"
      id="F_50642e08-b26d-4458-bb14-aeb959f0d44d">P60D</vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment
      contextRef="C_8d81f5ee-bce5-4497-8145-ef3258cee1b8"
      id="F_58804e90-aac1-4c95-8401-f41b8f2f86ad">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment>
    <us-gaap:Investments
      contextRef="C_55353dc3-d2db-42da-a649-4767a86be523"
      decimals="-5"
      id="F_648943a8-ac16-4ebe-bed7-f032cf32198a"
      unitRef="U_USD">5700000</us-gaap:Investments>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_eaceb94a-8ec3-4208-a7d4-ba474353d176"
      decimals="-5"
      id="F_70b36a0f-beed-4b47-a707-4bd2004dd3b8"
      unitRef="U_USD">3800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <vir:OptionExerciseFeeReceived
      contextRef="C_c0b1e9f3-2c15-4ace-bc47-71fc21bcc480"
      decimals="-5"
      id="F_a47e18da-d3e8-4b0e-a3e2-73785ba82f6c"
      unitRef="U_USD">20000000.0</vir:OptionExerciseFeeReceived>
    <vir:RegulatoryMilestonePaymentToBeReceived
      contextRef="C_71a5c221-44c0-4e41-a2fa-4f7fa314d849"
      decimals="-5"
      id="F_7f2659d5-fcb4-46ff-a397-5cb0fbfa2400"
      unitRef="U_USD">30000000.0</vir:RegulatoryMilestonePaymentToBeReceived>
    <vir:MaximumSalesMilestonToPay
      contextRef="C_05bb4f29-b066-4a68-b91c-484f95f96b0a"
      decimals="-5"
      id="F_d042f162-cd4a-4fd2-b880-d9c0fac1363b"
      unitRef="U_USD">175000000.0</vir:MaximumSalesMilestonToPay>
    <vir:RangeOfRoyaltyPaymentToBeReceived
      contextRef="C_71a5c221-44c0-4e41-a2fa-4f7fa314d849"
      id="F_e0d3ba82-79a6-4783-b73f-23da6853c4b5">high-teens to high-twenties</vir:RangeOfRoyaltyPaymentToBeReceived>
    <vir:DeterminedTransactionPrice
      contextRef="C_c0b1e9f3-2c15-4ace-bc47-71fc21bcc480"
      decimals="-5"
      id="F_5539bbf5-40b0-4f91-93db-4a0ac179db85"
      unitRef="U_USD">22700000</vir:DeterminedTransactionPrice>
    <us-gaap:DeferredRevenue
      contextRef="C_c64f8d89-5c82-4a9f-a80a-fb1f5a11ee70"
      decimals="-5"
      id="F_9802f136-4aa0-47ab-87fc-08a6611628c2"
      unitRef="U_USD">2700000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ec203b07-51b7-4cd9-82e7-1152642f49ca"
      decimals="-5"
      id="F_9f5385ee-5a22-42fc-8f3d-57bce802a854"
      unitRef="U_USD">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3f98ed76-99b8-4408-9b9c-7145868e41b8"
      decimals="0"
      id="F_3c51d49d-fa4f-45f4-9dd6-440b2d857ff5"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_a16ebff0-6b04-4a9b-bc6e-bc5cd87822d3"
      decimals="INF"
      id="F_02ca513a-2cdb-4e5c-837e-96387465fa72"
      unitRef="U_USD">0</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0be73e2a-ec59-4143-9931-80891ed3a51b"
      decimals="-5"
      id="F_3b971198-1cd3-451a-ba1e-3ce839934422"
      unitRef="U_USD">22700000</us-gaap:RevenueFromRelatedParties>
    <vir:PaymentToCollaboratorResultingFromProgramOptionExercise
      contextRef="C_819e77e6-c072-4b31-ba45-3c415b3f67d8"
      decimals="-5"
      id="F_1e3d749a-6a03-45fb-83ec-12e2a9ba43cb"
      unitRef="U_USD">10000000.0</vir:PaymentToCollaboratorResultingFromProgramOptionExercise>
    <vir:UpfrontFeePaid
      contextRef="C_9b3dd0d6-7971-4035-8623-0c23e6212871"
      decimals="-5"
      id="F_d83f475f-89d1-45dc-8bca-dd078c22de86"
      unitRef="U_USD">10000000.0</vir:UpfrontFeePaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_cd77bc9a-f90c-4d89-9139-053ac79a0a7a"
      decimals="INF"
      id="F_b9206a30-d440-4f71-be49-0f0201f329c1"
      unitRef="U_shares">1111111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vir:ValueOfSharesTransferredToCollaborator
      contextRef="C_808e2ec7-0dc9-49ea-8101-9ff9a724d929"
      decimals="-5"
      id="F_7c448ded-a87f-4723-8f36-fe3ec09a43de"
      unitRef="U_USD">800000</vir:ValueOfSharesTransferredToCollaborator>
    <vir:MaximumSharesToBeIssued
      contextRef="C_808e2ec7-0dc9-49ea-8101-9ff9a724d929"
      decimals="INF"
      id="F_76d3dbea-1125-477a-a2c1-c49c27d8449f"
      unitRef="U_shares">1111111</vir:MaximumSharesToBeIssued>
    <vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory
      contextRef="C_deffe243-ff55-4872-8584-6b06fc133c1a"
      decimals="-5"
      id="F_17b8680d-05bf-4e7a-aaa7-0768e982b62d"
      unitRef="U_USD">190000000.0</vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory>
    <vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory
      contextRef="C_647cf94d-4221-49c6-986a-76edcb5f1c62"
      decimals="-5"
      id="F_4f9fcc03-c8e4-4c18-865c-125727d5e14a"
      unitRef="U_USD">115000000.0</vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory>
    <vir:MaximumAggregateSalesMilestonePayment
      contextRef="C_deffe243-ff55-4872-8584-6b06fc133c1a"
      decimals="-5"
      id="F_ed2c8656-aca2-4584-942b-1114bce44c00"
      unitRef="U_USD">250000000.0</vir:MaximumAggregateSalesMilestonePayment>
    <vir:MaximumSalesMilestonePayment
      contextRef="C_647cf94d-4221-49c6-986a-76edcb5f1c62"
      decimals="-5"
      id="F_e0d031f2-2abc-4988-a773-22c9db6ac475"
      unitRef="U_USD">100000000.0</vir:MaximumSalesMilestonePayment>
    <vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts
      contextRef="C_6a35132f-d773-49ba-9363-edcb9df0bf0b"
      id="F_e8cba8fe-1694-4b27-ad96-db9328f1e338">The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. </vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts>
    <vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts
      contextRef="C_deffe243-ff55-4872-8584-6b06fc133c1a"
      id="F_e650a4f6-d1cc-4578-b1f4-3a7d749249ae">low double-digits to mid-teens</vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts>
    <vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts
      contextRef="C_647cf94d-4221-49c6-986a-76edcb5f1c62"
      id="F_5f85854b-f535-4ed1-a8ae-24a9abd34a7c">high single-digits to the sub-teen double-digits</vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts>
    <vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales
      contextRef="C_63b7f812-9b12-47ea-b2fb-128ab0685b44"
      id="F_bd26761e-6fbc-4970-bf8a-252d3d8fcc50">P10Y</vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales>
    <vir:WrittenNoticePeriodForTerminationOfLicensedProgram
      contextRef="C_9b3dd0d6-7971-4035-8623-0c23e6212871"
      id="F_6b356e14-ef7e-417d-86a1-912989890161">P90D</vir:WrittenNoticePeriodForTerminationOfLicensedProgram>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach
      contextRef="C_9b3dd0d6-7971-4035-8623-0c23e6212871"
      id="F_65bd5e96-fbfa-4dcf-b547-516a5e87a3e2">P60D</vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment
      contextRef="C_9b3dd0d6-7971-4035-8623-0c23e6212871"
      id="F_8e70e402-cb2d-4941-8ff0-dc2837e0c354">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge
      contextRef="C_9b3dd0d6-7971-4035-8623-0c23e6212871"
      id="F_68189944-af1e-4729-b842-ff110e41b283">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_97f0fbad-d4bf-4f2b-8e7f-fa6521b24a9c"
      decimals="-5"
      id="F_5bd91e14-0c0c-4bfe-93ff-a0e7d6d9f147"
      unitRef="U_USD">29200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_46e6f289-d1e5-40dd-8d37-0d010f7d5492"
      decimals="INF"
      id="F_c93b84d5-8039-48d4-81a7-4cc5983f2a9c"
      unitRef="U_shares">1111111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vir:MilestonePaymentsPaid
      contextRef="C_cd77bc9a-f90c-4d89-9139-053ac79a0a7a"
      decimals="-5"
      id="F_33b7e91b-1bae-4261-9bfa-786a39760047"
      unitRef="U_USD">15000000.0</vir:MilestonePaymentsPaid>
    <vir:CollaborationAgreementRelatedCostsAndExpenses
      contextRef="C_63b7f812-9b12-47ea-b2fb-128ab0685b44"
      decimals="-5"
      id="F_80e7f625-ef49-432c-9b85-31d6d3c75c1f"
      unitRef="U_USD">11200000</vir:CollaborationAgreementRelatedCostsAndExpenses>
    <vir:CollaborationAgreementRelatedCostsAndExpenses
      contextRef="C_c10e626c-f383-4183-bf3d-6e3516f85d94"
      decimals="-5"
      id="F_7feeed30-25d8-4ec4-8b42-3a697d09c1f7"
      unitRef="U_USD">18100000</vir:CollaborationAgreementRelatedCostsAndExpenses>
    <vir:MilestonePaymentsPaid
      contextRef="C_2f49ec3e-8e45-4cc0-8b2a-a2462edffcfb"
      decimals="-5"
      id="F_3efeedc1-7eb7-4622-8336-40e3c8c0434d"
      unitRef="U_USD">15000000.0</vir:MilestonePaymentsPaid>
    <vir:PaymentToCollaboratorResultingFromProgramOptionExercise
      contextRef="C_b7032bf3-35f9-44e1-bf55-389c77cec434"
      decimals="-5"
      id="F_a4101d18-67d2-410d-8bda-af7b34519383"
      unitRef="U_USD">10000000.0</vir:PaymentToCollaboratorResultingFromProgramOptionExercise>
    <vir:CollaborationAgreementRelatedCostsAndExpenses
      contextRef="C_3b8fb261-7fe1-496c-8e0b-dba547d8fd42"
      decimals="-5"
      id="F_4f34c200-80fd-47c3-8384-cc8168dda8c2"
      unitRef="U_USD">11500000</vir:CollaborationAgreementRelatedCostsAndExpenses>
    <vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct
      contextRef="C_92381b91-3b42-4fe2-ba53-ec4b175909d8"
      id="F_3a1fa20a-9b5f-487d-bd8c-57c5ec440dbd">high single-digits to mid-teens</vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_92381b91-3b42-4fe2-ba53-ec4b175909d8"
      id="F_2bad9462-ae0e-4c2a-8107-314ac355b5c0">the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days&#x2019; prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within 60 days.</vir:CollaborationAgreementTerminationDescription>
    <vir:UpfrontFeePaid
      contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b"
      decimals="-5"
      id="F_69919cd3-f9c4-4634-8849-d26d2c09c383"
      unitRef="U_USD">300000</vir:UpfrontFeePaid>
    <vir:AnnualLicenseMaintenanceFees
      contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b"
      decimals="-5"
      id="F_3f989048-36d8-4125-9296-cedba8e18366"
      unitRef="U_USD">1000000.0</vir:AnnualLicenseMaintenanceFees>
    <vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones
      contextRef="C_f7c9462b-dcbe-4e0d-ad24-fa03ee7db19f"
      decimals="-5"
      id="F_6ba4bd22-8f01-4d49-804b-2ae6457ed417"
      unitRef="U_USD">80300000</vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones>
    <vir:MaximumNumberOfProductsCoveredAgainstMilestonePayment
      contextRef="C_8a57dade-b465-4a49-be9a-5cb7b24a6ffc"
      decimals="INF"
      id="F_aee6d7dc-4208-4837-8adb-955b3cfaf115"
      unitRef="U_Product">6</vir:MaximumNumberOfProductsCoveredAgainstMilestonePayment>
    <vir:RoyaltyObligationPeriodFromDateOfFirstCommercialSale
      contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b"
      id="F_d5ba91a8-739e-4386-8a38-de24fa1c5feb">P12Y</vir:RoyaltyObligationPeriodFromDateOfFirstCommercialSale>
    <vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement
      contextRef="C_15e3e949-97fb-495d-b1d0-55b62ebddcc8"
      decimals="-5"
      id="F_861e8abd-91a9-4acd-bf6f-952e762cf840"
      unitRef="U_USD">4700000</vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement>
    <vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement
      contextRef="C_079288b4-6cb4-4671-8ab2-600c75753f48"
      decimals="-5"
      id="F_10f8847e-d6e8-4a30-a3c9-7ca20635dba0"
      unitRef="U_USD">1300000</vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement>
    <vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement
      contextRef="C_01417e77-f979-4120-a600-156314a4c210"
      decimals="-5"
      id="F_59160a44-dd25-46d0-8b15-06c7bb38afae"
      unitRef="U_USD">1000000.0</vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b"
      id="F_23df60a9-ce25-4269-9ee0-bbe5a14ddd15">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#x2019; written notice for the Company&#x2019;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#x2019;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement.</vir:CollaborationAgreementTerminationDescription>
    <vir:WrittenNoticePeriodToTerminateAgreementByCompany
      contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b"
      id="F_f7f59d64-a24a-44c5-afde-6f09e41f331b">P60D</vir:WrittenNoticePeriodToTerminateAgreementByCompany>
    <vir:WrittenNoticePeriodToTerminateAgreementByCounterparty
      contextRef="C_c461cceb-35c2-4d66-b92b-6b161fa4bd7b"
      id="F_b331d8d8-e139-40bd-a66f-ba2d4bdc6a6e">P90D</vir:WrittenNoticePeriodToTerminateAgreementByCounterparty>
    <vir:NumberOfAntibodiesToDevelop
      contextRef="C_d1073bf6-3fc5-4a5a-97f0-bbd26559fb5f"
      decimals="INF"
      id="F_8302178c-d62f-4778-86ef-e61a3a8fb9a9"
      unitRef="U_Antibodies">2</vir:NumberOfAntibodiesToDevelop>
    <vir:LicenseAgreementUpfrontPayment
      contextRef="C_d1073bf6-3fc5-4a5a-97f0-bbd26559fb5f"
      decimals="-5"
      id="F_30220f00-8b84-4362-a110-e74fb240db95"
      unitRef="U_USD">10000000.0</vir:LicenseAgreementUpfrontPayment>
    <vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones
      contextRef="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb"
      decimals="INF"
      id="F_4ac0503e-64fa-4ebc-ae0d-bb931a2f47f4"
      unitRef="U_USD">331500000</vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb"
      id="F_761e59d4-2b43-4ee5-a877-4a7c42fdca2e">The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#x2019; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on 60 days&#x2019; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on 30 days&#x2019; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.</vir:CollaborationAgreementTerminationDescription>
    <vir:WrittenNoticePeriodForTerminationOfLicensedProgram
      contextRef="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb"
      id="F_476b5e3e-2be8-4889-b864-df6846303f6c">P120D</vir:WrittenNoticePeriodForTerminationOfLicensedProgram>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach
      contextRef="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb"
      id="F_89148ab4-17df-49b4-889a-95399cbbcc24">P60D</vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges
      contextRef="C_ddb279e0-1bc0-4df6-b3de-335d5f7546cb"
      id="F_41b03840-a3cc-4edb-8d50-9a33321ba87e">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges>
    <vir:MaximumAggregateDevelopmentAndRegulatoryMilestonePayments
      contextRef="C_3a524056-f9aa-4720-b2b3-0ab25f4155a8"
      decimals="-5"
      id="F_3d5d93b2-3387-47e4-8525-b403a6676003"
      unitRef="U_USD">17800000</vir:MaximumAggregateDevelopmentAndRegulatoryMilestonePayments>
    <vir:MaximumAggregateCommercialSalesMilestonePayments
      contextRef="C_3a524056-f9aa-4720-b2b3-0ab25f4155a8"
      decimals="-5"
      id="F_77b8d1d8-1741-43aa-987c-c74cf5f15c56"
      unitRef="U_USD">60000000.0</vir:MaximumAggregateCommercialSalesMilestonePayments>
    <vir:MaximumAggregateMilestonePayments
      contextRef="C_a6f98428-747e-466a-907f-d4b24c98cc45"
      decimals="-5"
      id="F_1bc482d3-ab17-4628-aa78-fcdee82c6bb0"
      unitRef="U_USD">77800000</vir:MaximumAggregateMilestonePayments>
    <vir:MaximumAggregateMilestonePayments
      contextRef="C_6593689d-6c09-413e-8c82-082f1af9b2e3"
      decimals="-5"
      id="F_c62c5888-b394-48a5-915a-14cc315fcacf"
      unitRef="U_USD">77800000</vir:MaximumAggregateMilestonePayments>
    <vir:MaximumAggregateMilestonePayments
      contextRef="C_3a524056-f9aa-4720-b2b3-0ab25f4155a8"
      decimals="-5"
      id="F_bed402a3-0e58-4a51-889c-08835daafc91"
      unitRef="U_USD">155500000</vir:MaximumAggregateMilestonePayments>
    <vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct
      contextRef="C_3a524056-f9aa-4720-b2b3-0ab25f4155a8"
      id="F_2f2a63a0-de64-4e72-a82a-99b8734dd40b">low- to mid-single-digits</vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct>
    <vir:SpecifiedResearchAndDevelopmentExpensesMilestonePayments
      contextRef="C_5271e096-8828-4fdb-8093-e81baf518a38"
      decimals="-5"
      id="F_4edb7cae-d93b-4ca7-ab66-69fb4234a9cf"
      unitRef="U_USD">500000</vir:SpecifiedResearchAndDevelopmentExpensesMilestonePayments>
    <vir:SpecifiedResearchAndDevelopmentExpensesMilestonePayments
      contextRef="C_cb6f51fe-eb87-484b-a6ba-f5a1a6fa73d6"
      decimals="-5"
      id="F_dd1e7cb1-fbd2-49ed-b873-b8f51098361d"
      unitRef="U_USD">300000</vir:SpecifiedResearchAndDevelopmentExpensesMilestonePayments>
    <vir:SpecifiedResearchAndDevelopmentExpensesMilestonePayments
      contextRef="C_0e39b64d-0aec-4926-941a-2eeb4cc3e0c1"
      decimals="-5"
      id="F_f5774112-65fb-464c-958f-968259c79bd8"
      unitRef="U_USD">800000</vir:SpecifiedResearchAndDevelopmentExpensesMilestonePayments>
    <vir:RoyaltiesBasedOnNetSalesOfLicensedProducts
      contextRef="C_9df276b4-bb61-407c-a816-a86f5eb1f323"
      id="F_a75ac003-1aca-45ef-8f00-69315440e502"> mid-single-digits</vir:RoyaltiesBasedOnNetSalesOfLicensedProducts>
    <vir:RoyaltiesPaymentExpirationPeriod
      contextRef="C_9df276b4-bb61-407c-a816-a86f5eb1f323"
      id="F_482cfcb9-c831-41e2-9124-435cf7b57f74">P12Y</vir:RoyaltiesPaymentExpirationPeriod>
    <us-gaap:CostOfRevenue
      contextRef="C_9df276b4-bb61-407c-a816-a86f5eb1f323"
      decimals="-5"
      id="F_47b3968e-b835-4a87-8154-c44d4734069d"
      unitRef="U_USD">52700000</us-gaap:CostOfRevenue>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_e143173f-1c22-40fb-ba0b-999bdcd9677f"
      id="F_e803d627-0d25-40ec-a5e2-96c8bb4e6e91">The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon 60 days&#x2019; written notice. Either party may terminate each agreement for the other party&#x2019;s uncured material breach upon 60 days&#x2019; written notice (or 30 days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon 30 days&#x2019; written notice if any of the Company&#x2019;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.</vir:CollaborationAgreementTerminationDescription>
    <vir:WrittenNoticePeriodForTerminationOfLicensedProgram
      contextRef="C_e143173f-1c22-40fb-ba0b-999bdcd9677f"
      id="F_14f84538-a00c-4d0a-a84a-9bab4891f26b">P60D</vir:WrittenNoticePeriodForTerminationOfLicensedProgram>
    <vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach
      contextRef="C_e143173f-1c22-40fb-ba0b-999bdcd9677f"
      id="F_63329db0-ea5e-4a6b-96b6-7eae3d67c64e">P60D</vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment
      contextRef="C_e143173f-1c22-40fb-ba0b-999bdcd9677f"
      id="F_145c1e86-0ad6-4327-b068-9df3b0bb9e8c">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges
      contextRef="C_e143173f-1c22-40fb-ba0b-999bdcd9677f"
      id="F_6f384fe4-8d22-4f8b-85d2-06c885319351">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_548a961d-7cde-46fd-bcd8-8de54c630202">&lt;div style="display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;8.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance Sheet Components &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.55%;"/&gt;
        &lt;td style="width:1.279%;"/&gt;
        &lt;td style="width:2.132%;"/&gt;
        &lt;td style="width:14.07%;"/&gt;
        &lt;td style="width:1.421%;"/&gt;
        &lt;td style="width:1.279%;"/&gt;
        &lt;td style="width:2.132%;"/&gt;
        &lt;td style="width:13.715%;"/&gt;
        &lt;td style="width:1.421%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;57,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization expenses were &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accrued and Other Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other liabilities consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.825%;"/&gt;
        &lt;td style="width:1.521%;"/&gt;
        &lt;td style="width:2.118%;"/&gt;
        &lt;td style="width:14.895%;"/&gt;
        &lt;td style="width:0.853%;"/&gt;
        &lt;td style="width:1.521%;"/&gt;
        &lt;td style="width:2.118%;"/&gt;
        &lt;td style="width:14.298%;"/&gt;
        &lt;td style="width:0.853%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Milestone payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Excess funds payable under grant agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other professional and consulting expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;236,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_7944e04d-44b4-4213-a300-3ed5b13505a2">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.55%;"/&gt;
        &lt;td style="width:1.279%;"/&gt;
        &lt;td style="width:2.132%;"/&gt;
        &lt;td style="width:14.07%;"/&gt;
        &lt;td style="width:1.421%;"/&gt;
        &lt;td style="width:1.279%;"/&gt;
        &lt;td style="width:2.132%;"/&gt;
        &lt;td style="width:13.715%;"/&gt;
        &lt;td style="width:1.421%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;57,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6e34598c-0a2b-44cb-8608-379e7e560202"
      decimals="-3"
      id="F_676e7135-c20e-4524-9802-0bfc5bd582c5"
      unitRef="U_USD">20012000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c8ddf765-8bda-47c3-81a9-cbdb38c2d9e6"
      decimals="-3"
      id="F_9d41be22-17f3-4feb-a394-5bdc10219e99"
      unitRef="U_USD">16769000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bd868f7f-a86d-4911-a7c7-759ba388c5ee"
      decimals="-3"
      id="F_e45b6f63-a118-4979-ba5f-0101faef6102"
      unitRef="U_USD">1112000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_42be3ce6-3c6d-4c19-ad78-d6bba030babf"
      decimals="-3"
      id="F_10d519c5-438d-44fc-9759-b7f1c12d5450"
      unitRef="U_USD">556000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_05dda014-cb81-49d2-92f9-31d5a59a9ff3"
      decimals="-3"
      id="F_8d10ede1-83b5-43d2-9526-f133aaf038ef"
      unitRef="U_USD">1443000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d49462cf-7289-42fd-ade3-fc506e048127"
      decimals="-3"
      id="F_8b15857d-ff85-4dad-9655-a0827b72c907"
      unitRef="U_USD">1444000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_813ff2ee-1d90-44ea-b0f0-79248d502136"
      decimals="-3"
      id="F_5e213d8b-9b3b-48d7-88c5-16dda159b506"
      unitRef="U_USD">7834000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bbb0d6a6-cb1d-4c13-9791-01f69f5283a1"
      decimals="-3"
      id="F_0e681285-a7f3-4240-9d5e-3c8191ca1f24"
      unitRef="U_USD">7274000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_31279301-58e0-4e0d-beea-e0a2ac9b9cfa"
      decimals="-3"
      id="F_ae8cce4a-5cbe-4569-a111-11f47f721290"
      unitRef="U_USD">26925000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_da7048e3-08ee-4a8f-a9eb-1ecdc468ee9c"
      decimals="-3"
      id="F_b8327701-8b52-40d6-b3ab-529b4bc089bf"
      unitRef="U_USD">1135000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_e58b7ead-4ba3-4d40-b479-e32fd1fab63d"
      unitRef="U_USD">57326000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_f54faedb-5701-4cb3-a608-5adfd76576de"
      unitRef="U_USD">27178000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_1a8ea73e-f115-4602-a154-660349275608"
      unitRef="U_USD">14492000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_90ff0a36-9fa9-4531-92a2-41250aa05f8a"
      unitRef="U_USD">9232000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_b5ecab79-00bf-4110-8963-50c99478856f"
      unitRef="U_USD">42834000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_ffdbf698-f613-4fcd-9969-5baa84fe4bcd"
      unitRef="U_USD">17946000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-5"
      id="F_0e4aebee-23fc-44b3-bd3b-6ef291ef8251"
      unitRef="U_USD">5300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-5"
      id="F_afffadbc-4e60-4c2c-9f11-1ebe968eded9"
      unitRef="U_USD">4400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-5"
      id="F_4a74502d-0101-4ad5-85e7-6662ba09eb1c"
      unitRef="U_USD">3300000</us-gaap:DepreciationDepletionAndAmortization>
    <vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_cba575e3-5f63-46bd-88d2-b5dc385b0a64">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other liabilities consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.825%;"/&gt;
        &lt;td style="width:1.521%;"/&gt;
        &lt;td style="width:2.118%;"/&gt;
        &lt;td style="width:14.895%;"/&gt;
        &lt;td style="width:0.853%;"/&gt;
        &lt;td style="width:1.521%;"/&gt;
        &lt;td style="width:2.118%;"/&gt;
        &lt;td style="width:14.298%;"/&gt;
        &lt;td style="width:0.853%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Milestone payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Excess funds payable under grant agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other professional and consulting expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;236,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock>
    <vir:MilestonePayable
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_345e88fd-f917-475c-afd9-fbe6caf35065"
      unitRef="U_USD">95000000</vir:MilestonePayable>
    <vir:MilestonePayable
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_3e1a0ec1-4a53-4f7f-9f3e-16f627685d59"
      unitRef="U_USD">0</vir:MilestonePayable>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_60dcaa4c-5f80-4a25-ac7f-8cb1d1a0623b"
      unitRef="U_USD">58672000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_5beadb1a-f6fd-4129-afa7-2c546e45f75b"
      unitRef="U_USD">0</us-gaap:AccruedRoyaltiesCurrent>
    <vir:ResearchAndDevelopmentExpensesCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_8c1c1989-2801-4a8c-b455-735e6b65e413"
      unitRef="U_USD">28073000</vir:ResearchAndDevelopmentExpensesCurrent>
    <vir:ResearchAndDevelopmentExpensesCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_a94cbb83-206b-4a61-a28d-08ba2c979c76"
      unitRef="U_USD">49384000</vir:ResearchAndDevelopmentExpensesCurrent>
    <vir:PayrollAndRelatedExpensesCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_4d70fca5-61f6-421d-a4a3-5d857824ea28"
      unitRef="U_USD">29753000</vir:PayrollAndRelatedExpensesCurrent>
    <vir:PayrollAndRelatedExpensesCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_6ec475ed-68ab-40af-96d5-8127b71ba4b3"
      unitRef="U_USD">17060000</vir:PayrollAndRelatedExpensesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_8f02c431-966a-4f04-8454-c1e52763cab5"
      unitRef="U_USD">6217000</us-gaap:AccruedIncomeTaxesCurrent>
    <vir:ExcessFundsPayableUnderGrantAgreementsCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_a9657390-202a-4ef6-b0a2-ea0466684e50"
      unitRef="U_USD">1825000</vir:ExcessFundsPayableUnderGrantAgreementsCurrent>
    <vir:ExcessFundsPayableUnderGrantAgreementsCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_be0f29df-9963-4be1-ba5b-d9abe0f08d89"
      unitRef="U_USD">3467000</vir:ExcessFundsPayableUnderGrantAgreementsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_ecf9ce78-039d-4de2-8a11-a1aa35e42038"
      unitRef="U_USD">3927000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_f698b4e2-9e60-4ffe-84b7-92c771ccf58e"
      unitRef="U_USD">3625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_3fe8c6b9-d1f9-4a2e-b40c-0504c0ba35ac"
      unitRef="U_USD">2791000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_3edb6ad8-d442-41bb-9d99-e62fb727efad"
      unitRef="U_USD">2595000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_7a9dad4a-1c7b-42b0-a879-fce2755edae9"
      unitRef="U_USD">10254000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_45658e8e-bded-483c-8a81-ee46d06b7356"
      unitRef="U_USD">805000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_97a338fd-b0f2-45bf-a412-6a72c937a7dd"
      unitRef="U_USD">236512000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_231f5014-5a71-44ed-a255-7a73d33f2a0d"
      unitRef="U_USD">76936000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_46c37d78-6002-46ae-b89a-69b32f3ae2a7">&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;9.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Lease Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has various operating lease arrangements for office and laboratory spaces located in California, Oregon, Missouri, and Switzerland with contractual lease periods expiring between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2033&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b3ce71d6-2479-49ff-972d-2870edd2f042;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; These renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2021, the Company entered into a new sublease agreement for office and laboratory spaces in Missouri that will expire in December 2028, with no option to renew. Under this sublease arrangement, the Company is entitled to tenant improvement allowance of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;related to the design and construction of certain Company improvements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2021, the Company entered into a lease agreement with the new owner of the building at 1800 Owens Street in San Francisco for the lease of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133,896&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; rentable square feet of office and laboratory space of such building. The Company previously occupied the same premises under a sublease agreement with a sublessor, which sublease was terminated concurrently with the execution of the new lease agreement. Accordingly, the related ROU asset and lease liability under the sublease arrangement were extinguished and the Company recognized a gain of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the consolidated statement of operations for the year ended December 31, 2021. The new lease will expire in December 2033, with no option to renew. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under this lease arrangement, the Company is entitled to tenant improvement allowance of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;related to the design and construction of certain Company improvements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under two of the operating lease arrangements in California and Missouri discussed above, the Co&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;mpany expects to fully utilize the tenant improvement allow&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ance, and therefore, such amount is treated as a lease incentive that is payable to the Company at the lease commencement date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Throughout the term of the lease agreements, the Company is responsible for paying certain operating costs, in addition to rent, such as common area maintenance, taxes, utilities and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and additional information related to operating leases (in thousands, except weighted average amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.535%;"/&gt;
        &lt;td style="width:1.511%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:17.119%;"/&gt;
        &lt;td style="width:2.127%;"/&gt;
        &lt;td style="width:1.263%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:14.773%;"/&gt;
        &lt;td style="width:2.127%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total least cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average incremental borrowing rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The discount rate used to determine the present value of the lease payments is our estimated collateralized incremental borrowing rate, based on the yield curve for the respective lease terms, as we generally cannot determine the interest rate implicit in the leases.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of December 31, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.861%;"/&gt;
        &lt;td style="width:2.038%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:15.855%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;185,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: net tenant improvement allowance yet to be received&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following amounts were recorded in the consolidated balance sheets as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.716%;"/&gt;
        &lt;td style="width:1.581%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:16.938%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.451%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:15.477%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1cc61fe6-ac37-4ae9-8e25-9ed92a418e6e;"&gt;&lt;span style="-sec-ix-hidden:F_a8d2e9b9-02ae-4ff4-bd78-94a2d05ac43a;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;137,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Rent expense under the prior lease accounting standard was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2019.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Manufacturing and Supply Letter Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Letter Agreement, Assignment and Master Services Agreement with Samsung&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On April 9, 2020, the Company and Samsung Biologics Co., Ltd. (&#x201c;Samsung&#x201d;) entered into a binding letter agreement (the &#x201c;Samsung Letter Agreement&#x201d;), under which Samsung will perform process development and manufacturing services for the Company&#x2019;s SARS-CoV-2 antibody program. Under the terms of the Samsung Letter Agreement, the Company had committed to purchase a firm and binding capacity reservation for a specified number of manufacturing slots in 2021 and 2022. The Company was obligated to pay a total of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;362&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for such capacity reservation on a take-or-pay basis regardless of whether such manufacturing slots are utilized by the Company, subject to annual adjustment based on the Korean Consumer Price Index, which also includes certain fees relating to project management and technology transfer. The amounts were to be payable during 2021 and 2022 and invoiced on a per-batch basis, with shortfalls invoiced at the end of the year in which such shortfall occurs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On August 4, 2020, the Company, GlaxoSmithKline Trading Services Limited (&#x201c;GSKTSL&#x201d;) and Samsung entered into an Assignment and Novation Agreement effective as of July 31, 2020 under which the Company assigned and transferred to GSKTSL all of the Company&#x2019;s right, title, and interest in, to and under the Samsung Letter Agreement, and GSKTSL became the Company&#x2019;s successor in interest in and to all of the Company&#x2019;s rights, duties, and obligations in, to and under the Samsung Letter Agreement. On August 4, 2020, GSKTSL entered into a Master Services Agreement with Samsung effective as of July 31, 2020 (the &#x201c;Samsung MSA&#x201d;), thereby superseding the Samsung Letter Agreement, and under which, among other things, Samsung will perform technology transfer, development and manufacturing services for clinical and commercial supply of antibody products under the Company&#x2019;s SARS-CoV-2 antibody program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Letter Agreement, Assignment and Master Services Agreement with WuXi Biologics&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On June 15, 2020, the Company and WuXi Biologics entered into a binding letter of intent (the &#x201c;WuXi Biologics Letter Agreement&#x201d;), under which WuXi Biologics will perform certain development and manufacturing services for the Company&#x2019;s SARS-CoV-2 antibody program. Under the terms of the WuXi Biologics Letter Agreement, the Company had committed to purchase a firm and binding capacity reservation for the manufacture of a specified number of batches of drug substance of the Company&#x2019;s SARS-CoV-2 antibody in 2020 and 2021. In addition, the Company had the right to order an additional specified number of batches of drug substance, provided it makes such election by a specified date in the fourth calendar quarter in 2020. WuXi Biologics is obligated to reserve such manufacturing slots on a non-cancellable basis and will manufacture the agreed number of batches of drug substance per an agreed manufacturing schedule. The Company was obligated to pay a total of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;130.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for such capacity reservation, if all batches are manufactured, inclusive of estimated raw material costs, with between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of the batch production fees owed to WuXi Biologics on a take-or-pay basis regardless of whether such manufacturing slots are utilized by the Company. The amounts were to be payable during 2020 and 2021 and invoiced on a per-batch basis. The SARS-CoV-2 antibody drug substance contemplated to&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;be &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;manufactured per the terms of the WuXi Biologics Letter Agreement will be utilized in connection with progressing the development and commercialization of the SARS-CoV-2 antibody product under the Company&#x2019;s collaboration with GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On August 4, 2020, the Company, GSKTSL and WuXi Biologics entered into an Assignment and Novation Agreement effective as of July 29, 2020 under which the Company assigned and transferred to GSKTSL all of the Company&#x2019;s right, title, and interest in, to and under the WuXi Biologics Letter Agreement, and GSKTSL became the Company&#x2019;s successor in interest in and to all of the Company&#x2019;s rights, duties, and obligations in, to and under the WuXi Biologics Letter Agreement. On August 4, 2020, GSKTSL entered into a non-exclusive Master Services Agreement for Commercial Manufacture of Drug Substance with WuXi Biologics effective as of July 29, 2020 (the &#x201c;WuXi Biologics MSA&#x201d;), thereby superseding the WuXi Biologics Letter Agreement, and pursuant to which, among other things, WuXi Biologics will perform development and manufacturing services for clinical and commercial supply of antibody products under the Company&#x2019;s SARS-CoV-2 antibody program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;GSKTSL entered into the WuXi Biologics MSA and Samsung MSA in connection with the performance of the obligations of the Company and GSK, under the 2020 GSK Agreement. Per the terms of the 2020 GSK Agreement, the Company will continue to be responsible for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the costs under each of the WuXi Biologics MSA and Samsung MSA, and GSK will bear &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of such costs under each of the Samsung MSA and the WuXi Biologics MSA, subject to certain conditions and exceptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Indemnification&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Under such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#x2019;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vir:LeaseArrangementContractualExpirationBeginningYear
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_7b1edd13-0b01-4b71-884f-c9ed43c9eca8">2022</vir:LeaseArrangementContractualExpirationBeginningYear>
    <vir:LeaseArrangementContractualExpirationEndingYear
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_71ab9ab2-1be3-4efc-b2c0-5a502434f400">2033</vir:LeaseArrangementContractualExpirationEndingYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_45601290-fe01-4821-b42f-8e501c367046">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from one to five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_a8765b59-506d-4165-9487-b02bdc930b58"
      id="F_67ac1969-1d7f-4ef7-9488-6193eb03063b">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vir:TenantImprovementAllowanceAggregate
      contextRef="C_b2e6a670-5d82-408a-9795-8749e0878917"
      decimals="-5"
      id="F_4f9bfacd-b3b3-4a8a-877d-a2590c6879b5"
      unitRef="U_USD">14700000</vir:TenantImprovementAllowanceAggregate>
    <us-gaap:NetRentableArea
      contextRef="C_501b75ac-22be-4b07-9759-c03d7aa1ce0b"
      decimals="INF"
      id="F_20331f61-83f7-4ae3-b6b4-b266da372ea5"
      unitRef="U_sqft">133896</us-gaap:NetRentableArea>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-5"
      id="F_dd0a738b-0a4a-4819-b34d-dfb3555ee392"
      unitRef="U_USD">4800000</us-gaap:GainLossOnTerminationOfLease>
    <vir:TenantImprovementAllowanceAggregate
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-5"
      id="F_9d73570a-fd98-43f5-afe6-fa5e95dfea6e"
      unitRef="U_USD">37500000</vir:TenantImprovementAllowanceAggregate>
    <vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_e38db9ee-8e00-40b4-80f0-53bb53a12559">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and additional information related to operating leases (in thousands, except weighted average amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.535%;"/&gt;
        &lt;td style="width:1.511%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:17.119%;"/&gt;
        &lt;td style="width:2.127%;"/&gt;
        &lt;td style="width:1.263%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:14.773%;"/&gt;
        &lt;td style="width:2.127%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total least cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average incremental borrowing rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_1f2f4313-c1a8-4593-9df2-30b419b39b61"
      unitRef="U_USD">11921000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_44e8b0d0-726a-4f2b-90f3-6a0a088a3a01"
      unitRef="U_USD">4591000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_3bc365ec-16ee-4add-99f0-9518f2f737fa"
      unitRef="U_USD">261000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_b0c18e85-1b3a-4b74-be20-720f200f13bb"
      unitRef="U_USD">459000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_5b3b71f1-b17d-4b10-8f7f-45951e1c8751"
      unitRef="U_USD">4256000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_f546f125-1eda-4f85-8866-e77e0ae3a227"
      unitRef="U_USD">2299000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_0e69ef9f-7bbd-439f-acdb-368493c45971"
      unitRef="U_USD">16438000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_03d1c5fd-8800-4ca3-8720-84f9b739cd93"
      unitRef="U_USD">7349000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      id="F_80ab1b58-c186-413b-9bfd-b474af59b3f3">P10Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      id="F_25d378cb-0a0e-48e7-b45b-f199fcef0c5f">P10Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="3"
      id="F_f4644f78-3b9a-494f-ad70-a23091928eb9"
      unitRef="U_pure">0.052</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="3"
      id="F_27ba062d-b796-45ae-acce-b8f725d1c78c"
      unitRef="U_pure">0.077</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_d24c30e4-d488-4086-b96d-a03437de4fb7"
      unitRef="U_USD">6250000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_44800b0a-f35b-4a88-802e-bf13eec4e211"
      unitRef="U_USD">5081000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_f868164f-5a78-4d19-8a08-18cbb222e581"
      unitRef="U_USD">77187000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_166db8a8-d861-4157-8234-ee578acd1cd1"
      unitRef="U_USD">48495000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_ee57452d-2a3a-4b61-8dd3-8559f1cdbab4">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of December 31, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.861%;"/&gt;
        &lt;td style="width:2.038%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:15.855%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;185,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: net tenant improvement allowance yet to be received&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_8e00845f-a617-4aa6-916a-35de30d037f2"
      unitRef="U_USD">12432000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_e107de80-2195-4a16-9ab4-b36728a59883"
      unitRef="U_USD">19082000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_5cfc7ac1-a72f-49e8-bc22-1f226a22591e"
      unitRef="U_USD">18233000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_77aeaabb-95c9-4e98-a6be-59719258e629"
      unitRef="U_USD">15917000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_2da9bb99-320a-4706-94c1-39f68c7b0a69"
      unitRef="U_USD">16353000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_d3a36286-e6d6-41a1-92c8-b7835f8bf199"
      unitRef="U_USD">103413000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_5b2d7a4d-7226-4763-ba9d-7a73ae126b38"
      unitRef="U_USD">185430000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_849f35d4-4725-4706-b868-71b3e5367d70"
      unitRef="U_USD">45261000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <vir:LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_c64c693b-49e7-433c-98f3-088c4f53dabe"
      unitRef="U_USD">52217000</vir:LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived>
    <vir:PresentValueOfOperatingLeaseLiabilities
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_1128731d-125c-481b-82eb-cf66a2c07656"
      unitRef="U_USD">87952000</vir:PresentValueOfOperatingLeaseLiabilities>
    <vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_9f613f67-0010-4d76-b305-daf7b7a4ff7d">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following amounts were recorded in the consolidated balance sheets as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.716%;"/&gt;
        &lt;td style="width:1.581%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:16.938%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.451%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:15.477%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1cc61fe6-ac37-4ae9-8e25-9ed92a418e6e;"&gt;&lt;span style="-sec-ix-hidden:F_a8d2e9b9-02ae-4ff4-bd78-94a2d05ac43a;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;137,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock>
    <vir:OperatingLeaseIncentiveOverLeaseLiabilities
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_b1973014-1cf2-4eca-bc28-be136f876b81"
      unitRef="U_USD">49536000</vir:OperatingLeaseIncentiveOverLeaseLiabilities>
    <vir:OperatingLeaseIncentiveOverLeaseLiabilities
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_c0e4b230-b9af-41e0-b35c-1882aab2805f"
      unitRef="U_USD">7913000</vir:OperatingLeaseIncentiveOverLeaseLiabilities>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_c7d33294-d9e8-4f13-a3a0-dbd40bf9fbba"
      unitRef="U_USD">87220000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_20cf0a67-d83a-4e6e-9d81-c496aaaddf20"
      unitRef="U_USD">61947000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_6bda577f-a682-40db-8893-7dde3b829652"
      unitRef="U_USD">3927000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_2c5c673b-566d-4665-a79e-04257a3b886c"
      unitRef="U_USD">3625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_f73416f0-8ace-4d53-9f34-f42131f8e22f"
      unitRef="U_USD">133561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_addbfa14-bdf1-4135-9584-a8e7a5028cdd"
      unitRef="U_USD">66556000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_c3d09632-076e-4b09-8e6c-affe1c3c4cc8"
      unitRef="U_USD">137488000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_37b1c195-a3fd-4e21-8888-553031a3c4ef"
      unitRef="U_USD">70181000</us-gaap:OperatingLeaseLiability>
    <vir:OperatingAndFinanceRentExpense
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-5"
      id="F_30e3d525-147b-4c90-b884-469bf7da0efd"
      unitRef="U_USD">4400000</vir:OperatingAndFinanceRentExpense>
    <vir:ObligationToPayCapacityReservation
      contextRef="C_dcb52d16-86fa-4370-9fc3-793fe22d8181"
      decimals="-6"
      id="F_48ba9a7e-85aa-446e-9804-888eaf3ec2f7"
      unitRef="U_USD">362000000</vir:ObligationToPayCapacityReservation>
    <vir:ObligationToPayCapacityReservation
      contextRef="C_518a3141-66a8-47ab-978b-8e77ec8e8f30"
      decimals="-5"
      id="F_05730c0c-c62c-4637-9acc-5c2c2c759003"
      unitRef="U_USD">130000000.0</vir:ObligationToPayCapacityReservation>
    <vir:PercentageOfEstimatedBatchProductionFees
      contextRef="C_0ded0a8a-1711-44a2-8906-3b560cb68ef4"
      decimals="INF"
      id="F_e58d1f7b-661c-481f-9e50-2cb0bc41d68e"
      unitRef="U_pure">0.70</vir:PercentageOfEstimatedBatchProductionFees>
    <vir:PercentageOfEstimatedBatchProductionFees
      contextRef="C_cb8cdd31-0bed-4661-832a-fa3a50385e05"
      decimals="INF"
      id="F_c49aae05-f187-4c01-95db-3436dd6ba79a"
      unitRef="U_pure">0.80</vir:PercentageOfEstimatedBatchProductionFees>
    <vir:PercentageOfDevelopmentCosts
      contextRef="C_7b782a32-6679-4004-9be5-e91a7a28b3e9"
      decimals="3"
      id="F_58cb4d1d-e1d0-484d-8db3-c25dbdaa1d86"
      unitRef="U_pure">0.725</vir:PercentageOfDevelopmentCosts>
    <vir:PercentageOfDevelopmentCosts
      contextRef="C_accfab4e-3a9c-48c5-9d0d-b1f80346071b"
      decimals="3"
      id="F_c782a5f8-9f4e-4a3d-bd86-cd525263f957"
      unitRef="U_pure">0.275</vir:PercentageOfDevelopmentCosts>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_a54c853a-4847-4a1b-b58d-28cc030672ef">&lt;div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;10.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Related Party Transactions &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As a result of the Brii Agreement in May 2018, the Company holds a minority equity interest in Brii Bio through its parent company, Brii Bio Parent. At the time when the Company entered into the Brii Agreement, the Company's Chief Executive Officer, or CEO, and another member of the Company's board of directors served on Brii Bio Parent&#x2019;s board of directors. The Company's CEO, who is also a member of the Company's board of directors, resigned from Brii Bio Parent&#x2019;s board of directors in June 2021. As of December 31, 2021, one member of the Company&#x2019;s board of directors still serves on Brii Bio Parent&#x2019;s board of directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2019, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,202,213&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series B convertible preferred stock to existing Series A-1 preferred stockholders. See further discussion in Note 11&#x2014;Convertible Preferred Stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_931f9106-3768-4f05-bd7b-0855dd2f9745"
      decimals="INF"
      id="F_6b9e6aac-351c-4439-927c-0fd10c1bb335"
      unitRef="U_shares">18202213</us-gaap:TemporaryEquitySharesIssued>
    <vir:TemporaryEquityTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_1b7dd2ab-b1f4-4c9c-97e2-1736ad8bdcd7">&lt;div style="display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;11.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Convertible Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to the IPO, under the Company&#x2019;s amended and restated certificate of incorporation, the Company was authorized to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; classes of shares: preferred stock and common stock. The preferred stock was issued in series.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2019, under the Amended A&amp;amp;R Series A-1 and B Purchase Agreement, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,202,213&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series B convertible preferred stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;327.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in two closings. The Company was authorized to sell up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,020,009&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares of Series B convertible preferred stock in one or more additional closings.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon closing of the IPO, all of the outstanding convertible preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88,112,733&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. After the closing of the IPO, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of convertible preferred stock outstanding.&lt;/span&gt;&lt;/p&gt;</vir:TemporaryEquityTextBlock>
    <vir:NumberOfClassOfStock
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="0"
      id="F_c17b0253-15ea-4fc0-abed-f63800b03786"
      unitRef="U_shares">2</vir:NumberOfClassOfStock>
    <vir:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_24859036-8402-474d-a1b9-81a9c9af22a3"
      decimals="INF"
      id="F_a24b83f9-d9c7-42be-a91a-14ac864cb0db"
      unitRef="U_shares">18202213</vir:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_931f9106-3768-4f05-bd7b-0855dd2f9745"
      decimals="INF"
      id="F_5b729878-5e86-4e77-9c4d-979c6eae4f9d"
      unitRef="U_USDollarShare">18.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_24859036-8402-474d-a1b9-81a9c9af22a3"
      decimals="-5"
      id="F_3a0a5ac5-4eb3-4660-810d-c208f6d0cb18"
      unitRef="U_USD">327500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <vir:TemporaryEquityAdditionalSharesAuthorized
      contextRef="C_931f9106-3768-4f05-bd7b-0855dd2f9745"
      decimals="INF"
      id="F_c4bb5c4d-d562-4ca3-8f87-ee58e78735dc"
      unitRef="U_shares">4020009</vir:TemporaryEquityAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_c9443ba3-f289-4712-b80e-f1c93e0123cf"
      decimals="INF"
      id="F_558c8333-7e23-4da5-af34-da359730e727"
      unitRef="U_shares">88112733</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_4723e489-b2c6-419e-a302-89f09c349a7d"
      decimals="INF"
      id="F_3eb7025d-f69b-4b6f-8171-c23aa7edeeb4"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <vir:ConvertiblePreferredStockWarrantLiabilityTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_31467107-e2e8-463f-ba0a-efafc66ed7af">&lt;div style="display:flex;margin-top:18.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;12.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Convertible Preferred Stock Warrant Liability &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2016, the Company issued a warrant to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;244,444&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s Series A-1 convertible preferred stock with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share in connection with the termination of a sponsor research agreement. The warrant was fully vested upon the issuance date and had an expiration date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 11, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The warrant was initially accounted for as a liability and was subject to remeasurement at each reporting period, with changes in estimated fair value recognized as a component of other income (expense), net. Upon the completion of the IPO in October 2019, the warrant automatically converted into a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;244,444&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. Therefore, the convertible preferred stock warrant liability was reclassified to additional paid-in capital. In May 2020, the holder exercised its warrant in a cashless exercise for which the Company issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;211,774&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. &lt;/span&gt;</vir:ConvertiblePreferredStockWarrantLiabilityTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_04e2f054-346c-47c8-89fb-055997c2a180"
      decimals="INF"
      id="F_cda9a86f-dd42-44b9-bab8-39c50f150116"
      unitRef="U_shares">244444</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_04e2f054-346c-47c8-89fb-055997c2a180"
      decimals="2"
      id="F_3e1fca1a-d4d6-4da3-8c6a-03a8c8e2b53a"
      unitRef="U_USDollarShare">4.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_0c0012f8-5960-4879-bdde-f46b368e2ae9"
      id="F_edc1c5ca-b876-4670-b926-efce130f2212">2026-09-11</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_b1374ee0-34e2-4104-bf31-9dd183c22ca3"
      decimals="INF"
      id="F_c7ef9065-3b37-4cfa-8b52-5b343b38f199"
      unitRef="U_shares">244444</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <vir:StockIssuedDuringPeriodWarrantExercised
      contextRef="C_4f17c5a8-e2ce-47e8-9a5f-717bf5afb341"
      decimals="INF"
      id="F_9027ab35-1f41-4e1c-8e6d-06f8954dc512"
      unitRef="U_shares">211774</vir:StockIssuedDuringPeriodWarrantExercised>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_0bc030a5-5ece-4934-a3aa-591d23221b7c">&lt;div style="display:flex;margin-top:18.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;13.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-Based Awards &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2019 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2019, the Company&#x2019;s board of directors adopted, with the approval of its stockholders, the 2019 Equity Incentive Plan (the "2019 Plan") for the issuance of incentive stock options (&#x201c;ISO&#x201d;), non-qualified stock options (&#x201c;NSO&#x201d;), stock appreciation rights (&#x201c;SARs&#x201d;), restricted stock, other stock awards and performance cash awards, to employees, non-employee directors, and consultants. The 2019 Plan became effective concurrent with the IPO.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Awards granted under the 2019 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years from the date of grant. For ISO and NSO, the option price shall not be less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the estimated fair value on the date of grant. Options granted typically vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period but may be granted with different vesting terms. As of December 31, 2021, there are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,092,936&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares available for the Company to grant under the 2019 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2016 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2016, the Company adopted the 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;) for the issuance of ISO, NSO, SARs, restricted stock and other stock awards, to employees, non-employee directors, and consultants under terms and provisions established by the Company&#x2019;s board of directors and approved by the stockholders.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Awards granted under the 2016 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years from the date of grant. For ISO and NSO, the option price shall not be less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the estimated fair value on the date of grant. Options granted typically vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period but may be granted with different vesting terms.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In conjunction with adopting the 2019 Plan, the Company discontinued the 2016 Plan with respect to the new equity awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2019, the Company&#x2019;s board of directors adopted, with the approval of its stockholders, the ESPP. The ESPP became effective on the completion of the Company&#x2019;s IPO.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The ESPP initially authorized the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,280,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock under purchase rights granted to its employees or employees of any of the Company&#x2019;s designated affiliates. The number of shares of the Company&#x2019;s common stock reserved for issuance is subject to an automatic increase at each calendar year. Under the ESPP, the Company may specify offerings with durations of not more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; months and may specify shorter purchase periods within each offering. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of their earnings, subject to any plan limitations. Unless otherwise determined by the Company&#x2019;s board of directors, employees can purchase shares at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the lower of the fair market value of the Company&#x2019;s common stock on the first date of an offering or the purchase date. During the year ended December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65,021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were issued under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Option Activity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Activity under the Company&#x2019;s stock option plans is set forth below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.698%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:0.95%;"/&gt;
        &lt;td style="width:11.429%;"/&gt;
        &lt;td style="width:1.016%;"/&gt;
        &lt;td style="width:1.071%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:9.375%;"/&gt;
        &lt;td style="width:0.751%;"/&gt;
        &lt;td style="width:1.115%;"/&gt;
        &lt;td style="width:0.894%;"/&gt;
        &lt;td style="width:9.728%;"/&gt;
        &lt;td style="width:0.751%;"/&gt;
        &lt;td style="width:1.115%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:10.269%;"/&gt;
        &lt;td style="width:0.751%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,798,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,294,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,622,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,160,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,308,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;160,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,308,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;160,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,238,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the years ended December 31, 2021, 2020, and 2019, the estimated weighted-average grant date fair value of the options granted was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.83&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company expects to recognize the remaining unamortized stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;176.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to stock options, over an estimated weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Options Granted to Employees&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option- pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.483%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:15.338%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:15.338%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:15.338%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term of options (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;112.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;86.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The valuation assumptions for stock options was determined as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Term&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Volatility&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected volatility was determined by examining the historical volatilities for industry peers and using an average of historical volatilities of the Company&#x2019;s industry peers as the Company does not have a sufficient historical trading history for its stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its stock price becomes available.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risk-Free Interest Rate&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Dividend Rate&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Employees Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2021, the Company initiated its first offering period under the ESPP. Each offering period is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, which commences on the grant date on or after June 1 and December 1 of each year and ends on the purchase date on or before November 30 and May 31 of each year.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of employees' purchase rights under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions for the year ended December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.603%;"/&gt;
        &lt;td style="width:2.282%;"/&gt;
        &lt;td style="width:23.115%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term of ESPP (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;144.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.04&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected term of employees&#x2019; purchase rights is equal to the purchase period. The expected volatility was determined based on the Company's historical volatility. The risk-free interest rate is based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant over the expected term of the employees&#x2019; purchase rights. The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future. Based on the Black-Scholes option-pricing model, the estimated weighted-average grant date fair value of the employees' purchase rights granted for the year ended December 31, 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Stock Activity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s RSAs and RSUs were summarized as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.968%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:9.014%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:9.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.994%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.776%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,366,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,271,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;59.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The unvested shares of RSUs have not been included in the shares issued and outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2017, the Company entered into a restricted stock purchase agreement with an executive officer and a restricted stock purchase agreement with a director whereby the executive officer and the director purchased an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,624,355&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of restricted stock. The consideration for the restricted stock was the issuance of promissory notes which were non-recourse in nature and were accounted for as in-substance stock options. In August 2019, per the terms of the notes, the Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as repayment of the outstanding promissory notes and accrued interest. The Company reduced the restricted stock liability as the common stock vests, which was fully vested as of December 31, 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of total unrecognized compensation cost related to unvested restricted stock units, all of which is expected to be recognized over a remaining weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the total stock-based compensation expense for all awards granted to employees and non-employees, including shares sold through the issuance of non-recourse promissory notes of which all the shares are considered to be options for accounting purposes, and the ESPP in the consolidated statements of operations:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.649%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:11.375%;"/&gt;
        &lt;td style="width:0.82%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:11.375%;"/&gt;
        &lt;td style="width:0.82%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:11.039%;"/&gt;
        &lt;td style="width:0.82%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;83,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_8d0a5b8f-a0b0-4322-af0c-fa4c65561bb1"
      id="F_1e704867-a80c-4550-b427-e5aac26146a9">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_b91aebaf-cbdf-4bbc-b802-2169b53b199f"
      decimals="INF"
      id="F_9bf043b5-a09b-4184-82ab-aa19f2f8fb53"
      unitRef="U_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_b91aebaf-cbdf-4bbc-b802-2169b53b199f"
      id="F_07df8ee4-83e2-4c98-af9a-028c4d28afd9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f546f6f3-d48a-486c-8052-617336a81a7c"
      decimals="INF"
      id="F_a761d56e-b43d-4051-b1f0-f2d82200f99b"
      unitRef="U_shares">9092936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_d9c4bdc2-99a7-4b17-b04f-d11af920c552"
      id="F_a12ba7bf-bf4c-4416-8f67-6709c259a23d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0491c773-5dc7-4c46-bec3-e5a5ab07096c"
      decimals="2"
      id="F_f8fc5352-b9de-4e2a-9d91-8036223ecf3e"
      unitRef="U_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0491c773-5dc7-4c46-bec3-e5a5ab07096c"
      id="F_3d1527ce-88e4-44ca-90d5-5c7a49b8a211">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_49d8bcd1-7a7f-42e5-892b-9a0cd8d9902d"
      decimals="INF"
      id="F_05959d48-cee2-46c9-bb2c-f9ffa991a124"
      unitRef="U_shares">1280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <vir:OfferingPeriodEmployeeStockPurchasePlan
      contextRef="C_04d6bf1e-1ec8-4592-84fc-8ca7693ba159"
      id="F_fe5298fb-2090-4be2-8ec0-d358adc24791">P27M</vir:OfferingPeriodEmployeeStockPurchasePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_49d8bcd1-7a7f-42e5-892b-9a0cd8d9902d"
      decimals="INF"
      id="F_b03b5cb5-0d2b-4020-ac9c-61c449c416cf"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_5cbe6ca1-3aef-4d1a-beac-1c5b67ca8ba9"
      decimals="2"
      id="F_89119410-629b-465d-bcc6-0707097fbe56"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e"
      decimals="INF"
      id="F_075cfca8-381d-40ba-b992-8c5a5b5a2c2c"
      unitRef="U_shares">65021</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_8ded4d50-aaa2-4845-be5b-adbb36977c10">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Activity under the Company&#x2019;s stock option plans is set forth below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.698%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:0.95%;"/&gt;
        &lt;td style="width:11.429%;"/&gt;
        &lt;td style="width:1.016%;"/&gt;
        &lt;td style="width:1.071%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:9.375%;"/&gt;
        &lt;td style="width:0.751%;"/&gt;
        &lt;td style="width:1.115%;"/&gt;
        &lt;td style="width:0.894%;"/&gt;
        &lt;td style="width:9.728%;"/&gt;
        &lt;td style="width:0.751%;"/&gt;
        &lt;td style="width:1.115%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:10.269%;"/&gt;
        &lt;td style="width:0.751%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,798,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,294,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,622,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,160,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,308,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;160,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,308,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;160,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,238,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_bb04a465-c3d8-4109-889c-c33e0ccca055"
      decimals="INF"
      id="F_456aabcc-736a-40d9-bb86-023e9ab789ce"
      unitRef="U_shares">9798282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_bb04a465-c3d8-4109-889c-c33e0ccca055"
      decimals="2"
      id="F_452a877c-8c6b-4eef-a375-b76ed6066337"
      unitRef="U_USDollarShare">19.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_1c384113-a0b3-4e9a-b7a6-3c84846d53e8"
      id="F_096ce1ca-4f8b-4345-8743-b27472b042af">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      decimals="INF"
      id="F_53dc37ef-cb84-4be2-91d8-326a6c95ce41"
      unitRef="U_shares">3294000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      decimals="2"
      id="F_f2d62c37-3d04-41d3-b8ba-7474ca5bb808"
      unitRef="U_USDollarShare">58.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      decimals="INF"
      id="F_59a9f1ee-6c8e-43eb-9138-95a9b4c80237"
      unitRef="U_shares">1622718</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      decimals="2"
      id="F_1f211ecb-4524-4289-906d-81c226ede55d"
      unitRef="U_USDollarShare">8.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      decimals="INF"
      id="F_f1cdec29-9530-4b2c-af00-37586a0aa54c"
      unitRef="U_shares">1160636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      decimals="2"
      id="F_17d7a1f0-007c-4041-8e63-749080f38188"
      unitRef="U_USDollarShare">34.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383"
      decimals="INF"
      id="F_fd523523-416f-4740-a088-06536576fe2f"
      unitRef="U_shares">10308928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383"
      decimals="2"
      id="F_bfec424a-d61f-4ebc-9999-b2b151740ff6"
      unitRef="U_USDollarShare">31.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      id="F_95679337-bbb9-429f-88d2-059385f2f593">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383"
      decimals="-3"
      id="F_116d4451-0ac9-4125-8a09-8a466c7b4a80"
      unitRef="U_USD">160378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383"
      decimals="INF"
      id="F_75a3272a-7fa8-4492-8363-5fed5ca442fd"
      unitRef="U_shares">10308928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383"
      decimals="2"
      id="F_803ab477-10d1-4af9-b061-a59177e6f662"
      unitRef="U_USDollarShare">31.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      id="F_36bb5795-f481-4a13-9151-8df357ab2b7d">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383"
      decimals="-3"
      id="F_4673e61c-d99d-4e1c-9a51-4068ace03f9b"
      unitRef="U_USD">160378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383"
      decimals="INF"
      id="F_d11879e0-250e-4360-b0b7-ac7e35783ed8"
      unitRef="U_shares">4238107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383"
      decimals="2"
      id="F_5bc343ac-0c0d-45e4-b185-5e9f80f779b3"
      unitRef="U_USDollarShare">17.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      id="F_7a33d749-2ec1-4fb5-9297-1d2cd8846a04">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383"
      decimals="-3"
      id="F_26983bd7-5064-4121-8e90-b8794937b4f2"
      unitRef="U_USD">105698000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      decimals="-5"
      id="F_51300106-7721-4e87-9153-bbe3f868bbdb"
      unitRef="U_USD">65100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_1c384113-a0b3-4e9a-b7a6-3c84846d53e8"
      decimals="-5"
      id="F_1631ba9d-bb76-4126-ae58-2d2b97883cf9"
      unitRef="U_USD">53100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_9c4a05c0-ab68-4442-bfca-80dd0cb82f0d"
      decimals="-5"
      id="F_e6c717c0-92d6-4900-b8cc-30ffd298689c"
      unitRef="U_USD">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      decimals="2"
      id="F_a4111aad-fed4-4c0b-9995-757b0864506b"
      unitRef="U_USDollarShare">47.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1c384113-a0b3-4e9a-b7a6-3c84846d53e8"
      decimals="2"
      id="F_3ee6cdcb-79b8-45fd-97a6-50568da7d581"
      unitRef="U_USDollarShare">25.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9c4a05c0-ab68-4442-bfca-80dd0cb82f0d"
      decimals="2"
      id="F_e1d2d2a8-0dc1-4c25-8e57-9b9df6b3004f"
      unitRef="U_USDollarShare">7.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_b38fd327-4513-4808-ac50-5d5528a35383"
      decimals="-5"
      id="F_14b4fe26-74e2-4a55-9765-b6de441a9ad5"
      unitRef="U_USD">176400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_7ea779b6-e470-44f4-8cd2-792b82ad5755"
      id="F_d06edc98-1ac4-4db5-9f3f-2cf295b9987b">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_6b6e948f-a5eb-4518-aa13-774a6c1eb38f">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option- pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.483%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:15.338%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:15.338%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:15.338%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term of options (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;112.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;86.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e5046b1c-890a-4d88-9c47-8d81f489b3cf"
      id="F_c13881bb-a37b-41fb-8c73-cfe9f33a202d">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ec04e3a0-91fd-471d-9c5e-a88bcbb1c70d"
      id="F_a0e0750e-e3b7-47bf-b90c-577a955bdf91">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9599deea-454d-4e26-bedc-49ceb4cf2404"
      id="F_3e87d991-79b5-4b24-84e7-0b52b4275735">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c7bf9af0-7a63-47de-aa6e-7c2731d130ef"
      id="F_643dfa4f-7d44-47cc-bb45-b9e2cd90a30a">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0003b2b6-cfb3-4fa2-90d1-98eb440f3fcd"
      id="F_e9d280ec-9809-4d3a-a5db-c264f0d5ecd0">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a5f8399f-ee4b-45a3-a103-6773949f9073"
      id="F_831df72d-8573-459c-952c-bf3735bf67e2">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_0981f8f7-22e2-4a95-a6c0-4ed992769074"
      unitRef="U_pure">1.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_1de20286-44fa-4b62-b754-9a607969ff9d"
      unitRef="U_pure">1.121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_6371b364-d593-4a81-8e53-3db571ba1fcf"
      unitRef="U_pure">0.888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_1abde14c-3b93-4e75-afd8-10fa3d3f3daf"
      unitRef="U_pure">1.086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_caf3db4c-c71b-4bdf-83f8-a5a7898f8f74"
      unitRef="U_pure">0.865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_cb953a47-fc21-4bd3-af3f-4e61abdcea0c"
      unitRef="U_pure">0.894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_bb475237-e055-4988-8d67-d965b01c1600"
      unitRef="U_pure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_da554592-4996-400d-ad09-a1322494f00a"
      unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_e56081d2-31b0-4d51-9beb-2ea081fa5b17"
      unitRef="U_pure">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_fbd94a8a-7bf9-415d-9cd3-f8c4fe2152ab"
      unitRef="U_pure">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_db756dcd-72fe-4bda-8b04-677c56bc3b82"
      unitRef="U_pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_346d6bb5-bc4b-424d-94cd-e169c7b60b73"
      unitRef="U_pure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="2"
      id="F_f62ef879-a759-4495-ab49-455be9a9e394"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="2"
      id="F_d33084d5-9554-4979-88f8-f8fc95c5a73d"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="2"
      id="F_aae3f2db-6ae7-4445-9051-e2ef0f3e64f7"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <vir:OfferingPeriodEmployeeStockPurchasePlan
      contextRef="C_bc4e105a-e463-4014-aae3-86682a1d49a2"
      id="F_71063a7f-5dc9-4ad8-8f12-a1fe5ef35f7a">P6M</vir:OfferingPeriodEmployeeStockPurchasePlan>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_37c02f4a-1490-4a83-a3a2-7fdb4f07fac9">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of employees' purchase rights under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions for the year ended December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.603%;"/&gt;
        &lt;td style="width:2.282%;"/&gt;
        &lt;td style="width:23.115%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term of ESPP (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;144.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.04&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e"
      id="F_c94718a7-a6d3-4320-8816-25af65d908e7">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e"
      decimals="3"
      id="F_a4afd197-ec49-428d-a206-24fff296db42"
      unitRef="U_pure">0.761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e"
      decimals="3"
      id="F_ea416616-8b6c-408d-a7b6-a398a6d27ab8"
      unitRef="U_pure">1.441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e"
      decimals="4"
      id="F_37b653e9-6c25-4c07-8cfc-89cd1e768e1e"
      unitRef="U_pure">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e"
      decimals="3"
      id="F_dbf78b24-17d9-45de-8ca3-a7a2fddf936b"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e"
      decimals="2"
      id="F_56dea096-9b20-4343-b163-3e678492f1e8"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e"
      decimals="2"
      id="F_915fdb7e-d5ae-4da9-b695-571b2df993f3"
      unitRef="U_USDollarShare">19.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_6b98e6d6-09b5-4f64-9252-87ebbfa1ae33">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s RSAs and RSUs were summarized as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.968%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:9.014%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:9.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.994%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:8.776%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,366,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,271,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;59.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_c2a50417-42a1-40be-8caf-f0cebc94ffff"
      decimals="INF"
      id="F_6f347851-95b3-4077-a395-5185a1adfecf"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_7589f598-a536-40ef-ae5d-943416f75b64"
      decimals="INF"
      id="F_b094e072-332d-426f-afb1-460ad1353f54"
      unitRef="U_shares">89261</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_c2a50417-42a1-40be-8caf-f0cebc94ffff"
      decimals="0"
      id="F_71bfab36-bbcd-4414-8ef2-b7ac6e00725e"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_7589f598-a536-40ef-ae5d-943416f75b64"
      decimals="2"
      id="F_32c775cd-ed5f-42b7-a363-4f65838fcd02"
      unitRef="U_USDollarShare">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7"
      decimals="INF"
      id="F_c461ae35-92fa-4344-9402-6e0ee7527f34"
      unitRef="U_shares">1366189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427"
      decimals="INF"
      id="F_31cfb3cb-17e4-4353-80f8-1e0aedb2d274"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7"
      decimals="2"
      id="F_dfa8347c-d41c-4b19-bd13-d04433b285f0"
      unitRef="U_USDollarShare">60.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427"
      decimals="0"
      id="F_94bcb0d8-120d-4e33-b654-24a38de4417b"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7"
      decimals="INF"
      id="F_271c61e9-887a-4276-bacf-7ae9166ed7a7"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427"
      decimals="INF"
      id="F_bff3dd27-e372-4584-99ae-e3403ea2fe71"
      unitRef="U_shares">89261</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7"
      decimals="0"
      id="F_991883e8-f76c-4aa2-bf12-117f61eb7caf"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427"
      decimals="2"
      id="F_bd1ef70e-0a52-4046-b939-214d643e2d75"
      unitRef="U_USDollarShare">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7"
      decimals="INF"
      id="F_215912bd-affd-4f43-aa0c-1417f2b9efac"
      unitRef="U_shares">94855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427"
      decimals="INF"
      id="F_ddcafc55-28c4-4618-bfe4-930beb986955"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_dfc62d0d-b594-4ce9-a437-cfd3baa9f0f7"
      decimals="2"
      id="F_1cc38023-1939-47a6-919c-6012d4f7fc36"
      unitRef="U_USDollarShare">66.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_ad2a2cfc-b340-447d-9eaa-b40190d30427"
      decimals="0"
      id="F_399fb1fa-71a7-48f0-90fd-d05770af4cb6"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_7846e4d7-bd1e-4f8d-ab5e-2c405172b5fe"
      decimals="INF"
      id="F_82a4ad31-b6fa-47a9-bdb2-e08c52809237"
      unitRef="U_shares">1271334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_a27a1fab-d4d1-430e-a2ef-eaaa1ad83180"
      decimals="INF"
      id="F_69ae5598-5db4-4db8-9565-f1abef93343f"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_7846e4d7-bd1e-4f8d-ab5e-2c405172b5fe"
      decimals="2"
      id="F_361c3df7-68ec-4ea4-8f9f-2ce3da66d94a"
      unitRef="U_USDollarShare">59.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_a27a1fab-d4d1-430e-a2ef-eaaa1ad83180"
      decimals="0"
      id="F_943ff216-d6d7-40a0-8d2c-7cef362d26c7"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_7d78f477-8e15-46ec-9ae7-c436d7a5b269"
      decimals="INF"
      id="F_6b0d2287-f288-45a3-8cee-2e18c9b5b049"
      unitRef="U_shares">3624355</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <vir:RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived
      contextRef="C_587ac654-89df-4445-9d73-21454d8c728f"
      decimals="-5"
      id="F_6da09995-7ea2-4d37-a840-003e033728f3"
      unitRef="U_USD">3300000</vir:RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_46ac8ad0-5eff-4cd3-9959-e7aa7afae14f"
      decimals="-5"
      id="F_896d8f58-72c2-4b0d-8a8d-2055933f9c77"
      unitRef="U_USD">61300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0a07820f-763c-4577-b53f-29f5d29d5021"
      id="F_214ac1c2-89b7-4f66-8284-a118ebdacfdf">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_92b73988-9fc3-4ec8-9904-76cb7778b946">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the total stock-based compensation expense for all awards granted to employees and non-employees, including shares sold through the issuance of non-recourse promissory notes of which all the shares are considered to be options for accounting purposes, and the ESPP in the consolidated statements of operations:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.649%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:11.375%;"/&gt;
        &lt;td style="width:0.82%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:11.375%;"/&gt;
        &lt;td style="width:0.82%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:11.039%;"/&gt;
        &lt;td style="width:0.82%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;83,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1a31bf7c-9f6e-4b04-9a96-43549f6f4cc3"
      decimals="-3"
      id="F_eb7406e6-7f7c-4031-8ee7-11ec20a9ad92"
      unitRef="U_USD">42554000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f41d2de0-2ba6-4580-bbfa-01ae990de9ae"
      decimals="-3"
      id="F_b1e0f9ad-a2c6-4ff4-85c3-e72dad6ad38f"
      unitRef="U_USD">13663000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ad98faf6-018f-4435-8e8a-c91df1a4d6c0"
      decimals="-3"
      id="F_d7fd4fd7-5afc-4894-8f28-c8acf4290f40"
      unitRef="U_USD">3034000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bcf35168-3bb5-4a68-9f5c-cf54c4823054"
      decimals="-3"
      id="F_e4f60bb7-e345-4d50-9b14-26a009ec5f52"
      unitRef="U_USD">41230000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9f3bd2b3-b70a-4d36-b772-a1b2c9072a86"
      decimals="-3"
      id="F_2f637cb5-57a6-4cce-a3aa-d03915792004"
      unitRef="U_USD">13937000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f41c076b-5d7a-4003-8cb2-ca3259ad661b"
      decimals="-3"
      id="F_580cfd0f-0c76-41a5-80ba-77b14faad1bb"
      unitRef="U_USD">5685000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_04cd8341-ea6f-4bcd-ac63-09ef8111c2d1"
      unitRef="U_USD">83784000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_08a16d78-e72d-44de-9b0c-2929733009bf"
      unitRef="U_USD">27600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_a03774f0-2ab4-4ac2-a0d9-99a92c33c62e"
      unitRef="U_USD">8719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_e7726bb3-3b89-4aac-bfc7-0dfbd67eeaef">&lt;div style="display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;14.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following is a calculation of the basic and diluted net income (loss) per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.997%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:10.902%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:10.902%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:10.892%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss), basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;528,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;298,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;174,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;129,884,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;119,159,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,349,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average effect of dilutive securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,513,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingently issuable shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133,437,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;119,159,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,349,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.036%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:11.628%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:11.628%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:11.628%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,764,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,798,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,186,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,088,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,075,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;244,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,852,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,887,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,506,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company estimated shares issuable under the ESPP would be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65,967&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; based on expected total contributions from the plan participants and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the stock price at the beginning of the offering period.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_ed76be21-1b7b-4ae5-86e4-d0a227c79ee5">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following is a calculation of the basic and diluted net income (loss) per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.997%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:10.902%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:10.902%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:10.892%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss), basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;528,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;298,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;174,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;129,884,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;119,159,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,349,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average effect of dilutive securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,513,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingently issuable shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133,437,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;119,159,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,349,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_d9feb058-e6f4-4c42-a5b0-5133f9513eec"
      unitRef="U_USD">528584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_16a20fa6-71a8-423d-9fbd-5c96b4828916"
      unitRef="U_USD">-298665000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_bfe26a2b-ab27-4c69-8bb0-79e4c8f7d62f"
      unitRef="U_USD">-174683000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="0"
      id="F_6b2aca7b-6b09-4f72-bb49-81535f5dc015"
      unitRef="U_shares">129884967</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="0"
      id="F_8ce9145b-8553-4d66-9b9e-01caca4136cd"
      unitRef="U_shares">119159424</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="0"
      id="F_df4ef9ee-aa62-4fba-b941-da68f22977c4"
      unitRef="U_shares">30349920</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="0"
      id="F_03240b9a-dfad-45a8-9e3e-7d3481eda604"
      unitRef="U_shares">3513438</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="0"
      id="F_62367585-0fff-4815-86c2-360d6c2b66ab"
      unitRef="U_shares">35488</vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="0"
      id="F_11c21c06-cec7-4c13-af6e-d59be7c82fcf"
      unitRef="U_shares">3233</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="0"
      id="F_42ba86e3-d082-4d40-bc46-e8602a60034a"
      unitRef="U_shares">133437126</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="0"
      id="F_481f3460-fd62-4709-b1ae-1da068064faf"
      unitRef="U_shares">119159424</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="0"
      id="F_27b3bd54-b368-401b-93a9-c41a00be6653"
      unitRef="U_shares">30349920</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="2"
      id="F_ba9a9db7-f5b0-4be4-ad93-5628f2d38780"
      unitRef="U_USDollarShare">4.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="2"
      id="F_6706b92c-ed4a-4f16-94e8-35439d57bf6c"
      unitRef="U_USDollarShare">-2.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="2"
      id="F_e96d0e9d-f0a4-4087-ad5d-3c7dfb9220cd"
      unitRef="U_USDollarShare">-5.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="2"
      id="F_5a5b6ee3-6948-4461-b2b7-66692aa0f229"
      unitRef="U_USDollarShare">3.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="2"
      id="F_8ad6c726-9741-4304-a2de-f9f732a92944"
      unitRef="U_USDollarShare">-2.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="2"
      id="F_7cdd744e-33f6-40d7-99ed-12bb7ffb91d9"
      unitRef="U_USDollarShare">-5.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_d3a88dfb-3f35-423e-9672-631ee387f841">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.036%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:11.628%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:11.628%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:11.628%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,764,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,798,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,186,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,088,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,075,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;244,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,852,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,887,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,506,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_90261ef5-9966-431f-a299-6204c1e9115a"
      decimals="0"
      id="F_d4ff3e23-a589-45fd-a3aa-22b0982bb900"
      unitRef="U_shares">5764308</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_513fcea4-6032-4866-8906-83b5dc316354"
      decimals="INF"
      id="F_791aa1c7-36bb-431f-9651-5dc4c9fe3660"
      unitRef="U_shares">9798282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8a692092-b0fd-48e1-be4e-22e37c497148"
      decimals="INF"
      id="F_f4d1e02a-00a6-49bd-b2e8-9c0fa743c0fd"
      unitRef="U_shares">7186298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5e1d64ed-e161-4d09-a7bd-60b59d474ed8"
      decimals="0"
      id="F_035013cd-5208-4980-afac-efbfb52df19a"
      unitRef="U_shares">1088304</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f134ed1b-0d64-42e6-8b4d-545d2bec9296"
      decimals="INF"
      id="F_5c1982f9-2a6d-4421-b23a-4fcbf3990174"
      unitRef="U_shares">89261</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d3e6496b-39fc-4dee-953c-9b3b230bf6cb"
      decimals="INF"
      id="F_534d26be-2b29-49ef-bad7-29e2beacfb0d"
      unitRef="U_shares">2075511</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8d74b360-ce4a-44f2-9de1-d605ea9e3611"
      decimals="INF"
      id="F_cb9d7a39-6b82-46d9-b0ac-cc0d68b67948"
      unitRef="U_shares">244444</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="0"
      id="F_1b21d8ad-1f5a-4481-b72c-45f3a0c00075"
      unitRef="U_shares">6852612</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="INF"
      id="F_4a75ac93-b1a1-46d6-8998-33724a07c0ad"
      unitRef="U_shares">9887543</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="INF"
      id="F_1307bb73-218d-44c5-acf6-bc81e8c3aba8"
      unitRef="U_shares">9506253</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <vir:EstimatedSharesEmployeeStockPurchasePlans
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="0"
      id="F_3c5a6ed5-7f11-4ea6-aabe-7166a20ee1f3"
      unitRef="U_shares">65967</vir:EstimatedSharesEmployeeStockPurchasePlans>
    <vir:EsppDiscountedPurchasePricePercentage
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="2"
      id="F_040d3dea-cf07-4721-a9dd-ce7e318b0020"
      unitRef="U_pure">0.85</vir:EsppDiscountedPurchasePricePercentage>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_6996b93c-1f71-4f68-9e8e-9c44c3b69994">&lt;div style="display:flex;margin-top:18.0pt;line-height:1.0110416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;15.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Defined Contribution Plan &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2017, the Company began to sponsor a 401(k) retirement savings plan for the benefit of its employees. Eligible employees may contribute a percentage of their compensation to this plan, subject to statutory limitations. The Company made contributions to the plan for eligible participants, and recorded contribution expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-5"
      id="F_b31bfcb9-5d6f-455c-b8c8-563a1d2eac34"
      unitRef="U_USD">2700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-5"
      id="F_2a10e2eb-634e-4f2e-bafa-263c300bdc49"
      unitRef="U_USD">1800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-5"
      id="F_0c643b90-e5e5-4a3a-ad38-651113dba098"
      unitRef="U_USD">1200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_3266b92c-e231-4b62-8823-c03640c63ad5">&lt;div style="display:flex;margin-top:8.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;16.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Income (loss) before provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.829%;"/&gt;
        &lt;td style="width:1.144%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:11.563%;"/&gt;
        &lt;td style="width:0.746%;"/&gt;
        &lt;td style="width:1.144%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:11.824%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
        &lt;td style="width:1.144%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:11.886%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;535,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;309,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;138,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total income (loss) before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;549,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;298,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;174,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of income tax expense consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.868%;"/&gt;
        &lt;td style="width:1.976%;"/&gt;
        &lt;td style="width:1.802%;"/&gt;
        &lt;td style="width:17.004%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.976%;"/&gt;
        &lt;td style="width:1.802%;"/&gt;
        &lt;td style="width:15.935%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.976%;"/&gt;
        &lt;td style="width:1.802%;"/&gt;
        &lt;td style="width:16.109%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation between the expected income tax provision at the federal statutory rate and the reported income tax expense is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.674%;"/&gt;
        &lt;td style="width:1.641%;"/&gt;
        &lt;td style="width:0.746%;"/&gt;
        &lt;td style="width:13.249%;"/&gt;
        &lt;td style="width:2.946%;"/&gt;
        &lt;td style="width:1.641%;"/&gt;
        &lt;td style="width:0.746%;"/&gt;
        &lt;td style="width:13.249%;"/&gt;
        &lt;td style="width:2.946%;"/&gt;
        &lt;td style="width:1.641%;"/&gt;
        &lt;td style="width:0.746%;"/&gt;
        &lt;td style="width:12.652%;"/&gt;
        &lt;td style="width:4.126%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign tax at less than federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior year tax rate adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The tax effects of temporary differences that give rise to significant portions of the Company&#x2019;s deferred tax assets and liabilities as of December 31, 2021 and 2020, are related to the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.521%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:16.66%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:17.046%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;117,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development tax credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity compensations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reserves and accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;183,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unrealized gain on investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;159,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Although t&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;he Company has taxable income for the year ended December 31, 2021, it has otherwise incurred accumulated tax losses since inception. Based on the available objective evidence, the Company cannot conclude it is more likely than not that the net deferred tax assets will be fully realizable.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Accordingly, the Company has provided a valuation allowance against its net deferred tax assets. For the year ended December 31, 2021, the Company recorded a valuation allowance release of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;114.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, based on the estimated 2021 taxable income. For the years ended December 31, 2020 and 2019, the valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. As of December 31, 2021, the Company has net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for federal purposes and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;126.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for state tax purposes. If not utilized, these carryforwards will begin expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for federal and in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2031&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for state tax purposes. The federal net operating losses generated after December 31, 2017, have an infinite carryforward period and subject to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% deduction limitation based upon pre-NOL deduction taxable income. As of December 31, 2021, the Company also has net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for Australian tax purposes, which has an infinite carryforward period, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; net operating loss carryforward for Swiss tax purposes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Tax Reform Act of 1986, the amounts of and benefits from net operating loss carryforwards may be impaired or limited in certain circumstances. Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The Company completed its Section 382 analysis as of December 31, 2021 and based on this analysis, it does not expect that the annual limitations will significantly impact its ability to utilize its net operating loss or tax credit carryforwards prior to expiration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company has research tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for federal and state tax purposes, respectively. If not utilized, the federal carryforward will expire in various amounts beginning in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The California credits can be carried forward indefinitely. To the extent they were not utilized, Oregon carryforward began expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax Cuts and Jobs Act of 2017&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; subjects a U.S. shareholder to current tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Staff Q&amp;amp;A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, the Company had an unrecognized tax benefit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, related to transfer pricing and research and development tax credits. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; amount of unrecognized tax benefits as of December 31, 2021, if recognized, would reduce the Company&#x2019;s effective tax rate because the benefits would be in the form of net operating loss and tax credit carryforwards, which would attract a full valuation allowance. There are no provisions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date. Because the statute of limitations does not expire until after the net operating loss and credit carryforwards are actually used, the statutes are still open on calendar years ending December 31, 2017 forward for federal and state purposes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t recognize any expense for interest and penalties related to uncertain tax positions during 2021, 2020 and 2019, and the Company does &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have any amounts related to interest and penalties accrued at December 31, 2021. The Company files U.S. federal, state, Switzerland and Australia tax returns. The Company&#x2019;s tax years remain open for all years. As of December 31, 2021, the Company was not under examination by the Internal Revenue Service or any state or foreign tax jurisdiction.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the beginning and ending amounts of the liability for uncertain tax positions is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.204%;"/&gt;
        &lt;td style="width:1.182%;"/&gt;
        &lt;td style="width:1.791%;"/&gt;
        &lt;td style="width:10.995%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
        &lt;td style="width:1.182%;"/&gt;
        &lt;td style="width:1.791%;"/&gt;
        &lt;td style="width:10.995%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
        &lt;td style="width:1.182%;"/&gt;
        &lt;td style="width:1.791%;"/&gt;
        &lt;td style="width:11.306%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross unrecognized tax benefits at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Addition for tax positions taken in the prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b156a61b-ab05-4999-91a0-ada076026c19;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reduction for tax positions taken in the prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Addition for tax positions taken in current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross unrecognized tax benefits at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_ed18daa4-6ccd-43b1-ab3c-e46abc43c685">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Income (loss) before provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.829%;"/&gt;
        &lt;td style="width:1.144%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:11.563%;"/&gt;
        &lt;td style="width:0.746%;"/&gt;
        &lt;td style="width:1.144%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:11.824%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
        &lt;td style="width:1.144%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:11.886%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;535,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;309,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;138,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total income (loss) before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;549,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;298,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;174,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_6ffd4174-d018-4a2e-8a4f-c3b49607762d"
      unitRef="U_USD">535989000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_1c0d1bc3-f52c-4fb2-a3a0-06a54cef9477"
      unitRef="U_USD">-309697000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_cb253f1b-6617-4561-8225-b74d17e1c445"
      unitRef="U_USD">-138724000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_2801dda2-2967-491f-b07f-bb9e2657fc47"
      unitRef="U_USD">13813000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_e17a1362-de43-400d-b920-09fdcb303b76"
      unitRef="U_USD">11086000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_f347c8d5-2d64-42e7-a0bd-1aa7cc9eee90"
      unitRef="U_USD">-35805000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_1bd734f5-c791-4316-a6a6-5f9b1475028c"
      unitRef="U_USD">549802000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_aa958f58-96b6-4715-86e0-bcf0ad1cf6fa"
      unitRef="U_USD">-298611000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_244d7f35-9cc5-4798-ad73-1ead5bd03606"
      unitRef="U_USD">-174529000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_41529a92-aace-46d9-906f-afce95de93e2">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of income tax expense consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.868%;"/&gt;
        &lt;td style="width:1.976%;"/&gt;
        &lt;td style="width:1.802%;"/&gt;
        &lt;td style="width:17.004%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.976%;"/&gt;
        &lt;td style="width:1.802%;"/&gt;
        &lt;td style="width:15.935%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:1.976%;"/&gt;
        &lt;td style="width:1.802%;"/&gt;
        &lt;td style="width:16.109%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_98db6041-aea2-431f-9c70-1aef00d9e01a"
      unitRef="U_USD">3526000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_ce6f1fd1-3481-407c-83bc-b922c504abc2"
      unitRef="U_USD">105000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_e9e9ed32-9d8b-412c-b952-9ec302a2cbd2"
      unitRef="U_USD">2401000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_85a3140c-3f74-4fa6-8952-684e1f17a764"
      unitRef="U_USD">106000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_2f4ea125-9a84-4cc3-a8d6-f819b7528b13"
      unitRef="U_USD">154000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_3c2ea66d-3593-442c-a651-24327c7566d2"
      unitRef="U_USD">6032000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_f50d0ffa-3e85-4530-85a7-43c1366346de"
      unitRef="U_USD">106000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_4f2d495c-90bb-48a9-adbb-be1e19f4febc"
      unitRef="U_USD">154000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_c1d35e6e-a40d-48ec-8191-9dd26fd264f3"
      unitRef="U_USD">15186000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_f6c48f28-adc7-4105-9bd1-59e725632d52"
      unitRef="U_USD">-21000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_06794b66-6a46-4cc9-af09-0bc9a26b3b1b"
      unitRef="U_USD">-31000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_961ce5f8-74f4-41fb-b9a1-f13d80416479"
      unitRef="U_USD">15186000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_683c5de1-49f4-4e24-943e-f2591f35e47a"
      unitRef="U_USD">-52000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_05491fff-c876-4b90-88d4-d104bc0e2cda"
      unitRef="U_USD">21218000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_4ca96938-8f7a-4972-81d8-f5a311d6e12e"
      unitRef="U_USD">54000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_58678eb5-148d-4462-881c-80b0643de1ea"
      unitRef="U_USD">154000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_59c6cedb-82a2-47f0-a873-11742faba526">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation between the expected income tax provision at the federal statutory rate and the reported income tax expense is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.674%;"/&gt;
        &lt;td style="width:1.641%;"/&gt;
        &lt;td style="width:0.746%;"/&gt;
        &lt;td style="width:13.249%;"/&gt;
        &lt;td style="width:2.946%;"/&gt;
        &lt;td style="width:1.641%;"/&gt;
        &lt;td style="width:0.746%;"/&gt;
        &lt;td style="width:13.249%;"/&gt;
        &lt;td style="width:2.946%;"/&gt;
        &lt;td style="width:1.641%;"/&gt;
        &lt;td style="width:0.746%;"/&gt;
        &lt;td style="width:12.652%;"/&gt;
        &lt;td style="width:4.126%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign tax at less than federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior year tax rate adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_7da042f6-5713-4c06-916a-b1b108e00f2a"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="INF"
      id="F_585afd9f-c7c4-4c90-ad5b-149decf8c172"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="INF"
      id="F_fef30342-66b3-4c38-9ee6-c8fe3e6ed304"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_a1dd1198-5548-4979-abd6-a8c285f7be14"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_8d4def0f-3525-4aca-a399-e9d80700774d"
      unitRef="U_pure">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_77a2593a-8b65-4800-97d1-97f28d8a54b5"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_638e141b-f515-4c5a-adcb-2e787ff3c611"
      unitRef="U_pure">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_32bc0e03-bc5b-4121-a27f-3e6755b48613"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_9ee131e8-3ca7-4ec8-9a0b-d4bada1cba3f"
      unitRef="U_pure">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_5f770eb6-1c6b-4672-b016-82b5ec4eaab9"
      unitRef="U_pure">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_2e79d1a0-5c74-460a-8842-16d63b8749da"
      unitRef="U_pure">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_a0919172-aa30-4ffc-b25c-958ff7f93731"
      unitRef="U_pure">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_eb275e9d-18ee-4cfa-9b41-40b84c4bde01"
      unitRef="U_pure">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_5ab0ed63-fabb-4eeb-83bf-9db1334a2a28"
      unitRef="U_pure">0.018</vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent>
    <vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_da2befe2-ba4d-43bf-9b8f-5699b7ca00e7"
      unitRef="U_pure">0.013</vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent>
    <vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_6d5e8d27-5248-4f00-a020-f4c431dd6d69"
      unitRef="U_pure">-0.008</vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_f2905625-f57f-41e5-8027-32261672cc8f"
      unitRef="U_pure">-0.179</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_69878f41-9f89-4221-81a0-2fdfbe592e19"
      unitRef="U_pure">-0.253</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_3848315b-9149-4b34-89e8-0c3775eb8f6a"
      unitRef="U_pure">-0.243</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_f9c2633d-aa9d-4b78-b3a5-ef40b7e584ab"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_b74df50f-79be-4e10-898f-c6d29e9e6f83"
      unitRef="U_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_ac665075-71c0-4f41-8a1d-f7f36a740116"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="3"
      id="F_cf3f8610-cec5-4fd9-aa5f-66cf207e99b4"
      unitRef="U_pure">0.039</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="3"
      id="F_5753f246-554c-4bc9-9e77-5b388b62359e"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="3"
      id="F_7ca5c2d7-e9d5-457d-a231-f163030204b8"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_3932c2e5-215a-4e64-abc2-7ec60d8e41cb">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The tax effects of temporary differences that give rise to significant portions of the Company&#x2019;s deferred tax assets and liabilities as of December 31, 2021 and 2020, are related to the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.521%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:16.66%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.778%;"/&gt;
        &lt;td style="width:17.046%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;117,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development tax credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity compensations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reserves and accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;183,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unrealized gain on investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;159,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Although t&lt;/span&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_982b4d1d-7468-4a0f-94a9-15d5b51f619a"
      unitRef="U_USD">15030000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_41833b55-e8f8-4378-b26c-a3ad8e490873"
      unitRef="U_USD">117433000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_4119d04f-ed1b-4ce5-8e43-0ecc6eb6dafd"
      unitRef="U_USD">11375000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_e2bc34fa-997e-437a-94f1-91ba5998b5f9"
      unitRef="U_USD">12246000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_d9266b74-8749-40a0-9412-506c9c306f4c"
      unitRef="U_USD">15065000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_eb5294c1-d6dd-4212-9bbf-46ca8d5acb0a"
      unitRef="U_USD">4193000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_bb5a3639-cb3c-4d5e-92a4-9481ce5fe388"
      unitRef="U_USD">7115000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_fe97dde3-c7f7-4fc0-a7f0-e67632ca72de"
      unitRef="U_USD">10804000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <vir:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_55cac19f-3137-43a5-ade1-4da501770d08"
      unitRef="U_USD">28612000</vir:DeferredTaxAssetsLeaseLiabilities>
    <vir:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_8f6606f7-3503-4b21-a10d-2a6df0e3a858"
      unitRef="U_USD">16184000</vir:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_7da1de7a-2605-446b-910c-689bc5e11e4c"
      unitRef="U_USD">19657000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_66238d51-e55f-4a64-aa92-8ee2b2351e96"
      unitRef="U_USD">23006000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_b590a476-f236-444b-85f7-6fb84acf4af6"
      unitRef="U_USD">96854000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_1bbc5cba-75a8-46a4-b686-4facdc15fca1"
      unitRef="U_USD">183866000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_709b78a5-c3dc-419e-87d3-e88e4eb8f8e5"
      unitRef="U_USD">30170000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <vir:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_7a9b74ea-f5c9-4f2e-8b71-c07ef34bdabf"
      unitRef="U_USD">-28483000</vir:DeferredTaxLiabilitiesRightOfUseAssets>
    <vir:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_306e47a6-c834-4989-a1f1-deb863487bde"
      unitRef="U_USD">-16147000</vir:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_dd0fefd3-7d31-41ed-873e-72e83ae50510"
      unitRef="U_USD">2422000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_c89fb6ac-5f48-436a-be70-b4d3a0031308"
      unitRef="U_USD">2570000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_1b52b0cc-0329-464c-bbe1-acd85c1eec4b"
      unitRef="U_USD">-8511000</vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment>
    <vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_777bb395-72bc-4df8-9aef-83c1fb270c5a"
      unitRef="U_USD">-8511000</vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_7ac65b02-e392-487e-bd9f-3c3ca7543435"
      unitRef="U_USD">69586000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_93489623-49e4-4250-8100-4d59f20a481b"
      unitRef="U_USD">27228000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_1dfd22de-cbcd-482d-8ee1-6b3ad73e419b"
      unitRef="U_USD">45707000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_a01abf43-c82b-42cc-a59b-dc3d8fb5e6ef"
      unitRef="U_USD">159891000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_c5e37c2c-63b2-4d1e-8c2a-916034f9bdb3"
      unitRef="U_USD">18439000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_c69bbc64-c3c7-4ad0-98e7-d050c9951a94"
      unitRef="U_USD">3253000</us-gaap:DeferredTaxLiabilities>
    <vir:ReleaseOfValuationAllowanceDeferredTaxInAmount
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-5"
      id="F_6b54a45c-8a1e-47a6-880e-b8fa118353c9"
      unitRef="U_USD">114200000</vir:ReleaseOfValuationAllowanceDeferredTaxInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-5"
      id="F_dcdf6b46-58f5-4ce6-b71a-3d5f409f9cd6"
      unitRef="U_USD">74100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-5"
      id="F_c299767b-e7b8-4e17-9df9-ee24a5321fe9"
      unitRef="U_USD">42300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6095766d-f048-4375-875a-769201aac419"
      decimals="-5"
      id="F_4bb22ea7-de97-4488-a37b-d0411d2572d2"
      unitRef="U_USD">24200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_953e43a8-2a7e-48ad-a529-e63d37ac462c"
      decimals="-5"
      id="F_c0786420-32d6-4709-9ed4-6c2d9b19c9ca"
      unitRef="U_USD">126600000</us-gaap:OperatingLossCarryforwards>
    <vir:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_bb786dd2-2f22-47d4-9e9e-9a488bff4ab9"
      id="F_0926750a-00a7-4ed5-96e8-45b50cb5a3cb">2035</vir:OperatingLossCarryforwardsExpirationBeginningYear>
    <vir:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_a145aeb5-af85-4ad6-ba29-68511bbc994c"
      id="F_2f152c85-f25f-4b58-8aca-0778e50b8994">2031</vir:OperatingLossCarryforwardsExpirationBeginningYear>
    <vir:OperatingLossCarryforwardsLimitationOnUsePercentage
      contextRef="C_bb786dd2-2f22-47d4-9e9e-9a488bff4ab9"
      decimals="2"
      id="F_e37c6596-a612-40f2-ae8a-9f2ca6eddd28"
      unitRef="U_pure">0.80</vir:OperatingLossCarryforwardsLimitationOnUsePercentage>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ffe17dae-8660-4c99-8aab-15f3d99a9a63"
      decimals="-5"
      id="F_0734977e-5b4d-41f2-8c56-f92c187606b1"
      unitRef="U_USD">5400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_5ce5cca5-d328-4861-8f28-b94590239275"
      decimals="INF"
      id="F_6f4c61e8-f565-4898-a070-4aedd19c2794"
      unitRef="U_USD">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6095766d-f048-4375-875a-769201aac419"
      decimals="-5"
      id="F_ef71cdf3-4032-4f60-a4e3-30b2804fc756"
      unitRef="U_USD">6000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_953e43a8-2a7e-48ad-a529-e63d37ac462c"
      decimals="-5"
      id="F_f9229a67-879a-484d-99c6-f874d8645591"
      unitRef="U_USD">11000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <vir:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_8d214461-dd67-46fd-97ae-535ac3188674"
      id="F_97154365-7b2c-4417-b6e3-e3214e3332bc">2036</vir:OperatingLossCarryforwardsExpirationBeginningYear>
    <vir:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_547d334c-565b-45aa-a31d-cf0b5ec40a45"
      id="F_565a5721-691b-4e07-8073-6e849ac7e363">2022</vir:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-5"
      id="F_02d8658a-c0ef-4abe-a79c-40d7c19be4ac"
      unitRef="U_USD">7400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-5"
      id="F_c37f3e1b-1f43-481e-877a-fb9619cef4bf"
      unitRef="U_USD">4900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="INF"
      id="F_a1dc6308-589b-4aff-a879-43a7a9b0f4af"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="INF"
      id="F_308c65bb-68e4-4240-95fd-171c5bc18dd9"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="INF"
      id="F_5b3a59e6-d8e4-4323-8a73-f91d07bed816"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579"
      decimals="INF"
      id="F_0cbaf0a8-a7bf-454a-a2f9-4c342c4e8be6"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="INF"
      id="F_1f57f042-76c8-4dbc-a849-b2ad796d9ba4"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_aaa0224f-b0c9-4abb-8b64-47daa14f1614">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the beginning and ending amounts of the liability for uncertain tax positions is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.204%;"/&gt;
        &lt;td style="width:1.182%;"/&gt;
        &lt;td style="width:1.791%;"/&gt;
        &lt;td style="width:10.995%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
        &lt;td style="width:1.182%;"/&gt;
        &lt;td style="width:1.791%;"/&gt;
        &lt;td style="width:10.995%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
        &lt;td style="width:1.182%;"/&gt;
        &lt;td style="width:1.791%;"/&gt;
        &lt;td style="width:11.306%;"/&gt;
        &lt;td style="width:1.194%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross unrecognized tax benefits at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Addition for tax positions taken in the prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b156a61b-ab05-4999-91a0-ada076026c19;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reduction for tax positions taken in the prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Addition for tax positions taken in current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross unrecognized tax benefits at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_9d8977ee-722b-4856-9057-3c17c1875c5e"
      unitRef="U_USD">4877000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579"
      decimals="-3"
      id="F_b0d5edc7-a99b-4f17-8a8e-7cbfe71598a9"
      unitRef="U_USD">2725000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_88183c78-6814-4146-96c6-0cba18d5611c"
      decimals="-3"
      id="F_5415a072-2365-49d4-af4a-0f3007f9a002"
      unitRef="U_USD">2404000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_02a934a7-2af6-4749-be52-f3daf6326a1e"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_8c227681-25fe-4f08-8679-8af3a8fdb372"
      unitRef="U_USD">133000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_4de4d5c4-d61a-4341-894a-b2b026622618"
      unitRef="U_USD">62000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_7e9bb1ec-b9ae-41d1-91f8-e50d8e01b7fe"
      unitRef="U_USD">588000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_ff81bc26-1065-4b34-9155-f0e07a3b9a37"
      unitRef="U_USD">1596000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      decimals="-3"
      id="F_0e3f4782-b0a9-43ae-b97f-fa17b1be1ffd"
      unitRef="U_USD">2607000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_69329fa9-5ba5-4337-a561-386bfedc0568"
      decimals="-3"
      id="F_db517ef2-30fe-4d60-baf7-17bc23403b4d"
      unitRef="U_USD">2740000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_1c598293-0936-4d1f-99f5-0722e4f7437e"
      decimals="-3"
      id="F_07d0b0f1-8403-46b1-b093-539963c40fce"
      unitRef="U_USD">1784000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_68d98f4f-0d83-475e-8b52-0b892db80670"
      decimals="-3"
      id="F_84765d19-b7a7-4a0c-8b39-9a8c3e55e819"
      unitRef="U_USD">7422000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4d962b66-b38e-4b66-95b7-9a327531b9c9"
      decimals="-3"
      id="F_8a758b15-ed82-4acf-9c86-620fc49887bb"
      unitRef="U_USD">4877000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_374d06f8-fb5c-49ef-9129-8079100e5579"
      decimals="-3"
      id="F_32a15f19-f2c7-49e2-926f-82558f5329f8"
      unitRef="U_USD">2725000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_0125c984-0483-44b4-9fe9-ea8280d5aef7"
      id="F_80250db0-ca68-4f7f-b8e0-b6f27c47a10a">&lt;div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;17.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Subsequent Event &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Amended and Restated Letter Agreement with the Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2022, the Company e&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ntered into an amended and restated letter agreement with the Bill &amp;amp; Melinda Gates Foundation, which amended and restated the letter agreement with the Bill &amp;amp; Melinda Gates Foundation that was entered into in December 2016 (the "Gates Agreement"), to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;include the advancement of innovative platform technologies in the development of broadly neutralizing antibodies designed to provide a "vaccinal effect" for the treatment of HIV and prevention of malaria&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Under the Gates Agreement, in January 2022, the Bill &amp;amp; Melinda Gates Foundation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;881,365&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company's common stock with total value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and made a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million grant to the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <vir:StockIssuedGrantAgreement
      contextRef="C_1ad51e18-a052-4618-9f7f-dd217928f54d"
      decimals="0"
      id="F_b07c5ab6-14fc-4c5c-befd-3fe455348de0"
      unitRef="U_shares">881365</vir:StockIssuedGrantAgreement>
    <vir:ValueStockIssuedGrantAgreement
      contextRef="C_1ad51e18-a052-4618-9f7f-dd217928f54d"
      decimals="-5"
      id="F_24ca4c15-4115-4aea-ad4a-12fb4e013e32"
      unitRef="U_USD">40000000.0</vir:ValueStockIssuedGrantAgreement>
    <vir:CashGrantAwarded
      contextRef="C_1ad51e18-a052-4618-9f7f-dd217928f54d"
      decimals="-5"
      id="F_70ab7333-c95b-4bd2-8d66-f8ae057a0f61"
      unitRef="U_USD">10000000.0</vir:CashGrantAwarded>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_b1973014-1cf2-4eca-bc28-be136f876b81"
          xlink:label="F_b1973014-1cf2-4eca-bc28-be136f876b81"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c0e4b230-b9af-41e0-b35c-1882aab2805f"
          xlink:label="F_c0e4b230-b9af-41e0-b35c-1882aab2805f"
          xlink:type="locator"/>
        <link:footnote id="FNT_76d6ccb1-4db9-4ff8-9bba-9b4948c6b0ce" xlink:label="FNT_76d6ccb1-4db9-4ff8-9bba-9b4948c6b0ce" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b1973014-1cf2-4eca-bc28-be136f876b81"
          xlink:to="FNT_76d6ccb1-4db9-4ff8-9bba-9b4948c6b0ce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c0e4b230-b9af-41e0-b35c-1882aab2805f"
          xlink:to="FNT_76d6ccb1-4db9-4ff8-9bba-9b4948c6b0ce"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>124
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MO.&Y>+R:P,GSC;MLLU7UC=GU?,<V_)ZKK[O;2E_-^BQI5O!29J($%5]?33[
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MWN8L7^T^P$X9OW:/]\=TFC;HB#/O+DZG8[C?SN)%:KYM_CQT+'.HGP\=;J?
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M1&YP_MPYNNBNUN.[,DE]H9*CR W2'Q ZD-]+I'-T(+T2I,A-TO[2=>;N#.D
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MJS=UL6B_D?)0U'4Q;U_.1 R[4F, ?W\LBGK]IOF2R^:;;R?_ U!+ P04
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M;HMQ<!5 CBM6"_N@-C^P]3-T?)D2QO_"IHWM!9#5QJJR!9."DLMF9*]M'G8
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M#.NFES4+JRK?#I;*4G/QTX+:/VH70.<KI>QVX2[H_E F?P!02P,$%     @
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M?YLF8_7#Y_$WB4Z7Z.[KY>6]$YH"3:S!?F(]N# )H,-C862A)R#':.!;IX,
M.>S%@UWA0*-GX.YSWAX V^_6AZ% 38%7%7SSA88)(!7&L7F4 9 *\-#AH4#C
M;K#O"-PA.I95Z5+3QL_0\\QCN(!4$&.S0P6-M=WIV553LVS@9MG[2L:1(ZIL
M4$W['4ZP9 +DP)()D -+IO.M-YSGHG[JWA1O4%=Y]*\*;[[=O(T^[M[!-K[_
MC#\D_3OE>IC^%??OO)85=".YZE$.Z;T/I?WK_JWQ_H^V6G3O43]4;5O-NX\S
MP65N5 +R]\>J:M=_J DV[^Y?_!]02P,$%     @ YX%<5/<[2CPJ"@  <!@
M !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6R=66U/&ST6_2M6MKLJ4@AY
M \)3BA1HJ[)J"X*%76FU'YP9)V,Q8\]C>PCIK]]SKV<F$PILM1]*DAG[^MYS
MSWUS3]?6/?A,J2">BMSXC[TLA/*/@P.?9*J0?F!+9?!F:5TA WZZU8$OG9(I
M;RKR@_%P>'102&UZ9Z?\[-J=G=HJY-JH:R=\5132;<Y5;M<?>Z->\^!&K[)
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M1-[&9G@'.7,#D8P"Q21S+"<JKJF$,(6#R$&B(*9#\;#:BY%76J^I@J$4>CX
M^U/M$%;B=GYSNW]A[_?'1 &@"GH2_)$LD)9!L'#:/[!1 'L%(5Q7R;,(5;<U
M@4B7Y%5*BF36ESK(O$$-FU/ D W$/P!,G7.$S+V%5HF"=CANJZDG7@8-?@I;
MPF&0L'2V8%2QN= A*,4J?65"?P=<B38PX#J&&R4.7OVY<NA#L.3.['KO%><Q
MC5!+P'4 N^52*X>/CQ TC'DMA0"B;E80[[?'[+7ZW;5TV2%*APLRM;GR"9,
M+@'(CA)%&OV"M:U;H,&O;B&+@"IA4RU0R,35<HGDBK571EPEP9*AHV&?$T^_
M@9C]0ZD^YY2G&=$HIHQB;".FP?3R^JH%%5K1%JHC  +-2/+ R"))F[JM8F[2
M(NS;/1;P5BH&K0?!Q7%_-!WW9X<SX3-D%_^2=,'UH]6Q5:Y$#"G:\ [V#89#
M1):+8@9B3J4N!@6M(!5^T67+SA(P/\%W02&HWXG1^&@PI7C.R1AXTZ 1YFRD
M4DJVRZ"(\T1&TH-KQMK%Y(94S\T%UB4MG:*S6\61"]'!4EZ;!]8HR2U[N*OI
M;-8?C<;]X\FD PTZ:!1MD\8"8T"&H)&XJ;1"MH,M$;$UL02,M;")4FV^:9:3
MPPV8]*+X7=2)GV(M'84"D:^L7))Q&9M.^]/I=&?C&[I(__SPWQ?;Y=@7FV-<
MV"=J=VC^]PK&18Z/AV^3;=8?CZ;]\>RP<T1G/3%\=/SA&?F@GJ]J58E2JVV)
M@2M0W3BJC:!Y0-SNC\3[+QHH_+!H62>3_?'DY&AVLE>C^1O;EYH*<??4FPKR
MID?C]T@MV_[D5J%- N=@QCQADH].)A.P$V2#4- SEL Z@G>7M\'\B[+'TV,\
MQ03!(](C J+?;2EON@;<-@;X;4]!->"51>BY$FJGU'(999/=[+[CZ+VXNPUK
M.K9V%+NO3JO+2 .J/ T-B&+OQ'2\DP08\A?C/5B4+Z1XZWT;UMLBU$JE5/TL
M,TRFAX-ADQD0OK^5"5B1;C)X03",/VXSSHO)XJ5=H\&HV12]U$U4=1)X;L%X
M,AAO+;B5.3$"-28R$7G\AWUL*^2S@,(*Y;9!['FS;#?O\&U7<$LX+@T7=JVB
MF;7DOOCV[6+;&=/K;;\;.;_.=)+M:%.@(XQ>TV 5C1KTR<#%F,=8_U99H>*,
MNB)74')%#=NOE:4J22Y0&PZW?B=,G*W0/5%UM]&:/M\E4)_@6UPXM*FU0EW7
MI<PCOVN-UA"&B(B'=K/4-L2?YR5,]/GR?^>0R:XC\/OE@&Q]TN0FZN1I3$.#
MAP#%U!!S$;OL6<JA+9^?D+?-2G7[)MOA3Y.4=QM#MKN$ZVH2=")CB_@$:/^U
MR0%;![T4LDJ"%H0X#X>,;1^VZ&*!%*K0,Z\0ZTM5ZXR@Y.<Q(<6I%&U;JFIU
MZGF6KEBD0P6!+PI#S6K$+D:R0?>^J/B!XS&8^PT<WS:7S65%7QC;.#R3R'@\
M=M9UJ9/+=X-E('XH'L8<AII4TT&PX4)RVRWF.1I18M^SW&8=Y7S* *";+53;
M?-)D(6)%>$%!'7@&Y(EVC3F5=E=<OF625'&\BV+1I% >0J>2\"I5!LXA7>]2
MMN(6'?]P+%T<\"T B/YH(8JJ#8%(L4M :E-QZ/*AW5- (E>GM*<0^U[8SD/2
M&VAW(<DD#WQ=*^)8'&+/.)K,!D=MSAU@P#0(68ZEQHI6,;EU0ZU?4XPJC*QL
M :SARP"X&DJ"DTPWZ)W;DH72;W+3RNB?=%/ ML4YVDD"OG-(4OL:[Y85=6^:
MNG460\@N*CA!42CD\ID#8'4?^C?#&K2A49.,3Z3/^K#[9'@R.&SMIBZ+7]!?
MH?ZL]"/(R/TK*:S1M_E01\MKJ'/^X%*X/9B'9$@+FXX,0NW<:4W763P'8KX7
MWS1F/NI6>LTK<2WI_J>W]ZM#WXGCHVYS/A#GLKZI>K&3JV^2,-]1]J/4#L3H
MOJ?U]4+E&EZJ;SA(R/,S7K&[S>"^6L;;EA#]9>),59])!;^I%^T,WQ(;@W\1
M+TO;_H.R ]^CI+$FT4,?[\!LSM=,2 T8B W=X6T+@!^\='%YT+D%YIL/NNNF
M.HC&)%X(MT_;Z_1YO$7>+H]W\=^E6VD8DZLEMJ)?.>S%]-?\"+;D.^6%#4B?
M_#53$CF.%N#]TMK0_* #VO]D./LO4$L#!!0    ( .>!7%2R7)6XCB4  "9[
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;,4]:7/;1I9_!:6MFK&J
M*-I2CLG$2:IDQ<FX*H?+BF=V:VL_@$"3[!@$&#0@F?/K]YW=KT%04F9V9K_8
M(HGN?OWZW4?CJ_NN_Q"VS@W%QUW3AJ_/ML.P__+Y\U!MW:X,RV[O6OAEW?6[
M<H"/_>9YV/>NK&G0KGE^]>+%Y\]WI6_/OOF*OGO;?_-5-PZ-;]W;O@CC;E?V
MAU>NZ>Z_/KL\TR_>^<UVP"^>?_/5OMRX6S>\W[_MX=/S.$OM=ZX-OFN+WJV_
M/KN^_/+5I_@\/?!7[^Z#^;O G:RZ[@-^>%-_??8" 7*-JP:<H83_[MR-:QJ<
M",#X3>8\BTOB0/NWSOX=[1WVLBJ#N^F:O_EZV'Y]]L594;MU.3;#N^[^+T[V
M\QG.5W5-H'^+>W[VTT_.BFH,0[>3P0#!SK?\?_E1\& &?/'BQ( K&7!%</-"
M!.6WY5!^\U7?W1<]/@VSX1^T51H-P/D6#^5VZ.%7#^.&;V[Y,(IN7=SZ3>O7
MOBK;H;BNJFYL!]]NBK==XROOPE?/!U@/1SVO9.Y7//?5B;DOKXH?NW;8AN)U
M6[LZG^ Y !JAO5)H7UT]...WKEH6GUPNBJL75Y</S/=)W/TG--\G)^:;V6;Q
MW]>K,/1 +?_SP *?Q@4^I04^_9>@]^&YKY;%TZ<O7I7!!WSP;>^":X>2F.*7
MK2MNNMV^; ]_^(\OKB[_]#(45=<&&%67@ZN+M6_+MO)E4P08XH =AU!LRSM7
MK)QK"Q $^[*'YWR+XU!(^.$ -#QL@>$B%/O>PR3[!N#8N-;U9=,<\'>W'WCL
M '"\;SU^NL5U"-+KG>MA0\4S!.WJQ<OOKZ_?TI^7+\^+LL6!53/6KH#IBK+^
M%;B%X6M=Y4) Q ! -/>Z]#T"FW8.\P\SFT_[W7?!TY,ZQQZ@Z>J@T[AZ2>A[
M'%T*)DXB2*']_15@HFW Q_MM!SBYZ.Y;F"6,J^!K7_9P<,OB&G;G8;V^8EA!
M"C6P". (!P.IMJ$D$6</QC4>I 7!-.Z[UD )#RX+D&@@K]KB9NQ[UU8'VLEZ
M;&D>@+[2[T^A2<9;2 N@+SK'Y>VRJ&$[9;]$ > &/(DR!#<PR(TO5[X!Y/(Q
MS\X%1,5;:THFD:&S$\,#@QS(A8,IW<=J6[8;5_1$/+A*V[47NT=6GZPR76,,
M2+Q;#U(8";&9++,LWKD[UXZ.YG4?05&&XTD!4#B5OHS #=N^&S=;T)"$+J"F
MO2/=I!0&=)4.M=B 9A7(NZ#S"TD1[W0P2X_?=#M7/!,PSA? !4/1,6ME-&HH
M$[ /ZKTGH@@+6N3>X?0@5H#@D(Z5^@\.,>)0D!<@AMUN!8NJ**9_7]#XJQ>7
M?UX6[X/#R5^'P>]HTTA?+"PR]GL*\QP)%I0#@+;?1@^X V78 F[Q83R_7?G!
M%2XNBQ#!V8^[/3/(L,7C6*\!X8+\?=?3*>TB6YZB%?A<^U#!*8P][0[@0NF&
M*V</\M2XIZ=ODUCY!$#],945]=@C;:8A)&8C_226+=Q=V8R$#)0SIU&#)A*<
M2[OI<*H5J8L9!L U0#(P-$QZ:Z#4KI<920PCHKOPT$'<;T%(X4#^J?)]->X
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M(**A5+<=CG,4E4C9?+0U\2B+JBE# #KEA_LG8'!9O,7$03\<Z&<\@#WSV4^
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M^$?4$4'2#I54^I""U5 :.YHSJ,T=2Z[K / B$MH'*>6)J@(+64*Q49#_?>H
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MC$_$V2F9+.@R>7^)<-CE?)9-08&RT5#VT]#R(*EXK6UA<SQL2^V-L//I-O.
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M>-D$&HQ8L8(!77N%TI"J!'/B/<;[R8H#4L)2KX,-_FPVQ]>?T-XL^T=Y\IQ
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M +^O.V!R^8 +Q%=C?_._4$L#!!0    ( .>!7%2E+ZAM6@T  /0H   9
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M-RO^N%02NM,$/)\;DY=?Z(#JAXZW_P%02P,$%     @ YX%<5#??2"A<"P
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M:;]R'^=CWXQ1XI[+X:Z]YE>=2Y9JU'VPVS.U(OE!)48JZE.W* 7X^+>()=C
M\S"1X9TA?=,P@.Z/NC$ &*Z<I'Z:Y75N&OD'OME:[8&E4[-<!E3444*X 4&9
M6ZGN<\K#'3CPQ#C-*.RU"9U*+^S@2F)?IS_.^D,P4)+?>W%I55/*/-[C&+2(
ME?+K='-(K9_KNHK]3T,1[P]J0LU6RJ6$7=*E^_"$OU?&%.3FJ?CGX(HF/:40
M4G^6^VY8PCY0.YM'E(^)A*J4EW>D8F.HD;OO0^C9X+LRW]'1UW/*$Z ]?&+N
MGG8?Z&_"=^E^>?BZ_P'AUACO2K7$UMGT^O(D-,?IAS<-?Z7.C/>FXC_7"K.N
MI05XOS3&IQ]T0/>_+;SZ+U!+ P04    " #G@5Q4=+&;C!,&   6#P  &0
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MA802F2<)'/_NQ+E0B@1!C2])YJ#;DA;V?[?2WP7;8<N<.W%NU#]E[LOCP>&
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MC?60O@V&7+K,W F['+*LY!0IPJ:@"U&V8B* 5 (DS2JC3::,1J1!OIR;7,+
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M/LI!.IP4E%V=(WB&3./B-3..W1U\?JLPJ0.# ,O638<1![":<8OLHFE?VLO
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M)P!"\U)08A!&%14:%K]84*/CX@JL,[M)!YRS%YH#V=4D>-%Q*=7*)._Y''\
MNN*7$%NX;&60!,T[9VQ.(;0.&8>(LN<PM_#A4"=N9QG:OERQOP\,-%A";$C0
MSJRXW&X)9C5V8Z/O2G(=(C 9K UW2PD>"ARK<]4<.^46[8)-F(E4KDVTM!+V
M:A+@8,6)";=( O"NAK\T)7JX'DCY9CQ*&!JXB./5.&0#"]H "_YN]$YB9X7V
M+I.-1V><R2/B2,P1%[_UP#O G+!XY$>8:393S+XHZN%TL$BJ1U<N@T]:CW=
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MECIEF=2F>)-.\QRGT _K:8$@U' 4:K[5UTJPTDNQ<6>?9$,_ QKM';V5-15
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M4UG".3)L-@<]-5GJZ4AT+4]G. PWYW5F-DS/"/3)*"WZH)9U170+D#P()7\
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M;<4#&<D+\'MAV)?=P1OH1_SL?U!+ P04    " #G@5Q4E3D3C& #  #4!P
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MFD27%P'H_@WI#:L:W[?WRE*9_+"B9Q>U<Z#U@U+V:+@$XT.^_A=02P,$%
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M:,S:&QO@<$3J]@6,CV0=(/' 8R=8+/:A1;:DCGG(;')DY=?O5]7-2]+,V)L
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MU39-_%Y&/()V@2T)BLY-M21S10??\METE]4:5;\;$FT=\-KO@@Y#F(6^5<&
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M,..4&#X$I=46:M9!%<] Y05\9)3&PY6IL7X*D#*OGERQ(S<K7D2\Q&H(1_D
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MX[XP_ONUOW'EFK\9+TKGRIPO5THB]FD!WB_+TC4WQ*#]3P0O_P=02P,$%
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M3!W$$ZV(]C.<3!N4R?Q!]J="M4_5#ITS8_N9,IRJV0^]'S'9:,TQLX3@O38
M$B>R92%O+40820:1S+1]C17C^-*FBNO'C#:<"P6V_F'4A(UJ(1X>I UY$W!
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MPDQA'O=&R$RK2)SBS.RP]9"T _=X:.K'3+\=9RXG(Z)-0E%A&KI,!\*2K#B
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M1_2'OMWCDOA9A[[=T3^W+@=["1^ OZ];H #Y 3? SA0"[]O_!5!+ P04
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ME*5FX\4U=7?43H'VETK9P\0%:/\OS/X%4$L#!!0    ( .>!7%2C%55.&P0
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M&<74?E4S9C<;(RL[VBZEH4'9+C?TSP05'Z#O*RG-;L,&NO\Z\_\ 4$L#!!0
M   ( .>!7%2^)>#5)08   T0   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;*U8VW+;-A!]UU?LJ$UKS] 4+^+-L3UC)T[;AS0:RTZFCQ )21R3! M
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MK,KU_H'S!V>JB2J!F/!RQA7&Q<&X8' \^$>GSCG(UD9DY!6)@LB=IE-8[9'
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M [Q!J.9[0W-AY,J^X\^D,;*TRR5G,&?@!G@^E])T%ZB@_^AS_ ]02P,$%
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M><'=NS;K[O4)4;WL[+4,0ZNO3QU"NO'5ZN1SEWFQS\F7[KT:M3JYZC"7\LF
M!TU.^L"6$C"D! S)O-(N@)DFL4C"P,_WSF(?S>$J+);Y@>L%N@AB-_8"X,\-
M'&1054B!_OH,3M$,=L7?!DFTE$0S27:+I*_LCG'!$.#5^X'$.@SD6^0EL3J:
ME3!*3=-:S-VJ= )^515U-[&.R>;OI'_7(,HN1=E&45=0UZUYXC'F"^0N).-0
MLO@IE$+Q$J6QS_@]#[(=/Q!>DL8*O%X218%0HL$&1C-9+!A7;=@#%(.BF5.Y
MCF&E$Y@,;,MJUN^4^AVC_OE&^X(G$9H)D4(<&2B"H$<1C.J-&NTFN!C]JEKW
MG5B['COMK=5<X7>L-T%-.'%J_:*$$FR7_<KY4&^FNH]Q<_<'9?<'QNX7G<RG
MU)H'T/4UA#!;1NC?2MIL&H'<]6AK6EF6A;>5S_8VVU(^+)4/C<K/EDO.EK#6
M].S)]#=EDV%]B"WUUZQ@5"H8F15X7AJE(4CP59D>>(%L&J51/7!T-*A</!^E
M>K/!8(A'=K/&<:EQ;(ZO*U:PWN 7L9]I<.>&&9G4H@L '$)FI&J2G?MU*GK&
MUMAI&S-LZ<+->JXBL4JX/ *$1%5Q;X$*7ICZ&1_ 0CY6SC9F?:LVE,-!.REP
MI>;$>Q:+8JT,;D.F$@#,.@ZA;P#$MG^=<O#!Y!RLDPXV9YWK5 H)T5'#[U4&
M8%T.0 Z/UU!+YZAX ^ P5 2T-K$&XS&V'-(6'YV*L#D7W0 &H, _.\+HF:'2
M60,[!Q,JS7)LAOEWEW,WED@F:)UR;^6*+)&9HF:(U%5QM6JDB*W^6N*DR8W-
MZ&[/K-L.-8CQZ&"BH<F+S>B]2J-;2*5[ E"<@WV(6G&'FIE4\G+'I76)Z\P>
MC3 F0TJ;0T8TM8F9VK]V:GTJKM9U:A&-:+(/T7IJ@8(;R"X !*@46#U;;%^B
M<F-P,)0FFM+$3.EJX?J<N?.1U+'<PF.B>4S,/#8' XY\<1^"*(U,(Z")3 Z&
MR$03F9B)/&?<4U==EH');WO4O1K+;SD$C(HZV1J:]WNN0:&8_LVD5G.9F+D\
MFU^;_&@<DX/!,=$X)F8<OW2%G),Z78?8)B-GU+Q.J(8KW5,2O^ F[)S6JUVR
M<V_QP=QF6[5&+36C]A<7AN?%Y8S9J^A.UY:?&UJV]5OSGY+N3SSRIP:[ZR9/
MQX6?KK?LM/(<: _LY]<PDAVK**IQ3>U#6;948YV:G\^\=-E>%OZ[+UL-=VH&
M;_>),*A/A):+:U;3O:S>F0/9[G/N>J@&.ST8L%,-=GI@=?8'^M0ZV]:IP#:G
M@L:P5HKO^:;X?EZH;4UW&Q]*J&V-7GL/>O_W4!>"NMZHV)KAMIGA%TD8)O='
MV>CECR]-(U1Y&G\P#+<UPVTSP[N"<F;O?1:^K4"CVC:CNC[:W1.HK9EL#P]F
M\#6S;?-3ZI<FT&GA?XMV),N@.T^P.S3<[H-&O+WG*?8+"N1IX;LZJ>R6EUZ.
MYK1CYG37*3UUZJ4WM1VK]OB_H5U+C>!HACOF"GWN/N:3"D+?_"HN>^Q>>1O7
MV(-Z#4VL8>M[-PUSQPSSZPXO_:9.G;\8MUY;T]<QT[<>OF"S3 2#_.&[_!&M
MT]LP\,K72XWR:".P:@+[E2]=U+=H7UR^#&*!0K8 0^MX"!WD^>==^8Y,UMG'
M+[>)E$F4;:Z8"R%4#>#\(DGD9D=]3U-^9#?Y#U!+ P04    " #G@5Q4JDAD
MA\P#  !X#0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R]5VUOVS80
M_BL'81]:((Y>',=I81MPXA4+T&Q&C6X?BGV@I9-,E")5DK*383]^1TF1G<&F
MNZWK%UM\N>>>>^$=.=DI_=EL$"T\ED*::;"QMGH;AB;=8,G,I:I0TDJN=,DL
M#741FDHCRQJA4H1)%%V')>,RF$V:N:6>351M!9>XU&#JLF3ZZ1:%VDV#.'B>
M^,"+C743X6Q2L0)7:#]62TVCL$?)>(G2<"5!8SX-YO';N_C:"30[?N6X,P??
MX$Q9*_79#>ZS:1 Y1B@PM0Z"T=\6[U (AT0\OG2@0:_3"1Y^/Z._:XPG8];,
MX)T2O_',;J;!30 9YJP6]H/:_82=02.'ERIAFE_8M7O'M#FMC55E)TP,2B[;
M?_;8.>) X"8Z(9!T LG?!)+XA,"P$Q@VAK;,&K,6S++91*L=:+>;T-Q'XYM&
MFJSATH5Q936M<I*SLU4;/E YK'@A><Y3)BW,TU35TG)9P%()GG(T,(!YEG'G
M?";@7K8IY$+Q:H&6<6%>3T)+E!QPF';J;UOUR0GU<0(/2MJ-@1]EAME+@)!L
MZ0U*G@VZ3;R("TPO81A?0!(E\<?5 E[]\'J%!66>/4+O[NO!H@[,PW'8.WW8
MP [/./V7\T[_])YDX=YB:7[W:+[J-5\UFJ].:/ZY+M>H7;2I$&C6Z#*M=^!/
M..VGVQ9VU,"ZTK"=Q9-P>X3)J&<R\C*9"ZH@3*8(E$@@E#%DK3O76THEMA8X
MH/F!80+I5*XML4QK3=F'YAB]5M?X@%[4TVL#[=OQPH#KWH!KKP%+[5QHGX#)
M#/!+S2OGNPM 8SD=#,R@-IC7 @35*4-&F%3SRAV88P;X=2V0:G3*V^/F]+%2
M:<O_Z"8T0JK*JFZ5NIC:#8*QFKDB-G!H4*+=J S4EL+O5D_0I,QPJQI-A4V%
M!4:1L>8""I24,4(\T0:-"%9![M:?D&ESZ<G-<>_0L=?(^[)B7#>I2"PXU8.<
M2VYQX)AE-&&9+#AE1D?IF!O'7QOEFY[4C9?4.R^%BY>!Z'Q\)M1^A?-#0&[^
MQ\#ZO7L8<(-;E"[@\>A\N-_TGGWC-?2!U)=U"9\>T-4D7W6+HWTWB[YS98T/
M.FG\K0I"CD=;I1]_V/K>QS79<TW^?5K_$\I^->/SE/<],Q[Z\X4]NGSQ8>V[
M8'SUO=-DW_=B?^/[[VGBQQ^=]_F^Q<7^OO/-TL2O)O9P#@_NMB7JHKGRN[)(
M@6JON?UL_ZR8-Y?I<+^]?9,\,%UP:4!@3J+1Y9@<J=MK?CNPJFINRFMEZ=[=
M?&[H:83:;:#U7"G[/' *^L?6["]02P,$%     @ YX%<5*8#N6R' P  @0T
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M&SL#!Z4P)P73MV)]"55!?9LO$4R5OVA=83T')872(J^"#8.<\LT_^5$)T0C
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M(5)0OY 5PTT&=QCE2HELX7I]D9DJ7XRY%AJ^7Y%_N#28ZG\\Z-HENK9#USZ
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MV07X?B6E>9[8#FK5 )_^#U!+ P04    " #G@5Q44^S!.1X#  "N!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R=5=M.XS 0_951Q -(N^32EA;4
M5J(M:)% B[CMPVH?W&3:6#AVUG9:^/L=.VT(2^E*^Y+X,G/FS!E[/%PK_6QR
M1 LOA9!F%.36EF=A:-(<"V:.58F2=A9*%\S25"]#4VIDF7<J1)A$T4E8,"Z#
M\="OW>KQ4%56<(FW&DQ5%$R_3E"H]2B(@^W"'5_FUBV$XV')EGB/]K&\U30+
M&Y2,%R@-5Q(T+D;!>7PV&3A[;_#$<6U:8W"9S)5Z=I.K;!1$CA *3*U#8/1;
MX12%<$!$X_<&,VA".L?V>(M^Z7.G7.;,X%2)'SRS^2@8!)#A@E7"WJGU-]SD
MTW-XJ1+&?V&]L8T"2"MC5;%Q)@8%E_6?O6QT:#DD\2<.R<8A\;SK0)[EC%DV
M'FJU!NVL"<T-?*K>F\AQZ8IR;S7M<O*SXTO&-3PQ42'<(#.51E+<&O@*]W69
M0"U@FC.Y1 -<PH6QG+3 #%J>9'+))9,I9P*N.9MSP2TGA\,96L:%.2*\:URA
M@ Z-IDI:3H#2NJ'A&6KF2[1U?84#%^LA5Y5A,C/#T%*JCG"8;M*:U&DEGZ05
M)W!#47(#%S+#[#U 2!HU0B5;H2;)7L09IL?0B;] $B7QX_T,#@^.]L!V&OT[
M'K;S;_W;PFUJD<%W"7>85EJ38#!AAAMXE&IN4*_87"!<R;*RSD21^H+7.OZ\
MIBAP9;$PO_9P[#8<NYYC]Q..$R:HM@C, JF Q1SU5HEH5VEJM+Y'<TUA->[T
M3OO=8;C:0:+7D.CM)=$Z@PNGV<IIMBMZ#=-K13^-!]W![N@G3?23O=%)8,&,
MX0N>UA+3D:=CRU?,-140S<&UBAI-JBLJG6C5LRI]!\HY70)WP6I_NA"J]-."
M"Z2[+G=F=/(AHZ^GO2B*=J?4;U+J[TWIEKUNF:1O%S)]=R%WT;8YPH,J<,F>
MV,M^XOV/Q./H4^*#AOC@?X]CO(O%X,-Q3))!DOQ%(FSUT +UTK\4AO2HI*W;
M:;/:/$;G=0]^,Z]?LANFEUP:$+@@U^BX3PKH^G6H)U:5OB//E:7^[H<Y/:BH
MG0'M+Y2RVXD+T#S1XS]02P,$%     @ YX%<5((;]@=B"   %28  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&ULO5IM;]LX$OXKA*\XM$ 26V^VLYL$
M<%[:I-@<@G@W^V%Q'VB)EGF51)6DG&31'W]#2A;E2**=XGSY$,L29^;A</C,
M#.6S9\:_B14A$KVD22;.!RLI\U^&0Q&N2(K%"<M)!D^6C*=8PE<>#T7."8ZT
M4)H,W=%H/$PQS0879_K> [\X8X5,:$8>.!)%FF+^>DD2]GP^< :;&X\T7DEU
M8WAQEN.8S(G\(W_@\&U8:XEH2C)!688X69X/9LXO7X- ">@13Y0\B\8U4E-9
M,/9-?;F+S@<CA8@D))1*!8:/-;DB2:(T 8[OE=)!;5,)-J\WVC_KR<-D%EB0
M*Y;\22.Y.A],!R@B2UPD\I$]WY)J0AI@R!*A_Z/G:NQH@,)"2)96PH @I5GY
MB5\J1S0$7*='P*T$W#<"7I\%KQ+PWEJ8] CXE8#_UD(?I* 2"-X(]$YZ7 F,
M]YW#I!*8[.NE:24PW5?@M!(X?2O0NW"CS<J-= 252Z[CY1I+?''&V3/B:CSH
M4Q<ZZ+0\A G-U/Z82PY/*<C)BUGXO:""JE@5Z!C-HDA?XP3=9>7N4U'\\9I(
M3!/QZ6PHP:@2'8:5@<O2@-MCX&N1G*"1<X3<D>O\,;]&'S]T:;FR:_E,%B?(
MG6YIN:<) 0]EI$/=M5W=K(A/D*=!.9-*G5AA3D2'KAN[KCG)0==(ZQI7NCZ@
M(>K5]]FN[YJ$&VPVAWW97\MH#X?=[N]_MQ_4W8Y8P%D-RJ+EZQX1M7%0EY>'
ML ?JC>#6&\'56OT>K;^SE,3X";]8='FU+D_K\GIT718"[@B!&KL+_?4;W$-W
MDJ3BWQ8;?FW#M^*="0'9$S<,Y 4/5Y J4,YIV+7&-Z7&B=:H$N?Z(H \"G]G
MPW4'E*"&$KP/RA&2'&<"ERDP9$)V[JN@#<>"9ERC&5O1/.!7R-\26#(B""@,
MX9:G4LM&N!RW4$T="ZQ)#6MBA77%TA1,@]GP6\4-Z$Z(@D0:9 T)Y27^'YM!
M/_J9Y&MI,FA@]=V)-^E&.JV13JU(GW!2$,26L'#O@]SES6D+H7-J\>9IC?'4
MBO&>9C0MTFV(.NZ[H0D8"35=1'B9T'X@*T7?G+:"X+0'L3,RF7:T'\. ]7O\
MHO!;>,!I9'#G8&SC&'IT[/SX2%2U3;-XX])=>^M(U2GM258U@]MR<,E$?8'A
M&.YUO+W=? 4/:0C%S#590RN0MZ-TVX@A7\<_G,\-KSIV8CUTE#MM!O:#'O\;
M^G7L_-OTO[G^C4A).)K%G)!=JV HU9D<;A4,'3IV/KQONQG',(\82X)PR@K8
M"_ $+Q)KS-]49IK>]NPQ;]C0V46'+8B<)( O0N#UM+L*M:N4*X(@9^4X>X6F
M)$G0@H!.<#-72IDRI#[4,-4GP-KJ\%RQ!,)/J/1A%K\C4.%YD2L%.&MX$^Y^
M\$8G(R61J,6D2VTA)_Q8AW$5_:R\7>'[YS^FKC/Y54 %M$AHF+RJ\B,"F,U]
M<X1@Q] T3R@\*+48K3WZYH13R'FS8T=MK#7ADL(B@S19$J[\4.[(CZ!Y:XL6
MN2Y[E(0Z1_A4WL H! U HA5K"JP#AO 8G,?X)L_JNQ1B3**$8"'1!S] 'S'<
MB/X#'2%8!0T*;:AJ/4"N5JB4C>@:-G\6'6UTP6RE4LU@/!B@X%;,81E#G%.)
M$_JWYHE/1[#"<J655O$,:D41KLQZ140%$L1(A!:O>F1S/7 6#<&,OBUQW.O0
M<,/'D>%C-5$U5M*TEH/@)6L,SV 8_)><QN DE7QT-)2@3FQ5O\G*KCTKWP@P
MK'?*$E..UIOBAZ0+$JD@@G"F:ZQ.<;IV4:5]JXB=6/:T:]*ZZ^PH&#,),U;S
MWV9U6#X69_1O$G7UT976)B#'RC)NHT.REP#_*L G7#FGWM 0E>&*PBI%JJBQ
ME-57E>ZM2K 'D$GUKCW5'SH_5N;WR8^N*1U<>^-V6Z1X8>U837W@!@?+?ZY)
MZ*X]H?]<('ZNM&XM^.1-)U6>9+CMELL]M36FKJD07'O757MHJSL%YER]F4N.
M:=<LKBO]^R=MU]05KKVNZ,96]5FT[+,LS=^UV]%;C>$O&/<@,^6$:\_]^R#3
M1-D)J]T[N;:^WC-4[=FI>@ZI431V]89ZNJ*O4M5TSMBZ;IXA9L].S'>0TRC7
MJ0NHD&829[&N"W1:%T>(O(1)$:EL%3,6J>*I$Z'30M@'S3"T9V?H+Y4]@)"3
M4):5&A1ND,>*L"Q>%#'2#!@3,BZ49GG!<R:ZSRF]=I/6A[!Q,F:G[)+](*ZK
MC@P@_D["5<82%E-]VK$A];_N50KF-@[S#.EZA^O7/,/'GKU?,[4$K[OE0I!E
MD: $ZH=N)]M53M KP=R6+CQ#Y)Z=R/?P_<YC"<]0KW>XYLPS).K92?2G7&Y7
MZ;B[?6ZHU+-3:>WSV\LG*$V8VH>VTU]#AO[H<&?,ANM\.]<UW@>]S9>ZX:TZ
MFY*(-Y0H@'OH4O59AJMU(=^9QOPV#SI>8*-JW_"A;^?#>8VDL_-HE+']1YA?
M_/>>5?F&#?T]V7"6E2W:P^X(:;P@.!SG^8;S_!V'__^'"&D?4SDC>X083O3W
MY,3Y['%^?,6>CMU]%L&PH'\X%O0-"_IVROK)$MUOGTBU2O1M1(;W?#OOF5Y1
MM/?@^]O'+Y6Y)DNX/6^M#(4&.^K)_P4[!.T# #L[!(9\ SOY/I*X2+!D_+7+
M8UT+&K2YU$ZE@:'28 >5OJ/X#MJ,:2^^ \.8P9Z,V=ZOZF:Q$.1[H5;O9FT_
M90X,CP:'X]&@\0[5SJ.MUY:+C5FHU1<TPSO?7-X&;9YLN;U\3=\QLB=.AHV?
MEJ@?3-UC'M-,H(0L071T,@%-O/P-4OE%LES_VF3!I&2IOEP1F!-7 ^#YDC&Y
M^:)^P%+_$NSBOU!+ P04    " #G@5Q4X-P($<H#  ")#P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,BYX;6R]5UN/VC@4_BM6M%JU4CN)$Y+ %)"886B1
MMM)H1MT^5'TPB0&K3IRU#<SNKU_;R20P"295+R_@R_G.S5]\?,8'QK^)+<82
M/&4T%Q-G*V5Q[;HBV>(,B2M6X%SMK!G/D%13OG%%P3%*#2BCKN]YD9LADCO3
ML5F[Y],QVTE*<GS/@=AE&>+_WF#*#A,'.L\+#V2SE7K!G8X+M,&/6'XJ[KF:
MN;66E&0X%X3E@./UQ)G!ZP6,-<!(_$WP01R-@0YEQ=@W/5FF$\?3'F&*$ZE5
M(/6WQ[>84JU)^?%/I=2I;6K@\?A9^\($KX)9(8%O&?U,4KF=.$,'I'B-=E0^
ML,,'7 44:GT)H\+\@D,I&T<.2'9"LJP"*P\RDI?_Z*E*Q!% Z>D&^!7 [PL(
M*D#P$G#.I4$%&+P$#,X P@H0]@5$%2 RN2^393(]1Q)-QYP= -?22IL>F.,R
M:)5@DFMF/4JN=HG"R>E[QM(#H12@/ 7+7*)\0U84@YD06 KP%LS2E&@.(*JV
M2R9K1KR:8XD(%:^5R*?'.7CUQ^NQ*Y5#6JV;5,9O2N/^&>,0?&2YW IPEZ<X
M[<#?VO'!)?S\@GW?HL!5F:S3Z3^G\\:W:ISCY H$\ WP/=_K"L@.?\2%@GMG
MX?/^UF$'_.['G%_TAL.1)9=!3<W Z O.)4/=HNE.<9&MP06:?OE+8<%2XDQ\
MM5@>U)8'QO+@PD?1Q>@2&1NDOK;W4QB-@MCS5,;VQT?55_"NA^!)%&$=1=@K
M"D"R A&NRH$$E G1Q:M24WCDPQGC46T\LAJ?98Q+\E]Y6> G50B%.4C2G!TR
M9]?E3=3R)@R"=N+:8M ;^"VY1=1.L.\'9_,;UR'&UA"735K[!F95J!\1UZ)
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MV,<=XN\MC">=XL_6$:T#B1;Z&!A(UR*Z$RF@CM7J6*&.[E"G>!_RNR3E>OM
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M#(M+W794*\SZUSE=WM$4G25IP<EVF7 B;3C!C?@ ^8T[4SXE/IEJUINF:4>
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MEF(M9'P%2/[878A@K>>G6_'070!E0>(&;;^(MALL+#)2KON.?IR#O# 09U"
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M&7 Z=&7;:-1-NM!(!L>C G@04[%BF7D#G1MRJ^A4T&L>1^)SHW@: VJ'R=/
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M#H8X!-<3T060&NVS<V]>52>^Y,D*-G4[K"@[3Y;\XP,-8-)9 _C[(DER\>4
MZ#\EZ7?>QX?_ %!+ P04    " #G@5Q4 \A+G'\#  !?#0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T-RYX;6RU5UUOVS84_2N$T(<6:".1^K(+VT#C+%B
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M -S?"*%?-F;&;K^I%O\"4$L#!!0    ( .>!7%2SF65;:@(  -T%   9
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MDSO=2:VZVK1W#U4?')@$JP9SMK/)_O<=.X1E T%Y26R8C]^,A_',#D+^4@6
M)L>25VKN%%K7GUQ790645-V)&BI\LQ6RI!JW<N>J6@+-K5+)W<#S8K>DK'(6
M,_OL42YF8J\YJ^!1$K4O2RI?'H"+P]SQG?.#)[8KM'G@+F8UW<$:]/?Z4>+.
M;:WDK(1*,5$1"=NY<^]_6OJ!4; 2_S(XJ,Z:F% V0OPRFW_RN>,9(N"0:6."
MXM\S+(%S8PDY_F^,.JU/H]A=GZW_98/'8#94P5+P_UBNB[DS=4@.6[KG^DD<
M_H8FH,C8RP17]I<<&EG/(=E>:5$VRDA0LNKT3X]-(CH*_N2*0M H!+<JA(U"
M: ,]D=FP5E33Q4R* Y%&&JV9A<V-U<9H6&6.<:TEOF6HIQ</E-,J [*V-;,4
M92TJJ+0B?Y UEDR^YT#$EMQGF=Q#3FB5DZ^Z $D^,[IAG&D&BKQ?@::,JP^H
M]7V](N_??2#O"*O(MT+L%>JHF:L1UKATLP;LX0067 %;079'0O\C";S 'U!?
MWJ[NO55W,45MGH(V3X&U%]Z4IR?@5&,Z5DQE7*B]Q"3\N-\H+;$L?XZX"UMW
MH74WN>+N"^. 9U\!J>D+W7 82N#)1&)-F,_U>9%&GH?1/G?SU)=ZE7C#-FG9
M)J-LYUJ0XH5R<_Y#;"<34<=K-(V3X(*M+W6%+6K9HE&V)U! 95;80LWA&=M4
MC4U'$SABXU/#K%&/(IAZ27C!VI>:I.%T,LP;M[SQ*.\C?9&"<XLKFZ(:0XW[
MJ&D27:+VI?S$BZ^D-FE1DYN.G569*(%H>AQ&3'K.X\!/AGU/6]_34=]_'C-0
MBFSWV$K.7P3!#?:AG:1XO'0G <Q!#R)-^_F8!M%%TOI"X22^PIVVW.DH]]<:
M)-6LVA$.>-<0_MHT/V)WEQ*)AX#3/DL:)!?  T)Q)ZHWP+[W>A]XX\BVN]=2
M;#'C>-'24W%FHE)X,YI0QNJS,?ZF0)/4OR ?DHK2:^B=J\R_ 9TV=3J*Z?<K
MP@NBR25G7VSJ7<-\O4G\8!3SF] FJ9T;55CP3G$,,@>]1AZ$<>1?]M0!N21.
MP_@"V^W,#&9@^T+ECE4*"W6+>MY=@E'+TPQTVFA1VS%B(S0.)799X-P(T@C@
M^ZT0^KPQDTD[B2Y^ U!+ P04    " #G@5Q4D0NA V &   _&P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,"YX;6RU66UOVS80_BN$UPTMD-IZM>PN,9 Z
M;=(M68*Z70<4_4!+M,55$EV22F*@/WY'2A'](C-N.G])+(GW\'CW\+FC='S'
M^%>1$B+1?9X5XJ232KEXU>N)."4Y%EVV( 4\F3&>8PF7?-X3"TYPHHWRK.<Y
M3K^78UIT1L?ZW@T?';-29K0@-QR),L\Q7[XF&;L[Z;B=AQOOZ3R5ZD9O=+S
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M!K^9P=<S!+MF(*!K"'..80;%\B,4PWP<)+,$2I/[!>45HQ>$4Y8<H2F9TZ(
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MOM94%Y(M]+O_*9.2Y?IG2G!"N!H SV>,R8<+]3FA^68V^@]02P,$%     @
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M3MVWS">F]UP:]+)#77238P)T]WG0#:QJ?(?=*HO]VE\>\),*M%N \SNE[-/
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M-<$QX7J">KYD3.YO]#FS_)@R^0%02P,$%     @ YX%<5)&_WV<B P  ,0H
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M5;FY [RX4B@:DJW,J?R9277&-X]+2F+*]0#U?LZ8W#7T!-7%SN@_4$L#!!0
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M,"YX;6S-5UUOXR@4_2O(TDHS4FL;V\W'*(G4)%WM2#-2U&AV'U;[0.V;&-6
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M:H+YOA%"OW2J!9JB=_8=4$L#!!0    ( .>!7%0Q^A&3 P0  .H1   9
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MQ*O>ZB)C6AS?[?#B%N26<K5_!$IAH:9ZO:%*$2\N%HJ&9&MSF']B4K+,/*Z
MQL#U /5^P9A\;6@'U?7.Y%]02P,$%     @ YX%<5,]T\0<% P  E D  !D
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M%:N> %5'T)6^%!^ID%>L;J;RV81,!<CY!:5BUU$+- ^QT7]02P,$%     @
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M&]U I#_ 9EP6T_ZTZ2G)PO?VMY)W*L+HF!Q6TO?2-/2B(V4,&*93>)8<"6/
M+/"2./;]867X!U>U/YJ4GUA*S+4R4E@U,B^AWS'%J2 %:RWRA['4!_M3@I/2
MQ/XR\\,3T436,7E1P\A\CDKH'C1>%9%;V\ JE(N&Z[;IZ%?[)OG"MH9'ZY>F
M>;8-W=Y-VWE_Q7)+X6I@9 ,NO?,$2,FVF6TG6M2VO;L7&II%.RSA!8!(8P#[
M&P&-6S<Q!_2O%(M_4$L#!!0    ( .>!7%2615+?4 (  ",%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;'U446O;,!#^*X=AT,*(':=)N^(8DK9C
MA76$AFT/8P^*?8E%9<G3R4W[[W>2$R^#)"^2[G3WW7>G.V5;8U^H0G3P5BM-
MTZARKKF-8RHJK 4-3(.:;];&UL*Q:#<Q-19%&9QJ%:=),HEK(7649T&WL'EF
M6J>DQH4%:NM:V/<Y*K.=1L-HKWB6F\IY19QGC=C@$MWW9F%9BGN44M:H21H-
M%M?3:#:\G8^]?3#X(7%+!V?PF:R,>?'"8SF-$D\(%1;.(PC>7O$.E?) 3.//
M#C/J0WK'P_,>_7/(G7-9"<([HW[*TE73Z":"$M>B5>[9;+_@+I] L#"*P@K;
MSG8RBJ!HR9EZY\P,:JF[7;SMZG#@D"8G'-*=0QIX=X$"RWOA1)Y9LP7KK1G-
M'T*JP9O)2>T?9>DLWTKV<_DW?O='79@:X>*K(;J$!5I85L*R8E:6TM=.*+;I
M&H"E2[BX1R>DHLLL=LS!(\7%+MZ\BY>>B#=,X<EH5Q$\Z!++_P%B)M]GD.XS
MF*=G$>^Q&,!H^!'2)!V2)TYG4$=]748!=70"]4%8+?6&#LKQ:[8B9[F-?I_!
MO^KQKP+^U2E\<I++B25TE,$96"%(HI9U+=?&0J.$/E;A#GD<D/W0O>:3\:?)
M=1:_'B$T[@F-SQ-:+A902BI,JSVMIK5%Q>T.C94%KV@+U([G]!BC\] WXT&2
M?#A6M/B@<6NTFS">!(%#U\.]MO\!9EWC_S/OOH\G83=2$RA<LVLRN&9.MAO)
M3G"F"6.P,HZ'*APK_L70>@.^7QOC]H(/T/^+^5]02P,$%     @ YX%<5(-N
M^"!A @  Y 4  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULC5113]LP
M$/XK5L0#2*Q.TE(82B/19M.0AE11L3U,>W"3:V/AV)GMM/#O=W;2K+ "?4E\
MY_N^N\]G7[)5^M&4 )8\54*:25!:6U]3:O(2*F8&J@:).RNE*V;1U&MJ:@VL
M\*!*T#@,Q[1B7 9IXGUSG2:JL8)+F&MBFJIB^GD*0FTG013L'/=\75KGH&E2
MLS4LP#[4<XT6[5D*7H$T7$FB834);J+K;.3B?< /#ENSMR9.R5*I1V?<%I,@
M= 6!@-PZ!H:_#<Q "$>$9?SI.(,^I0/NKW?L7[UVU+)D!F9*_.2%+2?!54 *
M6+%&V'NU_0:=G@O'ERMA_)=LN]@P('ECK*HZ,%90<=G^V5-W#GN :/P&(.X
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M    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;(U576_:,!3]*U;4!RJ-YCM
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M&SA=!Z6P(.M"OK#M#Z@-19IOS@IA?M&VCO4<-%\+R<H:K!24.:W^R:Y>B".
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M/&:JDP.N ]3[!6-R/] )FMYP^!=02P,$%     @ YX%<5)T&QG>] P  +@X
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M@\\=*HT!/-\(H5\'YD#=?D#-_P-02P,$%     @ YX%<5$N0M*37!   $Q4
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MM\/;7L?ZK-M:=]5K.<_B,-[J>K]VO?\AU\T1$1/2O#O"SK+(4GR2+A(@,)E
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MY:)Y!S03Q2M[,RZYTO>L'>;ZZ83" /3W%>?J:6(<=(^Q^6]02P,$%     @
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M_Z3>P_AU*,.UYWN-U_])JL?SN>5Z^<OR>^?D5KG@7-]6#$]_ 5!+ P04
M" #G@5Q4^,,"'08"  !/*@  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-VLUN
MXC 4!>!70=E6Q/@WTQ&PF9EMAT5?P$TN)2*)+=MMX>W'"6VE5ATT%2/U;(C
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MWCFW_\_QT[/L;3N\Y+/I?Z3K/U!+ 0(4 Q0    ( .>!7%0'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ YX%<5.-0,$[N    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ YX%<5)E<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #G@5Q4
MZM<W%OP&   -'   &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ YX%<5$&AR/,&!P  &AT  !@
M     ("!/P\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M .>!7%2^]RKOP0(  $\)   8              " @7L6  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " #G@5Q4 LH-S/$%  !V&0  &
M            @(%R&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ YX%<5&M9B?=A P  5@H  !@              ("!F1\  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .>!7%2ZPT57OPD   4W
M   8              " @3 C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " #G@5Q4Z*A+ )@"  !<!@  &               @($E+0
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ YX%<5(N.+)20
M#   QS\  !@              ("!\R\  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( .>!7%3W.TH\*@H  ' 8   8              "
M@;D\  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #G@5Q4
MLER5N(XE   F>P  &0              @($91P  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( .>!7%2E+ZAM6@T  /0H   9
M      " @=YL  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ YX%<5#??2"A<"P  PB   !D              ("!;WH  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #G@5Q4=+&;C!,&   6#P
M&0              @($"A@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( .>!7%2@S(#140@  '0=   9              " @4R,  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ YX%<5/,$]OD<
M(@  2(8  !D              ("!U)0  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " #G@5Q4=&2]DCH$   U"0  &0
M@($GMP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .>!
M7%147%DR2@\  *$O   9              " @9B[  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ YX%<5&O4 )=. P  [@<  !D
M         ("!&<L  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " #G@5Q4E3D3C& #  #4!P  &0              @(&>S@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .>!7%1TFOJ QP,  *D(
M   9              " @372  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ YX%<5!(X**("#@  >2D  !D              ("!,]8
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #G@5Q4OG"3
MPV $  #F"0  &0              @(%LY   >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( .>!7%1<XP=1\@(  ( &   9
M  " @0/I  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MYX%<5!:'8V D#   4"   !D              ("!+.P  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " #G@5Q4Y[C'$$D#  "*!P  &0
M            @(&'^   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( .>!7%0K^;E &RD  -6,   9              " @0?\  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ YX%<5/AWH+ &!@
M_Q,  !D              ("!624! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " #G@5Q4UPT,/(0#   ["   &0              @(&6
M*P$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .>!7%2C
M%55.&P0   D)   9              " @5$O 0!X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ YX%<5#AT$Q%>!0  ]PP  !D
M     ("!HS,! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .>!7%2J2&2'S ,  '@-   9              "
M@:I2 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ YX%<
M5*8#N6R' P  @0T  !D              ("!K58! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " #G@5Q4.]$>P'@"  !_!0  &0
M        @(%K6@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( .>!7%1B\)RL] 0  $<3   9              " @1I= 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ YX%<5/H>&]3_ P  #!<
M !D              ("!16(! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " #G@5Q44^S!.1X#  "N!P  &0              @(%[9@$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( .>!7%2"&_8'
M8@@  !4F   9              " @=!I 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ YX%<5.#<"!'* P  B0\  !D
M ("!:7(! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #G
M@5Q4B8VS.&@#  #&"P  &0              @(%J=@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( .>!7%2*'W[+6@(  "H&   9
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M970T."YX;6Q02P$"% ,4    " #G@5Q44*?1!'H#  "5"@  &0
M    @('1HP$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M .>!7%21"Z$#8 8  #\;   9              " @8*G 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ YX%<5 ,E.IK9 P  ^ L  !D
M             ("!&:X! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " #G@5Q4%L13ERP#  "P"0  &0              @($IL@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( .>!7%2GQ>+'R ,
M "D+   9              " @8RU 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ YX%<5-PQM@D. @  600  !D              ("!
MB[D! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #G@5Q4
ML,=XS1X$  !8$0  &0              @('0NP$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( .>!7%21O]]G(@,  #$*   9
M      " @27  0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ YX%<5%10D"OH!@  N2   !D              ("!?L,! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #G@5Q4>9\A!(($  #D$0
M&0              @(&=R@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( .>!7%3"H)A+J ,  +P.   9              " @5;/ 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ YX%<5#A @ V.
M P    \  !D              ("!-=,! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " #G@5Q4,?H1DP,$  #J$0  &0
M@('ZU@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .>!
M7%3/=/$'!0,  )0)   9              " @33; 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ YX%<5+QC<2+; P  S@L  !D
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M=#8W+GAM;%!+ 0(4 Q0    ( .>!7%2.K% -%P,  "<*   9
M  " @6GN 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @
MYX%<5)T&QG>] P  +@X  !D              ("!M_$! 'AL+W=O<FMS:&5E
M=',O<VAE970V.2YX;6Q02P$"% ,4    " #G@5Q4VW7IN^L#  !,#0  &0
M            @(&K]0$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4
M Q0    ( .>!7%1+D+2DUP0  !,5   9              " @<WY 0!X;"]W
M;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ YX%<5'F/DMTZ P
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M96QS+RYR96QS4$L! A0#%     @ YX%<5!;^I6%?!0  B3    \
M     ( !.0D" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .>!7%2WQP,P
M0@(  $(K   :              "  <4. @!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( .>!7%3XPP(=!@(  $\J   3
M  "  3\1 @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !1 %$ +A8  '83
$ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>318</ContextCount>
  <ElementCount>641</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>126</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Grant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreements</Role>
      <ShortName>Grant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Convertible Preferred Stock Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability</Role>
      <ShortName>Convertible Preferred Stock Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Stock-Based Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwards</Role>
      <ShortName>Stock-Based Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShare1</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEvent1</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stock-Based Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables</Role>
      <ShortName>Stock-Based Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwards</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShare1</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Acquisitions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Grant Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails</Role>
      <ShortName>Grant Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Convertible Preferred Stock Warrant Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock Warrant Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-Based Awards - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Awards - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock-Based Awards - Summary of Stock Option Plans Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Stock Option Plans Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails</Role>
      <ShortName>Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Net Income (Loss) Per Share (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Income (Loss) Per Share (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Income Taxes - Schedule of Loss Before Provision for (Benefit from) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Provision for (Benefit from) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="vir-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Subsequent Event - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails</Role>
      <ShortName>Subsequent Event - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="vir-20211231.htm">vir-20211231.htm</File>
    <File>vir-20211231.xsd</File>
    <File>vir-20211231_cal.xml</File>
    <File>vir-20211231_def.xml</File>
    <File>vir-20211231_lab.xml</File>
    <File>vir-20211231_pre.xml</File>
    <File>vir-ex10_43.htm</File>
    <File>vir-ex10_44.htm</File>
    <File>vir-ex10_45.htm</File>
    <File>vir-ex10_46.htm</File>
    <File>vir-ex10_47.htm</File>
    <File>vir-ex10_66.htm</File>
    <File>vir-ex23_1.htm</File>
    <File>vir-ex31_1.htm</File>
    <File>vir-ex31_2.htm</File>
    <File>vir-ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img61678762_0.jpg</File>
    <File>img61678762_1.jpg</File>
    <File>img61678762_10.jpg</File>
    <File>img61678762_11.jpg</File>
    <File>img61678762_12.jpg</File>
    <File>img61678762_13.jpg</File>
    <File>img61678762_14.jpg</File>
    <File>img61678762_15.jpg</File>
    <File>img61678762_16.jpg</File>
    <File>img61678762_17.jpg</File>
    <File>img61678762_18.jpg</File>
    <File>img61678762_19.jpg</File>
    <File>img61678762_2.jpg</File>
    <File>img61678762_20.jpg</File>
    <File>img61678762_21.jpg</File>
    <File>img61678762_22.jpg</File>
    <File>img61678762_23.jpg</File>
    <File>img61678762_3.jpg</File>
    <File>img61678762_4.jpg</File>
    <File>img61678762_5.jpg</File>
    <File>img61678762_6.jpg</File>
    <File>img61678762_7.jpg</File>
    <File>img61678762_8.jpg</File>
    <File>img61678762_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="856">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>130
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vir-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 30,
   "contextCount": 318,
   "dts": {
    "calculationLink": {
     "local": [
      "vir-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vir-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vir-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vir-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vir-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vir-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 898,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 31,
    "http://www.vir.bio/20211231": 27,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 62
   },
   "keyCustom": 179,
   "keyStandard": 462,
   "memberCustom": 81,
   "memberStandard": 40,
   "nsprefix": "vir",
   "nsuri": "http://www.vir.bio/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Acquisitions",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:GrantAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Grant Agreements",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreements",
     "shortName": "Grant Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:GrantAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Balance Sheet Components",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Commitments and Contingencies",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Related Party Transactions",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Convertible Preferred Stock",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock",
     "shortName": "Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:ConvertiblePreferredStockWarrantLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Convertible Preferred Stock Warrant Liability",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability",
     "shortName": "Convertible Preferred Stock Warrant Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:ConvertiblePreferredStockWarrantLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Stock-Based Awards",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwards",
     "shortName": "Stock-Based Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Net Income (Loss) Per Share",
     "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShare1",
     "shortName": "Net Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Defined Contribution Plan",
     "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Income Taxes",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Subsequent Event",
     "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEvent1",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stock-Based Awards (Tables)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables",
     "shortName": "Stock-Based Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Net Income (Loss) Per Share (Tables)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables",
     "shortName": "Net Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_e52b7462-3e95-4a90-a2ac-eeb96cc91696",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Organization - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
     "shortName": "Organization - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_e52b7462-3e95-4a90-a2ac-eeb96cc91696",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:FinancialAssetsAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
     "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:FinancialAssetsAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_c65e2fa1-651b-49f1-8130-e10a86ed4b23",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails",
     "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_c65e2fa1-651b-49f1-8130-e10a86ed4b23",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_f999fb4c-9967-4386-a71c-e0a64a7891bc",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_f999fb4c-9967-4386-a71c-e0a64a7891bc",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Operations",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_7a978f36-d4af-4db5-8584-15add2567749",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_7a978f36-d4af-4db5-8584-15add2567749",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Acquisitions - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
     "shortName": "Acquisitions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_4d962b66-b38e-4b66-95b7-9a327531b9c9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_f506a175-6fde-4e73-bbbc-20e846b33555",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Grant Agreements - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
     "shortName": "Grant Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "vir:GrantAgreementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_064e544a-5338-44a5-8d21-57da4323d0ff",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_4535e3d1-cadf-43e9-a70d-52008cd60dfc",
      "decimals": "-2",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment Net (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:MilestonePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:MilestonePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:LeaseArrangementContractualExpirationBeginningYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:LeaseArrangementContractualExpirationBeginningYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:OperatingLeaseIncentiveOverLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails",
     "shortName": "Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:OperatingLeaseIncentiveOverLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_931f9106-3768-4f05-bd7b-0855dd2f9745",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_1c598293-0936-4d1f-99f5-0722e4f7437e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "vir:TemporaryEquityTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "0",
      "lang": null,
      "name": "vir:NumberOfClassOfStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0c0012f8-5960-4879-bdde-f46b368e2ae9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Convertible Preferred Stock Warrant Liability - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock Warrant Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0c0012f8-5960-4879-bdde-f46b368e2ae9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_7d78f477-8e15-46ec-9ae7-c436d7a5b269",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Stock-Based Awards - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
     "shortName": "Stock-Based Awards - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_7d78f477-8e15-46ec-9ae7-c436d7a5b269",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_bb04a465-c3d8-4109-889c-c33e0ccca055",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stock-Based Awards - Summary of Stock Option Plans Activity (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
     "shortName": "Stock-Based Awards - Summary of Stock Option Plans Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_7ea779b6-e470-44f4-8cd2-792b82ad5755",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
     "shortName": "Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_e5046b1c-890a-4d88-9c47-8d81f489b3cf",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_c8189099-45c1-41f2-b6ca-954b37c65618",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_6a0b0601-deb2-4157-ba2f-7613b7f73ba3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
     "shortName": "Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_c2a50417-42a1-40be-8caf-f0cebc94ffff",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails",
     "shortName": "Stock-Based Awards - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_c2a50417-42a1-40be-8caf-f0cebc94ffff",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
     "shortName": "Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vir:EstimatedSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Net Income (Loss) Per Share (Additional Information) (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails",
     "shortName": "Net Income (Loss) Per Share (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "vir:EstimatedSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Income Taxes - Schedule of Loss Before Provision for (Benefit from) Income Taxes (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Loss Before Provision for (Benefit from) Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_1c598293-0936-4d1f-99f5-0722e4f7437e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:InitialPublicOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_1c598293-0936-4d1f-99f5-0722e4f7437e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:InitialPublicOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_69329fa9-5ba5-4337-a561-386bfedc0568",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_69329fa9-5ba5-4337-a561-386bfedc0568",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_4d962b66-b38e-4b66-95b7-9a327531b9c9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails",
     "shortName": "Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_1ad51e18-a052-4618-9f7f-dd217928f54d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "vir:CashGrantAwarded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Subsequent Event - Additional Information (Details)",
     "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
     "shortName": "Subsequent Event - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_1ad51e18-a052-4618-9f7f-dd217928f54d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "vir:CashGrantAwarded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100090 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Organization",
     "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20211231.htm",
      "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 126,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China Territory"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "verboseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "verboseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r58",
      "r121",
      "r122",
      "r283",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r282",
      "r292",
      "r399",
      "r409",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r647",
      "r706",
      "r709",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r282",
      "r292",
      "r399",
      "r409",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r647",
      "r706",
      "r709",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r200",
      "r305",
      "r307",
      "r649",
      "r705",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r200",
      "r305",
      "r307",
      "r649",
      "r705",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r282",
      "r292",
      "r334",
      "r399",
      "r409",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r647",
      "r706",
      "r709",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r282",
      "r292",
      "r334",
      "r399",
      "r409",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r647",
      "r706",
      "r709",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r57",
      "r58",
      "r121",
      "r122",
      "r283",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r305",
      "r308",
      "r708",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r305",
      "r308",
      "r708",
      "r727",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r204",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r640",
      "r642",
      "r645",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_OR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OREGON",
        "terseLabel": "Oregon"
       }
      }
     },
     "localname": "OR",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASC 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "ASU 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201704Member": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2017-04 Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.",
        "label": "Accounting Standards Update 2017-04 [Member]",
        "terseLabel": "ASU 2017-04"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201704Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201813Member": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.",
        "label": "Accounting Standards Update 2018-13 [Member]",
        "terseLabel": "ASU 2018-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201813Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201814Member": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-14 Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans.",
        "label": "Accounting Standards Update 2018-14 [Member]",
        "terseLabel": "ASU 2018-14"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201814Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201818Member": {
     "auth_ref": [
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.",
        "label": "Accounting Standards Update 2018-18 [Member]",
        "terseLabel": "ASU 2018-18"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201818Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44",
      "r633"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r29",
      "r205",
      "r206"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Receivable from collaboration",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "(Accretion of discounts) amortization of premiums on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r22",
      "r672",
      "r688"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Total accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13",
      "r15",
      "r47"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Other professional and consulting expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r13",
      "r15",
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r43",
      "r250"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r63",
      "r64",
      "r65",
      "r691",
      "r717",
      "r721"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r62",
      "r65",
      "r75",
      "r76",
      "r77",
      "r124",
      "r125",
      "r126",
      "r546",
      "r712",
      "r713",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated remaining useful lives"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r30",
      "r454",
      "r633"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r451",
      "r452",
      "r453",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r127",
      "r128",
      "r129",
      "r130",
      "r139",
      "r208",
      "r209",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r268",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r492",
      "r493",
      "r494",
      "r495",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r621",
      "r651",
      "r652",
      "r653",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r411",
      "r413",
      "r457",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "auth_ref": [
      "r296",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.",
        "label": "Adjustments to Additional Paid in Capital, Stock Split",
        "negatedLabel": "Settlement of fractional shares from reverse stock split"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r413",
      "r443",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r103",
      "r235",
      "r243"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "totalLabel": "Amortization of Intangible Assets, Total",
        "verboseLabel": "Amortization expense of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Asset acquisition purchase price",
        "totalLabel": "Asset Acquisition, Consideration Transferred, Total"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r527",
      "r528",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Value of common stock shares Issued for milestone payment"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Asset acquisition, transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Estimated fair value of contingent consideration",
        "totalLabel": "Asset Acquisition, Contingent Consideration, Liability, Total"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current.",
        "label": "Asset Acquisition, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration recognized"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r183",
      "r192",
      "r198",
      "r214",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r541",
      "r547",
      "r582",
      "r631",
      "r633",
      "r671",
      "r687"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r54",
      "r115",
      "r214",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r541",
      "r547",
      "r582",
      "r631",
      "r633"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.",
        "label": "Assets, Fair Value Adjustment",
        "terseLabel": "Change in fair value of equity investments"
       }
      }
     },
     "localname": "AssetsFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australian Taxation Office"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r414",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r554",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Bank Time Deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r391",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r391",
      "r405",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Business acquisition, transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Business acquisition, shares issued"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill expected to be deductible for income tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r515",
      "r516",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business acquisition purchase price",
        "totalLabel": "Business Combination, Consideration Transferred, Total"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r515",
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Business acquisition, shares issued value"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r102",
      "r525"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Milestone payments aggregate amount payable, maximum"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r514",
      "r517",
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration recognized",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "verboseLabel": "Estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r514",
      "r518"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration, current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value contingent consideration measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r514",
      "r518"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration, noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r39",
      "r105"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r18",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r18",
      "r106",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r100",
      "r105",
      "r110"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash and cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash and cash equivalents at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r100",
      "r593"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r142",
      "r147",
      "r155",
      "r157",
      "r159",
      "r168",
      "r169",
      "r170",
      "r214",
      "r269",
      "r274",
      "r275",
      "r276",
      "r280",
      "r281",
      "r290",
      "r291",
      "r294",
      "r295",
      "r582",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "verboseLabel": "Warrant, expiration date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants issued, exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrant to purchase of convertible preferred stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r301",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r532",
      "r533",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r257",
      "r676",
      "r695"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r264",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r633"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2021 and 2020, respectively; 127,416,740 and 107,648,925 shares issued and outstanding as of December 31, 2021 and 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r70",
      "r72",
      "r73",
      "r81",
      "r679",
      "r699"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Contract-Based Intangible Asset"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r302",
      "r303",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r302",
      "r303",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r290",
      "r291",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r86",
      "r115",
      "r214",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r582"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue",
        "totalLabel": "Cost of Revenue, Total"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r488",
      "r498"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r488"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r488",
      "r498",
      "r500"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r488",
      "r498"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r210",
      "r223",
      "r224",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total",
        "verboseLabel": "Allowance for losses on available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Securities contractual term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)",
        "terseLabel": "Total unrealized gains recorded in accumulated other comprehensive income (loss)",
        "totalLabel": "Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r489",
      "r498"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncome": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r116",
      "r489",
      "r498",
      "r499",
      "r500"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r23",
      "r24",
      "r478",
      "r673",
      "r685"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r464",
      "r465"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "totalLabel": "Deferred Income Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Total"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.",
        "label": "Deferred Revenue [Domain]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue, current portion",
        "totalLabel": "Deferred Revenue, Current, Total"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, noncurrent",
        "totalLabel": "Deferred Revenue, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r489",
      "r498"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r484",
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Equity compensations"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Reserves and accruals",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r480"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r465",
      "r481"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.",
        "label": "Deferred Tax Liabilities, Unrealized Gains on Trading Securities",
        "negatedLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities": {
     "auth_ref": [
      "r312",
      "r333",
      "r674",
      "r689"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan",
        "terseLabel": "Net liability recognized under pension plans"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, contribution expenses"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Defined contribution plan, company contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution plan, employee contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r103",
      "r181"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "verboseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r556",
      "r646"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Estimated fair value of the derivative liability",
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Change in estimated fair value of derivative liability",
        "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesEmbeddedDerivatives": {
     "auth_ref": [
      "r552",
      "r553",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.",
        "label": "Derivatives, Embedded Derivatives [Policy Text Block]",
        "terseLabel": "Embedded Derivatives"
       }
      }
     },
     "localname": "DerivativesEmbeddedDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technologies"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Awards"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r82",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r140",
      "r142",
      "r157",
      "r158",
      "r159",
      "r163",
      "r164",
      "r571",
      "r572",
      "r680",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net income (loss) per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r82",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r142",
      "r157",
      "r158",
      "r159",
      "r163",
      "r164",
      "r571",
      "r572",
      "r680",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net income (loss) per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShare1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r118",
      "r467",
      "r502"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r467",
      "r502"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r467",
      "r502"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign tax at less than federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r467",
      "r502"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r467",
      "r502"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "terseLabel": "Prior year tax rate adjustment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r467",
      "r502"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r467",
      "r502"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development tax credit",
        "terseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Embedded derivative liability",
        "verboseLabel": "Estimated fair value of embedded derivative"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure embedded derivative liability.",
        "label": "Embedded Derivative Liability, Measurement Input",
        "terseLabel": "Fair value contingent consideration measurement input"
       }
      }
     },
     "localname": "EmbeddedDerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Estimated weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized stock-based compensation expense related to stock option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option",
        "verboseLabel": "Options Issued and Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r75",
      "r76",
      "r77",
      "r124",
      "r125",
      "r126",
      "r128",
      "r136",
      "r138",
      "r167",
      "r219",
      "r296",
      "r298",
      "r451",
      "r452",
      "r453",
      "r494",
      "r495",
      "r570",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r712",
      "r713",
      "r714",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r212",
      "r702"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Change in fair value of equity investments",
        "totalLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss), Total"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r103",
      "r288"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in estimated fair value of convertible preferred stock warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r573",
      "r574",
      "r575",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Estimated Fair Value of Significant Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r573",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r383",
      "r574",
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r284",
      "r335",
      "r337",
      "r342",
      "r383",
      "r574",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r335",
      "r337",
      "r342",
      "r383",
      "r574",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r383",
      "r574",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Estimated Fair Value of Financial Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Changes in fair value",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at December 31, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r383",
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r605"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease obligation",
        "verboseLabel": "Financing lease obligation, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r605"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of finance lease obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r607",
      "r614"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of principal on financing lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "auth_ref": [
      "r538",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "auth_ref": [
      "r538",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancingReceivableAccruedInterestWriteoff": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of writeoff of accrued interest on financing receivable recognized by reversing interest income.",
        "label": "Financing Receivable, Accrued Interest, Writeoff",
        "terseLabel": "Write off of accrued interest receivable"
       }
      }
     },
     "localname": "FinancingReceivableAccruedInterestWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, estimated useful life",
        "verboseLabel": "Weighted-Average Remaining Useful Life (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 0.0,
       "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.",
        "label": "Finite-Lived Intangible Assets, Amortization Method",
        "terseLabel": "Finite-lived intangible assets, amortization method description"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r236",
      "r238",
      "r242",
      "r245",
      "r650",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r242",
      "r654"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r236",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r242",
      "r650"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "totalLabel": "Finite-lived intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r104",
      "r591",
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "terseLabel": "Foreign Currency Transaction Gain Loss Unrealized"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Gain from a sublease termination",
        "terseLabel": "Gain from a sublease termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r226",
      "r228",
      "r633",
      "r669"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Acquired Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r103",
      "r227",
      "r229",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant Revenue [Member]",
        "verboseLabel": "Grant Member"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r103",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets, excluding goodwill",
        "totalLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r103",
      "r246"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "negatedLabel": "Less impairment of intangible assets",
        "terseLabel": "Impairment of intangible assets",
        "verboseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r103",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived impairment of intangible assets",
        "verboseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r117",
      "r501"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r183",
      "r191",
      "r194",
      "r197",
      "r199",
      "r667",
      "r677",
      "r682",
      "r703"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income (loss) before provision for income taxes",
        "totalLabel": "Income (loss) before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r117",
      "r501"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r118",
      "r468",
      "r476",
      "r483",
      "r496",
      "r503",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r119",
      "r137",
      "r138",
      "r182",
      "r466",
      "r497",
      "r504",
      "r704"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "negatedTotalLabel": "Provision for income taxes",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r462",
      "r463",
      "r476",
      "r477",
      "r482",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Receivable from collaboration"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued liabilities and other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Change in deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r98",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "terseLabel": "Increase Decrease In Equity Securities Fv Ni"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r102",
      "r614"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": {
     "auth_ref": [
      "r144",
      "r145",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r159"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares.  Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares",
        "terseLabel": "Contingently issuable shares"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r143",
      "r144",
      "r146",
      "r159"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Options to purchase common stock",
        "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-lived Intangible Assets Acquired",
        "terseLabel": "Indefinite-lived intangible assets IPR&amp;D"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r234",
      "r240"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "terseLabel": "Interest income",
        "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "auth_ref": [
      "r723",
      "r725",
      "r726"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.",
        "label": "Investment Owned, at Fair Value",
        "terseLabel": "Investment Owned At Fair Value"
       }
      }
     },
     "localname": "InvestmentOwnedAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r213",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Carrying value of investment at cost",
        "totalLabel": "Investments, Total"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r618",
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total least cost",
        "totalLabel": "Lease, Cost, Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Lease, term of contract"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lessee, operating lease, existence of option to extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r115",
      "r193",
      "r214",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r542",
      "r547",
      "r548",
      "r582",
      "r631",
      "r632"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r115",
      "r214",
      "r582",
      "r633",
      "r675",
      "r693"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r115",
      "r214",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r542",
      "r547",
      "r548",
      "r582",
      "r631",
      "r632",
      "r633"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments",
        "totalLabel": "Long-term Investments, Total"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r9",
      "r46"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term investments",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected Stock Price Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input Risk Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r100",
      "r101",
      "r104"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r68",
      "r71",
      "r77",
      "r80",
      "r104",
      "r115",
      "r127",
      "r131",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r156",
      "r183",
      "r191",
      "r194",
      "r197",
      "r199",
      "r214",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r572",
      "r582",
      "r678",
      "r698"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "NONCASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "terseLabel": "Issuance of preferred stock in connection with asset acquisition",
        "totalLabel": "Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r183",
      "r191",
      "r194",
      "r197",
      "r199"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r611",
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r608",
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities",
        "verboseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": -1.0
      },
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating right-of-use assets",
        "verboseLabel": "Operating ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r617",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r616",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r47"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r21",
      "r670",
      "r686"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Total"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r69",
      "r72",
      "r539",
      "r540",
      "r545"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r67",
      "r354"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax",
        "negatedLabel": "Amortization of actuarial loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r61",
      "r63"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gains (losses) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenseMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other expense.",
        "label": "Other Expense [Member]",
        "terseLabel": "Other Expense"
       }
      }
     },
     "localname": "OtherExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r93",
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Business acquisition, cash consideration paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments",
        "totalLabel": "Payments to Acquire Investments, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r334",
      "r336",
      "r342",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r383",
      "r386",
      "r388",
      "r389",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": {
     "auth_ref": [
      "r367",
      "r387",
      "r389",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]",
        "terseLabel": "Pension Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPensionsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r361",
      "r364",
      "r368",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r389",
      "r390",
      "r405",
      "r406",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r414",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r27",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r27",
      "r633"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2021 and 2020, respectively; no shares issued and outstanding as of December 31, 2021 and 2020",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r37",
      "r38"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds after deducting underwriting discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock in connection with a collaboration agreements"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance cost",
        "verboseLabel": "Net proceeds from sale of convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from disposal of an asset held for sale"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r96",
      "r446"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r68",
      "r71",
      "r77",
      "r99",
      "r115",
      "r127",
      "r137",
      "r138",
      "r183",
      "r191",
      "r194",
      "r197",
      "r199",
      "r214",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r539",
      "r543",
      "r544",
      "r549",
      "r550",
      "r572",
      "r582",
      "r682"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r43",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property and equipment, estimated useful lives description"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r42",
      "r249"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r19",
      "r20",
      "r251",
      "r633",
      "r684",
      "r694"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r251",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r19",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r19",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r361",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r361",
      "r624",
      "r628",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r622",
      "r623",
      "r625",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r460",
      "r648",
      "r745"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r18",
      "r105",
      "r110"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash and cash equivalents, current",
        "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r12",
      "r21",
      "r105",
      "r110",
      "r729"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash and cash equivalents, noncurrent",
        "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalents": {
     "auth_ref": [
      "r110",
      "r668",
      "r690",
      "r728",
      "r730"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents",
        "terseLabel": "Restricted cash equivalents",
        "totalLabel": "Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "RestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "verboseLabel": "Restricted Shares Subject to Future Vesting"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r298",
      "r454",
      "r633",
      "r692",
      "r716",
      "r721"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r124",
      "r125",
      "r126",
      "r128",
      "r136",
      "r138",
      "r219",
      "r451",
      "r452",
      "r453",
      "r494",
      "r495",
      "r570",
      "r712",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r364",
      "r368",
      "r369",
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]",
        "terseLabel": "Retirement Plan Name"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r364",
      "r368",
      "r369",
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]",
        "terseLabel": "Retirement Plan Name"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r361",
      "r364",
      "r368",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r405",
      "r406",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r361",
      "r364",
      "r368",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r405",
      "r406",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r179",
      "r180",
      "r190",
      "r195",
      "r196",
      "r200",
      "r201",
      "r203",
      "r304",
      "r305",
      "r649"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r85",
      "r272",
      "r274",
      "r275",
      "r279",
      "r280",
      "r281",
      "r724"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from Related Parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue from grants"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r78",
      "r115",
      "r179",
      "r180",
      "r190",
      "r195",
      "r196",
      "r200",
      "r201",
      "r203",
      "r214",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r582",
      "r682"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r615",
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets in exchange for operating lease liabilities",
        "verboseLabel": "Operating lease liabilities obtained in exchange of right-of-use asset"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule Of Acquired Finite Lived Intangible Asset By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r367",
      "r368",
      "r371",
      "r372",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Income (loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r236",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r43",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Selected Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r626",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r414",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r420",
      "r430",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Plans Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Employees Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r475",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of Liability for Uncertain Tax Positions"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "totalLabel": "Selling, General and Administrative Expense, Total"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Purchase price as percentage of lower of fair market value on offering date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Purchase price as percentage of lower of fair market value on purchase date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of shares, Forfeited",
        "terseLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Unvested, Ending Balance",
        "periodStartLabel": "Number of Shares, Unvested, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility",
        "verboseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility,maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility,minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of employee payroll deduction on earnings",
        "verboseLabel": "Percentage of employee payroll deduction on earnings, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized to issue under purchase rights granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options,Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options,Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r422",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options,Outstanding, Ending Balance",
        "periodStartLabel": "Number of Options,Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Number of Options,Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price,Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options,Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price,Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r412",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share purchase price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period of awards from issuance date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r437",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of options (in years)",
        "verboseLabel": "Expected term of ESPP (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term,Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term,Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term,Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price as percentage of lower of fair market value on offering date",
        "verboseLabel": "Option price as a percentage of estimated fair value on the date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Convertible preferred stock, shares sold, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r612",
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r111",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r114",
      "r115",
      "r142",
      "r147",
      "r155",
      "r157",
      "r159",
      "r168",
      "r169",
      "r170",
      "r214",
      "r269",
      "r274",
      "r275",
      "r276",
      "r280",
      "r281",
      "r290",
      "r291",
      "r294",
      "r295",
      "r296",
      "r582",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r52",
      "r75",
      "r76",
      "r77",
      "r124",
      "r125",
      "r126",
      "r128",
      "r136",
      "r138",
      "r167",
      "r219",
      "r296",
      "r298",
      "r451",
      "r452",
      "r453",
      "r494",
      "r495",
      "r570",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r712",
      "r713",
      "r714",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r167",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r51",
      "r285",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock (in shares)",
        "verboseLabel": "Number of convertible preferred stock converted to shares of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r27",
      "r28",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Share issued under plan",
        "verboseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Issuance of common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock (in shares)",
        "verboseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r28",
      "r296",
      "r298",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options,Exercised",
        "terseLabel": "Exercise of stock option (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r296",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r27",
      "r28",
      "r296",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r296",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net proceeds from IPO",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r27",
      "r28",
      "r296",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r296",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r33",
      "r34",
      "r115",
      "r207",
      "r214",
      "r582",
      "r633"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split, description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r600",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "verboseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r600",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r600",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r600",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r634",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEvent1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SwissFederalTaxAdministrationFTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Switzerland.",
        "label": "Swiss Federal Tax Administration (FTA) [Member]",
        "terseLabel": "Swiss Federal Tax Administration (FTA)"
       }
      }
     },
     "localname": "SwissFederalTaxAdministrationFTAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r17",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r269",
      "r274",
      "r275",
      "r276",
      "r280",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Preferred stock shares issued",
        "verboseLabel": "Issuance of convertible preferred stock, net of issuance cost (in Shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "verboseLabel": "Outstanding convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of convertible preferred stock, net of issuance cost"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r127",
      "r128",
      "r129",
      "r130",
      "r139",
      "r208",
      "r209",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r268",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r492",
      "r493",
      "r494",
      "r495",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r621",
      "r651",
      "r652",
      "r653",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r120",
      "r335",
      "r383",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Government Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r461",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Gross unrecognized tax benefits at December 31",
        "periodStartLabel": "Gross unrecognized tax benefits at January 1",
        "terseLabel": "Unrecognized tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reduction for tax positions taken in the prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties accrued related to uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties expense related to uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Addition for tax positions taken in current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Addition for tax positions taken in the prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits, if recognized, would reduce effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase/decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r613",
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant",
        "verboseLabel": "Warrants to Purchase Convertible Preferred Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrant, expiration date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r141",
      "r159"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r140",
      "r159"
     ],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_AccruedLiabilitiesAndOtherLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities And Other Liabilities.",
        "label": "Accrued Liabilities And Other Liabilities [Member]",
        "terseLabel": "Accrued Liabilities And Other Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced proceeds applied to convertible preferred stock issuance.",
        "label": "Advanced Proceeds Applied To Convertible Preferred Stock Issuance",
        "terseLabel": "Advanced proceeds applied to convertible preferred stock issuance"
       }
      }
     },
     "localname": "AdvancedProceedsAppliedToConvertiblePreferredStockIssuance",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AlnylamAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alnylam agreement.",
        "label": "Alnylam Agreement [Member]",
        "terseLabel": "Alnylam Agreement"
       }
      }
     },
     "localname": "AlnylamAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AlnylamPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alnylam Pharmaceuticals, Inc.",
        "label": "Alnylam Pharmaceuticals Inc [Member]",
        "terseLabel": "Alnylam Pharmaceuticals Inc"
       }
      }
     },
     "localname": "AlnylamPharmaceuticalsIncMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AnnualLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fees required to pay annually.",
        "label": "Annual License Maintenance Fees"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFees",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AnotherProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Another product.",
        "label": "Another Product [Member]",
        "terseLabel": "Another Product"
       }
      }
     },
     "localname": "AnotherProductMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AntibodyLicenseTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price for the Antibody License under the collaboration agreement",
        "label": "Antibody License Transaction Price",
        "terseLabel": "Antibody license transaction price"
       }
      }
     },
     "localname": "AntibodyLicenseTransactionPrice",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AntibodyProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antibody Program.",
        "label": "Antibody Program [Member]",
        "terseLabel": "Antibody Program"
       }
      }
     },
     "localname": "AntibodyProgramMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AssetAcquisitionMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition milestone achieved during the reporting period.",
        "label": "Asset Acquisition Milestone Achieved",
        "terseLabel": "Asset acquisition milestone achieved"
       }
      }
     },
     "localname": "AssetAcquisitionMilestoneAchieved",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AssetAcquisitionMilestonePaymentAggregate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Asset Acquisition Milestone Payment Aggregate",
        "terseLabel": "Milestone payments aggregate amount payable, maximum"
       }
      }
     },
     "localname": "AssetAcquisitionMilestonePaymentAggregate",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition number of milestones achieved related to contingent consideration.",
        "label": "Asset Acquisition Number Of Milestones Achieved Related To Contingent Consideration",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill &amp; Melinda Gates Foundation.",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill &amp; Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BillMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill &amp; Melinda Gates Foundation.",
        "label": "Bill &amp; Melinda Gates Foundation [Member]",
        "terseLabel": "Bill &amp; Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillMelindaGatesFoundationMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BiologicalMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biological materials.",
        "label": "Biological Materials [Member]",
        "terseLabel": "Biological Materials"
       }
      }
     },
     "localname": "BiologicalMaterialsMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BriiAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brii Agreement.",
        "label": "Brii Agreement [Member]",
        "terseLabel": "Brii Agreement"
       }
      }
     },
     "localname": "BriiAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BriiBioParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brii Bio Parent.",
        "label": "Brii Bio Parent [Member]",
        "terseLabel": "Brii Bio Parent"
       }
      }
     },
     "localname": "BriiBioParentMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BriiBiosciencesOffshoreLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brii Biosciences Offshore Limited.",
        "label": "Brii Biosciences Offshore Limited [Member]",
        "terseLabel": "Brii Bio"
       }
      }
     },
     "localname": "BriiBiosciencesOffshoreLimitedMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition number of milestones achieved related to contingent consideration.",
        "label": "Business Acquisition Number Of Milestones Achieved Related To Contingent Consideration",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition number of specified clinical milestones achieved.",
        "label": "Business Acquisition Number Of Specified Clinical Milestones Achieved",
        "terseLabel": "Number of specified clinical milestones achieved"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_BusinessAgreementEquityInvestmentCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business agreement equity investment commitment.",
        "label": "Business Agreement Equity Investment Commitment",
        "terseLabel": "Business agreement equity investment commitment."
       }
      }
     },
     "localname": "BusinessAgreementEquityInvestmentCommitment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_BusinessAgreementGrantAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business agreement grant amount.",
        "label": "Business Agreement Grant Amount",
        "terseLabel": "Business agreement grant amount"
       }
      }
     },
     "localname": "BusinessAgreementGrantAmount",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combinations additional consideration payable upon achievement of specified events.",
        "label": "Business Combinations Additional Consideration Payable Upon Achievement Of Specified Events",
        "terseLabel": "Additional consideration payable upon achievement of specified milestone events"
       }
      }
     },
     "localname": "BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and short-term investments, excluding equity investment.",
        "label": "Cash Cash Equivalents And Short Term Investments Excluding Equity Investment",
        "terseLabel": "Cash, cash equivalents and short-term investments, excluding equity investment"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CashGrantAwarded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash grant awarded.",
        "label": "Cash Grant Awarded",
        "terseLabel": "Business agreement grant amount"
       }
      }
     },
     "localname": "CashGrantAwarded",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid in lieu of fractional shares in reverse split of common stock",
        "label": "Cash Paid In Lieu Of Fractional Shares In Reverse Split Of Common Stock",
        "negatedLabel": "Cash paid in lieu of fractional shares related to reverse stock split"
       }
      }
     },
     "localname": "CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestones [Member]",
        "label": "Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and Regulatory Milestones"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ClinicalDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Development [Member]",
        "label": "Clinical Development [Member]",
        "terseLabel": "Clinical Development"
       }
      }
     },
     "localname": "ClinicalDevelopmentMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement, number of separate programs agreed to collaborate.",
        "label": "Collaboration Agreement Number Of Separate Programs Agreed To Collaborate",
        "terseLabel": "Number of separate programs"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_CollaborationAgreementNumberOfUnitsOfAccount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement, number of units of account.",
        "label": "Collaboration Agreement Number Of Units Of Account",
        "terseLabel": "Number of units of account"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfUnitsOfAccount",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_CollaborationAgreementRelatedCostsAndExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs and expenses for the period incurred under the collaboration agreements.",
        "label": "Collaboration Agreement Related Costs And Expenses",
        "terseLabel": "Expenses incurred under agreement"
       }
      }
     },
     "localname": "CollaborationAgreementRelatedCostsAndExpenses",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CollaborationAgreementTerminationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement termination description.",
        "label": "Collaboration Agreement Termination Description",
        "terseLabel": "Termination description"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationDescription",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_CollaborationAgreementTransactionPriceConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement transaction price consideration.",
        "label": "Collaboration Agreement Transaction Price Consideration",
        "terseLabel": "Collaboration Agreement Transaction Price Consideration"
       }
      }
     },
     "localname": "CollaborationAgreementTransactionPriceConsideration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CollaborationAgreementTransactionPriceUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received under the Collaboration agreement, which represents part of the transaction price.",
        "label": "Collaboration Agreement Transaction Price Upfront Fee",
        "verboseLabel": "Upfront fee"
       }
      }
     },
     "localname": "CollaborationAgreementTransactionPriceUpfrontFee",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration Revenue [Member]"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CollaborationTypeAndPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Type and Programs",
        "label": "Collaboration Type and Programs",
        "terseLabel": "Collaboration type and program"
       }
      }
     },
     "localname": "CollaborationTypeAndPrograms",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CommonStockIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issuance cost.",
        "label": "Common Stock Issuance Cost",
        "terseLabel": "Common stock issuance cost"
       }
      }
     },
     "localname": "CommonStockIssuanceCost",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CommonStockIssuedInConnectionWithLicenseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued in connection with license agreement.",
        "label": "Common Stock Issued In Connection With License Agreement",
        "terseLabel": "Common stock issued in connection with license agreement"
       }
      }
     },
     "localname": "CommonStockIssuedInConnectionWithLicenseAgreement",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CommonStockSharesIssuedForMilestonePaymentShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares issued for milestone payment.",
        "label": "Common stock shares Issued for milestone payment| shares",
        "terseLabel": "Common stock shares Issued for milestone payment| shares"
       }
      }
     },
     "localname": "CommonStockSharesIssuedForMilestonePaymentShares",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of credit risk credit loss and other risks and uncertainties.",
        "label": "Concentration Of Credit Risk Credit Loss And Other Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_ContingentConsiderationLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration liability",
        "label": "Contingent Consideration Liability [Member]",
        "terseLabel": "Contingent Consideration",
        "verboseLabel": "Contingent Consideration Liability"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ContractRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract revenue.",
        "label": "Contract Revenue [Member]",
        "terseLabel": "Contract Revenue"
       }
      }
     },
     "localname": "ContractRevenueMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of preferred stock into common stock upon completion of initial public offering.",
        "label": "Conversion Of Preferred Stock Into Common Stock Upon Completion Of Initial Public Offering",
        "terseLabel": "Conversion of preferred stock into common stock upon completion of initial public offering"
       }
      }
     },
     "localname": "ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ConvertiblePreferredStockIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock issuance cost.",
        "label": "Convertible Preferred Stock Issuance Cost",
        "terseLabel": "Convertible preferred stock, net of issuance cost"
       }
      }
     },
     "localname": "ConvertiblePreferredStockIssuanceCost",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ConvertiblePreferredStockWarrantLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock warrant liability.",
        "label": "Convertible Preferred Stock Warrant Liability [Abstract]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockWarrantLiabilityAbstract",
     "nsuri": "http://www.vir.bio/20211231",
     "xbrltype": "stringItemType"
    },
    "vir_ConvertiblePreferredStockWarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock warrant liability.",
        "label": "Convertible Preferred Stock Warrant Liability [Member]",
        "verboseLabel": "Warrant to Purchase Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockWarrantLiabilityMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ConvertiblePreferredStockWarrantLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of key terms of the warrant agreement and valuation assumptions.",
        "label": "Convertible Preferred Stock Warrant Liability [Text Block]",
        "terseLabel": "Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "localname": "ConvertiblePreferredStockWarrantLiabilityTextBlock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities in process research and development.",
        "label": "Deferred Tax Liabilities In Process Research And Development",
        "negatedLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInProcessResearchAndDevelopment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedLabel": "ROU assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DefinitiveCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Definitive collaboration agreement.",
        "label": "Definitive Collaboration Agreement [Member]",
        "terseLabel": "Definitive Collaboration Agreement"
       }
      }
     },
     "localname": "DefinitiveCollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_DeterminedTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determined transaction price.",
        "label": "Determined Transaction Price",
        "terseLabel": "Determined transaction price"
       }
      }
     },
     "localname": "DeterminedTransactionPrice",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DevelopedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed technology.",
        "label": "Developed Technology [Member]",
        "terseLabel": "Developed Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_DevelopmentAndManufacturingCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and manufacturing collaboration agreement.",
        "label": "Development And Manufacturing Collaboration Agreement [Member]",
        "terseLabel": "Development and Manufacturing Collaboration Agreement"
       }
      }
     },
     "localname": "DevelopmentAndManufacturingCollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_DevelopmentProgramsExercisedByBriiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Programs Exercised by Brii [Member]",
        "label": "Development Programs Exercised by Brii [Member]",
        "terseLabel": "Development Programs Exercised by Brii"
       }
      }
     },
     "localname": "DevelopmentProgramsExercisedByBriiMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_DevelopmentProgramsExercisedByVirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Programs Exercised by Vir [Member]",
        "label": "Development Programs Exercised by Vir [Member]",
        "terseLabel": "Development Programs Exercised by Vir"
       }
      }
     },
     "localname": "DevelopmentProgramsExercisedByVirMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_EachInfectiousDiseaseSiRNAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Each infectious disease siRNA.",
        "label": "Each Infectious Disease Si R N A [Member]",
        "terseLabel": "Each Infectious Disease siRNA"
       }
      }
     },
     "localname": "EachInfectiousDiseaseSiRNAMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent items percent.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items Percent",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItemsPercent",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_EquityInvestmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment Current",
        "label": "Equity Investment Current",
        "terseLabel": "Equity Investment Current"
       }
      }
     },
     "localname": "EquityInvestmentCurrent",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_EsppDiscountedPurchasePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP Discounted Purchase Price Percentage",
        "label": "ESPP Discounted Purchase Price Percentage",
        "terseLabel": "ESPP discounted purchase price percentage"
       }
      }
     },
     "localname": "EsppDiscountedPurchasePricePercentage",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_EstimatedSharesEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Shares Employee Stock Purchase Plans",
        "label": "Estimated Shares Employee Stock Purchase Plans",
        "terseLabel": "Estimated shares to be issued under plan"
       }
      }
     },
     "localname": "EstimatedSharesEmployeeStockPurchasePlans",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_EstimatedSharesIssuableUnderTheESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Shares Issuable Under the E S P P [Member]",
        "label": "Estimated Shares Issuable Under the E S P P [Member]",
        "terseLabel": "Estimated Shares Issuable Under The E S P P [Member]"
       }
      }
     },
     "localname": "EstimatedSharesIssuableUnderTheESPPMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ExcessFundsPayableUnderGrantAgreementsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess funds payable under grant agreements current.",
        "label": "Excess Funds Payable Under Grant Agreements Current",
        "terseLabel": "Excess funds payable under grant agreements"
       }
      }
     },
     "localname": "ExcessFundsPayableUnderGrantAgreementsCurrent",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ExecutiveOfficerAndDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive officer and director.",
        "label": "Executive Officer And Director [Member]",
        "terseLabel": "Executive Officer and Director"
       }
      }
     },
     "localname": "ExecutiveOfficerAndDirectorMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FailedSaleLeasebackTransactionProceedsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow received in a failed sale-leaseback recognized in financing activities.",
        "label": "Failed Sale Leaseback Transaction Proceeds Financing Activities",
        "terseLabel": "Proceeds received from financing lease obligation"
       }
      }
     },
     "localname": "FailedSaleLeasebackTransactionProceedsFinancingActivities",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FairMarketValueOfCommonStockIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair market value of common stock issued.",
        "label": "Fair Market Value Of Common Stock Issued",
        "terseLabel": "Fair market value of the common stock issued"
       }
      }
     },
     "localname": "FairMarketValueOfCommonStockIssued",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, reclassification of contingent consideration to accrued liabilities upon achievement of milestone.",
        "label": "Fair Value Reclassification Of Contingent Consideration To Accrued Liabilities Upon Achievement Of Milestone",
        "terseLabel": "Payment of contingent consideration upon achievement of the TomegaVax milestone"
       }
      }
     },
     "localname": "FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value reclassification of derivative liability to accrued liabilities upon achievement of development milestone.",
        "label": "Fair Value Reclassification Of Derivative Liability To Accrued Liabilities Upon Achievement Of Development Milestone",
        "terseLabel": "Reclassification of derivative liability to accrued liabilities upon achievement of development milestone"
       }
      }
     },
     "localname": "FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsAmortizedCostBasis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets amortized cost basis.",
        "label": "Financial Assets Amortized Cost Basis",
        "terseLabel": "Financial Assets, Amortized Cost",
        "totalLabel": "Financial Assets, Amortized Cost"
       }
      }
     },
     "localname": "FinancialAssetsAmortizedCostBasis",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets fair value.",
        "label": "Financial Assets Fair Value",
        "terseLabel": "Financial Assets, Aggregate Fair Value"
       }
      }
     },
     "localname": "FinancialAssetsFairValue",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsGrossUnrealizedHoldingGains": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets gross unrealized holding gains.",
        "label": "Financial Assets Gross Unrealized Holding Gains",
        "terseLabel": "Financial Assets, Gross Unrealized Holding Gains"
       }
      }
     },
     "localname": "FinancialAssetsGrossUnrealizedHoldingGains",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsGrossUnrealizedHoldingLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets gross unrealized holding losses.",
        "label": "Financial Assets Gross Unrealized Holding Losses",
        "negatedLabel": "Financial Assets, Gross Unrealized Holding Losses"
       }
      }
     },
     "localname": "FinancialAssetsGrossUnrealizedHoldingLosses",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FiniteLivedIntangibleAssetsAccumulatedImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite lived intangible assets accumulated impairment.",
        "label": "Finite Lived Intangible Assets Accumulated Impairment",
        "negatedLabel": "Less impairment of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FiniteLivedIntangibleAssetsAmortizationExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in the next five years following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpense",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-lived Intangible assets, reclassified from Indefinite-lived.",
        "label": "Finite Lived Intangible Assets Reclassified From Indefinite Lived",
        "terseLabel": "Finite-lived intangible asset, reclassified from indefinite-lived asset"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FirstAndSecondClosingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First and second closings.",
        "label": "First And Second Closings [Member]",
        "terseLabel": "Two Closings"
       }
      }
     },
     "localname": "FirstAndSecondClosingsMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FirstInfectiousDiseaseProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First infectious disease product.",
        "label": "First Infectious Disease Product [Member]",
        "terseLabel": "Infectious Disease Product"
       }
      }
     },
     "localname": "FirstInfectiousDiseaseProductMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FirstPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First plan.",
        "label": "First Plan [Member]",
        "terseLabel": "First Plan"
       }
      }
     },
     "localname": "FirstPlanMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FirstSiRNAProductHBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First SiRNA product HBV.",
        "label": "First Si R N A Product H B V [Member]",
        "terseLabel": "First siRNA Product HBV"
       }
      }
     },
     "localname": "FirstSiRNAProductHBVMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FirstSiRNAProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First siRNA product member.",
        "label": "First Si R N A Product [Member]",
        "terseLabel": "First siRNA Product HBV"
       }
      }
     },
     "localname": "FirstSiRNAProductMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on offering.",
        "label": "Follow On Offering [Member]",
        "terseLabel": "Follow-on Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FormerBusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of former liability recognized arising from contingent consideration in a business combination.",
        "label": "Former Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Estimated fair value of former contingent consideration"
       }
      }
     },
     "localname": "FormerBusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FundsReceivedInAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds received in advance.",
        "label": "Funds Received In Advance",
        "terseLabel": "Funds received in advance"
       }
      }
     },
     "localname": "FundsReceivedInAdvance",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_GlaxoGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Group Limited.",
        "label": "Glaxo Group Limited [Member]",
        "terseLabel": "GGL"
       }
      }
     },
     "localname": "GlaxoGroupLimitedMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA.",
        "label": "Glaxo Smith Kline Intellectual Property Development Limited And Glaxo Smith Kline Biologicals S A [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GlaxoSmithKlineTradingServiceLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo SmithKline Trading Service Limited.",
        "label": "Glaxo Smith Kline Trading Service Limited [Member]",
        "terseLabel": "GSKTSL"
       }
      }
     },
     "localname": "GlaxoSmithKlineTradingServiceLimitedMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GlaxoWellcomeUKLimitedAndBeechamSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Wellcome U K Limited And Beecham S A.",
        "label": "Glaxo Wellcome U K Limited And Beecham S A [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoWellcomeUKLimitedAndBeechamSAMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GrantAgreementAmendedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreement amended date.",
        "label": "Grant Agreement Amended Date",
        "verboseLabel": "Grant agreement amended date"
       }
      }
     },
     "localname": "GrantAgreementAmendedDate",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementAmendedExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreement amended expiration date.",
        "label": "Grant Agreement Amended Expiration Date",
        "terseLabel": "Grant agreement amended expiration date"
       }
      }
     },
     "localname": "GrantAgreementAmendedExpirationDate",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementEffectiveEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreement effective end date.",
        "label": "Grant Agreement Effective End Date",
        "terseLabel": "Grant agreement effective end date"
       }
      }
     },
     "localname": "GrantAgreementEffectiveEndDate",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The date the grant agreement expires.",
        "label": "Grant Agreement Expiration Date",
        "terseLabel": "Grant agreement expiration date"
       }
      }
     },
     "localname": "GrantAgreementExpirationDate",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementExpirationDateBeforeAmendment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreement expiration date before amendment.",
        "label": "Grant Agreement Expiration Date Before Amendment",
        "terseLabel": "Grant agreement expiration date before amendment"
       }
      }
     },
     "localname": "GrantAgreementExpirationDateBeforeAmendment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreements disclosure.",
        "label": "Grant Agreements Disclosure [Text Block]",
        "terseLabel": "Grant Agreements"
       }
      }
     },
     "localname": "GrantAgreementsDisclosureTextBlock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_GrantAwardedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant awarded amount.",
        "label": "Grant Awarded Amount",
        "terseLabel": "Grant awarded amount"
       }
      }
     },
     "localname": "GrantAwardedAmount",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_GrantAwardedAmountMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum grant awarded amount.",
        "label": "Grant Awarded Amount Maximum",
        "terseLabel": "Grant awarded amount. maximum"
       }
      }
     },
     "localname": "GrantAwardedAmountMaximum",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_GrantsAgreementAmendedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants Agreement Amended Date",
        "label": "Grants Agreement Amended Date"
       }
      }
     },
     "localname": "GrantsAgreementAmendedDate",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "vir_HBVProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HBV program.",
        "label": "H B V Program [Member]",
        "terseLabel": "HBV Program"
       }
      }
     },
     "localname": "HBVProgramMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HcmvVaccinePlatformGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hcmv Vaccine Platform Grant [Member].",
        "label": "Hcmv Vaccine Platform Grant [Member]",
        "terseLabel": "HCMV-Vaccine Platform Grant"
       }
      }
     },
     "localname": "HcmvVaccinePlatformGrantMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HepatitisBVirusProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus Product Member.",
        "label": "Hepatitis B Virus Product [Member]",
        "terseLabel": "HBV product"
       }
      }
     },
     "localname": "HepatitisBVirusProductMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HumabsBiomedSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humabs Biomed SA.",
        "label": "Humabs Biomed S A [Member]",
        "terseLabel": "Humabs",
        "verboseLabel": "Humabs IP Transfer"
       }
      }
     },
     "localname": "HumabsBiomedSAMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HumanImmunodeficiencyVirusGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Human immunodeficiency virus grant.",
        "label": "Human Immunodeficiency Virus Grant [Member]",
        "terseLabel": "Human Immunodeficiency Virus (\"HIV\") Grant"
       }
      }
     },
     "localname": "HumanImmunodeficiencyVirusGrantMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes line items.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes table.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in payment of contingent consideration in excess of acquisition date fair value.",
        "label": "Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value",
        "terseLabel": "Payment of contingent consideration in excess of acquisition date fair value"
       }
      }
     },
     "localname": "IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_IncreaseDecreaseInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in research And development expense.",
        "label": "Increase Decrease In Research And Development Expense",
        "terseLabel": "Research and development expense",
        "verboseLabel": "Increase (decrease) in research and development expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpense",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares subject to future vesting using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting",
        "terseLabel": "Restricted shares subject to future vesting"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_InfectiousDiseaseProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Disease Product [Member]",
        "label": "Infectious Disease Product [Member]"
       }
      }
     },
     "localname": "InfectiousDiseaseProductMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_InfluenzaAAndHBVResearchProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Influenza A and HBV research programs member.",
        "label": "Influenza A And H B V Research Programs [Member]",
        "terseLabel": "Influenza A and HBV Research Programs"
       }
      }
     },
     "localname": "InfluenzaAAndHBVResearchProgramsMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_InfluenzaAAndInfluenzaBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Influenza A and Influenza B member.",
        "label": "Influenza A And Influenza B [Member]",
        "terseLabel": "Influenza A and Influenza B"
       }
      }
     },
     "localname": "InfluenzaAAndInfluenzaBMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_InfluenzaAResearchProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Influenza A research programs.",
        "label": "Influenza A Research Programs [Member]",
        "terseLabel": "Influenza A Research Programs"
       }
      }
     },
     "localname": "InfluenzaAResearchProgramsMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_InitialFairValueOfDerivativeLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial fair value of derivative liability.",
        "label": "Initial Fair Value Of Derivative Liability",
        "terseLabel": "Initial fair value of derivative liability"
       }
      }
     },
     "localname": "InitialFairValueOfDerivativeLiability",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_InitialPublicOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering costs.",
        "label": "Initial Public Offering Costs",
        "terseLabel": "Initial public offering costs"
       }
      }
     },
     "localname": "InitialPublicOfferingCosts",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_IssuanceOfCommonStockToSettleAContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock to settle a contingent consideration",
        "label": "Issuance of common stock to settle a contingent consideration",
        "terseLabel": "Issuance of common stock to settle a contingent consideration"
       }
      }
     },
     "localname": "IssuanceOfCommonStockToSettleAContingentConsideration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_LeaseArrangementContractualExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease arrangement, contractual expiration beginning year.",
        "label": "Lease Arrangement Contractual Expiration Beginning Year",
        "terseLabel": "Lease arrangement, contractual expiration period, beginning year"
       }
      }
     },
     "localname": "LeaseArrangementContractualExpirationBeginningYear",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "vir_LeaseArrangementContractualExpirationEndingYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease arrangement, contractual expiration ending year.",
        "label": "Lease Arrangement Contractual Expiration Ending Year",
        "terseLabel": "Lease arrangement, contractual expiration period, ending year"
       }
      }
     },
     "localname": "LeaseArrangementContractualExpirationEndingYear",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability net tenant improvement allowance yet to be received.",
        "label": "Lessee Operating Lease Liability Net Tenant Improvement Allowance Yet To Be Received",
        "negatedLabel": "Less: net tenant improvement allowance yet to be received"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_LetterAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter agreement.",
        "label": "Letter Agreement [Member]",
        "terseLabel": "TomegaVax Letter Agreement",
        "verboseLabel": "Letter Agreement Member"
       }
      }
     },
     "localname": "LetterAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_LicenseAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement upfront payment.",
        "label": "License Agreement Upfront Payment",
        "terseLabel": "License agreement upfront payment"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPayment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateCommercialSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate commercial sales milestone payments.",
        "label": "Maximum Aggregate Commercial Sales Milestone Payments",
        "terseLabel": "Maximum aggregate commercial sales milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateCommercialSalesMilestonePayments",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate development and regulatory milestone payments.",
        "label": "Maximum Aggregate Development And Regulatory Milestone Payments",
        "terseLabel": "Maximum aggregate development and regulatory milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateDevelopmentAndRegulatoryMilestonePayments",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone payment for achievement of specified milestones, including development, regulatory and commercial.",
        "label": "Maximum aggregate milestone payment for achievement of specified milestones"
       }
      }
     },
     "localname": "MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone payments.",
        "label": "Maximum Aggregate Milestone Payments",
        "terseLabel": "Maximum aggregate milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateMilestonePayments",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone payment for achievement of specified annual net sales",
        "label": "Maximum Aggregate Sales Milestone Payment",
        "terseLabel": "Maximum aggregate sales milestone payment"
       }
      }
     },
     "localname": "MaximumAggregateSalesMilestonePayment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate sales milestone payments.",
        "label": "Maximum Aggregate Sales Milestone Payments",
        "terseLabel": "Maximum aggregate sales milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateSalesMilestonePayments",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment for achievement of specified development and regulatory.",
        "label": "Maximum Milestone Payment For Achievement Of Specified Development And Regulatory",
        "terseLabel": "Maximum milestone payment for achievement of specified development and regulatory"
       }
      }
     },
     "localname": "MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Number of Development Program Granted from Counterparty",
        "label": "Maximum Number of Development Program Granted from Counterparty",
        "terseLabel": "Maximum number of development program granted from Brii to Vir | Program"
       }
      }
     },
     "localname": "MaximumNumberOfDevelopmentProgramGrantedFromCounterparty",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Number of Development Program Granted to Counterparty",
        "label": "Maximum Number of Development Program Granted to Counterparty",
        "terseLabel": "Maximum number of development program granted from Vir to Brii | Program"
       }
      }
     },
     "localname": "MaximumNumberOfDevelopmentProgramGrantedToCounterparty",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of products covered against milestone payment.",
        "label": "Maximum Number of Products Covered Against Milestone Payment",
        "terseLabel": "Maximum number of products covered against milestone payment"
       }
      }
     },
     "localname": "MaximumNumberOfProductsCoveredAgainstMilestonePayment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of right to perform details in connection with antibody product.",
        "label": "Maximum Percentage Of Right To Perform Details In Connection With Antibody Product",
        "terseLabel": "Maximum percentage of right to perform details in connection with antibody product"
       }
      }
     },
     "localname": "MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_MaximumSalesMilestonToPay": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of proceeds to pay upon achievement of sales milestone",
        "label": "Maximum Sales Mileston To Pay",
        "terseLabel": "Maximum sales milestone to pay"
       }
      }
     },
     "localname": "MaximumSalesMilestonToPay",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment for achievement of specified annual net sales.",
        "label": "Maximum Sales Milestone Payment",
        "terseLabel": "Maximum sales milestone payment"
       }
      }
     },
     "localname": "MaximumSalesMilestonePayment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumSharesToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum shares to be issued.",
        "label": "Maximum Shares To Be Issued",
        "terseLabel": "Maximum shares to be issued"
       }
      }
     },
     "localname": "MaximumSharesToBeIssued",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum term of offering period specified under plan.",
        "label": "Maximum Term Of Offering Period Specified Under Plan",
        "terseLabel": "Maximum term of offering period specified under plan"
       }
      }
     },
     "localname": "MaximumTermOfOfferingPeriodSpecifiedUnderPlan",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_MeasurementInputExpectedRevenueVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input expected revenue volatility.",
        "label": "Measurement Input Expected Revenue Volatility [Member]",
        "terseLabel": "Measurement Input Expected Revenue Volatility"
       }
      }
     },
     "localname": "MeasurementInputExpectedRevenueVolatilityMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MeasurementInputExpectedVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input expected volatility.",
        "label": "Measurement Input Expected Volatility [Member]",
        "terseLabel": "Measurement Input Expected Volatility"
       }
      }
     },
     "localname": "MeasurementInputExpectedVolatilityMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MeasurementInputProbabilityRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, probability rate.",
        "label": "Measurement Input Probability Rate [Member]",
        "terseLabel": "Probability of Achievement"
       }
      }
     },
     "localname": "MeasurementInputProbabilityRateMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MedImmuneAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedImmune agreement.",
        "label": "Med Immune Agreement [Member]",
        "terseLabel": "MedImmune Agreement"
       }
      }
     },
     "localname": "MedImmuneAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MedImmuneLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedImmune, limited liability company.",
        "label": "Med Immune Limited Liability Company [Member]",
        "terseLabel": "MedImmune"
       }
      }
     },
     "localname": "MedImmuneLimitedLiabilityCompanyMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MilestonePayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payable.",
        "label": "Milestone Payable",
        "terseLabel": "Milestone payable"
       }
      }
     },
     "localname": "MilestonePayable",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MilestonePaymentDueToCompany": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment due to company under grant agreement.",
        "label": "Milestone Payment Due To Company",
        "terseLabel": "Milestone payment due to Vir"
       }
      }
     },
     "localname": "MilestonePaymentDueToCompany",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received.",
        "label": "Milestone Payment Received",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MilestonePaymentsPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments paid.",
        "label": "Milestone Payments Paid",
        "terseLabel": "Milestone payments paid"
       }
      }
     },
     "localname": "MilestonePaymentsPaid",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MilestonePaymentsRelatedTermsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments related terms description.",
        "label": "Milestone Payments Related Terms Description",
        "terseLabel": "Milestone payments related terms"
       }
      }
     },
     "localname": "MilestonePaymentsRelatedTermsDescription",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum common stock conversion price for milestone payments consideration.",
        "label": "Minimum Common Stock Conversion Price For Milestone Payments Consideration",
        "terseLabel": "Minimum common stock conversion price for milestone payments consideration"
       }
      }
     },
     "localname": "MinimumCommonStockConversionPriceForMilestonePaymentsConsideration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vir_MinimumCommonStockPriceForMilestonePaymentsConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum common stock price that triggers milestone payment.",
        "label": "Minimum Common Stock Price For Milestone Payments Consideration",
        "terseLabel": "Minimum common stock price for milestone payments consideration"
       }
      }
     },
     "localname": "MinimumCommonStockPriceForMilestonePaymentsConsideration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vir_NationalInstitutesOfHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National institutes of health.",
        "label": "National Institutes Of Health [Member]",
        "terseLabel": "National Institutes of Health"
       }
      }
     },
     "localname": "NationalInstitutesOfHealthMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_NetProceedsFromIssuanceSecondaryPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's follow on offering of stock to the public, net of commissions and expenses.",
        "label": "Net proceeds From Issuance Secondary Public Offering",
        "terseLabel": "Net proceeds from issuance secondary public offering"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceSecondaryPublicOffering",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_NonCashCommonStockIssuedForContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash common stock issued for contingent consideration.",
        "label": "Non Cash Common Stock Issued For Contingent Consideration",
        "terseLabel": "Common stock issued for payment of contingent consideration"
       }
      }
     },
     "localname": "NonCashCommonStockIssuedForContingentConsideration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_NumberOfAntibodiesToDevelop": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of antibodies to develop.",
        "label": "Number of Antibodies to Develop",
        "verboseLabel": "Number of antibodies to develop"
       }
      }
     },
     "localname": "NumberOfAntibodiesToDevelop",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_NumberOfClassOfStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of class of stock.",
        "label": "Number of Class of Stock",
        "terseLabel": "Number of class of stock"
       }
      }
     },
     "localname": "NumberOfClassOfStock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of years conduct certain research and development activities under mutually agreed development plans.",
        "label": "Number Of Years Conduct Certain Research And Development Activities Under Mutually Agreed Development Plans",
        "terseLabel": "Number of years conduct certain research and development activities under mutually agreed development plans"
       }
      }
     },
     "localname": "NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_ObligationToPayCapacityReservation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount obligated to pay for capacity reservation under the agreement.",
        "label": "Obligation To Pay Capacity Reservation",
        "terseLabel": "Obligation to pay capacity reservation"
       }
      }
     },
     "localname": "ObligationToPayCapacityReservation",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OfferingPeriodEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of offering period under the Plan.",
        "label": "Offering Period Employee Stock Purchase Plan",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "OfferingPeriodEmployeeStockPurchasePlan",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_OperatingAndFinanceRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance rent expense.",
        "label": "Operating And Finance Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingAndFinanceRentExpense",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OperatingLeaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease.",
        "label": "Operating Lease [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseAbstract",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OperatingLeaseIncentiveOverLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Incentive Over Lease Liabilities",
        "label": "Operating Lease Incentive Over Lease Liabilities",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OperatingLeaseIncentiveOverLeaseLiabilities",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OperatingLeaseOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease other information.",
        "label": "Operating Lease Other Information [Abstract]",
        "terseLabel": "Other Information"
       }
      }
     },
     "localname": "OperatingLeaseOtherInformationAbstract",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OperatingLossCarryforwardsExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration beginning year.",
        "label": "Operating Loss Carryforwards Expiration Beginning Year",
        "verboseLabel": "Net operating loss carryforwards expiration beginning year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationBeginningYear",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "vir_OperatingLossCarryforwardsLimitationOnUsePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards limitation on use percentage.",
        "label": "Operating Loss Carryforwards Limitation On Use Percentage",
        "terseLabel": "Net operating loss deduction limitation as percentage of taxable income"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationOnUsePercentage",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_OptionExerciseFeeConsiderationToBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise fee consideration to be received.",
        "label": "Option Exercise Fee Consideration To Be Received",
        "terseLabel": "Option exercise fee to be received"
       }
      }
     },
     "localname": "OptionExerciseFeeConsiderationToBeReceived",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OptionExerciseFeeHighEndOfTheRange": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the high end of the range of option exercise fee upon exercise of a program.",
        "label": "Option exercise fee, high end of the range",
        "terseLabel": "Option exercise fee, high end of the range"
       }
      }
     },
     "localname": "OptionExerciseFeeHighEndOfTheRange",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OptionExerciseFeeLowEndOfTheRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the low end of the range of option exercise fee upon exercise of a program.",
        "label": "Option exercise fee, low end of the range",
        "terseLabel": "Option exercise fee, low end of the range"
       }
      }
     },
     "localname": "OptionExerciseFeeLowEndOfTheRange",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OptionExerciseFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise fee received.",
        "label": "Option Exercise Fee Received",
        "terseLabel": "Option exercise fee received"
       }
      }
     },
     "localname": "OptionExerciseFeeReceived",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive income loss pension and other postretirement benefit plans adjustment to projected benefit obligations net of tax.",
        "label": "Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment To Projected Benefit Obligations Net Of Tax",
        "negatedLabel": "Adjustment to projected benefit obligations, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentMadeForAssetAcquisitionMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for asset acquisition milestone.",
        "label": "Payment Made For Asset Acquisition Milestone",
        "terseLabel": "Payment made for asset acquisition milestone"
       }
      }
     },
     "localname": "PaymentMadeForAssetAcquisitionMilestone",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentMadeForBusinessCombinationMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for business combination milestone.",
        "label": "Payment made for business combination milestone",
        "terseLabel": "Payment made for business combination milestone"
       }
      }
     },
     "localname": "PaymentMadeForBusinessCombinationMilestone",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of contingent consideration.",
        "label": "Payment Of Contingent Consideration",
        "negatedLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentOfContingentConsideration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentToCollaboratorResultingFromProgramOptionExercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to a collaborator due to a program option exercise under a separate agreement.",
        "label": "Payment to collaborator resulting from program option exercise",
        "terseLabel": "Payment to collaborator resulting from program option exercise"
       }
      }
     },
     "localname": "PaymentToCollaboratorResultingFromProgramOptionExercise",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentsOfUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of underwriting discounts and commissions.",
        "label": "Payments Of Underwriting Discounts And Commissions",
        "terseLabel": "Payments of underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsOfUnderwritingDiscountsAndCommissions",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PayrollAndRelatedExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll and related expenses current.",
        "label": "Payroll And Related Expenses Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "PayrollAndRelatedExpensesCurrent",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PercentageOfAggregateGrossProceedsFromSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate gross proceeds from sale of shares.",
        "label": "Percentage Of Aggregate Gross Proceeds From Sale Of Shares",
        "terseLabel": "Percentage of aggregate gross proceeds from sale of shares"
       }
      }
     },
     "localname": "PercentageOfAggregateGrossProceedsFromSaleOfShares",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfCommissionRateFromSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of maximum commission rate, based on aggregate gross proceeds from sale of shares.",
        "label": "Percentage of commission rate from sale of shares",
        "terseLabel": "Percentage of commission rate from sale of shares"
       }
      }
     },
     "localname": "PercentageOfCommissionRateFromSaleOfShares",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development costs.",
        "label": "Percentage Of Development Costs",
        "terseLabel": "Percentage of development costs"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCosts",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfEstimatedBatchProductionFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of estimated batch production fees owed.",
        "label": "Percentage Of Estimated Batch Production Fees",
        "terseLabel": "Percentage of estimated batch production fees"
       }
      }
     },
     "localname": "PercentageOfEstimatedBatchProductionFees",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfOrdinaryShareEqualToOutstandingShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ordinary share equal to outstanding share.",
        "label": "Percentage Of Ordinary Share Equal To Outstanding Share",
        "terseLabel": "Percentage of ordinary share equal to outstanding share"
       }
      }
     },
     "localname": "PercentageOfOrdinaryShareEqualToOutstandingShare",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfShareDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of share development costs.",
        "label": "Percentage Of Share Development Costs",
        "terseLabel": "Percentage of share development costs"
       }
      }
     },
     "localname": "PercentageOfShareDevelopmentCosts",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upfront payment receivable at effective date of agreement.",
        "label": "Percentage Of Upfront Payment Receivable At Effective Date Of Agreement",
        "terseLabel": "Percentage of upfront payment receivable at effective date of agreement"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upfront payment receivable at execution date of agreement",
        "label": "Percentage of upfront payment receivable at execution date of agreement"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PreDefinedRegulatoryMilestoneConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-defined regulatory milestone consideration receivable.",
        "label": "Pre Defined Regulatory Milestone Consideration Receivable",
        "terseLabel": "Pre-defined regulatory milestone payment"
       }
      }
     },
     "localname": "PreDefinedRegulatoryMilestoneConsiderationReceivable",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PreliminaryCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preliminary Collaboration Agreement.",
        "label": "Preliminary Collaboration Agreement [Member]",
        "terseLabel": "Preliminary Collaboration Agreement"
       }
      }
     },
     "localname": "PreliminaryCollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_PremiumReceivedOnSalePriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium received on sale price of common stock.",
        "label": "Premium Received On Sale Price Of Common Stock",
        "terseLabel": "Premium received on sale price of common stock"
       }
      }
     },
     "localname": "PremiumReceivedOnSalePriceOfCommonStock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PresentValueOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, net of tenant improvement allowance yet to be received.",
        "label": "Present Value Of Operating Lease Liabilities",
        "terseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "PresentValueOfOperatingLeaseLiabilities",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance of Common Stock in Connection With Collaboration.",
        "label": "Proceeds From Issuance of Common Stock in Connection With Collaboration",
        "terseLabel": "Proceeds from issuance of common stock in connection with a collaboration agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProceedsFromIssuanceSecondaryPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's follow on offering of stock to the public.",
        "label": "Proceeds From Issuance Secondary Public Offering",
        "terseLabel": "Net proceeds after deducting underwriting discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceSecondaryPublicOffering",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProceedsFromRepaymentOfPromissoryNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from repayment of promissory notes.",
        "label": "Proceeds From Repayment Of Promissory Notes",
        "terseLabel": "Proceeds from repayment of promissory notes"
       }
      }
     },
     "localname": "ProceedsFromRepaymentOfPromissoryNotes",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProfitsAndLossesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profits and losses sharing percentage.",
        "label": "Profits And Losses Sharing Percentage",
        "terseLabel": "Percentage of share Profit and loss"
       }
      }
     },
     "localname": "ProfitsAndLossesSharingPercentage",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_RangeOfRoyaltyPaymentToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of royalty payment to be paid by counterparty.",
        "label": "Range of Royalty Payment to be Paid",
        "terseLabel": "Range of royalty payment to be paid"
       }
      }
     },
     "localname": "RangeOfRoyaltyPaymentToBePaid",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RangeOfRoyaltyPaymentToBeReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of royalty payment to be received by the company upon exercised of the development programs by counterparty.",
        "label": "Range of Royalty Payment to be Received",
        "terseLabel": "Range of royalty payment to be received"
       }
      }
     },
     "localname": "RangeOfRoyaltyPaymentToBeReceived",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of tiered royalties to pay on annual net sales of products.",
        "label": "Range of Tiered Royalties to Pay to Net Sales of Products",
        "verboseLabel": "Range of tiered royalties to pay on net sales of products"
       }
      }
     },
     "localname": "RangeOfTieredRoyaltiesToPayToNetSalesOfProducts",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of derivative liability to additional paid In capital.",
        "label": "Reclassification Of Derivative Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of derivative liability to addition paid-in-capital"
       }
      }
     },
     "localname": "ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification\u200b of derivative liability\u200b to additional paid-\u200bin capital upon achievement of development milestone.",
        "label": "Reclassification Of Derivative Liability To Additional Paid In Capital Upon Achievement Of Development Milestone",
        "terseLabel": "Reclassification of derivative liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of preferred stock warrant liability to additional paid-in capital.",
        "label": "Reclassification Of Preferred Stock Warrant Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of preferred stock warrant liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of warrant liability to additional paid-in capital.",
        "label": "Reclassification Of Warrant Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of warrant liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReconciliationOfEffectiveIncomeTaxRateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of effective income tax rate.",
        "label": "Reconciliation Of Effective Income Tax Rate [Line Items]",
        "terseLabel": "Reconciliation Of Effective Income Tax Rate [Line Items]"
       }
      }
     },
     "localname": "ReconciliationOfEffectiveIncomeTaxRateLineItems",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_ReconciliationOfEffectiveIncomeTaxRateTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of effective income tax rate.",
        "label": "Reconciliation Of Effective Income Tax Rate [Table]",
        "terseLabel": "Reconciliation Of Effective Income Tax Rate [Table]"
       }
      }
     },
     "localname": "ReconciliationOfEffectiveIncomeTaxRateTable",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RegulatoryMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestones achieved during the reporting period.",
        "label": "Regulatory Milestone Achieved",
        "terseLabel": "Regulatory milestone achieved"
       }
      }
     },
     "localname": "RegulatoryMilestoneAchieved",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payment on licensed product, high end of the range.",
        "label": "Regulatory Milestone Payment On Licensed Product High End Of Range",
        "terseLabel": "Regulatory milestone payment on licensed product, high end of the range"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payment on licensed product, low end of the range.",
        "label": "Regulatory Milestone Payment On Licensed Product Low End Of The Range",
        "terseLabel": "Regulatory milestone payment on licensed product, low end of the range"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RegulatoryMilestonePaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payment to be received by the company upon exercised of the development programs by counterparty.",
        "label": "Regulatory Milestone Payment to be Received",
        "terseLabel": "Regulatory milestone payment to be received"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentToBeReceived",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RegulatoryMilestonesAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestones achieved during the reporting period.",
        "label": "Regulatory Milestones Achieved",
        "terseLabel": "Regulatory milestones achieved"
       }
      }
     },
     "localname": "RegulatoryMilestonesAchieved",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReleaseOfValuationAllowanceDeferredTaxInAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release of valuation allowance deferred tax in amount.",
        "label": "Release of Valuation Allowance Deferred Tax In Amount",
        "terseLabel": "Release of valuation allowance"
       }
      }
     },
     "localname": "ReleaseOfValuationAllowanceDeferredTaxInAmount",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the remaining consideration which may be paid.",
        "label": "Remaining Payment For Asset Acquisition Milestone Aggregate",
        "terseLabel": "Remaining payment for asset acquisition milestone, maximum"
       }
      }
     },
     "localname": "RemainingPaymentForAssetAcquisitionMilestoneAggregate",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RemainingPaymentMadeForAssetAcquisitionMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining payment made for asset acquisition milestone.",
        "label": "Remaining Payment Made For Asset Acquisition Milestone",
        "terseLabel": "Remaining payment made for asset acquisition milestone"
       }
      }
     },
     "localname": "RemainingPaymentMadeForAssetAcquisitionMilestone",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RemainingPaymentMadeForBusinessCombinationMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Payment Made For Business Combination Milestone",
        "label": "Remaining Payment Made For Business Combination Milestone",
        "terseLabel": "Remaining payment made for business combination milestone"
       }
      }
     },
     "localname": "RemainingPaymentMadeForBusinessCombinationMilestone",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of outstanding promissory notes and accrued interest received.",
        "label": "Repayment Of Outstanding Promissory Notes And Accrued Interest Received",
        "terseLabel": "Repayment of outstanding promissory notes and accrued interest received"
       }
      }
     },
     "localname": "RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense under license agreement",
        "label": "Research and development expense under license agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseUnderLicenseAgreement",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.",
        "label": "Research And Development Expenses Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RestrictedStockAwardsRSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock awards (RSA).",
        "label": "Restricted Stock Awards R S A [Member]",
        "terseLabel": "Restricted Stock Awards (RSAs)"
       }
      }
     },
     "localname": "RestrictedStockAwardsRSAMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock liability recognized for portion of promissory note repayment.",
        "label": "Restricted Stock Liability Recognized For Portion Of Promissory Note Repayment",
        "terseLabel": "Restricted stock liability recognized for portion of promissory note repayment"
       }
      }
     },
     "localname": "RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RestrictedStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock purchase agreement.",
        "label": "Restricted Stock Purchase Agreement [Member]",
        "terseLabel": "Restricted Stock Purchase Agreement"
       }
      }
     },
     "localname": "RestrictedStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RockefellerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockefeller agreement.",
        "label": "Rockefeller Agreement [Member]",
        "terseLabel": "Rockefeller Agreement"
       }
      }
     },
     "localname": "RockefellerAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RockefellerUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockefeller University.",
        "label": "Rockefeller University [Member]",
        "terseLabel": "Rockefeller"
       }
      }
     },
     "localname": "RockefellerUniversityMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RoyaltiesBasedOnNetSalesOfLicensedProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties payment based on net sales of licensed products.",
        "label": "Royalties Based on Net Sales of Licensed Products",
        "verboseLabel": "Royalties based on net sales of licensed products"
       }
      }
     },
     "localname": "RoyaltiesBasedOnNetSalesOfLicensedProducts",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RoyaltiesPaymentExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of years that royalties payment expired.",
        "label": "Royalties Payment Expiration Period",
        "verboseLabel": "Royalties payment expiration period"
       }
      }
     },
     "localname": "RoyaltiesPaymentExpirationPeriod",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties payment range on net sales of licensed product.",
        "label": "Royalties Payment Range on Net Sales of Licensed Product",
        "terseLabel": "Royalties payment range on net sales of licensed product"
       }
      }
     },
     "localname": "RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty obligation period from date of first commercial sale.",
        "label": "Royalty Obligation Period From Date Of First Commercial Sale",
        "terseLabel": "Royalty obligation period from date of first commercial sale"
       }
      }
     },
     "localname": "RoyaltyObligationPeriodFromDateOfFirstCommercialSale",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment obligation expiration period after first commercial sales.",
        "label": "Royalty Payment Obligation Expiration Period After First Commercial Sales",
        "terseLabel": "Royalty payment obligation expiration period after first commercial sales"
       }
      }
     },
     "localname": "RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_SARSCoV2ProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SARS-CoV-2 product.",
        "label": "S A R S Co V2 Product [Member]",
        "terseLabel": "SARS-CoV-2 Product"
       }
      }
     },
     "localname": "SARSCoV2ProductMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SaleLeasebackTransactionProceedsFromFinancingObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "sale leaseback transaction proceeds from financing obligations.",
        "label": "Sale Leaseback Transaction Proceeds From Financing Obligations",
        "terseLabel": "Proceeds from sale leaseback of financing obligation"
       }
      }
     },
     "localname": "SaleLeasebackTransactionProceedsFromFinancingObligations",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SaleOfStockConsiderationAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate offering price for which the entity may sell shares of its common stock under the sales agreement.",
        "label": "Sale Of Stock Consideration Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationAggregateOfferingPrice",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SalesMilestonesAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestones achieved during the reporting period",
        "label": "Sales Milestones Achieved",
        "terseLabel": "Sales milestone achieved"
       }
      }
     },
     "localname": "SalesMilestonesAchieved",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SamsungBiologicsCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung Biologics Co., Ltd.",
        "label": "Samsung Biologics Company Limited [Member]",
        "terseLabel": "Samsung Biologics Co., Ltd"
       }
      }
     },
     "localname": "SamsungBiologicsCompanyLimitedMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued liabilities and other liabilities.",
        "label": "Schedule Of Accrued Liabilities And Other Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and intangible assets.",
        "label": "Schedule Of Goodwill And Intangible Assets [Line Items]",
        "terseLabel": "Schedule of Goodwill and Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillAndIntangibleAssetsLineItems",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_ScheduleOfGoodwillAndIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and intangible assets.",
        "label": "Schedule Of Goodwill And Intangible Assets [Table]",
        "terseLabel": "Schedule Of Goodwill And Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillAndIntangibleAssetsTable",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating lease amounts recorded in condensed consolidated balance sheet.",
        "label": "Schedule Of Operating Lease Amounts Recorded In Condensed Consolidated Balance Sheet Table [Text Block]",
        "terseLabel": "Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_SecondPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second plan.",
        "label": "Second Plan [Member]",
        "terseLabel": "Second Plan"
       }
      }
     },
     "localname": "SecondPlanMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SeriesAOneConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 convertible preferred stock.",
        "label": "Series A One Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-1 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAOneConvertiblePreferredStockMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SeriesATwoConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A -2 convertible preferred stock member.",
        "label": "Series A Two Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-2 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesATwoConvertiblePreferredStockMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SpecifiedClinicalDevelopmentMilestonesPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified clinical development milestones payment.",
        "label": "Specified Clinical Development Milestones Payment",
        "terseLabel": "Specified clinical development milestones payment"
       }
      }
     },
     "localname": "SpecifiedClinicalDevelopmentMilestonesPayment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses related to certain development milestone payments",
        "label": "Specified Research And Development Expenses Milestone Payments",
        "terseLabel": "Specified research and development expenses milestone payments"
       }
      }
     },
     "localname": "SpecifiedResearchAndDevelopmentExpensesMilestonePayments",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SpecifiedSalesDevelopmentMilestonesPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified sales development milestones payment.",
        "label": "Specified Sales Development Milestones Payment",
        "terseLabel": "Specified sales development milestones payment"
       }
      }
     },
     "localname": "SpecifiedSalesDevelopmentMilestonesPayment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vested shares related to repayment of promissory notes.",
        "label": "Stock Issued During Period Repayment Of Promissory Notes Net Of Unvested Common Stock Shares",
        "terseLabel": "Repayment of promissory notes, net of unvested shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of promissory notes related to vested shares.",
        "label": "Stock Issued During Period Repayment Of Promissory Notes Net Of Unvested Common Stock Value",
        "terseLabel": "Repayment of promissory notes, net of unvested shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodSharesAchievementOfMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares achievement of milestone.",
        "label": "Stock Issued During Period Shares Achievement Of Milestone",
        "terseLabel": "Issuance of common stock in connection with the achievement of a milestone (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAchievementOfMilestone",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares cashless exercise of warrant.",
        "label": "Stock Issued During Period Shares Cashless Exercise Of Warrant",
        "terseLabel": "Issuance of common stock for cashless exercise of warrant (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in connection with a collaboration agreement.",
        "label": "Stock Issued During Period Shares Collaboration Agreement",
        "terseLabel": "Issuance of common stock in connection with a collaboration agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCollaborationAgreement",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for settlement of contingent consideration.",
        "label": "Stock Issued During Period Shares Issued For Settlement Of Contingent Consideration",
        "terseLabel": "Issuance of common stock to settle a contingent consideration (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issued in connection with a license agreement.",
        "label": "Stock Issued During Period Shares License Agreement",
        "terseLabel": "Issuance of common stock in connection with a license agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesLicenseAgreement",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodValueAchievementOfMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value achievement of milestone.",
        "label": "Stock Issued During Period Value Achievement Of Milestone",
        "terseLabel": "Issuance of common stock in connection with the achievement of a milestone"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAchievementOfMilestone",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodValueCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in connection with a collaboration agreement.",
        "label": "Stock Issued During Period Value Collaboration Agreement",
        "terseLabel": "Issuance of common stock in connection with a collaboration agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCollaborationAgreement",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued for settlement of contingent considerations.",
        "label": "Stock Issued During Period Value Issued For Settlement Of Contingent Consideration",
        "terseLabel": "Issuance of common stock to settle a contingent consideration"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodValueLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued in connection with a license agreement.",
        "label": "Stock Issued During Period Value License Agreement",
        "terseLabel": "Issuance of common stock in connection with a license agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueLicenseAgreement",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodWarrantExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the exercise of warrant during the period.",
        "label": "Stock Issued During Period Warrant Exercised",
        "terseLabel": "Common stock shares issued for conversion of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodWarrantExercised",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedGrantAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total common stock issued in connection with the grant agreement.",
        "label": "Stock Issued Grant Agreement",
        "terseLabel": "Common stock issued in connection with the grant agreement"
       }
      }
     },
     "localname": "StockIssuedGrantAgreement",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of lease cost and other information related to operating leases.",
        "label": "Summary Of Lease Cost And Other Information Related To Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Lease Costs and Additional Information Related to Operating Leases"
       }
      }
     },
     "localname": "SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_TaxCreditCarryforwardsExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards expiration beginning year.",
        "label": "Tax Credit Carryforwards Expiration Beginning Year",
        "verboseLabel": "Tax credit carryforwards expiration beginning year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardsExpirationBeginningYear",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "vir_TemporaryEquityAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity additional shares authorized.",
        "label": "Temporary Equity Additional Shares Authorized",
        "terseLabel": "Convertible preferred stock, additional shares authorized"
       }
      }
     },
     "localname": "TemporaryEquityAdditionalSharesAuthorized",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock into common stock shares.",
        "label": "Temporary Equity Conversion Of Convertible Preferred Stock Into Common Stock",
        "negatedLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock into common stock shares.",
        "label": "Temporary Equity Conversion Of Convertible Preferred Stock Into Common Stock Shares",
        "negatedLabel": "Conversion of convertible preferred stock into common (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of convertible preferred stock, net of issuance cost (in Shares)",
        "verboseLabel": "Convertible preferred stock, shares sold"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_TemporaryEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of key terms, rights and preferences of convertible preferred stock.",
        "label": "Temporary Equity [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTextBlock",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_TenantImprovementAllowanceAggregate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of tenant improvement allowance available.",
        "label": "Tenant Improvement Allowance Aggregate",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovementAllowanceAggregate",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ThirdClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third closing.",
        "label": "Third Closing [Member]",
        "terseLabel": "Third Closing"
       }
      }
     },
     "localname": "ThirdClosingMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TomegaVaxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TomegaVax, Inc.",
        "label": "Tomega Vax Inc [Member]",
        "terseLabel": "TomegaVax"
       }
      }
     },
     "localname": "TomegaVaxIncMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TuberculosisTBGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tuberculosis (\u201cTB\u201d) grant.",
        "label": "Tuberculosis T B Grant [Member]",
        "terseLabel": "Tuberculosis (\"TB\") Grant"
       }
      }
     },
     "localname": "TuberculosisTBGrantMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyGskAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Twenty GSK Agreement Member",
        "label": "Two Thousand And Twenty GSK Agreement Member",
        "terseLabel": "2020 GSK Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyGskAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyOneGSKAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 GSK Agreement [Member]",
        "label": "Two Thousand And Twenty One G S K Agreement [Member]",
        "terseLabel": "2021 GSK Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneGSKAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyOneGSKCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 GSK Collaboration [Member]",
        "label": "Two Thousand And Twenty One G S K Collaboration [Member]",
        "terseLabel": "2021 GSK Collaboration"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneGSKCollaborationMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one preliminary collaboration agreement and stock purchase agreement.",
        "label": "Two Thousand And Twenty One Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]",
        "terseLabel": "2021 Preliminary Collaboration Agreement and Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty preliminary collaboration agreement and stock purchase agreement.",
        "label": "Two Thousand And Twenty Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]",
        "terseLabel": "2020 Preliminary Collaboration Agreement and Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen And Two Thousand Twenty Xencor Agreement [Member]",
        "label": "Two Thousand Nineteen And Two Thousand Twenty Xencor Agreement [Member]",
        "terseLabel": "2019 and 2020 Xencor Agreement member"
       }
      }
     },
     "localname": "TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee stock purchase plan.",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandNineteenXencorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen xencor agreement.",
        "label": "Two Thousand Nineteen Xencor Agreement [Member]",
        "terseLabel": "2019 Xencor Agreement"
       }
      }
     },
     "localname": "TwoThousandNineteenXencorAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandSeventeenGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen grant.",
        "label": "Two Thousand Seventeen Grant [Member]",
        "terseLabel": "2017 Grant"
       }
      }
     },
     "localname": "TwoThousandSeventeenGrantMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandSixteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen equity incentive plan.",
        "label": "Two Thousand Sixteen Equity Incentive Plan [Member]",
        "terseLabel": "2016 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEquityIncentivePlanMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand wenty Glaxo Wellcome UK Limited and Beecham S.A.",
        "label": "Two Thousand Twenty Glaxo Wellcome U K Limited And Beecham S A [Member]",
        "terseLabel": "2020 GSK"
       }
      }
     },
     "localname": "TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one Glaxo Wellcome UK Limited and Beecham S.A.",
        "label": "Two Thousand Twenty One Glaxo Wellcome U K Limited And Beecham S A [Member]",
        "terseLabel": "2021 GSK"
       }
      }
     },
     "localname": "TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyOneStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one stock purchase agreement.",
        "label": "Two Thousand Twenty One Stock Purchase Agreement [Member]",
        "terseLabel": "2021 Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyOneStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty stock purchase agreement.",
        "label": "Two Thousand Twenty Stock Purchase Agreement [Member]",
        "terseLabel": "2020 Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyXencorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty xencor agreement.",
        "label": "Two Thousand Twenty Xencor Agreement [Member]",
        "terseLabel": "2020 Xencor Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyXencorAgreementMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_UnusedFundsReceivedInAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unused funds received in advance.",
        "label": "Unused Funds Received In Advance",
        "terseLabel": "Unused funds received in advance"
       }
      }
     },
     "localname": "UnusedFundsReceivedInAdvance",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_UpfrontFeePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee paid.",
        "label": "Upfront Fee Paid",
        "terseLabel": "Upfront fee paid"
       }
      }
     },
     "localname": "UpfrontFeePaid",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_UpfrontPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment receivable.",
        "label": "Upfront Payment Receivable",
        "terseLabel": "Upfront payment receivable"
       }
      }
     },
     "localname": "UpfrontPaymentReceivable",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_VaccineProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaccine Program.",
        "label": "Vaccine Program [Member]",
        "terseLabel": "Vaccine Program"
       }
      }
     },
     "localname": "VaccineProgramMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ValueOfCommonStockSharesIssuedForMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common shares issued for milestone payment.",
        "label": "Value of common stock shares Issued for milestone payment",
        "terseLabel": "Value of common stock shares Issued for milestone payment"
       }
      }
     },
     "localname": "ValueOfCommonStockSharesIssuedForMilestonePayment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ValueOfSharesTransferredToCollaborator": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares transferred to collaborator under the terms of the collaboration agreement.",
        "label": "Value of shares transferred to collaborator"
       }
      }
     },
     "localname": "ValueOfSharesTransferredToCollaborator",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ValueStockIssuedGrantAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total value of common stock issued in connection with the grant agreement.",
        "label": "Value Stock Issued Grant Agreement",
        "terseLabel": "Value of common stock issued in connection with the grant agreement"
       }
      }
     },
     "localname": "ValueStockIssuedGrantAgreement",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase common stock.",
        "label": "Warrants To Purchase Common Stock [Member]",
        "terseLabel": "Warrants to Purchase Common Stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period for licensed program, uncured material breach.",
        "label": "Written Notice Period For Licensed Program Uncured Material Breach",
        "terseLabel": "Written notice period for uncured material breach"
       }
      }
     },
     "localname": "WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodForTerminationOfLicensedProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period for termination of licensed program.",
        "label": "Written Notice Period For Termination Of Licensed Program",
        "terseLabel": "Written notice period for termination of licensed program"
       }
      }
     },
     "localname": "WrittenNoticePeriodForTerminationOfLicensedProgram",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateAgreementByCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate agreement by company.",
        "label": "Written Notice Period to Terminate Agreement by Company",
        "terseLabel": "Written notice period to terminate agreement by company"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateAgreementByCompany",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateAgreementByCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate agreement by counterparty.",
        "label": "Written Notice Period to Terminate Agreement by Counterparty",
        "terseLabel": "Written notice period to terminate agreement by counterparty"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateAgreementByCounterparty",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate licensed program for failure to make payment.",
        "label": "Written notice period to terminate licensed program for failure to make payment",
        "terseLabel": "Written notice period to terminate licensed program for failure to make payment"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate licensed program for uncured material breach.",
        "label": "Written notice period to terminate licensed program for uncured material breach"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.",
        "label": "Written Notice period to terminate licensed program if under challenge"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.",
        "label": "Written Notice period to terminate licensed program if under challenges"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticeToTerminateLicensedProgramIfExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice to terminate licensed program following the exercise of an option for such program.",
        "label": "Written notice to terminate licensed program if exercise"
       }
      }
     },
     "localname": "WrittenNoticeToTerminateLicensedProgramIfExercise",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice to terminate licensed program if not exercise.",
        "label": "Written notice to terminate licensed program if not exercise",
        "terseLabel": "Written notice to terminate licensed program if not exercise"
       }
      }
     },
     "localname": "WrittenNoticeToTerminateLicensedProgramIfNotExercise",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WuXiBiologicsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi Biologics Limited.",
        "label": "Wu Xi Biologics Limited [Member]",
        "terseLabel": "WuXi Biologics"
       }
      }
     },
     "localname": "WuXiBiologicsLimitedMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi biologics and Samsung letter agreement assignments and master services agreements.",
        "label": "Wuxi Biologics And Samsung Letter Agreement Assignments And Master Services Agreements [Member]",
        "terseLabel": "WuXi Biologics MSA and Samsung MSA"
       }
      }
     },
     "localname": "WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_XencorAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xencor Agreements.",
        "label": "Xencor Agreements [Member]",
        "verboseLabel": "Xencor Agreements"
       }
      }
     },
     "localname": "XencorAgreementsMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_XencorIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xencor, incorporation member.",
        "label": "Xencor Incorporation [Member]",
        "terseLabel": "Xencor"
       }
      }
     },
     "localname": "XencorIncorporationMember",
     "nsuri": "http://www.vir.bio/20211231",
     "presentation": [
      "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1828-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2062-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2538-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2538-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2574-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2597-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2600-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2603-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121329188&loc=SL108377954-173880"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121554622&loc=d3e15372-109273"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123573877&loc=SL118137113-114923"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=107671284&loc=SL5844817-113951"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515679&loc=d3e40733-113955"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123589689&loc=d3e48542-113965"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=56949186&loc=d3e50579-113967"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117817908&loc=SL117819236-161440"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r746": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r747": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r748": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r749": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r750": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r751": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r752": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r753": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r754": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r755": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r756": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>131
<FILENAME>0000950170-22-002295-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-002295-xbrl.zip
M4$L#!!0    ( .>!7%3Q(ZSWQG(! +I) @ 1    :6UG-C$V-S@W-C)?,"YJ
M<&?LO D\U-W[/_P142')5HBB4&+LRC:5(B0A>\R=?6E,LF>92@A))10Q9<EN
MLN^FK$62/0;3D'V;L8QAMF=T5W?=]_U[?M_?\[Q>_^?_>OX.A\_GS/F<]SG7
MN:[W=5U'?6B?:5^ /;I:.EH  P,#\ ?]"Z!AI7S.^;DX H"^/G , ( = #/
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M4T):-("'#.(OUCDR<RRZL?1YR/W;*=K9PLFGZ5..?8M:)GG0@%L=U,VY2M.
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M^H=X,&5[R2)I79P&<&EO#D97BA^C*<!=C.=:5EUVTD$U&^F:\P/U)N).H&(
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MM!346CLS#7@+'RZDARIT8FKLOS]F.6F;>YM: .ET]]J_:*'@X2[MLS<PJ^P
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M*:PW810*#)=&HN_[B3][">VC]W+:3,B05)[.!G<" ?^6/3GGW%ZF<WN? \P
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MSK[^CJ6/HJY1%GI-23&5UPOR0BV"IV'NZ-Z;OCSKXC@.;'],\)% \\)NLJ#
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M+6+"];X<55/P-N"*$%I'"EA2NPSF!4N$-,]-7!L8]P=7HXL7^C_9<. ^(KY
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M+PU8.TI<>E<P:Z#N W71!@TY_,5PY,!4IU^L7O\B3W[!D90^4/&Y:WVS3#1
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M6 L2L3J82^H\H=\RX0"I)+MB?+\E#*LH8@"D$4)/R7Y)&!"<\"F#'WXY&P6
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MPI *Y*  0;B?+)Y+C&T,9HO1JL+EV8CJ\Z//=J]J5Z"Z![4OE^NL!0V/V$-
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MXT@EH>P_@<T7!S.>?M,_E3>?)/Z'9W3O&]M^I_]+[NP(:X/F/1+-[=6I1'+
MAXZPZ0)?,5K;9$XCW!4CLH? H_V64;;RR]8KE0BX<\O#+DON_,+X*8U4?*GL
MI>#KB'3H&^Q*27@-R5<6+MZ9$9BM(#:-5BH1&UV)OH*4(!X81?M+Y"Y?:MW
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MR1:R4N"ID34!5I+6QA2JL,*G,8<4\MB?Q*5S_VGI,5S@*Y)D?2TU-@B'S \
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M<W&.$G>1^N.HYMCOO;?73HYX-@ZYT7V.4@^D4>*^&PV3LPV3Y7#BQ?/IX1Q
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MHMEL3T>S"\;RE9C;BGN!9)/7H0_*NJ]4L6Z)GY LE @\L6*Y1L\->](R:\,
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M-2=_=YCWA$=9%<Z>N 5>+"%;^MP^  3$Y'JVP16NJ$-7B7A>OD.V&-4]!E2
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M(?/^CDMN@(N)/=2:^UT:M/-NQJ4*@@%-H1V64JH6':.;;8*MG\)D8D4'),^
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M$^<@SOEN_F\G O*SIP("0/3Q!JQ%3W./+_VL[SI*9+!=R!&TM9-5LF2!]EG
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M>;JA4: #>4L]5X7[BL':^+=6@,HON[FYRJ>XWXC&ST2O;9"0ULP65V!M9#L
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M\ CX0'CF::=>W8+]%74VMY9F:"P+F\/T[#JT!')@XWVN70]>9;U=CZZO6T9
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MUHY)AP/!5/WF6IW+,7E9N0FOKE=6)/Y?['UW7%/WWO]IK55K%140%2'6!8I
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MF-SN;?,;96M>*_/V8W6<*88R5EZ56A,B2)PV'^RB:MJ<CBT>B7YE&X__MLE
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MEW("-)^Q'D87.999_:S)F?/%^A0E#'9P_$LKV*(Y.!?=:NI#\(Y2^Q!0>Z3
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MS5]<C:@<LNW6M&138W;O%5)W,RQ0D\):H=8+]9<$69WRH::*.Y(.YZ<F@91
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M1R8H[9UMMU29D\*1S<&;.=,YT'C-D;!!STC7?=FB,88;95E(L7HI!TW;C)S
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M2Y)U88529GAT[AM#$\]@_!+LR Q$@LNYJKX9GE#)W\U-F#1E:5F<YPF'NWM
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MQB1R&H:&"@^)0APT1>LXTQ5Q=D3A@:9)3=%NE/Z:0I86-9A2Z96\-&GY=OD
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M[SX$2_83IE\>];(?_!Z4Q2% :>$/#3@KI;M:#/UIP^G%H8^B.Y9[KSUY,BK
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MP@3[F?SC-OY5"-MO6!7:;DG>PN 4Q^]'M0@W=Z">%Q:>;J-M"KFK>;$CW_N
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MJ@*WVSB_+V2U32LG267S9M=V/>'<RQ*I\WZ"O_.GK4TO]E:![0_$MEWF56+
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M!>,A6^"\3:5WGG&2EN+'VO$\OKI@>5B[N<B2 ],"RXF@ W[V&_ADOD2&NN
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M?N88J=]BL?5DEH9[<)!95$QPX(R;B?2[/CEL=CUT!L]]D*)TY.!ZBAR6&<(
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MDU/V?:F%?O>$!0R0O_\_4$L#!!0    ( .>!7%3Q(ZSWQG(! +I) @ 1
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MP5HG!]5GNVK0,0OEE.4KYO?>7NPA*+_Z.K;($#^F3E]B6GOE"HPT\5J!8U/
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M$J&48):HJ>.I\9EW!Z\O27NASG00\[9Z(O43AQ\!\=^AYWY0$R4QD$_C35-
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MQPM$_WX>&T!)I %?C^ YJ(WZ,!J@$^VW.&;P6&32:0CU][^[]?SC$,/4!-,
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M)'S2L&UGR,K5#NUZ+T)S.&W0Q@#/O!;/-ZV-9ET>Y$2?78EFF\UN:CT'>Z:
M/AVW6@16XU?3*56K!,ZMXRE,*^_Q7/5(ROK?&;'\[_YP6"PGC;%]:]@3@18'
M)-+#'(4+=T'!G:S=)&'\P2[/ATECD0D!X5K[# IMEGI9B_N9U %($0G$XQ8
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M\]SG(6)VUGKG]:[?N]DKKQ!2&IWB).%9)H1@ :(@GQ]--$[3WG9V'A8E@TD
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M+)CW3$#H4]+*ZG]@F%N=OY9>II[X>QF]+,+-VS;]UPCU,VX/#F5H7 _ZL,Y
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MU#Q>C1AEJ0A(WUK4F*U%3('MH?7(M:@Q7(N88M>G8KC5 (2N$JM/OZE%7@W
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M\V&"[[FX)1BC"O(^O0P8A%8)(8X";L;_>U>? RPJE!E-!3I@W)F;ZGEK-V+
MA;N%W\-7%T)(DRUI<=[R?&ZHCP]W85U$^Y8&^(]6+:1C/64,V8"I4XGV71A)
MITU1!0 2CKR(;YI40J&4*_#Q\G+%1,D8!*;"R4:K?DZ+E@M[,1-M ::Q]06<
M:@GD"9/1CS;'TWRJ$GV4DJ[;I\B!\642.0^\B#\V-HXR_2B$-'\6F K6ZU]F
MHD:QSVN9\[5!N @>3/H>3R%0M1 =LJOG>X3]$;/6/4=;=Q4?IIR-:)^Q#&D9
M*:^WC\+K2],F!#\@[ELNMX97:_T><&& 8WE6555RY.$K/*8K@8H)A_D?G*&,
M\CNQP4C4<HGI^M[FL7 -BC3W]%OOGURM6"6J+0_9 HT^LC9WJ_'!6].C;CRJ
M3L,IW;?>6N/@IXK4/S]-QL60N=)SQ@S$"!_3^EC#K6S*&J,\&,Z##[)Y"NG(
M6';L@,#-<S\I9F>@RUG5?:X65Q*!Y.@J^W?%;[FXF/)N^\VURF#!NW/7[/.X
M)3'XZ4X/C!HJ0/&61F;UO%.5#<N >W_>B@_'4/8FCG!LK*;"F"I/2+_%F10#
M^DZ5CS64N;W2S@W 4L<U'FU:86> _'OGE'<='M?5WR4>F[D'!.^;_M@JZ/-
MI/#O9B1G^T"G$6_5:H"8N>E$6[$&[$8R3V%9A7ANR'Y_'4".=2T_Z8AR$:N[
MX1G)\F848Z^;X$F6@BG4LT)W)45\L&+\<)16Q[DN392A346I3LU,["N';;YA
M])T&4NS/X?0B<EM2AC.'/):"6G[]/V/3EE6;JJ[8=.73CZ)/#341>X%B(>0
M:5& Z'G'450Y68;8;I#I%GJ(&6<(?#(Y49M8,IFH?5'VG,K."87X1+! 5?9(
ML'_1/-(T8(?U;W)G,>Z''F#6!J -F8*P@J(<'ZK6(?61*F,9W PYJ'#^-*6+
M=.8C31GPFBI/?-D=IS'@G'I-@)GP/N1Z612,N[\&HS/M=;Z3YKO?X933\^24
MW]J>TXXN>?0+(32.I+1@O=&B3APL;XX;3NL"8C9J5H$(>F,K%\JB'ES:N+IX
MIDX];OD?++6<0BC;<(8,1CI)E-M#I_C1_YW+@B10"I]UJ99"R*C<0;Y?+ODK
M$QO!FTJI&X9SG!06?QGR!G>8P(;G-PXB(FWA)JX*L[XCBRUW4U*:PQ6+'VV8
M#S6-&PTGC0HAL36)W$TKW!*YWZS\SA&'S.)>R5WC6C'3\)G5Y@-N0?M=>_P0
M%/]EHV-110\3I6BPIBF6O9\6[([3C67"]-0P<AQ5EA+,UZ'5=N=F;SNQ!5]X
M\FK)W&X'"ZD1&%#3M5160-'F]RUC5SE,1D]O$^6CO..]NCF<17TQ=IX>\M(M
MJ(&.9NO#P=G+_F*^VGU:1UZHGVX+A$OP+_&XI) )EOLYTB9WEM3R70G[7HYV
MV@G0''&?XX60X8XFBUX6K,=;,,;U9= ^^B.F =IEX"I5%$LA9BU[;V!5QJ&E
MGL0LMK/)]B$]K>'I(+FEF.S)]JGE3&XU!5""3M]@1/3@6@G^W"WQQ;/[ET)Z
M>"Y[A!"GFHZKU,$M"^M&2X'&=KM32D"E()^% !A"2#'"0 BYLL:"?\=7T,AG
M6;QOG&[[3-ZE0=Z!1&QKGS,YW(>0<+,JKZK3\;W+^.UA=X_QS^$V7?:L7XO(
M7OJ++@%6GZ!AGOCH'Z8<E)B-8=4GO0N1Q]RU_*7[@EJ/^)'.?QOS<X+<Q+RA
MLH>H5UCIFG?BOB1SN]<C^K\QH:^P>W@J>&;+P ,!M',1B?BNZ%8P.MC+2[)*
MUUOW[8'S,>J$5F6TU67J'*\Y.;H6!L&<^Y1ZZE6;:_M$^46W[]V8M"F_GI[O
M[6FU,L[(0)09)A=,UK=2"7GK$.>$D->P%=4,>?M9(K/ZVDUCBO5-F&JOQ?<$
MY+_4%[MC<\?T ]W'9)_@Q-GKR%N!!UA2[2\CO23J2.:'FVC>?HRXF9Y32"9B
M2/S>-.X9<Z P@V(WZ?!#>UDX?G-5O'-I5>G]R_I&G/,V\'=<VOZBT&&K=MA'
M;02XLD$77@%7W(J!Z3_<P&H&^'^2CCCB^[P3ITH_%P*<[WIX8[)'YV&D7'K5
ML:0QD_="B(X'QP+6:V0B_6GLT8(8]%60<E] ,+RM3+J*G- 0<FVH5U7-8=+M
MBHL24O5SN*Q?:QRK$CUHNXQ8LV@>[(5JC81@.6?L:K/$:#T_U?<0YFKNVQ_Q
MG1K;Z*$FOJJRB$Y46F>S6A+^R"66^#[M?A2-*:,+8TXURF_",RW>/T.E3^H
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M3(#+X5AXX.=;5,%L\]M!A./M[Z8.Q$.?[=_H(-LA>COJ\+;N_ \/SC]<2!7
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MNOB+OQ,+=IB=%(S1RS>8ZV_R/L9C]G&#<)KD Y6D#(UQ$X%9Q1!_\ZE8/4&
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M]L"PW^[J4 ON&[_>BGJL%Y+YT">[5D7477A5RP=\P;PYQ[T3L)BWV^QY0?
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MNRFFJ4F(EQ8@EKA.!>R:2PC8*M06 W&13\!>ZCQ_4+BK[G8UO-14/R &7@3
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MN%V]3+FV<R&UR&^%>A]_^:_Z;I&!%/G!?,7 W.(?)!F,@ H5#O.1U^'EQE=
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MOAKBI]AU?@(_X_$,HR'R:OLCQ45YG=SO#O7UR+9G9-%<"C.':-Q4\(Y)&NX
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MQTJO+@'!VB#! -'V'6*:+1J&5P7+=[\$9[[WO@D;,PPVYDD"*P?G^"$96S&
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M^2%O+,BT$@.W,5H9F$,LQ+7Q[+RV F;D#7*7'[8S)1A#6 U6EZ14>/-_%;E
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M$'+)&P6^XG2+6D6-8>,QTU/>]"P;^;/-&/V'7:,*!@]<H5DDW=$M\^*9<W?
M#D\>,ADX_SX.AN<]3$&=O5C$LGNF)-=Z,SK+I_Q0HZ=Y*/5<B^8/JD.N5.\W
MWMT'UX!SB]8*1B S@T-A@9Y*)2S_ISURK;>C,[G-Y9UZ*0^\SS@K9'YC/!7P
M.FG?Z*AK]KF2H&W7CL0NM[AR-+QD@^/BV/E0;!1&NT.1CIS*NC5#UYQ);5KZ
MP+GST8_LJ&;!S%2;:I<6G=^E!<IG73JY##9_:CI]E]OY*:VR<HZ:2GKB+S]
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MBH$WYX6K]UQYJ#">)[W:^')BU\C:W_35TE<-WS]S1@SX9;[HDA_J(KMKU0E
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M;(/GW #M?H,4:=39K[ADR.8V$IL/?TX:>S4\YP8<,PES '(##!I.:"X2/]C
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M9B$]6TF*]F%V1&(.YX*'A\!Q<1/Y,W%O7].V4-S;%]*]0SP\D[;5:-]-GDS
ME1FW!J$)1?BS&.@87HS^3*48N!>9FJU\F/OL@0M<RDT'H]?HFMCUHV[E"ZVC
MZ>[2OXW?3=JD5S_02L:6 'Y#[!GR'(;MHAZ":!K'J?390*7OH-'UJJT3AHS:
M5+OT7_W$6EE/^G'M%%K/2U]$$)Y[VH/S%C[J9.*K5$S7^-RM.T1Z-8-=Y6Q]
M,Z$S_(;?HX-K)KL/1=D[;HT,/(Y_+@;@]99UFWSOC*.ZV-2>",E+4MXBEALL
MU6+-1%\]]UBFH\?9[W:2)QNY0<OXB']8C!=IO\W+L,F=N232IFVUU\O@,AJ@
MO _:O+4QM<FN:6+K=;/KYOHWD<O/\[JW=KXDNZN7K&NV:[GGA_U<FWU8OH&/
MPUFN/[J/+Z5KW=<V9:Y@$AYJG=K)4-/I?A1**MA ]1_TK&5V.;?@8!H';*0M
M2DN;/<,V&)YH.=^4\LK^J@*WVSB_+V2U32LG267S9M=V/>'<RQ*I\WZ"O_.G
MK4TO]E:![0_$MEWF56+ H'4:&40H;=;4"*O_9<\$0MB\AZ@-*AR@(,S-FN>]
MA7V?(6]?A+/ 1"\:)>_,>1<FVT74@CFEW#5.+C-9*/ULO>RB?\ V=1OAZX2+
MKZB;T-FV6>^>@G]0$>QJ>R^T[; 8 +(O%L>=$B;EE2A-57['=:G0TG8(RM:K
M?S3:QNPL7OMZ5QQ;F/3B0F?UA+YEW8ME4.)_)E3=R7OES!_R:W.W,(_?8A(#
MJH]%/5SU66H7XM:,,7U,RXDI15?NEJ3$VZM.IZ^@=9\W:<@5DN^FO/+T*=:_
M/Q*;GZ/A12E@OJZ(")@V-!$#NH 7;*&=AFQU6<FIY;BE8TK*+8D)+AOV=60[
MW&PT&_2TN)KKG^QQ:E'CG\#4.EVZAK6:=?&JZZ,->\V:CK^L8YM84\<I._+C
M?QX9Y6LI\]7N+:+^WW/5"=M[DBN0T5U^-9*W:D&_(>=^0V@>RUO4M-*KJPTZ
M/UY8Y#HF8=(YDYH%^.+HBGP;G\-L.VQY:@71+3]MI<_9@-]'OGFFUK"YEDI^
M$0D?(DYW"RS[<4QVPXWK(GN\PF(Q8&N%@UH.U)^6_-Q'[17I>F*''% )7S\C
M(5[;^^Y3E+L1Y!S>39W266^U)WGGR]WMD@=$!N<+MHJ!!RY5..X2A[E>6]Y9
MN@;:'^;WFPJ^R)7T.D$1L_IZ/EPNJ]^)B4:>YN0:369H<2S))01WD)A)+3\#
MMX_'Z[UX7,/&[:V;]!)TE4YTDWOP""'J:4^G<$B9,@;+H#+9V!OD:56?9B@4
MH0XFZ=3^IF6HV;7%3F+@%RM0$(F*MMW,O)E$0^4("S0O%(;;G]F(WJ/YFE0P
MP2<5"*@3.81NY\KGJ:+LWE@BFB%-7U$]"NU$=)-HZD(I6PTQ\%3%5"2Y52@X
M]X-&3I).QX/'[C6<+;DFXO2HTU<,C2T3Z.(^690D4FI@1HN"\ I@KURJ9!)X
M(W*LA\_X+Q$RBL%.N88V::X__ -8G*31+^"!KQ$TQL);Q^4YI4S1J^S QV!Y
MA^B]'?/>3A'C8F Y.&S-2A4ML@8G+0--!W]M%.%_(I=P@ME![C/7%^* 9A1I
M!ZZQ&#A$"8<S5S1+AH1)4.,B]BTT>)X*+A/&9(/O+9L%GS/LIUA1$;PD#3"C
M79T10!,^."O\Z7,;G?H<K0!7ORY):/L,])?8^C]M-=@H6XI/]0$=$?#3GRD,
M^RP*R,I3!DX?88/VD,%YF,\B4F]!1"9(L*$^QI9!4X:P:4+8%.&B8P_G GO+
MQVPL>0=B#33(K0+(0RQA8-%L!95IU7 #]Y'E2ANC3]U<MT[1:V =?FA7;Y7+
M[/K2O@%1$@]1Y[#?\^N29K9I'WG8[_==1\;<W3T@6035D@M07=@!)[C._:*"
M<\LK;RN]-+,JC.\WE]<1[_XMJGIX?U6$I!9+B@/WZ-N%*G$/-18U_?.E"++R
MDCDZV0,L^W&N+'5+_F"VC;"2'$WV?ADW0F;^AI1(X9R.I@9*S_9O. 6-(:(U
M4G,2 Z%IZ<:U.3'$N?GD7_(/B29N4H$P\#6U*>Z#PIXAZ6"VZ2SM_T%]_OH/
M\SUU1#/#Q?>"0<\^A*8T-7U&FBL&<,)9X/6\\^<[9O;%4&#DOS6 OI\O8[<O
M3OG;V!+AM._F6$W,\?V@W?\6/1>=7GZ98QRH<C;(!3*VS\EEAP>E44VAH:$
MKX[-%@,1-JQ489$8&+$O\6FH@"\>#MS.HM"UP$=.(]X!23Y^56.F12#9:6>[
MZ8X[(+&KSS2.(0:H:-2ET6X3>U6G=9,5+\T&]=9'E!-M2?UXV*CUS6B[-&<8
M,V-CJUZK^R6L>F=/E_IEDLCO#0[':&$39X)O7&32!Y]X:8RYFO9&EL;8:<1T
M>'H$GOM"#/@6[!'DL[OESO:_@>L6PY-3DL_UWM*QSW2<E0_:RMPC!NQMN,&F
M_J0CA3T8JLH%EBNQ*QA5VKV/G1U+?4J$WQ)X]HW9.$_ %5)PS)<]_KKF?<O"
M7ES OL'5HDG;31F".M3E1L/]ZW_E&E?*VW[%C8$VPM'/1-]%E\="I9V)'?%K
M"-4QR]!8R\G19Y^:S(KJ0\5TGCQ,X&_QLTH-T;&GT>WZK8+=[_OX=1VBT 6@
M7+CHP>5'!YP)QE&A]OX!60-(K1H"YE')G4!A0*[^^H%)V %1<SC8CU_+749+
MN+,R2U@YTT'Q5/%/C^W9EEO *\C+D+ED=.$UV5/4F\3^.<*<*5V!OX5;-1.&
M--$V($).C#N>EU/H2SNM=G;+HYR\RP<2GS\1 \O\9C?%MNKT,+;S B;.;4\,
M?3'WB/4,+W#4C3P6+&JPW-F-FXW#S]+$0.ZK)9;X>P*7^]1J%MJ<:[0>FL)^
M\NFRSF.I[ NTS+=A@$IB@)U\#<Z?;9TYW_PH2<W<7LFNGXJ%3VIC?*<A"#NK
MQ<!AS3:,9C.C6)5E724MX]SLW)F"IQ6* =JJUOSMT<^O>JDTN X8G+<9KI/%
M;:NR%^FIC#CO%*82#7,YV(W<>):^2(I[K)-?B8A5(_2YU.%SADM-R&S/HCL1
M=QFJ%:7F*08CWL).&N2$FQS1'JY[ZHA(@;7L9K&_ YAMG,%M<O0TO*9Z:&R[
MZ)#QE^;T,*'53 ?9.=6D 76\T>P%:@?K7K/S-P+-$A/KMKKR6#_,B<(ISRSM
M0>3-1G;WRP9MMQ YRRVG0FPX*KM(,3(3% L:&*H@7R94[D.%>.KJ8^P3MQ6A
M]\7T[;@1Z(7W>[639[23'EX<GT:*<$Z4K^X^AS(WLZ1_-: 3S/;E+TUV[5,-
M-%T];+N%=;/(<V7;X]F5TPBS,P*2*AUA)VPY!8>S,/4)*FTC]4UQ%IL29<WT
MC<Y]]G29SQY9E8Y2Y2*?SC(JT H8]U=9.OKH1$>_FWD%Q!N71\KZ1D_'MLK=
MW8%I.4W UXC2,T:/76DU./NP5J?Z!8IY+6Z#2W^QZ-OF_HA*!<V2_)2KN\)*
M7?8*PU;@<OLC(YO?].#\WW2?]7S.Q+%UR0(57*XOR+P*#9#,>P'7^=2+*!4Z
M:IKZ<BJ0PPCD,,^7-F0VK.$&2LMQO4^]FD@XE==R*?E)U%&D6MA.UP <73!C
M^RKA<'\AG*: T\]' [ZJ&J"T)HIKO/6):U?<>-A 0#(Y%#Q0SZ?NJZ<^L[''
MEH4OHY.E!?!S3DKQKOW@ERAKY\&M?0-M!_9O+$0SCMT]1MV+>8UH[ER%E0_.
MV[#W6('7W<[:'D7'!'3I<$CN4$:>_T&V0T7G3$\^2[%7#%2@9+BQR\^5,LG!
MBF5IN>Y$UJHQGBEISU.2&.AP[N'>Z0N0.<5M=-3 2W=V<*^;LJ(B7'PSNYW5
M//=^F_ #KO:ZRWB^_3TU86WV2SV$\ZSW4]'R7*9T<+/1D]B^D<#&K16$Z-M8
MS8J<8Y-U*L1-:.^+EY$M$@0UMC#^U_#U].1)R3VJ-NJW)LA/GN2.4YF_\8Y*
MWA%;YXT; )M=>UK+TYL\J#<#5[9Y2L5+GRG,>=PBP'W%#;I8.1I_[%))1.IK
M(L\+7UL_!:X,Z#HJ86WO(H75*VM"Y^IF<\T$T6(@"CY^:MKL3.PG3Q7ZP2.E
M.?@88&WY\+[G_65X:[\6S^_N2_\"[\VBLL:8U\<RP0/:@G$4"94(,JT8W"GN
MCS-M</9+\@'Y"<IH#(P?!,<--MRK!HN-!W@;P%^*,:+5L4C_WT4=#\_N&[DO
MVHIFJ LG2=%7)CK)>W*JZKH-?9/*[>3#E]S-9R0TYN.B)S7TK OH7:5L.I4)
MBRI&>CN/DFD:*.Z1:'V^/'/HY10Y;&*BBS!!%\$8&&C+F4?+HKSHG=SE,U;=
MS"6>SMIH=?THX:+C3^CB^BG)JZ8#]K6*-M1S8F+B[LFVHLNB\G\]975M5#LJ
MCACM>3(H,<)SG>Q7UCOV;']^?TEBQ*9?0X&_. AO ?+,W1[6W#]GI+_1>>F^
M.^E.^=]M]L8/>Y\4 ]ATL$=.P,P'#Q/#P&1CT0Q&689A.#2K-(%DEZ+23S;O
MJ#?!!^O2LMHDEQ/'G'!V_>Q.+F0IGPE2OAU-?O_+?WCC%[*%3%$6_GS[D66)
ML? *2/GJ'YPO^>C!R!:C,)88@/-GOH0'IK; ^T4@9_@_]:2ISSYS/=Y*_VVK
M7SH D=;D+!V5;=:Y)QH]U7+R2[UCX&7X3NBH+]!24W:1]%W<:]-:[%9X(2[2
M1!\X_":5(S/Y\/M4CEWZ\/VOH-/&/7QW"-M'_;9_(;T53MJ@= STTDX(!:[7
MF$Y4&][%==].3?SENTD+_I.6A&.@A\7"18M60.>C/F6?!*U5'K P._@-;X>P
M0I N6>"I*[MHF80=5B+%5!_X$3K53G)FM47CP6\D[(;GI$R?_'(.PW]RT:CI
M5CAQQY\NBOX41AK$/H3W)R;ZNV&]EY8.R5[M:R1L29YLYF?P3MT[N2Q"8"/\
M0Z0D"(PX!G5>1KF#M;99]#AJA+*V"JZ%CA&EG.HFU9F6"#M[X;37Y-PAX5>[
MP G--'!2/V [0M? B>R=*M?\M:6?V9M4L^31%_8&]^)?FTUY"PXDL?W$0"(H
M!B)+#D-;Z1T@K1N>2Q%^!>,A6^"\3:5WGG&2EN+'VO$\OKI@>5B[N<B2 ],"
MRXF@ W[V&_ADOD2&NN  GNT/[2P7BP$5ZV QL 71]*W&3XTSXPB!,%KT97F[
MV=PR,5 .S2X.Y/<+8<P)<@=#=$-:D.4,$]Q!'?VI\;HAY0EJBHWBRDB?,^0A
M7F.H8F#5F#!!# P?% .U;0^@?:LLN(!/P,;K!BMAMI5@0P?8>UPW"#: NCP%
M?H;*['-6<M,W5WZK$> O!V69O1BX^CU;%HP,J(8*T:?0#/^MXC^E8C>$:^1S
M%3^.HH#-?Z(A%**IDA#] ,H<+(<V)6_7$>;6;;W.,) N>;_2M@P[B2_DW0>?
M:<,="B[!%DW,CFF_52=CS<Y^UQ\<=)U:&\SSK3M;XP*S!^^DK@"_>-R@"B>2
M(Y6A[#P6&_KB53"4E,G*'Y>QQC?_C=HWOV@I='ZC&>^_MNA?7-*?+#*"_J2O
M]W]#TM^\J"5,(:UW>VKCP:\[=9?(SFY?W("C$6YUI5:BY-6;F@W%P)L56)$<
M+@0<SN26BP%@&BU"4!(;3[QIG\)SK0*W0B4TMU]:L+B1S$,9"E3@:\1 XQE6
ML&C1,%6 Q^LGA@5AM:'IT*$/-:NB][T8>*JK"%7<:; LEZ4NE,-^"_8JA4-I
M,3MMO;WP]'N63Q:R//TY2R<)2R4)2Q.(Y6_;/R>I-#HF]C\90C&S=(S%@+Y=
M%8R[/ F<7 );2/!3E3V[RY<B4#&=E_6%(U5PU7 AP39,7UY*R1/:(C=7D*>M
M=,Z)@5]BH:KPG=GG)$1BHWY9=3Q8EO>QHL]E_U3S3(GP3Q5-^A.KOV4XMQ[W
M?CV<=H8;+0IM^!7.E#80 P,![[7YU!GS#'W^G"'V(X;6/A##ZG<,WZR8-BEO
M"R]O,;O</D7F6B7,.^A+R$%?8!<22M:&JJW5&1/)I<X+6Z2!%AU,6DCXKSJ2
M9O>2_ &8S!PP^$+"^RCZ'P2I.P_2X1-2Y,QPGMGETW]'5N#^(BO^GD2;<V9;
M6/".(?"C/%CVEXGA]2_LS,7SSE29R\J&]RGH!Z6@RO#G]I XZ6=)2<@42!1U
M>*=Y:?1'R2'1"$H.,TERB '(?LIO[;?M?;I%?( )I9N289;$2AP)"_A'+!KG
MB@+NHZ*@,O8JW1'2J0%28<M'.J'F*@W8B'A7:/#X0_62'&;,D\&WY#F[PX<S
M)!=@OD7Y0)+""9(B X$$Y<7 >Y36/A!*LN3:QW<P-T@X#OW_S3'X$XX?>?N!
M>2,4%C@H_HT^BO]2[$)'22[AE%+RGHNU3SS[-M9,/PIT*-;N26(-7)!4$J:!
M6S]A&C+?5N8"&/./ OCRGS=*TX_[QW^Y5U7_;]=7],+ZNH#T4=V(^[@[P1<2
M/H#<]G&9P"XD? 22_*$MO@7Y,>'?(/^_!?G_U&!B\I>#25QPEF)PEOPJBY=B
MX.VT6/U^6H2]:X7S0T#I/VZG2G_53M_SP"XL3Q^JT3_%]+]OK-N?C.+;WHWB
MGQ+DY@7_P_W"-MJ8 6WLW8#PMW'])W8A$EM^=RJ$2:EPH?3AP^+&G)+$@/&*
M:05H;_$SBIDM^!&2!*]T$'5[X$0_)I(ZMQ>.7[1UODGY/]5]>5235[=WK%.M
M(J\#6$&)%9$J4U6&*I!H%1$HS44$A "IH (RI,@,@4=%14%-$9""E: (R"Q"
MF *)3((@(@)!$R$",D-&,I'DR?<$$/N^WWN_==?ZNNZZ]P_6VF<EY^Q]]OGM
MO7_["<G984D"5YZB#'X'B#\B6?D\%"UAR#B;'?>1<0.'?GS$)^C)A!SFM:$Q
MLK@+F69FAY#=NBW$2'H[<=ZBW +<08YVXP.D[977IW$V)9;9 ^8T4DU3D])4
M:??8F$C8>S'I5116N@LEAYG%R?A095VS20[KW""'13NUUJ3.'!GJWSO63$NN
M"4W2CL,=&#9ZPU]U9\#>,-+WA'TG8\SOPZUV\+5['?*TJ""O@S-VF*UQ;>6#
M#KS@;#J9%+:?5+O/T^\;$OS3>;]H&82D;UR?P0U1OHH;M%#B83D,?Q)HL-"6
M<N2PEH*=\7=O Z(3!#!<#AN&.#&$?%Z[' 8OC/2'^7\99H$;(3]F8$0RCZ[#
MZAAV(D7*A:8K/I"'3G(L%42>+O^/57W275AH1Q0.Q#<T ?$(I(JJMWD9<7%[
M<&E,+CB ?28>."&'.9>Q'%<ZRV%_8&45F6LA6O([1<J&"WOA[$3DO! ([B><
M)K(S2@('16?NNUZG.I5>GW ;3#^%2MF^H3L5KLTH,::235S=I'O8F!MF1DI%
MK^N&IDBFZNHVCU@K@JSW!5;;040SN.![0&B!V;.MI19"Y#%H/\\!QBG@L^3
M,\[F##???>]:=/60>=T4S@)8?417<-'JFWHYS-SMY%F&@72-(ZGSFCN2:F8Y
MA%43!;GXZ\]--58Z<I10%D[Q X"Q'AV7$TK?"Z@QL;7DY(MQ^Z88[-\K%W>S
M*(1C9U9RT$T$I>#P@-J#@^_X_WAFJ<7,CD2^F?'PH>X@:#(C,!UB)W#U;)+@
MNBA[R. :>;,O2\G;;O)NTZ.AH3DQI4O/P^F8NH \&L;@[@0JY+!ZR^^#-.B+
MOET&0<?N+[)3 MB%W&QVE%WYO#(R]_KLKE[6HWB;O "#2Q*M9+L'KWG^T:]8
M0CLG.>QL 5(#\9TH89!RF4547C=N4SBY#XT*YKD9MYN>]A^*<,NF\TQ:21N<
M6!1AI%W;MI:G0,-AR'GU "L?-2. 4*$)SI6HB.(XGJYLX(KT0(%/AEI2TQ:7
MWRM,U@8D1?R&]4Z"[T0*KT3+Z (_YYCHNZZX4]1?1<0LT1F<P6]SYORLGVG%
M] <W)%"D#4O5!4#8&.J!>N3;D=_%^/.*"UPA@.%!I.42N%IR>I+_3FQ"J;73
M0!J#%YU@@!' ,#_!0@%]!4!:H.7SF$9CE=""OZV?90BGOBIR#XX%J]ZL9(E.
M8,!P9<DD?CYZ(*$V:GBL2<]SD'!Y)L1625>KQZMG>EJ%^#7M]+V#_9X,HK,;
M*!1.J=&'S?LNXSR'S)</:8$IZ]2BKV7DJA)ST#8K;-=U$_,+NPY83X(^J*&S
M[^B@"_GD07S4H@]NR&'D/&!P)R#^!.4C;AUJ."YV%HW>:E#,_]:=NZ=X9SG8
M6BMQL=@T'>&BK-,1;R!(L_O1L,-SN.5RL+/?4#75/;2FV\FA$JV$&!)V$/W%
M53):93L7V2F%M]C<.SIJ6; 8(*U+ 0))#A_3*V<V/1X'-NCYZ1=G)354NJLE
MN!-)W=-,_7/)Y86D^*;;DA(M$^9[+A!#*C(9\KIN5)! BO)W67.>V.W/=_ZE
MQ4*B>[^VX&J8V#G&4=S-M&O?,7IS'*F(<^[G@%<(X:@XP%OOP$DJ#A,6';*]
MY*HA*7KO:(-DNG)-X*&!XR.H%&': \'T*5N&>;  L]4,_@3MW*&:M5]+D">+
MVT+3U=<\5R>'$2(<4C0@/!23O#_]'J3931G<L9# D?,"!=(SR_C64,+Z-CR&
M;D.=I4RC;Q*_QZHQUUY-2^_=3'D_\G[$SZF_NE\ !#&-@A%K12F9N"-6A"-5
M-37QNZR$KC[=M"Q-V0N,D?U%<F<M06O;LRW[&(K?+%_(J$^^(-9Y<XK6??C?
MA<?_%.[(>;T3P*!FTGP6[[U57KZL="GG1J:"&[6A"4@1W]/N\&;I.<Y>U)KB
MC.,9^F"/EE^$Q-B/AB2!O4&QP[R[C1(58&TGV% 6L^\3??RTWS97X,>"CITW
M'YY_^9I)%*$V<%2]+G?HG&'SJ\^H.SN'HO(1[0;M['>W#+U^G.(Q(Z=P$7=_
M_J'+21,D[)/#GIVZS6GC.W5 &_]-'!4F)OB8AC+I?>T@_S?$ULKKF]/1]*UG
M*WQ]G /"_!KDL()H2D-'];U'^*;6>[9G#:N ,A?LP4S>XX&.*4K8 %3*_>6P
M\[4W.,8!>7D]S2["9R-.7/+] S[G1%[Z+L'516-RV(I9 Q'FU9]*2NH3$7+8
M.WO*8 SB@.PJ1;05&CDM*SF*U:M+IJKN7VM1<1/LZ1"F,J43E2RF8Z'CZ^D^
MHU_VOLZS29W:PANY0[G<9:E7[X W*9-BQ!EE<MA:J)".?TT102WUNY/0:8/8
MN:\,P)5RF$#E4V:2]!147*)F"RE4*0L$0*B.:V*G<7!NC"Z?(,) #CAL 7$X
M"MB _Z=1[7T"*R8Y2,9ZB^=33"'L0IX"6I&E;."EJ(P*# (FLF60PJ_D, E$
MG/\ZXF)?X%_\#YX4 -3-V74**=;()8_L %N@DJH]U'D:(K:@'#:[ B.%ZO[T
M]XO#Y1CI.FBH\[(:%$Y85<UU@95C $_QGU;BU0*$LABI&MDG-1#*89EJ<MA'
M+SGL#$2;E&",S^OHO*2H'07Y\*F8,#D,*8=]#7%^P/.C');$\2H &N92K[MM
M/S%U.4R!A,P)<*\)+22;\9XCN+$SN5@.(U7;.+UJOAHXLWIWW7 CP-6;0/*'
M5X,)UA)0^35O7?>6DQGZN?OMNH_5B'?A0/_+6=>N!*?<*0 W[EX(+>T%,@=P
M)EL>[Z:X(LZ^6\H#YI9+K[UX=,EX/H,K6%A/7SH/W5'6NAI<>5K%"P(5OE/T
M#3"^>1D ;CR(5$RT6DP&4! _V_/XS:K.ORUG_ TI*=A$;=[\3NGZS"_KG,)2
MAMER6!5A;J5]IE+)XOO_2BQ=OE_NNV3.4G:<4HV'T;XL\Z78-T,NHWPVI^N+
M*:7>?]?RA[8:C=WY%MXJD<-F>I9F3%YKD49 _+1*#IO;?NI_R5;^7\LO4'R^
M63K/<IWR)RB="2 RXPJT/"B1KK^D^,;>8<8\-:9\)N 1F!:L!@:W3V0U9+!Y
MPH[VX8+:N:J[7P<D#JCZCU\EMZ!8?091')UF\B9.SL/!HO/"QKFRDKABXHV2
M6<G:!(>R\"LIZ*K:]QA/IJ25#MIQ>[F)KZ)8TEW*D+FK97S+)0FS3U0@N,I9
M'3?[?JPBX3@E7*J3->43N+VN)4FW,JP(J]_QNF3$SVV* K4P@"1E$OYM;5 8
M>W@P@S2DHWZ"I5_H<?Q8E5\#J7]3D#(S1];)3*X^NZTE!VCX:8GM+TH.8Q1E
M9JU=!#829QWL2^39S<KLCSK&JQ>$G8H&[4W]Q5!ZV80M/M!,4 ^0?B<Y' [4
MAX7>&VZDD?\L[AN!O[XB<#Y_(D4D*1E9(2%$](WE0G28!/Q;TC36LN>A+*O6
ME-UG6UY957J/YAR2\.(X8P7%*\+C-A ;V@PE.V D9+;XDC2(G9-#2\E)R%_;
M;VWJVU*IY/];A1 50#!)T<FWV-U!0":SYOE9T;_E9SQA7(S9WG?>M)9XOA+\
MEZXQ=@!AR/13_,#TAWI#KI\7:"1!=I:=E\F05TA*!L-.L2'12.>Z6&>N7GE4
M,(DLB28V)[4$B()3_?+O3$J.OT"E\"QWQ:9K/_GW;'#.9&9E]B1HQE%Z0K)!
M?>,] (]UO,<$&Z)TKJ5D)Z(OML73K;].BT$1 $Y?V,>2&S3EIEUDMXV35@,-
M#O&3 Y-M:.=?S[N]K-ECISYF1YDG@Y90K5ZS]B]-S&?9Z>9[T? +Y#]PJ"%?
M8/6#+59O9DVK#:M#E#S>HE-K21;'4QR_ST[PV/W)C7Y_5(_+<W$A-/O"X](1
M?V:8UY:7<594\%P[5^&Q(5'?/))-Q)Q^<,^@FF?25B69%5N\BF0L]=^62Y*[
M@?:+*0.1JUI8[,R,/E.WQ) P\W5)9C?SL5-8VLE-HX]FN*$F'08?,"QJ!IY#
M?SXG:VY2C1Q2UA_PI93;^.HZ\IJWS(W&6QYS5D'BV\(Z])V5T[7S_PF)\U'F
M4"\R&5*]QOEJS>.NG.H''L<2F_MO-Q=_ JJF1O,#G$ N+F4,5.&TX''1PP!\
M(C(@;[!#'<5FYM3@?IHZ7E5W[U3P1FPHNC6)(O3A)OPA[!2=4 ?#\?/=R()0
M2SHEZOW8K]UD[]WGTG@T3*G',76C[,[@],>J5%./]&#4'F>A01N+%.NR!;ZY
MUL KV_=0,BV';FY@[Z8A.(,U81:G/;KI(2$@-$Z0@\6(2-="LN<;RN?N [G4
MAIP7\3Z>QED8Q]->Y45C8VK.-<JN V7UH:_M/'RDA#W.[- M &%;'Y*3)(A]
M2X9/J#63DPX-B+)0&=3=%7<;(OQW1IQS>*_[A.10FQ/JX.64=?<83W-@J<U!
MS2<NQ7[> K?<-\0UOQS,,W($W_E2GL)G??%ELJP 5IE8@BLQP:J'!928E<L>
M%9L=&<1L8DQPCCS^X(/8 798$6?V@J;G*WS_R!RI+1&)@!]QA,9K'^*3+[8>
M3)P-6SA\RR480)([.A]W@1V0-+2G'%WG]I!T?5+'YB:BQ?1]?:!^:+/A./ED
M&1.3P@A;E8G%NZ^,@WQ<5-B62A5.Y;@BWWE)S.OH!RUNYG)QV5[U[]Q 7)"E
M+A10A5! 62XT"?DS&?D!I7] S?/S@O0B?TVBU?&Q/[QSN@YKJ$LPX7 7T6VV
M>M/ -O;(S9Z0^YW/Q*J@1S/)O^=GQH&:DGZG$C-1@<2,9G*+_.V%F)7LXPFY
MQ4E#/QJ$6,W2H]"[T0Z:ZBVM+,:(+9_OWYM*VY*+=,F2Q<MA_0K%67N.99QN
M%0//Y;#E?+0,.9R#'[J-G(X$;AG=+TA84_LNIW_;Y7@;+O)EZ5.(1@GW,J:S
MV%G-B+7=?%E8"_N&U"G/J.@&77?_]+.*RSL31NVEGD' <]\)[+0ER((8B^S&
M@J+;V[CK3_]1[M@G@*I0,, XGB11@E@65)G4[MZZ\)..[](0^?238N;A;X,=
MQP3;"(K)3\#&) E%Q(>=Z4(3WET$(,ZF80B<>2EC2,/?K-J^E\KXUS=Z.N#%
MU^4P^H4NL!%@0G7N10[8BBT51T'%U.15YKIOV/ X8%4(1!BE_CWZ)7; X.HW
M(W4]9B;/CL%0N VYATG@J03A$S(/[S+G^<6T4K@D"YPS<FVZ2-"Z@%F..UIX
M^H,S9EQ5>,\)J0)O.E ?:+BQ6?^N',;M3;D_AA(@A!(5&LY8A H95.$87"[6
M+9Z1KJ_$T [MSLJ^H'=N?V'AUB*WCRE:LN[H%LF=3,)@228 Z:"(.-E@TX+=
M=R*44S24.,,-<W7"!D<V_AK./%]TQ3?NTJZ.:/7H!QY5\9B!]I!#!TSSD4+R
M6,>S^YS)OB:RF0@)9(T/*/5Z]?!O"&3I-@4K? \G:8+\]&B*<"*]CB790%%L
MR>[S^3P9W;)G$+EMF*.-1ZR9G#-.^=COXN;I^NQNK]_ :+U+5^Q7>)T(22C0
MM_O"&U%>V)"R*FY[7_F,2?TATF3-0%I43G9"YZ_/WI>7&IYX6TD8\9<0 M-
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MSFRUH8Q:#%9KU7:S"HL-=I2][2B_U97$PW:FC4X[B"MFY##RA5L96TE<:;\
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MH4;&GLK'3%.)#07K+5FU<I]P>3AR1FH@SX4CT_*7ARN6+/!>GGR>?YQ>,K=
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M9CD(O:7#_^#<_J_J\(*P(.A-ZW!V/?K_11U>)_B7A)RX1C5QF GND\#2,=5
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M7+HUQ@G<Z;$=', + P\59<R7Q6+;M6=#[DL\RRA)0U[7#CE80X:EC@35'#G
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MF.C& 5DB,5$W"D-VE"XAKCH3"NP$+#Z 44N)==O/VZ@*3L@^WU%;DT;?*F-
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M3%J]$I*J3R-0TR V[.",/LFE9DL$5BJ4&0;-*H-VP+$>VN.;$=[VFJFF/TU
M@T4I<H3P:3(2[21;2*0>5_L#GL@ "@Z0!#1(YR@WBV3J>*3/K$UMJ$=8I]+S
MVFHGKTAQ*\B1=(FH2FPE3;KJ$&>5<8M2.$&8&B&23TROZ2L<3**],M<18"^R
M4+ ?8:587;<@V64JI3!E0.!P./%DO)(1? JN(H8OAQ.:YET7(%H99- AIFF)
MSD>-N*,/++V1B335S&&-83_*@>9HTL)RU1FP@]C5Z"Y-U!#)]&H#3+2S;KX2
MU_HP-VW4:\2$!>P.S#0IO,PBZ#B9O3"H9CF2KM)Z&-$8#CDY!6\4"^V93RD*
M/1N#D)HJTXP<C"84[&41P,4U@>Y(P!05 CN;=@Q6U\E$W]UZ'F5;;0 "$)W1
M:M616K2,@H"P'88QO1ELNH-"U<+2+8RL]D&K/ 3-N)-J)1H6,V0[*)$T4\@H
M3E>GHD&0V,V\I%'5=+LG Z%9@R!^T&PI:CI*DRH\B[$;>4*0==(*0RBB\:8^
M0;HFTL%"G)R0#M82$2O5;!FM)MR5B+B6+L@9LQITLGY4YL4.U"KV 1.6*-)%
M;7#V!=]B+Q^$": 4%9_B&F.58D*8QG%=;GD-AU%<.)UM97+C)I N3#<&V#<'
M["*$Y9FHPXZ"$BAFR2DZ##LAVR-!5_0&(0*6*(.CF&Z=KK)-LF:A_5(K/<7K
M"PRCHB\ 3<CJQ&&*JDRK(\Z@)+9+&G6Q-F*X(A997)2+4P6O-=+B9I(QR;(K
MU(JT.'+Y%ERPJITP:*:[4Z(QB[XBL-/,^%%^W#.JBBIE^X,R4*MTZ%(%SZ<#
M3F/Z@[0JN@T^9V2FEC M*0$VF-8U0YV J98%TVE'-!- %,5@9@]K'5#W)"%7
M!-HC2\ JF=#H5HVV7:ZQA2Z7=%_(-$/>)35#<"B]8'>D4J% 9.M<EXQA&-8R
M.:E?;P&EKDK-A&+4S"B6+"=41Z6@-=#4FBD8G<1*:IU)6Y%:.:E3:Q=$/*VC
M$F)51Y9>U*I:@<W'. 6":*J5A.O5M(/*3%6>&=A)5:E0&=VJ^;5B-R,,[3';
M3T#7: (ER<TP# ) +5$6(-\8%EJE<AW35;'5<MTQA]2A3*JO#PA*H<T [<^&
M#(.>4C>G:D<$; FMVUE[;$/581=AFC(_'4'Z0' E$<ETM5;;T*R&AI>9>I3)
MZ.8TM&JJK?< 4HNF,,T.J=EB&M&WP&ZFWP<(I)/1X$RD3H?U$5/N,D6Q;6JX
M*+2T@HMR33T))8=.H+71>NQ#G7Q-81D[QJ.7 3?+Z-\ K.O=2+K;95M#OH2Q
M'2B9F:&>UQLED0RIR32MJ!-^@>$PMF"H5VMK="11Z!#I#>J#; JT(GNLT!V\
M"ZGR8&RI(LR2J7'-AB8B'[E\'B7*5GF2JXL$CU2D-"F%N>'L2RND ]<FQ9BP
M]6J59_(C*&1;I!=Q*8N2:Y.*!F09O#'LFN-:%#02FUW-A&98%%03Z_M,;NA9
MHXA0-%/.H-X,-HS'E*HD336+()4?YUU.LG*,FNYZYICP^V22L!/5C!6E10QL
MN%/+=?@D)P.;.N-#45-5>OT!.DE)W31>DF?1EZ9)F1X.X5T-U0M,F:+)Z=#*
M-X)!S04[;#CJ0*Q<S\&08:1<T)!\MH6.'+[,AA,DYB<*+V&1&S&B5"CR,]5#
M?,?AM C(ND*Y4R>+-15BL@GP$K +1J+7(:7E Y_1^A,?A$VC88)HR-! !9XD
M 5W9U/U,,Y-#0W3@U:>S'HI%S?:"%-H#4T4T\= *! ;59J=IFA2!1+UAV^]G
M<;4Y\55KJ$]9>D3SV6QN$D9M$YX 7+\F!=RDJTG]YNS[CC+BHI@V)?(0@.MJ
MJ8GH/M0;TG2SPT[0-$7T,;,-M[%&F?9S8&Y" VJ7+$N2H'%%M!&GR:D*I U,
MS:(I:Y;>ZJ0<1R#CD36=B^N22ID9=\J+&L@,FY#;2^YA5E(T;&3Y*5HO#K!<
MAJR0C9[F1JI:+I1@&)3J98;/&'IY-F37!FDZ2=EJ&(MBB..._$*_2:?=^A"1
MIRHTMDH<53?+K:X9(S0)Y'(]CRL/@'+/BCH@W$6GV=%$EJM(EIN]_@#@,@/!
M>79HYD2$;&.^9U2ZU"B3F=(;J$FAQP!--!;]7,3G,E%9XBNE3F*S4P6>YVM(
M(IOZ;&'<(CH\XJJ4P_&JJ(S8<AUI<8B74GS!S,1(3XYL/^>4)XX[A0H#7:8*
MT) I5[MH-HNGU+)M@\UNJQK'N=HZ-]JP_;S&JU-55AE )[B6T"8<,AS9?="A
MFOTD9FMD?=RA@ZJG]E&@V^>]E)3CO!$T*C:S+C?*2BI>DWV_79R9+UW)H236
MS)7J+ Q 4,KL98A&KV_QU4 .,X%8Z)=PTX45+AR,0Y[7DQ0CW8$%@M"(IMOG
M]5X9K#OI9!JSXBQ88CI2!<Q,YF-3J.NT6=#C(]Z41S3$0 )?8T*<4%R450=N
MI0?TL$Z:*;?XJM;"2EPV9=,-V>MRH:L#;#6>.7I^JJIZ12)QH3(:ID<(D^]E
MJB5XF*[W<E.N 2>)J]=SRBV #[N:157*Z0G@A9Z U5FD+6L:3,5BKY5F<$>>
MK7!FR^;4J0 6H;242:DLM-KM1A6WY6XN+S9)"&!8D(5PW.H1$R\]+72A+L3@
M <F:"-# /:3MBF3*:$0PV9%F 6=Y,M0%T??#3*$EP;T:AR7-#@'"JO@:BP_K
ME:CF=_$2W @H',R.4UR%=?0(<%C#+;:Y#--F8X7G61E3@5D"SG;<,-L<3,P
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MZUK**]MJ.Z!*5-<J51P1R>%!7&*9<*Q$DYAP\]EV-^4T)XTHR7-F$:PF^H&
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MCNQD< 9=X>L1JL&=<6(2.OK\EPFTE[\[UVA.,5146[1-PDI+M4#&R$[JA@!
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MC[_PQ^=:HU,O.MZZY<K^;[-7;'?Y^=O\=-<;SZYFKKIOMYW=_3_VR^</V^]
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M4 BKUAA$8I/O'PST\FHF;60 U!!I!7<*+%,E/)Y=L)6P);%.5/_E6H5[(>H
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MPEUU+G*<V$8(0B=J>-"BV(PGBMUY4<>0$%?_$/_]L;*L:HG^*A:5]6NQ9P?
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MM;[H0)+90Z)SAZN>%S[^,/ <?9VN1FV@W<3P:UI<\20LJW/-VO7XV+4VNO2
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M,[*\MC,3&@U$35:GR;%.W&)M'!/:DAQ_7JDUZ/0A?_@\4\YG,POP<]R;TF#
MR- PC2IY!W7KV^+FU09TU<XX[+CT:;65&LZN)$<UNA]3I37W1RY=KXTGKSOV
M\R&Q?NM8@\7_HFE/1)!\%) W\;6?"C^X9^! 5G3V"T"J^[',W6X@]7W2+VL
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MEP%J1?=?TI%#7EV?)>I6%6SP6][YH-*Q**\>3D_S^Q"><F4/:09NBE-Y*>?
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M6;4Q*NC^XI"4(EV!(0CB^_KD%45E(;P%D>=^.T>&MH&XT9=5M!)%"1!^VU,
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MH97OOE+]\^1*\V;&,V%-KRV 0[--BO4[5.TUT["V?-Q%7URR"?3M'.M3[4;
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MOUOP(U S-+)PH%NHRD>%E@V4;$,GWMX,U%P)-5:<1'<L]G26'W7 +FZ 6][
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M*K];Z85*^'S3Z"3>PLE]AXD]FT:Q4Z'5/9OY)+ZV&3%>Z3C'^/KMPTEXCFO
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M7M-(C33X(@]WG_\R>B5M>+=WFMNLLI!6\4K6,Q-Q_T4QYUVIQK@^4.ZI7B/
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MPIEG1W,E,1DE[=[;>-)8 $E]+/*)B9"K3P!S5O6PI#F=J -6Y8Q'$O?(=6<
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M@.[E'1LN(\B9Y"*5C??GD"E5-H&QR(5,.F*9>_^HR!G1CJ[NY0!<7-Q%PU5
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M:H34$A\XH0Q8\<I"_4AHJ LJ?_&_+&I1A#[M4U[?[D^3B_30R\^Q:FM(ES(
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M)S'7E'MP#/X07_+$UA_CG<<D2#%LWJA<D>A]K:;6<2X+@[^F9+%4)22<ET'
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M-;E(BE+73#+'0H(MU7 .Y_*+/]AGW=KN(Y/+<(K(/UV. RU*W>O%2K4&T>R
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MG.?6[EV>F=K:."]YSDU8Z#NQ9D$J([C&I=B*OU _")')+Z,GF\%@S63.L@0
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M[R$6E/-79XQ6L'S"BF_ZAG;G^,/RY_RG@!88/J6BQ&#T[V GFM4A$;]I>I[
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MWK/(4S<X,DI%+_CFR5ZF!"(Q(4>I'65-4M+GS?_L2,7:F86&CF1M,X.$ERY
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MT.#IJ3EML*4YT1G9CK5R+QRV%-;4K%7C[> @VX3L$PH03.W]&'.W160;,*Q
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MZ16P:5=IS.3XII@$\QEC,EF0A8Q &2-V,&9'"=OE%125':F]8O,=[C_D*=1
MHB<'O#_DID7#N/M$D;:,-=LU_I16-MJ:H.MF5=,Q(+*[/MG*H[VBNDI_WI0@
M[T2VI=EK!%K9] $YS @%JEQ9;))= ?7Z&KX<$X@CB0R5ML!P&4+H6B7F<KWI
M5U #H>043&$/\A=RSHZPD< T:U@<+\(QAAVBGDIX';0I?"(V4D(,Q VZ ZPA
MD2DXS*7:*BY1I\I9P BQ/3+I8/Q89#NQ:6M;1T!_Y;LJ*Z !L,GF\]7LW/YA
M-B<RJ^]9:,;51=N ,E072D.CI,Z!FV"5CS"NJGO>+@O$;L+,1G!ZTF(?5'/.
M=WNIU\Y2.,I&X1Z!#Y:R4'&'(5&17]B^U&Z;95VMP]B'*&I<H0!D-3D1>[ :
M[$+;H[R &%0M[HXFA-#99T[68MI.N9EBXG)Z6.7 $LDE*$?9V/),+MY.$ZA1
MDRXYKFULN%B*7!3-._^KC@1IKBPZ@!&*T1AD$MR $W*ZKV:V9XIDX\^H<G+(
M4T:);.CQ-,BV7B^DAN+(W:T7JSF< -.]S?7F%$5(44/C8T(,31^XR]TE.#P$
MJ=LYK4'=-A'L8B$,]+OD$PQ+I(X#"!EJ4U=!^)U?KEU!E1LE,IETU$MYS?#7
M?%X(63&"X@/&MET\"H8FFYNSFM/6!>X3!NY.B)6^&,'DRM+9/(*G8\_JG#G>
MB#;"KL?A-K8L//97 4DV7G^RB%-*&W.'*4LF($) !QO!GD9 4QQ"4[>$:WX!
MXUX]YM5YFUJDY53X@DD-D:"$.C9$@ 9GN;RA=LN^)8U73#\O^[/>X>GM<B!6
MO;RLB*T))\4VV.$9.W0-7YWQ23?YR%GJ@E#(,XV;3BI:X[1-U:BLM@?2G;=7
M0"+(/,#JO"8IKP\;XW$$8N.N CYZW!$,P-D4;.==6=[H#.)LNO#6J$Y-4 Z!
M@M30#*Q\1F9.TH6"B G]T8:OI_PN'VHVNVT.06K"T868"V,"JL$);H)QP>H\
M!GEJ/Q_T75S.^JZDA9LH#)W1>-V6S6#GRX-R,I&\>*S,U.V,V?9FPWI4'I[K
MZ0YO1/LIQ^,36(;-T$5@:Y08&WPI'OGKX<1DF9TRVUK3+I5WIO-!Y\44"S=F
M[)8+NZS,#.GUO"WV(L,>&'9I&>-/$8RC<T>L6IJ&L@$R$;KAS@P:2L>FS?=5
MV>X !)'CZW(*ZL-]%&9< XQ[PTDJHJ '[<;<#DB#PYY#E^84/#/G)9:8D2JD
M>[R3N*TE+^N\:,&,V?%VNL$6>5UIQ&""CNJ-B0^@G=RN%KWM>%.GKK^*!2E<
MK G]F*$CP^I8L^<C'K$DMYYH@X5<S'C#6G-I95+Y:JFD#($("Z0S/1.W?+-3
M6T=D5\B^+5J!*:'4\18@&PISZ1#HUQRSFI$TLB06&Z$9''EH!M06(M;I@WP\
M<Z-2.Z1''TL##^"#GFB%*<]FU424JA39;'(5MP[?9U+XRNC0RZAEA-6"3M>4
MT'E&;=\H'&>5Y!!"V@TY@@*+YC-[,YY.TMS-TE'3]'H[5J8H-6K;=H0Q80["
M!V\S!"P3#)TIN*/@Y:PX5M"[T<V)R%?!%$=*SW"4NM^C@9#A47'.2)ETR.B#
MH!>NX'$ 4/UFE&\B(!:'N_YXWP%D;#:;LGHX]EF@WR['-K+B]TTYBO+1@%TN
M%7$[U5I5(U;5U%0+FVBY@[<A>^M"MNI5VRJ4L+?-:>13E>*%@]A8,7-Z-VCF
MRDIPNS]L1($("&<=5)L5-LJYEI,8K#KFTT63<J/T\,2'9X'=;C':DD[9[/UP
M8"NK)>V#B=E"82Z/^F+>4M&B&0HF.Z\Y*=(S&.W;/6\0H=P1OO(B>6J-=C""
MEH=GHU($TU!9F5O;0(0*[A!JQ#+Y8**'L:NO\R"M5KF%K!9YLR'G++90IL/Y
MQ%ZWK3\G)::D.(2C[&B?=O9\0+ X-&^*C3Y9B"ULH59?&,?UGLE1A1OO7,!8
MR6XB$6G0V6$K*)U".$"BVJPN>-'*R[D2)5!W:0[<&6B"![49CVP2Q='.X">P
MR-;%N!G6.Q4P.P\!@?S:<%!+13J/T:6BQLX9;Y(ZCO04F_@1BV@3"1UL2AT8
M]V<6<^ZAO[4!= ==F;[I5-B>:(R];\WEGE=D%M.D&M;X A_-K=3!0RJ,-_@B
MWU:=BF5I:K?0-L J8J_.K*+I0,^Y9Z-+CE(,&Q;7PW%4&9NQY':I4.%%;N'F
M*E80#8%1.V9=[T8=-"YA=A*,NYC*6I 6+O)V2'2^LJU6KE%-S\44VM:+VF#=
MGF71%N!DW*+GYWDH<K&]E)*^R%IPFN[X)()!;XP-62TFF@XA+J&JSYA"E.V7
M!FF(*Y"V#IG41-3&DZ6@+1MAN0K04=P?))$?<W+>H/UL,QSC&B]WH7Z=FC&6
M[S66+UULKEJ*;?9N?HYS\U/+PQ<GCAY=9H=L*-\(MW]"=.Y6]+P^+,8"78]"
MMZ_N8:=>IF6$;'-3KGH(HF>#E;)B#X 3[[/U:EDZ]9 %U#BNAZ@;N%$AIA.X
MP92RB'&)-9;+!6.L969,">6&U8'11I2]4&B*H(LS/F1[>S^>1_AARS0CB&GM
M68,EHB6<%$K!)@3&$+2 EWI68DLO;9DL7&5,V5FOE$T!G=U@436;P[EJ]@VB
MRUY1?5ELH<H^,,2#>CGINP8_]?VV0Y"[B=2N&1C)W:T^LV>$KE@0YB9<2PW=
M2M0HF/4,KY861VG*;9^''>4>!V]SE("HV\X3@9,N1^O=GJJ3]FYPV-C>\;F9
M("S@\JE*W_GI6G<[/&R=LHS<A;RFR:VRS_#I>*OZ1=.B5A,3Q'[4<V<%;^O3
MM3+?=]XV<+&59Q7*9K!?C!H?&,8)T'<3) D[#W;89F&9TE%@&EWW0F(R3=:%
ML!/[.T)'[94-=+GV?)7$5 ]K0V+' !#> IFQZH ) >]QQT/)'9@K5;NH"%5C
M#SN<>BK:?#;:VX:ZE$<#6D&J BM-@^.F,5&A4('O^HV45IPH6<R X7JD'K'N
M%@R O5^,^L$^F"Y<I^^UT?2P(3G$]^X:9708#X#0,RQ+W;2,K+$#EI"<:-[K
M;?*>+L]0K-Q.[7UA ?JH3/<K5!O#&SO =_.)Y*MDLFGQ77*(RRI2U'Y1H'O=
M,>K$:(@<U-*,ZR,4.BY\C")G,A[-E9$8U?A1UHTWQ6H;F4B": 2C*G@T6?24
M:3P2J,/CX'S6"(O$[GLRNP!@2]<UQR7:1'8D"&BVQ4*<YC*/].7]A,4&O1X^
MAN=#)FR#I:1VN;A?N-LCP*_G1F(<=C@1,MY;:Y0=<IZ\FRO<!,K8,;^V]!JM
M>9_<=# Y+RH'3K39M":%2E3*D:=EM4S%\&!J272^KL9C;MS&V6$C"&ACTG+G
M?$;2VZP+H=N%:H(^O.E\7MNEWBS6$I#7L\LNOZ_[CAG$D8$J<]ZA,&>M\/1"
M6I/SA@0B=:,?1DC P%+%EA B:EVX):V1(4EYR.01H/+[H27)@1>H"W#3R=F+
MU?W M5C;@/=<AFVA[9B/YV@TB+3I:$FCA^?+D9%J4T(N9'GK= !#G'MQC!,E
M+@YRV]#T3CM;*?5-<0@06CD:SL82N&STL;L@EQ$TE+EJ4=N.6:7S\>R L;.Y
M"E+39KW.6EW'*W#FYQO77:H68"Q$045Z5K-EU@[#Y'G/P):Z&BZIL#/O('2=
M@5_H?2RR8*)LW(5QB"D2F0CEE!MQ*>1&.SS=="E^P@R(!<>YD:"KIFPC_;H2
M*T=9KP.2)C:*Q9G10F!#:J%GHUVAHCL^<Y?DXK"I6_&0KVK<8JK)DI#DLYD[
MM>6\F+-+-(IE1N.'9E%#(Z"#!WCM-("A%D15C'$:R>K1QM\RT2)E,$B19?RP
M?V@[]+@' *PN=E,?4B2).2&,\ZAL*[-ELAQM)X )!&5;*Y*^QE-KAB=CM-$]
MRT)GCFO&,,*C/E!,Q]STX \].*="GZ]D/(^*E;?LM^LAF08>:Q1C<SE%6QRI
MI9T4P\;<D-+I%EV!6V6W] PYJ=96+M=3R:L8^R@S.<C0W=K[=L\5<-;):E>P
MTTDIUPN>V47KMA)'2]MQ8%3,-;-66=V62'U+FM#2T3>;*EY[\'!DNWT%E^%@
M41P4.P@W.F1'#8(6/6C.%^+4BVEQSV9[$XG]69HBY'PY"A="L)% )IQHXJX4
MRU+V\P#3"6B\GV55DX\2I*8/F[IH9#'9C%\O8UF"]=X*3ET#5@3= '11Z.)4
M4/9SO+*M@5:9C,K:V5)?!DQ94>W$8FA)'VJ3?B^OB0(OT0-R"%0,C2M;Q=/1
MK%IE T]"\S"BELS4Z"VEEMAR@XD(:?,9U+F_*5'TUZXU7F\E$YHS0%XV<R)G
MDH"QO.JP]Z6M@JJGCY:K2L4]7 T3$?=F>(<=\HU.Z3K+:C9%.9MXU-N[ARA=
M<K /P2RX%R'%Y?>&TBJT"O?[P>%;!(.>02MKKE6X8AF%F+U!,=NIUFT.ZN+4
MJ$P12RR]*%>6F+&)58UY(MQH&2_SU"*%.8P!4I[(%[D_3=1SJ5F7H0L\VJ5J
M7.9,%62<X9M]:01^3(4#%<(F>Z=HA_UJU$,S32O\7 =C3LQS=PE.J7(:&S-9
M4*?V;HY'AU6&(#Z J6T3]$92LK6T;*O0.;@'*1K?B3,Q<J:TLN+P?34;VF[>
M>&2?SH0N@%<35DXZM2Q%))#UJ;A?; ^6$H_W2TR4N6RA;:<!E"+RPI#:&*MR
M'LU!9M-!**)GZ#A5$.:DPUX>L""$*; $^4#,&;;@H];+X5J(=LKA&7ULC(H)
M-%E:&RNGR($6N.LY7TL"75+@G$?A4:_+="?V5,5LD.+,U#"A"6:Z['@3!I89
M#=DY7NS"I=$KM$-,@4A?RD?@'#?FT[;I4$P@[BP@&!CSN6'H_F0Y9]D@I89<
MH\?NFA(#B:4K,)G:)DMB6KGH932:*P($:<(!8YMB/K$-H^['.A>ZPFBS#*1<
M](=K/^"[AH/QQ..B@,.3G*8=SJ24+E&E2V8SG'&,AUJ\%W0)]&Q IOJY1^JL
MZA'[PG=A8F-J::TNRZS:B"[?2/FFT]> E]H^84&#!94LPJ%'Y08..G@R!52(
M14IHM\6F1AO&R48XEZ<T.TL16B$+TGV[XN,LS41M;:_S'.]R'F</Z+.,&ZX4
MFMPNIF.RRR/#:+<+PZ!#9+M%Q?$:E\[-9H9F7= YX$.0#R$"C!(%RU AW".E
MVN$B%IFR S-LIKH-V%ZQUGEQKY2+ FQ-!]%",J,X;.KHML:#NK%0TYUB^\4!
M.?CH*%'QSGD \R;RP:EDR#5LR Y/3O!@.??3(<Z*^CJ<&OC Q<?A.D-'?"9C
MRZJ(AT2*%:X"*G-CCFZA SZL:&4D+Z1B.^=" Q?DGD-[!0W.YFN^PMD, W=T
MY\P-+4YGS'!I6I[9XWKT(N+"%%JU^YA9#2"QH(9;O7_N:UICB5UX834;SW*O
MRX6=!LQ&B#O7>-J4/<7B,4=A\:G2&P-EO=31*-_-,D!EX,BU-N/)8&FN5#2"
M^1)B#G"N7+(IY+=FTL]X"$ :S7;R@2Z ;56.2K$E2ELRG7H.+1)J.Y65<E+P
MV'@P5JCUM,?*),*G-I'UDH#(T-6YF!)Q_C3W K?HS,<<4EUN/5+Z-83%E3'.
MIW6M;G4#;$M-<K6B,;8I%BE8LC!#H5RAG$'9\$AP8$_VE0,DSG=#2D=[?9C/
M$T!C&,*+6G#9[^,H.W.5#HP:P7*1(H&T9CC198T56(]UM&@7?4IK= F<]-6>
M/6[WWDXV#U D<3D@Y(Q!A[LGG;?:= YTDHXP'<4U8NCKKM^[Y6MES)K.$ I/
M6&.&;X %&M8JMICT$RT2X2Q2#B$@V@1QXCL)JVO*+B4<98:O2LZ7+)[2<2\>
M8C-GDHQR>;#T_898XV$U6>Q\:"D3LD L,CA?T8;4RPF ( XO9Z+A6 .%.D(\
MO0N14U.;*G:2>;#N:D+H[R=*&-;I?I)A#=0CX-G<W$H*/1*6M%2.H#TIM@F&
MUGVU:T8>GOA$,;%%=754*JD> ^RV2^8%+LP(L3\3:RH=*5,"MDQ;0=T$+U9X
MZLQ5U5CNYGS8VGF?I[W.AW<.RJ\\^O#57VDG[.9+K$QWPE;"N)D'+.NVA#VM
M+VK]&!#B#)<'I%=*FWJ2-0-!UGN]"3#<#[9BPS.VG?-CNEG"XTD8'O2PG;C*
MG&K+>6^2#_VCK_J/\+(_[P>, P_&*WD-TTI:K)EU8004>!SA==<".60#6-VX
M*\?TA5(OA*E/'VQYE+=Y1I?S+GMCO2'1A6Y-S>L(569ZM; -8&,I([K.!EU"
MBK":L!S/9^%BTR7SDEIWH*DV9W0U6T =\^5A402]FJ=2Z<OS=J/0\TFLZ'S?
M9HH*/H)P0U/D%3S )'"'VFB ^#0_8J?EI.YRQ2EOK677STLIT>>S>9=6'S,D
M)2)%XLS54V\*@ZN]*LG-CN-6NIYQHS4?"FA!+PUN27G^ $7Q#G;$<Q]7;4O.
M9DGFY,:L6NRR ;VDZ8,>TL)*+R1^ONYW(2T A;WB6+#=.BXR]W= G0N!/.K\
MES!&ENQT'(\D;UF4JD3.@)C/5[D\ _0NUQPIO(#/S^W!;I5JL@8*B,.V7>@<
M-SU-7"SRL$-1C0E&JD9&BRW<#BT36@T1?Q6OHHP297G3<D59<Y1%ZOV%;KJZ
M=MASF*M$RHG&L';WDADDL"R$ 8LM1SEFPIG!#="E#DP!T^W&L]T8&X_(ICY:
M<3T;3BI[)]79!)-#(J/*%7.PY0&K%60 -2-V@/0@I-%I5Y\JEDE$_9COA09L
M855!MF1O62@\RW&<2MA\X_(S=F9E#2N6>=HUFH%MO3ZHS1J< E! 6C2Y\ QU
M.+-B$S*U_5SK54)H)[NB ?0NYQ^ (6B9;(69-;LM4E3;; T=7:@;B)R/YD*S
M7:;VP1^&#3$7=UDSEAQ^D5<@!^!^7?,.-AWLF.4VZRQ@$VZ7=-O(W*A@L;U1
MLQ+;6TD#21L4&SX?8SQ"]H>8 Q^VJE!%W2DCP)'9E3RC6B :CD?J#E&RI6+P
M<C[7'=\*,]T#%,9)DR@FV<*5S7!19Y2Q=C&'6<A-9T6XOPX/>@A 3@#C"9.3
MS(X_Y_B,I+<:85"WW'RM)&ZUTA?[)4A0?(D;X&Z@@1(*$"@0K,0<G>)5:]7C
M&O>F!^=@5D9=AT3"-F._]@E$L H[S#.P+?9X81$B)),ZZ'A:[NFUBG.XF'DE
M*:J]58<KN0QIAUVPY,O..X"1<?B*$>SO0<7#1T )E"@N I6G>QKIQ:Z9 AEA
MBDD+[&N34^H<[FWI6M8-U_1@ &9=72083\] @O/2KG?\@+XZ!FF"=R/.5P,5
M%G, G6[4 FFGBX TNKFE'!#5.0A[\7P,%YL=!LWX%9E#1>2J:Z278WT3!0M[
MY8WKP[<(T!8MM@3(3:<%2%%#G$#AFF0]8\Z#AJ@#Q0H8LUM1C&HU:#.S,J>C
M+*0R2<.=_+;?83Z^';:=#Q\UMDC@,3DT45PB37R#,PE<= -'<R!J1!$"<[#?
MCQK<30BS2\9S!5!!@@9[XPTHF4.0]K+]N1< "S,G1!6K\:Z)*:+1W)Q&>(*7
MNFHTX(Z:>:D$:F+NX<->JY-#J,X3.B/5_KB_C2RB;AJ=045\!LIE<K#E O*@
M)2Z3-NR.4S=H4&Q5K[LU'%N=];J!EYKD6.[N> 4$GD^.\0CW4L\2IP%N[CRK
M,!*/U:T]D'KZ86.<5,DC57+KE'#'T]#U$"<G<J+V6&V +<%= @1[<!-T<3@
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M<OR:JU^<FB>#%IC"1]C?/[T &O]:P?%_1;#_SX3ZGP,G>U2'XWLW1:6QFH6
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M&Q,=0=WP$[X:23I+[Q KJJ.=1@'M'K)/ HM4TA%+Q?*NYC?4YQ$KSL)*A :
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MSW@["#=E%D!TRNA#0G215% )1M$;8!B-(9FG.Q#JG: #;1'Y_07S%B4ZS!&
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MB.97R@N@$77X"7+CD^'V;SG_7XC>.--EB+_TIQOQGF:JN+)3D\SVWD<;CQ<
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M5-QPBEV$=#SQ[2"6KR')8=G<V"@FH70?>74E?ETPV;O<?N, F>2I!H#(GKK
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M5N5.WOF;(DT&1$3 (E<CLH<BLO^.-QX>_I5GST8;99TZ!OC.@^C._?AF^.J
M07SUB!#G@5<]. .OQJ@![#VT?]^QOT\[+%3_OY8&)VS$H717=%]*_A ,/?F9
MV#[-G5&M*'7>K^\]*>ODN$_^>1I] >PZ^GE5XL">?R6_ +[8'<?XZ7@S-186
M3AO'.'C?;B!*_T2C?#C"AR*:(V/:LDL*)[BK;!^"G)7Q*&%*R%P&">(F5RIC
MM,\!$HM!BWJ1K_5]RLRJ/A;TZD*:WM*[R+&@<2/4$LC!?5SA\4_4J/WT/KJ1
MNPBF#F?LSX(X[A5B%'WMU72Q\OLT8(" >>DM9[,(#M8'TCUJ!W,F;D+"]9V*
M@=3J:R\A.%I[V&C1LM!I2[Y\L^L\]XXB[=U'(H=HU6Y&!;5HAFBMSV[N]]R&
M),H"'\S+TG 48L?B(;1]D_CI+KPY"C9UL)\18WL( CG4Z6;K?<H[?!84@3CN
M%I2&O7E"9 +VN_V@Y$$&63%[:; +X*LP3<IW<W-&]U2>6&<<]W719CE9)P%'
MFK 69IZ/Q3;!FM=\(Y_94&G4;^IZ4TPTZLW!UCSV$I4+!"!V5B4\ 0=37R%N
M"Y8&H&_%0-0(&3Q"NDE\M@B?#UHLRL$8K\U"NS1FCF 6^VY9!*X?(2W3XKH-
M=J!']%:[ ?432+$RH"DTD)XYV^_;ONHE]SXL>Y<>HFM0)";@F(C9O(GZ54WD
M![E*(6Z97!M2NQS85:!*?<!UV>R2AJBB/C)6G*($+ZR#/B$0%PG;01T,I>%$
MOX\=]!MP]1>"W^79O<?'"SF9F#[YM!R-,KB@#:%QHD/"=4!&6<Q8NM;9B0K]
M84=##GSS=X4]Q.9MR,YQ&;"I*2$Z4B"6_D3YY+@Z>B8L+.2WGOH- P9O; :=
M&9#![2>7 K-3Z[IIKLUDQTJ<?(ZDG-W5KE"]T..10:65*H?BN$KL=T['.>IY
M*1:5W^9G+F1'8-73L@1QG2]$1V6V^!G#R^7"&<EACV0:0#_YX2?YKV6M-QY'
M1R)&CNXCXMHWI2E.UA&DMPN(D;P]F@+$6HM!9X1V#$<\C&E*,N4?C_>"3?M"
M^-,'9-4YO5#HE1,%7O-'),"^?JWWRZ'L]/CS3-F)<M@36GDK6_K]%(X3:!)<
MOIC>5%/09$.O#.9=ZPAWG'='G+\HB<\O 98T9G&W009ZMBN]D:4UW]#T)G<3
MZ4^T54[7!V;J$O>9$%?9871\Q^LGXU3LMJ\F;-:-4?SJ:UW,\A9M.09/H)X\
MZJ?\])ZG2G<L?Q@MK\RK!@_%Y;QR_P3F!SEG68%2N#"XD1\[VQIJIJUXN3GW
MDY7<GOS@6R+QZCYI B_I%)\Z3@W->!K%HBK-[)V *OYV>2/BOMF$V0@6:Q3(
M5*A\X&H>;@P&)Z)T8;*0H_1AY( LXI4!(4LKE5B@L(*< @'A1X4A$.)[(94@
MW7QH=H]\1$A_9,:0/S%Q4P(P^JB!2S&;_2@G]O.F$5U1'JG,1X578"O<F@3+
MBL2NS[W%3I&U2=][2-XN33;TR4=*; 6;#H:CTGO^6)8R^;S=P3IRF0KVW3?-
M]=&4PZ<CL%YGG=L,S<X+ M E+_.XT,XK6,9#AR+6UF2),)1>2XJZ(28ED9#'
MNI*13P_3';DH2E)SJN5A=0$(<0C-P%:E+7]^VF8LK*=2E'"DO:YCT3J./YXS
MGL?$-U^B= 34 E:MTUD2S;A-+>%_T[2FGSD"FKR7N)IX\6$F,5P<2R\ "J--
M]-D,[^3-H;>9+A_J-5R9O>+)JR<F\3<9+T9PN\G@HB[!89?,:ZOR8IR,6R-/
M*G&DP$D&2%277IAG:)QE$*[LB7-2M/Q;\L()D<#%AB0B.?.E9]K/PQH_[XJ6
ML=3J\A#9WY>PI[FM()PCO!E/AY,S6 K)#,&=(X)WVCZ4ETM04/4I$R/'4"P!
M+7-_3SL;FO3=W@]&N)!+N1/;J7CF@JM,7/O1^3=CZW#@5+WQ8<S!&336^SZ1
M(6_[D$ZZMZF[S8^VCX?IX?,VXG:<6;L@2U"^H-D][038X'T'\\^)W8>DGB]*
M9\?'%O*'J#3KT5U4Z:8%AQ:W!#D%4I$U]G-.UJ1%08V$M:(,J61TF$F7WY-$
M[T%"E"=F/\B2,'8P6,97:M"9WAP TS9WE AZB(OKTA_FSW,$ZDO694E@Y8/\
M%EZFT5)1"# OJ(;\M@-:K=V3:_PVN;MP'4P<OX!F:<E6EPUC.#?.HLV>.]D5
M<QA+&V1,:^J,,&LL.^]X'6J_IE.94=?>6EQZ4.-3?$/O^WC/$'/#GEZ@?1(B
M&R]!Z00+8O^@@93"B<8A.Z215!!]Y=16E R1WT%-5Q15R2SJ3?6M0C&^3M@Y
ML/':=@:BQ0^*OP!RF N\:,/\E+*QW[1.^E\M.KGNLF_S_-HSV[5DJ'QKRP%K
MQ#O.2_[R!\B]["*7YS(6(1"[5D'V3&O$:[^>?_PP_1;9&HT>M21I>FP>4YX
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M2:0JWZGES;#RR@OIR^B7&%7*LYX9CN;G(-,2#\J+I*4>+[E8)&@Q>+DMD(_
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MRB3[2J&W\K9N!_[=7!NIUVTH@40_#WKE">OP'U_E_\)4Z-S#^508/,*(,&U
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M$56I^>=9E7E*?.B2=5%\<&Y3IJ1FZ+*D:Q*=L"($9DFVVS7VSS:>S^<!!I^
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MWU!E*=$#D-.%P?$5/8^D!'PL:PW''? ?A!W?BYG3$CJC@%F+,,P3Y&.)9S+
M$7EVE5.-9W>\7]:#\V9H<KC<(P@Y "U'\O22F@E+QG$E/S;Z5<G!HMBRX;TJ
M0!B#>'-]^DHLOJE_J*I&0H"^Y LR?H@,.@BO'X_O6U ?V*4E' [+&EZ=%ZU?
MF[C]4(]#C4.^(9*H^Y</<'.D8-]MV J]BH\$.2W#T_1W61T6 @V%-\/I@FC1
M^\.J9G>I7=C^"=._K$(\-FI%8"4SJ(=_R')CYF/4LM7Q]^L'PP57;FOS9>"M
M>.9QQ]FXG$-]LCD1&U4 R==2QQVAB_$_1"4VX3:8JYUO%2MFL,O.^XDCIP89
MK];X&(015@G,.X@5T14U7=;\66.3%?^I>Z5KB?[.:C-A:-AK,.MT(FYBH_T)
M#QMXSCA GDL*B]< 9+_07%EA.<B3&-QX3214V3)"@"['GS%+M&7X1V^*39"A
MK)ZR?%XFE-E)\:-=%CN51U-'W7;V,+=,+,R"4<AJ T@5V<OQ$=U32=)3;/47
MT, _^GYNJ= O93>;_:AGI29N)3WBRSH@=5#P3=" =,_)$O=4%Y7$7^N'L1%
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MO&D4S)@@HVIHDHB\_?8!!'&[QYNVYI]MJ2[B[ZN;8)8]LS8/=;T)CAX,%D[
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M1 Q4SN#-[?LPVQ4;'ELQA^PM#%NI*,[Q<,;7>,/C%#]F"PU#(*!6B/L>*_L
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MOWD8L+1+_MOZ98#_-6L&Q_]O1,*^\_=IWK*<[;<B)VH]=5X1YO':D?JX,*Q
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MQ+SI.JZ(\)[(!O(0]_8TC65S1A9<<VO1_&C WFW]&4EG1G0<5J<' (!-C53
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M:4+S?*J!NTHB#0+OJBT0Z<UW_NS;KG(>4]EI4:T+ RP*FP(_"9."@!?QR-_
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M,34#X/L&K4@5WR;*** W\^5&30K2[32.Y'LH5@"[&8.5:2?1L$D!.&[F49(
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M3\YV?=:K%G>.[UB5][5KH0.'AXE-LKEY6.<]OOT7+;523IK?SMUM5KXIJQV
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M@(4)GM%F,L1@.6&&DH8%@VO0Z'"JEQD+;P>D(+O*I*A(/\FT!%R%]1_3?\S
MXK%'TZ6PDYJNS>KXC7%% O%A59OBNY 2CUPC"]=2BVN=GO4M*2;UKU@R5TA!
M8)R^3H6)""ZV*;NXO2;F&SLO+B_0NK_)D$%F"XE8XBEY%M%-<ZXR>126C"=Y
M('E/I9F"--VX5^TS#Z6SH-&&]MY4X>3;UCM9E!:IHVZKH+F)C"D7W<BS3O\"
M+,\9FAB"&SSS7.:S_1K:(MF,QR&\9,W)1Q43;[;P]O!O<5-A337DC<4D88TL
MQ:>\/3?:(&Q00U(BF^3M; %3_@-I#!F&0C:MMM-2>$7W7KIL_D8X8]_O28V^
M?1+B;D_&CCWS?>0-_ N F:3==V\/79C^BY?0!%#K38@HO[F:OTT]H)"MN@9/
M+IO;J1O?Z-SY"@5 9KU"U-;K$QAGLSXTTH!*BH::1D@3&[TMN%2//KNI-K!L
MW*42?LZO=*B>E=FX]RM-.26':\^?0WQ@QK5$7Z+<>].E\8-.*5OLW*MD7IG9
M1)&WE9: F#RY-I"D=31Q8]G\.I>E&R]@2V#%@J]&D/\GF'G6B4KU'H4XA]Q-
M5YS]V/;FI7!5R+,7^MW^0H^>C,XF3'F=*$9:%:2R.@^+3<@P)/U-JZ"N=:A>
MGL4ES),P1:^<QZVG[C1ND@)./K&E^<B@\M 3;>Q*9=&A <KGKHWV,Q#4IUWW
M+UQ;)C%>K:W]!K,345-+!J08SC:+P0EW$\ZOU^X+:YH2B1&/HWO=:I%$A*_9
MX7MUCU\E+)_2S^NM(<"Z*0=YAO9B"_?M]K$/;P!Y,QB/LO&R AR^V5V^8HD6
M7+[+2BT1GW4.)]*S3$#2#2:]]%OY&STSS@9L!Y<6 ]\?RE?N( K5*M%LQ?#J
MN_ "9M[77\PQ&@8VB?*=+MQZS]!H4V*K25\):Y[H+&CO9?Y^EF"[CP[?QU F
MW+TL8587F=)>A>5;DEZQ^VJO-<[XGQFF5]CN 3WRCT69]#I7WT8X[GGUO!;8
M$LJK(&H^/CF7CUNB8J+-OUL\+E-OSX-I;I\Y*8[KXI=OT1LKB9.=0C1M;!#G
M]+"RMA*B3I\R4XV\DT"Q)\=%D,"_P43>_(4'2M!7^8E+Y)-#8KZ\=:+J$S87
M!'M%R6FK&!'MS77UE4='&>80*6=8F<>.9VEF%KR^/VTFN@^WG0@N+?#S$>B\
MTK:-P*I#FNU(0;C06.O>8US/.N7I68WD9/2[DF6-^_.U;31..8R\KVC.\G\-
MY%7[@K=DPNS\S.:$[_]!N>LN<MA<] 6WM6YX>'[WY85BOLJGS.1/[,HOW=K<
M97Z!? 0*04HJ?J,"/^/OT0,11F&UD,8IQQ3T^P5RH]S?@2KF#]ZMNV8YE5C$
MG-X;\3J"F1_<"'AI<1.S*#>[=5]V*V]NG_P^__*C!'_$RC"DY!]J+:MY9JC<
MXTCBM!E?N_<GJ6:OD,8M1_AK!E.\75EGQ<U7$DX(>K!OGXV5,5%"$5>[\EP%
M1;_$;F/L6+'_;!VRJ'ENO_&]O1%87#?MK&WM_ JXVO_#_B7NM\30_#?_J>>O
M?_:ZY[]N7-E>N=;HF2]0AD[:;5#8Z!76RK?1=K\F-H\CKLM>-4]*M%] 7?-W
M2HK1?$WT%TG3X_N,3B8FO%*R=K3)YMU9!%[N3OJY_M0_C-8O8/.7?R#+[/FE
M^*H#]!P(%V$NMLZ/7QE"K2=X%XA/SYQY^ HW@E2 S,6<.4"RO#J%L;5:TRU'
M@R^1F*5?&#U5RCOP&F]!N8#\D,098)1+U73OE]-8PW<08L."K6;/K#>%=[Q^
M#\U4!&Z\QG"IY5#):FK3IS#MW2)#MJ2;,AW>>Y HZ[U<5;N89AS"UKQ0RI#0
M>=8A-#+^OO92ZBHB*18P:I57RNVVA7TMR4]'N/R>'NBN:C89!;<JCZ3>?]#6
MG*+QI#<L!('-9RVM_"8;X-UR-A1CQ@LI;#\N+^5:I[H4LHQ/-SG]S&IOPJQT
M&5!H+?J19SSS[FT-J"T2\!*_:Z>NFWS]M/5X5X?VK["GDA<^HGKU-1S28.6\
MG=GJZ'>33MJ!"=&/DV\][XD( KTQE8SA@N'J':3YK=-]K*3>X(**X RY6EBI
M\2#%Q2R'._N\,1B*J:N6XX.HDY$-PU=B9HA44!AP9,U;+1/I3" [=3SR(S\3
M$LVG9K.SY8U#?PLV5DS,=Z1*'/]$O$%P7FAW%E^,?<RM]897R#J[&-HO;+=4
M=([PB\;-<P3X)8,I0P.$YCIF SD/0JB%/!*@?G,_#//0G:2FP,?+-V</K5=/
MP&;L=GN6H<'T+QX_VBI@[P#$K3[N/QC?#"UA)I@1B%CK5@NLAQ?)<ZI3.:W4
M;C<BSF8PTI"_@T+E\%KFFMUQ9TUXO9)TT+>E9@R7^*V]%WWH&FO@6WKR>Q_I
M&SI^F2<,$3$ETMH4O-E4O&;E8>,O=E4E(IT)G[%+N#D]>ER;//WC3P_!%3?R
M^]3,U;J8?>W(Q&XFAB=J *3]448$<%@#0*Q8D"=&O,\AIT>(P4EE5"/_I?!!
M-U#L(DD2HOI0N:J*T+7O5/3RJ=]L #L9]R(,(C^H%(:FA33^SH&<(4<HOR"<
MTTDQXT<'"DKT7+@;\C*2/;),=/E HS1!(],OEY[8.,>Z"*^>89N"EF*L]Z'3
M$R1I\R55<1:T1L,&A0@[H\2KZ/(/0N?[1(YG8WIDPX9]XC-+ /Y^AE_WRS_5
MVWS>:AF+#QN)-+09A H39]]Q-]DVYQ>J3>.'S._(;=*T2#(JY^+-*(M<EZ3=
MG)]55%AWL0,1%]@A@IIC0S%.KJW.2F;),*802BYJ?!O+Q!D;3\%?+J(=%3WG
MF7O.(^('.]",5*:/:R$]GY?;=0U[_+\X345R#YLU@6/)-OF>]$1H7L$FB^ZZ
M7VR;[MF:;1D'P_"ZM:T'/Y%T;C2&G%'GN2UQ/U>P[146.;86(NW.!(=\9W(:
MG HP>&A]%YJK>RWD3<<ZL3%E_JA::_6N;FI2A]N*+RO7!!SXW5NP-.*57Q>-
M:5S+V1*VY\E[Y[3&M6]43>_YVER(+.8 R7='>*Q^?;A^678.%S[VF06X]&8;
MFDD=_1D&-OYL6D>;]:NAF9\TCJOVX,NES9=$3,2]$;7JUR$.MA5ZYUG5,YI;
M/O:*?::#>0GDB_:4K^@@+S80V;9(B&("7U<:ED*612,Z:>PUH->NL+^*1PMB
MB.7G^U*4!*MJPB(BXKSO9%C5S3"ZQ=3;D08Y#O+MKE.ZQS"%&*BO>AV6AQQ7
MZSCQY;$)&]&ETB#E6A28POA 5I#K''VANT<I NP(\?=%\T7G.DT16.T,1F=*
MB!*O,6%G%^/^SE+ZR!6Y3@>%;FZ1R740J5M/VN9LOX%Z^E73]*SL_K.WKM3P
M669\9K"(F2!5LEW5\-?5Q^?^W)[6?U7H_6_EQ\5 V=]W^044NSQZ2;\E>\N$
M:O^)_1N]?98_'XLCRVQMPF=G0%$C?DC.^5BGHZ%<**L.YT]2&M/8=DO<;H;.
MZ X^DMPWQMKVFT_-*QVLNLH-?GDF-@&/$;;<>,V,U%+L:DQ2IX23*BZHI"<I
MXIY11ZK^V"D,QR9NCEHDW5O&8HB=%8=8O\N[+52^OL?1,Z:&<XH,3;.;M!9<
MIA9QP( -D@50BREJ'WAN9:8L8&#CF^EX,\[KVL.8=K-S_]"Z0T#'^,Y@$?][
M5 J)"%?R;3?>=/J9@3,[PR1WD?9>&LUG=:+;J,Q.$P\6MU%FASEWN3=/2:<8
M/EH?\MF IRF<[RLXJD^XB0V U5Q'XQ%!X=2_VN>87V=_3,IHWNT2(YA86A:P
M1*B]=1O)[EX#$5LRK]_ ]Q_O>K(G--PPY;DKS)F5_:>!NGT/;O'>-:"'E?K[
M?YUN"K>/]_:E%P34<R&S"*O(K=<?SKE\D+2E9D,OP#;&9T.KPGV,NTA.&QG?
M;$HB"IBI/W4LI)ID8*ZJDIC_:NW3%7@/95X?/K>F%M3\=SF,4JL]MBN>TU6=
MQ2BY9O?L'7G3G_-<VK/(J&:=HUU0-Y(C2=CYZ3&0][<^J:ZQ+FB1=X+F!GL&
MB$2%/I2+IK(_0MGI9$[_A#36IYP'4W5-N$IJ0VH_RSS$B84V-"%LCC#S-7&I
MNC330X+'1']07W^#1-*+F.*(\]FT_W" NI/)@B$&5Q^8YSSB6<G&'3S2ZRB[
MSB^@+1OIQW^1M@3G>.*??SW\DJOT\HZI.J/U=E_U %/'UX6O$HK'-2X,F-),
ML73!2[KTLOF71P^@]-]IZ/:[N2E41;M:DJ<RTJT_:ZGT?OV3DSG7@G5W$7"B
MRB+,;<7%96#4KN;-$FB.^:O@E#V!]EU<RC+<NR_D,&(6_%G;(B7\#SAU43HQ
MD--SJ3 /90-YJ*M5E_E1YDBF$JE&JDZ+1?N T05#H_'[I,C:&IWX9(XJ&SP/
MY9-)27-),J%^",@:F@!@K/,[%U9LR)+L0Z0US<?B_472:--6G23Z#E26)W;
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M3:K.\N'X,,$9+N2HNG,.B' 4_6-B,N95-X3MY9_KS3\2/&H2_/!>0U=@A?P
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MKAA_-^=MV<A"+.!J:<C?>(M/2L^MYE<I:S7C5D+"*DQ@GS"EXH'+F=:43'D
M!8E] ]Z$C51P2BRG);T).9$5/*V^S0(H*D-#K9D.]<+RM^HG*W-G.KW\71,*
M/&.NKUBR< P:X+C3\+Y "G):EJS*WZEL;HO*P[E1_T=:#@\)7F7F@PB\BYDX
MP6(XY6$OF=)LD.3N5V>['XOG&N!DB5)\M<[ 0WI0MQG:\G[5N*B_LXB_4*5-
M]UT2GU6"<U[/?H:-C_N#RL.$^C]:2YT*G6FVTA%EP^59&XQ5NG:9BA<]5X4C
MONS,)!GBP=@*T5YW)V4>%;=4O%>NC,H[EQF1B0S[\NHKD-P\1ZFX!>&,65*V
M>GRX6/BB2B-,IGW'YF[$;(H/'X1*%K+5A( I!,FH.HJ*F[CILUE&:F4\B'?9
MD>CWEX4GX#$)BD@G@88\>V!7QF6X:/47MQ[7/4%,\5_V3UOHT0WTD=R?^O3A
MHW<@(2*X)QA.TJR?']1S>DZS6OV#1R,_WX?_8VI ?2-%GRV']XS/H20OKB-P
M(W=GEBHN<TF::;IPNM</_<4M0?+B! E3_M?-V(,YX4Y35'_>K&@+TFKN>QC'
MUL#!SL'7M'Y*Z8YE,<EDSQI0((8ZA]IB:E[+SJ?HAFR7+<^6Z&  (UNTU10Y
M3!/R]3O@.XSV-:^KKI-/9V(,8+28ZTK(M&AX>?/;-Q9">89!"6,G_&'"BI>-
MK2FR224E&YE1LX8N_EZLSWWY-LEG<FD_)+%DL CB1G]7A;_H@8L:]:C,>:L8
MCMHF:;Q;C$A([BP W(?_ND*6BP6^]B-MSM X^G&3'_#Z!RL OD_E7>[=K ]Y
MV+/BY3% 6A4SBWF((!:+Q.& LQ&AX4E1%]49_BTL $N!'C@ 7(@<:O5U&B8,
M'JZH[R4 =0V%X"3@31LT"1,6$# "79;L@S'A-- %/IN+-Q"B_[@ZR/K,ALW5
M)-$M!#XS!*;657UWTYY: Q=R@UU@"*-ZK1HW=)A'_ +_.19($P(+FX\UZR-I
MB"=4A!U"EE/M#LMLE7TGN39PS(9@+ZG<8ZD^\F:$D)U1<9P3-2D13DT*X1GN
M&,9R'1'CZH-XL,#R-^!OO@E@QM'A.,D9VX:B%<?<AH//[R&)+O%P[W[1;OLE
M!1.>T5MR4Q3CJQ_V6 IYHS+]QAW97P?T88';1\!3>I#=W[Q.]7_9W/_KZK<M
M3(L[MDS:CR])VKQ]?3%U49!H>JI3SV:?IF+7M@CAL/K[Y21"HG@<G([I8X&/
M69681 M@[4(/.=-&C)Z5R_-MNMXTEI]*_Y"P#[F<L*0NM02<PBFO'?8\E1J3
M\4_=,^;9M0(=LP<+J=2[9#@Q;S\C#W,&VWS!2$Z(AQJAALIG75GU6^*R+_?<
M37Z4VP 5$B#NA'-;F(R*"_*\=V1IXD(2&:*PC5?CW4O.$^PE]DFN"\0NII3R
M';@WT<KK*HDN[42HT,W,$.]R/S=]O(6IFA3@)_K8SG?"1SY, *5"KW4UYB05
MCGT_,O12R4B!?((PSDAB@=*#9;!OSAY5.>"%IC*?W&O6^;!QBJBQ^/XJ7YNO
M*7[.[F:#^E,^WCTACK-A0L<6Y(Z'X,1NF5?HVQ!]V[';T1+QFE+DY5_WVCBG
MX!3F:D(W,[;I;C6&B>^4%Q5@CA&38'3 <;N*TP1,B"NQ\=J'C$]O+,]5*V:]
MN$3"XW^I[SGH _ZL6.#YV^MC->F8_O2ENS_XM!]6FP(QPJEDG !G#>CKNCJM
MO_@G/8Z)')^PTGG72<:Z@&MWR-V8^PD]7]_Y^6X8?[*-9=NCW)U/7\!+:>'K
MI_Q#D>N"B74U(<D$U<-/C C*H<B3#/@63X?>53[MW'C+-RKC]YC3\ D>7"SC
MD?2Z K.HNJI _\J@-*V6MX,>:AO6),3 :P?(9AN*/243V/R7)3GPRT_[)SEA
M 2^T[(I!5]\\3'G?,;#O]*12)>?ETB0]R-)B?WSB"<?<7%URB)>(!EX?E/*K
MJ6_4;!?[@F??"3W(QF#?H/:#7$&1^=R&M&&1P7.U?/CENYLC>[-T4!'B:YK;
M@2=PXC(52R1% !E9F)(RL]A*??9*8::@\\K--%MZJR^P"_94;U5G<"4*\T'V
M)Y7+V8?>E; *_)>%OC4IO\^9Z?YU8Y^#":-I@V.^DUWJ9U>$P$_^P:F(=_M9
M77*9#HG=77WD-*YR90?:[?>U,IM3@_!@DA>6.%Y!E"CBL7T,I=[H$0Y^UK?R
MLZN(-\%?A3H83GIV7-2)!6BL]'V"D2%\+NZ)<32N-$(TZ12]UH\) #,O-&ZZ
MK-^NS=\7?188,/'3P2-CWR-;Q,X]$EV%-B(,:,M'@ZU_N!_3+3'7;&P/EX$-
MQQ>?"?BF2@Z_.WCZ$L2_FX+JP%BR[/KK,^R6.YIG+L]^<?CLP'RYY1]ZK%8(
M$[ZUB)/;)J>5/D3/;1-]Y%/P-JM^!90+79F7S'GUT;!""&_MF4<HW<+WOJ*@
M67U/XP\SLYLC*CIIJ?<U ;4CD$YY\U7_#VYWK(-R;F,&6EHB[\9V%]_D<#0"
M7^6:^U9RH0\8R"3'Z%4D&F)HWWJ)6(75F&7=5:\FP0)KA0/'%SX0AGQ4;\<O
MP4R3R6U?L5Q91BX$]=( RR_H[/+^W@1,OEG'?R&'#F'9&8A\*QSLX4C7[N-1
MW,M>I;!;) .*SN9"!S)F<919BVL7QN_L\33K6TCZL"=)+*NWA:["2"Z44:M6
MUWX:)'=7:9#K;EU)-DF6WE.T$]#!3_L)X)R<5;VSQ*M\]_V^?DO.*W(C&1-$
MF7,:']1;75%AHYT>!.W,K(\YNK2Q^>$5JI?W/-%@G<&X+2$J7I:$ZVD^GN$$
M3$D<?;L9)]]N"*3AM$[57T3=FR ;3+2^($[4V?T6=>J+4JBV2_),0PQA+T8&
M@'8X+$+/6&1R+BB2+_[8(N[OP )'4B[J:#:<M"02]\RFB.>XQA)J63#$\*R>
MEC[D=970:X5K3STCH1L0.J50U8C!355!T^&:IKBE \R(E\H5V%<%7I4D0HTM
M"'/]$YOH"K_).D/.#>KF4S+5B9YGMR1N=6BMQ #</3YI:9,RH#P?M13)V@:;
MV"?&%B\E^MPG:6JN6 MP+PA<X$E(^**-B#0*@V+:SS1?N119H)/UJ"VZJ@2\
M\@1)):2__[%E_N_,_:V$,Z*PP+K]*!0E]X= I!,GP^G#OGP<AW;_0Q\*6.-@
M_GV:#@XQIG[KPVM!CF=C=R8NM'SM_"E^-#WH8C2SI\R/O:>2) 0N_ =K]&L7
MUH7Z4H-44F:C;N?.[[J%-;MOPV@:M'EYAX<)G(^HR/M*] H+?HQ9=T3H<+.6
M]QS?&TY9]8.3K]B :@RO;3WKB1V5IG ,)3!!6%XZ00R$\*P$9MI9MX<H7Y7)
M;A?+2VF4#6X35>!G">&%Z>FBDA(>61G>3?\Z$- C."&HOS8CY0NAG7/F9/[D
MYM#0U/!L3IL7IE;JK=+#RRV^IR@#(F>UB=SUOWJT+JO#UP*C$R$I,["2G!1>
MM;>%44CKHJ(_.;!:%XGNI0;T+;O1M7;NQ2G \1O'5*[8^?"W3.2I2/5^5&HM
M]R;=XQ. !L]&Q@/5@8L_*::8">:^SW*&1@C5;V: 0[+CU8/[D#!!*+%S59[R
MVY7[+'R;@<Q@#,8(7\Z:#;6;Y\2P\JI[KKLF[ZK(DX).82J[52-0\&(EY<;$
MXWEKPT O#]+=5'-9O:C[G/F_7H)$GM*,\"?:)U:^828T8<WJ(5;% A-&X+9%
MBA$LL('%^22AZ6]=)CR/]NIL],B;LQX*)FBD9M4:W\5+>$%H^&;S%F"&\P1Y
MG((KP@(7+ ^PP#Z../QM?2KT#3_H&10+M+\:P@+L.-^@GN/"Y& !E(,O%N@5
M OX3W^!I0-6%.WCP?Q^?]-:@W0WF^R'&8/PDU1X)$R+C(L@2/C=R'3JAF'DZ
M<EFM]GW^S:'2N1'>[%20U. WLIDL<V3M9X5XIPDG$L'A7Z]E0/FM5"/F-ZZV
M7M/4P/TV%>8FG."_X3?PQ,EGRI/**Z=O\>UX47196WQ7_F8J\5Y!3&?3%\+!
M_Y^@.\BGURJ*X*X3G$(CHO;9FR'!?GWIW+XQ^#VS4/_J7_' \H7Y8HD,FUW^
MC&4?=SVJ6G,@5CN8_*OE/E]:/#"-.GGS81T+4+O/W#<K:@J[&ITBPYA+S!&_
MDFJ5=R5:*>T29R'7YIA,0*-7K%^(<MAC#%-$"/I*ZJJRWMV?'0!? _=2DA!>
M4I,34ARM%RI;7/A<=3#-)="+,+5CQ9@YXEWZC6_5#VDMF1$$P+UAWG/YQ&P/
MS9Z%CE17\>!')TY<]G'A_,U#OUR:F,&J:#AE]:+^Q-L/Z.2[/Z[480;?S?"W
MM+Y+'V)M]XQ9$5D&!G6V]0'[H"1$R)8AH] AP5)0^H342(05+TB.9ALD> @G
MHS6LL)BORZR7KY>T",H5@H>\^SI_)_8=(^_N[AZ$14FNH52O8CW]U**PXO14
M:EZLR$/A$?"P\J,@LXI=>"8PA?:@+,FW1JO1!#Z=J#_S[WR@(2F@,&VYW+&T
MLH4>)E"/#[1XUE@9Y^[E6:N==TYO,QTP455]0T'PM.DCL7JR+N"P6XIDEG7A
M23HW>6X>CT2HBO4(O=T>G7EEU?VY?2E 1\46)H)PG1>,1.HO7_4-"3W05\H/
M3F&\\O$E%9O8=]@2>9'@$9S\)Z6-6V/Z<R3S<?GUX!V#1._)D0=Q9KT*1/B>
MD ]!YQ\,(<[@Z0M>_H%6\A&^IK[/;LRWHQK3/OJ?PBDR_S+MJ53K/C>G73_%
M<>H[F6&Z;NN.2>;31M?BR!]Z!SS\L%CU:QA<:TBY=0,R;O#A,)\TCB>M6"=4
M7B2^4Y)Y4KA70;''&2PEZG1^3=^TBVEB8G+,^N=-F=4D)CW[5X\0!X=I-7@@
M=_L7$#A9)O1$,T;M;:"/MU=-GXC8BUDRWZI=3OT#H=NA39\@G)'TH'FTW.AF
M;_L3T?+-3[/=+JQ?RW]HWVD_\X-3_/7TJ(2?S2^64#TL\/O<Z?HS.,4_V,0G
M3Z9Q.<V,SL&;BM7O8C*:O3:P0E.G8$L"I(P-#^.KN^S;7.+5)%\P]^, PADX
M-\0%R#I#/G2AQP8C#2%"A)KB%$@Y+RXBI7 QF@FHC2';S@A<N-"2&5@@81AT
MDL. PQQA;5R,)K1=.,*H:M"5F' ++0RY R[29("PHF[H$>FH.LH.!]8L<%)O
M\ZT31,%$ >7S?/X?H[FW.^^]I612#CKPR3:4 ?GN_%["@9ND8(%(%BBZ&_#-
M](KT],MZX)K^E'TT=4./N=_UE+)J]WR&ONOZVI01D=:?;!Z\H_9O&\!)C1^B
M*AIE&V,NIPBQ--&R*5KN\56K+]0^*50XM)KZO&\!(TS+@RE1[?QACOA_=W?\
MG3U<_^3Q('(V84UL62T-*>&ON3L_D%0U\VWT6E2B:;J#]5,;76#FOW+Z[S]*
MU+'3_PM02P,$%     @ YX%<5 A(L41G: ( Q[P" !(   !I;6<V,38W.#<V
M,E\Q,RYJ<&>4O$FR[,"5)9:I88VT!!K+K$PRB(F^HY(L0QOH GT_0QOH>R"
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ML"%ZA:7 7F_CV$H^:=(V(4^,J\:.,C+L"PMELR68$\1JESJE)+7T46_ (<Z
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MC,78& Q= D3ZPN61"BA"2?$G(:7$""R%C.0@%72(.X8!\93AU6I"&,R+!*&
MO&  D7>DMZ>/"DQ"P3W<I-XD9!"52.>Q/01C.TM!;&D0%H1F(AW%&NW1Y.E@
M,=E'2(!'2A5 # 5)$#'49*+(2^7D3G?G\L+#^6(/!1;H1/1U]\)[0@*D$ HV
M2(GQE>+5_+$M4P8G,(S(<>=R101/01 :#^& W"%X5I!*2I0(&9$LD0^(#\-+
M.2R1-R$8&Q 0+@-%D#P]X1QW?QD0% #3#-L=# [',"G$L1]!!:%]P6$HB*.;
MO[N$*^,P@S !(#C6.U@3HH31G8*E'/\ 37_\ WE*+_](*1("YZ$!_I$8*EY
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M5( [[OAFI]7Y(1/?^!V1EW?T:XM6G:G>.6/.^_$GIO"7ZR"\9CK=6.]Y8Q<
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M^&ZGND</EVO!(Q_/ON)W9&&F]W['*^^66]S^['\N:<6^P5?M)O'=?:?(=-_
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MSG6NSY_36*M;2F_;@6-7)@D(1R\J$[YJ3>Y@5NA<]#. 3*MD6SBUU'FTK*L
MUML>KN^*SLW*T\&$]MI.[#?6\VG+>MB=,ZOH\!G7T5OJF\T"96+Y!T)W!RA4
M3-'BVEEITU:LZ9]LTG#<X\(;T@!ETL#LH;SK$4]).RP;IJHZ&TB31]QV8*I6
M,06J;"[,BN</3DFB[^?/&V85,Y"5ZBDEW;WK]V6_Y6+V@_S2,Y<50Z/GM$TT
M=PYV#QO>$EZ_M]MOM=MFX[:KN[3C[US%I9CX2%?81C3(2FR>[UX6><HL84IA
MZ4%+4;WQPQMJ[.QQ%:'MQB7GC^:-6M_20_6".^SGP-\OWCZZ$&#T2GEO3:W@
M1O:XZ?.[9Z<X/^M^$6ZR:L_"&*,+YT>=9L,X/..V+?4BZ$L/@A>^TID0-7O&
MEJ)'9B+BH?Y#'Q=.;]]9%FMF5;;(5MYL;I>0F2E,?'E(1W]&)D^;JDCP;QG)
MKBFH%MU>ZCM1N#DOM8(Z*A-DORI?R7ZM#:Z;9# :]QYON-9<6I_P&&"OSEK@
M8=Y)&09_"$HY+,3TBDK/I81$Y7Q/6&"99?=B9_3C,LWUM>:[V9"57*2/Q3JE
MH7(2GZR3>WM'9OZRJ.328\EF";,STC)7S.ST,=D1'7YH9]'XZY"#DSYS>V#]
M*'UG5Z-MEU87/F+G/MXT>.8P5MJPGBP0H6CTY"5N)P]4N'GJSHNM@49Y>;W=
MW3#">AA7$?-N;;2#7OSCO@R,KP"%%2WK6"E&G&05G][;VKUY%\UZA19O:=V+
MB2;3K<)#.E:\9,#K[2)&:^K:.NO:QAM3E?K\UJ?>#3X($ZSS5ZWP-ZMW>I^:
MOKHU=$4^"J(]OX,PK;+OU**\(*VCS#41'R<*KZ^>D\"*$5]O/=8"&JZ]F&SV
ML.MT_KD+_0Y^G:*PBX"5C1#FXD<72_-PY3NFY^#-H+*+::7CET>"2&\:T<3+
MQD>M?**RAN9E7Z],T1LGH*DIUZ5%VUV59]>]&6SZ\/A1W_/IJ(UK7Q/Q:[_G
MT&& D#=+C(,6SU)W?:BR?[M]/?=QR?JD[.[Y^/SL)6>*0U@9V7P2KMTOO?1%
MFE6Q%:(2U%'V#M,3<]#=[^%CJVGI-JBUT F9.N-LC4 ^"*UIU=8W87< 41'K
M>;A&GB";9Q?TQ*?:SC+KR]J*O:$7'#ZWZJXZR?^0>_'Y@F%ES:M'@TT6REVE
MX/>V$ZDAZX55K7'IE SK]FBQ/B*6F7=BN4$J*:93?K.78?*.YV72F9]Z[HUM
M--EV1EKDR(=&W<SE,[)U5]TM-:[&!3U@V:YJCVC**0]=+HX5[9+OWB:LP@8:
MZR8^X@[:G-0N,=RUXQ+8*X=7M-KE NSR.03R8_F](YV?UWTY'_]5Z^5E6'#^
M07D1(/S4W1>UAW?+G3<^-)CCDSAW]>+6+>" @CN%M=!+PJ7KK=FGEY?:Y;Q8
MO.#:O<O-:?2JA?D?K,[%.W>-XWP >Y?IPP;9#VM44SZ?&35-NG0;^^!@0%W>
MAW57[N20%*;+,DY&J#Z(3 OW+AEYNPSS9!%FZ?(^9,<EJ_D=;ZP^.%\:M]N;
M8TXN>K/BX:M7AFZDPY"FK%R,Z6)MS%>MPC4EC4\GM"0FE>^N*>24E O<;EIN
MJ5TRAX6I0GLEFJ/ IV5Z>^<\5_6XFG3O+\J?JPVJ.'0HQJI:@%J7'<NX&>(]
M#,UJ6;+(%3-C-O31(>J9RU--IG7>,MU7.*$TGA]_NB8JYJI2_V)TCAY%ONS&
MTF<V6],VQ]'91QZ'LY7P8N9E.'FFM6>4;NXQ@X-K&LA\GSSXB5A!Q(['ND7R
M45:F':;A*BJ)1'4O*##"BASG7RI] /\HIS^<9ANI>)N4DEB2GI%7EWP^#QN,
MF9F0/#]QDBIGOZRUM%Q%V%+:XRDP3,KDVZZP77$=39 F -"I+9?VMC>5$%/*
M.L\>TSD^ZWDAL-1OLT=C2M9>:?+NJ+MD/",W(.9M])6%I0$[DUB9I5^U,H>E
M4VZ?6BQ=.#%T6/7NY:[SD@#Z6:O#M\T!:(,^1^J]ESK/MV87Z:ON-&H'#:WS
MTI]_DC(DW3XT$YOVI(:8N"L2EV'S?[%R5D%M.'&<#Z6E>'%W=_<"Q25X\ 0I
MDJ)!0M%"B[L&$J1H(4B1XNY2W-W=I7A;:,O][^'F;N8>[N5>]FE_LS.[GYG?
MY[NSLPS'5"9!R.9UGY?0W+XJ>L-&6"(IXPN6&CHA_?N%W%#F@6>0EP1IFHOG
MQ/#"[1>$(PLIXTZ"S#S0/U)]B1*M<98+V]"L^>^+[ 8<U70$\N$2#4PR*\L>
MSUNCB+PE&MCV.0%[;[?F?B=G-*M;:,;?[#;KF\S$]AKIUS?'IW'S7%1RF_2[
M2:[4EWOGU>JM.)/"F_ZQZNP"U0] J=3F*W/23K<[ ,?>[\]E_L)76G3"!/[Q
MUL1CO.)CC_^=2AR<15?+-N+:]L'X-(8A4V;3+;M^:.<W5X2GHK9]\=9=SV(&
MCK>;.#IXY["3K#&.F7D&_LRP^/FJ=V7S%5HK%L^$P^B/:A \7FV7N4ED1;]2
MBTO[W1 N'B=*9N^ 9(ENZ RY(A2_*-#0O,P5R6:&=/00)Z]MO-:E#HV$SC.:
M)T0E0YSL>TD*LKF5I-#H07-(?&WCX^B;K9O+G+YKI,S4+!&:'SEH.)3CZH$R
M:5RH=_+797VA(U%Q/"=VIL I._:/=QNOD#M!SFT(*L ^%3&8EA9%@F3F'1'+
M03003$@>9YML)5U*.+F6.)BZMCN@,LL=7H71ZZ\*?P8.*>UU]4\42X2R;PSI
MA,"26$Z+:M>8EP%J0VD@:@4>]ESO7/;=3E%O6>';\M1_::-!*7L*B:OKF1PV
MN'Y""PERG\UD^T^X<88G"-I0B73;M[2#-MHV>'BOFE8L(($[K/M<!X(R+06<
MK1Z$NL(IN$,7%P./L.%1HP:I-]$'')')'#H/D>-A,2JQ>2[=YL^$],F/ML!@
M_6VJV[#OM2,43:M]5@Z?W.;#+@==&^XIH,QQKAJ)8E3:Y3*]+&A< 2:2")FJ
M;9.'V)]+A^3C5<?=AAP^452&B,T@7H&RF.ZR?2XG\]Y0]0\,@%<\]WIZJ^]A
M(ZV!J-"ZDSAC#?^2GK0W>N-&G+P59LGX'_:B_8UJ@?'.3L3AJK*_]J12$7A7
M%U+QA$?+ICVGQP[RTH\NF,/<"=P8)0*@M9#X*AT79I;$L3FY9+-4ZM2^8*J9
MT'@&FZN78Z,]?'.1I^R1&I4/H8BW"2)7_%RBVXL7O,[SUTA_LU&64P-$BJ"Z
MI:N0B<UAD7EZ]6N[8+.IBTQ!EIA39O: (8^"O BXFH':3E4SF[V^FD:O2(5)
M!.P)@)2(>P*466E^VKD0NYM1_G?[7S@^G*#Z%S5 ;O0$N)AO^K/N^R_%H9QX
M4=*D_O_Q&I9W4N;G;X-&RH?,^4\KC0$/?$D/Y4V?BFN[+F/W:?[]9?]4./8$
MT/VF+/-[WOO]_RHU4/&<CY043V3.LF"B2"T3)G7?Z$MT(:5@>IEB8:XO<ET:
M0:\UAB47'A)B\:< AT3?=#,AEG;5*A54]QH/.B_^7M_+Y&S9 ^,:)XYQ.X#]
MY)][N5D_19Z\0!BD#H@EB.!=/T31 M@WN;Q)0['I2XP>[P;/O_&?6);(,JT\
MHKZ<MIK:"4(+]'I-?=@FTLK ?/-7RC06DSHTEFH^N[7+KYHS+9AHSJB31%I$
M+0,E7@8HW@;!SW])[^K2;H_&IW]+CD#6?S$:=>7-F9-D:MWS"442Z)M%W[3@
MGPB4TO-SM@.)>"/#!@+?^+2I0MM<PSS :6/^<.:>N2DE2ZOG(>R#R?%>0D38
M(Q/=W&H5Q:/G5+L'U2)I=$4F)VF6.[WC'N0Q11+B_DR(FR_U" T7FYX98(8+
M-3_U$-G5V>QH+QFJ8,VSYS\!)N[[P^^QHU;U0S& 5K-.T;A7'[4[7O9=/]W(
MD$Z4_K+)8Z::CI^57=IL>%#]?;M:?14N6\'=Y_"T ?MJ%(ID)_:_O-*ZD0:U
M8V=V^.;3PM\F&D'YV]M,,"!\M.+Z^UMQG54_XY8*Q F1.V4Q.<A01G86+O1/
M_#<^]*Q^,<$*;+@S&8CM>[K?DCONWF&9/X@+ZB.Z$&45H:APMN:.2DX =L]5
M2DM1BW,_6K8:9B_K,PW[:N@)_YK.]0(&<$*B0?5)&-FO<&,.6Z)Z.@1?8Q;O
MO,]!B7#Z=([)CL$<XF;25N;*U<G6@W3 3O?@<9%A;VKMH>;9@@7N15LKXL%@
M1\DQYHSK@ ^P\MA?7];A.S9!WM.]XU6:/MOO6P2V%MF1XQQKG1:)D&#1,LX\
MQE,EPH($I2R+4?XL"RW%QL:P +#Y- 6;V(!7QH[=#MB[H8PS,R((TM%;$#:U
MU"ROY]F9:DV!5899PTL^9+#9#_O8,O!10:%/O;:$0?A (0%//XP*E_Z_+&1%
M%+(\^D/JYNMWD]T<3W<-I#PP+YW]&%3$SSQ,DNOY,]N$9$7KFQ2ZN9V-G:FT
M-+P(H_I9*\7R.U[F1K 3"JPY-<L-:YS*F5.B54LK84L-QM+D_%X6]<M-"OWW
MV=[+L^+V/X:GIUUKDG%OXJ5\[]K2GP!.5:2/A>9O0M<_7;!\.OP*:?3Y<A4K
M\:V2#7KRX2N8TXOP*%2UJ[0H\ZTB4-NQ'X_O/#ZC]6^][TJ&EEY=%=L]IIY8
M% 1D>K*;_$G0[0_C)G1-*I;/'+5@?YD5>B!31DH+7,B=JO^*F= 'FLNWK4#K
M%@L_SP^5Y&Y!]M\OL*SD^<=HO?N%:Y<O20\$&H]HDNB783!SYB8KX>4G6%7\
M= Z\VS&FA(H/ N4[EL465#!^]TP;[<[G=IC9L8?]@$(3/KW"XABU#S7:J54L
M6\!.\HO@&F0CPZT.^#*V/?KG'ZVLE_S.W%*5?$:LR(%VJC?H/\;MU;[<X+DV
M(CEQQFI!2U0:MRY>E%KVD.;MYFER^KU&:XQ(5E'L%Y*3)M)N:$4HYZ?2=4N]
M!$/IB:G.,8IW!]2('0P$"=^(1KW_CZM%U>V;!-<FA+F[+7B&K8J>_8_4348J
MD3D^O_-=8;5ZULI').GEAU\&/GP.9KMBC7TURYZH)P!5<P1=(VK%:$6,A5CI
M?7[XL2*WKA!"@7RH:X".)BI7.5O>9(?>4T#PJ!S4P,_#[#Q7AJ$.JH7GXTQH
MC.O)I.8$XFZR)GWMF?+QX)D3MFI0,"GV6R?W_MJ#VDM/NQ(BUP')CP4\4]PY
MB.,>5EW<48)$4$>QRWF6OJW2BO6#)$CQ/_O])EHY:9U!I^/8Y+1AWBNO#]>3
M.^UF>J=R =,3$8R4.1"32$Y@(MLP=Y=]T\\CL=380=#G.@++],@O%K4V(S+J
M<_3>*^AMBHT!DAYSG0QO6'?<],5*R$61#KJ,DT+77[0J%O?>4%C)KD%/)NJH
MROP-,I/SS4^'EF8%"8WMYF+?R]=E1Y)U :V@9MJN+<1TYW51/Q(\;CLEFRQH
MPQ@6A11!A2.9-"?T?OTVP$0S>PD:D!NVTC!J)59ZF.LUN\^L@,_^NMGVL*<Q
M^W+-HP9A'?T1F/95*V;[(&Y#&+DJ*R*?<I198:_$$GG@@.LW+ <*+SY^]-:N
M;!$88]T[O1#1=1%K/=-,Z0D]6T(Y3[1D-332HJ(LL&7"+2>,9*5<S!+>MDA-
M[T,A,#J]0:*+6<L. 3M9<;(Q?\G/";W*(4TKB)/9%SQN8.4XG0[%;K00DFB(
MAPE*\TZG[G(O6GC:78O0<H-XJCS0+*&H$EV_HHU 5K\O&J'!)B0+/0 <E=54
M_AY0$V [4^.6./#!".$0&YVU4-GD7P,F:>'C)^/4%6K;PBX10E\24RREM6U"
M,ERPKY=AW'OC(UNEFHU? ^<AR9W.3-1Z&1H>94 !#FYK9EX>,+)"@KP,*#V2
MZ-8O]441Q:I&,I>#FT9CK\'53:.U=$"VA5%43@6P QAIY<(\;M0W3\$;!16"
MWG;W/:/)? _6M/QD'D,I3HM4PS?)).)9"0=S#J?2V:0F):M#0 L0'8@>M'I:
MG 3=8>"L6?L5\OC-):HO =U$VS*1]:>HOB@B<JL IN'$]5TD0K87CH4Q8-@F
MO^C0W-?0A)?\=QGJ9"1U]=F^@JNH"HAH7##._AGF1N<MSK7I^Y/TQY5.0LT1
M:CR$FG!W)D3=XE=<>\47+#"69T,:*86.E (SJF9NEYJW_XV7+C=A9R2\?3>[
MR4+ @W&\:EMD[3:!CW\)M*<"FD'',P\,@LF*>ZLK.?6'GN.'F,SLJ" V.%03
M^!MK=PR84=8XS)P\2I:X&&"XB)"'9[:QQ91ER1JO1!_I5V^K_.76(5X,Q+4F
M25TQ+ZR'1<',= ]?[J$Q_W.#N:Y0#?,*,535J&A#"4)]+/D\!C\U[.$-Y4?"
MYMYE&++?]'&.]@LSBZ@NOREMT3&Z"2U)7;QBM,2?@!V@6QOZ0)*63I9L]+X<
M4>-I&6O?"#,9#<P )I>@TJ*K=]5P8<C6!CYU1 6WAHMN_C);>*C"F@6MH$0]
MU+;E;6W:P@Z7\RU;Q3:KZ"#LCNZ83R7X]P^AN8@HBUZ%9[OCB<53]GMC*E(C
M)@RIJ0 V>8BU6%.OS[X\04N$1/KA6 (.4L8(A3@K2>YS]M0 +J!ZUUY N<"A
M<!"2#G,)&$2T,XPZ GV.HS\F9'_Q HHO46)"1%945(IF8^/6?+[+@QFP>)?W
M1HQALJAWPS9D[>JM[H>D9)P 4G>S:+M5M&Z,[UC&HC=>A]2D\!:=M_RD0VH?
MMB=+WM'>LAC&NZL7B=8$ZP?F#M+TR_HM=(LL_/.#IH[Q8T7PA1L^*8_5(V"#
M6#P?%X$FAIIXU=;X!B8E]K G_M"!H]9VO8RT;O-( SNA5 I2XHM0 Y2--"Q9
MQ@#B$)DL?GP2SU"!BOP*-D8NGQ);"*][SI_27(<W(?64HHK,$])-($JT(T58
MK-)*)+E/ %S/>*> ._\4#MG!BT7)_?X5OI*2$;CV6QPF]2"WL@5?MK_@U!;.
M2E>W58QBR\0Y*IWJ?S]$UOR.H.<U=Y5H9D)7P(^B<^/.KLXVB3-)N01-QCA%
M?)\&>K;A[$,"?2\231!%.YM9-(]*1RN&6:]H$OV_!FT'Z<D >I!00TECMM3U
MB^(^_P]Q L"X?E[^7ECYW5;G3 CF=9&@LB.U'-C["6 E,2E'>^6F?9J-=98\
M<U?&#"=K@W7P\[U-&=;G 25BW$YM-A:>^+H<8C6L&5:#GP#JYV ^UN]M;+?B
MK\V=P?V&M6PB4C]RSP(Y!I^K$_B'O+"929NP]DR)@KEQXS>FW8E^PFSWA;_7
M:-ZL%-W4LBGJD#CV3SMRX@$AECP?[>((T%K@T&?U$=PJ^*4'J#<,'G,J%%\@
MG&J.I15-#'18^B8*+U0)QH# :*"BB8@"YFO<U/>+CI,X0^%KB^O>)3[D& ^_
MGH'=$Q=O95U Z;ZUZUF:46@'[TP**@Y"F^D#.I7<J>IYUO;?MIH,QM\]931D
M#TDNU2D5<_HD/HR?R WX.A%"SK9-:;.;JX&F+R+02D8J5!6Y@3;1E5) FA[U
M^4:"RL+H"I#=!N?J^<4 D;EVV9Y*9-^,(HF%)EWZ_(0'?$/:W[$W>Z+J.OIL
MMDU=RGKD6+)A/0_DZH)-M-4&M^</^Z*\DCQ.R?!KJI3-^>[%>:40'8*Z6GY6
M]+FI<@*=:3S!<<JPK$*1K+4?:]R;ES6T';3]CKW:X1!IU.N(X4SU[-7:>JFJ
M83SA2;N1U'$3"RUUE&>9?&6[LOU.)FY3-&&[N9.AV-J7/@@FJEZTC#6/E?"?
M07@.9K.)./[6LLR[/SO%S4D\G%8@V)Q4H8Y12DW:!(M[5KL_',\F!>6OJ'@<
MK,8TCR^T6UH"@9R\]0&/7*]J /UP%GD3QOOEX'D26S>.^\S+,WFH'5I<4)@C
MY$*JJ!"45@D(/P$EBNAX$V\/1")9V!RG]=$N(-;Z41S0)1::/3_9.!CKBV@P
MEL<+HYR$E9!>\_%(@:XNIPZD'[)DW9#Z)?>[67)-->:2Z@^ 8C@%R;:\^ 55
M6FND99]9Z>!*323$29A:G!\OKP3\YB6=_6?J+O /C[=*>2ZB5M XY )?^O:U
MT4\69<^MZVP#M8(1PU$74/1\J([G[*^J;C=K->TF#22+6 ]]0PL)Z5@3:P;M
M@5B)_:G"?.(#!'@IFA!AP>O \FLP*-*GS;_<JLK[Y\;;]/S*;)W->RZ':/*/
MCM_:J(6+QW &([T8[ @KXRN1_]J<@5UZU@)1$K".*X[G+?KV:!Z@O7+RF<,,
M,IZ?><$DZIF1A#YN;^0@2YOD3@UW[5@Q%6*:6;5D:G8<D3,#I,/59+H@%)'E
MR729F"7$F[K'H.D#'YV'?".HME0IU?RL-7U[LB0BHJS5\9PN'@DOEYJ_4'TF
MI4CXBCK+QN< '+25465K//^]_"1=K^>05J<FD;5U\XO%%]7Z%A\8J4"Z$V(U
MVC:F2F+$OA>BX0]#,VMH'<-TV9E:@LDMC 2XMX]^,GZQ@3!&/\ZFO@ F$>+A
M\U]>)2(K=32!:2M&FKC\R' 2)9'W"QUM_H_+LP3U_ 9MI/&IZ:?)50,[SNOB
M@W(!:T6]:V'Q?NQI.>6LQEV[S(-2=!^LB1346U#/782/63B9*/XD4FQ]ZR5?
MZ'-O-O<K@IPC2'['X6\*>N(QM^C5'IU=L4C3=[@WGN:9-+QP6:C@!F(:GT9+
M@<DGC" )Z0W:C@T3R?P+A[\C7,5VY!L.9TYN&XM8VU,29-3?8X(F6LX_[F(-
MMO08[!P_[O M#VK2V6DNIJ3V):4 N.Z@'K=XT)$U6Z.E.">NB(H1F1E4^K"C
M!YBKYD1P,_0CZ_:C]NC8<J.IG9*6BS]QT01<*>R;1/<^>M6+OS2B%5&I6^2$
MRY0:[ "16IGWSF'89)#K>:7!J^7L7SKDZ ASRP&J-)%AI1$)1;B'5*]IN6U*
MB=PE^%+6YWUV\W&1,.47N(SRD+:#?R^LXRB[F^!5>Z?C!41,V(OR?*GUT9W0
M&OWWZ3+'DS6Z.40XG&W3G3N2BEA%T2N+%;NG4S^1ZM5U&,:W<H+G\-]!XS(^
M5?$KL(A=IE78@:)7MK4P2WK<2L.-5JMXNOC/WUD-SC\<7B]".Z<3Y:6;&&=_
MQ:V;93*TQ=$4RVNX0I\7I*&,CVM,W @^:#9]R-.[^GEWJD]]>2B5.4$Q89%1
M1=',&4D\$''T25W LRE2.>E^ZI*7)BXH+V7D@N$283K;LD]G9?MYI,*FZ1%L
MY_/E -4F*6B7$+CQKO-R%5GRVYC^&K-^-'9E$=-0L#ZARR^Z18G^=&=DEH0H
M^6"@<N"9O6N%P(E56X ]*!G-OA=&*4C1F%:,QTQXR/?N,$R*,EJJX-5:A==6
M-WR5N^BE/? SA1(CUT'CF7=?#+,F5S=SP"K8.$'>V[J?3MVUMJPYG6O&OMB.
MUT!9>S (*5FN-'5B'93O[?#^& 34_6?,>7SA<(6"@(V*'+V#,C5*D0PG6R<I
M=*ZKO D1E"\I(N)9&M"XHZJC+NR"*=F+G/;*5^U=PGOI)S3N.3L:E+S0Z]UG
M/P2;+ IET[325QB1DQ[U*S-5T]P$G0>T(-)T(B2!C&<PS\HT"]NHJ[D0U=DT
MO6M9))YKS:@&>$:=&\E=#U54QS:@/2P3;P!+LW\O;V=&?D;#_[I7#ME#-4S/
MZ0SV\/\PC^ 7ZY)RJ&HYS71SLF0)'1"D1UF9<4=JN/2>:H"==T;37]P"PWA4
MI/F=]X=C;U(VW<%D*[>R(\D[XHUH9K"1.#-0<XC-:'"WCATMRHRR%VEW<;J5
M. 7.Y!>=P+J+RH$(,A%",@S:$&,#N8IVC8)5FMGDK!_POAA([KL8&EF*RK"0
MX$17PQ0B&3OGY^8%%\0U?8=]**9Y3=R@8L,0R#>V']C2#[9O7JP9>M<G<L(/
MG?W+D@FVG9$2.WL_(1 L4,N(<4=_%3 U!US$S>[@Z[E1)6<!?1<AM9Q"XN*2
MQ*:@ 8TNC8U =P\1A'"S\T6\[U,(OU6/T&6^3[PZ6N_@+R$F;9T6)WZ^=C/+
M,P/!V<JEG][%[C[Z&D.H.T<^QF%0M+<LY\N(6U&/;N)IQ$Y\OZ&Y0=9<UWO5
MW*"G)+%L2/ZB$;1[X&RIA:#E@;R3>BOY5>32D!W8HSC=,NL7-V<JJ&<6RDBR
ME,C&WXMJ$U;4TL(!_A[H;9?-B5.PY^VH'O=YTU@76W.8A9EF^6<W&*61*)45
M1!_>7&,%X06;O89&>W&#4I VA<_)BJ_R,#"K3TQ6/A2_>69A],C7&1?U*EQV
MUJV(QW)07RL:3\.$'T@3S"IE0'VDL='2] ;;QR3;LT&UE5RB@5E%F/1Y@2HG
M=1:AB,302X9GC>?I*[1]O%CM\TVPJ+)[]GN:95G1!K\/NJ%CK>6@4]<T<1[9
MAO&:TI*L61@_CJ\5N!*TK)Q+O.3-_6FDJ.[R$UGQSWX*B/%V7."JF"DY/$"N
M=Y<XQF!&WVA45RUN(HBMDC.=N3A9@^V6NB8OJ(YGW:5Y/'BO]&9#(WJUYHO\
MKD!R!;^C]SD!$<F'\4KGZS+7?],;<NKG1SI2>[JG<&<XSO(!AV%1(RF&T&O6
M4=*4M:\YA!SSPF/%]'M;2T&^G+C9[1%M/*O/1N08%29QUJRWG0+!405XKMPQ
MX:>XGE?2NI5#E1$22_%F_">H97:0?@5[4*^24B5=AZKS]4""3B=T*-&^H!O5
M)J0$NHX&C?9TMPMUA*FXY=X?4O_ZN]SOF+TN2EYUYMFR3,T-(17^([MA<_"8
M&C2Z\.XXY;;<OWZORS_]SCS[;IEUW;Y]D[&*=[P4?OK>M_K&S?3EQ_C96W<1
M^XB_C(7(PNH3CWL=.M3[:^D ?WX[NGI;.).R>_U1##%]G:G+U"C..;CAY%Q*
MX_#D0+K\<[GLP.&,R?NX;]*_T-\MX1A$:9:IQ/HD-L1OC;EEO=M=S/)C,BS"
M,Y_C?KZS-@-E].U+&+ 3B@VV9A@(D R]^$GU*(GB9?^1)"C0[[855<43VZ([
MVJZ%VH88Q/&%?U5PMCL!@7:=8#R:&DJ>9<Q,-*?(WLT^DUOYTH'FD+W:2"91
M>AF3'\)CZ"H[@G $DMN>#DFWA=!QHOU1OQB35L/J](AG#6L[(]_IC!'9MK_M
MW=W6Q&0KP<$"T7JFJFJO@&[X.P[[!R>4?DW%%ZL+%F+K3+Z\I"3QQ$#*#WJ&
MN0?,B@T(MHF\U\0)9&4?FNB+? A]7YH0L&JUY]3S]?$GR0K,)GJ1"L$N*2/E
M)Q')*C_S>3Y!D/GGZO,]S!)@9/>A^/+NI),#Z3VNYI?3KX0KBY<-V#ZQN"RO
M@=2\6%1ZU/MOI8;XV2K#_RC[!=UU('.(2:D:N/T<FW"MTRH#G;K75/NXWAU_
M;.YM;O%$%&N-:>4(@#:TP"-[TB)LWEQDG!@6@^3)& !WJ^8/T96F$=*$RQ0J
M*BKVTJ.>&=/+0-S;\'H4HP?AU40.-[VNER'6Y#G&%+@6R>N+PO0:"2/9\W)_
MQA&Y*E[+,)8675,)):5E*%,M)8A<YR<L$_%Y2Q?$-;3%-/Q2#>>?0Y0KJ536
M#YIQC*&QD;3TN57$PJEG=V(?@K)2NXZY&TBCKXM"(HD(4Y!X<97#<;*4523Z
MI_&U8%PMC(96_ZJ"HF/@&HP3UXQGY#LI0L1'VN^?[=6NS8PBAQJK4YY%^WPD
MT\F?19JFG&!29M<:+H\,?W?G!11N_5+X,^?>UZOV!UMLF9#.^-]<AY^9C^"[
M(W66; .'\(.5D@[&>A7/_B,DEM+G0[4/!#(Y@N*5Z6*-6[W&X;PV'5'4S4K0
M"S,C_QJ(;]HOUY-W6HJ!39_GZND* BS43%);X04+E6X$V\L=Q<X[*P?-S?A#
MX>,XV"&*VW$-ZLF_;1EL&<=R%PI<LE83"H@O6%E>R=ZV??44B*-2&*-1R/F&
M)YC8W+JS7[4ZX*MF[4Q;1U:VN-KGBLKRCC1*+L9'IN,6,151] *58LR8,">M
M4OI\N*(S!89QOJ,>6,._-T$6#AH*!D)!A]PR'C,AS"I[B<?4K (_G :))5!I
M7:L5#YNN9J7SNU]V2HY-$H0&OLK["N3A'SD';D]4.Z?0$,WT"M=4I?/\[LR7
M6 .(X,+Y.=R\@J5RAP<D7&@II82_44K8:X;)X*^&\0]JP8 'IXAHUQ$G%UA4
MRAU?,QD%"1J MNOURYWTK%T3T/U/KK'=Q,8R9NP&P.N\$!FQVC(\J!.>9X/O
M @)7$Y/I7;7R?:2/=0<_Q12=/!]I#N)%];A#8BNK0#1X&,9*ML#*#]78[]D8
MH5=C_<YT5B9U&R_[! AI\)GY]+(K@J.P<W?-,9T&EFYR\H:J.0:\JD2&+@06
M/"\'*=(8*>EZ:)!/U W(4C6!E0/E00U2X076JN!4-%2!W5P[5 UG0F'H1/(;
MK.%BN!R&_5\#E:Y])\O-:6O]ZTN"7S[]J3F9,N5>OW5Y0Z9M^#4A8P\+EZ"Z
MU,]<42A?"BXT;_+N]@G09?%OY.C\4>'VW-,Q5Z)J?$;6XS,-N!ZTW TG CVO
M?A$Q.^A![;!GQ[(5C<A 1L='Y&:EQR<)2)!@.1L5L.+JFV(5YR;FAGV^7_$S
M>E=014'%WO,L);"!B7+%PG4T46TP"O>F$5N)Y> J0Y2S,.KMO=+/60*R[Y&@
M^CCW/V7UUG^!UUI/ $K/DBH$X\^23T\ >8_!6WFNKR5/ )_*KH/3KMLX.;/$
MEM:&__]___Q7&F/G3DC<RM=Z]]4B_UF89G0ML?]'7$>-X]_D><%71&PKVY!O
MP\5\)(.C3N]Z+<JA[XP<;'HHY#@8T X2Y.<!_[BDU8XI3S>TDS6HXQ>KE2='
M8B+P%1F:>S01<<K"Q[?_<E38#\E#K>F[>*6\>(%Y;O+_OI;0:&7-?%9JX;9-
MVY%DXGFGMJP;]E8C(/I>(H].@15/\51>4ZP6BWE_2&:DUTVJF$89VUM$K^PG
M%6W9SBAFH*2\+)8[OA7D(Z:H,8L0#JRA]38R'LHNPA;:^!O#'EFTW;^/T\V1
M-0@WWA"MM0C>[] 9@4LYG:NZ8,/0-XI\]>_+,PQK-49>^5V\Y%@^.!L'G #R
M/063&U56^<X44;>5QJ7BO=6G/8UE ,@+B:)A1#P)FDTD-P1J[H0SEB6T@QJ-
M_!54OFN:3M^NWD!KV>&E']6KF5N$GL<>=T[^3E%E)8)9TBE?\:OJI_BJ15,!
MD446QXBV-W=M/NL+,D+XY6BFQH+NZ[#6#[TM\ME>3P 9>9._9-*D9T\ _,>?
M_?^-K.M!>E$#1_(T3X SA_\(>/@1W_X$N'ET_]TZN'/*&)L7GZ?U_9Q1PT>P
MX):UP7'BM6[G]#?UQ-<2;]+-'XPGB_]%G^E>MPDZGC\@A^?CK^NO/<L7QR>O
M78Q"#M=C UYZZ%'VC?\2#JC/++91<\-1E[3MUQ(1K-Z+Z5<-_NNDRH=5?6+;
MW;1E(=M0O_W5II[43C+<KN]S[V5*O]"F.G$3,9P1QH]NTW."8(.@&,(VT.#K
MM$J7I.25$)QA[CB&^[/HGYFX#>TKE;A!_!)HKJ^^[ *E%#@V[+(39IA R]OO
MN*W4HI9>+%8_OFT+@.@L]@*Y9[HS()?=LUB9V,;Q-F',*/1X\C<J$+W"D*=;
M&X#DL^%7&)\L:N9FCG)4R^3#7)N6X7*S./5!EO8]**WVTK,XFQ<(.AW&>-$;
M%F7<2KB;7]LX;O'H19I.[VERXV(>NVW@61M1B<&&FH+G!Q>LT7+!P+KQ!VNY
MJY7 B7&/)\!'8^S$;#A[OBV/*]B,.0V D<'?!U4ODG^];![GP-)$8VBFK.&+
M5>96&<GOUQ7U>=O_JD"]L^:#\N4L-XC%28G&P/^@A0<;R44.F+("SGC4K%\)
M54BJ6MFV,:_"SP>:1IE+[KBU,!H7QYY7#\\ ;Q\XW^?\P9(,\IKYH)]D!*>,
M^GR]_4-@5&+7R_@)$&% '3VG5H9\F9&QNJ U3"WLYRG01!ER^=H?!MV?W_*G
MH^V-]P1=<*?T$[L&)0BGD?-S63N?O[C,3X#O_'-!X#99^8<QR\LTA][N(X7Q
M3 :K+ OTGJ%P4X?WL89X^GT[Y!U\[1\XO2#%>0?OJT;185ZHG2067O@[<A;>
ME*NT[0IML25V*5X7E?[4.U++T?%"/(A6A W^H;0387+X]KRQIQRRDZ%-SMGV
M:'P9]=FF1T0(&PH]F-G64&),SF[411*=--&&YX2?BO>8FO&/PUFVFAN:0_L&
M@)[,#6FA1F#'[;?VOE@;02Z2G_;MYAY@J!E*\M_$(JYTYB+::I^_%=I&RAUX
M[O0]UXSAE=6'M63_:\'O&Y9*VM>H.KSU)AQ_=0RIP'-)3<5H04 2RY+H&JAY
MI00JN!<0H#R6G9?7$>[-\LQ*2'[B1^!N?8DR]G/^G9Q;ML@%1?D X[-23DV?
M&/-[^_%(&:V(MIFBZ(!C4CXD'M7?B%TK^P(S#<$:5DBQ!--IW[*G:KU]6"G$
M28UUK??Z-"B)PD/6BBX.2UG6$.L6.J&B*DI/@#:8:5RS=K3*O(:''\TH K&,
M7O_#"AWL=[?,39Y%.5%L]4/EZ;RUF&>0:-F"C'$;=9-\>&7(2N>7-M5*$/C=
M:&/N]L=[VX N&UMLX [K$(O4M-5'#"35'7IEJ;9;)FT<4?%<3D(S8D\MN0SK
MTNX4@S/$5GVG_!,^9^S;US2!Y..6ZP2-+.I@8G&EUY4Q)Z[-A00 4O:7IZL7
M=(!"6;6;1DW3,(?DJ$(-[??=H/1)?QXC^QO].BHN-AQ<-BSD;_2/%NYJ)(,)
MI6O9O.L,G<U>,)9.=[_.:X;O78E(!K%,(37Q;944 3@38H5^4+9X+("'_YID
MA>$]!F5V]2:Q5S1_$V]"1YEFVIIT;4&QH>4"FN7UA$CZ5%IE_Y$?)UC!LYND
MXD6I6X"4N\^0)Y2_"EBD#KWNRP0M&U:BH0TDX3^3C8MRN*5IB][3?#PZ.+NH
M+ XT>#4@KVH^]O.M74>MR==U1VNN>A)TRH5!7 OI@3B*-/S5V3](,[BV-N.2
MDQ!\B0[)96O]2_-W02ZG<^PV<9F;"V+NF(]5W4*<6A9P+5\G-[LN3_3-5Y*?
MJ VBOYY;Y06#4_, +ZN_F";/E@#?;_V426FN($C/\:I>'#<W<8G.#DFF^<6J
MDB>B V-AM(3DTNTW#RU$IM X<8]T/134-43PMM&?<W;=:H7T\6G5>9*/FP[5
MI-M[ZC2\<%*$'Y'FWCP?403\<G*ZZ@)/<USLDI[K#[0<IGHJ@/:*RE7X=IE[
MAJ2_^XZLWON9>OEX5?5]_7(ZV'<EFGR?SG$H3*)P/=]N B&(3]Q=YH[:66EI
MMMM@LV% ;MLMCQ@C]\YXJ6#@7WJ1A5=\,6,:[0-UV!YC16W<V&![+GZN/5:+
MC&[>ER9** ^Y5S1W@6W2CLZB"0H^6_;R5"!J$ +\@MUBP"8=GE,3S^9^;.+K
M?//\W$DEJU794SEYME;H)%[CR@&$616KUSR*27%OD9$@,..8JX75_" T1MQ9
M\!TAFDE=@H(0-</G<IG:^^N'6II<G?63C25T*49EHR<U-< FCSBR R(TNI:Z
M9-5J7\0R)9TB%]T_>AF0"[M>U]!GHP>EOTE,SRCK,FQ9U87SMJ9.N4F,Y/$F
MU<V5FV#ZC0\K8%>;%AS@)=B&,+)PZ0&_)]IMU7J*3NOE2IT&N4H8$!M4I:T(
MW=1L5SK3MYZFJ:Q>&&XU,9.D8+TOC4Y;P(0;4O^DUH[L-=G"]F.2BI>J)BF(
M*"]#$NSRL)GSN-:6"2\':7]CUZ'\K!6!IL<9^0\Z1-I>PHP, 9[7C9N+H2%U
M38_GZ^1[)7(1,BN6HJ\)QF'*'"(N%R2I.UYP5H'&FM3PA+-CITUQ%_/XLOJ"
MTURR:M'^16/(WGKA\A1+&V>C%M#"M0PM%CQ!ET+E;.:1[)^)\1)'GDC05WQY
M&T>[%QX0-^105VV$!-17JHZATS^436%<>.NOF2JM3ZR2N]B?MG)E:^V)Q7LO
MH];E/;)^-#'B(3M/S37T"X7Y\+\+1UY6<(W2?Y(>J<TND-*EJ%R8H$[RJ-X4
MY&T?B+[+4>6'9"OA_<1GYAWE$8& O$J+G*#G@];\A@(7 RVKL./@FZ-<#(MZ
M;L72%@-=.@PD9KR#=Z&M<-;O2B\4W/EW_4F2)V.R IXJ]2M,(7%H[40-MTYS
MU_-LN['O<;C9T/_6(]O/D^ZMRV[,WL4!?2*H(YSL:Q+;*-2$WV\K)^NG1<%R
MMI[EL0"'7TK_$!O4HU%M$U!YK!"'K$$E]B)8@+&Q'/:DD8/L3.\O(3F^ XY?
M?$(G4POW[GN;3=LA6<]LFK^?E$5"4@3K6S1^_4'L%Q@?H,U\"6AJA42XV9K2
MJ96I^?G;:Z.:O,)8FP:F?[WUU!97_\A31#L%?,WK3+SY"5'D<YV@4DLSZ?S2
M,.;BL/5M832=<<SJY-0D>F&# ,^?Y[""$N*>0;X<6A^\;7V@._SZ5_Q&Z&'[
M_?I  RF=]*;1GF(Q*7XQ">9.VHBMZ?KEM;9VA3$IQEMM]::][3SO'OFRL]='
M[9%_+71%MR6D($>SC-%?K+4W%LMKV7&$\=U&2ZQB$'43ASELUT-[V<Z3OI]>
M;:QU^'2?5YZZO]O#F.0QE96;F,@>=+@)K+H7?[ K7EYJ<I"$WOX%RP];_Z>Z
MKL7T\F*L^</&U&754_WJP]FU*:Q$ZW/I.<HU8_7)BQ2O"9GO.@M7/'P&>5[A
M>-Q8&,(#-GGN&,96A;(SV+5Q/!LJFW9KJ8 6J=0R<VS<W?[AX8T%^:% ^TV!
MV-I^-T,ANF;N8>Q$\T2C"#0/;!$O')VNFPS&8=45J=F@Q13&&-X9>RZR.$BH
M(U(;3A=1G^!-=4(#.2N8ET@W=;+115.;@-+)1GFLA".@Q3=Y6-)1GPED3Q45
M;4KH7/G>FRG%*D4>0NU8O6I.G+<;7&!X<C/U[*J<)H9E3,=RT\T3,J^@BJ]W
M<PQE$N6?Z=)&M5VOJ<R%A!&MC3N1N^*$9,!NDX>%%38LA1<IVM$Z[5(X[CB]
M,X\C$Q ]FYXUH4FR+@G9N#\N-"PBLS$6U4CT/]NYT)5G^P. ?$Z#WO0:^NF%
M4O>?$<N0Q%.313?5GQ01[*%%J'HV+FX5H2N9NI#J(]_+RE=Z/BA+"=B:3'83
MGF^#(TM("C^\)C['CA\=+I,'*QH8-CIA:8Y*RWNV;C'+"Y6^*@@57=MP:RZ\
M_/ R"D:XMK0S"EO^OF%3@"NJPSP?A2(RP14@(8^\*5,04\,Z(;=^MY-):3X4
MN8^P(*MLHK"7;2(+1\V6LH61%VP>$19TA92],;IQ,[49.R,J^A73==KUPNQO
M/B:KLZO>&Z$%W#2'Q:SI<^-4(KU?'4U!7*J3#;M!_8])7@2M>J_[ V77(_E3
M#MRU+>73PU9RWDD!M5_ =[_5R15K/2#O]JE!YF^,J@Z#&^K7YKT"=E91/YE]
M<&3#I2[0.,J0LH,F%*3[H;HR]J_PQI5<T(\)ZB #3-+7I/WT?SUX0 [$[@GB
M)LZUJ_@/)#$].I\IQ+>O+7LCE:6HIYZ[C%I9W&48.MEL!C+V)7C*+@MM=JK7
M?!$S9!<<P3%T*\]>#4R+&(E]%NWQC=E92O/B5Y+DX]>SJ^7D]9911,XG!,2^
MC$=AOS)P@*BO/W%+5RQA:+-[/ '.SW4ILTG3PC&;LV1"EF"-CV3ET3O^3AD'
M-OZ3.?'Z":#^\<WXPX?6O;F&[*)*(/5@D8:47,#?+]^>&=1@,#U$Y7W3L7-=
MJY!_UF230YM@D2X;;2;M] [CD_5@:,\W=8!B O95A9E]+O$7BA%SCV*[I/?O
M!04:B;74J. ZG3P.>F$X[BPB[[03R$%T@"9Z$09EU?W0HF>1H:.Q+YR>L_U,
MG7-..TZ@40D./;:)RB7@U#=$%\]5K^@B;;2X9PA36XX"C'&> '@2/3<B/Z=X
M/?TW&%]]OO#Z^,[P"7"Y_XGGCQ7CWYR_FX\RCYP_61IW]7XJU!U?[]4DN<FG
M#P0^ :X.K+Q^U;R6#QP4_7$F77Z.-_RS9&N;@V!7D,V<19=%1K''L\IVTE&=
MD!B138T8JGE^12#2!%]A]&#*]N?N*R?RYN4KW 6M".V/QJ[^V5-#/.+XUZ%?
M85D:VLR%ERFP=R?7;P,!Q!$,)4?X?!J)?:<*,#V1671#J-&R)XZY*R*D%6?&
MAS8Q#/TN95CRLR[1)EV+6#CG+3OV0@HWT/-/QQ(0MO3]C=Z?I1-NMFR$IOQ_
M6> 2JSM8+FK?VEK3]N-$=O;?5=5/ ^NV&0QVN]>E$&LO*]"Y[_)=&2$K_!E=
M -G0]-7,]IQZAHS_JW2AWKCD)'$BS%[9>#6Q$W,LY[&(BG2B0MKN<QEKXP_5
MDH[UEW\'RD=)%S_$[D45B)"D\Z,)!LR@UYF"Y-R6!9HT66]#9]I*V#@0ZUY&
MOQ<UXH*;AYMD42G,ZZJBXOQ[-S0OTFQ8$>2U:\M.:WYCS7NAEP=6@[2_A:/J
MD@@MO]=&WXCD32>>?=O9I/!<C[=KD[[X2_4$^%P%X:2!>RY22TWFRA@OI&3O
M2Q]GTSU>Z:ME'3XOGH'O928RNK=.]I&<#6*7MI9+6(R(72?VQ@B2V,YVM,P]
MJ#A@QI=%+J:;;H!EB_;_]<4V>W;2ZI0.=JFW![&2PRE8P@MKTB(UG,9)BO;5
MLSST^'Z^\AV)'/4V7AHG7,T.66;0TA0\,77$%?"=1M%TTV I+!X3_LQ6]SX7
M:3:1>)Y#9?7*;=AL*/.[;21*N*XPUCN=K!<.+E KT@[E';I!IL6/_=;A[8NW
MW_.[27N_D-<S]AJ)D-L.A,(B;S-<$,V$$M-!#6Q\D12%<)@J< I+B_MUXO97
M_S53%O:!(YQJ8'*DM18W(J)"HOK]7UO#93( ]1&%VD9R>4FNAJ" S=E57RJU
MO]0E>NV4*[XE_%_>?.\__BL[QI(WA=07?Z6? 'ER@27_>_-,844.TKH!#B_E
M_QA)5[1,ONU<:8P(T(IICPZA"7FK+>8:3%XTGB+;6^0*V!L&$*HZ^G%>KHF^
M"A!BYSO;[V-T6!,*H6;Z5Q(MY1G'WA954N<7![>\QLFX?4<4W@+3MR5=S_F?
M(/!E.KOSPL)0E&O#W*K\56?[WRT71+;:B"66,<)E=]**M%\,$]R 1[DPI-X*
M0J6$=CZLBTZVM32(5C@E++-*?1YR<>+-PI(4-A17<RE UV8(SU/&8)^M8X^.
M[=D78![0\[=$F:"IOD. #%>])EC-B2?E'Q;][HVPOVF<(T!("2T7)^9L 16;
MLL#>@KO,WE?O[QB^I8NOV.#H],)WOCRZWOL 0X/!)E4VS/\)W'38VDE!<X7.
MY^PZ80@M>,:PG_\)P/9B0YJ=7L+2IB8IU,1#+3#ZE\]W!*Y-.S3M"8 +BVVN
M^#6?I[<1;S-,) 7+-.&]V]ID5?49NW(JAR-RO?L),#.&SS5 BG-!%%:WNO_
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M[(7Z$GI"$1O0[]<'Z1E8/K5[0IQ/;B[JRM9R.5=,'9 []LE8[4\G&T[#HC+
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M@9@09,GM3=*[Z-+*R'A)@RS&9L4!Q[>QLCAZ]%/)BEH2D[.EH1UA (LERU7
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MRE5^!0-9\C9[QGG<UR/GN&9Z;!])/TN"K_6!A/-9/I^ W5/O$'Q/D1JO;Y^
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MVB62;>F?;UOH#(RH8"Y^"#*;;96;I*2+*SSUW'#=?8N!0RF].JHMES.:4N_
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M\]<,'2&0=-'*VTVJ)WE7P:+%*,BMM_IAW$$FBY9QWR/IM$6?XCF!'=C-O<G
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M\=2+HWW&<"+3L2;UX")!5IBE;&IZAHM0:U]2@<P!I_28 =4^GMULU,3 \::
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M/ BAM&'I^&[K,]F'W^0]&0QU3)5QC'7E$B7]X1\X?/M8@U0^-K[9PDVUP;I
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M"4T1:%C3<MBF&U,F&^Z@OI\ 'ZO.(5E(W$%#")H0Z8@D,[DSQ:F-HW@@@W3
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MYT]F3FM,KM^CE[_]=?VYX,5EY>.;H#M?8\*.L7ICXD^DU>WMN[RG48X-)[\
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ME1D07V/NZJ,WZO(UY$?670Y4QK71'*?^4&BS\4_MB7GWP?A@"G/FRE[77P2
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M3KQ*FUG2BTIE:WZ_@9[QB\T,8MT]\%82C>8Q1P62CH^U:&9W8R&D1-Z51@]
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MFJ66+A/+=;\,\P )CNFX)!;Y%%L$_%5$@L^\[N'?PR.2O,!4FS,)E_F$1Y"
M3[VYS^UC9_3\X7'F;2<JWVQJI@=VTK8+M4RRR$%0EN^6MW/K2.*O)O2T8RU.
M'VF=&4CV.BWPK-"PE7X:'>YMU82_F\3?**<7PV\6DXGT;"+:&,',NI"/T'0
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M-YTUSX;=*?)]WS' 6YG^<#!V(Q/%-WTV>9'W%R7?)G,)G0L''9N\U'BL DF
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M7WR5XV<T%.^_0]\W]S49F4<YI*<*&!R2:F9S/'CE =ZH(XX_=QV%*3[Q7#!
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M9!P#++G:_%^;+(N2#,NXO(0_P3ZS2>;V9124'JUEV3BOF[ &WAU%+P:I+'G
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M1;#OMPT_1)$RV-:LZEQ*YAO\PTH<9E0(=O-N%K6H+FWI^FYU>-@"UAHT8>P
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M."4$+J9;RB_10>C1QH)%0+/[ I ]E_)@,B<7238T^90:JA9#&98=4\["7'\
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MQ\=8WW_2Z,@2AJX4Y5QES+;O0!(>-HNL&OSQF:[[_=>+/JX_"HF4-EP6363
M+Y\3O.>6AU7]?5V/\4XWMK\TGCYR;>F)A!5=:SZ[67O.E=T+5"0X]U/=<Q,/
M],KO=*0[Y\%'Y54>R0/8N4_O?'!-W_<&K=68L>@.KAK6/7 \\<8L&Y[UQ6Y9
M<KE[]@ESVPX/>Q@X%4V^!F>29;ETB*D2.(AS7VXA71:!B>0A3ED&X?QU9F[[
M,?I:7V3JAHR:6 U29DYT@<TVX" ,K685JH3J_1W5@C1\^R&8_6'&C,PD?0.V
MX;6RQG$(K!X1N5X2 ULZ>::^D%E2 %W/)IY-BI_\]>Z4Z?8.1ON/+TR'SS9O
M3S%1%O'0ZIC4%Q]))XXNPF&C.P-",(6+E$]-<IDUF?060YQ4)X+?--K'%>8_
M=@D'XD>YAL-I)C#HEG'CI9ZGHIJ#'MBCVNI(IT'FBYFAXW\9MQ_LZT3?]0J7
M7M7FNC/22->]*0#B_9E6[AIPP&!T\EI(&H XK__RE56+;* 7,Z>2,</757MW
M>7%^O5DA6.6G.QUHL+8\U3;E"'"TQZ^V_O#36C;<(O<JZ;UUGUU6@8.EV?$?
MTU]P_11,$SQII?F,,-C!N]Q%X893CJ2V.$[G4C**N&"0G";/V=V=ZV']L_ :
MJQ#"D!;GMBE\:EH_=^ H1WXC1"ZW;8<GD6>X4.9(,4JEQ2G2"(WEC3BP!<TM
M4G/SAYA#FQJKY>QSBODA(3#0(JE#85Q$MPP!Y>%Y_'[6F7>IWY&5W/)HK?"-
M8M69[W"YF+N+F,.]P-&QZL= ;^*T"^]VU4Y6][$5AT!]<"K1,'NY8,MH<CIB
MZ:G*7-J!-TET=FLX.*/FKG0[\U3.?K5/2.?BP=?;+ZW,;<G-_>NDW8V<5.6$
M;-7A06L(69U,JR$%4"M#(8I]&.DM);9;71JI2_#'??ODBF.PA=R2Z+N!KM+^
M\^<F2LZD6N84UB'[C<_^E2C77L$Q#2MYMED+BU'6+)G'*?I:>\ZZB!5L<Q9I
M.1/)"XM?*E &2WA1HR_:"H5Y+>9H]6FQ/XM-FN1\S6YD^'#&$?>JO)?-!T]"
MO<OCVK+'<0H7^4+)U+WX*)V[I)A4J9H[*AZE:=#HX,3:,7P3C7_>@\1C/OT/
MXBYANE +-K<?C+A (=].[ P5-WO0PDTE*$)0,,,.QO!N8!#1S/+)"*-;6-=H
M<VAG]E;)"K?#5/VPTI9(JKEDU%G>0=E>C3,]SWR1K&"_6=WA+.F[/H<[BWKI
MUK  &U%]I 7M%#8[$(^D;Z@V"(B&SXK8G(_5>GS[(+)[5@RSH$H7=_^*#32P
M]*"*V'1 Y_EHH5IC7VK!!HE+=_PLN99'43>AQ*V5\7WT*('[D-A@#OO0?O%\
MA[(L*96*K61A:*.VGO>P79C4U_?\P:EZAFO4$HY>U\27H#-?^_!UN." )&NY
M0'%I(*F*D-W[5PMK^&UYFIRI/_Q0)E4"XAB'MQ@=7]Q@/DQ'<LW)<4F5B<[Y
ML:LV,=:]DX'LIQBI4)Z_EMPM1H'G_Y)EJB(Q.-%75&E@*!O'S+.D:TA8M/ 5
MLAF#M3V3[P_-*=0B)@AF"!]\DTE5#7H+(QA*"@MMFCHR:R3UGH-DLR?CR/_H
M!O<.8?T:U+6G#R- +%J1>.<VFZ%6"B;N6K8GU JW[E,O3_EW8])*X:=Z+/6]
M> &4M+/YK]^SE&4_C82\ ,82'B2U:A]R>5\ *<0O@/RYXA7-F9!_N4LS&2U4
M/2O,JE2(>%NL6\TJF6 AAR+_S[TN\VI/=$;D]?MGZAOCGE)1@D+I$WH[)4H+
M4S0<=/4"-W?<OF[Y"'2IAE+'I<\U^5C89Y ;:2VIH7[4W&_^''U"=3?@ZB ]
M;U+CJNEEW\'))NK.Z6^]W^*'<)4:R/TU5)[Y7%XGZG*D\(+J?(2;$, YKS;I
MWI,3(] 4KB/2(FL/J ;'>>KO-KH^E4SFL.V_):&E;:+1<JI.$\7#5K)1IU]0
M73 /PPHUE-\#%DA:,U#0)[W*WJ>B 'B UHKDHC#G#.WEO7YT!850HKQ'S*>A
M9G(-:J+V2U)UI[/&MW*S>7"KU'A@N9GN=4"? F$C,+JZ_9PRRPV(I[?:C.2(
M>>]0A",KSC4\CJD!GS\<:ZQCH750P$4WG5H(?-.7 3D!UM?E,JJ^<Z17 21F
MEI%&+T4$'^T7N_5\1)D-+I>5^^GR7H;Z#2H5@?)J/IG Y0L@\X'.E!NR*)0N
M\"-70X\Y=TQ!C&>:<E]0@3VVK[.E65YEXFSJWFF$;RKY2JXI>'-I,WK(H!M2
MT/VMFW\A/6RNA"HY_NMGEX052/3JT!*>>E'6KRM)MBA&_FF2/FFQ9L#@<VDD
ML*W +X_MIH7K$YUYQ6QL:&35J/0G,G6-QWA%Z%N9N #FKTQNX0?[&/%,BH*'
MO[ 3V"K^&A4CY!,NF^E21L-/-2O5"F"NG+AZ?ORLZ@\$!M!GLOVES_R:(6/I
M2>4, 1OQ20P,RO*IRH@!N<OGQ-.C;KN5O!17/+7S;*09Q#7R9A!S>:PE#59,
M<PGQX*'"L^[S<US90]IUA'XVU"_JV[=::E1)!P97_1]23%QH2!OCM!AV--B1
MK>%?PP:E4MY-50UUN4][8^]-A]'(*E@8*&@PS!2'U+RZYGE;AAULZ8N>=P5+
M;QLGLQMT:CZO-7O@:;#*@+R=9%9T3^^OY41@0-^?>4O&-P""X8"OZ1,Q./D.
M9$JL#[F]F&)PS12K*&95C=@:XQ+8ZQ%[&$+R5/-?1='SZ4R"RT%#JKS*0NN;
M$;3J29^<+G%EO=Z_DT<$E5C35!>C@?A05.9-FWVCOIRP>%Z:I%3 VY(C%^I:
M[#0S>NTY//:\]+IE W631X"N1V%8>%75=L0]VG?"<LJ.5#;JW".GB<1HC.18
M9:/]GZAZ(@XGB=U-B"3D&:R[5,+42DR5&95)L1+JW;5:']. W*3VO6HP-Z),
M<?&+B<F@ FU9T-"W->+\.836ZYU-DL_A"U!W.X=^GI+D7<JH(B9,VT R-.I!
M>/C;]3?95%YPU70<R:TTH#":+:/?2(-P/0G")L='24Z<SM2  4?EN$1KQI_\
M+C"E<+*4$-22CQ\-,=4-F":UNZX1M_6/K,=XD+X?JE24'Y,<(]7;R;DY;"[X
M-U <7*KE2H\-]R-8QO#S@VX%J7$86E XXF0(=Q+^*%]GKQA\ _O+.@=173<O
M7R$#X1M+C3P;D_&J\\!M,U>9KL&U:31K"[M^4GMT,5TKU0#5(;TNL8.\1%.;
MJY;=U>D'[ N7F\I0_XPO)0=KKT=\OZC?W]8)]SQF/L'6<W;6"M@$^_NWE7)\
MU(Z4!L<7VPF?[?^H_<^G:< ,O"A;C*QYWRV>O@71,1B%P+1ION>A5I\K5U-;
M4/V0YV##"BF^<!ZUI389-0]<(ZO6K=(VL.[E?8\$I,X-H%JREENV1U$65X<7
MR MA)=&_RLM$I2;)O-<*>R?AP$ %B0]AH">J*4",Q^)YHFI8@KA#MPT_5B[6
M5-K-9R)O*1IL L,S1\0D1ITN:+G()8V2HE]/21^OW);5$SP7LHE&>FP0"=+J
M^]T:1/9 F>(F^^WBE^S:ZQ==!1==]YVH/Y05,/)-RLS'9\6$/LPV#NN6Y?:K
M##I!ZGB^EQ6]5Y5RCO4 ,!V7V/Y-;;CF(P;[^;W:W\#$GY?DY$G"?L=*U2)T
M(C9WEO<-^PK_G_;?2)/.,$U8NLBM -[8&"*"2(5L0L,\Y_F\0"=< X$4SGB+
MRB#1PVC)U5-J>'Z)U[!&NM]7-1!8L/@6.Z2$6%N<Q*M^6=L:11-G_2<RF24U
MAA=NR35#?::N]0Z084@704?E@H"P,DIV".W):?;ZO=!2X&-4Y>*.2;S>%I?9
M+=%F0 PO:^NJ-@YITD Z[I[%V2*Q88I%D:C,)N.8.CK1,+@IY5=HME/],GHN
M8Y<>05?HVTW$&"<N8WFG?&#/17+^MF*6CNP%2$:X.:[]GT=[J&C_OT=0#:OE
MS.%M-SISZZ$V[-KQ+]JE'CKG5*<NJD4V"[(H1[939W&G*3CN%8NZZ&$$ETY%
M,GAA]2'#!MTTYVF>:2KKZ4E)46FDH:06$M$R\O+6;Q1YY)SWD56_2LD(Q&*O
M()Y.%9H(7XX*=A&;-8>IOXX&M'*AQ'-C88G^I-&]0ZEY 0C?%,WG).34^7(^
M+EVC%_SVBHD9ROEG\*H0*?7NL>3RU,8O_![TH-4M,MHA9_0/6B&:CV.5/N5P
M?(W-\$X^EQ>=F$5;5;X;-+%SHYX^F-9,N@[<OU"%'.4U:?"F,#H3Q?0- +(:
M847S5:>T?RFGHZ*%^%4ODV;Y0P^7 TV4XM<,HJJ+0:5U]JDY @+"A)IY_V[3
MQ?6MF,3+VD? <\PX*R%N4742HT )==1NY7'2RGG1X?Q7'MOURQ+-NWE;/]45
M AQS=^6NU6^)"G"]5F:WWL%B^H11TX'J6BV4K0^8/Q1?(4=H"-YCYL$KK>9P
M4PJO9DNF835.3)E[U:PZA\TA:&J#X0N/Z.JJ%DF:81$C/TPY::A2'TE3SO"4
M>*F,6Q-? %$&-3(@T/*7;H.LJTJN_XK_+'4<;1<]7N4\9%R=F%YT%-AGOPU,
MG_^S2K&!,/_&IG%H)GO-K^I@1SGL:XTA$^X0/#B?FTBLVLE)E20B)@E%BR+J
M8UE@ G1S=SV'\O"L.#UKT:OOG7=T:[.,7:/7XNJRT7 !XZ!\4-*7MU2J\LZT
MM7V*_H[-K<8]:7@EQP7N);/4"Z+%L4&)'%X+J02><OJ%)B"=28]KMUO+&\NE
MJ%K=!L)[K5X'2?OCB-5<6 )V_278PGG=,GWNE<81OIP?KZ/]%Y%M^7J.,&B-
M]#2/0U;[3!J6Z%$]DPF*+Z>9I$R-IA]N60$]HXJX+(.8"H.LD)Q:YBO?S[SG
ME23P DEC!A2#5XD %&49 A2^00!I[92OQN'AJ,6_R,3(\TIS['DJ.QPR?B?*
MF&][7*^O/B$V<KEC+.N,M;0\SZ%S)4_#Z72H$UU_"O_-8^*'F%=;JF5K/&!/
MO_=]9?J:\4V?D_,[!W$1XR-YO/H((B:J#P6I)&V.6L>F:+&RX9B)?1WOR#CZ
M/+_6,H9)68E/WSP]?VP5_KCY AA"N<:X)\H378\!K=$1),ZBFZ)YSFQOOG<Q
MJ:F[I6JYGAV6U[HH@5N"P*RO[+0)G1[OCG9OW.2TO,^L,WUTGV?;6.<TL[\P
M!BF,/L@XI1VVVWY(:^"_I:G\Q0HR'?G\?-9@S/2HV]SYJ5SZ_E[=5:A]G(C,
M)?E5=A(I6OJUP'*[;6:\/&1FF Y$/S@)_NP"M:30:($,*Z:XN^8*_@3\-'C[
MG>T'&[I3D/I#[,W)8K"=5D+N-1)I3ZX/LP'$2B@,R=L2ZP70[1/?]N<%0%[(
M_%ZU(_ <N5G-..J/$%?N,_>])B:V+?"+9@/638%=0 W7<=&$+.'AIC(-XQ9I
MCSI/(3QJ[CNI[@%Q&8GK_;1/)0MIJUR'&KO/=*NO>UR& AZP7,CR1R?'MBV'
MJ<\D:49 ]?*NB7+QJ4J(K,0T\X7Q)HB"_IT)L1W^37,&+\.86@R^*U,RLLL;
M3WZ71%/"/F=OS]GZ% \6'E+[[[/P2V3@%A65"L'G4^@5KM4]M]VQJD.)X3@I
MO)\XJ-:B>X7OMT"-M#%?,:L][S4^<0TW3WCD&[+U?<[#@"H%\HT^I!M'\&%?
M% I!J)Z6O>KD:O1)E,Y<W)R,YJ*+&BVAV+LC:[DY6"M^/@!*VE<0=1DQX%0S
MMQBZC2(A&#3Y:,=Q'*D0"G!=V><4]<'ML L=H.]A:9D2Z$.[,I'F6.B)O#G;
M6AM*%#A#@%*$R=ZG?D22-E6=G@V,;].92S+S".#KR\'@'Y&@ABM4)0J4_::2
M)6++)#OX-N;F.9NA4G_3L*,4GX.SW\[71!(\_QP3[N+("*2$82P^!4U@XE8>
MF:T]HFY4!YN:(.15?2&V=T8)T<O,TSB._.#:_:L@B92TEK^E/;2<4.FI0UHK
M5)"S_*V#^:&<*-$#&9?'K4&4WR4TBG FNN@H@>M-);S:>Q*HVR_G5%8>=KA]
M3GWN\SPLZR?F?>M7B5(YP<6R7H&:&+)-PXKF)711'2-8M6FH&NRHD$LB6#&D
M7O@YBT9G[#.WMRA9TUGYA/QVK#D@I:8L&#$.>NN!0E5449@3 <JZ)NPC;[.8
M?4QW(\NWW_'KWM7HB[0[5AB[7;!JMO[""RI0(XY)"1)HV:8,MI 8#ST=QN=3
ME+!KF<=-=@$^&O27T'=OHJBVN6M2V,O)NTH<E24GML_ #N/=K%^W-0Z)^_O\
MRJ[#K*4?=.7#HD)\D@L _Z@X5<:3Z?<I)L,U;:??\9BV)/ARG:%[83TME]*0
M=HN1)?S/X&2&5\[G^ZF-:$L_*:>P4YVZ#MHLAO]!VFRY%_QR' <6:ITN HU:
M9M>LLBC>U$N?=T'G->N1]?JJZX2MIUXJ(5?.D9TD$YT,G\U#UV1COSSK:C[Z
MMKHT,>*8*N,(\0IV0Y[FCH-F[H_Q<*^/ZC6 ?)IR]:I$.PT2\DE@!#/0G=+,
M[99Z3A*[X@IB\/F$8-!HR"-$06H"L5OOZZTM;WP*_=N9C;IEB% E[O2?O?)-
M4R%/<10]3AH9F7XQL)S]2O7/@J;YJR=(@$%-.?W\K9LWY%$0*41<M>CF$T[N
M6QV=V>B=@"CY3B2#>-<](5]%O?-CDJD+PLLK1P+GV_BUK+6AK$+H?3OB?=:>
M8Q@K)7GEVI]BKVFZ>ZR-<R@3=__,9!'4R"SS[DC8;?1<FK,]CZ_[MFQQ+0&<
ME-4ZWNB[_S<L<6GD(6PL!\=%X( 3*N(]6G[/M:_XWT$[Z+!I,;1!J=?<!@]/
M+MO[&!1:"=IHRJS6<M=+?[M.,"BGTF8B,C32+@]7;OQVRK(F-4O+&9P[:S+D
M6?LV,O$N@C!F0#6REP[^QN:G)G9 9@![EOZ[/48F6EEO45\:YA#T,;7\)#K&
M04T<&;ZI:?3",HQ>DK$_T$V,U5K;+XK\D:KUE\+KET5_ ]4<.4_(^7U51DZ+
MQ]B>#GD:MJ8*>/X?H96>LMH>R_13'>Q%3C[:@P-&%: +B.#S9'J:A2?2R &G
MX7UO9UYC:=#7ZM>94E+6#'=UV_36P]A <HI/S/!O65'FDGZUJ5QT;=\;$LVR
MX+M$?V*]_:K5S6[@B 5""6*S%2=5K:P -$AU%AE2R=I@(="O!*75H=6^C;5O
MDF&@+H\HL,8#6J>8>TAV:G->S]4K CZZA[E\F8L8\AO;U)BI297[H,DTS"@'
MYF^/_?AV\\:- 8SW F"8@2&,TE^Y =AAA@I7-ZJ@>+VX1:S$>OQ[$#A>/4I^
M15NG<RJO@I>V3/IO*H3_7S:[J6[K#\)2) WU;> 0I9Q/">6O22MY<,/,).(P
M C_ITJ9PF\WR%__:2K89-YZO-T+'S97^ )=OW8]!1*D^>GA4='='N/DVM 8K
M"@LJ3# JK,J]^!A]&L2Q^8JTY"HZ3 >2B57V:="^,8F)JG%(IIO:RT B0HL4
M#>;C-$78.,CXJ6#1[MTWM>J WE@A7PD7<I(P2(RFM%\>#B'6>27L;M%X*R\X
M]G-"+W4-3FE!K<@0>_?XM<)NQP/X-X;<>.!-S+S-T<! ?W=_%I#YLY.3BG$2
M%1W=1WE*Z7[IX*Y!KDTHC3TZA0GJ5#"6+#K/,&I]@S[D0P@32J]+U0-US2"5
MX,3KV"G'J@=TREE#\VGCOFSSV8M\OJEOJII+WU1CX4PH8!?HIA"#7MM?'K",
M.Z+?H%AL:.$XX==,Q/0')5G%>3O5@*[.[G[4'$*DH6%983;,=72HN2..#FK5
MI-.&;GC__K[<9+E/I>*OWX?U/GT+L_#%E4:W%/4J2*5&Q",P4W,]J[I1T5L5
MHBQ:*&W3VGUYTD%R#N1&[IZL8*#@6G^GAC14?P4Y.-&8\G 8!#1#?E=;*39A
M8P[!2FMCA>;PJ,=_0WLMWK/[;S++_^YP'"#O%Y(N>L8N8-*;>W#4L _<@LZT
ML 362(:Z"Z5]M=(BNF[[5F2>EYH:[B"[^ C]BJ"7+R8^+)5?P)VP^8Y,U)!+
M>M'+1CWD7[J!NLBLQ;0*QDNMJ#"',N5]MVI.2N.&Y=V-TFO/#VR;=EL+,,1U
MHY[>\#!]Z[)X)SO.,!)[,A&L*6B)#*R.PUVVT4K>S<1$_V!+O[.XN.2NY!V=
MC5IT>P^PH.H3<"-%+]53-2TR0UX'&NMJN?2A*'DX52YIF%,CI$IVQH*&"-2]
M[T*CS32$9V/#9;RM$)A:UG[_6TKF+>*F3DA.,FY544@\0AA*YPCJQ&:$&J/&
M)R6,1EYS^,<<TDKN03S[3V!F53CC3.)/P[+(6MY:DD*HS:ET0 YA"N.-T+EL
MWV2IV)()><5##PE,HPH2[.S,E61)MW;1;VB\MM0F0V0:^NB\N0)?FOWQ'5<#
M/C!C44(KV^$]7V_6IE-UW')RDQIU\^!6[\U>1UAW$W*SDK#X#DM!Q)2%V93P
MJQ%!M3IU3D>5OX9.J(%9,H3" T+A3&2_0V[>PS\\T@P%%D'<"%5)K'L8F.Q[
M&&0@N"%TH#ZG[*2(.1@^Q'ZAI&@_>7&T*7T[PB#'V+M:"%=X&JT>89I=0#/=
MF?['!+Y)B%??0DJP +-L7_,&,9NF9OXFH^;H?YHOZ4!VS[[Q#.#%L&:S<P$>
M!7O?Q]:ICTN2L11?\]?U$&J8D2*!^!0!!<15(CC3H)D;?"SJ@<M*;/0"YR/Z
MXSP:'&+^'YMB!6,?Q5AD9(Z ]L8+$Y*21B9854&AY<?V4MH<*$!QX33>73,I
MT9$/+"::^XJI1-EK'3]GZ#='U>"GO^]S<GR*H-7)XY'Y;;DA>_*T7<-)AO9A
M-[?G['*KS5)LS"S2*W'';S2VS4(OGN1O3%/9C#YNR[/+A[-CP1N&B;Y>9EMH
MP$HTYZ>B#@15*'@J9E6+0&&R4@"T?3!"E]2?.E^F2[<9'_!3O\YCUHJ@A2 &
M%.D>"M^3)V6:5'\\$Y*X)YMKX^F^L3/.T<^Q#.0)HMT-^QDI\-XO)4B:7=0'
M7F N63LXD979V:F)?+)+>"C[2HSYQCDQGP^T& '6'1@ JWKT>9NT9 :4WJ2:
M&K)N:1YL,F>=KIH*OJ:*F8WRS[%Z9C]A\15S75LJQ!7&^"T2OI-8$W[Z_$H9
M _C%_6-JY]I0U_1L0@TG3'/1&_-P[#I-[V+V8V+!BH1;K%J1[[4LX;ZJ&[AD
M+"<$9HCCZ,#!:7'WA7B#UJ77+PZ87.37Z.AARQ'7VE'>+VO>A*&<.8"@'X@\
M=JK,S*R+SO.>"#\/<N^%/%T.N$8>G,HQ8$]?ANY)<[KM@VN0.PW>EGEX6_(5
M6\9I&$S;:<'\*3Q$" OHGJD=-_#B?A1=ST(JO;$>^UTH/59\>@B9C=;D<NS?
M8B%>>]SO9TL ^2BQ3 @";8_#(7%Y3<-CXA>\?%1VEN-=>4-8<I@+?WED4QT#
MY(F@6(Z$=B<5QX\V;36&I&\ND.S/LU63S@;(JH)MN0[+:/M/L%:;<DQ:%AJ@
M+?<R9-.5+C:_27R>!=%' ([?9&M\?C N$@F58S"L6+Y!#-[K<IJ0\#TXNUB%
MR^&_VCN*L =:$;Z?!+?"Z%RQH=8/+GKI-K ETK/5Q?N6!KXQM#!<P<=R:T@_
M/G.&U<W]R8X:C5:=396-SO7J0(Y[C>A1\=HZFW3W%YFW;]AB[0OLW%U;$Y&$
M.PQD@=O"T>H>?17!#E)7T2P(&#<A/)JZ?[YF4=",,+D9OZ;B]][-+>F7F!&0
M;=>3\CU9R32/GA=NUEV6-"2S;QCYSJIW6@?;X/>GO-HB%&9K+?!"51'U!+\
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M 0-8@;<Q+W^[04Q3( P3>)85-9Y33J71BU/:T)AE9NLH[)ZK. D8='_"+>S
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M+G[SURDEVRX6FNXW3Z;D!NT2:VG?RMGBJ2A0K7*%C0/Q#P@S/N?PKWN8WS/
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M'"RD:WNEY>WH_<&@ [8"]A,Z&+_S-!,:]*9A_0I^$@P7$U!ZU5!-PVWPB[N
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M*[]VR06BY3,V]0ZH$BZG92N,QB8P45/SQV_I.M>  /WJ)$(79GO%87Y"&%S
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MJW5^56VZ.M:%6E 2(B@)&87&=Y5->WA7QNO(F<S)R9$G\;'[OL'KMOSKFN=
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M @Q#$PZ>R#8VW+\QCWGV$76T]+?)L>+PQO%ELY]YUNT09JMQP\DU50.)(#:
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M<N46H*.(K32VT9O*N!U;2#< PPGDJ)*P)!>_*#(Y4:P)T!ZH^!@2&?H.MTC
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MF$NEM)ZT]%F<G 18_ES2B>Y5ZB3%^?*D0_/:5X/T[50D)87^Z-&C6 UD[&H
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MO^H)S"(A]2HJF)=U-,1.#I\H.S;2.;1K'X;\JE]IC2I$QTM="(LVE=[5?9,
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M&L5D$(!5/> \$?DT^):*Y#=@3H8=37;9ZD= _N7_ -RPWZO_!5!+ P04
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M!L[G:4+K-69;UG*OH48 H?J%@6Q/8U"?NC%D^^28,GO#T/43I^24JMU9@QY
M2 <W1F,:*=&]*CDJXH48B[Q2%MD*VAATHV7 L>H90<&?%)I:R&=<V)A$E0E;
MC3I>4?53J=]MTSZ8V:098R4=9RJ#64'UO%ZAF#EN88P./!D?*2.*0<$HMXAZ
MXK28!61ZYK5+2H^9EDM5/RWE@2#1:TIMT&TVJA6R 6-Q@N0GN:#2S'FLKTR&
M7#)NMC H IP\A)1;Q(1Q%W2.[#6QLAMB+8J3IWET[-NDF'%[UD<%T$];^$R?
M=_O]<F:"Z+@ "$X/2R(OJ<Y]WYP+?,[,0S%9M+K,V+*JRX 233J21.0[ NM"
M\Q[(5]JY5@Y)0MIL"WX\;N<=E:\VO";#=V9XU&_Y^,2?CVFLGU<5JX!B,Z;5
MZ3(1C^"5Q9#]1.7'?DCIH(,V@Q(R,AJ&&C3RLU::T34JA.&Q#_?SDH$%DAS%
M7A7LHQZ<+1RE7]<[&%>2RDR=%\PVGBPF)2YG?@V'JBV68<JZ:! ,7&[Z5&X.
MI66MTFHUZ=J4+E13==YP0FV>\EY!<L%<:I5ZT "$:"L<"^U BYK5+4\.M/(@
M<5D]G^9+-CPIZ6 .DWOYL.962H 3Q!@XA/P>PH=%<3"&1):MT7@W0K%:4Q6F
M#1&>="-V4#(EH18O"&<J>>PXT9,26TRI:@T+"ZK3R*)=G2_UZ;9#=A$JX&5.
M<(DJ%EF\M90->E8\Z10H.Q?+5BURA@(=H:@H+<A2.C%:]8G'E$$@EK0Y(W+C
MSM#2IZ/ 8^92E7#G4A\4#=.L3<HFTP<J<HKZ6'>&R!6/*>4'<]Z;DQ"/M_/8
M@A\:M7H3PCMFH=QH=<Q</1XZ,L9V_"@8T $Q@:?45.>X6H^<U@>&4&:=<MJC
M@9"KMQR%SV:CPG-(KA9,)8O5EP&U:K.N3D8LP;@#OX"(L)>JC)A'PB*3;X-H
M9,_Z-%^I-\?]U"'@8,SWH4*6/ EA=^)%+1:TH#K&- O# 35=>&R.X?H=$1I-
M.!=0<*P2U]5Y%Z#F0XHC78#"I[V>J[A,BXJ2*1S+O 2&I;KF\$.=!;/69:W?
M:D=%4 ET2EB8C=?/T5*UXZ;=(1FX8&_>E-$R0D4R :D\:V,I*O.I%D5EF:;(
M:2=F#;4Q<P0SBFNX[&6)&I$@W59;9>1%#W.UI-ZI%8,VYF=.5LS)3:"-%YV<
MKV2) C?M^-UH4/>'DC'%!U,A$""]B2E TNEC;%TV(:O=KSE8;E*,56R1T>NX
MJ"<SINWU*$_!B^(80,M"DB60KH'R4.3H4XZ?.,1P)(\%0+4,DTP[MH7 1&5B
M-JQAFK,MJY8/Y\*0F"[6,B\W_0I )9J1,=;>0)[GTE91U=I!,D9&15@H-(9&
M8NLU-$14A >!62F/4D@<Q^W(]2FG:^6YE!IPH@PLZ)P9RS03YHI*Y@7;'%*V
M1]4L1Y%3MCYKEF=T4APWH7D=RA*P+JSFHVZ9G5,HK<9A0[5+490;-^N17+:M
M&&\MGJ!5I[@(:A WI9IRVIY5C9)DTUQ>C#IH50JJ#M-6P"EMILVB(4PDE9*J
MSKR1#I">RM YV\_G+94K1AT:'R +YV#DT[9#T1!".U"EI;;,;DXH)FZNWL[2
M/ &'M8F,Z\/!'"N0]6ZO-J[@.<!)$S^'5@Q]X$^,BM-H%0I *7-A6W9%]-3&
MBC)7K?9'5L!K$<)7Y]*\-M1KDS&A"Q.C7$ ,5K"S3U2L-26ZZ6CE'-; !T/#
M&F$]NXDT&HTF.EH,&9B5B=*81,;C.L)R0X2@>0<8M3 5PW&WU8\3L9MHO2F7
MY3. +M:TZG *=F8#/$:[C(L.T@D_Z)-$6 @GR8(Y:&9] #1+O6(2J[C?RK5I
M0*G0>-_&IQ@PJP@]/$UA1J6'H-6#<SV4BUL"H@]8NA*W.N.40$I!G^@180+J
MBR=<0)9\U+MMFQ@7X)X\+S1R<LXDK%&=B89$;HYTXA8F6BA?[D,0/J2)*BMJ
MJ&$[+3:S7U2.X]*D69W L0//%PZVKX)#-<G1;:V:</BPBL>P#V>LF.;$P5QV
M:YVD6A<5!*H$OEH9Y1J=:@93RY*4 1QX<ZL[K#$#O#W2=$P&%BLEES'6\K1=
MB;UV-(11U1WG/)6#)Z#FX'ZCA,D6.*$MS]-"H<1ERV_8$9#6S%<IU%"+,5IL
MXKQ0L^R6!BX2\-3U9KD2!#22A*N@H<N@9KD\CNM:H3U("S6_.:OFO&G5I^-R
MF@>PTCA+_ENCFJ$@>K=DSFE!\9NHZ!AT4%OXPRQX.TZ)&,VCBIO-.([)<50<
M\^FP0B<2U0;<RKP-S;3:A*"YOF=->D6ZW"CDNJU@!E"3>KO0*C1=-4WZ0&FQ
MPTFHM(9(<E*H,H;<-;M1KN162:!#S"D1K2IQ0^S(IF.S2:O?F[8:!M\<"ZTR
M+"(#,V4T:D*9H(C5R-1DYPNRE"B#>)0WXP;.!3.2*UD<)S?YVC@C;$VJ[4T]
MPQ1JN69]K PT@XIE2!F2(DSB*F48(X.AY@,E*+:(L4TK"RHR:QHDG64O$3.#
MBT6[(^MQ,NC'%C[P$,Z!#17D585.Q+SE)CZ!:@0+AR)=LJUF:2[E8<)L>9!0
MF:#0O+G(]=K)A*H#?*2[)-/EZ;:K>+;+$SR54:HLULK-\KA2B_N#H>^AB:G1
M9!7KS< FFHI%32]5U8K'5N2,">@,M]B=,ZVH)DV('DNZ$CES!C-C,,H!@RP#
M)BJY=J_N#69!O38R+):#)<?6N69W. M*J5=.T6PE#=*.Q/5!;(IWBHM SY8<
MI@>.AF:E-FGU"VXWKKM-6LXE73B;20<+F[4(Y"R.9LD.C-E>FZF42&CD."VP
M4>PQ=E)J$"UU1,B:OYB4QEP%2FVY.,P(9>CS!:#6Q-#J($LU:,"S\:K?CJ%&
M0<<IL)>Z2(#E"K955U+([P-]T..+,4PUV-K4"G/M119@DC1!D7[8&:*I[\\0
MQ>I-1[K)20B>%[L8E[5<Z\WY::U@Y&&]K=%E=Z06C"G)LE)#FC2HC"1@7968
MI>9BNX]& $<(P&ZKPY>+()'C U*'AO,6X)& -VR/88]A8AP)\ODDY9TY-BK!
M8QI6 $.5HR@CZH8U$XLQ&&#S^B(!'XZ\+"SVTGHZS4)Q/$X+F1.LEUI97CZD
MC4X9KG!S:^C C#&N]'K37@H(0M8!9U+5B@E6,%B:K]?Y+H<0T6)7A(MZ Z,Y
MBDKE%,Z5$8.;9ZN0G8R@6742R-UBL5%ON.5RK/6((8SE;7I0H92F2RN2*/O3
M:5K.8RK>)U0(#Q;L:X!&I-8KHRC0P"FU:-3X;FV8Y*PL7"J,,Z;XL5/G"@RH
M"P@/TPI=ZE="&0?TZKA$VS6F7&JG))<B ":[B^2Q/:YQ:A7U@8;E^IV*7D%%
M2QS1,XVH4V6%L7'+QLSJ(%=H8C4=+0\;"1.;N0Z0I'1"-[P.UJ%].]>)D_E@
MN'!?$.7*(6(&KLQ:)E[N]$=)1#1[[L2KT ,1#J=@:K>:@P2J5:)*C\CUFL&$
MK@^]9JQU>GT18&2F .+DO--;K!1,SC<1<C*G IWK#8H]LEI 90R:2*8B9]R
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M[1:>]P&X,M7#!M^IBBGJ+L(H11H^DY:10:\^GH!"HK4QNE;W!OTPL]]!&8&
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M?(*OY\5"?#&$O'96F)'G!O:($;4>LZG@4CPTRXH=[4TWK) 5A+"Q+Y?,1Q5
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M<4[4&N (<3WHE\QH"N-2%OIV&E6^/1?$=2K"3(@\M%GQ]/?=C#B&/\*%]C]
MR5T 06]/@8;)&"R.A* G%43W[:>XB]A'/Y&U.8\0%ZIX)LI;!5W3KGU$FXW
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M:'\2_2+P\ASO+8^P<7^VU@$.OBUP\-UF3578*/%Y7V9U'82.9%C$-W)W^0_
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M/DSK-#447?BI?YCK\206G=8L-E="E;V,S'>YRL20+$O$/H+4SOR$9@0RX5N
M$9Q0;P[3SPH@BT&%#%]6=GG"QVWAF3\I"0NVQ#=GX#\+IM<L52>L>UE_2&]H
M&?&AM]@@LO,T$0H@[D5LQB1PEREM\B$V/#/Z9QI2I1TGMKAD5 E(NZA/*BVI
MD:UH$9 GR%J.;2CV) =;LR7P8.]4IG6UWGWEBK8=NJ&J*'Z*1M3NL?4G]I_>
M\5<+=>W3KIC3QW!+H!S_SK[5.$]$6&>>JR_&%7WI?!*1BBA/W=@[K_*=&[O\
M"R:4U*P.)8X.YYXAI;W]6.,SM\7(<<@W<1<'__VL08NS]4IJX2F%B)VFM&HQ
M[<Z"/F5*S0C=&HY!T^C@@UJKE=$#' X+P]*F)J^::?I4!9 <DRG8J[/-1A$K
M1#V9P'DYS6O3^^<$3"O#Z,D8K;L.Z"L,T:M-7\*6?5>[[]>&^W,FB[XYX@)<
M1?>%VYB9TOF7/]/K8W49D^WT%?OYA,\?K?-"4>LL;5,E[V,[<H6@T*3!1KCW
M6:!5WU];VG^ =(*G(M-Y)9'Y.JV%1+^N)O_/?2GO?X  =WE=J=D,GW\ V>;U
MF#\MCJ7AHX,$+$MK_ GVBSHJ"%2V@@J"D>CKW<65\G5FP5$F2%O=\)OV$6$5
MLE/$9"OAZ$XW[^*8,]3:R6)(-])0<8+?^H%L#\(9D2G'X]?7C+W?'TZU2]T>
MA;NK)LX0 !477H*K MBE17F HS\1&ZNMJNTCDT1F>/)S4QKVL=X&,T3H$"P)
M@+D4=#/1S</(?'"W/6#ZSA[NW11A8;V[EQ?F(0CQXI!79<9U]&>"Z,N3"+$9
MKK/ZV(P*=$4>WR'T'21!",7O&7JA?1[65_GV780PK=?Y9UNO%I^FK,UI]&54
M2PO&2:E&@_MA"UG%\XK@O5[2^P&?*2Y (M]]P#H$=D,A&9HIH8 ?9-VN 24&
M38AU !!YZM6^WOZYF=)_]-LT'EY62)51L GCCYE,X6]@7J#[$2;$F-_KD<#;
M\P]IQDQ2A?;#KU/]!]B)2W3$J$"KI7L%YHE1W"=RZJ]KZG=<3</OT-/"7<K1
M921>N]L&SN<P)PV3A9F@0[[C(&7!^]/5>N$PDLTO?$OG5&\%DJ95=TX?/C>\
ME(E&XI#?B?GVQEYS(M,]FQ7[.A8\/E"G],8K1U&*,M3!Q%:[_0W<>>0%(Q!U
M78WJQ\>W^+>WIH27QR33*2#Z.+%KD(FLG)/Y8:SG_N398:HT31,\X^:=M%B0
MUX5U<%3J'NIH8CATFQ#4=TT'^*K44V*(EAX&'T'8YE:@TOWFRFJ1T]0A?SOT
MF4UJ<B.JRVQEMA;CHQZF"JXR7F)+Q(SCX(]C"P:12)^E'";<3^2F:J1]PXQS
M=FR-I!@92(AL0+,;3((Z5F)H/^E3C.QSSSK0P:P!#\=JD=.&;P=A@)\-<+/U
MGLP'_Z+M)]#&AUV8D&->&DH=\6&SW-K 4(+<FHWB<@94(QM)&H/?QD#F<&.\
M0>0_]OO5YHR\8-^2K_!J.O#5"K%?]2]LY.C$X$> (.MQOOCHB\T'FE_([\?P
M<V3(D/357U\<-4@]66C5/P!&*Q>,M>&Z#[F>ML'CAB-FFV["FAE=(!HIZ-29
MLBVQ57PHB=/1[/!+K^GO9;A@8-H$CBDF^F37]WNAE:1];8B$,W"T &/["(;\
MYS-T"? /F9, Q9WL08ZR-X4.@?CR/"?S<5#?X60/R^EJTP!>LMS[Y48(KYNG
MGGB8(!]'[C0]L=(_ *$>"$2[BM!^;Z+!WU)CD7*)58%$<N3N]H%/ C[X4CB/
M?UO0A?DT7!>UC.\%GU 4NDB2AB)->@;'NI\8]79;DXTV8:"7S'>*YH]PIEIP
M_YD,I/4FB3R=+M)H)2!_@O$IM731#'H,\A#7X@;>$_+7YD]>T*SJVLE7CIMT
MBQEP%4"X-S#Y2.>IXO0L:(OR%<^=E[2[GFE+H0" &NKO55Z P+77WAP/Y)E!
M]<I3\&Q.$*0F=(RQC/I<$$P3]*FUDB==P-_^\5%.VQ-QL'RB/9,*T+-1'YV[
M;'M'S'VHOUL_.DXB:1]YGZG5PC$%I&" T']E7P)])9FW\_BK,H!$:,7+LM>C
MVDM&B>FW#_<;^^?5%S)9'$NK6% !L"462H')[LZ/RY>"OY<]$@ELBGQ_-.:K
MU>6NY:\55!U^2=QMS PRS<IL/#U.\Y(T"9DR0. 7[3U0$D<=G\Z")<H:@WE-
MH+U/PJ[8B?]XECF'3-XI O-4![!\IZ=%H;SV%WT^I+KCECX\",*[IU4O_=R1
MT#G;F/63**IAW3_Y:)*E9/;CH0YS,VB)[FN)*!Z[2E5\('@7[%M6J/4#-.>N
M#(UTU6GL[=8>YHMS"[8&>/ -487)^)F$9##A-9T'/"47Y'K_ &7G8/#J>1KS
MTH0Y.]:=5 VWL:PII 935O=L9%:::(Q'KBJC-.G +6.4J!RZOI*_UW&(*1=D
M<<C=^_OW%6I/Z.9U2Y,LM,-UBS/&UA#A_,;8C*&=6[*!?KQMQLF9I.Z1,)Y_
ME@#\Y%V<!Z&FTLM(5>>QFD-YQFJGO1168M6>]KH=K,M8+%WARJ/#'&C%*X:!
MG4[/UAAP.3[T9;Q12N*,7D.:=>2ON-7\M/:P8EKUSW>TI;%J9(W3,1N9.BI;
M5"+W[JR[3/XW.;E80KP]%KIK///=I\;[!3UYC;.<6EK!EU#=)Z--)5CK/YM3
MW\1,<E>Z8QK3[T;)(UFK$T7+75FOV1&B/-$N9'.Y=)O)C9LQ0VVC0(@AYS:_
MRZ-'8^$LJ*?DTOS9T+#9*.W22X+P@8*JT\^%8>M^XH:M:YN:X/>BD;6-S.46
M]%$S-HJA),%&N19 .>=(]6J:+1<&_P(\MVEB='KSKB!'4\KFXRFBHX-_>LR8
MO9QOMI,Q"6$^R+3I"92\B VR9D=CECXZT*VU8C"P=F0,4D^SM#*BF2Z"U4#*
M<PXI\+0UK8@Y3>5D9&!FBEYOX7VG!8;J,O7JY&7,$H:53#VL^S$X&JUY9X&>
M6K+]GVW6VWYMZ+D*I2C8Z0ANX>*FC=<Q]C4P1=:$Z%::4#5KF!A_JG)E;G&F
M=X</VHIO:Z][&2QTM%[AC(@I.&#29/3OE(]+(A^2EZ*>NZCG#6O52YI96$]>
MY4W!.-*Y4,13$43,>4T]$H>BXC=B83JX;P@WHLT"QA'H^QY@,"4+*Y7<H%&,
M'A1IQ_;FO63TN <G..\="0IQ?#@]'1:V7LZ\+ZM-''?F#^H3>^(GM9L2\_Z8
M.&+_C"],@TV0JA?$@%PJZ+K29'[!VXT>^MA ;.;Q6!Y5_*2>FAL_M-\U'S++
MVIH>-KV+53BD/P+?B2:76A^'8!";^)G9_'H)=U1@U&M"_K'&4X"-Y+I!?#=L
MICX&T3Y$B:B+MS!^30G[60&.FI!!J L*V##7XS,V_"VU\8WOX!3KY06!4"V&
M=-QE7B9I("E5]PEK] =]=;HJ'YK6RR^74M^O2ONM;41F5O-R\W"^V*/?+R[&
ML0>=?O#<@ $15P$Y+M[K;7EH/3TDG/.AU6[+;F1[P;#,@W9N=NRR,"'5EEGK
M[<TC_P!)CD11^-JQ,GTHUT'B4:'E(UPKMZ0ZH'2;H./%(.'/MY(\(2B:*T%;
MPR<]\8G8^@L#$IFE7P1CO!1F\:*P9KH60B7A&$(T$<#\,)?3NQ;@)CA;03IT
MNX*?'6?,#2 D8I08N$+0+"O<5S_8=IYKZAP'PD^VND5+\4N2S2V.O!9,DNY%
M&5/!$ 83QEG?.0S"0E%SM!UR/!IC@EG*<J7:[TF/48+MHYUQ>/X!%,WZ,2P5
MCT:ZQLHXLS$)4;I$RQ9,K<D80\C6#9#F3^IAY2D5G:_07:7+;F-Q-DP5'.F\
M@P3'I9HNXYOS58O3V9+P&[^6\!];O._Q%6Y(QB%LZYP/]_X#))[WU66]IEKU
MT0S77#03VIN/K(_*JH$40=3>4Z\2[-:%B8^KLBP/ ;O&8A33G>TQ?8(Z:Z&*
M[D=8_P 1]I3<?EDLAV69O*)1":K%\-I'_;PDY ?Y*!33:!RNX:E);*>TU+_7
MN#=8N<IZQY+"G*U4_TJG7,=)EZB>_9C_<$EZTA!V(M%5K@F!A'B,J.<SSX/\
MH6O3:1LG!>"R=M2_(>L&K7O"[^8%(H;904DPKJ(&@O!_N67H^GVK2?0V&Z&"
M3+7JVG.",2Z=&^TZ]E?:2%E6SC_C!:U[<#O;K+.6),]7+B5?3,E<(K6]8L&O
MWW*20&Z7UGT3(0:!J ]IJB86RL,_1^K/;ZW&6JC4/2D3(7_[\JI@>Z!$DCX[
M^]RAF((I,0BKPQTN2!.X69O/@>IP798& 3>#*"4IW:L+=I972DXL4SF?VNA^
M_L7#Q9#!!2UI04_!7-F/>*5$ FO4B[; 6I\)2"VQSVSEQ.^?)ZP%Y3+ ^^FI
M!;Y E>^2A$28,?'.<-=$4@+F+W DV2"91[:X'28>XPU"G^63R:7!Q30\DG[+
M9.L_8L,PXG76&.SC3T#M?CH8P_>D,;:A1GG2S(QQ\8A"KM=D61QF;%"\+ ME
M7L92QA=PH0.TS ?]&UHY?5S(@^O6F4@[EREL&GKE7Y]VD2F[PH"M^9'O1M0-
M$(NJ22DG<2"F(U %'^=E\X!&OD#!%0C#:#9CO.T+]SG57%?SS+JL5U8F7AS2
MZ*2]U%I]-6SRG0IA3^!;R.W-!*>*MYZCJ^;,@'IX?<"WR4>?#I3N&YJ@O.MO
M@G#PZ=$S\G>U1,E&CGR?K?'_.;"\]19-[\*3K>FV;DF-Y''2X2<<4U61+:X\
M;@\ZW)<6+"E,<K.*5XFY( KL]G8.;>I-KUM!%^M$R$C03V_BJ.5?_J]/EG-Z
MU]9'.3RUM_5O$HM\JSS3S@%MJ"[=$AJR+,I2O<7N505976;Z1M]Y"U-IDX^K
MBZ<_Y%49Y>3^ 9AQQ-/<__3MDAAQM%T<7BBQ+9N'*4:6FO#[E\+WFK=/]5>C
MG%XM"U$E4@P%FYS<N]F5O94FC$M*X4U5%*<4_8W*SJ?JV $"7*B3J:]YG.#A
MJ*B5ZN);U?V5'WN(;X07](],^_WH/G)1?)$UM3"1AM?:1' S9_QS45,[ +&S
M44<_Q<6I5W6]'-@T/*@[!/#ZR?JI#A+B";OM%Q;C1O\PUO7(R0@QAR>M)*TE
M96I[JHK"ZPVTJ5:C>9G#?,%7AM\"5 -^WWG3_T;W14=8RKC+5?I?U&=+])_>
MDJ4M@4LJ^16GCJFL1>8FU*_R ;S22/]%XY"P8: &]C<8HX/O-1CVNJMX1S)!
M20&>X:+ 7YS_ /;U-!$;&WH#?P?WREZW\ SR6V]2#7='S6NE?F'06F"O"[B2
M)VNT>4Q0$9DCS2G[_#DEKR>V3/,"^;N[:C%=U00L#>XQF]?KI9HFT\^!\ZLD
M[K$+Q+ -:4%'OFI=0+:!ND_C;UVHR>1^6;.9[A'=H]*(>LB%L9G0S-1XA0?O
M^X2GO2(K!LT;A)*<>ONR!=FR9'F\1XG^7 O5J_4N+;:I-!%+ BW5?\H=FL$S
MFG\$?I9FI9VM1N<Q8-MKI3%@UXA=8]W($H$%1LX@(/+47'P=$AZO VG51**D
MC@29 RFH9)D#35E*)V)B'3PX&)2^]!8"0>O2&:TSK@ >\08W9(>C*_"7N[@E
MTR27_O-&Z1#97:5HAVSKCDO42>]YA$#>W4323*II5J>?$H;,MJ[V_@UL:@Y3
M4\'K;JY\FYJ;I;\V=>A?NEW-[[EA;;!UER+4-9.ZQ_2?OVF&#%?Z,*QD2?2A
MRC_-KT'VKPY*R^6F7FU_U#W9^7+)3*;P#^,!;W@U'LZ2YN"[SU"Y'J2W4TD.
MI;U_&-"^28ZGZ=>TP03^<39D+AB+FR7+YT:)1AA8E4XD")G3R:_NHI/.'*<M
MA7\C*[H0>!Y\];!L4"8^N9[K#B&G]'9:TTL:JC5&VEW+:\K?DF3T-R6;@ TA
M'4\>R6SUE/ -70?93.E.>3"KN\LB?[^2D)XZA;(@';AM4]91 ^K7ZTJ"O_*-
MM$[]G[_BE?NAM^ F(].G_%J](0/VQCH#^#(=9 )K8<4#]+IB#XQVCY</MR%?
MCNJ0S#A^2!WYSR_!-(HEZ_Z'VV?;:R"F7^,7.=?-FPE'!'G[9=RO,JDX61;<
M%O-_!$*QB:J*U_<'':;Z<X>FK&>RUOAU:/W:32(04H*\B@V;\5\(>+,(U18;
M5\1YJ-7T.%(A*HWCRE=96^RI# P$"8F6:5V/ MUQ.D_3-@2&R_ U9Q(&]-8J
M*FM,?D0")D-UVBM'^CT%318&S;/L11W-]K2!M;F'%@$$*=2O6%X%KVK$G:Y<
MW4Q3G[/OL2XZ3>TB=^$=#3K\/*B@UG3KB;P1!TO(#&F3K^EJ)=K*QJH:IS=,
MF,G-G EE3;*\4+2/1HZ&U.;B$RK2-VF)G=LV6V7TGV9H"JK@1#V$X8]BHMJ4
M'M?" @ON6JY!.J2H*AY.0[F43<,.N2HVNC:^LBT!E@^VGX)CG E'Q7N3\V%I
M=!YI0K'QE6/II23^90N: LIPK^F*B*_N;P)^#KF7I!<=;?=J!S[LWI,6(_T.
M/5-)]?J377H>![?91G0]CAH1;4VSR79*NL03F>@+T%"Z=F&GB@F\ZO;0F'$#
MI)CLZL61=;D,.A->-7Y?:<0/G#4N#JSWR)-*SG,EJ\J)?W1O'YMIHX_#)K(:
MZ]0R?MK:+"\U)  +S=^<XK[SFI352R3\J7H8-PG^\3L\?E6WDSCZ@<".FYM.
M'E/Q->J%*TA( +6=X<=MRN _P,WW,6/;EU0]&TMF4)O]9)JRLT/@K28$G+?I
MW7%QS'1P1X%B.'U3;W,9ZU)Z').W#]D']\[\V+3E(Y5;PJ=9]Q[,9#7T[W[E
M5U&.C>CQ"^"YV)QT.U&3.94T[#/(:3T<,S-50[!V?F+4/D\UO=O)N*5G7]RJ
M]T@TC_AT3E=27GDIHK\[4K'G]1D$X9PRON=P-PZ""Z>=SC-'J*F6A69JX,':
M&8P8Y(;UB6T<A.40(W@_?'#R*.@)/BK;T]_XV4Q[4%V_15C:T9)'2&"IM$WS
M@(MQ'O)BF;&!:GX^W0>Z_CA08<3''=FJ= 1I5<:OOG=Y06 PCST^Y6%M<>RB
M4>B(M&Q!1Q$2,=IYVH?Y(EH4E!@TKS7$W*8W3%'F+^>; V$I2UNN"TY*N _R
M/*KD7V(^?"<:#N[W^*B^5@@:<_I>4AM_([XNE8E#400NC*(T2 /O?]*I7@;^
MMG]L;]IB]0IN)66B-D(,AES%9.[<KEB?7AGD[EDX#M2V^%)QL@ZIT71R*PW4
MIW7,IE9NC(FG9L73+Q4FT%Y>VU'SI\WVFPV[5P<\UOC]"FG.Q=AG[W)).!J5
M-"#>^.@5X,A)KA%2!,ZM^(QQSLM,3BWK=R-M\7[20X8_>6;IS5%F3R60/<)^
M28I2,[G?QE$S)<;]\/F!DPN#ITJ>Z'V(>[_B)8LCPHDZE9'ONOZW"%<(1VSZ
MY*;-]7)#^XS!EDH:50)U+:VE[;[-6;T4K^,(O!MA9*T)_M6CNK ZO'^A'5^8
MAQ(6NE:H*6BFAUK1S;;O2<W^H4G-MIRU";GHK R(X[90,Z=,=-$8%W0O3*.2
MYQB)PP<&V4!I')U>],[<;2EL*,Z'6I[DN,0ZQ27."-0XFE"4I+W69&S_#=P0
MX3I^LWV*Q%O!B^4-O9G)_[[+4V>Q?7'<^7RIG_4GP]A/;Y.0@T/%5(5[L3+S
MSU,W]^A050T?(3]QF]EKU!,R R'"DT*,6RRO3?0>&@,LD^L787&;_;M'(+.<
MV5%U=*S3BJ/X/T!I/CD>D@8\&;GV0))SA6!CNOO3<&3=BK86W9'@<<5)4E/+
MG0Q=EDJD$$Z;]QII]WQ@T];_)*8\8T4?55FN(&4<; >*?<.GG<]P<S=J ]<X
MM0Z3I4+;>T<T\7,6?VQX"H>N5(1W*R/[VLZ0H [[8C<%WCE20I ;S4S&#Q4)
M[;_5*O%/K:1C)HY?*PZWP/$W[7&W;+&=8Z6(/3D/6XVY$"[@CVK;_>A?JKM&
M#Z[6NB]"(='T5YUFTJ[K=IPG"^J1]RFKL-A\AHLOO\],6Q[)*]*I@V$@1'UC
M8$BCO*B!8Z<KG,6V<&2$,46-R#]77B?U.O8X6KJ9/M(5T/:# [GO90]A#4XP
M9LK%APW\V=9@]8I+Q9%/9;'@$-#[X(H: QV'#*U-1I#$X53VRK)H'/I^Q90F
M3]Y4T?2J-:R,;7I";*UH*>-A[H](/JRZ_SS3ME$;(XJO6B@>^;73QIDDQY!A
M=OVGZ,\VM9IC8'PFST@+UX (#FV$03(-5 CVB3$1+P1>0<M:_U0U="?,R@5K
MOV9A;_O)@S41>C V/OCV7:3A:3/?W%CL6B'\LNDGV/3*A!;D:/*,.@5QV!+3
M\^8A;!HBQ7'-[&:*Y6&,R\5W547<QWN$S$_-#+'8^>ATAV3SR ZN1%)^D485
M%[S1*T03QBO0KDYLO!$P315PAJ!8-(^I*-A9<E.M>18RZ;VU#58*K_X 8"_E
M%VYTS>"V#2DU70*JM$Y_7SQ^ \X3-V\ D<3T5&:OX_M(PR_6'>/OXX69A=[5
M+>[6:I]3-UC2VL02..U_#8M^$R>V'#%E.;CG.7=/]+![=ZQ19,QP:+%J#< O
MNMM8%YS:'SAK +&JW[-IQOCB;#,1MQG_54I9*T7E!9X^ZAJ!]+(Z+@?-[2/.
MX(1S4]R1M)0?-2#2E78N$SD(&=)_-K6;0QF>\E-7-W2^_*%?FD=1CZO3)@BZ
M.=8AFS,-2Q8APR?M@$J,4S)M- 6-NU<&X^9YI7H)*?P)4C+_P0N?=(:;X-[H
MS&1"GT!:&C:YZ?Q>=H!>W,<R9)8G \C?XQ^8ZT359<:T:\ VBDLE.K!MS";(
MX-*'?*3;F)F-RC.>OYP #_5_QVFE#$T03$$I 8F;LQ6A,"\5DD2:1X+_GOHU
MQGD;!M,,'F$C,FPD?#] 0R"HX_NAY7%*S.8='+3;V2F0\MR^V_5\V/7Q4$DQ
M[R]$2@I[H;'\$.9>K<_Z(ZUVX6XY0.KG^"1IMW-R/B'I<S)T^]Y(I=4I80+K
M:G326YBZIP],/!^Q/"5_P$/^/T!>?R+ Q^,XWRNY)%])JB:=M@'NU&H)^'>5
MZ#E8+D'[?NPXH5]:'DT@#ZV&U*GQTK#,#B\8QKN>)O[']W$[4?Q"X/%WU;QR
M6<X-5;DOJ^Z@PV6AHDT -=-((Z1JJG6$R^T\)5D& 9EM/^GWU>^/CN\?/G??
M#;_RCS;\_18,H1K]#K5S%QB6V/$6H(^FMUOZ:'BW83B K5Q8*R?9RWI!QF1#
MWO /P/2]BXU]C*QE#-GPV\4T/=C\"%$/]$,S610IB[@7 06U-.]\J P:2-7=
MH)+Q;1#CN^A2/QD4A8)6EQ,"26=KXS=>6;'TYU1MDN^/K@OC(=[2X7H-5XA7
M@*,VW\Q+_,_.=4]O\>)J$P<SN$6>)XLL6YS@$;&6IY@.UH!N#+O1C#[[+?AO
M9?\ M6@3)1N4Z3#OUB37NY\3BN<NAXB-8W%R7J=W489LM#\'&7_PHR]\ITQ\
MCKE7P(\A^X0^X[J<:2=T'$;-J"14%HHZ;4.=5:OC3M5&3W9OZ]2@)'/G@22,
M[+S] UA_6=%VL:KT5%=*;# QGQ9TPKMCL-$@AI7G^ ? (\^&N\C;P8*1,/2D
M-"A\O;^54/@A7:0CEM#=1E8)^"IYMU9D3HH&)=Y/G'AWK,?DB58C]O"^F7)K
M?-;X)4#P9H<D0%>9<-8>OK!]W021U>]M_AWA0@UF @4?N4VJ\G[13<O4V,D9
MJPBN-,9B.HHX<1MC#9CP#2E8^,@QZ:"H46HXKB(X)>GW'D]JB=H83?5/#6GE
MHK?_0==9!,7!15^^@[N[2^,0@KL'MP!!&G=W=X*[-<'=W=U=&W</[NZ! //-
M?W8S-9NWO%6OWKOG_,[FWN=]#<%E,X\OWQ4.=<,.>SWKF6UY20(0490U7\-)
M;DN$YL>UZ[SOV6"7\&5:%I%>@;B&S=IS<A#8Q M.@G LS]T0*(W\.N*FN6\8
MGMR_OSG*4(\H)(@=_HY=GB.UJ&"?QQ<,FO@UODFFS%PX"_XB- /(UO.0KIX1
M/76D/B$%,G%X^4+QDC"1J]R0!$X7? *.JTQ/F]XOU\0L]?>*5=RT-?+=$V-!
M' 7KF%0X%PFFE^;FAFP1KON"*W\[?W=(W" ])AB^%]5.D*D]N%%J)NJE/0?0
M$$;L. ($XSVV=P+'A>+*[]$SNOV^(E%*JJPIU%2@T^7(7 _Z=-4"Z:]+I'4;
MZ[Y4$[5$P"KDM#4P)MN7</7!L)KRK1,Q8)WF%2<52-A4U!0VFS)SR'#/(K0^
M1JU-!T.L86#-W)DQ<<)VO0XPI.UW\-!,=K"$Y)WYO9;&BW;W8@!Z&\G/;3OE
M\+W&WG*(?-2'H_"5L8+ODH=/'[V+&)NY6_O*GP#XWRX#U\D)\]_[W:9?,U;F
M<0X[U)Z_D>\,0'<$G_3QF)EAZ&G/]Z'V_001)/QL *IT4&$!/=C8!-E';O-/
MC?Y4)KL!7=9F,8:\"Z3!W]T-42R#)*$3IFOVRY6I2\.D=F[\1JE_^?$8'&?7
M2DC'<LGX;>]J3M]/U.)^\RY8Q^?/S%X[J&.=(I!G&L\.JB^OS&*QEAT\0 B;
MA@L)Y,3)+B57;8Z_!*Z_U]FKM7I4-'$,)(!JN:PH,] Y!9.H@?:3I 14 E*'
MTK>N3C,PL2[Q&-PU >XJ8\9G1_5NW.__X+3#)+ 3!UJ^ZW0;9S<56ET,.Q?=
MKE2:G2ES6<YP%'O$M&)_6VXV;1>I6K'R/&>L?.)/RZ>M1LVPO3[3L!;C",1(
MZ!;M4QLC+1WB[26&N82AD)#^!)C!]Z=S\Q"K5 L2K.4/11C0P>+C@F>9Q)?2
MC/8(#D7U92BLQ/]G?H;$MK@8_U.](S=_&%&*6('W8L5L(>=O*N]++#&8'[(T
M,CE6$ZQRV"18XR)R#X6"(?AVSB+7OOG7K4UQ*A"'LLOF2E*.MN'E2_QI'Q=
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M)"Q4C,*$AE:.@HV4HW65BP97IE5N RBD,G;3QB5'P!/(,JTQMJ;9GP EPD_
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MQH?!$.IU%.]ALY\ED-KJV/U*,^%CYK_@.6UZL7NKS#]PKBH8/:GJ]1W7UD:
MQZ%'J>1XLNE.3.U+6)TMP>Y]^L=BN7<>B5=B[55E<2<E,C23* 8[@Q66O/W!
M6^)(U9922%^7<U%JQ_9>I0-MG4 *6>2';;G! VS(@'1"1[[@9'*87<V1B5U5
M I@R,Y8Y<ZK@Q6TO-/467-)WBTP:Y8 3M]3:W/#75J=P+IZZ\=2HU2,[]+[L
M9_-7.A]CGJ&_&F!@0=O?EB9.=H+'1B&SRHOCEOF D-(90XL&[HE#BC&-2E/<
M[#S(E =>I4.!EPF>XU-=I69QS(C9>-.-\F%5F"X13 $FZ!#YBL#'ZN?ZV,#/
MQT/% R3@C>[D>BO<71(]LS\#K=EWBD_ X=<8AY/XHC0(QGB40Z/3525GZTK<
MFEU,IH/YH?O5W/!PNP>W#29L)S%X)9QWK#6TN%(?^>71TG#PI5 "Z^^_T986
M]AEP942ODC48R=+$)!6UX=P\3H)%XT,58G+;S-+%("[X&#8T9)JXDQL&WM[,
M&"O6',<S1ITJ,Y.5RA.B)*:OP>Q_R^1.?KK'RO+CV5:((+G.J-2N0/5(\G,-
M$Q)?>-@/WR>'5H0S7, X5FPY(T.UMV6)1S=O:CNY^7:I=:ZZR0.,HI>2H-2T
M-G1)SWHLC2)8!QW:9N5:*HIDVFY56VHGK((PN:8VXMK)W*@YFE?&"6D+L1I%
M$F'2F9K.5",XZGZ*Z7HA9&,B%,5#?H3*-J4H05?C-S3M-G;0Q\W)UC-4U_K
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M#,=[7',5<R'TT>P">;@6(.?P?N)VGQBK9E<*HSO1VCJ7U:GA,T7(1ZH/D]0
MD'L4_8*Z]W6,Q&U,X/YY8/.UCS^NN3IN$9G,M>Y;]CTL+C^&07[I,]P/J@-M
M%]/Q>YS\Z^ F/39I'!OH2!,1)@ZYQC#$:WK#,C%C5=4[C^M%>:_B]N-6H3;
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M\PZXWJ;"(]LV$T[SF3^=C=R:[( H7OJ%Q0HS>@BD1G;-OU.D1WA#^%/86CB
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M@T+)5;%Q#1O5#\U-9U%30;#JOAF/6\AUNS'SA.VSA&B+EX13]5 9]2X>K'4
M-G2,#&O3U_0O[+)=F687O>A=0K=T7'NL$7QM#2"%I\OBSBZV+1\;:F-;.P7:
M+=\LK78VA["*9%:31J_8[E;N?,C!<:?07V)BE=ME^GX2Q^JL'A>!UC-#QY_K
MW=9:[?4^T82)@7A#K:S5%G4M&INQS!P+E=X?RFLV0%FH:*S(>0MS]V1BJ2Y0
MAJ9]G.9(=M"<EWV<9!!O'_</$@1,-]HH/*N[_IJTXS?UK:2R6VD2HZ1"5?B1
MN\R6CF+2]]VG@3X'933'=L2&EZKL6H+JR].[%+)-9._?:[A;+Y,CXAOJXYM1
M?R)'/7=NGTQM:'4PI:/+W2I(Q)(6,^&S)[>&+*Y$D^W4XZV&_1E/*!,&V35Y
M*W$-(V3U:>/M_9*</1>EL'ALV(> 3WD-G09UV6&WES;3@W,+K,2%G?7%VWMI
MG$!Z7-XE*I5O*TZ:8E^/6+;;N'["I0E;C4]JZ;3;<M,K))&D>J '"Q-NOJ?;
M7J(V=S1@7ZZ4=KCH6+AFE3"O3MK[/:HY[P+##"V7AD#Q+MO;(-(N1_7ZAZXU
M]G()DF3VH.:()9ZP V7,%3;PJ&@ZJPBQ)G4<;A6S&]L+R.D9-RFRJ!G;Q&AH
MI>NKK. 6LM847TIK.O'7Q'.KJK'S0M.0)X$-U#^'2Z:7XT)1C^@+/'R7.7TM
M)-%%ZP1XPW@H]7A*4:TK&C'&@#6;SJ2SJ]+5SNV>M9O8@AD[5I3ZZA9-AZM_
MIC^,;]L5!YL\R-;RF]W]EZ>U@\Y$'YU[IF+'-*R;+RQ,XD:("6DE</%.M-C8
M@KG"?>/.T*49VJI0$GNCZJ[-AZWY%/RE;%,T:>1X0L: U4>K@4,--+1LFW5U
M(%LK7S>G4=&.Y2ND8SS-Y,11\_%!!,WX<FLB=H@-^RHU+^\.G6C.VK(Q"!L2
MI#ZIE)X"&!40FXA>W]I0'KA&\] ?W,(I^02@V??:;ZP*2C*PXQ\-F3NN/@Y<
MQ,1FMKW5VI"Q9WJ8'I;4*@O'2O/@"E<L&'3&^C19# X?/-,&$&:.RN7\B<'8
M:K<WJX4"E=L/ZDQJQA'F8RI>K-SCJLI:)G)QL%YC(=@BE&@(E<PL_S6 [7C=
M;T*6.ZKVX<3K-/N%^UH'<RZ'<('+'Q=Q\0D(B&8BBOW1S(/_Z#9-% H#<]Z3
M,-C3Z/E&=!U.QN99W.*K'739D9E)7'?3>+E5:CTLMV;KZ==K_.$_LI</HFU@
MV7'ZX)SM4XQ/^034+4YLMK,FVD^J5ZE-3Y;LKOL8T#1MTYN-@&:TWR3H<)PA
M&N[R0<TPHZL)1>;$C78"/&#7X.F4IA_EGH46<0:*Y!_D C!3?N;GE?+(HB@&
M*V*L_#;Y3@<W4<=N.#N\0V8./1TGNNK=P_^"_T'_#CV X#A==V78# MJ# ]&
MWCHXKN2GZ[:PM2PC37PW+66)^:KZ<7&+39<Z,,5"7W F=Z\?MF3614Z#@J^*
MS*&(XU9DGUIGVYU=#"HMLU[5+6YB66 ?=6[2RD*U3L4T-P>,)7"J$B#4S(OK
M<TI9X;"T14)([[DDFK,,0ZV0A3US"7-P[WL7H:OC=0Y\+?P\A(YB-W5W5B.X
MTZH*:D-CF^9QL7S]<7.^]YP<YS'';B04=W@>'W2YHJ%#E^6^A'5W;!*$JP#X
M+%=Z277=7$;I.EU63L=/5>[F/3)OE=)FXK15R8W$&_$J<KGAPIE]L&RU(]5@
M3(SJ5_M^ =RT]B9<P1R64 N9-7%>1M,W#E46, ,/+92@A!!S!F")@=C6#"F"
MEV (:7*$VMW.C<;B#P4C,^8*(MX0_]X3DD=>@..D,A!*>A(#P?QP[#&.;[MB
M]_?OHR52[KQ#2:]%N@G2G=?0J.3))+(1QP 65<'V-7K5''G8OF12NYIC^8K3
MIGX,4 AN9MDS6ICJL,S1M^_@!+X/&LD$-+#TCQV7RB2R,D_2='(($D' NJ,J
MA3+YP/1<S@Y9TOB^5DK6V62H!52*+!B-%':6Z?(3,+UA51R&'Y=@B)IP8OT2
M_LV7#P5W>HSU;ZAHPI$2ODTG&RR6+"@Y-O\:FQ$KY.DJ/_)L!XRH+Q<XPPP0
MBN3G5( UF0C$1NL1\MO+<P4+Q-5 8X]VCD/G<,6>/G22?@*J5"](=KO]G4)J
MD=2>S-A'X/1H[&?=E[@9BA%HY]H8J=8V][CL;Z4$30$]5/'03]R3$:9:NZZ_
MOQW.R 5>DQ61&K53%Y&EO0C-P#P)6G': <?F<"\*RR,O^$D><'?("OB+GGW0
M1 _B]:P[SR3/8:>+'9I\2,SJU8,:O=KH52JF=H$"4'S%M>-(L\_QF#)=AX:A
M>N_TT3%E,=/M^.RA+2Y\1._4.^;WH\#R9O,2&]V,6@6>$,C%$ZP-#PM0=902
M)84FB9H_7XKQG>T_/KOR4HY(0_85MK)EGD4,UW,.D<=,(3!F+I:6_QZI(>RU
M&]YUD'CJ*)R["9'-JWHJ@I.25"FM/?GKHI4IFYXU-8NU'FWX9F@2Z0MM7-8E
M!*W*O8#+T(D/$V175!<:5'0D3'- 8'9/P)<\^= :MS_!/!J'JEN61Q&?(^]6
M5F9*_2M/AM\'#+?5Q BME"+'7L!$(&A&&]\K[,=A./'/:6'>=^?7G=:#H\^7
M2K2P6OX 4)4@>.<"P<$MQWJD;>9O4FR7\\Q,V5+QQ'8>G%9_<M24FHV\];+L
M<+0SJ#T5W049SN6\5<@"W<Y"DI8[&>' :6VK74/H!1BN\J"O6;<\6?_PTU,O
M/*V^39!</X2$/;B?NC0OM_RYC2[6';"W15.,!MNB5M'?.:J#]PG(V%$@Q-8G
MJV'^P?P)P,3LB1SA<FTLBA*[DX+HH[051"4(SM3@3[39BC<X1_WS@F,? HR(
MR[LEG^W\VG0_E 5 ;R28BC'$P-$3*-&<PCR$[+"*"KI?SO3_ M[>G$+<""7/
MN/BG50B_UM@SD2PQ(>U9BMP<=!@/_W"PD+3G=5P]S[,L>[C*;OH$5))('IXE
M#$0?;,;^8H"_TE?JW55*-=]Y='7L)_Q"D5-.QEHJ>SSK4O0)Z)%Y%8E\392F
M+JW=^DKR2[HCDN+MS=>3[RDY;,R[E;.9Q#K1NO\GL((M@^04$[/W!WC1<357
M#7[6\.R^BJ&>G8ROOIZPHFG7]NNY%CDGWM*@&*<AFPN%TRTI38(C[Y46F0"&
M&$R.&'3&&D(.(>(7&'..T?Y?QGP'CAAQ/O=CAH5M=!HZ\Q<8G5N0R4#,\J7*
ME=I7G3QF+ZH$6_[AN'2]#0P(3J:E95%^.2.S:N'(^F!3T2FP-S#0Q-I\9U[)
M"YWD2!C]'P7'JR^"%0%Y*8D'O/KP6-NFARPE^M+,:[OZ_AE20>*_#Q.=_/N9
M9?]X(BO2"QZ53J=M>[.S: CP?#*5#8F6*^+JA%X *<,/\;U4N[U>5*;8GI(?
M#L@00N8>8R',\B4,Q#GIX[VJS<G.(VD;I^YXPZD$L2N?\>3L*Y/QS3C@?PR:
M-#.F%@VOBI.J<\:S7:P]5B]RD"&5$&>6UHH8$U+U @>5%OWB!YP9;W5SY7_'
MSQR4,Y!E>$5;KDM]=ZF0=UT^FX*M,*PP7D4/J^3'Z^"=/4J^39B@Y:[!JK>U
M.0+,[9@P=@<R314Z#9(\W\Q('9$7H-BSE,3CPT90@ATLX(:]?,?FM,>2/M;=
M#H'FY(-473:Q+7<_&4Q:F0EUA<4?8Z*V*N.:W2U-;6W#1E4-)-6H&Q@!U"&X
MEBM5SA/J3:Z_QSJL^=V2BFM#_<C__<+!M1H"&36,SU7QT$H U=7GZ/=AFN6>
M@=$D]L>>0U,IH>F%>L2-(C0ETW0^4XUYG4A:N!7'!\&82=7VV:"01)EEIBI5
M@96.VZ)H<]/[RCPI:;2K/"96EEL=U 8LO?*,;7 F<OC,'M4&(3/+Y)Q!R_W"
M_G84P@D7/',+D\93Q!UFO FXJQX'RVV4QN.ILL8UQV!>]7Z8732113/YCJNR
MHAB-@[*2'%]8(DC]B_ ";G9>2)9L;&M_Z+E@VVH,)O>" V>ND(-@]S@/K9P:
M57V.@Z6]B22I.R!#O*RB+&KZL -373,'5_2R=@$=JL4>MHM]8\*:G\NM789=
M*ZU30NY@R:9J7J I2?#'4.+?!@Z97;'$],[3R'-RS1-W1G)%__5*>,5<MZ,5
M3H360<U\3/^SHB3)O%BB)-,_"CM)/)\ !WIG$UKEM,,,KP!2GJE(NXM+"")=
MZJ4$_;P8G]0](*P!IH90BTH"&$<X+D7YRT&L?X^,WXB-]QKG6UU7"OU.:;^)
M,21C1\MSISFY*=79!OKMZ6JE&!O!^-X$!!713A+$(3C2;6?A'UW?W=?BHT*R
M9J+OW8Q].!\HVT[=W(.*V,V!6HD,U3B-!HT9L<- K$5'8W!>Q]6FD ZKOUXA
MS:FY/7Q6/XP,=+L8)+D>NGU\A) P1^E3 _T8S<_>U]LP*UMO_NK,.%^*U=5O
MH%L>VU\)^C-Y;6YJ;8"$VIS^$[5II&3WE,?&E)R&@78^AWXU4CBNXM^:*9>5
MZNKY85?_WFV?,*5=:]FQ'_28.G_LRM3F 5;9*..ES8=\#9JZFC>NVOJ5T\6*
M3P/=PJ&'F?G-43FWF2^/#QC>."(Q1@^TP!HU%1<7B>7BN*^_'%QER@B>G6/\
MB8YP65B2C>8A0#TFQCK2M/M-#!F*AZ2--^L)K^-S#NE8SL*SPL?]OLB ;RD=
MK;(/?U[C4-D-[@B:1O^(5(6PX\ND>1V-L)$_K!)(G^\I/D<&0'"<[50?_GG]
M]U;'%3J5NY\ (57Q=G@%Z4:\TD4R"!__M-?QE?8&XB$^^B[W4(;<L@7.M-TM
M\YQD(V'>FX4L+4K%-E@94Q.:=2:^I#J9>G?CN/AK3/(5F=MF_E&PWSBQ$UOI
M'[XXJI:02,3^;[*Q5.,--D6)9[3&=%8-*M$%ZU95+DL5;HG3JW1&GP"6PESV
MZ]C\5%F>3>7)EY[YXZ>>NRN%4?28TY:&"__)_7F9PT\ !S&-OR+73,FK0U?2
M>3;5HAT5V*YE7I%FF][]MR<'6:)\[,,["+A-'Q$S[A9]G?A@4].9K,]2TD87
MPM<T.OVM,_KK@B1!IPF((T:L*5.Q:&,*;5\2;T.VGH_,2?0== ]L[-=*D9TR
M7-!CP(W]2J-7I"(JY;;")H,2%HKC=$"^C!%;&*2;2%D(VU1@\LW:":O_);&C
MD]GGXF0D Y%,O/[-.$LFTR9^Q!91D/B4#"&5V)8W!(M:G&+HQWD,P[+?JC&S
MDI1JDZ/I7]W^DD  (K/V.0YO#-4]8=*1N @5;08?6T\)3XX:,&+5?;+3ABV3
M#<Y1=H6\QDZWO%<1HKQR_N%MXV+/YW#B/& ]Y5J]O#OD9.7"B/@P_L.JZ\WD
MGXII(H(/X?[?HFBZ'-'F:O<-8TK8]KE)'T9YV,LS?X/[)3%YOS^U82W4*A6A
MBM^),)3<)S"I5W2S#1U=2KY?QSK5S$^J-(S??AC$"<\B$PQ(?@)<J4?C'^[F
M!)^79GE)K!4/K%W_9Z,(88!\Z7I<%6?CDDT+[<_4W(/%_6T:W<6)ZGCD*;7P
MI7DE(J\DWH$1!< @S4:<.0QGXBWW_P)J0)6_(YM]=LF"Y;JI9CK6K%>.Y#[-
M;CAFDB2U7\Q)?(L*C*)H?,CCD\N0,G6BMQR!JU)!!,T3RPQ2O!)YL#21J[0R
M]+)YD18$QOT,R]2\-TL1SP=:6/KF?_M/PS_S#L/_ +;U\[=X$?\ I;/?_#JW
M_P!R=<Z\2?\ S+&?^]3?^$-:XO<O_P"S;Z;/_E[V;_W#1?.D[+_]=?$S_P"(
M8/\ ^VOZU+<'_H#:'_NF0_\ %K:]+'J\K6//4+UY2NEP+=.W]<N3JVREH) >
MM9K3^:(13E[ $J.44T$T6648L0F*2 B"22&:/>/?;7/S)NN22'>.Y)H9'BEB
MW+F)(I8V9)(Y$REEDDC=2&1T8!E92&5@"""-=@PJ))@<3'(JNCXB@CHZAD=&
MIQ*RLK AE8$AE((()!'&GW7Z^BJ:)/5ZNF5UVMUY8$E0H$@ JM,E4+1XPURM
M6M"BA# 7@BPQ#"""PQ0#P1Z11::Z:XQC7YYY[4\UFS-+8L6)'FGGF=I9II9&
M+R2RR.2[R.Q+.[$LS$DDDZ]2...&-(HD2**)%CCCC4)'&B *J(B@*JJH 55
M    XUE_+6J]'C31XTT>--'C349K5+I],P]Q4*K7:MBT6)G;[+BO)5R;%@M;
MK,67%F=?SAA_ZC]KF"#+%N;\YYGPQ?L$2?'I]LFS<MW/(]KM6+/LU>.I7]HF
MDF\BK#SY-:'S&;RH(NIO+B3IC3J/2HY.K44$$'F>1#%#YTKSR^5&L?FS2<=<
MLG2!UR/P.IVY9N!R3KS%^I'_ /6(?_\ G9[4_P#_ !>L^?4F[O\ \&H?_@6T
M_P#[C#ZXU@__ %_E_P#B6;_\._KZ^E'_ /?Y<O\ _4^L_P#N)3Y'BW_^']/_
M -\Q/_V\VFQ__6>Q_P"[W?\ Q8]>G(JET\ZUJ+X;5:Z9=Z^H;5]#<"4JZ>SI
M43Z< EVF5/91]F8"MN0K6SL@12HAC901=R(Y-H(\Z_+BW+:59:*6K"4K$L4\
M]19I%K330!UAEE@#".22)9)!&[*60.P4CDZ[*8(&F2RT,36(T>*.<QJ9HXY"
MIDC20CK5'*(64$!BH)!X&I-YC:NZ/&FCQIH\::C-US+BFVW,,FT,V*R^S%-K
MG.-HI<*B_CDUSC.,XVCV^VV,XSC.,X^_W\\'=)XVQN,_+ Y<^O'IC[!]>W'W
M\]M95'O=IC_^JK_^*FOY^'L7T3:X=QY>THR8<])Q7EOK+SE69J$4*,>;3*14
M]92+01M%#(&2PMY#=;G8[]<F,4<<+/VF%SC'U9X>X/$3^!7B#C]W98X2QXO6
M?&3*Y:K7EK/?K16X<G@,Y8VS7+-]KI%C,5_B""2FEFK)[:LL$DU!X)Y>";CO
MV?\ &V!L8FK[9%M2OLZG5D=)%AE: 5;M1,B_ ]E9[5DT768QRKY/2X28.BQ6
MR]8Y2MOU4L%&36S?6K*7"[=RS_0@)_H0/2C*D2L4YFDTF6K%N@HC:(V=6>WP
MP;1:Y68C#D\U+;'@/XPY[P:W-L[Q#S.SZN1WKE,/ELOA,;9R-_%W*M[#)1WK
M5M9>*A6L8S(96:8V</+3BW%0PMS#XJXWVM'8N5=9^2WKM2ENS'9; U,K)!B*
MUNK6N6(J\%B.6&XT^'DBJ--(EB"LB".VLK8^>W%:M1#V4QPR:F?JH92N>-_8
MS7I#%PL1V/U#Z4)560*_&"F;2Y9J8U0V_1(Q)\L?[IT9,N@1\6HKI3IK_6E#
M#+U)V'QXN9#?^!\';&UDK6MPX#]H[;]'(;<CS$+XTY_:<.ZER^(S%V.K)(<9
M&E">Z7L8Z&X^&GKY0XN*P\%9<78L5;!7=WIE&EBH7_#S)2U\@:CBP:>4;&>Q
MV:L+R*OM#-,D73'8:);<;UA9:-7D,3J'= EU%]OZ4K3R3F^PT:(A40UB&ERH
MKU4Z#)TEU'O)C>7$+N81:!F+:''P29"*S@S4B($<UD?!K<.'W?\ LC;GR.6Q
MZX7P7V5E?#O>*8EYHY,AN#=&.\.<)MF[CEGJ+*V!7<>UGI6F\VKD(Z>;B@DJ
MRXVYFFJT5=WT;&)\5,97JS&WO'*U<YBFM!&6O1QEK.WLA#.4E*"\:.066(!7
M@>6HSB5;$--9L!5;-4*OSEU7^E([/*Z#BZW5$"$.&(#]:UL*ZG$3FVC5A(,2
MMQ2K$P*8$0PCDL&.L\R68<:+3)$=>ZME;PW?XW8/=?AGG-K_ .%+U;P:WING
M/SWGL6)]N8O.;PL6*NSYZ%/)T\U6WUB\7@JDT=F>CC:=7%_:U'(-=NQ\4XS+
MXG%;/NXS<=/)?:<#[NQ&,HI"(T3(6:6+CCERR3RUY:CX6U9N2J8TFL326#5F
M@$,3<K^VM8KK5JZ<I$80:\_KB6OO@]QM)QM=RBV$6C^$\;.,P@R9C5*-ASAH
M-X)\@8_;8EFDS[=&V!@9?#3?.[\7G\AB+4GBUO'<F[=KY".Y+4MNE*CB9Y=J
M3XJXI$^3A6;.[@2UC;MJ.S57*GV##T,=3J)K^<NKN'"XJS2@M1KM?%8_%Y*!
MHEDB#3SVD7)QV8CRE=RE*B8K$4;1RFL/.M33S2FV'N#U'F#7IO'2J40]<"5O
MG_KR]M>I$(D0_P#1%XMRH<U0NECW&T,E7")X56DFX@L(^!]8,$E;9GFUX%^S
M]X6;TGVCXT//9QU:INS$;I\.MI7K]JQ:S$&7P^0W;AMS6<K&E$"EBJN_KFX!
M36&>[;OTX$N2PQCV=[.^;^W-AER^T!$EF5\7-A\[E888XXZK5K-/$V:$55C-
M^_LR86"CYK-'#%!(QA5V_>"-=]+Z7-U#VIMO;VB.5=3KQ9##C/YX6X\(%,<T
MO\9!/SBBR+):1*!-DTT&.4C<US&1^,ID<_[4VS8C9]K _LI4O"NIF:$WB5MW
M&*V.I6;E:6*3Q#P'B7YF,2, 5+9V2WB33JX6CGK-2G83;QKWK\53(B>O'YE[
M+QY#Q/GW1+4G3;^1M'SYHXG1EP-W;W38)Y$L7VP-O2R6YJ4<DR&^'AA:6 I(
MT/?]2YW+:[6RJZJSK1++0@*M(Z/U7$L,MRT$B&VFS)-#<#X3,A32HU@<#F(H
M39<H8$;SR[%@Y];$>"'B2-E>'.(W!D]JWK&Q_$-MZR;9KWLHF,EJ8S.T=T[7
MJT=SC#16HLKC<_BXK5RQ<VW<JV:.7S.&B:-5IY5<.WO';WVQGK6/K9."/,8
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MJNA[$</P?4:V5>@@=+KC7JX1N5""\N[B4OI53V$P!,'RNNI4I$'^,R2"CC'
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ML:;$O\H@CY_GCBCC(!DE(FF_#6&6*4R:/?\ WL6"/VM31MY9 PI"& [B#['
M--?"6)K$Y$9LMU1DP$PAT5>(%B/KX/\ N/QT)8PGPRRV*>/7&\ Y'VU@@V_/
M9'JUP+$MT::LXJ]H;[IN$-O7ZZ^R5G J]>H7-('#0R/>6/<)<,(U::S3Z9CU
MTQ^((XHVD9&[297+%J)O;*#Y\??Q_P M5AS\N?Z_K^6KH5%E9&Z,-A:JY!5&
MY.F))4<+F-YN'KG7'VT)-A"#'^?.WY9S%!^QIII^&-I\R?GII0>/@>?Y<:N#
MDCN.-2;R-3H\::/&FCQIK1E]<S_]I^&?^8=A_P#;>OG=_ C_ -+9[_X=6_\
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M&2385["]-05A$YAXKT&B=9RX8J &$EL(85NS5X-\2 A9RW.K- $)$$ >"?R
M<Z39 B6QZ;,@H10))B=>RN9:B#'$]9<G!)5>2M<G7R_999XUDG]H$J*6Z)0Y
MZG'O$NW*]73\];[WVNW<?8Q^V+VV;FX:,N(>[CLU;&,@IX>Y=I4[5J5'GI1P
M^5';B-4>T>4G6AD3R8Y"-BOIA2>='5PNLEFTKH9%9KZ18;+).O<E"L\L6;)I
MHM#*SLR 3PR%+AOV-PPX"]Q0L8UR4.3I';SV(QV1L-:OXNM,\ZB,O9K)(S01
MN)(HW=E(;ID4R*O)Z6[^G3KN>"S64QE=*V.R]J!(&,P6K:DC5+$L;12R(J,.
MGJA81,W ZE[?,:V/:::1::1QZZZ1QZZZ1Z:XQKKIIIC&NNNNN/\ 3&NNN,8Q
MC'^F,8^V/+:J%4*H"JH"J!V  '  'P '8:AF9V9F)9F)9F)Y)8GDDGXDD\DZ
M^O)U&L6W!2&!SY>AJR@(HMY"<MQQ)PXX=-<[223Y,TVATBTUQG;?:3[::ZXS
MG;.,??Q]WKJ#Q\>./KJA75+MRQG@BO<SHR(G??\ :AGN< DJ2N0YFQH*?E"*
MM*3:68C70:" @[><9 /C4/4H\B*6"'>ZH;XG^7_7TU;8KZ #[_\ IZZ0&@LN
ML,4.6##.@7P[Z9SM]BY98]=R/FGT&4[L!CX=?P$Q^@&:4L3XAT5C,%68&QE>
MJ-<.V#XA(IM)!?VM=8(M1OT\8WEVCBTQ!%'N$<0%%&7/F M4.#"/%\<.V*20
M<UE$SLY[_G^.FN[O)-%C[ZP_<:723&=-#<YEDBFWAT&DT-(&' ^ HC2;4G[D
M&!_-J"$QA)<RBRZ--<,AVT8V2)X#HY8I-Y<"8@_*;&V-]X6&=@Q92=B"(!]!
MRBMY==2PU\H6I,[8204&%IK@RR'AQH1,:/#-O'%^.Y.^P4@V8Q-2U<N(IY R
M5LFH?^@LPA\.@&F!M #$&WZJF)V^7U_G\]-=W&NN_P!QI-L8AS'-G&N,:YVW
M&CS\DT/X[0C;SQ!D_$9O%*LAB%EE#-F"1D;!.!VFL7 U'<DC0A;ZY#%(QK,R
MA%@+@BSKMH,?,J5RG+]GD^\7ZVS"?8D1-KKL+ARR;2;J,:--73Y9<O7ZBP9(
M!/<8L3**'1K9+&C9,'A6V(\YT!(.4 G@IQX(8M=XD@\@0X@7Z4F1_AE%FEML
M'/W?0ZN*5'W_ #(_ZZM)7+17K>LB<UAP"[5S;9TT-7SZSP_GK]OSCVSC[;1R
MZ??&-XI-=9--OOKOKC;&<8MD$>NJP0?36>\:G1XTT>--'C36F/ZS?.^@]$YC
MQ@+G]%N-Z,77Q\4P$IU8=V<D :6OZQ1$&0) 3I18))?^5'-/II'O)_U-=L[?
MZ>=J\%<ECL;E,V^1OTJ"24*ZQO=M055D86"2J-/(@=@.Y"DD#N>VN>^(-2U;
MIXY:M:Q99+,I=:\,DQ4&( %A&K%03V!/ )U0'VVXAVE]ZF?3X0H^0]0<O*G1
M.MBVE,IH%K8M:T2>^I<H([]<&IF,33FQ#D2"1,81I"8X)MX==]8M\Z]"VCG,
M)7W?XB6)\QBX(+=[#-4GFR%2.&TL=>\)&KR/,J3*A90YC9@I90W!(UJ^=QN0
MEP>UHHJ%V26"K>6>..K.[PEI:Y42HJ%HRP4E0X!/!X]#K=+0O5>E]:XSZ!V#
MJ8-P477U=JG*>B499"7)7IZ[T@+DHE-/VLJ<Q?N09,&H;/D92-KII -N<5O,
M)HR&$($^<=U2Q3[HW)/!)'-#-GLQ+#-$ZR12Q29"P\<D<B$H\;H0R.I*LI#*
M2"#KK&$62+#8J-U:.1,70CDC=2KHRU80Z.K ,K*PX92 P((/!TYQ/5CE:GV(
M:>SE=_RZJ]&LM'JO/KN!6+@Z247H"*@RN]^?RW2E!SZ)7#6D161\#7F6(1YH
MEC*58=@\& * ;P=>GSVX^O/Z.K'>-1H\::/&FCQIH\::/&FO-]ZP\U[JK^JH
M[MEAH'65W.]^O>R1L-E<U6X"4O9:S4=-C1%QN3@(T>P+"0L#11/J3D<O<D/4
M/>3::'&W>-P8CPYA\.8[V,QFRHMTG%X&1[E&E@DSYMS38X9)VL5XQD39E1[0
MNL7\UU>?SR0TG/+\5+N([PD2S)FCB_;LJ L[WC0\D);]F 60^S^6&$7D #I!
M$?E]PNOWZ:7,^Y5CW:M+N^<^ZQ7JEM6>F1!M[=5+>IKF2"7BW*^,8]R .LS,
M0/B7(>D4OYRPXDS!C;3&WD>(6)\.H-JU[FWL9LJ'.M;HM+;PU+!1Y9A+#-[6
MTD]*,7")&;_,%FX=F_>\DZ;3DW$<[,F0DS1H^1:"I=:][)R)8_*"K.?)Y '[
ML =@/=]->D#SA&NH:/&FCQIH\::/&FCQIK^>!]062OM?;7N-RK+'#%/>>J]5
M>A2:??,/P@=0N57TG#DSG/S F9KVQ(TOW_';\Y,18_7Q#G/UO^R_N1\YL"YC
M4J5XL?MS+5$PUVK*DD62P^\=L;=\3,78E5#TQ6EQ^^*JRQ+Z0FLTI-EK 7Y]
M\3J"5=QFT)7>7(QV6LQ2*0T%K%93(;>L(I/=HS/AY"K'_6) G[L1Z<5A]36%
M*Y4^N7Z\\EIXMUWC%0+VVWVD_,"S\XZ-TQA-#-!II'J,;=@QTPGXQ[[P#Q";
M;DRR;YWD^8L%X\Y3=^X-XPYWRL=M#?FU=TU;-"%$\BOE]R;SE\/]O26HIWED
MFGQ7A?L'[?MRF:*M;N9VS%'5@C>%(^AWMB08G'8Z6GU3Y7!9;$]$S,>N2M3P
MQSM[RF1554L[CS(I1+T-)%#2C9I9&5BU05% !#[655U#W!:NO:6&WI6I0^P\
M[I;5*@RZ&G!P-)B"2)I8A%8J<>':**71DPBUR+KOC]?SZ1SGBGDLI^SA5WIG
M]OQ4,SNR3;/A_N/$T[GGT-OY?>N_L7X3;@R:7@MA9\+MF]F+V<>;KDCGQ>.;
MFV$<VQSNEMJO7W_+B*5]IJF,7(YS'VY8O+GO5</A+.YZ%<PDQE+>1AJ0TU3A
M62S8'$74!%JP'>O743DJ3F]2)CPK9L_7FD]BM3+7$V<-'#W_ ([61)+/B?;.
M@_SJ]Z74]=8](M<2ZB1_'DR?:7?FVP?&O*;DS_\ C+B3+1[@\2\KLS:V(F=
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MAA1K"3LO6GO7&PVW<?>Q.5R]!,Y31XLQ:J07K5.3S)(_*$33P-(T<T;P5Y9
ML1#A0K(2SL4TYJSR)]>E>\%7LW^1 KG&C?J?,A)CTNCH)3@)70U>($N*Q7XU
MZ"'3+'6,\IA(U<3$8+-FD.VT7PD\+]S>'V<WQN/=^[,-NK.;U.T#E<C@=J0;
M2M7LKM7;XPF0RN:>ME<I!?GR5@M+4J0)5JXJM''!7ZUD?I]+<^>I9NMBJ.,Q
MDV.JXE<C[/'>O/DUB@R-TVX:]-9*]=JZ0( LDK&22P[%F"]*DHNN]<_R"[U!
M*F/JW,5@M4MJ2YRNJTYBYY$RY8O%"2**FQ7 QZP-6T333]"N:$Z#9W4[C[L!
M]V2F%CE#Q(AS_B'MK [6R\&0PGM.YZNY8I\=DH\E8R-&D7CK5&M4(VC2A:"3
MW,C(Z8ZQ#*(*]F>P/+/2Y/"RUMSPSW?N3>F$M4=Q/4VC?VI9ARV*FQ4&,R>0
M"3W<C[+DYO.DR5,O!2QD:2Y2M/"UFU4@JMYPL=SNGHK%4*H+R;(]LO 5L<$6
M$IC:A5P5C96D8B/.F4>T4FE+8:?IC"U^8O!8K,?4X8IB/N9'+'V"W/-'+^]A
M;R7\M/< ZH(DY_>!G*BPJN09D4JZJ2T:NR>6_":\4;1*8'5Y59W;E^!([]BO
M2.?*8JO[MF!5N.EF ;J23\ZY6UTY-[9]@Z K7TPIUOMR>&N&"2-,D3T:UIU[
M/8MH$O)C+RYL(0U;6-5FI(RMA&8<02-E?B4?+NX^#V_$4JYJ9*2>M#>,T1A;
MI\U&G2"0R$=,M3RO,>)R"'1 HZN.<2EAXLLV1GEQ5?VN>05/+L5X&DG%&6&P
MC-+*@#IYE>*2N_41')$DB%7C0B0\/XSTZ;V'YK9$G+K5RY+1)FLMTL#Y%I5@
MF*F<'876M@:1[_#9,&;YW%Q(!DP,?0C]O6?XH<2>8=BQ"M.='L1SM* (HT?S
M"'Y!\P\_P<>OO<'MQQR=9L,$K7('C@>!8NHRNR",%2".@#T?GN.5YXZN?AK<
MAYJLO550&UH4!1I*"VUQ*.Y.<7=I<2T>'(H[Q2U(@986=[?B$@CNKL$=@DMQ
M0J!(<'GWV3R9>3//?M;'^3@?9_;:>Z]U[+030<4_&U9^H7B?3/_>JVLHW[7M
MZ>(W>W5JFY\HHFDF><\SU$[%)']5U!EW@.>)4C!*K5M/S$;U3"M7$O ",-'2
MRXMX 7R#7<Z2=.N:Q13=5S07\NW_.I\L+I:0O%"CHG]R+J:1=_:9T[P96(72
MM&'JGT]\3TOL8#E'<\"Y)"O]\PB%(Y&S3W'5)B:N]\>LC)S,9&JU5,<G  35
MW^>A5877W"VQ[47"0QF]27+904W%.\Z$T95Q@R4.<+,\ZN$70+-H:7Z766X^
MYAWBB:(U)X9N'5+G&(.SQ/]3/(ELHC*1H"'I#UY%:_YJH-7\VH')/WGK.;2>
M!WNI(G$D3OJ\:Y!"\YRF0?#2&,N)!\V/;PUS47@,RNPM]/I>O^.2KAE'"L]H
M!N!4K?$337GDD]17)$</=M"\7W-G+X! ^2[O-+%^/+]5I_V/=$.72@QDGXLT
MG25#E6*L5FB+IB4NN>O5NU 7G%95^1.U1T:D]TI:!%<HK[-V!U;".']:.*E?
M('($)STS?K?WBY/M.M-EB0BGWV"HT4P.$ WJO0" #QP",QF*:-"6'Z@?ZIW/
MX24/4,QB@N95^X)-!F?2=L)RLJ?S&.;X/N4UIRFBZQ8HLW'#HO3;W;6BGE**
M0B/U#KS0'(UZ(OM$G*:5P1J,PCS[JXR #"[%3%E9BS#LP:/ZE%KS4(L5AZ7+
M/ -!)L5U).8.'J*DA2H6)7-2LL;6C^D)Q);0\,M;XZ^?%?W;12=>8=M$>\;>
MBT3C^E6NB\?@/7!D'L%M<*#QUWX\W\)00.$/W%I[0,$[3,MH<1YXC&7D6SJ8
M8D&<FEN,YYR:%\S8$A%M266T,.$=\+]S_/[O0G7.?^H;^JW__/$%0/%,G;9Y
M_MBU_!C,U;PI%;>)N'FP%'D(7M_C@DT_FZEGS*Y3!EQY_?/WOWU]A71;Z&&.
M]:4X5J"(A?CN>D"KJ:E$$%-4V?!>]<Z-)D_#S>!C^Y/\WTW0\4#?_4[@_*NE
M!AJ":\8<M 1'\8\*_.ET"RF0I<5%<\TQ<?>$VJ5QU!/YS2I8L(T$W-+:UZWA
MW_)$VQ*<' S-F:AQ8FAU6"SITVMMK"?/LC>I%3!$H*E,Y4>LDCN\CQ>P*L;6
MRB?@M0S,A3*=<Z&YM\>QV30NI%M<2_*)B[*)V[O]'9X=VK.,L8H7IQ3DV'77
M4N[39NME.:2:V5=HW-4UHJ_6%1L?G,1N NM+J6TD_Q )6ZO]35\(A#>^$9'B
M2T)3[%U,)#]QH5UCH0F5"!U8=2Q*.ON'7'-1)W8,XE]@#TQI="<]EA;UJXBP
MY(A;;7K4'55*Z!\1%.Z-[&2:F7#V5?5[Z_)C3+>1GK]A)<_,.5S?66OH1RJ7
MXTAO6 -FHQ4/+(\1>Z6"IHDHJ)T[NDHUR@-5YME0<?Y-VN2.3"7;X@Z[0+?U
M*D'1KF>>59NBU&0N'<./\J.YN=,TII]U0]X;GA=R@?.O=OJ>ZN_[N!.-$=6/
M<5)RO,M.%,\DIW&HB85RT3W/D[YOR$,+%ZLL,">#"3R^(1[EI7"W'8%3"AS&
M0#.R3<<XSFL%TO>>M2H*!PY(%\@V])MMLD#VK]^DU!>\$0RQR@WLO?'#1KE+
M$NXSUK4652$G75?<!C:(<<.UJ?GJ)'VL@TZZ.<SW:Q%#3UQ7*_GF0>W;MW\9
M7P!**O'\.+NL? P?SOYV6$*6S:2VL.4&AM!O?GL$J?XC>CI[;/!5CHGT7BT5
M21Q1L@'%0['7QE;_25((LH/>_B87<M]AN$UWT4NQJ*@Q"%747ZT\1Y[A.LA[
MQQ[&Z\>MT@WL.+Z)9>((JCLC:A0QB HZ)=N80*B1E]O"8Q9Z8N7\"P\W^9H\
MQGS4"NOH.%X7>'-]:INK+R6S>P$8$Z?U#$IK['R-N8HU^0GO4<\X>$HOC Y>
M&==\)HOGW'Q0<S&B8G)^ :#=[!.3++T G'N?9SY4L]K0&/#,GZ]Z/V^&SJDQ
MB7R1%;1HU'\*1Q]</AI5H? ^*1A3H-^^=8PF=W]&]!G7,!/645&N1#<JL(FG
M\G(;6[UEQT,A=!KNLW^3?@>IG)$?M*E&(M\=" :EG9H<Q%1Y4+RS/,X=\<)4
M)[L3ZDN :8)O5$)LT2MW!OQ0Z8N<RWX<ZO"<8>]$Y7REX_40.%N&\:CW97/%
M/-,L]4\DC6EW-ET_^6OM@J%H\DTR@V8$)SM!(TW))X:#@R=9);7C.WO%0FH=
MC%$SX@TEE8[:?SE(FP7U'+_2-S16*/,N,V<X#D^9P!$Y[0CY>7G%@KH^5:N"
M(CBK!^'PEDM&ZF?Z7]-%4YN!$D^U"E2?9PK/ QW!"^%L>"=^FBN=<0U@ X;$
M#);IGH9F\@]O:[9^>\VY[?-=>][)CY/=Q-98VM]"=ZA\",A7'5X 7[ML2";\
M:]532AN:U,9CQ*T*1-)WV;9K&TK'3%/4_)A;8\HM<)>BN)B+:R8RFKZ@I:3J
M/VZS:MG ?90O]SUP]1)[V+]_9AS95YXNQP831B3<UGUW?%C:D'(^R(6"<+S?
M"L_#^SL3#KP0L^^EUKQ(VLY<:W3H\$W>YPH3EU+]%LU'A[E[)N(/W$8^T@S9
MWJ/WY2R_ $[U^LXP?:BXI[N[Q6G.08B ,"O+FBL?JHG6Z,']\[D?$&UZ#VX?
MM*VQJ62"OE GPD3S&G<4N,?Z0H35!BC/32-;"1O=&V%NV-8S7*<Y-F@S0;K#
M>/\G_ ]TMBQE5.2H%1>N3A\AI+".9]AZ!HDU8/X8E.9B<-9=8QO-U#^6\";N
M&;<9KO&7KIC^NC%=U(+D'>E_:CV+E%90X-)247;S\@7@\I=7Q%B.<"W92:\X
M;?2K:X:H;EUR'9^N4Z2O;LV%()BT' CVP9)$@-,ZF3XF-H[\:U)#]8;(*[%_
MWG1/&E0[$+XK!'VP&5FM9D_9#Q5Y_:Z5KT;^B7>$P3OIPX*%$<T(OO%GJ21V
M%,TKV]X[M43PHH2A,SUNP6H;*\_A2A-).A&MXMP?HSNZ(4[%* L?3E*S/PO#
M65MV_+'VA/"[QVX+_B?,IS\W-FR@6^L=X+*39_S@]O7^\I4KK-RP2J"J/VV0
M"<-OW][R>"F\TK.P6!IS$IV[W&9G)*HZQYR KE$D*& I/<LW<*2>]Y6G]YKP
M8]&U>>Y'(E9"#B40EI8COOP%:71]H]&"4BQ-$U4Z^SM\R)1DQ9K7P@N@VI Z
MK&P'(^C&L+R_YAKO3Q*Y\&K2@E0RK>:0E7M2,G<G9R!]*BYRPUM5('J682G[
MS>7!";+%_4%E@)K8Y\/2KV&+:]B/+GH7YT[,9?VOU?&C%C?C-S><@FV@-U$D
MP%8LB8(,S"R!)<XAMPE*P@#9<)CL.36I&5OD:O+L:*^DBL^6FYZ5\@1]+U8T
M@\9TKLR!?.IC:A;#M!Z5RL#&=(D[>QP7W]4Y,JGY >]XS/1KE/\G1>&SNLX?
M/C/&5A8?10VB2\]G9$E$ON/^M8@V@]7MAOSCG)Z@)7.1W1GEGDE+>OC<).-V
M6QXSACC1:]ANYOK9S@62"T8H(VVJ0%*V M&9Q6U\/89]:_V(B4X.<H$#W7)&
MS"+O_&"7DB/U7XV/__$HIAV#,MOT:,+"E"A4P8"^%.O=HF*)_+8X6*^Z<J:-
M@"6S77YL=YC<(^AOT5+719YSWXIS)05U?FBILUOSZ&=DK@P"Q<.)>@?BD9A"
M8"/#E 6_27RWC,X>_%]BQ+S+T'\^VSX=%>W:3VP&//8>N6S*5+OTW#Q)6(H'
M*@]^?3:N_BO @?19W'"V_]NL@'#_M_@4D::B.M$J5\E_W*/<MM?/9E.(:QC*
M#;;+^"AC'L9L/D!>6[U8WZ'%)5^#=Y3JHQ?S28->?PHU8>&AZ+44^JX^E:@B
M/%C>PDM'HY ^:827/^?!O4-Y@' W8$&=.6_;[#NJCFG*>,J*O;AMWD1X =2Q
MG?V@)+[[JX)],8]_L#;2J073ZMWG1>Y42CM!-=ZFSPKCIT)KQAC14"H5$2SZ
MW"?&O;,12JO5[;@@4'Q8;A#J_/T.W:O:ZJ"WB@]N4Y\(/Z,V4_@$@=S6'L6P
M<D!X/7<U:[,3(!F]$(FD='>BX^,7P"!-8TBO4?E@9X)_!/ -/VU]C&H(D32/
M>J3;ELV7$D3)$/:[S]O]_#_[^+S>46\<4]Q\\\Q]SKY&C_OU3=IO+)6D+TUW
M:RBG39WJ^&:GN9KR]F!G<QZ;Q4QLIS$V"R92+ DK+$OHJB+WL,/W^$INQ+RE
MN_ AVN3K]_$Y*ZRB X ]2[R#R/'J9'EF. ;))Q17:_[*A/IJ=5I=%/I;4/[[
M#J%SKO0@\U]Z>O2U4+S*V K_%O9QWQ> 'NU\TK!$7"HZ:ELN">YZO]E2EYF6
MTDFOG&Q+E<Y5D&/[V*N0AM=>%\03=\%NXC@[4(#&.%-A%K"4R%@,5Y5$;#M5
M.'PYPH#NMTDFP]DZ96C2B.1C"C1(";V^A0+@>]"ZHZL:8FV!;BO'@"UU;2\&
MZ/H!&OT5NY/WRZ,$5M;5<7G=$8IP;"IY1OYJXVOE;*7P@0\*EB48D.AH_S)A
MQY.V*,%*T]44^)E:BGMFF5;(!FS[;%KU-G7^HJV--9>(\4O"9JLU7.+3M=30
M9PK/?T;-'0/KX8P?Z;EW1Z?F \509X6W7HFQB+\ B*W/^LH,%Q9:+S*E3(\)
M/XR-A)CX9'LT$58FFRM0"-A3ML^U%2DXV2>JJLXX"9A<S$8FJM_O0,S1EA?9
MQ^*XV/B&2&Z..7%0:]V;-F/1H6FO<>+H]\#L(0RLZ"BB_G[,\9VZQ'G5_VJ8
M#SV7T1<@]GFEE_FU!!=9AK<5094>UP1EYG:#/VVYEK_;%WRU$"E8QC:7N+</
M8>&-2B:WACC'/K?/D3FK-R@AOL<""#X<47[VY<5^RLI5>*_P&F4Z+!:=+,]6
MW4JR(STL]4;%G5ZBO9R2@0]U-9$R3CS1,ZWP(G-3_6A-L-P"LSY)) '1MTO$
M*WBN3Z1SSUROQ8(WSA>I8P6[X3%1^Y@9X';&N@[#>F=)V,'@I^E!X=1?S^J9
M_P+X4:>[&Z<."G>7"!*/%4 A4B(T:K$Y-E_=T 6)N[^5/&L+^[<5UKL0=5,:
MJZ6I4261PIN3O*1$:PBWY,'@95P-8Q2=DOX4<$27)Y=8\^-F8: FIV45GX7L
MN044EZ\:[+U@3YDNKT[CJD-M.LM6@PZ+1:4^]D6-2J670],057<=\(#Z+J-L
M!?BQBCR*Y5X$:T'[NM9/CK-16LB?[U$/T,_NK($&5YPP"TR_ZTDI&'IU7?17
MD2&/F*%8M?H7P/6!@^T+H/[W?>PCU1KUNC0.M9OI"V#L;@']?%0J;WV\GILZ
M#,OLC,<KY3_%HWL-T9T$*0C43HMVRK,M4$9+\]KJ)S=]?0$H1IX7=AE4RI4*
M@$AL(Q*WK7\AQZ)V-U7E.!E"E>@VI4@3.R/:"4^\PL$NG(VQ7CKN!3IV192\
M;/E8Y'6YQ>(>PUO?Y>ZO2XM9Z@UE/LR$'WF]'_#Z" 1P6Y\6Q>[LK'8UL,Q1
M5&=C+9:X.<9%:>?JR]<[FX45B)?/H?PN$IC_+(CB883V)T]$ ;W">-)4?<52
M(<+8$-I4@Q53MC*\YD_)ZC1E*!3)'%DI;?YP=R+E2Z?UEE>\^!=EA+MZ!]2T
M,\@X1'+=LD%1BV2^DI7.AO=R.@0HSZNXG9$2)]&0?D.T<$*:C9/#SQ2'Z'N8
M(^X85I!H*LCW9MO\MQ1U6!1,ZK)B!.8DG\KD42>=)'U%T& %OQC7\C]*1:=Q
M%G/^1^A.<E='@/AHWLQD1$[%Q>B@R'@]%S%L$(F8M5^+$&_]Z*E[,3UF,=Z8
MCSH1SPMOAMMP:;0ML.W/J@8Z^)$+5<A""D)W#^?M\C];M(\L((9M][Z'O\GT
M>&CXNEC43!'RR>%[-48G&:N5E11N4%:1@"*B8,L&M>YK[(*-*"-M&RIF74^"
MDRK;.0FG]_> OD\AO0=BJ0T\4YR&?^<)JH 5=X1XR,7R?88JS+KOD$;5!# N
M:8+1!HW[ $*7"CD(_CX(3:AK<BE"UIPS7#0^[ N%BK#I?LGGV(C M'OUS@IX
M 9L!:/L_@;8DFI=,;W%T\/Q2_%\IBY*QR@*9$$/'-S!'=;><B%H/DUCY;H?]
MWO 2RDO'%;H1!TGO+#(V*TE>[HR<'LZ]H/Y(@:I(<%P='X_:ESXU=4;,V8F9
M-V6CR1%@PN.X"1LK\]F8GD586X#DX'93T]R$M8O1@X>KT=K\I9CRJ>"0X.1&
M;?.I1OBOADFG=R5YS%H71A>FG<$V/PO89]\E-+(VD_UA-'F+YNVCLS3IN3)F
M7,A4UVFD1R;/'?D)?]%A<R89C9[(KA9'LOM=)B39&#SG=<X1I1C(U.@RGKSV
MNU@ +*-F@RL=6],_'T*Y(VL^&ZV@N=7-&&$QD.M;(+HQ/<*_L.MG51-9/R[L
M!Y!P"SW(+5PZ7\+56\?H64<'TWB2W"),SM2#[3W<&K^+[5L86L59:&W%>,]_
M&@K3#$]F&4;7U,?%$]TW5V7U%1P(IJ*;TQ\9>YTJRM:+R=/7I6'WF<K-S( Z
ME:99/%;O^R?T&*?&O43#A4R[!48\%O?"HM9;L5A?[+%>EU<WXIYAJT"^*3&]
M_^T:Z7]@8A&&>=CT?4:>%ZNVJ5U:!P^/:.4L#NKL'6OB,R>\:GQ@4IL=6!]W
M-;5)Q3__+HYV'\N-&3'#)GHFR#^0%%IF;6W+<Y9!OXK&/LW;D"AQF;.3IM28
MI%9_Y]C$]]REKGF7HSU;NOV\.:=R'51[2= P%.)HI7 .QT8?77WW(Z@:KI#^
MZ\E8O#\:IY+LP"1_EMV^B$ !CQM.R@,79(5_RW\*%*#$0%)70_[$=FH,/*BP
M8IQ_5FJ0E2F!L/7RS?VCY_EVG:6A\H5]DZ(6P200SU&0JB3UM2R"$T4Q5.9)
M2NIZWC,PF$/D+IB\W'W;*L%)2Z NAZJMM5E@*$G4NGE5?92#\<%6%]XXF1G
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MW<6[[G**2GD-KY]5UQ?<;P>+J ^=ZUD+#(O'XN:88PP#N>C2;U@40)>1M!%
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M*W@VL54Y#*/5Y7[PE>7-T3?W=C)W7'A?IIW^:^">$;-D ? -XQUH-##S,V#
M)]5=R%/I+;/T%FOOQYW#H$[DSW55 ^HKZJ;1Y13D,WC+5I.6I89&LW^)./Q)
M+X=%P"8.Z5U$XK)BE%%1J1#=B&;@"=XY&G8,$E/!K.\=H1YG;&KIT'.7=BP2
MB%IM9-RS'T&@H[J*S!WE"D,>]*2!7'GV_5;+HK$4<JG>U:^]WPX0XH<U;4;2
MS1_G!8U*>'X:#?C6EM>QA?2,/*SZ_%W_*D-2+N(,%\M2")G"2*L)2U[[12I+
M# -VS-B-0W$UI77Y-ZR&"$(" Q@FW@+]8*72PGN?8Q0;P59!74?-CQ?LNM(,
M%KP89!K4?IDH1J/[\!2>F2]N*-KB'!ZY[.WF1D_TV$J9&[E06\(PO09^V9]@
MH@O.RXL/.V*NC@$ON+41Y2MR,YL^LN0:<SO44ZR%&NW'6Z=Q'&WGS[[$>P30
MX) ^GKD^1]MNFF/93@MZNM%6<QV6&@QK=!LN_3$R0+EPL_A T<HH'U]:F^9_
M6/AKT.#=< ER5,#%0FIWH(A3A>5MPVV]5%YBC> W&98YWC&W7FB[1,$SIK-(
M$OJ)B-VK-Q)H7Y8)^Q).6_9XT[>UHONW_E!QN")?O)2X_N_OH[7];86JVB;%
MQ3(F0E?S4X.2%;SL9!YD(#L_'OK0D6/0UI@@X8W*9_80>--@7Q[KB ,XK*P\
MQN E>G)W-G2PB7NXN;]T-"RQF5VKXV=LS;0/3[9VR7"4Q0ZY%NC#9LXLHX2&
MCHR[[RZUHK*6:;16 % V80U+DDR\B>&R/"ZLS)9GDV>_9^2_S^6F]6H]M'R(
M(S/P![)OO#1-N/5FXWC*Y\Y7WS V@[&3/_^..F1=KY#1P?L+?NRF4$X!427S
M\. DM%NY18)'JRD(.%>HDVG67[4GS/J<L#]C>L.407U!VOYI4<G$[ /4J'#Q
MK*6-ZMTNU8;:*W4!61;-7/P_\^XIAA8N(TF'Q$4__/]2C2G*C!KF<;'[$1 5
M!"+AK&RWQJX7OK?(J9>ZF7G3H%C2L5.IB,]N8 \1KLB69&[HS6G6D6QOZZ;_
M8NJCX$[N!U'FNP>;103<^AR]T=)$+L-L>&2(9K?604&,B[84&QX.R[D9W/D"
MC"\V-C,1*503K3W#O/JJXA1P'_/P!U<: >R2Z&)S%YK]FZ*&,KXY!01;-'^!
M!X/YB^=>S1D1O>Y*CS>?:Y321/'4N\;EHLRP)V55P26)QRZ>J>-%HWE<Z'.3
MWDTZKAJ7W1S0:9@&_E?7=P0O5/SI-H</-O CIA'!<G*!)S53I;3'?M[JI?<W
MG,K,^8\56OXI8[4WW'D6KYP4WTB,MTQ'C9<(7X?*K5QH_\[A9HPNJ?!TXM9Z
MRWVK2H[I0D#U:XTKBS6B*DMKC)WSSX].X* U"E8A\L9ZG.O>N;$2N8XX7J%3
M0%C@/FYB)N;!*8!G__$TG/)KY@:R!](CR<D>7J"%/?AU_27_2\:#[PF!#B/;
MWKP1RSN48XI03I#T\_YG>9=&F3!>O>#&H*":^'&9/S4T';.^ U GUMG</EDA
M.R=+5)IMO;=HA*AUF)WH=XL/D%''MO1.H'JFD+C9Z;9W"MC[!)EK7?FYF=]L
MN7Z'!+4 &7;8DTK5\ZTX"EE O_3:MPLQ6&V6O5!+N>#;-1\[)F[YI?,M2U=9
M#4^'-V9 /P<\>D%/TYY$Y.Z=R/V@MW @W.<*3@%/%D9=N3US]NAYW*@HG8Q=
M<KJM,@L3=U1F37KJ=6'Q1HP$AVXF+J]]AWCSIY<)D=JIGGST1^GW[%O;7X5B
M3#>Z-CME=W:/6Y :BE>#'H ]50>^KGR>;@+&Y L6)6(UDUB(OU0^4PER>5[*
MF<K(:1U@&;G]2CO1R]0I11,]F2_Z(2ON.I_Z2QMWP7>F"NTG38C<@Y/@N)&H
M+)A-CS2RDGW.QC%/^N,IX(6>^J5HU4^33TT6E?"N?L@$L4H\HJ( BW.R>T0
M]LQ8$1-GSH*J_70N^*M(V0D5W,1[CK,F@^G@4X!$K\'2G]S_4HHV&3F89RUT
MOC#&395V [S/6S'W80+K_.9Q[7*GVD).# MVE414:J&IM>E@!8[HN3&[);5%
M?N\U4([FYX<ALJA7CP=. >5C)$(15V"P)6LO(CB9E]N ,UCR((J>F%(IP;(E
M<"<V<$\C60LS2)J.5GTF%V"QR-/6,:9?X\^FHQ>P\B!N/'U7>Y%AM31<NV8]
MRKSLS+5?'X!\,3(GL3PMS?5+9,KFD5/=7C-A=G-W (BOKS,V]2LR(&6PA$
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M=WN]M>CAWKC1=O]L#NDMH@VC:A*QJ6,-/1,_A$Z\'1YZ\5:XR<?.Y@.?I5-
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M@\VUXEA5XB%LIQ-\'/.<,.B.+4?- W_P<N3^AUY2"\^U>T%Z1??=8:%@[U-
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M_W?SN1GVZS<(VM(=V.@YR#DE'EA/%_-PXC2]C-REF[6IGP_ B\GGNS:X? 4
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M[P$R*,=<F1&=F)'950C/[ 6LT,U:%S874G/"#&LP \4KKCX8#!>] L][]2U
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MP5-12W$2*W*5%R3&KFI;@ N S2-F@,=F)CN<5^D,;V]ZC&8CSVK 6F.E-.9
M+0'G#0-O9(TRY7&;%MPAN&*"P(.8ZR/#-FZL<SU_0BV97L]VM2JYJ(7>*(A$
MI)>VJDM$9]6)VV )+VZ8NBRT1AJ@N,-&C9CE(Y-UVD1A 5*;,B=5W9[-&\S:
M#NV)P-$CTK"+*IZI&<^. CK'IBY6=6LP5+1+X+'3KLW!62U:C=U.FT]6/4S1
MP8'N2?4B& 0<#LJ]%%Q1:^:P&@)X5._7U<Y(+Z.Y8[6$=:/1L5:+.:I6&2O
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M_?;"]R!S;V"33(_#V/+3>T*Z0^#N,",YWZPN8ZWTO_)U$:=L#=G.Y2ZX#>\
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M#U;=SZ10;+CD%UL KURE^P:\^)H\&^:BQ/NM>70LGTP5&.2W:EK6FX+TT..
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MC(5HM+A%NL5@(*SX&KW VJ@PGYC32NM02]$3.'.FYNB.CB#14FF5"$X(429
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MG;7W-J"IMVC\0<RD '6'A7(L?&K1:6NKC+Z/2;(#ZNZJ? VQ-IE/ANQ^558
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M--OU_6=X,P @X/,I)]Q0(].H^U!*T%[^^"N_PAWJ8')'>Z2'NN2,PVL4+/[
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M,':%$U]V?=L)(_=>?G)BF@3B>6@<[A04)S,L_BG9+IVB$;8U8[L95EQNYN[
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M8&,A!IQ4^*%*!M+E+B&0PGX.PJ*C@,8.>21\PZ<C"OCVY4C#C+UO*R1J:^@
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M>>X.*E:\L5F3$K='K;C)\:ZB%(]/V#GY@A?_OZ)MKF'NUOL_KR0^ZJ\HT#?
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M)Y'O82'_>)5;[O[NT4EWFXRER3.J 53[C1VKW1 TM^B76@>"N[<^!_5U"X@
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MO I-5F\K3/\9>0?49K'4[Z#5"OKIXB/B\HV('MMP(R6B$I>:Z.<3EW,<!Z<
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M2^OQW6%;_R_*FX97>7Z0UO/=YZO)?TA<S8Y'C,(7_^>J?^O_%U!+ P04
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MR6Z9$\NBOM9\50*>D5;D^(8KY"V0^O*BE\ 5,]&MCA+)UN,K4A2\J9QS+.U
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MR8M)!>"BH5%Z@NO.;J23$!P.K5(MB -K_>1 O(<2R".Q(08=1:\6G)OU"]W
M-U5\K)5)0<\C8,1DSTVD_=J3:IVYVYRY<4Y''\^>:VZ@?7=K\R$+KJ1SO%!<
M)8]6V,ZR.V2U%?)75KI?7?Z-Q7 .W!7(D1U0M,'N,)ASX$"#LZ/J'M]*2[H_
M4<4:!X7,38%YL='@6NSWP:GBMUT.#7!!_*;=BBT)Z7*Y.3:MWL=LO1AWM,Q$
M+*HIY2X9JQAF\3X^K+Z:3H!]S+H1W?*70J/3U'U%(,_F QZ'L/W ,J>R13L$
MUY#.?T!$2ZOP4VJT:M]TG!W36UE2#[S)EY#"3@A>R6Y54J3<1Z\QK*'^^7RN
M![325?5>'VX,ZW?/-E C%5Q<NSO17#Z!\)1CTZ!5G"BKL?-X,*YEF1?!!+)1
MGH60YBR<JUZ+&+)UOE2VLP..BW-HR>T>XM:Z@ TGS!!"8J_<0HM67I+8K5/:
MB^F@9\Z-HIR!^;,--(D#;A1?R&'B:2](G-0K?T#O'AQQ.0#'FN&)J3**1647
M:0SS>W>'^UMH,%%EG:9T2\@LV'%MG*2#^V,5A$"P%(#%;%[#Y+7S2#V+A9&O
MBAB&.7&NL&O9"(\#Y#+T(!XA&T\(&U>F83[B_T8NVC#FVVZ@^[IIFV4A2A2Y
M!3I@L<1PSBM)>:^-\1-GJ?W!#=2'*K.)DLNV>><?0"/>N6K8#2$S>)5Q)X=2
M"P+ !!HXWS!MJFW,2G"XP0?154O^98>H N\=8>SJ7HH>U],Q8TZF$@HT,YX8
M<U=:QXI+GGI#Z^ZA40@I$.+1IX@=8>\2[=JE0&\MWV\Q^'HI65SQ9#G-)R-"
M&7)[N,5X-J:49J1HO-_,.C!ER5.[I9*K(P 6]FG@VS5HQ$L)"U5Y>212$^*E
MO1_T/_=>:PX$*O9B[M,WN)\?P9"B-N%U>!)$ER"R>4P@:85W:!KQ@U"[6;WH
MG^O;Z8Q('3, O0MWB7@--Y)5/.\5'/(.E95C/!ZUGF<7%:5A)[!\BX'N4S,X
MG1$\N L)>TAY&1?N5J6>+SDW@7$+F-T5NNF;/9@Z8[0#*GN!I4KEK:V]7&XK
MNG-Q#0-U+!RNY! HB/,=Z')NVC6&!KS=H&]ZG\*K;>3D,Y#E7B)"+M$-=UAK
M6[#"ZK6O1QN7NT[>X%L5'%$3Q9LUZ7 .ML:R+!5)C-S+L[^F4)CH?A?0*)>G
MH]X<9-"+;4"JI461]SNXY9![?^64_ 2[6]?'Z[43#10V?']:$Y=4%Z),.S%E
MN0.@ZB":BK:HG6<[DKIN2)JT/+=(CP9$=18O$%<3NPLI+P3;FG?Y&NW[NCO/
M #W<_';7B$6\2:5DFIZZ7@9S2'$Z.)@]=_+SA(0OG%C6DZ!!A62,ANF,_<0)
MSZR[OJ@9V0*W[&(+ $MCMFY325K*_IUH6NZD:I=L]N4:>)2AG>TH:_)K&4CN
MR7IXXS$&Y8J#G#/Q3^D@$4NZ7=\53GA\KZ9)FP$[*Z/]@CO@?!8Y+C Z1N7+
M?7M8P+ I;/QL 3'E(JF/]RNX%[;61BP+RA0O7&=!R&-'?VUR#3H"R=IZ9B=1
M@+/./7F 8/?K4Z(2R-4I#4I-[_ 8*)9MOBPM8S-V@^MPOB[]3D02/=\W)<U#
MSOK)CH_CLH\B*TNZM^R:UD8)N\LRK[?L<B2A?<$!^&JD4MT%956=HQQZ!('!
MX4Z&"QFN<.E#)>WS:T]*P$[-<Q=)04?C*#9\H*3<QNG3YAP%?A#AE#35D3L@
M]DI7@"GS)!L-DW , \R:0&GR)\OJ[SMW=LK]%0][7GI2--D#:0C@%6P\#>A1
M/* -5UCE65$I7$GD[%.WO WJYM)Y,>&SV"J,&)$?'D-W!..Y#,HUW U[1>Q$
M#TH9.BB^!ZUZA]PDO6+9,8'E7>VC _['_2B9W>[PAGZM+$5Z&)M$AHKF*1*>
M*$+W[(+MKEID7).OMY'3VF3::HBOQI,ZJ:$3D=/$==5)V+7(/1OXXP+,;9[
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M);DR2&R1\\1:*KY8S)0/F?:I!JK2\"U+: 6,+I93B9OEFFOBKJI-I=2OET^
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M(,%7.U5QGBR/N$JM*IY"!W^=#6?VFQ'CD_LD$CN'2'8P+FN]G)PCFWUN(?D
M=(C-!SP^?%FY*2W7A-GM)HOZ84$ A[CI:!Z\ =>$IGP(BVYN5)<_3P>K'YUX
MY@#YX7JBF4(6B+U6B5/:ZQN%98_@<D3@8+VO$IOG][-MVQQGV_R3OMZ]@VT?
MW&F1$% [&3*_&02\Z*<-=@B8)Z"3B4S%-=(_[_@<8(.&G[[/A$+.ZX"V)F?B
MF)R#*3*!LNNY9LACLD1(-86#E#"E&^-:R.'L9?: BS-HZ^W$/N)YEL;7/[Z
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M7ZZPP==3X^@'-@IZX^'9W1TTB[)9N2);([J[H-:<@UAEW%Q;MF6RDH*('%^
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M@"Y-:LDM ZE8$:T;>Q>%1%[DV-54MRG90=*A*YW2ZQO"HT 1?"'82>LB;N
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M7SCE[K>.N/LIGCGZ_?$:C'8^YF&5W)9DZ-Z&_Y,YS,F[!?V2P*^I,8>@&8_
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M"X!P@M<S.1$!"I'/\U\4Q#[3#.E\@K@U<K*51U*S_*C':TWR[_,./NCU$)F
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M1V>U!4'4$KBR7I<[60RJ%ENV^"$+B*T(O?:'90=*DMWM6O6=1KJL3-Q"FPS
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M! 0O@96:)OT44B7^<A\Y+MER?(80-4E@8^B/\0LW,I0_X8P7%J^M7Y:H/*(
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M@.#/RT.5N'79\C!8+^VM%ITR54N?R)]O'3:</H9ZW +*+/2TXQ+ZQ@7EDO[
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MFP1EFQ16U#!\X $L2E%LHA-:V!2_=\XC M.! H=Y(4A7Z(/4T!#1)JE;9^V
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MP/C/[UI@0:P<.S(/4X^ D$? ;$5.*]K#,=W#;M"ASMV#2F90J2?K]:K:L<Y
M(<&MW /)(T SIQ7S?Z\(/#?[-+<L6;3JZ6@2%&7<_&J1@W/!@G*L\I*4:9M[
MTTAK&?"LOTJ6U8;A>?"O$7V'B2[PP@8U^Q)*F-Z JO5VF*R\)>?6Y[$T(VZO
MPY%N8;J?_K>_,#]U.Z@T%?T: -+'"&A,66"TSIJ&?6;/$E.613,RYF)@"M1*
M/:PW8@)5R'S?:\+R\TU\I<]$!!24M#:)9[:<IW2F(GPO,A+7UF,DRU?((C*<
M'&-E .,]'Q<I\7O.![A(>#<I0K(;KCAM,2.]+UE8F<(JTICB8&G.NEOQ%N#D
M;F2(R'49%EW<E[PZ'C)/-1VVYF'O5:D<A=-OZ)]"F:C&>9$[2''D13#$GW0C
M%CR8ED ]O>>%&1!L0CXN$3^K3=%9@4&(XO?UO7B^._JWMDI7H@LKTM&T\<90
M7@;LD?U*RG$7>': Y+'(*31 _&K+)#OV(*58W,F6=\#Q@/%^IMF8S4^!TSDJ
M-3$>TI!@QM1;N=*T,*PXMT'@X/QC(@OS5)+OZ.=H(L7J_5D _>G&JI'DZ=1E
MJUG^PI]SWP#[L^OC73V(Z+5%_H5Q&COKUXLNX#558;1P$;2U5;@UO7+'9>FB
MLPK4MNW)>\'))SLDP< D1GWK2^5G;2O4G<=XT5EM'OBI)6C(^R[H <)Y'YC^
M")@OAM]UF]T;/0)L*">N1,,OS1C.O2<N2QX!-TO=%Z52.R@/3S[Y1N$N%?((
M\ H+&L]Y!)P&2GD</P+T8AX!OD_?5A8?: 9-H]WK!IVR!+8] KI.?\6^<C;/
MR\@ 1PC8MWRNI+J5+=RRU$APY>*OH63L5+OKG?I[]37'ZS# ]'K"+"0 9?'_
MX>PM@^*(NJ[1(5B   FNP=W=(<&=X.[N,KB3!'>"N_O@#!:<X&XSN/O@#@%N
MGN>M6_7>NG5_W*^JJ[M_G>KNLVKMM<_JO<^]\Y3%1%3U,L6/&,*)&E"_%+9]
M !9=LUGIKU3LNQ24CF>SU3QRM]TN+ZM&;Y@*PDU+$[<[1O5IZ5Y9.5<[ZR)
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MY<8]^4'AG:&=*9'):/LZ9O%*(D&]##)5H6AST]*<X(39'2]1]IG5IAQ9@Y?
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MTI>Z/0^ XQC7B_Y55U1$=]9X?^F,+RNT2$=9S%RB5\2@:PUV>GY+<TUWL5?
M'88FD;8&9K#:I_PQ.DJ"D.0UW[]#2V1P9?MC^HX[C J?,EP/Q+ ^5K\(3#N\
MXNO'0F:V"-P=4SL^55O24"LG)O)<CZ54VR;)\/*^<Q^_1XJC9IL1@_Z)4MW,
M":_/UO^8./-MZUDA9D%3%KK!E/'!VQ/#:(O$=,H'_K[:UG43MWN^:U$T\>PE
M477^Z=Q<1\&PED8-KU50JZ,C*I[Y>[JOO)Y[Y,?$S0&5]KCC3EC:BO.H2YYV
MBCGA3;5UW?J&"8&A$U?DEOOTM.E%QG&)%5WX^+XDR>*J%*Y$L4]'6(RM"!KD
MPFF<&"7>S-U;E#!R?L+8F(]""?MB^4'OD;/MCG,,WMQD%$+<UF/K>*=/>9!:
MJ_Q_\N>FU GZO4K>[,NBRMF0]<MNQ^2&Z8N/_KF5/[WQE\"A<ZOZ-T"O^QN
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M@I)A_7*J8>IB#8'L!]LI23-]^X[*\Y9QLG5/,*G)U#-DBJ@PZ0\A0\E^K/!
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M& O:W[#O1A3:VC)2A^;]W8;E;8F]KGO<(!SL;[_@_I_).[][V?8I<]@$-H2
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MY>6PHR/&Y\8:Y#YE'/_GYDQ,XT4TJ#_[WV-A4FH^[:#=W^05N2*6##H>YHX
MGT0TG>^-;<XJS^E80PU=12?.GG/PN*%.!>?;9A_BPS14Z7W7!_YRPLO*.!D0
MUAM)"A<<SF[_GH,)QNRQ<F]K91\0#O'4#+*7"DQX4DE#N%/;2@O9)4+J$:RF
MOS.+[^ZN=,:&R5&FV=;9[$6>Q4D+M@/V98?P.N,(FX &[ZE"T,Q%1P/#O"0T
M_+ZVS]2!M77X-#_'ZS9#+:$LGG:?9K[\D$[\"HXWO4*@D7(2MLK)8F766MR>
M"Q5]5MJY2(L!JL2;I3L\2#E\@ZB-,>W86+A.$*_OC XZ+#8/Y, )NB#4$#?P
M0F$U-/4ZM[A(TZ::'AXX%[RH-DP42;8&R\O6K1RQKJP4L< ($CBF#:I<M2YA
MS<:&(A3L6@@QD:@K,C$7A1,?TG_L<"X4V[[%5&)7667-;#I4+8YX,151GX/.
MA(I*1AN7N[E>'HDLK7N!NH%'!1E*J54J^PC\V0.%6@68M::20L2V<F7%]XR:
MPEB0^[4,FL&98>D$IT!^EKTIJ%GC!)93==-H\@; _O0&D#Y(]L6-"L*#O $D
MRM\ Z'YT100JEZ6D+[Q9?S7G%4+9_8YC1:G3U=1_5JCNU<&L9U-VYD,9RA+"
M.4+I^$>!R0]:HJW7<9*IA/D^<=[%85_@.$:'I"_>M]+4PO5\*I]3;5,,\V:D
MPIJ;P+G$^I)$2,AL\<,,'FHP^W4Z^M"=B;SV\5%I9^A(CR[OH6MY[@U ]N#O
M%H#XK$VT?\-+_ 8P,-72^RL#2<??TNW^NL.$MU_OJ.4PV=(M:UGQ01W&QOYL
MXY.FC\_@V#Y7T;?BBMKOTY?0Q(0J7Y]'J.R:'2#09C6YD\11:X5KL"\"\B-A
M6)?(W$0S0&]&^"@C/M-MZQG(U\ZWPP_\/"00;UY9B&&?J6  >7?R??8]^1F%
M;'OE#T_<NLI=%,VXKS_P@'&R:?3NJ>9U,?U),0Q#6C$T**/)R3L"D\)[.D,[
M4WS/7"'F.*UGI*JJ88L2'X "LPK4;/8$'S@!!MO,B,.DED _W28"&J/)[>0;
M*.C#]1@\,0F'AO3C9\E+_K F_B0'E+E@QM?K5?RIXXJ[ 3FU6_E^RK"/M"=:
M^ 8>!1>[$Z[@*U[Y@)V(F)5*<1'=OO\L1QW_U\;:R<FPJ6)R\:=(=D_A<;:B
MOA=)GE80REQ?2+ "FIF/Z;LA#K_;7UELP;;/P?'1.]!3<OONN)IK*1GXQZ!;
M7LOY$L7XQLC_\A!)Z*]"=)"V5M#WIM\QW7:_+DFO69-<'G>H&2GHU89&Y=6:
MI7,(#Y.P_CO[:=,KZ?)SM\IN>:A#$,))@=KRTO+BY'Y-%1[N"4!Z)642X1>7
M#KDXZ>8>?CL4/*IOU2Q I6PT%0X$,CA=*?TGE']YL&E"T$]&LKQ7DA53T:%3
MF4U!YU/12>.!AJ%C1M&KE2 QY.&Z29M%7'*9!6)&]0^CL=*-W9\56+KZ)]ZG
M@M<M=VD&<QQUG/L2MG%2"G2>+ 4&71\>9__4KVARNT[@39G-2C$14KMQ1EES
M7'86C/L9$)M!N,.Y8]^35_=EY@=+<B9X(%.U?+Y*=C]K@E+<.0IGZ#E&>#]8
MS,,J&OZ,6G%[OF+)BSBU@R^2Z>:+R_[K%7$\^D <1$<=63 635(\TC_3*2DA
MZOK/3<@QNTJO2ZMFG ._V+2]VSTG9]!(4!Y-SSXLMI>('3$/)AU9=P ;3U5I
M?VGZ>GJ5;W2':>1>MXS.N.)%A0QD=8?BHBY%,T-=N@9T=1[:5,7[,_]Z=[TL
M9CR$ZTL8W0ZNW#XM9EL?!D'W(DVA3G/F#=L\-SK^:B;B_+N@RN^I?".'H50-
M'-<CQ 9_\SOHJ:'8]N^Z EX2'CPI(F#KB'AD$KK&U-Y;?CM%I9D5,&L;33ZA
M)?C/^RT<Z.-?\,F-]GPK ZV<A@/+3M=>[9SSCC\'A![56G;/*L(_[6"\ :ZT
MA]=3[K)>2(>"*CDP_P46:<^HT(8XW1Y\^<ZH?(]2G:1#_2_BFE<30TEY!M:K
M)'K<<A%6XF+HX1J3'X^#4)J9R(P<;9EL+M]+*2$:LC@* #/IBG,9TQ72'?8C
M3?V@!G-%P1Z]TTMVQX<G]+3<M_/-W!YP(-?O-2BV^^@N'09F&=7>]F$@&C#5
MM](7_(-SUU4RLHI6LKR';AYCG?\215#X$#>Q!*QT(*B9APSZ4JU_FG?'Y2BV
M%!5TZCE:N399 D1=13Y4<:^F1"1#7GA9U&#HK5,(9T#ZZ2E)*3XB;6?S>+'A
MQ/KMKV[B9RM)K\3L@L%L\;GL+9T#?#$+QQ^EF79VL: >T]Q<7?)<0@XBSQ&<
M&>$A:F?;@.4[D1K[3 \,!%QH+_3>R<XTK#3/DF,IOSQ*8#-36+!@9NQ#-98,
M%0FA-0<,: !!1Y.E,#RWCI?S\ZAY!D'TFT]JA'S+5&N,,\A]!WV3+%Q"/B;1
M9^FFB#I$#%MQ$;@NSJ21_*=FV_5@TG42OL%JPT&+KLY/Y6OXJ32*OKYF6#NC
MKY[O TVN[8<9DL1!"+[ (@(4O:?FOKZF[S25L$6?QSC"89)'1DHI H61L9*>
M+HI =UAQ]4IV'ZFY+1MQI'G8"&;PP! P_W_:([LKP&CC#7"<>=H-U<I_Q0
M(;PJ4'GG+HV_0I#E@##1'I>-@.V@SQG?E."?,+RBGU=L_E/^>MS"VQS8UO?R
MS':X?+MD;C0*"]]:GH)U35?6CIP4&6LZ=;P!%%YC7G?:Q^Z3L7,_Z9Z,=OM/
M7=08Y^A &OE;M@3? +'RI:S2>@/_%6/VD+KN0E>5Q8LW0!/1P<_3@R5<F<ZC
M0 2V0B'2E^A9O^W&'4S5-;^G3[XO4?TOSW-M!?FWN7P/O&1S!&J']61&)F2A
MI2^(L<S:F<U@??VJ5T_[[FIQ,>#.]=&X$/2)S&?.'PU_I#6O02>\N_*5@_+<
MA^/K_W3BJO>3>&+%>;%%?I8B>61KV%@"6?_^]Q#1/$!H6HU*JW6B5+/S(>W0
M2VC?ZT>;[%WV>/.[H@M<L;LL:PV=%\DW@"\9)FK?8Z%.ZH'M1@Y1"\R%[LS"
M*  2XH?R(Q"U_Y4!]<3\:35PJSL33V:BLO._TM,HL6L-\^@-T/P&  98/X<=
MB#Z]Q.?MKT=?E+)<!G=]A#V_NMJ+(9D:XVMP2;Z&O0R\WO48W]><((O@VP0D
M0^/O2HN>R9JCI\!!T(E_8UC^9ZAG^BIKP92QVF)MW>Z2[MJ-51F-UXN>ZZL5
MN]=1SU\7KQQ/TB6!V; R*'CB%=#[!I!19^C(1.S^WYH81Z[I/K5Q=J[9G30Y
M8!FR$6\5,I?,,(G,):Q*^LLN0MY0KTXR?QB;')+78*$X#&>M\YF(T2?O.](X
M+(V>%:=/[_YP04:?KW497G6)UU#^P)YQZ50$9.\'M!)'5&Q=QE8MU(]/!&E'
M?OQEA"3/M!N1A,LQKA7>R3E&H$5%DD[);WM!-\((/2I]&?O=Z!FO, O2?K)L
M'Y#_[:<SZV'XNO$Y0&NZU/S[VMV*%++: !HM0:3B"@O?\P+KC%+U;&44CS.=
M-6YP?1^C*WMU$DWDY4.S**!8/FX8V97=M^.C1S7'T_3RY8]W(!Z)E+TFSOG+
M.\!8J*@_;W^&Y)_%Z&WQ=UB4%^'FVX3@P2DC2I?RN@![Z)HSN-BO4D$[8\;5
M9\EWH1^[N1G&C\1&%+C@5.SP!4LY&>ZC@775W3)-->9@-\.[T2G<9,1L*6P9
M5E,\5YNE9OF *=UII:ZO57BK3)9H"D[\;;/Y\A3J%2GMZ18ATKH:</)?  /4
M$I('R^X_8OCG>=?'5/8*F4_O7?K91)(%SPAMA]Q6T"L@V?TVHU=A>BI;_,=_
M??4=Q7XV'Z ,080I-Q'H?X5($DEB?9\V,7@72>"$5CB!(?<^5D$1:\?XU8F_
M6%$DXGJS\^\B-7@M[F"K)?>3*^R.(@5UX3O45NW;Y[J/H)\-6^+)\F9(8=\?
M"4>C1-%4)G(H.,R%4LTD38\X2?KT+)M;F\JHO['L@#.!AB=/6M--LK_YY+JT
M*Q:_E?;9LX0X1.-X]K!IP"G97*?('Y4&?ZK+:@<0,-O*4"FF41S5L,]N1]%1
M4N![$3<(0D-T;GL=C>3U@<9I3DP*X35L9 YVM_2>P)MYZ&E*!: HI?8+AVGE
MDLE<T<>8F8#OF8\C[G!@[Y"1[H_1B*'K&&WC]5]  G8-T>GR?\HJ/T40+6:1
M2WET*+\!/O#O9P&DQP0KA\F+SR^CHX-Q?Z@/[>!Q2AQSI6$MB!)8CX)%C:C"
M7OBJ[/L*_S^Z,QTLG+X!7BMJ5EY"[3 W-Y%%@!8O/TN?]U3Z.P/*H.8P9/3[
M=;K+HQ2$:;'\ ^_N3G#\&\ _L IHKWV2S;;1\!I;:YC* ZL9#B2M?AT[1:W\
MF]O.<ZMUTGW3?3AU)E3=[?-58 LW]W?5_?@; '7O<2'6CRLZ$+OV8;[2;->R
M^G]8J-,/[8D.Y\49\_EKC;?R>D"BAM]ZVJ;X$U7]!K23KHM)E/V6%-)=@%\+
MK1;;Z!3*),+4W0GZ8?K"$<H:_>EV'^Y!SWE:9_:/3Y6^97-[]X%5Q], U;VH
MF&AV?V=\P7T.7T^]?U;D,TV$WU/M#A;K_2\<G/]A7?PFL<(ME<6$H";5J:1G
MEI?,1;\IS(=&;9%(W]WG,!\<?:W7[PY!4 .V+:3(28GW=V)V8G#J;P!;L(=4
M_+S*?<'%135;)DVDDV?.XTQ5X-"[P'VI@S5O_+ITOLUJL>V$&K 8:.B,^+'
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M(S\OO5TE96QQ5OMX[%81A\<(O)J<8,4_'A=<\U^Z0\<O:Z_0_;U^LFRM<QH
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M7[T$B@^YB0Z+^S5UT0A)>#S8!PT<A@]28A 2@2EQ\&H><^J=\LFYFZIW8=-
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M7(Y%-8&>1FN!&0;SR*@_.S0L8895-?3QVEVZDJ(.BL_%0T4-2/-@IUKM38E
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M?2%(R%SZL%.L*V251TY!1.O!NJ9Y1!/=MN&X7LK1KJ"2HG7A.S4<"2+SZ8"
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MK##()C2==T(Y#<]OL.Y?KII19[JD"D9#&KEY$RB6+-ARW:@J_/):OE:]0"H
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M8T1+(S^VOFUUFWOIJTU+CGQ%2X>>KT\7$U"Y9FB^4S@Q=K(6>-*)6Z-Y0@6
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M5H+TN=Q0*0"W(UC-KHG)ZLU61:NO$@*5:ORG>2-_PV$AY?7T38;*I4&9L:2
M.#E#?<3"YD]O4DC*K3'Q()UY!S4U0@S_Z0_*&29K&K=021L@-L).A/BY,OZW
M-$*?[L]8.;;KJ>A'9:.V';^")I4Y RTGV ]$1 D$F 01HQH2$S&+O4!G;B/O
M%^%C^UM'@YX,W6$SIWO2B.%*08/!$NI+>?Z?&(_(B:,9B8T^647V-M-V;6A%
M1IX,R_UDXL33_++BCQHE54>=$6@FGBWP7AI@Y$Q **[N'^Z+.H"749*0-QAH
MR1=/.R$YV#6M1;$'8H\?;A3[D*8?=6QHAEB<6%%XDJRAIA(RYE!,9&4-+ 9+
M:7Z5-8?EY3'3Q1**X4G=$<S[-50W'79R6]O/.)Q?U&5?BX"NJPE^-HNFV<^H
M_H:# "JW/7P/G7S]86S-J91LCDA4& PN;^)Q5[023=N&HU:7I?$R@ P]')W*
M?U[Y!X3N!_GY]89'J3]WTE$M>R^.;*^N!IZTAZ5I" L+[34K3O736_%B<$@O
M)@44G'H:K<!\V<N'_TFX0I#3^VV./LW"SB)%K V7E<JVQNSWJ.TK%@'R$:<9
MJJ8,4T*=(L*;?]+EGS9=HH;.511#)798G%<3V&&DHR'MHT$W^ZL*C?&;?.5-
M+FXNW,Q1'\WWC%7OU]QU>X=&EM:0]5?NYH%4@AS*7L2X]9J;/-_\W].NX"B+
M5U.HD+\A9F;E#XW(H?\$Z@RD0YW0'E';Z;G,'XJW- ,>KC#D"]5-1&0IM0^]
M5>(>A,*JD6]PW)A!O.8M:2'LA%%XB$H8U%!FJ]*8R\";:TUWE-T@522]N$U2
M76(PCHS20YF"3WRP;V3^;[B<*]Z"D,[ X>=9G[C@)YMYWW>SO^$4XI_Q'"65
MU"@DWI2T<>4B;BEIR&EK)LTS<-KOM3'R#6C]A?5OO ?OGPUV]RSIF&*_/V=$
M@^Z,&</M[0AJ;E'E(I68N3]966=E$89_:K).XFFK(V5!!O])N#=E[NL_,X-V
M16J'K"HDKBSVN&J8FXR)_GW"]5U>A5[2 -F(T\H_"4_^37AR9S+*1=<5A13*
M:$.J>C^:<;N'#@YVVF9UVFIW;YB%K-TC,]*2DI%B*.CA<CA5%GO9"95Q8B=6
M-UFW_,D749!#\2OCWWQY8TQ3/OZ;K[TN/-*=PH09\*.\JJ']8WR@)8/IQXL(
M5@;%5!XG6A%DU!(L9L8\NGA[)V(5H472A4:VH!N^+#0]A666PEP2:8U L5D)
MZ9%"OS_$T<I^6%V^&T;_AEKS%'[4M:H;)V _#M"_SA!\AM"]8*5Z,TD]LZCL
MIU\GB*YJE]UG93\:9&^6A5 ZA8;BRREM%;PE175*DZ^IJRMQ3/-EWM(;X"BG
M8O%P*-_YNTLKWV VR3_Q5@<XDD2;T$7IX&]T@DYPX]/2Y %Q4[UJ*NA[W]:X
M1HG-F5\K^*4M5K4G \=LQ/\IB3*CB8UW/_ ;C__&RS/&IUY-?W@N ZBE+V].
M -7)./+UB.)S'EUE#V8 ,S&)_64,Y5>"-44XC/ZDBTDZ7']FP%O)NP)IS8;K
M-PZ6^=,,"Q+H;65_FB$TL3GDCUZN=<^C:D?OU(_BI$'JI3%$0V+C">+_A OF
MPY5I_J<7'/S+?!<C&$4*U:/)"!+-%%L%<>V+_JJ<?1^ZN[KF]VIF[3/@^"W^
M/HW-H2?-W)Q$B/S?8BA>U9SZ(SR'>TXS]0]=-9O<O\DRF\G^+[U@\;_IA?=Z
M1PPD<E(-2=JRMBA'((:1F9E"*1OQ=/G:")"<M,'(?XQV/SHN3=>O*4IF &7F
M@43?TV7E>/'' ;=F0CU-3E!N&LHH?)-U&NT0 ".PUQEP2U!_TLH"5-?XCXN;
M2I\GF_&B>L)9B9M$I<M4?&<@[;1EM [QYZZTETD]\@40 S48\U:TW.*2Z!G_
M#!3J*L;K;S^_[T?(_XERS 54V*2%OW.PS<#NNWQ@U3C]F=FIVV5.R_4SK(:/
M%]OLYL0[[*; OI5<&7Y>$/</?_GED@\RZMQ$\)1XI:RCWY8'%9.ZFM-U3UEP
M&''D&^?(@%L$'>W"5-V>B<G+'L@FM_-5MC>VXS:&K9D;5G%-ZJZ\1J]M6[Q&
M,!<KK:KZ>U[A>IISDXCT(=%)!F<;+G$"^'6AX1332>U:UE%#P:\36>U\L4@]
M!'P!QSSDM6?'T+G9&[Z7Y[?O:UTQ#Y:P^&ZSJ 0H4+SKU[\VABQ.XUILP!(4
M(U7=FC]<F,:*:!>YDG/31&IN KKG5!9&&A=N]R\P?_T2H40Z'^GP%,RW=>1E
MJ AV82%5WM5HO-KE-EP\)K0F6K0'Q\GHZ@>8IGHPL#M9%PWCLA$>)KJS*:"H
MKASZ*3-0(-*B?EE9<29'.(,(O^5V:B5>'G#=Q#]?I(,YP68&;(8OP))[2X_#
M6?7!+LS0EQP.50,DLNM6.0*ZS"KE*N:AQ#65MWSFA!AX0L^?U3/3RVA1Q8Z?
MOWA2PK4:1<WS*O&R6*<Q+@AX;V=7E4 %YC,U2DI:D&.86A2F2F6ZQ\<SRH"Y
M,OQ&R>_S-<Z50K0Z13J,,<M:CJ-UMF[Z,@NJ=%Z?X%%JDF+!2K="@Z&M<&_3
MZ PY85*R_#9JRQ$KH:3DI*%7^?5&E69";7P9O(R8CU,2E4:-#%53WIG:+9JE
M6'WV,<A(QV&_X91+3"BHE/ZLXXY\%1N,CCO4ENA$!3T\U9F2<IXBN[3CJP?[
MB$+K]Y7?5'1;A?M1XBE4]F:<$X_7KT_5,-S5+FY:)WN  B!<VL*UE8A<*;UP
M-T^)O9K'4D"([4NO]*H)]4B[;HI=MUS="?NN'[H3;T% PC1RG%Y=Q^:^G/>*
MW<.7ZI],OW24C.V=9EW=1C-QBV/K#+5T6G5N7>/0:FQIF1XM;CXO0YDS*^UF
M(&*_;C\'-"I]\:I_3K\IJQF3M54+RRU>?,-8/\Q@G&>$?_A=P(/[8 -*$G[K
ME8HE?]QN)7+YQ T\WH_)/_STA%E06114I1^@$8SWONFVBY-'+@VC(\.Q&3Y4
M6&*9F_FK2".(@&=>ED97!.2<@YQ&<W?]?#?MZA&0NW#J""TUF#RKXFF&$\1#
MJY;<%IM?8)L@$EB4>>V2Z\:%6W46/OTQEBZ<)#,D]2J+EX%>)[-R"PM3@9/0
MV<5WF'6Z9R/1=[[;%ASXGS^RP'SZ?H59^.Y2^#I3.7=V"4<$KX__C#(6O)5\
M^EAVUT[>OY0W<GZ-\_3TWN_IIL395'31ZN7R/'0>YHEY$R5ZSY%]O8!3S2('
M"&Q863QPZGP<8KP-(+D\JC28\_YE_-7I<1;S5B3XN\L&0O_Z%4+*OT?\05U9
MK]48']>(;P,,SJNP@,"GW8TLG4G26)_A(^]3F9\8:N/.CQ@^+V'B+\^S[E7%
MCZ=8'=D7#/T36QTU@[_AD#X].K_63:9A%E_5TKFJ-G@QQ7K*)L\RU#I.B^X<
M_7/Q>J99 UN_+O+OV\ =^TC\_]PKX.3$_L<WA9LJT5-JYXXNX<CH\W@?=V.A
M6ZDGNN*["O+NC]^;7UYW^O3E_/IU:+ T>7-$[C5\030_8=I1]V?,5U*/]LBZ
MR=05XJM*&E<5^B\F6$^9Q/]A3-TMH_ZMCI]Y?\;LW$<2_G?,\Q/?']F"-_DR
MI[97[<N_X8!Z=\N^_%XWR\0G:?8>ZEZ$:A7@QW=>+R&#+X\:#U4E?V]TLN]H
MD3?(8Y'L^>WD+)]XGSNS#?ZT*1$E9KQJ#$^!:6/+3]6(9M1FR@HR38M?ZB._
MZ&\ )_4A-M%'\GK7 \F4*FV.A/?VT&!2^]&CE\\:%9TCM/<RSJSE;-EF5>.L
MO^%Z?W0PDPMLOOQD-EZ1L?H-%W&]>-$XAD^R,WA%?R<TV']5M($P_Y+O&GT_
MJ>1+[*7K'$T^EOS_\_URUZV&BIN1Q-R>@>AE-"\,E^4D-;:L@GMN 2;SU/%"
MG:Y3/4X?0@7@>]_-'=G$LYK*8-/%=HSBU[(7S\/.8U[& H<"G6VGAGX+,?;:
MZXQ>,^;4G@F;W(MO?PZ[M"RV/V1"; RH9B3H^2%*BH* RGV9#FF9;U]=8#JO
M=%?NQ.S@M043M#0U5MA.@VKG7F;K2WG33QE6R[F]N^8!2AR;KF6D=/E\V*IC
MR>8D0Z)";IRJU%4<\- QU!6T.%?980YGE'N0]CF1(PEK$5Z43@8O70L!62UI
MFVW.8TWDP@CM_D(OZ,0S7#LR%KPLJ&^K?:LX3(R4AVYL^Z'.;<6U!4>DZ25-
MDYU_36UOQ2SA+N%UP+O ^XUTZ)=&Z99[@7G.M58)1_#W0<7%NM/YZ@TX7/+:
M#UZ0.XOF#U%%>7EFISX]<"L\Z[6J7W:_6?Z&XPH$:BW<B!WF'6&7B=^"6NJ@
MZ=+EB@\\#?(M@!>6]3GFS?:;F9$=5W)78]E3H]H%KJ;1*C1;S$7 S?"2IYCT
MU-QC'@CS<U%F7QTGALR%;BJ:^>S "O>\QSH9R!82Q"@EOF#.SF<F-T@UR &?
MT\G=7[^-W'+8&196^GTF7:E."GTJDPW39;0=[N1DQL36ZO#C.TNTHQY/ 89,
MD4,@ADY!(3<,7_<5_)U19-"1Y2$Q8%2@@7:?K*D&U$@JHK"R,^9BIY?(V[G/
MNJ!:#W#M(+&M<BTI;$@@AJ<72.M#J+0_85F<,D\+E%[.IFFNKX*N11I^&,\-
M?,M=@JR2BB9=KKM/V:W9J"N?=#B;[=/PX^!JWS!8]>ZEMXJXY]S7X)9PL94U
M+Y-L(VTE&'])MRNLI>&EM]%^\G[?2*+'=&4WI'S67W]LT93[;?K\D%(ILC9]
M(RA1MNJ71N##::*,B[V5W7I-Y+>E"&MO!R:,CNHIP;%K].5;,]" SE/_$F>F
M@XFM= '8T>$@]9MN7^[N=5%^]U<KJM)*BA#G9^)NCN/.58?;W.=?/C3)4X+'
MH&6KF12@X0+CS:\Y@IRO,PTEZ;CL2"B)=O.>=S9Z"+9AZR89HWANIYK:H?&Z
M!,DTB_O+MQ@%CW'(.G2JY3A[>,S@:Q>RZ.R\ 5R:^:R=%2D-CQ?=#M 5P6GR
M@HIEA$4#9-9:O[Q>KU&D*Z\A<HC9%EU=2)8*X\- %!-]?(^15+SC,B3MK #(
M@H>((/*^5#K_9VL=*?[#T^H]?<79ZBFV(.-)&\1:(MZM$?\H\&-8ZL9G?:,:
M' V'V3LU?_/2^X%V,[288VV,SVPR X@(R,I=V-2F.SB#HP'H0AQ%V5C9Z46^
M@*-BHZG5_5%88)5&7::15[? @I_C"EX <5JR4@)UTN#L+7,(TH@?^.N7B;32
M9@@6HG$/GW2+ +M!I[/ <U74L757.37E8.XN(N16Q!,&"S:X2U#:DW-[#L+%
M'! 9M*P@+L9' A:NEO79S%)*TO),RC?*1-D2AJ!^$.6,);RJ'V:*>0^HMJY9
M&$/BDRPN)_]/_HV)TFJ+>ML9B@H)='[;C8(63KZYO:]><PSQG/>8#<R;R9;9
MGLQXF)P=I)U653$ZJ$%/CLR9F#C)[5O2EX 6#%0_B\*%$5:_EE_0E/V1QRX)
MXE]9V]_$-K5CX'N>\9A\6=NX+S"^?U[R,.SS/1+-%/WDW-D@,O;24/M(]2NN
MF-AUCO; C=*+(?^C5TI>&IA#;^QSNZ,I1V]'84V!VV";>#O_53;?1194UY"I
MSD6MF\=(#1:34<16FV7 7;7IGAQSZL,H%[$3OSA-2*I"S75B'1O$NQ]&6[UH
M31WU@]BYW*<]^Q;_(?IDX8//BXU![)_9N?WR-USH?(4/B>]0]=9DD,9]=3F-
MF5=</<//-R?SU&ZQ,:1HUOI5P3TA1ZL1=,PE0]-I(!M[!K9$$*HZ9\*>G'Q-
MQLZ(8W81WW*#:XU<08R2(N*N9Q=+TB9_?Q>QN-0)=-X3RFH^AH]J8T4J%48@
M\8J=KT% L6!Z8 &'51LCE(  ;M4-C;WT%K7 K@H=AO4.&,V6!^/HG:6*D#2G
M;SH;FC#40"+_C#)"J,W^P]K]!B3R=[-]2BT3+<TJ.37JNC-S,0)D ?&=S\B'
M;FF\6=3,'7C+B"C]%ZBV EGQ;Z-LBIHCO,8*L>L:>(<41AF,-IEZD%*@C1B:
MY^.49POO7#L7ZY_Y-,H94X+HA@UD?\.])N9(3E9=,-*IX ,(TU\#1? .1)RO
M+X83-#D7VT\":):F#BQ=U<QLF7.:6V:!NK?D7R30[P,*;)U'S"+ZL1,.T%EY
MX<+1OQWE18_3E?^&6Q__#1>F]1LN>CRZ8$WF5][#[#4!_Q/P9'(5+)HK>LCL
M#H&-6S$N;%-BMC="=\,Y(Z-(P\(;!49=YY3"M*7XER9T'+1 JK?, 2':<=^!
M'I<>N%6_LE,&/3@$#!C8Y>1'Y$ !R>!=1R -.#*3 E&)],C/>E8&87TS<&_5
ME"EE@)&'54K&R.'A0Q'8AB8OC99,.36.;Y^9>728OR8@;8".1T7U$Y];5O</
MQWKO?,VH@WF'5P&%"BDF=<<W@ _5,66MM"&4O3R.A$C$P61OW^%LA_ R#\:_
ME[-&C_APXCY!$W%0G 5/0QPQC=Q0*+YM;@+'$U<!HXXW(=HFVO$FL86JLHWQ
M8D-9>(FM&$FIET",E$#K0M;8&2"?8G5])/K8@1PQ*34$X3R"H [_J!GJ6<]Q
M_CYB!-10"PDAR?\"VEU0#A?HRE,CC*94=5(.3Z1_*R]MIJFSBY506% SEG+6
M-*)Z9:.YT![=(</]H*P#<H!FP-$4]BU]^52]T.=<@3YW-9O4D$MHXKQ$;9+$
M.V!,'(H1Z[=I8<KL@$E@_>&+'6I[7=;:T<R\JA/<9GT(F"KWD]40 =P[;.XA
M=%X<B9@W4GQ-E\L*I\R=;C/S7RL8(3[)^HXH._G+CR7Y<=HJ\GK4<<+Y(A)Y
M64HP2LH=QVH!__92S*$E+0QA;AIITG .&P\KREA84&H1ER/WUSUO#2/X^M74
M"II\8K02VHHE@<B&+HX6(:7(T$!C#71A#KX^:?&XT6A+EI*XZ-:OCX!_L5N2
MJY YA]3S86@QX6C*,0NFOG/F8Y\A(!6;>O^/=1C!7^O5?ZRC*DKSEV;I#HZ-
MF!++ K,_)VFV=^E]M9JM2+CZ"QW/M5/GQ]N<R2H8@&HBH=C6@L1VV,A(0=Z3
M#^!0YZ'Q0]H7;<*G@WTG_N,/RTK/G0!:"U[!VM:/]5VS$A4C_Z5SW_\CYY]/
MSR9_, [L9L!ASA?P6T+]IMYIQ9J][4_'R4MWBMG&)]C1X>8;'^ **R5(>D&K
MYOAA8+FO!&/YJUQ&?D2O(#@)O$L3F0CC<0G,4P@X:HW\7M;\O:W3ECJ>L)^F
M_T<)HV%P1U9F17%<DNZR6\G72MX/#3TXM.V_ZB2S\M=-_3VQ<P;F74MRB8,-
M/J&B)DGK 3E.MZB" S'+JHMW3C4R/I[T=6FB5A,0$UMDS 7V5<8Y(D8(H]I4
M#3C/:8K1Y#FFL2W,C1ALWP9]66%H:(KWU(,Y@"-/9L0<D<1ZV<8D9X%J#4$E
M,TJ!&AP?5U\%R7386K[Q8D+'F$RSX)X,;1AGA/<R'7\%8R*M+Y/3@2QL/>''
M<U16SJCIC+[RY+-\->/P5L$RPFR=GY.C'R+>W38<]X:C22&$YE:V(T'"O3&1
M20$;O$8=T2!X&85EIPTBS,SX/E[KF9>V0)2)'SNG%9'TAE1!=;G4R;5.FA#Q
MB%_FTG87H._N/(1&'"-PCI37\HJQN_!I8W&\0!S;9-XUI%6D&KZA#+8"?6A)
MA+74;&WU67VE#7]=+1]2@EVSP^ >T92\HC .6E@=N8ARG.@J*HW3VRS-C>.G
MB1UWIO$<@-'VU?#RLKTR0+#5J6^T+W9PHV=[EG@S<&AC?4B?\N.@P)\@9BB=
MS&'81O<YFLG1FID U:'L%C\/+,+1"O?7N[F%()9"%#MVNA&QXP8K?5SE'^_Z
M$T(Y!0<3CM<7!WS1&E_F9S]1GR=ECH4V9Q =HH4T$1E]8*W$P7UFK<%\%ZXS
M:SJE;L8^KD41&9V:T,,3,RARSE3B^:56>3_>TZH(9DW@5M5:?XV$@"[.@S<J
M:5USA1+1&YG*.'H/&GRF_UOK=Y"RGVT'QSMD(FVI,A+"SALDA)SLJ1.?081V
MQ#G5"[O,/-Q16_?HV)IFF(G5XZR4O;C2&ME4V6;P^(0 Z,&T]$::BMYON-;T
MWW"X9;_AR-/)%9JB7V2NBGZP.-\.+F<W+/A*^LX +M8,OTWI& [2=KRS49^W
M]."[&"H=J7X3#;IO&NSH%_@N86%6Z-;?RU=FZG-./Q[.AW;PJO/:R"5%T2PJ
ML:Y6X343M3N3>87C6?X0U]2&J"/8H^/ )WR,IT>/O5S=P"@HKGX.L[#(ZE_R
MAV,3?\BO1<_[=51[:\S95$V3!DU3,0JJ-I-VPDQ"X)58'@)P*KIUL9&%E>]4
MPR%QAS*TM,AF<WM%;*?JZ3%--\U-8YQVG^*?1U./+(,3\CXSO@?;Y+,X>DJ(
M@6ATW5EH%TRG]V^MIQ<8C0.W4D*+!H"XW-)R5<7$N&8HZ-$N2QTX/P#OB=.Y
MQI&FZB)FZ@BD2;@-3)XT]'0E],K%;O&8BHGD"VCWS?!2.'=*4?UI F8U;))"
M4RU:BK_D#_!2(1-@,07'DZ2G*-*M>#M+5N,W]\B.ZGF=85FC5V'R#_% TB2B
MP'KYI'UX>7%A,+I>W(1Z]+C<==B@Q >OARPS>\J9U=$T,2 A(NRGKN W\8Z6
M@Z;'H$$-_);>W?)I";9^5Z\I.\1,(O8O%U0RV0@R^3-&H>R!H$:28/;BRU70
M/HGC5YK]2YB( 4)IKG5AE(?ZXCAC\&<**L[1FI;IMR2LQ1V!GI*D,3_'>)*B
MHLHP^E.9<%VFTWOEB7X.I9/3$T)U62+[@QDK*IK>BB66"0<5 U30*C]AFYOI
MZ?&%]<[L1"A:K*EKMM'O<6@=.$2_F<SX(WTRNGL7D($,2T.A\_JSA%$:VUR4
M-9#JFKF ]W:+:7"S-">APZLLZ-W,[P.FE2HK12?^<9X!@W[7T[R#M\@<=^Q$
M$KZ2;>W[G]_,&&*DE>FT!&3J-6MWK8)!Q!*2Q[<F.Y.(E+-V%+N\?'*ZEYL*
M$,R&8-50[#5Y W&""%.Y 0>I60!W5F-K#:;PK+$Z\\4Q%H,4)%Q*%>46/ GC
MH6#^"<'W8T8P,A RH\SXDG*L:6L:4<8,?+-%$&97OD"=72=/!;-RWEWOEBXS
MI%8JUMD3M2_OL=ZG6(1@B0@/8OF'C*6B#[S54Q^LFCWGF7.AF-^2-+BZ)F(N
MIT:=+TQ4KUE$$D66'7EXW'2F0![&GTDAI(3+9=OM"KK?QV\P:24-6@N9F5N#
M\@1:$E+V1UA%DINQ?GP)4+*)#[:4L'*9E>;>DTQU!R[!XHLYD=7H<S92*8FY
M.:7!&%+0O:IUEVJV8FGDR43"&4/GBR(H&:J&THXV.()HD275URBYGZSV2I[J
MEEN@%6UN^3<<XWU+:Y'VU2C'IHQ)>6XF5*/FEX&VD]1CJ0V&@L0'\WIR'7"I
MJ3ZQ$U%57*DZ6&OF-2!%WC$5DIKRP9P?B3C!()6R!IM[<.:!\EV18*!\TA,,
MVV%Y^E%;R.WB_1Q1<T@U!3PQ/J? K\(UM][2PK6:^4T9$(+Z*EN9*V^6"#*C
MM0+\>,N6VNE@QG;V,.O!8KL;08X+,,"V>VWF,;.;0%^?=S2FX+C4(VC5'GN/
MDT=X8ASITQ7N345H==ZH19]6"6@ED33U34HR0'Q&H9)XW7=J!KQGX\25E!>K
MS?=&2G?=^A2BY-IA5FM,05U%=*@ZBIK3!_^*D<>4'8%FP,UM!F=W/)@TE;5E
M>]AYHC69&[_(PYF&=('H8L8Q"S84)36B!7%.B54)_ "1NP456YASW1BX##LP
MPG+ZRJGIU2DC-"W(H?4XOWQ$&8YB_URV4Y^*O:*-BTKEO.(TW+AT2U&AKKQ4
M^/:526%(7,R]&T3SS'+B8=R#:/FMR@[HV9;W%\VY'DO-%X_; -U$!(A-M$JE
M(B[7-[6X[@7_T 0N_A[5B/1W\/=O\UK1K?UW9/#H$016P\02WF@4U%T7EPLL
MXYO^)[OIE+:7/I_-^QH5_)J>%/!.?7S1^9[ZL.=N"1(%5G7ZC/Y$TE#[,DZL
M,81.D@,=E-=^1,9*%E8L<)]X6Q2/G>RTHI-0AC+R,X.1?H(]XX#P0)]ZJ@?^
M[Q:KTX5R1%VRW^$="1K%+T9LB%9F+F3DM+2!<$/T)7L950);!=NT0G5\ 680
M3V([P$$3%-%Q[$QZME[UNC_BC9FA:*_ KP>!&)"6HV&.IY,MVB@^G>&#Y^3'
M9U :G$$.[B"TI(>CY3$S$3L4?G56Q$9#GW&G)!^LA)?GGL7D7SQ)G=JNQQ^X
M<D!L(Y@IU7-F4M@OC2B#H4P:KD#%/F5CG2ZA,RKZ&H+$S1Z"*8NI&+(+)';0
MIYMW<<1Y_V-2R_7!V,)N:C% 8+J9XG9/6 'O4^UHJCI;F5*MDV+'$0)!LT([
M\V^X@&4+YJ2P9L&FIV\]!]N]A/@NS0/@Z+</+DW<&AHM84D\H]AE8(-EPU%)
MPY';\NXSEXR"[!&%,O,QZ9;F@DW!W!YZQX^.)X!"*YL@+*9J)>F)V1);2+X=
MO>P/RJB$V>#9, \9 =Z92\>V()RE/7.ITUB7.V-!<OWYS)T2P_JLP](EEM;7
MIL1%*O,)O 7SQKFK/SY):&'<G(6"O!? =&D$2!IV7 J*=\9@B$6?'&,*T]1^
MK0A1FFN_P>!\UZ"('!HI[D]S)B\(F%2%>)<BJJIUQUU4>\P.L-F\\LS1 1C/
MS,I&+4MC\ #H'D! > XIFMT:U/$R89K]BNC3R:U,>&^KN*:=%&L-!O%$79[$
M($H4.1_4SQ)?;P_ EIBC4:H_+11QCY3C\0]D9V".VQ5/:#8<-=1@FV_1(3?2
MI%2TC:IP";%V#JE=%EL4F2M^T9P1?OA.A2W"TR*=C#-CAD4M*U.*F'9K7T($
MR<OKLRQ/:MM*J6.[?)L6H($D634K.X \2LRPCD;TZ,KGK2SC:8:V87O6"E"X
MUBCZ#3=:X+.OO,>>#61XZ?7!#DO'N]4(>/EE'*[<8#TI8*Q06KE2.3%O?'.I
M<OJ:?]9V$L;@<[DQ:62XK++4QKEQ?M\6EAJ!;+6R;LOF'[AF2J__X[V(P4U-
MX &]>*:B=J:&-: Z@T9A@*U\AV_ .<,RTR5>X@VR-3!$4#J5&@Q/Y8;49[2.
M-E!27 966/V7>YN&QBB_";17H4_1W8KZ+4K]":19XUA'\;-67CTQ'9BR1;ZS
M\IQ4)'QQZ95D1+79)>959+QKJS DA.IDAW(E$JE54R\ A;([+MO*I&*O"]3Y
MF1NPJ"!_U$Q[>B0]\,BNC&8#W".Z8(IF1=AJ@-\,R'H(VFJ'.LQN5VW.)<B\
M&@"5% UBTNYW8I2>NM.WJF=EB!WLLM(,X"Q6]<?'.< /:I?#>Q.?;$5;3/0=
M>J:M9")<<I;X7V.(7URX[L.1,U&?-;TFZEE3/ Y6"HHV?86IE#2/TC T^174
M^$W:]O[VRD2YHV!:)"PN1'/*PH3M,K<@, F"IVAZ5NO,7DG37,?C#H:']D;+
M!*&&.*X!27V(HR^Y,:/:9D114U0^ ]V@$B4[M&+#NZ%MWZ)9]&>K+UOC1GXL
MOE(1?_I$KOIY$""O60@SS$K\S"SSG3FZGO*48C6KFEP>E<H"&4_][2O*FW0)
M"@V$],6/%NPC+A]E= S0[!YR1T:Q N+ZJ*[%HX758@9%;:6I'_/%>4(!;\#N
M3#F1+MIC7:2)-0:9DI'EW*N\VNM9 \WHI'4GQ;WMZ"6G#O3'Y*H/]-1N<7J"
MMFUS<J1JM +! B+:LAR[->MV4ZN]*F#*;ZXNC*]"JNU<9^;ASPHG?/";%VJ+
M<J!$R)"B 7%*,QHC5.T^/<EW"9%!SP[LU')DM"3!H!D51/VAVW6A*)?HW3R0
M!+4SD/8D-#_C?(37RE8P1M:*42Y*37N<O]P"(U1#BI1)N%F#AU28D[88J&*K
M+9PK(D^FU4=@,W6 2!5@< </<:G\D:?\XNAY^W5"/_R)6.>N^N%4Q]9X61KK
M//C9"%3KXS[R:*H%F_L%+1.M//MU('N@4"O27/+WZ.-*EI.B$R/"\[MG(RE%
MY%=<$+N&]Y_$S]@2*FX'Q)*%;7/<1]0;-?"*-%<TRT'TZA<1EGQ_:YWD>#?M
MO1BG LFG@:ZAVZIW8_]LF\VM)*4',%H1D"]ME(;WM/Z6Y-0E!]<F.9CD_PDN
M'>%338FV7=I9.AW83C\8CA9YL0&6U[YX:X2'L/"]ZYUC?(WR>K+U5U9NW  +
M:AZ%AFL<^MJ/N<K2O4<D"6ZQX^#" JA^X>D*S\"1LABV!OE',A#K&+%7 ]P:
MR=WXTW?&DJ!LO&!D_^ I(1OY8L>&;7-1]!*NRB((M<LV@<A:CG,XT[X3/S^G
M[=VT3)4'Z_)PUOAI\LSGXCG=VR9#%>VO^1L9L9YA)!=\%O1XU=KNXH[E-'B5
M(C:MF"#_Q3>>#?QJ\F9>;RK?DS1B4B)]"IQS25 J_<9BXD7Y27WM"RI1<3I5
MES43%K7%_(:F@Q7+&.J/G]^7HLGZ+PZV/,67#M@6B62VG%#DKNW12KVY,%TJ
M(!+;Z&XAH*CKBQ:=-Y?X]._*#877'[T6S3AK&$XW<L\P0G@>4$^JM>,(XO,2
MY2NU5@MLQ68.<QF: RJVOT1JYJ54T <Q<;_9V<LJ#ZSY4%?+>5A8$#@O5 #!
M];>6]'NI)8SM&EAP<D*0@+RU,@>U"+!QLL->M6;T'U;+[YMZE_CO),!R"KS9
MB]Y#%.BW/[-2#^0F21^D<^OGN]Q@CSKCGCF$65,RV3HG%<ZL(@*.%_)6COJI
MLCYHS[JW*0?A]HA+UZR?@)B#*3]1<9F_SD9 D/.MK7]PWNF+O743*UR/)E[?
M%E3_5E)0"\33G$P\<PX'9O$2B,@0X%=9C&VBC(RS)F @[Y7V_7Q6FQE6/6'$
M#8K+>I]KGHC+S8ZLH=XWI$<]P;2[X[PRH6UW4B=_ES%PQ_D]]067OA,6]E)"
MEU)M#[3Y=?.R7R)(>*L2\+2W <^PO"BTY<U1>FXC*@#M7,;I=+9PSE_.-M3T
MW/@-AQT^)DCO^2[8!_LWW&FA9I6)!.T:]%L/2C+TJ^E@.B&"YATA1.^ZP.[O
MF6)U],8!@:S_GG%]515G90HWSN2(8(L>#887/$$+>;7ZQ8CU+W&#/\33&ME>
M"]=-*?";T'8U_27N\FH)IS0QO"C]VV\X2*1=PB(H;+%0($-'?$O"9&6Y,[(I
M?KFLK7!,R'(9/<"&A(?DKEK.N^ ASV(5\ALNR8/]@F2AQ49'F_#)-4+:&D,D
MD?W2;]](@XU@%.PX[K5&H(7'PXC_FHS\!RW78_%%TX7(^1_>$WX)WA5#S;=[
M:!DNS+LU3AX6FWDQPO@G,]X9Z:+YYS,?#VLECU+'WTDO875Z!E%?R!3IE,%#
MWDD ]13I#=( ;;NS#4-YYLL@*2I_B2TA*Z]@#&Z$SWU6AU;I6N+;W]4Q-34;
MF2/Q-)5B-[F27EL@[9_5KA&AU1JZI/C:-I+U5]]MZ8LM**W<3.2[$M QNN[H
M:FG6_10:6ICC]^<-D=8=]HN*[1$*+"O)<Z&K@48ZKH_P5VF-^IV-!-&G9775
M^;>2T C(17)C :+R("/'+E-=>S/<'3)2,"VY>>&Y,CQB/H]NG4#+3_3!^=5S
M)U'-00U^9Z7@&MG'D&&:J3<!M':1[/TF"_@>32_ZB%<$-@Q2+O.>HAKXK^O8
M9+X.30#2F'C<EJ9&[K0Z<L.,2V49&*Y2+<P7;;4$9!AS1I;V83E07NN; (UE
M>IZE!2!5QWW2L:%7:LA -!FVPD<_" *66V<<S"_[LP .%U)W?\J8D*(YHMAQ
M::K QS<SW^,E:+B8V%!'W T.C8 (N?SFS- :]HDFKTHXP%[!LE/# ?-$I55.
M'_B(V,C!0#J.KS@'I+$>K#DS$VHV<5@81DF.1XW),@8$]_(KJ^NS#0%8&K)>
MWI5D5V+\AEMJ'_T?P,L%B?\"__&,&VZY=A5X/?-_L25P6(M&J^-"^LW+BX[&
MVK6_)V&XX??@,&!^$DLWPTWY5@]-=8G$-P(+Q +(-;MY,'Z3MK297LM2Z,]1
M@H"W+DGFY67 \=DM;=9 *=+O/ NU"Z$D9:?[C5K#8"W4&/Z:OIUJ2J5*JZ4+
MM<4OL\2H!E\5FY:]3;N>%F+F#B/D)>P\S.0UJ&NN6*V.]V^_>C/M52EX:H-P
M?":#I1WG&UPM.O&]0)J9-=30A@0Y3($^*S'WF??0R:\9RHBL!6VC0$;*R28I
M0T\\K6J WR)P47*$Z5F]QBAF33-'WKJ@;P2G_G$ANGOD-]QK,J$7]RD3/,WK
MFCF!7.T^<F)$A<H23&H_$S=6H9/@0#.^>DQR,E(Y&OWMTMA+'J%&(#I-SB!G
M&I-R&M-GF$N9EFIDSNI;N5S]U#= 1QWFC\ID^JRC&B4R.>#''$9IYX/!:=U]
M+Y^:I%(!4Q5.&B:OP.[&*?PZ!#OD)V9?8-L[O![+?M*0:079Y9P"6VG%S&7@
M/@LB8^:11+KGJD?OU3+QC/:MMDAARLE3G86X-+'S8F+K#\CMTL,,-?_%\F#3
M6]XI?R3#"7,W<HS&#/L4H\(V)5?EY^W:Q+ 2BH8USPU+;)2]CW=*CSHH'$[.
MZ(*4C"D:_;)40UL^(D81L7'!9'($T:2)'24,(S*:J@DU*_,49E%[Z#D'WLQ*
M[E_3[^[_=$IWU$> 8UQ101FAZ5LJBD%U*=9JDZI39DZ[N)QR\[%Z'(*W)@N&
MRK[7((E16_K!@A$;R3&/Q0N;B+M>J=A@&1K[9I1EE8E><W/NN1G9S:%EFK6=
M)O0B]3I/!25A"\0P]5GIPU*Z D_*T(:QN[A5+@,_GQI<@I+ZQ&O:WG(\9AVZ
M5U[\3B2)S-?<0:GBP:/6#$;J1[4[+,QO!B,LC\J=2_O9&0B+&<S""GF';NNX
M\[B'<=@.B]AHW/%'; =$)>KX0(9&A&I(0IRRAR!?NL0OW8R?>-P%FKNL,&]\
MFGLKW;4VJK7T,8HQ/+A=%',G^UF>+HG"$NB5.(K!$!;&A3K@;.(!RJ.EJ)']
M3]12#[TBJ&1%*"PTIV!Q+OA[3]=/(^]E--0^=@,1?R:!)/EFRG*7N#\^P.BL
M=L#4<?PQL0UHQ,U$/+@4M[;=[#67@L8'+!N.O8*ZK0.B6 H[&K+ 2OX1G/P#
M$<<(MPE^*O+R@M*H%(VQ805R"@?(-5(%7+I?QZC>TOFK?H>T#*7[2-RYR#14
MU[Y##KTS\S@"^,2)M3<"?XB8NZI?CTX6(1[9@!J)(%@FUHE/?9YC>5@TA1.@
M_A8M/7&I"/ B,SISB5-F;YSN%YBI1^[S+VO/?:V,YZS2A*=#V5Z]""GYD665
M1,F^NO1[V^=:5/GQI&LS=*T=-BIV6ITVQSC6"4%&+W7-<LP2BO?6@: ;-+[\
M');F'Y+]@W*3(2.6K'Q1)/)"<4RWZCLV81-:/RB3MY;*!164UJC+;;U2$N-Z
M3"/?SZ;TU)*R<P0)'\_L<3.8:>]$CAE85N,+U0GQHWH[9"13VI%24<(*XV20
MV>/\#TB[P"4U,Q :KIL43'HE)>+"+ \YJC#:5<[O$(OP&!8/6=0W\P(CSP2F
M6B-X9?'^(B0'!O\2D38=MD?]AP@C0.-ZP*=T4*!-!2<GS;_P8RG0*]H$PZI]
M>&+6U'$,]1(C<3G")]B*;:2TC2,7U<W"LR#Q.4N;JY?Q$[^12JD#$6*[\83#
M\?=$]Q,E0*]-)5RX$=['NI!"@UB*XB;QI%E^_RLW1UW ]#T_H"J[T/EF@K^C
MB\&D(.NSIOQ2V@\)@*&WLH,M$Q;2P7I,5;D$7N\/RMX2\[(XAD$Y*N"H:U7/
M;3#)A%6#&4)_RX%<_3SJ<E8U8AI-2< F-Z'3S->" Z*XRS5Q833C>7IUYVP1
MD=3=\K\5PN Z^\<'M?M?']\0[%[CE9]\]C=K4M*F?98.LY$>1Q(T<TEENN.0
M0_LR<F"#Z+>P>JW[-6OX>THLQ7M237UF64@^7VR09I%:X+U\W(CRXSQ;!\=*
M,)IX(B6Z5"-?_*];24>8T_$\0:1P8D<9O[:4IOJ*%B/CU?OLO(<P+Q81FN?C
MM4?D SZ]N%_GFWG-F[;2M(KJ&;;A#U$C&W@'?,2:"FZ2MGO]8;Q'?SX] ^1.
M#,I/ST)R>@JFO50,'WYQI&*UC.B<_2D0S!I=UZR,9CD'%]N4^*N8GX-AUG,-
M^[IF+*H]9![FA7LC$K"6L49@2\K8&.3^S=U(4+,ZK>DE!\.*'K4#D)#3X(!T
M'.Y(?N843VC>#9_QCX^"+ _ZO']\["]7$'PPR')"\(-:5'<B+W$[!3+T;6$%
M2;",)%P2]2HV_IS,6V@KF+<<+)$;G"5\_/,$XL@D'V1#E+)3$GDI(OBW0L:X
MB%C)EB$I@S\: M!+2WL9*(J"G Y!G^D2(]EEIY1UXL$Q7*\].I^WDMM+'Y;"
MVOWG]9%PVAC4K-FC+"1.^N5Q&U+N490\^TW!TL(B%]8JL_R/923?-[G9U.<4
M'T/UWQEB:B<;]:_E8=2]_D+C0!I3U?;'AY7I'Q^E20)G:B?1S"L3XMK[_!G3
MMA.(OG@AT)E8V]+4ZJ&_0E*!E)R$PW(0>O<Y>?6%KQXD1LX)>3]K#]X_.AF)
MZBMH80A:[YO#;&'. ?;?AL'I?OTV@F0F;@WO]$+E0J;&98=+<LSMXFFR]D<.
M^-!AKM^(CT$1HR?0,ZYE1:_2NCI.X:6(QLN:\3%?9H^?:XH<6R<TU.8TY'@4
M!27LW5(WY0G!-2O5$X8>-5MY-8N=G\^U13+/VGNC3*][.(-(!@PO0B.;\D0Z
M$P<&. E3&2PWR)/W@-M]D5^99U@I/>F]_TRV;X1-/]Z=\B;]Y"K-WY.W_T[M
M"=E]5*VYPHX8NK=M2H+K[BDB3,BGPV * V"#JD^%.>T2GM_8I29-Y[#E?;60
M<-C?8@?R#7:5VA9]3\@V"!R\GW]FU,#OR9>."H%Q[-2R/1#B09CB^-@C4F'.
M4?M?H#36KF%9'FUH>(6%D3.3PKC3_>\@J>?.M@O_M(@J6=4"P<^[QVH.J)G#
M-W':X )Y=PS30J)>Y1U&(X<SYYT)Q^A"SON'A6W=1/0Y;G8I#>)=+U>PU)E2
M=U43R>B@JS'HXI')%ZVTM.?HCY$\KIK6^)&!2WO(Q'\WLD3 !SK_=RGU4RZ>
M"-?Z':VL&35?A""M9@E+0Y_5= I$N9-2XJP$@Z.7F4)9X#A, =*0R&S3XYBQ
M&?Y$I.@>NY2,?0N23!AUHI*/."*/IA0<ZHWHZ!VG5VH;K2AAX3FV42<1K\HO
MHY_@[&'E?9-+6M'.#8M/+S,]R;-?U%_S%$).RXU3S77^.K;,LY2?/W<L)1L=
MSB#L/<KI;X&!*CGS+20%H@J_[8&&_P[3D=GGMI1_>7UH:B5JM-9&^Q@[D706
M,%'?Z.JBBL=($XI'Q-WV0+3NX;),*2,7S52"@+#7GC949+E,^>9>(O[K *:L
M[3)(_QV$]^S<_6'Y<T/4S.&(<*V)^IGTR"(FF$BYJ&,5D*G/3Y$48"\86&1T
MQ+Z90?#&OV)A].4V'ERP< B5'@>$ZGW]INC(F&#1YK];_7.C#UX$SAY*-<?#
M%^X7/S\@J0^G"Y9@+%1$J5N0"]208+;/-D$OIC&PGD*^8-:*V\"=XMC-1W9,
MVLJT,K_3>!<H%0 6&5#EF?T59HNVFR+7;GMJ<5B#R\C7A7TNX+ILE_O?"'L+
MIKB^-NV70""X2W GN+N[0W!W"=(X- 0($-R"NP4)#HUW8\'=O=&&$)Q&@VO>
M_S/OS)EYZIRI\P'V6KM^^ZIU2^UUW2?2^-]4J6*T,U%@\N"O,B0;+CS^_1?)
M$<HMTJ9I*N[)]R'[S<Y4,]4G_D\4KD[]JEG5MQ2GUFXNR6-R$D/5R,X@5_\V
M:N((YJ_+B&8RXW$:$<_L/Y4M;$'#<]'$"K07L?W,MQ7-U:UJOM.EX1YQB<=L
M"*Q38^T_&&6^C:E1BA/MVBBJI$;0U!JRW?*X<[JHL_(R@ [;/#5'_-#HDML4
M%K^+$]<1@A*']3YS(T1/L-J-&:OWD;&[$!O2V1TM,'! Z!6^#0" !P4F6A$?
M1*8_*\P2=7U#(;<VPL1LQ,$#S<JJ.+DCIQ],*\57Q;=.L>C9"/6D6%$MZFBB
M#C22#L0WHO$R0M)/*$#]G/TY+CA?*I:X! ZH?9"G6]!7L%;56=FSY%8BA[AY
MQO"R\NO$X)$\D:+]5QF\^WIKS7LBV\1J_Z'J)$"@*,BYVR7(@['?N-FYITD*
M0);)J\>L/+0BGV:5R>D205L"$D%AV\)_EC+%VZ75UMNW<%VDB9/]U^2+'I/S
MU?;V<JSS_3E^FCVD)J] PRV-FY,'9IW+C\$9ZF!?.35$Z*+&&"\C86@5R'3-
MPW2G&?^%IE341X#73L X37,BL[6P,,=PGW)&()=R$6OTTIMUXB=S5R6B9?F:
M]I%Y<V2KV)NREQ\,/#]V;WU+4'])E C5B1+:8PM/@#"\42OQ2^8%KWPU,M18
MG'J,038.:[4&_+*D[&%.H56#0.H4/2-+8*@;I#M+_(6,',-I2]?Q+/WNN"*D
MQ\Q,8W@FJ//6=E6EB7U=M/ G#2*)Q_(CN9E3W($GS22JP5\$T[QLQ5-"6 (/
M4&5I$:<EK#F1C+9*^P/^>]8JWQ6G]GKRME2O>ZX18$>Z^(QJ5^7EMZWS@7!3
MTQ,U<^%3BYR,SG'WW+396]_!+K_^\$YG=8#3^Y7!DXY)QIDZ 9%%DW85@820
M.PA[QR^2WXCDIN]M:'5.#\$CV,20'VKKP2^&#>],!5[B6G_0Z-?]@>PZ[<=;
MG+#AM' L^:\SQ0E>>H@YQ=8O."Y"D:2+D8N:'$Y 6'&GF].GP>FL'=3$L=.)
MTR:5@C1'%<)O_?K:).39*-ZT;0/\&!(IL".H4ES]6+%.Q<_=+24R _XB&+M(
M=!J=# ^0MK@QLH31P!-F?">WKR+?:H^4X3U];.E3NE>BKV#_)^9*WG7/; NF
M!Y-P[9E/45_Q!"$#:' $D9_J:Q>"^*8;W>UFP#5UK_/Q!@=UCB_ %55QF+YE
M15Z#5"?G.*2?EGA6?A<5"\')% 5^H?.C@T[UH#U*Z6D__UM^QU^$SFLP(-\<
M$'5T:C1\[]5BV5W/_<=,96KZKL>ODVG]GL7^_@]%#LL( 2VJLPQ1V^\--3=(
MO<Z\'#59$H=5ZL)U YGU3-0[:C9\CKTI+SVP264;:#AHJV_BLRNJLZ#A<=2Q
M32,U:;_5 U7FXI5MGC>+-"ZS^[X!K[#K ;FZ'<L7NM?MZ,5][JC2![4FO:2!
M_D*UHV'3W(/A#Q/8V>/<Y5-DKJKA%@F1&&0] 5DDJ?X/#Z]5N7,KX_5:'<:M
M@2R>B $3V@NR4V88H=6<[Z;C$N(:>2XIWNKR#O=%P^\A2WAOF4;DH017D1*%
M.1_&]# 'W_P$65_/G&4\UL,LIIS=ZF:ON:R<,V$==D72$'(O@6FV< 9T$'FS
M^)%Z5 ?!AS.S&&QYWU=\S,AGN<G'U,P7@(K%8?ZLF9J+2/W@>DX@Y44CR"Y0
M\Z5R+6D54 >N&UWON+-UX0D4/99-9D)I&W)@>)=,A74U/4%_FWW(_!<!I>UR
M<5R2]&#S;OQC52W]^(4A3^1^_WI]?<Z!ME+37X1UN9*N:F)8L]:B:(TKH+TC
MKM.DB2RCB4!S4,?397<,,Z:WIYE8M^Y9WD]1=#<IWDTL^'3X91Y:KZ.C'XC!
M$0@(6MYV"YUNUG$*ZN<C+"\5.LQ4.LKBCD4S,?=D\+Z,Z3>1'_S R33VJ5]G
M X<-FP3+_KVZ3:,']%O->U6C.\]<=1]KD:B#SKM@W0MA+PS+*>*LYHC?G49.
MQKKW!FB$=W6=WZSBG\Y*.8Q4R9+S&<?4'KN20LYGDWP5AF;<'[(FDS>#5J\.
M9_J62]AVK9['=<^9XQP;?*E BXG99Y*C9F\H&Q>O>_.0%T?)>GIIMK7#Z5$_
M]B-^-3$Z1/+:^2CPYWYA?T3M$G].:/.N>2D_0[H=*3]TVZ3C:!G&>6/8#LM:
M[+(J.=3LTW?M_/(\?J&&W$AV0#27:AW&'N2>/AI816>Q[1DA/BZ)CQDM\03R
M5R2_ 3$&EGC+>'(T[/<0N-F?A/</@_-.16^+CBWM(<W+8E)N@-/XAL&3FL5<
MW.+'':+:E*^*S&BW1).TM]F_F+?>5LY26$MA/LT\W?R8,')?_$DT:>W? ('#
M]_T794YZ;N<="YV#1@ + MC5ZR9GOJ4@0Y=]>Y>(A4;<=#52E?Z2$9);FW'@
M>8SU(;8(_>_UQ.4.$XFU?SZ5A_X7^TR&!/_Z*^3\C $XHX@F_]5G^1+CBXJ&
M+*W\4>]]U<G;BW3:&6%O8C&A"- JU1^$>H\)]5:*6C,IK^.,B.T,P87/"=\^
M<$/3!?-MJ;ET1BI(#?B2#"2GH+J1HJV\J7:SK<L11?$/F=\-/"+X_VCE3UCP
MY9#*OC@.ZZCLI7Q,+[Z=K==('/M6E>)2LVO5M;N<[QVA:YW8"Q4M6 A:6EG_
MS <A@V3B?.JB0#(9)/Y(1(RK%:V/R3S?-)*$WTI?51H?*NKB4XU-KYG]RC 5
M(L(:ZH7P6_KB$&R[2-UA>USH^<12^3BF-!L47K,NA)4!_)J)82(PS-:_5Z2-
MOYIL2,=9JO)%TI@,;G2OS$MY5R=T3Y6DDVK8\8&?!'\=&W IN&\Q^LP.,+%8
M2'+:++\U<YX*!-_N]ZSDH4H.]=1;?".O\S09$V:8,^>PFUS]B^"4B!A_(1)'
M>\MS\8<JY1(;_#P">X2FMG_C$B2&!7V9$8T,RI9<Z\(YU?AYRLI4O$3N;9ZR
M)""=N4 @*.O4%J&(UW^.DO3>?36>9?F5)6M5M_Z+KKK 67.27)QE^J_J^PEV
M%;(KRWUT:>;Q=/F2+<!#4D]6$C;+R'LSA2GOA\)N30FW""]%GEC>A;\(Y3 5
MVPD+9$8(C,T/^"!EF5;O1P!3\=RH<E7K;WCTO&>G]>;AF\N'1.48QDP7ZJ(9
MV Y9!)OJ4T9.YI=#DUA9N8C)=*M&,O/4S90,0L@?(K*QN_9FU,;[+3W$YG7S
M)_-[WKJ5+APJXO*T"/2S1(UU5L.<CMR>M[)FH6E #57LG<\M4>4I1FIC/,5O
M8E-8F<=.T]_\24OB3F=ZU\[-]\OFF=XXF!P$BE)&L7DG@I3G?VCB>*P$>WN=
MUT:9LBCA4'J4"#?@"(Q;A*F3/FF>-=K\Y 0D?YH93&TGZ(I)O3<30AYTV*95
M\8.V?'9GN7$@:C^\P,FQXQ8I2E6(AHD$,@4=LH:<0^;^(DB2U]SW_C[XT2MI
M'S=0T1_L\S2K]Q=AR_7'ZQ<AP\O0H1FEKU_&K!>VI43_/QZQ:SBZ*"R0O":2
MNOO78+1"K*5G*T_ON5_4O$8^]Q^G.\0$HZJ,V7S1CY-<[JO$,1OT52WV-ACP
MR)%IE,.SEA!=;SSVR_*ESHGP34C(- DR+55S31HS_GO'(]$9:!R7@< .V7&$
MR;&=&Y5ZN[>;0>H'B@!?G5K1BVU6S[@]UV@],,LHL.'W6EJ^X#;F=/J\W87&
MC33'P8&]C8B"OEZGYW+TDY@*"$#*1HU2=_G$@B$0S>2  =8SY-(]"<B0W*G/
MB4'-]V\-,/^S9-SQQLM?%$ZW;TC.U$=2/I* ][M2\.KHG;Z\((F\F(QOO;M"
M>L.1J>#P5I=,D7,\;%JAZ4K]FVE [RKD"3PX0*\( /#/KBU*8S!W?&I/7;7)
MC $_)M-&(/??"7\/:Q/&<&]@N .Y!3V-;8B+.G0&E@1J'G7<*BY4D-=()_QQ
M^[HNX*(VO;!F&!OIFZ7>>ON\,5)]=^<"7$BK>=R__^ Q4!TA82IB2V_(+ZFQ
MSB^2FBT=9J^^]N:L?M%UH>XL$; ./*4W7L_#](A6M< !WCK^D(V3P-'&A]X=
M^3IJDV>% 2>,73M+3WZLU./YW[\>\5\4<6"64#&VND55G:-'&-P__D78KW$P
M>#QH;:GZP^ J4YE**?&S,\.?P4?R?ATB3"]P9R]&VM!Z_\;J1@84@!A+M8,N
M0QF,.*@C7EP5'>.[NA-+.D:DQ*K/='ON08'<>JY%M7OK?S*5T"#4M9ED570,
M>#E^:N?D3[A%L:X05,O0*)A/![99%(,;)+LI\DT\$AI"\]+CM3CMMD?R%"LR
MZJ63/'./5/-F9OR(M/S\ZN^77\RONWS\@(0<#NUS7YTZ-CG+('R<1_+FFAC+
MZ7ABY%67+3D[ M[T G91I<ELC1'QS;F@H7)#>7**00!_SAS'&6$\>]:B^SSL
MB3J[EKFPN;GASX]UU:5$)Y!U"XB$W/C->EP%H$VM8P% '&+?(%E@(]R>O=2+
MBA>,\XEM6PCP-=U**U6N9MM5YT/KY]CW>CJ?*(/> :\L"_,T'RC9&%;- U?2
MJ7*>=/:-@6X59:J;!<&M&>5P<P:7)2B?[T60/'5-$QVFX4W&FP?[T8WC!GV-
MT6+OJ?>^5KO5['Q839.IB)R;X:"[@)J-YYIXA]O@#:S"AIQ:K>O5!%J(:U8)
M5+-%J-TWL;IX2;?AQBVBIK6SLE5"5VWL[<DVM$#74W*7V_I8C8,:\+X]Z>>;
ME<\?N,>X@IEV/ 6[(U8^CTC"W9IBZ'SD>ZR<NZ)H=:H JD&)"G=KI/5YC494
M'_ MUI,:[@(A6/KF/?Q#TJ40@5$D6=*>4-[',W?DD).]DDS.P,QXG('4I]8\
M>T@'QIO@OP@XZ U9=9GN)=#3!CL-=QFBY3PQ%TN0VQ%^*QN#B8LUR?>T0ZI.
M-(CH3Z=5>D^OY4X"';/R>-2XG9+QN5M/[TIANE4BFD+&:PIVCF#O[.^>KCOF
MFO%D%=<$GL,Q7RR&0  UEL(N*^<@);>E0/*.:A+NL#A'F%-5W6-";AK9W#';
M4O&PD]VIOEA7!#";?_ EQ^<VTVNXC\^(\1JI ACU<R3H$77_MQ\;KEPU.=5
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MQ5GE3V2HJ]G3>^>/,_FLT4?;#?;CXRCJ.(7:%OHZ\WR[;ES7CS6C')]-U8
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M_FB\-5<]^N9&2-X0(TZ2M=Y*YNLZ;U=;T4Q>LV".0_>#@"L+1EVQRQ6^P9%
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MO#7KWP?BC]_K/*3__R8 4$L#!!0    ( .>!7%2ECU9Q2Y$!  70 0 2
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M4Q@&_0(^X0OXN)2K^E6"0)NJ5B,2(#%W9(B8?O;($Y_;/B1V(YJSS/'1)#)
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M1E0>#Z4*D*][;B<[@@H!Y=;+H\;8&'H=<#9CX(1PC'74T9 A@8I)D40<6^8
M 7=4:@F8'E3T.FT;\' ")YHA&I0EDBDF!W*] X1%IR> R6XS#(@6J2/E3'4
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M!C(4IZE(IV_C;20!:0D]@X:=QB"M!Q0]UN%:BNUGDV BV^\D52?LXSC21HL
M42]DHG2E.%2;*-;NTK'!.IU2'"FQNC\'..F $5Q+%MQL:#?:?LGOTE$YQV8=
M(FV,.$\,1N-L"1UB>AEU8*HRQ/R!7JZ4*P*'B>*8Y502Q7+VF/7[Y'0N-]$X
M S'C_#-M9$)4ZA>1@=<>3]@"IB<&0EQ5FES2<SB'POJF.VJUF8KL1/4485-
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M%F>$"I3KV"V;;_)81>;*LA3I0(MR<;/K!'J9H>,HEV>54I^U:R$Z:S"#24-
M"*^=:W1;6=R8FHTG=(:2&+"JEQC8Y5GAPQU03Q+]&L8R:% O&)&2MR1>I*M
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MLE:S%4W2*<L3>-I:5:<4^1"&M$RFV+6[Z7()59O-N)AGE:PL$DV*Z9"<Z15
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M03*98KB.#L6CBXW6-:)RL(X2=ZP9F(\KO/T;L*KX0OX=C?+?_T_ _/_[K-1
M*W9&^8:[A@0,:P.GYPN]JCFW/JXYH?1:2#3;QH0,82[3D<PE86;NN4ZP<3R5
MW//X\M3NF^RH!1ZWPZ?=]%] !?)B1)+Z?ZS%U82!@N :W\@!B)L6?:)  MRO
MUX:HR;X4(FM^WZ6.LDH<RT/KD&LY=QCF5;^>]BR;E618'CGI@Q!\AY,.=C1E
M\-]%WMWF5SYMB_LO@BY(%1VQJ=/!,Z"O$;:24@UN&EO*';IU,\!ZSO/.6.+O
M^HJSIZ ES;ARG$OK6;.22L<"O4>8T3(ULGJEVJ@+D[N[-SK9VPO^R]0O;)!%
M.[-V@HKW"2IR9MH\EZW9&*B^XP8'N>F2=&^Z'UO9]M4>O 7>11CFI766[&E2
M#1N*,=BS6GKX6JF; 411-X(;\[\Y5E(>K1X\Z8D22IT6;M\T[/;5B-BYC(U!
M@8&3=GD8RM(>ZKTU*M+L8<UV4*0O?P$J";@>^QBZ<6E457%9 1JI@RT:UT[*
M(_Y"PABRD'_J\C,&)H? 85W'XEO,@VY'E3,-;LQA?&!*#H-[&\.'?9V26@X4
M8>K(FU8)..YJQLD4T>8]!6IOK=D0Y[*E\QNX"\%^X]4R96/0Q9'0W!/#//.1
MJ0$!9>GO"R=EDI*><O!Y6D[VY7?1"X$WE(HD0P:/W\R:F;/'5ZB&"]4$':4Z
MA:8U='II;(=]FJ+07G\BEI;.JZL/BO[7I<W_,*IDP;T=[6XW:Q^(1_G=6Z"0
M3JU7>J/KI=!:@\J61;N/U5GWAI_57S6EVU,Y<*<?XUKI'\2JXI5K:M^_5O(*
MK2+$IL+:E:"I)WA]?/"^%(21-7\J] JH;?]F<\K@S2IKG%;7A=RA .>:_^C[
M4EN[%Q=\N$1W&CZ\_BNDI5-UID;BGNF:G**-2PN);CPJ$QJ]#.V2..MT*4'/
M7$M82UFMUO.< ?'T<@1^S)&\*?:#&6,]%^4GD^!F\W)M:Q7(A5Q/'DDD'3JZ
MXQ,L;X&#%14N-LJN:8V-<;8ST*G><BC@]WFXO?L@7.L/?&MX2X!]2$[<J&%F
M:-,7(G.Q=)(ZX_"8?-7X4-X@7F_O6S7O4%_YLL+[9=2HP9TC$IB[R8]8KD"Z
MZE'^!;7XS#5'^>S]-ZPP"<B@#F[W-:.9<-]+ZTAAFZ>4@S/X5X*?2IM:;&Y8
MTR4&_U#941H!&\3N:;S(9C3C1:9X'Q5@D6/L=45%E/!KUH?&O]*Z\N[[.'99
M+^M^FQLVEW7?9CZ _<V%F;N=XBCGLD^=PKEV,6[S7')/OP)S_3O5.H42'GT?
MW^5VGHF3M,\(+^H-3UICN-4L!.VF%ZV//YF.YSO4#5VJ(>N ^HU-&X_$WPW>
MEO0]PD6'9"I]W5D5\W3 "]!Z3> SMWGBJWC>TS6*A#BED8"2OF+IUN)KYF=M
M\U4]FKKXN<Z1=\LHIH.]FWF54@2)XX0O;H?JC_SK3^!'J9[5 E'.]X>:''D"
M%?$HIG!->J!PD2#[O("+@I=P5485)^_UO8&1H095/7SOT'G:W<VE50NNP3B>
M^#:3$Q"+BK#<3UB8.$;2)WVUHL;LDEQ%FV5C59,=?>2 KB5_ZS._! 2JYA;Y
MU!!4+=$C5!4Q_WGS7/47('4H\%BK5SW)IU *++>Y\E B+SN("J'O>EC=C"8(
MZW5 T=7,Y-X.780N:X8:=[*_S*;%*E!PVTIPGJ.K67N,>K#GF$[+CED @GA7
M#'!.&8N7>$G,K&W: _MRO'O"[.OK<0N2504:BX0\'!F4A@N;[IT+E11.=,S'
MAFWD_L% K-?@Z5K^<$&8NWJN0<39UN^(A1!$RR*C\S2_Q.JH=-Y((\$?>,Q[
M\%%%8XWR+(U$-9C3Q%WCE$G7;9ECG6,"6ASW_[74\(]1V/(7L"R<IGO4I@N^
M[YN>[_U>=[U4I'P-W.Q7"PG<FCKB]G>K#JP":]\\$6R;J0,W<<H+KA?/.'1\
M2Z9GEO)D+7-,3'EU@=<3D^/$?_S\A89<;D<%BCY%/UDR+UP[0*%%$XOO#:J:
M*^?=H"P\?8+:F.S0F@66^IN?? 4E&KMN/13?$=O>C"$7<TCU=%&-&EJEELZ^
MBPM/%Q1G6RP(:Z#)^!+A]/I#M=%)",;D:W3Y<\;PM<L[7E[B3B.^I7%K8;L,
M\%SG;=9<C4IJB;7_9F*2!HU?)VVAXJL/E:T^"-X]+H:25"J7ZS<%\(* <@^(
MT*?EE=W3#YG+=3_<Y3RR7\A:Z1;0]R>1+CRB8TX$47)*(E<736%]C'!X#C-X
M+H#"QN5K">/;T;W9UW5OEWTY]GTYEW&M8(-#H.>:@[\'V+#Q;FSS.O:09XX]
MUQK_Y7!4TO=?;G:8GW#=A]^Z\K[7G6\V4_\+ZQH]T5(N:' 6XK-WJ2+3M-9L
M,&$T&_?(# X%960R&W0AQ9.BP&J@119Q7B5*P?,<2U)4Y2!<2E-JRNIZ)TE1
MJ%T#O%+5DVY9[2ZWK]=C0"4'KF5_VDD&2?[B:IDH'_>_LIL+[E [VZ Z0]-J
M'%2YHI8,Z#>NC[#+&_\C0K%],R8X?%4),%[J7S')Y;7C%#O&FZO%DA]I!;W#
M&5#']IW/.WT45U"WE95@>^;754V-W8WPQDRK-ZR,C:TQ>5<8HSL_^3DHI^$+
MHWWO\/N-UGWP743]Z\J;NJ^HJ[*^Q&V&\ =(+D'BY!]^@?\/#5,;+;D/%9RJ
MUY%LO' DR^%P7OM,N**?Y]-]LIE#TLK)=B^AE&1;43K\F#?=.A2Z#2R5[5<0
M5BKU+9K&QCF 2FU3O]K/+F[T& %?\Y?VS *36(5CNJ*"[583]FYYA49U,@ZR
M<N1.RJ:HN6TND34)$L[0AN/Y?TG*"Z M$4-=<J:/VQ]Q7HI9I<M-54G]ZCT7
MQ+S*[Y44M6W?JG[PE2/(R[OP%11$"7ZU8Q7TK<),*QQ;%34-@1SB4*E,MEOV
MKOB7@AU]Y;.3/ ]<X^JHEV-N]#;#KXMDMU,W]2XOZ5/1!U1[AEG&)C>APJ8(
MF_IO9\LH!?8,A)K7PYR&Q#-$$5@NM8WK8C:5T D+PG-9\L)*"6K+.]\CQ52,
M;U[D!SX16^AZN<M8:Q8<=*X1!2.!Y=P5!4#R9A%I^^O(+^[R<785E6H$_*7V
M^XX]:2*17=C<),8+>"0F/-BM<I^"@NJG&7R6OXO%/:L&18$Z(+V7!Z5PNZ#\
MI?2GU)5QF!]\<W*>"CB53VC5=0LA0Q3L"!;Q;*S,&C3KV&S?"PX3KNAJ0AZ&
M'E9; QN:"_0;7PR#<$K)##.:<+2%:VD*G_*MC7[<NYWV7@WG+]"O?#/M>FG5
M"^,IF;PL!SL?RQRTB^JRLN5$_04$S3O^Z0V7O;VM1K@LK]GR6Y'C5P*-5H]K
M7][6WCC5/]F;->CI"W0($]DH&C4[65C,O,908EV$S"7-HK^-0.L?H'4D1I6I
M)/LMO_YWI +-ZY--\-L9A)'H]ZFX<*&DK=J^,8.)^MTW(L.0^'J_TWD?T.C:
MD?U3V/@W0Y.R32 $OJ&6B(RIM86?!8QWNE0X5YIZQ]V\XZZV\&+/\)NU;S)I
M_*"ASEF5F-U/[#@;._YR6RT8XE/CYJ6;XMW7ICVGQ&^G:V/<B-A:$W\V-+'-
M(ZXRLE[-Y#$^8[4N\L8?X(25"1='"LJ_5;*/W8J]OC^QZ=+A$'N_G&SSEW<Z
M'#3;'^R]_068Q>64K=[KYV_T,QNPJ3M($?"_;H#\N*Z:+2G#F^C9I(2@,< =
ME FGBIR[I1FEDUNZ!=6GJRO7M5HLUV-X-,:7*C=-$]V=&J!4F%DG16;O^#;O
M[;;D\/L?""V8LO#A&LW73/;>BR-EAV#A&O/7[P&//^#.1<]Y-&=6L%5]$2D7
M,H<M6;7?U]S$%*VZ=JJM2[A.5\13'TAG:MVL6AGBPK[0L]D.BWA+0CV;*?(A
M7DUI3'Y"?/Z3$#49Z"HU?;>Y.I@'UJIDOJRJA'5"XW;8)M81J35Z,DY:,]9&
M0,N0K0>79T8UEUGDZU*!@;\K2O\"_I7[ZERPW\SN*'"V[)K=Y\T>3^JS-FM2
M\V6^J0:B.HTZ>OZIR^DH\#BA ]0BVZ*E/FJ(Z%?^<E_M)>^5R3!?6E:EKFNQ
MR"VU[-YCO[REP!M\Z_W\5'18_0M0^&YT.9[]9/UI-.[@YWHDB'/HU+")/O/[
M&G1HM"3P# %3-UC4E9S:\/6VMI^-X.O%12CVQU(A9*NAHF$L3_2=:LK'^";7
M7P"]8GE ^@=LV#QGX4I=W@];N9.]L,7ZMXT+S!V?0S1=A:;I,1W-TN205HW.
M2T0F1OKC89<JO<&FM<-@ A;@AMQHUH7U'EK GX]#X>GMZ 3&OX!BFHJG:(EE
MV4V/Q$#&S6DMID<_*9 )Z[4/YXJL5M)\UWVU N=E;61\F'U#GF\EG'&7UE5-
MTU)N?_&GH.F=>L>'\/7Y@[_0SC"1";).$+**R2;H![(-3(29+.F09Z1W:[A@
M)&,E-6WE?5GF3$D*1XDRS2SCHA,U&)AFKB_T/_F?ZKCTE4%,?'!ON<&%_V$Z
MDX/"CRKSG[?8V3R,,^&"EIF:QQO9#(1#9C% BW2(DF2=0[#AT]K74_P[A2_K
M5GG8?H9&-T&6=1D6HD[5720W*1OT-[C"(NO&E3W&KHU#R4@&WG\!6KP4;T-)
MC-_5%1]>^X">8UC_+PR6!7YI0IISA4>VVMV5<SS!I<";!.,U7K-29>H2C .&
MT5!SI@7N94M4I<L69?NZ+G/W("@!;,H 5%F:!LC00 0:@*OL'H _V5X'-TH/
M:P0['KN14R!D:(M%!UY7[H0910Z'FB*!(SF$C/RZDF),*0G(06#/X;TI<.A$
M&<PB0R'8!#_?G6!D!P%'BNZR"TWH]_IPD"80G?UO4*Q1F8?@LU(]B8R\HUPX
MD;%8-&2EO9?AQ; &L;?UJT&2IR.TO'S\5"1,<HKS6@(ZE]K WE% *>A!A5FS
M&OX%S %@!\04X?YDF_9?!@]SW<?\!>@0>PN?'R[]R48H^@M82@!Y),,#$D4$
MH^#@SC@!P3+0F/R!4M*+=.H3E?]E@"33-)!A#W@<&%80O4,<LT"[-2'BPB'
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M4<2 5F4X&:DFA(;G<19(2%%O..@L*$,#C;E!U;!!2$$&\+_Q!F:=_06(FNU
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M >[IIC8H:KN>3N-P.NQ.AXF?,G=B,-![I%+%\&C#Q2#H*]"C*[X@<*Q0_%G
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M!6G@JQLJSV0QGLC(5\$RTB*9'"!YH#?9DH]5MN%C/,\C&/0TUC'GGXB$7H5
M&0C I\P' %QE!0#\JY1A,)F! ,ID9P#1)"><P)-^4O%.>5Z-;R,FF'$]\''3
MON,"FG 21\FM8BI5'&85=M,"4GN 3DERA%$GN8D*P9#%V):QCJ3RB'1\B^2
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M6\+%R0A0.^Q_MEI'_F_Y+POG3X)L$:6Y2;,.%()O<X26$=Q;S?RP67&T2^I
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MHX][>-C^ M9[BW5[J?*XD4C>:YIKS1 U[O[Y/A#UP"(0UBHQBIQ2<T)C\6I
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M;XUSMKMMILI5 !/3?HK^],X+D2G!K;NHKDSKH"BQFG65E3H>"\>YMGA<BJ0
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M!,P!]B28QF#,]:#K+-]3<@W;8KY]_K$2017;Y&%A(FSF-T!<@+U$#*>JJH2
MI=L*I\JJ3@ C"T[%T-_&^\8DC<J@).Q\-Y&+#)94!RWSF8\D@DM^AG:2/3:/
M3>333:;;.D6NVVNNTN^--Y<Z1XSG&=]L11R29UUQG.---]\X^77;./-5Z2HZ
M:]CY(C5MG3CI_/UJA"XCKSMD9<*_"$H?S?5S$C9$;L,1A.-\0S[:K"=HS<Z0
M3;_0^2&3;52HA;>YOKRANAE-<7Q>OP!#-N1:R)PL4W[F"K?O7<*)SH;O+/\
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MK'' 447/%'O*1+MOF%"[@$4;L%@N.2>,D8 )P/?[@!6!=CM+,Q )VYR<#.<
MY[9)X'8EOKG6@-*@L%ZY/T*VW$7#K\;D>:O.8G ]AL8[F5WHEN54TL*\FWKF
M^@YD^S>:PA"IR!\_79:MV>D0U699#[.(HXSLS\]<%4V!=T;[&$;+D#9L)<9
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M\)&XVWG8TH*@N;AP=D<80D <!\EB,Y&1M48((.[M@&N/JFZ0VUNF-[R[P"2
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M $]HY$F/,S$X4'&TD<R;R:25DMH.HO3)CD8E$8XX?<>\>?* !YC@AP"<(O\
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M@L26N0!VQ/& _3[X.5:H&9N5PMV3(UOM#+&.'Q@MAMIC/^]06&)-T;91N"7
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MML JAF3RQJ#N(C3C/9M^3A<DABO^7ULC90W('$+.*,<!R@$F;Q$0,%I2_?\
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MQ0!EOB5N,M)X\11QD,[4)L.?O"UCVA^\(BAI9Y8H#;KT6W*<./D]@!!1B%!
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M?463=BM%G=6/2C+I:Y7HV;>*TPR":5:VJD>_Z/U[Q^/?M5G/5/)6?6?@6#7
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M-F#-R/(&0M^4W=2ZC$^+,Q6Q(CP('$1G8R3?[34W%9 P4C!W '*,&49&<AN
MRYX##N?=WQDT1!D!W#8Q #(0S8)&"!N*-CS%2>WO[9QHZTV=V$.OJTUB;,RQ
M]LX5UU3.U>2Z96[E22AJ1],3EZ1"?]:GAS]':0;2;ZD\'QS/H9U5"[,BJ#W=
MMJ_.P,MR!SQ[Q\/=18V9PBJ[$CLB[F[>X#W>\G';[:WWZ1$E_;X!$=M7/,SE
M_N]:XKT:\A7#DR",'11H0QBG:$;!8(FFT-$211D_3%TDFT^8K$*SL'(Z97'R
M;*^X,><EO*0HSCL6XR<#M63HBE >HK9/45DP1R/F]B3C/!5 /=G.:M!TWCIW
M/JGE]R2D^R RMN.,<\?7"M+TR8)!IF,J" ]4J&8M,,A6T(QX3PXQ*.KACA^S
M$)*WV;248+@2R;;B6R++D*D<A=RYSV9B%VE<@JH?)X) \HNSVYB3?;Q7@5AE
MFDC"J$X."H#,6W ,&8KMXP"W-1O)S;J%^M4D]ML-4K3EA3XSI)KM9J_0AX5J
MI;&J!KFJO7[#0 H: ,88:O0 0:0"QQ$FCC#8GWTW]:&),1I*ZB0CY-'F)8L6
M9\\D@DDER3DG@GBM)@GED/4>-&:,'Y21(L*J[0FT8QV&$ &!@D8YK-7/6SKE
M@K-:Z*I!!*3.K0 AB,TM*G9JG=F-(%JJ!L-.Q5Y3FE'X!&&W/8"_/ELGSG83
M)(\OD27D$;O"Q(9$+XZ;;60+EBI ;< ,D[0<;6'.#1+.X=4F4 JT@7)D!*N2
M H8$KM)( R2/G+VX-7K_ $]J]T9/TWN6UQ&LD6X_TEMIE;E[[QRWG5X47/JQ
M^H05^7=[!3$F_E=""/IB';;;D30LPYI>5J[PM!:],QG.63:/_E;0..!M7( V
MX'([ J0.KI*3+-<]0..PD+'CJ[B2#RVYL>;=DX#>C"NKWG!KNTF.CRU:=HR!
M2LK(: O+,$KZ:9..W=DC0230J5D]A:HD,)["334425RZ4J])Y=-CF00V)"(U
M*H@E]Z)K.EJ-@KO(&!RZZ4.OG*1][=!H\QUFT^KS_P!LTW.=E4%>(BFKN><H
M<J3.@CLMYX[@R 5!TL\#1DW7JG')'H?ZXSWJ0'?4@[A:_3#5DALM8M%NOI]O
MFKY];LDP26,GUK]AM25QMLT2Z5C0X8F B.$2=F,><-@=@,#L(:+)*IVS]GXB
MJ%^D7L;QSV*]Y?8*O<XA.S8.)6#NLEQ9F(L+!W)#WHJ.MI#$YOS;3G+1UZTP
M'Y#X@"HF0[6>$+<$T9BP^A>*/"6M>&]!T*_U-(5M]=M;6:S$4ZRO&(X3*T<Z
M#A)"DD4WD,B;)44N)4DCC\;HFM:?JVL:G;VA<RZ;+<K<%XR@=GF6-6C8\L@,
M;IY]K;E8A-C*S=)K)ZG\3M_36/4[+5]7#INGE6-%!LV):X<5,)A=E_,MS%B7
M#R-;C 4!,1<8T.VD3*(35S#"RT\4E_<QP+ C[55MRL!AP,[MN<XV[N>1D\C.
MTE:]*]A;23&=TW,RD,I/D)(V[L?[MO&<X[$#< :@J_\ Z=?(+*/4!:@:RHFB
M#[L9U./IAT79@"=BS(Y#9S9HM\-QSYHXXC]M]XM57S@?:XQ #N-9BUBX0R&0
M"7?@J#Y0A&!Q@'RD#M_NY[DYJS:1;N(Q&3%LR&/SBX.3R21Y@<<]MI(QV(YQ
MO_6:V*:YT-D5S:[C-:W;%(D33602.GJ0RRF0[):R@8$?GC1H(,JFT-F1L;$M
M&&,$#-,G@FT?G=I+V-GA59XBKQDXY,A8!2"I4;!GS*48(<@D $%!QWLG"3,8
M9 R2  Y'353N!#;CO('#;U+C!P<Y#-9?CG)K1QR\5:Y]?Y>M.HLU"6"V>VM5
M6\H%05F5K";0YZH&T8Z"MEF-L59QH6(1KJB+96%]LC@WGD#HW-S'<1/';S,L
MPF/316YD8.6PC'!VM\]2I&6 1-W -VWMWMY$DN(%,)B4.[+Q&ICVY90#AE_T
MVSG"$LY7W20=2+3>G=8D])WL=+Y&J,#&LS'3#!;7(;;D)@(P< J;#-LR:'!5
M@[138=!4X^Q#8U;@R=DS$*85;2)4B1_WFG5N""8QY2YCRI"ED&U07!9"6.%#
M8"@@2;NF\K)^[6Z=NN YY5!)@@L%?S,P0A7PH\Q&2S E(KI?HG=K1_$9([4(
MN: :O8)UI\GY2SRL)0V)>1DB,]@5"1BI1*"(V$[K$,K9DSW6CSGXP,[1+=\N
MJ1)T75FG.T@KQ'C(&7< $"0G*[<[57<0.59M$6ER/UT95A7<,$[GW8/"J6/S
M-ISOP6+8&>&42%+^GJ\DOA@L=Y&&YY-4Y (VD*=?"SR=*DC1_0VK GVR7\EG
M>'[\Q]IK%@D??&^L.+%+(X@U?O=1$#TCUNIN*[FVXW;OGG+;2#@+S@Y_@P#N
M.DMU2!+B+ID;MHW;BNSY@VKN_B+XY'_6=P]&>E?3JJ+4$53>(7H[IIEC=W!B
M.L;&5QWJ,8LB9*'S8#2T@*1*V:7&ME1R%GK[;H.U2I:]H9]TI#4H':1W5U*K
MB)=SX=<J=K(K=,L749#8!CRK.V,,.FS((U1U;>VZ1BB$HV" RNP$@4(3MVDD
M28943.5A^S<O;U3EM\6="]?9(<K+6HA0],5'0@FJV&,: '?N%FZT,RWJQX6O
MY':P(E.*PSM[J6>$%-8"=/PUA)EDGB:&\!W1L7@89##OY N KJ?+L=NHL:]V
M7YU=X3%!*LMIC;(H2=3@J>QW%L[D*\[E78TC'A6QMD"O=F]GEEBUX9RRG%Z"
MP4F!?1@^AK-%]NJJ7"41J!8[$7L.(O*(51E25<8Z>..NSL U@A >[#4G=KI>
MVL63VJ>09ZI,IA;<CMNVE$&2P#<28Y< MSC;C:MS>J_LT$9QT\1"4 2(NW<'
M8X .,]/)\I(7C.2S6=*_9*!MZ_XZUS<JW6=A/A1AM PF*L%A006I4^"I%@9"
M!3BTFTI=5K"V27 -@.08@Q% S/U,2L\P[%:S*W?L\PCC W;2,(CE&1I54\R1
MG<J",@@.#M7S#.IEO-UJ9X3)(<+N!)9U$@<1,P!$3KM:3J C*\$Y4UV;\\W7
MI*/%*/%*/%*9G1;=+0*%<KQ!6W%PDJ-:<V/%8KY"(1V\U3@SGR+UI-F;H$,!
M4\<&^(Y&C@ 77X9SM/\ -\NFRE5&G]SX]F;711RF<^*)2.H4,3+FE2;L^D;<
M4Y]["9J#64Y;]E7:;!SOI0)4G1&#244)PDM C*MKPH$[5ZJ<?KX9QG[?YTNM
MNK)+;TSBA2TR-/<9>#]4OIE4+WQAW6(7U<YDX!U9CL0QOI2"2&0PR_?!08^K
MIG!(D7^W#K*XW#=\W(S]&>>W/;TK%@VUMO?! /'SL''?C\<>M<W?TZL#LO8B
MQ64W;622N\\M+H\O/RYVTSDI'#)MOKKGY8),1V(G?Z?R0[?)-OM\GR;8VSZ7
M5 JV@2, ;IH8<#T6,LJX[C;QPW(SZ$5YO3-[79>3)VQ32YQW9Y-K,/7=R,C(
MXQZU"5QY(4(T+L*NE_7M&0TUTM5U:3D)9!5MX6K '<=M!P2R"3\X32WQD>PZ
M 8H7SMDE9K;4-LNFK&^K+1*(XI%OB^1$[((D)'4(9HHRK@@;Q$J]5 &X3#AE
M)%;X3)+&UD$QU$5^JX!*!E660&/!.TR,W3<E02_E(8 EH5.F;]+L=*K_ #"=
M>Q?&GBUAGG9B$."';?N#6>TD<A.N)MTFBF,;;+#Z[L)HT6-]ZZ>R33((-^A%
M?0/!).[X1<X!&) ,*I4@$C>68 !2!M9#G)8USY+*>.>*%5)<[03GY,DER&!(
M!VA=W+<[E< 8P*5KWZ]=>YKMMO;*F>O69M#*GZ&A[0,X#G"Y1(ZBF##!DE;&
M*R!-(MAV4 &\7TR)-LQYE"-B&V)>PR&,0D293>_(0QH<@,<K@MO&PH&! .[!
M7!K6]G+$).L"F&V(0"XD8<D#!X782X8@\@C.>*A&.A=;@F@N"S1K&5#&,TT!
MU,Q-782-:=!9":X,U'$$@TLH->SO<=!1IIG8$<,SW=::$),YEH=1R^6N0+@W
M!S:-*>EDC:;<X&" G:3)CW^7:6[WMBA"%MC[/T!BZ6/$Q (/M')X)?.4.'$?
MFW!0*G?GGKIUCLU9 <*\P *"+LUY\C^#A %)NSPDKK>!D62P.5%3"XU9,1-(
MP=7\Z^5)*/HH)).6>;9KR..659C)%F-6CV,")$.[#H-OEEW$KALQNH5LG:KU
MK@LY)(HC$$DQ(RON3!1O*2K$MAHMH#$KYU8[<#)6K#[^C7,(E_89E'LE3V3G
MGLD<"V U+LI"3[3SQP[CV9KJ:S+<[$_ 2N0FU<:6+-B"('E@E-DCKZJM%>7"
MR0;K0!)%94Z:9?L,%<L"N(U0E&92R8?=MV;;<EG R3[;MBZ,K-O;"'!.0V%P
MV79U#JIVME=I?>6I[VJL2\=ZRVYTM7C7(916Y@T]FJ]@GJ<%CN=MHH=RI5^T
MW.(-"T4+F]Q3J2%ZQ_JGM_[8*E/@43G1 NJSW>H2;WB1XXA,%"J@RK!OF'@%
MB7(,F5/G;:2 ^UMT=I81]-99%>4PDEFD(#*1PXYPNU>(\$>4;@,KE6:, VD7
M!V-Z:E^;8NRH:ZMK#9_'.JW+KB;6U,I<?9(H01#YC58)>!!_NFXVWX\,=[*A
M>$!VT$LLL@NK%6=8\H0 5()R\8+-M+NP;#;BR$N/>6%1VBBB0VMZR*\N'5B=
MV1PK[ NY51=H*[0LB["0WE6GH17>J2K^C/UPC<NM1PJBGUG44Z"O_M]085L#
M6&"]P-].Q+5UEKQC"O.@YW[?]Y*[ 8;8)FA46K2#8UJG^5,UVP<,Q$890"XY
M$<>S:5$9^3\H)YPHCS@8"Y<"ZZ-HI0JHZI5R=A\IDDW!]W4!+Y;@<LY;'+[H
MO(O8SHN:-/6N9;=#J4[+)5<B=O0I*$<%7;"28[376"9A]R$ +CY5Y S/:1C:
MTS(+.IS$MB83C7<7,-NMQ:NDTF['G+C<R2<XZF"5"#<J[Q(7'#' (K;;VTMP
MUO<H\,>.=@0[%>(X!Z>0&WG#';L"')7DY.U9J]TRR@5+^)G(:GSRM_Q"NZ^&
MX.ZS6>4)(VAY$!=G464@&!*<7!7"E\,]8B!KKPF23-I@7D-QZ]/H/ICEM8YL
M6\$K;H-S *SKA?E%S$P4LYC\IDW;58@J6R6.R2*ZDA#3SPC;,0"6"-ELHP$R
MDA4W\B/;DH,.5P%7]"?$89AN+\B'(&:A$0<PH,,X;V+$#L2:*JJ=)1G,&,YQ
M"U@WUVB8Q8SG$9FLVN/]/.*[;W9N?,S-YF+'DD\L>6//+'DGDUVD7:BKY>%
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M'\^W-.;K78N<]*X7[<UBAO@WQ/.>+7@.P3+-H)E<,C_FEG-71+RX)-XBXXM
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M@G\5%%8@BR 1LQC0$R$36!;+M"N3TQO!)3/*D,Q(4@XXV\;_ "$ GDCA&HZ
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MSC(!8J3DY)E#2;95N&CF9I5=>NF[SJV68,RME0I("$!CM4X\I $95&ER*Z]
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M(Q*6VS<R*^T!9$&X[FPI#.I'H#Y1GOCF5;=4GFG>)1ON-^Q'*[B6C<E!M7+
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M-M/F3<C3$&,1;9GVDVDU^/U-ML[;9SSR23G/.<^G).>,=N?2N@  ,8XQCUX
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M,]P_F;Y::6]:69=S;'?IAB%!K[/^SG4EU"UULK";?.JM>"W/_P A+R%.G$O
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ME]1XI#LBA3",C=Y8B*3U^M?7J;L< _P[\/I)'>0*W&%3U@X!@J<Y5PS<1T:
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M"Q46?D%>(=+L^4/>6_,;7G#R.,(WZ3[Z? 0\'DK7V%R/*9^T,65MDTB"7[R
MO414O+X]'KS:3P!Y&4@)!F:H&68 [?O5[=OU#''R4.\$F'OE,%X>6+;-]'(&
M[B6TV@&W04AF<&=^2>\3DJ@,P<,%LPFB<J;L)#S\^\_[^K$71+SV_B<=FY^
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MV[]23G9).O+<&/;MV=9"[7A8:SC8CFH$"'8';(B.KR]!Y_-;>7S<CXAQ%UX
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MGI]_/Y?C@5O*<^(:!V?#.I]Z>,AO PY(?G59,0Z%57DY:K*?>O1 S,.74N6
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MX).3:^7:&OD\<9GQ(AEULP!E?#^-0&8M]M4?#\5?X_(C+Z53_@ VT;AF&/\
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MG[Z*8*[=J<Q@I@$%T[> !6X+T(GR"N^S?@*7YT; 24*?>^JSXBX *8%#EG_
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MMS\;)>S=ZYSM_([XE].'_DD>@G\F_W4PO72:SQG]4ZG+=]CG\Y^/[L^%_NQ
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M&H6:GK3>$.&/C7*5QJ,,B.6W+M,(F\/89]<E-_@97>Y/N],"5=!!(X*(G(0
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M^SK\KSF?ILZ_S_E^:X0/^A$'_U_PP-]BN8Z_IY>UL^>_S_=XN:$\O/\O.I^
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M^!,)ZZ_P   45#1T#$PL;!S<'W3XC[M#04-#14/#Q,0AQ,5!Q?J53 + )&6
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MH+B*XG%,:,!QN8=C:JVH>B6.V157]R6PNP@/F7'ATDP&;0IJ7>D^<90[Q4L
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M)E8$A4K12=%A?R$LD@2%HF 58U4]LEMJY.Y<#AZ2D0R3J<#">IQ%/V 62=F
M*:9+?I$H=-'B-C<9&KS+-.R__)A>D=E ((O6W;DW@\MP<E@)A_/Q! _[8!,$
M<8XSK2AQ$>"@10T@9P14)J-(HD39H%%AG=!YEZ[?O:]T*9(:'-<JDHD-6R41
M-29)=G=OG+M^*.1#!$P[+4:E@1M0<\4PKJ;1JW4L,*[-AZ:W5E+MG8A5*1$.
M9D\:6AJ$"[TK^T9K#J<:Z=%N)>$!E 1#2"TD-4T"5XC*\V]GW-]H,^CF6BS.
M56,B'3%U7]O)H]5DH)#+>>D!KKY0RH=[R0TWSCZ5#91? [+>'R]4P+[:?57X
M$-^ #U-XPD,L,7#O4#SHKC T8W?(+Q[021O@<Q3O]=%QVP7-U/%=I<UP Q)Q
M<2OD_RH+A,ZIR]-(['+G2<G4NBW=F P>U?7DY:VR7;#+DK9*U=Z-%RP;X3Y,
M8K8<Q"?5 *\&%E368Q:'2TW$5FFJ2Z)%GV]&22VPP [U?![6T'2'&)YA5RPX
M;(L$A193N*Z3W%:+3[]@P(GQ8.)H&#4PDYHC$L?%^:"W:Y#V"T"H]D5.!G_R
MDG1> Y>X*C=R4)26(SVZI10MF 9O]B[:9/<H(/ XWG-A,DX3MVJ"U1ZUE,TD
MM:R@M&@__AM]=^H]RQ-IZWZZL4W*G+,#*KFAQBX13*:/^ &+\0JD:,K/MIR(
MD>5P%#$1ZU7MEGB>VD.A?0D!*@CGAL6T.F10X4W:VJ.&]LI]C8*+JRQT;]5Q
M\9&=7P#Z079NON<M/F3:JY6ZUNK,=79)'0D.)M>WU775)'%2[0EL+)89ODRU
MW9>9O0/J>L6<$-(Y,JGX9(6@]TK]:U5P1"C,1-B:[76TC1X[I7EI!4T2D^7+
MM/P4!-K"#!EME1[!A!@LV$6+4MRCO%$7>BX29/0Y+__XZ<O%#T;>S@F/?:MG
M(>_:C,_8Z[^_:%<A$'.ZP2 %/ \A/3IM[,'SL$>QI;.=T"'LHI:IA2!0<BF<
M8$J,/4"2,L)W9P<@=HKGO2U)I?';#]0[SXKXQV@8HS<U2T0>8()2B3V!=X;#
M_M[O @MRTRVARX%[K6W*6-2FAZ)2JJ?\9S;@4_%8H_0XT;TVF]C,2*(MH(E:
M>'[FQCMF?'JFPC'69+LH<1./O$!IP-0AX]A01EYNU.Z-(@M*YW<EX$@/#"MY
MK^HJOP*6[F;9VY<,LFIXX"<T\](X5""QW4Y3VM5T;AV7LX,HGH1"B!R/UG/.
M6:K7'%R&S\_@\JIY4C2<,'++@ZNB%-D;O08<++!ZKI']69P(T7V[O]Q@IE_3
M\+(A2&U_9-9-E;#(G8Y0:,_KZ.CH@]=9;9Q7+)R/Q(?202"R<GNG"0-': -=
MFYGA+>E:[J"82:[L0-.E@;VR*\F.Q&BVL[(\\.I0:$^X#_?:A=.?]TH(_@9B
MBWZX%7 L=H^ALUZR7PB(MDW(BX44N"9K8,548*?M%A"KBGA=T5O5[,C3,,*.
M@LDH1>R ,9LN:#$;Z)R?/=F6G JW8\&WV"OWBTZ5]* ;F.&,!%T-\^4?"AT5
M?#JJ1!\6XH:.T,I#\W>IAOF6Z5H:NIF+=4*"FHN.;U>TC<SGC!B9206%/PRG
M07-P&-:]H#GN^(KT0H?4\[#("6BD4A"WV#QE]CV?.]6I]1ZR%7-?B;>S3[#4
M4*N.*:2.>0%TTQJN,<=/6>K;N540K;]]L+8DH<?.[2,TZM^Y\CDZAY*2,]RD
M"CZJ0,N7?>$&1^7JB&2+@G[DREHS=AS9*#M,04=@**%[H].2?"!!.J!CHO.@
MTX>3)#^=#: SQUA&$DLWR(<I5F'1:3_DA2E>.FJ61ABFZ-$K)S7@CBI:DB^:
MAT)32XV!7]]^;,H2HS/+A8-3!WM27^.KD!H\H3JL^N)-B"T4'!<AK#48H#$4
MX/7(IO1$P82_K8T_I:R*HJFDRG?A@ZHJNJR8+LQ'>IE-O54+HMHT$$T*MET3
M>>&60]L.4?"&]!4K^JMHUNVFU<E.3,909<7+&Z0:@+S=*&+&WZ;#L78O%P5#
MF=^FFX!S   ,3EAR)L"BN59J] 2A.3[D(-]7G1\1@'_<W&_#Y5W**,G>USDP
MNPX?80=>+M,643E7)(_ZTX!;(_.4:90U\RVS;0@F^3"G_5%E;'<+/M]=5Y?K
M)D)0.T=(4:@^P=LEZIZ9+W/,N:#>6)'S>\ZE8#<,=^,;, K?1UV/[]X <=!%
M(B'2=+2^)-3#Q@3</./ST^3SO-F4\/PF8;%$)6&7OM)+<0V=9<0L*U4_&EKT
MC_]M";3CLX8-.[O@7/'@G5)92]T6HG0K<SD+!+A,C,>_LGU!42KB>3Q\BU2>
MUJ\0/V#"+ K( F2I !P'H*P018JOF>-OH^2G+72)CWT)NGN=)U>F1/284OXY
M3,PHK.21-M7:C93,XA9*13;&\<F#R%VWQ/ )_&9P"@((;YU0:TEG:(63$&XW
M$?;W^1./<!5\30PX?)-_J,D:%<U>QHT;6G0YXB(N M],7/M&H5Q1'^33AJQA
M;^TNSMS/T(0J%[I;H)N8.YI,RT[&(B%.(9>[;+*'G.CVE@+I/"I3=5.?P@\V
MY-UZDTC2TD+RO4%D"PC@0JC'_I"_UZT[;3<^8>>,I.)]?34XYN+=+&N.$/'M
M/I6B<+$F_B3K(BLFHW6(4PN$AE!=N.H&TZ^ND 'D@,669:AD2Z6L%17C[YB4
MPRSCGS06$+FWB@6PHMW[4?!_1+E HKL'ZS)BB&/C\BCHA$+#D&G+.T]%QB/4
M*H=SR,!TNG4A#"B$U:<D;Z7D8JVX@ASL'4-CV$*,GPK2J5ADL/,(-).F3RA/
M "?LID&/1T$MQ"-IJ(.1KN^C9W1N"[JC852OJG:$Z@%49L&?",.*CA;,XJU)
M4_#X@S*I\V Q3>.=.LV>EQGO@IG+G@M_37>,&H^E4:!Z&WX((6^^[R[[*+_[
M7.]PU^WQ*.[CV'@+%5),3$P4(2HZK'X[$A1."AGZ/5;TPSYU7L^&@3K?AI64
MT&S+.'4;TUKJW1/>!#T&FI1ZP('I^$"H,& [.W@Y]?[X<)*7#RQK:UJK4.NI
MW>=4BZR\MXD&'D+P2XM\LMOG0LQ2VUVFL7[Q56?![@OGRW<)_I+.>3SO2A=F
MAQ;W23PL*+)U6YR#GCX37;*YH"01N_JF_V1:N:RM!FD6VW*H'S>9MG#R3&'V
M]K[&-_J^PA[JJ,R"X@&>-RKSXF8WW=Y?;E/IZPR(687F')/!"GITUG>S:(,*
MS13^ET,@AJTPBJ;Y095:3$-IWFV"Q/8(2,A<>NMUM*XP%))I:5Q*F]^Q%O0M
M*DAM2!+ BO(TNO_5S8C4^3O%H_.CAC!^7,:$YZE3[.4Y-/(R4]E?EQFNG..@
MYX(7P.<<#'=7GS$.<KT>);LE.>TZUQ4R)N>_G;HHS;-X&KWGUO5^T+;B:9U,
MJ%4!1^8(>-"Z:9V%SOU\QMG^,E<[AZ[K-/!HA&7?A_R;&#5VF:I:JI>X>CY4
M2HD&33URFH807P4=Z<;7?H\T%3<UG2)*5\:)/V1!.&>2 ZN,L2NM:, 6%&SP
M40@]XA.!(J,6A]HQ]R@98A2&3LOZT2I88_#X\3X7;"'A3]]M_&6P>._TH5X[
M9O_*0H^HSB9"4UO_3(&BW =F9CFP!0'9.&;4F R-%UH'YRTM;P:ZU:_6-"^Q
MS8U9Q/B":Z&VK0RX"5X0TF^G%*PIT?L*#$Q\\G/-F'K6V,>O9+VMS6LVK!6/
M\H^G WQ]>66/RW=)%.MI$3#+T7&MN8STEJ=ZV.!VD>7QEPOR P8K:XG+#%TZ
M3?"CE,?^<GWRYX*O;9:9+$\&:S>0JIN^ ILY-&2_ &(T,IWW$SSDRKO?JBF2
M[3<G"#, \R([:Q38HY\T'Y0FH=TG;@.@UHWS!@F=Y^-9!=&#=?5",A57)@XP
MB#T>3$+ME!BRXH,#6E:[W(4EB@8=\?7G5Y8%ZK23"<<;9$?U^*THVQCE16H@
M !_'Q_"F19<!A<F9$G8?7JT5-FF.)/UR*GHU1%,&YU?DDUAE"\Z>^_F_ *BF
MX38$?$JAVQEZE79""'8%)H)16O-+0#R=LO-(:&5V42VC6(20C>&2^50D%E82
M6=@$ O3U&:*A(F,O.R'H@_&/VG7IG3]-;T+)(B;F>C)#ARN-KG,!G&%X[<.+
MS!>-#$;0)-WJZ;$0$9X3UX)#^OT@V13,*KQ83(^Y'@3.D,$@5LDC3JLRY;E\
MKWT:5+*YY5('YI"+?"M=<Y,6UK2K/=*GNO'U(E8U"(RKUT#PX] ##D/QOSQ_
MK?I];Z/%59_C2=E1^RXJ.X- 52V8^$)-?E<8#=^C['(YIUBZ5PT"VBOI-6UP
MDH;8E%W.SN!"]*^02W0)(2#YUKQN^2/.&!E*/2+R?"78--S+?*Z[W0/'5%EJ
M +2KEZ%[]HB6*C:XO[;I&I!O*6O-_NXDWLL%0E\*HI-O(XQWPI6;]%Q=TQ7]
MBCY(F".W--/F'5!/X[TNG[M0V$1\Y76BM/0PI*YD(Q*SI9"UB:!)4GG4R/T^
M*+"=9<K2MS9A&9,E/C(O=(@%^]/$@[PHS2Z7^[*$L?WX(0DZR@KR,]F)N$-3
M94GI^25Q$^,=#S0X/:9QM(V!TR6KOP#*7T?";C <J$\TJ9Q]B]AS[UEAJS(=
M4+//9BO=#66:60P0-32TYA"U+J3R6%O-GI):-RO=M[5^GB*5,;PNTKQQL8B1
M,I,CJ@'$CTC/\-9E5MQPU]P4"EE(1B.H=G8=?U6\C(/[:KL&PXFWR8UD]@IB
MM9]DRM)Y\NE'J51A1;V5XG):_5;K"S6+U["NS1Y<$*?=+6=+]"F6TXIL>_CY
M*QCYMN56N .%&846[03-I-Q,LBHTE!I298+T9YEP'<I6 4$O)529&08_/QEA
M'.IN)R?E6467<&69PE@F9,9UVV_BCV,@.-E=2.2]QS6[9W[HM%&H'DBP=Y;"
M(M>[@#C8Z.!JL=:_;\/\'M6967"_[+:@,CT^@3W#,R0NS2KT]CJ-4F0SM>L1
MK%M^#$H$@A@7<\LB+#K9_2T5-U\-IKQ$$/&F*;%"1*!T$-S:VMIP*U(1!WL[
ME2S6X_P]7SI:\D-\=UIR;RPF'&MS6,@P)F^ KU:D8)=NK7Y9><LC,(9I1*2$
M+_3MH(W=2N=<"+LQ%#JF^L3&RLSB-1\]KC:58> Z?C[//'32D7AR$HO8(+F+
M!9 ?DH;<;=?0>:-_C%N-$(O6Q#/'3^91QY(J^$2'U6-,Q(1<^]VGOE7@%NI4
MWR?VHNWY8>T'B4O#U"(-=DV\'!$%4YCR)NA.V)V1LR=J'5SP2F:'3I3P_0')
M &,L"6'%^^NB1@6P4*N,M,*L3!@+6C;6!,NQ_LY@X&6"5@&87X/8A?:B=NL[
MD+;_$Z5)E<3I(1;5HF#(G==+[56*(]:Z>N\>F+QK@OT*W$&4EUXP(,BW6AVQ
M&I!INSHJ'6;6 !+^I$+8Q>K4]5B)I'S6HTW(N!G[2>!PIV="2#2D @@B(F'O
MI3<H!^(;-M>F$I6'0C["ZZJ*=T$2%GZ#<U/#DE37BF71MRBZJ$"BN7<Z73.*
M[UPK"D8(1/387@QI!+14C2]<E:+$AG^5*F2H[L&PW$B*AA)3V@W;P#FU^$K[
MT<7?QLD&048K]ZH;7]&)Z$;#)-R3+D?&GNK@2(DAXY50A]+&<+3+_4DC5,*B
M(*R8&N;N^T0"?B/[M&Z@JT2;K"L#U%J::*)1!J F'NT3M!N/78*.NU(9NAR$
M Q.IQ.&CE;@3DHM+)-XW#YK L0]8<K,\P+1! [46F$^?IN' #L-*A![3X?TG
MOP#(C-'"C"+9*X6(6%!0K;+D>:*9/21Q*4I./0L<2NEPD!@T./:S5B68?'WD
MD! ;/NEL3N/4L3<50FG+]0*-@]\>N@83M!=K=7! O3D&TK-J%H6B:>+#\64R
M3 >7'Z;-6[1X=Z\S'260TG(F!/%7A]^Q.6872LPE8[DW@:-".N6?E.Y#O0['
M)EC T\^+![:C[]=@'NP6D','IO$4NS'1.T0\I=7E<,>P);-=.I]8263?X!UJ
M%'7P.='7<*&F\3WE2OP^$,8<9QO?C492[SC7/CE,Q."V@GCYY-/G7F,76:UO
M406*PKC/Z65%@F(MG;Z(IF@]:$2WNV%G3_73?L05AI"VLLQA@%]]*L#.OYZ-
M?-)<A9>&S)W5$>/M^1Q<BCEH+L@[[[E_8LL6GPS#UH-TD,SB?9F@,_W+EQE_
MMF^L5JU =EO9K5UOQLJ^=>+8 R-+!,]4P$:0=9P3#@TJ<Z'8Y[F$5^L'WE_T
M_*IKZYD8-Y,:@=0ZI.XSK:NU^A70F.2)D:B:HP8(P4"X]3(6.V3'P'Q?:A1<
M487$P><&[\\LW&A0LE/=PUVELLP/S8\G%4F\*X+O_GC/='IXPX\YWW!<+M#,
M3=U>W(E,2&BDSZC6;NT&V1\4!K49.7L?5[SJZVF5H&?7Z]];*8*RZC[E",EX
M/-KQ"V#)^?6,W9K94%D"T<XN2H&+.BICC9C]OE7(8"K*G@R9]3>O/MO49NQO
MKM03GT:8M#G9N"?'Z[_;H#CM0N 5%0X4+U]<#Y]G?['IK>R@'4KOK#Y@KO7@
M;QM<+&@Z[:?/6"9=7*,+\5621U@X*OGY&38/DW=U^2LDK3:B]]Z*E$O+EJ#2
MDTKX[4=K?G:!YBO6GO1[\J)*SA!#:8B,E^1KF#7?=>Y)CG%$[(/&*?3V_+!'
ML2J4)L/$2/%G!0JV!QY5PVN<77&YI'WN-60\7WEZEO_,7B/A6=3REW8=/Q.$
ME!-'QL;=F8M#/W-)0Y\.7D(HL_D>A5F=OV$>)/>Z#>Q?NZ72Z! 9+HVNLI\#
M(@9_M@O)9LN(\@PY=EDKQEU\D(F5'RN+!TW_')6MI#H9LCJ*_TJ I6@,_8%G
MG8;]AY$ND?8$&O@JR!:&.:7=0OID;]_3,-+K8"=V*6_>9X+,$'/&'I7>J/RA
M3_7)'*$?RR4T]OH\2\<^>&^T$-4.8<_DT93VH"Y:<S[ @E>R:A*F1%AUY7MS
MU>^RH0I!(!+0%,5ZV4.5AX45P1G9K#8 A+?40@-M!II8^%1[RA8-YW#ARJ*?
M57!N9-.J#X-C>H_4_-Q2#V<K91,FJHKE0B7H=A9U,X30U6(,6<5>T+H$$P",
M0C0(8QCG]UE?Q,C.M=BFIR!L-7&K>"FO-HU4BSFH[(5J+%K"$F#),#[98^BP
M,!5[TVLHR24O!SIMI$FU57R],/YS19&^D2W#KE4XTPYC?G!(93:,_KXURKW:
MIA8KO+7E=T*>@F*WVAV-^[=?W^6V4M>5=5(ORCG?XU0UME582@-#R6C4Y4IP
M>328+2:'50LT2< DU#WR=*KE66D2TH<8%S@%@C605!24($9)\#5.2C^WKK \
MR:4EA9NZ"+<B'1;\@76FAS*U4WSKEIESE-XUUXMT.'=Q5KY]1/>\_H&*2UVD
MW@XT@JWB.K^4DOK%?;-G3P7N+BOZA/'ID@D'+:-4,V582(X?X(W&B'(VK+'6
M/OQ2H?#Z>X'IZV=)F5]7-';]/,! X%E!YZ? 6[1\6M\1U:]!:[M]+?KNYDK+
M[%4C[R]K#Q<$IO1;4XU7)S"^5TT?-+LXR^$Y=MF_ T[(S#HM<_"C/@R_='68
M?.W05$0F-Q',+2N *Z@GI?A*W8:0H<S!%1S[*#UY7(N)/6?O"EO_LBN]0Z*(
M-M^2N@B^PXP/HRR:&D,JSP\"2S!B+W$.'^Y<!+M],E=>6W#])F7U@2F ?K'*
M_ERR0\YX)$F,KCN<(-5$!'FU*/1M6A#Q)*Q"^7D@(2G=VFI2IB-%:6Q. F*L
M^=V\Y4(J.PD-14;7O:/09@K:K(7^5NL15$4GE%%W3AXI!&U;.9)?)1$-%"DY
M$F=UC?M6Z0FA^*N]"'$!0D7@QO&W2OCZ[3=C?]%6^/GCQ+R\T(Z9-PU&@#6\
M=/LL_B%7DU>&^R4UVE?23ONZ<[C?>^L6*PAK"*RFP@").HP55>3Q*36]]%I&
MWGHPV7RE2?\I!DT#H@<I%F#>R-T1%MV9-@Y1^1;_D$K.VNF+].TGY9*#;(/Y
M[OT<%/OY!$I?PAKINI#V*Z!'A,*-2#9_6&$'B_>G6?Z.VQ.D,V-G3_B3D$RA
MXZX/\G4MQL\M=*F?CZ&/+9N?\$;?)R5YH*8=BVOXI!F' $058Y;V.?]@G)@B
M^P%%%+=^"R5P8$C)!I&4/2([LZMLX><>A8]C7M[%OZ(9D('KYIZOF4?4)IXQ
M%W"QUJ=+X.#9N!I5N':#\WG<^X-1E.+94))9*FI51O%7<_:*XX"OWO6+/F'K
MXT\BVCC,9%%W(/1I>UN/!?BG[]?4"7.0Q]91]\S7A$WUI>$85#/$;6]THR!D
MD#.D[N\JGO!'*W?)55GURYWV&>!/,YTLNH>JMR?8MWPY<6_6?%O;1NF@Q;L4
M6](N=EI?RPSL=O\%T+1TTGSJ[ XH.6U676'3_'!<4(A8[% V8A7N$,1/#:-W
M2M;NYYV@(,5B_=I8MU^5_A!Z(-TTN@)CWZ?6L_-,V8_/F#$L36T:#^V5LCY0
M]=OQ4YX.XXK4G""M?1'C&:QX-!=@N(S#/FBX?+Q!)[]QAS,YY-/AP'V&0[U#
MP%1,3%!T_((3H9N,BL&UWV,0.SJ8?*$DQ0ID3DMR"XF6MS'-MM&,#_ >CW03
MV0L"IRQ7N-?L<>K>@^F=9.AQ8^G$0W59P%COXNF?NZ>U>CQ6^ZO? ?QO#>HX
MK%76.-:.OSU2C%#+/,)2;E-!<L2IU,A^*Q'$OC9GT(W46YA0K6UA1"UK/7&I
M(3HDJ,.;IHC9Q9UG['&7]R9\LX4P!_:]34- .$G&\3OEV24X4=@EKD/JS4Z>
MSKV'S$@.S)^]]S%B/Z&HA)>?TV!FT_?$(;^X7.1]:;\SGG8\QO!]$()VWS@^
ME3GO(1V;5V5G._Q,<%_8(L'M27KZ[*4G8R"?O#4#^!G/!"DY[NO)E.XF2S0$
M]K?% -H5!2U!77"@I#LQ]TF_ MCSH"_<=$!J1\I:'-@=[TKMVO=%P=8H(OY9
MS=(0X'MIV2EGOQ[GS4<?<.1:VU993_=I4,"U90GO8QA"+4U T]+IL/C5Y'-"
M+2[%YX(W=99MD%;H</@7Y3W5R_V,K[V<J95Z<D\$P?KLO.Z@=^28]B6U_E1$
M#(UPA9W:/MMJH3<E/<SZW/KBF#I=3M7+L?K>@3AH31^4/J)9-;2)W!S"\U)+
M<FC4W5_X$DB=]A(P1K&)+#[0U^,T^B[X4#>-CQUAK';M# UT8[ )]^@4*?"_
M1Z2@/C?2C[T2^\S4C!?(EK/Q0-C0BED3DU(HWA]T-5Q5KCM^;G*MN1" K2&I
M](K!A:2&,?IJU?:I%:I0@H&0Q/=U%D$!]MKG[BA H\XS<LWB"LA>G;.B\?:>
M*$4/_[8OKI&6H0F;I(R>M[7ELMAD?E6L(8T(2HI>OWVTSY2+G18\I7>8.^5S
M.*!3FNUM>NE=,QY_;;5"-_,HBY@C[C)WW'Z5?EHPI-U0=4&63EP(Q.DPE;8\
M:4(+S]+T3UB2^?EJ+G"=V=;*QMWQD:MIRXCO[>ZG=\[*&IN%/8^>0C_:?OQ,
M@@RY/<8J8CE>1O520"JTHK>I%*Q#@R?Z%^^N\UQFE$\L=-&:39T\UJ[-Y5>H
MLJ@YDT)"R^V".B33LR2=2OB['E86"* ^O!^5-S7A6G'+:17I_TKAF!.F*^;4
MJW3+-T,>$K2-$G]H8.=8S5,AB6V IG2$"]P8?MN,5:X-),[')QLMV&2Q[_OB
M;/\XLL0>KA6R./387C=2)3?U5O(IU]G^EIJ!VGB+HPT)_!Y3,]JL46]WJ_U9
M(>[J$HK%+IW ZD'Y9@FKI<&(A(TZ]R>M949<86G>JS-@@>:@^5L/R=T$/8%4
MH#B#K'4*IH8JT&'WH&X$D2P#U P2-G^9,6$@W5>:QRQ?]BV L,'$\IA)/;RR
M?*V5[U$CV*J"WR5IXTH_3K[=)8H"'8/XXP?_M=N<N3(#:WV(0B,G2"TK)#S;
M>)=@+*?3TRE1# [2X)>BU.#IX &3NH/?6:6ZIQ&Y)M>C-DBP?38I0W]-7KXE
M@8L:,.Z!=;3M3N<NJ"<ZX[;J1?#5;HUYB-J9),?/P(,C34#T[F2$F'D,B+?N
MG:8<(9%MK34NZ_6\&[_SLV\C4S-$4CK=.774)TP+X@K@0QR&^F.J2U+]B+(\
M^+0/>4E"T-B5P$(4>DV;+(R4&"AH,?H[[BP?8! *CGY*$[)C %KUYZ+O1<NY
MWQY??;"*L/EBI'T$"'&FM(RB,ZX=G[[]Z'<ZN4C7ZA@-8#M^GOKB6$C\*68O
M+X0FR#P.23J=TD@CC$&X/R2'FHG*,[K5K%F;O\)Y,3(3'Y5%G)J#'YSA0C G
MW>(0+U!?DX/;?<?37P1C!I;MC@O@3>1;"%'@]Z:G#@4CDY\AQZ=Y#Z@=U9&:
M;C!@C:CWJEKK!D8)K1T-851H@-XV5V8EFDG#LA/@7,?9RY_ES,!E#@^F>.S#
MVF5=SYW<P3:RFT<;FDGBH6UH8TY<VD*)"4H4N@->(PG;Q%]T?V>3VM$@8Z:R
M*$9OM-8LBE%AV#_&.V>I5/0J&)7?1G9_M"W"M/R^OKC+LI$$7.7%(+@&#BN:
M,QXPU,QCA4;-'Z"D^E!1EH7?:) 08LH0]5CP/]5M5LB_L.P"H;J_!U$"OLJK
MBSK<L5S#E:")#C1T ;9ODW'NHX6D+&LGL3G\EX"^?";(<^S&RW?8JO-Z)'%W
MU4XJFFE$+YV#2R _<6(%V&'RRD@K_$XJX?!U>-^"P7@3+\(&EX?O\GMAOTBA
M3Y$ZIGK1[$.Z&$JAXDE<TIE[_'C[!Z(FB!.K5E1C6M]G[U'A*M 26N(H79+C
MT1"%1U&OV46D1GHOIY%7(V1(!-7Q)\TWYB#Z%]C'BG3#(L>F"A([CVX#4C[\
M M!HT7;&LL#PIK#WKV!D 6H),_=]KGO2>$:H;N ]4O+FP]4NR)9R-KS3R^\I
ML__%^M/8'.-4$;=') L$YX^>N;:@WR!U#X\?$1U]XT/<2W5P_MV'OTL]HLYU
M>O11] /\^"H+5]BQ44XC04ST@05FK*??5H?Y=MKG*VG'@=*;]GCN'-ZM-6J;
M!0Q.S^.T.M@>/CUH/3M.V/2+'6C?Z4)B4Y_YYD4G)N85 S)3(?;ET(41R,VE
M$J^2%FZ?\AO;[L?:[2K>!'*6QHC<^K8B=>F"YQZJ2>L;M=+UCT.%80Q4T;<T
M;TSWA<8P5$)W3@F65VA'E=#)U<U\\0F$^J?X3U;K2*\:)_C4&9K2?P$$?[YZ
MF=Y1\.C>>,_ 5?#BL@N'R?Q[;)\()HH11U/+_X^4MPZ**XKV-3L)28#@%MS=
M/3C!+7CC;L$;;=P"!*=Q=W>7Q@G!/4ACC01W=Y^\>^>^>6]FZM7(?ZOJG+WV
MV:=6K?7[MK5H/FJ(3T^!RG7QK<L9E8:J2TV4%=IH((P?R_JI<"K,?S3S+A!%
MD?7WRPA4M9YPRJ'Z<H2PL:#$_Y%C:B-OD\+?N6(<IX\YSS)['UR+$^63 1(F
M=G1&J9?X+; GQ:YGCR/PS/G!:0!O0T7BTY-,FJ;CIL*31A'_8^L>D<7&C%>(
M;@;/](I;24E%66YV_J*>HA$*SZRSIX:K\Z@"<]V@E@(]Q^Q,.U)NK&,2;INM
M2G9Z?E(2HW%ZUBIW&I9'-IY'$7%!DJ:4VM105Z$C<LM!8;1OYM !Y/^73HFA
MY:&MK36DX#7??EO$4FL;%$6-.R*.+%2!8]S#JKAP\S,1_!,G>*"=A_/*T'E'
M _^JKR+7W)WZFSH,H;Z<VY8J#"X4RX'L$K7E=MCO<OYKTE[6-*HE-C_%< *(
MAS_![GTU/-A+1S)1**(^^_#?.JT4>KJ2,B04[Q&R=?IS+E%:, Y&:TDFD(_/
M(9,+6?&%E=E*V#>.*@D<1BK8YREH8F>YN(-6VFMO8)L>('@AKWVK<8'78].$
MQP$M)#Z-@&I[2TU"54.5:IC:24)9$0&&/?[/P(D7*.N P@]9FQKG#GU0U?6T
MR".RWYNK4\4J\<L.$P)R&P3;\DN9QP!TJCI$CX;U?E)VX5QOG5'# VA[W[/V
MC2;KT5,S-JI'^#9\:L'G"O/Q>@4TB*7)=T1>""0U9W_2N6@]\TO>FU756 /Q
M#C=7T6XU@C+ 93:\)YLMR]8%U<U'1 B36K@#W7W>22A_8%-'KX ,TQ8YXFR]
M>S 2-5/SX/K.9GRF_-1TK\!\)ZX4 NP]$_UZ^)BZ0?FL])_>[R$:5ELM]^.(
M5+%;P1QK%9_3QUL#8)C4@UVL#.%)8GB;X@OB,;Z34NBR$BS+Z93L+YP3^GI^
M$9D7#Z"6I.:BZZSPC>+!<ZQX..M*Y_33H5.M&LAR*86@;,_]9_64#D<QI/R\
MN3"KVNVN7[>)29F9-FEG@[PTG=\D7M'OT+AML3#+EL'\QL-F-5B?0BL9+BQI
M.S:HJ(\AQO6O,.%CZHU]RI8MTD8)%C;M-N(=IT+"P#&9Y]\YNLD/MD05%C:V
MZ7ZO 3*4TGX%7(]+.=<9A2HLGDV\"4/*6;4DWNM/"PR40^P D@T;?EL@TZ(U
MNTFH)-=0ZT/! RE>-[_=>A[YN/"A83E%_5]81J\W?:BO,=QQLV-AQ1*X-R8^
MM[#KA73(BHPUU)Z.%66R]*,AER#6_$H0^HN"?+3.7B>IP#Q8T*^G@5+/B3A:
M)S6 DYW%%0.-H=U GQH>X 230WB<UP$NF=#N:JX;RW=\IS^R>]5D& Y\_Z>$
M]Q^&&/Q6!*?(<I0_Y^.W >(H"P>IB"+)(9KW.A@_5B<'BSQE>ZH4"-Z-X9*:
MAF,O_9UBE+KJ7#V%MAS/^CX_F'N?68#69OYZOP*4[F91OJP9%VY[(';;HMWX
M"N/O4!>997WGIDB\*E]B_5V"0L#*R"O;[_T]AN!/8EI@?9(,*W0+NB1:?_6Q
M['C*^XK<N[N3Y)JNPS<G80VZ]N"[N595H=:=3&L;9?&@/=0WU5O.Z[2,U( @
M@<E+H8WCE"WTD;//"1U*JGT?B"O99==3U8\4<B9Q,3HO*OL@HWJ%/B6*[N_W
M''  QKUU>Q1^>07L+[@+M!!#8?^&;K0+X7B\'R2TWHQY\7@%7$*X9P;)GLY?
M ;O$UI5OJY)<=>+D#2)0/W\TF3'^7MGZ-<[8#\D""X\6/TQ]0?AN#)^"LG(G
M5?NX:SK=J:^FE\"Z,C$S+/:\'FNWI3@@$J$5VT !)%0<C.".1-/7.*UY6"[!
MPJ)MW\C2OTL*I)&?X,C4N+EV@"<K#*RWC\W>9*"6KWNUSE)S 87P'@VH8; &
M%F$!.:%C7&ZLMEX$9T4&E;B"=L:,"%WK"INRTOU982D#2>X_%!9?+Y4I^[%2
MG$M_9,WBN6GH;X<!LIQ37%:.YS/>F'PEL<JJSC)%'9)*(Z9_@3C _@P%5/9#
M_IRDD]7@-"ST^KT"R(1F(GS/",%)5?^J"!E##<Z3]+FZN]92L^^,'Z@SS6V5
MM_6F8YZ(!_5S S2RG1>NT<C+$Q*?'>^=!5TZ8G$ONNARUUR)':51-"C.]K*F
M*;\>&*I=K,3;*V<%WJ1_2A)N!E=KVUBDI,+G&0I:5FRV//&0.MKJ%.G8+%\!
M02OB,BK[E.7B1ZK-V"CAY#R@D1E.>NO:47PJK'@5"5L?5]Y#N2?SV(511]==
MOMX7B"\S&\, _PZC,K+0]\)BJ*$5K])=25&'A#)NV[H$J)5R3DP' =;H)"/,
MCM"O@XHRHR;=KUDZ@PF(E_Q4M7_ZZ"Q'6YR\;VO-$-GX9U@(H6^J?I"*LW7/
MS!K7G*K2Y]GCH^9HE3=C#SK-)U1>X'N;"E$:%A[*;\&\E"\S!.PAMF<@"5*V
M )U8X!:#N,B$%.03Q6#FACYWHW"<R,^GL [[54&O\Z:;G;VJ)4$J$Q!\=7T9
MF@X?@.-A=X$$XQC<0F9+X5JZ*'J$IZQ'<"TF,/!#X*BMK6_^+N6X<XN4"CW?
M*R""R'!%3]% 3P)W8-\-JC:MJBZEJ'?LSR,F:;CIJ+ODZ2+:@(R\]SWZ:2FM
M[YI[?P!?1V@UQN68MV/T_V4-M+V4&&O9K**8FSLD$#>R_R2?::%$A4;!6D P
MDC$"5].,8L,?B:UD(F68X!I(KR9)6[RITM.H&9U=14J@MB,CEH>@?H#&=7%/
M^V LS692^%6@[DY&W=T[9?K79-/>.WL<=W<@G+T"K$[8T$N:9I9K!/MT;'4/
M[2&[GU2>1EVK-XG5Y/ A1E:%P?<!";\X-V'56>L@6"-HM'\ <I;0@3,WHX$1
MZ/8CN NFC*>3B*45'+U_G$GF5NYA$'^D'^51WX.*)6E=^ V1HS0 _8]C*GYW
M1K(9DRI^[S_(V0"I[":P<88*=Y<7+\O[^>J^Z(FR?()E!SGJ'K>[-0^[5"Z[
M/1!EZLD'+=)6+VF2+4JO%W)V>H650+7?K:"X>-JK*^*\##!2!YHK]8B&B!"J
M T?EA)+B9GM(<*9_S2,]]4>L:QUQ.SMA9BOP&)*_=\8<N<]\Q\"'#G=O%SF]
M+!7M1IH0/;L4]<-+8B 8W'R^TU5IHN-[3$RLX#O_[;)>2G80Z5,J0PRS%QLV
M T^,1\[6%\AALVT^5,85=)B[NDI;4#-04=T1+71?:#PC?7S!\@O&0'P0[B$G
M^T%.6J)SAS9\0_JG@2A(T:<),(I D$*Y\<,^.<*SKG_"()9/,S'?"%P<:O])
MO89O VL)-\DLP^W//<BG_E^"I7=K%.3=N(FPD6\/3^\W;1I4>._[C1O(/&-P
M<H71/J<Q*Z:L@*(F!,,:)Y0B2M'?K!;!]["WUM;M6#;!1:=V/"^OS,K:D$Y6
MP4M'TD8LD/8D"9#4H$DU/L0PLOM22HU%41Z.D3ODH39(V1B2C1_WCUO1+FTU
M<>!CL4GLA[8#.*'JR; H-E+B>1 9[,.]MJXMD_TM#[SYX=#>0K%K74ZG;BX[
M/Z(MHFCO8)_1--G"PX:A?#,^W<,<^5PI&CO@;W6-R5F0,5 *YP_R<'XZ=SH!
M51M789ULH/:6M(H$U8!DV*_8(8EWD+;[!GCG7.+]+! />S/QOL'0$NF23@1Y
M$*)_=J[D$F5)*L(WN9*M(WHM+0+$+$F]]E:DVAH>OW%ES/QS[KIE\_9"\[V.
M2Y(PXD>-CT'>.)F(ML._^#XS(/40?"1V"12("8/5'-X\]0] >=U&FV=-+:0R
M;NJ.$ETU?$&#CV](K]4XI!JA,R?ZGB)M3HEW)2QW=P5\NW^,XFY'_GJDU+L+
MSP^<8@@)PN<?4&<N?8O3F_=-ECB5+>^+U]1WBW!]!P@8U>'?RV.6XN2=)? \
MI:5;/X:MDA*Q3(>@UEAVS*DI?*4M]3"N:"F??90<[AO%8<6X5R"X&)Y M#-I
M$OC<V#1#&7_YY4!BDEMPHG&.Q=%FM)IW*3'D+)%L1U.STD0$Z<GN[L[L]&RW
M D0J>/=%0<Q 77EC_N?EI+*,NA &ZG.3]C@W>T=<'R[K,GP,#-S(+LADT[<5
M"[4^T4JG]NWTD_3$-'BQJB'62/U@E^Z#1IZ0\,>L1E%:V'-%73!600X;XSR.
M,8"6)AF;L#XY989\ZM"%S;M$?X)S55(:<^MLP+')L\/OQ#$F;G#$V_FIR!Y^
M W4Z;B==\2W0@^Y;8PWS^%0 H6&LTR,PTA7N?EULARB9[20$V:<?%. FC[BZ
M4K=O<ZFE%385[P<8!V-AS(QFW)-*Y=@C&D,.?!?;V;VDSU]]XQ>Q&K!E>M30
M6RB,9>"'>/B-6&$MTO-:D@80+^M:QXNAI!$3,E<?/#WQYE]5YJ5%(E"<(D^Z
M[89-@U> TXE@\\Q9\_&&D//2T0N5G<&F6407$=K"SQMB39+]=G=NWCBA).A-
MC*T&<*IJI.V3#W<C>Y-]B'PKS7>_T'7(0F%^7DF+4=E191,NKVU5<UF^3=N.
M7EE%,WQ/-S>_7Y:PC3NQ]]/8M/P&8U,4_=OL J.U(KB7&48\G7EB _FZ4FQO
M,6D9WY4R]Z.L1XXGN9S3%J4,@PEZ?*/@ 8N(3P7Q?>OGH%6V$UF;+Y3'WK#%
MBKGT<Q:?ZT:7Y>I)[T:IMK_E@0+IERX=6OHLN'&&\FK]6@;,ZO?3):G:MHV\
MF_#&;XG27<DY(VS?:@N=F;DWDO.J3HEP(H>*(PA3ES(XN9V8Z# \-M5XZ](7
M9AG,_(0EYDF)K4KI*CE5R$=Y$+C/4>!$8J!F@GKE?EGQ?GEYKZ_D_7_=9K6'
MR AT&([]$$[\"9]HEMTE&SM91TH+\VN/=:LVO9?<LGK09G-7DA)?*&1(?N<S
M^8Y<ZIATVD>^O[G?TLUODT^,$QX(%/AJ7JEH"58YSNJ5>E.JPVI-W00^AY>!
M<'$<C%BZOC0T?(T6PJF#S6AI3*M=E+*7Q05S-F91"1/"O>UQLE ]EV'4,HN8
M!@5R>NM$3#1<)$Q'?:I4S=*8R8H6*2XQ3%4O6Q(ZOV,[*/HJ\)])/-Q=:SUB
ME)M8'_V.229!H*$]QF.H%W4<5GE@"Y.,*@Z/;()XOQSJ^V]R0E@?0CRF@:ZD
M[\_5+EW.=JT<%/9SHT_:U6:<JN_;FC*&O=+QT_JP.P4#S4P_&'[N94")$ONH
M,5.>M5$$BC8\[K6%@WFK&_,G6=#2A[7"4MTU\#"F:I!HCH[BCX?NY1WK]7I;
ME*%&T G""6"*D #MX<)ULUYN09.:075B<3)!9Y&51:IG]?3'F"QN6M&O4GP/
M$BE&;BW0(%%ZVP\OBZ>^J^Z=20VGG]RK\O#2H*BX[](%/,I(D;LI#_6;M--V
MDM[]V/Z2*$X< DMZKB/Q?VK=7YNV9WH\39\_^L=S+^\Z_&XT7P$M\]I/]!Z6
M+QR\;/<KQB^.,S=]X%? Q6Z)OUQCS6F7J-G\*^",9/.V'OH\D/,3'>45,$#;
M_PH0K"2;(/1;@'2_Z%^=[O,F/=\._D]>9\[RUG/N^A:Z=\%!][W*<,Q_;D:S
MLYYII[N[[IYCC%X!O]QC5D?6;@G]<(2X_I%5QN>GDUI_/MLCR.J#B/[9QH8[
M:UEB0BQ%'@ "60!C*_-!YT,6<-@'4ET#93W[:5 Y1VV=^G>1Q)TK-XGC%7!/
M\%=U[.:U\Z,5AJF3'QJC,:5ULI8PRG/!S'T @82*""/,#N'JLD!(I._1TLA(
MF1JRC:[!E'EI66FV]"=B=C%<EU'N>@[DN('*H[[W"%GRR_VVSO\#%/'@G>!_
MI+.:D3?O_>A%*R*OF#?HQ(>_S4.L+F^\ QS-7D>RF-?'QG<T GE)<[U'^SL>
M"Y.=('8]^?J">?V2N4M58E:F;>Z;?;I_;=.(&(5I4KB.%F@H':I;OQI/$V]1
MD+AL%40SC++5.@G\I>?",5V\_?;O.EG,*Z!SY:S/#/8\?C(\N2F-<WWK2B+\
MU_VC\$=?]=M_3_]>OP(<7OQ)9'6_(VPN(]Y,&8$XWYI<BR3TT8S^HJDG'J(:
MV!I 0O&X$;.1,L7O45DOO<U)=\$T]AKR2*,QYII]2'0;?,N)Y@T6%MQZ;'NB
M57TB*W3_1[D@ ?>')NM[A_)_ K&)X>$]UJR9&EZ$AOR0-Q4YKU).5>\W_#_1
M;8=#N/GFXA0[ Q)](@?X\F?3!I[S[)D,_;L<PR3A,Z2O +]:_]JYW*?$0X<Q
MF^Y;(P)1[ >E=+]>W: +]:INCO)7P(J/^9/ROH M 4GN5:;47Y($W/)2)VAI
M2TYP9/T;G0B,N]*G#K,32K8_!"C2\>(Q+/F%8A;A6/WN;W#4>QIG4.N]S??+
M>#42PB/C29F+ ^-]WA% >&ZPU-\2[YV0BV<3&$4H2,06KSC]]&,:DM:;7*XV
M9;N:UX7C'D#Z#91M.V%+(."<;98&Y?PTO+IA:ARWJZWXYY#\B)<\-"3?1H;"
MABHZSRQ4H*70@[*\.+Z<+CM9(,RP&'&+0XX;B;)QBKJ@4IG:),Z<1"6VMW2>
M-JQ+L,J.>CTO;_=YY:+,)C[..K7L S5*\88AXU)L7UKP,$]!L1W;$!GAU[]2
M"6B?*FG9QDG/)FHNUPTVQEX^G@I,O?^PO)*_N[$;^OARZU527&MHS?:9#?6S
MD[:0-&31?AEN4=$L#'<^96QO6AW6DK&MF[=OU[\J,V&Q+,O/5C8:A,ZXZIGN
MLMBW#\/GO:58N#H-N!/_&(Z3&&1.\J"Z)[F6Y#4/*BMK$#?AJFI.0&S.U>)S
M[U!648KQN#U2Q1$R(:"TXRUB?28[B '?C3+Q6!<*^<RT!]V4]@(D.9V167/8
MZ4;RECFBN?:6+4F#\3B#AG9UZ;KY><8\J%?4K%V1=B$D/7E]O6DU^5C.R6M4
M<R%O9;ZO&N?BSR?>]678#2,^4TE9,31BQ(O!^L1D08WPH8R):2-Y#3C?S9FE
MV5H83[0B.#.*",EOTP-31*:/'@-=.33DIYB=%;;E&!OCRIQO1I<"%<0DQ'K%
M!^*T)'F^CUAVQ("*], *F7U?_2:1D^M";,='/M@(-V 6RQ%#NS&B3$@:MLYF
M[M8WC]$VEC(L;8ZS:LPK%N*.LR([3Q0<&\76=T9*/;]H'3DO7KH+]W:RS.N6
MLC6/9HI#(,/.G09%90ZLI<Q> ^>8Q[Y%+"2^]KY@,-!=70_<U+LUV[2Q$Z!"
MN-AQ07^<\#5&05B0P+P\)#U+O=(<*L$Z*S_1&V:#-L>P(UWOPJG81")J7"T:
MA&_^8TDWIFI$DK2Y=LIA78)/[:>3O 2$$TI@8?\\]9%L1N"BCN E=5;C4;.Q
MYA70H]LMWVYYO1DW_-#]]85%XMWA,]W==1ZTJKRMNW;)(D+>3C5(QT8O'#LO
MPZ-]02R^3P)'9A/GCE<!IR75D4Z!QDYHAJ4MJJ-[\&PRE*3G>-D[X.Z)>Q#^
M(/?LU4(<4O#_A I+H2"ND\/: /JT-Z'Q"X0G0C!IN:'>Q#.:99,E>B-_'!49
MWN%OV]]B0\(=T&N;ZD_3BJJ0PUX!)L\R*J+'9)6V>\_A#*(/O [3[U\!USFQ
ML^!*F-=I)4.[M+N3^!MCQ9.>-R3:O.+BVW9)Z!AQV>6I2!S.V B 5T!D#<,_
M"4;>4P@Y?06\/8LNLZ_FYQMLL<$_S/&WER19)+F@!U-#>B?+>$]YU49MP=K*
MO7)FXYD4C!,<FYEF@Z+N$*>8Z\L=K6N5O4,F'YJS&P$!W?16[#Z5H\0_"H+E
M?@,UD</)-&Z?AGX,!7!^G9"==SQCE=U8_A(2+QE%Q %H9WSKVY;X%X_<$I#I
MJUNL@1HCJEY57IW>?L%1P^72@TBU#(W*L [^@$\@EA"0.532P\N1:K_,,D:,
MTA'E-<UI>'U_*=,;0^0>&MI.?L2]P)-2P7S515NE#_9;0_RB^-QL[PV:]\^3
M:AH_^FQ?\AYWF")3:./09EDK0R@P1"!!HWK%"\X+[Q\SB%X2T"WT)DN>PD^]
MQTL_B%C<IZ$%7UJ?H#+3I'PZNIR: 3(DEJ14;8_?FP#G1XNC-J,+:8K"-O5[
MWKZAWP<QK<@\8%"T+!O7R8SW24OB%R21CO6PY4L-<B2VPRSN#4YIEPL<:X*O
ML?N2A['21UURX"QS%4?S2&OP*M+11OL9"3/H BN\ +1PLSU\4F5=O)R4Y+1*
MFX4\&6"$SA(8NC#Q5\.,CQ/XJTL?AE.!',-8,M:B5*7!8B&,:J]A3ID)%,9Q
M2K=03XHA;-E*(QJ];&P-VJCVB+' C*L']0NBX0C%AO3)U'J?<:[^50E&D)U$
M"1.L1IY/0ZO?<4H\+Q62MSG<C8!EU/Q^'@;7>J0WVWA4:@H>2Z_FV.O>C)^L
MN<"3(Q2:-*>711;%[*!+]G.4J%V0?!M"?T[^_6+RXJ$;55R>0$'?FXCLZ@$;
M@_*#,JPZ6\NJHG3DI= 2R+K,MJ)0$[:&Y7@2GE8O=02:F\L7W!#]P<R,"OD$
M8GWSH1#)P6$"4E9SFF;U=AK.0)J[,CQIIT U'*8A1^=P5FZ-"CKVQR&5Q^W!
M;::.6]P1SUN9T,? MG$#D^6;@^=NJT[]8YP/YRT^H(R!EII9) WH*?>5\]3<
MH"T<ET-1SD#'J?Z/[,Z^G+HZD9IIWJ+F$I^J%>C*"=BK(<'-DX3S!_B-H?2F
M[3A(C@-2G;:M0\DU3R%'$4%8!O3$HF1/.>ZT>V/OROG5[M,G[/KI )PG7@)^
ME3C%4"[[1/#4HAZBV?O$M"D5U3$!*$VVM*P/?1%[X>>X<[T!9#(,(9J:AEZK
M56![C9-1Y?6UGI7:BI'M\1U+1D(?T;7D+/!BJE\:B@Q;<>709YU-4.3=* NO
M8*S2_%ADWJI::[]H3Q3(F%S:W/F>A.8;@ZYY"2[,7A@W.PE/!HO@FRJ13S&C
M)ZY:-+X,\;5)KT3C/_58W71<I9^>6C^L0Q$1G7$WM1#SBYEW[Z5/K5.C\.Y"
M?^199BZ&$R?14SW*TV=APJ73)]9/ZE%P^TT]5&1K[7/5:3,(SV#:+C$Q&=PT
M+:8J<ZG8U;U$H]"9WO8]9:(B6415-LY1BI@_Q"S\'+NO'3+5^F=*=]\>_&?V
MCS<P'IBV99ZP1!L9F.Z5FLB&#ZO]U:S7Q5$VU)6@0H"3HMU@0.*;M^J4W"FK
MX07):V)H?BH-^0W;-63/8739F8P)]'L%H'F5=S^D^&&H_]&<53O-P2YG-"XL
M2\]^(S+O+^"1YQ["BGD<>[HC6YZI$FJWKB0[]Q,=TAZ^$T[=I#W-&X>[%NVX
M$?6+RWPNEJ^,CBYW0%G1+^M+F:Y-W/RLSF%"TG:ZO:])/HA^H0DG&3^Y=X2$
MMG["4$$'W,&??%9)Q4J%/,%9Z3'_4@P-U7OLA;-%.IYVIK2YN4(5BB>3X:0[
M=?J5,48D++3KNBD%>M$\_*6Z;MFX:?EHE%S29,3SG'>+GHTK!VZ7NM6NGVD"
M/X5EE=K\+<<DH"Z@IV87#&;%C CI,2XA@>2//]+1R"Y>N-%M(]2--V!:8+B*
MQD2SDD*]@N*"*P+X:%#T[7YI4%VR.[%!EE;BO'3JS.LG< ^0>EZTW$?7?G;Q
M&WVI4CQ9Z[B5HEU>G3N@*?\P[ C/8.J/KO!::L>:DK&KRFW1<:=IZ(6W+KM[
M'93+&N:?JK<8YW8*D;KG2#1[N"LH^"TU-O<5I2^*7S>W%G'DV(0T[QK7%->T
MS<H)J?5J2 EO9*JJ]Q-7EGU+C&:A]W%*9W]7ZQ=VM"%>?5_4$&91UK.3'XBX
MFW\0 !N2#% "HH$!0[E2\7MGH6+)@N:5TM1.6V)\?^=BDK_43ZNS;!K#5D#<
M9<U9.T4K>)\LJH_531?P.B.U2#86OX1^ED\]UDJ$RAGQD,ZWV]O^)-:(<2CJ
M0*=EG&H">H!(Y5!YEO@H8N<"ZE5@D\("&BN[;0.S,U4["#81WU,EX[7$C%"B
M"<=I.$8E'?^X35??Y0)7"#G)V-&\/3]1)P9FO#547Z1]&R6Y*1_#AH0,,'^'
M'8LQ%H(>,Q9B]&NC[45Z[J8D+ 4=5^LW.OKWW#K[AD8:;JWH0^^.#E[?0?_[
M(K>8GSS>Y1\:M,Z:CP7HJ_0\EBA+.EAVIN==-!L3>7CL97P=&Z1,!"/.ZF&:
MD8'WB7,CNL8P'*"?9\O:9JZ)*IYEBSP,-S O.V/Q0#A5VCR)"LOPI'>6.11,
M9JEFNN$D;.NM*B<6C:X2XC)*QYEJ#LFS/7/:7!_C%6,P? ,04\VDHK<O)AI@
M7_*7[4+18^2-;N^U%7[00\%M]UIL/IX//^)]\,9;DC_T1>41_FTKU8Q?5E;E
MEJ!.7",CAX/S9T8=?U/> U-2[K)F<($12A?J1S^SL%>=0EC1#WEI;@/0M:X<
MI)=9<,_NAF:IZF@?C%1JC<?K<'KR"\70/M1<=0<O+?7 I8]=' \.TYFGIZPJ
MVPE(#-3R@@EY_IB_B$SJT"KP,6PH.""83-KM-H_H*N&$"OGBMG6H9,-<<9HY
MOK>I>G-SIL=1-XE"W&+ER-(4@'%>;_,V(1(IZK.V/8:H3['V\$DKX<T^O#4]
MD1?6ZT9;*QM=/1UN#"GYJVN_<?=&14V?W63PI<2]\K8)@'&QWNC'C/B+VLWI
MRTG&0]&XPUF__RO@P^(K8'CN%< \K_6<GTWDY^80<W%#MB,L^J[XYU/1\=KS
MRI=KA9A>W%? $Y'E*X!.[ZE!>8EA';K[_>X5P&;R8C9S)F!E-&*X\H^&9OR!
M+4\<_\BXI]G_ MP]ROW_S>.\X./@K+RH6J6N?3E-]IIP1L4<)\1MXDD\Z_W2
M(LS\9^JU1+^4EZ?+CI'ZB/><5EHQYYS>F5%.OIWOFD&[=8UT5S($W537-4JM
M\I<LHUGY[@Y2<0;?!1#%"9\EULML=(W>_]W-::"[07"&\ZE/J]\03=NXVJTG
MO<[^ZHSZ=YR=I%+ZTI;+FWN4$&7V;2IZ==3163*A[IJ:__GJH7+V& [>B BU
MELWX/AW^JT;OU'O\L7PA5:<4V(EYIWB/>!()M>G@N^7 KX98#)H<.,=K6U"_
MS4<VAUD![_DN1"K29[5!U=.'^8/#&^Q;'Q&!Y"O@K'% V@=@HK8EADT= :)=
M$(N.V@_?$43$L'EGP8-O9O;<OU=!(H*LF>%?,B-0^>U_6W]#(K_]14#NY;=Y
M_5Q2+)#C.AQ3^PI O_H'P%ZHVA.J_[E<_W]\\BW45=)O"+R/%V&NE5HS&L'-
M2K6IC;^_NW*/N$]'VYEQH:K$*I:WE$Q.NTQ^=U6JP=(\)RY[?CM"M95G>5YM
MD]&G<=6H/GWTW"\FU2R5/RHG!5Y) K\]M^R<;'VQJ^I<H$X^5Y91;K$Y=AS5
M 3<R37'72=&H:5SY9FR\EUX %EL9 N,W9;B;5F<TJ&OU-I6_EQ7IDHD(Z#;I
M6L;M;68E"WC%TR"/U:4>-EHJR9-/I2=;MTQ%XMZ+H^'U7J!(9(3D6,G7%^#B
M,,1O;$5%F;@HR@^VY7'>O5N/)P!]G218> 64-6CI..<%O@*44>,A78'_ %T'
MG+LJ?2D'90UD#+-__+C#X';\OM=)[[EBX>0+ZB3NRY0JS3L-708\Y#9MT"UI
M@L8F4+6'::I=0P%E6(X86T]***G663KYA/&G?NW4"-4E1<C/T@,,Q=_Y2DY#
MLV=ZJ#IE)CQ7Q(3R4=6X#E& ,Z3Z_EXNTLM>$EK]T";KL77)LF(]BCI?K<S1
M+9H<P33ETN+S*_1?1@ES\V?^ML<6575VY:>8=LF15=GMWMJ\XSS9Q<4A^[XU
M'=XH6+7Q+3W*N/K<+*KJ@AH:11S):I%<XAVA;J?(QX-&CAP:^AL-&L"9V7[;
MBJKX/"QM!HKB2P-G2K1C(H4>'!D"/Z;L-U'MDU*VBC/1/(:G_@-,-3GC!KO/
MR@87(ILW,;.NL."M_W')G*=RX02W+?"]USAMF$H$R.!:@9C?OD<Z\AVR;X3^
M_?T36JGNK!7[N27^5E+PW2_<XXM>23ZU)0M['L.=]KSYOXP.^A5ST\W?U.BH
M#S9X*DT*6:7'M'NFFPT>R= 19KWEOEL\:G97XJ9;.VV)?OY>/_0;9H;NY2Q7
M.SWKZ#<)+18M!C>#>^N 7>,J45UJ"T 7#C<=QL)E3,TL)YO4P%0(H8@4Q01_
M9?5\BY7+:&AR>*H-GAI0$'!^(8;E(QN52A3,\Y;C9;+21[KDY#\'Y8_: B\;
M27="H_ODU%'61&/=&]52G.7 K^02Q5*BTIRI_&+.]Y-"^W="IDEQ=]=__0C5
M[.D7I I_N?291VOT(<@_BOO'@L)=YP\#A1,2JO_7<[7_85BU?XA@_14,PDGC
MRCM;3G2%*,38T24_F*VJ=_7U%'Z@Y_KJ/U;91O%-0&!900%<HO*3>Y?QW/]W
M.=GGYD;![_6/8'@DZLFX)\^-AWT2IP9+?EFYB$W+E"%]-1X\J[@F@^#X>K9A
M6DY ?90;>Q"[A]4?9+0-;SHV(*$1MK;137=@+"H1(RC]FCV%T'C1RXV+^=<Q
MG0'K:Q&,Y--'72]_92.=>J4P%B<*1N-82FF06]]H6%6JQ$F#*.7A)M%NO21:
M7;\-\[<O*.[%]61G:NR+1E].NF?7TA6*#O+70(NVMO:#>M;P6?:3E7T%3KOV
M)'L+*=Z3CEF-/RM"X\=0^NU\Z,R"%8+@]\,M!1U-R3#*ZF.<%V[RP"3:Y!U+
M'%6@IOS<HWD$R'&04,ZA6'8["*]M&$].MUH-]L=9>W//4TK85J1+LVF?:Y@.
M$R]L>C*$LVVLZ3N%LXI-B-R(><FV\PQD2)YEL[Z#,"1(]MX2&3-N^B+-86[U
MHT],LVA0DW>]0#^\_638R .NI9BFV.(FLNR]"DNPIQDO.SR OBE)+S[W2R[?
MNXC,EP#I<GVK A450/+V\W;;2_ILB[<B5DUYFLM3K0]S6SM)IFO5YB-FE$CI
M]]^5JT\SJO\X.KI,X]_0BLUUJ]6_?FF=^Q]R:#6>KYGH=':C?VN=Z([ *R!K
MIF?MV&#\%:#E7]!BNVLT6O-8MT[W7/8*T%UZ.,GA,^R*^.\S$S8TV7".V@2K
M4'+<P:C=P@UF-_$XPVH^2GG[-*K^6(XFXQZJ)2?DWJHBE$0Q  4Z]YL<>IA4
M5.T0O[ ON45#T(^8<-&>'(^!(I:HJ\$Y+_3*YZ#CPRPI7I)6X\P2'7;Z]X#B
MX!$NRXKV"]Q:?2_NOO@W":/B0L?Q.V\8:;4__@T?Q8X#X6]]ZL')MT&<91\>
M>KFNQ;_>^_KR%DU&(FK+U% 2LO H\.,:^U_DHZT,KN4&Y;B+*LB4(V1+!;O@
MDWWC2Y3O9_:H^_ ;2:LS\3H&HM :D_ %-3Q>@IR,@+N(+XK2Y\K_P6";!%W-
MR^V7\*#36K'7 >GYS+)(C']M3JG[8U.$<8T]*NG$=X:Z.\(ITAU H@73 N9"
M-*5<)A^6FD<:.9\07^D^XI$X3\(**U@NS$3ID5]VDUD.934H7H!BZ!B>)WRA
ME_NNYO>[YC>#AEG*;/[SUYO- M<#4"<0;_ILI*I30C]04I()C=I^6DFSUZ9/
M5YC-_!603AS<^"WLJ%>:IE$DF*^O,:CR(3N102U)C5,K;O))Z]$K;F&[W3O$
MGUXQ7B1O9M]_>_[@W8:?,(^0+=-RTB]UO<1H"F@0\TYH.O%'[9\)^*:=W<4I
MG<X#(/TOG'744OB_0_0VA;[64!%XD%NU_1Q ESB9D'TV0&_YZVLFD*;D<NT7
M<W, W!;^OSVJ8-.Y^@J(TC(236^??,ANW_(=/"8KW:] &OJOEVH;\!!3/U.D
M)_FNPT39QQ!,,Q N%O7SWA![H^!]-8WMTV-K(%:P)Z'_:\SG'!0EQA\?%X-1
MG+X#&7H([1D7E0N>Y:P\U,Z(SI:S7O,NT/FFTZ1[#90$WV!T5ND$51\1ZC<F
M"=E/&938,!%WMKE%;4O+F$T5%U%JO:FU4G>)EB&]?!!^.9U?=M_C^81>[AZR
M4S-]JVQYFAB!US+17'ATAY05KY=T+^SOD+XX^]@/5S6HP*8$FHT5)'R5'I\]
M@_+3,;G/7)V,$Z9XU7!Y5'Z#VS>5E97;TLG;R%L?E%/O$^-,"5VT'@=#>"S-
MX'MEI^6X&L!&E6%U+=7W+$(2G,JJS(Z_@SZ^+TI*^BRJYTZ"5M!CO\+/L0)^
M)Z9LXUTD6E&FJYMD&CGEFO8;//&[[OJ,0+;3P6_A0H<4F;YUG6JW:'-7/ZRU
M/,$ADL^QZDP38YWI6Y\#I@?8.X(G_5[K^]*Y0(A1SHGK51-SR;H89G8CK[ ^
M*>)RC0KB7#1;N":_A0>S*[1JDI.+R:?'IK2B6'K_S_P(PU[$5H YQ!-3&T/6
M+MK5L@1==O#7&E42+ .JES=/]U$(29#(/+JNNIU5MC1XWBBN5O:S<:-NOU>%
M?ODLD]->PR3)\5_"GS^"?M7Q[ 1;ZG?#69*32R#PEM(O")#X]#P)11UE7*JR
M*/$0FY8-N:>GT?[\(55LY\, EQNBINFC)G0G.&P.<=/J)QL4.#7)HNW$D!IF
M31.7>X'</Z0 ,70^W\,/!PI#ZY &])7R[M_4YA!W&R[@>O;?;=X^?;1D9O C
M\Q/"ZGCAY8HAOASJ'4 GWE],;]^:<2HMB7HH@7?1';5O]?N.DWS*<)V0/?Q5
M'RL0 DH[5&[FW4,6_<X^TXZ%"\)CZL07=KH:<V:S(]Y="WPS!_2]52/8"89*
MP>DM!#IXUY9&S@."FRK(W#"I1;Y]HI_P\7?3&^=97]],W!4A;BNZ5[-#%B@M
M_7*=XG>G;L#E:7TGOG@KJ%@O]X%K:XV^?V1BZO;)>TX*8[ LA6DD\DBOL71Z
MB=%>,)!'[8CY%M&R5(-L34UQ"W@QJ!9.5$MR7;]FE_P;#)YVD(W4:3LBUJ C
MF0?(*[*S*&FNQY*"VI:/?E5X4WVEU#'EY[U+]>B3;E83M]CD'&6Z>I]_:[F,
MPZY_I*4'WH&K%>U7XY4?Z/W$.:CJC^(!QH^C_-";7B8^-]:H7>$I4U94E6,2
MTT"8G:'H[1=RP"EWEB:@1OYU)3S8KN]>#?*^E;B)9JK1>LQ<G9UM.R/P?+_(
MH+L#E>QV\%UI,T=K61J!SZVD^(;.UM6U7640P9F^'_6 "$=(UQO:,?/WG#BJ
MX1<&SO!$F)"Y9;-_ %K0\:2=<7;PS;S5]?5#16/I-4FD;.*W?J5SK:IEVY+U
MDI^NJ41V*.!TA'@Q!E0BTO/:^*E!;ZI4XV9=AAJ=1 9#8AM%D-!_)I"HFY0S
M1;V';W,Y<%D_2??'F .!'\>W,7,\M,Z$_V]V'*];SG$],QS*/&9@OYC5W*\(
MD;S EM>NW1\$0[K 3VVO@'92+/^EG.NJFNK]RY^'>__5KF=QB%X>%IR;V2L=
M_9'Y*Z1,6UR/(1;1T1VGB6]$/5@@D8E1?=R$;Q"B[X!_:<H$2R3MBYDO)1T\
M@K$JJ9-QZ'/!&-]T1Z$4;_/Z"5UK&,MM8X6S2ZDQ+7Q#$9>]_V'6V:NMWQ=%
MJI8:'+%\F6*X0X+>CC35!LE]9E,]SB0-N)W@42:IBSL=%A:\O?6#!.^NG/ZB
MJ/Q>9^Q+-;I-)</.J5S1&65K]52J \7&.4V#$KI2/P5J:3"HO:6D9!W$F%#7
M!>KZ]KD<$%"535;LYZCPG][6'L:7$#=D2>!_7(%D"=38^8AT9;4_UE4^$LBY
M$8ICU%DX"TF$7[E>WIDJ\8L/A P67X;[/'7XF&H<62B/&O_-E7W#'V^&U*>#
M<2OZS'8W,4B=$[#GNX9"FA[3J?P*@!X=GQZ?3OH\Z_:S*YB)R:"4V53Z-]4'
MG-;&6[.N?97TGC;[&X!YTCLZ=2:G2568GX V/\SW]%"'Q1G^"ZM.5*$!L^^:
M3'(++<?Z,"@[2^#JZI?;GE]WI9FPWV3I[JI3941= %UM4A'NDP\R1S+4Z\S8
M2DZCI* ^64^7"G@IO<E?V=\40GH31 G>YEP:&O<H):UXOC6ZZ\I)1C<LJ=DF
M"]^<+Y;TJUX193IZ)E-YO#R;>R[15:NDBO_!,J*0<&/'3WMX[Y=_6T04UP&A
MH<)+TM$918SB6QY)"ITGE*]CWL@>X[N0]^4;N?HTT^#^*%-2+2.QQG<$QIWP
M?7D%-#QW^@G+@%H%FGW^8S/K?Y?91@%]46:H6!0H.%Q[O5&Q7%5=O4.3IRS_
M>LYP(G@%J,56;KX":L@K*]\QH)246I 'BI!#0D]@<J;)2*0$!?$$9J;U4HS<
MSE1H!WM_.6MO0P"'MUM@Y?]@GO\E%VF=]#C$N@9+<7_=V&1N)[+1JZNYEA)W
M_M-/V&W<5/P!M$A]G7T!U%^8?2CZGJ=;MW24(!N<DWI7JK5YT!1I4'LG,%LA
M5BT(=,-=ZTIH)APCO22=,E@ JMLG';/BMB$/R\,2?BSLZBZDSWL0J%?.N0D'
M*1Z'[>0?D<@?$TLBO&\ $GS&4 .$=G+I_UA@41( #ZZ=/K9?W\6TDUP;2W8$
M%=.L'>9HDO<<K5G8)N I6%PZKF5$1<'2\7J]/G#;QSBV:%.&?N61&X_D0O&]
M-3X<]VA9UKE!Z-_XM>7#CV5=;09NMH\@U#,]\=UVY$5MP2TJT9>Y;-JF4KOX
M!!8:J\!E+"4%CU3\%"(/>3-[04@S#]8$ZL/M[1[])]L#<'33/LDV9W D)D4M
MVU"A7,S&(T6L?2/U%.>LBZZM(L2M8.1EF&;5R[<97S5H0.B]Z),UP'CZHL_S
M.[;P;Z8Z6-\E2!P', *N765U1ZMCV3:>@@617<%&0:\ ^LBLW^4&!7^58$+I
M4D7IFY+R99S.ANZ*@X+JRGS4GR_^ED&GSYD9R@_2Q-GDFYYR[),?)%=>!$ Y
M\@,V)KF5AA:J[!/-G:U*="'8?0&&5JQ<NS_2T]^S?EOC]NNSKF-R^9Q<SE$E
M(8^-I#S_+52])F*,*DX:%PW9#!XMKS/^W9P)(.\9I#/FR;(^B)U8@3A7UL%X
MSN:QL]TE)%D%E1$ZJ]*HL:V,F&*QS/@U[I(PS)58&JC+H"CYF78')5"GMIXD
ML*3?"/7&C07.U-LF<!N2G+?/ZIT5+YDZU2@M%0@GRR+ACX^W.C2^,,]3QT9<
MPD^MIQF"X3"&M'V?XD*B$F2XQ!EB&'Z[:PX72FK,R=$;&HFEMZ/H(2:993'4
M9R MB3M%)V;B5ZQ;AY5\[[3.+6T'SBX;+3+1M,XA)[O(;PVHJN&KHMF0E:HI
M*2'"JO^>OSWL]/W!E-LT/?U'.HF;0\_J.<D,MQQ/F2.JOJ-[J>Z*Y0=D:2=4
M3J"A5)[(>4SBN2(@/MRO!"?4[#L)R;=A$>K&$/S![F_IET]4I"4<*7K^2"Y(
M:FJ5-/U+(*.$T- ;:RO")8>Y_0JJ\KB=HHZ1$TT&3/X8*PA898*: OB>L8#T
MO KV ERE<Z"?$^YE"3Q4MM5@[Q6.2'_/IJM+)T<87396,E10]%>?BSRN+8>+
ML%,>UNZ%_+WW335O[TTNA=GZFDA[/1'(^*T6<QD-%*6>Q$8"I>V/<81:+1PS
MFWDHI%)D&C>%HTA?B'/U9M3%9[C#SP^J^2BI9K^R+X,Z$EB?31E)[=PQK(XM
M0<?U1K:L#.=>26AO>.1W1A])I$]E?([34:I]$O>ATK'7D@LA<AA-*H?^], 9
M0YP&0N6T O\G3M.W7UE(D:Q-2\S&P!!>]1JB-THF9$RHKP OFT,D_*NYQ.'>
M^U%$L>7?4UNN=.'$O,GQGRB*+)%V,P^:45GG.CM[[17<[P4=EJ"<R*-O/Z7\
M;,^6O+IWSZI0N=8,,TF-H0?JUE[Y=!;G+;EJ&(S8BDYJWI;6STU[I$'_#B='
M-,TE>.CB0(H)XVMGA_9"8W4V8B;LF-EE2[*;CUNQ1(XJ:2/=:^;R;C'JIB=L
M/@UKC@<9YBJD";U3[6^]B=1:*+]9?#!O*<<]A!11^F@+1V XG6%72%"CF!O9
M+*Q^T<];QB$E\1BT*EC,V/@;_4C<^6<V/3I\@YI>5;/$VF![,,6 /)Z*!M*:
MW&EHE4QC38,SY:Q7/1^EKNP&OU0T A6;0I$94X.U,JC3>B6<BPBV">-^:"'^
M%0C'8N?_PA?98B"2_N77:A.PW$7]T@M*.;Q4WM" %'-L</+]4NL'UF-=GDY0
M5&M3RR<#4%D%]TG:X4GN*FRB?<Z-2R5>\^NU7&)I*;I,4'9!W4OV2]M,^Y/W
MLX& 98F^;V%<]K/7(72IQ/5P? (W*AUGD[-?S8Y:K2:NRFS.+\D_&D/<SA6I
M-WB8?00*S.)(/00"]3,C<@N?Q/D'LD>P6@Z^F77#R_3^6V:7]E:XHZUZIK55
M/BX4I11\'KPF^7KS.'A(F,"/*O-_GM[Y7QB.#8<$+XG7!<_CX:\ COFGDVRT
M5X#-B<-#^S-)KY' BX'_2@R2Z+'RP]S\O.O][^LK]?^]H3^:IR_/_9-0MI3G
MT\(EW>CV9,983O=X##H9L8?OW6/+#%"'U5@G?3WL5J,&,==<E:LN0P^FA86S
M:F2CS6X(I"LR"-/A2S'EFB,YFI"7$,KLI7;51FP73O5E;=G((BH]4JZ8]8KZ
M>_6Q54B*+;0]=T!9V9/,<7]_Z-:W[1<%*4_X]2._I3#BS3O)*OM^*B-IK_SQ
M[=3YV&FUD5ZUPD[=M&%F6A,SYKHPW_+Y 4_4C(M!?; PT7Y<W.Q6PLDH"IAI
M>9>2='-M??^!JIA=9/,'G.!XIMK'8:62N]"C3C!N/5D4.@LIE*,?_!B!5%E_
M *<XJI;F:=J2D]#_:DV.]69 &5U$^[?%9-%#K-P_^#WR2C@[\ET]>4;C*NEP
MG>PE$0UV'QRL,?;=U8X+5V?'',\WA)*$5/[%#MO'=+R>Q2O(CB.A&2R@07FL
M^X.DN[E->?:)-7NSX47VUX6TF<6&M-Q>WSE5B13_+T8O8NP9U)EW)'($F$>B
MRDJ[=3T(X,%!J/YC^)R=<:3SV(^W[_<H70!-WL)M,_''#-#R+>2#= O[R)2/
M/FZ( 9&_$8SZ!U&-R8L)>T<KL5EE2)_:KBXN$*_?S71Q+#_)J:!O?^Q>O^;
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MQ0.)1;[C]^TT^E[02CC:A+V26P#Y#EG#J:M4U]? W*>L>5 ^^A'FN?'MVV9
MK_18U8_NF>63Y/M29G<!/0M@$X:ZIA8[Y[B4_)-NQ6)@6R7/BT2!>N,6I0L6
MJ4C(_*>^MEC?0%$-FX5#S8"#G9(FP7#\2W%ZX1_-(/*DU&$%ORWZ9%T!V44=
MS5JA#IUQOF4S!1 Q_;;L6X%<CT?XD]B]PHG-8].#=\C:V0G,B(482*.(.ND\
M#HI+M@63,)7I$OE25D;VYW,W@DA%<#^_4SE[:++J8+UGL"-D$LZ/F.SLT%[A
M+2UG9!VE=E? &RUJ5Q^8G9=C,G&T/8'Q0ZPJ& [R2JN?U,/_UGMS:ZR8SPIB
MM1N7?G\KA&%J=A$H:\J&VEQ<4-1K/60KQ$%-Q5:Z]XB@4!A'K%:_,:L+O$03
M#2'D]QT@R1!KW"_;8TX$7@&!!V'A<F2)#53L\?%%/XPXRK'R_,F88ZBC7%+,
MAL%;A)UKSLNWR(NGUS,:RS3Q,FD'J?S1FQ\$6MYL;U>Q2'%'6>="^.(I P*D
M$:O;"?;#^)8>"*_3DHJ6Y$-0%>2-/.X6GL9Z>+&'!WSZ,,PEV"O9@QEVH][/
M:5LH/5KJ:\DT/O)(7OL9J[\?@0BDO -(<:]*J5BH7N$QC$TX!9 0B2H0;G])
M*2T.#%=/+6V:4Y CHYG,4%;>G<:)S>2N8L:<^4D=/U7OM/7&R9I@(4AJK_52
M>!,?F-V!58/Q.%& 6E^!X1SNA%[E\=O1V$-K1*"W7%,K?G;);VN3<;JXF1LZ
ME,L4SZJ!-;[]T,DNIX0T"*)II06^W^O[&^U:H3''5QE2.2344M6X3.V#\@%2
M_!4?)78D@L:"'\1/CKG*O&_WR'-' J4@[T%V6Q?^7%=@[%SXF+^8F9@5'1 A
M[A3Z^12OS\<;@>6J# 49:YC!"E^&1$G+ZY=-N;TUP1L&2J^/6=*4FB&$GHS4
M#NZ 4ZJ@?;K4-\X>!W#;661;UVGY*$-M4Y>/S",SR!$YC$+73R9R#+"'I*_\
M@N]1I"Y*T].#6?+5=,:(3#(:AI*U4I@N$HU5G8Y)BS-'G)MS-QP91"(/KSL3
MU=]!DC!D<GO;:'335I/YVB24%0@I'BA4"]WU,\^Y%(:U V2^,#L%;-D#Z1;-
M*I)!3;BX:J-T^I?Q?&8RFS.Q(6S,I<SLI9C..HG$;1779?+OPA94>Q2:3"5N
MD)S,,\3G3ZF)%(YYIR\:MTPIQ6_B>I,%Q\QY ZT5.Z8Q?YI]]&Z .YPKVK:H
M]#CF^:B'T44;^!(H<Z#Q]S/XJ2&962091#)]F',>=6_1)F6J>F]WQ7.8GB.2
MK<PJ;B"!G^DJ1XDT0(7S(]\*IC$+N9I6^J"@*4&CCGG!V]6I@WI-8/R3!4[;
MY5C"$;:_5U(?)<"$QG="&N/)8(%%5=9(2J\FLQW?4;/A$'*%IZ#X?6YYUN6D
M&QG4A'G?5;G&RS.5ZLVR-&D8,:T^JRKXYKTBG_9"8V,2IKQ%7/GCR4KWS%UL
MW-S4H\CJ.67\9QM/#$_-%;@4H=??RA*7P<RILN]R"D-UB6DZUJU2"K2R8@/V
M!S_:N$P6MCB?CA 20S*6KRT'WJY2<8+W;2Y8KFRIQK"D]+YKY5H6O?FVI1<T
MP8D0%9C*4B1R;K%R)]%]^FCKJ'[W94/CKQ%(#=[E<M;@7[N.'BZHE"5#7U[X
MG?X+.(2,!32[O%1>G_'Y@XX ;.[R>=STY]_L>_M"KW>*:K/>\?\R_:*=EHB%
M,@( &U06:YIU/O"%B52\_OV.6T>=;EM/1ZT0+"1:K/J0G\F"<IR,3;W(AD6R
MEXNG-H_G!;E+.9I)^@ 473<!8_ LM7WV9.KTMN\RQE1>TG,&1AQ3:R,:J1V*
M"_N)G/[3J!?>3X #$<*KSU&;? -.F98$ UQ1FR)\$URWFWP3(D>;?,]'YV7@
ME_/B N&B)VS-EP2>DIMILCB2E\T'2*ZW[^9UM%SF?]M[:U-R$]JVXK\/=PUU
MKXHW[8@.;L<&^_3-T1YE'VL >\HMT3?PQ>O)\B)QC(KBA5*IYERF+[U8/<&'
M-WL-QWGRH)EAQ$HN1*$6FIR4AGM#D$\1B.^R8)#9DHX$TLX6[/?6(VDSR&BF
MMUT#=[QY9&GI]#C%V[=BZ'.0(XZ($702/6>'R,!2E"DEI<=S<^S;;$ZOY=7C
M4^&RJ-1MS G$MOLG2=8K0*3LN4?CY=2@X";(IZB;ASEGUVWUY7^CXRV#XF""
M=M%-(#@$"!#<=7%W]\6"N[N[6R!! XLO[NZZN 1=- 2718('#^YPW^_6.57G
M5-W[?[IGJGKFZ:=[NMNX?*OY,?A5PX6BZ EV)T_Q?ZY46\6\A#S/-X7FP@,?
M?/(CIP_O'A3;0WZ<4ZR3AN#Y^#X_EM]]T'WJ$;?C'S>\TAA[]74^WUL-(1$O
MW]RCWWID[P[U<K]77]F\.LI?PS<]NWXIV&1RG5)B>%AOZTNWOW=ZS0]-S8[Z
MVWOQ,@/;DK<-G:X*==,.[9K[O\Y7O;,4 G.HFSUN.645Y*025#5:R_5G4)0:
MDTBY3#PDDN<^H=,C[%/I)H EG:O->4[E4S?OZ4;"K7O@Y]<FFTY)>V575E'9
M0__:,BEP=[Z'&2(D'L=1^'0?;_M&=,$&,'_Y1#X4EK5M?NA-WK<_=#QD4P\D
MLT_5[&N946(1R>BGMSR8<A-\EU397B2/8H'!-,_!&">DR-Z1C[1"%CE__*M>
M_$CZ?\8YA"[$V6;JF%7I@_$E;1@: %8IMUB=OZEC%?=B4=1+(/:XC,7J$']:
ML^A8T9-)J; +H2BO XN64#-8'COH9+5UC+CNVN_V<S52Q;Q,'S!\'6PW65GV
MPINQC,2:8PF;"EN;7M^ZVW%NJ];^H[S8>12P][5HTGXS(VZ4L,#EVX=P3@KS
MQ8O>((X+A$%%Y]_GZ^5^JTWK.Y60%;*-'$VHDY<SFK8(0-A#C[CH0^)U?UJ(
MT/[2@F:W9K!/Q2HOJ1;?0"G(F'<J9%!E??[8VJ&/[NIA^>*GRNR1Q'C+<Z$&
MR_S.[FC3<A$Q8VRT9D,]"Z(H*Z&+5P(VOU:K@<,/+W<=C3%M68SY)9!#-%6H
M,%R=KK1<_UU2CB:,*L]ND%=H"H<1(_KQ1G[T:O=)>COX;*;'X;AUZA$\V,FF
M,W'VLU>_KDW(-#O48D&;X.GF*( /G S49^?52EJM]:['\*WZX1W JB0OJZM6
MS[O(7M'[TKA6VR:E"J)GAPK4.OMGR(8?L<;NU!3*?L4&UC0V\NE5/?-\.ZJ'
M,C.Y%"S8\]'L[[.<_2DL9.'"QG)';:O=<*C**G,=T=&$2>LRY&HU:_T>:JB2
MI)$5<1O:':!-+@/G06PA^O\F\*9Q'JL=']C]7!T;]9TXYB"%\/2LJ86V"I,5
MLZPER_6T*Z.RO OY#]9530?&*H0=O&1D*1XFKK>= 6CH4AG6[89,=4I+_SV#
MA0)(K@VTM[9U12C8UN3(.=BTK/\XBN5R1B=H>; @N)W!++@PI56?VIHPH%<;
MZI/Z'.MTZVY1Q1G!1<#-.M,:&FU+30*554[]K0[_NUT6^WV:UC-S,6%UM?E7
M<I'?+A)!!3<X).B83,0)SS^/Z0'T'$=M%5@?Q6?(2G=VVM&6M]]AZD)2RHJG
M#4ERS/=XA17!3?DT]&NU6Y+I?I$ 5^ K*D4SO-9'=9]S8L5!?(:T^&+O3>9L
M4W%Q>]ZC7WKB'K"S1I$"*B:^$RAE##1%&LAQE5833D>*+_RZ45$1M9;A:6D4
MN?DTVBB-8<E.&^=64;PQ=(U@2L.V9.@="S?VZUJ4=H7"[4NKZVLK7; UYJ2Z
M2[-T^K>CBUG<W'C#EN!L$= "?+LEOHKL"'^&)()*.]M+";]$' PAA4Q/1KE@
M&T.ZB%HQ"A\RN:"05]UV0\=3;?()]](L<,%(TP-W_>?+M0;=$34YX/(35F.7
MI8]SSX$S?WRM?U&OX0?E%IO6<&F6]V4?XO>BDK2?K1Q9K".%D$W!;7EZQQ;_
M*V-AQ/(X$EHJ:O<&\+0(G?POXA$N_]:WVI7]6O<&D'=;^M67;GIG.:#VI/D*
MA=ZLB[GU!./][_0[Z8\)<I$#N&G2" +3+CO3P+^(UH'%M#VB7QSUP)2X!\\<
M<Q-RHE\B?F0C48T+_&'H@FV:!A(:!;U&?C)8QE!"+GJ9Q#V(WJPZS@:EF1\E
M*E4']E>ULXX&D'3OG/H9UMK*G?S?7M#U&=X?<$;_XS^!W8,"T<<PA<">]:Y;
M<=MCV-"+P:S;=(3%D YBBC\UK$!$27?C9XO"-8L@E)ISRQWB5FAJE&=4D99L
M.8-.8OLA =2><<)/([Z'M:[JMJE\HYGLN>;KOI2D>=T\BT H[KLL'(<#/_EY
MF/<XC?D]VZRD-0TJFF1N9&]QM/9L]-TB,AZG)#;M<;-S5(YJTY'>Q0#3];V$
MG5LB9ZK\)_;=MMWP /]<R?.EG6_@W,>$D.)STU#)ZP"*OI.GWID:)?H2/TJB
MH04/?DS],"J<,H1C>-A]VVY&_\7WW<(7O=4CTEL-]=Z5.+(CM4*)R.(T?';R
MDP#.:_+J:U7Y&9KM=0[)P[!_HX%11F9/3W=BSSX4L!M,):'Q7IJEFY)V0XP
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M0/1RY2(PD6[C&"3CK-V1\*4N;>;[DF725>:3UU@Q#(-7I4Z0S[P7*J9CLE[
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M&49CT#I9\> /WK-63MV32?I5PX%S8R^H45U.7M98>TW#;,L$W2^O;]2Z7X1
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M\.R5"46"U5!0*^1@(VNU59LX0J7>20'(R[5"+FIK2E<&6L?EH,O6:%9P6H]
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MVL*R,D_@U(LV<(#L*IC5GE3MZ:CQ^>/[P/'K0&,1QD83>U4?8I/Y>-'W&$V
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MZ7ONH5RQ;X"4ISF*<0KK4%'>_'OQ*<U_XJWB![Y]ZUJF4ZO7_*_)H61]?$'
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M3#9?%B_;/&EV7=E&8(+DW:.E*O+ $H;ZKC(%BC3XO?S"A>!\_:.P]YV7^,^
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MJP"!HR&>S H+5G@J[3TT^Y.C]CQ$OFKGYU@C%3\E,.?MP_8U#9K0$4'KB)N
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M>R.CB"VXR]E#D?G-4?!N/YAD*"27FAF%Y:W+S3T* GU[>X,K\&4N6.6-_!C
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MD3 :B+ -.4C,V)2VJ&\WN@JJ/J+@Q[UM,?'[,S_$DUWGN<GNUZ6EHZFG+((
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M#D@\'XR W7=>GE9;GADLSVQ>2FGE6)@I@=W 1SO8]L<0B#3KA\%J>M0V:W4
M^Q5334]%R /G9W_;;_L-5 LD%U.JC*-6'4;^%(!I[ UCA[Y?= CPMLH*Y("7
M?F@#HM@T[>[&'A&EQ"2GQ&?33A>7P:)XSF[R/K11T%,1#ZTY?X-P9)6"]_,(
M)TK2PZ$C>/LD?!G87F17ZKJG:3EP6,;^A0OD\IT40]AQK"IYJ(VL9]:67VR1
MI6>BJ1PN.75"*7! /=FVN^@[2&R.P<81PU=6?RLV2^'<CR\3?S?!?K?8>N-&
MH)*J'RF#WK4W_->1P%M.J]1#PB[/A/WB!#LM9!V&N^YTI>\_0JD^']1+'2J*
MY3MK&I%7+/+0@;(9ZL&GA8RG-N'U\07:>7T/+(1(,6(:>[QY9U)%-&R*?CQZ
M'E\X<DZ^I6%9_G+'F]4%3; 7-Y>-&5%)STCFT 63B;-!427^"NO_2&37*O=8
M83F]PA'1^ <P,!WBUQ6T1\8<E<$;)<R#Y"LDE)[4TC^EA,]W5KBM,,K6LIX!
M TPNIGLG=/1XEO@<%DC7#?6;&=EHW;E /A%\G,BJ-*S/]U3&1?IYZ2D&WCHQ
M1*TR@)KWA^DVQUQM:&ZHX, Y,4X35TY:U(\;T8.4M@ORV;%>KG^5NQY?W\PU
M+9FYW? 1)[,G2RODJ60&UJ$RD@]B=JF<OQ;H:!,!C;2S\O$?J,IW7T.NNK76
M:C%@1+I,PC' W$PL518+HX99Z2(0[RN(F8U]F@1?3\>17T5@/A?3O[T =KZ8
MY]S\6A<Y'9QAR3*!>9YDH'DB;W25^B25>F%2LZ$<:@_43.PDXTRNR,(/8S2R
M;>I^M&@U.W=V=O^D.13XL\S>!VOL@:-E-7Q2)\.!H8 QD93>R^:4].,Q&590
MGS7BH0>T^FES"_DOP6\V$<^UG;SDKQK7]A..%\N!FO/ 4P<V9-.?WJ,,E>&I
M K=T.8F:AW[..L["%3G+=_F&\B@$8&$J+\YF5)I<N">2;.SJA']F-V3B3=8>
M)=_-<IZ@X3"^=B]G=_=QMZ:6I*2BNJQ*@:DH.RLJVR*=X!@QN[R?A1#O%W9%
MX>N'DXVVX/WVGT'0?P MYX^?PP_U?3MTJ&/O=5-;ZAJ9'8KBZ(#^^F^Q62D=
MD*O(DP.\:W#S'*O2O$9&59>KK[6Y^Y5'<IOX<^7D)J*%=DA6$ ZZSS(@;;?$
MEQ"?<C-Y8Z.O$TK=(I[Q-_1]&Z&:<#SW[I#&FJ0+[LH^1O*56Y+ZUY71_S&A
M5:#WAWRK4766<#3R_2OOJ O+EWOSRHHK@D2BT/YMF"/+LK$00&]@RXI)6\);
MR!>^-X)S*E+>E^)3PS-*85-PK +P3O *.MM>-!OVRU@KM^4+)@WRU\6\',9"
MJ4>PWG>'Z[2DDP$$,BYN&ZZ(H[*QP;96M'?\IT^F6D0MED:</YM-W)I^P+"1
M;4%"RU)V($[&=9[2ZR9:(<P@>^I7_[%#[=W_@.R:Y[09ZF>;\;E%(#=X'?,Q
MJ+QB^V!*5U.6 9/DT%AAX5;!1J0$MWH,6_(#^5N-T\REHTCR:5&QYBS2^5V6
MI0<9W->28(']^[K^((?YS"2CP2M=1M.N=)-V;ZS)<KT)D R1]:]R<<JC/IQ,
M?^TJ!:L;. -!&)"%BR2G;&E@2_HLL:BY.J^7++E12M^$<VD7;[)S3"4](]>S
MN#(Q<4HB13IX340/IRLD>,9&K/.!J60[,,.HRFF"7Y8I(U6Q(-&0%6$#.GM<
M%H.)\]K4+)54>_$>ZQS8Y'YKN._EY!AT_* \NM)#:LF B"7.0,U/4PG;?[/(
M6]<]P5N5RL"53UUBU):G)=(HD\*7@"6>R=A(E$6\S/[!#8!$?P- HA5*%L*4
MDTL;4@>/=';6[;NU:B'.V"IA<!T.G-"HEI89QAS,3B=</D^=6G:'%'V=V.C]
M&*V.?,8ZXG=#6&.ESKVQP;KW.K2_B!+L#9/PSPF_O)E.S3T/S@DD7X=[S[,;
M 1^49?*F7Y6&!5%%?C3[9K-D<YN8=Y)6Q$G1J&(ZO[DHDTO$- "KA%L87J:.
MIZ&Q,,8:&AZ ),K"KH6Y1"6QD4B-T</-62\;945Q<MV,'?=R=MIL,TJ:AZ82
M7*GF6;? G'I3D9,5=9U+'HGHMK&M"$UE;4(:'B$M#4H[MDV>YU;=:7!RS,K]
MSR\?:6JM%?WDO&MOS39[)&78#)V'Z"FRTH6J8F+O<:646F+:1X<S1%B%WMM,
M<RULLO'*VVS.O[>I3.)L@2J+-JD$$0N55]@<31/L5=I%*V3YZ5M-3P^?76W_
MIV7)&K_*72L03Z .IT.='J[W.\#P,*'2)M/-@*G"J#-[(;5NV[J@9 /6,D6L
M\PL.%U595&53\L[M*_L'T*1:E"Z:GSK7]<,C?O?7S,PUO[H\.AVFOI>K6<8D
M<R.9&<&5MT=70+YLFG?NFI4YKBV[-@X0W(F F%IO@.%WO_A;^6[4/R7K:F3F
MJ#.1"C7J)R25$)^SJ;(RX[#JRAIO'N]L)R$&)ZR;IG:7>J.-RA\Z.Y<V7L24
MJO,]6HQ<2DH"+*M+<]3/E578%S8J.C?* C"GO/QI*T&<>7=IITO53L$>99)^
MSG7"H])>T:XP/Z]C:V#KZ:<W3 @^U5"\.5E"X%M'V>#581Z0VA>ZIG3L(PK?
M\M;\BK$V5LO6 :I9A,)2<<6M2@SVK&3V=$"*\O??3>U(B>AJ$<X+U#A?"Q]F
MZH<0'.^C_]*X=B9L$ZUH>V6TYJSX0AP..I<5)6<[,Y2J;+$D[B:_V5F3H\6$
M-Q&3A%@7O8H!F30<MF"GW\H4$OG#WLX :6MPG8>$5^L/1X>-$W8KX5$\+;3.
M\IG3Z=6"H[S@(+3\E' $BS2Q!5[S*)?"!\K(\8''Q-+-.K#NCGO$@A9\3'UW
M:RXQ@/5(@4' 29=@>KYI]#"#R7;OT/C#.^[DMZ?0X[O^4X'UTWCJW83U9B)6
MKX\W\*%B7;G,_ Q'D// ZI@0#S"W9H5H*)'3P"7AVP\CO7313*)9K7BA^/5E
MX2Z@7JWQ8D>5 YEH_H$'JI7&1O=XR=@BZ6CPTUA?P9]<$?)-,7S-J_7@.4/K
MZJ!+W0(G7IOJ6JB.$D8=*U<5?RO"4\Y:GR:#_AT(Z8FH'V=6O>K1_"$1NOJ%
MK3>GS'C/62 FSH3H:UH3C"V+ O_OU&(]^D_NG?U#&M4]$AL;*3H@9QV A*B,
MV::F863%7-EUTMDX8U-749-?EHB00:M[OCH3Y*FU(LCLM!,[MDZP$H4:S5Y0
MH%4JFV1>&**12^AU&?>Z=]OBTN;T7].F8UEUK26]KF&*\% "U_>01ZBFI-;>
MK:P^:3%1R_*X13L2%MS$X:A-4!9R<!84U!/,2MEG49?/2D_>?FA85D6D2.&O
M1BR/9S0Y/;(^7=<C_I_WEXZ-]:^R6U%O#$]*D:C<4N?:OC. C^SU+673V]NR
M'<%$/ZN4%Q'5G;+)V2@R?-,38M##8R;VL_YP7,^)1_S81AY^?T<(AVOS"W7H
M&-2 WQNHM!JT7NJ:<LPZH==5M*\8.NX4U[?+"B\M8UA!"NQK)+6KN9>5*GY=
M@(<4CVTDKSZ;%93@HIM:,/(_]-D,G<%FDLR;A_CYB./7)\#^=UH /L,8"I\7
MD,JP#(J1'??1#R)+34,V$]T5H:K@<C:[DC .&'5!'J\TE8I7D6]*B4/FVM+W
ME@6O5#Z#\/U8'A]W7([<Q6'EUIG7Y'FW\XJ%)GGTJ#M^/0I,5?ZF[7863CYG
M0YS!()?E24^[< ?H&>?2#(<M(SO)8:4O_N*4\MFYFY,0A;GQE;!:*?W9A,+Y
M>P?^)^>([(CVVYHA_G=OEX5 TGQ[,0'LM*="J!&2J/AM"E- HYN"+Y<P0W7;
M+L-SYMN#BE;XHB(SMK+&M>28((^(TTV#6?FFM( BO?"S<^^#K>G_QME;!L79
M->VB$R'!"00(3G!WET&#NPRNP1T&]P1W&6#P(3B#N[L[P8-[<'??S_O5/M]^
MWSKG[-JU?ZRJ^\>J[E5KW75UK]7=5S]V'_=4,=;1VS#<Y"UYK6AZ%F?VR!S)
MR;R_I1]<+RJ*7R9O4Q";'J&,,5!BK#'1.YQ\!<CH !+KZOZ0CR2T/TT>V&:Z
M.O UOWP%#WK$V,DDE0XD72#Y?S3-6/>7FU8CD<+)XOX\?0ICTB-I$/#5H,>@
M9E7=DL(ONKQX,1X%L5= I="%2K>Y1?8K&.X\+VB76/_@"RJD6;<-'5]3F2W.
M#R?5^RRJ8IB),3!AUWA+QZGC*R7UA,=&?HZC)NT"SKP"GHEC[[?7;H597P'!
MT0O/SRVW7UX![KKSQTQGNB]*KGZO )8+8N'WMVJO@"LWX=T$_^4G/UP>B]N;
MTV7#YQ5A*X> M0OODMM[_[C].YKFK%= ;M4K0##]97?KK*I%N*/!;_,5<++_
M*/>O!]V$%<..D:=0I?]03/IO:I46==<;GF 'SR^&V_Q_E6:^%#>7E'(3TW)7
M280SZ>-8>]G@(@6-[#+\Y"_X0S)/AZHD*J0-?K:U0/=*O>JXN!<F++CS;2YO
M@:7=S8LK*GS*U_*%D=+DG<_A\WFE)]]@#]BZWAT.D=)U?'"S".(1QLA91'%!
M\O<>6488;]0T7;)FC%38WD3TJ8K8?^KT=+YRVYJ?9A&<J"CS^N]D^ODRZ7Z;
M"\6_HF%)B,-*W^"897(->-O>92D)+\!MIO>-S-K7Z;*.R:J;JO5Z5C/9O:,=
MTB[C7B:\_PQA@U_>I.[S:_5%Q?@CUU;W1%T=/$']U8O,\>QK**C,E.+ILKI8
MC0D;"3]V0#3!(-)>#V%L-*AHTE<NA/A"YE< G10S\/F]Z14%GRU)+DEYH:!4
M[V9RX]7C@.WS"J)P5X;UJK48*XA3\"^8VYO)VPG[2(^=['UL#Z;3WIT/ZD_
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M5Y8>1_ T>4PR24YYC_MX([(_@^M2;@S$"7]K85[PMOI3PZ]I.P9KY]6 M^*
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MH*+\C:5?]VCZ^>HD VT%.)CGDT5IJ1D)U'&5(^HAY6R%IR*T)=)(SB'4D8H
M.,X?;N4;4Z0>4%N&-3(:I/@>/R'L$-:!9IF.T5M6M2FH25<_/<^ODY<?4;%D
MA4:&H5$C**3%_-2%?0$&\EZ=9H*G#Q%6 HL<Y\;;I2Q .GO>;T-Q,5'[]9C0
M;4.X@=YF$H/:OVC\>D>"^G2J/NM$O0D/2ZW.,2^-U0)C&SL@$NUEWRB]]0'&
M[*J(-U/='T3LV#0IT+?.8'^?LN/22,W)+2ZX[\8GJ*_V&C*S]H1/>7EQY5^:
M1PDF3M"@WHM[)'$5IW58B5^B^1:?6H?0:-GC]%\T1 C,"M;5)AERJTO6<K*J
MB&.I=ZE1 16L2MG$*:2(U:W^GIC4$N: ]88"C]^U?HM3.8/\(?^ +'&()O95
M&D!6Q$/GZ;&/@O82B(VC4?_'E>%H+(V42BR057I;D0QL[S6.EMX 7X^!\?.
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M:XY'NL@\,++14LW^97C5R]H/E]36^IW.Y+SJ,*5.'H0FNLC#9ST"0B$_DX/
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M:>_Q>=4YWM'CH3WZE_L]E2,S3,%*NN;;@XO0TS/O *QR;9H0<><_N6JAW5\
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MAL.#!=R30#TJIX51R\="O1,6RXHU8^EZ-ZRE79+>"^,=FBRGI\$EN9YI,]8
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MP#SOK.?$),2_9M+RB7@CI^OM:9WILZS=JKSF%6<RFL*=^8/2R$/%.G(2V<1
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MSX[RUV9E7ZDN,,6@Q4+*D+%I[)![Q%A.;@XW)2?,/='=&\%"==-,L5C4["9
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M.A%41OMUM5I\?O[40WUD6RMN4_2>EA06FT-*O'IL>,S.8\+=86F#BY.16^+
MZ[6_'V7A$])3Y4(;AU1OM; >K#"3X3SC6KXA\1U?40K<0LR\CU=@4&&B,=!Y
M/3GCKHZJLZAG#JP<N%N:QWI7PUDAW#ODH]C^RA@*?8;<;$('7Z3N^K6'YJ57
M@3A,Z>G@(2("F.J%?NR.N2XH'>1++/%2N7;[MH<PG2_EQ("5="7SQFW'C3S1
M<QI=@ ?(5&G4OHD/_IABG3SSJAB\@H,]J==#C15BDPZE#T+X7ONV-.WCF1.R
M_BIET-Z62M18VP ^D4)C.9X%C23&:^^VO_?H+V<\#M9[/H\H)/2"HTR:*#XT
M\8:)?G"BJ_!V'S<DZ:+ "MHG@4(L>*8 1G7!(2!"L*?+HUW/U$"^0/Q3H(^X
M3 6VJ5>!5<&!>4D"6Y!'<NP.YD,N+O:5&V><L3U!S:LY>GJOSGJPW)W#7'1]
M4LQIJP^Q_]AA8]X8^VQ-G/P1H;B?WWBT*K([\=L2@HVRG,\'(:7K!_G+W9UO
MHR5]?1."]_;'SZR I(%?$@+2!A63[%:U;9BC'+@1N<XGNSIPK0=ZP4XIE*[\
MX<1,P1-;9A%YOQY3;I?MCGJ@<WF$IE$+E1*!F,5C!!EJ8!6AH,KY&CE<5G4
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MSXIY\>'ES/>%OA0MXH=>3C F(9N$'SI[[MQ0:WJ_?++UT#4NB#0Y>/;DC%U
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MP5^J7Y] 0@Z3K%F5-&C<P>6BV)H BB+G,#C,D"C?N-&YF3D!DRUY=M0QJ!(
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MLE:'/H4X\$28;PDWM*1VT= ,+4DWJ<R0IXX@ID_8J^[\"(<TCA753V:O8?1
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M[,"@;^A0KUK/%.'1%8$T%D$9F#TI56&#OUPV[;:*M _N50=WUV0UK&UD7^/
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M&VMT?@46W."['9TA.7KS*K2O7SQ=7A!MGJ!MV[P!:JGNPIRT7^,N[JY."=X
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MI(='9*IX(^JJ"BRM-O330/3!1C[F]5CQU8K"AX;5#D3\." SC-WJ6@J!1L\
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M63;C!"?Y.X]:O-GMGE+9_N-EA%!AO^S\!15QR)+6MG;@O)X8&DS/?L(=$VJ
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MQF4"J4T2&EODQY>Y_=/K^+R8_%*_X=V.,E@_<G<*@SO'&*=Q()DJ^ IZ;C9
M?WH-EZ2X,:H(/+R,I!C,$ZW8QDA,:8$U.IW<4H/!XM+O#&8?H(1O/L^RT-W
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MI1R+"Z"\+H6Z[N3<4'%JE$B\+DS1LB=+J.+@5SYE1Z6%0Q_?^%T4],WU)K1
MW3U1*D*03IW'QA3;]KNRRF!#@&&&M]3C]S,N3^HK,9I1*?&<\I_HG_)X$'!-
M\)/;@(G\/"C[!,A>WUJ'<%0IQ9.3IP!(IA+<W64>\9F]L6M'Y7C;K,[;5G=2
MV$U9(T!CAO!9'/K5WU&_83)N8=5J6KQ?"81GEGW,YT&/QDV1"C-<IA7<VY$]
M=HWA7II9D<.:)[:3*%.37U1QI2S(JU>KC[PP#\A>?'3[T_;V$*%46LR_$WHK
ML16O\CL[O3I+7!4MIG6X6)%#(*EHIRMYZ:^IB>GTCP#:F9RE1DMW>=F]_FK:
M/KIIUXW[IXJ P).-WU%['6KO@$_QC\KO@'YZXX)W0+3D2ZK0'\ZF<>?;68UR
MG\OGUGQ_JXXGLW%77J%_._&@[1WPIW["EJ2G[^WX'9"NCKJW7H_MZ9I45JS;
M/--POC17;GC'2;TM%U&!$HY\GDV-<C-*>B6:_$FS5IP2)(QH49(K;F4)YTA<
M+19-%4R?5E863M$&"1U&81G!*M^W$_Q%UZ2"+[4R#R^6<8_VM*0K0ICD,C*X
M-T886XHR,LO^A;24]Q[:.]+T2I/&WLT!3M=VP];/-R,P-C3WN(;Y+L5+5E7"
MI/G9DXS] N-.2/@$^!AV#0#.20^A_2F+O_F 50ZG6ZZR_CJ_CL>,T2//&L*E
M==E*8G1*+(:Z!JQ7<-]!RXU?HE>DTP&#^] 39]O=G\T^GBBL9PTU6\+>F)#U
MWE;N0'8S',:JI"O[%JUOL?3SRLWD9G8K/)R^Q896]<B(B4L)&H^BF&"S'05:
M"!(P-OT<LT0F4MQY=-4R[!HEBM/F$8<>K.F5LC2WP(6-9$)D?%'RWNJLC4FZ
MV5HFYG[\,2(Q\06EN#RB-X-$ZL^' 15>2U+D<K"1K=^$2ZL6^9&J=^G(9QGG
MAH!AA>9?B"HP9J&*=%QT<A[03$+T)C"L9^BCX>)U0(F! ;29./2O1Q8-T936
M.*[6'I7KQ5!G*,,BJ'-#_0!2.)K\OG@$![/80 ZTF@2>\2L)9V$*6#,F]CAG
M*9C*+YKZYY.757(CY-@=L?"_975MCWE%/JE;$44KYI1)3S2,ZD:RT3XJE;"F
MQ.V:;[XIPV,JY[8>I3GL)W7WTIW?C(Y\VG27N@!UTV'V%!\'=JE?N->464RK
MJXQ^GMK%^TSC:LO::]?C"#R,*4AU_OJE1-+\MM1=TNKL#UTUQY@Y<HEI&7L2
M71.DQ.NB[&(&^Z ';*5AS>T^F"I6YK8$+0E$Q>7K>TD#]'N3O3()M%V5XQ1*
M)'DT66,3?@O33EPTRFW_C+O\T4,N#L[F9M[!L@DAMKL:UD.,@D7<3#7FA*VG
MQ(2OW[V8&SM0YM;44DS[=*XG&2;)6JVQX@>[Z8?'$D\J];^\5"#8B/,3K%M8
M_[I3XI-9+A3=A^_Y:$)SIKU.[0;ZHG#17Z'> <CTHL6B]->?RVA7-^&$DF=C
MX+1^:"SWNWJAG_8"R\NW79@9JV%02_5N:01#Y<L5 &/"+E-HG?(C7>U*\&T?
MJ5U-B\2Q?YJ,:5$VLOV*8J650 9DU!_^I$&0("&R;PDJ0KKH-V%QU83Z;HX:
M@FL<F\%RBW%,G*=5WJ*=$"-3HU<RR,T]*%CM)SE/7V'Y.E?U\"U@?8#.!]09
MH"[11NP25KGU'R&Z1A45Z-X!$CJ7%+,OG1$QK"</GAQ?Y+BET2P'N <"\>UM
M)J*!(,N%/KI,%5Y6>K]"-4=Q< ^5/CTZ3K>VU][D]3>MK: 4KR*EU@(K( 1%
M12.Q"$FF)H,>=YP]VJ0V,NOM>NUBKC,5L-^Q_O94MY!28&O0-19=MYO6<(]8
M9H:\3FR5=Q)1;A1SCVMGS#VL)'=KQDU VJ23/N0HL:@6R2A7EDQF5[EZ2[0!
M=7QW4=S8]>#?#QXW*)[Y&Y ]-'PYI'H'D+"_ \)<,L$^']YDWG+T1,Z%$%_=
M.G=*$U<79& 1#TSS$U2$D>0HD <9V*2]S%0(_*2(DH=0$QOW\ZX_'2):TUZW
MONP:.*84-U)I,;&I_8@3'L(]$J;9XZ0B98O/@$;L'#I<^$WI7Z-9.K#2_'4:
MV@.L[AT<LU)V6R<Z1\K@(/[3L%)ZKS&BY7H:KC^=W"^8)VI(RX$LY[=J,%8K
MD[R!#7:4C/6,%[ZV-*4)Z7.^ZZK^@E>\38@ZX@)Q+//:B??-4MN+@=I".$$J
MDGT4B=4W^W3DN/RD&Y>#39_71+5PVU*4H$ .+Q],QZ[U"LU4V@ -+!Q6&E-Q
M<_M4 DK"W.AOWRTUV=P-;Z&<BA0'<FY]?P8G5VM)>7PPW4DQ#=:DS*RYYF5+
M7 FD[&<#@@R\C3A2U<BRTZCB-!Q^3OL;(%7;G7U@ST K*O+0CKY>K'%?>P?H
MV]F'8/WDDN%J,&F6CJF9LJCE\?J96"<USP@[@&_GF0*R2K72YFGL,Y<G_F9<
M(P9F\#KE)>;0D'?$NNA6&^!8Z70WTJ!6PY1 "G06!9=Y_X2CK.893#I19&"7
M07O(09 )YBN0B,F+D<(=H>>^3:0#P)I6%]RQP>#KVAR.I6.Y]MHO5IL?@6:/
ML1[@CI*4? U>R/W"=KOK247RH]!_AMPPMA^0H5.;8RT-RW(D#;V4KN_!J;%"
M@Q$I$T?# L+86P#0B\?K(@,RY1ZV.S,KHP5!01P6'%%<W&\\R! >,F>^"X2U
M^5)X+O4?"K0:\87O@(XYVY?/%J^PCIQ/10\9V<.@-U9=5.879Z&=H7< 5,6X
M2W)E;KWI!FAME^):_!TP0^V2,_4.^)[\>OX.^%#IH_5&S'QO^+)<[,AU6US&
M*;V:2+>AQ]6>Q$_PJ3:=VKF)8[0S4(*)CH8S52H5H\\-4J#%,I' BEMHX(<*
M.C*H3LR)%T!3N8-MF&X[;9M.N>N.#I:V'VME&>R.86W9&!=03R7JM;84:/K8
M;BF! GVJ'RP%SX X_C&$C>^X;(K H:W,]"L+^^^QM+V).1P!&YA8E, MD[4:
MSCTFK5%<3QFOZJL9 RCV/[EQVUF4H(.90TL/AWM4.Z7?Z'J4IZW94C27PD@^
MU^L^K:@2RZ[!#C!P_ ?X&'5HP1V1SI+N?*$!;=%M#57K+&YM)FW*#M$I>J0M
MWF6-Y+OT)]#:[P#:;A8&USJ\0"D2W'G8Q"@40[4X*PAA)&,1U@[P%&.OAN"7
MI-=++I?^WK*LA2;#9]O=Q!]*:^KAP]LH'[UCYYWT2L4&8[BFG)*1!J'X$@##
M(A1Y !:7@]A5%^W,JKHI7;BJ14]9?0,EMGOL>8A;H#?*GPP+/+<,-%(6<!EG
MTNRU$#4 66$8@3?3,P/]?&B,JI<*QW1F&8]AG0?KEU46#1J:KK^T>=?=J!^F
M!!QO6N-]MUJ+-L:/QCB>S];$T=T #9K7& %2ONOICO2?8/6*BHC5=T!V'?V=
MAW&IDL?P'Y=M9CWB7>M+MM- +C*X:I%=')9&69;0>F+<W:<2VUB_+N+;IY7%
M(<<VH:XUF,%+/K)/E2]/'ZJ% =D6;%*#G;#&0,_XDX">LL0H<^%WP \JA)O.
M<6E2'TP ?.4)2)8><M?PRZ+NSK]WSG^9_.LM=97F+^Q^XU5UU](7W%A%3)^2
M) 54PF331:]6M) ,>S"13%P!6F2L#:.@U7:U_&4V19*D:=)-3Y/=1\D<P':E
MS4[R%']R):;(KC+YE^ZG#^A,B@6SA)9%H+:%9ZH53W[[0?T\9>IW@#P7_@^I
M_$TY2>%1=FI.J^0:3A(^Z-?OI%1_3DA+(AOF%9%$B>5_Y,,P3R."%/!='ME%
M2$.$9V29-=SH6[VI2$RQ707;"K2E5>A"'GUS+"-'\+3R0(MY9C1@E().<^/S
M$HTN^"(=OUI[98^H8)=&T4Y4C7#PXJZ%Z?&6MY (%FT?][-HT63##*X!9I7
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MP##"CZ^SIG^PN_(QA#8RH(%^3@8^H*9VG;MD$G.6TH59C/ ]5HG=V:*>NUY
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MXI1Y1MUKYA$4KI:WL.!,> !$D:M?$<2545^%>[WV*3OWD32$=*<G-L_O#K_
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M YJ:'O#:L]NU,%>$5UM:,JS>=M;X0%CMA@6FG#Z1=U!S.6D3?A9,WYE*23*
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M&PKA-]QN8OX.;Z?$N4%.2TNI!0M$Z(D6>)(%25/1V,"]"O3\T2UX/Q"@ =!
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M6(MX%K0V&>.'[*S3<Y0U-NV4"7)9R,=XJQ@Z3/Z34MI]_ZS_-U!+ P04
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M%-<CW,6M0880>QP0HK_]R\+F;X'7U)^C2A=5]X#\!#_O=R+":[+'($(Q",P
M#O#>*KIT$X_6P" \!OQ^K=6,N6NO"4YX.9Q2JE<N-*5\#-N-A(</F%\S"<V:
M,5_.KXO!;ZA[X2"!S>U[?9K[6E@OI15&+P;F&\ Q_5/)M/:'&J)K&3ZK?*T%
M)00@12M2>0LLZ8(41$E,C((]LS&,FOKE1;(H\KU;)6$CM&FND?OO%K)#,'LK
M@(\=.EE!\#%(>H3XMT;SV@#9Q7M_KN %3:K$QI=P<&/;6KTI5H;),1V >HN2
MJ0Y?5[7B!V/+%\^I(W"^[K,CIX$BQ#L6)P_C;G;A)@SD([F>^(HUCEX_U:W
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M[ F@*M955IZBSGW2:"[!EC,?6*ZZJL(GE2)'U?N:$)'<!(1EY#<U@&YNRUW
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M%\)*_P'"^H KZ7!H^I2C REHV>*+DGI'S*?F(+]GX,:ZVO9Z'V9CX=V+D/4
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MIL(FX=.=*-@+<M[+HHA36*VJ$+:*M,R,6W$0[0%\%6$<X?S! M#"]YNF#%U
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M< 6Q]XL=G30JCRTZ39#$:N-T)8C/""5]<82'>;_P]:D8K(0<6$^*#K*R7/=
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M +K!FR#M%>-D+XE9JL02?[OO01D7J1M_O_%A'/N8?7+*A\O\PU:N_U 7U[?
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M^Q(EL+LIR'@PFJ[02K6OG_ 5&1,4'BR"7P1R8! &"GBIHG)[0ST" IQ16M+
M37(&>[4+OG#6%T]PUF-7L;0IZ ZU#H^& 0XB\?SS1*$8[0;3U\C6 $_5(8A-
MT3*U\.@47B">I8B3EO!*[[IE3XL57H(.I90,'BAM(+3U+0PU!(K!<'E%WG^X
M7M$)%^.\]W6U.,3_S]YW0#6U90T'1:4I(H(4Z4TZ 1)ZD-Y"[]V0! @0>D?
M1E-Z!U%$FO0>E*K2NW2D2I<F M+;'_6]F5=TWLSWS;?^-EFL<-<YNYVS]]DE
MN=E71TW&$P0%HSRM[?34=:34O*45E:3X1#RTK(15'7E5-9V EEH:W@["UF!/
M)X2[(P);C$,M#72M42AK6VOX+VV1]*VDC9#:EO*N.I;N[BA#.64;>RL=39 +
MR$L6_H<6&%^/O2 ("/R:M!MI"$NAE+U4>1VA&O(BFB)@ _!W@L[\UE!'$3=W
ML+:KGJ&6DHRLFJ(+-OVUL;.#J[JH* A:N*#MO>!:(JINEG!=91 <J"_@BE 3
M^?K]"!](R,5;1UL5Z*J"<M36U_O^N8VZ$,(2Q>L-!EEH0%'N?/86 JZ&?)P&
M6(]KJ\O'ZRGM@)4$"'<VX+6U5,1*!C22]31$".IP&GA9>AM98LM"#RE-F"SO
M-Y#O1P^;#?%ZR*KI:Z \A#S<09;*6(\JC+)S<\5Z'"]-30&XO(B%CH&\HXH+
M2LM934';RU5?70MA8R D:P^&&1IZHW1$-#DM%) :RM_O:5?&IH.<@O):?(XB
MTJY"[B+* @K._-Y@:W5K3E<YG:^NPE;.&F9OYZFKXF3#+^6M:*6$,I SLN#D
M-=)R=+''>D=A%-H;+ 1"(KX3M ';P.3UY64T#&QXI=1A+F[JVM+R<C8@%W<O
M3AU."RA(WL8-;:".UN=%>X'=C-2TK6! ;7Y5A!,(C7+DY+25<['3!P&5L=LE
M_,L/ &U4!'6D[-RTA/F=L!4N2DM16L4=[J5@H,\+M76"*UMP>B-4K(3UT2@E
M)UE="SD07)5/RTN)T\((JNVMY."IX85UL.I*:M*\X.\_--!SYO72L.$%.7D@
MH;+N,I:_RB7 ^1WH;_.>POJ*2'E>*$@#*[VM@:6@%9\BKQ-('RO95X"OJ_MN
MV/+6 M9_(R,%$\':D;L#TL')S8'?617HK"JOJZ-E:XM6Y9.2AUO;>7D*ZKBI
MZU@XBFC8*FAK.&JH(K"Q1\0.>\!_W[4#^V:%96UI!W>WAWFY@J#Z8&S6[6JD
MIR]CY 6R@:GQNCKHZ0K)86M_'7Y.74$=1P=O0:0JPA,)0^ICK<1>P4;_>^8
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MTKS'DLDG6]L8,S@J:. 8E%#@$_KS&C1^^QPBVDGA]D'QSNT?@KK9B=8!3[_
MBEB62!;+:*0U3I6P!L]F,+JB]Z'PG$?6X]J.T<_>0SBAFZ' P_^[YEYU@_/&
M/X2:4MMLEY56:[-2_17YNOIR70X[/:-ZED"C6.\%NUWUT"(,<1=.I3_;J;6&
MZD6A(A&O9:?XXC_"6,'$[F]2(@S0G)BIV5EOL')4P,/,#&^@(RH>8U6>:K;G
MH!S^X,38SG_$;!*EJE-S;:406EP[-95U+T=A!;'--)TXC=0[M6H^/Z!K?L/1
M(F)BUM$26GY EHYCA!G.>-W7.3-KC2]:0 &<E-8ZYZ4M%2$'QRT]:_)1DGRD
MM-S.V%%Y'5SG'/)>_<*PKQMUW" 8:OMD4.*G7#OE=%EM.1,+G!45]E)!EUK'
M30J]0I!AG;EL UZQ8P//O<KNBAHX.D=#@;9,,=_+S?^X9.J$SRBX$BOFUSB1
M^^WCQWC0ZOM8%JI\"AJFYAOWL+DX"*^L%XXL+5J$G0"UAPN?=$-J<RJT#]]9
M;/NC'@P^K3&08U\'+@JA:"Z9O/^L%L%MI,?@)!"WZ;70[OX-N9L0GT;2CFFC
M(#$T(+$A=Z',U%3!TR2R_GHJH<#RD(-X;.265=G+B#X+Q,N6K)LL;7,[F-@B
M>8(8(("5=.W\(<8OQFWLL#DK85A5I <@]</"LY'[0V:H)ITFFR O9\Y*">^Y
MRDV%QL"B1/S@)J"]7N'M&PJWG=VGXR8WZ K;IUF]3\,1%-I2AN6< A)?P)NE
MNZ:UX^?EAOM7=E/+A^PW+<2I=+HL^L,+56W*[S,]2&B&SUH%CCNX0G.BE.(/
M\I?5U=M-2*>BJ]2HF%.-"$9$LCHSU2;5)JUZ[:>^,_ +[P+V<Q,7;*0;X,'J
MOC>@#2[J"?=#]\.TC_BS6^ 5PTEPCQ$9FDG^$Y<)!BV8DVY%)4CP;F&5S#DS
MI/C"O$L%^@R_U%OF,?ZSL]YC6.?['%EZHF-3?<,/U''3KYO9MGU0>YYN6?5)
ML,A)%9E\K+)-N3$54LK5(.ES98_OF\.WR&EL%V'6"9<V! 866]XP>;7:%N9H
M,4XS]R=OZ^7KPS3'#]P@%^YSBI$'%?"3YW\(C+M]B9-K*BTKM^@S:^;4#_05
MB0+>1ZB-HF2^+03\]4EZQWA%*,XJNYL1F\U^(4F ^+\_/GR,D">;$G7"W/ *
M= FALDX+&E<R??'@:_L^1ALK_-2,B.CU/N]][+Z9P[M?J(BU5XWKDA-W/[.E
MM F24_)L63\OEK3YB !RPU-)L+&$4H^IHAD:'L>+^X<-'CU/6% @KK]KA4$;
MT;@03X^PJE&6T3L""MN#S(VJ3&<$SNZ"_.=TMO8UAXRYFQLOTY3_D<8(]Q:/
MG#[ I[#MCW4]- PW>S"C#WU_/B;PF93$T,!IWOU#* [F?NU2U''M>=E;^)BW
M4O)3*B#+XK[[0X#A;S0MLOF-^O$]M9CK#F?0\97\V5A^6."GLV$3'Q;CA/I+
M@TH3)UQ=WF\W[6>H7^P8)CT*$W5=>K4\Z3J!,_XFP'#I$+9IM>Y5XY#L'8W!
MX6W5C/T"]?:DS)D^,U*VJ>,:RT$OY(FP^N^?.E+I+)\S-0[Y"&E2QU8GJXGM
MWMN6"!-,9X[Y;D*8+;] 4L"Y)4JYFQ 6(UOF3USE-0-+K S \Q GB>K'Y[.1
M?1TDW%V]BU^*,_W[]_+9,A.<^\S$T4K\[;8U#I_RI;9'^M(X1GM(/5&F?:>9
M$EM@&W*Z;>CM2/VT" .?\B5*P8J\YD,9*UDKL.1WF'PG3LBA+1[H71[]('55
M^2E&>?%CXI^:=#P'J,=R7*3U-Z)@H+AHVFH;@5 $*H*J,^"WWFG"M#)$++)W
MT>PWIVS?OM9Q6XFX4 F5DH_VE2KA]"P^?=#4.B$J7 [:&Y9\*.:&)[L^9)\Y
MHNJ?N/FPY%Q,(H]M\.V(1]E-+ONU>852.I$&J#+O:!(M&B?(95G5K*/35H.E
MHA?% M313P2RJ< V_B.,]L@T/ K_4\3%[&FP;V9&B)0RI3'D!K%'U-34H""0
M1"6SF)JF8Y+->;5+M5&;"JS&Q^2(C7F0(J\O2<NF/%K"R_QY&]-RN2:'4@%X
MN[;"&^*)B>\T&@!)L,I,F-5:7[2CB7<WJD#H#4X;?AIQEL;FS9>A-[-+ %MB
M9GF%.ZT&W"E,UY$'^C@9*=NP>Z/EI72'IS9^>"N74Q:5^& RB(%[^PRKA:"_
MBZA%D2U:S+[::*7EJD#"4MP^-:8?#K1=SU6JEM='BN;6Q2>P2F%%[V)E!8L5
M<"26!QK&%TJ!/:5T2,C;XT5,2<QWC3^5J,"X*N)'W?7*F4%MU=8DQ-(5_Q!"
MEMLT=.4L+UBE1J+JC4M!IFXQ\Y)C@I'K%$0D=>RV61S:MDIF@=R8UQPVJ<W%
M:I8BSN>T#'GVE-]JYV8R72MZ7-%\LD?M>+_CKM?2P7_818:P;;R7F0U4<D;)
M[X9-QDALQ'T_I;)L5^H#ON?:F"UF2N,%M!=@C?3*6T2I4L;CJ%>P-4J@).M'
MK==AJU^0K69BJU%Y8]YD9AFMY.'8*[==3H!0_SSTXW9BSL<*7JXHR%20"S\[
M^0RTM/:N"#S0'*_H:QTURR>8JJV3)C;(L-G TBBV^=[J4HU/DO6B9]<\%U?'
M0EB_':[@O7+81I;QGMHK^?HP(0&HR0$K]=7 A(2K;D'RC/AP_U)Y"^/?-\[^
M":D-B>-;=2I+U4*,*UW3UOKZA&!R#\WJGDCW+26R3[J.7.1T-U_,D/%+/4*!
MP9P9DP<;EC3V9"%M "S.T>B6$O@[C1D\GF,;C/HHB%9+P%=T^A4'LU0A$V]A
MJK9@1^(KE?WR1)(6SKM<V_A)1(O*-*X'+TY>QB1/4?4L"&H+"0ERBY&3\4Q5
MYCD[+#U8?ACN[R=D314RV3856;F<Z>4M@HU2 Q^TP9B=V',WDJLM0*NM\=HG
MR<#163Q&N)<.B#C95!&,WZY@Z#[]H\G9%57@DI;&-&YAK5ZQ;K!:[5V 4[5X
MM'9@O?*S&GX;*<8M;)(TOO9][!EV;E<9GQ)/"OB'L)2]"YJ@4(,LZE03!*0O
MF;\/E6FU"H__/1D7%Z6Z3J6S*T(Z8_*P(H51CY*\?0E"3R^*1I]B\"QQ'YD[
MEORQZW.SVD[*NAR+N2%7_J0=Y;V%7::[/S)::5-U N63I%Z?DKBR2DU/50WX
MAR 73K J&0^:G@8S.:N45SB"&=$?S@'UEG1)N;'A7H*G'E>45PPB/XT?;@D=
ME=R6J,),%V#>V3SMMU ^RALD B^J\J.JO?JV,P0&\*0."P:U($GTC7)Y"SO
M8^;11#%?YMM>DM,SJX;^CLJC-=G\</;NG8&%P7"66=# />6 EC31)6AN$O\$
M> GZ>BM1Q@(^LL2?L:&5^.+)"M@-80C(3?Y[I5-<^&S1>W95ZM$+;I*:'U6/
MH$5/0GPM:"&<HV$6C_ BT0/PT;<XG-FN,"'A,U>D.U](-PA$E3>&# 53I ^<
M>)*Q!PALRF<).!-G5,!M&U%'$]P'/Y$@8U\A:.0Q$PTC0RSOS,GW31Y-&RX>
M/+%:ZK @ S(F',&PL@F?7% 8"3;V Z+KD6TKK?56K^F/YST!I>>"L^?)9<8=
M%964X*;8667Y436%PH!D/G+=47[9=+H#NHQ7/F4HAM7O:24L'51"6)*OH:O/
MZ"N??7R]CBL?4$LA#$2BX\I+Q*NF8HQO:M*>&WLLP%<AAN R\8M\P;\N^LJ#
MXDPP6:9[K$JTL)*"T4#.76?E3K[$=5-$Z7W5.M)5VIZA(*N0==FA]1[HB700
M@6<WE>5G1A&1[[K[D"3;2X"J@H7?F?U5@N'X!PM11 ,5E4PUYO3E]@S-G^M2
M>+Q#]P_)UKD]\P%%KI,8.IDMO(Z<ELC#+Y5*V-AY'P]$DAV?3GSB7')7+S,O
M<$!U[,0!08F,;=C <R <4[DR^A!#*_%I)M5 .T?WM(V^63&U/< )&B!S'9&-
MLE%A37-*JC$FTW.^RFL9P51OFK(9KJ2>+C;.T[1YG+<)\2VR.EHZ^;%9+@BI
M:S3T\>[(I_T\P^@'V$6'[XI\EF@T*JID<5PF6\R.@CO$O]6*KEDGY08.LF&$
M*\J(!UWC.Z"$@]TKBU())+:+@#$;RC52#C+DR1B27AMCP9VXN/O3O6+&!XW&
MNE/3V9:U1T,R5A!9%H*5ZN[DDU@;*3DYH >R^0]<O/V+P@_&F_\)._E/6#DA
M!EM4'':AJK37LAN_+#TB/9WJ0\*.TVY VH9W.!4T&@!UDWR95E5KF5:>VO99
M(\TLA6_)Z+4W. UI%=JJS($23PL*Y3('$I7QU:02Y69F9J[P\:E.[(+D% .*
MH,_[<C-R\P@C]93EWC-&8'/Y]#A^1SR,86==U6E4U(OAODCA*'@O_* YJT)I
MWI9%>!Q>4VT%G((84TAS?E:U_(4/FD'#T^Y54W/#WX3X*.6R[C(SLRQ"_.)>
M08WCV?=F_\>^&0'5#L,VTO*_)? ;;ZYOFW2&\(OGQL%.Z6I\&OIA>SWG[_/%
ME1E._)9GM)IJ N!"5T1<R#2Y2^D[^+"#;#K(7T@ <.%+>$)4PW@OSQLT;@T$
M[*4S:\C9Q.1&VD-/0D;A_:D'B<R\_Q F<[CBF]29]XCP,J7I9!:W&K4$1JLP
M[-5=W/$G1GQ/<)U$*D.: R4#543R9C\L$P=9N9I_=KZ;W#'@Y&6;]EJ@G=-O
MNR(H#=U-NS9 SE HW;&W+1NOG>P%\NJZB=#RVXC8R&7O\9%%-?-ND!HRU>@,
MN(G'@H\C&)#5DF=X/G'YQQU3;V6Z51MO!R5ZZR!]R=3OR4'\\B/)IWN.KW:D
MMJ\PE7-[I<Z(A;W,D]<ECQ4E,_("&CCL<0[=P&&'++VP);716E[J9)'EY1.7
MD:^0D=I'W? !$0*:*P'"+:6"6DV]A-.RNYG-TRIZ(.ON2Q.=(R*LS%%\;$ "
M0KB-ZK<R3'K?HDJAQY'Q>@WXL]^/(Q)HJ6O[*&=E-&]K]G<T;E<??(YXVG'_
M/+*B!SINY;@\ENSVG/_1<H@BQ6_/ZS@19YURFTB'<AK%]67YM_;X4*H1B$09
M1'T6T0@DQ"80?JR#FU"@XY''!4RV#W:Q;AYJ)F;M)5!^ZMX%E[QGMW6\=4++
M1T\58&ZK@\3^D)8? )A.V^IXT 9]W_E^.!100'+;SUV'YU_^^]S_(P$ 5:Q\
MA(7M)R/E^0V5/*@UA[$UV@4L5D<9;(-:BE-[:\%X7WK>IGQ5LZ[*]8IEO>(J
MXW1N;?PLF2/4=%^YU6Y2_Z-+NKM MOG2N7-+('[L$GEX./DRB1PGA@T*'*K$
ML%\4H1\-I;DK&7V3[*X:_PM[_(?P9<GXJ0BM5"*CKNW^H^.O-Q^I];L0Q8;2
M2YX']0;="A=AF>TJ&1@I3C.['WUNJYQ*N-$L]F<.F#384_6)1!9+9.:T./(H
MY /-Z:^U=(SB%\VE#K>/P_M;_<,_\I8U5==VI]9L43)(&Z$8P<DQ3!Y+"V'W
MA)4V#$5YV@ZZEB2O$BDK"JG?$L!SX\(/*M,)E(G"FZEMA.=@KSVW@J6+N*L]
MC>(MM_[]I([[N]?3)1.9Y2"+\OA[,L+ -9^SR4!K!W]Z3G<3ZB*0N>K],015
MO7 V@D>+_J5MHCV,%A5G&&07_=C8QG?9FVB2EW>_5@V@J;I]_1NB@G:/4T:_
MS53#.5XOI>6L*_<\O6+IPGM.'U?L425^)F?;01&)/AF#U\NDE(!=@V*-B'L[
M45E7'Q!B[-V]7&Y#\2;O<'U2:8?>)"?;W^XPJZ(\'Y.F8P- 8/-#(>6A3\9!
M4>!9BL%M&9.=H=-LCVI[:L])Z^/O=!,5";(P0W\!':MT+QB*_KY0LV1S1)TX
MYE;Z(HPL+SZES"U\=WA\TGP1.QW[<PF\$*)SMXY8(-USH1E;Y5G>$>XKH)S8
MH(2T6R?C?MGB65'&_5K95D6FP]#_D1U <=7KV&BCJ/,FMFYYQ/&-8EY[;@T2
MEX6KXDL!6;:E?\>&<:I0 *BAM=W#]MN?M P[)@LX$J%^_-4",?+((<C.?U/R
M85FZ-# ?J;Q8@>WFE4MJ:/:MRBK-<$G*&''CE3%N#7,&M3#K*([]U"F1I:"U
M^*B!S\6_9(H@6GU6K./MU.NG)6JY!7)*4UI9@$-!9VMK[Z/L]''DA/AKT$@I
M(ME92I%JI/?9)@%N_WU%Y!?5.9(2SYE:/[Q]&A?9'613NE7D@V6GHCOQQQ+W
M"Z^DX$S:O:SENT(5<Z%ET%GJ3VIG=L?&U+F:;J?D=WG*5$]5UE_VIM(7JESR
MW<LZVS!%ZF24 FVQ:Y3085@&/"=!F%HC]E?<;>UMKX3WH1;1SU/\+H7>JUG+
MA'BG,4!"8-T/7OQTCZ,6E^#$@"QP&9(P(:I)1#:9=>?6(<%P,N\+%]UJ=CE0
M9%I=Q?2_CM,YW]J=+8!YN=50P:;A9F6K83M+;5+@R4;&)OS"AW$"'?UT[/-=
MG579U)288=.PN46J0Y^''6@1$)7:1$AC3D08)[,V!]QM):.+:+M;^3O5TOZZ
ML>F<J@*>,1R!H88P11Q]KQ/T^\2DU(A<*?"2$?NHBCR'W+89+!8U<7IX)^[O
M4T!-T3"<.^-JY,?5299W39X-:?>8V&F/04Z_;2.B-5CP<>U=+6>$3*Z^E6VE
M[\LL_QD\N L1Y'/T0:OS'DGG2*$!"=1B=E%U??FY<A4&3MK MU,P8G7]QK:!
MJ1,H4W%3<R;&CE5E*)^<E"ZH'JSLLW*VCE>6VI%6I]3=HN"#,>IMWH-)04>_
M>6MF6CFD::R>MJ"'GOG#[Q5WW\7</HYGIG5TPX128M!4=E2)#2%_13C)O\V]
M[EJH.0\+P(X)D^45J4\QZ..W^:IA%HA&ICH3]"V_ B:ZL&G(&N'[>C9B,)'_
M(\%LTT;@DNK69IDUG03_^870@ 6B+]]@;EF/%]NY/$KMB:MG=,"H4JT2@<3)
M;A7NGTE!:"W@^-T08"9BA]L:WWUIK.YIXX&L?\L6!38A75631=A/UTDGSH,%
M#7J[L$292B2T-0(JL_;(BSE.09.S)L/?/?,B=;A1C49TPR=:_M+OL/]'<?"<
M;==/244=78@>.RTW8AX+P21"MDE1X*X*:G?_$/22/KOQ.RP*7#5?6 :IY'&M
M:2>>-Q]SAL%H.W6'^YTC]AOUAH\FUH@!+]C-^^N-.+HQ:1U($F^IHH;0&_][
MG*!=!6?^(I)TC_3X5&@LES(%<2QE.+ ^S6H$]"V7Y3W-"_8A_2G.P8IA$B_W
MK'N8A^>M__*AT?"&<<5 U8AZ4Z)C&2=3I\LY%-)2(V7O:0 T$-0:S=9;2/0Q
M:+Z_Z'KP;18]9!%2J)52?^$3S=UNT<M5V[0,U8;&,]UU@X;T?[J;8%(?FJ>G
M(*(0X#<,JI.*Z.$:0S%Y;DL2B^/B7$.O:BL/^8'VPV2JY5'3ALL=YB.?2S7-
M/GE.R </(WB.2A>JI2DU!W)RHSX:QMR>CZ[5Y4Z:UAS^0OC='MS>G]$HST4Q
M8Y63H\H+J,M5!?=,!%U-N1!/)52EVSIE8,C(C(KQ!;Z5]M@!)B<L?=X,\5<F
MWDJP (Q#4!TXG?1J"*G><V;4MJ!R.*>PIZ[9%J>NXV=XC#'1P0(#@2_7L4;W
M:X#(W@9Q,S.'<UV6MJ,UVHH@^LI0%6-/@XA;A]'<!VZ*2]TYE+5LM<1SAN\Y
M.)OZJNJS-K9_S(8?BC=;DQODD^<?Z]*_BP6#9*JM'YH*QPYK-6S*E6M,RZ9"
ME<U :(TSWJ 5Z$N-(KS<=1 S>B:*'*N*7<[16_@I]_-.RN[;AT7X$TCGG;HQ
M9TJOF:O=(!!]I X->2:7 ?O@0 98QG-4B<5NS20X-K 6W@A835PC1$_K3Y&?
M1"1TMK.U&T87IHL ) W8L82\'_V%R[.-+"[\RNZ%7#CZ561\W<#VWJ7-8G#;
M.7O_4W/T\KBUE'Y@!=OJ'*QBW&S&<C2[/F>ZF=J%_&#S__O=C_^QTV3(((*!
M]T--54U^[ /S/X3*)#L%*:FB5)9NC[,AEYQ\([<_QJ!C4 SES[;#X3O8+HQ0
M[(I0S*^H;T\#MN=: 5$R:C?O6I?,?_?3..[RZI(1+,LA>7T92?0G>>?^+2T6
M5Y53^,;49K W-%Y._R@ (?,TAGWBZ,M9@"L0?B.58O4M4=7182'.NL>HNPIF
M.L2'W+I5_279E@_Z<()Q-8O/-V4]-?J+MQ7Q5Y,@&_,\'26>B.D.!1O0+%+9
M<^9N@^I)18XI3IA?%/7=N8,K7WV_HV9;K)L=O/V+R:7QP-L"-XQ3WL )M@!G
MK@ZKJ(Z]FYC)<R@P"_PV@=+,/@01J>[T3!/5K:Q[-X")V'*J^/MV>/*:E,&W
MP277*DNF>:,-VB24X-MBD%9;#=/+)= *T:@+U^*A<6E6W"1DR6V-T'E=E'GE
M+\>[+\GF_;2IPLE=.1IA:6,'2&GO?<X@/D?_1 1<,K3X;;)GHNB"6>>A=T&]
MX5,@WQ=$O9X_4EM.X]CY\+GLJWJ84]$H6S4A>H.A%Q$CQ\QZ.,C6-105HJ%F
MV%5">,AGRC=*=HD,V<EH3^C4-\I Y8*S3-7EUF+F,;Y\HX7?NXRGG\F/F_.P
M\OZX8'GA'%Q'!FU@@O_Z(S,WO&2=-]M]^!G1J'*11X:?5LY(ODH6J7"#9-QH
M? >I(8*.2W"9MIGU6,[;3O61%XF>.Q^/;*%G5)>8I>708"OC.#>NN1#?HXG&
MH0\:=XZ2,0H_QM/+42L&5G!P=AS7VS@<+/=F?6[6<\FWT.G<[5 8=IHW$\S\
M7F.;/4#@#J\"*/T 0V'U&\E4^X4Z?!UDPW?VQU@IS5'$J'VSD6GM!EGZEHM1
MEW!UN,QW*9GRL/=*E:B2]8JR1&R.OY0OT;?&7)4+8IG.*$<=-U>B]^WH%_@D
M8)NMHP4:"(#-ZFE M3N2.!96O6J;5]J^PD"GKZ1T9W#!3MKM\NU4:V;^HP!L
M_6*2,I0-,=%T)H?7#6"S%&O,/,V);R!G!#-:&;KL*^ ,/B5T]X6F*7=1:LAC
MFIGP\6S*W:D,^+8L_.@>NI2Q&J =4XE=_L;_L\I9,FNYG0S"W4Y5X[&0[3P"
M-7V19)344W#:_/$;!IM+0*%I6.;BY)\.(+A11I2/*\"Q>O&.I"3C2<]&8"%C
M^M&W%GXE&?V13-BD=G1647^31P1S4%K5F]BQ ;"Z1CMA9+DE LOTN6YUC2S3
MFP(%+!,CY;(9D/H!(91CO5 P=-RH0/T6A>"AX>8?0D=:\P  FB!+PDR_G2@)
M1BHX5[_P/A,DJ;7%>=[9 U.91645K=!NL\J)BJJC6[_/J3_I=X%1H' D"I\H
MFWV2LBC)IG.9'D\\5.\E"6K9F&:LS];YJG!UH=3X8H1?Y3ELWME82G),:&:
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MV>"F#5.!HK-VD@J4&+RVE0?6==>@&,FC".2:]O$P@Z8V0MGCM%%?#L]U1]2
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M&58=%X-J;/8A9=%Z_^FO5ZUBP)[#9M"O7\5[)1]']_YS/>-_"&9MPYK.?>H
MTI\9'S@EC"+5*FCYHV=&;4>P7!3+VU.(";ID:MKK,($G*NS$&UG2"K9G'++5
ME#GJ!F+/@1\5W0:ION)?7!<9]P49HJ;)5.@<'*)$)E8O7[3'KEN::R.,* Z,
MQ)$0@34;*@U^?\)FE\$^V'!TMBT'JI<:3;FO^.3^-RL;N=YA '4(:&MD,K.
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M,+\I*PAY<)S-%"HLYMMZ\A7P4P%Z2^\+O ,$KPB/SH_:65W0UP=<TVK,2/.
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M76=5BQ0YOMFRAK>+T-KNYM Y)0(7I&5(*<J-WY<93XQWA1';#/-CWS7!I7J
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M^_\P]WRFX^N)1]!UXV^TKP*'XM:MY(%<Y-!?=6-9[?C_/GW]X\3[N[X]%]5
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MO*'H26UBLE]SQCOM&HSD9\:@IIY3\L*II?&J"OJF#ED+\_R&VE7MS.#?!O#
M!96QN3ZU.NER-'VG$Y3]_)%*?6V;EW*+[I7@68=E.(TD$S'6+E3]%CSWJKG%
M ZHY;O,DZN&M78*?.HW$08;2_I9__6ZZ,K'_?*F99SA*>9)=DIV7J'2C[;()
M,E$/#XQ8-ATPVU1_+LZ<!J",#5>DN"K_3?5Z2R=^D\#0.IW2KR;P@.R310Q-
M#;/^!K?&_HJKX^J\+.15,5=0;-K4S0 R0OV]H8)_E ^&=>DTNE3<0PX*Y*FL
MJM)"MS*1+*CH+/@A,;$%:]?J9,::;2Y+S<3/]R'U;2Z7B8<G^38!_;7_T0P)
M1S@\33KK6DC!?VYSP/,_FVQBZ;H)MV$I4OO%A<!YE:5+24:%(?K] V8:W>]L
M>_V(7M:/*S^[4.%*B-!"'X66-5@^JPZJ)V_5'.7O5BI.8*I,Q(;4W;"$WBYM
M)"9:UD4.XJY3";OLKVG"(E-EIZGG/5&6"Y]K3F9F=+K"ZZ6!:[ST'$0$#H9G
M9=3,,_@X1T?&/U$-J=HA*CUH%@N=Z-W@)O0MCPIX1A/[]EEU8N;MZR!_UNG,
MT]1YU(+UJZ6=Z.9F](W 2,!0RIS51-AC6)-K@S;WCJ3, 6%2S.8L8 E7(J(7
MY*WIZ.BH+#RCSV86&ST"$+Q8HSGVS#3H*[AX0V'H9"4EIMLZ-R0&8R*[,\?,
MVT44T/:+5]4RU_)OMD@K7;FZXP@LX>+/P.&$R'HQV 3#:XIF$A8VY@395/E1
MPK(O(YS"+I\NQ3&O-C^O;)*4\14:]*VUC8EJURZK\; H-( 0;C@C >T1Q&B^
M<; 5'00!Q7R&N41T8H9:L+&V"N:&-/[],?H(.5.LPDF3WS@C^'"CQETG9SG^
MA#7CHQ]TR-,8?$C#O<)2E7>I(DY Y^I(P%BS)+)/P'^C0@ F!%:!*9#@0A3\
M'<A]PJ9VW 18\D_Y=)H7QG?K2!T\9R5Z5-"-$RV5;'&4B59*>=L0E-$D(BH*
MM6Y9,Y._EEM0\95%?'Q9I%(],6I%-$I(M5=!;DDFM8K,C<D/.%"2]^5CZ?L-
MQ% GZRY9Y\#_H*%PN,&^/9J$L\.U0SBE.PYW 7:HQF,RQ#P0K#2+VJ:F-DXP
MCU\9D="[G\TE&820R6\)U(Y =I)(:H<=1GWQ-1,<ZHT^L<:C0?0E9=-4L)%.
M'KV5[VCS::5KA-)%]5Y.1?,7\S7=M-H7/GL^)QFB$>DM+# &003'?14T!B=T
MEM3XH)[Z#./P:*VPF?&P4^9R/'V!=*NOZD,K#8C]P_SGA^LF4;HY?ZKH&<8M
MPEK2*4X]@=>'U@B;#9Z<WCU.9KI9)..I05]V7K9B"-Z81X$/0;5G.\KV$SA?
MM(O:E$&)D7L-D>;&D@8[2 J<LA\TV"'[!>MDARS+P'^KOT9@= O_KO\E4U ?
M(MP\E.HC54O<C?N7E;\AI=A,QIGJ=5S*#E<#_@U^=!4E)+>."(?1@H+(_D7;
M5R^D#A$M>/4F$C8:O;F?URD#_3\L$DGFP.S[EG5EP6B.!\J.EB$O3)[^N2R@
MW3'%<GC(2AXQJVH90QENC@M@)L&S%^3[P#+>2IGV)_M[LY[!$*Y,SC4B42--
MFV.TP12]22Q=V5?O#+'+O_'(?P,J,VE5(O]>^1!4P4;M*-M5<F3!^DW$XQ0I
M2>J,5.#O&'1'?%%7)DVWFB<,(VRG4D*,C<4R-H-;A$7<2OU>R(G)C?4S-M_;
M>$#TK7#.9?BD[K4BUZICU:J-9TI>2H7G)]:Z4\>::P;?&G8"+8(D**(8$8J5
ML?N?IJJ[L/8R>.O_A\O; DCN'3"R'G^3C/]4LIA7]R3WX^6F1J[N57R&*/6_
M.[A)9+Z.Q9"VZBVE'OS8\E.HXJJ0$%M&&QWMJ"A'CB?1B\NT@N3QCAF,?7W=
MV3"G0,3^Q+$JNLF#'Q7;G'9DB2F-5)<Z%%ODA8]G060)P]RX$)4Q+:=;  C1
MJ7#9B *6; N0N8D09^WT\CZ$VE=YS\O.!/ >_)[^HZ4"[;BW9VPE-Y(XW+M@
M\5JT6G;C03098H&U&5!RR'= _SJ^8L&HTVU0]2-R!<C<*C<<S^%_!4J>0"21
MVN9SC/F!/1?%%>-$X'N_79:Y)ES[ ?,MF96W(3[FF=_W3J6&UWL6V>,8J3N0
MX.W4;>;(-R?2M;JWI8/7NJ=D;]&J;./CEX+S7%9& HYA#2-'Q_*%CK4U=\,^
M/-9#7&DN_&H*D'([I_S/%GZ9)F6%J90'R)[@&29VGURP7L'1D-=E'_\VGUS<
MJ:L-XI6.<0&5QO9^:YR]97U-!V\?KPN-N1%GMY$Z,MVB&1L0^"DC29 ?0ID5
M9(67_.HO=/Q*97=Q29\U(.WRX"_ZUJST9EK5V#(@_ ZH?@<@B-^J,KX#[L?4
MLF5*WP$FLSU?Y7/\7Q!W]V3? =&M6R<X7_>? L%76Z]J#_^D00E([1W0(10P
MR4K^=.^Y^"0]O_5;C9R*_T6TX!V@5_X.8)\_;4QZ!QP'#Z&_8L<%OS8O.AR?
M2#O^0BVJSU4L7;K0_^G^G?L)RF'FZ'UF*2T(8^153Y?.EI8;-7_I!@%QW%,O
M$0].1OTYI+$0<:8LY]IS-B2WCX1?T_'FL4:IX6!IUI T7TH)WTI+FSLGT."B
MQX9K^[MNMR7"O8M&ODO&#;V\5QLR13J9[U:*82&NVNX*884%!0AF3NF 9P88
MNDUDG=25>8CU2T:F8&W3PDC3[>O):SVJL#Z<U*2X0E4QPNOY@(AB@SX]D[1B
MZ &;+EY8Y6SX"@F5?YYG9WCI+(@OF^;KFZ+69*<T$@TDU?6I/DX<.%@K)/N^
M YR?4=+<Y]X!V,J53B5T5%2\0P+)\5WQ<1M1AUPJ;37FC&/ !<3RF)'E[*W)
M[<M;75/\N-JOP>S)U<8:AMF()*G*S=/]#G[_9Q^?_S5H9S]#O0?=UO8=^Z]7
MJZ1JMBF?K<VF=2E\GBTU_P67E.@6+I>=4H^ :U==F#XDA^0ST)8"EV@&G&&3
MV,6X2H,7NR\=,>*/'<A]%&:TV]#&)UH],(7!-NE.*]+^-!\:1F9'0!#&2,6Z
M5V%SFQQF(O@0/T3(AOY;!$^)7#?*Y<J:$^\H$QMKK,]=T*]Z +K%-.#;:/$/
MJ<@V6\FH1U1'2BDB3;,GF)8\3K1"#]_;Q\:7J R))2RYH62S_]@XUA1&,Z>!
ML3TF%&$N#3D.N,Z?+ Q4\G4PZ# PGZ_6$HSI9BXS2_)-*-+AQ)(YEA'V9KS@
MWO0_B03Q)O./9#]KY-P=0!T8CF2T;QV8]#T/*8TY:1'EIZ=9I43B24,H)"RH
MI ]4B_YUJS0POR_PE_D[)]/+KJAQ)U;68$39^&-V:E+58)?E6KY9GE<8 OYB
MC]2H*$/#C UK!HRCO*\TF?OZ^U5$]<OZ.'\.:([0JLOZGJM#G"P7J:,;2&Q&
MYKH;-?E2[JN$#[--ILD(<7SM-F2W+0C^M55,?\O^X+X[AP2Z]TYX6&8,[Q_V
MD@2+!!%MTE4#F<G$V,:PK'?I5?=61G.MVG^6%P@&O^2G'!N'T::Q56H;Y!I[
M\LZKQ*@D FP/=&MD3[MB3LGV/)/ ;O'5BGC,M/MMVWJNP1J6RA!9I&94*Y=:
ME/*#4<JDT<$7=6_<%)5II<Q<58.:]5HSRK3V5=Z,DE]N>Q8)!#!2XO9B5L_<
M$[1P#]RQS'1YUE_B%0;Z["PMZH^O1)%!:@V('1!VAU(+?%2]+%_]$;6@IW//
MAI;4HX)X_09[^=9Z/S\F0?9&$Y%G&F,'IE206\L-SE$8UY 3ZK@"@4=?OH'3
MP9Z.G;6P$632#=<*A.^6+7(7-K?J#>E-,_;GJVTQM[=\] 3(4#/N5Y@5P\$0
M!2GDQ<=:$=[@&:9%ZF;4*ZWU BP^02HTSIZ?K36Y,B>4S]W%C"J .<S?TM'[
MBC=/EN+AC]>O(IEDX;O@@A+0N 9A<C89VZ^=6X?8!*#Z*4GI6J/[X_H(\W D
M!V5F/REA:;<O$^3HIA79#3&I+/OC#9(0V5*KFB6/FZTPS,;'?:]T.91;R.BJ
M+2#5>6&:<+;UU).'(E.9@?D[\LP5:%YW>)%)IGJA-AP7GZJAQ5C2I-9$/(NT
M;BKP60=DLOYEV<-+K8?(4%#>;K/;/I&:Y>%@,G^+6!+G]#X;5GL-<@%.DZD&
M,%-_GH"L6,[WT'KCD)M+6H9&DY:;VWHPGF0(=1_$@;3)5Q"W@P<I+,"AQ.;>
MM.;//PSTO/*]8<_\"[KC-2T/S7L'G+5H=YWNOB%DN(B_&+63-O")\3+A+SWO
MO@->''[<-X0^Y*[>#GHL?_W14R$&R9<C533R$L775M+C=93<KYO.)QE:6+ _
M((^+"QS]?>1%E1(=: ^=U+-3 &6M$):0\$1E?&OP"MTY>71TQKQOJLK:P&.P
MEM$T2TG+/A91QS!60(WP2J5$$#27CE'M3$:YW. MV)F$G#-U\5Q9QZ,0"',J
M>)W5R:HKGTTG2QABV6#1M9JS?&F-XO$^N+UP7.%W4C=I.OT3*;46K__'%TVN
M@7;WFUDG47*&'^-(L82 [='0]2:Q7>7/C!QN5A1-ULHM))/)/5>PDS4F[WF+
M(1Q6]6=>R0E<@51.K&HSZ+,CE3K&-TQ8@G@R:@L![T^CW23>R!OQD(Q$7QAB
M6%>,>QK%T2\=W)QF7R8@!VG41M/%44[J&9,=E#E<7X6HK]FEFK1X('-*23OZ
M5*R50X&5-'J>IC*5H9(M2JK,?XJ=:/4?@+F2=.9'D"\#YK60S\D<0F8[?M+B
M/7B!@^@#=$ #;/G/*MP">C#3B>G"DB.REDG6_M(HTIDWETL%/?!']L/SNV[$
M;A=./#.![=MC,*R\1_ZT=JZ#UL"%13;\9E@&. Z>;XH@E)Z1A)3%C)F.;IDZ
M;O34B,V'YQ$2;RQJ8M4&7G"JZED[U[,"%\P^1S6,PVWG*Z5CUH)*.GA8T#Z6
MUA)856<B>!LSL]_<]!%1O<]CEMX]RJ6S ZY+=OWMY&M@NZ]0]8^G\_U*IT_3
MHUA[_;(\)S0LYS3*5)[P4=2QWPZ4QKM 8]"^M;[*SYR'V8H::]#;"Y[YJCW?
M4U&6&;^J+I8U+AP)@M(]BYV9$6UOEFF,9T4[+TJ&L%#63H)EK<MW0+) >$@K
MG#?,Y/H>G);S<E=LL_X1?>C'%&2<07LE-TV\[Y0'G&Q6V:%>-&,3MZUJ-R>*
MVK6J$CS#A#53>)FLGI]H4"6F^XWSY2>M@P@FW'/U?V#/E"@*RN)X!!Q]:!I!
MLFKJ:E&?']'!S,DE^KZ:BJ^#B>W"/+:"S P)"W7U.(UUDY+<:]O,)T]Z6*TW
M\4[HBJ]VOBK,;9J,,S@8+EC4:331[&)4Q.(I=D(M1T#O8!MYEL(P%$HI(\OG
M[[/$TM;%14T4E&T>PX]6 QW_@E:\6>4#BB*'RE8!WT^PT:)69L#_T#:&8&1@
M76Z>ID4T"AUV1@_30;/D*]V,/QT:ASOH7IL#+&2VG/0U:(XB(V,2?Y*>]D-5
M,DHE]\Y(\P;S\/*Y41G?#Z^X&2S>$OAV\#KS#--BCR7U?D8G$6)R*Q4U#7*F
M:K]XA:0.FHW+U A$.]JM8+01.HB)UHZM8I40+UF7=)+F9,,Z*F'5,GM9BF!T
M6M?;-7GY%9]ZC!Y_E;]ZOMLBM-KS*C&F!F(MRF792\K,EW+)?.&4$(J<ULG"
M4E,KYU>*R;*&S^G<+$6MW^[&>\K#A6"KN%);\@5=/?8Z:TT0OF8\1-5A69G$
M'66V.:FHP^MWZ:0$6"6<P6!8?41^.N]%H!6E[R%I8#M,(85ISIE)Q.? D)F]
M*$3>@(1Q[DOFJ([Z6)_*SE>,RVP1B4LHW090!6N=3F#4"FFQV5THXU3%A7\_
MC7=4%JM"IVFSM$R_I;\@=A"2A#V^V^(\MV[ 2G. Q]*]3XM;3*5N)S7+<9.I
M!"\=.23*$6MRFN32#ZS5,\1QB&;6<(XR@IUT]I#O:1/MD,7\B[T+I:D%([/L
M3XI&YXQ5(ZX*C3,+R%!>Y;@3SG(N.U@SZ56:'*[ON^CAY/MU-)0IARB'.:JK
MU%Q1PW4/\M%RKHW0_"7X\4M9TC?+CD4]51+-O!0UIM#&_6C&LY#MIP/_2*U/
ME-N<DT7477>M)5U"72(EI3RBTK>3%5W;.]T=*B)%]_1Q-CICE&E9!<YU*KEH
MB\1D)8TX5;I5U.)?I&^)X-\!%?R1ZJ-L[5]L>;5.5SZFZ[OU,U\WURU*TV2,
M\6P9NY.,XA;_\D46Q6J8E=(<>=$!QK-<JK+BP]+Q.:NKRM0J_.3?'1WSTP(L
M\:85-3S63G=I9[*833@(4($9<QLKMQVL)Y>]9GNSXNV&3*XDC;99?JHF"2?M
MSH @K4G@U-0T:MJ9C+R$[?-")H--)S7&T=I\LSJMJ56+JWNFE4ZKO0Q-[4CL
M>8,B"*4T_&P/5*MCB[(99A2<A>W-YLYZOICGC08TM;\IR6<"LC0=NJ?30$#=
M+10*#<WFT[&04#K>F35X^1)>=HT+W,!PA'A4176L9GO*;;QK?0H;/=8$2C4D
M^=&V"=B!"*'Y@D\&:HE9!KY]]96&!I7G&JV?YTU^EJN$AL=D8X7!;%)$1%G*
M6UL ?;(OL+$WZ7B5V=SQ1W!**6/;^&JF4&E<4?3K!V'I*JI+4/2_I>"-<$[#
MPPN'(JKJ3QLK_7_6F/\'#-L+_$-8=IQ&'\?B7]7M9W4"J?^\^2Y2+P45'B3*
MOU34_C>X7,,[C"5W(13=I>;/NW)=O)I^M7[Z^>%PO5,M5YCL1;!7$9[B%DUH
MR,BU7IV%36"^ 8$[$@;'!S/G#L(]N71$<BN1]>G):OA^I6G'5C'N*=-0CI[B
M4<X%FQI+DN+#&D>Z1F?TZM<,!S:N3$V?8V5S3I=U(CTC>\XE75\2RM1^/<A@
M$Y]1@%S"!\Y//+@6H[EX^\\%ETL+'YSWUZS'DVQ,Y!9H616U1(:^8WA/ "EJ
M&A+N/]S^U$O+!#2!(8=Q\FAM=0H,RD!!Z' #^\D:[R?'H)HG3\B",)OQ3%V5
MGL"@976+YJZ<'O5$?/,T=)4@&<$&(<S7I'UT>5]G^"SA85R^VM?9EP:M,L>>
M>ID *G2R (%J%VS.[+UHW_U]7?DC?CI&8?,V'[V)]PY@H#<.#6[#_?KR>^P=
MT.VKXEB8OK;[K\UP#?,9_0L:G]Q-K]0[X :QYO'32'#3O7A0\4NQKG'PM^!U
M*;B_K0G!&P54B\=[!]WP7353"5P[N3=*[KT-E'V/ @:]N\Q*K(=B^7U PM,(
MJ\5=<1+?I/OSLG:5=X#XV*.XZ-T3+1(HLIP)Q/3$]*QC.!PWA >N[K.:MB*X
M<<UKJ_NKZ@H^9 "U/Q@I\DHF0H$W=\N_M=LRS#SX=DWR.UPKEB)W4;=MA](2
M!*_L%NG)X1Y5!2-J25OS @06@6W20<'B^\N4:.9!8BLF(LB3W#N2J0F'!*KN
M&59Z8XGB2IV)HO,[0^E;(V @JN[_K![_WX/_^W/=014#JAQ3JP[L7//=5M,B
MLT9.R%-J]$B*_\!N:$ G%KA: "0*3F#4@_K;B!YQ8G=<8;==$$.?E?UWM\7%
M^A$A[A*$'PG&R1GE;R*FE4.=.*>YJ;BIA4>FI<_Z9(N22IS :_?]V<GI?Q6X
M.O1N''Z 1@LH6A0MG"+'R#S\5=F7^D,)_)E,2YWTIKK-T?=9K?2AV3MH-I1#
M+\S^<9PK>-:_8CWUP_^LY3R<MT;1[?=J/;)H2Q8%EFJ>$.+4^1W'II.<RO*3
MYD\PPZ6,UT18IEI]QEK;MA]1C%'06GH=36)S_C'O*"T]77>_7] 2W;)GL !:
M%J0T-0" NDR]Q0K)^T2)$T(&U7\**#DG"4.N+*/1[=5]*6RRG38"N!ILDJZT
M5Y*1PI.YNOY"-/VN@ D$V?&GR$CEQFTNW-:Z=4:CRTX_QDFX>G7@;:8^<4*V
MOX\=(F/J;.F[EG<0;)J42(<IZJP826-34='QA1Y@PT (LO/M>T&>NJ8+_M:)
M];]KL'9,7>Y3G9YA+1 I(H?F>$%K6-?-X"F\7D+1B^9FQR*]J+D@YU8+&,YD
M*;3KTLT V.>QL%O[A^7MQGO?Y"8?88+>Y:OS4G-2ZY?*>,66S& U9(>R/P/[
M^R9ZN-955DEZJ,+B%9BPZ>-0:FI3<G.NV\0O$=U6@./K_>9 2Q<XT?HI5D4"
MH[P1C6I#51+AQ.K3.GDEJFROV!EJ<]HL$V>,M'XC48AY4Z$ZJTR352JD&5J*
MI!01G0G;-%SLM..&)XZ6='*+3S2N;2MC[3Z9!?]F,.%$"U/";J=#0R5?W7G6
M/+[ZV:"ANDUG)1LA'"NJK-+<=F3$I6V.&MZ_NE?Z'.YD4KK%8H? ^.43=#5
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M/:<>]#8N>9>HM37]MHB7M_59!3]DG^VR_4Q$3@(66V0I8MO')\4PL\Q3.8D
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MV!S:$VW/Q+Z1W>M[L6@ML_N0\4 RN;/LLA";+T2<\:U6M1:'<8ZAM2,-]V+
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M4X19H1]\9\P7R:)D?=-G*-Q9EV8Y5W_0Z#]E9G^KRZ'Q+.=7^+":D]GBLLJ
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M9Q4_(!_UV!$9%3]I=WYZ];U,C!3_$]@XTTQG/GNS?%3QKHH2HW_=#\?&8<O
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MK:&4IUVR3\!]O<I:U0Z^S%V@+[]/L%@K&!23^>VZ3<,&1Z?TPNKDJ#%]11$
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M[=VICNM=<BLRG22^CZ:ZS&8,&(YXQWY+!=&^G_.+;BR3M,4/6L5QG&S;"6I
M19,I)9;\KHJ<0CU/,"K-_O0%_7K4&]6?S88C@+OL^VW,"F0V]^W9P-/RO;2O
MX20:84\J3E7 AGNBX&I4=DR#8B,7MD^3]J'/]9RL6";5'86;NN10UM@"++E
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M5S0@\#5@XU:>#B-/6>U;-NH>9<(;EGI^L#6))?)@$9EN\<B'J]&K-ZZ\7BB
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MA_ZB5Y@1V)(8P$-/+V#=4S5QLCD&&V'KPP/%C/D(2/=B_!,UXU\ E^($_B^
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M^]Z%4YZ!IY(9J](5& XX?'UG!@1PNR0KHJ#!N29X<>!O(&3\P%<"^E-TXW$
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M]MGS6TY:1%'?Q4;%YW-'Q6-6FS972?(I!IEMX%H'RO8"BOK2!PD.#L'39YY
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M@3CN!5!]QO%W]_L'=LFENS<?_J:,C<_\^S?T CA=_ORK^S\$[$,B'<,+H*E
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M7XV.P6#7W9K1_1,VJD=^<GYEOSX%X_AS$U1\(',TP_Y/UA5PFY!CI;T^Y:C
M!I<OWL'=)[=><Q=Z2JNMP0(%XYBZ[88#M<3 1 -." ^9/)$TA^G[=I:JK0TF
M?EPV2IZ9#(E#*^9?@?[);M]W8</ZN%Y;)F<;&-* '"$3]UJ )^ %X( V:/WZ
M"OO(Y7?82F\2P<["%Y6GGZ0_Y$ED#-1[(<0G)M 4J>@7 .)VEX!_Y4/]7E;Q
MV(SE]&E[PR'A?S62 )LPQ-6\8,%1_NMV.T"JDQ7=PSKCAF6[WFZBY#I'>,,)
MC_&R3=A)[-2T]T].^)IH]OV'_R$C\'\J^;>4)/R->)-(Z^\9<:,E_<+#]:D
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MP?N+M,;RO+ -$*C\5(-69 KXUH5?]"=,6L_C=-E >EU/N;]C),(+SY:EDJJ
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MJ-=27*RF&CA%$&@1I#$A=N>=9!&D<#9MS#&]5W!'O$?,53(;/8[H%0>?E%2
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MD#)6^R,Z&I']7A,D?#FQS5J3(6IT'%5!&*FO,(QUHZPR"1W67;"L!"H>"#9
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MA.39="!0G5FTT+@G@%37%38C,=,3P-UNM3A$7&/#3]C2?'_\L/4)T(>K] 1
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M[*AZ8HWNM71;1<#1(#&L[8CO+NL+AH(.R-\Q\.:-ZXG4<((O/=<V77?;2Y0
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M8&C,HV$1CI!!0>$T)9[%X-\Y2*1Y^H0($6%'M2#T@SS/K,UN2!@PG 9^YT^
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M3NEW:56<Q<MN&AL?< S5(XRAWA]6.^^JK6N.#TVJ>H4--CFJ^\B'RK^<-P\
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M'.HK:(#_)Z8*_T=45;8OZ2[I\HHS6Y$<I1+(OE/@(?[3R"+4M%K[N#\'VQ9
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M]*'EV4&X<CXQS>_>Y+[/3+Q6+OC=57X\Y8J2<U<LZ2J)WT?/!.9L32I-VET
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M.UJD[K(V4BWB=[^5'T&[[PL NU:\3_"AY?$!(AY.Q_[*GDXC5T^(,5&T\'=
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MLQ490RRVY?-J_M=-*2T:'Z'F&^OSD>4'%G8&59,B@?:Z2AU>^1H3**@^0IK
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M.=YX[!SH<EP^?GX$M:55Z<>DOS4*X=J  D+$'RKO@?>OJOJ-6/@/Y-5IUST
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M&LW1#$B>UFG<X4::A.7S917WTP4;]^8;<KCC''.20I.>?PI/CVR*G+,$.5.
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ME +Z4C!'#X#R7C*"D"S!V&F"XUX/:?REG;65)B<G"KH=_LO@HY[N%^_:EY=
MG\?7]GVB-CJ<7^7.4DFD_H^!:V1A]_[:L-#JC\U1>8^@[=0>,5S?^P(*_ZOT
MA!W[L/$.Z6P2J<2G;M*@6(,NR-K-Z5I2NK_FT;/HCHO!VE\$Y;\(F"_L#L8E
MQW\1; IPXRW5J]&@/?=,#MT+@/>:EC& EGDU#["O"Y)_Q%(B^DGR8H]D4,8+
MM\718V1QT+#-;29><U5!*2=@8J:!N0K.XE_=-QAH*/;.@?A,@:<8!<%J)\QA
M7$OHT1]:7F!:A$^*6TNWHK>3DPSX?'\EZB88Q-Y%:?X^(ZMN8*;US"WJF%V2
M;%E/RDZN##[3X$4QX^U0]QN#V@M@JMX*\-!V.#'UM98<K%^0? 3[ P-XT9XV
MM]MVAGHI4IM,P@)Y;/T8@[_<>G_2K&Y<)!98'*^T7HI7,>O_!74BO8R(NPO*
MY>?/'@^BW<'@MYSC.+8T*\ML#7@;^0MOFI%&[^>7W]N5[@L1N[QIM(JSI@3I
M@OW!G&LK&H92R2V'6JW@6J"A5X\7$3GDN$S&]U:S2G/5WNMN*6[4O6J.U2"\
M]4)+Q!JC)IUYZ*/;DK5#I^QA6U.'Y@O!BYC=@TA*_UP'4D69K?,5<MX2!# R
MZV[*J.:DV(JE/LEMRS_-J8E(R2AXV)I:_B- 20E^RE.&:3Y<V7P<<-?P:KXW
M<X+=-VF8$-:(PCM-1/@90[#+OOJ=6R,--$\07^NYW2VB^H">U&%.KEBLTB2^
MG)9V!L6B[K?S^-@<D84U<Z$Z<\M.KKX>K$_9;F%A?W0(3*!5]KO3&>34_&-6
MK,CE.KEZ)E_,FIM]6.>E_#>KL2[3SJ$!D(1S0QW(G.+.=?6I')'K(T/--ZD-
M;2#X4,_'X'[.:I,#8I38OS#(%(]7NN#+!EUQX>LT:4K]X==PTO(<Y+MSQQS+
M<4!MY).?ZU;HNM:DD]*(Z*36)PF:/78_8E1,=_(]B4P<KK=G70 6H[?DUV>6
MKL;+\!SR;*FY7U\ [0^76_5;$8$Q$]:Z.QIWO*(R0(L8G5\=@=:+[ />EM.#
M@L.VGA-LUU9S3XK5UH=?]6/F=P\>-_5<FUTK%(_*&6H"Z0[V"#O?UJ1/)UHF
M\/FT_T4HG%2?K>K*S-/R\P(8[.BR4V^EAY=/G]N*^QIJOI/,B#TLE>!]G\N%
M2$JV^_KY\K>-E+^!6[@M=<4?*_OL=GYB!:1[4*N3UFF"8&DKW\FLES6P<IBQ
M=CZ25O"IRH_-KX94D'?8V>P^ F50_XNU*$ B77IS_,$-QC:'H].A[3'4S2SD
ME1"F$&GY295CZ0DW5VJG_=D_W=D(_?TC%B?)L3=[3CT! >O-".AH"KJB,,U+
ML5]%X.VB/#313$GQXJ.MJO=+"0(8K5:<Y:/I7!CJ,LF$3C7@Q:[K_G/C- WZ
M&/,X C5NJ%1$H[4VX:\F!+05Y;WD8CBCY;()'VU^(&P<!)TRYA@IU:/6:;,P
M&<H,%,1DIEKNOZ"U^[7IG<EOZ/1?&H;*[]_ E:'9U>_7OGI>'6M_,E<@"Q G
MWOV^C'R(KP-M@!PU^FO'IB8ZB[(%%O:77I[7#PP5XUV#>&AC69"/ PP.RZ#+
M]ABIT5Y>Z,X*M</-T?%* (RC_?U1/6BMP=A:B\&+.3YA4YG"O':M]NJ1V<\&
M':GVC=RWD[R.EO^A*K3F7P2A#XN_[M<MM'V7.+(X/+>]# ,6'0W=J:_&773+
M%LY.[8?N2IM)E-4*);9+RF==!Z&Y7&L+6?")ZZ[DJEBO,?_S&H?!N2:.9-!&
MP I0"/!,/57-KNS597E;HV7B?^SA>:,S:L(6;7#FB0*,KU1L#?1+^H,MK/>&
M)3$_[)'X,VFW&]M8BM2OCGB6JF,F#T1SS$8],UDW[RKUGW!?>@9I518^*C-I
MI'!ZNM$E*"SGAH;GEO9,B-J$P,<OOPJ?T<'-O67#JW5Q05VQ@>A!VP#%N_91
MLK3I] ;644]1G=CPYT<MOPX1+*C7%F9-G2W/5/)$R+PO9M !QB%]IT-K\2&I
M)J\%3U3NZ_S\&W(GQL\')ES>L:KZ-/;!BM\I<C49QQ0]KOB0MX'O/TC6VK0O
M.3ZJD[?L1Q[KJ$\%T ,,U,-ET^VG>59%#Y4A$9A=I5L'E6IG%"LU:7..$]5$
M%0QS(\6$L;?*@]]CR%R.SX!NBUO6&F,&RTT5"F^O6$_9#0F[NG][23N;V@&2
M-QB#[$<>U!T/*&F15FH"@\:LC_2JXG-F[1W&T'.C4KR-6$3XLB*_?7 5_">R
M(7>8<CY2?0&-? DN7L126?'%^*2>5^G LU$6;<,C""3XX,_I=G$Q*;*T4*MP
M;;6W#+VS:M;9//SF%E<V>9NC&?UE"'04;DE0;4#PE7@:N]B@3PXI(T51 / U
M,TO5,5K+F3Y] G\P?;C\?EQM'XP,$7<,5MA:Y3KXH!MM>G^20V^UFM*! S/]
MCKO,W^O(IC+_P?*L>S]R2F<O&0.<+U[Y>]EK:+ZS%];DVJB"T;9(DH_B!X-%
M5FZ!9+1,>E' Q(>@N!_>#8!8G=R9CJ]R?HDM8]5LARH'*=6'FYL$:^'S1)>L
MX?KDZ$$P= 1?7-3\/8&+H[PK02]($75S.<5^(D[N=)T/HGL-&'ZA$=K"(.&H
MG./=;6&5(4O?AD@CZT 4TI#M0&3>0,NXX;Q@ \[+S8Q--R^K5S^%H7PD22_&
MP@ T=QE<7,PN:?,ZWW(1-L'H:QL7SSY[*50O<' V<&D;XGW"?29EJD&;=FMB
M\:M5Z"5EMO:^;0?C;-)EE[Z^C A^PN41Y9B6MIWO%NJ1:9>*NNI[_TLS]R%P
M+&7&R,Y<A.]$J3#5R'Y.,+V*;T(*SIE_&X^B.WL#J79@J^HL^FD<=DQXN.[B
M^$TOU-KPK-_B%"V)]-N=^L/\ 6D3>>DQ@[.R7P2#BFSRT%IIG::B*++RN]?J
M[E9$!@8U$YW-->WY?I+XEC3(F+L2???S48WZ$+?T)>FMM&N,50MJ*[V?AW(6
M-3&+VDB]X\KD7BDN630XE;IQ>P6(N'W88;](CMYBBZ<V=\7YN<FUBOMGT1@,
MQG2&44R<?- >ZI:)Z@50#MQJC;;31C]8GP8_&OMI7-/'+V..WE(V+_/9<R?,
MVK(7NLV?7P%)D&L/*T.\?OA?>&$(Y@)N'!IS652FVAVA_'KSEE8;(F"1I3^3
MCL[UDL2^J4I^TA?NFZ=RG/K+CR=X6\TX"PQI5H<?P$IF17%L>#(P(]["A+<1
MLV%L.+&I7_GSV=<&['T-_B+<?.-H F@U5;/,R(S,_T6PK;2OG*B%MIW.#%5W
M_[$EDYG7F^N1.OB+,%,^PY"\'_5(/3KO&??$R<%UP27D]^AM;)#*4%MA6KFW
MI1NK^<&K-)>%$;-S:KJ<)HZ/@$$D4ZO]Y%M&V5HU%$!G)AXWUAHWQU@RR+Y%
M\[ A@^^9L,K0?BI%ZX+XWIU*)I%)&J<L-A\7[A*)3#(-"!2LP9)95N$A*:5=
M:$)NC./@SWF$75M\J&HFJ!99;GTFW-I*MJ3EB4BOK3(X:TVE;16;[9^1!5=Z
MDVKPW/HH-D_OMBP_::ID9EO<#K-=BT@U@QG<>;TJR]E5"JH/Y[O9>>8TXR#I
MV9Z[^IGE9K/6OD=D J]ALOR5FP;UN/4J61H]R]]PI#5Q(B#P#B*TSQDV+9:'
MY^4N7UBA,&V3!^06.VI9]+PTS/:VWFOSLJT_[.F&Z_U'?-;&E49VK4W5D-(:
MBZ787A0T'SO)!"0RD<.5H2<[4[:3GFO8"=C^R6RU9W)HIO&L7F;VVOA3LZ#J
M@3%/"^GU"OPJU^ 7["-@7$76T'J'/F.9DV+YU(AWMH+$F; 42-4P>HD8>8M6
MKBZLSHI7+*?H)N@5*"W'/D>!OM88 <TASWN.KW1;-5)W3C;S.,J:DS.BYMHN
M5M;AF&E5&=\UZU9AH)[E7K$=Y*-7<;UAXV\F[!W15L2V6@:):-4IZ)#TF=SR
M5[+R+Y&W'9>7=5&V''VK=W2!B\(.KX\^Q:;FQIMT+"7,^Q"P!9;-GOB?GP%9
MT(Z5 CJ?/&,O]3D2OB@9^7-Q<NS=.&ZNVB8]H&Y-/D=@;2?*["372!T3BM$,
MNIDTT10J)EM@'M#IU?F$I$BF%8P[$PK^J<A0_ $IR0]0L=CF-W#N%GQU^YHS
M;-=X<4/:V-!PG6>)B+T 4=$I_V:]I-<V86#09IXS1O'X^<2?N:A6LC/_0+,#
M@6F# K8_I7L2I&HNQ/O2U3NHLJ 9:<->Q4;T\ 'X:WQD<'B4=V-ET?OQE)[_
M8;W*D2/4*G]#IPZ?\"_"X-K!%D?6&_Y(7&+KO>1>;;!9T8R+,/SGY8,/&FXI
M;[D?$N63+#*)BP2RI"_A'G&S1))6;NHXM\H(J"3;0FF2CX^+16VL@XMW=V2T
MJ^VD=60E+P0!Z8TZCF2I5U&M5U$5356%.FS)<=52WY*K(V\I-V-OHP$! X2&
M@."$@&CO6)/>\)'DH:JT@O\)R6&(TT[SY[B,@]W,KZAA(_W?C#*^ /O[&4L(
M* ]HOP9*=YF=#<J=K_K407+8Q''LYU(T ,IUM*@WCNI+GH[\/-:++1UN(ZLK
M"QB38F%>K"3K>^?QCIC2;4WX4PQL9^[H#C/:IC9@RQDFXTFJF8FD$=9(D)4,
MF$_9IF'H@VP39JN.RC1\%.-E!Y\;4&55. CY0O++;2K=MXWCPV6>Z4QM"/F'
M;JJ)8T&R,G:K4T$[7: RB#8DC561-'/-G4B(_LN3/U##U2=.GGY58F-+Z I0
MA:7!MY+MP=,$_8^T[:-WLS\P#%!E(6Y192,[O&N4&<"+@4X/#$V9N]GTYF%*
MDEEHR;NMND5_$ X''2EJ$.:5^R\85<&9FCHJ&P]!Y8: )A#3S6(8IR!GDG9Z
M"*#W^_L5>1TKLS&%IJ2QL2]4H6U4"6:A4!R!/Y)F3D2A6P"%XKXXJ"P!I],O
MSENH]\RL?XIX[&7Y1/!B7H"^IM5(VN.+4> >F48FQ'@B87)%6&4P$8W-L5TH
M'U]&2Z)'1AM-$.$=KCS=2;M07@AB01+"FW,$5-)K3!ZI PD7<Z?0$I<GN1H.
MY6:"2(X%:+M!''C52OR@*<B>QJSP06/'F159+V'[P-T6,K,GW$XZV3_/]1DX
M (HT/=;'2)=Q^CGWR>Q-Z_Q7_V% 5:>*XCMM<4E,8N_JX\IJ*]H;U34JVJ6M
METWD%;DDTA257LP?Y>U3 O>8U@;/E08K)S'/?>[-+H><Z@"5L;53%!<=@I-M
MSE]!Z NDQ');7&7768VK#BS!JYSQ#@O.UDMWCX//Y'L>L7(-I;H= T/EN,F-
MC%EE,?WD+V5(B9S6O(L+8%)@#QHC=<-RBP%LZE;+9=<7NLY!W_:/Y@+66O^U
M*A%<>^2W!JXW=C%\^H=ZA2_</!YARSXG?O;%#K#2_\V_0UO\.8\X9!N7M154
M3/*A18)F/*AJ+<?D=K;1NKF4V5!1DU:L[&7\GM1:T0#<TCM_Y;G[HOSMB&U@
M;AE]097=,LL:& &OQGCV6531;2%/^/TDIT?<PD/\OI/'9J-I.B6VG5K^CU^M
MN#RU<UUO!QCEC84R+_BKE+VO2E6E/SH'V@U<2>^G"G[92V!@A;O:!-'L6D'=
MBA*O2*#/_HS7XRU18,N@B;X>'Z/RI!#,^=6*+6]R;6=+])9KJ+5 4K#U1W 1
MSS&IUEEO3H+(?:G$N:-;A)W'*[6"R]./]M[2 )S3L[8N'O:H5W#7HV N*GZA
MX<WZA:/*=^!$L)ARL6G]NDEW=^[ADT<A1K31SIT?!._LP)>2=@\Z)0B]1H(_
M$7\W_2DFJL1#]A/K\?K&.= /Z\>511#)R]>.Y<>;S1 TFKO]UE[/AZ4*V&E]
MNBN_W=CZY4*T(\RT*O7HMFTM^3I']X9(X*Z!+/Q[#(O836R=VY3+Z>M!;?WC
M9^]9 = <S^ODP8W 4@%Y*[GDC4E8C"$Z<IF0Y^L<WP6-@K08QCK!@=',M=R(
M8\R4CE$E<:AU"QR]]^<L(.F]I#MB!F%K>\$'WS>G\DK?FI7S:0F9D3=$!XP5
M[4O/TA>>@JL<[A?^S,N*8A)L?5^&/<G<%@J=B]P"*HQOJ>:557M.I@RN U](
MGJ@7XW716_1S$LJ7R8-56DS#4QV#XF8O.!$ G\I5!UJ/?="@I5P>S1QC!?<(
M";3*PBX71V&O5$:(Q2$$LQ^E+T/3FJTORFM\3K'UVY+]\VC5;!'+C?VT3<A
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MZ?[$V,<<X"\\:N:00@<$SU"5I+8S#N1-[6T!OIKVPVJBM:U3\ (\]WF:?W4
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M!V>MFN %3+G> KA)+$'!]0DJW_Y?"S"X=3=_$:AZ&,<RD"OF!*S-*Y62:'D
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M4=#XUV,QD_4QG\#&H+?Z]3NM\X%>!_5+SJAL]]/L/RC&\RBOF'KX* +(G]+
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M^#OFQP>_1;KU&SO,Q6_X[]%_RB 8_HT@?@]C.$' __-O" 0C('3_(_X)QOZ
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M,3]69_/,GR];8#ZR>*M%8IGF7M[]V4OF_OJ^7SIDV'NUMUXRF;4'[?Z8O;^
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MAC)$G0M O1</\<I"F^6WYC!^?@I\Y+A6Z9_3OAF$9B-UR7,VJ/9*D)8@HZ!
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M@!A?1O]8=FUP&16RZNY8%[NA.])C6F+PYE-F&@_"@1[5Y/)*H0>_--MS;F\
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M8T1*XIEW!^]%PL'^.B2/*'3$LL;>6?DVH!:^7$[AT2[L(TUFSF%V.6/B45#
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M&I@+RH6,@"+5 K%4KG!U8W 82IP+1#M'A+'A2"(4I52HQS;6BMT#<&!B@#A
MZ0V&RT@4+%CM)_;T5Z#H7@%89R>57,#D$Z52&I$MA.#I0'^F!YB' C/))+)8
MAH4JW>@RB!^?3:8+:="Q#S1D I G<O- 8?WP;BZ.H "ILQ>%*:/"%1H$&\ND
MNKCR07YB-X6ORMM-P:&+P!*)IU+#"172!:[^0F<"'N'IB-?@_4/)/AYCGS^
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M6%LXU!8\MCG2A4CZ ?AOX,$06^A?X(G?FVU"8<GDVK;_%0MJ/186?EV,_M=
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MSXG(Q6Q%F':&Y3@Z8O[]8T)_A/3GQ!E<FHC#8MJ#?D'\Y<'_=-[YG[39WP^
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M;YSCGTARFW>EK:RFS5@\(V/N/>^HK6 &;O_ JLSX;44[ZT71?2<,J_/OO'Q
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MH+KJYPGOW-;DI=LW)+Q5.FQ'SQNP1?6R'(Y- $_@V6XYG1/DFY%SLJ%Z/B_
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M#T6UD^L#7NSSF(>8Q]F?>9_R1KVJ.GO:O/T&QW8!R\S IOO6+_W*B:C4;$F
MQ+^_W9U6"NFKD ]>*V7$=NCCE[?NNTR9_>8C,N-M[%,G;]-%: \TX,9=?X^2
MR1/+YB[;D0Z8:A8<O131;.:XM:GSW92NOLS"Q]C/F"XSM]70G^)OK#F?=.7"
M4H*&GI2^6C)KZA1T:J!_=AZ1%7UR,64E[W46(U2TD+G[^O5IE%?' @+EEGLW
M"((N3^1ZQE]G/K&TL#B"1F?K>,7F'W&_=6??HRSJH2G)>[J DTJ:)Q62(2.
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MUHX2-V?G/)HT;4/_D C]^P*<*'LH6Y;OT\8;B9BR7FMJ%]=KAX,S"BL] ER
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MLGDDS:Q%%[,Z=+O7VN.T)W-M<DEG8OS$YK$5Y2QX. U.HM'C,!5]HQ@NP6<
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M@A%9-^/%A* 8[*IMHS8A9,+G26N>9#8R7TH+]_N@G.445N#XP6_54RSCY,)
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M(V07NK"<JVK/K<)1=>HF>!GTM0=EG6XT4Y?9/8T'NFVD FA?9D=PTGP#U-G
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M+Q;2]/E0P\FD3PEG/Z3%/K_5]MO/_8*4&!V@2#WDF?UT5.YS1-V :40\=XV
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M_B&5I'9 ;@^A[_=0K<T&RN4VB6E:7M0?;]40M#9O4<SH/^<KQ0Z=J*W7QD*
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M9\Y/1Q2<MF3!ER7GT25%?#ISUH_76'FVA0X_4ZC[C7A?GO:PL+;#!P['P-_
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M-Q)#H,3:J2%</Q;IA%^22:,""WQ)8+\YH80OS@UGOA]<?I7E3<ZD),H+-]'
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MU=$W<=;6]VNX!P4[V5"AH2+4*GLUT=(N?0P9/1C7J- \\@#2C(39'*K']/D
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MO0[ZAL2(+J;"CG9RE\0HQZ(M\*!O@,:JX3= E3O6O8SB/I+Q@2_'D\]_4%.
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M4*ROYF(+-$RK(4.6+RR;C-/'ZB,OGF)^SJC2\->+>%.$<22UO@OK!2/D8Z$
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M&9^S[JPM[.#/E5ZHF%X4+TSH( >NVEJUX*PV>\"E6/2!<-J<;](/.$LX138
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MO3&B4,!H#O$FZL/1!5=@EFG6Q-GM/SP2!O=85+(>COHSDO<-<>SFWP-I:-\
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M"40[E"E5+ALN33Q7LF@MN V]B\;E]?L;4+[EFWJEB248PBN+"@GI=)$_5#N
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M55,CM0S!N96(770B=4-8U$[.3M4I8KCZZ2+BYIBJ:%8'Z;KY^&SMW^C[^\_
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M.!K*JO<PC8ZZ=]-E&8=[!%M>V;A^C?/#;*YN["3MJPR"GIRP+!\;)F<LEOC
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M4;5D\,*3B_X4B+6(GZX4-5B5Y=U[&ET[IY47854DMMOM[M^C0B6VQ?/G0EW
M.="(3==JVXMHIB<K;3%:HV=3^92<CA'SS4Z)IA0R>./4S$WO3*3[(X^\_5)+
MZ9Q-P9^PI5,AO>*F*P/[CZ;%E1TSZJO28\L5>R+_5J6$1M:9N;Q&:'8<F]UR
M]NFUH\Y^+_?>VDY,+;XD&"S>D;;C?/?T$WM1SO59>"*1)]JD>#_'JR\LPSWP
MK0V%(#D<^*^$NZ?FXD,L)]O-URBN,G+1"29&F8H-C9P;4!S-"7RN <R/KZO+
MP>>>"+K-SRFJ\_L;JN\=*?LC4N;<0K!V);R_!A0!B>56YB -WP_GVHOG8:F0
M51N C?VKI9/?C1ZYS@EE^EJ[QI\ST6YM[XP1A&^3B;%"90!]5STO*4C]5=2[
MZKB,VE3'QV8E<2\Q>75O)+6.+/&A;]=R]#9&LK9Q=<@5#?9((#8Y/V=+&UJ2
MY:#"E_X5Z+1>N_*IM.&P@B2!S*4'-SQ?QFC[E:&&5CN4\3GC(G&,\H<O3_,[
M2,*]T8$)@(RYO!0M#U.A]F&0(!JBWYL(M493=8G>$9@4X8G>$?_/X-F:^-F:
M;&:?72.-_/MF1H)L>;;5!CY(-D]$.UW#W2^U7,%!L#508L09AXM2"XQ7PY30
MN?8]N4P:4>NT+SJJNOVJ-FSD?H@TB 3T-"$V-EK?.;_:6!?*&ZODSL\UJY(6
M(2F]2K1;8MO^+[*,+:-.AK;[@\?5.\]E4IW]4U]U^2OF7Q:1II]R80!C 5[-
MG]\ )-)4S>.Q?I?=AZ<,QC.-Q"9(R5RV-<N3"7_@;+^M/2((.T*\^8XL.K*>
M9H!Q!,UDCN%] U&!?0@2P8$" OLX)+C<E?RK]ORPT0E:%[U0%,U*9H\>T'6Y
MS!38"'L@[?>82*(P;Y+B.4NME6",F6?-5KBVC'J"=,X(OOV]AG^7IA*EIYG^
M4U8\>S)LL*\,R-C\=1K.)_S=C. )!7@XNIV(J\F38"7K-EPDL*$[%SFF5K.C
M22,:NBOK40)S[-]::#0#I[$M@//K0=H9Q.K_1F@=B/7]L!!] U%,ATTD:-B&
M:/J/:!UT9H)8L-*H+L4??H;?BJW@VF1;-WKP2FJO^L/,'>QG<.0D%K74%LDH
M&P(_1I8I[XH>;V*O]E3G]/O(RI#YM0YXS4-KF:[L:>C@\OM#S@&&M1:-!B"/
M)4MKWQ.,7X\/%DYS^_/ETQ&V=RT).7AF7JE@'$2-U52H$GJ_D-3N:'^Z9!=G
MK;C^=+7[SQQOHUN-TR%B$^_B<0>7Z!Y^2Y'&QWC/'-P'F\6DV$9<>J=D*/)
MJ3(Z=OB%5<^P &?[NZM1-#N;4*4G9*NP\3= ,E&Q@E3XE;>[PY#JO*YEB=&C
M-+"#K?K+W/!+- TWE%OZ+&%85XK22\%7I.6=K(F3] E9Y"F)\J>DO9'UY:&@
MH>^:1;^\1-O_K7WWBYBR:EK2(5>2KCCQ(2I"*M,:X*9B?!:"AZGW 0VJ%=+9
M)=>21!)0G8:IU9.;R5.DD\NT(*WP=,P_D),F3WZX40M#IM5X*-#X5V%2-UIY
M'K-L) %-S%=M&6UU@J_]=>VS(G5?W-H(S>&B;X"OHK\0EM_! 0!?*TUE_3YU
MNDAN(513MQ5M[SZ%_C@QQ.63US;<K5''Y4MBXU"1"1'8=#76J-LXO8X'XW$5
M5,#2A%C?7YI"@C*?^*RQ@K<D<D$8;[X1(8*J'@2DRB%&'MG.H%>@<;FV,.D[
M=/U3.Z_".DJ5WW.;OA)Z23WB#MZ8EMA)7HXD31"JZ]VM<RI=K$#_94(2(9MY
MC)+Z6TW$%LD26#7+^HJ.G>,=2C.*$L=5TFZ^1WQ[)W$M]>\U/2-S8M[?.+5Y
MI03L?9O@:=S0J3OY53J3Z$^R]X\LO$U'K^R6NR1Q5H^/2EQI*^.D%EGU>Z0,
M&QN5FI>@R+[OJY1ET967]D!RU2_;_4R1-,?#$9&_7M&I,ECY=_6-I)%S3,/O
MY/8HV]2\PD9Y3L^)_L,VGL6+/URYOW_7O/*;8!\FC?3T5:;>;0QN_MX(]PE7
MZ9L1*X4:MW6T!X*B.>-H&"AK$#__G&YU #(_7O#PN5BL,/V 'B)::FIA<R.S
MM&$1J-8</P=M(YOXG3A%C7!F&I5$%/X"\^T7TWCN2B+S9=BB3-%V_F&_NOH'
MQN%X"ZLF_6C>;+-VYY :X4]Z.G+6)%"S]C3L!JES3Y5=L>^ON#3[1OT<Q$(8
M..-,^ T_2%UR^;M38_A5,)DC20-/S5\1#F,FZ!+-:/ *I4U!U2C5R^.&H>U.
MMLGO<?N]!F>2Y)06)(M**L //?!'.=IOMW4\F*)7"-:^SO5+*TLC;6N236S\
MDX);RS \[?6KS0^/]<3R<6ZZ'K$3?N$4Y8(["HA9I1/L3A3!#H8FNMJ\.DTZ
MP[B*EC.>/MYC"<N))\,W>"25W(PC=24A%=[DE_)E";:U)PEQ+-PH3:&T+2N\
M5^Z>D_@!V]H'UQN)H&8*1G+;A#Y[305?0C^7-\#Q#!ZJ^L?^: %*;(\VKZO9
M9OJP!0_V$\/;GF.T3!7&98>\W-(@!$H]%:,*-3[,2C+,'_P)GJ@,/DLMO-)*
M=#X1"[Y(OPH##V*6=1@/Z2-X]O4="/^>8>(W[*GJ;O=E<_,>G#@U/76&>(36
MHT)$)D&>'UWR.W EKQ^-VJGEMTHL8SQ+<'5L]O8C=LEMO-H216WIVH[Q=F/E
M]4=T$-+TCIU)/9=@6:M&!7-ZPFF/D3>58T;%G\KF:G=.*)5L!D0[:Z)I'3_<
MF N_U_GY%$&6V :T):'\%H&[_*>.G:7_1V+RA.>YQ=T*.D1!&Q9*(8%HBE^G
MF"7A9H\J^X'I*#VM3UDED%T;9?:848E%<7Y+TMSNF"9&<D#^R2^7Z./H#(HO
MDL2=A*^<,W.1)\]2MIYBD<>GLB]XU$91+JPISBL9]MER1+JOA-^LDM);\_>-
MU9\&WP#RO%"XU;8"P78F83Z$2?/[6J:]K:>=H3VZ(6NE&78<ZWR'1E#*,$3#
M]M)5/M80L.%7;[05W#]N%;B4B=54G;_P"ZL@Q->4K_!41HO\R]D5XU W>4.6
ML#<X;)WBW)*\]K;OMI/QIIZXSX,=II-K27@VG'*:3KBDOL25L:YD:J3)<$Q2
MC"(JMJUZ,K*7=(#'%L2K8[8 UA-]Q>%?I=Q0ZR]Z4@(G\IM\U:5[&CULKY&A
M&&SFH8W<ZU$^P.C7WD]FZCE&!MZ+%I&+EMVC0-!N>Q<*F'\K\Q:ATQ6^4Q=I
MU:P8IJCSVQSZ%W*YQ=5S2\%R<W[QZT6M$>SH4+"Q84!XD.XI*J=38&>H4@.D
M<_E16L;GL]^Y_?WN]Z^'Q)%C=I^TV*&JBC&'%$Y9V% 77<0K5Q4AXT,(I6#Z
MV7N,,5H-N(32 W7:=S<*E)B(REW?^&22/WFK&1U\)>3YC!+$L0R5J!&2?#Z)
M=^FEW>H(&$SM*S]':V_[E2[?I^5QN:F<1QM]'CG^N5$&,_C$3W"7B=1LYVO?
M>"PD)K_D(3MCG2(14,:WD5)=N ZZXI#;);"U4-);7)I%GLM552RS&<U>O.0<
M6S*+3K.JH%\7^6VF(^K".,(M\7N1AL %OA"8G*B<WV7_CK5+Q 4'>[?S+V=C
MPF<!+-#<K,ZQ0>T1526!S7NY52 -MI1)'G]!Y?+[(>SD^!FY?EM&=QVT/*Q9
MCG<^J?W92\&/]A2?G9I7,7(V@.>*3YG-=%T-^>1A*FPOT[6??9<R,@HE?/ZF
MK"U@V.Z!]Q)V'2-<N;(-_C<?\B=+W0YOJ+YMR@P7ELZIJ8(>]+,U#4NH.E=X
M;#?->TG-(H[9)(([D&8FB%PN<W(NW(7)B$.W5E0)&U9)(V767CN%6.IELQ<1
M5%@M$JOS2^QOT"55G,-U[$QK*Y>>+#I4S/3W+LY3K&FK&TAQ7MN+EX&C&2.8
MERP"77=T8^.3T#!S71;OLEU_/8ULM/L556%S6BUZNI/&BLMS!)V8>0S=AJ7#
M.?OHZAK^B::WCO+%/"XMKMJ994VM FT@'@_%?B1U3=G!F QR=(M(@3=Z#DAV
MXFQ;3/(_]:5";Z*O;Z>E7@CR+K(@DYMQBLO_W4J&N=/6T*-.$8W''NTZO<_
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M2?17,*Y*L([9+Z3NKAFM&R!+& :977AKTHBX<)=3CQ(+AYN=G/^[]$Z9ZE:
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MWLW;;L-0KUL)Z$(S3W8A <W-=6Q19B;6U.OR5$4FAOA3V:[#GJKQ!WXT\GZ
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M"SW%0,O<3X3R8?\[6TBNL$..$K;IV)Z.@O0=2JX,G7F&5Q&S@N8"PJ34WU+
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MV&5.V>.%;H9\X1"6U5H\0?CCVK]X]I]S+/;_EV?_EV/_MU_3 !<C SUXC'P
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MA-8P@G)O&]N7*JE=!WR<@_H;&S'S&*FU"_8G/&\B>WA/ADE[W M;E?R&@M.
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M=Y'.^V,:Y'NATY">PZ<Y':5/M)SNIBE9<9Z(+R(ASC'JS9MPK83=C+H.:54
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MU+7*>PI%D%57(ID&Y'P$:^BRFRZT1H3;?M']A*+['Q!LZ8T<?JAT'E3^CS$
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MRP[-LRY.Y /QE<<QWEP#I+=SA$Q(!-V7DR#KU7&LSUQ$CUW/<9\6J405$5U
M,DUK)U8AZ9=2-HQ2=^BX??HVAIG>Z76):+QJ=5PK7XE%R;I&CLR>NVN2I7CI
MXV&U5<:<$8 % $(Q#1,]!1DQ"W7P;NC1*<MC7^_.G<P>L-?DW_!RD@Z(Z,Y^
MWM< (+^1X.@.FR+09KD#W[=HGA*X#'\HMZXBG[]2Y^QR[3VS\*)=N8V:)1.+
M70DNVU2A&_Q%B"*V47):V<O(%@2=2ERP^!JGEL;&H4WA$]FS[?WA&?.*#IXJ
M9X.'>0;W,OU_AA+E"!:)2!A=O\((T/2PJ/NZYVJ^GOBJKJUJEG+<,G-0-J"/
M*5<SKF.S.9EB2FF@ 0'J,5@!F"?ZX?S1+\;'UUJ&:M!ES/4UL>;J*N5*!O$#
MOP8>@':L6.I'6 ,Z >:/3EC 9Z]=TGGR>JI?]5>@L"_CH,=),<9P%G#R5CG.
MF^FZT'68/@SW!B/9IK/I*$P5'2<K1N)_+P9^FZV9[#GQ25VG$?_8^%:O;H#T
M;$7-73&F7.G GQF@++P[98$5->$2D5C\;.(BP1T3YG&'!W66</;WR7?0>19A
M._3Z<\G-=75039><C&6';?ZVI\OE\'T&0O5_E5%2[H",!!DZ[TA:K): 0)%&
M^-VN85[GTC*R3&7(GHUO^);G3_*BQ$Z[@B4A5C^G[23\V0+>S/; (%B0+M.?
MA-& TG%MTF43:!8-X(?AJK!'44(@J=L8,H%DQM6/:QFN!ZBU/@@GY*4EYYK_
M-+^R+)VI)Q,#OX<:H $2K8XD*^K@/<=N!L]B7RF5;_R_I)NFE)U*:JY9"WKV
M4K[;YI:^G5I9PO+#@JH/C" I:*+&-;0!!45/V*OT\DY'L%+?^\$/X7=,H$ID
M'_JKE<@@4(A@VFW,2!"):>4Y[$VY+9UO?3G\BR6'<O%SS0<-6=\23(SVF.\W
MD+A07PX7MFWPVLC@)>Y3MJ-AC*]GG2@8&\CWP%0YR-"GD BI7R!]J#%KT8?W
M,DCO&6X5Z/W8:>QY+"X#ON=-)W8>S+_WDJ,-,3,YR[][JJ<R.D+ WYWW=..U
MZ>)QNI77O>.UZL#\3&O&6ZM'F3+F3B^(UUV;/T*544-8O /F(5;,6!\AWW$4
M\X"L[EFVV?+4X=2L"R=&1]OCH]MH%N:5]OX$6>@RG?GV+?R:L?G#?.^1#4'8
M"W\I!?#UHBIGU^\ZW^FAZM<SZ[E-X2N)\:N99LU\8^+#1AY?[5C7J[=SZ/<>
M]-5(?-EUEQ4IEFCSP4;'/);4/?%%;#G;4U;35>[L8_N3/W1P?8;F&GVSL.O0
MZ>4ED6TXWK;7?J'C1<_RYR/? [>K?S1EJ02=>^AR2L5GBDGH=CA?[U@&_"+!
M>XL3#^N%<=S% G,(N:'A"Z/+5^NP8X]<%[H7;WN>>C6[->>*PO5ELS-*-FW]
M)NF"4.)-O"D(;Q\7<'7^?'O"T=$QY&!"USY3Y&Y&S!<3  #Z&&6S&0X^TW4[
MQP2A'/>[.Y@/H>R.5X^]6/U\WLKS]GCO]HOPRUW/-6.O)K#ULS+=XGF\@6*E
MQ_PY6+=DVVFCI,Y"UJ,!<:O+QD43_-9%:W87B4?=:BWM]7=<3[0%W(Y)N)=[
MK6IW& TJ1) +\WK@)/9JZL-DK"T:ET$5&-5"3ZEQ^PUU*H2Y>5QM\2>]A47"
M'OW0ZX#-797@B<X];=7/VH-'=] %M0^<$3Q<@@C[NJB4>X:,+(#A/\_[ZQ]7
MZC:*JOMAOESV^3T3UX,AM)LQ,_G6"!T.B9>2(NPF7DAYN<D;67AN\J?JBH.B
MK&W&DH4#W#0UG:VZ&P8J>58X8)ODNV%*VAF?; S,.30X)8T7Y G5(\.@C,U6
M$[S6X;G T\JF9/7C&5,7A(?)LR.LE=093&-Z$DD*%!X@;#FZ$;S>#@OG%!^\
M%]R&&NT5OI ]82%1<YU%WY, C:,:49J,-9#:HU2%M=]H[J*Q7PIIWS/BU56]
MDG:*F+8/.@PYE[_/*>!BST\,P?"N-HQ.B<N),=KOLB\7S8(16^&C@<9.S>D_
MO)^$CH5/W8!=<%0GL:$[+OR"3BU??(L7R:CTFC"&GOL>J*X:K9MOYZ5B MT;
M5^U^5I)P[5E)-'^T<3\E&QV$?@B'8OTJX8O#J4B90)SEOCK/G#8QO<+S28/"
M3N!(OUNT4HR4">\MY-3L+-_O,"0)MYM@S H^)\QT8>LCHEM-/5^YSH.H98L/
MV3T1+U^4%FN\"XC-MJC)>IRPQ7RYR4MY3>E_@Z^3_/V6W/^NUD;OR['E9,YF
ML(.D/N_7XM::9S#Q8,>\CLONM5?N K.:(,-:V@_TC/H]DE+6(X/'U\4L.UB?
MTZGEO8&]^SI[G.]]7<3_D76^F76O6+%?9I97^3 4-"6(VX(?\.\[V[1&5ZP"
M&CX;B'^;1"UK'B%@S!UF2\*5S%"NU#DH_OQ<A,6$=K 44FQLJ.:%V_D)$7>^
M^@R*W,>"7)TWL/&^IQB5&WG2"C=^(VD 49)^G['^\)I--Z0NF/=\8\*8-ST<
M4=F*4:,!YH\+-!D$"R+,NW,5+*6SN[+/ )2F%VTW1^FTM72ASNMU64$W6. ?
M](9E+:A^L[_4WL+FI40C;*K_=[4NP9$L:'@9_!892J>N4^B._+*,5BOYG87N
MZ;0"E_6C?DU2H9'OG;*F;K$9>*#GI*%!KAL.>8Z.#B.S7=J?7U]M3M#E(@C;
M#4CP7'DLG4J4GL!!R8(S7;_=H91&U'%*B<[@E*KZ]7"JWORH5&'' W4R"]:3
M!MS:G=JTHV"0G*\[EJ"";HB^7M3QK^(N$[^B$DYXOK][19E7QE#P>$SAQ5/Q
MHE</AJD<3TA"?ABHD789\@S>N' Z,0T)8W1U\QU)'7PUN=+,E[&4JZ-R]=[;
M"$99!6D(?:?4!FI1 RY[KS]F]$SXS=Z%W:J#]2?3R32HICV"YD<>:UP^.>T7
M(A5Y4#B)WGHL0N:W(!;@X1US\GU0[C;IS4849VN>_='2DL.5<E].6&Z-K<#'
M8QSI;5<0#M)/&_5%JT_2_T<.\DH#I0KK.\R#<%T\%P(N:J4PO.Q02T\(:VV)
M%/M^4FBQ^.HD)V7A<7IXZ@@K76\P71C9V8'Y0"4V%<2W= I%_:UL@S7]WT?8
MCK+#7 Y/43GI*EEN!K= $J?_,&KXAK@ RM. K>R%VN".W+$&KP2TV&:=*K%!
MB_N=S/7FY#E7,%=;=3@\0AJ7?("F<IH1HCKOE77M<B!A8[\V)4U[=/+7OJK?
MW73.=0Y8MO:UB^RPVAL4>Q0?P*^_;@)51W?(TH"5_588#;C^V90&G#M*4:1[
M]09-IU DZGM?["$\&/X8C;?!)+5)@;8D-X2M,^%BN?_SM>R."$^UXBCI=+:C
MUA%L;L,<I9U5R^US.3'9, MZQE5 CQH)>9,4_.;YI63'JI!F2^9C.UIS!M/?
M3^3[WPG)N5_LEWWNQ VD)<K^-H-<-$P5>P-.)W)Q&*(&?9(:4.8I%>B5<90F
M>O))!0U8Y_I&IJ(&"_7&4$>I7S#<K;85L_<S+,>T-ZUVU71V]HKX7V7U;YC8
M6_7I283"FQ8:;;<A^&4+2E9K*!+I_6*^8ZF:>\,E*"X@>.GIQF4KSADJ3@:J
M(9L-? \18 U78,2+=Z+WM'T6?I$@U%07:LGFP?6Q8![,:Q<WM8@S2N<U6% .
MK-A1;!D\ 2W8*D](Z0R?E\4'??!8DI0*@!CWAN4,9+YXEVS"KBC-\\Z\BRLU
M&2 KT[>QF$Y%B4@Z0VOVIN9O*^]?IK+-T*.;$4EGB-IT =E4/80%E6!DC'?W
M BD!O5XUVA9-O^PV=<*"Z &>)=( WGW.-6.AS:.?Z/$AH#!!$^S>*/YCVA\Z
MY9R4Y7,'3(:Y@*!P("J1+-R[I$UYUBK$</T$6LA\X\- 96F__$]/\N9B-7@B
M*/%.!6IFGKE0,#SEX@.[]\]R0(&MR^;LQ 4E2)_0-+K#%AL(X:1^/4IG261]
M/'7IOG7G(5ONDHVY=:0TR?/K^RO,Z2:B2DHX83NKK.9V)LJ?3UH+*!EA&0^,
MQ;^AY,!AVYP+!/F'VPYC-F.KXEX-8X,J\267!UJK7H47GNU]UW$38)V"0HT-
M$![$4/!&.6*Y)X);"G/K^<W&AQD&>^$TP)'))"O/ P0X)0!+<A4>TSN<@L%?
M&<[@Q%,#P^$,2*UTUJ_:-O+G,E.=BM]DR2:R1$H6:HFWF5S$8119UZI!E=\Q
M2-NEC!AWP7&M*-_=NZ<Y';*7'9+G."//$P33PQE?*,Z7$'^:H7Q0?5@H.8QD
M2+[9,$YF**Y.T@X\SS+Z?61ZWJIM0:"V*;<<.@0-462.9+HKG6EB_(@>C@:D
M-![=3MJ-,Q;!7XSW+UHC'KKM[E1.K#XF3\9D.\*TTN\,GI3/\-NAIWTB;$\;
M24_@:E5=>D>^YO@/NL,*J4[8[,F'Q!@K(%V^[,_Q]_X<KFD<N8M(2>.[V&?V
M[E'NISKDJOA#*0=C^_.I6/!$8N]VQ&)PCZV CY0XWNQWNG:UX%1'L'^POUXL
MIW?R6>3F$XZF/#9GT3I<5C1PXA7CKR9B-UV)V(%=-.!F[FL:4%+K^/,U3L]^
MN<]8,MEL3B(_K:7V\(%2K/+O52(5?+=HFPBKI0'=JJ?<)NZ2N+W=1]2VM.8T
M7>-%=$/.%SKN% ^M<MQBRM1@E1<BTP"$K7V*&>%BVJMK07NJZC<*;8KE_9H]
M,I < +5DK0J^N- #82.[X,DN"P^0%B_!'.NL*Y3BB^^<D;7MO%4, \80I7:-
M-9/*#QXN8V3#TCF_>Y6_&I^\G.[U;&YM?7(C05#2>>XA!^MK+0:0WDZ9K_R1
M5(3?E#MC=$4UWT8#Z/NO0:^B5_YHHLX\>EVU%!6 [C UEEV#"L/\=Z&(E,[#
M5(.V>)EI5]>%&9VU,HUI4X%:77.W-9P&+IH--S$/QYO#4]WYZD!8-=(8.[%/
M@@AC'_YHJQ_=J>)7K%K,GF9F$?)XPN9SJ]_.$A 8CS8NHKQ!>\$3X8T1B;\@
M['XNCX0+3^*G')J^;B5_C"BUTF0U>WPJ1S"90>%.,U<L&Q/J&'4479O1#9WR
M[H%/&6O2Q^V(MY?PT;E"]X$#B[O(VY,;:0F2=V+9*8R48JR?C361WF9CL_R/
M'M0T?R.?J 31%S/@;QO$2W@5E.KZLH%L31Y="=ZM=^*UIU.(;RAO:8 W- 56
M&YRZ6-!KH/L0<WG4ZZA7JOY7?K 7-31ORDVH/7]E5YKAP4<Q)L;O,% &NRU9
M[8,6/@&>04>JKB9HO_=/^6 P[2#K/-?]TO'DZHM6?[GO$D%73X<6AE(Y#1=)
ME8;$XB_:^HSB-M9=#E3KPH+BPK PJ"T]\=LWZ_Z<_*1^.J3L=J=@4EUZXL:E
M),8"?M1]^?&,XW[CCTLU\T89^5H9G^R[8H< >7\&HC=9T)5H6D!\ YYA1*#T
ML(N&^)D/\UD_-,Z$I +YDS6X8(Y2J^5["K)'; #D1WH3T7KL:@M^%H49#!;7
MB&Z9K4'[)\+H:5#;PDXR!J5F4C\NQ6>&#@_ZWH81[QU@J.RAA#I+2BY5'S'1
M@14\$<SX+&1:/*+ U32@L2E\I\?C:9M1T: *YM3U6UR%9F%HO -Z6KF3!DAI
M#R<N\+2)^V4BEG[T1E;M>(U<<S>3W8M+9SONLR>+#)95N_/.XEHTPQ(:?UZ2
M9]>!TF0D'A8DVE4ZM:$;H;<M5I?+AP$E/L)+8'B'X0/-!5[TI*TM#?BR5$.O
M^7_0->ZE)!V$KCT!G;J=.]/G?B))AL0NW5C@Q;,HP$<#5"7?#NGW=DN:.EB0
MA4A+$W'UPU.]F^W9_HWVB"[[KRH_4LR2/:,>Q4OT>V5K1!R_P<;5?N0B2V0[
MZX\)LD ?U=9ZT9$21Q\<YZSAU0OXR[8')X>3:,"OWCX:8+U=3@@EZA)^/,8/
M$U^ _DMNX82[VU)]3BG;$=GW^SUN>W@'FXGOV5YGKQY'@TKR?>J,,Z@^ V)2
M\%*:$@UP(-QU4'\Q/357LAT)O$]V:+:)^Z&:92Q+*L%YRW( Y&Q*.IT>;%(A
MZ,F94OH8OA)&D9WXJ4O2![&V()ID@M0AJ%6J3^T_D^^^=W][95)^,-;PD:\X
M8Y6@ .BXCUE$"_FTZ8X$:F-Y-H@&.VF(TLI?W#J+:M+_L"B=[X][W76$!\+$
M-QVM[=]/ _RK(7.(,N(UL/*E4T+4.[(V^OOQL' GL=B,JEF4]N:C*1EGCUMA
M/*D: UW2&:8FT$$>C%+'*U?+53_9-Y_NC!QAK]Z(Q3)B@Q<F$]TI3]ID-NZ-
MIY4.A^'[KC3[[F^?95*7C G-\3_)N*)DQ6;+4W0]EXMU QJ-QKW ,._^.7':
M.UV=KE5PVF'"VOP#?G/N^ ;:S[(=X=$H'_5]3RAZ^@RK]*UH2#=Z6FD-CAJ!
M"U29G]1-UK9B&<OZ/%N6,80-I6="@8OD0B+V)BR^L2DFUU=E)V@B@ORS<"^2
MS@/Z9%W(291<.NM=$*-.+XA4A?%YWGF)..MFMJO]^7[FPYL..<C,SNX;/XZ]
M%?06XYH4(GV'$EF[@ME<.W\Z(]!=^:<KP@D?N@>Y/U2P/>>SKF&X A3GT!E<
M,@SO1"=.K#2@!M5W, AW07?PTT,6@]BD]GK01\%;QRYZRNPF%XJ [T@.&_?*
MXK13W-!6=6.!=W^^<NH_T91[A6OX>_/B5Y'>Q4Q+/5G'KVB\^4(ZBA7O'4/V
MQ^WR@67G\=2&L/*^^Y[!;]PL HFE/@Z:Q[VE#1FA2OH=K)*W&0[+S 3M6'NQ
M^*OHF BH*,R3]-G1NBE[U05_OW_\1K*0RN@,KK0S^C1?ZS#)<Q<>1W3,66_*
M=)LY/S+;<7Q0,.6;V,4S4K@8^#=.A3"E=LVL6(@I/ O69$'F;W+[\NNS:Q^&
MY>[/"I\\^X:>B;A &1I@5>OU/>U-QJ^:5?E!4<]^#M'[(Y"O&7$POGH:D++
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MSK4H"3WD>Y;,9S(L+]:9JA2-I#-*YO;X@L7AS@-SG:KR\+().4'Z3IW1_KE
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M:' /):H4KIBK%7CSW\MP$7Q?^!'J?=G6("KTY^43U7]VO2^IPK"AK4C&7+,
M^T5!UO:U%;MX+]>;$CY)&FV7*UKK5 -R?C LR&P>4FN$%*PMN8-*Z7*D JD>
M3J=. 9(8T'!2V 9R[V'J81?!)$!K.$@J:&C^+-$JI[$_;ZVA:<2L_T*J[*TK
MI7C5^#:?1SMR X'48I$ND)37Q(!)6T3S1 2XH%U8F?3*FM__AK\HLY1JKBZZ
M*GX[PN2\48MO+UU<' 7P#@;;E!T6DCZH@KU0[E.:Z(AT7UZ(.]I*,VWMJYM@
M*G+ACF:0 NF28^96%MI5>O[!T#Z3E8E^_<G<ILKW3R)NG*8K*Q'>.;6 0WR#
MX,4/-L#E^&)K,%\3;<% V5V,I+7HB&2^#'AK5-+',=B^NY6M=8G.N$V@%SBB
M<NE$\0$"2\ 5N^LG)/979YQYA,DY$\LR1&[S%<N@\:D 6[[0=IS'.Y#9E@6<
ML-;RYTF8:=#$/$N3'$$%$:QJCR:!VOD'(Q%N=N%>_;T;BU]J,S4O.RZ]#G]R
M9N=$\!8O Z\"=GM3'U86- >MK:V'G]YK1'"8]TKM33-%V4KPA7 ^],_@C=-A
M>_V%^>?AG8-K.:REL(5(9<%99$20]+JTP(:23Z9]@4Y=!J-E(SFEY\@D#=;F
M"EYJP?.0NY*H.>+!Q"I\(XN@LDHME@]:24RMM2D7-S=4*FI4ENZ?'%MZ*UO/
M@-?FXE'=U!J\CHA"+E3!:53UT5GNIP+N#LD?UJB):%6GWQOK:N#QOR7+$/.$
M]GU858E;C/?RM@$]A'BVA^SB0&H#X\C(^S5J]T:T1MQJ6&[^%I!@NIWI'YL5
M>?J<X0?)[]]\ 4!7;!C)2.5^U,*GECZ>(('OZ,(U+$=Z(<ZVH6/]'5US?YS7
MW6H98=+]U2WRQ*J-^)N/03A\86EQ;QE=%(EU05. #4VLD"#TKI5$C[7(R%:%
M9).2,ZV>K>/MJS_E$O=3Y,7;$D&JA<\ 3AHLPR8/M:R[@@\G:!)UJO$V&$4S
M52EJU?3FI591I0#O/LL=75$V$2H73'?LOR+B/IB@QYPJ2 $V7Q&$\"HX*]*K
M?90MXWJ08O.H/&X\P,BW<6O[HM-HO?'CNQY;*\&[P18O["9^S8<UZ9<3KV+'
M4Q"K]GO;9U>4PWR\R9XP>:6SO;STVGOV;0^V6(*2@WZH7R91$_!3T"3("LO=
MN!"OU*;..&P3^B!0=F[<]L-ZH>C-X>YD]B$-_K0L56ZF8$LJ?7X#7LB:W_&'
M,L'6<=2B65<,L7(?F3D_^0#M@5<BW/+EZ*;5;9Z 57EQB>F/1*QG!:\-<4;!
M.%X395[T\"'F)UO4G;)/XC5L%Q-C3_2@WJ2?[5-Q4H[(2[X+]\L/8^?Y]JZ;
M\^T/=MY4@<ID&N*T\_P.5S,%J!BD +G\9*H#/X%2J4DX"/>7$_A(APLF?^ #
M<F[(=&T,Z'&8?K<H=@VQ$HKCH\XGD!A0E7M'HSXK=&1?T%8;\QMN6^KTPU+$
M<DJ?DXG)KY+V"XWCSY ;=)X#0""#%A?$=-R3 K ZI?,GE 6Z%CGAUEM<&OO2
M+N=!C;V%:;;T@2!J-=[V#+:D@:<F:AN5>1*78 "8FBJH/"QE"D^MW:!UH"-=
MM4 QZNA&D7*)+-B;BZWJ[!B?J U5_1?Y_3X^'V:<7I1W-5WL=#H7Y,S^D0)(
M9A@$63+O(Q)@=JS1F3IM\U.VJ.TXA=6"VB'/ 5WS'=_1RA@Q[7@X;3(0\%KV
M-D/H#5 5&&,P_Q/'.I6/$H'D3W<CSZHJ)UNN[#XK6O7(D.(]4J<?#EH/7SHQ
M2>3YU#(6(("6\.\W<ZL.=-=K,'N<]((3-])]R#!F9A:4$T/.:F+"0MJ0'.5V
M7S"1,7M03DU^D=XI+:*)NNG3S3FVA)E-MWI"\8^)7W5$KCJ<+ 4(\S%*7_0)
MW5!<]=DI]<T</XEFBCA_?X-FR$Z46N/4&GV1O@T00G$<I/*/,!=0Z"=G$U9.
M(?FA=G,7W-6%QY:"*7FX!(/"R'P&:^^E95B;?K59S>#/4+2E 4<+[\>M*,%Q
ME9^"512 YCZ,D6A&2@4["?K@S/$=A;Z#M^<][%@G:ZSD%<=:JI[0WQ[,?\9G
M426>K:U!VL* NR#A\S7+[23CZ8ZIS<CH/34+B(L5Y)ZNR:;QT/>XHNLHL/Q=
M;8S2F3O)LO2.M!@FG 7V4B0*-"6!FBM!N[A((,[TE%MT?>@IN9EB$>LGT)]4
MH'/RMM'SF434 .PF==(>A#$.BJ"*0WLIP"<6! 400"Q/X]Z3WA*A!&GB[1;,
M?+3D$V7_.\MZX\:R4ON\<CL-2OH_19X[B/NJ/H)7P)[ \)+T=9@JU%8&BE40
M?Q/"![-OK:U5;DY=J:N_DA>><#TI*?13J] CX=?TFN>2:8X:\X@">#]4H/G$
M_>$ %M1[L0?AT2$[_;?K(NP>%P@F?#AU;5!S1.%PF>IIW=0YS@0E1@I:@QY)
MS[4DD;)LJ)E%VW>J9Q':.4M+/KO)"JE+EJ'#*^LXI$U_MZIRYA$M39$HWAH1
MOY* -VQ\\0R&,0$%MURD4C*96^-$*1M%A ]*955&>L/U1]. BZB_71+G\R[&
M7'%Z[S1PQPV0,*R-"[RTVO2  CRVGR"GFTY0IP=5:L> -V4*R%]A((:8?9(T
M!7@XM"W?MY?UH7K,^$O<;6Q#@XALQ'FT@89-![NL-NOF\L;VXJ  T6BH!L;G
MFZ^1U<XO5*8,.N/K3;YHL2*9"IZ8/>N;_.1B$W+!R%I7] <#"KJ)8M(@/ XP
M-^Z^URSGL?),9\5E?YU\VK@-:3-/$ZPAH5[ 6G<4L'^(I/:*%5ZD/. ZZ4,-
M@KO/0<+7I0LML2[Q2_/7Z;2+"8YZGG-\3(N$SS+-+W4V_D3KN6J\ $9['O4(
M0]^X".+N";S^H[S:-5SZVT"3EIB)\1F+5)U>D5<Q  ;RSX\$C*@9X"4U X A
M!%X9Y!NC0RF"E4P"!4#E-=G+= Y^+DZ0?A*R;A@R\"KF9[\K9U)K@7>,4H)Z
M\5;@;T+/7C_YU 36IWTW@&54E<:CXN>T;P.+]^_?+$+^87I9L3X1EW8OW-1X
M?2)Y:_K]'S*?PVKS3^NZB?.?9OX";P9BXJU\+F.YRFQG%#6(K8A1"H"7<.\:
M9'2$?28W+SC5S*KBZ\R^?+KB6/:LW/N"WINW7X=HOSPX^VE&^_1B>= =<A]9
M<5C]7- PG*5)'S$;&*LUXM7HM"T=DW:VIXG^.<,U8&GQ'>T-T' \5PH*QKT2
MI#24.T94^;AZA$M5#"C;E%V5%@[PZL@5ARG#K2:J!YE6#E[65GV8<N(W>O?$
M)6M]=?R4L,;8^Y_A!FJZ70!,'80QV#Y4DXE!XCB@)#:NH-*_+V+W_TFI-FJ:
M%$ GDQA#JE;URR/JDTI:1'W3.^IB/SBF3^4'IFVJ+WV-JMR&&ET\S5 O/+&Z
M3&0'+8J%6>#LZS'O)Z+VUM5@-UM:FAM&MK9L8TPW^LQ86HV%WT;L\!W]Q7MM
M41C$ &LS B_AB5228NDY3Q*N0U!]9B$.O./,/T^*KX,?Z3E!J94 Q@ 1;<[:
M!9\B],Q=P+3DTR-R=2^6U]3L5[G%P"X-\[Y/:I#=UNDX<PJ("\TD+))/M6%=
MVBN)@A,M(,OU-,5L&7<V",RU8%"YX,!XVX5AD)TC0_'MQ=EJP5R-:_3!ZEVD
MW)8S1&5249.2/Z:QFT-#NF"\PZ@FX;21^X;V(K]5YYG;-)\+7C]<*OGN@F7%
M59,BU(7)?0T=^J735.*.5W3R-O/-[)9;4@Q:N]OTUHX"V">PJIA]\CCH(7*:
M+$9&@9\D3FTO+'>"6*?>ZX[<:JQJ&7GNX>>T3"OI0!L:P2SPFH_S]8VV POX
M]#3. 8_ V!JU3!"M"FNC_1ZO?O!U,+M1MU5X;R5HH"^ID58(]>[L[ KMKASY
M-(R@XS)/K4X<!UGQNNX7T]O5KS;I*Q[H/[ETU4-XDFX%'-ZQ<5_'2%0H-G%.
MG'B%ZJ]6Y&]'\UV)4Q):V F<5U?=JR81;_>ET4OWV5W>T+6=4+SR_5Q^K;+X
MNX7/RP?J_^7'<1T?!?:_M538=D.9 OBP?+90;E^=F]@;\=["XYX_W7 5+U[]
MEGCDD+FZDL-ZKH843Z:;L@K, X>2&66?>UP*=UL?)$B&!;TS*7,\DH:C9I4%
MP7<^U8Q(GA=X7%,5_CB:(:\TF %EXOBWWY*=8>H! V3^ /T&)6LI/ P%9YMC
MJ]M\F9U"M_OJ]3-1>TGE,Q'534P8>!N(^4(:F $/UL"4W@'2"0+Z$2/?NM6Q
M\=I;H8A"+T\#&K,)(8%A]TM^Q<,;Q1G?S76EAMZ2=+GRM0!JP+:+Y5* 'P)4
MPMIJ2OU4] 5#3O?M=9.?OOY5./[N:Q%7PR%M'>"E<3@G30H%.)5-]8,;KM3\
M2$.=>QC3(&=6'V@RRSJEN3-?WUET\13/N*ZB?:UOKYS_,JT8F4V-E1P\!2.?
MZ"%SO>R!U(P\OFHVK>G$YMHE'"<L5O2,P9KAE[&$7.=4X59LSCS4:4IA(DHF
M)ZI)V>K-IRZ%?F\MI_<B#[:^G02"&&%MAM3,3%"_1 %FY"B OG?J$0=UU@L=
MVE"@ #\G'H[4J$@$ZD'JL1?7]%U\V/LYRWY98'I;0]2B$,DP9YF?Z;AL4KZZ
MFF\C6AA_:^JN^2CV[=/I3G.+:D,MYF?:?.&])VMO%2S&I4!-86W7B*>QC3@;
MC''N JM@@. H\C-B'[YY2J%<R6*XB'O.68LSVU-[0[&+C>&;_\]?P?<]7K-^
M;)(B* 1<Q*C7-O1$DOE\=;3&\F&R*M."[%-_Y;F;3C[XB]IC72_U.0UH+T9?
MBE],XKX]PV5G\[IUG^ZE,4]DD!#>I.W A$>9-<(SD!V]D"(_Y15FO'U>3+12
MBVYYKH'Q\HG:W&)S9]P#LWGS#G\GV<VT.?154;>6N()'B>7V>&AK"S]&54X3
M-<CJ9 V*>,QONM=XN3RU=\7T0AR\W&WH!N=VM3^+81)"TK5BDIYSD/$+Z&Y,
MV3\-YWA>L(3I:NU+NZ=IWJ_-1<Y];N//$1M=>%C'C;6ZB1G@U^>(DW]^V=YF
M16/]ON$-/C F>@6V1S]"G:6XP9@25Z)2P>2W%(W"20W9<Q^3IO,^'9V5T(X!
MOB:V-\@K[Y-K,ZWRUGEPV"DKJ)_$,H39_IM'E>W%A[U+M#W? EW"&DAI9)9Y
M%_@T#X@Q@$?]@X5?0\J-&NF!=]O@QE]51!WXRWUJ-ZCX^Y8_2C@E<MLF_J:H
MQP<C(UH 4 94'KXQO'$N,J'E#)X5'9*#C0PA@M$IO)VN'YU>S\H'L.U4E8@_
M@XAP6;3"3I#/$67J"3IAJ@PH)/,LU\\)<^/4DTW?FC##%R+4( ^LNC@!(Z8!
MAKNCE^2LG,;391>%['Y(U*K):D'S@F5A*(X?%&"%A4I7%R1AJ <0U*;XZF.S
MZO[KQA<G>9-G>2\<,2<PU#C^4^^4,UG<EG0=9W*TK0M_47OMM7C<NW<T6\[.
M?TLH)P3ZKRDPF;E6Y"3\GC.2$)43]O12TV (D>AW ]LA0TS,,T8OX;46_*2_
MZZGXOAQAUA6MDDD/F52[/?"RBY/&1&]XHUI-G8E%^?M<>_?)2:Z:CWKG/!#4
M7 (<48?NQ]Q-S" [A.EO0P<V<#;_-Y')68:R8N.57<$QMBZQ.6> "IV'_L^3
MS\_UQ+5PX^70LMTMDIB$</0K_@V-CZN?9C<MEVF_&;<.*K1-D:G%_PE7Z98A
MT)^C3?BN7TNY6>>U3$J[";XG\7,EA]%</;88[W,O$C+\4<JS_Y3VS_*G*-,\
MC972'!J\T=3EG!--PQ0 9X_7+/5-)6KZ89!M!R]G$G\W[TT)5GW=<?!YVUDL
MD^TC%+@^3+U9.K]^_*]J[P-NX]WIGOC7?>R?I>GI:7C/>1B!_W%@S$<-3CI5
M3^ME:=5DCO.Y/@3.^[;=8-"HCO-XB/RG*^D#D9%[C49O-(HFVR]JG@NYQN93
MLE9,F[1I\$_IL>9##O,Z],RJL9SD^)'].PYI[SZN!@GFN'-GU4Y_^'?N;*?.
M-[3Y2_?Q\%/;5%[9!@MA<1WAT 06IR$MX%F+*IX#LXA.RSUY$$=UQD&.^1LG
M>KS*G)[-W"D]<W/;2ZI.;&M9:&QH19WM1Y-4KDZ>8X/T^P+'H9);(Q^E1$)F
M'^Z?4*"Y@>MR&?JWSE9FL(+CQCTWU[)W%_R8(7/B5JZ VO/ZMA7Q7_]N$I_O
M>*G_KD^>W^H-Q_FO?8(-$JRY)ZH=<YA)+SJ.H#'RDYZ;#OI58WN'L''S^1LI
MMZBTZI$&L20;A/F>B%)3>RJO=JE'N_)!DFOQM"@;[8B* 8VYIP&]4G23 (H"
M\$\6%D=Y2BE95VO/?'+V3IKI+E_C:N,KR_SC%C#]O[E%=?\I^K^[1=Q+\0\
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M+^9K(C=VRU:1&#TUUO:\F;Z/>#F]$2^+7D7BUR&9(VOPC-F3I]F]CK2K\/_
MN]#N\<IQV6Q4;_X6H-K\V5U:7WOJ^VE<8LOGZ0&WMLJ)7SW6;X52<3X;?Z%=
MW+F#J.75:7=7^]W\R!MUGY[L^7O@?*!M>2(81)+7X!D(UH7,I/3TZ5A!)>9>
MQLE9XE<E21O)#N'!>_8-T3#P'8!T->]?EL)+#Z;"^%V_9/Z&2 M[--+M'QG%
M)/C[5N1/RNO*>DU?B  EY3##\7?E$P\)U!H<0N:$M=L4P ;GR3=AF#+DSP88
M$6].#9Y4"L (KO2D (>8&@J E"!STNB1.5A$R$$48(?C;P_!WSJ!=@\HP&LX
M47P;)PVG .K<R(-?L/;$#2LP.4 *MOV5>AEPGP*$==RF ' D,8P"H'2(E_AU
MB"1J%J9F7<9&4FPQ!1@,1Y .H9A\ @^$>AT3E+"#1-W@1**N#(.7MRG >3#>
MD-HY$=2D!(8=GJ8 [144X/$J!=A%N5" (!/B97+7" 58;I\@$Q%X@Y,RQ^B.
MT1VC.T9WC.X8W3&Z8W3'Z([1':,[1G>,[AC=,;IC=,?HCM$=HSM&=XSN&-TQ
MNF-TQ^B.T1VC.T9WC.X8W3&Z8W3'Z([1':,[1G>,[K\.G7EMW=4YBX(?M?AW
M]A9T#KNE%. ?OK/FG"ZS<U)>=VRK$2\M)H=A2(L3,/Q'H5F4-]0"7C)T4!M'
MJT\!H"P4(*?<<^P;$4QMC?S\/F;^B'%"_^]G*P0<$G2"!EN4\)%8VE8*<)9\
MSG=MNEU(!O-&R4#+M<2T9B MG_FW&F:PID,<).G)_)(MA :D,70#Q.ETY+[)
M@PCZ 3_[M/P7AB$\0,,')<4_M6Q=DXS#"?@&C90</I_6$+W-_[0ZK"#!R+O[
M.2$*&DC*A#V99PGZ!F:%1%2?=E,0:"R+:!E3R%I .HU*P[=OXU<8M*P[OHA6
M[I=>!A!OB4:$BVMD85*CJ@!V3>WE5RF1F\,%(P7#_&)*[%46LUU?++9>9:6J
M4@#/B9$W!B==]>[5C,L3RIC6?1&2%7F.8G49M#V23QD_RV:?$GZML8]((_,%
M?8=QP>SQ^_,L1)'Q)HERHOJHC&C+B">23V'FQ<KSV[+8'E%Q<H!%L(I%ORH\
MZ[K4OBLG#1I:Y;#1[X !D=GC_>^/S7?!SC99^7JQGO5-,+UUP4])3M*@\S3;
MK:QIIN1[?M<8N=,W90C2Q=T##]JS93%SGUO.XM\O$)*\\ES(.N\%I)^/3YPZ
M)<.TH_S+1U&6+[5Y+08X=/BSSR2RTWWJN3NK$YA? <SL-$<[+,-AT( Y")U:
M,QXOOM%&M_OMP^,H!W5S"8YZXB%CQVK?1LSJ<W,SY=7EOJLWL-JG0G^UOVY6
MM[ZVVF6>%ZSN08IM.4DTP?\Y_H!K*N A/H$ZP!4U@K<L356L!E_@'%O/)QP&
MVTO?OG0U]7X31\I]HA,IW4L0M@B*),L2Y<>?!LA@9>Z$35I5%-+V%:][VSUJ
M\Q0YWT:[U?M%Q#E.L-1D)?,R[6\7Q&1Q%U) 7=Q7KQO)O[W')T\!&'K=JB$,
M>-O!M,'-L!*"T4#GU_BK]_.?/E8PK':X_FC^MK.Y5T5E\:PIU*++S]Z+0T.M
MJ5?HNNTCHZ0W& VZ$-9R,VKS[^/M"=>)1J3TQ8D )4RB.::B#D,P:$HFZ \3
M[28\!G/[A/M[SKTN.\2Z 9ONDCM!3Y?J<H(&X%52\%88_H["IIX)C(MX$^N%
M&E750%^W.1N]-/.M4O.LJ!:[^U-IW>M+"Y>AKO_UQUP=R['\?R7'1ZH=R['\
M9X2VVS$O!MAC_<=0*<OXQU#Z+P_P8_G?0,0%&OL#U6>7&[)5'#G2TAQ.E>V+
MO3(P=3$/*I6S#W3U!:_.V<.6G/W0<(F7Z7UB0G;5TD-:7+?^QUEG_]U%2.[/
MR[=R OZ!K5@._ALZ,_IO:<^Q_#<38VATDWZQKXYV_9B"7GAM=9A=Y5K/YP];
M/9\^-%F@-^7:E$6/BLJN14Q=#<Y/3VJ\D+ !.UJFS<3WHWVZ6"!HZTI<;-ZC
M3V%)+G;%OZ(#(65"RT<F P[7QR0KX.+C^9-!B/Y=]7R1WK7?8]<+MX8MD$-^
M9*W$&#BW@DQT9J43D_GJE4J"PFM55AQ\+''UAS_FZ[<X/EWC!Z]UZ$P<,!TH
MMV*LG.F.U*O:D5SA6:CL+UNAT+%$FT,L5+^/H(IGU^-UG=9QQ>9 JJ4Z8T5L
M\5DL(9!AI%*'_?4(OX%8]Z#/+2UI$*T#3_"]+@<^-\V^4-W5847O_49S)+)D
M)R@#R]!YI#ADCV:Y,\M3X.)) &^_6]RKJ+I+RB-Z%6VRENJ\#,6[E;\FY] >
M37Q:@WY.C*"R3O.$0KN>O*J"*/")'')-'_7?:D3_!#A:PHG$_7LVCRA;B$SU
MAMDY_ 2CE-RW^O<:B DRF]F@;AB?-@68BUQW.$RM'IR:L(ATQT5$VG@R0*L:
MVR&_S1N:E7#5/XI:D4->3#=?ON6[1+LK86U?0OY&OC:RNS0UY2P,&RP?CJ,
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M6AOP^*0BITQHG*H*FJGYQ+Y\,'K.]D3WK:^";U&=&><60L[0>T O!'7"ZI[
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MEPI1R%/K?$I3;HF>/?C"B$ON@WR("PCZYE43PL0:?(7:Z%E7\\@9"J"-?+"
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MYHN>TKXJ^"(2:BZY=^^N)B'F/_;SW:BE93E3H1USL4?PJ,[[4"SU\TXQ)VD
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MO((^^G]W.F4N5=@M#05.S'I^>.^A-AP"*E=Q@1+]QQB@[M5AVA:T+H*L[,
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M/ZFB[<&F+F$&)^RC]8.FJA2E.X.SY@C)-.#>(B^P4U+FT)IL(]E,D*:F%3)
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M8;".NA>37^F3T4]ZS5F9_,I;LVE@Z)9]]KE%RV*WSZ@R^?N0!&^E %)H;8W
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M&:A7Q :O)DKSRX*;RP.T[H^,EJU^+^ '_3.%73U2MRV3YL,W? <V;,, U3)
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M3,5K1(VX;S56BHVLG>,R?JY9*Q,G_0.^\;GM6HDSPV5>@#]7>/:&X^PYX)@
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M^"RO=IZ15?>MDFS[3^AZ&XT8\Q$]2"KN790_JG8GU>LIDG:-#*)Z9W46/EW
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M4T^*L2>B^I5GL94+9M7<D7G9:*WQ(51.<7%EW_IL69FO/,SJ!=_KYE3MN^N
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M["WGIW3C7)+2690=A?-:/_@4IYE4W\8_D/8;_OEACE.MD*3I+3^ L)P>9VM
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MT984NC5 N6ONWSCG'LVZ :M1MC\4Y:NA II*#74DZ)K8-4V5C#7-!P\Z"%1
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M%<B<,4 12,-#I03$',M>_P'B<_]MV#VRLPX;$;:0+L8H!RXW"9@'UCA7#<V
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MN7E:\?SDXUKUAC=W_?G\0*;FW>I5J:SBNQ]OWYP>QFI!GYODC^ZT6G!^)<9
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M3SRC@8/L<O6[L&!L[P$QIMS;4O2YEA_*&K34VFVJ18V;Q;9],,#*A2/#<,5
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MR_Q>*WH> ]M$0?=+;GA2SI9<1K^EIZ"*QQB=HI4$_G8P;,WX5?BJ9VA^AOK
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MZ-_;4*J1O2_R:4V-B=3HJ8ZRPB\PUDY)+>1=W%/(CUW;*1I9![N.%!@OH\;
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MW.KGXM63[?;5^XO&&NCEMWG2+MCI3RJS53;S#'KL*\P@(WJ IN3@N6%_X6
M^BL),XKM\ $JCS2?N0MV[ <7(R:S!MAO?BOI>5/W?G(*^DR-?-]X(/?2J8R(
M&5BPP9,Z_0W??.LL6O=%C*$5@*+YO#SM&-^" OW[_\_J_P9M#@68^*\ZL&,Q
MU%'^,#EN[H04&HC"(]AS 'OOXE(0[6J*2 9$4[\B0%FWX$HE0)^:6R!T0:X8
MHT X87E.%'X/F D&LFH'FLDBU!?_VLAG,34O4R<:&W91[KW'(2\$:2&8MN#F
M]B\" VDAE>,'X&'D(M<"T4X3G<;R_Q!C)MO@2D6X#01=# WM(Y@!8RLL &83
M8S;"S\M30E$"@&,ON+KTO&P2M83M]MG?./$\D>B:OFGN0%GW;5YR;^(-F019
MT<OR5\EI0KF_FRJ@EV>5( ZZAW]B<,Z8#9!]1J=N%R@%L6'*7-ZN["ZJ(T71
M)+S0WY ^=>FD-K]&_;>TNMK3_I?UN2]DM5[WL(TU$N8([-\7>AS<]\/%MQ.)
MCM:.]'QJU:& ZZS!1#'FYOA2U()PL^5"0^@-LJMI0"=_-:?;B#[+,5Y&Z:=&
M>+"I%8+'3.SG,)C3Y'(I0)_MD2N87NF^YLF@]X532XF?W6>425]9?5N> 9C$
MJ;L5#1V\;G@HR\:%]D-KV]?N@ ;?2]C3.!O:K:L_LS*LI99<^),DVOW6?*7O
MBD\7.DPF"KXHY\7):.7C03 ^<.84M,*AB!S7GB12*&*5A]_Y3&O=X])7S]6(
MS.>3FHIX3HP59;\\@S_>=AZG__E(?T1![V'1];2N]/*!+1<UHR#C#*ON_2NS
MK6*&]AY0+N<4\53ZS7)Z$.TKGTOX;N<XW2?4]P_.>?/N>$4%&*M<T2XY5-R)
M#4&(S\(8O:=X+MA:Y,DO6WP*KKH#56[WT!YR\WW:/[7%KC+7N'1+0:I4%;S>
MABW[>/9YC7<P-4:VP2?0U@N4JE77?A>4%M;53DW]'*2/-#GW$NO057$[#DTZ
M+WJ"R:\Z$7B'+&@38ZXXK^8YEIN'C1]X_EN,D6->-=;U&Z$?"K!,3^0*ZWTE
MCXO%0!]QP"Z3;*50B%YPGQJO. >\UJ%O.;5MHOMA -QP<O ZC%'?#__LWE$;
M/5!K0="QD*%\.X*;(WK* I&H_:'M>9%=5"JZG-F,MFTQ#CN4.^E,FY^4(]=)
MMP;-%;#?0,1.' 4@<L^MZ%GIOH0Y@[;.+?C'&H3.P'PMCL/%?&*=\>Y+=VP^
M1:"?AY[!,<YDIZ1C_'(A^KHA@@R7OJ3/?6%+BS'OFF?J)2[H;,)D.]A8BS&?
M3+X-TEC99[UH<0'G*/8.>M\LA+MX TK7_EHB=[F)XUI>+,3FXZIV$D?"UR&#
M\[Y/R;4C7KC"[Z];"3Q X@_//1^=%Y(M"D5YV;9;X!!-E4&*YB2!4KW$U1;M
M1!4]RHGA6;B)X4<4; *)U4"^]Q+Z]%V,D;F4J$2<.DD'><>!W^%16P$I=C/A
M8!_GK[53DYLE$.TJVMKTFFV"2&"X<<&3B F6<5RA*-M0SKB/[?:)/S%BNZNV
MTSV^M5#T%L4V%1(SO#Q?ECLEIF'M,MV'S,B+>!$T7PI#=%8F3:KQ0Z07/\>Y
MU[4P]FZIT+2_9[ZTKLMKMBY%Z+M9EJ0^0N&'SH4H'TJ=QWKVH,T$V7=Y^55/
MWYV&[BP&]>/UUAQU^(G]LI(:VKHQ!S5L:1$ I<UYA(4M^"TJ53X/82QWE[./
M?S7V-6!#JPVU?-"4JOCCO9.BOAES6IJ,C;6@(\D'?8MV7/<2%C\KGNGO9,K(
M?_2+@MVB)/!4<4^KW64>)?46?J11_UR/2WW\R?Q.AS64;Q]?LT.H'A0UV[;D
MODZGWB H,F>P*G+"3/+DC4V3P@6BVFBJ/%\D6TW8V,-T(14$4:;I)^F-\2U!
M@VED#Y3Y.%=V@Z@?A[JY^U3=,OB*+@W32>O8(ZP@\4+H<U&\4"D['^<-7]9>
M_,H?VJJ7ZBD\[S>NY!EG4?2E=EKC,(WZS<1CR[8*H[:X>OB%^[Z4+HJS)4&Y
M!^TD:I(7>NCCGB^H7_TM&^;L@$X!"^3I!?<P>?XU%M-WO U<QA('"B/NWK];
MGQNM>S%8JI-EG)Y<[EHH^D <+6)1A$U;7B/WR8*.9]3)QV_VTZ'*SA8!WUME
MD%OMH<1<I,6_PX,X&@XWIB>)+LTQ^!#)F&NC%WKH7'@8_>11\I]&8DR'RXSD
M@8B4+_D. 24/E0;G8XMKJ=_,/95H4AJ9*2:D5VBWT0,2=Q/<;<88HM^UNWKZ
MQN)8;S1@FWROGV=U//1DC_E(>/JQ=-N0[J85-]-:[@]AT]]E^F7*)V4TZ0_]
MT NW\;[])%HO/9DTIO?_X54![SP'U"IS5P5<8%U/8UBL']OK[K\T5>&9M\N-
M51M\5B[[:KUXX<:3NP]O?:#^)C<)U2>V&;A\\>Q69U!# VRS*E/\]*MMK%/D
M['HS55<3:C7R[@_%/$E>YQK]KK?N#6L?!C(.<&6Y#,0A<IV#S+!9VGV%PE\[
M6!'DU ONBB,O_!]<NGC)[-:CZ)HW&ZUU/'9QGZIO#6#I1PMPPNUH&[I)E&.L
M4#N0LTKAA^?D&Z%FUIL_&$,?BKI7Z:_T/"&UF[=Q8__JP\/.O"2&[&)B"T7>
M\.* [&K73\8;0[^48U_,+G>Q#FZV<U_\<"ME;^)J^9NF_0O=Z^'^9Y"T#[1R
M%+NN?)M%2A.#*LN;MK7-D3I9]*2FY4(5]^/-Q2K#U@J;\&W'E_4_.&Q<PNL3
M8U0)M?0YK7&LP'Q[ (!%$A(;#5D(-VA18ZQFIB=ELG_RX'ZHZM#D*<ZF30<0
M*&"+>^BR5PF^&,=YU7M29T\N+#\+"M#^B5@\_4/25))\H\9=AX%-5(,^QZ7'
M\1'KK9W&%]1_G?[8+-7GNYYM5\&BK367>Z)[<Z?3Y=$C$_9R[!]S6WE&[/G#
M)1\ZD,UOQ^+?/#JN.$6^%EOXWOB QZC4<ZEYU=XROVD[>JU%>+F2Z"51<9QX
MD'VAS$#S98MJ5EK/BU0-51)IX= "[MZAIT8"_ H&O2>K7_]QZ;J7:H6\I%>V
MW?N6NF]J* @[8ZTB(G3)3K_@/EV8T1=4J!*/X2>@RU/O#LH^(&Q$]Q";B+O;
MH(^3 7N69J6>.E)1-;W!^8_H E73_FAGHK7+E+D7E->792-94C8VW/'*^^:?
M'8Y!KQBY.1<ASII)@@VQB2I3('-W4*'*DVR#1OLRA/0-&N4)R:/=#XEV[>_B
MKC_*VC/1KIKTU'3XI>71H.^'633R2WFXRQ.57M)/)WMNLD$.LF\1?A)WM*TQ
MC:@9&^"<-3VYX>3/U/RIV8@_."<.&Y-%G]]>@!UH87\P,:,ZN0,WI/X/]MX[
MJJFNZQ>-%16!QX(@"E'!BH!*4RG11Q$!$9%>H]*)@(!(@)"MHB @1$! :5&*
M2(TTZ01ID1HZTGMO"8$04G;.QO?[OK><[WYGG#'NN>?>>YX_]AA[)'NNO?::
M<\\U?WO-]9MSJ'K$2)A"GAE8%Z,?'G[?]Q%XNXC4(,'+8#=TN8-[KHPSV"84
M:<0K<'>,S'XT:^QD<U9"=(I#WOGP@MR&"*TGORX;/ZO-+_VCR,W]M83/="7R
M=0FP,$LY4C6TU^P5RH5_]KG%X+EWN5I-T?M?O!U-=C@B^L1^6_O\RC"XJ]&Q
M&_E'!:)_6+0O4W:66CQB'4BXB6=0D+0@EB?=AI.MO)MEXH ]5D&YUB6NO7_6
M*3NI2RI*2*E:>.)>=F72CL?6_N/O)">7=S!\$8^X,,:9Z""[KH99^%Y0ZH=$
MB7/JZ7K4H=2R.P_"R T!7D5[RB_*81FP9<AC9Q\X#^3X%V4^L>YZNH8DQ FL
M[*RPY7R1*V401W!<& _6ZKMDUM6QQ]FRO"DM/S;JX9.6\US8CJ-FN#ZM>PQ?
ME@KCT)B*3DU,5(Y87E:]8]7-=CE&6$=+\;'1Z[+.L+B<M[!+C?C/6&6PN019
M*]"+-&&H?5$7+=LWTV9B7V?U^B7*1L_1^$4EG\C.8[[M0_E;W.E**XC1"%#
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M0.0.TR"[T6F>DUQ]YB2@7509K5,0+:I8F0K_\)4X>GAS1_8!*\@>ZD%!Q-P
M\6]2R-_WV49+".((;VI.?5-S.'#;;[+W72TX+NQ:+)R]4X>2Q#'#_]L FX%
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MO;FB698:(X!NS:R')W0Y]FB55Y!Z%Y:D93L: F,1[PAM9DYB54U30W5]V^+
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M=Z!*.Y-_9Y;O)O\L*$>D1,S#5P]50!V-YL)$"&OA<-HL!U+SWSCG$+?.$%H
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M8EP,;A]]64JJ4Q)760%H]N9S(C'NKKB+3^?-QSD>W:[X=?U5@FWT]@<]U7Z
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M#B<&G=G6J@J'7A$1%R;#A;,#]27;#@*%[!=?N# "!"%:#4L<_[<5OC^3F)2
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M%5+#DN,$@N=1$2DR$5F?$+M?#_FPS3(%P>\:S"C.4I^)@>!Y;_/Y:AG691'
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MG4)-1N-UZK/"4<_(_!!3VMU+SR58<DVQ.1V7E;FPM?GD0L;L>#^R> Q578=
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MM<W\))&DLV7PZ.G S)XX+,T-F+EFF%)8*\ S]$!M+%XT\/(>E\2]P-;>K/'
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M_ 'K%;KZ^ZH"2U^$F%S2J9%KB1#=2YE@;2Y_S:*PH8T'8V/NH0.\)SU_VOC
M>#0,@N#RAE^N_]Y[_&.Y+1Y:$)XZ<)U+'4(/&GA"W>WI7;Y>P$5UA4W?JOYI
MGUE/&B_LCO5T=WV$RK$:WYW9+%3O?9U^NJ'=X\;5D7Y^,YIVM_LH57#DT06G
MN/Y!W\F3]N1]8.N)<M*Q>I$B6WA^,S?X%BP'-$H_\0LKDA^_IF0<- *?%<=*
M-*U\H]_%1B?_$DQII6<B*NTF[LXA/\BH;"C=:ACNG1X)7RG]]::@'-N5Q,H
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MT^D[*=O5A50W$K@ =-BO1TBJ?FAS_M>%TZ0?4P]+K_)TR$A-+P8;*CS1D6M
MEX"I_#;7B *YKX)YH,8#F-!Z&V=7CT\+@F42>AZ?3[44[+L<_" YWDEQO2,V
MA/,<XC-5A1AO0EJC7" EM9IS'N8F/\IS]G7EG[I?]27,,7K&_OG3]5>SW,(F
M :2G]$.\!&S3&&+9F2#84F*93[T6-Z+77Y$L&T\[OZU2=B#S9+#SH<9#Z==*
M 7O_=O:%\!9YP 7"7R]8X&?2,AP'F3]>J*7WL]!"85S8OOTTM#WY+FO4$2$'
M!]$0/>A)XCB=@P%,IZY(>;A/#Q?D^<FT#H,7CBG["B(U/Y;)=^5+/G ,*V.3
MG/I!7_/:V:\E6TIZ2AC7'T2=\ LW[K.>ZAD3T[TUA+2O"ETY+6"C<+7Q26_:
MTVYOSKQ15(K2@;H7A8?M_&KY>,Y@JGUHNVT33]-F^%F(N=2C)MOOB?!6+)=?
M,VZMI?$Q S@"9?6I\O6U2/UCA%?QZ@M'C)6]WP=A= 2_JF2I%B_N_>P0>+J:
M/#B"EJSRNMI7 'OF\OKXS&*,"=Y]G@&,LG\ED%*W0T@+Q-[K=TP.^:'(6.,^
M2>TK6%VW$/4WK5LQAF^7'U$L-T\@3M"RJ2H,X! [_=!3 AQ/^\9/P$0ISX^,
MQ'THU?'S&.OR?!2I45WME5X'*DL#@DHI>J<,*5K4&X; Q>JP+>W1:?OEN%\H
M-080<J:;V>QR2)0$--6!Z#!E9Z*O[%/WG %@8&ID]>U5XA:R&3DJB(_)?JIV
M9<1:EGP'-=/9_0SMK)U=TY5,/JO)4FQ!/]A,<)J9EE^.QXW;/N+-=1MK-L*+
MZ:NB3"2[!#MY$+5-'+C#/%<X5K1!MRQ^,KNM6%6>.5I9V(K@[,!U-TZI4A']
M27V:+2=/QIGL=62_)POT&@'1*B=N:],X)=E/-?VDIVZC.17OD\0K6Q#=;G40
MF Z%Z[-GLJ$.DF X-,D)39*1?WT/I<L62KQM5%O3O_I+W;38P6_UM/8DIW_?
MM<P ^C9X[?#S('9FY"/U1_RV!.FC)( <E;O:^[G^.7Q$8+>&Z$,Q]21)FC0*
M.7!M*Q.CIWGBVRT&J^"?KJ?!RB$!L$8+#>M+B%$94T)WB7NT<^M8T:O8^\Z'
MDE)\CWZ</15C<F2%7")VM5AW.X06XUG$5"Y9S:3YC8B]%]Z3[4=C\1OW^^CN
M!N-UNW/VB>WI2X]4I3V+@"!GBNJHP2=Z+^RPW,F3F=4$5!*?PN:YJE@6\B'J
M#E'1Z'>A>_1WXUQRQ\FH:_SI%A3>9F?Z/D62Q1BL!-GB#HX$E4&:Y<R'+:>,
M;,6YSBT([/"G#_W!+?)%NI,K=+1Q7@]:0U$AZ:'48(TW4!>HD+!CL,,DG7']
ML@;3=<, N?ZNEYI"'-E?)&/2'_C<UP9E/_OGHBDF=]!!RGU=B6M/1ED[X4A-
M\IUO9UB3&<#+IAGZ\QT(D@$<-:!*"8(VV6MI,%+*PN<,;F?Z44XXF74R&$TU
M!A'>WX7UB2]M,0"\^Z>LYZH(TO7SX'D>;S(#(%Z"-=WW8@#:@<@1!O"Z."42
M^ 7#7?C"C-LU1Y880,MW!G P#$-C645#Z%*U;GMR]^3NR=V3NR=W3^Z>W#VY
M>W+WY.[)W9.[)W=/[I[</;E[<O?D[LG=D_L_3:X2VO[)2*+7]>^79&>DE!?/
M!?S="]99VURR(H%-GG &L,Z62D>),  =ZX6"9!*, 9QP12_AT)L"Q2G/#YW)
M^O^@!2%*+PM/3TJ!CRU"N+9@_%3UH<I.&WBEE1_,RJ$4_6&HQ"G$.^&"$>]7
M@.WA@THZ&QT3+$20M>,DRD?VY,SP@%Q2-(L2&N8BY+N7K8T*KXK)XIM:^5X)
M'2ZH8UU[8DB6B@2F@U6H/ 3X"A>!O-&(4BH)I!W']=^?_?8@4?CF3\EHS.3]
M^&6=$R$'!?!@'MAT*NP0]<!^<T4WE"+1(ASW5#)8;*1R5[*_<;*.;>QTM-A3
MZGDA$)X-59CU_&1Y>:A)1<CP,,=*T3V]R#/WM5\?/].4_WD: (!#OX+/0L\2
M<MO@;':DVVTI<JBZ3-OIAHK= Y9!(P:WA$5]'$]$I;LSGZ(A<9460Y40+\JT
M(R$@1.<6RXJ#YC,& ]3[!:F=-L+O[COROM21#4V[-'5?^/*I!D2+&E=2Y#,N
M$[W!K(W-E6O#-NKOR_1)'Z_$U(@I?(SL8SXP?-N=EJ1QE'*.9'*+P !"+&ZZ
MV^IO(5>E!E?W#R@F'"IXF[\O_S-@K_G$\%<U70'*28!A@M@&KA/M$)+]EG?E
M?GW(L^H:'AGS;GIK[N[?]RJZ$2 \?JS +8-F/MRSD0&4]89!U6<\U-O4IHKP
MH CQL_TS+L^*3%K'PL?&C?5Q]1%#?)<>7#B<>CB<5<ZN0X^?9=H74@H/]?".
M]EEK&F, ;X)!EDO]%>2J-SC-NZ,_[*XV\TB_,ZU/NO_<^JAP4TS W%"P"%61
M@&X"L?\@V322E5"A&:/[3I97L0M+RW:U)/I(QW492N<5I__79XCO80__J_"_
MP]<(>]C#_X'XCZ2*[&$/>_B?Y';FH(I$5EUB<#7>0\*HGJ+' %ZM)9D,9HU9
M="1GQ#QF"R:,*CRYW&-PTSWKO]Q8[&$/_ZOQ/^J@9'">XYSX!NQK]$.34$3Y
M%KW2'X=E(45B*0:V<6T_5QP'.RN;=)P<KPB;?JSBN')A<LZ^!%GK_A,TWKP-
MJJ054-5SEXZ+D>?!O)O[):X-?DA^D*SBN7Y:YELT5N'+3Z%T#JGGJCQ <"OL
MH(87'A:CIN9GCFT>43.(/%GYO3+Z<&7.=B(W//?J<>&WK_"&8H26$-LR[AD$
MC!;_D'H[A\I"Z/DPXW%MQY)X(WTG47#L5<;JQET-E?@6L62ZT[>LZ;@G%X?1
M6@S  3V>:D%+#I;QZ\4A5T0\_%V1;M;UM[%^*196*5/>Y=75.H\EVOVZ+C1-
MN?$%>W1QXYNWW$T&Y;P#.=V71-Y[/BRVM\JHJ7YK*%I:<L#64E3AK<[^QSH9
MG/_Z C\K<ENU1U83_+%EXF4S;4Z07>[$3;8P@2X&T/1U@ ',18_0UM'4.R!"
MR24&L#OCS0"@2 8@H"VFM,>SQ[/'L\>SQ[/'L\>SQ[/'L\>SQ[/'L\>SQ[/'
ML\>SQ[/'L\>SQ[/'L\>SQ[/'\W\%C^>/*:E,5X&6^R%758!)EWT!_R*'\Y^A
MX?3['$O[S]F>-8@_9X-^_GN)H_^ 8MT;I.1/BR"!2BP0YE(9)&]8-FRD>-B8
MJZ6:%YJ-;!_&7ER@M!2CZ@5G!)>3'(GR^.)D(O@*$?U:"T35'B@4O!YN]MWQ
M]73BCZO]_K=MOD65%<])NYX0/1SZ0EO<>,9S=*D15*&$6%'-(;7U<Z1C6CF]
M[8N6]P4IW.E[-KQA2E[9U?\Y__7>M@0K_: I#3W# '[XFO=5IBX5!$H-5HI)
M&]8?OOYV3./BAK!FG)441H,WYJ*M8#C, 29.O3)(EYF'\&J==G?':=JW*&],
M&62[)I+=_6).#Q3&?L@1&;O\.JKI.Z;:]]W<Y8<\11I'IS]PXM O-]&'2<[7
M0PWZGK7K->1$?U$_I=.C*AEG^$^_%(#D21=380!W=O#L-#H#6%Y:[@T%<S$
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M@HD<Z J 4J!Q4*#>T"0-G=:T"+PD<I GR1=.\T@L!5RXOO*_%6E8:5@MEU)
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MK)$O_E(L8(\M('&\[LLTZ3LFRX6-9*M5XR3?^DAX?!R6P*]%K/YP;+HI\,6
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M909&?2%\GQ11@T=1^BOW*O8@%;O;144D![QP >XF]OE'VO)>%E8SB[7&2*Y
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M@IODDF:'TLSMPFN^W7W-$Y%N /.<[7/ZMC50@)W"U\?TJ@2N8M0WL?QD>8F
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M5"9\O5'V#*0!'4'UGL!YC2XB!R1&>Q<#9^C'">?YM*W&-+GBG!T_-X:.:DX
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MB4)'7L&_R^>YI243_"M&B;#(T9Z5R'8>\E"CR=C/\RHZNR:0=-_4'!Q!*X^
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M$U4C9E:X7U.B/M<O&(_&K<WXYOT%9/+W][[VFH;36=^VO$>.^,H_Y?#F(1P
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M?5;S/_H21:W)K]96G(P:\:J"O[6/0M&#SUT>#.PX,$4T.)-^A&>M(0K+MWX
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MV+SE%T'4ZIT\ZO/CST)1NL3E8',6?=,7RC,' )):.0&-1_'5HA)A_'1#PJB
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MMQ4_[IL]6C1'1_MP_RN$.-5,J=0_@^0EN+5G$R(&")2GSE.(P@_%6^B#ML&
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MA9^51Y42FOY.LIAO2K@1V,]]:< _3'EHL):!^W2!E<^-N@PF:YX8$.=O?,D
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M"'J%$4BMALE-_0XHM)N\*YK+-51K$^&STR70TYG_V'RJUFF1W7^4@?W=",*
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MBC/V/$TRAOG-D.76N5++V<FBRD4=.>2XR$C^LA>U%_TZID-"*C3<EUJ-'WW
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MQWAMO*:@OX%L]W3C@CHSJC"F/&ENTHGW94-WB]5[GR /6J$EJ-]FEL-7<'$
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MRARN2,?=_#T2:25YS;<F,X!X\:>5Y,&PQ/HGA^""27;%NY(2/83I_Y7(UE^
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MSS#+UMQV[AZWM&%$*N##K@1-M";!R)\/9X9A/"RNV9O_OC]M-OPNF$Z.T3M
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M)*'$VE=<!A@YQ\YC"I[43S+)T356CI>Q\V^2+\5NDM/D XLJ!J&.DTF<L+X
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M!GAU:X-=29.@>H\^O<68)P2V\'<T2'BJG.6^WX=LTM'Y;RVD%]F/L)=*Z F
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M"0+H;X.@2SRUI"8H=J_RQ4__?$+O4['R5QG]V;W',:CA>W>6NB >D("*.4C
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MO@5C#(X6WP 1 NO*AS7%B[]SY3#_&#@KN RVIJ&N22NW=&U9CBH<J5,<<9]
M:R^=X@C<->]'0G_(U87#KB54$(_<?B\B<<9K1E.H7:+C("@MD;GNH<0-^4
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M4'4 X/57<5VZ:22HUV;]W'W.S69:MLJ(1[PRGN3^<6%&V_D"<$?1FZL4$0
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M[D5 ]*KX^ZTG0H@>U8>N3,^I5,HPT %+X!"O++8F6J:U_T],Y*$$VH>\LK)
M^S-3>2)O/O>U ,KKB(Z%C9+P4S[$4Q(P&F[=7H</\H R3B;(ZA0%>98*JMO#
M])HHJ5(48\<;&&Z5IQLYB%\#G$<H<06L\_VX "#=85 *<\L+@&W"4!3I.+A
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M[CQ\/8A'C;1T:A+GLTG*6[TUJH(3&:*T@OR]=Y_/,9/%$ 3Q?/U\#"$4.RI
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M/X&Y %@L=-V&<& ]8M!&>U#&_84[I='I-K0EEB:3S),C7+$IYBF%@A]YYS;
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M9W(9@U-!33T!TITL@1^.O$?:2I/J6W#+V=N_^=YQ6G/?_T)ZZ,L7 $M;K0P
MG < .OOJ_^O*=A#^5UUK2PC>?%<-95^7WN^E*=RQRC8:C51N9*5#P P=:]/9
M+R5_B3QU@UD*4]=,Y7$B8(AF6"B;.QD!(OI*Q*P;\NRD%=-"G!@2C!_QIQ?+
M.2H#T=(1>JI[I6!\-54*-%)*4K-]VFPO83GV8Z*YMRXD)Q1Q670VN8>%4H;.
M+0?2CE,A&DICO$Q>7H)V;T YK!7?X,W8UW_;3&R6^L[;V1N)^,T,G'5;M1M4
M]1:/Y(CJZB*&ZR'Y:7R^75 Q\)K1#].J!\%9-UG=N-KE)23F86.P3*L]/_(H
M^)+$0EA-$#-7";M]J;ZEY<*0]/GRY^'L N$\=,MHTDU(9#X3N6P3LQQ*M#(9
MW]RFZI1J%!:O*W>G#7JKZ?/$"[#S'@&3F3^#4U3H1+&;HQ1#E"R81D!#0--N
M*(<:ALLSQS+;UUNA^)::%5?(3=FVJD>,00XJQ@RL4\><F(ZB\Q/3D!5?A@SM
M>XRK9XH6SR7RYRAF/VPBKU\__:)WB^?=E3-Q!G)9LB:?$L#@O;KCL.OY$\'0
MSG?,-VD," \'/K),Y,0&UXP)<I]%_OS*@O'+NL&S$=:15^LBS^M$A.>:")D)
M&YVM+#I15:7"K'>1]T\(0="6=JJ9$FP'>JS\5V/19[%/1EHQ_;>^&PT;_'+V
M%_:G5=QQ2F<,3Z$JD*.HET G I37!&C,L!O=W-5X<OV*ZX-;EPHH?TL0"A0G
MVJ=?X=-9X7RD3&K3+#1F9W!W4K'QY_!+]+YDTNS<7]& @*KQIO[L"R-X /V:
MT"_(C!N!]HY41@@;?MI8:=$493K=Z#QFG&DW6*:W,S;[;O;Z^,J'D^,? 'I[
MI6YX)(X/E"'\W,&RS<[S_;H?$V9T\UUHVUQ)$D?DW6*I./LOC2<Y@SDJ"I;:
M*OZS8!$K!DY3[H 0O$RR+A,AE6?]))MYW_X1X-1D_2G-*W:%G]N96OLGFAM6
M97[%*Y0-"($0W9;-.:B:AQCJ[:5%5GOUTK)"%F^3F;,FFK-]_MS?I 4X?^M+
MV:48/F+N<T0Y@MPN%'V4!^A>CDSO4^^(=1 >WVYTJ4_KL;7W\-D;]'!)A;<;
M)!)9Z02&F<[$P9K)PMWGJ?I@Z!*:9=Z; FLN^>9>YR,H[!I?=($JU *=H>\;
M!Y?W[H&>%?:KQ(W774XA+=\/7W\-R__;I )[0-^-QI<NUD]'M-^DJ*_CI+/-
MQ]HO+$$A9JX!ASY:EO1"'X]!#4]2 ;<@5T9S/6!T&6%,/0<>DN:6SYIZXWW_
M:@!:ZI,$\?5M5BT& L*SJC&GS<E.@MMV^T1>BM*Q^1W69!>!/0Y3>%)>8FZ\
MFH)T0'/*WO+KCSI$5\<HG9O_)2QP(IC/)NY!4O>4Z\=HNE26R5V=?ZAG_'F'
MRHH7Y__TX?\*!A@9WLS_MV#@0S\STWIRN!WX1?BOJ2%MD:^_V8SC!WI_.'>D
MJ!]^22KY+4/_Y/N')8/.(\!"KN)[%*),2*PB9RN^;/UFD8'H2GOPZ>3)R^6.
MD [U)4QCV>84VF.;Y><"\\26]PZ&I:?<Z,W"NE^J"E7MWG,#K^B@,X[$E]:O
MV!F\VV3IB.F-,<W.4U\D-;.FL[X_MV*5BHY1.1]R"W)SP\&>(@5J]B+8T6X=
MS,C;?1I?/"M_^IF51KOS[MOV^9VUA=U)^ZU?JZ&=A(\P\*$*@VQX3 1..-:0
M%)32I%QEPMJ<T68>_+!R_TK&!?E.9X)_XZ.@""WLQ7\I!CZ1S1,:T S(X!O3
MC8=7YXQ'&T";T,J-CPQ^EZ+>W$=_E#P-^EL?._ 7*O<XU>P0XUZ$K+\]-J6?
M7-GC<MK0\*&]4XCEI2*LK#!6K "*LDKYN/S%W_2PYAXI<(7LR^HIQNIM?KWQ
MP3.&]TWMIQY>?O(NT<"/;M:$_IZ$H/H\507,(V"2'$Z-Z]H3V"Q%W?0GG!89
M)_138EFKBD]:WF*6[>0P4O^^V!#\EUP)PMVVA5)W@VA2+:3) =]O'I;I9[\?
MA)!L:5H%[*I[NH>O=.$B^>I@V3*;V)P=F+B$X/$\N[1_)]HM5*"@(W]&//9A
MM^*9(2M!!O:$ N0TE4=GSVL$Q@^F$K #2K&M!M@8]4.9/AN44(Z[GT*[:M$G
M5G^5<_3(0&9CZ/GL'T-R.\[G'("!QW^V]\9&ELBI43@HTJ+_QS0JY/6<]V[*
MA>3/ Z)DMO8R4@&DT'/YFV>?$%,O!/R'E49']H[!O%D[0/2LTCZ-[]HB5Q-L
M7VZ]SB*DB7!8]XDXE09U?ZL_-G]'L.PUE1MT6X((@Y%F.9;)7CY2%BZ6S[XS
M)C_2E_]LH;]EC!4X? -W$E::Y>Z#"8!1A%0^>R3]DENLA6'NDH[ TS7)BXFO
M3<4(+2>&(R$F N<='P*Z1\ >[OCW!5)%R;'='3S(V)YPX;<DIH2&4);DJ],W
M1I8I"FUJ-QOR[=XJ2GR=\VLYY[(.N1&\8\X*[B_%=IK/>/9#7!2+ELT@MT<;
M[:^;%'-^GE*9T^5_=.%94FW,/0G6E9</F;1J-HQ!?C)TX+&L.U0P_*PU,O<B
M03' G&T-.E/K$?>>\7NI8;#A^JBAA"6E^MVIV]NU_<_Z:_LKX@ID*Y( )GU&
M0/O?BV('R.C$'00 NMTB\\<UZG@+7QDO5/VV:-]BO'1Q'F.'!RY(1J@88Y.J
M.O"U4+HMZ@,UJ]C>O0.GJV<1'*9EX@VK%X(0JD.GQC'R^2$W$P!*5KO/\,#L
M2BPQ^ WR[ %EB+15@O^@7JTX4V3!,7\Q1%)3_[QP[J-AKQ 9 3R[_T:35=-!
MYBO^H(R!0$\_H4%64DM FH#+7>N'%QDXC*J1_$2Z8^XS@J[?3@I?:<C!%1),
MFQVJFJ>\2%'$U;L#T^_V"^CW/ YS=E(9W</%R8A$71WW8+)P7VOC7DG5H@=G
M26]%NMVG>T].?:M3?]JO\4^_?WXG4BS3A12Z]W<L>!0X8('I;56*"(!P(!47
MG(H_= MP[7F."1@6W./W+J4^9'J%!!(. >PSW;!C2-@+(LC!O:W#";JA-<C*
M7IS<9+&[S*3P#>,KNM[&A'BGV;1^X'19$""HH ^U^BDF/D:U*++Q.) N<:]R
MMXK_,8>POE[?I0)=,KIE$=NB_@/1:+5)^>_6B8OX4+*(53#G8=&U]F=NF]GE
MIQ+,2TTL!RR"1#=6X%]C.V'RAZE'@,>P )5^(M"D<9O!4TB9;!Z[#8UX(FV=
M*S=J%R.+?WC-N!.8/.#6AY[Z>TUP!#SP-D608K"DRP-F4IA>2.R87HZM??-V
M25TR]6W[[GG-K6&*M&+[] A:C'JJ&EG9=P2<U+4@>%XL1R!]^]*& ]94Q,U4
MEJ9"0YL9XQ@8TX3I)8F=#&D.[KX4.J3M **!KXV<L23):>=IDUB61G@O'6S*
M?/.L=92Y./,^EW:!_/GXW[QRXG]2)Q\'Y;D7?;7]^M6FQ\7%6ZB/L;']OM:2
M@8"%!?UI $^GS_?O*FS5-J?G*<(V9#VG*K%51_BNSTN3_DMG[JN"5I_1;Z'$
M!DSC$1"UNTU,U%$0[K=1F*%<SW.U'?0T$7@A9=:;$7%:$QY"A]?BH=L^ @0D
MIPM!\^4+*(6@*3'I5,/V,,65^W=9@R_QGV^:8K1EYX]D5B<XJ)%LPV<ZF&@G
MFHI$LG&GIF3JR9!X0HROW%!\P!_G%*8NAL+6!U'G5E>&#%41-P/QO^16CX"O
M4=KPKO=&7;ZTYDZ:])2N^A'@16A+PR^__245*_:U@'5X3F;/#_1=1LS$]F=E
M+XB,[D2/J)E67[Z*:ZQ/.3E>',F7QNIRA_?2#;ESA.=I:[?"^SM$84)@+(&_
MIX/N 88C0.\8Z<%CY;VV&D E?B*;I.6'NDW#'JU;99E,@+]#(ODW/JR,> H_
M28JI76)#&) F>PMW=;SYKL387U)?<0RY:UUE\,ZQ@*]3D%Z<JD Q0W?)M>N0
MI@F'P[V02.VFQD)D3W=<8$!SRWN5^#$.9R?NZ(6,<W9822X-O-M#X/@-?3IB
M8><.4] >WI"]/!)OV:P:FR'9L-%=X P78=KYHZ*V5+=S#%':G,D5;0+CI%J3
M%ONW8ULUDZC_A.?$)+_IEC*\I=E[! SP1(3-<*S<#>6TF^XRY[8-'X76^T;M
M8GG<@UJ?PLZ-.&;<?ML:[1SIBNS,O,H96=+,H3R20$8PT+JTASL1 AX'F./4
MGQA\!$"H\,J.W&!"LJVQF<<'N!/?'R=G<<>34KGTC"_\]$6,-H-)C3BN8ZO7
M1[M[<QLRHI3W0H5_\S@S+V5M'I9JD>=\7SZLI'W8QQ9WN**!#0R;VF*<MO0;
MESV]?]K=*CR$.+GDY+/XKS<#$:=D&>J&7GA!,_1^V_-W+48%04_)!\:G% 4N
M0;D]]S&SVJMQ@8P&+1.*&M$,%4!M?\()20^-UTF/3&1&_J_&EG;5O<+#6IQ8
M^,=9T?<#B35;BH&)/[_M$"'FJ6%?IA9.?>Q^?<+P;MQV4KY<PF'LL:>:)QP!
M#<_S5<ANR7\WU3&[/=EBQ%#/IO&<*3%?%)QO(ZQ\.$\CR99!SU$FZ(@8L1KJ
MY3(J)WEW]>FV[76R7DUTJ%_I?+'G&=.GT;.Z<B?*Y('O8HW?$1SMIS%-,E$T
M!O,W-J*7"3]>CX!%#HTI]O%:E%.A#^Q.L)S)<9%O6773PI:41BN>118;I&O>
M^DL"=#D\.]'W7A:/TX Y\"KA)1;%6[6>SY?K)W-BZM>=1.RA\GE: -T0[1NT
MOJ.G0R#\$T[;LP/RX,!L(&;'M-K<!-?4D,)4G\6<<^6*"_#TT9/3[,P^3Y_8
M0S>SR8,$; ). (1VTD3!J$(PHS=')G;3J\:+N,TSWW;96\B8P"X8(?NHDT/N
M[6$!C-XZ?-2!*[;[\5Y'Y9H#?_H]Q1*GH@_/<*]Y(M-,Y.0X.>ZU5.!K63[T
M0[K1C?Q4KGT#4 =O@I-!L4ZI5W/W.7#<KLPUS>W0&4H1^3#,0F2M*V>,^&C)
MT@R\>@89_T3]<(A5$S7:$SS$MJM2#$";L=MX+,^\,(37>NX$QP=0U3G@<P7N
MT1$P;FV=W[B_VID:=XMJ#2K@?07G]15J K\)3=_(X?V9;L)5_X38\BKT_CO,
M;"Z^>I7(2VI:)<SJ1:=D5)ER3JC;EKB[UJ?\PZ4_1::+S4P@L@X57I19I133
MCZ-TEL+D^EK%LJL>[),\A'S>>&5G67&TR.G*%V9.3]S+_HV5/\RD03<Z6%#\
M2QA6CSWI ;-ZLD^M1O1+"^H7C="LENBWQ<0_I6D/O\(5_2)E5S>/ (H"%7Z8
MJZOC78HT,DVK*8K]F&$U4:+)7_=&)^$EA+GX=]WY-_E!JSF[K?\7'V(FK_8E
MV_8O"EOAAY_X'@%UNRQZNAX+LF01ORIL\>R[$\)(WB?FC69YG2UG)!B;:L4A
M?@W-?$%O.[&2KR7O0%2S@SK[[Z9*'F1,1>BFF(MYYB"(_I HK%(BTLF:Y.3Q
M.+#R2H04L1%O&BG"]ME&+HY]S%CXE,#'FM"]X,.<!@RS W*P?T%AQ!M+.P/6
M.TSX^F*QDSYB<K>#96<O<E[XM<RWQ-T@5L:DH\]",4+W*9$S]L+_=N];^2[9
MIK+9!1U.E;B?530OPS!V+"<<G(Z T85!\?N;QVF;D662:N2WQ"9,V(M=@M#_
MJ5OS6;@"]<[Z8Z7\.KDB*>MS[T-ZYWUL$?S!XE.<\&$]W)6(Z#DPK"WST)@M
M/OO[RA11VC8QH#4I@R?AI[&LL?-]E:"VE,95."<<__((8*6I(MNLR6Z]HKY]
M,!DR[,T9M_>::[ZB=4Z</0Q7<V^I"9P6]ELWD<SYU?%UFE"6T.&D-/N[%T._
M.KDZC1,#LPV.[9_G5[X3LL1Z:+>?SZPM<X\T=]^+%0\XH;O.H]T5+G=I9[VA
MJ*/,A^*7L!"[0;ZX[,^\Q72)IFX9/2KI#KK<[P26H^T.,%3>>D)F;'*'L[TM
MXH6LAP,WKFG"VT6+H2J]I#UM=:2JJW:^OW'M"&ADVC3%*\U&;3XN+?9I5UVV
MUZITI\F.&J?\.EMV#GL$Z/':,M#'W()9VKV:&$6[+ HA$Q:OC-$4J':Y2[XQ
M :$O?.^/<>O'7N,?[^XJU*R33Q><%)#S$J97B:34)@"Y XL07=LE<P;:\$%C
MYO-LG"RIIJUHT>.2":\DW[;7U/3W+'$N+K='VND1K*N\._^^%^7-78)SK<$@
MHXJ[R<&WZT<;<M54[!"(H;<]7"F;F_KT&_I"=ZQ6W?K-P7_ZF\GT]N])FIM]
M!)9AD8W:?J)FO&N#:U.S 5- VA6_9SHFRA8?H'*1JKO!F_[D^_O+P9L?2?O]
M-GG#<X'>EZ]S+LYOWE&9[S[V00M]H+Y_ * ;!FZ<F $I=F\/:W:5&!"(D 71
MB7;!DXTE<VH>KX7CE"1C?IZD]_>Y2TR57!:A&PHY F:PQR@1Q5\"1O6%*Y"(
M):N]OGSKS;-9]6'EAMDJ%2;^_T0RR 1]F.(6^%HF.!0*A(\(DK!$)@H,'-BR
M-:E<%^-I"UP?#',=9H8M!+X*"\4\/N"*@,,;WL/QVYO^QS;+1 ZO]5LRX^_4
MAL3I\C)TS*B<CV%HS]^)^35JR!DTZSL A Q$,&/;CX&K>[CL:+5Z&/>MABFU
MRM[?WM@JF;OXEQ"RQ!O9GGFA/T8#BZ1KB!@H?[M9%5@TT+J8T&ZZ]/[NK,GN
MY?!GS.'V;T24Y4-O:772640YLIM:Y83WPNC(;IMHBB5R "]65&&&14I8CZ8F
MH.!(*L,IE=X9AX3ORE;TD?<-@9,%D$JX!W9F_]IA*8X9C.K<7]*JV9*@&+X,
M$1^>4;K!S8.YEEZ=4K&I,ST$)9EVS K?FJ:>J:1RD,=-W,CTA)U4UZQI;\J:
M5Q%:7DGO&ANEGO8Q$:N^[X+*_O\&,>.8RJA($JQ^"<N#$B4;11-/%H81.O@,
M_!^2/\?QF[4TY2\0N^[3T4E9=G[4.4\G:54WZ:USO6%T4V'32^%>75U3\OW(
MV05E$;^S2;(53Z*!AT"EVK]DU$Y@6]^L4@1*M1R,[;7)PZ6^=A]YN86MF9?T
M$]\R?Z,%L)N(LZ:?H[^?\"=[X-B[FI.IH@3;5*%9U FR0Q%>[D'TQ$%FWV%U
MX\$<NPWZK8_[);K?]_;.B]25,Z3>!Q7(&3UP*$SX 4V+E#F1K:U8&IWFII]Q
M:?UJ^ZUS,IZ5)Y@94E1.,7#1??J)TYU60'LJ\2"AMW":0J*+3S<#B4)SGPSX
M-K-5Y[Y%=/K<-YU3GK^NHIRP"G=5FLDV!,,(]N8(LE4L40EW%EEWL'%G>I?-
M@.N'JWMID/5E#6)M!8\PS[)X1@ZZ?Q@L/@+<%R-P<M!W31.NDRB)$*5]W+B'
MHO?$$3!G*P_93PZCW]G0AV(6.)O!"Q0AV@*&2U%1U[0(R:0_C5*^IVMS;2SD
MO-3$/I<@GQ0]<X%M[  =BLJJ"%#&KTRK+7*[:^34I);;K+?:S]^W#9W[[R)1
MVD2F8]A%;#K*^YA;M8'V9"N'*93I<G5P7[XT.0@K81I8];%<4DH@HJ+V2NVF
M\0C R>P%T$FWP+_"N\04#Y\?/W)J'*)^"EOQL0:\:L^#[.C9]^VT#A_+VKQT
M!+!<>,9TL_^G"FQ?''HM?!I37X.AW$"Q3+?S/Y)(O".W]T7LU\4C0&QZ-/*^
MUY[EH.'BYH>OJ[SX#I+I\"QL?P ."80\A:D&-X#1I-U<\U#;HOACWM3>^&%8
M@04B53O"'"]9BVVI_)X'I1VS+0*"#_68#.DWC]O;V\>)3TE:FK.YW]9>"_I4
M*X]X[R5AKU/ALB\KP>]XLW6$J13E0U*L7T+'+3*@W BA!A,_2-MQQ13/X@\5
M.2[?GH_:767A;*'__NRDR3(PW7B'S]+RP/L57]8S T_/$_(W+YYF,!XUY+4P
M^GL'_^;GOS#GK]0$:(-B'IXMI%VU".EO#SY9-FB@>(+HGAN2Z7/=)J>D>NM4
MC$[7,BC^F/^J8_'V ?WD1A2X&[PD"L>GIF)U91[/!L<3 ^3FDC56).Z>MI-4
M'"58\UYP9!+?Q7*"QW" D0M$'S^R.1XBO":TW:TD%&.\/(YR\FDB#PWO6T@Q
M8.'==N>\DDOJ$P[R']Q:DDFX<E<B4/93CWA4U\D(F#L8C;]S6*L+)9T-NSJR
M#H6H\\7V">U6/=HT&?AJ.G<)SW&7=?P?EP&="WV6A^^. #=T;/CYPTS4(Q^J
M7M&:IICPJ&*@GC1M=DQ+;,CZK#LGYW-6B>?,-QY>#OC .T+K434IH](UDS)[
M5!U N;N3N@H:2]<9J[^_X4<<W+]'W3C&D;@3,^&CX5Q1W3;;<>IA$MUCUZ0F
MJ@+<N035.8H%EM(M+>7^ LD(Z^CO3L_8X7NFX IIN@_!V@[!H]FI%T=U39;L
MN7NF-*PT@O83?$0+FZZD=8NH1MQ9><ZA^@5E\G>T EESTX!B]^ 8QI=%;B:O
M/MVMG-_@>YA<GO&AS>=>ABA?X+>S[X8DOZ5UKQ8>EG?@LV=ENK;IOI U\:[8
MZ@?A<J3'>7:S\_9_%@(>1DGH*C2H?"K@HY<\;]_"\ -'!!'5:XL-;IO;!'O;
MWEGUZMW81#5AS[S+IJWQSD\^U\H91U^_:-^[_!-R,D+;-P;.U:Y'CNK,@2=2
MY<J-WOQ\7,6BRWU&4)#R 0_-G/AOP>!5<'!/$+2$06BSB$:9F(; !U1U;UBN
M'\]-,H_ABDMK@CC\JTF>T=L?;:ETM&ZA(Z!3B=NC&<J .[\NQDC"O9'!^!/"
MW Q3;1KN:OO$M=?6<9Q7"58&3BH\0>BCSH#P,I3$6*-!PL&&W71CV]3$;G7H
M#9:]/,.UB%N;/(Q7+"SN).O?L0#8BR/\$?5,$;O#,3!NLEO,KB>W4^D<LMFJ
M920V)T5RO$;1YH<TG<DLO9DLX6WXM64&J]K_J3?==+A+OKW<$$Y/EL80H!#0
M[39Y.U6=Q;(CMN?@VK/N>PU6S-.:W-<V1)1]_ER4S/+A$>$"]*ZWI^Z]):_&
MT?AIPSA%,CK:Q;HQC/U<("2'][EZNW__M%SC$\'SIPQ#N?,G?^ XCH#()TA3
M&M\CJB:81WCOAM]/+CZG0&PW= J5JYY7R@P6YG$T%E?NYCHOT,R[(]/KR]QS
MG-6VXZE*?LV;!PO9@:4?6YR]<Z235DD>P*_A63G\)J(A8)&EP?8KO!$F5MIX
MV%QSJ6[3M/Q^PXLYP_G(#^,F@G+S2CZ-J10O%!M)*07NDBIJL_Y8,?-^*U]T
M(+ID0:'.,."/8WQQZJ CG8'4I4P1CE[''ZV^7\?[QL'%O;N@VQO[+4J C9I-
MX+\& 9EBT"I\PSC/X.6!SFJEO1C2*Q@OF:^VRAKILLKM(12>IMUU^+HR,LU,
M>FS!VO=%!:]D],?.+N W].O?Q=<62]CH#@A-# Q=8L^H0989D(C)3_=@3@:Z
MZ1>]XF6RTF5? K+A6P\9PY01.<?)SXC*-=TMQ@3Z!R\O1M[^VXL=&RWA[: 3
MU)'E\LZ:+K.]R:OU>MNCIR)<YXUT8N?1]9A>3VPBAH[*N"SWL]?J8"K9.SB@
M,D+W1U+(4Z=:Q]Y03GTHL$'&@-+3Q$6^9JY<>"2&1]AE['7:28PRJOGM+\FP
MY3'!E_J25NL,MXI'B]-:/PI'?%I_)"#V%'KUSQ&PUW^8ZP/W. *8?BXP/)]9
MLY'UX%RW>DSM>-_:^*L'HC@K[]B>L%DR$UF1T9/QY!N5ZQ!#E2!!>C1FC6(*
MVEO2Y9#$XDEUS[*V]SEJE/*Q"W]N^,>-R"I>YW$>.:FY.4G:MP/O%2.WKTQZ
M6TZ;H@766U-BFPP<I_A5$J,))G/Q+B^#7HF<T]OX^N#?"D%N4)UBAX0L8_H0
M4!#28Q43=KM;5?[1-6N![8RM07D!RD>1CC:9B3>"K&Q J$L(?Q3NK&<PM&&@
M%WW"DY]YUKLFM7CC,8\<5R6SE";'_$K$8/@!Y\>U%KH46AL"1C7\+TG49]"@
MIFP0DJ"FY]0]+3_/1H[#5@],[VN*AYE7 ]:'^6BW,)TN[>%47;\E!:%3U-"E
M10Z/8$VK:7TSR2"X1Z:">%)ZD-'>/4Y9[:T>MP?TJQT"2ET=,U#:::%\Y8G&
M]ZJ=VL%QNMQRW^X6*YY-)V]S\G9?>2H>$/WB%5VKRN-:;$?EBN_?R<::-!Z4
M'=FU<0D;IPHF]HM)34K*3^_;Y.HKW!8P=DP1+T\KZ+1P'$A*-Y&,L#QLP#']
M1#=K;G[R09VJ<,>)3^[L:9?%!@H+/\WZY_L-2U/T>1&(\J,6R7N3+$[>?L=H
M<G'V ^H&B(3Q@*VN=<?IY0.N-VO_:?%TEA\U(:@9YJS%V;+1K?S]E3^\+KBK
M@X/6V]$4\X;T>LZJ91HFC)PS:)D*B&WQTE6U;8WZ 9SX4_&TB!?0>I";Y"TV
M3;E"ZX()@GW+B9"X!<YI19H ZM;XRET"63KY=.NP^,]ICI4KR4DU^,YGQM[+
M !!B1>4M(@3,#D>%"U+U1R;*$JAZ2YZ>PFY)P%8SZVFZ=<L'KV5U?'QM#CSW
MDD!T#7(,'BN4'4.TW+8D#2?M?+OW[%,MM_L[?-N?%T]ZN3]]70^*H--BRB5M
M=T*AR!X;$JZ(C!EX[)9(I*H^;LW'%/U\K/E5H>2]@1SOY*!:BK/S_.?R0IX+
M;+\=G7YJ_X?05_D*@(-7P%!"F&EON.2D0H,WY'K<<'!8$$4BGDE09B(=H$\W
M!K@,4**5QS_+ \9]%UEN/8,T[]-.B:MC"+OK%*DA(<EO;',M\Z?A4MG7&TP_
M+9#;/1WQ0ELE%".4+4FQ\5'JO>(Y=Z'2:('HF]'5O2J2G6\%4>8,K_)S.XGV
M9=V8A 5^< 9OIMHOQCXI,=F@<)'%0.5$51*[D.;M3]KYI_,-0I225?'' #.7
M@*L^ N11+@2]VSWICT.F'@V$LH?MZ0WI-=]@')XIVT.^!='>2QU\R R#YMPE
M_L3=:J.;D]BMR"]*&5(3'6Y/!%:=/>E2OQ^_EE[$GPV+7/SPYC%)8X1,Z9J5
M>\ZZ131@.9&"UPX"'K;$8TLZ;MC?4C^K_H]GRW>ZEJPMSYV3N%OD9BJW+4&F
MSYS;TT&&O(D[2T8GJ+O;F#3:?KE9^,#P?%J/R,6;$A>C+62_GE8QOP <(+IQ
M"J.Z@02*GG]/:V/^NR('F9>^Z+*A^LNR.Y_JTMG9+^Z()_R-0+3#[.7#,MJ)
M=:' Z-:.I "]V?QH19CK2ZO5*%AZ^5Q*;B3WOF</W*DC&B=QF'@$>"EQHWAI
MD\=&*G8<;S-Z'XN,:W[A2;M:^VP=N"D]]F%%GY5/NI-2><"BFRJBHNOW,N].
M9K(Q8XJ6H*[_MC[TW/&_U$)[R!R^AC$;E&[LRR_ 2&GVJG=3'J'6GI\X\\XQ
M9#!:=H:FM5AJ\#B5R'0<P<@Q6%*9+>E;Q?QZ/C\YN;0(YFS]Z:ON;=L%QUK!
MPXF^IA03?4;D:O<1 ,JDQFR&*X/-2]BD;RG8)=./-;G=.>H3:6N6'R5\'I1*
M.-EG2?B?9!&4[QF4.(GKC&0FWDL1<+(N3+XDZ5=N84$/ ,?V>>+J_\, H?\?
MPX0J9K.*W(O6]JWV]\_/6,_VC@_[/R1()*@SOIQ)/5UPPD07D/V"E"%&D\S[
MCS$:HL>V T B>J=P[&-80HBZZ"7C''>?3_@^5]Z[05>(OTVD3;H93W?- 6)K
M3F&^;V9L%VS,1;^4]'K*JW9WI5^YE^DB$<DL'K6-$$=WW<5B-X^ ^\-<)1G&
M;^<]A%!6N4S46LJEIE.;FE7H@FV[6"K7ZO)4I7_!QA$ 4$-PPP,(R$KZP@)+
MU.]!Y]2W!;3]=-!NYRMY64L:5W^,53EGJ$A0:>D(H$-HQ2CX=!6D.(T)3L3&
M7%[GNV,X0%&C*R$M]N? ^]'1,"A9O2IH/T<S;J>EQJSMB:2+5))O?!<>GV5X
M>Y[#\]?BDFMN);I+_MBNO'7ZQ(1,HTB^_>:Y>8HJ7[BZ!4)&_*>,6?ZDB;59
M*UY'P(Z_+,-K<*T<!9]&F5$TJ/IW S"<:YK-W#_WFMT8SDM^LWDSQ,ZLJJ@B
MH%:FU1]><=B!8_BKQ\JFVI8HM&3;CCEZ>YJ@4(/^)^J]$ =KT)=0*D2OG [^
M8(/BK3G043_0:RN8_F-LL<^SZ.7R!:/&26_))PCX-Y7#%ZG=N"3LL%*L4$HU
M68YVBJULO2 D9SHF8&!"_ON0-=H9T? V[2>JS0(QA#LD[;WS7/*%K.7T)?K6
M32C<;WORWBF-_@TUK@""@:FBN_1Q/"A.,,T/SV9I%FQ#?L["1X1>'%OXX219
MCA4Q32_,2QN-8"IB]_3'(YY0#9;@<?EGP.'E9!'0OU=[+\^WR%T,FC9ELI,G
M+1-B(1.('Y:O4TLI.@,S^"CK^37VZ8X!F<6SQW"\OW4T[OJ;O3L4$_WS_%_Z
MB>WYJ@F3_RJI'I]RT5 S>[^ V^4VR?>JDY?6:(_^_ "Z6-M4VQQ=6=H$/O;9
MIR7T]]UIHWM6) B;GU[Q)=H3,$GHNM2!Q5.TB=:F-F@\T:<FPWPJP)9Y5BN@
MS8B!3<^ZENO*[8=<F7:?Z9\S1@/A%59#B$;HIA$>.^O4@Y/.MDRQ(N=]>SU0
MY&FEJDS[]&!\_V9O96=T\?Q0,9^O\CN"!@43274J1ETBI:0N>9\@J[/Q6S:F
M_!K[ 4L5+G?1V@SI8GIVD2G-]@X="4OEVM^+G%3?9MY ,.@&_K!!'E/<^63G
MM_8:+ED?H8,L6XXH0[_^<3[5+V&3B%P,Z<8VL(&H1_1O,X5/AM,U21%]7K\E
M&[Q"R]K](V:C^P(:9/V;1?EG-Q?,*><0 /W)] 9@)5Z/I8\FVLJ?HUCO+KI2
MU>[FR4ITA+"6R0[./$^9H/L.K2VC&J,4R$R=BWXHZ'(8XGIS?&MUU7A8TR+I
MUU8G=(MB54TU S,)1T 4C7X*Y;14N;A)I#>)'6YMX6R(ONA8<:)<,OUS!2!J
MC)4D0:BWX$V8/GO>U*UV*\(WB5X2W?CGB$$G^'*C@O^N6..V4&FV2XW[/I]0
M<AZNT.EAS(5JG]=WSV::6[@X7A3KCX#IMAQ6W#]LUI6K1L% Y8*-X7M5<[C<
M:N2T51W?;%"&NVPFQM6Z85I:P\6X4T!>X!G/]+08-VD(@\>R_*2)C=VCP+*+
M9WKNN4/VS\2?.$L[_;IJ35LO)JJLYU[I7=NUJ?/)M3:S5VH-!(8>5A30@1:?
M_IW)96/W:"\"QU^S79K88/%28L>L*N6+R]\PK==IXF,,=A)DL'CW;3G&* 6N
M87#+\KS^O%_GQ[4<:N5AJ1H\\:^078J F/5$3!>175]6?TO6M!_? 7.T C:"
MH;\@9I^#^R5NW;K%KV+P[CG?=_K=^[C;AW%H-V_^;AS7U#$RM#_+9KKDEJ#^
M_M:R]:0Z<^]XM\'WT;!\C7N9^MP*23ZN%SZ<9AH7XR-KO%PV9UNSH26&B!46
M>V35+MC87WE4UW<VQA!ZP\#C!M.J%96'&W\RD52_A.A62LD_.49L8 M:[.?C
MTV[]>K9']&NZV4>YUQ$L+D(:$EE<K*LBX0G3P^@F2.P2^2VH20A&J.\JQ=DX
M_Q!Q"]"H'0[1,"K+]NFA,<B-AZM2[4?"&:G:D[HN2Q>>:KND9I4$5S2D;)7'
MO=--MPX'\B?H?B!JE:C&-$&PJ!/L)!DEJ>>=/(^$&<W:_)A?'O_X+E&LTZJ2
M:@F6$#HB.R"[J4)@ZY^&;<C:S<KY>7DS.;:AVM?1-TSDMRKTOEH]1RG\%\3N
M <<)TX?SL+/C:KY\-H;O3W%^='JT:#\UDD';?Q\Z5%W\=6/6NQ]SG#?6-?A/
MK7SQ#.8:Y*E 1Z<]8?C+::!VM+&WM&_AW%,P,:K$2.-WTEXC_=K"&7(3UE7!
MJX'RS\F9Y0BN:_M*@LYW ,8%@5>G#W[W'+!E1^^(:AJ,WSNVMSQOWKP&N3&M
M(OVXHI\%IW.OC6TVV#)[!6P8R\L7V-?:VO36#@@=R)8#D!*;_X2EOP>G==AX
M!#C"(;01L1-DGX[2@< 0LNW)_6L36S4OLJT'/I95.!L^RV2T CA60Y6E!L-2
M#0!4QG%JF#LLESHLA#&59F"'5@?R(?^4K).'>^O%&2X^[/R=92$[LXKR07[
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M4['>9(".(Z83X'I O^$-L1]'F17;>+3""CTKW8/]XKVWJ]SN%KR$&/ZWJ(F
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MB?KZ%O:RUT<61K8/G/U$#5@5G$L$7;*7,M;^<HF?%M\)5/CB>A9VM\_C8GK
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ML(X;)^C]N,?[N]D@@5TN^^=?2E1P4Q(?V:%F @PU14>VA\S$L\1G=J(\:CF
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M4XXY^/A(8?YDUI,C*5<00^B)Q]YP@45D!(<-64>YS/48H%?;&(>^59=_:=O
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M!>MY12*^K7KO?.K]+N'YIPZP?[02)1*[<!4WB+.XODX'.CRGEO?+,ANEF@1
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M:M\36GB/\EI DC;$D=;J3G3DM=<*UB7+8O>T<(E/+82P+ZL>OCRDNJOD=7'
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MH NFCQVX?1C0=O8.$%CRHDSI0ZVI(#_IKI[4)2X[Q2Z]-M%/#-I)+7U'*<>
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M&!3+DE#;MRZ3CV=^"VUXRCHUH\B6N\^0[W^PTA*J_+UH6:,XW^Y-$\CP^5+
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M!_Y/!#;[\MM09<H5$D ((X?YRFAR+#9I=OX1 B$!_5SNQZ#[";7+^_]$[OZ
MRN[L.[/3)A?X$R.LU4M"!MO/3KB_;TJVNM-AJ]@^XB(5X$+<77M"LVJ-U/!\
MXF$6]$27A5K4U;N%/KD;E0-W3I9;ZDM =(F 6L1PA>D3$A!# I(,20!#P0KD
M^,P6[) ((<I:CVMX(!Y_1QZL\*7@<$XD +H&;R1((2(1/P7+$<L@ IR$8+X0
M6<A917(]"4"0ZW+5>$?&\"2&G*R.1$+F9XL))" -O?SW-QG]_2>;UGW3PO%9
MD@ 59H2[?<$!4>N_0@XR$^!. -5.VK(1(T=\8G]W@];?,@W48_O7[T+S[U\%
M5X 7@ROT[E]9*S!JTY[W#$?[["_/[&C($URF5Y.>)!FR7;S<69((T*A2*\3O
M=3VJFI&9XJ,C%UQ!?-^3ZB$E/2UR@=+TY=./$87@(E:8BD:F.9D\YP$7^@_X
MEVNWRB-F0KV8GE!4]H[,DH"^=D50E.Q2O'&:\8K16*VXWT7?ZA*ZU6N^O?.D
MWAEY&.FB*GR?B5MZ"?G4I7L9]P#30IS$$OS)&=NY[]_.9N(DA)Y*KS]J6<[=
MVY<^*YGTZ5?%>.AO"2I02P]$H$Z8NKADH YC/H&7GXI=W*V^'<:A4DPG%9B=
M\1\'0*8JN-$C800M<C+EKW C:O5*$#?O8FO#M)Q)<Y"_'/5#ZJ]/U\^H+@Z/
M!?1WL%%@1/Z7P0Q$A_5+IIEE@R^]OJ4 =*^A?'DV!D?3>I)1+W;'_720T:3P
M^&_-N,I?0UIWPLT<)'?GU*BDKI_MNJIEK?:YHAA7?)+F*S'7J*'/Y++,LN?C
M3J\!;ZS>>&;_XLPE#1.C V'[:WAU.4K*W%1M-HHP3 JJ@!P2'/= D92N$4HP
M75(X^LV*BP#[V&4I\X5KZH/Y4$U-0N]W)5;1S]!'D&1K@9.<D&O.R!IDSY>>
M^IZ\<2;Z36E)%IW6769!ONH!IE?G QC,F82-@G/P\@2Z*:3#\NF-=F9WW@6P
MLLO"JL5R9GYYXYN&$IVE5XHLT]?2+."Z")5W*+47M+YO6W$%,C<&8W)62'X7
MN()@_9FLT=[T[NVK.5;= +W\URJ\][R*_52PKYD*?U;>!.4PZSU(QKJ4[1$6
M@M:$BH!E#VN/JTKY8P8YR9W=L;X(@3Y_ZF0IG4K-_[,KTSUKR'0IG]%U"&#.
M7E*+?M W&C$SS1IRYN?M#%RY:F! ' GH-GUC:'W:)M4NH&[5E#<F24?8=FYJ
ML7)FMVNU6MYH5=/M2GX@":#3ND7VQ6WJ1*(6^2V&?W_AK_^A?YS9A?Q%P]1'
M&*[<"4(03ASRR7X[;12YOF=  I!I) #+AOC;U^P_C0R)[SSV3BBZR))]G3C=
M1^[<4P%[A"N\],20WTSX(W+$9M'ZVY?641J03=.SY)C. X4<,/W__E&"*\O1
M"G+1OZG;8G8XY&@/N5:ZJ%1> S>/I[5*<YWDBC!*Y)@RJF=9(8)N#"=HK"Z?
MU2]R5)'(Z/CB2S5U*&=R'.3_(-.7CL%>O?X,=U,'ONN]Z,]]0B--YGW<!:X[
MN>Z!PM/(5^O3W<;=@_EUN06OOL,P^I0%,XTK)M"?Y*SB6,4"BP"O0+:-@[$W
MAB&), 9T]B :$7/JX==LO_O!FA<\^G^:%M1IU+$)9ADVIC.;COXU'KA]4!HR
MU,XP3N"E21%OU5^QNFEWWN]9=!Z;MUK;8.HE]?265\D7^#Y1 =2!=L^T;AZ-
MDP"J?O"DE#@&XR3;3V3W^6_S6Z4KBTSZ[>E\K&@SB^]W.SSW]RX\*0S5Z;M0
MJ7]2A'3<8W.&U9N&0AT@5,Y;*Z(IS/,G+9;8VXXIOJYNK$X,Y]]TW,XL#&OW
M*H^X^,B6"Z<?M5Q+$ZW"1' $PU;_"K!5(HDK#7)S2IX4#*:2K64'O6HHG1^G
M'O!<MRG(H1PAYQ"5,W+J)^^4?%>6>6?@M<88FF0?(^W'4W7/SXYPW83ORUTQ
MU;2?V_R,2O4."V7*( &H<BA5*R?F!4H_PF&T#GV\<QC[W'HK.[-KR?E%AZO]
ME^P?]\?DO]"X^87#3R%OM=^T!&EZ^#C&"!Q8NDY>2S5L_NML(9,#AMYI1K;:
MGBPJ-NC/=9>/_5XO^PQ14 XD*KN=!_R&02]K8R$I0;IE\#'1[F85F2DK=_'X
MJ\TYMK&9VJ\5!Y^FN)D;OZQFGPY2.XGQ0?(%L6/V0BW[5(0:VL9^EP:'(-B'
MH'.RNBV?'L$+O04A&6X_<3L7C..,;/8,:'J7>1 VRW%(C'[]1+L8X31V]XU(
MY%-;\]]ZIX\BE#RRZ/$3),#4^\(P[=6*T#4'ZNA* MM@[W%!G_Z,*6JD.[9,
MJ+IVPI<^<.C6\'5S_FQ+<]6;1)3'9MFS/>L?[4BLZ?80E@;M'P'[3%0"!X[7
MPRLB/3=9G(@\\5T/D%%G;-@:;SFHEMW:E>R,3$Q,S/Z-8"&<Q\#BV\_I8D8,
M1EW7,.HS6N^3A*7B>%BB6"+YO]]Y>K_LK)J!=S: Z$#P.2'95%A!]9YG&MW^
M"B'E[]6\4B :PH"/8+4)0Y'?52UGT ''_8F>!%"?/_G(W_?U4.[L3>+.+A3G
MO-?.]M>AYP0=S(/[;>,$3KPZO$\-P[[0:QX$=7(ZDY,N9;+RLN2F 85/E-DJ
MIKPR H'10S(0!,!Q-#36KUT!JS[X<>'.Z$9S\':#8\/>Q?['GW*UQQ_R#A15
M^RYH:@\!=F#.:F,<PE%_7M_\I*!5&4U?205".X^]85MS%6F7$XPF><YXNU+U
M7:)B] A[!2 6OT0#\5C(O/J*0T0["W$&4F,<$R5CJ<?K@-5HZUD;T%VP@N*2
M4ED7[JY]$?70W+B0SR3["]8[ HI4Y& %5R>@'*T"6!HKT&Z5YHR$FXSC9$^'
M$<O>PYIM^T3J1_ZB@!0R\&8!!Q3U*H0=?",242\?Y(L.ENY58/_6W(QU_=IY
M^&!BYN5 77H3-Y<T\W[G8\&%F7N.E/U(U <^(40TLNYP>W"UW-03TYY4PIT0
MS<+!$F#J-W873A3D&Z.!922BD5I/?R?PJNO$&#6TA@=+.5)_]4_K9]!GL>KH
M\KEJFONK)X"F1V*6^S.,HYVFN(LW1'2K_,9YN1O'=8V7K&XI=GVJ7WE5VV[B
MX-43QM@6=F$##:-$H+(K,0TK/LLL!!NL0U(K!56^'3*<<ZUV;&$MKY&%=M'^
MUKV[CPW-3E!=\0 *BDJZ7[3$ G8)N=5H$H4U31^D?NZ=X3\V_=D6XD.N:FYV
M&TQ!K[ Q72G:^*_%G-\;V8_%_J^?-PI>3KM3Q5!V78V3ZOXW53[9TI !:_J)
M>MH*FQ=&XU.:B[A G?%!_4-U06;E6F/H2BJ!EP2HB7D324 7">@M7;A<*?G]
MY8W=#<$7FW70-#YRD&>(0>T=T[H4_+NQ@T0@?PI7_)NQBV)#UF!@!QOTF\__
M2W<C[%#(]3&F$@/B;3CB;_\*P?2'D)7D=5;3O]O973;#DQ?A9!755OFH?L1"
MOO;WMY#-K "H2 RW6/]W,_O)4 MG34\,YC]^Q[2F1;[T=S<8Y\GA]#%64=NF
MK/HERT)/+\POC$"RB'U/G3U_R6[_,JAI9?7':2.,WQ!BGWJ6299<++D86E)R
M'> %V ]@V[V?B=\@=;BS"/1[L@#\FF<,ID&+BND;?%MO').5^?:;IN]%@'#5
M)Y9]:7S-9Y[$Y%8'I>FP((&3YT%Z& 1:)($ <\*Z&$R)MUH%\.+J73[\Q/W@
M7-/KN//TZA,!LP]SGHFVO&_;U#^,G]1";8?H<?7@ Y4H_^]F\.PNW^&8,JFU
M>?UDP]BUGDNG/AU?YS2$Y4-KH#TCL6)X_2 6D!=[J1=>7QGS;*J4L?50[U5A
M6-V73-<9$L E/FKCH7UY@&: ;7K;"KZ>C+2',, '5P]#521Z$34$RQ7[_)MV
MT?Q=]QO2E\PB[^]?-QAL@N4R#JA1L0,HLDJ\AM9'O\%?)@A632A!'5P"T&W/
M\'@Y/;GE3;'V6R.*B4GSJ@:G50?#O2AH(DZ*D0Z,3)TDH$:N&\$&'S1L A.P
M=!)GAP3A.=U21TNWO[Z6FWE- AXXYL317=20E[_6EWVH/U>+,\?T[3AA)H.N
MH!43\FY8NF2VC?_6O?[>TCP\<WB\ZXJ)P/-5):\S5 %N$63E/1BO:+^P#%=$
M<W2/G"?H-"@$;AR;38K?L-C@?W,[FSNHIJZ?:6"?8PZ@.Q_*?Q).,"\"(41:
MY(H^JXOSN&.V2E*9,\<7GB<FC@(M+0&JZEV\)5V\QZ9I!"\2$/Y(['U1B$C(
M$-_59HQIW WN^>"+<SMO&W*O+R:83T3'7O^9U"R=*I5@O8[QQM&,A; 0Z+&(
MKJY55Y=NJ:VY&X5O.CXLIRPZF1S&=QK7-RP8R]TTA^2V7%Q+9' .4CQY%7(Y
M2 "C5QD1= 4[9H*9+-)<^NJRQ!E_C!NX]O@^9S>V@@.\G=9_&J"D9*,XZ LE
M0N%;N$HR*[<@AY3N&\-+-S&_WRV]"/!T/]WUK+H[0_K"Q"/M!\^D/O1JJG)7
M*9._)#>6\@Y6?SNB"/YL[(?<!$$2$> 4Z"8/)VS%B0L^4>:TX^=[I<F;% S!
M"*(DHDB 0T',Q@J4H4^I85]?^/OOWP=Q;NZ[17VOE(9".><!#X!"E3+^Z.T6
MD3:3)IPH:@7.HY ]5MZHH_:GBQM^YUT"W(QRZQRY-"CD'D5Y\C\8I0@%E YP
M]8^0&./*V6D1"/9: ^1(-M#Z&]XM9,):"+1<A49#Z5II/9V*P!;TV4+>M.F]
M)^89.HT!A3%#VO/? ^BU/5OX VP?95WHP)H2SD&TL<6]3/1PLHZ#'U>YDTRU
M&B(78 &#)X7^ 3SE%X?%=41/ <;G+Z,I;MG>T)%=(DX45*5$09U&Z$&+X77K
M*1E&1)=P= Z:.J]2W$_R_J#TG?FB+\:/_$\5>7AH\_-1DN55B"QQ$,P@3FW:
M]YUN)0N\UQ)_YA+6-$X\&_\@E[/#SAQV<C\?X<]\^S.^]0'RZ3S]B3Z15A$5
MX+,_0MT0MU*:4'UA\:722U,1WL8Z!Y7)+15RXACNNP$]IW)NDX\3N]Z=P@ZN
M=A\(N3B@\]P\%9U:>"W/X]:V]?" GU _*M6Z30Y5N5VX@HR"TKBU0S;GL@I7
MY_74]:U$#5JFWSM(FY=(:;EP.3!_CM]E82.\FUD7D:$0V;;"GM,"\_!B!)E)
M'Y</N_>7U>O&W<94JJPL.]/T6'@U><]*3][)CS0=X*-N"3\@TFNL_FC,OCFI
M)%]=G11![5M3RU#,>X8_7/%),^0,66&NC'3!>*RMX9#5RB0"]PK]AK^UHX)2
MDKNG3!!:VB?]@SQ5Z- YEJU\EUA0&M7&O;).8#_HR><;O?9"?ZRL58RKARZ]
M.\/._NMN=Y:__;6OV[K2DD+I.J^9QO]?G?7UOQ&4[/\Z\UP51)  ?B?DU@KR
M%WM%=E,!6<+V3^<0V[G)JFVQ\>$_6_3S!_]?H-19(?-]BIW8]Y.)&R:I26,/
M'VH+)M'<S1*AQ%8$DNT3>^LY])#VQC$DT8?1GN!PHSGD(]4^-I?PH1NGW&)
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MZ$&R@@D]2TJ38JQ;!M/Y?69)V[N+4AK96LSQ9U9M(HVLBBY?XQ:11'1($F_
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M,%D)&E"PCT]JS$=QELM=N.+IC\  GLO^44LSSX4N\_"<U:9H*BFH+=C61Y&
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M9!*S4FYRJ.56ARJ3]FDR";\V(PG^_I-6:>5I/Z24<3UL#QY-V&E3V^+5==6
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M$$T:?8"-U!$8;DR*HV;"X@@$>6Z/U)6!#4%(2P3M01/D<[@"$)X2JQV^7,'
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M7A>.""T:M5%M!34"0)NPRT,%L9&+(C0OC@11MXI-<"52P.)W&S(N6N'B8^%
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M5W;I,+2^LBLDD]503M#UJX\^[I9[T"$E14Q;W-OS7)\O-F0FZ6? GT&SYWX
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M46Y%D1=&E"%$5/C&%&F9J\@"9_C/D_S"0'C-=]\AZ5\12"0 $K0%5 $ F(\
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M,?).'/X -$UH_]%N=X8"_[(5>G,'2ZV^]$#PH/2'\QR6Y4BH;I]N*FCB[;!
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MPA(9K3.,&K-9<3*9R+.W2JTC1@%7'UM[4 P48R:&IWK]81+I75@T%9U,W$?
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MKY7$ 56^5BR74VKCH>()<-#+46=HX)%RMO<&J6&G5ZPU8RS=^ -M+3G*'M0
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M/ ["O0[DN/G5Z9$.]>FYT?=1=>H%9JHNR"[VN1LJ%=)]9P)\@3GYE0IU9_D
M=+;T["OF7/!6=N/2P62Y\ 6FYIH+JF349.P%YOI6.\/<_R&G0;;J4K[QX1D4
M]33U\##:/!6U&-A%#9ZB?^9]^&8+^GWJ.T[>/$4_<P85<B-[=L:^(<-A>G\;
MN2"5>3MS]JI$8-SS*@-J1+ET0WNQ>XVBNZ,]@ @\^11T 9YBN)_Y<0CE,.JT
MBC783[1P_NI@?AJ[L6[4%:V_#[7R>8H=:@6::)*@M4YL[K_@K%<X?T^W1'*X
M0OA0>'.3<E9(T$9*$9%WJ=@=#=HJG7 (O*TQB;D-<.&%W%6O_Y&N6"\PU_27
M,+8-&39WP;?8$ONI06](OOW#;.H?LR:G$QOK!G_,>OYMEEO@<W7#O[-<%_\Q
M2?30\$\FKXLW(#+0!DDG.!$KD[;!MS)O<]4UVTX38&!.X1GX?+%V:;;P_O,Y
M'OEL^^W0NK#_]> 94(5G:^K? P)F'R*$1MUH[R]E'*8]MU&8=B97\1T<1M[V
M)0*=?T"H8/XA0NW%KO;O&^MZ_R:N;TK@?F@=)S%;6$9XVQ9T!G7"V>!$N=YK
MKHWKQMKYC.6/FR(FV*8GRG]B AUWWJYXJL<$&2MS=1XU5TX=!90WJ=PW2S\?
MGSSM^.T/5(<C;K**E3>?)W;\W2<2<R/.PCO^UVAHN@[?^*CD['MRQ.-+:.>8
MP%XU!?+*[NZH-(+6[X]'Z7"P^#.W5TAB%G2,2%N_6IJW@@;H@=;(H)#"T_/Y
MHLX=&J#WYP08LP^WP^M_-?SK6.-QJ-V&RJE]H_)^N;9FZ:OU_XB\DSK[I_Q_
M1C!<=W,>6@7K^:@RRO&.\YT]$-4ZUN Z0XR$C).*_/FZ5SN*PTCLT[QQ_-Z2
M_/,Z5:K%__;J9^1^]UBQ]*7U7]N4DO_;SYS\LW^F^I^69]'$P;'?B[5F$52.
MO/3$[X:IU'7V*&0L2Y!5#\[0Y$@)O)'7Y,225(L8>?J-(6*?R/)/"57:T19^
MH-7LM4T\#Y>\#=7%_,3=G7/T]H$^[1G[@SC,R+,?]#[K.,/\5OK3+1S+W6G#
M"TR];>Q/ KC_+S]"I*YP\7&-R!#82TY )+C+SJ18Z0NQ"HU*R8_6 RQNR27'
M]2]^GRE^S0NFHIS!;J)YM<5BG:;]G;,G@M;__TK 4*!9/FN1+Q>!9 ]LO^-'
MD3U0-F3?Z.B82Q2O3!V5@]NOWS1!1*K"P!DL1Y%C-4'B_$56G4]A93[L_ FV
M**)((1&;R(?5''\!>)N:/B_0=N2G?2%DZ+B9&,SH_D$N$L.-GZXF05.9/R22
M)=2S]Z"UGG_P&_^P[75SEXX<$8RB.OHHN;YI):8MO6T@%I,2J-P$,E<3Z*>N
M@FLY;GLC+1=SKE_1?9S1IG0*'4S64Q;(9P:.XKAI88%:!OR=!<4*(_"'FI.*
MA@J::S)"<AH$ H.E!--%;+;(-_NO,UJ46EY@BCEB]G.QQ9G[EP(6%"+E,=@-
M* I],$YM+V3D[N66D5;9_+8^[9#Z%MVQX3!U."8FCU5L Y;O[R)*0>_?G923
M%#Y(C;^QZ8T1M ^)O_U^%_$"8\7]71PGET;H\P<U_Y@JEKTTV%[&%60^44C&
MAFU8ZY*\ON-7G)F@,-_J.HT!^O%8,/^>#4H$YS0_7"6_.GRRGO.I:^J--F<C
M_D%11*6^,TGS='*E6Z>>*I+SD5^RNQC5L->,W?XQ_W%LQ]AH5081;7O*^S>I
M7UUF%80+'.JMP/6RS+%8T4UWO[K@!G&RSIO)^(IMV2J94E/MJ.G3G2<2+DT3
M7P43:9HDQ&S(WWB=Y00$,_SX[^IJ/M+T54]3Z2RQKXUONX>8A9M*S3F;W]?L
MZET!?C.BE3!N]^@ZH?4:(..\P/@77?":OJ=?XHB_ PDB=%//S+(99T^6D!$#
METKFS*RL<D%L2E?R!Y&KQ4  ;@ZW9KR3!,2N/,S[!+D\$4/$C4?* JM9"&EQ
MZ3VI"CVPWC+:GEQFK[YQ2'LFHT6QR3@NW(Z?E$??U(K$94PP:#!MC%B#H\(<
M-F1)_B<O,[(#0C2S(YI#L(KA3ZUC?@$N_W (:0;-'$G#US _',=WN][F=HJX
MV(PKWVTM1:_K!ZR+SX]X?B8:3JO0+^Q.)8U7X7^=A[6UD#5MG+-I>X,;QV"=
M*M(PDL#5T? >0RJHIZEW)6$X78#%V8X*-3!+$TQ:^TF86+V VEEY86%"BL_:
MY04F.-6-2!@6I<H4:=CX8@/WBO@!KFKVK=@7)M3/ETZNX44J/^JEL<,A5.HM
M]RE\MNO4E1%I*U@9R2B>!4C88*XS_ K&+N&Q8G5;";^2XIGPT/+I/HL";D*:
MU(ZBFBQCTAE\,G^BE"[A9!0O'4HWCO4K.SYR=\V+=@.YVBM(M F(AN#! )."
MN5SA4P//3'+_LJ[]UXP\?H'> AP@U5EXRU N*28*(#,[!]T; #F^/Z[T51.
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MX<][8OX"(#:+8KS 7#:_>H&)<-S8D X+R_*5[6=[QOI_9J1X6?H?4$L#!!0
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MF$];;F4Q!3>Y14VW&K5\JY=\^U"\/[85:9KSAM!3((:"6@4JSDI6?Z*3ZL-
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MX0ID0-T-@?TME_H[9MK3-X>$R"0#7RE]'@/DKR]W)BG&4@*9=&4(GFT T9B
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M_:^K34C\#<7-0^85,)Z##,R:G2>=\8UO\XBTK%6K.4 M!%F7QC8&:Z9GHBG
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M!W'2KY$S%BP_IYAUHGX5$\I(6$57Y?W_.')EP+N]U9<_NE2MN<3NA^APT;N
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M,IK?:62%9B6)5I*HX8I:0.253@X0 N'9'I_YEFEU:LE-?76D:@XZ4NG[..S
M#+8C,I6 1'9894WRO;;K3CS#C,41@LIE">T+I%+/EU2[%ZM'G*]5O%ZP ;><
MAJ+2WL]%GL!S_6G!1"-2##T0_Q:GT5!.PUC6@3<$TPM]V^,!M"@@T@?E'U$?
M_8UJ3GTY_>OL74_FY2+@R@3LRK%QF).+Q!5[@UZ,IWKL)3M)KKNZT]S1J&-(
MF;R:AH=:F(=99N6.7O7E;YE88P57L$] L2QUTCJ+,@4$C]HU:QK,98P^=\U?
M"'+/;&21?Q5Q"95A&3JE/2K*C;0ZBWVCU[I_L Z,YN:;T!D]>GH)&-IS+F5?
M3#2PZSGJWI.I.H;H-0_O5''VFDW+O0^E-<HA$]\<U23Z8-]"TZA:L$/N3KG%
MYV\2]F%@M(S4PQB*Z&"[O<O^^97U[NJ ]&]B&F!X68$VYCDR74Z][U&%F_*<
M"RL_Q^2*Y72=F<8BS4RZI+YD^2E?SN\K#SUR($PPOME"U2A0N N<!EI[BM]V
MI^=84A?]@)G0LBTR=M *YW5^7?=,D([CCL!V)_BB$/P0+1*R5!TW5RA^<UY3
MF:E6O.S-$D)KR)I;NFGLXY=9KQP%U\F3+/)2._C7HX5P<_81S[!C^WQ9+Z?:
MCBRL=1UB<,(@#^<SRFQ6<_Z6VMO4.?C7B[1CJ7NR3#/R/B?)Z(KVTT[]%5-#
M ?&++6>+,@,I X,\3(7B^"@]H\KT8ESZ)V;R&+."S.$ D?^66N&.19]V\A(A
MYPJ=5)9_-;A^V<EJ?[D\0;OHE[+>+ HVMPCU=3":#$XU:=!9O=EF:(#= <7N
M6[ L6)AN&;C-F0VP]_\J-5I-_"1$L2_+U+G$/YW<X?LQ]?TG2;-'=]WHY-:[
M_7.1BJN8B8<>Z':$F,%]%?!S5ZK#]-ALKIBLF<YW5R^FV!Y861!YM/E&C&)Z
MZTGVKL  0'M^-9E(9 =*?@FP@]WNHKYE7:AX$>R/8TZ1'>R&$*('RJ\U*V4'
M@%YPPE-D"'%.]56CS*C],.=?)PF,U34U@N A47$%RS$-N8S$HZ9_R[IT=4P[
MG6\EZ482)-0%+(]_WY=YZ.W<;IM:.LTX)U5P"/HC+RC+2$JY7M-"CY-V;JDS
M*:F>BU2D6D#PR+_: @)3[_-&QP1EQJN&5R#J/US8$4YRPC/WFT4PT9N9/:+C
M=NT 1:JEYL4$0^J%NU+RX-9^F!F9Z-)3J>^*M::$LD U#0_2PIOV.6%BA+]>
MU>&VR;!+U*'"QX^<WDQPS:ATS5L2'IFFG/TD%=,>9SM8JFYH>B?F9#C_C CF
M- GF1XM^6]T9S@UFL!+>*20:I8@[NQH]!R!]H[3C&O&-L67^N8.E:=@1;\RH
M/N4"8I&-94*!ETG<OF#:_0B QHQ+A[8V.2^RFLX9&U^;M.Z3)-AZ\@0JL<$K
M0V!47#-=Y1=.#WH<PBY+5"M92/BE$;.PQ!V;35E1V=8CT&$B@W 5&5@ /T,S
M'GQ/-:S3XVUXZ[2ZO&% 1+F3!+K9*&37EC'MF%-S74W(4J:6IBQ( ^49FG=F
M,Z%<&;Y,8R2590IMC0'! &"1)3V7W9DNM]_#,@=[RKP99]*.HLUA5X9Q<R?)
MG+V\ADF7>\7L3.GFV$#O.F'69L84//U?#[LHXEV*MQ]B,1NF:"448?3U:K4@
MG/7.Z1PT1R;U]M=T;_F= RV/GF:12G-T2#2'DC:*3D>M%L3??'C_NZZTTJ3W
M%H3[6R6F:NF3^ G4CF=V_?T0-S#?U4+.W.Y$XJ,3XUAB4\=;-WW#Q ^@L%+)
M@1 9FJ:XN:,PK4G+)TFR,@%WB59EF=QMT=LZD9E5]DD5D:]\7@ZEG:?MP;#
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M5[?1)V!##XSNN$*EWT /6:54@+==2=.+[%CYVFD@QZW&>SRCP;<0?JJ>@-4
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MRZ0E!,;CYVDRI\BZLKC[6QRW/<']%1.'3$1[!7I GD3V\-QYLY@F3JL3&7G
M28@TYK2VFXJ7?\P27UI0R!KX%Z;=E'EB-L+2B$Z<&U?5<"*X$Q75;'+'=KOA
M"$X-+[H$V(!(FS.1J5$*=L:/.9PB3(K,"P:C9X&M@T25Q<&:#P#2-WC_:SHL
M$WW CQO[]61O&'P;521M5S"HXVD$#C<[PBOQ8MXO,0W(^;SK6CXU2=LG7P":
M)FZ''S;C,A+1%INRM__U(C=XVA2UWUTQB&8 3JP<G1>2X^$N/5;Q[.>C@]Z
MJ56E;BG+IZ=PRPH,$+G];OY]<O*+(WY.4^@"LPZ>&..L088AZ[$->^XJ?D@K
MQQ$]YX.H4?>&RV:1T8&"9&BBY:$5+['JGHT[<B<BWZY85<O/A:.;H?AS%W19
M?@2@O0H%"MU!WE/,,=QA%&LM@XI>'VNP(-O4%SRKGK9.;_S2A<F2%S_JILR1
M!\B?V$'7XZ$+++F;K7^MC\+52R=$.GJ/R)L9J$<R6FAH>Z[PIU+K6[A)1#M.
M_%&+LV5\[KZTOH-F:A+IJD!F59]_#GU?S?.L\_%>+S2XY?FNA9A#O=I\>*&:
MI=_UI%/--"GGW'O[W9O[LI2<V0GB*VC9V^H1M'QLADM1>7'1E'>M$C9NV-GY
M,[:@*8\\DS2%>M>+=#Z<W<G,6ID8;B'&$W0B?2CTQF,RP0:WW[92:H"Q:,2Z
M+%WF-1DZ>-#1@U&^G*L5/'B::.6NGM( *P=1#6/)F+W$N\=_^O^_A1^-6DLP
MZC8)QO&J)4;CON?#O ;O3\^C?LI=?R[>)WF72,ICW^(A6.X2$%B+'YB_5>_H
M!-*<D+)E*5=P(E2[F(Y#+-3:!9%[S'+Y).X8<%<-5!;"/X.L]S&<B \@AX5P
M _\[J(%0*?D\<[F"GL)/Z<;B5*(OWNN;*G+'3L5:UA#E^2HB+@'3R\B)G9Y2
MC#YBZ<;Q6C)U6//0B=^&$YWWZP-PT[S=R]J!E-IIV. ZXVX!D\GQS/D9!=#W
M9/,20.8G3?EI\8H;VP'O-DK:P[UMC<HGCDRJYF[@TR7Z;R\N!O1>&=R]T;MR
ML&(Z^ZEPX;'!*X$;\@^UR>ZY>7/"R\%C^N[ KTZ[N8F$D9'%\4*[G>!U+,A_
M6.8QYMORAK"9.2F?I&)5O)L3\WM(+P%#LI0_Y5%'.=M0HQM+#WU@::0@L;0<
M4V)"'D:L_9QQL&[DO;281BV)KIJC/8,SP99@%H/FS?X'.H]BGU-T+WCHEB.J
M .!+ %879RS#-)S\,\5T)R7QP+D^7E NA&+RKF_-03_8#/:",COV#I34"W2O
M48TCLM$#MG5PWW_(K8U@H#?"L["-@X$L8ZU.[1E08EAN]D[$V8YNNK/EP0Z9
M#_]Q2!*?QJSVZB6@QCP3]JOOZ1.H\8Q.+>&VZ6YEJDIFZ_ANB?-'/U?STKSC
MR.IT]>].X(R6KZ?SCQ;K<A09*5?PCKB))57Y!P:Q_M=E'IO?RDD2$^BC)U(T
M+Y;K9FG>Q!"@[<#JJ"*3+OGQ'0'*8<Y65YP@P7XT9!LI<1PSE=RQW)[YX.V2
MK;6:O'^W@?OK\*>$=@QIT;D!W 7D6C_MW]L.K]!LOD+'15U,;5P"%$\SW;7D
M*7>!5<%_M6'E,58)#$8#?UK<W_3U_T26SD8M&B69VFTV\^ZM:Z@Y]X9Q[U@C
M1[9WH%6R[M#1A8JN60G[7+%*KS3!JRL_ $+"P\H:S1:ER8V:#)/V3J9L8I_E
MZ;@>7<\ T6TZT$M*0F3&)1T-6:MK(IV47LN&Y5PI*$J1O_O>T3_QUP&NP\KC
MN"5NYN(?C;RY\CD>,U=V+D^7.=L-C3R97@@56=([I_2QO?G-D;?JE[)T8[&V
MT@JMOL[H/0MQ\,N+E(+R>"?%GQ\**F=J-W/WXDPN C58)P^D-PC;.$L,4LSV
M,CJ=81S5K]-*AQ)9B8B8L6@]06D[ KNBG2-LNERYDPO;NOC%=+S0I.UXDR1R
MH-7,H'->;^Y .BIZ4>-+GA>\?#LSZSQ.EN'TYT)H<H84FK+2D8(W4,:F=OEV
MM.]==PN[30DK.M%4%VM'NL[KCZOT%(A6CTLO ;<PBFHH\P2JS/P.;38 E662
M2Q&L_K^D//H/*!!\N&[%1"QRX'6U^@?S+EZ\KFH2I9(0V4Z*TP*8V).CT$,:
M6@CC\]ZLYO*:,9ZURH9 R53[S[EQ2@V)GX^O:Q*M5U'N+]QOL0G?7:D=E7J<
M&O9EC\[RR4V09J0&ZR"3?]62!"*T"D3^W4RERX]J\<W[:3FI12Q6\R:$4G!R
MMA'_;.;ER++79]8WF"[W2%N:DGI0B(C&76BW1*]JLTH,CU42HR[9^J2[+&WB
MCL4U?XI93)#A)X/1AW;O)Q4POY5LWJ(1WYA:$M\#2:_8ZGAJ3Q.:Y0>_CEW[
M/KDZF>+HX0SC]H892*-ZN'2YJC+XU95E&TYD/2"08.F*"/NFIW"ML)5P./T_
MF#;2=ZY -O%W//ERS$W,3TT/]0U(LQ4?,-5/?$"P9IR\L[W8L+%JN,O'DZ(_
M>_!<P$9J/8C9J07%H'.T,'78-NT=4)4[H2WWRTV961&H0V.V@.*9R-.2I9W6
M"'T_1^KZVIJT?*;&C;\_YN4QHLINZ&^XN3^WZU/^ JMAHK+!K*B;#<O >[,7
M"?)#,/.])?729]&4BIZ6P81UK[@+X /\&%ZQ&+Y*8(#_ U1G)>R^X_D\-K:)
M+6)>$*M1\P5=@[NN3YF/)/?RLCYM\*=/U8[XO',R=M&[O@Y%P*?IEY)W5]&!
MT[WTCA?/N#\E4'U DHJY=[YM7-QE$$YU,]<_Q18#F)IL+P'70S'P?)ST.-AD
M:=>]'4_[26V$8]1"5=G\8,='J^+,J?R%;'IM;W>K33/LBKR)X8B&<)(HFTO
M4F)_KCLFIH/:W<C$3&(5MO/M5?#=C-05 ][H;SK#S>.8TRL>++3$<?&I/A2?
MH&S\YLWW2O8>-.?"NN,5.UZ +XO[2.EY'^[,M=!#VX&Q4)0"]$R25 ??Z==R
M 72Q,(*VZ;18+H1#*]V]+3N:;P0.& :U>PIU\D78"LRK#$M42#T,Z3K3M%:]
M*;XHL-2L=G5O0I> GDF'S!/NN4O !M;WHK8L\N53I/RQRO9^_,5+SKXD/4FQ
M\Q=X7Y#EP'1[YT+Y0&>>:@(X@SIE?V>>%;7Z\P>*WK*;U:5.RGOYFZ1G!BE4
M+D4=9@^WU_=-_+CI8>E#8FHR0-O;0U]H_0I"S(P7.;NRVANY&*$\C,421Y#_
MP\VDH>E9[Z1;.\<"-"3L&0M]!ZNL#0\2[&7B8) KB7!]#NTQ$-GR9B%DPL#9
MW$_5J'*N(^' 9(!-X!*P'!:$RE-WKB)Z#-;RQ%T]A\DHU_/),=.6.XEXZ-C(
MD<R7[ ANP9__.-7Y?X K-(P_=^0]H\H!8[-34V5\/C*N3C<NTYE[[1(PM7\2
MC;;HV ^[:S?=.B*?,ZTL@.6Y$U,GBV ?  8#(" C)K[:^)&?]8VHZA[+RL3$
M)N+G0<;')EI5)KLR:W-#5D9OK#CGZ)DCZ33><'%P"L?\2HS+MQ#XO0[]FCJ:
MH9S?S_7B8UWKIG[5MLW@L=JS8;L.-Y-9Y7M1&H1W%(BJW(>51I[:/!69B%L1
MZJ<OT3L8,?.MF?(OQ>U_Q,A40\3,&][E4-N<]\"&=YWA^=-'!:?6'@QWT,9)
M%%3:0OTV:A\$OZ]+T:7,VP3_D-3W!I8@'=^@5)3;S/L=40UE%WPQFV^W.?'#
M?7D?(R'[%?Y8F 4DBCZ</69-47Q/8OAY$=/U3XCBD>58-9K7W2+J2_R/:[$%
M>7Y39F\SA0N.39]%)"NB:@Z']ZM/07R]@K-PX8\_2@?NY.B+J2B[]:F-./Q&
M'S9-?"LK^\%I_92I:AC\M+%N!.>:,SLMMSXK_RZRY;&,Q2^"!$)LUNGR>*VJ
M7T@-.%K1 VZ*(?C6#\<I#;-]7)N_I;=&[U;V\2!J ' )4#G#S;"5).I'90JS
M'4%S#G$#_8?S%!TK-.<JI+\_K^[U%4_8KB4U^Y4508[E'^C;;LK]C5TI-;N/
MT=L=+;=P:GF&=D$:!WQ.=%Y84_8K#OON.1DGX48*]U>,[1(WG,J;Z-DX?V-+
MU?P,S_ 9=Y484"ZA\_WH_\YVAS_Q?W%KR7/=P??];B!^K1&8R_)OS]F?/\@D
MWLF[3P")<:P>$,IENZ&\#M!6RF.K2/GH#]>^DTB'<'_/#A"HO 3<W#!^V66B
MQM)[:V#^ZRL+@::I\GA(#RSE_T*%3W;*.'VD3SE;[6:37*>J/. U\)KWV]G4
MH"S[%CN.1Q8_%!LSRX2,45-M;Y5#B)?87GV6!26J_>=[]C_)#8#R;.3**9:A
MG,9A*%";#&O@HWA&H(D='ZW<&96W.@W6.5QQ+-C_DP$YN@')] F]@+0(P]V"
MET!MMD7S";D YK<(2!E*,I<42=HOIM?AU)Q^#?F9L_N85*WXR..I.<@6HBL3
MI0B,G+:(\ <L@*5\EF,L4$U'(Y_>+ A7)[1\^?%A]A:=O/CFP?H^"1:XO("+
M'0C+/.'; IZKL?L3>O>U70*H0*\R8YB,Y\PPCAW35I$G=%6%_4T7=>)D7V]8
MA7>)L1(&);XB[H2\:D$9J9ET0F][[)-@1I!CL*Z"8GL#8Y]Q83.YK)CW<8+<
M]#[W&KYSW/==](2Y:AN62N5I>-'[4UT"0ENTGZ"]'=!ZHMHMRU",XWOQ 0PK
M")<>4G0)>-.T@(^I@<]$7+&05YG3CNU7LR2FZ],E@-8[X>7HL2-MI?T19O<H
M+[)G32KN"8=?X>VPW^K**ZX6+W">5PRGWWNBRUAM/@ZU\/,$3Q3]:BC]S<FB
MN7DPJ)-NUW#)N>E%NC?SH1EEP9Z<HGXR?O:7O>)\@N^C2\ +2?QM:72)*CJT
M8_\66&:X3'M+XW:;R._<H2?6T4O+-I/1H'#M)QH7[YF.3Q$XBH2V&AFBBTA_
MNBFS+LO:^HID;:ZIWS/A*U]!:(0*+O@B$FJU\  _N4"=M*Z)M<J@J&ZD]F=#
MW^@3HA6<F7[X<'4]@:..6<!R_^+:YC2D.JY@>G)*CA&67JIZ_>Z+!FWQT1MZ
MA-\!!!CM G++4-?D3@[H .[HB"3A9"R9OYW2)?/8\T+UR@YL#/\SU[7_T]VK
MA%91CZ)RXO2&0L;U::\S947\&@$_SK8[O;;4KOC]1QIIMHF?;E3Y9JQ0Q-@?
M]*A88O? WI?W8B4XD?G#"KL,BD!Y>3Y%7;W;WFP*F FJ5"BQ+ &_0;/5O^NL
M_\WJ>=^%G*N0K'TD0V#'L9^VQH\D4[/)Z=GYVFKZJE#O07+L:JK[_5NG:R7C
M4FH9*IDXME?6?>ITRK"GF7J;$&Q#9M,JK1,/%=.]2">G%M$+DU&KDL_G[BI1
M@R=Y^?QSB&_P^!XT20@+[^ZY!XZLU$FL_U<]O/.M475FM[__YN+XQ[ *!;D5
MNM[M@<(2?2]ZC:0Y2;JN7/^2L*+@C)Y*?TBG#P/Z;K1'\J:^J/-,9?/P8<Q2
M$[&I,&_5)8#00@[?Y9L(@W>H]CE^T>T3*<)*K09P3JU"#B3];!JYEF;56W;)
M0NKY@YI99"@QZ<B&'B;#;).-Y2\=#6DY#'>EHQ5<+;Y9336B=6T_+UN(C&WV
M[+^']^$MO"PS0B3).[Z:K@HWE5*N-(Z/Q!SGX*"J5Z)_58;XKW9,$]-%C<?!
M>N,=)/02<6&B)7,FN1_)90V9N%4B !'CX_3TWHLU(9+>K/3:G)^Y"H\ [XOL
M_@&R8G_B_VF Q"\!?ZOVH K%\3>/L@V0H/L'>(K_,\ ?7A2VV*M1G.AA;)I%
M)HZ:GAM\=]PHE1G(WSGT4J().9N\0QK:XOM56=[<8NR(2\#-4U$';;G8$BCS
M%&.&DUZ&DTYYQZB^,6*M?\86'-:%R=5F$D70QP;M6Q"#7UQY1G8,M5&]#XX:
M36B,^BE$)3J=E^O[V3$C(MB8"@"M-,2F-%P"R"LQ9I> 9\!/+0<&EX#HH?_Y
M-[WP=VN>Y6O<5V)=;$QM2!_38L.+59*26;UHMJBT/(8;8:Z^=MT<8X$T*>3#
M.2U%.2*T7TR)QF9O5L?'*.K:)N//$AT*<#(C2*\+8G^^*QUO@9=4_!]^UD\U
MN3LVT")%O1A#CI- S66&XOASC.PDV%-V [M^4D:P[:D3N?FP'2BS'9IXG V#
M%JLS;_\06M2@_G )<&[!>=9GWKZBF5;XZXX3FTZ%DYB&=M<:DZ;G:A%*!MLK
M:JQX90TCR>_#7-W8ZHBEY@<X.Q0(04X6Y=6:\>@[FB\U]H>R+<? [7NQ/[I:
MI9RB/>N#HL>FA^T[IP(=5#:NUM#G_VFS_G]TKQ/KB-W52P"''XKCXNIS. \^
MZ/LW@[L#Z!M'*<Y!16;ME6HN3FQ%M5;.>FRV:,I#BYU]K+QWS9)M!XTPQ,9,
M>F=^6#FLIF9RYO,=]UJTA98$3UCW%B/-JY([@=)<P3&APNE\KT4RDFWMG]"#
MNWF'Z)F^7@L0=B1$]%>TXIG?VE)1 ''OQB]>8Y;$4MM2ME@J&@Q_72OLX7B]
M2/(T37JU7C@_K>!!>A6(=W?&H]%V3.Z"2\6*2Y]-_X:1[/5[@>1Y,BV"::O:
MZFY>+OK0E^S6KPH'^CBP8^RL (=-W1-W;0&8VFA4TO*=B* U\7683$Z2=*_<
MA@*I9DVCH[Y RZ\(USWN+:&W@ATZ!=%Y)XEY>+86/<OEU71%SHY2/A'CM.ID
M%X[5]6&$O*WK&FG4::B&[P1J/Y$\0OCK2HRW26U%\C31;YFW6 ,AA@^!]0RG
M-ZLKOP9W=O"H%"G<F1)OO=E82O5(=TN^P%Y^#IB)%C4P8(5?5"4VZ"2=3%D<
M1C:OX!6W!+];W\FE_*,I3RK;4'N,H/S+HUG9?K U!*N)B4:TVV=OWB^,%]1U
M2'AT=MT;J<LD"&IT-P<MD3_8HCONKAT_MM_/YPAM3*M934 @+71X=/5[UY<Q
MT3SM(\I:00G8Y 48?OE(0B-LGB)"/QRGE9T;,4-+K_GQ[E07\=R$2 /IJ!CK
MDWZ&'-HS&B9I;WB?>YE];P=];<4([*V=/TO]T/Z-WS%%?;9NM3+6::OT,Y(:
MAZ7CO,?A;61\A9G[=O8KEX!^8'ZE0?<E@.02X+"KH5P;JHX.\>"F>G@SN_CZ
M8(P!82CA9B8,8I"S+2K#//)J5'BF$/XVWVQHX+:S/E-7@_U8E/Q>IFWRVI>W
MO0RCYB7O3^6G.;.KI%_]97H;GM9BGQD]SX'168KB:G^>U,-<5^&3N:OI$_KN
M[3LO,NZ-Z6^%=A(V,)8>2(&QN414\<1=[EAI I8  3P-)F2_,Y/\B/<-IFLB
M.:F$)Y]]NB$F:]=,6M'%A3+W\9U[;$^R?B+H@O68 L@2V?_N"NY/_+^-/X,4
M $JD175H&Y0([(*A+;+/D$93+@0W\N>IU/?/%]CH@!U)9-R;#"WO>!.R+9*<
M&N/.KOC% %BQ"36P<X%L(9EZ.5@0[A%SU-1R,'S[_:$HT$4@&X2B6^N0?+X&
MV_:P/?!-'3+([+D8]\(.G<F]1O7C^<!F"3^AQ,).+N:!!\B<X=W]7TY>;*KC
M1A'!T0)CT?ZZ1#>B!?W/,7]D8Q3'X948OD8(FFE"J=[9:N0]-Z%'I2<3.#)(
M)DM!\9NTX_05F8R&WA3.),$/3$#O1C6Z>0=U4E<\/\D6')J671,)\R5DZ49,
M<&?6<Q]=:UB](<_IO%-V"8 C?BU'INNO_F@8&=' 6!Y"-:^>BA4G&3^6A%@"
MAN_N04-4PYSRY(XU(S0NCBW$P/Y7?P?A5# FW^8<,VZ/P_Q9-T_*O]I6U%0Y
M2LMRKGS^6%'ZA3'QE*G7\:0K8CW>Q=;2N[+& )2F,:6Q" R!VF6&#V&H.YAD
M$I GY7X']O&J.9\FG?-I?_',@Q7$F,%9@32!@F2$D$_+Y!@6\HC*"SY[,#_Z
MN?($_\3GJM&C(IY[%XT=26^!&#+I[3[H8O'5#-R5(<&/CS>SHFKQW1#_WXQ@
M>IV*GF:C=*LX@5-EN_&75\K^R\1.9AL_(ZAC/ZB9&/V^:+6_S&X\Y6/A3='&
MV)+O.)J46N,J<KM*^ZGS;;P&ZI'],*S[6,W,'[C60H$B^IG!AH%CKX']HTT^
M2<+)O%-5/:CKS=K7%K2J+.,C=1.3. A#M-\IR-UIA,IF$N,Y[(&TS;08EZYI
MBJ3AXP;QO25]YDJKF!11!)KUILY>?O.]JQ$< PM]'Y,A\P8AE)V##(8]7/.;
M6@%")AKTU<-^ >C'3*FIHQ,65Z_="6W]NPG[V,+>B\Q,6./NG'$K.:H+W2D*
MVJ^SPFUMJ(WGB6MX0UNO##7AP&M/S8Y+[Z'X+@@#6IGH]Y39^R,Y%/B/DQCB
M!G6(_=BLOYGG=>N:'6]NXNT[ ;T?(_$LS;87:9< .Q?JJVD5?#,&9C:E9G,2
M_U+_]JNH6H)HN2SR8B[),/\A%QZCF2:5]1%62O8'!&<>RW!R#22(SC%%>N!\
M6[+G;KPB<WHK2FGEGF'B<<%N,,K9L=J"T?YN)8R.^%@\ENPN9 KBO0&I@\=O
M'S::,QGZ_B9WS@@]$M6)";'\&&S7Y&2[<GX),+L:KC*AB?M%%E.TY*DT/7CV
MDE&#EH\=JEN'N2TE3GCST."456_P</+W#EX)D?HC =X]IKD?39(P9_OD."':
M%#FZ+L&9!CW)$LK:L^35A".1#QZ/#+.>ZHDO?RO,H7ECE5]IA^,/<Z6-(5G<
M6DUD'U#YX0 J4<T_AV4N>7&7L!])PF9.;2-/+P';!NRP266G=];L&6)20@QQ
M.PZ\W%JB%(>_U-K)M\U>E'="G'67E&;?06&^"[=P6SD[[/D(2I72H>_6[(9N
MQ.(B(L>ID[,T"QG()GDY?<_\E'JQRDQ*#;L^QB&A]A%7;!]>Y,AB9QU=@;\K
M[2QIDIJ<V6X<]-%C]MI,M_KU+]+2Y[X3O6-%6=M$JO7MJ[ 5Y(04N2_ETEE.
M;5&OMW')O=!A+1PX9J)P13G'B-7:>_*FODZLW(9<@4$"_A>>!TJ!X_\>[9=4
M7UO.)!=7_QE/5L!F&8DUR/).Z*+C"-KU'X(Y5->_593T'V+6!WOJ;2$FKSE.
M1G[.SO7O"^W4@85&LS?(EVP/3F8W:AA>E$F1%Y1F#SK0I87-/&MW*3>%>E.S
MQL"T1J!O+8CGU+7WU<;>LL[$L2K$6YV_-DR)<5(_61//\$A6,"VKA,*E8WRS
M:V.(KN2.2[14Y8A(@^O["YX]C011R+5J,6BKNUF30VYNV=<M;9A*H\^FLK*/
M9/ #K9>3G-G-+A<%5R(S!VD;(9S*2+(V?-LO52Q%SA40FT3Z(5 C#P!Y*.]V
M";B-D_-:@H=.D\']NT__H'$PNEUMQ*!GV=];6?^)_]?Q9_R(!'=TY4N'O:_M
M=P !C;Q+GPR-#7$@F%,]]["X,^OC1JQ/^/U+0&NG?_ $"$W8ZLO?27Y]VYP"
MS9BRL)'25#)M9E)#'Q<B2&Y#=/U>-S/36+#=TY]]'K:GDJG:\1_W3L8@6XAU
M ]R]A9.,(3XI<@^4I4ES!,+L1WT2]H51JEUCH$:&86Q&64Q=]3'7&6#7X4($
MOCYS4GX1*L."[\[@3=6M"<'JHZS<PRL7J.PW6I\?D@:ZI;5Q2BJH$S+I9L@N
M8"PO 3?T+[*:Z3?1AAKP3;Q 93"5>'+'N#DX H 04ACJ7I^;BFGR\#.<4#&1
M;MZ?P#.LG;AE3\])^Q^>%G]K; S2J$K9VK+;A7U3B#?*?U5$]R'^EP: X+>:
M/X_:U:4+,,L\+S\AX03/.MYM%IC?E_G:P'H$!V!&L$Y@IXO<;Q+\X8TF7O\?
M>^\=U537;PM' ;$A-J0;%:47E5XC(B @(#7TH/0F(AU"HB @-0("@D"4%JD1
MZ372140ZD=Y[2R@AI%Z>]WSO=\_W/F>\][OCG'//O7<\?\PQ]MXC9>]5]F_.
MM>;Z+94$WVLF?3X!IB-CA@_'8A, @]ZQI\[L#GR%CJN[NM;Z)_6M';6S;$C%
M+<2F(OF1M0W1^L/C/JG/?'U[!4\-8:.5H^DFO*U=?$S[CU&-L 7H:=PC#$O3
M:>*EEFH@?C?'V<]/TALYI7E:A Z8_X9=FJ9<2J6=*B]UH0D.P(0IY@/CVA'-
M*=L/<)-S3V>7>/+:6X#[3\Z=[H ]_2UZ69Q[$S*^.R]3CP,2S/%.T12)SW '
M8KQL9>67^IU$(^[NY]%M(J&Y&]-#0)OAW-KG[^&.^Q[YU"#H^+/U_"SG<*@)
M+"31U"8==NK6>L$NB'*E:"XE,X_"AXM\R5>C,>)K;>R::%G E#C&L:#;LUJG
MQ7ZUGKL/:_<'\<+E=821A:;74D^:2&/.3UJK)L3UYWJI(<E;\B!A2@71 8>9
MPVRVXQ$_HCWTV[F&-S[[ZI]W?;33:G<*M'[K+2[Z(^_G.QD>!F.8CYC7\+,^
MB##068KL3.:ITZOIM][Y)4@"N.XS]_#9$3-C[AS8F6B<BQ-.3-FE UZA9U*S
M&J-*0&Z&Y^/[Z( PFL>AN;\"23"[7/0_RAY)(5(;, O;,$8ZH %#,JXDL4*0
MP.I42N;V-^1!*AV@G8)17?EGOOYCQ44WDFTYS6P+.!E-=*S9];Z\T_%XXN;)
M?Z=)T$1/^2Z3];]TT.OU%1&D$4NW]XG!@<:Y"=]K30UOJUY-QJ,Z64=E'^,V
MVSO*9WXC#09RD[Q7WX""75D-<Y%IS*C'RNHA.>I><\\K\ :+R*ZL#LOTIW?K
M,O9L$#X$.-9[)U3]SD,\YERL281J,Z_Z+5A2 &8&$4KQD#K@2HGT)'25+5E;
MHE-%[/+G5 Z4/_"--)2;4M]0Q+P\%UW&.C[9_QQ/#VSI$2 7Q14R#VOMW6AZ
MFJ]O(S'A@LR?)=8S&$BX9P#SL+,TS?9WQ/G 5,'ZEVN:VN0P36H<E-=)])*-
MU:15]\DQTVM%EW.&!_0EEPX,/_H=KX0)0"_@J.A6\O2&K@RW98R[WD^88[*Q
M;83C0F;C[EBC4K5($5=#I86V!90$PN!JI6O03$(:EY/\@S>@UPL?2$V?ZQ%O
M#XY"VLHIYLQ7RS63P"PV"?.Z8GN'%_EV'[15N,.CW%XV59&5TB UD\J-A2%)
M+:8I5UU_4MS:W*LJ7?M[G@@(FO/7^[EUY^R665166%MN%%][3UNA#E*G:97V
M_99;,*!@@8@D>DC4R+!J[/36&@++UC/IXB^3T6"//DA-,%PEM:4\8F"]*[Z>
M/ETY+(:^?0%'!TP^8]'XO'2P&ICS-KMNO.3JR/K-SC),0P979QUN ^]]X9($
M2LW$VVPX%N%)9,</[,XB7_DJLO"/.@U[VC.5/KOS%9!SVD1S2DY@V[_38EFZ
MQ_\QGA\EDU,XI0,/OM/=(VF/1-DJ1S!YJ9RUXTE]?/?N[6,?_+%L@T/:NN3&
M<U:F-RH&/@D%)XSZ8!\?B1G)7O9/C,]5O_-5!G<V8\;\'^,^J.42/RT.2\46
M>TV6_1PI6M.[N[Z_$$1 G\BN>+VH.R7@Q\H-83 P^20":B;E[(VUT,:-OX9N
M_?*IK4QCZ)3R2'90/BG]M,F ^JY)7,<!EG5F:''21<92[P7SUG0!0B6RVL9M
M;8U0,&3"]Q,Q_F("*BFJ@&:YVN/WQ$1"*H97=7BKN&3+6H-!]V(MPV""Z4J)
MOK'][4[/B^V7W2Z[WOX<#6#H.Z;_G^1Q_@M_X>^@S!_QH"KX=\W9SH%U.L !
MW43CI0.Z0+A>:I@8?,\0^PV),^T]/$F1(UG#-RH/IELQAP(T3CK@BP.:%FT!
M6''^W^ A_GTH7*LKR8K,FURSB!N240C)D/#R\GT^RQ<MS90VB@  3MTD&7JH
M6\?Q3R8H]>6UZ5_^_%5CIH@O-H+Y,U\-.DOE&AW0K QWPD3YQP464B0'-K:Y
MY3^H!_I,) U'6];Q\1PX2./I@,YMHM@-EZ">J61<9(M?74G%Q<N0\P&QWV\@
M&4/MJN(20K-..CT/7&0*,$;BS"40GGRWRW%0VXQP:W$KUB=I706F*55"4PI6
MY#DL[9086=YR2FDGP,VT-NK-C3%KUQF-IF]%)Y8GXX(C6_1']6>!WVHO>C(0
MF37[/=^R66O^D&5_>35G\V)**O.@G\@.F :\CM^EA33P'55]+9RX#\0=LB*0
MNYNS0 I;]]&M%JGS5TFZ*/=.<+7B(U\UR.+/:"KH1S> \H@?M.^*YG>:?8W?
M8ED_L+2/!O,),/,X8JY@9G> 0-#R> N(*'+$ A#@HZ:TL3]?HC/G_PUS+*#>
M_'P<V++?P_?,)_=POHM:%\L]#/5.Z#/P%XW6JO9FN^W3 =>]+;25(?NDS,A(
MBFPN45\G\E'?7KT8M^[KIR+**I/7PD&3#P"LWTR3+QMOUUJZ7S90O_8?IH;^
MW?.*O_!L"W7^D?N*-0_-/U:E&#^]RR!\48X4?9A*\*)^5++#\\W=Y-*HAKMY
MVQ,2'QF*V,=N 6P7P,.//KTK.AO6?*)H?+7*[ZMGZ,!)",<DCRMJ]_A+T?Y_
M93<RLH]SC,OQG8@]_35KAH RN <$T/IMSB6U!%7VY&A,6<DJSOHR2KP[["3"
MV&;]3>=,[)59U2!0V'#3,00$5^=:IADU?_5!Z>60P1]E)"#:@JBRPUZ1]BGM
MT8N.<4[+LM*,]=/XWP^7+C?)02'B&#$J:V7.&U1,"UE4HRRQ'#.![?7^D"C)
MG?PD5*BR5B;=4Z;*SZY)(3I%C&M,NE7H+:D,'47:EVOW?@9S ;+L0C7XO5IW
M"B&.AGYU>UJ-,F.=RNH^.RZ$34Z#BT(=Q\8DS1(M"LN%K,Y[61BTMU1N% >F
M+3/8[:AHRG>X6IL<;'ZV6#N0>7^:W <_LR/R=+#M<4]XVB,QZE:1V0&77>?Y
M%,FE#HV0=I,(F71U=4Y'.;9ASOO9#>:XVGB3-]V%P@%US\2*2GM4"DJX=C6S
M78J_:E@_=%#FU'-=-!IPIS7;\6ANVXDA%\'"K.^2:S-#HP5S'_YAYOHT2S4B
MLUI]&7I^JC+-\?#5-=ME.49'S,.*8'RABXQLX4G+]Q=MN=$_/^X>8I=>"_=(
MN;ZY^6*-C</^3B\ X0WY-'UJJ;Z&Z/VQD=B^/$KX@9FT?3BF''$'X;KW'&&*
MZ)>[G[-<I).7I#!V6$[X2)R<0X?3A ;<?<Z,!UL&Q\BFJZ=/WKP59LN#="7I
M%4VX$*ICN8*=G6QOGTV(X-M%/Z3>7FYB=\-F"1*#/[J.O8X1VUPL[!;)#F="
M/&?67G,IZWC;4< E?".6R>"ET%^&Z+_PGXJ_,J->!H!;(#@S_1C9)@9JNGN#
M-.I1G_[<IJY[*2='A$Q908HZ!VWWY#M2:&MCR#@D XBSU#\]Z0IDAAY#MW(K
M5WTHT?%0%)Q56GF12W;D"7E8:J7_+34#+N7SA*9X".I"WCPB%$I'9<6!<>..
M,VJCB6#J!QI.Y4Z<N5_%9#I'6W:VXRH_?H'-7$?FE.)+C@7$P"2(=@I.EES%
MO0:RI,Q^8=#R*EX[UQ-/!ZSC0 "1-T=17F4]W2^/?+W=SOFQS>K8Y *XD+6G
M,?I[L6:= BN1)01CDVR?/62X@KF<UJQ>*R P23LW_6F7G:(((KC0 =D0-SH@
M3&>;!M+\TQ6(7K_5TO)/"&[CJ*)1M*@0-(U% D.DAK#, D^MJC#@FI)G>T[\
M="&))WOP9F86ULM%WWQ<6/\^1>Z/#%IH=<5ZRX_%Z.?9T4)G_T-9[;]WF *0
M7=Z@'BB.G*7JK9T8E;KR]4>LQO,?K\,0G]'O,8[;B"Q)8A3^"HN U?#U^C(W
M^5MW.MUXG)XS, L?^\A:]/E/].!*#.N;"L7-N_!]L(&4;A>OIHWR^F[,7%62
M9WY ]ESS(%5E>$PD\03#^8";0?/(#LR])N& $5!DT[$1WQ%A^\J7[PT^<"\H
M"2.@Z921IF'Q_9+[2R2:?UUC[=MNJ8$[CG[*>KK^,UXXE.7:42=+C:(#(-+P
M&O(O[F;M1H7D?#3C2):#OJN0/8=\+KH;3P2'MO6>(RDK*\"8URN6-V_DLF46
M6,Y$:?;1 7'.@_:Q#\,M/Y5:F/#*%US5\$YIE6G69Q$[B-F\57T(XI/51=J]
M_TTI&5RWJ+..JPB*S "[??D&;$7FV79QJPK9A.N?J!)#[7X",[-,_\9^,M2+
M'79V/P )=3_WD4.(E;361E<^A"3LQV#T->O6,N.SHB-^V4G7E9$G671M*NQS
MWZ4:':IQAQ6ESA4^$4'#6-I)*-OL:.'X:T=U<IP6GE=573SZF^^N=-LK!J%C
M$2%WO=*IO+A-)$$_TF<=?(T[V+G_ \>"("-R&<(*/6?-K(-7<(/QOS^B5Z[V
MIG?839_T>65I$2AUPW1 S'2%3#7^AEN<2L^X-FYKKLB3\X9.^/Z[9>2!!G.I
M6U7LO(:XOE](E6[\IW=/4&^*BI>SHZ>Z,0Y+(6)SVV.RWZ;.)YK9#Y]#^7,*
M>^P-[W[@J]H(!\: CQ7 QKB49-7=E61#?#U?D;NC!J[T>E6<H/GN^)HTU 18
MW\\X+CQO46+^HE,-Q9KEF)9__7&K7#-&?.H9'9! \(LA/PW0P]M::^H.[759
MS6D8FV<CIJ^' 9O=1AH$YK=9 Y8F\_KVW4(>7.O.]=A%D7\$ I-AGBWMV89Z
M6FS!6B,2%2S:O&JZ=2D=A$MU\K/N=Y&[8XGM>N(#0]%*!K&M)CYX R.MT7'-
M_'0?"NN@L$@+C(G6WQ>P9.8#/']RH[+GU9,:Y@M3%[!4+&%[?*!QK)%#UQ@<
M15)AY=3DU3+]N/7_Y%@:^Z]V7/R%_SOQEYD(P+: J=0,AP$#MF<0;Z"2>,DV
M+D@X1;;H8Y6UD4EC]+#8EG<3NV9"LG_11]O:91=>29M*R&UX\X,F +&>D$!%
MSN-20TLVG_DF%%O:7&ZH.2^0$G/-KN;@,)(MW..)FPV!,H(1ZREP49P:P<Q4
MD'N[)5Y"*C3?@&8RX;S2F3+CIGVT&T098B$$'>GK_*S$,YOQ$'R^F_MVO E3
MDV9SLW!K\A.2Y0P=0!1>WIB?BY,Y$S-]93K@Z99JRI?ABIBDF[#VCUI\E SL
M,HBB($ X8A\?]<*.V,+100N"Z*._>8$.N)?)3 <P'QV$^^QJM6M8C!?T_JC-
MR,DC 5$0W"[K$9&(#D?33F]CB.W ?SB'/:4#6K/AS@@2XPJ(*(>@"-(!D0]H
M_<"]4WUPG!>0:/P.E@EO_0ER1)*$KV"((DUTP#S;GNQKJ'DN<;>%!'ZSQ]W\
MV;FNI,(_Q5\[-M0L4TW$PY;#_D(S #M+!_SIEC'V&"<0XQJ2!7:< L+E5_-X
MN9+$HUR>^+W]SLM8UE;X[?;:75;I[-A G@\CZ_N8%37/-/%T6F1VOSI;VO\X
M)_O_1 :P?V-,XL\LYY]NC'7RGJTJ)]MEO[?WQW,BI)ZE&0.&AO[\/[] 580*
M,17@JH)SBG$B@<@;_1!LS/AV&.^L:,9%9B<L#2Q^:('Q##$(1H_M)[Q;]A)_
MSX&.+YJ_LX]2NUK8&3"*3B#[G^E@%8ZVMD(?T ')41S/+*)S8Q==8F4J0]@O
M&,2+L&K>S2LWA2LW+?L$_W:1TQHX*BCPMZM1FH;5$UG.Y&[LJDD%&<'OD4LI
MH:R;O[O[5D.UV/+-HTMW"6LB ZU=QF%Y?#OB@BU#/^[LE1??F"1/-<$,+4!$
M@0(B^RP-/;?):M0X8*JX7&8D.G)'Q>E"6.AL\.YX :=T"K[!GEE#+7;V71@)
MVX?Y$I+9^//J]:$<4?&<4V[/.7"CBF\_DQB04' -<7<&^!H*#_!$B^J6YDVM
M#4>SS\>M]Y<=DK&8\):NV3D2$N&5HJ,C][/04=Z'#HAR'!PC6-<=[*HP9S=E
M#(/L.*]H+0Q2[B?FW[E\J<U.OM/TK6=OW[7>SX4*3AM.A5W/V!]CW3=1+$B9
M<9_O8'+]Z4_,T_!9BQ";_!'072@H3>@%6:(=GK;[EO$MH$L)(#)$NP1E'H&&
M%&J*39:/N=RI$@@\U\G\I7DYG<3= OIZ$ Y5]&(:[DND+5U*V+W\B&:/_QW*
M.M+(W<X5&@!J#LI<S*S+-AO3NOFX[?BKEP\[.7C(8%TEL<95I-JKV4C]@]\'
M6R7N#?7(,U"S,+T^J('_["37XI;/I#*!D_>>F #^G,)\?D#I#:1T6VJ2EI?(
MLQ0G%^NRV'*>I,-TA^=:DQ-$X6$VB\1T4WV'4;_3@MFY;7^PWO1?.R$J:]Q%
MYEE32^P7U:6<SL8JG'?;!KX"7>ILVV92]Y;O*'*&QK3OV\K! !Q/>J 7;';)
MUP/>K-*4Z@9D%ERO;!R>5OCX2ZMW]B6(:[VUI\-OI;=P]J<[KN;W *9>F6MW
MA;:[82&8W1A&L/VG3/XO_(4_0</V8^)SYIOI (LEJ#E>I/7JB?N^C:XC'8_L
M[_76.9(T:NWVVP,T.WK'(H(5QS//-'_M.!L8'V(&^.V^4\;0W*G;B=M'O]]Z
MYMA0DS@W9RZ0I3&Q\Z,]#5$@4/)\J%VP7M-HUEM% !61E!=NM6/9A,3I?]G7
M'S_3/'*D=[J-ASC*SEYA0SCO=\M*I4,VPV?6\Y(V4Q3RLXQ??FSY^NS@T#*:
M.!>]2!I66\2,Q':F']BDT)!SL)@ S3G_\ :?'#*[165#*J<,F?!(I:R*^RJQ
MW9?M,(9Q9ZR7I^\AKH=S(E&CW5S_,U]>B#0.3,A)T2KQD>#4:LSU%.=]\J5F
MHTB0@0X 4JANA5E"6F-!0*,4+W6E1\FB%@N>3H,TYH405?4;7WS/YMY->*MY
M;0#K=?!OI6]@7@;^4X]0$^,_GUCJ8U;[3]G-^'\EV-J@;L3:;.@IHN6<!&]
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M3A_V5(:LNLJK' PT@:)WA19K[9>UQKQ=A0A-VUMZ4T[/SB46F0A\'=*.#WB
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MIU>(5F1/K'#@X:LW:B$\;)W*CM#A)D9I=O^DT-L@J5*<?.]6D1<HH @VB>B
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MSZI[#DQ_+I/EY&N)FB !T)&;P".J4O*G6Y( 5-4V%HZYG3KC<R*6 GRO'WV
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M51+,7W[7198;Y<;=_ZNH/4TI^K(K.VHG"!W2;ERYEYN'O3.W=GZ@G^R=O+7
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M<6"C0 )<TL&*Y/9;+(/#JW_RGG\TH'@\8H;B!S!8U5B=OL+<\:>@6T.^%%D
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M0G?=CF>#UK782K<N6@+[# RRB?VE0BJCE;E^TOU<1;?>-_6U+Q"9YON-342
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MXGY* O!KDP#TA=AY$D"INHT$P+- 8 =6_IDD %T0(0VYWM4.P4H[$_ECL&[
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M9W6$:-;JW=?HS_%Q?N!7ZJ#C68=SY1*$3:^2I&\563.!AW?7&^T>OXW#FY
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M$/PAC3\2]A89VG#K+L6[T8HV.<9Y!Y.*CS'O,S?-4N#HEXC).)E3\?;@SR2
MNQN7!JBXAHG6,&O/W^RE%,%7$UT2YE_DP/+;+EDO4LS%W=O]IEIZE(K1MQ@
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M)PA%81Z/VF9Q?TGT.],O>^T#4Y W> BXPT)4(\#PCH2TP 4X1R=7:YAIH.N
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M,4!/M>4WU,?MSFO=?"AL>,O4E(\U(.HD A/1R1M/9Y.1\6Y\?5QA=V735I3
M>RIPU&W(G+$6B>,.O^#'$\T9-BI)@B_(;C0K]\KSFE>Y%;[867F^(<@73M^J
M#[Y#DB04@CY*=6<M.A^^L%S3*[H*C0QJ50^2=@R\D._*/E1;KMI2QB_\^,NO
MXZHH;[;1PV^7@U2\E2N%Z\'(1P%B>76J=_Z[P]+\GRIE3=G%SGD;QYQ(Y!74
MGYG<Q!<%]XT-)M+KP+R4"2 G;W?Z"78X31GZVGDD.OS1@^Q7$U?FS.I;[4SS
MBGFSU9R_=4IT-HU-;J?ZDM^",,@=[3)"[NHX1&+,Z=3T:<:O]Y[WZ4M OPI\
MMG:5S#YI[0C'"M6HQ'@,(X1S# /3W=B7]#Q*]FX&BT?W(!'&^.057X+T$YJ&
M.;S+@G7"H^>%"8Y^L,)YN9\O!M.].SE"R'XC_4&(+; S1)+0F <Q'9L/DD]G
M[+TC]<;Q5Z),8(R F2K+/FPD:@ZK&5/' B"DCUB.:Q'5FSUYK_U\ O+GY?]<
M52:?I>!8?7BBX6\IE?X)+:]67I].!4@5;S"Q1RS .<T):YWW>*:RB96[^4SU
M30JX6\<7ZL6G]3;7R>G78K5*V^=4GQNHLPW\ES>O]L$H!4P&1!GK7%_]KFFX
MB(?1X^*@3GSZLY>'%(=6ES8A<EG+P_?E)-/TX6<5/&Y-ZE?7A%9/OATNJ02;
MC'S.^"05GSF"^]'^TO[VV[&4Z#7XHB<B4J(K*5%/6[5O3UN='0.,_->;TD=$
M29)Y1F>V8'P'*K;S7E+)/<F6GI.7&;_?C[;]Y=#6!1L<$C=,TIS8<<]CL/^9
M8&_]2^#A2,!I@#X*V(7$W_DF^*-&HJQ]2F8OQDLYDGZ??7UQ2PR1HKD^"\IZ
M%,YC?)>IS;I5&?AT3/:\H?8OOD37Y2$=3&I4G;Z<;J651J*WUL48EJ+?%TE;
M5[6]=3TTLE#'!N_NI6G[:QV>.[ &FEM?V=/Y?&M^8J.> $T[2CZ.:U$M*N/-
M<NFY@Z [WO0G,7E:1"#<+YF7^_N:<595UMNW,)U\G#X7++]HX=L)9-M\=HZ'
M?6S%]T+:DZ>:DY_9QYS_1NZ1>RKY[Z9\Q#HE5Y]:)TV'<9%BI9T-+9\,$'7N
M5I)NWSL!$2YNR4NC-$95)K^/%J4"-Y<;OEX'/9>-'VYL?8S_C&/J5/CC)O'F
M=]4%DX*700^%6<;JY=!_ZE<TX$CF';22Y<-VL(-=.TF\J)IP9M'5Y-6=EE;A
M9;GQ'41]+^=1WF0!R#X322@<.);NW\9%4P'1-I(3#-SRC4NHN\0P\Y#3'3KY
M#TB>(OCU3WV!I?=%N@*S;56U^)"3/D!FE;M%-5QRXM?-7YXDT%,!OVNLS]W#
M6?:4LCGSB'64B0%8'FI6)Q$*@-/?HM"(2F@KY<V)M"[!&1-KU'_'*?6A,/''
MTS8+BDAU?$^3-0@/Q:FCRO7>5&ALLZ?8#M+#^B^"LH)$U0US!8I-5$*9@'&Z
MV3?LB/(QH!GO*5&0])^=7TMM'KI>>"  (N[4-9B:^L?*+7VAA'[B#0/4XC!*
M7/TI8^[Z>#_6"_^/8#P*121%['!B[Q1*)+TWNE:YA[]Z5\^3,$5NK;CW[O-?
MX?<%;2)YP@P(#"E1H\(_52\:%NMKJ?_#?O^QR4JWXH[*6!BP&!&-.;3T<7I]
MW>4>MN<N$+C5L)8=$;H%EC?;6$XH&*WU$//ZEP"*!Q'=.7\TF#2<C\#T;VK3
M4D6U%VT=CC1$5TZ]#KO])[$[;4[ C+5,5<6)%/$+L*"EM3EHZBRD4-V-$-JN
M=!SF"W7=4+#PF=T]&.=:XQ[)554--#7\,ZOR)6]F<.3^X%,AX5Y58[M5DOAP
MC87L0:-1)E BZ5EXU-@81*%T*U7&\L^+/KG1GP@;3CN!D)H88&4@M /]Q]T
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M7>XET5 .6"F"DJ(+MD(61E(DXI7BVP^@&32LVJC[[XG8_VJ!D7-=J0#0'2H
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M"K?W)WZ1DK8(.FN)GAEBG\_U8\E1@=CE-&CH<?E2DK>33S1\8T_G15- E[U
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M? +(P4<*'>7U\BM92WG]%<Y-+S1A8(X/>>,7]DC:FRYJ(GS1P>:^4$FI8J&
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M/3Y"K-/TA1WX""AJ"J1M:->]S84_.CWD7S\Q28P[JV!I<^';?;%?3DJ,3P\
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M>KA#[DEIA17IDRZSW4\OAP3]&Y*)P,7='<T7.(0WMC.-WSTT3^A28_W]BP'
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M0IRAWJ/9H0-J C !O\X3:Y2RU<DTV0=Q1M==5KC7:-"AA/1LA'V3/2>)=;N
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M%T:D *I'A$JY#79V=QSZ-9<-5VT <M^OV;+[JJ(?7J/WXD[U9K@F\:GX\0'
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MFFF[QV_;]OA6J[\3#;F;N)E%^(C=Z6Q-LFIM8OMP.]GWNZ0V:7 C>Z 6.GQ
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M [$Y&&A1HRL34B->EM?0RC5=CC4HOD^Y=%8C]U?1E\4B8LD9T(*56D+WDE<
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MB!M_4VMCU,CTO914ARLEQ[?: C'UN\\>)YK[0<"TH7R[J.^'>Y7QQ,\DEJ6
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MY-/98&F=W*]L-SE_KTXO83E;[KM>"=W0)%SSDDD$@8W5FV95AKU_NCTB&;'
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MIK%3BQRXS8G5P0&=THA+25%N7=U;3E/[+QW\CKEW?O:^ 5 FNGQ&RW0C+Q+
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M;.2L:'J:'##:9>CMT'P._QM__B,<9_@%^N<EPZ"K_X'"9Q9]^+\'\]N\Q\@
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M:I#"R^Z&>_&96>6/GJH M54.8,=CE.V$\TH==/FYV\%NJ;3$T6D4Q#;+V]#
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MA1=,2@T1"1XN[HG _;D#.I9/TA#& !G"I18MY33W9!3@5I\F+O<&.Q;=4J/
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M-W;O@/Z@-I#F<)JLF24WA0G\V?E1U1G;,8*,N.C'E'?OV4K%U1TE:ZD+G:C
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MXBCG:O6ZX7/I[U8O%+=@<YTD0(S(R4;.Y>2"$/AK,$P1-G1ZC& >AS_'PY:
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M_M7?2GCQJ3#89J<."8#2A&$&P'7R9R$7(G<NJ6G:3NU_.B:@80Z^G9 :<SF
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M!NG_426+W6#VH!$X]B#QZXGE63B[H45VD9'1\$-Z=3%VP$<.1KJ;+('\:3&
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M *G,UMC^CZ]&TL'#S&<AWW?\Q84..595^?&SRP97@V)5:V5*F2=X1!]_#7:
M>J(S>L=C_AZ4K/T-#M:<.U)M0S=Z?@VTD7,W,ZNJF!X7_.AYYGZ#G+IJ(TCZ
M[LM#&W@4HKIM\O+*9![IMSUN^] .<ZG9<Q@B]".PQ,AWX/ZAD:V&?<0=K]XN
M75^@D=M8HP1!-##%F.%.>8#[MX[@+A#L+O$< P4 -WZKW;^HB3@F.@H]519%
M_4"J 3OFJP+B&A_^KD%[;4R<]B1T/I@-[*\Q6'VW:T5+U%=^54P!].]50BF
M_0$A<#<-*#S$?!$VB6A3Y.P53P[Q6/!S*^@(PJFW=*-E-J<<XPLW?IXJAL17
M?U 0ZJ\)M[/*+KQ\D6_0"/]IPC*ZPRVJ^(QJ*50U,.L[T\LJ7KENF<Z^;OZ
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MM< '= 3#P_UBW<VT&I+[SF;;\Y(0?Q(63BZA'I'IB):5^.K%:T@U34ZDQX4
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MJH+B'?@]+F;NI:65-T&TC-^G$^J.D)DN(P.W.T;TI#PS-"25KNJ_R$H9JBM
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M#%'KZ<?68[7QH-=W]*O\AI'6SPM%W W?^MXJ,X*D'3!L_S7F (>KM">[63O
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MD=9X\:K\]P$7R7?ZJIWO9'>%V=$!7C51JZ:O9%>&30S#\C@O.G(K:&J"@NF
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M(.>=DGR>Q5H#WW ,);Q3RO;S??87SUBEN! <I,59Z'DHLDD"Z1KIT=,JQVD
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M:E.T#:JC^MO'SL;V"3?GAY$JYSDW'(M@7=E#\)MV Z_@LU/"HEXJ0*M&2E@
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M6J;IB1^D]T-[HN'8+[ @8L5D5!)?H/$['@?T1_>U;0DZ@(-D?+O-2S8OJL6
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MB#Z]VNZ/)#*A%]1&.XE,L[VMM?6W67"&Q3DW8]0H@$36VYJ_8]>[0WE^":_
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M!P[O$MZ83R[^;3VB::3_]MLW1*$D$,<OODM?/GVELG:?<2/U*N/4_K&/$W<
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M2V8W'("C$KF4AR *VH&$5T.MMJL6-M>*MBI HS^@?NO$:%(T];8!X3%.M#
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MP,566CB3)-%$BJ4KSRF]X(72\<YJ#F+Z=NA(D_ &MG1_EUN3*ON+@.$B<]O
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M5U$MF /OUXCD)MS]0_!G3K52P5IK5%X_NQ9]8[/1QW;';>-K4WE#37>E XJ
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M!23:NV)&UUX#M_$+'Q,?:3GUD1V\$?(,PYC$572\K.[<2^O@GAZ/X38COK:
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M6@.J4>H7ZFW8Y?'825B7-V59 J%__NV_^CDIG@R KI$!R\;;*"H2^Q:,WF=
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MF1Z:"R,PQYRXCOMTC]EC<U^</B69Q2UT'[A R1[#^T.G>LM.P'0[O%:P\QS
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M#4:^Q 6*Q_$H:-!3TX3RUS!@;DGBF*P%000V28'/'V$T"I^(FPH&S"25P7/
M0_VXN ;NK)6=X2;R33\K78&/\J E2$Q3"();S+]Z F00:/EL\9C,P ZVSP%[
M(O_X+TNW^5_=HQGT>.1HG_;/B;E.K(U[GI.OOACKE&^LF%X;9Z3(+:$+1O0
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MMUKQS .D;1^>B;(_+AP/QIU+%*=7&N%)\Y7VHWHIWENOSP$,H.WI #IBZCG
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M#V* J^!O*6&[DVA*'70 -K9%#/(J@"5LF'7J=%/@\**<OB,HL)$8E\R# :?
M::;)#B H%MZF<@O3-K91A;[_WL/=3V2(@B: R_Y'$[TZK^W8Q:=KJ]"OO<_&
MHD N'_.O5$4T'I@XD6Q\%-.I?KA-)J4V*#60[Y$+42-SM1<S+Z*N<K(L?#D0
MVLD^!0XI6PD2KCL8A>D1PPE2M,]H9ITY0YHRN9>C.OJ"-P]Z\S'(S+]>\\/)
M.8";1(WM:4VBCX6[;HY9=$@'BS*O_@Y5 <W&ZJ.H"61(%>0#FZQ!E2]&-5FA
MW5<(7I!7[:X:#0N6?,SCR"]7Y^T P/G>(H[K]%=&=/M_AGZQ^V'>9-=$7/]]
MI+NGA;%6\^$;4(NP>*R^Z>!PBFHE1B&[W9E$L'@2C<Q%"P9%<8*^2WJV'%X@
MBVU_IGTQ ?8.ZO[7+1*8L8^7Y.?=>GH>LD7)N(N'A$8L[ZJ)]I7>[NDO?25V
MR_+8H?N*1_P[F#3Y:CW"30Q#EWLT[[V_Z71N[5=2=E^7\D>&U*/J/:>OJR.6
MHSB2QB67N MSPU!3V88Y3.[36C"3L^CFEA(AGU2M]1+2+LE:?5N 65_#X7<^
M@?64I GO .%I?Y&]QWOP*U+W/7Y0A7N[@"HU"AWYG)O!D#H>EX+=)M&05S@_
M:AE!#'6#'SU"EI,-(/B,_$ ?P">BY$V&N^G\9K&C$QX-PCW:AGJCVLFF,'MC
M$2OF0$@1 Y_<,X/_83+]&]:K#KE)#&L!2MZAC2F0#T#4#DF=7;#4);!*D;19
M)?#LQ:@CJJ*_<VUY#NB+AC[$;0%Q8 _C$!(O'\'C'#"F_ND<D,0;<QA;2T:G
M[.> >%%L+AG:,<(WGQ@ODZW2/RJ9)NP!T?HQ9Y*H</#Q,AOIBZHU\%^II.K2
M8%;@'4"B,'TMNN <$ [&/57Z*_[KRMQ"_HW"KJP:V)/'+F&1P*E\R!$U%@JR
M(O=H3DQ"=H/GM%3_ZIF1^]6C 47<-[>LS:"?=O\]>>L 8I:=QAC@FA&D>F<G
M$Q/,<=RS"?Q;40/Y+D,:W<2Y6]NE2[M9II$Z-_Q\(JNB*?+4),C$M'>S]<8)
M_XL)_<IV ],IT01<GNJ3U4^%>7%OK9V06,H?<+3YS OWV>&V S)J9NIB+'ZM
M^R/8Q:..H1>FTI)*#"/3N!$2(WRFGOS\F=2$HO]Z9J=!=O?!2B!;QP*E'U*!
M<;F0YZ<1)$6ZI>FSC6<HX(.1 7/9I;@-]C;DI.X,G*3-L,Q&C$A$X #?,Q$5
MA:+N F<RN, V,Z2+CF+6.8 \X8:__EF*D>CJ/E;D;??V?C"BHCO;-<=2,0^Y
M4I0SLI)QOZ.'IDAA1ZD\^W: 7S*RS.50E$3S7GJU%43SRFK1WE4'@XB6O9I-
M,UQ* ZL>^(2]OC>&GT,M>;\DR9]H$_LJ5R1F4"><&-#NIY(M5X?"KF4$C9.
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M</OPSW]WD<!T[PU_.;M6JQ\B_!ES/="A9-]ZH1Q)K"K*+)K+FP+9+:.^HR>
M]!-R./,$5UW_9T A/WUDJMX7EM1W?OIEOTP%=3WJ^L\ ,DY61+^]UF[YMJIY
MU[+N1;BEKS7IOH_CI[K[32Q\G=2[Y-&YP<=M)QL)ABG$;U$\)L].Y?O>=TJX
M;)0HV#L@^3IJ5+QH[K#O-@J+WL#,8Z:<Z"=8YX1DZUH].W4/(ZV=M/PY'#%?
M1$]/QSP2_JWLE][7F_'\*M:0/2,/-&N3<F&3 3C\ ;;YXL,W][8=DE*B3"_<
M9VO*2I^6V<:UJJLR^D9M[^S8L.FP#4EE<3C:4@?3\4;FBBHGG]DA]6,>YUCZ
MOR8[SZ2M6]O-]W9^0TR[D<B)6]TY7*GN>(%GU"43XPTB6ZT3OX>Z%Y:B6;L=
MHRT0U7DF9?+H48)G-WKZ")T-@S,5GL=QMF!.407"=3OEB/.KJMFFR;775ZT%
M3GVI/=W\D9-M"FM4H<N?:1[* (P54>T6QGK7]?DZJ%SD[C=4*-D)RP"(D?U^
MK42TB-])= Y_;L3F( &%GU;W4)^;EWSJ,JJAWV&F-,,C=%'>G=<"?!3>?NT/
MG^T4\K,.#(-%=LK8AP#CPP(+75R-!::.Y?UF #ZDJC<9:[E?YC@.J+1IN.-Q
M\5%M@[^;?6_.ECNB=1GU94.&9$%KU;VX0B#GVI*[0[ BTV^9M[G/0 JV>VZP
MEMRI27A[B["]P)U_58,O#0N>]B4ET.+ILO80!=+3V*5N<:%<_P/]SZF^B)K-
MJ8=R#U]P:8G=O&D2^/1CSNBY_K?2]QF BO[</6=<9=H!0?_VCY!I+EZO"%A-
ML8MA5(D//V'&<>;ZH_2N52%1X/7C*OLS%']FF[3]W0@^"M% P 9]?)XGH#ZL
MJ?;4N:Z.1?3BU(PH+XLA)NT)>]]^:%;YPJ_[[Z=G(YQ01-I#9[\+C9@9EPA@
M$:_=PLSX>@8ETBO"@> .%-A2$7-4IACCJ:[R3>E^,[=@UO%RQL 93,.PRCH0
M;XXF7U"+A\F3OZYA@=W3-A_)3WW..9E>F^-'00B> PWYHH",=QR8"X"8NW4W
MJ5,]VAO=H'!?_VT)RT7G 6\,=?#'S4LR9>\>^-UO;,P\\R<'QKFT^@\7F//U
M#@#U!9, KL?T@J85YO6W.A&3K:4_6M3\6YUL&Z8Y=CHJZBI+/MW-A=2D?'@9
ME#::.I0YG?/,!K/"1!;@#.5JBZ",:I##,JH/*4(5H#6#/&9.P,7T" :47OY0
MF277J<FU,,W>M%.+>1LHB4,OPA1CS[CC#TEN ">D26.U-!24)9)6Z'TL;3Z%
MH\"G7G5A7ZGL2#7NE/%9P5@6XW-&/49G\B1>#"]&5 R]SDUYG87PI,'!X40Y
M7@O+V_^LA6;7"\;;**2,HUGA'LUK<A*+&RIPOIG*!-&AU]H!U5>^?R;U>UGI
MM'RE\*.O, 6V82Q, 8_!IDQM4D0CZD8L0WI(,3<C@PUIOMD\5*TP;V@N.+_7
M #B/=L?\RD-P_(DYIG<ZJO7F3F\EZ.K4N.AU".M@)F6#PZ]M$]F+;>Y[PUM/
M'P-G%U:U8XW\1P>3<W3BXA@ 3Z38RI1+2GUNZ33$]W8JNXEZUH4""[_S?!97
M3["^X=OII9[6<QPF@B8&;]35I DOF8\J;&QQF\M<?/GU"C'5:"#J'&&+;N39
M94X1".&BG4]O"E((?397;T&=CV0 7#@NBQ,AIEL#^S=[%X!4;B3=K-.: :AR
MW6( #*?'-[B2M"4+(#N=>SD"\;NY.D$&+:;9_&IXV1]].J-/1,6OK1OX$B+I
MQP<9 .F['^ 3J# &H'!CC81K*BN^%#Q,!].:#'ASK7)=&( ;L"/P]AMH]V;P
MI-:\7 '9NP3,"HD^W_;3UH'=V&OYLXE_RW8[^UE;[8V0H^ELH&I,U5:W%B(%
M6*/6B1%P_;:TJM9TSS!<86_S['DA)P)D@JZ"CZ,*\'3QGP1V1''P1IEROHWH
ME P.0)YC_<3Q%;/7OHMZQQRCK /H 7S=< Y8>U'O"N;68P8@$'6^G1I!5XD5
M:KS[0?JG(PA-%UGPBS>V+55I=D2M#8%>$:.8PO.OI<OY+Z<"9>']XF$D$2X5
MDJK,\FIB[H*8L4Z,N[>K"I[4&BQ7.Q-Y:^3AS:Q34[.&,L\U7\OP) *F_ODC
MA2]CVBYO(1'N<3;,>:=DY[(BMC@2>$7ASTX?P-?B]N3L]*IJE?.4N=AH;5F3
MQMN Y?D1[G8^E?]R,%\@AJ=-W!%Z]8?K,7T7@U../^?5+\P^8P""]_BV(_*L
MVETEEOH_CCXXMW DNEPK,AITV7=3>-L_A0$X$9=8SEE5W"F\2EI[Q3JCQOUD
M>#A@ UD<;M^O5NLZ!CRM6RC=G\E*]&$ CJ*YR!QK=%'RP3B.*^[GP;E3SCW0
MYJ2HSR\Q5"Z?U3(<ZA!Y:NLS[$R259W5):[TR$==;%:?=.<;6J,2L+30X:XF
M_?IBMTO?_#6/L1BIZXQ04C/K>7@VYKVA1HL#U4M/W@]P/=E87/!B NU9R-G_
M2;DXK!1K>;Q/YQKJ##D%?ZS79<=_]V1.Z)M'@P\AL58C2)(]W6:=UTZ?0_^6
M=N/[9I$AE!67O,_#WLZ]>LV&I\2W?%UAPJ[%#Z=?1-N\."CC1-_VG= 5I?\8
M9,V\BTMW1\2XZ O\!A)_,/\!.D%"\$ ,;Q)B\\<B*@J<>ZER0S^8M^A#IPD"
M<ZEE<X.JV[VA[XL4SNL#6^/A]:S^@0=VP\/==_^[BTCI[R@Q;3/@941-987"
MFN<!T&("X[1J6_5KZE8V__;)+U)^S_7-P<)D(,Z@9DZF8HQG/RLYZ-SKHI?(
MD?F:2,186S:>J]M%I/?'LX:,]9QXH4BAE_X,P&,D3AS7\N"^BQW[EIP;<Q&2
MYLL>Z8S\9K_' %RI*4B4^:+]G[I6_N\I?>,M+H60>SH')<7^GCW7^^;##Q2L
M]FT,E#)J;28MDOZ\HO0A@_$,@+??^0%''>&.J.NNT=X,0 AP7+2*&A-NEPB[
M BGL!O2>V_]8M[3'[Y!\*O**I_1.;UW$[J-R?1?W1CODOGBQ: VWE8.\S1+=
M<'CV#&'L"=9=VFK4;P-9Z[1G!(M7@M_<WN*&#=M>ENDM\$YW07M7#F8]Q7A]
M 15#LA*PIO[=5L#U&<U5VDOJSP^G&YF5&10ZR-G%<,(&-.M^3ZKD71?3U,5/
M(U3-2R 6!^/%1%%. ><;FQ3X9\?\N!$\Q,7W^];!<IUN 'FT @PIZSE9B=F'
MA?SR>9D0^B%F#@ 2)WX>GVE3H[T,/NGVN6$J]&4UW.^.B5]DH+SYRU9>PN/2
MMY^IOMA6$]/&H3J9,O:)9(&L:N4K-\Q"/ZI+M'V3Z;W=;;E06"J?M;T<Y>J4
M7)A0^L7$S$5NP98YHM,Z 7]ZNL*<?472F<"/O&.1)_W*(M--*3 ?=ON:Y'C.
M-]0'D#OZJ9_4T^ZF<HYHM>[R1Q=M.;0R=0PX@Q#%X62J\V5(N$WVMQ%L#Z[P
M6>&E]/T(Y&V(I[$+:^=!Z.M"K_HG$E.<U^>"67\$5VA>0/5X2)]?.$!F&#>J
M3C"M)HF_ZPIT2>1;GS+%X>%##Z,S"2;:Z:*7GOS*V<?@PGI7B @U4WQ_NN.D
M./"VD+$[D8TVM#6^XDPLZXAN0>BQ/JE(1<JIE-H-B<<0M.9=D7.9Z3V=]]]6
MN,4?= LTIV%H:8,_VP):6L=A9R%/H;%+MB.ETNY>['Y"RX5D:YC-VSEX[,$X
M8NMJ]9/T0?@6JN2H0<O.4ZKINLPJ\!!5[:?VH7L25?$FH9VG9[\6#F1,Z\1]
M1)TUJ->TRTK3K;:Y_$I4XR*%"":B/!8;>Z"7R5R^V*PXJW'MY@T;LV6<Z[TX
MA#G.'Y:?N9:GSEMK5V?VXD)OUG'R+[-+E?*PGV7-]/H+OH[\>3A353^0=?73
MV]4O[\Y]NKH*/T)=ZX#:4/C))C8IZ"J%A\$7V:0>'L,*2/_X^%#KY(1X;%M,
M04&]>"8<9_![PKF3[TE8YT@@M6T#@=A"WYVQU%IFR6_UULF!5WI_,Y1";SY.
MEJ2:'%#L3+&8B6R3ZI8=HJDWZJS4Y3K[1VY,?-/_ZP@B2)#4':6B']@KU]&-
M>4%<#3SO::G=-C:;((IXHLL'\<<.?.@N]%X32=7>-]O76/NRDD]>PZB,6^A'
M*";?:;Q7CL@KLRWV;AS-\"/>U>>U>?7__1GO_[D%^!K^CS8;R3S_ [>"JV(G
M_]Z38?:0YCD,8A/J4&'*]81J+&OIVK\BX2W XG K^=I1Z3.)-/."%N=!F5CW
M-Z7G&_T;7FTN.M1NOS>[G9BMTK -.H_&WJ3J,0!ON;HP9.E/# #N @,0(T/@
MHC\#\<#G\N<9@'C4F*-,.P-@X\4 #([O22ZCQPX8@)V5J'5JXKBN"*2YD_\8
MQ0%?7U<T>>SX0__:E;?)BLMJ2D\RG!=A5=3[9"B:MTW(=U;XEV3^-L=TWPR_
M^QU">N3)KX=(Y]$74 ^6AOVE:YL2WC0VI!5D20NZAZA[2(Z<\EVL@:(HJD76
M+O/GT$C_OH/U;%7Z:*GTN6\76EN:0/VQB1=0@(/+%2>Y.J=0"5O=J2DEKC[C
MY<7==2G- V<M1C9NF[%XCD\B/[)VOIK/<"&TCMS\: PD^66(.[3=&;XL-'>R
M*GG^=<,MT0,-V,GY*L4W]9%M?3M79'V^X:N[=!PGPSS[,?ABV%D&X$<<SI_*
M\PM.X(5W9)*9EL%U8 (:;Q[( '39K<GQD1B U0K@_@%] <IU@ '3HQ1:D1G@
MO[F5CP1:E\&>C.S0%2#<<MQ,>+=</1#.<R,GI2AK?>[LT7<!2KJ9NT2^Y3N/
MA.V%5UON3]M1S;4NXRXUQHK;AUL9:X4M;_Y)H'UM^P_$85TLI?*7S26D#[8C
M^97)BE(<P7)F-T0WM(KJ@W9U?99HQ7\JM>Y&> Z%T'*@)W%?[O/X6-I7Y!=$
MTBJ!,S>--AJSPX9B'M*'P:P;=!TH*P'YI-1&:36+4T[LP##X93HK5<I:>EIE
MGXD&CKJ0JP(+UX"G8*=\CYGXOL-0[G^?NJ-G*,'-\O/.+FC53"<G68W:VLD
M3'\C@G/A9[K\S!K\0^C(@OTK1#.T $Q&ACZ#Q%NMP4_>,%V*48Y<');J"65G
MEQ@,#EJ1RO=BI>?(P=[2QS!"/'/ ];5YN+!LM-::UK'$3IW-Q:[;@1C.5?./
M*@1I*K?_7.$4.;('S%^G[E!)-$97U4X6L08F'$_'MF\*F\L%K?%8Q.U5:6_Y
M,%&G6@&E:?]R^;[7HXK?&]M,>_CSCN%*5V"Y8KG76^ZK-C:" ,YHIE#^-?<>
MVG>-H/<W''WO?S  T-(5A1]-.7?^3L+2^08JMR'=3+('3)(%T3.O@:MTSS,
M:?XV# #*&+Y[!#RHMN[_#AHV#(67H3\?S:/>GO)EQ]1,3_;#OOPN@319%BY-
M]BWA!\S$G3^]:@;/4$>&^.8'KE]B 'R)"32^G\$+XPOGT00@_80AMD+>[SII
MVCG2R\#985E89^0ED;N;78/* NF-@7N!IR)) \Q>DA%JDVTO_083%I*K8T]R
M.2E-YW_V4L+XG/3S>[>[DJE%]U/<]^^6G91H+"U0;K%YY_B'F3(:Y>0*$1I;
M'?,7M6\)XW_#"Z^I!7N_<(MNC+4;O*ZQ!6Y2(:#6F8;WT:4AD ?[*VT;E$\
MN13'TG6,I2E6(JLI^(%N\&.U_OX9CN1#DH_+LF:(:BGT<Q ];%Y*ZU*RMDT!
MQ/([SOR\2$J01>QW#;#05(7,!6G :\X &?UO!C&:;)AL5&XU37?;*<37K*("
M3E8@:MYT;^XWDSQC_+2VX19I(-R?JH)HYSJ017(Q /AW50S ?-T$!(CS?TH_
M/^4\ P%U1P 3-_R<];6GQ M/XFXLN,LHWVHW%IT;\PLZG]CZB@!?9R+%HP2"
MYSJ%8@!YB@.G0/7?DHM1LINV/WT5+WQR>K]HD&YKE\RR#^WNNP<+ZM6.6M.'
M@#<\*"X0-=(MO,CJP>Y:%&I&4CX#2W8_C#NXAFGK>]*S<OSSLE+7Q7,JQPT4
MO,H4^HL%+(N*&C*:0;KHN88P35$D=YOP-;\%Y&G#$A>5S?[PZ%]?\Z\^)/^2
M[J6>0.NI@ #,7K1;C^1Z:F6%,"*XUF&/*T^B*I\J=<IF]67P]VJT!Q)5]NLH
M8O3O=#5:"]Q+!)F*Y+/ =/#O=:SM#64F6>0H:9<9\3( WUH@AQ"2B]/IW?&T
MM)7/<U8I\LXRA5;A]5/K>0R %EU@]=:'H'LVCOY&,M(S*_M.N\O0)&:'[- 2
MB? )YA+3IIC4U3"EBZKT#:L2W K.D#SD*PR-G[UWD36R+T!)0W1\/-BN!]W0
M2^4]HL?$OEIA6#C'K_8RJ'EKW /5=WHE+\K5\V'3'Q]5Y3M%![3>K_"5FD6Y
M-S, 8+RA6>:TB1^&2 LU[ +6*8\QUS2\K2D'Y(KW2':7H["+2H,>I 2H3%C^
M=')31&>-E+=3534N:O=;@7IZAZ0XGM&%(%!P#]1 TVJS#P[$*M^P?4HK&7P%
MEP]G>7KYUK;>E3TK<&EF:4UP *'S"^7KQKZ:GZ[MOE_3E2";LIOE,+'3.PU@
M)%4,T<?%M/?;M71U8./BVKI*Y"V<BU[GE)[1S<KB"[F6D##/;]&_8)N31H.S
M[+4[BW4!;3QDMS=08>;DJ"%'ML/XZR)U6 W'_<[4)QH[VK57&=R_[Y;N\.HE
M)?^R.FHZYV\3A0J&?4LL-+OTC<YAF$3[+5YGV$Q5SHJG(5#?@62Y[-@0/\,Y
MS&-BF?U"MO%PR"NWU@DV^RG[*IZ&-U^5%O8"M,:7B=!A"@3V$\,%\L0\LYJ"
M+.G%]3R")$C5UN#+<Z]C_  U1EUB:>]EL@'/;VX(K7R)MXL;@'&2Z*UF.?+#
M^Z!N>^84.4HD#,9I^U$DJ)I@SE_3?<%Y2CJJ]"F)(],S/8H70L385<'(%E&U
MB!U_LDQ<"E7E#?V+9N63#S/7:,V5KE,E&?>[A%SF\Z32]<6N?Y Y/*,; (JW
M:X?7(-8]*=>A3MFWR4_Q>7'M"B=7N^J>Q8';JGBN9=2YN>](I[&Z;&W7/V+;
MR"5TDMS(:(H*9.<F.8$PW-DY#XXIR%)'*6!<FAIC7<WZBO/J!P1TV$LZS#2^
MRY3Q^ R;E3;W#X<M;\'[.[DH[RCY>Y>\G5#F9/@/VC'F4.B1P^Q^P-W9C>N,
MBF)/FCLTMWYT4&)KT.()8'VC(/HL@K@%]AU_3O\&$J=R4_2H9W]2]>;4[<Q^
M;ES]F&VP/:8V+)5B1Q,MH+YAD:E%L1CUOB&NSC8_+/DPK9!N"WX2<_2%<A1F
M=I,!.(5Z0I7^B[Z(0FU,*_0">2!)U\:U=:<JQCYD 6[)%]XW=+*><KL +>_^
M3M@[)*9!P24N(1HM;)S*Z.>W]]XW^7O28&^9BR'>*;*"#<9-U6E ?M&5\GMH
M6",:7C!QM0,:-MW2CHRJ(RWU#DZQMR-K_#LI:'[RL*63EM%VUE@:MM*_I,=6
MT IT!=C'D77FL.^V'98!>$*7@+?;HKU?4<$X^_M#=-$5RW*K%O>7LGZ\FTX7
M!)^TA7UWJ.K!=1VJ,C/CXE8QTQ'V(]6CQ[._'KR_I!AR;E0Y.W*%%D[=.!"C
MB$'2F6LB'&\./T:.<V( '(K(KO,6XG<9@&P(=?+L]\CP:Z 3Y SZ<0Q6@6P/
M%J=+4HW&!J>)?JI#H8,7CM)*2';>YTCWJHRN+&^ "^&UI&QO+&82B'N86^)4
MG!*3_71KHZ("*V)[X>?0J(7A'<#A-K$_5'D,0!\7;HD&]48?G.P.-;A9(M_J
M\5,-3-K-@3^E<G^[$*DM=LF_O)P!V!A![M.65E5@*O#V6W)@$I36 A4A*%R+
M6\]PO>96T7=W_T;#J5M#7SE!K:*!L<1?06-H#]]M:3K[XWC=LU"Y -:7P<V?
M>]N.5LWOY^""@LN&WC58TD1HW*."[W^6L3T87T74PN<*,3SG\(;K=O-1)J:Y
MWY .]4]-8J\&A#KWO3^O0RT\%ZY&Y49BZTKC0)YB;MV_^>C#A/-5EX3P:E'Y
MOXX/75D6[8?/V3C13\1(+9$.X5^]K.[?:S+,T?1H^[X0K5NW@L'?1.XK@9AJ
M9_S[6P:@.,/.YL*V=7>X"C +0:7OY#P**HSU1[7N>*.&@$Y-LO%]JT*"=\HX
MHG5D"*6D1VX4%::^LE=!'5LI(YER68VB:A'5I5^3_#1%DH(!H;;;@>LRI'MH
M0;HB:QR=7;HD5Y^&)9@EF_W@<HJ,PI3X7%ZCU:=OA>S5HF6RP;3O91N>>V B
MR/-"0:*>[A^.WB38>+XB+0TJ@CWIU'[P,.Z]\YK CN/WI@6>FXGO!>_<UI=U
M%\U?&$^GWOZ##\Q]<EACVGC),G1^\R[V5J79I=N1@K^S>J86<8;I@@5)P1D;
M]\]@7\@K-J8&9OP'VCKF5?L5^O%E.!-N>2#95L=";Z? NVT3RE8=8]M_#_SV
M>)O<X/)>Z+9 B8EXN:\FVXC-Z_RT] ;ZX=K=&?3U#VW&EHLSI2L$_[7J?>1%
MLB&=G84@_1FFD61 GL17CAO5A9IKZJC^7#-KJTM^+:2=FPV_TG;,2EU[_ >\
MMI3*.]^!X7@8[,])5?PI@BM-4<FU1\EM!)/<_(]:]DC%MW5[A@O=;'CQ1E2T
MRO70;]!<33[73Z+Y9,-U L?8NY H&==8$=^*PHA>Y4=LDH-[QC?4B==LX7,(
M9B.5@2?HW]\3V->YC7%PGIE?,CZGS[NGC@G=,CG!,V1BL!XXDO9Z0_ G<JM0
M>7<ALK+!Q+P7+KU@JK_N+%6W! X]H(M$A.>+"%#YAN<].T'\CM-0>[).Z4H$
M=!X^D=6S9]RJN,3RXY?V$\)*[>'(1)H&V9!@Q839(C#195=5?.LW%Z^<+G&H
MG,1&VO%SKFI"ZB%WOAJ87PI7V6$ J'SL[8[@)+@;2&0&[*BG\CN)%'6]!W>#
M9>ZYLT&Y-5$D+<],2R5\BRG@#I]&T!XZMC\][R>9$U1&3L5JG*A@:7G&=:W)
M &3ILUQG8YWDV#&X, 5&89<*W@MP&I<6Y8*54;2(??%%B@ML2OP$[3E5P3^L
MLJAI,)[(XE8"@0UT# 0VE#6+QA>P AJ/'LB<TH?JE_QA,49[;PD;0/6QH,?/
M5V$<\@X/Y6KE+'<?L/X&^J1TN2>'3/9HVN5 (@WC2,QE-/JM#Y[\(G?KA'?V
MWHW)&@_ACJX7B6>T9%-Y/V[]1E? ?DQ,3*]D!3@ZM(M5%#?)6EP[<=1HR.#P
MAU0 X,XA^Y]FUH6.Y@X^V1Y+-!C+B+=U<$&;F,C.-AT]!_,@8^CLHMG((Y)C
M5""6IF9 SO8MT_.$8]'<; _?J Z(%I<^F8>\^K@B>/:C7>AQC9/@"/IW.'>=
M0A+F,)1]WN4>NY.?G<O/.^C&V&ZA,\9BCZX?NW\';2L]BU9CR@^\YGL"MAG%
M3K4?DKW[L7ET,_?FF.W1$PT\#Y3TM "Z^]9I#LU8'9DMY%_E9*VX:&Q=JJ%R
MORB[!.'O AQ<T+^!M>0V-^2GA3@=^+09?K+0YXW]S_;Q^79*-X@4'6?83W#-
M0S1V1IY;+4%6*,3OK/HQD_@GM(F]8.]3GLD?=<J6FV0TGY/2 NDM*1<'AM/3
M04CT1!SI^SC(#1BOF=)67.KBX\H]4F0?4B% <\;W/4/EG7IPZ!+T<]F=RW//
MK\H<5.'0T[YS\.ZMQ[IJ&=?(:6_UP\/>@/7%7WV8D4O!/I]6YXZ_?ZE_4GW_
M&FN52@]L$H._!6*'#1UD8I*HDE%<3[7#+RL$;'#[BAD3VE_9O7@4^,I:="?3
MK8_:3TYAKK=8VEN8B+GZ)W)8%&K*H-MRJS.Y*?HKJ*6JY]8;>,MCBN5[:=>,
M8AN'J7$ZFA-]=CBQT,:F]$/K!@W>*8[\0T<\)JNL,)5AVSR"JJBEV.!;9U<V
M2^R?P^B_MONO;H"+P&(@IM(_0F=;WE.23BIO\:Z\!*Q9GA7*4Q W%/4+?_X2
M!\@/4PU\+<.=2#4"3X+G34P6N9Z):RO! R#W]T#9F:ZM>!2=[2GE&M2LJ?X*
M1(]^:D/5U>DV07G-1U(<GS+L29^<'TE<R<VT[Y$QD8')T4NUP[T;I"LPRVGM
MU.L$3!?7="<I/7JQ C:* YV:,;Q;LO+1O=/C(=NDH#J6VT1+ XAQ _\P[S"/
M"P4?IPM"G-HC@OQK?M0NRYZ^=:?/ N I.9HK&S4 "5OWI["0%4@&P\5M#2_)
MV3U[:>%VL#--S\[>4#\O ]F&%DEQ;#O$+\P!=/-+-RU+W@T3X>,#:Z-5D:.7
M(AT.%-86:I?_9#Y/>_.O]+']CTE5T7\;O?X/<Y>RG(SH,377&WF NW3N4T.Z
ME'R TK^YUJ.8ZH"B2B[%^B/NCM5%YLD[W:A+/UP?9+35^/A(;(H!2/C@_O]"
MQ/@2>DIKCBN>+D?.,!E1]DU1%?3S$V85J-%4O#<Y[Z/&MWN.]]  5 V_,?X,
MRE;@-5[!,^/@)*ND+/5"5H<-,(^OS/H7!10M^2.0[/":^]E=4\Y&60\-I\\D
MN[GQT#]&BC, >8\8@&/T\^@G*HAJE^H\8=)5:3GDKX9K9TA$/N(#O&$(>Z>2
M;)51L8.@^V6=:WS;GMU;L8\@1QQW_';DTR#]/U1_:A<BB>Z[!Y%V,8F%LMJT
M5LF-[19WQ1'7(WQE*[0PP['G V)=%V7-J@WFE)K^0ONAVP8ELQ.L'95A0J-+
M1AN$)"%D,A.ZE4D/_T 61[&Z5IP80G%Z(152VD?:;8-+M_^$#O+]"/AGMD+%
MS0DB<_)Y.+ J17^RQ,?SM]?GKBOBI6>BQG0+"7P[/14%J[.<HRU)$]+#_EBM
MM">7X+,&8H:?5$@T-TAAAZ9=LC*I9M3O- Z$A2&$B+:K)R,_:?\,COK:M@OG
MF>KX;56X:;-72,Y7Q*^18M./\,4E7I&"7O+A?M?' %0F:L%K-4BH\.JVAI$*
MB::Z5_)RBRY?9!\(V4<\!<M3;Y E/Y#5^ENJ9CYX2TI]$:9OGQU?LIB 0V"9
MW\E G&[-G!;JBOEK8Y]>)8>!#!X*!1CH,EI]H-[W[V[RH6.?A[H-_]U-ODDF
M&2_0;2K0^Y'ESP%<=/(7#\5.1(B.8!3HYOK:[TM6>1?531V0&I:O5TRR?/X$
M)?;_IY&)__7R?C6G.S7.YV$(>]^#-Z+A&7W<\"NFTM+NRKE_8LJ^:AM2#"!A
M-V?$<T4/NCH+#=J<PYES.19^UM4%!YHZTJTYNU";+B9^9,C/3H'<#+\J,UJ8
MB?/UF?_:PA2/_#S9!FX[)X=PI(FOJ]1/JA97[OM5?M+%9(3FU2(:JY6K!\Y\
MRN3Z\)YAD>,OG^K4],O;!=3!?OBE?=*X^6B+S3O%AN@=FY:TZOX//ZMTBW8.
MQ@L@8:0@@OC[*N+%,T-8'9O!7'G0C!5BK%4_&WOY _G5#&D:_VNW[6U,YUI\
M'H8X'*30A1'3ML(II_,VFLJ/?MI>S_9UFQD<V'=;<4[-?K,F?K')_^.DBT]0
MU?X,+QJTH88:&?_I*D9#0N4*UB,_+8Y)BSFN?'Q%NO9D_W>KQ-B8R 5+$8A;
M-*^@_?SM#ZQO#K^HN:4K]@CK34?B[8M?W7[3&/#C3P8!-68U_<9#3E;[C-_V
MMA"O>KM33-.UV,\A@CBH[/B&.*E4S_HHRQ6-TZ[UBZR3K-_VGQ)1>@4M.9.I
MY^M3;5T=Q5T>P"3^\HDC5G!CWAZGGZHB:'WM,>L;WH,+J,L[T2U6\PWKF%*J
M):9L)5W^%4Y]7A*&F9FY RV39EH6/JV5B2N=.!^LSZ5:EQS-"_<NW2WY8!GJ
MN;B7U")43N:QT7S8?(\D\'*F*OZ.X;N[[509?K0E$<6UDB_18*]BPAY)?K%H
MB[L\S?4A8\_\T^\6M"TM4Q>X:G?ZEV&IJ8=6Y>CEKPZGW*I5[707>'(H+2 >
MRQ=^KB=!<G;$/:2'7KQWG<\/[WT_6M32YTR=O!<',1W7_'A,9<0/,P!*D5Q!
MX !O>!7FR8,S7O+ VR,%<LUJIPOZN&H*9-RFU5'&> P3G4,L[E*.9;#FLLV(
MULB3#'K8Y2&6!DK6'/,Y8PVG[Q:@0P2D]X1'<1S:=INX:0HBI^T$_6M8=O;8
MU&#":Z>I#LK/46OUW!]/\R]'IB%N$8$N#I/MI5/=?GZG.X^:U$E:?.93X<.3
M?T4]"-Y?1>L/ 8%)/:,]@SF%NW^HOE[_?;45U*9,^)TQYZ(\XV,',/K\TN_%
M;^/X]<*#W4H]7%@/A>O8?@[LU>*J\'?-D%C@7I\VDF0XG[@_YEV'B=<](T4K
MM1O99#MK8/\D_W&P#? YZ@IWLC7M:T3?@3-:.NMLY /#9JYNIHFTH](F ;T]
M"CLSP_T(<W^8>T_O7MPB.!34!>^K[,0B/CNA3H5K(N/YUFOGZXTJ(#O28C#_
M3=2J;QOY+EY^L,./O[@\/.R@*6\H9C"352PN=(]:-KHFK*YA2G$V0#40]\4@
M_;.\=XD/#M?:@;<9 !#Y47UNR=0RR<)ATJG7U_=4A_[I#1OQCO(A_4@M+\1S
MOR\S,<S&1_\+4Z__WUZXOH/(,I[49S#1*'DTR9&RA<50F08P!P,PH33. .C+
M09E@B.4! _ <T8DH'J=_ T=1M9@C#\<B*<<<&8#EXC><L?\PH\Y=6BD#X(XA
MVX_SD,LZN'NY$NR/A-SI?R]&NGSDF-31#+&@SCN>K%(T'?U '/Y%8&V>\->U
M[1W#4"X1IT,.MF^8R(EU8; 7<0H29(TO>:^:6^Z])^RQ>R,N>E4II5U24L?@
MVD* KR;Z;AWZY(KXN893/@<V666 H\>W*GYZM/<8"(I_ CXO'P!BD4^I6I#L
M"+L891VE%4[;2!U-P3RSXWT>MR.1W]LDG&7DX8]0S2NHWU'KZAW:^31@Y)>5
M?> 1* LM@ZI'T+.L&U'YYI3"WI%X(]WY5HE&93;EXWLQ!J#- * AI&VWG)I4
M,$$.,ZX;5OYF7_Y SHU;S__$Q@V+'X?LO%#EWZJ_:CP0+BW/WSI8AH9ZYMH-
MG"^V,JI(GX3GGKA0T!K4_5<N!=1@6J$LDB3]AYS/"WC*[\<DV:[++N%#_]?C
MB"^?SHL0]R[U;[O5+Y!0$TUD)_H) EZ/SF^XC@$FRU90!\#M8=?QU97VD]_B
ME\!O=)WCIJXXW"S]^/X$ _"5N&-NT*KJ_T780'R*IX#^<WC4;V>YU9P)TJ*_
M0&T;":JE^/FY\;B7L[.K//*H('^V+YDSR?SQ.H]N]0(W<VAL-"2=9Y+*05;
M<AV>9)DL]":T*R?]=.B;44;B+PI-$U!?_,G2J4]1L#%,O4'>/$90$5V/-\OP
M5DX_=5/YX]6LL<0@Y,MJ(429I#B18N-R4[PG6V[S]Z^VFZN@N.4@C:8ZGI6C
MV0-K"KUW_J>H^ :YZ/OF/\%OA^QH7U$?J$6P[^1<NGZK';WU' /PXR1,"][.
M"U_ :7LP /<Z&8 5:SX*#\Y_GY\(/MC-9CY4A;S!M+DL&(",>$(V+8F+ 2B^
M;=4!;S6G<FV_RI*FS0)QX-?FDTW41F8'?:3W&/,U4T/P<J]JV^I"_$\[.5RT
M[#QS;GMC^6N :.H$K-]\5<5Z=#=7#F[<.JPB8H\*IO2YSN*F/#C2>U9MTIZL
M'I?BWK*W3LHL/BE53V?BC0K3E2^&QE"%H'D@^3QXXZW:QED\"<Y&KB3<)S_%
MOGMA<@6)M*S!6L[/C&#!O\K@XJS%L&EDU195%13=HH-E ,@F<.PI^I<1809@
M SB)]ML)$CD_T!8<"2,%90P7PZRAWGB%1/A<#KI>/[4!B]+8-5K23$V22@YU
MG="8EBM*^?5.3B2,@NC1ATU3SY$+WT*]R8%O(..=88>7#,?D;''R!LN#ABF$
MH:&G,IS=IL'F&7S&MB8?FM:'&0"5O=*?O=KA'XEB,@<1(#*\L;(!I(K&]H"(
M3J#M$09@<XIRA'26QK2)L2DMTC@7 ?KI/_5E .K]W5IV&( :W>Z%#<3]F;;@
MW)IQ#>#- \O&P01QY7IR('ZOJTVF1>]<94+)+Q^EGE:'>RFOW^UI!9+''KU?
M?WM1IP)5P@"\]4'6O;9TQ)B[H*V6%*;+2-L_T.Y(SI+L4GW.9H* Y;/6V!?K
MT#)WC<.X>=:S2IRG[C0>/0R0U;U"RP+=18C!)F>5P"E (%'N&A4$6POT]PRX
M9>?8XI9YXIAVDG/PU*&[>ZK1XFW2B/G%W\V$ _/$-HVA"F@X7/7-5/*!:ZE,
M13F* 9 MO*.A:+C]!'CKC%7:<]@0F"PWF%IXNPP_WIGXX3*@^37@XM#-BS;Y
M-51)NO_!>L:'7[FEK)MT!3HK\3<#X*(LQFJ*KT]R*UPF\1_<SW0[,3TU.64@
MF2@X<M?&.@ @%@-&]6+(44NI3!V;"V'.@<-+J'H&P!LQ]=2&'$9A!R;:<ANZ
MX5R"#*I43;B_3CO/2D"_Y;?9A][-+S[F]6Y1^%$YL<9DM+6-8'73*N5<,0-P
M#OT+@MF@,=6Y1 ;6['T(O@%[43B[BTW0">PS9+@DGRL9<#;F\HULT=2NLV?N
MYIX-1T^$T=FR _T_7"/8S7<]\M4]WY2],=8F.B(ZL-C7&X:,L$<J69I!:YYK
MUIM_1>>A:\PWSC*7CBV"$ES<%"L&ZA67F.KY.>^4KT=R<$[?28Y:X0S\M*TT
M\]UWC2D,?]6T4N-+)OE[N6O3PP?4$#Z#55T31_92.'@-#[IS]03@R.$LM/2?
M#?AVCQ;_>?-X<2'\+H8KF-TKQ,]RK/UWZNJCH?+J#_P XAE57V(L4F;1<ID!
M0(TX?\O-;B >L,#4(85T*PLN6G(H_, _%>VV1NCL!F[GQ,/7W6H8@&%HB#((
MXPUWN2>(V--$CQL#JXADIKY@"7XY2Y^$<5:/>Z2#.$L2[FCFE;&[F"Y=7GG:
MOD65S*'EHY[#YPK 55+(NNPGNQLFG>GMWO-;7.7(.Q2]!XDD_O;(,'^LQJ$T
M!&!!])B4QWFL9HA?B$ D-(<&F_>JA'S/V^BO@#?2D>'$+(2G1^F*JFW3@T"]
M4KW#AGZB@.-C9]Z<N:W^&7"O$9@ZI9N"HO(19I$XWH1=XUJ3]K E-Y^>L_><
MI-\*]NG$'T/+Z0K#VZ_3M6 ],& ]'M@]&+/7M%&2A?08WE3QS#9KY"[]RNN\
M_\@P4#B9Q4,,E!!["=5M/D4A/6-JMJ=>I9^!''0A5R]Q_I&7^N^,[VP[AW\;
MZ=79*0HTY)Z7B9%+/GUMRI>;U54I1GI@("HJHMK+9.+3UX+%Q0;L]*XFF'QV
M\^T[!J##AF#;[?(]_4'Y_9 O4S7AZ3'J1!DT?5\\\V 4K 'K!%6K(-=3\"^6
MAYT[WT-0MFG^*JW73T'K7\CS"WX!O)P_^MA<JD;UV#I7H6]EC>F[TD@9\,%&
M0X'&^_.-10?-#(!K,[6C18#42D.U7*1(D@&^PGWT80(+WFLWZI@ N]S"8XX:
M\= ;C2)(L<^ =);(EG19Q9;4T(+HKH-#X.^&&T*4&RY0"*TH!"Q.3AU9BU".
M>&RBP^^=K]Z#Y$'*8V2^'K/(DHEV^)7,XZP$';;.J-N+RB8>Y%6EO%E5B0S>
M9 K4CX.PN8;UE3_TG(&$,U13<EF9BS>0"_NBEV-(.JO:0"371?=\G[5@Y\V@
MOJ7((XAQ9!R8$ZJ&SVYO\H^!GBMR6L[A1 *S_3T??#K2>%\ZZ]XC$\4_E)'C
M"_5I3'$K(H0^*9[RSO'L0+-/>(\%RO*3ZL=Y#$45WQVR8&H$ (#%B0&(FX5L
MT1,:XN!X^8C5AXJ(FI(*X.   P N@XZ]*!ZTF*&[(L>Q;P_J""8=;KU(#JH3
MMD!))>7\ECD#@/Y8#5\?W0_\0^)$L/0"G=:]"#E/K:LO#O/T"Q>K;>00GG*0
M?.$V$KZ63XVT6VY8+R/D4$C19%:L.7#5,:0M,[*\6SG=8:I&.7 ]W^@S2Z/V
M&5 *#$:?0%8#NQ4FUT@Q_@C,H?*'1)'(I/H1!66:/(\V*8P+J:U\XHI<2^.]
MZT\;@CP!1QS68KJ^33T8E]GV(5'A4DYP^\[BD\._72/!V^"$@P9P"@9O*[-$
MKJ-X0'BPOU/7@B+][WJ6O$#\OA@4$M!U<6_BQ^L(E1 F2&WWU#WCDZ.!)V7C
M'TYJ1ZPLR'Z+U!Y*.#@M^TS"K/745_/&RC(Z&X7"![TV3E<TIURE!D9OGGQH
M[-XR'+SA$#IK&CP/],Y1 @6_*WJ6_/A:>\<SE^]YNC[X]PK1G'M;Q>6M_C29
MB4RSFU;)L(LR"G)6S;L-Q)H#+OH)#_RV.3>LDRY36Q4_<#ZZ/N*93V&:Z.DW
M:6W12DO+,LS!C-8FSTYW@:LCO;POJ.4#QQY6+"(TSIZ3"'X0P2.)(+.AZEJN
MO9F E%T;"7:QG50('K@^:V)2%G[,UC[O9A/R'AL?>>,]]/)?\$D3>:@<DO&Y
M26<\N4T8O#20Z;>0/X8;4;R0?4_W3L[EWM,!1>D&U]S?EZJ859A%E3302;D'
M1>A3S(98CZ@]G?Z**9ZFM(%K5,@#^#(@$^K-H0Y2&TJ>A)1X3]%FUGZ=X<@W
M?7V>-T,W9CZ)E?;6B:[+K'T9U(E6H*T2,H=ZACFQI:P3:9$\/1A5_&N@S-50
MA$,QQO(XM61I*V_:(/!I+/ VO%T%?9?" $PF=6HB$ZG>HB#\1^UKI[M(0TU?
M:+D^Q_VE(7-] [&/V( 2 #,V-0-YE<QPKX*\ENFZMM_9\SLY/Y/?-<G8G4<M
MU*%G7Y%&>2TL+?;?_X=#N D&H I%S8%W*%#X=AD VJDZ0N_?<@2ZT7O0V]X,
MP''TNAT3I>Q>'\&BX^(9 %'X[I,Q\@H\AHD"#0?1>/O!?65[]/J]:B9./%^Y
M1F<+8@#.:^#7UM[!5Z*Z _Y'7W 5(-LC"+T,@+&X--TY O3= $/E=:/?0N&R
M:1!])HSDMHMCBB<? [ P 67B2S>_7GJZH]TG>+L!:.$K_2)\_!GXP((/ J=R
M@^FF<=U DNHO^,JY8D$P@H<NR*RC40@ZQI!JR0#\M-A16^=F_O@)-/V$'VZ+
M<TV]OJ4%Z?C3JE\DS.C\%?DKM,5G\^,2Z/ME.TQ30(["#1F^349X$N;G6@0L
MR96C!9]&=C?4Z+K4Y<#%F6D4H9[/YKE[WIO'CT8[R$%T]G,$]D[5VV3?'N"Q
M;&M"+?A36"S)3V<AX\V,UP^C=D2 H/L2(%AH*)W$NTQ[)^\4MCY.),]^+0?7
MY^GC!V9I2&NF6NSH+8:W/V@Q\?#&@SXWL?>AI]1FSZ@%ZN=#W_DMV#V(.):C
M2!X?!7UD *@Y0.;H"<B!=@^!$?#Z>B1A'&>;5,3$G5]*N3BF?!J0$P? .(^$
MC87Z)Q8+LF<>5%^4W#(*:]3H^5%'8:-P1:.K@1VRR?!NC;^P"/Y,=O:V^8UY
MY1*ZYY)=4?'HTI>;Q;HN+\"#-@?Y6'U>2\&_O\\/U6'*UK/&G'&2<<)<)A9.
M-GK0LSSQGI(1QI=Y,_^[]MAJ]NQ/FJEWYY16N-K>^<%/7JC%S) \XXE+&)<K
M/(^/#F0<C Z2WZ%7+S( :3)6D@>I!>ALX+__X0(#D)A$+T#NGWX,>K<J\T?;
M_C_7B/_^E2-_?8O,@3P- <60/?R?S8;^<7;BSCU)OQ_FV>>\I+-FPSX<U#:@
MT,:4);WLML)9!J!T/[]=G]=6/^9?Z=G['_(-K>W,D[:9IE$KF8?.?%^Q'%_6
M^8>Q.$K>Z;,"67;V.'W9[TN'KBZD1Y[H'J*&8U'<KNRF,EV:ML7!UI]BOY,T
MG-^MAI;Q)*)1]E\^>$7$O-:W=4H*/VM).^1QQG,Z9W]^#K@^BO./R=>.<QSU
MKRU+LJY+/YSUJ&^P\3$ 6VB!Z'FLF_G/GE&4^_GWY /Q_83.LK6<AYG*2:V2
MK<VI_!XKSP63$R=12 ; "SW) '0!!:#&)3[".K]S_4Y6E%U=BY1*[$[RE/11
MXSVTI:HV-I7WVLXVC-O%L;^Y,$> ,U5'C_/X^[5<<A"V&7D<(G!CR%_\XL/R
MBBPA\<,W3__;"4OZOR;CZ#>"0MP#JDV!BW?8EZ99K&HZX&M^_Y4?B2,%&3?_
M\'1TW+0(]2(7]N1SM^*!\;^'*TU^JV)8OO\LL%G]P\J0QK>KT&Z>F#0OI^P=
M\7IN+6LU_"Y"5W$HKHR3 <@+AO/HBD]1K_\0'C.X/*OW2JX$C(4&Z[[9167<
MS;7%F\>K7<PV'2TO:F>-+OUQ\'2?&PPZ)\OBZH&OV?+^FA\>LY"?*4D##_WA
M=M;%%GQBOL%/5>B>\5+\)5G@<_EQ@^U\=,HJZYZYFTM,Y(^<]WP7U@=CRFX&
MWU\9L?V32ZOFS#\QE(>.][4+\2T"N=L.K]#/*V&\BI4'3-ON(XJ4D &Z*WNB
MD7;E%BZ\OB.=W_)S:]0*'8O9@JQ"=<^,UD8YM1_TID5R3/E161]=UC+:];A+
M;4<YD^&4&]^\/DY 7@GCM&-<KH-:"FEU=(5W2Q/C=?]V4!/\YZ#&%J<;"C),
MSE^=28&N$7CF;$NQBN<VL\ V/\>S/M-V]1KOL$K^@MGLCA @#WHNY9]U!(\-
M[NHF"I;KZE[*"_&&.X%^'/B:CE2$)%VH7*^4;*S/#).J>AU]:0 *GD/'"_<^
M\=?>4%K:XPB2*W^E:+QIB/J$*J8#J<Y#+>&GNRIE56Y!QZS4I&F=5+V5P;IP
MP?[Z2I'9U*HMNF=VXK?5N[3E->!:4&-!HDR?]IO_U7.\=YOR$G4QO_-OQ$J)
MY!@+7GHG9BQ=?(\\W7-@WKG%^6M-<^#K]-1U=3%7@_5$K:I=U%.8/#2"(-"=
M]/[NI\Q:VG$-1>_G52<,'I584?T..#M:RYLO5;R\N694@=D/TX$><[(3W:Q-
MG&'*(A&<Q #X @%D5X/8*9)?!-;LA'?:IL5WKN]=%ZEL P$"#$"#_HLPLWK7
M4Y_RI\GNG]#VKVG6DH<8@"CA?8E$2HZSSI.2"JG%50;@:^_$<!\^P#;]$1&^
MZ+8AQD.:PA?/.Y64%J[FN'VDK<>?ALSK/HX6BFL;<AV<VXK/%R'0RIR]A%OK
M"\HZ>T7NW6  PCD%81)HQ552',I'5VCT[$AP[F0MA6S^)?!AMWT$(B!*:UQ5
M.A8_*C%S#$<GTCUU)<]T#L 6/Z%;X:\.<O4AAI^!4XX8G'72V[4R3B3N''A&
M2=00 EBHC !%H;.+(UMA\(2.T0[KX#*9*SA%P8B7CJEY-O=Y+2P&M$-_M-08
M5=UX*KOY^8)X4<ZB1L(%E 9!K1?!#@E9B)5)4''*G/=XSO%J[U$HW0$E1Q#8
M.(L[:?+(.Q3OK2B.0&B"^U/0Q1'!CWZ9^ED_:&%BHN@(Y4=4_;]<Z*8WMS8,
MSWE7EJ;.\@EYGPOXP-JH\KM-@O86JEBX:7(^U_YE,/]:O38#T(;Y(;R/MA@+
M@?.Y*DS+;Q)-LM1OA'IS1K* \7R3$+<Y4"+TQGOECX9%TVI:6VQ<"'=1.@3E
MJN$*Y&RLL@&9DV6)DED_WC167:&!YK);#"DW(-FVLCD1[84=$>%Z_1GT@[N(
MOA,[DYM$?SZ?$^>R=FQ;GS]^^ZKD421  _6V18VBMBS\<%+%*8$8;F@]F"FP
M4 JJB+B/P-*N=.+W-?UB6I,A/6>2Y6&?UO3Z UYZ/%#1H@-3YR%4>3$G+G8Z
M$&^>TZ)%T2$C':;VRC@1AU8?BD!?DFSH17;OR&&D$/QL1AWQ&-+^9<B.TS<$
M:!-%/-]JF;A==A^2,Q7D$ ZWT_[:F"I1^7K,%3SZ->=AAD>A$WLDNY'L&S')
MAF0)^O6*(?UPO_K-097ZF0DF?/@GJ"R=MU*TPXL@/*9JCB_(CT!A?D+'',PI
M,LCQ-^]?O+!9V%4N-0MQ?\L2.M"\MA:E^MVW['WZ[!2?@E3UOX60+>'">M=2
M[+^5D+UGQP:UP+=%M3M%8XY""S&HGY_@\6#>$/]X <@G>(WW4-7V YR4O!8_
M?<?N+KYW3FZL9<C']:RQ;.WZXH/OM@X]ZE)/MU&K467=[Q/>)V17OZG=HCV(
MR@?*=R[6TFM2PZ($B,U4T)5$/%>GBQ..A?1-G5IV82)\+YTV>G0'L:56%V4X
M!X]K,GP<3#B&/!X9*YBUK7_, 58JIA/'UUKJ/39EFJP:&G"NKOS2:?5"P1,L
M#I7KNJ=Y^?8\$U[>KPL<S(S\N$&_J\]K%XC]5R*6_[^4_TTQ5_^'%. K!D
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M6[AH_^ %!+4!!J8"'SW<\)NR3>+BNJ+ISE5&MS#'3J!C,<Q!W_]T.8X[NHY
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M<DM*OP(.KN%W1@.8K,X!WF4C4SG>HL%OW6KSLB&PS;6Q_FH:[J \95?=K7,
M"3RC_0*_,5@M:-%GE5P[H@"QJK8J4@U2]_I"6\<;+2+X)_.>TEKV7O9SY*+1
MIP/:ZOXN2#-*S?@3+:'^.P7)&@>.KH+P"$BID 0Z$_0_0>T1U'[KB]M,]N>
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MY/@XNB%N6IF9LU>\ADBU0+YH,1)&O^691"6![3OH61.8LW6&=HV#^KBLD]X
MM=4(52.LT?A":"B.)O.!^-E+'%6EL,)MC%G'](!PF,2>@/O^KI[20'F</>DY
M8 D>)&!(<IQ1.S,[R^#G[P7[LH-C@9D^^Z2<:4?!E<I[QA]%X+: 2YP#@L!B
MHVQC$@\R^,2_ACYIQM[T+B+TMKPDW &UWSX'5+S[3KBCV<XU 0/::I(;#Y2S
M.*CLRA&OJM[,QYI_X1ANB%TZ!W0^:7!"G6@-"[H5E'#%V835^ :HO?@QG\^&
M%[-7:3UV1[LOOQT1C XG(>*IZ598LOB>AXD_MAC7_.!^CT.O2DK=<>_8R\)Z
M^F$_\4V9I>$Z$52OR%&&)'\E4N\<P&4GTOO]R/+.Q1-H7T$Y,\9'9++U?5[9
M+B]L2+/^?VT='\]-W!)&+-A.-9!?"5!AX.]0X_/P75)(6-0]7-M^N0"1-1D]
M6O'[8GE_IZH<(-WRO?/R$0E/@!>,ZWY^P7PA?'+.>V7550?ESK+M#U&FU5_J
M7#'_6Z=B$V0T@=.6_=)(7T?6_8TOX,WAV^3E^*L^OH>EP$7/3G[A:Y5U'O$5
M+\9I=^(?[,\OU>[^!=E32PZ$L7,22S%7%[Q[*.#-:8VPTCHE/1!E;-?8?SFN
M.F)U*E<$<P@_,<<@]LW>0-NHPE/@;60S2!=O>M[.KHJPM*+TKXB&V7- @B>(
M'$QD8D]!G[/XV-=88$6 ZN8ST68+JA[Y.CQ_ \82)=/9O,6>47CJ$U,6 [T@
M%S.772"3P&"?-"O5J\OX7"[]*5Q_JJ,SZ0ML-9$1/^P4DGPE.KHIV9HB)_N>
MDP/IAQC>#KJ'VWP^O+!7I_13O[G2BS^RN_VO^-\5R'_T377_M0/&AB\"VIKR
M'+_$:$I%'_G?/C&)W-'ZU6K]>CUJO\:B/CFV!W&KFRCV.84OG9_X.>!*U 4J
M5(XD=/ +XR_9K<&DKO&P;_CO</F(ODS(F4#4WO<S1@<1R*C1L9T:DO"@XD-8
MJ(\K1\*.!0.R9I=\1&B@W4);WGXMC7AAH!,Z1=)&!K'.Q< 7E1?>Q)YI8PWO
MPD-KE5S%KV5Q;"<2#^I'34YW6SNSHJJ[+5]U_2*Y[":'+)XB(,\!K ([2^_G
M%N>BYM]+DG[J+)GFRV<#$&'HAAB;[<9S*;5]N+9A%W!;&<1DGZZ\U@9CW" P
M5LF:5L[04>P,<;1%<SG$W&<O6HTXBY_?P]%XSO,T5[WW=;JJO!BM)T(TVJ#=
M@O\5]''V)1'I=_EQ$?\MM#&!A6L)CJ>G8H','Z^= R*S_O<OBM;\);@2W$<)
M'[^]ES709K0TR(Q^E.V<K_M"!D"BJ*U_X'H.H/B$GB)$DD0C4+X73^U#_^Z;
M47K(D]'_Z*?(O=CMO-)-!1Y\"IC1#MMXU)%7"/+RZ%G<W-]5XJYX,EA@[2%7
M<=-%K826)0CZ)FD.LL_U=59K[QQ C!O0S8S@%VOY,X]T#<1.]1*>G\QKGO6>
M W+40=^._OW!]K]:;L15DRYKP)UB?9$D]?JR'[K$W/$;)L>!:.&6=#Z$L2!'
MFY%CGE>/B:*]2_D#K=%Y]@18J4%30>8FO59Y=A+]_J/B&2(K3II3Y,#<)> ;
M?\B"?LRM\2,V_><-<'7]@$[[5:=> -'I9_(7)$.'?Y1;#&!B%TE"&FZYTC7!
M2S>P.OL9G[CJ:PPF/K/>))+G_P:[C,^ 6/?9+YX#PBK[E)Z-%@MD5E79,#F>
M[')7N]P/:@?X)GXM,-JB%S'[-:WJ:2NS%^%E(":3/A^368R41>VUNF* S<Q"
MD>X"KB8&4P+"W ]^M7DRK=$-_?G2!A>:?P$/:Z.BZK;98O4<BAZ'"]2*PC'L
M1_O&0EGS S=?K2)?CN1M^X@ \X'C38LP?LP,JM*K58,P/C+T4J_BT=/@U042
M5)QLS-C*DLCLD.\3OR=8/ZB8@;>_&;Q9N)5 +.,4 KTAV,3IY2^$[(W  A-7
M)XSOL"#7??5-0;1>7!WZLY?1EXT2OI#KG[@J<2Z,R!4<7ORC-M1>6+'?RZRI
M32._+?F&WM2"%4UWA0]Z7YYIPJ-ST%S0^[UFI'ER##7'^Q?4D^MY!"_L(>IO
MZJI-=_&5#4K._NC;K4_,JZ<TRPU?6-]*>>3B'"/"0'?<!_8B#->? Q8\O;Z"
M]XX^[<RD?R71M,.6LN3F1;GXT^"I#VLOTY8Y:F9"EKT3:+5 >1P9_\:Z:0RG
M662[>$P<P\<Z=*0XUZ3E[7<<.(ZSJY-:$YWPX>Z2&X$NP\\R3 ,ZU(BCEN1E
MD6WN1U*MP(D34S35A\.S[BH6?O?XO:#:+Y0/&!GE+!O]=ETUR7@?>:7':IP#
ME%KZ;!=R&'NI![>$$;;XYT\>5@X)<B;)58Y(9+%_(8*D66QR5((BG4B]KW9T
M.FF1L\#]/1/Q_+ J?)+#^(+&0)A5(N461;X*\)%A *[H3>>Q/:JO(<I1J(JL
MG8O(2/D9!RA!V2^ONF<#)XKH1OP\13@DCDQ*G0)'T46P*+!878WM\WHY9<3[
M.\I:AXS%#W#F,)/3]Z9.6I]>]Q_9%XBXCEI*=U;YRUNAA)L]WGD[9..SEZ%B
MWJGP$<Z(*3C&=<'>P#("2&5;;\FH?9S?ARF[#.V(W7G&#0Q51ST!5G[_CKE'
MN,[!F.$;8A#O5MQ)QKP2KA"@EQ ;+)GV"'(7J=J48F)M-Z7P#DAZ9B'+8A/Q
M&1Y.>L@78)&7G^A%Z -V$HAN]H,F0B^P+P"SIXE17F)32U7^9JI: 9N\WWKJ
MQ 4,=OA%& "+UG]H2#Q.=$CU]F3@\D0NDP.-L+D1JXGN81!R[;-SP,^U1"?3
M[3B%=Q7X+T<%7.&EDKZ\K'C,&-OQP2]TRMQ%,HNU%YB70+6) /#KF!FMV,$X
MYU/F$U+^%,-<(9#='+>KNEB[^H[Q<BQ?&?XK[I[]/=OL46&=J&NKJ;SLYX#;
M!7A[N];YV" !NA]#<4O._8[<WM>PK]&F,W2] F_N&H]"O <$S&X;]^'7@%:H
MLU89_YH0"A)-ZO?/F6=,#G85):LHBNF_9[]H9=7B;,GD)<T:)!K.S:S-T7;%
MI/5[/]?&I%W,Z/F<]YB4"O2(/D?=4%',R0Q0(,)G*]R8]I-$9Y\D5N^< ZX1
M\K@T'/CRNFGB$\-2TQ6[V:05QI9UL:Y+<T0;0&J<E&OFEHAW]0AY$8R*)K9N
MTY<:1(+3PY M@H)]@J[/^VNJO3*2?SI^5S0P/<YY7PH9-(EXWEUA8V%;*)F6
MB^# R \,B:7V2T?8)>C;PCH)UU='M93]M0X#E>FJ%J!7M]A%Z@PDBJZ7-KV+
MYG9.U.5!$L=O/RCXG'6EC^?UL^S,VNSM"!_V6-=%-HN!9Q6F)_K:UY9,EKBQ
MOLCUO.:YT'<X291I:4JR%.7E>'&B>F<.MZ48^:((#,F9O")JMD^2PIRS%FFP
MV^/7RY''3:F:9SF-A.NO)L_:E,4=TX)J$ P$U;6)CM=EVL<2T#H$_<7L[I=Q
MH/C'Y=%>KZW%^['S+#22N%FK7JH9P[8?O3PU3/.^Z7Q6O,VN:A/,(WDR(R]R
M2R<&[6022N.M!6=VVCRJRR@&)(KI='Q33I&+D,ZB--_^$3FY >L\W%"O^[!:
MIV;261$V9:'!&\VBCPG,OR[\>G]'*PQ>$2I+PQ-[\G6V?B\$4;'37SBTR7Y7
MI;*<R\6@R,)0GHSZ1!4.RO%*$*43U3YVHT\[!Y3$5K2N8-Z6DU''>"8IXQTO
M0!HF%=@Z%XR%M_&7'5N=W4^)KK9?8](YUH(F-X8N16!CFQ6(AOU(\L@<[@/N
M6%VRS^5H^!*S? YX.EU>!A]QL*RN"A;<63(M8+4/!OCJ',V%MCQZW[17N_"&
M*>>MZ\HD&V*@1DN9;MHK\)\N7?__/_Z;;T 8S/*AG$)Q[CG14FUU]%\7V61_
MWL3'ZE;$K+(M23O$7.OJ7F/;>A-AO$OR]8*32>!N7>1$=QZ*XWE[#L#,<*#Z
M@-<@ZPE>/+]E)R!!RNR3LHC<'($I;X$*?Q-VD;H%6>MS0,?Z14)M?U]8][BH
M&8AY?L'WT'6'%^2O[^('*> ;%S2/#Z5)H*F&X!QC,6^@'X"'3QMHS@$?=J#G
M !;8D\R _^!O;C4.NWUE(]&H&JGLY?>7U:R*-H=75H9;1-!J!>LH _@"!XDB
MX,I S@NX^_%/+6C[^\5Z6AU/!NI)XUZY_K)6YB1/RX#"JVK 8%<%-DS. @>#
M'9EY)B92<W2/B?P]F6V0J-;HTG" 3.$?/E10ZM0V=U-.>+X^OZ1JQJ/S:;J.
MF"K;: 89KS2W=;4-<79FX89/3FY57K._N3/;3%I+:(1-C.[HR=62?\PX&P!Q
M@.GQ,6I^6CD=SYZK3@DN/;]H^ '%F-G:4J7Y<T#;AAQ),9EO 611U6T.85J[
M/U41N[4#,NAEUF#IO!VJ>L50\Q&5%H@'9XZQ(!"/RYT]CM.@7X]GC1*[;3DN
M!DGP\BH4RP ZJ:_Z-^E'Y45GHAA+?"&F2*7-+?LO,,&E].OT-J]?=-]F#2')
MN)H#2U>XC#-B=@M?F''<CGQSZVU>4K8UP3MQF\H.R][XE"[+C+7K-,J#THNY
M/_5X_>S;!8/[=O"'*=Q?\*^\L^4%_M6WK)MZ46[P<>>'7E1JU%IJ2)]_A9GE
MF:+?/5!$^I64R9F'XP(#DP)0UD3B+]@81F>S<:V(&"H&IH$%'V#REI77EP5G
MK=3CB\^G*\KJGM;.>3,:]NZ7$Y$BM3$&5B9B(O/OY>WX\+[^6MB/_^9U9J]>
MP1R28V_W,[_B:;YA.''\)E&'CS5)"?@+AD11@1%E%IW#-K=>W?/5N!"=EC=Z
M 9/1H-N$'L@U:'O*(B;NB.K8X3.TGBNK1J[@!,M\9IUW"2&S^,S$3B>&G6IA
M;A0C=PZ@8T[@>B1\\6#$F]DD<OJ?EJ;E"[]U..(W%"R=CUF=5:Q:3";FIWI$
M990>X5F=[VL72X>VWDZ:=[JA>NM[=;QB<KAL<?\+FM'@MTLQ 6Q9PS7\YX!?
M/E=KX&=4X1[&G82*G?OMLV;^NC_,I.?U1P_U8>I2G5IZT?H'R -Y&>]<L;A*
M.V Z(OE@//",V<M>H^E,8S;#V2N/9'N'N5Q%]<33F@OI97?,<0UWP0H#'<8%
M&=1#!HC9K85Y1EQ?+\&( W_IJRF[ZG=:./.-O9D4*8EJLY HNG_1!TJ)P_Y?
M.5EE<_-RH_B7G";YCU/KQ_=*Y207R+H%);H,,^M';Y^:+80HW6;/('GD \UQ
M7BQ[T=*:#KDS?;0_7=YD:SRA->&(Y9IJN@,>::+ N'H*I8]H%&\.K9@-:!(U
M5!]Z<E_!B?D7M;H/3(6V)3UR'VX YAGP<\RH.7/][)+_,7D=5[3Z0_1'#BRN
M),7"#NB^#^,Z2N4A6_GE!;-E]_:$+%?B!B C$ <G5J,9IX:RH;V,9G;M%C0K
M=I<<DN"C^OX<X-#'\,+F&UHAVCF[J^U>7863 G7\*(R<9,3=SUG96E.L_:7G
M&J)@!!3JTK,YVYMP8@3Y@:,:HR!I8W:*D,B7%+Q[S')VO6-]+;B\Q(CN- >%
M6)P+4Z"QOWJ@4M-769R[V6%FD::XKFH9N\B*'$P7P6?M@F_9;%"^C]LP<NO2
M7O*^:OW6I9;#C<I1<P.DI"J9IYVV7')G$'? TO(K5=Z=V?%P;G)GLQ[KM.SC
MV78.B!E/9["MG*'I18Q]WHY3^OG">0NGL7.*'#BNKMMKX[CAH%EI-YG63+3\
MMGHHO=B'+[9+;Z 5%NP#:V-)L&'83M&^/^'TA9R<,@(81@AJ]%>>GR/>4+@Z
MHC?R#*YC0?+U7>M)//5,]&/;\4[U%!]5+*'47KN)ACLH1]%5YW^6C'3[B6%X
M\C""EDVC]^UD^BE!Q5J0FFM;A"&81F;$\<9(-.]^LR$'2UB;;KO&:.'N12<J
MH7SUSY8>_P^)_^X*\O\G*?Y[RX1)C58B[5($\7$BJC7P.+HWZV3W -#^!I)Y
MT'9OB=\]=)O,S'&9N>\E8[FK_&[O)EY=]89EKO]QP:F!X_@]/OW(*8K]]H@[
M&U"W_'O,^-BWU[6JW'$379UV)Q>ODH[Q7:AM8)M/8WE<D_)@K0QN8/8DD+3-
MDZDTY!^4P.(Y:B_P0+N,9'\RA"EN?,'C.\EEGQO^RK9::CEWWNB\7KC#6R_A
M9[PT=\7,BZ1->^/@-)K><\K4TBFE,:S3>;9Q:1[2#L(\+=97'G.4LG]Q3[2>
MW!L=<[K;VNC!0=U 8HLF;MVS?&<D&]8=-VFU&1L[RA[2]"1%$-2LP,DWZ_BU
M<$*MF?6&ZB-Y15P8[))SXE68!)C>?X=I9$"D-$&#3Q6+R+J8Q,C]6Y6=Y\C!
MMXS]% ?I%\39\#4&NPOF0^A1GZ#Q>N83<TEM/JT)*)G>YW6-D?R_7#+\1O&/
M0L#^<T EPW9'^H,::!N8:;_$O3RGU('E0P/G.T4"PTYZ**+$S[78QB<V=,]L
M0*>L9F1W9$_1E4F5(Q VNKG28(5"M,S=H!<O7:]&#G<22CU,R_.&0J6/Y7PB
ML#_A"NGT? GN?71P=X+UR"OQ@H7, CV3(9 /4-P&5EGE] O6RJ"OK6E5:#9U
MJ4;=^U*#]UIBQ[A<>AMIU_ YP!RO(/TZ4AO-G70G1L_7V)(\3!X@U*,Z^J:I
MP!ISM729L.I_NQ^E 4K&_SRET\UV5];N;^,KC(K3?,@_V41%Z//9BY'D=:PR
MAFSC[]XC2G8D)N8\-"&GV:S%+F5@G5H@%:#W#4*#79,^FU+4+K!WW\B72#C]
MYWV+;C8%Z.=/3;7;DRJ3V],^$2E@#OCF2V3&+AMVFKD0K'< R5BV%-^UV3=/
M:)A;UT*= T*W_81SE/)L4<7T0Y0 P&LLU&<X,P+CK=9=?:(@">?QN* 73][_
M(USDKN.+"7P:\\ KRMFVPU^J3.W='BEWB;:0]/^(>G40> 0+)F'5KR(@4[8V
MYYB$'/S65X(TJR)H#?H]1*]\8?<YA-'!WO^TE_D5[F'$=0)F:^Z\GC1BZSMR
M AUPJKU@56;FA\V_>XEI9W/:RV=EF, <8_N(81MXO  #:7;4S7<EG=+]XC$=
M-3Z)P[O&9/F.KP1XPEMS._@FV !<GS"Z(TG<G^L9]7-V"IY"W<!%1I.MEDZL
M]&@!D8X,;0E&4I)7?$9K3>R;VEOL)(-[/),\B</BMV&HZJ%/1VP/2D,0ZI':
M$38$AP*&ZSUB,Q<@EB^JY1]LRO??*?[A!H3_BC]A1_!V;4U$_ZSAJC.KZ#U/
MC_6_*!(N!"9,U04U9[)3SUM/OU4^"C,D?\_(FL@GDYXP:*]'46B#/'ZR*%7S
M_HF22->5SU&$JGD$\3G@C;S^@FIT!E)8LE<6HSTQ+]),5F05P-0M070H_T<%
M%U=V/LS7!1#Q3*L]S#XQQ;2MZW6,;&BS%<GEV(XZ'Q0L=JZB/P<=VL;LF&55
M;+31;6\W*&;RN-\@L5^% N"K%U]D9)_BT(@/;C$UG.:,NY?U0/_EM&[=&H$#
M8P>ZBA%6'>))%K*Z  %&!LT7( " 5/S''8;T]NQ !/\V:-CT<9.MZK5J"7[K
MO2Z3<:20L"FAIWNOH]B$VVT!32=2I6ODI..G-3]'#\)0M7V<FSJ-&%+HC;3P
M.(V@^AD%[*?P#UZ 4D]@*I2JQ@0,JAI;=HF:]M,W_:_!:#!'J&SC9#GUK"F^
M]EY02RCC.2 W  +LKXG] +RYC(&4T$+=)I4GR.3,$6.I:$XV,=DS_4B5[._N
MIGQ0,D*I?ZXXE:9TJX >QY(I4'-?H28SZ[W7;D:,C:E5A#)Y3.BMP'7% OXY
MA6O_./?GOR]PJ_BLMVL5F)G%,CD-AC27"M5ZS,?,A="R9EQ1/_\Z<$J]Q<46
M2%U<U3X]:)>8<5TNV O3^5Q:(;?)#]9?]M$-31.Y.[#NEUD.2QI*(>@T[0 ?
M9D;P?SQZ_WN8!7>L]+YE8G+:/4"B,JO\[F6? YR\DC1&</ $ZV2M3UP'UYD(
MNRJJ,/E[.3^WPU,_WUX^5EWW_)$F8\JS(!RR\^;+M(SQVL #_+S $T=_1;K9
M<:>0P^!!.6#>1L^EDF(R^K$'Q,3?EK[M[!CI8DUY]U]&^7*=PFE>3NFG/=]!
M-/X^9<#:_,^6B_\/BO_FPO_?'73+T$J2G3L+T  S#MNJZXEGILE4ORJ]3+S+
MX6^<=GF*.%HEOFKI6S[%DN._ 6UAY(0!O3KS\5=UHWM5)+?Y62ZEVRB.*]4&
MD$UMF3JU ,,308QRQ+E>L.>5-665"+W7[[><OM18/)A\LK,%BD7<;.*VA]++
M64$603=,\)F$C1K=LX\="MLVLKQT6-\SZHN&J<0H$6J[SP%9S*77:QZHN[P9
MCM.2GXS@+?B+291^+.X5OK"!! 5LHY\4#K=&,)S<\,_0[A_\><F:-15MU@R*
M1\ YP@?"$#9S-TIWT!ME[18!'GRUP"*=^Z=QRCE9;\\X".RW4)$$7WL(1M )
MG?5_>X)]:1#]?1L7)G@12KE1U\8\%^J0T017_Q"R:!]XFQ_P\-4M+FGY:#M(
M:R6!ZQPPV+X .3L'N)X#.NQ54CS>V,Z8<CR&8GA#6VX-I)6< ^:K$!V_KR12
M$!G!01;DQ=N,U!(J=U2HY:Z^_G6F67@LI[]6 6F6:.+ZJ(KC-F,X!R!.@+@W
M36B,^'S]7"B0S$]RH43%1DC8K5<9GFBLW7'_E2:? 7&,;Z#F<SWL.: UTLQJ
MBL"X\V^'R?]^]$#*QU_TI7@GIR:M[5U;B*KKD YY_*D^SP(DBIT"79I?YQ$*
MF]R4*@Y1))<MUW&7BP!LV_SAZ;T6Q."GC<H+V+M5A3RJ]Q=:M/E9UGE_NSSH
MO1=)(\!=1U>>2[\"6=GKH*J9YEA<>D.-MCM5)GVQ]!\Z#HCOALB&F=W3>AW=
MK*?"=)G]6\2IYI)4*P-*Z+O3VR%(F3!W&Q]BO[TL[H./#T=+$PQ&A"]N$IK"
M2+4LM2:6*;H7VT6 #3]_AX=!>A^*1D_,NW8:'92A\[9-UG)B,[L*+11JF77H
M3N%FI@35=(SF<2HHV(>B_Y.SC7LRC: U:2^\QQ(GU"EMAB,_TT_QZCU.Q00N
M76>#5!NK5%DFP(==KU[U8FF>A<CL9[9_2;SS9=\P1NTDLTG&:_(@(E0R#O@J
M*VZ^0,<]36(5VPA>*9=P%[ZYQ=P^90K:1"+A @#;4B'3Z<#!UZGC':%H_0XS
M%F/W$3FM(J-V)T(AM<?.S3/OMT\_'='U:IE$9"_NIN<5\='FL:LI2DYV87T7
MH#M9^1,SRM9+QD_V!+[,;^K95AO@)T5;8W.IQILJAR1[J:@W/+ QR9YT.PDM
M)#$V!F+?@<A)!+_]B,)EG'431GDQ+&WU$T[6G9,YN%2* G$P=-7+'!MQ\MT[
M>^$.Z>X60L=/R+GET%YQO%G($%8QA/6 A*Z"([1T*V>>3AF,[,"*5V@FIU7*
MVV\?6G%QCJ5@\4>JRP[2];\W*6[\B7?*_,VA!ZZ%V1)81K*;1DNS*JNB7/8Y
M!BFSST@7"=PXJV$<&<MD,UQK7,8_@>620&S#&GP$-MQD@]:,DH2PV 'MQAS3
M%Y\M2NLKF'AO1TZ=(M/".EIBZ]D,#Q^ -?69[!+D?X&%1W!]B%@0-7#!T: Z
MP<&:K2JXH<FJ<CC RIKU:K_"0Q5%8KC1:82-V:SMK4\>W2P.5H>2QZ!64 "#
MSXAJOE>T64\K2]Q/5@V>#*==V-9A:>P2SS8BP^_AR%+-D&7DH_&26Z(M@]^H
MGP-.M1_*GP,B8?);K26!;1;QI2<[TV=1])X!/:O?M3"R)=H06#+*G0ZQI$FT
MA:!R-\_=&J>R<FOEQSTY!^S"57#\EYI\M)S]RO6LUR4V'Q7KS.]"=6BU] 0D
MSM*T%Z4%S6VS/RYXQ,AWRP/8^M0TLDM[CHY"MS^AK$;/ 2VF15.5;XOUQN_I
M9(6P=?%\"DI_^&!#5^$ZH?M$#&1L;\8+N<L+\O.(^!;NKX"Z;#D:^TW>?LM8
M_<E;ARPX/-H\1'(R+ M BO6K%XZ+*S$TFN(Z4+B]2.J2B_)2,SL'T."I)6FU
M0-I@L[_E3,Z_XO\YP,X7Z]M?4>7MYS7_NFH <)/X+_ :_ZSP*SI[!QY6N(>Y
MXY1IR\Y@;&R?9G'/\(@IWN_C%4Z_"+#)P>C:!H@>)XAA0E,=?T$_AJ-*^MJD
M;NXVH=GS?UJP(T17IO )>/[#M46>'Z"K?@9H^MABKZ)G,@TIVF+&4QJW;OBU
MW30EF=V8B[7;/<0K()]6A SW3/*K/]'A?O<PD)K6C4@5H/W^Z:Y163?<BHVJ
M"S3INB#T%:6YJ .F'UY+V>5UP]Q)7)W'#??\V'WKIK4NJ[]NO:UZ#K@[LD"%
M7>,A1-EAX 12BG, #\-%\[^:<EJVWQ'^%4O0R&OA..K7Q#..N1DGW)/"VW47
M?K:F1910>61&\*G\?G5E]W?5B17/SP$NW-9.WYA@'?)JN9@,=,OR-]O7XU6+
MA3)Q)?>!'V'CH%AV7M!5'!L:_/WU?E]3FJC>.<"F0 N;@ON(D5TR!H8"J2LU
M:>WTM.W"<[H<]<:E2*V^$,,%?"@ZN4='[*?N'H.0ZSI[VRG&B*TCH$WE%.V(
MQ):Q]#E@;*JM3'CH(?&I;@HN'A-[9N.GC0GTYN>@[E[HO<IC%1,Q9ZT+4N*9
ML]Q+678#3O(L.@:Z" G(^<,82 C&<XTMT,(N W""OLM8O*/N:W"?%N@&N!^(
M>G$5626K2>FGINYK'_Y+V0EF#$NB$9T7Z!YRQ2]TYK/9[XRZ?])-".(G#WGY
M4;7D9>13_/7G6,K,B+SB+?ITCF$G2?E'3A6_)MI&!H2&IZA5#.8O/0=L\ST5
MT@+)"^^< U"DRGJ@,&HZ\T_G@)OU<P31BP2&X# 7^$[YDC"._F*N0Z< 3O?^
M_3Z/.7@$P=S @*X_SL<(%WCQ&)NZ]'0LROJ&Z\W:>#Q!DOZP>*SMQ59T>/Q7
M >*]WW+1^LGXT\7[M>^?*'WZF/-;+EH 7H:\85-: $;?1@JYGSFH2%1[R7TI
M21%3!XC'=30%_0T^FJB]6%!%XTF'\ W;R>C2*J?<.R45#RU39K(%U*T?D/-/
MVWRCA/Q08(IO;B(?EE"S-BX0<!BG3Z;-=Y$-G*PC_<>J=*38X&4?]^B^Z3QJ
M19:G:Y=1W^)Q10<TG6"A.O1:E*2ISZX2=U*\.$]F!^4-*D4X1YH_^DQUZWHF
MCA[]N#2*X%X&9Z&\)O209 .4QO_C4M-+F<+3##6'6FS>5?/,@K&VJB*_HI4B
M''):\&+)D@#_+PL'_]@S&LRDOWJK3UY(:9XAL&)NH.K1A%5X#*/E=XJ13?N-
M% S_L?)8O :FRH$V22!SD2="5JO^Y@/&F8W]6%!+TQ&LMF=3YLMKJ 95:PV4
M_/OIYU2]N NJ_$5+F6X+>O>?.Q6:2+5I1OJHMF)^WI2:<M<S[;:B7B8>^G*H
MA<7J/'?.8[>5Y;*3L+.X6S"L_W:K2D-OY/'(6E/3;XL*TV'U6Q=9],)$GRG.
MVBLXA(9*_3+D2( Q6MB2G &G.6###6<=T!N2L6RSWMB<SMT7J_P&Y;<CUV6A
MKGT>4 KP91 F7Q52?%KW)BFUV->C3Z3#14Q!]P08[)4@JNLL=NQ&#T5.^^=R
M"+9:?<=V/,@]<SL'O#\'P,0#49T?CIR8[2"OAW=25BU<N:/ 3_;!!W"G-= S
MG!1&/,>+7;ITE\Z=PA[P-93)X&M-E&5LP=J&:7K0 A[8*N/F(6-5[)%8,,3%
MINFBZ;IKKU+_#L.K=9)3).?7^J HLE$&O UDV"(H*M/J9_IMJ.L.O97LA7!I
M5;P_9EWF1H<"#KL&E';Y?QXY37@NK!;(P<FRJM+:(BO5+F<7DENN1)^H />@
MX*HM"3U)WI$B=+MX:8@X=0B!0I5#9>#F,.0U1^BD0[VBG-1DJL!4F:<8"<GD
M8^5W\G#+4?UL+\\%1 B.KPQB;?M"E5OUGD! UZ9S5,C;C\[3[J6)$2E>/A*$
M:]SVQB+MBW2%8PX^P;1:IB3I_^RU]/_$^!>\^AM"[2$=B^'(DD6)_]OBO"O/
M>J[A;1%3*9[XRX*0O8OU,!K\R$\'H[4D.Q ^*U 3U SF3+_NKAZJ9CDLQ&2J
MGGKCT:M89Q,$[MYO-_K!R$4@CL8$@J83]1O2K-4V*<DZ_FCOXWKC"KX >#0!
MZ2C57UP-145VH+=2[!&!N,>%<*V;?5G3 (!SMRS_L9.&=IU_X7>^QT^O<7WZ
M4>+M/VNIX.3[N4*95H<6;'S1M(J(Y<5=Q#:+ R[:/^=_T[^:!'_?^0'I;I^!
M_+H_=<I\IG[,=;&JVZ)"\:X7;:PB20L,$MXJ8G-:%-[*V!W54K[T>^64VUM:
M:^F%1<V1'PE?G]S<RI3<T$!J$'UQT.LVS4@JE5EMTD=1X6@TBOT,XC&(MFHL
M-#23I:DW3P6M(6L=; '>Q,[''VZ!/+2ODD@_R.1/F*$XZ_FY['</%=JL0%)F
MK$'64O<\C32*AB[3R<G#14KTA'M<LPTXL;=PTDZA8.S@VH+U[>D-;JP.-J^-
MPA9'$.$H5?-ARIFA>XYW=K?!,N A"+%3TR7<(^BC=-6&$1Y0I2VRN$9<.?75
M$N8S"B)S-G=,@:ER1W/-GP../?)D3>S ')\-)4I=!NC%F8"*G?/\/X'S>7H>
M%QU\]DK]CS/09%X8JVO%&\@7NHN<7&Z/<]H!LG$.3.#J/12^ED-R9 1[Q"(W
ML*3E%5&?3OI<(3<E9!$T?D T>[Q%X0E\TN\8550])M3UL'M;S#X[\^- YQD$
M<S>O4WH^FC(ATTJ'^(([6AV> SR@YP!*)&;E'/"PA.$<<+7W'-"&W-JA)<)4
M,/P09@0/("H96MF$.^X?>R!30O*<7"]-3(<W*W^^UPUXM8S<D?QC93;72DLS
MRZI2%CWW%X+)8]8P?U'A.!: 4;-DZ/[".L=@F&+^G!C38]%.SCNJ+P]XZ4:W
M[I/H#NT5!YV^627Y\(!IJO9)/Y 9-? >47%EK@7"I%RJL<CH+J'N&=0=,]CQ
M?/ZJB\DY@ ]P@OVCL&RYP1)MV0*BVN.L1%^MHDQVEGACL/2)+9)7FF?EY6S=
M)%HX9JZB:J!#WE=S]!728CAQ?.*;:+>=E6!BOPNK18!\D,JX $XQ9\K.R&_+
MW<KE_9,W+QZZRU/)C4W^0'&$@)J;*(<E5&N,X65P@V<]7XF7FL2<3\?Q_]#Y
MPCMVAS\;\M:/%BT']HQ?GL)GR;JF?6!UW]L"I05]I  7;C&_-1J/]S:7"0U9
M90@>#1P*Y!A'B,@9+A1!KV*@.H.[(Z^/Q2NYK1^\ +],/S71[U[3F4SE\QS$
M&P>)7A\J"G72V3O9P#+I:"G[36"E_Z=L= ?@"221W, )+]EKZ$W.WLNK/AW*
MO1S8R=_,INROGPT>?7Y?J""#^(!M?V(@2O@M%Z4F[IK^E3,QW/5R-# 8)JGA
M<SU3_ G]S((E:X#[*]>/ONZ   CSH?_+8].J3^$C5=T9O=8./V\_9!CAC+'?
M0+DYNZT7O)S8PIO@>J7;5PQ230H6/6.2D(<R&N+'X:CHD\\\<9O-T_/A\]P\
MM?R?3$-BE_8H[6<-OH]OYWF+T0M+"X2R@95"\/QK?>K'3FC3E%UX7,LY8/6'
M02[OKR/9SU2M=VLI7B[ (MR@&.R@\*-=/F;IJ&]+^&GTGNF<4=L(@9N*YDQ8
ML URJ0I:" F).I-G>_VBI_GS(9_+O3'46&R8I /]D[[2+._7@W'4ELF?>?*)
MI>G&U\\!;')6V6'(LQ>@QP'129\$D@=<6LDA,C6K+R"T1B(%K0F)E:O04NBJ
MO[.RWU8.893YL\JM?)MJ).E5MI(5FXG8_,LW^+\/0VPUR6?YR*9\=V0>U;I8
MWORF$%!P,<,V*;MW,CT"V>P7OL9,&H\@<O-*M$S2D]'&+485MXVWQLTG/!T2
M<.4D3=NOD)I.KA33]P1N9@])3Y>K-">$YG.5N*LX0UMVO=UY1W-RGE1MAMO\
MAP[Y^5M&J]"%OOL.2CH-(2T]U$DI"RV\Q]U[.[-->IB$,SN3K]UO<3165!-)
M@05S630\=:H=)/5@W>ZP=NU6_E&(4%Y)0 _:^W/M.W2=<6/<Z3G@&78V C>"
M5)# [+5!;1@(_*/+,4OXUZ(:*RK@B"_$J$OE;G,<7E#5.H;[9K?''$IIZ6[>
M64YNWAI%QAP4>@Y3=B([WV_MS^HFX#G6\I;!&5H@(B^IXU+T.2"867H7MH2^
MD@)-85.34HLZ"%=A >XY8O7'@20$>2_(XA$LP::CU2A<:B#W.=B*8U9E?6M7
MQI-NW?R E#&IE\%Z @K\@B)("4862/91;AUM(H3%1W@S(PX'4OZ4NQ5^Q_O]
M8PJ9<>/?'MRS=X2YX_[BP;WJYXV6549=06#=<NV1ID.&K4%<9V=4KB QKX/%
MD*JEK:#C[J:^5WFB$X^<F<_*"%Q'./Y0ZLA@"BGKVH >>TNC^!/S.5RL"B;R
M[+&:\^HO+V-1U1-C;??36+SKRY%-%?^B+@D'&EUTXG?!8O.O+QJ3RW=Z+7GV
M9#W85^N!(>> *Y) 5H>&!N&<#:9S@-'FX_)S0,VU#<(03ARD[F79(J,9='A4
M,5P\/'GKY&M1[=$;N7BSM[QZ'0H^I;W87UCF7]-WM4A4R5@&8#@&K/"/!3"K
M'^F('-<*R.ZKI(8A^-43_$\>?.#T&72X437O4N+O2N1@WOUF TR#RMU2/O!P
M<6E+!&_)\U?_KN_]*_[\$MI_52G_O2G<G_OK@B':"4?+0G@NM$5HKI[K0DZ"
MRCAP7S4_ +=2H5C1_ P<$\348 M"#3']K27RWM ")<S1(^P0D494;0/TMI.0
M&.&2MV^/F#+>TX5<XE)^"Q!GA\C@J?!0/^4"KXIYQ ?W:+.=O2K^7KI$WW
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M'#;AX_3ANP [&8V5@JFX0;K/](=,7!';E7/19N2CGQ.0M^!\&1$S_,I1Q[V
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M66HJ7P")9)8RB\U?ZI*)\_V(,+9%()/_P=Y[AS79;7G#052LH-*D1@4!J8J
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M"ZX$3I<"[Z>/8JQB'K/P'JBT0S,;V.^0L^O5\R"UB94EQ< 2Q21@Q#P4'AU
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M9U< 1E'PV@AY)DN+%NP2WML7\HD*8+5AWA)/X3H#/UQNJ?Y,6AM0YH5<[:<
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M=(6D<)$[]F%?E5_WD6P^$CYH#.R9F@[<?!MSYXM5X]07DHAM(^\(1*2(X&+
M^>Z#E_7#'?ZX-PT^![70RM(,DA$.'!IQVMS6]ZGVT5N"/0_\(!.42K?OSS8>
MR]PH:)GH3CFK+[U$<2+%EMDCTBO :.BVC/[PKKVM6=J L9S*QG85+,U/)AC7
MVW0XTS2DG2;@MC"=]TY'=NT;I::$\'1Y"*T>:BK<;KF7*(-ZAXR;[G]D,GG'
M_]0/5RF/UDG^\*!K)%5-<[O$JBA:D'*498S_GI4#OTV,]+$/[V< \O%.[.T6
MD@,0^EEBL9UQK:FIB%?7SWPK?9Y1/"O6KIT)S=0*9G,1J/)E_#!+[N@>M.1W
M?>B>JPO_@+R\,56_;B&??MZIJ ZH\G;^?13:,+3N6#U\91)NY-."+R0$S,IQ
M\@]ECVSJS;3DJ"_.I0)3W\ )>[Z;'XE>#H_,:T<)VOC%T8 Q<?$!09#^J:]0
MV\;;F8VVOE4".I,.$.1WLG#LR86*X4+!6XL;!T9$5Q5RE2('#.\Y5+%A>#^N
M8PO\32,SZM#&U(V7*#)6SS?7RT38_E%2<=9D7#=<&]@%*0.J663A6 \"3)2!
M.+:"6243'AWUQA1M9.BF#OV3N2_*&?O'J[-2]2/)J[4D;44[AEE'U7K1U*M+
MA50 J)6LDUG/- /?T,HA+'XSE6!6:@PO&E>O[^P-<]%C-/;H;S#<+H*%@X$(
MZ?;XEI;8JR'P?8OEZ'+-7MFE!? 0T;"OWHO)ME!UB@KP/=CNNH$T\O%M22R>
MUD$6K$Q?4)9RL& P+MJ(6.7L/'K:4^Y>C*PD[_2=WH%&.YQ$1.7/PRY.P^(6
MF^YNW%8*S*#FR%&]=&:L"V+.67T]6;_\P1AY_D<<M_'FQO@!:A!XMI'1 4H?
M[9([GN_$D."YUNK+7<C8,EV N+5/6$*#4%,![$0V=:;% @(5\!4\DO<!(D=.
MW]QS%:8"6E.*GE&V1PM:!YCPL=B@=8]=Q$>I!O%!U<\AW]HGQ9PMS4O;+GX]
M4MQOT<:M*"2BZ@@)N0D$\X@,^WF:GWNDRCK@V_2G5];XGTN_:K+\YVNX8V.!
M"A#TQPJ2:3\'<A!]?B0"N1XYOP6E*;<>>:A7><CTNX6L6*7]F3;,!?"=R+?B
MEC[><PK>US@ZH)68:0;:%R%0F'UJQ=P@:H<?-;V#.IUNL'D#;J8M'1C6_@,5
MLWRFVWO'1D!1R0LAF8=$!X&1R6)2906S2[>=W-07A'7FR^ND\[-Q,],G'4PN
M?KGUM/U8:.^U<JC"G" PS>6?8'WO'R69>R/ZPJLE>8%%DF?=:O>;ID\0@C[L
M^CC/4P'I[V U(,+FL1=O]>Z?3ZY(_%$P4J ZE9H,57^]-EU&$KUE7_L]+G6'
M=?LXC[_DW &PV+>G :O3=LCT_D=.Y>Y)*D#LV7L-.(%IBBR+0 B5<+X_=7-<
M9>)C^MPU!X'L>BI@!GAF=-4D+P1!CYZ87$D2!KU*%F@/4(@=J&M@P@?B7.([
MQ>V"],.\3/-?6E$!1\P,!TVJ0ST;_*XGOTMS@F2]$;]LV+$HTKLW/3;>G)SW
MPS:)\RY\=^.R#2AH\0LES^)=1=XA+P+?SL":*_RN89_D+5D!0CNIU7U;K77N
M23V8_7C%>FVMB2S2OPL"^GBWIL#**U,TDRSA$M]/"RCU?V[91IQ (6W3_#J^
M!T@>HG3# H8@+9=)C(:Q".D%J"RV$3F3)K"Z]&C I>B;VOUO76^[5G:B2@+*
M5=J>VHL,1Z/VQG_+2ESXLOB.+2=E!=:_:D<9I +8@9A;T=F#8C0(&<X6*Z)Z
M8D.T)30A-^ E'L&1E;XD6"!EV&7P27B81V.S=^3Y>Q,?X?,M R:J,)U%VK=Z
MZO7S1B*F$ >Q7(VG'MSYWB*,&2B:4#HH-ZP9/:AK6%MKZBQ_4K%@-FK1T*O=
MD/Q&'0I-W-X(D":>)^04UZL6$2 271Y,Z!@6NL0Y_B7^G9< >M[*%1M2&>*B
MCBUD^IR_T8R@25!%%JJ[8*\]\N.HC[=.1(=69<S "*B.VRJV8$]Y$?%(-6!5
M0X0/&Z[15:/Q\S[R!V_^"6#D_V3ZM4KQ?T'%_Z>K%"<D7*\,KB_5IE6U''46
M^7QT5L\Z->#8<R@#87\&&98\X"#/EB,VO*,V>&)JQ*B]?VCA[:E-:2>ZPA7#
M=ZJD4H_3S69G-B:R[8#1/KW-P#'H]"PH\BGJ"NX,.N5J7=.\4F$[X\QQ]XM]
M#%_Z_V .@.'9N:UHBPL$NWQ38Y^@A_$#& R?E..[ <U$AJ,+>G/)FTX=C=+0
MGCZ(]<BZ-(?7F&>6DTO?B;FJ"YLTSR@J1#\$ 2&,"2FJY<.>!V=&#-W"+>/>
M%-@H,3+QX8I/M6)U0@R;&ID'=N]^N>5D=:19P 8-YL$E1(S_Z55,_T.HW@I?
MESA'N%SX[(46ZIR(,[\UQ_$[>(1=B<2<VBLW3&PP5'!@ S:'P70U0W)JN.?H
M5\Q&W]?TIQKJ]:J+Y>?/V0^]^Z:Y Y):SN;8S#']J#L$O&]"FJ%$_7]K-/BM
M,?:--9S)V,PEHV<V-8K6\<A+>^T!LGN(\XA<*N I[/2'^CL%:ZMCVT]EUEE?
M ;B?MW#?6)6;IV_SGKFR$!YHWLN@5,!I[&PG7CCMB_]9JR$#_O(_K>KH+_J[
M"9@*PQKT'IP@R1Z:P]8K]Z=;D >"% XJX+,-@A)A0K,SOV_2;_.<_2?HQ3\S
M_8?<G<2.BG,8,63WB/_<Q'5__LR;0DF?PU,[M&@4VL=[EA!;(A#W<6I"QP\G
MU613Z=/>CXJ_<9LW]@]#)=8FR&^$R5F=X,/HRABDMU)#6ZN:_8B(W1M6!H9$
MW@JZJ7[C*1Y4$>G1QS%'M'_%.\.X\*>VC[,+]ACB3*3^]-IR_Q&D:VZ@:F-S
MINBZ?LB=G]E^/QUN#$'5#=O1P<X\_G5ZE/-MM%)VX?M[HZD5=P^#.E>:\ @!
MQ" R#,RT"P]/9Z_IEPZ+'._>X0]O:;E$+,D;XB3P8?*^(IDAUX:B#-_]R%\I
M.JU:8*+VX[S9+E19#:_HQPQF??_$YC>7'.E-Y%=R5NC.-Q_THQ948F&'#DZ<
MTD#9Z5G.SD&<(S[,C!C!;KW><V4S%^4TCT+9^:C%RXXEGER)9P"[5 RXO[C[
M[2^57ZZ41&=/.*$K<U/LTVV&AP)E!R]=T+%,WSN4P()GZ\%G2*S.>3$NV4>,
MQT*X^ ,&=Y?R@#U?P+0YCO>,G)VL\,NMX6;G7.-IL12_LBMWZ0GQQ9[TYAY>
MSN58G\5(7BL50(_;Y.^9BXEOL9RNX9GV_DO%E7J(T)_]X7X1"]U!Q[]34Q[Q
M"O1["<\5='W]?WXW_IF)[F\S?)'*(%>) X7I5Z M"4JB&#2H[_=L[#$MDZ^.
MM>8+"7+1+I8^FJ_BZWZ6!)N#GZ ";+DD7E-$8\V"P#5#UO=XF01,O6ZKG+&[
MA*K^!_R.+T.[Z]C4X!Q;I57^A),WIY7)>,41V2>&9T[;R0DT0", ;5APB&Y3
M(^O [KTEI^S25Y;,\L$2,?.,B95_OI;_PTC?65VK8GA]H:*Q*F)[Y%'5/;O;
MRRU]00;V60$7!QTF>=DQO:-4P-?#77<>,8$^P:?W9):^1S%/B'#C1H^C0;5.
M+X= EGG$!T<Z6@OPGE2 B8NEPL)2U>#KN9B]O336)1V)%CWOY\0*Y<#8<[9Z
M[*).,O5[I-Y411"1=9DS %N#'!:H"YLAOV\OXN/KCSVCY/WQD+%R?>HTP6H6
M$8I?XXW,57_V[;K L_K4O8/82_Z,(@6953G!6>I&:M\Q;;;O)YXN(/0KQ_-F
M:"& 5[K1GZW,7_07^F5E_R^H>(OH5]9!-(><LGU2F*-A*PL(R'':0FQLW*($
MRB#WR;#V1BLR OFTC@I ^[?5'B]WP'2[,@DDV5S-4I$.,N,X+>O\-9R=YT:4
MX2L:5,FJA!U>DX=13H*I@-B'#,M(//X#%7"'2X=(0<ZI__4#. V(7=X 4R*T
MX51 H"$5,#<$^\7^3\,>O17AF7):;C-GR!F2;^4 ?/9-&]#UM;?RN<5Q<H[B
M:1R3J9;(O2$;HNG=@=B*NT_-,ZRWM2!T.%/*R90"B"C!#2/!KC4WSJ.FQ/EC
MBW-$Z6J6PPLJX(35M0[4\49;PE5L)44:HMU'XCI+\GN0G%46V77YIJB_7K70
MB5X=&HRK@XVC[<A'G4%;AU1 -/"O'Z">_ZJQCZ@ QIAAFC'(7J$""%=A%*7;
MP$PJX)> 7P+^&PIXCCP'LM<Y!I$>$BO:2U.M7PN+ZL(;D?HKN-WOS*!:P?]J
M9@]OPS>XL *N8RB,=2/CE^&/J*N:LBX4U-G25_<2O+LKRCW'44K+]/C>%HI\
M'TDS<VRURB\*:%T7I<F><B7+63DC742%Z/^ "LB(SB-3 6 <XIOK2R16>U)E
M#MF\P=?^CB)3WH\9NH7I,1?+M4:W^;H)+^7E^+&3Y!5HK\],R*,"9A)I?=D#
M0".I %<'^.[Y"BH N4:1@OW5@_1!_]_T7/V7B%\B_CN+,+-KUR$(-&9A8;.P
M,)(=**;(ZUZ%DT&MD^QN;G@.X%7%C;=S"#-. /D^96H0M,SG0 7 4"3[OWYP
MPE;/"#9U$#9PFII8\\8LQFBQ[?N8;5,/R=RVR>A727*'*!3L7_MZND,)<D,N
MK$]MD$(%( C]?_V 6OK;COU-L/!+P"\!_Q,$S"9M,& ?Z[P$L4C4LWL4M!1W
M.QV]F=)9_%UXZHD@EZ;,C5B3_:U &%:+K#ZGWCS-1!B8[I QT3.I%[ I3[CO
M8")Z4_ST237H5D8&TQ 5L+%QDP:HX#\!5>Q?_8Z4!\WVHY%DEC00%7 4005T
MY%,!H>J.5,#N8T\J@'0!207P9C#UPW[Q_^+_[\@O3)&C IKDO)@"0:>]>CG-
M?*:Z#2,UH^X]FQM "R2('J?_H"U_:!@,[:$"Z.?)&8U"Q@3)<;W0N^\P4TZO
M?,5*TPR[S4?1''YD>_I]P7\1JF;]R\"U)Y;@^8+60%5!'=H+1:@ W.K?-)U^
M%_Q+Q"\1OT3\_R((-#]9W7R+P(-3,<*:';XV::U]'I72.;.MOU^R56M<&EL,
M@*[]7N3KA@VBG"S()YD1[&:G+S;-U?%(BCT=,BM.3=:\UV\=5_'YK5V>V:GU
M?X[>_A+Q2\0_KX@=!)J><G(!AF6>?5$PIPGG'%N[853A^ PS@&8+6&??^F!Z
ML3<' "V!_9NSD>!+E(4<2\*'$]ZFGZL:_MB7XZ3ATHBBN5'H;>6?US#X+386
M_=<*('[Q_^+_,_D9*-(D"=<@$'/]G9FQ+:OAG %^(_2VK&).DA#790W9M56G
M5:9@*@#[($T3X]U"@XDE0-[1%=SJ2+AG%2*[(D1LNMGH_LV]KS24R/3/VL=?
M_+_X_TQ^09 ]G" X206L[V,;=]J]E6^6CV"JOH30V[&][ROWC:U6^%X<93=0
MGX6W(Z?;DK.AE\Q\+%!&0;?CN63JB7HCN<]O7W)&<P3X+;X$N2"K*WH/3Z!A
MTWM4 "?HKQ](RW_;K"P*#\\G*J!?8Y VA^_3_NKW$J1*!?R2\4O&+QG_&QF(
M2,IUDASH1.-5GZ1F9O..0LU,LY07=3' :[:76<M8$F(;5OT>,FR!_NWTA _*
M=%1 H/DJ5!&K'8J1;;QD9-Q1:-SQHFHC6^%]2[YS7?ULJEW),==?Z2:_V/^G
ML0\OP"J2UID"B'(0:1C[I$]SKWFXRVP%D5_>Z?;8F[D7<WR>NVT :.7O+,@0
MTH@2E!\)E$&+F\.*2@[%XX2 ]6>-:!>!BEMT[=BZ%R%F7CT>8*W_REKZQ?Z+
M_1]E=_U[V7LI!;.S.83"G;OB\4I5&?CCS]^?,=#E)?FYI1I.O(!C-9Q--D<X
M.EJCE>[F(ZJ)K(3.'A"*)G+KOY8^?K'_8O_/9(^!5ZJO.WD3Q5=X@<@ZG!(B
M+ 3A<;6LX^RKZANL6F/\=79*"GJ@,L1Z@!?QD0DAPE_G IK@3>0URK1);IWP
MK1M*C9*?N[B?P30&_&=%K[_X_PY^!BJ@R0A1C/!B"A68PEQKCDP]T.8">@\@
M;S?^BQ(\J"4425[%R )^81?7Z\SZ,ZT#&N'CJN',T%)K\7[@9/*W$1&K2V8,
M0J\\8L;:  [_!#GV_Y6);AY<B2*E2+3"B4=Z29^V>_',5$!"/A9(]DJB E23
MR3KDHN*%6G(RA4_UZ&,MD>7!X!AIT>]N?71=B&XJ8-2[I;82OJ$Z8UPBE?;;
M%.L[\P$MARO"E/6]J\^%Z/&.?_3P/?(*<B87N.U9#<8?+Z,"T(F':^!X&EA]
M['Q:=PCD0"PHENI>RX>5KG=\.%;>64->X@!$ (AVE),;5(! U@P5D#U]*/UI
M^?!@G'*2"G!0BEU'S)YP>?(.;</L$F/_[3IYSNNH;6/X'ZP(H(E'T92B1Z!I
MY F-^MXU5-6;XGNKD[?P)H2X,^>Z%'MS9(TPOZUWN&,!\WT,BWDDYFF*-K(9
MMM>\1=,B)_DMH@,QRM!R6!R[H3MK7.+YB6AO<+J^2[HH+&M?O8"/E7CZCY^%
MCJ'IY1'B0'X#1FG"@P_I#9>]UZ_1U #';E'J:899K0$*HTTZE5T> R(^#Y5;
M.;!5\E&&[8G&L:*8O'F7F:?(.S#+<>,B*L &'-HWH7*UOMNZ*>O#*4G*WF%0
M9P:3UQ\MJ+'4.[Y$T0)UP/?6X8><J*]@K!;R0'Z2G=)4/7THC+R-=#UMO 6S
M<>51<3Y:?5.Z;".&1;QCR>+EF62"!.7DCXS5=\!*Y6CID:0 IQ.#B%?Q_L;G
M[]S 2MYFH3M<^*/GK\%1X.HE4IIW%!4P444%]'L1%< QH.J\T#VG:32\_::I
M@^'^]3+3C7@N8QZ=3>*YZ_;TNTGX&[3/;$IPI7UF&L+J0S?DUCOA9:N3!_&6
M!*\S.(VC73GY]@N_%>7Y/[\S;UCVNZ<3_[9%4K2/H0J:'X+H4P'F8C3KZ(@:
M&-Z!D5B$>S!$O"'N@<S(CMGW 5.,+)]XQ_ZG/KID ,&#<C*%"A $,9$#Q9%O
M$"AY4C+-"S^S-TF'$Q^T2$]]"'!@PFOU[8B+I4OW,'!<.D6V^<,5+YA:M\:3
M*-I9& DRI(,*R#1 &L!L@ <R-",.QY\(/> D59&K%14^34&'0.=RJP>\3H=9
M+,ATG<V.*28F+O\V@UJU6T<<K9HN1[0LYX;/)GJ^5U&_DF@CJWC.EX5NM>(/
M%J^"5%,!QX1HWT%_!+E^V88*R J&A-+\2BWM3V%#L/73$I00D74)@M!&6L]'
MHMC:=?3X#Z\;R+(KLGP.%S&6Z0"!1@V:BJSLD]^E$7]SE)Q<J:Z*@UG=.YK$
MULNYY#,G"LA@&K[_1^NJDD#D"M#\4J,0;%0+N?O8</,85) RQLL]O(ETB TO
M:\IV9&X]3&")%]'@,/+5Z+S\W)Y^KQKO0P7$L\^ B/0_S[*56H1:!!"5V_B!
M]*33W/G]]VJ5/EM["7\]L IDNK_+^0>+P2,(UY9(*6>F\1PT,]GW(\ )+ 1K
M>B#J4LDTEF[D+)9;ET)\VGGP B<5';V4"M "0-IH.LRCM6<2@R#2Q9*Y*P\_
M@&FV#*NIQ?YH$"KMDZOY0WZ[1Z8?P.3F@@N$S'X599 ^?/7'K=(K7E':6RJ+
M8:-MMRB)R>2U?N0\DQ458,9':Z<JE-GG4POG(,1@Q,R^-DX%P_'^>MG;0.41
M;8_J'.CZ\DQ)PM,33=O,093EC--O_^C(H5G\8TY40!QH%D5^O0G:57U,&PBT
MP= IB-$A!YC EJN*801A?))_ 4%]=G7,V&Q*TM'[6'"%V.5'\WL*=]I^_OM#
M!V^T;2+NHL7HI'%2;84(_CVGTG2=2\K+'X  \C]!_;W_UJ2A^0\4O'M;\0^]
M[,CC_C_^LJMBOWKUW[I7O^@_E\R8VA%1:/:OTT<G?$+-W$D'+ZK<XA8GOOE=
MH0)T1PT#P(FP:L$V)W@8DDNB(C_';@"B#&UQ/I7Z2;/C_>@>_RN"@;O+JL@+
ML\?E"<L/";%$>X@N(:'PGIAT#4G.4N19J%:_!T?3\IF@)5N2^N>2WT"1<'9%
M/BGO,I^\MD/?R>VN  ^WS_ 'FHF@1&@0M!-6KAV-S?I:^Z*RP $[Z8-\'.PB
M6/N!7KKL\[<V7NCF<4EU?A32R80W#2,F[W3V<?OTH[(/][M<O<[%7>3-"!0Q
M5D]0K4E.4D9889C&LO $Y+!T-^@,1,.>VUPV8MPB_*B_&9;-AOL)''-Q'U''
M&B1T:9[W#NO!(Z(-I9<->83DX>26Z0H^ZW0YNS(\7 !]&VK_:G=39*-W- ]3
M,<W2>')E\=!5P:!_G*B\\'[AO=#!1;+A@;YJ89R[Z4>IE2[QJ/UO0ID9&7]O
MA%YHTE-J,TL6V-(=<N&K**T(STWV960]=R9>RQS1"QOOP,<GM!Z60R2QE2U:
M5D<C:HM&6A/<9*"F7AT/&6^N/A?FG^J?3&*I]N?K@=Z$CD-!.,.82H7>$X28
M_99&[JCW1<7.PW2>X -[XMNT'ZC1ITAU*.,J*GF_&7EJ53ZX97+:W*&O6VK;
MRJ/FH88LHD,"Z,.G1_!&Z'Q<NU'$^?:ZNNCGH 3>O0D6*J"";A'YI)&>"NBZ
MB 63 XMID3*=J>I5K4/$4+M6;60_)=17E46/[>^U [[L&QQ$=7M8^72(55U]
M+%'=I'ZBBM/,M3+'<O@]%7"*<0G+>H":BT7O8'I;G6GA B:G?N#CAU*VM(^+
MQ[BQ&8B>CE4/ Y"SZT4+GW)\"$[8[+[%6;%WS2.*V(C"DZ2NQ48<.1%D!S]+
M$B3X9SN*6!Z;#O?BLM]TJ;SV1C'(+^3$:_(P((;!8D\*I1B0-5K0J.'.M_,.
M% FFC4QABRX,_*)#AZRQ:XG+"^:5</?<QD1R&A4PDV&2N8KW8VA%"&_VS(X(
M[2V_4><7]>%UC^& H0'GIZ7W8SYEC:Z]DQQSE'D.'ON>8QV(N7'ENM*=HT^1
MHB!GT*M#<!,LO"\W"#BVJ_24WNM8KKO8*+>\!%&I(\<0)!KOI*8C*.FL].BP
M]$R7VP5-YJ*XVA!#W3=?MT\HM2G7,^&!N,2E**1=&J/F@8E3Y,FKGW> \=T<
M!^[0UTS-#=LECQ82PZ-J$ILCA/*%_MU8-940A*-7(5C-FFZ=(P3NB5:LZ4T8
MQW[?&&/Q?NH#,$R!>)*+%<]CY>Q*ZVKED>'ZMP2BK3TN\3^W=HF+12BW(Q4H
M5R"/"<%$(Y]M]%"3]&YP[*BGDB+SV=K]9]ZRJQN'GOEU[^+$NYSX/B;@XW%Y
M;4QH)HUA0_!P1;'PCD&@K&>*Z8K5JTN,  /5)]EQ*+Y4U.HP]!I)LCJ^%[,4
MO)$#T&0L/Z--UWFF[,G.'BO1V)0_46B\=U?2N3:& LZO;(.8$2HS(.Q89U18
M_1TY31_*/>>Y1=-PILEH!G?89?-BJ/5/D$WAU\+H1+GY.+C<S+.7Z2:^F?#=
M/E/*-W2&J?US@M_5H1&1%X<7J0!FI"LP/%VN\:T#9R !='^2^"E [DZ*J_/V
M9W[X_G.1'IU6B<A!6"X5T'QG[H7*SD&WA^_"'"JHFG6?:5V7>(, :^&E'R Y
ME*R,'.:%2]^C]-.;J_$\PX \K\2];'4W14COA47KRQQ[^+Y]PBWV_EA'@G:N
MHQEZ%W2-PDF9 +% Z&#LXY5!F.(;1B>?53[A^!9SO>Q5C0Y*&8-4:SQ)<L)2
M 1TZQ]L0]H\E697-)]^V^E:5S;UU758_:AA)&8.7,X22G&;,#=O0 FFNN3YY
MFN$E%J;VS:<[AVSB;\N*Q42/-)J27U$N3?KHS%6&O(T'X5\T,)MJ,6Z]_<(5
M5[IZ@FR?2\YZ[A_A%'>M.':(9KVR?]]ZE4'T,3^ 39RL(^4(1YE#@R3'NIS:
MFH!\)"8@5*#Q/#D3.9.ANS:R;\+0\D@Z^.W+#ID&R?4/';"K3!/ #=X 0('[
M<O4U-6(:;*.+J!_+A.Z: 1YW+%,I5J O6&63?.NDSWUP?]6=>[]IQM"0!H^V
M<6KE&$2PWT)/Y:?I-?:3A9+\Z.#!GM4Z=4 -/Y,C:6VD'HA8\6.$8\0,VA>G
M=887W)R\O-Z@'LC9<<S'XNM0RTPD9EV*!B^2"K"TI<&=8P[:,KJ-/Y=I6*]Z
M<SE3 71PBWY5.Y](LRIL3U"^(RJZ;*2=X<N;A-C$.X('>C*9)=\TJJUI!DN$
M^(AFL!9CN=6N#I-T?(*+=BL#,I@.5JY16'HQ_H9+J"BDDTXD\H*TX!V,T]K1
M]Q@EA3NZ1UXMURF_(&E(]ZQQAH;1<&ETO"; *=JTE7W*O/Z9AM'E'A9_880@
M#C$$?H4LGPZ&'O=Q.2TFW,ZQ9_#09<\AZ[CO-/)'5'"O*O<I/K:YWNMOXY/X
M=;K'85'3;"1F;YX6G_*V9,\?^Z *%SMARKAM)R@Q(( H1IE,('2;5&"36D'E
M3?F3UV.Z38+ONGTGQ^LO%_E?GSD\=;C6EGZV7]$K<\*!DY+D7+BR4V 8LGB]
M956)Z<LBDH8*[6&ORR$7"&T%!+^F7'_[;U,.94\^*.;*6:3=CXLBZD9MB!N+
M74QUY6I;C1TM%.F% GP&YC ,3=.GG9(B5OR5DL6^OCDW]914I!W@!F]O.%7X
M:,&9F<.#GV:<"OY-X_0LGO]&1?SUNP^-/\0 Z NDL;$;9VGH\7A#V8B$%%-(
MN,N5:BN6VKWO4%L\ T.72CO#?HK<N@*JBC(Q?4&0X(ME?VPJ$EL.7MW.3>-^
M.1,,:U1O[(/)$Q!X,0)]'LD%1_Y>B_E0KY#97FYF&JB.-H/'2ZIC]Y4K;VAG
M)R]')#R,"#!N-8<X$AKFPJ>\<'81>VRZ(92>="]]?*OLD2)[9(5=VW0H.O H
M#MK@*OFF'67@_?[6L,!1#-)\UYS^ 78*SAJ3F(=>J7(3NALX<C6:A?$E0(0!
M VI&G"89]KE(P2^LL!V^OG#MI$C&CN6SYYUDO5@K/?+TZT1$JP_3>B7QF0D)
M/'096QUY*4@#IXLXE,+.FTX_<0> W(@;/4RN]P]+D!>APCZ"CPA,. _=?LLZ
M#Z\L<U&\=^1VN>!4=..7&?)9:"U$!&>)0[7$GB6\:N<?$GV:UD%45=M"2?MI
M<R^GR&K&)4\)X&129C:.$$U&Q+/*!I\]=<A+5WE9R+"#^#$=#:]&14.<"LU,
M?606ZJ_.[CXMU;Q04)<&J]^\,P;?1&C/H[)A31K*(A-WT8(MQ&O)LC;@C;.W
MK[5C&?E4-E+AS1^(])0??MJE6<"P1L'!N2&.A1LK,M5"G%*GGMO26JYX9K?-
MYM@&EZNUPZW.^-7>=RD8U[8OAL1']9IS=T/)=FB3U7756+.$:F".OT03:)S8
M#F4<%BM6=);#&89.!G8I9$9VTE&D+:,)NY:[TH<F(S@-NN!,M=?1N9(9)4HW
M5L#TE"E0.5OL;( HZ2ZV.-7OF9I-K-[GZH>E-C%'.[."Y589N!?A(+[Q.^X[
MAW O@G>K/"Q22H''2J,V9E^[(=PVT*='?RCFK#VJ!8[50D8,3!FM00&-[[]4
M %T'6ZKO6H6?"V!D6@*[C<1'IZ?<E*TK]K[S>U$/ZSPM<)+8.)]!Z6UDU]Q0
MU:(4>R5^'L \4UR7CX<%,WA8E(+C@)5)K5R(\&E@_>WN6_!CB;UX\Z@[9:QZ
M&S/^I7+YB1-OV1_/6:?"5=0[IJO@;;' :5 BYJ0BR.&R"$](6*,!'86'5 >$
MH*Y,GV\47X&M#/A$MH\L(V\D.WUJNKBO$(,F7R$GPVQA9R%<6!>X8K)7PWZ$
M2X:QJ[0<ANF2+<?V(,A-S>T5JL$?\J9#RID[K$SMYXW"P.8*M_D7:H[:)N4[
MS+-,&_MS-%.\>DX5$QE+>. I^?5^]:E/GI$3V2_/P&T9L(C^7H /4960,JO
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M+9&GS @)^##L^IN@!0>'J^M;8_J&]#N"K"E$54H?Y_3&U;E\Q4A?3']&0N>
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MU<_+P(W$\%4+_6N%IK;5;J G[Z6BBJQ0<!]*7P&<CQ(2,J=SIRSUPO;&QCX
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M=MAAAQUVV&&''?X? >8,_A=02P,$%     @ YX%<5,PTJA.W P( M4\" !$
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MM:"[79N6RQN'6;X:TZW>7M0>[86'6:.<!])=ESO?V'K*1Y%('#&\Q0R/S=N
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MA]RW6/5I\!VU< /(T#'K._MZB0?A'B,R)ES<&N'D,K39<L,H.THVC*PM)R#
M2B.&@SZ\>FM2EQ+YF:AG=7C3.;U!YTV+I<IQ7GY7&DR]TDK97&J5]ZP9>YWQ
M1,;CRG5JBW,D=I>! T#I(KQB% _V@6E$T<$G@W"#J?<8SE440V#)Y&7,$H=B
MEX)WR+#JLMYPJ>[<:WB^ROST)TO-[FSU*'B&2W2: F$]ML'!&^4L2$Y<0/05
M]3\-6IY!SMX9SQ*<2QY3E%^?@/@"COK9W"N+#[RVIL\Q6Y9MTL*#+0<MW:/(
M>:V:7$.#0/FH+]\=/KP%UMN@'38R+LN":\&J;DJ EV']E P[A^'%R09K0&]
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M$)2MM]AI8XQ?IN1AX,&"M\CJF?S6#(]Y*M6!1RV?Z89QJ[I-]ZVIK8P-HDC
MR/>YNH5CDL!0@%?@G^+R[7Y?;]D(,1UT7\<V&90;T^=AO;*D[B=F$4O4"H-B
MC7JGRRA%[W2JU,B>3OBB762\A&UY9W9J=I;N+2N8"ILI+Y U/@Y9*MDVX5Y[
M'H#6,&"@,WBYCI*(9F!_4/- 2!E\4N^#( 4)B-(HNRW]O5K'ON69B++OW\X?
M&D(/>L_MNJL&!MY)I.D@\Y)CH$-Y"=AHP%T<DI!.X1KW1*6%">PZZ!:1"Z\T
M@D0) "%?6"1VR((W^QHG  "+<R"7^D4*'?6\TRA&K46WYPT/W$$W"VG/U:8A
M[Z^$RB1FYD-M(IQ14L>]G1JI$2#1_&Z6K^J=Q)@>N4I=/H*'0[U>NDE!4><L
M=K>2K[*'T(KTJ*2XLP41TQK=O$)3HI[AZ0RK*[;$[2[C\1(/%CXVN?T^G*S8
M6>055+D;<7?<R-F=-GFPLX5;+I(;O!;"A]R[G3E59E;FTR+N_4[F=T.J,FE$
M^],_O#C?M)983(&W@\U!^U2VY8$=0A\ )^E"D8 ;7]6P+Q=ZA"_(Z \P;Z9%
MOE+)J[=N,2AB9_0+G=5I?19 %U D,KOAYN#M8+VFTIA9ONQ*9T9)!'EV_J*G
M$A:)$60N$  _F*MVS$$>'(A(\);./,,+7'L--G2WL,2IYV9EEFRX;?W.M+=E
MO5Y#DDPD'(SW->_TXG+C/-A0Z\")20?V>M=F]@F5QTS> -)L"RB7&'D?8#MB
M234?7E8KR :[K^_$^,;6)Z&Y[RO99/8%2X$V8<FG!XXBNC"5;V&PNE3M:Q0<
M\UE+8=P6HF8\ W(-\4P/Z^FB]/G=2PK;2-["YX,-J8*KKRH9HRA-#H5_T9-"
M0'&^E3[2S^"5W2Y\5-)C&8S!R9WM-4;;01VI9%<1C2I\EU&X<@?2=YH%T(,S
MP$#WAK;YAK:VS?-QKM!7L?;2DX*,10>$^^(U$B(C6(X ;0_AJ1Y8NP3)0AD$
M5  3U ;4@P^]]?+$^_8HU?>KW5J>F-S0F'#@O0OOZ'%2':R+V>74<T>M2(R
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M/"+2QYP"\"&R@# P $AE^1$I6@!-$)B$T<1!<+ZD'^]]873]^+X ;ZH?4A,
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M2 S%,Q.3#FVX1=L\UYE6T$FZO@5(73PRJBD=C#WEE!J]:'(@8#?,XJ9=AOE
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M6J'[/7=4FOMP,%B#$<7W;.)IG]7N=V\63^(1@FHM#QRZM\YZR45ER6M*43&
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M+6?OE3I2%&?TG)=>^(#J.J:6-+!6YYIB:J8U77+%$=CF(6G-M""^Q*;PD(O
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M&1N&CP1C>(+<OCUF\B!12LE0 9OD"3P>%*!K7&F/G6HJ1JC7-PID5ZIUZPW
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M<?O[>/-)I/*@5-:-5-#)-F'<2%.?YL9$W%;3]'KN,/1ZL@-U#;5*<VY&WC;
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M1,U]B/7I9D<AQRJ^8&V=$.27NC^GB6MMBGA"OGU-U?S<R> 7O%9$3]EJ+2E
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MCQ=IG94T'JO[O^F^2=8*.N"O>P!T0SFP0:LMN4$]87<8J3/$&"^6R'Q;X0%
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M7;8;.1F9XP\X3DC;P,38,^&B*MZ*3<V4]8>V F8[<S1L=L)Z4P\V6I^UF;/
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MOX@/X'0!S$Q8+9">K&K+*>_K. 1^".!\SE]' 8/,+_S,![?_^E[ZZ GSVYX
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M>3%#11. %MC&77,_'X@.':V7L""MO)*QS +!>F_.H89(W^P%:!0W5-/BKFD
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ME$<B(&S @HN^4D=74]*83S%T##,*G9V2S755'*V&SXL\D)%J421#8I=K^L3
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MLK=(?PW*5>?M%\"9PG.K?]W6G6$"Y8EES0M@\O#]P]>A*+'!AON,Y]7XSR^
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MK>#>/!N-]*K4IA7=( /)H.>0Z#?%02E">Z['(L3--8G*/+KGTYW*D\$OWQ>
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MM\=CB=]M!IG6:4G(ZO>P-E:2'NVTU*X\]6[@H(49\'88FDDD9 \%ZW#MODH
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M%[B>,"6]4+L,(8AGCR:XX(Y;SJ(_"2<(\^C$S(&D5$SML14ADENM5(EKA'%
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MB0!D3Q7$!^^Y?)-[(J"0C;"3(A?F=G]Y2JL0V,Y0Z27L\1GL>LRS04U()H:
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M<Y59H :*EH" 1>]^;74PKI>+[^DD"50<2MH:5^<ZBJL:G1KVWFT,NETA'JK
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MN5T]K19-YR-<*HM_N1Z>OD*ZH#; =1:=E)>*-%/W90D/N8G&*U9\PAHRIJ=
MG&\6IV%\&+.4VMG\6\6_9HBGSOM2,D+"&/SD:"WMS:0'-%7- *TB5.[OB^KO
M"8U@/!NXO9\*^[ BA7W=MT2K@Y;O^F:L+\E'Y^N@@IWPIT4977(^K49';U/V
MXJDN"?93?@^8IIY:9KK?6P?BVZ&V],*PSK22HS^T!Z%B9^Y6MCL4AVE%3!1X
M$H;Z7T#SB2J%-L9N9;+;<[G380ESK\Q7714V#_W*2^4&/'BK*1:])[^&&-$S
MY_&G%([D<O$ R5OM/XB;6PU,)E^^_7@KK]Q19[C\N[=M0^U&(<Q3V]I[>XI
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MOFQCCAD')I\Z_=$9'9H,28RF84+(/O)5?FF_S?]-#Q67"5[K#3R6MH]OH@1
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M0;1>6SSZ&R;*C3&LEN4=X"N2==X>^?G-U:\&E ^TZ9FUS6-YQ@[Y5_6-Q\K
MNKGTN02/"'N<1'D0,$%R0[>FS5)[>8I?-OQ8?$*_:]ME5<TG;40%RB=!6AUO
MU:VKGQB(542):B2Q"^?/X0)_.#"K7J/:H->T(O((7 0T@2FW*@+QRRA0TWV
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M_P- _@O,7.(KS):C_#OO8?(7,Y,[,OL S4#RI)O]OY:!9P1K7O$,SY*MS@]
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M"'S0_%&]SK>?S$FGHV_#398&MI-19BE:L;FSJ)+_EM*;05O"@00H_:,V7L)
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MY?EF->#KS> 7_>5[E&>J&,B">Q:.H.',]=%9U^)P;;D20C-KJE9VL4>EGH?
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M7KV;: OW(/[T)I\(W@X5?SIO']X/CGO<-4;)WRSFRH[80NJPLUHIB?9QESA
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MS(H3UI_=7"<.YU^$^O/B^9SJ)L-<%KR9+IBEPLO,?>\NH+JQ$YZ/IR*&+Z\
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M&W+&)RDSSC'=_U/H+4 :-5W1K"O9E^A9FZYR<%"4T$4[<"]S67771Y)V>@4
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M@]II?2M4J0V9:)E-3(CVVWN_W<1$\VPVX9$2N2>S,:L8CH*59=.LTOR3L$"
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M9&LO?3TF;IH:]BR["^\=E\E0T&RU',E5DW)D-U=SNY<)?=55VSRH8FK^[N^
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MT%,[7-!98O+$<YZ[O+ONLQD\<< "XIO.?SV_5[U\2'%X2W@T.)^6*Q+\+7$
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M2 WC6A. WK^'D7_=!<=NE#[B+^%10ND1:>!^IW AJD7@#@0)J>)!<6^\0=6
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M= #&)M7>S(R1%37K,%LK!ZXSK?&.N\FHG2DJH\??!M14D5='+&F3C N)S#/
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MJ P,BPIH"8H,V!DA88N1%3=D)B++<>MN4B:C=-X4S4E.C)/I1'66M>G2[LZ
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MU8VD"/9OMA4E2S^RMTBV;M\^\\*-:F/#*$7DF)Z^$:6.'F^HI:TM=&TC\3?
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M5K>_ZTV'OE&*>T>]\'.GHF_^V,WGC][PM8]__"3NO</+_OT9W"=/_.6K/E7
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M,C/J7&H77YPIWL4Z4F-% F8U27R<IV^F?[C=(\P<#O&_=4C/52+S(5[Y3/C
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M[6JD4!R<Z09JK-_P0>%QKYHEA[,$4R(>-7GL?+>*GEYDZ_7\#_I34MVTD\D
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MFW%S9J^T6+E"3CG,3I>0GAXJS)CZ9#[Z&K_3VG<J.S]7Y_U&Z:68\4JHG%T
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M 8R?P"^BVV,)CS%W%A-!QR3_M[7(-(/F33K(_HL/W6V\X;H;Y7U7"_[';;'
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MCNM(>F-"\FP[W_(P SL>?V$QZ:F(1X]**$O'W9BQ^/I?>I\>-O/%6S1-S1X
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M/^=,B$U_2."%EEHOWR*MB>]0M#_C59$>LP"3CY.)S8V:E1C7Z"RS\M!Q3LI
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MCY-W@5=/#6Y150>7+@E8GU,[O0-=#9=K]D7)?Z^8@!*@A\\PL8-'MY&EU#>
MHG,MQGK/X;0X-L9_!;J=6(/9(Q?O.ED^3!C' *T XQ6.@F'SFJ'6N?_J#]_@
M53UN^>O:K1^D&;"\,\E;FNL=D(40&Q!4A_=!X/%53+,N]@UPN2L\*E;S!M@E
MWTC[5[!@TB'RZ6:=4468I*9/];5X,:;@T;QSRN4-H,J*HR!6%B0Z?!.2_B 7
M5/PH]R++$_5H74I'."&=3-1S*QH+D7,@? /$1L5U;]4]ZP80OHH:,X^(>+>L
M\+X8!$(:?T?,N3S*'IX_N@ISE$Q)*:QAB%)86@SSF\T_(?N\(A:C&-1EY 82
M G>X8E_Y583].4Z:$Y__Z1S?D/=<DURQUUY_?0UYJJ>F9([,8HQ4P<WDU+@9
M!^IKV(_Y^PL?C-7MNG3N/WTA'DN$WC)."21#('Q I$<9'TSQI;B$Q?P(IM1A
M@DG'MO(#&LE3ES8#UX-Q Q@B5^Q]UF)]G@6?VJQ:K!50@\1"H"[28:R4SQR1
M0>[";I3>;\AR+^*0='CO4[,)L8O9-=FPH&98X3S%$"R#V(7!P(E"%X@?MOU9
MX4_)/C]0,W>;09LKUX9PR*4 76;/*;!UB/]_PAN'D7%7!!E;5W/I1":-DM(8
M!,R,X1A5&DB^]F=B;1PH-YVTYQJ7, @8<4V<3:TX-T,U.U0O;L/+V*GM;RC0
MM%46O@*U<2I0R66V7JHUT0#)I?B32RO+:EMPB+@CX+G<X]&*A%$_;2%IBHI?
MS!'E,3+R3*R^HR1D9B2@6%L&FQ%I^J";_=XN3LA_WJR8LI:R1AVVY%RA$B[A
M2/I@ZC,DA-:0FV:3QN_$4U.1^:<T!H.T>59FL6,UCIB+2LK)(9)@C9DF0OO6
M..F8C1-VEP:E-5B6!>.9&?U7['Y-%2Y=WI$#2FCEEDU\E0"H#Z2OU@&D^\J5
M\8MMU!VNQIC[\=RT"JMJA_'L0(H '3EMUYF<Y$J;I+8*%:,^6O\]6H7_Z?][
ML*;NG(5<&$>XE51Z_XR5=.**L;F2'5IE^5) Z::<1T:V?HY+4SF#/FX)F'#(
M+5Z/67V2)'&22!&UXE(1-YI,@"I)0=@I]G.]X'\A@&1%C2D^+6>5WEFGBIB
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MJG=;L4AQW0FO/FJT+5&"\]UPK]1E_,P]\G_EK$R>U$SQC0_ 5WCA=OCE^=K
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M.E459\O40%O6I>KPO5A-DOH[81,(-5?!Y2O_*]K'YJ%'P1G/[,?<?""X0[%
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M!/(X52$!4/=WE2OBV9K#-6<VSDMTBNYY;MA5]3=X1X6]-1KF+-6#41:1FTY
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M,V6J2MAS//OII:8VDTHAS%8I$QLR\J;J2K?]1V&[$OK* ^%C')1;6?VR2JQ
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M3M&4RP%I%&_F:*7N$80DETRM!A?S?E?]4RIE]1$L=O\N<+H 5K51P3T/']Q
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M)!!>7F9H939(A$*8J?0'CH]IN,X$C9:TB'G0*=X]+892,I!JL0&\,2GV'2/
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M$OY"L7PJX!W;1D N@CKVU84%B;S14B&VLSBH\?.B CG"@K$/HB!H)-=6!_6
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M*CG?%RJ1S@5?+T4#"_Z\))XS8R89*4631/@1REQ!574)=S@9\I4"$X;V[\!
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MVY*;)E<9S.7](Y%H,+'V4-;N@=5V].=NXD_5Q6TIE*1)Y)$:B,CT,S1+!SV
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MZ:DY(<)(#VB&GP7DQCDD*?[7T>1T^T&]AKUH)E_/35@9P?J+_SUZ!WX/YC7
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M0LHY=^7IW;ZZ<ST.5#7/!IRZNSXFEW*OZLV3$U\57 L6Z6C%VQ?/6@>)&J/
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M=BR(S59TW0FH*7V&5V>\A @S[]J84FDY_5150'769"]12N4[OBI_G2IG"/4
MN\(LE:_I":X- X)*Y?&T2:8KM^S]2UMW1S755OQTI]GI;%>"0]T8\RLTYWQ>
MLPV$9A$.:E<A3&B&:V+JAB??6"/[D #17JT10)N_T1M(@<=_H5SB%;,P_H7F
M]<HY,,:8<NF W:/._"&9YP+QTB3-ZZ@1>-_5ZTP<I<FY:@2YV<-Z?/Z:%/>Q
MWUIBUY_V(N]P=*V7JMN0N>/<L%>T/Y6*"O5-2GT-&C>Y[M)Y;0U_<%)=%18&
MV^U6IANB]A"S(YG5H_FX?P>?9/8?A!36FA/0+5LI./5Y,[*50/;=^P)%R2R%
MQ7IX@Z"1ES-O^*)15X:>J]AR)F.JR" >-T).FD=YE^-44* /U;Y.1D+5VC4T
M%#W"PIE5#[A_U\&):!6(IRJB;%Y/E@C'55O9<;/O]5.W *N<<6"%..55NRA]
M1JDP)@T#B>80BK.[DSLMZ>"V'7R>$/GEAXP),#,^L2B>8.H33]'*+%\VX75X
MTPH"ZYAE!A6N<!O<L3_IIC M"K)[ \@.2?L.K%(4<-MN96UDCX1^GV#EW7",
M2J25G;D,ZS3]& 4,E?$3@/1?S6%@_%;16BA+E1O=9.#>,5YZ6RTDN=B"BY1/
M"#J235]]K!,1^L;V209.=O#X(]H=!IPJ\[8N2X_V:A,"89#RN>@HCS2S <B)
M&#%&3[95+[SI59&-SJ:J[(T?:\(S*D($9ARU_&H-\]49@HQG@IARD8'EGHP!
M[>?", FO,TZA$A-("D.S099^5$(U;6U02BA/RGK:5$-Q^!4"7;C@QY(@&87/
M@]1DSB^%?<^BO@^_7(MKL0<)^356-\ YCOP,YT-8KYKYX-&ZQO)U[UI=Z;Z
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M)]IUFER;?$GLW_8U[Z[4.F D_R@+$S?H7V!+TB;.?Q V"8*"5=]#J-UOYM;
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MFWSZ4G#;X6!E][7-UKIGW-7H?*)\4E/U.&O#FR&F3ON-P0<N/6MWT[ZS"]5
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MDCO-JVIQ"1-@3!U)-KH3*:L)-6\C)7J'+"M@@PPD)2G3A=VNS2B+9_[/%$U
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M@H-'!LE>#(U%%%2D7!B;(\".#BO80)=S(/)X'?*C!=%L4#^Z):O!FQ+3;O:
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M,OB,B&=YMO]>E_$/ZG\!4$L#!!0    ( .>!7%0/Q**KMP<! %!B 0 1
M:6UG-C$V-S@W-C)?-RYJ<&?LO =85,NV+CJ1)(@@ I*# I)!<J8-"Q 06D1
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M"CR0Y+_FI.K"B:IIH, #]Q:Q<3!"[,K\4V/_O^DEI#(7V[^GZ"/TD1#L.I?
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MA''%Y4W?4_"LUEG,'[#AH$+EAF!I'!#0CR";FG.H3-5C<9+\U8 -DE@R;RY
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M6HKU<"-+5$^HGJMZH/L!3'?D>P '1-?/"GE9:GK%9B>>Q3Y8[^"-J;-R+U>
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M* 4<I%4*$?T?I7\-NRMSF!F<\7>41\N_B.)5ENA6.G\9_V4W*J%PUNZ&5\*
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MOY(BVS_+[IT9'S0\HVN:LG!GS-%#:PM$ _$^DAY=V2_AM:_X0-XMF/Y.Y,P
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M*'Y\3?FI->&*_GE2LISG%IOUM8>LDLQ'M?@0A'Y:0G1CNG$;GN7'D5S8";A
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MU)$JM<CJ&*<R<RG?&P6752\I$HWW(<7I37-<BN>>X+FKBMS%6+UO<+S?I$\
M4*]Y1ZC W4K)19QN?523H;CH^T]J/% E"YR1#U$C</]:^1F_5X( AT<8_M35
MLP"\4*W"18]E3*M^/_L@M,<%J(=]$&N$&IM[!N50&Q!L'DL,WEU45DG;I\Z'
M!53X?S3M=<B#4.-LH0+: 6=\^&NK/X:D2^NR8.A7V^0O,]?F*H=8XO.R8L:L
M$1/VHH+^?">UZIW+!?[?\6?VP8?N1NP*\.TQ)6[R9!K4T=R;:,QT./S2?,OB
MN@)4MD4!:Y+9E9=-IV2YK_GBL?V[U]V&I#:D9!29SY38[1823MI"V#H-6;=7
M03T"9'Z4:[.T&.<&/#-J2$O9+E:MQ<J8)-AJK#%II,L-(*<0)(^SOI!,YM_H
M]0![090BJ7\=2?:VKR2NB_3<!=,+V&21%<4U?KC['K+K8'?"J]FY-/16(*;*
M>FL>Q_>D7X H3PZVORU[+^AR+:N(YH0S43+I1?#,"8U,2Z.8X_ 3CK0'EB8)
M&R43T+4ZX0E9=^]I\JE[I)%Y],_O%,>*ON^9S4%D[DD8-\8<T/BB@DYH&3)G
M^SX\<2BY7</7//_F G;B7.!.F&\%:0#G4.U<B.SHAD,G!8VB638@YKB#A'7F
MFP:=0[N[EC@/ZGU"Z-#HU(% #$.?FLJN>$V!N:C2?N77NJP5S<6Y#;LGMI>(
MG,ZQ1#RB.^^*>%&*6T<-W];%)30@(\VVV4@ND%0/&+^33H*/%Z%W\Q%^#/<%
MIV_VJ_3 C8O[2T%#QM72'?>N-KV:@OD+B]M_$EE+<,QCE2_3R?3<O:_^/D)!
MJWQ)2+-8QU#)TB'A@8]LJ$RKF([RY59T3DZ>5A-D6W@-O$< @/'!%C\*RBJ;
M^"CSU_]\K\9_89F1?<C[&"_RHNJ^AV\JA)*9!CP6 B>,X/%?/ K/P*T%"Q%1
M"W29?S-'@4OH.T1G?/,3M"LGBHV-!5<$SQ8/8M;B-KVFF&R[X+5:BTB-+3Q0
MKUE*[H4H*'+BT_ \Q5A,(K>+W<BK9OF[5U-%&IB<A<?</[40]=589OLWNENN
M6.IUV^0ICHZKIE4_/Y@9#(W+T]9>->3V&2UES#.C:0MJORM>T(,CBJYCB; -
M>Q$VTTB"H"<]:$)^6BT"*4(M8CH6G[;(LC"R";-82Y#I/S_"D!B>25P"@/&H
M6GDZ?"%*RW@6YG\'?P]+F9O5Z7@]6%>:=]J >ZHPFD.8SO2^7O\[2WT/4/_&
M">?7M2.AH+L#4'Z<04OLFQ]=K1G11GJ@'J.=3_9:'$JLE4+CM08?<CKS,ERK
MR;7ZAR/7= 5#SHSVHE[^:D49'C;;18PSPX1W?SGS?&)@HBS3R':>(=X)XK+R
M?#]VV#INYSK%JN2]?GX$U8EA/_\QYX/C)^Y93:?5 R17H.5O',>4G5F9)%J)
MXZ>P+$TF6^"/D(9DJIY\+97^UD#5F?=WFY6Y9471+$XJ D"=R 55WW&M4LS+
M8_*"!4Y!\<>!:Y*,N" IK&#I&2/PWXWC'^))*=FXFJ;5Y0PUY!MFJ:5H&W[!
MO$ ^A@H/CE!NFSA3= O_2$RT7E?/F->9,7EF@MT^,RI[\R!&6BWX?]#9_88
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M_SAF&K@P4)+N7-35^OTV660E\TD+7:(1J?T42I>XU^N^"WWIN85[YC?'8JS
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M+C9-<XH:B1VF??3V'$8WF35^6!U[*>7B9/5&,6/A3FB865F(3MC1**W-]R6
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M0(YYL8!5(!90-8P%$&YB :J*&%4LX,+&TX44;+[<G(0P6*%7RY@Y%)7^HY3
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M<J6YNU730\7-_%\2M_E_&"+P/ZN%_[,[HW]'(Z>@@2AE+. 69[-XSF7Y"1;
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MJ&=2!/0^3167#6=+U-H7Q<VP-;H!T3+/F3W13MR\V_;OL YQQ8 <N&)5A05
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MU QZ_1J%:^C?PL4ZVDTUH[R>P7TBS,V)9+-5PU649Y1=>%6*"N/1OW$(O<<
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M)LHUS\5=+K(1T.2IG7E<FRA+9:C/X;01EW?1TW+(DI?1,4CTOF/6GDJ&V,M
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M>#1 L5$A"2S!P_<^YAO%F@,TI53QV(5P;=-R6..D2+=;;]2T>62#C'3D UL
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M8I'F=3,GI:/1PZ>5G2Y8U$B!N?CD*$%?-D5U$8)Z"3&>',TL I]%126(-V#
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M>79Z,I]OWS8W3;@+EFMS;"EF0MOU=(<?@PI#V_)*UF2)[YZ_QAG1^S*'+EK
M/?&"0"?L&DPJD@L1'5R>CS[S["Q$I-<YA<:_U=2F<(IQ#TE;VY4 6CK.<ZK?
M+]?\D1:*X#,PQ+J8BF1[_292X3327+)>$BN;."5J!<,$"C[MD,(>]LS0I7Z
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M H7?/QAT]ISJN[70HP?B 5Y^3\Q+3S8/%\5)9\(T"2UV/+6G[4SPM*[82+M
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MU(ABL5R 6&J/P%35.%6F.#>K!;R?)K/9D_&W^^'V)7^CQTX?SP'EZ6<]W^O
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M2Z$32Y6G3P\W?XYV0EX1Z'HGT).AU?""C@L+V*:_42!X1([ZCH$!+8<B^EC
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MXVE2\Z7=>;IDH3NJ[=9"U4(X.!RZ+9.T4H?_UK_O#+<8,/7[ X+T7$Q^@9W
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MG5Q9OWKW,<4>D(4T(J61A= ]KCBM68DW;\/6F);B)_(L^A?%99659.;5J\/
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M=>IFO'NG@.DVY<EQ@4Z/$]/Q])ZO=".!LA:RH2F]?^A8# GG*R>:M:;VS?.
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M4BYP6TI+PD;WIR8_,MA=LWY/M-(/OH,"[.^ZKZR;_%8"H;EJ2*EC]C\"^".
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M]%%.\+I[G92HA)5$"D+[Y(Z[&4;,9G1,(-9NS$VA3&JF:T'>U2&UN?HM'M>
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M^\J2CP+,MA[*!J]:UKI26! .(4Y +T;<%/4A3OJOHN5<LXZ[+-.:$6\,O=\
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MD,&3)NW/WQ*BM'<X#PKJV]1PK4UGP7>UZN1&Z>CFM[HQW::S+YDP?V1E*>W
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M_\#^@?T#^P?V#^P?V/\NL-?Y_K.?&=D@2'Y>P)QS^GA>3H$:&AW!-UPQU17
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MDCN)6T40^2SWU(&V-F(\V/!&G281<J6!+KFI[*AH0<GEH=Z&<>]JAD.].$[
MBL&.3AI1K5ZFC/ 7LO<]^:.?2O$O2; .&]H$PM=5[/JPIM?JZ"SP<5D%L\8E
MPM/?X@O'3L@ =ML$7!0WL\>/]ZF+LEVUM!!+!HI ]/B9]1XI>0N);69S\QN9
MC[:L#)^DYR/[;B1WGY*)S_2\<HH>E-"WI*\!'AU??_:MJX*._0V.%-6G6I@@
MS-U[5*78K?KS/355#VK=6$B9G])  1N-KXQ!J>]LG%@)J?;-MBWKH+,S59Z8
ME(FU,LW@"3:L5Z8[SH-">9+.#8KO;5H.-K>?Y<OG9N*GO&;M <O9\@0P#1Q
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MDCB<I520'5)1'\UL#"J# TX[".DC[MS'_4#+E#3(Q_^GO>^,:JKMVHR*H/*
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M)#]:OJ$FRL(D:K'GO#8G3$1V=IV=DNE76\0'3DWA <8"+A.9%^$A]W&-Y'C
MYE ?/;R=JA%^=#OT3(=YM$S5+,;6\85^:TO$#<9G>1YA-==2YX_6UQ@5<^.^
MZ][O"C +^Q$"KZQ8%?<E^[; O#U<5^W8S";3BDFO71CEEQ'TYMI=CH/V7 X'
M$]YJFP[C5*R0JVA?J'%$/AK@!X+F\( @UCI4_ BU20B9A93O&&\'8+]53@(W
MW+LZ,?QM>+EJEQNSM1C-4Q8V^:/<M[[>1*%A(9C!>G2X^HW%>Y![)L25IF6S
M;.F!9[ZV2?>73$:UZQY(5,>FM22[O<X)G!@>/HY=4ZXL=CG)J['%65(9Y:9B
M,"<132]W@?MLAG>$F88>1D8P/IJ76/GNY6BDI<TXQ W#6J#*JI <[GC 2&-$
MM )H&C"+X\<81>;$<I3@ >+4#?YYV0K['(7#UHB@QK//$X4M'(_.(^-L;*M;
M5X0Z6!DD!RI#Z+<\273F@</I?FQS$"-!NM<!9@V%O)_FH>#/R!$]QO@741$"
M[)U>DG3L6D/;0Y/1->6$VR#($^W+(Q45G+=-9F&^I0Y)[\%$AU?O<JF]40^T
M!G,^'"JYDQG,7:W&]5YPGD3#:OI4OK0ZI!J-4.ET66#WNCM8WL8+X8J=PP35
MB#9/TXB$++Z@Y+0U\S&A-;TC3)0EX5>QNNAFKO?$18',AX.M04/DGI>U8E57
MPKE?>6UY_+)%/>2IPZ;]EGN.KENK:JQ\;9"R]]]=E&PRCE"6X8W,[HUJT;D@
MU?O&,U"&M_%M4J4FROD5D$67^LL)6K.S2 S3.L=)P0)X.!W]9376PR;6YF\!
M;:1T3HH8J?Q2B,DXU*,@X;:_RM V\(G%I :QOPPPV!)P..O]^O1")G^*'=A;
ME*64-2]#;B@*>]/^)K*!OK0F6A72DZ8(.\ #?)9!,-5Q!^9!SXD)/*!^3[1N
M4['NVMBS@8.J?+FK(?9^U![SHL7LUFKBFV0Z/.!2KM=FH2)P3ZM.06/%Q>S^
M=096I&,O5!I'WD<&_PG_CTVL':#6$AL;R^IRSZ"*=*2EL#N+0_>,ACO?ZF#B
M(\<2V\+#GXDR^HX*FI6*F8=#Z^^]\(#G?9=!1W7G_,[Z5U-"H!/\GKZN&]>(
MZJ96(),%^FA>/I/@>DL"78?PHGT?=8\[K&6J9R;Z*#? <L^43&Y9&/9%Y%G?
M2W'V8715[CC&"SFH5?/I[ND295,.[N5\JJ[+ F4:ZABC*3\?$87,.1JVS52-
MR]V]WMO8U#KZ$_(JX$XTD,9K;#*+,PT#BE49'AP3SU]I3 *2!@B@T:[/@[[
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MF\!GWZ[_N?ZW7G?QX_\%4$L#!!0    ( .>!7%15O[:%@AP! %]= 0 1
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M<\]? UV^0T./[IW!(R93GJV++(9Y4Q792RJY1N,6I8H4.E>P G#C^R?1ANC
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M@.C FUT.T ^5:?9.[7-9CVS8IR#$><$G#6VD]KLHQ-6US:C_576"I>50&-3
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MM>9)&M1?98_)/0*^+,L=)]D;JQ=6%I.TP82C "IU37>1/53"3G WF!=/'%<
M"4MBQ8[WN%%?R=R+AIK9[3I93CX[[%JUH2;K3E; %F--KO5+MTOSCM3.;<%
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MN((^_*I*<(3^>)LXPF9BK44-:%)A0CC_EBP672N<^\W<OJ;.1*/+F1H-]NG
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M95L_S;LE$=T'HUM\]8DN4C!,P: N@H<+\O"]><-_86?_#N0'QXL/*5.P\_T
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M,H-GNO6PSX\ <$1I...5MI1W!9=FKUA1G77QW*Z!N5=[!EFR8[9Q5>IW- K
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M+?K-)=OI"W[M/]S6+12-DBRX3)Z%Z)Q\55*4+*\^O@Q]I4[07[JJ+IJL,WY
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MR<)LM<DGY@0G)T69)1,'D7T\=56P[W"VNL.FB.HO _9=);(G<O!C@ 5%)8\
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MG%JS,J&ML\IF7JZ&A(^(NBLOR9'HO0\ET7Q^^W]XT#N-RI$>?!@-]75!X&
M3VZG7+]?P0!&M6"%^LGH7\ C!D/PE#KPFI3;<Q$R_WC;XB.:)#:]>-+%6:#%
MN+WU=NL[DS%0($D/[5 .[(9U7_)31>VIVZ^5>G!:? 5)3W7M_.73$2Y(4/?[
M"Y=UOR.'&?<@Z(IVHFZ-F%OR?2_8_=7@,ZVG]"+=*S$M:J9BKQT@][@>F_H-
M*$3MN*N<?2U$5;^ADSV*;P-VX@9XEI.44M9<JX,)VKZKN#>IU7T>(J$SBBYS
M3VRBCIV7(#8Y:@=ZQR.LSLU10R!#A\$ZR H(=AI+;IN:EB%^)93K++OUTJB-
M*:'H:YTFR_+;H]D?-#:GI'GS A404W'CT5/>NX8E0A:6Z/'P:$03P.TC:3 G
M/+9#M#R3K?#R/3?DU!(B?6UM&@-9@GWD\M (%_++*V&,F6H.3M=!O&^,HR!\
MKBX9+#BZ99?O0]^=ZE5>@&P?,:QSN*#]7I64_]A,R%Q*]0T%&25-IHQKQ-$,
M9U8>K;K:@J?-=<#@BF:7$=S>[WKPTB84);Y"R2.A:5$JU8QG9&PXZUN>S'U<
MOYES!P/H\3LA)8^1_[(\$(M4.L$ * RF9FJ_KGW%_=+ZJ^3&H-G+#3L)XK%M
MSC[;DI70ZH:&F@M?<+QZS43I]WWZ@T^;PO.DT !VUR+#F0>R':,R,U'N94YY
M.O2-G]ZU9[CET_8$B5+[[ H"W[G9JI5N)7M?6A<S#_2XNF6/Z$:_/>H=1B7_
M9(PX-F)7N/O]H+7NXEW96N.15,@HTX'46\:$,<.*^F0G 3CW7'?9"#LU_UJU
MPJK<2HR"Q T#-!VL^B-/*R5EC3%;UR?R]LV6=L*JY$@\^LP4UCS7U$,C#JFL
MFN:OD O!RZ33#[DIIQX8@.RT *5'\3652+/<LB3)EM[8G K-Z[6EUBIK+\9^
MCJ WTR,,IRN"ZT8I'_+&3FB!!E=JU9.-D;T_LI2^:%L /IB\\:6]M[/'^20_
MXVQ]?7Y^WG<U@5J7'=]QFBA$Y2%N Q-,3HPGK0R[%SA07=-4,LP>#\!=3N<9
M6SHI+31MH\M=FLZK'WL5WU[=ZJCZ_;E$W7!GFL=R8O<\*]093<O<G>GJQ%*Z
M3%8KEN9:SY,A UJG[$?]!$GZ[IAIRBE,/$9(YEXN7%YLZ]>E\/*>7AO+SK(>
M\GS% .X/='C;E1IA #:RN9_7/YN6)T2!4CB&TG#2T^BN @MGZ,,]!B"X4UN7
M3B.AW&4" WV1767YO22]@PGMTC2+9]?B2"?2KS^[<LIK(/>Q#*WR<+_N-/^"
MKJ'4)V/FZF>&X+%@H)3Q3HL\;<AHE(R'YJ/D%Z\-RD@V"G9F&A;"Q:(S<O.1
MRBH.O3Q[C*,6$6O9G\2SWSXKD^YE2&P[%6P?-1KKD/^J)@GI7_C^J&2U! ,H
M=?8S;T=HR[= 3PGO(\NVY^$:";;EWQ.6Y>3FHYH2N5R/V7#HOA:BZ0\]:\L/
MT;1^Z#U.8_IG5A$JX;?L:&3(=?J<R25<MP-W!FVS# SJA,'AQM"KD!)HQ*X_
M6>+*BX.-8)2^9XY]LEVA4",4_@+**#":HAJ7L_:I;$^A]8$E<L?T1Q/,(Y/:
M+G%JN]B=8/HD7;ISP3J._;81]_1T'V/M4L9R\W"$9KL,_X8Q.GG*N3K-5QVN
MT@"5L%EF9YJP&@O@=*=MO XM04Q2:W-4B,8]>J/N=Q5X8S= 847E 7N J&_I
M[%80%^SD8C5!B<OD;J>5 =M\<=WCVA\7X _?=LSXY$0M0.PL\Y'Y*-HNJF%.
MM1$+%VH?8UVD_[)OSJ_EVH:F#"%_44]O7YX<+CZ&8>J[OC\I5FCP).XVNGPP
M&M,>E7#(,[;SCI>?:0G+K4+<3A25,[%!?KYY]_2B43]6\^6!ZYJKVC0* ^"[
M\O:8F3IQ01I(4=5"702(EWAKMYP*U-S")&547 15*F+=BE81IMFW,ALY\KNN
MC14GFOU=6:))>'1?J@7>AJ6F* RH/L3M;U(8Z#%Q'WKS2:^B0X986W]GXK3B
M63&[0E+&&%T3@01-H\;'$W_1Q5\9]]!P!MOP)\#9OG>?6"E'<-=0G&'(:*?O
M1MMZ1+;D;V;%9FYX)*<\D&S62/#J'%2"]XF,4%["Z.74))[E\UCV<#3W#]'+
M('T_^X#:$]H]# -DZ3*T>J[D+U4,B8Q#[]_57H\B:+:AI'7X."G(GQ7P%,H5
M!'<4G.,T3U!RFM2UB1[-N8AXE^;<(\GYM0+Y=>6!L'*D>N7D:LPD"5%WAHZC
MYO.?-R*2*>A.!P:X$E6/!A%,,5WILZL5DDJ20Q8:]YA9-AS,,(#,N8:<'992
M^AV7(TGO;C3G+Z=JV_Q?S"'K&@_-90NVR3:WNP6C7U[PX#*D]&VT;F_6C%#,
M])\WSD<7^P@8CUCJ4JV3B[VCA6Q_YL2).D=LNJ9>7$:4%[3WF;OLG)!/,GM_
MWU4P'TO115IJZ]4031L5-'7U+^/42!..]/O%N,[72\KJU%0A*SR+"HTC13SK
M&NX\H;2,4C=>8PRYNV4R1%HC(6$!RX6080#:HKINDO"N5K;:%#682W6+<5LW
M3+/2=KR'.%WF55]T#(XE4<8]"AI+O+Z*P[!/F039L)DCHF5_6L$3G^5C0%*P
MU32#=M],@^A6PL3*B9YFF[2<_#4XQ[A3J2ECXYM/43L&T)9!9WQ_ 6]FSDYI
M33WUDOX9BTG0$0U1@FN&I%\(9]JDA)Q3X &DT]:3DZ6E^9!8;<U8.&5#H4;*
M,SH&D1-UG.$PL)E/0P/BL;Q<.*Q/]YJ(!1WH?W0B7DIT$,N15UFXUQQNP8@3
M=IQBS^*_%*O^$\?,9FG.5<"%U&A'?Q*D?<3,+_"L=8'OX(W*JR.*L$U?4I.=
MU."#R\T,'RJWD;-89I#F%[[HKK>S/BN).IS*'B0F^V<0WNW=+SHNR7.$YI$]
M9J03S:S+5\7EA HN[EY.J<:&->%T*F?'!'BK-R4@+:$4W3=^E@DO9=2Y9/FL
M3]3<T^*D[O17R4L,O;M"D]'Q1DOC6YER!&/8>Q ;=RY:#]=(+>^2[C0/F=]!
M6#QK>WY^9J-R\*LV4^5+'D7Z4E08AWO8Z\&G=]QAJ5T'YI%.@L"[VY>!XZUT
M[W0:QC,N$LUDG,IP%C/<.VZ*[/RD\:8#REF=LAD6GZ& (X5@@Z0S29C&84NB
M3[EQY?@ID%!%<C[]04M+;VA7L.UY(O4>*/YJ^-OB6_%#C3$)%0?<6!20K+C$
MQTS<GU,E/IWA<^GB/#F>Z5>[X7D 5FA)%T]TFO$%8?E;%MB. E(ZHC_A.<!+
M''O?)U9MLJ1:''Y/"[K<+W]37(;@1457VB<)G)BI/FHE2@R :'D4 _B!V-/7
M'N/QA'_=2%X3\,]/F'_!@#XH9&)<95NA[-N!#[.59H=I)MAM0HH?;L\)3&)[
M0WW-CYIR)(#_R?&_=<M0<]+#@?"A';]=:C.];56FRQ>Z,U.XP=,U1<GGD@[)
M&$"H^*+&Y0WPZBH&@#+U.M'[4:J%]RO1+"I<YI%W0D,GN#W]@/4: #ER Z-Y
M8I':K;<P@&_D:'4-#* +YB*G/^F  8A?3;4D =?,7?^[J^D-RU'[^Q:[A1@
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MB\-[&WP#%!S?>^NFB.B6J2G)WJ]2]ZC$]M2"7WL2XB3)-BH9:SE7VDV^ ]3
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M8<T%$RF8UX 7&\#("'.D!OHQ!C#6@[X/PP#"RY]GQ5A-B9J[CV  2T#D!PQ
M@Q[):XYFB44:T#],*<@\'/OCLAPFCN37 !RFC'%WGC;LK+@H+MZ/]',I&
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ML6BP!^3J"MN54&>C23(_8GN(<Q4LB)7@P\9S9;:S!((76$EE!Q)A&[D]K"Z
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M1<L2&=I+E/*I1JL' IM-T225M=0?DG_;_CLX#H-<;X7W[P Z<D<XE!QFZ;_
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MQT')OKFA8C:8P\IZ5A\O\ZZ+%,M;IMPY':R*!(SRJ(8[U*MC<76MTUW4PO3
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ME%)F,#I-=P$,3]*$J\-XL/#YD2%YM.<Y2ID"/OSI^?.9=N@(D:L7H;7<!1.
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M>_@W'Q8\42](J[)5]^9HIN+S*<S<\@>M?'K/B19PWAQ2=0)74R^L#MZGS;,
MM1<[&[2&YA^WZ-.N45UO/#XR$9 H3I_M6Z_I*,JJ)^&UK8!>XZ-<<TI.:1(@
M+W2[=^*"%Z&:NQE(<A?9YALG<I?YGW-*4$G)TASH02>%B1Z*7A%'7T_>GNZR
MU=7@UN-&ME VKZK'=[:@2:T<00[DJU!6+7PK:83H5E#QX@PX^I1WTN50%;RV
M#*=RW=)1L<.Z/UK\F<DV?4!P/0M1ZZ,KLH)0FWQPZJ(0,QE:5MT924NG%;J:
M*>0IM^=QKY8;D>B7F2= W150[-:L;>E'V'Y>VZWGMU'HU"W&)O1T!]V2</."
M+N<%_(JE2@?X&JPF[]G#)X"RUZ O<)'H6>EH+5JPE\";YANEL2_A5K$XT)OY
M'8/IO"_R'9+T\B4_ZT>@ZB[S=.T^[P.[VE.I4!Z>22Y.FMS@S(\6AK7^H,15
MGFM9,5^Y^0B7O;%:D)\6TL6\%+J*27W._IQO7 9'^P"GE;T3FQ*<RZZPL*M1
M,]7$(XD[2W"/XK&4A75U8FQA;)B(>G: R]S,AO8I] 6770_["KYWA3-0RU_I
M!/Z@J3.NI!F:I@9U>3;A"WA/+L?ZCN8D9:V0[V;<$R!T^%5[18E#^=Z$C)!S
MGO./\R'<!L%C*K5/1.P_^Q>C%N,;5G^HL9Q/M0F[^<6[!_8-@IXM^A"5\YN;
M#(8,$O3CBDP-5!7Q=_V:2/0B"G!>L;<"N(W&BPI\;+?2X-]_!,/_\8!<P1^!
M\>1@>C"$_/@+,"PKEWER?SPD]S.2\@6G;V"ZCHT7/F9?CVM4>J-O*0T><:MA
M-^/%KY&6^5O*20-GY1W>"6PW#?*Q$!,TK-$5^,2%VSS>G\A^B^QGCR,]O=^W
M7LF5Y+&<).%W@)78V._IHZP#I?\Y7O-_S07=V[8A#29D4WV;=D\XA36<>%\5
M>6:.?+=#<8/BNMH'&3?^\;%WFNN=\;9]$<3\QR? <J0W&F\"\\!%:.4!D,;B
M$6B3QCXSJJEC (?\/8XE[E:[:J+T</.467'&AXH1V1_*A@T#AF^8K4P0Z_,[
MURG3&JIW1"Y5$60?'TX;@*KV-C"9#8KS)SLC1#RZBZA=2SMQ<WA9V=1H9\)/
M #,!EA*B%P9DWB$B9#9L&Q"H(K(G$'%E^<K++'D6N%7-64AMED;270+N9VS#
M?.O@W)!2KH&Z,;3951?(!1:@]YEU::]-6+[-+^ZFZ40K)SI[MWO%!*!;+7U,
MA73IW_SF7%P4_EIUT?C25>1RD!PB2-3)@3@#+LL(NN&KJ-[TB%MBP1H*MJQF
MJIY=];:3D.ZU[B&%.W8>=U%.F]\PDT%HA\X4?2S;=X\BSHY$H;":]+:"W6,1
M#Q=GN"AQN@6YZ-.\*T W6X]8E<) ?*QEV8/'^E93L97J]TL6CMC-BVP\A:X=
M.6N%>?//<)#S*>GKM9C<NP?6Q\ZAE24LZQ)F,YU[^>(&)C9.;V$B\^7J9B[F
ML/$VP!1H2@ZLW,E*54VF1Q<U5#6K%A!($?:E*1#;MFU>&N4QQY0'J9D>+->\
MY\Y4)7;%16W=G0NI'SPQXW!#1@NV0%T5>B2+\'/@_=!VOV?V(9(9B&Z*E?V1
MN+K*E_I@ 0$CLJGW?D)!!"F'5KZ)]_]T=]U1367=_BHH*DH14#IH0#I*EQK+
M4!4C4J4*#""A2.\0 >F0" C2)$) JA1!>A&!A"8@13I([Q!Z@) \=)RB\]9;
M\\TWZZWWO3_.7_?L?<\NYYQ[S]E[_UA@Q^]E)KZ14N%.K8CX%LG<LK;+1"%Q
M.]N[+H=NLD9BK23K<K"@M=-BN8W :PXAPG1)T1NL,BBY?*+<7B?3..4#2"J&
M3LS%DXYNE@B<\=+SS%6V?P6-BI\.!(OS)*[2-9&R&2K-+AKZ:M^HLNK6O'A5
M]8[$%TC7Z9B9F$][ [3C1B[CB[Y:?/55UR='3-5[IJWX!G*7-9L"V&V"'IDH
M344;(.MAYT<7(7*)V<JSJJ=]K!VI \V^<$4A7[L7%_&*0?<Y8>HG^L+36^![
M7]&_>&L3B,"@CY8/A,M%=D<S%#L"PR2TI^<H"[S8_!3;-'63F;)TNH,TL@?I
M,=EH,AX0ZO!I1I.7UTI].#,//#X6LN)U,ZWCW,NZ%>N!FTK')7(L2/>Q,)4E
M/@\Q4]V$+)9X^ZBHBE/<F9?SHC"0LLIG9@(3ECJ4\@S@EF(;3I>[R=_E-?'5
M/:IRG" ?D<_K4TL80T9QZT&Y-S$W<7VOW;@:SN(0]9:N#K3Z"C,,*N'''QQI
MEZVCJPMLXS&Y-$YK?*?8? GN=RC1M6'>*N%*(WT4<[;-H*PP;WZPLW$*SF=5
MC:?J7;RF;/]3L@5YMZ0:\37:TEHHH;=,L?T&R)BL9#1H+>^TEE0RHXJPMC4Z
M_6&WBT6MF@XK^1H)+KH^Q-4NQ1;D>'I(X<B#(TU[?GP^E3P]$4H\&'.K<U]R
M\ODD&G1+M]F"\K98?-M.QJAW%K)3]H0Z1#W13VYB>E,IH*NR[K[?[M+6(OLX
MA^ZS$381%[9_;21"RVZZJ A<N6<]OZ?]ULU5BS""W4I.O0NZ@Q2&^_KR]F\W
MB34&8-0;FM&\'QC47S/"F[I30_FJ^GFKT_*YD%6SUFVH_E,3/AQN%3OR46.J
M75/KY@E@<>7'4X)*@(<#I1C:#8891#_/5N@K+3(8E$9(22:Z8QQ.3E'O:B=J
M"Z-4\M^X;EV)<4/KY^XP<J=6@^R^AN\''O[#8V96QMI=OP)4?@$GB_T-G.SK
M_0=\/%2WI<6NY8D_3LVV<=G$7-+\FC*>I^O/<&/7*+YN(2OTZ;FY&:<SE< !
MRJJ_14E>.U-JLETHPES$SD&@XQ3_/4CQVRU,"[:_:>U%KI _+K10;?B/P>3?
M[I96M!%-_?859NHK9W0R9^*-UW?\7,NNPQLZ?RN_K%T9,[DNSFP;K['OK\4K
M^4K'J_KSBQ4JT\)O)9S_TYJY$<ZG]5[ODC/38X)W)*=X$MDLNP3SYW"$1_*D
M:N"L9E&MB[U 0E-A)LB2 I"</(C4$,0;HW3&# ;U51UG!FSVE>%H][,L+?2V
MSC=0T^SKEGVL_!^79TJ"(6(-S^]ZOZ(K*HZ=];I/ EOI+6MFB\M]?<N@ZN#N
M0>)R62TVO!])&7$AP?144Q='8E <7+_FLWT=:9*];NJ%;7O:)RWBRR:XUC7_
M)/L/%K7!Q?U.^<M,66G%)6,%3#GN%UQLWX$R32#6%)[J_#*JZ0L2K1:D11B'
M)H.+Y<6QQYU95$+H7"G3J34F"WAMH)&TK.=*@I8^5D]/;9? .?P^::LS4N]X
M<)O"WT7K2@QZZ3XNI1')'YA5[C,FX<]@9Y52RX*Z),B'&4*%=\7GFL+W;STH
M.F8(<,4^ #.B'"=>"_;=2ZZ+F.H3K[O=;),Q#)E>8="/ZX0K5C,_FRB79W35
MO= GQPKWK$P,\UQL%7$!7@B,W&CV#5]/\X<+"VD;%Y26=FN]'Y')<0IKT31L
M#==T<SX0]U8Y(W/GXZB^WL$K:?=4MQ%4NT@@X)^,04(+Q,A-LUFN*A-B+]#$
M;2/+=/(<PYW)X,63]%Q.S+%S4N@N6?"=DJ(G18J/SC8$M"N? AAV)HKTZD/8
MDD1'%'8@<'/^SJ$WUJ<]GC(H&\(JY*U[#10UWG0)R'5GZ7-62?L%/IHP_7B-
M.<J;3%2%RLK0;[HF@))\0-^RXDIAY5L=5C*S#>IZ<KCCC#,'S3 KH=<' PE]
M-QQW?VA9I'BU"D[_^ 2STT2VCEOTK9[\8R^JNC!.=ROJ'&TX*]_ T_A#T^"*
M%Y$V$RR"J]>C[_LMB2//-G6(@ 3?/0ELB8R,R B_]\28/BVY7F-8,U="$;L5
M&):A:@;-Q;8OK9]4XEBAQP#V<%Y5&OFWG:+%!86C)EH"%3?(A;ADGI)U8U^U
M3K#P4E*^*N4<) (62L'S5Q2D_9^>/W7<09F$_H.E&J-3;[G6V--R28]CM&JZ
MX5]/ EJKS+"+:I5]EWI$?U+NFBYMIK8+#_=(MCLA:]4#K?X=KD-;#G0&0DVA
M'"D%A;9-51WYW(R_6C0*O5UK]<+E1.>40GD'5SD'94NE+G<.2H'V0<J9IY-T
MQWX^G%%0M2G#BSC3;$SV+<$01@/=END8F48%A"Q\X@A)GUBO&UE=M)O-I<J>
M^ZI3"S0FS,%]DFC/*/M=;6U1V[Y/[2C>Q!VVVZ&%^K3K>[39^SJK.'IT.$CP
M"V/7Q&/NQVNQ&"V$5DRQ3M1,ES8_LDI#R+_?3Q$"W=K+GZ[=SHA'1#</(;U[
M6T/>=S<T\FR*9-T1HXOW_?R('!PH&G]NNG=E14>T4FYA,A5AF+&1EQS*!]68
M5#E%/4!'GYG#GKEB,UGY-G;4OD+R*7JRA]K_GIJNK!/WFN=JP!Y>RE_>C%E;
M?+]&&=]K*%LGV=$M-D^@[3Q?[T&J)8UO=F7@M.\L7T38 G@^Q5;8,D2$C2NZ
M5&X_N]%N'"MJM^$8.',712_]!>ZPK"<]US+22DJV'6FGDOZ>;IAL1/8Z_L3Q
MJL!'@:P@^$YS*+U9V%6:D&>"LDI@B7G#/LWQB$][T_W&1N;=B[[Z.DET_+?N
M>.:A-7D47LW  HI)L:/^+'ZU<?MA+9,HR5^&8!+*ETT5?A'%$IFJS,>>+=7^
M_-Q;E/[\QHLLNT37(R\R,L&^0.\";SH=Q\3V@][>^(E:; Y>?GL5U.+?/((H
M=J^WE;7?J579^L!T*TS^X^OB.?HW>J]&,#C$/=A95=7? 7_H3,JP.%X=\U]2
M!OV_)M8=?F%A:DX_;\@Z,YH\5_J41Q5NQZ$_R[!TO6-6'QE40[_P!AJIG/=3
M;$GA%7,CH?MI=7/BT0ATM4?. 'IM=Q\M<;M-MM%.HW5.,V?9K/:S*>^59^7Q
M)K_BBA^5=@J]2O> '2WB1^'9$W/LF<"Q!,5+$E^3I+]F(9^))"V48B7A(45X
M@*[3*OD_S0:X!A/MTI?--!E,GAPYW%_3!4RTZ!\\IL9] Q48H+I%D_)9^*G2
M3H:&ZRG#3YIJL=S7V ( *5'JGX(E3[T\ZIW5RU+Q[&V(CK$?H#C^2U4M4E<J
M\F#&2QS',:#%A*B<,?1Z?U-D1)O]8[G47\MF?P 26X>5^L?1TA-IWP'MG/NU
MZA;\(>FHX80"AD)HC(Y3NRIB:EW\]'*\SOZIPM]A+_^#&C-GM)41-LGMO>S9
MP;J=#]:G2UTI:N[O"SL6WEUAPW)F>_@$>*>XM<IWB88M.L5VUZ^#(,[673D(
M.9EQS4XXA#F)0G:Q$_6V-- ](_#$9*S#Z2Y>H(OJ"CDK#J#PU#2X>;U+S/VL
MJK;*FQHW=(]5HM/3S,UCOHTF\T3 2#HQN[:O!2.2%V_M93IN]<''S;!+R)[F
M3F%<ZJU8M<)@SI*IXR3\[JL?K QQH3/=C2Z,-P8&6UE3F/-)WR\%':-Q;4N\
M2HH]8;H([\UXE&99DN"I,SB_73!0XJJ'.9IK(>OPTB3>^.4\H\8K51&5PJ+(
M0'*](8Z?">RGO-Y ;KBG?LH0F0QQYO$B\7#6NZ5G<5XK\=C;[MLG]F\;W%*(
M.[ L$8)VX7]:@VRK+K\H.-KM5E[DON,S-\ED=MOG[8#^X-#HNP=5?M+!<7ZF
M,20\['X4E"G @3SUX%"CO5C#785H2.F'R+O'HTE([!?LI,R#[JQ7$X'7L#9H
M.LH*I@N+1"_L26QC$(Q<R.;J("6XGF?F\^,,3SX$DG#!7^:YDX8V]LA ,B^E
MY!LIVFS;6*AVNJA22)R8.ELX6KY0=J%N<W&T6F()ZYTYO"NT.RU3)/BQTM:Q
M5-8^V5Y5W 4]OZ):I>"*:+%T.=,6W][E$1GEMI,V7UK$F!T[-Y&R[D0$F'"V
MK9"^_+RNA5'/D,F$K9G[V#A%]F21\F 2\O7-23'7AMR2&FEL[TIJ2X4#>7"L
MXCBHS(R)G-6?_0HK$= =1M0G</#F4$1DH'.XXV\,OCQZ_>.>]ZK/6P^WB^6^
M*>4AET+0#!QW6^J'68M[6!)H,O/BFW%=#RUZJ\0L'K9>>B6F8QX!8J^X4;ZA
MLR?X_OI64Y['"EE0(V.0'QWST,)>N*[?VF.!N/-)%@5CYX9AI09.R:<+WO8L
MO:6D4+1)'1XJ/WN0T'M#_Z?^$:;LY8YKUY?D;1.ES:OUT*7!([STGQS\W6XX
M:$CH6R1I5-C>6=V3YPWEX3P0^2!@$@6AU<4Q1-9T9$ ?9=&4@I90.Y&7N]N>
M7L:38?/5,N73"ZHE_$8O.'T,#M\_OG[X [%2UMS."RV[&3OCS-5QN)+QW;SR
MY4L^/T%&<4+VIM&G],K*LNBC-Z<P9;Y4'0#%F.Z>8=5J ^SDY@A$RVK1X/HF
M$2A6?A[6O$%;3E@%,>"MVC%J.;HGU65E*JH916PS1NWVP(T0:DM&Z'U$D2&_
MQ734LL$PY>U !C;=0W<A1S: -V9?P<:RP+B*S==L[^18NT1[WMJ(#V[5M4)<
MCRHM^:39R088$H$GZO5CFT>ZP5@*,#8W): Q,WV9_Y&,X9GF6C/'9B(P[H@+
M(GAM=NQO<7T)F,$+PJB(0$=R/!'P22,"$XN?P..TV)T#P*D#3X+ <W_/+WNO
MY#+!AWHKEPV_)X,DG <'PV8[;A.!VGNP+Q?CLVN4^-UYY,X"A"!8K5DE-)X>
M0UTL>T7:XN$^HR.\.HL(8$/=/ F/I2P(1S $6F^]\T0 3+*H ][== ?_.)(Y
M(A#0,<&VN]$-7NU!X@T\,/B+7S!Q7E(<]GAL?_B4[1_E)D*@1IQQ)QAML\;/
MV(P@"C-N'W!_%9?L4P%L8VX]'Z=/N$ $D+(BA /E+W>\/QAE"X&3_Y*K=(U%
MA @ DT3@U/>:_",OV/\F+R.<@HS8["ZLW\,BOM1%#OU"9#.#"+SG&5_= ^:1
M.#(VG-J6M1$>3_GZ 1&8_3AU:*5R_$TB(.=A<; 7_34ZXSM#.R]^KWC8/\>J
M$8L)3-"6[]Q\OQA1OV2)]G!!+?37[N+8=.L.C8EJJ?VWO/<[7O_N5/A7F?6:
M'LJ&A#U/F0^RHGNT*?J9H$$$?K2RW.NP0TOZ_C*_8B'A-2"W^'-#=\(+V*4:
M=HWLGX/$&CJRC89'$\M7N:*FDG9?7QA!OO9FX7KB)<D/87JH:T>1KJRG<4]D
M[EJ3W$19".'D0/6:FU@(JH3KXJ7'(D?F*T&[VF)>K+Q:.^7P7#D),J9!F0QY
M;)]!51^>O0C*_W/RJ/GC%H\F@)1F-1#MG9-1$O]JPQ405VD2FN.MB4 -S$EI
MZ/J\8&TR86F_Q3J5/-6;>5NQ;=U^IQU/.;%JV,C=(MKS\TH'13%**NH9733'
MX2*ISO[U!"4\7^R9@Y(#1O+JCI@)JC3FDN_/P<84=D*_H359" TU349E*W44
MI)X7UD//^K6<Q)2E1S\(P7>4%Z]TI%,O_0J\])+LEZ+4CBQ5<$G>M/#]4][B
MJK^A.@%/RZ-&)63.W;TCVRB7R%I_UAWF^' (H>+\]34WW47T!F4RC_"%DVQE
M94O[4_E&H&5J1")_J[0ZW-:YJ_<-B4GLCTA,F;^7:RV/3UDO>>S:DNDX!X7"
M3:G6\4O>:T4@7.4WX+K_L':D'5IQ.<1V2]*B6^;^ 1+:/V!SD,A<>04 "TE*
M2H(C#MWTB2O:://04:=9V=;R*D)=30J;#A<0Z<G+>X<KZ#J"$G>XYIQ8#:^=
M\R0"+3+@20-G6L<K;R39<(I>9D3@YAA!;9P(,(+'6=:>'U#"=A6#\%9YJ7#S
M<XJ@[^D4\: :82*0LDH$N+%$(,*Y1ZWM?=,4[ ^$#_\T&LFX^\R('PC9L'!<
M*R&H%H^J)XCUJ2F*D(,BOR=$$:C'&&"=.T3@F1L,7;' /6/\LP/X#V2BL#\*
MV&<@S]S&#U?\C@KQO7R+F:CX@,@?---3X 9K:)WQ+FU,716*I'#JGUS_F<!P
M%2PNN0LA$^OY*-^O\\_(%XNH)UPZUWT2KWNI7-HK#+'4W]<T.[-[O=Z6V;$K
M]4]<!=]C_G7E0XUPBGC5;=E:;"RB9#=^WV+;&K:P1L@WM^][,>*IK2Y_WMCT
M']&S'H&:"-!X(Q[A.5'+->8^ P>);'M5L)R!).=95\/>\W\>JLNY?]W=[C4?
M]J-A>O@3JP#5<,2H-V;;VF9V8QV?-NX"O[IHH$IK$/ W+/[?SP5+/'C"?)W0
M./'1,OA=(J.U@WL7C#8)^5S&"^4;&O:CDBK)_X9+9UD<]@M);-T_'R;_"G34
MVK*P>589?\_!1W]M'7Z<+RLUK."?FK=\]N.KM S]_6YUULNX@:/S]F6&DM-Q
MT='1N![8]^/\:_Z=9LBZ]B#^3$>$W,<3QC,W#V+.NH>-N))$1J(553BQ.V&G
MVVVJ++?=;K$)LBUE(EL-6\N2DBB$/?JT_Y;'X:ID)^J$F9",WJE4]6U!^[P<
M&^<K5LA H'!X3.^7&3G]/[RS^P=U_%6E6AE1XN(%-1;D!,YOUTLOMR<RZ^$F
M9]0C_?UQ&D9_1V<_.L@MLB#\[1J+(2]=P0T&JEE5./@29#S:?\,4^0SK^,\Z
M\T,9\(39AMS0Q$?7N*8@*6O[76'8Z22V1&9\AG_"7W%FO:YBH[.#4'M(%JYH
M_T:O8\W0OOC5TBDJN0<.5^Q@I^;F4I?X#_?K"P'_!PY%_K\U-N+ ?P%02P,$
M%     @ YX%<5+T^)+>V+@8 EPQ- !    !V:7(M,C R,3$R,S$N:'1M[+WI
M=IM'DB;\OZ^"G^;,=[K/=%BY+RK;<[1851I;EHXHVS6_ZD1F1DJH @$V%EGL
MJY](@*2XB8)$+$E*U5TJDGCQ;AD9\<3VQ/?_^_W!<.\=3::#\>B'>_([<6^/
M1GE<!J,W/]Q[N/_XV;-[__O'[_\_@+TG3Y_]NO<K_;GW,,\&[^C)8)J'X^E\
M0GO_OO_\/_:>C8:#$>W]_=&K7_:>C//\@$:S/=A[.YL=/KA__\\___RNU,%H
M.A[.9WRIZ7=Y?'!_#V!Y[L<3PO;GO2<XH[T'2B@%0H$*KZ5[(,(#:;\+TJC_
M)<0#(3Y\:WQX-!F\>3O;^_?\'WOM2WSET8B&PZ.]IX,1CO( AWO[)Y?\3[['
M_-W>P^%P[U7[UG3O%4UI\H[*=^V4__;]VQF_"WX?H^D/]\[<]Y_ZN_'DS7T9
M8[S_OAUS;WG0@_=I,BR#TV/;KXLCE1#N_O+#<X?.KCS4+@^=G3UT<.X&SAZM
M[_-+G/&CT<GQ_-K_=<WA[>.$T]/#WU\Z_MSSM4]/#AV\_]AY9;N-MMYMN4\.
M'XU'O_*R3P;YZJ^5V>3^[.B0[O.!,%H>^>%2LZN_].$R]V<3'$WK>'*P$)5V
M%W8A).[,26!*YZ_.OW_W9OSND^<)H.7I*YH.KGI!_#KE_;\__V4_OZ4#A(OK
M,)T=3LXO\,FUVR?\;75Z@4*#JX_D#Q8'_I<Y.70^A3>(AZ>'5YRFQ=T<?[ X
M'(0\<_N#Z=@HZ:\3H>41)U\@7@QUE6PJ<9_>SV@T':0A 2W6;/'2IJ":ICA^
MFMD$VKI./['L[7SM3C^\ASR>CV:3HZO?Q?&'YU[<N\'DW$7X]^_28+PX1JH/
MKV ZF5U^8_S'*][6?#;YZ)N*]_G3>S_^V][W;PD+_^_>][/!;$@_2@$_?W]_
M^7/[ZP'-<*'J@/YK/GCWP[W'XQ&_MQF\Y@>_MY>7O_UP;\:O\_Y2A=QOI[U_
M?-[OT[@<+<Y4!N_VIK.C(?UPKPRFAT,\:ON*_G+OQ^\'[Q^TPVFR_'%0"HT6
M/_(!3R>8%PIT4'ZX]_0?WJM<LA5 %"08YS0DE2-(&S&B+09=N;<WP@.^#+_#
M!T]Q,*2RCT/ZA5A7),S_>MUVR?*D+R?C3%2FQSIU]&9A 0:S 4V/G^W][!55
M?NI_N*A5K!C!)K1@M/: UO'[#BY5*EE8%^[MS4>#Y1=^^\=O^T]X)::#!Z/!
MD-_/9$[\I/?//]1''A(-%9E9I@)Y#285_LD$"S%;?N DA0VG#WF\6QZP!9BT
M)WQ"R_]]-GJ8%X(V?469!N^0!7V7SZ1MRAYE!5Z"Q N7'" *#TG$Y%-*Q<AX
M\9E.EV<R/FA+^*(^Q_R6M=WDZ.&H_,0">=B,\<7'$E+9'(,!80*_/I,,Q$H1
M"(,*HEBDZM?U6,48-(D*""H>C"@((?C*U_(QH\NQ!#HKC\_XJFR[62PGO^-P
MSH_TA*W%.VS XY<!IL%P,#O:ZCH=6[:3YU%&Y,H")UR(O$P"><%\ N>4T#)@
MU5%=7*:'F5=B0H5WT6#&3\&XX]F(+<B;IEP?3J<TF_Y!#9=0><B #-_0;U.J
M\^$O@WI))(VW%&M0D%-[GY0=;X+$MM D+"HZ:8J\]^-+_W]/'N?X]C^ZDPI9
M*2KPCFE29P)@]![X-^=#SEZ1/;L\9R7N%1WB49.O%Y7_?#"83L>3HU_'L\NZ
M8:,"=WY]B-]&=BY E2:#\4U)),_O1SN'VO,"4;IB&QW29';T<HBCV=F-\_%E
M("MXB\H,(;($F!("*Q_3WEN0U828=*Z\#/ICRW#^IF7.3E;B'9]9= WRJPFD
M6)]1B0J-#.3HXDV_.%Q8Y-&;A=X^W1J/YY,)W_G^C.'T<FU.\?#+\7307MQ/
MIX;]E\'TDG)PH<103051VEJQN/$+M S*4XBJI""<%_=^_#0F^1^L7GG=RLF=
ML<G@5_MB]I8F9_ZTFI2R V +\HL6Q;-1DS5!$"Q$CHSRLBA"NJ3OOU WRFQC
M4%&#B-KQPK)"CK$R3/1*D:G>:$_KTHV6E474D5^PB8$?R_)>%KZ %EA%J;6&
M?$E6+YNQCPC"+A^,Y58:XQ2$K(FOE1(DZ3)4WNHR)V5]/:?TV0(/<3H=U$%>
M@,RF4*@22W+9GXWSO_[ "6.2V>FSO1X_+&4ARRS5.&!M^A@/!S,<[M* 9R-\
M\(RW,F464G0.HHT%K+!%"Z6IX#GD];"\:TY$.1'4AX>'PP&5UV-&D&P%9FV#
MGG\-SZ;3^=+OV)T]SS+YRGB$#4XQ8&QFZ14E\J6]*U2LK0%O;,^W^4 D# 5-
M'AC[LB:7U QZ*H#!IF38W&/,9Q_H,4[?+F7NEP'-6;T>GPZ'^V]Q0M-GHU?4
MHBJTS\O)ZO?Q^.!@/%JLWPYA"]LC8DWI>-D\PY98>?=[54 %S\"LJ"K,)=CR
M"S$TH?/JY16-Z$\<OJ;)P<6G82U23"8#52?>])0$I(;1642"8YP>E8IL$N6*
MR"0&]E<D[Z3,7V1DPO ^&:D@L6(L-:N )"_><7O7@UE3Z\W6-$^,[YO8^%WA
MKJQBYM8D8EX[4BEX\)JMH\F2#;UA]"9$M8P<G/ 5;PZRMJGKR(6*GBQ8:L8$
MHP34QH'0T1F/U@9CKS/()YJL;8^/*+N=.BTJ6E;9$0JR$3/!$+"[XB'J]FC(
MBER)2X;YX)!UW'*E+J+[)? ?-N"_2[.L$V_V9#-HQQ#?6$<091"@JJU&),::
M^;RJ^Z"ZVH(UK^5QB[(NSOG'8/;VET%F)$D/WTR(K@)36_6?4972]G*DVEYD
M+9 "ZPM=J=HHC*40UBR2VWP\I=C@LJZ"RAJ;M:MBUX-U+&!-3KF C#'T#=2A
M*=&IQ) EZ<#*.RW 2V*)1ZV\U3+%'->F#E7AM\K>6="9=W*0Q)K=L+40SFCV
MG7+T<BOH<)LJ10ED((&L3115,$+S/F_.N\%D?991L$.S)I6RS<>*P;(E8_WH
M*^M'DP1+I+>\&6S2+DJ+Y4,X9+V@=ZOF+DII*F\^$WUH6$3Q&[4"HC(.&3R2
M$')#&'&;BYF,$^RR1*@V,4XA*7B+,BAF8UC9'+)3)_PYG'*"3$Y5RXQ_F@[*
M<:Y@E\^B40C2; 30-B7#C@H$Q_BN&M::BKUKYR[MM[_B8/3+>#I],6KX=C Z
MUC8+X+M3\3/.:J4J!%X"QJK8]+*R@$3*5O[$F$NAX2\)=V\3BS@=A(^B,&1,
MK!0+L>E) <$Z30*]U"'4ZXW %7[D1S7_;X=C?OZW ]YU2XE]PC\-QXL(T//!
MD*:S\6B[;O7%J+*LV?%+)[:T;!UPX>Q4P(6<6I3)GH*70H,'/_%^FQT]YKN?
MX/#9J-#[G^G+O.@?!>LNWRRO7"E4&570*7D)BCS+2&0(DIQ0["Y71L>Y9G9O
MSM[I0W[%I;WFIT-\\V5W6'$XI=6<QD)9H@H2G"Q-JMC LHRQX^4D>WOLFF1E
M+D7GE_;T)$#QL/QS/IUM'<V>?\L8BJ+(HB 4,ARKU;#?RZ8G&D:YPF(V&K<5
M$%X)&FXY(,SJSY7 IPUE@:8R>S(F,#@V2:%**=NR0N3TR3'.X$_&!_0:WU_&
MQ5L-!P=2E$0&V9PR8TSE5\[*49*H@FUSK#F>=\]&Q^4[%Q$Q@\7Q&4S1M!__
M>CBDI>8\CLF]G*?A(+^H_$66FET:ZZ!9Y:&P4%UM,3C+9AOY'6@E,IMK*WVY
M-IRP>,J6O=GN^EW8LVWM%*L=K2Q;:<7J(<6D>35%S<%B\/4<%/YK<UJFI[[S
M0E%2:650%Q^B6BK%MIQCU)D]!L\/(61+06)(KHAH-/OMR[J6'^X-WL\>E+;9
M^1QOCP@GK.,=M'VXVM[RO'V4\@K8,C3$JY =:>(W*)7GDS"*<N9\A/?BOOH4
M+GS&&B<3XZRZR(PNE5![\%,EO%MDPD9"Z0*,L_A:6O(ZYNC :<&":(,/WJ\:
M2.@"UNM<= VA@*5LP&37PH_\!JT35A<OL?ISX<>UE81L\R%E=-FV/==L-*L0
M1I:13024Q(LI$75)YWR77UDELI=V*<3U=#Q9T9O99O0^EFH9(P*#?19)DQ-$
M4@QKJB.AG4%$=Q9T'=O\IX-IQN'_917PT^A*Q;(:_@)H8;05M0??$=]J*E!"
M\U4L"7XK['SQ^RDUY6I9""_NGBNPUXMZ'-79;IC[_&OWR;0"J@*2+\E^5V9
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M80TOH5QPV& ;BY*070*C@Z>L>==UETK^=*77-I#+;M8K%1]%2_BCS %,YGM
MW^BUA$M22FRE>;VMU]8\JC4X,RL66[9#UQ620.DHU2K )=&V8$R0LB/^Q^82
M?%"J=(<[OA5;WM%B@FID485!L$KHP-@@(*6*?"-(,8I"$;N-;-X&_;*#8$DV
M3F8&RZ!M;I.=VSSBJ!*K&^ED1<,FI;MB[AUV'7RK_W_\#XVU2 H)K'+L>4D6
MQZ2, %^EJ@:=1(.]BDP_K)2[V>[%6VU%<& #%3"1L6*4@4 U(.I%"IFZ6[OK
MRX?.,2\?-\W?R:7+/M6(K=P'74M.%0)$U]HKE=>R2"VHNUC'-ED].UBBF!*1
MSAG8"9,M>5\ G6!\I&0JA6Q-^ELEQS:'$_21TS@3^[R0IKA1B[$W1;@:H*96
M"1JILBI7L0VNC5((LM9OG.?JLP._ZPHS8F/&KI@:OP;O--9]T$;< B&B; 1!
M,G3+!],+5],ZR3$]"UR;6T=F0:SK)42A!12&@@J5,]YTNQR[KB/KP*_W2:I<
MDX1::ALNKQ1@8SL)259%2;O;RC/_N1U?:S8LIWPY7]3TM@994B!7&GIVX=";
MT1BXJ$14K32]=2F0A$2F>1BD?3;12],MT6H;2E<&PWF;3+5/>3Y9,"3_]#X/
MYX5*&Z7<<J?SV?&,\)]P,AJ,WDQ?TF3_+4[HT='5)_@ZF]EXB712R0%K%O97
M*K*K*=A8QT#)&%%US5TFCW;!A[^KRG-+FJ*)$'U-#"%M@22+ &N38[U?2L[=
M[M6O/?BWJQ2 EH;5NVA=A &,"!I"<W9S+(5]D)RLZZY*]#/K8%[1<K#\B7J_
MDZ$*BLFR!V6A6!%9.S>69)OX7@0YKVWRQG<7"+PC74J?_YQ7][]^M!;EF,?_
M9,C#IK,0BWHNL0K-P?)0N9;$>"PD',7<$A ,+V)F*V9,:X15R@9I)$MS;P*\
MTX#7#KD?6_9)@G+K"#5DLD[E5HD4BVFSPQVDTJ8N45;(.M*;VMUPRUY"#9L)
M_EB78Y:8P6%K''&*?3_%>+)@- 6SL])W5Z+RC7#__.ZT:Y*%*I#WIK6 6!E6
ML!L!6%T&AHR8J].VJ"XS()O5RA^ORO_8$4\&T]R\C5=L'K=2D_]UC2G9$#]#
M4EH)*HRI72.-]@6"%1DTF52]TJ&H;C'U':3+<"B2< P\"J76LF$])%05O),Z
M^>IUN@4M&[>?^F9]#'FA==KX ([A?>,==1!==B!R0AEXSTFY<>J;SS6LZ^L_
M"C9''P(8I5K<130*)_;7<PK!8D E2[>4YROZZP]SGA\TY4_+(87MN F];6=[
M1\ORS0W#H/7E0T.()I322/?8.;6- \8% ]ZZ9"LE$4-WEN!395:CV03S["Y7
M6%D58U6^0@W8)H=I <&;!*HB)L\_D>XN'+ZN6OO;N6(&3?$U1G R23"EL%9,
M'L%*:V2EG&WMUL2O-1BP!CFYPVU1V9 4%H%,JYP4C!X0VRPIYX)"64SL=\)O
MXTL[GVNZ@M7A7$KYI,R@?7/S*:A5Y_3)]<WI$\4$-J8$N147F)(T8&-*+LY)
M$7+[;[>S>9ZRHSNC7QC0E&<CAA=O&G9_.)W2;/KHZ#G^<SQ9 /[+KO&9$-%6
MX@%WGNNG^MR&""4H.1$;>]%F""D#%84F\B7)V%TY]9W)?=\0C#X=3*:S+QSS
M<5-IW4W/3:G9J<(RFFQDWS=3!#3:0ZY%)\181>W6_=LUT4$'51/1:C(: RCT
M"THB5C;L;0 Y7;3'W*:9];I\2\_[-;Y_.)^]'4_XULZOX\*[?S@JK:-R^'_F
MD\&T#/)FJMHV$R=$K5JQ/$$2J8V)9G<BI6C!>5,"^N)5ZLY97\$2_$*SV1J-
M0&>H84<;.?OJ7"X92*$%XWUKEXV9L2>9%*6GU.]&[HL&:)T[N'@A5:T* D79
M2DUY518SO"V[ H%TLM1M_7HW16F;61JE3$Y::(B9/6YC<N1%:N3&C%ZRJ(6P
M=M=??CW>O53?OV@R^(,!<+.3O_U\W&G %O$1$7OB!^M+IUZC[5].:,@7'N'D
MZ%Q'[!:I'E<-!8CUA0)L=<4VXH(H6XUY1L].7&WUS*)02I1-N8U.W-TSW1M"
M;CE73(9 8RL$#-E"7#A)L@:AC1.^STF$'U<N"UVRSPKD[<]#7JMG?!@[UGDV
MQ^')!(4SD: /JN;"]QX-QL/QF\6$UJUHGS_F[P<GUYSR[>SCP70^>G-!CA].
MIX,WHX.%<1N5YSCE#X]]^^GI03<>,G]]Z*!UZ*1Q.3JNL]J\5@P@5FK!NG#H
MC;Q-;[)P;'.#UJP52R:(SO+>:'U^4B4J_7+P=47E-%T4R=+T1:U3=GUI*V/C
M+I;C?2+"9-?EV4A!3KD,53?N<\G_I*H+.-)6NAILB=U%U;]-K-YM04Y1TA@G
MH91&!.1J816#!%9;S%J&X'QW(K-J5.L)?SIEB5F(UV1MO,A\P<<3*H/98YQ,
MCNIXTF*C5W.0W<GXB8DEI%PD>&STL(H:-[M*$%'D$DJ,0G77%+J55.RZXP7;
M(W,^EY&[4:B@!BSLMH&M338L4>,R*1!,CJQGK->WH%YSZRUI3]GG'^4!#O?G
MAX?CR>SU^-<QZ[;1=#P<E%9+]PN[=<.?%J_K3 $I#L]@[CNI:F+POJ7%H-5^
ML',H6H ?/=04R84BK*O=5GVL6C%9RL*+9^<0!^79Z#$>#F8X7)NJ^7IGLEDA
MDV<4 TJUZH D/$,;&R$+73RBS"2ZBRQ\48W)N9&+*SOAW42 HO31Z#8NK86!
MC,F>G=ZH(!9%P@=4IK]"V]M5%KW>C@SV);6J4+QO/;L)(6JG@4I.L521:G^[
M:D<^Y@H%,/N#5[\^/#[F;X]^OWM>K3\_*.3Z\3_G#KV15YM:SJIHD+F5 V1&
MH,D%![R\1LF4A0K=NBC7M7_G@W>_8\[LI[ [,F/7\^#N%!;OBC<MFZ!K#6"-
M""T H@ 9(#!H*,ZI[&2NW09 >N9->WB26OUD5K/E&KZ$6VWE&WY8_CF?SA:8
MZ.EX\BO]R>:X68/!Z U+_8A_S$O$=,EH'Q_%5GY4&IWC;X?-'6-=943<J,$6
M( RHN Z#K;6RJM%W^6 ;KR,Q#+9.@BI6FYJ3D9N?9?WY.1?Y&9TH<DV9Z 9?
MK P%V,5DJU%4AJB2 0RDDA-1!]%M)OJ+'(:3AK!'O.LN?6W#\KT^ZHKBC0G)
M@XAMNHHQ&M"T2G"7LE*$;;!%;ZOVF=4I+T9TXP*5;AR(4'S-BIUQ%Y)E@QL)
M4BO$0Y](1OXH]3>0ZI:Y>VO<75K(*BU%UK*-I%DX;"6V!"JCS]DD;TUW =V.
MNF!W%/J*6M8H6XF6=PQJV:Q!&P(#(EA;BJK1FVX)EKJC33B?*9'KBJ/85&)I
M@1/R'@PO"YNM&!EL5)&T%-E2=R2,??B)NVE39K-EDG8",AD&AZ:V "5)*$Y8
MPDC:R6X+<C;*B;RH'5NR%4Y?CT^<N(WF+CO0L$&T$NC,J+/DV"8W( 3)-Q)K
MC>B5*5%M?'+#>E'GW2ZU.3>_8VVSBR5JF:IG/[&Z18K)0,3HP&AK^$_5Y-P=
M.KHUP_1V$P],-N5H$0%U9#VO4H2@2H90)9F8=8ZANWC@#N?_]$U:NDY/J%HJ
MQ99&DZLSF%;[%$5CS748DBLB&MUMVUA/J]/!'G=1JU@Q@DVM U!K#]A"HCJX
M5*ED8=W&28)N!^JE9)P-RH,5633>L@SH@P64(89 ,EO37;;W"_,4+<BV__.Y
M%,7FA7\'PUUR"KD4S6=,;7RD8[D/6B'4-EI<Z&!)=!<;V!R]Z_6F\X_YWS_T
MQ&RE<V#962?M:OO\W*$W0CUDL\O5 ^_WP!JQS12-Y(!<%3D9FU2_HP2^0A*N
M'=E-"MI7EYO6R)6EI#@(Q&94A&JM$R7FVEW,ZELAY#\8VW@C7 %7V]HAWP.*
MK,!&ETQ.7OK4;>CJ*0XFO^-P3H^.3F=A7*37NIJ@>M71&5]R*Z<__HT?KOG'
M1[\T[_B\.)T>M& #GRZ.T+<E2Y=%DA2K!I4E0V3,!"D;#U[6W"JHLNEW.&=7
M_8<O<;*1@%8'G?N\<&2-0;!:,V@P[$NU=C*POJ#12A=1NZN7V/&HY)TCAUT-
M$O11A9 ,.$:3#!\\.QV8%#@ALK?>ZMKO1,E;S]1W.Q-NC"9-*HT7)*('DR0[
M)\)4*%)BC4ID:[OK_=G\&))K&QCW!^\7_8N+XI1GH]P>Y-T62&1W1/^IK*@N
ML!8)2BDP529 G2)4XW.,MA:R&R=4_#R IEH81ZEU +0BA=>ILBVON0$TBVT"
MJ("4BG+6QIIL=\9W!8WZG,HB&+V^*N#K]>GI]8ZC.Q^<C/'!(8XV/7<OK+YQ
MPOHVCG&8 [8AL539CV^-$KQ?(I!']%B1I.E6=E9C(KTM;E;A!2!E--1J6X.K
M9V5F \.D)-A9EUIGV5W<[5LWU6Z[J593%VOLIA(FRMRZ_6S)C,2R<9 H:R#+
M5B<)+Z+K-O/Y#2^=:75BM>[:J."HB?&2*(%_XA7%&DH(6B8MNZV\WNWXO2MP
M_1\T>/.VE>"S#X9OO@WXNRT6EPJ[",2;0*5 #3<K0$D&"CJ?C; 157?M(J?"
M@:R:,NV_)?I(O=;+"1WBH!P7:#6*OF4#PGS2HI"WJ[''B6B]<P6J,"TGZ2T$
MSVZ.=^S]2\1L9'<EEINAINIF\P09R7MRD 4C5<,& Q(:"SJW6=VZ.E]N8QAO
MBUF!C5?9=E_6N6AMW7JN(M2<:VZS%S5%,$9'0,O@RK/R+RAE3-1=6>=6F(1N
MNIP[JD3@O9.BP38R7H-1(@#Z8IHV\D9;7:3OMA*A#T6T;7K4S<PJ9Q,4E*\&
M8A6-)C=:2(8L2!E,Q)R09+=RT',S:0?YGU2CEAD1;$Z"U;84$-A+96\U%4*A
MO5/=5JULT8N[/BSV-W8'^,T,IH\6)=U;&:^UJWRAK9IRFR5=10'C6YS#B 08
MG?7(UXJU6WGI616<:W]=WTR18H6BTNI7,;$!MQ78\U:0:I9%9QV=ZK9SJI-2
M0E:(4JRPR2X>>K,A:#$6(@1C#6\R4BT47#*8R'C,Y*J,Z Y&7Y64'XQ62,K?
M3CUHO*58@X*<BN<ERJU(-RE0)F%1T4E3NM.#7[Q$*^_9+^+'.?:-J;RF_';4
MV@".7K6H[XWG6ZP?)]Q.-\[9:,GIYH:K-M59&PA.(C@4WE;GJL_=99;64\9W
M0^_M5UQZ^L_8! ]F\UESX/Y&.)QMFG)^-SI-F^"<+&U0'SOY1C!:"#+GYO!I
MA])4F[J+.][EIMPM;9*;8Z2=M%M$EJ/2$O69_S&1X1%&TZI>=0@UR&!D=X6+
M/4TFZ$#?Y.)]RA&A1M&T3&!?4FH6)ZLQ^XB-(+"W)?R:V3TZ2#!05D(WCGDK
M4RN2*8TW@CQ(:94SJK*'U)W(=!F17JEAY@8&:&E]3V;K/>?UG@QX*]Q)?%VM
M8'CD+;A:B'U!KR&EE$$)"L8EK:WMLM=[Y]!A5Z.IT0K1TAFV%8$:Z0/[0WPC
MR1@?O/ QIFZAPP8'V]Y0L6R$3W6E>_JB7I ;Q6@O,D7<)$;K@[#8>D"30/;.
MK5.0-*L0:5F'F(*L/[H+]GVZ7G!9]7_^4]8WZ;CN?T/E@FMN _I6)KCI,2<V
M:A=B 9=%9$VL"4(."D10M?6?)47=Y2<^D0I\]/MJ W-OJ&W_3J,\GK1LU.1P
M-1Z==9B8*\;X+6]DB^,[P\JQ!CYT374P9#*:4J T']7H*"!Y_M58*972CD6U
M.S']RH>G7ZSHOQ$[-UIEA'50(R(8SPYM4DF#P*1L-=):[#(N^G$M]6Q4AW,:
M_3<^9 /"*NND4O%8=:UELO@WW=6%[I(FJR*E!M\J]PSE!(@E@U;)ZL9$AGTF
M*C_#T=B\E[$%[^MVNM(Z>Z=SDN#%(@VN-(38G&J332"*PN=N>UQ[B,*?J]=<
M'ZPV.J.H%7(ROM5B9XC29Y#.UY15KM5U2ROT624$;>-=43ZP4?=GC;TW#"JD
M$55!%8MR^<S (N0*Q92@-6KA^PL<?JZCRKN')FWJ\LK>Z1JB#]OH5NRBNF0S
M;KG/,D8JC)]526!:Q2#J0""S]JZJZ-E'[U4N>R[R["!M[KPE850&2NS0F)H\
MP\%6::BS#8DU$-[ZT?&O:(:\(\O)@(T[N8XHC1&J"HCH"A@A+$0G!-B4V"6U
M56]AH.;GIXSY\;=/KNW(N$(!JH\63(P2DI5M_&"UQA8AV=K><HG?24_:C@1?
MRR#0"X12&V&9% JB5P9T2)AJT46D;BL /MY9ODV&U2?'@[R.1[.=\6;/0[>[
M'!Y<)O!46 =:DA5KCA4;L5,%XU* I,D"H:X&+>7BNN4ZN):XY21,]M/!X7!\
M1'1N?O#F^5MV%=*0RD?-5[:!!!@2!5+KQ2"!"G-,,==N%<S+"3O"D]E16YPV
M\;F9C473^5FW[(P'-YU-YKGMP&>C1>B7M^5M\5%(%_Y_W;+PC4L_IP@IV@08
M"EMVYVK$;B-/JT6IE\'-S0[M7NML\YO&5=8VC%M8@3GX-JR8)<(X[5DV @L?
M>SHQ%)UDO/7^Z[8@WV8B7XFD$8S,V^A4V;(2O'O11CY[K$5$;S%TV9*RPWJ3
M;4(C?\;LWF@C(@5EJH&J2AOSYBU@*2T0K2EKEXS';C?B-LMU/YZI/4,<<Y*<
M_>E]"ZA.J3PZ:C>R82]O02.Q,G>J75>;.;MX)I &$:CQAX4*&"F!9#2=V> 3
MQ>[TPVT!8>N<UA<CJVY>>$6&EZD-N(I>5-#9^59,&RQV6[OX18/+MIC-962K
M5MAUZQQ:%AK/CY<12 ;5&G("8*H!,M5,HB+CJFYWW35T 0OFVO%P./[SQ>A%
MK?Q"1F_69;)[2")?[,OQJS$67#ST1DZS)Z%():#<]+6L$6(C_J):;8PB.$?=
MQD#6,7%(KDN>SMS,(NE]1;_\<Q:PH^<X^1?-GLY'Y=88"[(J>>/X=-0"\1@%
MM(@*$*7H,IL1%S?.(O7Y,>[681I7V$WKY/]P.OD:^,7'Q/\83PA)548_*F 2
M+MADNC.KWQHC=QJU+)H]YAPU)-^F1.E4V'3S/UH$JW2RN:CN1*8G&[H9E1=S
MMCK$ %$T_J5 !H*4"5S0VN5@;$S=!2F_QN++E5[*QYWTA_RRT[@<K=;YL0:$
M=S90^@F$=_;0&]':*X]"Y,J^@6T%!XEM4FW*+M5%/C;[U*]OT(&"Z<!&F.*5
M\M'P$KK6IVP,Q$8K5BF)K"42]4?*_JF--V[%6ZL1+JXL+IU4]$E_O@O@1O%V
M58*PC ="91MDD+<PJEA!LX39Y*3*_0ZGO05\_&O,:THGT)G:.D!L8[C0CM>L
MU;>8Q'\@54Q_D<]O)$R[8%(XG[*1:TK9Z&0PES8XIS)N-:PV(%!(H$A;YY.V
M%#<^[N^+-44_^;/U* ,L,52L;>IPJ(U/W[;%0,A1EBK1%)>[;>3H?43"CNH7
M971!"B<AV++HS4GL'$8!U67MK0NJ]EN_N(Y(J=IBI/2W_=>310?(T3[E^805
MPH:I$=;9&V19U>HB(6.IRWD:[&85L$J(D(L3I=XR'+"#T,'UWL.Y4,%Q->R=
M=/SX9$0)!8C&E69<])!R95LBDT7/3J&,W9J1ZX!=/GCW.^;,-O_E$&=U/#G8
M!M1:WUC2*H)6V,@DK.)E41D22;Z 4R*SGU:R[(Y78#/IUC6$Q';"EQMC2#E!
MI="*V!Q"T#&SJZ:"T$F'U"=-^\<UXO[#5_N/Q[^K-0=4FK#0?\T;LF,E>T6?
MYH4#[E@@YW@@^5J:#4()LEHB5N!DV2-@51ZDL4!5*QLRD>R/HWG-%74WQ?V[
MJ6@+6B05[((I@<"$FB$:!G6Y%4A:M,::[O#<1JK$UR$N5W$-?E&A_%;QG-!K
M2_:2,]$ET+$VXF16!]%J%JBDDV(Y8U\R]2I++5=6!L-YFP']P2O[Z7T>S@N5
MIY/Q04O/S&<+4/ZBGC3QOJ3)_EN<-&?ORA-L>4Y]!X&$@!1;(P,4E Y,<A(B
M9H0%:1[CDB1B=[GE&\T):?V1$\RS1[R_+WVMIWV^MB6V,J"61H)S&,!X3!!]
M2!#:>-@<*%3=G=]V?0S@C_G?!R>TT-,M=16UZ5?K@%["IF2JBI"$XPV'+D"*
MDO5O,#7:ROI8=!NY^WJ;&2[*PGHH 86I53KAH29IP"BT$*6J[/H5XX)J--+=
M3L2\?3STMQ/QEYRL*FR;@ZN-8,4+8+BFP4==22EVY$)W.??KUVR?-^Q\].94
M@3>DAJ.CK76'BK5TAV)1J#(#YZ2-8!?:%XB$",DP/A-%"Z.ZS7 ^_!,GY3Q-
MPP6LNSAB^NJ.CC*STJ*V*O/I%'O1J6K&NY4WK4DBL V6V&\5VK?LV2?V^!I#
MZ[JH8$1J=$.%]WBKI0J*)4;8Z'2)Q477G>[MOP-\G:-IO:3$6EA#LLZS;V/R
M<H!F5-%@]=7GTEWP_*ODU#Z'I!:LVJLAJ0L$W#>B\)(8B0J"6.3"0W#0F+?!
MDL\NJC:D_#9Z7MO+7W9@N84RB1=-@XLMV5F5;PTJ%82H'DV5Q?KN+/==KFOL
MQE1'DHKW-8%3*H&1EMTD[P,D5W52R;N<NV6D[#DQ<MJY_LGF&#YRLRQ##\L_
MY]-9.R/OD,FO].?#O*#A'8S>O)R,1_QC7ESO,D?K\5$,B7A?L5_SVR%O+V+K
M8D2\DVTVPFN=#%7(Q@0PD=5D*($@F()&1I4,=M>C<9N"C*P?MQ%LTML.-F'P
MSB8;P8K&!RN=A6B"AR14*CEJD6QW=0$[F]VV/MOEJZ@)"Q3#4(9!S2(W4Z&B
MLTHF9?"V-6O<[4;M\P%%O28IL%9;7;*&LJ!+;U17Z$QDI]9Y#"Z15=TBF*\B
M&7"^.6-=.2"=2%'4!JKPS507 S$Z!5@S61+9>]DML?2N>ZFW/$9T#2[S#NB8
MT(:*,5I %*Q7"AOVF#,[2B51-(6"KMT*V$:#F*O?Q;<JY<;1%FLRN2FGUG 4
M'*"7N?$9.X,^1-E?RN0J9#@8K9-J\Z[-CEGYDE_7@%FJ3@9M'$AJK!4U1PB!
M]T+K<A54!6/W[MSI]304W] ,_XI+M?R,7_Y@-I_1]$7]&^%P]O9.%E.R 9"^
M($%P3H#)D>4$,8&T59<8,:+K%L(O&VU?X_N'\]G;\61P=BE/[>Q\.IO@<( C
M/NZXM+:R7*U+JUR^APNY[/&$!F]&"WF;;'8^VSK'4Y,V-H8, EMHVF1V[UWC
MY/"1/%G'=KI;^N*56&@7&<LEPF?U?GK(;5D?)8)20E +D<JV/@JB:2T6T>84
MC795=5N%UTE&]R+;]R=<F[.'WD3?)D4.G1=@2V.:%:$1![.G$[R))$)#I1NO
MP?ILL17K"APTF56(4$+6[->U&6PN9<8HP6! X9WN+E;;H=CNHOPLD\T9+12M
M IC0:!RJ:G7@;">$TE'Y;@=VKM5$KQ6<[/\YF$Z?4G-%ANW(<L"^1\,K3;J>
MOKX]8S.+#]5X#X&D!>/:V%TD#YDM4?%HDW*Q5^FX)B!XH<!T[5GBYHB\'LQ:
M?.;9J S>#<H<AQ\N_]-[RHMFKR5BG32JF,&$,B.6#;LB?G579''HFKK*JS0V
ML4'$$!%,DA42$8%DT^ PA<HRVYL4M25\\>>()M.W@\/=A/77-YI&A\KJW0,C
M2;;.@?$^9MN0BK4JH+8Z=.L*7B@//_GSN0%N+PY7J$_J9C5L+-K[YICK!O%M
M22T&;L O1A+PSI-]ML#UQ#JSHYB*Q\CV4#LHILU%+(GAO0T&I,52E'6>L7YO
M2W=%>?SI_,T+<^>W-:YS'6T#>L.I]+5M]^PL5<\*Q*LVE%HDS2YA*,#"4Y/T
MT2G5+<!>EVNT\@4WFL/HQ@+XX(I+P@+:[,!DER"5%I,+J=;8N@=BMUG0/@@I
MU[@_BU-:^]P:KDIS@ /QLB0!%(,3C%"5P^[,<8_T,UNO#[3&%ZU-!NO:2$R+
M[%]H62!7D2QE(]!TIU@;CCJM(_@KM5K.P[>+I.0R*SP[G#QX\>KF>O0UOG\\
MH3*8/<;)Y*B.)PU%7\U3NJU\R>*QV=-MK*G#_S.?#*9ED#>#VSL(JV$K<<ZU
M@)38YHY% M8G"-5*JI(W JN8WH3STT:X*9:+G[);D([QX3KJ"#9?)[%JN<#X
MX*#56.-PY1J!]1C1+;*XK9/D/=L85-0@(OM'IL@*,58+PBM%IGJC_<;+$FZ'
M$YE2PW]%@:JJC<)J19;4] ,R^&  :#!UZT1^2LD_X4^GLT'>6%:\ ]5>3&I
M!B'%$I>CN$.6"%:H9+,2.=KNT'MO\9L=+5VCDFQY+:#<",:(4DO/!F#LZ+-R
MR1K7+<O<;AKS=M+GM@[_YR,#;S?6.7A30RPTJ+5P>FF#[ $UY)E,87\V6HBJ
ME9%(G8*M2;E^*WR^Q2AO@1(M)2D?2;" 9<%(KSI(NA!H;8NMGG5H?U2=U]N_
M9Z/*"S?Z;WS(N__TET=;T%+/J2S:W=>;>OYX#>SI]8[-Q(==MN2]VGR@:%6N
MC; ^K@WVOIU*KHEI: Q+_%.TR3/@ULI;+5/,&P?<.PMOZAH#%<^/'%, 8T2
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M:JXB&I+"R^X"K)VPJ>U(Q677JN%"!)L#;R",;.N"X!5+LEJ4DNA6EF;?G0J
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M<S^!I2;S+D@6A_ZVKGB_NX793/>CHMNE*SQ[(GHTVNF,0=4;RG93=B?4Q&J
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MM=%RWL@POD37!K![3EGB"!'KW>OVQ5<4 ?A,>!^9;)LOQ,@3144NR-+"MZQ
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M@[,&A/&:=K.)V:#I*]1!*?VR:N\7\,%EX&=S.G @'7;D,.BE"B):%EJQ[WK
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MV^S_]7[^W5F*'\(<;E[0*@?)_YR6L6O6<6M<[$F4):#@1*@SO#C\\G(=^JE
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M)A86F<9JLUYA:II8S,1.&IM(BQ5<X8;T]!@\#C?!@8?!5[D.+*E"B-W2V$J
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M:$#K'5$W>"A#:P [*O7'N'8<:V!\%4,HP>EPUP\%]T"%3 R^P-ERAIZQ08Y
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MZ#[<;@_#%7Z=:WTF;[YL].2YE5M"NP VO!'<18?[YR@71*=-W@N$Y$JU9X'
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M8-NH]-!IOF$-IIH4X:K80PI2L1B=WJJ<B<IJ4VFL9';I;NP8>36?Z\*)/#6
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M414EFI-R/ ]"V*MHMG8Z-C:ZXFX<X$G@&N[TX<-^0P%$3,FM2&Y^-:OW(KF
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M!C2R*OON+7-;YPC(\2* 2_%T? @66$"N@4(43",>(R)#^@PHL<Y-OM/YW?-
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MK'+A2=BO7X)G,$.W-+/_[^NB)O_R/&HJ[L(?M622M6"GY"3TEZ27#GTME\:
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M+<IK=Z(QOG[U1E$*[S#7'0VW[8Y6O:5TUH,6QM>\C2WW7CA72?<ISD0 A-P
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M6R$O6=LX*CF>F&D;-#G&5(VV!N[M<RE]J]EQ#S/&>,P3<?>L?0(=E-S<YC!
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M.J%($Z+#S<R<91+))^R_4%B,X)TER9<FFR:#=CHH];@=D$Z*1K#IR)O!Q07
M7XZA@DYPS<KS9YN*5N:(;D+KT7M?%;D7]/3WXU!8#X-U[VOK1ZMJZT=]K81[
M1UXKX=YZU-:_:H:^KT["33GR;J1D_HS-H@012K"(5&7W:)I?DB-:XU(S'UF(
M:CI'XXR.=5_-N7LRVR/8%(@5V1ZM8CE#6:? "880)JW..5@,@RB^0.I4#IT@
M0086=S6>PB)X(*?;0X3-!LZG82_G<K-T7$9EFCADVYV]@6M9]TWK'O1ZUQSK
MFY8:/^;%Y"/Z"!L1D4(E,6*HX%,X5_/"J.=42R\+Y2_K7DDI/4&7C4$LNE*:
M>"',*FI1C*%)C716K2Z,J;A36,2Z;JVKZ:UE(;'*D$SP1F,6-#]#RXO*Y.>H
M= _EWTAY@ /U3QD+Z7(&Q6PF78(]WJ4FE72,J?K5[>%Q8V"[!J/='JVGX6*&
M!R>- KP"[VY;P2ON.RG/T[Q@-MO@I^#5VP\#U&#]CJ_;UEI?=80-HNN#AM"@
M(;2\+I_GY_!5C/VUI6RI7W=V4]AF]/$DI^T)T.1EDG$589#1&K; 1FR!5RAV
MC*.2?+A22&^K%+6520)'8^*776A9MPLW4O;*TH] 4+(G5&/##"M^6/%KO.)/
MU2N?6"JVCXEFK$UY#1!>\KM[2VH>2]N72,$-&)U!(>R[@V[\>DE,$B3Y15HI
MMP]H=209A_"8P_$BR.E*'IMCAUNGW;\9C8N+]>5/_ZL)VPVV#3?5ROV.5D>P
M\Z,IC;V32A:S(T5S7@E:<@M^CO*XFD2B0W?:TL+JP "'?O5[L5S^]L]?3 #F
M='P,R ?H&[(@<RD^]]6?E[L%%H;NM4S^TZ3H,T+ 1W,/%B.O0AUJCEOHU_@7
M)NYC/C!3W?9OFOB!8Y3[;@47>]?6A@V G2L .WL#8&< [-Q&DXB'J_%)UZ1F
M(L44 \\QS;V=VHPVF#D[QU4%3GMQH]ED41<?'=RT+M/I-%ERW5B]AN;P/#12
M;[EAS1(LK>B")!6;3,BGH>T3[5^_<=DHQXQ[)-BJDD)_XB?I5'3ZI.,ZUUZ8
MDLXXS5T)A]NKM'BI@!>!-<FO;&8NY)1YG40S[N"32E,LSR:HUSK-&S+,C"NB
MI1'S2)G,8D[36INV:R093/K0U(\RWPEI"W)V(4;WPN"OAS&Z[V"<W>T58!SS
MAS889]<'XQSMK@489R"Z&% [7Q4;:>"GYQU.!",#?E%DRG3[]MT'WS_?,&#&
M5G!LPEOO_%YHZW4R-XP'EN91\*1X:.%:E@=/Z#I\WK->5UK$[2/(4DW0UY!+
M27,;P#!5TUG6%/03+)'-],N-N*^]$L',JBG+8HISC$G 6 >V%1FI1P!NB I#
MYYR-4'.>@703+L<LH8@*0)'"8\WL/)EW49Z(.,%!S5S7<%#TAZW@69+,/8_"
ME?.L-FSR^3P="QK)7<2_O&!!%)"D05J97"11EK :1YS&BD5A]\0/#='U"DAU
M&[]\TH+L1O1?BRK%5QU-A^H EMPL0LLT\6XII)_*F&OA*<#\"K\G4F2%Y5XW
MS26!4<*F(?%;H.<OG6*Q:4B7;PHGN!L.)KBHE?";YB"7GA;E)2,[A6\F-3.?
MTJ"R6Q8F&8 FWU;&D.4$+56>#^CO6?38G33N3X@'/K&^(-*Z6$3&2#MF.A.?
MN#:[)0MG66QYL='%5W+U2:Z7>]00@LR;TF&LC/)BW+(HWM:'[6$5^.FY]P1;
MP;LETX&_XM.>";%;4Z;#;QI?FAK7@A7\CF'R]O\SB;L0M+"]M1.SM2LI1+G#
M[1J;VN'Y7$>^J6EA7(9.V!HSZ9%KO;J4%D=4FE?(+T/Y;C*:H#\C.J0$98;I
M?O56& /.1/2!86L4F.%0<6.ISMFJ&@IQ?K4K+[>EXLMX$:UH5QOJ1'Z *W2P
MER#RGM/I4Q?E0B^T])#<,#(6#F;+#7#%*#8A*!M,6#^CABX196P!\0QJ!U:*
MU<_%^GP443OD;^8Q&ZIK1?A]_4N]P;[M)XHR6HGQPMM[%D6D20O)1'@<%GXR
M0QMA+^B=*$>(MCMAPZ6Y):3:B(4\U+^N6?_:_;'C4QX;GQ+6?1G8\$9-H9C4
M@9_Y?BR/O_WSK6KPL(EK!<:&*$AP6[:QG7.B?#R?)QE:7EJ-FL9%(&^?3 8<
M,FF$%S(M!S1G/\83*E D.L@$1&U]"0D?+N%J%#<?S:!*TM>86?JX>1/**I&P
M!ZAO/9YVIESZ,-9$>^VFK#V2.,]*K:I\P8<?X'R05+<P1'3;"! O394+V;3+
M",U78N#\:)1I<N5,8E'MY>JA*$B8;DTK$HZB8\SR)1-MBW$NH&E,P*&@KM+(
M,2LXV2:-VG"J\-0+JQL8HHJ!Y6@CS<#*4V+O1VOXGQGUG3L$5 UF_JOA4\#?
M1DOF"=4JIIJ<D,%+\E!Y^F-ZI'IA6^KBM"J;N?:,F-R0^K"&?Z;RBWBPMF]L
MV*C7@[T!&"+-)UE#ITH%.2@G%A7ZM#IDV*KT[>MCL,0:=A8^&ZP&%!)E15E7
MAL\EMUP#?JXADAZII3B.#H.,*0"$;3^D@4W.89Q!!IL;FCOKK\^D*-@1#O!H
M8))1\CFMV&9/SI,9GR2SJ,9Y(RUFE?72/^9(0^#K.6<2&+GA#B/OX%$.E^X%
MF?4'#TQ#H9G0A$6E!]O],+_?(>9C?\!\W'Z9]7LS^S"I(^NN<@^NM!]Q?K-$
M\J R1A*.*,;,&<!2&K]!%NSR?T53TX<2#1:,@]#''\8WN(0=['Y8J<UU$F\&
MR\Y']#H08 YTE_>&[G)P\;_6J+ULIP",MQK!T54R2K+F,Q14++:Y6N3D2B)#
M4- 3%GDSR9*"]1]^#!ZD#]DEK[A4V_W[$S;Q#U+ZD/'4NPR5P,0I&[,3R\SH
MSV7$\E_R/8X).(]=16>)XJA-ZRPS@"@/YP5P""O'HW*Q:4GN\XMGQR.^(<I=
M8J2T[/=;GB+M\JYF6FS4"G]]_>;X_?NWOY*3<;C_)'A AV5:I664/S0D6P(5
M,*QFXX4\5Y%ET;C@:E%(P42^R*)[*SLUX.]N 7^WLPI_M].#O]L_VG?XN[W=
MO>\3?S>P8:TWKNZ79'(>Y6G%"H-B=S5ES-W@R@[5256O,;)N \6A3J$Z9%/Z
M<=$ K !L'JW@.* WPLC[N.)_B18$XSXL6;5A9H[325):)F;A%OZLPB1QPRW]
M?'H+J72"N-"6+AAD G$%J<J,JF:,DK7% .K5)-M(5\'^:B9\5F<*G+$? 03F
M]-V).8RG32HP-3> PL]#SO P.3H.S+/.^!\&S"-N@JS-N.%G:O)/=/_*=B)X
M3H9,'"U=>$U5,!9H2L$CD@PA4S57=$%^O0950_'T!3DMG1RI/!.+V9<+'I<=
M5JA( U%%E;_%F,O8U?]1N,$D>2Y>^_HZO5O!@^.'>? 3.5'9(B+#M5 -\0%<
MMW9F]^O\/%WY$33FTX@1N.SBDK_!O&A83P7O@#2D'6&,LB# V//69>>6++.U
MQ<A,8TW)>A*O'HW7FI57!C5:<FD9X+-5,0*W&A9E'B/%A-Y#&9VE6]=!ZE9/
MW7@TO=W^I8E::)%G16I*I)H!!RD_!RR5Z-6YZ,4W1@);J<5,<6;<H\ OY$D#
M?E3O.54@3[96J\#K\Y2TV.BV@C=-635*G=X."LR>I87.AB2:EDGBFJ0T7F"P
MHT!XZ%9S<U*:+^FG'"FPF"V/_Q %8!#DD\EHYOCJ&88A]=@>D@F?DT*Q0/C2
MA].WH]W=G<=\N5=//P#!*$7_2H'>=5KC)9NS 4OBQ'_6,/C9/"@]],L2<W)L
M'KFRIX@4P\E^3\IT[A>1KC%Q&Q%;#<;JKU#.R?*V.#K.4<N^%JPO[?^!?6X@
M(AJ(B);7Y8E/^:[>+5,3P\>F$4[/.S;6/X8&EJUA<:_SXG[&05;07\MTZ6(N
M4<+%8(1T,2/_3WLMAO4]K.^U7M_ %U7GZ.$[.QMI5")6W&BN(X1JI', W >!
MQWWP_-W)?_M!021$ZTJ1G:)"T>I'E/! TW-:EDELO'8>=75U&:HD38Z2;6!5
MJJ1!W 6_]_,-D]=]A]B?@P'[\R7Y^L%P#X;[[B?O;_]\;GNU:]MH:"H?-C&=
M <.O[>HOH^SU\<0WUH-K,JSP=5[A+(*&_*[Z(;:P!]1&%E72A/(I23Z*/!I=
M[9P3C-Q_LI*R?,B>7?,%V-PL4"BNY5W,R7+2;".RI .P<N O_N[0>:99VW3^
MH:U&0&7HCY$F#G4<*!A4)@C.9BS5<2I3-A'7PE-)IO]>YF6P0,"8PTQ! U;-
M>-+449YPAWK(13,068CN-4 #BI@;9T41HQ .<CON(H?$DW%\Z.-QPL,P-?_S
M9$X1YV2!&R-H59>G:J91J4]J.&VX)XG9%^1! %L(76E?])8GM8!'&'.P5)?K
M8$FV@G?@>=!YU.<^:TJ.>.TTN^MYX78;&^_3<5P>_-(M6=O@UTE=C.DNN]L[
MAZZNYY*NAHW$Y%Q1YQ,H9"+, MI_C_%9]S!TI!G3(F*>5YIM>HW2'FK)YK7W
MLM.H:F>K:LJ+]()Y@QC,4' 1>)9.RF*,"-^RR3:(DV?TL$UYJV0\0\7MEDU-
M"X?[ZND'<$-4+-(+0@>HB,=-8B*4-J!$"+ALP=L)E5?'4ZL[V]H>IHV-N_=H
MS;[7G=PEK4@,$:>@=1E]1(/,:\DX=3XC=4% :5A3C>O23^WMC/S@$AB&OMA^
M MZ,AB">_@&9'H;9R.U\KBN=)+%KED3(B=S1L%^(,8&(&E^X-=&./E0K]:K?
MSIO8*K(98E5;]Y2$G''AJE [)*4+T;1$FFFM>J954]UD 4(5>@?94,,>.0T@
MC;.%T5+LD8XW5?]-V.Z#ZWB]GIQG<B@O @O)'-S(-7O=7[=+Q-EH<N<S=C%0
MIDDY7^W' 11&KD',!@(?2S,:P/*E1#$=[>%SLA>):2,Q+HPS4XW1\DQ+E",\
M#V8CK,K@1/00^.6N9T?87@Q5 +>_DUL 5_.LR42O2Z, <_ 5GDM?,3D \V#^
MT3#/ITN0>HP$$B%(=SR7L"1R@,M15' +)LD<I:P4''RT\"KNW#<. (!^M5#Q
MP:VFF]*1[L4B'<6]9EY''[F:EL']#_X#&)]0%-@,5S><V0I.9_.BI*"IYHA)
M!SBRSQ5[<<LX\0*C5B9XO&@%7W2;/PR5^BSZR(>^!FJE80K,E*8 C'KS;'VU
M:88ZWQ5UOD=#G>_V6[EZ7<#MO8VPU3?C7+WQPK/G-N"!"7KOI2].N79/YLC@
M#_"A7\_.1D+Q%AP;A(TM:0T^Y)HMEZ\\VI%(1 3=Z$NG$ '<7A275MP*?.8@
MX?SB)92G7Y\U-2)&'VU/,3!"3I/+;,/;A15(F'D<E:#PH3GO @1#L@+]A)Q7
M<4*+P);?+BP)SR;_% G5-%J<E9^7F:QS<Q'.CDD[0F1ZG9R/T9O^DPR'L* ;
M?MCJG,[]$;*.69%/1TB2T8T^LS+35O#^\GRB7)"G D!,SF?"/6@2FXQ!Y0S9
M.-NSI+-NKY$RA9!+[W$?5B(,'K:S(O(V+-8=.R-T=W2 I>C$,NE>0UK.:9"Z
MDMOY&=!^LN0QO>%/6];]KS@#S$DE#A1<C##/(J>$'+G$JVO7#K1M) JFV8*6
MOOR)UEXT26.>@I?<H):KZ\2SI%EODUN)+ HJT4<803_6/L<6KM%*.3L?5A[/
M)8*[,R"SIE-LC.?2)/-(I*-,4C]VB2_=F3<0YWD<G9/W=]-_(B+2^H@:F=&]
MP (E$]8!>Y%/BFNG,[D>^;U"\*?DTW8UMI^OL[I9.LRPV"^CN_ .L5<_TUUJ
M>*%GY(R.SLB$0V4 +C>S7'6_U@LDD\S4F;)FVW@A+E#54(FSB#<9_2UNRLCK
M$D$JS;P9]..!&EIU!J*+HN1@5RD$:+1G]+&MH%4^K2U!@(U2V&&4%A2R_S1V
MME_=21[\[:]K<=]=U>*^V]?BOK/G2<P\?KP6+>Y?YS@.$C/]K?";Z81_77/K
MK[GQHV'Z+W.KU[C%_!LVP'_QI'MV<0UG;F5J7A*T[##U>(MTO"7&<QNC*YU=
M0_;C1#>%-4B9IE@Z>$$*.3D/?:UC]*Q75F7"E<=*TU9N,K[V<&URSC&!.![^
M)=AV'HB,#!3+'QH>R@+< G#W/"4'A8<YC[O/"34^L'VB2%O<36]2)(]A"Y+D
M+[#8CVF.]YZ.OV<;[!_ )IA1\I]^\B@ RG1<^([E$VG<_VGI#ZL)"#:S:7[(
MD73I;[^L8WG]^<\VCLIN[R#<VPGW=K]A?JCUPKVW*_;KY;M_W<N)OMUHI&^>
M=[=WMX,5D_U%<SWDZI:, 87W_P.(!^98D2RU ]N!3.&,X8(72R0*2V^ TRHX
M7OE]T2_<6PJA?&6I+)3V3LD75,/.XM@D:U(E40F_P^3]8$6AQY"4$W)/4$VV
M>!>CN*M@GXYHL(H-S,\76?0YY72?A3ERFH]+SN^.W[X;G10?1KL"$!2%)0'=
MX$-5</+KA]-GHYVC9?R>IEV*LL@C_IXA"VQ/&"N?3/B&JJ2GSV:'Z3^?EY@H
M$T\LOGU-.P>TDCC/@,^RGDXT \/BSD.?]-PUD?B/>XW'L6_V6#%8(.W'/9X$
M#W8?!A?11-E/_O(-/LBES/7ERP_V'KHG'4<Z@RQNE*!!(FGKBFB73$MAPU5Q
MF1Z*Q0)MFSK]L0 B$2OO:P?^PH&>7HKJ4F4>0A:#@F[]]V%>VO*\BA9944,?
M91:-@P=8VZGD5I%R.GR\QZ\V-C_M;@TXA*\S@"^*MOHH,]PLR/H@DTN/Q<OI
M>%ZFF=I(DRYFL7+/@.4"BU9).6/!A,7+W^@2O[CW/VOJAI>77LS_\#R+C")X
M515D&9BPJ(FM2EZ" H=AZ6KM?EF^;HF!WK3BF(MSYG\49.#I;21)J='(+*WI
M)U[0__/N9"MXUI1.V(ZG)W0\*2$P!G\D IZVSXS+5\&TE*H)_>7WYM]I\#1%
MEA,;0D9CE0PBYS$9P3V5M6M_KSWGG](LLZ1&%JGA)KR'AP*03QVK09%Z<$GN
M_I?QNMW/^QH?[]GV!GG:-21#&G=#81.' VSB&\ FOK>3Q<-!3XU+T!% @PGO
MR,YTSXL>?Z5MI7K=S]]%7H&.+9K"E#5?&?6>HHAE'.8E_Y-+5"P$DS=H^9 3
MP#NQSE;X@:$JJY;F'#0E3>/UK#@!?=L;&3_25(4[ON 6AQ0,ZK_LH9:=Z&N,
M/WA !TDR[YWM*LK$]5X^.I1$KN^H@ZHLLQF6P<EYFD</Y1!#%K1$>^^T-?UA
M=\I[HX&>!^G,D:48O8EK7^K2_JZ)+7HE(LRMDL(T$X!.N!OP:XHJN@S>DA%5
M\CPF!G"XNY.C0UM;KL3>#<[]A7$=\(NN@R0/#17BY*/4P<?J@DVE:V$A]>4+
MI>]9$4(IMV-J.D.D,<4-K)?AG3GD!&&*[';T![+@4?F1_#/TBED72?@71T53
M.RI*#K?-)++P,,K7K<>;4 Q3=5\@_U)?H_D7&/#0]W+)-NBE0C1/KXU@#3PQ
MZ8<YW-TZ^(%K2 T[5947:2_MA##8/5S]<;.OW:<QY,[#XYZTB,03IFGHN4Z?
M06U?$U_DVGRM?N+82CKKZZNB&:U6/#SPMF?^*+ASTE^9D4^DP%6/,UJ#](SM
M]^%]2%8I(HA.>J1C'1Y$E6T;%+K*,:M.9\6GA[PL=/!1Z=Z#O#S,ARFF8,UC
MEE8.QX[966>S*CI?TNLOFSAY(MD+ESU2:*?1#;UG34@LW'+EHZPJ=/F;A8M(
M).Z\?('*V*7<V1(1'=XH"MFC#8<JA2AD:5'$8F+0I6<SZ*."+$6!R_"Z6/T2
MWU%8U<""TLBA?1Y5_BH5&+44D=Q#7#+.Y0%%HC9GI264,IO",56()A^#:UCT
MOT/ _]5*A2R?W6,%1V/0</3\ 4FGE):X=QX9]!$TJ/BU</ ;HDG G0=S!-F\
MSEKG,3BRYI OX5@<MFI2C,BX<0FR&-,<"F;+,89K!Q_?>18M^#;X'ILL3G@F
MJ7P$:=;$JM&S3]#D*;L=$K=CX6''3;CE^#II"C8>9G1V,_=,$QM4'JX>=:SO
M6S'\#.LZ+\" #/NC65<S:'XN+Z' V8RDG-E&]+Z,LI\3<*>GL?[,\5M4#/NB
M,YW[,K"%$-#WO^/E P*_DERU?R_Z8K)\2/..[I\:<9A>F&Q-_]VCRF7&(YT1
M,U<5OVLSJ;K0NH<\GE"^-H?&KLZB?1/\E[)81)DTH;#*KO-M/10MW+058ZP#
M 4/:'*SI"S=-O#R!M3+3^W-TZ;K!A?F5LWE;&K6;!KZ$V6AP(<Z3^MSDMUK?
M46"PB'/B-[+P _37>,X0K3E#!,W% T!FSRZ9VLEYP4A"/GGM5TT0]@F^(R25
MJ]KDPLP1O6*__,K@R.Y! #O4_9TQ09;0&S:#_C8K!(?!F3V[!I>^W>>\AGK2
MV7(,7YC/VE1AQ/.D9*ID(?_>W?Y!WBNYUUG5&ROUW7S+N05&![ ;?-"['!?%
M1W'\>$URAJWZNKC"KQ)=LN4<571?I/#E[O[UT4*[!P>A^?^=;WKX,=#&J^DY
M#Z=JT)V> &PC+ X,LI;CQZ6_4603@HART5,"_)))N*-J9W?)KCI>$!C@G.S4
M0ZL:[/YTS%(0U^+=I_7B5PEZZYTLI1X'C\)'NX_"[=U#.;?8  N]/^O-RRWH
M>R^SZ#/]-\W<//B9)IT6HD#77_X<LMTX.TLSU 08$8X"+")8Y$= 90*WG8]%
M^N-_[1W^7_;>O+EM8TL?_BJLF<R,705IM-BQ/:F:*ME);-_$L5_+<:9^_X%D
M4\(U"?!BD<Q\^O=LO:+!39)%RKA5,Y%) NAN=)_U.<\Y?'::B-D)HX9A4Z6D
MF0A?U()B_W#R%-9U ,LY=3M\]#;GIL<NMLE8)G+S%]P_7)'22EG$11B9=O0^
M*\*SB_K%WA15EX$+;AF*.]MLSG,)83;&Y0@4)WZ$52^>DDVH<L6Q- \'O[@&
MG3:1C39!DR[+I<-';#U$YH[2RK2VR?*JF%Y1KS[YQ+&%Z10T.;),H#3& B.0
MW!BNMUDQUW1N)8,ZEK4K2,1&1-5*V<FBB86X%W#^_I1&M<//:J1F3+-T<IP,
M7BH,ULT&YX=GAS8R25Z9A%9*Q5$GM-#9YDNXFTEB^KBPK2KM*/0>C^Q^+?'/
M0=)?_H;+;L(KH(EH#!YUB_=4*OKB&,,TS6;QP,U#V9G?9?YL?XEG;A$'>#SX
MY>N<>\WAX?% @?>ZN?OZX5N5P^_2A8C@$)(HPO,X$)ZN*QM'Z"C:.-WAI$)D
M:QC](+ >(FLJ!3<EH]D'V!FS84W@XNQLN JTB.1Z/F:1;:')M%'YW^E 8"AR
MC[?F<Y..)5P,J0FJ4'SR_ 16:(K%R93I" -+Y(1782J"T7V$LH&E<QL"RNK^
MEVF_O"17R&W#1@T%G6(I')T,=Y/!&K?GP)Z,\9:5[*J'$#PC&98,YB<#*-0-
MRIC)C=ZGRYF9JP94O 1_Z(VYP^-X"&\+M(OMF]&M$H4:$6:G"3G!2'1!LN?Z
M\P_ZIVPGN :U [RTHY695(>#/PVX*[(#=!)I"V0M^J)A$XBM-JU9%BXCECG
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MK1^(+U,R>#1\'+'J/83K!L8\<K(8.AQ_'XE]-L?34\G4->&Q'JZN]U[7'0@
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M>?*YK04EEJS?H5\T&$BT0O">PCN[14)[23E:'BAS;TMJ?V?YKR(:O],]<:T
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M3SU](2??],&7(,H'&'7PGDQ693.DIP?CZAB*20YVV]R5== )E^28D4[1BJ+
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MVQ#25<D;RCC=U&M<^'PC09XSS9=E?E:E/"ULI7M=:$8.B88_0W(\;+\5&9G
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MU)[TM67):,/D;06( 7D,=173;"QH&3/=1.KZL#0GO&ZD4ED::K+!$;%*@9K
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M5"8WHL.@WU./Q-E3),[S'HG3<WK=^K8*Q+'?T P,K8NBSG0E>9BM2<'*PMX
MV+>3Z#@DI$6X6M6E:\F&+[%OEVX=E/H$CZ2O1Z#UJDQ+R4_%3%VDG].OC-+I
MEM4DY8R30-Y^-9A2W[!J;;-:7Z]3 JEK]:'A7R]ZH^]&N*]6TL\$*I 4:?ML
M6 Q-[D=R7#2YEQPEPLO!!_VS$#*^MI[^M'&VDIST[BF" ?3#DZ>'I\^?'$L8
M!VFBZ *=Q^7N&P-P!$OA%B6X1C%%:Y%?%SJU\K7$@L@3OTQ+%7VJCD2>'J'5
M3>'X<;J0_D=^K&4L9%:KUY)79_EO=)1?K%:+?N*H322<HWELN2749KXS14+
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M-L,1C$EKBJZR6LK9UNIWXG98'0AS]UR5!YR(,IDIJ@HC%")B_\H4W38W/<4
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M\G^)<MMK68QUA)H@H*!&I67Q-9M1WX?!#Z<_GC@5?*871_2!-,TZ_:(.BO(
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M<[=\G"*L)13<NF]6J.CM7F7CABI58/\9EC8L?8NT*=,E";H9'FZKZ*!38N*
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M!W%Q7<#1Y6 15MA4\P9%%:5&2YRQ#<6)'0I7:D<0KN+P'AX@[Y2;7=3;H+>
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MQI+/"WBE^A($0Q08/^QV#2GJEM6,SZ("*[@97M2?X_X<[_8Y+M4\M25;RRW
M00Y7<J3$6H%T(O_X^8S^^_+W,\JN6T<+_CDA-AW/O4N13SF[*FK$Y/N"H3\R
M_9'9Z2-3P;:ON&IJ$6[KG,[*V?@JJ_#;5\8&9",Q&61N>6._U?NMOM-;'>PE
MA?7,&4/.W;@Y&FQ@POUX-!BGBTH7!99JI+)Y+6?A#]0;I!10DV M?:NY]83
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MR.&LYCH/O.@:80CV*&$00R29"-\P;RV"'C85,>J9;7C\03>7YR-X>T83P]/
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M D<6MKHO9Q^=/,H(I_.,6/S6Q[@RH+]'QNQ<A$CR!CG?X*Y>NU+=G:AM@B"
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MB^U0E'@?J?X?VRVBUZ\!K_LZU?,.!8E[]K9_*4NX?\^GBUV>=6*<$ PEOS*
M@$] +Z=PZ2U56R<2+Q8[LR5_$J%.NUDH_'E57AO.Z.3Q8])0 P<>PM%>$R$8
M^,\U ^DS-%1)56,CS2-O\3/7^;,SO?6Z28"E<B9J& -XUJ+I6&31\K3Q96P$
M?I0BZ,E;3DRFX-& 8[S9TOA/SI%1.H!&Y8K!AM#H%^OREJ?CH(=W/+:UP \R
MH*6*""A["@X':<I1K.V(:<P'3EA+7$==7$B#Z\N:8Z2)1:0<:W;("*B \N52
M@!$&]UWGCGF],#E49+F1NGZICL/Z9G2:[1E*$DDB2]N-G)!+T*D6C#ZYIK0
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MCV@6LA%-NMC'LQ]K>1,Q-YP25M)&,X2B4/78[X9LC20/9:K&GI:229RGVHS
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M=$*!PH< .$OFHT=3<"?,FJ7^HVF7DF- L$0O /^!K\L]FLU&!4H81,HE2KD
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MO%Z65A&JVBZQ/]Q&<WOJFL#SY ]25L+P4^LE+9V6LS_A:2-4!-%7K?U^0'K
M,0WK7(C/RU*R_3?&"*+WB7U!! 6B\ )J+"T5X,E5RL^+M4NC*9\^ZNV$DZ/>
M=5^J>D'$0+P +.+KE N[*+8 \[.>:I[REY*ZX@^U\F T8^8[2[O/N<1< VU
M,+,#.I.\DUB5I-302_[.>E&1 [6H-&K-8A:-.3UKE8KD$?&2,HH09&BX.=?X
MRDCF)08-,\6&=]>\6BT'D8'\#G5IO!#4/3.:>INESCW8B^_.3L,#[(3D"2H
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M8LLPC10(Y'1)GD$O>Q.I:TU291ZN0:K3!&]/&:7*X;C/;R3@_.FRG"!)H-.
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MD759\: ?$- OFZ1L[0!_"J4>8*BUA-H-3C?C?1RJ9.]3R+8Y%-)5B])Y\H_
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M"\/*/2:T+G"JLP@XBI/Z:@^A/22T#-]\U67)#3F>+"\GSC(^;H ]"#<5_W>
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M7VB7O[X*\D-8-$E3WN48LG Y*T:\B9;QH>[]'I1UWCQ,FL_"XUX*%*:.8N;
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MSO6=Q)BM\U!8P$!5E5+3N;MJ!SH(Z29>?/F5;G#Y[Z=?XAT]RUDOOS?-LO"
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M6]?\W559]^TNO'GT#YRGZ&M="=.FSP?82O)^5;IK[QW1GU\7/1]!B.$&0P6
M($[@=SI.P'97KKL6?OUL4LMTZ1@[J5Y,#%GB^N^.Q*#FX-1(46Y^F4"RB89H
M"B$4:4JA(1'E@_T>//M=O2:#VG:'/DG&3^FM9I=G=GGNN<OSV SF%$]M65W5
MNROF&4!JVUT>-7@Y )=_Y<1&M6V@PRVK==_DN*Y6=YW?XB"X1(B2-$6QDX-Q
M.@P66@Y89%9PS^^6^YI]D _O@_P:$SH9M&ZI]9,E^]3JCF=\RP35=!7?GSC^
MM$](#B<@?$/9D]OA'2)!,T<*K&C "3*T#G4?[^ PD4>2BI FLL3U-=H%!?K
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M]MY*D6 RAR%?B8P&M/!G[1HJ?8?RJNY2;X+MPRVZ7=>%J*SQTK303/VB))P
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MX9@7_[SX[]SBE_J&G0QLC!L4'_R'ZJ;SRWI>U_.ZOA_KV@>+KKKH NT:L2C
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M4RF*0UP"W#*H'\9/7_MAI+D)\OOXP<0;FNR=OY__HXW*A0]$S&2$&$.M*R@
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MT2[5&3QQQ>58<O2$F[X<:DAH5B&K3YV^$6S0QH^7D1+6MS=V(AWI?]5J-2#
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M!R=(UVK \MDX!FB$\/VR9<,>_"T*MJ4C+3*-2'\\T"]J<E>9WCD<U7B&OWV
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M@5UVQQGO7 9VXFME83.TMU4.*4/4^ [HE4,[G6BV9$.=R <%+#<"[$M'F$9
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M7X_?R*L4X&,)+2[?88#3%5%G)Y)_I3(U154A9['=];:%#08WUC4(,$;]Y'(
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MPJTO*RA:'U%GJMHMH: 3J%GA*8B%)XA@MUUHHD#K059X8J'[T)1" H!S!W5
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M75B&-G'OLKH,:H!9>NZBN6+M3W9'9.@("DCW6]@#GR22[^?6OIN[^ $,QUU
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M@YHEI20X!F MLT>@27+>*@G=D1+KNNS+V^0KRX-5TI!"7APZH$6%T,*N%^^
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M1:G\.AI5&S(#L(:N[@@8"_%&3!8KC.!V>"E(A)*1/8\>W 6J5\%^[9'^&I?
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MQ)T35Z39@0",?#G?GH>9]9GP@5]AZ7X[LX8A*[4W+)8H*$(.W :&IZ3>_[4
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MT>U,;F+#7?;%>2 )Z/U%O-'P.KYM2$E[ZA_K*H% R-V%B>E(1]=9KNA:MMM
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M<^*:V[7/'W? +M'F4(=I;N=26)HFOP\8M,U!?Q=A:Y4L'PS&KKF=8U4.M(<
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MF[\"E )*JWW/&I(R;M3719:N)%SR>U(=E$^W6@<552B"'@3OGVB(EOFS(DD
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MMC #K5=B5:G&IE((OK "S+[.\F#DHF(15:GF$ABTF1Y),N(BX98/"1-R@*&
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MJ$Q8A57J<'C*]/Z?8ZFAR0<1IG25PCRT5KC$V-X10!1NG..P&U8O#/*@V;4
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M(F>15BFYE)I;F: #&NYC(J&&4^;)'+Z-ID5>MAFXLIVBHQM'-XVFFZIOL%$
M.7EA,TJ\+8WAZUT7KZAW+UMX8-6$@/<X4G&DTFA2*1T-9#'98J7T5ZZMCB:$
MW2JOZ764T!U1AV:B*LMJLIMA<5F:(P='#@TF!UW 'V-;MUWZ5I7#2L/JM=/
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M\O&!QTRRC"@@5V177,4;N:: 0ULR=$+?X7/C\1DGS/"0;8Q(5-HKS3FBX2N
M-G,*1IG1*PZO'5XW'J^M29P:;3G^Q7-N.2!V/;W68;7#ZL<'WB96AVG92+!$
M<%VAZ##987+C,3G,TA4.U:.Q<%A_3#/3=/M4"F=;K-MAM,/H1F.TE0>B4S<P
M-X43 ?6\;>Z'\5<AE<XEM+,9,77+53$Y/&\ZGM<R]RH&;6G5^$5-K^;,+6IY
M?E2L'(8[#&\\AE.K(YU.3@5WL\T*O*V9GPZW'6XW'K=IJ#H9D-?IXN,*Y!Q:
MMP*MRTH;SMHGQ9MF6%1C@+:EZM]M*/M;[S?WD6=B^-Z/5'+!2?%G(:!@I')4
M&L^W-K]VK>=:F?6MS&G/K=,6M=.^HB/6[EXB&PU!J+LU#C*+L+*(YX+6IEO7
MWSHKDD"7.E@EL-;E6VII^9O:^],BQSX^Q$>D4MJHURWA:F7I<HY=N 3\Q7JC
M""A,3)U0K.L56$ZX<$Z-?\"N0AWO_6Y06].I;MBVY3Z+-J[5=MM5;=Q)>?*-
M*/EFE<JFC'!7H;+V^THS4)$F]^II4?AY>)WF/_Y&.6I9P5=>49;YOO[]K%0$
MKJKDXP(HRN"485D"!0=X03<82N,RNUBE=JT==WFA^K+*(5@UOE0JQ=I[V!ZU
MITC+]M0"ZRQUY1B2&BS0YC0&\A;Y6ETOB 'YAAU5_D6]=O&E)/ZJL>7&2JA/
M /R?RGTWFFA095X12S/VD!Y/'$A7&WQ\_4KSB[*>M1J J+MRB 2/(X[("XIG
MY''U(;%6@!D?E_S"G-&WP5<Q4+L% A9*4],#LQCKU'=*"*[,W,+66U&'YC31
M*QN3EW+U#<K5/XQ<?0TR$2R#MV5YO9L]W#0$V+.'^@Y%2O*!5_T42GVGY%I8
M@2J4F?&KI4&] 8.9QN*]%]A<Y;^Q[ASX,=4UXBA#514TXA/_*E+D;MS$ %5>
M5%9SKBOFH87(7FL]@!VYWX9JWM+$9M!AWR8@8YR1V;13WH^FRU.-Z%1KA!N9
M[_0TA%1W21%JX=._1/G !KBN/PEM%N"$_$%0_3O2[)CDO6=ZL,MS'^YR$PZ:
M=N)[NIGHA#7Y/Y/E">-\$YL;S&D6/5)YG*IRE"\:G;!'/4\E6&.W_D2)0)L)
MNF'')?&_T^=B65K(:RP'"][V"=8X%W^(+SZB9(>&A9:?.8YS$!SG/38!4J9A
ML>8\G\07Z<R(IAWX?G12/V#->'(\8,-O:K-32!$QUQ@=)(2_51X%.O&%>5 U
MNON.5/YOL6SRQ)5-/M*LP.[QY.1X,C#_]=O  6[.26FTBVD\]JZDV$?D[7<E
MN;?Q\6_C3+=Z!]$/G46*%;?_DQBH>)U@I?L/,I!483'H^5Z_V^\1$X=?NM^0
M@&\C8NPY08U"4YB:2@T,*4ZABB5*]_]@!0*WH"Q;$98<H6S N\+&F:'R])A&
M&3:M@=G=";[[QHJKQ.!U L);Q: ^ULN):J+(T]-IFH&!1^_%#K[=4[K\*!;K
MM,A?S*(O,CSE_*E>E^"F;Z ^7"LE7R@)O 3L0K-G&K[-SWZ"[X<%E&H*ZI;<
MY/.%N5]?!%>%)23H=<>C3G\\QA2M__D^#W=<U.L,Q[TKK^F/^U==T^V<C =7
M7-3M3$;'#[B@XZ8M: \(P2_9)A9HDF(]Z_+Q7\$>+P#_6-5]P0HO?G!Z+C$!
M7\2:P)CPMI'<+H9@:(N(;7(]AG#WUL853&"R#P_8>EYW".0& 74/OGH'( 4
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M$9WC;(ZS-?=HFL/9NHZSM8SH'&=SG*VY1],0SO9J@7G\CK>UA^R<;Z Y9^&
M_.!RIM=U/M[FB(]GE'R:%DHDX8-VHVO=@3V63'#3<QJ6!/<+)[LKOU[!J716
M>()U%IC;AL5Y4:C+\%P#Z89U+CE@T#:'5/9L2G*+LW']1FY52=#W!\=[=LHZ
M8()RO,J!MGV@;0Y?<6*@76*@U_4'XX<?IM:D(W*\RH'V,$#;'+[BQ$"KQ$"_
MYY^,QXZ>'J6=H!OCTF1.]EYF*DT2&;M6Q(T1X0ZH30&JD[JW,;Y [(['#]GS
MMTF'<S TX(#J@-H.H#IN?0MN/3KQ1_V''&K5I+,Y&!)P0'5 ;0=0';.^U0A"
MO[=O=-N1@,MI.V"'UJM4]Q"'/XL9]M['*0'.]]LPF>% VT30.J%\"\XSZ/FC
MWL"1P^&0@P.M VW[0.N8^&V8^,@_F;B\X0,B!P=:!]KV@=8Q\5LP\6?'_F#<
M=^30V /:6I[K$L;:<'2O8*LT%1*G,"KG@FZ,L'% ;0I0G>R^!7\Y&?O'71?:
M:CD).* ZH+8#J(Y9WZ:PYL0?C1ZR'663SN9@2, !U0&U'4!US/HV&;YC?S)T
MFK5+&FL*_)M#&N_RA<R<O[AA(N(6H+U^MV9W" TX!"?7;R/7A_[X>,_*G?L\
MW<O=LYMTJ =&:PZT#6!C[A :< A.EMRFL.C8'X^<+/FV:<V!M@%LS!U" P[!
MR9);R)*)?W*R9VS(B9(V^BE=VMW]$=.G-!>QETDE118L:$!#*,]EG*Z6.*%!
M?EG1) ?GW6^,@-H+J'7NU>_TCY%[A6DQC67+%(3FT,Z>W5KO^P"=<G&+,QT.
M)WZW.VK4R3K-P@F>M@+5"1XG>)IQI T7/(-NWQ_V>HTZ62=XG.!I*U"=X'&"
MIQE'VG#!TQL>^\<G#YF_Z03/OKY4^"D 2/3K+G!\MP<T)B?'DX'YK__0L.GO
M YN=(!AVC@>#Y@&A.03_:2&]* F 2A7^<K7SUYNEF9?#76NXSI, YM#[009R
M.969-^CY7K_;[WE!NER)#+[*4[I8B:7T5C*+TA#? M=TO0NAO%46 ?A@:5Y8
M2'/Q+(WC]")*YAZV5DPS]6+CJ,/HW$!2 Q^!C(?=GWQW&D9J%8OUBUDLO]@'
M/=IRT+WCTW\7*H]FZR,<18PH@[<=J5QD^2D=X!' ?:E>3 % >._6XU["!Q=1
MF"\(X<;?M>7\#:BBA,!"$+O1 [X"/!LFX^-^;SP9#4_Z@_%PW#_^CHCX"Z!!
MOR1CZU#KRVHJ\)[\(ZBU*2CI*/2F:^_I:-R9>'!C'*6)[\$*@*CJ*"_R/(NF
M!7%QQ'U ]N@\RB-X2R9CD3/YI$7FJ33/TG.X;^I[?[S]<-3O]R9$H?C'8#@8
M>N52X)$B5A5S!+#J?QWE.,II!O">_&-E)D(=&4POY4N=BHY!([PA%24U@8;D
MLY B#&#;^:GGZ,+118/I(HX"H@(?1$H<"S".1 Z8KXC9(TA *T)M#'Y5$=A-
M].TNVNF#+GTSVC'W*R^= >U-.B?F?B0EEG( )=#TD*QJ2_3$/),2547E743Y
MPOOQX\^^]_2D(E]\Q$Q$F7<N8E#VX VH[.W<U"Q+E_0:$?Q51"JB#^&FGPH0
M@\I[&:5+V.?',]\#A90_]&TM4@2+"/174E[AM@"L3P$K@,5(E:<)08N550#)
MA8QC_!DL!*R%OA)*%<M5!?U5ED[%-(I90!<(9(2)B(,".!AJJZ2[7MI@)I?P
M7OP^COC^M4\/?-JKC@<?E2\B,)M!;<[7U2J]E5@34'T/OP'9#L>6SF9*YGC&
MH;0/;-"K5 X#B@TPT!JC3.4UY;YZ776ZH+&3<K_CE/F0S^)D'8NE]WXA -T#
M69"%#XM]FP0=.AE\X9E^E+GZS#S$YWV;)?U5P!;Q]3.R$ !]D&C*'6E0X*[,
MD\!<*6("/J'+RRR*$#/^6P%-R"R(%!U#!#B9KABK8$FE!J5?KB1@7GCY[71(
MH\ZP3@,V-#8I8N=&G>!Q@J?1@B?%XM1K6/]U"7-R.P&S05O$M<'T#X3A]6#_
M&X:+*^)%,M$9]O85;8_N60!0X*:8KM#;T*3=[XSMUZMBJL6O-Y.2W\"D+3SS
MA:@(&A[A:-K1=(-I&G=]>4J)(8)2=]"&5D6+U[2SR@<0+?<&G>/+RN*&'^/5
MNS_>_G#4.T%E*BQ@90%0413")<I#+0E>LR'1645<KF)I>$+IZ:CORG*>:%9"
M^M1EJ;Y-C;*Y"&YF8FFM&UOXZ>4?7I@5<V 7JQ4\Q"@P\!WH0_6W]3H[.,1^
M[OK>9#N+:(%S>IK&X<W0ER_&%;V(<EAL ,O\"%HZG+7O_2@3,!-B8N-G(9!R
MI')4R<ZE]WHC2=G>V2,NW;NC:,4.*=$"%+B;^(0R*#"W4$#44>"!0A5U769P
M4E=F;F#I6AQ&"3#$CJ;$E2U+]0I;.%\(L,=D5AJ]X=?9DD_+K1F?7W'(;7!D
M$8;T?H!]J6D9@[;;&=D/!22364+^\<0\0\GL')0IU;DS MT/L:Y%D(XE7\77
M7I'#! _[#2+\'P;A7P.>YFOO;7(..$P.#,>0&X8 ^]'-V\3[9P%,D/F(<;AX
M[X&% F.;R@#9I_!69$S!=<"4V8L$7#8!G8OYTL<\#3Z#K&9_&[&R%)C#S_C/
M+]$25AYV 'F0<20R('9'_J:<Q$&$"IQ^!6IQ,B.1@ PR*A&.I,4"ED7\>>="
MX3 ^2U9J)>.L]0CD:F 6*O@&_B3M= DLO]#BPN+QP( E,%^X8)5FQ.A8A'2\
M-]<00J!QHZ,P2.<)'$2(^FB1@'")Z:\Y^BU9QYY87-OR=08E%5X6.Y=VU?%^
M2[74HVV+)1G+*.- I!49;LY(SBW"\$ 8=__.Z;;*-FLFY?8&O0W0+<I:S)68
M2\[8.A(SV,4+$5^(M3I]XGU_Q_E%=\\;[R7;RJD$>TO6MT@&P&LP!I NI9/[
M#3OE_0VQTN$3H7JO3SFB4]YN(L4I6"75I1DY>BRO+(@>$);_*?V]L-YE5"P]
M,A]**3P5L4B".[3G.H[0[X*4J*&E<;CX<''N:+UA!WTW3A>.N]RW6\5R@URE
MTU['E;+%7?()&-5<_"&^'(@.^ZTSH/>8%*E,6)_5#>^3^%)K4>$(?W_"7]4
MK"5]C@"^[S1P\85L4_U*?!FGZFP$H13 -)I%@2!.8*=F9/)<)O"P,HJ$KE5D
M E4NK9WXLVENE[===@K MQO>!,=.6L=.GOSCEPA.-J1LK%=BA3S%^R 52(U
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M!2(R-<3V.E0E_?'TEY>4XE:L4L[9I[0#%-4E&P2^DY".-Y4QIK1QDAM>*[\
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ME&20S9M!4B9**TO$J.M*U1*5*I9[T1(+3P3%>U;X:X'N4E"U+%<(&*<$&@\
M#NOB5C11,HNU+5!+U/5F,<B2HMY_"%:;J,U,O<N69*D5U<\-UHCEZ+H&2*L&
MO!FT";14MW,P+'TZT7 F.U]?J@5\J62XL,6>=/FGCB=RY:FVQ_\M#>+-+#],
M%<JH7+.DUEG]DDKU$T-;I,1-.9<+[(\@M[TP&",!S<\HG96Z>#EB8GM;+C@$
M$.0=[Z4,A(ZTD,>K6$H *2!II#XS$A6)\:U0+$*I%-@$XB_I]$8U\Z_GJYA&
MJ1T=88V+>4A=;2V].VS&(N+K2BN]UZ^#M.-]E-*T)Z*7YU$>PZ*I,44O./T
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M\D"5WK!GLC/O>(!2[(*98<H=/$?).*;(!=P%Y/E9DEUC[GI>/U[:(O5(T(8
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MKC;XWL8S-_F7"/]=4"Z8A@ S1S97]%V^E@\8?Y%LY'BK&%8D/*:(\DI/FS+
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M;9;_(S4:MVKXOF;QCG__[;<7K]X-6O/Q&00R*B3_[TTJ !4]1.H&4 :J *J
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MU]_@:'$G!?(=*ZD>:KK702"@I)"U/\1(PKO7[XY>#H[>OGWQ[BU$V:H2XN\
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M3/.M+--]RC/6P+XMN+ZQL]>SMPN[B.$?=GP1W\39VU,[B]<34-/QV*Y^<IF
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M9(-.B >;M,H_Y9IW$OK8KW93I4&[>ZK=4-G0D]7;#*R$F$9^M(#88U7FPW<
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ML+,-4ZK"90HQ_XYBR#GG$<51<^D8$T+<8M"\FBYNLVDZL5_TD'$%J?D#(PD
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M$,0C]8@KSY'U3B J30K2Z(BCZZ)VL!\V@*A@/&U-VQ-,@'ZM38]U"J %$^!
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M3GP<V,7@Y^CCF8NS 2/#0=Z%NMKSU0>K:@!LSX#MX2'F;\'U04XW?<WRWC*
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MJUX__[\BU!A^OIB-)A_>9.&;AO8L0K[BYD?S[SR)0/208CJDA $#'Q1= *0
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M)Y/C-GO;2<$%&V(%TZ\.ET$ 6 "V7\""RP(N"VP& !: [26P0-] W[ 9 %@
MMI? 0L1IGQ$G*;W&SFL4L&&(>R:1(S:@$(AR.B45G?G>82T0<7KT#-*#J5>/
M_73/V[A8C.-9AJ:<ZTG+;6+'@[8#;O[.]&PPBV5.71RTX[#FYWGSPD&Y2C08
M(*T#4O!'H9'$H]X  "E 6C^D0-- TP>W >!P3C_(!R %2.N'%"02)/)1;P"
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MW]:^OOME/U_\BB4X^!(@-A_?](XOKJ[0>G[]U4"%I4%%1@<L5&1$2P 5@8K
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MYX%I%^Y\0="!9$ZP%M=Y![&;+'4 6  [+F!Q_(?C/Q@#@ 6PHP06] WZAC$
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M;VNGQ"U-7[]XOY3-MMGAT'VW;@_7B[0M^7=]?6B [41= 6D?D"+21%/]41L
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MY:$::' YT/TRR9/MR[+>-="LR\MFIHO797:^VN!NH+[4&,#V!RQB4HQP@#$
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MI5(_ENW" PLE,3)>,U+%1(HN&1))*<>4\LR6AY9M8^R<.P7AAG"/=&7&JR\
M%L(]06E,T@H192 ;G"?E6U@;> MK@Y?)1*]D43<B6I6]$=$8BM(54L,CKZ,E
M'Z2P6O+HDW^@%++E9NZT@"(>DAYP263WCLC99G.Y:\9<U6;,0\E=^XC-(F>+
MY6#<RW+%";\NMB]GH3US?A[B:AUV3X87ZU)>-50?HJ5Z!(LZQG$1@'3OD*+!
M9TR#&CM:F]$; #@:6W0<D(*CP=&3,X#]-EZ"S+&7 >F10HK<ZR%SKY4;Y7+P
M9$VII)Q,Y+4.%&S@1F=MN6 ?YUZML(&Q5*EPG4FQ&"A6P8G%RH)E(=F8KG.O
MKQ?KJ[SKD/TI^8?+]6+YXFE9+U;YJM?R],,\S\EUFN>N;9=S+U3[LH<<R0>N
M *2 ] @A1<2'B.^H#0"0 M+^(47@<= >>%EMK<60J4/?H-62G&]!1%8B".&K
MT\K<:&.H*=7DAO;WXDDIZ2EH;JC%*B4'SGTLZBL"CU_"^67YBKCCM@4A3L_%
MWGKDP19]L 4@!:3]0XK0 Z''41L ( 6D_4,*F@9-'[4! %) VC^DR! =,D,4
MK'4A\D0J\>%H6FF*+EH2V5OG9&0EWYPLQ85.WBEBRDE2*BKRM7@JP0G'L@YE
MF*R(#-%1LP7N;AM[Q]!V-=N4[?:\[!J%EMMFN V_X>%FD<N5Q:+]KBL!!K#]
M 8LP%/<#P1@ +( =);"@;]#WI(T!U[L=>@4 +("=+K#([QYTD+%0/#J3J4IA
MKZYWBU%XJJH$5I(JCMUOZ]'5\S^NUL]VN:0AN_NDGKY+)YU^F$WZ0D,2^\-T
MKQ)S*_?5BP0BZ8]( "R '1>PB!T1.\(8 "R '26PB%P.&;G$JF46.I%C@9&2
MJE#0AA$S6A=F79))W6?OTJT#E]O?DN8,+K">+IT 6  [+F 1OR!^@3$ 6  [
M2F!!WZ!O& . !;"C!!;IIX,>G ?A)%>:O$F:E R&?(J)3&%6RYB4"3<.SO?9
M&(7TT_'1">Y7ZKY;ZI>R&2QP:)9:MX?K1=J6_+N^*?07=B*]@+0/2!&&8@['
M41L ( 6D_4,*F@9-3\X T-PT#O(!I("T?TB1D3UD1I9%K8S.B5@=YE69F"@J
M7<FRJ-I_B8FD[]+*]+L;[#_7SO3SNZ3/[MM.?@WK_/?U:K.YXV5*SL^%X1A6
M-2F^ *2 M']($?@A\#MJ P"D@+1_2$'3H.FC-@! "DC[AQ0T#9H^:@, I("T
M?TA!TZ#IHS8 0 I(^X<4- V:'H<!X+Z;D71P//JMK--BL[OOYNJBF]7%<-:^
M0:M35WH!8/L#%G*,B0(P!@ +8$<)+.@;]#UI8T"[QZ%7 , "V.D"BP:00S:
M"!622"*29DJ3XBF1T]92+$GRR*P)ZOX;0'8O/KG*&%VGDO(=FS_XW @QM]QA
M_,YDJ0/  MAQ 8MH$=$BC '  MA1 HM8Y9"Q2M96NJ8!9*UO<4=UBD(MB8P)
MQ92JF,GN+K?7?"%6V8T0_7*H<NM9H7+.+.[:G"YY %@ .RY@$:T@6H$Q %@
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M@%8<\#B@'"64D$1((@P $0OHN4LH.]B=H&?0\U$;P-0@!3U/:7>"GD'/1VT
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MDD@D8VC1EXZ6HE6*=);6-/$JT=1]%&L]F+#)N?!HISH01=Q7Z142T8<HS_K
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M^%*Y2_>2X'[:N'%/G=-SR?;5.PU20'$:I R[]J&E[% ;MQMUNE%A# ,8DP&
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MU^W!=^?^IFBR>=6L:OD%5O'+O,K^_,F28'<L\/#KE1[ 790K*8Z7-]W6/QR
M20^<HF@6<W[Y*I_+[S= F'^NFF617S*"#2 >W@9J#6@HKPDM&"# >?,JY8W$
M>[<BT3E\\*T0R[-7_E'@17\9P?3C&U"G 511$E (7K=ZP!6@VX (*".M@-AR
M6&H-XX333S_WL=YJ"1FV8?[=RL)PY]X=I)T;VKX3MG\.TGEV,SVBJ*U?"A!I
MV5D);SV]!#VBS(ZL%__[?WUW;2=[#1>H'\5KJZK17+#,5R?*QC!?O[0*,#.
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MD(2S^4K@0LZJ9D'^(0TWN%D &,Z.+'06:39N\7E3P:HR":N#UW4K;9#*0<N
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M@$7YG4/\/K=#S\L% R*0S$^CD'$[RU@01&F"W9V$MSGDXA8$0YD\58GUH.J
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M9ACTL>WK!\]WCD3*/3M*69CSA/EAE"!CL%F0Y)DC?1&Z2?R#(VOFJRFBML]
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MX4SS7-(H^"U[H*A3/RN(G*8]H%7=3/?;8LN1]48IQ8@JQB<($%F=:[N=G)4
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M;KGQ2+U2$M(WV9DQE=H/#,QA;3=)\'E-;!;4 )5<T@]64ZI96R/7[T_Y&DV
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ML,R;M&?>TH9GQ_GM ]  G.V[&@N<B7$?/)@G?)[P^='Q&8"*W_[G3X[_TP]
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M(]OW;W!=<A2[R1Z?YQRYL7N#Z^(C]T;OM8]"/YS6MV5]]DT>9Q_%X3[1Y6'
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MI.DC(>7!6E* ?R!)5^>K.1G[VD\ /+669[)L0+^%2^!W:;U #OKR3JKQ*2:
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M:(/ 8T"W!>8'QD1SQFNE\?]2%X7U2U%9?W T:X:V#L^4F4(OZP?0P6;C8(0
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M#X.)Q.C2DB2+F I&"^F.US [O:SR3TJ?_*1,P,].P;KCF.'Q;#[VD@SK)M7
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M\GA[H4^W!OI."M[K"0]/I=K],>OD5^/!B\4%P"2L!E3;:06-ZERK1I\LYF"
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ML<S0CNI\>DS&;YO0U=4#H([^C//SP8MY4\D(;[/I(<X/6A8\YJ^6(C3%C9*
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MKY%F:Y[PSY'B:PE8?Q*>?U//_%I],:@6T^EDECUONY@* %4>S7!]EON]PV8
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M9PC/FN%=2R-T;4FUJ=BNZDFDE@19.K#>-#&"8O&,]407BI*R]"8 C(Z,ITX
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ME8BA!?RUM-J5@1K!_6WC--_EP=TO<(/PRY,-VW22&4\R=H.P],XB@KZPUJI
M$L?\1@P&.A<+4@+YE6AT2LQ5/"2EO:C9[I$$!E_[^62-P-A)$M@92+U1K$"Z
MV=EH"&^#XFXXS@Y,=WUK8ZMUT'1B]!B6\I=G@V2'(W2% CUGY(N/S$.H%UFD
MPF?_BGY^-AC6SD[TB.W/IO&7=GR1G9!(G;/)Z*S]J/EYYQ=S^P'VWLX7U=D
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M"QJZ?^=D?7%G:G,Q +ZP^>P1&&Q4#YSZ".>'\ "_'@]^C&ZVP!+(0NRRGMO
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MPL6+C[SOO//"O=K(;=RS:3?N#$'D>!H\KE*"IXGH-J6/55.JIB/>&UI^,*Y
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MW_?\Q5[B0$I+*1 9DH!2CH!D, ><4*AL)A$9\MDRD_L/JAQ  :G_#B5 4FB
MS)3&V$J(Y(#/]OLRR"K%_R B+= %.U6)#N.Y2UD4"78TR'?)Z3Z(1DN+7>KQ
M_R>-]=8))B67T6\K+JW=]GT&[P;*-+6X)SB?E\%R^'"WL;-HC9C498Q;6D57
M8:"P!LV)[#YQIK9I**QZ<<;/9==+2A6@%,Z4CU.Y%JVX/IFK7<G*KM>;Y%Y'
M_V>PC&.N21-+Q5 .X=F5W[W+HGGC[O)&UJHIP#]!GRD29[3Y]V*\UI!)]4/\
M\KS8-J^R['0KM %7[HP(FI"S=72+.B,<!W*ORS1"4=(OA'/0"6I2BU!XC_(H
M>3^M/(]Q]KX3I$1XWNKV%[/$M1N?(7#*S2+1\S[K6)W"UE&1#8W0*NJ9VU_X
M==A.DL-,4:) 1D(_*,<02"LUR+GP[B,UD+&L;SL)E()CI(!B5@":*02X-!+X
MCVNM#$6X.XWV8QF(^JV*__UQ#R_B#VGA#V)7X>F:U=N:C";-?8J:.W%$QOQE
MN:VPWSM69E7OBH O2RU9H28E*]\="WD5>HLA8RRA%N0J@*MF-@<*6@L,A]ZU
MYUQ3.IBB9<Z[^$@HD!/MPV/IM9X/#P(:I:2"4ZFUQ'V?_VU*K!4-4-4O=OM=
M\G,/HJCRG%R@4U55^QSAH]=2=U=(^<GJJ(>7U-.'PQ-]'7K'%MH_YK>;Q6+V
M[6)=Z$6 -GK)BO_8XQW$$!V^O^.X[="/ ?_AQA]1Q+MFI0.U$WX1=[\Q3]&9
MKR3"1\Z;RF;5/XLL'C+A*S:L(H/$[;K^1ADAM)B&$P[CV5LN2JVTU$F J5.
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M \2]CAH?$#+>R>)]PA%C5*XM+(@NI=H>K=U.@@>4Q(I\98 G<$?:+E),)R2
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M<$RH^O[[X41_$[_4,(N$;TCE#\EZ5:%!-G>2P3FMIX03A>$G_[25H_JDYZ@
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MY<.X84<KIHVW$Y$-ZLV-4N+7YY-=1:BW)%5)#4?=U&:V[8W"1=J/ 0++8IN
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M+Y/3\'D8Z@G+ M(4[Q"G(?7Q-C.M@\'9.OOR7*V,%AH2<@0@%Q$$AQ.@<N(
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M>XDWV>.XCS[$0Q1ZRK)5>>T DI\:J-XLOCI_]R//##'*:S.$,/.Z,)= 8HV
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MC=,7B>Z$7NW3VFKS6\T+>[VM5U'FX]#F+L,,6$<%H 1K(!1G@""3&:)SIM$
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ME1V6^N/!R2(2.8FA!$(Q%U#:#%"&:\!RS7Q@1J%1@XR"P(0C)1 @(?=&G<7
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MS/&,A= )F&,"YCB"(W),P!SWJ"B]9$$),S:O_D%?5!??6?7N8KK7P!S2'XJ
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MUBGXOH'=-_NRP$=+?[5EJ 43G25; W[\.;APNG@"-6@1?SRY#/C#HNE^#5<
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M'-L/KG^ "I)]ECAM0"O>;.4+'K4OQUXM4GNWX/<NC]V GWW707=2*^H,-GT
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MX,@&FGQP'"G&D3"[U07[+D[W/8$8%SJ#V&.KAIRP[Y_+_?OVYL\<JNHHL/X
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M,[P:P8'/ $N<.4NL/P6WXN[F;-E;6;A[SGHS6+F!U:MP)4A#6$I#$[N\P&Z
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MPRR_]R*_S9:7E( LEAG((GDP_9'A)=>V")HX:[I[%T\Q 0EL0?/R<(]U?-]
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M?U=GO;4OZ.KF?*0O3\+(?_E>$SU(V--_SYM9'2Y!^[C1,]+[0#/3T]G3=J1
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M;>;FWZDH9S:IPGPVG_KJ(EY3CS^5A%>F1%3,FZMY.\CVO8I3<DRX8)(!&$(
M5"(&)+<8$ Y=_-MPKLU#XI07]72[&.7+97GCJ[;@\6VXAMWVZ@\+S/TX^:U%
MW'\N /=AL4LVH'*7@<N",KFB3#%O,6]WS=M!CLR']AZ^(BX3(]>)4<Q;S-M=
M\Q98+[#>U8E1:B[[%^A\$7\;U]31.*/+JFZ:>5J8+V.>)9^0'?/<R[#;]THO
M0W#T(>B@0.A5;!0ABY&%'%AO4X,:1( .W /'E/'"2ASL1H.:O=5PKJ/SZR4X
M?UA&/!]4P(G)+OO7[&=*8,8&J__B>!9X*M3;.<,6ZNW0$'20>O-ATR,5(146
MR6>F%<,>'<+*$!Q]" J+%!9Y%#.M'#77O7#O5GU1VD/GO"M9EDP)K)@W5_-V
MD/M[%;REV&C)/0$.2@RHHQ 82SGPDD.L.82$ZCWV2GFY ,Z-(W8?=HH\27OM
MQ0!A7LI6'P&&%/,6\W;7O(4!C\R $@5".03!I=/E!53 (.T!<AIR"3D->B-]
MN<,N*OMAP+WT42D8DBN&%/,6\W;7O(4!C\N 6!AB'*/ $"X!A<@ 12*Y68HT
MA,9SSL@>^ZOLA0'WTF&E0,@.@]^/NN]W#HA=,M8'.#?\L9SMTUF'+K8NX%'
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M$B@+@Q:4Q+\V3OB3FBL,%08F_C+RHD? >.KC"M,38:D2B&YLY,Z!%\4 23[
MJJP7,T&6T@*J2Y'R][Z936N;=@ MYE[5S,V_O9U5LTD5YK/YU%<7\9H'A<WW
MFO3M[TPJANV688OL.:[L@81!1*P##$,998^$0 =M@0\F&(9=0$IOA ,\<IQZ
M!SSB"% '%= BZB4.#5..BOBKH\B>;P?)T0!*.2"0'OLXY)P<O%=84@Q;#-LM
MPQ;V._(!L!8IB8,"6/.X@*<X'0!+4D\A:P)1"B*Q<7I;0"02'#( 1A($%'L.
MI*&10"ESV'BKL.(Y+OJE&F!^]/9#.?EWKZ"D&+88MEN&+>1W9/(CU&%N/, &
MJ[CT\P$8[03 RD<>TS88N!'Q=L1SJK@!1 4;EW[> \6(!<J02)PP==XS.9(?
M'D#!!@P5_CLZFI3:\.Y%O/]'3Z=Z/&M2@/M\/K6GNO$1&<[.)NEA)_;/DC?*
ME)EW=A#BM[8WE8'(9" Z**GR ;F__>4+AHAF.L;=.W2TX[.NF#<34"L#D<E
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MM],IZ0R'% 'M-4X''@6@K(  :1\@=,I#M'&(P'UVLRPCCDN<W=B_LI-#B\B
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MMK=, ^VL =@+*4(@EB-TJ%!\*_G3$8=7U_AFQ^MYM-,X?(]1+Q^_?4!ZNXB
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M9Z\78B_$?FS$>CQTDM-0%&+OV#3)!];ZGT 25C.+G0!>N:@AF'! 8X) 0)Q
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M'@,]F#I0VP=>4F@@+R)A]U^RNV7RGXJ0!(RW-;0Q/ [DX O7$/2??Z5N7UP
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M.SW&8L#VZ,%3^A@^LUJ!IL_*G^7I4%EWRR2,+-MG<B_DJ\598*BJ55/5$]>
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MMG!.=&_/,O^$QL&J@?E.#I8;T,B"./F2.*HHDY_M>Q"]>V_6@5_C(=6X?/D
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M_HLC^OD( ''1K&W0K_\'4$L#!!0    ( .>!7%0#$%LMI!<  "-= 0 4
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MS.9W<9;<XLC%FMYPI0<05GLMP^&RLE4UQ-I>B071PFYA0EN&W]A;&B#J-)9
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M@+E%%DQ>P0?>8!KE!T\DJG0KHOGB/A;=(#VRH=X?Z$[,%L\$QT7%<,^>GL(
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M;\TG$BT"PJ.Z1THYS\4<BS<DBJO0:5S'45+]$_, 04KZ4_)[C_QU%/R9H_1
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M=.1"VZFLEWG_ASK&@JO%;V_.CDW9%2(^Q!&>F/ DL=L:/$R[O#&2X]-N9_[
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M/!^OFD1?)\]E2O+#J<D[ 4VOGJ_Z/,V"#7%>./$R?UWJ\?"WBD+S!Y-4[CK
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MAV<*A5^W%UXN_Z:BRP>!&' &[L)\8*@R@;3>)-P%F_&$FX!;=QKV M[[F3=
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MH:[AQ#D@NK(+,D.+G4 ,>!&&2OQD] P(V$69;<K)B!A5_8G(E&7GPGN??(E
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MGC O'8>0D2Z,[E 9;<\)A,R@"1@."B:"KHJG7ZC'XF4Y,&;F<(H3,]E*?U_
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M* R9DBM(61*',,%G62C/W%7:>\11$V8Q2;LA>*CRLSL)%=8NS8(E\S8E[>
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M EBBWNP%,N^'( T(#CYD%(.J=]H=#]S8; ()@WJ%NKVMN["J.(KEF> [05C
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M#[,HRKV09_JV9#I4FEF%N=$*XM/4SHY':+&#NF(N*+DBWL!=??FV#'.6*B(
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M3P &K9X'AOKZ[(?SW1?O;W'"<!Y[YGH?0=-8;F3=:M1:4*?AP!Q*P5T '8P
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MMGPS,,6VV,@*S9&R/YLE M.09GI!H/61/#VV-;CFX\)Z"9PG!-X7 ;EW7C)
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M]"O:>84'.P_*=00BJQ=6\\R9!7F@L" ("XR ,G,<$<ALY6B:8T;L(LE$#0B
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M4]#9TNOL9]::;<P4]MC6=M6U-<)<);#KK'"/"UWB PNXZHY0@LGV"'U)N^]
MV@%7LG8TC;[I1'=7>0#;R2C/-XLLAS?]<.IP"J%@L3-E[7OU%;B_]/WT$FP@
M;ZH>;^9J+ #@K/\  _[O[WRD[,.8^&OOLDV40%2FL>HG$LQ:<]W(?K:!H*+[
MB3!R8[.#Y%#B,TWG^SF3U!?4'C</*)3@[_4\*V=/:?RW=?.SN$>21(U8:H+
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MX^I1DW6(5V$11] S/OD1X[439/^.%U\CB'66X_P.XHM!T-+^LJ#?%A\./H&
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ME5#?$.WKY$G*$D+^209JG,54?BO/$O60#B;Z="X,M:Q )\+S(GX%/P(=L7*
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M^F3DM0!V4;H-/TSG^%-9W9" H<#SPH-J%L:F,6;>+*QE3[N6G\5(*N*[?IH
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M:>!:-^YR:E"C.>$IZKR[H"[Y:2"&G!%AGW*:*#6;;YQ#(FLRRWP<: ])\B.
MJ*P9(1@B@F5<!MXBX(=BOAAEF$6)_=[!C()O53(<:!5AK>\"KKWO0]X@F[#A
M,?HFU#@#V*5&22GO"PE[@L34X#*&-)=P _AWTI2NGN@.#<]Z1FM%7/J")Z#Y
MJ(#J4(6G75!A,48 B_8QO887<)J\-A#9J^[,SL'L&T8IE6% ]31RE%X]W\1M
M[-:$<:%0FJL>YT5</8N;N&\XDPI$M_V"+>D6R(&X^O+^9L1\ >31C>XX2+92
M08J^?&[3W4GW@P[+2+F[(&F"OK^PWU(IO2MLP%C'6!]:P=O/&_F"OVFTJ$*>
MU,H0+2._\NAVW#,\^XH;752Q9Z!>#0+:0A[E0G^!Z287R.W.8DI*:X\N3YFD
M##PNF9KF[::'4&EO!_2$#=N]103I&L_3YJ&:&!^R^88N_UH9)<:FN5%D&B:M
M--TLFI4F,X^45IH>'+$J[>=I-F5OVV1P**<OJI6DATZ8)C7<6D<IA4*X,D#C
MH$_@=N6_6Y %@MPJC>52Q>!!&91MOADB6[*/%K50>Z([2;[&"_7Q,BZ*+-_<
M9&5C/93;8.>5&S>P=5E91R(%3UPL6"PPZ5UT2B4 SYJ'&TKG0*"'/J&K%2EY
M_0GR;4#_>QWEJE')QO+'C=)%EB]QE%W$Q2S)@$5N^%"4(!YUX-.T7CR:.L^/
M<([$K\85T\*GD]]-@4#A/!],R%=Y,742ORU!*,3<NF!Z$=N'1(^-ZA$<%/\Y
ML68L\< *TI0JV'@P>&*A+1*T^W*JW4G:MD/77MOV[I1@VR5O]\%PBT+?22@
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MV%&'J_1A3YQO_;J1)10TW>;9LUHVYF>;^P*Z@(@$TT<J7CC\&A22Z;!DRK@
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M,7&^J5<] YXJ2 XP$HLM*LU\_/GCS\)K@-@E 0?3MD[7L.JKS!1RI]!5]*(
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MP).V$<:VN.,&]6K]1BN;ZS<4MG"1B_'@HR?WEH(=WIH<)GR57)O70#*F$%%
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M7.]L5[1U#"(O@MP@Y:]_Y"WXY2A8(0=2(P;W^"1PJS$&5ZYJ*_T<SR%^>E_
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MVZJR/91#QIBE \C U-!ZIOL#JKH+I=WE@]Y=HLZEYM-E%+KDP>0?6=Q1I-?
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M-<*6R+,=,SOM&SME>WM;/W]]:Y\+*6V&;LPXYR:.Z+9+=NYH#Q\K1V!$/-L
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M7 8>NNWE>*PH#QOQ"^-MV_"2(7Q4$=P^C9_T1._"QKU3G_P#D52HBW\(F9=
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MIT08'6:A558O#X13)6SJF5=@RU1N>%PL_?C &$1M[V(:K\@ZR" ?YY8NJO?
MS[WP>Y#M6&DTT.AWP6$=<_3)H' B&P5,B6*<B0.*$\^K5(JF/KD)-6XSQ9]@
M\V>0(%@MJRW7B )J#HIRVM>?&8![7T/:*^V=$.C@_1//((!)TGA4SZ'*F2_^
M4CP*/<VH8LP131/NZ+7W>9D0/^#G]C9. (_1K[B]7-'>YX*+7.@RORRXU+.8
M2FD1T_EL^'PVFN )%2F%EN*^4S/9\T/,XE+$9PB:E&D[^N^01OT09W\&'[JL
M[,$0-X(!>@12;<657?!.?UFHYRI3:']AB>90Q8F5F2Z>:?IU,<O7J:^PE\C;
MQTD&(CE82;S?C4Y:+HPN:@OS6J%9+.!]O"#J1'  L@=497+D<5>>8I<RC[0U
MN>\VRF*-H'.@0Z 8DH,=BQR_@\KQX^\AB%@%60T-R<GMIH)^G/[5R -6CBP#
M\MH[6FT7KCQ(>( 2N>GYOQNCBW; JIGN'+KWDA^$A2&?R29/6&;8L I'A<1%
M(?($!8Q&G$FIT,6.GH(GK"$VYC0T-X7[JTSNF'C.7U/R]QS\?0#@2L>I0:*$
M+IC4,WC\T/SD4Z?1V>GBJ?V:Y/2(*N6%,F]^8;H4OXU+F2_&7E3S87DP0;-=
MBM]_/Z^F% (7+R*LO(B8O8A0E0$,IWP1K*8%2<"_X0$GY"KQJ2V8\)(M],[T
MPG6LL8WW8@&I%K=0P\&-&(L!N8H$[F%JA=*+,"X&Y3]-I#Q-/7FQ&;1)4\5(
M#B2@Z&PHH '0!IL*87^*.9<0./V^]C035WX.#DA;2EL'3"JH9S64 [GPH\@Z
M&<J: J*OQ2N,,=%"'GUN8N46<Q(H0B69V]%,]IE,2=>-JO/Z4IG8N4Q)VVNG
MGY)6=P%8$ 0_ "2V%?P#=_27VXSL^RY R; @A'/N:HUJZ2\PP(*-,*$2-<D,
M3402.-.$M<DR(@I\^W9+-E!GX#KRKZA!.V1NWRJ\5T3*7A"J\/A4^CG,*-0G
MH^4BJ,E<0S'$,YE,Y>9J_D(35O5<1EG@0Q%).EYAIP[.C]/%ENS?$W'XCSVM
MDO'@FMN$U#,)0+VR(QQ.&36,P*MV@ 4S])"7@K^P<R]3#$D'7AGW)$?\^).K
M0-&9=#'!Y0DG*!CP0 ]/!(J;AZ>>@O0'_Q-D]DI#%_X5_O)">R097:BPL@:&
MT^N^].)IF&.4A[42.K3\,W!U:@8Q_,3_GNO/-1U3(N;K"I7S6'M-X%'GKP:&
ME'^&1V&KB3M0V-.POY>>1V$T3D&UB/GF*NE"Y56FO;XOI??G5=Z?5WU_$\:*
M::/55@M<#DC7N8Q#^B=&/O).]& HFY#^=S[9;.<![;;>:6K.HE&F6_[(0^<\
M#;CEF;S!J-](_)9XAUVP\<)!VHPN:&)<SFB/7K(!-&D3^NS!>?3J*$<MJE&_
M5JM1*RH88":&X*"*_PD/UJ"[7_'>,-YC+P7J8\TM%L8?=&72/[!:;WL6M9$E
MW^#@VA)&J3*-H32_5U<NA"EXXM2K\RHOCZC"8WJEO(A1+ON,?6G+F1?^([PZ
M&6IJ47"^H=Y\05/$7CS<GJ52I.(!IU3'"7"_BE0!I32(X.4(^=)B )D H6L!
M8I#3)4Y/-]FR#5*9\=(RX^DF^A(E"K6T]CXEHZ@,Q*5/),U#B++=)/&>+KTX
MX8Q-4#) 8!/[:D?ZT(S>4 [^9:%BE6KXQ9:.OV /(*BL6!?U#+^O-U1R+0CN
M959X/J-S/DBI]&\_2 1!7#A;#^S='(F73,G?E;^F@1] @*JH23! 0RY55)A<
MV1WMZ4L "'T*DZ:M!AFY S;6&I&#][<XN00F[\$^.C[*']@P=<:*+PLVU(*-
M=2JWW<03KP1L.LU^PI6ZV1$_#[D.4H*:WL1)@5.5NDNA1:3+D)KIPM@W UI9
M&:4+YE9; Q9I,(ZF"?C+XI*OW-.V^ L;\S1)*6?Q%LM@JOT>PO'R.#&IC)/E
MAZH-)TMH%]&NP5@KK2JX)O5$@*M1)U0Z+XI9W5-=($^FRCJ:'K"N)/%.3 E=
M[[SHU#D!UY^;,&>XD]]Q=L#(+[N<,: IU:4T 89XT7($<OGF-5[4B7#.X(=^
M/I!-L WH[*F^E%Z1=Q+&+-AR']"_9W%$4K%"!AV@<I1%"L,L_&*<Q5X-)(L@
MG]M,P^HDV0@+;8A%,8;<<.<VR4IHJML7G9[-DYKHZP\ZTG$5D6_/ORH P'B\
MGN $X$,LZ!B+;XOGQ:\:ON%D-)_CSK3R67_^Z>>O"RKU_"=69C*MSFK2\/B&
M$#\%MX.D?2^Y+ =&QYEP[G8)+*SR9S2YL@^[W?3 L[*)HXCPVK ?0;9;>/1?
M5*P*B@2JXL-G]#)"TUO02P>T3@1;)IO23+QD(Q^$_K'A642+?]I 7/B0_8$_
MEN@.SU3QZ->4K[I'_Z+JT5>Z_[*HY@@6%*@[O\60V@Z)V$]4*;KW/H-]OE=?
M)L88G7W)?SKY:X8#DB6G:W.2Y)ZY%])'#OAZYT0:?R9>HK^G'MV1)JJP8.#1
M*56>CM+ %TGUK.0TSP6L5)\V+8Z>HI!?0.\ES?Y'5%7@CNZOHVX9@WS$32&V
MY?*-'O.01JHINE2+>")O.=W$<7)46J\D$JQNC]Z"D-<);&/Z)?B&+M;UQ1&
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MN>QCSED..JAS!Q?-D!^\;C=8""=-TVG=&7'?+L/H&'K[QYV7[+T-R3/(&0
MI/E6;FB..!%Y<:V]3XTTAMIYX A/ <E)J"0@+];<,]7I]1*"J'U<,\K6ZSU)
MWNBB^I;$']D.?')>=*QJ(HZFZ'M,LGZU\-)8&Z-/0M2'+W!(+EW%T1QY(GI
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M7(C*3T/_S@_7.VM=QNYR,$$+TE?7-J&-EW33/*&]TN=.-"PVVQYMXJ6[50*
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MFNO%U1LC:L6LV-7C+HY(/??8]#O^^Q:T.,^06P*PDY>#3\^HGW_Z^J\__>R
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M+BM>0G:N<(!4\:IWKM*38\G&MATFYV'E7H=18R\=Q\9^Q<JZ&KAF6MAO8XR
M[0PO,*QE0(DKQ][992;?/]XZPDDW>48M;$-0R9[O-85\Q$N1QTN+Q!WZ/W3)
M5KEEW"WQERZ$@YG&<1LQWRJU1IWKUMH>>]&.RF%\6@JFLR):@@5]&VWI T3_
M[BT9,%W\Y<*L'#H;HZ)N9+[M1MPN!<^.PCNN8TO-V3H:9X@T?/X_#]RH\GK5
MLC7!P;HQ$Y$T]YH?L[3(E>]%+&WLBTE]F.^]U_0BH&:T_VSAPC&UF8N3H&5
MV-4>]?@0N/S^SN >(K"]BO+RT8(LKK"%JSV^HV?Y1G?Q&SVONN!QW)VP 1J
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M!3"BN, 6Q>^(%X;PHO$KC)W_PA<3%R[$N*8\M.N%O<#ZGG]NQ7ZPU+FXE!F
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MP)PZQIKC;ZHINM? 37+B+K[=OC?^Y=2!C@NTW/4N(<:EWE,4MF]0>?*>08$
M]?[EX-/M]/-/7__MIW^QZUZM.B*>Y5<D8VD+Q&]"L]A;SD#=$)>FB]2XT@C;
MZV;+FK77X';VF$D-%D;^6][5+56^;A+PCX.$A=OB+6$,*UYX0Y1_QW(..'J@
MHREX =*;,/9J%0UK#3 !>+ >-%:JJJ6NM)SJX=6Z([H^D04\B +;'()D]BQ6
M6UO$Q7094]O;9*/7?D2DAJSX"<P4D<9&F#876 *K[5-\]$*Z&_FJ7<<7A"<G
M&"ROI@[G:G\UEKA7^<FGY?<?\;FPM7WY'!='=FXR%(4MZ&UMC!W=,.1D&YST
M$DMAC&9T$S$7Y)E*,I (^A=J<:6 FF&F2/6@Z-(7=8JJFDZ9JT@/0-?GUJ(3
M-F*FS/M6\U0;T3,-?; AKUIDB)UNUJ0[=^NYG(-:"%?P=/JKZ GJ.4'="'H3
M!.E+%+\"PP/XVAB!9YD.QPIJ&WL,[%M=POX%.J1$EN1,2FS3$7MR"H!HM<5;
M@!?=?9&G*(]]Y6U])F],F3'-R=IX+OM6(]4%$%9M_Z3E#926MYOR,5MUQ4D&
MFD>NXT,0$5:86S("Z317K2I[MY2 #AD#G9P=/!\15<DSIW%@;XU]-)F+&7'%
MH @SL&;,6K&Z&?M)0E?V7[7ZBLMW+PAA[]W$"5 > V[#K-\W]<*>5ELXU:L.
MIW*2P0R2.)=S?;BN=.=*0IIB'$S4E[BFF64NU*L:KLO0!O&1J_77RGP<U8=W
MMT8%2I2.2W7/%[QX]*QYA* GL#A0Q1#XVN.$L8H^D8-YMJ,(G5_-/O5HU6=.
M'T@&?@CN.]/B>&8&_)'%S^]%B:P*CJ+A,[+6GNLA CT 4EK=S/WT]/SB2N!S
M=,".3 -4M@SIH :?JI-5:)/&:ZA];]0C3NTKS?]4V6*2]))!/@A=>IDU:C%,
MW%R#^A='5^V7%MVP<5JLI"!_Y_5\!B-<R]D#,41Y%6]8>(:!6 *N^Q[HEJI&
M*VWM4!-)&?<8-:^I&@\H.&=ZMKLU_DXIZA["N;V2[/B<Y,1()=38"9.+3GLV
M(Y[W%CB\(O9%(I81J(==JM]NF#3,ZX"%F^E&%\IWD0/#-8_:>=_0'CO3"W(T
M21EZ^D0B\N&%-J="0Q=LCP(G:F:IJ9"4*VB:9=7;*,HA>;?X,:6?03KP!$&B
M)5(Z5"R^WMDN);]5!VR]TY!YK.Q$-R2Y9=<Y9@^MMK9D']-$.XJ8AU=^*>D$
M5Q'Y]OQKZ=1O=,@W=\;V[W6&AM_0MD8/7B])V*#2,(PWGEQ\-0B2XRQJUQ-Q
M"5^GAP.XG@%#0GP5!!)L-8)VM[IT6W6:3?B(UQ1Y()F^P. \X1/@G*W[(#<J
M#3W$H.8,L/L.$F(WNPCR](_FP\?:$/N@Z1FWM81MN:I:Y9$8,V#<:6#LE\LK
M/W%+?W/4DD6^>4%T5ZJ4;'Q''?KCXM&8HB0(7VPEP V-,%W*&H56U35#CQ;F
MM-'^B2%2C%D;@X6AQ\L5W$B19S_&HM1U.YB2M=\\5$6NZGT+O<_X.PE#N%5>
M?A4L*O3K7!!Z)'O[YV5+_NJV@K"_ZQ2E&J^"]\ GD7_2^I#ZH.?Z4ALA\3QO
M^=;@'#KUV,BON%K^7>I[\/7ML:_F7NCNID-"-H&HB74(B2A?H"NW9G]2<S_D
MN]] R:#T,KLRT-P+_8M5<AX<>9D63V#K_MBVV_Y SU]^F5<?C3L0PFJ(LF/7
M&7JO"]M!8+NN<J<GI:L,[!*:+4K3+K,; IN/54O)@9NDU-CT%D80BWV'=T3C
MSQ2"[SA-JG_GY:=-L^LL!-LQZ."0^./7GN03JB-F$;P\#2)ZP"CD'D__V9O2
MU%QMD;\/^",D]H[N=E$%-97^&$!-YR%\!0CG/E)M,^$Z)VTK;4?C73J&7%S>
M:W[\$7-]J^KOJ-%[5DY+%%XPWW9!'6O8LALF!6+%0GA,XE>)%S6:%JT[87XM
MF<RNE\.H; 962:%<O;#V]?J)08_MFE'[_*9J8M5KTW5._JM55,X;ZEIVK:$_
MMC8C'-JK2*L=O=K>V<('KO:87VT7)/YE2*^<Z,WR76HM$!_W>Q)D&8D>XHQ'
M$N'&C.4++5;(Q?&211Z3@Y>4*>EZ"\&V!^/HK07NV- ,6P&NL/<T>5)</$S]
M1&'#)253=BQ*GS1\0E=[5&W$O]WO\ZCI&+>UP[:A5<!+5@N2I78@++L!)!A'
M#]GC9@-%8;^ )F=\VL!3*G6H5+K=1Z^Z..H3X.NX]YX/^:A6^C*+3MO4#9%]
M"Q*GDW07'*K9$+4?L=W#M;H@RL"[] Y!YH4N#UK[WMA*00<'KY74M;,0=,+#
M6J*?!2[:KL=,@C;<H^(*R_ 6J$XA>A)YH8I\K[97]!A^9Z5%C?S/K3NAPANS
M8*_PEZF5\:+F0&K=$1T=KU--/GC[UK241=LYDB<^>D%[XD1HC#@)7D$>-G!R
M<$*^K0VQK3A0PUQYD*4&F Z"_#-0]:<@Y9:7I+HCU.)/E$E"E:O@+9(U*NZ]
ME/[X3))WJC<600I#M:YI1L N4B:C,[IEG69%J4Y^AVI@3FM]N9ZBT#6*YQT)
M0U&MS*Q!Z"WFD- +CY*0';6B5&0;O(N,$ %B2$9TL4OI'2X5V\#UP"3GUV]C
MW5U+VSER9'[WP$+.E*YDQ?1VEX#*/; !NII@&VR$)[SVE/'2]]D1XH5P?=]&
MPOBJ7?K]16';;R70=3>81]N^V-Y/.$L8_H\=,(_TN$^4DJFBXNW*#/25A;C,
MR^''&V*E_+8VQ/>D\$#_,L]V<0*)I-0JL&F!]M:(5_SM9ILL<[K_XV1)=31J
M]\.KO@F]FK/ WA)=0RF9!"R3@06GDN-E[!.SRN+L@GU9F\F-F(? :DD;;_(^
M@F8\^3'X'MV"L%&>E9B)\\2W-D9T@C^10Q60H,>)S0Z63AWG >)XAKPW((%E
M8+U&S(:I^9S@B3*G1,92BS*5U4EUZ(IX+2SI^#X\@^DB*_V(#GKB>90LJE?%
MZ+J*?C5VP^;;)MD3)++#4U%#V#2)2A/$4TL02*VD$\H4P3.UP?8[YF#%A($7
M4:526'?4SG/D5;E[8"^9.(IEH(WKRH+?P67I-7;"3AK7JAD_4BUD$QS S#Y:
M$2[.#G-PKEG?N-5Q9NV!:GN*!Z(&LWCE3V9>I.;6V'>(L<3JDM?RH<]L)7UO
MU1'[4" ?1;('/8,C^L<-CP]P=&\+>'!7&8@WT3K(P/EZ&_F0)9U[(9!H,$@S
M8'QVP6$=<_O5K$5W[(Y]G)AA%0*9Z&(DN/[,P-U%-8>[(#5[[$>2C5U#R528
MJYY'U*(YMF4KW0U<>S+#W50A.6:0I^LX\T+]=XB'/<39GTE6<(+K?)E&*_D4
M V,:I>6*63S.D3+-SAKSH!9#K*%^:H;K<)'8K ->\H,PRZ(H@^' 3CN:8WO#
M\M>4_#T'7>.=X9Z=V%M;8WPW>04R:.?5*<YM<W;:6#(Q$;"*XVVU724^O7\2
M#NVEV\T+U[$&OZO%:/OT1YRJNEQ+%(4\.XLQ?E7GUM@!'Y (?+ BG@;N\B*D
M=N<JO=*J(^*7*M<G5+0 UY%_9:@Z[6Z-[1:A&JX/20;TB8KSW(WM:^J#'2BV
M$>D[UUQS+UQ(!YQBB?!"<;7U*4A_\#\!LD:>W_"O\)<7VB/)Z-=@O-IVNV\"
M\=AF )6^VFK9(+88L[$AHCTK"B=^(Y!O?-@%&R\T6Z[6AM@*F*H9YJ;I>JVF
MY91H74L4]PZZ\>E&0S_ R,$+?.$P4UM/*-E-X8[VO>=)F"&5U;$),SK)Q=Y(
MU#BA5RSHJ@6^T':,61OC>_-M]-OWWM_BA%69<VL:'45@?S65SEEUAT QR5H^
MHI:N**B[V>UK=KHP=/,%TTZZY)6>\$&P5YM,"RI,!;<#P-GA=^L 5))XIRH=
MYFF=@@T/@TF1?"";8!O09Z1':JJ5]E#)L[)63567;M]S'N"<2CV(]M0J[H[H
M*E1#Z22+">CN5$SJ?_U3,2=J(/[XW_])_@O]'U X__?_!U!+ P04    " #G
M@5Q459>%1U2'  #I7PH %    '9I<BTR,#(Q,3(S,5]P<F4N>&UL[+U;<^0V
MMB;Z/K^BCN=E)N:4RU6VVW;'[IE(W<J*5BDUDLKN/B\.BD1FHHM)RKRHE/[U
M!P")Y"5Q)4&"B63$WFU;"8# AX6%=<-:__5_7K?AFQ>0I#"._O'-^V^_^^8-
MB/PX@-'Z']]\?GB[>#B_OO[F__SO__9?_\_;MV\NKJYOW]R"KV\6?@9?P 5,
M_3!.\P2\^1\/G_[GFW^=W=^\N8'1ER<O!6\N8C_?@BA[\_;-)LN>__[NW=>O
M7[\-5C!*XS#/T ?3;_UX^^[-V[?E\.<)\/#?WUQX&7CS]P_???CP]KL/;S_\
M_/C^;W__[N>_?__=MS^^_^'#__KNN[]_]UVM6_R\2^!ZD[WY'_[_?(-[H6]'
M$0C#W9LK&'F1#[WPS0/]Z/_[YCKROWVS",,W][A7^N8>I"!Y <&WQ9@A6L'?
M0[J,UQ3^/?4W8.O=Q#Z9WC^^J:WG]2D)OXV3];L/WWWW_;M]+VX+_%]O:;.W
M^$]OWW]X^_W[;U_3X)LW:#>BE'Q;X2.T^>M!^Z_?D];O?_GEEW?DUWW3%+(:
MHF'?O_O7IYL'LLZW:(<RA!KXYG__MS=O"CB2. 3W8/4&__/S_75CD!>8?/L$
M8S3*A_?O/WS__EWFO<91O-V]PZW?W:/_^8,2 _WG(@HNHPQFN^MH%2=;@BN:
M)/G6)@&K?WR#1GU+1\3@_'?M<;+=,_C'-RG</H?@FW?FUO*0(?+$'S^/,2G#
M /UG<.:%&+*'#0!9JK(2]5'LK>/.2]#/&Y!!WPO-+(HYY*@KW/\Q7:Z6SR A
M---]R\3##; RZ2S.X^US C8@2A&/1KPNWH*;.)6ML.^PUO80_1U=8!E\"L$=
M6AI($OQ[[']!O('\<Q.' ;KA+O_,$9^X "OHP\S(=O?Z\G'A9883##,->TAZ
MZ>8JC+^:81X'HPVUKDIL6R9K+X)_J=^^PI[#S_<AWVZ]9+=</<!U!!%%>$@"
M\/TX1R) M+Y#J/H0*.U&US&'7^.5!Y/?O# 'GX"'_YM0A]Z2A$,,OX*%CXYL
M"I6O57'/X>?[,8Z#KS ,$>.YCI#@N\8\:9&FBH*<UD CK";!!+Q.0!?*X70>
M?M;G<1AZ3W$A/2'\;J"/! W0=1W*PPV_LKKTBT6H.-)?CGB,,79GNX49 0Z!
MB2XPS!I!I,]L%08:?C7W(,1W+Y(ELMTC(OC4\SOP*MDH8^P*1X+2W1/),!97
M\KN78(YT [TG&"(QT-#*>,..(,'@SY]Y*0@67[TDT)55.+T'F'?UT5N05=K>
M'4@>-D@(?R^9N&KW06>.E88($#:3P"=B_;M#C%1YZI+^PU-+ =RC]ZK+9QD=
M!T7Z(7]*P9\YXNN7+^A_U*F#UW$JNL20.L5$=(M'#_%'$QI&<R"K<GN7-2D/
M9TMF[+(HE9&LRH]=%J4\W/CW>9?EB,<8_VY76H/6&*/>E%VV@-M]! H"(?"1
M(O%_<Z1)@"3<[5V6%U[F?8Z\/(#HYTZ$U67H<:V.BR @YAXOK#GP+D#FP5!S
ML;JC3D7",(> N>]9DD3VY%G<NN5/P2+;MUY&]\#/DP2M!S%,F)[M;L +"'^'
MV09&^U:_0I!XB;_9=8+1RM1<0;SAH)DP_*)Y6MH+<XR@\_"65GZ99G"+C6G5
M;M9YV.<H?L(!.OB:NHZ>\RPUATK?3UM";,_JSS=(40'I=<1:R/[44$,78O_F
MH#,VAW$]4N:.F>ZH5C5B<\ON^1&K*.  MR /"[I$LN\-? $'C4RCTN6C$T&I
M.M%YABE^&R=9*6-?OCYCE]IP8&E_>W3?JL$SI3_P!'RRYM9OY%.V['(5R=XE
M\3-(LAV.2D5WPS.>^BW(.D%BYENV,#%'&MW'MT\/2/M.<J2F1,$2Z1I)7S',
MV.>L6GQ-<HU>'[&*PEYZOD$B-6J8DB;,:9>1!H]Q&5X<K4F?;C0TZI3L(KP_
M%Y\\)$"0<[ /T2XGW/=$#O;YB2#7G"X2P7+4_![X<1)@$1;U"O ]'?#"_8<#
MU?#,[$4=F6.'?;Y@,<;'Y'W0XQ,3BG(: 9$NGQS?FVK0-])AY/'76WEP\ _+
M9QIQE)+WEN09A(&UZW[%(@Z+-,VW9(+I9_3K59R45@'$^.L6VVHA*5&E06 6
M*6/S&#8*"W_^B3']2_2Y> ?0_8E;W.6)OT&M\)ZKP63R$Q:IZ1ZD60+]C-X*
M@QPJM8_8YBWD!ZQ#(B&IMSG/R*?&CW.IA$GL,?21K'D!PQQM'+.U[DDQ_TF;
M"-W%&9+'H1>&.S)C^ (>L+^5Z"ZW,>X;YD3R+A=$ASCW0C\/BT>QAB$<8D[C
M8]Q#QC$PLHWX:R,K[C'VJ-%H%;GBK3D#:%)(%(]?(,ZX@>2(,Q"AE6172;RM
M]>K$ADU_=52<*GOF<K7_<WE3E+/M"XK^)T9% !LO(A]I8X1FST#V%0!R5V)9
M8M]NOXN+[ H$(/%"_(8XS^)D=X^T?W2CW(/G.*EW,03?R/.S=$HO2BT9_;GT
M:6-O5#\KH8$/C8J&.;5;<U"+YPUQ2FH+0?SQ<^2#!$TMPA0=ES$>9@^0_@?'
M?,%CY([N,"9OC<\)2-$0I,L-^D/9'"]BT%Q$Z,_X"^W/-Z<+7I$@B@1-DB^)
MSCB,_4:C$&>/BI,F>'CF*9HZ2?"4 O_;=?SR+@"0S/_/'_"_OBW^E4"+_O./
M\_@%)(LGI&1Z_CZ92.@]@? ?WQS^_FZ,*5$@']&HC!DU?AYE0@OTN0!_\BKT
MUHP9-7\?%2,DG,,8T5N <YP)P&JV&W6*5^@ >^&_@9=<H;^D@DFV6UJ89H&3
MVD3K;4>9ZF/BX4QZ#[OM4QPRIM?\?90IE1KR[OV'IT?,VQBS.F@RZL0N7WT2
M3WKK;463:S0;98+%'7$/UA#SUBCC3)#9;,0)GB-R3_ 5&X#7?X(==X;M=J-,
M\3Q/D@;?X#-";M,1L;R"(4C.T4?72'WA(MEL->+T'K9>&)[E*8Q RN)^K%8C
M3N]R"Y(U8F\?D_AKML':MQ?Q462W'O/@Q-MM'!&3-3&?I<L\PWDP,8?FGR)1
MIQ$G?Y<_A="_"F./)1,>MAD3U^(@%VH_ONVP/8!/KISF(T[X.LH %IYQAELO
M\\H)<2?,:3XF']B ,)2=KT:C$2?W._KL/Z/X:_0 O#2.0'"=ICE(N//DM1]Q
MRK_%88Z4O:3@['Q2;;<;5?Q=1%'NA<4Q$4B^C6;C:H,X! D6T8*221XT'?F.
MO\VW3P*2K#49E0WY<?)<QL231)'G.,@M07=.P!<\Q;U&G/ZC]WH=8/\<?DF'
M)R,!F==^Q"DO@@#=X&GYCQLD,+WG3I?5=ORIGJ-_72:/B%O*)EIK.?XT"1TN
M$^(;P'G%)7-M-Q]_PG<Q$N+"_P\^"\\:L_$X>A3^>@(\SO0:/X\R(9P;/[S;
MH/N:>\P/FHPRL6M_E2QPGHLX66092 L;+L<N*&@\ZM695EP<!&>[>^PJ N@D
M/(+7["RLI>9CW*7RON.88 L8KV"RO0Y8)MC&[V-.B6.WJ?\ZYG1H50G^E/8M
M&M.JNR0627.*7N+3X="_'CA)FN4DRA;OGDE*A+?^!H;[#5LE\9;E5J!?BQD6
M_C<X!#_YQS????/F.8$Q-M;]XYL/W[S)4S2+^+GP .'?2@?H3;%@[OS(Y)"*
ME0+2<KHHM+P.)0SO3PT&CJ>CA./#J<)QX%4I ?G^M %I^&]*2'XX-4A:?J(2
MAA]/#89#WU2)Q-].%8FF,ZQ$XZ=30X/M>2O1^/DTT3AP\Y5P_')J</!=BE0
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MV,%1M!N6F)E)#G^LF UBOG2\NKT>-2I:/!VO9*V'F<"4ZG@53Q.TI6JO=;T
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M853FB'J,FWS_.'/ GU!>G>9VX2U6>LQ!&II^P5#8K;#V4R,L#LP:'2>"[>\
M2TT@6+R@OZ[138\-[_1';$3AU7S2'L;:@A\V<9+A.<B(B=%PFKN$CRKVF-PC
MYE9>$5UVB37,1!9\9&^X?O,2B$U&,@H[;#<_.^OX[,QD*A'!CG%VZA@?VK N
M54?CT/0O<#Y0*C>DHS :(SW6%>QHX-& I,>\]F<8]0VF1DU7DRH'V?ND,B09
M1T.1^E&8"6.SJS;!_D^"#XAOAHI1QD&5>ATN RDR$^YK07[RLCPA"=YQ""_K
M3!YK6<@3,@FR8GWV+)7>\!<YN$6;\O@5A"_@$UK*AIOWO>MPDP< A_4_?HU[
MKIN.<AS+15_F9EW7'N<HEGP5Y_R,IYK#',>"X8N)+2;#3'[!BQ6Z7PVMNCG6
MY)?><[437>#G*"B5=US7#5??6FSQ?W59+7<L8PEB!1^_!1D_?NO?Z,?X#-P#
M'^! 9H9SS-S8IO)8%0+>;UZ8 X%TR%B*:L^)>%1DUGLER_PQ:4C]!<?9JFL&
MV;U$ZJBMT@Z@A<SKJ''."J2%3#U;G PB2L17QQ]YC89H2RMP_-W.:+ .5*>U
M5?71623YJHW1)T&_%+!&Y'U(<.3 &E:SC#XM<@YH917/\3='A@.(&(]GC&I*
MAW[U*?N8FM@4'#!%)Q1#$UQ'J%> G\_@[FD<PJ!X_%!5,Y[=3P.YGQ2"NY6#
MN8>=QG6$(WH01U\BTE<P0.GTGH@1JA4UH62*:O>9R%+V[*^LO?Z 3BFYII>K
MXM4<],*[."5O4DBVBQ1G=+B!BD\9>@P_48 Z+7MRB[F-([_+>FK]IK:D4S$(
MBQB_HZ9>^5W'!D9R%9TT6HHWVQ"V[DF$FO9!J<^EZ5ZR19-(.FNW-@)2_=9V
MU!IM!*>!C,HM4Z@E/;Y\#'Z'DTS6*V(P7XX?I3[.6>%-.[U ^^&>K)O%<HG;
MYSCQDMWEGSDBQ8<-(O_T.DWS@^ 2E1[6ED%2]RU7#UGL?Q%68&<T-%7"&R1(
M=#M#XC(2(C)\J][1,TR^QB_BK=;1WNMN*D+4L1.43^>WM[>$O161QZ+.=HU?
MZEG^VLOK-):]5\@\GBPV&DJ[V59253EQ,VF<@-DYJG+).>2^KH8B W,<*"F[
MJU,4"U77\>G#2QM/EOE .PZA*D]NH-4-=L>1-$:,\NMDC-!*:_Y7#LMW1W%K
M7?UGNSK3$8E["AUGR=P!Q6VQC/CG0**[J?2=BH:O'#8@[V=M2<6,<-VW.$+4
M+*0;=EM[]!YOMW'$)RI^._M<I@5EJL)IF'WL+<7#H@)!%1?!6:YJ5[V0BA0Z
M&N)&5S!),U+;U8^CX!P=.1BM4RX#$C:WAW/^E,( (N91 TY$+MSV4V&;,@LO
MM[DALFB;+C! A>7B(D_0EM^ABR@."HO&+?A*?F*%-'4;Q]0B-C"A-,JE:$8C
MBXDM*PO170)]G!2*_(U'Q]SVLY%9C/1=$OL !.D54N\P?AXI!\B=+@=_W5$L
MB@$Z&ZC:R]IRKN^6PHE7OP_##BL]M3B!BSS;(!7]+^8+:?6^%D4N 5LNJ""%
MN&!<C2*0!%#FX.'*9+T&G<I-7,QWF6=IYI$JJSI^RGHW0Z1XFV/"1JC5%%0&
MU3&;V3:?J5M%9L.MCA-%R9C@.%;*=@>!AXY)D([C)C1N-'Q/AZ8$QZ%1LD34
M(>)@Z3I,RE8.RK7$1@?7X9(9*QIWGP*VKN,U.\AU+KX#RU%5I:^326<(]"81
M]MZ=?;'L2HYGPE$A,@4KEN,H&0]Z<A6HCHH@_^:<\1(ISFSYU?%,4SHL2]L<
M['[= 2$K4[8K.TYC>K(#PWSM.#[=^!;_Y#KZ)*ZG*"]R1\R(F7)(N/K.L N4
M<A^)X[GL5$\JVULS2'JZB<?V_NXEZ&[,]B]3)Q#KR_2OJ2^ GV1(?PS; ;'E
MQ)8)27L@"E 6=)C6(@[.I,I";NP_D67.B_*1ZCXZ]\(0!&>[LEU:-M1:K<:H
MMN&8([;GL'XG([3+DR:,9VJVL4\HQQ^9S62'EZ\@\6$*B-%Z_^.>!_(*IW<;
M:WX2T&^WTNP"418VV/V^@?ZF#7")OZ8@HS&H;8:!<Z45LZKI765AO!U>A9B7
MR+N;NCS96G<Y#7I,6(&3JCUM)NCIK"TPG-9,&=QQY[6:Y"X%2T<\/@U$YYC!
M.;1DO-C EA#K."QS7&!WWM[367U26.G?@W(-QO% B8XTQWU9X"I.!J*^785&
MCX1D!]=Q![\9OJ6CRY]*Y(T&I.H6 <>C =2AT[),C.'XM^2N)1B<>6B9BZ]>
M$CB4.G>!=W$-:%F!6[2FZB_UC%U"(ZCN*(:,9O<@S9 (EY7J^%V>^!N< 'J=
M /)EKKM)L:,UXV5%>3C,9OL,$( 8OS(?VGF<9BF))GG"-$EK^DE2!_4<= )I
M8LGLR#&LS[].?&>[JDVY G)BU5+']AW?7IZ&T(MP9*7 P]1H8GVB0M=CJY&I
MY 1?X\=-G*?HPG^ B.V"J)#N]S4_\&?Y^4\T>L^>QY-V51^AY[#@8>@S D)I
MMK&;_*<3CZX6$ 5*?&B03]D[4=OG,-Z!0I9=$GE<2)[\]M/=>]Y^'"@WNCLM
M']@N*$_RN3^UYW[Y^@P3TKC0Z$38&!G?7JX:](7EJC9E 9MCMS4U]33):M-&
M_]6>,OK3'X]8<URNKJ, OL @]\+?8;8A4CI6H3;P^3&^1#)'MF-RKRXC&!*Q
M+E^!GY/R::L5]$&"N-\%3("/>G,%*WD?N]@S2(7?;M2IWF,*Y4RO^FW\*3&W
MNOWKJ-/ZY+W";;[E3JSY^[A3@Y%X:HW?S:M"M^@"ZZ$+R;L?W[U(K4&E=[ F
MIJ-[#"_0]$4I_Z#%.C4-0YE08&2W/3YAD?S/;V@Q>ULW+Z35Z"<&/-MU27Y/
M;+HG7#+(\>WS/AJN> WZXL$06_&NXN0C]FR8WG/9YXX>0%YVS^&^8^C((,D3
M5(XM+J$SSHEJ3T,3+>641Y!LEZOFMQ^>@0]7$ 2?HP DG.GJ]3\^@BS7M]^'
M_"GU$TA,%_?\4._!/G=\ &(749Q'&8XQ^.0E7T!6RB0%J0CBY0?]I#- 4J8P
M(I"-3TXS=3*7;W;*F2P8[?CHJ+"[TM >D%Z7MK1'7%KX.D+R=I1"_S<OS(W3
MD\ZGCQ98(GKME_8[P)$P(%B\@,1; _(C";GR8#(DQKJSL.]# ,D+XBWL==_B
MYQ)I1F-E"+W4?\>!!K=Q]F^0W0,_7D=8E*LY&7B'?IQONP=M051(S2C_A-OQ
M%-J1)S'-ZZAEQR"K_)C$::?;B#^8L1BHYX*A((F^BF>\0T( 3-,XV:&= #@F
M:^'["9HA8MP 30MO#8 OS >%?4<<)KAK_T2P(BI$3G=QDI%D1,WI[9<@C_WJ
M.*Y[?*(:J>BTS#8@>=QXD2VV+)N/[3#:CJ&3-*Y6-7C1\2<]9D(=V35Y>\<+
M.HZ]\<C*1K+01DRBXTBR C!98)S(FT9V>-4^+Z-.)*;C2,V/9.?R*SW%$%;L
MYD&B>>,1DXZC.F28:>,X\Z,R3QUAY6#. V(W$PWI./["H,@ZI-IZCJ/ ]0C-
MI)*/0H#D*8'7IKA."#L,V$&$)P6I$6?I.@"'YA-&3*>C( RJJ;=(S-&$%3(Z
M:@;@.@J"MF*N$!?L.%03DT\5HI*'V)!)Y?P82RGC1#W/!-^5X(V%83N>)TB?
M/<M"NQT';% /QFD7AIL8.Y!&ZSN>M&E02F_9D&<HNT/),:LY7A5KVLSBL-";
ML_LPE)V 8[MSO'Z96;+6>FOD.K*#"FX&MFV,XG-.4;;FX[09WS$O1.G+N'([
M?CI=V]&X&Z+TTJ[<E)_G,V)Q2YIO]LHM^67>$ITMZ?KZCUI<G77K3>L$:+TV
MI'MSPNX&*[NC_621;M1LJ-39II&>.M+-<=;6=ER;PWDL27?)6;/1^->^X)4E
M1=NH[</AF\7(,U *^JR0JT-NY($J!=ZHZNTL\/:?G>XW;%"U?"*%3A[R[=9+
M=F7-KP("HILM_ R^X"C<8RQZ,I?7F,MKS'G'+:?>J8DIA;O6-$;<[\QE%N8R
M"W.9A;&2:@E3YPSPI6DF%:I;?6HU\]BHZ ]TM+2"5*05@!F2FO;;.!"ML+YT
MM+!9NSS_^.%X0?NMT 4C_-878+W],<9_&@M+Y<^[!G"M,*T-@ \_?[0 UVBE
MY?AIE#0?GAD(OSY=>+F2I(IOS0C$!F=PO# ?.)AM(*TWB>,%FR'WV(!;=QK3
M!=P%'OW'>YO95P<7I"P WW-2KFU&3>B:SF:H3NKX:E9)3_\]P&8Q]/?S."(.
MA]P+<:CV!]$.C#R3HX5=^^SS,! 6FIK&!(]VD_B'?^S=Z#*3HX5=FQ5/Y&P<
MWR:9D1I'*2K"_][10BAGL8OU.@%K+P.C0-Q]/JYM0>TD3V(+%.9C.V9K3LKN
M6KS<  ZG(?;AN?!T9EZ2360WQD^[X2IASXFJK;"+.5&UDPR9&63C>H:Z(TD:
MX2S^XS\3XL1-&<V]]DL!=$0D\<!IJ(>(UC*:+6S>BSZA68.DMRID\LMHW@TC
ML66N)W8ZINUA1*;->8GL\C*QMWB(-$73LSG8V2.3P7%SYB(;.Z095S?G,K*Q
M2=KQ>',2I E?23B0;IA42+/8/4(HX)P;:4*[IAPS."=-&K7T3)_@PCESDHVM
M,AF0.$@VIGD'AXA6G',X3>BP]=K!.1F4)5F?E^5TMF1,0$!4"::D&S9;-2:P
M82JAE]25.ZAY8VKIU!9IFF\+Z#ZG)%'@99K!K8>+W>U3]S:RKA7F5Q#,"=<,
M#3HG7)L3KAU?PK4N<NJ>H=2XSIY/#_&R1OY!4R"F258#$/U7&SQ.]>=RI>U?
M1YU6J_+TP<2:OX^/&"-)7?.WXV,/(L+\+4;71I' EU3Z,,L_-+X\+A$6A8'X
M1-CXW>4=+X^;O8VG$W :Y(*<+()<3L -D.]A^N4J 6"?SGTDSL7\KKN0CL@:
M1)]W&.#QV(+H\VX 3!G?!:[4BO3^L<69QG=MF\OFEZQ.FBH'4H,=W1".$DQK
M.[<44==!:#\_/4#'40 &?4770G>&<'Z(>)PWR]!F)4=W1G;%-,U,CH)P].2Y
M5W2-OJ^=-\B\_<SHH]MY@XS9WH9X@#OOBS$#WOSX=I+;T^)J<_RJ]6NG:3P<
MXMFMK1"M5G36$R,ZB^8Z*K*/W.6)OT&M<(ZDHXR^4JK"UKM^&H+]+86<?![7
MR'W\&C]NXCSUHN 6T7 &0-1()%7'ENF#[CB(-4O^'.DV1[IU.9N"BI"-)L?G
MHCJXN^:0/*=#\J;A_'0NFFN*L,XA4W/(U+&!/,?WS/$][@$\!_W-(5.FK%3\
M7-!=-7K'HP%.+L8LG 3L@P9A-/5RAT&<8_003B\@>8JGPDY8)B$6:0Y9X& B
MQ#F'6;G*'(XQS&I27.)H]V:.,9KZ!LTQ1E/9()58ECG4:%K;TSH]<ZC1I+9G
MF!BC63*8HXRZ)8*Z1W290(P%:;+P,P1)MCO*.*.JH!P_F*'99KK6XQY5\W0-
MQET^-8?T3#>D9XZ4,0G*Y9\YXH?7$6*3.=GU9;8!R>/&B\J\>+=Q]$*R#](*
M/F:QT_[^''HXA=##UKW*C"T5MYW*U#]',$OO'S[K+*'5Q\%3WRQ&-/JA;WW>
M4+1T6Q@DHN+]PX(;&2WIX."^%XEFK>U[Z_,. ER6)[*(\>$,'(1Y8E++'S\X
M#7(K 3_AWA=(?MG;)NSA+Y^:@QLC+"4X@=W1G9^#6]2\Z::W1;KS<W"+:I4$
MI[<_6I-S<'.<N'O^^,6Z-X-I5#93D%-DRG4\9'70R*K6EKD.Y;3<;?J:QQ#[
M,[F:VB<7HWU,)Z2'LZV^(QR;[XSN$.BVS=*NA\+.H<C3IO*)W;)M_\2I;T]/
M)J3B'9GCB2=U MJ>&J/;\TNQ/1&I*!C,&V3(TV,TXGO>HR'<-(.$?1?JVF4T
M[]+@MKXAPL(GIVT?VP9J^Z/F1)63VC]M9]48H>;S_@WDR2HW;R[)/HW-TW(G
MT<TS6IZ=);Y,[:%']4,=?_P0)DK!43[WN([\>(L6C'88T\4-_A2:J? QA+B/
MS9!;@ [H9A$%%^ %A/$SGEVY.;+ 6VG/^;'&=!]K< A2\())U,/>3GNAET!T
M>R*^FR):7*Y6T$=76F,WQ)'^6D,<7\#&P>7HT..:14A&!P%[$24WXKW(4^ML
M;7$?083$B1!1Y"+8P@AB"LS@"U#ASFI];0M\2A=IRQ4GOZY<=WL.Z9 3W@JN
M ]OA*IGC(J:CZ*E>!HZ#JR#8*9SX.1QPCFZ8H@2@*!2- =OX=7MN058 =A.G
MZ1U("/54)(SH"/I8-()ACCUGK-9':7"Y])((1NO](B0*';>Y-5&^L16<63?;
M6)MJRY99N%]+BB)HILL\2S,O"A#$B^ _>9H1OB7>DKZCVC23)(0U>2%BXMLX
M*F:[R+($/N499OV/\2$7KUT;?&M*WX$-/;Y6F@G9*\QG5RO@9XWT/80)Y4__
M07]_C*]R[,S ;BFTD8R'VP-^;%I'II0HZG1-^+/. >&.,>WC<!Y'>$-0JW!W
MG:8Y_FO1KL]9$(PZM9WG,3:]O>>.8FVY[8M51-#LMI.9>@FNXN1I:]OBLDP0
MJDO*+9G#^>SAA@27EF[<^_)W7($VB/K0LHCCJK0.;]"46&;DS-&[X\'ZMKBP
M2.:<(=>%7%NN'21C>HQV?!H0ZW (CI \!$*3DK_Z8+27QH>(\3]$:7*6V[LX
M0Y^#7ACNJ'#S /P<K1^"]#;&?<,\P(&^)5)TB',O]/.0S#,]2M/N BT[.%CR
MY6NQWBM$8=AWDA?S7Z[:A'/@$&S'>)@:WEZ(2[\5++9Q'O&LLF;&GA@TTKS4
MTF[6%G2. XJ3#"+9Y0(\9=7DA+$^LEX3VQ]E\CK;L0<0)5D?\(L3"&;MN3RU
MB%8C'YF,G>_H7(6-FJ+%0P/AZ>>WGTH>YU%24#,]6Y=I!K?[B*"4ZH6?D<23
M/&[ Y</='3?#L'I?>]X'#UL:,R&^S3:&<"T'31]C6O2V5,RYVZW:R[828UH<
M;<2GF9'D'#<HJPIU=62E<M-)8F94T)(3\DDF$30ID1GD%>(==7QW= Q1IG?2
M<6@G3_@W)Q,YV^6>%.@6SI<-[H*7.*^B47_2T6*EJ6<Y7EJW"Y6UU+AQ7"!'
M@I&RMCE&T=F)N(T600"+!5U'JSC9%B\FCM'Y8\]8IV(N:MR6E/1PIL:V]5FO
MK[')/C]C0L%& 1#L/X&N*X#P\?&NK]O&7O5^MGF$B@RON66.B^;JB"G1C9L/
MJ"[ "BD( 0X6(K%#:%Q,'>YPU'N0P2)82JE$+[>Y(29U!9.4#,TU"K=;6'1:
MM*$0^!DYC>U50"WH^@Q$Z%_(G,@#=IROZBY&?& _W7J+ZEA(:Z&:&GX"/E3&
M6FHS57.1JHPQ(5JHYG;@GY!N-*NO[:6UV3>N87$/_'@=P;^X3SK4^DZ$_4AJ
MR7,:6YP\J25RYR793G+?'#0T=-/\FF^]I_0,(ETI$-2-93:;!&Z/2,=-$8_$
MD7QGN_HO0D)0'F!"E*TADM2:6UO '8C2DEND308I]+Q+NQFB_ ?$O8H* ERJ
M/V@R-0Y>ZFW))R]#*DZT;OQ>:"7+%?E1C[MKC#LU2#YYKW";;Q=1E.-W#]6/
M6,.C>N[_W]ZU-3=N0N%_U+YTVNY+9[S>)...N\XD3CM]VE$D;#.5)2^2G/6_
M+^ABZ\)50@8COVR3%!!\' [G3KD&-5"41C8-2R6*7 [3/$-$%\8"Z-<X\HM?
MEM![AV%N1Y23;.2',ZW7BS2Z2J_OJ%J.VSOX^EK3B\-"T'&(=&N%=,>YE$(U
M.:0Y.E<=1DF-QG'X>FGG[",^F1<XV7I7=2O0U:()P2*G5C5IJ0NJ\X#QC _\
M@S99B-@.?;'"."FPV#)K5W5U/&A+MYR@HC<[#JUF&>*B4-QQ$^$F?]LZ7HE!
M]_%6LP'=P>6"V\.2Y'BPXN"C+[DEUX#1T*M'173>VOL!D@N:)%CO,]C$"#RC
M^ @)N3W&J$2)A+#7>MUDE,EY_A<@!!$$O!Z&G\ ANU7D%9 *0AF6HE8'@(J2
M&L4NUK<+_Y"DS**'0T:\)1@P.0.XY;]UU6O 6P+AX0>F7\S;8.2A4\[JR#5"
M;NDXQ!/<+B+,I/#>ZD-)^HNF;Q8)!M%]@Z#G071<EQX?RO-A=ES3&1])>8XP
MBJS>JI=F7B0BJ7IQ!,C3F9OSG\N7&DIQZ";EGU)Q8"R)1BH"\6C @.:*%15S
M?@0!>9"C,VG^2IF]3,8;Y$=-WZ8.&=$X#.4&,>8N6+&@LV$A[^;UE@KF_-F<
M61205W-Z[I34$*993&.2BHQ&T-<\*4HMQKJ=$?"V?AS1.*&5DK#J7<;J97HY
M:ILCZ&1:>A\N<S4J!HF$%\>U2@W23LL0+"4U.(ZJHH8YA*0=1W(D^I23F!RW
M@XS"244RFN.8*I[\0>1]A[)KIF-3G!X3VZ<"I@AL243#VIZ7"49BE-=!U;Z'
M'L:1,IEJA>,A&Z.@*2+-4=\@,6]3)VD!D0]#F'_B,T@_ ,C?-B=ERL[MSH$'
MLTK'(1=TAA7.TTMQ4;^ 0XSJ78P8Y*D9C<TEKC;%.U_P>(&!K&')R&7O,X*Y
M:M_4B36GW]W"1F.&.J]C9//6,4.&V@%D2:L@H=K;&.Z?LP2?B229^=\SS#YR
M&F%GG[-:6S5]\B,"_)QS<;\I5RF0X22EB--H\07BCN3&AN3>[<VDA$-;#<PS
M$47^!1ZJ7>$#P* .9S4 =)/+(!"80UH-!/[C'(N=,,4B7()WD%G+H.=@NNH*
MRE A0'N/Q'7DTA.]",&PL:S>R?F.O.^[B"IE&3>:)0E(D[^],"L$JS",/[S(
M'R*<J7S%:KCRA//+NY-#3GYG*,L63E-IE99+'<"4&C] %VM4'=>AXSCN[Y T
M>BJK(8["UE,=JU,E4]5Q%#))%4\$44N=FB!85(7R^O46K"CI?L4;0JQA.NH7
M&\#K>FW/Y&$<3*ITG=]17\\5<66;$AQ-U+TBMC3KA-:72)H>])O&=:"9Y!I/
ME=P>J*,98$JX?[W#W1?NK@&GQ/2W.Z;RF-)M0R62O[L=M-"H--$\LN0^O]3<
MN,ETP-J::DN1S YC=#*>V=&<UUN$@!>28I1/6.M-5M$:>0$FY<O[74K+E!C.
M!@ *"GU"<:*PF[1.]BRFY#W1EB0VSSV$3IL8?7@HD-A X0B3C1<9:[?.4GD#
M9X'_4'4438Y#^DE_@=M=NMJ\):"8"\5+*-G1JEVI_E;&())$=_S?0D:)JH)(
M2?$6LY>0REZ7!J2XK\+6#?Z4/<!)^T>M]GG2Z?49Q9@QIB=2!8N4%'OXGL'#
MONL7[SO*J*=T$>$/^R Y,P7\Z2_@",*8MH3^XUBV9TI;8\7D65R!X(V.@$C3
M,]]'F1=*W^=R@^DGO^+K2X!Y%GM+Y/H8WYFS-"%/7-0NQA=RD5_C./B 88AI
M8($UKV@+WT/Z%=YK"(L62@1U):G>N%=23M^DI?6H*W5:79<VV8#5U#T&F&*=
MRG$'><^\1Q;8CJ.E@=9$&J&CWEMUUJ>BDFH%S48FU_^84E&>#I$-.*;#302.
M1@SHNCLXSKXQDK[M $V7[,<Q5]PQE+A$A!83K2$I-J*HY4X9%2<+RS1HO5*H
M1A]'0Z'4@90T-VD-<K(:+\7[@F[3&C$FS*WCRC6@.1H"IA.^PBPW2O"6=>$Q
MLR" Q5H6$5;I]_F7;C(4AFJ>Z#X U[*SBGH9?+N^$.ZX#[VW&DTV"(+J\*E1
M.:LR1J>)>01G6;K+N0VG^@6CL463YYXY9G-SKIGR28]YG$4I.G'/'+VM1=BW
M'R07HG_N8-DB%(G(!J[]^@&3Y%+:=Q;L800)6\OSR-;TNBN*G74M+D%I;6'X
MM_:B\)^^Y8DOQ*SP!.(M\@X[Z'LAA;KX;:\[9;!M3X)*2?RV Z>< /^G;7S\
M.4D/J)@R^2F?;C%1_-NWU4M[2N5?C=$O51SB,!-V>_V7^))3=8W:S!B*7?-P
M6\FHTDAF>W*+,,!5'D9;M;&0V"I6&^X$&)/O,8"Q?9IEA+N&T",Y:&72Q0;Z
M@,NE!9W,73WU%,4_,P23 .;/X?+O'$$O8\LIDZYE)#)J4V,35PYSUQK53CW0
M["\\_#A 5);SW,(HPFU(]C#E3*N/,?KDEW /"W/$*GI+JM>(O2U-T^LSBF6W
M,.^JX/70M _T\ ]Y E+K;PQ[$IGFQ]N(Q*:MSZ5I66>7U=JVZ:]W7OI/G(7!
M8G_P_/2<)KCF%G+M.9AMB[^4)@:1%^9.B-PRGC^(6#JTU!"0&O&F8,B]>"#0
M"$,UHFF/@*1=N.X2:-M>'8\-5*@ UK6I.HH-SX!,?0.B9;=U%!8Y<S4?H(D4
M\!(9Q1L^2+K]>7((M4W7?$*J,_%)0L4F*%D[M*.P25FN"5X">['+\(BLY#D\
ME97:42"DS=[ULR44*!T%2V2.KV.D;@&?,&A];.Z.YT&HWG<B2[ZC</774BZ2
MEJ/0]!'#A2Z4.U9\IXNK>4,J5Y]$2J[C\'38D$ <GP8JS*N_AW=NC$P+:ZIZ
MRUQH'('=T2P4$3)L:G,TS63X\>+XCR>,F903VM$L$EF:4O2%CY%*8B.[YM(3
MT['N<$7?@=@(O?:CE/!U CHYGW^)WZ<[?DKXG8,%*GUX5*N=^22Y=F'N*BWU
MA)7@M\@'*,5*,L$J+A[JN<U:TJ:3N.X!7/SSB(B!F!1]R$(BSC[BHYX_]X+E
M5A@'=?)3CN)1&-HV8+Z T8!1&]HV8.C;.L\0N37&H1GVX+:!H[;:;[_88YJ5
M*WDB$K:U7MB'?+]?4P^EEMFQ!X&ER'*GXAL8A*DBMW:^'M28E,IA]8[:2/6B
MBKG^*'; @ET^1($!'><"R&OVGH#O&1[SX8C_<:<.R PA$EF2/Q>%==:O>$V7
MOZSQ3XF7^W03?I:?XBB:DFR>$0CA'N*/G>9QB.<4%P;%V1:!_-/42:OT-)?4
MA+^PVM1PY:454]N:2ZULGA5:-1%N4VLFCC_(09W5VJ;I<VM"L-O;L@1^+BZU
MK2U3[U@1^;-?#DC#I[+&\X/8%4-[0J1^*"L'G=O<%DQ%;WLQFVO"=.XENP(7
MXL#JI']1F^A[C@-&D'@S%"\ZR8ZZLEX_XO4NSA(O"M8?>/33*@*O:>S_]YPA
M?X=E;O&$E8?0-'4225I\:)$D&0B*7:R^19FHH(.F::G,:/3)+$&*]1;Q'M+;
MC<792$7D]+2(CJ!X]G0>[_<P96"DTEO7A&$8_H7%S2CPGK NG3QBIAIXS%H3
M4EU,ZXP]U88J(D!:<'<TSEU*RF]$;*OB[3AP/!VC$:/,$NDGAD]+E1% Y'AJ
MCK3"Q(%IFN>LH]54#)VO;DP+)&[]9#KCFA9 [#AE^G7HN*](]HQUU4_'@1DH
M9,KJS'<4>2BJJ_2.)JBH'E>106%:,,E*Z,M.)L9$ &+2D9B$7'5,#^1<#&N5
MXZ#UEMAY9C1'$WPT$9K8P#<&?J%$/$3Y/\@_[_BJ_N-_4$L#!!0    ( .>!
M7%0*I=/=H0@  ,NR   /    =FER+65X,3!?-#,N:'1M[9WK;^*X%L"_[U]A
M=7=&TQ&O,'U08"M1R+3H3J&BZ6BKU?U@$@.^&V*4&"C[U]_CA$!?E)8.Q8&C
M&0H-]O'KY_/PH:3<DWWW]#=2[C'JP#,I2RY==FK^E39RF8-OY6ST.Y3(3HN4
MV\*9A$4')) 3E_VY)]F=3'//89XLYC*Y3Z6.\&0ZX/^R(DC)#62I3_TN]])2
M#(K1!9=[+-UCO-N312-C'$95.K3/W4G1XGT6D 8;DY;H4R^NW192BOY40-@F
M=7G7*[JL(TM[IV4E(N[2N,<E2P<#:K/BP&?IL4\'][MEA$+N-UH%86V?@Z#/
MOQM'N5(YJ]X]+6<'6@W65U(>C[9-[7^ZOAAZ3MH6KO"+?K=-O^12X;_]TI-K
MQGYI\02-HXZVA>N\/&./>[YW:M[U>)M+$L_=&_H8"AY1GU.8UZ!/73=MTT'P
M<7V?\J[EHN\4X<\-=C. SR>L:K:L2KU!JLW&]WK-;%CUR@]2;WQOMBXK5KT9
MOJ$*F#6X2JR+^C6I-:LWEU R12XKK?_ &V>WY.^O7[_^-T4N*M?DS#0;I'E9
MMRSUEEFMW%R;I&X1J'G6M"[(E_H^:30MJ&R9+=5:I5&#BW 52E@7)K%NK^#'
M1<4B/^LM<E9O6F;UHM'\T3R_34$GJAEBM<R*=4V@L:M6_2?((<W6@Q%D$D3
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MU-[,'QO0+HLV7IIV0.<6J3NFDR#TS,K9MG FI[^5LSW9=T__#U!+ P04
M" #G@5Q4K+!T6&@K   SN@$ #P   '9I<BUE>#$P7S0T+FAT;>U]:5,;2;;H
MY[F_(J/OG0Z8$#*+5^C;$4((K#L@\23A?HX7[T.J*B5ENU2EJ06L]^O?63)K
M$<(&>]RNLK,GQH!42^;)LZ^_+=)E\/M_B-\62OKP4_R6ZC10O_?^]][!?OOY
M\]^>\=]PQ3-SR6_3R%_3I2N1I.M _?<OJ?J8[NG05V%ZO-_>__O)+ K3O43_
M/W4,3]E?I2=+&<]UN)=&JV/^(-"AVELH/5^DQP?M@Q=\RTPN=; ^GNBE2L1
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M+><*$:>"&;Z^M=LP.[?G]^+@Z'7IOU=P$+Y.P)):'\\"]?$1O5C^!*ZG9VL
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M.D#XR"Q=1#$LP8>3A[4F<)%$5$H(<0 C@NANLSU]'5L;/W_3?G/T\C.MC5_
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MM5B!O[K#P634Z4YJDG75 )Y7=Q V@]V5"]NIYPAP+[*HDZW%HZQ'D$N,,Q!
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MHIANLOPC/'?.M.4V9':$.:L'.)AV"J8",0(Z !V"6%X!^^F)WGO# F+P<\$
MJ R$!9T%RPK[A";:4"!8L=Q(W>NIS:M7O^,HMEJ?UNU7(M2A6:#[CC'38U.
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MV.&W6BPP0]9"/S!]\KQ*],SAWW57>EP[D))D:V,M)Z[L7T8?+0TEHO;>6^U
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M->-?#81ELDC'_<%8>DH#LC ;D[7F%3,XG+ ^J\2WL(OK?+W5L6?-QH%$W!U
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M*6HNEN5Q772,27G:FT+[1$P,<JI/PP$8QJ<+G&PK,;>Y"5>3-7+$N2UE)H1
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M'A5>@K.#%GI%? Y7J/*8CW>_T)GWW[_#XN%__*^_?[<HE\D__G]02P,$%
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M+I0%P\?FUCX0"0/"I2)%ZR2?S>!!-B"8:O2[BDM\%AM#4AO#!4^ $2IQK4&
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M-#B:TV-ID4;,NKD)BX3.\W#X+? E9NB[?8]M,<XJDU6BN4G<XMG2(EF<%IH
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M&$SFFW.[ I/YRVY=KH>8S#_DZ.X>IR")@(#R$WHZ,[I!)^YXDQ,<(SX&^_G
MQ ;[^9^RG_^9,I^W(/D0K[HCE$]89?-.L#[;-7X#:IBQI1ALQ"25#:-9R;G>
M9I?,K[2IHV=K4_KQC(-9<3P7RJ;BG30+N)YY>#VKB+:^]&:!0'HVNU&2FU]Y
M-+8EKT3$2AB/4W$R5S"?:'E"*!9S9,#R;"+[LD7^@6<3-9;X(@D?45,HP5!=
MO$(5 OL1(!UH@)SMN*PL6RDGLAHCC/;F)08E+]S(!D*NTPXCEQ"9)2["!9M
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M96V]"3VTS>J?C<="C^9@$]@<0AG:!)YWBU ^K"@Y!D^+,[*#V6KD9&/KN$E
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M;;[,,?\<2%["954^$_:]?;T&7T+(/E!GT, 5VS*8RUGM=28669X,\P]+/!G
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MM3V9(BTO%E$@1\3NQW:";C%UWZF$BC[QTT:7)6%R9VO>:E2TP??QAE;P$ D
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M?<PJJ@K-<B.+O19W*:T*E#61^5QA21UHT,@C^FTF35SA0HF)HJ#MU=?'"C9
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MQ?+0W!GGG5@=U"WG ".R> =>\S[@%T=SN+ZPJ+S:< 1?[NGLZ JUFEBF]D[
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MJ<PFBJ.N;,R5AKE+M$E,*KA/.8B/HSQQWAUJ56 JOS_A,'\BIQB*CE]?:[A
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M/9M+77 ++IIT75<X?)O@)#2.= 27S07%!8%P)-X#(3'2AL2BQ5/-YBF%S%%
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M*RZQ9[V8@^1IM' /XM]'1-5.MCT)LU<=HU8L4DU,+.\J3ZN99XIA4: A/F7
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M'E-IP4%%[H!,>+#[?) )!PK1(0I1"Q?'/<.NH2SDQO"YZM_A85BR+?+9R0@
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M+A?9#$^9L)Z<TK0QAY\<"DFR ^LRTYF>X?J"%*\16RR) I!F^:4!^;P^[SX
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M,8+ 7D^M<_QS'QTT0Q U@Z<,_2>,QZ+<@Q1X*@;*72Q#B4A\P&SI?"V#M&4
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M6+T<@'G7ZU)B-&F7?Y"#HW/V;M#M=!VK?T;Y\5HI:\&(R%8J2ZEBR)A[Y,9
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M'YLIA:UAX#<4&39$(G0XP\BD/[-8)H'T\Y1<XB([C2WOU7$.^P!:]NA?@U>
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MAO6&4&UIAWN1IMXJ=JZ59Z3'UDJNU#??<R,(2AO"2\!D1%42E@)*A-!"NM1
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MTU].+AW#;33#=7EDW<!KW]6H-?L CR_.WY]\.A\Z)=?Q7 ?91AQTWQ6J-?L
MAU=7IS^=XU0J<C-<_?SN[.3Z^O3\)\> &\V 7499-_#;=S5KS3[ JY\O+T]
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M.K[K^*Z#;?T/>N#*W)I]@*?GUZ#ETJR*L]_8Q:?3Z^N3]X[Y-IGY[KB!%=W
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M,=;NNZHV!VX'[G: .X*--OT=Y_,XNN.!@W>[X.WZ0W45WA_Y__%X$F4)V-D
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M%-U4ZIS.^NB2]7$=\S"9BMC9'YVR/QRX6PSN6,Q\5_32-D [OW]G\1S=@EF
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MMPO<.R[-MK/@SA(Q86<_'F,*_5B(B<-VN["][01W1[']JQAMG(28@C=AOW*
M#;L281(YU;QE"/]ZEPJ7/.^2Y]N1/._7>WTN>[[^V?/+*<DO B7]/B5/%Y#*
M83:?BWC,$_$R<AM%P>3;I2I??SQA)_][_'%X_M.)V_0WVO2SD^'5DW9[M[>[
MN_=G[W?S5-7K6S]A9P).DZVEMX+)?,SQT5MQ?**&YYXY+K?>(DENX^1HW6,3
M,  FC"<LFC+<8?R;)2)E *;TEODA>^-7^6;8NQ)CO 'KU_LL],:KP1OXYSN>
M^&-%]J<A<C7:BN9 H#1$I)X;;X%@)(+HWF/ :V9\(MAHP7@X@4_3>R'>#@ O
MV>G_7.92G5W\>GYRR<[.CNN]\1[C[+T(^#V/!0O\F8\<*/"YK-ICXV@VY^&"
MK36!TL^ 4.!1DWKON$7J2-AUWM!?3B_9N].+ZY/CC^<79Q<__>:QT_/C7KWW
MMT#1(+GF2G@U@X:+K>;KN<.&@GM.FW[Q)@Y[?U.-#N&F"6Q4L&")K&N"*U&Y
M2/@,6#+^/<%K9)>T-2Z_-&W30"E,C6*^SN99G&1XUS2"SWG*QB)..5RD:J8$
M([,.;NF'<(G4-<^C.S$;B9AM>VRP.=CTRE+W?1S-1]$#P#\<]YH-,/4J#4$8
MG8*BD\9HG"<//H OO#$TUY#-/F):@\A+#>$Y8/^()(EB8&CP/PB>)/78?R[9
M)S])D.[?\86'FM[3="D/_A$BX.%+ JE@2QM6@#$W&#Z6/\0/S96D)$L8OX>%
M$HP'?8ECQY]?3A7O>G_[7."E%<?D:6C>P@&,D%'>1_$7O.+>!WM=L1K"L*8L
M#\]JQA.,] 7F,WC '"/["1 <?)J@P4^/1%))XTP:SW#$/( ?$K=-]*JTT+"$
M!!+-&,DM\)-;H)]1Y@<3%F6IMF^7?^-(Y>6D<MS[FYZNK<X$#FF6T+G# 4Y\
M>5ZT]UI2&]*9B,2/Y9E)0!>D^P2^&Z-J,(VCF45$^  _Y$2-TF&AV $^,Q9
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MZZV(53NMP=%)3B=[F GIDI^Z2P#?]P=>?^\ _[<W<%9FA^G V^QO>P=;?5=
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MNIZT4NE/9_,XNI-FW3 (HGL>PG.:3036&= 7M:**M[=.G^LHW]KU^CM][V
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M"[/8C'NM:+E5)S):J:A68 J1:,>1OA8V:HK3NA1LJS?=Y!F)F+VJCQNSI:R
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M S :9[.17.]2)Q2<YQW%^"8W'#O /?;8LCR(*#JZ(N<<>S::%WL?C:F/+@X
M7_/O2FP$]C89\[EBE1L!G\T->Y3A-6QY0_PUBE!]SV>=RV/&T>H\L%WD(A=N
MFOVJ:W/V5Q1ZWHJWA 7#>N58I\=X =V.Q]0'XX.<E [+QCL 6J=JDK"F/+R;
M9UD?ME!'!3\+B,7ASSS5+]/< CNJ@":2?Z\X@.;B.$=95@[3?4C&KEBO_5AK
MS\IR0NUA<<_HS>#53#9,3O'Y$2E@F6'6N1R8XAW5UW<\R(0V5BPN2/J>? X\
MZ)[32/N$ S?T2]LY0U&@&I; QZJO06&+4_X@L/?HG:_+X?!5U=[)V;\)0 ;A
M5$5'R[)3C;=?VA7_85V12[XC5C=I+/&3.H#&"J@FL:H8EK]3I8OY+>&.2R1=
M>4Q:W=/OI50!J1\4@(-[%H5T) ;2Y3=Y*,F9WU'_B!!N@$\XA5FN=%JGH>1I
MXI47=$_]ZN Z9.FQ$0FD0O@!;8@?J(.=^@_(*HERK;G"R:-O#<L9):H=5/ %
MRZT,#\#N-%$T3=3/-O />"J]*+PI1V[J_Q_7W9,TX>!CHU#US@1N(W S)'UD
MH?J1F- FP3%A[QO97D\VWK/;ZTH=U-P/6SK)'E#"TYMO1/H8&:MBQ=3V2JE&
MRG3 EKIZ3KJ9CFZSP()ID"O[*^&\F@,^+.D;R*])7LY0G]*UL/I3>?O$EK/R
M"R)N5R/J:D3_A.7U-^N]/E<DZHI$_P2R>E0AU0;><%V[R&,IQJC!"/5KHPI%
M[?%:TGS(H'VVXJS;%ZJ[RZ:.M@E4X:&1OQ#A+3U'IF).A6Q)MT+;(H\9^N3&
MXVS.20JMO5M7Y;&Q99O!C5'A 9&KW #&)(-?D;&.9KFTSZ,86QN*^&8A?>VQ
M:IRG#'!\QK&]FY8"0B\QBR;2':*3D$+=GS%#P]DGA2R(QCS-I;6MXA16_46(
M^?(5=JKJ#9K'LL>DZMTGZ\)XHK64%1V/90/0]U7;E2NN3_5N5#0OI=O>\X0Z
MDAES$_OS2T]./DIZQ0)7ES[GWAEE-%1H)%9S"Z.C65H=T8'1Y]0]A[8*>*J_
MO+3FF!;U/6D"+ZMS!>>+4@I)7TS$-$/?R=0 R:P<R )WZ8\,O6+D47VBYHC1
M%IVPC 3K)]2^RO" .36.'LL6(H&Z(_VA0PJP\W,>DX:K/0")<8VO^3W1\XP;
M:J0O,"1L'@0DQ+'UG#].W[8>Z,^9QT1AESI'6]XZ$?"9RRL-BUK/343J?ES1
M&S8AMQCUPA&2WUC.@)+KPZ+J6#HM=:F.9/8 SH3?X94:823B@#EFL?+6DP."
MK-#%CW.^P)U[KM56@;VG *\*<'_2]G@63\ (+GG3)F36W:UK1Y3T(^G.=>3:
M XF<2)$&/#62WEE/<GCCG<*@M7+94%MY?27P2K-[HX7W#$%"@67T =/[S".,
M,J 42*5B@WY.GN!)SZ([O!DZIN$VZ<+R.N2]F]1'2E9/(I)$U"W9ISZ7FO_9
MF3HYW^.J53)-W,4F^:TI="36ME-O[@&".XCNT67\H.B4)*:LA(E%4-3);'@B
M-D:!G]R6)_P@2<'=JGV650[K5M* SL(>U#P-6Q% :0AM(=4&H;X\#TLR1>F
MHME8B6E%;SB"+@*S&N 6XQ_3*2PUU4']>^I$ES/GD="W)&XG+U4Q[YP)KQ=C
MPN05-"LPVJE%N?")TJE S50Q8>7<0X>W6FS.>^T[6F,'1B(?] F$NFQJ]=AY
ME*)( :2$)OO)BI^7&\_9!;%UUHA6QOV!\=NCLN7NU)O^GU1#,'!>D8JM6^/K
MRR&V/(KFR< 2SK]#Q2W1K$-]R2<T4CC18R6PC6*DRH5$(>=@%$=?@.!NA S.
M/>:,B6(?]I4<X?DX.CE_Z0YXW5S%X>+\PMQ?@M%A%2,JN%]D**?TJC('P],Y
M&J5<#.MZN=RR\HP/4$/!\@PA*7AMC[_L=46<5&7R4/Y2O@=6=DMA[HF\"3$:
M+=#PWW/T,JF+X0[F&W;'QUQ' XO/*SJ#UN0L8KJ9P;I,0B1?06R5@*'(MUTJ
MJB^LG%62R'>Q?&)?/UBX<30V6T63CHLKK(BK/\GGZ>!=">_1NC6<K#"+3#K7
M*)[GJ<B5UOO0W.$C(%ZD.EC-V%?AU-P)1&"'PR:C)!\]%9H\"SOHC",J#914
MYA#0"P]2'9S6-[90NBIZ1IKF1,ZFR:3J2A(^!.6B(JYFNQS7'26]G)+&.E2/
M;*64P.DCQ_!GHRQ.\NP>Q0>CV/B<E[B0U: ##K645;U.(_VLI"GZ V<[4-96
MK/WI:7D(1/ZU7 F.BA-!(D=E2_V4BA-I7(^U;B!-\T:W?&*RPQ235XLHOK3E
M-(>K%\L-)<V$)!&25W="KZ"&+NF$(CGCZ-:/)QO8:'LA6YN; 5;K)FMQC).J
MP-B_UYDQUFE8>SZAG0P65KJBX<#(?P/=I#E/:YS-*8<^ELFXY@96RQ4'GI>#
M9R(G@XV JH@98BJ?S*53_Y3>(C@-97'I*Q4/4]>Y(WCY$0C-OWB21"C1;'_\
M4HKW* ,=$O.QU=\(2Y57+L&<HB=- B]WDR6V"R7) T_4_&M99!5B,RNSS-=4
M6Y256=D>K#;5$_0H%Y4XDFU?/^?5\VSRX[?;+Y-A;O;#OH/U(L@(I7TRXRDH
M#:;P 'Y"8]\F.D\ZX/=)YFO61\Y7I9L(>Y@?A6/&Y08R*F,5]:0DR9 #FZ<D
M(@A(<4X6\+"Q4LFG/@9]9>ZZ?(Q28F\7<Q1S8UZ>#&;&^4TK/#-&TU+QRV4K
MYM%L:R"X.>WQ2*3W*.H*XUUP8\1L'D0+LN0JK]$++>0^QM77*E&>FS<FT.R8
MULN9UE1FD]T;A5JG:VKK21\A0"MBDT@D:JC5742S:T?HMDI].2)'UFR@4B+3
MF_6/)WDYG46=68CIV5(UJ7@^CZW!KY2^, W(*,9; 9<**?//%'<PD[5?1L&=
MGVSPC3L<*53XJ8(WK(.,4?F4Q^]G1\+ES 4L,%0N4<E#*UQ?J[UXAC&9/?B1
M(*"W(06-#-BOKM21F8:A"*0!)34N]%G@78MXBK]-+H]+L*O;\NH^H] EV+TV
MP<Y)JTII=;.N2C_5>/I$E^^HC&P=2M)\T HYNFU_^;;?&A\?U9KG2>Y6SL,4
ME5Y9G&4ZZ\DV?"#=$EG$)1.KUOY85_%$C[*Q;@6?:.<^QO] 'L:J\@X/V>[)
MJJ<PC!)_XLO*$US0=.H':#\DMJHK9SOK$%]1RRT-P35F%+ZEF"1%NZD8*Y3#
MIZ432@^2FJ!V'B?IQC@ 6P8K$?2*)M+I0K8&K19S5*A$!NP3[!I 4^P=;;Z<
M-GTU$MTN.])T,PY$_ 7C0RGFV!J[@0P)765$MHVIJ 0S!PXYD;8::7'EQ(5B
MHXF5CY9?@+TFXANA4QHU]95"PZ3:H3^N(C[L2./EI/&[+!?T3=55(>6@,(^]
M,/A>Q]>*+,/X<1-R\_IF5K8V3]37ZSD'>H+[N=RH0%(71E+REM%HEH0R32N*
MA3&![;O+UU@W!<-F-<A''0V]G(:^K$OGZ-3X4J;HSI;Q3_) J/+N95>&9:I5
MB!M8@O:\8CR)\O"4K"D\PQ9)^D=4KPE[^T68JDY3MKER@94+6Y'_J)(X\TE'
M0*<"$P'G*/ICE&QY[V9:E)KY8"(*2,DNM/HZV@O6RXZX4ND$.B +D709 *=\
M3#R2C_S_>#S!NOM/IC3;YAI5WZ>+N7+^3DFSEO)14\@HIQ Y"PN?/UZ,92.1
MO "<*HOEG8H9%N82V]%8>JVB_[=<+8Z9(CK*Z^*MKR"OV7J%6UBWE#"*N4F\
M0+>?Y2BS/6+N$%Y\".%Z(1E*Q2%0OA<RH0JPE8]BHRCZ@B5)B'UA=(K<5?ZD
ME!GCPS=Y19:.;#SL5?7)%4$;%8&VQSB;J1FR'0?']<CK\X?A=119D;74RT0)
MMI)T?NH1P\MQ"U/[!H:6J9=V=/EBNHRD6:5"QFP*:W)FZBOV<VZ"P[',9L1I
M)&@GLCL_4JE]=I.@*H.D#$(;8:K)B*HWI(8T@<P1QCNI9YJ8,&Q* AQ=W,#N
MB5!6 N+<:"R(PQ8]<*-,/B$W?%5YI\SB]NS0WAT8UY&,DYJN)W2]LF;B1#:\
MTLJ!Y9=Q)/5RDOICO=RC!20%-:^P3=MR<TFJDB)WU#C#&L)"_[O<V(@%I=6/
M:43JU@_K>>0ZOV$^WW#--*-$.B3JPLK5N=UH3U5SF4Z>7[D;DDZQAGD=[6T^
M0G'C=+Y7T SV_7LLI=J4Y14R)1-X0?*6H790%+T^[CB\MPZ44H/$%2U-*EF9
M.]&7GVBRKE3'ZGS7<HG@LG(UY7Z 6>UJHA$>TI(74GHG)^@%"%%RN0-[^8&E
MZ]56[S#WG9RA72\]+F1EYRH"X*9\G7CP)><U6CK5?]K8P\)_7<< CT,C/M6U
MY$ %^^O4R-V=Z8O/---!"#Q78*( N@2K'Q]4Y1=!KR(K!).&Y3GK>3*4$M*K
M"N_7K3&3&]=4N7>GTT("-WI-IED<^LFM481RY>L^BK]8ZC!;LVL424TB3U=>
MWU@(1<E,\T<K#->EG9'J$7@1N^6JVC;E7T2HLHID428E8Y56!7<-?)&9S$MY
MK>X,0^WJ"NM:6?DW0CM?S*0#2:X;ZWUT1K^.[0N,JVH?$\_G0U7<URX)M8HW
M\^Q[X_M0FJC=#J[0E'4*U@TEY6-&%ZH\]Z%I\*8.4$RJ]X="TF/MTNBQTZ+F
MHZ@ [HL664JQG%O8?FK5J57L_N8F*MG:7Z_UYH#JSKC=2+_<M-HK=T>8P:'2
M;EK.>LN3+_>U"1S&9:8U+S.MYA.%76:::_WV)Y"5U< 5./2*]%^2$33-!%BP
MZ5NC.UEETBJN^*WLW56J*C-R#456(>4-OWV"B#DRW7_5PY/([IE5(;#SAS^Z
MY,+K]HIY_"KC LXNC.X#,;F1-='4ECCO*.;KD7,F6;KI/3[JWN+#)XMT*KME
MH\ZP["K0'9I6G#I:F7/9=0CN)".),I5>I_9)Z>H&T+QR ,U.0[NY76/;[WK#
MX$FTZ;P@*RFSUV_$<*3FS0,LCT4J]G##V!N(8]D53A9@%SJ"%EJ\4??]BD9S
M,MA(C>/RJ<V5\Y4\]$[2U2I?Q)-UH_@/D!A^R..%[-J1QMQ\\-AD$[N;GEJC
M3D>A[$WY!+L?GB>GMX!D4=>;1A&VST)^90I([;ZD6#,;^Z VJ6WP9-04YWJH
M(068GT#_&'$9TU+!#Y"%PI^3 A13W6+>\D5&5]4%,MS)L9>^O(^5(V<RM@JW
M4ON48'JX'AH7;6!.ELB';8*ZIX^)'1L:H2>L>[JTSNX>@&VR,#=YM#!#\):;
MULL5ZM:!YEWU  !L^#^^A5W$L4=FA(&'K\1!-F28%58UY("NR&*5P86DAPX5
MZJ63IZNL:*'_],DYJ_H?KWO,+G#6&V'&@4U6C@-;R]-I;WAL\KHG_G0J9%:H
MGR#42*G7JR6]=S7X> :WQ/;)Z\^>-J;[#M&>K2BJ7K4)CX*/Z@CQSG3J^;!%
MG1-:&-]1.5[%HY)-U35MW0G25PK2 ;.%E")>4Y"_?(1R.MHP)!0SPZ5HW!PN
M1B:IA];,);A9-!-Y5LA3^HCSI#"DR*[*U^3YA%NI&68T[,UP<P\7[LDDAD#<
MD0"1;)F2%I0?F/H.2+A0]3&6^1,!DUN=XEM4)413OCS-0)_T%#C".YQ2E3<^
MF-@#\:C?I,FO(6%E,TX/'<@C00#-;5N+X1)N#2\C2]?FXOTMBM/Q231712?X
M4"RSCDUD[RI5>>+'6'@4 1/E.@_NOS.P^?L'>_NRBPO-36F")E;<@F;H8NO*
M=X(%0 5EQ%:L:+J12LQ2.I;N^6":^!;E!*96C7W;?6(*5H PJ!.OW7X7-!<A
M4NP&/A$X7T?.DXGXI#AO)A93%#(Z+9P&^A@64'B^71XSPP:L>;&39C<**1@Q
MTJ0O!52A(4,^_A8$/3T'/0<W.7@DG&3P1Q.P+&+'Y5%9G9PO4+T^\A>9^98(
M&I7FH&K@+8+RJK@H#Y*H,'&R+*[GL7]'81.K]7*QM-3J!@4D0Q7ZDCG=<^PK
MS5?>$J-[&WK*E)G%9:HI5(\ XEO9#7ZENGR81GUTF;5%*W9%4KA]AJO(34\Q
M_#J?]"Q&*7NCCDQ.+A@E21;G3(N:SQN]1,Q\/5+B5F5X@9I./T=I0-X$2[M8
M/=(T%S:QTK&5!".!1]EKV-(0_ZIJHVBIV02N6+<;(8V',B"7?S2/:$=H#4K
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M4KA4)>S0"$/4X6]DO%8.+\OFY%? ,E1E9AIY6'C\\G :6&%Z:UFLLN0SEHW
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MT;9A>(<MMIR?A'0Z .'7=CM <M3^#EH4;>1WVV37S!)T]AB8@9QC/5$J;!<
M36^N=X'772\Y%)C,1Z1FO)'.\K,"N ET\+A YM5,'7)W%J!K354P+PT:RAF7
MN2G!OV]D,=I:%E3FWO!R!1$I64X>!I$J$3@#GV>0@H#N&Z"1N;'CS,:]&^8
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MP.#XQ JV[JU+-F"@"':'4PW@5;@GEEXA/O!]%)A+:*<[0\&%V$#K#/?- *+
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M:.8<"4+/52:IM&C3FIW]^\SZS%%6A?=U?&?N_*<UE0CI4\%MD,8,(:^??'K
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M7^ T367M1=Z52[$)GC&!B(C9T>VI/O82X0_6PS-7#4^NO3*4D*YB)S&M *R
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MX@VZ7 ']N"I@B8E<'$@.=OW0SBF;BPIV3:U8L6^;]H-=[PM,&-EALL&'#>]
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M>E 0"2B]$$Q$GD,_1-VM(45-F(2% 7P@?YE&C(C6<H34#P@>"& 8-"*WI&@
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M!C.4=^.E)3@O=D0Q#2/I2<G+);)VJ-*"7%S8Q<>\,)PJQ(T1/I-ZF%,7\;W
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M9F=M6\\*LF8C[&] @2K_Y=<Y0XN?U]!PYR_Q&S1P_@G;!$#6_J94'5:SV?I
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M->ICO? 9L*JY+650;:P22=[9A)/>CO, [9@+@7Z,T02U>3%G#TD$MP "BS!
MD[N0? >4QF;#5XP%YKKI+KSOYBQ /JDP!GX:U2^1*0"YPFUBP^JSPW27I=:^
M@D+9YB2=UL 'XC)Q;:32()%&9=X9^*5"TA\]"BD[31VTMM"H<V],'(X&DYLP
MA-'9>%=K,-=UG].7YK"VURL0F3+2TK#,%D73=J%.E\\LOWDH4I*6)M97NU <
MG.>;-AIG*!#.[=/U"JS1A"WRHN17C+C"6.0&JT^H0\O3&DG#Q9.).Z2H>L.C
MO%1OX6#%-BP.DT78H!0.AC8KZL6(!J:WEAZS@>QYR!%CMYF\7XT.5K P[-OF
M41,&_'$T:GYJJ\@*BA%%6?+4^E$<4P=W21T\/M#4P?N E]YO-Z$G.""&!Z4H
M-3D7:T1K7(X-,(2TU>TS!3E?.#E-T^9 LK+MF7MJP@BU$:M<:H?%52O,IL,E
MRKK^"-@D0&. WTE]:NZCOSEZMI"9]G\":S(9/D=B6$4?9])[V+X4K62N-5-9
MM$9[=FH %NI\,-Z>@4]8 ^#'0K0]27?!"^5^(G)>1)>&F/$PV:&*8S R3J@,
M+M&#[A-:*C$-L:X&7C8)_C^BC(\HXV^!,M[S$M\19;S_*./#\V]"#W6.8N>F
M\*_R6923QJJQ)FN2)PD?BLD3.Y$GHL0X@!BO,]50E@^U*)=N +O[N.DXQZHN
M%<I)V'=*]$RMS0<$R@4M+N.9""$W,+"M23,#W7U24."K0W7ZDYNMN0M.Z]DV
M)C4/R >M]-CQ2<]__X'8!A[OMZ6EZ,S'T5/$6FWW1,3#L;@'%()UA:D%P:+S
M5X,@MHU 7.'E]O3HB!<$J0J%N0_=4R+CH:O"TI<K25\=YGK:HC.7Y?(9P:;]
M4IV[A1\M^ED=*L; '2YKU$EOEIQB<U$M"_D%F54IJ!-"'D5X#']G[R_2$)PP
M'Y&@GR=$O*-M;BQ% M/B]^DQ1+U+B/KD0$/4/OX%SX<W(5._WW9B +=J&*6<
MZGD%C&UC6U^3>LH02%)2B&EM2%U9M)CGRA<QI/Q!-HDPGP%NF+=1\JJ?<O6C
M2F("\0 &BC9;?.<S&E.C[IJH* 9#:Y#5IS=&R%P[#N=M3MI4FN3D]7%HR0/6
M@_=%^)I@5.F(!OZW4&U7KP AJ$D0(XZ 7UP^A]V-J;PA4!/2Q(X*#C53=B!C
MT;6?B,V]1;UNLM'#1V/_M<J;;6J1('L* S"OWAOH#M"KZ5_V"!QA:>R-,3Q,
M5/O/!VH-A_ 3E#.'%?4B;]=Y:5ON]]TT]O:DT&M=VOV[A1* /8P><=M\C?FV
MA4P)N2@SFA@()X1535+\ETB8UK:A7<QO-/VY$JC(=K=$9H%$:@NC68*F+&(W
M0XO,;9.#.Z6[,*<#4B#VNCB[![710NHL-7]3&&6'E%.3@=TGZH."8+3X_^8D
MF#NXB%^T@S>'0%DZVQKJ/\478W@.PRE>4FD$/<B53'FHH<1U&V-H<Q&'%IO-
MS F!?TT;%Q=E7<_M-)LSCUI3X=&CH5J!:9H\+ VC><<OK/*-<S%ZN4\P BXR
MTG8NH@HB+5#G^*!JX#1QU6R]G%H9:Q9K-'/1$V[,N%+$_9C^7T8VF 0:30C*
M6H_<ZKGR0R$4*]?1=C+@I;2T?X"(\N?]-H>3'C5=M<612U;]L9VTXF?%"G]L
M17&;XK[+!7HY 6MB/:OZE@.@TB_4N\U0C)E8->LY@C"M?Y;TS51[DARNH1.I
M#YAL^DDQ+XYCASOI0*O+K$T'00Z3"KL30B@P2U/<S2 (E*BO&&HO$F2SIC<U
MB,=-WZ^&O<U@C=>TNQ,_H;13RW@-\J+%+JS@.^ME*+ DTF?^>U4<@03R.)U<
M:0CGB]!=3D(=>L<,<E33FZQF7:(@ @A5MA/+XD3QO9DX?MZSI;>%,^]%&PIB
M;]&$$W4$$!2P=?CEUSG;\N=UWF" @#[0GV CH$#O;TI9$86Z2+9L6L]OQWQV
M.&03>('.3UD+<_3K>N67X@R05-^-^/?!@Y/LY=D?9W\[S\Y>O\Q>GK__\.[/
M%Q]>O7E]#%&^/$3QCWB@(<H[M\H+=(J"1I-MN!*[L]_'\9"NC(Z*'IN".'MS
M?=3(?,?I365.#JT ')ML\&SH=]K"UP"1!:3F8)2IKY98CNGH1 QD$FMEF&AQ
M: GF9KGWQ(*(\,R$)!,TC+;1N>[=X(+0OG):*B:,S;CPC9DBAF11JLR[M\72
M?!G#"^^S^,'GA$UJ:.6$*\%1AX"_0H(9+?GH<[) M9!3H]N",U*P5Z,CF/><
M(@R:[?1BHQ4A05!3W7M4S+32=MJ:3($+=V0%>!^.CD;]C)-?A!&3IN4I)L 0
M/$=Y^*O"+S>,-5;><V!G>QC?Y\T,5CC1T-DV[=$AL,(/G^<%83]A\E[C#.VW
M'3#R';V@-[2L0MFN\.>*7R,0W6ZCA"\!D;>H+3$F)1>%^(2V)7$C 2!R4QN
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M;L%^2;^E+?>7+3KSK OLVA-\)")BS.P,?)\>>3YM#.+K*DMY2MQ^N#ND#<D
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M[H@+8"> $9.N-2R>B#(=/>Z3P04*ISZ(!76/*.:T5!0\!K^I %&GZDZP#TJ
M00(_!)TR<M;P4D/&B*MB_.,0BSS:=X;]29AT[,YFXP'5N=7*E;*+D3K>]FIQ
M9085G"C= F)'U+Z9?[\7]W7SH^>?+OW>[;('>PY%.<G.;$ >,<C?I)0FL5^0
MG1O^@A#92/5;K>%;5W5!C8784J9-]JH6=\-U+#D#^" Y<#(;K"_FQBP&?IN&
M&P^^5::;X9D5A;#0M+I3"L#HL6%1V1LSD.I%W22_C*\=DNWT%)#@JPO*M7FC
M#U_VYFLW(X/?(G53N4TKHYA(R1L:(\R'0MQM/G. F7;^&)2/)*L&U-;VYS@4
MD#_ (SLZT%1CB865_O(8^.]Q%T,M<")'P("*EP(\63Q\9'QV4]RQE+2ME/3C
M2/N\H+VY[Y8ST6L?085A(X"@QL2VRP,M2.EM"22W>\DS-4&<QD\Y8)A-UP)"
MOUI0F1![P*+=2Y\$D\OM;-QP "/FW@$>GOIT_?Q.@I$3FRW(1QSJFH=,K1#X
M:K:X/SCK((R*$W?B#=K@2Z050,FLECAV.#)A;%;DIK-O_D-)6.R]4QBOT/%)
M1GGET+2?%R43Z$/ HP$$RS_$*XZ1+A'+?NLP@)5C1188)%?0%Z#$LJRS&VZ.
M5.;(-4V'4S^:>2[1S,MPH/6SE#>,@$%!3#5?<9PW9$L96D51>1V$<S)<[^P,
M_ 7,V]1#%"*M#D(SR:YG+:06*Y-=X% 2T"@6 WG311J/>M6^^X6[D#X$ W<6
MU!Y_SZ\C75NL#XGUN<DN1B;P&D:W6^ ).)LVO][&NWAP>G)Z>GIT+U+NQ<D#
M!/F:O$R!*J#;]+2;6<%@25T?F@T(NED(Q=/L!O%RA=P&E*DO4. %>8#T]ZI<
M"8<NYHK;3HXJ?/G_6N?8C5,/9<>Z0*OU=;#FQP:0?1O>Z9[#5(X-('=M #D:
MZAV&^N' 4(,>\!P] <CL#J.*12#.$.,JPMXKQ;CU3_?CB[KKBSH=GJC"8I=G
M%]#N@3Z.]_E C)L@5H%EA$XX+GD<7\9=7\:CQ,OP,6?^Z=[Y)[=<==DYH-4W
MV2C_MU0_OTU^^M')=RQ^?DF]_'O'Z)\YO%[!8CS)K$)G5&@%@6'2!HUH'S 5
M E$6-S4(Y5[!*0WI0 JQTQ]<*'N> R4:IC4HY]$XP$-0'=9D2^A?@W7<U^(Z
M+N3C0M:%W._VBXF?(DXC$A/])W.4:/Y$5V6/AC/:&,=3ZZZGUN/$J25BGG<*
MS',FTL7F,/UB0"A<H]U@:$B$Z& B#.1 8V),XI<RD(9"UXXV<E8I>$N4N.;\
M-B::)4=DT0?'U737U?1$:/-[L+SK>@UY.62>RK.KH@[ N[RBY"*RM6$@@4.3
MJH-2U-=RE0NB]I3& =,H2&Q&>>"4F@$C;XFU$KS\,W^5XSN^XSO^.3LON-]B
M"VQ(.C8(N4^](K"C67\5:69*#D;D7\19V]0EY 1;^4>)M6,BBVLY@)R1"C-_
M(R.BL:UC 2=<.C4J=U%W!;DX:!TL=]HE:CK3%QB(9&26C5IEO6XR4"\@(4KA
MGO-V<5X0HU0@DE9K,ZQE)0')?LG2-DAM <&V-FBCD]_ TH#2@]&>8;UN0QKF
M7RO,-VZUV,L,M??/4PXX[I<=^^4IL!/LA'X(B(\1&C#[WB.ZU] Y:I13F9F;
M#"8U7[>!3*!&HNYF'0E>8B$4"Q]YBY@0*GUP+CMT9,DBP'5^BS9VOP2G.6PV
M/E2+RN]+(E!MZD5!@,Q@!29*3VB*SXT,#(YC<T ,;SMX5HN0C.GWM'8$G()^
MS</_8S9_$;5J->A;XNSX-Q%X K6B;+;"TN45-_BSKE3V]/&3T5RI+U]!MIWZ
M[*\<T&X+?<F#7YX^0?A.O@0*R -J%X GV.^(PW0)\%IE[E9:6$@L2LN1Y24Z
MT71H!%3;6W0"SJ65O(B*BXFEQ%^,8*5V?<S&('@C(C=^/H\ I3NQ2F_%WNDY
MNIN(\P= :^R[[-L(?!1E%'*?(%;DS>5-=[Y".#DS144DQ,C20_[=#_":'NWY
M:XI!-1$>1O SQ:=L]$09:0BJLK5]<X(L-/#*2ZO ['JTN2B?X*]\S[K.$]M)
M'N-2$IW@RD<CC1H(&(NYHM%_@AX6VOX,424OJL7#N'%QZC(%;UNL&^#IC)PI
MVUIPQ(']^Y;LI,?+6BPX,((W2WHV>77AE.8]N1"85+5NW<U81^AT):Z@*(])
M#D11%;SRT(I- 7(6,Q,MP,/H(3;CI6YJHS_ 8MKS8ZHO80M,ZM1!U,5OW^[W
M!;-D*XPNL/.1NM&/\ Z5CVW?3[#0Y;!5$ H3S^QS!'V'HX_Q;P+NWIK=L*@B
M2U\HBX1D)%(=GL29'UMGR.@A)M25<P7.NWEDB/W-HFST0>_>P[' <>X)7A1I
M7/';L>*N1ZOZ'<]%_TH*H,K!?C3(:$<T\"1YMB"*)R128K7:-AL9"B;Y#$_,
MZI]K(%8D_BODH>+>:4[<]QMYM9)X0QN;D.ERME%)>K$LA%G,,>UY;QK\^X/^
M;!63(VHA'%M%.T:H,!M7%FXA9$)R7[ Z/F1Q'9@G?KJ)X=+OL2)S+<(H1^O&
M_.67QR>G#^YK4BBM?"SI+,UAL>KP1,F6!8]/K^A&%6:53H9B>IFC5C&4V$EN
M(*5U,X&\+F[%:V#L]$L SL_Y@,2W!^Z#L<4H_1:OQ%?8WFO>(]HKD'2W6/@#
M>^X6V*(!C?8 [K_,FR4B9&+A1DM%_3O*\4PHLT>):)I_;:[$\@RLL:NZ9*KE
M#78<SJ5JW6CW@G$UAG,[%)XQS09=.+<PZ^W<&$BL6%3%SX1?,A"UT)**DMKA
M@M=-75TLUF749F$E5#DSO34X/V8=[U3 .3U08--A$<7$C551@C>$8]J\33MV
MT,CH#.MA*"T-&,21\RVT5$I9@&H"6_N6"ENR2S1W1[%BL>@V027M\7U220,C
M<PBUG\-:.K?B&#IH__%PB(8F484V+D''2 /K,,*^&%+A.H@:C]OEFQ%LDNF"
MVC:+G.Y$&\2$:O8M]]_L32B\2*:QNS2D]7W">M&<V\[/88$YN.O[5'_@]($A
M[E/,'Y6CCHV#WZ)Q\)?]'M^Q<?"H'/4-EM6B!C+7O/5FN5@82M>$V#<J  ?^
MU(FR((#BH9AR@XVS0;E*'UE>(2,).RJ(9 _HAB\JY2;JFC6=1= \8WX<B_UP
MR= /J.SXF$LH- V$BG<?=L(QZP>U@+,1('-TL"*8DPG,P@U@QNKK'*D%#1-,
MJ';6T>5O<=J.$@J6.)1;CL+P2L ;PFDC[=>HNX,K[H7D[4(IM<^SBH(OL3=A
MSOF>,Q$88/T,3IOZH__)A4,(,#4QT2OR&^BCZXA_@E[Q#6\%F>: YZ]T%T*<
MA="5HIVNFU;[H?0-Z**Y<;YGAAM^<AC^:U\05-&BV0N8SOT^T@SA^$%,]B$'
M"WG9UK+! ^8'6+PA(8KVB9+-Y7KI3\_U4A3")]E'1SETOR>F=;5NZ1\FOLC;
MRX%9*,C"!VL7U+IOIK)5 8$@4A[BCD5>-&PVLJN\7'/GB6NN"K*]+-@>87_,
M0*!GB?*Z#HH/(ND'F7A@)J\;_YR085^I3@?BB1#_-AK*5;SJJP">A4-H'/&-
M;QO03?-QDOUF>_3AP!/#S.EOTOA3!O>&#P+E\F)-#UL0 G$4OY;H*/6KM\EA
MK=T#YX?= >A!E\J*N\)A^S#M!-N$(MA[C/1.)[1-#VLDL]C?4V&$I X!@T/(
MF3?D-*R\W1G>%FTJCR'!IS.3^KK><7<YU[:(CPU3'L=4_9U2]8\.-%4_7.EO
M5H9\ZX"8^_][BUCN?7D_$K%DJP;O 522\@X9%DV:3FJCS"@R>C#NJ7% >\-B
M[6W=HJQ!4BDM=8EY.8)I*CL)1&KA6LJ/MP%I2#PM,6S"Z&+>!I&I7E<0= V7
M_K\PGWS*/X]+01_\S>F"?JQ0_/:?=LCV!H\3!@]_PQHP=)F;UI];WR*J!V&+
MJE:##DV;!KJ9*E']/%"A&B$*,*O;M"./KF-69S%,@V^2IQ>UDNRX;(#_*BW_
M?$R^SJXYY45#(&2"KYN%CF[LY^FL4B53'67E;@K/?RA+\45RG@_@(#3-:8/%
M)?I$2*;@W6I;P$X_\&&^KW.-)5[Z?Q_,^S(20N%92E==>+?=B!#MM@6&D=YL
M;$G [;0&6+A&3EA*^&WO<SU4A^F 4,RH<S]G$B3(BD9-H:YDUIK0W+9]$Z/5
MPM.@<9CTGO09P/'\@ NHZL$&7 E$GC$_,?L2(0\R.@SYPG<Z08?E1^P6(\ D
MP:H3;,^N;3WYS&7RGGB0Y/NT0)C/A++V0] FI1: )\>2*>VX#028J8,GMMPG
M0& 0X@9DW TCBZ0=BHA/7A,A-&YAU3 ##*4BO#[)M@>DEJ(#_$]<<\7L4M"L
MHRF6!JQ1H"'@K!,]4X72O%O=IL9Q !I2/$G1^QLNTPMD(Z09'B6!S;K-VEJI
M /B5UD2%13 T6E9 &8Z12=TPS[Z5.<&.1V$8]X/BD I+9#'O-MV!E72L[,JB
M$%I[GBDHWL00/ !. Q";<I="=$X&#[F4B48D\QNF(O-XZ\7](T#Z^0C;;S-V
ML+.[_XX!T?!/+',='MR4V?\A: <.)ZU%>29F8@*W/&Y>/YCHZ7WQZ=X?,&8H
M#?AGV>]Y#TX2![+8B$!'8 E9-E#<D""IYT!I[W]" P>]X-"Q\EDG2]^_B-A!
ML!AD (-^NC,[W?VN<BV*6;WQF&H@5LSI4PKL]@>Y&85NN%@W4A1,W5C]G9Z]
M\9Z&2&<>;<[W;E? 5Y1'JP/6;UN3(MIRF1M%2UYPT?[.1M 3M^A=(_X]Z[V@
MTS=DU+#)B&BMR[[;M5D2H\3?](<Y3O;+HW(+:R)AJ('M\WE6^6G:F=^P*8UH
MOR)Q0W*\.Y-C+"R:MV$WY=/ZRAU\7>EPTB3#LA\Q)3;NHD[4_BSA3-#[0Z&F
M^P-IL%Z,W4\D0,=!ZX^>^8T6E\B).F[JJ=P%!<_.'"\WK[-QIIU"L-I71+T=
MGQO\<$J#Q!V' 2R67N2<Z6D*XJ[K8M+N0RW*T)=A3+\6H#@P@^5RA#G<!>;P
M^$!A#I15@DTFZW>?%^[M>A(G6,K>RC%4)_)A!61QLVOO! >U-G_-4#S$-O(Y
MR9'-D9:(8<21JF)PF,-E>L)GXE2JN?!VC[-%AE(CUBE'M&UTW',Q(E8=\#9M
MN0(27\I848Z)>\W]58L+K)NKB+/5A[])_=TV"J&HLX'AYK.96U$*+AH.8GFC
M43-]%SE.*?95RI_EF4A)!BWYR4 P'DS2RJ%=,G];K:?>GAGU7,R5]=&TLTM@
M% @$YRH^[\,%Q-YIR#"'?&3))\32"K1'KIW S(1[ .5$&EPRH>9$GR1:[T1E
M>PR+T"@ !N4'*PC:4/,K5BBQ,PBSG*RU%P(MX?R7LCK^E94!TTK02AQ'PT7>
MA2O78WJY6.>@+%JK TBCDG[_8P_7L8?K&PSOT?W]'M^QA^O8P_4-EE59B/!&
MO\GV1GJ9+3TQ$6[5R%T+D=[:7ZE!^'CC5E#A0Y_@2@M76@Y7ZAHZ*D)O&#Z$
MJ8GI7U9-43>F6)[[T1/,:UK7'UML4_=#H1^O<N H1[^4CI](!\D>O1K<A8.,
MCG,+]^@-VU]CF7^$(WU5$#D0$)>B;YG$KO.A*JC\80IP :N%7A*Z+/,X/3.Y
MH68]=TLD\D'."D3A^P<H0!V.'J)8V&N# Q2#/I75XN%?^XDAN&3JJ&^[@)S#
M-W$, .\4 #XYT "0&\O<3[JHWWD?O"G0;NQYF]D.9'L  # ZH0]USUF77.VF
M9,@N7.4:%1K^ ?*4^\XBC(GAGM7RI\2OV2@?BSPXBU\ B"+%0$VD0VGQC"AV
M(EX3 J0$[F!*.*(FYT#)@P2MI.VM(QF0(8D8G2%T2A,#\90ZB^=X%%]? GT?
MLNWA0TRV2W1(W,AW4^X]5,PAD2T!B*0&\BP;33]SVF)]CJ1*$#Y",;L4KE99
M7B2Y,7HX'CV/5!4FV>_ D.80G7?6E5"<FV7OSE]]F&2OJMD)2)&]]"?Z-2!V
M_&I?\8(_G+KPBWJYVA+O[L_>&LIQY-XU*@L&.]/;PN< 3D'O@J5UH/R2VF#>
M>\.FE=OWO4_E?^;7RF6QRIIUZ7KUUGB58#>)62, Z\4*@WHO#Y"3J\DNO-?(
M]/-^4[7=,VP6F7WYLBXJHR7"Z*C(6'!J!K[$.Y+J"5]% B=(G% 1F3G0OHD6
M3F_*HRVI&BO]IXHT5I+/<GNQ%3L _\;Z:BO8>!%)21YZ>?QP*H)\MI;%1X>+
M'G=T/R\]E*427:AZD+?FY3P\A$ZR,XP*F5:V-4Z861]V85 ;NR0>1>$6#!8@
M,YGG@\*T+5)"K:0\CX',G0*9GP\TD'F#',/(8NS7R$NWR-=EM]\;TF\3FTT(
M'J2%%GGS2YARS&;$4*.8T=AFASAKD )^*TI]GF)JL_F-[<T0FD;!^CVPA(=S
MC?,.5'[OP4KPT.245E>/?Z5*'1SW/7"5/UT(H%YR":5Q*V00;H=I+#%%WIT$
M3EXX#4W#*A\VIM/'-!+F?J,V%=D:%(*L+RK_^L*HX90#I5+Y-U,J]\%@F#J*
M(IBIH_(1+L,A1][4;6KFPC"  DZ.8<$2L ^$R&O->RB4 ;7PB_VJGE$)3M-V
MB+GIY\/R"V78QN=U&V\&_;($]+I_='+SHC=/M!Z8(^,D$IE@>@Z*8W92[JCK
M:)%%(W(_>HM*CB$?"\R'8]]".T\*!OZ3KF V#)EJ$"KU<S?G=@WS1%K6VD@@
M:'.<P(AM/1Z#&D$&);V!;M-)1$9> 9R$>=@#EE_.+&UG.,G^7/'=P_%*+0(:
M2_*\M.UZB:L(N@14 M+,!Q6VK_"Z-E=JVA8X?'4-5&VI@%U/N6^C/YW(G"%4
M213^<6V7C2K2<]A)4I;OP2R'^G=.M?-&M2=5^^_0/;]# 4:JS*>HY/3,O&-V
M9J"#87)FRQ*+$8*NND0E0BK,['\!Q(QO*:L0)5#]"L:NI:KFIB5:*</DM*NP
MR49:<-.+AKMW /;8#FQ7>O5M$Z6!'II*^GHVAK-T<)NX%$X.,>5*S &0MEWA
M< ^@$JZE.V= UX-R_*#@$8%, C?0NBKE= PU>O2J+4HF/K6.GO)=/.6G!^HI
MOZZK>[($#C?#?^2N^7>_G F3>Z;THPE&Q>@R:@7:(EJ-YBW.2VH;=16KU \U
MZ(,^_8UJ]'31L;)_)I0*>F.*[IW/,(QHY8'BGA-#JDKT<_"5J:NPCIN7FLEL
MLQ%D+3EG.O'OM)Y]U.3*.#Q\X-C\S'$6+9<S6N^K(E,0_14[A)>NN2#_'<Z$
MNBSF"F>3.2=Z(+ .K,]RC2*.P1.FRD-S1<AHF[OGT=%-QAR!78WCXU)X\\(]
MPXF'LS$A;CABH(/)O1?BLCE/F/M$S+"P1#;*/"30=L@K'T()(46OO]\[WM03
M4E!7TS/S [03'XX9CEL=1F=C)-5<=8'NE[SZ68DI?[3:4=$5\@X+J"P&/- B
M)#D2YAV=8NJ5(\AQN^:VBSC?@\S/C"UN*6\ @:@(%B#>MU=J\)LX;_"HWW5S
MR@%?AG/#&\SGXYT_X5:PG%+6S6)]X6+FSORJ+G9JW7&\,WHQ'C0UAJF=T"!2
MFSO$QFB-O0T#O3;,)V&"2]#%2'S9(HNS9E:P[-*IL7N^+DH"?R%T^.5P1/')
M@0#YY)@BN'G$9T//U-)#X:E).;6P?.*39IL>A,D=^J/%V^T"<UW./QU6"D?P
M6H*@UT5=SZ\+3(#P0[ANS.AK\NX W=W,<Q&L$\B&8M'!%!$ '*ZW:ORUBQ54
M)T>'<"R\]A/S#YB8_38[H=58*?P<+%)QS/4QC'?!H(=YSL1+?HG\'^7Q^[_2
M&TY 06$SUP!7*+IV['%(J(<T6L+#8#83<<=T%!@G;]D@H,".?_?[]F,%VGLH
M5G4(2RD\SQE/RF&LJ<.@#7]!\<5A3"D6!M;M#Q >FX+[T_V>>_&24<\)J4@$
M+3,Y]LD<^V2^19_,GH,]CWTRQSZ9;["LTK#%"899XIRB_N<]8)D.&J /_JKH
MM*L:@X76S=:-H&PQA<6P Y/@TJJ1_XU3 F_":8 8-=Z>OX]--0M0MFB_9#CJ
MJ!:L&#U Y@HS:D!52#V?/6V_*.Z!P\VC4 ^Z?R6L_LI?V&O<GM@=P,'"CV[=
M:/KCD*<>2JI(R&^A_D\D3B73I??*O8L;TR"F=\P_G@^+2C>_<"3V.C$<EABU
M$0AB*"Q/V5Q2'YN+9 FW<(<<[^NS]R_/_M>OV=]?O1N39 HN>,C6"#)A7J^G
MT+A<9V4-1:(ACN0VMYI ;;K-2]31V=R#]^:ON?+[*BQXS5]?^P=M:W>U(Y6=
MP$)(7"/[1N&\@_G]L0X#O #-G5^YOZY78/7\8WZ_:.W!XY/L_9_OWIV_?GG^
M+GOS6_;VW?D?K]Z?OW^6O?G'Z_-W[__CU=OL[/7+S'_\YN]GO\-7/KP[>WF>
M_?;J?W_X\]WY^V.U_,NKY8]/'AQHM?P]HDKGM,VE\K;?9AZ/\GS6$0H'SNLY
M.!HVRR[M(!=\M@/U4;VAI%G@FPWPT""K,3!J71U$X!UF; -H++KE G/O9C:C
M6B;C5] #07T$3,P13WLQX^RN'C1SBXLS=Q$5*Z1'P8/LH]L,)2(M*O%64Q'*
M7?99=SP.7(BX=7)%W [P2P$[940O<,!Y$[$/6UKDP+ "OE_5PT<P%I*?OP])
M15>O#**5_KKKIE*?D&[=,38RZNF.*8X)=YG.\2.TB=I5RHU!&].KN:I+(&9I
MC,Q<;Q(#1G:CQ7"9)LWO]]:RGP5J<<J6ZPZ3T&;*Q?L([_"Z;CYJ.9Q5Z6CR
MB>4]\>KA<1"%W0XK*]$21W4V2D>W[#5C@\0,8HJ<LMF\J>QB"=SAZ( U0>8-
MK^9CD.'ECOBM.YU(#P_T1'KGE@+CY/W]EIO#PI;9]P/JS^W<F3V1J+7 I5WN
M9\LUNZQIS+EP<[/$P<>;C_?[/4^R?ZV+CCM7Q,@/$RK)8[G .AL4@UGM(Z)Q
M@[]= PFKEN_KC_;*:-);>X2REG)\=/C__TGYP2;VS+OVRXU%'7)_1/A8Q1\K
MG&]IW I3*8P, RD(ZZ8@IS&7QE=0RN?4C#U4 AR8H!IP/.*>(,5/LRFB!9^B
M%8$<"ZMPQP1L#=@)+/!3JR?U M"GC-V/9A].'*-QVF^!L,RR?.E$+?Y0MY3V
M)9Z<[O>>&G9Z@;CZM"FH'Z193Z=%>\GD-^A,=XY8J%7M-I+!!>'Q>YGZC[-\
M6C TX^,D@X,&N7M O2(TG3!% EDAO#9E$TV?LB$HPH7U.PM77,?B'IBP]3='
M1"=D6TL_7?8+4)_O6EW@23D/<I,*/V%Y/*H^2K\%3(O_GA\3;3Y!/<X.7B!<
M7(#]7KQ6TLM@Q9!SV+]:>-,M,&7,BW;F8Q.T>-K %YFO48K?=_M% ,3!1HNQ
MNOT)'*Q@LOZ0+312TD:2<L)0M9+EJX->LS10F9.&-<RB>(R.$5GA "R158YL
MD?G2AZ2#R!6N(N O@[T*I)(->8<GMWA 5@WW]ZX@4KNL88.AM2#*^\81P-/?
MKB.*R<%0\(L8]A$4E+1LB!^"=G38WC9,/T8N=XE<3@\T<CFOKHJFQKC9K\,S
M]-;@'_MMM$[\DK>(M"T1RXAK7MMIWK9$,7W*-G]ZY54X9YF@!)H:"G9N2^XH
M*# AT"SR&<(T]< E[5_O'OIOMD"=ZQW0ZH)/2P1&>EO@;[LJ5H@A1?3N)F-Q
MJ>N\[1S]@T"^Y7HYI6HD9B!<<]7/8' .!96M+KVS:0HF<V\),-^RZ]?^;]A$
MCDAEMBG0 =XTR+3,=:IY3-J"UL:_C;HEIQ2F]S_R__(FN5ZWV1] (5/D9>M'
M8,3Y@CU<$XRXGLW6*^^_;OK1B.4/##>EEQ/908 .8NQ"-5#\X[:5GLW(%D*C
M,#(\'7 4JD"LQWOO,Y/OX+?/&@*MG=M9TX]WW\^3%#DEG_&2CJRGD-G%]1"B
M4F0[:*@#ZA"<T<.TZP;!/)\WD&*-M5U'R,F9>H7LX&E3&3)0,((?PJ6RF,$[
MGF<NFAA7><_#"8'"? T\B_[CR\U%X:K"P)&]3^9=$>'ZE$BHFF_A6@?SF:)3
MUV2&]80I:<$+3 L#4S*OHOF8&G6XLG?I5@'B,O )&63085>&&69R:*W?,NTB
MY_FD!I:<V/N3MMQR36'75]'XB0,XB5"_X!;V 6M^X9?)Y23L\P[CW0(]=1\"
M?_(SSOT!9 VX=!(.6CP;0TU#0H]$UN,L<'C\GE^W1,('L_"5GD$&_26#"9F>
MH<_0?WW?W(<(C@(GNG9X"_%AO"1QAL8AB!DW'/1@0D$*\G^:3O!KG3P" +%4
M)"50;)\<R:#Y!U\W6.[$7%Y>"D<N][)U^4?[1]2/F4-,B*9[[M]&6= :I@'D
M)7@U5\ZOL0M.W>5J%R?D1C"2J@GY?)R4U)JQ=*4L2L-D,0DFEFU7>4;-0KR]
M]*7KS*(K5+!W(B3*0)"2-Y#GK$"!],J5-6>._)?*? IN1-ULP)V:\#RTE^2J
M-:[R#R:8L*\PRY\YLT>0]1%D_2U U@_W>WQ'D/419/T-EI4YIKZ*5_-Y9UKB
MEB?9;T1:26JSJW4#!W\;.IU;<L/@S)N-0UH_.GH4@.FOT/]".'[T6Z:A1T^N
M\+4)UQPICT'G*CNU1 K-_?)T#((;LT:Z7/R-]_>-WEW2"6B3'T.&U>7H\%1U
M=>]2O[(,,T6TJ\;GQXY&3@!'H0()'OGIG[FFDDP-'JKWUBMX\A;/8W]2NVH2
M_[&L9U0ZG#"E($Q0LZX"2+W*RPTP05/BNCV)$U^L5VDC&W1;YX'#HHL5^% N
ML^R0_TQNTL[JE4XC*L>#-[@U(6,C[V2$TKBKPF\#]%N%04MA_*?W*2&@0831
MW87[HR\;MD;'1*AU8SH!_$O9W%M B^OHT>-Q[WHW8R0PH$,<LM]=G(XXYM>_
MW,X%)D>@/);$'JJ>[0#%'Y-XWQY,,M!K"/5=ZLFA8,K--Y->;=$_(&TPO[^4
M41\VFNQXWG" * 5*\J!2PTM!5@"&5A$'X]8,'P3M1@^.L*-H'"C/-*\A<RPB
MOR PL* V]Z#$/2@9)G59O4V0<9.03#;JZ@NC^@:A.; O(1#8"/T!.6JQG*Z;
MUC">+AA[:"R@G_-[]>+>JIY]=!V?>\C[2@_:FO-L$R6EDH$IF,1A=?*XK?[-
M/4%(Z>0&YTUS,^X.61WS^9SS'WFJY2ND3.W&E$SB((?X$_M$;YL:(7RP*),>
M4;J]K.WL^M0]5GR")/X3LV\&;3M;\=R,#_[LJ1F(,<G^8N'0N^TEDXDM%H./
MO.?B8):HFA_X/6%ND7,9.5V5]#,UP9@EU:>7UU$W9F):O#2X8>J@S<@QKJ5@
M:6C-\ @EN4WO)@K6OF4J-_]+3#JBLW6!I$$CYC**TKA]Y -0&@T70N*! B]T
M:J!MA-%+.H8T*C-R9E.3L8^/C5M?NW'KR4GV'V]^?_GJ]=^R-W\_?[<OKNW3
M _9L+_U[\"L7@@;FB;XAS-AF[3IIKE"B*G\5J*6I2R+-OF9G,446]3%LC(H>
M;&4D 8*F9?P/@B:%JM*@ \>;:W<-1335A@!&1# 2:'D6W-TC\A8P=DO6_@43
ML;AY(L!)O>-<A.:JJ2.='/P[<M@O%JZASM=O,CF5"%+/$&#Z'![]72!L1CFL
M#3J&>*S,?92TR; Y1@F@P!Y#R]FE7_5PEF&WNQ'Z>7P_M+J'ZYO WK2>E1 D
MLSP7.<:)MR))%$HZC;XW#<85"%#/\I(M@;<O9F\^.?GYQJW9[GFM?(PZDZ#F
MPR1=4JR"#03;AXGH\&3UWY07'Y0I[\,K-WC\5;ENHS5B9*!X=2 @G?U*__)A
MC3"K?\](R.Y L#S]YW1C-DHZ+V=5-J11Q%';(.&;PW+L,-,B7/OLGH@(=U]K
M$$F+>RJ$ATZZI!TG3_9[G8:7RC!49+%0P]O3M +C!PL8RX57)&JDT!W_CO6[
M;,C!SCED3VAC)A#!* <RR<_N=\G;P.-91.IEZU2OE/(1[ @]?M"FI\-8@C$U
MKG_3F+42[F4]HF-Q#)/,:C6;Q9*/05A.EDF<3,ZOK6.CN<NP$.-V:UE4T0)J
MML+A$*,I0;[L'1JNJ%07_17-J@]D]<&YZVL3-W7G0(1F[A:N0J7,N5M6J"[G
M=Q_L3-,QE3=+A-H32PD(F?F-->$0V@!73.)*Y&Y"FF_A(S8J"05M[12*'J8/
M.V6VR6RGY6+[/-1^CK#CI*6F,-5,F\V<P\$R;@7UHQUK9ML!Q&^0,R,H=@1)
M#M$,Y=8X!L,4I&,J1$C<21"_F_#,^G(T5X$GFV0-2'R#A]MFE0/=-6C?1JLW
M0ZNYW<*%SNVI$UT0.OYWUS0B*^[7>H,J4!E3DAO!#EG!/0&L04$0H_UK)A;F
MS2:K(P3WL#IZN1:<'GCS>Q+7?Z6H<P_"^I]/LO/W']Z\?7O^>_;B_-V'5[^]
M>G'V87]H5@XOOO]'KSH053K\E@ U7BR;*(]#FD2C9Z;=)S=; Y;3\&\P&@QI
M)F*C[Z/'UL__RI79#*(BZ(KMW$3T@_.6R[P]%H?8'3?2"H(FJ"GV/M#&ET^7
MQ=2?_@]^WF<8]_=V#3]S>-Y>Y[-+]GL@R2 D\.2&8'&MF=&J,4X KIS<P!SY
M+YO0T<SGLC_H*'=^Y8/$NNDN_+%)VMSK9G;IK:,I"V B7&651=R$LT!C=&5@
MX>L)RQ+$E,RV<J5TSL+@,-=.J7;X'VPQ#,D=D7+"=@&KVFL)]:-'&W+K)S/:
M\9.FIH!T*JE@$;9TF-"R$-?ELR92I&&&NLH\O2=).Q29'F!A(PZVG6N@P%B0
M5 AVK(.%K"AQ'4ZRW]@/,^IZ-;Z;<G.S822,<\(<AOC-CHS;O[:1*='D'$&M
M1U#KMP"U[GF9^@AJW7]0Z^%YS%'?$EI;,>1+3A>JI"I47J"EB4PU(R<5[)HT
M\DCBUJQ9T+=N&G09 F<+NP+^> VL EM(]T: %(64TK(F+6-_VVN */FX+=L@
M18VFA0)E"PFK#)5K57[X1NGA\00QJEAHZJD)H8R07CN<CT8?EZ36 @@3N%4I
MK;4HD,.,@O&^1\4:,^%W0UT.FZF-$"7#3&Q:B3K/2"X<F)AQ*'D9WB].0^)S
M325(,01FO@?6W'59^#I7,,PU0UD-&"&:.VK<8-.B@D$H3TV;PW\+$B@SX\R8
MJ"M?SXM.?&',Q*T<&@Y9TE"B(;Y<OC&J&;\"T+'^./70@/GF!^-B9_@;ZOQ
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MHQ,XF,8CW9X00H'B)-Y.XZ_*KP"(OGZ14-&$0]Q"X5V[CH+5;:QKHO<6OKG
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M\QT<X2(.5*I4M+,[V%2 7-.B(UA+ PSNDHWTL>@5T^5F?N:IPPZNT!\)7'Z
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M97GR9+\7)M;.L)=2E3C76]IOY)0['A-W/28>$=8F4)462Y*@I0"4WH"E,$)
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MD;/$CZ:;B'WB)4=LKZIVW:!S^:)N5FPZ%8."&#<D,C#2EP"AZ(@*(!>AS$D
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MY1AZ?/^A#^I&3U1;[L^3+.T2J=T:<DZ$9J =X6"4!+HYL6=:DP:P)9;2L\%
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MJ.1#2@HY'T5GA&OP P@\M@\,S0CSA/(Q1Q003BCP$4G;1B>:*A0,C"D>?E.
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M51 SU1/2!,WRFNEEWD3(LC*M;J?LD)3EKGCQ_@"!2PEI$&!CD<S^].^L=P%
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MX!!6R%"/T6)&"Z"5=8W4< @-Y)[=2A)E0Y!4/0S?&3)!F\& Y)W'80.2'E@
M3FR)*I_RJET,0??),X0$2%V2,PNZ5W&PG0QQHT;FJFU:#B5>5,:6B\15%1<7
MGF5K*S@X)%K0['"POO../*?K>*,!?8+:& <\ZLZ)5$];0-(J_B05&$(!"(MK
M<'?$S-L-DAQI+B4<K_R*7[2KO+(478*Y+8#?;6'NJJ1DN;G4R%2(8=^^XYS
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M"(=P:H1AB[XYP"-LW<5#:I]*N9VV8+/E#'S^7[!-0E8GY7CLVZ&W',E!Y@5
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MV2(E<6BB,\R[UB0ZX;.<G+D/[2+7AM]OP5Z916O\I$8'1A"5+.7/P;=*8TK
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MG.N];!GX%K&?O=OG* N_%>4'[21LPE\JM'#@"713N@?<SAY_=WB^"EK7*U#
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M5'>\]52Z<$\Y,E:*H0/J)& VKHKI%[/KF39B&W)]+$@2= M&G=%<<\>A1<5
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MF(IAYN\4BDXR]+PLHK";XP55,7H%6+AWEUA-1/522Z*NE!U.C5]IUN#4Y9L
MU@/OVJ7;]";Q;JCO2M[=R[[8CVR,81UOY(TI5*TTVEHQU5]FQL):B#JQ=B95
MRR[N+7CU6=C^@R8+\R\Z?*DJ1;B/'@;A:ODJOL[)T=VJ.<?: >2-N3)YN5Y9
M(66#B#NN1B=3[YX;=K0.[EF[2#.V_'=\C]Z6S@1CA@1TS6^4<@H-U8DM\P_/
MI#,>+;O$0$?S&;-W,+JSUXY-BM"HK@V5E*G%CPN#[9Z2<VPRA3&I=<[I#B'Q
M!I469Q5<CJ5@Z)!WZG24,$,7<"K]^#%+/WYZN-OCFTH_[EOZ,>G6FW3K6,,H
M&#SF4,JQ5VVYVV=Y'ATOMU5[$[I&2QSC](\X\3"S>LU(4=!C6R</$HW!AVLI
MFL5,=(_ZS=DBGE72L N_YI /QHQ)22-Z@EHZNW"#)7O"IW!KS6NF6F,G6,@C
M9:_T)Y)1B10:H4C<DH)*20:?)>CUVXB,%,0+WL*K?/:0&%N>(6!/C8,ES#W@
M< Q!?"N(@7F%T/IDY9!96@O2HXKZLB%Y8X)[E8F#%71O^(;KTX^T=YD<JX'I
MU$?*&V&>7W]$7\6?36V?.KP<(6J5(G57;J0M1XO\F=F^N!XZ1N=D"U>8=[^9
M%XL1]"G>Q'Q.XJL D'>G![I.\!@O8[RN$.-T:5)=%(@M;TMZX>(^PMLPD')1
M3X.)Q>ZP.8)8EA=R[-P34<-U4F4+(PZ%;<(WQ9'N93J,M6751R04B<X,8G9V
M7 ^!O3#,7B.^=7!TX3P<V)Q$;2L_/=!P!U@,ASBZILF (\%0(V-K8&HD1?^$
MU _9&B/GR[A-#,I=_L4E,L@0:6C;E$D>7W'U)9QN#" GEXP+QQRX^XM_F68U
MR=.J%CX?_'!)3*8PV/W979).@\VW""6.\B?C;$,=T'BX7VA"%S4DM<D4>8?8
MP%IX6H4.S-II-L=P^\0CVPZ3S;N>'-9("_:>96"'I5'M)>\G).Y>'0!JH43@
M!E@&@=H1*7L^>7TI.TL\CPYJ1LIKDZZ;AX&VCM0>7YO% T,)\)3J\Z@NEY>*
MGEG33V$@C&7 MAY$^$XT<H:)WG2NB#&^N8:IVCQ8(J)P[_'3_8BPA3564T1[
M/^]':4Q)$'BP^10MXCHC3OC8?R9R=FY[5<W.\^7!Z/;J?1]G/U >01.]-)6D
M0$2YP?X9@VG]$5;J2%9J1)+-6=BP4 6*-G_';=UH9-L1/^'006619XO\@LJ^
M,:SE"<S#V-=S'IT'O#R#;1)1D@>5,22[55B2H W>_>OK/18A.GQ)6%Q+-T><
MCOZ#R$&W77OH.GC/FY:%7P-%IU><!COO*JN:5GVL+"1N:*1-!>S<C/F,YV8^
MHV1W(-Z]<Q!V34&$ ]C6>5SA$=">E08/462&1JDLUZC'D&G,-G@<>-8^Q16*
MSI13G+YO8FN-+T?POZ(2!X=]\P1S)H"WQO:K,F[[7*6QI1O[47HM/_EIM\_^
M//HX .+96N9]P\G^HF)NOTAR2.3_M6JSHU&5#\^_6J#[Q'%C7[)=KZ8/R=:I
M.0">XE#P;K.MX>\+I+36BAPXDDPO+665J5=LC!H4B[EH",,,RG^QTSRJK=%G
M596V%@)Z[K2M[@429R%^5 FP$$?OJ,NQWK L,I#\/@^YBRS:7I<]HXX91'MW
M8[O0,HB2WPK;MI$B=FH_YB@[PTUOZZO%47=E<<,_^)?410NC;W_T&15"DB$J
M??'LD7)DQFU-^0JOHPXJ;\O_27:HO+V61<==$H<>AZHT4>L/R7KB;;$ B?))
M%#_H^)0!N&@9T"/@;:OT 36*NQN*?@KA;@WACK5+\.\-([-?9^S'';MMNMMR
MDP*Z) 6N;$L:*_NXI*CV<+T6H6QKC6VPT@I7.&+,04(M;&?116RS.!H-DXJC
M#A>V\RF](Z6YQ$IA\QV1HJE&.VAIEJ3=C8@!+RNN2@S]VAZ.5BC&CFJBE36T
M#\1>%.LF$'I=FY!NN+9M).8A\0CY^@[*;+M[^4*,JJZH%T_OYBC"+U#N86FN
MK?LNM4HH01YS3B#A6G%_HUO9!;>UX)(>71Y-?P\/,)J*,-D@1SQ_O]>8;M46
M8+M]'/VH54#0*?1CTA<E#V+_@^\IS0:^CB2_*%%5V'CYTD_Q##^MU]9D'OW"
M",TNA;TVFO)(T/$P^@W!E5)3."XMLV:0^/9H-OV>$(X2$W<^=W;A+'\ IKSM
MA; WE)'N96K1C-6$]R,WNV[&W[L%UV2!W<\"&VMS\E\K+"H[!-F"NO3OIR;9
M)&2*?6#:C-W>]YUR[J1DM(_A]@1II[6 E9R6OP2ITBYH!A*9 9^QA.6?3@C9
M875C?-X7O7@90FT"!N6!%B2$R'<:1,B.Z[I,,O(]+3R U%5G@+V!Z2"\*D J
M:Z90SGL+?U+,U'32[W?2Q]J2^-W1T9OH$(Q?FVC=];,==G,:)(JDX#+9/POX
M)Q:EH+=0&3;:R9\BTV^-\49L9\-,M]BL3<-,<40SD_@STSW0T1Y1Y@5M,/==
M):3O#H7W&0#Y#;P$;'L8B98IK]%3)$>O-PI$\W YRY9?8/Y2LY)>%G-HI?],
M\V0JN?DQ2VX>[?;XII*;^Y;<?/^7'J$5$+:/;F[30KV.Y?LW1@]):=5,R^AE
M0ASE[JW:ZNM1-C9TYRQI&USLZRV-?&QA>-1F7T-Q1B1CE1)/492<KL%J3V;1
M31EX&<Q!C/P2^!MN?Q9.@B '=>3,T.AQ_"S:QFMQ1@WQ5AD#,>V$<6+2\@YJ
MJ)#287&54I<X_,3OHRG!0'2GM<6AH#6W=*STP;W='G.VS6*A'= LB*ECC[C"
ME2Z/1AXOT%@LL=T:>AF, XJ4#Q'&&4Y]^$Y?-L+AT?6(--/N"'HM5R0!X(=X
M.W-=Q;7EZI6<DGI RJII23O<C>UFZ+;RG').]_.#GHZUQ_B!X,9W'(@YCSY>
MF@(;4_O8#<F+U%1[)B\RTRCWS!K]DK1@RC0) ?[1IA?,)+11=+@5RF5EV5W:
M@GLW%2QA5/0A:AO4!#RZ]EMKSZ*@T\:7#D7I7%V_810V94V=2CANXD&['9>;
MI>$743[8UH/I>O)X8R:JF7N>];'R=H"LO\P6I.4_4"?2^E7T"]@0,/'185E5
M[;H!?:#.\X%4*AZ @?'@-S Q,"U#SP8EL^O2XD3.M-?<I]#*.B&B(BY+3%IR
M%EKP+\*+S-!BJ@\=4*.VA&>F=^Q>@?S@.88O+4QGXT#38IU@;F)ED)H:ZY'B
MJBGXN31PE&S-AGK)84)USWS6]AYX*_U8DFKK=I%G"<9TJA@CG753)I]</$;N
M19V+3=UX;&?:N1:C-S?/!T@\?A-N@L2]D <Q;3.&O<.'F+L&&Q+;/G/G6TOS
M)6BWZTOP!7Z?G\WE^X#^FZ(W2N>MV?:4>O/:#LO,>K87<R>4#S%<"R+P0()#
M"$6GB(_)RVMXQ;W%OE=;*<J#[3B'W1*["#L$:B-#US9>*TR9!Q7^TN-S4(,2
MJ.$4%4U5@N!_8W!!_3+8<Y3)V/1W%#4;[W\Y.-SM,^Y*;;S6-[BZ.KT"N+)U
M8+TMF&>UA_ \ -?D,^[K(VY."8?S/;E=)V4]CQX]?O'TYUGTZ,G#%R]H5SQZ
M\OCQ4ZNQ5V7J%^PPQ9ZP.6)TM,-0UQU)$5.=<1'AM#LA<H9U0)1@?T.5:&35
MOQ8<F4CPZ!V\!94;[27^[J93!>8*<MK->N_D31F^^YE9-R2(HL=/9]'CAP\?
M]7]"SY54F+ Y,.DBJ11"GB"+O;;XIO.M8_QX61*+=X;.^&6%19:$5>3/</!G
M[1H#RBA JK+*ZM6^$U]!UP%IA-!AC!C#D>IKWY$<,)M6!*,7+4R*$K-[2EZ_
M@VE:/!>5Y>A?L\'V/#GVY/$@%U%:M1?:68,;;ZS(Z,BMT<%<(B;%@V:BI*(A
M,X VN&Y[A>A.[P^GO<:Q,<3I6)F8)>CO9P>!"H:%9E'RZ.'/T0<R4; 34_3L
MIVCO/1@8)&]^8GFS;V$[UM%"R45F6$I6R8T*F:2=DQ-<7 7Z^"J&T;2VX? 5
M)H)4,2.VZ<(422:W90.(6\%4:PQ72D,5FQ^W7:S<2T[T:3]H+N?Q;H]ORN7<
M-Y?S9\0WQA?>.#Z)/AZ?GQR=G44?WQZ='KW_9398ZTRTT=(Y+F2@7!AEQ.0P
M-U(@$#4FZNQE5F&298$ELEIC2QT::Q-C\>LA%D2659'%7O?VG0E7W74YO]M&
MYH:9\A09&YZDETA7\FI!JI*>"YKJY<-7=/F#/-Z4;?-RF7TVZ:OK+&TN801T
MY.4':$K'Z]J\K%$WPC+I:Q/1$-^;I <,P(H9A.DSWN*E_EXN@JM2.Q/TN"?S
M9X\>_1O.TM^;=,LUC^8/'_YTRS4_SQ_>>I^GC^=/?WIZZ\-^?G;;PY["@)Y\
M@P$]>3)__.3GX"+X1]6=3]V1O#>\F839A14M_I__\?1_W%%<K)$YMKC0/?_H
M85:\NH:E9JWPDG4#?O#J"E.&29S+=H8?X#"WZ0C=LU]PO!Y^<R4Q!JCTNX.3
M-^_>G[[9;1/BI2=<!O?O7WF;?1<1'LZR/=B/IX,]DH-]?G1R<'(^'9Q_V<'Q
M-><T[7^NO)IF>9KE:9:G69YF>9KE:9:G69YF>82S/(6>=LM#_9I$\7^<'D5'
M_WGX]N#DUZ/H_<>3H]/HW;O#V?]95/]WMR-.<?3&Y/$UXKJTVL"U(\5B@[C8
M3*)A-X)23Z8COT-'_A_'I]'KX_?G1X=O3]Z_^_6?L^CXY' ^KB.?E-5:(G!3
M:&>W3OTTR],L3[,\S?(TR],L3[,\S?(TRR.<Y2\*[4RKL4-.TNO-!"G8D;#'
MGX/%$>"EG81G#^$-D(4D2W=^-7;GV/R]_GOT)BXRDT>G6,OVKSQ#-ZQH1(]Y
M_.S93/^'=]_?^86>;(*_UG&Z20M-\G&$"\J'#Z7DV_(:24O>EM6MH==Q6XZ#
MA723:)RF>9KF,4BLDWAE_J6NT/=1/'^Y=?Q+6N634/R1A.(TS7\QF37IGA]C
M'2=?9Q*$TS1/T[SK<NJXJ5\.8??^18TH)G4WSFUTT#:79067I]$94026U;\4
M0SVY7)-LGJ9YEZ=Y=V27KP)W3%9-RWCW93S\Y?WD:4WR;YKF:9JG:9ZF>9KF
M:9K';]3\\&BHO]R*(A#J5U-6%R8Z2^+BHJPGJW62C-,T3],\3?,TS=,T3],\
M3?-.3_/NF)(35NC'6,?)'9ADX33-TS1/TSQ-\S3-TS1/TSRB:=X=,W+"L?P0
MRWAX="..!?Z+_=2F-HI3;]-;9F_7>YL^V>WQ3;U-O_NAO/=+/WK\KSN41*!,
M3_X6/;V._O/M\>OC\P@F8/[HP2.B5(;_?3@]^NWX[.AL1Z:[M\EVOI/L+WE9
M5G7T?!:]P [@\+]'U ?VT6-MVGU25LUE=%Y>FXK8WZNLQ@[;CYX\F3U_\5-4
MP=1RO]/_:I$_>FG,U&[[:U>CN\MW8E>/;A9W7+$_VNWA37I]TNO_*KW^.%+%
MSCT\HX_O3_\C>G=T?GYTNBOMQ4>HY,_?'I]%_1F-]J@G_/_ZGY\?/WR4O/JS
MQ-+7=-;X6%:?HG>F@3V^V]*3)S-]M1_!S,9-$R>7)HV:DHRJ59R:*([6<=6P
M=14W46*J)LX*>+FX-K@B9A0+0L,=RU(L3'-M3!%M:<D4W:7C4;0WBF6!;0:/
M2D>R,C,Z%F';G/>V;TXTW)9F'"MQ;HJX:$:R#O/H(,^C)%YG#:@TK%('0;NJ
MH[:&?R[:)BK*)DK-$K1F&EV:RH# JB]C^,UE?&7(3:Q,O39)D\&?*Q,7X"+6
MT07\!1>VR:7<#WZ&UY+PF$?GJ'T\R1[5IJFC)?F;>!G_!G=(4A9IAFM?PW-R
MV 7@@(),Q8O@J[JIVH1V!@A5GG=^LQ>OZN@8/-;RRJS /*BC/7V'A<G+ZWT=
MSX?*K++:U-_&;QVU=?>M>[&?'1V>'[\_B1ZK8??ZX.PH>OW[\;LWQR>_3C;=
M5Y_=LW;Q!YPW/0:#9X5LC/",S>2 T"E>;*(X2<P:3@;>8P&G<@;GVL"YYCN!
MX-W+]C42I,>$OMS+W!=+#"+MU?;OUVV68YXL@B,)KY]<=GZ.>K9,8M2S>S!E
M.<N-?#.+QF+^O$9C35]S)$)^AN(N@[5.V@JC=G:B#\ZBXS.]S.V?R'S.:A*U
M<:TKF\*BZ;_98L6]X/XZ+%<@:1,2M]$;N'BN^XW5Q<)$\$W6Y&H41YF3SQ%<
M45['\',5S*OX<[9J5U%\<5&9"WQVO((Y)>OY_+J,?LOR'$=Z?ED9$[V%V:[@
MQK^ !MD\X,_.+\NVAC'.HO>%N^((YW,3O8&]%U>@%O[V>/;DZ9/9H^<PH0_W
M86_/#9@??WOT\_S9PV@-FJD7Y2S+IGLL]L=CO0?;UU>1: ?P$HQD4^,N@DW%
MALK&;K8R!W&"WZWC#5H4@Z:"NEZ9;R*(/ UG*&:AM4*!B-Y;EK2P<> )&:JH
M;)G!T^%&?_*<?3,E?4!^*JW_C@<G>7DZ9N,>ZYC*_%>;X>D.UA/7K3)+4U4L
M<E#OX7K^ $<U%3V_VTOFCNH\\HP6]52=I5XNP/)B#T\.+OQ'#G3_2 X*+3R$
M8-' ;>FOZ^PF3^(FZ\AJ*Y$D& [(#4D2_*(NEPW=[A))+).RQHU6UV62D5%C
MGWN'Q9M'1Y_1!+-2ZBZOJ4I71CM\$7A3XDR1MS.S4RYOASX=O*%,.Y^.5?P)
M/JFLV,3 1YS#S,0R9]6@M+2FG;Z##/].#M5DX ]G9F4N:UH2T%:@<;)&;&0T
MU<$QETWB3#8UP(,]Q"HR-3D8V17K2;L5W!$KBYOL. QGALJ.[;.FRCY'>V7;
MP.+@LZS-N&6$]> 0T31-\E;_B4(=5BF>16M,.\\B&$=U >/9Z =YO(!'7<:P
MB/Q'G%51W:[7<%;Q<)3+98;GQ'ZZ[X*QJ '0]JPC3^\]'M8LX]02;WBI-[",
M,NTC41'66X"A%>4U> D7XF[&X "8FD/FOKGB-F7M;S*Z#E6_DY).T6"H"B[*
M), +"Y^!88@B<8\\!=@9&+.:T0W,9WC1NH9]A?*2MRD?@&#WP&\6!N?>OZ)_
M%/LK VY9[;1B9;+5HJUJ/G@B74%HF:(9/MN#HG\2NU^_%ZUD#+9@D*H9B#*"
M"$(KO(25[>K'&&16Y0MGJRS%8(UBL07BO"_H<._;(24@E3.^ZS5*J:0LUZ2:
M,7C"5H>>'_@9N?JPS]N\B64L<E@V(.Q)S9-# R9.RZ<&-7[WS;S!T9"BPIBT
M?A7A2\+MX+A<PL=7.%;VL6K:J:FI8;G)=\*A\/DB9=3;PEFQK&)VS%H*.&'D
M(8$SIQ/6F;\[&4@-**9%RSZ[U7&WO15YDW"F,R-![?@JSG)-!,'C>S]+8MA_
M(D2"M;4&).R+PIJ1SD.5$(,_9?B#=GU1Q3!WL\#J@BG\.QIC:C/"?3<EF8!E
MC8J]3N!E[RYRW.#6<9;VQK8_A<&_6QC\B8;!#]Z]>__QX.3PZ)4FYH]_^W#Z
M_A]'OQV=G-\)SOBGR._>$NR\_'XR?S3>.,PX@F_SZ+BPPF@X8#8HE?O>=1 +
M1J7TH(&GA7'@N-"@+QI@<"$J!_C)WY[\-'OT[-'LQ6,,VK+VDR1D3QJ+8'1A
MY-$8]C=Y^+N]2VQ"@8(5Y86!*:_N%!IQ^V4LJS2R)0&?P\7$,7;53:JS]3;#
MU <8G(V:<=T .EYZW#%W%UZ</8C).Y>,+L);QP7\"CUV\-8_._O%'ML]C+N#
M]YXE:,>-9SOT#^U88K0DVBG2M(1)]]<9-HRY*"E <Q<?_=;HY'7&*H R-[U$
M#5O$ _/H\MT%")*]1P__Y(D=J.MT<_W3_.=;I[JYW.VM ++!Y.#_\/3^V>F@
M'W]Z61U>FWQ)$_QXFN!O/<%++FD2#YMS@_*91@0Q8LP?"001-$\!EB5N>Y9,
M-N8RF"%)L]I&Z>IH#?]L8XW7=4+(G$7QU)@7SMBAQD)3F=;7%RWL1KAD=+,X
ME6E-95I_M3*MG0^?=<,F+OI"9CW'7A@]XZ!XMQK[GO8#'4F \"U)D<'$@MQ[
M!2X"N M1N\:[_.W1[.'#A_@_#/_<913++>B%HBP>.(M@'IV4#88IZ@9L '9]
M-Z#6 \AY4\75QD-8,"9^AD9$Y\4\/(9&O=1Z"#/Q=%;1,BR:S8-EV5;1WN.G
M^]$*'G99Z[?;$_0<9T&\A@Q@%F5+_'O6'PDM)=@IA.H?' R.OX*Q+BE!A.M%
MR$]^A0I7)0#QT+.#X![5!<!L5+@7:;]@TGU*3-XGL/UXM('M-YZ]W-N.NZUG
M[[1E'SV9/WGR9-JSW<G;B_='NV>=N#QNS&K' W@618A0?12VUZ!,/?U$D=4N
MUO&+U%-9Y"Y MRSQ9Y2\Q[F1X#!&DH-ZCM$$;$>UUC98^_(NHNGQ1'LS))BR
M_>A#O/'UT1)CUZJ;J@2?FS0S1$V L9<TI;-##RX862X@7)O$.O3 -GL$,4=X
MAF"/*Q.%Q8=W\E&FU1M>/5B^<T0&N25<Y^"J))<F^:1I*UH@<#M,4<OJWE8[
M.NQ!U--*W6>E9*DTIW/'.0\0P>B-E6W#Q?DQ.S?L$,''50W+#O.$H*G&U(V'
M.:."9'@,J2;XMHIKQ BLRJLXUP\EKREGO%:(&&\8_!(.NZGH>D67[LQ^&%]X
M82^["K<#.JRP? 6!+,M GLY\;[8'GI3B!(LPKS<UF2*UJ:[$:=_ZV^M++4O7
M1W.5D-0/+=AP.?1WZILJ1GNGGLGO</@$'":T+V'W8E4:+6X7P>R9 A;,F J'
M9+>4^;Q&H80!%JK%I/P#[*]"]BMYR[CIIYWV]3OM]HTVN,"1Q<"&>6=_=WCA
M+*_"(37U6,N9#V'P(S%ZIR-QCR,ANEA-W2XJ&K8[%2+ Y?$%EK]P!'%?(JZQ
MK<>NX7_P^[\]?J8!V&E9[K,LGHU$"],OCA03A]0'+=_>F2B+Q_.?]H,R ?>C
MWV@=R4+^Q9@N^PE%C*=EN\^RP;J=Q;DL"Z8FFOBS_'6.P-;H\5-:K=V)>X]O
MGK?60=X%AN:5PW2%G7CQA/9@%A2JA.A6AV'(Z^#- =TB4/9$#)9G-K.$)F"0
M76(0I8^![#Y\,-GE%2 Q-<O7#JB/LNW2L[ M"GY4AN.O3(RH&76[P+EN+NDG
M50S63+2LRA67X[0+L'Y@H\ TNQHU\* V?48,I5.SE6Q2'>J<J7ETW%=$>)2V
M&/QW**F&$6<7H+]@.XC)A_9U^#I]++J=9JWSAH?=.L_R)%YDSZ/H/W"'\@CC
MDP%[B_'F$;JYK['DO:(W;:4%>T-!FT%$VUU9#VY@,*A[1 4$N:,\>+[I0.^^
MI"3P#IP)5/L;(,Z]DES])0G@,&'0JSXA43#D1N(H^*WBMKDL*U@/H<_+*:\/
M+[2$U4<Z"<FR2(S*974&."XX0^]O-'AD8M*V,G2GSH2BI"\+>,.-K4%EZ8[%
M-RBJX;]WDE=3T'-;<F&LTNI#55Y@O;O-COCB:\<38W?;LA.\9'C3'NQ'[WW4
M#^7$,D*I/VLN]Z,T)OO.Q&CD@--3I''%4CE*;]840W)0*_*V*A%7!%16+-](
M C(.R1=IB IC4QN^V>_8=4)Z$F"5[BJK7T8X)S&)2%.SW->$$XE+EQKL$8O"
M>^%]/-M_IJ\,MUEQ0#(Z.#Z(?OWYX>._P_][HG-!D^ _"R> 2(@KY2 :SE!/
MR/'=QSQ/R/&_ '+\SZ[I^=K9FY#CNXL<'Y\!X3D5OO93M8L\1Y>,&:-H'E)Q
MM>AB8;85.4\(I[PV%0H?V(>,%5BM<[/%Z1ST'%/3Q)GEF>F8%,*90_<TJ74(
M]2I$0[MO]]#000KZ,>3OU%@_95-EM^6/2^5%>Z^1@_VJS!*XAFPJ--H&,E,2
MK.V:66@F$?42$O2F%(?C/AL8TXSSVB.]ZU!"P+,/]R/SV20MKK:-1\9YM#(8
MP\L2C]TI,X5ZZ'<:Y_5ER0AX_B5CX(<8*I3ZJ[. T5Z<E[")Z2=M,30ZAU0)
M1]=]BEB1-3<?\4L5^]F_C$SM!4Q0C0<"40CD2.XS/L%&/>D9%,-PQS&/KRG4
MX(D!.(P(Q"I"0> A>P: /=W;4H"\5N+ 0Y"%L.9%%D>'V5661YBXCB035D?/
M'SUY'#W _SR']7V#QGM2KFU8FM!A1%->(9P5!A8MXN(3#J1"USFMI5I41 M,
M0^N*TSE*0\L#'];MJAZ:1 WL$T7ZT3[O$W)<L@(M=W[)3@"&;^FC;4>*(^AN
MX[-V3=(5::C*I,7OXC'1$4X!A7L$%$"V?\RP<(HPZ)L'2^P-LO?T&842M**I
M>WY292OS/78A1[OK[NH%D#4*$+,(\$A/62C&FY G#EUN4/W-0$K=Y"QLR&ZY
MQL@I&"]%O82[PRBSU<JDR &,1A!SQZ''C@'=?4X)!9#CW-0U_?!EM/=YWR^J
MJ\M0,*A$8@+_SD3,Z$;P=@TH K&@D!KCW_;A)DB404US0@(D5[Q'X0][G7*X
M8$ZU&!-/]B\9:L=3?8^12!B.[>]M]H75-R?]*G U,%5B9M5U>ZECTGJ:TJ4D
M]AQ3J5K"G=F!YVKF68H!EX%^CB[*,HV6,1S?&>85UF DU30FK/>@#$3O-"+A
M+Q4.8CFE9RS(RY#Q;=F?#M1#P((4.L *O^N:>*"KT]9PLPA,L2ZH+!-IM^F.
M9663M:QF6;7RO,JYQZ-Q764-'H^2["WA+:.M3V]4&V8YXFH9L:%$1_N4_YB
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MD2BD34RI,=ZMU-!%I"-OWDL41E+/AZW.KO !TE')$H]A.Q=7B$X03+]!4&=
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M]Z;-;2-9NO#G^A>(?J?G2A$T2ZOE96;BTI)<5H\MZ4IRUW3<N%$! DDQRR#
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MN\W4[D2O6[X87QNUROY2Z[+.\9M":_<M6HL<;X7OT8%;CE)XO.OYS+T]*%=
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M?1DMIK Z#XRD??'+#TM[CC<@E<X4EH=H:Y0"ZN0TJQ*G@HG3\^6N7I_&:2E
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MRYH_#S,!E7L?K(V96@)I(3;<0_!UL770:E$1=<\BVD"A,G(8P[C,54,!_K<
MGE$KC%2K]E:KJ/8-=[O1:),7I_K1J/8U.IT I3SQCL9OU*7'2 W.@*S7;UO^
M?GVEDH=\(XTYVI+8C=Y8>N6 PWE:]"K=4P[33Q$:OC7_A]Y3?\40S#N3QC+
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MN(9=1=LZ+RA^@YU)Q$RD;WKG@>K.)AZE01A%(&E"X!7!M2RG=/E9 *_A7_O
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M;<7J(6B<A"TGJ/Q&[#O+00>\I""[0GP= +O))>:@$^0(NU/*B$P)6#^5VJA
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M;U+;<TUUT.C_L4#A!O12M 21-MO3X T-N;9CPW>R_J8AKF)YI2E'B1,T/+7
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MV]VX0;,BV*K(6OQ.[\CC!!EZ  L!K'Z!$!TS]#R U2/:Z<X>=AS >MGMZ7D
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MDATEZC0-!T+WVV]832X./D5?0BI&\+=LF@;_#0PT64&UAA'25P*='DBI(Y5
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M<!AX?R G38$7"S$+P-A/!6Q&$>8TAUGX1? O%7$-@^.L1**&8TH18$.*@"/
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M78<O2QA;J9V)G C],>Q$N? "[/X";&?XR['2ATO@Z0,@.AJ.*!%XTWSF@!C
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MA,-@>T+!#;C'[^$*RBD..%P1R.=-7-/S<+3]A L,A+W"6A9QS_2B</^?3/Z
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M88E;06Z:)Q8 2)HG%I@G]IS(U4RQ4/2FF6(!@*298H&9XKD9:9Y8*'+3/+$
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MB/_;;'6!;:0MSXSS\TZCV_U_^<:2$NN:'CMW^- OL3IP%H"7YY@E(DS1ZPN
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MF:4W.Y]LODXXHU>FW%]%_6D>F4/V'!EKZ' =<* 9TRT)W"?A@K4F+A$+ZK%
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MGV62.0!&$2E.<\.=AHUF7._.N+1V5S":*2(_>Y&6_L\ V'Q+_Y.C2M+2/Q?
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M<B <,OEBK-,PSA$B1E>"9S5(LHF2V=GG$DHGY8/#FH;2/)3VC/T/0,=&I\$
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MU#7TX#[25<SZN%W!!#F+>#!.W,X95!,4@Q^2I(6'2:8*LM8)R-L6\HB!NB-
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MF?B-GB6O@97* BR>W[&HYPR]V;#G4LL!8(V"YIKYVO4,%Z[#'O-W<^_@^L"
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M;34//QQTCEKMP\YAJXN$WZ/[N\#X4VY@I8$!+@_]/CTKF")'-#>;-\%<->1
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MO0Z]F BZ^#V'=8!.]YX(Q^ &(*8^DBO4C,#:73$?Z_SN]I;79=]K,J9FL9O
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MOP;M3!(":P3*<$1 [9@+HO?!L2H%FV[;LL-BAN$N ";*KB%=E<*X/M"(,"*
M\#=GU]"DH,$8@Q*W^I-,XVF!@%VU[*X1!UZMNR"9?3S. ;.B8K",.7R<3O!4
MF@_*G7KQ[U2=NOE'K'\!4$L! A0#%     @ YX%<5/$CK/?&<@$ NDD" !$
M             ( !     &EM9S8Q-C<X-S8R7S N:G!G4$L! A0#%     @
MYX%<5/$CK/?&<@$ NDD" !$              ( !]7(! &EM9S8Q-C<X-S8R
M7S$N:G!G4$L! A0#%     @ YX%<5*S2759 +P$ 5FT! !(
M ( !ZN4" &EM9S8Q-C<X-S8R7S$P+FIP9U!+ 0(4 Q0    ( .>!7%33(M%Y
M80 ! "4[ 0 2              "  5H5! !I;6<V,38W.#<V,E\Q,2YJ<&=0
M2P$"% ,4    " #G@5Q4"!*!P:PQ   9/@  $@              @ 'K%04
M:6UG-C$V-S@W-C)?,3(N:G!G4$L! A0#%     @ YX%<5 A(L41G: ( Q[P"
M !(              ( !QT<% &EM9S8Q-C<X-S8R7S$S+FIP9U!+ 0(4 Q0
M   ( .>!7%0Z:<EA"Q4  $P:   2              "  5ZP!P!I;6<V,38W
M.#<V,E\Q-"YJ<&=02P$"% ,4    " #G@5Q4Q_(A!7]Q 0"]H@$ $@
M        @ &9Q0< :6UG-C$V-S@W-C)?,34N:G!G4$L! A0#%     @ YX%<
M5)_Q1[KA/@$ '7@! !(              ( !2#<) &EM9S8Q-C<X-S8R7S$V
M+FIP9U!+ 0(4 Q0    ( .>!7%0<M SP>3\! -N% 0 2              "
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M,E\R,"YJ<&=02P$"% ,4    " #G@5Q4>.CQ1R@C 0!P7 $ $@
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M-S@W-C)?-"YJ<&=02P$"% ,4    " #G@5Q4S#2J$[<# @"U3P( $0
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M-S@W-C)?.2YJ<&=02P$"% ,4    " #G@5Q4O3XDM[8N!@"7#$T $
M        @ 'P,R, =FER+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( .>!7%3-
MQYY@>B0  #+4 0 0              "  =1B*0!V:7(M,C R,3$R,S$N>'-D
M4$L! A0#%     @ YX%<5 ,06RVD%P  (UT! !0              ( !?(<I
M '9I<BTR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ YX%<5(4?8X\L9P
M+' ' !0              ( !4I\I '9I<BTR,#(Q,3(S,5]D968N>&UL4$L!
M A0#%     @ YX%<5)9SG,U-2 $ >QT. !0              ( !L 8J '9I
M<BTR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ YX%<5%67A4=4AP  Z5\*
M !0              ( !+T\K '9I<BTR,#(Q,3(S,5]P<F4N>&UL4$L! A0#
M%     @ YX%<5 JET]VA"   R[(   \              ( !M=8K '9I<BUE
M>#$P7S0S+FAT;5!+ 0(4 Q0    ( .>!7%2LL'18:"L  #.Z 0 /
M      "  8/?*P!V:7(M97@Q,%\T-"YH=&U02P$"% ,4    " #G@5Q47=_Z
M!B)I  "B!P0 #P              @ $8"RP =FER+65X,3!?-#4N:'1M4$L!
M A0#%     @ YX%<5,5Y 3</90  P"\$  \              ( !9W0L '9I
M<BUE>#$P7S0V+FAT;5!+ 0(4 Q0    ( .>!7%3<EY?=22D  #V@ 0 /
M          "  :/9+ !V:7(M97@Q,%\T-RYH=&U02P$"% ,4    " #G@5Q4
M98GU*G.. @#^+AH #P              @ $9 RT =FER+65X,3!?-C8N:'1M
M4$L! A0#%     @ YX%<5'ZA=[[5 P  )1P   X              ( !N9$O
M '9I<BUE>#(S7S$N:'1M4$L! A0#%     @ YX%<5*6="YW7"   =DH   X
M             ( !NI4O '9I<BUE>#,Q7S$N:'1M4$L! A0#%     @ YX%<
M5(!=4E38"   .DL   X              ( !O9XO '9I<BUE>#,Q7S(N:'1M
M4$L! A0#%     @ YX%<5+#>E76\!@  CS4   X              ( !P:<O
E '9I<BUE>#,R7S$N:'1M4$L%!@     H "@ V D  *FN+P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
